{"meta":{"query_hash":"7e571f374015","filters":{"topic":"Acute Myeloid Leukemia Research"},"cohort_total":2888,"direct_labels_cover":3,"predictions_cover":2888,"exported":2888,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/7e571f374015","api":"https://metacan.xera.ac/api/v1/cohort?topic=Acute+Myeloid+Leukemia+Research"},"results":[{"id":"W1040989942","doi":"10.1182/blood.v124.21.621.621","title":"Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with &gt;30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; CancerCare Manitoba","funders":"","keywords":"Medicine; Azacitidine; Internal medicine; Myeloid leukemia; Oncology; Bone marrow; Cytogenetics; Decitabine; Leukemia; Surgery","score_opus":0.006703207031544652,"score_gpt":0.22732603675827773,"score_spread":0.22062282972673308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1040989942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99454933,0.00008044118,0.000025552068,0.00012655098,0.000032823842,0.0036671138,0.00063428865,0.00008643892,0.0007974817],"genre_scores_gemma":[0.9975583,0.00012190797,0.0004655324,0.00010024524,0.00008211474,0.0002002902,0.00044216873,0.00017715724,0.0008522996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942327,0.0007231831,0.00085232616,0.0010768613,0.0019434812,0.0011714512],"domain_scores_gemma":[0.9963248,0.00046970925,0.00058506377,0.0015571442,0.0006035973,0.000459688],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007183164,0.00070481293,0.0011595684,0.00030622145,0.00016140772,0.000054844924,0.0004613942,0.0002065498,0.000059228805],"category_scores_gemma":[0.00032092418,0.00039651335,0.00008896109,0.0011670813,0.0003957087,0.00016777826,0.00020634072,0.0008862199,0.000021177288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011013583,0.0056798668,0.9751929,0.00008212676,0.0012491422,0.0002743965,0.0010343689,0.00018765098,0.0033464115,0.000002420092,0.0011447956,0.00079231994],"study_design_scores_gemma":[0.15891708,0.009738335,0.81958735,0.00037083778,0.0012453264,0.000027347003,0.00032031108,0.00013630406,0.00891248,0.0000023972648,0.00027203973,0.0004701673],"about_ca_topic_score_codex":0.0043522646,"about_ca_topic_score_gemma":0.0034118798,"teacher_disagreement_score":0.15560555,"about_ca_system_score_codex":0.00051772076,"about_ca_system_score_gemma":0.0008261307,"threshold_uncertainty_score":0.99984866},"labels":[],"label_agreement":null},{"id":"W1219679791","doi":"10.1182/blood.v124.21.2592.2592","title":"Risk Factors for Poor Survival after Hematopoietic Stem Cell Transplantation in Inherited Bone Marrow Failure Syndromes","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Janeway Children's Health and Rehabilitation Centre; London Health Sciences Centre; McMaster University; University of Alberta; Centre hospitalier universitaire de Québec; Centre Hospitalier Universitaire de Sherbrooke; University of Saskatchewan; Hospital for Sick Children; Université de Montréal; CancerCare Manitoba; Princess Margaret Cancer Centre; Kingston General Hospital; University of Manitoba; Alberta Children's Hospital; Izaak Walton Killam Health Centre; Genome Canada; Children's Hospital of Eastern Ontario; BC Children's Hospital; Montreal Children's Hospital; University of Toronto; SickKids Foundation; Dalhousie University","funders":"","keywords":"Medicine; Cytopenia; Hematopoietic stem cell transplantation; Transplantation; Univariate analysis; Population; Pediatrics; Internal medicine; Proportional hazards model; Surgery; Bone marrow; Multivariate analysis","score_opus":0.013914643467913204,"score_gpt":0.24856435683270112,"score_spread":0.2346497133647879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1219679791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99752194,0.00017003919,0.0006477646,0.000398272,0.00006273628,0.0008244831,0.000100644735,0.00006711322,0.00020699928],"genre_scores_gemma":[0.99788016,0.00006744695,0.000971635,0.000059380513,0.00007283642,0.00014338919,0.00011392091,0.00005548624,0.0006357217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984506,0.00014772476,0.00032200565,0.00033614007,0.00033179662,0.00041177173],"domain_scores_gemma":[0.9990876,0.0003401829,0.000073618925,0.00026719432,0.000072476396,0.00015894482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041051512,0.00020255311,0.000415728,0.00021583501,0.000044639015,0.00002455987,0.00010083232,0.00018674467,0.000078181736],"category_scores_gemma":[0.00005664282,0.00017108694,0.00011765162,0.00025162645,0.000045620993,0.00008431547,0.000018949277,0.00031318655,0.00003753877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001974536,0.0017605064,0.9289498,0.004601614,0.0003050855,0.00063732686,0.0075124865,0.00001806896,0.05204656,0.000093726754,0.0007299883,0.0013703511],"study_design_scores_gemma":[0.0464149,0.0020511753,0.7732046,0.00067455193,0.0014475087,0.0004852946,0.0035475998,0.0011393941,0.16674434,0.0002289017,0.003031992,0.0010297073],"about_ca_topic_score_codex":0.0001193491,"about_ca_topic_score_gemma":0.00018214404,"teacher_disagreement_score":0.1557451,"about_ca_system_score_codex":0.000069351794,"about_ca_system_score_gemma":0.000084328385,"threshold_uncertainty_score":0.69767225},"labels":[],"label_agreement":null},{"id":"W1259513005","doi":"10.1016/j.bbmt.2015.08.024","title":"Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies","year":2015,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Onyx Pharmaceuticals; Health Resources and Services Administration; Medac; Swedish Orphan Biovitrum; Miltenyi Biotec; Incyte; Genentech; Seattle Genetics; Chimerix; Medical College of Wisconsin; University of Utah; Blue Cross and Blue Shield Association; Takeda Oncology; University of Minnesota; Kiadis Pharma; Sigma-Tau Pharmaceuticals; Therakos; Milliman; National Marrow Donor Program; St. Baldrick's Foundation; National Institute of Allergy and Infectious Diseases; Roswell Park Cancer Institute; Fred Hutchinson Cancer Research Center; Health Research; Celgene; Osiris Therapeutics; Merck; GlaxoSmithKline; StemCyte; Tarix Pharmaceuticals; Genzyme; Leukemia and Lymphoma Society; Be The Match Foundation; Allos Therapeutics; Actinium Pharmaceuticals; Ariad Pharmaceuticals; Otsuka America Pharmaceutical; Amgen; National Center for Advancing Translational Sciences; HistoGenetics; WellPoint; Sanofi","keywords":"Hazard ratio; Medicine; Internal medicine; Transplantation; Myeloid leukemia; Oncology; Hematopoietic stem cell transplantation; Population; Myelodysplastic syndromes; Myeloid; Gastroenterology; Bone marrow; Confidence interval","score_opus":0.02042976214488929,"score_gpt":0.2722262757307615,"score_spread":0.25179651358587224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1259513005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99680495,0.00084108487,0.00029088667,0.0004830388,0.00006889816,0.00034260578,0.000058363625,0.000029478731,0.0010806866],"genre_scores_gemma":[0.99574286,0.0021793684,0.0015282528,0.000088673965,0.000023398892,0.000023746692,0.00025244802,0.000013347206,0.00014792454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896693,0.00009422529,0.00033338883,0.00023805807,0.00013670597,0.00023069022],"domain_scores_gemma":[0.99952126,0.00010569269,0.00007008546,0.0001114332,0.000075044685,0.00011648476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025714212,0.00014699009,0.00035789912,0.0002229612,0.000024858164,0.000004883749,0.00006481398,0.0001796272,0.000012644095],"category_scores_gemma":[0.000017074188,0.00012338978,0.000048334776,0.00013959743,0.00014346592,0.00009186852,0.000006371871,0.00014537333,0.000006966127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010594183,0.00020635908,0.53913784,0.0009421485,0.00005472503,0.00014969571,0.00247556,0.000006940678,0.45475668,0.0005566445,0.000022836075,0.0006311368],"study_design_scores_gemma":[0.015800793,0.001749246,0.50469905,0.00024792497,0.000672696,0.0007627489,0.00075424614,0.000077552606,0.4738408,0.0009971638,0.00007076883,0.00032701207],"about_ca_topic_score_codex":0.00020556689,"about_ca_topic_score_gemma":0.000085349195,"teacher_disagreement_score":0.034438796,"about_ca_system_score_codex":0.000021209215,"about_ca_system_score_gemma":0.00015965391,"threshold_uncertainty_score":0.5031689},"labels":[],"label_agreement":null},{"id":"W135063420","doi":"10.1182/blood.v124.21.529.529","title":"First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Decitabine; Medicine; Hypomethylating agent; Pharmacodynamics; Internal medicine; Adverse effect; Myelodysplastic syndromes; Phases of clinical research; Neutropenia; Pharmacokinetics; Clinical trial; Gastroenterology; Azacitidine; Febrile neutropenia; Oncology; Bone marrow; Chemotherapy; DNA methylation; Chemistry","score_opus":0.028520101506330022,"score_gpt":0.3203481299052177,"score_spread":0.2918280283988877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W135063420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934945,0.00012017841,0.00020566341,0.000059787617,0.00021730216,0.005561838,0.00021366347,0.000087546476,0.00003953124],"genre_scores_gemma":[0.99723095,0.00034561646,0.0013404188,0.000030253144,0.00017857064,0.00033158896,0.0000692622,0.00014669361,0.00032664466],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9898678,0.0024555111,0.003844493,0.0012325444,0.0015613281,0.0010382988],"domain_scores_gemma":[0.9770605,0.018461803,0.0019304372,0.0014291579,0.00057808857,0.0005399925],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007043893,0.0007330202,0.0036734445,0.0010398994,0.00013714905,0.000039933104,0.0006853435,0.0003740376,0.00012341957],"category_scores_gemma":[0.038233384,0.00046411197,0.00038318217,0.00141815,0.0007968277,0.00015456225,0.00045941188,0.0013696317,0.00003514173],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95579994,0.01593166,0.011060407,0.00069471204,0.0023210126,0.0016415281,0.0033723295,0.00059042795,0.00066564087,0.0000024229398,0.00006897147,0.007850939],"study_design_scores_gemma":[0.8442381,0.0625397,0.07231345,0.0017995844,0.0025181016,0.0002523522,0.0004946368,0.014487131,0.0007585549,0.000007666842,0.000050516952,0.00054017286],"about_ca_topic_score_codex":0.0016196484,"about_ca_topic_score_gemma":0.0018389485,"teacher_disagreement_score":0.11156182,"about_ca_system_score_codex":0.0012249922,"about_ca_system_score_gemma":0.0026653865,"threshold_uncertainty_score":0.9997811},"labels":[],"label_agreement":null},{"id":"W136049078","doi":"10.1016/s0165-4608(00)00352-6","title":"Tetrasomy 8 is associated with a major cellular proliferative advantage and a poor prognosis","year":2001,"lang":"en","type":"review","venue":"Cancer Genetics and Cytogenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec; Hôpital Saint-François d'Assise","funders":"Medical Research Council; Natural Sciences and Engineering Research Council of Canada","keywords":"Tetrasomy; Biology; Interphase; Aneuploidy; Metaphase; Fluorescence in situ hybridization; Trisomy; Molecular biology; Uniparental disomy; Genetics; Chromosome; Karyotype","score_opus":0.04901061188304751,"score_gpt":0.347666022020678,"score_spread":0.2986554101376305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W136049078","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00782838,0.98778325,0.00006177279,0.00022279605,0.000051151055,0.0032027524,0.0005462769,0.00003999136,0.00026364005],"genre_scores_gemma":[0.0009712045,0.99336255,0.0011630247,0.00036318204,0.00031656554,0.0008207179,0.00019692977,0.00021698109,0.002588867],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969868,0.00013118591,0.0005920263,0.00096986775,0.0005752546,0.0007448355],"domain_scores_gemma":[0.9982171,0.00012255787,0.0003236882,0.0004169475,0.00036321452,0.00055649603],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017912946,0.00078606966,0.0019656408,0.00025466504,0.00017335526,0.00011992634,0.00020245188,0.0005941651,0.000112265545],"category_scores_gemma":[0.000051314666,0.0005785969,0.0001818282,0.0006957265,0.00034500845,0.000023950539,0.00021875749,0.0007551545,0.0000069900498],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010061912,0.00020287826,0.009242231,0.012236025,0.0024801176,0.00057463406,0.0003611139,7.255147e-7,0.000097463184,0.00000923685,0.0019744714,0.9727205],"study_design_scores_gemma":[0.0021393148,0.0012069807,0.00018850355,0.0095880125,0.0055818735,0.00037014514,0.00009472844,0.00012480772,0.0010599083,0.000013620199,0.9788224,0.0008097118],"about_ca_topic_score_codex":0.00002004096,"about_ca_topic_score_gemma":0.00004978665,"teacher_disagreement_score":0.97684795,"about_ca_system_score_codex":0.0004175489,"about_ca_system_score_gemma":0.0016918943,"threshold_uncertainty_score":0.9996666},"labels":[],"label_agreement":null},{"id":"W1484902841","doi":"10.1111/ijlh.12368","title":"Flow cytometry immunophenotyping in integrated diagnostics of patients with newly diagnosed cytopenia: one tube 10‐color 14‐antibody screening panel and 3‐tube extensive panel for detection of<scp>MDS</scp>‐related features","year":2015,"lang":"en","type":"review","venue":"International Journal of Laboratory Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Cytopenia; Flow cytometry; Immunophenotyping; Pathology; Cytometry; Myeloid leukemia; Acute promyelocytic leukemia; Leukemia; Bone marrow; Immunology; Biology; Cell culture","score_opus":0.035785622758690266,"score_gpt":0.3354396619856253,"score_spread":0.299654039226935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1484902841","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19956025,0.7946717,0.0021220113,0.00007526026,0.000849931,0.0018626556,0.00081339706,0.00002245818,0.000022304253],"genre_scores_gemma":[0.08245776,0.9050316,0.010598716,0.00010806149,0.0003143578,0.00012250456,0.0010715844,0.00023307426,0.00006231973],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99526215,0.00050638354,0.0022491303,0.0004548162,0.0010870633,0.000440435],"domain_scores_gemma":[0.9817924,0.0044626906,0.002717276,0.0003115975,0.010464865,0.0002511819],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012096727,0.00055961043,0.003477524,0.002209781,0.00005098092,0.000038887,0.0005899032,0.00084727106,0.000022111244],"category_scores_gemma":[0.013637594,0.0004338208,0.00029954,0.0011856209,0.00037216322,0.00029222885,0.00020491303,0.0016543652,0.0000037597306],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016628262,0.006251803,0.050833687,0.03864639,0.03611355,0.008836608,0.003927503,0.00049325905,0.005708556,0.00070566044,0.0049078506,0.82694685],"study_design_scores_gemma":[0.17131814,0.023691587,0.13288341,0.28894255,0.023296205,0.018435773,0.008421367,0.002937611,0.014614353,0.0007935923,0.31105143,0.0036139765],"about_ca_topic_score_codex":0.00003089225,"about_ca_topic_score_gemma":0.000021396056,"teacher_disagreement_score":0.8233329,"about_ca_system_score_codex":0.0006839586,"about_ca_system_score_gemma":0.0022759642,"threshold_uncertainty_score":0.99981135},"labels":[],"label_agreement":null},{"id":"W1493823666","doi":"10.1007/978-3-642-18156-6_3","title":"Molecular Cytogenetic Characterization of a Critical Region in Bands 7q35-q36 Commonly Deleted in Malignant Myeloid Disorders","year":2001,"lang":"en","type":"book-chapter","venue":"Hämatologie und Bluttransfusion","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Myeloid leukemia; Myelodysplastic syndromes; Cancer research; Myeloid; Cytogenetics; Chromosome; Biology; Gene; Medicine; Genetics; Immunology; Bone marrow","score_opus":0.028819412765637993,"score_gpt":0.2986084680897868,"score_spread":0.2697890553241488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1493823666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9369448,0.0022061414,0.005265089,0.0052116793,0.00021127128,0.0028265296,0.000058093192,0.00015241386,0.047124002],"genre_scores_gemma":[0.9810879,0.01467879,0.00023314511,0.00027258517,0.00004369021,0.00006816325,0.0006223976,0.00016394732,0.0028293347],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9963053,0.00017067311,0.0012010741,0.0008664505,0.0007248337,0.0007316575],"domain_scores_gemma":[0.9984197,0.00023529197,0.00018908271,0.00075683114,0.0001955718,0.00020350316],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034945496,0.00059884554,0.0013826472,0.0012915897,0.000056873523,0.0000177959,0.00033481076,0.0012757257,0.0001733436],"category_scores_gemma":[0.00020136089,0.0005646048,0.00027514566,0.00040456982,0.000491294,0.00008934519,0.00012726922,0.0012546668,0.000025261237],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009753643,0.0030708704,0.10628881,0.008179405,0.0005487294,0.025801318,0.0017063232,0.00013998219,0.67767155,0.047088437,0.00028058892,0.11947035],"study_design_scores_gemma":[0.09402778,0.017976044,0.2784655,0.0683127,0.005694877,0.010807621,0.0012830242,0.027765315,0.27304354,0.07280687,0.1348746,0.014942134],"about_ca_topic_score_codex":0.00027564057,"about_ca_topic_score_gemma":0.00047106863,"teacher_disagreement_score":0.404628,"about_ca_system_score_codex":0.0005375182,"about_ca_system_score_gemma":0.00052151905,"threshold_uncertainty_score":0.9996805},"labels":[],"label_agreement":null},{"id":"W1494718766","doi":"10.1158/1538-7445.am2014-3604","title":"Abstract 3604: Investigation of the role of CSF-1 and its receptor in the bone marrow stroma microenvironment in acute myeloid leukemia","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Bone marrow; Stromal cell; Macrophage colony-stimulating factor; Myeloid leukemia; Myeloid; Cytokine; Biology; Cancer research; Leukemia; Immunology; Cell biology; Chemistry; Macrophage; In vitro; Biochemistry","score_opus":0.028607013694659525,"score_gpt":0.3174480148794716,"score_spread":0.2888410011848121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1494718766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914799,0.0017486303,4.4982775e-7,0.0048669754,0.000024943127,0.0009936332,0.00002865992,0.000003841347,0.00085299887],"genre_scores_gemma":[0.99771345,0.0014932858,0.000064864274,0.00013082552,0.00007756269,0.0001714538,0.000010644441,0.000023028108,0.0003149019],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99724716,0.00050849846,0.0004040046,0.00031275375,0.0010544278,0.00047317334],"domain_scores_gemma":[0.99876136,0.00037345508,0.000104037805,0.00051882264,0.00013047786,0.00011182905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029143055,0.00012881873,0.00030215824,0.00027887002,0.00006738134,0.000016026595,0.00041495127,0.0001291116,0.00016853926],"category_scores_gemma":[0.00035416795,0.00008125075,0.000049769747,0.00068536866,0.00055213104,0.00009526787,0.00023766265,0.0010687642,0.000013539826],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032685118,0.000037177477,0.057905607,0.00019252118,0.000025970412,0.000005601729,0.0017244891,0.000019795696,0.93323874,0.00016112257,0.0009369405,0.005425193],"study_design_scores_gemma":[0.0015744976,0.00019702749,0.5723606,0.00037883478,0.00001222296,0.000008877603,0.00095199386,0.0003919441,0.42156154,0.0003203532,0.0021698044,0.00007235076],"about_ca_topic_score_codex":0.001433245,"about_ca_topic_score_gemma":0.000309527,"teacher_disagreement_score":0.51445496,"about_ca_system_score_codex":0.0010423604,"about_ca_system_score_gemma":0.00070262427,"threshold_uncertainty_score":0.46433085},"labels":[],"label_agreement":null},{"id":"W1499075266","doi":"10.1002/ijc.28180","title":"Nucleophosmin 1, upregulated in adenomas and cancers of the colon, inhibits p53‐mediated cellular senescence","year":2013,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Canada's Michael Smith Genome Sciences Centre; University of British Columbia Hospital","funders":"Canadian Institutes of Health Research","keywords":"Cancer research; Biology; Colorectal adenoma; Carcinogenesis; Nucleophosmin; Colorectal cancer; Senescence; Downregulation and upregulation; Cell cycle; NPM1; Gene expression profiling; Cell; Pathology; Gene expression; Cancer; Medicine; Cell biology; Gene; Genetics","score_opus":0.008733848418216833,"score_gpt":0.2835667566929589,"score_spread":0.27483290827474205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1499075266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900608,0.0018068833,0.000018123725,0.007264015,0.00035025485,0.00021423637,0.000010576503,0.0000030941571,0.00027200292],"genre_scores_gemma":[0.9982443,0.00068752933,0.00008927628,0.00046997998,0.00018297698,0.000008702694,0.0000013275229,0.0000127003095,0.00030321773],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99857664,0.00004970832,0.00044590968,0.000104269515,0.0006738746,0.00014961763],"domain_scores_gemma":[0.9984614,0.00008592894,0.0003197375,0.0000863816,0.00094616186,0.000100372374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020332447,0.000090710586,0.00021717206,0.00019369878,0.00001582371,0.000018156758,0.00027911447,0.0000719283,0.00037928554],"category_scores_gemma":[0.00018681218,0.00006140511,0.00006420545,0.00023567416,0.00017027855,0.00015132585,0.00008577056,0.00034397104,0.000004810279],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005656191,0.000066456945,0.20089912,0.00004115027,0.00030970128,0.000109180844,0.0009277064,0.00020402136,0.7882222,0.000064371154,0.003027326,0.0055631213],"study_design_scores_gemma":[0.0053877463,0.00017501634,0.76656413,0.0012329518,0.000058725407,0.00021685693,0.00031941882,0.002711621,0.22028053,0.00027955134,0.0026475037,0.00012593],"about_ca_topic_score_codex":0.0019682485,"about_ca_topic_score_gemma":0.00017555212,"teacher_disagreement_score":0.56794167,"about_ca_system_score_codex":0.000816219,"about_ca_system_score_gemma":0.000902079,"threshold_uncertainty_score":0.41529107},"labels":[],"label_agreement":null},{"id":"W1499934474","doi":"","title":"Novel anti-CD33 immunoconjugate demonstrating in vitro and in vivo activity against human acute myeloid leukemia (AML) cells.","year":2006,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Immunoconjugate; Myeloid leukemia; Cytotoxic T cell; CD33; Clonogenic assay; Cancer research; Cytotoxicity; Leukemia; Chemistry; In vivo; Antigen; Haematopoiesis; Stem cell; Monoclonal antibody; Antibody; Immunology; In vitro; Biology; CD34; Cell biology; Biochemistry","score_opus":0.0378726971746742,"score_gpt":0.3588795019694974,"score_spread":0.32100680479482324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1499934474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910781,0.0006830393,0.000028961424,0.0009347435,0.0000641312,0.0013433043,0.00007968593,0.000056015302,0.005732013],"genre_scores_gemma":[0.9956947,0.0011230814,0.00049812713,0.00011156149,0.00029653808,0.00032649795,0.000027719,0.00008710642,0.0018346625],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99544495,0.00031632232,0.00056649104,0.00092275004,0.0011124078,0.0016371016],"domain_scores_gemma":[0.9983643,0.0003241823,0.00009488875,0.0006362097,0.0002944208,0.00028596853],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0023280678,0.00034388996,0.00070226385,0.0011077096,0.00033701028,0.0001475699,0.00040765706,0.00032245903,0.0000945344],"category_scores_gemma":[0.00012008859,0.00033575372,0.00008937937,0.0016155216,0.00075195247,0.00035039114,0.0004645464,0.002798995,0.00002199267],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008600825,0.00018334325,0.008545635,0.00018552264,0.00004977984,0.00056201214,0.0002275502,0.00009474318,0.9827546,0.00003448873,0.0007214639,0.0057808137],"study_design_scores_gemma":[0.005824455,0.00012518665,0.046037327,0.00035838626,0.000012502801,0.000044136777,0.0002562632,0.0020123215,0.94399744,0.000056711357,0.000958495,0.0003167462],"about_ca_topic_score_codex":0.022170907,"about_ca_topic_score_gemma":0.0030183634,"teacher_disagreement_score":0.038757097,"about_ca_system_score_codex":0.004280345,"about_ca_system_score_gemma":0.0021504103,"threshold_uncertainty_score":0.99990946},"labels":[],"label_agreement":null},{"id":"W1512898985","doi":"10.1038/bmt.2015.151","title":"Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation","year":2015,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Univariate analysis; Transplantation; Hematopoietic stem cell transplantation; Myelodysplastic syndromes; Cytogenetics; Oncology; Confidence interval; Surgery; Gastroenterology; Multivariate analysis; Bone marrow","score_opus":0.0138439214628383,"score_gpt":0.2484407024132744,"score_spread":0.2345967809504361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1512898985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945396,0.00020219352,0.0021950994,0.00021815235,0.00017766163,0.0012792696,0.00010766426,0.00013198511,0.0011483687],"genre_scores_gemma":[0.9966405,0.00020477177,0.0013108975,0.000074877855,0.000012828313,0.00006552538,0.0011448592,0.00008594716,0.00045979372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970071,0.00015026791,0.0007241395,0.00045462194,0.0011970049,0.00046688458],"domain_scores_gemma":[0.998635,0.00021967078,0.00022800609,0.0003410013,0.00027077604,0.0003055324],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039635022,0.0003754,0.00071022863,0.0004080816,0.000086182416,0.000025184985,0.0001507929,0.00021705862,0.00007629514],"category_scores_gemma":[0.000028566099,0.00029582845,0.00019023455,0.00056745013,0.000105287814,0.00034147548,0.0000078182375,0.00033624354,0.000067462475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009301118,0.0012145785,0.95918363,0.0021798396,0.00075026863,0.0020096116,0.009369117,0.000530633,0.013744708,0.00012624475,0.00013656526,0.0014536895],"study_design_scores_gemma":[0.0321441,0.0018753002,0.95108324,0.0004901683,0.0009890787,0.00042026484,0.00033971883,0.00025333968,0.011749783,0.00011853237,0.00004088105,0.00049560727],"about_ca_topic_score_codex":0.00012317738,"about_ca_topic_score_gemma":0.00002443847,"teacher_disagreement_score":0.02284298,"about_ca_system_score_codex":0.00019276439,"about_ca_system_score_gemma":0.00033380408,"threshold_uncertainty_score":0.9999494},"labels":[],"label_agreement":null},{"id":"W1514606780","doi":"10.1002/ajh.23640","title":"Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies","year":2013,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"Leukemia and Lymphoma Society","keywords":"Medicine; Dosing; Pharmacology; Pharmacokinetics; Adverse effect; Drug; Pharmacodynamics","score_opus":0.017367300387844092,"score_gpt":0.31955335801566315,"score_spread":0.302186057627819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1514606780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99784553,0.000066511275,0.000107193046,0.0009511825,0.000039659226,0.0009309567,0.000002338043,0.000012574781,0.00004403175],"genre_scores_gemma":[0.9978137,0.000027028513,0.0018715372,0.00018704479,0.0000128581805,0.00005511944,0.0000032903727,0.000019856825,0.000009549692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975928,0.00045057514,0.00071081775,0.00030835433,0.0003543735,0.000583102],"domain_scores_gemma":[0.9983735,0.00032508597,0.0005445185,0.00027242018,0.0002769501,0.0002075258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041810592,0.00025025805,0.0015384678,0.0005283029,0.000030581243,0.000010759362,0.00024717257,0.000080186444,0.00012040361],"category_scores_gemma":[0.00043102767,0.00015203241,0.00007649766,0.0008063962,0.0005547457,0.00021911079,0.00009786261,0.000742781,0.000018026798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004115052,0.004577517,0.97741604,0.000022724835,0.00007701719,0.0015239822,0.00035898783,0.0000049089676,0.0014795568,0.000030440497,0.00006381804,0.010329933],"study_design_scores_gemma":[0.018838195,0.0237999,0.952683,0.000114575014,0.000025338251,0.0011258607,0.0024229335,0.000058459205,0.0006859444,0.00005306405,0.0000183502,0.00017438483],"about_ca_topic_score_codex":0.000171169,"about_ca_topic_score_gemma":0.000054380605,"teacher_disagreement_score":0.024733067,"about_ca_system_score_codex":0.0002701424,"about_ca_system_score_gemma":0.00022410187,"threshold_uncertainty_score":0.61997014},"labels":[],"label_agreement":null},{"id":"W1529302721","doi":"10.1002/pbc.24942","title":"Outcome of children treated for relapsed acute myeloid leukemia in Central America","year":2014,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster Children's Hospital; Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research; Pediatric Oncology Group of Ontario; St. Jude Children's Research Hospital","keywords":"Medicine; Blood cancer; Myeloid leukemia; Acute promyelocytic leukemia; Overall survival; Leukemia; Population; Pediatrics; Cancer; Surgery; Internal medicine","score_opus":0.013284080925879398,"score_gpt":0.2947442708655636,"score_spread":0.2814601899396842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1529302721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99612886,0.0009484204,0.00018084276,0.00054505817,0.00013242781,0.0012035086,0.0001825806,0.000078413555,0.0005999075],"genre_scores_gemma":[0.9924847,0.0022998026,0.001668419,0.0004870892,0.0012958321,0.00028683685,0.00013174352,0.00007898928,0.0012666283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974525,0.0000747267,0.0006831859,0.0005099916,0.00043561772,0.00084400224],"domain_scores_gemma":[0.9986082,0.00022035287,0.00023131799,0.00048112587,0.00016913208,0.00028992177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022822327,0.00028397792,0.00080532697,0.0004130127,0.000051527266,0.000011645824,0.00027764728,0.00020416571,0.0001633957],"category_scores_gemma":[0.00028156684,0.00024479817,0.00023119603,0.0009886735,0.00009756171,0.00008539224,0.00007774898,0.0004759637,0.000019032212],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000705969,0.00014984475,0.987082,0.00022977189,0.00027627152,0.000012930874,0.00014317906,0.00008362125,0.0017725074,0.00002253332,0.0045845066,0.004936854],"study_design_scores_gemma":[0.019382272,0.0010398066,0.9675307,0.00005115225,0.0022780574,0.00003320602,0.000024427201,0.0015939972,0.0054405443,0.000035073936,0.0021682184,0.00042251468],"about_ca_topic_score_codex":0.0033526418,"about_ca_topic_score_gemma":0.00008279917,"teacher_disagreement_score":0.01955128,"about_ca_system_score_codex":0.0007263234,"about_ca_system_score_gemma":0.0008418533,"threshold_uncertainty_score":0.99825794},"labels":[],"label_agreement":null},{"id":"W1545841937","doi":"10.1002/cncr.28674","title":"AAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia","year":2014,"lang":"en","type":"article","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Institutes of Health; National Cancer Institute; Sanofi","keywords":"Clofarabine; Medicine; Cytarabine; Internal medicine; Tolerability; Myeloid leukemia; Gastroenterology; Refractory (planetary science); Hematopoietic stem cell transplantation; Transplantation; Induction chemotherapy; Chemotherapy; Oncology; Surgery; Adverse effect","score_opus":0.01072879102324693,"score_gpt":0.2772337030144342,"score_spread":0.26650491199118725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1545841937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99318075,0.00018259595,0.000041948053,0.0042165285,0.00011715295,0.0016936717,0.000027945336,0.000019806972,0.00051957456],"genre_scores_gemma":[0.99801016,0.00033838177,0.0001221862,0.0006253702,0.00025560905,0.00026649632,0.0002659636,0.000039940525,0.00007592148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977372,0.00026985668,0.00048519412,0.00047145723,0.00066513557,0.00037113865],"domain_scores_gemma":[0.9979508,0.0007311286,0.00034470187,0.00067583245,0.00020877768,0.00008878324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069381046,0.00023771389,0.0004868971,0.0001907692,0.000058990245,0.000010822027,0.00029576177,0.00013018181,0.00006973538],"category_scores_gemma":[0.00036391593,0.00011539754,0.00005007504,0.0008965974,0.00020331457,0.000066677356,0.00007900889,0.0008706217,0.000009094731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004816177,0.0006521554,0.9705717,0.000022487584,0.00011743424,0.00005486131,0.0005331713,0.00014035896,0.000078308236,0.00014288098,0.0021444163,0.020726036],"study_design_scores_gemma":[0.014083919,0.0023419866,0.9814477,0.00020433722,0.00015115264,0.000011608509,0.000028970206,0.00028615523,0.0001405914,0.000040600447,0.0011217992,0.00014115633],"about_ca_topic_score_codex":0.0016112722,"about_ca_topic_score_gemma":0.001177575,"teacher_disagreement_score":0.02058488,"about_ca_system_score_codex":0.0017989469,"about_ca_system_score_gemma":0.00080664386,"threshold_uncertainty_score":0.4705775},"labels":[],"label_agreement":null},{"id":"W1556345025","doi":"10.1002/cncr.27683","title":"Influence of FLT3‐internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate‐risk karyotype acute myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"NPM1; Medicine; Internal medicine; Oncology; White blood cell; Myeloid leukemia; Leukemia; Fms-Like Tyrosine Kinase 3; Chemotherapy regimen; Gastroenterology; Chemotherapy; Mutation; Karyotype; Genetics; Biology","score_opus":0.009474740998101569,"score_gpt":0.26589337404468855,"score_spread":0.25641863304658696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1556345025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982065,0.00019506513,0.000011335992,0.0004143796,0.000045546058,0.0005761603,0.000037220052,0.000013096048,0.00050072843],"genre_scores_gemma":[0.99836975,0.0003837024,0.00004435409,0.00036458168,0.00018758669,0.00009240122,0.000018275063,0.000027748843,0.0005115945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864614,0.000055518234,0.00029060734,0.00023011914,0.00041408002,0.00036352253],"domain_scores_gemma":[0.9990225,0.000094848,0.00019071488,0.00036327186,0.0001808442,0.000147859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031716315,0.00016784447,0.0002702782,0.00010031784,0.000046549165,0.0000109895645,0.00018879975,0.00009023826,0.00007195457],"category_scores_gemma":[0.000081240185,0.000101663754,0.000030851414,0.00019118711,0.00016856236,0.00014068365,0.00009465955,0.00047571908,0.000019621382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058137986,0.000057158562,0.9952895,0.000048956874,0.00009532175,0.0000031484662,0.001367143,0.0001810402,0.00092615536,0.000010107289,0.00035075625,0.001089346],"study_design_scores_gemma":[0.0031174105,0.0003880441,0.9928449,0.0001359254,0.00013058216,0.0000029268806,0.00011817367,0.00015864997,0.0024510166,0.0000044461485,0.0005376008,0.000110352594],"about_ca_topic_score_codex":0.00084593974,"about_ca_topic_score_gemma":0.000096311465,"teacher_disagreement_score":0.0025360305,"about_ca_system_score_codex":0.0008287409,"about_ca_system_score_gemma":0.00032360904,"threshold_uncertainty_score":0.41457278},"labels":[],"label_agreement":null},{"id":"W1563045693","doi":"","title":"Un cas de syndrome myélodysplasique traité avec de la décitabine","year":2007,"lang":"fr","type":"article","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Gynecology; Medicine","score_opus":0.010026967862952187,"score_gpt":0.30728687874550975,"score_spread":0.29725991088255754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1563045693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76829994,0.0049520507,0.031351004,0.014425136,0.00047860428,0.0006687766,0.000028843242,0.00014907008,0.1796466],"genre_scores_gemma":[0.8105098,0.0014271361,0.019175371,0.0021843708,0.0013273588,0.00002381238,0.000024137735,0.00013145193,0.16519657],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9950145,0.00054282654,0.000657063,0.00058532815,0.0006741386,0.0025261745],"domain_scores_gemma":[0.9953046,0.0022364159,0.00008582356,0.00067413796,0.00018076527,0.0015182805],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0062555643,0.00045514552,0.00063672924,0.00041832755,0.00015963799,0.00007128313,0.00044318743,0.0009861343,0.01248786],"category_scores_gemma":[0.0013266867,0.00043400886,0.00023207405,0.0008461238,0.0007950557,0.00017634369,0.00018209474,0.0019836302,0.0020493597],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016582323,0.0025306272,0.07239528,0.0019811972,0.0018375999,0.2091227,0.012340522,0.00011504701,0.09901955,0.115864374,0.09040714,0.39272773],"study_design_scores_gemma":[0.010336443,0.0018617463,0.51087195,0.0009402763,0.0005970917,0.1045064,0.002295418,0.0054648956,0.09344489,0.003823814,0.26473415,0.0011229084],"about_ca_topic_score_codex":0.003050664,"about_ca_topic_score_gemma":0.00044067315,"teacher_disagreement_score":0.43847668,"about_ca_system_score_codex":0.004177288,"about_ca_system_score_gemma":0.0024290704,"threshold_uncertainty_score":0.9998112},"labels":[],"label_agreement":null},{"id":"W1563338513","doi":"10.1002/pbc.24573","title":"Outcome of pediatric patients with acute myeloid leukemia (AML) and −5/5q− abnormalities from five pediatric AML treatment protocols: A report from the Children's Oncology Group","year":2013,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"National Cancer Institute","keywords":"Medicine; Myeloid leukemia; Internal medicine; Acute promyelocytic leukemia; Induction chemotherapy; Disease; Chemotherapy; Leukemia; Oncology; Down syndrome; Cytogenetics; Myeloid; Chromosome; Gene","score_opus":0.016079983662588795,"score_gpt":0.2946204145379009,"score_spread":0.2785404308753121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1563338513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97558534,0.003634982,0.000014756067,0.0006247789,0.00020721994,0.018310111,0.0012589014,0.00012238203,0.00024153164],"genre_scores_gemma":[0.9547376,0.00794308,0.0020468277,0.0005198501,0.0078767305,0.024800852,0.0008860582,0.00018203493,0.0010069791],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948218,0.00027019653,0.001420327,0.001197018,0.0012676587,0.0010229837],"domain_scores_gemma":[0.99562836,0.0008648734,0.001110307,0.001213656,0.00063547085,0.0005473515],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034425905,0.0007700077,0.0014300732,0.00039571768,0.00026321254,0.000089581685,0.00053124013,0.00044051142,0.0006673596],"category_scores_gemma":[0.00021480625,0.0004747886,0.00026668457,0.0010607715,0.00025590573,0.00041096535,0.0003647908,0.0008731641,0.000061024624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073498435,0.00071767496,0.9879025,0.00014118431,0.0010464953,0.00022719105,0.0011402895,0.000006105207,0.000014163316,0.0000048819743,0.00593236,0.00213217],"study_design_scores_gemma":[0.014634218,0.0025577557,0.9735029,0.000023864344,0.007522542,0.00007004243,0.00018400748,0.000020423862,0.00006775373,0.0000611641,0.0008337192,0.00052160816],"about_ca_topic_score_codex":0.045517493,"about_ca_topic_score_gemma":0.00062927196,"teacher_disagreement_score":0.04488822,"about_ca_system_score_codex":0.001186835,"about_ca_system_score_gemma":0.0024355594,"threshold_uncertainty_score":0.9997704},"labels":[],"label_agreement":null},{"id":"W1568498224","doi":"10.1002/cncr.28974","title":"Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML","year":2014,"lang":"en","type":"article","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Cytarabine; Internal medicine; Clinical endpoint; Oncology; Population; Salvage therapy; Regimen; Randomized controlled trial; Chemotherapy regimen; Surgery; Chemotherapy","score_opus":0.01974977082148697,"score_gpt":0.32062873502946165,"score_spread":0.30087896420797466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1568498224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923953,0.0006421042,0.00015143178,0.001839501,0.0009033644,0.0034873744,0.000017379196,0.000052622723,0.0005109635],"genre_scores_gemma":[0.99469095,0.0026938308,0.00017638943,0.00052061223,0.0006351961,0.0006225785,0.00004611838,0.000057443416,0.00055689685],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978325,0.00025288682,0.0005806818,0.0004529583,0.00046022038,0.00042077937],"domain_scores_gemma":[0.9976511,0.0007815555,0.00027022112,0.00048831734,0.0006405592,0.00016822186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006652882,0.00027875867,0.001057816,0.00033170436,0.00007809807,0.000011306001,0.00016083832,0.00017243596,0.00023439415],"category_scores_gemma":[0.0018087302,0.0001945549,0.00018531678,0.00046747387,0.00034815006,0.0001503856,0.00005923492,0.00055131875,0.000013230321],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97975326,0.00081530126,0.00020904483,0.00012755512,0.00029099293,0.000028954588,0.0031574997,0.00008022294,0.0025766087,0.00001767365,0.0017834082,0.011159482],"study_design_scores_gemma":[0.9683113,0.015248777,0.00010783401,0.0008872268,0.00012361242,0.0000072467783,0.00043805357,0.005666936,0.0070592533,0.000007800862,0.0019484522,0.00019347349],"about_ca_topic_score_codex":0.0031218678,"about_ca_topic_score_gemma":0.001356018,"teacher_disagreement_score":0.014433476,"about_ca_system_score_codex":0.00065712765,"about_ca_system_score_gemma":0.00039823336,"threshold_uncertainty_score":0.79337186},"labels":[],"label_agreement":null},{"id":"W1579043925","doi":"10.1002/9781119252863.ch3","title":"The genetics of acute myeloid leukemias","year":2019,"lang":"nl","type":"other","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"","keywords":"Myeloid leukemia; Genetics; Myeloid leukaemia; Myeloid; Biology; Medicine; Computational biology; Cancer research","score_opus":0.019036239782909328,"score_gpt":0.29819852082465625,"score_spread":0.27916228104174695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1579043925","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014883255,0.014773011,0.00022315665,0.002150808,0.0018080731,0.0026045786,0.00016609268,0.00008023312,0.97670573],"genre_scores_gemma":[0.0011522691,0.053466983,0.0011132277,0.0005707265,0.0013912034,0.0000406955,0.000077923745,0.00066997594,0.941517],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945638,0.00028596437,0.0011152182,0.0009073615,0.0017231578,0.0014044862],"domain_scores_gemma":[0.9943957,0.00083654193,0.00064526853,0.0032049525,0.00049343373,0.00042412113],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001024316,0.00083540624,0.0014629825,0.0003842277,0.00017416793,0.00007746789,0.0017646544,0.0012874317,0.030933702],"category_scores_gemma":[0.0002323591,0.0005010226,0.00056401885,0.00061941677,0.0010952273,0.000037709946,0.00085852924,0.0018705069,0.09639832],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003568063,0.00008660638,0.0007263489,0.00051342085,0.00376428,0.000099037425,0.000106183696,0.000003115329,0.0041917795,0.0021205011,0.97241026,0.015621637],"study_design_scores_gemma":[0.0030583204,0.00071372074,0.00084995735,0.00051335944,0.0012116309,0.00009044235,0.00047869998,0.0009222997,0.006497775,0.00005636548,0.9850972,0.00051020004],"about_ca_topic_score_codex":0.0005122039,"about_ca_topic_score_gemma":0.000026643644,"teacher_disagreement_score":0.065464616,"about_ca_system_score_codex":0.001160084,"about_ca_system_score_gemma":0.0044239974,"threshold_uncertainty_score":0.9997441},"labels":[],"label_agreement":null},{"id":"W1584887708","doi":"10.1111/j.1365-2141.2011.08586.x","title":"Regulation of the adaptor molecule LAT2, an <i>in vivo</i> target gene of AML1/ETO (<i>RUNX1/RUNX1T1</i>), during myeloid differentiation","year":2011,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Albert-Ludwigs-Universität Freiburg","keywords":"RUNX1; Biology; Myeloid; RUNX1T1; Downregulation and upregulation; Cancer research; Transcription factor; Retinoic acid; Molecular biology; Immunology; Gene expression; Gene; Genetics","score_opus":0.016897106971341534,"score_gpt":0.24438462493283045,"score_spread":0.22748751796148892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1584887708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99794465,0.0007158121,0.00032136135,0.00017613624,0.00014680786,0.0002895579,0.000019536019,0.000008345678,0.00037778274],"genre_scores_gemma":[0.9964708,0.0002528055,0.0029794828,0.0000621371,0.00008504606,0.0000052411024,0.00000576495,0.00003178435,0.000106922416],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976493,0.00031638215,0.0010385582,0.00019208736,0.0004894812,0.0003141829],"domain_scores_gemma":[0.9982191,0.00005445484,0.00081203645,0.00031154702,0.00046803168,0.00013485353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051525474,0.00013871706,0.0007531255,0.0002687062,0.00005189071,0.000008134452,0.00032876167,0.00018620843,0.00020777337],"category_scores_gemma":[0.0002730175,0.00012527767,0.00019312896,0.000295326,0.00021001404,0.00021478659,0.0000991738,0.0004543129,0.0000013842371],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011550797,0.0006732401,0.060991425,0.0003891418,0.00018171305,0.0025570851,0.00080966303,0.00005544799,0.9317773,0.00032151994,0.0005577368,0.0005306538],"study_design_scores_gemma":[0.0024316728,0.0002383183,0.39846075,0.000387189,0.00006639357,0.024109324,0.00012731194,0.00020772859,0.5734876,0.0003833721,0.000016195614,0.00008417423],"about_ca_topic_score_codex":0.00025026724,"about_ca_topic_score_gemma":0.00016148409,"teacher_disagreement_score":0.35828972,"about_ca_system_score_codex":0.0001262024,"about_ca_system_score_gemma":0.00026681088,"threshold_uncertainty_score":0.51086754},"labels":[],"label_agreement":null},{"id":"W1600365609","doi":"10.1182/blood-2015-01-621664","title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1149,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre; CancerCare Manitoba","funders":"","keywords":"Azacitidine; Medicine; Internal medicine; Hypomethylating agent; Phases of clinical research; Complete remission; Oncology; Clinical trial; Chemotherapy","score_opus":0.01641405087413181,"score_gpt":0.2939353942663254,"score_spread":0.2775213433921936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1600365609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99688816,0.000028800385,0.000018963361,0.00015195899,0.000044612923,0.0011747357,0.00016242299,0.00002465885,0.0015057075],"genre_scores_gemma":[0.9981484,0.0000029625642,0.00060935033,0.00005822153,0.000094776995,0.0001237099,0.00061533967,0.00003300754,0.00031427835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802595,0.00006498583,0.0002826683,0.0003227404,0.001056536,0.0002471099],"domain_scores_gemma":[0.9984392,0.00007580867,0.00012425183,0.00028860752,0.0008639288,0.00020819629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012616522,0.00016941027,0.00031416913,0.0002525866,0.000022757356,0.000013149765,0.00016283413,0.000056001852,0.000526542],"category_scores_gemma":[0.00014130214,0.00012480558,0.000030117062,0.0002836834,0.00009718516,0.000108648834,0.00007820658,0.00023230354,0.000021654958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033498518,0.016133394,0.9712701,0.00006164056,0.00045709673,0.00067509117,0.004045264,0.00002779384,0.000097375116,0.00001641992,0.003370305,0.00049565884],"study_design_scores_gemma":[0.28852716,0.013700557,0.6884015,0.00042027913,0.00024601756,0.000039312075,0.005803185,0.0000792838,0.0008877475,0.0000032089843,0.0016539397,0.00023777783],"about_ca_topic_score_codex":0.0001375865,"about_ca_topic_score_gemma":0.00014615148,"teacher_disagreement_score":0.28517732,"about_ca_system_score_codex":0.0002004985,"about_ca_system_score_gemma":0.000449096,"threshold_uncertainty_score":0.5765266},"labels":[],"label_agreement":null},{"id":"W1606682320","doi":"10.1038/bmt.2015.165","title":"Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2","year":2015,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Transplantation; Cumulative incidence; Hematopoietic cell; Hematopoietic stem cell transplantation; Proportional hazards model; Incidence (geometry); Young adult; Retrospective cohort study; Gastroenterology; Surgery; Confidence interval; Haematopoiesis; Stem cell","score_opus":0.018026374442588495,"score_gpt":0.2510863650757224,"score_spread":0.2330599906331339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1606682320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961947,0.00026762477,0.0006824968,0.00020557456,0.000029472598,0.002417701,0.0000798153,0.000033138524,0.000089476416],"genre_scores_gemma":[0.99613047,0.0006871505,0.0017179286,0.00007663406,0.000010182503,0.00018705871,0.0011162836,0.00004308673,0.00003118956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998211,0.000110245695,0.00042423568,0.00043104318,0.00041384436,0.00040959794],"domain_scores_gemma":[0.9991005,0.0002487921,0.00012613159,0.00012925587,0.00013222842,0.0002630636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023770404,0.0002336421,0.0003570139,0.00035111373,0.00005763134,0.000034909976,0.000035984685,0.00013490711,0.0000032410755],"category_scores_gemma":[0.000070558766,0.00020172604,0.000025420451,0.0002866568,0.000076032695,0.0001786957,0.000008677259,0.00020791846,0.0000012762202],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009040275,0.0003843872,0.975736,0.003624052,0.00001609272,0.00040901772,0.006508376,0.00011756303,0.0027125615,0.000018081842,0.000033269505,0.001400303],"study_design_scores_gemma":[0.028507123,0.0023363987,0.9619003,0.0021444487,0.00018662654,0.00008691009,0.0009623476,0.00065443653,0.0026274768,0.00026497588,0.000016666272,0.00031231449],"about_ca_topic_score_codex":0.00013579288,"about_ca_topic_score_gemma":0.00097460323,"teacher_disagreement_score":0.019466849,"about_ca_system_score_codex":0.00023302183,"about_ca_system_score_gemma":0.00025797996,"threshold_uncertainty_score":0.8226149},"labels":[],"label_agreement":null},{"id":"W1606797829","doi":"10.1002/9780470910085.ch7","title":"Use of Flow Cytometry to Study Drug Target Inhibition in Laboratory Animals and in Early‐Phase Clinical Trials","year":2010,"lang":"en","type":"other","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Flow cytometry; Drug; Pharmacology; Drug trial; Clinical trial; Medicine; Chemistry; Internal medicine; Immunology","score_opus":0.10958744229442587,"score_gpt":0.4582945108898538,"score_spread":0.34870706859542794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1606797829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991367,0.00025459577,0.000044256976,0.00027690307,0.00014271909,0.0042750365,0.00031629717,0.000049465423,0.003273719],"genre_scores_gemma":[0.87197113,0.0005487682,0.029833237,0.0009696973,0.0012543957,0.00029434753,0.00011749667,0.0008119429,0.094198994],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9949973,0.0017113654,0.0016550691,0.00067490333,0.00060662837,0.0003547342],"domain_scores_gemma":[0.9972141,0.0013322163,0.00032519014,0.0006183788,0.0001502702,0.0003598693],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010112822,0.00031480275,0.0020871696,0.0023405934,0.000010858069,0.000029541194,0.00009966177,0.0007245732,0.0024618674],"category_scores_gemma":[0.00851642,0.00025196705,0.00010120818,0.0011933869,0.00013248481,0.000057778205,0.00019687814,0.0014706658,0.00006462744],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009745781,0.009390597,0.44306862,0.0005647208,0.0005583497,0.002464495,0.0014194287,0.0000011219026,0.035171587,0.000019012801,0.48594195,0.011654309],"study_design_scores_gemma":[0.1789779,0.014670879,0.48857534,0.00417877,0.0007730824,0.00004096089,0.0030427682,0.00055541086,0.02484836,0.00006763094,0.2816176,0.0026512742],"about_ca_topic_score_codex":0.0014929792,"about_ca_topic_score_gemma":0.0021086934,"teacher_disagreement_score":0.20432435,"about_ca_system_score_codex":0.00013196183,"about_ca_system_score_gemma":0.00053216954,"threshold_uncertainty_score":0.99999326},"labels":[],"label_agreement":null},{"id":"W1608094604","doi":"10.1016/j.leukres.2015.04.018","title":"Identification of prognostic subgroups among acute myeloid leukemia patients with intermediate risk cytogenetics using a flow-cytometry-based assessment of ABC-transporter function","year":2015,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Cytogenetics; Mitoxantrone; Internal medicine; Myeloid leukemia; NPM1; Oncology; Medicine; Leukemia; Multivariate analysis; Flow cytometry; Chemotherapy; Biology; Immunology; Karyotype; Gene; Chromosome; Genetics","score_opus":0.0411452183642174,"score_gpt":0.34695582293462646,"score_spread":0.30581060457040904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1608094604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96232516,0.000065074746,0.03445909,0.00003685802,0.00015487666,0.002488752,0.00022102604,0.000065693996,0.00018345386],"genre_scores_gemma":[0.99150914,0.00006453256,0.0072168433,0.000027301116,0.00014568024,0.0001730641,0.0005686926,0.00013632116,0.00015842298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9916186,0.000731849,0.0014057053,0.00090228295,0.004245983,0.0010955821],"domain_scores_gemma":[0.9922263,0.0005028674,0.00070102065,0.0013370982,0.0045382194,0.0006945103],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0041751126,0.0004323176,0.0008827051,0.0018504224,0.00019748141,0.0000739496,0.00059709203,0.0004150194,0.000065227854],"category_scores_gemma":[0.0008263692,0.0003599454,0.0002091023,0.0029318926,0.0012493711,0.0003479995,0.00020654513,0.0017779561,0.000023484721],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0034281702,0.00042327313,0.9585787,0.00068861904,0.00054201786,0.00007205199,0.0004186399,0.0053926883,0.027797187,0.000012604096,0.00027193624,0.0023741063],"study_design_scores_gemma":[0.009744618,0.002767296,0.8000932,0.00045452395,0.0005827889,0.000007752063,0.00031329936,0.16152978,0.0241311,0.000052350602,0.00003441339,0.00028888253],"about_ca_topic_score_codex":0.00081165874,"about_ca_topic_score_gemma":0.00009864649,"teacher_disagreement_score":0.1584855,"about_ca_system_score_codex":0.006959019,"about_ca_system_score_gemma":0.008776146,"threshold_uncertainty_score":0.99988526},"labels":[],"label_agreement":null},{"id":"W1609956234","doi":"10.1002/stem.1776","title":"Targeting the bHLH Transcriptional Networks by Mutated E Proteins in Experimental Glioma","year":2014,"lang":"en","type":"article","venue":"Stem Cells","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children’s Health Research Institute; Western University","funders":"Universität Zürich; Institut National de la Santé et de la Recherche Médicale","keywords":"Biology; Transcription factor; Cell biology; Glioma; Cancer research; Downregulation and upregulation; OLIG2; Gene; Genetics; Neuroscience; Oligodendrocyte","score_opus":0.013237322771412239,"score_gpt":0.26030244532014396,"score_spread":0.24706512254873172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1609956234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99190104,0.0012526135,0.0022386992,0.0010043298,0.0001632766,0.0011658547,0.000007332839,0.000060267113,0.0022065819],"genre_scores_gemma":[0.99749386,0.000013787258,0.00021891973,0.000337975,0.0002244957,0.00011493485,0.00004044551,0.000032763422,0.0015228278],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984887,0.00019093353,0.0002680935,0.0002630623,0.0003699887,0.00041916946],"domain_scores_gemma":[0.9994866,0.000095252275,0.00004448213,0.00021666022,0.000042277672,0.00011471004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058933825,0.00014560204,0.0002036204,0.00006922221,0.000095272975,0.000028143242,0.00016960144,0.000103315346,0.00027953647],"category_scores_gemma":[0.000009977041,0.00010047898,0.00006325537,0.00028410938,0.000106183004,0.000058332946,0.000038674036,0.00041582892,0.00009036357],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018137322,0.00011441526,0.00024515993,0.00002444519,0.000022749657,0.00003788119,0.0005842582,0.00031625142,0.9875706,0.00009379269,0.009789764,0.0010193507],"study_design_scores_gemma":[0.004558681,0.0004597014,0.00050262694,0.00011012196,0.000019133047,0.00005260286,0.0016628478,0.09691865,0.8673716,0.000017124887,0.028070662,0.0002562484],"about_ca_topic_score_codex":0.000113883885,"about_ca_topic_score_gemma":0.0000043498353,"teacher_disagreement_score":0.12019896,"about_ca_system_score_codex":0.00023040616,"about_ca_system_score_gemma":0.000073605326,"threshold_uncertainty_score":0.4097414},"labels":[],"label_agreement":null},{"id":"W1610042796","doi":"10.1182/blood.v122.21.2153.2153","title":"The Modified Pre-Transplant EBMT Risk Score Is Superior To The HCT-CI Score In Predicting Overall Survival and Non-Relapse Mortality After Allogeneic Hematopoietic Cell Transplantation In Patients With Acute Myeloid Leukemia","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Transplantation; Univariate analysis; Hematopoietic stem cell transplantation; Hematopoietic cell; Single Center; Gastroenterology; Surgery; Multivariate analysis; Haematopoiesis; Stem cell","score_opus":0.009088373344935492,"score_gpt":0.23278313764684783,"score_spread":0.22369476430191235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1610042796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957335,0.00018761143,0.00008864244,0.0003358632,0.000060856135,0.003189424,0.00023740396,0.000032228163,0.00013446661],"genre_scores_gemma":[0.99806654,0.00067613984,0.00012838044,0.00022555323,0.00006322141,0.000584895,0.00008849469,0.000058581325,0.000108172884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971373,0.00021040149,0.0005591049,0.00060743315,0.0007760641,0.00070969475],"domain_scores_gemma":[0.9986893,0.00020562287,0.00010510676,0.00062958547,0.00012508353,0.0002453272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005962312,0.00036207712,0.00044840292,0.00014622403,0.0001872713,0.000104106504,0.0003046852,0.00018589344,0.00002980098],"category_scores_gemma":[0.00003075654,0.00020700581,0.000077053104,0.0003802134,0.00015817281,0.00020224541,0.0000756295,0.0007591067,0.000022947082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001675972,0.00024344081,0.9890087,0.00022573714,0.00017593977,0.00013924131,0.006659383,0.00012054723,0.0014307947,0.000002448139,0.000031116386,0.00028666243],"study_design_scores_gemma":[0.010049325,0.00046164042,0.9840758,0.00037228156,0.00042624032,0.00003397746,0.00021700557,0.00075528433,0.0033410643,0.000019653224,0.000005584689,0.00024217254],"about_ca_topic_score_codex":0.0039679967,"about_ca_topic_score_gemma":0.0027469678,"teacher_disagreement_score":0.008373354,"about_ca_system_score_codex":0.00020484273,"about_ca_system_score_gemma":0.00032541784,"threshold_uncertainty_score":0.84414524},"labels":[],"label_agreement":null},{"id":"W1613210947","doi":"","title":"Cellular Responses to Anthracyclines Identify Ku70, a DNA Repair Factor that Changes Compartment and Remains Stable in Leukemic Cells","year":2013,"lang":"en","type":"article","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"Daunorubicin; Ku70; Myeloid leukemia; Anthracycline; Doxorubicin; DNA repair; Biology; Cancer research; DNA damage; Gene; Leukemia; DNA; Immunology; Genetics; Chemotherapy; Cancer","score_opus":0.05406232079053538,"score_gpt":0.33321988599491487,"score_spread":0.2791575652043795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1613210947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891057,0.0005231346,0.00008624936,0.006935107,0.000121004065,0.0020722512,0.000029863164,0.00020581445,0.0009208495],"genre_scores_gemma":[0.96706486,0.0005269705,0.002940238,0.001402407,0.00013296555,0.00019082532,0.000023230315,0.000050912426,0.02766761],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974683,0.0001937091,0.0003865834,0.0006351048,0.0005665498,0.00074974186],"domain_scores_gemma":[0.9982297,0.00038313444,0.00007141426,0.0006774713,0.00014672807,0.00049156597],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054974714,0.00029987254,0.0005889731,0.0005468593,0.00009694721,0.00009027705,0.00017974572,0.00014770073,0.0012250047],"category_scores_gemma":[0.00022734937,0.00023388103,0.00007923791,0.0004006447,0.00013248906,0.00022065552,0.0002993984,0.0003296437,0.00052732334],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004635611,0.00018440823,0.07417702,0.0002194692,0.0000618614,0.00022134728,0.0010744038,0.000002280668,0.8793457,0.00003491029,0.043502357,0.00071266433],"study_design_scores_gemma":[0.002872351,0.0006253155,0.2722424,0.0002706427,0.000038995106,0.00004478203,0.00266498,0.0013293789,0.69878584,0.000049940627,0.020664133,0.00041128075],"about_ca_topic_score_codex":0.001790314,"about_ca_topic_score_gemma":0.00097383617,"teacher_disagreement_score":0.19806537,"about_ca_system_score_codex":0.0006267926,"about_ca_system_score_gemma":0.00024212155,"threshold_uncertainty_score":0.999688},"labels":[],"label_agreement":null},{"id":"W1622378427","doi":"10.1002/cyto.a.22628","title":"Single‐cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3‐ITD‐mutated AML stem/progenitor cells","year":2015,"lang":"en","type":"article","venue":"Cytometry Part A","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Custom Security Industries (Canada); Integrity Testing Laboratory (Canada); University of Toronto","funders":"National Cancer Institute; National Institutes of Health","keywords":"Biology; Stem cell; Progenitor cell; Mass cytometry; PI3K/AKT/mTOR pathway; Ex vivo; Myeloid leukemia; Flow cytometry; Cancer research; Cell biology; Myeloid; CD34; Molecular biology; Signal transduction; Phenotype; In vivo; Biochemistry; Genetics","score_opus":0.06709867804722308,"score_gpt":0.3096014800967691,"score_spread":0.242502802049546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1622378427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881629,0.0022395842,0.0020036874,0.00040570795,0.0008843729,0.001839921,0.00008122959,0.00030533315,0.0040772962],"genre_scores_gemma":[0.9882536,0.0000611832,0.0036897375,0.00030179118,0.0010908517,0.00014319515,0.0001531286,0.00020538614,0.0061011096],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9933319,0.0007856909,0.0012948477,0.0011863164,0.0018161092,0.0015851445],"domain_scores_gemma":[0.9956485,0.00067608093,0.00034562207,0.001084816,0.0009153574,0.0013296101],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033095747,0.0006989659,0.001450318,0.0019970208,0.00013604853,0.00017690538,0.0005998919,0.00060638797,0.0003333713],"category_scores_gemma":[0.0008195194,0.0006580038,0.00025936536,0.005382678,0.00027728977,0.00037248657,0.00029395442,0.0015735497,0.0013604731],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009788406,0.0006560546,0.057374727,0.0003716362,0.00023481347,0.0018668589,0.00097416696,0.0000942401,0.93186116,0.000013146404,0.004843883,0.00073046266],"study_design_scores_gemma":[0.0071832202,0.0010961231,0.0007346227,0.000317936,0.00017920238,0.00009579465,0.0032862858,0.0014769018,0.9783116,0.00008720543,0.006452103,0.00077900215],"about_ca_topic_score_codex":0.000053474716,"about_ca_topic_score_gemma":0.0000054910943,"teacher_disagreement_score":0.056640103,"about_ca_system_score_codex":0.0022127086,"about_ca_system_score_gemma":0.001013443,"threshold_uncertainty_score":0.9995871},"labels":[],"label_agreement":null},{"id":"W1716931544","doi":"10.1016/j.jmoldx.2015.06.004","title":"Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes","year":2015,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; Vancouver Coastal Health Research Institute","keywords":"IDH2; Myeloid leukemia; IDH1; Myelodysplastic syndromes; Myeloid; Biology; Cancer research; Computational biology; Mutation; Genetics; Gene; Immunology; Bone marrow","score_opus":0.0366237940418235,"score_gpt":0.28206296034247086,"score_spread":0.24543916630064735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1716931544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850928,0.0041072816,0.010093498,0.00031212208,0.00012318375,0.00022734287,0.00001585528,0.0000074540235,0.00002042712],"genre_scores_gemma":[0.99419576,0.0020255432,0.003518455,0.0001049774,0.00008219199,0.0000057626603,0.000025751087,0.000027545844,0.000014043139],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99835324,0.00013375623,0.0005922782,0.00016559754,0.0005339913,0.00022114345],"domain_scores_gemma":[0.99842817,0.00033730746,0.00030079336,0.00012276854,0.00051031326,0.00030065756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000561835,0.00015812891,0.00039966143,0.0004225104,0.000042325584,0.000042596206,0.000061752085,0.00014997915,0.0000037595128],"category_scores_gemma":[0.0031380083,0.00014558496,0.000049780458,0.0003437824,0.0001348304,0.00023858939,0.000051785868,0.00046747754,0.0000014382058],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013489308,0.00003648622,0.002581595,0.00006467684,0.00016428989,0.0012794022,0.00052638893,0.0013095456,0.9906751,0.000020799758,0.00051696494,0.0026898896],"study_design_scores_gemma":[0.009018529,0.0033178646,0.013953356,0.0005700187,0.00099942,0.008657843,0.0014619807,0.051433988,0.9093956,0.00055646297,0.0002539486,0.00038099638],"about_ca_topic_score_codex":0.00007973648,"about_ca_topic_score_gemma":0.00002314955,"teacher_disagreement_score":0.08127948,"about_ca_system_score_codex":0.0009021464,"about_ca_system_score_gemma":0.0010191235,"threshold_uncertainty_score":0.5936782},"labels":[],"label_agreement":null},{"id":"W173867029","doi":"","title":"Detecting and characterizing fusions and tandem duplications in acute myeloid leukemia transcriptome assemblies using Barnacle","year":2012,"lang":"en","type":"dissertation","venue":"Summit (Simon Fraser University)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Foundation; Provincial Health Services Authority; Michael Smith Health Research BC; Genome British Columbia; Canadian Institutes of Health Research; Canada's Michael Smith Genome Sciences Centre; Genome Canada","keywords":"Transcriptome; Myeloid leukemia; Barnacle; Computational biology; Biology; Tandem; Bioinformatics; Genetics; Cancer research; Engineering; Ecology; Gene","score_opus":0.02316117815865903,"score_gpt":0.2725622304133126,"score_spread":0.2494010522546536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W173867029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954784,0.0006941625,0.000069303656,0.00019055756,0.00015069506,0.0006570965,0.000047771755,0.000090938134,0.002621054],"genre_scores_gemma":[0.9912527,0.0019416795,0.00054734765,0.00006919529,0.000117800424,0.0000050471835,0.00046745825,0.00007856442,0.0055201612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980286,0.00010308855,0.00032059464,0.00062173174,0.00032264294,0.0006033863],"domain_scores_gemma":[0.99875283,0.00014137418,0.00019142982,0.00035516356,0.00016992545,0.00038926816],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025360548,0.00039723548,0.00062054966,0.0015348118,0.00045512442,0.00006818607,0.00020757325,0.00057761127,0.000074005235],"category_scores_gemma":[0.00007365294,0.00045535655,0.0001116029,0.0011036998,0.0001145145,0.0005782327,0.00010388199,0.0011752294,0.000009411162],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007802619,0.00012433006,0.81326133,0.0006991657,0.000511421,0.00057570654,0.0011973213,0.0000052673186,0.16993119,0.00019937177,0.0003328203,0.012381803],"study_design_scores_gemma":[0.007561333,0.00028568268,0.81545126,0.0020072812,0.002571435,0.0000032590851,0.106801964,0.0024008765,0.022336468,0.000054147564,0.03884959,0.00167669],"about_ca_topic_score_codex":0.0007893899,"about_ca_topic_score_gemma":0.021479419,"teacher_disagreement_score":0.14759472,"about_ca_system_score_codex":0.0012064311,"about_ca_system_score_gemma":0.0006056373,"threshold_uncertainty_score":0.99978983},"labels":[],"label_agreement":null},{"id":"W1739197012","doi":"10.1182/blood.v114.22.788.788","title":"Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Chemotherapy; Cytarabine; Oncology; Randomized controlled trial; Chemotherapy regimen; Surgery; Adverse effect","score_opus":0.012123361364622977,"score_gpt":0.27660090809294163,"score_spread":0.26447754672831864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1739197012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990846,0.00012647595,0.00006610866,0.0024489134,0.0001103664,0.005047706,0.0004331048,0.000044349108,0.00087701716],"genre_scores_gemma":[0.99605536,0.0002681471,0.0018773588,0.00036910264,0.00020268084,0.00016491352,0.0006297242,0.00004149037,0.00039123461],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99744505,0.00015217566,0.0010321031,0.000446078,0.000509697,0.0004149134],"domain_scores_gemma":[0.9976988,0.0012101596,0.00030220745,0.0005097133,0.00013480788,0.00014432803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010688711,0.0002258127,0.0011748169,0.00016166159,0.000041993248,0.00001379496,0.00020480747,0.00022395884,0.00003127456],"category_scores_gemma":[0.0033796453,0.00018034056,0.00032836772,0.0002789521,0.00008906554,0.000060538783,0.000024520998,0.00027505207,0.000006801807],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9719023,0.0034895146,0.0004431728,0.000023591074,0.00020938131,0.000023022194,0.000856519,5.408504e-7,0.013502955,0.000011275243,0.007579465,0.0019582708],"study_design_scores_gemma":[0.95474887,0.0022417922,0.0018509257,0.00015721735,0.00020010222,0.0000011340942,0.000036528632,0.00015545066,0.038650658,0.00017394993,0.0016258165,0.00015757326],"about_ca_topic_score_codex":0.00041468907,"about_ca_topic_score_gemma":0.000047609636,"teacher_disagreement_score":0.025147703,"about_ca_system_score_codex":0.0001151269,"about_ca_system_score_gemma":0.0001998256,"threshold_uncertainty_score":0.7354075},"labels":[],"label_agreement":null},{"id":"W1741176048","doi":"10.1111/j.1365-2141.2011.08872.x","title":"T cells of patients with myelodysplastic syndrome are frequently derived from the malignant clone","year":2011,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency; BC Children's Hospital","funders":"National Institute of Dental and Craniofacial Research; Canadian Institutes of Health Research; Michael Smith Health Research BC; Genome Canada; Leukemia and Lymphoma Society","keywords":"Biology; Progenitor cell; Stem cell; CD34; clone (Java method); Myeloid; Myelodysplastic syndromes; Cancer research; Immunology; Bone marrow; Molecular biology; Genetics; DNA","score_opus":0.01710947392432581,"score_gpt":0.22225848332022255,"score_spread":0.20514900939589675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1741176048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997509,0.0011675294,0.00037181497,0.00024299581,0.00019602028,0.0002911958,0.00008543227,0.000008578754,0.00012741238],"genre_scores_gemma":[0.996839,0.00025096885,0.0025531938,0.0002278981,0.000043659573,0.0000046748937,0.0000124231965,0.000034075136,0.000034140434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980277,0.00020764548,0.000712946,0.00018665603,0.00050858443,0.00035647338],"domain_scores_gemma":[0.9978139,0.00029582015,0.00074372324,0.00026397142,0.00068205025,0.00020056366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026529294,0.00015426773,0.0008891453,0.00011356792,0.000069645015,0.000013309501,0.0003733292,0.00013910788,0.00058472395],"category_scores_gemma":[0.00027071623,0.00010731375,0.00012945247,0.0001719483,0.00046616787,0.00010879478,0.00008505145,0.00058838475,0.000027536707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004257383,0.0016984517,0.63933283,0.00039234688,0.0021553056,0.3305642,0.001331477,0.000006290662,0.008545337,0.00011465547,0.008725953,0.0028757479],"study_design_scores_gemma":[0.0054008504,0.0012842568,0.86363095,0.0014953635,0.00035519226,0.117836796,0.00039377582,0.000008318909,0.009123675,0.00022063528,0.00010937274,0.00014082222],"about_ca_topic_score_codex":0.0004997678,"about_ca_topic_score_gemma":0.000092318915,"teacher_disagreement_score":0.2242981,"about_ca_system_score_codex":0.00007882537,"about_ca_system_score_gemma":0.0003064202,"threshold_uncertainty_score":0.6402317},"labels":[],"label_agreement":null},{"id":"W1789365696","doi":"10.1186/1471-2407-10-516","title":"Clinical characteristics and outcomes of patients with acute myelogenous leukemia admitted to intensive care: a case-control study","year":2010,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton","funders":"Fondation pour la Recherche Médicale","keywords":"Medicine; Intensive care unit; Internal medicine; Univariate analysis; Mechanical ventilation; SOFA score; Sepsis; Renal replacement therapy; SAPS II; Retrospective cohort study; Intensive care medicine; APACHE II; Multivariate analysis","score_opus":0.022018360183289374,"score_gpt":0.34947532912788043,"score_spread":0.32745696894459103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1789365696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99645025,0.000035225763,0.0000739872,0.00018716283,0.0003081321,0.002351291,0.00053707685,0.000030047744,0.000026825535],"genre_scores_gemma":[0.9970107,0.000012766999,0.00083571847,0.0015210912,0.00018080443,0.00016831383,0.00001919552,0.000046361747,0.00020505898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825805,0.000084614316,0.0004916588,0.00042958104,0.00039285328,0.00034323355],"domain_scores_gemma":[0.9966467,0.0003082193,0.00016569746,0.0005317958,0.0019697654,0.00037780052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023487394,0.00022341424,0.00081507687,0.00013142615,0.000066986606,0.000015963526,0.00012506114,0.00014329002,0.00009219208],"category_scores_gemma":[0.00095528486,0.00015352668,0.00007645268,0.00019496039,0.00017520909,0.000044538036,0.00012142875,0.0006213437,0.000010343018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031313335,0.00013822255,0.97877353,0.00005217818,0.00064065814,0.00080034515,0.0021634647,5.561365e-7,0.00022691081,0.0000016072852,0.00025534598,0.013815817],"study_design_scores_gemma":[0.010359301,0.0020629826,0.98450315,0.000029663663,0.00073271524,0.00011873136,0.0016211101,0.000051722498,0.000046546844,5.4286676e-7,0.00030913565,0.00016440959],"about_ca_topic_score_codex":0.0009621164,"about_ca_topic_score_gemma":0.003195135,"teacher_disagreement_score":0.013651408,"about_ca_system_score_codex":0.00029768966,"about_ca_system_score_gemma":0.0012766605,"threshold_uncertainty_score":0.62606364},"labels":[],"label_agreement":null},{"id":"W1821791817","doi":"10.1309/ajcpstu55drqegte","title":"Acute Leukemias of Ambiguous Origin","year":2015,"lang":"en","type":"review","venue":"American Journal of Clinical Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Immunophenotyping; Hematopathology; Myeloid; Medicine; Myeloid leukemia; Leukemia; Immunology; Pathology; Flow cytometry; Biology; Cytogenetics","score_opus":0.20948796338647835,"score_gpt":0.5408217317847057,"score_spread":0.33133376839822737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1821791817","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00577148,0.99048334,0.00014440417,0.00034457247,0.0008859419,0.00050296925,0.000042512613,0.000019691575,0.0018050811],"genre_scores_gemma":[0.00022279246,0.99079245,0.0058850176,0.00047144463,0.0017316958,0.000008688276,0.000027428167,0.00011494744,0.00074554584],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98977184,0.0024020125,0.005727858,0.0005143595,0.0009620234,0.0006219305],"domain_scores_gemma":[0.9875863,0.0018429041,0.0071322564,0.0009837062,0.001428685,0.0010261345],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0068187397,0.0005294287,0.012207987,0.0007183707,0.000025099886,0.000009217344,0.0009702921,0.00072972174,0.00009249341],"category_scores_gemma":[0.004615561,0.00035076807,0.0027406511,0.0009411422,0.0027241514,0.00007046289,0.00027449982,0.0046293614,0.00017458313],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069336843,0.00027138618,0.00015315785,0.0012280521,0.0014263497,0.00960574,0.00003773233,2.8316626e-7,0.0000016822778,0.000021603757,0.009600212,0.9769604],"study_design_scores_gemma":[0.0023865304,0.0112964185,0.00011075,0.0037439459,0.0049492037,0.027420048,0.00007099683,0.0000017406372,0.0000010829627,0.00006727228,0.949697,0.00025497598],"about_ca_topic_score_codex":0.000024612604,"about_ca_topic_score_gemma":0.0000013678647,"teacher_disagreement_score":0.97670543,"about_ca_system_score_codex":0.00055107253,"about_ca_system_score_gemma":0.012229595,"threshold_uncertainty_score":0.99998987},"labels":[],"label_agreement":null},{"id":"W1833477067","doi":"10.3324/haematol.2015.130898","title":"Response to comments from Drs. Alter and Rosenberg","year":2015,"lang":"en","type":"letter","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Psychoanalysis; Psychology; Gerontology; Internal medicine; Bone marrow","score_opus":0.056557573008704586,"score_gpt":0.3344096317781854,"score_spread":0.2778520587694808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1833477067","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13804837,0.0004909379,0.000027940181,0.85688853,0.00020420394,0.0009962785,0.00021400863,0.00014766025,0.0029820453],"genre_scores_gemma":[0.008407388,0.000062745734,0.0034922985,0.9708491,0.0010227099,0.00015834419,0.00074779225,0.0001020063,0.015157644],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99654853,0.0005920952,0.00043593097,0.00084660784,0.0008438095,0.0007330185],"domain_scores_gemma":[0.9972319,0.0008851038,0.00012495692,0.0010801954,0.00022042336,0.0004574072],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00066955783,0.0004629177,0.0012387874,0.00030666366,0.00009103779,0.000072530536,0.00038602488,0.001224711,0.00068162516],"category_scores_gemma":[0.0012221677,0.0003403931,0.00011416655,0.00020838407,0.00020576704,0.000047031284,0.00064266846,0.0022370878,0.0019202246],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021136836,0.000033318556,0.000641343,0.00008242559,0.00014377291,0.014714696,0.00023716869,6.53982e-8,0.00042403725,0.000003312932,0.98112994,0.00047622717],"study_design_scores_gemma":[0.001708361,0.0005212594,0.0014149188,0.00024991803,0.00010753152,0.0009391841,0.000046840705,0.000015536485,0.0004430765,0.0003158702,0.9938927,0.00034477946],"about_ca_topic_score_codex":0.0002452567,"about_ca_topic_score_gemma":0.0000064573837,"teacher_disagreement_score":0.12964098,"about_ca_system_score_codex":0.00041156454,"about_ca_system_score_gemma":0.0003552692,"threshold_uncertainty_score":0.9999048},"labels":[],"label_agreement":null},{"id":"W1855200385","doi":"10.1016/j.bbmt.2015.07.030","title":"DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation","year":2015,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Ministry of Education, Science and Technology; National Research Foundation of Korea; Chonnam National University; Ministry of Health and Welfare; National Research Foundation","keywords":"NPM1; CEBPA; Medicine; Oncology; Internal medicine; IDH1; Myeloid leukemia; Hematopoietic stem cell transplantation; Hazard ratio; Transplantation; Neuroblastoma RAS viral oncogene homolog; Mutation; Cancer research; Karyotype; Cancer; KRAS; Genetics; Biology; Gene","score_opus":0.011824167187389822,"score_gpt":0.23751606804106012,"score_spread":0.2256919008536703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1855200385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99710935,0.00018741898,0.0009968232,0.0001272604,0.00003285506,0.0010636812,0.00034460242,0.00003905952,0.0000989324],"genre_scores_gemma":[0.9953338,0.00027957963,0.0022293634,0.00014697868,0.000026827853,0.00008382045,0.0018313274,0.00003630829,0.000032032494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982834,0.00017376202,0.00037777252,0.00048567422,0.0003120667,0.0003673125],"domain_scores_gemma":[0.999106,0.000078756595,0.00015183017,0.00017750268,0.0002590286,0.00022687018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019228137,0.00029204108,0.00041908943,0.00028975564,0.000049170078,0.000015422087,0.00008689532,0.00024133807,0.000022967739],"category_scores_gemma":[0.000007271411,0.0002228328,0.000038902373,0.0002528862,0.00019267421,0.0003605114,0.000007457502,0.00023543504,0.000004496853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012875881,0.00041278286,0.9209395,0.0007049012,0.00018419565,0.0002977985,0.0042037433,0.000013217003,0.058746986,0.000009804051,0.000004437002,0.0016067694],"study_design_scores_gemma":[0.013918663,0.0054268604,0.89514625,0.0002240567,0.0010765679,0.0003181648,0.00017823365,0.00006967929,0.08331104,0.000031940683,0.0000033840277,0.00029515201],"about_ca_topic_score_codex":0.00026815402,"about_ca_topic_score_gemma":0.00039930543,"teacher_disagreement_score":0.025793232,"about_ca_system_score_codex":0.00008228967,"about_ca_system_score_gemma":0.00038788593,"threshold_uncertainty_score":0.90868574},"labels":[],"label_agreement":null},{"id":"W1865212210","doi":"10.3324/haematol.2015.126227","title":"Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype","year":2015,"lang":"en","type":"letter","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Samsung; Chonnam National University Hwasun Hospital; National Research Foundation of Korea; Kyungpook National University Hospital; Korea Research Institute of Bioscience and Biotechnology; National Research Foundation; University of Toronto; Ministry of Education, Science and Technology; Kyungpook National University; Catholic University of Korea; Chonnam National University; Dong-A University","keywords":"Myeloid leukemia; Karyotype; Medicine; Oncology; Internal medicine; Mutation; Adverse effect; Cancer research; Genetics; Biology; Gene; Chromosome","score_opus":0.013902527992961034,"score_gpt":0.26301818645545605,"score_spread":0.249115658462495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1865212210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988521,0.00011119663,0.0000043020486,0.00566301,0.00015879217,0.0030726816,0.00027001443,0.000037402053,0.002161645],"genre_scores_gemma":[0.99372274,0.00013223544,0.0002161376,0.00440791,0.00012350346,0.00019647759,0.0007927074,0.000074380725,0.0003339297],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9952756,0.0011941751,0.0011067842,0.00051349617,0.0013666427,0.00054329325],"domain_scores_gemma":[0.99458027,0.0024571165,0.0012599663,0.0010015478,0.000609069,0.00009205483],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012734135,0.0004878861,0.0017957411,0.00055529736,0.00004699847,0.0000046064356,0.0005485376,0.0010980214,0.000111175876],"category_scores_gemma":[0.0040930263,0.000280929,0.0003346314,0.0006714525,0.00057767256,0.0000668656,0.00022460605,0.0027560582,0.00009161866],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013569128,0.00056601,0.32929847,0.0064530787,0.0020857388,0.01027413,0.0012836359,0.00013605604,0.00023422543,0.000056905392,0.6333159,0.0027267148],"study_design_scores_gemma":[0.06646083,0.106554106,0.7003718,0.015865743,0.014201311,0.0031427222,0.00052739383,0.0023471517,0.06579079,0.001273459,0.020160764,0.0033039204],"about_ca_topic_score_codex":0.00030041995,"about_ca_topic_score_gemma":0.0000069097305,"teacher_disagreement_score":0.6131551,"about_ca_system_score_codex":0.00069182576,"about_ca_system_score_gemma":0.00082433363,"threshold_uncertainty_score":0.9999643},"labels":[],"label_agreement":null},{"id":"W1870122945","doi":"10.1038/leu.2015.264","title":"Clonal dynamics in a single AML case tracked for 9 years reveals the complexity of leukemia progression","year":2015,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Leukemia; Dynamics (music); Somatic evolution in cancer; Hematology; Myeloid leukemia; Oncology; Medicine; Biology; Cancer research; Internal medicine; Cancer; Psychology","score_opus":0.09765468801876845,"score_gpt":0.3593394590796658,"score_spread":0.2616847710608974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1870122945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99434274,0.00018499637,0.0002731199,0.0014288644,0.00011762723,0.0016383155,0.000094736504,0.00005393498,0.0018656345],"genre_scores_gemma":[0.98981094,0.00000837448,0.008552908,0.00028933125,0.00019993556,0.00013140021,0.00014741291,0.000053395237,0.0008062892],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9977104,0.00016874877,0.00058793044,0.00038070968,0.0005944375,0.00055776065],"domain_scores_gemma":[0.9982601,0.0003137048,0.00020456257,0.0006167557,0.00032273665,0.00028217267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013483627,0.00021788516,0.0005331716,0.0001892188,0.00007175524,0.000025828414,0.00029417014,0.00024317572,0.00002542854],"category_scores_gemma":[0.00083265314,0.00016012798,0.0001548411,0.00053014944,0.0007249696,0.0001071024,0.00015439063,0.000615947,0.00001869744],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03720716,0.0038067629,0.15650696,0.0055603483,0.0012299285,0.034304585,0.028738147,0.0020471876,0.098371655,0.07084237,0.23097277,0.33041215],"study_design_scores_gemma":[0.089186236,0.010464553,0.10685638,0.0033314978,0.00085184263,0.026609827,0.02208654,0.63812757,0.032479256,0.039055243,0.028347889,0.0026031772],"about_ca_topic_score_codex":0.0008688552,"about_ca_topic_score_gemma":0.00096353993,"teacher_disagreement_score":0.6360804,"about_ca_system_score_codex":0.008849016,"about_ca_system_score_gemma":0.0022195934,"threshold_uncertainty_score":0.99495584},"labels":[],"label_agreement":null},{"id":"W1871654462","doi":"10.4049/jimmunol.0801931","title":"Ectodomain Shedding of FLT3 Ligand Is Mediated by TNF-α Converting Enzyme","year":2009,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"National Institute of General Medical Sciences","keywords":"Ectodomain; Metalloproteinase; Haematopoiesis; Cell biology; ADAM10; Biology; Tumor necrosis factor alpha; Chemistry; Enzyme; Molecular biology; Stem cell; Receptor; Immunology; Biochemistry; Disintegrin","score_opus":0.01328591284495006,"score_gpt":0.2861136513268337,"score_spread":0.27282773848188363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1871654462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97782075,0.007445105,0.00024048841,0.013552953,0.000112707625,0.0001254152,0.000004011718,0.000010789681,0.0006877737],"genre_scores_gemma":[0.99626005,0.0017772631,0.00020137824,0.0012912105,0.000114750306,3.883116e-7,0.000002653111,0.00001530659,0.00033700815],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99827474,0.0002473882,0.00068949774,0.00008465493,0.0003566393,0.00034709263],"domain_scores_gemma":[0.9981888,0.00063037,0.0005233102,0.0002703152,0.00030833547,0.00007884653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016860975,0.0001298054,0.0005317297,0.00020796372,0.00007427684,0.000006323318,0.00040643133,0.00015106032,0.00019962335],"category_scores_gemma":[0.0008881135,0.00008008025,0.00011670564,0.0002739524,0.00024206463,0.00008491509,0.00006535102,0.0008646196,0.000024217556],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013025481,0.00007303183,0.0004904034,0.000011939501,0.00032921878,0.00006387675,0.0013670803,0.0000018699651,0.97919667,0.00002972299,0.01270583,0.004427822],"study_design_scores_gemma":[0.004867422,0.0025282989,0.005786118,0.00020009169,0.0001821872,0.0027084716,0.0012075932,0.00031082524,0.97850674,0.0003458931,0.0032501966,0.00010618709],"about_ca_topic_score_codex":0.000037178244,"about_ca_topic_score_gemma":7.370563e-7,"teacher_disagreement_score":0.018439285,"about_ca_system_score_codex":0.00018378385,"about_ca_system_score_gemma":0.000278807,"threshold_uncertainty_score":0.37563902},"labels":[],"label_agreement":null},{"id":"W187560422","doi":"10.1097/00029330-200809010-00029","title":"Expression of ETV6 rearrangement in a subject with acute myeloid leukemia-M4Eo","year":2008,"lang":"en","type":"article","venue":"Chinese Medical Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"","keywords":"ETV6; Myeloid leukemia; Cancer research; Medicine; Myeloid; Leukemia; Chromosomal translocation; Biology; Immunology; Genetics; Gene","score_opus":0.0162115412316131,"score_gpt":0.30274027372574247,"score_spread":0.28652873249412936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W187560422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916603,0.00053879933,0.00082849676,0.0031478745,0.00012723758,0.0003133877,0.000003506124,0.000029474972,0.0033509023],"genre_scores_gemma":[0.9930734,0.0024706111,0.0023843434,0.00063940993,0.000635702,0.000018539085,0.00001390569,0.000045968114,0.0007181233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99569494,0.00019075745,0.00072138396,0.00030598705,0.002514597,0.00057232514],"domain_scores_gemma":[0.9980625,0.0001954306,0.00019617133,0.00038537284,0.00024360388,0.0009169339],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012562326,0.00027043448,0.00073462597,0.0004895523,0.00013288997,0.000012300231,0.00039894602,0.00024194973,0.0012521553],"category_scores_gemma":[0.0009650268,0.00015002572,0.00015806098,0.0007789931,0.00044250727,0.000158163,0.00015637885,0.0020351354,0.000030392466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0137344515,0.0018991624,0.63378674,0.00046271653,0.000687078,0.09974735,0.0066477326,0.000056278765,0.17614217,0.000029700723,0.04103699,0.025769629],"study_design_scores_gemma":[0.046019167,0.004807389,0.7760684,0.0046238704,0.00021821308,0.12471104,0.00064885925,0.0023597118,0.03250214,0.00036688498,0.0068737017,0.00080062094],"about_ca_topic_score_codex":0.00010633335,"about_ca_topic_score_gemma":0.000029368219,"teacher_disagreement_score":0.14364003,"about_ca_system_score_codex":0.00069456943,"about_ca_system_score_gemma":0.003184071,"threshold_uncertainty_score":0.99966085},"labels":[],"label_agreement":null},{"id":"W1886638497","doi":"10.1007/s00277-015-2519-4","title":"Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?","year":2015,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; International Prognostic Scoring System; Myelodysplastic syndromes; Internal medicine; Ferritin; Erythropoiesis; Gastroenterology; Hemoglobin; Hematology; Anemia; Bone marrow","score_opus":0.08651732193006928,"score_gpt":0.3571977235027097,"score_spread":0.2706804015726404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1886638497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996904,0.00016458593,0.000027036762,0.0018841814,0.0001238502,0.0004793702,0.00002811202,0.00003061481,0.0003582299],"genre_scores_gemma":[0.9983848,0.000025608108,0.0011451903,0.00026719883,0.00002539365,0.000009233721,0.000044597757,0.000045377532,0.000052600903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977264,0.00017476395,0.00049922377,0.00039907754,0.00056326744,0.0006373024],"domain_scores_gemma":[0.9983978,0.0002158537,0.00029593747,0.0004457813,0.00036113226,0.0002834866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003276076,0.0002451001,0.00081762846,0.0003968078,0.000058679027,0.000009276136,0.00015963802,0.00019162905,0.00007963314],"category_scores_gemma":[0.0011831436,0.00020309442,0.00006963417,0.0004418997,0.00028782777,0.00011393886,0.0001336992,0.0003891356,0.0000105528425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023612645,0.0005941229,0.9898547,0.0003455732,0.00022020002,0.0005763993,0.0009278289,0.0012064812,0.0004950835,0.00015250614,0.0027617519,0.00050410983],"study_design_scores_gemma":[0.039048955,0.015221333,0.8817037,0.0031219928,0.0006436944,0.0015995352,0.0031595354,0.034642316,0.017909741,0.0008228565,0.00043716817,0.001689184],"about_ca_topic_score_codex":0.0008330573,"about_ca_topic_score_gemma":0.00007541222,"teacher_disagreement_score":0.10815099,"about_ca_system_score_codex":0.00013673928,"about_ca_system_score_gemma":0.00053509366,"threshold_uncertainty_score":0.828195},"labels":[],"label_agreement":null},{"id":"W1891681578","doi":"","title":"L’utilisation du gemtuzumab ozogamicin (Mylotarg®) pour le traitement d’un cas de leucémie myéloïde aiguë réfractaire","year":2004,"lang":"fr","type":"article","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Université de Montréal","funders":"","keywords":"Gemtuzumab ozogamicin; Gynecology; Medicine; Calicheamicin; Myeloid leukemia; CD33","score_opus":0.02007449904593993,"score_gpt":0.2850482372464084,"score_spread":0.26497373820046843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1891681578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75646,0.0051258076,0.040187623,0.15637396,0.0010516661,0.0017092011,0.00004824519,0.00032009152,0.038723394],"genre_scores_gemma":[0.94512933,0.0015709667,0.0096758865,0.0041428525,0.0026663758,0.00009126048,0.0001486025,0.00018412109,0.03639063],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9942159,0.00039517437,0.0010313136,0.0010180626,0.0011522763,0.002187289],"domain_scores_gemma":[0.9969872,0.0003713475,0.00023362218,0.0009802653,0.00042019525,0.0010073198],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0016668714,0.00071641675,0.0008294042,0.00044932144,0.00050557207,0.00012711248,0.0005684611,0.0006850561,0.0051858397],"category_scores_gemma":[0.00069425127,0.00071375864,0.0003737708,0.0007498075,0.0004676845,0.00059697515,0.000255867,0.0014008314,0.0029385558],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0023847353,0.008235696,0.016906943,0.0025021676,0.0027290697,0.0102276215,0.029573342,0.036143538,0.2065772,0.14643373,0.14768018,0.39060578],"study_design_scores_gemma":[0.06890563,0.0039133183,0.15365754,0.0024806038,0.0017346912,0.0053099575,0.042763337,0.106838085,0.43583754,0.020803938,0.15456912,0.0031862445],"about_ca_topic_score_codex":0.029073248,"about_ca_topic_score_gemma":0.0019438142,"teacher_disagreement_score":0.38741955,"about_ca_system_score_codex":0.012207503,"about_ca_system_score_gemma":0.008629153,"threshold_uncertainty_score":0.9995313},"labels":[],"label_agreement":null},{"id":"W1892702544","doi":"10.1111/j.1600-0463.2008.00780.x","title":"Acute megakaryoblastic leukemia mimicking small round cell tumor with novel t(1;5)(q21;p13). Case report","year":2008,"lang":"en","type":"article","venue":"Apmis","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Acute megakaryoblastic leukemia; Bone marrow; Pathology; Acute promyelocytic leukemia; Acute leukemia; Chromosomal translocation; Leukemia; Fine-needle aspiration; Precursor cell; Medicine; Lymph; Biopsy; Cytoplasm; Cancer research; Biology; Cell; Immunology; Cell culture; Cell biology; Gene","score_opus":0.032223162713138,"score_gpt":0.26849215420382616,"score_spread":0.23626899149068817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1892702544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97972405,0.00013953951,0.003069315,0.0006346521,0.00013242582,0.0007289598,0.00003117884,0.00022535601,0.015314498],"genre_scores_gemma":[0.9693173,0.000036391073,0.012125155,0.0016235572,0.00039928048,0.00007067633,0.0000727194,0.0001484055,0.01620649],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99687064,0.000033945416,0.00058494136,0.00084951124,0.00073087786,0.0009300719],"domain_scores_gemma":[0.9975497,0.00018499432,0.00025282515,0.0010948862,0.00037862814,0.00053896825],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033876367,0.00044418746,0.00064488075,0.00027353756,0.0003751661,0.00004903866,0.00026588663,0.00014343897,0.0001713464],"category_scores_gemma":[0.00020702566,0.0003574447,0.00015990731,0.00063232123,0.00034219286,0.00018777691,0.00019265988,0.0009147854,0.00019135607],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007663691,0.0002394177,0.005272522,0.00017371801,0.00035679934,0.9442145,0.0007498474,0.000060008086,0.03684402,0.000026495334,0.011038025,0.00025822973],"study_design_scores_gemma":[0.0061163204,0.0007679052,0.002587088,0.00013390329,0.00046748214,0.93853915,0.00039307415,0.002215777,0.0362295,0.000007951008,0.011996708,0.0005451325],"about_ca_topic_score_codex":0.001308114,"about_ca_topic_score_gemma":0.00015138809,"teacher_disagreement_score":0.010406748,"about_ca_system_score_codex":0.0013859844,"about_ca_system_score_gemma":0.002337928,"threshold_uncertainty_score":0.99988776},"labels":[],"label_agreement":null},{"id":"W1912448446","doi":"10.1182/blood.v122.21.2647.2647","title":"Early Mortality In Hyperleukocytosis In Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis","year":2013,"lang":"en","type":"review","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; University of Toronto; Hospital for Sick Children","funders":"","keywords":"Medicine; Leukapheresis; Population; Induction chemotherapy; Chemotherapy regimen; Leukemia; Randomized controlled trial; Chemotherapy; Internal medicine; Pediatrics; Surgery","score_opus":0.05904027087799214,"score_gpt":0.3314646582679944,"score_spread":0.2724243873900023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1912448446","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0068633216,0.98049355,0.0000014984439,0.000042200485,0.0000066123275,0.012219123,0.00015862074,0.000036857953,0.000178203],"genre_scores_gemma":[0.0003273391,0.9936293,0.0003068059,0.00023600462,0.000015608259,0.0043766247,0.00031564225,0.000115728275,0.00067699805],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9936522,0.0010544123,0.002252082,0.0011768413,0.0011355557,0.0007288577],"domain_scores_gemma":[0.9963177,0.00031445583,0.00086775183,0.001866888,0.000275108,0.00035809647],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0014110362,0.0009840075,0.018078871,0.0013494118,0.000042183266,0.00007798717,0.0005100227,0.0005342886,0.0002039462],"category_scores_gemma":[0.0003283965,0.0005605046,0.0017976923,0.0035918741,0.00012490767,0.00020171415,0.0002643097,0.001453966,0.00012292339],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000075792077,0.00032878335,0.002285567,0.7408225,0.2558032,0.0002584381,0.000032200533,6.716197e-8,3.1503223e-8,0.0000033709587,0.000031592033,0.00042664915],"study_design_scores_gemma":[0.0019496381,0.00021648855,0.0027021177,0.055217706,0.9387927,0.000067445064,0.000005210154,0.0000013184608,2.725316e-7,0.0000014586016,0.00056002446,0.00048561592],"about_ca_topic_score_codex":0.0010138714,"about_ca_topic_score_gemma":0.0001645735,"teacher_disagreement_score":0.6856048,"about_ca_system_score_codex":0.0009654009,"about_ca_system_score_gemma":0.0010482892,"threshold_uncertainty_score":0.99968463},"labels":[],"label_agreement":null},{"id":"W1914163760","doi":"10.1002/pbc.25437","title":"Sorafenib treatment following hematopoietic stem cell transplant in pediatric <i>FLT3</i>/ITD acute myeloid leukemia","year":2015,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"St. Baldrick's Foundation","keywords":"Sorafenib; Medicine; Myeloid leukemia; Oncology; Internal medicine; Hematopoietic stem cell transplantation; Leukemia; Dosing; Context (archaeology); Minimal residual disease; Transplantation; Hepatocellular carcinoma","score_opus":0.024689698826444433,"score_gpt":0.28523286715354873,"score_spread":0.2605431683271043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1914163760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669811,0.02690672,0.000044880257,0.0008614141,0.00074874196,0.00145676,0.00010624456,0.00023413471,0.0026599756],"genre_scores_gemma":[0.9658559,0.025891999,0.00040645548,0.00030520692,0.002626213,0.0006696078,0.0000639306,0.00017049776,0.004010192],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949347,0.00017635446,0.0009664652,0.0011022197,0.0013061285,0.0015141418],"domain_scores_gemma":[0.99747056,0.00021381727,0.00023753638,0.000830019,0.00017131738,0.0010767368],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006083183,0.0007280203,0.0012203613,0.0008444846,0.00012618612,0.000068282316,0.00045352618,0.00041280594,0.00010834619],"category_scores_gemma":[0.000020417026,0.0006212796,0.00049005885,0.0020131269,0.000054137476,0.00027171744,0.0001147726,0.0008587735,0.00030856297],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016934355,0.0020254233,0.9510456,0.0017619014,0.0008631014,0.010479978,0.01147538,0.00048300723,0.0020330085,0.00003830231,0.014733071,0.003367821],"study_design_scores_gemma":[0.4712498,0.023154624,0.1721109,0.0014713065,0.12849773,0.0053292215,0.009029609,0.0056766146,0.12409519,0.0008828882,0.042253662,0.01624845],"about_ca_topic_score_codex":0.0013777758,"about_ca_topic_score_gemma":0.00023537767,"teacher_disagreement_score":0.77893466,"about_ca_system_score_codex":0.002814063,"about_ca_system_score_gemma":0.005675313,"threshold_uncertainty_score":0.9999616},"labels":[],"label_agreement":null},{"id":"W1926600236","doi":"10.1002/gcc.22105","title":"Identification of a novel fusion gene involving <i>RUNX1</i> and the antisense strand of <i>SV2B</i> in a <i>BCR‐ABL1</i>‐positive acute leukemia","year":2013,"lang":"en","type":"article","venue":"Genes Chromosomes and Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"RUNX1; Chromosomal translocation; Fusion gene; Biology; Leukemia; breakpoint cluster region; Fusion transcript; ABL; Molecular biology; Fusion protein; Myeloid leukemia; Cancer research; Haploinsufficiency; Gene; Genetics; Phenotype; Transcription factor; Receptor; Recombinant DNA","score_opus":0.011498676373387369,"score_gpt":0.26956546496796197,"score_spread":0.2580667885945746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1926600236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97855014,0.019195205,0.000077036704,0.0009724772,0.000058845293,0.00093559915,0.00012303468,0.000009175699,0.00007846402],"genre_scores_gemma":[0.95601445,0.042991046,0.00021509068,0.00026887184,0.000081467115,0.00012376436,0.000019304687,0.00002230458,0.00026370387],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99856555,0.000057496454,0.0004831772,0.00032036914,0.0003091002,0.00026429977],"domain_scores_gemma":[0.9990525,0.0001254556,0.0002127882,0.00027929473,0.00023316107,0.00009679745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003259401,0.00017402299,0.00048952294,0.000120264696,0.00007455938,0.000030131776,0.00010480991,0.000109993656,0.000044041477],"category_scores_gemma":[0.000027484817,0.00011838367,0.000065282395,0.00032722438,0.00048907805,0.00016008847,0.00012982568,0.00017902491,0.000001019585],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040945696,0.000051667175,0.0073039928,0.00027288144,0.00014019782,0.000008910659,0.0014464014,0.0000257103,0.9768629,0.00007731862,0.00022703546,0.013173542],"study_design_scores_gemma":[0.014560509,0.00020083669,0.09414823,0.00054685486,0.00031123735,0.0001630892,0.0009642403,0.008616049,0.87987995,0.00011504968,0.00025549985,0.0002384645],"about_ca_topic_score_codex":0.0038211145,"about_ca_topic_score_gemma":0.00016472976,"teacher_disagreement_score":0.09698295,"about_ca_system_score_codex":0.00014278175,"about_ca_system_score_gemma":0.00026153182,"threshold_uncertainty_score":0.5776408},"labels":[],"label_agreement":null},{"id":"W1943598347","doi":"10.1016/j.tig.2015.05.003","title":"IKAROS: a multifunctional regulator of the polymerase II transcription cycle","year":2015,"lang":"en","type":"review","venue":"Trends in Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Biology; RNA polymerase II; General transcription factor; Transcription factor; Transcription coregulator; Transcription preinitiation complex; Transcription factor II F; Transcription (linguistics); Transcription factor II E; Cell biology; Genetics; Chromatin remodeling; Promoter; Transcriptional regulation; Gene expression; Gene","score_opus":0.08705127661855283,"score_gpt":0.38320499808548564,"score_spread":0.2961537214669328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1943598347","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013063938,0.99616146,0.000006147008,0.00019142157,0.00034740628,0.00045465215,0.00014853684,0.000020260286,0.0013637429],"genre_scores_gemma":[0.00081573764,0.98605496,0.00061201816,0.000042264277,0.00035145378,0.000074718235,0.00023670544,0.00007737033,0.011734773],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976943,0.00019817805,0.00071019144,0.00036047734,0.0007199082,0.00031691324],"domain_scores_gemma":[0.9986415,0.000047870366,0.00021523066,0.00082170917,0.000121248246,0.00015242654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037640485,0.00031431983,0.0011385779,0.0004898443,0.00005408184,0.000006852239,0.00032623147,0.0004201348,0.00027490218],"category_scores_gemma":[0.00005691346,0.00020538348,0.00048289663,0.0010701327,0.00021080639,0.000019997984,0.00014133376,0.00069574185,0.000016560234],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044644057,0.0001692699,0.000042439253,0.0020358914,0.00010559116,0.0000093046965,0.0001593519,0.000011413706,0.000059622314,0.000026154834,0.0043360284,0.99300027],"study_design_scores_gemma":[0.0014099085,0.00020153723,0.00045126965,0.0029137428,0.0006986065,0.00010804555,0.00001869195,0.0002700783,0.00007779286,0.000023700035,0.9936378,0.00018884266],"about_ca_topic_score_codex":0.000043450007,"about_ca_topic_score_gemma":0.000029891838,"teacher_disagreement_score":0.99281144,"about_ca_system_score_codex":0.00060383027,"about_ca_system_score_gemma":0.0010772906,"threshold_uncertainty_score":0.8375295},"labels":[],"label_agreement":null},{"id":"W1950612017","doi":"10.1182/blood-2015-02-629204","title":"Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Acute megakaryoblastic leukemia; Cytarabine; Internal medicine; Karyotype; Retrospective cohort study; Medicine; Gastroenterology; Leukemia; Cytogenetics; Down syndrome; Pediatrics; Chromosome; Biology; Genetics; Gene","score_opus":0.016625725144221584,"score_gpt":0.2908076055371023,"score_spread":0.2741818803928807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1950612017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99720484,0.00021440932,0.000016799826,0.00039166666,0.0001277824,0.0009837501,0.000023379363,0.0000668411,0.00097055326],"genre_scores_gemma":[0.9986913,0.000049986345,0.00041413915,0.00017162263,0.00014614534,0.0000939716,0.000017817938,0.00004424722,0.00037075992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797666,0.00008624443,0.00034024758,0.0005204991,0.0006876235,0.0003887048],"domain_scores_gemma":[0.999009,0.00007379315,0.000065920845,0.0003715599,0.00016450876,0.00031521753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033582808,0.00024152645,0.0004956225,0.00033169804,0.00004117109,0.000046726753,0.00022322919,0.00011358441,0.00003141184],"category_scores_gemma":[0.00041062193,0.00020368441,0.00006596105,0.00027803992,0.000087097695,0.00009045696,0.00029408405,0.00046568146,0.000048511254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020882425,0.0017635582,0.99247354,0.000007643012,0.00084759283,0.0019010636,0.0018286908,0.000013634418,0.00062142755,0.000018101144,0.000068771114,0.00024717933],"study_design_scores_gemma":[0.020372758,0.002001529,0.9737774,0.000029542083,0.0003351801,0.001124534,0.0005741881,0.00022555886,0.0011597791,0.00017287816,0.000028946344,0.0001976902],"about_ca_topic_score_codex":0.00017479557,"about_ca_topic_score_gemma":0.00018950409,"teacher_disagreement_score":0.020163933,"about_ca_system_score_codex":0.00072710094,"about_ca_system_score_gemma":0.00042379633,"threshold_uncertainty_score":0.8306009},"labels":[],"label_agreement":null},{"id":"W195349586","doi":"10.71781/27559","title":"Mécanisme de leucémogénèse par les oncogènes SCL et LMO1","year":2009,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Molecular biology; Biology","score_opus":0.00985445744462788,"score_gpt":0.22663335313303132,"score_spread":0.21677889568840344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W195349586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.832047,0.05513392,0.0006997013,0.0038122437,0.0017210001,0.001199842,0.00014916171,0.00043486655,0.10480229],"genre_scores_gemma":[0.84566224,0.0049358425,0.0027799718,0.0006968432,0.0011908391,0.00005738554,0.0011016189,0.0001594141,0.14341584],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99400413,0.0006570733,0.0008213037,0.0012621912,0.0016877779,0.0015675273],"domain_scores_gemma":[0.99595606,0.00043384221,0.0005741778,0.00089433533,0.0008148041,0.0013267822],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007482207,0.0010098215,0.0010822283,0.0008138773,0.009024498,0.00014309025,0.0009110921,0.0015250525,0.0002835245],"category_scores_gemma":[0.00045000904,0.0011596077,0.0007448347,0.00074018916,0.0008390894,0.0006054201,0.00028060476,0.0022298992,0.0005784291],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011976837,0.002844075,0.10983197,0.0026945632,0.0040219408,0.10625604,0.10769686,0.008368969,0.388647,0.114055656,0.022162126,0.12144397],"study_design_scores_gemma":[0.009297728,0.0015345546,0.5241269,0.004198383,0.0030645973,0.014060351,0.09585563,0.009426701,0.078677975,0.0012305815,0.2558455,0.0026811068],"about_ca_topic_score_codex":0.12781894,"about_ca_topic_score_gemma":0.018003862,"teacher_disagreement_score":0.41429493,"about_ca_system_score_codex":0.033194482,"about_ca_system_score_gemma":0.016562056,"threshold_uncertainty_score":0.999915},"labels":[],"label_agreement":null},{"id":"W1958659287","doi":"10.1111/nyas.12414","title":"Aldehyde dehydrogenases in acute myeloid leukemia","year":2014,"lang":"en","type":"review","venue":"Annals of the New York Academy of Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Myeloid leukemia; Aldehyde dehydrogenase; Haematopoiesis; Leukemia; Disease; Cancer research; Medicine; Cancer; Myeloid; Stem cell; Immunology; Acute leukemia; Oncology; Biology; Internal medicine; Gene; Genetics","score_opus":0.1503469841743599,"score_gpt":0.4229224562486562,"score_spread":0.27257547207429633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1958659287","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018843149,0.98923016,0.000002322683,0.0057846713,0.00009444785,0.0011151794,0.00003351884,0.000024500325,0.001830861],"genre_scores_gemma":[0.001008728,0.9941512,0.0005204712,0.001285106,0.00032982157,0.0000271034,0.000004976689,0.000042760046,0.0026298624],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948196,0.00040776975,0.00151164,0.00077346154,0.0016190336,0.00086853164],"domain_scores_gemma":[0.9970868,0.0008278386,0.0012319098,0.00045321937,0.000068452755,0.00033172723],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031101794,0.0005230647,0.0029313648,0.0008293186,0.00014382528,0.000026961661,0.0030912498,0.0007001403,0.000067757705],"category_scores_gemma":[0.00076139753,0.00029872856,0.0010903975,0.0030143915,0.002019942,0.00015948735,0.00065096666,0.0014744351,0.00006146039],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005805081,0.00006559769,0.00012600093,0.008725836,0.0004489871,0.0000060764014,0.00016575828,0.000026656977,0.00019705555,0.0010633027,0.10442774,0.8846889],"study_design_scores_gemma":[0.00037201808,0.00022398877,0.00012262556,0.021242816,0.00048115122,0.00012406573,0.00003259332,0.000050563962,0.0046883505,0.001093075,0.97127324,0.0002955314],"about_ca_topic_score_codex":0.00034726696,"about_ca_topic_score_gemma":0.000008170854,"teacher_disagreement_score":0.8843934,"about_ca_system_score_codex":0.00018863035,"about_ca_system_score_gemma":0.0035219453,"threshold_uncertainty_score":0.9999465},"labels":[],"label_agreement":null},{"id":"W1960760923","doi":"10.1007/s00277-015-2540-7","title":"Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant","year":2015,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"CEBPA; NPM1; Internal medicine; Myeloid leukemia; Hematopoietic stem cell transplantation; Oncology; Medicine; Chemotherapy; Hematology; Induction chemotherapy; Transplantation; Leukemia; Melphalan; Immunology; Cancer research; Biology; Karyotype; Mutation; Genetics; Gene","score_opus":0.04535198571691033,"score_gpt":0.29059420863287017,"score_spread":0.24524222291595985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1960760923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937798,0.0004861731,0.00013699305,0.0007645584,0.00018247154,0.0009918904,0.00030213935,0.00007140487,0.0032846162],"genre_scores_gemma":[0.99633336,0.00017099641,0.001057779,0.0003423347,0.00007400412,0.00010092844,0.0010713373,0.000069748654,0.0007795214],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99704176,0.00011805885,0.0006603235,0.0005934951,0.00078663486,0.00079974334],"domain_scores_gemma":[0.9974417,0.00016836422,0.0003130754,0.0005125354,0.0011007254,0.0004636172],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003201006,0.00036914696,0.0010104806,0.00025306683,0.00008119203,0.000020386455,0.00032401463,0.0003531272,0.00010897082],"category_scores_gemma":[0.000018356637,0.00029663986,0.00014002749,0.00026295445,0.00020840047,0.00023858556,0.00009224645,0.00041887874,0.00017427518],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029613629,0.0014183256,0.94423246,0.00069208245,0.0019957183,0.0015762582,0.002994114,0.00024310942,0.0077949343,0.00038700798,0.006724974,0.0023274107],"study_design_scores_gemma":[0.033298675,0.007958612,0.07632606,0.00045507774,0.0010029898,0.0004795025,0.0016319029,0.0013830716,0.87473077,0.00026492108,0.0014088886,0.0010595367],"about_ca_topic_score_codex":0.0020538145,"about_ca_topic_score_gemma":0.00023668061,"teacher_disagreement_score":0.8679064,"about_ca_system_score_codex":0.0001276659,"about_ca_system_score_gemma":0.00093852286,"threshold_uncertainty_score":0.99994856},"labels":[],"label_agreement":null},{"id":"W1963188318","doi":"10.1186/s40364-015-0041-4","title":"Paediatric acute myeloid leukaemia with the t(7;12)(q36;p13) rearrangement: a review of the biological and clinical management aspects","year":2015,"lang":"en","type":"review","venue":"Biomarker Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"Myeloid leukaemia; Medicine; Disease; Abnormality; Disease entity; Myeloid; Chromosomal translocation; Chromosomal Abnormality; Bioinformatics; Pediatrics; Pathology; Chromosome; Immunology; Karyotype; Biology; Gene; Genetics; Psychiatry","score_opus":0.2531841610977899,"score_gpt":0.47887692929504483,"score_spread":0.22569276819725492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963188318","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006923586,0.959979,0.0000034480101,0.0043446864,0.00012179055,0.009660902,0.00008044894,0.00003532413,0.025705155],"genre_scores_gemma":[0.000031101266,0.9918994,0.00022663538,0.00033399469,0.00041657165,0.0007320003,0.00012106782,0.000114965645,0.0061243027],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9869096,0.0053768135,0.0015426562,0.0013656069,0.0034960886,0.0013092299],"domain_scores_gemma":[0.9931591,0.001852249,0.0005712022,0.002828396,0.0009584831,0.00063052983],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.021027153,0.00071326486,0.0029478846,0.00060420553,0.0003389877,0.000087301814,0.0020094987,0.00066990877,0.000380123],"category_scores_gemma":[0.0012378587,0.0002836292,0.0009262684,0.0036427032,0.0027464435,0.00006665725,0.0033067653,0.0031421506,0.00025569467],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000362773,0.00017685388,0.00020775363,0.059284847,0.0023585195,0.00037662784,0.000017427818,2.1260724e-9,0.0000014177425,0.00013697427,0.18793288,0.7491439],"study_design_scores_gemma":[0.001372136,0.0008019651,0.0013900773,0.047170896,0.002665517,0.00048703054,0.000057642075,0.0000030499727,7.408112e-7,0.000029971283,0.9457259,0.00029502859],"about_ca_topic_score_codex":0.00004003136,"about_ca_topic_score_gemma":0.000013065176,"teacher_disagreement_score":0.75779307,"about_ca_system_score_codex":0.0009514191,"about_ca_system_score_gemma":0.002778726,"threshold_uncertainty_score":0.9999675},"labels":[],"label_agreement":null},{"id":"W1963542292","doi":"10.3390/cancers4041161","title":"The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)","year":2012,"lang":"en","type":"article","venue":"Cancers","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"Myeloid leukemia; Medicine; Cytarabine; Regimen; Oncology; Anthracycline; Leukemia; Internal medicine; Intensive care medicine; Bioinformatics; Cancer; Biology","score_opus":0.04788249548489562,"score_gpt":0.3353519310239755,"score_spread":0.2874694355390799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963542292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97973734,0.011470863,0.0035622146,0.0015069811,0.0004592314,0.0019038531,0.000064864485,0.00002389997,0.001270766],"genre_scores_gemma":[0.98483515,0.003786679,0.006903354,0.00012800745,0.00030423573,0.0005645865,0.000015116584,0.000034526736,0.0034283244],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989448,0.00001463744,0.00028067015,0.00011591127,0.00026819165,0.00037579617],"domain_scores_gemma":[0.9988265,0.00044686673,0.00012155342,0.00037237006,0.00014512242,0.00008757675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033678734,0.0001326382,0.00024530626,0.000038842587,0.00018946458,0.0000059964323,0.00018577384,0.000053659398,0.000026001617],"category_scores_gemma":[0.00003011237,0.00006134059,0.00012488666,0.00014478642,0.00027253572,0.000040273433,0.000024530333,0.00007240722,0.0000033955664],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004248126,0.00030421562,0.00694811,0.00026435556,0.0087501025,0.0000015136136,0.0641486,0.00016776848,0.21817744,0.0022295462,0.011028906,0.6837313],"study_design_scores_gemma":[0.0059009525,0.00074593595,0.016475271,0.000066552544,0.00045327278,0.000010396242,0.00514483,0.00082401896,0.318152,0.000016705022,0.6520521,0.00015794138],"about_ca_topic_score_codex":0.00014340694,"about_ca_topic_score_gemma":0.000053132746,"teacher_disagreement_score":0.68357337,"about_ca_system_score_codex":0.004217628,"about_ca_system_score_gemma":0.002726647,"threshold_uncertainty_score":0.999605},"labels":[],"label_agreement":null},{"id":"W1963756566","doi":"10.1080/10428190500467917","title":"Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group","year":2006,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Royal University Hospital; Toronto General Hospital; Royal Victoria Hospital; McGill University; University of Saskatchewan; University of Alberta; Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Idarubicin; Mitoxantrone; Etoposide; Cytarabine; Medicine; Internal medicine; Induction chemotherapy; Leukemia; Gastroenterology; Myeloid leukemia; Chemotherapy; Surgery","score_opus":0.015760184884850897,"score_gpt":0.2675952253422972,"score_spread":0.2518350404574463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963756566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906798,0.0038598957,0.000017951495,0.0011560513,0.00034275308,0.0029146038,0.00019943391,0.00015297024,0.00067656266],"genre_scores_gemma":[0.99271345,0.0017983625,0.00034099544,0.0006604319,0.00035951432,0.00032124828,0.0003207279,0.00018685301,0.0032984256],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9924234,0.0010479037,0.0017556392,0.0017685734,0.0013135999,0.001690889],"domain_scores_gemma":[0.9957846,0.0008488344,0.0006455752,0.0012185687,0.0007597557,0.0007426571],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020596194,0.0011584972,0.0018992637,0.0012235757,0.0010673545,0.00024347307,0.00049594167,0.000968224,0.00003614915],"category_scores_gemma":[0.0006421892,0.0009712088,0.0002147453,0.0014265821,0.0017740482,0.0005648331,0.00044816796,0.00069566886,0.000021748285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07952483,0.0014246755,0.11452924,0.0017599119,0.008050842,0.0067211613,0.03309136,0.0003148946,0.5749548,0.0039006812,0.09045508,0.085272536],"study_design_scores_gemma":[0.20938927,0.009169016,0.6411736,0.0016729569,0.0048459047,0.010847372,0.037435275,0.009284722,0.05405326,0.0012485228,0.016675504,0.004204628],"about_ca_topic_score_codex":0.3022431,"about_ca_topic_score_gemma":0.15292107,"teacher_disagreement_score":0.52664435,"about_ca_system_score_codex":0.03239385,"about_ca_system_score_gemma":0.011358444,"threshold_uncertainty_score":0.99927384},"labels":[],"label_agreement":null},{"id":"W1963793158","doi":"10.1111/j.0736-8046.2004.21408.x","title":"Aleukemic Congenital Leukemia Cutis","year":2004,"lang":"en","type":"article","venue":"Pediatric Dermatology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Medicine; Leukemia cutis; Leukemia; Infiltration (HVAC); Bone marrow; Cutis; Pathology; Lymphocytic infiltration; Dermatology; Immunology","score_opus":0.013834939601734271,"score_gpt":0.2788324193625582,"score_spread":0.26499747976082394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963793158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798059,0.0017085813,0.0006803694,0.0035244501,0.00035681453,0.00046197578,0.000013537205,0.00027565073,0.013172709],"genre_scores_gemma":[0.993959,0.0009405283,0.0019404924,0.0013735177,0.00069036015,0.00005670463,0.000061728504,0.00005673756,0.0009209128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778384,0.000060388214,0.00046323836,0.00047644024,0.00038097874,0.000835101],"domain_scores_gemma":[0.9986578,0.00014765687,0.0000982584,0.00051849266,0.00016159775,0.00041614554],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011983139,0.0002663552,0.0005363444,0.0004551381,0.00012063963,0.000020074625,0.00027204893,0.00035262614,0.0003347087],"category_scores_gemma":[0.00028143532,0.00024874,0.00016356245,0.0006581825,0.00020414882,0.00012969057,0.00016580189,0.00069976266,0.0030091016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011638219,0.00065552176,0.755642,0.0010436524,0.0007194626,0.030709118,0.0015482112,0.00016736441,0.0056271628,0.011743699,0.18449885,0.0064811157],"study_design_scores_gemma":[0.090709634,0.0020514103,0.41016975,0.000091399364,0.0037195955,0.282719,0.0011008643,0.0018726431,0.03609941,0.013513145,0.15390342,0.004049725],"about_ca_topic_score_codex":0.00022849727,"about_ca_topic_score_gemma":0.000020441834,"teacher_disagreement_score":0.34547228,"about_ca_system_score_codex":0.0013385947,"about_ca_system_score_gemma":0.0025729039,"threshold_uncertainty_score":0.9999965},"labels":[],"label_agreement":null},{"id":"W1963823009","doi":"10.1016/s0165-4608(01)00494-0","title":"Isochromosome (17)(q10) and translocation (4;12)(q12;p13) in a child with acute myeloid leukemia","year":2001,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; University of Toronto","funders":"","keywords":"Isochromosome; Chromosomal translocation; Biology; Acute myeloblastic leukemia; Myeloid leukemia; clone (Java method); Leukocytosis; Myeloid; Cytogenetics; Leukemia; Karyotype; Cancer research; Immunology; Genetics; Gene; Chromosome","score_opus":0.017851866122044098,"score_gpt":0.28394357406195025,"score_spread":0.26609170793990616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963823009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97776026,0.017124612,0.0005470947,0.0022696818,0.00004884551,0.0007175886,0.00004310015,0.00003243398,0.0014564153],"genre_scores_gemma":[0.85704565,0.13893588,0.0020008897,0.0006723049,0.0002434961,0.000109012275,0.000038113198,0.00006903296,0.00088565657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980775,0.00003848777,0.00035008916,0.00058291876,0.00038533894,0.00056567864],"domain_scores_gemma":[0.998989,0.00003078164,0.00007518043,0.00040733276,0.00013452314,0.00036321458],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014012706,0.00032300467,0.00043528582,0.00019962272,0.00012982637,0.00006049972,0.00014003212,0.00022089212,0.00008522311],"category_scores_gemma":[0.000009038394,0.0002827675,0.000041651823,0.00043006436,0.00030443398,0.00004765796,0.00007758859,0.00041225227,0.0000044920926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028759988,0.00032358608,0.5061085,0.00057837355,0.0009829464,0.0021678715,0.004547443,0.0020012672,0.08273507,0.00019779213,0.0019589725,0.39552215],"study_design_scores_gemma":[0.023923893,0.0041569555,0.7497187,0.001342153,0.0011734683,0.008090579,0.0010517563,0.022432601,0.08105474,0.00040447316,0.10467116,0.001979501],"about_ca_topic_score_codex":0.00018335154,"about_ca_topic_score_gemma":0.0008335557,"teacher_disagreement_score":0.39354265,"about_ca_system_score_codex":0.0003798379,"about_ca_system_score_gemma":0.00064686855,"threshold_uncertainty_score":0.99996245},"labels":[],"label_agreement":null},{"id":"W1963863480","doi":"10.1038/sj.bmt.1704243","title":"Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis","year":2003,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital; BC Children's Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Malignancy; Transplantation; Cumulative incidence; Internal medicine; Incidence (geometry); Population; Autologous stem-cell transplantation; Radiation therapy; Hematopoietic stem cell transplantation; Relative risk; Surgery; Risk factor; Confidence interval; Leukemia; Oncology; Gastroenterology","score_opus":0.015662182052916283,"score_gpt":0.2573365391365267,"score_spread":0.24167435708361043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963863480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919674,0.0024008965,0.0039952886,0.00009540303,0.000068855836,0.00061771134,0.00024769112,0.00007940353,0.0005273779],"genre_scores_gemma":[0.98181885,0.014740882,0.002536994,0.00010061464,0.000022041291,0.00004259576,0.00015548924,0.00003307912,0.0005494274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997996,0.0002937935,0.00041408234,0.0005379485,0.00040063818,0.0003575579],"domain_scores_gemma":[0.99907357,0.0002751417,0.00013115784,0.00023845813,0.000066379995,0.00021530339],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040842846,0.00027661864,0.0005149799,0.0003986792,0.00021096825,0.00006185239,0.000063988016,0.00018479076,0.00022529815],"category_scores_gemma":[0.000009501772,0.00024991366,0.00014410699,0.00057900057,0.00007984293,0.00027904837,0.0000045358024,0.00030585946,0.000009265595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003004682,0.0002082403,0.7783485,0.0017545008,0.0020324767,0.0034955773,0.013421079,0.00008940759,0.147064,0.00044551175,0.000049768827,0.050086237],"study_design_scores_gemma":[0.006930047,0.0003423236,0.9396816,0.000087660796,0.0020819586,0.0005236604,0.0002776356,0.00038056902,0.049141616,0.00010164741,0.00009689966,0.00035441126],"about_ca_topic_score_codex":0.00021862994,"about_ca_topic_score_gemma":0.00032721634,"teacher_disagreement_score":0.16133305,"about_ca_system_score_codex":0.000078123216,"about_ca_system_score_gemma":0.00013986534,"threshold_uncertainty_score":0.9999953},"labels":[],"label_agreement":null},{"id":"W1964125608","doi":"10.1016/j.leukres.2012.11.013","title":"Correlation between cytokine levels and changes in fatigue and quality of life in patients with acute myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University; University Health Network","funders":"Canadian Institutes of Health Research; Ministerul Cercetării, Inovării şi Digitalizării","keywords":"Myeloid leukemia; Cancer-related fatigue; Medicine; Cytokine; Tumor necrosis factor alpha; Internal medicine; Chemokine; Myeloid; Oncology; Leukemia; Immunology; Cancer; Gastroenterology; Inflammation","score_opus":0.1157119307328995,"score_gpt":0.3813353205692868,"score_spread":0.26562338983638734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964125608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966747,0.00035792365,0.00008023207,0.0005976983,0.000024532254,0.0013998635,0.00008223724,0.000023055833,0.00075976714],"genre_scores_gemma":[0.9984159,0.00020206622,0.0005921334,0.00007477584,0.00014915715,0.000084476735,0.00012451253,0.000052918123,0.00030407292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99540466,0.00071104406,0.0006676308,0.00053307135,0.0015563237,0.0011272827],"domain_scores_gemma":[0.9972242,0.0011254017,0.00011988147,0.00051588647,0.0004293386,0.0005852945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004324647,0.00027409487,0.00084629835,0.001168603,0.00010079487,0.000031725816,0.00017671369,0.00036136273,0.000051321385],"category_scores_gemma":[0.0012179044,0.00022537267,0.00003067752,0.0014177784,0.00060523074,0.00039487763,0.0003927697,0.0016224037,0.000011039864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016351538,0.000092888964,0.9891608,0.00038532875,0.00008395312,0.0000135876,0.0013988792,0.0000101052565,0.0019862591,0.00020305745,0.00012423495,0.00490575],"study_design_scores_gemma":[0.010041334,0.00065010594,0.9859615,0.00028960968,0.000024355248,0.000005197088,0.0003517845,0.00037752226,0.0019035707,0.00004547926,0.0001367334,0.0002127816],"about_ca_topic_score_codex":0.0038572908,"about_ca_topic_score_gemma":0.00087973836,"teacher_disagreement_score":0.00840618,"about_ca_system_score_codex":0.0029561922,"about_ca_system_score_gemma":0.0014171338,"threshold_uncertainty_score":0.91904306},"labels":[],"label_agreement":null},{"id":"W1964843845","doi":"10.1182/blood-2011-01-333179","title":"AF1q/MLLT11 regulates the emergence of human prothymocytes through cooperative interaction with the Notch signaling pathway","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Ligue Contre le Cancer; University of Toronto; Institut National de la Santé et de la Recherche Médicale; Sunnybrook Research Institute; Association pour la Recherche sur le Cancer","keywords":"Notch signaling pathway; Lymphopoiesis; Cell biology; Biology; Progenitor cell; Gene silencing; Cellular differentiation; Transcriptome; Stem cell; Myogenesis; Signal transduction; Gene expression; Genetics; Gene; Myocyte","score_opus":0.052714381523233766,"score_gpt":0.30118578887335845,"score_spread":0.24847140735012468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964843845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891174,0.00022438659,0.00013141333,0.0007591244,0.00003194444,0.0010480317,0.0000043994924,0.00003700488,0.0086463215],"genre_scores_gemma":[0.998184,0.000021906482,0.00062069425,0.0001511047,0.00013368938,0.00014082166,0.000007045735,0.000026349022,0.00071433675],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988323,0.00013638794,0.00023341781,0.00022355991,0.0003382908,0.00023605749],"domain_scores_gemma":[0.9989153,0.00012771488,0.00013296762,0.00045266608,0.00033049332,0.000040866846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033419876,0.00015091032,0.000212548,0.000035148296,0.0002414084,0.00001582109,0.00025311834,0.000057044646,0.00048741593],"category_scores_gemma":[0.00008602762,0.00006731049,0.000050570055,0.00030400822,0.0003259757,0.00015505335,0.000079262754,0.00039040658,0.000020445537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052350684,0.00062292453,0.0035125548,0.000105657025,0.0005080776,0.000047994767,0.032356486,0.000012926107,0.9584601,0.0021809996,0.0011634548,0.0005053025],"study_design_scores_gemma":[0.0012251423,0.0011645658,0.0020688118,0.00015940878,0.00013727073,0.00007202114,0.0066125495,0.00004431613,0.98794556,0.00012014034,0.0003558304,0.0000943636],"about_ca_topic_score_codex":0.0003709794,"about_ca_topic_score_gemma":0.000071006,"teacher_disagreement_score":0.029485462,"about_ca_system_score_codex":0.000024652507,"about_ca_system_score_gemma":0.000162657,"threshold_uncertainty_score":0.5336863},"labels":[],"label_agreement":null},{"id":"W1965573739","doi":"10.1038/sj.bmt.1704285","title":"Myeloablative conditioning regimens for AML allografts: 30 years later","year":2003,"lang":"en","type":"review","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"University of Toronto; University Health Network","keywords":"Medicine; Busulfan; Cyclophosphamide; Total body irradiation; Internal medicine; Incidence (geometry); Conditioning; Surgery; Oncology; Chemotherapy","score_opus":0.042758455368969356,"score_gpt":0.34351490343360563,"score_spread":0.3007564480646363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965573739","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001372582,0.9870028,0.0026465086,0.00012746702,0.00025371028,0.0047811633,0.0012695898,0.00016101047,0.0036204983],"genre_scores_gemma":[0.0000818874,0.9800683,0.0038343873,0.00020671733,0.00020216581,0.0008434186,0.010100746,0.00015723996,0.0045051035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974147,0.00023346457,0.00074144115,0.0006351754,0.00042386152,0.00055132544],"domain_scores_gemma":[0.9985682,0.0004097052,0.0003008281,0.0003582088,0.00017063032,0.00019246456],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050705153,0.00047076563,0.001486635,0.00046603434,0.00012650585,0.00005156174,0.00012753377,0.00054524414,0.00043165698],"category_scores_gemma":[0.000052113992,0.00042944687,0.0005639689,0.00036168983,0.00012263785,0.00013312836,0.000010194935,0.00061097264,0.0002572028],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082722906,0.00027804627,0.00004654927,0.120257206,0.002785916,0.0021747728,0.001847102,0.000009406416,0.0003118289,0.0018207368,0.035066303,0.8345749],"study_design_scores_gemma":[0.0025976954,0.0002584071,0.00005508978,0.008993396,0.0033179957,0.0008674125,0.000036822606,0.000019035582,0.00004730088,0.00012227557,0.98321414,0.00047041377],"about_ca_topic_score_codex":0.000018949328,"about_ca_topic_score_gemma":0.000009140138,"teacher_disagreement_score":0.94814783,"about_ca_system_score_codex":0.00049392116,"about_ca_system_score_gemma":0.000681712,"threshold_uncertainty_score":0.99981576},"labels":[],"label_agreement":null},{"id":"W1965889017","doi":"10.1002/ajh.21034","title":"Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy","year":2007,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Mitoxantrone; Medicine; Cytarabine; Internal medicine; Etoposide; Induction chemotherapy; Chemotherapy; Myeloid leukemia; Oncology; Leukemia; Regimen; Bone marrow; Surgery; Gastroenterology","score_opus":0.010878838440427353,"score_gpt":0.2888395293219061,"score_spread":0.27796069088147873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965889017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96994406,0.00002533262,0.02162677,0.0073003066,0.00013807106,0.0008931892,0.000017575068,0.000022141456,0.000032557444],"genre_scores_gemma":[0.96139157,0.00009631336,0.037029438,0.00093216554,0.00026089494,0.000012980181,0.000018924242,0.0000912154,0.00016648609],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99734765,0.00017098381,0.00090091745,0.0003626799,0.000701267,0.0005165173],"domain_scores_gemma":[0.9963878,0.00033469414,0.0012251408,0.00041537962,0.0012232165,0.00041377184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012941154,0.00030197704,0.0012034787,0.0006876061,0.00009124697,0.000010264548,0.00024005592,0.00014829944,0.000036404086],"category_scores_gemma":[0.00023707701,0.00020217011,0.00013824085,0.00073898846,0.0005118406,0.00016283612,0.000026747291,0.0005795893,0.0000018621405],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67392594,0.0006289595,0.08114206,0.00009161614,0.0020087648,0.00018297769,0.0026829115,0.00007736906,0.16421111,0.000048327984,0.006570577,0.06842938],"study_design_scores_gemma":[0.05967005,0.15240899,0.4949932,0.001612765,0.0008153421,0.012162992,0.0039732344,0.0002028302,0.24999857,0.000092296126,0.023062324,0.0010074031],"about_ca_topic_score_codex":0.00003808492,"about_ca_topic_score_gemma":0.0000052758623,"teacher_disagreement_score":0.6142559,"about_ca_system_score_codex":0.00082054094,"about_ca_system_score_gemma":0.00080283935,"threshold_uncertainty_score":0.82442576},"labels":[],"label_agreement":null},{"id":"W1965922185","doi":"10.1002/ajh.23281","title":"A genome‐wide single‐nucleotide polymorphism‐array can improve the prognostic stratification of the core binding factor acute myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Research Foundation of Korea","keywords":"Core binding factor; SNP array; SNP; Single-nucleotide polymorphism; Myeloid leukemia; Internal medicine; Cytogenetics; Leukemia; Medicine; Oncology; Gastroenterology; Biology; Pathology; Genetics; Gene; Genotype; Chromosome; Transcription factor","score_opus":0.024239111791797253,"score_gpt":0.28446918928598314,"score_spread":0.26023007749418586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965922185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913183,0.00048150276,0.00030838154,0.006667805,0.00040450372,0.00053640886,0.000025739639,0.000014350077,0.00024300987],"genre_scores_gemma":[0.9978847,0.00008712908,0.0010132263,0.00051945465,0.00028018642,0.00001301155,0.0000059601016,0.00004714598,0.00014917723],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973758,0.00028390926,0.00089794956,0.00019427086,0.00058184407,0.000666218],"domain_scores_gemma":[0.99638206,0.0007757122,0.0015853334,0.00058237993,0.00037354088,0.00030094624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005838798,0.00024550842,0.0008048314,0.0002403203,0.00016571398,0.000019049476,0.0006113341,0.000093462346,0.00007720957],"category_scores_gemma":[0.00079392234,0.00013337491,0.00027204579,0.0006533872,0.0012062287,0.00013795338,0.00009594902,0.0009363301,0.000014267208],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029011944,0.00013109444,0.19614577,0.00004713407,0.00053349126,0.0000437757,0.0022049274,0.0000019029835,0.79654074,0.00018392253,0.00029313215,0.0035840129],"study_design_scores_gemma":[0.0027304392,0.0037175866,0.5433332,0.0003401465,0.0013015184,0.01662141,0.0106457705,0.000056409026,0.4184778,0.00018733439,0.0021019499,0.00048644972],"about_ca_topic_score_codex":0.00010418313,"about_ca_topic_score_gemma":0.000016144191,"teacher_disagreement_score":0.37806293,"about_ca_system_score_codex":0.0007145441,"about_ca_system_score_gemma":0.0012232286,"threshold_uncertainty_score":0.54388714},"labels":[],"label_agreement":null},{"id":"W1967208726","doi":"10.1016/j.bbmt.2011.05.022","title":"A Prospective Study Comparing the Outcomes and Health-Related Quality of Life in Adult Patients with Myeloid Malignancies Undergoing Allogeneic Transplantation Using Myeloablative or Reduced-Intensity Conditioning","year":2011,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Public Health Ontario; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Prospective cohort study; Quality of life (healthcare); Transplantation; Confidence interval; Myeloid leukemia; Observational study; Myeloid; Oncology","score_opus":0.06528374256371124,"score_gpt":0.3147218568327441,"score_spread":0.2494381142690329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967208726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982467,0.00010428148,0.00023849624,0.00008767892,0.000019973912,0.0011983075,0.000056470013,0.0000147356395,0.000033307537],"genre_scores_gemma":[0.9987476,0.00024387521,0.0008074237,0.000051047395,0.0000043178234,0.00002157255,0.00011103481,0.0000102345375,0.0000028855136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853206,0.00027448955,0.000600475,0.00026576302,0.00014143136,0.0001857749],"domain_scores_gemma":[0.99905556,0.0002190871,0.00033801238,0.00009393889,0.00023398973,0.000059420967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005348469,0.00015003573,0.0005765197,0.0001560352,0.00011791145,0.000004049686,0.000046558933,0.00008173616,0.0000037998227],"category_scores_gemma":[0.000064550964,0.00009478735,0.000027405122,0.00018373046,0.0003123144,0.00010510215,0.000009862268,0.00016720935,7.418447e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004959797,0.00030148454,0.96025556,0.00051657605,0.0003600622,0.000008420593,0.020804487,0.000009713139,0.012486607,0.00022856002,1.9458132e-7,0.00006853172],"study_design_scores_gemma":[0.010691377,0.0014934164,0.97735274,0.00027709024,0.00031441776,0.000037150367,0.004191893,0.000062364605,0.005403232,0.00007884625,1.06080655e-8,0.00009746454],"about_ca_topic_score_codex":0.0050616832,"about_ca_topic_score_gemma":0.0047149397,"teacher_disagreement_score":0.01709717,"about_ca_system_score_codex":0.000037841986,"about_ca_system_score_gemma":0.00021949483,"threshold_uncertainty_score":0.76517844},"labels":[],"label_agreement":null},{"id":"W1968124066","doi":"10.1007/s00277-012-1475-5","title":"Mechanisms of defective erythropoiesis and anemia in pediatric acute lymphoblastic leukemia (ALL)","year":2012,"lang":"en","type":"review","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Children's Hospital","funders":"","keywords":"Erythropoiesis; Anemia; Medicine; Leukemia; Bone marrow; Disease; Ineffective erythropoiesis; Hematology; Immunology; Bioinformatics; Cancer research; Internal medicine; Biology","score_opus":0.07454213810316791,"score_gpt":0.38083549500626207,"score_spread":0.30629335690309417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968124066","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00322087,0.99463314,0.00009299435,0.00012605799,0.00011960121,0.001070992,0.00007461188,0.00002442397,0.00063729496],"genre_scores_gemma":[0.013043104,0.98582035,0.00064465345,0.00009439606,0.00006500483,0.000107180276,0.000081326245,0.0000883584,0.000055619286],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965092,0.00037828187,0.0013279052,0.0005752046,0.00039288925,0.0008165368],"domain_scores_gemma":[0.9968157,0.0012223695,0.00083254685,0.0006297813,0.00022471804,0.00027493088],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064957706,0.00054640183,0.0045598,0.0013601688,0.000027064385,0.00000459092,0.00031002308,0.0010330597,0.00012442404],"category_scores_gemma":[0.00045145434,0.0004428221,0.00047767907,0.0008361745,0.00036143916,0.000088914,0.00036149274,0.0007020414,0.00004427564],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010633806,0.0012287542,0.0031101513,0.46815336,0.0054404135,0.0028175793,0.0009784794,0.0000011193754,0.00019046456,0.0318206,0.006897053,0.47829866],"study_design_scores_gemma":[0.0348869,0.019726936,0.010068104,0.11895549,0.12799339,0.12858489,0.0017619855,0.00020963304,0.019571697,0.03602734,0.49018595,0.012027685],"about_ca_topic_score_codex":0.0001409788,"about_ca_topic_score_gemma":0.00001665168,"teacher_disagreement_score":0.48328888,"about_ca_system_score_codex":0.00022403731,"about_ca_system_score_gemma":0.0017033743,"threshold_uncertainty_score":0.99980235},"labels":[],"label_agreement":null},{"id":"W1969317366","doi":"10.1016/s1521-6926(03)00072-0","title":"Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukaemia","year":2003,"lang":"en","type":"article","venue":"Best Practice & Research Clinical Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Associazione Italiana per la Ricerca sul Cancro; Ministero dell’Istruzione, dell’Università e della Ricerca; Ministero della Salute","keywords":"Chromosomal translocation; Cytogenetics; Fusion gene; Karyotype; Chromosome; Biology; Childhood leukaemia; Bioinformatics; Computational biology; Gene; Medicine; Genetics","score_opus":0.11405815447290812,"score_gpt":0.4800122548072619,"score_spread":0.36595410033435377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969317366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818185,0.0010144064,0.0013804582,0.009285562,0.00017069909,0.0028246567,0.000022300917,0.00005294267,0.003430491],"genre_scores_gemma":[0.9752417,0.0029237063,0.020643635,0.0002797968,0.00013653545,0.0004965604,0.000039645456,0.000073727,0.0001646883],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98699075,0.0072789327,0.001975442,0.0010656536,0.0014214965,0.0012677258],"domain_scores_gemma":[0.9374752,0.058648404,0.00042371333,0.0013322824,0.0014621927,0.00065822375],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.010315184,0.00029494162,0.0013574766,0.0006612577,0.00026366854,0.000039978157,0.0005620863,0.0008080165,0.00047020614],"category_scores_gemma":[0.20632789,0.00027091452,0.0002445656,0.0017456297,0.0013513477,0.00046771503,0.0002879387,0.004541112,0.0005097446],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017336495,0.036065474,0.44028875,0.0023171818,0.0034677614,0.062207155,0.005995728,0.00011558849,0.32661957,0.034397025,0.00222924,0.068960056],"study_design_scores_gemma":[0.09681907,0.045933284,0.22108108,0.010246941,0.0045984867,0.031517737,0.030225422,0.013444016,0.43892288,0.025617568,0.077662714,0.003930801],"about_ca_topic_score_codex":0.0027133445,"about_ca_topic_score_gemma":0.0006595725,"teacher_disagreement_score":0.21920766,"about_ca_system_score_codex":0.00046769876,"about_ca_system_score_gemma":0.0038098972,"threshold_uncertainty_score":0.9999743},"labels":[],"label_agreement":null},{"id":"W1969355036","doi":"10.1038/leu.2011.153","title":"The clathrin-binding domain of CALM and the OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice","year":2011,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Science and Technology of the People's Republic of China; Deutsche Krebshilfe; National Natural Science Foundation of China; Canadian Institutes of Health Research; Universität Ulm; Deutsche Forschungsgemeinschaft","keywords":"Myeloid leukemia; Fusion protein; Leucine zipper; Biology; Fusion gene; Leukemia; Cell biology; Cancer research; Gene; Computational biology; Genetics; Transcription factor; Recombinant DNA","score_opus":0.021843322858401883,"score_gpt":0.27397117694640616,"score_spread":0.25212785408800426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969355036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900183,0.00054237864,0.00013127972,0.0013230024,0.0001526038,0.0015175465,0.000037706188,0.00003391359,0.0062432457],"genre_scores_gemma":[0.9956281,0.00032638415,0.0021982049,0.0004997646,0.00011235461,0.0001127115,0.000009402173,0.00006375269,0.0010493301],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99627095,0.00039222295,0.000995241,0.00058063096,0.00088719866,0.0008737766],"domain_scores_gemma":[0.9971005,0.00089517067,0.0004184903,0.0010419557,0.00024071438,0.00030321043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027459257,0.00037611782,0.00087204826,0.00038306706,0.0002353447,0.0000329156,0.00081032654,0.00031386892,0.000045077348],"category_scores_gemma":[0.00052554265,0.00022736767,0.00018344042,0.0011697127,0.0010531024,0.00010835038,0.00060863263,0.0011771439,0.00004179998],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033400856,0.0005952961,0.08505944,0.0014417645,0.0020767308,0.0017640126,0.18224543,0.00030349838,0.5926356,0.063047975,0.018793631,0.018635789],"study_design_scores_gemma":[0.065910615,0.0029219573,0.40421382,0.003343791,0.0009281138,0.0014833998,0.0860251,0.0029858893,0.39689174,0.008937925,0.02409296,0.002264695],"about_ca_topic_score_codex":0.0023460523,"about_ca_topic_score_gemma":0.00057322823,"teacher_disagreement_score":0.31915435,"about_ca_system_score_codex":0.0029945055,"about_ca_system_score_gemma":0.0016553582,"threshold_uncertainty_score":0.92717844},"labels":[],"label_agreement":null},{"id":"W1969714189","doi":"10.1016/j.leukres.2009.03.019","title":"Reduction in multi-lineage and erythroid progenitors distinguishes myelodysplastic syndromes from non-malignant cytopenias","year":2009,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Vancouver General Hospital","funders":"BC Cancer Agency","keywords":"Cytopenia; Myelodysplastic syndromes; Progenitor cell; Bone marrow; Haematopoiesis; Dysplasia; Lineage (genetic); Progenitor; Peripheral blood; Medicine; Cancer research; Pathology; Internal medicine; Immunology; Stem cell; Biology; Genetics; Gene","score_opus":0.08105111945671498,"score_gpt":0.3819588372743892,"score_spread":0.3009077178176742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969714189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994537,0.0007544859,0.00013020588,0.0014925317,0.00015182287,0.0016721821,0.000025347017,0.0001092723,0.0011271699],"genre_scores_gemma":[0.9902803,0.0004887384,0.0056249644,0.00006814334,0.0005971865,0.00013333892,0.00010634046,0.00006992754,0.0026310608],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9950085,0.00039057888,0.00067116745,0.0011281073,0.001423257,0.0013783701],"domain_scores_gemma":[0.9973958,0.00066038215,0.000087222536,0.0007880556,0.0004752969,0.0005932235],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018970484,0.00037694362,0.0007183846,0.0009283764,0.0003287303,0.00018079448,0.0004107082,0.00038031032,0.000108515895],"category_scores_gemma":[0.002450065,0.00032573013,0.00010125797,0.0014747218,0.00057702017,0.00027732144,0.00030674826,0.0021296632,0.00021428033],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059628277,0.0018284408,0.095401876,0.00091561425,0.00040525116,0.013496141,0.0088950405,0.00021371199,0.76903087,0.00037352153,0.011557649,0.09191907],"study_design_scores_gemma":[0.018731315,0.0034478703,0.78649825,0.0023838314,0.00013154397,0.0019948436,0.0049450193,0.056644563,0.11992962,0.00086051103,0.0031771653,0.0012554958],"about_ca_topic_score_codex":0.0027516636,"about_ca_topic_score_gemma":0.0001819154,"teacher_disagreement_score":0.69109637,"about_ca_system_score_codex":0.002990435,"about_ca_system_score_gemma":0.0017717164,"threshold_uncertainty_score":0.9999195},"labels":[],"label_agreement":null},{"id":"W1969954034","doi":"10.1111/bjh.12871","title":"Evaluation of allelic strength of human <i><scp>TET</scp>2</i> mutations and cooperation between <i>Tet2</i> knockdown and oncogenic <i>Nras</i> mutation","year":2014,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Heart, Lung, and Blood Institute; University of Wisconsin Carbone Cancer Center; National Cancer Institute; National Institutes of Health; Greater Milwaukee Foundation; Leukemia and Lymphoma Society","keywords":"Missense mutation; Genetics; Frameshift mutation; Biology; Mutation; Nonsense mutation; Molecular biology; Allele; Gene; Cancer research","score_opus":0.03862735782896338,"score_gpt":0.3271464282958629,"score_spread":0.2885190704668995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969954034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97253525,0.0081481505,0.00041317474,0.017181627,0.0001390995,0.00089371187,0.00013031243,0.000015383252,0.0005432738],"genre_scores_gemma":[0.9826902,0.0019226791,0.0011649034,0.011506965,0.0012639853,0.00003320557,0.0011345878,0.00010589778,0.00017754492],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9944353,0.001319992,0.001891682,0.00041224126,0.0015348266,0.00040596162],"domain_scores_gemma":[0.9928932,0.0012725325,0.0018754854,0.0002894293,0.0034876526,0.00018168971],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029613897,0.00033124312,0.0018708153,0.00068639294,0.0001574182,0.000055720484,0.00023589886,0.0009189752,0.00004408476],"category_scores_gemma":[0.0022644622,0.00036536437,0.00021333086,0.0002931502,0.00064027065,0.00023152167,0.000089420595,0.0019156701,0.0000035618332],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007021808,0.00034193727,0.004775416,0.0036870465,0.002867426,0.010892935,0.0012814414,0.00007060815,0.015361196,0.00008898896,0.90597457,0.054588214],"study_design_scores_gemma":[0.044720147,0.009545371,0.017256662,0.009286613,0.023742506,0.7220694,0.0012954335,0.0021399865,0.054990932,0.005620914,0.108240224,0.0010918002],"about_ca_topic_score_codex":0.0001835757,"about_ca_topic_score_gemma":0.000085337815,"teacher_disagreement_score":0.7977343,"about_ca_system_score_codex":0.0001981205,"about_ca_system_score_gemma":0.0011534996,"threshold_uncertainty_score":0.99987984},"labels":[],"label_agreement":null},{"id":"W1969962466","doi":"10.1038/onc.2013.596","title":"Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway","year":2014,"lang":"en","type":"article","venue":"Oncogene","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Biology; LYN; Apoptosis; PI3K/AKT/mTOR pathway; Cancer research; Mutation; Juvenile myelomonocytic leukemia; Protein kinase B; Genetics; Signal transduction; Gene; Haematopoiesis; Stem cell","score_opus":0.01822985459531816,"score_gpt":0.282023403705128,"score_spread":0.26379354910980984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969962466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98003733,0.00019883197,0.001181549,0.008012947,0.0001283911,0.0012489257,0.000017656668,0.00012308337,0.009051255],"genre_scores_gemma":[0.990792,0.00001832776,0.0017713339,0.001251218,0.00021606291,0.00024636535,0.00007059896,0.00006696245,0.0055671465],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973389,0.00033726462,0.0005032613,0.00051511504,0.0006567119,0.0006487826],"domain_scores_gemma":[0.9982491,0.00042542323,0.00014793238,0.0006934589,0.00024307033,0.00024100335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001496937,0.00025297925,0.0004808367,0.00023381165,0.0001667162,0.00004694111,0.00034152117,0.00020043204,0.00009635633],"category_scores_gemma":[0.0018297029,0.00019159794,0.00011179393,0.001089988,0.00009018892,0.000097515804,0.00012635929,0.0004074406,0.0003524946],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013545785,0.00074535154,0.0067059514,0.00033796183,0.00029264562,0.00021050792,0.005490106,0.0002594453,0.81551725,0.0007720478,0.02565152,0.14266261],"study_design_scores_gemma":[0.0079141185,0.0014595605,0.017589275,0.0006733508,0.00017915497,0.000058976377,0.0006031408,0.0070722,0.9163158,0.0021315636,0.045197174,0.0008056988],"about_ca_topic_score_codex":0.00030888646,"about_ca_topic_score_gemma":0.0011472851,"teacher_disagreement_score":0.14185692,"about_ca_system_score_codex":0.0017983825,"about_ca_system_score_gemma":0.0005403611,"threshold_uncertainty_score":0.7813137},"labels":[],"label_agreement":null},{"id":"W1970504500","doi":"10.1038/ng.3253","title":"Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia","year":2015,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":329,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University Health Network; Toronto Western Hospital; Hospital for Sick Children; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Institute of General Medical Sciences; National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research","keywords":"Biology; Mutation; Cancer research; Genetics; Leukemia; Germline mutation; Exon; Exome sequencing; Molecular biology; Immunology; Gene","score_opus":0.015936053758994394,"score_gpt":0.28557057557877735,"score_spread":0.269634521819783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970504500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99566793,0.00077723956,0.0001907493,0.0013625491,0.00006964026,0.0007889789,0.00007060196,0.000055155324,0.0010171379],"genre_scores_gemma":[0.9932322,0.00006915396,0.004772033,0.0008381848,0.00012098342,0.00004576869,0.00021695346,0.000050326573,0.0006543815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983061,0.000078756086,0.00025502854,0.00040461618,0.0005671768,0.0003883263],"domain_scores_gemma":[0.9986133,0.000114166636,0.00009364438,0.00030035918,0.00046933303,0.00040918478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002563473,0.00021014633,0.00037181942,0.0002628635,0.000060069502,0.000040392526,0.00012934156,0.0004638278,0.000014735906],"category_scores_gemma":[0.00045968645,0.00018062028,0.000029006409,0.0007814706,0.000075668424,0.00005509546,0.00010208564,0.0007162898,0.000019322262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00676746,0.0014155154,0.78075546,0.0006874194,0.00059639895,0.0024407317,0.010840069,0.013573922,0.11312536,0.00005188047,0.064269364,0.0054764054],"study_design_scores_gemma":[0.012172956,0.0015959255,0.93936324,0.0005164007,0.0002992689,0.00015388326,0.0008945084,0.010022593,0.03313977,0.00014974485,0.0012285282,0.0004631833],"about_ca_topic_score_codex":0.00003091427,"about_ca_topic_score_gemma":0.0003812605,"teacher_disagreement_score":0.15860777,"about_ca_system_score_codex":0.0017172216,"about_ca_system_score_gemma":0.00084072567,"threshold_uncertainty_score":0.7365481},"labels":[],"label_agreement":null},{"id":"W1970909276","doi":"10.1111/j.1365-2141.2005.05770.x","title":"Florid bone marrow haematogones in a child following treatment for acute lymphoblastic leukaemia","year":2005,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Bone marrow; Terminal deoxynucleotidyl transferase; Pathology; Medicine; Population; CD20; Acute lymphocytic leukemia; Immunology; Leukemia; Lymphoblastic Leukemia; Lymphoma; TUNEL assay","score_opus":0.015941426168312473,"score_gpt":0.3077857726505146,"score_spread":0.29184434648220214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970909276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98471177,0.007221729,0.0008853801,0.0054880837,0.000403718,0.0006695508,0.000017995684,0.000027928536,0.0005738261],"genre_scores_gemma":[0.98778814,0.0016186363,0.008885253,0.0004586057,0.0005828692,0.000072985975,0.00001908598,0.00006741417,0.0005070344],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99738896,0.00010948848,0.0011035183,0.0003078069,0.00036978742,0.00072045455],"domain_scores_gemma":[0.99862194,0.00030976537,0.00032483798,0.00022136344,0.00020617513,0.0003159162],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005562416,0.00025463986,0.0015746332,0.00051677605,0.0001317998,0.000046898876,0.00021460181,0.00023997563,0.000082162995],"category_scores_gemma":[0.00049282983,0.0002508348,0.00056377944,0.00027509264,0.000113642534,0.00025074626,0.000055273293,0.00042882905,0.000034154516],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054953066,0.0020539125,0.0068200063,0.0005307244,0.0037251345,0.80056375,0.0010290848,0.00022313737,0.007798608,0.00072705955,0.030110631,0.14092265],"study_design_scores_gemma":[0.021264883,0.0014651578,0.0015558016,0.001546884,0.00070609787,0.95432276,0.00022850622,0.0008904657,0.008063035,0.00023628098,0.009438182,0.0002819633],"about_ca_topic_score_codex":0.00007493716,"about_ca_topic_score_gemma":0.00036859303,"teacher_disagreement_score":0.15375899,"about_ca_system_score_codex":0.0010653897,"about_ca_system_score_gemma":0.0007078987,"threshold_uncertainty_score":0.9999944},"labels":[],"label_agreement":null},{"id":"W1971236526","doi":"10.1016/j.leukres.2013.01.001","title":"High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission","year":2013,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Cytarabine; Mitoxantrone; Etoposide; Medicine; Internal medicine; Daunorubicin; Cytogenetics; Regimen; Multivariate analysis; Oncology; Leukemia; Surgery; Gastroenterology; Chemotherapy; Biology","score_opus":0.03875802131210687,"score_gpt":0.3175527483247753,"score_spread":0.27879472701266844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971236526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897277,0.00004277409,0.00045855186,0.0022829496,0.00009464063,0.0064530256,0.00045579698,0.00008335437,0.0004012348],"genre_scores_gemma":[0.9889053,0.00011004999,0.0066080857,0.00026998064,0.00022977487,0.0012729408,0.0016288904,0.00011178489,0.00086319994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99403304,0.0005541621,0.00091579056,0.0010837367,0.0018530685,0.0015601838],"domain_scores_gemma":[0.99393797,0.0019402121,0.0001868666,0.0012075697,0.0020502396,0.00067714177],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020295186,0.00042116517,0.00068358745,0.0010331774,0.00041140307,0.00017354748,0.00057963084,0.00038987395,0.000287895],"category_scores_gemma":[0.0030088255,0.00032617876,0.0001212384,0.001143263,0.00062971923,0.00026088284,0.00022884028,0.0017395342,0.00026614201],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05771843,0.002150421,0.71910363,0.0023662145,0.00038873314,0.00041866046,0.0028749644,0.0030631213,0.035225924,0.000095770374,0.12317014,0.053423986],"study_design_scores_gemma":[0.058079023,0.003225791,0.8682404,0.00096783467,0.000054865544,0.0000112323605,0.00029142678,0.04684101,0.016161274,0.00012551883,0.0054517845,0.00054983364],"about_ca_topic_score_codex":0.003433974,"about_ca_topic_score_gemma":0.00073526596,"teacher_disagreement_score":0.14913677,"about_ca_system_score_codex":0.004098215,"about_ca_system_score_gemma":0.0026091721,"threshold_uncertainty_score":0.999919},"labels":[],"label_agreement":null},{"id":"W1971583640","doi":"10.1080/1042819021000046994","title":"Evaluation for the Development of 11q23 Rearrangements in Lymphoma Patients Treated with a High Dose VP-16 and Cyclophosphamide Salvage Regimen","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"McGill University","keywords":"Cyclophosphamide; Medicine; Regimen; Internal medicine; Salvage therapy; Lymphoma; Chemotherapy; Oncology; Cytogenetics; Chromosomal translocation; Transplantation; Gastroenterology; Surgery; Biology; Chromosome","score_opus":0.017610928255528475,"score_gpt":0.26809840145091446,"score_spread":0.250487473195386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971583640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906579,0.0019360319,0.00016238143,0.000119817574,0.00012290596,0.0042199627,0.00004416423,0.00008710374,0.002649678],"genre_scores_gemma":[0.99249446,0.00054334564,0.0039008996,0.00039532653,0.00007241299,0.0011938589,0.00025085834,0.00015968713,0.0009891427],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941416,0.0003957065,0.001290177,0.0012445811,0.0017458347,0.0011821269],"domain_scores_gemma":[0.9964708,0.0007244487,0.0005206017,0.0009923961,0.0008278924,0.0004638227],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024752207,0.000814748,0.0011172805,0.0005433063,0.0004952006,0.00010235749,0.0003690699,0.00046208774,0.00005840291],"category_scores_gemma":[0.00067231385,0.0005845168,0.00014152225,0.0010996647,0.00052775705,0.00033804867,0.00018564373,0.000145978,0.000013242524],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008843048,0.0010225589,0.20442078,0.00084241136,0.0014804263,0.00011567879,0.004648604,0.00006836563,0.0031317112,0.00073606486,0.0021145502,0.7725758],"study_design_scores_gemma":[0.09445614,0.0010623013,0.8681654,0.0007063847,0.00085146184,0.00019204937,0.0012993662,0.0029166157,0.019073332,0.0003165833,0.010118202,0.00084219873],"about_ca_topic_score_codex":0.0019780225,"about_ca_topic_score_gemma":0.0004898841,"teacher_disagreement_score":0.77173364,"about_ca_system_score_codex":0.0155094825,"about_ca_system_score_gemma":0.008036297,"threshold_uncertainty_score":0.9996606},"labels":[],"label_agreement":null},{"id":"W1971694764","doi":"10.1111/ijlh.12068","title":"Technical issues: flow cytometry and rare event analysis","year":2013,"lang":"en","type":"review","venue":"International Journal of Laboratory Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Minimal residual disease; Flow cytometry; Population; Enumeration; Identification (biology); Computational biology; Medicine; Immunology; Biology; Oncology; Leukemia; Mathematics","score_opus":0.03232873573028084,"score_gpt":0.41976086237037813,"score_spread":0.3874321266400973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971694764","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001214864,0.9965576,0.000993185,0.0011840457,0.0005389253,0.00034272368,0.0001259038,0.000021027843,0.00011509013],"genre_scores_gemma":[0.00020679118,0.99211955,0.00639304,0.00022031751,0.0006504427,0.000029358845,0.00008714528,0.000050877177,0.00024248188],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964051,0.000336307,0.0016157128,0.00034988028,0.0009995317,0.0002934357],"domain_scores_gemma":[0.9952641,0.0004910696,0.0011716989,0.0003663835,0.0023409883,0.0003657202],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00079144153,0.00037793175,0.003175479,0.0029472199,0.000032824246,0.00006181446,0.0007167984,0.00065105804,0.0011828056],"category_scores_gemma":[0.0010869829,0.00027018908,0.0008151849,0.0013140432,0.00022460111,0.00016922134,0.00027009158,0.001472773,0.00012357363],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033161003,0.00081241044,0.0026172518,0.011401342,0.039084774,0.020944186,0.00010885373,0.0000064065093,0.00006733535,0.0016933827,0.07885955,0.8440729],"study_design_scores_gemma":[0.0007344457,0.00017862796,0.00006201015,0.0036989294,0.0043400493,0.014051812,0.000036683687,0.000051651026,0.000015874555,0.000047618043,0.9765637,0.00021858065],"about_ca_topic_score_codex":0.0000055286478,"about_ca_topic_score_gemma":0.0000028031966,"teacher_disagreement_score":0.8977042,"about_ca_system_score_codex":0.0007309846,"about_ca_system_score_gemma":0.0017175557,"threshold_uncertainty_score":0.999975},"labels":[],"label_agreement":null},{"id":"W1972459469","doi":"10.1182/blood-2011-01-331850","title":"Acute nonlymphocytic leukemia presenting with pancytopenia","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Pancytopenia; Medicine; Population; Bone marrow; Leukemia; Pathology; Acute leukemia; Cytarabine; CD33; Immunology; Basophilic; Myeloid; Gastroenterology; Biology; CD34; Genetics","score_opus":0.01726833773703098,"score_gpt":0.28039639199500405,"score_spread":0.2631280542579731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972459469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97343165,0.00043898236,0.00009071606,0.00025981694,0.000057661622,0.00047924923,0.0000057764837,0.00012930998,0.025106866],"genre_scores_gemma":[0.9872415,0.000057083023,0.004988054,0.00036578366,0.00061190245,0.00005515209,0.000024291703,0.000062666964,0.0065935357],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99820435,0.000041178286,0.0001973276,0.00025813252,0.0004852505,0.0008137424],"domain_scores_gemma":[0.9988804,0.000071642935,0.00006158957,0.00052280026,0.00010187593,0.00036172863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024014253,0.00019251653,0.00031387166,0.000110037385,0.000104825136,0.000031158856,0.00017251274,0.000106622174,0.00017965004],"category_scores_gemma":[0.000075795084,0.00013958095,0.000070664675,0.0003313659,0.00009184209,0.00024427343,0.00013394176,0.0003335008,0.0005371057],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000986196,0.0012990874,0.86859787,0.0004438633,0.0024706197,0.001938932,0.0019383118,0.000003747939,0.10939708,0.00048632844,0.009727977,0.0027099985],"study_design_scores_gemma":[0.050340068,0.0011845046,0.31985727,0.0003946497,0.0041593467,0.01284305,0.0004742489,0.00077915576,0.57373106,0.000038634942,0.035034418,0.0011635751],"about_ca_topic_score_codex":0.000060866972,"about_ca_topic_score_gemma":0.000004709184,"teacher_disagreement_score":0.54874057,"about_ca_system_score_codex":0.0004394174,"about_ca_system_score_gemma":0.00082860555,"threshold_uncertainty_score":0.6903587},"labels":[],"label_agreement":null},{"id":"W1972544764","doi":"10.3747/co.22.2100","title":"A Case of Transfusion Independence in a Patient with Myelodysplastic Syndrome Using Deferasirox, Sustained for Two Years after Stopping Therapy","year":2015,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Deferasirox; Medicine; Myelodysplastic syndromes; Pediatrics; Independence (probability theory); Intensive care medicine; Family medicine; Internal medicine; Thalassemia","score_opus":0.11516020995248566,"score_gpt":0.4081221561140482,"score_spread":0.2929619461615625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972544764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99402344,0.00061132543,0.003507378,0.00008862581,0.0001767849,0.0015329283,0.0000128376,0.000016039467,0.000030625757],"genre_scores_gemma":[0.99794483,0.000042166204,0.0016933836,0.00004042238,0.000039924187,0.00019357291,0.000010161336,0.000027887196,0.000007656501],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9985352,0.00014318152,0.0003361938,0.0003065918,0.00028108893,0.00039775288],"domain_scores_gemma":[0.9989695,0.00020441701,0.000096271855,0.0002030991,0.00033125473,0.00019544642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042840498,0.00015377303,0.00044663865,0.00036310958,0.000024715659,0.00000600102,0.00007687031,0.00012085705,0.000021689928],"category_scores_gemma":[0.00014897271,0.00012394058,0.00005473851,0.0003487547,0.00013178977,0.00007500584,0.0000448508,0.0003914421,0.0000018125195],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07365387,0.0059274877,0.20088163,0.0015978956,0.00042228278,0.16324994,0.05162892,0.0019382209,0.014462738,0.00026229906,0.00020568616,0.48576903],"study_design_scores_gemma":[0.29132304,0.101360865,0.062055375,0.0052755107,0.0010959816,0.33033374,0.043067317,0.14332344,0.005194968,0.0010061277,0.013146006,0.0028176582],"about_ca_topic_score_codex":0.00019950452,"about_ca_topic_score_gemma":0.00027078183,"teacher_disagreement_score":0.48295137,"about_ca_system_score_codex":0.0011141006,"about_ca_system_score_gemma":0.0015884944,"threshold_uncertainty_score":0.505415},"labels":[],"label_agreement":null},{"id":"W1972668806","doi":"10.4161/cc.6.9.4208","title":"Lineage-Specific Transcription Factors in Multipotent Hematopoietic Progenitors: A Little Bit Goes a Long Way","year":2007,"lang":"en","type":"review","venue":"Cell Cycle","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Biology; Chromatin; Epigenetics; Transcription factor; Lineage (genetic); Gene silencing; Genetics; Haematopoiesis; Progenitor cell; Cell biology; Bivalent chromatin; Chromatin remodeling; Gene; Stem cell","score_opus":0.07528709112531728,"score_gpt":0.3477442198248293,"score_spread":0.272457128699512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972668806","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0111282645,0.9832929,0.0001913176,0.000026758915,0.000377097,0.0037991677,0.000032511565,0.00014730662,0.0010047017],"genre_scores_gemma":[0.003996615,0.9913301,0.00049615034,0.000019606878,0.0007273837,0.00027318558,0.0004410571,0.00022097056,0.0024949554],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959635,0.00022109471,0.0011992919,0.0009138712,0.0007460732,0.00095614744],"domain_scores_gemma":[0.99805105,0.0002885608,0.00024151125,0.0008645149,0.00011764474,0.0004367078],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00069684983,0.0007208282,0.002101989,0.00092602713,0.000083193874,0.000067078676,0.0004034205,0.0008546098,0.00035967186],"category_scores_gemma":[0.000074356874,0.00055072113,0.00088541646,0.0010958976,0.00015618608,0.00010651069,0.00009536826,0.0017302977,0.00074743317],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013647093,0.0014576397,0.00043431108,0.072474115,0.00021737558,0.0017906055,0.001913357,0.000004805952,0.0006690364,0.0000109466655,0.0016276905,0.91926366],"study_design_scores_gemma":[0.0015108886,0.0001786797,0.00015727145,0.010860877,0.00036183387,0.00014634387,0.00026150572,0.000047061432,0.002544357,0.000003746556,0.9833526,0.0005748205],"about_ca_topic_score_codex":0.00010916915,"about_ca_topic_score_gemma":0.00002978048,"teacher_disagreement_score":0.9817249,"about_ca_system_score_codex":0.0015476994,"about_ca_system_score_gemma":0.0004923106,"threshold_uncertainty_score":0.9996944},"labels":[],"label_agreement":null},{"id":"W1972836307","doi":"10.1016/j.gep.2014.05.001","title":"MLLT11/AF1q is differentially expressed in maturing neurons during development","year":2014,"lang":"en","type":"article","venue":"Gene Expression Patterns","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research; Nova Scotia Health Research Foundation; Plum Foundation","keywords":"Biology; Neural crest; Subplate; Central nervous system; Nervous system; In situ hybridization; Peripheral nervous system; Spinal cord; Forebrain; Anatomy; Neuroscience; Cell biology; Cerebral cortex; Embryo; Gene expression; Genetics; Gene","score_opus":0.019198880099686094,"score_gpt":0.271223324028661,"score_spread":0.25202444392897494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972836307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993898,0.000036945796,0.004060347,0.000636245,0.00019615056,0.00042384607,0.000014175521,0.00012190134,0.00061240647],"genre_scores_gemma":[0.993508,0.000053443397,0.0033622324,0.00055048824,0.00028428357,0.00011556226,0.00005303809,0.00007766222,0.0019953027],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99729365,0.00014252185,0.0005158211,0.00066680723,0.0006649305,0.0007162549],"domain_scores_gemma":[0.9986825,0.0000716318,0.000105923355,0.0007511674,0.000061562416,0.00032723864],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021971644,0.0003094662,0.0004134386,0.00036014855,0.00015386718,0.000056448625,0.00034539233,0.00016845622,0.0007865643],"category_scores_gemma":[0.00008438647,0.00026562464,0.0000782026,0.00015927732,0.000030796902,0.00012670328,0.00054166996,0.0005679044,0.00017427985],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001810995,0.00013187474,0.09373041,0.00022617067,0.000018048206,0.00011323342,0.0011681016,0.000015970016,0.9001324,0.0000014596524,0.0010628564,0.0032183533],"study_design_scores_gemma":[0.0020075708,0.00003671236,0.35684457,0.00041662026,0.0000071680765,0.000024246265,0.00004735458,0.00018625033,0.638012,0.000008129747,0.002223811,0.0001855616],"about_ca_topic_score_codex":0.000041906325,"about_ca_topic_score_gemma":0.000013421987,"teacher_disagreement_score":0.26311415,"about_ca_system_score_codex":0.00024658637,"about_ca_system_score_gemma":0.00013377435,"threshold_uncertainty_score":0.9999796},"labels":[],"label_agreement":null},{"id":"W1972902934","doi":"10.1016/j.ccr.2011.06.020","title":"Cell of Origin in AML: Susceptibility to MN1-Induced Transformation Is Regulated by the MEIS1/AbdB-like HOX Protein Complex","year":2011,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Terry Fox Research Institute; BC Cancer Agency","funders":"Deutsche Krebshilfe; Biotechnology and Biological Sciences Research Council; José Carreras Leukämie-Stiftung; Terry Fox Foundation; Deutsche Forschungsgemeinschaft; National Centre for the Replacement, Refinement and Reduction of Animals in Research; Canadian Institutes of Health Research; Cancer Research Society; European Hematology Association","keywords":"Hox gene; Biology; Chromatin; Transformation (genetics); Gene; Psychological repression; Cell biology; Genetics; Cancer research; Transcription factor; Computational biology; Gene expression","score_opus":0.07163301436425436,"score_gpt":0.3197919472549218,"score_spread":0.24815893289066748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972902934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820641,0.0002192728,0.00012000155,0.0012785508,0.00006319453,0.0023720658,0.00006413079,0.000037514543,0.013781151],"genre_scores_gemma":[0.99605507,0.00005476755,0.00034603683,0.0006291661,0.00004145887,0.0001905539,0.000039727136,0.00003367427,0.0026095374],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99818593,0.00013417339,0.00047616038,0.00035049536,0.0004254469,0.00042780314],"domain_scores_gemma":[0.9988321,0.000032580527,0.000108542845,0.00063450914,0.00020812001,0.00018415503],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052684505,0.00019696707,0.00035976106,0.00009234107,0.000052233194,0.000009230234,0.00030721567,0.00014902985,0.002146645],"category_scores_gemma":[0.000015759051,0.000144525,0.00008610883,0.00053720095,0.000106013715,0.00012423885,0.00004485593,0.00036914684,0.00006986464],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085208606,0.0002561885,0.0018041187,0.0004275679,0.000022709299,0.000004802731,0.011224559,0.0000044622693,0.9585736,0.000018429311,0.023154216,0.0036572784],"study_design_scores_gemma":[0.0029318284,0.00045238077,0.011817552,0.00009422623,0.000037345286,0.0000018285111,0.0010928201,0.00072698324,0.9670265,0.000041478772,0.015592192,0.00018486423],"about_ca_topic_score_codex":0.012623661,"about_ca_topic_score_gemma":0.0011566406,"teacher_disagreement_score":0.01399096,"about_ca_system_score_codex":0.00084806216,"about_ca_system_score_gemma":0.000450623,"threshold_uncertainty_score":0.9987655},"labels":[],"label_agreement":null},{"id":"W1972960063","doi":"10.1182/blood-2013-10-535104","title":"PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Idelalisib; Juvenile myelomonocytic leukemia; PI3K/AKT/mTOR pathway; MAPK/ERK pathway; Cancer research; Protein kinase B; Biology; Signal transduction; Haematopoiesis; Leukemia; Immunology; Cell biology; Stem cell; Chronic lymphocytic leukemia","score_opus":0.03552750516043019,"score_gpt":0.28006651919053577,"score_spread":0.24453901403010558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972960063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885077,0.000024620422,0.0012255427,0.00043206813,0.000027565566,0.0005102591,0.0000073830056,0.000043484717,0.009221371],"genre_scores_gemma":[0.99723935,0.00001094399,0.0022288328,0.00012336687,0.00005469879,0.000019623287,0.000013136014,0.000031369724,0.00027868993],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849963,0.00016818815,0.0003370977,0.0002902874,0.00039912903,0.00030564994],"domain_scores_gemma":[0.9988883,0.00016728533,0.000115164396,0.0004577347,0.00025643763,0.000115037335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008252017,0.0001522955,0.00045193327,0.00026663893,0.000025394667,0.0000051021407,0.00009677569,0.00017626658,0.000013727618],"category_scores_gemma":[0.0007514295,0.0001362697,0.00009286584,0.0003496938,0.0000880922,0.00008585942,0.00007892827,0.00037780017,0.0000138321375],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003689741,0.0010597528,0.0059825527,0.0003009168,0.00009028389,0.000023121656,0.0004708459,0.00009631232,0.98447007,0.0010443584,0.000078895195,0.0060139447],"study_design_scores_gemma":[0.008350654,0.0016559035,0.022933748,0.00033238227,0.00023946217,0.000060862814,0.00017828972,0.12064795,0.8437858,0.0015430404,0.0000418054,0.00023004944],"about_ca_topic_score_codex":0.0003550209,"about_ca_topic_score_gemma":0.00007170798,"teacher_disagreement_score":0.14068419,"about_ca_system_score_codex":0.00008145879,"about_ca_system_score_gemma":0.00037618168,"threshold_uncertainty_score":0.55569166},"labels":[],"label_agreement":null},{"id":"W1973713328","doi":"10.1038/sj.onc.1207933","title":"Concepts of human leukemic development","year":2004,"lang":"en","type":"review","venue":"Oncogene","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Cancer Institute; Stem Cell Network","keywords":"Biology; clone (Java method); Stem cell; Cancer stem cell; Progenitor cell; Carcinogenesis; Cancer research; Cancer; Haematopoiesis; Identification (biology); Immunology; Genetics; Gene","score_opus":0.09839748201582701,"score_gpt":0.4412575637575409,"score_spread":0.3428600817417139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973713328","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024815547,0.990486,0.000018112225,0.000013163432,0.00009075633,0.0011343661,0.000021726875,0.000051327377,0.007936358],"genre_scores_gemma":[0.00006273516,0.98812246,0.0023618622,0.000034654546,0.00025792242,0.00012252814,0.00053239573,0.00011521189,0.00839024],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99735504,0.00008712105,0.0009947936,0.00048893073,0.0006149326,0.00045918985],"domain_scores_gemma":[0.9984163,0.000077313205,0.00038663507,0.00068815186,0.0001706949,0.00026092044],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037342514,0.00044312136,0.0024730894,0.00035199846,0.00007322601,0.000008652491,0.00038366392,0.00048080162,0.0005549424],"category_scores_gemma":[0.00007818078,0.0003477653,0.000475707,0.00045059915,0.00019056663,0.000025510191,0.0002136351,0.0006689903,0.0005699426],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009304218,0.000095708776,0.0000029397909,0.039582938,0.00045078376,0.00019499454,0.00010895933,1.5468873e-7,0.00040904994,0.00009957527,0.0010685407,0.95797706],"study_design_scores_gemma":[0.0010793223,0.00018601948,0.0000040728955,0.030891942,0.00060361536,0.0002781821,0.000013179077,1.3972092e-7,0.0012042484,0.0000096349395,0.96545327,0.00027639742],"about_ca_topic_score_codex":0.000046697645,"about_ca_topic_score_gemma":0.000005305148,"teacher_disagreement_score":0.96438473,"about_ca_system_score_codex":0.0037167629,"about_ca_system_score_gemma":0.0108731715,"threshold_uncertainty_score":0.9998974},"labels":[],"label_agreement":null},{"id":"W1973911102","doi":"10.1182/blood-2009-06-225573","title":"Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Biology; Cyclin A; Cell cycle; Cancer research; Cyclin D1; Cyclin A2; Hox gene; Retinoblastoma protein; Cell growth; Cyclin E; Progenitor cell; Cell biology; Molecular biology; Stem cell; Transcription factor; Genetics; Cell; Gene","score_opus":0.009435480159513076,"score_gpt":0.24848418930992097,"score_spread":0.2390487091504079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973911102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974418,0.000085211665,0.0000805927,0.0007250182,0.000058656067,0.00039326292,0.000039529175,0.000006740551,0.0011691331],"genre_scores_gemma":[0.9983827,0.00002460296,0.0010247233,0.000033094253,0.0000692859,0.0000055839914,0.0000053435842,0.000011595727,0.0004430611],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990506,0.0000506047,0.0002292462,0.00015191581,0.00038708316,0.00013055517],"domain_scores_gemma":[0.99928516,0.000068555535,0.00010367772,0.0003388858,0.0001199116,0.000083779545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002822762,0.000079175035,0.00021750585,0.00007660928,0.000027674598,0.0000022626177,0.00011149108,0.000109333094,0.00008164253],"category_scores_gemma":[0.000094528266,0.000058040467,0.000099456614,0.00016914477,0.00012747564,0.00003854327,0.000055827993,0.0002621386,0.0000020411765],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015761744,0.0004479872,0.008717547,0.00016393069,0.00005410331,8.692312e-7,0.00033770013,0.000012849169,0.98810834,0.00015775165,0.000055022385,0.0017862638],"study_design_scores_gemma":[0.0017461273,0.000101807105,0.3909777,0.00003059846,0.00009383991,0.000010740424,0.000023599454,0.00013484321,0.6067158,0.00006725264,0.000067860696,0.000029793862],"about_ca_topic_score_codex":0.00012999709,"about_ca_topic_score_gemma":0.000032275508,"teacher_disagreement_score":0.38226017,"about_ca_system_score_codex":0.000023518201,"about_ca_system_score_gemma":0.00021686836,"threshold_uncertainty_score":0.23668216},"labels":[],"label_agreement":null},{"id":"W1973986104","doi":"10.1111/his.12242","title":"<scp>LMO</scp>2 (<scp>LIM</scp> domain only 2) is expressed in a subset of acute myeloid leukaemia and correlates with normal karyotype","year":2013,"lang":"en","type":"article","venue":"Histopathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"Calgary Laboratory Services","keywords":"Karyotype; Chromosomal translocation; Immunohistochemistry; Biology; Myeloid; Myeloid leukemia; Haematopoiesis; Core binding factor; Cytogenetics; Immunology; Cancer research; Pathology; Molecular biology; Medicine; Transcription factor; Gene; Chromosome; Genetics; Stem cell","score_opus":0.008731237095120163,"score_gpt":0.23738589206187138,"score_spread":0.22865465496675122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973986104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98419017,0.0011627284,0.00017871207,0.0005837845,0.00016628196,0.0009905729,0.0000880847,0.00008980698,0.012549851],"genre_scores_gemma":[0.9804589,0.00054918684,0.004698511,0.0011745354,0.00011970007,0.0001837786,0.00014064061,0.000113457056,0.012561275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966665,0.0002747279,0.00068825047,0.0008259678,0.0004980032,0.0010465612],"domain_scores_gemma":[0.99737084,0.0007974894,0.0002971569,0.00083556405,0.00030803218,0.00039093866],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005676191,0.00046417527,0.0010603553,0.0006677999,0.00011420651,0.000025039952,0.0003847184,0.000541553,0.00014897157],"category_scores_gemma":[0.00048363194,0.00039314746,0.00010992777,0.0006161086,0.001007173,0.0002808579,0.0002902635,0.001128505,0.00029065297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031499742,0.00040313747,0.6420199,0.0003634551,0.000092975715,0.0037089272,0.011797959,0.00000915747,0.24773544,0.00044979967,0.09180505,0.0012991759],"study_design_scores_gemma":[0.00908921,0.002684956,0.94071496,0.00025698112,0.00028556373,0.0051391623,0.002282616,0.00043204942,0.011458242,0.0005494642,0.026921552,0.00018525166],"about_ca_topic_score_codex":0.00039753827,"about_ca_topic_score_gemma":0.0001020209,"teacher_disagreement_score":0.29869503,"about_ca_system_score_codex":0.00040993385,"about_ca_system_score_gemma":0.00068550685,"threshold_uncertainty_score":0.99985206},"labels":[],"label_agreement":null},{"id":"W1974101399","doi":"10.1016/j.leukres.2011.05.001","title":"Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosis","year":2011,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Macrocytosis; Medicine; Myelodysplastic syndromes; Internal medicine; Bone marrow; Red blood cell distribution width; International Prognostic Scoring System; Bone marrow examination; Gastroenterology; Anemia","score_opus":0.06880836050930669,"score_gpt":0.31004931206278535,"score_spread":0.24124095155347866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974101399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942835,0.000010371146,0.00010913276,0.00012064603,0.000035064906,0.0036086114,0.000027145183,0.000033947974,0.0017715968],"genre_scores_gemma":[0.99709105,0.000004491649,0.0021186608,0.000013168735,0.000021875141,0.00036516637,0.000019503746,0.000049821894,0.00031624376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951138,0.00062109204,0.00077117234,0.0005817521,0.0020853719,0.00082681834],"domain_scores_gemma":[0.9959928,0.00090456044,0.00015672288,0.0011324061,0.001529435,0.00028409134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036172797,0.00022393183,0.00065856456,0.00086378347,0.00012528768,0.000030178187,0.0006965242,0.00015672315,0.00011808476],"category_scores_gemma":[0.0020946255,0.00013229162,0.00006558934,0.0033100827,0.00041198375,0.00022911625,0.00047291323,0.00087590044,0.000042474283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04667799,0.0011961957,0.9201109,0.0073385173,0.00034153674,0.0005072369,0.010089333,0.0005027998,0.008206574,0.001588247,0.00041042402,0.0030302533],"study_design_scores_gemma":[0.009026747,0.0058025825,0.9205056,0.0028681564,0.000072011,0.00008532449,0.0026475477,0.0008246322,0.057795964,0.00006207861,0.000040590487,0.00026879404],"about_ca_topic_score_codex":0.0028634735,"about_ca_topic_score_gemma":0.00021813271,"teacher_disagreement_score":0.04958939,"about_ca_system_score_codex":0.0035358036,"about_ca_system_score_gemma":0.002398978,"threshold_uncertainty_score":0.92460036},"labels":[],"label_agreement":null},{"id":"W1974674483","doi":"10.1182/blood-2006-04-015560","title":"A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":413,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Myeloid leukemia; Medicine; Internal medicine; Fms-Like Tyrosine Kinase 3; Tyrosine-kinase inhibitor; Chemotherapy; Adverse effect; Oncology; Pharmacology; Leukemia; Chemotherapy regimen; Cancer; Biology; Mutation","score_opus":0.026505635100703077,"score_gpt":0.3123375602894287,"score_spread":0.28583192518872563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974674483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854622,0.000049826915,0.00022503115,0.0031161106,0.00016182553,0.010070531,0.0007184701,0.00005165278,0.00014437063],"genre_scores_gemma":[0.9914669,0.000040262923,0.0024587042,0.0009980884,0.0007864646,0.001303474,0.00038592954,0.000119384094,0.0024407883],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997756,0.00004250314,0.0006323559,0.0005161437,0.00050439424,0.00054858025],"domain_scores_gemma":[0.9972055,0.0004922966,0.00035691075,0.0006421154,0.0011559129,0.00014724322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016465878,0.0003854419,0.0007682107,0.0001225066,0.00017551836,0.000025921088,0.00018359369,0.00019971536,0.000053111067],"category_scores_gemma":[0.00039631597,0.00022960058,0.00038129432,0.00023263799,0.00024592958,0.00007011835,0.00004837281,0.0001779111,0.000007677048],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81795603,0.03682878,0.0038653917,0.00068160833,0.0068153804,0.00013828234,0.002889372,0.00004092909,0.048574418,0.0002661219,0.05009153,0.03185216],"study_design_scores_gemma":[0.62789315,0.01660444,0.0009397722,0.00016896892,0.0012335266,0.000035434598,0.00013037099,0.00017597123,0.3447972,0.00009453986,0.007683102,0.00024351977],"about_ca_topic_score_codex":0.00024834764,"about_ca_topic_score_gemma":0.00009894035,"teacher_disagreement_score":0.29622278,"about_ca_system_score_codex":0.0004957649,"about_ca_system_score_gemma":0.0012342079,"threshold_uncertainty_score":0.936284},"labels":[],"label_agreement":null},{"id":"W1975033967","doi":"10.1097/01.mph.0000159934.35079.b5","title":"A Basic Classification and a Comprehensive Examination of Pediatric Myeloproliferative Syndromes","year":2005,"lang":"en","type":"review","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medicine; Myeloproliferative Disorders; Thrombocytosis; Essential thrombocythemia; Polycythemia vera; Myelofibrosis; Population; Myeloproliferative neoplasm; Systemic mastocytosis; Bone marrow; Myelodysplastic syndromes; Leukemia; Immunology; Pathology; Platelet","score_opus":0.12328855120956818,"score_gpt":0.4178243544242295,"score_spread":0.29453580321466133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975033967","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013359631,0.9834116,0.00009898187,0.0006127178,0.00040039382,0.001420568,0.00002916192,0.000022479575,0.00064448063],"genre_scores_gemma":[0.003617763,0.9895589,0.0033298705,0.000076882374,0.003063776,0.00007396822,0.000046752957,0.00007985205,0.00015224416],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932654,0.001666253,0.0031851765,0.00055459753,0.0007520783,0.000576499],"domain_scores_gemma":[0.9889355,0.0033644957,0.005044648,0.00041647244,0.0017843622,0.00045454205],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0018689237,0.0006224244,0.005751293,0.003212775,0.000094607596,0.000017669629,0.00042692682,0.0017103422,0.00010218375],"category_scores_gemma":[0.0014901328,0.00047554143,0.0006741794,0.0015100564,0.00034087803,0.0002182845,0.00020096153,0.0024337333,0.00005572462],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023401901,0.0008376147,0.0014052851,0.024466937,0.0010281686,0.0018378504,0.0008300943,5.854349e-7,0.000006277626,0.0004653887,0.008982328,0.95990545],"study_design_scores_gemma":[0.006149739,0.0059897243,0.0052528596,0.0014199427,0.017724266,0.07108676,0.00090847653,0.000081148566,0.000004621325,0.0000838818,0.89058787,0.0007106965],"about_ca_topic_score_codex":0.0000033176295,"about_ca_topic_score_gemma":0.0000023015598,"teacher_disagreement_score":0.9591948,"about_ca_system_score_codex":0.001608941,"about_ca_system_score_gemma":0.0075696306,"threshold_uncertainty_score":0.9998677},"labels":[],"label_agreement":null},{"id":"W1975568044","doi":"10.1016/j.bbagrm.2012.02.009","title":"E2A proteins enhance the histone acetyltransferase activity of the transcriptional co-activators CBP and p300","year":2012,"lang":"en","type":"article","venue":"Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research","keywords":"CREB-binding protein; Histone acetyltransferase; Acetyltransferase; Transcription factor; CREB; Acetylation; Molecular biology; Transactivation; P300-CBP Transcription Factors; Histone; Histone H4; Bromodomain; Transcription (linguistics); Biology; Enhancer; Chemistry; Gene; Genetics; Histone Acetyltransferases","score_opus":0.019131091033289103,"score_gpt":0.29692805766367775,"score_spread":0.27779696663038866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975568044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99041086,0.00023500728,0.0013351678,0.005420224,0.00025382004,0.0018932611,0.00016790461,0.00008171947,0.00020205679],"genre_scores_gemma":[0.9971031,0.00013931502,0.0010368179,0.0005339405,0.0003423783,0.00018513434,0.00002933201,0.00009724373,0.0005327247],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996678,0.0004513554,0.00043259512,0.00059807545,0.0011005632,0.000739402],"domain_scores_gemma":[0.9978618,0.00014070942,0.00025309055,0.0012373677,0.00013781546,0.00036920552],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00080471335,0.00049065985,0.00061927596,0.00013548008,0.00040178478,0.000031059397,0.00052578823,0.00029281905,0.00008551556],"category_scores_gemma":[0.000061133615,0.00031100676,0.00038252873,0.0005053626,0.0008612383,0.00032461504,0.00014328398,0.0007628667,0.000015329117],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061750546,0.0005239084,0.0000037385275,0.0001331568,0.00023322018,0.0000017056961,0.00088261446,5.966042e-7,0.99276024,0.003622233,0.0002617547,0.0009592981],"study_design_scores_gemma":[0.0010704171,0.00029113935,0.0312534,0.0000948162,0.00020716697,0.00006592556,0.000102773185,0.000063464395,0.9660056,0.00030687655,0.000224494,0.00031389223],"about_ca_topic_score_codex":0.000050075585,"about_ca_topic_score_gemma":0.0000033945403,"teacher_disagreement_score":0.031249663,"about_ca_system_score_codex":0.0003672624,"about_ca_system_score_gemma":0.0005629258,"threshold_uncertainty_score":0.9999342},"labels":[],"label_agreement":null},{"id":"W1975798779","doi":"10.1046/j.1365-2141.2001.02927.x","title":"Detection and clinical significance of human acute myeloid leukaemia progenitors capable of long‐term proliferation <i>in vitro</i>","year":2001,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Terry Fox Research Institute; BC Cancer Agency","funders":"National Cancer Institute; Terry Fox Foundation","keywords":"Progenitor cell; Nod; Myeloid; Immunology; Cancer research; Biology; In vitro; Cell culture; Stem cell; Medicine; Cell biology; In vivo; Genetics","score_opus":0.02277607601601483,"score_gpt":0.33292596399756547,"score_spread":0.31014988798155063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975798779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99759084,0.0011094129,0.0003702169,0.00018124947,0.00013230012,0.00048857887,0.000005763499,0.000007975144,0.00011368031],"genre_scores_gemma":[0.9973691,0.0016117521,0.00069124874,0.00004991679,0.00016661182,0.000010593072,0.0000057524157,0.00002218313,0.00007285092],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974364,0.0002859098,0.0014277451,0.0002142477,0.00034229786,0.0002933889],"domain_scores_gemma":[0.998309,0.0001413997,0.00072463,0.00015284782,0.00050557574,0.0001665355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010596246,0.00012435047,0.0010089506,0.00028126303,0.00005446858,0.000014817051,0.00014344369,0.00025521076,0.000023051256],"category_scores_gemma":[0.00032729396,0.000131535,0.00015564817,0.00027037947,0.00040457112,0.00018715444,0.00004488353,0.0007093796,0.0000013715962],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033266365,0.000690985,0.3696418,0.00052626623,0.0004199581,0.03166274,0.00018254758,0.000003908014,0.53732485,0.000019570438,0.00029018396,0.05591053],"study_design_scores_gemma":[0.0072207646,0.0019897728,0.21188036,0.0006453137,0.00030062764,0.32208064,0.00013499153,0.00015271323,0.45525205,0.00012704908,0.000053111842,0.0001626122],"about_ca_topic_score_codex":0.00015825685,"about_ca_topic_score_gemma":0.00026167164,"teacher_disagreement_score":0.2904179,"about_ca_system_score_codex":0.00013360269,"about_ca_system_score_gemma":0.00040985714,"threshold_uncertainty_score":0.5363841},"labels":[],"label_agreement":null},{"id":"W1976033939","doi":"10.1053/j.semdp.2011.08.004","title":"Acute leukemias of ambiguous lineage","year":2012,"lang":"en","type":"review","venue":"Seminars in Diagnostic Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Immunophenotyping; Myeloid; Lineage (genetic); Biology; CD19; Haematopoiesis; Immunology; Stem cell; Cancer research; Pathology; Medicine; Antigen; Genetics; Gene","score_opus":0.05215731831987574,"score_gpt":0.3767755785924724,"score_spread":0.32461826027259666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976033939","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017310289,0.9930317,0.00003292299,0.000051963827,0.0006085391,0.0018923455,0.00022424934,0.00006328296,0.0023639956],"genre_scores_gemma":[0.00024047474,0.99441993,0.0019563753,0.00014078309,0.00047834267,0.00052650255,0.00058419263,0.00017813117,0.001475291],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951424,0.00061400223,0.0017349329,0.0008199623,0.0004744247,0.0012142493],"domain_scores_gemma":[0.992268,0.005126781,0.0006692337,0.0014400753,0.00013849797,0.00035736768],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0013964686,0.0007425056,0.0045347484,0.0011178511,0.00003676645,0.000007515736,0.00068047555,0.0016217965,0.00025748153],"category_scores_gemma":[0.0076381974,0.0006239506,0.0006638341,0.0010145823,0.00063753605,0.00006512632,0.00059371337,0.0023061645,0.0005474276],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046197478,0.0003815141,0.00033164618,0.0150626805,0.00025791422,0.01726302,0.00024188592,3.7438778e-7,0.00002157766,0.00006533412,0.0025767002,0.96375114],"study_design_scores_gemma":[0.0016109773,0.0007387454,0.00025300187,0.035720818,0.0047108554,0.013850118,0.00004967144,0.00000563668,0.00014344105,0.000036091624,0.9422433,0.0006373962],"about_ca_topic_score_codex":0.000059753886,"about_ca_topic_score_gemma":0.000008280203,"teacher_disagreement_score":0.9631138,"about_ca_system_score_codex":0.0011866854,"about_ca_system_score_gemma":0.0016612503,"threshold_uncertainty_score":0.9999955},"labels":[],"label_agreement":null},{"id":"W1976209487","doi":"10.1371/journal.pgen.1004827","title":"The IKAROS Interaction with a Complex Including Chromatin Remodeling and Transcription Elongation Activities Is Required for Hematopoiesis","year":2014,"lang":"en","type":"article","venue":"PLoS Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Fonds de Recherche du Québec - Santé; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Biology; P-TEFb; Chromatin remodeling; Cell biology; RNA polymerase II; Transcription factor; Nucleosome; Chromatin; Regulation of gene expression; Transcription (linguistics); Promoter; Gene expression; Genetics; Gene","score_opus":0.08895951876804382,"score_gpt":0.32841466620963283,"score_spread":0.23945514744158902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976209487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746944,0.00011688998,0.021511395,0.0026183065,0.00003069072,0.000722229,0.0000061978844,0.000048158,0.00025173472],"genre_scores_gemma":[0.9873087,0.00015019349,0.01185126,0.00022453567,0.00016128315,0.000089807945,0.00002636108,0.000033934684,0.00015396731],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9990427,0.00005873869,0.00020971187,0.00020127291,0.00027438035,0.00021320683],"domain_scores_gemma":[0.99918777,0.00029949442,0.000089257264,0.00021351824,0.0001467579,0.00006321871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028773784,0.000120543904,0.00018554149,0.00007116762,0.00036581696,0.00007541992,0.000062711435,0.000063337946,0.000007829025],"category_scores_gemma":[0.00011707043,0.00008515268,0.00003448152,0.00009346888,0.00009599918,0.0001029991,0.000026451422,0.00013221329,0.0000019740228],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063741376,0.000042782955,0.0004048524,0.0003766539,0.00009776694,5.1036807e-7,0.003462901,0.000095509764,0.9783566,0.00013095068,0.00057646685,0.015817571],"study_design_scores_gemma":[0.0013342273,0.0004477178,0.00048636293,0.00020147032,0.000118957054,0.000039290255,0.0015454707,0.69193083,0.30116728,0.00035774536,0.0022576402,0.00011300347],"about_ca_topic_score_codex":0.000008055944,"about_ca_topic_score_gemma":0.000030901618,"teacher_disagreement_score":0.69183534,"about_ca_system_score_codex":0.00015965583,"about_ca_system_score_gemma":0.000056511864,"threshold_uncertainty_score":0.34724256},"labels":[],"label_agreement":null},{"id":"W1976335329","doi":"10.1182/blood-2008-03-144063","title":"Targeting LSCs: powering an old tool","year":2008,"lang":"en","type":"letter","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Institute of Allergy and Infectious Diseases","keywords":"In silico; Computational biology; Medicine; Biology; Bioinformatics; Cancer research; Gene; Genetics","score_opus":0.021650785209127547,"score_gpt":0.27770298500170093,"score_spread":0.2560521997925734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976335329","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3727183,0.0029803433,0.00013188328,0.5885398,0.0010244823,0.002719883,0.00015302088,0.0012604776,0.030471845],"genre_scores_gemma":[0.004670663,0.0009196687,0.008002915,0.9097986,0.033071067,0.00013848481,0.0023283947,0.00052117,0.040549036],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99689245,0.00009874962,0.00043766902,0.000723142,0.00091451366,0.000933497],"domain_scores_gemma":[0.99846596,0.00011845741,0.00012736858,0.0009524703,0.00016788309,0.00016786688],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00026898843,0.0004234554,0.00067209045,0.00030616377,0.00014229972,0.00005138636,0.00040867686,0.0010361854,0.0005422998],"category_scores_gemma":[0.00033295856,0.00038772624,0.00019653983,0.00023398941,0.000107021486,0.00012715795,0.00018864273,0.004022016,0.0005154226],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002449276,0.00014110813,0.0009509735,0.00035589578,0.00024284674,0.015308079,0.00019910844,0.0000010176251,0.004347212,0.0000025858135,0.9780297,0.0003969694],"study_design_scores_gemma":[0.0029719688,0.00034635662,0.0003634604,0.00026227563,0.00025540424,0.0017567613,0.000032993947,0.000069261725,0.0020942055,0.000009180876,0.99134177,0.00049639033],"about_ca_topic_score_codex":0.000118507174,"about_ca_topic_score_gemma":8.371514e-7,"teacher_disagreement_score":0.36804762,"about_ca_system_score_codex":0.00022697226,"about_ca_system_score_gemma":0.00052571076,"threshold_uncertainty_score":0.9998575},"labels":[],"label_agreement":null},{"id":"W1977194755","doi":"10.1111/j.1365-2257.1984.tb00530.x","title":"Acute myeloblastic leukaemia and autoimmune haemolytic anaemia","year":2008,"lang":"en","type":"article","venue":"Clinical & Laboratory Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; General hospital; University hospital; Family medicine; Hematology; Pediatrics; Library science; Internal medicine; Computer science","score_opus":0.04471554794019499,"score_gpt":0.36998378599168336,"score_spread":0.32526823805148836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977194755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916213,0.0017460937,0.00022270193,0.0037190386,0.0005227087,0.0005975692,0.000035182202,0.0002964914,0.0012388726],"genre_scores_gemma":[0.9893065,0.001983443,0.002450661,0.004383179,0.00030268484,0.00005689803,0.000042117106,0.00009090152,0.0013836062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959454,0.00046944217,0.001347873,0.0009427944,0.0004100817,0.00088439824],"domain_scores_gemma":[0.9959228,0.0014616591,0.00025761532,0.001061295,0.00049979286,0.0007968361],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008829192,0.00040781955,0.0018174911,0.00025423258,0.00028947822,0.0000186643,0.00034225895,0.0008300541,0.0003268539],"category_scores_gemma":[0.0028193532,0.00035311884,0.00021016982,0.00076216814,0.0025896148,0.00016210672,0.0003576304,0.0016658438,0.00090728526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038331768,0.001344459,0.70837855,0.0007772128,0.002440045,0.09632637,0.0006667283,0.0000049311216,0.008964921,0.008465546,0.16119803,0.007600043],"study_design_scores_gemma":[0.022376087,0.0037913304,0.814625,0.00044945788,0.001430692,0.04056928,0.0002506524,0.0032007692,0.0035290993,0.0010399307,0.10721882,0.0015188507],"about_ca_topic_score_codex":0.000015317462,"about_ca_topic_score_gemma":0.000007584026,"teacher_disagreement_score":0.10624651,"about_ca_system_score_codex":0.00020577895,"about_ca_system_score_gemma":0.0021930053,"threshold_uncertainty_score":0.99989206},"labels":[],"label_agreement":null},{"id":"W1977446491","doi":"10.1002/pbc.21353","title":"Acute megakaryoblastic leukemia in Down syndrome","year":2007,"lang":"en","type":"review","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; SickKids Foundation","funders":"","keywords":"Acute megakaryoblastic leukemia; GATA1; Down syndrome; Medicine; Leukemia; Phenotype; Acute leukemia; Somatic cell; Immunology; Blood cancer; Disease; Cancer research; Cancer; Internal medicine; Genetics; Gene; Biology; Anemia; Erythropoiesis","score_opus":0.04455622027800609,"score_gpt":0.37948097504344797,"score_spread":0.33492475476544187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977446491","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014931789,0.9928109,0.00001115887,0.000061785126,0.0007031182,0.0024075026,0.00024369977,0.00016638952,0.0021022554],"genre_scores_gemma":[0.000115854185,0.9897743,0.0003137495,0.00021542973,0.003147907,0.0008992569,0.00023310515,0.00028969717,0.0050106957],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939467,0.00017252879,0.001594376,0.0013438829,0.0012713105,0.0016712196],"domain_scores_gemma":[0.9968066,0.0006793672,0.0005106333,0.0011167891,0.00018856152,0.0006980013],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008247661,0.0010561177,0.004056116,0.0023091182,0.000087655884,0.000053428426,0.0007747125,0.0012640918,0.001242627],"category_scores_gemma":[0.00023303123,0.00085686974,0.0008697567,0.0040603643,0.00013106354,0.00013995972,0.0003878522,0.003510161,0.0009180362],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00021421583,0.000399685,0.0017945867,0.12023866,0.0030734863,0.028089037,0.00011777477,0.000008855172,0.0000015977298,0.000042516796,0.024491293,0.8215283],"study_design_scores_gemma":[0.0033594624,0.00036671467,0.0003769219,0.008523113,0.021095058,0.0043603643,0.0000062015743,0.000014595107,0.0000016506958,0.000011406008,0.9608905,0.0009940454],"about_ca_topic_score_codex":0.00080674735,"about_ca_topic_score_gemma":0.000114143295,"teacher_disagreement_score":0.93639916,"about_ca_system_score_codex":0.0051314645,"about_ca_system_score_gemma":0.013371711,"threshold_uncertainty_score":0.99985987},"labels":[],"label_agreement":null},{"id":"W1977693378","doi":"10.1038/sj.leu.2403112","title":"Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL","year":2003,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Apoptosis; Programmed cell death; Caspase; Caspase 8; Leukemia; Cell culture; Cancer research; Viability assay; Biology; Flip; Downregulation and upregulation; Intrinsic apoptosis; Chemistry; Immunology; Biochemistry; Genetics","score_opus":0.018689794074309717,"score_gpt":0.26835058163641035,"score_spread":0.24966078756210064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977693378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938553,0.0000546753,0.0038678173,0.00039386787,0.000039455528,0.0011029659,0.000014876959,0.000022322649,0.0006487003],"genre_scores_gemma":[0.99211943,0.00003226391,0.0066698873,0.00019745734,0.000045471137,0.00006667041,0.00002301819,0.00003612262,0.00080965576],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986748,0.00010499241,0.0003457398,0.00033303435,0.0002274155,0.00031398464],"domain_scores_gemma":[0.9990626,0.00032571575,0.00007878292,0.00025582267,0.00013118247,0.00014590913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005273619,0.00015274236,0.00034882492,0.00036132507,0.000047688543,0.000019853062,0.0000540554,0.00015469937,0.000031363554],"category_scores_gemma":[0.0005911683,0.00014591229,0.000058359772,0.00047512798,0.000051050407,0.000113642054,0.000026151443,0.0001646644,0.0000061579553],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033601135,0.000036909874,0.0007290732,0.00026008024,0.000019787196,0.0000034680133,0.0011993507,0.000321464,0.984194,0.0007334698,0.00018221451,0.01198419],"study_design_scores_gemma":[0.0033604319,0.0003024059,0.008762697,0.0003414693,0.00003623343,0.000015875135,0.00030132986,0.008517072,0.9767913,0.00028581405,0.0011059269,0.00017941084],"about_ca_topic_score_codex":0.00010355545,"about_ca_topic_score_gemma":0.00003173124,"teacher_disagreement_score":0.011804779,"about_ca_system_score_codex":0.0008576223,"about_ca_system_score_gemma":0.0003625512,"threshold_uncertainty_score":0.595013},"labels":[],"label_agreement":null},{"id":"W1978153987","doi":"10.1182/asheducation-2009.1.664","title":"Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?","year":2009,"lang":"en","type":"review","venue":"Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Deferasirox; Intensive care medicine; Chelation therapy; Anemia; Thalassemia; Adverse effect; Deferiprone; Blood transfusion; Internal medicine; Bone marrow","score_opus":0.09077381371139502,"score_gpt":0.40620704699250476,"score_spread":0.3154332332811097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978153987","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017365468,0.99559575,0.000010398568,0.00026899693,0.00007727236,0.0013782625,0.000010628324,0.000053659165,0.0008684929],"genre_scores_gemma":[0.0018629013,0.99699867,0.0002934473,0.00008276487,0.0001179631,0.00011950011,0.00011422715,0.000065775625,0.00034478251],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979546,0.00017250929,0.00062714797,0.00057170866,0.00019205263,0.00048199215],"domain_scores_gemma":[0.9987258,0.00037007843,0.00031056875,0.00037261014,0.000085970176,0.00013497453],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018288603,0.00040025942,0.0022431402,0.0005056928,0.000056104134,0.000016996697,0.0001433364,0.00058193994,0.00026065749],"category_scores_gemma":[0.00021919265,0.00028620582,0.00016014105,0.00035373063,0.0001248672,0.00006877784,0.00009504277,0.00094276154,0.000044217566],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011131772,0.00005329664,0.0008291713,0.030357001,0.000083815976,0.00226542,0.0019022248,1.5225426e-7,0.0000020488171,0.000046443227,0.00039493354,0.96395415],"study_design_scores_gemma":[0.003401813,0.0012590343,0.001202002,0.070662476,0.00055334973,0.010948619,0.0073303385,0.000019106621,0.000037627535,0.000042614436,0.9036715,0.0008715353],"about_ca_topic_score_codex":0.000023305362,"about_ca_topic_score_gemma":0.00008245599,"teacher_disagreement_score":0.9630826,"about_ca_system_score_codex":0.00049952476,"about_ca_system_score_gemma":0.00068546186,"threshold_uncertainty_score":0.999959},"labels":[],"label_agreement":null},{"id":"W1978540403","doi":"10.1097/mph.0000000000000097","title":"Testicular Myeloid Sarcoma","year":2014,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; McMaster Children's Hospital; McMaster University Medical Centre","funders":"","keywords":"Medicine; Myeloid sarcoma; Sarcoma; Cerebrospinal fluid; Bone marrow; Pathology; Myeloid; Testicular tumor; Myeloid leukaemia; Internal medicine","score_opus":0.022421815071087318,"score_gpt":0.3316208612866224,"score_spread":0.30919904621553507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978540403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9574757,0.003305205,0.0055805566,0.017483622,0.0011236978,0.00039778915,0.0000027223828,0.00006659322,0.014564094],"genre_scores_gemma":[0.96685654,0.001088969,0.02511966,0.0020443222,0.004380383,0.000011086779,0.0000047781195,0.000057235822,0.00043702006],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965894,0.00054732285,0.0012764974,0.00028718394,0.0005942808,0.0007053127],"domain_scores_gemma":[0.9954046,0.001788133,0.000883905,0.00041106582,0.00083888497,0.0006734124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024736533,0.00025974645,0.001447258,0.00086634874,0.000098012264,0.000013980482,0.00043557043,0.00061628484,0.0003316853],"category_scores_gemma":[0.004709734,0.00019819477,0.00033954467,0.0006446607,0.00023840486,0.00013008747,0.00015650716,0.0015555597,0.0003797224],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029197002,0.0031697666,0.41625655,0.00094074855,0.0010123482,0.023037443,0.0010785433,0.000042775577,0.010915957,0.009503338,0.45760217,0.073520675],"study_design_scores_gemma":[0.024608223,0.019061504,0.04026215,0.00009265747,0.0025221277,0.16795695,0.00069652504,0.0015369494,0.0038151976,0.0050293286,0.73363996,0.00077840395],"about_ca_topic_score_codex":0.000008979284,"about_ca_topic_score_gemma":0.000002894394,"teacher_disagreement_score":0.37599438,"about_ca_system_score_codex":0.0007342465,"about_ca_system_score_gemma":0.0024389827,"threshold_uncertainty_score":0.8082148},"labels":[],"label_agreement":null},{"id":"W1978596654","doi":"10.1016/s0165-4608(03)00273-5","title":"Interphase cytogenetic analysis of clonality in peripheral blood cells from a patient with Down syndrome and acute megakaryoblastic leukemia","year":2004,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Biology; Acute megakaryoblastic leukemia; Trisomy; Fluorescence in situ hybridization; Trisomy 8; Aneuploidy; Interphase; Myeloid leukemia; Myeloid; Immunology; Leukemia; Chromosome abnormality; Cytogenetics; Molecular biology; Karyotype; Chromosome; Genetics","score_opus":0.010679726688260378,"score_gpt":0.26915714131798707,"score_spread":0.2584774146297267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978596654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910061,0.0072245076,0.00052327407,0.00014176467,0.000043680928,0.000521343,0.0004958078,0.000013423811,0.000030130554],"genre_scores_gemma":[0.98637605,0.008040166,0.005084373,0.0002609373,0.0000342524,0.00006157536,0.0000649921,0.000046954592,0.00003070828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776506,0.000045673638,0.0005735387,0.0006694749,0.00047889375,0.00046733773],"domain_scores_gemma":[0.9986822,0.00007536389,0.00016271719,0.00051143795,0.00018397662,0.00038428768],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009502418,0.00035464918,0.0008408031,0.00037344586,0.000056724653,0.000035857953,0.00015596431,0.0001794326,0.0000866484],"category_scores_gemma":[0.000014556336,0.00030226397,0.00010976435,0.00090572896,0.00043188018,0.000025905369,0.00019164452,0.0002914318,8.227295e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00199214,0.0006756938,0.64021486,0.00033638877,0.009527843,0.0022616053,0.0037929523,0.0459843,0.28472087,0.000040082592,0.000026331563,0.010426935],"study_design_scores_gemma":[0.01327414,0.005357314,0.67315364,0.0005228205,0.013910265,0.00045649963,0.00046238484,0.010232772,0.2811749,0.0003135572,0.0002455797,0.0008961516],"about_ca_topic_score_codex":0.0014204162,"about_ca_topic_score_gemma":0.0018143804,"teacher_disagreement_score":0.03575153,"about_ca_system_score_codex":0.0004227384,"about_ca_system_score_gemma":0.00079039315,"threshold_uncertainty_score":0.99994296},"labels":[],"label_agreement":null},{"id":"W1979470678","doi":"10.1002/1096-8652(200008)64:4<306::aid-ajh12>3.0.co;2-v","title":"Prolonged complete remission of myelodysplastic syndrome treated with danazol, retinoic acid and low-dose prednisone","year":2000,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Pancytopenia; Macrocytosis; Gastroenterology; Prednisone; Internal medicine; Danazol; Myelodysplastic syndromes; Bone marrow; Myeloid; Anemia","score_opus":0.009845085584709527,"score_gpt":0.25939139876208434,"score_spread":0.2495463131773748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979470678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975776,0.00042079043,0.000054930904,0.0013002735,0.0000145566655,0.00025867063,0.0000062629256,0.000016396036,0.00035050072],"genre_scores_gemma":[0.9967919,0.0002793508,0.0025866823,0.00011205593,0.000024083283,0.0000048368115,0.0000062699073,0.000033606462,0.00016122968],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9981144,0.00021352869,0.00065893104,0.00023704069,0.00039367107,0.00038240413],"domain_scores_gemma":[0.9983044,0.00023727342,0.00056193664,0.00028839934,0.0002600599,0.0003478854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028807958,0.00020554672,0.00122613,0.0002928865,0.000056361816,0.0000068423005,0.00016971053,0.00007818732,0.0004241466],"category_scores_gemma":[0.00016462737,0.00013850055,0.00007521764,0.00047302144,0.0010396278,0.000079552,0.000034475543,0.00051516487,0.000011198948],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07533631,0.001846724,0.38959256,0.0016870401,0.0030001742,0.03611293,0.0023108164,0.000062937375,0.36909497,0.00015786463,0.0028333892,0.117964305],"study_design_scores_gemma":[0.024141591,0.052350402,0.30898705,0.0035249894,0.0011996962,0.548661,0.0015832348,0.0018004703,0.055704392,0.00009700778,0.0012554764,0.00069470983],"about_ca_topic_score_codex":0.000037772123,"about_ca_topic_score_gemma":0.0000025343138,"teacher_disagreement_score":0.512548,"about_ca_system_score_codex":0.000093471026,"about_ca_system_score_gemma":0.00034875644,"threshold_uncertainty_score":0.5647888},"labels":[],"label_agreement":null},{"id":"W1979616872","doi":"10.1002/ajh.22193","title":"Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity","year":2011,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Internal medicine; Myeloid leukemia; Gastroenterology; Medicine; Leukemia; Oncology; Multiple drug resistance; Drug resistance; Biology; Genetics","score_opus":0.02171115480259071,"score_gpt":0.2723642155425807,"score_spread":0.25065306073999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979616872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99781126,0.00016643562,0.00011026516,0.0011618019,0.00008518424,0.00021496495,0.000011328859,0.000017880813,0.00042090396],"genre_scores_gemma":[0.992387,0.00028821413,0.0066166404,0.00015178917,0.00005421335,0.000014223121,0.000004061393,0.000028774284,0.0004550678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831,0.0001810144,0.00048168757,0.00027123364,0.00033487545,0.00042116974],"domain_scores_gemma":[0.9984509,0.00028871465,0.0005804748,0.00021584201,0.00019173566,0.0002723372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024850783,0.00023553608,0.0010046278,0.00032060104,0.000059896163,0.0000051116726,0.00011281392,0.00009144305,0.00007359679],"category_scores_gemma":[0.00011258249,0.0001629042,0.00009540417,0.00030386983,0.00056541973,0.00018973449,0.00004627035,0.0005218489,0.0000092504215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011462691,0.00033647192,0.978608,0.000029353698,0.000824517,0.0036854753,0.00075951306,0.000006335624,0.0012394758,0.00020328125,0.00024595688,0.0025989183],"study_design_scores_gemma":[0.006763364,0.003915645,0.98041797,0.000091180256,0.0002648132,0.0039031184,0.0006733255,0.00006221842,0.003532269,0.000076019416,0.00013947574,0.00016062892],"about_ca_topic_score_codex":0.0005374636,"about_ca_topic_score_gemma":0.0003019956,"teacher_disagreement_score":0.0065063755,"about_ca_system_score_codex":0.0011141016,"about_ca_system_score_gemma":0.0007646182,"threshold_uncertainty_score":0.664304},"labels":[],"label_agreement":null},{"id":"W1980521997","doi":"10.1182/blood-2012-01-404699","title":"Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":203,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Progenitor cell; Stem cell; Biology; Haematopoiesis; Cancer research; CD34; Myeloid leukemia; Immunology; Myeloid; Medicine; Internal medicine; Cell biology","score_opus":0.0276494854823044,"score_gpt":0.2961478709077594,"score_spread":0.268498385425455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980521997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998002,0.000723384,0.0000036454187,0.00008640744,0.000025139305,0.00096790254,0.000011395868,0.000009841786,0.00017029318],"genre_scores_gemma":[0.9985886,0.000051881805,0.00083301624,0.000014280928,0.000060889393,0.00004938832,0.0000050537806,0.000014726472,0.00038213405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990991,0.00008340676,0.00025601842,0.00016675485,0.00018483722,0.00020992223],"domain_scores_gemma":[0.99958336,0.00007114385,0.000072949,0.00012378303,0.000028987202,0.00011976276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039617004,0.000096635034,0.0002318598,0.00016041845,0.000018003144,0.00000952877,0.000036019417,0.00012990137,0.000015114586],"category_scores_gemma":[0.00007807614,0.00007886208,0.000011452292,0.00013227362,0.000065002045,0.00019524718,0.00010176479,0.00023278785,0.0000027414671],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013806717,0.00018665114,0.6581621,0.0002875413,0.00000784139,0.0000029539651,0.00057034096,8.012804e-8,0.3386748,0.0000150048645,0.000026407863,0.0019281628],"study_design_scores_gemma":[0.007268068,0.00023100986,0.62796646,0.00049960543,0.00002990287,0.000020898819,0.00039616262,0.00014457459,0.3630413,0.000011094955,0.00027037092,0.0001205165],"about_ca_topic_score_codex":0.000060882605,"about_ca_topic_score_gemma":0.000005797034,"teacher_disagreement_score":0.03019564,"about_ca_system_score_codex":0.000045045337,"about_ca_system_score_gemma":0.000044505898,"threshold_uncertainty_score":0.32159024},"labels":[],"label_agreement":null},{"id":"W1980640814","doi":"10.1038/bmt.2014.272","title":"Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation","year":2014,"lang":"en","type":"letter","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"University of Calgary","keywords":"Medicine; Fludarabine; Transplantation; Haematopoiesis; Juvenile myelomonocytic leukemia; Internal medicine; Hematopoietic cell; Oncology; Immunology; Stem cell; Cyclophosphamide; Chemotherapy","score_opus":0.01642800557601236,"score_gpt":0.25659825394145047,"score_spread":0.2401702483654381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980640814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93699473,0.0028961238,0.0032906118,0.049725186,0.00013177285,0.00468567,0.00056244916,0.0001193384,0.0015941021],"genre_scores_gemma":[0.94941247,0.020885475,0.0018001499,0.017455133,0.0006679793,0.0005373801,0.008068165,0.00020466003,0.0009685723],"study_design_codex":"systematic_review","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99587685,0.0005930232,0.0009802722,0.0008918354,0.0009885451,0.0006694645],"domain_scores_gemma":[0.99794024,0.00088355236,0.00033106402,0.00058021717,0.00015304254,0.00011185673],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052080106,0.0007454723,0.0012845643,0.0006543241,0.00012267404,0.00007706783,0.00023096947,0.0007562348,0.000053436834],"category_scores_gemma":[0.000010544243,0.0005109964,0.00021700926,0.00058601686,0.0003549358,0.00019996629,0.0000053327212,0.0009956496,0.000021924063],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061476294,0.0049446453,0.034316536,0.20542824,0.004438381,0.19992046,0.16040325,0.003979649,0.17593965,0.0003346648,0.08773922,0.06107901],"study_design_scores_gemma":[0.17152813,0.0430662,0.23226118,0.033241887,0.028544804,0.058824975,0.0033616803,0.02466811,0.29052117,0.00069019705,0.103691965,0.009599685],"about_ca_topic_score_codex":0.0007383723,"about_ca_topic_score_gemma":0.00029137608,"teacher_disagreement_score":0.19794466,"about_ca_system_score_codex":0.0005973073,"about_ca_system_score_gemma":0.00081931,"threshold_uncertainty_score":0.99973416},"labels":[],"label_agreement":null},{"id":"W1980675800","doi":"10.1111/j.1365-2257.1991.tb00254.x","title":"The myelokathexis-like variant of the myelodysplastic syndrome-a second example","year":2008,"lang":"en","type":"article","venue":"Clinical & Laboratory Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"University hospital; Medicine; General hospital; Medical school; Family medicine; Medical education","score_opus":0.05051619077532176,"score_gpt":0.3360697915940607,"score_spread":0.28555360081873893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980675800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99212253,0.00097556046,0.000091346825,0.0031779332,0.0014104795,0.00071969576,0.000048040783,0.00007186487,0.001382539],"genre_scores_gemma":[0.9941947,0.0003990944,0.00036823214,0.0023844987,0.0001707749,0.00006132321,0.000007757142,0.00005915291,0.002354461],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956002,0.0011185063,0.0014393327,0.00059542555,0.00053405866,0.0007124742],"domain_scores_gemma":[0.9911878,0.0056231604,0.00044431823,0.0017828525,0.0006077646,0.00035411035],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0019746064,0.00028425004,0.0011763524,0.00008559902,0.00051599677,0.0000123671025,0.0008723517,0.0004950516,0.000511789],"category_scores_gemma":[0.0040333867,0.00015440398,0.0003249756,0.00084237586,0.0033988457,0.00007144541,0.0004388486,0.00143071,0.00038047982],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003818688,0.00287427,0.48362204,0.0013437319,0.0032491363,0.03401781,0.001832567,0.000015143404,0.0039357226,0.06964916,0.39269695,0.0029447514],"study_design_scores_gemma":[0.0068939086,0.0015592749,0.45463577,0.0002321267,0.00037620057,0.026207706,0.00039086712,0.00039154137,0.0015020963,0.0016231042,0.5056697,0.0005176702],"about_ca_topic_score_codex":0.000026377966,"about_ca_topic_score_gemma":0.00007394894,"teacher_disagreement_score":0.11297278,"about_ca_system_score_codex":0.00010336001,"about_ca_system_score_gemma":0.0024925184,"threshold_uncertainty_score":0.99931335},"labels":[],"label_agreement":null},{"id":"W1981572464","doi":"10.1016/j.leukres.2006.03.029","title":"Synergistic effects of troglitazone in combination with cytotoxic agents in acute myelogenous leukaemia cells","year":2006,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Cytotoxic T cell; Daunorubicin; Cytarabine; Etoposide; Bone marrow; Troglitazone; Pharmacology; Leukemia; Chemistry; Medicine; In vitro; Immunology; Internal medicine; Chemotherapy; Biochemistry","score_opus":0.024792458038532843,"score_gpt":0.3256734553512945,"score_spread":0.30088099731276163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981572464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928223,0.0002965594,0.00015837034,0.00030992556,0.000057809324,0.0025239792,0.000011710685,0.000050614224,0.0037687547],"genre_scores_gemma":[0.994594,0.00017258221,0.00090325344,0.000051028106,0.00009264435,0.00035396972,0.00009476014,0.00009430367,0.003643482],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99412245,0.00071650086,0.000768478,0.0007707199,0.0021152433,0.0015066206],"domain_scores_gemma":[0.99702287,0.0012204412,0.00012265843,0.00086696644,0.0005109968,0.00025609482],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020470368,0.0003406182,0.0008435676,0.0021344554,0.000107143365,0.00004124233,0.00051966944,0.0003815503,0.000059810234],"category_scores_gemma":[0.00042239396,0.0002936255,0.00010031329,0.003264269,0.0006071773,0.00017588721,0.00024791164,0.0019287589,0.00013131752],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034840885,0.0016112305,0.050901495,0.0020686097,0.00015416484,0.010339016,0.00068872486,0.00091636943,0.9221503,0.0015613418,0.0030837294,0.003040931],"study_design_scores_gemma":[0.027050251,0.0036617315,0.32904276,0.0014403078,0.00008173304,0.00010839809,0.00026561914,0.009144831,0.62712187,0.0012752076,0.00031004855,0.0004972176],"about_ca_topic_score_codex":0.0082189655,"about_ca_topic_score_gemma":0.001024068,"teacher_disagreement_score":0.29502842,"about_ca_system_score_codex":0.008418513,"about_ca_system_score_gemma":0.002618357,"threshold_uncertainty_score":0.9999516},"labels":[],"label_agreement":null},{"id":"W1981802649","doi":"10.1002/pbc.20951","title":"Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: Report from the Children's Oncology Group","year":2006,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre","funders":"","keywords":"Medicine; Internal medicine; Myelodysplastic syndromes; Acute promyelocytic leukemia; Leukemia; Pediatrics; Blood cancer; Myeloid leukemia; Oncology; Cancer; Bone marrow","score_opus":0.017273792192636264,"score_gpt":0.3255942772659304,"score_spread":0.3083204850732941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981802649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98479295,0.009812952,0.000114892464,0.0017457458,0.000573132,0.0012005143,0.00030566106,0.00012257477,0.0013315587],"genre_scores_gemma":[0.99075115,0.0015768532,0.0009847959,0.00033613984,0.004713406,0.00022469254,0.00044383027,0.00009317006,0.0008759378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99590725,0.00018002043,0.0012189179,0.0008034653,0.0010694341,0.00082088873],"domain_scores_gemma":[0.99675775,0.0010543197,0.0007091361,0.00097269745,0.00024809732,0.0002580205],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047400396,0.0004239915,0.0012055928,0.00025351753,0.00019971823,0.000029542958,0.0005522465,0.0003727837,0.0011227927],"category_scores_gemma":[0.00046940544,0.00027974206,0.00024730124,0.0011568572,0.0002573298,0.00010400322,0.00026157382,0.0011634718,0.000085399035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037366257,0.0016019729,0.93951976,0.000097758864,0.00049931457,0.0009853037,0.00027466915,0.00006184108,0.00020520843,0.0000281452,0.05391946,0.0024328933],"study_design_scores_gemma":[0.0057981317,0.0010297067,0.98206216,0.00007008291,0.0027613572,0.0016668882,0.00011008711,0.00007300873,0.00038096114,0.000051984585,0.0056748074,0.00032080227],"about_ca_topic_score_codex":0.013932696,"about_ca_topic_score_gemma":0.0015888454,"teacher_disagreement_score":0.04824465,"about_ca_system_score_codex":0.0003911947,"about_ca_system_score_gemma":0.0020001794,"threshold_uncertainty_score":0.9999655},"labels":[],"label_agreement":null},{"id":"W1982166080","doi":"10.1038/sj.onc.1205367","title":"MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2","year":2002,"lang":"en","type":"article","venue":"Oncogene","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research; National Cancer Institute; National Institute for Health and Care Research","keywords":"RUNX2; Transcription factor; Biology; Transcriptional regulation; Enhancer; Transcription (linguistics); P300-CBP Transcription Factors; Bromodomain; Epigenetics; Histone acetyltransferase; Histone; Genetics; Cell biology; Histone Acetyltransferases; Gene","score_opus":0.029489622945943417,"score_gpt":0.28726282014041404,"score_spread":0.2577731971944706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982166080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815905,0.0020628872,0.0010097087,0.011902992,0.00005086818,0.00055649324,0.000035859975,0.00006422007,0.002726476],"genre_scores_gemma":[0.99253047,0.0006651114,0.0007456811,0.0009404248,0.00018472702,0.00004953627,0.000025739737,0.000044084063,0.004814239],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99870914,0.00007495571,0.00017617224,0.00030319748,0.0003967933,0.0003397444],"domain_scores_gemma":[0.9992711,0.0000950631,0.00003166144,0.00034164533,0.00007253917,0.00018799036],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013986864,0.00020213383,0.00028271947,0.00009580233,0.00014670199,0.000032442076,0.00012625955,0.00008216152,0.0010228275],"category_scores_gemma":[0.0000225586,0.00011935339,0.0000707466,0.00020761299,0.00022890331,0.00012310877,0.000018248296,0.00036796567,0.00006507871],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059980404,0.00019991283,0.0016586205,0.00007679939,0.00017511616,0.00019084674,0.003286313,0.0000023985128,0.95837396,0.000041502524,0.0070494637,0.028345274],"study_design_scores_gemma":[0.020014392,0.005041384,0.027282098,0.00045795,0.0006395913,0.0028846683,0.0034096462,0.0021017217,0.43981385,0.000059082053,0.49717507,0.0011205474],"about_ca_topic_score_codex":0.00016412266,"about_ca_topic_score_gemma":0.00015043309,"teacher_disagreement_score":0.5185601,"about_ca_system_score_codex":0.00028424888,"about_ca_system_score_gemma":0.00005289183,"threshold_uncertainty_score":0.9998904},"labels":[],"label_agreement":null},{"id":"W1982396632","doi":"10.1196/annals.1349.001","title":"Acute Myeloid Leukemia Stem Cells","year":2005,"lang":"en","type":"review","venue":"Annals of the New York Academy of Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":194,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Cancer Institute; Canadian Institutes of Health Research; China Scholarship Council; Stem Cell Network","keywords":"clone (Java method); Stem cell; Myeloid leukemia; Cancer stem cell; Cancer research; Leukemia; Biology; Neoplasm; Cancer; Myeloid; Immunology; Genetics; Gene","score_opus":0.1764541304627773,"score_gpt":0.4174707510188455,"score_spread":0.2410166205560682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982396632","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023322465,0.9884921,0.0000029029582,0.0067693815,0.00016281912,0.0012055075,0.00006876732,0.00003393768,0.00303139],"genre_scores_gemma":[0.00010710149,0.977833,0.0007067236,0.001231534,0.0007279881,0.00001644392,0.0000021389412,0.000046859408,0.019328233],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946009,0.00028407425,0.0014230005,0.000789284,0.0020245546,0.000878195],"domain_scores_gemma":[0.99699116,0.00055674225,0.0014498539,0.00048828434,0.00010194907,0.00041203812],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023318958,0.000561067,0.0026542482,0.0005609534,0.00022217864,0.000038240196,0.0036045972,0.000779549,0.00012834018],"category_scores_gemma":[0.000092108654,0.00031190697,0.0013682451,0.002507992,0.0020531774,0.000202999,0.0007324538,0.0015744267,0.00014808789],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023138551,0.000026074573,0.0000025479064,0.0028665417,0.00032317085,0.000001626465,0.00008598331,0.000008317058,0.00024078604,0.0002924418,0.1633425,0.83278686],"study_design_scores_gemma":[0.0002596811,0.00018143111,0.00000985997,0.011779245,0.0007474317,0.00009212353,0.00004771885,0.000016187456,0.014289888,0.00013778075,0.9721733,0.00026535607],"about_ca_topic_score_codex":0.00007191681,"about_ca_topic_score_gemma":9.988079e-7,"teacher_disagreement_score":0.8325215,"about_ca_system_score_codex":0.00022429004,"about_ca_system_score_gemma":0.004375318,"threshold_uncertainty_score":0.9999333},"labels":[],"label_agreement":null},{"id":"W1982833799","doi":"10.14740/jmc.v5i11.1410","title":"A Case of Multiple Cutaneous Granulocytic Sarcomas in an Elderly Patient","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Sarcoma; Leukemia; Myeloid leukemia; Head and neck; Lesion; Myelodysplastic syndromes; Myeloid; Myeloid sarcoma; Soft tissue; Pathology; Bone marrow; Internal medicine; Surgery","score_opus":0.031389973580349145,"score_gpt":0.32900470314560837,"score_spread":0.29761472956525925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982833799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974616,0.0003928765,0.00019162247,0.0015664381,0.000119676486,0.00015491243,0.0000046066766,0.000007361623,0.00010088865],"genre_scores_gemma":[0.9983047,0.00008706879,0.00087349926,0.00040933746,0.00028663967,0.0000022003412,0.0000024764606,0.000018733983,0.000015302456],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9969626,0.00028593084,0.00085692026,0.00013869526,0.0014584203,0.0002974503],"domain_scores_gemma":[0.9970461,0.0013481837,0.00026989315,0.00024987318,0.00031017288,0.0007757603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011203322,0.00012842605,0.0005695889,0.0003554328,0.000030844825,0.000010410608,0.00019767182,0.00017605704,0.00031908057],"category_scores_gemma":[0.008281024,0.000089480156,0.00013768375,0.00023300204,0.00020186255,0.00008931328,0.000058731577,0.00086868956,0.000005926789],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021991457,0.0014284939,0.022654463,0.00029753306,0.000076916556,0.6585142,0.0016042716,0.000034693174,0.0021496515,0.00006380437,0.0024925629,0.30848426],"study_design_scores_gemma":[0.009814303,0.018171802,0.0017521769,0.00091564533,0.0001283799,0.944675,0.0019401206,0.015211361,0.0031996951,0.00014484662,0.0038648704,0.00018174101],"about_ca_topic_score_codex":0.00056325144,"about_ca_topic_score_gemma":0.00049702445,"teacher_disagreement_score":0.30830252,"about_ca_system_score_codex":0.00022866645,"about_ca_system_score_gemma":0.0007398847,"threshold_uncertainty_score":0.99137574},"labels":[],"label_agreement":null},{"id":"W1983636872","doi":"10.1089/152581600750062372","title":"<i>In Vitro</i> Culture of Human Acute Myelogenous Leukemia (AML) Cells in Serum-Free Media: Studies of Native AML Blasts and AML Cell Lines","year":2000,"lang":"en","type":"article","venue":"Journal of Hematotherapy & Stem Cell Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Kreftforeningen","keywords":"Clonogenic assay; Cell culture; Cytokine; Leukemia; In vivo; In vitro; Stem cell; Cancer research; Immunology; Biology; Secretion; Chemistry; Cell biology; Endocrinology; Biochemistry","score_opus":0.03965975882355117,"score_gpt":0.36122593412068765,"score_spread":0.3215661752971365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983636872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97506416,0.021048006,0.0000027590092,0.000878628,0.00007211801,0.000970686,0.000069616086,0.000008903248,0.0018851048],"genre_scores_gemma":[0.95023674,0.04016024,0.0010352392,0.00013879608,0.00028277285,0.000024616429,0.000003915855,0.000101594276,0.008016105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9931466,0.00088547147,0.0018780113,0.00050306023,0.0025593003,0.0010275769],"domain_scores_gemma":[0.9950916,0.0013533463,0.00062765606,0.0007058631,0.0018254358,0.00039605756],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004291347,0.00044118086,0.0019738774,0.001558956,0.00014124399,0.000035544483,0.00090608146,0.0003839737,0.00022507728],"category_scores_gemma":[0.000095342984,0.0003237259,0.00029310258,0.0015499854,0.0009203529,0.00031278838,0.00023302979,0.0024061524,0.0000122806005],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040786685,0.0007934762,0.0010314947,0.0015146065,0.00042770378,0.0017844149,0.028413223,0.000037586236,0.94795525,0.000008048215,0.010324188,0.0036313469],"study_design_scores_gemma":[0.011544029,0.0026984178,0.00057282293,0.0009343156,0.0000660886,0.00031406467,0.0127213085,0.000058174246,0.96934223,0.00037673186,0.001134305,0.0002374886],"about_ca_topic_score_codex":0.00018242338,"about_ca_topic_score_gemma":0.00012566238,"teacher_disagreement_score":0.024827458,"about_ca_system_score_codex":0.0011504946,"about_ca_system_score_gemma":0.0012895138,"threshold_uncertainty_score":0.9999215},"labels":[],"label_agreement":null},{"id":"W1984221496","doi":"10.1016/j.exphem.2014.07.090","title":"Identification of TET2 loss-of-function phenotype by LC-ESI-MS/MS-MRM in the normal aging population","year":2014,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Phenotype; Biology; Population; Myeloid; Myeloid leukemia; Myelodysplastic syndromes; Genetics; Allele; Loss function; Gene; Internal medicine; Cancer research; Molecular biology; Immunology; Medicine; Bone marrow","score_opus":0.01489183350695922,"score_gpt":0.3216884720177247,"score_spread":0.3067966385107655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984221496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99535584,0.0011304425,0.00104304,0.00045926016,0.00017190895,0.0003874696,0.0000037704226,0.000020066269,0.0014281826],"genre_scores_gemma":[0.9993713,0.000009188464,0.00014428551,0.00011633488,0.000059363538,0.000042039672,0.0001408352,0.000016343733,0.000100329264],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998595,0.00018151209,0.00049834454,0.00021675936,0.0002964843,0.0002118777],"domain_scores_gemma":[0.999262,0.00012372242,0.0001947579,0.0003261736,0.000055170745,0.000038203438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004994437,0.00011181099,0.00029553814,0.0001579632,0.00005023847,0.0000063199022,0.00014733586,0.00011293837,0.00017061167],"category_scores_gemma":[0.00009143157,0.000089771085,0.000054422468,0.00024109626,0.0001402153,0.0001130173,0.00004981105,0.00017947666,0.000034389817],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000696075,0.0007650289,0.13816938,0.0002601724,0.00005557713,0.000011512508,0.0026795128,0.000015368705,0.81375927,0.039192162,0.0021894826,0.0022064436],"study_design_scores_gemma":[0.0019203197,0.00042405218,0.046992444,0.00005650097,0.00002749603,0.00012345034,0.0012567859,0.0019652725,0.9461583,0.00036089364,0.0005998263,0.00011468334],"about_ca_topic_score_codex":0.00041580634,"about_ca_topic_score_gemma":0.000014506514,"teacher_disagreement_score":0.132399,"about_ca_system_score_codex":0.00013723726,"about_ca_system_score_gemma":0.000031514468,"threshold_uncertainty_score":0.36607584},"labels":[],"label_agreement":null},{"id":"W1984405988","doi":"10.1016/j.bbmt.2011.12.317","title":"Dose, Schedule and PK Practices with IV Busulfan-Based Conditioning Regimens in a Non-Inferiority Study: Heterogenous Practices But Low VOD and TRM","year":2012,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Busulfan; Dosing; Internal medicine; Regimen; Cyclophosphamide; Surgery; Gastroenterology; Chemotherapy","score_opus":0.024548687865385582,"score_gpt":0.32144897556727337,"score_spread":0.2969002877018878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984405988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997614,0.00086458784,0.00009036573,0.0004983088,0.000023323953,0.0007549347,0.000038526814,0.00001618256,0.00009975832],"genre_scores_gemma":[0.99720114,0.00073712535,0.0017611487,0.000078270765,0.00004696251,0.00004959686,0.000102202524,0.000012073473,0.000011500017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896,0.00018484473,0.00022030606,0.000267925,0.000115204086,0.00025168576],"domain_scores_gemma":[0.99892426,0.0003877696,0.00038546295,0.00011057718,0.00007373315,0.00011817614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059460144,0.00014549003,0.00031194347,0.000165646,0.00009510771,0.000017696218,0.000034759847,0.00013326967,0.000006065583],"category_scores_gemma":[0.00011339741,0.00011624434,0.000013954703,0.00011290176,0.00024371425,0.0003139966,0.0000095802125,0.00023545962,6.102214e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021497342,0.0005628883,0.7457327,0.0006158358,0.00018019807,0.00008536643,0.0021683264,9.5362924e-7,0.24775901,0.00002390626,0.0000017299366,0.00071935245],"study_design_scores_gemma":[0.013524022,0.0033965176,0.94200355,0.00022089716,0.0009066198,0.00083365716,0.002103687,0.00013438768,0.03665881,0.000010123131,0.00002226327,0.00018548907],"about_ca_topic_score_codex":0.00074126245,"about_ca_topic_score_gemma":0.0006984846,"teacher_disagreement_score":0.2111002,"about_ca_system_score_codex":0.00001515353,"about_ca_system_score_gemma":0.00013042548,"threshold_uncertainty_score":0.47403064},"labels":[],"label_agreement":null},{"id":"W1984806209","doi":"10.1016/j.exphem.2010.06.006","title":"Identification of E74-like factor 1 (ELF1) as a transcriptional regulator of the Hox cofactor MEIS1","year":2010,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Transcription factor; Biology; ETS transcription factor family; Chromatin immunoprecipitation; Promoter; Gene knockdown; Genetics; Reporter gene; Chromatin; Hox gene; Regulator; Molecular biology; Gene; Gene expression","score_opus":0.016273079558584234,"score_gpt":0.3229667741397964,"score_spread":0.30669369458121215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984806209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99664444,0.0005994257,0.000029684317,0.0008541598,0.00068301626,0.0005623206,0.000049125032,0.000025886633,0.0005519463],"genre_scores_gemma":[0.99836755,0.000005303,0.0002771321,0.00011580253,0.000053439075,0.00005292588,0.000021734091,0.000025153939,0.0010809485],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845517,0.000059804235,0.0005237471,0.0002677052,0.00045895734,0.00023464533],"domain_scores_gemma":[0.9989081,0.00007116852,0.00020727832,0.0005655656,0.00013523272,0.000112652946],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012854482,0.00014982844,0.00039758583,0.00010900594,0.000062327665,0.0000052896044,0.0002810879,0.00020873436,0.0021682687],"category_scores_gemma":[0.00008266904,0.000108764776,0.00018825682,0.00017662953,0.0005898095,0.00007733235,0.00007559324,0.000335324,0.00006263528],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026443438,0.00034281047,0.005859652,0.000068977715,0.00006669432,0.0000051567695,0.00095182145,9.609318e-8,0.951254,0.04033269,0.00079169637,0.00006195249],"study_design_scores_gemma":[0.0013391667,0.00016031119,0.026250266,0.000023223965,0.000020394464,0.00040822834,0.0005416645,0.00006027958,0.969461,0.00014449874,0.0015101708,0.000080776794],"about_ca_topic_score_codex":0.00006789448,"about_ca_topic_score_gemma":0.000009313299,"teacher_disagreement_score":0.04018819,"about_ca_system_score_codex":0.00009288551,"about_ca_system_score_gemma":0.00027571063,"threshold_uncertainty_score":0.9987439},"labels":[],"label_agreement":null},{"id":"W1985605429","doi":"10.1111/bjh.13146","title":"A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis","year":2014,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; University of Alberta; Sunnybrook Health Science Centre; Canadian Blood Services; Health Sciences Centre; ErinoakKids Centre for Treatment and Development; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Leukapheresis; Internal medicine; Hydroxycarbamide; Hazard ratio; Retrospective cohort study; Myeloid leukaemia; White blood cell; Cohort; Myeloid; Gastroenterology; Chemotherapy; Confidence interval; Stem cell","score_opus":0.024058456871464837,"score_gpt":0.2904321657146944,"score_spread":0.26637370884322953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985605429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967499,0.00005567222,0.0010338917,0.00030401975,0.00006744448,0.00088674825,0.000016019536,0.000017532735,0.0008688157],"genre_scores_gemma":[0.99385715,0.00002301194,0.0057352385,0.00010017533,0.00010562346,0.000028483524,0.0000120664945,0.00004711481,0.000091169415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725735,0.00023547943,0.0007193253,0.00035837496,0.001007549,0.00042190403],"domain_scores_gemma":[0.99661875,0.00014149335,0.0006389254,0.00026912955,0.0021024432,0.00022927596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004503244,0.0002212635,0.0011289839,0.0003741007,0.0001310134,0.00006430536,0.00031871436,0.00010155097,0.00004495352],"category_scores_gemma":[0.00031961995,0.0001848502,0.00008713672,0.000511637,0.0002462203,0.00044776747,0.00012588559,0.0006662595,0.0000047510457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004558318,0.0016464194,0.9702583,0.00017851994,0.0025333874,0.013732746,0.0031163578,0.00021932025,0.00042796912,0.0004953391,0.0011208047,0.001712536],"study_design_scores_gemma":[0.009118717,0.00828046,0.93919915,0.00049243576,0.00053563365,0.03633029,0.004858544,0.00005517248,0.00055971515,0.00028551498,0.000067735775,0.0002166503],"about_ca_topic_score_codex":0.00031971568,"about_ca_topic_score_gemma":0.00028133468,"teacher_disagreement_score":0.03105915,"about_ca_system_score_codex":0.00028844006,"about_ca_system_score_gemma":0.00046424574,"threshold_uncertainty_score":0.75379723},"labels":[],"label_agreement":null},{"id":"W1986307017","doi":"10.1016/j.clml.2012.01.003","title":"Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by Flow Cytometry Is Associated With NPM1 and FLT3 Mutation Status in Cytogenetically Normal Acute Myeloid Leukemia","year":2012,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Vancouver General Hospital","funders":"BC Cancer Agency; University of British Columbia","keywords":"NPM1; CD34; Flow cytometry; CD19; Myeloid leukemia; CD33; CD14; Mutation; Gene mutation; Leukemia; Medicine; Molecular biology; Cancer research; Myeloid; Internal medicine; Immunology; Oncology; Biology; Gene; Karyotype; Genetics; Stem cell","score_opus":0.01838067840154703,"score_gpt":0.3085404674738134,"score_spread":0.29015978907226636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986307017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463314,0.0014289754,0.0012574921,0.00025864274,0.00021402334,0.0010555054,0.00021396509,0.00014007995,0.0007981806],"genre_scores_gemma":[0.99338317,0.0011882667,0.003115644,0.0009118202,0.00034124227,0.00008853806,0.00027379487,0.00015550385,0.00054203713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99327314,0.0006919291,0.0019323314,0.0011554629,0.0012370462,0.0017100779],"domain_scores_gemma":[0.99489284,0.0017665899,0.00061913434,0.0007922432,0.0005189405,0.001410235],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002720669,0.000710912,0.001630464,0.00063614594,0.00020861268,0.00008414044,0.00029251812,0.0011771268,0.00009945372],"category_scores_gemma":[0.0022867064,0.00063056854,0.0002452547,0.001540319,0.0012466796,0.0006040601,0.0003705687,0.0010486383,0.00005262685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041873194,0.0004948634,0.48132786,0.00022699147,0.0009509725,0.0003868892,0.00080377224,0.000012815237,0.037296057,0.000029970146,0.0012747394,0.47300777],"study_design_scores_gemma":[0.014715067,0.00226844,0.9540532,0.00029248756,0.0005512031,0.0006875112,0.0002648179,0.009295472,0.016019981,0.00006734533,0.0011315707,0.0006528642],"about_ca_topic_score_codex":0.00040117148,"about_ca_topic_score_gemma":0.00011548703,"teacher_disagreement_score":0.4727254,"about_ca_system_score_codex":0.0039237705,"about_ca_system_score_gemma":0.0021903955,"threshold_uncertainty_score":0.9999},"labels":[],"label_agreement":null},{"id":"W1986439120","doi":"10.1002/gcc.10258","title":"Heterogeneity of the 7q36 breakpoints in the t(7;12) involving <i>ETV6</i> in infant leukemia","year":2003,"lang":"en","type":"article","venue":"Genes Chromosomes and Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Canadian Institutes of Health Research; Hospital for Sick Children; University of Toronto","funders":"National Institutes of Health","keywords":"ETV6; Cosmid; Breakpoint; Biology; Chromosomal translocation; Contig; Genetics; Fluorescence in situ hybridization; Southern blot; Fusion transcript; Gene rearrangement; Molecular biology; Gene; Chromosome; Genome","score_opus":0.02198816371669318,"score_gpt":0.29096255172667035,"score_spread":0.2689743880099772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986439120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98240453,0.015186089,0.0000012834888,0.0007849705,0.000099715995,0.00046198844,0.000014170613,0.0000062248196,0.0010410368],"genre_scores_gemma":[0.99073976,0.007518527,0.000039424995,0.0013462307,0.00007480562,0.000094786345,0.0000026159385,0.00001699568,0.00016685223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985732,0.00018150143,0.00029833333,0.00026162897,0.00033810508,0.0003472403],"domain_scores_gemma":[0.99930143,0.0000870392,0.00007506944,0.00043179095,0.00004441264,0.000060281614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005113045,0.00015277337,0.0003003984,0.000080874815,0.00006468721,0.00001713817,0.00021491453,0.00009314278,0.00008258777],"category_scores_gemma":[0.00006879291,0.000084619045,0.00007599792,0.0004323706,0.00019654301,0.00006254683,0.00010017842,0.00031487466,0.0000021424223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096024196,0.00007311688,0.93589175,0.00026978579,0.00005093918,0.000046548863,0.0019764465,0.00010577402,0.046857495,0.0002728579,0.00093839964,0.013420872],"study_design_scores_gemma":[0.0036872108,0.00012626385,0.8658517,0.00047133645,0.000050164406,0.00019635887,0.0012227016,0.000344495,0.10139126,0.0002520538,0.026170852,0.00023557959],"about_ca_topic_score_codex":0.0023896268,"about_ca_topic_score_gemma":0.0049653715,"teacher_disagreement_score":0.07004002,"about_ca_system_score_codex":0.000402484,"about_ca_system_score_gemma":0.0006336627,"threshold_uncertainty_score":0.36124167},"labels":[],"label_agreement":null},{"id":"W1987180172","doi":"10.1016/j.bbmt.2010.12.471","title":"Attempts to Optimizing the Outcomes of Allogeneic Hematopoietic Cell Transplantation in Older Patients (≥60 Years) With Acute Myeloid Leukemia and Myelodysplastic Syndrome","year":2011,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Regimen; Internal medicine; Fludarabine; Cohort; Myelodysplastic syndromes; Transplantation; Hematopoietic stem cell transplantation; Gastroenterology; Surgery; Total body irradiation; Chemotherapy; Cyclophosphamide; Bone marrow","score_opus":0.011326467776578166,"score_gpt":0.2370741307025244,"score_spread":0.22574766292594622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987180172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984188,0.00013614575,0.00048865454,0.00007867188,0.000028947514,0.00066444126,0.00007130513,0.000011733726,0.000101297104],"genre_scores_gemma":[0.99585605,0.0011941185,0.0026765212,0.000080386,0.0000048270176,0.00003708789,0.00010803748,0.000017966891,0.000025017393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998926,0.00008176077,0.00034595584,0.00027455686,0.00014465781,0.00022707148],"domain_scores_gemma":[0.9994708,0.0001406816,0.0001063763,0.00013577058,0.000060292463,0.00008609107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018024397,0.00016690724,0.0003884992,0.00021824683,0.00003570775,0.0000037928223,0.000088969704,0.00013312462,0.00001635026],"category_scores_gemma":[0.000006864628,0.000114074915,0.000034791065,0.00015570641,0.00019611798,0.00006967635,0.000012502833,0.00014522772,0.000001913625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022131063,0.00023847545,0.83836544,0.0011591307,0.00038909647,0.0003935665,0.011395899,0.000017816392,0.14480853,0.000073091476,0.0000044524886,0.00094137026],"study_design_scores_gemma":[0.005209357,0.0011589833,0.9595042,0.00019398954,0.00076253625,0.00039417463,0.00018319419,0.000011114699,0.032428857,0.00002692231,0.0000012232512,0.00012545627],"about_ca_topic_score_codex":0.00022061334,"about_ca_topic_score_gemma":0.00009045821,"teacher_disagreement_score":0.12113873,"about_ca_system_score_codex":0.000019938649,"about_ca_system_score_gemma":0.00008927518,"threshold_uncertainty_score":0.465184},"labels":[],"label_agreement":null},{"id":"W1987493240","doi":"10.3109/10428194.2010.483750","title":"Revisiting late relapses in acute myeloid leukemia","year":2010,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Myeloid leukemia; Medicine; Myeloid; Leukemia; Internal medicine; Cancer research; Oncology","score_opus":0.013045270587988864,"score_gpt":0.26275512068170864,"score_spread":0.24970985009371977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987493240","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8310063,0.006247867,0.000047885827,0.13019484,0.0021740186,0.0039278883,0.000501402,0.0014241738,0.024475634],"genre_scores_gemma":[0.09799275,0.021791367,0.0069639157,0.739263,0.025637755,0.001637737,0.0069727995,0.0029955409,0.09674513],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9819746,0.0008321339,0.0037245236,0.004909172,0.0032790683,0.0052805017],"domain_scores_gemma":[0.98997587,0.0017682656,0.0015680336,0.004349088,0.00076896406,0.0015697873],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0021134554,0.003687055,0.005358992,0.0030927307,0.0009474115,0.0008308532,0.0023227392,0.012980459,0.0006464061],"category_scores_gemma":[0.0010889428,0.0035611833,0.0014357712,0.002733734,0.0018011063,0.0010495216,0.001805425,0.011003456,0.0012288981],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0018353872,0.0001203563,0.003978112,0.0034747506,0.0016668683,0.055577725,0.0010764918,0.000028147639,0.009609408,0.00021260398,0.72218263,0.2002375],"study_design_scores_gemma":[0.027794328,0.00058623776,0.023505,0.003997422,0.001768375,0.013810245,0.0002220073,0.0044664247,0.0035206366,0.00069321645,0.9155424,0.0040936726],"about_ca_topic_score_codex":0.00631255,"about_ca_topic_score_gemma":0.00020183716,"teacher_disagreement_score":0.7330135,"about_ca_system_score_codex":0.05084578,"about_ca_system_score_gemma":0.027720906,"threshold_uncertainty_score":0.99954873},"labels":[],"label_agreement":null},{"id":"W1987714872","doi":"10.1038/onc.2011.32","title":"The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO","year":2011,"lang":"en","type":"article","venue":"Oncogene","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; BC Cancer Agency","funders":"Foundation for Chiropractic Education and Research","keywords":"Biology; Histone H3; Epigenetics; Histone; Gene silencing; Histone deacetylase; Acetylation; Histone methyltransferase; DNA methylation; Vorinostat; Regulation of gene expression; Gene expression; Molecular biology; Cancer research; Genetics; Gene","score_opus":0.021803493565760647,"score_gpt":0.25202032621243514,"score_spread":0.2302168326466745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987714872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98645645,0.0066040372,0.000107141626,0.000682856,0.00049735943,0.0012026413,0.00007919448,0.00006827349,0.004302043],"genre_scores_gemma":[0.9935459,0.0028182417,0.0005784727,0.00024286486,0.00037742156,0.000093103,0.00003773094,0.00009496302,0.0022113377],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99667937,0.00043457662,0.00063615316,0.0005327502,0.0009481392,0.00076899026],"domain_scores_gemma":[0.9971606,0.00080980535,0.00029468743,0.0010920903,0.00036061744,0.00028217208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010524157,0.0003363398,0.0004982228,0.00011173756,0.00034720788,0.000027632066,0.0006370838,0.00023775057,0.00021139825],"category_scores_gemma":[0.00064141216,0.00019518465,0.000250646,0.00069748133,0.0005881544,0.00007024264,0.00036723292,0.00063202076,0.00020002872],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004941825,0.00017445907,0.008521188,0.00005490888,0.000182616,0.000035765126,0.0012445053,0.0000018367357,0.9631522,0.000047694823,0.019248497,0.0068421275],"study_design_scores_gemma":[0.0020026495,0.0004938606,0.037632022,0.00012755305,0.000102582235,0.000043548927,0.0003942969,0.00007304126,0.9309648,0.00007570773,0.027878862,0.00021107259],"about_ca_topic_score_codex":0.0002746553,"about_ca_topic_score_gemma":0.000059191017,"teacher_disagreement_score":0.032187413,"about_ca_system_score_codex":0.00051349675,"about_ca_system_score_gemma":0.00049682654,"threshold_uncertainty_score":0.79593986},"labels":[],"label_agreement":null},{"id":"W1988345778","doi":"10.1016/s1535-6108(03)00214-9","title":"Dimerization of MLL fusion proteins immortalizes hematopoietic cells","year":2003,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Ariad Pharmaceuticals","keywords":"Hox gene; Downregulation and upregulation; Gene duplication; Tandem exon duplication; Fusion protein; Biology; Transcription factor; Cell biology; Exon; Fusion gene; Molecular biology; Gene; Chemistry; Genetics; Recombinant DNA","score_opus":0.015882230051208323,"score_gpt":0.2866555645833966,"score_spread":0.27077333453218827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988345778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93714625,0.003289857,0.00088744675,0.00017435654,0.00023640117,0.0011065486,0.000014627494,0.00004643982,0.057098094],"genre_scores_gemma":[0.99023277,0.0010771313,0.00097527355,0.00013462806,0.000062939485,0.00008060451,0.000014638316,0.000033973804,0.0073880544],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989941,0.000035398396,0.00022525522,0.00021391222,0.00029850105,0.00023279629],"domain_scores_gemma":[0.9993228,0.00002176769,0.00009299142,0.00031060012,0.00013396998,0.00011788454],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012345401,0.00011552143,0.00023745769,0.00005364091,0.000037635982,0.0000059777,0.00007691847,0.00008671263,0.0020459879],"category_scores_gemma":[0.00003111412,0.000097981996,0.00006606532,0.00024308654,0.000076059434,0.000055512683,0.000026372712,0.00013030814,0.00005024589],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067646324,0.00012305753,0.0019396404,0.0005497539,0.000020935238,0.000021113936,0.00034854075,0.000021574422,0.9930984,0.00020716463,0.0026197983,0.0009824121],"study_design_scores_gemma":[0.001200221,0.00014463134,0.00085888547,0.00010712853,0.000049207345,0.000006354676,0.0001728049,0.00010657178,0.9815516,0.000046049186,0.015658457,0.000098073375],"about_ca_topic_score_codex":0.00036435702,"about_ca_topic_score_gemma":0.000021047848,"teacher_disagreement_score":0.05308653,"about_ca_system_score_codex":0.000215259,"about_ca_system_score_gemma":0.0004152965,"threshold_uncertainty_score":0.99886626},"labels":[],"label_agreement":null},{"id":"W1988365839","doi":"10.1016/s0165-4608(02)00606-4","title":"Constitutional rearrangements of 7q22 in hematologic malignancies","year":2002,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Izaak Walton Killam Health Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Biology; Chromosome Band; Genetics; Myeloid; Chromosome; Breakpoint; Myeloproliferative Disorders; Gene; Gene mapping; Cancer research; Immunology","score_opus":0.06636711872710943,"score_gpt":0.31862555247354657,"score_spread":0.25225843374643714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988365839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758561,0.020778675,0.000115360715,0.00056441454,0.000061061066,0.00025958975,0.000036973077,0.000007891707,0.0023199155],"genre_scores_gemma":[0.9721304,0.025221985,0.0018884361,0.00023387733,0.00004641207,0.000029998817,0.0000052749897,0.000008215282,0.00043537572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990613,0.000019650946,0.00025237867,0.00019933635,0.00023287194,0.00023448665],"domain_scores_gemma":[0.9995191,0.000023682123,0.00005219361,0.00018753967,0.00011634414,0.0001011196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000078327066,0.000109729546,0.00024261007,0.00007544329,0.000031218882,0.0000072900307,0.00007791679,0.00008858304,0.00035500695],"category_scores_gemma":[0.000027844308,0.0000996714,0.00003324436,0.00019157761,0.0005359571,0.000010339826,0.00007125276,0.00010808388,0.0000076055717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007133332,0.0001726404,0.91862726,0.00033085904,0.00008591214,0.0000943779,0.00037710686,0.00023270666,0.059553035,0.0018730039,0.0025630884,0.016018644],"study_design_scores_gemma":[0.011523769,0.0013111763,0.48687202,0.0008364894,0.0003170824,0.00049628137,0.0006474271,0.012540201,0.3605454,0.0012760564,0.1227462,0.0008878896],"about_ca_topic_score_codex":0.000023171053,"about_ca_topic_score_gemma":0.000024546362,"teacher_disagreement_score":0.43175527,"about_ca_system_score_codex":0.00008352774,"about_ca_system_score_gemma":0.0000933014,"threshold_uncertainty_score":0.4064482},"labels":[],"label_agreement":null},{"id":"W1988547264","doi":"10.1158/0008-5472.can-05-1041","title":"Leukemogenic MLL Fusion Proteins Bind across a Broad Region of the <i>Hox a9</i> Locus, Promoting Transcription and Multiple Histone Modifications","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Biology; Fusion protein; Hox gene; Histone methyltransferase; Histone; Chromosomal translocation; Transcription factor; Histone methylation; Histone H3; Molecular biology; Genetics; Gene; DNA methylation; Gene expression","score_opus":0.08448096084190837,"score_gpt":0.39670136655725086,"score_spread":0.3122204057153425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988547264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799115,0.0031196934,0.00014316331,0.013361122,0.00004652224,0.0028857149,0.000041047217,0.00004250985,0.00044871017],"genre_scores_gemma":[0.99177283,0.001396289,0.00024024142,0.0000909588,0.00028681068,0.0004142466,0.0000135242435,0.000049625512,0.0057354774],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969599,0.00025584633,0.00040116132,0.0005288027,0.0011111455,0.0007431134],"domain_scores_gemma":[0.99804765,0.00012991385,0.00010562222,0.00077158277,0.00070585485,0.00023937154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013813993,0.0001688468,0.00028534335,0.00020443236,0.00060780696,0.00004199612,0.00036518188,0.0001831804,0.000051491243],"category_scores_gemma":[0.00038700222,0.0001237007,0.00010960111,0.0011574052,0.0008255366,0.00019038758,0.00021877665,0.0010921165,0.000019758761],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051584275,0.00019003601,0.0021797111,0.0003925201,0.000037314312,0.000011094829,0.0045999684,0.000042473403,0.9217504,0.000045044944,0.0022881737,0.06794742],"study_design_scores_gemma":[0.007400035,0.00052301475,0.023132278,0.0011105536,0.00006301309,0.00019578173,0.0012443374,0.009526545,0.9140077,0.00009706281,0.042385884,0.0003137674],"about_ca_topic_score_codex":0.0027173993,"about_ca_topic_score_gemma":0.0010876866,"teacher_disagreement_score":0.06763365,"about_ca_system_score_codex":0.0017007025,"about_ca_system_score_gemma":0.0010870215,"threshold_uncertainty_score":0.5044368},"labels":[],"label_agreement":null},{"id":"W1988939498","doi":"10.1097/coc.0b013e31818a6c93","title":"Acute Leukemia in Patients Sixty Years of Age and Older","year":2009,"lang":"en","type":"article","venue":"American Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Leukemia; Acute leukemia; Induction chemotherapy; Myeloid leukemia; Univariate analysis; Internal medicine; Chemotherapy; Acute lymphocytic leukemia; Retrospective cohort study; Surgery; Cytarabine; Population; Chemotherapy regimen; Multivariate analysis; Gastroenterology; Lymphoblastic Leukemia","score_opus":0.03619018415307079,"score_gpt":0.43539085076266326,"score_spread":0.39920066660959247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988939498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962943,0.000048186455,0.000025080122,0.0022186527,0.000119901204,0.00013743297,0.0000021621324,0.0000034852471,0.0011507795],"genre_scores_gemma":[0.9913071,0.00061225385,0.004908574,0.0028885556,0.0001866914,5.9399065e-7,0.0000018692323,0.000010447212,0.00008391408],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973604,0.00035974538,0.0015027522,0.00016723418,0.00034927804,0.00026060647],"domain_scores_gemma":[0.99716467,0.0010936824,0.0009826664,0.00017802071,0.00023955965,0.00034142582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014713954,0.00009834151,0.0013976084,0.00022530793,0.000009658304,0.0000033946246,0.00017258499,0.00014858626,0.00003324513],"category_scores_gemma":[0.0016435813,0.000079510355,0.00018985335,0.0003139054,0.0007413944,0.00006806609,0.000052412444,0.0010704766,0.000005412265],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003554841,0.0005108961,0.23369095,0.0000051281622,0.00013989767,0.0015001827,0.00020144449,0.0000030288702,0.00017413091,0.0000203144,0.0015877148,0.7586115],"study_design_scores_gemma":[0.0090354895,0.023920592,0.96217877,0.000062455576,0.000105477666,0.0001202907,0.00011517427,0.000026456322,0.00002411407,0.00011209007,0.0042357543,0.00006332659],"about_ca_topic_score_codex":0.000042002335,"about_ca_topic_score_gemma":0.0000057999164,"teacher_disagreement_score":0.75854814,"about_ca_system_score_codex":0.00041954927,"about_ca_system_score_gemma":0.0015225781,"threshold_uncertainty_score":0.46507478},"labels":[],"label_agreement":null},{"id":"W1989402731","doi":"10.3324/haematol.11203","title":"Pediatric acute myeloid leukemia: towards high-quality cure of all patients","year":2007,"lang":"en","type":"review","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Medicine; Myeloid leukemia; Pharmacogenomics; Minimal residual disease; Oncology; Disease; Internal medicine; Leukemia; Intensive care medicine; Pharmacology","score_opus":0.11254359432220473,"score_gpt":0.41814936660063895,"score_spread":0.3056057722784342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989402731","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0047082063,0.98586726,0.000051938678,0.000108608976,0.000416178,0.0030601092,0.00045157815,0.0002337531,0.0051023453],"genre_scores_gemma":[0.00043157238,0.9936695,0.0023655738,0.00027437607,0.00041524554,0.00018159422,0.001567387,0.00014247448,0.00095227105],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927104,0.0005902381,0.002572817,0.0012174546,0.0016674411,0.0012416573],"domain_scores_gemma":[0.99480426,0.0007184472,0.0015651044,0.0016266258,0.0007008262,0.0005847335],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0014496509,0.0010574578,0.0068245544,0.0008976778,0.000102005,0.0000269752,0.0010500015,0.0022265653,0.0005924144],"category_scores_gemma":[0.0009990656,0.00071093295,0.0014173493,0.0014981071,0.00033134417,0.000098293545,0.0007655521,0.0024572543,0.0007122534],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029750846,0.00072292204,0.0010956974,0.09601409,0.0017342812,0.0023025607,0.00009106655,1.2381064e-7,0.0000013105388,0.0012075377,0.041508675,0.8550242],"study_design_scores_gemma":[0.0019132288,0.00072338193,0.0017469595,0.0029698797,0.0050511598,0.0007061191,0.000014025281,8.215052e-7,0.000025044907,0.00010099355,0.98597986,0.0007685518],"about_ca_topic_score_codex":0.0001739431,"about_ca_topic_score_gemma":0.0000042906254,"teacher_disagreement_score":0.9444712,"about_ca_system_score_codex":0.001620417,"about_ca_system_score_gemma":0.0028407096,"threshold_uncertainty_score":0.99984413},"labels":[],"label_agreement":null},{"id":"W1989721541","doi":"10.1038/emm.2013.98","title":"Developmental changes in hematopoietic stem cell properties","year":2013,"lang":"en","type":"review","venue":"Experimental & Molecular Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Terry Fox Research Institute; BC Cancer Agency","funders":"National Cancer Institute; Medical Research Council; Canadian Institutes of Health Research; Terry Fox Foundation; Michael Smith Health Research BC","keywords":"Stem cell; Haematopoiesis; Biology; Progenitor cell; Regulator; Population; Cell biology; Immunology; Hematopoietic stem cell; Cancer research; Leukemia; Gene; Medicine; Genetics","score_opus":0.0711033573122382,"score_gpt":0.35227352771438647,"score_spread":0.28117017040214826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989721541","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002662684,0.9860505,0.000007758238,0.000383173,0.00018647869,0.0041937996,0.000004693044,0.00010286308,0.00640804],"genre_scores_gemma":[0.002569113,0.98817694,0.0005086328,0.00064128824,0.00028404596,0.0019901425,0.0001709309,0.0002713214,0.0053875633],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956163,0.00028275614,0.0010484233,0.0009891426,0.0011448546,0.00091852824],"domain_scores_gemma":[0.99853146,0.000057731468,0.0002641946,0.00056113827,0.00007609705,0.00050938665],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00035991473,0.0009928341,0.0031472424,0.00084196904,0.00007248294,0.000029736631,0.0005121059,0.00050667755,0.0014392213],"category_scores_gemma":[0.00003078717,0.0006712912,0.00029068737,0.00074201665,0.00044828973,0.00007341008,0.00045953106,0.0011185344,0.0009424216],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011706198,0.001151907,0.0000094436955,0.055711262,0.0006244182,0.0067966003,0.0076411054,1.286348e-7,0.27006176,0.00009768869,0.010410799,0.64737785],"study_design_scores_gemma":[0.0029939646,0.00096708635,0.0000017664323,0.039448775,0.00037879808,0.0017413311,0.005326365,0.000005866767,0.096293874,0.0000021395,0.8520262,0.000813831],"about_ca_topic_score_codex":0.0001576875,"about_ca_topic_score_gemma":0.0000043216382,"teacher_disagreement_score":0.8416154,"about_ca_system_score_codex":0.0022663767,"about_ca_system_score_gemma":0.0009376823,"threshold_uncertainty_score":0.99983543},"labels":[],"label_agreement":null},{"id":"W1990093837","doi":"10.1038/sj.bmt.1705038","title":"Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?","year":2005,"lang":"en","type":"review","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; University of British Columbia","funders":"","keywords":"Medicine; Myeloid leukemia; Transplantation; Internal medicine; Oncology; Regimen; Refractory (planetary science); Leukemia; Hematopoietic stem cell transplantation; Induction chemotherapy; Stem cell; Chemotherapy; Surgery","score_opus":0.027418349544798246,"score_gpt":0.29421964506266945,"score_spread":0.2668012955178712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990093837","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.095802255,0.8463939,0.010289257,0.0017346635,0.0007548207,0.030634075,0.0064809034,0.0007853901,0.0071247336],"genre_scores_gemma":[0.0013570308,0.9766541,0.0041692033,0.002220206,0.0002998034,0.0010775321,0.008906385,0.0004101139,0.004905619],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99327743,0.0003623482,0.0016612665,0.0016666863,0.0019049632,0.0011273345],"domain_scores_gemma":[0.9968992,0.00022706404,0.0004982171,0.0010600531,0.00039435443,0.0009211238],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00051974365,0.0013083607,0.002757054,0.0012309019,0.00020232068,0.00010456824,0.00052225316,0.00086914864,0.00023680233],"category_scores_gemma":[0.0000060245416,0.0010631006,0.00058144133,0.0012225428,0.000080731596,0.00033557802,0.000046804686,0.001191711,0.0012907158],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005018765,0.00054144725,0.00021064552,0.091820516,0.0010199284,0.0010832092,0.005885692,0.000041556348,0.0008296889,0.000007390205,0.0039217835,0.88961935],"study_design_scores_gemma":[0.013556018,0.003093203,0.004654545,0.039097037,0.021386994,0.0017363663,0.00013129231,0.000013994776,0.0015052067,0.000004961798,0.91112864,0.003691733],"about_ca_topic_score_codex":0.00008210402,"about_ca_topic_score_gemma":0.00006601781,"teacher_disagreement_score":0.9072069,"about_ca_system_score_codex":0.0029042475,"about_ca_system_score_gemma":0.0021003496,"threshold_uncertainty_score":0.9999668},"labels":[],"label_agreement":null},{"id":"W1990741783","doi":"10.1038/bmt.2008.16","title":"A comparison of the outcomes of children with acute myelogenous leukemia in either first or second complete remission (CR1 vs CR2) following allogeneic hematopoietic stem cell transplantation at a single transplant center","year":2008,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Stem cell; Transplantation; Hematopoietic stem cell transplantation; Single Center; Complete remission; Haematopoiesis; Leukemia; Oncology; Hematopoietic cell; Internal medicine; Immunology; Chemotherapy","score_opus":0.02906445714008306,"score_gpt":0.2684197987530706,"score_spread":0.23935534161298752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990741783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963521,0.00018998807,0.0006672564,0.00021379766,0.00006355227,0.001605773,0.00049324526,0.00004445034,0.00036985276],"genre_scores_gemma":[0.99752635,0.00046530095,0.0006763467,0.00010444109,0.00001580289,0.000053717613,0.0005506887,0.00007700317,0.0005303691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968456,0.00020285705,0.001053435,0.0005089677,0.00088041136,0.0005087462],"domain_scores_gemma":[0.9987176,0.00021383597,0.00037620866,0.00046086166,0.00008360574,0.00014786751],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024829802,0.0004177159,0.0010549591,0.0002908216,0.00022468214,0.000009926127,0.00027354312,0.00023250478,0.00011479361],"category_scores_gemma":[0.0000036540869,0.00027152835,0.0003032552,0.00050374825,0.00020473018,0.0001468274,0.000018684374,0.00037788105,0.000006364458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008459433,0.0004132325,0.72276604,0.0012537314,0.00037787756,0.0006055563,0.016623145,0.00037072675,0.2489614,0.000003176789,0.000046594476,0.00011910143],"study_design_scores_gemma":[0.012529084,0.00089163467,0.6890961,0.0009762663,0.00090404483,0.003283635,0.00023523557,0.00029251166,0.2914182,0.0000030122455,0.000029463003,0.00034083528],"about_ca_topic_score_codex":0.00030530253,"about_ca_topic_score_gemma":0.0026888202,"teacher_disagreement_score":0.042456787,"about_ca_system_score_codex":0.00059308077,"about_ca_system_score_gemma":0.00042817823,"threshold_uncertainty_score":0.9999737},"labels":[],"label_agreement":null},{"id":"W1991475752","doi":"10.1016/j.yexmp.2007.05.007","title":"Frequent but nonrandom expression of lymphoid markers on de novo childhood acute myeloid leukemia","year":2007,"lang":"en","type":"article","venue":"Experimental and Molecular Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation","funders":"Hospital for Sick Children","keywords":"Lymphoid leukemia; Leukemia; Myeloid leukemia; Myeloid; CD19; Biology; Fusion gene; Childhood leukemia; Immunology; Immunophenotyping; Cancer research; Gene; Flow cytometry; Genetics; Lymphoblastic Leukemia","score_opus":0.007007301973568186,"score_gpt":0.28091701953777204,"score_spread":0.27390971756420385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991475752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898402,0.0015493864,0.0023694953,0.00015737308,0.00009764149,0.00050384074,0.000015777638,0.000038697224,0.005427595],"genre_scores_gemma":[0.9940626,0.00014068025,0.003908685,0.0014807867,0.000073519965,0.000039120372,0.00004567597,0.000042594624,0.0002063109],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982669,0.000115051276,0.0003296698,0.00044010687,0.00031365428,0.000534659],"domain_scores_gemma":[0.9991543,0.000061198836,0.00008809638,0.00035551653,0.000042748055,0.00029813754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041356747,0.0002441608,0.00041449443,0.00019829253,0.000077465724,0.000007852404,0.00013030213,0.00022964565,0.000108245586],"category_scores_gemma":[0.00005246092,0.00020660574,0.00013587133,0.00011419457,0.00028923075,0.00003806947,0.00016380507,0.00027372225,0.000014802537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025629264,0.00032373724,0.0010228876,0.00001926165,0.000075241755,0.00484035,0.00080069643,0.0000018425554,0.988255,0.00017160039,0.00018152416,0.0017449333],"study_design_scores_gemma":[0.008257432,0.0015647481,0.0060799513,0.00007764974,0.000043503365,0.004395308,0.00071643584,0.000018134124,0.97834754,0.000037233764,0.00028959493,0.00017245747],"about_ca_topic_score_codex":0.00005127573,"about_ca_topic_score_gemma":9.205493e-7,"teacher_disagreement_score":0.009907447,"about_ca_system_score_codex":0.0005053865,"about_ca_system_score_gemma":0.00022481603,"threshold_uncertainty_score":0.84251374},"labels":[],"label_agreement":null},{"id":"W1991761325","doi":"10.1002/cyto.b.21036","title":"Issue Highlights—September 2012","year":2012,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.08878989178417439,"score_gpt":0.42786740080265284,"score_spread":0.33907750901847844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991761325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7829123,0.007936334,0.0017434417,0.0061367303,0.00783449,0.0016425926,0.00009403386,0.0009990411,0.19070102],"genre_scores_gemma":[0.8777742,0.00078219967,0.004255323,0.0054025664,0.013232156,0.00008380442,0.00014938906,0.0001971147,0.09812326],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925493,0.00056552445,0.001957623,0.0010460023,0.0016286164,0.002252931],"domain_scores_gemma":[0.9916935,0.0025783572,0.00036270267,0.0020036763,0.00044568576,0.0029161044],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.005217716,0.00065470126,0.0016881021,0.0014917987,0.00025407464,0.00008260317,0.0006792436,0.0011186613,0.020883763],"category_scores_gemma":[0.0035828014,0.0005321241,0.0009098068,0.0045574373,0.0007457996,0.00089852756,0.00064136717,0.0023677025,0.055340715],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044718484,0.001427999,0.4542274,0.00015755516,0.00041832041,0.00011484434,0.000036069792,1.8962655e-7,0.00077349384,0.0002574575,0.5347796,0.007359854],"study_design_scores_gemma":[0.0029225983,0.00049427955,0.23686925,0.00009046419,0.00025516498,0.00022661814,0.000075051335,0.000028006256,0.0028757728,0.000021095664,0.7556539,0.00048778337],"about_ca_topic_score_codex":0.000009506104,"about_ca_topic_score_gemma":0.0000014989411,"teacher_disagreement_score":0.22087428,"about_ca_system_score_codex":0.0005342464,"about_ca_system_score_gemma":0.00039214428,"threshold_uncertainty_score":0.9999339},"labels":[],"label_agreement":null},{"id":"W1991767526","doi":"10.1016/s0008-4182(03)80120-5","title":"Intraocular leukemia as the primary manifestation of relapsing acute myelogenous leukemia","year":2003,"lang":"en","type":"article","venue":"Canadian Journal of Ophthalmology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Leukemia; Primary (astronomy); Medicine; Cancer research; Immunology; Physics","score_opus":0.019702756007365804,"score_gpt":0.2822413868910895,"score_spread":0.2625386308837237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991767526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94116426,0.0017008103,0.00010440684,0.00084924843,0.00046095936,0.0002929184,0.000009319364,0.0000035828089,0.055414505],"genre_scores_gemma":[0.995638,0.000069412505,0.0018009596,0.00033389634,0.0001510475,0.0000040684586,0.000012295212,0.00004449414,0.0019458355],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99771386,0.00037309364,0.00072682614,0.00020164676,0.00036779462,0.0006167498],"domain_scores_gemma":[0.9975806,0.00024662504,0.00043847167,0.000426634,0.00059694797,0.0007107114],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012294549,0.00020227021,0.00056383945,0.0005327611,0.00019665241,0.000023929446,0.0003833821,0.0002717845,0.0010025817],"category_scores_gemma":[0.0008836143,0.00015327834,0.00020637274,0.0004436601,0.0005126853,0.00013249753,0.000020269325,0.00100924,0.0000424078],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016909058,0.00012888515,0.06928235,0.0005356242,0.0036545957,0.7759839,0.007083308,0.0012732653,0.09795302,0.0163237,0.017613687,0.008476736],"study_design_scores_gemma":[0.0021076791,0.0015829063,0.026658518,0.0001595279,0.00037030483,0.9524229,0.00063408725,0.00004668299,0.008175699,0.0024221449,0.0052197203,0.00019981062],"about_ca_topic_score_codex":0.004122671,"about_ca_topic_score_gemma":0.00008115554,"teacher_disagreement_score":0.176439,"about_ca_system_score_codex":0.0037831096,"about_ca_system_score_gemma":0.022032829,"threshold_uncertainty_score":0.99991065},"labels":[],"label_agreement":null},{"id":"W1991892158","doi":"10.1016/j.cancergencyto.2008.01.003","title":"Spontaneous remission of myelodysplastic syndrome with monosomy 7 in a young boy","year":2008,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Ottawa","funders":"","keywords":"Monosomy; Spontaneous remission; Complete remission; Myeloid leukemia; Chromosome 7 (human); Biology; Myelodysplastic syndromes; Myeloid; Aneuploidy; Pediatrics; Internal medicine; Oncology; Immunology; Pathology; Genetics; Karyotype; Chemotherapy; Medicine; Chromosome; Bone marrow; Gene","score_opus":0.020494335750897222,"score_gpt":0.2725130481563035,"score_spread":0.2520187124054063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991892158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939783,0.004752927,0.00017378203,0.0001950249,0.000046357844,0.00038657742,0.000018426326,0.000013036509,0.0004355751],"genre_scores_gemma":[0.9798518,0.015805148,0.0034217194,0.00005540655,0.000051487008,0.000030361056,0.000008029274,0.00004385934,0.00073223235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986149,0.000027197193,0.00030838852,0.00032850867,0.00036806997,0.00035295027],"domain_scores_gemma":[0.99917483,0.000036983445,0.00007832396,0.0003233457,0.00014864853,0.00023787962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000069219015,0.00019384724,0.00038661886,0.00016528423,0.00005692538,0.000006943096,0.000110973786,0.0001290639,0.000037088623],"category_scores_gemma":[0.000025290894,0.00016028121,0.00003437748,0.00032716143,0.00020103989,0.000014075145,0.0000811865,0.00022919009,0.000002613628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001285668,0.00018355428,0.9142444,0.00045439764,0.00013588344,0.013589544,0.0010741154,0.0014823175,0.05938043,0.000014036211,0.00031349255,0.007842138],"study_design_scores_gemma":[0.0055479207,0.0026339986,0.8770805,0.0007134598,0.00020140497,0.05044381,0.0003104657,0.007349411,0.05297792,0.000053766566,0.0021843938,0.00050296495],"about_ca_topic_score_codex":0.00015702486,"about_ca_topic_score_gemma":0.0001931998,"teacher_disagreement_score":0.03716394,"about_ca_system_score_codex":0.00017083579,"about_ca_system_score_gemma":0.0006094582,"threshold_uncertainty_score":0.6536078},"labels":[],"label_agreement":null},{"id":"W1992106179","doi":"10.1097/moh.0b013e328347888a","title":"Roles for MSI2 and PROX1 in hematopoietic stem cell activity","year":2011,"lang":"en","type":"review","venue":"Current Opinion in Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Biology; Haematopoiesis; Stem cell; Progenitor cell; Hematopoietic stem cell; Myeloid; Cell biology; Cell fate determination; Leukemia; Cancer research; Immunology; Genetics; Transcription factor; Gene","score_opus":0.17255039568018754,"score_gpt":0.43242241755806937,"score_spread":0.25987202187788183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992106179","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001840506,0.9937141,0.000113071415,0.00008552626,0.0013009867,0.0043581575,0.00004481306,0.000037945,0.00016134973],"genre_scores_gemma":[0.00027306975,0.9972974,0.00012821089,0.0000053031717,0.00015134909,0.00189434,0.00009817252,0.00007867162,0.00007347143],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970678,0.00033778744,0.00089959666,0.00084116665,0.00017350791,0.0006801486],"domain_scores_gemma":[0.99819076,0.00065207167,0.0003507544,0.0005455202,0.00006959509,0.00019128855],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057384744,0.0005069803,0.0029657553,0.000839128,0.000035705936,0.000013510726,0.00026606652,0.00068736495,0.000037285565],"category_scores_gemma":[0.000078348276,0.00041698356,0.0002653577,0.00040200553,0.00018119259,0.00006739001,0.00026830728,0.0012386622,0.000048288617],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008884666,0.00039524748,0.0004107317,0.23644136,0.00002956687,0.000011733621,0.00023603601,1.6682522e-8,4.4241636e-7,0.0018636389,0.0011579036,0.7593645],"study_design_scores_gemma":[0.0020715867,0.00021251374,0.00004577157,0.03608534,0.000118489006,0.00078420836,0.000057974852,0.00005480543,0.000023055356,0.00025917956,0.9598859,0.00040117718],"about_ca_topic_score_codex":0.000010865308,"about_ca_topic_score_gemma":0.0000070114675,"teacher_disagreement_score":0.958728,"about_ca_system_score_codex":0.00038225757,"about_ca_system_score_gemma":0.0008869088,"threshold_uncertainty_score":0.9998282},"labels":[],"label_agreement":null},{"id":"W1993140349","doi":"10.1097/00062752-200301000-00006","title":"Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies","year":2003,"lang":"en","type":"review","venue":"Current Opinion in Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Myeloid leukemia; Medicine; Leukemia; Immunology; Myeloid; Cancer research; Targeted therapy; Cancer; Internal medicine","score_opus":0.07076103519389623,"score_gpt":0.3876003972556198,"score_spread":0.3168393620617236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993140349","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010343788,0.9948847,0.000053626893,0.0006131017,0.00072173605,0.0025478739,0.00006649909,0.000011632115,0.000066417335],"genre_scores_gemma":[0.00030397286,0.9979384,0.00033250466,0.00010631505,0.00003559985,0.00071224454,0.00050895347,0.00005742875,0.0000045587044],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960463,0.0006803965,0.0014246382,0.0007509112,0.00046317047,0.00063459924],"domain_scores_gemma":[0.99842006,0.0003040342,0.00037573653,0.0006535441,0.000081701415,0.00016492241],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008918463,0.00055231404,0.0022758087,0.0011167774,0.00003213449,0.00001555669,0.00048448556,0.000403213,0.000043747445],"category_scores_gemma":[0.00031830993,0.00038802953,0.00018887651,0.0013591108,0.00023618237,0.000062287436,0.00024661073,0.0015058164,0.000015399042],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022213333,0.0015695292,0.008064664,0.050176002,0.0005523179,0.00021540847,0.0010679832,0.0000014305322,0.0000025133595,0.012964462,0.0010920267,0.92407155],"study_design_scores_gemma":[0.004196246,0.00008642776,0.004624467,0.029256225,0.0002633462,0.0006348566,0.00012358505,0.000011784678,0.000007916851,0.0003330879,0.9599472,0.0005148075],"about_ca_topic_score_codex":0.000012328488,"about_ca_topic_score_gemma":0.000004279116,"teacher_disagreement_score":0.9588552,"about_ca_system_score_codex":0.00075920555,"about_ca_system_score_gemma":0.0024952653,"threshold_uncertainty_score":0.9998572},"labels":[],"label_agreement":null},{"id":"W1994002042","doi":"10.1038/leu.2010.30","title":"Functional differences between myeloid leukemia-initiating and transient leukemia cells in Down's syndrome","year":2010,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Hospital for Sick Children","funders":"National Cancer Institute; Ontario Institute for Cancer Research; Cancer Research Society","keywords":"Down syndrome; Leukemia; Bone marrow; Myeloid leukemia; clone (Java method); GATA1; Immunology; Biology; Trisomy; Somatic evolution in cancer; Myeloid; Nod; Cancer research; Haematopoiesis; Medicine; Genetics; Stem cell; Cancer; In vivo; DNA","score_opus":0.024135977880562008,"score_gpt":0.2631661623230431,"score_spread":0.23903018444248106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994002042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99075884,0.00012813308,0.00021789756,0.00074073696,0.00048079604,0.00083378,0.0000751997,0.00019961121,0.0065649995],"genre_scores_gemma":[0.99447185,0.00012735263,0.0018644508,0.0005487908,0.00068351906,0.000114328985,0.00014680356,0.000099024066,0.0019438694],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9955578,0.00015066526,0.0009183469,0.0010883813,0.0010675727,0.0012172619],"domain_scores_gemma":[0.99740773,0.0007887648,0.00018987089,0.00072339183,0.00017141743,0.000718829],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00091077667,0.00060138974,0.0010381974,0.00065879,0.00028209315,0.00013086667,0.00038927738,0.000695965,0.0007294046],"category_scores_gemma":[0.0002840074,0.00053644826,0.00019916124,0.00078191125,0.00054352573,0.0003722006,0.00022179635,0.0031591002,0.0002649203],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008414812,0.00016617565,0.46167755,0.0011084175,0.00049136265,0.002748047,0.0028908048,0.00019946703,0.4746881,0.00094664254,0.010612249,0.043629684],"study_design_scores_gemma":[0.005955112,0.0004391998,0.9725523,0.00027773678,0.00014704933,0.0008753535,0.00043756442,0.002489317,0.012058202,0.00031940176,0.0037555895,0.0006931462],"about_ca_topic_score_codex":0.0012654596,"about_ca_topic_score_gemma":0.00033078477,"teacher_disagreement_score":0.5108748,"about_ca_system_score_codex":0.0036532758,"about_ca_system_score_gemma":0.0033926298,"threshold_uncertainty_score":0.9997087},"labels":[],"label_agreement":null},{"id":"W1994072109","doi":"10.1532/ijh97.05027","title":"A Novel Chromosomal Abnormality, t(6;10)(q27;q22), Found in a Polycythemic Potential Donor for Allogeneic Hematopoietic Stem Cell Transplantation","year":2005,"lang":"en","type":"article","venue":"International Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Foundation","keywords":"Karyotype; Haematopoiesis; Bone marrow; Stem cell; Hematology; Transplantation; Biology; Internal medicine; Immunology; Andrology; Abnormality; Peripheral blood mononuclear cell; Medicine; Genetics; Chromosome; In vitro","score_opus":0.02027731379734181,"score_gpt":0.3131298421487186,"score_spread":0.29285252835137676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994072109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691101,0.00071576145,0.022415532,0.006377525,0.00052890106,0.00039280942,0.00003848052,0.00001567414,0.000405264],"genre_scores_gemma":[0.9911654,0.00015487894,0.0069634854,0.0004787453,0.00066682685,0.00002642741,0.00003627871,0.00003343511,0.00047455207],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.99767894,0.000058551548,0.0010233257,0.00023657331,0.000616721,0.0003859134],"domain_scores_gemma":[0.9983532,0.0002254759,0.00043240137,0.00014818282,0.0006785224,0.00016222305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005056045,0.00019807866,0.00053116266,0.00061033794,0.000037146157,0.000033009914,0.0004568858,0.00019548403,0.00031776607],"category_scores_gemma":[0.0000456725,0.00017715094,0.0002534751,0.00014609446,0.00010259086,0.00025207104,0.000052632437,0.00040096336,0.000041136373],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047815554,0.0076636607,0.037595313,0.002719623,0.003238978,0.019392315,0.007051803,0.0050525623,0.82754123,0.00981982,0.011620737,0.020488415],"study_design_scores_gemma":[0.07610872,0.0031424323,0.020340728,0.0015750878,0.0008005463,0.5320393,0.001326379,0.011865678,0.3391108,0.0016511882,0.010955885,0.001083312],"about_ca_topic_score_codex":0.000029484396,"about_ca_topic_score_gemma":0.000057329366,"teacher_disagreement_score":0.512647,"about_ca_system_score_codex":0.0005361411,"about_ca_system_score_gemma":0.00062291214,"threshold_uncertainty_score":0.72240055},"labels":[],"label_agreement":null},{"id":"W1994350539","doi":"10.1158/1538-7445.am2014-4792","title":"Abstract 4792: Elucidating stem cell-specific metabolic pathways in normal and malignant hematopoiesis to target human acute myeloid leukemia stem cells","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Stem cell; Biology; Haematopoiesis; Progenitor cell; Myeloid leukemia; Myeloid; Leukemia; Cancer research; Hematopoietic stem cell; Cell biology; Immunology","score_opus":0.053982309339953426,"score_gpt":0.33564307272110006,"score_spread":0.28166076338114665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994350539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878592,0.003543206,0.00012070003,0.00072759495,0.00013528542,0.0016802611,0.0001055256,0.00009114519,0.0057371217],"genre_scores_gemma":[0.9919438,0.0016748282,0.0008726317,0.00024058095,0.00057958,0.0006150556,0.00002938252,0.00015779365,0.0038863437],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9933277,0.00048838963,0.00087461266,0.0012868713,0.0019287474,0.0020937067],"domain_scores_gemma":[0.99657786,0.0005002393,0.00013544137,0.001175518,0.00054695905,0.0010639742],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004515788,0.00047150464,0.001014607,0.0012197106,0.0005166817,0.00024170999,0.00075320224,0.00031159428,0.0007990836],"category_scores_gemma":[0.000037698097,0.0004198168,0.00013765896,0.0015355312,0.00033529077,0.0003066853,0.00079968583,0.0019936406,0.00041439926],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004371244,0.0000987625,0.0017921828,0.0006605754,0.000094027644,0.0005857777,0.0026706045,0.00009228718,0.9658076,0.0008425035,0.010921557,0.015997006],"study_design_scores_gemma":[0.0031260378,0.0004138697,0.009353643,0.0005350161,0.00003226235,0.00006596464,0.002506524,0.00029277257,0.93984735,0.000098831006,0.043194376,0.0005333673],"about_ca_topic_score_codex":0.001432462,"about_ca_topic_score_gemma":0.00013788152,"teacher_disagreement_score":0.03227282,"about_ca_system_score_codex":0.0020449306,"about_ca_system_score_gemma":0.00120104,"threshold_uncertainty_score":0.99982536},"labels":[],"label_agreement":null},{"id":"W1994726114","doi":"10.1158/1538-7445.am2011-2136","title":"Abstract 2136: Expression of fusion proteins in acute myeloid leukemia cells increases sensitivity to histone deacetylase inhibitors","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Vorinostat; Programmed cell death; Biology; Histone deacetylase; DNA damage; Cancer research; Histone deacetylase inhibitor; Molecular biology; Histone; Apoptosis; Cell biology; DNA; Biochemistry","score_opus":0.05718878108002325,"score_gpt":0.369191659511069,"score_spread":0.3120028784310458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994726114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424136,0.00034661594,0.000034866665,0.00040644666,0.000095061,0.0025058866,0.000083426436,0.000058563044,0.002227782],"genre_scores_gemma":[0.9956302,0.00061574916,0.0015028388,0.000100858844,0.000242363,0.00047267313,0.000022075994,0.00008165545,0.0013315955],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952001,0.00050283934,0.0006150007,0.00079959404,0.0017405758,0.0011419097],"domain_scores_gemma":[0.99701416,0.00034483083,0.00012121746,0.00092055893,0.00080387027,0.0007953748],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030128853,0.00029942582,0.00064973946,0.001215739,0.00016459147,0.000020463613,0.00033413112,0.00031050155,0.0008679531],"category_scores_gemma":[0.00067894784,0.00025977264,0.00013320932,0.0015018999,0.00046052993,0.00023352518,0.0006976753,0.0016146487,0.00019320568],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040694377,0.00043461198,0.0027866375,0.0004084382,0.00003372691,0.001070552,0.0016057983,0.00001677576,0.97325593,0.000011178283,0.008934809,0.00737208],"study_design_scores_gemma":[0.0020486566,0.00053415284,0.048916694,0.0012534332,0.000018545363,0.000025948542,0.00041499105,0.000043303884,0.9456108,0.000027131151,0.00088322983,0.00022311804],"about_ca_topic_score_codex":0.039351214,"about_ca_topic_score_gemma":0.0015434594,"teacher_disagreement_score":0.046130054,"about_ca_system_score_codex":0.0041282563,"about_ca_system_score_gemma":0.0030649449,"threshold_uncertainty_score":0.99998546},"labels":[],"label_agreement":null},{"id":"W1995357901","doi":"10.3109/10428194.2010.490312","title":"Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celator Pharmaceuticals (Canada)","funders":"","keywords":"Daunorubicin; Cytarabine; Pharmacology; Medicine; Bone marrow; Leukemia; Drug; Therapeutic index; Myeloid leukemia; Internal medicine","score_opus":0.015134411913510911,"score_gpt":0.28125515738351764,"score_spread":0.26612074547000675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995357901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99229354,0.000843519,0.00019523942,0.00026250293,0.00032603866,0.0020230552,0.00007818527,0.00024623875,0.0037317092],"genre_scores_gemma":[0.9936993,0.0009311185,0.0020593475,0.00040042482,0.0005980843,0.00033162886,0.0006319683,0.00019332158,0.0011547757],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9937081,0.00027575507,0.0019482343,0.0015946946,0.001060028,0.0014132264],"domain_scores_gemma":[0.99588597,0.00062299974,0.00067687366,0.0014247586,0.00050242036,0.0008869785],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00092311425,0.0011403774,0.0017760261,0.0013112938,0.0005647057,0.00019371998,0.00045731728,0.0010775871,0.00012884807],"category_scores_gemma":[0.0005592886,0.0010433021,0.00030964497,0.001199858,0.0008687483,0.00072334165,0.00030770578,0.0005380019,0.000044133412],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0025046398,0.0007585145,0.08980388,0.0008814923,0.00058991543,0.00092606567,0.0030960154,0.00031577024,0.78220034,0.008743032,0.00092024135,0.10926009],"study_design_scores_gemma":[0.08931558,0.0026136797,0.61336637,0.001077828,0.0007067203,0.001611812,0.0013526799,0.06199304,0.21882385,0.0014342559,0.0053754784,0.0023287],"about_ca_topic_score_codex":0.005503441,"about_ca_topic_score_gemma":0.0015463968,"teacher_disagreement_score":0.5633765,"about_ca_system_score_codex":0.011762964,"about_ca_system_score_gemma":0.007905026,"threshold_uncertainty_score":0.9992017},"labels":[],"label_agreement":null},{"id":"W1995752013","doi":"10.1038/onc.2010.254","title":"Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells","year":2010,"lang":"en","type":"article","venue":"Oncogene","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Ligue Contre le Cancer; Institut National de la Santé et de la Recherche Médicale; Fondation de France; Association pour la Recherche sur le Cancer","keywords":"Biology; H3K4me3; Histone; Chromatin; Cancer research; Molecular biology; Histone methyltransferase; Histone H3; Chromatin immunoprecipitation; Cell biology; Promoter; Genetics; Gene expression; Gene","score_opus":0.019198265912610417,"score_gpt":0.3002725885846118,"score_spread":0.2810743226720014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995752013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99703103,0.00019724673,0.00001556585,0.00026032922,0.00008020757,0.0011617929,0.000079244535,0.000117043004,0.0010575202],"genre_scores_gemma":[0.99038935,0.00008310046,0.004046855,0.00008990945,0.00042751632,0.000087503286,0.00020702425,0.00009159989,0.0045771366],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973795,0.000114598464,0.00052440347,0.00066338386,0.00058118306,0.00073693995],"domain_scores_gemma":[0.99841434,0.00013039629,0.0001844612,0.00067603914,0.0001794922,0.0004152822],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00072204246,0.00033275623,0.00064556696,0.00028286144,0.00023182417,0.00007152457,0.00026868304,0.0005410121,0.00020642922],"category_scores_gemma":[0.00023670311,0.00029476194,0.00009727345,0.00041961507,0.00028696022,0.00013672808,0.0003024872,0.0010971952,0.00003698616],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013549661,0.00019734722,0.048144307,0.00006302103,0.00006436437,0.0003354681,0.00021413736,0.000001832223,0.9474694,0.0000052582254,0.0007327312,0.0026366385],"study_design_scores_gemma":[0.005547752,0.00060130656,0.08816905,0.00014632866,0.00009851724,0.000043266373,0.00003766846,0.000048680802,0.9032379,0.00012678902,0.0016638777,0.0002788617],"about_ca_topic_score_codex":0.0006361635,"about_ca_topic_score_gemma":0.00031308734,"teacher_disagreement_score":0.044231497,"about_ca_system_score_codex":0.00043356244,"about_ca_system_score_gemma":0.0004971104,"threshold_uncertainty_score":0.99995047},"labels":[],"label_agreement":null},{"id":"W1995888220","doi":"10.1080/146532401317248054","title":"CD133 (AC133) expression on AML cells and progenitors","year":2001,"lang":"en","type":"article","venue":"Cytotherapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver Hospital and Health Sciences Centre","funders":"National Cancer Institute","keywords":"CD34; Progenitor cell; Biology; Molecular biology; Haematopoiesis; Stem cell; Cancer research; Ex vivo; In vivo; Immunology; Andrology; Cell biology; Medicine; Genetics","score_opus":0.021952016060014068,"score_gpt":0.30656277793227527,"score_spread":0.2846107618722612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995888220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911819,0.00038485992,0.0001225533,0.0012957446,0.00010541333,0.00053737685,0.000003543096,0.00009660934,0.0062719737],"genre_scores_gemma":[0.98144716,0.0020339468,0.0015412944,0.0019745047,0.00064761663,0.000059201877,0.000009415772,0.00007400177,0.012212868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99890125,0.000048267666,0.00014190831,0.000298962,0.00029756705,0.00031202188],"domain_scores_gemma":[0.9992965,0.00006726593,0.000033113407,0.0003425283,0.00004907448,0.00021155772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014600287,0.00015227648,0.0002075354,0.0001287135,0.00008479174,0.000024831701,0.00009108178,0.00011687165,0.0005412578],"category_scores_gemma":[0.000020000758,0.00011236261,0.000053028376,0.00017194169,0.000093515766,0.000055701403,0.000024799368,0.00025697015,0.00022500646],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012038994,0.00018039189,0.009966142,0.000029518418,0.000039334052,0.00020536083,0.000431744,0.0000017101481,0.92217547,0.000054782067,0.021513503,0.04419813],"study_design_scores_gemma":[0.0039033035,0.0009481575,0.006708915,0.00012694753,0.000012026877,0.00012429697,0.000132382,0.00015165878,0.7477279,0.00011174177,0.23986466,0.00018802064],"about_ca_topic_score_codex":0.000015357487,"about_ca_topic_score_gemma":0.0000011034175,"teacher_disagreement_score":0.21835116,"about_ca_system_score_codex":0.00012665072,"about_ca_system_score_gemma":0.0000823595,"threshold_uncertainty_score":0.59263927},"labels":[],"label_agreement":null},{"id":"W1995904464","doi":"10.1016/j.exphem.2014.07.164","title":"AML with EVI1 rearrangements are characterized by SF3B1 and IKZF1 mutations and distinct expression of MECOM isoforms","year":2014,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Gene isoform; Cancer research; Genetics; Expression (computer science); Biology; Focus (optics); Mutation; Gene; Computer science; Physics","score_opus":0.012311912329915416,"score_gpt":0.2978523996464606,"score_spread":0.2855404873165452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995904464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99663556,0.0013609922,0.00029000008,0.0003277263,0.000028328408,0.0005137197,0.000019618223,0.000029382887,0.0007946853],"genre_scores_gemma":[0.9981232,0.000026918935,0.0011625465,0.00010414138,0.000022193626,0.00012761436,0.000100586294,0.000023866507,0.00030891417],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990143,0.000064078944,0.0002288571,0.00028111582,0.00018209203,0.0002295381],"domain_scores_gemma":[0.9993917,0.000082910134,0.00012878305,0.00020307633,0.00003985516,0.00015370536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001013919,0.00015220341,0.00043428017,0.000078737154,0.00008932453,0.000009784487,0.000060486225,0.00008554387,0.00020018868],"category_scores_gemma":[0.00003217483,0.000107293934,0.000023071325,0.00006940208,0.00030863655,0.00009394668,0.00010953042,0.00012590754,0.000008607414],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017933722,0.00060851284,0.11028694,0.00049496366,0.00010509187,0.000057411413,0.0016821949,3.9574438e-8,0.87993664,0.00097477564,0.0023073019,0.0017527783],"study_design_scores_gemma":[0.0063614314,0.0010170707,0.018911863,0.00025272637,0.00003162971,0.0005499921,0.0016672383,0.00013873146,0.9687149,0.00004680914,0.0021402189,0.00016740245],"about_ca_topic_score_codex":0.00002663072,"about_ca_topic_score_gemma":0.0000032338362,"teacher_disagreement_score":0.09137508,"about_ca_system_score_codex":0.000047172387,"about_ca_system_score_gemma":0.000021699052,"threshold_uncertainty_score":0.43753198},"labels":[],"label_agreement":null},{"id":"W1996100423","doi":"10.1182/blood-2007-11-122028","title":"High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Comparative genomic hybridization; Biology; Myelodysplastic syndromes; Copy-number variation; Myeloid leukemia; Karyotype; Genetics; Myeloid; Genome; Cancer research; Chromosome; Gene; Bone marrow; Immunology","score_opus":0.00905751583533974,"score_gpt":0.22145495604387486,"score_spread":0.21239744020853513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996100423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966623,0.00023267703,0.0010117106,0.000036733887,0.00005248856,0.0005607363,0.0012789159,0.00004608836,0.000118326374],"genre_scores_gemma":[0.9921602,0.00042968438,0.0061616264,0.00003738236,0.00010222345,0.000025996469,0.0008238593,0.00004353722,0.00021550203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975437,0.00016663915,0.0005222984,0.00057927595,0.0007692596,0.00041882854],"domain_scores_gemma":[0.9980426,0.00045309492,0.00026009316,0.0006399493,0.00029853868,0.00030572785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023713207,0.00029175167,0.000819789,0.0002991741,0.0002278806,0.000035776313,0.00015295485,0.00016066937,0.00008446466],"category_scores_gemma":[0.00026370838,0.00024373284,0.00008928065,0.00056915835,0.00027082535,0.00019998629,0.000116566356,0.00035492942,0.00001637675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047709528,0.00064923585,0.9482886,0.00018168708,0.0033798458,0.00013010134,0.0010861492,0.0014095419,0.044122837,0.000020176236,0.00020856234,0.000046140216],"study_design_scores_gemma":[0.011202774,0.0005735197,0.97847074,0.00019590669,0.004310328,0.000022382053,0.000052619784,0.0024781916,0.0023243993,0.00007620851,0.000024336978,0.00026858787],"about_ca_topic_score_codex":0.00088867266,"about_ca_topic_score_gemma":0.000070941045,"teacher_disagreement_score":0.04179844,"about_ca_system_score_codex":0.0001878856,"about_ca_system_score_gemma":0.00028281077,"threshold_uncertainty_score":0.9939137},"labels":[],"label_agreement":null},{"id":"W1996122750","doi":"10.1038/leu.2008.395","title":"The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia","year":2009,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Ligue Contre le Cancer; Institut National Du Cancer; Association pour la Recherche sur le Cancer","keywords":"Phosphorylation; Protein kinase B; Cancer research; Biology; AKT1; Clonogenic assay; PTEN; Internal medicine; Cytogenetics; Myeloid leukemia; PI3K/AKT/mTOR pathway; Oncology; Apoptosis; Medicine; Genetics; Gene","score_opus":0.030125440859411753,"score_gpt":0.27579310577551125,"score_spread":0.24566766491609948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996122750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951174,0.00014910016,0.00006330967,0.0022473964,0.00009525086,0.00087196496,0.00032639768,0.00007081153,0.0010583544],"genre_scores_gemma":[0.99364114,0.0010238012,0.00037538982,0.0014898257,0.00011808851,0.000023785215,0.00012842909,0.000066479726,0.0031330576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670124,0.00017436052,0.0006086637,0.000608267,0.0012061973,0.00070124655],"domain_scores_gemma":[0.9978909,0.000582731,0.0003502826,0.0006881632,0.0002822697,0.00020568017],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00079606153,0.00043432106,0.0007053276,0.00021579895,0.0001951501,0.00004698436,0.0002893954,0.0003503138,0.000030510966],"category_scores_gemma":[0.0004923387,0.00029860364,0.00008775741,0.0005439279,0.00023137325,0.00010185232,0.00009181973,0.0011184999,0.000018772307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08843808,0.002108698,0.37459722,0.00038171452,0.004601265,0.002359639,0.004662814,0.010872187,0.29815105,0.0071271188,0.024244726,0.1824555],"study_design_scores_gemma":[0.011550528,0.0042021433,0.79792786,0.00034549684,0.00019399126,0.000031448904,0.000062929634,0.0043650027,0.18029697,0.0003295354,0.00037908368,0.00031502228],"about_ca_topic_score_codex":0.0011785646,"about_ca_topic_score_gemma":0.00035003832,"teacher_disagreement_score":0.42333063,"about_ca_system_score_codex":0.0021369942,"about_ca_system_score_gemma":0.00086649496,"threshold_uncertainty_score":0.9999466},"labels":[],"label_agreement":null},{"id":"W1996138754","doi":"10.1002/gcc.20045","title":"Cryptic insertion of <i>MLL</i> gene into 9p22 leads to <i>MLL–MLLT3</i> (<i>AF9</i>) fusion in a case of acute myelogenous leukemia","year":2004,"lang":"en","type":"article","venue":"Genes Chromosomes and Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Fusion gene; Chromosomal translocation; Molecular biology; Karyotype; Biology; Fusion transcript; Myeloid leukemia; Fluorescence in situ hybridization; Metaphase; Leukemia; breakpoint cluster region; Chromosome; Cancer research; Gene; Genetics","score_opus":0.012749225343512452,"score_gpt":0.29410308708817445,"score_spread":0.281353861744662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996138754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875281,0.010205073,0.00011088873,0.0009852882,0.00014814889,0.0008061881,0.00007367409,0.00003117864,0.000111503476],"genre_scores_gemma":[0.9828267,0.013548431,0.0020950283,0.00087931205,0.00020854306,0.00014764786,0.00003534163,0.000055540597,0.00020343384],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99782014,0.000052964402,0.00064127037,0.0005351018,0.00042462893,0.0005258947],"domain_scores_gemma":[0.9987254,0.00003922862,0.00016603021,0.00050360314,0.00026073816,0.0003050113],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025353348,0.000306062,0.0007446644,0.0003673771,0.00009481586,0.000015221172,0.00017711829,0.00022433115,0.000104160965],"category_scores_gemma":[0.00003006823,0.0002682988,0.00012691492,0.0008926931,0.00020984042,0.00013436704,0.000232575,0.00027794988,0.000012242249],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007868621,0.00014973294,0.009040153,0.00061264617,0.00014469185,0.0024802238,0.002366381,0.00076494546,0.9323535,0.0000321816,0.00025537427,0.05101333],"study_design_scores_gemma":[0.009223432,0.0021211838,0.020376625,0.00083194504,0.00041789832,0.0030325819,0.0006706294,0.00022855746,0.95954585,0.0002468998,0.0027509867,0.0005534245],"about_ca_topic_score_codex":0.010925761,"about_ca_topic_score_gemma":0.0021677937,"teacher_disagreement_score":0.050459906,"about_ca_system_score_codex":0.0012290484,"about_ca_system_score_gemma":0.0013084993,"threshold_uncertainty_score":0.99997693},"labels":[],"label_agreement":null},{"id":"W1996471732","doi":"10.1158/1538-7445.am2014-4713","title":"Abstract 4713: High-throughput multiplex Sequenom MassARRAY clinical diagnostic assay for the identification of actionable genetic variants in hematologic malignancies","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"CEBPA; NPM1; Multiplex; Biology; Myeloid leukemia; Cancer research; Leukemia; Computational biology; Oncology; Medicine; Genetics; Gene; Mutation; Karyotype","score_opus":0.13507085675158792,"score_gpt":0.44778748288117304,"score_spread":0.3127166261295851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996471732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843019,0.0011343843,0.0050833514,0.006258787,0.00034918563,0.0025790604,0.00006775279,0.000031160354,0.00019438348],"genre_scores_gemma":[0.99367386,0.002015118,0.0011563482,0.00011864898,0.0004548738,0.0014334497,0.000031270934,0.000045213954,0.0010711856],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996078,0.00061075663,0.0009904667,0.00059676514,0.0009545813,0.000769427],"domain_scores_gemma":[0.9849918,0.012829198,0.00021275082,0.0008753965,0.00092638994,0.00016450061],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009041486,0.00016628623,0.0004957527,0.0002780424,0.0002234104,0.000055845456,0.0005398648,0.0002558009,0.0003033761],"category_scores_gemma":[0.016419489,0.0001178195,0.00012907755,0.00065852696,0.00066990213,0.00011891529,0.00015369718,0.00091887993,0.00009624266],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002199113,0.0009703744,0.21106172,0.0023202044,0.00041790353,0.00011192154,0.00060214143,0.0021013324,0.7211128,0.0041296254,0.02309969,0.031873174],"study_design_scores_gemma":[0.003597278,0.00039408868,0.93362916,0.00031767256,0.0000534264,0.000022829281,0.00036757145,0.006723337,0.04592003,0.0029398531,0.005849267,0.00018550294],"about_ca_topic_score_codex":0.0023691147,"about_ca_topic_score_gemma":0.00030578568,"teacher_disagreement_score":0.72256744,"about_ca_system_score_codex":0.000733531,"about_ca_system_score_gemma":0.0011627749,"threshold_uncertainty_score":0.99186563},"labels":[],"label_agreement":null},{"id":"W1997303669","doi":"10.1080/10428190601043252","title":"Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (&gt;5 years)","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cohort; Internal medicine; Complete remission; Leukemia; Chemotherapy; Oncology; Surgery","score_opus":0.0068160636290141114,"score_gpt":0.23682244162637736,"score_spread":0.23000637799736326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997303669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99525017,0.0005520848,0.00011512492,0.00010107024,0.00031351528,0.0012499191,0.00025857225,0.00025829766,0.0019012264],"genre_scores_gemma":[0.9915895,0.0014372227,0.0022416534,0.0012133978,0.0002482189,0.000049743972,0.00042134203,0.00026662898,0.0025323199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936204,0.00013593235,0.0015251521,0.0014192021,0.0015079008,0.001791442],"domain_scores_gemma":[0.99548614,0.00060767116,0.0007082563,0.0013926585,0.0005894034,0.0012158443],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009780229,0.0011011146,0.0020343214,0.0008424122,0.0003746173,0.00013160573,0.00053595705,0.0009164251,0.00006273605],"category_scores_gemma":[0.00024694245,0.0009285349,0.0003020154,0.0009657268,0.0011997742,0.0004924379,0.0005707272,0.0004701095,0.00007248054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006904699,0.00042244498,0.82152677,0.0005894045,0.002078257,0.0027412758,0.0019678306,0.0000057253264,0.006169555,0.0005456915,0.00096450874,0.15608385],"study_design_scores_gemma":[0.026151698,0.0013130793,0.95971054,0.0003236796,0.0010390005,0.0008175643,0.00016857668,0.0004728973,0.002838731,0.00009022554,0.0061020916,0.0009719418],"about_ca_topic_score_codex":0.0009545682,"about_ca_topic_score_gemma":0.000056777506,"teacher_disagreement_score":0.15511191,"about_ca_system_score_codex":0.010138077,"about_ca_system_score_gemma":0.0047692973,"threshold_uncertainty_score":0.9993165},"labels":[],"label_agreement":null},{"id":"W1997651065","doi":"10.1111/j.1445-5994.2006.01177.x","title":"Myeloid sarcoma of the uterus presenting as vaginal bleeding","year":2006,"lang":"en","type":"article","venue":"Internal Medicine Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Manitoba","funders":"","keywords":"Medicine; Asymptomatic; Vaginal bleeding; Myeloid; Uterus; Female circumcision; Infiltration (HVAC); Sarcoma; Pathology; Gynecology; Internal medicine; Pregnancy","score_opus":0.0185841427753218,"score_gpt":0.31957478901252817,"score_spread":0.3009906462372064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997651065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9068071,0.00086362957,0.0007443951,0.014337784,0.0011174665,0.00022819923,0.0000017771183,0.000025931631,0.07587371],"genre_scores_gemma":[0.97517085,0.00008962177,0.0005089117,0.0004314534,0.0051066545,0.0000035580956,0.0000015824138,0.00003836371,0.018648993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966874,0.0001339041,0.0009017843,0.00022570886,0.0015074147,0.00054377294],"domain_scores_gemma":[0.99816346,0.00023080074,0.0004942222,0.00035375747,0.0004927192,0.0002650236],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010904642,0.00022828473,0.0005013873,0.0003604277,0.00018080362,0.0000389667,0.0006428936,0.000097633136,0.0015334297],"category_scores_gemma":[0.00082314754,0.00012761341,0.00024025506,0.00038334803,0.00045724463,0.00016106242,0.00024599122,0.0016529489,0.000036721318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011044114,0.00039499177,0.5016976,0.00028210104,0.0005626796,0.002093645,0.0013005504,0.00004453539,0.27598858,0.0012376179,0.20481078,0.010482514],"study_design_scores_gemma":[0.017466133,0.0036042572,0.6037642,0.008666493,0.0008002833,0.13005851,0.0021925035,0.0033840574,0.10256136,0.007845186,0.11910713,0.00054990733],"about_ca_topic_score_codex":0.0013163812,"about_ca_topic_score_gemma":0.000015549758,"teacher_disagreement_score":0.17342724,"about_ca_system_score_codex":0.00036857196,"about_ca_system_score_gemma":0.00036208698,"threshold_uncertainty_score":0.9993793},"labels":[],"label_agreement":null},{"id":"W1997651643","doi":"10.1016/j.cancergencyto.2004.08.027","title":"A der(19)t(12;19)(q12;p13.3) in a case of pediatric acute leukemia with unusual immunophenotype","year":2005,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Immunophenotyping; Biology; Chromosomal translocation; Cytogenetics; Myeloid leukemia; Leukemia; Lineage (genetic); Fusion gene; Myeloid; Immunology; Cancer research; Antigen; Genetics; Gene; Chromosome","score_opus":0.026527783115193746,"score_gpt":0.32358955840795156,"score_spread":0.2970617752927578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997651643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97281915,0.025095403,0.00028641676,0.00059366587,0.000055963483,0.0006098867,0.00008858405,0.000023304505,0.00042761402],"genre_scores_gemma":[0.96024835,0.029877776,0.008014291,0.0004881374,0.00049245363,0.00007346276,0.000018966784,0.00007854095,0.0007080013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979211,0.00005572523,0.0005179928,0.000502756,0.00039343262,0.00060897955],"domain_scores_gemma":[0.9985307,0.00007339277,0.00015362568,0.00055420777,0.00023741616,0.00045069656],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001984465,0.00032838006,0.0005179006,0.0003258008,0.00009357668,0.000029700404,0.0001898921,0.00022896113,0.00009128922],"category_scores_gemma":[0.00003436294,0.0002855537,0.000067864006,0.00063369033,0.00026133592,0.000035292134,0.00017899304,0.00042131863,0.000007200986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003884563,0.0005430199,0.7668884,0.0011774916,0.0012764938,0.0076076197,0.004988383,0.0106899515,0.03234552,0.00020846633,0.005345112,0.16504498],"study_design_scores_gemma":[0.07967439,0.015447023,0.44771186,0.0007438785,0.009570227,0.02891874,0.0038821269,0.0644573,0.22572085,0.0005449445,0.117984824,0.0053438437],"about_ca_topic_score_codex":0.00065736036,"about_ca_topic_score_gemma":0.0014257944,"teacher_disagreement_score":0.31917655,"about_ca_system_score_codex":0.0006948376,"about_ca_system_score_gemma":0.0022675558,"threshold_uncertainty_score":0.99995965},"labels":[],"label_agreement":null},{"id":"W1998321969","doi":"10.1182/blood-2002-10-3062","title":"Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML)","year":2003,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":286,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Myeloid leukemia; Progenitor cell; Biology; Leukemia; Cancer research; Myeloid; Haematopoiesis; Stem cell; Immunology; Interleukin 3; Bone marrow; Molecular biology; Cell biology; T cell; Antigen-presenting cell; Immune system","score_opus":0.0073893000109682,"score_gpt":0.22956871322963482,"score_spread":0.22217941321866663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998321969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616474,0.0001267914,0.0020209246,0.00002032239,0.00006703396,0.0011872522,0.0000591525,0.00005241631,0.00030136495],"genre_scores_gemma":[0.9950174,0.000057128585,0.0044611082,0.000048043607,0.000081157086,0.00004149817,0.00009849663,0.000045800905,0.00014935754],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983313,0.00009713384,0.0003645878,0.00040910355,0.000501987,0.0002958517],"domain_scores_gemma":[0.9986717,0.00010821963,0.00019265071,0.0003227983,0.000523871,0.00018075717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013394642,0.00022190475,0.00033794087,0.00015977817,0.000104677034,0.00002070341,0.0000710091,0.00015461375,0.000046491146],"category_scores_gemma":[0.00010125112,0.0001841127,0.00005070708,0.00031675288,0.00013616135,0.00016992456,0.000037562004,0.00026841823,0.000015382251],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013317876,0.00069372036,0.40517512,0.00011478601,0.0009162868,0.000026157542,0.0009267845,0.00003693107,0.58683133,0.000030900937,0.000105159896,0.0038110304],"study_design_scores_gemma":[0.0116175935,0.00087594363,0.29513603,0.000090301386,0.00062365964,0.000020395715,0.000110591456,0.00035447537,0.6907268,0.000043214066,0.00020900481,0.00019197317],"about_ca_topic_score_codex":0.00014905557,"about_ca_topic_score_gemma":0.000021154305,"teacher_disagreement_score":0.110039085,"about_ca_system_score_codex":0.0004565298,"about_ca_system_score_gemma":0.00065203314,"threshold_uncertainty_score":0.7507898},"labels":[],"label_agreement":null},{"id":"W1998367819","doi":"10.1038/ng.2413","title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis","year":2012,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":808,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; Howard Hughes Medical Institute","keywords":"Biology; Somatic cell; Haematopoiesis; Myeloid; Exome sequencing; Somatic evolution in cancer; Genetics; DNA methylation; Mutation; Exome; Stem cell; Cancer research; Gene","score_opus":0.014817905483908753,"score_gpt":0.3101964165340708,"score_spread":0.29537851105016205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998367819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910432,0.0049006096,0.000101631995,0.0012513633,0.00014952364,0.00053747237,0.000026609863,0.000037863665,0.0019517189],"genre_scores_gemma":[0.9747884,0.000101131685,0.024032617,0.00027626692,0.0003214445,0.000053731706,0.00010415695,0.000035832254,0.00028637992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981799,0.0000655828,0.00027600632,0.00020513835,0.0007017989,0.000571588],"domain_scores_gemma":[0.9990575,0.00013714615,0.000071463655,0.00033108232,0.0001411238,0.00026169413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034133988,0.00018340298,0.000270446,0.00028294587,0.00006584159,0.000022871971,0.00015761012,0.0003476364,0.00015961687],"category_scores_gemma":[0.0001733915,0.00014229213,0.00005086234,0.00056827825,0.00009560836,0.0000899299,0.000071207425,0.0011890935,0.00008020746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015526931,0.00061612215,0.9715069,0.0003588242,0.00018858796,0.00007555979,0.0032025732,0.000039833994,0.0015487311,0.00022849909,0.0033584996,0.018720634],"study_design_scores_gemma":[0.0042831358,0.0008798022,0.944808,0.00033702952,0.00024670013,0.0006702522,0.0010050382,0.00041589502,0.022773866,0.00032227513,0.023811596,0.00044639249],"about_ca_topic_score_codex":0.000005844582,"about_ca_topic_score_gemma":0.000029022714,"teacher_disagreement_score":0.026698848,"about_ca_system_score_codex":0.00022381706,"about_ca_system_score_gemma":0.00037077747,"threshold_uncertainty_score":0.5802505},"labels":[],"label_agreement":null},{"id":"W1998475390","doi":"10.1002/cncr.24373","title":"Outcomes and quality of care in acute myeloid leukemia over 40 years","year":2009,"lang":"en","type":"article","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Toronto Rehabilitation Institute; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Comorbidity; Cancer registry; Chemotherapy; Multivariate analysis; Referral; Internal medicine; Cancer; Pediatrics; Logistic regression; Population","score_opus":0.02880503527379301,"score_gpt":0.37478091616179765,"score_spread":0.3459758808880046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998475390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947004,0.0022833045,0.0000030796693,0.0007085898,0.00005063877,0.00023623057,0.000028866727,0.00001812047,0.0019707852],"genre_scores_gemma":[0.9963489,0.00088559283,0.00020395209,0.0010507609,0.000054472832,0.000013567881,0.000010266049,0.000012053396,0.0014204107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990099,0.000035989564,0.00023919508,0.00021275441,0.00027005284,0.000232095],"domain_scores_gemma":[0.9994592,0.000049306684,0.000054450244,0.00026148316,0.00007305632,0.00010247725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000152597,0.00010343703,0.00038995792,0.000112838585,0.000013910283,0.0000061645105,0.00008204062,0.000099592056,0.00014803688],"category_scores_gemma":[0.00006869668,0.00008801509,0.000057668105,0.00019690876,0.00008377232,0.00006103151,0.000039701903,0.00024829357,0.000005965449],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010810705,0.000030940908,0.9055672,0.00020648244,0.00010254935,0.0000789706,0.0028470966,0.000009922053,0.01947797,0.0003136524,0.0023611395,0.067922994],"study_design_scores_gemma":[0.0026902838,0.00012567407,0.9916813,0.0000748183,0.000027474023,0.0000025211025,0.00022290013,0.000020532969,0.002527535,0.000043445074,0.0024947014,0.00008880776],"about_ca_topic_score_codex":0.0010119831,"about_ca_topic_score_gemma":0.000314473,"teacher_disagreement_score":0.0861141,"about_ca_system_score_codex":0.0008911578,"about_ca_system_score_gemma":0.0004877964,"threshold_uncertainty_score":0.35891512},"labels":[],"label_agreement":null},{"id":"W1998480851","doi":"10.1182/blood-2008-05-156745","title":"Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":240,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Calgary; Vancouver General Hospital; University of British Columbia; Calgary Laboratory Services; BC Cancer Agency","funders":"Tata Trusts; Cancer Research UK; Lady Tata Memorial Trust","keywords":"Pedigree chart; Genetics; Platelet disorder; Medicine; Mutation; Malignancy; RUNX1; Oncology; Biology; Internal medicine; Cancer research; Platelet; Haematopoiesis; Gene; Stem cell","score_opus":0.025227572264911013,"score_gpt":0.2602151961115375,"score_spread":0.23498762384662647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998480851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945457,0.000112740505,0.0006866915,0.0014551753,0.000025994494,0.0013739156,0.000021697091,0.00014807956,0.0016299973],"genre_scores_gemma":[0.97996116,0.000036354773,0.012431229,0.0004900722,0.00030423,0.000060318926,0.00008618885,0.000075432974,0.0065550143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980934,0.000044268534,0.00023403046,0.00047483708,0.00061820395,0.00053525687],"domain_scores_gemma":[0.9987005,0.00005158693,0.00006719129,0.00042693838,0.0003155267,0.00043824187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008273764,0.00026814718,0.0004084173,0.0001937406,0.00029212862,0.000029817293,0.000118595664,0.000103771235,0.0000771047],"category_scores_gemma":[0.00011274944,0.00018831558,0.00004342374,0.0008145059,0.00018112198,0.00016286467,0.000091831316,0.0003884089,0.000090514644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008281535,0.003870051,0.8517032,0.0005010294,0.0018959957,0.031750232,0.030401642,0.0010164963,0.046085853,0.00019432456,0.014938044,0.00936159],"study_design_scores_gemma":[0.032043513,0.0052728658,0.91264266,0.0007542886,0.00060961494,0.014267088,0.001687728,0.00019166105,0.02409661,0.000024700757,0.0073622814,0.0010470108],"about_ca_topic_score_codex":0.0024448188,"about_ca_topic_score_gemma":0.0014122999,"teacher_disagreement_score":0.06093943,"about_ca_system_score_codex":0.00010656016,"about_ca_system_score_gemma":0.001370542,"threshold_uncertainty_score":0.76792866},"labels":[],"label_agreement":null},{"id":"W1999580244","doi":"10.1038/ng.913","title":"Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia","year":2011,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":601,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; University of Washington","keywords":"GATA2; Biology; Myeloid leukemia; Transactivation; Missense mutation; Genetics; Myelodysplastic syndromes; Cancer research; Mutation; Zinc finger; Myeloid; Leukemia; Gene; Transcription factor; Bone marrow; Immunology","score_opus":0.015048788931000591,"score_gpt":0.2598435909749958,"score_spread":0.24479480204399523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999580244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935645,0.0011134226,0.00021174004,0.00016105597,0.00016976072,0.00058155385,0.00010241554,0.00013158577,0.0039639915],"genre_scores_gemma":[0.98624724,0.00034662388,0.009656917,0.00045643162,0.00009821817,0.0000367756,0.00020417213,0.00008234737,0.0028712784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799246,0.000058676676,0.00026673207,0.0004880425,0.0005860873,0.00060801295],"domain_scores_gemma":[0.9986188,0.00013086908,0.00009527812,0.00043728828,0.00035685205,0.0003609373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019642043,0.00029816106,0.00041683455,0.00019906192,0.00017862856,0.000034996825,0.00020209154,0.0006363423,0.00013594794],"category_scores_gemma":[0.00026170636,0.00024332854,0.00005577085,0.00059189025,0.00030287242,0.00009218424,0.00012639734,0.0014109792,0.000051131712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009593345,0.0025282325,0.7357766,0.0015943598,0.016208338,0.0354331,0.016959284,0.0003613484,0.10199572,0.0018381776,0.048703168,0.029008303],"study_design_scores_gemma":[0.0063505014,0.0024285915,0.9723696,0.00027740112,0.001267277,0.0030112336,0.0004175103,0.0024878883,0.00808228,0.00042652994,0.002230071,0.0006510873],"about_ca_topic_score_codex":0.000045317436,"about_ca_topic_score_gemma":0.000073192554,"teacher_disagreement_score":0.23659301,"about_ca_system_score_codex":0.00051125017,"about_ca_system_score_gemma":0.00083230046,"threshold_uncertainty_score":0.992265},"labels":[],"label_agreement":null},{"id":"W1999705499","doi":"10.1016/j.leukres.2012.07.006","title":"Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celator Pharmaceuticals (Canada)","funders":"","keywords":"Daunorubicin; Cytarabine; Pharmacokinetics; Medicine; Pharmacology; Leukemia; Liposome; Internal medicine; Drug; Chemotherapy; Gastroenterology; Chemistry","score_opus":0.023859024702157484,"score_gpt":0.3293869841911375,"score_spread":0.30552795948898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999705499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99461687,0.00037298255,0.00021285984,0.00016234936,0.00008503176,0.002387998,0.000049099468,0.000041642394,0.0020711815],"genre_scores_gemma":[0.9947579,0.00014779468,0.003672459,0.000061705396,0.0001832543,0.00014228222,0.00023053664,0.00010545446,0.0006985965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936764,0.0004569968,0.0010443161,0.00055718835,0.0027357228,0.0015293334],"domain_scores_gemma":[0.99600303,0.0005637767,0.00021551899,0.0009553961,0.0017586331,0.0005036279],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020154372,0.00037483624,0.00087092526,0.001190176,0.00012678567,0.000019761777,0.000488052,0.00034228587,0.00024921453],"category_scores_gemma":[0.0006367142,0.0003120447,0.00013899783,0.0022981248,0.0004439295,0.0006449934,0.00033401587,0.0015144084,0.000051005616],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0090573905,0.00081202225,0.6098202,0.00091423787,0.00014859867,0.000018904082,0.0016666523,0.001173522,0.3666702,0.0002622687,0.0011631737,0.008292822],"study_design_scores_gemma":[0.020864286,0.0023841925,0.55394834,0.0005211706,0.000072726434,0.000013326151,0.00033632436,0.006721143,0.41369593,0.000037821123,0.0010570291,0.00034771184],"about_ca_topic_score_codex":0.0006372105,"about_ca_topic_score_gemma":0.000059097183,"teacher_disagreement_score":0.05587187,"about_ca_system_score_codex":0.004495393,"about_ca_system_score_gemma":0.002503033,"threshold_uncertainty_score":0.9999332},"labels":[],"label_agreement":null},{"id":"W2000580405","doi":"10.1182/blood-2006-10-043299","title":"Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; Astellas Pharma; Novo Nordisk; IC Design Education Center; Valeant Pharmaceuticals International; Edwards Lifesciences; Therakos; Celgene; Osiris Therapeutics; WellPoint; HistoGenetics; Medical College of Wisconsin; StemCyte; Enzon Pharmaceuticals; Takeda Oncology; Amgen; Pfizer; Biogen; Blue Cross and Blue Shield Association; U.S. Department of Health and Human Services; Astellas Pharma US; Abbott Laboratories","keywords":"Cytogenetics; Medicine; Internal medicine; Myeloid leukemia; Hematopoietic stem cell transplantation; Transplantation; Leukemia; Gastroenterology; Confidence interval; Oncology; Surgery; Biology; Chromosome","score_opus":0.03772353118532175,"score_gpt":0.3325197765562388,"score_spread":0.2947962453709171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000580405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971424,0.00007832206,0.0006557174,0.000052116025,0.0000342685,0.0012513398,0.00027420057,0.000027913431,0.0004837669],"genre_scores_gemma":[0.99681014,0.00015282663,0.00208423,0.00003441749,0.000031892207,0.000018463821,0.00014416945,0.000056533587,0.00066734414],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978089,0.0000435234,0.00097003323,0.00032024828,0.0003947355,0.00046256476],"domain_scores_gemma":[0.99836546,0.000562063,0.00028944798,0.00041116576,0.00016957248,0.00020227298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005864773,0.00025457097,0.00074237137,0.00037762424,0.000041508098,0.0000064003857,0.00018792163,0.0002806293,0.00015463858],"category_scores_gemma":[0.000035341185,0.00019070152,0.0002316494,0.0004639053,0.00007391572,0.00004451379,0.000026899335,0.00032857052,0.000009236739],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013138989,0.0009640746,0.17032233,0.003778465,0.00057980337,0.00039386653,0.002972003,0.00030006366,0.8066352,0.000021079002,0.00020846083,0.0006856469],"study_design_scores_gemma":[0.023508199,0.0032712966,0.2167886,0.00057151646,0.0006272025,0.0002212101,0.00026738635,0.00052854867,0.7538852,0.000022318261,0.00006155447,0.00024694498],"about_ca_topic_score_codex":0.00011584161,"about_ca_topic_score_gemma":0.00012410888,"teacher_disagreement_score":0.052749995,"about_ca_system_score_codex":0.00058603275,"about_ca_system_score_gemma":0.00048680327,"threshold_uncertainty_score":0.7776582},"labels":[],"label_agreement":null},{"id":"W2000610923","doi":"10.1158/1535-7163.targ-09-a106","title":"Abstract A106: A phase 1 study of ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML)","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Adverse effect; Refractory (planetary science); Internal medicine; Gastroenterology; Dosing; Surgery","score_opus":0.025273758897927222,"score_gpt":0.3350625837744868,"score_spread":0.30978882487655957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000610923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996591,0.00047367217,0.00009792052,0.00032808297,0.0000615981,0.0018581839,0.000032975742,0.000054056803,0.0005025288],"genre_scores_gemma":[0.9971268,0.00024914314,0.00036742789,0.0017234186,0.000046659778,0.00007913848,0.000045160374,0.000082870494,0.00027938845],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99711406,0.000112216105,0.0005956228,0.0005405187,0.0010523949,0.0005851559],"domain_scores_gemma":[0.9982941,0.00005392379,0.00024752948,0.0008742602,0.00033609863,0.00019408822],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002393531,0.00038027717,0.000678027,0.00034733675,0.00005775337,0.00002044928,0.00032483521,0.00020415321,0.00015142237],"category_scores_gemma":[0.000023680834,0.00027926944,0.0000944671,0.0007966622,0.00010775485,0.0001224604,0.000047249552,0.0007402964,0.000007427388],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09031575,0.02374537,0.09395196,0.00031091072,0.0044321013,0.004423531,0.010013574,0.00048440133,0.45786795,0.000034353416,0.0005291935,0.3138909],"study_design_scores_gemma":[0.16901757,0.050456263,0.67915493,0.0007881676,0.0018703865,0.000031941978,0.0015663619,0.0005157638,0.08715248,0.00007378692,0.008007533,0.0013648275],"about_ca_topic_score_codex":0.00025902505,"about_ca_topic_score_gemma":0.0000983079,"teacher_disagreement_score":0.58520293,"about_ca_system_score_codex":0.0014701192,"about_ca_system_score_gemma":0.0013231484,"threshold_uncertainty_score":0.99996597},"labels":[],"label_agreement":null},{"id":"W2000860927","doi":"10.1532/ijh97.06162","title":"Donor Cell-Derived Chronic Myeloproliferative Disease with t(7;11)(p15;p15) after Cord Blood Transplantation in a Patient with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","year":2007,"lang":"en","type":"article","venue":"International Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Foundation","keywords":"Hematology; Medicine; Philadelphia chromosome; Cord blood; Transplantation; Lymphoblastic Leukemia; Internal medicine; Disease; Leukemia; Hematopoietic cell; Oncology; Pathology; Immunology; Stem cell; Haematopoiesis; Chromosomal translocation; Biology; Genetics; Gene","score_opus":0.005913877237130289,"score_gpt":0.2625242552532337,"score_spread":0.2566103780161034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000860927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892749,0.0004790726,0.0066863545,0.0025935837,0.00018739111,0.0005440168,0.000064875254,0.00001710488,0.00015265467],"genre_scores_gemma":[0.9970817,0.000335365,0.0015657144,0.0005711716,0.00024110048,0.00004891427,0.00007423022,0.000047731843,0.00003405412],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9972128,0.00010362341,0.0008457018,0.00035991217,0.0009787489,0.00049915764],"domain_scores_gemma":[0.9975469,0.0002971488,0.0005175581,0.00016508174,0.0010824342,0.00039088578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023317421,0.00032630345,0.0006026089,0.00076757517,0.000048386853,0.00003533065,0.0002832589,0.00013913432,0.00018081148],"category_scores_gemma":[0.00005014138,0.00023166103,0.00012306742,0.00029243017,0.00028404055,0.00031592167,0.000045204037,0.0005811394,0.000015838972],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2398832,0.0025910698,0.16839129,0.0005819144,0.0048814625,0.5134565,0.006333585,0.0011948746,0.05878101,0.00082329713,0.00030649587,0.0027752537],"study_design_scores_gemma":[0.07010662,0.019478856,0.34430686,0.005054936,0.002523356,0.22224995,0.0012755521,0.0018673127,0.33136827,0.00024709446,0.00033122755,0.0011899774],"about_ca_topic_score_codex":0.00004893271,"about_ca_topic_score_gemma":0.00029394543,"teacher_disagreement_score":0.29120657,"about_ca_system_score_codex":0.0018252183,"about_ca_system_score_gemma":0.002404605,"threshold_uncertainty_score":0.9446863},"labels":[],"label_agreement":null},{"id":"W2002686984","doi":"10.3747/co.21.1311","title":"Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes","year":2013,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"Celgene","keywords":"Azacitidine; Medicine; Myelodysplastic syndromes; Internal medicine; Myeloid leukemia; Oncology; Clinical trial; Confidence interval; Cost effectiveness; Pediatrics","score_opus":0.1394931245970889,"score_gpt":0.417179708885142,"score_spread":0.2776865842880531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002686984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99219424,0.0027582448,0.00023370485,0.00057908095,0.0007105084,0.0033139712,0.00009433921,0.000005830529,0.00011006663],"genre_scores_gemma":[0.99678624,0.0013807351,0.000085748194,0.000012025601,0.00007630643,0.0015142045,0.000031131593,0.000015062293,0.00009856882],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987778,0.00018192503,0.00034048303,0.00019684546,0.00018418714,0.00031875842],"domain_scores_gemma":[0.9957089,0.003555388,0.00015172162,0.00025795575,0.0002306639,0.00009537947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020127626,0.0001392904,0.00060391694,0.000109539316,0.00003041628,0.0000018958569,0.0001284877,0.00006555013,0.00020357735],"category_scores_gemma":[0.00020735068,0.00008501365,0.00008085385,0.00021129374,0.00015412527,0.00002549422,0.0000288631,0.00015413649,0.0000063649213],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012890733,0.0017111979,0.3830788,0.00088596094,0.00044024354,0.00003674742,0.00041614706,0.00023903769,0.0020619573,0.00022118293,0.004989001,0.60463065],"study_design_scores_gemma":[0.010545863,0.0047549787,0.8786154,0.00016851029,0.0002729315,0.000032101943,0.00036026852,0.0040237936,0.0050777383,0.00012064477,0.09590676,0.000121018704],"about_ca_topic_score_codex":0.34915295,"about_ca_topic_score_gemma":0.17696929,"teacher_disagreement_score":0.60450965,"about_ca_system_score_codex":0.0033723968,"about_ca_system_score_gemma":0.002544314,"threshold_uncertainty_score":0.88187003},"labels":[],"label_agreement":null},{"id":"W2002784005","doi":"10.1038/nature09999","title":"A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia","year":2011,"lang":"en","type":"article","venue":"Nature","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":380,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Vlaamse regering; Fonds Wetenschappelijk Onderzoek; Agentschap voor Innovatie door Wetenschap en Technologie; York University; National Cancer Institute; National Institutes of Health; Edward Mallinckrodt, Jr. Foundation; Memorial Sloan-Kettering Cancer Center; Irma T. Hirschl Trust; Alex's Lemonade Stand Foundation for Childhood Cancer; Howard Hughes Medical Institute","keywords":"Notch signaling pathway; HES1; Biology; Haematopoiesis; Cyclin-dependent kinase 8; Cancer research; Notch proteins; Stem cell; Myeloid; Cell biology; Cellular differentiation; Progenitor cell; Transcriptome; Signal transduction; Genetics; Gene; Gene expression","score_opus":0.03378567249484475,"score_gpt":0.2885894207259861,"score_spread":0.2548037482311413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002784005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9214619,0.005091077,0.010841358,0.02002371,0.0024242878,0.0070746695,0.00024439188,0.00037216605,0.032466456],"genre_scores_gemma":[0.99074876,0.000026852556,0.0023956215,0.002922188,0.0005300421,0.00023128864,0.000041838503,0.000046045927,0.0030573783],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986304,0.000026114285,0.0002087913,0.00033165235,0.00037597737,0.00042704368],"domain_scores_gemma":[0.9989297,0.00026414896,0.000057613535,0.00043560102,0.00021001635,0.00010294794],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005232614,0.0001718249,0.00023319223,0.00014031415,0.000097322685,0.000016530605,0.0002653788,0.0010581776,0.0002074103],"category_scores_gemma":[0.0005714222,0.00010704751,0.00012254885,0.0003701624,0.000072653966,0.00010116517,0.000080095044,0.0033158066,0.000051555748],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007911507,0.0006013909,0.005706495,0.0003689758,0.00026005902,0.0001103366,0.002772643,0.000011536678,0.84058213,0.0069930246,0.10720125,0.027480664],"study_design_scores_gemma":[0.015757337,0.0011906386,0.43447116,0.00028200212,0.00021241592,0.00031609792,0.0011247618,0.004762451,0.2740455,0.0012972248,0.26594913,0.0005912867],"about_ca_topic_score_codex":0.00015467753,"about_ca_topic_score_gemma":0.00014021604,"teacher_disagreement_score":0.5665366,"about_ca_system_score_codex":0.00027443265,"about_ca_system_score_gemma":0.00034026985,"threshold_uncertainty_score":0.99898356},"labels":[],"label_agreement":null},{"id":"W2003095359","doi":"10.1016/s0301-472x(00)00347-7","title":"The NUP98-HOXD13 fusion gene implicated in human leukemia induces myeloproliferation and blocks early b cell development in murine hematopoiesis","year":2000,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fusion gene; Haematopoiesis; Cancer research; Leukemia; Biology; Gene; Cell growth; Cell biology; Stem cell; Immunology; Genetics","score_opus":0.015102781399037039,"score_gpt":0.29680301605700843,"score_spread":0.2817002346579714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003095359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933107,0.0030665311,0.0000022837592,0.00050474325,0.000034103494,0.00085593713,0.0000010017329,0.00004960736,0.0021750801],"genre_scores_gemma":[0.9977727,0.00012712895,0.0006091888,0.00016938498,0.00003646078,0.0003412248,0.000039080813,0.00003454713,0.0008702972],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99791443,0.00011494059,0.0006369363,0.0004918911,0.00027535888,0.00056641176],"domain_scores_gemma":[0.9993322,0.00008543879,0.00007361822,0.0003222306,0.00003500161,0.00015149835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030012926,0.00025759448,0.00045248886,0.0002348346,0.00027317757,0.000036409634,0.00018284647,0.00023679661,0.00046237276],"category_scores_gemma":[0.000014834566,0.0002019672,0.000035085726,0.00033172968,0.00020166046,0.000098704295,0.00016609297,0.00041882053,0.00006620253],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009703547,0.0006504942,0.041935265,0.00009025457,0.000043171494,0.0004916842,0.0076304646,0.0000048890092,0.9415058,0.0013613962,0.00058529305,0.004730955],"study_design_scores_gemma":[0.0032353436,0.00021083164,0.029720476,0.00005747115,0.0000043733207,0.0004938984,0.00071698794,0.00010677504,0.9644574,0.00007772861,0.00072613463,0.00019256996],"about_ca_topic_score_codex":0.0004534764,"about_ca_topic_score_gemma":0.00012476055,"teacher_disagreement_score":0.02295163,"about_ca_system_score_codex":0.0008346507,"about_ca_system_score_gemma":0.00025049422,"threshold_uncertainty_score":0.8235983},"labels":[],"label_agreement":null},{"id":"W2003281936","doi":"10.1016/j.bbmt.2013.04.022","title":"Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research","year":2013,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Takeda Oncology; Osiris Therapeutics; Celgene; U.S. Navy; CellGenix; Genentech; Health Resources and Services Administration; Kiadis Pharma; Therakos; Sigma-Tau Pharmaceuticals; Tarix Pharmaceuticals; StemCyte; Blue Cross and Blue Shield Association; Swedish Orphan Biovitrum; Teva Pharmaceutical Industries; WellPoint; HistoGenetics; Otsuka America; Amgen; Ariad Pharmaceuticals; Leukemia and Lymphoma Society; GlaxoSmithKline; Sanofi; U.S. Department of Defense","keywords":"Medicine; Hazard ratio; Transplantation; Internal medicine; Leukemia; Gastroenterology; Hematopoietic stem cell transplantation; Confidence interval; Cumulative incidence; Acute leukemia; Surgery","score_opus":0.01906230113154463,"score_gpt":0.3049247741383178,"score_spread":0.2858624730067732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003281936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836044,0.0006806976,0.004508326,0.0014020965,0.00018293619,0.0048853857,0.0046541095,0.000045686047,0.000036412966],"genre_scores_gemma":[0.9791216,0.008888105,0.004028808,0.00011363082,0.00014866993,0.0012618303,0.0063382285,0.00004984231,0.00004927015],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99706495,0.00040700904,0.0009000776,0.0007229936,0.0003800629,0.0005249209],"domain_scores_gemma":[0.99728626,0.0012908346,0.00025256188,0.00025743953,0.00076941156,0.00014349932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00086437305,0.00036188128,0.0006281445,0.0004011967,0.00023913059,0.00003936895,0.00025824993,0.00049655663,0.00005261654],"category_scores_gemma":[0.000050940158,0.00027989698,0.00016783949,0.00024199381,0.00047736824,0.0002710622,0.0000139689655,0.0004067332,0.0000022592683],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015002193,0.00071278046,0.10512625,0.0017431636,0.0030416683,0.00010903072,0.013757116,0.000014110788,0.8538579,0.0002089141,0.000084196654,0.0063427296],"study_design_scores_gemma":[0.06594918,0.009684419,0.5565485,0.0008699252,0.016955173,0.0020327826,0.0029872435,0.00091682334,0.34104618,0.0019718593,0.00016208681,0.00087585376],"about_ca_topic_score_codex":0.0010860489,"about_ca_topic_score_gemma":0.0011106964,"teacher_disagreement_score":0.51281166,"about_ca_system_score_codex":0.00005317956,"about_ca_system_score_gemma":0.0002313065,"threshold_uncertainty_score":0.9999653},"labels":[],"label_agreement":null},{"id":"W2003595190","doi":"10.1002/pbc.21562","title":"Multiple intracranial tumors in Philadelphia chromosome positive acute lymphoblastic leukemia: Successful treatment following aggressive supportive care, early cranial radiation, high dose chemotherapy and imatinib","year":2008,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Children's Hospital","funders":"","keywords":"Medicine; Intracranial pressure; Chemotherapy; Imatinib mesylate; Imatinib; Radiation therapy; Oncology; Surgery; Pediatrics; Internal medicine; Myeloid leukemia","score_opus":0.00826898059601079,"score_gpt":0.26732851948537034,"score_spread":0.25905953888935956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003595190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99127525,0.005189715,0.000023970608,0.0007883354,0.00030980346,0.0018286394,0.00042973916,0.000105076164,0.000049448063],"genre_scores_gemma":[0.9827439,0.01326558,0.00044852248,0.0002822234,0.0022945823,0.0005664623,0.00018849519,0.000121379504,0.000088830835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964357,0.00012888871,0.00076558103,0.0009458374,0.00075844274,0.00096553646],"domain_scores_gemma":[0.9980723,0.00039084943,0.00045319935,0.00036357713,0.00025223524,0.00046780205],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012821793,0.00060802297,0.0010550834,0.00055999856,0.00030291337,0.000051797215,0.00021356317,0.00031800606,0.0001610944],"category_scores_gemma":[0.00016454062,0.0005411785,0.00023995676,0.0010207957,0.0002061407,0.00040117468,0.000085486055,0.0005141322,0.000021135893],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003951402,0.00074445823,0.9500269,0.0002544888,0.0014304126,0.014123083,0.018457878,0.00012666747,0.003969327,0.0000057458833,0.00037571692,0.006533915],"study_design_scores_gemma":[0.055923562,0.0024044507,0.9299956,0.00019368113,0.0019018285,0.00079703314,0.00041203434,0.0007260736,0.006842469,0.00002083192,0.000034225344,0.000748186],"about_ca_topic_score_codex":0.0090228105,"about_ca_topic_score_gemma":0.00029997618,"teacher_disagreement_score":0.05197216,"about_ca_system_score_codex":0.0027598026,"about_ca_system_score_gemma":0.0032908635,"threshold_uncertainty_score":0.999704},"labels":[],"label_agreement":null},{"id":"W2004029643","doi":"10.1182/blood-2009-07-230698","title":"Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Héma-Québec; BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Biology; Chronic myelomonocytic leukemia; Haematopoiesis; Myeloid; Leukemia; Progenitor cell; Myeloid leukemia; Phenotype; Cancer research; Myelodysplastic syndromes; Loss function; Genetics; Stem cell; Gene; Bone marrow; Immunology","score_opus":0.02249879591221831,"score_gpt":0.2886989593274928,"score_spread":0.26620016341527447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004029643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98923326,0.0000859497,0.0002732204,0.0016201445,0.00013038014,0.000755808,0.0016406762,0.00020755247,0.0060530375],"genre_scores_gemma":[0.98504126,0.000049450362,0.0023293123,0.0009088389,0.00039220322,0.00008633986,0.0015951915,0.000046433375,0.00955098],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9976642,0.00007600152,0.00050596707,0.00044973003,0.00083868677,0.0004653926],"domain_scores_gemma":[0.9981479,0.0004824041,0.00016057932,0.0005737587,0.0003339481,0.00030139723],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001955459,0.00028067856,0.0004959405,0.00028363417,0.00020009515,0.000041363874,0.00019423605,0.00024522183,0.0061311745],"category_scores_gemma":[0.0004204663,0.00023524702,0.00016955663,0.0005732598,0.00019852225,0.00021941216,0.00006499458,0.00049513986,0.00034089453],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013070416,0.013046949,0.03851234,0.0024619615,0.0069021895,0.010605406,0.005484496,0.0004428307,0.10266833,0.012408791,0.7621316,0.032264724],"study_design_scores_gemma":[0.07510298,0.01123355,0.6435667,0.0024824087,0.0071147056,0.025782792,0.00582706,0.0022669286,0.13395421,0.004562622,0.08477446,0.00333157],"about_ca_topic_score_codex":0.00004511669,"about_ca_topic_score_gemma":0.0000196284,"teacher_disagreement_score":0.67735714,"about_ca_system_score_codex":0.00037272042,"about_ca_system_score_gemma":0.0013238614,"threshold_uncertainty_score":0.9947774},"labels":[],"label_agreement":null},{"id":"W2004079646","doi":"10.5737/1181912x224222227","title":"Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: A practice standard for Canadian nurses","year":2012,"lang":"en","type":"article","venue":"Canadian Oncology Nursing Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"Celgene","keywords":"Azacitidine; Medicine; Myelodysplastic syndromes; Myeloid leukemia; Adverse effect; Oncology; Disease; Internal medicine; Intensive care medicine","score_opus":0.020212212224211705,"score_gpt":0.3280875448646202,"score_spread":0.3078753326404085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004079646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86335045,0.00942126,0.06026161,0.045085534,0.0046813344,0.00960056,0.0005814034,0.00007431449,0.0069435313],"genre_scores_gemma":[0.97587895,0.0017896533,0.019081628,0.0019512562,0.00053034857,0.00010763034,0.000077602985,0.00009326168,0.0004896387],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99768615,0.000097784,0.0003215746,0.0002554691,0.00029772337,0.0013413171],"domain_scores_gemma":[0.99594885,0.0007051201,0.00018279991,0.00015673846,0.000605142,0.002401331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008958657,0.00023553199,0.00039191998,0.0007391691,0.00089690275,0.000060041475,0.00011523961,0.0001727228,0.000053018444],"category_scores_gemma":[0.0002699108,0.00020436509,0.00007359423,0.00018960677,0.00021571646,0.0003529566,0.0000029605833,0.00042701123,0.0000039067804],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.024920324,0.0017149032,0.054719444,0.0008978078,0.0052833464,0.0024288993,0.019400574,0.000334256,0.000051377683,0.0071688574,0.16541505,0.71766514],"study_design_scores_gemma":[0.02347552,0.010277848,0.014871114,0.0024954898,0.0012574064,0.004997107,0.008196725,0.00061756547,0.00002382488,0.0006722546,0.9325297,0.0005854872],"about_ca_topic_score_codex":0.0047869,"about_ca_topic_score_gemma":0.08027184,"teacher_disagreement_score":0.7671146,"about_ca_system_score_codex":0.01150825,"about_ca_system_score_gemma":0.008114497,"threshold_uncertainty_score":0.9975086},"labels":[],"label_agreement":null},{"id":"W2004739140","doi":"10.1007/s00277-012-1580-5","title":"KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement","year":2012,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Mutation; Internal medicine; Idarubicin; Cytarabine; Myeloid leukemia; Core binding factor; Leukemia; Oncology; Hematology; Gene mutation; Cancer research; Biology; Genetics; Gene","score_opus":0.06405843739247338,"score_gpt":0.35387222646365485,"score_spread":0.2898137890711815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004739140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99245554,0.00026484148,0.000018502496,0.0049537974,0.000059121554,0.00094735174,0.00002794535,0.000028442675,0.0012444314],"genre_scores_gemma":[0.9978398,0.00022523564,0.0005110135,0.00096098916,0.000053817563,0.000109875444,0.00007307106,0.000038604485,0.00018755958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974367,0.00020121841,0.00054398703,0.00030877936,0.0006506853,0.00085860357],"domain_scores_gemma":[0.9984322,0.0005678452,0.00030690702,0.00040244218,0.0001568602,0.00013369825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008208292,0.00027792988,0.00084489834,0.0004941775,0.00006412751,0.000011367909,0.0002750017,0.00021098887,0.00011031575],"category_scores_gemma":[0.00024751306,0.00016601053,0.000091363705,0.00062108826,0.00022106024,0.00026162015,0.00006933488,0.0005484074,0.000038457016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011368005,0.00033579004,0.98592365,0.00012412289,0.00037159992,0.0007135628,0.005234564,0.0000073411693,0.003095736,0.0018731278,0.00075539463,0.00042833245],"study_design_scores_gemma":[0.005086209,0.0010721845,0.9716509,0.00025749535,0.00011293646,0.0005877416,0.0049327468,0.00003955374,0.015474114,0.00011227665,0.00038585084,0.00028796922],"about_ca_topic_score_codex":0.00045510635,"about_ca_topic_score_gemma":0.0009767123,"teacher_disagreement_score":0.014272705,"about_ca_system_score_codex":0.00026203916,"about_ca_system_score_gemma":0.00037831275,"threshold_uncertainty_score":0.67697126},"labels":[],"label_agreement":null},{"id":"W2005085994","doi":"10.1182/blood-2012-11-468702","title":"Leukemia surfaceome analysis reveals new disease-associated features","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Universität Zürich; Mach-Gaensslen Foundation of Canada; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Leukemia; Computational biology; Disease; Biology; Bioinformatics; Immunology; Medicine; Pathology","score_opus":0.013864755107328892,"score_gpt":0.2697139147235016,"score_spread":0.2558491596161727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005085994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990588,0.0011123806,0.00003336585,0.0032870944,0.000036804344,0.0006368385,0.000030117957,0.00019439784,0.0040810206],"genre_scores_gemma":[0.9367862,0.00009880445,0.0007647484,0.0007555079,0.00019485955,0.000037378446,0.0002143599,0.000042633914,0.061105505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788594,0.00010520912,0.00030375193,0.00044283972,0.000652883,0.00060937344],"domain_scores_gemma":[0.9978358,0.00015509792,0.00009966758,0.00071031245,0.00024128746,0.0009578419],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025306485,0.00022907951,0.0005697058,0.0003467893,0.000096055934,0.000081797654,0.000245255,0.00017432583,0.0019979144],"category_scores_gemma":[0.0008157887,0.00018786328,0.0003472528,0.0015649621,0.00006531897,0.0001352341,0.00011076909,0.0004333044,0.0008761346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001061162,0.0005097535,0.7153489,0.000074554024,0.0056529865,0.00034606986,0.00019905313,0.00006229713,0.01688386,0.00011140453,0.25953057,0.0011744678],"study_design_scores_gemma":[0.003570889,0.00009542877,0.9902278,0.0000447348,0.003356059,0.000012865202,0.000040628805,0.00021969012,0.0009860981,0.00047679964,0.00075370487,0.00021528541],"about_ca_topic_score_codex":0.0020084865,"about_ca_topic_score_gemma":0.000080568934,"teacher_disagreement_score":0.27487895,"about_ca_system_score_codex":0.00045467252,"about_ca_system_score_gemma":0.0008783314,"threshold_uncertainty_score":0.9999018},"labels":[],"label_agreement":null},{"id":"W2005171788","doi":"10.1080/08880010390232754","title":"Transient Myelodysplastic Syndrome Associated with Isochromosome 7q Abnormality","year":2003,"lang":"en","type":"article","venue":"Pediatric Hematology and Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; University of Calgary; Hospital for Sick Children","funders":"","keywords":"Isochromosome; Medicine; Bone marrow; Myelodysplastic syndromes; Cytogenetics; Abnormality; Chromosome 7 (human); Leukemia; Pathology; Internal medicine; Karyotype; Genetics; Chromosome; Biology; Psychiatry","score_opus":0.015947780664183068,"score_gpt":0.2839951572215374,"score_spread":0.26804737655735433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005171788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891395,0.0012284644,0.00042766207,0.0013670087,0.00015362584,0.00050992105,0.000011312371,0.00010385425,0.007058624],"genre_scores_gemma":[0.9975416,0.00046014166,0.00067887094,0.000609222,0.00006120685,0.0000770016,0.000029056217,0.000030581396,0.00051229895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756837,0.0004562844,0.00044382177,0.0005051522,0.0002536851,0.0007727139],"domain_scores_gemma":[0.9978949,0.0011285486,0.00014635027,0.00026281265,0.00015989416,0.0004074936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077093515,0.0002609441,0.00092607783,0.00027530908,0.00018125954,0.000008428364,0.000103438426,0.0005886285,0.00044257528],"category_scores_gemma":[0.00084515096,0.00020463261,0.00007085882,0.00058476726,0.00039892938,0.0000774247,0.000037776346,0.00076863024,0.00010134068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013205278,0.002183946,0.9391145,0.00084763294,0.0008208033,0.031097077,0.0012996368,0.000012824406,0.0001342725,0.015624248,0.006875772,0.0006687215],"study_design_scores_gemma":[0.025665209,0.011623726,0.77981406,0.00008967704,0.0024038504,0.1629806,0.0006004051,0.00029597635,0.0003903206,0.0012900342,0.013733372,0.0011127653],"about_ca_topic_score_codex":0.000015960193,"about_ca_topic_score_gemma":0.000046594814,"teacher_disagreement_score":0.15930048,"about_ca_system_score_codex":0.0003769367,"about_ca_system_score_gemma":0.0012523395,"threshold_uncertainty_score":0.8344676},"labels":[],"label_agreement":null},{"id":"W2005368067","doi":"10.1002/jcb.22221","title":"Runx transcription factors: Lineage‐specific regulators of neuronal precursor cell proliferation and post‐mitotic neuron subtype development","year":2009,"lang":"en","type":"review","venue":"Journal of Cellular Biochemistry","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Transcription factor; Cell biology; Mitosis; Lineage (genetic); Cell growth; Neuron; Cell lineage; Biology; Cellular differentiation; Gene; Neuroscience; Genetics","score_opus":0.028149456139706076,"score_gpt":0.2790158111039943,"score_spread":0.2508663549642882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005368067","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25359267,0.745494,0.000083910265,0.000046232373,0.000160169,0.0005248045,0.000013583306,0.000011456314,0.00007317044],"genre_scores_gemma":[0.040419996,0.9556751,0.0012142094,0.000021770964,0.0008295354,0.000005514895,0.00034880903,0.000096848176,0.0013881848],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964454,0.00015605753,0.0016756076,0.00041703926,0.0009589858,0.0003469089],"domain_scores_gemma":[0.9971821,0.00009545524,0.0013847067,0.00038037167,0.00058114267,0.00037625758],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005555253,0.00053658115,0.0016941685,0.00038366296,0.00006560177,0.000050921677,0.00029778393,0.0006193837,0.000056830453],"category_scores_gemma":[0.00013343392,0.00041801183,0.0005587467,0.00031338993,0.00011643519,0.000101493926,0.00004383707,0.0013676684,0.0000051995858],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007073709,0.00097166136,0.00010611943,0.064712204,0.00050740293,0.00039474934,0.00045260167,0.0000028360407,0.71043134,0.0000026841367,0.0017608454,0.21995021],"study_design_scores_gemma":[0.0015463232,0.001038398,0.00035070637,0.009741413,0.0012836175,0.0008201922,0.00006189854,0.000010831579,0.7706988,0.0000024403098,0.2139579,0.0004874682],"about_ca_topic_score_codex":8.1452384e-7,"about_ca_topic_score_gemma":8.273271e-8,"teacher_disagreement_score":0.21946275,"about_ca_system_score_codex":0.0004452192,"about_ca_system_score_gemma":0.002354996,"threshold_uncertainty_score":0.99982715},"labels":[],"label_agreement":null},{"id":"W2005412609","doi":"10.1093/emboj/20.3.350","title":"NUP98–HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice","year":2001,"lang":"en","type":"article","venue":"The EMBO Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Montreal Clinical Research Institute","funders":"","keywords":"Haematopoiesis; Myeloid leukemia; Stem cell; Cancer research; Myeloid; Biology; Leukemia; Phenotype; Bone marrow; Acute leukemia; Transformation (genetics); Immunology; Fusion gene; Cell biology; Gene; Genetics","score_opus":0.022541422459721485,"score_gpt":0.2913887987731456,"score_spread":0.26884737631342415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005412609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99123806,0.003216317,0.000043704393,0.0038955775,0.00017071568,0.00039088272,0.0000018172692,0.000019704992,0.0010232239],"genre_scores_gemma":[0.9897991,0.0068987696,0.00022221662,0.00035235012,0.00053057674,0.00001345038,0.0000016368089,0.000040881598,0.0021410238],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99759394,0.00032309318,0.00052870566,0.00029041653,0.0005672114,0.000696658],"domain_scores_gemma":[0.9989466,0.00022863547,0.00015564161,0.0003196376,0.00007274071,0.0002767183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001428189,0.000236683,0.00042507472,0.00038325464,0.00017256833,0.000088392066,0.00039133453,0.0001587255,0.00020281014],"category_scores_gemma":[0.00004091871,0.00015175006,0.00007462402,0.000540115,0.00016929646,0.0002470146,0.00020601154,0.0020978958,0.00007685432],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012789959,0.00025013863,0.012843545,0.00011379195,0.00010423669,0.0030825168,0.004748881,0.00023222748,0.94641143,0.000017399061,0.006368163,0.024548646],"study_design_scores_gemma":[0.037308645,0.0027672367,0.15435448,0.005017142,0.00035653354,0.03559777,0.011715583,0.009450412,0.72391963,0.0017975555,0.016304996,0.001410008],"about_ca_topic_score_codex":0.00007739387,"about_ca_topic_score_gemma":0.000058334273,"teacher_disagreement_score":0.22249182,"about_ca_system_score_codex":0.001517215,"about_ca_system_score_gemma":0.00078672316,"threshold_uncertainty_score":0.911443},"labels":[],"label_agreement":null},{"id":"W2005515451","doi":"10.1111/bjh.13094","title":"Phase <scp>II</scp> study of targeted therapy with temozolomide in acute myeloid leukaemia and high‐risk myelodysplastic syndrome patients pre‐screened for low O<sup>6</sup>‐methylguanine DNA methyltransferase expression","year":2014,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; BC Cancer Agency; Juravinski Cancer Centre; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"Merck Canada; Merck","keywords":"Temozolomide; O-6-methylguanine-DNA methyltransferase; Myelodysplastic syndromes; Myeloid leukaemia; Medicine; Methyltransferase; Oncology; Decitabine; Cancer research; DNA methyltransferase; Internal medicine; DNA; DNA methylation; Glioblastoma; Methylation; Gene expression; Gene; Biology; Genetics; Bone marrow","score_opus":0.008527743002371874,"score_gpt":0.26581174349831876,"score_spread":0.2572840004959469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005515451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925916,0.001007441,0.0037699384,0.00010089372,0.0000881304,0.0022638731,0.00014027645,0.000029496237,0.000008349127],"genre_scores_gemma":[0.9931602,0.0012453003,0.0050856303,0.00010572037,0.0000685716,0.000106076935,0.00007073006,0.00010912057,0.000048669648],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99517184,0.0009632316,0.001638747,0.0006150076,0.0008197874,0.0007913813],"domain_scores_gemma":[0.9955745,0.0018227136,0.000856652,0.00040277993,0.0008644917,0.00047887416],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001478145,0.00046014696,0.0023416553,0.0008057477,0.00022182838,0.000040274586,0.00042702275,0.00035821684,0.000020038558],"category_scores_gemma":[0.0019468393,0.00039294348,0.0001784641,0.0005238862,0.00033839396,0.00035467808,0.00011650916,0.0011409218,0.000001392553],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.088862516,0.06545179,0.31348816,0.003598878,0.013482237,0.10935148,0.021157676,0.0030248654,0.2172319,0.00007860053,0.008316774,0.15595512],"study_design_scores_gemma":[0.35155678,0.15174353,0.19490077,0.0041785617,0.0022398485,0.11852423,0.0037110162,0.00652259,0.16515744,0.00042115588,0.0002970808,0.0007469972],"about_ca_topic_score_codex":0.00024913825,"about_ca_topic_score_gemma":0.00008304107,"teacher_disagreement_score":0.26269427,"about_ca_system_score_codex":0.00015417213,"about_ca_system_score_gemma":0.0003495236,"threshold_uncertainty_score":0.99985224},"labels":[],"label_agreement":null},{"id":"W2005559239","doi":"10.1038/leu.2014.299","title":"Overexpression of ERG in cord blood progenitors promotes expansion and recapitulates molecular signatures of high ERG leukemias","year":2014,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Stem Cell Network","keywords":"Erg; CD34; Biology; Progenitor cell; Haematopoiesis; Cancer research; Stem cell; Leukemia; Myeloid; Myeloid leukemia; Molecular biology; Immunology; Cell biology","score_opus":0.008953837421727014,"score_gpt":0.2608036794394963,"score_spread":0.2518498420177693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005559239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975846,0.00086454843,0.000049894577,0.00014118577,0.000057205063,0.00079279265,0.000011419728,0.00004989913,0.00044848045],"genre_scores_gemma":[0.9956965,0.0001557397,0.003666293,0.000078523786,0.000090018664,0.000038189744,0.000043757416,0.000059783564,0.0001712373],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975123,0.00020731425,0.0006471235,0.0005288103,0.00065900304,0.00044549766],"domain_scores_gemma":[0.9984127,0.00028403834,0.00026505202,0.00061725103,0.00021845274,0.00020245084],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005089459,0.00030347786,0.00074525655,0.00039393074,0.00004192313,0.0000121712355,0.00023263456,0.00042742395,0.000048177448],"category_scores_gemma":[0.00072573166,0.00024847154,0.000109707005,0.0004583304,0.0002692732,0.00012261493,0.00022847908,0.00062717433,0.0000037005404],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009039496,0.00015703296,0.013011921,0.00076508755,0.00008325159,0.00006665131,0.00036855997,0.00011882295,0.97630316,0.0006073936,0.00031597016,0.0072981757],"study_design_scores_gemma":[0.0049781753,0.0012454739,0.036448833,0.0013249826,0.00010318376,0.0000554749,0.00009793821,0.0018690622,0.95234245,0.0011663431,0.00013531091,0.00023276886],"about_ca_topic_score_codex":0.0010906268,"about_ca_topic_score_gemma":0.000017179269,"teacher_disagreement_score":0.02396073,"about_ca_system_score_codex":0.0003448072,"about_ca_system_score_gemma":0.00060484034,"threshold_uncertainty_score":0.9999968},"labels":[],"label_agreement":null},{"id":"W2006474544","doi":"10.1038/leu.2008.341","title":"A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over","year":2008,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Princess Margaret Cancer Centre; London Health Sciences Centre; University of Toronto","funders":"","keywords":"Myeloid leukemia; Induction therapy; Medicine; Leukemia; Internal medicine; Oncology; Induction chemotherapy; Myeloid; Cancer research; Immunology; Chemotherapy","score_opus":0.01980105232891731,"score_gpt":0.28967510237767397,"score_spread":0.26987405004875664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006474544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99600506,0.000063786836,0.000108078086,0.000034776196,0.00002747641,0.0036115495,0.000048882397,0.00005313765,0.000047256795],"genre_scores_gemma":[0.998,0.00018419795,0.00058675325,0.000098191194,0.000045275905,0.00020571172,0.0004564206,0.0000526322,0.00037080955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982966,0.00009559467,0.00034193462,0.00045544034,0.0005088688,0.00030153984],"domain_scores_gemma":[0.9988764,0.00011293236,0.00023248774,0.00028543198,0.000318362,0.00017438503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001861252,0.00025370877,0.00049039675,0.00022245523,0.0001644206,0.000021979225,0.000074681775,0.00013188442,0.00004091226],"category_scores_gemma":[0.000038656795,0.00018963731,0.000036609403,0.00032275458,0.00033218917,0.00021501804,0.000036371322,0.00028846023,0.0000015777302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12387323,0.0054878495,0.8119162,0.00036823575,0.00417187,0.000645604,0.011030651,0.000055378143,0.017431676,0.000076707904,0.0039575603,0.020985052],"study_design_scores_gemma":[0.15083799,0.024904612,0.8207044,0.000112251175,0.00033086157,0.00013481216,0.00034391382,0.00055553945,0.0015843159,0.00001618503,0.00022540952,0.00024969602],"about_ca_topic_score_codex":0.0002538806,"about_ca_topic_score_gemma":0.000036716134,"teacher_disagreement_score":0.026964758,"about_ca_system_score_codex":0.00064397906,"about_ca_system_score_gemma":0.0008704474,"threshold_uncertainty_score":0.7733185},"labels":[],"label_agreement":null},{"id":"W2006822498","doi":"10.1007/s004390100498","title":"Mutation analysis of the origin recognition complex subunit 5 ( ORC5L ) gene in adult patients with myeloid leukemias exhibiting deletions of chromosome band 7q22","year":2001,"lang":"en","type":"article","venue":"Human Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Deutsche Forschungsgemeinschaft","keywords":"Biology; Myeloid leukemia; Gene; Myeloid; Genetics; RUNX1T1; Molecular biology; Tumor suppressor gene; Locus (genetics); Allele; Cancer research; Gene expression; Carcinogenesis","score_opus":0.045664420547380256,"score_gpt":0.2985595109935024,"score_spread":0.2528950904461222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006822498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981104,0.000033835888,0.00021529959,0.000069282905,0.000012858924,0.00055201986,0.00008326479,0.000014063279,0.00090898457],"genre_scores_gemma":[0.99733007,0.000070334514,0.001357866,0.00008798931,0.000041689236,0.000022177883,0.0009422387,0.000029096547,0.000118552685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981844,0.00013038944,0.0005654561,0.0002575702,0.00058972836,0.0002724739],"domain_scores_gemma":[0.99826753,0.0000819897,0.00029661282,0.00041688452,0.0008573164,0.000079662466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001923673,0.0001579156,0.0003979129,0.00056939834,0.000110138135,0.000011212393,0.0001577193,0.00009531604,0.00031190648],"category_scores_gemma":[0.000084088766,0.00012327843,0.00010865495,0.0019039245,0.00020501755,0.000047126767,0.00004921532,0.00024404415,0.0000055760074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002509771,0.00044953063,0.90934616,0.0001491867,0.0004995092,0.00002569231,0.0011743591,0.002723235,0.080582544,0.00003440628,0.000094646355,0.00466974],"study_design_scores_gemma":[0.0037426893,0.00039798737,0.9602082,0.00013216441,0.0008438582,0.000012999284,0.0002913796,0.0054633664,0.028626386,0.00005878144,0.00006664096,0.00015555775],"about_ca_topic_score_codex":0.0003470221,"about_ca_topic_score_gemma":0.0011741453,"teacher_disagreement_score":0.051956158,"about_ca_system_score_codex":0.0003772526,"about_ca_system_score_gemma":0.00020170325,"threshold_uncertainty_score":0.5027149},"labels":[],"label_agreement":null},{"id":"W2006924573","doi":"10.2165/00002512-200522110-00004","title":"Trends in the Treatment of Acute Myeloid Leukaemia in the Elderly","year":2005,"lang":"en","type":"article","venue":"Drugs & Aging","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Medicine; Epidemiology; Myeloid leukaemia; Pediatrics; Health care; Chemotherapy; Internal medicine; Emergency medicine","score_opus":0.020552090951143652,"score_gpt":0.32470399505709246,"score_spread":0.30415190410594883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006924573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95980495,0.00060446846,0.000006721745,0.021122966,0.000024253284,0.0003153146,0.0000069008433,0.000017890916,0.018096548],"genre_scores_gemma":[0.99648833,0.00042516872,0.0002553058,0.00093908864,0.000231744,0.0000756062,0.000038874667,0.00001818252,0.0015276746],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839246,0.0001751083,0.0003112545,0.00023359073,0.0004682567,0.0004193117],"domain_scores_gemma":[0.99908155,0.00024839025,0.000057709673,0.00054052926,0.00002703629,0.000044785098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006836505,0.00016453331,0.0002865259,0.00038190605,0.000054292566,0.000024391064,0.00032413212,0.000063381034,0.000081590595],"category_scores_gemma":[0.000013841819,0.00008612993,0.000121230085,0.00085910613,0.00008689594,0.000086598964,0.000024083973,0.00033990818,0.000032665317],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015579887,0.00054184755,0.010502251,0.000019855044,0.000105483654,0.00029829246,0.1055606,0.00003552231,0.0019207076,0.00030075476,0.00451115,0.87604773],"study_design_scores_gemma":[0.02716825,0.004219214,0.4052826,0.0004928051,0.0007458689,0.00070017675,0.035420448,0.0069106785,0.019079985,0.00035753683,0.49880525,0.00081720116],"about_ca_topic_score_codex":0.0009271093,"about_ca_topic_score_gemma":0.00032760846,"teacher_disagreement_score":0.87523055,"about_ca_system_score_codex":0.0005859728,"about_ca_system_score_gemma":0.00012493314,"threshold_uncertainty_score":0.35122764},"labels":[],"label_agreement":null},{"id":"W2006973868","doi":"10.1182/blood-2005-12-007005","title":"The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in acute myeloid leukemia","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Cancerfonden; Terry Fox Foundation; Stem Cell Network; National Cancer Institute; Genome Canada","keywords":"Hox gene; Fms-Like Tyrosine Kinase 3; Myeloid leukemia; Cancer research; Biology; Haematopoiesis; Leukemia; Myeloid; Progenitor cell; Receptor tyrosine kinase; Tyrosine kinase; CD135; Transcription factor; Immunology; Stem cell; Cell biology; Genetics; Signal transduction; Mutation; Gene","score_opus":0.007726766008522415,"score_gpt":0.24947704544714133,"score_spread":0.24175027943861893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006973868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98508584,0.00129977,0.000014316958,0.005298105,0.00008457023,0.00092807366,0.000065581866,0.00012663323,0.00709708],"genre_scores_gemma":[0.97541887,0.0010839298,0.0036198527,0.00041181457,0.00058771955,0.00025722722,0.00020732499,0.00010997608,0.018303271],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977444,0.00010648824,0.00038937558,0.0004395896,0.0005826955,0.00073745305],"domain_scores_gemma":[0.99840945,0.00026402582,0.00009819493,0.0007018288,0.0003219354,0.00020457752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039805128,0.00028134935,0.00039511197,0.00018689255,0.00031701333,0.000093059876,0.00030741302,0.00016904683,0.00016505737],"category_scores_gemma":[0.00015828469,0.00017236517,0.00006373639,0.001548184,0.00030128527,0.000110644076,0.00013514062,0.00060879986,0.0002485087],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035721143,0.0021924656,0.15662943,0.00016070138,0.0006785927,0.0027573141,0.00055371964,0.00008337264,0.6614947,0.003096285,0.16272928,0.0060520456],"study_design_scores_gemma":[0.04283257,0.0026719358,0.25453195,0.00073036406,0.00093033205,0.0007360871,0.001162081,0.0005889187,0.4248632,0.00033509333,0.26944247,0.0011750204],"about_ca_topic_score_codex":0.0007003168,"about_ca_topic_score_gemma":0.0009265259,"teacher_disagreement_score":0.2366315,"about_ca_system_score_codex":0.00054136955,"about_ca_system_score_gemma":0.0015706841,"threshold_uncertainty_score":0.7028848},"labels":[],"label_agreement":null},{"id":"W2007007433","doi":"10.1016/j.bbmt.2006.12.246","title":"241: Neurological complications in the recipients of allogeneic hematopoietic cell transplant","year":2007,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hematopoietic cell; Haematopoiesis; Immunology; Oncology; Stem cell; Genetics","score_opus":0.021414901337374604,"score_gpt":0.2874401055662866,"score_spread":0.26602520422891196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007007433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968397,0.00038591734,0.0008819872,0.0006579683,0.000020977983,0.0003319461,0.00004491341,0.0000075878675,0.0008289934],"genre_scores_gemma":[0.99782985,0.0011629472,0.0006067999,0.00021374926,0.000012746125,0.000011244758,0.00014966933,0.0000047751478,0.000008197934],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99914783,0.000101716796,0.00031600345,0.00016574342,0.00009860102,0.00017010633],"domain_scores_gemma":[0.99942386,0.00030212896,0.000066700944,0.00012897984,0.000036883117,0.000041437357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051092735,0.00008126626,0.00020013869,0.000118656375,0.000029017368,0.0000013144182,0.000102394006,0.00012527162,0.000011748288],"category_scores_gemma":[0.00000942818,0.00005408384,0.00004252701,0.00013563914,0.00021852207,0.000016972428,0.000004541745,0.00015631222,0.0000015238035],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006072354,0.00034215182,0.34487903,0.00026294813,0.000026230922,0.000045261597,0.0014754459,0.0000014629662,0.6505322,0.0009101029,0.000009484508,0.0009084297],"study_design_scores_gemma":[0.0032438121,0.0009917141,0.89322,0.00006326705,0.00026312523,0.00053444103,0.00012939678,0.000019124795,0.10103116,0.0003469383,0.00007838679,0.00007862272],"about_ca_topic_score_codex":0.000041556035,"about_ca_topic_score_gemma":0.000038800514,"teacher_disagreement_score":0.54950106,"about_ca_system_score_codex":0.0000037567906,"about_ca_system_score_gemma":0.000031676394,"threshold_uncertainty_score":0.2205475},"labels":[],"label_agreement":null},{"id":"W2007253664","doi":"10.1016/j.leukres.2014.11.028","title":"One day at a time: Improving the patient experience during and after intensive chemotherapy for younger and older AML patients","year":2014,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Medicine; Chemotherapy; Pediatrics; Oncology; Internal medicine","score_opus":0.017615000180275193,"score_gpt":0.3000844991968336,"score_spread":0.28246949901655843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007253664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99527,0.00026169792,0.000057592868,0.0018344785,0.000042723295,0.0022055872,0.000012708114,0.000034795117,0.00028038392],"genre_scores_gemma":[0.9939722,0.0001264506,0.000414881,0.0013819697,0.00019242182,0.00085260975,0.0000173192,0.000074791664,0.0029673823],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9967792,0.0002492613,0.00030745816,0.0007158456,0.0009991352,0.0009491048],"domain_scores_gemma":[0.99708307,0.0007750602,0.00006506294,0.0006566181,0.0010783923,0.0003418126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010724969,0.00022745939,0.00034642124,0.00022016517,0.00051644765,0.000115076575,0.00021490434,0.00017072281,0.00014507046],"category_scores_gemma":[0.0015521295,0.00016153797,0.00006430222,0.00028878852,0.00075145386,0.00019328929,0.00072444475,0.0007111518,0.00004674268],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014902805,0.00041098968,0.12903397,0.0018028386,0.0004171877,0.000105183935,0.065198556,0.0000029443188,0.5427344,0.00011882645,0.011896248,0.23337609],"study_design_scores_gemma":[0.01539922,0.0021653448,0.870644,0.0004872065,0.00005292562,0.00009217534,0.0021870695,0.010646027,0.088957585,0.00011023442,0.008691083,0.00056716177],"about_ca_topic_score_codex":0.00019419129,"about_ca_topic_score_gemma":0.000012929314,"teacher_disagreement_score":0.74161,"about_ca_system_score_codex":0.0015338535,"about_ca_system_score_gemma":0.00022925167,"threshold_uncertainty_score":0.6587328},"labels":[],"label_agreement":null},{"id":"W2007299475","doi":"10.1016/j.bbmt.2008.11.016","title":"Is There a Role for Autotransplants in AML in First Remission?","year":2009,"lang":"en","type":"review","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"University of Toronto","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.03528301937327008,"score_gpt":0.3455025322199963,"score_spread":0.3102195128467262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007299475","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007636705,0.98968714,0.000031222335,0.00024023346,0.000030240266,0.0015518735,0.00046931292,0.000016196322,0.00033709782],"genre_scores_gemma":[0.013177671,0.98492014,0.00051824574,0.000046854362,0.000046185385,0.00012071452,0.0010434795,0.000023992407,0.00010273641],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984854,0.00010854558,0.00060808525,0.00041008773,0.00008793321,0.00029996238],"domain_scores_gemma":[0.99930805,0.00028187403,0.00014241942,0.00015791443,0.000031667787,0.00007806809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033888375,0.0002651675,0.0012653124,0.0004314135,0.000028864906,0.0000038596236,0.00011514828,0.000657376,0.000025215868],"category_scores_gemma":[0.000020726902,0.00020407056,0.00017042489,0.00021154979,0.00007897986,0.000035292665,0.0000054312227,0.00034857416,0.000001896335],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008863243,0.0003237253,0.0033834903,0.0738325,0.00025212672,0.00016680526,0.00095746235,3.1794514e-7,0.0015136658,0.000137333,0.00008206357,0.9184642],"study_design_scores_gemma":[0.027633559,0.0037791526,0.0110268025,0.13876653,0.0076843733,0.00192978,0.00013659694,0.00012352751,0.0023590878,0.0014510391,0.8037009,0.0014086472],"about_ca_topic_score_codex":0.00013300258,"about_ca_topic_score_gemma":0.00021650837,"teacher_disagreement_score":0.91705555,"about_ca_system_score_codex":0.000041040483,"about_ca_system_score_gemma":0.00030287312,"threshold_uncertainty_score":0.8321756},"labels":[],"label_agreement":null},{"id":"W2007339739","doi":"10.1038/bmt.2008.205","title":"Acute myeloid leukemia in a healthy hematopoietic stem cell donor following past exposure to a short course of G-CSF","year":2008,"lang":"en","type":"review","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Haematopoiesis; Stem cell; Leukemia; Hematopoietic cell; Myeloid; Immunology; Hematopoietic stem cell; Hematopoietic stem cell transplantation; Hematology; Transplantation; Internal medicine; Genetics; Biology","score_opus":0.029290194747183723,"score_gpt":0.32200287547240813,"score_spread":0.2927126807252244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007339739","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049876057,0.9426946,0.00051418575,0.00019124305,0.00026092262,0.0052299118,0.00045849566,0.00011492736,0.00065966917],"genre_scores_gemma":[0.026552266,0.96952194,0.0009081167,0.00016231977,0.0001652886,0.00064348604,0.0013604979,0.0001956607,0.0004904382],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994832,0.0003690249,0.0019375649,0.0009679675,0.0010040973,0.0008893571],"domain_scores_gemma":[0.9978999,0.0003248489,0.0003292794,0.00078791234,0.00014486657,0.0005132191],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058864144,0.000820057,0.0034725755,0.0010438514,0.000099457095,0.000027639293,0.00036699235,0.0007272457,0.00002524666],"category_scores_gemma":[0.0000094684565,0.0007303585,0.0009602068,0.0014206636,0.00007890809,0.0001650537,0.000045512046,0.0011764475,0.000081949125],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004787596,0.0007110346,0.00087521615,0.19940884,0.0014447966,0.014850795,0.01049638,0.0000775778,0.0013524073,0.000024680628,0.003288028,0.7626826],"study_design_scores_gemma":[0.044929523,0.014922884,0.0025859927,0.27870035,0.0288308,0.038494,0.003569402,0.00034231952,0.0031522342,0.00002812339,0.5760088,0.0084355865],"about_ca_topic_score_codex":0.00014513478,"about_ca_topic_score_gemma":0.00012771536,"teacher_disagreement_score":0.75424707,"about_ca_system_score_codex":0.0021879326,"about_ca_system_score_gemma":0.0041503897,"threshold_uncertainty_score":0.99951476},"labels":[],"label_agreement":null},{"id":"W2007525719","doi":"10.1038/ncb1464","title":"Leukaemic transformation by CALM–AF10 involves upregulation of Hoxa5 by hDOT1L","year":2006,"lang":"en","type":"article","venue":"Nature Cell Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":179,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; Fonds de Recherche du Québec - Santé; National Institutes of Health; Howard Hughes Medical Institute","keywords":"Chromosomal translocation; Downregulation and upregulation; Transformation (genetics); Methylation; Cancer research; Mechanism (biology); Biology; Cell biology; Gene; Genetics","score_opus":0.004495342764216262,"score_gpt":0.2602766834435041,"score_spread":0.2557813406792878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007525719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97489697,0.007952708,0.001062837,0.0016203367,0.0001388878,0.00047498522,0.00013953893,0.00006110162,0.013652611],"genre_scores_gemma":[0.99477977,0.00021384397,0.00032490215,0.00031636585,0.00012900757,0.000013241056,0.0025763335,0.000019042922,0.0016274841],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988268,0.00009293789,0.00034436584,0.00024912375,0.0001824014,0.0003043462],"domain_scores_gemma":[0.9993416,0.000102206286,0.000110088244,0.00023199868,0.00014628509,0.00006782151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021199459,0.0001580493,0.00030596132,0.00014412082,0.000044157885,0.0000049957453,0.0001348752,0.0009486704,0.00010954435],"category_scores_gemma":[0.000039404364,0.00012704087,0.000083731196,0.00024957952,0.00017147521,0.00008174962,0.000016130316,0.00075725105,0.000026240205],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015865278,0.00007636229,0.0024412768,0.000099788114,0.000016299517,0.0000010681476,0.00007636495,0.0000032871994,0.9057456,0.0005381688,0.088295095,0.002548006],"study_design_scores_gemma":[0.002007793,0.00029293,0.0021146566,0.00002013582,0.000039487597,0.000013113342,0.00005563296,0.00035414865,0.84959507,0.0005452998,0.14482582,0.00013593187],"about_ca_topic_score_codex":0.00024946043,"about_ca_topic_score_gemma":0.000022139002,"teacher_disagreement_score":0.05653073,"about_ca_system_score_codex":0.00019490848,"about_ca_system_score_gemma":0.00011659374,"threshold_uncertainty_score":0.73170143},"labels":[],"label_agreement":null},{"id":"W2008136854","doi":"10.1182/blood-2012-10-464248","title":"Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Hematologic Neoplasms; Transplantation; Population; Oncology; Internal medicine; Myelofibrosis; Intensive care medicine; Immunology; Bone marrow","score_opus":0.020425017707359622,"score_gpt":0.2917525927474074,"score_spread":0.2713275750400478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008136854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866506,0.00009897485,0.000069331145,0.006220725,0.00005840374,0.0018785911,0.000008202818,0.000088322005,0.0049268515],"genre_scores_gemma":[0.9970181,0.00007671177,0.0010967766,0.0002998155,0.000056896886,0.0005711963,0.00004389526,0.000032815096,0.00080378185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838394,0.00007965031,0.000403149,0.00030371762,0.0003648159,0.00046475002],"domain_scores_gemma":[0.9992173,0.00020701518,0.000055447123,0.00026120243,0.0000824342,0.00017662061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012207459,0.0002623371,0.0004936076,0.0002887951,0.000082799335,0.00004021725,0.000100615405,0.00014034289,0.00015599804],"category_scores_gemma":[0.00013239498,0.00019120911,0.00019253795,0.0003586334,0.000050735904,0.00041223186,0.000021925503,0.00028821226,0.00040596066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048455276,0.0050071543,0.83185714,0.00027209488,0.003323721,0.0009612146,0.06689336,0.00012443184,0.068299785,0.0016607714,0.00069700665,0.02041874],"study_design_scores_gemma":[0.06782505,0.0027406604,0.7888274,0.00027531618,0.00061999616,0.0002442384,0.006281653,0.0049599507,0.12547635,0.0014906797,0.00045348963,0.000805236],"about_ca_topic_score_codex":0.0009199202,"about_ca_topic_score_gemma":0.000103230566,"teacher_disagreement_score":0.06734049,"about_ca_system_score_codex":0.0007426083,"about_ca_system_score_gemma":0.00039606608,"threshold_uncertainty_score":0.7797282},"labels":[],"label_agreement":null},{"id":"W2008241288","doi":"10.1007/s00520-013-2044-8","title":"A pilot phase II RCT of a home-based exercise intervention for survivors of AML","year":2013,"lang":"en","type":"article","venue":"Supportive Care in Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta; Toronto Rehabilitation Institute; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Randomized controlled trial; Physical therapy; Quality of life (healthcare); Psychological intervention; Adverse effect; Intervention (counseling); Internal medicine","score_opus":0.03433714825944251,"score_gpt":0.3769117170624479,"score_spread":0.3425745688030054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008241288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489754,0.0013138655,0.00034522603,0.00039532673,0.00017730327,0.0022006263,0.00042488187,0.000016463788,0.00022873704],"genre_scores_gemma":[0.9974132,0.00010976362,0.00039620505,0.00007159521,0.000048691338,0.001286053,0.00018407598,0.000034126955,0.00045626672],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984968,0.00005012883,0.00055396336,0.00027417621,0.0003099864,0.00031495985],"domain_scores_gemma":[0.99801713,0.00012230416,0.00023997719,0.00028056797,0.0012263721,0.00011363274],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027080835,0.00015027089,0.00051650335,0.00033127915,0.000022897711,0.000004246197,0.00012974319,0.00006643595,0.0015961606],"category_scores_gemma":[0.00022202785,0.00013163996,0.0002126326,0.00036034425,0.00017095168,0.00011543229,0.000057711342,0.00017521963,0.000005182328],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027876584,0.0063184267,0.19855289,0.016143199,0.00048566188,0.00007892047,0.011969746,0.00009686259,0.12587906,0.00009510155,0.030386154,0.5821174],"study_design_scores_gemma":[0.07692805,0.038695477,0.08845118,0.007822551,0.00047149716,0.0000049401347,0.01501147,0.0026657355,0.7654783,0.00032286838,0.0034473888,0.00070053496],"about_ca_topic_score_codex":0.009681541,"about_ca_topic_score_gemma":0.00190287,"teacher_disagreement_score":0.63959926,"about_ca_system_score_codex":0.0006262728,"about_ca_system_score_gemma":0.0007686938,"threshold_uncertainty_score":0.9993165},"labels":[],"label_agreement":null},{"id":"W2008241551","doi":"10.1080/10428190600572673","title":"Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia","year":2006,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Induction chemotherapy; Myeloid leukemia; Internal medicine; Cohort; Myeloid; Immunology; Acute leukemia; Leukemia; Chemotherapy; Oncology; Gastroenterology","score_opus":0.010336622605659828,"score_gpt":0.25548349084621347,"score_spread":0.24514686824055365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008241551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98467636,0.0022167808,0.00006389757,0.00023906991,0.0004073362,0.0016184396,0.000072282244,0.00043013287,0.01027572],"genre_scores_gemma":[0.9867916,0.0024471013,0.0012348875,0.00033543384,0.0008878757,0.00024523618,0.00033852734,0.0002805913,0.007438763],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99140024,0.0003068616,0.002249971,0.0020035638,0.0019930408,0.0020463297],"domain_scores_gemma":[0.995855,0.00032260374,0.00077807787,0.0016180581,0.0005066517,0.00091963395],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009892869,0.0012966513,0.0020297056,0.0015450454,0.00048378916,0.0001577974,0.0007271351,0.0014289134,0.00018356906],"category_scores_gemma":[0.00031195238,0.0012244881,0.0004952037,0.0018922664,0.0007125343,0.0008767083,0.00059752533,0.0007255593,0.00012641553],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016343256,0.0009719023,0.1770702,0.0026731498,0.0010861998,0.006847479,0.0022605332,0.00080498646,0.72585416,0.003675378,0.0067277225,0.055685002],"study_design_scores_gemma":[0.03954372,0.0008909326,0.70272416,0.0015706419,0.0005443373,0.007001881,0.0006061495,0.0069806245,0.22924879,0.0010057809,0.0085073225,0.0013756591],"about_ca_topic_score_codex":0.016466748,"about_ca_topic_score_gemma":0.00021633458,"teacher_disagreement_score":0.52565396,"about_ca_system_score_codex":0.04192316,"about_ca_system_score_gemma":0.01318155,"threshold_uncertainty_score":0.99997854},"labels":[],"label_agreement":null},{"id":"W2008305848","doi":"10.1016/j.ygyno.2005.04.028","title":"Granulocytic sarcoma presenting as tumors of the cervix","year":2005,"lang":"en","type":"review","venue":"Gynecologic Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Cervix; Sarcoma; Pathology; Cancer; Internal medicine","score_opus":0.07411037779845352,"score_gpt":0.4128194413785617,"score_spread":0.33870906358010816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008305848","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010313609,0.935522,0.0000016459882,0.0011500381,0.0005735509,0.0034004524,0.000024476285,0.00009139628,0.05820504],"genre_scores_gemma":[0.0006554452,0.98691374,0.00057382,0.0006125401,0.0006217754,0.00039225823,0.00005898768,0.00009160108,0.010079855],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99481446,0.0013503557,0.0014576608,0.0007648485,0.00058860093,0.0010241044],"domain_scores_gemma":[0.9938267,0.0032499,0.001107095,0.0013401702,0.0002264351,0.00024972938],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0012494869,0.0005954195,0.0039365254,0.0003935483,0.00018153425,0.000014039917,0.0013433964,0.0013660211,0.002244388],"category_scores_gemma":[0.0038652292,0.00034225872,0.0012353358,0.0009836416,0.00078425603,0.000046426663,0.0012026188,0.002315964,0.0008563632],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029300001,0.00035316433,0.00017731958,0.007920881,0.00034269094,0.00062684,0.000072601186,0.0000011945851,0.0000033169254,0.0003900093,0.0073951953,0.9826875],"study_design_scores_gemma":[0.0010736347,0.00092411763,0.0004619218,0.0019308031,0.0015055581,0.002330473,0.00006177654,0.000019566962,0.0000071473355,0.00020881672,0.9912103,0.00026591326],"about_ca_topic_score_codex":0.000095362135,"about_ca_topic_score_gemma":0.00007306644,"teacher_disagreement_score":0.9838151,"about_ca_system_score_codex":0.003306318,"about_ca_system_score_gemma":0.0077043404,"threshold_uncertainty_score":0.99998575},"labels":[],"label_agreement":null},{"id":"W2008960258","doi":"10.1016/s0301-472x(00)00155-7","title":"Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117)","year":2000,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver Hospital and Health Sciences Centre","funders":"National Cancer Institute; Terry Fox Foundation","keywords":"CD34; Myeloid leukemia; CD117; Progenitor cell; clone (Java method); Biology; Haematopoiesis; Molecular biology; Myeloid; Leukemia; In vivo; Cell culture; Cancer research; Stem cell; In vitro; Immunology; Cell biology; Biochemistry; Genetics; Gene","score_opus":0.015595371123297124,"score_gpt":0.31500644670614625,"score_spread":0.29941107558284913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008960258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995577,0.0011297237,0.000009092656,0.00014547566,0.000027231923,0.0014599803,0.000025770767,0.000029234396,0.0015965092],"genre_scores_gemma":[0.9971547,0.000111968155,0.0019271226,0.000116360454,0.000016132208,0.00011003744,0.000023400486,0.000037052065,0.00050323765],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99774325,0.00024632673,0.00051852735,0.0006495664,0.00031163348,0.0005306933],"domain_scores_gemma":[0.9991149,0.0001661705,0.000103829945,0.0003753598,0.000057755773,0.0001820004],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020448837,0.00030867607,0.0008867608,0.00015364712,0.000044251086,0.000009655914,0.000144856,0.00024248808,0.0008468864],"category_scores_gemma":[0.000015290429,0.0002480153,0.00005163606,0.00028403517,0.0006332942,0.00017939536,0.00013254335,0.0004800178,0.000020144333],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010277415,0.0005837029,0.054841325,0.00015312973,0.000043587148,0.00070003036,0.0037041646,0.000016933824,0.92939526,0.00004623,0.000091838185,0.0001463885],"study_design_scores_gemma":[0.0060087913,0.0006614262,0.018087067,0.00025133233,0.000014764195,0.0005124446,0.0008737693,0.0002463548,0.97312117,0.00000804301,0.000011562905,0.00020326416],"about_ca_topic_score_codex":0.00014778489,"about_ca_topic_score_gemma":0.000040261923,"teacher_disagreement_score":0.043725926,"about_ca_system_score_codex":0.0008518699,"about_ca_system_score_gemma":0.00035501472,"threshold_uncertainty_score":0.9999972},"labels":[],"label_agreement":null},{"id":"W2009166249","doi":"10.1016/j.ccr.2012.01.021","title":"DNA Damage Response and Inflammatory Signaling Limit the MLL-ENL-Induced Leukemogenesis In Vivo","year":2012,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Medicine and Dentistry, University of Alberta; Ministerstvo Zdravotnictví Ceské Republiky; Grantová Agentura České Republiky; Akademie Věd České Republiky; Ministerstvo Školství, Mládeže a Tělovýchovy; Danmarks Grundforskningsfond; Deutsche Forschungsgemeinschaft; European Commission; Kræftens Bekæmpelse","keywords":"DNA damage; Cell biology; Biology; Senescence; Progenitor cell; Cancer research; Transcription factor; Myeloid leukemia; Stem cell; DNA; Genetics; Gene","score_opus":0.031399104277281355,"score_gpt":0.2965980130578145,"score_spread":0.26519890878053315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009166249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99142766,0.0036827568,0.000005297402,0.0009631641,0.00014288787,0.00047156555,0.000007098646,0.000036155976,0.0032634195],"genre_scores_gemma":[0.9948969,0.00044738996,0.00007307837,0.0008520965,0.00044222793,0.000105498286,0.0000016142503,0.000047685404,0.0031335421],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837255,0.00027340988,0.00024560178,0.0002459891,0.0003027995,0.0005596292],"domain_scores_gemma":[0.9987232,0.00044278987,0.00006596232,0.00043977753,0.0000671366,0.0002611514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012662731,0.00017652875,0.00024543604,0.0001141858,0.000105667474,0.000024534764,0.00017142063,0.00013908437,0.00049722457],"category_scores_gemma":[0.00015505246,0.00012887595,0.0000534139,0.0002511773,0.000106238826,0.00014517711,0.00013580921,0.00037988747,0.00004186743],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012328043,0.000033164106,0.032934166,0.000112288195,0.000027098058,0.00007881742,0.0023050325,0.000010816333,0.9598225,0.000017390075,0.0015719323,0.0018540265],"study_design_scores_gemma":[0.0026215238,0.000115026676,0.15016699,0.00012796027,0.000076292104,0.000023108114,0.0016971466,0.0003379264,0.8199003,0.000007151668,0.024687795,0.0002388099],"about_ca_topic_score_codex":0.00046190908,"about_ca_topic_score_gemma":0.00013075015,"teacher_disagreement_score":0.13992219,"about_ca_system_score_codex":0.0009709707,"about_ca_system_score_gemma":0.0006513762,"threshold_uncertainty_score":0.5444261},"labels":[],"label_agreement":null},{"id":"W2009764353","doi":"10.3109/10428194.2013.835404","title":"Genetic polymorphisms of<i>RAD51</i>and<i>XRCC3</i>and acute myeloid leukemia risk: a meta-analysis","year":2013,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"XRCC3; Odds ratio; Meta-analysis; Myeloid leukemia; Internal medicine; Oncology; Confidence interval; Population; Medicine; RAD51; Genotype; Biology; Bioinformatics; Genetics; Gene; Single-nucleotide polymorphism; DNA repair","score_opus":0.04042416432050826,"score_gpt":0.30393356689123646,"score_spread":0.2635094025707282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009764353","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.040475007,0.95134693,0.00022583836,0.00012799763,0.0002718425,0.004484941,0.0012255426,0.00039896436,0.0014429153],"genre_scores_gemma":[0.0043741274,0.9771606,0.0064402795,0.00071679126,0.0006788876,0.0016713694,0.0007170089,0.0007659576,0.0074749934],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9831521,0.001609952,0.0048651374,0.004710767,0.00257389,0.0030881343],"domain_scores_gemma":[0.9864728,0.002344098,0.0033157498,0.004295773,0.000705851,0.0028657427],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0018638271,0.00422667,0.0190432,0.0037852523,0.00090420386,0.0005871096,0.0016786231,0.0034928732,0.000681651],"category_scores_gemma":[0.00051291886,0.0032653823,0.0069156783,0.004588878,0.0026764146,0.00066228217,0.002198963,0.0016083176,0.00030425252],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003226533,0.00014668127,0.00032157823,0.0104125645,0.20269726,0.0011851005,0.00055361487,0.000011617918,0.00009884417,0.0002586547,0.003077656,0.7809138],"study_design_scores_gemma":[0.008333013,0.0006896792,0.0024039997,0.0014002633,0.5410822,0.007818799,0.0001197902,0.0016586117,0.0001425033,0.00020584092,0.43338606,0.0027592322],"about_ca_topic_score_codex":0.010744257,"about_ca_topic_score_gemma":0.00012206368,"teacher_disagreement_score":0.77815455,"about_ca_system_score_codex":0.01390371,"about_ca_system_score_gemma":0.016879676,"threshold_uncertainty_score":0.9978008},"labels":[],"label_agreement":null},{"id":"W2010726561","doi":"10.1080/1042819031000116698","title":"Acute Myelogenous Leukemia with t(8;21)—Identification of a Specific Immunophenotype","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver Hospital and Health Sciences Centre; University of British Columbia; Leukemia & Lymphoma Society of Canada","funders":"","keywords":"CD33; CD34; Immunophenotyping; Leukemia; CD19; Medicine; Immunology; Internal medicine; Gastroenterology; Antigen; Oncology; Biology; Stem cell; Genetics","score_opus":0.010713451643626224,"score_gpt":0.2410863234620763,"score_spread":0.2303728718184501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010726561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791526,0.0045500854,0.0010676859,0.00015927783,0.00038768677,0.0016712379,0.000099261924,0.00035022132,0.012561945],"genre_scores_gemma":[0.9839178,0.0034288315,0.0044001495,0.00055589085,0.0002919371,0.0002259944,0.0002473029,0.00031859888,0.006613552],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9923681,0.00037687438,0.0019139481,0.0018597594,0.001654702,0.0018266026],"domain_scores_gemma":[0.99448633,0.0004112625,0.0008777719,0.0024375957,0.00085470546,0.0009323183],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011691132,0.0012167309,0.0018545283,0.0009057942,0.0006359459,0.00021549323,0.0007821825,0.00088235823,0.0002718619],"category_scores_gemma":[0.00024942824,0.0010537896,0.0004337311,0.0020200638,0.0013286887,0.0005614879,0.00025689433,0.0004867833,0.0003167001],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013953724,0.0011027965,0.015101069,0.0016914374,0.0042599402,0.0041173426,0.0052613905,0.00033610003,0.68090725,0.02055306,0.01159592,0.24111997],"study_design_scores_gemma":[0.07867722,0.004335499,0.19336808,0.0012064804,0.002710409,0.022921767,0.0034506256,0.0042165,0.5478724,0.0019289101,0.13522682,0.004085298],"about_ca_topic_score_codex":0.00087753567,"about_ca_topic_score_gemma":0.00003499366,"teacher_disagreement_score":0.23703466,"about_ca_system_score_codex":0.016776247,"about_ca_system_score_gemma":0.012717004,"threshold_uncertainty_score":0.9991912},"labels":[],"label_agreement":null},{"id":"W2010936602","doi":"10.1016/j.bbmt.2014.01.027","title":"Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute Myeloid Leukemia","year":2014,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"University Health Network","keywords":"Medicine; Internal medicine; Myeloid leukemia; Univariate analysis; Transplantation; Oncology; Hematopoietic stem cell transplantation; Leukemia; Karyotype; Myeloid; Gastroenterology; Multivariate analysis","score_opus":0.010319891954391026,"score_gpt":0.2553772184855509,"score_spread":0.24505732653115986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010936602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99826324,0.0001069312,0.00031807055,0.00015350449,0.00001691514,0.0007325796,0.00016616037,0.000015400296,0.00022720618],"genre_scores_gemma":[0.9973067,0.001345422,0.0006838573,0.00005937765,0.000019229,0.000024819115,0.00052729825,0.000017348826,0.000015968524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989044,0.00017780492,0.00028270745,0.00026543243,0.00015545364,0.00021422243],"domain_scores_gemma":[0.99910057,0.0004025522,0.00016405081,0.00013496245,0.00011382021,0.000084049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016026368,0.00019888076,0.0003641472,0.00011787159,0.000077422534,0.000006157286,0.00007685104,0.00012371264,0.000012849128],"category_scores_gemma":[0.000013735576,0.000116537114,0.000060374296,0.00010638305,0.00037400043,0.000056528184,0.00000733856,0.00015426852,0.0000012883877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063481936,0.00023637559,0.71707785,0.0010499839,0.0007109523,0.000018192844,0.0021694025,0.00004182022,0.2697032,0.0002866658,0.000018678744,0.0023386753],"study_design_scores_gemma":[0.0068458775,0.0050397003,0.93731433,0.00015930503,0.0012051886,0.00011018316,0.000043964472,0.00012139544,0.048876867,0.00014756611,0.0000035924575,0.00013202775],"about_ca_topic_score_codex":0.00016462503,"about_ca_topic_score_gemma":0.00003810096,"teacher_disagreement_score":0.22082636,"about_ca_system_score_codex":0.000021628,"about_ca_system_score_gemma":0.00011238254,"threshold_uncertainty_score":0.47522458},"labels":[],"label_agreement":null},{"id":"W2011109198","doi":"10.1073/pnas.1311055110","title":"<i>TP53</i> suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients","year":2013,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health; National Cancer Institute; National Institute for Health and Care Research; Moffitt Cancer Center","keywords":"Lenalidomide; Erythropoiesis; Myelodysplastic syndromes; Biology; Anemia; Internal medicine; Cancer research; Bone marrow; Dexamethasone; Immunology; Medicine; Endocrinology","score_opus":0.04050074129285762,"score_gpt":0.3195955734382278,"score_spread":0.2790948321453702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011109198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99256563,0.00023921073,2.1323045e-7,0.004225942,0.000009441226,0.00083562516,0.000008430503,0.000012120755,0.002103409],"genre_scores_gemma":[0.99874955,0.000039579136,0.00075281796,0.00024882532,0.000032334236,0.000055711105,7.971081e-7,0.000009879506,0.000110499415],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9969479,0.000028285625,0.000627134,0.000351504,0.0016800305,0.00036516305],"domain_scores_gemma":[0.99870116,0.0002776284,0.00037813294,0.000016894805,0.00055800984,0.00006820611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016126937,0.00015236557,0.00030944016,0.00047956983,0.0001219674,0.00003618721,0.00061523967,0.000139229,0.000060571274],"category_scores_gemma":[0.0014484985,0.00009484964,0.000067977075,0.0015170526,0.0007662501,0.0006487196,0.00018571262,0.0004424138,0.0000034137101],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014682469,0.00026126608,0.26557156,0.00021350189,0.000016805681,7.129196e-8,0.00036248396,0.00006432231,0.72959757,0.0012999142,0.00080555456,0.0016601519],"study_design_scores_gemma":[0.001315997,0.00019570021,0.7435152,0.00060225755,0.000010686638,0.000004617489,0.00052539184,0.004511128,0.23733495,0.011849659,0.000021848939,0.00011256636],"about_ca_topic_score_codex":0.0003001751,"about_ca_topic_score_gemma":0.0000013162437,"teacher_disagreement_score":0.4922626,"about_ca_system_score_codex":0.0002294001,"about_ca_system_score_gemma":0.00018426671,"threshold_uncertainty_score":0.3867856},"labels":[],"label_agreement":null},{"id":"W2011435372","doi":"10.1111/bjh.13088","title":"Safety and efficacy of thrombopoietin‐receptor agonists in myelodysplastic syndromes: a systematic review and meta‐analysis of randomized controlled trials","year":2014,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Princess Margaret Cancer Centre; University of Toronto; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"","keywords":"Romiplostim; Eltrombopag; Medicine; Placebo; Randomized controlled trial; Relative risk; Thrombopoietin receptor; Meta-analysis; Internal medicine; Myelodysplastic syndromes; Thrombopoietin; Confidence interval; Platelet; Bone marrow; Pathology; Haematopoiesis","score_opus":0.053660986097755686,"score_gpt":0.38175215643695076,"score_spread":0.3280911703391951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011435372","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016784397,0.98931515,0.00017458138,0.00023252516,0.0000704216,0.009882119,0.000109413355,0.000005970585,0.000041944797],"genre_scores_gemma":[0.0005076156,0.99847466,0.0004845364,0.00007038487,0.000026297776,0.00025669095,0.00004168694,0.000054943208,0.000083163155],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.96556526,0.01840317,0.014389782,0.00044622013,0.00078771455,0.0004078349],"domain_scores_gemma":[0.94172204,0.04329975,0.013402589,0.00045384423,0.0008341905,0.00028757416],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.03955325,0.0006381729,0.16118641,0.0020429296,0.00004155757,0.000034819685,0.00040890445,0.0005734025,0.00040915053],"category_scores_gemma":[0.08263625,0.00039572286,0.010106843,0.0010977652,0.0008112997,0.00006727778,0.00014154158,0.0010723309,0.000003429621],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00670146,0.00012037184,4.0933875e-7,0.6408758,0.3494522,0.0017854739,0.000026959475,4.7664153e-7,3.867713e-7,0.00007358924,0.00009953232,0.00086332555],"study_design_scores_gemma":[0.090564586,0.00015449672,0.0000011286508,0.24139218,0.60122985,0.06615736,0.000013649088,0.000011178338,2.0917606e-7,0.000009229452,0.00031903587,0.00014711129],"about_ca_topic_score_codex":0.000058128084,"about_ca_topic_score_gemma":0.000017538041,"teacher_disagreement_score":0.39948365,"about_ca_system_score_codex":0.00012838293,"about_ca_system_score_gemma":0.0009513093,"threshold_uncertainty_score":0.99984944},"labels":[],"label_agreement":null},{"id":"W2012049957","doi":"10.1016/j.leukres.2010.02.023","title":"Mutational analysis of K-ras codon 12 in blood samples of patients with acute myeloid leukemia","year":2010,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AGE-WELL","keywords":"Myeloid leukemia; Mutation; Valine; Leukemia; Biology; Myeloid; Cancer research; Medicine; Amino acid; Gene; Immunology; Genetics","score_opus":0.030270332726815365,"score_gpt":0.3350075359139783,"score_spread":0.30473720318716296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012049957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958069,0.000039866052,0.000065129694,0.00020441417,0.000041592684,0.0010394545,0.0003107304,0.000030665655,0.0024612527],"genre_scores_gemma":[0.9938019,0.000093847906,0.004184423,0.000049179762,0.0000833636,0.00010368022,0.0008587639,0.000067670815,0.0007571754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99350935,0.00035244183,0.00095715583,0.00076828036,0.0033542265,0.0010585388],"domain_scores_gemma":[0.99463636,0.0015068286,0.0001950044,0.0011741102,0.002076384,0.0004113301],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0024013678,0.00031833127,0.0011191479,0.0036405665,0.0001238067,0.00003313195,0.0007016317,0.00040327563,0.00085707323],"category_scores_gemma":[0.0012996431,0.00025774742,0.0002648652,0.005565723,0.0011956316,0.00022564942,0.00034037075,0.002432145,0.000028397244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033770963,0.00059383764,0.8938761,0.00026595814,0.0037461957,0.00024759083,0.00086594326,0.00037369065,0.09306081,0.0011210865,0.0005120382,0.0019596627],"study_design_scores_gemma":[0.007946258,0.00093968486,0.9386561,0.00010454942,0.0010754865,0.000019258789,0.00024252181,0.0021754552,0.04810858,0.00013812276,0.00036024637,0.00023374644],"about_ca_topic_score_codex":0.005068853,"about_ca_topic_score_gemma":0.0030948436,"teacher_disagreement_score":0.044952225,"about_ca_system_score_codex":0.0016497384,"about_ca_system_score_gemma":0.0061273472,"threshold_uncertainty_score":0.9999875},"labels":[],"label_agreement":null},{"id":"W2012998597","doi":"10.1080/10428190400025112","title":"Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University of British Columbia","funders":"","keywords":"Myeloid leukemia; Medicine; Karyotype; Oncology; Value (mathematics); Internal medicine; Myeloid; Cancer research; Leukemia; Biology; Chromosome; Genetics; Gene","score_opus":0.015803030289344492,"score_gpt":0.29667028888014974,"score_spread":0.28086725859080525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012998597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876011,0.00094936264,0.0003384275,0.00031397026,0.00028056547,0.0021986687,0.00063127937,0.00017213359,0.0075144786],"genre_scores_gemma":[0.98845464,0.0010236781,0.004427199,0.0009766597,0.0004254812,0.00022419699,0.0003011655,0.00021382795,0.003953167],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.993155,0.00022935172,0.0023146484,0.0015078309,0.0012981246,0.0014950468],"domain_scores_gemma":[0.99565095,0.0010359758,0.0007581534,0.0013388171,0.00043835086,0.0007777452],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001180341,0.0010286579,0.002331438,0.0011892105,0.00021740487,0.000040720213,0.00073933,0.0011459347,0.00018136874],"category_scores_gemma":[0.00038476373,0.0009250273,0.0005876952,0.0010601148,0.0006737659,0.0004725503,0.00024957387,0.00049020903,0.000039562423],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.077145085,0.002100017,0.14306436,0.008576999,0.0043003894,0.0015559874,0.00970139,0.0057658665,0.3304352,0.009265427,0.01845422,0.3896351],"study_design_scores_gemma":[0.0778773,0.005147024,0.46610284,0.00292131,0.0013409635,0.0014803499,0.0006734905,0.10204564,0.3194001,0.0008349865,0.020363525,0.0018124938],"about_ca_topic_score_codex":0.0009912796,"about_ca_topic_score_gemma":0.00012073147,"teacher_disagreement_score":0.38782257,"about_ca_system_score_codex":0.019658538,"about_ca_system_score_gemma":0.008273468,"threshold_uncertainty_score":0.99932003},"labels":[],"label_agreement":null},{"id":"W2013169247","doi":"10.1038/leu.2014.191","title":"Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes—proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS","year":2014,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Work flow; Flow cytometry; Myeloid; Working group; Medical physics; Family medicine; Pathology; Internal medicine; Immunology; Bone marrow; Computer science","score_opus":0.07863022784703433,"score_gpt":0.34813966630218435,"score_spread":0.26950943845515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013169247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8214515,0.00036076832,0.16056144,0.010949243,0.0005925817,0.0029937904,0.00036863596,0.00006628299,0.0026557478],"genre_scores_gemma":[0.9534623,0.00009956436,0.043106303,0.00064508256,0.0011552791,0.00013777861,0.0011848288,0.00006482477,0.00014402682],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.996099,0.00048408803,0.0016308088,0.00057499856,0.0007959662,0.00041516448],"domain_scores_gemma":[0.9935047,0.004378747,0.00060970994,0.000784219,0.0006575303,0.00006509498],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006913272,0.00028251807,0.0005998825,0.00061914284,0.00009440696,0.00006961719,0.00094089494,0.0001982198,0.000010531791],"category_scores_gemma":[0.015533954,0.00018505815,0.00019358132,0.00119449,0.0001596987,0.00016678528,0.00013759338,0.0006491022,0.000006664783],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008635173,0.00027343747,0.03597372,0.0012093281,0.00043423517,0.00004743236,0.00672272,0.004797641,0.1991791,0.00513502,0.035920624,0.7016716],"study_design_scores_gemma":[0.008249494,0.0004089417,0.17409462,0.0030839525,0.00012161001,0.000034889123,0.0022133687,0.80166245,0.0026804043,0.00063192676,0.0065491125,0.00026921372],"about_ca_topic_score_codex":0.0003927064,"about_ca_topic_score_gemma":0.00024347598,"teacher_disagreement_score":0.7968648,"about_ca_system_score_codex":0.0013729698,"about_ca_system_score_gemma":0.0004541507,"threshold_uncertainty_score":0.99275863},"labels":[],"label_agreement":null},{"id":"W2013349424","doi":"10.1159/000205829","title":"Bone Marrow Cultures in Dysmyelopoietic Syndrome: Diagnostic and Prognostic Evaluation","year":2009,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Haematopoiesis; Progenitor cell; Bone marrow; Acute leukemia; Myeloid leukemia; Preleukemia; Leukemia; Immunology; Biology; In vitro; Medicine; Internal medicine; Gastroenterology; Pathology; Stem cell; Genetics","score_opus":0.024258940772799612,"score_gpt":0.32076701964202614,"score_spread":0.29650807886922653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013349424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794862,0.002150901,0.000008302592,0.014540007,0.00003716925,0.0017297211,0.0000024154838,0.00009479971,0.0019504735],"genre_scores_gemma":[0.9975144,0.00043048506,0.00088142883,0.000771851,0.000025213938,0.00016483058,0.000046983307,0.0000147635965,0.00015001741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790406,0.00019977803,0.0003746024,0.00046522226,0.00057237473,0.00048398125],"domain_scores_gemma":[0.99849534,0.0007338225,0.00008523414,0.00034337185,0.00014887922,0.00019335224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072363263,0.00022373007,0.0005441676,0.00022977336,0.000072067654,0.00004161544,0.00013277192,0.00022507831,0.00025166775],"category_scores_gemma":[0.007479174,0.00016419275,0.000049995484,0.00047191133,0.00014639605,0.00012885706,0.00006951333,0.00044014098,0.00007365925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017507849,0.0034649381,0.73192203,0.0016679361,0.000323154,0.046945293,0.0048156767,0.000047269645,0.030936142,0.004938084,0.051031917,0.12215675],"study_design_scores_gemma":[0.0026201166,0.0010719642,0.97941107,0.0003899282,0.0001557587,0.009858472,0.00021871577,0.0013479238,0.00045292987,0.0036222918,0.00059731206,0.00025351247],"about_ca_topic_score_codex":0.000020677555,"about_ca_topic_score_gemma":0.000016168795,"teacher_disagreement_score":0.24748902,"about_ca_system_score_codex":0.00019936822,"about_ca_system_score_gemma":0.00018443326,"threshold_uncertainty_score":0.89538103},"labels":[],"label_agreement":null},{"id":"W2013502877","doi":"10.1182/blood-2006-05-019539","title":"Alert and sniffy-nosed about Mll-AF4?","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Biology","score_opus":0.010691965048473296,"score_gpt":0.26371968690008246,"score_spread":0.25302772185160916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013502877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.958017,0.0011522244,0.000019291208,0.0013429802,0.000034812536,0.00027275705,0.0000084329995,0.00008641421,0.03906609],"genre_scores_gemma":[0.9903392,0.00010699758,0.0009946452,0.00041568605,0.00046840453,0.000017179933,0.000036213278,0.000028757351,0.007592924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897075,0.000024479246,0.00016368055,0.00024511074,0.0002744952,0.00032146892],"domain_scores_gemma":[0.9994234,0.00005929911,0.00002856851,0.00028459704,0.00006537068,0.00013875542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014115607,0.00011869736,0.00020859556,0.00009557523,0.00006153078,0.000024578932,0.00007703223,0.00009880493,0.0001742543],"category_scores_gemma":[0.00006935901,0.00009843971,0.00004419253,0.00015912502,0.00010011157,0.00004612291,0.00006033682,0.00022407837,0.00011983102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045642018,0.0025598772,0.44639012,0.00055321964,0.00047690154,0.003754469,0.0003703504,0.0000028400727,0.4035316,0.003405486,0.124722615,0.013776074],"study_design_scores_gemma":[0.0152895525,0.00041009943,0.85993075,0.000114743685,0.00026243276,0.0007055467,0.00005210687,0.00016653448,0.05176295,0.0004357767,0.07058173,0.00028778554],"about_ca_topic_score_codex":0.00035913842,"about_ca_topic_score_gemma":0.00003207133,"teacher_disagreement_score":0.41354063,"about_ca_system_score_codex":0.000038052174,"about_ca_system_score_gemma":0.00013286625,"threshold_uncertainty_score":0.40142548},"labels":[],"label_agreement":null},{"id":"W2013781993","doi":"10.1038/nrc2047","title":"Myelodysplastic syndromes: the complexity of stem-cell diseases","year":2007,"lang":"en","type":"review","venue":"Nature reviews. Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":341,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"Leukemia and Lymphoma Society; Diamond Blackfan Anemia Foundation","keywords":"Myelodysplastic syndromes; Bone marrow failure; Context (archaeology); Stem cell; Bone marrow; Haematopoiesis; Disease; Population; Myeloid; Medicine; Myeloid leukemia; Immunology; Biology; Bioinformatics; Cancer research; Internal medicine; Genetics","score_opus":0.15081134662786075,"score_gpt":0.4384797511620897,"score_spread":0.2876684045342289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013781993","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000023817279,0.99112767,0.000022155697,0.00023981166,0.0006421866,0.005227361,0.0006349156,0.000052195064,0.0020513325],"genre_scores_gemma":[0.000015296113,0.993429,0.00015964206,0.0005688652,0.00090819487,0.0006162,0.00027466856,0.00015127589,0.0038768253],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994897,0.0006482499,0.0016632181,0.00083341537,0.0011831797,0.0007749004],"domain_scores_gemma":[0.9952001,0.0011085842,0.0011757078,0.0017318713,0.00037326908,0.00041049282],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011888182,0.00090915494,0.00577112,0.00037328494,0.00012950882,0.000028426737,0.0010644799,0.0011996481,0.000964756],"category_scores_gemma":[0.00032199937,0.0004576147,0.0018579216,0.0017744008,0.00092960143,0.0000630547,0.00030522616,0.004570142,0.00033301392],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029999306,0.00008955278,0.000009600961,0.17302862,0.00031978253,0.00007573575,0.000016976433,9.334883e-8,4.4206817e-7,0.0001752373,0.039207518,0.78704643],"study_design_scores_gemma":[0.00041634956,0.00009077545,0.000034377732,0.07237457,0.0051439945,0.00021280027,0.000009618823,0.000002591056,0.0000019595827,0.000015135771,0.9213415,0.00035635708],"about_ca_topic_score_codex":0.000049636124,"about_ca_topic_score_gemma":0.000024598965,"teacher_disagreement_score":0.88213396,"about_ca_system_score_codex":0.0013714742,"about_ca_system_score_gemma":0.00279353,"threshold_uncertainty_score":0.9999485},"labels":[],"label_agreement":null},{"id":"W2015141816","doi":"10.1097/lgt.0b013e3181be2999","title":"Myeloid Sarcoma of the Vagina","year":2010,"lang":"en","type":"article","venue":"Journal of Lower Genital Tract Disease","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Mount Sinai Hospital; Health Sciences Centre; Lakeridge Health; Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"Medicine; Myeloid sarcoma; Vagina; Sarcoma; Myeloid leukemia; Biopsy; Myeloid; Presentation (obstetrics); Past medical history; Radiation therapy; Surgery; Pathology; Internal medicine","score_opus":0.012349001173412661,"score_gpt":0.28358562202521054,"score_spread":0.2712366208517979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015141816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992319,0.00036455164,0.000020820795,0.0041162507,0.0007605805,0.0002147583,0.000028462518,0.000007969838,0.002167614],"genre_scores_gemma":[0.997432,0.00003199101,0.0004312894,0.00035736593,0.0006438525,0.0000018240007,0.0000015632047,0.000029069091,0.0010710246],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981374,0.000057940466,0.00050937844,0.00012232093,0.0008986656,0.00027426076],"domain_scores_gemma":[0.99788916,0.00013985236,0.00031385495,0.00049856695,0.000494343,0.0006642103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044260587,0.0001496325,0.00031385443,0.00016328969,0.00006119261,0.000023061011,0.0004275779,0.000078248275,0.0005347131],"category_scores_gemma":[0.0009113227,0.00008834403,0.000526393,0.0002666573,0.00023848398,0.00021601318,0.00008288305,0.0011855931,0.000032612505],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00977469,0.0059642713,0.32419363,0.0004718353,0.00060057594,0.0082880845,0.00053244183,0.000013320071,0.605691,0.00039992912,0.020426374,0.023643875],"study_design_scores_gemma":[0.003021652,0.00062704395,0.971201,0.000108445245,0.0004023814,0.0017432735,0.00010835808,0.00007445837,0.008811271,0.00045953275,0.013298169,0.000144415],"about_ca_topic_score_codex":0.000005926813,"about_ca_topic_score_gemma":0.0000022503016,"teacher_disagreement_score":0.6470074,"about_ca_system_score_codex":0.00008588813,"about_ca_system_score_gemma":0.001256092,"threshold_uncertainty_score":0.5854733},"labels":[],"label_agreement":null},{"id":"W2015268376","doi":"10.1007/s00280-011-1679-8","title":"Hematologic adverse events associated with temozolomide","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Pancytopenia; Medicine; Aplastic anemia; Internal medicine; Adverse effect; Myelodysplastic syndromes; Temozolomide; Bone marrow suppression; Bone marrow failure; Bone Marrow Aplasia; Pediatrics; Surgery; Bone marrow; Chemotherapy","score_opus":0.04505727237691332,"score_gpt":0.3367991244967081,"score_spread":0.2917418521197948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015268376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397427,0.0005966411,0.00004090991,0.0015302727,0.00012786391,0.00046264593,0.000009140301,0.000075490585,0.0031827693],"genre_scores_gemma":[0.98821145,0.0016076519,0.0003321323,0.007707133,0.00010393457,0.0001295887,0.000009264375,0.00003092448,0.001867901],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990463,0.00006731513,0.00014485828,0.0002775349,0.00011230941,0.00035168338],"domain_scores_gemma":[0.9994866,0.000063335705,0.00007814155,0.00010876489,0.00008506885,0.00017805281],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001475893,0.00015968172,0.00032526292,0.00007200646,0.000069147085,0.0000011402755,0.000091240705,0.00014217455,0.004272687],"category_scores_gemma":[0.0000118544385,0.00011593175,0.000040719304,0.00017886514,0.00020335653,0.000052699193,0.000024966088,0.000294448,0.000016586073],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015983934,0.0011842354,0.6831054,0.00032398658,0.003527963,0.00095264416,0.0046907905,0.000004272806,0.23741141,0.00016310379,0.03670296,0.015949314],"study_design_scores_gemma":[0.042560056,0.002463751,0.2502774,0.00020974311,0.0006864476,0.00052212685,0.0003752033,0.00065450586,0.6783331,0.0005569374,0.022641065,0.00071968074],"about_ca_topic_score_codex":0.00006589649,"about_ca_topic_score_gemma":0.0000128850315,"teacher_disagreement_score":0.4409217,"about_ca_system_score_codex":0.00020197242,"about_ca_system_score_gemma":0.00022535463,"threshold_uncertainty_score":0.9966375},"labels":[],"label_agreement":null},{"id":"W2015398257","doi":"10.1016/s0008-4182(00)80063-0","title":"Acute lymphocytic blast crisis as an ocular manifestation of chronic granulocytic leukemia","year":2000,"lang":"en","type":"article","venue":"Canadian Journal of Ophthalmology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Blast Crisis; Chronic granulocytic leukemia; Medicine; Chronic lymphocytic leukemia; Leukemia; Immunology","score_opus":0.016127576624520374,"score_gpt":0.30048523906138463,"score_spread":0.2843576624368643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015398257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888178,0.0007276061,0.000017373892,0.00050609175,0.00018649096,0.0002232295,0.00002331866,0.000005037012,0.009493034],"genre_scores_gemma":[0.9971176,0.00007723355,0.00038455206,0.00014898766,0.00028479192,0.000004266268,0.000027632137,0.000048150792,0.0019068108],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99785036,0.00019462762,0.0006951405,0.00025051492,0.0003556004,0.00065374625],"domain_scores_gemma":[0.99746513,0.0000706421,0.0002460249,0.00043162686,0.00046285303,0.0013237246],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004539226,0.00021573523,0.000624224,0.0007430628,0.00010835095,0.000023554974,0.0003920041,0.00025481748,0.010373657],"category_scores_gemma":[0.00012268186,0.00020294385,0.00019942233,0.00042367665,0.00032336582,0.00023416405,0.000011407121,0.00050370645,0.0001917949],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0036989108,0.00024555906,0.01236372,0.00064587494,0.0025477293,0.93193203,0.0034898159,0.003988203,0.011149888,0.00091863563,0.011230411,0.017789198],"study_design_scores_gemma":[0.0062351385,0.007067603,0.015403038,0.00019067632,0.0005571005,0.9600727,0.0005280068,0.0020123324,0.0048253695,0.0010132571,0.001798431,0.00029637796],"about_ca_topic_score_codex":0.0154290255,"about_ca_topic_score_gemma":0.00038192084,"teacher_disagreement_score":0.028140614,"about_ca_system_score_codex":0.007088558,"about_ca_system_score_gemma":0.024071971,"threshold_uncertainty_score":0.99672306},"labels":[],"label_agreement":null},{"id":"W2016241204","doi":"10.1186/1753-6561-7-s2-o6","title":"Hematopoietic stem cells have an intrinsic expansion limit","year":2013,"lang":"en","type":"article","venue":"BMC Proceedings","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Limit (mathematics); Medicine; Stem cell; Haematopoiesis; Cell biology; Biology; Mathematics; Mathematical analysis","score_opus":0.0352514145274802,"score_gpt":0.2792365805325434,"score_spread":0.2439851660050632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016241204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99061775,0.0001038626,0.00008677137,0.00076735474,0.00008232123,0.0012110744,0.0000012816905,0.00025847708,0.0068711275],"genre_scores_gemma":[0.9870363,0.000040694424,0.0033463782,0.00061618764,0.00038069702,0.00018275317,0.000005732252,0.00007598842,0.008315263],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99790007,0.000013070643,0.0003459744,0.0005340947,0.00060001435,0.000606784],"domain_scores_gemma":[0.9984787,0.000053431737,0.00010074883,0.00029794034,0.00054253556,0.00052660407],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030541053,0.0002513591,0.0003820686,0.00023352193,0.00011073691,0.00013611918,0.00027227378,0.00020549487,0.00046589412],"category_scores_gemma":[0.000070835755,0.00020392402,0.00009558871,0.00030154106,0.00011365029,0.0005530155,0.00018234336,0.00046443558,0.0018179998],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048012345,0.00068029575,0.060766228,0.002323741,0.00008601103,0.000058716647,0.007544636,0.0000015072884,0.77126175,0.0018987412,0.117386706,0.037511542],"study_design_scores_gemma":[0.00714994,0.0026183142,0.04563792,0.0008299967,0.00020992337,0.00088136626,0.020350369,0.008867987,0.89673364,0.0012619552,0.014284621,0.0011739804],"about_ca_topic_score_codex":0.00009637223,"about_ca_topic_score_gemma":0.0000034949192,"teacher_disagreement_score":0.12547188,"about_ca_system_score_codex":0.00030963728,"about_ca_system_score_gemma":0.0002491487,"threshold_uncertainty_score":0.9989592},"labels":[],"label_agreement":null},{"id":"W2016307611","doi":"10.1371/journal.pcbi.1003599","title":"Feedback Signals in Myelodysplastic Syndromes: Increased Self-Renewal of the Malignant Clone Suppresses Normal Hematopoiesis","year":2014,"lang":"en","type":"article","venue":"PLoS Computational Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"RWTH Aachen University; Deutsche Forschungsgemeinschaft; Stem Cell Network","keywords":"clone (Java method); Haematopoiesis; Cytopenia; Biology; Stem cell; Myelodysplastic syndromes; Progenitor cell; Bone marrow; Immunology; Hematopoietic stem cell; Cell biology; Phenotype; Cancer research; Genetics; Gene","score_opus":0.01750164767282208,"score_gpt":0.2663458641853977,"score_spread":0.2488442165125756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016307611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99684656,0.0000839283,0.00063750695,0.0012800299,0.00006819753,0.0004215613,0.000050760576,0.00004479498,0.00056666974],"genre_scores_gemma":[0.99588853,0.000011045044,0.0034367533,0.00033243475,0.000087876055,0.000042057945,0.00013689492,0.000021092563,0.000043292748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980289,0.0004128255,0.00051325955,0.00032309632,0.00035058806,0.00037133525],"domain_scores_gemma":[0.9971282,0.0020785094,0.0001588282,0.00025792926,0.00026249746,0.00011402597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036572374,0.00018741765,0.0005225561,0.00024088073,0.00006780867,0.000008657955,0.00029360794,0.00016266617,0.00025376052],"category_scores_gemma":[0.0007458256,0.0001274636,0.000101936275,0.00042715063,0.00027893975,0.000045643952,0.0002005806,0.00025824693,0.00006705698],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017703777,0.0027575283,0.6605928,0.0019111403,0.0014931968,0.00012354934,0.0011293109,0.016587105,0.29483816,0.01611725,0.002025464,0.0006541458],"study_design_scores_gemma":[0.012720548,0.0021756748,0.73875374,0.0010112221,0.00042895135,0.0011005135,0.00028046587,0.13476752,0.08684837,0.020571157,0.00056143955,0.00078041654],"about_ca_topic_score_codex":0.00015726413,"about_ca_topic_score_gemma":0.000014209706,"teacher_disagreement_score":0.20798978,"about_ca_system_score_codex":0.0001343909,"about_ca_system_score_gemma":0.00046290574,"threshold_uncertainty_score":0.5197815},"labels":[],"label_agreement":null},{"id":"W2016456457","doi":"10.1182/blood-2002-08-2484","title":"Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1","year":2003,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Biology; Hox gene; Myeloid leukemia; Leukemia; Myeloid; Haematopoiesis; Fusion gene; Cancer research; Myelopoiesis; Immunology; Genetics; Stem cell; Gene; Gene expression","score_opus":0.020360188347642093,"score_gpt":0.27121115397927337,"score_spread":0.2508509656316313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016456457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99101657,0.0010573372,0.000042055268,0.000324482,0.00006662883,0.00095226127,0.000019184043,0.00004074936,0.006480764],"genre_scores_gemma":[0.9965035,0.0006794852,0.0007557522,0.00020171577,0.00011495448,0.00009679291,0.00008608807,0.000065186585,0.0014965351],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997298,0.0002717148,0.0006044871,0.00055375264,0.00068638485,0.0005856756],"domain_scores_gemma":[0.99878895,0.00011312026,0.00018672818,0.0006166505,0.00015166015,0.00014287447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078471797,0.00030221292,0.0005476804,0.000326965,0.00011510116,0.000024164254,0.00031878552,0.0002792952,0.00012677854],"category_scores_gemma":[0.00006348901,0.0002118563,0.00007787636,0.0011175076,0.00032142462,0.00015317697,0.00008067607,0.0010411069,0.000027234708],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034772765,0.00032038393,0.010369274,0.000060225968,0.00016154183,0.00020837467,0.0009787913,0.000033180902,0.98173016,0.0006646588,0.0043172725,0.0008083848],"study_design_scores_gemma":[0.01886392,0.0007701247,0.02318098,0.00027994058,0.00019278818,0.0006521198,0.00096614764,0.0000668089,0.94795746,0.00016962668,0.00654244,0.00035764743],"about_ca_topic_score_codex":0.0011304935,"about_ca_topic_score_gemma":0.00016937386,"teacher_disagreement_score":0.03377273,"about_ca_system_score_codex":0.0019479165,"about_ca_system_score_gemma":0.0011708965,"threshold_uncertainty_score":0.8639249},"labels":[],"label_agreement":null},{"id":"W2016908144","doi":"10.1016/j.leukres.2014.01.004","title":"Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: A systematic review and meta-analysis","year":2014,"lang":"en","type":"review","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; SickKids Foundation; Institute for Clinical Evaluative Sciences; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Leukapheresis; Myeloid leukemia; Meta-analysis; Chemotherapy; Leukocytosis; Oncology; Leukostasis; Leukemia; Internal medicine; Intensive care medicine; Biology","score_opus":0.13781208528964473,"score_gpt":0.4313074187190795,"score_spread":0.2934953334294348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016908144","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032234725,0.98001754,0.000009219495,0.0008108089,0.00003294455,0.014677498,0.00024346626,0.00014938325,0.00083565485],"genre_scores_gemma":[0.0015320075,0.98089325,0.00038151557,0.0011419805,0.00018235127,0.0065436466,0.00022859433,0.0004432654,0.00865336],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97725683,0.007205558,0.0044490863,0.003844279,0.0044075507,0.0028366882],"domain_scores_gemma":[0.98742586,0.0031519148,0.0012145252,0.005381615,0.0011721395,0.0016539244],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.018070124,0.0022154069,0.026374198,0.0041447487,0.0004660345,0.0006800392,0.0020508221,0.0019136028,0.00064371445],"category_scores_gemma":[0.002717624,0.0015691603,0.004374202,0.008973461,0.0014127073,0.00043150247,0.0014139791,0.0069417744,0.0003639003],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00016068369,0.00009910542,0.00003373264,0.82102376,0.16767223,0.00068135717,0.00020574065,8.2254115e-7,0.00002521633,0.00009980429,0.0015100533,0.0084875],"study_design_scores_gemma":[0.0029929855,0.0005141669,0.00039271763,0.107693225,0.86863554,0.00081063557,0.00011014932,0.00019600868,0.00003461337,0.0000688547,0.016725795,0.0018253003],"about_ca_topic_score_codex":0.0036597636,"about_ca_topic_score_gemma":0.00025414422,"teacher_disagreement_score":0.7133305,"about_ca_system_score_codex":0.0110997185,"about_ca_system_score_gemma":0.008152306,"threshold_uncertainty_score":0.99938214},"labels":[],"label_agreement":null},{"id":"W2017107901","doi":"10.1182/blood-2011-06-363960","title":"Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"University of Hong Kong; Croucher Foundation; Lee Hysan Foundation; Lady Tata Memorial Trust; Pfizer","keywords":"Sorafenib; Myeloid leukemia; Leukemia; Cancer research; Medicine; Internal medicine; Tyrosine kinase; Biology; Oncology; Hepatocellular carcinoma; Receptor","score_opus":0.03747264596254492,"score_gpt":0.31744743224974614,"score_spread":0.27997478628720124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017107901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99718183,0.00035892168,0.0010341553,0.0002482652,0.000046832636,0.000792897,0.0001227128,0.000018008137,0.00019639147],"genre_scores_gemma":[0.998734,0.00011532446,0.0006709654,0.000029960265,0.00003700032,0.00006883314,0.00006341585,0.000030343244,0.00025014827],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99818027,0.00022445289,0.00046146807,0.00020265317,0.0005632739,0.00036789718],"domain_scores_gemma":[0.998413,0.00032011504,0.00037459168,0.00035188068,0.00040635464,0.00013402296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063843775,0.00020509926,0.0006121359,0.00014878905,0.00006528105,0.0000050655553,0.00012355042,0.00013782532,0.00006206899],"category_scores_gemma":[0.00020073219,0.0001271778,0.00009961851,0.0004127386,0.00023014896,0.000121595374,0.000055266704,0.00014297299,0.000002678421],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041899118,0.0035222827,0.08456212,0.00042692077,0.004018765,0.0002541211,0.0064439825,0.000057059555,0.8924689,0.002351659,0.00007315823,0.0016310876],"study_design_scores_gemma":[0.01041905,0.003265155,0.07730831,0.00012648747,0.0017959338,0.00015042983,0.0017067011,0.00013895384,0.90479386,0.00011055775,0.000020857296,0.00016370839],"about_ca_topic_score_codex":0.0002974762,"about_ca_topic_score_gemma":0.00005245227,"teacher_disagreement_score":0.012324929,"about_ca_system_score_codex":0.0002037457,"about_ca_system_score_gemma":0.00059079076,"threshold_uncertainty_score":0.518616},"labels":[],"label_agreement":null},{"id":"W2017451441","doi":"10.1038/bmt.2009.91","title":"Early lymphocyte recovery after allogeneic hematopoietic SCT is associated with significant GVL effect in pediatric ALL but not acute myelogenous leukemia—Update study","year":2009,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Medical Research Council","keywords":"Medicine; Hazard ratio; Internal medicine; Leukemia; Cohort; Hematopoietic stem cell transplantation; Lymphocyte; Haematopoiesis; Cord blood; Stem cell; Progenitor cell; Oncology; Immunology; Transplantation; Confidence interval","score_opus":0.0099749593728265,"score_gpt":0.2502626787632562,"score_spread":0.2402877193904297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017451441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955929,0.00027525928,0.00018519809,0.0005326644,0.000073448646,0.0028187484,0.00017095635,0.00017048525,0.00018034571],"genre_scores_gemma":[0.99524343,0.001561305,0.00024754542,0.001561954,0.000107499494,0.00028497254,0.00045895006,0.000093426206,0.00044089905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99566996,0.0005033484,0.00079509284,0.0009236118,0.0011406989,0.0009672826],"domain_scores_gemma":[0.998461,0.0002899437,0.00022526969,0.00055385684,0.0001618925,0.00030804306],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011222643,0.00057541503,0.0009566468,0.00071510696,0.000107306165,0.00008749979,0.00023895079,0.00032915888,0.0000734466],"category_scores_gemma":[0.000049247174,0.00048430866,0.00018912768,0.0009779647,0.000068709254,0.00028808773,0.000020419848,0.000606954,0.00015054001],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12803051,0.0033183484,0.5581474,0.0014606427,0.0025955336,0.08235772,0.015268883,0.0005415908,0.19375521,0.000009325932,0.0007560954,0.013758739],"study_design_scores_gemma":[0.021652685,0.008570188,0.94064957,0.0002555034,0.0026451421,0.00059971854,0.000094451716,0.00021367152,0.024546824,0.000036601665,0.000009194326,0.0007264651],"about_ca_topic_score_codex":0.00050015986,"about_ca_topic_score_gemma":0.00025447021,"teacher_disagreement_score":0.38250217,"about_ca_system_score_codex":0.0018070727,"about_ca_system_score_gemma":0.00083141396,"threshold_uncertainty_score":0.99976087},"labels":[],"label_agreement":null},{"id":"W2018097894","doi":"10.1016/j.bbmt.2006.12.364","title":"359: Outcome of matched sibling donor hematopoietic stem cell transplantation for standard risk pediatric acute myelogenous leukemia in first complete remission","year":2007,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Total body irradiation; Hematopoietic stem cell transplantation; Cyclophosphamide; Melphalan; Transplantation; Internal medicine; Leukemia; Chemotherapy; Surgery; Busulfan; Oncology; Pediatrics","score_opus":0.020866529918616088,"score_gpt":0.2870895030267935,"score_spread":0.2662229731081774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018097894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789357,0.0006945956,0.018430945,0.00009178565,0.00007038574,0.0009562337,0.0007103317,0.0000277793,0.00008222609],"genre_scores_gemma":[0.9846673,0.009263582,0.005424046,0.000026135363,0.000056009827,0.000023127928,0.00048708997,0.0000253701,0.000027351383],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981209,0.00008221132,0.0008878889,0.0003482962,0.00018884212,0.00037186706],"domain_scores_gemma":[0.99863964,0.00060572237,0.00033428392,0.00015875092,0.00014000546,0.00012158708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010539864,0.00020898212,0.0006382152,0.00050891214,0.00009053115,0.000004930017,0.000102468366,0.0003051695,0.000008799872],"category_scores_gemma":[0.000015961168,0.00018439797,0.00011598052,0.00030622896,0.00011691286,0.00007020294,0.000008464619,0.00024220182,8.5618944e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007857951,0.00010378294,0.45211953,0.0065343427,0.00012418164,0.00008472963,0.0034477918,0.000046079927,0.52735645,0.000072309726,0.0000097248485,0.0022431402],"study_design_scores_gemma":[0.030464979,0.0034884636,0.18554613,0.00047693952,0.0043142014,0.00052993104,0.0010758591,0.00042226695,0.7726531,0.0004101912,0.00008052379,0.0005373961],"about_ca_topic_score_codex":0.00022256693,"about_ca_topic_score_gemma":0.00019460186,"teacher_disagreement_score":0.2665734,"about_ca_system_score_codex":0.000101154874,"about_ca_system_score_gemma":0.00018910004,"threshold_uncertainty_score":0.7519531},"labels":[],"label_agreement":null},{"id":"W2018591383","doi":"10.1182/blood-2007-04-084293","title":"Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":272,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"Idarubicin; Cytarabine; Fludarabine; Medicine; Internal medicine; Transplantation; Randomized controlled trial; Oncology; Leukemia; Surgery; Chemotherapy; Cyclophosphamide","score_opus":0.018910234001831377,"score_gpt":0.3422142945803145,"score_spread":0.3233040605784831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018591383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98608655,0.00054637704,0.0005043567,0.0027621025,0.0006072361,0.007939354,0.00037808076,0.00024943656,0.0009265048],"genre_scores_gemma":[0.9837289,0.00056542305,0.0038217073,0.0018228355,0.0051790522,0.00097220036,0.0030902864,0.00018198357,0.00063764764],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938505,0.0004335304,0.0018295342,0.0013683047,0.0008452666,0.001672854],"domain_scores_gemma":[0.99382097,0.0033319173,0.00072623807,0.0013452901,0.00022592407,0.0005496648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031131916,0.0006954545,0.001876829,0.00068617065,0.00029702275,0.00005092802,0.0007839797,0.0011438852,0.00014512107],"category_scores_gemma":[0.0021069138,0.0004929978,0.0006057424,0.0012068035,0.00032405512,0.00017814226,0.0003508355,0.0018686194,0.00007197551],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1262985,0.019140797,0.78552186,0.00004806162,0.00503238,0.014533627,0.001240237,0.000002205922,0.0036702068,0.00023435448,0.014436435,0.029841354],"study_design_scores_gemma":[0.5659843,0.011751285,0.40705654,0.000026383452,0.003908696,0.0034923605,0.00019278974,0.00003250163,0.0010536347,0.00020761382,0.0056736562,0.00062020967],"about_ca_topic_score_codex":0.0032127157,"about_ca_topic_score_gemma":0.0014438095,"teacher_disagreement_score":0.43968582,"about_ca_system_score_codex":0.0022042212,"about_ca_system_score_gemma":0.0023907414,"threshold_uncertainty_score":0.99975216},"labels":[],"label_agreement":null},{"id":"W2018746774","doi":"10.1182/blood-2011-08-369835","title":"Auer rods in mature granulocytes of a patient with mixed lineage leukemia","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pancytopenia; Bone marrow; Precursor cell; Pathology; Peripheral blood; Medicine; Population; Lineage (genetic); Biopsy; Leukemia; Immunology; Biology; Cell; Genetics","score_opus":0.009756219693277874,"score_gpt":0.2529869034099073,"score_spread":0.24323068371662945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018746774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99548787,0.0011226871,0.000014203244,0.00017040572,0.000042713793,0.00040096277,0.000009680421,0.000031737076,0.002719716],"genre_scores_gemma":[0.9956971,0.000035687946,0.0035096642,0.00013574853,0.00012347064,0.000036566948,0.000025673493,0.000032374926,0.0004037052],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987119,0.000055127606,0.00024546022,0.00017395131,0.00038495113,0.0004286228],"domain_scores_gemma":[0.99922746,0.00006213515,0.00007018326,0.0003689639,0.00008993354,0.00018130265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022578069,0.00014641917,0.00033662326,0.00017683051,0.000019472223,0.0000052382115,0.00009591892,0.00013839042,0.000068847025],"category_scores_gemma":[0.00010960129,0.00010104473,0.000053879423,0.00039126017,0.00006895979,0.000084444095,0.00006530395,0.00041676738,0.000028386938],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017874239,0.003923731,0.89950305,0.0009964835,0.00047840705,0.0006872994,0.006089206,0.000025859332,0.07429231,0.00049337215,0.0050720735,0.006650794],"study_design_scores_gemma":[0.015947971,0.0014037468,0.32772022,0.0006134432,0.00029886325,0.00041110688,0.0010564894,0.00011562437,0.64593035,0.000014077105,0.0061590383,0.00032905952],"about_ca_topic_score_codex":0.00015174673,"about_ca_topic_score_gemma":0.000034282773,"teacher_disagreement_score":0.5717828,"about_ca_system_score_codex":0.00015704092,"about_ca_system_score_gemma":0.00028884324,"threshold_uncertainty_score":0.41204846},"labels":[],"label_agreement":null},{"id":"W2018925795","doi":"10.1038/sj.leu.2403489","title":"The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML)","year":2004,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Bundesministerium für Bildung und Forschung; Børnecancerfonden","keywords":"Juvenile myelomonocytic leukemia; International Prognostic Scoring System; Myelodysplastic syndromes; Medicine; Cytopenia; Internal medicine; Oncology; Cytogenetics; Bone marrow; Leukemia; Stem cell; Biology; Haematopoiesis","score_opus":0.01381745438902266,"score_gpt":0.2584082319384484,"score_spread":0.24459077754942576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018925795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98897433,0.00078909344,0.0023655654,0.0017390976,0.000930756,0.0023650713,0.000045257697,0.0003626449,0.00242821],"genre_scores_gemma":[0.99437976,0.0001510826,0.0024107096,0.00026675736,0.0006227809,0.00060138525,0.00007397764,0.000121765894,0.0013717592],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9966916,0.000049035636,0.0006991291,0.00077883137,0.00081272505,0.0009686652],"domain_scores_gemma":[0.9974974,0.00092297595,0.00020836305,0.0006739972,0.00026718312,0.0004300927],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007519896,0.00043371253,0.0005791333,0.00026307112,0.00065330626,0.00026369063,0.00062485295,0.00024981808,0.000018034614],"category_scores_gemma":[0.0012121128,0.00032820078,0.00019530712,0.0003816989,0.00029646792,0.00024299078,0.00033899237,0.0007770162,0.00018383896],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016581694,0.0019514395,0.094254196,0.023931954,0.016167011,0.021727938,0.020492021,0.03350383,0.07091756,0.34208176,0.038222402,0.3201682],"study_design_scores_gemma":[0.1059638,0.00792305,0.5662987,0.015811164,0.0035925827,0.0647395,0.0108070625,0.12298108,0.018342735,0.009047232,0.06933325,0.005159821],"about_ca_topic_score_codex":0.00018494518,"about_ca_topic_score_gemma":0.000044051776,"teacher_disagreement_score":0.47204453,"about_ca_system_score_codex":0.010141985,"about_ca_system_score_gemma":0.0036085506,"threshold_uncertainty_score":0.99991703},"labels":[],"label_agreement":null},{"id":"W2019059796","doi":"10.1016/j.leukres.2007.06.019","title":"The morphological subcategories of acute monocytic leukemia (M5a and M5b) share similar immunophenotypic and cytogenetic features and clinical outcomes","year":2007,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Immunophenotyping; Medicine; Internal medicine; Leukemia; Oncology; Immunology; Flow cytometry","score_opus":0.06637282434756417,"score_gpt":0.41099995334369255,"score_spread":0.34462712899612835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019059796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98698294,0.0080039725,0.00004529725,0.0025346053,0.00008781649,0.0011766878,0.000034967277,0.000058729456,0.0010749958],"genre_scores_gemma":[0.98366266,0.010804083,0.0014302109,0.00028857993,0.00018498105,0.00004685331,0.000031963857,0.00006919617,0.0034814775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99467456,0.00058933004,0.0009683904,0.0009421135,0.0013866719,0.0014389195],"domain_scores_gemma":[0.99167085,0.00575606,0.00014792471,0.001043982,0.0006879854,0.00069317286],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0067510577,0.00041742544,0.0009513206,0.0004042091,0.0007749722,0.00019549487,0.0005651628,0.00063180266,0.000046825706],"category_scores_gemma":[0.0027706595,0.00026154047,0.0001672416,0.0007272207,0.004127398,0.00014054237,0.0013422649,0.0027877283,0.000020945241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010860898,0.00020823673,0.82436943,0.0007366483,0.0023460484,0.0027172111,0.0014334,0.000005931824,0.019412307,0.008313847,0.010309384,0.11928667],"study_design_scores_gemma":[0.004655128,0.0014139008,0.98314166,0.00008676401,0.00020123538,0.00095803745,0.0012762087,0.00033416026,0.0031883284,0.0027870154,0.0016733004,0.00028427853],"about_ca_topic_score_codex":0.000587124,"about_ca_topic_score_gemma":0.00012989309,"teacher_disagreement_score":0.15877223,"about_ca_system_score_codex":0.0014088961,"about_ca_system_score_gemma":0.0016822485,"threshold_uncertainty_score":0.99998367},"labels":[],"label_agreement":null},{"id":"W2019668210","doi":"10.1016/j.bbmt.2006.12.020","title":"17: Impact of disease and mobilizing agents on initial and remobilization failure","year":2007,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Mobilization; Autologous stem-cell transplantation; Internal medicine; Multiple myeloma; Regimen; Transplantation; Apheresis; CD34; Population; Surgery; Gastroenterology; Oncology; Urology; Stem cell","score_opus":0.020013444907040358,"score_gpt":0.3341634404041282,"score_spread":0.31414999549708783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019668210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988093,0.0003513241,0.00025385618,0.00008626448,0.000012668256,0.00027060788,0.00006395594,0.000008762055,0.00014326848],"genre_scores_gemma":[0.9980646,0.0013492286,0.000303515,0.00003678776,0.00003012405,0.000002704499,0.00019503923,0.0000066184484,0.00001141705],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9994365,0.000033570876,0.00018070295,0.00016112695,0.00006901144,0.000119083525],"domain_scores_gemma":[0.99961185,0.0001033119,0.000058602942,0.00006558753,0.000048982143,0.000111651396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021864951,0.000083738654,0.00016974263,0.0001418041,0.000030675994,0.000002458745,0.000018529607,0.00009393742,0.000011447256],"category_scores_gemma":[0.00003052277,0.000065977256,0.000027840091,0.0000677082,0.00017931279,0.00004482205,0.000006057509,0.00007518188,1.4500039e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038460626,0.00012532249,0.26289108,0.0006800529,0.00015195091,0.0000365249,0.0006673666,0.0000036657286,0.72504705,0.00021614226,0.000031331805,0.0063034724],"study_design_scores_gemma":[0.005866582,0.0025026342,0.9246457,0.00026584606,0.0005394612,0.0001214118,0.00015103047,0.00014853205,0.065394744,0.0002306739,0.000018373094,0.00011498115],"about_ca_topic_score_codex":0.000060845858,"about_ca_topic_score_gemma":0.000025006852,"teacher_disagreement_score":0.66175467,"about_ca_system_score_codex":0.000009945064,"about_ca_system_score_gemma":0.00005310125,"threshold_uncertainty_score":0.26904744},"labels":[],"label_agreement":null},{"id":"W2019981271","doi":"10.1002/ajmg.a.33021","title":"Perspectives on<i>RUNX</i>genes: An update","year":2009,"lang":"en","type":"review","venue":"American Journal of Medical Genetics Part A","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Biology; RUNX1; Gene silencing; Gene; Genetics; Promoter; Core binding factor; Transcription factor; Molecular biology; Gene expression","score_opus":0.0503382508211701,"score_gpt":0.41604892462854765,"score_spread":0.36571067380737754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019981271","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046159961,0.9956456,0.00014747669,0.0024735532,0.0002733036,0.00042175432,0.000018237311,0.000024871293,0.0005336333],"genre_scores_gemma":[0.00006625947,0.9917442,0.0028520038,0.0016346156,0.003321563,0.000011805728,0.00003310489,0.00012297732,0.00021347345],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99234074,0.0008521948,0.0016690638,0.00058063347,0.0037991956,0.00075817906],"domain_scores_gemma":[0.9944007,0.00041033173,0.0013322292,0.00091012777,0.00051986467,0.002426757],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0022330494,0.0006308849,0.0038841134,0.0007068376,0.000079659854,0.000055591678,0.0013795701,0.00043868306,0.00074831577],"category_scores_gemma":[0.0009239687,0.00042522192,0.0010535228,0.0009269588,0.0011530286,0.00004861968,0.0001399702,0.0032698447,0.00020277673],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000120997494,0.0004632969,0.0000050962403,0.00057085184,0.0006102569,0.0018751966,0.00025259814,0.0000010230256,6.0005834e-7,0.000050251783,0.008680986,0.9873688],"study_design_scores_gemma":[0.0009054976,0.0072117723,0.000011121822,0.009332654,0.0012959959,0.0049243034,0.0010439727,0.000023749673,0.000001877427,0.000017642134,0.9748821,0.00034926215],"about_ca_topic_score_codex":0.000008356535,"about_ca_topic_score_gemma":0.0000018763618,"teacher_disagreement_score":0.9870196,"about_ca_system_score_codex":0.00060947455,"about_ca_system_score_gemma":0.0066057816,"threshold_uncertainty_score":0.99981993},"labels":[],"label_agreement":null},{"id":"W2021202703","doi":"10.1016/j.exphem.2006.04.020","title":"Retroviral integration site analysis identifies ICSBP as a collaborating tumor suppressor gene in NUP98-TOP1-induced leukemia","year":2006,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; Terry Fox Foundation; Michael Smith Health Research BC; Stem Cell Network","keywords":"Tumor suppressor gene; Suppressor; Leukemia; Gene; Biology; Cancer research; Virology; Genetics; Carcinogenesis","score_opus":0.014592567057366267,"score_gpt":0.3243123215755843,"score_spread":0.30971975451821804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021202703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941603,0.0013651224,0.000096679556,0.00034715486,0.00020326069,0.00065209944,0.0000148193385,0.000104626415,0.0030559688],"genre_scores_gemma":[0.99598485,0.0000046596,0.001683463,0.00028342268,0.00016269158,0.00020147322,0.00042453973,0.0000457227,0.0012091788],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99724764,0.00022165354,0.0007694711,0.00066093943,0.0004732784,0.0006270018],"domain_scores_gemma":[0.99888223,0.00012548594,0.00019703245,0.0005037632,0.00015219177,0.00013927369],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003005218,0.0003174878,0.0008870289,0.0008523387,0.00013825673,0.00007229104,0.00019600218,0.00023815989,0.0005420429],"category_scores_gemma":[0.00018004385,0.0003036407,0.00019674242,0.0017111861,0.00016820412,0.00024851732,0.00016888403,0.0004821141,0.00023502366],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005365445,0.00026029747,0.029477159,0.000035266952,0.00017184103,0.0012291507,0.0010681966,0.000023122515,0.96170527,0.0033478925,0.0021041974,0.000041093044],"study_design_scores_gemma":[0.0020352926,0.00033760114,0.0077464087,0.000043519438,0.000118074204,0.0004886463,0.002525246,0.00471053,0.9815714,0.000112513815,0.00006273813,0.00024804095],"about_ca_topic_score_codex":0.0040943013,"about_ca_topic_score_gemma":0.0008657357,"teacher_disagreement_score":0.021730749,"about_ca_system_score_codex":0.0017166076,"about_ca_system_score_gemma":0.00044256786,"threshold_uncertainty_score":0.9999416},"labels":[],"label_agreement":null},{"id":"W2021311274","doi":"10.1016/j.exphem.2014.07.033","title":"Senescence dependent genomic mutagenesis and the development of myeloid cancers","year":2014,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Myeloid; Biology; Haematopoiesis; Myeloid leukemia; Myelodysplastic syndromes; Cancer; Cohort; Dominance (genetics); Immunology; Cancer research; Genetics; Oncology; Internal medicine; Stem cell; Gene; Medicine; Bone marrow","score_opus":0.015918889028032894,"score_gpt":0.2989872612397796,"score_spread":0.2830683722117467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021311274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99180394,0.0042804223,0.00070630945,0.00041648516,0.00010716751,0.00042053146,0.0000010087639,0.000022538614,0.0022415814],"genre_scores_gemma":[0.9945102,0.000041604188,0.004810198,0.00024919855,0.00003339724,0.00009072207,0.000004202391,0.00001851678,0.00024199075],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988292,0.00010816648,0.00032654463,0.00025857385,0.00020797616,0.00026954844],"domain_scores_gemma":[0.9993661,0.00014062112,0.00008447527,0.00026568308,0.000034963636,0.00010817543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003552824,0.0001371814,0.00040726556,0.000070336544,0.00011144435,0.000005724764,0.00014466922,0.00007545248,0.00015180909],"category_scores_gemma":[0.00004105509,0.00009303363,0.000044091736,0.00007541134,0.0004991888,0.000024929623,0.00020221062,0.00011954474,0.000034257937],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035855684,0.0002744021,0.02882106,0.00041843226,0.00043637073,0.00007125005,0.016632482,0.00000868051,0.8807056,0.053370066,0.0005995792,0.015076495],"study_design_scores_gemma":[0.0038865707,0.000092097645,0.004070466,0.000030942778,0.00001763007,0.0005149074,0.0020695243,0.00044265873,0.9880179,0.000032829914,0.00072297064,0.00010151276],"about_ca_topic_score_codex":0.00012026102,"about_ca_topic_score_gemma":0.000027589544,"teacher_disagreement_score":0.10731228,"about_ca_system_score_codex":0.00031766813,"about_ca_system_score_gemma":0.0002943205,"threshold_uncertainty_score":0.37938017},"labels":[],"label_agreement":null},{"id":"W2021663709","doi":"10.1182/blood-2012-03-362608","title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","year":2012,"lang":"en","type":"review","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":575,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Children's Hospital of Eastern Ontario","funders":"University of Calgary","keywords":"Medicine; Childhood leukemia; Myeloid leukemia; Pediatrics; Disease; Intensive care medicine; Malignancy; Leukemia; Internal medicine; Lymphoblastic Leukemia","score_opus":0.05332780296015282,"score_gpt":0.3576143848579419,"score_spread":0.30428658189778907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021663709","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020792572,0.9766136,0.0000049805935,0.00017400498,0.00009710507,0.0014825717,0.00063048344,0.000026049882,0.00017865728],"genre_scores_gemma":[0.0011782569,0.9938265,0.0019198367,0.00008904361,0.00027090972,0.00034855556,0.002238464,0.00005597669,0.00007241885],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998242,0.00012439821,0.000555965,0.000493442,0.00030006346,0.00028410254],"domain_scores_gemma":[0.9990263,0.000064297245,0.00019786818,0.00045038134,0.00004487212,0.0002162874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022596348,0.00031491066,0.0009514756,0.00036023342,0.000033837263,0.000029607432,0.00028578888,0.0002403485,0.00012998232],"category_scores_gemma":[0.000016031458,0.0002702104,0.00010723318,0.00019770983,0.000086472595,0.0001954334,0.0004014855,0.00044693347,0.000012687359],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019687195,0.0005201991,0.030467851,0.0020916264,0.002239846,0.000036220612,0.00014119531,9.906162e-9,0.0000018638906,0.000024313036,0.00032338002,0.9641338],"study_design_scores_gemma":[0.010415243,0.00021971781,0.30159596,0.05317768,0.010399088,0.00044308786,0.00013940521,0.000009893609,0.000039874325,0.000022959617,0.6227169,0.00082021044],"about_ca_topic_score_codex":0.00047110475,"about_ca_topic_score_gemma":0.000013870875,"teacher_disagreement_score":0.9633136,"about_ca_system_score_codex":0.00038549895,"about_ca_system_score_gemma":0.00015378873,"threshold_uncertainty_score":0.999975},"labels":[],"label_agreement":null},{"id":"W2022970282","doi":"10.1371/journal.pone.0108694","title":"A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Teva Pharmaceutical Industries; Leukemia and Lymphoma Society","keywords":"Medicine; Adverse effect; Toxicity; Phases of clinical research; Myeloid leukemia; Somnolence; Gastroenterology; Internal medicine; Anesthesia","score_opus":0.03177334780687289,"score_gpt":0.29778722595521595,"score_spread":0.26601387814834304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022970282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99372745,0.000017818546,0.000007106733,0.00019013409,0.000023067249,0.005484488,0.00002713714,0.00009813618,0.00042466083],"genre_scores_gemma":[0.9954999,0.000044991702,0.0007878087,0.00029638744,0.000054423974,0.00029954102,0.00013426496,0.00010346389,0.0027792065],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962998,0.00028085927,0.00079163106,0.000673977,0.0012731152,0.0006805892],"domain_scores_gemma":[0.9976772,0.00016021653,0.0003103077,0.00091188616,0.0005543659,0.0003860232],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036205407,0.00041453663,0.0010700183,0.00046941146,0.00010315374,0.000026439866,0.00030936612,0.00018575546,0.0004235756],"category_scores_gemma":[0.0005157302,0.00028337227,0.000066428045,0.0007538447,0.00010652699,0.0001890408,0.000331625,0.0005973551,0.00009349806],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12736246,0.11332214,0.680469,0.0014097022,0.00453597,0.0009883762,0.01871268,0.0000095319365,0.039139204,0.0000050123094,0.00070368627,0.013342264],"study_design_scores_gemma":[0.40215653,0.21365124,0.3063939,0.006718193,0.0042610583,0.000043928903,0.001814502,0.010185084,0.053083222,0.000009602694,0.00037775014,0.0013049851],"about_ca_topic_score_codex":0.00055506214,"about_ca_topic_score_gemma":0.00041899612,"teacher_disagreement_score":0.37407508,"about_ca_system_score_codex":0.00082803256,"about_ca_system_score_gemma":0.0006318584,"threshold_uncertainty_score":0.99996185},"labels":[],"label_agreement":null},{"id":"W2023392477","doi":"10.1002/cncr.27484","title":"Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced‐dose chemotherapy on Children's Oncology Group trial A2971","year":2012,"lang":"en","type":"article","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Cytarabine; Myeloid leukemia; Internal medicine; Etoposide; Leukemia; Regimen; Cog; Chemotherapy regimen; Chemotherapy; Surgery; Gastroenterology; Oncology","score_opus":0.027690347493378134,"score_gpt":0.3242755471427766,"score_spread":0.2965851996493985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023392477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99415785,0.0003307655,0.00003173477,0.00083254784,0.00033641208,0.0026882896,0.00008047865,0.000110607616,0.0014313249],"genre_scores_gemma":[0.9948923,0.00021046674,0.00028242468,0.0010881142,0.001284683,0.0002094653,0.00026964844,0.00016717282,0.0015957028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959751,0.0004264063,0.00055514363,0.00070759765,0.0007980324,0.0015377133],"domain_scores_gemma":[0.9982097,0.00021958692,0.00029410858,0.00062069675,0.00014305662,0.0005128332],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012745771,0.0005102264,0.00119688,0.00043584555,0.00017701763,0.00004255758,0.000323298,0.00055362395,0.00059231225],"category_scores_gemma":[0.0002596657,0.00041976452,0.00016129491,0.00079717237,0.00028783237,0.00027070945,0.00009471938,0.001369564,0.000029471215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.089875594,0.002573992,0.8695424,0.000058212332,0.0029758487,0.00036465193,0.002304882,0.0008317711,0.009101357,0.0002978783,0.006300959,0.015772445],"study_design_scores_gemma":[0.11801191,0.0030168144,0.87436956,0.00047611125,0.00020134135,0.0003512796,0.00015943951,0.00046137194,0.001876724,0.00002422932,0.00042673884,0.00062450883],"about_ca_topic_score_codex":0.0033361102,"about_ca_topic_score_gemma":0.0002266615,"teacher_disagreement_score":0.028136306,"about_ca_system_score_codex":0.012748621,"about_ca_system_score_gemma":0.0023369351,"threshold_uncertainty_score":0.9998254},"labels":[],"label_agreement":null},{"id":"W2023728706","doi":"10.1126/science.1139851","title":"Modeling the Initiation and Progression of Human Acute Leukemia in Mice","year":2007,"lang":"en","type":"article","venue":"Science","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":344,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec; Hôpital de l'Enfant-Jésus; University of Toronto; University Health Network","funders":"","keywords":"Biology; Haematopoiesis; Leukemia; Myeloid; Myeloid leukemia; Cancer research; Lineage (genetic); Transplantation; Immunoglobulin heavy chain; Fusion gene; Immunology; Germline; Gene; Stem cell; Antibody; Genetics; Medicine","score_opus":0.036692253088992204,"score_gpt":0.38739757094252897,"score_spread":0.35070531785353676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023728706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99715924,0.000094448296,0.00064057676,0.00026689252,0.00001883513,0.00020543062,3.492694e-7,0.000008238787,0.0016059949],"genre_scores_gemma":[0.998781,0.000022594357,0.0010339725,0.00008930079,0.000023494707,0.000002865781,9.4323946e-7,0.0000033008753,0.000042514886],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990544,0.000013213299,0.00015004833,0.00015696308,0.0004152368,0.00021017913],"domain_scores_gemma":[0.9996256,0.00003773991,0.00003110075,0.00013548128,0.00011140831,0.000058658406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002100671,0.00004200062,0.000075054275,0.00018053739,0.00011990622,0.000013195638,0.00014716486,0.000028919207,0.000003506846],"category_scores_gemma":[0.00015515921,0.00002603678,0.000009374361,0.0006606761,0.0004191874,0.0001562108,0.000096278054,0.00017080939,0.0000017178434],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006016876,0.00001370922,0.008193965,0.000022775059,0.0000022888248,0.000019667776,0.0017608149,0.000098583165,0.97759986,0.00044459756,0.000010883793,0.011772712],"study_design_scores_gemma":[0.0020619337,0.00049321586,0.16359574,0.00042692982,0.000026324382,0.00011355821,0.002162575,0.38187802,0.44797483,0.0010718387,0.000044835488,0.0001502044],"about_ca_topic_score_codex":0.00008385202,"about_ca_topic_score_gemma":0.00003583701,"teacher_disagreement_score":0.529625,"about_ca_system_score_codex":0.00033682698,"about_ca_system_score_gemma":0.0004486141,"threshold_uncertainty_score":0.15445134},"labels":[],"label_agreement":null},{"id":"W2024119815","doi":"10.3324/haematol.2011.054361","title":"Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival","year":2012,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"Lady Tata Memorial Trust; European Hematology Association","keywords":"CEBPA; Germline mutation; Germline; Myeloid leukemia; Cancer research; Monosomy; Mutation; Chromosome 7 (human); Myelodysplastic syndromes; Biology; Genetics; Acute leukemia; Leukemia; Medicine; Immunology; Karyotype; Chromosome; Gene; Bone marrow","score_opus":0.029065012473407464,"score_gpt":0.28838651818110395,"score_spread":0.25932150570769646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024119815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99641097,0.0006660965,0.0008055788,0.00073714467,0.00006934867,0.0008008591,0.00002252708,0.00008743166,0.0004000681],"genre_scores_gemma":[0.9937243,0.00010529243,0.005675308,0.00013840853,0.00005351004,0.0000813418,0.00013872133,0.000029712823,0.00005344659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792004,0.00024991005,0.0004448513,0.0004152465,0.00038478052,0.0005851986],"domain_scores_gemma":[0.9985878,0.00068406865,0.00015558355,0.00019818169,0.00008857667,0.00028580858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064572995,0.0002726409,0.0006258802,0.00026870304,0.00014194584,0.000042681582,0.00007648379,0.00020960985,0.00007415264],"category_scores_gemma":[0.00065772276,0.00020448316,0.000031015963,0.00037532044,0.00033416835,0.00033986027,0.0000820807,0.00029464476,0.0000305633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0078030634,0.0011431563,0.9012378,0.0020869875,0.0005130663,0.02159268,0.004526492,0.00012726437,0.013339311,0.0018548366,0.00036817262,0.045407172],"study_design_scores_gemma":[0.0067462334,0.002198515,0.93766534,0.0003653646,0.00018633514,0.037207387,0.0025009254,0.010469597,0.001925759,0.00022972627,0.000047297017,0.00045753483],"about_ca_topic_score_codex":0.00011102908,"about_ca_topic_score_gemma":0.000053549644,"teacher_disagreement_score":0.044949636,"about_ca_system_score_codex":0.00010774716,"about_ca_system_score_gemma":0.00015713306,"threshold_uncertainty_score":0.83385813},"labels":[],"label_agreement":null},{"id":"W2024284445","doi":"10.1158/1538-7445.am2012-lb-214","title":"Abstract LB-214: Interim results from a randomized Phase 1-2 first-in-human (FIH) study of PK/PD guided escalating doses of SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent (HMA) in relapsed/refractory MDS and AML","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Decitabine; Medicine; Tolerability; Neutropenia; Adverse effect; Pharmacology; Phases of clinical research; Oncology; Internal medicine; Hypomethylating agent; Lethargy; Clinical trial; Toxicity; Chemistry","score_opus":0.1592843577178699,"score_gpt":0.4433153469677062,"score_spread":0.2840309892498363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024284445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99351877,0.002021274,0.000017359112,0.00018011563,0.00013103518,0.0031271055,0.00018766623,0.000022026836,0.0007946226],"genre_scores_gemma":[0.99792606,0.0002673484,0.000559762,0.000021031668,0.00039614044,0.00034912664,0.00010775455,0.0000739452,0.00029883924],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939894,0.0009239308,0.0019575846,0.0007379225,0.0014263702,0.00096475525],"domain_scores_gemma":[0.9942907,0.0034955603,0.0005152249,0.0007407935,0.00059766526,0.00036003735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008489789,0.00032801382,0.0014141935,0.0012304496,0.00017106201,0.000051191157,0.00032455777,0.0002525583,0.0004619133],"category_scores_gemma":[0.0053712553,0.00028919266,0.00012825914,0.000946473,0.00046352056,0.00026856826,0.00037170853,0.0015678845,0.0000044136755],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05508871,0.0027328413,0.006763685,0.00042406502,0.00026229175,0.00017325359,0.022900391,0.00015411618,0.9044523,0.000009656671,0.00051482866,0.0065238285],"study_design_scores_gemma":[0.7188078,0.004696455,0.05704071,0.002618457,0.00018971476,0.000059819336,0.015432766,0.011669562,0.18827751,0.00007538124,0.00034731688,0.00078451977],"about_ca_topic_score_codex":0.024038726,"about_ca_topic_score_gemma":0.007611728,"teacher_disagreement_score":0.71617484,"about_ca_system_score_codex":0.0013629433,"about_ca_system_score_gemma":0.0005547657,"threshold_uncertainty_score":0.999956},"labels":[],"label_agreement":null},{"id":"W2024483006","doi":"10.3324/haematol.2014.121079","title":"The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features","year":2015,"lang":"en","type":"letter","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Dysplasia; Medicine; Myeloid; Bone marrow; Myeloid leukemia; Chromosomal translocation; Gastroenterology; Population; Megakaryocyte; CEBPA; Internal medicine; Pathology; Biology; Gene; Genetics; Haematopoiesis","score_opus":0.06178628481314611,"score_gpt":0.31755517810562645,"score_spread":0.2557688932924803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024483006","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11191013,0.027429063,0.000007170916,0.8313161,0.0009962419,0.0067274505,0.0006930764,0.0012650054,0.019655757],"genre_scores_gemma":[0.044299923,0.027081635,0.0061602765,0.7072727,0.0059636775,0.0017998,0.0124927545,0.0009747148,0.19395454],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933452,0.00087289035,0.0010017398,0.0016249196,0.0014625419,0.0016927201],"domain_scores_gemma":[0.9956511,0.001134786,0.0005449873,0.001561494,0.00066595955,0.00044164545],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0011130308,0.0010978078,0.0020481192,0.00028446986,0.0008965042,0.0003113146,0.0011117844,0.0037117363,0.0005818981],"category_scores_gemma":[0.002692539,0.0005493625,0.0003742031,0.00064005767,0.0009766446,0.0001425186,0.0010940853,0.0066329935,0.00030858384],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012448564,0.000030360367,0.0006198836,0.00047447518,0.0010827394,0.034989722,0.0003511799,2.9574997e-7,0.00014043004,0.000039957034,0.9576828,0.0033433232],"study_design_scores_gemma":[0.003135239,0.0010207077,0.0011427428,0.0010864743,0.0006478086,0.027218506,0.00043244415,0.000033571603,0.00012474632,0.00066278747,0.9636216,0.00087335537],"about_ca_topic_score_codex":0.000072510484,"about_ca_topic_score_gemma":0.000013733243,"teacher_disagreement_score":0.17429878,"about_ca_system_score_codex":0.001016198,"about_ca_system_score_gemma":0.0011917748,"threshold_uncertainty_score":0.9996958},"labels":[],"label_agreement":null},{"id":"W2024614395","doi":"10.1182/blood-2010-04-278317","title":"Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Toronto","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; European Society for Medical Oncology; National Comprehensive Cancer Network","keywords":"Internal medicine; Medicine; Gastroenterology; Myeloid leukemia; Cytogenetics; Transplantation; Hematopoietic stem cell transplantation; Oncology; Leukemia; Hazard ratio; Human leukocyte antigen; Myelodysplastic syndromes; Immunology; Confidence interval; Chromosome; Biology; Bone marrow; Antigen; Genetics","score_opus":0.02030462989051362,"score_gpt":0.2896976178591662,"score_spread":0.2693929879686526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024614395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555105,0.00015576271,0.00035803625,0.00084138993,0.00014749294,0.0019226578,0.0001009738,0.00017402282,0.0007486375],"genre_scores_gemma":[0.9788024,0.0015291662,0.015335243,0.00019777211,0.00017489336,0.000642311,0.0004492731,0.00014532876,0.0027236126],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99709857,0.000076756936,0.00063637004,0.00071555364,0.00059106713,0.00088169635],"domain_scores_gemma":[0.99789953,0.0006664648,0.00016172808,0.0006176211,0.0002530335,0.00040160344],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006004112,0.00043296083,0.00080174406,0.00036256484,0.0002126704,0.00006858209,0.00027252405,0.00048160687,0.00052524894],"category_scores_gemma":[0.00011506416,0.00032609896,0.0001260261,0.00088522915,0.00013034699,0.00018114694,0.0000749386,0.00083049445,0.000092261515],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033751756,0.0012761021,0.7326101,0.0018401062,0.0011382173,0.0019669659,0.0029417358,0.0012736395,0.22065595,0.000020840176,0.002144075,0.00038049082],"study_design_scores_gemma":[0.06290395,0.0020914322,0.09890776,0.0016106155,0.003104005,0.00094125536,0.0005106462,0.010227406,0.8108107,0.00007913186,0.0075360523,0.0012770656],"about_ca_topic_score_codex":0.0005267763,"about_ca_topic_score_gemma":0.00576628,"teacher_disagreement_score":0.63370234,"about_ca_system_score_codex":0.0006065149,"about_ca_system_score_gemma":0.0008845852,"threshold_uncertainty_score":0.9999191},"labels":[],"label_agreement":null},{"id":"W2024797586","doi":"10.1016/j.bbmt.2013.08.013","title":"Providing Personalized Prognostic Information for Adult Leukemia Survivors","year":2013,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Takeda Oncology; Health Resources and Services Administration; National Institutes of Health; Therakos; Sigma-Tau Pharmaceuticals; Kiadis Pharma; Genentech; CellGenix; Medical College of Wisconsin; Tarix Pharmaceuticals; StemCyte; Blue Cross and Blue Shield Association; Swedish Orphan Biovitrum; Amgen; Otsuka America Pharmaceutical; Teva Pharmaceutical Industries; WellPoint; HistoGenetics; Otsuka America; U.S. Navy; Osiris Therapeutics; Celgene; Ariad Pharmaceuticals; GlaxoSmithKline; U.S. Department of Defense; Sanofi; Be The Match Foundation","keywords":"Medicine; Myeloid leukemia; Internal medicine; Transplantation; Hematopoietic stem cell transplantation; Leukemia; Disease; Oncology; Chronic leukemia; Graft-versus-host disease; Immunology; Acute leukemia","score_opus":0.011520137724102588,"score_gpt":0.25661262729036927,"score_spread":0.24509248956626667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024797586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99402887,0.00012577816,0.0034588904,0.0006216086,0.00004285364,0.0013240434,0.000060582443,0.000032555712,0.00030480154],"genre_scores_gemma":[0.9946748,0.0004932189,0.0035968807,0.00021092505,0.00003746417,0.0002192442,0.0006854928,0.0000073362485,0.00007464681],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99934924,0.000035876987,0.00024119308,0.00012059615,0.00007637263,0.0001767265],"domain_scores_gemma":[0.9993236,0.00017650423,0.00008102534,0.00006200353,0.00029093924,0.000065920925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015253022,0.00009362874,0.0001908071,0.00012222663,0.00005497713,0.000009940042,0.000040071627,0.00013035993,0.000024248357],"category_scores_gemma":[0.00013531331,0.00007556081,0.00004508179,0.00007191662,0.00012217849,0.0002221248,0.0000047547537,0.00008090777,0.000005513196],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013718458,0.00007940954,0.10068106,0.0042603854,0.00030110974,0.0000032812766,0.0032601913,0.0000019069574,0.85653234,0.0054590837,0.0004069515,0.027642444],"study_design_scores_gemma":[0.07055973,0.009914078,0.22860628,0.0015793192,0.004353681,0.0012098469,0.0050246324,0.011898307,0.6569025,0.00475398,0.0038155126,0.0013821478],"about_ca_topic_score_codex":0.00040736274,"about_ca_topic_score_gemma":0.000024312809,"teacher_disagreement_score":0.19962986,"about_ca_system_score_codex":0.000022077294,"about_ca_system_score_gemma":0.00014186867,"threshold_uncertainty_score":0.30812806},"labels":[],"label_agreement":null},{"id":"W2025338891","doi":"10.1182/blood-2013-01-466706","title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":633,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Vancouver General Hospital","funders":"National Cancer Institute","keywords":"Gemtuzumab ozogamicin; Cytarabine; Medicine; Daunorubicin; Gastroenterology; Internal medicine; Randomization; Myeloid leukemia; Induction chemotherapy; Surgery; Randomized controlled trial; Leukemia; Chemotherapy; CD33","score_opus":0.01245108116759154,"score_gpt":0.27324175031770004,"score_spread":0.2607906691501085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025338891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976166,0.00004361597,0.0000021006701,0.00006587112,0.000020051091,0.0021057918,0.000005678402,0.000027294382,0.00011298567],"genre_scores_gemma":[0.99942863,0.0000815773,0.00014689843,0.000036210135,0.000040249117,0.00010699676,0.000034911853,0.000029751649,0.00009476729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987311,0.00007003326,0.00029187923,0.00030095645,0.0003590623,0.0002469884],"domain_scores_gemma":[0.9992665,0.000025355677,0.00010854714,0.00028675416,0.00022289495,0.00008995048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011130122,0.000159291,0.00030739082,0.00032416717,0.0000490696,0.000020545795,0.00007154774,0.0000831551,0.0000542424],"category_scores_gemma":[0.000029181354,0.000120347126,0.00001911307,0.00033987773,0.000060464663,0.00035650912,0.000047877023,0.00027108515,0.000009067797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034657733,0.011703493,0.69286394,0.00008982953,0.00076913845,0.000098219214,0.0046857833,0.000004474945,0.27189088,0.0000061221817,0.000031868818,0.014390473],"study_design_scores_gemma":[0.078969516,0.0059836437,0.8798008,0.0000615039,0.00011944163,0.000048986094,0.0010006592,0.000043400076,0.03383509,0.0000069202724,0.000004132793,0.00012593277],"about_ca_topic_score_codex":0.0009021282,"about_ca_topic_score_gemma":0.000021767106,"teacher_disagreement_score":0.2380558,"about_ca_system_score_codex":0.00022516894,"about_ca_system_score_gemma":0.00016800276,"threshold_uncertainty_score":0.49076134},"labels":[],"label_agreement":null},{"id":"W2025391163","doi":"10.1111/j.1365-2141.2009.07697.x","title":"Mutations of polycomb‐associated gene <i>ASXL1</i> in myelodysplastic syndromes and chronic myelomonocytic leukaemia","year":2009,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":556,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Myelodysplastic syndromes; Haematopoiesis; Myeloid; Chronic myelomonocytic leukemia; Biology; Epigenetics; Cancer research; Gene; Comparative genomic hybridization; Mutation; Genetics; Genome; Immunology; Stem cell; Bone marrow","score_opus":0.014716156334597125,"score_gpt":0.2851794044656786,"score_spread":0.27046324813108147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025391163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890302,0.008661968,0.00015397025,0.0015246626,0.00009667638,0.00022623716,0.000012564761,0.00001399686,0.000279748],"genre_scores_gemma":[0.996962,0.0017884218,0.0008339847,0.00021592437,0.0000506362,0.0000029994512,0.000013354044,0.00002083782,0.00011180477],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.997878,0.00018373156,0.00097111403,0.0001944092,0.00033252983,0.0004401881],"domain_scores_gemma":[0.9985558,0.00034979812,0.00044188567,0.00013936705,0.0003007569,0.00021244174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005130639,0.00015313645,0.0010629247,0.0005131112,0.000058535166,0.000021831347,0.00017831563,0.00021505315,0.0000638581],"category_scores_gemma":[0.0010649704,0.00016826444,0.00012112527,0.00046366564,0.00028415042,0.00015470621,0.000043356576,0.0007302713,0.000006099793],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021771463,0.0030497278,0.059940305,0.0016141975,0.0020308318,0.66345274,0.001858513,0.00056892354,0.12791926,0.002551991,0.015231361,0.119605005],"study_design_scores_gemma":[0.011074738,0.002475328,0.19624354,0.0019371194,0.00030532407,0.7779471,0.000252522,0.0009918751,0.006300251,0.0020432253,0.00016782258,0.0002611413],"about_ca_topic_score_codex":0.0001211525,"about_ca_topic_score_gemma":0.00014506854,"teacher_disagreement_score":0.13630323,"about_ca_system_score_codex":0.00053831766,"about_ca_system_score_gemma":0.0010839739,"threshold_uncertainty_score":0.6861625},"labels":[],"label_agreement":null},{"id":"W2025498967","doi":"10.1016/j.hoc.2009.11.009","title":"Acute Leukemias in Children with Down Syndrome","year":2010,"lang":"en","type":"review","venue":"Hematology/Oncology Clinics of North America","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Down syndrome; Leukemia; Myeloid leukemia; Medicine; Aneuploidy; clone (Java method); Myeloid; Preleukemia; Immunology; Cancer research; Gene; Biology; Genetics; Psychiatry","score_opus":0.03019437164985942,"score_gpt":0.38016792280556727,"score_spread":0.34997355115570783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025498967","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.043016024,0.9502163,0.0000341628,0.00035495232,0.0002985957,0.004371473,0.00028134216,0.00014750268,0.0012796627],"genre_scores_gemma":[0.00058981933,0.9892023,0.007000376,0.00057145563,0.00012114782,0.0005824407,0.0013648425,0.00022138181,0.00034622115],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99290776,0.00065777573,0.00292305,0.0015282294,0.00059322995,0.0013899438],"domain_scores_gemma":[0.992599,0.0020509216,0.0023791818,0.0020410512,0.00034307898,0.00058676593],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0007251952,0.0011013105,0.010468883,0.0013932971,0.00009029241,0.000010124266,0.0012608785,0.0025947182,0.00022079977],"category_scores_gemma":[0.0007545126,0.0008176986,0.0009583984,0.0019822866,0.0026428855,0.000097593394,0.00059067615,0.0071060522,0.00061830896],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040671974,0.0008509123,0.08631514,0.0041808644,0.0028457914,0.0055100364,0.00004986129,9.958889e-7,1.229546e-7,0.000040708237,0.0016315304,0.8981673],"study_design_scores_gemma":[0.0041250754,0.0043935697,0.006895082,0.0034624639,0.004490015,0.054834038,0.000018980456,0.000011336142,6.1483127e-7,0.000015023109,0.9209723,0.00078151625],"about_ca_topic_score_codex":0.00009184496,"about_ca_topic_score_gemma":0.00027819996,"teacher_disagreement_score":0.9193407,"about_ca_system_score_codex":0.0008537286,"about_ca_system_score_gemma":0.0109892255,"threshold_uncertainty_score":0.9994274},"labels":[],"label_agreement":null},{"id":"W2025800129","doi":"10.1016/j.bbadis.2004.05.008","title":"Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas","year":2004,"lang":"en","type":"article","venue":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Transfection; Cell culture; Null cell; Cell; Biotinylation; Osteosarcoma; Biology; Cell biology; Membrane protein; Molecular biology; Cancer research; Chemistry; Biochemistry; Membrane; Genetics","score_opus":0.028956246571602787,"score_gpt":0.3055852377195142,"score_spread":0.2766289911479114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025800129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283814,0.00020519337,0.000078178084,0.0053927996,0.00006802123,0.00066925137,0.0006208769,0.000041788462,0.00008573229],"genre_scores_gemma":[0.9979065,0.00010789382,0.00047517836,0.00040289853,0.00006004392,0.000078767865,0.00085440103,0.00005804155,0.000056272],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968538,0.0002130471,0.0006342833,0.00077519054,0.0010188606,0.0005048011],"domain_scores_gemma":[0.99757457,0.00007823172,0.00034706361,0.001129158,0.0003501601,0.00052079506],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029147023,0.00037211526,0.0008918618,0.0012489894,0.00005068345,0.000028219598,0.000393014,0.00014415823,0.00007152606],"category_scores_gemma":[0.00032677868,0.00036229444,0.00069402857,0.0024863728,0.00037856845,0.00013738836,0.00022013928,0.00031745114,0.000008489368],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001772643,0.00066141353,0.00017792333,0.0002286244,0.0017857961,0.00012311884,0.00023076715,0.00015351977,0.9942624,0.00032231552,0.000073276875,0.0002081818],"study_design_scores_gemma":[0.0025261685,0.00028227427,0.11182461,0.00018956976,0.0022823876,0.000002766512,0.000083913365,0.0003359632,0.8818914,0.00030283275,0.000005566569,0.0002725368],"about_ca_topic_score_codex":0.00036885703,"about_ca_topic_score_gemma":0.000042688185,"teacher_disagreement_score":0.112371005,"about_ca_system_score_codex":0.0003220747,"about_ca_system_score_gemma":0.0010226308,"threshold_uncertainty_score":0.9998829},"labels":[],"label_agreement":null},{"id":"W2026212356","doi":"10.1111/j.1749-6632.2009.04965.x","title":"The Role of PLZF in Human Myeloid Development","year":2009,"lang":"en","type":"article","venue":"Annals of the New York Academy of Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Haematopoiesis; Transcription factor; Myeloid cells; Progenitor cell; Biology; Cell biology; Progenitor; Myeloid; Key (lock); Immunology; Computational biology; Stem cell; Genetics; Gene","score_opus":0.07986197836960261,"score_gpt":0.3741355025566525,"score_spread":0.2942735241870499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026212356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95086,0.0031569712,0.0000012616351,0.039599728,0.000018095536,0.00026556215,9.4358944e-7,0.00000636656,0.0060910727],"genre_scores_gemma":[0.99698853,0.0002702372,0.0005964623,0.00094043417,0.000050602262,0.0000021562566,1.7729009e-7,0.0000037415923,0.0011476591],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979434,0.00006950454,0.0005140815,0.00019216661,0.00092820876,0.00035262958],"domain_scores_gemma":[0.99929285,0.00015113021,0.00027007723,0.0001411886,0.00005464281,0.00009008301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021159714,0.00010036877,0.000273281,0.00015830668,0.00020002844,0.000009524176,0.0011590883,0.00008954212,0.000015808306],"category_scores_gemma":[0.0002442285,0.000051935574,0.000089827554,0.00092956977,0.00092027476,0.0000839379,0.00014111969,0.00031629362,0.0000030530814],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002848631,0.00025651604,0.028517535,0.000064215026,0.00007783209,7.678764e-7,0.005843102,0.00014167388,0.59186643,0.02168681,0.029436339,0.32182392],"study_design_scores_gemma":[0.00030561362,0.00019518434,0.16686037,0.00022527378,0.0000058090654,0.0000033406857,0.00063311233,0.00006422371,0.791849,0.018760996,0.021037726,0.00005931234],"about_ca_topic_score_codex":0.00010930518,"about_ca_topic_score_gemma":0.00000895213,"teacher_disagreement_score":0.32176462,"about_ca_system_score_codex":0.000027072681,"about_ca_system_score_gemma":0.00048290615,"threshold_uncertainty_score":0.33907908},"labels":[],"label_agreement":null},{"id":"W2026255716","doi":"10.1007/s00277-010-1059-1","title":"Aggressive LGL leukaemia presentation in old age","year":2010,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Hematology; Presentation (obstetrics); Medicine; Pediatrics; Internal medicine; Medical emergency; Emergency medicine; Surgery","score_opus":0.05435863746157886,"score_gpt":0.3956210204230223,"score_spread":0.3412623829614434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026255716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853862,0.0002544844,0.00001338193,0.0067598294,0.00012002738,0.00030469385,0.0000042429233,0.000022139733,0.0071350345],"genre_scores_gemma":[0.99766904,0.00015773087,0.00062333175,0.00081121345,0.000058921574,0.000030357627,0.000032239503,0.000016357655,0.00060081173],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988316,0.00006381228,0.00033597898,0.00022117948,0.00020833852,0.00033907327],"domain_scores_gemma":[0.9990024,0.00022333527,0.00017344955,0.00035704862,0.00013512156,0.00010865506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023555124,0.00010452506,0.00041248454,0.00028739928,0.000019640973,0.000004512194,0.00014935798,0.0002217863,0.00030500448],"category_scores_gemma":[0.0009699103,0.00009146352,0.00007050692,0.00023228652,0.00022674377,0.000072493305,0.00007498026,0.00054262346,0.00006649354],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014668609,0.00076932064,0.3795862,0.00088580005,0.00022797643,0.009054412,0.002123205,0.000008048643,0.45736253,0.055208623,0.07948617,0.013820868],"study_design_scores_gemma":[0.003422424,0.0004412256,0.14645834,0.00022714438,0.000026934535,0.0019202636,0.0003377226,0.00041174688,0.83689594,0.0060139173,0.0036248744,0.0002194707],"about_ca_topic_score_codex":0.00028848168,"about_ca_topic_score_gemma":0.00018854556,"teacher_disagreement_score":0.37953338,"about_ca_system_score_codex":0.000010560733,"about_ca_system_score_gemma":0.0001839368,"threshold_uncertainty_score":0.3729774},"labels":[],"label_agreement":null},{"id":"W2026509109","doi":"10.1182/blood-2007-02-075804","title":"AML1/ETO, a promiscuous fusion oncoprotein","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Cancer research","score_opus":0.015930705848493286,"score_gpt":0.2963118403653234,"score_spread":0.2803811345168301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026509109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.950751,0.00030711072,0.00028227124,0.0009249419,0.00005205127,0.0008447967,0.0000025129411,0.00014778781,0.046687502],"genre_scores_gemma":[0.9834562,0.00003449487,0.005959501,0.00045526546,0.0005920284,0.00003114646,0.000017277662,0.000042252977,0.009411856],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849653,0.00002595627,0.00023049656,0.0002805863,0.00047498016,0.0004914199],"domain_scores_gemma":[0.9990826,0.000052953626,0.00004427134,0.00042712703,0.000110741516,0.00028229615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069636054,0.00013266751,0.00022479483,0.00015608233,0.000076845,0.000014761623,0.00013079279,0.00014434612,0.00042075475],"category_scores_gemma":[0.0002408105,0.000104784995,0.00008029957,0.000313145,0.0000664381,0.00004362189,0.00010367796,0.0003974526,0.0005777829],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010348046,0.002255122,0.019816723,0.00029204472,0.00021366523,0.0039840746,0.0007386337,3.8380463e-7,0.87132895,0.00041683356,0.00832539,0.09159337],"study_design_scores_gemma":[0.020208647,0.0019257179,0.08214258,0.0002891872,0.0002569995,0.0015687307,0.00031080062,0.00007435726,0.8124657,0.0002474964,0.0800938,0.00041597435],"about_ca_topic_score_codex":0.00014444657,"about_ca_topic_score_gemma":0.000035805297,"teacher_disagreement_score":0.0911774,"about_ca_system_score_codex":0.000144327,"about_ca_system_score_gemma":0.00029053842,"threshold_uncertainty_score":0.74264234},"labels":[],"label_agreement":null},{"id":"W2026749772","doi":"10.1182/blood-2013-09-527317","title":"Acute myeloid leukemia relapse first presenting in the cerebrospinal fluid","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Acute myelomonocytic leukemia; Medicine; Myeloid leukemia; Headaches; Cerebrospinal fluid; Leukemia; Chemotherapy; Internal medicine; Chemotherapy regimen; Oncology; Surgery","score_opus":0.01466600944539647,"score_gpt":0.27042637859906504,"score_spread":0.25576036915366857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026749772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97438383,0.00016214028,0.00006851316,0.003916765,0.000080723985,0.0005806811,0.000004707086,0.00008142974,0.020721227],"genre_scores_gemma":[0.99504423,0.00010307448,0.001020553,0.0009023962,0.0006432023,0.00008616473,0.000027765938,0.00004495897,0.0021276374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977781,0.000162103,0.0003543503,0.00041048633,0.0006463277,0.00064863317],"domain_scores_gemma":[0.9985698,0.00029732272,0.00007263899,0.00082680746,0.00008247238,0.00015096138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009992365,0.00021022432,0.0003208126,0.0001641883,0.00019717198,0.000065977685,0.0004959872,0.00016131756,0.000101760386],"category_scores_gemma":[0.00059339474,0.00014495311,0.00012420859,0.0005077604,0.00013082646,0.000119807824,0.00019280161,0.00078680186,0.00031550773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015445952,0.0030634673,0.71466774,0.0013299484,0.0014287052,0.003890107,0.009790767,0.000103717066,0.13510384,0.008001206,0.11103267,0.010043214],"study_design_scores_gemma":[0.039593097,0.0021458848,0.6749687,0.0007202838,0.0013225878,0.0041746506,0.0010377672,0.00918047,0.05843436,0.0010371986,0.2062504,0.0011345783],"about_ca_topic_score_codex":0.00023369247,"about_ca_topic_score_gemma":0.00009503484,"teacher_disagreement_score":0.09521772,"about_ca_system_score_codex":0.00020816992,"about_ca_system_score_gemma":0.00027795447,"threshold_uncertainty_score":0.59110165},"labels":[],"label_agreement":null},{"id":"W2027056052","doi":"10.1182/blood-2004-06-2161","title":"Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University College London; Medical Research Council; Kay Kendall Leukaemia Fund; University of Oxford; York University","keywords":"Myeloid leukemia; Medicine; Chemotherapy regimen; Oncology; Internal medicine; Chemotherapy","score_opus":0.013370217289115669,"score_gpt":0.278721538104365,"score_spread":0.2653513208152493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027056052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99801445,0.00039361464,0.0002563752,0.00025163408,0.000039824477,0.00065211044,0.000018042032,0.000037085574,0.00033688493],"genre_scores_gemma":[0.9901789,0.0018119491,0.0075601735,0.00007395058,0.00008604422,0.00004238635,0.000011110019,0.00003228716,0.00020319158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872994,0.00004548264,0.0003595557,0.0002913593,0.0002911172,0.00028251528],"domain_scores_gemma":[0.999378,0.00005636281,0.000096704796,0.00031239004,0.000034007357,0.00012251499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021134366,0.00017024482,0.00039737113,0.00018712967,0.000038668324,0.000011066062,0.00007477176,0.00013125778,0.000016977534],"category_scores_gemma":[0.0000646084,0.000139158,0.00010215481,0.00024892046,0.000042111264,0.000061973216,0.000030426683,0.00017227554,0.000008183071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022506587,0.0005749157,0.9392476,0.00005873219,0.0012864193,0.00029821126,0.0017937614,0.000090023954,0.05161835,0.000027334774,0.0000077223285,0.0047718366],"study_design_scores_gemma":[0.028979255,0.0009348304,0.94923455,0.000069395275,0.00083992566,0.00007353008,0.000036256915,0.00021574642,0.019285085,0.00015768087,0.0000610947,0.00011264016],"about_ca_topic_score_codex":0.0010802726,"about_ca_topic_score_gemma":0.000059264923,"teacher_disagreement_score":0.032333262,"about_ca_system_score_codex":0.00067274686,"about_ca_system_score_gemma":0.00042634388,"threshold_uncertainty_score":0.56746984},"labels":[],"label_agreement":null},{"id":"W2027093999","doi":"10.1080/1042819021000016087","title":"Allogeneic Bone Marrow Transplantation in the Management of Chronic Neutrophilic Leukemia","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Leukocytosis; Leukemia; Myeloproliferative Disorders; Disease; Chronic myelogenous leukemia; Bone marrow; Stage (stratigraphy); Transplantation; Immunology; Internal medicine; Oncology; Pathology; Biology","score_opus":0.015940342000825072,"score_gpt":0.24849738086645873,"score_spread":0.23255703886563367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027093999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733579,0.008669571,0.000099129255,0.00084691064,0.00021661942,0.0017632167,0.00004697535,0.00015532925,0.014844318],"genre_scores_gemma":[0.97463226,0.019873045,0.0007629528,0.0011920031,0.00036989173,0.0003533058,0.000155102,0.00014332635,0.0025181132],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99401015,0.0003628271,0.001423924,0.0012734744,0.0014295323,0.001500111],"domain_scores_gemma":[0.9972106,0.00032685592,0.00037124008,0.0015054385,0.00015351472,0.00043235868],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000977919,0.0008660361,0.001199646,0.00074643124,0.0003241122,0.000107120075,0.00085336016,0.0006012619,0.00030059222],"category_scores_gemma":[0.000031506763,0.0006944081,0.00040267908,0.0016844007,0.0006745945,0.00037277868,0.00020731342,0.00041867152,0.00017179245],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003631751,0.0013607333,0.009557577,0.008849452,0.0015796493,0.01711176,0.008343017,0.001047735,0.05424864,0.008680629,0.012618027,0.87297106],"study_design_scores_gemma":[0.122770004,0.0038511257,0.6611235,0.0040460727,0.0030402504,0.02333733,0.004353946,0.08263628,0.026870817,0.0013642233,0.06298407,0.003622352],"about_ca_topic_score_codex":0.0012006393,"about_ca_topic_score_gemma":0.0001599145,"teacher_disagreement_score":0.8693487,"about_ca_system_score_codex":0.015624779,"about_ca_system_score_gemma":0.0017798274,"threshold_uncertainty_score":0.9995507},"labels":[],"label_agreement":null},{"id":"W2027130911","doi":"10.1038/bmt.2008.182","title":"Pediatric standard-risk AML with fully matched sibling donors: to transplant in first CR or not?","year":2008,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Sibling; Confidence interval; Internal medicine; Pediatrics; Transplantation; Hematopoietic stem cell transplantation; Hematopoietic cell; Surgery; Haematopoiesis; Stem cell","score_opus":0.021137812010986974,"score_gpt":0.26497167966141877,"score_spread":0.2438338676504318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027130911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98417395,0.000087395405,0.0120607475,0.0014812454,0.00005903968,0.0012800632,0.00034118106,0.00014520013,0.0003711829],"genre_scores_gemma":[0.9836778,0.006386519,0.0084323175,0.00032708,0.00023602878,0.00014657903,0.00026615494,0.00007641151,0.00045112567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722666,0.0001032784,0.0005859948,0.0005669042,0.0008801449,0.00063704146],"domain_scores_gemma":[0.9988149,0.000264228,0.00010488451,0.00032424816,0.00015150181,0.00034024325],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005131543,0.00032783474,0.0005700997,0.00086270855,0.0002073774,0.00003257972,0.00015151531,0.00018082892,0.00017293493],"category_scores_gemma":[0.000050395647,0.0002540222,0.000087004875,0.0013043006,0.00006842603,0.00023776453,0.000009113124,0.00055486505,0.00008702264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16174187,0.0005344622,0.75195956,0.0035584501,0.00019629874,0.022536833,0.03206829,0.0035340479,0.019462537,0.000039823957,0.0017578818,0.0026099267],"study_design_scores_gemma":[0.03453463,0.004171678,0.91713357,0.0010519156,0.0009820363,0.005872179,0.00087946776,0.0010655746,0.031851415,0.000020325235,0.0012129262,0.0012242722],"about_ca_topic_score_codex":0.001053515,"about_ca_topic_score_gemma":0.005431506,"teacher_disagreement_score":0.16517399,"about_ca_system_score_codex":0.00039268818,"about_ca_system_score_gemma":0.00071113784,"threshold_uncertainty_score":0.9999912},"labels":[],"label_agreement":null},{"id":"W2027313932","doi":"10.1038/bmt.2015.59","title":"Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission","year":2015,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Otsuka Pharmaceutical","keywords":"Medicine; Cumulative incidence; Internal medicine; Transplantation; Myeloid leukemia; Chemotherapy; Oncology; Hematopoietic stem cell transplantation; Leukemia; Hematopoietic cell; Incidence (geometry); Comorbidity; Haematopoiesis; Stem cell; Biology","score_opus":0.018290031119443377,"score_gpt":0.26910240573938493,"score_spread":0.25081237461994155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027313932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936501,0.000089900095,0.0019466602,0.00088224217,0.00007639645,0.0018308434,0.00044082393,0.00008868681,0.0009943879],"genre_scores_gemma":[0.9897989,0.00022205725,0.0056047994,0.00048814967,0.000035261608,0.00020317775,0.0023019293,0.00008066196,0.0012650435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760664,0.000080748374,0.00055905373,0.00049587357,0.000586982,0.00067072135],"domain_scores_gemma":[0.9986363,0.00024789752,0.00012177694,0.00031461276,0.00025147665,0.00042792023],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004425189,0.0003573415,0.0006283097,0.00031297788,0.00012135584,0.000034664838,0.00017552872,0.000228244,0.000080814105],"category_scores_gemma":[0.000029563063,0.00026033568,0.000108722656,0.00032045803,0.00007739725,0.00023906837,0.000009370869,0.0003872692,0.00002655429],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07678566,0.0011357054,0.85820454,0.0057139415,0.0003477906,0.0027593041,0.011257006,0.00085878314,0.03909988,0.000058596073,0.0026152816,0.0011634921],"study_design_scores_gemma":[0.13695055,0.0071434802,0.7582561,0.0024742389,0.0019620813,0.0027205735,0.0016638284,0.0029767316,0.08039221,0.000175005,0.003421562,0.0018636602],"about_ca_topic_score_codex":0.00039055845,"about_ca_topic_score_gemma":0.0011388467,"teacher_disagreement_score":0.09994849,"about_ca_system_score_codex":0.0015933823,"about_ca_system_score_gemma":0.0018878748,"threshold_uncertainty_score":0.99998486},"labels":[],"label_agreement":null},{"id":"W2027382887","doi":"10.1016/j.humpath.2013.03.007","title":"CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia","year":2013,"lang":"en","type":"article","venue":"Human Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Myeloid leukemia; NPM1; Medicine; Adverse effect; Oncology; Internal medicine; Leukemia; CD34; Myeloid; Immunology; Biology; Stem cell; Karyotype; Genetics; Gene","score_opus":0.0167855637421857,"score_gpt":0.2920085030084133,"score_spread":0.2752229392662276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027382887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99477965,0.000013704773,0.00006172863,0.00015991175,0.0000814234,0.0015314219,0.00003286253,0.00012127373,0.003218019],"genre_scores_gemma":[0.9951158,0.0000063008024,0.0014808873,0.0008486068,0.00012156069,0.0002168134,0.00049198157,0.00007486812,0.0016431551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724925,0.00027279646,0.0005011244,0.0007144013,0.0004884645,0.00077398936],"domain_scores_gemma":[0.9983399,0.000060465754,0.0001515952,0.00078366237,0.00029008364,0.0003742929],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025903375,0.00033300635,0.0005981357,0.00042978185,0.00014836386,0.000019282987,0.00029120155,0.00034062364,0.0006880705],"category_scores_gemma":[0.00007466647,0.00025156842,0.00006973385,0.00025008197,0.00036715114,0.00044307174,0.00022587717,0.00085325196,0.00045297286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007483226,0.00043296034,0.95927334,0.000047489913,0.000052204992,0.0013027422,0.0016880083,0.000009892394,0.033358227,0.00008517423,0.0017414674,0.0012601905],"study_design_scores_gemma":[0.009023757,0.002561669,0.9851117,0.000108128275,0.00006148437,0.000092054135,0.00023080668,0.000081008795,0.00227706,0.000093469134,0.000099089615,0.00025974456],"about_ca_topic_score_codex":0.00014338162,"about_ca_topic_score_gemma":0.00003797658,"teacher_disagreement_score":0.031081166,"about_ca_system_score_codex":0.0008477846,"about_ca_system_score_gemma":0.00021439369,"threshold_uncertainty_score":0.9999937},"labels":[],"label_agreement":null},{"id":"W2027414674","doi":"10.1182/blood-2010-07-293332","title":"RNA-seq analysis of 2 closely related leukemia clones that differ in their self-renewal capacity","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Canadian Institutes of Health Research; University of California, Santa Cruz","keywords":"Biology; Genetics; RNA; Leukemia; RNA-Seq; Computational biology; Transcriptome; Gene; Gene expression","score_opus":0.019472873156119716,"score_gpt":0.2597172290457295,"score_spread":0.2402443558896098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027414674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946696,0.00010555832,0.0000048973056,0.00038244697,0.00009421351,0.00034057832,0.00004628808,0.00010545011,0.0042509474],"genre_scores_gemma":[0.99824494,0.00011474609,0.0008583075,0.00008777078,0.0000846927,0.000024019479,0.00007432646,0.000037479225,0.0004737315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979736,0.000124312,0.00047566046,0.0004299094,0.00051550847,0.00048098937],"domain_scores_gemma":[0.99841475,0.00024878254,0.00015348126,0.0008078372,0.00015543349,0.00021973814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060679676,0.00024909293,0.00081012916,0.0008077601,0.0000518424,0.000015832347,0.0002991752,0.00040514302,0.00032256427],"category_scores_gemma":[0.00025041195,0.00018938465,0.0003171942,0.0016739053,0.00018701272,0.00008660628,0.000120034056,0.0011240913,0.00002740508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014882846,0.0009514122,0.6592351,0.00008962736,0.0036114457,0.00014046553,0.0020950278,0.000012894774,0.3325654,0.0003814527,0.00018679872,0.0005815189],"study_design_scores_gemma":[0.0067386734,0.00018574245,0.74479115,0.000045635097,0.002741913,0.00007385376,0.00018845013,0.0019130019,0.24234259,0.00034136983,0.00036884364,0.00026878834],"about_ca_topic_score_codex":0.0015339704,"about_ca_topic_score_gemma":0.0012926301,"teacher_disagreement_score":0.09022278,"about_ca_system_score_codex":0.00020225291,"about_ca_system_score_gemma":0.00042898578,"threshold_uncertainty_score":0.7722882},"labels":[],"label_agreement":null},{"id":"W2027611958","doi":"10.1016/j.leukres.2014.03.022","title":"Lenalidomide and metronomic melphalan for CMML and higher risk MDS: A phase 2 clinical study with biomarkers of angiogenesis","year":2014,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Celgene","keywords":"Lenalidomide; Medicine; Melphalan; Oncology; Angiogenesis; Internal medicine; Pazopanib; Pharmacology; Multiple myeloma; Cancer; Sunitinib","score_opus":0.09011501660460082,"score_gpt":0.44628126325013334,"score_spread":0.35616624664553254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027611958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99498427,0.0006526152,0.00037957812,0.0005752798,0.00003998272,0.002574406,0.000058392696,0.000036899153,0.00069860514],"genre_scores_gemma":[0.9942503,0.00038268892,0.0038646348,0.000055252294,0.00029258654,0.00027621826,0.00002295249,0.00008178274,0.00077359483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955177,0.0012204798,0.00067271676,0.00088745303,0.0008792009,0.0008224788],"domain_scores_gemma":[0.9941165,0.0037335875,0.00016464069,0.0008118642,0.0005681165,0.00060533395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009717106,0.0002684143,0.00088191224,0.0007004053,0.00024319405,0.00006203502,0.00028454844,0.00021296764,0.000060666334],"category_scores_gemma":[0.0016615761,0.0001959848,0.00012832666,0.0007073341,0.0010854851,0.000114551774,0.000307209,0.00069441454,0.000010659166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046351187,0.0018755877,0.73567045,0.0007684379,0.00401927,0.00012489466,0.00072326727,0.0000051681236,0.010621431,0.00037233665,0.013958001,0.18550998],"study_design_scores_gemma":[0.17432986,0.052751973,0.71249616,0.0003806984,0.001728745,0.00014917029,0.0047613266,0.014384221,0.011094948,0.00052574027,0.02644628,0.00095090066],"about_ca_topic_score_codex":0.0017731413,"about_ca_topic_score_gemma":0.00014599586,"teacher_disagreement_score":0.18455908,"about_ca_system_score_codex":0.0005973771,"about_ca_system_score_gemma":0.0010358212,"threshold_uncertainty_score":0.79920286},"labels":[],"label_agreement":null},{"id":"W2027913461","doi":"10.1016/j.molcel.2010.05.011","title":"Multiple Interactions Recruit MLL1 and MLL1 Fusion Proteins to the HOXA9 Locus in Leukemogenesis","year":2010,"lang":"en","type":"article","venue":"Molecular Cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":228,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Institutes of Health; National Cancer Institute; Canadian Institutes of Health Research; Leukemia and Lymphoma Society; Charles H. Revson Foundation","keywords":"Biology; Locus (genetics); Genetics; Fusion protein; Computational biology; Gene","score_opus":0.014547249081724065,"score_gpt":0.2779362120781484,"score_spread":0.26338896299642434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027913461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868742,0.00015690815,0.0014609748,0.0063359835,0.000135489,0.0016424101,0.0000064457904,0.000039862723,0.0033476823],"genre_scores_gemma":[0.99197,0.000033111024,0.0038223378,0.00094919535,0.00010265885,0.00022279612,0.000014351934,0.000044471162,0.0028410654],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986458,0.000094059666,0.00021364584,0.00037654763,0.00030925707,0.00036068723],"domain_scores_gemma":[0.9989153,0.000093513896,0.000038847553,0.00062694115,0.0000949626,0.00023043086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003459004,0.000165931,0.00019782595,0.00023498436,0.00010928254,0.000042891425,0.00019787891,0.00011041046,0.00015700811],"category_scores_gemma":[0.00035743203,0.00012161782,0.000068868576,0.00044681501,0.00006907606,0.000050934814,0.00024760584,0.00073775224,0.00023851998],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015807593,0.00010654912,0.0032999755,0.000036203364,0.000012944635,0.00019079541,0.0004775185,0.00002282647,0.9787691,0.000016598624,0.0012944567,0.015614946],"study_design_scores_gemma":[0.0030453596,0.00029372337,0.020962527,0.00009455341,0.000054705564,0.00010154081,0.00038833648,0.0033761952,0.7432,0.000044096563,0.22813082,0.00030813005],"about_ca_topic_score_codex":0.00094121083,"about_ca_topic_score_gemma":0.0019226684,"teacher_disagreement_score":0.2355691,"about_ca_system_score_codex":0.00016363907,"about_ca_system_score_gemma":0.00018460675,"threshold_uncertainty_score":0.4959431},"labels":[],"label_agreement":null},{"id":"W2028085912","doi":"10.1158/1538-7445.am10-3842","title":"Abstract 3842: Identification of distinct apoptosis and myeloid signaling profiles within acute myeloid leukemia (AML) blast subpopulations","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cancer research; Myeloid; PI3K/AKT/mTOR pathway; Biology; Staurosporine; Signal transduction; Myeloid leukemia; Intracellular; Flow cytometry; Immunology; Cell biology; Protein kinase C","score_opus":0.047422226889339426,"score_gpt":0.3781963677225734,"score_spread":0.330774140833234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028085912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99570495,0.0002578162,0.00007689441,0.0013903971,0.00022032454,0.0012919394,0.00018720698,0.00007635775,0.0007940895],"genre_scores_gemma":[0.9957504,0.0003335366,0.00079835876,0.000029960009,0.0004928233,0.00043851242,0.00016275578,0.00008258892,0.001911017],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959663,0.00014884672,0.0008245917,0.00074719754,0.0015235128,0.000789565],"domain_scores_gemma":[0.9966443,0.00046423828,0.00025447787,0.0008470687,0.0013212257,0.00046867135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024735164,0.0002643803,0.00048149205,0.0007046825,0.00047680977,0.0001416184,0.00043790092,0.00029644516,0.0006966166],"category_scores_gemma":[0.0011022778,0.00023460168,0.00011086124,0.0011646086,0.001031399,0.00032278363,0.00026633003,0.0021238476,0.00007286786],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042300724,0.00007284689,0.020079866,0.00044901457,0.00016514033,0.000014864999,0.0007234138,0.000030622727,0.9700616,0.00048890937,0.0015122911,0.0059784134],"study_design_scores_gemma":[0.0012516025,0.00014436075,0.12860201,0.0002441551,0.00009617251,0.000031354793,0.00067499786,0.00083519635,0.86681217,0.00035957995,0.00071039767,0.00023797981],"about_ca_topic_score_codex":0.0020583037,"about_ca_topic_score_gemma":0.00036518107,"teacher_disagreement_score":0.108522154,"about_ca_system_score_codex":0.0006587797,"about_ca_system_score_gemma":0.0020316197,"threshold_uncertainty_score":0.9566779},"labels":[],"label_agreement":null},{"id":"W2028130619","doi":"10.1038/onc.2014.162","title":"The ets transcription factor Fli-1 in development, cancer and disease","year":2014,"lang":"en","type":"review","venue":"Oncogene","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Biology; Transcription factor; Cancer research; FLI1; Haematopoiesis; ETS transcription factor family; Progenitor cell; Carcinogenesis; Immunology; Leukemia; Malignant transformation; Cancer; Stem cell; Genetics; Gene","score_opus":0.07861936980314839,"score_gpt":0.39471261112191475,"score_spread":0.31609324131876637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028130619","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005010123,0.99732417,0.000017091628,0.0004493611,0.00014504454,0.0010845447,0.000048246475,0.000022124577,0.00040842174],"genre_scores_gemma":[0.00012620537,0.994285,0.00009030208,0.00013307642,0.00026952027,0.0004440456,0.0001205466,0.00006028568,0.004471008],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983196,0.00014049133,0.00044263486,0.0003817793,0.00033607052,0.00037937882],"domain_scores_gemma":[0.99893874,0.00015426306,0.00010626453,0.00033842828,0.00005038158,0.0004119396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035547573,0.00029433655,0.0009144636,0.00015435393,0.00010927546,0.00003471907,0.00017615386,0.00019529642,0.00008258979],"category_scores_gemma":[0.00017300704,0.00017297467,0.00014263534,0.00023295009,0.000087547116,0.000033192406,0.00005665722,0.0005066759,0.0000722544],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004043441,0.000020097534,0.000071408496,0.0069503025,0.00009097244,0.00004036262,0.000064605214,3.4933652e-8,0.000025131036,0.000011323803,0.0009648444,0.9917205],"study_design_scores_gemma":[0.00056968164,0.000021482458,0.00035795284,0.0058811344,0.00023415794,0.000015466847,0.0000045972865,0.0000070339306,0.0000100381085,0.000004975631,0.99271685,0.00017663157],"about_ca_topic_score_codex":0.000053686745,"about_ca_topic_score_gemma":0.00019925112,"teacher_disagreement_score":0.991752,"about_ca_system_score_codex":0.0009093423,"about_ca_system_score_gemma":0.0031478507,"threshold_uncertainty_score":0.70537025},"labels":[],"label_agreement":null},{"id":"W2028619564","doi":"10.1016/j.leukres.2010.01.006","title":"Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors","year":2010,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Terry Fox Research Institute","funders":"Cancer Research Society; Leukemia and Lymphoma Society","keywords":"Haematopoiesis; Myeloid leukemia; Cancer research; Progenitor cell; Fms-Like Tyrosine Kinase 3; Stem cell; Leukemia; Myeloid; Cytotoxic T cell; Bone marrow; Integrin-linked kinase; CD135; Tyrosine-kinase inhibitor; Tyrosine kinase; Medicine; Biology; Immunology; Kinase; Signal transduction; Cell biology; Internal medicine; Cancer; Protein kinase A","score_opus":0.03293949577269067,"score_gpt":0.32414813245436985,"score_spread":0.2912086366816792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028619564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98958665,0.0004668256,0.00010535494,0.0030758432,0.0006866825,0.0039642667,0.00021268909,0.0003683078,0.001533398],"genre_scores_gemma":[0.9653754,0.0006088153,0.00623239,0.0012120842,0.0021305378,0.0007782349,0.00013008172,0.00034992388,0.023182482],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98902804,0.00060807826,0.001249959,0.0021511558,0.0034453312,0.0035174466],"domain_scores_gemma":[0.992208,0.0010020876,0.00019420858,0.0021039012,0.0017633872,0.002728409],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004376227,0.00095901574,0.0012522842,0.0018233852,0.0010754104,0.0005594503,0.0015027099,0.0011143005,0.00078519346],"category_scores_gemma":[0.0008491574,0.0008478653,0.00030857904,0.0026888726,0.0013025772,0.00054854905,0.0022701698,0.008065427,0.001788156],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0019512364,0.00014850554,0.005461904,0.00047839494,0.0002688041,0.0017958739,0.0014595853,0.000029497365,0.9253097,0.00012591292,0.05009706,0.0128734885],"study_design_scores_gemma":[0.0062905084,0.0019300411,0.005835672,0.0004342103,0.00014264196,0.0005412604,0.0022419456,0.006920191,0.91096133,0.000069584516,0.06344167,0.0011909204],"about_ca_topic_score_codex":0.002822992,"about_ca_topic_score_gemma":0.0002384821,"teacher_disagreement_score":0.024211181,"about_ca_system_score_codex":0.005654551,"about_ca_system_score_gemma":0.006138148,"threshold_uncertainty_score":0.9994961},"labels":[],"label_agreement":null},{"id":"W2028626714","doi":"10.1038/leu.2015.51","title":"INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia","year":2015,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"NPM1; Myeloid leukemia; Oncology; Internal medicine; Carcinogenesis; Cancer research; Biomarker; Leukemia; Medicine; Hematology; Haematopoiesis; Myeloid; Cytarabine; Biology; Immunology; Stem cell; Cancer; Karyotype; Gene; Genetics; Chromosome","score_opus":0.06164805654009614,"score_gpt":0.3624402128200965,"score_spread":0.30079215628000033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028626714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885233,0.0010070066,0.000030836494,0.0024264676,0.00010506536,0.0008294285,0.000036388872,0.0001518783,0.0068896334],"genre_scores_gemma":[0.9762381,0.00096335565,0.0022389686,0.005829346,0.00023257187,0.00006829066,0.0000800262,0.00011212977,0.01423726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99598926,0.00033558047,0.0009299606,0.0008796798,0.0010463778,0.00081913825],"domain_scores_gemma":[0.9974358,0.00045182696,0.0002822866,0.0007813051,0.00032015683,0.0007286081],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00169982,0.00043537072,0.0010369476,0.00026827774,0.00009900719,0.000070549504,0.0003391036,0.00059650245,0.000084358144],"category_scores_gemma":[0.0009586749,0.00031803892,0.00012617063,0.0007418269,0.00039439488,0.00029743966,0.00021417541,0.0016025647,0.00008022545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010162825,0.00022608611,0.87528425,0.0000790301,0.0005078435,0.0016151351,0.00149149,0.000008225417,0.0047966302,0.00015714957,0.099044725,0.006626582],"study_design_scores_gemma":[0.056588348,0.0020974404,0.8794952,0.0014884075,0.00018005063,0.00019012406,0.0004915259,0.001868756,0.004340904,0.00078390684,0.051375527,0.0010998028],"about_ca_topic_score_codex":0.0003000412,"about_ca_topic_score_gemma":0.0001891817,"teacher_disagreement_score":0.047669195,"about_ca_system_score_codex":0.004295976,"about_ca_system_score_gemma":0.002997073,"threshold_uncertainty_score":0.99992716},"labels":[],"label_agreement":null},{"id":"W2029078006","doi":"10.1016/s0165-4608(00)00355-1","title":"Trisomy 8 and monosomy 7 detected in bone marrow using primed in situ labeling, fluorescence in situ hybridization, and conventional cytogenetic analyses.","year":2001,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université Laval; Hôpital Saint-François d'Assise","funders":"","keywords":"Biology; In situ; Fluorescence in situ hybridization; Trisomy; Monosomy; In situ hybridization; Aneuploidy; Cytogenetics; Molecular biology; Genetics; Chromosome; Karyotype; Gene","score_opus":0.056993772631300295,"score_gpt":0.35191508304354296,"score_spread":0.2949213104122427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029078006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96278113,0.035771433,0.00036795565,0.00025872505,0.000040269344,0.0007055543,0.000015341613,0.000012176518,0.00004741996],"genre_scores_gemma":[0.94829124,0.045295075,0.006011848,0.00013271453,0.00008116655,0.000047958958,0.0000281658,0.000044688994,0.000067119305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977345,0.00011670373,0.0006382138,0.0006254597,0.00034483772,0.0005403133],"domain_scores_gemma":[0.99908555,0.0000695343,0.00011806026,0.00026723344,0.00018853041,0.00027112532],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027325304,0.00029182705,0.00050462247,0.0005877883,0.000068116446,0.00005576282,0.00010248512,0.00020027127,0.000022524107],"category_scores_gemma":[0.00009538377,0.00031284778,0.000031213873,0.0009847675,0.00026243302,0.000044721226,0.00016805854,0.00033831998,8.3155294e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016333675,0.000064749365,0.55926836,0.00009021826,0.000025431891,0.00014025683,0.00017248771,0.0008185674,0.43020675,0.0000040539885,0.000012944734,0.009032846],"study_design_scores_gemma":[0.008149126,0.00023408563,0.7703351,0.00036474445,0.00013086156,0.0002225177,0.00019817114,0.036730424,0.1824585,0.00014871091,0.00057438004,0.0004533753],"about_ca_topic_score_codex":0.00037676055,"about_ca_topic_score_gemma":0.0024016004,"teacher_disagreement_score":0.24774824,"about_ca_system_score_codex":0.00032178522,"about_ca_system_score_gemma":0.00056574726,"threshold_uncertainty_score":0.99993235},"labels":[],"label_agreement":null},{"id":"W2029306793","doi":"10.1038/bmt.2010.164","title":"Impact of intensity of conditioning therapy in patients aged 40–60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation","year":2010,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster Divinity College; Princess Margaret Cancer Centre; McMaster University; Ontario Clinical Oncology Group; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Transplantation; Confidence interval; Cumulative incidence; Myelodysplastic syndromes; Conditioning; Surgery; Proportional hazards model; Gastroenterology; Bone marrow","score_opus":0.010942465241106569,"score_gpt":0.26290642770691913,"score_spread":0.25196396246581254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029306793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998235,0.000013500532,0.0007375757,0.000024846495,0.000059879323,0.00068663695,0.00012435453,0.000028965795,0.00008924327],"genre_scores_gemma":[0.9976694,0.00023991993,0.0009944504,0.000020308402,0.0000136221315,0.00002029083,0.0009894276,0.000036429654,0.000016178723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983941,0.000084939085,0.00048683034,0.00027580245,0.00047802384,0.0002803528],"domain_scores_gemma":[0.999057,0.00021479191,0.00020726315,0.00020360154,0.00021635689,0.00010099915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028510846,0.00019674924,0.00045377167,0.00047512513,0.00004091548,0.000010267833,0.000086547494,0.00015332003,0.00009168258],"category_scores_gemma":[0.00003702331,0.00017005616,0.00010913639,0.00042848114,0.00015398936,0.00020705619,0.0000043953805,0.00041396864,0.0000045291777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010856569,0.00030011017,0.6931904,0.000521362,0.00017270123,0.00053150253,0.0018778957,0.0005097924,0.29124075,0.00001659821,0.000007630295,0.00077473023],"study_design_scores_gemma":[0.01056709,0.0020064048,0.972209,0.0004259333,0.00013266577,0.00038537933,0.000053287135,0.00017355972,0.013863111,0.00003094468,2.7296585e-7,0.00015239923],"about_ca_topic_score_codex":0.00055701693,"about_ca_topic_score_gemma":0.00077998743,"teacher_disagreement_score":0.27901858,"about_ca_system_score_codex":0.00013182552,"about_ca_system_score_gemma":0.00035223996,"threshold_uncertainty_score":0.69346887},"labels":[],"label_agreement":null},{"id":"W2029477694","doi":"10.1182/blood-2014-07-591529","title":"EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Université de Montréal; Government of Canada; Génome Québec; Compute Canada; Genome Canada","keywords":"Transcriptome; Cancer research; Biology; Gene; Myeloid; Mutation; Alternative splicing; Myeloid leukemia; Genetics; RNA splicing; Gene expression; Exon; RNA","score_opus":0.011914150821125973,"score_gpt":0.2669286659811775,"score_spread":0.2550145151600515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029477694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848194,0.00033835293,0.0037475175,0.0029823696,0.00008595098,0.00095633,0.0001346725,0.00024311343,0.0066922978],"genre_scores_gemma":[0.9911693,0.00009250944,0.001588311,0.0015885591,0.0004978919,0.0002768424,0.0006757131,0.00009349168,0.004017389],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978044,0.00017932439,0.00036805772,0.00051612937,0.0005582288,0.0005738829],"domain_scores_gemma":[0.99838865,0.00011239515,0.00013586285,0.0007671249,0.00019589471,0.00040004542],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035282824,0.00029401033,0.0005362298,0.0001376371,0.00017929878,0.00008172367,0.00026235564,0.00018069868,0.00030027798],"category_scores_gemma":[0.00030900736,0.00025821503,0.00018148625,0.00031265078,0.00011813247,0.00012437474,0.000111844674,0.0005302508,0.0004740487],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018639733,0.0004753645,0.0037659567,0.00011823247,0.00048625216,0.0002831359,0.000106607986,3.137421e-7,0.9841133,0.0001159725,0.006901754,0.0034467161],"study_design_scores_gemma":[0.033070486,0.0011680666,0.036564324,0.000381756,0.0020428877,0.00094780046,0.00008894826,0.00093038456,0.6844541,0.0001910863,0.2390303,0.0011298631],"about_ca_topic_score_codex":0.00003722415,"about_ca_topic_score_gemma":0.0000053541307,"teacher_disagreement_score":0.2996592,"about_ca_system_score_codex":0.00016747674,"about_ca_system_score_gemma":0.0002244351,"threshold_uncertainty_score":0.999987},"labels":[],"label_agreement":null},{"id":"W2030437009","doi":"10.1182/blood-2009-03-211797","title":"Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute; U.S. Department of Veterans Affairs","keywords":"Granulocyte colony-stimulating factor; Erythropoietin; Medicine; Internal medicine; Myelodysplastic syndromes; Oncology; Randomized controlled trial; Anemia; Granulocyte; Chemotherapy; Bone marrow","score_opus":0.01824722101255351,"score_gpt":0.31507436125200056,"score_spread":0.29682714023944706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030437009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98838556,0.00008546012,0.00027824793,0.00021425982,0.000037770045,0.010211901,0.0002572485,0.000040700106,0.0004888377],"genre_scores_gemma":[0.9976162,0.000030401794,0.0011369038,0.00003116047,0.000060706552,0.0003762112,0.00016537464,0.00004295432,0.0005400915],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99673593,0.00059165794,0.0008772141,0.0005524728,0.0007882762,0.00045443047],"domain_scores_gemma":[0.9966152,0.0014886458,0.00068103656,0.00046450357,0.0005696671,0.0001810023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036115886,0.00042789636,0.002027625,0.00013978055,0.00013778043,0.000018589635,0.00016280895,0.00015461244,0.000032978107],"category_scores_gemma":[0.0006367552,0.00019189982,0.00014220632,0.00045993706,0.0007772501,0.00009302105,0.00003161246,0.00029386536,0.000004395991],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97255796,0.012348074,0.0070852195,0.000039740244,0.0015464113,0.00018896951,0.004019812,0.000023076074,0.00084056566,0.000006920866,0.00003108975,0.0013121606],"study_design_scores_gemma":[0.82057613,0.17181303,0.0015092556,0.00021295657,0.0013381508,0.00015059914,0.00033310815,0.00094752375,0.0028906153,0.0000030333192,0.00004239615,0.00018322268],"about_ca_topic_score_codex":0.00025327547,"about_ca_topic_score_gemma":0.00010721935,"teacher_disagreement_score":0.15946496,"about_ca_system_score_codex":0.00039742904,"about_ca_system_score_gemma":0.0008444275,"threshold_uncertainty_score":0.78254473},"labels":[],"label_agreement":null},{"id":"W2031759349","doi":"10.1038/sj.leu.2403917","title":"Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells","year":2005,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Haematopoiesis; Telomerase; Biology; Cancer research; Leukemia; Myeloid; Stem cell; Myeloid leukemia; Telomerase reverse transcriptase; Immunology; Genetics; Gene","score_opus":0.04273951744049179,"score_gpt":0.3378140450614088,"score_spread":0.295074527620917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031759349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942721,0.00041020845,0.0011375506,0.00067048304,0.000038024216,0.0015402694,0.000007338875,0.000029913786,0.001894077],"genre_scores_gemma":[0.99645513,0.000101375095,0.0020785658,0.00048740598,0.00020379564,0.00018998074,0.00002179894,0.00002935031,0.000432585],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980267,0.00013717043,0.0006494611,0.00025752242,0.00049169926,0.00043739114],"domain_scores_gemma":[0.9988128,0.0004468608,0.00011702508,0.00041419332,0.00013124435,0.000077868426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009960313,0.00018448736,0.00035319556,0.00016712263,0.00012839561,0.000014797136,0.00034346007,0.00012807752,0.00006142977],"category_scores_gemma":[0.00017826147,0.00013699692,0.00013288579,0.0003765532,0.00008191026,0.00024419813,0.000031377866,0.00035303712,0.000035339144],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007235021,0.00023084553,0.009124942,0.0021133937,0.00009105476,0.000026615098,0.017940583,0.008316718,0.9396248,0.0004833443,0.003309635,0.018014599],"study_design_scores_gemma":[0.012873271,0.0015107489,0.076619245,0.0024123418,0.00030043835,0.00031384357,0.0019222792,0.06237425,0.83753383,0.00014445923,0.0033198048,0.0006754777],"about_ca_topic_score_codex":0.00023007143,"about_ca_topic_score_gemma":0.00012002549,"teacher_disagreement_score":0.102090925,"about_ca_system_score_codex":0.0012182097,"about_ca_system_score_gemma":0.0006396862,"threshold_uncertainty_score":0.5586573},"labels":[],"label_agreement":null},{"id":"W2031777014","doi":"10.1371/journal.pone.0012405","title":"Distinct Patterns of DNA Damage Response and Apoptosis Correlate with Jak/Stat and PI3Kinase Response Profiles in Human Acute Myelogenous Leukemia","year":2010,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Apoptosis; Cancer research; DNA damage; Leukemia; Myeloid leukemia; Biology; stat; Signal transduction; Cytokine; PI3K/AKT/mTOR pathway; Immunology; Medicine; Cell biology; STAT3; DNA","score_opus":0.021593547701939796,"score_gpt":0.2636676955870699,"score_spread":0.24207414788513007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031777014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975944,0.000041150328,0.000007701206,0.00088992703,0.000013377627,0.001126633,0.00017656625,0.00005671652,0.000093519106],"genre_scores_gemma":[0.9969109,0.00006748249,0.0011864516,0.00009020144,0.000042653275,0.000099878656,0.00005832077,0.00007399118,0.0014701145],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975671,0.00039374077,0.00041964243,0.0005342783,0.0005693491,0.00051589886],"domain_scores_gemma":[0.9977613,0.00088105485,0.00015829218,0.00068229216,0.00018349527,0.00033353278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013345822,0.00029534058,0.00066143874,0.00046322477,0.00013934865,0.00003612833,0.0001754358,0.00021584122,0.000088161934],"category_scores_gemma":[0.00095821626,0.0002406648,0.00003516282,0.00031305687,0.0004914122,0.00013457904,0.00023167647,0.0010103903,0.000008092752],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029909946,0.00053534715,0.17861468,0.0003221767,0.0002516489,0.000629819,0.0015884334,1.6202073e-7,0.78786206,0.000016408125,0.000036034,0.0002332836],"study_design_scores_gemma":[0.004996012,0.0022947886,0.7060306,0.00057103444,0.00031755478,0.00011755231,0.00035494452,0.00018359987,0.2848566,0.000014913988,0.000025395344,0.0002369877],"about_ca_topic_score_codex":0.00037389915,"about_ca_topic_score_gemma":0.00027829717,"teacher_disagreement_score":0.52741593,"about_ca_system_score_codex":0.00026029503,"about_ca_system_score_gemma":0.00049871736,"threshold_uncertainty_score":0.9814026},"labels":[],"label_agreement":null},{"id":"W2031912770","doi":"10.3109/10428194.2014.900763","title":"Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Chronic myelomonocytic leukemia; Sunitinib malate; Myelodysplastic syndromes; Medicine; Internal medicine; Oncology; Cancer research; Gastroenterology; Sunitinib; Cancer; Bone marrow","score_opus":0.01136352221495713,"score_gpt":0.23605733998542885,"score_spread":0.22469381777047173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031912770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98427886,0.0006300128,0.000107206244,0.0064710304,0.0011820483,0.004824366,0.0006588181,0.00083131174,0.0010163708],"genre_scores_gemma":[0.83666265,0.0028895936,0.0010381419,0.12196517,0.0051099346,0.0014573417,0.006469958,0.001965462,0.02244175],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.98146355,0.0012704023,0.0034939328,0.0047313618,0.003600913,0.0054398295],"domain_scores_gemma":[0.9883028,0.0031529327,0.0020198333,0.003941766,0.00084046845,0.0017421657],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0012668095,0.0041766604,0.0059526907,0.0033425358,0.0007766149,0.0006662555,0.0023429785,0.0055745468,0.0012229348],"category_scores_gemma":[0.0011692157,0.0030336767,0.0007132554,0.0029322624,0.0022485666,0.0009299134,0.0013663743,0.004924454,0.0012213341],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.048561648,0.0008229632,0.060096752,0.015075345,0.0053574704,0.124671645,0.0015213166,0.00051443634,0.000066083514,0.00006938214,0.5947119,0.14853106],"study_design_scores_gemma":[0.16086641,0.016022932,0.53221047,0.011256935,0.0039345105,0.015455935,0.0002417838,0.009494639,0.00024326674,0.00017372258,0.2430053,0.0070940736],"about_ca_topic_score_codex":0.00861518,"about_ca_topic_score_gemma":0.0012586304,"teacher_disagreement_score":0.47211373,"about_ca_system_score_codex":0.09794548,"about_ca_system_score_gemma":0.044143025,"threshold_uncertainty_score":0.99969006},"labels":[],"label_agreement":null},{"id":"W2032903538","doi":"10.1016/j.ccr.2013.01.011","title":"Growth Factor Independence 1 Antagonizes a p53-Induced DNA Damage Response Pathway in Lymphoblastic Leukemia","year":2013,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Montreal Clinical Research Institute","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council; Canadian Institutes of Health Research; National Cancer Institute; Cancer Research UK; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; National Centre for the Replacement, Refinement and Reduction of Animals in Research; Wellcome Trust","keywords":"Puma; Apoptosis; Cancer research; DNA damage; Leukemia; Lymphoblastic Leukemia; Biology; Function (biology); Immunology; Cell biology; DNA; Genetics","score_opus":0.021820065694349397,"score_gpt":0.2807889967071203,"score_spread":0.2589689310127709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032903538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99394375,0.00043407662,0.000028377137,0.00065678527,0.0002221447,0.0009624058,0.00004064375,0.00009701953,0.0036148173],"genre_scores_gemma":[0.9938848,0.00022362045,0.00016589383,0.00077052857,0.00020294296,0.0003283543,0.000012476216,0.00007730487,0.0043340717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99721104,0.00024312199,0.0004175329,0.00063028006,0.0006703157,0.00082770974],"domain_scores_gemma":[0.9980779,0.00043841806,0.00011063651,0.0006277606,0.00030236633,0.00044287267],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038821806,0.00032827354,0.00047652767,0.00026419185,0.00007777323,0.00006534928,0.00040035613,0.00031395178,0.0029196169],"category_scores_gemma":[0.00047871345,0.0002836565,0.00009650232,0.0005599093,0.0001234067,0.00038123011,0.00019183086,0.0007025038,0.00076152914],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014446796,0.0000919995,0.012387805,0.00020081559,0.000026114152,0.0004233589,0.0011984005,0.0000056523118,0.9790621,0.0000142412855,0.0025401718,0.002604662],"study_design_scores_gemma":[0.0063531003,0.0005106215,0.26145324,0.00028474088,0.00002123498,0.000040414372,0.00083185424,0.0015757694,0.72699374,0.0000684208,0.0013957826,0.00047103764],"about_ca_topic_score_codex":0.0078633595,"about_ca_topic_score_gemma":0.00038423718,"teacher_disagreement_score":0.25206834,"about_ca_system_score_codex":0.005320591,"about_ca_system_score_gemma":0.0043301587,"threshold_uncertainty_score":0.99996156},"labels":[],"label_agreement":null},{"id":"W2034404910","doi":"10.1016/s0165-4608(00)00294-6","title":"Myelodysplastic syndrome and a nonrandom chromosomal abnormality t(1;19):","year":2000,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Chromosomal Abnormality; Abnormality; Biology; Myelodysplastic syndromes; Haematopoiesis; Immunology; Genetics; Karyotype; Bone marrow; Chromosome; Stem cell; Medicine; Gene","score_opus":0.01831157079865387,"score_gpt":0.2954243689678248,"score_spread":0.27711279816917095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034404910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810719,0.016307218,0.00009089786,0.00070417416,0.00007534243,0.0004955585,0.000081581806,0.000038043778,0.001135264],"genre_scores_gemma":[0.95299137,0.0424466,0.0013629104,0.0006954282,0.00021496459,0.00006517527,0.000018575744,0.000048907328,0.0021560881],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827534,0.00005028861,0.00032100466,0.0004892316,0.0003438628,0.0005202607],"domain_scores_gemma":[0.99878967,0.00007255586,0.000045642988,0.00037611034,0.000101044236,0.0006149554],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001565273,0.00027063963,0.00042161698,0.000081732775,0.00017374656,0.00006306106,0.00011720389,0.00018052034,0.0009922076],"category_scores_gemma":[0.000023636012,0.00024619332,0.000058499016,0.00020478157,0.00038824746,0.000028424034,0.00010465778,0.00027367668,0.000028424227],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029824239,0.00041970823,0.50357497,0.0016679821,0.0010052139,0.002562146,0.0016818946,0.00093466364,0.020568442,0.00016287748,0.0040741786,0.46036547],"study_design_scores_gemma":[0.014590559,0.0022021753,0.81977534,0.00027942832,0.000816461,0.007320005,0.00012567258,0.009849836,0.010134518,0.00037399892,0.133508,0.0010239838],"about_ca_topic_score_codex":0.00009778038,"about_ca_topic_score_gemma":0.000045240784,"teacher_disagreement_score":0.4593415,"about_ca_system_score_codex":0.0001165877,"about_ca_system_score_gemma":0.00038092624,"threshold_uncertainty_score":0.99999905},"labels":[],"label_agreement":null},{"id":"W2034409643","doi":"10.1016/s0145-2126(03)00180-2","title":"Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia","year":2003,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Immunophenotyping; CD33; Medicine; Internal medicine; Gastroenterology; CD34; Acute promyelocytic leukemia; Myeloid leukemia; Daunorubicin; Leukemia; Oncology; Immunology; Flow cytometry; Biology; Stem cell","score_opus":0.025738497860918738,"score_gpt":0.31812977727637065,"score_spread":0.2923912794154519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034409643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828005,0.0005801026,0.00011531468,0.00020045444,0.000072502975,0.0023730607,0.000023322455,0.00006960905,0.013765141],"genre_scores_gemma":[0.9910243,0.00043293167,0.0053454936,0.00009810543,0.00006549537,0.00028295672,0.00008618139,0.0001397215,0.0025248155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929958,0.00071469904,0.00085594534,0.0009574136,0.0026266049,0.0018495135],"domain_scores_gemma":[0.99517447,0.0013535301,0.00012183535,0.0013611071,0.0015621543,0.00042691227],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0026777175,0.00041123273,0.0008557763,0.0012195555,0.0002258827,0.00005725174,0.00063972914,0.00035921848,0.0002238095],"category_scores_gemma":[0.0037584333,0.00033732475,0.00012390604,0.0034333877,0.00083458546,0.00032395349,0.0002809878,0.0028554613,0.00021682771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0102557745,0.0011216522,0.89112514,0.0017591156,0.00082124455,0.0018955016,0.0025526679,0.0005059723,0.05658234,0.006419802,0.003838889,0.023121899],"study_design_scores_gemma":[0.034049895,0.0049748113,0.8827627,0.0029759174,0.00018853086,0.000262075,0.0009112284,0.0023341475,0.054996688,0.0017878393,0.013533864,0.0012223038],"about_ca_topic_score_codex":0.0009059799,"about_ca_topic_score_gemma":0.00011123634,"teacher_disagreement_score":0.02379412,"about_ca_system_score_codex":0.008162766,"about_ca_system_score_gemma":0.008023709,"threshold_uncertainty_score":0.99990785},"labels":[],"label_agreement":null},{"id":"W2034633743","doi":"10.1371/journal.pone.0112671","title":"Cell Fate Decisions in Malignant Hematopoiesis: Leukemia Phenotype Is Determined by Distinct Functional Domains of the MN1 Oncogene","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; BC Cancer Agency; University of British Columbia","funders":"Deutsche Krebshilfe; José Carreras Leukämie-Stiftung; Bundesministerium für Bildung und Forschung; Leuka; University of British Columbia; Kay Kendall Leukaemia Fund; Hector Stiftung; Stem Cell Network; Terry Fox Foundation; Deutsche Forschungsgemeinschaft; BC Cancer Agency; European Hematology Association; Child and Family Research Institute; Cancer Research Society","keywords":"Biology; Phenotype; Oncogene; Myeloid; Myeloid leukemia; Haematopoiesis; Cancer research; Leukemia; Cellular differentiation; Cell; Genetics; Gene; Stem cell; Cell cycle","score_opus":0.03790517298169907,"score_gpt":0.2523687331641194,"score_spread":0.21446356018242033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034633743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99307245,0.00021273374,0.0004246282,0.0012716878,0.000043407275,0.000543318,0.00005929267,0.000031323638,0.0043411693],"genre_scores_gemma":[0.9936187,0.00007611721,0.0015244789,0.00057346147,0.00012242871,0.000062471634,0.00003905677,0.00004424894,0.00393898],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975874,0.00013596886,0.00049862114,0.0003732408,0.0009850932,0.00041969595],"domain_scores_gemma":[0.99815106,0.0005399902,0.00015248987,0.0007775764,0.00019523501,0.00018366182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047163013,0.0002054925,0.000512189,0.00013561118,0.00010645161,0.0000133739295,0.00031724697,0.00014119044,0.00047754552],"category_scores_gemma":[0.00073921843,0.00013977426,0.00012891606,0.0004652611,0.00017704355,0.00005516444,0.00023160464,0.00037570807,0.0001547832],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007092356,0.0017676975,0.02470616,0.00024189182,0.00021865215,0.00002402818,0.00035424024,0.000008761456,0.95391643,0.00015734586,0.016680341,0.001215204],"study_design_scores_gemma":[0.005937001,0.0004158757,0.036800086,0.0009301073,0.00037553482,0.000017903136,0.00012957581,0.0046265335,0.9467812,0.0007715029,0.002902457,0.00031219455],"about_ca_topic_score_codex":0.00014043573,"about_ca_topic_score_gemma":0.00006492063,"teacher_disagreement_score":0.013777885,"about_ca_system_score_codex":0.0005740714,"about_ca_system_score_gemma":0.00047285864,"threshold_uncertainty_score":0.5699829},"labels":[],"label_agreement":null},{"id":"W2035386163","doi":"10.1038/sj.bmt.1704506","title":"Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia","year":2004,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"University Health Network","keywords":"Medicine; Etoposide; Melphalan; Myeloid leukemia; Transplantation; Internal medicine; Total body irradiation; Complete remission; Surgery; Leukemia; Oncology; Chemotherapy; Cyclophosphamide","score_opus":0.015201493144691382,"score_gpt":0.2910370363663591,"score_spread":0.2758355432216677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035386163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807757,0.00040919715,0.013977895,0.0021367674,0.000103501494,0.0020721408,0.00028978573,0.00013954531,0.00009542729],"genre_scores_gemma":[0.99221146,0.0016039034,0.002886316,0.0010008612,0.00014297767,0.00042513353,0.0012669717,0.00008353889,0.00037883347],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997932,0.000045250064,0.00047903755,0.0005608654,0.00046890322,0.0005139382],"domain_scores_gemma":[0.99893093,0.00010380145,0.00011846492,0.00027151502,0.00032791644,0.00024739464],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022498111,0.00037592967,0.0005156358,0.00027932183,0.00013753831,0.000066655106,0.000080129736,0.00022326224,0.000035212426],"category_scores_gemma":[0.000014463137,0.00029730392,0.00012719711,0.00020895358,0.00014719335,0.00034941675,0.0000077512905,0.00034673637,0.000016480222],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0849066,0.00040658316,0.3859352,0.0032375886,0.0021172063,0.007414213,0.011907115,0.0004160444,0.48898643,0.00090082514,0.00012822368,0.013643998],"study_design_scores_gemma":[0.02211673,0.001911531,0.93188,0.00034271317,0.0010040035,0.0046929405,0.00009350113,0.00031917097,0.037016746,0.000111974776,0.000030350075,0.00048033943],"about_ca_topic_score_codex":0.00016816244,"about_ca_topic_score_gemma":0.00017075456,"teacher_disagreement_score":0.5459448,"about_ca_system_score_codex":0.0005330402,"about_ca_system_score_gemma":0.00041233253,"threshold_uncertainty_score":0.9999479},"labels":[],"label_agreement":null},{"id":"W2036607694","doi":"10.1097/mph.0b013e31821503c8","title":"HLA-DRnegative, CD34negative Hypergranular Acute Myeloid Leukemia With Trisomy 6 and del(5)(q22q33)","year":2011,"lang":"en","type":"review","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Children's Hospital of Eastern Ontario; University of Ottawa","funders":"","keywords":"Immunophenotyping; Medicine; Leukocytosis; Acute promyelocytic leukemia; Myeloid leukemia; Pathology; Acute leukemia; Trisomy 8; Trisomy; Myeloid; Leukemia; Bone marrow; Immunology; Karyotype; Biology; Chromosome; Genetics; Antigen","score_opus":0.045443892316924375,"score_gpt":0.35918735544349867,"score_spread":0.3137434631265743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036607694","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031329533,0.9899863,0.00033026867,0.00047328512,0.0005218858,0.0020290047,0.000053066276,0.00006137097,0.0034118854],"genre_scores_gemma":[0.00018574181,0.9818716,0.01441166,0.00024351681,0.0020257803,0.0001426645,0.00004408273,0.00023188093,0.0008430905],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99157345,0.0017195576,0.0033962412,0.0010380684,0.00088640733,0.0013862603],"domain_scores_gemma":[0.98880064,0.002802258,0.004819502,0.0008016284,0.0014808752,0.0012950666],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0023100267,0.0013384428,0.009848523,0.0027607237,0.00023382528,0.000040631458,0.0009961945,0.0026577143,0.00026770774],"category_scores_gemma":[0.0011409612,0.0008700931,0.0011592946,0.0018384876,0.0010744956,0.00038174327,0.00045673893,0.006073301,0.0001872631],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045329845,0.0012773527,0.0019245471,0.023898458,0.012757441,0.053844143,0.0020513632,0.0000014513556,0.000009806938,0.0013887135,0.060314264,0.83799946],"study_design_scores_gemma":[0.0074269557,0.007559306,0.000064383676,0.001837172,0.020255292,0.12095411,0.00032935207,0.000010849316,0.000014196664,0.00014850078,0.8406626,0.0007372732],"about_ca_topic_score_codex":0.00005551222,"about_ca_topic_score_gemma":0.000016399039,"teacher_disagreement_score":0.8372622,"about_ca_system_score_codex":0.003601112,"about_ca_system_score_gemma":0.020286994,"threshold_uncertainty_score":0.99993664},"labels":[],"label_agreement":null},{"id":"W2036982348","doi":"10.1186/1471-2164-14-550","title":"Barnacle: detecting and characterizing tandem duplications and fusions in transcriptome assemblies","year":2013,"lang":"en","type":"article","venue":"BMC Genomics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre; Simon Fraser University","funders":"Provincial Health Services Authority; Genome British Columbia; Michael Smith Health Research BC; BC Cancer Foundation; Canadian Institutes of Health Research; Genome Canada","keywords":"Biology; Computational biology; Transcriptome; DNA microarray; Genetics; Gene; Bioinformatics; Gene expression","score_opus":0.03369318438311283,"score_gpt":0.28485349404102206,"score_spread":0.25116030965790925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036982348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99640113,0.00037137518,0.00039911916,0.0016944957,0.000024845926,0.0005420934,0.0000037769096,0.000033987024,0.00052915316],"genre_scores_gemma":[0.9933178,0.00050823385,0.0054431637,0.00026583657,0.00007254395,0.00007626973,0.0000068213326,0.000023794177,0.00028557223],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99918574,0.00003053793,0.00020897768,0.00023066357,0.000088043285,0.0002560188],"domain_scores_gemma":[0.99943286,0.00013448873,0.000037114416,0.00018867916,0.000050862076,0.00015600315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021245959,0.00010340265,0.0001897144,0.0001776332,0.00012358844,0.00006224262,0.000061032988,0.000085391584,0.000041771214],"category_scores_gemma":[0.00014164811,0.0000979891,0.000022996961,0.00016994584,0.00006465149,0.00012612414,0.00007026612,0.00026146785,0.00002422729],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012839195,0.00002020559,0.11484302,0.000055386437,0.0000103635575,0.0000030952936,0.0010808533,0.0000011618423,0.8750249,0.000070036476,0.000057145473,0.008820998],"study_design_scores_gemma":[0.0011156178,0.00005538554,0.9854876,0.000043891363,0.00002174098,0.00010798105,0.0014199301,0.004686241,0.0047219736,0.0001437187,0.0020647165,0.00013119352],"about_ca_topic_score_codex":0.0002094802,"about_ca_topic_score_gemma":0.00017840945,"teacher_disagreement_score":0.87064457,"about_ca_system_score_codex":0.0001495066,"about_ca_system_score_gemma":0.00013734006,"threshold_uncertainty_score":0.39958793},"labels":[],"label_agreement":null},{"id":"W2037269347","doi":"10.1182/blood-2011-12-397844","title":"Posttranslational regulation of self-renewal capacity: insights from proteome and phosphoproteome analyses of stem cell leukemia","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Canadian Institutes of Health Research","keywords":"Stem cell; Proteome; Biology; Leukemia; Myeloid leukemia; Proteomics; Cell biology; Molecular biology; Cancer research; Biochemistry; Genetics; Gene","score_opus":0.03750007853129773,"score_gpt":0.27936754703710853,"score_spread":0.2418674685058108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037269347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960282,0.0017174587,0.00012552884,0.000046297322,0.000026254926,0.00066819234,0.000054552882,0.00003382693,0.001299688],"genre_scores_gemma":[0.9888976,0.0000412486,0.010671031,0.000016608526,0.00015422459,0.000024578701,0.00006909671,0.000023162704,0.00010240499],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99852335,0.00007701482,0.00040569433,0.00021346081,0.0005528094,0.0002276425],"domain_scores_gemma":[0.99900806,0.000110160145,0.00019476084,0.0002989795,0.00021077562,0.00017723507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016919662,0.00015635781,0.00041485886,0.00019585974,0.00004184962,0.0000065770623,0.00008303853,0.00016658755,0.0000777301],"category_scores_gemma":[0.000017572685,0.00013106276,0.00008212839,0.00030443526,0.00011469879,0.00018670227,0.000041347983,0.00018941073,0.000006974622],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016629648,0.00040717903,0.04270842,0.0002551489,0.00029198098,0.0000026978132,0.001694411,0.000007106293,0.9539927,0.00011656338,0.000014864977,0.0003425892],"study_design_scores_gemma":[0.0031366686,0.00018378276,0.1836434,0.00007040479,0.00038972532,0.000015222077,0.00009224018,0.00019885076,0.811932,0.00018160747,0.000055883742,0.00010018062],"about_ca_topic_score_codex":0.0007015226,"about_ca_topic_score_gemma":0.0000097485545,"teacher_disagreement_score":0.14206071,"about_ca_system_score_codex":0.00010409145,"about_ca_system_score_gemma":0.00030761212,"threshold_uncertainty_score":0.5344584},"labels":[],"label_agreement":null},{"id":"W2037777034","doi":"10.1016/s0301-472x(02)00824-x","title":"Polyclonal normal hematopoietic progenitors in patients with acute myeloid leukemia","year":2002,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Biology; Clonogenic assay; Polyclonal antibodies; Myeloid leukemia; Haematopoiesis; Myeloid; Progenitor cell; Monoclonal; Leukemia; clone (Java method); Cytogenetics; Molecular biology; Immunology; Cancer research; Pathology; Stem cell; Monoclonal antibody; Medicine; Antibody; Genetics; Cell culture; Gene; Chromosome","score_opus":0.011317356546322935,"score_gpt":0.2688421215350201,"score_spread":0.25752476498869714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037777034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914882,0.0014199202,0.0000074555815,0.00040476982,0.00016440602,0.00093400566,0.000008243902,0.00009770526,0.0054752557],"genre_scores_gemma":[0.9964773,0.0000129374885,0.0015004246,0.00036653783,0.00007825704,0.00019720559,0.000060908373,0.00006815964,0.0012382821],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99756086,0.000073011885,0.00044443668,0.0005359067,0.00055798603,0.00082777767],"domain_scores_gemma":[0.9990568,0.000046964637,0.00009055434,0.00042704248,0.00006604936,0.00031257517],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007551364,0.0003372951,0.0006168903,0.00031095254,0.00009667146,0.00001731416,0.00022107313,0.00022553967,0.0028681133],"category_scores_gemma":[0.000016752805,0.0002766998,0.000095707735,0.00041701013,0.0003340151,0.00017714823,0.00016685261,0.0005035949,0.0007539532],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004777506,0.0039443052,0.9558177,0.00018677978,0.0005752527,0.0045095193,0.003319271,0.000003465185,0.0055800355,0.006492007,0.013669337,0.0011248214],"study_design_scores_gemma":[0.04208736,0.006437686,0.08102192,0.00032259262,0.00015107736,0.009155499,0.0013471474,0.0012611616,0.8540206,0.000044672626,0.0027247232,0.0014255871],"about_ca_topic_score_codex":0.00005556017,"about_ca_topic_score_gemma":0.000005213922,"teacher_disagreement_score":0.8747958,"about_ca_system_score_codex":0.0010070305,"about_ca_system_score_gemma":0.00016603924,"threshold_uncertainty_score":0.9999685},"labels":[],"label_agreement":null},{"id":"W2038019363","doi":"10.1182/blood-2004-04-1508","title":"Identification of cooperative genes for NUP98-HOXA9 in myeloid leukemogenesis using a mouse model","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer","funders":"","keywords":"Biology; Fusion gene; Myeloid leukemia; Myeloid; Cancer research; Leukemia; Carcinogenesis; Transgene; Genetically modified mouse; Chromosomal translocation; Fusion protein; Gene; Haematopoiesis; Stem cell; Genetics","score_opus":0.04206000187329901,"score_gpt":0.3206554688923874,"score_spread":0.2785954670190884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038019363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97674245,0.0003419607,0.021592434,0.00020405918,0.000017996723,0.0009693574,0.000059681926,0.000027725458,0.000044337405],"genre_scores_gemma":[0.98433244,0.00012209952,0.014674128,0.00007131387,0.000067921595,0.0001036635,0.000029308272,0.000041394716,0.0005577337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99871856,0.00002890148,0.0004294574,0.00029396793,0.00025555288,0.00027354044],"domain_scores_gemma":[0.99912834,0.00004522985,0.00010217885,0.00032308322,0.00031783228,0.00008331369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032053774,0.00013505624,0.00031089172,0.0002518844,0.00005789093,0.00001419751,0.00012784233,0.00011281718,0.0000058331634],"category_scores_gemma":[0.00019023287,0.00012756133,0.00008435504,0.0003340087,0.00008225797,0.00011800123,0.000045000113,0.00011062751,0.000006889814],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018625865,0.0004999454,0.0014007139,0.0001299504,0.00007519989,0.000006005526,0.0005823503,0.02437274,0.97203845,0.00034829447,0.000012460216,0.00034762593],"study_design_scores_gemma":[0.007510698,0.00013090673,0.0007009358,0.00005893039,0.00012824684,0.000019169182,0.00019400174,0.05945485,0.93146926,0.00020309268,0.000012582713,0.00011735056],"about_ca_topic_score_codex":0.00015799588,"about_ca_topic_score_gemma":0.000048191694,"teacher_disagreement_score":0.04056922,"about_ca_system_score_codex":0.0003538838,"about_ca_system_score_gemma":0.0009818908,"threshold_uncertainty_score":0.52018},"labels":[],"label_agreement":null},{"id":"W2038656901","doi":"10.1038/bcj.2011.52","title":"Drug-mediated inhibition of Fli-1 for the treatment of leukemia","year":2012,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Ontario Institute for Cancer Research","keywords":"Cancer research; Oncogene; Carcinogenesis; Leukemia; Transcription factor; Haematopoiesis; Drug; Biology; Cell growth; Apoptosis; Loss function; Oncogene Proteins; Gene; Medicine; Pharmacology; Regulation of gene expression; Immunology; Stem cell; Phenotype; Cell biology; Cell cycle; Genetics","score_opus":0.030514505918436734,"score_gpt":0.3259653408600217,"score_spread":0.29545083494158497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038656901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98436457,0.012989056,0.00013478514,0.0013712406,0.00024057824,0.0005052056,0.00005915658,0.000007496978,0.00032793806],"genre_scores_gemma":[0.9891251,0.008113925,0.00056273007,0.0001055861,0.0013469715,0.00008681916,0.000011125938,0.000022021357,0.0006257314],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989049,0.000041138766,0.00033209712,0.0000761793,0.00033184586,0.00031384104],"domain_scores_gemma":[0.99892247,0.00024303605,0.00022029933,0.00016970461,0.00027502447,0.0001694712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039031124,0.000103893806,0.00027572925,0.00009888937,0.00008275136,0.0000062591043,0.00006894665,0.000056510296,0.00023146815],"category_scores_gemma":[0.000073201394,0.000059135935,0.00017452975,0.00016345519,0.00009697059,0.00008237624,0.000011370803,0.00016644213,0.000003663596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051515424,0.005413216,0.16177727,0.00081926276,0.0054305866,0.000058336664,0.014108382,0.00015588345,0.55486274,0.00045451583,0.069075294,0.18269295],"study_design_scores_gemma":[0.024099993,0.0029740883,0.0393816,0.0004076426,0.0020654153,0.00053666555,0.0012748449,0.00046596077,0.86284274,0.000073298164,0.06569188,0.00018586038],"about_ca_topic_score_codex":0.00020088247,"about_ca_topic_score_gemma":0.000021482752,"teacher_disagreement_score":0.30798,"about_ca_system_score_codex":0.00061930186,"about_ca_system_score_gemma":0.00086366636,"threshold_uncertainty_score":0.2534414},"labels":[],"label_agreement":null},{"id":"W2039249445","doi":"10.1016/j.leukres.2006.06.001","title":"CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype","year":2006,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Myeloid leukemia; Internal medicine; Karyotype; Medicine; Gastroenterology; Leukemia; Multivariate analysis; CD34; Myeloid; Complete remission; Oncology; Chemotherapy; Biology; Chromosome; Stem cell","score_opus":0.015210120782076229,"score_gpt":0.2828162813017182,"score_spread":0.267606160519642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039249445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915897,0.00059920293,0.00003042362,0.001496878,0.000120062505,0.0019010687,0.00021089037,0.00012684218,0.003924912],"genre_scores_gemma":[0.9932964,0.0003748616,0.00083462585,0.00011385118,0.00042831321,0.00012534403,0.0006519158,0.00015340305,0.0040212916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919076,0.00072395377,0.0006750245,0.0013738225,0.0034956024,0.0018239913],"domain_scores_gemma":[0.9954842,0.000735097,0.00012016424,0.0012411412,0.0010057545,0.0014136417],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002089766,0.00057538954,0.000789081,0.0010207403,0.0005029987,0.00019400426,0.0006123049,0.00044725937,0.0001420312],"category_scores_gemma":[0.0010339172,0.00044198873,0.00008403106,0.0012119603,0.0008942755,0.00063301926,0.0014547698,0.0023554212,0.000042192158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028056554,0.0004772488,0.9292082,0.00067873514,0.00012684312,0.0018659905,0.0002641433,0.00004994968,0.022523206,0.0003182598,0.010115746,0.006315134],"study_design_scores_gemma":[0.01950142,0.0014002273,0.9717765,0.00062618696,0.00007666575,0.000035078338,0.00021580746,0.0016599874,0.0026998282,0.00027413206,0.0012453448,0.0004888523],"about_ca_topic_score_codex":0.003802891,"about_ca_topic_score_gemma":0.00037828783,"teacher_disagreement_score":0.04256828,"about_ca_system_score_codex":0.003221392,"about_ca_system_score_gemma":0.0039034202,"threshold_uncertainty_score":0.9999462},"labels":[],"label_agreement":null},{"id":"W2040066655","doi":"10.1016/j.bbmt.2005.10.013","title":"Pretransplantation Consolidation Chemotherapy Decreases Leukemia Relapse after Autologous Blood and Bone Marrow Transplants for Acute Myelogenous Leukemia in First Remission","year":2006,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Cytarabine; Medicine; Leukemia; Internal medicine; Chemotherapy; Transplantation; Confidence interval; Surgery; Gastroenterology","score_opus":0.008283287537447687,"score_gpt":0.25862140468610967,"score_spread":0.250338117148662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040066655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940053,0.0021094067,0.0013665133,0.00037346059,0.00006045748,0.0013526832,0.00053480436,0.00006730176,0.00013007963],"genre_scores_gemma":[0.97838134,0.014669929,0.0042226603,0.00012834712,0.00008095273,0.00019088168,0.0021771276,0.000041687836,0.00010706841],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979547,0.00011775804,0.000691112,0.00060262403,0.00017579689,0.00045796082],"domain_scores_gemma":[0.99901044,0.00035288275,0.00018993723,0.00018971197,0.00011197252,0.00014506665],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037285234,0.00033720766,0.0006369053,0.0003861324,0.00013108162,0.00001667372,0.00008190576,0.00055253145,0.00002556453],"category_scores_gemma":[0.000025459492,0.00030992588,0.00009627393,0.00019895633,0.00032367342,0.00016855076,0.00000712259,0.00025425374,0.0000010019932],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012067584,0.0002098092,0.104505725,0.0019565204,0.00034667613,0.00036606376,0.0011459498,0.00001892043,0.87551725,0.00021563807,0.00005112302,0.0035987631],"study_design_scores_gemma":[0.038379584,0.0027732998,0.29969594,0.001311805,0.0043693897,0.0051611117,0.00010988234,0.0009738788,0.64505607,0.00121686,0.0002136511,0.00073852285],"about_ca_topic_score_codex":0.00074971566,"about_ca_topic_score_gemma":0.0006789282,"teacher_disagreement_score":0.23046114,"about_ca_system_score_codex":0.0001231975,"about_ca_system_score_gemma":0.0004002678,"threshold_uncertainty_score":0.99993527},"labels":[],"label_agreement":null},{"id":"W2040596732","doi":"10.1038/leu.2012.153","title":"A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission","year":2012,"lang":"en","type":"letter","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Vrije Universiteit Brussel; Eisai; Fonds Wetenschappelijk Onderzoek; Stem Cell Network","keywords":"Decitabine; Myeloid leukemia; Medicine; Randomized controlled trial; Internal medicine; Leukemia; Oncology; Complete remission; Maintenance therapy; Myeloid; Cytarabine; Intensive care medicine; Chemotherapy; Biology","score_opus":0.0290794654399181,"score_gpt":0.2998485099609,"score_spread":0.27076904452098194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040596732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769513,0.00054105336,0.00008454278,0.0067803264,0.0004973655,0.014157016,0.0003505008,0.00005640381,0.0005814869],"genre_scores_gemma":[0.9496504,0.00043701284,0.003033722,0.028731255,0.0019061348,0.003920825,0.009405756,0.00054068025,0.0023742123],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99402046,0.0005901063,0.0014862258,0.0010375694,0.0016163798,0.0012492843],"domain_scores_gemma":[0.9956568,0.0014161533,0.0007287377,0.001058667,0.00094005704,0.00019957704],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.000995363,0.0008340993,0.0030645826,0.0009622597,0.000088550456,0.000027076143,0.00060945534,0.0009894104,0.00014576277],"category_scores_gemma":[0.0004227584,0.00060695084,0.00042934762,0.00072497723,0.0003575833,0.00017428893,0.00018042208,0.0029627602,0.0000151042],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8655142,0.0005273402,0.019974446,0.0011903517,0.0017732,0.000628281,0.0032755327,0.00008737734,0.00011199172,0.000019219591,0.104094684,0.002803328],"study_design_scores_gemma":[0.9293958,0.003978767,0.02054715,0.0014603097,0.0005120377,0.000015164995,0.0006011596,0.00044114076,0.00006641932,0.000035480858,0.042231288,0.00071531517],"about_ca_topic_score_codex":0.0013135439,"about_ca_topic_score_gemma":0.0001925233,"teacher_disagreement_score":0.06388152,"about_ca_system_score_codex":0.011816188,"about_ca_system_score_gemma":0.0032896025,"threshold_uncertainty_score":0.9996382},"labels":[],"label_agreement":null},{"id":"W2040812277","doi":"10.1182/blood-2011-04-350017","title":"Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Izaak Walton Killam Health Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Organomegaly; Leukocytosis; Internal medicine; Natural history; Pediatrics; Natural history study; Prospective cohort study; Gastroenterology; Surgery; Disease","score_opus":0.025564693285829193,"score_gpt":0.29264464683577374,"score_spread":0.2670799535499445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040812277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99402744,0.0014862822,0.0000097939665,0.00059689226,0.00025724288,0.0023271556,0.000019500498,0.00004491977,0.0012307483],"genre_scores_gemma":[0.9979637,0.00011372202,0.0006912111,0.00045576273,0.00009204243,0.00026920665,0.00008152529,0.00003799995,0.00029478205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968942,0.0004934602,0.001044255,0.0006080362,0.0005510391,0.00040904403],"domain_scores_gemma":[0.99780774,0.0008190082,0.00027835992,0.0007816635,0.00016713089,0.00014607259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011596944,0.00025339593,0.0007997716,0.00014329617,0.000042327898,0.000004537593,0.00040139223,0.0002040437,0.00028909917],"category_scores_gemma":[0.0009255402,0.00016644965,0.00017821169,0.00027193633,0.0004001743,0.00008046535,0.0001345986,0.0011184802,0.000016436059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013403026,0.011372066,0.93525726,0.000016951351,0.0009040233,0.009335104,0.037852548,3.9674677e-7,0.0005334249,0.000011154882,0.0008518998,0.0025248686],"study_design_scores_gemma":[0.014784979,0.0037134495,0.9768828,0.00006747865,0.0003545737,0.0007166659,0.0020001621,0.000014198016,0.000030064684,0.000033786433,0.0012346746,0.00016717345],"about_ca_topic_score_codex":0.005383216,"about_ca_topic_score_gemma":0.002086558,"teacher_disagreement_score":0.041625533,"about_ca_system_score_codex":0.0005006903,"about_ca_system_score_gemma":0.0010794855,"threshold_uncertainty_score":0.8137848},"labels":[],"label_agreement":null},{"id":"W2040814011","doi":"10.1016/j.exphem.2014.10.007","title":"Bloody signals: From birth to disease and death","year":2014,"lang":"en","type":"editorial","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Heart, Lung, and Blood Institute","keywords":"Bloody; Disease; Art; History; Ancient history; Medicine; Literature; Internal medicine","score_opus":0.01573760479614174,"score_gpt":0.3399948631078242,"score_spread":0.32425725831168245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040814011","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10947552,0.059404314,0.0002018928,0.0018204994,0.8216332,0.0029620887,0.0010760898,0.0004286864,0.002997715],"genre_scores_gemma":[0.17570162,0.00028114422,0.0022087712,0.001192666,0.812748,0.00065582327,0.0021331124,0.00029654958,0.0047823107],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99683726,0.00017372544,0.00046165186,0.0010755507,0.0007923678,0.00065944553],"domain_scores_gemma":[0.99693614,0.000856449,0.000117911295,0.0007624909,0.000117736614,0.00120928],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017302476,0.0005270425,0.0012560872,0.0002790254,0.00010705519,0.0000432563,0.00031601096,0.00079276564,0.0012757378],"category_scores_gemma":[0.0006904469,0.0004726486,0.00014605412,0.000118030875,0.00016429163,0.000047550722,0.0005631166,0.0008933119,0.00071681396],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014644144,0.00027476976,0.000548015,0.00018607343,0.0002463943,0.0009732329,0.00023446948,1.4687653e-7,0.002379408,0.0007220133,0.99286795,0.000103105645],"study_design_scores_gemma":[0.004042672,0.0010227963,0.00011441729,0.00040594907,0.00019929008,0.00007824567,0.00019911329,0.00006656016,0.04907107,0.0002085321,0.94401675,0.00057457923],"about_ca_topic_score_codex":0.00035742804,"about_ca_topic_score_gemma":0.000008655204,"teacher_disagreement_score":0.0662261,"about_ca_system_score_codex":0.00037443358,"about_ca_system_score_gemma":0.0006333963,"threshold_uncertainty_score":0.99977255},"labels":[],"label_agreement":null},{"id":"W2041118485","doi":"10.1503/cmaj.090703","title":"Leukemia cutis: an unusual rash in a child","year":2009,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Buttocks; Rash; Medicine; Dermatology; Girl; Leukemia cutis; Cutis; Leukemia; Surgery; Internal medicine; Psychology","score_opus":0.008452544093284458,"score_gpt":0.28052008367845543,"score_spread":0.272067539585171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041118485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8646583,0.00023242588,0.00004013177,0.11406088,0.0003159006,0.00023754152,0.000011912747,0.000036344252,0.020406572],"genre_scores_gemma":[0.9638934,0.00019707618,0.00018283274,0.03235849,0.002389473,0.000003721924,0.000027597598,0.000020012132,0.00092737656],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99634254,0.00024315213,0.0005077255,0.00022367791,0.0018042439,0.0008786499],"domain_scores_gemma":[0.995708,0.00008331063,0.00012287532,0.0001649675,0.00029402893,0.0036268495],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024830117,0.00014775146,0.00033461876,0.0005875477,0.00021066924,0.00008584518,0.0002755758,0.0005790393,0.0022637304],"category_scores_gemma":[0.0028432193,0.00013693128,0.00009534184,0.00059571955,0.00003943396,0.0002258518,0.000011516474,0.0028328162,0.00021645732],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00011480455,0.0003243822,0.31933883,0.000018797524,0.00018615428,0.021650441,0.0016836722,0.00002385925,0.00012227718,0.0014029664,0.37114578,0.28398803],"study_design_scores_gemma":[0.0060393536,0.0004902314,0.7840855,0.00027440212,0.000034233664,0.0063993526,0.0006683564,0.0024289817,0.00005383476,0.0004785106,0.19876662,0.00028064253],"about_ca_topic_score_codex":0.0041457713,"about_ca_topic_score_gemma":0.03238347,"teacher_disagreement_score":0.46474665,"about_ca_system_score_codex":0.010261787,"about_ca_system_score_gemma":0.013144198,"threshold_uncertainty_score":0.9994677},"labels":[],"label_agreement":null},{"id":"W2042130205","doi":"10.1158/1535-7163.targ-13-c175","title":"Abstract C175: Effective targeting of PI3K/mTOR pathways with GDC-0980 in FLT-3 mutant pediatric leukemia.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"PI3K/AKT/mTOR pathway; Protein kinase B; Apoptosis; Caspase; Caspase 3; Kinase; Growth inhibition; Pharmacology; Cancer research; Caspase 8; Chemistry; Cell growth; Biology; Cell biology; Programmed cell death; Biochemistry","score_opus":0.01573195703276472,"score_gpt":0.27608041828657137,"score_spread":0.2603484612538067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042130205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99192256,0.0039716773,0.00061459886,0.00044579088,0.00008492665,0.0017150611,0.00002572005,0.000058047008,0.0011616141],"genre_scores_gemma":[0.99659467,0.0009113911,0.0009483469,0.00080754474,0.00019086499,0.00035757545,0.000016356815,0.00011086941,0.000062391475],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99758005,0.00011270985,0.00046714707,0.00046852534,0.0006996343,0.00067193614],"domain_scores_gemma":[0.9985829,0.00015304054,0.00020664479,0.00048868224,0.00038244156,0.00018629673],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034601323,0.00033810158,0.0005608121,0.0003009018,0.000053384018,0.000028228837,0.0002522348,0.00021629725,0.0002735267],"category_scores_gemma":[0.00005007163,0.00026477003,0.00012910548,0.000765282,0.00014064094,0.00011169864,0.00007904452,0.00068476447,0.000040720315],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005705677,0.00022771372,0.034590326,0.0005555072,0.00037854252,0.00045180155,0.0011866374,0.000598586,0.9234874,0.000065132415,0.00015968228,0.037728097],"study_design_scores_gemma":[0.010785085,0.0016597701,0.2399401,0.0005053541,0.00058147527,0.000048579994,0.000968119,0.004780367,0.73749965,0.00046996004,0.0017891214,0.0009724053],"about_ca_topic_score_codex":0.00089826505,"about_ca_topic_score_gemma":0.000039495808,"teacher_disagreement_score":0.20534977,"about_ca_system_score_codex":0.001316813,"about_ca_system_score_gemma":0.0011101384,"threshold_uncertainty_score":0.99998045},"labels":[],"label_agreement":null},{"id":"W2042482546","doi":"10.1111/ejh.12382","title":"Transient myeloproliferative disorder in neonates without Down syndrome: case report and review","year":2014,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Trisomy; Down syndrome; Myeloproliferative Disorders; Medicine; Population; Aneuploidy; Pathology; Trisomy 8; Disease; Pediatrics; Immunology; Chromosome; Cytogenetics; Genetics; Biology","score_opus":0.015522874665339048,"score_gpt":0.2970291577226387,"score_spread":0.2815062830572997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042482546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728183,0.012290807,0.001023356,0.010600772,0.00008762732,0.00033164464,9.971498e-7,0.000011075364,0.0028353808],"genre_scores_gemma":[0.99367905,0.0030700152,0.0017881278,0.0011494625,0.00004916098,0.0000028112688,0.0000028658565,0.000034806646,0.0002236893],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9972478,0.0010537128,0.0009601733,0.00022307075,0.00023817965,0.000277054],"domain_scores_gemma":[0.9987648,0.00014942605,0.00035201843,0.00025246665,0.00024507052,0.00023622002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028492804,0.0001687328,0.0009357627,0.00025187034,0.000048901074,0.000011414315,0.00011407006,0.000036769405,0.00008845124],"category_scores_gemma":[0.0010613406,0.000117873366,0.00008857516,0.00020087934,0.00020864431,0.00008904623,0.000055899283,0.000670613,0.000027264943],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015880032,0.0000706773,0.013159237,0.0006855969,0.00008115944,0.9752561,0.00047919666,0.0000026997957,0.00007262727,0.00008194229,0.001798362,0.008153637],"study_design_scores_gemma":[0.0023607528,0.00072834245,0.011435037,0.0015960352,0.00009963816,0.96835476,0.00013411988,0.000081316866,0.00003893183,0.000025804826,0.015041686,0.00010356721],"about_ca_topic_score_codex":0.00001110741,"about_ca_topic_score_gemma":0.000016309203,"teacher_disagreement_score":0.02086072,"about_ca_system_score_codex":0.000056489862,"about_ca_system_score_gemma":0.00015859569,"threshold_uncertainty_score":0.48067364},"labels":[],"label_agreement":null},{"id":"W2042896255","doi":"10.1016/j.ejca.2011.10.009","title":"Treatment-related mortality in children with acute myeloid leukaemia in Central America: Incidence, timing and predictors","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"Canadian Institutes of Health Research; Hospital for Sick Children","keywords":"Myeloid leukaemia; Incidence (geometry); Medicine; Pediatrics; Myeloid; Chronic myeloid leukaemia; Oncology; Demography; Internal medicine","score_opus":0.024512929396593688,"score_gpt":0.28862630455080257,"score_spread":0.2641133751542089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042896255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954439,0.00091180677,0.000023670296,0.00015353988,0.00005133865,0.000247424,0.000008085275,0.0000112342395,0.0031490338],"genre_scores_gemma":[0.9962521,0.0026407025,0.0006044399,0.00008452529,0.000113024646,0.0000030768474,0.000003664309,0.00003840048,0.00026003155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834025,0.00023820178,0.0005076091,0.00020360884,0.00033327757,0.00037705989],"domain_scores_gemma":[0.9991914,0.000019288049,0.00026591105,0.00016597462,0.00008802719,0.0002694008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029603875,0.00018074378,0.00040375325,0.00029352854,0.000028179065,0.000014160364,0.00014440685,0.000032617874,0.00014156493],"category_scores_gemma":[0.000037611746,0.00012190484,0.00005574211,0.00038810406,0.0001932589,0.00021717473,0.000045770787,0.0005436316,0.000005314173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070486224,0.000087263594,0.9752696,0.000006464999,0.00052568864,0.0030499743,0.0027174414,0.000039545204,0.00053125265,0.0000025945526,0.00008064335,0.016984643],"study_design_scores_gemma":[0.005714563,0.0011280156,0.9905985,0.00023427319,0.00021656753,0.0010315321,0.00015001764,0.00009032745,0.00052300724,0.0000035753678,0.00019844944,0.00011114756],"about_ca_topic_score_codex":0.00091509655,"about_ca_topic_score_gemma":0.00012980896,"teacher_disagreement_score":0.016873496,"about_ca_system_score_codex":0.0007108831,"about_ca_system_score_gemma":0.0005574219,"threshold_uncertainty_score":0.49711353},"labels":[],"label_agreement":null},{"id":"W2043169671","doi":"10.1016/j.leukres.2011.03.007","title":"Mouse models of myelodysplastic syndromes","year":2011,"lang":"en","type":"review","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Genome British Columbia","funders":"Canadian Institutes of Health Research; University of British Columbia; Michael Smith Health Research BC; European Molecular Biology Organization","keywords":"Myelodysplastic syndromes; Phenotype; Bone marrow; Haematopoiesis; Progenitor cell; Biology; Xenotransplantation; Cancer research; Disease; Leukemia; clone (Java method); Hematopoietic stem cell; Stem cell; Immunology; Computational biology; Medicine; Pathology; Genetics; Transplantation; Gene; Internal medicine","score_opus":0.2860556436850702,"score_gpt":0.4401797091625552,"score_spread":0.15412406547748503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043169671","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001460958,0.96513355,0.0000908761,0.000026350473,0.00011523884,0.003223336,0.00014687276,0.00013864656,0.03097904],"genre_scores_gemma":[0.0001467572,0.96150905,0.0010750252,0.000015848813,0.00032993278,0.0006267791,0.00026373786,0.00038093547,0.03565194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9908569,0.0012576871,0.00168464,0.0014066433,0.0026880594,0.002106071],"domain_scores_gemma":[0.99236196,0.002129877,0.00038125063,0.0027714968,0.001397487,0.000957911],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0036268774,0.0008793197,0.004593305,0.003229865,0.00021036359,0.00006251206,0.0018117424,0.0015580682,0.0010430255],"category_scores_gemma":[0.0014497208,0.0006748605,0.0011629461,0.0029424685,0.0013071555,0.00023370431,0.0014055958,0.006037916,0.0022078045],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00030810822,0.00028375213,0.000003894124,0.11710722,0.0013055468,0.0010550426,0.00026750052,0.0000064269298,0.000027195085,0.0064933263,0.020534731,0.85260725],"study_design_scores_gemma":[0.0013712016,0.00084883766,0.0000025183776,0.02298166,0.0008105568,0.0011515635,0.000072859046,0.0005296847,0.00007961084,0.0007523981,0.97080255,0.0005965565],"about_ca_topic_score_codex":0.00077248126,"about_ca_topic_score_gemma":0.000013082828,"teacher_disagreement_score":0.9502678,"about_ca_system_score_codex":0.006293459,"about_ca_system_score_gemma":0.017495187,"threshold_uncertainty_score":0.9998702},"labels":[],"label_agreement":null},{"id":"W2043874839","doi":"10.1182/blood-2007-03-080523","title":"MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Terry Fox Foundation; Deutsche Forschungsgemeinschaft; Michael Smith Health Research BC","keywords":"Myeloid leukemia; Cancer research; Biology; Haematopoiesis; Tretinoin; Leukemia; Myeloid; Retinoic acid; Stem cell; Bone marrow; Immunology; Cell culture; Genetics","score_opus":0.008264420068514402,"score_gpt":0.24980049431693735,"score_spread":0.24153607424842294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043874839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946724,0.0003235995,0.00000978805,0.000118558855,0.000022796032,0.000680879,0.00001774137,0.000037645194,0.004116592],"genre_scores_gemma":[0.9970324,0.000100500656,0.0020145027,0.00016999652,0.00007496961,0.000018476258,0.000041456777,0.000036399622,0.00051132275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800146,0.000052236814,0.00034864765,0.00045589567,0.0005842795,0.0005575036],"domain_scores_gemma":[0.99917674,0.00012692838,0.000089554174,0.0002981795,0.000089959125,0.00021862851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044369927,0.00020675588,0.00032863842,0.00033048075,0.000048042682,0.0000203841,0.00014723041,0.00020254076,0.000015106412],"category_scores_gemma":[0.00012683304,0.00016334013,0.000022846367,0.000535325,0.000117310796,0.0002065429,0.000108362015,0.0006252656,0.0000075345724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039959224,0.0005690683,0.9496237,0.00021184712,0.00009457099,0.00059604074,0.0014758435,0.0000015856482,0.041651506,0.000051386043,0.00048924045,0.001239295],"study_design_scores_gemma":[0.01785555,0.0004125823,0.95278746,0.0009416415,0.000053399443,0.000014252484,0.000099067736,0.000007684267,0.027264057,0.000041611063,0.00034535668,0.0001773476],"about_ca_topic_score_codex":0.00017794258,"about_ca_topic_score_gemma":0.00046220605,"teacher_disagreement_score":0.01438745,"about_ca_system_score_codex":0.0005221559,"about_ca_system_score_gemma":0.00038994302,"threshold_uncertainty_score":0.6660817},"labels":[],"label_agreement":null},{"id":"W2046185040","doi":"10.1002/cncr.21006","title":"Disease biology rather than age is the most important determinant of survival of patients ≥ 60 years with acute myeloid leukemia treated with uniform intensive therapy","year":2005,"lang":"en","type":"article","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Acute promyelocytic leukemia; Myeloid leukemia; Cytarabine; Univariate analysis; Leukemia; Gastroenterology; Daunorubicin; Adverse effect; Oncology; Multivariate analysis","score_opus":0.0165981271074076,"score_gpt":0.29212863476091966,"score_spread":0.27553050765351206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046185040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975537,0.0004676942,0.000013022421,0.0005784023,0.000033140786,0.00079498196,0.00033957695,0.000016810614,0.00020265291],"genre_scores_gemma":[0.9961757,0.0015751305,0.00009084928,0.0008278244,0.00008081945,0.000083137784,0.00009278101,0.000053091113,0.0010206461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863404,0.00005404659,0.0003226731,0.00030002173,0.00032894043,0.00036029698],"domain_scores_gemma":[0.99835485,0.000059684626,0.00025096253,0.0005407653,0.0006217305,0.00017199501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011938567,0.00022515137,0.0004770694,0.00009848295,0.00004051317,0.0000062810327,0.00021772667,0.00008302572,0.00018430037],"category_scores_gemma":[0.000028489378,0.00010990857,0.000078798876,0.0003697928,0.0005845758,0.000060908587,0.000052026095,0.00023644856,0.000003915667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01697318,0.00019976297,0.93243635,0.00006482204,0.0013689717,0.00062546023,0.0031856429,0.000022519096,0.013198017,0.00004040152,0.0016006887,0.030284174],"study_design_scores_gemma":[0.009170755,0.0022071996,0.9487583,0.00025129647,0.00037997024,0.000016491484,0.00060124276,0.00044701944,0.031000614,0.000014965088,0.00686837,0.00028378426],"about_ca_topic_score_codex":0.00095994875,"about_ca_topic_score_gemma":0.00038398514,"teacher_disagreement_score":0.030000389,"about_ca_system_score_codex":0.00045285714,"about_ca_system_score_gemma":0.0011410175,"threshold_uncertainty_score":0.44819415},"labels":[],"label_agreement":null},{"id":"W2046364242","doi":"10.1016/j.critrevonc.2012.07.003","title":"The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline","year":2012,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal General Hospital; Jewish General Hospital; McGill University Health Centre; Sunnybrook Health Science Centre; St. Paul's Hospital; Health Sciences Centre; University of British Columbia","funders":"","keywords":"Lenalidomide; Thalidomide; Myelodysplastic syndromes; Guideline; Medicine; Intensive care medicine; Oncology; Internal medicine; Multiple myeloma; Pathology; Bone marrow","score_opus":0.2543962427450863,"score_gpt":0.5526891098308602,"score_spread":0.29829286708577385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046364242","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024726487,0.9831931,0.00018739431,0.006059077,0.0016028446,0.00800046,0.000047542908,0.00001922546,0.0008656142],"genre_scores_gemma":[0.000053639676,0.98859024,0.0064323097,0.0010908456,0.00045919072,0.0029168893,0.000048152022,0.00010818938,0.00030054475],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98584926,0.005809718,0.005732829,0.00095928257,0.00039434058,0.0012545547],"domain_scores_gemma":[0.93594664,0.059693716,0.0014684204,0.0018880321,0.00053882075,0.00046435432],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009398698,0.0008315257,0.008494353,0.00021553652,0.00025916565,0.000024041668,0.0008167462,0.0014993297,0.000084560306],"category_scores_gemma":[0.0766605,0.0003967963,0.0016929511,0.00046819,0.0027095145,0.00010188888,0.0005235496,0.0012632634,0.000120089644],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004861048,0.0011606985,0.00006696161,0.015696969,0.0007014752,0.0002580831,0.000059593625,2.7067372e-8,5.905703e-7,0.012241197,0.010297573,0.95903075],"study_design_scores_gemma":[0.0028892453,0.0014449727,0.000019533089,0.011944477,0.0062770504,0.010473545,0.00007354883,0.000027741236,0.0000014401144,0.00036360772,0.96620196,0.00028285163],"about_ca_topic_score_codex":0.000018101846,"about_ca_topic_score_gemma":0.000020519969,"teacher_disagreement_score":0.95874786,"about_ca_system_score_codex":0.0015597156,"about_ca_system_score_gemma":0.0030206947,"threshold_uncertainty_score":0.99984837},"labels":[],"label_agreement":null},{"id":"W2046948982","doi":"10.1007/s10227-002-1162-6","title":"Leukemia Cutis Presenting with Fingertip Hypertrophy","year":2003,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Leukemia cutis; Medicine; Cutis; Leukemia; Biopsy; Pathology; Lesion; Dermatology; Histopathological examination; Physical examination; Chronic lymphocytic leukemia; Bone marrow; Surgery; Internal medicine","score_opus":0.028936271605662284,"score_gpt":0.2736973881650686,"score_spread":0.24476111655940633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046948982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98477143,0.0034485774,0.0001833333,0.004189585,0.00021101211,0.00013430727,5.5112355e-7,0.000017784758,0.0070434413],"genre_scores_gemma":[0.9925643,0.0024057832,0.0010916359,0.0014584672,0.000689874,0.0000017834575,0.000001914683,0.00004165832,0.0017445711],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99769497,0.00013428654,0.0007100932,0.00019427072,0.0008346897,0.00043169616],"domain_scores_gemma":[0.997114,0.0013776452,0.0003572117,0.00023153925,0.00044688376,0.00047272368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009700734,0.00021072356,0.00091900013,0.0004995982,0.00010652341,0.000020222777,0.000077269055,0.000105925224,0.00025247145],"category_scores_gemma":[0.002304633,0.0001248462,0.00013566263,0.0003747458,0.0002859909,0.00011831495,0.000018378532,0.00068585953,0.0000056548183],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005238211,0.00033420758,0.44126406,0.0011971358,0.0017521787,0.13808659,0.002930385,0.00007175832,0.033810522,0.00039747765,0.3423902,0.032527264],"study_design_scores_gemma":[0.006178701,0.0039336244,0.010927315,0.0029559026,0.0011334296,0.6268927,0.0024534075,0.00051024405,0.0062361513,0.000518681,0.33760443,0.0006554387],"about_ca_topic_score_codex":0.00003683525,"about_ca_topic_score_gemma":0.0000024649041,"teacher_disagreement_score":0.4888061,"about_ca_system_score_codex":0.00021010694,"about_ca_system_score_gemma":0.0010819901,"threshold_uncertainty_score":0.50910807},"labels":[],"label_agreement":null},{"id":"W2047081341","doi":"10.1016/s0165-4608(03)00056-6","title":"Rearrangement of the MLL gene and a region proximal to the RARα gene in a case of acute myelocytic leukemia M5 with a t(11;17)(q23;q21)","year":2003,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; McGill University; Montreal Children's Hospital; Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"Biology; Chromosomal translocation; Fusion gene; Acute promyelocytic leukemia; Fluorescence in situ hybridization; Gene rearrangement; Gene; Molecular biology; Leukemia; Chromosomal rearrangement; Locus (genetics); Karyotype; Exon; Genetics; Cancer research; Chromosome","score_opus":0.023973719305161824,"score_gpt":0.28810276830506226,"score_spread":0.2641290489999004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047081341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905624,0.006118135,0.00033521873,0.001235628,0.000042882293,0.0015275081,0.00005537794,0.000005658367,0.00011721645],"genre_scores_gemma":[0.9883649,0.0068450263,0.0036403944,0.0004849083,0.00007159429,0.00014961627,0.0000031760223,0.000046375644,0.00039403676],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982497,0.00011672476,0.00041905083,0.0004145424,0.0003844223,0.0004155715],"domain_scores_gemma":[0.99861866,0.000043038384,0.00015328369,0.0007284009,0.00025011122,0.00020651951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002966109,0.00025165745,0.0004133413,0.00012336316,0.00009826807,0.000020224192,0.00019157083,0.00012033486,0.000012303943],"category_scores_gemma":[0.00003212391,0.00015115316,0.00005776295,0.00058766274,0.00037391292,0.0000144425585,0.00018850288,0.00019469566,4.203561e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031209537,0.0003873624,0.54821104,0.0012703763,0.0014874799,0.003255195,0.011400677,0.0055553373,0.37660506,0.0003709201,0.004601143,0.043734465],"study_design_scores_gemma":[0.01100787,0.0030965083,0.15037692,0.0005645446,0.0015929996,0.0064096735,0.0016718901,0.0043217153,0.7966628,0.00014395885,0.02343523,0.0007158962],"about_ca_topic_score_codex":0.00042011385,"about_ca_topic_score_gemma":0.0015124949,"teacher_disagreement_score":0.42005774,"about_ca_system_score_codex":0.00031798345,"about_ca_system_score_gemma":0.0010303631,"threshold_uncertainty_score":0.6163847},"labels":[],"label_agreement":null},{"id":"W2047446466","doi":"10.1111/j.1600-0609.2007.00985.x","title":"Relative response of patients with myelodysplastic syndromes and other transfusion‐dependent anaemias to deferasirox (ICL670): a 1‐yr prospective study","year":2007,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":239,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Toronto General Hospital","funders":"","keywords":"Deferasirox; Medicine; Myelodysplastic syndromes; Internal medicine; Tolerability; Adverse effect; Gastroenterology; Rash; Creatinine; Deferiprone; Prospective cohort study; Anemia; Deferoxamine; Thalassemia","score_opus":0.01761672658062096,"score_gpt":0.28468205114405354,"score_spread":0.26706532456343257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047446466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99516,0.000098289216,0.0026114464,0.0002772615,0.000066937384,0.000968794,0.000009177105,0.000011984943,0.00079610053],"genre_scores_gemma":[0.99777067,0.000006950547,0.0018206232,0.00013436201,0.000030084955,0.0000021976912,5.9221685e-7,0.00005819852,0.00017633465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996882,0.0010643377,0.0008097919,0.0002842841,0.0006120903,0.00034745157],"domain_scores_gemma":[0.9977691,0.00066773256,0.00036797996,0.0002489086,0.0005967861,0.00034946765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028418277,0.00021571848,0.0007751939,0.00066280336,0.00007350692,0.0000100971465,0.00018514425,0.000046635072,0.00006526141],"category_scores_gemma":[0.00091916305,0.00014481659,0.00006894027,0.00037889963,0.00021661093,0.0001000487,0.000084663756,0.0005958718,0.000021343061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055008817,0.0010432956,0.9018182,0.00006184723,0.00067934615,0.027296407,0.012169406,0.000011171381,0.0010461966,0.00008610106,0.00009919073,0.0006800227],"study_design_scores_gemma":[0.010659042,0.017729314,0.95852244,0.00024368193,0.00023417018,0.00873396,0.0026975842,0.0000024141439,0.0008900538,0.000015223717,0.0001348071,0.0001373338],"about_ca_topic_score_codex":0.000007898169,"about_ca_topic_score_gemma":0.000021310745,"teacher_disagreement_score":0.056704216,"about_ca_system_score_codex":0.00017159471,"about_ca_system_score_gemma":0.00019153458,"threshold_uncertainty_score":0.5905449},"labels":[],"label_agreement":null},{"id":"W2047676216","doi":"10.1590/s1516-84842006000300016","title":"Síndrome mielodisplásica na infância","year":2006,"lang":"pt","type":"article","venue":"Revista Brasileira de Hematologia e Hemoterapia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Humanities; Medicine; Physics; Philosophy","score_opus":0.01975405028644899,"score_gpt":0.2955066997648189,"score_spread":0.2757526494783699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047676216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96610236,0.016617866,0.003568302,0.0015924379,0.00055927655,0.0026716825,0.00019279723,0.0007486201,0.007946669],"genre_scores_gemma":[0.9762779,0.0003378649,0.0036609392,0.0021938926,0.0011310052,0.000109931,0.00039549492,0.0003370487,0.015555934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98985887,0.0008882221,0.0023503886,0.0019711473,0.0016880892,0.0032432596],"domain_scores_gemma":[0.99377126,0.0010089956,0.0007953979,0.0027066981,0.000582785,0.0011348393],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0018355806,0.001528445,0.0028688323,0.0009142081,0.0005795255,0.00070500304,0.0016303519,0.0015939143,0.0030693738],"category_scores_gemma":[0.0011513102,0.0014641918,0.0009946721,0.0021111998,0.0008390975,0.00044515452,0.00074179977,0.0028082032,0.005188675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069521484,0.0012339535,0.6835278,0.006998178,0.00064376043,0.0076433853,0.0005592321,0.000010594242,0.011766923,0.021328842,0.26350874,0.0020833544],"study_design_scores_gemma":[0.011843564,0.0014841154,0.8939443,0.0067588324,0.0014766516,0.016643334,0.00074707676,0.009623546,0.010563917,0.0004065356,0.042596847,0.003911282],"about_ca_topic_score_codex":0.00056678086,"about_ca_topic_score_gemma":0.000027203045,"teacher_disagreement_score":0.2209119,"about_ca_system_score_codex":0.0022558956,"about_ca_system_score_gemma":0.002314157,"threshold_uncertainty_score":0.99974644},"labels":[],"label_agreement":null},{"id":"W2047733926","doi":"10.1158/1055-9965.epi-06-0964","title":"Concordance of Pharmacogenetic Polymorphisms in Tumor and Germ Line DNA in Adult Patients with Acute Myeloid Leukemia","year":2007,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Buccal swab; Genotype; Myeloid leukemia; Biology; Genotyping; Cancer research; Bone marrow; XRCC1; Molecular biology; Immunology; Genetics; Single-nucleotide polymorphism; Gene","score_opus":0.023116566097873277,"score_gpt":0.3503680302357269,"score_spread":0.3272514641378536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047733926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936185,0.0029604067,0.0009323951,0.0009999044,0.0001554292,0.0011773007,0.000025335017,0.000022207443,0.00010853745],"genre_scores_gemma":[0.993666,0.0016397383,0.00315285,0.0010218101,0.00007720876,0.00012635392,0.00010682596,0.000036504003,0.0001727063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703586,0.0004008821,0.0010514299,0.0006112296,0.00020402021,0.0006965637],"domain_scores_gemma":[0.9983268,0.00049539376,0.0004675734,0.00029196622,0.00019952674,0.00021878492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021481244,0.00027170876,0.0008244927,0.000500819,0.00003319955,0.0000022670713,0.00014991594,0.0002040239,0.00007043871],"category_scores_gemma":[0.00040143335,0.00023122353,0.00008549802,0.00060535985,0.00052466244,0.00011581989,0.00008422751,0.00041375915,0.0000038783346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058130077,0.00013196582,0.9356057,0.00012637318,0.00027782246,0.000101776124,0.00009007797,0.000012217509,0.023034712,0.000024798343,0.0003739164,0.0344076],"study_design_scores_gemma":[0.010403735,0.00068687554,0.9748455,0.00072828773,0.00014732368,0.00003970719,0.000041940522,0.0006911307,0.011847824,0.00024088558,0.00011835249,0.00020838826],"about_ca_topic_score_codex":0.0011419271,"about_ca_topic_score_gemma":0.0014896415,"teacher_disagreement_score":0.03923982,"about_ca_system_score_codex":0.0011715794,"about_ca_system_score_gemma":0.0006213848,"threshold_uncertainty_score":0.94290215},"labels":[],"label_agreement":null},{"id":"W2047861370","doi":"10.1155/2015/253294","title":"Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy","year":2015,"lang":"en","type":"article","venue":"Case Reports in Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Discontinuation; Chelation therapy; Blood transfusion; Internal medicine; Intensive care medicine; Thalassemia","score_opus":0.022251113120137465,"score_gpt":0.28581568624862624,"score_spread":0.2635645731284888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047861370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974413,0.00039725588,0.00009816164,0.00012992436,0.00009099392,0.0010847321,0.0000010047092,0.000024414607,0.00073220767],"genre_scores_gemma":[0.9988485,0.000049150676,0.00088809815,0.00001816266,0.000007788594,0.000084878586,0.000037824164,0.000027369546,0.000038203878],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99782526,0.00018290854,0.0007701297,0.0004424143,0.0004781215,0.0003011712],"domain_scores_gemma":[0.9988706,0.00007944387,0.0002963764,0.0004768764,0.00013532954,0.00014135457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009128124,0.00016435576,0.00054581574,0.00035527762,0.000027588772,0.0000072042308,0.000039159175,0.00025048634,0.000024365572],"category_scores_gemma":[0.00020210902,0.00013452755,0.0000516868,0.00043314626,0.000062962186,0.00026144067,0.00002401817,0.00037506205,8.777725e-7],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096718944,0.0010231696,0.39074022,0.00014076031,0.000029270022,0.5838343,0.0039253333,0.00026067393,0.018111918,0.000034171393,0.000008063946,0.0009249365],"study_design_scores_gemma":[0.012583915,0.0060675563,0.033433057,0.00076483993,0.00010955211,0.85844684,0.005077717,0.002992349,0.07967039,0.0004183305,0.000024696104,0.00041074812],"about_ca_topic_score_codex":0.0012625537,"about_ca_topic_score_gemma":0.0004696747,"teacher_disagreement_score":0.35730717,"about_ca_system_score_codex":0.00023796552,"about_ca_system_score_gemma":0.0004971087,"threshold_uncertainty_score":0.54858744},"labels":[],"label_agreement":null},{"id":"W2047924751","doi":"10.1038/sj.bmt.1705680","title":"Autologous bone marrow transplantation for children with AML in first remission","year":2007,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia; Izaak Walton Killam Health Centre","funders":"","keywords":"Medicine; Internal medicine; Bone marrow; Surgery; Transplantation; Confidence interval; Chemotherapy; Induction chemotherapy; Randomized controlled trial; Gastroenterology; Oncology","score_opus":0.012943456360372039,"score_gpt":0.27416254494974857,"score_spread":0.26121908858937654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047924751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96038365,0.0002100959,0.033093505,0.0021265268,0.000082028906,0.0023937388,0.00015043758,0.00018406173,0.0013759433],"genre_scores_gemma":[0.9865473,0.00079667964,0.008858484,0.00023711043,0.000151965,0.00013449584,0.002587421,0.00008188937,0.00060463755],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973391,0.00006428549,0.0006637228,0.0006060975,0.000601905,0.00072487287],"domain_scores_gemma":[0.9988664,0.00028059012,0.00014980567,0.00030122284,0.00014434729,0.00025762705],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001009372,0.000337313,0.0004902449,0.00058925786,0.0001830658,0.000030258,0.00012096555,0.00031703728,0.00006637336],"category_scores_gemma":[0.000044327386,0.00029451866,0.000117434625,0.0005706769,0.0001088185,0.0002579831,0.0000047928033,0.00043493847,0.000021950624],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09497174,0.0013402156,0.3898012,0.0070569064,0.00045088178,0.0060359314,0.011064566,0.00084714254,0.4001552,0.0011426846,0.0031948618,0.08393868],"study_design_scores_gemma":[0.01795376,0.0011129885,0.9063032,0.00086016324,0.00045068422,0.004088033,0.00016463903,0.0008641435,0.067088984,0.00011567966,0.0004814345,0.0005162843],"about_ca_topic_score_codex":0.00042083245,"about_ca_topic_score_gemma":0.0024515172,"teacher_disagreement_score":0.516502,"about_ca_system_score_codex":0.00038369355,"about_ca_system_score_gemma":0.00024290924,"threshold_uncertainty_score":0.9999507},"labels":[],"label_agreement":null},{"id":"W2048050781","doi":"10.1038/bcj.2012.44","title":"The role of tumor suppressor p15Ink4b in the regulation of hematopoietic progenitor cell fate","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"National Cancer Institute","keywords":"Haematopoiesis; Progenitor cell; Suppressor; Cancer research; Hematopoietic cell; Progenitor; Immunology; Stem cell; Hematopoietic stem cell; Biology; Medicine; Cell biology; Internal medicine; Cancer","score_opus":0.009836884992128394,"score_gpt":0.26679489073152185,"score_spread":0.2569580057393935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048050781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912631,0.0046751727,0.000004077268,0.002315758,0.00006693658,0.0006134486,0.0000045479137,0.0000042671572,0.0010526807],"genre_scores_gemma":[0.9987864,0.00027658493,0.0002070027,0.00006969785,0.00028493445,0.000092277005,0.0000010127286,0.00001661181,0.00026546844],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840695,0.00016508186,0.0004418938,0.00010139423,0.00060082163,0.0002838372],"domain_scores_gemma":[0.9988996,0.00014969762,0.00027554214,0.00028896413,0.00030629,0.000079920355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065859355,0.00009669475,0.0002188424,0.00008252155,0.00009963711,0.000036882597,0.0003198081,0.000045491433,0.0002672596],"category_scores_gemma":[0.00008229398,0.000049240258,0.00009537223,0.00023536896,0.00013234196,0.00009255619,0.00004124826,0.00047286556,0.000008857134],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003474023,0.000556581,0.045369733,0.00025940043,0.0001799708,0.00002890136,0.0034841702,0.000058414167,0.93845373,0.00019544977,0.0051932735,0.0058729635],"study_design_scores_gemma":[0.0035010085,0.0004121047,0.078290895,0.00026236853,0.0001783926,0.0006849549,0.0030233972,0.00087105774,0.9082563,0.0017876999,0.0026362485,0.000095610325],"about_ca_topic_score_codex":0.00027246418,"about_ca_topic_score_gemma":0.00002237469,"teacher_disagreement_score":0.032921158,"about_ca_system_score_codex":0.00007715663,"about_ca_system_score_gemma":0.0004657783,"threshold_uncertainty_score":0.29263052},"labels":[],"label_agreement":null},{"id":"W2048159897","doi":"10.1016/j.leukres.2009.07.006","title":"Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: An International Working Group on MDS Cytogenetics Study","year":2009,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"North York General Hospital","funders":"","keywords":"Karyotype; International Prognostic Scoring System; Cytogenetics; Myelodysplastic syndromes; Medicine; Internal medicine; Biology; Chromosome; Genetics; Bone marrow","score_opus":0.12957703736855045,"score_gpt":0.47788043306124756,"score_spread":0.3483033956926971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048159897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901661,0.000017122515,0.0010128842,0.00047101377,0.00016146663,0.007984582,0.000049436156,0.000025206478,0.00011218463],"genre_scores_gemma":[0.9921789,0.000012922887,0.00698181,0.00011446679,0.00014344393,0.00034186724,0.00014769766,0.000044473403,0.00003441444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944551,0.00045295674,0.0006932928,0.0006165051,0.003290125,0.0004920489],"domain_scores_gemma":[0.99585015,0.0006364429,0.00041608335,0.0004448891,0.0024155083,0.00023694507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004277027,0.000233098,0.000468051,0.0011049722,0.00023775124,0.00025947354,0.0003778889,0.00009319233,0.000057471112],"category_scores_gemma":[0.0017889156,0.00019446049,0.000043943313,0.000658997,0.0000683993,0.00055337633,0.00015596475,0.00038866495,0.00000295152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06582531,0.0048507284,0.76405096,0.01053453,0.0038743375,0.00026381636,0.028000088,0.002473543,0.053908415,0.00081168825,0.00046869623,0.06493789],"study_design_scores_gemma":[0.05577839,0.05136977,0.65967786,0.011160621,0.0012392817,0.00018168791,0.040949725,0.17014061,0.008039128,0.00035685164,0.00015760773,0.0009484685],"about_ca_topic_score_codex":0.00046952243,"about_ca_topic_score_gemma":0.00010868214,"teacher_disagreement_score":0.16766706,"about_ca_system_score_codex":0.003965461,"about_ca_system_score_gemma":0.0011029103,"threshold_uncertainty_score":0.99985814},"labels":[],"label_agreement":null},{"id":"W2048267487","doi":"10.1038/onc.2012.469","title":"Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"Oncogene","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Labex Immuno-Oncology; Institut National Du Cancer; Fondation de France; Ligue Contre le Cancer","keywords":"Erlotinib; Azacitidine; Decitabine; Myeloid leukemia; Gefitinib; Cancer research; Pharmacology; Biology; Erlotinib Hydrochloride; Leukemia; Myeloid; Epidermal growth factor receptor; Immunology; Cancer; DNA methylation","score_opus":0.015578185956418,"score_gpt":0.29262277260902037,"score_spread":0.27704458665260234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048267487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97861046,0.0035693417,0.0002951033,0.00061109354,0.00037594582,0.00081647496,0.000018956467,0.00017677146,0.015525841],"genre_scores_gemma":[0.9846333,0.0014938482,0.0030252156,0.0013950045,0.001292109,0.000099152356,0.00011640826,0.00010404841,0.007840895],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975889,0.00010186101,0.00033675344,0.000439959,0.0005346152,0.0009979453],"domain_scores_gemma":[0.9979637,0.00032043448,0.00009092391,0.0006111424,0.00011840903,0.00089533697],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054752786,0.00035322527,0.00060715777,0.00021673788,0.00016029226,0.000033463755,0.00018065477,0.00022947736,0.00011978096],"category_scores_gemma":[0.00040881062,0.00029466284,0.00012055039,0.00039415914,0.00020166063,0.00019356555,0.0002475014,0.00049487315,0.0005027423],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040936304,0.00015730588,0.0075807325,0.0003477541,0.00039358914,0.0005129075,0.00034673692,0.0000031794602,0.914967,0.00025726302,0.015425116,0.059599064],"study_design_scores_gemma":[0.01333298,0.0013415255,0.03780519,0.0006094962,0.0013141888,0.0011736983,0.00020305142,0.0016823736,0.80568504,0.00007389332,0.13555916,0.0012194301],"about_ca_topic_score_codex":0.00006480318,"about_ca_topic_score_gemma":0.000004414201,"teacher_disagreement_score":0.12013404,"about_ca_system_score_codex":0.0009497922,"about_ca_system_score_gemma":0.0004724575,"threshold_uncertainty_score":0.9999505},"labels":[],"label_agreement":null},{"id":"W2048337856","doi":"10.1038/sj.leu.2404655","title":"The outcome of intensive induction therapy in patients ⩾70 years with acute myeloid leukemia","year":2007,"lang":"en","type":"letter","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"Israel Cancer Association","keywords":"Myeloid leukemia; Medicine; Induction therapy; Internal medicine; Oncology; Myeloid; Cytarabine; Hematology; Leukemia; Intensive care medicine; Chemotherapy","score_opus":0.02528736010437574,"score_gpt":0.2957891180866036,"score_spread":0.27050175798222786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048337856","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90801495,0.0002771041,0.000032633452,0.08600804,0.0008307579,0.002672369,0.00007111589,0.00010968179,0.0019833392],"genre_scores_gemma":[0.12360623,0.0023945011,0.0011667243,0.8410056,0.0053978804,0.00034481223,0.0020871174,0.00078049494,0.023216646],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946581,0.00021596279,0.001182042,0.0008681416,0.0018474498,0.0012282724],"domain_scores_gemma":[0.9955742,0.0004676093,0.0006645623,0.0014888145,0.0016384363,0.00016640086],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0007561251,0.0007096138,0.0012754594,0.00087219424,0.00012352866,0.000057686564,0.0007793652,0.001663424,0.00006660263],"category_scores_gemma":[0.0004050368,0.00046139644,0.00029939116,0.0011217812,0.0007539924,0.00016371656,0.00021330286,0.0070364983,0.0001206433],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004051262,0.0000481463,0.05859664,0.00019405763,0.0010609137,0.002595223,0.00075614924,0.000010844938,0.00029821097,0.000012143186,0.90268356,0.02969283],"study_design_scores_gemma":[0.015251436,0.0030788162,0.37966543,0.00076135393,0.00035433058,0.00032092372,0.0005051542,0.000060592265,0.0020100141,0.00008271969,0.59685946,0.0010497638],"about_ca_topic_score_codex":0.0014036169,"about_ca_topic_score_gemma":0.00008915581,"teacher_disagreement_score":0.78440875,"about_ca_system_score_codex":0.00894309,"about_ca_system_score_gemma":0.00261166,"threshold_uncertainty_score":0.99978375},"labels":[],"label_agreement":null},{"id":"W2049288252","doi":"10.1002/biof.36","title":"C/EBPα in leukemogenesis: Identity and origin of the leukemia‐initiating cell","year":2009,"lang":"en","type":"review","venue":"BioFactors","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Tellabs (Canada)","funders":"","keywords":"CEBPA; Myeloid leukemia; RUNX1; Myelopoiesis; Biology; Epigenetics; Transcription factor; Leukemia; Cancer research; Myeloid; Ccaat-enhancer-binding proteins; Genetics; Population; Gene; Medicine; DNA-binding protein; Haematopoiesis; Stem cell","score_opus":0.09669181009230585,"score_gpt":0.37742993911454453,"score_spread":0.2807381290222387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049288252","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025626728,0.97060317,0.0000033475228,0.000026657239,0.0001744692,0.0012592464,0.0000525998,0.000031748456,0.0022220067],"genre_scores_gemma":[0.0061305272,0.9926875,0.0001312907,0.000058929236,0.00017695084,0.000028143406,0.000033261073,0.00006645846,0.0006869147],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99719745,0.0002901091,0.00090436474,0.0005190258,0.00060575677,0.00048329358],"domain_scores_gemma":[0.9982551,0.00027559264,0.00047999792,0.000735843,0.00008016068,0.00017334108],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062747585,0.0004635846,0.0018160065,0.00045232056,0.00007115803,0.00003467131,0.0004889265,0.00057075004,0.00006208788],"category_scores_gemma":[0.00033887706,0.0002926169,0.00047166052,0.0010672027,0.00018328534,0.00013323153,0.00027267906,0.0010296926,0.000028946688],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029897745,0.00013603276,0.0073627196,0.041775897,0.00018655395,0.00013336811,0.00022992695,9.5087887e-7,0.00014827558,0.0001635614,0.00069869234,0.9491341],"study_design_scores_gemma":[0.0016752442,0.00018844705,0.009541234,0.022904154,0.0012071556,0.00016015916,0.00014014044,0.000020692736,0.00047929547,0.00005985773,0.9629563,0.0006673242],"about_ca_topic_score_codex":0.00063609,"about_ca_topic_score_gemma":0.00006277352,"teacher_disagreement_score":0.9622576,"about_ca_system_score_codex":0.001911846,"about_ca_system_score_gemma":0.0030583877,"threshold_uncertainty_score":0.9999526},"labels":[],"label_agreement":null},{"id":"W2049295282","doi":"10.1016/j.leukres.2010.07.021","title":"Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation","year":2010,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"NPM1; Internal medicine; Myeloid leukemia; Oncology; Medicine; Karyotype; Leukemia; Clinical significance; Gastroenterology; CD34; Stage (stratigraphy); Biology; Stem cell; Gene; Genetics; Chromosome","score_opus":0.03491698175438952,"score_gpt":0.34600353556413654,"score_spread":0.31108655380974704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049295282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98962766,0.0000720707,0.000009910333,0.0018774724,0.00021086,0.0022821103,0.00001901098,0.000032969234,0.0058679157],"genre_scores_gemma":[0.9976561,0.00008861716,0.00025145742,0.00017061434,0.00019977728,0.00022594609,0.000045683344,0.000056583587,0.0013052108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99364907,0.0009028569,0.00075490656,0.0006423657,0.0026950128,0.00135582],"domain_scores_gemma":[0.99530387,0.002312857,0.00013898232,0.0014601604,0.0005689486,0.0002152077],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0048675067,0.00031256877,0.0004825915,0.00086187833,0.0002682799,0.00008596438,0.0016800882,0.0004443133,0.00019118874],"category_scores_gemma":[0.003910529,0.00018334988,0.00016905685,0.0038202927,0.001127063,0.00029789036,0.0005330668,0.0059983847,0.00011490362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095613825,0.00022104649,0.80528545,0.00035681622,0.00008769045,0.00088316493,0.008143393,0.0002482883,0.17281632,0.0018646016,0.0029991362,0.006137953],"study_design_scores_gemma":[0.002609691,0.00037017406,0.9599103,0.00021332869,0.000023735933,0.00021323394,0.0026418248,0.005478963,0.02683963,0.0006062952,0.00088010466,0.00021274148],"about_ca_topic_score_codex":0.006108461,"about_ca_topic_score_gemma":0.0039452217,"teacher_disagreement_score":0.15462483,"about_ca_system_score_codex":0.003283684,"about_ca_system_score_gemma":0.007160721,"threshold_uncertainty_score":0.99846774},"labels":[],"label_agreement":null},{"id":"W2049623932","doi":"10.1038/bmt.2008.226","title":"Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML","year":2008,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Myelodysplastic syndromes; Gastroenterology; International Prognostic Scoring System; Multivariate analysis; Oncology; Chemotherapy; Bone marrow; Surgery","score_opus":0.026328181154204724,"score_gpt":0.28131599229627524,"score_spread":0.25498781114207053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049623932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99491394,0.00038579424,0.0023404001,0.00029217417,0.00015369209,0.0013152234,0.000101026555,0.000085565436,0.00041220148],"genre_scores_gemma":[0.9962503,0.00081807846,0.0015031346,0.00006465891,0.000030048457,0.00008954684,0.00031395117,0.000050289684,0.00088002207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982396,0.00007189453,0.0005845063,0.00034016924,0.00042844182,0.00033542648],"domain_scores_gemma":[0.99899656,0.0004279976,0.00013427719,0.00017918591,0.000108454624,0.00015353989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003462021,0.00022704675,0.0005391106,0.0002836629,0.00014241491,0.000007821581,0.00007480806,0.00017750665,0.00003677186],"category_scores_gemma":[0.0000898586,0.0001984618,0.00018514026,0.00028795324,0.00016045145,0.00018682702,0.000009227758,0.00022351675,0.000007117544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076113963,0.0003813838,0.76368296,0.001991464,0.0020494158,0.0023410022,0.012417218,0.00017929969,0.20565103,0.00040203304,0.0003896918,0.0029031283],"study_design_scores_gemma":[0.017489085,0.0018476485,0.96128225,0.00037563872,0.00064579514,0.002707979,0.00020849818,0.0020284702,0.012684747,0.00015088443,0.00019916084,0.00037986742],"about_ca_topic_score_codex":0.000069901034,"about_ca_topic_score_gemma":0.000010644468,"teacher_disagreement_score":0.19759929,"about_ca_system_score_codex":0.00010170872,"about_ca_system_score_gemma":0.0001472838,"threshold_uncertainty_score":0.8093037},"labels":[],"label_agreement":null},{"id":"W2050127987","doi":"10.1182/blood-2003-09-3192","title":"Engraftment of NOD/SCID-β2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Nod; Cancer research; Myelodysplastic syndromes; Beta-2 microglobulin; Biology; Medicine; Immunology; Bone marrow; In vivo; Genetics","score_opus":0.005244723828822886,"score_gpt":0.20918674837958198,"score_spread":0.2039420245507591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050127987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972924,0.00013600512,0.0007269732,0.000102587386,0.00007373988,0.0011586364,0.00027882215,0.000076945704,0.00015386516],"genre_scores_gemma":[0.9782935,0.000017232394,0.02096403,0.00012456304,0.000070561604,0.000045578083,0.00021359966,0.00008761318,0.00018334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99739313,0.000049816717,0.00045869072,0.00062566466,0.0008687744,0.000603899],"domain_scores_gemma":[0.9982111,0.0002927977,0.00020086356,0.0005923822,0.00032826595,0.00037463088],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010340284,0.0003962353,0.00065705593,0.00020029282,0.00007682343,0.00002345795,0.0002647559,0.00015613221,0.00013489832],"category_scores_gemma":[0.00009522981,0.00027916682,0.0000845751,0.00042860632,0.00024360696,0.00009549529,0.000107287924,0.00045376577,0.00022945488],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018983131,0.036232658,0.31698272,0.002335244,0.0069820005,0.011959986,0.0044999225,0.0034096332,0.5966024,0.000050824896,0.000609742,0.0013517379],"study_design_scores_gemma":[0.08240038,0.008625615,0.31750938,0.001628317,0.0020600967,0.00039969574,0.0002535389,0.00019157484,0.5859002,0.000017405644,0.00030296308,0.0007108558],"about_ca_topic_score_codex":0.00064063305,"about_ca_topic_score_gemma":0.00011691953,"teacher_disagreement_score":0.06341725,"about_ca_system_score_codex":0.00025779745,"about_ca_system_score_gemma":0.000633224,"threshold_uncertainty_score":0.999966},"labels":[],"label_agreement":null},{"id":"W2050306927","doi":"10.1016/j.leukres.2006.10.023","title":"Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes","year":2006,"lang":"en","type":"review","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Celgene","keywords":"Myelodysplastic syndromes; Lenalidomide; Chromosomal Abnormality; Abnormality; Medicine; Cytogenetics; Disease; Chromosome abnormality; Oncology; Internal medicine; Karyotype; Chromosome; Bone marrow; Biology; Multiple myeloma; Genetics","score_opus":0.3313275746400015,"score_gpt":0.49310803610809817,"score_spread":0.16178046146809666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050306927","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019237371,0.96893245,0.0000026064038,0.000035451107,0.00006351789,0.0048381235,0.00007019866,0.000013781683,0.006806526],"genre_scores_gemma":[0.010581754,0.9864014,0.00011438292,0.000002922059,0.00023730118,0.0013886949,0.00022327651,0.00008678798,0.0009635076],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98597884,0.0048751323,0.0015763519,0.00067311816,0.005878155,0.0010184273],"domain_scores_gemma":[0.9929319,0.0036803312,0.00034860006,0.0014329712,0.0014826054,0.00012358652],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.012263076,0.00048297158,0.0023771552,0.0021025338,0.00010525528,0.000036585265,0.00077717286,0.00052254915,0.000154888],"category_scores_gemma":[0.0013330721,0.0002980154,0.0005731664,0.0025270837,0.000675604,0.00006435444,0.00013828985,0.0012201236,0.000067470435],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00008729037,0.00047115792,0.00013601665,0.02474982,0.00043741678,0.00019993349,0.0008678214,0.000082111364,0.000010450986,0.00018030299,0.0006429374,0.97213477],"study_design_scores_gemma":[0.008033969,0.0058599464,0.0015786737,0.04561968,0.005861143,0.0011592617,0.0014782524,0.0024008725,0.000285948,0.0005781491,0.9264126,0.0007315013],"about_ca_topic_score_codex":0.002505414,"about_ca_topic_score_gemma":0.00022654772,"teacher_disagreement_score":0.97140324,"about_ca_system_score_codex":0.011782357,"about_ca_system_score_gemma":0.013683636,"threshold_uncertainty_score":0.9999472},"labels":[],"label_agreement":null},{"id":"W2050419792","doi":"10.1503/cmaj.080674","title":"Granulocytic sarcoma of the skin","year":2008,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Connective tissue; Biopsy; Sarcoma; Infiltration (HVAC); Medicine; Peripheral blood; Pathology; Skin biopsy; Anemia; Equine infectious anemia; Subcutaneous tissue; Refractory anemia; Internal medicine; Bone marrow; Immunology; Virus; Myelodysplastic syndromes; Materials science","score_opus":0.011879079335849687,"score_gpt":0.25345165470370823,"score_spread":0.24157257536785853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050419792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9256529,0.00018441801,0.00002596297,0.06456538,0.00040282286,0.0001471797,0.00000991507,0.000007796419,0.009003612],"genre_scores_gemma":[0.9882282,0.00016255506,0.00008654812,0.007768769,0.00091502076,0.0000021602884,0.000002218909,0.000012784017,0.0028217372],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9970849,0.0001699687,0.00034945447,0.00008785505,0.0019028106,0.0004050188],"domain_scores_gemma":[0.9977743,0.00015512508,0.00014998818,0.00015567036,0.0004518733,0.0013130386],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011339167,0.00007515104,0.00021248078,0.00015226648,0.00027748622,0.0000095845535,0.0002659354,0.00025517642,0.0025853883],"category_scores_gemma":[0.0033999318,0.00005006665,0.00015914215,0.0003892382,0.00013259724,0.000044720084,0.000022428148,0.0012776407,0.00010399598],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027786735,0.000068196765,0.4186719,0.000019762612,0.0001919559,0.00143199,0.00070953934,0.0000019414797,0.00011444205,0.00022884709,0.5642269,0.014306728],"study_design_scores_gemma":[0.0030616047,0.00012663192,0.6289919,0.00012320402,0.000043993834,0.008301509,0.00022686945,0.00039909143,0.00046986315,0.00014858645,0.35799864,0.00010810986],"about_ca_topic_score_codex":0.0034306243,"about_ca_topic_score_gemma":0.006423284,"teacher_disagreement_score":0.21032,"about_ca_system_score_codex":0.0022794567,"about_ca_system_score_gemma":0.011980555,"threshold_uncertainty_score":0.99832636},"labels":[],"label_agreement":null},{"id":"W2050743369","doi":"10.1053/bbmt.2002.v8.pm12234169","title":"Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission","year":2002,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Vancouver Hospital and Health Sciences Centre; University of British Columbia Hospital","funders":"BC Cancer Agency","keywords":"Medicine; Busulfan; Internal medicine; Cyclophosphamide; Myeloid leukemia; Transplantation; Bone marrow; Gastroenterology; Leukemia; Chemotherapy; Cytogenetics; Surgery; Oncology; Chromosome","score_opus":0.02466393784816168,"score_gpt":0.2827154245450197,"score_spread":0.258051486696858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050743369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99715805,0.00077610323,0.00020754983,0.00038711051,0.0000345347,0.00075254525,0.0005494916,0.000020211553,0.00011438738],"genre_scores_gemma":[0.9905254,0.0072842524,0.0013415073,0.00017501623,0.00003273096,0.000113782255,0.00039270625,0.000021827238,0.00011272877],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99837995,0.000092530674,0.0006806074,0.00035063087,0.00017590668,0.00032036786],"domain_scores_gemma":[0.99918514,0.00026820254,0.00016475665,0.00018255168,0.000101812875,0.000097515775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028108622,0.00022208947,0.00052859087,0.0003434981,0.00005717696,0.0000045585284,0.00009566774,0.00025971723,0.000037390644],"category_scores_gemma":[0.000027506649,0.00019494044,0.00009860484,0.00015894024,0.00024645776,0.00008938874,0.000008255098,0.00017586198,0.0000026266719],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045620734,0.000104079605,0.1442984,0.0026249436,0.00015184683,0.000101787766,0.0015025258,0.00028769101,0.8451474,0.00015087512,0.0000130924545,0.0010553265],"study_design_scores_gemma":[0.017425524,0.0036102878,0.5265621,0.0010425763,0.0017259741,0.00079456787,0.00011081101,0.0009303272,0.4468152,0.0002887417,0.00019863149,0.0004952848],"about_ca_topic_score_codex":0.00015713458,"about_ca_topic_score_gemma":0.00016727608,"teacher_disagreement_score":0.39833218,"about_ca_system_score_codex":0.00006673721,"about_ca_system_score_gemma":0.00006484501,"threshold_uncertainty_score":0.79494405},"labels":[],"label_agreement":null},{"id":"W2050745303","doi":"10.1016/j.bbmt.2013.02.017","title":"Outcome of Transplantation for Acute Myelogenous Leukemia in Children with Down Syndrome","year":2013,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; SickKids Foundation","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Health Resources and Services Administration","keywords":"Medicine; Hazard ratio; Internal medicine; Transplantation; Leukemia; Multivariate analysis; Cohort; Confidence interval","score_opus":0.010472637787333431,"score_gpt":0.26852643837766094,"score_spread":0.2580538005903275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050745303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99679327,0.00017149751,0.0012193045,0.00014375756,0.000016627328,0.0013115669,0.0002535761,0.00001655235,0.00007385067],"genre_scores_gemma":[0.9940123,0.0012888483,0.0037009194,0.000050162078,0.000013582078,0.00011517071,0.00076746324,0.000015554047,0.000036003454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900126,0.0000443148,0.00039392157,0.00023695712,0.00009666079,0.00022690247],"domain_scores_gemma":[0.99952596,0.00009712841,0.0001068538,0.00011339622,0.00009210396,0.000064580505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001629514,0.00014218724,0.0004243924,0.00023640608,0.000029502302,0.0000033599426,0.00007099209,0.0001775069,0.000020745394],"category_scores_gemma":[0.0000067750025,0.00010861913,0.00005190457,0.00013575007,0.00018378512,0.00009264685,0.0000036148022,0.00012428632,0.0000015922366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000982035,0.00006824799,0.6152729,0.0006144905,0.0004525974,0.000021717766,0.00049743033,0.0000075139524,0.37982795,0.00017764827,0.0000044293665,0.002073061],"study_design_scores_gemma":[0.009523735,0.002214259,0.9073387,0.00012274424,0.001235672,0.002260027,0.000052194446,0.00006001223,0.07686983,0.00017684317,0.0000024039007,0.000143581],"about_ca_topic_score_codex":0.0008635358,"about_ca_topic_score_gemma":0.00009827258,"teacher_disagreement_score":0.3029581,"about_ca_system_score_codex":0.000031828542,"about_ca_system_score_gemma":0.00013108936,"threshold_uncertainty_score":0.44293597},"labels":[],"label_agreement":null},{"id":"W2052372808","doi":"10.1182/blood-2007-07-103291","title":"Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Myeloid leukemia; Biology; Myeloid; Cancer research; Gene knockdown; Haematopoiesis; Fusion gene; Haploinsufficiency; Cell growth; Leukemia; Progenitor cell; Stem cell; Cell culture; Gene; Genetics; Phenotype","score_opus":0.019289677595388816,"score_gpt":0.24994862589184258,"score_spread":0.23065894829645375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052372808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964004,0.0006073346,0.00009931177,0.0016754285,0.000011534131,0.0009120755,0.00001694584,0.000022699822,0.00025427196],"genre_scores_gemma":[0.998486,0.0003284335,0.0005019402,0.00034455597,0.00008885273,0.00003469191,0.000042961445,0.00002717413,0.00014542868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988012,0.00017245943,0.00020935487,0.00029186072,0.00028856553,0.00023656865],"domain_scores_gemma":[0.99905986,0.0003011792,0.00005314732,0.0002995187,0.00015386949,0.00013240211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024611317,0.00015913595,0.0003304768,0.00009393556,0.00009385421,0.000018776087,0.000097500684,0.00009216778,0.000006395109],"category_scores_gemma":[0.00012552703,0.000101514146,0.000018101398,0.00035375368,0.00019698996,0.00009012715,0.00007777277,0.0002675543,0.0000047385297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012290654,0.00033209447,0.9677955,0.00007888214,0.00007677155,0.0003138054,0.0016080282,0.000017961147,0.027286487,0.000037227095,0.000796312,0.0004278678],"study_design_scores_gemma":[0.013373861,0.0019506604,0.846838,0.0002578703,0.00014862216,0.0004959736,0.0006005394,0.0007142919,0.13494664,0.000015825288,0.00040326235,0.00025444955],"about_ca_topic_score_codex":0.0019399645,"about_ca_topic_score_gemma":0.0017301594,"teacher_disagreement_score":0.120957494,"about_ca_system_score_codex":0.000053983218,"about_ca_system_score_gemma":0.00021050984,"threshold_uncertainty_score":0.41396266},"labels":[],"label_agreement":null},{"id":"W2052934106","doi":"10.1097/00043426-200210000-00014","title":"Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia","year":2002,"lang":"en","type":"review","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"National Cancer Institute","keywords":"Medicine; Acute megakaryoblastic leukemia; Down syndrome; Presentation (obstetrics); Leukemia; Pediatrics; Myeloid leukemia; Acute leukemia; Pathology; Bone marrow; Radiology; Internal medicine","score_opus":0.05824694902020815,"score_gpt":0.39241212380296103,"score_spread":0.33416517478275287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052934106","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017579884,0.9918744,0.00031091218,0.00038183347,0.0015258035,0.0012723539,0.00011106467,0.000048590777,0.0027170603],"genre_scores_gemma":[0.0003386712,0.9871065,0.0052095014,0.00008632161,0.0059563085,0.00006523231,0.00007297446,0.00018402531,0.0009804409],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99034977,0.0011864492,0.0052790153,0.0007018472,0.001253348,0.0012295531],"domain_scores_gemma":[0.9859366,0.004402374,0.006513353,0.0008100001,0.0014060513,0.0009316157],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0018544354,0.000980492,0.008271316,0.004377944,0.00014199049,0.000021226702,0.0012019582,0.002531302,0.00084283453],"category_scores_gemma":[0.00221013,0.00075772905,0.0023329873,0.0025906619,0.00039775638,0.0002416144,0.00038486294,0.004857376,0.0005618236],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00051494467,0.0027443734,0.0015158182,0.07879869,0.007878046,0.110830255,0.0006552499,0.000012075267,0.000006900436,0.0008607879,0.37126672,0.42491612],"study_design_scores_gemma":[0.0042162836,0.0047556334,0.000072403556,0.00090387365,0.041783683,0.16821945,0.00009889649,0.00003993181,0.0000020200912,0.00011468553,0.77914613,0.00064701244],"about_ca_topic_score_codex":0.000010760863,"about_ca_topic_score_gemma":0.0000036493032,"teacher_disagreement_score":0.4242691,"about_ca_system_score_codex":0.003966269,"about_ca_system_score_gemma":0.019371726,"threshold_uncertainty_score":0.9998573},"labels":[],"label_agreement":null},{"id":"W2053468615","doi":"10.1016/j.ccr.2006.08.023","title":"Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia","year":2006,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Deutsche Krebshilfe","keywords":"Myeloid leukemia; Leukemia; Haematopoiesis; Stem cell; Myeloid; Lymphoid leukemia; Cancer research; Progenitor cell; Biology; Antibody; Immunology; Cell biology","score_opus":0.010216748028649783,"score_gpt":0.24096547749255198,"score_spread":0.2307487294639022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053468615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98784864,0.0012094646,0.0008300187,0.0001663438,0.000056784713,0.0015898186,0.0019180543,0.00011706472,0.006263795],"genre_scores_gemma":[0.94733995,0.0015940311,0.0007509377,0.0007275732,0.00014006595,0.0003174589,0.00041013336,0.00020340626,0.048516437],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958273,0.000103695966,0.0010052988,0.0009948,0.00091463875,0.0011542505],"domain_scores_gemma":[0.99763197,0.00008574078,0.00050233613,0.0008625986,0.0005383571,0.00037897995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024762593,0.00067944184,0.001216976,0.00028323752,0.00010064416,0.000044159435,0.00047484544,0.00045099703,0.00012932057],"category_scores_gemma":[0.000006373063,0.00058618665,0.00017093316,0.00072830974,0.00038142686,0.0002837555,0.00017274181,0.00086184806,0.00004760504],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.002991558,0.00028558695,0.0061979503,0.0007442653,0.00014245656,0.00022094263,0.001245906,0.0012736878,0.9691438,0.000011184356,0.016518699,0.0012239513],"study_design_scores_gemma":[0.01019917,0.0005309596,0.0006366907,0.00034374758,0.0002951287,0.000063906766,0.0002838836,0.0722561,0.9140944,0.000009548379,0.0006451621,0.000641319],"about_ca_topic_score_codex":0.009280944,"about_ca_topic_score_gemma":0.00025789757,"teacher_disagreement_score":0.07098241,"about_ca_system_score_codex":0.016089872,"about_ca_system_score_gemma":0.00819073,"threshold_uncertainty_score":0.99965894},"labels":[],"label_agreement":null},{"id":"W2053997093","doi":"10.1038/leu.2008.319","title":"Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms","year":2008,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Heart, Lung, and Blood Institute; Howard Hughes Medical Institute","keywords":"Telomere; Allele; Biology; clone (Java method); Internal medicine; Population; Haematopoiesis; Stem cell; Genetics; Gastroenterology; Molecular biology; Medicine; DNA; Gene","score_opus":0.020583033961096918,"score_gpt":0.2731370967227952,"score_spread":0.2525540627616983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053997093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867509,0.00064560527,0.000016367068,0.0024284942,0.000044663004,0.00094781513,0.000055465298,0.00006601804,0.009044673],"genre_scores_gemma":[0.9902365,0.0014299708,0.0022319118,0.0023622063,0.00014970626,0.00007322821,0.00002213417,0.00005953438,0.0034347936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975511,0.00015062868,0.00040445855,0.00076858315,0.00049192953,0.0006332979],"domain_scores_gemma":[0.9985065,0.00042523324,0.000100467434,0.00033811995,0.000234627,0.00039505438],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002599437,0.00038777548,0.0006688311,0.0003475552,0.0002512345,0.000042113184,0.00012603328,0.00032004784,0.000101156875],"category_scores_gemma":[0.00044177886,0.0003436408,0.000062484454,0.00058110966,0.00062146975,0.00035337172,0.00019458773,0.0011223705,0.000056184184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01865263,0.0007975527,0.415124,0.0011542017,0.001874379,0.01583533,0.29341093,0.000072020055,0.08532741,0.0037730394,0.08282434,0.081154175],"study_design_scores_gemma":[0.012230706,0.0013096505,0.89421296,0.0004297287,0.0001026174,0.002840193,0.002953728,0.004261751,0.0781974,0.0009843247,0.0016822038,0.00079475256],"about_ca_topic_score_codex":0.0007878545,"about_ca_topic_score_gemma":0.000092350136,"teacher_disagreement_score":0.47908896,"about_ca_system_score_codex":0.0013839379,"about_ca_system_score_gemma":0.0013735218,"threshold_uncertainty_score":0.99990153},"labels":[],"label_agreement":null},{"id":"W2054216490","doi":"10.1182/blood-2010-04-277806","title":"NUP98-MLL fusion in human acute myeloblastic leukemia","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut National Du Cancer; Institute of Cancer Research; Institut National de la Santé et de la Recherche Médicale","keywords":"Biology; Fusion protein; Chromatin; Homeobox; Histone; PHD finger; Cancer research; Myeloid leukemia; Fusion gene; Histone H3; Genetics; Gene; Molecular biology; Cell biology; Transcription factor; Zinc finger","score_opus":0.011260707043239377,"score_gpt":0.2915121533797395,"score_spread":0.2802514463365001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054216490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97514963,0.00003832624,0.000013412887,0.00053891935,0.00014238323,0.00042858513,0.0000071643203,0.00010830065,0.02357329],"genre_scores_gemma":[0.9936734,0.000030363974,0.00088445406,0.0003016281,0.00043523998,0.00003995696,0.000043925935,0.000049222384,0.0045418083],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982859,0.00002809133,0.00030770537,0.00039479675,0.00043449498,0.000549028],"domain_scores_gemma":[0.9989076,0.00008165995,0.00005366911,0.00059745595,0.00009072033,0.00026885362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003169263,0.00019573965,0.0003437244,0.00030333773,0.00010000426,0.000027442626,0.00025279852,0.00025548172,0.00073663116],"category_scores_gemma":[0.00020629665,0.00016973968,0.00008613554,0.0004036377,0.0001296852,0.00008983388,0.00018244729,0.0012619488,0.00044136442],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010286114,0.0004289189,0.020253228,0.000062468156,0.000086324144,0.0015915048,0.00028572843,9.968632e-7,0.9710765,0.0005322505,0.0029750045,0.0026042452],"study_design_scores_gemma":[0.03615072,0.0016193636,0.5658871,0.00038232107,0.0007334868,0.0019016879,0.00023400817,0.00088760833,0.36282223,0.0011725313,0.027283508,0.00092544674],"about_ca_topic_score_codex":0.0002505109,"about_ca_topic_score_gemma":0.00030359154,"teacher_disagreement_score":0.60825425,"about_ca_system_score_codex":0.00020030534,"about_ca_system_score_gemma":0.00049542106,"threshold_uncertainty_score":0.8065595},"labels":[],"label_agreement":null},{"id":"W2054346225","doi":"10.1111/bjh.12233","title":"Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta‐analysis","year":2013,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; University of Toronto; SickKids Foundation; Public Health Ontario; Hospital for Sick Children; McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Idarubicin; Daunorubicin; Internal medicine; Anthracycline; Confidence interval; Relative risk; Meta-analysis; Gastroenterology; Randomized controlled trial; Myeloid leukemia; Chemotherapy; Cytarabine; Cancer; Breast cancer","score_opus":0.06713767490013349,"score_gpt":0.3773710469999473,"score_spread":0.3102333720998138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054346225","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017322348,0.99440557,0.000012661878,0.00062770984,0.00007265762,0.0030890105,0.00002164384,0.000017054437,0.000021445703],"genre_scores_gemma":[0.00007211274,0.9983171,0.0004573326,0.00023278965,0.00008685847,0.00035485788,0.000027749806,0.00007811828,0.00037306664],"study_design_codex":"systematic_review","study_design_gemma":"case_report","domain_scores_codex":[0.9935019,0.0015140821,0.003449,0.0004895466,0.0005276301,0.000517832],"domain_scores_gemma":[0.9956662,0.00043220024,0.002554159,0.00049090665,0.0005725485,0.00028397114],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0017956097,0.0005534415,0.01996777,0.0016692181,0.000087963665,0.000086254455,0.00043463559,0.00066367874,0.000301375],"category_scores_gemma":[0.0007677356,0.00040719548,0.002628195,0.0015674375,0.00021943919,0.0003026349,0.00013284427,0.0022577494,0.000026938433],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015449861,0.00009045931,0.0000045123097,0.7743171,0.17821565,0.034313325,0.00002031324,1.3550525e-7,0.0000014541597,0.000005409088,0.00038714308,0.0126290675],"study_design_scores_gemma":[0.0005175714,0.000090966954,0.000009923209,0.10956148,0.4432787,0.44455606,0.000018712783,8.6898075e-7,0.000001846269,0.000009555058,0.0017650151,0.00018929614],"about_ca_topic_score_codex":0.00013565077,"about_ca_topic_score_gemma":0.00004408559,"teacher_disagreement_score":0.6647556,"about_ca_system_score_codex":0.00031574763,"about_ca_system_score_gemma":0.0006129162,"threshold_uncertainty_score":0.999838},"labels":[],"label_agreement":null},{"id":"W2054529093","doi":"10.1002/cyto.b.21028","title":"Flow cytometry‐based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Mitoxantrone; Chemotherapy; Myeloid leukemia; Medicine; Internal medicine; Induction chemotherapy; Flow cytometry; Gastroenterology; Oncology; Pharmacology; Immunology","score_opus":0.04395661293656691,"score_gpt":0.39256885943673747,"score_spread":0.34861224650017053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054529093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771426,0.00032607658,0.016483085,0.002073256,0.0010004101,0.0019615758,0.00036392693,0.0002621086,0.00038699264],"genre_scores_gemma":[0.9419465,0.00023399414,0.052289285,0.0023232268,0.0016767423,0.00022676309,0.00034673666,0.00025427618,0.00070247345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9889885,0.0015558978,0.002899087,0.0017047457,0.0026950324,0.002156719],"domain_scores_gemma":[0.98845243,0.0057191546,0.0008062291,0.0023810845,0.0006915657,0.0019495083],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008269742,0.0010372875,0.00296789,0.004893979,0.00019355923,0.000103981474,0.0009515121,0.0012725887,0.0011199955],"category_scores_gemma":[0.004702263,0.00088550145,0.0006131275,0.01165475,0.00096564076,0.0006872835,0.00044473654,0.0032025864,0.00037920364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028667523,0.002240413,0.84030735,0.00020625732,0.001288183,0.00017347914,0.00023910384,0.00021119216,0.113536924,0.000011520744,0.0047062295,0.008411813],"study_design_scores_gemma":[0.018056827,0.004219849,0.9199578,0.0006154494,0.000451105,0.00009652696,0.00030844138,0.0029877813,0.045475286,0.000012285847,0.006931306,0.0008873293],"about_ca_topic_score_codex":0.00016806056,"about_ca_topic_score_gemma":0.00001637733,"teacher_disagreement_score":0.07965045,"about_ca_system_score_codex":0.004830512,"about_ca_system_score_gemma":0.003986131,"threshold_uncertainty_score":0.9997931},"labels":[],"label_agreement":null},{"id":"W2054701803","doi":"10.1016/j.leukres.2010.08.003","title":"Copy number alterations at polymorphic loci may be acquired somatically in patients with myelodysplastic syndromes","year":2010,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Biology; Copy-number variation; Myelodysplastic syndromes; Genetics; Somatic cell; clone (Java method); Genome; Gene; Immunology","score_opus":0.03185149492784102,"score_gpt":0.3371596112225978,"score_spread":0.3053081162947568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054701803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855979,0.000015953885,0.000043466727,0.0041831913,0.00011061699,0.0017471676,0.000047142013,0.00010786518,0.008146665],"genre_scores_gemma":[0.9845287,0.00001800564,0.0030650084,0.0003650849,0.0002046586,0.00031745763,0.00035177567,0.00012962254,0.011019672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933561,0.00039955208,0.0006437388,0.0008947759,0.0029434448,0.0017623937],"domain_scores_gemma":[0.99556893,0.0012247404,0.00008165806,0.0013070969,0.0009820183,0.00083555444],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015145467,0.00039191713,0.0006423577,0.0007901585,0.00048497695,0.00016258396,0.00062303373,0.00045204678,0.0057363305],"category_scores_gemma":[0.0015718294,0.0003087705,0.00010124693,0.0017803429,0.001156542,0.0003304775,0.0005796229,0.0023174665,0.0024154354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002668564,0.0006180483,0.95878863,0.0003121751,0.00016595988,0.0008069148,0.0006263237,0.00001778312,0.012098922,0.0016972119,0.02115698,0.0010425015],"study_design_scores_gemma":[0.019192617,0.0015219117,0.9603135,0.00039116424,0.00007216468,0.00044525616,0.0002606029,0.0043520294,0.006273256,0.00036916562,0.0060867947,0.0007215281],"about_ca_topic_score_codex":0.0006598676,"about_ca_topic_score_gemma":0.0010461244,"teacher_disagreement_score":0.016524054,"about_ca_system_score_codex":0.0036877848,"about_ca_system_score_gemma":0.003383814,"threshold_uncertainty_score":0.9999842},"labels":[],"label_agreement":null},{"id":"W2054837595","doi":"10.1038/sj.bmt.1705747","title":"Blood and marrow transplantation in elderly acute myeloid leukaemia patients – older certainly is not better","year":2007,"lang":"en","type":"review","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Transplantation; Internal medicine; Chemotherapy; Stem cell; Hematology; Oncology; Myeloid leukaemia; Myelodysplastic syndromes; Concomitant; Myeloid; Myeloid leukemia; Disease; Bone marrow; Surgery","score_opus":0.026840089919608612,"score_gpt":0.3150991565485932,"score_spread":0.2882590666289846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054837595","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17515801,0.8085487,0.0007368993,0.0008997364,0.0004967398,0.00897321,0.002719381,0.0002987477,0.0021685644],"genre_scores_gemma":[0.006554524,0.980946,0.0012631454,0.0008701956,0.0002245759,0.00031591236,0.008625424,0.00023901525,0.00096118654],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99418783,0.00033736348,0.0017744949,0.0013585378,0.0012585211,0.001083254],"domain_scores_gemma":[0.997896,0.00042802325,0.0004544157,0.0005838614,0.00021979774,0.00041790926],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007530002,0.0010790302,0.0023260205,0.0015760707,0.00015805046,0.0001059686,0.00028531576,0.0012791596,0.00020156795],"category_scores_gemma":[0.000025315187,0.0009892248,0.0005121894,0.0009596896,0.00017474257,0.00041879897,0.000026319412,0.0016545542,0.00012018714],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001476783,0.00037170562,0.0029620351,0.06393243,0.0007788629,0.003515365,0.002066236,4.9596895e-7,0.00046081745,0.000023671579,0.00069522904,0.92371637],"study_design_scores_gemma":[0.10244702,0.0058645164,0.083524115,0.14569081,0.07719206,0.019088851,0.00027736448,0.00017956024,0.0059298603,0.00018415104,0.5495203,0.010101344],"about_ca_topic_score_codex":0.00029315398,"about_ca_topic_score_gemma":0.00021810154,"teacher_disagreement_score":0.913615,"about_ca_system_score_codex":0.000539564,"about_ca_system_score_gemma":0.00064169924,"threshold_uncertainty_score":0.99925584},"labels":[],"label_agreement":null},{"id":"W2055241026","doi":"10.1038/leu.2011.137","title":"Identification of a role for the nuclear receptor EAR-2 in the maintenance of clonogenic status within the leukemia cell hierarchy","year":2011,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Ottawa Hospital; Ontario Institute for Cancer Research; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Biology; Clonogenic assay; Stem cell; Leukemia; Progenitor cell; Haematopoiesis; Cancer research; Cellular differentiation; Population; Small hairpin RNA; Immunology; Cell culture; Cell biology; Genetics; Medicine; Gene","score_opus":0.022837575014579215,"score_gpt":0.26479060160628703,"score_spread":0.2419530265917078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055241026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99243075,0.0006528366,0.00026834136,0.00103746,0.00014406793,0.0021243978,0.00006274083,0.000025931178,0.0032534504],"genre_scores_gemma":[0.9961453,0.00031611221,0.0009905358,0.000531024,0.000110243294,0.00020570657,0.000017322924,0.000054204782,0.0016295245],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975078,0.0002539032,0.00080173765,0.00033967794,0.0005795071,0.0005173872],"domain_scores_gemma":[0.99719757,0.0007250725,0.0004639582,0.0012560415,0.00027808957,0.00007926658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024242532,0.00020010915,0.0003446266,0.0001254761,0.00015703702,0.000022865152,0.0009790391,0.00015650307,0.00010849754],"category_scores_gemma":[0.00060793187,0.000099817604,0.00021110731,0.00062961417,0.00058571,0.00010598723,0.00013212106,0.0007247995,0.000055428885],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009038626,0.0005292176,0.009308533,0.0011396542,0.00052945333,0.00003172605,0.12945344,0.00045021175,0.74512506,0.030068021,0.05672266,0.017603382],"study_design_scores_gemma":[0.017095068,0.0026022855,0.1952862,0.000599388,0.0008370033,0.00016889512,0.08354293,0.059802823,0.56519204,0.008423705,0.065509446,0.0009401971],"about_ca_topic_score_codex":0.0019511105,"about_ca_topic_score_gemma":0.00012829107,"teacher_disagreement_score":0.18597767,"about_ca_system_score_codex":0.0011158411,"about_ca_system_score_gemma":0.0013499422,"threshold_uncertainty_score":0.40704438},"labels":[],"label_agreement":null},{"id":"W2055257308","doi":"10.1053/j.semdp.2011.06.003","title":"Role of flow cytometry in diagnostics of myelodysplastic syndromes—beyond the WHO 2008 classification","year":2011,"lang":"en","type":"review","venue":"Seminars in Diagnostic Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Myelodysplastic syndromes; Flow cytometry; Bone marrow; Myeloid; Medicine; Immunophenotyping; Pathology; Monoclonal antibody; Phenotype; Bioinformatics; Immunology; Biology; Antibody; Gene; Genetics","score_opus":0.04073566276661532,"score_gpt":0.33662332569628717,"score_spread":0.29588766292967184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055257308","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054411455,0.9900637,0.000048408812,0.000058617563,0.00030984962,0.002185875,0.00027384498,0.000020524358,0.0015980346],"genre_scores_gemma":[0.0046779574,0.993001,0.00094439986,0.000040956635,0.00010175121,0.0006789046,0.00029768047,0.00011712274,0.00014022447],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946276,0.0009998244,0.0022216435,0.00081120693,0.000517161,0.0008225456],"domain_scores_gemma":[0.9667443,0.030368557,0.000994496,0.0014937003,0.0002327736,0.0001661799],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018608929,0.00063132396,0.003611781,0.002004128,0.000036330108,0.000006574801,0.0009687484,0.0012231682,0.00014444883],"category_scores_gemma":[0.04557719,0.00046989738,0.00038247064,0.0024090318,0.0011103975,0.00006034524,0.0004445912,0.001975117,0.00010257516],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009544306,0.00092189974,0.009819781,0.014620026,0.00016389614,0.0027602338,0.0013234873,0.000008060052,0.000056052508,0.000581985,0.003388642,0.9662605],"study_design_scores_gemma":[0.008487607,0.004736229,0.12232117,0.24679147,0.0072819614,0.016557967,0.0027642269,0.0013695656,0.00036158675,0.004611412,0.5817736,0.0029432252],"about_ca_topic_score_codex":0.000054298365,"about_ca_topic_score_gemma":0.000056466244,"teacher_disagreement_score":0.9633173,"about_ca_system_score_codex":0.0006771287,"about_ca_system_score_gemma":0.0014390993,"threshold_uncertainty_score":0.9997753},"labels":[],"label_agreement":null},{"id":"W2055450998","doi":"10.1182/blood-2005-11-025536","title":"Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; BC Children's Hospital","funders":"National Cancer Institute","keywords":"Myeloid leukemia; Internal medicine; White blood cell; Gastroenterology; Medicine; Leukemia; Trisomy; Incidence (geometry); Biology","score_opus":0.017075726083339123,"score_gpt":0.2920350298965719,"score_spread":0.27495930381323275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055450998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947873,0.0009786917,0.000004542255,0.0015085401,0.0000684128,0.0017567043,0.00027494144,0.00021117007,0.00040973283],"genre_scores_gemma":[0.99486667,0.0003273109,0.0006922684,0.0010401717,0.0003906645,0.00015313769,0.0016107772,0.00011596186,0.0008030511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954425,0.0004139895,0.0010813656,0.0011872977,0.0008839017,0.0009909254],"domain_scores_gemma":[0.9973926,0.00047054543,0.00053720264,0.0010349334,0.00028528355,0.00027942503],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077577104,0.00064705755,0.0014130083,0.00028186443,0.00029461406,0.00005982661,0.00045016382,0.0004768145,0.00006904431],"category_scores_gemma":[0.00048431434,0.00042736816,0.00017492936,0.0007326661,0.0006611193,0.00024220766,0.00038315807,0.0012526637,0.000022279366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007324825,0.0015456317,0.98557293,0.000013160298,0.0037369106,0.002596908,0.0008841293,0.0000017110079,0.0024930544,0.000011508047,0.0019521584,0.00045940946],"study_design_scores_gemma":[0.024733193,0.0015166801,0.9678291,0.00015363938,0.0020285316,0.0015319181,0.00051729655,0.00005973622,0.0009747529,0.000072537354,0.00011053829,0.00047206154],"about_ca_topic_score_codex":0.0049029887,"about_ca_topic_score_gemma":0.003401453,"teacher_disagreement_score":0.024000712,"about_ca_system_score_codex":0.0010298659,"about_ca_system_score_gemma":0.00067130383,"threshold_uncertainty_score":0.9998178},"labels":[],"label_agreement":null},{"id":"W2055778798","doi":"10.1007/s13139-012-0128-x","title":"Myeloid Sarcoma and Acute Myelomonocytic Leukemia in an Adolescent with Tetrasomy 8: Staging with 18F-FDG PET/CT","year":2012,"lang":"en","type":"article","venue":"Nuclear Medicine and Molecular Imaging","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre; Brandon University; Montreal Children's Hospital; Brandon Regional Health Authority","funders":"","keywords":"Myeloid sarcoma; Medicine; Myeloid leukemia; Sarcoma; Myeloid; Malignancy; Pathology; Biopsy; Radiology; Internal medicine","score_opus":0.013843190700730508,"score_gpt":0.2831691617902389,"score_spread":0.26932597108950834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055778798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989993,0.0019144365,0.00032405692,0.004377852,0.000034336143,0.00061936484,0.0000021719097,0.0001032617,0.0026315297],"genre_scores_gemma":[0.9868978,0.00037473338,0.006298677,0.0060732975,0.00012923096,0.000014577161,0.000022754704,0.00014199839,0.000046898513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974193,0.000111707566,0.00031890336,0.0005890335,0.00062875747,0.00093229057],"domain_scores_gemma":[0.99846923,0.00005163608,0.00009063539,0.00050431927,0.00010854906,0.0007756467],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052336784,0.00040704908,0.00060138386,0.00048444205,0.00014714242,0.00005851058,0.00014750661,0.000019114577,0.000053212956],"category_scores_gemma":[0.000059491173,0.00028827632,0.000031324747,0.00043520096,0.00060200825,0.00045919692,0.00013981923,0.00085551356,0.000008663969],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026641642,0.00034043624,0.7386112,0.0010508473,0.0004944161,0.04891081,0.0059071854,0.0000124662565,0.15696007,0.0009361469,0.002446937,0.041665323],"study_design_scores_gemma":[0.06497057,0.006155179,0.6693985,0.009987684,0.002951148,0.11908003,0.041370966,0.027168687,0.009400324,0.00014381399,0.04604383,0.0033292957],"about_ca_topic_score_codex":0.00033547822,"about_ca_topic_score_gemma":0.000015581427,"teacher_disagreement_score":0.14755975,"about_ca_system_score_codex":0.0005962797,"about_ca_system_score_gemma":0.00029240394,"threshold_uncertainty_score":0.99995697},"labels":[],"label_agreement":null},{"id":"W2055884944","doi":"10.1182/blood-2013-12-540971","title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":336,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Celator Pharmaceuticals","keywords":"Daunorubicin; Cytarabine; Medicine; Internal medicine; Leukemia; Oncology; Gastroenterology","score_opus":0.008712615199877411,"score_gpt":0.268214824499536,"score_spread":0.25950220929965856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055884944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941513,0.0002021686,0.0003339314,0.00064184534,0.00007716498,0.003051094,0.000070430804,0.00008437615,0.0013877004],"genre_scores_gemma":[0.99697435,0.000099435594,0.0012929579,0.00018442518,0.000282208,0.00016317534,0.00025348522,0.00010115141,0.000648797],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99575305,0.00039804625,0.0012623298,0.0007557084,0.0010514437,0.0007793996],"domain_scores_gemma":[0.9970293,0.0004016994,0.0004665153,0.0011596351,0.0006102259,0.00033263743],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009577667,0.00050529087,0.0015298451,0.0007359299,0.000060234415,0.000017291644,0.00039037917,0.0003399307,0.00032403364],"category_scores_gemma":[0.0008751726,0.00039220092,0.000213194,0.001327402,0.00033407554,0.0001795989,0.000108921755,0.0006907537,0.00003701594],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51378816,0.039057042,0.037016034,0.0022964287,0.0015716645,0.0008839256,0.005277124,0.00017820316,0.3881347,0.00040764644,0.0035175367,0.007871539],"study_design_scores_gemma":[0.63310987,0.018820297,0.009557768,0.0012126486,0.0006170558,0.00011520412,0.00033001901,0.0032155118,0.33217236,0.00002246691,0.0003777319,0.00044908962],"about_ca_topic_score_codex":0.0016029011,"about_ca_topic_score_gemma":0.0002962342,"teacher_disagreement_score":0.1193217,"about_ca_system_score_codex":0.00016047762,"about_ca_system_score_gemma":0.0007479514,"threshold_uncertainty_score":0.999853},"labels":[],"label_agreement":null},{"id":"W2055946535","doi":"10.1016/j.leukres.2013.03.012","title":"CD11b expression correlates with monosomal karyotype and predicts an extremely poor prognosis in cytogenetically unfavourable acute myeloid leukemia","year":2013,"lang":"en","type":"letter","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Lipid droplet; Biosynthesis; Biochemistry; Biogenesis; Retinoic acid; Mitochondrion; Chemistry; Organelle; Retinol binding protein; Biology; Cell biology; Retinol; Enzyme; Gene","score_opus":0.04582927067193436,"score_gpt":0.31709003017872234,"score_spread":0.27126075950678796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055946535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87400466,0.0020407082,0.00003366279,0.110013366,0.00018171193,0.0071834615,0.00015254228,0.00038374774,0.006006142],"genre_scores_gemma":[0.7429679,0.012507619,0.020721992,0.112223156,0.010788945,0.009646655,0.006491357,0.0028968747,0.08175552],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98401326,0.0017293305,0.0014220849,0.0033037518,0.005185955,0.004345645],"domain_scores_gemma":[0.9927191,0.0015564378,0.00024970493,0.0021355893,0.0017883678,0.0015507906],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0023017803,0.0015073373,0.002134398,0.0027242757,0.0006223376,0.00069918577,0.0017712694,0.0040221065,0.0008258615],"category_scores_gemma":[0.0006768656,0.0011716015,0.00023228968,0.0023318771,0.0019357993,0.00091986835,0.0014663548,0.017901065,0.0006685138],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004424519,0.00026960843,0.031672582,0.0017952715,0.00062733155,0.019811537,0.0006487524,0.000052216157,0.05893413,0.00003361058,0.8757512,0.0059792623],"study_design_scores_gemma":[0.0661736,0.042005274,0.13709217,0.024370205,0.0023682555,0.014351184,0.0020712558,0.07115542,0.17405888,0.0020665522,0.45380533,0.01048188],"about_ca_topic_score_codex":0.002718991,"about_ca_topic_score_gemma":0.0001712615,"teacher_disagreement_score":0.42194587,"about_ca_system_score_codex":0.008876916,"about_ca_system_score_gemma":0.011406297,"threshold_uncertainty_score":0.99976754},"labels":[],"label_agreement":null},{"id":"W2056771226","doi":"10.1038/leu.2013.373","title":"GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia","year":2013,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute","keywords":"GATA1; Eosinophil; Cancer research; Haematopoiesis; Biology; Eosinophilia; Ectopic expression; Progenitor cell; Gene knockdown; Immunology; Cell biology; Stem cell; Genetics; Gene","score_opus":0.01673979098268131,"score_gpt":0.26526912931153923,"score_spread":0.24852933832885793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056771226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99069566,0.0002752116,0.00004559278,0.0013858521,0.00013352874,0.0015247246,0.000014576613,0.00008529555,0.005839552],"genre_scores_gemma":[0.9964136,0.0001216014,0.0011243783,0.00044592985,0.00011243908,0.00024369992,0.00008412667,0.000059596125,0.0013946552],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9970901,0.00013395151,0.0007798801,0.00055698893,0.0007661186,0.0006729852],"domain_scores_gemma":[0.99848634,0.00014494457,0.00014927876,0.000666852,0.0002445948,0.00030800523],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041419663,0.0003252596,0.00069825834,0.00054869044,0.000064079686,0.00004246285,0.00031965092,0.00037821932,0.00067899906],"category_scores_gemma":[0.00021302167,0.00028325204,0.00014757563,0.0008264055,0.000229627,0.00043451367,0.00007988962,0.0008514516,0.0004025689],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012464698,0.00065865146,0.050793555,0.0018194435,0.0004199883,0.0009298674,0.007084107,0.0018297491,0.86951315,0.0011707436,0.024925195,0.039609082],"study_design_scores_gemma":[0.010046545,0.0015907001,0.8684004,0.0009918762,0.00015097718,0.0011527032,0.00085827766,0.010303833,0.10249899,0.00078530953,0.0024056144,0.0008147626],"about_ca_topic_score_codex":0.002970675,"about_ca_topic_score_gemma":0.00007453529,"teacher_disagreement_score":0.81760687,"about_ca_system_score_codex":0.003259909,"about_ca_system_score_gemma":0.00204407,"threshold_uncertainty_score":0.999962},"labels":[],"label_agreement":null},{"id":"W2056871730","doi":"10.1371/journal.pone.0053518","title":"AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Children’s Oncology Group","keywords":"Gemtuzumab ozogamicin; Calicheamicin; Protein kinase B; CD33; Cancer research; PI3K/AKT/mTOR pathway; DNA damage; Myeloid leukemia; Biology; Cell biology; Signal transduction; Stem cell; CD34; Biochemistry; DNA","score_opus":0.05426376436216998,"score_gpt":0.2816663360104763,"score_spread":0.22740257164830632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056871730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956169,0.000043393316,0.000036660316,0.0011189696,0.000004763415,0.001135113,0.00003618464,0.000056183253,0.0019518376],"genre_scores_gemma":[0.9912102,0.0000021731546,0.0027371747,0.00037109584,0.00004738301,0.00009240185,0.000041075753,0.000052926138,0.005445524],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99788415,0.000053683034,0.00036648326,0.0003334397,0.00089169544,0.00047053082],"domain_scores_gemma":[0.99867296,0.00019140997,0.00012605544,0.00038477473,0.0004169721,0.00020783034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022415086,0.00017707194,0.0005872262,0.00030676203,0.000053724252,0.000021323878,0.00021217538,0.0001186658,0.00033828046],"category_scores_gemma":[0.00075492077,0.00015159814,0.000041669315,0.00060969853,0.000073951094,0.000102291735,0.000079470236,0.0004327149,0.00012213178],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000558424,0.0013154999,0.0040575084,0.00015689238,0.00026963273,0.00003019552,0.00073597365,0.0000020766395,0.9926056,0.00002959808,0.00018760117,0.00005095101],"study_design_scores_gemma":[0.003903502,0.0006833628,0.02419075,0.0014127042,0.00007761379,0.0000012818084,0.00024953266,0.00013844002,0.969101,0.000044911983,0.0000118554435,0.0001850157],"about_ca_topic_score_codex":0.0011018415,"about_ca_topic_score_gemma":0.00029678788,"teacher_disagreement_score":0.023504617,"about_ca_system_score_codex":0.0008796168,"about_ca_system_score_gemma":0.00026168197,"threshold_uncertainty_score":0.6181993},"labels":[],"label_agreement":null},{"id":"W2057466968","doi":"10.1016/j.lrr.2014.06.003","title":"An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes","year":2014,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Takeda Oncology","keywords":"Medicine; Nausea; Neutropenia; Internal medicine; Adverse effect; Febrile neutropenia; Leukemia; Myeloid leukemia; Myelodysplastic syndromes; Oncology; Gastroenterology; Bone marrow; Toxicity","score_opus":0.05372415204847806,"score_gpt":0.37175913493930307,"score_spread":0.318034982890825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057466968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959601,0.00022817384,0.000049428163,0.00027314163,0.00015028148,0.0026881776,0.00001993672,0.0001303502,0.00050041266],"genre_scores_gemma":[0.9973213,0.00009273713,0.0008470344,0.00014117146,0.0003015765,0.0005639837,0.00013561844,0.00014100807,0.0004555616],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.98966104,0.0016311032,0.0017216825,0.0016282736,0.0038691182,0.0014888],"domain_scores_gemma":[0.99367696,0.00092713285,0.00039705264,0.0019321358,0.0016051849,0.0014615073],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00812272,0.00055393716,0.001237659,0.0020409995,0.00035590606,0.00013647237,0.00045095955,0.00043115354,0.00009101852],"category_scores_gemma":[0.0045458796,0.0005102754,0.00011384819,0.0020988418,0.0011805425,0.00070712966,0.00055959396,0.0021854043,0.00003305721],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007552709,0.008603104,0.2062881,0.0020337175,0.001208615,0.09160518,0.026774243,0.00096958457,0.6179872,0.0006759934,0.008936165,0.027365394],"study_design_scores_gemma":[0.1139438,0.092629015,0.45467487,0.0040731216,0.0013910612,0.02609582,0.03485307,0.09113041,0.15805379,0.008848611,0.009468028,0.0048384136],"about_ca_topic_score_codex":0.001846277,"about_ca_topic_score_gemma":0.0007210056,"teacher_disagreement_score":0.4599334,"about_ca_system_score_codex":0.0051317024,"about_ca_system_score_gemma":0.008789045,"threshold_uncertainty_score":0.9997349},"labels":[],"label_agreement":null},{"id":"W2057787725","doi":"10.3109/10428194.2012.701738","title":"Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes","year":2012,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Psychosocial; Genetic testing; Cancer; Intensive care medicine; Genetic counseling; Genetic predisposition; Clinical Practice; Acute leukemia; Leukemia; Family medicine; Psychiatry; Immunology; Internal medicine; Disease; Genetics; Bone marrow","score_opus":0.02981002818768919,"score_gpt":0.3052547347914638,"score_spread":0.2754447066037746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057787725","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2898159,0.6974599,0.0006781738,0.000048742615,0.00079532317,0.009943426,0.00073311664,0.00021052605,0.00031491675],"genre_scores_gemma":[0.11602087,0.8789617,0.0014653924,0.00012940782,0.00038101908,0.0015870107,0.0006566851,0.00035383736,0.00044408606],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927975,0.00043199662,0.002232179,0.0019403578,0.00108166,0.0015163402],"domain_scores_gemma":[0.99460775,0.0016122706,0.0012396942,0.0012311825,0.00039855062,0.00091057515],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00137324,0.0017918522,0.0040298793,0.0006317124,0.000680153,0.00019500325,0.00060621666,0.0014898046,0.000010401932],"category_scores_gemma":[0.000079968035,0.0011038255,0.0007479184,0.0008651227,0.0017661978,0.0004783279,0.000734426,0.0006531137,0.0000117040245],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0024046723,0.00020535223,0.00053056225,0.028696688,0.0050151465,0.00023014138,0.00030411527,0.0000026216733,0.000009553505,0.00016937038,0.00029499986,0.9621368],"study_design_scores_gemma":[0.08547525,0.014096813,0.1778728,0.043617737,0.06916804,0.02579079,0.0024517018,0.008805124,0.00012101643,0.00027325575,0.566571,0.005756472],"about_ca_topic_score_codex":0.0003953019,"about_ca_topic_score_gemma":0.000049769562,"teacher_disagreement_score":0.9563803,"about_ca_system_score_codex":0.008116919,"about_ca_system_score_gemma":0.0058925413,"threshold_uncertainty_score":0.99980646},"labels":[],"label_agreement":null},{"id":"W2058169114","doi":"10.1016/j.leukres.2013.08.021","title":"Income and outcome in myelodysplastic syndrome: The prognostic impact of SES in a single-payer system","year":2013,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Quartile; Medicine; Internal medicine; Demography; Overall survival; Pediatrics; Confidence interval","score_opus":0.05507466281810802,"score_gpt":0.36357585916393176,"score_spread":0.30850119634582374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058169114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949369,0.0004081699,0.000008067202,0.0005703497,0.000034787387,0.0028229568,0.000009224886,0.00004137744,0.0011682131],"genre_scores_gemma":[0.9985851,0.00003925836,0.00015143011,0.000016181788,0.00004778758,0.0004553492,0.0000076084048,0.00006110217,0.0006362048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950904,0.00080927234,0.0008706271,0.0005507518,0.0013910674,0.0012878488],"domain_scores_gemma":[0.9949842,0.0032944963,0.000097556265,0.0007977808,0.00047242493,0.00035351233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030510759,0.00028743708,0.0007847169,0.0014844228,0.00010566787,0.0001060083,0.0005148067,0.00026614915,0.00015007018],"category_scores_gemma":[0.003166688,0.00017605712,0.00012029651,0.0024832594,0.00070207,0.00024443868,0.00055457966,0.00204165,0.00023849601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028795854,0.00014709638,0.98928815,0.0012182975,0.000069536436,0.0010560256,0.0005425669,0.000076887176,0.0055564595,0.00016162866,0.0001404759,0.0014548994],"study_design_scores_gemma":[0.0030423207,0.0010850277,0.9815736,0.0010863909,0.000016134256,0.0011072524,0.0012587893,0.010315515,0.00021174493,0.00013450897,0.000011263036,0.00015744379],"about_ca_topic_score_codex":0.010816208,"about_ca_topic_score_gemma":0.00023905006,"teacher_disagreement_score":0.010577158,"about_ca_system_score_codex":0.0065391883,"about_ca_system_score_gemma":0.0018344839,"threshold_uncertainty_score":0.9972745},"labels":[],"label_agreement":null},{"id":"W2058360832","doi":"10.1158/1538-7445.am2014-lb-169","title":"Abstract LB-169: Ratios of immunoproteasome over constitutive proteasome expression are an indicator for sensitivity to bortezomib-containing reinduction chemotherapy in pediatric relapsed ALL and AML","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Bortezomib; Medicine; Proteasome inhibitor; Chemotherapy; Refractory (planetary science); Internal medicine; Leukemia; In vivo; Oncology; Ex vivo; Clinical trial; Pharmacology; Cancer research; Biology; Multiple myeloma","score_opus":0.05144887532731268,"score_gpt":0.39021148127625394,"score_spread":0.33876260594894125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058360832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925147,0.00022914258,0.00025706238,0.0019552521,0.000060333998,0.0047872593,0.000044099408,0.00003312794,0.000118972974],"genre_scores_gemma":[0.99688476,0.00028634365,0.00067561725,0.00017853316,0.0005113697,0.0012562942,0.000030028325,0.000053024043,0.0001240117],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99698436,0.0003670028,0.00042453173,0.0006940228,0.00084009796,0.00068997976],"domain_scores_gemma":[0.99791276,0.00046777024,0.00018545671,0.000520218,0.0005252735,0.0003885258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004152341,0.00021029053,0.00052437984,0.0008105998,0.00016587724,0.000044558703,0.00015643938,0.0002638971,0.00006306714],"category_scores_gemma":[0.0014670329,0.00018879138,0.00005878298,0.0005875935,0.00026078345,0.0003358937,0.00011403447,0.0010191383,0.000006901919],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071649193,0.00022217854,0.076312244,0.0006113052,0.000048074802,0.000027287315,0.0018216551,0.000030184945,0.905669,0.000098685516,0.00077097694,0.007223491],"study_design_scores_gemma":[0.009914227,0.0016928049,0.6129847,0.0006830434,0.000025542064,0.000018036266,0.0009614089,0.00053940533,0.37127814,0.0002085883,0.001370832,0.0003232308],"about_ca_topic_score_codex":0.0012518351,"about_ca_topic_score_gemma":0.00019529325,"teacher_disagreement_score":0.5366725,"about_ca_system_score_codex":0.0010778356,"about_ca_system_score_gemma":0.0010900602,"threshold_uncertainty_score":0.7698689},"labels":[],"label_agreement":null},{"id":"W2059117184","doi":"10.3324/haematol.2012.062059","title":"Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research","year":2012,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Center for Research Resources; National Institute of Allergy and Infectious Diseases; National Cancer Institute; CellGenix; Genentech; Health Resources and Services Administration; Sigma-Tau Pharmaceuticals; Therakos; Kiadis Pharma; Amgen; Otsuka America Pharmaceutical; National Heart, Lung, and Blood Institute; Blue Cross and Blue Shield Association; Otsuka America; National Center for Advancing Translational Sciences; Teva Pharmaceutical Industries; WellPoint; Celgene; Takeda Oncology; Ariad Pharmaceuticals; GlaxoSmithKline; Swedish Orphan Biovitrum; Office of Naval Research; Be The Match Foundation; Medical College of Wisconsin; U.S. Department of Health and Human Services","keywords":"Medicine; Cumulative incidence; Transplantation; Myeloid leukemia; Bone marrow; Internal medicine; Leukemia; Gastroenterology; Incidence (geometry); Surgery","score_opus":0.07775151225751975,"score_gpt":0.36749665238917967,"score_spread":0.2897451401316599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059117184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893765,0.00030019038,0.0028488792,0.0023508149,0.00038921766,0.0034389198,0.00081851275,0.00007662762,0.00040034248],"genre_scores_gemma":[0.98925716,0.0018988304,0.0055207354,0.000119514254,0.00032519436,0.0007979877,0.0019306687,0.000044325043,0.00010557643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99667794,0.00035213033,0.000767408,0.0006613775,0.0007467066,0.0007944291],"domain_scores_gemma":[0.9955942,0.0033238942,0.00016623226,0.00035769827,0.00032753832,0.00023044524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017033288,0.00030478544,0.000538619,0.0002951755,0.00047080984,0.00010253707,0.00039618972,0.00032022208,0.000066490815],"category_scores_gemma":[0.0004074049,0.00022752534,0.00014334201,0.00034135516,0.00022714387,0.00028886786,0.000040704388,0.0006910941,0.000010092898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13898896,0.006473757,0.66147864,0.006221606,0.0036109926,0.005691745,0.058003355,0.00012322827,0.106297135,0.002278147,0.0067581367,0.0040742788],"study_design_scores_gemma":[0.18925844,0.007895164,0.6861075,0.002237273,0.009981399,0.007948237,0.014089803,0.010954984,0.06321819,0.0012376349,0.005247785,0.0018235688],"about_ca_topic_score_codex":0.0003020368,"about_ca_topic_score_gemma":0.0004860088,"teacher_disagreement_score":0.05026949,"about_ca_system_score_codex":0.00026200552,"about_ca_system_score_gemma":0.00022196547,"threshold_uncertainty_score":0.9278214},"labels":[],"label_agreement":null},{"id":"W2059523034","doi":"10.3109/08880018.2010.531521","title":"Childhood Acute Myeloid Leukemia: An Indian Perspective","year":2011,"lang":"en","type":"article","venue":"Pediatric Hematology and Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Stollery Children's Hospital","funders":"","keywords":"Medicine; Abandonment (legal); Myeloid leukemia; Intensive care medicine; Pediatrics; Oncology; Internal medicine","score_opus":0.022540881751204694,"score_gpt":0.3138821701481698,"score_spread":0.29134128839696516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059523034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96558994,0.0015612957,0.00007781602,0.0015086578,0.00022812748,0.0005752164,0.00001263877,0.00015729705,0.030289019],"genre_scores_gemma":[0.9904307,0.0024305638,0.0043895915,0.0015902972,0.0006412474,0.00008856893,0.000027803866,0.0000445575,0.00035665903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977439,0.00024879348,0.000394439,0.0006826247,0.00017352532,0.0007567427],"domain_scores_gemma":[0.9983792,0.00022745207,0.00014405414,0.0004239004,0.00021515903,0.0006102471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044061829,0.00028034847,0.00080701127,0.0005249685,0.00020763784,0.000007425987,0.00022994903,0.0008413777,0.0004924341],"category_scores_gemma":[0.00028467472,0.00024325939,0.0000948003,0.00043727038,0.0004281806,0.00017423145,0.00018916297,0.0011163912,0.00023150649],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031726658,0.0031394288,0.7757418,0.0003311258,0.0013732413,0.023507537,0.07057204,3.7283985e-7,0.00037494086,0.08513627,0.0144961225,0.022154441],"study_design_scores_gemma":[0.015943352,0.012463943,0.8589181,0.000020695554,0.0023042592,0.06657035,0.014639964,0.000092910865,0.0019866014,0.019495841,0.006398206,0.0011657868],"about_ca_topic_score_codex":0.00041406276,"about_ca_topic_score_gemma":0.00013871692,"teacher_disagreement_score":0.083176285,"about_ca_system_score_codex":0.0007718657,"about_ca_system_score_gemma":0.0021630207,"threshold_uncertainty_score":0.991983},"labels":[],"label_agreement":null},{"id":"W2060013642","doi":"10.1182/blood-2012-04-415034","title":"Chopped and diced: Dicer1 deletion generates myeloid dysplasia","year":2012,"lang":"en","type":"letter","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Myeloid; Cancer research","score_opus":0.01913930568128071,"score_gpt":0.2655508589859952,"score_spread":0.24641155330471445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060013642","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30741456,0.010096106,0.000060835588,0.6701012,0.0005837191,0.0017192123,0.00014431655,0.0003571754,0.009522885],"genre_scores_gemma":[0.054436713,0.005138348,0.0038320723,0.8441579,0.04925934,0.00038845785,0.005208143,0.00064349856,0.03693557],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970832,0.00014078082,0.00039390413,0.00065781985,0.0007749746,0.0009493452],"domain_scores_gemma":[0.9984926,0.00017559057,0.00016178584,0.00068577426,0.00017398533,0.0003102871],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00032645365,0.0005002027,0.0007164586,0.0003628991,0.00014510099,0.000080990314,0.00022119067,0.001352468,0.0004982304],"category_scores_gemma":[0.0001550707,0.00042396455,0.00013761954,0.00023177925,0.00019469837,0.00012671073,0.0001989293,0.0029021138,0.00048473538],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006112773,0.0001573149,0.006134613,0.0008038359,0.0005434181,0.001133046,0.00011658486,6.954452e-8,0.01197039,0.000009910015,0.9766437,0.0024260122],"study_design_scores_gemma":[0.004753618,0.00027738375,0.006023416,0.00023921621,0.0013360434,0.0016517409,0.000018080003,0.000029229745,0.005980141,0.000023995195,0.9791497,0.00051743136],"about_ca_topic_score_codex":0.00010654307,"about_ca_topic_score_gemma":0.0000062592626,"teacher_disagreement_score":0.25297785,"about_ca_system_score_codex":0.00018930394,"about_ca_system_score_gemma":0.00033434544,"threshold_uncertainty_score":0.999944},"labels":[],"label_agreement":null},{"id":"W2060515423","doi":"10.1016/j.scr.2015.01.006","title":"Despite differential gene expression profiles pediatric MDS derived mesenchymal stromal cells display functionality in vitro","year":2015,"lang":"en","type":"article","venue":"Stem Cell Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Leids Universitair Medisch Centrum; Stichting Kinderen Kankervrij; Universiteit Leiden","keywords":"Biology; Mesenchymal stem cell; Stromal cell; Bone marrow; Haematopoiesis; Myelodysplastic syndromes; Cancer research; Phenotype; Immunology; Stem cell; Gene; Genetics","score_opus":0.07631000079991025,"score_gpt":0.3448802973984369,"score_spread":0.26857029659852666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060515423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940068,0.00059210754,0.0004350876,0.00029728658,0.00029260007,0.0015374679,0.00007571288,0.000072109484,0.0026908182],"genre_scores_gemma":[0.9895045,0.0001372892,0.0016763351,0.000020380672,0.0008916218,0.0002573616,0.00019192498,0.00007555659,0.007245009],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9923586,0.0012729979,0.0006054003,0.0009463661,0.0032789102,0.0015376875],"domain_scores_gemma":[0.9965466,0.0005773935,0.00009559293,0.00083824183,0.00086720975,0.001074956],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002899437,0.00033971993,0.0005574747,0.000937469,0.00023578698,0.00011349195,0.0005124373,0.0003596465,0.00036226495],"category_scores_gemma":[0.0001699063,0.0002740004,0.00015625643,0.0012259485,0.00028892665,0.00022893406,0.00081950944,0.0018677356,0.0005083685],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039075143,0.00055827905,0.026054306,0.0003432683,0.000020003257,0.00037820253,0.00046455004,0.000019749903,0.96204793,0.000012452124,0.005277591,0.00091617357],"study_design_scores_gemma":[0.0054637925,0.0007176075,0.03391675,0.00004748461,0.000031252377,0.000026742631,0.0009509647,0.0017903792,0.956081,0.000048120626,0.0006382617,0.00028766628],"about_ca_topic_score_codex":0.00028980023,"about_ca_topic_score_gemma":0.000011870575,"teacher_disagreement_score":0.007862442,"about_ca_system_score_codex":0.0013175128,"about_ca_system_score_gemma":0.002155859,"threshold_uncertainty_score":0.9999712},"labels":[],"label_agreement":null},{"id":"W2061122794","doi":"10.1016/j.exphem.2013.12.001","title":"Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations","year":2013,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institute of Neurological Disorders and Stroke; National Heart, Lung, and Blood Institute; National Institutes of Health; Agios Pharmaceuticals; Johns Hopkins University; Leukemia and Lymphoma Society","keywords":"Myeloid leukemia; Glutaminase; Cancer research; Primary (astronomy); Myeloid; Myeloid cells; Leukemia; Chemistry; Biology; Immunology; Genetics; Glutamine","score_opus":0.010672770858105899,"score_gpt":0.26771546833529464,"score_spread":0.2570426974771887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061122794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993628,0.0007599954,0.00021569457,0.00047381825,0.000044437635,0.0011167916,0.00002673084,0.000037093396,0.0036973942],"genre_scores_gemma":[0.9963918,0.000030876286,0.0026812502,0.00019953387,0.000027460721,0.0002846741,0.00008118849,0.00003511089,0.00026810745],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99852514,0.00011736371,0.00039626702,0.0002850921,0.00034515257,0.00033098142],"domain_scores_gemma":[0.99883145,0.00023980407,0.00019822275,0.00031151104,0.00031188942,0.00010710415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009541916,0.00019826833,0.0005208961,0.00016596464,0.00008875981,0.000008586727,0.00015178265,0.00012516431,0.00040091682],"category_scores_gemma":[0.000029951383,0.0001306224,0.000083192135,0.00037153158,0.0007966302,0.00018533715,0.00012090591,0.00025965672,0.000057396624],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048507046,0.00036882164,0.0019961551,0.00020686106,0.00023137286,0.00007883637,0.0018919137,0.0000028722982,0.9875373,0.0037700646,0.0033472949,0.000083426654],"study_design_scores_gemma":[0.0021156077,0.0009997139,0.005363848,0.000077957455,0.00007456021,0.0008666214,0.0021279484,0.00008852224,0.98798555,0.00016676237,0.00001780336,0.000115130715],"about_ca_topic_score_codex":0.00042810527,"about_ca_topic_score_gemma":0.0000051025427,"teacher_disagreement_score":0.0036033022,"about_ca_system_score_codex":0.00039934844,"about_ca_system_score_gemma":0.00050179707,"threshold_uncertainty_score":0.5326627},"labels":[],"label_agreement":null},{"id":"W2061216977","doi":"10.1053/j.seminhematol.2005.05.007","title":"Decitabine in Acute Myeloid Leukemia","year":2005,"lang":"en","type":"review","venue":"Seminars in Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Decitabine; Medicine; Azacitidine; Oncology; Myelodysplastic syndromes; Myeloid leukemia; Demethylating agent; Internal medicine; Chemotherapy; Tolerability; Epigenetic therapy; Myeloid; DNA methylation; Bone marrow; Adverse effect; Biology","score_opus":0.037108946504880426,"score_gpt":0.3763968879141379,"score_spread":0.33928794140925744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061216977","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00051588396,0.99096954,0.000007367426,0.00040215265,0.00030603874,0.0020930737,0.000030121384,0.00008922372,0.0055865725],"genre_scores_gemma":[0.000035576097,0.9915046,0.0029664934,0.00022542766,0.00024337371,0.0006537183,0.00035502648,0.00019890763,0.0038168759],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944056,0.00042262432,0.0019417704,0.0012395019,0.0004982767,0.0014921896],"domain_scores_gemma":[0.9968394,0.0010568277,0.0003720619,0.0013236792,0.000083364735,0.00032469176],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0009811711,0.0008921259,0.0057623284,0.002327883,0.00004068913,0.000017302307,0.00080148526,0.0019694879,0.00071278005],"category_scores_gemma":[0.00070968666,0.0007731769,0.00055983616,0.0019804165,0.00035087488,0.00009905765,0.0005211016,0.0034011826,0.0010238845],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000105944884,0.00014789515,0.00042227533,0.010929798,0.00021022442,0.010819352,0.00013204088,8.887029e-7,0.0000019938318,0.0006046228,0.009933262,0.9666917],"study_design_scores_gemma":[0.0017349597,0.00016731177,0.00003169042,0.032364834,0.00048421204,0.018237207,0.00005100572,0.000052160154,0.00001052717,0.00011045055,0.94620156,0.0005540745],"about_ca_topic_score_codex":0.00008993805,"about_ca_topic_score_gemma":0.0001601857,"teacher_disagreement_score":0.96613765,"about_ca_system_score_codex":0.005344803,"about_ca_system_score_gemma":0.0034065002,"threshold_uncertainty_score":0.99975395},"labels":[],"label_agreement":null},{"id":"W2062375341","doi":"10.1016/j.exphem.2006.10.005","title":"Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression","year":2007,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Royal University Hospital","funders":"Canadian Institutes of Health Research; Saskatchewan Health Research Foundation","keywords":"Cancer research; Myeloid leukemia; DNA methylation; Trichostatin A; Azacitidine; Biology; Cell growth; Decitabine; Histone deacetylase inhibitor; Cell cycle; Histone deacetylase; Apoptosis; Molecular biology; Histone; DNA; Gene expression; Biochemistry","score_opus":0.010370828296613297,"score_gpt":0.3014071881327695,"score_spread":0.2910363598361562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062375341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994858,0.001049393,0.00013126993,0.00029132882,0.000043287884,0.00062134606,0.0000021333863,0.000047771115,0.002955427],"genre_scores_gemma":[0.9961513,0.00003440939,0.0030133459,0.00019019916,0.000047216676,0.00004878497,0.00009804456,0.000038771643,0.00037787665],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979791,0.00011774263,0.00048724285,0.00045768655,0.00038850252,0.0005697255],"domain_scores_gemma":[0.9992808,0.0001477298,0.00016627913,0.00018391706,0.000065422806,0.00015585263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006914886,0.00022376383,0.00049972266,0.00051162776,0.00008086216,0.000014136846,0.00008648682,0.00034626044,0.000050526163],"category_scores_gemma":[0.00005646541,0.00019998812,0.000033360702,0.00042336783,0.00009206557,0.00018418799,0.00014779162,0.000591744,0.000015560297],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013049314,0.00020616007,0.18950242,0.000050522656,0.000021855258,0.00043684052,0.0009819755,6.41241e-7,0.8065489,0.0006578778,0.0001323785,0.00015547972],"study_design_scores_gemma":[0.006646,0.00043140978,0.04402233,0.00008909367,0.00001464398,0.00024475716,0.00073684653,0.00014084393,0.947372,0.00008197552,0.000045796147,0.00017426228],"about_ca_topic_score_codex":0.0004396428,"about_ca_topic_score_gemma":0.00009937852,"teacher_disagreement_score":0.1454801,"about_ca_system_score_codex":0.0022681307,"about_ca_system_score_gemma":0.00012354592,"threshold_uncertainty_score":0.8155279},"labels":[],"label_agreement":null},{"id":"W2062456268","doi":"10.1503/cmaj.109-4925","title":"Stem-cell replication to treat blood diseases","year":2014,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Replication (statistics); Clinical trial; Leukemia; Medicine; Blood cancer; Human blood; Bioinformatics; Immunology; Cancer; Intensive care medicine; Biology; Pathology; Virology; Physiology; Internal medicine","score_opus":0.008232775373744129,"score_gpt":0.2606414409642638,"score_spread":0.25240866559051967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062456268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82355326,0.0002464129,0.0005130284,0.15068515,0.0003447164,0.00040491114,0.000042470776,0.000060768944,0.024149302],"genre_scores_gemma":[0.94679916,0.00013696199,0.00030347,0.033831824,0.003435817,0.00002780775,0.000039651462,0.000041407588,0.015383886],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99706006,0.0002104946,0.0003666422,0.00026103298,0.0015395207,0.00056223664],"domain_scores_gemma":[0.99391043,0.0002339544,0.00012478475,0.00032840477,0.00050579396,0.004896607],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015991355,0.00011867448,0.00025303417,0.00029766074,0.00022994465,0.00007980458,0.00022586598,0.00027718898,0.0021035129],"category_scores_gemma":[0.0024701506,0.00010340509,0.00010383535,0.00035428285,0.000024474344,0.000078236095,0.000021154214,0.0007770675,0.00079440116],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044237175,0.00017825948,0.13258365,0.000040980263,0.00009712086,0.00044160365,0.00025511373,0.0000038377048,0.0005429482,0.00025627983,0.6628634,0.20269261],"study_design_scores_gemma":[0.004071511,0.00058500684,0.08051214,0.00011916112,0.00023123041,0.0008232979,0.00023401962,0.00057828584,0.0008961477,0.00011741445,0.9115799,0.00025188716],"about_ca_topic_score_codex":0.0012781182,"about_ca_topic_score_gemma":0.0019336643,"teacher_disagreement_score":0.24871653,"about_ca_system_score_codex":0.00202952,"about_ca_system_score_gemma":0.003940033,"threshold_uncertainty_score":0.9999836},"labels":[],"label_agreement":null},{"id":"W2062483137","doi":"10.1016/j.leukres.2004.01.006","title":"Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome","year":2004,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; CD34; Pathology; Chemotherapy; Myeloid; Internal medicine; Biology","score_opus":0.11430635881337432,"score_gpt":0.41852287938176536,"score_spread":0.30421652056839105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062483137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940593,0.0008677325,0.000074830044,0.0015025558,0.000054887616,0.00097122166,0.000049525952,0.00011390126,0.0023060332],"genre_scores_gemma":[0.99452734,0.0007074814,0.0018000802,0.00030300667,0.00020997356,0.00010486579,0.00006331953,0.0000865025,0.0021974288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994211,0.00070502586,0.0011075689,0.0007033002,0.0020692006,0.0012038791],"domain_scores_gemma":[0.99456656,0.0021177984,0.00026176477,0.0009011891,0.0014276864,0.00072501344],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0045983824,0.00033943562,0.0010450113,0.0006101102,0.00028665212,0.000095650976,0.0004501177,0.00056442205,0.00017645261],"category_scores_gemma":[0.005812599,0.00024846988,0.00015447257,0.0011072945,0.00217598,0.00031176655,0.00047536634,0.0028160722,0.000052670588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014973449,0.0003345178,0.98727924,0.0005138368,0.00023062545,0.00082333764,0.00074080867,0.00004852997,0.004329997,0.0007447249,0.0022825252,0.0011744866],"study_design_scores_gemma":[0.0132781025,0.0024933373,0.9581312,0.0020428114,0.00007886984,0.0003493884,0.0039370996,0.00019261749,0.016309384,0.0012544855,0.0014883648,0.0004443325],"about_ca_topic_score_codex":0.00082402834,"about_ca_topic_score_gemma":0.00021080989,"teacher_disagreement_score":0.029148057,"about_ca_system_score_codex":0.0017525192,"about_ca_system_score_gemma":0.0037440099,"threshold_uncertainty_score":0.9999968},"labels":[],"label_agreement":null},{"id":"W2062602243","doi":"10.1016/j.bbagrm.2012.09.004","title":"Suspected leukemia oncoproteins CREB1 and LYL1 regulate Op18/STMN1 expression","year":2012,"lang":"en","type":"article","venue":"Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"CREB1; Biology; Transcription factor; Cancer research; Cell biology; CREB; Genetics; Gene","score_opus":0.018217913721467298,"score_gpt":0.2730057908518405,"score_spread":0.2547878771303732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062602243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934024,0.0005147705,0.0007407627,0.0016506054,0.0004135043,0.0017213782,0.00007617882,0.00053694664,0.00094342267],"genre_scores_gemma":[0.9794801,0.00032461758,0.015278429,0.0007350061,0.0011689488,0.00016114723,0.00025005438,0.00028117458,0.0023205595],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99445415,0.00040000083,0.0008170645,0.0012955244,0.0013768984,0.0016563411],"domain_scores_gemma":[0.99583054,0.00014378144,0.00043013433,0.0019575893,0.00028401945,0.0013539172],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009663461,0.0009256177,0.0011240928,0.0005129798,0.0004571187,0.00012276464,0.0005692432,0.0007353012,0.00023556127],"category_scores_gemma":[0.00015009292,0.0008101476,0.00037533938,0.0007941463,0.0004561047,0.0006011274,0.0007889852,0.00096065825,0.000192435],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006728537,0.0003252016,0.00000415879,0.00014697228,0.00020878372,0.000039526876,0.0005749507,0.0000012385547,0.9905859,0.0031342432,0.0028448505,0.0014613072],"study_design_scores_gemma":[0.002831854,0.0006240972,0.019324014,0.00030860308,0.00025230693,0.0002862868,0.00019710687,0.0004204669,0.9731198,0.0013696484,0.00042244577,0.0008433468],"about_ca_topic_score_codex":0.00006426428,"about_ca_topic_score_gemma":0.0000029360494,"teacher_disagreement_score":0.019319857,"about_ca_system_score_codex":0.0012285977,"about_ca_system_score_gemma":0.00086237065,"threshold_uncertainty_score":0.99943495},"labels":[],"label_agreement":null},{"id":"W2062894106","doi":"10.1038/leu.2013.187","title":"Monosomal karyotype in MDS: explaining the poor prognosis?","year":2013,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Internal medicine; Myelodysplastic syndromes; Multivariate analysis; Myeloid leukemia; International Prognostic Scoring System; Karyotype; Oncology; Medicine; Prognostic variable; Gastroenterology; Biology; Bone marrow; Chromosome; Genetics; Gene","score_opus":0.02215683526851599,"score_gpt":0.2820200830860277,"score_spread":0.25986324781751174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062894106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96973765,0.0002932337,0.000021353082,0.008239884,0.00010017138,0.0011638344,0.0000016044107,0.000105069936,0.020337228],"genre_scores_gemma":[0.99239373,0.000053501903,0.0010885815,0.0023793844,0.0003320391,0.00048372895,0.000017202061,0.000046299476,0.003205507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817115,0.00009763227,0.00032797313,0.00034917606,0.00041799314,0.000636047],"domain_scores_gemma":[0.9989763,0.00024247794,0.00005905374,0.00042726984,0.00010886483,0.00018607244],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033911818,0.00019494245,0.00028636292,0.00016625614,0.00010637654,0.000066886445,0.0003270941,0.00016278909,0.00077252724],"category_scores_gemma":[0.000287494,0.00012620591,0.000084513165,0.0005191182,0.00014091165,0.00021817298,0.0001704548,0.00083784194,0.0017381106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069580774,0.00031619795,0.56695807,0.0003095005,0.00027379204,0.00095253903,0.005565329,0.00013300189,0.053610068,0.003080057,0.2494013,0.118704356],"study_design_scores_gemma":[0.006766821,0.00066715875,0.91199183,0.00041146047,0.00007243224,0.00035350365,0.003005018,0.027152427,0.017354919,0.00089721614,0.03075285,0.0005743739],"about_ca_topic_score_codex":0.0016049092,"about_ca_topic_score_gemma":0.000057965724,"teacher_disagreement_score":0.34503376,"about_ca_system_score_codex":0.0011196621,"about_ca_system_score_gemma":0.000705955,"threshold_uncertainty_score":0.9990392},"labels":[],"label_agreement":null},{"id":"W2063188258","doi":"10.1016/j.cancergen.2012.04.007","title":"A cytogenetic study of 397 consecutive acute myeloid leukemia cases identified three with a t(7;21) associated with 5q abnormalities and exhibiting similar clinical and biological features, suggesting a new, rare acute myeloid leukemia entity","year":2012,"lang":"en","type":"article","venue":"Cancer Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Ligue Contre le Cancer","keywords":"RUNX1; Fluorescence in situ hybridization; Chromosomal translocation; Myeloid leukemia; Biology; Fusion gene; Myeloid; Cytogenetics; Leukemia; Immunophenotyping; Cancer research; Pathology; Molecular biology; Gene; Immunology; Antigen; Medicine; Genetics; Chromosome","score_opus":0.06896613705583324,"score_gpt":0.34517508711237566,"score_spread":0.27620895005654245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063188258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99054074,0.006549873,0.0001213149,0.0001737241,0.000120255805,0.0019414376,0.00029222123,0.000106113075,0.00015428891],"genre_scores_gemma":[0.9937316,0.002740397,0.0017936416,0.00030378794,0.0005018937,0.00013533501,0.00009458195,0.00010347786,0.0005952794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955862,0.0004579541,0.0009513094,0.00096236326,0.0008594561,0.0011826715],"domain_scores_gemma":[0.9963057,0.0009803044,0.00059200724,0.0006336051,0.0006414182,0.0008469753],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001016015,0.0006705926,0.0013970842,0.00022685264,0.0003595387,0.00011774649,0.0002926212,0.00048356046,0.000044856853],"category_scores_gemma":[0.00067963236,0.00049610075,0.000114586546,0.0006172723,0.0013738852,0.00018925723,0.0005364636,0.0011712511,0.0000019353527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028746915,0.00022276405,0.9807067,0.00014450122,0.0026785794,0.00092085934,0.003853763,0.000050553896,0.003441841,0.000011774835,0.00086811645,0.004225835],"study_design_scores_gemma":[0.012324245,0.004944072,0.9645063,0.00068565406,0.0026268992,0.0015973385,0.0063857483,0.00032063577,0.0057054516,0.000024305542,0.00016996847,0.00070937903],"about_ca_topic_score_codex":0.0016814272,"about_ca_topic_score_gemma":0.00372322,"teacher_disagreement_score":0.016200418,"about_ca_system_score_codex":0.0009839626,"about_ca_system_score_gemma":0.0025909683,"threshold_uncertainty_score":0.99974906},"labels":[],"label_agreement":null},{"id":"W2063570009","doi":"10.1159/000059424","title":"MCEF, the Newest Member of the AF4 Family of Transcription Factors Involved in Leukemia, Is a Positive Transcription Elongation Factor-b-Associated Protein","year":2002,"lang":"en","type":"article","venue":"Journal of Biomedical Science","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"Transcription factor; Genetics; Elongation factor; Biology; Transcription (linguistics); Cell biology; Gene; RNA","score_opus":0.04432110545572787,"score_gpt":0.2893295161517042,"score_spread":0.24500841069597634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063570009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933377,0.00017853994,0.00028080723,0.0052779345,0.00017711641,0.0005606072,0.000027170736,0.0000054795223,0.00015463884],"genre_scores_gemma":[0.99937373,0.000093601964,0.00010795311,0.00022681135,0.000056480538,0.000003967829,0.0000023163182,0.000009369595,0.00012578082],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9957244,0.00025969135,0.00090871216,0.00020358982,0.0025356254,0.00036802824],"domain_scores_gemma":[0.9981697,0.00015172812,0.0005998567,0.00022600076,0.0006235746,0.00022914873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019888596,0.00015119821,0.00040465148,0.00042189466,0.0001350792,0.000023747307,0.0006105013,0.00018106043,0.00016776122],"category_scores_gemma":[0.00095008535,0.000076664124,0.00023362608,0.0026285006,0.0017864816,0.00041441552,0.000036173715,0.00080217724,0.0000020047034],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001238361,0.00027882133,0.007635937,0.00003860868,0.000035715133,0.000008023698,0.006487962,0.0000043362893,0.9816797,0.00002633042,0.00028350324,0.003397258],"study_design_scores_gemma":[0.0026897695,0.00092700927,0.74648637,0.0007941299,0.00006528348,0.000024751029,0.0020633182,0.0030624445,0.24345514,0.00013022772,0.00019717855,0.000104374],"about_ca_topic_score_codex":0.0006891912,"about_ca_topic_score_gemma":0.00008181539,"teacher_disagreement_score":0.7388504,"about_ca_system_score_codex":0.0013478184,"about_ca_system_score_gemma":0.00096009794,"threshold_uncertainty_score":0.65823656},"labels":[],"label_agreement":null},{"id":"W2063827970","doi":"10.1002/ajh.20812","title":"Pathological splenic rupture: A rare complication of chronic myelomonocytic leukemia","year":2006,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Chronic myelomonocytic leukemia; Medicine; Complication; Pathological; Spleen; Pathology; Internal medicine; Bone marrow; Myelodysplastic syndromes","score_opus":0.015037321804729647,"score_gpt":0.2978919273949417,"score_spread":0.282854605590212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063827970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905471,0.0021454298,0.0035692602,0.0025297103,0.00007287043,0.00020082008,0.0000046839814,0.000020281137,0.0009098089],"genre_scores_gemma":[0.9942476,0.00019937234,0.0049612266,0.00025561123,0.00022307543,0.000006825126,0.000012227113,0.000023625811,0.0000704173],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979683,0.00019962298,0.00088461087,0.00020752945,0.00035584893,0.00038408343],"domain_scores_gemma":[0.99787736,0.00029458484,0.00092573254,0.000355969,0.00039304653,0.00015331942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036636184,0.00017238982,0.0010619388,0.00030883285,0.000040677292,0.000005911601,0.00028585957,0.00011202828,0.0001742854],"category_scores_gemma":[0.00018326593,0.00012922063,0.00023898938,0.00048851373,0.00090537017,0.000063286534,0.000067911315,0.0006249634,0.000033110693],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008607465,0.0030644918,0.24425527,0.0015731092,0.0016059347,0.015943045,0.001054481,0.00091143046,0.3531701,0.051124018,0.06470518,0.2539855],"study_design_scores_gemma":[0.022107469,0.034592763,0.4620886,0.0012798739,0.001346294,0.34589764,0.002355095,0.005882505,0.08634541,0.0094677815,0.027357483,0.0012790593],"about_ca_topic_score_codex":0.00009497408,"about_ca_topic_score_gemma":0.000007967099,"teacher_disagreement_score":0.3299546,"about_ca_system_score_codex":0.000885754,"about_ca_system_score_gemma":0.0011826227,"threshold_uncertainty_score":0.5269464},"labels":[],"label_agreement":null},{"id":"W2063893413","doi":"10.1371/journal.pone.0027486","title":"A Unique Role of GATA1s in Down Syndrome Acute Megakaryocytic Leukemia Biology and Therapy","year":2011,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Izaak Walton Killam Health Centre","funders":"National Cancer Institute; National Institute of Environmental Health Sciences; Barbara Ann Karmanos Cancer Institute; Wayne State University; Leukemia and Lymphoma Society","keywords":"Daunorubicin; Gene knockdown; Small hairpin RNA; GATA1; Biology; NPM1; Chromatin immunoprecipitation; Cancer research; Molecular biology; Cell cycle; Apoptosis; Leukemia; Cell biology; Gene expression; Immunology; Gene; Haematopoiesis; Promoter; Genetics; Stem cell","score_opus":0.05181913412381833,"score_gpt":0.277655502175327,"score_spread":0.22583636805150864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063893413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943461,0.0012261678,0.0000059824006,0.00020369583,0.0000067481246,0.0005863899,0.000016863667,0.000037673355,0.0035704148],"genre_scores_gemma":[0.99407643,0.0027118255,0.002536941,0.00019531143,0.00002140618,0.00006155339,0.000021905296,0.00002846317,0.00034617956],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998824,0.000094280076,0.0002782166,0.00027932727,0.00018892069,0.0003352591],"domain_scores_gemma":[0.99922353,0.000089814916,0.00006468313,0.00039166745,0.000088623434,0.00014168111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027307312,0.00014607838,0.00053125835,0.00028808825,0.000020467,0.0000036569274,0.00016028852,0.00017966278,0.00022680275],"category_scores_gemma":[0.00008064263,0.000119067,0.00003728688,0.0002884317,0.00022234865,0.000071565686,0.00010193295,0.00038491405,0.000032009822],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014068517,0.001179174,0.13932669,0.00019410832,0.0010608188,0.0004320306,0.0016504772,1.2116033e-7,0.85087234,0.0010995179,0.000055747714,0.002722135],"study_design_scores_gemma":[0.009628758,0.0042760037,0.2737461,0.0006492616,0.00029676539,0.0004907894,0.00029686786,0.0011009368,0.70359445,0.005347083,0.00018574533,0.00038721535],"about_ca_topic_score_codex":0.00086242706,"about_ca_topic_score_gemma":0.0000217069,"teacher_disagreement_score":0.14727786,"about_ca_system_score_codex":0.00025698458,"about_ca_system_score_gemma":0.00038610055,"threshold_uncertainty_score":0.48554114},"labels":[],"label_agreement":null},{"id":"W2064418887","doi":"10.1182/blood-2013-03-491589","title":"Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"National Cancer Institute","keywords":"Transplantation; Juvenile myelomonocytic leukemia; Medicine; Cumulative incidence; Umbilical Cord Blood Transplantation; Hazard ratio; Internal medicine; Leukemia; Monosomy; Gastroenterology; Umbilical cord; Surgery; Hematopoietic stem cell transplantation; Immunology; Biology; Confidence interval; Karyotype; Stem cell; Haematopoiesis","score_opus":0.010444806798033151,"score_gpt":0.26005862940927016,"score_spread":0.24961382261123702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064418887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975767,0.00009123614,0.000037338166,0.000022227383,0.000014873196,0.0019802304,0.000102148246,0.000071577546,0.00010363086],"genre_scores_gemma":[0.9988732,0.000092881965,0.00044252933,0.00005916363,0.000029820623,0.00024825914,0.000117577336,0.00006126263,0.00007535287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99700886,0.00023116033,0.00079574314,0.0006365021,0.00077107456,0.00055667316],"domain_scores_gemma":[0.99827266,0.00028013665,0.00028787018,0.00071980775,0.00020909247,0.00023042041],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003472345,0.0003975955,0.0011327197,0.0013023755,0.00006935895,0.000042513908,0.00027235958,0.00016008553,0.00021883646],"category_scores_gemma":[0.00015819824,0.00029340704,0.00023253035,0.002030471,0.00010797424,0.0002650327,0.000067536566,0.0006916087,0.000027850538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033941003,0.0012290654,0.98769414,0.000058362242,0.005150074,0.00013845142,0.004206566,0.00018268578,0.00058053364,8.463908e-7,0.000004726208,0.00041515718],"study_design_scores_gemma":[0.012851978,0.0010835861,0.96838146,0.000066259,0.013628577,0.0000435328,0.0016285774,0.00022942678,0.0018022716,0.000004640786,8.3327376e-7,0.00027887328],"about_ca_topic_score_codex":0.016026698,"about_ca_topic_score_gemma":0.0023437412,"teacher_disagreement_score":0.019312678,"about_ca_system_score_codex":0.00024039365,"about_ca_system_score_gemma":0.00041680058,"threshold_uncertainty_score":0.9999518},"labels":[],"label_agreement":null},{"id":"W2064563134","doi":"10.1016/j.exphem.2012.07.006","title":"Selective small molecule inhibitors of p110α and δ isoforms of phosphoinosityl-3-kinase are cytotoxic to human acute myeloid leukemia progenitors","year":2012,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; University of British Columbia","keywords":"Myeloid leukemia; Cytotoxic T cell; Gene isoform; Leukemia; Progenitor cell; Cancer research; CD135; Kinase; Biology; Chemistry; Stem cell; Cell biology; Immunology; Biochemistry; Gene; In vitro","score_opus":0.01800763054451551,"score_gpt":0.3110570026765477,"score_spread":0.2930493721320322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064563134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952647,0.0026034107,0.000017744616,0.00009356346,0.00012587913,0.0012472844,0.000019081468,0.000050716113,0.00057761074],"genre_scores_gemma":[0.99824864,0.000016348982,0.0011238973,0.000119878394,0.00009143034,0.00018117498,0.000020242904,0.000058440244,0.00013997695],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979324,0.00007836772,0.0005557604,0.0004033585,0.00032370235,0.00070646516],"domain_scores_gemma":[0.99869585,0.000051427265,0.00024494043,0.0003829353,0.00014316344,0.00048169517],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018825728,0.0003169793,0.000856404,0.00032015523,0.0001079918,0.000006161489,0.00017779463,0.00025933585,0.000109107525],"category_scores_gemma":[0.000042887834,0.00028212505,0.00014007385,0.00040153065,0.00038054914,0.00012018539,0.0003640471,0.00032292766,0.000027422806],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055581646,0.00052286504,0.09990909,0.00019888913,0.0002569189,0.000057258356,0.0032493973,2.379397e-7,0.89276415,0.0013014271,0.0010980084,0.000085964726],"study_design_scores_gemma":[0.0020902494,0.0013917906,0.014971556,0.00010982182,0.000062831474,0.0005007841,0.0037386063,0.000007932846,0.9768349,0.000012318102,0.000052825213,0.00022639644],"about_ca_topic_score_codex":0.0002521592,"about_ca_topic_score_gemma":0.000012793113,"teacher_disagreement_score":0.084937535,"about_ca_system_score_codex":0.000673196,"about_ca_system_score_gemma":0.00021397915,"threshold_uncertainty_score":0.9999631},"labels":[],"label_agreement":null},{"id":"W2065183816","doi":"10.1016/j.leukres.2012.06.011","title":"FCHSD2 predicts response to chemotherapy in acute myeloid leukemia patients","year":2012,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research; Ontario Institute for Cancer Research; Leukemia and Lymphoma Research; Leukemia and Lymphoma Society","keywords":"Medicine; Chemotherapy; Myeloid leukemia; Induction chemotherapy; Gene knockdown; Bone marrow; Internal medicine; Oncology; Small hairpin RNA; Leukemia; Myeloid; Puma; Cytarabine; Cancer research; Clinical significance; Immunology; Gastroenterology; Biology; Apoptosis","score_opus":0.03905140989411161,"score_gpt":0.36528964764357685,"score_spread":0.32623823774946525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065183816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98244154,0.00024831115,0.000049247687,0.004995621,0.0002672256,0.003194388,0.000049165985,0.0002605383,0.008493968],"genre_scores_gemma":[0.9790559,0.00032363826,0.0020442493,0.0022127475,0.0007535959,0.0006234883,0.00010556303,0.00022398515,0.014656876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9892263,0.0014122603,0.0008862879,0.0010869224,0.0035946798,0.003793578],"domain_scores_gemma":[0.99359983,0.0013097113,0.000090323985,0.0017995957,0.001002013,0.0021985054],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008735695,0.0005489193,0.0008717827,0.0024830587,0.00032860538,0.000120443634,0.0010492818,0.0006527275,0.0005761348],"category_scores_gemma":[0.0033844751,0.0004978792,0.00020899557,0.004128211,0.00044577377,0.0005907433,0.0008642318,0.0032780918,0.0036378521],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062918864,0.0013679377,0.46929634,0.00035379047,0.00044337657,0.00075563893,0.009241462,0.000056432105,0.1319093,0.0003320151,0.28261253,0.04071235],"study_design_scores_gemma":[0.015261381,0.0021338,0.824531,0.00034790626,0.00003475905,0.00010081582,0.0004964435,0.0008417945,0.027401865,0.0000745331,0.12815967,0.00061602454],"about_ca_topic_score_codex":0.0008181328,"about_ca_topic_score_gemma":0.00004566605,"teacher_disagreement_score":0.35523468,"about_ca_system_score_codex":0.023512589,"about_ca_system_score_gemma":0.0054528215,"threshold_uncertainty_score":0.9997473},"labels":[],"label_agreement":null},{"id":"W2065589801","doi":"10.1016/j.cancergencyto.2004.03.017","title":"Clonality analysis of cell lineages in acute myeloid leukemia with inversion 16","year":2005,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Biology; Myeloid; Fluorescence in situ hybridization; Myeloid leukemia; clone (Java method); Cell sorting; Bone marrow; Leukemia; Lineage (genetic); Molecular biology; Immunology; Interphase; Cancer research; Genetics; Flow cytometry; Gene; Chromosome","score_opus":0.020189552701085734,"score_gpt":0.30144097074797954,"score_spread":0.2812514180468938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065589801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920062,0.0061178138,0.00037996747,0.0005407755,0.000021116675,0.00027551892,0.00009117211,0.000011242445,0.0005561879],"genre_scores_gemma":[0.96331584,0.029210037,0.0059779063,0.00046192852,0.00010564788,0.00001962161,0.00005727769,0.00002912076,0.0008226389],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984177,0.000043448417,0.00038222113,0.00039657,0.00041134062,0.00034871776],"domain_scores_gemma":[0.9989495,0.000046961562,0.00012425528,0.00042637065,0.00022320545,0.00022965207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017668834,0.000209216,0.0005298284,0.0003892676,0.00004296767,0.000015434092,0.00014946055,0.00015924373,0.000119739816],"category_scores_gemma":[0.000008846189,0.00017485638,0.00009652878,0.0010846256,0.00022368018,0.000023931489,0.000123274,0.00025343028,0.0000026534283],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062535994,0.00013698621,0.86999583,0.00018951335,0.0012112127,0.00003705366,0.0005628674,0.010894634,0.08161593,0.000015239864,0.0006458497,0.034069534],"study_design_scores_gemma":[0.0038213022,0.0006546348,0.42559847,0.000083379586,0.003393061,0.000011466679,0.00023081135,0.037700042,0.51376027,0.000015863065,0.014364408,0.00036630163],"about_ca_topic_score_codex":0.000283047,"about_ca_topic_score_gemma":0.001298339,"teacher_disagreement_score":0.44439736,"about_ca_system_score_codex":0.0005970214,"about_ca_system_score_gemma":0.000653005,"threshold_uncertainty_score":0.71304363},"labels":[],"label_agreement":null},{"id":"W2066235768","doi":"10.1182/blood-2008-06-162263","title":"Loss of Mll5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Biology; DNA demethylation; Chromatin; Haematopoiesis; Myeloid; Hematopoietic stem cell; DNA methylation; Stem cell; Genetics; Cell biology; Immunology; Cancer research; Gene; Gene expression","score_opus":0.027270030575987567,"score_gpt":0.258535515493873,"score_spread":0.23126548491788543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066235768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99729806,0.00051852263,0.00013567,0.0010743997,0.000045317447,0.0005445996,0.000008341884,0.000040013852,0.00033504787],"genre_scores_gemma":[0.998707,0.00015505256,0.0007310002,0.000082003906,0.0001058619,0.000015594454,0.00002598147,0.000025132027,0.00015235461],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983724,0.0001732928,0.0004440901,0.00036187732,0.00034385332,0.00030453483],"domain_scores_gemma":[0.9989575,0.00018900313,0.00009473639,0.00042041973,0.00017975862,0.00015854793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004651736,0.00015432738,0.0004051307,0.00029736105,0.00006994666,0.0000067533174,0.000050416435,0.0001243514,0.000010380806],"category_scores_gemma":[0.00062928617,0.00014622306,0.000058741687,0.00058051985,0.00011309092,0.0000920721,0.00008601732,0.00027526307,0.00001921233],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011627389,0.00045346923,0.06162693,0.00015142423,0.00006757349,0.0004024561,0.0006686131,0.00002337519,0.9346922,0.00008416579,0.00016285603,0.0005042139],"study_design_scores_gemma":[0.0073396596,0.00051652984,0.85056925,0.000120734316,0.00008131334,0.00048944977,0.000060570987,0.000078673074,0.14047383,0.000078465775,0.00007191065,0.00011963508],"about_ca_topic_score_codex":0.00026370393,"about_ca_topic_score_gemma":0.00004297849,"teacher_disagreement_score":0.79421836,"about_ca_system_score_codex":0.000096328346,"about_ca_system_score_gemma":0.00019965456,"threshold_uncertainty_score":0.59628034},"labels":[],"label_agreement":null},{"id":"W2066443904","doi":"10.1016/j.leukres.2009.02.010","title":"Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: A retrospective study of 322 bone marrows","year":2009,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Western University; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Internal medicine; Anemia; Pediatrics; Bone marrow","score_opus":0.027599261148578996,"score_gpt":0.32929654646346235,"score_spread":0.3016972853148834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066443904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994954,0.000086697015,0.00002881459,0.00035973688,0.000024951909,0.0034682679,0.000018149469,0.000026884883,0.0010324903],"genre_scores_gemma":[0.9976841,0.000014036518,0.00113028,0.000025206564,0.000045312972,0.0001262287,0.000008372312,0.000039221133,0.000927195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99399126,0.0006901686,0.00078315905,0.0006579634,0.0030058718,0.0008715641],"domain_scores_gemma":[0.9963698,0.00079020346,0.00022929178,0.001143464,0.0012830971,0.00018417947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029855382,0.0002661796,0.00078593486,0.0007977774,0.00018191956,0.00003030975,0.00069103745,0.00013308458,0.00011583259],"category_scores_gemma":[0.002836894,0.00016986049,0.0000658979,0.0026634445,0.00051536626,0.00019827938,0.0002982665,0.0016607451,0.000016419637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069388165,0.0021637045,0.97691864,0.0010926978,0.00016146139,0.00035264803,0.006217782,0.0008115885,0.002173038,0.00015964569,0.00037176264,0.0026382343],"study_design_scores_gemma":[0.010621051,0.010772887,0.97001684,0.00081889983,0.00006044416,0.000027927637,0.001443451,0.0053939996,0.00054429006,0.0001451443,0.0000041822254,0.00015087289],"about_ca_topic_score_codex":0.0006451103,"about_ca_topic_score_gemma":0.00010310652,"teacher_disagreement_score":0.008609182,"about_ca_system_score_codex":0.0023982327,"about_ca_system_score_gemma":0.0014353903,"threshold_uncertainty_score":0.72152036},"labels":[],"label_agreement":null},{"id":"W2067079282","doi":"10.1182/blood-2014-04-564666","title":"Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Cord blood; Haematopoiesis; Biology; Immunology; CD34; Leukemia; Cell biology; Stem cell; Medicine; Cancer research","score_opus":0.020307337593836673,"score_gpt":0.2718908760961658,"score_spread":0.2515835385023291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067079282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440986,0.0003599873,0.002271115,0.0002955324,0.000015573536,0.00027287123,0.000012587812,0.00011642821,0.0022460725],"genre_scores_gemma":[0.9880082,0.00006683474,0.010481955,0.0004431598,0.00042260002,0.00002888455,0.000037323123,0.000068637455,0.00044242406],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983991,0.00007330144,0.00022735927,0.00045149928,0.0003694635,0.0004793037],"domain_scores_gemma":[0.9988948,0.000099686,0.000043144904,0.00051820127,0.0001122044,0.0003319678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003007545,0.00021460798,0.00037038355,0.00011977964,0.00016367491,0.000045537687,0.00016195286,0.00015682774,0.00007679323],"category_scores_gemma":[0.00011518424,0.00017381363,0.000050392227,0.00015808252,0.00010218012,0.00006977713,0.00010605126,0.00034609594,0.000029469033],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012716979,0.0020100623,0.3365369,0.00040809473,0.0020543982,0.0011948887,0.0014805765,0.00037216127,0.6415438,0.0011253443,0.00038445805,0.011617612],"study_design_scores_gemma":[0.16124585,0.012781602,0.13232364,0.00200254,0.012136413,0.0066402173,0.001816176,0.17438805,0.48503923,0.0035875752,0.0046033873,0.0034352953],"about_ca_topic_score_codex":0.00114398,"about_ca_topic_score_gemma":0.00017798465,"teacher_disagreement_score":0.20421328,"about_ca_system_score_codex":0.00006928647,"about_ca_system_score_gemma":0.00023447101,"threshold_uncertainty_score":0.70879143},"labels":[],"label_agreement":null},{"id":"W2067397385","doi":"10.1002/gcc.20370","title":"Overexpression of <i>PRDM16</i> in the presence and absence of the <i>RUNX1/PRDM16</i> fusion gene in myeloid leukemias","year":2006,"lang":"en","type":"letter","venue":"Genes Chromosomes and Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Leukemia & Lymphoma Society of Canada","funders":"Canadian Institutes of Health Research","keywords":"Library science; Gerontology; Medicine; History; Computer science","score_opus":0.015239305153172115,"score_gpt":0.26879430164217194,"score_spread":0.2535549964889998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067397385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91488564,0.034539565,0.0000019120268,0.04847569,0.00017061798,0.0011788775,0.00020298314,0.000009368906,0.0005353436],"genre_scores_gemma":[0.79208136,0.088752545,0.00027898396,0.11024967,0.0027719678,0.00059773267,0.00021636291,0.00017741797,0.0048739705],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99695456,0.00024810282,0.00065454934,0.00063228165,0.0009714722,0.0005390192],"domain_scores_gemma":[0.998295,0.0003250886,0.00035909656,0.00084708893,0.000119331475,0.000054397184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041868904,0.00039531564,0.00078658666,0.00019482228,0.000083568135,0.000025388168,0.00055776985,0.00060154515,0.00006834482],"category_scores_gemma":[0.000046100224,0.0002242077,0.00012928458,0.0005926335,0.00060870155,0.00009571676,0.00047510833,0.001432102,9.100056e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029828958,0.0001349752,0.09694586,0.00418158,0.00008048251,0.00030457787,0.0018718211,0.00014713894,0.3852587,0.000014695678,0.48760754,0.023154335],"study_design_scores_gemma":[0.007751854,0.0004939898,0.27451897,0.010711592,0.0002281841,0.00041312247,0.00064994796,0.00068159547,0.18227643,0.00036201443,0.5208335,0.0010787898],"about_ca_topic_score_codex":0.004846721,"about_ca_topic_score_gemma":0.00041150657,"teacher_disagreement_score":0.20298226,"about_ca_system_score_codex":0.00027048273,"about_ca_system_score_gemma":0.0006987985,"threshold_uncertainty_score":0.91429245},"labels":[],"label_agreement":null},{"id":"W2067941152","doi":"10.1038/86966","title":"Characterizing gene expression profile of Inv(16)-associated leukemia","year":2001,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada)","funders":"","keywords":"Biology; Genetics; Leukemia; Gene expression; Gene; Computational biology; Expression (computer science); Cancer research","score_opus":0.016925075790903677,"score_gpt":0.29740863356572106,"score_spread":0.28048355777481737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067941152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99198157,0.0019221548,0.00008516863,0.00042915228,0.00021436492,0.0004952662,0.00003723426,0.00007632612,0.004758776],"genre_scores_gemma":[0.98988295,0.0010537447,0.0046624024,0.0007767656,0.00039554763,0.000019578329,0.00027736725,0.000057875746,0.0028737788],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981052,0.00007085885,0.00036040857,0.00034306597,0.0006618811,0.0004585329],"domain_scores_gemma":[0.9986283,0.000064188585,0.00017930559,0.0005278839,0.00039826066,0.00020202692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028600745,0.00020439121,0.0003915918,0.00018789536,0.00007130995,0.000014280687,0.00023882967,0.0007782747,0.00028183917],"category_scores_gemma":[0.0003947205,0.00017503236,0.000109398505,0.00052352087,0.00008213125,0.000048438666,0.00016573482,0.0012092633,0.00003987692],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025937948,0.00010267624,0.04115938,0.00007670835,0.00006484023,0.00012373432,0.00022563734,0.00000401493,0.9427085,0.0000054990005,0.009086643,0.0061829994],"study_design_scores_gemma":[0.001919686,0.0002548868,0.10458456,0.00019433549,0.000060162944,0.000085160194,0.00006486087,0.00049070216,0.87390727,0.000038884165,0.018218257,0.00018122944],"about_ca_topic_score_codex":0.000014452523,"about_ca_topic_score_gemma":0.0000052565997,"teacher_disagreement_score":0.06880122,"about_ca_system_score_codex":0.00080664,"about_ca_system_score_gemma":0.00054658274,"threshold_uncertainty_score":0.7137612},"labels":[],"label_agreement":null},{"id":"W2068527999","doi":"10.1097/moh.0000000000000111","title":"Preleukemia","year":2015,"lang":"en","type":"review","venue":"Current Opinion in Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Preleukemia; Medicine; Internal medicine; Leukemia","score_opus":0.23423667468100226,"score_gpt":0.49165300510684407,"score_spread":0.2574163304258418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068527999","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000011736037,0.9905685,0.000029123805,0.000097282515,0.0060595516,0.0019137823,0.000027829215,0.00009414657,0.0012086054],"genre_scores_gemma":[7.0222944e-7,0.99722856,0.0001478174,0.000008760069,0.00077615975,0.0006044327,0.00091449707,0.00009330716,0.00022577887],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99652773,0.0003944743,0.001165144,0.00076472235,0.00043427397,0.00071364996],"domain_scores_gemma":[0.99794555,0.00032363427,0.0003170709,0.00086572627,0.00017335168,0.00037464921],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006159181,0.0005297265,0.0035661557,0.0009193653,0.000027435977,0.000014197159,0.00043024396,0.0008381834,0.00026467728],"category_scores_gemma":[0.00053399306,0.00041953157,0.00041350166,0.0008163703,0.00018124646,0.000051385297,0.00035376326,0.0021152592,0.0015801506],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022488663,0.00013196799,0.000090233676,0.0963311,0.000057934252,0.00003636947,0.000030994728,6.0333825e-8,1.0066389e-8,0.0021495845,0.09325642,0.80789286],"study_design_scores_gemma":[0.0010310961,0.000097897355,0.0000033229703,0.039615892,0.0001300538,0.002443148,0.000008785933,0.000027586688,1.7381484e-7,0.00016309056,0.9561871,0.00029184378],"about_ca_topic_score_codex":0.000008091244,"about_ca_topic_score_gemma":5.679961e-7,"teacher_disagreement_score":0.8629307,"about_ca_system_score_codex":0.0017368224,"about_ca_system_score_gemma":0.004396099,"threshold_uncertainty_score":0.99982566},"labels":[],"label_agreement":null},{"id":"W2068756407","doi":"10.1016/j.blre.2010.09.003","title":"Controversies surrounding iron chelation therapy for MDS","year":2010,"lang":"en","type":"review","venue":"Blood Reviews","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"World Health Organization","keywords":"Myelodysplastic syndromes; Chelation therapy; Medicine; Deferasirox; Deferiprone; Thalassemia; Clinical trial; Internal medicine; Adverse effect; Anemia; Intensive care medicine; Oncology; Bone marrow","score_opus":0.1137436141616385,"score_gpt":0.41469462045544286,"score_spread":0.30095100629380434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068756407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000050091744,0.98591304,0.00012143195,0.00019881286,0.0004267933,0.011002626,0.000045671164,0.000065813096,0.002220831],"genre_scores_gemma":[3.737007e-7,0.9876531,0.0025546027,0.00038246246,0.0017260206,0.0015173435,0.00067849254,0.00013994219,0.0053476854],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99701273,0.00031605246,0.0011435867,0.00063198054,0.00034649626,0.0005491661],"domain_scores_gemma":[0.9964651,0.0014792155,0.0007336313,0.0009488115,0.00015618614,0.00021704251],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022115752,0.00060490024,0.0039819777,0.00028151675,0.00014717414,0.00006547579,0.00034939515,0.00076190504,0.00026176593],"category_scores_gemma":[0.0027878473,0.00039019473,0.0015802443,0.00037124316,0.00009576135,0.00010911469,0.000065257664,0.0012294722,0.00034398522],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026527001,0.00009290072,0.0000056001677,0.034068327,0.00018678274,0.0000076625,0.000026790554,3.6241583e-9,0.000026054255,0.00014476161,0.0116209,0.9537937],"study_design_scores_gemma":[0.002253364,0.00029423842,0.0000018000443,0.015375473,0.0027027577,0.00015205496,0.000004495164,0.0000026745597,0.000008102795,0.0000101846545,0.9788635,0.0003313992],"about_ca_topic_score_codex":0.000010667749,"about_ca_topic_score_gemma":0.0000034164127,"teacher_disagreement_score":0.96724254,"about_ca_system_score_codex":0.0002714745,"about_ca_system_score_gemma":0.0007945634,"threshold_uncertainty_score":0.999855},"labels":[],"label_agreement":null},{"id":"W2069457631","doi":"10.1182/blood-2009-06-227603","title":"Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"China Scholarship Council","keywords":"Leukemia; Cancer research; Stem cell; Myeloid leukemia; Oncogene; Biology; Myeloid; STAT5; Cancer stem cell; Immunology; Cancer; Signal transduction; Cell cycle; Cell biology; Genetics","score_opus":0.02054020114975398,"score_gpt":0.24900982127370838,"score_spread":0.2284696201239544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069457631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958457,0.0013263153,0.0002041595,0.00007544036,0.000051400806,0.0005295659,0.000030908333,0.000053914613,0.001882603],"genre_scores_gemma":[0.9986047,0.00017876725,0.0006550589,0.00010673034,0.00013272882,0.000017850924,0.000014506766,0.000032846656,0.00025678638],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974003,0.0001619044,0.000717639,0.00040659495,0.0008183285,0.00049525395],"domain_scores_gemma":[0.9986349,0.00013729562,0.00016956724,0.00065783976,0.00023767586,0.00016274718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006764944,0.00025110872,0.0005308204,0.00021710811,0.00006541225,0.000013229879,0.00032343104,0.00020556197,0.000027714696],"category_scores_gemma":[0.000009555735,0.00019080732,0.00019147675,0.00044016604,0.00007386172,0.00009345751,0.00011025765,0.00056098687,0.000017506643],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011861378,0.0018096761,0.019636644,0.0005305209,0.00040625816,0.00009674298,0.0023713624,0.062495068,0.9037578,0.00026444203,0.0003713198,0.007074025],"study_design_scores_gemma":[0.007931266,0.00072920445,0.0037654913,0.00013394076,0.00026715716,0.000056590638,0.0014766003,0.08667462,0.898435,0.00014044743,0.00015309264,0.00023661602],"about_ca_topic_score_codex":0.00039893712,"about_ca_topic_score_gemma":0.000060503702,"teacher_disagreement_score":0.024179557,"about_ca_system_score_codex":0.00078401074,"about_ca_system_score_gemma":0.0017054033,"threshold_uncertainty_score":0.77808964},"labels":[],"label_agreement":null},{"id":"W2069816258","doi":"10.1007/s00018-012-0956-y","title":"Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations","year":2012,"lang":"en","type":"review","venue":"Cellular and Molecular Life Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Chronic myelomonocytic leukemia; Chronic myelogenous leukemia; Leukemia; Disease; Phenotype; Pathognomonic; Biology; Cancer research; Immunology; Genetic heterogeneity; Gene; Medicine; Genetics; Pathology; Bone marrow; Myelodysplastic syndromes","score_opus":0.043416026097503745,"score_gpt":0.3229469228327599,"score_spread":0.27953089673525616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069816258","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.053710595,0.9435076,0.0010194592,0.00005391915,0.000054659435,0.0013825018,0.000047766494,0.000024902221,0.00019859328],"genre_scores_gemma":[0.14023401,0.8583236,0.00056987186,0.0001521271,0.000078423494,0.00016149593,0.00031779756,0.00007289646,0.00008979656],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963733,0.00051354826,0.00066658197,0.00080766826,0.00085494,0.0007839554],"domain_scores_gemma":[0.9981505,0.00011456378,0.00032187052,0.0005516912,0.00011346227,0.00074788893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010639551,0.00051299256,0.0014727692,0.0005829882,0.00014572876,0.000053193402,0.00038994057,0.0002851492,0.00002623727],"category_scores_gemma":[0.0003021782,0.00038547657,0.00036635803,0.0012563778,0.0009454693,0.00014163,0.00022298594,0.00058932346,0.000007939406],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014962889,0.0032307776,0.00706979,0.16951925,0.013285094,0.028164936,0.001581787,0.0074894596,0.05827452,0.0030166479,0.00085151306,0.70601994],"study_design_scores_gemma":[0.045566227,0.015558542,0.006778251,0.19808076,0.07130109,0.0027417974,0.00086000696,0.07831883,0.054325815,0.0006638977,0.50615203,0.019652735],"about_ca_topic_score_codex":0.00006436383,"about_ca_topic_score_gemma":0.000018730105,"teacher_disagreement_score":0.6863672,"about_ca_system_score_codex":0.0013738209,"about_ca_system_score_gemma":0.008884767,"threshold_uncertainty_score":0.9998597},"labels":[],"label_agreement":null},{"id":"W2069848482","doi":"10.1002/(sici)1096-8652(200005)64:1<53::aid-ajh9>3.0.co;2-9","title":"Familial myelodysplastic syndrome with early age of onset","year":2000,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Bone marrow; Sepsis; Disease; Family member; Bone marrow failure; Myelodysplastic syndromes; Bone marrow transplantation; Leukemia; Pathogenesis; Internal medicine; Pediatrics; Immunology; Stem cell; Genetics; Biology; Haematopoiesis","score_opus":0.00852336114054926,"score_gpt":0.2665449508785553,"score_spread":0.25802158973800604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069848482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975075,0.00011752484,0.00026875123,0.0008590152,0.000043985037,0.00011295429,0.0000054566035,0.000010101096,0.0010746847],"genre_scores_gemma":[0.995354,0.00009909686,0.0038882932,0.00022712736,0.000040054543,0.0000023911275,0.0000029532364,0.000027367554,0.0003587376],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9983639,0.00013509211,0.0005645008,0.00014954775,0.00042820573,0.00035872703],"domain_scores_gemma":[0.9986287,0.00030128594,0.00036030475,0.0002520922,0.00020169005,0.00025592637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002224009,0.00015134375,0.001043109,0.0003027202,0.000029694898,0.0000051195393,0.00021824829,0.000056567183,0.0007095985],"category_scores_gemma":[0.00010683171,0.00010501576,0.000120668345,0.00044350437,0.0010784074,0.00006769532,0.000021306842,0.0005271343,0.00006439397],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04186022,0.0019735617,0.57810843,0.0006265564,0.0042466354,0.2386604,0.004260348,0.00018013826,0.012317631,0.0009915632,0.0072305235,0.10954402],"study_design_scores_gemma":[0.008281213,0.03686422,0.40784073,0.0007139465,0.00054354494,0.53834236,0.0013305115,0.000073006624,0.002597447,0.00021010601,0.0028373892,0.00036556824],"about_ca_topic_score_codex":0.00012979202,"about_ca_topic_score_gemma":0.0000066855196,"teacher_disagreement_score":0.29968193,"about_ca_system_score_codex":0.0000857516,"about_ca_system_score_gemma":0.0005280836,"threshold_uncertainty_score":0.77696055},"labels":[],"label_agreement":null},{"id":"W2070079310","doi":"10.1038/bmt.2008.106","title":"Current status of blood and marrow transplantation for patients with AML","year":2008,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Oncology; Haematopoiesis; Internal medicine; Transplantation; Malignancy; Hematopoietic cell; Immunology; Stem cell","score_opus":0.015294722060319685,"score_gpt":0.2636221299292452,"score_spread":0.24832740786892554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070079310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932913,0.00047844226,0.0038950092,0.00009669215,0.000055000517,0.0013636581,0.000574487,0.00004340717,0.0002019574],"genre_scores_gemma":[0.9859966,0.007371269,0.0042094267,0.000032588487,0.00004239255,0.00010174431,0.002138498,0.000037999307,0.000069472946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984096,0.000046524692,0.00036513194,0.00031709383,0.0004701576,0.00039148284],"domain_scores_gemma":[0.9991231,0.00013641083,0.000120063014,0.00015623946,0.00026566774,0.00019849888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000120674056,0.00019443066,0.0003240115,0.00022158051,0.000108856446,0.000008154181,0.000046780628,0.00008555534,0.000022792228],"category_scores_gemma":[0.000021933507,0.00016442026,0.00006324805,0.00020215899,0.0001437116,0.00018228362,0.0000035167666,0.00016182705,0.0000025828508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022612574,0.0013106252,0.87442,0.008224452,0.00034433338,0.00020768237,0.0063913893,0.000033935405,0.060721137,0.0003326078,0.00039578124,0.025005516],"study_design_scores_gemma":[0.028275276,0.0023035705,0.9365939,0.0005100517,0.0013219992,0.00039677348,0.00006782032,0.0002459454,0.029291762,0.000056188157,0.0006042285,0.0003324855],"about_ca_topic_score_codex":0.000090620546,"about_ca_topic_score_gemma":0.000049025366,"teacher_disagreement_score":0.06217393,"about_ca_system_score_codex":0.00005693957,"about_ca_system_score_gemma":0.00023783438,"threshold_uncertainty_score":0.6704864},"labels":[],"label_agreement":null},{"id":"W2070276500","doi":"10.1038/sj.leu.2403165","title":"Reply to Hasle et al","year":2003,"lang":"fr","type":"letter","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Environmental science","score_opus":0.027982919855833496,"score_gpt":0.31827630553378955,"score_spread":0.29029338567795604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070276500","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004257012,0.002367157,0.0010958895,0.8849192,0.005043951,0.0021081846,0.00021192327,0.00023042496,0.099766254],"genre_scores_gemma":[0.00019426404,0.00059433334,0.005549896,0.71336544,0.00479136,0.00023533455,0.00062638085,0.00037592533,0.27426705],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9900135,0.00096243614,0.0012748052,0.0022776807,0.0022135356,0.0032580362],"domain_scores_gemma":[0.9937042,0.00095807354,0.0002967309,0.0031517649,0.0005107297,0.0013785295],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.002019784,0.0013168756,0.0017804346,0.0008169111,0.00028242072,0.0002399754,0.001255926,0.001655388,0.009131145],"category_scores_gemma":[0.002092841,0.0013071683,0.00063019694,0.0013582443,0.00047193098,0.00024112735,0.00061699207,0.009687903,0.04104015],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0002457912,0.00006304374,0.00045804353,0.00049494853,0.00044010804,0.0083229765,0.0005461591,0.000086341555,0.0022826004,0.0004896131,0.97842926,0.008141111],"study_design_scores_gemma":[0.003246624,0.0007852175,0.00060980103,0.0011931405,0.00027234972,0.0011907449,0.0001368382,0.0003250753,0.0018748294,0.00011412254,0.9890549,0.0011963423],"about_ca_topic_score_codex":0.003709448,"about_ca_topic_score_gemma":0.000054554166,"teacher_disagreement_score":0.1745008,"about_ca_system_score_codex":0.017978124,"about_ca_system_score_gemma":0.009312221,"threshold_uncertainty_score":0.9999583},"labels":[],"label_agreement":null},{"id":"W2070748566","doi":"10.4161/cc.11.1.18408","title":"Inhibiting mitochondrial-dependent proteolysis of Mcl-1 promotes resistance to DNA damage","year":2012,"lang":"en","type":"article","venue":"Cell Cycle","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Biology; Proteolysis; DNA damage; Cell biology; Proteasome; Ubiquitin; Mitochondrion; Neurodegeneration; DNA repair; Myeloid leukemia; Ubiquitin ligase; Programmed cell death; Cancer research; DNA; Apoptosis; Biochemistry; Gene","score_opus":0.015182058598107265,"score_gpt":0.2759267615252033,"score_spread":0.260744702927096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070748566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97102857,0.00025926647,0.0003020655,0.0008994429,0.000095579526,0.0012896319,0.000011972513,0.0000616515,0.02605185],"genre_scores_gemma":[0.976732,0.00000592809,0.011508799,0.00014108651,0.0004274156,0.00010800037,0.000013040583,0.00004647718,0.011017211],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981105,0.00008568497,0.00036029448,0.00029590708,0.0005523953,0.0005952212],"domain_scores_gemma":[0.99868685,0.000096361044,0.00011211341,0.00054174307,0.00017463003,0.0003882805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045134072,0.00016395267,0.00034496532,0.00016901546,0.000081991755,0.000020889598,0.00018348232,0.00010497549,0.00024640645],"category_scores_gemma":[0.0004844345,0.00014603094,0.00009669812,0.00041137487,0.00007107058,0.00018540367,0.00018120774,0.0002858628,0.0002998659],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021194264,0.0002539797,0.002882661,0.00038778927,0.000025983392,0.00001798954,0.0013953939,0.0000036669524,0.9899539,0.000050438168,0.0043237433,0.0004925641],"study_design_scores_gemma":[0.0011539998,0.000112107235,0.0036229833,0.0001670488,0.00005057219,0.00000598065,0.00048300155,0.00003831014,0.99145246,0.0000412498,0.0027212708,0.00015100613],"about_ca_topic_score_codex":0.000059963397,"about_ca_topic_score_gemma":0.000015384116,"teacher_disagreement_score":0.015034639,"about_ca_system_score_codex":0.00023706497,"about_ca_system_score_gemma":0.00014394773,"threshold_uncertainty_score":0.5954969},"labels":[],"label_agreement":null},{"id":"W2071011415","doi":"10.1002/gcc.10044","title":"Rare recurring balanced chromosome abnormalities in therapy‐related myelodysplastic syndromes and acute leukemia: Report from an International Workshop†","year":2002,"lang":"en","type":"article","venue":"Genes Chromosomes and Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Radiation therapy; Myelodysplastic syndromes; Lymphoma; Acute leukemia; Leukemia; Oncology; Bone marrow","score_opus":0.02718265016655138,"score_gpt":0.303662015098215,"score_spread":0.27647936493166364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071011415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657237,0.031220036,0.000007540554,0.001366535,0.00042436967,0.0003664211,0.00010045609,0.000087251625,0.00070370495],"genre_scores_gemma":[0.916,0.08012372,0.0001808066,0.0003277048,0.00038418014,0.00014919385,0.00017872501,0.000053075615,0.0026025616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784666,0.000059806756,0.0004920824,0.0006966698,0.00041776634,0.000487031],"domain_scores_gemma":[0.9989999,0.00011424061,0.00013604286,0.00038998344,0.00010209319,0.00025774143],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015769908,0.00032213944,0.0005525917,0.00023041897,0.00011813174,0.00010547798,0.00019068382,0.00024867986,0.0019880438],"category_scores_gemma":[0.000043346936,0.00027772138,0.000064137625,0.00030206807,0.00021793091,0.0005066452,0.00014893211,0.00046015406,0.000010608069],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008736327,0.00026348245,0.6038741,0.00026610575,0.0020197995,0.011624403,0.007235008,0.00026535356,0.038542125,0.00012059567,0.0022138262,0.3327016],"study_design_scores_gemma":[0.023723995,0.0009246397,0.86410606,0.0023122241,0.00045868792,0.012419243,0.0029905837,0.033964206,0.01168496,0.00062352343,0.044678524,0.0021133402],"about_ca_topic_score_codex":0.00060658524,"about_ca_topic_score_gemma":0.00010428341,"teacher_disagreement_score":0.33058825,"about_ca_system_score_codex":0.0005573858,"about_ca_system_score_gemma":0.00017562763,"threshold_uncertainty_score":0.9999675},"labels":[],"label_agreement":null},{"id":"W2071184266","doi":"10.1007/s00277-011-1193-4","title":"Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions","year":2011,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Methylenetetrahydrofolate reductase; Myelodysplastic syndromes; Methylation; Myeloid leukemia; DNA methylation; CpG site; Epigenetics; Cancer research; Genotype; Biology; Internal medicine; Medicine; Genetics; Gene; Bone marrow; Gene expression","score_opus":0.059405463235470385,"score_gpt":0.32725283944674993,"score_spread":0.2678473762112795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071184266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921301,0.0035718852,0.0008547656,0.0022180292,0.00011911619,0.00065872894,0.000050690996,0.00004547163,0.00035123632],"genre_scores_gemma":[0.984594,0.0044161566,0.009418112,0.0011349545,0.000025875152,0.000067279194,0.00002388424,0.000067064466,0.00025269174],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9969659,0.00013184176,0.00095726637,0.00079030835,0.0002982245,0.00085649383],"domain_scores_gemma":[0.9980235,0.00033860988,0.00022480906,0.00067254,0.00025878966,0.0004817699],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025219098,0.0004080207,0.0010883225,0.00079626834,0.00008670679,0.000015543243,0.00024444185,0.00036741846,0.0003610526],"category_scores_gemma":[0.0002650865,0.00038337742,0.00011553691,0.00053406326,0.0008482027,0.00009984764,0.0003206182,0.0005420851,0.000038123606],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059409644,0.002286498,0.19059381,0.0023822964,0.0036576777,0.007909974,0.009300038,0.00003281262,0.7508772,0.0041541317,0.0038749843,0.018989582],"study_design_scores_gemma":[0.0057562473,0.0025439102,0.7463332,0.00062660273,0.00050962006,0.018787747,0.00043914706,0.0042325254,0.2170742,0.0020555803,0.00087673665,0.0007644814],"about_ca_topic_score_codex":0.0005742281,"about_ca_topic_score_gemma":0.00009067289,"teacher_disagreement_score":0.5557394,"about_ca_system_score_codex":0.00009407016,"about_ca_system_score_gemma":0.00048213283,"threshold_uncertainty_score":0.99986184},"labels":[],"label_agreement":null},{"id":"W2071370702","doi":"10.1182/blood-2013-03-491571","title":"Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":208,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"","keywords":"IDH1; Mutant; In vivo; Cancer research; Bone marrow; Biology; CD34; Cell biology; Immunology; Stem cell; Genetics; Gene","score_opus":0.02048177892487313,"score_gpt":0.26649814917300285,"score_spread":0.24601637024812972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071370702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994234,0.00021690635,0.0000016556114,0.0025485305,0.000016625985,0.0009768907,0.00001371009,0.00004494584,0.0019466843],"genre_scores_gemma":[0.99805295,0.00007415083,0.00074695534,0.00026059308,0.00010508696,0.00010415076,0.00001608461,0.000039429688,0.00060058763],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983283,0.000081123246,0.00036171218,0.00040079208,0.00032196433,0.000506085],"domain_scores_gemma":[0.9992383,0.00006870256,0.000044352506,0.0003394281,0.00007924831,0.00022996137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027291104,0.00018273717,0.00037466086,0.0003249534,0.000047353198,0.00003688002,0.0001438839,0.0001471678,0.000689996],"category_scores_gemma":[0.00018525281,0.00015679178,0.00003859009,0.00041649787,0.00012525741,0.00006086422,0.00010645221,0.00035688246,0.000023723598],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031229378,0.0003962028,0.10487692,0.000079640675,0.000036553032,0.00047288687,0.00057854276,4.6563937e-7,0.89209837,0.00010228911,0.0005197481,0.0008071518],"study_design_scores_gemma":[0.009550127,0.0005007038,0.3944123,0.00014776037,0.000049054015,0.00015888519,0.00046418823,0.00024335571,0.59313995,0.00027222864,0.00076682406,0.0002946231],"about_ca_topic_score_codex":0.0034593025,"about_ca_topic_score_gemma":0.0015355209,"teacher_disagreement_score":0.29895842,"about_ca_system_score_codex":0.00021803768,"about_ca_system_score_gemma":0.00024121902,"threshold_uncertainty_score":0.7554972},"labels":[],"label_agreement":null},{"id":"W2071523584","doi":"10.1111/bjh.12492","title":"Genome‐wide genotype‐based risk model for survival in acute myeloid leukaemia patients with normal karyotype","year":2013,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Chonnam National University Hwasun Hospital","keywords":"Single-nucleotide polymorphism; SNP; Genotyping; Oncology; SNP array; Genotype; Tag SNP; Internal medicine; Genome-wide association study; SNP genotyping; Biology; Medicine; Genetics; Gene","score_opus":0.012529249896750734,"score_gpt":0.25487343524030087,"score_spread":0.24234418534355015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071523584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835275,0.00046909213,0.013986489,0.00061317976,0.0001287796,0.0009670909,0.00006626047,0.000018143173,0.00022347104],"genre_scores_gemma":[0.978843,0.0002502789,0.019904459,0.0004757628,0.000088270586,0.000052538286,0.000073005234,0.000072777926,0.00023995376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740344,0.00017114372,0.0008679448,0.00029838397,0.0005252125,0.0007338481],"domain_scores_gemma":[0.9973995,0.00033700324,0.0004784281,0.0002531461,0.001181527,0.00035038104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005953358,0.00023141853,0.0010383647,0.00039373635,0.00011145935,0.000050041628,0.00034631052,0.000248164,0.00018866247],"category_scores_gemma":[0.0005948844,0.00021462693,0.00018365511,0.00026611582,0.00020775585,0.00032117707,0.00007291101,0.0009896198,0.000047860296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065674856,0.0009714698,0.95428866,0.00038118532,0.0009273043,0.013295995,0.0003183804,0.0041032718,0.00070141227,0.00005414125,0.008195141,0.010195537],"study_design_scores_gemma":[0.025702264,0.0020817036,0.91330254,0.0003632222,0.00041472315,0.019100528,0.000091008595,0.037069935,0.00035073332,0.0005633664,0.0005023002,0.00045766277],"about_ca_topic_score_codex":0.00035647675,"about_ca_topic_score_gemma":0.00036554027,"teacher_disagreement_score":0.04098613,"about_ca_system_score_codex":0.00034018353,"about_ca_system_score_gemma":0.0010562841,"threshold_uncertainty_score":0.87522316},"labels":[],"label_agreement":null},{"id":"W2071897702","doi":"10.1002/pbc.22511","title":"The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: A Children's Oncology Group study","year":2010,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"National Cancer Institute","keywords":"Medicine; Disease; Internal medicine; Myeloid leukemia; Incidence (geometry); Myeloid; Oncology; Central nervous system","score_opus":0.01020620476442871,"score_gpt":0.2897893563177761,"score_spread":0.2795831515533474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071897702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894301,0.0032326523,0.000002280936,0.0010445493,0.0018570839,0.003853756,0.00030290778,0.0001460005,0.00013065473],"genre_scores_gemma":[0.97373927,0.019227842,0.00006407078,0.00007275126,0.0043323776,0.0021478639,0.000032500055,0.00010739455,0.00027590967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943892,0.0006530457,0.0009877081,0.0010589614,0.001429823,0.0014812645],"domain_scores_gemma":[0.9949755,0.0021303517,0.00050973496,0.0012723531,0.00026565036,0.0008464258],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014460162,0.000542212,0.001056785,0.00047881147,0.0003321558,0.000054639764,0.0009724645,0.00031306848,0.00009134418],"category_scores_gemma":[0.0008235328,0.0003439336,0.00031609155,0.0016120813,0.00025172593,0.00020246001,0.0007130838,0.0016082168,0.000026680918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016608131,0.0010627587,0.99124867,0.00060737744,0.0003565244,0.0006000099,0.00058461045,0.00003517113,0.00036511238,0.000051966854,0.0012888645,0.0021380973],"study_design_scores_gemma":[0.0067790574,0.00086801546,0.98718095,0.00003290323,0.0037085267,0.00004375866,0.00021442407,0.00015352256,0.00037958167,0.000004308672,0.0002628075,0.0003721735],"about_ca_topic_score_codex":0.007866278,"about_ca_topic_score_gemma":0.009999829,"teacher_disagreement_score":0.01599519,"about_ca_system_score_codex":0.0014755138,"about_ca_system_score_gemma":0.0026560342,"threshold_uncertainty_score":0.9999013},"labels":[],"label_agreement":null},{"id":"W2072037914","doi":"10.1182/blood-2008-10-182626","title":"Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Haematopoiesis; Myelofibrosis; Myeloproliferative Disorders; Immunology; Leukemia; Ruxolitinib; Cancer research; Preleukemia; Polycythemia vera; Medicine; Bone marrow; Biology; Stem cell; Genetics","score_opus":0.009768974421783826,"score_gpt":0.260517977871734,"score_spread":0.25074900344995016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072037914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955516,0.00086147286,0.00017121356,0.00060401676,0.000051017938,0.001067314,0.000034452492,0.00012170239,0.001537253],"genre_scores_gemma":[0.9971145,0.00008340819,0.001040029,0.00042380876,0.00017284391,0.000055144297,0.000049543218,0.000048329523,0.0010124404],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979495,0.0001093637,0.00038382947,0.0004712039,0.00054949056,0.00053662714],"domain_scores_gemma":[0.99835837,0.00049980386,0.00013078909,0.0006216462,0.00016040176,0.00022899121],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017571021,0.00032853486,0.000639673,0.0002447478,0.000113512695,0.000019849676,0.00021428568,0.00017706885,0.00007733581],"category_scores_gemma":[0.00043256074,0.00027091725,0.00019003169,0.00034055547,0.000110924295,0.00009867679,0.00007650999,0.00040910687,0.000114224626],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014338506,0.0062841373,0.12663682,0.0014106393,0.000938812,0.0012662117,0.003360831,0.00007562625,0.8412025,0.00024866773,0.0020717867,0.015070121],"study_design_scores_gemma":[0.009282799,0.0024625603,0.061263308,0.00013254008,0.00024318349,0.000091975875,0.00016887541,0.00014641746,0.9255643,0.00007028813,0.00030679937,0.0002669648],"about_ca_topic_score_codex":0.000103006176,"about_ca_topic_score_gemma":0.000027821896,"teacher_disagreement_score":0.08436179,"about_ca_system_score_codex":0.00016377843,"about_ca_system_score_gemma":0.00036500438,"threshold_uncertainty_score":0.9999743},"labels":[],"label_agreement":null},{"id":"W2072360499","doi":"10.1016/j.pcl.2007.11.001","title":"Acute Leukemias in Children with Down Syndrome","year":2008,"lang":"en","type":"review","venue":"Pediatric Clinics of North America","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Down syndrome; Leukemia; Myeloid leukemia; Aneuploidy; Myeloid; clone (Java method); Immunology; Preleukemia; Pediatrics; Gene; Genetics; Psychiatry; Biology","score_opus":0.02868468802489831,"score_gpt":0.34046558892288253,"score_spread":0.3117809008979842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072360499","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026666483,0.96966165,0.000017279008,0.0000355255,0.00008647889,0.0025975874,0.00053748005,0.00008630665,0.0003112147],"genre_scores_gemma":[0.00020665517,0.9947116,0.0018445151,0.00012235252,0.0005660142,0.00019009887,0.0017187662,0.00020400398,0.0004359939],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99432176,0.00022130445,0.0022045278,0.0011314431,0.0011536472,0.00096730003],"domain_scores_gemma":[0.99524564,0.00090445986,0.0015621452,0.0015051113,0.00024739755,0.00053524575],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00025761744,0.0008858413,0.0053303153,0.0015025731,0.00006767095,0.000013495853,0.0008915924,0.0005370497,0.00009136093],"category_scores_gemma":[0.00045230446,0.0006609009,0.0009781799,0.0042543714,0.00043672216,0.00009927025,0.00036661635,0.0027923973,0.00038636886],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011377199,0.00035628848,0.17866755,0.0036936754,0.0010273801,0.0014203024,0.000029515393,0.0000058931173,1.292588e-9,3.706481e-7,0.003565432,0.81111985],"study_design_scores_gemma":[0.0040724482,0.0028161544,0.057011213,0.0019878033,0.0074571255,0.009273869,0.000006538628,0.000017284461,1.9822206e-8,0.000001940349,0.916149,0.0012066067],"about_ca_topic_score_codex":0.0002656989,"about_ca_topic_score_gemma":0.000025082427,"teacher_disagreement_score":0.9125836,"about_ca_system_score_codex":0.0007328431,"about_ca_system_score_gemma":0.007206179,"threshold_uncertainty_score":0.9995842},"labels":[],"label_agreement":null},{"id":"W2072778470","doi":"10.1371/journal.pone.0013543","title":"Functional Characterization of FLT3 Receptor Signaling Deregulation in Acute Myeloid Leukemia by Single Cell Network Profiling (SCNP)","year":2010,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myeloid leukemia; Signal transduction; MAPK/ERK pathway; Cancer research; Myeloid; Biology; STAT5; PI3K/AKT/mTOR pathway; Fms-Like Tyrosine Kinase 3; Cell biology; Mutation; Genetics","score_opus":0.0279964722787089,"score_gpt":0.23296176847190708,"score_spread":0.20496529619319817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072778470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712735,0.000036830417,0.0010171152,0.0004311798,0.0001190524,0.00075495767,0.000031994976,0.00007076253,0.00041076227],"genre_scores_gemma":[0.98311263,0.000041400996,0.012530026,0.00012068774,0.0007007672,0.000060877544,0.0017576468,0.0000591348,0.0016168203],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99802995,0.0000682267,0.0004981913,0.00035052068,0.0006547499,0.0003983454],"domain_scores_gemma":[0.99893844,0.000111018904,0.00021495586,0.0002865499,0.00031335794,0.0001356846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004433576,0.00017898802,0.00038840788,0.00018351185,0.00007833258,0.000023289142,0.000109064385,0.00025536184,0.000521455],"category_scores_gemma":[0.0001321987,0.00018243691,0.000057400375,0.00053674384,0.000078625475,0.00022266406,0.000059667414,0.0006689894,0.00006411996],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046093052,0.00064432295,0.023619598,0.0001955845,0.000109643086,0.0000034620984,0.00008794139,0.000065822096,0.9738625,0.000030394278,0.00030391352,0.0006158412],"study_design_scores_gemma":[0.0015504241,0.0002085047,0.015216573,0.00023372329,0.000118767544,0.0000035713379,0.000022284248,0.0074484954,0.9748866,0.000031395135,0.00011985274,0.00015983131],"about_ca_topic_score_codex":0.000021251179,"about_ca_topic_score_gemma":0.000006143853,"teacher_disagreement_score":0.014014706,"about_ca_system_score_codex":0.00044061764,"about_ca_system_score_gemma":0.00036712526,"threshold_uncertainty_score":0.74395615},"labels":[],"label_agreement":null},{"id":"W2072945684","doi":"10.1055/s-2005-922034","title":"Myeloid Leukemias and Lung Involvement","year":2005,"lang":"en","type":"review","venue":"Seminars in Respiratory and Critical Care Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Leukostasis; Medicine; Pathology; Myeloid; Infiltration (HVAC); Leukemia; Myeloid leukemia; Lung; Immunology; Internal medicine","score_opus":0.0665941776538018,"score_gpt":0.41142727072413465,"score_spread":0.34483309307033283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072945684","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046782574,0.9935388,0.000007381078,0.00078841456,0.00019644646,0.0013732909,0.000032753545,0.00005984359,0.003535252],"genre_scores_gemma":[0.0004039842,0.99479216,0.0001962675,0.0023817755,0.0013866142,0.0002516726,0.000099806995,0.00010829528,0.00037944972],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955982,0.00040413896,0.0011892637,0.0011134387,0.00084348914,0.00085148355],"domain_scores_gemma":[0.99679637,0.0012923431,0.00010658233,0.00069568603,0.00023524786,0.0008737556],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012784419,0.0007626838,0.0028762901,0.00080258196,0.0001483489,0.000031656156,0.00024513202,0.0008569431,0.0002851395],"category_scores_gemma":[0.0020954532,0.0005638285,0.00017770463,0.0006051646,0.0016864908,0.00010531001,0.00038127002,0.002244834,0.0000171085],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005096536,0.000042793446,0.00023824413,0.05639853,0.000059286904,0.0014442237,0.00057872845,2.570981e-8,0.000006119446,0.0006610866,0.0046925712,0.93582743],"study_design_scores_gemma":[0.0016310104,0.0011182466,0.000051231626,0.058949836,0.0012679945,0.0003664267,0.0020157844,0.000008733158,0.000004661452,0.000034150715,0.934105,0.00044692145],"about_ca_topic_score_codex":0.000028767658,"about_ca_topic_score_gemma":0.000022484188,"teacher_disagreement_score":0.9353805,"about_ca_system_score_codex":0.0014597765,"about_ca_system_score_gemma":0.0010608467,"threshold_uncertainty_score":0.9996813},"labels":[],"label_agreement":null},{"id":"W2073061598","doi":"10.1016/j.bbmt.2014.08.008","title":"The Outcome of Allogeneic Hematopoietic Cell Transplantation for Children with FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication–Positive Acute Myelogenous Leukemia","year":2014,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Medical Research Council","keywords":"Medicine; Hazard ratio; Hematopoietic stem cell transplantation; Cumulative incidence; Internal medicine; Transplantation; Total body irradiation; Univariate analysis; Chronic myelogenous leukemia; Leukemia; Oncology; Regimen; Gastroenterology; Confidence interval; Chemotherapy; Multivariate analysis; Cyclophosphamide","score_opus":0.008449183211850274,"score_gpt":0.2556932644642565,"score_spread":0.2472440812524062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073061598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9736722,0.00050308625,0.024154402,0.00032981765,0.000038495164,0.00091345713,0.00026316207,0.00002003328,0.000105309955],"genre_scores_gemma":[0.9939316,0.0025366647,0.0022871443,0.000107213775,0.000049274742,0.00007831453,0.0009059424,0.000021640682,0.0000822227],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99881136,0.00009385374,0.0004277111,0.00028733633,0.00013729751,0.00024245624],"domain_scores_gemma":[0.9990154,0.0003137378,0.00022244948,0.00018516263,0.00018265889,0.000080626094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034823333,0.00017946454,0.0003609814,0.00009920307,0.00013560697,0.000007845926,0.00013176083,0.00015611036,0.000004537383],"category_scores_gemma":[0.000012285088,0.000119092954,0.00008392152,0.000097124364,0.00034244364,0.000048525228,0.0000074550194,0.00013894345,0.000001226912],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003142877,0.00012959074,0.22791795,0.00062899484,0.0006266593,0.000008260038,0.00094993366,0.000012813419,0.7609923,0.0011407111,0.000021864515,0.0044280635],"study_design_scores_gemma":[0.009791116,0.0030565562,0.36781758,0.00015612396,0.0028092633,0.0009120872,0.000076978846,0.00011457008,0.6147455,0.00026411115,0.000039844675,0.00021624856],"about_ca_topic_score_codex":0.000109338594,"about_ca_topic_score_gemma":0.000074398675,"teacher_disagreement_score":0.14624676,"about_ca_system_score_codex":0.000030196998,"about_ca_system_score_gemma":0.00011015209,"threshold_uncertainty_score":0.48564696},"labels":[],"label_agreement":null},{"id":"W2073081174","doi":"10.1038/bmt.2013.71","title":"Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR","year":2013,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Otsuka Pharmaceutical; Otsuka America; Otsuka America Pharmaceutical","keywords":"Medicine; Internal medicine; Transplantation; Comorbidity; Hematopoietic cell; Hematopoietic stem cell transplantation; Surgery; Haematopoiesis; Stem cell","score_opus":0.009608440460533808,"score_gpt":0.21649949985525652,"score_spread":0.20689105939472272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073081174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956885,0.00009519987,0.0013950905,0.00012467486,0.000049536764,0.0016042428,0.0004128669,0.000029549425,0.00060032867],"genre_scores_gemma":[0.99665356,0.0011685063,0.0005086358,0.0000194166,0.0000123244245,0.00007322485,0.0014923055,0.00003674872,0.00003525123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975749,0.00013860365,0.0008999196,0.0003843551,0.0007082654,0.00029395166],"domain_scores_gemma":[0.9988134,0.00021350216,0.000271302,0.00024795686,0.00028842146,0.0001653998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001993147,0.00026382145,0.00053432514,0.00035688444,0.00006528971,0.000017076522,0.000086883665,0.00018384082,0.00030373686],"category_scores_gemma":[0.000009890849,0.00022435759,0.00006261761,0.00039998814,0.00017885347,0.00029771635,0.0000061553446,0.00029016504,0.0000035106777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007999932,0.0009662455,0.89891505,0.009089779,0.000072051334,0.0002363993,0.011534973,0.000107970685,0.06935981,0.000032322503,0.0001906827,0.00149477],"study_design_scores_gemma":[0.00976476,0.0006524725,0.93926966,0.0008842693,0.00010520093,0.00005293794,0.00036499268,0.0003796549,0.048230592,0.000032271986,0.00004653976,0.0002166176],"about_ca_topic_score_codex":0.00033638603,"about_ca_topic_score_gemma":0.000681152,"teacher_disagreement_score":0.040354628,"about_ca_system_score_codex":0.00008810148,"about_ca_system_score_gemma":0.00009811287,"threshold_uncertainty_score":0.9149037},"labels":[],"label_agreement":null},{"id":"W2073151803","doi":"10.1182/blood-2011-01-328096","title":"Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; AGE-WELL","keywords":"Allele; Biology; Genetics; Wild type; Myeloid; Immunology; Medicine; Gene; Mutant","score_opus":0.01940632800509075,"score_gpt":0.26534982991946454,"score_spread":0.24594350191437378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073151803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952983,0.0021271918,0.00002133157,0.001448447,0.000057233487,0.0007347322,0.000019347299,0.00001731543,0.00027608586],"genre_scores_gemma":[0.99877447,0.00017687143,0.00021652474,0.00042573316,0.000047624268,0.00003411387,0.000010342757,0.00002209621,0.00029225028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988146,0.000111683534,0.0002398014,0.00027211566,0.00026647944,0.00029531203],"domain_scores_gemma":[0.99895066,0.000091697984,0.00007180355,0.0004353557,0.00018392764,0.00026652965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025446803,0.0001367903,0.00029116176,0.00012678659,0.000050292863,0.0000077063,0.00021727575,0.000081292885,0.000046738583],"category_scores_gemma":[0.0008875066,0.000092772956,0.000049936825,0.0004298323,0.00014625171,0.00005246181,0.00025024824,0.00020278782,0.000015429752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021954495,0.0010298954,0.9212668,0.00029192027,0.0001583626,0.0004008672,0.0014372477,0.0000035897706,0.06904386,0.00031173008,0.0013592748,0.0025010284],"study_design_scores_gemma":[0.006670771,0.00024602338,0.8769669,0.0006698508,0.00021657548,0.00003625886,0.00021381387,0.000053378404,0.11290485,0.00040203406,0.0014642985,0.00015527762],"about_ca_topic_score_codex":0.0003211286,"about_ca_topic_score_gemma":0.000060849732,"teacher_disagreement_score":0.044299904,"about_ca_system_score_codex":0.00005274486,"about_ca_system_score_gemma":0.00038656077,"threshold_uncertainty_score":0.37831715},"labels":[],"label_agreement":null},{"id":"W2073595456","doi":"10.1016/j.critrevonc.2008.07.015","title":"Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia","year":2008,"lang":"en","type":"article","venue":"Critical Reviews in Oncology/Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Quality of life (healthcare); Myeloid leukemia; Cognition; Pediatrics; Adverse effect; Gerontology; Intensive care medicine; Internal medicine; Psychiatry","score_opus":0.04108414178077232,"score_gpt":0.38816088368181106,"score_spread":0.34707674190103877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073595456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94750077,0.036320616,0.00014591755,0.008473401,0.00016093427,0.0024490773,0.000023408336,0.00004092607,0.004884933],"genre_scores_gemma":[0.952372,0.033457376,0.0068008155,0.0044024508,0.00008503791,0.0026882505,0.00002628134,0.000056259385,0.00011149232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938219,0.001370988,0.002270333,0.0009288439,0.00048710566,0.0011208302],"domain_scores_gemma":[0.9941695,0.0037353134,0.00024854057,0.0009359282,0.00034344546,0.00056729926],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017872463,0.0004578293,0.0035053436,0.00049407815,0.000055605924,0.0000048941843,0.0004041642,0.000830879,0.0009981823],"category_scores_gemma":[0.010801783,0.00034870824,0.00026641678,0.0009381767,0.0019637474,0.0001608376,0.00026873263,0.0015648312,0.00021022325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008556122,0.0028270506,0.9234686,0.003995612,0.00016845745,0.0139754405,0.002397174,8.9473997e-7,0.00013539384,0.0077758436,0.015524472,0.021174947],"study_design_scores_gemma":[0.033418417,0.004778109,0.8989829,0.008986744,0.00039685078,0.0080402605,0.0011693563,0.00023077602,0.0021554295,0.0018077572,0.038521625,0.0015117712],"about_ca_topic_score_codex":0.00025621327,"about_ca_topic_score_gemma":0.00073085376,"teacher_disagreement_score":0.024862297,"about_ca_system_score_codex":0.0013063321,"about_ca_system_score_gemma":0.0021845517,"threshold_uncertainty_score":0.99991506},"labels":[],"label_agreement":null},{"id":"W2073782881","doi":"10.1034/j.1600-0609.2001.5790554.x","title":"VIII International Myeloma Workshop, Banff Springs Hotel, Banff, Alberta, Canada, 4–8 May 2001","year":2001,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"","keywords":"Medicine; Library science; Citation","score_opus":0.021366092669647382,"score_gpt":0.2802701939600759,"score_spread":0.2589041012904285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073782881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87480295,0.0003550955,0.0007480226,0.031260625,0.0012492094,0.00015756123,0.0000034492496,0.000020226518,0.091402896],"genre_scores_gemma":[0.97582614,0.00038388945,0.0020129366,0.003083446,0.0009090131,0.0000012761957,0.000010840681,0.000086820684,0.017685605],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99678564,0.00047441488,0.0009996308,0.00030070715,0.00075431814,0.0006852603],"domain_scores_gemma":[0.9975716,0.00039272793,0.0004998823,0.00040698567,0.0005345462,0.0005942657],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011469132,0.0002716833,0.00072605093,0.00042335014,0.000097544915,0.00003982888,0.0007789578,0.00006773605,0.0029639911],"category_scores_gemma":[0.0011919815,0.0002273158,0.00019935709,0.00030156184,0.00019341207,0.00017187378,0.00022554376,0.0011334602,0.0003570138],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021330235,0.00023426383,0.057147164,0.000064549924,0.0008714346,0.31963983,0.00052427006,0.0000675631,0.0016961184,0.00045644894,0.60363096,0.0135343475],"study_design_scores_gemma":[0.0045981165,0.00036798717,0.049595177,0.00028856483,0.000118939206,0.25454086,0.00042896272,0.00023014306,0.00077969534,0.000025922001,0.68872744,0.00029821263],"about_ca_topic_score_codex":0.009774298,"about_ca_topic_score_gemma":0.028482463,"teacher_disagreement_score":0.10102325,"about_ca_system_score_codex":0.00055494974,"about_ca_system_score_gemma":0.0012838234,"threshold_uncertainty_score":0.99794745},"labels":[],"label_agreement":null},{"id":"W2075163562","doi":"10.1016/j.beha.2005.11.007","title":"How good is allogeneic transplantation for high-risk patients with AML?","year":2006,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Oncology; Transplantation; Myeloid leukemia; Malignancy; Cytogenetics; Induction therapy; Internal medicine; Leukemia; Immunology; Chemotherapy; Gene","score_opus":0.16462483010440607,"score_gpt":0.511375033474166,"score_spread":0.3467502033697599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075163562","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019681882,0.9694843,0.0013887711,0.008849443,0.00045275822,0.014804098,0.0014141062,0.00013371922,0.0015046006],"genre_scores_gemma":[0.00020353221,0.97945184,0.00987395,0.00030862956,0.00084306125,0.0020259514,0.003266372,0.0003154122,0.0037112285],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9838588,0.00707826,0.0023141853,0.0021926952,0.002509984,0.002046068],"domain_scores_gemma":[0.95312166,0.038835973,0.001548729,0.0018359626,0.003807267,0.0008503775],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0092406925,0.0008754059,0.005170842,0.0009957226,0.00050677103,0.00024399297,0.0010596059,0.0024348586,0.0000916595],"category_scores_gemma":[0.024169423,0.0006105826,0.0009631725,0.0013768089,0.0015025714,0.00057182263,0.00030020636,0.0071107736,0.0006620602],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043549445,0.0047823973,0.0029900928,0.033240907,0.002365722,0.0026886987,0.00004132266,1.3128509e-7,1.1142315e-7,0.0013266525,0.028727066,0.91948193],"study_design_scores_gemma":[0.007413124,0.009005021,0.0001957622,0.004551621,0.006660355,0.0016756166,0.00006828995,0.000008121829,0.0000025626196,0.00015195162,0.96972215,0.00054543285],"about_ca_topic_score_codex":0.0006540781,"about_ca_topic_score_gemma":0.00021270676,"teacher_disagreement_score":0.9409951,"about_ca_system_score_codex":0.00066878705,"about_ca_system_score_gemma":0.0054344386,"threshold_uncertainty_score":0.99963456},"labels":[],"label_agreement":null},{"id":"W2075841564","doi":"10.1038/leu.2014.67","title":"Epigenetic regulation of GATA2 and its impact on normal karyotype acute myeloid leukemia","year":2014,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Louisiana State University","keywords":"GATA2; Myeloid leukemia; Biology; Cancer research; Epigenetics; Leukemia; Genetics; Myeloid; Gene; Transcription factor","score_opus":0.013007390370230706,"score_gpt":0.29419933267608517,"score_spread":0.2811919423058545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075841564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889187,0.0002667569,0.00027561974,0.00034248814,0.000105409075,0.0005426731,0.000028378678,0.00008433391,0.009435644],"genre_scores_gemma":[0.99533874,0.00025747909,0.00068496395,0.0003870663,0.0003700314,0.000020062496,0.00011579198,0.00007070266,0.0027551563],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99758595,0.00013856679,0.00049137085,0.0005137189,0.00066525926,0.0006051038],"domain_scores_gemma":[0.998191,0.0002718532,0.00019079408,0.00070342596,0.00023392492,0.00040898361],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005578021,0.0003485228,0.0006161057,0.00033943827,0.00010935348,0.000026699263,0.00022859828,0.00030470546,0.0002783701],"category_scores_gemma":[0.0003006843,0.0002779207,0.00016465627,0.00043722402,0.00015711076,0.00016781225,0.00014391806,0.00057829,0.00022256577],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007176326,0.00016969118,0.04087589,0.00094921456,0.0010707229,0.00015309826,0.0010161544,0.0033015434,0.824496,0.0040142494,0.019026484,0.097750634],"study_design_scores_gemma":[0.0050334167,0.002515143,0.76019317,0.00026833286,0.00027100832,0.00025256132,0.000038076825,0.045909256,0.18264574,0.00043025095,0.002032191,0.00041084478],"about_ca_topic_score_codex":0.00022326164,"about_ca_topic_score_gemma":0.0000122427855,"teacher_disagreement_score":0.71931726,"about_ca_system_score_codex":0.0019549937,"about_ca_system_score_gemma":0.0010785019,"threshold_uncertainty_score":0.9999673},"labels":[],"label_agreement":null},{"id":"W2076031927","doi":"10.1038/nature13038","title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","year":2014,"lang":"en","type":"article","venue":"Nature","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1429,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research; Hospital for Sick Children","keywords":"Haematopoiesis; Stem cell; NPM1; Cancer research; Biology; Progenitor cell; Myeloid; Mutation; Immunology; Genetics; Gene; Karyotype","score_opus":0.008380715083805107,"score_gpt":0.2922844584368306,"score_spread":0.2839037433530255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076031927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962219,0.00042241463,0.0002566393,0.0010693168,0.00019578448,0.00054146524,0.000014893555,0.000048436046,0.0012291764],"genre_scores_gemma":[0.9944966,0.000088360124,0.00029876753,0.00039813833,0.0000911096,0.000024622172,0.000021584574,0.000031318108,0.0045495383],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998296,0.00009898713,0.00044276903,0.00033537875,0.000531129,0.00029570563],"domain_scores_gemma":[0.9987879,0.00012765099,0.00014984842,0.00063746114,0.00018893261,0.00010819877],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006594871,0.00014969781,0.00038109953,0.0002783459,0.000026777581,0.000014555514,0.00027635758,0.0011257211,0.00005066824],"category_scores_gemma":[0.0001081019,0.0001287473,0.000090940775,0.00051353103,0.00008404241,0.00009676956,0.00007686107,0.0024715743,0.00010196714],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005123442,0.00014959581,0.009437173,0.0007438525,0.000100674486,0.0000716112,0.00080363266,0.00004619111,0.9598864,0.001724761,0.019308997,0.007214815],"study_design_scores_gemma":[0.0029559564,0.00019965885,0.051882394,0.00031814814,0.00013286152,0.00012927761,0.000142819,0.0059420792,0.93289673,0.0005035407,0.0046750926,0.00022146688],"about_ca_topic_score_codex":0.000017814167,"about_ca_topic_score_gemma":0.000010343388,"teacher_disagreement_score":0.04244522,"about_ca_system_score_codex":0.00033531117,"about_ca_system_score_gemma":0.00021013453,"threshold_uncertainty_score":0.99982977},"labels":[],"label_agreement":null},{"id":"W2076592061","doi":"10.1002/ajh.22256","title":"A basis for updating our approach to resistant acute leukemia","year":2011,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Occult; Oncology; Leukemia; Disease; Breast cancer; Acute leukemia; Minimal residual disease; Incidence (geometry); Bone marrow; Cancer; Surgery; Pathology","score_opus":0.037725766569255546,"score_gpt":0.32343155262773143,"score_spread":0.2857057860584759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076592061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9571602,0.00015656269,0.028860895,0.0044192104,0.00017568262,0.0006078975,0.000014173486,0.00003374605,0.008571658],"genre_scores_gemma":[0.7353321,0.000027632488,0.2634818,0.00082268787,0.00012219399,0.000026225387,0.0000019304427,0.00003667176,0.00014876934],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980962,0.00011782241,0.00069543044,0.0002487937,0.0003032408,0.00053849595],"domain_scores_gemma":[0.9980528,0.00015592531,0.0005302111,0.00032974483,0.00048377793,0.00044755678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072119426,0.00018007308,0.0009889717,0.00043617148,0.000073881085,0.000009490251,0.0003470873,0.00007149663,0.000031310625],"category_scores_gemma":[0.00067465025,0.00013840295,0.0002404881,0.0004683356,0.00014601316,0.000077097095,0.00008264698,0.00043947672,0.000022748882],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09843391,0.0033605187,0.10357414,0.001664489,0.014505398,0.010147054,0.03946405,0.000040284613,0.17108233,0.046064407,0.30471793,0.2069455],"study_design_scores_gemma":[0.03340388,0.0860893,0.07013854,0.0025365518,0.006082121,0.22960961,0.25674284,0.0017922742,0.2670971,0.0036193172,0.039539333,0.0033491584],"about_ca_topic_score_codex":0.00006282892,"about_ca_topic_score_gemma":0.0000016121992,"teacher_disagreement_score":0.2651786,"about_ca_system_score_codex":0.0004464498,"about_ca_system_score_gemma":0.0009062655,"threshold_uncertainty_score":0.5643908},"labels":[],"label_agreement":null},{"id":"W2076649976","doi":"10.1097/mph.0b013e318142b547","title":"Childhood Acute Myeloid Leukemia With Hemophagocytosis by the Blasts and inv(8)(p11q13) With MOZ-TIF2 Fusion Transcripts","year":2007,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Hemophagocytosis; Myeloid leukemia; Medicine; Fusion transcript; Fusion gene; Myeloid; Leukemia; Myeloid leukaemia; Bone marrow; Cancer research; Immunology; Gene; Genetics; Pancytopenia; Biology","score_opus":0.011150359004429629,"score_gpt":0.2843779366074751,"score_spread":0.2732275776030455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076649976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98145145,0.004595969,0.0019693647,0.009658552,0.00022625156,0.00072829623,0.000012912973,0.000043870066,0.0013133566],"genre_scores_gemma":[0.98824906,0.00361275,0.0046742493,0.0019739564,0.0010590802,0.000018306238,0.000011024363,0.00008663016,0.00031491963],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9959558,0.00031400594,0.0012249023,0.0004959607,0.0009514304,0.0010578725],"domain_scores_gemma":[0.99599934,0.0011550951,0.000985971,0.0004503396,0.00062132,0.0007879413],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0022304596,0.00050016254,0.0015302352,0.0007210033,0.0002974733,0.000033507866,0.0005052766,0.000678429,0.00007806155],"category_scores_gemma":[0.00024774545,0.00026641318,0.0001905991,0.0010676138,0.000652406,0.00025731194,0.00012636125,0.0024121676,0.000020606938],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0524042,0.004556164,0.43215945,0.0011523484,0.0075051403,0.058891535,0.022771811,0.000044078188,0.052654255,0.00075222284,0.2753649,0.091743894],"study_design_scores_gemma":[0.08150767,0.056429096,0.15266012,0.00038687943,0.011754861,0.5647901,0.010306414,0.00022237834,0.045158703,0.0003903459,0.074484535,0.0019088812],"about_ca_topic_score_codex":0.000046204586,"about_ca_topic_score_gemma":0.00007697159,"teacher_disagreement_score":0.5058986,"about_ca_system_score_codex":0.0012307663,"about_ca_system_score_gemma":0.0036241156,"threshold_uncertainty_score":0.9999788},"labels":[],"label_agreement":null},{"id":"W2076840161","doi":"10.1038/leu.2008.156","title":"On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia","year":2008,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Farnesyltransferase; Chronic myelomonocytic leukemia; Farnesyltransferase inhibitor; Gastroenterology; Internal medicine; Medicine; Nausea; Prenylation; Myelodysplastic syndromes; Leukemia; Hematology; Immunology; Biology; Bone marrow","score_opus":0.0519968984772759,"score_gpt":0.27386489832119637,"score_spread":0.22186799984392047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076840161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970024,0.00037567777,0.00007651487,0.0006840287,0.000075595024,0.00078135356,0.00001165917,0.000056162193,0.00093656295],"genre_scores_gemma":[0.99529123,0.0006578678,0.0003202768,0.00065912155,0.00007580016,0.00006451531,0.000016379277,0.0000632007,0.002851596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974976,0.00015652883,0.0005392759,0.0005167329,0.00063189707,0.00065796793],"domain_scores_gemma":[0.9971114,0.0016239474,0.00013379018,0.00080717937,0.000095777614,0.00022790208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033009422,0.000325923,0.00061999215,0.00040182818,0.00014437624,0.00002164855,0.00027006256,0.00024192434,0.00023513225],"category_scores_gemma":[0.0009567599,0.00022904246,0.000110020235,0.0007224222,0.0006871537,0.00016950787,0.00018382042,0.0011005688,0.0001879729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017612485,0.0018210594,0.36182696,0.00788945,0.0032509682,0.07388227,0.014582801,0.055385426,0.15722284,0.056769904,0.18341167,0.066344164],"study_design_scores_gemma":[0.01456108,0.0037445282,0.8706441,0.001961333,0.00021655105,0.010814952,0.00022022659,0.07539335,0.0081705665,0.0008337804,0.012427269,0.0010122808],"about_ca_topic_score_codex":0.0006148858,"about_ca_topic_score_gemma":0.0000694771,"teacher_disagreement_score":0.50881714,"about_ca_system_score_codex":0.005937819,"about_ca_system_score_gemma":0.0031375175,"threshold_uncertainty_score":0.9978782},"labels":[],"label_agreement":null},{"id":"W2076954345","doi":"10.1016/j.celrep.2014.10.036","title":"Hematopoietic Stem Cells Are Intrinsically Protected against MLL-ENL-Mediated Transformation","year":2014,"lang":"en","type":"article","venue":"Cell Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Center for Advancing Translational Sciences","keywords":"Haematopoiesis; Biology; Permissiveness; Leukemia; Stem cell; Progenitor cell; Cancer research; Myeloid leukemia; Transcription factor; Immunology; Myeloid; Hematopoietic stem cell; Cell biology; Gene; Genetics","score_opus":0.011890547022319016,"score_gpt":0.23659323331496362,"score_spread":0.22470268629264462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076954345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9549104,0.00007018156,0.002639856,0.0009376914,0.00028063386,0.0019742444,0.000003889049,0.0003593435,0.03882374],"genre_scores_gemma":[0.9948987,0.00005481253,0.00037329053,0.00045201567,0.0001978014,0.0001166417,0.00009398929,0.00006265544,0.0037501222],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99727905,0.00012764151,0.0008146036,0.0004883647,0.0007682815,0.000522073],"domain_scores_gemma":[0.9979239,0.00012456786,0.0003655298,0.0007906136,0.00037594046,0.00041942982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079291814,0.00026249274,0.0005093005,0.0002229504,0.00010795967,0.000047054877,0.0001162033,0.0002690002,0.00012229236],"category_scores_gemma":[0.00020316514,0.0002214179,0.00014125655,0.00048216202,0.0000948748,0.00013597652,0.000050283837,0.00063479156,0.0005026489],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004742002,0.000841121,0.0030088585,0.003458979,0.0001470213,0.008924947,0.002642641,0.000097487406,0.9282303,0.00007745912,0.022717135,0.02937985],"study_design_scores_gemma":[0.0036306276,0.0005275109,0.0037663332,0.0005306837,0.0001443784,0.0012149645,0.00075196626,0.005598824,0.85200256,0.00012622421,0.13104096,0.0006649445],"about_ca_topic_score_codex":0.00001930282,"about_ca_topic_score_gemma":0.0000059010945,"teacher_disagreement_score":0.10832382,"about_ca_system_score_codex":0.00045715374,"about_ca_system_score_gemma":0.00036805478,"threshold_uncertainty_score":0.902916},"labels":[],"label_agreement":null},{"id":"W2077650731","doi":"10.1159/000226011","title":"Acute Leukemia Secondary to Lung Cancer","year":2009,"lang":"en","type":"article","venue":"Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus","funders":"","keywords":"Medicine; Leukemia; Macrocytosis; Acute myelomonocytic leukemia; Lung cancer; Cyclophosphamide; Oncology; Acute leukemia; Chemotherapy; Internal medicine; Cancer; Immunology; Pathology; Anemia","score_opus":0.017456394944508333,"score_gpt":0.38447153341235807,"score_spread":0.3670151384678497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077650731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7292537,0.0006883708,0.00031679834,0.068301246,0.00042465725,0.00083951454,0.000026215634,0.00015204572,0.19999744],"genre_scores_gemma":[0.874445,0.0005453834,0.0068230294,0.06826871,0.0013999757,0.00016417948,0.00005284342,0.00004962118,0.048251264],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986938,0.000051726885,0.00020679299,0.0003256553,0.00020427696,0.00051772315],"domain_scores_gemma":[0.9990625,0.000068685324,0.0000387752,0.00033059777,0.00011862416,0.00038082156],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019434842,0.0001384839,0.00039141855,0.00017815054,0.00006738174,0.000009520243,0.00017762335,0.00022267664,0.0023343924],"category_scores_gemma":[0.000069434114,0.00012022114,0.00007158272,0.0003071805,0.000054909156,0.00005623587,0.00007595441,0.0005879736,0.00040339274],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008187305,0.00011268268,0.0011708736,0.000027537126,0.00017838957,0.0013357541,0.00050097733,0.000019667774,0.07112394,0.00039206704,0.6702617,0.2540577],"study_design_scores_gemma":[0.004431238,0.0035874313,0.041821335,0.000056008186,0.00022031856,0.00062070915,0.00008864619,0.0007871684,0.010880388,0.00014845256,0.9371079,0.00025038657],"about_ca_topic_score_codex":0.00012667802,"about_ca_topic_score_gemma":0.000070958966,"teacher_disagreement_score":0.26684624,"about_ca_system_score_codex":0.003862469,"about_ca_system_score_gemma":0.0033136995,"threshold_uncertainty_score":0.99996156},"labels":[],"label_agreement":null},{"id":"W2078074124","doi":"10.1002/cncr.11098","title":"Treatment options for patients with acute myeloid leukemia with a matched sibling donor","year":2003,"lang":"en","type":"article","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; SickKids Foundation; Hospital for Sick Children; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Sibling; Myeloid leukemia; Oncology; Internal medicine; Leukemia; Pediatrics; Surgery","score_opus":0.021750144126952364,"score_gpt":0.30708093205053905,"score_spread":0.2853307879235867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078074124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931124,0.00027312041,0.0018148877,0.0006573544,0.000070875205,0.0019760707,0.000114356524,0.00007316413,0.0019077873],"genre_scores_gemma":[0.95200604,0.0007219368,0.028518498,0.0005562118,0.00022292933,0.0030855883,0.00020441983,0.0001356994,0.014548653],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99871975,0.000021731765,0.00016001401,0.00036693044,0.0002683889,0.00046319852],"domain_scores_gemma":[0.9989731,0.0000628633,0.000067033136,0.0003515602,0.00031453412,0.00023095332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057698137,0.00022295603,0.00033221164,0.00013133633,0.0001390107,0.00002890515,0.00007202874,0.000079441794,0.00019372135],"category_scores_gemma":[0.000024843474,0.00013645465,0.00006634231,0.00035784,0.000088502,0.000100729805,0.000011509168,0.00013988999,0.00002288814],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03634281,0.002959674,0.8220444,0.0010732865,0.012184388,0.0006628819,0.005895093,0.002843164,0.014406962,0.0045741363,0.02507447,0.071938746],"study_design_scores_gemma":[0.19880846,0.03009538,0.15202126,0.0014748698,0.006487592,0.00043779332,0.0020807523,0.0034235648,0.06596508,0.00032769056,0.5360345,0.0028430123],"about_ca_topic_score_codex":0.00015244007,"about_ca_topic_score_gemma":0.000097469456,"teacher_disagreement_score":0.67002314,"about_ca_system_score_codex":0.0028834208,"about_ca_system_score_gemma":0.0018802097,"threshold_uncertainty_score":0.7540045},"labels":[],"label_agreement":null},{"id":"W2078389671","doi":"10.2174/138161208785061382","title":"Therapeutic Drug Monitoring of Busulfan in Transplantation","year":2008,"lang":"en","type":"review","venue":"Current Pharmaceutical Design","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Busulfan; Dosing; Therapeutic drug monitoring; Medicine; Therapeutic index; Pharmacokinetics; Transplantation; Hematopoietic stem cell transplantation; Pharmacology; Drug; Toxicity; Oncology; Therapeutic effect; Internal medicine","score_opus":0.300016826053494,"score_gpt":0.48973584184088537,"score_spread":0.18971901578739137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078389671","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000053763477,0.99480784,0.0021042707,0.0000342025,0.00048917625,0.0022895047,0.00002273498,0.00005162906,0.00014690118],"genre_scores_gemma":[0.00060517556,0.9980309,0.0005529467,0.000010575678,0.0003461023,0.00021767369,0.0000833858,0.00008478302,0.00006845733],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964984,0.00074191915,0.000996831,0.0005181401,0.00066722574,0.0005774498],"domain_scores_gemma":[0.99816746,0.0008908773,0.00018200287,0.00034767375,0.00010283083,0.00030914083],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005474417,0.00047740556,0.0017795427,0.0006053104,0.000041369763,0.000011927453,0.00032689565,0.00024222874,0.00007959529],"category_scores_gemma":[0.000076619355,0.00038141178,0.0004510364,0.00085792365,0.00019254605,0.00008426177,0.00003893749,0.0018221702,0.00010710081],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017116766,0.00029104584,0.00013701686,0.031968,0.0001310226,0.00018807327,0.00015646301,0.0000024596343,0.00003031301,0.000031886742,0.00023962045,0.9666529],"study_design_scores_gemma":[0.0031372306,0.00016083456,0.0002935925,0.03980762,0.0020413555,0.0006055788,0.000016597523,0.00047670992,0.0010144192,0.000032978885,0.9518205,0.00059258175],"about_ca_topic_score_codex":0.0000034565358,"about_ca_topic_score_gemma":6.322442e-8,"teacher_disagreement_score":0.96606034,"about_ca_system_score_codex":0.00059414125,"about_ca_system_score_gemma":0.0011177475,"threshold_uncertainty_score":0.9998638},"labels":[],"label_agreement":null},{"id":"W2078786399","doi":"10.1182/blood-2011-05-352039","title":"Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut Gustave-Roussy; Institut National Du Cancer; Association pour la Recherche sur le Cancer","keywords":"Decitabine; Chronic myelomonocytic leukemia; Medicine; Internal medicine; Oncology; Neuroblastoma RAS viral oncogene homolog; Azacitidine; KRAS; Hypomethylating agent; Leukemia; Phases of clinical research; Myelodysplastic syndromes; Clinical trial; Bone marrow; Biology; Cancer; Gene; DNA methylation; Gene expression","score_opus":0.023853825533364036,"score_gpt":0.31250658665482584,"score_spread":0.2886527611214618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078786399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996014,0.00043364472,0.00015474783,0.00013651901,0.00010250614,0.0019420375,0.000016809747,0.00005688407,0.0011428581],"genre_scores_gemma":[0.99716073,0.000039286486,0.0020492622,0.000096605116,0.00012581804,0.0002159422,0.000010921234,0.000052152755,0.00024926354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978131,0.00019496927,0.00056692155,0.0004239673,0.000470002,0.0005310253],"domain_scores_gemma":[0.99855316,0.00016806572,0.000094385214,0.0007123108,0.00012765378,0.00034440865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007888985,0.00021347725,0.00054337125,0.00055982504,0.00002235341,0.0000049773143,0.00026938392,0.00016646986,0.00014965219],"category_scores_gemma":[0.0015786341,0.00019675567,0.00012883663,0.00081780116,0.000101050166,0.00008051953,0.0001377147,0.00039216995,0.000053127933],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3395718,0.0023831434,0.0011855534,0.0001335119,0.00022401186,0.0017502671,0.0015875674,0.00003220235,0.6488001,0.000046967798,0.00015468543,0.0041301837],"study_design_scores_gemma":[0.42457354,0.016272511,0.007379274,0.00027774184,0.00024141074,0.00008613432,0.0001871036,0.0001736481,0.5497392,0.000045069723,0.0007770643,0.00024731224],"about_ca_topic_score_codex":0.00010814208,"about_ca_topic_score_gemma":0.000022677514,"teacher_disagreement_score":0.0990609,"about_ca_system_score_codex":0.0010189195,"about_ca_system_score_gemma":0.0022379244,"threshold_uncertainty_score":0.80234635},"labels":[],"label_agreement":null},{"id":"W2078833442","doi":"10.1016/j.bbmt.2004.12.174","title":"Developement of chronic GvH is the strongest predictor of survival in patients with poor-risk AML in remission after related or unrelated SCT","year":2005,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Gastroenterology; Regimen; Transplantation; Oncology","score_opus":0.0074407306063283595,"score_gpt":0.24179074374446718,"score_spread":0.23435001313813883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078833442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99854296,0.00040217998,0.00002102437,0.00032071813,0.000018629931,0.00051926234,0.00011510058,0.00000503797,0.000055074604],"genre_scores_gemma":[0.9976891,0.0017544659,0.00030931845,0.000014493259,0.000009470431,0.000013820558,0.00015974039,0.000008825973,0.000040764164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989439,0.00014621066,0.0004253647,0.00017543144,0.00015041209,0.0001586799],"domain_scores_gemma":[0.9995003,0.00012263907,0.00014962738,0.0001082493,0.00008305472,0.000036175596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033445537,0.00010098445,0.00027572946,0.0001560124,0.000014677269,9.26385e-7,0.000059666243,0.00015496793,0.00005930213],"category_scores_gemma":[0.000028895873,0.000059761045,0.000021102655,0.00022237201,0.00017173159,0.000044151104,0.000010384869,0.00020084863,4.7030673e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006904208,0.00027400893,0.96346444,0.00029913284,0.0001467237,0.0000071086915,0.0012128679,0.000016225285,0.020510573,0.000010657019,0.0000066760012,0.007147356],"study_design_scores_gemma":[0.012255414,0.001691913,0.9581509,0.0005243185,0.00021036505,0.0000059518966,0.000058177815,0.00012086146,0.026878554,0.0000072437633,0.000032328488,0.00006396744],"about_ca_topic_score_codex":0.00023423006,"about_ca_topic_score_gemma":0.00057954655,"teacher_disagreement_score":0.0070833885,"about_ca_system_score_codex":0.000049249076,"about_ca_system_score_gemma":0.00021174856,"threshold_uncertainty_score":0.24369848},"labels":[],"label_agreement":null},{"id":"W2078892073","doi":"10.1016/j.leukres.2013.04.019","title":"Epigenetic action of decitabine (5-aza-2′-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C)","year":2013,"lang":"en","type":"letter","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Canadian Cancer Society","keywords":"Decitabine; Cytarabine; Myeloid leukemia; Deoxycytidine; Medicine; Azacitidine; Oncology; Chemotherapy; Leukopenia; Leukemia; Clinical trial; Pharmacology; Acute leukemia; Internal medicine; DNA methylation; Gemcitabine; Biology","score_opus":0.06026619633971207,"score_gpt":0.370613817139751,"score_spread":0.3103476208000389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078892073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9029075,0.0012533581,0.00032628875,0.08052336,0.00071716594,0.010285205,0.0006698185,0.00021745669,0.0030998678],"genre_scores_gemma":[0.81330097,0.023986356,0.0037791028,0.05374666,0.01659376,0.006319298,0.007826078,0.0022684494,0.07217931],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9812813,0.0021179935,0.002638643,0.002860925,0.00748212,0.0036190113],"domain_scores_gemma":[0.98545706,0.003106224,0.0013527864,0.004209878,0.0049562785,0.0009177499],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0035692342,0.0018014002,0.0038248547,0.004903789,0.00051191123,0.00015632703,0.0022257254,0.004729554,0.0015188382],"category_scores_gemma":[0.0018162153,0.0016312718,0.0014190322,0.0044184905,0.0025816618,0.00066603004,0.0012936301,0.016253548,0.001344814],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0023438123,0.00018808027,0.0006144395,0.0046615223,0.0021951501,0.0010585001,0.00072112697,0.00008270279,0.4626879,0.000009063897,0.50216436,0.023273332],"study_design_scores_gemma":[0.011189642,0.004515673,0.01510978,0.0034869614,0.0010683142,0.0005812543,0.0007710962,0.005341544,0.85702664,0.00032770727,0.09881941,0.0017619688],"about_ca_topic_score_codex":0.005725552,"about_ca_topic_score_gemma":0.00008433413,"teacher_disagreement_score":0.40334496,"about_ca_system_score_codex":0.026079267,"about_ca_system_score_gemma":0.01084742,"threshold_uncertainty_score":0.9994731},"labels":[],"label_agreement":null},{"id":"W2079025304","doi":"10.1056/nejmoa0901409","title":"High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia","year":2009,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":822,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc; Institut du Savoir Montfort","funders":"Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung","keywords":"Medicine; Daunorubicin; Cytarabine; Gastroenterology; Regimen; Leukemia; Myeloid leukemia; Adverse effect; Internal medicine; Surgery","score_opus":0.009801749104587323,"score_gpt":0.27104331475085264,"score_spread":0.26124156564626533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079025304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97975636,0.0004763051,0.00030660848,0.017467143,0.0002732545,0.00040337065,0.00000272124,0.000018502195,0.0012957616],"genre_scores_gemma":[0.9907488,0.0004975185,0.0021817577,0.0026300284,0.0027172773,0.0000013264776,0.00002965234,0.000033735578,0.0011598947],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99696034,0.00011618238,0.0008515581,0.000252057,0.001304586,0.00051529147],"domain_scores_gemma":[0.99795,0.00018673562,0.00036665951,0.00034589058,0.00046312445,0.0006875746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097267877,0.00029501738,0.00096939126,0.0007271072,0.000045318546,0.000012928511,0.000273551,0.00013723203,0.00035500297],"category_scores_gemma":[0.00038025525,0.00016874255,0.00007280537,0.0006645954,0.00013943271,0.0002228037,0.000027638293,0.0012758209,0.000014256433],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030721165,0.00084139046,0.18565425,0.00009858851,0.0006824077,0.011892855,0.0037207915,0.00019094218,0.011843029,0.00032289815,0.084684126,0.6693475],"study_design_scores_gemma":[0.23955907,0.009780741,0.73721373,0.0012207404,0.00034248026,0.0018074954,0.00012513643,0.000047033183,0.0007458314,0.0003731839,0.008581124,0.00020340721],"about_ca_topic_score_codex":0.00026031624,"about_ca_topic_score_gemma":0.000045753903,"teacher_disagreement_score":0.66914415,"about_ca_system_score_codex":0.000758847,"about_ca_system_score_gemma":0.0011408373,"threshold_uncertainty_score":0.68811214},"labels":[],"label_agreement":null},{"id":"W2079039169","doi":"10.1002/pbc.21157","title":"Toxicity and outcome of children with treatment related acute myeloid leukemia","year":2007,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Hospital for Sick Children","keywords":"Medicine; Myeloid leukemia; Internal medicine; Hematopoietic stem cell transplantation; Adverse effect; Population; Toxicity; Oncology; Surgery; Transplantation","score_opus":0.013850217074993551,"score_gpt":0.2969564617912093,"score_spread":0.28310624471621576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079039169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940468,0.0034782905,0.00003012844,0.00034368542,0.000057825335,0.00074365496,0.00006472546,0.00007589879,0.0011589824],"genre_scores_gemma":[0.9914968,0.0052143387,0.0009577428,0.00015409777,0.0004747078,0.000038984374,0.00002445446,0.000050188446,0.0015886935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804664,0.000027145883,0.00047855044,0.00043980405,0.00046910217,0.00053874834],"domain_scores_gemma":[0.99884444,0.000099537356,0.00018986603,0.00038921973,0.00014112974,0.0003357955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030922226,0.00027620935,0.0005724542,0.0002833226,0.00007501048,0.000010400138,0.000115908784,0.00018655248,0.00013378642],"category_scores_gemma":[0.00003600774,0.00019231284,0.000094610295,0.00070916285,0.00013670043,0.00008139461,0.000067562105,0.00035527998,0.000011884435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050688226,0.00023302331,0.9922215,0.00007835272,0.0009148303,0.00011891738,0.00025656185,0.0000056867543,0.0011526352,0.000028761351,0.00026205883,0.0042208177],"study_design_scores_gemma":[0.011935613,0.0016329148,0.96672046,0.000026089197,0.0035730673,0.0003811654,0.00003626474,0.000023670114,0.015252209,0.0000126407695,0.00014793042,0.00025794542],"about_ca_topic_score_codex":0.0018341887,"about_ca_topic_score_gemma":0.00021297978,"teacher_disagreement_score":0.025500983,"about_ca_system_score_codex":0.0006252938,"about_ca_system_score_gemma":0.00071886944,"threshold_uncertainty_score":0.78422904},"labels":[],"label_agreement":null},{"id":"W2079049316","doi":"10.1002/gcc.22005","title":"Different characteristics identified by single nucleotide polymorphism array analysis in leukemia suggest the need for different application strategies depending on disease category","year":2012,"lang":"en","type":"article","venue":"Genes Chromosomes and Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"SNP array; Myeloid leukemia; SNP; Single-nucleotide polymorphism; Karyotype; Leukemia; Loss of heterozygosity; Biology; Cytogenetics; Oncology; Genetics; Cancer research; Genotype; Medicine; Chromosome; Gene; Allele","score_opus":0.01958942383660524,"score_gpt":0.2873497563477802,"score_spread":0.267760332511175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079049316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912947,0.005399314,0.0009866633,0.0010808264,0.00018023497,0.00080832187,0.0001649798,0.000031114338,0.000053862812],"genre_scores_gemma":[0.99516314,0.0023851567,0.000009601475,0.00026023365,0.00055923266,0.0006634959,0.0004785786,0.000040177318,0.00044039858],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99845296,0.000055370936,0.0003092437,0.00035944782,0.0003046793,0.0005183095],"domain_scores_gemma":[0.9990101,0.0001386237,0.00013311015,0.00038118192,0.00004959911,0.00028739628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013799865,0.0002644089,0.00044485624,0.00018067367,0.00014940737,0.00010097882,0.00014652511,0.00008426485,0.00014349943],"category_scores_gemma":[0.000017517246,0.00017146999,0.00013994792,0.00027399044,0.00010849954,0.00012410502,0.00005154308,0.0001922196,0.000004184541],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008738975,0.00043706672,0.478445,0.00042574925,0.00070739567,0.0000058998676,0.00083760277,0.00004295122,0.48639628,0.00048419656,0.0008891817,0.030454772],"study_design_scores_gemma":[0.0015397193,0.00010104255,0.96297365,0.00007623097,0.0009860485,0.0000027835972,0.0009883811,0.0016663815,0.028413333,0.00007944105,0.0028644006,0.0003085726],"about_ca_topic_score_codex":0.00045533708,"about_ca_topic_score_gemma":0.00018831527,"teacher_disagreement_score":0.48452866,"about_ca_system_score_codex":0.00083465036,"about_ca_system_score_gemma":0.00013003984,"threshold_uncertainty_score":0.6992343},"labels":[],"label_agreement":null},{"id":"W2080006818","doi":"10.1182/blood.v100.2.427","title":"Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation","year":2002,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Myeloid leukemia; Cancer; Myelodysplastic syndromes; Leukemia; Presentation (obstetrics); Pediatrics; Oncology; Internal medicine; Bone marrow; Surgery","score_opus":0.015664000661924266,"score_gpt":0.27331925464448975,"score_spread":0.2576552539825655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080006818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99608487,0.0010805518,0.00007674367,0.00038407728,0.000013918526,0.0016572324,0.00006569087,0.00007446442,0.0005624526],"genre_scores_gemma":[0.9958467,0.0006055893,0.0014047209,0.00011029749,0.00007518825,0.0003649133,0.0001940685,0.000051476327,0.0013470714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985319,0.00003758688,0.00028279383,0.00041560445,0.0003037493,0.00042837788],"domain_scores_gemma":[0.9993076,0.00012300065,0.000083814186,0.00023360821,0.000076593875,0.00017541823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000093200484,0.00021433318,0.00047099064,0.00024042062,0.00007641135,0.000031585452,0.00010206827,0.000121297315,0.000058628717],"category_scores_gemma":[0.000032384625,0.00017398392,0.000038027516,0.00037659492,0.000109122404,0.00013585229,0.000043751694,0.00028963602,0.000013356895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076305354,0.0005134347,0.9839883,0.0002161609,0.0007680282,0.00019462129,0.00031282988,0.00005623628,0.0062252115,0.000016019067,0.001286862,0.0056592296],"study_design_scores_gemma":[0.022893284,0.0014212452,0.9626041,0.0002141178,0.00084543973,0.0014875334,0.00003983904,0.004702827,0.0053605395,0.000008569815,0.00016917742,0.00025335012],"about_ca_topic_score_codex":0.0003621992,"about_ca_topic_score_gemma":0.000079436984,"teacher_disagreement_score":0.02213023,"about_ca_system_score_codex":0.0003749584,"about_ca_system_score_gemma":0.00016242139,"threshold_uncertainty_score":0.7094858},"labels":[],"label_agreement":null},{"id":"W2080348075","doi":"10.1007/s00520-014-2230-3","title":"Finding new bearings: a qualitative study on the transition from inpatient to ambulatory care of patients with acute myeloid leukemia","year":2014,"lang":"en","type":"article","venue":"Supportive Care in Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; York University; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Ambulatory care; Ambulatory; Qualitative research; Myeloid leukemia; Psychological intervention; Nursing research; Grounded theory; Intensive care medicine; Family medicine; Emergency medicine; Nursing; Health care; Internal medicine","score_opus":0.025136100765679834,"score_gpt":0.3493143637810292,"score_spread":0.32417826301534935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080348075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959524,0.00008012006,0.00012479992,0.0004978027,0.00010603986,0.0023103496,0.00042723972,0.000022121896,0.00047910138],"genre_scores_gemma":[0.9982139,0.0000081012995,0.00015033304,0.00087594864,0.00010418721,0.00031382806,0.00023132523,0.000048833434,0.000053527507],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9974961,0.0002966311,0.00042312843,0.0005238324,0.0008906255,0.00036966812],"domain_scores_gemma":[0.99818176,0.0002943028,0.00017491981,0.00043324698,0.0007146495,0.00020110415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023561422,0.00026066232,0.00048049408,0.00024643214,0.00007353131,0.000014095773,0.00018802258,0.00009343223,0.00018016159],"category_scores_gemma":[0.00015111515,0.00017564216,0.00007901493,0.00048263793,0.00010058526,0.000103082406,0.00007030759,0.00048745773,0.000015199775],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037527713,0.0001561806,0.15937631,0.00008026888,0.00032903987,0.000028688184,0.8259776,0.00020586561,0.00037907643,0.000025068726,0.0009977994,0.0086913295],"study_design_scores_gemma":[0.00561248,0.0061283167,0.58025306,0.00069674867,0.00020267411,2.6936942e-7,0.40050712,0.000018220342,0.0058180215,0.000025622527,0.00047295657,0.00026449098],"about_ca_topic_score_codex":0.004971851,"about_ca_topic_score_gemma":0.0019461004,"teacher_disagreement_score":0.4254705,"about_ca_system_score_codex":0.0033730306,"about_ca_system_score_gemma":0.0012591949,"threshold_uncertainty_score":0.88203573},"labels":[],"label_agreement":null},{"id":"W2080556827","doi":"10.4161/cbt.19074","title":"Evaluation of checkpoint kinase targeting therapy in Acute Myeloid Leukemia with complex karyotype","year":2012,"lang":"en","type":"article","venue":"Cancer Biology & Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"","keywords":"Cancer research; Myeloid leukemia; CHEK1; Clonogenic assay; Biology; Haematopoiesis; Progenitor cell; Myeloid; Cell cycle checkpoint; Cell cycle; Stem cell; Cancer; Cell; Cell biology; Genetics","score_opus":0.08234554429849508,"score_gpt":0.3817412113552125,"score_spread":0.2993956670567174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080556827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807111,0.016115205,0.00006156346,0.0010596015,0.00015112579,0.0011267354,0.000020490623,0.00003754639,0.00071659934],"genre_scores_gemma":[0.9874474,0.009627188,0.00097316806,0.0010248002,0.00037410358,0.00030597806,0.00013460465,0.000046554884,0.00006619599],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9977493,0.00045182733,0.0003914401,0.00034217277,0.00044119995,0.0006240163],"domain_scores_gemma":[0.9986057,0.00009165644,0.00019058322,0.000392965,0.00056954206,0.00014950101],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023552254,0.00024932084,0.00052752433,0.00021858327,0.000058563124,0.000005288534,0.00019390212,0.00021456163,0.0012002887],"category_scores_gemma":[0.000057756046,0.00017004984,0.0000834857,0.0004691858,0.00033238655,0.0001090873,0.00003557319,0.00041101073,0.00001755676],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026886803,0.00014515495,0.23495834,0.000014079325,0.00050315267,0.000004479659,0.0012438869,0.000039083407,0.6204746,0.000060141057,0.00058112864,0.13928728],"study_design_scores_gemma":[0.021725234,0.002432232,0.7071045,0.00012467263,0.00017386023,0.000038553,0.00041277555,0.0017859342,0.24977821,0.00026598698,0.015719231,0.0004387994],"about_ca_topic_score_codex":0.000772373,"about_ca_topic_score_gemma":0.000049583545,"teacher_disagreement_score":0.47214618,"about_ca_system_score_codex":0.0014051102,"about_ca_system_score_gemma":0.0014418411,"threshold_uncertainty_score":0.99971277},"labels":[],"label_agreement":null},{"id":"W2081009834","doi":"10.1007/s00277-012-1635-7","title":"Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment","year":2012,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Decitabine; Chronic myelomonocytic leukemia; Medicine; Internal medicine; International Prognostic Scoring System; Oncology; Myelodysplastic syndromes; Single-nucleotide polymorphism; Hematology; Univariate analysis; SNP array; SNP; Leukemia; Gastroenterology; Multivariate analysis; Bone marrow; Genotype; Biology; Genetics; DNA methylation; Gene","score_opus":0.05182636321930983,"score_gpt":0.3443971151118689,"score_spread":0.29257075189255904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081009834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98540175,0.0111706415,0.000027755012,0.0021592623,0.00010816029,0.00089419296,0.000018259076,0.000046843485,0.00017311197],"genre_scores_gemma":[0.998631,0.0005610874,0.00019656218,0.00028685486,0.00004327132,0.00008417474,0.000040516683,0.0000689808,0.000087546505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728245,0.00015373003,0.00064826745,0.00051016535,0.0002659077,0.0011394672],"domain_scores_gemma":[0.99765813,0.0011750838,0.00018874172,0.00043184496,0.000044244644,0.00050196],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027166633,0.00055438525,0.0015918255,0.0007702086,0.00009434584,0.000016090571,0.00010761474,0.00022701791,0.00005026361],"category_scores_gemma":[0.00027744556,0.00039122708,0.00028372087,0.00028754692,0.0001508076,0.00017543075,0.000054768487,0.00021562698,0.00003462534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001158785,0.0014185751,0.9405809,0.00042284906,0.0016265096,0.0017940125,0.00096347264,0.00015073078,0.04881503,0.00016288794,0.000019134859,0.002887103],"study_design_scores_gemma":[0.010713969,0.010015336,0.91080874,0.0005661668,0.00036605334,0.0012257362,0.00016027878,0.0006843017,0.06479029,0.00007528629,0.00010936226,0.00048449144],"about_ca_topic_score_codex":0.00022174562,"about_ca_topic_score_gemma":0.000037400045,"teacher_disagreement_score":0.029772187,"about_ca_system_score_codex":0.0018526409,"about_ca_system_score_gemma":0.0006837276,"threshold_uncertainty_score":0.99985397},"labels":[],"label_agreement":null},{"id":"W2081607021","doi":"10.1203/00006450-200212000-00003","title":"GATA1 — A Player in Normal and Leukemic Megakaryopoiesis","year":2002,"lang":"en","type":"letter","venue":"Pediatric Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"GATA1; Cell biology; Internal medicine; Medicine; Biology; Haematopoiesis; Stem cell","score_opus":0.07860688165056015,"score_gpt":0.3541647613303781,"score_spread":0.27555787967981793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081607021","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29179922,0.014730606,0.000007718334,0.64978033,0.00032834284,0.0036628267,0.00016637791,0.00018733664,0.039337214],"genre_scores_gemma":[0.10807803,0.13423894,0.0023863625,0.31272814,0.09421953,0.0026906685,0.0019982979,0.0015261527,0.34213385],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99043286,0.0008713611,0.00086297264,0.0014369352,0.0037243606,0.0026715163],"domain_scores_gemma":[0.9951363,0.0023568266,0.00011997681,0.0013168566,0.00058106316,0.00048895617],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0032180506,0.00058260135,0.0011648048,0.004818225,0.00023739906,0.00018027631,0.00082618155,0.0020026474,0.0019810086],"category_scores_gemma":[0.0017481106,0.000525757,0.00019447817,0.00307299,0.00049733697,0.00023153232,0.0010126852,0.016086753,0.0015133871],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018335928,0.000069148184,0.039371654,0.0015927269,0.000058194677,0.009918614,0.0002865512,6.3439745e-7,0.000029283812,0.0000044119042,0.9467866,0.0016988412],"study_design_scores_gemma":[0.0075460696,0.00117065,0.048708536,0.0002843156,0.0002767484,0.0016480761,0.0002585318,0.001505919,0.00006477138,0.00026530123,0.9369872,0.0012838887],"about_ca_topic_score_codex":0.0013165245,"about_ca_topic_score_gemma":0.000029522496,"teacher_disagreement_score":0.3370522,"about_ca_system_score_codex":0.002130318,"about_ca_system_score_gemma":0.0019755191,"threshold_uncertainty_score":0.9997194},"labels":[],"label_agreement":null},{"id":"W2081736209","doi":"10.1172/jci30525","title":"A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Deutsche Forschungsgemeinschaft; Lymphoma Research Foundation","keywords":"Enhancer; Biology; Myeloid leukemia; Progenitor cell; Myeloid; Cancer research; Transcription factor; Molecular biology; Chromatin; Core binding factor; Leukemia; Single-nucleotide polymorphism; Cell biology; Gene; Genetics; Stem cell","score_opus":0.062083860409709604,"score_gpt":0.35878551316418006,"score_spread":0.29670165275447047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081736209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927657,0.00013173642,0.0011197408,0.0048049074,0.0005533387,0.00031702363,0.0000043654577,0.0000096040585,0.00029353655],"genre_scores_gemma":[0.99353915,0.00008001262,0.0043015652,0.0008225565,0.00089802366,0.0000012513138,0.00001044376,0.00002785856,0.00031911887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958736,0.0003039158,0.002369725,0.00020166575,0.0009505265,0.00030062607],"domain_scores_gemma":[0.99666554,0.00071069144,0.0014697476,0.0003544208,0.00043837697,0.00036124166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004719915,0.00015415167,0.00060626987,0.00029478868,0.000051445648,0.000019290244,0.0002727862,0.00025684448,0.000033276865],"category_scores_gemma":[0.0024689105,0.00010700191,0.00037204454,0.0006465389,0.00060343393,0.0003158441,0.000079237056,0.0010329686,0.000007705567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018965317,0.00024159598,0.6380952,0.0000688042,0.00019414394,0.00023422841,0.00045731678,0.00011623645,0.34620062,0.00013705956,0.0016405026,0.010717788],"study_design_scores_gemma":[0.0033915436,0.0005358729,0.9342441,0.0003754846,0.00016023275,0.00034008923,0.000060819388,0.0008563979,0.058705147,0.0010248978,0.00021084091,0.00009457723],"about_ca_topic_score_codex":0.000081286424,"about_ca_topic_score_gemma":0.00005787812,"teacher_disagreement_score":0.29614893,"about_ca_system_score_codex":0.00075323554,"about_ca_system_score_gemma":0.0010166231,"threshold_uncertainty_score":0.4487792},"labels":[],"label_agreement":null},{"id":"W2081988140","doi":"10.1182/blood-2011-01-329078","title":"Identification of T-lymphocytic leukemia–initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; McMaster University","funders":"","keywords":"Severe combined immunodeficiency; Leukemia; Biology; Stem cell; Myeloid leukemia; Cancer research; Nod; CD34; Myeloid; Immunology; Transplantation; In vivo; Haematopoiesis; Medicine; Internal medicine; Cell biology; Genetics","score_opus":0.025634963787461336,"score_gpt":0.2402346682524661,"score_spread":0.21459970446500476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081988140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984057,0.00013557401,0.00009163255,0.0000071583163,0.0000350211,0.0008430136,0.00010559763,0.000038251463,0.00033805906],"genre_scores_gemma":[0.99867207,0.00008024321,0.00084257877,0.000027788443,0.000026578371,0.000052383013,0.00006273727,0.000054065375,0.00018156477],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99777424,0.00011661315,0.00081808836,0.0004099654,0.00047398513,0.0004071183],"domain_scores_gemma":[0.99821305,0.00011831436,0.00046861576,0.00063702103,0.00034427087,0.0002187246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045060212,0.0002161407,0.00047456016,0.0004134609,0.000042258904,0.000009541519,0.0002717637,0.00010627261,0.000025768848],"category_scores_gemma":[0.000099939134,0.00018888955,0.00008891925,0.00060499227,0.00014440759,0.00015282762,0.00010846713,0.00025196385,0.000015367936],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004540439,0.0011586512,0.74315816,0.0017694354,0.0005757647,0.00044522525,0.0040888437,0.00006098661,0.24273525,0.00014970767,0.000052436626,0.0012650839],"study_design_scores_gemma":[0.012654794,0.00045867,0.44221088,0.0006285073,0.00064591225,0.000011270879,0.0003847884,0.000812854,0.5419193,0.000050060426,0.000003019651,0.0002199746],"about_ca_topic_score_codex":0.0003649765,"about_ca_topic_score_gemma":0.000032837368,"teacher_disagreement_score":0.3009473,"about_ca_system_score_codex":0.0011825501,"about_ca_system_score_gemma":0.0023070413,"threshold_uncertainty_score":0.7702693},"labels":[],"label_agreement":null},{"id":"W2082440968","doi":"10.1016/j.leukres.2010.01.015","title":"Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts","year":2010,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celator Pharmaceuticals (Canada)","funders":"Celator Pharmaceuticals","keywords":"Daunorubicin; Cytarabine; Leukemia; Bone marrow; Pharmacology; Medicine; Cancer research; Immunology","score_opus":0.031563724515059406,"score_gpt":0.33557359054153746,"score_spread":0.30400986602647806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082440968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98949695,0.0003780947,0.00032538828,0.0010041358,0.00012513236,0.0022522972,0.000045868364,0.000097202625,0.0062749563],"genre_scores_gemma":[0.99281174,0.00023203544,0.0027287714,0.00014093582,0.00045847814,0.00031400737,0.000106197724,0.00011548892,0.0030923611],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9931644,0.0005089282,0.0012206237,0.0011514544,0.002214433,0.001740163],"domain_scores_gemma":[0.9946932,0.0015252391,0.00021353907,0.0012651982,0.001590415,0.00071238726],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0048072836,0.00049371086,0.0010879632,0.0019871683,0.00036889737,0.000105742634,0.00055230747,0.0007479229,0.0002845616],"category_scores_gemma":[0.005038418,0.00045515885,0.00017605026,0.0031187818,0.0010592552,0.00042999286,0.00052183995,0.0046422128,0.00008698744],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0022654855,0.00026981058,0.039836276,0.00065849745,0.00012968738,0.00048568877,0.0014358835,0.00016808696,0.93807125,0.0050929273,0.0066263033,0.00496011],"study_design_scores_gemma":[0.016940597,0.0023934136,0.49595237,0.0006905761,0.000112413174,0.000563626,0.0010564725,0.06406439,0.40994194,0.0037325341,0.0034919516,0.0010597348],"about_ca_topic_score_codex":0.004972399,"about_ca_topic_score_gemma":0.0037962687,"teacher_disagreement_score":0.52812934,"about_ca_system_score_codex":0.0043645217,"about_ca_system_score_gemma":0.0058493335,"threshold_uncertainty_score":0.99979},"labels":[],"label_agreement":null},{"id":"W2082471565","doi":"10.1159/000205398","title":"Multiple Granulocytic Sarcoma during Complete Hematologic Remission of Acute Nonlymphoid Leukemia","year":2009,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Bone marrow; Medicine; Leukemia; Pathology; Sarcoma; Immunohistochemistry; Chemotherapy; Complete remission; Lymph; Internal medicine","score_opus":0.026614163136061707,"score_gpt":0.29124145434472004,"score_spread":0.26462729120865836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082471565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99166113,0.0003070969,0.00007815306,0.0027638308,0.000063571824,0.00086804933,0.00002855279,0.00031338443,0.003916222],"genre_scores_gemma":[0.9931379,0.00031960977,0.0053045484,0.00058369694,0.000052400927,0.00002524379,0.00008712084,0.000035435438,0.00045406603],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966895,0.00015347752,0.00086775946,0.000705724,0.0006832615,0.0009002848],"domain_scores_gemma":[0.9975857,0.00035586304,0.00034362936,0.0010753853,0.00023298738,0.00040642044],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003162546,0.00044101296,0.0014165845,0.00032242233,0.0002501296,0.00002425804,0.00058587146,0.00040765872,0.0002684155],"category_scores_gemma":[0.00063789776,0.00032339932,0.00033768595,0.0006247625,0.00030950372,0.00015867574,0.00023960475,0.0006175619,0.00012567402],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026844847,0.00040334353,0.01964647,0.0004944414,0.00026299854,0.004352409,0.0002526589,0.0000052535584,0.9660893,0.00045308497,0.0040456653,0.0013098926],"study_design_scores_gemma":[0.018288674,0.0028262257,0.23439446,0.0011256561,0.00063227577,0.031947907,0.0003464031,0.0063726897,0.69765896,0.001979071,0.0032700552,0.0011576252],"about_ca_topic_score_codex":0.000056596702,"about_ca_topic_score_gemma":0.0000031306556,"teacher_disagreement_score":0.26843035,"about_ca_system_score_codex":0.0007324727,"about_ca_system_score_gemma":0.00040877634,"threshold_uncertainty_score":0.9999218},"labels":[],"label_agreement":null},{"id":"W2083131489","doi":"10.1182/blood-2013-02-485524","title":"Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Münster AML-study group","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"National Cancer Institute; Stichting Kinder Oncologisch Centrum Rotterdam","keywords":"Medicine; Cohort; Myeloid leukemia; Leukemia; Internal medicine; Myeloid; Immunophenotyping; Pediatrics; Oncology; Immunology; Flow cytometry","score_opus":0.02079256657621617,"score_gpt":0.30876192464696384,"score_spread":0.28796935807074764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083131489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99171996,0.00034373175,0.00005510076,0.001534604,0.00016610097,0.0047520883,0.00008748183,0.00010607396,0.0012348634],"genre_scores_gemma":[0.99584055,0.0003232759,0.00030316648,0.00064266473,0.00073065294,0.00076169474,0.0000810391,0.000051984025,0.0012649652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961522,0.00058788905,0.00076508545,0.0009748093,0.0009576173,0.0005623637],"domain_scores_gemma":[0.9974073,0.0007384707,0.00023562681,0.000707153,0.00053156127,0.00037987795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012881667,0.00042748335,0.00074623193,0.00016037193,0.00027429315,0.00026254324,0.0006171175,0.00020292487,0.00039057815],"category_scores_gemma":[0.0005063223,0.00023193815,0.00011227043,0.00076507597,0.000489797,0.00023194382,0.00062166614,0.0010373617,0.00019814914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006482575,0.0047426703,0.978165,0.000013610959,0.0016092875,0.0002986797,0.0011162071,8.0699365e-8,0.00022145019,0.000013726535,0.011617811,0.0015532243],"study_design_scores_gemma":[0.025784053,0.008926089,0.9535075,0.00001969702,0.0015397493,0.0002173221,0.0063763205,0.00006693335,0.000058707512,0.00004368383,0.0030771906,0.00038274887],"about_ca_topic_score_codex":0.00066069886,"about_ca_topic_score_gemma":0.0005023182,"teacher_disagreement_score":0.025135795,"about_ca_system_score_codex":0.00023440781,"about_ca_system_score_gemma":0.0004641887,"threshold_uncertainty_score":0.9458163},"labels":[],"label_agreement":null},{"id":"W2083158296","doi":"10.1007/s00520-008-0512-3","title":"Associations between quality of life, fatigue, and cytokine levels in patients aged 50+ with acute myeloid leukemia","year":2008,"lang":"en","type":"article","venue":"Supportive Care in Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University Health Network","funders":"Toronto Rehabilitation Institute","keywords":"Medicine; Myeloid leukemia; Cytokine; Quality of life (healthcare); Internal medicine; Myeloid; Population; Immunology","score_opus":0.06885570331776278,"score_gpt":0.3691713034105063,"score_spread":0.3003156000927435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083158296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953995,0.00026894352,0.000027918964,0.00030682507,0.000036865877,0.0008236939,0.0023426428,0.000019947636,0.0007736663],"genre_scores_gemma":[0.99822074,0.00029965374,0.00032217018,0.00021909409,0.00007221643,0.00009337926,0.00052756025,0.000034818964,0.00021033936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975373,0.0001798443,0.0007424239,0.000417725,0.0006832624,0.00043945928],"domain_scores_gemma":[0.99829906,0.0002453649,0.00033106512,0.00027395276,0.0006447607,0.00020578844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034554856,0.0002175918,0.0008191588,0.00030912823,0.00006411779,0.0000059597323,0.00011948471,0.00018099272,0.00011631634],"category_scores_gemma":[0.00048721387,0.00018739917,0.00006196548,0.00066491746,0.00027507497,0.00019259038,0.0000899962,0.0005808313,0.000002409175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005121615,0.000057736564,0.99223673,0.00010303837,0.00019145908,0.00005129604,0.004289231,0.000012240785,0.00037022983,0.000005750259,0.0006588833,0.0015112589],"study_design_scores_gemma":[0.0070412005,0.00045481813,0.98903793,0.00015886957,0.00005688148,0.0000014247152,0.00064992474,0.0000032994622,0.0022828372,0.00001060723,0.000111457375,0.00019075333],"about_ca_topic_score_codex":0.00602675,"about_ca_topic_score_gemma":0.0037124853,"teacher_disagreement_score":0.006529039,"about_ca_system_score_codex":0.0029997246,"about_ca_system_score_gemma":0.0028292257,"threshold_uncertainty_score":0.9110683},"labels":[],"label_agreement":null},{"id":"W2083163833","doi":"10.1515/cclm.2009.093","title":"Expression of lineage markers using real-time quantitative polymerase chain reaction (RT-qPCR) in normal and in leukemia bone marrow","year":2009,"lang":"en","type":"article","venue":"Clinical Chemistry and Laboratory Medicine (CCLM)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Manitoba","keywords":"Real-time polymerase chain reaction; Polymerase chain reaction; Bone marrow; Leukemia; Lineage (genetic); Biology; Pathology; Molecular biology; Immunology; Cancer research; Medicine; Genetics; Gene","score_opus":0.03526031442910058,"score_gpt":0.3659290027712113,"score_spread":0.3306686883421107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083163833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553347,0.0013326376,0.000011870456,0.0009910073,0.00004613474,0.0003036938,0.000020159605,0.000024076007,0.0017369266],"genre_scores_gemma":[0.9953394,0.0019285878,0.001357259,0.0004360303,0.00037282423,0.0000061990954,0.00006396236,0.000026821906,0.00046892007],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99718726,0.0002738984,0.001206638,0.00057551905,0.0003714526,0.00038523544],"domain_scores_gemma":[0.9979118,0.0007988655,0.00032406824,0.00036250104,0.00017153467,0.0004311922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002436759,0.00027610213,0.00096803904,0.0001424054,0.000047764046,0.0000065274908,0.000095912605,0.00046519985,0.000170642],"category_scores_gemma":[0.0023607889,0.00023551204,0.000053219333,0.00059830834,0.00069442793,0.00016834645,0.00006691308,0.0010845222,0.0000026281004],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042673275,0.00019187966,0.020044722,0.00038737702,0.000017648568,0.0003887538,0.00023923324,0.000004240572,0.97258776,0.000005141642,0.0008627798,0.0010031151],"study_design_scores_gemma":[0.034030695,0.0028415015,0.265006,0.007680703,0.0002503617,0.00022363251,0.0039954595,0.012660456,0.6713191,0.00007622966,0.0010044186,0.0009114451],"about_ca_topic_score_codex":0.00017112873,"about_ca_topic_score_gemma":0.0000057769835,"teacher_disagreement_score":0.3012687,"about_ca_system_score_codex":0.0002568002,"about_ca_system_score_gemma":0.0005858738,"threshold_uncertainty_score":0.9603902},"labels":[],"label_agreement":null},{"id":"W2083398319","doi":"10.1182/blood-2012-12-475863","title":"NrasG12D/+ promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"National Cancer Institute; Canadian Institutes of Health Research; University of Wisconsin Carbone Cancer Center; Greater Milwaukee Foundation; University of Wisconsin-Madison; American Society of Hematology; V Foundation for Cancer Research","keywords":"Neuroblastoma RAS viral oncogene homolog; Cancer research; Myeloid; Haematopoiesis; Biology; Progenitor cell; Stem cell; MAPK/ERK pathway; Immunology; Signal transduction; Cell biology; Mutation; Genetics; KRAS; Gene","score_opus":0.014754856163675209,"score_gpt":0.23780090715364857,"score_spread":0.22304605098997338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083398319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810367,0.0010084402,0.00020947645,0.0010219172,0.000067274756,0.0010155437,0.000014293836,0.00022695548,0.015399393],"genre_scores_gemma":[0.9638247,0.000028951426,0.0012863649,0.0002059872,0.00018470109,0.00020461186,0.000044555178,0.00007733558,0.034142796],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99801743,0.0000739726,0.00037637143,0.000450219,0.0004951868,0.00058681006],"domain_scores_gemma":[0.99859595,0.00014153103,0.00009648938,0.0006327871,0.00020890553,0.0003243337],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00021365791,0.00024085856,0.00036652992,0.00013224492,0.00020372384,0.000067412766,0.00017995185,0.00017043187,0.0009801198],"category_scores_gemma":[0.00003691661,0.00020458797,0.00013365666,0.0004059544,0.00009793214,0.00015463431,0.0001049965,0.0003265369,0.0016765422],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035363206,0.0012158599,0.013541874,0.0006099764,0.00026249888,0.000053595075,0.00086135365,0.000003553405,0.9080536,0.00003443383,0.06426696,0.011060947],"study_design_scores_gemma":[0.010445044,0.00088255695,0.009404515,0.00029874122,0.00076281966,0.0007855627,0.0025925133,0.0014322869,0.96433914,0.00015116968,0.008168225,0.0007374317],"about_ca_topic_score_codex":0.0002715068,"about_ca_topic_score_gemma":0.0000045600636,"teacher_disagreement_score":0.056285545,"about_ca_system_score_codex":0.00014290669,"about_ca_system_score_gemma":0.00026398493,"threshold_uncertainty_score":0.9999331},"labels":[],"label_agreement":null},{"id":"W2083420643","doi":"10.1182/blood-2013-11-540021","title":"Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Laurentian University; Children's Hospital of Eastern Ontario","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Quality of life (healthcare); Intensive care medicine; Gerontology; Pediatrics; Internal medicine; Bone marrow","score_opus":0.06565081009864157,"score_gpt":0.3199981261636594,"score_spread":0.2543473160650178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083420643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911397,0.00072076183,0.0043492615,0.0017371047,0.00013994159,0.0011524749,0.00002925104,0.000041932533,0.000689563],"genre_scores_gemma":[0.99754274,0.000037494192,0.001591596,0.00018675387,0.00010565111,0.000045333847,0.00001452886,0.00003287275,0.00044302558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976943,0.00012427208,0.0008307155,0.00026886657,0.0007782502,0.00030357525],"domain_scores_gemma":[0.9962598,0.0018427063,0.00040426175,0.0008404946,0.0004320299,0.00022070798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096376764,0.00017293898,0.0007363569,0.00010981341,0.000056106128,0.000008370861,0.0002154933,0.00011754886,0.00008671356],"category_scores_gemma":[0.0055066096,0.00010569547,0.0002565705,0.00027137448,0.00015155172,0.000037602847,0.00007197809,0.00021267687,0.000011407673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054196035,0.0070546027,0.76183283,0.004163625,0.009694668,0.00005099413,0.0050909845,0.000071510476,0.11024571,0.008845871,0.040874105,0.046655502],"study_design_scores_gemma":[0.034055214,0.00304577,0.92482483,0.00040288985,0.0013376367,0.00011019334,0.0009950256,0.00033502685,0.020066103,0.0006652575,0.0137376515,0.00042439357],"about_ca_topic_score_codex":0.00021602106,"about_ca_topic_score_gemma":0.000018195957,"teacher_disagreement_score":0.16299202,"about_ca_system_score_codex":0.00003894651,"about_ca_system_score_gemma":0.00058910204,"threshold_uncertainty_score":0.6592324},"labels":[],"label_agreement":null},{"id":"W2084056048","doi":"10.1038/onc.2008.210","title":"Leukemogenic properties of NUP98-PMX1 are linked to NUP98 and homeodomain sequence functions but not to binding properties of PMX1 to serum response factor","year":2008,"lang":"en","type":"article","venue":"Oncogene","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Biology; Homeobox; Cancer research; Haematopoiesis; Myeloid; Myeloid leukemia; Hox gene; Leukemia; Myeloproliferative Disorders; Progenitor cell; Stem cell; Carcinogenesis; Genetics; Molecular biology; Cell biology; Gene; Transcription factor; Immunology","score_opus":0.11775836168935733,"score_gpt":0.3106922652476507,"score_spread":0.19293390355829337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084056048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99227506,0.00045306672,0.000119246426,0.00466705,0.000117677846,0.0019029963,0.00030647684,0.000086244254,0.00007220519],"genre_scores_gemma":[0.9842021,0.00011423462,0.002094426,0.0007642419,0.00015335789,0.00015811749,0.000006503609,0.000083961575,0.012423045],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968333,0.00025411934,0.00069195137,0.0006489712,0.0008890338,0.00068260636],"domain_scores_gemma":[0.997612,0.00012126695,0.00015651126,0.0007944107,0.00060767547,0.0007081359],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00065281417,0.00035903737,0.0008331229,0.0007913747,0.0002468056,0.000022453474,0.00033710536,0.00019579298,0.00008571983],"category_scores_gemma":[0.0018336591,0.0002818784,0.00013952785,0.0010758428,0.00029815277,0.0001499093,0.00039735308,0.0003266655,0.0002671357],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0080291815,0.000121612924,0.004486112,0.00031027466,0.00013638525,0.00012503099,0.004576246,0.00007445702,0.9794745,0.0000021221888,0.001115732,0.0015483873],"study_design_scores_gemma":[0.0016311281,0.0016329476,0.032625034,0.0008771219,0.00006585234,0.00029696262,0.0025329483,0.00006717832,0.9564791,8.574932e-7,0.0034443135,0.00034661015],"about_ca_topic_score_codex":0.0003836053,"about_ca_topic_score_gemma":0.000082413906,"teacher_disagreement_score":0.028138923,"about_ca_system_score_codex":0.0009699883,"about_ca_system_score_gemma":0.0014425354,"threshold_uncertainty_score":0.99996334},"labels":[],"label_agreement":null},{"id":"W2084507055","doi":"10.1038/leu.2008.206","title":"Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia","year":2008,"lang":"en","type":"review","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Université Laval; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Haematopoiesis; Biology; Leukemia; Context (archaeology); Epigenetics; Stem cell; Immunology; Cancer research; In vivo; Cell biology; Genetics; Gene","score_opus":0.09552228716037843,"score_gpt":0.36064900140991857,"score_spread":0.26512671424954015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084507055","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09708697,0.889082,0.00004139616,0.00003395205,0.00017398378,0.0034266158,0.00024238297,0.00023763743,0.009675051],"genre_scores_gemma":[0.0030112022,0.9838259,0.0041916952,0.00039735538,0.001331662,0.0006019427,0.0008343756,0.0005688227,0.005237012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99113303,0.0005423644,0.003317217,0.001966157,0.0015408032,0.0015004006],"domain_scores_gemma":[0.9944383,0.00057762297,0.0011189806,0.0024465774,0.00038136967,0.0010371716],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.00063429755,0.001579279,0.0061584017,0.0019676741,0.00029330116,0.00006217996,0.0016283097,0.0017339407,0.00030877028],"category_scores_gemma":[0.00033913384,0.0014523035,0.0012283942,0.002320122,0.0004590323,0.00026038234,0.00094206,0.0027269863,0.00029544407],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00023136445,0.0009541585,0.0017933956,0.14028488,0.0026050336,0.0046972646,0.0082493685,0.0033199447,0.0626537,0.0010767507,0.10824968,0.66588444],"study_design_scores_gemma":[0.011188816,0.0016308557,0.00030113567,0.13015266,0.0032365166,0.0005675069,0.00054164237,0.0022084275,0.021083755,0.0015931301,0.82204765,0.0054478915],"about_ca_topic_score_codex":0.01270069,"about_ca_topic_score_gemma":0.00058002496,"teacher_disagreement_score":0.713798,"about_ca_system_score_codex":0.014522377,"about_ca_system_score_gemma":0.009792847,"threshold_uncertainty_score":0.99969554},"labels":[],"label_agreement":null},{"id":"W2085527445","doi":"10.1309/ajcpci1ffe2drxiv","title":"Cytoplasmic Expression of Nucleophosmin Accurately Predicts Mutation in the Nucleophosmin Gene in Patients With Acute Myeloid Leukemia and Normal Karyotype","year":2009,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"NPM1; Nucleophosmin; Myeloid leukemia; Exon; Cancer research; Mutation; Gene mutation; Biology; Karyotype; Leukemia; Myeloid; Molecular biology; Gene; Genetics; Chromosome","score_opus":0.02217021340432547,"score_gpt":0.34100537869918907,"score_spread":0.3188351652948636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085527445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99815035,0.000081314414,0.000075174714,0.0011267845,0.000076486394,0.00033675745,0.000009426744,0.0000055385535,0.00013813918],"genre_scores_gemma":[0.9936622,0.00045071132,0.004361724,0.0013791026,0.00010531955,0.000003130301,0.000011607418,0.000018363866,0.000007848783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965227,0.00074403326,0.0015412433,0.00028548212,0.00054598495,0.00036053624],"domain_scores_gemma":[0.9972787,0.00083839265,0.0011099535,0.0003011068,0.0002807691,0.00019106237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018841703,0.00019317368,0.0010309706,0.00035930733,0.00003210753,0.0000104359615,0.0003067632,0.0001591993,0.0000134815145],"category_scores_gemma":[0.0008808117,0.00011850668,0.000109263456,0.00058283476,0.000714436,0.00020259818,0.00005586624,0.0012495916,0.0000039188008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022560965,0.0009509941,0.79410166,0.000021587051,0.0000681904,0.004397524,0.0019626007,0.000086925495,0.005317333,0.000012229418,0.00029899602,0.17022099],"study_design_scores_gemma":[0.008935339,0.01668892,0.9714477,0.00015274587,0.00007924481,0.0009382867,0.00047546925,0.00010747698,0.00093637645,0.0000935091,0.000038952956,0.0001059663],"about_ca_topic_score_codex":0.000029693347,"about_ca_topic_score_gemma":0.000009772032,"teacher_disagreement_score":0.17734604,"about_ca_system_score_codex":0.00013076737,"about_ca_system_score_gemma":0.00063143566,"threshold_uncertainty_score":0.54289234},"labels":[],"label_agreement":null},{"id":"W2086149372","doi":"10.1073/pnas.2034201100","title":"Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?","year":2003,"lang":"en","type":"review","venue":"Proceedings of the National Academy of Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":678,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health; Leukemia and Lymphoma Society","keywords":"Stem cell; Haematopoiesis; Leukemia; Biology; Progenitor cell; Cancer research; Hematopoietic stem cell; Cancer stem cell; Cell biology; Immunology","score_opus":0.06959034464232351,"score_gpt":0.3387884473112493,"score_spread":0.2691981026689258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086149372","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.119474195,0.8720665,0.0000012276303,0.00035136405,0.000040113264,0.0018950297,0.00024966183,0.00002083474,0.00590106],"genre_scores_gemma":[0.06921104,0.9257866,0.00050931796,0.00013971826,0.00012748154,0.00009167308,0.0000029578418,0.000037880556,0.004093282],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99597216,0.000040317318,0.0012340619,0.00056919706,0.0018245758,0.00035968353],"domain_scores_gemma":[0.996318,0.00037829296,0.0024766363,0.00003765446,0.0006660246,0.00012340631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020106542,0.00037386813,0.0015641018,0.00059446384,0.00018073343,0.00003469159,0.00088373857,0.0004495032,0.000044445344],"category_scores_gemma":[0.00013096274,0.00022158993,0.00030844056,0.0014553547,0.0011838307,0.0003547249,0.00033018002,0.0007399743,0.0000056958324],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009582742,0.0014446065,0.0041407505,0.60142255,0.00085304864,0.0000030746703,0.0027219593,0.0000062743857,0.026231512,0.009298665,0.0136268,0.3392925],"study_design_scores_gemma":[0.01355237,0.0040213526,0.0139541095,0.25554493,0.00921239,0.004572195,0.018780757,0.0016815535,0.13006775,0.0041404883,0.5393938,0.0050783316],"about_ca_topic_score_codex":0.0000068404497,"about_ca_topic_score_gemma":5.413327e-8,"teacher_disagreement_score":0.52576697,"about_ca_system_score_codex":0.00045772403,"about_ca_system_score_gemma":0.00094339775,"threshold_uncertainty_score":0.9036175},"labels":[],"label_agreement":null},{"id":"W2086232358","doi":"10.1182/blood-2010-10-265603","title":"Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns","year":2010,"lang":"en","type":"review","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":173,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Transplantation; Medicine; Myeloid leukemia; Oncology; Hematopoietic stem cell transplantation; Clinical trial; Hematopoietic cell; Internal medicine; Leukemia; Risk stratification; Intensive care medicine; Immunology; Stem cell; Haematopoiesis; Biology","score_opus":0.013622806329370279,"score_gpt":0.2795107550460868,"score_spread":0.2658879487167165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086232358","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019198619,0.9906366,0.00026476727,0.000110613306,0.00010185012,0.0050255326,0.0007198159,0.000106983854,0.0011140117],"genre_scores_gemma":[0.00018692961,0.9914825,0.003576535,0.000121298384,0.00036406406,0.0006977422,0.001666476,0.00018611204,0.0017183324],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973124,0.00008247892,0.0005896423,0.00085706805,0.0004612635,0.0006971251],"domain_scores_gemma":[0.9977584,0.0006833062,0.00031868345,0.0006297497,0.00020999812,0.00039987502],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027506167,0.00069108984,0.0021271443,0.0002981562,0.00014967588,0.000054421558,0.0002803773,0.00090985186,0.000033514967],"category_scores_gemma":[0.000070744754,0.0004931428,0.00037608756,0.00027923568,0.00021047733,0.000091445654,0.000052065014,0.0012263962,0.00003886577],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027626194,0.0010076688,0.00007203671,0.2912065,0.0051473365,0.0034049426,0.0015423299,3.271946e-7,0.00067196327,0.00027268557,0.0038346439,0.69007695],"study_design_scores_gemma":[0.01891202,0.0014126117,0.000016718575,0.0111040715,0.022993537,0.0071129766,0.00010672047,0.0000052476807,0.00067678443,0.000010828162,0.9369344,0.00071404764],"about_ca_topic_score_codex":0.000032691696,"about_ca_topic_score_gemma":0.00005294337,"teacher_disagreement_score":0.9330998,"about_ca_system_score_codex":0.00026456465,"about_ca_system_score_gemma":0.0025000288,"threshold_uncertainty_score":0.99975204},"labels":[],"label_agreement":null},{"id":"W2086250536","doi":"10.1038/leu.2013.362","title":"Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia","year":2013,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Deutsche Forschungsgemeinschaft; Stem Cell Network","keywords":"Biology; DNA methylation; Myeloid leukemia; Epigenetics; Genetics; Cancer research; Gene; Gene expression","score_opus":0.01687621822198426,"score_gpt":0.2892591265371202,"score_spread":0.27238290831513595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086250536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850301,0.00022413893,0.00039319717,0.0015126159,0.00011396969,0.0013203239,0.000042550437,0.000107515116,0.011255587],"genre_scores_gemma":[0.98442316,0.0001764839,0.0071589234,0.00062936667,0.00012496235,0.00031632185,0.00022946698,0.00008192636,0.006859386],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973069,0.00010853601,0.00085065566,0.0005176838,0.0004911247,0.0007251285],"domain_scores_gemma":[0.9980739,0.00031846348,0.00019620401,0.00075538707,0.00033291243,0.00032315074],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002934077,0.00030853006,0.0006313743,0.00075730664,0.000104111416,0.000039186885,0.00037430198,0.0002803616,0.0011763555],"category_scores_gemma":[0.00026793045,0.0002965115,0.00019832309,0.0010648983,0.00032958778,0.00033204973,0.00015233946,0.0008090966,0.0016135483],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036813933,0.0002768568,0.057113428,0.00048659262,0.0007373628,0.00047938523,0.0045836954,0.003696535,0.8665927,0.0024205542,0.036128934,0.027115839],"study_design_scores_gemma":[0.010684573,0.0005655795,0.9002017,0.00034566494,0.00041123817,0.0005400881,0.0018142302,0.036030147,0.039838478,0.004534294,0.004205668,0.0008283637],"about_ca_topic_score_codex":0.003743094,"about_ca_topic_score_gemma":0.0001657759,"teacher_disagreement_score":0.84308827,"about_ca_system_score_codex":0.005134841,"about_ca_system_score_gemma":0.0033388045,"threshold_uncertainty_score":0.9999487},"labels":[],"label_agreement":null},{"id":"W2086582033","doi":"10.1016/j.hoc.2010.02.008","title":"Innate Immune Signaling in the Myelodysplastic Syndromes","year":2010,"lang":"en","type":"review","venue":"Hematology/Oncology Clinics of North America","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Terry Fox Research Institute; Canada's Michael Smith Genome Sciences Centre","funders":"Canadian Institutes of Health Research","keywords":"Innate immune system; Myelodysplastic syndromes; Haematopoiesis; Myeloid; Immunology; Immune system; Myeloid leukemia; Biology; Signal transduction; Classical complement pathway; Cancer research; Bone marrow; Complement system; Stem cell; Cell biology","score_opus":0.06166198427961423,"score_gpt":0.406901258497368,"score_spread":0.3452392742177538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086582033","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049970197,0.9897638,0.000032856806,0.0007943762,0.00065557676,0.0024069676,0.000057461068,0.00006866703,0.0012233055],"genre_scores_gemma":[0.0016141974,0.9939878,0.0021775777,0.0008314602,0.0002045231,0.00050711905,0.00043025232,0.00013038039,0.000116691604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927757,0.0012246334,0.0033644626,0.000963258,0.00056886766,0.0011030986],"domain_scores_gemma":[0.9844036,0.011080399,0.0023220775,0.0016511191,0.0003434855,0.00019933745],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0019484038,0.0008078883,0.0075910348,0.0011246022,0.00012445537,0.000014189512,0.0016276466,0.0017934622,0.0001768094],"category_scores_gemma":[0.0043563894,0.0005371957,0.0011171678,0.0019750819,0.002159766,0.00007323248,0.0005036013,0.006821866,0.00060912035],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020082959,0.0007731402,0.0025703479,0.013033956,0.00058807165,0.0035466151,0.00019932834,0.0000022741426,0.0000011853286,0.00019031561,0.0009415416,0.9779524],"study_design_scores_gemma":[0.001330715,0.0012505051,0.00043038686,0.0036127283,0.0016468315,0.0057930844,0.00011795084,0.000038354337,7.194392e-7,0.0000629511,0.9853001,0.0004156717],"about_ca_topic_score_codex":0.00004822443,"about_ca_topic_score_gemma":0.00009943714,"teacher_disagreement_score":0.98435855,"about_ca_system_score_codex":0.0003072878,"about_ca_system_score_gemma":0.0049773995,"threshold_uncertainty_score":0.99970794},"labels":[],"label_agreement":null},{"id":"W2087522964","doi":"10.1159/000226357","title":"Acute Leukemia after Treatment for Ovarian Cancer","year":2009,"lang":"en","type":"article","venue":"Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"","keywords":"Preleukemia; Medicine; Ovarian cancer; Leukemia; Internal medicine; Chemotherapy; Cancer; Oncology; Acute leukemia; Gastroenterology","score_opus":0.03429595517661912,"score_gpt":0.3947645905203956,"score_spread":0.3604686353437765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087522964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87552434,0.0009864088,0.0010448913,0.07549623,0.00054884783,0.0027087498,0.00012675671,0.00017245552,0.043391302],"genre_scores_gemma":[0.933012,0.0008342975,0.011184681,0.010834218,0.0013116588,0.0013154112,0.00008541422,0.000040293133,0.041382045],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989317,0.000032909,0.00017703442,0.00029260246,0.000112691974,0.00045304772],"domain_scores_gemma":[0.99930465,0.00008669426,0.000040765128,0.00027638488,0.000096191194,0.0001952962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000103119004,0.0001471681,0.00038370857,0.00009937372,0.000053534113,0.000008011712,0.00007220572,0.00021887687,0.0006855226],"category_scores_gemma":[0.000028623273,0.00011002215,0.00012300059,0.00011644523,0.000059589293,0.0000381132,0.000018357086,0.00015011705,0.000109216926],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010710622,0.00078930816,0.0026092622,0.000034423858,0.0007802623,0.0017220133,0.00091969327,0.000009655312,0.03570032,0.0012284926,0.09635638,0.8491396],"study_design_scores_gemma":[0.012264406,0.011655219,0.023695176,0.00002464406,0.0004585781,0.0002687922,0.000049859736,0.00056583644,0.007446721,0.00047574853,0.9429197,0.00017535707],"about_ca_topic_score_codex":0.00014755045,"about_ca_topic_score_gemma":0.0001252082,"teacher_disagreement_score":0.8489642,"about_ca_system_score_codex":0.005364605,"about_ca_system_score_gemma":0.0019922068,"threshold_uncertainty_score":0.9984536},"labels":[],"label_agreement":null},{"id":"W2089222839","doi":"10.1016/s0301-472x(02)01078-0","title":"The role of mitochondrial-mediated apoptosis in a myelodysplastic syndrome secondary to congenital deletion of the short arm of chromosome 4","year":2003,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Sick Kids Foundation","keywords":"Apoptosis; Cytopenia; Biology; Fas receptor; Fas ligand; Intrinsic apoptosis; Cancer research; Bone marrow; Myelodysplastic syndromes; FADD; Haematopoiesis; Survivin; Programmed cell death; Caspase; Molecular biology; Cell biology; Immunology; Stem cell; Biochemistry","score_opus":0.009037838272247769,"score_gpt":0.27141361781834406,"score_spread":0.2623757795460963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089222839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942472,0.0025348216,0.000009422453,0.00013670193,0.00025178064,0.00090980256,0.00002298992,0.000009214423,0.0018780822],"genre_scores_gemma":[0.9993924,0.000016880575,0.000307616,0.00004141977,0.000011793537,0.00013419402,0.000011472094,0.00002336841,0.000060876988],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982471,0.00019895291,0.00063235284,0.00023862765,0.00034826418,0.0003347214],"domain_scores_gemma":[0.9988859,0.0003789279,0.0001243178,0.0004160022,0.000093773924,0.00010104716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017731813,0.00016071608,0.00057062466,0.00016695022,0.000048419945,0.0000029534779,0.00024612405,0.00014989763,0.00028777734],"category_scores_gemma":[0.00034031086,0.00010689525,0.000120468714,0.00046315728,0.00045372214,0.00003951994,0.00013136298,0.0002609876,0.000016590311],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059338927,0.0005661733,0.008884616,0.000082159044,0.00014287123,0.000024647727,0.0010158247,0.0000037338689,0.9825572,0.0058242544,0.00017652247,0.00012864739],"study_design_scores_gemma":[0.0014417308,0.0007854271,0.002316842,0.000087207554,0.000023298393,0.00069754163,0.0029161219,0.00006149697,0.99123603,0.00007254152,0.00027792665,0.00008384385],"about_ca_topic_score_codex":0.00008517222,"about_ca_topic_score_gemma":0.00002531709,"teacher_disagreement_score":0.008678861,"about_ca_system_score_codex":0.00019707133,"about_ca_system_score_gemma":0.00033381826,"threshold_uncertainty_score":0.43590617},"labels":[],"label_agreement":null},{"id":"W2089425361","doi":"10.1182/blood-2012-12-476200","title":"Erk1 and Erk2 are required for maintenance of hematopoietic stem cells and adult hematopoiesis","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Haematopoiesis; Stem cell; Biology; Immunology; Cell biology","score_opus":0.015457546402777151,"score_gpt":0.2494663806990245,"score_spread":0.23400883429624733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089425361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950811,0.00076694635,0.00014097175,0.0023642655,0.000023085684,0.0011551286,0.000034393954,0.000035567846,0.0003985367],"genre_scores_gemma":[0.99378794,0.00020499286,0.0034699072,0.00025809417,0.0000508436,0.00015806334,0.000003988833,0.000035580193,0.0020306066],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988157,0.000025258616,0.00029451965,0.00030959304,0.00021531046,0.0003396269],"domain_scores_gemma":[0.99879956,0.00018216894,0.00012243296,0.0003560978,0.0003422819,0.00019745958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016457785,0.00015393418,0.00045092832,0.0000845339,0.00005221617,0.000022185663,0.00009040044,0.00011124502,0.00003663848],"category_scores_gemma":[0.00011768629,0.000121633806,0.000059706144,0.00011905754,0.00018975932,0.00009102509,0.000093976094,0.00011670093,0.000015540189],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087626633,0.0018607025,0.059059173,0.020463644,0.0012518386,0.00024701332,0.0053086183,8.492341e-7,0.8065016,0.009475124,0.08632649,0.008628632],"study_design_scores_gemma":[0.022988493,0.0012322488,0.016811991,0.0014372234,0.00062636763,0.00087020884,0.007011045,0.00079654675,0.94366956,0.0020173746,0.001988434,0.00055052736],"about_ca_topic_score_codex":0.00004878236,"about_ca_topic_score_gemma":0.0000066570783,"teacher_disagreement_score":0.13716789,"about_ca_system_score_codex":0.00002745987,"about_ca_system_score_gemma":0.00006736893,"threshold_uncertainty_score":0.49600828},"labels":[],"label_agreement":null},{"id":"W2089532685","doi":"10.1038/leu.2014.44","title":"BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies","year":2014,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":197,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; U.S. Public Health Service","keywords":"Azacitidine; Myeloid; Gene silencing; Cancer research; RNA interference; Hypomethylating agent; Bcl-2 family; Biology; Gene expression; RNA; Gene; DNA methylation; Apoptosis; Programmed cell death; Genetics","score_opus":0.01767716885988376,"score_gpt":0.2858078276040187,"score_spread":0.26813065874413494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089532685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964461,0.0004264165,0.00007290754,0.00043490206,0.000055317934,0.00076201686,0.000007719065,0.00005579336,0.0017388549],"genre_scores_gemma":[0.99488854,0.00013688994,0.0026774383,0.0005424097,0.000100719175,0.000048019105,0.000005841688,0.0000528721,0.0015472504],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997647,0.00030059068,0.0005335921,0.00045933013,0.00047669036,0.0005827944],"domain_scores_gemma":[0.99850523,0.00043329474,0.00014246709,0.00053069665,0.00015928144,0.00022902053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015563515,0.00025508372,0.0006449222,0.0004144365,0.000072793795,0.00002164007,0.00016127391,0.00022024596,0.000019239324],"category_scores_gemma":[0.0019801455,0.00022657703,0.000076772754,0.00039119215,0.0002585352,0.00013491909,0.00019650548,0.0004418538,0.000066682915],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005090335,0.000053735897,0.043274347,0.00046522517,0.000027358687,0.00081280177,0.0012358198,0.00001754422,0.9345032,0.00015578006,0.00056778116,0.013796067],"study_design_scores_gemma":[0.0064244117,0.0016367735,0.6833847,0.0011269831,0.00004531045,0.0006219596,0.00077633094,0.0074928487,0.29221025,0.0002818502,0.0055676624,0.0004308757],"about_ca_topic_score_codex":0.0010327352,"about_ca_topic_score_gemma":0.00009114476,"teacher_disagreement_score":0.6422929,"about_ca_system_score_codex":0.0007862615,"about_ca_system_score_gemma":0.0010038444,"threshold_uncertainty_score":0.9239543},"labels":[],"label_agreement":null},{"id":"W2089621615","doi":"10.1182/blood-2012-02-411397","title":"Structural basis of CBP/p300 recruitment in leukemia induction by E2A-PBX1","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Queen's University","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Queen's University","keywords":"Transcription factor; Gene silencing; Biology; Cell biology; Coactivator; Molecular biology; Genetics; Gene","score_opus":0.058289341079211625,"score_gpt":0.3263323527270245,"score_spread":0.26804301164781286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089621615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955896,0.0008440555,0.0000045187367,0.0004665657,0.00013701206,0.00064782845,0.0000166722,0.000029419187,0.002264312],"genre_scores_gemma":[0.99760544,0.00008658838,0.000922926,0.00010664307,0.00026998398,0.0000677899,0.000057557158,0.00002576205,0.0008572961],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985508,0.00008296412,0.00032120605,0.00019999765,0.0004009333,0.00044413688],"domain_scores_gemma":[0.99927676,0.000052126717,0.00008375808,0.00033038572,0.000068408575,0.00018857927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037608188,0.000142291,0.0003006074,0.00019539538,0.000030901316,0.0000062420104,0.0001104832,0.00016018412,0.00032233575],"category_scores_gemma":[0.00014258602,0.00011958141,0.000063959385,0.00036916067,0.000072474584,0.00015953455,0.00007078401,0.00038094184,0.000044615863],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003466818,0.000724736,0.6083323,0.00029843565,0.00028958186,0.000032565702,0.0016983513,0.0000033894025,0.33934873,0.00020833888,0.0127833765,0.03593352],"study_design_scores_gemma":[0.008579766,0.00042780148,0.43388516,0.00013033512,0.00019885473,0.00019700728,0.00044418062,0.00008292312,0.5507109,0.00004956346,0.005051218,0.00024229912],"about_ca_topic_score_codex":0.00045643363,"about_ca_topic_score_gemma":0.000014167598,"teacher_disagreement_score":0.21136215,"about_ca_system_score_codex":0.00058571505,"about_ca_system_score_gemma":0.00024227817,"threshold_uncertainty_score":0.48763886},"labels":[],"label_agreement":null},{"id":"W2089904379","doi":"10.1111/j.1939-165x.2011.00363.x","title":"Myeloperoxidase‐positive acute megakaryoblastic leukemia in a dog","year":2011,"lang":"en","type":"article","venue":"Veterinary Clinical Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Edinburgh","keywords":"Acute megakaryoblastic leukemia; Pathology; Bone marrow; Immunophenotyping; Medicine; Myeloperoxidase; Spleen; Megakaryocyte; Immunohistochemistry; Anemia; Leukemia; Haematopoiesis; Biology; Internal medicine; Immunology; Antigen; Stem cell","score_opus":0.11485156877809494,"score_gpt":0.39957622422356287,"score_spread":0.28472465544546793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089904379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98359066,0.00009349427,0.00032177693,0.00043906565,0.00040853416,0.0006223818,0.000027602522,0.00011528626,0.014381202],"genre_scores_gemma":[0.98832077,0.0003243581,0.0076170787,0.002284881,0.0002527327,0.000095679185,0.000043983415,0.00006281575,0.0009976992],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99616754,0.0007932483,0.0010920683,0.0008859651,0.0002498478,0.0008113007],"domain_scores_gemma":[0.99780506,0.00073404814,0.0001411596,0.00076546834,0.00012764783,0.00042661862],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012185731,0.00031840423,0.0009608916,0.00034194434,0.00006271101,0.0000088708475,0.0003673802,0.00058959884,0.0006568919],"category_scores_gemma":[0.0008824754,0.00027336378,0.00027005962,0.00043723223,0.0007945555,0.00013870394,0.00051028957,0.001494409,0.0010806044],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03001502,0.0032942062,0.24327126,0.00031795766,0.0010090332,0.5071824,0.004233436,0.00000513737,0.14262056,0.001404613,0.006123873,0.060522486],"study_design_scores_gemma":[0.0072286436,0.017676797,0.9603621,0.00017426831,0.00016645448,0.010042721,0.00013036543,0.0004290724,0.0010709136,0.00063710514,0.0016614243,0.00042013504],"about_ca_topic_score_codex":0.00009190832,"about_ca_topic_score_gemma":0.000010313307,"teacher_disagreement_score":0.71709085,"about_ca_system_score_codex":0.0006279936,"about_ca_system_score_gemma":0.00061962,"threshold_uncertainty_score":0.99997187},"labels":[],"label_agreement":null},{"id":"W2090022523","doi":"10.1159/000205898","title":"Genetically Determined Regulators Acting on the Blast Cells of Acute Myeloblastic Leukemia","year":2009,"lang":"en","type":"review","venue":"Acta Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Clonogenic assay; Precursor cell; Progenitor cell; Stem cell; Acute myeloblastic leukemia; Biology; Cell biology; Cell culture; Cancer research; Leukemia; Cell; Immunology; Genetics","score_opus":0.05027009700595245,"score_gpt":0.33488346981316824,"score_spread":0.28461337280721577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090022523","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016330251,0.9543522,0.00007116642,0.0016636747,0.00046703147,0.007927916,0.00018644214,0.00044961774,0.018551694],"genre_scores_gemma":[0.013364785,0.9833548,0.0012013179,0.00042481683,0.00021894375,0.00014590663,0.00006879959,0.00013659308,0.0010840148],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949216,0.00055902195,0.0015242965,0.0009898598,0.0009837035,0.0010214762],"domain_scores_gemma":[0.9938879,0.0025841887,0.0010211027,0.0019274822,0.00021304343,0.0003662547],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007093483,0.00096201414,0.004194657,0.00041203055,0.00020355423,0.00005633807,0.0012949414,0.0010873728,0.00038988626],"category_scores_gemma":[0.0011579826,0.0005122444,0.001134257,0.00088391843,0.00054579455,0.00005094095,0.00041332422,0.0019655207,0.00037573391],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003874077,0.00023385602,0.0000036352542,0.012505596,0.0020204803,0.002460532,0.000100527766,0.0000015877205,0.0009134747,0.0007612606,0.017664336,0.9629473],"study_design_scores_gemma":[0.0010133375,0.0023232035,0.000060733044,0.026767835,0.0062405104,0.0037064773,0.000055681066,0.00018972585,0.0032574628,0.0001378756,0.95525146,0.0009956852],"about_ca_topic_score_codex":0.000007749453,"about_ca_topic_score_gemma":0.000001498607,"teacher_disagreement_score":0.9619516,"about_ca_system_score_codex":0.0008208773,"about_ca_system_score_gemma":0.0017993737,"threshold_uncertainty_score":0.9997329},"labels":[],"label_agreement":null},{"id":"W2090075310","doi":"10.1016/j.arcmed.2003.08.007","title":"Human acute myeloid leukemia stem cells","year":2003,"lang":"en","type":"review","venue":"Archives of Medical Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Myeloid leukemia; clone (Java method); Leukemia; Myeloid; Stem cell; Cancer research; Biology; Population; Somatic evolution in cancer; Immunology; Progenitor cell; Medicine; Cancer; Genetics; Gene","score_opus":0.11847039099527933,"score_gpt":0.45396159408414694,"score_spread":0.3354912030888676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090075310","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013054589,0.95350784,0.00006335074,0.0004888371,0.0001869591,0.0028305608,0.000109069566,0.00008053803,0.042602327],"genre_scores_gemma":[0.000022522896,0.95973885,0.0005999487,0.00010623004,0.00061370694,0.00035190245,0.000170724,0.0002685232,0.038127564],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98008114,0.0036154476,0.0021141646,0.0015563614,0.010178355,0.0024545353],"domain_scores_gemma":[0.98804593,0.0058405763,0.00039395416,0.0025036107,0.00035280458,0.002863097],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0078951195,0.0008612079,0.0046342984,0.0026060597,0.0003782028,0.00007444605,0.0034224081,0.0015506222,0.0026428797],"category_scores_gemma":[0.00117679,0.00063252443,0.0015608022,0.0019982324,0.003773749,0.00008014178,0.0021680715,0.010561487,0.0010853024],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007143058,0.00025004632,0.0000027063102,0.033506624,0.0011691299,0.001988904,0.0001828738,5.6968872e-8,0.00012870312,0.0017928698,0.028258126,0.93264854],"study_design_scores_gemma":[0.0016699666,0.000875782,0.0000042188412,0.030993205,0.000626571,0.0005549613,0.00012416845,0.00004155248,0.00022274966,0.00027974194,0.9641754,0.0004317015],"about_ca_topic_score_codex":0.0002509474,"about_ca_topic_score_gemma":0.000013079649,"teacher_disagreement_score":0.93591726,"about_ca_system_score_codex":0.0011645033,"about_ca_system_score_gemma":0.019297738,"threshold_uncertainty_score":0.99974555},"labels":[],"label_agreement":null},{"id":"W2090218255","doi":"10.3109/10428194.2013.878934","title":"Initial transfusion intensity predicts survival in myelodysplastic syndrome","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Aplastic Anemia and Myelodysplasia Association of Canada; Celgene","keywords":"Medicine; Myelodysplastic syndromes; International Prognostic Scoring System; Internal medicine; Blood transfusion; Overall survival; Myeloid leukemia; Myeloid; Leukemia; Gastroenterology; Surgery; Bone marrow","score_opus":0.0135262473141188,"score_gpt":0.2563653017870442,"score_spread":0.2428390544729254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090218255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98500264,0.00035219462,0.0007471733,0.00049637875,0.00088635506,0.0011356138,0.000041596475,0.00043587235,0.010902179],"genre_scores_gemma":[0.9949294,0.0006402493,0.00062715856,0.0014654137,0.0006318063,0.00013736426,0.00019483312,0.00020048936,0.0011733094],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9932367,0.00044648707,0.0013219111,0.0017072051,0.0014300866,0.0018575765],"domain_scores_gemma":[0.99610484,0.0009037435,0.00023596821,0.0012102626,0.00033321904,0.0012119841],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001459027,0.0010209652,0.0018693333,0.0010084787,0.00040600327,0.00015947696,0.0005915351,0.0010239355,0.00017937954],"category_scores_gemma":[0.00089594064,0.00095424353,0.00034399217,0.0013272587,0.0008057126,0.0005054229,0.00044449032,0.0006348457,0.00028299706],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024774136,0.0019741978,0.23780346,0.0038058225,0.0012292356,0.020223074,0.0062379274,0.00047194934,0.042620435,0.006059283,0.008569815,0.64623064],"study_design_scores_gemma":[0.050094455,0.0020614213,0.86995876,0.0011784816,0.00037670284,0.012224981,0.00074373273,0.044676263,0.0046739164,0.0008832943,0.01162589,0.0015020941],"about_ca_topic_score_codex":0.0035576692,"about_ca_topic_score_gemma":0.00036479393,"teacher_disagreement_score":0.64472854,"about_ca_system_score_codex":0.010335633,"about_ca_system_score_gemma":0.004550032,"threshold_uncertainty_score":0.9992908},"labels":[],"label_agreement":null},{"id":"W2090715900","doi":"10.1016/j.exphem.2011.04.001","title":"Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells","year":2011,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celator Pharmaceuticals (Canada); Terry Fox Research Institute","funders":"","keywords":"Cytarabine; Daunorubicin; Myeloid leukemia; Leukemia; Mitoxantrone; Pharmacology; Medicine; CD34; Bone marrow; Chemistry; Cancer research; Stem cell; Immunology; Internal medicine; Chemotherapy; Biology","score_opus":0.019823470262164668,"score_gpt":0.312533301045015,"score_spread":0.2927098307828503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090715900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950193,0.0007571508,0.0016150792,0.00003984298,0.00012185072,0.001837537,0.00003671341,0.00003742715,0.00053505437],"genre_scores_gemma":[0.9913453,0.000014664416,0.0080457255,0.00006536465,0.000047278492,0.0002756725,0.00004757925,0.000035979458,0.00012242823],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979818,0.00010401654,0.00069462747,0.00047293317,0.00029903438,0.00044762815],"domain_scores_gemma":[0.9987908,0.0001554096,0.00026126314,0.00029498085,0.00025963056,0.00023792125],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017808797,0.0002831559,0.00094719767,0.00028234196,0.00009271592,0.0000061440846,0.00017642346,0.00018873825,0.0001615144],"category_scores_gemma":[0.00008370829,0.0002635077,0.00011885481,0.00032933315,0.00035934968,0.000121045465,0.00013627861,0.00017340235,0.00001608371],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032038456,0.00044282922,0.0017318159,0.00025495404,0.00035423593,0.000055961915,0.005721618,0.000009513114,0.98491615,0.0030091633,0.0002356229,0.00006427674],"study_design_scores_gemma":[0.0023779725,0.0032261424,0.0013257441,0.000087718334,0.00015794714,0.0004887745,0.0012568597,0.001247639,0.98950917,0.000110491426,0.000008704234,0.00020283798],"about_ca_topic_score_codex":0.00039523048,"about_ca_topic_score_gemma":0.000018388659,"teacher_disagreement_score":0.006430646,"about_ca_system_score_codex":0.00032865177,"about_ca_system_score_gemma":0.00037840797,"threshold_uncertainty_score":0.9999817},"labels":[],"label_agreement":null},{"id":"W2090747590","doi":"10.1038/bmt.2009.253","title":"Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes","year":2009,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; U.S. Public Health Service; National Institutes of Health","keywords":"Cytogenetics; Myelodysplastic syndromes; Medicine; Internal medicine; Transplantation; Oncology; Cohort; Retrospective cohort study; Bone marrow; Chromosome; Biology","score_opus":0.02160825606223817,"score_gpt":0.276378561082001,"score_spread":0.25477030501976283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090747590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97460353,0.00003721301,0.022027574,0.00010659524,0.00005736122,0.0029106836,0.00012068461,0.00005799646,0.00007833279],"genre_scores_gemma":[0.9878742,0.00021558929,0.010301686,0.0000431201,0.000044057284,0.00010764352,0.0013363172,0.000039429702,0.000037938153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980045,0.00007160031,0.00055802317,0.0004022989,0.0006423581,0.00032122392],"domain_scores_gemma":[0.99888915,0.00019083134,0.00017337671,0.00024137727,0.00039024395,0.00011503078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019330776,0.00024422441,0.00038578123,0.00032854758,0.00011489509,0.000027858709,0.0000953347,0.00009825142,0.00002398493],"category_scores_gemma":[0.000019515053,0.00021408904,0.000075033044,0.00033236336,0.000044130455,0.0002070952,0.0000032335042,0.00015434231,0.0000061736796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05497312,0.009577003,0.73325175,0.0045396294,0.00075636886,0.00038531923,0.0185729,0.0014249544,0.1597707,0.00033511067,0.00017100651,0.016242111],"study_design_scores_gemma":[0.03342388,0.0069248294,0.9380003,0.0005101202,0.0007518863,0.000083224164,0.0005024043,0.0011370688,0.018256294,0.000029180641,0.00003203211,0.00034878813],"about_ca_topic_score_codex":0.000016787802,"about_ca_topic_score_gemma":0.000019900119,"teacher_disagreement_score":0.20474851,"about_ca_system_score_codex":0.000118492935,"about_ca_system_score_gemma":0.00007632765,"threshold_uncertainty_score":0.8730298},"labels":[],"label_agreement":null},{"id":"W2091036980","doi":"10.1158/1535-7163.targ-11-b72","title":"Abstract B72: Assessing specific biological mechanisms of drug resistance in adult and pediatric AML.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Clofarabine; Gemtuzumab ozogamicin; Azacitidine; Daunorubicin; Decitabine; DNA damage; Cancer research; Flow cytometry; Apoptosis; Cytarabine; Pharmacology; Myeloid leukemia; Medicine; Biology; Leukemia; Immunology; Stem cell; CD34; CD33; DNA; DNA methylation; Biochemistry; Cell biology","score_opus":0.05734255629292785,"score_gpt":0.3173960237299353,"score_spread":0.26005346743700747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091036980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98662263,0.0077389525,0.0025724526,0.00045035325,0.00007201601,0.00032137014,0.000007953669,0.000027328106,0.0021869144],"genre_scores_gemma":[0.9840544,0.0054759886,0.009688743,0.0005905656,0.000049802373,0.000025739586,0.0000046729688,0.00003338422,0.00007673915],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986414,0.000073124174,0.00032227207,0.0003303007,0.00030139525,0.000331512],"domain_scores_gemma":[0.99927783,0.0000503565,0.00011433192,0.0003075882,0.00015478156,0.00009509411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027713354,0.00017230988,0.00031981157,0.00017271435,0.000033171873,0.000014803864,0.00015022942,0.00014269682,0.000102672624],"category_scores_gemma":[0.000019785379,0.00014332232,0.00006437713,0.00036918014,0.00012917758,0.000054416916,0.000056217246,0.00038604124,0.0000042574256],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012560398,0.0005080802,0.06822191,0.00056553073,0.00021574825,0.0009827393,0.0028095914,0.0000035611483,0.8976497,0.010710649,0.0001721083,0.016904337],"study_design_scores_gemma":[0.0053449296,0.00023689975,0.50427556,0.00036365812,0.00020374669,0.000026535188,0.00094540865,0.00013684583,0.47212493,0.013969617,0.0017305284,0.00064132013],"about_ca_topic_score_codex":0.000107867934,"about_ca_topic_score_gemma":0.000044892335,"teacher_disagreement_score":0.43605366,"about_ca_system_score_codex":0.00017564256,"about_ca_system_score_gemma":0.00019498181,"threshold_uncertainty_score":0.58445144},"labels":[],"label_agreement":null},{"id":"W2091123759","doi":"10.1371/journal.pone.0067537","title":"A Meta-Analysis of the Relationship between Cigarette Smoking and Incidence of Myelodysplastic Syndromes","year":2013,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Science Fund for Distinguished Young Scholars of Zhejiang Province; National Natural Science Foundation of China","keywords":"Medicine; Publication bias; Meta-analysis; Odds ratio; Incidence (geometry); Funnel plot; Confidence interval; Internal medicine; Observational study; Myelodysplastic syndromes; Epidemiology; Demography","score_opus":0.407420143651914,"score_gpt":0.3786482839591915,"score_spread":0.0287718596927225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091123759","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025758475,0.97241044,0.00001385403,0.00018744307,0.000006591274,0.0013303729,0.00015267255,0.000014403131,0.00012575704],"genre_scores_gemma":[0.09452239,0.9029777,0.00048914336,0.00002215579,0.00005151459,0.00021826912,0.000102818354,0.000059800634,0.001556218],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9965926,0.00045538959,0.0010624733,0.00039315183,0.0012507688,0.00024562312],"domain_scores_gemma":[0.991981,0.005664933,0.00089768297,0.0010344692,0.0002963751,0.0001255355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009101215,0.00031124632,0.0056845094,0.0008327418,0.00006410742,0.000015018755,0.0004165151,0.00033690422,0.00028257514],"category_scores_gemma":[0.0034147087,0.00017719467,0.0013958946,0.0022018945,0.0002984174,0.00007011771,0.0003368922,0.0009854784,0.000009432747],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000053415674,0.00016657717,0.06962669,0.04735144,0.87572116,0.000011288084,0.00013447295,7.996593e-7,0.0000069190655,0.0001444946,0.000061347215,0.006769447],"study_design_scores_gemma":[0.00012236487,0.000060395945,0.029661162,0.006010357,0.9633394,0.000009584284,0.000007997129,0.000028047989,0.000018309496,0.0000388581,0.0005611824,0.0001423574],"about_ca_topic_score_codex":0.00008984583,"about_ca_topic_score_gemma":0.000005803657,"teacher_disagreement_score":0.0876182,"about_ca_system_score_codex":0.00017755436,"about_ca_system_score_gemma":0.00046522592,"threshold_uncertainty_score":0.7225789},"labels":[],"label_agreement":null},{"id":"W2091231814","doi":"10.1016/j.leukres.2012.02.022","title":"Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML","year":2012,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Clofarabine; Gemtuzumab ozogamicin; Decitabine; Cytarabine; Myeloid leukemia; Daunorubicin; Azacitidine; In vitro; Leukemia; Cancer research; Medicine; Pharmacology; Biology; Immunology; Stem cell; CD33; Biochemistry; DNA methylation; Cell biology; CD34","score_opus":0.1375267582072328,"score_gpt":0.40075598130245965,"score_spread":0.26322922309522684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091231814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877797,0.00029631058,0.000074229094,0.0008567909,0.00004306367,0.0010161239,0.00000951533,0.00006550089,0.009858761],"genre_scores_gemma":[0.99506235,0.000021897757,0.002100398,0.0003887137,0.00020399147,0.00029513813,0.00005545533,0.00010083087,0.0017712504],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.993154,0.00093269866,0.0005268009,0.0006265693,0.0023781997,0.0023817667],"domain_scores_gemma":[0.99699426,0.001165074,0.00007410031,0.00066081574,0.0003714572,0.0007342998],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007826089,0.00026302316,0.00052333635,0.0015163505,0.0002276952,0.00018062675,0.0004850792,0.0003118773,0.00013260584],"category_scores_gemma":[0.0033610372,0.00023968909,0.00006593697,0.0040364657,0.00019874577,0.00058514037,0.00034895257,0.0025212453,0.00021968648],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004165427,0.00071080093,0.12820075,0.0003457277,0.000103161176,0.002751826,0.004883008,0.00016905737,0.84901863,0.0003198719,0.0047613406,0.0045703733],"study_design_scores_gemma":[0.01101301,0.0004758827,0.48908123,0.0032964388,0.000025254969,0.000055124696,0.0043649534,0.0030339474,0.48547307,0.00020634894,0.0022076964,0.0007670261],"about_ca_topic_score_codex":0.0005744304,"about_ca_topic_score_gemma":0.000522305,"teacher_disagreement_score":0.36354557,"about_ca_system_score_codex":0.011941011,"about_ca_system_score_gemma":0.0026321686,"threshold_uncertainty_score":0.99978},"labels":[],"label_agreement":null},{"id":"W2091962088","doi":"10.1038/leu.2012.184","title":"Immunoglobulin gamma heavy chain gene with somatic hypermutation is frequently expressed in acute myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; University of British Columbia; National Natural Science Foundation of China","keywords":"Somatic hypermutation; Immunoglobulin heavy chain; Myeloid leukemia; Myeloid; Biology; Minimal residual disease; Antibody; Immunoglobulin gene; Haematopoiesis; Cancer research; Immunology; Leukemia; B cell; Stem cell; Genetics","score_opus":0.017394203566630566,"score_gpt":0.2744746978745839,"score_spread":0.2570804943079533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091962088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915604,0.0011315035,0.00074552273,0.001586071,0.00017555275,0.0013959453,0.000054059015,0.00022941023,0.0031215139],"genre_scores_gemma":[0.98176366,0.0003486833,0.010087612,0.0020984814,0.00051799696,0.00032582722,0.00028132612,0.00016552121,0.004410901],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955848,0.00019148822,0.0008310557,0.00070857606,0.001097265,0.0015868407],"domain_scores_gemma":[0.9976254,0.00015979137,0.0002455097,0.0011675651,0.00020338818,0.00059832615],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078924553,0.00059447624,0.0008850395,0.00054341747,0.0002478016,0.00006509237,0.00044661597,0.00043914097,0.00047197295],"category_scores_gemma":[0.00014472722,0.0004998983,0.00017478163,0.0010738531,0.00023674747,0.0006876008,0.00023308345,0.0011351418,0.0005967547],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004417957,0.000575029,0.0656286,0.0007048853,0.0010035917,0.0012898117,0.015435572,0.0005004387,0.8814288,0.0004109224,0.01197711,0.016627282],"study_design_scores_gemma":[0.026497712,0.0017741973,0.20720412,0.0012220832,0.0007014674,0.002421354,0.0015504858,0.012280631,0.7316487,0.00048313927,0.012304422,0.0019116807],"about_ca_topic_score_codex":0.001083518,"about_ca_topic_score_gemma":0.000039019622,"teacher_disagreement_score":0.1497801,"about_ca_system_score_codex":0.008308341,"about_ca_system_score_gemma":0.0023903563,"threshold_uncertainty_score":0.99974525},"labels":[],"label_agreement":null},{"id":"W2092029921","doi":"10.1002/pbc.23201","title":"Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: A report from the Children's Oncology Group","year":2011,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"National Cancer Institute","keywords":"Medicine; Myeloid leukemia; Myeloid sarcoma; Leukemia; Cerebrospinal fluid; Internal medicine; Myeloid; Chemotherapy; Oncology; Gastroenterology; Pathology","score_opus":0.017892080948448942,"score_gpt":0.2711076529539062,"score_spread":0.25321557200545725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092029921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924229,0.004255688,0.000020154692,0.0003129152,0.0003242755,0.0014818271,0.00047149294,0.00009594647,0.0006148217],"genre_scores_gemma":[0.9908436,0.0034275681,0.002105012,0.0003541033,0.0024389678,0.00024515847,0.00022773216,0.00011851135,0.00023934121],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99595237,0.00014803803,0.001077196,0.0009479799,0.0010121788,0.0008622456],"domain_scores_gemma":[0.9971513,0.0003600899,0.000627875,0.0009768445,0.00042717202,0.00045668962],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048006515,0.0005261798,0.0010786525,0.0003148706,0.00020314782,0.000027380707,0.0005088053,0.00035803663,0.0004512053],"category_scores_gemma":[0.0002448869,0.00033945753,0.00020190494,0.0010317044,0.00035824472,0.00024636782,0.00043136592,0.0010694121,0.000025104864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010677822,0.0005337212,0.9923829,0.00009470618,0.00074394845,0.00060147967,0.0009744935,4.1732545e-7,0.00007187951,0.00000985942,0.002102157,0.0014166671],"study_design_scores_gemma":[0.009272905,0.0014632482,0.98245263,0.000016392754,0.005417678,0.00039426214,0.000097413744,0.000005405056,0.00014296139,0.000023002107,0.00032433972,0.00038975503],"about_ca_topic_score_codex":0.009660447,"about_ca_topic_score_gemma":0.0004000331,"teacher_disagreement_score":0.009930251,"about_ca_system_score_codex":0.00049304427,"about_ca_system_score_gemma":0.001681488,"threshold_uncertainty_score":0.99990577},"labels":[],"label_agreement":null},{"id":"W2092260323","doi":"10.1007/s12308-011-0088-6","title":"The AML–MDS interface—leukemic transformation in myelodysplastic syndromes","year":2011,"lang":"en","type":"article","venue":"Journal of Hematopathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Myelodysplastic syndromes; Myeloid leukemia; Immunophenotyping; Bone marrow; Oncology; Medicine; Hematology; Myeloid; Disease; Internal medicine; Cancer research; Immunology; Bioinformatics; Biology; Flow cytometry","score_opus":0.03536541230068184,"score_gpt":0.30868937521243855,"score_spread":0.2733239629117567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092260323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99240065,0.0008899653,0.001988837,0.0012297636,0.0002907615,0.00019325688,9.635011e-7,0.000011507516,0.0029943003],"genre_scores_gemma":[0.9982135,0.00052085414,0.0008280179,0.00011534557,0.00006536758,0.000006945971,6.45699e-7,0.000018027307,0.00023124806],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983152,0.00016677719,0.00079021516,0.000105760475,0.00027639524,0.0003456172],"domain_scores_gemma":[0.9989895,0.00024127055,0.00025801003,0.00020584564,0.00018639522,0.00011893805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001318904,0.00012871058,0.00042760037,0.00036806022,0.000061852435,0.0000121339135,0.00025985652,0.000133508,0.000103503284],"category_scores_gemma":[0.00039566346,0.00007755336,0.00012036156,0.00023348429,0.000191945,0.00018832272,0.000038470636,0.00082368264,0.00007381624],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02467721,0.0027273097,0.25362232,0.002324404,0.0010639724,0.05265932,0.114530735,0.00015731218,0.40371373,0.030154997,0.013274635,0.10109404],"study_design_scores_gemma":[0.015870241,0.006986324,0.50830615,0.0014480954,0.00037461665,0.37356013,0.011377048,0.001715107,0.062260587,0.010511174,0.007016535,0.0005740053],"about_ca_topic_score_codex":0.000009783516,"about_ca_topic_score_gemma":0.000010400168,"teacher_disagreement_score":0.34145314,"about_ca_system_score_codex":0.00034189443,"about_ca_system_score_gemma":0.00035260577,"threshold_uncertainty_score":0.3578537},"labels":[],"label_agreement":null},{"id":"W2092321494","doi":"10.1155/2015/594970","title":"Extramedullary Hematopoiesis in a Sentinel Lymph Node as an Early Sign of Chronic Myelomonocytic Leukemia","year":2015,"lang":"en","type":"article","venue":"Case Reports in Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Monocytosis; Bone marrow; Chronic myelomonocytic leukemia; Pathology; Extramedullary hematopoiesis; Lymph node; Lymph node biopsy; Haematopoiesis; Myeloproliferative neoplasm; Leukemia; Malignancy; Biopsy; Myelodysplastic syndromes; Lymph; Internal medicine; Myelofibrosis; Stem cell","score_opus":0.03429523764693277,"score_gpt":0.32756650172442736,"score_spread":0.2932712640774946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092321494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944776,0.0013811933,0.000117130374,0.00015622862,0.00018472146,0.0005578489,0.0000031953293,0.000059492115,0.0030625486],"genre_scores_gemma":[0.9979432,0.00008285973,0.0010073683,0.00018736866,0.0001323604,0.00010548517,0.00003064703,0.00006387333,0.00044683012],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9966006,0.00034899297,0.0011743878,0.00073823193,0.00042224833,0.00071553537],"domain_scores_gemma":[0.9976626,0.00015960238,0.0003319741,0.0011998712,0.00023527519,0.00041067618],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019530405,0.0002812465,0.00088669924,0.0007309579,0.000028140938,0.000012606525,0.000112357586,0.00046443375,0.00007554821],"category_scores_gemma":[0.0012554127,0.0002735051,0.0001044252,0.0006780698,0.00041068444,0.00016419939,0.0001883705,0.0005952007,0.0000337421],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002444223,0.00026024831,0.1321916,0.0002305092,0.000023537887,0.8558893,0.001401601,0.00010232502,0.006618626,0.00006863475,0.00012059563,0.0028485598],"study_design_scores_gemma":[0.0051360982,0.0005163564,0.062394068,0.00031271804,0.000082636325,0.9180464,0.001725753,0.0036140096,0.006226741,0.0014252004,0.000142116,0.00037788425],"about_ca_topic_score_codex":0.0016604776,"about_ca_topic_score_gemma":0.000096976655,"teacher_disagreement_score":0.06979753,"about_ca_system_score_codex":0.0034345943,"about_ca_system_score_gemma":0.004683043,"threshold_uncertainty_score":0.9999717},"labels":[],"label_agreement":null},{"id":"W2092757645","doi":"10.1016/j.bbmt.2009.12.345","title":"A Prospective Comparison Of Outcomes And Resource Utilization In Patients With Myeloid Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation (AlloHCT) Using Myeloablative Or Reduced Intensity Conditioning","year":2010,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Univariate analysis; Transplantation; Myeloid leukemia; Regimen; Hematopoietic cell; Prospective cohort study; Myeloid; Oncology; Odds ratio; Multivariate analysis; Haematopoiesis; Stem cell","score_opus":0.02235951815868517,"score_gpt":0.28912935439174475,"score_spread":0.2667698362330596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092757645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981676,0.000062596264,0.0009142373,0.00004648449,0.000023578226,0.00065818505,0.000056606194,0.000014888139,0.000055872788],"genre_scores_gemma":[0.99652076,0.000111771944,0.0029837622,0.000020499976,0.00000765679,0.000011729612,0.00032074784,0.000013877226,0.000009195551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894553,0.00008234027,0.0003874219,0.00027433853,0.00013854308,0.00017180451],"domain_scores_gemma":[0.9992341,0.00021737,0.00022030064,0.000088065244,0.0001864458,0.000053727133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017894382,0.00015710533,0.00044826188,0.00023416357,0.0000758392,0.000006271841,0.00003876696,0.00016219262,0.0000073867495],"category_scores_gemma":[0.000042711883,0.00012056499,0.00002559435,0.00018340717,0.00032402496,0.000114392205,0.000008518002,0.00020311498,1.0741219e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020919887,0.00013418858,0.6478172,0.00065971457,0.000053568183,0.0000054444276,0.0036533542,0.000013622663,0.34535956,0.00010105918,3.4081268e-7,0.00010996633],"study_design_scores_gemma":[0.005814113,0.0007973003,0.73535466,0.00025210867,0.00034489084,0.000048012134,0.00087192596,0.0001234928,0.2562296,0.000058993814,3.6322098e-7,0.00010451504],"about_ca_topic_score_codex":0.00008629924,"about_ca_topic_score_gemma":0.0003429472,"teacher_disagreement_score":0.08912996,"about_ca_system_score_codex":0.000021655333,"about_ca_system_score_gemma":0.00013424293,"threshold_uncertainty_score":0.49164978},"labels":[],"label_agreement":null},{"id":"W2093592416","doi":"10.1016/j.leukres.2005.06.011","title":"Progression of myelodysplasia to acute lymphoblastic leukaemia: Implications for disease biology","year":2005,"lang":"en","type":"review","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research; World Health Organization","keywords":"Myelodysplastic syndromes; Haematopoiesis; Leukemia; Bone marrow; Stem cell; Preleukemia; Disease; Immunology; Hematology; Pathogenesis; Cancer research; Acute leukemia; Medicine; Biology; Pathology; Genetics","score_opus":0.14402969213854586,"score_gpt":0.5130137743359242,"score_spread":0.3689840821973783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093592416","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014773649,0.97965485,0.001240875,0.0023760535,0.00015020675,0.013255836,0.0016981583,0.00015244984,0.001323819],"genre_scores_gemma":[0.00021816223,0.97543657,0.0072600627,0.00011933107,0.0012539182,0.00912183,0.0020268436,0.00032118082,0.0042421073],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99244654,0.00072214764,0.0016360891,0.0017898072,0.0011883847,0.0022170027],"domain_scores_gemma":[0.98995924,0.0032827042,0.0003839506,0.0025606223,0.001862705,0.0019507861],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00251843,0.0008299164,0.003177748,0.0026564552,0.00042215837,0.00007350096,0.0016738684,0.001208802,0.00014491743],"category_scores_gemma":[0.0029506246,0.0006375325,0.0010970801,0.0031746486,0.0008163146,0.00011274658,0.001208144,0.0022432744,0.00066241785],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007601683,0.00020932862,0.000046604426,0.019737098,0.0005889239,0.000053003772,0.000040224233,0.0000021371836,0.00022954009,0.0024349939,0.026516292,0.9493817],"study_design_scores_gemma":[0.0018224475,0.0012491983,0.0001348734,0.012678287,0.001367427,0.00017700222,0.000013509177,0.0001390257,0.00004641433,0.00038770417,0.98148584,0.0004982399],"about_ca_topic_score_codex":0.000045728862,"about_ca_topic_score_gemma":0.000009565991,"teacher_disagreement_score":0.9549696,"about_ca_system_score_codex":0.010666325,"about_ca_system_score_gemma":0.0255802,"threshold_uncertainty_score":0.9996076},"labels":[],"label_agreement":null},{"id":"W2093949714","doi":"10.1007/s00262-005-0674-5","title":"Development of a whole cell vaccine for acute myeloid leukaemia","year":2005,"lang":"en","type":"review","venue":"Cancer Immunology Immunotherapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Immunotherapy; Minimal residual disease; Oncology; Disease; Myeloid; Internal medicine; Stem cell; Clinical trial; Haematopoiesis; Myeloid leukaemia; Immunology; Immune system; Leukemia; Biology","score_opus":0.0490583581798695,"score_gpt":0.3946298846418152,"score_spread":0.3455715264619457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093949714","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036858147,0.9935957,0.00044820207,0.0002829404,0.00057325064,0.0040180795,0.00027135998,0.000116682655,0.0003251947],"genre_scores_gemma":[0.0000035132268,0.96899164,0.015051271,0.00029038943,0.0003804943,0.0036377693,0.0007702242,0.00035510343,0.010519625],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954224,0.00014902613,0.0019931034,0.00093809306,0.0003621877,0.0011351929],"domain_scores_gemma":[0.99656063,0.00028467117,0.0010945789,0.0014795493,0.0004505558,0.00012999939],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005450708,0.0010158255,0.0046221297,0.0007886753,0.00021302728,0.000023240502,0.0010734458,0.0013004114,0.00080161507],"category_scores_gemma":[0.00003119006,0.0008290064,0.0011289361,0.0006907215,0.00024188134,0.00010346415,0.00020488304,0.0013989755,0.00020159822],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010399632,0.00021545039,0.0000029230207,0.005510752,0.007284221,0.000014919881,0.00047881185,3.3346018e-7,0.009950146,0.000017246146,0.0040223603,0.97146285],"study_design_scores_gemma":[0.006888544,0.00046080523,0.000024793431,0.0054357923,0.0016619095,0.00015943652,0.000053781365,0.0000033622794,0.0034323807,0.000005700106,0.9812218,0.0006516824],"about_ca_topic_score_codex":0.000032459797,"about_ca_topic_score_gemma":0.000013054542,"teacher_disagreement_score":0.97719944,"about_ca_system_score_codex":0.003007675,"about_ca_system_score_gemma":0.008675534,"threshold_uncertainty_score":0.9999961},"labels":[],"label_agreement":null},{"id":"W2094331477","doi":"10.1038/modpathol.3800168","title":"Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21)","year":2004,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Leukemia & Lymphoma Society of Canada; Vancouver Hospital and Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Immunophenotyping; Leukemia; CD33; CD34; Acute leukemia; Pathology; Cytogenetics; Medicine; Karyotype; Internal medicine; Molecular biology; Immunology; Antigen; Biology; Chromosome; Stem cell; Genetics","score_opus":0.0214004321107668,"score_gpt":0.2913613097337744,"score_spread":0.2699608776230076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094331477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96964145,0.0006645674,0.027226934,0.00085372746,0.00004210821,0.00052006583,0.000016100714,0.00006136392,0.00097369053],"genre_scores_gemma":[0.9887416,0.00013840887,0.010331541,0.00025701005,0.00004307554,0.000032277778,0.00010852927,0.000046840298,0.0003007231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984745,0.00010306225,0.00027857692,0.00046780356,0.00021627793,0.0004597869],"domain_scores_gemma":[0.9992159,0.00012151366,0.000082036684,0.00034383667,0.00011713264,0.00011960857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030484202,0.00020882749,0.0004731324,0.00028369966,0.00008933591,0.0000127408375,0.000089994006,0.0002607453,0.000014498394],"category_scores_gemma":[0.00008443099,0.00017304963,0.0000311411,0.00030831396,0.00031104696,0.0001176304,0.00009260733,0.00064802164,0.00008819594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0099930605,0.0003995585,0.761829,0.00024228056,0.0008509912,0.02061697,0.031862285,0.0084874015,0.112376116,0.008870891,0.00009683977,0.044374608],"study_design_scores_gemma":[0.009492495,0.0035559584,0.96884465,0.000116956064,0.00022507105,0.0021309182,0.000289681,0.0038169639,0.0014201361,0.009675166,0.00007319178,0.00035880468],"about_ca_topic_score_codex":0.00031489902,"about_ca_topic_score_gemma":0.00014339351,"teacher_disagreement_score":0.20701565,"about_ca_system_score_codex":0.00075333455,"about_ca_system_score_gemma":0.0006496501,"threshold_uncertainty_score":0.7056759},"labels":[],"label_agreement":null},{"id":"W2095286549","doi":"10.1182/blood-2011-12-399683","title":"Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":239,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Leukemia and Lymphoma Research; U.S. Public Health Service; New York State Stem Cell Science; National Heart, Lung, and Blood Institute; U.S. Department of Defense","keywords":"Biology; Progenitor cell; Stem cell; Myelodysplastic syndromes; Myeloid; Epigenetics; Cancer research; Haematopoiesis; CD34; CD90; Immunology; Genetics; Bone marrow; Gene","score_opus":0.027211408439502576,"score_gpt":0.26049681042555756,"score_spread":0.233285401986055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095286549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98242605,0.016285775,0.00009905201,0.0001670102,0.00008134217,0.0008464435,0.000023218794,0.000028005075,0.000043107088],"genre_scores_gemma":[0.99359226,0.0028259144,0.00280623,0.00003560544,0.0001590042,0.00008702552,0.0000057532316,0.00003818199,0.00045003678],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985659,0.00008878323,0.0002750129,0.00035169616,0.00025373464,0.00046485907],"domain_scores_gemma":[0.99912655,0.0001593913,0.000043774406,0.00025188908,0.000046131598,0.00037225374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002115777,0.00019762665,0.000304989,0.00021245744,0.00009949839,0.000059848284,0.00005314204,0.0001083092,0.00004042457],"category_scores_gemma":[0.00002239847,0.0001694126,0.000020828105,0.00016759262,0.00014757576,0.00011460577,0.00009729267,0.00023170191,0.000016425083],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016695056,0.00088785414,0.40572178,0.00083336706,0.00015117065,0.00038701316,0.0028687818,0.000006579885,0.577389,0.00008920237,0.00023574696,0.01126258],"study_design_scores_gemma":[0.0074985153,0.00069857144,0.91127735,0.00027260184,0.00024304815,0.0007366357,0.00066005514,0.0009488023,0.07503754,0.000011518918,0.0022200642,0.0003952646],"about_ca_topic_score_codex":0.000016865491,"about_ca_topic_score_gemma":0.000009360907,"teacher_disagreement_score":0.5055556,"about_ca_system_score_codex":0.000048064383,"about_ca_system_score_gemma":0.00009553342,"threshold_uncertainty_score":0.6908445},"labels":[],"label_agreement":null},{"id":"W2095588623","doi":"10.1038/bcj.2013.14","title":"The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"NPM1; Internal medicine; Oncology; Myeloid leukemia; Medicine; Univariate analysis; Fms-Like Tyrosine Kinase 3; Cytogenetics; Leukemia; Karyotype; Multivariate analysis; Mutation; Biology; Chromosome; Genetics; Gene","score_opus":0.006879801731779407,"score_gpt":0.26989237800630467,"score_spread":0.26301257627452523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095588623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749607,0.0014173876,0.000016693059,0.00023989653,0.000049122853,0.0006914678,0.0000383191,0.000007201532,0.000043833745],"genre_scores_gemma":[0.99466276,0.0046133157,0.00043046565,0.00003123083,0.00009386242,0.000059089834,0.000007940624,0.000030207655,0.000071115035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985593,0.00010563578,0.00037924165,0.00017894845,0.00039601285,0.0003808924],"domain_scores_gemma":[0.9986639,0.00021804633,0.00025287145,0.0001829117,0.0003940397,0.00028822504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002672308,0.00017149195,0.00028610794,0.00016946324,0.00017473548,0.000085403146,0.0001260859,0.00007946739,0.00005082375],"category_scores_gemma":[0.00023363833,0.00009512582,0.000052156236,0.00025353284,0.00031594932,0.00014585222,0.000070895025,0.000743926,0.0000025406068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041395373,0.000089171284,0.98232585,0.000025230356,0.000552609,0.000026597389,0.00062688,0.000045025703,0.00059069233,0.0000014456311,0.00035288872,0.014949683],"study_design_scores_gemma":[0.00855045,0.0022291357,0.9871119,0.00022382144,0.0004411927,0.00018763254,0.00018436884,0.00040671698,0.00045196622,0.00008850998,0.000018864997,0.00010538883],"about_ca_topic_score_codex":0.00053285056,"about_ca_topic_score_gemma":0.00014400441,"teacher_disagreement_score":0.014844294,"about_ca_system_score_codex":0.00036408062,"about_ca_system_score_gemma":0.0011930586,"threshold_uncertainty_score":0.38791183},"labels":[],"label_agreement":null},{"id":"W2097160518","doi":"10.1182/blood-2009-08-238360","title":"Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"National Cancer Institute; National Institutes of Health","keywords":"Myeloid leukemia; Monocytosis; Leukemia; Myeloid; Cancer research; Chronic myelomonocytic leukemia; RUNX1T1; Immunology; Biology; IRF8; Bone marrow; Medicine; Myelodysplastic syndromes; Gene; Genetics; Chromosomal translocation; Gene expression","score_opus":0.016485117287437068,"score_gpt":0.27291041167528896,"score_spread":0.2564252943878519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097160518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938171,0.000070341426,0.000076752556,0.0013603328,0.00007372267,0.0007425834,0.00003659973,0.000045712288,0.003776855],"genre_scores_gemma":[0.9948897,0.00015199483,0.0042028944,0.00011020542,0.00021294135,0.000059181766,0.00006797944,0.000030131234,0.00027496976],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838984,0.000048620906,0.00045208476,0.00042052605,0.00037417654,0.000314729],"domain_scores_gemma":[0.9989004,0.00015090694,0.00010106429,0.00046484178,0.00017070002,0.0002120705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050763844,0.00016455518,0.00033586,0.00047297758,0.000049883693,0.000022457247,0.00012747703,0.00021648622,0.000028651932],"category_scores_gemma":[0.00040827252,0.00015653508,0.000043972526,0.00062026875,0.000092578346,0.00016688387,0.00010686485,0.00056929904,0.000023928804],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012799929,0.0002855656,0.010576392,0.00008778323,0.000035225825,0.00003183129,0.00096488034,0.0000061148635,0.97292566,0.00032546648,0.00082939136,0.012651709],"study_design_scores_gemma":[0.0071876384,0.00052277895,0.44181165,0.00014549494,0.00004108295,0.00006896388,0.00020021392,0.00016102096,0.54734224,0.000111685265,0.0022539177,0.0001532923],"about_ca_topic_score_codex":0.00029527943,"about_ca_topic_score_gemma":0.00011350167,"teacher_disagreement_score":0.43123525,"about_ca_system_score_codex":0.00024638756,"about_ca_system_score_gemma":0.00025125252,"threshold_uncertainty_score":0.63833153},"labels":[],"label_agreement":null},{"id":"W2097408234","doi":"10.1182/blood.v99.1.245","title":"Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome","year":2002,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":179,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AGE-WELL","keywords":"Peripheral blood mononuclear cell; Medicine; Myeloid leukemia; Drug; Lymphoblastic Leukemia; Peripheral blood; Immunology; Myeloid; Leukemia; Pharmacology; In vitro; Biology","score_opus":0.00571626148610074,"score_gpt":0.20601559138740946,"score_spread":0.20029932990130872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097408234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982794,0.0005379808,0.000006543244,0.0001071385,0.000008981676,0.00079798937,0.00006915753,0.00004079679,0.00015201597],"genre_scores_gemma":[0.9978128,0.00085915945,0.0008206154,0.000050302915,0.000041814135,0.000021115016,0.000012337151,0.000052257972,0.00032960612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982529,0.000113344926,0.0002874107,0.00051857834,0.0003581364,0.000469598],"domain_scores_gemma":[0.9992009,0.00006792656,0.00009548354,0.0002895647,0.000054826764,0.00029129925],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018010492,0.00032846615,0.0006636988,0.00019054094,0.000084433785,0.000043115975,0.00006675641,0.00012817075,0.000038894228],"category_scores_gemma":[0.00002045502,0.00024718212,0.000036214806,0.00017895405,0.00044080568,0.00014878552,0.00019066273,0.00037442637,0.0000030502476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004281743,0.0006666774,0.93641436,0.00027218802,0.0009312849,0.0005070398,0.0014642536,0.0000057622333,0.058088355,0.000010526235,0.000040032,0.0011713735],"study_design_scores_gemma":[0.01521601,0.0010610488,0.94251615,0.00024383004,0.0008922523,0.008696879,0.000098401855,0.0022536903,0.02871849,0.000004737079,0.000003520746,0.00029501884],"about_ca_topic_score_codex":0.00038718997,"about_ca_topic_score_gemma":0.00006508191,"teacher_disagreement_score":0.029369865,"about_ca_system_score_codex":0.00008781215,"about_ca_system_score_gemma":0.00008913844,"threshold_uncertainty_score":0.99999803},"labels":[],"label_agreement":null},{"id":"W2097501344","doi":"10.1016/j.cancergen.2011.05.005","title":"Inversion and deletion of 16q22 defined by array CGH, FISH, and RT-PCR in a patient with AML","year":2011,"lang":"en","type":"article","venue":"Cancer Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diagnostic Services Manitoba; University of Manitoba; Manitoba Health; Health Sciences Centre","funders":"","keywords":"Chromosomal inversion; Fusion gene; Biology; Molecular biology; Derivative chromosome; Myeloid leukemia; Fluorescence in situ hybridization; Chromosome 16; Gene; Genetics; Karyotype; Chromosome; Cancer research","score_opus":0.02216018536485092,"score_gpt":0.2513144483156821,"score_spread":0.2291542629508312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097501344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972099,0.0014492361,0.00013310663,0.00035558036,0.00002174927,0.00032857223,0.00002009454,0.0000062739045,0.00047549765],"genre_scores_gemma":[0.9937684,0.003215352,0.0024337322,0.00042769624,0.000016823338,0.00003290563,0.0000130818935,0.0000152477805,0.000076740274],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993517,0.000023027753,0.00013110887,0.00017560966,0.00016254782,0.00015604195],"domain_scores_gemma":[0.9996066,0.000017356222,0.00005031355,0.0001397724,0.0000817826,0.00010416213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005536303,0.00008610184,0.00015732323,0.00007409831,0.000017913115,0.0000034091,0.00003538703,0.00006587687,0.000042611522],"category_scores_gemma":[0.000017944312,0.00006896509,0.000009569821,0.00013332847,0.00012765244,0.00002178039,0.00003628699,0.00011837334,7.438563e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020445895,0.00025861894,0.709538,0.0006081138,0.00010760539,0.00008025362,0.009220265,0.000017272192,0.15599714,0.000024281211,0.019777002,0.102326855],"study_design_scores_gemma":[0.010307606,0.004758622,0.30518255,0.0006364558,0.00019266008,0.00009663982,0.0016939986,0.0020242664,0.6502982,0.00013173527,0.024218557,0.00045869444],"about_ca_topic_score_codex":0.0005997071,"about_ca_topic_score_gemma":0.00041346112,"teacher_disagreement_score":0.49430105,"about_ca_system_score_codex":0.00013728222,"about_ca_system_score_gemma":0.00013256604,"threshold_uncertainty_score":0.2812315},"labels":[],"label_agreement":null},{"id":"W2099016852","doi":"10.3324/haematol.2010.038281","title":"Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring","year":2011,"lang":"en","type":"letter","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Myelodysplastic syndromes; Macrocytic anemia; Somatic evolution in cancer; Myeloid leukemia; Myeloid; Biology; Cytogenetics; Chromosome; Anemia; Medicine; Immunology; Genetics; Internal medicine; Gene; Bone marrow","score_opus":0.03348741278418695,"score_gpt":0.2733394353099151,"score_spread":0.23985202252572815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099016852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94152457,0.0031670183,0.00056705205,0.051880706,0.00021934145,0.0014890858,0.000022014015,0.0001103894,0.0010198256],"genre_scores_gemma":[0.98453474,0.00027929718,0.0029437826,0.010638989,0.00048746623,0.00024008327,0.00006539539,0.00009237269,0.00071785407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707556,0.00020086585,0.0007076799,0.0005897721,0.00070876384,0.00071733247],"domain_scores_gemma":[0.9980606,0.0004166615,0.00041394393,0.00080274045,0.00022671328,0.00007935977],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00025530084,0.00042105926,0.0010532003,0.00033891952,0.00008156493,0.000013689748,0.00050085335,0.0008816415,0.00021770422],"category_scores_gemma":[0.00022556368,0.0002380386,0.00012845652,0.0005908103,0.00046809387,0.00005083394,0.00014964303,0.0026383772,0.00007382316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010179896,0.00012747989,0.8813846,0.0016307925,0.00044594164,0.028195081,0.00030055572,0.000023134387,0.00020248337,0.00011052818,0.0863767,0.00018468656],"study_design_scores_gemma":[0.0027550654,0.0020594173,0.9594148,0.003047463,0.00057621254,0.021599228,0.0002336613,0.0007228922,0.00030789882,0.0007744145,0.0077261217,0.00078285555],"about_ca_topic_score_codex":0.00019807782,"about_ca_topic_score_gemma":0.00002247036,"teacher_disagreement_score":0.07865058,"about_ca_system_score_codex":0.0004004377,"about_ca_system_score_gemma":0.00054356456,"threshold_uncertainty_score":0.9996626},"labels":[],"label_agreement":null},{"id":"W2099215382","doi":"10.1186/2162-3619-2-20","title":"Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia","year":2013,"lang":"en","type":"article","venue":"Experimental Hematology and Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Cancer Society Research Institute","keywords":"Cytarabine; Medicine; Myeloid leukemia; Leukemia; Pharmacology; Myeloid; Internal medicine; Oncology","score_opus":0.021737496306857704,"score_gpt":0.3558260449127454,"score_spread":0.33408854860588766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099215382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854863,0.0044726734,0.0027401524,0.0023858096,0.00017075147,0.0018031044,0.000008233233,0.00005125542,0.0028816778],"genre_scores_gemma":[0.96591336,0.0007580616,0.030577943,0.0011586422,0.000083075494,0.00064821815,0.000083891435,0.00003139614,0.0007453891],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99884313,0.000071545095,0.00035068305,0.00030465436,0.000097027696,0.00033295967],"domain_scores_gemma":[0.99920744,0.00020545183,0.000117212694,0.0002003674,0.0001286996,0.0001408221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013320638,0.00016841773,0.00062179955,0.0001335831,0.000089562454,0.000005300774,0.00009861128,0.00033047737,0.0008103604],"category_scores_gemma":[0.00003175885,0.000137761,0.00008082808,0.00010423806,0.0004353677,0.00010418751,0.00006898488,0.00017497556,0.000029070434],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010687698,0.0021240488,0.010141273,0.000261844,0.0016214916,0.00018897475,0.0039363513,0.00014994509,0.87764925,0.02690995,0.041435417,0.024893787],"study_design_scores_gemma":[0.01411206,0.0074298587,0.0016437266,0.000030852607,0.00007634569,0.001944512,0.0012441973,0.010049052,0.9573076,0.0004041672,0.0055185226,0.00023910741],"about_ca_topic_score_codex":0.00006995398,"about_ca_topic_score_gemma":0.0000017900278,"teacher_disagreement_score":0.07965838,"about_ca_system_score_codex":0.00033416657,"about_ca_system_score_gemma":0.00032511007,"threshold_uncertainty_score":0.8872878},"labels":[],"label_agreement":null},{"id":"W2101725260","doi":"10.1182/blood-2014-03-560557","title":"Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":229,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cytarabine; Hazard ratio; Internal medicine; Adverse effect; Myeloid leukemia; Confidence interval; Surgery; Oncology","score_opus":0.030154932912024094,"score_gpt":0.32413933032379777,"score_spread":0.2939843974117737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101725260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938821,0.000025484891,0.00030730825,0.00021438561,0.00009892357,0.005262757,0.000016869342,0.000027940152,0.00016422091],"genre_scores_gemma":[0.99693227,0.000056685523,0.0010914825,0.00014182742,0.00029424968,0.00057112536,0.0000880773,0.0000460073,0.00077827007],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998211,0.00021276952,0.0004914525,0.00030157843,0.00043695502,0.00034620828],"domain_scores_gemma":[0.9986404,0.00040969052,0.00018611479,0.00035482677,0.00028819952,0.00012077834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012902955,0.00018597781,0.00089895475,0.0002286395,0.000039981504,0.0000119430415,0.00011527535,0.00013033459,0.000060138773],"category_scores_gemma":[0.0011696962,0.00011155688,0.000108782915,0.00029708003,0.00012618976,0.000121781,0.000021778558,0.00023885249,0.0000055274527],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9745785,0.0052041765,0.0031743147,0.00011724603,0.00018918513,0.000004272568,0.0002649832,0.0000032092244,0.011090571,0.00001304485,0.00013576687,0.0052247043],"study_design_scores_gemma":[0.9099881,0.009139423,0.000576076,0.00012488558,0.00014773036,0.0000063932403,0.000033929256,0.0009096797,0.07860799,0.000016469712,0.0003268542,0.00012244281],"about_ca_topic_score_codex":0.00022277691,"about_ca_topic_score_gemma":0.00004970959,"teacher_disagreement_score":0.06751742,"about_ca_system_score_codex":0.00007167898,"about_ca_system_score_gemma":0.0003265843,"threshold_uncertainty_score":0.45491576},"labels":[],"label_agreement":null},{"id":"W2103254744","doi":"10.3109/10428194.2012.660631","title":"Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre","funders":"Takeda Oncology","keywords":"Cytarabine; Medicine; Myeloid leukemia; Neutropenia; Refractory (planetary science); Fms-Like Tyrosine Kinase 3; Phases of clinical research; Internal medicine; Pharmacology; Clinical trial; Chemotherapy; Chemistry; Biology","score_opus":0.016781957473714398,"score_gpt":0.2891959538203783,"score_spread":0.2724139963466639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103254744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990001,0.00084615336,0.000055904322,0.00012362938,0.00075374387,0.0035291768,0.0001906216,0.00030359594,0.004196156],"genre_scores_gemma":[0.9894493,0.0011721312,0.0024251041,0.00092654483,0.0010065695,0.0003893354,0.0005829339,0.0003777629,0.0036703],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9904514,0.00049941003,0.0023834195,0.0016602474,0.0022773866,0.002728146],"domain_scores_gemma":[0.99363786,0.0008915998,0.0010248967,0.0021100203,0.0006089053,0.0017267292],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0015376325,0.0014844185,0.0026849753,0.0013482313,0.0003576131,0.00011497902,0.0008601104,0.0013907207,0.00033091957],"category_scores_gemma":[0.0007010315,0.0011401188,0.0004619259,0.0021438336,0.0010594758,0.0013675439,0.000524185,0.0008321214,0.00016506342],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6312938,0.009109416,0.05880365,0.0011111146,0.001973098,0.0012696981,0.003995566,0.000020953914,0.007034099,0.0005306343,0.009105941,0.27575207],"study_design_scores_gemma":[0.74844664,0.016645093,0.18825419,0.0009965277,0.001174177,0.00065741927,0.00071969046,0.00095045695,0.008514349,0.00005419032,0.03168878,0.0018984694],"about_ca_topic_score_codex":0.0015147945,"about_ca_topic_score_gemma":0.00008945221,"teacher_disagreement_score":0.2738536,"about_ca_system_score_codex":0.022622287,"about_ca_system_score_gemma":0.014276642,"threshold_uncertainty_score":0.9999057},"labels":[],"label_agreement":null},{"id":"W2103713040","doi":"10.1101/gad.1788109","title":"PLZF is a regulator of homeostatic and cytokine-induced myeloid development","year":2009,"lang":"en","type":"article","venue":"Genes & Development","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Hospital for Sick Children; University of Toronto; Terry Fox Foundation; Canadian Institutes of Health Research; Leukemia and Lymphoma Society; Genome Canada; Ontario Genomics; Ontario Genomics Institute; National Cancer Institute; National Institutes of Health; Ontario Institute for Cancer Research","keywords":"Myelopoiesis; Biology; Cell biology; Haematopoiesis; Progenitor cell; Myeloid; Progenitor; Transcription factor; Cellular differentiation; Homeostasis; Regulator; Lymphopoiesis; Immunology; Stem cell; Genetics","score_opus":0.024472213705017926,"score_gpt":0.2879298394063583,"score_spread":0.26345762570134035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103713040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951855,0.0012408751,0.00024316108,0.0017590839,0.00006354051,0.00067932473,0.0000034367094,0.000065483626,0.0007596153],"genre_scores_gemma":[0.92303246,0.00035292542,0.07381363,0.0013418369,0.00006455589,0.000050384013,0.00003653527,0.000036290545,0.0012713519],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99740076,0.00003575338,0.00070728,0.00050455466,0.00077487796,0.0005767512],"domain_scores_gemma":[0.99879885,0.000047291953,0.00014427408,0.0003968655,0.00025744745,0.00035524496],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044775888,0.00031505612,0.0005609203,0.0003461924,0.00014420258,0.000022953393,0.00018314656,0.00014195238,0.0001325829],"category_scores_gemma":[0.00006117694,0.00027276066,0.000054043237,0.00041875153,0.00006483673,0.000074338794,0.00014862933,0.00019899948,0.00008434118],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028691118,0.00018407662,0.004501122,0.0002547913,0.00023574976,0.00009482209,0.0083239,6.9920736e-7,0.23071192,0.000087070235,0.0016936341,0.7536253],"study_design_scores_gemma":[0.0020268539,0.00023656922,0.27450258,0.00020856361,0.000036870733,0.0001296388,0.0002948362,0.000035759276,0.6584977,0.00009788741,0.063609466,0.0003233137],"about_ca_topic_score_codex":0.0000113717615,"about_ca_topic_score_gemma":0.000005415607,"teacher_disagreement_score":0.753302,"about_ca_system_score_codex":0.00051847997,"about_ca_system_score_gemma":0.0020694146,"threshold_uncertainty_score":0.99997246},"labels":[],"label_agreement":null},{"id":"W2103945928","doi":"10.3324/haematol.2012.066068","title":"Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del(5q) myelodysplastic syndrome","year":2012,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Celgene","keywords":"Lenalidomide; CD34; Myelodysplastic syndromes; Progenitor cell; Haematopoiesis; Medicine; Stem cell; microRNA; Cancer research; Gene knockdown; Immunology; Internal medicine; Bone marrow; Oncology; Biology; Cell culture; Multiple myeloma; Gene; Cell biology","score_opus":0.02584716796054585,"score_gpt":0.3004767009760496,"score_spread":0.27462953301550375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103945928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99766153,0.00012283358,0.00071352965,0.00045825276,0.0000926349,0.00084330916,0.000038193844,0.00003742163,0.00003227912],"genre_scores_gemma":[0.997216,0.000026586109,0.0023554408,0.00008065169,0.000022068047,0.000044785087,0.00011804291,0.000027054177,0.00010938055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967185,0.0012478008,0.0007824108,0.00038761896,0.0005045126,0.00035913344],"domain_scores_gemma":[0.99653673,0.002326958,0.0003909987,0.00032826597,0.0001868767,0.00023014104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018677318,0.00021525525,0.000688293,0.00023915982,0.000066669905,0.000013507293,0.000082519655,0.00032655074,0.00007846883],"category_scores_gemma":[0.0018603853,0.00014316324,0.00003901349,0.0003838433,0.00031385818,0.00030642966,0.000054861524,0.00051527884,0.000038946637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15239373,0.0006306137,0.8355618,0.00005546825,0.00008426174,0.00017365123,0.0005599271,0.000017625114,0.00928677,0.000015748992,0.0008099502,0.0004104752],"study_design_scores_gemma":[0.007329023,0.0025986629,0.98462427,0.00027498664,0.00010057225,0.00029422608,0.0002618229,0.00041320774,0.003720568,0.000013916462,0.00019503392,0.0001737397],"about_ca_topic_score_codex":0.00011777527,"about_ca_topic_score_gemma":0.000020063959,"teacher_disagreement_score":0.14906245,"about_ca_system_score_codex":0.00017154471,"about_ca_system_score_gemma":0.0002511911,"threshold_uncertainty_score":0.58380276},"labels":[],"label_agreement":null},{"id":"W2104086696","doi":"10.1309/ajcph27zizejlorf","title":"Array Comparative Genomic Hybridization of Peripheral Blood Granulocytes of Patients With Myelodysplastic Syndrome Detects Karyotypic Abnormalities","year":2010,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia; Vancouver General Hospital; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Comparative genomic hybridization; Karyotype; Bone marrow; Biology; Pathology; CD34; Myelodysplastic syndromes; Cytogenetics; Peripheral blood; Immunology; Chromosome; Stem cell; Genetics; Medicine; Gene","score_opus":0.019085540933250135,"score_gpt":0.32499218048962014,"score_spread":0.30590663955637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104086696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981777,0.00005524741,0.0010100406,0.0001075609,0.00025291336,0.00023467783,0.00002671665,0.000007751779,0.00012740244],"genre_scores_gemma":[0.990175,0.000055616132,0.00944696,0.00011999592,0.0001376558,0.0000033248498,0.000012130747,0.000025663703,0.000023614342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99677783,0.0004966554,0.001727575,0.00022633739,0.00046261217,0.00030898422],"domain_scores_gemma":[0.9949841,0.0013071698,0.002044489,0.00030889967,0.0010864561,0.00026889928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010082752,0.00019738084,0.0016914308,0.00026403015,0.000038972707,0.0000053478343,0.0002688508,0.00011128885,0.00009928476],"category_scores_gemma":[0.0011501312,0.00013989137,0.00023424668,0.00031340387,0.0025731896,0.000114393915,0.00004650219,0.0011339848,0.0000044668805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062473076,0.0009144392,0.9692478,0.00008246157,0.0005057122,0.0004178366,0.00072996155,0.000068557885,0.018154602,0.000050123483,0.000026427004,0.0035547428],"study_design_scores_gemma":[0.0060683694,0.019921161,0.96764964,0.00009491241,0.00036530127,0.001609974,0.00039080542,0.00003679912,0.0036289713,0.0000607042,0.00004446784,0.0001289211],"about_ca_topic_score_codex":0.000020361224,"about_ca_topic_score_gemma":0.000015145512,"teacher_disagreement_score":0.019006722,"about_ca_system_score_codex":0.000034012723,"about_ca_system_score_gemma":0.0007267395,"threshold_uncertainty_score":0.9481024},"labels":[],"label_agreement":null},{"id":"W2104831309","doi":"10.6000/1929-2279.2013.02.04.3","title":"Is FLT3 Internal Tandem Duplication an Unfavorable Risk Factor for High Risk Children with Acute Myeloid Leukemia? - Polish Experience","year":2013,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Tandem exon duplication; Fms-Like Tyrosine Kinase 3; Myeloid leukemia; Oncology; Exon; Pediatrics; Mutation; Gene; Genetics; Biology","score_opus":0.031069972860257852,"score_gpt":0.3788117054814837,"score_spread":0.3477417326212258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104831309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99265975,0.0008350941,0.0012135456,0.0030890708,0.00009983031,0.0015153085,0.0004569562,0.00003268519,0.00009778646],"genre_scores_gemma":[0.98389095,0.008803641,0.0039989296,0.00027259797,0.0012940422,0.00031973512,0.000031263582,0.00009059594,0.0012982176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952588,0.00032984625,0.00074281526,0.00053938996,0.0020370414,0.0010921265],"domain_scores_gemma":[0.99391127,0.00033022105,0.0006866841,0.0006959057,0.0034530486,0.0009228842],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015261486,0.00031031983,0.00064636517,0.00067651115,0.0004707633,0.0003863676,0.0009916662,0.00019793372,0.001934711],"category_scores_gemma":[0.00057575555,0.00020882586,0.00017365986,0.0007510875,0.0005000208,0.0015644934,0.0001784392,0.0021521884,0.000055771412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004405742,0.0003242895,0.8003853,0.000080502265,0.0026270004,0.000056657555,0.003931356,0.000089832734,0.039953332,0.000088744615,0.051129293,0.096927956],"study_design_scores_gemma":[0.0076035853,0.0048987297,0.8154554,0.00035325153,0.00028896323,0.0003964047,0.0012090035,0.0017261008,0.16110279,0.0013598078,0.0052069686,0.0003990344],"about_ca_topic_score_codex":0.017810121,"about_ca_topic_score_gemma":0.00035037624,"teacher_disagreement_score":0.12114945,"about_ca_system_score_codex":0.002352288,"about_ca_system_score_gemma":0.0028189984,"threshold_uncertainty_score":0.99897766},"labels":[],"label_agreement":null},{"id":"W2104892237","doi":"10.1002/cyto.a.22582","title":"Notch affects the prodifferentiating effect of retinoic acid and <scp>PMA</scp> on leukemic cells","year":2014,"lang":"en","type":"article","venue":"Cytometry Part A","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hrvatska Zaklada za Znanost; University of Toronto; Hrvatska Akademija znanosti i umjetnosti; European Commission","keywords":"Retinoic acid; Cell biology; Chemistry; Tretinoin; Molecular biology; Biology; Biochemistry; Gene","score_opus":0.012084417126392985,"score_gpt":0.27263580378552815,"score_spread":0.2605513866591352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104892237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930985,0.00029027992,0.00010019999,0.0002114178,0.00018777743,0.0010058788,0.0000066899684,0.00007600522,0.0050232396],"genre_scores_gemma":[0.9975568,0.000055682798,0.00010960999,0.0002740606,0.00039285002,0.000069802016,0.000016358013,0.0000526814,0.0014721421],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99760884,0.0004606818,0.00028150034,0.0004582988,0.0006368117,0.0005538547],"domain_scores_gemma":[0.9958651,0.0029315979,0.0001726991,0.0007379945,0.00007913056,0.00021347993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016915174,0.00028475933,0.00060520624,0.00032481924,0.00014804982,0.000038827184,0.00025165037,0.00018134106,0.000028306295],"category_scores_gemma":[0.003062192,0.00017321156,0.00013038008,0.00074652414,0.00024098353,0.000052031854,0.00019538717,0.00072470267,0.00014844221],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019433006,0.00007388886,0.05294684,0.0011836538,0.00014008705,0.000020849819,0.00042390233,0.0000041497133,0.91889167,0.00005046038,0.015949262,0.01012091],"study_design_scores_gemma":[0.002644514,0.0021420943,0.04149505,0.00033752725,0.00014092276,0.000043368942,0.0000670905,0.001474831,0.94827753,0.0000126134855,0.003287223,0.000077245626],"about_ca_topic_score_codex":0.000008806119,"about_ca_topic_score_gemma":9.22211e-7,"teacher_disagreement_score":0.029385848,"about_ca_system_score_codex":0.00016995938,"about_ca_system_score_gemma":0.0000904552,"threshold_uncertainty_score":0.70633626},"labels":[],"label_agreement":null},{"id":"W2105667676","doi":"10.1007/s10689-009-9289-x","title":"Molecular study of CEPBA in familial hematological malignancies","year":2009,"lang":"en","type":"article","venue":"Familial Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Société Française d'Hématologie; Institut National Du Cancer","keywords":"CEBPA; Germline; Hematology; Germline mutation; Human genetics; Myeloid leukemia; Myeloid; Medicine; Biology; Genetics; Internal medicine; Cancer research; Mutation; Gene","score_opus":0.030080014283446734,"score_gpt":0.33986154235960686,"score_spread":0.3097815280761601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105667676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952208,0.00070891937,0.000024686851,0.0007416215,0.00011467426,0.0008602344,0.000011455866,0.000040846135,0.0022767775],"genre_scores_gemma":[0.9984526,0.00012287716,0.00016350349,0.0008008127,0.000117319614,0.0000704601,0.0000052928217,0.000015144208,0.00025196976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981363,0.00009565635,0.00040461682,0.0003605475,0.00059516256,0.00040775203],"domain_scores_gemma":[0.9992729,0.000042286683,0.000062995554,0.0003554057,0.00014477437,0.00012164007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021458027,0.00017832701,0.00055169594,0.00018510423,0.000028270042,0.0000063854704,0.00018957845,0.00014055669,0.00012739876],"category_scores_gemma":[0.00016469565,0.00014408895,0.00008611986,0.00050998974,0.00009587279,0.000052082138,0.000066432374,0.00036264252,0.000016508153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006509109,0.0059942813,0.49266526,0.00029912655,0.00022155365,0.0053750407,0.006416217,0.0008833359,0.443637,0.0015520853,0.0070504406,0.02939654],"study_design_scores_gemma":[0.010654925,0.004484422,0.95256585,0.00018202362,0.00009011667,0.000044722216,0.0032892998,0.0006100178,0.026560303,0.00031420434,0.00088175666,0.00032236878],"about_ca_topic_score_codex":0.0016336029,"about_ca_topic_score_gemma":0.00026929186,"teacher_disagreement_score":0.45990056,"about_ca_system_score_codex":0.00032112686,"about_ca_system_score_gemma":0.0003433923,"threshold_uncertainty_score":0.5875777},"labels":[],"label_agreement":null},{"id":"W2106169155","doi":"10.1200/jco.2003.07.113","title":"Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin’s Lymphoma Patients","year":2003,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cumulative incidence; Total body irradiation; Internal medicine; Incidence (geometry); Lymphoma; Leukemia; Oncology; Transplantation; Chemotherapy; Cyclophosphamide","score_opus":0.10202499788244729,"score_gpt":0.4875894393266744,"score_spread":0.38556444144422714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106169155","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03043088,0.9589946,0.0000036968995,0.00037546805,0.0019032421,0.0016091713,0.000026698024,0.000012906307,0.006643306],"genre_scores_gemma":[0.0003981118,0.9950952,0.0011822012,0.00034886526,0.00054228515,0.000030076233,0.00004750645,0.00010046043,0.002255297],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98963916,0.0017520908,0.006713573,0.0005878842,0.000632466,0.00067480205],"domain_scores_gemma":[0.98967737,0.0041320226,0.0042513637,0.00047089692,0.00047807855,0.0009902692],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0030855082,0.0006440547,0.010015264,0.00086524937,0.00005011928,0.000021610193,0.00038158632,0.0029151,0.00013678939],"category_scores_gemma":[0.0027745522,0.00040697877,0.0016907845,0.0006064977,0.0004368633,0.00014631663,0.00014581754,0.0027492,0.00013759844],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010031748,0.0011765657,0.0024350018,0.0009245486,0.0025367006,0.0065153195,0.000046184497,2.738675e-7,1.7085563e-7,0.0000128192305,0.0030253239,0.98232394],"study_design_scores_gemma":[0.02762321,0.01959477,0.008031252,0.003684698,0.0048688925,0.0045307092,0.000015463716,0.00002350756,2.4530024e-7,0.00003636251,0.9313166,0.0002742453],"about_ca_topic_score_codex":0.000039585408,"about_ca_topic_score_gemma":0.00001683529,"teacher_disagreement_score":0.98204964,"about_ca_system_score_codex":0.009162851,"about_ca_system_score_gemma":0.024499506,"threshold_uncertainty_score":0.99983823},"labels":[],"label_agreement":null},{"id":"W2106234158","doi":"10.1016/s0145-2126(03)00076-6","title":"Prognostic significance of trisomy 4 as the sole cytogenetic abnormality in acute myeloid leukemia","year":2003,"lang":"en","type":"review","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Abnormality; Trisomy; Cytogenetics; Chromosomal Abnormality; Clinical significance; Myeloid leukemia; Acute myeloblastic leukemia; Trisomy 8; Chromosome abnormality; Internal medicine; Medicine; Aneuploidy; Leukemia; Oncology; Karyotype; Pathology; Biology; Chromosome; Genetics","score_opus":0.10789559779961926,"score_gpt":0.42323121666036095,"score_spread":0.3153356188607417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106234158","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003701816,0.9665767,0.000023190241,0.00030652588,0.00018792415,0.012077601,0.00013960464,0.000086130545,0.016900485],"genre_scores_gemma":[0.0014402298,0.9786591,0.00047546253,0.0001495705,0.00039097437,0.0034012094,0.0002483739,0.00033726022,0.014897846],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98194695,0.00538715,0.0028594371,0.0020654798,0.004501011,0.003239985],"domain_scores_gemma":[0.988234,0.005384135,0.0005242619,0.0037432488,0.00127717,0.0008372085],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.010944568,0.0012344242,0.0045957738,0.0021229193,0.00043105468,0.00016731021,0.0029342552,0.0016712685,0.0005332954],"category_scores_gemma":[0.0034054886,0.00084230735,0.0012215088,0.0071823266,0.0022880994,0.00018703254,0.0011444592,0.00978998,0.0012910002],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0013109071,0.00068684155,0.0011517758,0.07871395,0.0024690963,0.0062209647,0.00091684796,0.000042673506,0.00040324224,0.0012806102,0.027839785,0.8789633],"study_design_scores_gemma":[0.0029889098,0.0010229162,0.000312868,0.012572924,0.0010925039,0.0015257209,0.00025118867,0.00013158271,0.00050829625,0.00032778375,0.9784392,0.0008261091],"about_ca_topic_score_codex":0.0023831474,"about_ca_topic_score_gemma":0.00012466912,"teacher_disagreement_score":0.95059943,"about_ca_system_score_codex":0.018489644,"about_ca_system_score_gemma":0.052900095,"threshold_uncertainty_score":0.9996248},"labels":[],"label_agreement":null},{"id":"W2106592889","doi":"10.3324/haematol.11201","title":"Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia","year":2007,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child, Adolescent and Family Mental Health","funders":"","keywords":"Juvenile myelomonocytic leukemia; Cancer research; Mutation; Myeloid leukemia; Myeloid; Biology; Molecular biology; Gene; Genetics; Haematopoiesis; Stem cell","score_opus":0.02223505742380733,"score_gpt":0.3065633143863526,"score_spread":0.28432825696254527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106592889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791591,0.000102166974,0.0014771568,0.0000841536,0.000022393575,0.00055636547,0.0000040323903,0.000026156733,0.018568486],"genre_scores_gemma":[0.9981789,0.00001655778,0.0016317022,0.000044368076,0.000014563407,0.00001701666,0.00002497241,0.000009054694,0.00006284005],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99852306,0.00005853963,0.00056705973,0.00021690168,0.00037171275,0.00026272415],"domain_scores_gemma":[0.9989276,0.00031853965,0.0002488635,0.00022398388,0.0002056866,0.000075334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065033074,0.000116876225,0.00049051654,0.0003679352,0.000025282498,0.000003036975,0.000109068766,0.00020174679,0.00011336178],"category_scores_gemma":[0.0006545318,0.00009814432,0.000065582564,0.0004675369,0.00025009117,0.00009091557,0.000060595034,0.00029285756,0.000021481026],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006075006,0.0009906373,0.18643801,0.00097618875,0.00026473563,0.0015522076,0.0069325063,0.0005076582,0.6845401,0.052203868,0.0003849594,0.059134167],"study_design_scores_gemma":[0.002402066,0.00035539165,0.19524568,0.00023384758,0.000029452212,0.0002902689,0.0031505525,0.0010288921,0.7951117,0.0019300055,0.000113939874,0.00010818364],"about_ca_topic_score_codex":0.0003456061,"about_ca_topic_score_gemma":0.000056823283,"teacher_disagreement_score":0.11057165,"about_ca_system_score_codex":0.00066601386,"about_ca_system_score_gemma":0.0006075937,"threshold_uncertainty_score":0.40022093},"labels":[],"label_agreement":null},{"id":"W2107027906","doi":"10.1182/blood-2014-11-610543","title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":977,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institutes of Health; Lady Tata Memorial Trust; Edward P. Evans Foundation; Harvard Catalyst; Leukemia and Lymphoma Society","keywords":"Biology; Mutation; Myeloid leukemia; Genetics; Leukemia; Myeloid; Cancer research; Somatic cell; Gene","score_opus":0.012657192205586809,"score_gpt":0.2708781713231564,"score_spread":0.2582209791175696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107027906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97523385,0.00020789205,0.0015227182,0.0025974256,0.00007781798,0.0005146956,0.00010560386,0.00022213742,0.019517833],"genre_scores_gemma":[0.9850893,0.000039803166,0.0049209166,0.0012578282,0.000261286,0.00010290781,0.00033248204,0.00007139908,0.007924087],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99802,0.00008161507,0.0003731145,0.00042052002,0.00054500403,0.0005597592],"domain_scores_gemma":[0.99846035,0.00026339153,0.000096850905,0.00069286494,0.00012162766,0.00036493485],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027069607,0.00024973977,0.000413635,0.00013251274,0.00018624596,0.00004877303,0.0002550648,0.000158011,0.0006560779],"category_scores_gemma":[0.0004348141,0.00021535989,0.0001507327,0.0003023427,0.000134617,0.00009637085,0.000104354665,0.0003743097,0.0013476969],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040635237,0.0029697593,0.08036127,0.00089068344,0.003531505,0.00052528677,0.0031363906,0.000005435182,0.56698394,0.0020469108,0.31379953,0.025342956],"study_design_scores_gemma":[0.061930783,0.0033430331,0.14372303,0.00054528395,0.00719654,0.0025043415,0.00055155315,0.01176524,0.60798967,0.0051410203,0.1530156,0.0022939027],"about_ca_topic_score_codex":0.00016474011,"about_ca_topic_score_gemma":0.00002631567,"teacher_disagreement_score":0.16078392,"about_ca_system_score_codex":0.0003163073,"about_ca_system_score_gemma":0.00048561805,"threshold_uncertainty_score":0.9994299},"labels":[],"label_agreement":null},{"id":"W2107365189","doi":"10.1158/1078-0432.ccr-04-0097","title":"A Phase I and Pharmacodynamic Study of Fludarabine, Carboplatin, and Topotecan in Patients With Relapsed, Refractory, or High-Risk Acute Leukemia","year":2004,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Carboplatin; Medicine; Topotecan; Fludarabine; Internal medicine; Leukemia; Regimen; Gastroenterology; Acute leukemia; Platelet transfusion; Oncology; Surgery; Chemotherapy; Cyclophosphamide; Platelet; Cisplatin","score_opus":0.06352704510688084,"score_gpt":0.4685404394304402,"score_spread":0.4050133943235594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107365189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963953,0.00028289188,0.0000059582862,0.00048344582,0.00006901172,0.0025330533,0.000102518454,0.000025704594,0.000102096485],"genre_scores_gemma":[0.9969056,0.0020357813,0.0002486255,0.00007696896,0.00013118809,0.00018998384,0.00002435394,0.00006016534,0.00032728064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955295,0.0006434287,0.0009002753,0.0008698427,0.0013569767,0.0007000309],"domain_scores_gemma":[0.997106,0.0009024089,0.00018266274,0.00061319803,0.0006345112,0.0005611912],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0025860365,0.00024778428,0.0008569896,0.0004920809,0.00014603042,0.000030315869,0.00025644622,0.0002239706,0.000111590816],"category_scores_gemma":[0.0010466954,0.00017150404,0.00004490285,0.0010800527,0.00090945914,0.00015957504,0.0003503277,0.002757825,0.000005173043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06689877,0.0073285378,0.8250526,0.00025731654,0.00064328674,0.00074676925,0.001338814,0.000044523582,0.000665296,0.00001662084,0.0004092663,0.096598156],"study_design_scores_gemma":[0.17290235,0.04398792,0.78037953,0.00037780177,0.00025272166,0.000010196547,0.00076271675,0.00044690416,0.000288868,0.00008893098,0.00023752336,0.0002645498],"about_ca_topic_score_codex":0.012105111,"about_ca_topic_score_gemma":0.0032631094,"teacher_disagreement_score":0.106003575,"about_ca_system_score_codex":0.0012661283,"about_ca_system_score_gemma":0.0024262182,"threshold_uncertainty_score":0.99954283},"labels":[],"label_agreement":null},{"id":"W2107942053","doi":"10.1111/vox.12266","title":"Monthly blood transfusions decrease after four months of azacitidine","year":2015,"lang":"en","type":"article","venue":"Vox Sanguinis","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Health Sciences Centre; Western University; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Azacitidine; Blood transfusion; Internal medicine; Transfusion therapy; Retrospective cohort study; Myelodysplastic syndromes; Pediatrics; Surgery","score_opus":0.034112832041874756,"score_gpt":0.29098555655673386,"score_spread":0.2568727245148591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107942053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97016585,0.0013454687,0.0000699568,0.0021540055,0.000099202276,0.0005688196,0.00015136159,0.00009101316,0.025354352],"genre_scores_gemma":[0.99421555,0.000079212004,0.0031691229,0.0005401292,0.0002899213,0.00010246087,0.000033617544,0.000054038872,0.001515971],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811316,0.00008028798,0.00038514106,0.00032852468,0.0006565659,0.0004363029],"domain_scores_gemma":[0.99781877,0.00011104209,0.000042802363,0.000654486,0.00039795676,0.00097497087],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038492182,0.0002083522,0.00044432137,0.00025343953,0.000037915175,0.000011609883,0.00018373915,0.00016107508,0.00094959215],"category_scores_gemma":[0.0009930389,0.00017272061,0.00019578193,0.00043469676,0.00016424134,0.00008506264,0.00007597934,0.0003061277,0.00013648675],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025592199,0.009476974,0.2958678,0.0017673726,0.0038491348,0.026534112,0.027800098,0.000121691926,0.24330121,0.0026073821,0.30371898,0.059363045],"study_design_scores_gemma":[0.07579016,0.01119344,0.29160708,0.001577891,0.004510589,0.0019248239,0.007239234,0.0048441547,0.28107348,0.001959619,0.31581295,0.00246658],"about_ca_topic_score_codex":0.0011936066,"about_ca_topic_score_gemma":0.00013527516,"teacher_disagreement_score":0.056896463,"about_ca_system_score_codex":0.00013955982,"about_ca_system_score_gemma":0.0007609685,"threshold_uncertainty_score":0.9999637},"labels":[],"label_agreement":null},{"id":"W2107949981","doi":"10.1186/s13148-015-0129-6","title":"Nucleated red blood cells impact DNA methylation and expression analyses of cord blood hematopoietic cells","year":2015,"lang":"en","type":"article","venue":"Clinical Epigenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"Canadian Institutes of Health Research; Mitacs; BC Children's Hospital; Michael Smith Health Research BC; Child and Family Research Institute","keywords":"dNaM; Nucleated Red Blood Cell; Cord blood; Biology; DNA methylation; Haematopoiesis; Epigenetics; Immune system; Cell sorting; Immunology; Transcriptome; Blood cell; Molecular biology; Stem cell; Flow cytometry; Cell biology; Genetics; Fetus; Gene expression; Gene","score_opus":0.15117686396579272,"score_gpt":0.4526627684138403,"score_spread":0.30148590444804757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107949981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722195,0.0010440593,0.0003768125,0.00019734148,0.00014412325,0.00048725592,0.00002467942,0.00004940372,0.00045437543],"genre_scores_gemma":[0.9878356,0.0014946398,0.009996732,0.00010733822,0.00018310276,0.000005084867,0.000029800147,0.00005368793,0.00029405297],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99689835,0.0004274935,0.001207501,0.0004861345,0.00059839943,0.00038213003],"domain_scores_gemma":[0.9966547,0.0008952506,0.00037789508,0.0007472288,0.0005191707,0.0008057694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013233018,0.00025009856,0.00090285076,0.00016830809,0.000045926725,0.00002338892,0.00020204893,0.00041105598,0.00013367247],"category_scores_gemma":[0.0015569861,0.00019137218,0.00026055326,0.000415968,0.0003927871,0.00005129185,0.00021519564,0.0004958234,0.00003460148],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082349294,0.0009545412,0.022130856,0.00013844998,0.00038041663,0.00007924783,0.00016600294,0.000121717545,0.9701028,0.0000038504936,0.0026211885,0.002477463],"study_design_scores_gemma":[0.005953429,0.0037978024,0.017947214,0.00015513548,0.001130224,0.000023934641,0.00012319871,0.0016172107,0.9684617,0.00029864785,0.00028488509,0.00020664702],"about_ca_topic_score_codex":0.000050831066,"about_ca_topic_score_gemma":0.0000017292365,"teacher_disagreement_score":0.00961992,"about_ca_system_score_codex":0.000048060545,"about_ca_system_score_gemma":0.00043738648,"threshold_uncertainty_score":0.78039306},"labels":[],"label_agreement":null},{"id":"W2108810107","doi":"10.1080/00984100050166514","title":"BENZENE STATUS OF ASSESSMENT? PRIORITY SUBSTANCES PROGRAM","year":2000,"lang":"en","type":"article","venue":"Journal of Toxicology and Environmental Health","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Benzene; Chemistry; Organic chemistry","score_opus":0.018976777361297586,"score_gpt":0.36325796802052995,"score_spread":0.34428119065923235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108810107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935006,0.0036235729,0.000011484998,0.0017363974,0.00004983443,0.00030627951,0.000015003755,0.000005165364,0.0007516572],"genre_scores_gemma":[0.970297,0.022625675,0.0062500243,0.00046613655,0.000080339574,0.0000034269112,0.000008539661,0.00000897657,0.00025988003],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985981,0.00013355384,0.00048723753,0.00011745901,0.00027981808,0.00038382184],"domain_scores_gemma":[0.9991589,0.00006453161,0.00026061037,0.00010575234,0.000009754577,0.00040040474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005332548,0.00009497542,0.00042739,0.00008292391,0.00007973918,0.000004096957,0.000065165594,0.0000977225,0.000812466],"category_scores_gemma":[0.000010689587,0.000074527874,0.0000652871,0.000063258725,0.00027182515,0.00009512046,0.000022800186,0.000484268,0.0000034220818],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011018503,0.0015667182,0.31605408,0.00017241208,0.0001240644,0.00010721013,0.00042054665,0.000010169362,0.006282432,0.000037639387,0.00083265326,0.67329025],"study_design_scores_gemma":[0.0030625274,0.00907526,0.96041995,0.00006135902,0.000039957155,0.00071770506,0.0005297539,0.00012620792,0.0009895073,0.00008927485,0.024820711,0.0000677535],"about_ca_topic_score_codex":0.00003000398,"about_ca_topic_score_gemma":0.000016217184,"teacher_disagreement_score":0.6732225,"about_ca_system_score_codex":0.00058737723,"about_ca_system_score_gemma":0.00044358408,"threshold_uncertainty_score":0.8895933},"labels":[],"label_agreement":null},{"id":"W2108880951","doi":"10.3324/haematol.2013.098103","title":"p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)","year":2014,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"Celgene","keywords":"Myelodysplastic syndromes; Oncology; Internal medicine; Medicine; Outcome (game theory); Protein expression; Biology; Genetics; Gene; Bone marrow","score_opus":0.01351225560887367,"score_gpt":0.24831775188288377,"score_spread":0.2348054962740101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108880951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947863,0.000030276418,0.0010325478,0.00025415266,0.00004910395,0.002091292,0.000013079429,0.00018445114,0.0015588022],"genre_scores_gemma":[0.9953802,0.0000053348313,0.003440516,0.00012474299,0.000030705134,0.00028787082,0.000038303388,0.000061563376,0.0006307699],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99660516,0.0002770206,0.00048116522,0.0007269118,0.001141585,0.0007681687],"domain_scores_gemma":[0.99820495,0.00021097503,0.00027115442,0.0007467722,0.00021635449,0.00034982208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045764097,0.0004049349,0.00089379546,0.00033012935,0.00014071562,0.00003969311,0.00033608964,0.00030409,0.00022521784],"category_scores_gemma":[0.0008912978,0.00022846175,0.00006150531,0.00047669947,0.00024375127,0.00018887526,0.00020501226,0.00094544404,0.00019518398],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034809972,0.00057464687,0.99352956,0.00027608854,0.000055347886,0.0008310881,0.00009773495,0.000050373274,0.000096796226,0.000089703404,0.0002956919,0.0006220018],"study_design_scores_gemma":[0.012771764,0.0061570294,0.97621846,0.0013102255,0.000097535325,0.00034622182,0.00008404303,0.00083789503,0.0011893056,0.0000946531,0.00044460382,0.0004482373],"about_ca_topic_score_codex":0.00005913424,"about_ca_topic_score_gemma":0.000041869032,"teacher_disagreement_score":0.017311044,"about_ca_system_score_codex":0.00022444889,"about_ca_system_score_gemma":0.00017591885,"threshold_uncertainty_score":0.93163997},"labels":[],"label_agreement":null},{"id":"W2109336877","doi":"10.1038/nature04980","title":"Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9","year":2006,"lang":"en","type":"article","venue":"Nature","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1524,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Institutes of Health; Damon Runyon Cancer Research Foundation","keywords":"Progenitor cell; Stem cell; Cancer stem cell; Biology; Haematopoiesis; Cancer research; Population; Cancer cell; Endothelial stem cell; Stem cell theory of aging; Cell biology; Immunology; Cancer; Genetics; Stem cell factor; Medicine","score_opus":0.012329190016317944,"score_gpt":0.2804131572389025,"score_spread":0.26808396722258454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109336877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98027694,0.0010780933,0.00017365106,0.004025387,0.00015855985,0.0010662467,0.0003334128,0.00020469684,0.012683032],"genre_scores_gemma":[0.9917597,0.000013186637,0.00057518977,0.002472317,0.00040150757,0.0000524687,0.0018104712,0.000044514007,0.0028706125],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840045,0.000070941525,0.00028580427,0.00027744193,0.00059560663,0.00036977348],"domain_scores_gemma":[0.9991235,0.00008233911,0.000050547373,0.0003155839,0.00023052785,0.00019749923],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00014199954,0.00019781392,0.0002710897,0.00014604261,0.000086383676,0.000038952134,0.0001948108,0.0013071182,0.0001624233],"category_scores_gemma":[0.000019465726,0.00016900833,0.0000789496,0.0005328255,0.000030216243,0.00013886142,0.000028975008,0.0025957767,0.00033482836],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067266234,0.00022468668,0.004049466,0.00011948625,0.000062257386,0.00011957909,0.0006567015,0.000006695768,0.27547425,0.000058419566,0.7115847,0.006971134],"study_design_scores_gemma":[0.005568189,0.00030230658,0.021090815,0.000112511196,0.00010882072,0.000023286038,0.000367007,0.00065724226,0.6141487,0.00006832577,0.3571946,0.0003581912],"about_ca_topic_score_codex":0.00039761307,"about_ca_topic_score_gemma":0.000052111784,"teacher_disagreement_score":0.35439005,"about_ca_system_score_codex":0.00045581473,"about_ca_system_score_gemma":0.00020211392,"threshold_uncertainty_score":0.9999894},"labels":[],"label_agreement":null},{"id":"W2109362035","doi":"10.1093/annonc/mdu010","title":"Do quality of life or physical function at diagnosis predict short-term outcomes during intensive chemotherapy in AML?","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Alberta; Institute of Health Services and Policy Research; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Quality of life (healthcare); Logistic regression; Internal medicine; Intensive care unit; Comorbidity; Prospective cohort study; Performance status; Univariate analysis; Cancer; Physical therapy; Multivariate analysis","score_opus":0.1495393917303485,"score_gpt":0.4498326209629911,"score_spread":0.30029322923264257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109362035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896708,0.000059276877,0.000019049794,0.008915065,0.00008883662,0.00039747477,0.000012013661,0.000022200564,0.0008152622],"genre_scores_gemma":[0.9965455,0.00042926008,0.000049804617,0.0024158547,0.00019560296,0.00007323624,0.000013345099,0.000022509219,0.00025487578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814475,0.0002939014,0.00058863894,0.000299254,0.00033944516,0.00033400016],"domain_scores_gemma":[0.99757606,0.0011478368,0.00020462954,0.00038172555,0.0005286093,0.0001611223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074922334,0.00015618537,0.0010547176,0.0002047462,0.000026281665,0.0000026103517,0.00014377582,0.00019800171,0.00019556122],"category_scores_gemma":[0.0026179762,0.00011357518,0.00018509975,0.00021654309,0.00027407391,0.000066341316,0.00013416345,0.00029778027,0.00001452993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0078080203,0.0007935671,0.94540536,0.00028583544,0.00026930423,0.00001931454,0.0010304201,0.000006613848,0.01823533,0.00007403096,0.003796987,0.022275202],"study_design_scores_gemma":[0.0040142783,0.0035673243,0.96605486,0.00007122134,0.00002855201,0.0000075928197,0.0003018292,0.000097982665,0.024211742,0.00008300626,0.0014678697,0.000093755276],"about_ca_topic_score_codex":0.00016698282,"about_ca_topic_score_gemma":0.00013882076,"teacher_disagreement_score":0.022181446,"about_ca_system_score_codex":0.00020073808,"about_ca_system_score_gemma":0.00024797607,"threshold_uncertainty_score":0.46314615},"labels":[],"label_agreement":null},{"id":"W2109468984","doi":"10.2174/13816128113199990312","title":"Apolipoprotein B Antisense Inhibition -Update on Mipomersen","year":2013,"lang":"en","type":"review","venue":"Current Pharmaceutical Design","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute","funders":"","keywords":"Apolipoprotein B; Medicine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Internal medicine; Biology; Genetics; Pharmacology; Cholesterol","score_opus":0.3071946929735512,"score_gpt":0.481888465205928,"score_spread":0.1746937722323768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109468984","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010365769,0.98802906,0.0019302588,0.00043425223,0.0007726584,0.0076112356,0.00009375201,0.00024534354,0.00087309757],"genre_scores_gemma":[0.000020285876,0.9949117,0.0008934423,0.00036033348,0.0013500231,0.00094379525,0.00060949934,0.0002140634,0.00069689855],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99432844,0.0011506267,0.0010600806,0.0011424989,0.0011012021,0.001217156],"domain_scores_gemma":[0.9968182,0.00060320244,0.0002822032,0.00089083833,0.00020772508,0.0011978562],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008929433,0.0009846857,0.0024226794,0.00074087444,0.00013836421,0.00011249036,0.0003214002,0.0005873335,0.0019032034],"category_scores_gemma":[0.00042771947,0.00073290785,0.0008212201,0.00083119393,0.000343032,0.00014243572,0.00023034686,0.0034190575,0.020314498],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012371468,0.00041235518,1.9750085e-7,0.018998438,0.00023157442,0.0003110404,0.000007416698,3.1512985e-7,0.00007338015,0.0003618395,0.06555488,0.9139249],"study_design_scores_gemma":[0.0016156962,0.00033952817,5.093538e-7,0.018152501,0.001701152,0.0003431631,0.0000021247254,0.00044511762,0.0007672758,0.000069928654,0.97592235,0.00064068043],"about_ca_topic_score_codex":0.0000035252979,"about_ca_topic_score_gemma":3.641598e-8,"teacher_disagreement_score":0.9132842,"about_ca_system_score_codex":0.0011584811,"about_ca_system_score_gemma":0.0011137784,"threshold_uncertainty_score":0.9995122},"labels":[],"label_agreement":null},{"id":"W2109611268","doi":"10.1016/s1470-2045(15)00201-6","title":"Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"National Cancer Institute; Sunesis","keywords":"Cytarabine; Medicine; Refractory (planetary science); Placebo; Myeloid leukaemia; Double blind; Internal medicine; Chemotherapy; Physics","score_opus":0.09009627044355988,"score_gpt":0.38511582346662937,"score_spread":0.2950195530230695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109611268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97237617,0.00019003464,0.00009158526,0.0077502676,0.00061797164,0.015323391,0.00006141999,0.00016712805,0.003422032],"genre_scores_gemma":[0.989919,0.00017380403,0.0009776512,0.00092294806,0.0010010004,0.0032818136,0.00043230123,0.0001246809,0.0031667785],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941397,0.0011630397,0.0011679714,0.0008993927,0.0014200306,0.0012099149],"domain_scores_gemma":[0.99315107,0.0036195735,0.0006082805,0.0012479604,0.0008614329,0.0005116573],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004155756,0.00064574904,0.0028024062,0.00051609206,0.0002556917,0.00005208016,0.00087151077,0.00042294402,0.00027719818],"category_scores_gemma":[0.0023538603,0.00037085378,0.00016956193,0.00094742636,0.00050686207,0.00028965034,0.00033630125,0.0018417815,0.00023799324],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.970024,0.0037053952,0.0036970729,0.000058124508,0.001454376,0.001118746,0.003641857,0.00095750944,0.00007559603,0.000029645465,0.014423744,0.00081393577],"study_design_scores_gemma":[0.9522977,0.023834415,0.0028984402,0.000085287735,0.00082239637,0.0000708324,0.0014090899,0.004227944,0.00004610452,0.000010299105,0.013874338,0.00042314318],"about_ca_topic_score_codex":0.00059531257,"about_ca_topic_score_gemma":0.0028248404,"teacher_disagreement_score":0.02012902,"about_ca_system_score_codex":0.0068519292,"about_ca_system_score_gemma":0.005553394,"threshold_uncertainty_score":0.99987435},"labels":[],"label_agreement":null},{"id":"W2109841776","doi":"10.1182/blood.v100.3.998","title":"Heterozygous PU.1 mutations are associated with acute myeloid leukemia","year":2002,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":239,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Myeloid leukemia; Mutation; Genetics; Medicine; Leukemia; Biology; Cancer research; Gene","score_opus":0.021889131417652963,"score_gpt":0.2607821144595538,"score_spread":0.23889298304190082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109841776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98350704,0.0002612124,0.00006110016,0.0014827057,0.00004199262,0.0005286092,0.000062190695,0.00029287173,0.013762304],"genre_scores_gemma":[0.9848897,0.000105548526,0.000830252,0.00066210184,0.00016134224,0.000088105706,0.00012172896,0.00007428675,0.0130669195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980959,0.000068688176,0.00025760412,0.00039490568,0.0005997939,0.00058305694],"domain_scores_gemma":[0.9986969,0.00012964213,0.00012881901,0.00049203384,0.00024858996,0.00030401887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001342272,0.00023539485,0.00040451484,0.00019112192,0.00018304995,0.000049244605,0.00018574038,0.00018046143,0.00060325454],"category_scores_gemma":[0.00027621136,0.00018879183,0.00010223592,0.00061742886,0.00015554925,0.00012739531,0.00006280593,0.0005605869,0.000544357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016635305,0.016698135,0.4796046,0.0007238943,0.029579747,0.08751299,0.010996541,0.00034116552,0.13605292,0.0006426713,0.21116917,0.025014624],"study_design_scores_gemma":[0.12023055,0.008448838,0.7054582,0.0020475157,0.010697454,0.015700804,0.0020823819,0.012279656,0.09549819,0.00039307066,0.023714323,0.003449013],"about_ca_topic_score_codex":0.000044876924,"about_ca_topic_score_gemma":0.000060335886,"teacher_disagreement_score":0.2258536,"about_ca_system_score_codex":0.00050893606,"about_ca_system_score_gemma":0.00022441431,"threshold_uncertainty_score":0.76987076},"labels":[],"label_agreement":null},{"id":"W2110048169","doi":"10.1107/s0907444900015791","title":"Crystallization and preliminary studies of the DNA-binding runt domain of AML1","year":2001,"lang":"en","type":"article","venue":"Acta Crystallographica Section D Biological Crystallography","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"RUNX1; Gene; Transcription factor; Haematopoiesis; DNA; Core binding factor; Myeloid; DNA-binding domain; Biology; Myeloid leukemia; Promoter; ETS transcription factor family; Genetics; Molecular biology; Cancer research; Stem cell; Gene expression","score_opus":0.03696362731074828,"score_gpt":0.29300521683197733,"score_spread":0.2560415895212291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110048169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945925,0.0012877198,0.00029875498,0.0012904857,0.00018559683,0.0012682183,0.00003345278,0.00012758203,0.00091572216],"genre_scores_gemma":[0.99340814,0.0050475025,0.001005631,0.00018658514,0.00011528543,0.00008506246,0.00003698044,0.000035456836,0.00007935023],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99666464,0.00044589626,0.00097377854,0.00070595316,0.0006317297,0.0005779789],"domain_scores_gemma":[0.9974646,0.00050970045,0.0005710323,0.0006630732,0.00057774724,0.00021382446],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009715539,0.00042986072,0.0009026156,0.00097539445,0.00034692377,0.000022899672,0.00037109808,0.00051469705,0.00009656941],"category_scores_gemma":[0.00054071186,0.0002655196,0.00062567974,0.0034506598,0.0026275674,0.00017693423,0.0004720685,0.0006055549,1.3503066e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001117393,0.00034697284,0.1931428,0.00023570884,0.00055540696,0.000020012349,0.00031301382,0.000004316675,0.80331665,0.0003094497,0.00037763696,0.00026063735],"study_design_scores_gemma":[0.005347804,0.00847075,0.91624266,0.00080304407,0.00056400435,0.0011900332,0.008367647,0.000063753934,0.0071510947,0.0057735876,0.045147344,0.0008783062],"about_ca_topic_score_codex":0.000027816186,"about_ca_topic_score_gemma":0.000026590526,"teacher_disagreement_score":0.7961655,"about_ca_system_score_codex":0.00008284511,"about_ca_system_score_gemma":0.00008772685,"threshold_uncertainty_score":0.9999797},"labels":[],"label_agreement":null},{"id":"W2110335058","doi":"10.1016/j.bbmt.2013.10.023","title":"Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission","year":2013,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; University of Manitoba","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Takeda Oncology; Health Resources and Services Administration; National Institutes of Health; Swedish Orphan Biovitrum; Otsuka America; Genentech; Seattle Genetics; Kiadis Pharma; Therakos; Sigma-Tau Pharmaceuticals; Medical College of Wisconsin; Tarix Pharmaceuticals; StemCyte; Blue Cross and Blue Shield Association; Merck; Spectrum Pharmaceuticals; U.S. Navy; Osiris Therapeutics; Celgene; National Center for Advancing Translational Sciences; HistoGenetics; Teva Pharmaceutical Industries; WellPoint; GlaxoSmithKline; Leukemia and Lymphoma Society; Be The Match Foundation; Allos Therapeutics; Ariad Pharmaceuticals; Otsuka America Pharmaceutical; Amgen; Sanofi; Onyx Pharmaceuticals; U.S. Department of Defense; U.S. Department of Health and Human Services; National Marrow Donor Program","keywords":"Medicine; Cytarabine; Internal medicine; Myeloid leukemia; Transplantation; Oncology; Leukemia; Surgery","score_opus":0.013121059107107012,"score_gpt":0.28770273962375664,"score_spread":0.2745816805166496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110335058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971214,0.0002938179,0.00043393372,0.00040000494,0.00005521413,0.001415093,0.00019399276,0.000024964256,0.000061590596],"genre_scores_gemma":[0.99264634,0.003934775,0.0011502221,0.00005440892,0.00003795886,0.00009250651,0.0020382209,0.00001874662,0.000026839232],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998726,0.00012399882,0.00045496976,0.00031917036,0.00012323608,0.00025258784],"domain_scores_gemma":[0.9991232,0.00030645376,0.00016948987,0.00013393836,0.00016783137,0.00009906925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038154586,0.00019586385,0.00053136464,0.00023096781,0.00008616182,0.000005278409,0.00007860493,0.00026959062,0.00003081539],"category_scores_gemma":[0.00003405076,0.00015101046,0.000102,0.00013601156,0.00018051878,0.00010817153,0.0000065503154,0.00017060131,0.0000010664737],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049896347,0.000040252726,0.0324885,0.0011189799,0.00016829043,0.000013594006,0.0007022401,0.0000074318746,0.9516575,0.000030532545,0.000034615845,0.008748487],"study_design_scores_gemma":[0.010253498,0.0040255664,0.107575774,0.00058451283,0.0004930144,0.00031008158,0.0000434646,0.00055638613,0.87582594,0.00017304118,0.00002487588,0.00013386487],"about_ca_topic_score_codex":0.00038318633,"about_ca_topic_score_gemma":0.000037197493,"teacher_disagreement_score":0.075831525,"about_ca_system_score_codex":0.000059349244,"about_ca_system_score_gemma":0.000121568046,"threshold_uncertainty_score":0.6158028},"labels":[],"label_agreement":null},{"id":"W2110943230","doi":"10.1016/j.jgo.2015.04.002","title":"Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age","year":2015,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Sunnybrook Health Science Centre; University Health Network; University of Toronto; Health Sciences Centre; Canada Research Chairs","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Myeloid leukemia; Chemotherapy; Quality of life (healthcare); Myeloid; Oncology; Internal medicine; Intensive care medicine","score_opus":0.019921578686642197,"score_gpt":0.3357158532106135,"score_spread":0.3157942745239713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110943230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99822557,0.00014551012,0.00023296669,0.0005481546,0.00008369945,0.00057269813,0.000016201366,0.0000049749533,0.00017024213],"genre_scores_gemma":[0.99794376,0.00016032571,0.0010214333,0.00024664405,0.00038251473,0.000010048685,0.000008653905,0.000023679026,0.00020296378],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9982021,0.00017261476,0.0007876639,0.00018812188,0.0004171978,0.00023231642],"domain_scores_gemma":[0.99680597,0.00036854376,0.0009593907,0.00015893808,0.0014554495,0.00025173032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009895205,0.00015726931,0.0012045597,0.00037450166,0.000012269137,0.0000043177597,0.00010239658,0.00022449731,0.00001736434],"category_scores_gemma":[0.0006017543,0.000107948785,0.0001314945,0.00033583646,0.00016146417,0.000118512085,0.00004262215,0.00044300003,0.0000013795191],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4096395,0.0018936337,0.11926578,0.00064826163,0.0030407119,0.0004948423,0.0066711167,0.00005664166,0.4082434,0.000059494036,0.009274084,0.040712543],"study_design_scores_gemma":[0.13618787,0.06896045,0.7737956,0.0001943783,0.0008566433,0.00059572305,0.002754859,0.0022470567,0.012765201,0.00042049223,0.00087579456,0.0003459008],"about_ca_topic_score_codex":0.0002188297,"about_ca_topic_score_gemma":0.000025093985,"teacher_disagreement_score":0.65452987,"about_ca_system_score_codex":0.0011603319,"about_ca_system_score_gemma":0.002327834,"threshold_uncertainty_score":0.44020236},"labels":[],"label_agreement":null},{"id":"W2111261438","doi":"10.1053/sarh.2001.27717","title":"Systemic medium-sized vessel vasculitis associated with chronic myelomonocytic leukemia","year":2001,"lang":"en","type":"article","venue":"Seminars in Arthritis and Rheumatism","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Vasculitis; Polyarteritis nodosa; Systemic vasculitis; Pathology; Rheumatology; Anti-neutrophil cytoplasmic antibody; Internal medicine; Dermatology; Gastroenterology","score_opus":0.010416325802089144,"score_gpt":0.25051831972742494,"score_spread":0.2401019939253358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111261438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89049965,0.10499504,0.00008432674,0.0007830064,0.00013505117,0.0008550457,0.000018175126,0.00013201979,0.0024976847],"genre_scores_gemma":[0.6777331,0.32027233,0.00033619232,0.00008933581,0.000060712195,0.00011768335,0.00006745668,0.000053303447,0.0012698565],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99707204,0.00018801902,0.0006426165,0.000600049,0.00065085635,0.00084640784],"domain_scores_gemma":[0.99850655,0.00036809954,0.00016460147,0.00048009833,0.00013188044,0.00034879718],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008705233,0.00036373112,0.0009147793,0.0003298789,0.00018438118,0.000072293755,0.00018774914,0.00031873325,0.00027331442],"category_scores_gemma":[0.00041224476,0.0003088438,0.00008869724,0.00067540066,0.00037962254,0.00023832741,0.00011562181,0.0007568212,0.000061991355],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036286787,0.00013998996,0.05047222,0.00038885404,0.00031961713,0.00436571,0.0019280533,0.000046040906,0.00263816,0.00042118435,0.0056631323,0.9332542],"study_design_scores_gemma":[0.06607517,0.003757294,0.58995324,0.2832934,0.00022489048,0.0334595,0.002477085,0.01258912,0.001506932,0.0010497308,0.0036715008,0.0019421418],"about_ca_topic_score_codex":0.000632604,"about_ca_topic_score_gemma":0.0008938976,"teacher_disagreement_score":0.931312,"about_ca_system_score_codex":0.0023060688,"about_ca_system_score_gemma":0.0013825104,"threshold_uncertainty_score":0.99993634},"labels":[],"label_agreement":null},{"id":"W2112926904","doi":"10.1177/0300985810389317","title":"Prognostic Markers for Myeloid Neoplasms","year":2010,"lang":"en","type":"review","venue":"Veterinary Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Myelodysplastic syndromes; Myeloid; Medicine; Immunophenotyping; Essential thrombocythemia; International Prognostic Scoring System; Internal medicine; Cytogenetics; Hematology; Pathology; Oncology; Immunology; Bone marrow; Polycythemia vera; Biology; Chromosome; Genetics","score_opus":0.08864793962350237,"score_gpt":0.39303405198249897,"score_spread":0.3043861123589966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112926904","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00095598307,0.9897663,0.00017677667,0.00014158948,0.0011464572,0.0053422744,0.0002518424,0.0001910175,0.002027769],"genre_scores_gemma":[0.000010692268,0.98021126,0.0102851195,0.00017906363,0.0008208311,0.0026728949,0.0009980476,0.00024753378,0.004574572],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966862,0.00032168612,0.0007649929,0.0010055768,0.00024395666,0.000977583],"domain_scores_gemma":[0.99702156,0.0010930616,0.00029518435,0.0011015865,0.00014943683,0.00033916597],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007293205,0.00067997415,0.0026585609,0.00064764847,0.00012485939,0.000027300779,0.00049296924,0.0015274793,0.0002457994],"category_scores_gemma":[0.00093061215,0.0005406272,0.0008603977,0.0003786106,0.0003732448,0.00005393873,0.000367044,0.0018384246,0.000612598],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030977343,0.00010063276,0.00001159029,0.0263681,0.00015245806,0.0056005437,0.00002041735,1.516844e-8,0.00016595045,0.000046249865,0.003438043,0.96378624],"study_design_scores_gemma":[0.0008991253,0.0047109993,0.00003670143,0.003363607,0.0010917705,0.04445167,0.00000761571,0.000012535772,0.0000013801986,0.000023808936,0.9449856,0.00041518573],"about_ca_topic_score_codex":0.0000027478793,"about_ca_topic_score_gemma":0.0000010377715,"teacher_disagreement_score":0.96337104,"about_ca_system_score_codex":0.0002549565,"about_ca_system_score_gemma":0.0013238308,"threshold_uncertainty_score":0.99976873},"labels":[],"label_agreement":null},{"id":"W2114492926","doi":"10.1158/0008-5472.can-07-6559","title":"Identification of 6-Benzylthioinosine as a Myeloid Leukemia Differentiation–Inducing Compound","year":2008,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Myeloid; Myeloid leukemia; Cancer research; Leukemia; Cellular differentiation; Biology; Cell growth; Chronic myelogenous leukemia; Cell culture; Immunology; Cell biology; Pharmacology; Chemistry; Biochemistry","score_opus":0.0890473418401391,"score_gpt":0.4010026533048339,"score_spread":0.3119553114646948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114492926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993007,0.0010180146,0.00019765057,0.0019373604,0.00013635319,0.00089172035,0.000023255167,0.00005979579,0.0027288555],"genre_scores_gemma":[0.9875677,0.0018253368,0.00011491217,0.00009743757,0.00040803137,0.00021082388,0.00006133322,0.000054228844,0.009660156],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960129,0.0002667078,0.0006166837,0.00053697475,0.0018655959,0.00070108456],"domain_scores_gemma":[0.99687874,0.0003310381,0.000146644,0.0007988042,0.0015268726,0.0003178793],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012773721,0.0001753549,0.00042563747,0.0007339936,0.0004246721,0.000036598245,0.0003847756,0.00017745323,0.0009241917],"category_scores_gemma":[0.0007391009,0.00016097378,0.000117264026,0.0013783429,0.00065065874,0.00019601086,0.00021618334,0.0010801197,0.00033463354],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053378445,0.00015574972,0.012356127,0.0003873754,0.00013210441,0.00012001099,0.0013560008,0.000039811945,0.96612483,0.0007210278,0.015058037,0.0030151634],"study_design_scores_gemma":[0.003078959,0.00039405958,0.15915918,0.00033283955,0.00004516329,0.00027593787,0.00049248035,0.0017683469,0.82973474,0.0004293963,0.0040509673,0.00023794077],"about_ca_topic_score_codex":0.0020723166,"about_ca_topic_score_gemma":0.000044408316,"teacher_disagreement_score":0.14680307,"about_ca_system_score_codex":0.0024598136,"about_ca_system_score_gemma":0.0034402865,"threshold_uncertainty_score":0.9999891},"labels":[],"label_agreement":null},{"id":"W2114549720","doi":"10.1158/1078-0432.ccr-08-1325","title":"CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome Subtypes","year":2009,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Core binding factor; Midostaurin; Myeloid leukemia; Cancer research; Biology; Autophosphorylation; Haematopoiesis; Exon; Leukemia; Fms-Like Tyrosine Kinase 3; Mutant; Tyrosine kinase; Protein kinase B; Molecular biology; Mutation; Transcription factor; Kinase; Signal transduction; Genetics; Gene; Protein kinase A; Stem cell","score_opus":0.14834580115023244,"score_gpt":0.45602768931853915,"score_spread":0.3076818881683067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114549720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885444,0.0006192889,0.000041613886,0.008147796,0.0002731932,0.0016535517,0.00006679679,0.00007410897,0.0005792473],"genre_scores_gemma":[0.991621,0.0045625623,0.00011277761,0.00073774916,0.00048579546,0.00015263083,0.000036299785,0.00006938818,0.002221754],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9936259,0.0009684702,0.0010228248,0.0011107918,0.0017282327,0.0015437995],"domain_scores_gemma":[0.9942478,0.0035713972,0.00015870055,0.00085963076,0.0005058785,0.0006565956],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004905149,0.0003757957,0.0008700615,0.0006206294,0.00042239935,0.0001519075,0.0006323525,0.0005775581,0.00037647667],"category_scores_gemma":[0.0029588838,0.00025477732,0.00017765617,0.0015435249,0.00096156145,0.00029612405,0.00044975133,0.0044053462,0.00023053923],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021497207,0.0009932148,0.3643413,0.0006830679,0.00087511673,0.0067699314,0.0022560281,0.00008755095,0.1164932,0.0004576455,0.009279021,0.4762667],"study_design_scores_gemma":[0.008560935,0.0033606174,0.96927774,0.0010689385,0.00008994296,0.00058437366,0.0004259328,0.004197269,0.0045473324,0.0007497962,0.0065969415,0.00054021017],"about_ca_topic_score_codex":0.0004618502,"about_ca_topic_score_gemma":0.0002877957,"teacher_disagreement_score":0.6049364,"about_ca_system_score_codex":0.0024251319,"about_ca_system_score_gemma":0.0023422174,"threshold_uncertainty_score":0.99999046},"labels":[],"label_agreement":null},{"id":"W2115528152","doi":"10.1016/s1470-2045(15)00038-8","title":"Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Astex Pharmaceuticals; National Cancer Institute; Stand Up To Cancer; Entertainment Industry Foundation","keywords":"Tolerability; Medicine; Decitabine; International Prognostic Scoring System; Internal medicine; Hypomethylating agent; Myelodysplastic syndromes; Adverse effect; Neutropenia; Febrile neutropenia; Oncology; Pharmacology; Gastroenterology; Bone marrow; Toxicity; Biology; DNA methylation","score_opus":0.029835544640734405,"score_gpt":0.33339687282781183,"score_spread":0.30356132818707743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115528152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99475765,0.00010650937,0.00007928524,0.0013825062,0.0000638538,0.0031813942,0.000033589407,0.000026814483,0.00036837778],"genre_scores_gemma":[0.99892324,0.00007719749,0.0005791194,0.00015219119,0.00006523077,0.0000754147,0.000040725477,0.000021919743,0.00006493303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754846,0.0006267449,0.00058521406,0.00040008238,0.00041541847,0.0004241035],"domain_scores_gemma":[0.99796313,0.0008822665,0.00021215095,0.0004671736,0.00025270515,0.00022254982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019161938,0.00021959824,0.0012288014,0.0001446612,0.00006152816,0.000011186221,0.00016021816,0.0001490428,0.000025972857],"category_scores_gemma":[0.0007440055,0.00013307687,0.000027941664,0.00033983585,0.00040022764,0.0001250972,0.00018346458,0.0005503343,0.000005452789],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21772376,0.002762782,0.7624103,0.00013056093,0.0003862571,0.00022366336,0.0050308695,0.00006036277,0.00022663172,0.000022091692,0.00016506108,0.010857705],"study_design_scores_gemma":[0.27319378,0.0072698887,0.71633875,0.00004892046,0.00028602214,0.000108945416,0.00078461185,0.0016102991,0.000018785679,0.000034156663,0.00019306202,0.00011278381],"about_ca_topic_score_codex":0.00013590847,"about_ca_topic_score_gemma":0.00021211094,"teacher_disagreement_score":0.05547002,"about_ca_system_score_codex":0.0005741566,"about_ca_system_score_gemma":0.00038901102,"threshold_uncertainty_score":0.54267174},"labels":[],"label_agreement":null},{"id":"W2115640225","doi":"10.1016/j.exphem.2010.01.003","title":"Extrinsic signals determine myeloid-erythroid lineage switch in MN1 leukemia","year":2010,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Deutsche Forschungsgemeinschaft; Terry Fox Foundation; Cancer Research Society","keywords":"Haematopoiesis; Leukemia; Myeloid leukemia; Bone marrow; Biology; Myeloid; Cancer research; Phenotype; Lineage (genetic); Knockout mouse; Transplantation; Cell biology; Immunology; Stem cell; Receptor; Genetics; Medicine; Gene; Internal medicine","score_opus":0.021772756170148948,"score_gpt":0.33094683044037376,"score_spread":0.3091740742702248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115640225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883598,0.0022546046,0.000043097243,0.000771237,0.00052668,0.0008166249,0.000005350282,0.00014688287,0.0070757065],"genre_scores_gemma":[0.99388367,0.0000409777,0.0029447144,0.0008662475,0.00032734146,0.00020949836,0.000045494828,0.00008340932,0.0015986309],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99720204,0.000095186384,0.0006956237,0.00071040756,0.00040035511,0.000896361],"domain_scores_gemma":[0.9984186,0.00024352554,0.00011937953,0.00075733376,0.00007703573,0.0003841027],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00034809954,0.0003812926,0.0008721913,0.0004505614,0.00009680744,0.000024439953,0.00034701134,0.00046594933,0.0030612452],"category_scores_gemma":[0.0001850966,0.0003514183,0.00016193221,0.00044265477,0.0004089498,0.00016309878,0.00031370838,0.0012827533,0.00078173133],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005474786,0.0005143708,0.012196687,0.00008279513,0.000044187105,0.0026281246,0.0006679404,0.0000012700684,0.974231,0.0041455603,0.0030885683,0.0018520376],"study_design_scores_gemma":[0.0047195437,0.0004745729,0.002768679,0.00006189252,0.000013524502,0.0045848875,0.00068729784,0.00093457464,0.9806042,0.000066245426,0.004763848,0.00032076307],"about_ca_topic_score_codex":0.0002289408,"about_ca_topic_score_gemma":0.00012755145,"teacher_disagreement_score":0.0094280075,"about_ca_system_score_codex":0.0006476877,"about_ca_system_score_gemma":0.00058942474,"threshold_uncertainty_score":0.9999963},"labels":[],"label_agreement":null},{"id":"W2115740244","doi":"10.1586/ehm.10.68","title":"Older patients with acute myeloid leukemia","year":2010,"lang":"en","type":"review","venue":"Expert Review of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Disease; Oncology; Tolerability; Induction chemotherapy; Clinical trial; Internal medicine; Chemotherapy; Intensive care medicine; Adverse effect","score_opus":0.020115558474148244,"score_gpt":0.363715221955897,"score_spread":0.34359966348174875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115740244","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000996178,0.99197286,0.000030019137,0.00037380095,0.00035851452,0.004519519,0.0000512633,0.00007573036,0.0026083053],"genre_scores_gemma":[5.838233e-7,0.9913658,0.0042023407,0.0014591729,0.00021160385,0.0008021156,0.0010093334,0.0002113909,0.00073768705],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952111,0.0003432524,0.001829463,0.00096772524,0.0008355437,0.0008128843],"domain_scores_gemma":[0.99546653,0.00036052236,0.0011104209,0.002037199,0.0006277419,0.00039760332],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044885924,0.0009566723,0.0084167775,0.0004131636,0.00006940658,0.000009854716,0.00079369254,0.0010424022,0.0018088885],"category_scores_gemma":[0.000430695,0.000563413,0.0010577524,0.00073444453,0.00053254265,0.00008771361,0.00033479626,0.0020723396,0.00054061017],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031698666,0.00015196277,0.000023126788,0.25100777,0.0007724002,0.0003304313,0.000026976057,4.6539503e-10,5.927024e-7,0.00023755545,0.050782174,0.6966353],"study_design_scores_gemma":[0.0008934869,0.00025794227,0.000006217393,0.21622218,0.0015469037,0.0027712395,0.000002878414,2.2521438e-7,0.000011511421,0.0000023899065,0.7779066,0.00037843382],"about_ca_topic_score_codex":0.000019635938,"about_ca_topic_score_gemma":0.0000024494893,"teacher_disagreement_score":0.7271244,"about_ca_system_score_codex":0.00056663976,"about_ca_system_score_gemma":0.0034741962,"threshold_uncertainty_score":0.9996817},"labels":[],"label_agreement":null},{"id":"W2117198005","doi":"10.1172/jci24225","title":"The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":240,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Leukemia; Biology; Neuroblastoma RAS viral oncogene homolog; Haematopoiesis; Cancer research; Gene; Signal transduction; Mutation; Genetics; Stem cell","score_opus":0.05203177064518576,"score_gpt":0.38833981176546956,"score_spread":0.3363080411202838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117198005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96177804,0.0005793083,0.000048987502,0.03684889,0.00017673409,0.00040205056,0.0000011880694,0.000005691958,0.00015907588],"genre_scores_gemma":[0.9910045,0.0029708708,0.0031321356,0.0019360785,0.0007655676,0.000008433591,0.0000051720795,0.000015784797,0.00016144385],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99639,0.0009015606,0.0017625006,0.00017892453,0.0005387821,0.0002282726],"domain_scores_gemma":[0.995803,0.0025682077,0.0008105807,0.0001813772,0.00043613938,0.00020070627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009797522,0.00012163738,0.00046239985,0.00019317014,0.0001202145,0.00007094202,0.00017821857,0.00020634345,0.0000051922466],"category_scores_gemma":[0.0063041924,0.00006648542,0.000085700754,0.0006684844,0.0005079769,0.0003547809,0.00006494019,0.0014826813,0.00000857591],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026794877,0.0004022085,0.33056435,0.00018797156,0.0008185612,0.0011584817,0.015461488,0.010265013,0.12678272,0.0037452993,0.012406177,0.47141287],"study_design_scores_gemma":[0.036410876,0.0010187753,0.81345385,0.00081266765,0.00029706763,0.0006959003,0.001663284,0.11502495,0.01954426,0.007469699,0.00334314,0.00026555354],"about_ca_topic_score_codex":0.00011022276,"about_ca_topic_score_gemma":0.0003659152,"teacher_disagreement_score":0.4828895,"about_ca_system_score_codex":0.00069606386,"about_ca_system_score_gemma":0.0017899906,"threshold_uncertainty_score":0.7547162},"labels":[],"label_agreement":null},{"id":"W2117991861","doi":"10.1158/0008-5472.can-05-1400","title":"OLIG2 (BHLHB1), a bHLH Transcription Factor, Contributes to Leukemogenesis in Concert with LMO1","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health","keywords":"Transcription factor; OLIG2; Biology; Transcription (linguistics); Genetics; Gene; Neuroscience; Linguistics","score_opus":0.08823737294699335,"score_gpt":0.41583509566814575,"score_spread":0.3275977227211524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117991861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675542,0.0029025879,0.00028671263,0.025057811,0.000059325932,0.0019973423,0.00006571816,0.000076903954,0.0019993808],"genre_scores_gemma":[0.99020106,0.0010707196,0.00041844047,0.0012393668,0.00042855408,0.0009973185,0.000022850483,0.00007618274,0.005545491],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959117,0.00026889265,0.0003850632,0.0007010406,0.0013699237,0.0013633663],"domain_scores_gemma":[0.9977236,0.00026197784,0.00003027513,0.0005912885,0.00082611485,0.0005667609],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010836797,0.0002503504,0.0005350292,0.0010152771,0.00016573242,0.00008177826,0.00039421994,0.00020226248,0.0010294068],"category_scores_gemma":[0.00027340936,0.0001999366,0.00008127902,0.0021603403,0.00034385177,0.00016574623,0.00010126939,0.0010858946,0.00036446154],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008534747,0.00030950367,0.062786475,0.0003704662,0.00028392364,0.0003925782,0.0028849079,0.0004967648,0.7938331,0.00058336736,0.034002673,0.09552152],"study_design_scores_gemma":[0.015845535,0.0016914834,0.13844378,0.0011830551,0.000057131754,0.00007635795,0.0012754588,0.0010186328,0.49059975,0.0000883568,0.34908968,0.0006307606],"about_ca_topic_score_codex":0.0038815138,"about_ca_topic_score_gemma":0.0046115387,"teacher_disagreement_score":0.31508702,"about_ca_system_score_codex":0.005251309,"about_ca_system_score_gemma":0.00255814,"threshold_uncertainty_score":0.9998838},"labels":[],"label_agreement":null},{"id":"W2118515712","doi":"10.3109/10428194.2015.1018248","title":"A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Decitabine; Vorinostat; Medicine; Myeloid leukemia; Schedule; Myeloid; Internal medicine; Phases of clinical research; Oncology; Clinical trial; Biology","score_opus":0.027536819723377324,"score_gpt":0.29850660911470805,"score_spread":0.2709697893913307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118515712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942765,0.001330349,0.00013624088,0.000099786026,0.00030494694,0.0023768588,0.00026500507,0.000112073896,0.0010982152],"genre_scores_gemma":[0.990887,0.0013232251,0.0063134297,0.00018758408,0.000268607,0.00016185553,0.00034501633,0.00017652371,0.0003367678],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931181,0.0003152363,0.0018652807,0.0014618969,0.0018761669,0.0013632963],"domain_scores_gemma":[0.9952183,0.00045738544,0.00077980885,0.0013772398,0.00094149547,0.0012258168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011165256,0.0010257591,0.0022691833,0.001151565,0.00015258578,0.000089547255,0.0005781239,0.0005886818,0.000034252564],"category_scores_gemma":[0.00033932773,0.0008537057,0.00023605974,0.0016417078,0.0015837754,0.00070581795,0.00048496874,0.00041115517,0.000015574586],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.4278571,0.004161816,0.15621848,0.0011440433,0.0016504906,0.0020343217,0.0046788105,0.00012899541,0.011769232,0.004508953,0.0021246623,0.38372308],"study_design_scores_gemma":[0.8755259,0.014072043,0.08039785,0.0010822156,0.00063744956,0.00069806,0.0010761829,0.0040063434,0.016798753,0.00077933684,0.003572358,0.0013535235],"about_ca_topic_score_codex":0.002041428,"about_ca_topic_score_gemma":0.00009253364,"teacher_disagreement_score":0.44766876,"about_ca_system_score_codex":0.010028788,"about_ca_system_score_gemma":0.01175225,"threshold_uncertainty_score":0.9993914},"labels":[],"label_agreement":null},{"id":"W2119374609","doi":"10.71781/31642","title":"Caractérisation du facteur hématopoïétique spécifique MNDA (Myeloid Nuclear Differentiation Antigen)","year":2007,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Molecular biology","score_opus":0.03375613646549801,"score_gpt":0.34709706257593487,"score_spread":0.31334092611043685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119374609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92637736,0.0005742981,0.0011853068,0.0008573098,0.0026417195,0.0042319214,0.00019401991,0.000018404244,0.06391967],"genre_scores_gemma":[0.9203123,0.0031898106,0.006664591,0.00026127638,0.0025631273,0.000096228316,0.013007166,0.00039401907,0.05351147],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9933645,0.00063328113,0.0016046745,0.0015846324,0.0013772286,0.0014356587],"domain_scores_gemma":[0.9954734,0.00049593,0.0010562487,0.0011281815,0.0010672883,0.0007789913],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0021280926,0.0010417185,0.0014331611,0.00081147277,0.00066994684,0.0008465994,0.0013614371,0.0019729983,0.028683057],"category_scores_gemma":[0.00097145245,0.0010866926,0.00039116252,0.0008446855,0.0002060619,0.0011505388,0.00040438276,0.0023909092,0.013494618],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004252121,0.0016176199,0.054570105,0.0014164182,0.0014666623,0.0013335729,0.03942283,0.000059152724,0.23537888,0.0014245133,0.005047245,0.6540109],"study_design_scores_gemma":[0.00633626,0.0008531991,0.50831956,0.0034257267,0.0009351693,0.000339178,0.021743614,0.008158575,0.17559074,0.00013269969,0.27193835,0.0022269264],"about_ca_topic_score_codex":0.004765583,"about_ca_topic_score_gemma":0.0027146589,"teacher_disagreement_score":0.65178394,"about_ca_system_score_codex":0.0025416536,"about_ca_system_score_gemma":0.0022698622,"threshold_uncertainty_score":0.9999106},"labels":[],"label_agreement":null},{"id":"W2120566462","doi":"10.1182/blood-2011-11-391748","title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":500,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Institut National Du Cancer; National Institutes of Health; Institut Universitaire de France; Terry Fox Foundation; Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"IDH2; Isocitrate dehydrogenase; IDH1; Cancer research; Lymphoma; Biology; Mutation; Angioimmunoblastic T-cell lymphoma; Pathology; Medicine; T cell; Immunology; Gene; Genetics; Enzyme","score_opus":0.017626236859604884,"score_gpt":0.27175941811233933,"score_spread":0.25413318125273443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120566462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98859125,0.0017487915,0.000057985137,0.00033972174,0.00008092216,0.00029963948,0.000009629306,0.000053047217,0.008819034],"genre_scores_gemma":[0.99753636,0.000037074034,0.0009315762,0.00019576513,0.00019387652,0.00005745963,0.000031615764,0.00002899074,0.0009872534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988726,0.000046828496,0.00020031829,0.00015208675,0.00025772065,0.00047046907],"domain_scores_gemma":[0.99930334,0.00010300012,0.00004686821,0.00030089627,0.000058103065,0.00018777545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019490754,0.00011483862,0.00019222197,0.00019956214,0.000045626635,0.000012034266,0.00010007392,0.00008811983,0.00017399152],"category_scores_gemma":[0.00017295893,0.000103404214,0.00006472496,0.00034056779,0.00005453692,0.00010043074,0.000053793694,0.00015831976,0.0006616689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016318394,0.011997544,0.8562395,0.00039597123,0.0002453435,0.00083215476,0.003616546,0.00001633768,0.11675666,0.0005362527,0.0038371207,0.005363376],"study_design_scores_gemma":[0.018275408,0.00021953748,0.91940665,0.00019141128,0.00024413744,0.00035748296,0.0011930318,0.00012663094,0.055131946,0.00008708473,0.0044921935,0.00027446786],"about_ca_topic_score_codex":0.00012082494,"about_ca_topic_score_gemma":0.000015680891,"teacher_disagreement_score":0.06316716,"about_ca_system_score_codex":0.0002262879,"about_ca_system_score_gemma":0.00019933473,"threshold_uncertainty_score":0.85046357},"labels":[],"label_agreement":null},{"id":"W2120629149","doi":"10.3109/10428194.2012.737917","title":"A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network; McGill University; Jewish General Hospital; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Sorafenib; Myeloid leukemia; Myelodysplastic syndromes; Oncology; Rash; Cancer; Leukemia; Bone marrow","score_opus":0.03020316122113193,"score_gpt":0.3264832382603513,"score_spread":0.2962800770392194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120629149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206203,0.0002328288,0.00004158457,0.00017307494,0.00070971175,0.0059108404,0.00076246494,0.000050720948,0.000056714],"genre_scores_gemma":[0.99675345,0.00031465385,0.000367627,0.00032101976,0.00045944634,0.0008724123,0.0005864974,0.00013804124,0.00018682705],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9892795,0.0017691777,0.0033873925,0.001275042,0.0029272926,0.0013616097],"domain_scores_gemma":[0.9920039,0.0035324395,0.002082812,0.0009160293,0.00075074437,0.0007140394],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004461394,0.0010186442,0.003218067,0.0007349337,0.00037336088,0.0000655,0.00076454546,0.00064981985,0.00008832252],"category_scores_gemma":[0.002162233,0.000639996,0.00021187941,0.0021700673,0.0008111128,0.0009244379,0.00035539482,0.00082477607,0.0000035029072],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.5228918,0.01920349,0.3511044,0.00041148698,0.004264914,0.0011867404,0.004812072,0.00084579596,0.000607884,0.00019542694,0.002011264,0.09246473],"study_design_scores_gemma":[0.43367037,0.016894272,0.5442885,0.0007774996,0.00084613776,0.00011197208,0.0006382918,0.0016469985,0.00020271548,0.00004011871,0.0003148206,0.00056827965],"about_ca_topic_score_codex":0.44782406,"about_ca_topic_score_gemma":0.2799508,"teacher_disagreement_score":0.19318412,"about_ca_system_score_codex":0.01914441,"about_ca_system_score_gemma":0.03366124,"threshold_uncertainty_score":0.9996051},"labels":[],"label_agreement":null},{"id":"W2121112512","doi":"10.1016/j.leukres.2007.06.013","title":"Bone marrow mononuclear cells of MDS patients are characterized by in vitro proliferation and increased apoptosis independently of stromal interactions","year":2007,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Sciences Centre Foundation; Amgen","keywords":"Apoptosis; Bone marrow; Stromal cell; Progenitor cell; Biology; In vitro; Myeloid leukemia; In vivo; Myeloid; Cell growth; Cancer research; Peripheral blood mononuclear cell; Immunology; Leukemia; Cell biology; Stem cell; Genetics","score_opus":0.022879054072160572,"score_gpt":0.3158942908060971,"score_spread":0.29301523673393653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121112512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733263,0.0000600289,0.000052900832,0.00018593237,0.000046873658,0.001581807,0.00010957448,0.000020625539,0.0006096141],"genre_scores_gemma":[0.99808645,0.000101456615,0.0007397274,0.00005039947,0.00007946066,0.000083349114,0.00020437589,0.000051131166,0.000603654],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99613875,0.00038010173,0.00081298477,0.0004681536,0.0014677542,0.0007322541],"domain_scores_gemma":[0.9976039,0.00051188434,0.00024316463,0.00044940927,0.0008452571,0.00034641757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024560995,0.00020588803,0.0006102769,0.0011961255,0.000097084674,0.00003374991,0.0002173796,0.00025311715,0.00011208848],"category_scores_gemma":[0.0005118562,0.00019887045,0.00008504224,0.0009479164,0.0003221361,0.00028629322,0.00026676783,0.0013599396,0.000018419074],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007888838,0.0005433136,0.05305865,0.00041546268,0.000057483692,0.000025523754,0.00033185506,7.269012e-7,0.93051994,0.000007649139,0.00086371537,0.0062868386],"study_design_scores_gemma":[0.007412644,0.00058527116,0.12139044,0.00020058501,0.000021043654,0.000009686303,0.0006497156,0.0005107502,0.8685725,0.000016516644,0.0004898326,0.00014103935],"about_ca_topic_score_codex":0.0015385587,"about_ca_topic_score_gemma":0.00006701494,"teacher_disagreement_score":0.06833179,"about_ca_system_score_codex":0.0017847804,"about_ca_system_score_gemma":0.0006425406,"threshold_uncertainty_score":0.8109701},"labels":[],"label_agreement":null},{"id":"W2122059243","doi":"10.1177/2040620715571077","title":"Targeting polo-like kinase 1 in acute myeloid leukemia","year":2015,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"PLK1; Medicine; Cytarabine; Myeloid leukemia; Leukemia; Polo-like kinase; Myeloid; Clinical trial; Oncology; Cancer research; Internal medicine; Cell cycle; Pharmacology; Cancer","score_opus":0.053688199064231314,"score_gpt":0.4039952893888705,"score_spread":0.3503070903246392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122059243","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007103778,0.99436164,0.00015618293,0.00019145283,0.0006440155,0.002242541,0.000024596198,0.00012638734,0.0021821747],"genre_scores_gemma":[0.00015012267,0.9955947,0.0018137865,0.00044681,0.00019432296,0.0006243559,0.00026006636,0.00020550474,0.00071035954],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99404967,0.00083466346,0.0018092719,0.0011971124,0.00057529646,0.0015339986],"domain_scores_gemma":[0.99700975,0.00089584204,0.0005599509,0.0010675334,0.00015057239,0.00031636292],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013572129,0.0009505922,0.005367553,0.0013033749,0.000059191443,0.00001827818,0.0008415497,0.0011649933,0.0002567104],"category_scores_gemma":[0.00023713615,0.0007650434,0.00036798982,0.0015854301,0.00054350507,0.00025373744,0.0003816352,0.002840116,0.0004153326],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000272372,0.00012847884,0.00020855114,0.012123747,0.00025678056,0.0034528642,0.00020419578,0.000011295032,0.0000042008883,0.0014270957,0.00038055461,0.9815299],"study_design_scores_gemma":[0.0021050733,0.00023125872,0.0000034529342,0.006890468,0.00050037116,0.0029907308,0.00016104136,0.00015315932,0.000006204184,0.0016544256,0.9846825,0.00062130735],"about_ca_topic_score_codex":0.000057527945,"about_ca_topic_score_gemma":0.00004963743,"teacher_disagreement_score":0.9843019,"about_ca_system_score_codex":0.0037601346,"about_ca_system_score_gemma":0.0033872004,"threshold_uncertainty_score":0.99948007},"labels":[],"label_agreement":null},{"id":"W2123051805","doi":"10.7573/dic.212252","title":"Targeting the metabolism of leukemia stem cells as a novel therapeutic strategy","year":2013,"lang":"en","type":"article","venue":"Drugs in Context","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Leukemia; Stem cell; Cancer research; Bioinformatics; Pharmacology; Biology; Immunology; Cell biology","score_opus":0.0278855862510363,"score_gpt":0.2910846615499272,"score_spread":0.26319907529889086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123051805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845691,0.002984471,0.00013591081,0.0015221479,0.00014321516,0.0012055545,0.000007819333,0.000033554552,0.009398248],"genre_scores_gemma":[0.99297285,0.00011439481,0.00013975379,0.0013330467,0.0001293402,0.00010638467,0.000004238361,0.000039436207,0.005160545],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998156,0.00013008926,0.0004872783,0.00028942942,0.00047438353,0.00046278597],"domain_scores_gemma":[0.99850374,0.00050327816,0.00013998513,0.00049448706,0.00024681905,0.00011168079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007332125,0.00019700117,0.00044842754,0.00013794517,0.000058996575,0.000037797516,0.00037030134,0.00013398255,0.00058224617],"category_scores_gemma":[0.000059745034,0.00012506882,0.0001109283,0.00037028783,0.00021733192,0.0001319162,0.00011100828,0.0006520924,0.00042583092],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026999298,0.00021434143,0.0009458092,0.0002000591,0.00030177578,0.000020344867,0.01072077,0.00017378543,0.7630891,0.008198635,0.0069099935,0.20895536],"study_design_scores_gemma":[0.025464,0.00083737995,0.025006112,0.00074564014,0.00039776776,0.0001327199,0.13491428,0.052890822,0.666435,0.0027060963,0.08914425,0.0013259259],"about_ca_topic_score_codex":0.0032327094,"about_ca_topic_score_gemma":0.000022319338,"teacher_disagreement_score":0.20762943,"about_ca_system_score_codex":0.0003080279,"about_ca_system_score_gemma":0.00071067346,"threshold_uncertainty_score":0.63751876},"labels":[],"label_agreement":null},{"id":"W2127765975","doi":"10.3324/haematol.2013.101386","title":"Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia","year":2014,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Hector Stiftung; Deutsche Krebshilfe; José Carreras Leukämie-Stiftung; Bundesministerium für Bildung und Forschung; Medizinischen Hochschule Hannover; Deutsche Forschungsgemeinschaft","keywords":"Decitabine; Myeloid leukemia; DNA methylation; Myelodysplastic syndromes; Internal medicine; Azacitidine; Medicine; Hypomethylating agent; Biology; Leukemia; Oncology; Cancer research; Bone marrow; Gene expression; Genetics; Gene","score_opus":0.024916716205095293,"score_gpt":0.33503992879084227,"score_spread":0.310123212585747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127765975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99603695,0.00011649406,0.0002844934,0.00032600583,0.000025267196,0.00051215856,0.0000050957774,0.000054681783,0.002638871],"genre_scores_gemma":[0.99766845,0.00014265688,0.001879537,0.00009183843,0.00003483238,0.000024976349,0.000029252345,0.000021794709,0.00010668315],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99830574,0.00020332185,0.0004080085,0.00038250562,0.00034391443,0.00035650676],"domain_scores_gemma":[0.99850446,0.0006403781,0.00014497933,0.00044190197,0.000087659595,0.00018060366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005353202,0.00021300423,0.00068331003,0.00032566529,0.00005032869,0.000011956866,0.00013573564,0.00023259658,0.00014519785],"category_scores_gemma":[0.0010529247,0.00013747106,0.00010063294,0.00034719415,0.00014213643,0.0000815794,0.00011394704,0.00037737843,0.000044140877],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005195315,0.0004525039,0.060376197,0.00021613593,0.00016091691,0.00029167035,0.0007859216,0.00012910375,0.8952859,0.0012445026,0.0028134638,0.033048347],"study_design_scores_gemma":[0.006070717,0.0024466198,0.8755822,0.00036684697,0.00005497077,0.00025199787,0.000033118908,0.0019293227,0.11213782,0.00072743866,0.0002036704,0.00019527708],"about_ca_topic_score_codex":0.00006134486,"about_ca_topic_score_gemma":0.0000029033974,"teacher_disagreement_score":0.815206,"about_ca_system_score_codex":0.00033232066,"about_ca_system_score_gemma":0.00014841904,"threshold_uncertainty_score":0.56059074},"labels":[],"label_agreement":null},{"id":"W2128096360","doi":"10.1080/1042819021000015989-1","title":"Molecular Analysis of a New Variant of the CBFβ - MYH11 Gene Fusion","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Fusion gene; Chromosomal inversion; Molecular biology; Biology; Breakpoint; Gene; Genetics; Chromosome; Karyotype","score_opus":0.01559876478246606,"score_gpt":0.24700998108138367,"score_spread":0.23141121629891762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128096360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882554,0.003667652,0.0005346814,0.0005925635,0.0001777034,0.0007791842,0.00007596808,0.00009366045,0.005823224],"genre_scores_gemma":[0.99180144,0.001367924,0.001613012,0.001065781,0.00014481023,0.000034283607,0.00006116412,0.00010617196,0.0038054255],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9948833,0.0002601596,0.0013438244,0.0010250898,0.0015185649,0.00096906355],"domain_scores_gemma":[0.99593043,0.00028700253,0.00064349564,0.0020651198,0.00037228613,0.0007016783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054540555,0.00067151734,0.0017252775,0.000999008,0.00023897916,0.000051212206,0.0008409527,0.00060975784,0.000561331],"category_scores_gemma":[0.0003679414,0.00050007075,0.0010149474,0.004157379,0.0006492371,0.00018665704,0.00063522294,0.00025048942,0.00003668693],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021463821,0.0010632694,0.02716376,0.0009426081,0.010384921,0.0018409699,0.0062197945,0.0019525834,0.5952272,0.004366029,0.019182615,0.3295099],"study_design_scores_gemma":[0.035716675,0.0010796443,0.43583828,0.00068486534,0.0114535885,0.0023586089,0.0007322852,0.19329953,0.2989655,0.00054810167,0.017841896,0.0014809957],"about_ca_topic_score_codex":0.0051300297,"about_ca_topic_score_gemma":0.000073844196,"teacher_disagreement_score":0.4086745,"about_ca_system_score_codex":0.004566905,"about_ca_system_score_gemma":0.0034306648,"threshold_uncertainty_score":0.9997451},"labels":[],"label_agreement":null},{"id":"W2128185662","doi":"10.3324/haematol.2012.079012","title":"HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy","year":2013,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Blood Cancer UK; Queen's University","keywords":"Myeloid leukemia; Leukemia; Gene knockdown; Cancer research; Gene signature; Biology; Myeloid; Microarray analysis techniques; Chemotherapy; Gene; Microarray; Acute leukemia; Induction chemotherapy; Oncology; Immunology; Gene expression; Medicine; Genetics","score_opus":0.011518499260826579,"score_gpt":0.2593300131477613,"score_spread":0.2478115138869347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128185662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804855,0.00015861604,0.00037231535,0.010682663,0.00007842476,0.0015967956,0.000017308226,0.00027217244,0.006336234],"genre_scores_gemma":[0.9729067,0.0006011217,0.017698513,0.0070860405,0.00016061327,0.00016242257,0.000020468187,0.00007057691,0.001293561],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970569,0.00009171754,0.00050111255,0.000763294,0.0005344649,0.0010525322],"domain_scores_gemma":[0.9978488,0.0002211799,0.000091094735,0.0006237696,0.00029433618,0.0009207869],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002473181,0.0004524357,0.0009124351,0.00024524936,0.00019718567,0.00011560677,0.00030155524,0.00037145996,0.0011772183],"category_scores_gemma":[0.00017478182,0.00033421608,0.0001617505,0.0004407444,0.0003654181,0.00013902031,0.00034218593,0.000529373,0.0016281802],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011489287,0.00018802339,0.014243711,0.00032608263,0.0005195381,0.0016617823,0.0010644154,0.000006989577,0.8978495,0.000819406,0.071955964,0.010215634],"study_design_scores_gemma":[0.005938236,0.0028022625,0.15047972,0.00017612311,0.0002415188,0.0070794895,0.00060739287,0.0012507847,0.824973,0.00076930574,0.0045524463,0.0011297613],"about_ca_topic_score_codex":0.00031886727,"about_ca_topic_score_gemma":0.000007330937,"teacher_disagreement_score":0.136236,"about_ca_system_score_codex":0.00023458546,"about_ca_system_score_gemma":0.00032682557,"threshold_uncertainty_score":0.999911},"labels":[],"label_agreement":null},{"id":"W2128330888","doi":"10.1016/j.ijscr.2014.02.003","title":"Relapse of acute myeloid leukemia manifested by cholecystitis","year":2014,"lang":"en","type":"article","venue":"International Journal of Surgery Case Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"University Health Network","keywords":"Medicine; Myeloid leukemia; Gallbladder; Infiltration (HVAC); Cholecystectomy; Pathology; CD117; Leukemia; Rare disease; Myeloid; Cholecystitis; Gallbladder cancer; Disease; Gastroenterology; CD34; Internal medicine; Stem cell","score_opus":0.019261344608688773,"score_gpt":0.2992944724260308,"score_spread":0.280033127817342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128330888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931953,0.000276807,0.00095350476,0.0014987992,0.0015981636,0.00011047693,0.000027669741,0.00001971885,0.0023195737],"genre_scores_gemma":[0.9960145,0.00048547232,0.0007017115,0.0003935866,0.00063427753,0.0000034729132,0.00005493472,0.000038255414,0.0016738222],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99629414,0.00010972633,0.0016661081,0.00022989478,0.0014394853,0.00026064354],"domain_scores_gemma":[0.9953232,0.00052559195,0.0015856922,0.00033470828,0.0019054768,0.0003253301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019980785,0.00018616949,0.00065295136,0.0006578002,0.00003759197,0.00003666714,0.00012810132,0.00014535474,0.0003027842],"category_scores_gemma":[0.001386634,0.00015971635,0.00044120627,0.0002226199,0.00013031744,0.00030646852,0.00008526883,0.0005368275,0.0000139512595],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007625425,0.00020140401,0.036389403,0.000061033887,0.0018681453,0.7751172,0.000093081675,0.000022467208,0.041166723,0.000052399682,0.12650694,0.017758653],"study_design_scores_gemma":[0.0010067715,0.000156416,0.0068869987,0.0004211616,0.00022406575,0.9246917,0.000033318778,0.00013197491,0.029631983,0.00015307809,0.03651255,0.00015002451],"about_ca_topic_score_codex":0.0001754195,"about_ca_topic_score_gemma":0.0000031767318,"teacher_disagreement_score":0.14957446,"about_ca_system_score_codex":0.00083653437,"about_ca_system_score_gemma":0.0011584371,"threshold_uncertainty_score":0.6513044},"labels":[],"label_agreement":null},{"id":"W2129077074","doi":"10.1016/j.ccell.2015.05.004","title":"Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia","year":2015,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of British Columbia; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; Occupational Cancer Research Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Gene knockdown; Myeloid leukemia; K562 cells; Biology; Mitochondrion; Oxidative phosphorylation; Molecular biology; Mitochondrial respiratory chain; Cell culture; Small hairpin RNA; Cell biology; Haematopoiesis; Leukemia; Biochemistry; Cancer research; Stem cell; Genetics","score_opus":0.05606377012581656,"score_gpt":0.34871400458539864,"score_spread":0.2926502344595821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129077074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840757,0.0015993923,0.0003536802,0.000986746,0.000491903,0.0039469646,0.00009910669,0.00005239088,0.008394098],"genre_scores_gemma":[0.987587,0.00008813627,0.00029640167,0.00068800116,0.0010663489,0.0007902336,0.000059083297,0.000055076656,0.009369724],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985476,0.00007455404,0.00028802993,0.000297799,0.00044156893,0.00035046297],"domain_scores_gemma":[0.99874336,0.00003550849,0.00015208928,0.0004734288,0.00037686352,0.00021872863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019030638,0.00017624197,0.00028562237,0.000048643564,0.00009538847,0.000021000385,0.00019235013,0.00015521365,0.00019167266],"category_scores_gemma":[0.00004048515,0.000119930104,0.00016446828,0.00019830967,0.00017598791,0.00009307541,0.00006965549,0.00030515532,0.000034236167],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002040264,0.00013407011,0.00028328362,0.00033293988,0.00019133398,0.000018577855,0.0012188299,0.000078286284,0.96854043,0.0004653456,0.021908676,0.004787953],"study_design_scores_gemma":[0.013432291,0.0016172717,0.00037917803,0.00019368141,0.0005026386,0.000020565665,0.0008615405,0.00041912787,0.946661,0.0043068044,0.03134375,0.00026214833],"about_ca_topic_score_codex":0.0010741556,"about_ca_topic_score_gemma":0.000099435194,"teacher_disagreement_score":0.021879438,"about_ca_system_score_codex":0.0015284772,"about_ca_system_score_gemma":0.0032773202,"threshold_uncertainty_score":0.5813825},"labels":[],"label_agreement":null},{"id":"W2129652709","doi":"10.1182/blood-2003-01-0013","title":"GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome","year":2003,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":325,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Acute megakaryoblastic leukemia; GATA1; Down syndrome; Trisomy; Leukemia; Medicine; Myeloid leukemia; Acute leukemia; Mutation; Haematopoiesis; Cancer research; Immunology; Genetics; Biology; Gene","score_opus":0.011725930574856092,"score_gpt":0.2629574799329259,"score_spread":0.2512315493580698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129652709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939864,0.0003927,0.00014052505,0.00018171384,0.000039470564,0.0005285885,0.000034301836,0.000035113488,0.004661167],"genre_scores_gemma":[0.9967161,0.00014930076,0.0022080638,0.00009282458,0.000015809197,0.000048107297,0.00003244196,0.000032968826,0.0007044257],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998324,0.000087569424,0.00043517677,0.00035608522,0.00038298883,0.00041422245],"domain_scores_gemma":[0.9990638,0.00019624585,0.00006686726,0.00035762414,0.00008896509,0.00022649608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029982033,0.00019052261,0.00046812155,0.00035076393,0.00005010049,0.000013228963,0.000108536675,0.00014519399,0.00013342225],"category_scores_gemma":[0.00024632175,0.00017262998,0.00007535164,0.0005886227,0.00020808987,0.000103946775,0.00003072061,0.00041236755,0.000029530029],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022439193,0.005545125,0.16216381,0.004734056,0.005473096,0.029849075,0.014862466,0.0013966465,0.74364257,0.016056558,0.0052357265,0.008796941],"study_design_scores_gemma":[0.062059365,0.0038296904,0.7442916,0.0012924543,0.0030410006,0.01993534,0.0016068157,0.0027435552,0.1554878,0.0015184222,0.0029929534,0.0012009613],"about_ca_topic_score_codex":0.00014577789,"about_ca_topic_score_gemma":0.00004286067,"teacher_disagreement_score":0.5881548,"about_ca_system_score_codex":0.00049028575,"about_ca_system_score_gemma":0.0013601916,"threshold_uncertainty_score":0.70396465},"labels":[],"label_agreement":null},{"id":"W2129834424","doi":"10.1182/blood-2005-06-2317","title":"131I–anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Research Resources; National Cancer Institute; Cancer Research Society","keywords":"Busulfan; Medicine; Cyclophosphamide; Myeloid leukemia; Transplantation; Myeloid; Bone marrow; Total body irradiation; Internal medicine; Leukemia; Gastroenterology; Hazard ratio; Haematopoiesis; Hematopoietic stem cell transplantation; Immunology; Surgery; Oncology; Chemotherapy; Stem cell; Biology; Confidence interval","score_opus":0.01081085101877537,"score_gpt":0.2814298008304982,"score_spread":0.2706189498117228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129834424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956601,0.0014374709,0.0002296279,0.0007060347,0.000031890584,0.0014328022,0.00008510382,0.00004376139,0.00037319248],"genre_scores_gemma":[0.98659515,0.008142422,0.0036776722,0.000060134575,0.00013044091,0.00008611178,0.0003787107,0.00005602547,0.0008733289],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99819803,0.000031557483,0.00052836194,0.00046571513,0.0003054285,0.0004709072],"domain_scores_gemma":[0.9991132,0.000107597734,0.00013129173,0.00034831476,0.00008440253,0.00021516663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018353,0.0002878074,0.00064587203,0.00023191089,0.00010241841,0.0000140152015,0.000117351316,0.00022184184,0.000028416971],"category_scores_gemma":[0.000020184394,0.00023578486,0.00013501444,0.00026127155,0.000094747236,0.00010055428,0.000025137038,0.000114331146,0.000008295979],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036426687,0.0020274643,0.1808845,0.0032570362,0.0006803207,0.0008664045,0.010624782,0.00040770628,0.78405684,0.00009674645,0.00020454885,0.013250958],"study_design_scores_gemma":[0.04068329,0.0025265643,0.21549624,0.000548705,0.0014279025,0.00072058017,0.00024615956,0.0019161404,0.7332947,0.000055375735,0.0027014376,0.00038285635],"about_ca_topic_score_codex":0.00021182426,"about_ca_topic_score_gemma":0.00015150513,"teacher_disagreement_score":0.05076212,"about_ca_system_score_codex":0.0006832387,"about_ca_system_score_gemma":0.00052855036,"threshold_uncertainty_score":0.9615028},"labels":[],"label_agreement":null},{"id":"W2129879298","doi":"10.4049/jimmunol.176.9.5267","title":"Notch Signaling Requires GATA-2 to Inhibit Myelopoiesis from Embryonic Stem Cells and Primary Hemopoietic Progenitors","year":2006,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Hospital; Women's College Hospital; Sunnybrook Health Science Centre","funders":"RIKEN","keywords":"Myelopoiesis; Haematopoiesis; Lymphopoiesis; Biology; Cell biology; Progenitor cell; Myeloid; Stem cell; Embryonic stem cell; Notch signaling pathway; Cellular differentiation; Immunology; Signal transduction; Genetics; Gene","score_opus":0.013374638362192734,"score_gpt":0.2476545570029569,"score_spread":0.23427991864076417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129879298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842042,0.0078436555,0.00018738318,0.006936513,0.000233655,0.00035265397,0.000008386759,0.00002037661,0.00021320356],"genre_scores_gemma":[0.99551237,0.0005910196,0.0017792735,0.0005229098,0.0005432246,0.0000050939693,0.000004040037,0.00004250023,0.0009995637],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979498,0.00033756066,0.00066625385,0.00017919613,0.00041780906,0.00044942132],"domain_scores_gemma":[0.99821407,0.0006480514,0.0003351562,0.00038236746,0.00030070593,0.0001196495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010067968,0.00020625527,0.00058858085,0.0002815735,0.00014943413,0.000030499095,0.0003749609,0.00016548333,0.00007279404],"category_scores_gemma":[0.00007267524,0.00013317291,0.00011168409,0.0003166698,0.0003007454,0.00011852581,0.00025552275,0.00078214065,0.00006509984],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016594366,0.00007116304,0.00073112035,0.000037498885,0.0003093445,0.0001790562,0.0006753517,0.00003057263,0.98699796,0.000014376413,0.003980467,0.0053136437],"study_design_scores_gemma":[0.0032838816,0.0014394845,0.015337886,0.00032031024,0.00043005645,0.0019870433,0.0018281877,0.000024560168,0.9704383,0.0004392926,0.004248524,0.00022246584],"about_ca_topic_score_codex":0.00024822992,"about_ca_topic_score_gemma":0.000009957716,"teacher_disagreement_score":0.016559662,"about_ca_system_score_codex":0.00043501987,"about_ca_system_score_gemma":0.000501916,"threshold_uncertainty_score":0.54306334},"labels":[],"label_agreement":null},{"id":"W2130318810","doi":"10.1016/j.bbmt.2013.12.560","title":"Benefit of Allogeneic Transplantation in Patients Age ≥ 60 Years with Acute Myeloid Leukemia Is Limited to Those in First Complete Remission at Time of Transplant","year":2013,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Myeloid leukemia; Transplantation; Internal medicine; Univariate analysis; Complete remission; Leukemia; Proportional hazards model; Surgery; Multivariate analysis; Confidence interval; Chemotherapy","score_opus":0.012190120352931492,"score_gpt":0.239927975621666,"score_spread":0.22773785526873452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130318810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980703,0.00009816028,0.000051738654,0.0001785499,0.0000147111705,0.0009744158,0.0005136017,0.00001063864,0.00008789631],"genre_scores_gemma":[0.9947345,0.0024259917,0.0013305187,0.00008363112,0.000007309775,0.00003750231,0.0013043059,0.000019856901,0.000056365443],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99853283,0.00007311449,0.000582823,0.000331701,0.0002112161,0.0002682864],"domain_scores_gemma":[0.99934447,0.00012327984,0.00015192472,0.00016573675,0.00010164221,0.00011294456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017155134,0.0001894496,0.00054737634,0.00043719416,0.000023899205,0.0000025724337,0.00010816092,0.00022160594,0.00007632253],"category_scores_gemma":[0.0000063560856,0.00015930067,0.000054584234,0.00029726248,0.00014980527,0.00008281697,0.0000101444275,0.00014706627,0.000005864999],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052030333,0.00018138505,0.22670867,0.0007863261,0.00013341336,0.00014167129,0.0050295093,0.000038184127,0.760402,0.000009843789,0.000017467873,0.0013484464],"study_design_scores_gemma":[0.009267759,0.0018164866,0.84766454,0.0009043806,0.0003355827,0.00006188098,0.00003483912,0.00012448912,0.13959065,0.000026884172,0.000015278143,0.00015725789],"about_ca_topic_score_codex":0.0009468148,"about_ca_topic_score_gemma":0.0005007494,"teacher_disagreement_score":0.6209558,"about_ca_system_score_codex":0.00006723645,"about_ca_system_score_gemma":0.00008178772,"threshold_uncertainty_score":0.64960927},"labels":[],"label_agreement":null},{"id":"W2131996949","doi":"10.1016/j.bbmt.2014.10.025","title":"Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy","year":2014,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Vancouver General Hospital","funders":"National Cancer Institute; U.S. Department of Health and Human Services","keywords":"Medicine; Internal medicine; Myeloid leukemia; Regimen; Transplantation; Hematopoietic stem cell transplantation; Cohort; Leukemia; Oncology; Surgery","score_opus":0.009010116579552396,"score_gpt":0.23662050965143555,"score_spread":0.22761039307188316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131996949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980306,0.00016331686,0.00078305247,0.00014807683,0.000042258886,0.00042821714,0.00007389992,0.000021558853,0.0003090446],"genre_scores_gemma":[0.99391776,0.0038930606,0.0011893978,0.00013331222,0.00004758023,0.000019452838,0.0007384147,0.000016013106,0.000045021632],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99906546,0.0001036922,0.00026495993,0.000235491,0.00015231014,0.00017808308],"domain_scores_gemma":[0.99937946,0.000106796215,0.00014832386,0.00014477242,0.00015069424,0.00006996582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017803746,0.00014124147,0.00036022827,0.00015074744,0.000041844163,0.0000034290993,0.00006467239,0.00017351867,0.00001451114],"category_scores_gemma":[0.000012238792,0.00010221265,0.000041636325,0.00012713598,0.00023973364,0.00009624732,0.000007239512,0.0001510228,0.0000010232399],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047005084,0.00016120744,0.29777277,0.00043334556,0.00048083928,0.000007689985,0.000985469,0.0000038916587,0.6417158,0.0001783477,0.000055525794,0.053504582],"study_design_scores_gemma":[0.017135754,0.003488754,0.81568164,0.00013914071,0.0004692702,0.00002922319,0.00004350309,0.000023474628,0.16248828,0.000093161994,0.00025848346,0.00014933082],"about_ca_topic_score_codex":0.00012275217,"about_ca_topic_score_gemma":0.000014752228,"teacher_disagreement_score":0.5179089,"about_ca_system_score_codex":0.000025954158,"about_ca_system_score_gemma":0.00012760416,"threshold_uncertainty_score":0.4168111},"labels":[],"label_agreement":null},{"id":"W2132847741","doi":"10.4172/2165-7920.1000133","title":"A Case of a Young Girl with Myelodysplastic Syndrome (MDS), Dysmorphic Features, Short Stature, and Developmental Delay – Is there a Link?","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Case Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Ottawa","funders":"","keywords":"Girl; Short stature; Medicine; Pediatrics; Tall Stature; Myelodysplastic syndromes; Link (geometry); Global developmental delay; Omics; Bioinformatics; Genetics; Internal medicine; Computer science; Biology; Phenotype; Computer network","score_opus":0.05034275848701534,"score_gpt":0.36780334655471575,"score_spread":0.3174605880677004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132847741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951106,0.0030080243,0.0001160218,0.00037468463,0.00033294124,0.00042205252,0.000017942275,0.000013096272,0.00060465746],"genre_scores_gemma":[0.991008,0.00036448357,0.007333106,0.00022101752,0.0004976317,0.000006286721,0.000006308536,0.000059220114,0.00050398597],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9954074,0.00021409105,0.0024776175,0.00034482614,0.0009887196,0.00056733127],"domain_scores_gemma":[0.9954117,0.0009874657,0.0012217788,0.0003993963,0.0007298771,0.001249817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004197093,0.00032035293,0.0013694712,0.00028473046,0.00010607078,0.000033027012,0.00006901683,0.00041634266,0.00016940014],"category_scores_gemma":[0.0022953586,0.00020311172,0.00030011253,0.0003571311,0.0003629812,0.00031646312,0.00012991023,0.002086352,0.000003876328],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012736464,0.0003148192,0.21966283,0.00018186994,0.00072085223,0.77122456,0.00039188325,0.0000011217072,0.00005103145,0.00000413995,0.0018990012,0.0042742454],"study_design_scores_gemma":[0.0018337389,0.0017534127,0.11145397,0.00047217216,0.000689636,0.8812787,0.00044412378,0.000023292492,0.00012552006,0.000019165298,0.0017141829,0.00019207051],"about_ca_topic_score_codex":0.000107254564,"about_ca_topic_score_gemma":0.00008607101,"teacher_disagreement_score":0.11005415,"about_ca_system_score_codex":0.00022128648,"about_ca_system_score_gemma":0.0019234853,"threshold_uncertainty_score":0.9064278},"labels":[],"label_agreement":null},{"id":"W2133104631","doi":"10.1002/14651858.cd006648.pub2","title":"Stem cell transplantation for acute myelocytic leukaemia in paediatric patients in first remission","year":2013,"lang":"en","type":"reference-entry","venue":"Cochrane Database of Systematic Reviews","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Alberta Cancer Foundation; University of Alberta; Hospital for Sick Children","funders":"","keywords":"Transplantation; Medicine; Myelocytic leukemia; Stem cell; Complete remission; Pediatrics; Oncology; Internal medicine; Leukemia; Chemotherapy; Biology; Genetics","score_opus":0.0542280354463218,"score_gpt":0.3399953899808661,"score_spread":0.28576735453454427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133104631","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.051105253,0.82866573,0.0010991421,0.00020342431,0.0015442829,0.100122415,0.0075774314,0.00008967245,0.009592641],"genre_scores_gemma":[0.0018512846,0.96837574,0.0014233306,0.000049920145,0.00020499788,0.004576196,0.01699126,0.0001294041,0.006397845],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99124503,0.00096902234,0.0047625336,0.0009775374,0.0013078414,0.0007380451],"domain_scores_gemma":[0.99347967,0.0016720635,0.0021807763,0.0018360135,0.0005056368,0.0003258329],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033993295,0.0008280085,0.0055805454,0.0012821581,0.000057955483,0.000037055044,0.00073260645,0.00066180923,0.00013591768],"category_scores_gemma":[0.0008167575,0.0005843904,0.0005436081,0.0010668883,0.000064585496,0.00029331702,0.00013302128,0.0008494513,0.00029144713],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002468059,0.00028752204,0.00056307093,0.93216443,0.00008048361,0.00009336533,0.00042918752,0.0000015021981,0.000027245174,0.0000038666094,0.063128024,0.0029744685],"study_design_scores_gemma":[0.009038847,0.00043080596,0.000468057,0.98038846,0.0029162476,0.00007272661,0.00019862126,0.00095714186,0.00020700555,0.0000053736894,0.0046035866,0.0007131228],"about_ca_topic_score_codex":0.00026847198,"about_ca_topic_score_gemma":0.00009455346,"teacher_disagreement_score":0.13971002,"about_ca_system_score_codex":0.0016351907,"about_ca_system_score_gemma":0.0009850007,"threshold_uncertainty_score":0.99966073},"labels":[],"label_agreement":null},{"id":"W2133493764","doi":"10.1016/j.ctrv.2010.05.006","title":"5-Azacytidine in myelodysplastic syndromes: A clinical practice guideline","year":2010,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Context (archaeology); Guideline; Intensive care medicine; Clinical trial; Disease; Internal medicine; Palliative care; Oncology; Pathology; Bone marrow","score_opus":0.21304195759432804,"score_gpt":0.5385010240775383,"score_spread":0.32545906648321027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133493764","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000031942086,0.9841724,0.000025472094,0.0010883303,0.00091694936,0.00924717,0.000105022926,0.000077479395,0.0043639913],"genre_scores_gemma":[1.1788088e-7,0.9762684,0.009078813,0.00092305563,0.0019121469,0.005723192,0.0007718328,0.0002075343,0.0051148986],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99082285,0.0012529342,0.004834004,0.001571147,0.0005753652,0.00094369677],"domain_scores_gemma":[0.9935655,0.0017942588,0.0015669034,0.0020822454,0.00028036517,0.0007107406],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0029299215,0.0013079421,0.009239726,0.00056763884,0.00007216327,0.000052934145,0.0005133124,0.001103554,0.0013162836],"category_scores_gemma":[0.004164997,0.0007829164,0.0020225702,0.0013282185,0.00021187445,0.00017750546,0.00018477268,0.002558428,0.0026570235],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000075046424,0.000716218,0.00004619052,0.013817163,0.0005701695,0.0015057616,0.000019332852,1.08419236e-7,2.4851448e-7,0.000012989936,0.030825553,0.95241123],"study_design_scores_gemma":[0.0026114124,0.0008810778,0.000006657956,0.044949684,0.007850849,0.001525288,0.000007917001,0.000011010824,2.2574794e-7,0.0000025070397,0.9416317,0.0005217107],"about_ca_topic_score_codex":0.00039129154,"about_ca_topic_score_gemma":0.00017264961,"teacher_disagreement_score":0.9518895,"about_ca_system_score_codex":0.0050092395,"about_ca_system_score_gemma":0.0066444566,"threshold_uncertainty_score":0.9999672},"labels":[],"label_agreement":null},{"id":"W2133581509","doi":"10.3324/haematol.13044","title":"Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO","year":2008,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"Studienstiftung des Deutschen Volkes","keywords":"Myeloid leukemia; Leukemia; Downregulation and upregulation; Cancer research; Myeloid; Biology; Microarray analysis techniques; Cell growth; Molecular biology; Cell culture; Gene expression; Gene; Immunology; Genetics","score_opus":0.053897946218395276,"score_gpt":0.2971970424751597,"score_spread":0.24329909625676444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133581509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924701,0.00059067114,0.0007931656,0.00073437375,0.00006509446,0.0004829969,0.000008446384,0.000090481844,0.004764704],"genre_scores_gemma":[0.99405557,0.00018171247,0.004594908,0.0001738024,0.00006909165,0.000052055628,0.000050144685,0.000026031805,0.0007966927],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99783146,0.000135409,0.0006055149,0.00040327103,0.00057582074,0.00044852644],"domain_scores_gemma":[0.99902797,0.00016536252,0.00013956572,0.0003726988,0.00014908453,0.00014534322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028906183,0.00021119467,0.0006372896,0.0003337409,0.00010681719,0.000008036625,0.00019302526,0.0002552138,0.0004804821],"category_scores_gemma":[0.00022862581,0.00017710529,0.00014605926,0.0004549321,0.00039371348,0.00017199137,0.000061018436,0.0004186839,0.000076458535],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025676792,0.00081704604,0.17848131,0.0007667927,0.00012599553,0.002304836,0.004298838,0.0005573361,0.7937885,0.00443888,0.0065660784,0.0052867224],"study_design_scores_gemma":[0.006167791,0.00048765214,0.88482666,0.00070369773,0.00005281332,0.004538927,0.00050229736,0.00563108,0.09288912,0.0010261018,0.002752889,0.00042096502],"about_ca_topic_score_codex":0.000070785136,"about_ca_topic_score_gemma":0.000014251878,"teacher_disagreement_score":0.7063454,"about_ca_system_score_codex":0.00031843572,"about_ca_system_score_gemma":0.00039387378,"threshold_uncertainty_score":0.7222144},"labels":[],"label_agreement":null},{"id":"W2133904591","doi":"10.1016/j.exphem.2008.02.011","title":"Linkage of Meis1 leukemogenic activity to multiple downstream effectors including Trib2 and Ccl3","year":2008,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Hox gene; Biology; Homeobox; Myeloid leukemia; Cancer research; Downregulation and upregulation; Cell biology; Transcription factor; Genetics; Gene","score_opus":0.04514763524759335,"score_gpt":0.3432770664440574,"score_spread":0.29812943119646407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133904591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99564326,0.0020931687,0.00009483049,0.0003020933,0.00011738395,0.00079607434,0.000009016833,0.00006615023,0.00087803666],"genre_scores_gemma":[0.9979058,0.000049746548,0.0015213504,0.00012701731,0.000057531193,0.000088196284,0.000011796129,0.000034029486,0.00020451767],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99847776,0.00011933319,0.0002870963,0.00041889373,0.0002667509,0.00043017187],"domain_scores_gemma":[0.9988456,0.00036354532,0.00007922501,0.0003518067,0.000045777837,0.00031408624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015861668,0.00022242639,0.0007034025,0.00024695753,0.0001395042,0.0000038739304,0.00012696962,0.00018747416,0.0001476622],"category_scores_gemma":[0.00022132711,0.00019846813,0.000108694854,0.00026572318,0.00031102303,0.00007963515,0.00034739156,0.00027523926,0.00006489243],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011976021,0.0005818509,0.08269018,0.00015957547,0.00014605504,0.00051752187,0.001797431,9.925315e-7,0.9097632,0.00044415123,0.0014801896,0.0012212542],"study_design_scores_gemma":[0.0040921546,0.00089582405,0.011050896,0.000057935624,0.000018532315,0.0022800837,0.00032163487,0.00024332714,0.98049694,0.000004530889,0.00038476667,0.00015338612],"about_ca_topic_score_codex":0.00021453014,"about_ca_topic_score_gemma":0.000009855628,"teacher_disagreement_score":0.071639284,"about_ca_system_score_codex":0.0003677741,"about_ca_system_score_gemma":0.00015914871,"threshold_uncertainty_score":0.8093295},"labels":[],"label_agreement":null},{"id":"W2135057615","doi":"10.3109/10428190903585286","title":"A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Sorafenib; Internal medicine; Myeloid leukemia; Refractory (planetary science); Regimen; Myelodysplastic syndromes; Oncology; Population; Phases of clinical research; Chemotherapy; Leukemia; Clinical trial; Gastroenterology; Bone marrow","score_opus":0.053731407724228554,"score_gpt":0.3961122256343599,"score_spread":0.3423808179101313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135057615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913209,0.00028881902,0.000042474334,0.00005773695,0.00089387747,0.0069413627,0.00031531136,0.000054020493,0.00008547151],"genre_scores_gemma":[0.9971207,0.0004517677,0.001035335,0.00017897788,0.00024287107,0.0006045177,0.00011347859,0.00010811909,0.00014426585],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98567444,0.0028599792,0.006293651,0.001742949,0.0023661482,0.0010628228],"domain_scores_gemma":[0.98805296,0.0061634113,0.0026084005,0.001085978,0.0012201373,0.00086908386],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.011880421,0.0010356185,0.0069971997,0.00094780896,0.00021895864,0.00004944733,0.00072651106,0.00079209486,0.00008734],"category_scores_gemma":[0.0075578624,0.0006938462,0.00045184838,0.0014279665,0.0029273606,0.0004158564,0.0005460395,0.0009545447,0.0000017331695],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32812423,0.0079296585,0.6348251,0.00046051142,0.0045778374,0.00094845815,0.0008066331,0.00007178038,0.0006364883,0.00026918607,0.00017456946,0.021175535],"study_design_scores_gemma":[0.5296668,0.007538257,0.45647934,0.0003557544,0.001684819,0.0001857647,0.0007487512,0.0025658172,0.00014333565,0.00008244911,0.000052818206,0.0004960881],"about_ca_topic_score_codex":0.094405204,"about_ca_topic_score_gemma":0.115182854,"teacher_disagreement_score":0.20154259,"about_ca_system_score_codex":0.0037010775,"about_ca_system_score_gemma":0.0360927,"threshold_uncertainty_score":0.9997861},"labels":[],"label_agreement":null},{"id":"W2135283317","doi":"10.1111/j.1600-0560.2010.01533.x","title":"CD163 expression in leukemia cutis","year":2010,"lang":"en","type":"article","venue":"Journal of Cutaneous Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Leukemia cutis; Pathology; Cutis; Leukemia; Medicine; CD163; Dermatology; Biology; Immunology; Phenotype; Bone marrow; Gene; Genetics","score_opus":0.011477606302217858,"score_gpt":0.29869198249921064,"score_spread":0.2872143761969928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135283317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934447,0.00017202675,0.00014915965,0.0014746912,0.0006213292,0.0001435891,0.0000024439573,0.000014538733,0.0039775386],"genre_scores_gemma":[0.98865795,0.00022427607,0.0089372145,0.00047838283,0.00058959064,0.0000025676563,0.0000021693243,0.000030034416,0.0010777886],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.9982681,0.00012275905,0.00063152367,0.00018262892,0.00039228197,0.00040267088],"domain_scores_gemma":[0.9986606,0.00022457576,0.0002801564,0.00032483012,0.00025498972,0.00025485212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006257764,0.00014764638,0.00053388736,0.00049965637,0.00003880011,0.000012200487,0.00025596935,0.00034903619,0.00049250945],"category_scores_gemma":[0.00089710974,0.000111573856,0.00013855066,0.00021527916,0.00017671919,0.00008674611,0.00008387748,0.0022348901,0.000079107645],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077299995,0.000104113715,0.017745651,0.00002708163,0.000014373324,0.07585716,0.0004007962,0.000017398796,0.8920361,0.000062194886,0.0044700466,0.008492113],"study_design_scores_gemma":[0.005404161,0.0026189284,0.035268847,0.00023925169,0.00007804146,0.80209476,0.00032514773,0.00039707386,0.11244075,0.0014657481,0.03938425,0.00028306333],"about_ca_topic_score_codex":0.000009929096,"about_ca_topic_score_gemma":0.00004465356,"teacher_disagreement_score":0.7795953,"about_ca_system_score_codex":0.00035040616,"about_ca_system_score_gemma":0.0008573241,"threshold_uncertainty_score":0.970961},"labels":[],"label_agreement":null},{"id":"W2136006080","doi":"10.25011/cim.v34i6.15889","title":"Targeting the oncogene eIF4E in cancer: From the bench to clinical trials","year":2011,"lang":"en","type":"article","venue":"Clinical and investigative medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer","funders":"Dalhousie University; Jewish General Hospital; McMaster University","keywords":"EIF4E; Medicine; Myeloid leukemia; Cancer; Clinical trial; Translation (biology); Oncogene; Cancer research; Bench to bedside; Eukaryotic translation; Ribavirin; Oncology; Immunology; Internal medicine; Biology; Gene; Cell cycle; Messenger RNA; Genetics; Virus","score_opus":0.5885935776291776,"score_gpt":0.5074475092548277,"score_spread":0.0811460683743499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136006080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77933496,0.0029371874,0.000078392564,0.2143281,0.00085340237,0.0012972069,0.000023605542,0.000026606469,0.0011205678],"genre_scores_gemma":[0.92503583,0.0045499555,0.0016965334,0.061159607,0.006682945,0.0001698853,0.00003899075,0.00003601406,0.00063026045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992319,0.0035260946,0.0025323445,0.0006848132,0.00049772597,0.0004400152],"domain_scores_gemma":[0.986888,0.0109163765,0.00041003354,0.0006280875,0.0002629621,0.0008945209],"candidate_categories":["metaresearch","sts"],"consensus_categories":[],"category_scores_codex":[0.023809034,0.00026441013,0.0015208618,0.000066451066,0.00016143938,0.000011604008,0.00045826068,0.0002510304,0.00087771035],"category_scores_gemma":[0.07910203,0.00010842354,0.00018100244,0.00056964153,0.009965658,0.00007012676,0.00032493906,0.0018272416,0.00006593554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006805084,0.0001621411,0.8400052,0.000017028484,0.00025379573,0.00006461278,0.00428173,6.0716945e-7,0.001169825,0.00084795256,0.09967634,0.05284025],"study_design_scores_gemma":[0.006780012,0.0023529553,0.9221053,0.0007598098,0.0003612449,0.0000064952515,0.0027317198,0.00048744536,0.0006692318,0.01588213,0.047654472,0.00020914905],"about_ca_topic_score_codex":0.005390195,"about_ca_topic_score_gemma":0.00041991906,"teacher_disagreement_score":0.15316848,"about_ca_system_score_codex":0.00006867727,"about_ca_system_score_gemma":0.00058726134,"threshold_uncertainty_score":0.99272865},"labels":[],"label_agreement":null},{"id":"W2136752052","doi":"10.1016/j.leukres.2012.08.022","title":"Corrigendum to ‘Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia’ [Leuk. Res. 36 (10) (2012) 1241–1248]","year":2012,"lang":"en","type":"erratum","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Medicine; Gerontology; Oncology; Quality of life (healthcare); Chemotherapy; Internal medicine","score_opus":0.09005882696424405,"score_gpt":0.3805983479039067,"score_spread":0.2905395209396626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136752052","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.961756,0.0016191474,0.00052821,0.007725404,0.0041547245,0.014666343,0.0023539779,0.00045227094,0.0067439135],"genre_scores_gemma":[0.244798,0.001004893,0.0010759938,0.00767604,0.0068625403,0.002356235,0.004980747,0.001173049,0.7300725],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9855697,0.0011166934,0.0017043275,0.0026559099,0.0051622316,0.0037911104],"domain_scores_gemma":[0.9851488,0.0012853169,0.0007043055,0.0026597746,0.0069443434,0.0032574497],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0042958055,0.0015283986,0.0041917576,0.0021062975,0.0007511217,0.00027719728,0.0013106253,0.0020121913,0.0008053467],"category_scores_gemma":[0.005758584,0.0013194997,0.00065211306,0.0028199889,0.0011945326,0.0005285919,0.0012531995,0.006436932,0.00025837027],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.029662468,0.0003531612,0.00037520085,0.0016866856,0.0036107162,0.00035483713,0.006833539,0.000010882559,0.034713972,0.000028008526,0.92148125,0.00088928966],"study_design_scores_gemma":[0.058798507,0.01186198,0.21593317,0.007878135,0.0026121028,0.00019442983,0.008140687,0.0023899593,0.019770568,0.00029933557,0.6663264,0.005794714],"about_ca_topic_score_codex":0.0019947507,"about_ca_topic_score_gemma":0.00048890867,"teacher_disagreement_score":0.7233286,"about_ca_system_score_codex":0.016159398,"about_ca_system_score_gemma":0.009772882,"threshold_uncertainty_score":0.99974644},"labels":[],"label_agreement":null},{"id":"W2139638366","doi":"10.1158/1078-0432.ccr-10-0093","title":"Dynamic Single-Cell Network Profiles in Acute Myelogenous Leukemia Are Associated with Patient Response to Standard Induction Therapy","year":2010,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Induction chemotherapy; Oncology; Leukemia; Medicine; Chemotherapy; Univariate analysis; Internal medicine; Flow cytometry; Immunology; Multivariate analysis","score_opus":0.09079508066410974,"score_gpt":0.43003394922789573,"score_spread":0.339238868563786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139638366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98876977,0.0003176146,0.000019335306,0.007053525,0.00040016518,0.0028954658,0.000093238865,0.00009583398,0.00035506242],"genre_scores_gemma":[0.99467427,0.0005837327,0.000989219,0.0007583544,0.0003997361,0.00070014095,0.000050603572,0.00012177845,0.0017221835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99257773,0.0019518596,0.0008835632,0.001024517,0.002014435,0.0015478875],"domain_scores_gemma":[0.99403334,0.002415977,0.00020581923,0.0009684161,0.0015903815,0.00078608],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009117911,0.00030820086,0.00081821403,0.00052167114,0.0002977931,0.00009479952,0.00047891185,0.0006447382,0.0003345637],"category_scores_gemma":[0.003818817,0.00023296225,0.00013769738,0.0024422344,0.00074602,0.00011538774,0.00030363645,0.0054377457,0.000086043794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.25463802,0.0022139216,0.31394696,0.00010217414,0.0006481982,0.0024240797,0.0019270581,0.0005457418,0.19808105,0.000012553945,0.03297508,0.19248518],"study_design_scores_gemma":[0.018589232,0.028973503,0.89829946,0.001124861,0.0000712495,0.00006038338,0.0010582815,0.00086998375,0.014921544,0.00020980854,0.035006233,0.00081547897],"about_ca_topic_score_codex":0.00041332797,"about_ca_topic_score_gemma":0.0033667856,"teacher_disagreement_score":0.5843525,"about_ca_system_score_codex":0.004482834,"about_ca_system_score_gemma":0.0058358437,"threshold_uncertainty_score":0.99980015},"labels":[],"label_agreement":null},{"id":"W2139663853","doi":"10.3324/haematol.2014.117457","title":"The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes","year":2015,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; Janeway Children's Health and Rehabilitation Centre; McMaster University; McMaster Children's Hospital; Alberta Health; University of Alberta; University of British Columbia; Centre Hospitalier Universitaire de Sherbrooke; Queen's University; Centre Hospitalier Universitaire Sainte-Justine; Population Health Research Institute; Children's Hospital of Western Ontario; Children's Hospital of Eastern Ontario; Princess Margaret Cancer Centre; Alberta Children's Hospital; Izaak Walton Killam Health Centre; University of Saskatchewan; Hospital for Sick Children; Health Sciences Centre; CancerCare Manitoba; BC Children's Hospital; Montreal Children's Hospital; University of Toronto","funders":"","keywords":"Bone marrow failure; Cytogenetics; Myelodysplastic syndromes; Cytopathology; Myeloid; Bone marrow; Myeloid leukemia; Somatic evolution in cancer; Medicine; Hematopathology; Pathology; Leukemia; Neoplastic transformation; Immunology; Oncology; Internal medicine; Biology; Cancer; Haematopoiesis; Stem cell; Genetics; Cytology; Chromosome; Carcinogenesis","score_opus":0.04833145918210546,"score_gpt":0.3331537975892342,"score_spread":0.28482233840712873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139663853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967353,0.0016833153,0.00002249795,0.00087057496,0.000007680655,0.00052346877,0.000005569383,0.000010042899,0.00014158644],"genre_scores_gemma":[0.99759704,0.00044282337,0.001874049,0.000014847253,0.0000036161905,0.00003046036,0.00001433597,0.000008308016,0.00001452554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888283,0.00012591573,0.00037650793,0.00017502996,0.00022304316,0.00021664896],"domain_scores_gemma":[0.9994245,0.00010811189,0.00011952512,0.00012840981,0.00009917939,0.00012028136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059901417,0.00013535596,0.00041837306,0.00014166109,0.000050493225,0.000009522919,0.000053582702,0.0001481999,0.0000032567955],"category_scores_gemma":[0.00013792574,0.00007256431,0.000022523749,0.00014662616,0.00034456042,0.00003708982,0.00006447873,0.00016955665,7.341391e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007007073,0.00064267305,0.7838757,0.0016295632,0.00020297682,0.0016420155,0.018564623,0.000023151812,0.09910253,0.0027373403,0.0007784067,0.08379395],"study_design_scores_gemma":[0.005995244,0.0048036375,0.8925035,0.0005989998,0.000044623703,0.009878553,0.0031629638,0.0009432815,0.08050009,0.0007999499,0.0005062635,0.00026287386],"about_ca_topic_score_codex":0.000025986017,"about_ca_topic_score_gemma":0.000026569,"teacher_disagreement_score":0.108627826,"about_ca_system_score_codex":0.00006776974,"about_ca_system_score_gemma":0.00022062521,"threshold_uncertainty_score":0.29590866},"labels":[],"label_agreement":null},{"id":"W2140061942","doi":"10.4103/0377-4929.68240","title":"Two steps forward, one step back: 4<sup>th</sup> WHO classification of myeloid neoplasms (2008)","year":2010,"lang":"en","type":"review","venue":"Indian Journal of Pathology and Microbiology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Myeloid; Computer science; Cancer research; Medicine","score_opus":0.03234855453176441,"score_gpt":0.32099049444004424,"score_spread":0.2886419399082798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140061942","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025210712,0.97145987,0.00022963043,0.0005968783,0.00058586407,0.0010582642,0.00037060902,0.000012553501,0.00047561634],"genre_scores_gemma":[0.00084348314,0.99183863,0.0047237393,0.0002577078,0.00070956955,0.00001796425,0.0004249948,0.000088439505,0.0010954796],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99541336,0.0010746106,0.0020320893,0.00057510537,0.00014698732,0.0007578482],"domain_scores_gemma":[0.9956314,0.0005750186,0.0021190075,0.0006518113,0.00062273635,0.0004000129],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0019420263,0.0005805182,0.003986626,0.0013289093,0.00010839522,0.000016641785,0.0005954437,0.0021793055,0.000344571],"category_scores_gemma":[0.00048243007,0.00044487417,0.0006653222,0.0003850533,0.0013545144,0.000103675215,0.00019301972,0.0039493465,0.00014385956],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005730055,0.00036411203,0.00034448292,0.008535074,0.0013335987,0.01169033,0.0008419481,5.717144e-7,0.01721322,0.00023860102,0.00786561,0.95099944],"study_design_scores_gemma":[0.0027983428,0.0015306586,0.00006769682,0.004098859,0.0011928406,0.24209055,0.00015474804,0.0000019743213,0.00017833078,0.00003521891,0.74754876,0.00030202392],"about_ca_topic_score_codex":0.000006808296,"about_ca_topic_score_gemma":0.000024488669,"teacher_disagreement_score":0.9506974,"about_ca_system_score_codex":0.00023732428,"about_ca_system_score_gemma":0.0023378783,"threshold_uncertainty_score":0.9998003},"labels":[],"label_agreement":null},{"id":"W2140196635","doi":"10.1182/blood-2002-11-3444","title":"Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7","year":2003,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Monosomy; Medicine; Internal medicine; Trisomy 8; Chromosome 7 (human); Anemia; Pediatrics; Retrospective cohort study; Transplantation; Gastroenterology; Trisomy; Myelodysplastic syndromes; Chromosome abnormality; Cytogenetics; Bone marrow; Karyotype; Biology; Chromosome","score_opus":0.009881563413163173,"score_gpt":0.256108841303417,"score_spread":0.2462272778902538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140196635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99488866,0.00005333212,0.00001997829,0.000051136078,0.0000059293084,0.0004950984,0.000020548143,0.0000177386,0.0044475775],"genre_scores_gemma":[0.9983335,0.000015193987,0.0013513109,0.00010949486,0.000008728704,0.000040634426,0.000038933093,0.000018695484,0.00008348813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842864,0.00008955686,0.00027700272,0.00037112154,0.00051275047,0.00032090262],"domain_scores_gemma":[0.9988899,0.000046396617,0.000083354345,0.0005287197,0.000256827,0.00019480693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020134945,0.00014229512,0.00047596698,0.0005247025,0.000026513913,0.0000070580736,0.00010283202,0.00008932997,0.00014528853],"category_scores_gemma":[0.00046547272,0.00011088056,0.00006464231,0.0020327922,0.000051787447,0.000060101887,0.000033963544,0.0003126161,0.000018396157],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012171704,0.0014729676,0.9957324,0.00001731419,0.00059690827,0.000048901853,0.00047750262,0.000025079546,0.0012279395,0.00012370563,0.000048706464,0.00010682567],"study_design_scores_gemma":[0.004329633,0.0008222682,0.9866452,0.00005776937,0.00089507893,0.0000023578684,0.00009563168,0.000009610567,0.006798252,0.000015553582,0.000209992,0.000118650096],"about_ca_topic_score_codex":0.00013288771,"about_ca_topic_score_gemma":0.000099067875,"teacher_disagreement_score":0.009087229,"about_ca_system_score_codex":0.00022551067,"about_ca_system_score_gemma":0.00023301717,"threshold_uncertainty_score":0.4521578},"labels":[],"label_agreement":null},{"id":"W2140822587","doi":"10.1016/j.cancergencyto.2009.11.001","title":"Concomitant and successive amplifications of MYC in APL-like leukemia","year":2010,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Biology; Acute promyelocytic leukemia; Chromosomal translocation; Concomitant; Cytogenetics; Bone marrow; Fluorescence in situ hybridization; Myeloid leukemia; Pathology; Gene rearrangement; Leukemia; Myeloid; Molecular biology; Cancer research; Chromosome; Internal medicine; Immunology; Genetics; Medicine; Cell culture","score_opus":0.02282563978395335,"score_gpt":0.3226325246729324,"score_spread":0.29980688488897905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140822587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929976,0.0052581825,0.00018147072,0.0005989808,0.000115432405,0.00036505057,0.000060981805,0.000008234556,0.00041405248],"genre_scores_gemma":[0.9856375,0.011242939,0.0024478084,0.0002185881,0.00010549478,0.000048724574,0.000011741405,0.000026710111,0.00026053571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893475,0.000020634488,0.00030380586,0.00029189704,0.00019041011,0.00025851457],"domain_scores_gemma":[0.9990584,0.00009422082,0.00008257912,0.00035080197,0.00019957844,0.00021438296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012845326,0.00014365911,0.00028158707,0.00012692179,0.000050539133,0.00001998221,0.000114917355,0.0001596017,0.00005255977],"category_scores_gemma":[0.00005778647,0.00013332753,0.000028715107,0.0002120269,0.0004067622,0.000015557558,0.00011056473,0.00037510472,0.0000016877896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010205914,0.000050166676,0.6065329,0.00018223264,0.000060034152,0.000018829269,0.0006422156,0.000050337203,0.36559197,0.0011047442,0.00045564567,0.025208881],"study_design_scores_gemma":[0.004269364,0.0004061259,0.7797195,0.00013201928,0.0001791342,0.00007885933,0.00049755117,0.0059924,0.17871603,0.0009205167,0.028696045,0.00039248003],"about_ca_topic_score_codex":0.00020312193,"about_ca_topic_score_gemma":0.00067109487,"teacher_disagreement_score":0.18687594,"about_ca_system_score_codex":0.00009490873,"about_ca_system_score_gemma":0.0007214205,"threshold_uncertainty_score":0.5436939},"labels":[],"label_agreement":null},{"id":"W2141368398","doi":"10.1016/j.critrevonc.2007.07.003","title":"The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults","year":2007,"lang":"en","type":"article","venue":"Critical Reviews in Oncology/Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; Toronto Rehabilitation Institute; University of Toronto","funders":"National Cancer Institute; Canadian Institutes of Health Research; Toronto Rehabilitation Institute","keywords":"Medicine; Myeloid leukemia; Quality of life (healthcare); Activities of daily living; Performance status; Internal medicine; Palliative care; Gerontology; Chemotherapy; Oncology; Physical therapy","score_opus":0.06820022062710904,"score_gpt":0.4493297000785055,"score_spread":0.3811294794513964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141368398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9631372,0.03244512,0.000035085428,0.0017915892,0.000081084545,0.0011744432,0.000021691347,0.000007433933,0.0013063407],"genre_scores_gemma":[0.9620291,0.03718693,0.00028502548,0.00028988157,0.000037355338,0.00009723629,0.00001302997,0.000014761586,0.000046684443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662805,0.00069388474,0.0013748402,0.00041478564,0.0002167021,0.0006717201],"domain_scores_gemma":[0.9922288,0.0067163706,0.00018603727,0.00032654696,0.00018571717,0.00035650897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025782504,0.0002414111,0.001605315,0.00023600821,0.000048860817,0.0000038038954,0.000083450344,0.0003638181,0.00010145535],"category_scores_gemma":[0.008261404,0.00014224093,0.00015092456,0.0003078048,0.0008376979,0.000046520436,0.000099566314,0.00054097216,0.000012237148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030622758,0.0040062694,0.55733526,0.0032461016,0.00069822255,0.000953378,0.0021343909,0.0000024329897,0.005072733,0.12023011,0.0036190697,0.2720793],"study_design_scores_gemma":[0.013204508,0.0057505737,0.97331524,0.001140702,0.00011052828,0.0005813646,0.0005226202,0.00028667354,0.0014557362,0.0009882607,0.00241285,0.00023096302],"about_ca_topic_score_codex":0.0002228224,"about_ca_topic_score_gemma":0.000260978,"teacher_disagreement_score":0.41597998,"about_ca_system_score_codex":0.0014118262,"about_ca_system_score_gemma":0.0011516537,"threshold_uncertainty_score":0.9890269},"labels":[],"label_agreement":null},{"id":"W2141368628","doi":"10.1016/j.bbmt.2011.07.024","title":"Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study","year":2011,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; Alberta Cancer Foundation; Princess Margaret Cancer Centre","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Medical Research Council; Dana-Farber Cancer Institute","keywords":"Medicine; Cytogenetics; Internal medicine; Transplantation; Leukemia; Single Center; Oncology; Surgery; Chromosome","score_opus":0.05461379470728807,"score_gpt":0.3103912514750783,"score_spread":0.25577745676779023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141368628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997017,0.00016200611,0.0003908822,0.000089655325,0.00007196085,0.0017005877,0.00040497008,0.000016555456,0.0001463337],"genre_scores_gemma":[0.9922884,0.0031496736,0.0033769351,0.00003822717,0.00003910476,0.00010763061,0.00095459924,0.0000305096,0.000014925971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978848,0.000257917,0.00056234124,0.00054875267,0.00029937353,0.00044677837],"domain_scores_gemma":[0.9990622,0.00025135677,0.00010661712,0.0001573149,0.00029600455,0.0001264993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067844253,0.00023321375,0.00042752043,0.00061541895,0.000106684514,0.000011994021,0.00015115221,0.00022213746,0.000011065177],"category_scores_gemma":[0.00003109921,0.00019683572,0.00004213221,0.0002373084,0.0002170581,0.000105302905,0.000018598494,0.00034744432,4.1236638e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009890185,0.00071214867,0.8853543,0.000611217,0.00040553193,0.00022972426,0.0068933964,0.000004368515,0.09474669,0.000052102845,0.0000024216756,0.0010979126],"study_design_scores_gemma":[0.042529862,0.005928084,0.92738277,0.0007304546,0.0008501097,0.00028673522,0.00081090163,0.00011007031,0.020908581,0.00014508046,0.000017445971,0.00029990074],"about_ca_topic_score_codex":0.0002660704,"about_ca_topic_score_gemma":0.0014177688,"teacher_disagreement_score":0.07383811,"about_ca_system_score_codex":0.000091907,"about_ca_system_score_gemma":0.00028405158,"threshold_uncertainty_score":0.8026728},"labels":[],"label_agreement":null},{"id":"W2141772696","doi":"10.1038/sj.leu.2403836","title":"Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia","year":2005,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Leukemia and Lymphoma Society","keywords":"Acute myeloblastic leukemia; K562 cells; Cancer research; Biology; Myeloid; Haematopoiesis; Leukemia; Cell culture; Molecular biology; Stem cell; Immunology; Cell biology; Genetics","score_opus":0.014493267088491931,"score_gpt":0.2726629767075332,"score_spread":0.2581697096190413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141772696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945716,0.0002207986,0.00042573785,0.001658312,0.0002594605,0.00074470905,0.00004431204,0.00006752174,0.0020075443],"genre_scores_gemma":[0.9929133,0.00015370666,0.0007632211,0.0006061756,0.0003909229,0.000035980014,0.000024043598,0.000056945337,0.005055675],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973038,0.00012910296,0.0006622429,0.00044745597,0.0008093487,0.00064809143],"domain_scores_gemma":[0.9987138,0.00008064435,0.00014934524,0.00072386366,0.00013427352,0.0001980989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026059608,0.0002942627,0.00052004115,0.00027275627,0.000086401524,0.000021177302,0.00047753562,0.00032256858,0.0005950985],"category_scores_gemma":[0.00012616804,0.0002138583,0.0003462861,0.00074110227,0.0002468485,0.00020695674,0.00011787248,0.0009943853,0.00027902308],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010207877,0.000111544985,0.0049312524,0.00015519655,0.00023108383,0.00012104172,0.0008958167,0.0015030307,0.9647624,0.00018126405,0.0038908983,0.022195708],"study_design_scores_gemma":[0.016224481,0.0006444779,0.59505516,0.00054449117,0.0005994028,0.00068265334,0.0003314555,0.035120457,0.33351198,0.00024555094,0.016337436,0.00070241926],"about_ca_topic_score_codex":0.00036227965,"about_ca_topic_score_gemma":0.00014527958,"teacher_disagreement_score":0.6312504,"about_ca_system_score_codex":0.0060153445,"about_ca_system_score_gemma":0.002490784,"threshold_uncertainty_score":0.9978004},"labels":[],"label_agreement":null},{"id":"W2142586916","doi":"10.1080/14653240601164042","title":"Primitive AML progenitors from most CD34+ patients lack CD33 expression but progenitors from many CD34− AML patients express CD33","year":2007,"lang":"en","type":"article","venue":"Cytotherapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Vancouver General Hospital","funders":"National Cancer Institute","keywords":"CD33; CD34; Progenitor cell; Myeloid leukemia; Haematopoiesis; Cancer research; Stem cell; Biology; Clonogenic assay; Myeloid; Leukemia; Immunology; Cell biology; In vivo; Genetics","score_opus":0.020941803049957356,"score_gpt":0.29842430446164275,"score_spread":0.2774825014116854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142586916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99088377,0.00045727816,0.00077551487,0.00015077034,0.0010586873,0.004091592,0.00092116714,0.00037855122,0.0012826793],"genre_scores_gemma":[0.9872663,0.00021189629,0.004919252,0.0011942205,0.0020690882,0.00035484222,0.0022557725,0.00037207908,0.0013565228],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9932063,0.00031472978,0.0011875324,0.0015757675,0.002132549,0.0015830959],"domain_scores_gemma":[0.99562657,0.0004840022,0.00050535443,0.0014421082,0.00094881083,0.0009931661],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040958426,0.00092401396,0.0010569814,0.00045188933,0.00039146363,0.00013596972,0.00082814833,0.00076253136,0.0010304948],"category_scores_gemma":[0.00029542932,0.00078919553,0.0003771494,0.0006747998,0.00040275633,0.0005044382,0.00031188608,0.0011169566,0.00062511617],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005456357,0.0024404372,0.72221893,0.000063458734,0.00056524976,0.00017660536,0.0037367304,0.0000018589362,0.22090365,0.000009884076,0.013211972,0.03121484],"study_design_scores_gemma":[0.014093048,0.0010577956,0.45387664,0.00042456956,0.000113650916,0.0000029739076,0.0007620487,0.0000620662,0.5102033,0.000114024515,0.018484779,0.0008050766],"about_ca_topic_score_codex":0.0010879529,"about_ca_topic_score_gemma":0.00003138616,"teacher_disagreement_score":0.28929967,"about_ca_system_score_codex":0.0014476457,"about_ca_system_score_gemma":0.0004683674,"threshold_uncertainty_score":0.9998827},"labels":[],"label_agreement":null},{"id":"W2143505663","doi":"10.1158/2159-8290.cd-13-0117","title":"Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma","year":2013,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":214,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer; BC Cancer Agency","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; Wellcome Trust; National Cancer Institute; Celgene","keywords":"Azacitidine; Methyltransferase; DNA methylation; Cancer research; Diffuse large B-cell lymphoma; Lymphoma; Decitabine; Epigenetics; Medicine; Biology; Methylation; Internal medicine; DNA; Gene; Gene expression","score_opus":0.015051778420798852,"score_gpt":0.27075239155282843,"score_spread":0.2557006131320296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143505663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99097866,0.0011332763,0.005349763,0.0008265934,0.00012055887,0.0007377536,0.00004403352,0.000037810547,0.0007715816],"genre_scores_gemma":[0.99421084,0.0013259829,0.0002614296,0.0016202118,0.00015032229,0.00014616546,0.00006908199,0.000050562845,0.0021654184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987372,0.000045815526,0.00023481167,0.00027434403,0.00035695336,0.0003508582],"domain_scores_gemma":[0.9990824,0.000059785452,0.00010042259,0.0004311903,0.00020118446,0.00012504193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000102544,0.00016343707,0.00029708818,0.0001095066,0.00004545486,0.000031058884,0.00011722667,0.000104947525,0.000419876],"category_scores_gemma":[0.000028382361,0.00013282448,0.00011016328,0.0002657047,0.00007064685,0.00017148643,0.000039801696,0.000090015754,0.00006718812],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044564228,0.002310849,0.006495005,0.0003053218,0.00010820646,0.00002420317,0.00029960784,0.000039619084,0.9703424,0.00041349404,0.005006708,0.014208933],"study_design_scores_gemma":[0.015486349,0.0002057386,0.016365333,0.000098894336,0.000028883042,0.000002968708,0.00013121273,0.004075826,0.96204424,0.00026013667,0.0011351702,0.0001652739],"about_ca_topic_score_codex":0.00041821518,"about_ca_topic_score_gemma":0.000011505977,"teacher_disagreement_score":0.015040707,"about_ca_system_score_codex":0.0003454643,"about_ca_system_score_gemma":0.0007421222,"threshold_uncertainty_score":0.5416425},"labels":[],"label_agreement":null},{"id":"W2143588214","doi":"10.1016/j.cancergencyto.2007.05.027","title":"Childhood myeloid/natural killer precursor acute leukemia with novel chromosomal aberrations der(5)t(4;5)(q31;q31.3) and t(14;17)(q32;q23)","year":2007,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Myeloid leukemia; CD33; Biology; Immunophenotyping; Leukemia; Lymphoblast; Karyotype; Myeloid; Acute leukemia; Cancer research; Immunology; CD34; Genetics; Flow cytometry; Chromosome; Cell culture; Gene; Stem cell","score_opus":0.015198337850654596,"score_gpt":0.2874565090429767,"score_spread":0.2722581711923221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143588214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97614837,0.017370747,0.002139808,0.0011898427,0.00038675455,0.0011391181,0.00014405718,0.00007912206,0.0014022087],"genre_scores_gemma":[0.96369255,0.012312694,0.015748508,0.0013956372,0.0008773424,0.00009222385,0.0001239604,0.00015170938,0.0056053894],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9968384,0.000028562774,0.0005326157,0.00086942106,0.0007007765,0.0010302188],"domain_scores_gemma":[0.9979174,0.000095571384,0.00016633258,0.00064303435,0.00042279644,0.0007548639],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002409132,0.0005598442,0.0005851759,0.00023289553,0.00037316544,0.0001334105,0.00025086972,0.00035153882,0.00010971626],"category_scores_gemma":[0.00003788168,0.0004688465,0.00009265074,0.00050349603,0.00060397317,0.00008224785,0.0002585254,0.000732762,0.000008378639],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032297838,0.001144324,0.32898918,0.0008524522,0.006136157,0.0008339018,0.010278046,0.0014744482,0.37025732,0.0008627692,0.033962946,0.24197868],"study_design_scores_gemma":[0.0137813445,0.0025318845,0.7790642,0.0004231655,0.0019614059,0.0020240324,0.0006518746,0.004671307,0.09032786,0.00011865509,0.10278846,0.0016558303],"about_ca_topic_score_codex":0.00007271839,"about_ca_topic_score_gemma":0.00062813493,"teacher_disagreement_score":0.450075,"about_ca_system_score_codex":0.00049080356,"about_ca_system_score_gemma":0.0011612239,"threshold_uncertainty_score":0.9997763},"labels":[],"label_agreement":null},{"id":"W2143913090","doi":"10.5430/jhm.v2n4p22","title":"Treating the Elderly Patient with Acute Myelogenous Leukemia","year":2012,"lang":"en","type":"article","venue":"Journal of Hematological Malignancies","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Disease; Myeloid leukemia; Regimen; Population; Intensive care medicine; Leukemia; Palliative care; Quality of life (healthcare); Pediatrics; Internal medicine","score_opus":0.022052479656168345,"score_gpt":0.27631194732208386,"score_spread":0.2542594676659155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143913090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913175,0.0024917214,0.00042161503,0.0021052582,0.0000937602,0.00027751055,0.0000024697074,0.000026193073,0.0032639618],"genre_scores_gemma":[0.9930688,0.00017529898,0.0056445505,0.0006240915,0.00023595845,0.000013612955,0.000001299633,0.000020944146,0.00021543476],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9977839,0.00013053385,0.00059300486,0.00012768313,0.00072735077,0.0006375071],"domain_scores_gemma":[0.9981992,0.0004028336,0.00043586158,0.00026880502,0.0003783389,0.0003149139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058326375,0.00021294801,0.0006222068,0.00010492559,0.00019871902,0.00003643662,0.00024249637,0.00013459448,0.00012565657],"category_scores_gemma":[0.00037129334,0.00008750363,0.0002036326,0.00029271556,0.0002837897,0.00019907019,0.00008679466,0.000674721,0.000035293633],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015399139,0.003815843,0.43808734,0.0010336307,0.0069914865,0.060156,0.024280978,0.00017968229,0.19692603,0.032311603,0.060084905,0.16073336],"study_design_scores_gemma":[0.009018596,0.035829116,0.111398414,0.0016418239,0.0022571168,0.6426947,0.016609441,0.00014645388,0.14318565,0.0013314538,0.034806885,0.0010803553],"about_ca_topic_score_codex":0.00001042426,"about_ca_topic_score_gemma":0.0000012941953,"teacher_disagreement_score":0.5825387,"about_ca_system_score_codex":0.00036283734,"about_ca_system_score_gemma":0.00044503727,"threshold_uncertainty_score":0.35682943},"labels":[],"label_agreement":null},{"id":"W2144031672","doi":"10.1016/j.bbmt.2010.08.016","title":"Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children","year":2010,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Health Resources and Services Administration","keywords":"Medicine; Bone marrow transplantation; Myelodysplastic syndromes; Bone marrow; Transplantation; Oncology; Internal medicine","score_opus":0.007831159973114407,"score_gpt":0.2533368104139553,"score_spread":0.24550565044084088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144031672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968057,0.00023328103,0.0009590582,0.00042673195,0.00011186301,0.0010029052,0.00030608696,0.00003938804,0.00011492901],"genre_scores_gemma":[0.9941421,0.0014157282,0.0024936183,0.000055051412,0.000046935307,0.00008352784,0.0016702944,0.000023372879,0.000069337795],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998765,0.00005834287,0.00041656473,0.00034744045,0.00010465732,0.00030800083],"domain_scores_gemma":[0.99933887,0.00024698756,0.00009751103,0.00013379281,0.00007425578,0.00010859943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034609085,0.00018143977,0.00038365804,0.00035117095,0.00005803357,0.0000066064163,0.000075234035,0.00036403272,0.00003792555],"category_scores_gemma":[0.000043095104,0.00016357453,0.000069910275,0.00018736545,0.00020073744,0.00009480746,0.0000048544666,0.00034978343,0.0000037211391],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017121787,0.00014997816,0.15697622,0.00062956807,0.00016274808,0.00006606253,0.0003037395,0.0000034251673,0.8368513,0.0008033827,0.00001099748,0.0023303991],"study_design_scores_gemma":[0.020084482,0.0017337607,0.8602181,0.00025578565,0.0013261454,0.006432685,0.00003661273,0.00030299777,0.10852563,0.0007056452,0.000045630597,0.00033253685],"about_ca_topic_score_codex":0.00016061046,"about_ca_topic_score_gemma":0.00022422422,"teacher_disagreement_score":0.72832566,"about_ca_system_score_codex":0.000012359656,"about_ca_system_score_gemma":0.00011274373,"threshold_uncertainty_score":0.66703755},"labels":[],"label_agreement":null},{"id":"W2144166819","doi":"10.1200/jco.2005.02.7482","title":"Risk Factors and Therapy for Isolated Central Nervous System Relapse of Pediatric Acute Myeloid Leukemia","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Medicine; Myeloid leukemia; Central nervous system; Oncology; Pediatrics; Intensive care medicine; Internal medicine","score_opus":0.062822204268044,"score_gpt":0.41274447062483166,"score_spread":0.3499222663567877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144166819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941895,0.0016641242,0.0006073779,0.0019198363,0.0007467663,0.0005554794,0.00002967631,0.00002004281,0.00026720308],"genre_scores_gemma":[0.9724894,0.017729504,0.005918497,0.00034074113,0.00323144,0.0000045410025,0.0000052729047,0.000038255323,0.00024233217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953326,0.00055003347,0.0029226232,0.00025891315,0.0004441189,0.0004917219],"domain_scores_gemma":[0.99162686,0.004099937,0.0025941567,0.00025191772,0.00072611216,0.0007010369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003530964,0.00021810185,0.0020075063,0.00027259917,0.000070801056,0.000010146703,0.00026219612,0.00075041555,0.00003893122],"category_scores_gemma":[0.0028358782,0.00013844848,0.00068658014,0.00024175356,0.00022225165,0.00015612827,0.00006358949,0.0017114609,0.0000058762985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038000457,0.0013762825,0.62093633,0.00022956227,0.003155914,0.0005580728,0.0006733179,0.00016086643,0.0012654538,0.0001161064,0.023237107,0.31029055],"study_design_scores_gemma":[0.042141616,0.045429446,0.84466165,0.00009468397,0.0025652072,0.0012726729,0.000518136,0.006886336,0.00069976447,0.00007287215,0.055360135,0.00029749546],"about_ca_topic_score_codex":0.00005712347,"about_ca_topic_score_gemma":0.000009715265,"teacher_disagreement_score":0.30999306,"about_ca_system_score_codex":0.0008489632,"about_ca_system_score_gemma":0.0037357553,"threshold_uncertainty_score":0.7435541},"labels":[],"label_agreement":null},{"id":"W2147127394","doi":"10.1111/j.1749-6632.2003.tb03229.x","title":"Normalization of Previously Shortened Telomere Length under Treatment with Imatinib Argues against a Preexisting Telomere Length Deficit in Normal Hematopoietic Stem Cells from Patients with Chronic Myeloid Leukemia","year":2003,"lang":"en","type":"article","venue":"Annals of the New York Academy of Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Telomere; Myeloid leukemia; Imatinib mesylate; Imatinib; Fluorescence in situ hybridization; Telomerase; Biology; Stem cell; Molecular biology; Immunology; Cancer research; Internal medicine; Medicine; Genetics; Chromosome; Gene","score_opus":0.05085097234260278,"score_gpt":0.29715229444125546,"score_spread":0.2463013220986527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147127394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949009,0.0021021033,0.000039445862,0.0004953084,0.000023677536,0.0012877444,0.000030552128,0.000021438818,0.0010988413],"genre_scores_gemma":[0.99721557,0.00061380723,0.0016988231,0.00016136451,0.000037627327,0.000025607444,0.0000073694064,0.000032397915,0.00020741782],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99624944,0.00022340336,0.00090928166,0.0005630334,0.0013809823,0.00067387894],"domain_scores_gemma":[0.9981419,0.00031205523,0.0008663726,0.00030635312,0.00018069838,0.00019266378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007843806,0.00037074412,0.00082619657,0.00030411957,0.00017388996,0.000025655614,0.0006393448,0.00018482475,0.00003110139],"category_scores_gemma":[0.000059091737,0.00021299534,0.00013320833,0.0014894301,0.000928608,0.00035792388,0.00009970875,0.0003497337,0.0000035349872],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002241407,0.001570788,0.8560865,0.0018484945,0.0012639706,0.000008265297,0.011639449,0.043641012,0.034114555,0.00205361,0.0008889131,0.044643026],"study_design_scores_gemma":[0.008085198,0.0053928196,0.09657893,0.004987883,0.00032426714,0.00001826379,0.0034867201,0.0029923816,0.8768208,0.00036078106,0.00029775887,0.0006541736],"about_ca_topic_score_codex":0.0006536403,"about_ca_topic_score_gemma":0.00012390524,"teacher_disagreement_score":0.84270626,"about_ca_system_score_codex":0.0003572564,"about_ca_system_score_gemma":0.0017268077,"threshold_uncertainty_score":0.86856973},"labels":[],"label_agreement":null},{"id":"W2148012189","doi":"10.1200/jco.2004.12.142","title":"Autologous Hematopoietic Stem-Cell Transplantation for Children With Acute Myeloid Leukemia in First or Second Complete Remission: A Prognostic Factor Analysis","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Myeloid leukemia; Hematopoietic stem cell transplantation; Transplantation; Internal medicine; Leukemia; Surgery; Multivariate analysis","score_opus":0.07018696342816678,"score_gpt":0.40033568973615213,"score_spread":0.33014872630798536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148012189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98908347,0.00014555553,0.0055886614,0.0037321835,0.00013291591,0.0010565894,0.00006365871,0.000019208926,0.00017777085],"genre_scores_gemma":[0.9839249,0.00060867507,0.013860652,0.0007574866,0.00031234924,0.00003137825,0.000044771707,0.000036065077,0.00042372252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99574256,0.00028116096,0.0025474788,0.00039972743,0.0005387848,0.00049027364],"domain_scores_gemma":[0.9941468,0.0031419445,0.0014204715,0.0002788587,0.00044467443,0.00056722603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017142202,0.0002598917,0.0024118635,0.0005438207,0.000085019834,0.000019655747,0.00032267597,0.0005679292,0.00027059604],"category_scores_gemma":[0.0005464741,0.00015767955,0.00061838044,0.0007926279,0.00024949657,0.0001515706,0.000033030337,0.0014909791,0.0000127301855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11729193,0.004836874,0.77766556,0.0014990522,0.016362252,0.024169076,0.00417064,0.0051252777,0.0020862252,0.000090282694,0.0028559165,0.043846935],"study_design_scores_gemma":[0.043035645,0.027145874,0.9120427,0.00036803397,0.005531471,0.0074478877,0.00020596788,0.00068398635,0.0006159481,0.00012770097,0.0025032691,0.00029155143],"about_ca_topic_score_codex":0.000042853746,"about_ca_topic_score_gemma":0.0008787852,"teacher_disagreement_score":0.13437712,"about_ca_system_score_codex":0.001458944,"about_ca_system_score_gemma":0.008375721,"threshold_uncertainty_score":0.99724585},"labels":[],"label_agreement":null},{"id":"W2148741536","doi":"10.1097/moh.0b013e3282f3de99","title":"Alternative donor transplants for high-risk acute myeloid leukemia","year":2008,"lang":"en","type":"review","venue":"Current Opinion in Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Transplantation; Acute leukemia; Leukemia; Population; Disease; Sibling; Intensive care medicine; Internal medicine; Immunology; Oncology","score_opus":0.1015070123660373,"score_gpt":0.4164182572724201,"score_spread":0.3149112449063828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148741536","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006887675,0.98359203,0.001981478,0.00009705167,0.007856276,0.0048965216,0.0013303832,0.00010551412,0.00007186005],"genre_scores_gemma":[0.000017459517,0.9910336,0.00084122166,0.000017492071,0.0012653333,0.0024575568,0.0040781787,0.00017125606,0.00011791504],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994832,0.000483462,0.0017350754,0.0013250145,0.00047426854,0.0011502053],"domain_scores_gemma":[0.9963889,0.0014063121,0.0007752775,0.00086309813,0.00020667024,0.00035975108],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00035892072,0.0009363255,0.004660794,0.0011844104,0.00014323,0.000018515453,0.00071969506,0.0010000404,0.00011992173],"category_scores_gemma":[0.0003229681,0.00076392764,0.00089006865,0.000657542,0.00033868809,0.00010100397,0.00017096857,0.0023683931,0.0003078864],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037901694,0.00026177996,0.00023972314,0.068766035,0.0010101409,0.00016381385,0.0002051445,0.0000016148521,2.5118464e-7,0.0034509003,0.023973644,0.9015479],"study_design_scores_gemma":[0.0044284416,0.00037159448,0.000023390457,0.027225291,0.0006749283,0.0045202454,0.000009020526,0.00014434947,0.000012847816,0.0004401435,0.96152717,0.0006225643],"about_ca_topic_score_codex":0.00012337518,"about_ca_topic_score_gemma":0.0000067139013,"teacher_disagreement_score":0.9375535,"about_ca_system_score_codex":0.0018826654,"about_ca_system_score_gemma":0.002837254,"threshold_uncertainty_score":0.9999332},"labels":[],"label_agreement":null},{"id":"W2149242646","doi":"10.1007/s00277-008-0449-0","title":"Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes","year":2008,"lang":"en","type":"review","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Celgene","keywords":"Lenalidomide; Myelodysplastic syndromes; Medicine; Disease; Internal medicine; Intensive care medicine; Hematology; International Prognostic Scoring System; Oncology; Food and drug administration; Multiple myeloma; Bone marrow; Pharmacology","score_opus":0.45914163368655825,"score_gpt":0.489439714819162,"score_spread":0.030298081132603738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149242646","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006262648,0.9485275,0.000076974175,0.045405347,0.00011212803,0.002900195,0.000091240465,0.0000113587985,0.0022490046],"genre_scores_gemma":[0.00066901435,0.9973561,0.0012151728,0.0004042801,0.000013279797,0.00014472065,0.00005946825,0.000025294548,0.00011263874],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969555,0.0009074077,0.001154436,0.00025484286,0.00042323436,0.00030458122],"domain_scores_gemma":[0.9907749,0.007510782,0.0006864429,0.00084589125,0.00013800354,0.000043940483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067056814,0.00023971665,0.001904066,0.00040679966,0.000035405315,0.000003959709,0.00038278612,0.00022833406,0.00015349746],"category_scores_gemma":[0.0011106427,0.000121251505,0.00038408057,0.0005781513,0.0004225358,0.0000439892,0.00015207283,0.00071629114,0.00003164157],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005601612,0.0023309225,0.00006343538,0.07501956,0.0053343484,0.0028771549,0.00044781464,0.000005305121,0.0000017258278,0.22222172,0.45635304,0.2347848],"study_design_scores_gemma":[0.00044420076,0.0004019091,0.000046173795,0.017960204,0.0005740627,0.0044457074,0.00019231848,0.000015035938,0.00005329737,0.00014994896,0.97560126,0.00011591323],"about_ca_topic_score_codex":0.00003316466,"about_ca_topic_score_gemma":0.000003583264,"teacher_disagreement_score":0.5192482,"about_ca_system_score_codex":0.000027443848,"about_ca_system_score_gemma":0.00037832474,"threshold_uncertainty_score":0.4944493},"labels":[],"label_agreement":null},{"id":"W2149546612","doi":"10.3324/haematol.2014.111245","title":"A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E","year":2014,"lang":"en","type":"letter","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer; Jewish General Hospital","funders":"U.S. Public Health Service; National Institutes of Health; Université de Montréal; Jewish General Hospital; Centre National de la Recherche Scientifique; McGill University; Leukemia and Lymphoma Society","keywords":"Cytarabine; Medicine; Refractory (planetary science); Ribavirin; Myeloid leukemia; Internal medicine; Acute leukemia; Myeloid; Gastroenterology; Oncology; Pharmacology; Leukemia; Virology; Biology","score_opus":0.036414860354981995,"score_gpt":0.31857175451332226,"score_spread":0.2821568941583403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149546612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9078553,0.0015947487,0.00017674842,0.0827881,0.000117977426,0.0069294353,0.00026814794,0.000070908725,0.0001986363],"genre_scores_gemma":[0.81062526,0.037871946,0.008887674,0.11257359,0.0044192257,0.0063621015,0.004367559,0.000765514,0.01412711],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99704665,0.0002494759,0.0008420584,0.0007378977,0.0005578679,0.00056603836],"domain_scores_gemma":[0.99565995,0.0021461302,0.00072502194,0.0010211134,0.0003048923,0.00014292226],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045189715,0.00059925177,0.0022315253,0.00025677544,0.00012433053,0.000021388376,0.00025604182,0.00095460226,0.0000483124],"category_scores_gemma":[0.00030656366,0.0003017232,0.00024208115,0.00022856648,0.001015805,0.000048502603,0.000071128234,0.00091320585,0.0000041226526],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44127634,0.0028906849,0.00013365883,0.0040004444,0.0059369863,0.0044152443,0.0009773517,0.0000016870134,0.02188105,0.0001024032,0.5007424,0.017641768],"study_design_scores_gemma":[0.4026166,0.08129947,0.00014348523,0.0008645496,0.004087464,0.0020673305,0.00009507796,0.0008041319,0.01570415,0.00010901406,0.4915768,0.00063194946],"about_ca_topic_score_codex":0.00011107707,"about_ca_topic_score_gemma":0.000007022759,"teacher_disagreement_score":0.09723001,"about_ca_system_score_codex":0.00035596717,"about_ca_system_score_gemma":0.00064994156,"threshold_uncertainty_score":0.9999435},"labels":[],"label_agreement":null},{"id":"W2149573012","doi":"10.1038/bcj.2014.51","title":"High DNA-methyltransferase 3B expression predicts poor outcome in acute myeloid leukemia, especially among patients with co-occurring NPM1 and FLT3 mutations","year":2014,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"NPM1; DNMT3B; CEBPA; Methyltransferase; Oncology; Myeloid leukemia; Hazard ratio; Internal medicine; Medicine; Hematology; Transplantation; Biology; Immunology; Cancer research; Genetics; Confidence interval; Mutation; Methylation; Karyotype; Gene","score_opus":0.014389393370973946,"score_gpt":0.28279065290005134,"score_spread":0.2684012595290774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149573012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96151465,0.00045730095,0.0002980853,0.034764834,0.0005887813,0.0014642577,0.0005477278,0.00007863357,0.00028572383],"genre_scores_gemma":[0.65469927,0.0032229712,0.006211876,0.30133414,0.02605481,0.0009606747,0.0025726408,0.0010919791,0.0038516135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940172,0.00040621986,0.0012880566,0.00091652083,0.002098086,0.0012739557],"domain_scores_gemma":[0.99729115,0.00031957228,0.0005972519,0.0005622391,0.0005527999,0.0006770177],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006521956,0.0008342982,0.0014652372,0.0011245573,0.00040513158,0.0002821585,0.00054076343,0.001025631,0.0004671883],"category_scores_gemma":[0.00017094862,0.0006461892,0.00023068256,0.0004431681,0.0003837998,0.0004799669,0.0001141625,0.0076136976,0.000013945171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012966876,0.00030173743,0.737052,0.0008295319,0.0018048477,0.008252209,0.0009826926,0.00013946305,0.0017430112,0.000002000234,0.24445467,0.0031411299],"study_design_scores_gemma":[0.09885628,0.0047336062,0.73396623,0.0135982325,0.008241933,0.0030995414,0.00024152712,0.00021698659,0.014753371,0.00012054982,0.11874142,0.0034303355],"about_ca_topic_score_codex":0.00057921454,"about_ca_topic_score_gemma":0.0001502276,"teacher_disagreement_score":0.30681536,"about_ca_system_score_codex":0.00179801,"about_ca_system_score_gemma":0.0023484663,"threshold_uncertainty_score":0.9995989},"labels":[],"label_agreement":null},{"id":"W2149787089","doi":"10.1182/blood.v99.4.1364","title":"In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis","year":2002,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":364,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Japan Society for the Promotion of Science; Ligue Genevoise Contre le Cancer; National Institute of Diabetes and Digestive and Kidney Diseases; Fonds De La Recherche Scientifique - FNRS; Australian Government; National Institutes of Health; American Cancer Society","keywords":"RUNX1; Platelet disorder; Missense mutation; Nonsense mutation; Haploinsufficiency; Frameshift mutation; Point mutation; Biology; Genetics; Leukemia; Mutation; Cancer research; Molecular biology; Gene; Immunology; Phenotype; Transcription factor","score_opus":0.02523519962083143,"score_gpt":0.3024561867370647,"score_spread":0.2772209871162333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149787089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97257185,0.00014600622,0.024267161,0.0008019949,0.000010065416,0.0014437382,0.0006955811,0.000009589569,0.000054023272],"genre_scores_gemma":[0.9770129,0.00008032023,0.022169558,0.000077117096,0.00002265719,0.00044038554,0.00011466611,0.000026677677,0.000055734024],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988067,0.000026911332,0.00040913813,0.00030393671,0.00017556734,0.0002777229],"domain_scores_gemma":[0.999195,0.00015279611,0.00010316212,0.0002714844,0.00017803088,0.00009954173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015594796,0.00014822805,0.00042918124,0.00047136343,0.000049032038,0.000005808389,0.000099352466,0.00011262916,0.000007987252],"category_scores_gemma":[0.00008436073,0.00012374735,0.000056692505,0.0006988784,0.00007549945,0.00007887712,0.000046014153,0.00011249657,0.0000010711766],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061799644,0.0009186965,0.0010224556,0.000108488704,0.00015518189,0.000017803377,0.00063569535,0.00015101266,0.9943041,0.00037501365,0.000016317732,0.001677235],"study_design_scores_gemma":[0.013002168,0.0012028583,0.05985191,0.00009671273,0.0005739954,0.00016325027,0.00035176612,0.0018511075,0.9223801,0.00033523052,0.000019406081,0.00017152313],"about_ca_topic_score_codex":0.0005132062,"about_ca_topic_score_gemma":0.0002864267,"teacher_disagreement_score":0.07192403,"about_ca_system_score_codex":0.00014087124,"about_ca_system_score_gemma":0.0001738055,"threshold_uncertainty_score":0.50462705},"labels":[],"label_agreement":null},{"id":"W2152277063","doi":"10.1016/j.bbmt.2008.11.015","title":"IPSS Poor-Risk Karyotype as a Predictor of Outcome for Patients with Myelodysplastic Syndrome following Myeloablative Stem Cell Transplantation","year":2009,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; International Prognostic Scoring System; Myelodysplastic syndromes; Transplantation; Oncology; Cohort; Multivariate analysis; Retrospective cohort study; Hematopoietic stem cell transplantation; Gastroenterology; Surgery; Bone marrow","score_opus":0.00907346139392321,"score_gpt":0.2505792102387063,"score_spread":0.24150574884478307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152277063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949912,0.00018378826,0.0027358765,0.00008220995,0.0000680883,0.001154496,0.00060295925,0.00003100893,0.00015040791],"genre_scores_gemma":[0.99647784,0.00044526038,0.0020942357,0.00004444675,0.000018936498,0.000030656574,0.00080610195,0.000019232888,0.00006330502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862415,0.00009160812,0.0004835318,0.00032466714,0.00020994425,0.00026609207],"domain_scores_gemma":[0.99902004,0.00034651754,0.0002463522,0.00012008377,0.00015868859,0.0001083275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021243934,0.00020854642,0.0005177521,0.00022579853,0.00007456009,0.0000045240654,0.00007835445,0.0001972297,0.000007548884],"category_scores_gemma":[0.000020869518,0.00016322274,0.000107030915,0.00016590799,0.000113621325,0.00012518812,0.0000034453087,0.0001591716,0.000001279193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01181683,0.00061139837,0.8700395,0.0022139358,0.00064073835,0.00008254125,0.002384943,0.000019194778,0.1079558,0.00027891755,0.000007581621,0.003948612],"study_design_scores_gemma":[0.022036295,0.016164573,0.92260474,0.00041227834,0.0034799078,0.00013443426,0.00014992693,0.00010316489,0.034372993,0.00027036862,0.000009868734,0.00026147955],"about_ca_topic_score_codex":0.000051287425,"about_ca_topic_score_gemma":0.000010659296,"teacher_disagreement_score":0.073582806,"about_ca_system_score_codex":0.000021154847,"about_ca_system_score_gemma":0.0001050163,"threshold_uncertainty_score":0.66560304},"labels":[],"label_agreement":null},{"id":"W2152393412","doi":"10.1111/j.1365-2257.1992.tb01075.x","title":"Myelodysplastic syndrome with t(8; 12) (q22; q13) translocation","year":2008,"lang":"en","type":"letter","venue":"Clinical & Laboratory Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Christie (Canada)","funders":"","keywords":"Medicine; Associate editor; Cancer genetics; Citation; Library science; Hematologic Neoplasms; Family medicine; Internal medicine; Cancer; Computer science","score_opus":0.04721793760731824,"score_gpt":0.34413243858661496,"score_spread":0.2969145009792967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152393412","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21821024,0.0024165355,0.0009777149,0.77014726,0.002101512,0.003118048,0.00032326742,0.0008009222,0.0019044757],"genre_scores_gemma":[0.053331487,0.0029195969,0.0029467917,0.9285077,0.0051363404,0.00053658977,0.0019282169,0.0006379248,0.0040553873],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923564,0.0012833357,0.0021122757,0.0017693773,0.001092125,0.0013864912],"domain_scores_gemma":[0.9926394,0.0030953453,0.0006558149,0.0019977163,0.0010169048,0.0005947929],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00092995417,0.0009129791,0.0037168958,0.00056926615,0.00021242675,0.000033343167,0.0007623063,0.004527288,0.0006631963],"category_scores_gemma":[0.0016966955,0.00072524656,0.00041600651,0.00089575304,0.002503058,0.00014486712,0.00012536747,0.009663227,0.002354883],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005957351,0.00024191184,0.0062648165,0.00095283985,0.0007761263,0.15552491,0.000054186035,0.0000015321816,0.000013811962,0.000053222077,0.83512586,0.0003950207],"study_design_scores_gemma":[0.0060873306,0.0026485068,0.0067700343,0.0008866342,0.00080504577,0.040676817,0.000026298028,0.00007768046,0.000058054375,0.00006242998,0.9410146,0.00088657864],"about_ca_topic_score_codex":0.000021416792,"about_ca_topic_score_gemma":0.00002984377,"teacher_disagreement_score":0.16487876,"about_ca_system_score_codex":0.00038753133,"about_ca_system_score_gemma":0.005824252,"threshold_uncertainty_score":0.9998118},"labels":[],"label_agreement":null},{"id":"W2152961603","doi":"10.1128/mcb.24.3.1033-1043.2004","title":"The Corepressor mSin3A Regulates Phosphorylation-Induced Activation, Intranuclear Location, and Stability of AML1","year":2004,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Corepressor; Phosphorylation; Biology; Cell biology; Transcription factor; Gene; Genetics; Repressor","score_opus":0.012307349092848748,"score_gpt":0.2558501069067209,"score_spread":0.24354275781387213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152961603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98533803,0.001067528,0.010219331,0.0028435083,0.00002181924,0.00036783135,0.0000023244884,0.00001675622,0.00012287975],"genre_scores_gemma":[0.9990763,0.00013307443,0.0005170536,0.00017712178,0.00001990165,0.000011796558,0.000037750797,0.000013233041,0.000013761927],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991344,0.000093091476,0.00022607337,0.0002646159,0.00010282446,0.00017895481],"domain_scores_gemma":[0.99919206,0.000088597444,0.0000725367,0.00032294114,0.00024483463,0.000079043435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034743178,0.00010408146,0.00018568145,0.00004229597,0.00013118524,0.000012783793,0.00007245991,0.00013163807,0.00001651576],"category_scores_gemma":[0.00023552126,0.00007369368,0.00003264731,0.00016734633,0.0003479826,0.000027848348,0.00006042296,0.00015896063,0.0000022196427],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018063854,0.000038061444,0.002179327,0.000046864305,0.000060496594,0.0000037068862,0.00027619064,0.000008694441,0.98492104,0.007471498,0.000013097437,0.0048003756],"study_design_scores_gemma":[0.0011345362,0.00024558636,0.007699501,0.000020669373,0.00003165441,0.00001650097,0.00015567886,0.00030876056,0.98577935,0.0039511477,0.00058287446,0.000073740004],"about_ca_topic_score_codex":0.00026162964,"about_ca_topic_score_gemma":0.00000654748,"teacher_disagreement_score":0.013738285,"about_ca_system_score_codex":0.000053993837,"about_ca_system_score_gemma":0.00013993436,"threshold_uncertainty_score":0.3005141},"labels":[],"label_agreement":null},{"id":"W2155265055","doi":"10.1158/0008-5472.can-12-3425","title":"Inhibition of SRC Corrects GM-CSF Hypersensitivity That Underlies Juvenile Myelomonocytic Leukemia","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research; University of California, San Francisco; U.S. Food and Drug Administration","keywords":"Juvenile myelomonocytic leukemia; Cancer research; Leukemia; Immunology; Myeloid; Dasatinib; Haematopoiesis; Medicine; Myeloid leukemia; Biology; Internal medicine; Stem cell; Cell biology","score_opus":0.09768547454312058,"score_gpt":0.37555996042031553,"score_spread":0.27787448587719493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155265055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96626073,0.00064768596,0.00007601841,0.0028287088,0.00016942462,0.0014503319,0.000025708438,0.000082019505,0.028459378],"genre_scores_gemma":[0.99008596,0.0007760206,0.0002217109,0.00038080564,0.00031385335,0.0003745426,0.00003976523,0.00006935001,0.007737977],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959967,0.0004071802,0.00035335103,0.0005757643,0.0016177335,0.001049268],"domain_scores_gemma":[0.99662834,0.00067789474,0.00009462853,0.00074453943,0.0014110993,0.00044350408],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013322666,0.00023359101,0.000576773,0.00061576103,0.00022984859,0.00007826634,0.00021467637,0.00024890306,0.0011323635],"category_scores_gemma":[0.0006273382,0.00020397187,0.0001442176,0.0010299984,0.0009399039,0.00036921687,0.0003302992,0.0013409638,0.00081221864],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006625882,0.00017554268,0.0040629613,0.00095929415,0.00018352049,0.0002493255,0.001471651,0.00005394641,0.8292059,0.00036299595,0.097402535,0.0652098],"study_design_scores_gemma":[0.004527754,0.00087975775,0.03456324,0.0010359281,0.00006885017,0.00013597055,0.0059564663,0.0031139979,0.9412687,0.0013702802,0.006630966,0.00044812742],"about_ca_topic_score_codex":0.0075334334,"about_ca_topic_score_gemma":0.0002552854,"teacher_disagreement_score":0.11206282,"about_ca_system_score_codex":0.004113828,"about_ca_system_score_gemma":0.0034033605,"threshold_uncertainty_score":0.9999658},"labels":[],"label_agreement":null},{"id":"W2155367541","doi":"10.1081/iph-51761","title":"Bone Marrow Progenitor Cells from Chemically Exposed Workers Display an Intrinsic Ability for Autonomous Proliferation","year":2005,"lang":"en","type":"article","venue":"Immunopharmacology and Immunotoxicology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Conselho Nacional de Desenvolvimento Científico e Tecnológico; McMaster University","keywords":"Bone marrow; Progenitor cell; Neutropenia; Immunology; Population; Pathological; Biology; Medicine; Pathology; Stem cell; Toxicity; Internal medicine; Cell biology; Environmental health","score_opus":0.017037954788228223,"score_gpt":0.30862047112897595,"score_spread":0.2915825163407477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155367541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894783,0.0018119931,0.00018882721,0.0036980945,0.0006649861,0.003818575,0.000072409035,0.0001680161,0.00009878485],"genre_scores_gemma":[0.9874793,0.00020118953,0.007116572,0.0018518581,0.0008285512,0.001573448,0.00034741298,0.00006616736,0.000535479],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99705094,0.00034573735,0.0007814527,0.0008129156,0.00017163892,0.0008373061],"domain_scores_gemma":[0.9981656,0.0005425995,0.0002088796,0.0005246378,0.00027204075,0.0002862306],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00070786185,0.00039291187,0.000774096,0.00018660899,0.00033527805,0.00004546296,0.00029171008,0.00069817185,0.0006296647],"category_scores_gemma":[0.00017632739,0.00037005806,0.00015474412,0.00018206626,0.0006876452,0.000328801,0.00017862757,0.0008800407,0.0000810315],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011017564,0.0010681964,0.0028273165,0.000063473795,0.00038263714,0.00003572528,0.00044554326,0.00000824442,0.94651043,0.000036540907,0.0014477698,0.036156524],"study_design_scores_gemma":[0.015647955,0.0031058972,0.024456311,0.000021408458,0.00038125418,0.00015569807,0.00012948512,0.0031423266,0.92780274,0.00015127883,0.024554564,0.0004510674],"about_ca_topic_score_codex":0.000041798707,"about_ca_topic_score_gemma":0.00002507798,"teacher_disagreement_score":0.03570546,"about_ca_system_score_codex":0.0007041183,"about_ca_system_score_gemma":0.0008272133,"threshold_uncertainty_score":0.9998751},"labels":[],"label_agreement":null},{"id":"W2155633869","doi":"10.1016/j.humpath.2012.04.008","title":"Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype","year":2012,"lang":"en","type":"article","venue":"Human Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"NPM1; Myeloid leukemia; Immunophenotyping; Internal medicine; Karyotype; Univariate analysis; Medicine; Oncology; Myeloid; Population; Gastroenterology; Immunology; Multivariate analysis; Biology; Antigen; Chromosome; Gene; Genetics","score_opus":0.01222391645298323,"score_gpt":0.267094824951969,"score_spread":0.2548709084989858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155633869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997991,0.00024745494,0.00021450149,0.000049463895,0.00002964272,0.0006872805,0.000013406804,0.00002822971,0.00073897804],"genre_scores_gemma":[0.9944543,0.000016240198,0.0050020227,0.00008322522,0.000050956933,0.00006732402,0.0001622548,0.000040748542,0.0001229145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985944,0.00010955811,0.0002925374,0.00025593335,0.00023549677,0.000512076],"domain_scores_gemma":[0.9991945,0.000088548106,0.00012127826,0.0002936017,0.00016823984,0.0001338547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023901898,0.00018156812,0.00037179844,0.00028643018,0.00010033335,0.000007696701,0.0000966053,0.00012469117,0.000041064213],"category_scores_gemma":[0.00005689622,0.00013783117,0.000022573773,0.00027456292,0.00037909887,0.00017850888,0.000080879334,0.0003922589,0.00001302035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073338376,0.00022717565,0.9793967,0.00009313387,0.00011494825,0.00025194965,0.002314189,0.000019447807,0.0146075105,0.0006583408,0.00001687623,0.0015663696],"study_design_scores_gemma":[0.0045888447,0.0023072078,0.9904802,0.00009060808,0.00017397881,0.00042311838,0.00013596451,0.00004098729,0.0015294629,0.000054695218,0.000022427963,0.00015254789],"about_ca_topic_score_codex":0.00008911337,"about_ca_topic_score_gemma":0.000039628183,"teacher_disagreement_score":0.013078048,"about_ca_system_score_codex":0.00020775509,"about_ca_system_score_gemma":0.0002736951,"threshold_uncertainty_score":0.5620592},"labels":[],"label_agreement":null},{"id":"W2156311382","doi":"10.1128/mcb.01458-10","title":"Mtg16/Eto2 Contributes to Murine T-Cell Development","year":2011,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Vanderbilt Digestive Diseases Research Center, Vanderbilt University Medical Center; University of Toronto; University of California, San Diego; National Cancer Institute; National Institutes of Health; Vanderbilt-Ingram Cancer Center; Vanderbilt University","keywords":"Biology; Cell biology","score_opus":0.018512366272942653,"score_gpt":0.25326487616410304,"score_spread":0.2347525098911604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156311382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97063076,0.0019751207,0.014511906,0.00051019614,0.00006476021,0.0004414561,0.0000032973571,0.000045069457,0.011817414],"genre_scores_gemma":[0.99017936,0.000023276176,0.006682139,0.0016194348,0.000027711685,0.000045368663,0.00006105299,0.000024389034,0.001337249],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988263,0.0000693,0.00021962915,0.00036760326,0.00008814553,0.0004289809],"domain_scores_gemma":[0.9993225,0.00001867664,0.000028287654,0.00027987294,0.00009353988,0.0002571296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002403537,0.0001680542,0.00029637857,0.00016911821,0.000064738524,0.000007236589,0.0001207301,0.0001621271,0.00019200824],"category_scores_gemma":[0.000054247786,0.0001385393,0.000052860192,0.00016757323,0.000108792156,0.00000805128,0.00028096093,0.00020700613,0.00021755397],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020246576,0.00011728832,0.0060876454,0.00004727848,0.00009647969,0.00036764727,0.00025991822,1.1932691e-7,0.9840354,0.0019829103,0.00046638228,0.006336483],"study_design_scores_gemma":[0.0014534326,0.00038509592,0.001768468,0.00001537534,0.00003652031,0.00003666348,0.000054600634,0.000011042171,0.94400024,0.0005322681,0.05155591,0.00015039962],"about_ca_topic_score_codex":0.00006450915,"about_ca_topic_score_gemma":0.0000045719285,"teacher_disagreement_score":0.051089525,"about_ca_system_score_codex":0.00007290141,"about_ca_system_score_gemma":0.000171743,"threshold_uncertainty_score":0.56494683},"labels":[],"label_agreement":null},{"id":"W2156394741","doi":"10.1016/j.exphem.2003.09.013","title":"The fps/fes proto-oncogene regulates hematopoietic lineage output","year":2003,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Haematopoiesis; Progenitor cell; Biology; Cell biology; Bone marrow; Myeloid; Transgene; Cancer research; Stem cell; Immunology; Genetics; Gene","score_opus":0.023499950302459844,"score_gpt":0.32807873953809047,"score_spread":0.30457878923563064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156394741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9132301,0.043155234,0.00011143634,0.003329355,0.0007091227,0.0038911877,0.000004695649,0.00030676,0.035262085],"genre_scores_gemma":[0.98862565,0.00008353267,0.0018184573,0.00046008313,0.00010838753,0.00070156006,0.000013205131,0.00006513207,0.0081239855],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977317,0.0002158354,0.000476466,0.00046320373,0.0003782613,0.00073455676],"domain_scores_gemma":[0.9985551,0.00025887685,0.000103146376,0.0007417921,0.00008638236,0.00025467156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039199743,0.0002850693,0.0005154545,0.000094872936,0.00036623448,0.00003748764,0.00026144317,0.0002108788,0.00058933115],"category_scores_gemma":[0.00024259974,0.000190179,0.00016289079,0.00023255528,0.000555214,0.00006470712,0.0001447884,0.00037138618,0.0005857131],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017633685,0.0022242635,0.009978952,0.0004825663,0.0007348733,0.0024210853,0.0047518183,0.000002516026,0.33635256,0.56300104,0.07612114,0.0021658216],"study_design_scores_gemma":[0.0018775485,0.0003831555,0.00009455015,0.000045977806,0.000018225901,0.004450257,0.0021642551,0.00006956361,0.9455846,0.0003263002,0.044804383,0.00018118329],"about_ca_topic_score_codex":0.000014748055,"about_ca_topic_score_gemma":0.0000029724724,"teacher_disagreement_score":0.60923207,"about_ca_system_score_codex":0.0002660287,"about_ca_system_score_gemma":0.0002581295,"threshold_uncertainty_score":0.7755274},"labels":[],"label_agreement":null},{"id":"W2156665587","doi":"10.1186/1868-7083-6-19","title":"Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation","year":2014,"lang":"en","type":"article","venue":"Clinical Epigenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"Université de Montréal","keywords":"Trichostatin A; Decitabine; EZH2; Epigenetics; Epigenetic therapy; Cancer research; Biology; Gene silencing; Chromatin; DNA methylation; Acetylation; PRC2; Histone; Methylation; Histone deacetylase; Genetics; Gene; Gene expression","score_opus":0.05031231532236087,"score_gpt":0.3895590017751555,"score_spread":0.33924668645279465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156665587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809177,0.00077364536,0.017069869,0.00027317123,0.00009873873,0.0007256091,0.0000059176637,0.000018087001,0.00011726112],"genre_scores_gemma":[0.978173,0.0029931082,0.018511668,0.000073585616,0.00011403504,0.000008875188,0.00003662435,0.000047783007,0.000041313688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99702317,0.0003779507,0.0013664888,0.00042140635,0.0005291612,0.00028184766],"domain_scores_gemma":[0.9974965,0.0008357748,0.00055169157,0.0004672832,0.00047101322,0.0001777337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001887264,0.00022052041,0.0008181133,0.00033041148,0.00004281165,0.000008089339,0.00012366494,0.0003201469,0.00001940191],"category_scores_gemma":[0.0007074591,0.00018792012,0.00010691413,0.0005546637,0.00053418503,0.00007583724,0.00007247271,0.00042123714,0.0000022084887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002755857,0.00082631974,0.59134424,0.0002788416,0.00035604124,0.000011867688,0.00064158725,0.0024955315,0.23069926,0.0005033521,0.000039525377,0.1700476],"study_design_scores_gemma":[0.012136673,0.004516649,0.75980973,0.0003093435,0.00021631425,0.000015787364,0.00006326568,0.06667851,0.15462561,0.0010924573,0.00025349655,0.00028216065],"about_ca_topic_score_codex":0.00017773367,"about_ca_topic_score_gemma":0.000022894299,"teacher_disagreement_score":0.16976544,"about_ca_system_score_codex":0.00031899448,"about_ca_system_score_gemma":0.0004761679,"threshold_uncertainty_score":0.766316},"labels":[],"label_agreement":null},{"id":"W2157912932","doi":"10.3109/10428194.2014.971407","title":"The deregulated promoter methylation of the<i>Polo-like kinases</i>as a potential biomarker in hematological malignancies","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; University of Windsor","funders":"Windsor Cancer Centre Foundation","keywords":"Polo-like kinase; Methylation; DNA methylation; Carcinogenesis; PLK1; Biology; Cancer research; Leukemia; Kinase; Biomarker; Myelodysplastic syndromes; Bone marrow; Molecular biology; Cancer; Genetics; Immunology; DNA; Gene; Cell cycle; Gene expression","score_opus":0.011268430685235196,"score_gpt":0.2545168655827003,"score_spread":0.24324843489746512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157912932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247134,0.0015156376,0.00015551443,0.0016590621,0.00036526768,0.0012991283,0.000013351702,0.00013143854,0.0023892717],"genre_scores_gemma":[0.99584764,0.00037941616,0.00031569894,0.0011098698,0.00012266278,0.00014734572,0.000041077008,0.00009143954,0.0019448383],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9946922,0.000772924,0.0012215097,0.0009589996,0.0011436347,0.001210725],"domain_scores_gemma":[0.9967266,0.00076598424,0.00046255338,0.0013461943,0.0003297141,0.00036899513],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014889365,0.00065833406,0.0010196767,0.00033122473,0.0005852782,0.00013453553,0.0007506427,0.0007410528,0.00006582507],"category_scores_gemma":[0.000860365,0.0003944778,0.00040786687,0.0012882607,0.0014452619,0.00023323661,0.0005878323,0.0003113363,0.000052581843],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009702514,0.0009587331,0.05963998,0.0015042722,0.0011030697,0.0011722357,0.0029393774,0.000230093,0.41378015,0.01526956,0.011714255,0.48198578],"study_design_scores_gemma":[0.025480272,0.000753167,0.80243623,0.0008606782,0.00039854785,0.0052225552,0.00082201743,0.04612943,0.08645119,0.005046267,0.025388995,0.0010106245],"about_ca_topic_score_codex":0.0020947426,"about_ca_topic_score_gemma":0.00017847944,"teacher_disagreement_score":0.74279624,"about_ca_system_score_codex":0.00361264,"about_ca_system_score_gemma":0.0030884328,"threshold_uncertainty_score":0.9998507},"labels":[],"label_agreement":null},{"id":"W2158060003","doi":"10.1111/j.1365-2141.2007.06909.x","title":"Familial myelodysplasia and acute myeloid leukaemia – a review","year":2007,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"Cancer Research UK; Lady Tata Memorial Trust","keywords":"CEBPA; Medicine; Myeloid; Germline; Pedigree chart; RUNX1; Germline mutation; Myelodysplastic syndromes; Oncology; Internal medicine; Mutation; Genetics; Gene; Biology; Haematopoiesis; Bone marrow; Stem cell","score_opus":0.04561530417102781,"score_gpt":0.3816885380774147,"score_spread":0.3360732339063869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158060003","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022672933,0.9960555,0.00007865914,0.0004291833,0.0004981455,0.0013063077,0.00006016735,0.000031980097,0.0013133525],"genre_scores_gemma":[0.0000033037402,0.99501276,0.0020593929,0.0010730644,0.0006826812,0.00002767787,0.00007431879,0.0001461069,0.0009206649],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99417424,0.00057262223,0.0029057583,0.0005787224,0.000852665,0.0009159987],"domain_scores_gemma":[0.9957051,0.0006226812,0.0017168912,0.00047604766,0.00070982915,0.0007694222],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002289641,0.0006465088,0.008320081,0.00079101557,0.00013134333,0.00006408576,0.00063033524,0.0010674511,0.00028207526],"category_scores_gemma":[0.0012574465,0.0005881499,0.0012586104,0.0006923691,0.00057004445,0.00017320063,0.000311337,0.0037984487,0.00012653961],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052588144,0.000049102273,0.0000034143493,0.06476572,0.0009802302,0.22035466,0.000007479655,3.6846461e-9,8.502999e-7,0.00004024484,0.052454717,0.661291],"study_design_scores_gemma":[0.0006780461,0.00020431001,0.000006351746,0.11018413,0.0031122677,0.44044897,0.0000057284024,3.0216117e-7,8.6662e-7,0.000015973299,0.44515795,0.00018509863],"about_ca_topic_score_codex":0.000037045695,"about_ca_topic_score_gemma":0.000017975877,"teacher_disagreement_score":0.6611059,"about_ca_system_score_codex":0.0005422579,"about_ca_system_score_gemma":0.0030732546,"threshold_uncertainty_score":0.999657},"labels":[],"label_agreement":null},{"id":"W2158429148","doi":"10.1016/j.leukres.2015.03.017","title":"Whole genome and transcriptome analysis of a novel AML cell line with a normal karyotype","year":2015,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Louisiana State University","keywords":"Biology; Karyotype; Cancer research; Transcriptome; Cell culture; Myeloid leukemia; Myeloid; Progenitor cell; Haematopoiesis; Gene; Cell growth; CD34; Genetics; Stem cell; Gene expression; Chromosome","score_opus":0.081088432951783,"score_gpt":0.3520627893634922,"score_spread":0.2709743564117092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158429148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98591703,0.0008744854,0.0011713963,0.001290811,0.000017947717,0.0007371191,0.00012337697,0.000048953334,0.009818893],"genre_scores_gemma":[0.9861513,0.00012401026,0.004095949,0.00013873496,0.00013829212,0.000060162845,0.00020089332,0.000062332765,0.009028339],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99559635,0.00019313597,0.0004541893,0.0006404009,0.0021157416,0.0010002088],"domain_scores_gemma":[0.99638873,0.00027644567,0.00007725282,0.0008574289,0.0014545929,0.00094556884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025563806,0.00025404815,0.00082333136,0.002033363,0.000117338685,0.00005674782,0.00039729886,0.00023288513,0.00013273791],"category_scores_gemma":[0.00025215326,0.00019491879,0.00014334246,0.0049713682,0.0007480596,0.00019226232,0.00024084153,0.0013481692,0.00006017267],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009931038,0.0010967662,0.030435005,0.00090396666,0.002832063,0.0007625848,0.006718096,0.002340884,0.9399479,0.00029969605,0.0031181418,0.0016138569],"study_design_scores_gemma":[0.103489526,0.028140312,0.32987374,0.0006151096,0.0069312896,0.0008681807,0.014236765,0.3420038,0.08022602,0.00016966213,0.09097557,0.002470017],"about_ca_topic_score_codex":0.001798834,"about_ca_topic_score_gemma":0.00024804613,"teacher_disagreement_score":0.8597219,"about_ca_system_score_codex":0.0014011298,"about_ca_system_score_gemma":0.003383893,"threshold_uncertainty_score":0.7948557},"labels":[],"label_agreement":null},{"id":"W2158664264","doi":"10.3109/10428194.2012.722217","title":"Correlation of the microculture-kinetic drug-induced apoptosis assay with patient outcomes in initial treatment of adult acute myelocytic leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Semtech (Canada)","funders":"Leukemia and Lymphoma Society","keywords":"Idarubicin; Microculture; Apoptosis; Medicine; Daunorubicin; Myeloid leukemia; Chemotherapy; Internal medicine; Leukemia; Oncology; Pharmacology; Immunology; Cytarabine; Biology; Cell culture; Biochemistry","score_opus":0.010439009679549102,"score_gpt":0.2573961836601869,"score_spread":0.2469571739806378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158664264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99428,0.0005797168,0.000035384222,0.00030275123,0.00041057187,0.0020129932,0.00009041668,0.00008510615,0.0022030782],"genre_scores_gemma":[0.9965792,0.00042579378,0.00075844803,0.000524712,0.0001787396,0.0002885372,0.00011259617,0.00014395597,0.0009880584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99439526,0.00044158855,0.0015666712,0.00088053267,0.00133209,0.0013838625],"domain_scores_gemma":[0.996159,0.0005854405,0.000854658,0.0013095825,0.0005114382,0.00057984696],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037173534,0.0009993172,0.0018197299,0.000574641,0.0002444549,0.000046909503,0.00046159205,0.00064155244,0.000041883923],"category_scores_gemma":[0.00020770672,0.0006338193,0.00048897916,0.0013295168,0.0006446081,0.0004265142,0.0002608764,0.00024836362,0.000027334416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00817989,0.002773619,0.6275636,0.0010039785,0.003015678,0.0002458482,0.026602881,0.0003883781,0.111930534,0.0012770315,0.0017699377,0.21524861],"study_design_scores_gemma":[0.04444544,0.0024289773,0.50517535,0.0010103069,0.0015767855,0.0011480126,0.0029071232,0.0039011978,0.4344309,0.000055407956,0.0018052593,0.0011152278],"about_ca_topic_score_codex":0.0063777855,"about_ca_topic_score_gemma":0.0002872909,"teacher_disagreement_score":0.32250038,"about_ca_system_score_codex":0.021454506,"about_ca_system_score_gemma":0.005670812,"threshold_uncertainty_score":0.9999661},"labels":[],"label_agreement":null},{"id":"W2159289068","doi":"10.1182/blood.v97.1.56","title":"A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer Group","year":2001,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":361,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grace (Canada)","funders":"","keywords":"Medicine; Chemotherapy; Cytarabine; Regimen; Internal medicine; Surgery; Bone marrow; Chemotherapy regimen; Transplantation; Randomization; Leukemia; Oncology; Myeloid leukemia; Randomized controlled trial","score_opus":0.0107190085006928,"score_gpt":0.2846117187186004,"score_spread":0.2738927102179076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159289068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99095213,0.005084733,0.000112767266,0.0020654025,0.000024681762,0.0014449656,0.00016358666,0.000051394574,0.00010033874],"genre_scores_gemma":[0.9818156,0.014764836,0.001721677,0.0003235175,0.00012912111,0.00017563101,0.00089248084,0.0000628282,0.00011433898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971331,0.0001753566,0.00086469244,0.0007018869,0.0006200143,0.00050496234],"domain_scores_gemma":[0.99854934,0.00015289443,0.0004943213,0.0005105429,0.00011363739,0.00017925675],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040327015,0.00037274754,0.0008723361,0.00024167956,0.00010330142,0.00002414079,0.0002248408,0.00027274602,0.00012133271],"category_scores_gemma":[0.000040946336,0.0002630534,0.0000817645,0.0006805441,0.00028730463,0.00013023481,0.00002263138,0.0006727329,0.0000021170056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030878154,0.00038751226,0.9562266,0.000061014653,0.000621558,0.0044482015,0.0029600859,0.00004538067,0.028651262,0.000005198302,0.0002480059,0.0032573496],"study_design_scores_gemma":[0.018923063,0.00031981932,0.94368,0.00073597545,0.0006714135,0.01881375,0.00013233087,0.00013524601,0.016229216,0.000033680735,0.0000414962,0.0002840419],"about_ca_topic_score_codex":0.005838291,"about_ca_topic_score_gemma":0.00305201,"teacher_disagreement_score":0.015835248,"about_ca_system_score_codex":0.00026471433,"about_ca_system_score_gemma":0.00074260053,"threshold_uncertainty_score":0.9999822},"labels":[],"label_agreement":null},{"id":"W2159601358","doi":"10.3324/haematol.2011.043422","title":"Familial myelodysplastic syndromes: a review of the literature","year":2011,"lang":"en","type":"review","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":146,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Myelodysplastic syndromes; Platelet disorder; Medicine; RUNX1; Myeloid leukemia; Transplantation; Hematopoietic stem cell transplantation; Leukemia; Immunology; Disease; Internal medicine; Stem cell; Genetics; Haematopoiesis; Biology; Bone marrow; Platelet","score_opus":0.08086625824052283,"score_gpt":0.35863915398657736,"score_spread":0.2777728957460545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159601358","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000054193933,0.9890464,0.0000030840843,0.00016949487,0.0002678575,0.0029081004,0.00009879671,0.00006525665,0.0074356208],"genre_scores_gemma":[0.0000068126037,0.9962464,0.00027902372,0.0005052479,0.00009601492,0.00031145356,0.000118921576,0.00006519548,0.0023709047],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99664676,0.0005751859,0.0011583365,0.0005959788,0.0005277614,0.0004959875],"domain_scores_gemma":[0.9967729,0.0004383469,0.0006929423,0.0016269732,0.00028627418,0.00018256434],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005216133,0.0006039277,0.004676589,0.00020243794,0.000080247475,0.000013347728,0.0009965195,0.0007831916,0.0008378382],"category_scores_gemma":[0.0021420044,0.0002690004,0.0015234802,0.001386713,0.0003702885,0.000037933107,0.0005191752,0.0017043572,0.0004751504],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019988149,0.00008752203,0.0000039835036,0.7752614,0.00032517425,0.00082740735,0.000048119404,1.4585283e-9,2.05312e-7,0.00093919126,0.028182255,0.19430476],"study_design_scores_gemma":[0.00012577459,0.00010217813,0.000007204279,0.41076365,0.0013105896,0.009059554,0.0000030240556,1.8533409e-7,7.7361847e-7,0.000031273084,0.5784562,0.00013958692],"about_ca_topic_score_codex":0.0000061071823,"about_ca_topic_score_gemma":6.238941e-7,"teacher_disagreement_score":0.55027395,"about_ca_system_score_codex":0.00018511058,"about_ca_system_score_gemma":0.0012772359,"threshold_uncertainty_score":0.9999762},"labels":[],"label_agreement":null},{"id":"W2159889484","doi":"10.1158/1055-9965.epi-13-0671","title":"Single-Nucleotide Polymorphisms in Reductase Genes Are not Associated with Response to Daunorubicin-Based Remission Induction","year":2013,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Daunorubicin; Single-nucleotide polymorphism; Gene; Medicine; Genetics; Reductase; Biology; Genotype; Enzyme; Chemotherapy; Biochemistry","score_opus":0.0720650930586125,"score_gpt":0.3549447166044747,"score_spread":0.28287962354586216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159889484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9421702,0.0009070831,0.0005507302,0.054024138,0.00033894164,0.0018135005,0.000018087307,0.0001254439,0.000051869574],"genre_scores_gemma":[0.9906262,0.000086592314,0.0035495358,0.0029402697,0.00019877344,0.00061243656,0.00021498495,0.00007291285,0.0016982652],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99435943,0.0026991914,0.0008786581,0.0009104686,0.0003032587,0.0008490163],"domain_scores_gemma":[0.9968835,0.0011515921,0.00053879444,0.00061355205,0.00033896245,0.00047360227],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0042061578,0.00035861577,0.00081239623,0.0007799756,0.00014055653,0.000014669213,0.00019949842,0.00048616738,0.00041327192],"category_scores_gemma":[0.004828705,0.0002982808,0.00015725265,0.0010292499,0.00029521142,0.00020984185,0.00007523096,0.000515657,0.0000760354],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012961796,0.0003413277,0.2596704,0.000044795153,0.00025777795,0.00006332239,0.00007393661,0.00016215983,0.66909355,0.000003205881,0.018406883,0.03892082],"study_design_scores_gemma":[0.0041711163,0.0013013802,0.93280345,0.0020361056,0.00014381424,0.00003126721,0.0001928669,0.0016061338,0.05550266,0.00020554138,0.0016199914,0.00038566784],"about_ca_topic_score_codex":0.0017430701,"about_ca_topic_score_gemma":0.00047588977,"teacher_disagreement_score":0.6731331,"about_ca_system_score_codex":0.0027871507,"about_ca_system_score_gemma":0.0007262808,"threshold_uncertainty_score":0.99994695},"labels":[],"label_agreement":null},{"id":"W2160614740","doi":"10.1158/1078-0432.ccr-08-1007","title":"Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Romidepsin; Medicine; Myeloid leukemia; Histone deacetylase inhibitor; Leukemia; Myeloid; Bone marrow; Internal medicine; Oncology; Cohort; Hematology; Cancer research; Immunology; Histone deacetylase; Biology; Histone; Genetics","score_opus":0.32182533066670976,"score_gpt":0.5046025705707391,"score_spread":0.18277723990402933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160614740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929003,0.00040927017,0.000053151587,0.0035197872,0.00068700576,0.0015882934,0.00015138781,0.00012981011,0.0005609608],"genre_scores_gemma":[0.9854229,0.0029935462,0.00027806265,0.0001947256,0.0017466081,0.00032979588,0.0000593291,0.00013320899,0.00884184],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9919173,0.0009952021,0.001194654,0.0014472298,0.0024866136,0.0019589642],"domain_scores_gemma":[0.9947953,0.0019227009,0.0001838663,0.0011645033,0.00064020895,0.0012933707],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025715271,0.00045022974,0.0013566888,0.0009614749,0.00064554403,0.00008649693,0.0007331576,0.0008029817,0.0019534004],"category_scores_gemma":[0.0028536823,0.000391879,0.00044633806,0.0016941329,0.0026477126,0.00030957753,0.0008917321,0.006560183,0.00064543646],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.025216106,0.0024350984,0.29792044,0.00052375376,0.0007656425,0.008276763,0.0013372658,0.000009400336,0.49237758,0.000067500514,0.112534225,0.058536228],"study_design_scores_gemma":[0.026071686,0.002919571,0.828287,0.00080852053,0.00012890414,0.00030333136,0.00018266871,0.0032917738,0.12056189,0.00007367661,0.016317504,0.001053484],"about_ca_topic_score_codex":0.0039331266,"about_ca_topic_score_gemma":0.0010343391,"teacher_disagreement_score":0.53036654,"about_ca_system_score_codex":0.008108083,"about_ca_system_score_gemma":0.008668175,"threshold_uncertainty_score":0.9998533},"labels":[],"label_agreement":null},{"id":"W2160746673","doi":"10.1056/nejmoa1010222","title":"Cytarabine Dose for Acute Myeloid Leukemia","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":407,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc; Institut du Savoir Montfort","funders":"Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung","keywords":"Cytarabine; Medicine; Myeloid leukemia; Leukemia; Myeloid; Body surface area; Chemotherapy; Oncology; Internal medicine","score_opus":0.04713119116700721,"score_gpt":0.32660723434661765,"score_spread":0.27947604317961044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160746673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93147165,0.003509552,0.01553082,0.027105497,0.0019807788,0.0012489823,0.000015988344,0.00007782785,0.019058928],"genre_scores_gemma":[0.9352492,0.0027464612,0.029362053,0.0032853335,0.017600976,0.000012860838,0.000033317232,0.00011187072,0.011597945],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976527,0.000071646326,0.0008481495,0.00021624091,0.00073519116,0.0004760685],"domain_scores_gemma":[0.997414,0.00031248608,0.0003900073,0.00034717467,0.00066251075,0.0008738481],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016875692,0.0002525165,0.0009102164,0.00045900166,0.0000701296,0.0000074239674,0.00032329204,0.0001460999,0.0010123008],"category_scores_gemma":[0.0009688443,0.00015522154,0.00019590528,0.00031021342,0.00021540988,0.0001616,0.000044947243,0.0007768106,0.000025039228],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034076516,0.0002520587,0.0061228215,0.00024321882,0.002361838,0.004071039,0.007293633,0.0000076267756,0.09492851,0.001187477,0.33260664,0.5168486],"study_design_scores_gemma":[0.39978227,0.026467657,0.028555384,0.0014043858,0.0035520447,0.025193715,0.00077546004,0.0004902161,0.02239449,0.0061162235,0.4847311,0.00053702045],"about_ca_topic_score_codex":0.00018127041,"about_ca_topic_score_gemma":0.000014534016,"teacher_disagreement_score":0.5163116,"about_ca_system_score_codex":0.00043753796,"about_ca_system_score_gemma":0.001403923,"threshold_uncertainty_score":0.99990094},"labels":[],"label_agreement":null},{"id":"W2160791743","doi":"10.1186/1476-4598-9-246","title":"Phosphorylation of HOX11/TLX1 on Threonine-247 during mitosis modulates expression of cyclin B1","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Biology; Mitosis; Phosphorylation; Threonine; Cancer research; Cell biology; Cyclin; Protein expression; Expression (computer science); Protein-Serine-Threonine Kinases; Cell cycle; Biochemistry; Serine; Apoptosis; Protein kinase A; Computer science","score_opus":0.009933290810669093,"score_gpt":0.2929316445512172,"score_spread":0.2829983537405481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160791743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972747,0.0005686914,0.00022293185,0.00045139494,0.00014298264,0.00035342196,0.000015623953,0.000027125652,0.00094312435],"genre_scores_gemma":[0.9978081,0.00015379395,0.0014295067,0.00008012147,0.0000963496,0.000049607388,0.000016078431,0.00004258675,0.00032388646],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99860996,0.000035710655,0.00030744288,0.0002853493,0.0005208243,0.0002406984],"domain_scores_gemma":[0.99895453,0.000040764106,0.00015205058,0.0005084771,0.00023659361,0.0001075711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015072108,0.00015175,0.00031705206,0.00016277088,0.000038199752,0.0000054760594,0.00013811231,0.00016223935,0.00036494966],"category_scores_gemma":[0.00017273967,0.00012903335,0.0001195076,0.00028702262,0.000102853126,0.000052770207,0.00007488033,0.0004054344,0.0000091036145],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042659833,0.00008952732,0.011460629,0.00016586752,0.000045868706,0.000023879942,0.00016147006,0.00039739592,0.9841041,0.000056443507,0.0002629207,0.0028053247],"study_design_scores_gemma":[0.0014661695,0.00011706716,0.050380275,0.00028751435,0.000043922584,0.000004241697,0.000024110372,0.00083218276,0.9464088,0.000050471564,0.00028229906,0.00010293994],"about_ca_topic_score_codex":0.0002985754,"about_ca_topic_score_gemma":0.000017664144,"teacher_disagreement_score":0.038919643,"about_ca_system_score_codex":0.00012280936,"about_ca_system_score_gemma":0.00018399574,"threshold_uncertainty_score":0.5261827},"labels":[],"label_agreement":null},{"id":"W2160932375","doi":"10.3109/10428194.2014.927457","title":"Shelf-life extension of azacitidine: waste and cost reduction in the treatment of myelodysplastic syndromes","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Azacitidine; Myelodysplastic syndromes; Reduction (mathematics); Medicine; Extension (predicate logic); Oncology; Internal medicine; Computer science; Biology; Genetics","score_opus":0.02607203243919772,"score_gpt":0.27239053465651586,"score_spread":0.24631850221731813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160932375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669129,0.00534318,0.000041500363,0.023063147,0.000444473,0.0026278668,0.0001356036,0.000088459696,0.0013428454],"genre_scores_gemma":[0.94453394,0.01608381,0.00045589305,0.032128576,0.0027262939,0.0005168199,0.0009901394,0.00031893366,0.0022456036],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9930134,0.0006630427,0.0018408227,0.0016213689,0.0015641054,0.0012973077],"domain_scores_gemma":[0.9950178,0.001463282,0.0009334166,0.0017890497,0.0003887114,0.00040771434],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008237331,0.001311742,0.002827621,0.0012452326,0.00023867349,0.00009281375,0.0005610388,0.0019241226,0.000052692896],"category_scores_gemma":[0.00036104448,0.0009400149,0.00047626943,0.0009825288,0.0014294747,0.00021987289,0.00018470928,0.0006788926,0.00002414212],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067487685,0.0015053812,0.0046662404,0.012324621,0.0025778753,0.009135444,0.008293243,0.00017892799,0.01820982,0.00046829882,0.66436404,0.27152735],"study_design_scores_gemma":[0.08952759,0.012228041,0.05977097,0.0075187217,0.00478595,0.04152124,0.004793767,0.01577809,0.014973129,0.00055997923,0.74494183,0.003600704],"about_ca_topic_score_codex":0.0028400794,"about_ca_topic_score_gemma":0.000031654003,"teacher_disagreement_score":0.26792666,"about_ca_system_score_codex":0.008098158,"about_ca_system_score_gemma":0.004919562,"threshold_uncertainty_score":0.9999634},"labels":[],"label_agreement":null},{"id":"W2161854495","doi":"10.1016/s0165-4608(02)00682-9","title":"A unique clone involving multiple structural chromosome rearrangements in a myelodysplastic syndrome case","year":2003,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Hôpital Saint-François d'Assise; Université Laval","funders":"Medical Research Council; Fonds de Recherche du Québec - Santé; Natural Sciences and Engineering Research Council of Canada","keywords":"Biology; Karyotype; clone (Java method); Chromosome; Fluorescence in situ hybridization; Myelodysplastic syndromes; Cytogenetics; Genetics; Chromosome 7 (human); Molecular biology; Bone marrow; Pathology; Immunology; DNA; Gene; Medicine","score_opus":0.03057987410101013,"score_gpt":0.30894238411010794,"score_spread":0.2783625100090978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161854495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879286,0.0107758595,0.00012404082,0.000119228825,0.00015903573,0.0006961856,0.000059908754,0.00002468156,0.000112448586],"genre_scores_gemma":[0.9887974,0.0066602128,0.003761888,0.00023475768,0.00007232277,0.000099637975,0.000017842256,0.000065177956,0.0002907508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811715,0.000100327896,0.00038841035,0.00048718596,0.00030387053,0.000603066],"domain_scores_gemma":[0.998936,0.00008530302,0.00007444733,0.00039849756,0.00014340183,0.0003623749],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019136132,0.0002815677,0.00039979175,0.00021900675,0.0001222084,0.000045535468,0.00010643107,0.00018566073,0.00013721915],"category_scores_gemma":[0.00013841991,0.00027196057,0.000051160314,0.0004377328,0.00017622442,0.0000327779,0.00011085721,0.00036963733,0.000006689107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020635447,0.000110191926,0.88244456,0.00061879755,0.0002391175,0.014710299,0.0012672114,0.0012336711,0.09228607,0.00014945214,0.0002634313,0.006470841],"study_design_scores_gemma":[0.034952138,0.0038044334,0.64013016,0.0016011026,0.0009633817,0.074012205,0.0031348611,0.07382404,0.14352754,0.0012089766,0.019716293,0.0031248769],"about_ca_topic_score_codex":0.00026238253,"about_ca_topic_score_gemma":0.0006119718,"teacher_disagreement_score":0.24231441,"about_ca_system_score_codex":0.00039017576,"about_ca_system_score_gemma":0.0004562408,"threshold_uncertainty_score":0.99997324},"labels":[],"label_agreement":null},{"id":"W2161938647","doi":"10.1200/jco.2014.58.3518","title":"Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Medicine; Minimal residual disease; Internal medicine; Oncology; Myeloid leukemia; Bone marrow; Myeloid; Complete response; Leukemia; Refractory (planetary science); Immunology; Chemotherapy","score_opus":0.1883688330891963,"score_gpt":0.5171872309117762,"score_spread":0.32881839782257993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161938647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868116,0.00040903306,0.000015595155,0.011750378,0.00037122742,0.00040697335,0.000016849452,0.0000075487064,0.00021081649],"genre_scores_gemma":[0.99611974,0.0005973242,0.0015340502,0.00080717064,0.00070400105,0.000003793214,0.0000044043136,0.000025304864,0.00020418887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915778,0.0029407956,0.004242815,0.00033264994,0.0005641009,0.0003418638],"domain_scores_gemma":[0.9769296,0.018844191,0.001800179,0.00030510747,0.00055257865,0.0015683646],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.022390805,0.00021914979,0.0022261473,0.00039077952,0.000025604091,0.000011800044,0.00018151883,0.00062804826,0.000018715407],"category_scores_gemma":[0.07406512,0.00013116591,0.00038435514,0.00022378987,0.00073630403,0.00018111039,0.00016020752,0.0024435937,0.000008032887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18485585,0.00069770915,0.79029256,0.00002699476,0.00030772478,0.0016818595,0.00019093795,0.000019370797,0.00011914498,0.000022392807,0.002315283,0.01947016],"study_design_scores_gemma":[0.018533396,0.03408454,0.94361013,0.00017159246,0.0003174698,0.000417784,0.0001871643,0.0008908248,0.000014124635,0.00037352013,0.0012960045,0.000103455255],"about_ca_topic_score_codex":0.00002188474,"about_ca_topic_score_gemma":0.000009903266,"teacher_disagreement_score":0.16632245,"about_ca_system_score_codex":0.00058791897,"about_ca_system_score_gemma":0.009587015,"threshold_uncertainty_score":0.9998578},"labels":[],"label_agreement":null},{"id":"W2162079601","doi":"10.1038/ng.3400","title":"The genomic landscape of juvenile myelomonocytic leukemia","year":2015,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":309,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Biology; Juvenile myelomonocytic leukemia; Juvenile; Chronic myelomonocytic leukemia; Genetics; Evolutionary biology; Leukemia; Computational biology; Immunology; Myelodysplastic syndromes","score_opus":0.02087007176139491,"score_gpt":0.30146217795745617,"score_spread":0.28059210619606123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162079601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635635,0.020548956,0.000042317864,0.0011507291,0.0003735903,0.0003738482,0.000011220019,0.000036752634,0.013899056],"genre_scores_gemma":[0.9929052,0.0007812331,0.0022563033,0.0003729934,0.0004502471,0.000009954329,0.000020217987,0.000036792735,0.003167075],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99860054,0.00005033086,0.00028164886,0.00020937964,0.00051265315,0.00034543182],"domain_scores_gemma":[0.99852604,0.00013020777,0.000091474576,0.000652898,0.00035941292,0.00023995242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005193667,0.00013822573,0.00026370405,0.00008265881,0.00006751397,0.00001988009,0.00033895115,0.0003543524,0.000024514751],"category_scores_gemma":[0.00038012918,0.000089849615,0.00008423088,0.00028406188,0.00014630005,0.000017101653,0.00016033984,0.0009071123,0.000090829635],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024997294,0.00018352017,0.11035784,0.0003571727,0.00071290473,0.00029875318,0.0025498269,0.0010628996,0.04139322,0.0012936366,0.73114383,0.10814668],"study_design_scores_gemma":[0.007878839,0.001205795,0.10343829,0.00008251101,0.00030303196,0.00040384204,0.0012882642,0.0139995525,0.05630474,0.001674565,0.8129797,0.00044087518],"about_ca_topic_score_codex":0.0000117514555,"about_ca_topic_score_gemma":0.000014953913,"teacher_disagreement_score":0.10770581,"about_ca_system_score_codex":0.0005174285,"about_ca_system_score_gemma":0.001918869,"threshold_uncertainty_score":0.3941002},"labels":[],"label_agreement":null},{"id":"W2162327900","doi":"10.1016/s1470-2045(13)70037-8","title":"Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Refractory (planetary science); Internal medicine; Clinical endpoint; Dosing; Regimen; Intention-to-treat analysis; Surgery; Complete remission; Clinical trial; Gastroenterology; Chemotherapy","score_opus":0.05924214384470794,"score_gpt":0.3954304370345984,"score_spread":0.33618829318989046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162327900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845771,0.00006187783,0.000017957886,0.0030765906,0.000109648136,0.00767021,0.000020986798,0.000048027287,0.00441756],"genre_scores_gemma":[0.9932418,0.00010270084,0.0024838569,0.0013660127,0.00017062004,0.0007308029,0.00005989025,0.00006573927,0.0017785889],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99637663,0.0010593033,0.00074037537,0.0005150963,0.0005180181,0.0007905895],"domain_scores_gemma":[0.99675095,0.0011496674,0.0004413366,0.0010993949,0.00036158485,0.0001970762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017183296,0.00031323778,0.0015906072,0.00022983502,0.0001259383,0.00004394217,0.00085764163,0.00016596433,0.0003005881],"category_scores_gemma":[0.0004434974,0.00017126091,0.000044384604,0.00063396385,0.00036347585,0.00029071516,0.0003822015,0.0010617258,0.00006917176],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7016032,0.024753548,0.04760155,0.00023020867,0.0021616335,0.001725074,0.015710726,0.000015062338,0.058036942,0.00010872468,0.03010306,0.1179503],"study_design_scores_gemma":[0.9228147,0.042476553,0.02449878,0.00022871615,0.0004643646,0.00008639365,0.0022540118,0.00034432072,0.0010093646,0.00008740021,0.0053895977,0.0003457913],"about_ca_topic_score_codex":0.001468355,"about_ca_topic_score_gemma":0.0006292034,"teacher_disagreement_score":0.22121154,"about_ca_system_score_codex":0.0009298897,"about_ca_system_score_gemma":0.0012409866,"threshold_uncertainty_score":0.6983817},"labels":[],"label_agreement":null},{"id":"W2162523466","doi":"10.1371/journal.pone.0137300","title":"Cigarette Smoking and the Risk of Adult Myeloid Disease: A Meta-Analysis","year":2015,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Medicine; Odds ratio; Myeloid; Myelodysplastic syndromes; Meta-analysis; Internal medicine; Disease; Odds; Cochrane Library; Oncology; Logistic regression; Bone marrow","score_opus":0.18609647732687834,"score_gpt":0.34639728182456836,"score_spread":0.16030080449769002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162523466","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014674777,0.9956257,0.0000119952665,0.0008322061,0.000008701602,0.002039936,0.00059662305,0.00003764993,0.0007004783],"genre_scores_gemma":[0.0001451178,0.9957823,0.00032306346,0.00015484352,0.00018765852,0.0005055678,0.00026916497,0.00008194579,0.0025503081],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9950648,0.0010748026,0.0009335337,0.0006241442,0.0019153823,0.0003873385],"domain_scores_gemma":[0.9952361,0.0010705761,0.0007947559,0.0016295826,0.0008054022,0.00046360883],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002124484,0.0004963378,0.008071594,0.0005700218,0.00008669448,0.00003805359,0.00044799465,0.00026579792,0.00036742524],"category_scores_gemma":[0.0028035115,0.0002461885,0.0031514508,0.001465586,0.0004882899,0.000050114824,0.00035189028,0.0013380793,0.000022923256],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018745252,0.00031931166,0.00013963353,0.020372478,0.9374981,0.00005545972,0.00009373361,4.440773e-7,2.3420627e-7,0.00011904305,0.0006150165,0.04059913],"study_design_scores_gemma":[0.0010281169,0.000044762426,0.000030583135,0.0016202738,0.9446656,0.00000528518,0.000016255488,0.0001554323,0.0000027782407,0.00006028724,0.052164298,0.00020634197],"about_ca_topic_score_codex":0.00014343894,"about_ca_topic_score_gemma":0.000009542962,"teacher_disagreement_score":0.051549282,"about_ca_system_score_codex":0.00025135386,"about_ca_system_score_gemma":0.0008596492,"threshold_uncertainty_score":0.99999905},"labels":[],"label_agreement":null},{"id":"W2163123363","doi":"10.1200/jco.2005.09.133","title":"Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Cytarabine; Gastroenterology; Etoposide; Induction chemotherapy; Mitoxantrone; Chills; CD33; Refractory (planetary science); Chemotherapy regimen; Surgery; Oncology","score_opus":0.046368179104427636,"score_gpt":0.427938840716764,"score_spread":0.3815706616123364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163123363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940905,0.000055410957,0.00012892262,0.0023551073,0.00025688313,0.0029706655,0.0000040568516,0.0000143763045,0.00012408498],"genre_scores_gemma":[0.9931631,0.00092053023,0.004617224,0.00074195775,0.0002973711,0.00003338881,0.000024588231,0.00006929159,0.00013256427],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9926005,0.0011428748,0.0041452968,0.00046063564,0.0011533896,0.0004973249],"domain_scores_gemma":[0.99120927,0.003900321,0.0030885735,0.00040990012,0.001061922,0.00033001814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005047583,0.00038770845,0.0045129694,0.00072057586,0.00005320824,0.00001570366,0.0003994564,0.0005150393,0.0002610913],"category_scores_gemma":[0.0015220986,0.00023228937,0.00034073126,0.0005746804,0.0005427134,0.00036248338,0.00006658578,0.0022233794,0.000005501581],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.856476,0.04472093,0.069772415,0.00003386283,0.0020840396,0.0005953176,0.0017797688,0.000084845895,0.00022287246,0.0000026958696,0.00020125673,0.024026008],"study_design_scores_gemma":[0.7625263,0.08067385,0.15218373,0.00025621746,0.0004369463,0.000022220069,0.0003326894,0.002387144,0.0001434745,0.0000030765855,0.0008437696,0.00019063732],"about_ca_topic_score_codex":0.00020609071,"about_ca_topic_score_gemma":0.00079033873,"teacher_disagreement_score":0.09394974,"about_ca_system_score_codex":0.0019065482,"about_ca_system_score_gemma":0.0029958286,"threshold_uncertainty_score":0.96596},"labels":[],"label_agreement":null},{"id":"W2163344214","doi":"10.1038/leu.2009.33","title":"New insights to the MLL recombinome of acute leukemias","year":2009,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":411,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Minimal residual disease; Myeloid leukemia; Fusion gene; Chromosomal translocation; Leukemia; Gene; Acute leukemia; Cancer research; Breakpoint; Biology; Acute lymphocytic leukemia; Medicine; Lymphoblastic Leukemia; Genetics; Oncology","score_opus":0.019537398384540692,"score_gpt":0.2949568201005775,"score_spread":0.2754194217160368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163344214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9283035,0.00048271066,0.0014455866,0.021552967,0.00032129386,0.0012194015,0.000012103035,0.00017313988,0.046489343],"genre_scores_gemma":[0.9556379,0.00018871328,0.005299262,0.008087084,0.00066706847,0.000017993094,0.000033111246,0.000046781926,0.03002211],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977074,0.00007422215,0.0005017184,0.000454097,0.0006780562,0.00058448664],"domain_scores_gemma":[0.997845,0.00012348012,0.0001147629,0.0011725518,0.00018979012,0.0005544094],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028053526,0.0002781371,0.0005438964,0.00028067693,0.00011112432,0.00003286413,0.000629066,0.00021266082,0.00032907174],"category_scores_gemma":[0.00015976402,0.00018351377,0.0002069099,0.0010122794,0.00006965495,0.00012607948,0.00014683035,0.00071948365,0.0008335914],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016998348,0.0001274991,0.0009449093,0.00007225621,0.00056062016,0.00074383244,0.0040504048,0.0001576905,0.100264244,0.0064329514,0.70961386,0.1753319],"study_design_scores_gemma":[0.012523387,0.004464382,0.21200931,0.0005042045,0.00078177487,0.0008788908,0.00041710574,0.0015231598,0.13731973,0.0067983535,0.62173945,0.0010402824],"about_ca_topic_score_codex":0.0004986025,"about_ca_topic_score_gemma":0.000029140128,"teacher_disagreement_score":0.2110644,"about_ca_system_score_codex":0.0019311312,"about_ca_system_score_gemma":0.0024091436,"threshold_uncertainty_score":0.9999444},"labels":[],"label_agreement":null},{"id":"W2163907105","doi":"10.1093/annonc/mdq233","title":"Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Cytopenia; Medicine; Myelodysplastic syndromes; Clinical significance; Internal medicine; Oncology; Bone marrow; Pediatrics","score_opus":0.07041987427966254,"score_gpt":0.375204870353179,"score_spread":0.3047849960735165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163907105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997154,0.00009277808,0.000050443115,0.00055734307,0.00021755807,0.00054697075,0.00018232816,0.000014007683,0.0011845925],"genre_scores_gemma":[0.99855083,0.000048846483,0.000983038,0.00015437133,0.0000796258,0.000027902217,0.00007066149,0.000027759192,0.00005693873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997077,0.000305298,0.001191436,0.00042561305,0.000545314,0.00045537445],"domain_scores_gemma":[0.9964683,0.001325738,0.0007415186,0.00054854684,0.0007425592,0.00017335286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013355654,0.00021711594,0.0012617384,0.00028406837,0.00003223683,0.0000056795116,0.00043378476,0.00036482813,0.00016089088],"category_scores_gemma":[0.0041741906,0.000198096,0.00015003835,0.00040830433,0.00063365826,0.00010485827,0.00021677812,0.00078715605,0.000008178628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028470438,0.0017055538,0.6961251,0.0008022266,0.00019147154,0.00028357597,0.001416584,0.000009969055,0.2811857,0.000641296,0.0002523006,0.014539178],"study_design_scores_gemma":[0.0036489444,0.0029445419,0.9403941,0.0003714559,0.0000616076,0.0000138010255,0.00009823702,0.0003099098,0.0506017,0.00091454224,0.0004743712,0.00016679152],"about_ca_topic_score_codex":0.0026650962,"about_ca_topic_score_gemma":0.0009313063,"teacher_disagreement_score":0.244269,"about_ca_system_score_codex":0.00011778248,"about_ca_system_score_gemma":0.0009688154,"threshold_uncertainty_score":0.80781204},"labels":[],"label_agreement":null},{"id":"W2164059454","doi":"10.3324/haematol.2011.040840","title":"TET2 mutations in secondary acute myeloid leukemias: a French retrospective study","year":2011,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Myeloid leukemia; Medicine; Chromosomal translocation; Myeloid; Retrospective cohort study; Internal medicine; Karyotype; Mutation; Hematology; Oncology; Gastroenterology; Immunology; Cancer research; Gene; Biology; Genetics; Chromosome","score_opus":0.04183800821531778,"score_gpt":0.3073875758651325,"score_spread":0.2655495676498147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164059454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.910556,0.00013122043,0.00006354149,0.00030412897,0.00008235556,0.0015425202,0.000021638689,0.00019984796,0.0870987],"genre_scores_gemma":[0.9943637,0.0000425678,0.0032382226,0.00023502653,0.000042736723,0.0003733318,0.000032447224,0.000035612524,0.0016363553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975359,0.00019951304,0.0005367769,0.000670467,0.00043967,0.000617693],"domain_scores_gemma":[0.99866354,0.000103899925,0.00012223821,0.00068038964,0.00020488513,0.00022505454],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048616756,0.00028560925,0.0007896269,0.0004460152,0.00014291449,0.000021804364,0.00032563,0.00022735239,0.002450719],"category_scores_gemma":[0.00043931013,0.00022374027,0.0001225291,0.0009021771,0.00025872845,0.00016846042,0.00022520921,0.0010760573,0.0005850122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007489757,0.0030768707,0.93121856,0.00011497205,0.00072931923,0.024506735,0.025787864,7.8885313e-7,0.0022099286,0.0015814914,0.005458135,0.004566345],"study_design_scores_gemma":[0.0041529397,0.0017794681,0.9812566,0.00005893995,0.0001490828,0.0014581063,0.0051979907,0.000073137395,0.002541567,0.0027799131,0.00027293927,0.00027932838],"about_ca_topic_score_codex":0.0008537724,"about_ca_topic_score_gemma":0.00044460708,"teacher_disagreement_score":0.085462354,"about_ca_system_score_codex":0.00072424766,"about_ca_system_score_gemma":0.0005972291,"threshold_uncertainty_score":0.9984612},"labels":[],"label_agreement":null},{"id":"W2164110159","doi":"10.1016/j.critrevonc.2005.04.006","title":"Management of patients with higher risk myelodysplastic syndromes","year":2005,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"York University; University of Southern California","keywords":"Myelodysplastic syndromes; Medicine; International Prognostic Scoring System; Oncology; Internal medicine; Hematopoietic stem cell transplantation; Azacitidine; Disease; Radiation therapy; Intensive care medicine; Bone marrow","score_opus":0.0678892869649371,"score_gpt":0.4310722778615204,"score_spread":0.36318299089658335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164110159","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003233078,0.9864408,0.000087674845,0.00035035715,0.00041474417,0.0043278923,0.000063313346,0.000043803797,0.008239097],"genre_scores_gemma":[0.00008020436,0.9879546,0.009406045,0.00016627605,0.00010929322,0.0013075005,0.00017660516,0.00012896804,0.00067047955],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926134,0.0016425119,0.0028326148,0.0011658492,0.0005613767,0.0011843019],"domain_scores_gemma":[0.9938041,0.00348778,0.00073748844,0.0012580776,0.00027390136,0.00043867464],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0013546534,0.00089027995,0.009250625,0.0007341489,0.00006376631,0.000009781396,0.00069666596,0.0013046885,0.001825904],"category_scores_gemma":[0.0020437264,0.0005843128,0.00066855823,0.0010617287,0.0012309526,0.00007720042,0.00048701337,0.0023730719,0.001140986],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013454421,0.0011229989,0.0005496523,0.08047049,0.00044836657,0.00197775,0.000010962724,5.530304e-8,6.178171e-9,0.014737466,0.0030655658,0.89748216],"study_design_scores_gemma":[0.0020014974,0.0010969668,0.00047245773,0.06568984,0.0038880587,0.00066321046,0.000008755959,0.000002229112,1.2259713e-7,0.0001434998,0.9256131,0.0004202714],"about_ca_topic_score_codex":0.000004678958,"about_ca_topic_score_gemma":0.0000061037736,"teacher_disagreement_score":0.9225475,"about_ca_system_score_codex":0.001539225,"about_ca_system_score_gemma":0.0008159895,"threshold_uncertainty_score":0.99999183},"labels":[],"label_agreement":null},{"id":"W2164485413","doi":"10.1186/2193-1801-3-406","title":"Expressive aphasia in a patient with chronic myelomonocytic leukemia","year":2014,"lang":"en","type":"article","venue":"SpringerPlus","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia","funders":"","keywords":"Chronic myelomonocytic leukemia; Aphasia; Medicine; Myelodysplastic syndromes; Complication; Leukemia; Immunology; Internal medicine; Psychiatry; Bone marrow","score_opus":0.009641291072897133,"score_gpt":0.25729463449145035,"score_spread":0.24765334341855322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164485413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791452,0.00037189902,0.00074293214,0.00038334925,0.000071872484,0.00069766596,0.000001533607,0.000100877565,0.01848466],"genre_scores_gemma":[0.9970453,0.00004540951,0.0015770828,0.00027890745,0.00022137705,0.00013532848,0.000007741633,0.00005760774,0.00063126656],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980526,0.00007473629,0.00028568076,0.0004751936,0.00046430726,0.00064751424],"domain_scores_gemma":[0.99882835,0.000096951546,0.0000856136,0.00064693304,0.0000881462,0.00025403156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022615174,0.00023377223,0.0003995136,0.00028933745,0.000058763293,0.000027234122,0.00018556813,0.00012153616,0.00013381317],"category_scores_gemma":[0.00015470796,0.00018244314,0.00006488138,0.00040321113,0.00013811346,0.000099689314,0.00014336096,0.0005851691,0.0002534629],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007450239,0.0007713787,0.07310389,0.0020031894,0.00063074834,0.018824276,0.009035458,0.0052808183,0.11460987,0.0037571776,0.0063109715,0.758222],"study_design_scores_gemma":[0.076902024,0.019317465,0.2955753,0.0068226526,0.0004909658,0.008027353,0.0017676239,0.14856476,0.20441724,0.0010744636,0.23316053,0.0038796219],"about_ca_topic_score_codex":0.00038807408,"about_ca_topic_score_gemma":0.00017924904,"teacher_disagreement_score":0.7543424,"about_ca_system_score_codex":0.0035584264,"about_ca_system_score_gemma":0.0011752577,"threshold_uncertainty_score":0.9305161},"labels":[],"label_agreement":null},{"id":"W2165275170","doi":"10.1016/j.leukres.2012.03.013","title":"Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?","year":2012,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"North York General Hospital","funders":"","keywords":"Bone marrow; Fluorescence in situ hybridization; Concomitant; Myelodysplastic syndromes; Peripheral blood; clone (Java method); Fish <Actinopterygii>; Pathology; Abnormality; Karyotype; Biology; Cytogenetics; Medicine; Chromosome; Internal medicine; DNA; Genetics","score_opus":0.08444588771323226,"score_gpt":0.3568744699875528,"score_spread":0.27242858227432054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165275170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.965235,0.009737414,0.000053974636,0.019137423,0.00013896057,0.0036011315,0.0001336968,0.000066794615,0.0018956306],"genre_scores_gemma":[0.99174935,0.0027333647,0.00064127747,0.0012494047,0.0009713614,0.00064374914,0.00013574267,0.0001177607,0.0017579842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923608,0.0013067317,0.00069323066,0.0009687658,0.0022109253,0.0024595752],"domain_scores_gemma":[0.9714015,0.024210185,0.00010735256,0.0031191322,0.00035805992,0.0008037313],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00747922,0.00044181425,0.0006441069,0.00037565074,0.00068011787,0.0002722187,0.0017250517,0.00034275485,0.00063393405],"category_scores_gemma":[0.035584375,0.00026125487,0.00009341769,0.00153878,0.0017692152,0.00053796015,0.0025212297,0.0034783296,0.00024133241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026002834,0.0012937429,0.86370885,0.0010471131,0.0008341046,0.0026553017,0.011375312,0.00004265479,0.044128608,0.005108775,0.042040102,0.025165146],"study_design_scores_gemma":[0.023079978,0.0048206067,0.7625981,0.002541407,0.0011115198,0.010424908,0.015648521,0.01583648,0.010523698,0.004407916,0.1468891,0.0021177784],"about_ca_topic_score_codex":0.006270033,"about_ca_topic_score_gemma":0.0013779878,"teacher_disagreement_score":0.10484901,"about_ca_system_score_codex":0.0013833412,"about_ca_system_score_gemma":0.0028116293,"threshold_uncertainty_score":0.99998397},"labels":[],"label_agreement":null},{"id":"W2166042057","doi":"10.1007/s10637-011-9660-2","title":"Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Tolerability; Medicine; Pharmacokinetics; Pharmacodynamics; Myeloid leukemia; Refractory (planetary science); Pharmacology; Internal medicine; Adverse effect; Gastroenterology","score_opus":0.038472222433530136,"score_gpt":0.32911549674982593,"score_spread":0.2906432743162958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166042057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956576,0.000020929003,0.000087022636,0.0012839751,0.00008778238,0.002173681,0.00008308518,0.000028482278,0.00057743216],"genre_scores_gemma":[0.9940418,0.000020911479,0.0038136449,0.0015198009,0.00009111222,0.000045778736,0.00009023008,0.000043276683,0.00033341494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742585,0.0001939103,0.00062970206,0.0004659768,0.00093297125,0.0003515939],"domain_scores_gemma":[0.9982737,0.00023712871,0.00017819743,0.00040845992,0.00042171334,0.00048085692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005970275,0.00027483428,0.00040071423,0.00023727657,0.000116792566,0.00001764036,0.00031942336,0.00006191314,0.0001397759],"category_scores_gemma":[0.00016372235,0.00019316669,0.00004457119,0.00052485004,0.00037212283,0.0002231638,0.00035284524,0.00057310006,0.000010024858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01044609,0.0082710935,0.92626023,0.00013094793,0.0007063599,0.000059110203,0.029821713,0.00018041277,0.009009643,0.00018338668,0.0024010038,0.0125300335],"study_design_scores_gemma":[0.04288195,0.005197128,0.9385398,0.00016393926,0.0004085249,0.000007994744,0.0009889134,0.0040943576,0.005920364,0.0002228865,0.001202998,0.0003711582],"about_ca_topic_score_codex":0.00046899318,"about_ca_topic_score_gemma":0.000048791517,"teacher_disagreement_score":0.03243586,"about_ca_system_score_codex":0.0006057854,"about_ca_system_score_gemma":0.0010657144,"threshold_uncertainty_score":0.7877109},"labels":[],"label_agreement":null},{"id":"W2167359672","doi":"10.1159/000431061","title":"Bringing Leukemia Stem Cells into the Clinic","year":2015,"lang":"en","type":"article","venue":"Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Stem cell; Haematopoiesis; Leukemia; Myeloid leukemia; Cancer stem cell; Xenotransplantation; Immunology; Hematopoietic stem cell; Medicine; Biology; Cancer research; Transplantation; Internal medicine; Genetics","score_opus":0.07217087078661405,"score_gpt":0.3798290821308617,"score_spread":0.30765821134424765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167359672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8506664,0.0005486229,0.0001915239,0.0106083155,0.00073133607,0.00047151904,8.8622147e-7,0.00010326183,0.1366781],"genre_scores_gemma":[0.9380541,0.00014603171,0.0017573609,0.0040548085,0.00086903403,0.00004719142,0.0000052240193,0.000042147574,0.055024125],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986017,0.00020867407,0.00026684016,0.00025263688,0.00027574072,0.00039446],"domain_scores_gemma":[0.99858606,0.00044522615,0.000074948635,0.00046311645,0.00015203477,0.00027861583],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014093237,0.00011288363,0.0003143779,0.000086627246,0.00008005832,0.0000136257395,0.00026505854,0.00019672746,0.00026381252],"category_scores_gemma":[0.00014955226,0.00007388602,0.000073811,0.00022650445,0.00021652355,0.000042972704,0.000228286,0.0006639149,0.0028757746],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008858565,0.0002166031,0.005426774,0.00008265127,0.00021147954,0.0011590697,0.009136203,0.0000454383,0.01928109,0.0004980532,0.6678249,0.29523188],"study_design_scores_gemma":[0.0030477226,0.0015262108,0.0007854059,0.000024634388,0.00006752473,0.00025834984,0.0029842039,0.0016384727,0.0068320557,0.00020138233,0.98251885,0.00011518016],"about_ca_topic_score_codex":0.0003225257,"about_ca_topic_score_gemma":0.000068675916,"teacher_disagreement_score":0.31469393,"about_ca_system_score_codex":0.0027557332,"about_ca_system_score_gemma":0.0028538895,"threshold_uncertainty_score":0.9979006},"labels":[],"label_agreement":null},{"id":"W2167424771","doi":"10.1016/j.bbmt.2017.01.078","title":"Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia","year":2017,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Actinium Pharmaceuticals; Alexion Pharmaceuticals; U.S. Public Health Service; National Institute of Allergy and Infectious Diseases; Amgen","keywords":"Chronic myelomonocytic leukemia; Medicine; Transplantation; Internal medicine; Hematopoietic stem cell transplantation; Oncology; Leukemia; Surgery; Bone marrow; Gastroenterology; Myelodysplastic syndromes","score_opus":0.016767180737445465,"score_gpt":0.2900340861546368,"score_spread":0.27326690541719134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167424771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926427,0.00091499585,0.0039633214,0.000621839,0.00009951087,0.00079953787,0.00016862286,0.000032119417,0.0007573723],"genre_scores_gemma":[0.9877018,0.009059266,0.0022064499,0.00010249383,0.00012026177,0.00008878216,0.00049995707,0.000023186009,0.00019782192],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889266,0.000043229364,0.0003226251,0.00033965553,0.0001023055,0.0002995455],"domain_scores_gemma":[0.99911404,0.00013047515,0.00018464183,0.0002886311,0.00017388506,0.00010833567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020843206,0.00017769774,0.0003553925,0.000120351666,0.00023473588,0.000017243576,0.00015473497,0.00024366884,0.000017699644],"category_scores_gemma":[0.000037798465,0.00015746024,0.00010354165,0.000035261848,0.00029772084,0.00010776926,0.000009068697,0.00013882898,0.0000046021846],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012336901,0.00006693763,0.01314495,0.0041915374,0.00015585861,0.00004225382,0.00057159417,0.000004719729,0.9719468,0.0010927557,0.000048505644,0.0075004045],"study_design_scores_gemma":[0.015351633,0.0019164025,0.0510623,0.00034772634,0.0019021964,0.0005948566,0.00009114717,0.0003209614,0.92705965,0.00089146476,0.00016267324,0.0002989909],"about_ca_topic_score_codex":0.00014292206,"about_ca_topic_score_gemma":0.00010842281,"teacher_disagreement_score":0.044887148,"about_ca_system_score_codex":0.00006278497,"about_ca_system_score_gemma":0.00034345206,"threshold_uncertainty_score":0.64210415},"labels":[],"label_agreement":null},{"id":"W2167517686","doi":"10.1016/j.bbmt.2008.03.009","title":"Once Daily i.v. Busulfan and Fludarabine (i.v. Bu-Flu) Compares Favorably with i.v. Busulfan and Cyclophosphamide (i.v. BuCy2) as Pretransplant Conditioning Therapy in AML/MDS","year":2008,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Bone and Joint Health Institute","funders":"National Cancer Institute; National Institutes of Health; Amgen","keywords":"Medicine; Busulfan; Fludarabine; Cyclophosphamide; Internal medicine; Hematopoietic stem cell transplantation; Melphalan; Transplantation; Gastroenterology; Chemotherapy; Surgery","score_opus":0.014431621058826694,"score_gpt":0.25848939646633984,"score_spread":0.24405777540751314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167517686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99320745,0.004695817,0.00023478219,0.0005893629,0.000031869142,0.0006697982,0.00014953365,0.00004715767,0.0003742367],"genre_scores_gemma":[0.9590731,0.038622234,0.0014120134,0.00021781371,0.000041556665,0.000041805575,0.00049492205,0.000026989697,0.00006956553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983218,0.0001372775,0.00043437406,0.00052002916,0.0002033531,0.00038319084],"domain_scores_gemma":[0.9991869,0.00023026389,0.00012696536,0.00016735231,0.00010558885,0.00018296568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027947006,0.0002938679,0.000596157,0.00027669012,0.00018346445,0.000014583712,0.00008443466,0.00022796563,0.000021697197],"category_scores_gemma":[0.000019712705,0.00023727589,0.000034109133,0.00023716928,0.0008833768,0.00017773741,0.000012358566,0.00034771234,0.0000011703593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004613251,0.00018692498,0.5472446,0.0005815798,0.00026565546,0.00051313854,0.003852567,0.000014088915,0.43841407,0.00039868633,0.000027232649,0.0038881844],"study_design_scores_gemma":[0.018073112,0.0039738338,0.85411876,0.00068166427,0.0003025617,0.0048085535,0.0004531069,0.00014256286,0.11664891,0.00023630816,0.0001517646,0.00040884508],"about_ca_topic_score_codex":0.0009349363,"about_ca_topic_score_gemma":0.00023558924,"teacher_disagreement_score":0.32176515,"about_ca_system_score_codex":0.000021750977,"about_ca_system_score_gemma":0.00017635906,"threshold_uncertainty_score":0.967583},"labels":[],"label_agreement":null},{"id":"W2168061975","doi":"10.1016/j.cancergencyto.2010.07.116","title":"CLCA2, a novel RUNX1 partner gene in a therapy-related leukemia with t(1;21)(p22;q22)","year":2010,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"RUNX1; Biology; Exon; Fusion transcript; Fusion gene; Myeloid leukemia; Genetics; Fusion protein; Gene isoform; Transactivation; Molecular biology; Gene; Cancer research; Gene expression; Transcription factor; Recombinant DNA","score_opus":0.026577126432142505,"score_gpt":0.3062774941291024,"score_spread":0.2797003676969599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168061975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900682,0.006729384,0.00017162363,0.0010861456,0.0001788112,0.00081424956,0.000045250574,0.000043960856,0.0008623672],"genre_scores_gemma":[0.9753369,0.015167561,0.006397384,0.0010243994,0.00030892456,0.0001805589,0.000031139974,0.00012208146,0.0014310534],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99768865,0.000029362214,0.00043636587,0.00063946465,0.0004749781,0.00073119346],"domain_scores_gemma":[0.9984551,0.000050968447,0.00010890519,0.0006948754,0.00024468562,0.0004454856],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023762164,0.00037977262,0.0004763851,0.00021554147,0.00010592752,0.000059298363,0.00024162287,0.00037217655,0.00021019604],"category_scores_gemma":[0.000024998946,0.00030333103,0.00007098764,0.000517787,0.0004322726,0.000029588327,0.00012921896,0.00090391503,0.000013704596],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067917956,0.00021220506,0.2621984,0.000077115095,0.00026383577,0.00014432856,0.0012007072,0.000721656,0.6860529,0.00014524799,0.0005812676,0.04772317],"study_design_scores_gemma":[0.018254694,0.0014419829,0.44266403,0.00017068884,0.00022554012,0.00057643815,0.00019254377,0.011361626,0.36587203,0.00017216834,0.15801539,0.0010528779],"about_ca_topic_score_codex":0.000269124,"about_ca_topic_score_gemma":0.00074773695,"teacher_disagreement_score":0.3201809,"about_ca_system_score_codex":0.00025997884,"about_ca_system_score_gemma":0.0014633174,"threshold_uncertainty_score":0.9999419},"labels":[],"label_agreement":null},{"id":"W2168302119","doi":"10.1155/2010/164045","title":"Red Blood Cell Transfusion Independence Following the Initiation of Iron Chelation Therapy in Myelodysplastic Syndrome","year":2010,"lang":"en","type":"article","venue":"Advances in Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Chelation therapy; Cytopenia; Deferiprone; Deferasirox; Transfusion therapy; Myelodysplastic syndromes; Blood transfusion; Chelation; Internal medicine; Refractory (planetary science); Gastroenterology; Surgery; Thalassemia; Bone marrow","score_opus":0.009963595376551653,"score_gpt":0.29281244625280917,"score_spread":0.2828488508762575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168302119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99603605,0.0010061375,0.00026757913,0.00049927336,0.00021894704,0.0005755954,0.000001009947,0.000016568833,0.0013788646],"genre_scores_gemma":[0.997385,0.0015641344,0.00087644835,0.00005210466,0.000014071202,0.000064276464,0.000011029752,0.000015686357,0.00001721104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868023,0.00011810898,0.0004145639,0.00024955402,0.00028324852,0.00025429574],"domain_scores_gemma":[0.99892884,0.00060659344,0.00011097559,0.00027126804,0.000047088157,0.000035228368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051166286,0.00011806724,0.00033294642,0.00025308185,0.000037495523,0.0000034464147,0.00016398307,0.00022655714,0.000080569735],"category_scores_gemma":[0.00029476447,0.00008805599,0.00005167142,0.00046076503,0.00011246426,0.00025135672,0.000026501932,0.00077791297,0.0000061700316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053671305,0.00037855518,0.71820396,0.00025858943,0.000016741848,0.0005399245,0.0011870373,0.0002853512,0.27206782,0.0017155344,0.000002447027,0.0048073614],"study_design_scores_gemma":[0.022834148,0.0020284043,0.598448,0.0007280724,0.0001061458,0.0030777974,0.0011527485,0.0048936936,0.35691252,0.00893118,0.00035817205,0.00052912097],"about_ca_topic_score_codex":0.000055986096,"about_ca_topic_score_gemma":0.00038024073,"teacher_disagreement_score":0.11975593,"about_ca_system_score_codex":0.00004389395,"about_ca_system_score_gemma":0.00012931488,"threshold_uncertainty_score":0.3590819},"labels":[],"label_agreement":null},{"id":"W2169007954","doi":"10.1200/jco.2008.19.6550","title":"Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":314,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"American Society of Clinical Oncology","keywords":"Medicine; Decitabine; Myelodysplastic syndromes; International Prognostic Scoring System; Dosing; Regimen; Hypomethylating agent; Internal medicine; Complete response; Clinical trial; Clinical endpoint; Oncology; Chemotherapy; Bone marrow","score_opus":0.16209615505307287,"score_gpt":0.4795324990879281,"score_spread":0.3174363440348552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169007954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848749,0.00005390539,0.002667083,0.0051872656,0.0009596711,0.0061405525,0.000028565208,0.00000633703,0.00008173213],"genre_scores_gemma":[0.9884652,0.000052069736,0.008857443,0.0009963788,0.0012579595,0.00014843447,0.0000066780512,0.000028235414,0.00018759226],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99532807,0.0004847489,0.0027828251,0.0003520757,0.00063804997,0.0004142219],"domain_scores_gemma":[0.98577094,0.010319616,0.0018275215,0.00036570535,0.0012513743,0.00046486137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026264363,0.00025573123,0.0019813702,0.00021756177,0.00008939236,0.000016509568,0.000343284,0.0002158903,0.000014151565],"category_scores_gemma":[0.0074773254,0.00012821448,0.0005039326,0.0001698571,0.0001363502,0.00009801447,0.000053071646,0.00054996257,0.0000028359987],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8756524,0.01931164,0.002850909,0.000041793526,0.0016592524,0.0003412777,0.0042477865,0.0001729037,0.000064276916,0.000012574061,0.0012568246,0.09438841],"study_design_scores_gemma":[0.35122272,0.603657,0.033759646,0.0003519291,0.0012715135,0.000113877526,0.003749894,0.0012089099,0.00011273479,0.000029330833,0.004399091,0.00012332576],"about_ca_topic_score_codex":0.000024787889,"about_ca_topic_score_gemma":0.00008724515,"teacher_disagreement_score":0.5843454,"about_ca_system_score_codex":0.00077945343,"about_ca_system_score_gemma":0.0018660885,"threshold_uncertainty_score":0.8951597},"labels":[],"label_agreement":null},{"id":"W2169923083","doi":"10.1200/jco.2014.55.3628","title":"Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":472,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health; Children’s Oncology Group","keywords":"Gemtuzumab ozogamicin; Medicine; Hazard ratio; Internal medicine; Chemotherapy; Induction chemotherapy; Randomized controlled trial; Calicheamicin; Myeloid leukemia; Oncology; Confidence interval; CD33","score_opus":0.022563698295226035,"score_gpt":0.37694985155636374,"score_spread":0.3543861532611377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169923083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877671,0.00043625146,0.0008419689,0.007205451,0.0009147219,0.0024136237,0.00014034247,0.000026736401,0.0002537748],"genre_scores_gemma":[0.986454,0.004420017,0.0033243182,0.0015892587,0.0038804596,0.000028246948,0.00010621251,0.00007517614,0.00012231339],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9836039,0.008410789,0.0052206977,0.0008478055,0.0009931435,0.0009236983],"domain_scores_gemma":[0.97916067,0.014068983,0.0045411866,0.0009907273,0.00036816281,0.00087024615],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03040837,0.00050336745,0.004731571,0.00028241033,0.00019441367,0.00004932956,0.0010801639,0.0012103468,0.000021119167],"category_scores_gemma":[0.034837868,0.00029383172,0.000724497,0.00036369392,0.0014201347,0.0002496355,0.00045464677,0.0061171483,0.0000072321054],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8850654,0.0021459535,0.0151983835,0.000006923554,0.0019350748,0.00029084002,0.00033430092,0.00001940579,0.0008496751,0.000017471903,0.0064233956,0.08771323],"study_design_scores_gemma":[0.8606508,0.030385157,0.10286517,0.0003293573,0.002118804,0.0010149564,0.00011033015,0.00082469865,0.00009368915,0.00027946776,0.0010583209,0.0002692472],"about_ca_topic_score_codex":0.003975934,"about_ca_topic_score_gemma":0.0005699129,"teacher_disagreement_score":0.08766678,"about_ca_system_score_codex":0.0018784131,"about_ca_system_score_gemma":0.0053206896,"threshold_uncertainty_score":0.99995136},"labels":[],"label_agreement":null},{"id":"W2170557614","doi":"10.3747/co.21.1871","title":"Optimizing Outcomes with Azacitidine: Recommendations from Canadian Centres of Excellence","year":2014,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; University of Alberta; McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Celgene; Alexion Pharmaceuticals; Bristol-Myers Squibb","keywords":"Azacitidine; Medicine; Myelodysplastic syndromes; Guideline; Intensive care medicine; Referral; Myeloid leukemia; Nice; Internal medicine; Oncology; Family medicine; Bone marrow; Pathology","score_opus":0.0698146835246792,"score_gpt":0.3847697687081106,"score_spread":0.3149550851834314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170557614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93404865,0.0007933108,0.0033147356,0.035926785,0.0011140037,0.00075437815,0.00016211045,0.00007423332,0.023811797],"genre_scores_gemma":[0.98957855,0.00034233186,0.008977383,0.0003392684,0.00017060369,0.0000311801,0.00022508138,0.000020477417,0.00031515324],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887264,0.0001184229,0.00024244153,0.00024089724,0.00016353092,0.00036209598],"domain_scores_gemma":[0.9986452,0.00042963013,0.00009214632,0.0003034358,0.00017499858,0.00035461085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019279397,0.00012265691,0.00038229907,0.000213664,0.00007384438,0.0000066155044,0.00015840199,0.00008602208,0.00077234703],"category_scores_gemma":[0.00027772842,0.00009436651,0.00004964619,0.0001679955,0.00015371903,0.000049146318,0.000050240284,0.00033181073,0.000058694164],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025111675,0.0004802554,0.65378463,0.00012648113,0.00023260566,0.00004795994,0.0022023455,0.00004442571,0.0009934977,0.0013127293,0.05110254,0.2894214],"study_design_scores_gemma":[0.004354191,0.000846009,0.06540736,0.0002671043,0.0001568149,0.000026654701,0.0010985328,0.002696267,0.0011717175,0.00013858483,0.92360735,0.00022939393],"about_ca_topic_score_codex":0.023298038,"about_ca_topic_score_gemma":0.04268685,"teacher_disagreement_score":0.87250483,"about_ca_system_score_codex":0.0005903976,"about_ca_system_score_gemma":0.0009909791,"threshold_uncertainty_score":0.9832059},"labels":[],"label_agreement":null},{"id":"W2171229387","doi":"10.1080/08880010490276917","title":"Characterization of Bone Marrow Stromal Abnormalities in a Patient with Constitutional Trisomy 8 Mosaicism and Myelodysplastic Syndrome","year":2004,"lang":"en","type":"article","venue":"Pediatric Hematology and Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Alberta Children's Hospital","funders":"","keywords":"Trisomy; Stromal cell; Trisomy 8; Bone marrow; Medicine; Haematopoiesis; Myelodysplastic syndromes; Cancer research; Myeloid; Leukemia; Pathology; Progenitor cell; Immunology; Myeloid leukemia; Stem cell; Cytogenetics; Chromosome; Biology; Genetics","score_opus":0.008994029602853499,"score_gpt":0.25100161342877,"score_spread":0.24200758382591647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171229387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971382,0.00054025144,0.00054977305,0.0010343051,0.000052464242,0.00038577124,0.000024321487,0.0000158918,0.00025900433],"genre_scores_gemma":[0.99827373,0.0004481897,0.0009649595,0.00013708313,0.00003600273,0.00005395657,0.000054505817,0.000007405272,0.000024159928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988544,0.00008092062,0.0004022176,0.00023793096,0.00014060845,0.00028394093],"domain_scores_gemma":[0.9993285,0.00023574977,0.00014592631,0.000088531815,0.00007829471,0.00012300536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001825361,0.00013253842,0.00057903136,0.0003826689,0.000052143747,0.000003397229,0.00003126212,0.00023813968,0.000034354744],"category_scores_gemma":[0.00011881166,0.00010887656,0.000019344074,0.00024152196,0.000724698,0.00008578926,0.0000552118,0.0002881012,0.00000412288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039391634,0.0010717012,0.898626,0.0015423887,0.00014933055,0.016350763,0.002585473,0.000035796507,0.0041514086,0.07001161,0.000055122084,0.0014811932],"study_design_scores_gemma":[0.029481675,0.010965709,0.7650654,0.00020533385,0.00049162254,0.18758777,0.0011937625,0.00021666869,0.0018903972,0.0016245889,0.00075433566,0.000522759],"about_ca_topic_score_codex":0.00003909312,"about_ca_topic_score_gemma":0.000029715236,"teacher_disagreement_score":0.171237,"about_ca_system_score_codex":0.00015063806,"about_ca_system_score_gemma":0.0009677079,"threshold_uncertainty_score":0.4439857},"labels":[],"label_agreement":null},{"id":"W2171830805","doi":"10.3109/10428194.2014.953152","title":"Aggressive congenital juvenile myelomonocytic leukemia associated with somatic<i>KRAS</i>p.G13D mutation and concurrent germline<i>IGF1R</i>duplication","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Juvenile myelomonocytic leukemia; Germline mutation; Germline; KRAS; Cancer research; Gene duplication; Mutation; Biology; Somatic cell; Genetics; Medicine; Gene; Haematopoiesis","score_opus":0.015535477822808326,"score_gpt":0.2567419644317981,"score_spread":0.24120648660898977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171830805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9567749,0.0056337905,0.0005785914,0.02551845,0.0008265822,0.005014315,0.0006171872,0.0011643809,0.0038718053],"genre_scores_gemma":[0.8116956,0.002504657,0.0009485791,0.15601523,0.0050411928,0.0016667262,0.011785373,0.0011606406,0.00918205],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9872681,0.0008820499,0.0025889508,0.003538866,0.0027930175,0.0029290337],"domain_scores_gemma":[0.98964244,0.0023041568,0.0030624026,0.0022543168,0.0013842519,0.0013524222],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0011425783,0.0028429353,0.003902371,0.0012649669,0.001033693,0.00077253394,0.0010303288,0.004146276,0.00015526787],"category_scores_gemma":[0.0013498766,0.002522336,0.0006314154,0.0013453563,0.002153708,0.0007806547,0.0006386858,0.0023889362,0.00025022242],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001916699,0.0003676901,0.002734363,0.004754322,0.005091965,0.019667776,0.0028566143,0.00010037762,0.0030531636,0.00024543254,0.77200264,0.18720894],"study_design_scores_gemma":[0.13102806,0.006325545,0.060990427,0.0125318905,0.012431112,0.052422743,0.0013325122,0.12734321,0.0070159053,0.001098083,0.57611126,0.011369285],"about_ca_topic_score_codex":0.0015313029,"about_ca_topic_score_gemma":0.00012040502,"teacher_disagreement_score":0.19589141,"about_ca_system_score_codex":0.036291808,"about_ca_system_score_gemma":0.017543769,"threshold_uncertainty_score":0.9999126},"labels":[],"label_agreement":null},{"id":"W2173631987","doi":"10.3324/haematol.2015.126938","title":"Gene-expression and in vitro function of mesenchymal stromal cells are affected in juvenile myelomonocytic leukemia","year":2015,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Leids Universitair Medisch Centrum; Stichting Kinderen Kankervrij; Universiteit Leiden","keywords":"Mesenchymal stem cell; Biology; Haematopoiesis; Stromal cell; Juvenile myelomonocytic leukemia; Cancer research; Bone marrow; Chronic myelomonocytic leukemia; Leukemia; Stem cell; Immunology; Cell biology; Myelodysplastic syndromes","score_opus":0.0343891697055586,"score_gpt":0.28186470427964533,"score_spread":0.24747553457408672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2173631987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99786365,0.00044355507,0.00007230437,0.00016247241,0.00006871304,0.00055021147,0.000008428505,0.000046911366,0.000783762],"genre_scores_gemma":[0.99722105,0.00004067532,0.0024275437,0.000058951864,0.000031688476,0.000048021357,0.000027429076,0.00001800332,0.00012664802],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99823725,0.00021728111,0.0004204646,0.00038291886,0.00035100718,0.00039106954],"domain_scores_gemma":[0.99910253,0.00013320372,0.00015138433,0.00030537657,0.00009918929,0.00020828769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046691488,0.00018530503,0.0006961538,0.0003409592,0.000025253394,0.000010198231,0.00011286106,0.00026806165,0.00004164692],"category_scores_gemma":[0.00037379633,0.00014405871,0.00004979366,0.00042975415,0.00014113207,0.000099469515,0.00016137806,0.0004382527,0.000024918665],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003732664,0.00018941879,0.035650432,0.00025814326,0.000016926026,0.0012500178,0.0003576363,0.000082913655,0.9559494,0.000016095839,0.0015146865,0.0009816411],"study_design_scores_gemma":[0.0065622916,0.0006288149,0.16283727,0.00027918527,0.000032898435,0.00032675973,0.0010689874,0.0034462817,0.8243152,0.000179939,0.00012336104,0.00019902912],"about_ca_topic_score_codex":0.00012915982,"about_ca_topic_score_gemma":0.00003687292,"teacher_disagreement_score":0.13163424,"about_ca_system_score_codex":0.0005447814,"about_ca_system_score_gemma":0.00038464065,"threshold_uncertainty_score":0.5874544},"labels":[],"label_agreement":null},{"id":"W2173804501","doi":"10.1200/jco.2015.61.1947","title":"Clinical Impact of Additional Cytogenetic Aberrations, <i>cKIT</i> and <i>RAS</i> Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Barncancerfonden; Hospital for Sick Children; European Organisation for Research and Treatment of Cancer; Erasmus Medisch Centrum; National Cancer Institute; Newcastle University","keywords":"Cytarabine; Medicine; Etoposide; Internal medicine; Cumulative incidence; Retrospective cohort study; Oncology; Anthracycline; Gastroenterology; Idarubicin; Myeloid leukemia; Cohort; Chemotherapy; Cancer","score_opus":0.12033803460152205,"score_gpt":0.4976702984608705,"score_spread":0.3773322638593485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2173804501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993924,0.00017401252,0.000017838125,0.0028195968,0.00074190483,0.00097498414,0.00095748826,0.0000064164988,0.00038375516],"genre_scores_gemma":[0.9947745,0.0010171504,0.001412453,0.0004102821,0.0018265538,0.000037839975,0.0003961055,0.000021412216,0.00010367699],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925858,0.0016287515,0.0039278986,0.0005023554,0.0011261769,0.0002290626],"domain_scores_gemma":[0.99223083,0.0040190713,0.0019105157,0.00031841776,0.0010200135,0.00050114654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072473204,0.00023072031,0.0011741613,0.00028601935,0.00005941062,0.000046058572,0.00039323294,0.00024759193,0.00018382951],"category_scores_gemma":[0.0064353137,0.00014686059,0.00026114727,0.00022403938,0.00031465795,0.00034276478,0.00018280945,0.0010188142,0.0000054955094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009198277,0.013423571,0.9471346,0.000001246659,0.0013405066,0.00021022656,0.0011369255,0.00001874278,0.000016037997,0.000004607261,0.013481551,0.014033712],"study_design_scores_gemma":[0.04282793,0.040458083,0.91098756,0.000016706948,0.00047202912,0.00009475584,0.0020645733,0.0005320651,0.0000017413853,0.00017945662,0.0022626787,0.00010240831],"about_ca_topic_score_codex":0.00051736,"about_ca_topic_score_gemma":0.0010265481,"teacher_disagreement_score":0.036147024,"about_ca_system_score_codex":0.0009287441,"about_ca_system_score_gemma":0.002073707,"threshold_uncertainty_score":0.77041364},"labels":[],"label_agreement":null},{"id":"W2178680838","doi":"10.1200/jco.2000.18.9.1867","title":"Mitoxantrone, Etoposide, and Cyclosporine Therapy in Pediatric Patients With Recurrent or Refractory Acute Myeloid Leukemia","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Medicine; Mitoxantrone; Etoposide; Gastroenterology; Internal medicine; Myeloid leukemia; Toxicity; Cytarabine; Pharmacology; Refractory (planetary science); Pharmacokinetics; Chemotherapy","score_opus":0.05112776183792007,"score_gpt":0.4122730866566613,"score_spread":0.36114532481874123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2178680838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99411696,0.00089704397,0.0000037953168,0.00277092,0.0003699626,0.00042151814,0.000004979037,0.0000105641775,0.0014042471],"genre_scores_gemma":[0.9258827,0.0659047,0.0033568146,0.0016837736,0.0019257814,0.00000836265,0.000008556652,0.000043121643,0.0011861897],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99587137,0.0004754182,0.0022102213,0.00032435643,0.0006769745,0.00044164516],"domain_scores_gemma":[0.995956,0.0017596385,0.0009636284,0.00026624845,0.0004457933,0.0006086739],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0021422727,0.00022993467,0.0016044708,0.00030803418,0.00004100048,0.000012163659,0.00023204421,0.00046794978,0.0006264879],"category_scores_gemma":[0.0010161558,0.00012979163,0.00019262136,0.00040294765,0.00024141127,0.00021871379,0.00004950957,0.0024737192,0.0000278828],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047090936,0.0014644086,0.45777896,0.00002046726,0.00020491381,0.0013862061,0.00006949653,0.0000037170846,0.000014460132,0.0000028064428,0.0036073185,0.4883563],"study_design_scores_gemma":[0.030227588,0.040234566,0.86977524,0.000065876484,0.00020157,0.00024375066,0.000019640702,0.000031522606,0.0000100758,0.000031890086,0.05902501,0.00013329132],"about_ca_topic_score_codex":0.000028565195,"about_ca_topic_score_gemma":0.00006474061,"teacher_disagreement_score":0.48822302,"about_ca_system_score_codex":0.00078810466,"about_ca_system_score_gemma":0.004199668,"threshold_uncertainty_score":0.9998276},"labels":[],"label_agreement":null},{"id":"W2179229194","doi":"10.1007/s12185-015-1870-5","title":"Aging, clonal hematopoiesis and preleukemia: not just bad luck?","year":2015,"lang":"en","type":"review","venue":"International Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Haematopoiesis; Preleukemia; Biology; Somatic evolution in cancer; Stem cell; Progenitor cell; Leukemia; Hematology; Bone marrow; Immunology; Genetics; Cancer","score_opus":0.06885324902180759,"score_gpt":0.41655841755498146,"score_spread":0.3477051685331739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2179229194","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040671226,0.99385434,0.00010987719,0.0024699012,0.0013596369,0.00035792764,0.000047689548,0.000022595894,0.0013713413],"genre_scores_gemma":[0.00032299582,0.9948902,0.0018904913,0.00040584904,0.0012558608,0.000019769888,0.000060653947,0.00008192188,0.0010722708],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99592584,0.00024252188,0.0016847304,0.00037944625,0.0013589887,0.0004084766],"domain_scores_gemma":[0.9954948,0.00061383104,0.001381039,0.00031075304,0.0017330798,0.00046652174],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00110162,0.00046202895,0.0029978317,0.0011575539,0.000042430478,0.000064299405,0.00084683206,0.00064447435,0.0003768724],"category_scores_gemma":[0.0009595587,0.00034171087,0.00064624776,0.00019641341,0.00030756916,0.0001755086,0.00043277905,0.0018481162,0.00013322051],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007784198,0.00045163312,0.00037048387,0.015762985,0.008069768,0.02464602,0.0003465282,0.0000012276395,0.000012900467,0.011712648,0.15639187,0.7814555],"study_design_scores_gemma":[0.001563551,0.00021019488,0.000013481726,0.0075239,0.00089668704,0.16472715,0.000040171817,0.000013737764,0.000027813441,0.0002225128,0.8245568,0.00020395008],"about_ca_topic_score_codex":0.000012731345,"about_ca_topic_score_gemma":0.0000024710794,"teacher_disagreement_score":0.78125155,"about_ca_system_score_codex":0.001275604,"about_ca_system_score_gemma":0.003709234,"threshold_uncertainty_score":0.9999035},"labels":[],"label_agreement":null},{"id":"W2180842484","doi":"10.1016/j.beha.2015.10.004","title":"AML evolution from preleukemia to leukemia and relapse","year":2015,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Preleukemia; Disease; Myeloid leukemia; Leukemia; Medicine; Intensive care medicine; Oncology; Immunology; Internal medicine","score_opus":0.3052768403061487,"score_gpt":0.5753250734818967,"score_spread":0.27004823317574794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2180842484","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008992925,0.97630066,0.00011990857,0.0058636405,0.00067643914,0.005984972,0.0001482049,0.00017701715,0.009829861],"genre_scores_gemma":[0.00008036907,0.98347497,0.0073703104,0.0005350484,0.0018254728,0.0009808665,0.00041556964,0.00030187142,0.0050154924],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9747734,0.013101655,0.0035856343,0.0030575783,0.0031197106,0.0023619856],"domain_scores_gemma":[0.9510922,0.037273858,0.00097564654,0.0032854136,0.003625895,0.0037470132],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.023513852,0.0010011089,0.0071216784,0.0015151452,0.00039737657,0.00022914335,0.001470862,0.003937099,0.0003038161],"category_scores_gemma":[0.15640639,0.0008166709,0.00077107205,0.0023818067,0.0026613928,0.0006382071,0.003406872,0.014397496,0.013726528],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.002057635,0.00095673214,0.00013353734,0.0068592974,0.0010156088,0.009187563,0.00011693983,2.8038852e-7,9.905647e-7,0.0024003026,0.17156419,0.8057069],"study_design_scores_gemma":[0.002490561,0.0038303607,0.000023544117,0.009635973,0.0023366585,0.008437763,0.00040079368,0.00008773538,5.2991476e-7,0.00091510295,0.97122025,0.00062074454],"about_ca_topic_score_codex":0.002765087,"about_ca_topic_score_gemma":0.00015655997,"teacher_disagreement_score":0.8050862,"about_ca_system_score_codex":0.0073853713,"about_ca_system_score_gemma":0.030942764,"threshold_uncertainty_score":0.9994284},"labels":[],"label_agreement":null},{"id":"W2183269172","doi":"10.1139/bcb-2012-0109","title":"Unveiling the paradoxical nature of myelodysplastic syndromes (MDS): Why hypercellular marrow strongly favors accelerated apoptosis","year":2013,"lang":"en","type":"article","venue":"Biochemistry and Cell Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Department of Science and Technology, Ministry of Science and Technology, India","keywords":"Bone marrow; Myelodysplastic syndromes; Haematopoiesis; Apoptosis; Bone marrow failure; Progenitor cell; Biology; Cell biology; Immunology; Cancer research; Stem cell; Genetics","score_opus":0.014546334226113398,"score_gpt":0.25804233077728117,"score_spread":0.24349599655116777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2183269172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99403286,0.0022958221,0.00003348274,0.0012219483,0.00007408291,0.0002924786,0.000019956286,0.000030305242,0.0019990888],"genre_scores_gemma":[0.99745494,0.00028996746,0.00022954024,0.00026521663,0.00012943888,0.00003396108,0.00013895065,0.000018495411,0.0014395143],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986637,0.00007883816,0.00029409435,0.00040764335,0.00014101857,0.00041470857],"domain_scores_gemma":[0.99896145,0.00024710177,0.00008910745,0.00037963368,0.00013366896,0.00018903863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016609333,0.0002260525,0.00037654198,0.00004624223,0.000105328865,0.000020094663,0.00024186788,0.0006551368,0.00066750095],"category_scores_gemma":[0.00014598724,0.00014357654,0.000089903326,0.00020389359,0.0005237118,0.000031566018,0.00013393625,0.00077888154,0.00004082114],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010501255,0.00007388534,0.002874058,0.00022683486,0.000081916936,0.000007510779,0.00003235538,0.0000021204453,0.99307185,0.000031025495,0.002733839,0.0007595699],"study_design_scores_gemma":[0.0009412149,0.00026087966,0.0013556081,0.000044290817,0.00008083289,0.000093400995,0.00045979716,0.0007276656,0.99292135,0.000044088716,0.0029007269,0.00017016938],"about_ca_topic_score_codex":0.000062296196,"about_ca_topic_score_gemma":3.4659396e-7,"teacher_disagreement_score":0.0034220803,"about_ca_system_score_codex":0.000051462,"about_ca_system_score_gemma":0.00015694974,"threshold_uncertainty_score":0.73086673},"labels":[],"label_agreement":null},{"id":"W2185048627","doi":"10.1182/blood.v124.21.3740.3740","title":"Quantitative Whole Body Autoradiography (QWBA) Analysis Reveals That CPX-351 Shifts the Exposure of Cytarabine (Cyt) and Daunorubicin (Daun) Away from Many Tissues While Providing Prolonged Exposure to Cytotoxic Drug Concentrations in the Bone Marrow Compared to Conventional Free Drug Administration","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celator Pharmaceuticals (Canada)","funders":"","keywords":"Pharmacology; Chemistry; In vivo; Context (archaeology); Therapeutic index; Toxicity; Drug; Pharmacokinetics; Cytarabine; Daunorubicin; Pharmacodynamics; Medicine; Internal medicine; Chemotherapy; Biology","score_opus":0.0226830958486664,"score_gpt":0.2858542061588398,"score_spread":0.2631711103101734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2185048627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813476,0.00094266824,0.00052806793,0.013675697,0.000046623165,0.0028710125,0.00038154263,0.000047898153,0.00015884155],"genre_scores_gemma":[0.99523014,0.000025953812,0.0029057595,0.00048082753,0.00014488654,0.00044776485,0.0005306795,0.000031805488,0.00020217393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996249,0.00093562814,0.0007407799,0.0006506641,0.000972683,0.00045121906],"domain_scores_gemma":[0.9974111,0.00086772104,0.00029235252,0.000961792,0.0002290115,0.00023806153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018547266,0.0003239993,0.0007988413,0.00052356155,0.0002701508,0.00014478934,0.00051603705,0.000111101406,0.000059236172],"category_scores_gemma":[0.00049009843,0.00022591866,0.00020978361,0.0016637277,0.0002331183,0.00022066574,0.000122167,0.0004368474,0.000011493659],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014068751,0.0013193653,0.6885708,0.00017400854,0.0016953802,0.00007207687,0.020992087,0.000163142,0.27507916,0.0018424513,0.008563491,0.00012113098],"study_design_scores_gemma":[0.007687341,0.0018119393,0.92529786,0.0003910504,0.0018245584,0.000020197602,0.00797658,0.001964313,0.051242344,0.0005021063,0.00086582,0.00041588573],"about_ca_topic_score_codex":0.000563588,"about_ca_topic_score_gemma":0.0028425467,"teacher_disagreement_score":0.23672704,"about_ca_system_score_codex":0.00008630481,"about_ca_system_score_gemma":0.00023269469,"threshold_uncertainty_score":0.92126954},"labels":[],"label_agreement":null},{"id":"W2185261149","doi":"10.7314/apjcp.2015.16.9.4095","title":"Mutation Analysis of IDH1/2 Genes in Unselected De novo Acute Myeloid Leukaemia Patients in India - Identification of A Novel IDH2 Mutation","year":2015,"lang":"en","type":"article","venue":"Asian Pacific Journal of Cancer Prevention","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Children’s Oncology Group","keywords":"NPM1; Mutation; IDH2; IDH1; Biology; Gene mutation; Myeloid leukemia; Cytogenetics; Gene; Genetics; Molecular biology; Cancer research; Karyotype; Chromosome","score_opus":0.01882836505970507,"score_gpt":0.3384038712080908,"score_spread":0.3195755061483857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2185261149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895105,0.00031659787,0.009278511,0.00013768279,0.00010889621,0.0004444918,0.000037341917,0.0000055201144,0.00016045339],"genre_scores_gemma":[0.9980515,0.00022748637,0.0013093486,0.000009236398,0.000043999036,0.000024319366,0.00023977362,0.000019857538,0.000074438605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969367,0.00024832564,0.0015522146,0.00020426665,0.0008146413,0.00024388601],"domain_scores_gemma":[0.99681854,0.000050863124,0.0015352344,0.00019768793,0.0012638303,0.00013384334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001600821,0.00014500771,0.00059715216,0.0024123336,0.000017861714,0.000016438922,0.00015178412,0.00016314202,0.000023194538],"category_scores_gemma":[0.00031273914,0.0001432181,0.00019620114,0.003138104,0.000068316294,0.0004418633,0.000017997798,0.00033060092,0.0000010690887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002768976,0.001352391,0.71397656,0.00024417284,0.0021507097,0.00009185132,0.00954107,0.005379511,0.1907523,0.00006336494,0.000101135985,0.07357796],"study_design_scores_gemma":[0.0072841775,0.0005269522,0.9473932,0.00032889066,0.0012259426,0.000054376782,0.0020077787,0.005417569,0.035376973,0.00025833136,0.000012035829,0.0001137671],"about_ca_topic_score_codex":0.0002938149,"about_ca_topic_score_gemma":0.00051841495,"teacher_disagreement_score":0.23341665,"about_ca_system_score_codex":0.0015679403,"about_ca_system_score_gemma":0.001456556,"threshold_uncertainty_score":0.58402646},"labels":[],"label_agreement":null},{"id":"W2187343514","doi":"10.1182/blood-2015-05-647172","title":"Disease evolution and outcomes in familial AML with germline CEBPA mutations","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":194,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"Novo Nordisk Fonden; National Institute for Health and Care Research; Lundbeckfonden; Cancer Research UK","keywords":"CEBPA; Myeloid leukemia; Germline; Biology; Exome sequencing; Germline mutation; Leukemia; Mutation; Oncology; Genetics; Cancer research; Internal medicine; Medicine; Gene","score_opus":0.020404323616219588,"score_gpt":0.2953762748293807,"score_spread":0.27497195121316115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2187343514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996632,0.0002531709,0.00013848627,0.0019428278,0.000020968419,0.00032831467,0.000019218916,0.0000361684,0.00062885735],"genre_scores_gemma":[0.99782246,0.000010134625,0.00099979,0.00011551744,0.00007628822,0.000035678364,0.00004120674,0.000013947662,0.00088498666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99923974,0.000033755645,0.00011971411,0.00017087422,0.00025247457,0.00018346103],"domain_scores_gemma":[0.9993576,0.000043876622,0.000021082622,0.00017554939,0.000091364425,0.00031053837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013346148,0.00008338477,0.00015744664,0.00013739007,0.000025919031,0.000009326552,0.00003952137,0.000036481844,0.00000914379],"category_scores_gemma":[0.00030645003,0.00006106523,0.000017837116,0.00018285698,0.00009326189,0.000074291536,0.00003415153,0.00014955926,0.000023838842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000311577,0.00045823064,0.99756485,0.000030458537,0.000040447194,0.0003005235,0.00023757906,0.000013389122,0.00034336818,0.00020928284,0.00018379418,0.00030647538],"study_design_scores_gemma":[0.011682453,0.00027480506,0.9863822,0.00003138537,0.00013029228,0.00004730249,0.00026165854,0.0005691206,0.00009143291,0.00026051924,0.00018614653,0.000082709754],"about_ca_topic_score_codex":0.00021487533,"about_ca_topic_score_gemma":0.00012753828,"teacher_disagreement_score":0.011370875,"about_ca_system_score_codex":0.00011429328,"about_ca_system_score_gemma":0.00048244416,"threshold_uncertainty_score":0.24901678},"labels":[],"label_agreement":null},{"id":"W2189263041","doi":"10.3324/haematol.2015.128066","title":"Comment on: \"The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes\"","year":2015,"lang":"en","type":"letter","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytopathology; Cytogenetics; Transformation (genetics); Myeloid; Bone marrow; Medicine; Malignant transformation; Pathology; Somatic evolution in cancer; Immunology; Cancer research; Biology; Genetics; Internal medicine; Cancer; Cytology; Chromosome; Gene","score_opus":0.05633848446140335,"score_gpt":0.32228155396511143,"score_spread":0.2659430695037081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2189263041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7915644,0.0007689392,0.000008719342,0.20622315,0.000014951733,0.0012231851,0.000043681128,0.000012814515,0.00014017119],"genre_scores_gemma":[0.97786,0.0004242945,0.0013943975,0.019782983,0.00003417961,0.00014138596,0.00029283733,0.00003558313,0.00003436535],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976508,0.00035243554,0.00069278333,0.00038915864,0.00052793336,0.00038686217],"domain_scores_gemma":[0.99886197,0.00025686447,0.0003160199,0.00030546496,0.0001452458,0.00011446255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007845742,0.00037345558,0.0010988723,0.00037498353,0.000059486923,0.000014698761,0.000125508,0.0007448554,0.000025241401],"category_scores_gemma":[0.00010868891,0.00020963937,0.00006027093,0.00018791288,0.0004757498,0.000028487033,0.00012195237,0.0010967897,0.0000023885373],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006872888,0.0013200436,0.06267399,0.0111011,0.0008474806,0.017634844,0.014053258,0.000013070071,0.011802832,0.0010321722,0.8506137,0.022034613],"study_design_scores_gemma":[0.03980683,0.053456843,0.32433817,0.021347724,0.000960508,0.09030754,0.004835134,0.0017780492,0.09881551,0.0030817525,0.357011,0.0042609423],"about_ca_topic_score_codex":0.000032076074,"about_ca_topic_score_gemma":0.000007105252,"teacher_disagreement_score":0.4936027,"about_ca_system_score_codex":0.00022954783,"about_ca_system_score_gemma":0.0003500225,"threshold_uncertainty_score":0.8548845},"labels":[],"label_agreement":null},{"id":"W2190773055","doi":"10.1111/nyas.12981","title":"Molecular landscapes of human hematopoietic stem cells in health and leukemia","year":2015,"lang":"en","type":"review","venue":"Annals of the New York Academy of Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Medical Research Council; Wellcome Trust; Texas Health and Human Services Commission","keywords":"Haematopoiesis; Stem cell; Biology; Epigenetics; Myeloid leukemia; Transcriptome; Leukemia; Cell biology; Computational biology; Cancer research; Immunology; Genetics; Gene; Gene expression","score_opus":0.16847437477479058,"score_gpt":0.4274337053691703,"score_spread":0.2589593305943797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2190773055","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010961293,0.9849945,6.0840483e-7,0.0027817679,0.000024358365,0.0008079689,0.000015592157,0.0000065069544,0.0004074611],"genre_scores_gemma":[0.0070449593,0.99193317,0.00012798926,0.0003375922,0.00004882969,0.000006990185,0.0000013128496,0.000020033287,0.00047913002],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964898,0.00035168426,0.0011788198,0.00041527802,0.001133113,0.00043127377],"domain_scores_gemma":[0.99802136,0.00021688476,0.00115024,0.00023394614,0.00006327668,0.0003143098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003407099,0.00026938488,0.0021740363,0.00046668097,0.00006378089,0.000011093132,0.0011235359,0.00030391096,0.000007758408],"category_scores_gemma":[0.000081762395,0.00015812195,0.00029791865,0.0013162618,0.00094548386,0.00006594372,0.00035583912,0.00068446464,0.000002558944],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075246004,0.0001824322,0.00030473535,0.12180451,0.000361926,0.0000076104197,0.0031836345,0.00006868113,0.0012638498,0.004767723,0.077166215,0.79081345],"study_design_scores_gemma":[0.0014446193,0.0016477165,0.00006834953,0.10453882,0.00030961653,0.00012913281,0.0013069585,0.00007322441,0.021419639,0.003699711,0.8648117,0.0005504845],"about_ca_topic_score_codex":0.0002988058,"about_ca_topic_score_gemma":0.0000030597184,"teacher_disagreement_score":0.79026294,"about_ca_system_score_codex":0.00009337107,"about_ca_system_score_gemma":0.0032299988,"threshold_uncertainty_score":0.64480263},"labels":[],"label_agreement":null},{"id":"W2191286751","doi":"10.2217/ijh.15.22","title":"Update on Recurrent Genetic Aberrations in Acute Myeloid Leukemia","year":2015,"lang":"en","type":"article","venue":"International Journal of Hematologic Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Myeloid leukemia; Medicine; Karyotype; Risk stratification; Oncology; Internal medicine; Bioinformatics; Gene; Chromosome; Genetics; Biology","score_opus":0.04949742693997719,"score_gpt":0.39014997771168153,"score_spread":0.3406525507717043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2191286751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9593877,0.00047420262,0.0005303812,0.027840277,0.0017946169,0.00023544247,0.000008131738,0.00001890817,0.0097102905],"genre_scores_gemma":[0.9867046,0.0007368188,0.009477554,0.0022945122,0.00041861017,0.000016193335,0.000016086646,0.000016913966,0.00031870234],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977107,0.0001933697,0.000858024,0.00020114896,0.0007538496,0.00028288137],"domain_scores_gemma":[0.99792695,0.00022719779,0.00043410336,0.00017583453,0.0009548532,0.0002810863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070340704,0.00015710393,0.0005405431,0.0007048603,0.000022232403,0.000021863696,0.0004956738,0.00020630243,0.00018700662],"category_scores_gemma":[0.0008247347,0.00011904165,0.00013532618,0.00020932854,0.00013305467,0.00012066606,0.00011595082,0.00085783494,0.00024076446],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027286947,0.0056240223,0.10961517,0.0000852447,0.0037465645,0.12470692,0.003950173,0.003690444,0.010473344,0.027534397,0.508868,0.17441879],"study_design_scores_gemma":[0.056925155,0.025459336,0.111958295,0.0010803418,0.0006197765,0.19790575,0.002942022,0.009493628,0.011537325,0.037490703,0.5434715,0.0011161241],"about_ca_topic_score_codex":0.000017343797,"about_ca_topic_score_gemma":0.00003618874,"teacher_disagreement_score":0.17330267,"about_ca_system_score_codex":0.0037396196,"about_ca_system_score_gemma":0.0026554307,"threshold_uncertainty_score":0.9778975},"labels":[],"label_agreement":null},{"id":"W2191511762","doi":"10.1158/1078-0432.ccr-15-1349","title":"Gemtuzumab Ozogamicin Reduces Relapse Risk in <i>FLT3</i> /ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"Gemtuzumab ozogamicin; Medicine; Oncology; Myeloid leukemia; Internal medicine; Leukemia; Calicheamicin; Biology; CD33","score_opus":0.1479212835732433,"score_gpt":0.48909489567443043,"score_spread":0.34117361210118713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2191511762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96068513,0.0046490585,0.000024749956,0.02457094,0.0008617919,0.0023518729,0.00017962296,0.00012650315,0.00655034],"genre_scores_gemma":[0.9688747,0.017433085,0.0010794849,0.0018827986,0.0045582713,0.0007559917,0.00035633898,0.00016331208,0.004896029],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9868598,0.0043643396,0.002133689,0.0018978681,0.0028570374,0.0018872513],"domain_scores_gemma":[0.9876007,0.0069243177,0.00047084666,0.0024397527,0.0011916585,0.001372739],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.022493836,0.0004515367,0.0014580934,0.00041990489,0.00037059016,0.00011747933,0.0016425687,0.0010877876,0.00040952227],"category_scores_gemma":[0.016370919,0.0003086986,0.00041605256,0.0021109716,0.0025404834,0.000258936,0.0015581608,0.010727244,0.0006736183],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.014310807,0.00082286116,0.42464536,0.000022726903,0.0010252584,0.0075976625,0.00096014136,0.000026190824,0.0009975564,0.00009362815,0.43248948,0.11700832],"study_design_scores_gemma":[0.02921784,0.0072060623,0.687429,0.00051273865,0.0006383045,0.0012012423,0.0021319264,0.00075919187,0.0015762122,0.0039908765,0.26448417,0.000852443],"about_ca_topic_score_codex":0.04596873,"about_ca_topic_score_gemma":0.0049709445,"teacher_disagreement_score":0.26278365,"about_ca_system_score_codex":0.0078706555,"about_ca_system_score_gemma":0.014154457,"threshold_uncertainty_score":0.9999365},"labels":[],"label_agreement":null},{"id":"W219456170","doi":"10.1007/s00520-015-2752-3","title":"A systematic review on the use of exercise interventions for individuals with myeloid leukemia","year":2015,"lang":"en","type":"review","venue":"Supportive Care in Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; PsycINFO; CINAHL; Psychological intervention; Myeloid leukemia; MEDLINE; Population; Cochrane Library; Physical therapy; Nursing research; Randomized controlled trial; Clinical trial; Meta-analysis; Adverse effect; Internal medicine; Psychiatry; Pathology","score_opus":0.1777433466722328,"score_gpt":0.4424795896236249,"score_spread":0.2647362429513921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W219456170","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009024422,0.9754182,0.000012578169,0.00022084582,0.00009508888,0.02207513,0.0020267677,0.000021443755,0.000120909186],"genre_scores_gemma":[0.0000083839095,0.97627836,0.00020289197,0.00028053805,0.00006256064,0.020819845,0.0006649163,0.0001251708,0.0015573191],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99579716,0.00049115747,0.0018093726,0.00057652505,0.0008535217,0.00047225785],"domain_scores_gemma":[0.99464667,0.0011272563,0.0013866365,0.0011414959,0.0015130084,0.00018491806],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001431612,0.0005609713,0.005097732,0.0004568477,0.000044313954,0.000028351544,0.00047602045,0.00027923463,0.00022760476],"category_scores_gemma":[0.0021331243,0.00028308973,0.0012056014,0.0009577627,0.00021563782,0.00011042921,0.00014199688,0.0008669648,0.00003068921],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00006149656,0.000041677828,0.000018770257,0.92473966,0.00058309804,0.00003547536,0.0003272531,9.0814285e-7,1.8866881e-8,0.00003246451,0.026243437,0.047915764],"study_design_scores_gemma":[0.00047069305,0.00042166107,0.0000019685076,0.6925873,0.0067506735,0.00002356807,0.00033398857,0.0000010055256,0.0000016167056,0.0000030351953,0.29921424,0.00019024746],"about_ca_topic_score_codex":0.00014073236,"about_ca_topic_score_gemma":0.00010994529,"teacher_disagreement_score":0.2729708,"about_ca_system_score_codex":0.005022332,"about_ca_system_score_gemma":0.007628968,"threshold_uncertainty_score":0.99996215},"labels":[],"label_agreement":null},{"id":"W2199894139","doi":"10.1016/s2352-3026(15)00200-8","title":"Eltrombopag in patients with high-risk myelodysplastic syndrome or acute myeloid leukaemia: cautious optimism","year":2015,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Eltrombopag; Myelodysplastic syndromes; Internal medicine; International Prognostic Scoring System; Placebo; Tolerability; Oncology; Adverse effect; Platelet; Bone marrow; Pathology; Immune thrombocytopenia; Alternative medicine","score_opus":0.02247899036029892,"score_gpt":0.2737507969408261,"score_spread":0.25127180658052717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2199894139","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6855386,0.0002592988,0.000070910304,0.30945575,0.0006828548,0.0024911556,0.0005048774,0.00027732065,0.0007192381],"genre_scores_gemma":[0.33442816,0.0013221047,0.00582872,0.6219523,0.0062674563,0.0015608028,0.007111749,0.0012173206,0.020311408],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932251,0.00090153166,0.00095392857,0.0012355006,0.0014402205,0.002243705],"domain_scores_gemma":[0.99509746,0.0010576588,0.00065665395,0.002425563,0.00047494035,0.00028773956],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00085880223,0.0010258916,0.0045597213,0.00067594793,0.00018115781,0.000061739636,0.0014501709,0.0020739764,0.00035065637],"category_scores_gemma":[0.00060962565,0.00057293667,0.00015845364,0.000865563,0.0009649456,0.00013395098,0.0005392557,0.009378469,0.0009888374],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003717617,0.00012346791,0.021510616,0.0007222535,0.0010704318,0.05768656,0.00026030594,0.000047712183,0.0000022113875,0.000050232422,0.9146577,0.00015086922],"study_design_scores_gemma":[0.12530662,0.017622668,0.25997716,0.0045168228,0.011087102,0.14395174,0.00022415849,0.000791026,0.0001031045,0.0035902143,0.4270051,0.005824273],"about_ca_topic_score_codex":0.0008763614,"about_ca_topic_score_gemma":0.00021490491,"teacher_disagreement_score":0.48765263,"about_ca_system_score_codex":0.0014989987,"about_ca_system_score_gemma":0.00201381,"threshold_uncertainty_score":0.999789},"labels":[],"label_agreement":null},{"id":"W2211416430","doi":"10.1038/ng.3371","title":"The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias","year":2015,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Hôpital de l'Enfant-Jésus; Institute for Research in Immunology and Cancer; Université Laval; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Biology; Myeloid leukemia; Transcriptome; Fusion gene; Myeloid; Cancer research; Gene; Gene rearrangement; Leukemia; Genetics; Computational biology; Gene expression","score_opus":0.016134963382756225,"score_gpt":0.2926540907233576,"score_spread":0.27651912734060136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2211416430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98823315,0.0073364777,0.00003517891,0.002075246,0.00018982557,0.0003355304,0.00001826243,0.000060727554,0.001715577],"genre_scores_gemma":[0.99631816,0.0008582891,0.001671239,0.00028119617,0.00021241447,0.000011661909,0.00006118331,0.00003019033,0.00055564736],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987322,0.000061481136,0.00024549558,0.00023515357,0.00046063648,0.00026501084],"domain_scores_gemma":[0.9988941,0.00012775644,0.000066301305,0.00034527056,0.0003530384,0.00021353543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034043434,0.00015065646,0.0002571441,0.0000802681,0.00004737411,0.000022221024,0.00018766947,0.00041535907,0.000010532715],"category_scores_gemma":[0.00024008515,0.000100959085,0.000063259366,0.0002669869,0.00019088876,0.000029013658,0.00006582494,0.0008942409,0.0000068274535],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004085262,0.0001468966,0.016835177,0.0001934612,0.00085053965,0.00009914717,0.005452954,0.0000078486,0.8572229,0.00012018141,0.07579218,0.03919347],"study_design_scores_gemma":[0.015791424,0.0011295478,0.053732794,0.00020833267,0.0008816945,0.0006324727,0.002455594,0.015425168,0.8273466,0.00051776005,0.08132651,0.0005520799],"about_ca_topic_score_codex":0.000009895327,"about_ca_topic_score_gemma":0.000023539667,"teacher_disagreement_score":0.03864139,"about_ca_system_score_codex":0.00020332754,"about_ca_system_score_gemma":0.00048207055,"threshold_uncertainty_score":0.41169918},"labels":[],"label_agreement":null},{"id":"W2213050627","doi":"10.1038/leu.2015.243","title":"Unrelated cord blood transplantation for childhood acute myelogenous leukemia: The influence of cytogenetic risk group stratification","year":2015,"lang":"en","type":"letter","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Risk stratification; Leukemia; Transplantation; Medicine; Cord blood; Oncology; Internal medicine; Hematology; Cytogenetics; Biology; Genetics; Gene","score_opus":0.01800898845357867,"score_gpt":0.2758178988531593,"score_spread":0.25780891039958065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2213050627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95454955,0.0010879746,0.001187553,0.032680668,0.0003110759,0.0068097715,0.0022762774,0.00024413098,0.00085301115],"genre_scores_gemma":[0.84685344,0.008049356,0.0058646356,0.10618453,0.00481784,0.0020174417,0.021967828,0.00070689747,0.003538067],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948098,0.00042133435,0.0013095384,0.0010650334,0.0014058567,0.0009884259],"domain_scores_gemma":[0.9951348,0.00085773104,0.0010678931,0.0016806512,0.0010348766,0.00022404882],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0010451325,0.00078114506,0.0011504083,0.00041213882,0.00031428732,0.00007149511,0.0010107191,0.0021590882,0.00003516462],"category_scores_gemma":[0.00037264745,0.0005909795,0.0004451695,0.0007775215,0.0005145688,0.0001607487,0.00007842336,0.0044409293,0.00007472666],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057464396,0.0004543306,0.0023618364,0.0056266813,0.010782773,0.0025347278,0.007012091,0.0055110743,0.078331105,0.00031134515,0.85764945,0.02367815],"study_design_scores_gemma":[0.096612886,0.030223822,0.31817082,0.0065292153,0.10263426,0.01721458,0.001219339,0.0073464215,0.07658337,0.013415119,0.3212311,0.008819079],"about_ca_topic_score_codex":0.00093074923,"about_ca_topic_score_gemma":0.000064913176,"teacher_disagreement_score":0.5364183,"about_ca_system_score_codex":0.0025896241,"about_ca_system_score_gemma":0.0056145755,"threshold_uncertainty_score":0.9996542},"labels":[],"label_agreement":null},{"id":"W2215815605","doi":"10.1084/jem.20150524","title":"Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles","year":2015,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"PTPN11; Myeloid leukemia; Biology; Allele; Chromosomal translocation; Genetics; Leukemia; Cancer research; Mutation; Gene; KRAS","score_opus":0.04488760938246655,"score_gpt":0.37581362202384716,"score_spread":0.3309260126413806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2215815605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98751116,0.010529886,0.00012956541,0.0012667932,0.000050887993,0.00018066468,0.000003877749,0.0000052740165,0.00032191435],"genre_scores_gemma":[0.99831176,0.00024847963,0.0002634026,0.00021245804,0.00020328215,0.0000029044277,0.000008346317,0.000014624821,0.00073474646],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982494,0.00020834597,0.00059808465,0.00010405209,0.00068546203,0.00015461532],"domain_scores_gemma":[0.9984409,0.0001643698,0.00031608972,0.00023299782,0.00043965617,0.00040598717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088377256,0.00014710015,0.00061954826,0.00039529774,0.00007827395,0.000009961787,0.00018567684,0.00003034829,0.00015228869],"category_scores_gemma":[0.0005172117,0.00007345011,0.00008910324,0.0004182706,0.00068159704,0.000091423004,0.00009594601,0.00027443288,0.000001303017],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014380884,0.00021673892,0.010956699,0.000028128767,0.001833597,0.00014461667,0.018212227,0.00008454568,0.96185344,0.00012752795,0.0048913634,0.00021299701],"study_design_scores_gemma":[0.016081687,0.010842702,0.07677813,0.0011535275,0.010006654,0.0006717177,0.2380636,0.0050405823,0.64047796,0.00015910606,0.0003346075,0.00038971618],"about_ca_topic_score_codex":0.0002715926,"about_ca_topic_score_gemma":0.000020488864,"teacher_disagreement_score":0.32137552,"about_ca_system_score_codex":0.00016478286,"about_ca_system_score_gemma":0.00015369146,"threshold_uncertainty_score":0.29952085},"labels":[],"label_agreement":null},{"id":"W2217124386","doi":"10.1016/j.jcjo.2015.06.005","title":"Orbital myeloid sarcoma in adults presenting with exposure keratopathy and hearing loss","year":2015,"lang":"en","type":"letter","venue":"Canadian Journal of Ophthalmology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid sarcoma; Histopathology; Biopsy; Pathology; Sarcoma; Surgery","score_opus":0.028394490612684422,"score_gpt":0.27662157415556904,"score_spread":0.2482270835428846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2217124386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8918893,0.0025607743,0.000001229175,0.099450566,0.00028700999,0.00034995336,0.000028901919,0.000003842391,0.0054284325],"genre_scores_gemma":[0.9865716,0.000011707536,0.00056801736,0.008185409,0.0025174725,0.000009218951,0.000052675194,0.00011233391,0.0019715587],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99699855,0.0002760946,0.000736587,0.0004166045,0.0004983133,0.0010738672],"domain_scores_gemma":[0.99732786,0.00017128247,0.0003820294,0.0003751629,0.000672438,0.0010712398],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00076283026,0.0003843906,0.001100212,0.0013902575,0.00008383607,0.00006830019,0.00036814602,0.0009289897,0.00025453581],"category_scores_gemma":[0.0004917735,0.00031990788,0.00010287095,0.0003571769,0.00046981254,0.0001693048,0.000067847344,0.005038316,0.000011972968],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027313275,0.000009832342,0.29375067,0.0002779787,0.000102622515,0.63001543,0.00055831467,0.0000032710357,0.0000065660442,0.0000021559572,0.07491575,0.00008424608],"study_design_scores_gemma":[0.0037510386,0.001778805,0.061775714,0.0010179192,0.000066671615,0.9154465,0.00026163046,0.000020699354,0.000018220124,0.000079152975,0.015474522,0.0003091173],"about_ca_topic_score_codex":0.009069853,"about_ca_topic_score_gemma":0.00082684075,"teacher_disagreement_score":0.28543106,"about_ca_system_score_codex":0.0010393212,"about_ca_system_score_gemma":0.007932713,"threshold_uncertainty_score":0.9999253},"labels":[],"label_agreement":null},{"id":"W2218612843","doi":"10.5376/cge.2015.03.00011","title":"The Aberrant Methylation Sites Identification and Function Analysis Associated With DNMT3A And IDH Mutations in AML","year":2015,"lang":"en","type":"article","venue":"Cancer Genetics and Epigenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Identification (biology); Methylation; DNA methylation; Genetics; Biology; Epigenetics; Computational biology; Gene; Gene expression","score_opus":0.042796987583386716,"score_gpt":0.32149129284827327,"score_spread":0.27869430526488653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2218612843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98719496,0.009124345,0.0023388974,0.0009307684,0.00003371652,0.00029252737,0.000016364434,0.000010010634,0.00005842964],"genre_scores_gemma":[0.9885861,0.010521313,0.0003312486,0.000057265752,0.000039511408,0.000043896725,0.0000827932,0.000014216969,0.00032364114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905926,0.00007291834,0.00022241277,0.0002353406,0.00023252769,0.00017752047],"domain_scores_gemma":[0.9991895,0.00012107629,0.00009193622,0.00016429131,0.0002861352,0.00014706787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004589293,0.00010370756,0.00017461559,0.00016241621,0.0001395509,0.000085167616,0.000034933244,0.00007945235,0.00000460821],"category_scores_gemma":[0.00013284225,0.00007533732,0.000016751692,0.00059593667,0.00018424833,0.000032069587,0.000032398268,0.00012552693,7.863427e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017461326,0.000038696922,0.93804246,0.000029079914,0.00061259896,0.000004077702,0.0019078114,0.003666759,0.006306512,0.00008760175,0.00016646888,0.04896335],"study_design_scores_gemma":[0.0010511269,0.00020033098,0.93532526,0.000017101096,0.0008305511,0.000002480349,0.0006795598,0.05879984,0.0013960811,0.0005736109,0.0010224573,0.00010161947],"about_ca_topic_score_codex":0.00016629265,"about_ca_topic_score_gemma":0.0029953413,"teacher_disagreement_score":0.05513308,"about_ca_system_score_codex":0.00013020776,"about_ca_system_score_gemma":0.00015658347,"threshold_uncertainty_score":0.30721664},"labels":[],"label_agreement":null},{"id":"W2223593075","doi":"10.1200/jco.2006.24.18_suppl.6565","title":"Fatigue in older adults with acute myeloid leukemia (AML): Predictors and impact on quality of life (QOL) and functional status","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Quality of life (healthcare); Depression (economics); Anemia; Cancer; Myeloid leukemia; Physical therapy","score_opus":0.07087920437950193,"score_gpt":0.43787409845773245,"score_spread":0.3669948940782305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2223593075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961849,0.00037333168,0.0001345642,0.0019157088,0.00016511187,0.0003169804,0.000025851099,0.0000067356073,0.0008768012],"genre_scores_gemma":[0.9963899,0.0010780878,0.0011499408,0.0005904141,0.0006213206,0.0000041885523,0.000012807149,0.000020177054,0.00013312315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956285,0.0006044622,0.0023891144,0.00028249,0.00071938965,0.00037605283],"domain_scores_gemma":[0.9935208,0.0037542004,0.001393116,0.00018922583,0.000487108,0.00065552973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003391375,0.00019983947,0.0016949464,0.00029532294,0.000030894727,0.000009213212,0.000080978636,0.00045050652,0.00010215069],"category_scores_gemma":[0.0022615474,0.00011952142,0.00020660977,0.0002315699,0.0005819532,0.00015013707,0.000051225223,0.0016474938,0.0000017120719],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05739605,0.0009459902,0.9245,0.000086632346,0.000502719,0.00038023395,0.00016690564,0.00014020993,0.00021123308,0.0000687052,0.0043922924,0.011209036],"study_design_scores_gemma":[0.027823662,0.015046896,0.9552319,0.0002160014,0.00013985646,0.00027126115,0.0001986298,0.00024234326,0.000046228713,0.00008665982,0.00059677643,0.00009979837],"about_ca_topic_score_codex":0.00075469,"about_ca_topic_score_gemma":0.00030515614,"teacher_disagreement_score":0.030731896,"about_ca_system_score_codex":0.00069879676,"about_ca_system_score_gemma":0.0055751824,"threshold_uncertainty_score":0.98901343},"labels":[],"label_agreement":null},{"id":"W2224508227","doi":"10.1016/j.clml.2015.04.042","title":"Decitabine Improves Outcomes in Older Patients with AML and Higher Blast Counts","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Decitabine; Medicine; Cytarabine; Azacitidine; Myeloid leukemia; Myelodysplastic syndromes; Hypomethylating agent; Internal medicine; Oncology; Chemotherapy; Bone marrow","score_opus":0.028737950033295146,"score_gpt":0.3252584698696322,"score_spread":0.29652051983633704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2224508227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987686,0.00016221269,0.0000101475625,0.00069753814,0.00034503953,0.0005709853,0.00001536939,0.00008151739,0.010431209],"genre_scores_gemma":[0.9903935,0.000043178257,0.0010179924,0.0015580809,0.00025658662,0.000037576163,0.00004454216,0.00007154258,0.006577009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973964,0.00010998752,0.0007020461,0.0006029229,0.0006458573,0.0005428031],"domain_scores_gemma":[0.99788284,0.00045161956,0.00013544374,0.00056166126,0.0003142184,0.0006542066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005825566,0.0003043025,0.000762455,0.0001612876,0.000042234282,0.00004251146,0.0002094189,0.00033171164,0.00014342407],"category_scores_gemma":[0.000808373,0.00021180556,0.00009619008,0.0003188334,0.00044515578,0.00017081923,0.000202973,0.00036878916,0.00046915878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080605934,0.00029484014,0.7542674,0.000032438675,0.000087861816,0.00014612637,0.000060292372,2.6610473e-7,0.00001704834,0.00008442258,0.008979291,0.23522398],"study_design_scores_gemma":[0.015822202,0.00072856847,0.96912247,0.00010957017,0.0000538356,0.000024395635,0.000038012895,0.00013347427,0.000022928609,0.00010708511,0.013589577,0.000247903],"about_ca_topic_score_codex":0.0000894357,"about_ca_topic_score_gemma":0.000019234783,"teacher_disagreement_score":0.23497608,"about_ca_system_score_codex":0.0011427987,"about_ca_system_score_gemma":0.001302196,"threshold_uncertainty_score":0.863718},"labels":[],"label_agreement":null},{"id":"W2229326747","doi":"10.1200/jco.2004.22.14_suppl.6611","title":"A randomized phase I clinical and biologic study of two schedules of BAY 43–9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A National Cancer Institute of Cancer Clinical Trials Group Study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Nausea; Gastroenterology; Regimen; Myelodysplastic syndromes; Vomiting; Oncology; Surgery; Adverse effect; Bone marrow","score_opus":0.2024794012292822,"score_gpt":0.55521098114729,"score_spread":0.35273157991800774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2229326747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282265,0.00038392894,0.00017322582,0.0005997927,0.00161394,0.004279133,0.00009157678,0.000009423973,0.000026318512],"genre_scores_gemma":[0.99301744,0.0024637391,0.003332868,0.00030975018,0.000656859,0.0001395281,0.0000111410045,0.00003917351,0.000029512743],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9712965,0.008970998,0.016634256,0.0007726108,0.0018045071,0.0005211593],"domain_scores_gemma":[0.96170247,0.024923917,0.009796541,0.00042253852,0.0024977336,0.00065681594],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.051218554,0.00045738564,0.0115532745,0.0007791193,0.000055717894,0.0000113268325,0.0005830922,0.0007777878,0.00013348181],"category_scores_gemma":[0.054276943,0.0002535016,0.0009918801,0.00084844965,0.002895971,0.00030010688,0.00030461457,0.0028305615,0.000001946286],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42975104,0.027593069,0.52487713,0.000076873665,0.0056622857,0.00062221417,0.00017371718,0.00028825866,0.00002959359,0.000049726958,0.000035398556,0.010840672],"study_design_scores_gemma":[0.5019066,0.07764101,0.41658285,0.00045501164,0.0026200153,0.000054486092,0.00027036646,0.00012199268,0.000007444793,0.00014648416,0.000051705858,0.000142047],"about_ca_topic_score_codex":0.000900886,"about_ca_topic_score_gemma":0.002923052,"teacher_disagreement_score":0.108294286,"about_ca_system_score_codex":0.0007966036,"about_ca_system_score_gemma":0.015852598,"threshold_uncertainty_score":0.9999917},"labels":[],"label_agreement":null},{"id":"W2236408391","doi":"10.1073/pnas.1515071113","title":"The LMO2 oncogene regulates DNA replication in hematopoietic cells","year":2016,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Government of Canada; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Society; Leukemia and Lymphoma Society","keywords":"Biology; DNA replication factor CDT1; DNA replication; Origin recognition complex; Control of chromosome duplication; Cell cycle; Cell biology; Pre-replication complex; Minichromosome maintenance; Eukaryotic DNA replication; Molecular biology; Cancer research; DNA; Genetics; Cell","score_opus":0.04188322511963959,"score_gpt":0.3372871730931088,"score_spread":0.2954039479734692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2236408391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9476903,0.00014973381,5.196401e-7,0.047291804,0.000009825903,0.00029840192,0.0000031893808,0.000008531038,0.004547703],"genre_scores_gemma":[0.99752873,0.00017460359,0.00046223222,0.00020460205,0.000060793056,0.000020313968,4.2887695e-8,0.0000043946466,0.0015443129],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979912,0.00000840611,0.00034320928,0.00026023126,0.0012117684,0.00018517094],"domain_scores_gemma":[0.9989501,0.00037587818,0.0002800412,0.000025309182,0.0003292696,0.00003938802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029150418,0.00006972693,0.00013315771,0.00014191585,0.00015099172,0.000013469074,0.00069686817,0.00007378253,0.000012730197],"category_scores_gemma":[0.0015876661,0.000029416602,0.000056820645,0.0008294564,0.0011681495,0.00020478189,0.00014640964,0.00013442864,0.0000059768104],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035316272,0.00002434929,0.0033822185,0.00003407244,0.000007057372,7.779117e-9,0.00008606893,0.000001831711,0.9746761,0.017819202,0.001888872,0.0020449301],"study_design_scores_gemma":[0.0003082036,0.000042332336,0.04741239,0.00018448733,0.0000058226897,0.000016023383,0.000106477295,0.0002247474,0.91737723,0.03344347,0.0008402153,0.000038584745],"about_ca_topic_score_codex":0.0000046682985,"about_ca_topic_score_gemma":9.839838e-8,"teacher_disagreement_score":0.05729883,"about_ca_system_score_codex":0.00015697425,"about_ca_system_score_gemma":0.00010962172,"threshold_uncertainty_score":0.43040958},"labels":[],"label_agreement":null},{"id":"W2238288150","doi":"10.1186/s13046-016-0283-5","title":"The leukemogenic fusion gene MLL-AF9 alters microRNA expression pattern and inhibits monoblastic differentiation via miR-511 repression","year":2016,"lang":"en","type":"article","venue":"Journal of Experimental & Clinical Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Université de Montréal; Deutsche Forschungsgemeinschaft","keywords":"Biology; microRNA; Cancer research; Myeloid leukemia; Gene knockdown; Fusion gene; Cell cycle; Cellular differentiation; Cell biology; Gene; Genetics","score_opus":0.09427000511076064,"score_gpt":0.45936120399767066,"score_spread":0.36509119888691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2238288150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854902,0.007915209,0.0006603537,0.004708879,0.0005343748,0.0006177993,0.0000089711675,0.000014022745,0.0000501746],"genre_scores_gemma":[0.98796034,0.009742503,0.00019076801,0.00019626602,0.0012050875,0.00005272839,0.00000356354,0.00005610418,0.00059265865],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9942733,0.0011106833,0.0014286959,0.00055765343,0.0018916876,0.0007379868],"domain_scores_gemma":[0.9954337,0.002046083,0.00052858883,0.00055217504,0.00069039135,0.0007490649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00358876,0.0002538824,0.00057864975,0.00027743584,0.0004991737,0.00010151053,0.00046380112,0.00025846207,0.00032079406],"category_scores_gemma":[0.0010229358,0.00012577283,0.00030369897,0.00026366298,0.00070312835,0.0003033872,0.0007449316,0.0013900008,0.00003665444],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005446513,0.00032650676,0.014680721,0.000027111897,0.00010079879,0.000115495364,0.00020600512,8.19838e-7,0.9076813,0.0000016472338,0.004729956,0.06668315],"study_design_scores_gemma":[0.007560745,0.0029746022,0.045472056,0.0012823662,0.00004217024,0.00021805825,0.0003068672,0.00029040308,0.9396502,0.00007738064,0.0019534829,0.0001716763],"about_ca_topic_score_codex":0.000115923365,"about_ca_topic_score_gemma":0.000015961601,"teacher_disagreement_score":0.066511475,"about_ca_system_score_codex":0.0011593655,"about_ca_system_score_gemma":0.00058965344,"threshold_uncertainty_score":0.60389394},"labels":[],"label_agreement":null},{"id":"W2243527806","doi":"10.1200/jco.2007.25.18_suppl.19566","title":"Relationship between fatigue and cytokine levels in patients age 50+ with acute myeloid leukemia (AML)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Cancer-related fatigue; Cancer; Cytokine; Chemotherapy; Malignancy; Oncology; Gastroenterology","score_opus":0.18758518186517248,"score_gpt":0.47077759836317057,"score_spread":0.2831924164979981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243527806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99246806,0.000059963935,0.0013504361,0.0027149545,0.00018290247,0.00033146655,0.000009058515,0.000009946094,0.0028731832],"genre_scores_gemma":[0.9861618,0.0000707031,0.011556928,0.0009244987,0.00083405466,0.0000018344501,0.000012763324,0.000029554905,0.00040784164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955438,0.00041550334,0.0026226235,0.00026635587,0.0006897323,0.00046203414],"domain_scores_gemma":[0.9904552,0.0069316234,0.0012127142,0.00024018346,0.00046576117,0.00069447805],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007236433,0.0001874455,0.0015143735,0.00045399656,0.000056213416,0.000012718742,0.00021277161,0.00064667343,0.00003574812],"category_scores_gemma":[0.0059353854,0.00012826214,0.00017072557,0.00039898904,0.0004265747,0.00021544084,0.000103276674,0.0029354796,0.000013144897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050502503,0.00029899398,0.9556726,0.00002309676,0.00021771998,0.0023398958,0.00012822708,0.000004405546,0.000052098832,0.00007938839,0.00086746935,0.035265807],"study_design_scores_gemma":[0.018898554,0.011260608,0.9612265,0.00011639938,0.00027309463,0.0002416192,0.00006378979,0.000007947212,0.00007288471,0.00033703545,0.0073808418,0.00012071824],"about_ca_topic_score_codex":0.00004297897,"about_ca_topic_score_gemma":0.00011560821,"teacher_disagreement_score":0.03514509,"about_ca_system_score_codex":0.0011187193,"about_ca_system_score_gemma":0.0026433265,"threshold_uncertainty_score":0.9993648},"labels":[],"label_agreement":null},{"id":"W2256505962","doi":"10.3324/haematol.2015.139717","title":"Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts","year":2016,"lang":"en","type":"letter","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Flow cytometry; Mdm2; Biomarker; Medicine; Myeloid leukemia; Clinical trial; Oncology; Internal medicine; Cancer research; Immunology; Biology; Cell culture","score_opus":0.0318626593060773,"score_gpt":0.3298666151708328,"score_spread":0.29800395586475553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256505962","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80137354,0.00007382564,0.000030502753,0.18961164,0.00016947942,0.007188801,0.00062257156,0.00034186005,0.0005877937],"genre_scores_gemma":[0.26124486,0.00072610984,0.0052630953,0.60948014,0.0022102066,0.008664541,0.0027409121,0.0010252638,0.10864486],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9887075,0.0024886865,0.002065939,0.0025640475,0.0019773825,0.0021964577],"domain_scores_gemma":[0.9935635,0.0020119622,0.0009624091,0.0021572043,0.00060769037,0.00069726526],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0014810448,0.0014524075,0.0033936754,0.0010028046,0.00019755647,0.00007431915,0.0009921953,0.0037487394,0.00056273624],"category_scores_gemma":[0.0026208477,0.0008557798,0.00055505906,0.00096005027,0.00048562876,0.00018040511,0.00068693043,0.0038945465,0.0012804959],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035383508,0.0006996516,0.01264328,0.00020984157,0.000900554,0.023142431,0.00038893925,0.0000012852557,0.0062298174,9.745648e-7,0.91517097,0.005228772],"study_design_scores_gemma":[0.041569386,0.024491329,0.07079144,0.012585238,0.00078631233,0.0007430437,0.000052330077,0.00006590953,0.032543063,0.00009811322,0.81353873,0.0027350811],"about_ca_topic_score_codex":0.000076970675,"about_ca_topic_score_gemma":0.000032959117,"teacher_disagreement_score":0.54012865,"about_ca_system_score_codex":0.009816486,"about_ca_system_score_gemma":0.0029821072,"threshold_uncertainty_score":0.99982256},"labels":[],"label_agreement":null},{"id":"W2259852344","doi":"10.1038/leu.2016.19","title":"Identification of MYC mutations in acute myeloid leukemias with NUP98–NSD1 translocations","year":2016,"lang":"en","type":"letter","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Chromosomal translocation; Myeloid leukemia; Cancer research; Identification (biology); Myeloid; Leukemia; Mutation; Biology; Genetics; Gene","score_opus":0.017242860189325155,"score_gpt":0.2882329442918651,"score_spread":0.27099008410253994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259852344","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10471201,0.0005318451,0.008323352,0.868377,0.0005588645,0.0051624454,0.0013236997,0.00042589233,0.010584914],"genre_scores_gemma":[0.49136472,0.0022295956,0.0066230725,0.30989626,0.009026224,0.0034671768,0.011588839,0.0013654567,0.16443865],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948344,0.00022212324,0.0014754494,0.00108937,0.0013720833,0.0010065701],"domain_scores_gemma":[0.99622554,0.000515523,0.0006276778,0.0017266663,0.00070466,0.00019994185],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0005512441,0.0006652742,0.0011889872,0.0014556667,0.00013141967,0.000056310128,0.0007188157,0.0014242651,0.00033823936],"category_scores_gemma":[0.00017883794,0.00051729474,0.00029916997,0.0014368185,0.0006788842,0.0003242939,0.000076238946,0.0032130585,0.00045103533],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00071291917,0.00012276103,0.0014923807,0.0018537481,0.0013441453,0.0025659471,0.0018829559,0.00011884994,0.054608207,0.00031514635,0.92373925,0.011243709],"study_design_scores_gemma":[0.023509515,0.0014007707,0.020711716,0.0055791275,0.003778604,0.0021860779,0.0006016209,0.0020564161,0.07785732,0.0018293927,0.8575122,0.002977247],"about_ca_topic_score_codex":0.00043269593,"about_ca_topic_score_gemma":0.00011381662,"teacher_disagreement_score":0.55848074,"about_ca_system_score_codex":0.0057062013,"about_ca_system_score_gemma":0.006483688,"threshold_uncertainty_score":0.9998721},"labels":[],"label_agreement":null},{"id":"W2260042699","doi":"10.1136/jmedgenet-2015-103270","title":"Improving diagnostic precision, care and syndrome definitions using comprehensive next-generation sequencing for the inherited bone marrow failure syndromes","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Janeway Children's Health and Rehabilitation Centre; McMaster University; London Health Sciences Centre; McMaster Children's Hospital; University of Alberta; University of Toronto; Montreal Children's Hospital; Queen's University; Centre Hospitalier Universitaire Sainte-Justine; CancerCare Manitoba; Population Health Research Institute; Genome Canada; Children's Hospital of Eastern Ontario; BC Children's Hospital; SickKids Foundation; Centre Hospitalier Universitaire de Sherbrooke; Princess Margaret Cancer Centre; Stollery Children's Hospital; Alberta Children's Hospital; Izaak Walton Killam Health Centre; University of Saskatchewan; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Sanger sequencing; Genotyping; Medicine; Mutation; Fanconi anemia; Bioinformatics; Genetic testing; Genotype; Genetics; Bone marrow failure; DNA sequencing; Phenotype; Gene; Biology; DNA repair","score_opus":0.1963530863585887,"score_gpt":0.34567435198255875,"score_spread":0.14932126562397005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2260042699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94380844,0.030273901,0.021083353,0.00393186,0.0003338067,0.0005388717,0.000014571835,0.000010095137,0.000005098442],"genre_scores_gemma":[0.9554381,0.0031153383,0.040162224,0.0005212473,0.0006859004,0.000012718483,0.000018430494,0.00003661402,0.000009449888],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99737924,0.00013685336,0.00062350003,0.00017137002,0.0013999327,0.00028909525],"domain_scores_gemma":[0.99593294,0.0015636296,0.00027312856,0.00021053843,0.0013961194,0.00062365615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088966615,0.00016056177,0.0004101117,0.00017815398,0.00018636783,0.00009399384,0.00020192126,0.00023894831,0.000025941263],"category_scores_gemma":[0.0069355043,0.00010657829,0.000107229804,0.00023530918,0.00020996488,0.00010834181,0.00013409021,0.000668179,0.0000017713488],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014273551,0.00064369495,0.015045601,0.004266869,0.0026853853,0.016876308,0.023625381,0.013313383,0.3659022,0.00037756,0.057728156,0.49810812],"study_design_scores_gemma":[0.022403609,0.0086773615,0.007962203,0.0040847817,0.0030316524,0.14885454,0.05043073,0.73214555,0.0049884603,0.00080235925,0.015713608,0.0009051707],"about_ca_topic_score_codex":0.000042235333,"about_ca_topic_score_gemma":0.00002766361,"teacher_disagreement_score":0.71883214,"about_ca_system_score_codex":0.00046536323,"about_ca_system_score_gemma":0.0020280343,"threshold_uncertainty_score":0.8302947},"labels":[],"label_agreement":null},{"id":"W2261541794","doi":"10.1158/0008-5472.can-15-2743","title":"An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); University Health Network; University of Toronto; Princess Margaret Cancer Centre; BC Cancer Agency; Hospital for Sick Children","funders":"Hospital for Sick Children","keywords":"Myeloid leukemia; Drug; Medicine; Leukemia; Drug discovery; Oncology; Computational biology; Pharmacology; Internal medicine; Bioinformatics; Biology","score_opus":0.04404891370566785,"score_gpt":0.3766089575067579,"score_spread":0.33256004380109006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2261541794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949871,0.0012028369,0.00021996908,0.0017145325,0.000042953852,0.00087379734,0.0007488066,0.000023282337,0.00018672783],"genre_scores_gemma":[0.9930011,0.003850628,0.00006755699,0.000045458833,0.000048726237,0.00026165857,0.00004458838,0.00004345746,0.0026368415],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950457,0.0014656842,0.0005294415,0.0006117573,0.0015505408,0.00079686404],"domain_scores_gemma":[0.99566346,0.0019035871,0.00015387074,0.0012276679,0.0008391348,0.00021226476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033670382,0.00022458288,0.0007437902,0.0021935145,0.00010491823,0.000038114755,0.00082361203,0.00015557138,0.00026146066],"category_scores_gemma":[0.0007651394,0.00011559552,0.00024861985,0.0043703094,0.0017554924,0.0003445111,0.00027896097,0.00059133064,0.00000511343],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020549988,0.0001880805,0.16522485,0.0001273542,0.0059127943,0.00021395765,0.002045597,0.0002615607,0.78956175,0.00004959666,0.0020256867,0.013838788],"study_design_scores_gemma":[0.0028680554,0.00087434263,0.17081669,0.000662795,0.00074006343,0.000017188151,0.0035848748,0.002116204,0.81722444,0.00008678047,0.00080317806,0.00020535737],"about_ca_topic_score_codex":0.009210336,"about_ca_topic_score_gemma":0.0025023867,"teacher_disagreement_score":0.027662713,"about_ca_system_score_codex":0.0027361384,"about_ca_system_score_gemma":0.0036064452,"threshold_uncertainty_score":0.9973874},"labels":[],"label_agreement":null},{"id":"W2263636488","doi":"10.1073/pnas.1525354113","title":"<i>Idh1</i> mutations contribute to the development of T-cell malignancies in genetically engineered mice","year":2016,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; York University; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; Institut National Du Cancer; Government of Canada; University Health Network; Leukemia and Lymphoma Society","keywords":"Isocitrate dehydrogenase; IDH1; Carcinogenesis; Cancer research; Biology; Malignancy; Mutation; Leukemia; Myeloid leukemia; Mutant; Cancer; Immunology; Genetics; Gene; Enzyme; Biochemistry","score_opus":0.03331471223844819,"score_gpt":0.30685007153950694,"score_spread":0.27353535930105877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263636488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741362,0.00007918568,0.000042001444,0.023381192,0.000008617119,0.00039359537,0.000020017409,0.0000049015925,0.0019343176],"genre_scores_gemma":[0.9865441,0.000017409622,0.012714822,0.00033606068,0.000028237548,0.000028504579,1.2541157e-7,0.0000036216245,0.00032714393],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99803567,0.000006530027,0.00041959394,0.00016724668,0.0011826038,0.0001883806],"domain_scores_gemma":[0.9988726,0.00031599673,0.00017215766,0.000011169469,0.00057689653,0.00005120077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017867701,0.0000729189,0.00015933973,0.00020422896,0.00008093987,0.0000065282875,0.00061227527,0.000053866766,0.000011355621],"category_scores_gemma":[0.0014936859,0.000033906574,0.000041843083,0.0009237733,0.00051424373,0.000107789805,0.00015117587,0.000107951426,0.0000043987566],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003072999,0.000037875965,0.002585022,0.00005045006,0.000009990203,8.788427e-9,0.0005256689,0.000027722774,0.9913856,0.004157801,0.0006325557,0.0005566077],"study_design_scores_gemma":[0.00048689108,0.000045539702,0.08584028,0.00019615299,0.000008070185,0.000004042475,0.00022289586,0.00015587338,0.9106721,0.0015886873,0.00073464325,0.00004478461],"about_ca_topic_score_codex":0.0000029814357,"about_ca_topic_score_gemma":3.920516e-7,"teacher_disagreement_score":0.083255254,"about_ca_system_score_codex":0.00011118334,"about_ca_system_score_gemma":0.00029520746,"threshold_uncertainty_score":0.18947524},"labels":[],"label_agreement":null},{"id":"W2264231165","doi":"10.1038/leu.2016.11","title":"GFI1 as a novel prognostic and therapeutic factor for AML/MDS","year":2016,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Histone acetyltransferase; Epigenetics; Cancer research; Myeloid leukemia; Leukemia; Histone; Biology; Zinc finger; Haematopoiesis; Downregulation and upregulation; Gene; Genetics; Stem cell; Transcription factor","score_opus":0.038548874968308874,"score_gpt":0.3211772837034835,"score_spread":0.2826284087351746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264231165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862985,0.00039288434,0.0049439715,0.004597804,0.00010720999,0.0014941137,0.000076680655,0.00014048415,0.0019483266],"genre_scores_gemma":[0.98505914,0.00007789288,0.0017176417,0.0013971302,0.00030514642,0.0001949158,0.0000078117455,0.000063609354,0.011176683],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998518,0.000021694557,0.00021964757,0.0004112205,0.0003004916,0.00052895217],"domain_scores_gemma":[0.99852353,0.0006249514,0.00005424447,0.00037188697,0.00014862162,0.00027673392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017021346,0.00020744503,0.00030729568,0.00012177355,0.000087406486,0.000029730094,0.0001429548,0.00017591345,0.0002433573],"category_scores_gemma":[0.0006301092,0.00012456521,0.00008987643,0.00014520461,0.00017795053,0.00007651972,0.00007807888,0.0001949458,0.00018253081],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014173584,0.00013751359,0.026736278,0.00042734251,0.00037436196,0.00007894409,0.0007657021,4.6199034e-7,0.6390769,0.0042014364,0.0036170895,0.32316658],"study_design_scores_gemma":[0.05314585,0.006369827,0.43351454,0.0014661466,0.0007367082,0.0019018033,0.00040557855,0.0034197653,0.12161722,0.0063670264,0.3693626,0.0016929433],"about_ca_topic_score_codex":0.000047190133,"about_ca_topic_score_gemma":0.0000081816515,"teacher_disagreement_score":0.5174597,"about_ca_system_score_codex":0.0008533917,"about_ca_system_score_gemma":0.0009194725,"threshold_uncertainty_score":0.50796217},"labels":[],"label_agreement":null},{"id":"W2264492492","doi":"10.1200/jco.2006.24.18_suppl.6566","title":"Quality of life (QOL) of older adults with acute myeloid leukemia (AML): Effects of treatment and time","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Quality of life (healthcare); Life expectancy; Referral; Cancer; Physical therapy; Gerontology; Internal medicine; Population; Family medicine","score_opus":0.03837030684735885,"score_gpt":0.4168341794211532,"score_spread":0.3784638725737943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264492492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571085,0.00072906655,0.00010699366,0.0011739638,0.00011976087,0.00049351365,0.00001209555,0.0000053953345,0.001648355],"genre_scores_gemma":[0.99324703,0.0010635526,0.0043897773,0.00023036948,0.00042796586,0.0000050980875,0.0000053934846,0.000022681284,0.00060810806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949319,0.0007741127,0.0032463623,0.0002327121,0.0005390936,0.00027582786],"domain_scores_gemma":[0.98915803,0.006092153,0.003156274,0.00032033672,0.0008710115,0.0004021646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026081323,0.00020069465,0.0030735594,0.00019138028,0.00001930606,0.0000024729356,0.000176156,0.0004561583,0.00006773312],"category_scores_gemma":[0.0024284173,0.00012084472,0.0004486154,0.00020750522,0.000756144,0.000083080165,0.000071104536,0.0006615165,0.000004656974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18238112,0.013060758,0.5095175,0.0030604685,0.009270058,0.0021470357,0.0012211617,0.00009478402,0.06726269,0.00047616073,0.012949465,0.1985588],"study_design_scores_gemma":[0.059242025,0.06921769,0.85443103,0.00069045124,0.0011375779,0.00038579514,0.00011417218,0.00015823211,0.012729035,0.00013100197,0.0016102792,0.00015271478],"about_ca_topic_score_codex":0.00052836974,"about_ca_topic_score_gemma":0.00005062658,"teacher_disagreement_score":0.3449135,"about_ca_system_score_codex":0.00055301836,"about_ca_system_score_gemma":0.0056748027,"threshold_uncertainty_score":0.9999621},"labels":[],"label_agreement":null},{"id":"W2265325729","doi":"10.1182/blood.v124.21.3764.3764","title":"A Phase 1 Study of Azacitidine (AZA) in Combination with Fludarabine and Cytarabine in Relapse/Refractory Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia &amp; Lymphoma (TACL) Study","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Cytarabine; Fludarabine; Acute myeloblastic leukemia; Leukemia; Decitabine; Internal medicine; Oncology; Childhood leukemia; Refractory (planetary science); Chemotherapy; Azacitidine; Gastroenterology; DNA methylation; Cyclophosphamide; Biology","score_opus":0.011283265791433681,"score_gpt":0.2820521748959951,"score_spread":0.2707689091045614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265325729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930826,0.0020515204,0.000028548266,0.00013758129,0.000038022306,0.004152835,0.0000100818925,0.00006890568,0.00042993613],"genre_scores_gemma":[0.99848044,0.0005288593,0.0002039514,0.00010129626,0.00007234109,0.00040487098,0.00005871288,0.000097915945,0.000051630075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955645,0.0006474284,0.0011169239,0.0009891901,0.00097029685,0.0007116263],"domain_scores_gemma":[0.9980418,0.0003874633,0.00031792614,0.0008667414,0.00017047094,0.00021556311],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015435852,0.00054548803,0.0013252645,0.001357975,0.00008778657,0.000031040847,0.00032828076,0.00022005542,0.00002279117],"category_scores_gemma":[0.00039855007,0.00045613243,0.000059765825,0.0017741914,0.0001834196,0.00048146976,0.00016540382,0.0009319237,0.0000078468365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040948596,0.14055441,0.7636563,0.00030605527,0.00041257165,0.0006496916,0.023103494,0.0002160009,0.0041365493,0.00007842156,0.000011471508,0.06278017],"study_design_scores_gemma":[0.23064725,0.020433597,0.7416196,0.00045344495,0.00022172969,0.0001838319,0.004564328,0.00037875958,0.0008485543,0.00012947098,0.00011334195,0.00040607958],"about_ca_topic_score_codex":0.0010021776,"about_ca_topic_score_gemma":0.0044002444,"teacher_disagreement_score":0.22655238,"about_ca_system_score_codex":0.0011086821,"about_ca_system_score_gemma":0.0008860437,"threshold_uncertainty_score":0.99978906},"labels":[],"label_agreement":null},{"id":"W2268193178","doi":"10.1017/cjn.2015.355","title":"Myeloid Sarcoma “en plaque” Disguised as Acute Subdural Hematoma","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Hematoma; Subdural Hematomas; Sarcoma; Myeloid sarcoma; Radiology; Pathology","score_opus":0.027945611987797155,"score_gpt":0.3006732624591916,"score_spread":0.27272765047139447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268193178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9481607,0.0006023773,0.000051356717,0.046159245,0.0007496626,0.000284217,0.000021494214,0.00004117944,0.0039297454],"genre_scores_gemma":[0.9900279,0.00086399546,0.001963558,0.0061741155,0.0005873075,0.000005041224,4.1403703e-7,0.00002727321,0.00035039565],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9926886,0.0012370792,0.0012278309,0.0007965597,0.0016071028,0.0024428577],"domain_scores_gemma":[0.992063,0.0013743655,0.0007628563,0.00031312252,0.00079971435,0.0046869265],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["sts"],"category_scores_codex":[0.005200152,0.0005071268,0.00090187753,0.0016145817,0.0023839853,0.0006120025,0.0028666882,0.0003521809,0.0008385187],"category_scores_gemma":[0.0051998254,0.00026810414,0.00047336493,0.0017711297,0.010347702,0.0014033924,0.00016755876,0.0017697786,0.00005449766],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086578284,0.000073111456,0.9055386,0.000016475919,0.00010230171,0.06813624,0.00044883622,0.000059274113,0.002514823,0.0028278378,0.005267792,0.014148932],"study_design_scores_gemma":[0.003039506,0.1655813,0.36146313,0.00026910982,0.00021241068,0.41866004,0.00043740147,0.0004962216,0.0029065656,0.029493751,0.016541567,0.0008989974],"about_ca_topic_score_codex":0.0011626848,"about_ca_topic_score_gemma":0.016092667,"teacher_disagreement_score":0.5440755,"about_ca_system_score_codex":0.0009881795,"about_ca_system_score_gemma":0.01072275,"threshold_uncertainty_score":0.9999771},"labels":[],"label_agreement":null},{"id":"W2275325872","doi":"10.1007/s00277-015-2580-z","title":"Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML","year":2015,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Ministry of Education, Science and Technology","keywords":"CEBPA; Internal medicine; Medicine; NPM1; Group (periodic table); Oncology; Mutation; Subgroup analysis; Hematology; Biology; Genetics; Confidence interval; Gene; Chemistry","score_opus":0.0443843640306183,"score_gpt":0.31337752795770224,"score_spread":0.26899316392708394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275325872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880842,0.00072690565,0.00030185538,0.007786643,0.0003205713,0.0018984016,0.00076839264,0.000018075394,0.00009497107],"genre_scores_gemma":[0.997684,0.0006983012,0.000148133,0.0010591211,0.000046200115,0.00021362025,0.000034790217,0.000048058333,0.00006775805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99514407,0.0015029996,0.0012766777,0.000502626,0.00082470494,0.00074893865],"domain_scores_gemma":[0.99643594,0.0011688332,0.0008543364,0.001016936,0.00031739508,0.00020654331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018809446,0.00041119818,0.0012721927,0.00031830187,0.00009538753,0.000010418862,0.0009432304,0.00029580292,0.00005599526],"category_scores_gemma":[0.00066253176,0.0002080914,0.00048945093,0.0006308916,0.0007654407,0.00013512086,0.00018076437,0.0009079246,0.000014510605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004793599,0.0005106896,0.9741313,0.00034737488,0.00060732017,0.0001613091,0.012192248,0.00008986042,0.0056796437,0.00020741364,0.0007338415,0.0005454218],"study_design_scores_gemma":[0.0035082728,0.0010135112,0.8817074,0.0005177651,0.00037463664,0.00016695602,0.0027724358,0.00023715454,0.108239226,0.0011727642,0.00005175714,0.00023817235],"about_ca_topic_score_codex":0.002711223,"about_ca_topic_score_gemma":0.0032988184,"teacher_disagreement_score":0.10255958,"about_ca_system_score_codex":0.000074402764,"about_ca_system_score_gemma":0.0002435805,"threshold_uncertainty_score":0.8485721},"labels":[],"label_agreement":null},{"id":"W2277138589","doi":"10.1002/ajh.24287","title":"<sup>18</sup>FDG‐PET/CT: 21st century approach to leukemic tumors in 124 cases","year":2015,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Medicine; Occult; Leukemia; Chemotherapy; Disease; Radiology; Refractory (planetary science); Minimal residual disease; Oncology; Internal medicine; Pathology","score_opus":0.03395286486311565,"score_gpt":0.31540887691118596,"score_spread":0.2814560120480703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2277138589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98627,0.00092276395,0.00014528145,0.0029395754,0.00011469851,0.00036104646,0.000006277917,0.000026821313,0.009213535],"genre_scores_gemma":[0.9905214,0.00020072453,0.0072399457,0.0015708838,0.0002070799,0.000019099809,0.0000080198715,0.000058729707,0.00017413693],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.996773,0.0003626911,0.0009980978,0.000366852,0.0006738834,0.00082549435],"domain_scores_gemma":[0.99729615,0.00038016553,0.0004555752,0.0004562125,0.00039368376,0.0010181956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009467325,0.0002970317,0.0014764305,0.0009977581,0.00004263595,0.000018873927,0.00048475427,0.00003137661,0.00009591945],"category_scores_gemma":[0.0011683012,0.00023934494,0.00015857421,0.0010789579,0.0005692662,0.00014102098,0.00017387146,0.0011304716,0.00012613843],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014040441,0.0046377145,0.3558478,0.00081861194,0.0015655955,0.3051454,0.012352711,0.005621804,0.003104679,0.008829663,0.21796319,0.070072375],"study_design_scores_gemma":[0.007653256,0.0065524047,0.0036346416,0.00046823037,0.00016058565,0.89005077,0.061427496,0.001498676,0.0015450004,0.0001665777,0.02623622,0.0006061307],"about_ca_topic_score_codex":0.0005401767,"about_ca_topic_score_gemma":0.0000098369555,"teacher_disagreement_score":0.5849054,"about_ca_system_score_codex":0.0010736743,"about_ca_system_score_gemma":0.001943496,"threshold_uncertainty_score":0.97602034},"labels":[],"label_agreement":null},{"id":"W2280596398","doi":"10.1155/2016/8502641","title":"Higher Risk Myelodysplastic Syndromes in Patients with Well-Controlled HIV Infection: Clinical Features, Treatment, and Outcome","year":2016,"lang":"en","type":"article","venue":"Case Reports in Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"Celgene; Novartis","keywords":"Medicine; Myelodysplastic syndromes; Human immunodeficiency virus (HIV); Outcome (game theory); Intensive care medicine; Pediatrics; Internal medicine; Immunology; Bone marrow","score_opus":0.024707820043429134,"score_gpt":0.3323869848715671,"score_spread":0.30767916482813795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280596398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99659693,0.00028745373,0.00002136692,0.0005935469,0.00034343053,0.0012098926,0.0000061722876,0.00004865022,0.0008925765],"genre_scores_gemma":[0.9971084,0.00022153414,0.00017969786,0.000058853457,0.00005772661,0.0001651335,0.0000118675825,0.000035500998,0.002161311],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725276,0.00030997832,0.0011407011,0.0006582397,0.00018078164,0.00045753512],"domain_scores_gemma":[0.9973994,0.0012991301,0.00038217814,0.0005880671,0.00009795189,0.00023328848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059735304,0.0002787574,0.0013598477,0.00039288396,0.00005253757,0.000010588826,0.000027155838,0.0003534339,0.00023703884],"category_scores_gemma":[0.0013130041,0.00014844809,0.000102471284,0.00022950023,0.00030257896,0.000085607906,0.000062187406,0.0004072894,0.000026891053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018744433,0.00037933356,0.8232704,0.000044231234,0.00015796171,0.1726535,0.000019922358,8.579344e-7,9.853949e-7,0.000074724616,0.0002630289,0.001260639],"study_design_scores_gemma":[0.02988797,0.0009437859,0.83206654,0.0001394817,0.00017148233,0.13546619,0.000007880814,0.000010360434,0.000011562409,0.0000780937,0.0010594297,0.00015722791],"about_ca_topic_score_codex":0.000291596,"about_ca_topic_score_gemma":0.0003920417,"teacher_disagreement_score":0.037187304,"about_ca_system_score_codex":0.00044099087,"about_ca_system_score_gemma":0.00021993251,"threshold_uncertainty_score":0.6053538},"labels":[],"label_agreement":null},{"id":"W2282189730","doi":"10.1182/blood.v122.21.497.497","title":"First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Decitabine; Medicine; Hypomethylating agent; Pharmacodynamics; Internal medicine; Phases of clinical research; Clinical endpoint; Cytarabine; Adverse effect; Gastroenterology; Refractory (planetary science); Myeloid leukemia; Pharmacokinetics; Randomized controlled trial; Surgery; Oncology; Chemotherapy; DNA methylation; Chemistry; Biology","score_opus":0.021949113843195613,"score_gpt":0.3130125473374891,"score_spread":0.29106343349429353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2282189730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99236697,0.0000543142,0.000053787728,0.00016555219,0.0000721448,0.006454163,0.00015939298,0.00004605145,0.00062761287],"genre_scores_gemma":[0.9943178,0.000105584506,0.0047234995,0.000079246776,0.00009312279,0.00030598542,0.00008725771,0.00007414495,0.00021333387],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99405634,0.0004810602,0.002718457,0.0007658693,0.0013228623,0.0006553785],"domain_scores_gemma":[0.9941464,0.0022610333,0.0010193787,0.0009995158,0.0012081295,0.00036554728],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019155806,0.00041322227,0.0023430842,0.0004946949,0.00006834148,0.000018929357,0.00039544087,0.0002499614,0.000058871166],"category_scores_gemma":[0.0052509774,0.0002943686,0.00031007812,0.0009117584,0.00037261142,0.00015013629,0.0002524699,0.0008446589,0.000024789124],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7633891,0.084300935,0.10902936,0.00075749465,0.0077762376,0.0019469713,0.011029669,0.0001481664,0.010152989,0.00002998482,0.00080200547,0.010637058],"study_design_scores_gemma":[0.9510806,0.013083157,0.027882116,0.000544731,0.0013831652,0.00009418337,0.0011175394,0.002301868,0.0021459712,0.000012913709,0.00002354442,0.00033018034],"about_ca_topic_score_codex":0.0031962644,"about_ca_topic_score_gemma":0.00033273202,"teacher_disagreement_score":0.1876915,"about_ca_system_score_codex":0.00027153434,"about_ca_system_score_gemma":0.0006766186,"threshold_uncertainty_score":0.9999508},"labels":[],"label_agreement":null},{"id":"W2282452816","doi":"10.1200/jco.2009.27.15_suppl.3579","title":"A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Clinical endpoint; Adverse effect; Internal medicine; Phases of clinical research; Randomized controlled trial; Myeloid leukemia; Gastroenterology; Clinical trial; Surgery","score_opus":0.03596982520855698,"score_gpt":0.393713692261301,"score_spread":0.357743867052744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2282452816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942492,0.00020377879,0.000111193556,0.0030737533,0.00027754984,0.0010417766,0.0000051584157,0.000010351177,0.0010272006],"genre_scores_gemma":[0.99317044,0.00090779504,0.0039958498,0.0009852361,0.000701156,0.0000040930163,0.000008498848,0.000024843137,0.00020208077],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99456286,0.00067747774,0.0032585799,0.00031648562,0.0007328918,0.00045170236],"domain_scores_gemma":[0.9949969,0.0015537498,0.0018911263,0.00027587079,0.00076185475,0.00052050856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037606484,0.00023109964,0.0023276026,0.00035288106,0.00004051715,0.000011869512,0.00021357038,0.00063818076,0.000052507494],"category_scores_gemma":[0.0032833791,0.00015061171,0.00027410494,0.00044540406,0.00032648072,0.00021845393,0.00007852823,0.001955181,0.0000053331364],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5895244,0.003834832,0.18873933,0.00007950297,0.00092891173,0.0017818725,0.00042110815,0.000026631258,0.00064974,0.00006339934,0.0015559671,0.21239433],"study_design_scores_gemma":[0.38189277,0.07577841,0.53500116,0.00072422816,0.0006122586,0.00034650942,0.00008806554,0.00030244055,0.00020221765,0.00010029071,0.0047551193,0.00019652849],"about_ca_topic_score_codex":0.000034041317,"about_ca_topic_score_gemma":0.000042173422,"teacher_disagreement_score":0.34626183,"about_ca_system_score_codex":0.0012515456,"about_ca_system_score_gemma":0.0061347364,"threshold_uncertainty_score":0.99949956},"labels":[],"label_agreement":null},{"id":"W2286459480","doi":"10.1182/blood.v124.21.3246.3246","title":"Activation of Non-Canonical Immune Signalling Pathways Drives Marrow Failure in a Murine Model of MDS","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Biology; Haploinsufficiency; Bone marrow; Cancer research; Haematopoiesis; Myeloid; Myeloid leukemia; Immunology; Leukemia; Cell biology; Phenotype; Stem cell; Genetics; Gene","score_opus":0.018425006199023295,"score_gpt":0.25886869139027896,"score_spread":0.24044368519125567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286459480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926438,0.000034447075,0.005269462,0.00036514658,0.0000076085557,0.00028699226,0.000005174237,0.00001488389,0.0013725368],"genre_scores_gemma":[0.99031544,0.000022933902,0.009390722,0.000028775627,0.0000595202,0.000019277517,0.00001959239,0.00002356484,0.000120203134],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987494,0.00005278896,0.0004128983,0.00019948435,0.00035365112,0.00023181865],"domain_scores_gemma":[0.9992038,0.00014581565,0.0001266472,0.0003083238,0.00014152251,0.000073901865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004337113,0.00011598397,0.00041148203,0.00020544582,0.000016871527,0.0000035900414,0.00014830245,0.00013453844,0.000035941513],"category_scores_gemma":[0.0002749046,0.00010201683,0.00008676136,0.00025369774,0.000083517225,0.00007277564,0.00008640534,0.0003205032,0.0000041075946],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017563537,0.0005284028,0.0049513616,0.00024223299,0.000054513832,0.000004747447,0.0004579455,0.0010633849,0.9913347,0.00036401776,0.00002606468,0.0007970115],"study_design_scores_gemma":[0.0061968467,0.00041347928,0.009817169,0.000372628,0.00005414397,0.000006842852,0.00012483877,0.12280923,0.8598421,0.0002443065,0.000020505291,0.00009789143],"about_ca_topic_score_codex":0.000121253725,"about_ca_topic_score_gemma":0.000019058367,"teacher_disagreement_score":0.13149256,"about_ca_system_score_codex":0.000054972967,"about_ca_system_score_gemma":0.0003348011,"threshold_uncertainty_score":0.41601256},"labels":[],"label_agreement":null},{"id":"W2286542660","doi":"10.1002/gcc.22333","title":"Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes","year":2015,"lang":"en","type":"article","venue":"Genes Chromosomes and Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Infection and Immunity; Celgene; Society of Gastrointestinal Radiologists","keywords":"Chronic myelomonocytic leukemia; Chromosomal translocation; Myelodysplastic syndromes; International Prognostic Scoring System; Internal medicine; Cytogenetics; Karyotype; Context (archaeology); Univariate analysis; Incidence (geometry); Medicine; Leukemia; Oncology; Multivariate analysis; Biology; Bone marrow; Chromosome; Genetics; Gene","score_opus":0.02643885306255353,"score_gpt":0.30695473471187645,"score_spread":0.28051588164932295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286542660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750911,0.02230362,0.000026129333,0.00012664798,0.0001144949,0.002060458,0.00020337071,0.000029359931,0.00004481962],"genre_scores_gemma":[0.9962246,0.0029521722,0.000043532014,0.000018072806,0.00008591064,0.00042611692,0.00006974666,0.00006501969,0.000114859824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712485,0.0001746465,0.0007603212,0.00060960953,0.0006896536,0.00064092525],"domain_scores_gemma":[0.99824286,0.00038457077,0.00025089725,0.00047352223,0.00028398543,0.00036418345],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034739604,0.00044540048,0.0009797189,0.00028929883,0.00011056454,0.000040980583,0.00027852057,0.0001621213,0.00009699337],"category_scores_gemma":[0.00017295426,0.0003057453,0.00012991608,0.0008324639,0.0006422388,0.00021154071,0.00016786088,0.00037181575,0.0000038017572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006204115,0.0010000389,0.95623624,0.0012587338,0.0009884959,0.000081409555,0.0038296396,0.00065072847,0.0069963974,0.000031775962,0.0005390686,0.027767047],"study_design_scores_gemma":[0.011058766,0.007983011,0.9720959,0.0007231081,0.00074641703,0.00029126948,0.0019038465,0.0038555346,0.00072533253,0.000047660644,0.00014417282,0.00042495277],"about_ca_topic_score_codex":0.0022515382,"about_ca_topic_score_gemma":0.000595624,"teacher_disagreement_score":0.027342094,"about_ca_system_score_codex":0.0014971953,"about_ca_system_score_gemma":0.0021916027,"threshold_uncertainty_score":0.99993944},"labels":[],"label_agreement":null},{"id":"W2292463206","doi":"10.1182/blood.v122.21.3969.3969","title":"Sorafenib Treatment Following Hematopoietic Stem Cell Transplant In Pediatric FLT3/ITD+ AML","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Sorafenib; Tolerability; Internal medicine; Hematopoietic stem cell transplantation; Oncology; Retrospective cohort study; Transplantation; Context (archaeology); Pediatrics; Surgery; Adverse effect; Hepatocellular carcinoma","score_opus":0.015353110844020967,"score_gpt":0.2507643596960034,"score_spread":0.23541124885198245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292463206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99238396,0.0014610001,0.000021780277,0.0006604282,0.00007904414,0.0010875986,0.0000069484854,0.00008933725,0.004209885],"genre_scores_gemma":[0.9950643,0.00050590903,0.00033927846,0.00008484704,0.00019667011,0.00023734142,0.000024254194,0.000051265586,0.003496088],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815375,0.000075290154,0.00036917714,0.0003922121,0.00039931195,0.0006102745],"domain_scores_gemma":[0.9991008,0.00011843346,0.000047597186,0.0004235645,0.00003456395,0.00027504703],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016416886,0.00024891703,0.00045690974,0.00027334222,0.000054834654,0.00003314997,0.0001523824,0.00014824224,0.00019753868],"category_scores_gemma":[0.000006670268,0.00019443166,0.00020931591,0.000401434,0.000022326694,0.00010181054,0.000029719355,0.000260699,0.00087499607],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032998272,0.011783559,0.8584895,0.002159477,0.0007129152,0.011659273,0.018192168,0.000026970552,0.084328495,0.00013236565,0.003761938,0.008423328],"study_design_scores_gemma":[0.1620485,0.0070504374,0.26695028,0.0008165459,0.006125056,0.0017095433,0.00525732,0.0015060997,0.5417731,0.00040455098,0.0035619743,0.00279657],"about_ca_topic_score_codex":0.00034300724,"about_ca_topic_score_gemma":0.000030656734,"teacher_disagreement_score":0.59153926,"about_ca_system_score_codex":0.00025026884,"about_ca_system_score_gemma":0.0003000976,"threshold_uncertainty_score":0.99990296},"labels":[],"label_agreement":null},{"id":"W2294644359","doi":"10.1038/bmt.2016.60","title":"Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study","year":2016,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University Health Centre; Juravinski Cancer Centre; University of Manitoba; Juravinski Hospital; Hôpital Maisonneuve-Rosemont; University of British Columbia; Princess Margaret Cancer Centre; Vancouver General Hospital; Université de Montréal; Queen Elizabeth II Health Sciences Centre; CancerCare Manitoba; Ottawa Hospital; University Health Network; Dalhousie University; Foothills Medical Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Hematopoietic cell; Internal medicine; Retrospective cohort study; Hematopoietic stem cell transplantation; Multicenter study; Comorbidity; Transplantation; Oncology; Overall survival; Haematopoiesis; Stem cell; Randomized controlled trial","score_opus":0.01322816702729029,"score_gpt":0.24242085566406466,"score_spread":0.22919268863677436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294644359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931592,0.000022565038,0.0037576412,0.000121209865,0.000052382442,0.0020232957,0.0006880437,0.000033842643,0.00014184293],"genre_scores_gemma":[0.9980767,0.0011103326,0.00023475432,0.0000074538752,0.000019408619,0.00005657516,0.00040956168,0.000039155126,0.000046075027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728847,0.00021889509,0.0008313975,0.00048939197,0.0008845744,0.00028726296],"domain_scores_gemma":[0.9987462,0.0002897696,0.00027516042,0.00027510512,0.00028216682,0.00013155444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044858127,0.00027635618,0.00059981254,0.00037415905,0.00006794084,0.000011376358,0.00009784425,0.00015424956,0.000053320226],"category_scores_gemma":[0.000023726021,0.00019708356,0.00006439756,0.0003528509,0.00018858234,0.0002629156,0.000007836953,0.00023972843,0.0000016995835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02046413,0.0011631165,0.8892284,0.0017563686,0.000055184588,0.00025866384,0.0061909533,0.000008291038,0.08060268,0.000008229707,0.00000673412,0.00025726637],"study_design_scores_gemma":[0.025059968,0.0011167853,0.9110769,0.0012038386,0.00019789746,0.000019594974,0.00043880675,0.0001174739,0.060571004,0.0000073514875,0.000003432464,0.00018695246],"about_ca_topic_score_codex":0.0003054616,"about_ca_topic_score_gemma":0.0011553654,"teacher_disagreement_score":0.021848518,"about_ca_system_score_codex":0.00018731649,"about_ca_system_score_gemma":0.00008097704,"threshold_uncertainty_score":0.8036834},"labels":[],"label_agreement":null},{"id":"W2295901681","doi":"10.1097/mph.0000000000000490","title":"Early Complications of Hyperleukocytosis and Leukapheresis in Childhood Acute Leukemias","year":2016,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Leukapheresis; Leukostasis; Medicine; Surgery; Chemotherapy; Leukemia; Acute leukemia; Pediatrics; Internal medicine; Stem cell","score_opus":0.023660301387310484,"score_gpt":0.3243444336672151,"score_spread":0.30068413227990465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2295901681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98556244,0.0018474839,0.00033294474,0.009932702,0.000119181546,0.00031365704,0.000014132906,0.000014112553,0.0018633463],"genre_scores_gemma":[0.9885369,0.0052601094,0.005439915,0.0002719379,0.00031729118,0.000016822649,0.0000013954862,0.000029455692,0.00012615851],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972875,0.00028836925,0.0013310326,0.00027515314,0.0003492981,0.00046861242],"domain_scores_gemma":[0.9964899,0.0014795488,0.00087415765,0.00032614678,0.0004784688,0.0003518048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009117785,0.00020690108,0.0012703105,0.0009993167,0.000050712657,0.0000059017443,0.00031834975,0.0004689765,0.00010159389],"category_scores_gemma":[0.0008541349,0.00013754253,0.00019247999,0.00064814184,0.0003340179,0.0001798719,0.00015135936,0.0006706282,0.000035467136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014252192,0.0013930032,0.91773987,0.00020411101,0.00075609866,0.0021316456,0.0015314172,0.0000015614767,0.017791739,0.001672443,0.02127653,0.03407634],"study_design_scores_gemma":[0.019357964,0.0047496064,0.94298506,0.00015560181,0.0011166161,0.019471573,0.00053763477,0.000018893108,0.004269383,0.0011468336,0.0058865976,0.00030424367],"about_ca_topic_score_codex":0.0000446325,"about_ca_topic_score_gemma":0.000019756368,"teacher_disagreement_score":0.0337721,"about_ca_system_score_codex":0.000884772,"about_ca_system_score_gemma":0.0025610584,"threshold_uncertainty_score":0.5608822},"labels":[],"label_agreement":null},{"id":"W2296606154","doi":"10.1021/acs.jmedchem.5b01630","title":"Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1)","year":2016,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of New Brunswick; Structural Genomics Consortium; University of Toronto; Ontario Institute for Cancer Research","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Structural Genomics Consortium; National Research Council Canada; Ontario Ministry of Economic Development and Innovation; Consejo Nacional de Ciencia y Tecnología; Ontario Institute for Cancer Research; Canadian Light Source; Wellcome Trust; Western Economic Diversification Canada; Wellcome","keywords":"Chemistry; Small molecule; In silico; Peptidomimetic; Stereochemistry; Myeloid leukemia; Computational biology; Cancer research; Biochemistry; Gene; Biology","score_opus":0.016920817187446636,"score_gpt":0.27583186922827385,"score_spread":0.2589110520408272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296606154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927032,0.00017583929,0.0048563364,0.0017129022,0.00006207489,0.00020803866,0.000019325737,0.000006325143,0.0002559386],"genre_scores_gemma":[0.9963875,0.000027034004,0.0028784992,0.00005174781,0.0004549074,0.0000023172129,0.000008177474,0.0000232816,0.00016652668],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99802864,0.000084303174,0.0008381338,0.00017416758,0.00067569496,0.00019904246],"domain_scores_gemma":[0.9976803,0.00020300964,0.0010743504,0.00030186377,0.00055557763,0.00018487095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007504113,0.00016894726,0.0005294448,0.000096239935,0.000048667913,0.000008706354,0.00023122551,0.00017280283,0.00008041241],"category_scores_gemma":[0.00147729,0.000092801885,0.00013942209,0.00019096323,0.0002738793,0.000078936486,0.000066734734,0.00062363944,1.6012588e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015117903,0.000033659187,0.012223603,0.0005820821,0.0001389153,0.00006171048,0.00009427734,0.00022199281,0.9814377,0.00000146544,0.00012889615,0.0035638998],"study_design_scores_gemma":[0.004427525,0.0005538361,0.002851139,0.002712886,0.00022067239,0.00044371485,0.0003990773,0.0009866175,0.9872291,0.000011440108,0.00008035564,0.0000836134],"about_ca_topic_score_codex":0.000034112763,"about_ca_topic_score_gemma":0.000001425424,"teacher_disagreement_score":0.009372464,"about_ca_system_score_codex":0.00053524255,"about_ca_system_score_gemma":0.0011421858,"threshold_uncertainty_score":0.3784351},"labels":[],"label_agreement":null},{"id":"W2297856459","doi":"10.3324/haematol.2015.140335","title":"Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)","year":2016,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Children's Hospital of Eastern Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Quality of life (healthcare); Psychosocial; International Prognostic Scoring System; Medicine; Cohort; Myelodysplastic syndromes; Scale (ratio); Gerontology; Internal medicine; Psychology; Psychiatry","score_opus":0.040397248204170844,"score_gpt":0.34331150305323793,"score_spread":0.3029142548490671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2297856459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869746,0.000022768527,0.00015966072,0.004819572,0.000069451744,0.00042829337,0.00001604562,0.000014956399,0.0074946256],"genre_scores_gemma":[0.99897206,0.000025566873,0.00044905223,0.00007111482,0.000022163238,0.00003171945,0.0000028508928,0.0000060652915,0.00041943192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998599,0.00017610067,0.00047541995,0.00018194102,0.0004303741,0.0001371782],"domain_scores_gemma":[0.99888325,0.00030129153,0.00023525288,0.0003011684,0.00023357992,0.00004544011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061070354,0.00007679971,0.000351717,0.00009092391,0.000018283597,0.0000026092057,0.00023144999,0.000092881186,0.0003131542],"category_scores_gemma":[0.0022767233,0.00003673006,0.00008206375,0.0002341465,0.00026221928,0.000060939048,0.00013687182,0.00012273013,0.00002382339],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051520055,0.00017026793,0.9513213,0.00007936179,0.000036980193,0.0000046619184,0.0002869532,0.0000011659391,0.040936347,0.005550163,0.00043030837,0.00066728547],"study_design_scores_gemma":[0.0016925326,0.000074063195,0.8357778,0.00015164567,0.000007120976,0.000021810007,0.00016919221,0.000016872915,0.1604922,0.0014506849,0.000100145735,0.00004590503],"about_ca_topic_score_codex":0.000090761154,"about_ca_topic_score_gemma":0.000030575684,"teacher_disagreement_score":0.119555846,"about_ca_system_score_codex":0.0001481195,"about_ca_system_score_gemma":0.00019764686,"threshold_uncertainty_score":0.3428819},"labels":[],"label_agreement":null},{"id":"W2298793090","doi":"10.1111/bjh.14033","title":"Patient‐related factors independently impact overall survival in patients with myelodysplastic syndromes: an <scp>MDS</scp>‐<scp>CAN</scp> prospective study","year":2016,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Statistics Canada; Queen Elizabeth II Health Sciences Centre; Royal Victoria Hospital; Royal Victoria Regional Health Centre; McGill University Health Centre; Dalhousie University; University of Ottawa; Vancouver General Hospital; Princess Margaret Cancer Centre; Alberta Hospital Edmonton; Hamilton Health Sciences; Dr. Georges-L.-Dumont University Hospital Centre; Saskatchewan Cancer Agency; CancerCare Manitoba; Ottawa Hospital; Health Sciences Centre; University of Alberta Hospital; University Health Network; Nova Scotia Health Authority; St. Paul's Hospital; University of British Columbia; Juravinski Cancer Centre; Jewish General Hospital; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Celgene","keywords":"Medicine; Comorbidity; Hazard ratio; Proportional hazards model; Internal medicine; Myelodysplastic syndromes; International Prognostic Scoring System; Prospective cohort study; Confidence interval; Multivariate analysis; Grip strength; Physical therapy","score_opus":0.011184719016116514,"score_gpt":0.26630601102931284,"score_spread":0.25512129201319633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2298793090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722326,0.00028968765,0.000040506562,0.000043031254,0.0004574368,0.0015316472,0.00011315107,0.000050538198,0.0002507435],"genre_scores_gemma":[0.9993503,0.00008562629,0.0000797926,0.00003653878,0.00005734756,0.000023946575,0.00003279823,0.00012331174,0.00021030981],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941202,0.0008685062,0.0014691947,0.00068377145,0.0016275663,0.0012307696],"domain_scores_gemma":[0.9947188,0.0018747824,0.0009672222,0.00043405365,0.0011781227,0.0008270481],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007483936,0.0005322826,0.0019042308,0.0009619781,0.00014768292,0.00009957743,0.0004901442,0.0004181913,0.000102878425],"category_scores_gemma":[0.004984117,0.00037673887,0.0002391959,0.0006562224,0.00037185504,0.0007587727,0.0001948808,0.0015905931,0.000034800527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030450558,0.0029302696,0.94679415,0.000060781957,0.0010526594,0.04459875,0.0025065804,0.000018515582,0.00006797696,0.000014770088,0.00081092597,0.00084011455],"study_design_scores_gemma":[0.022373559,0.012986897,0.92086995,0.0008035727,0.00020168071,0.038740456,0.0035428829,0.000010325963,0.0001348497,0.00018905463,0.00003701725,0.00010978746],"about_ca_topic_score_codex":0.0005037499,"about_ca_topic_score_gemma":0.00048407566,"teacher_disagreement_score":0.025924228,"about_ca_system_score_codex":0.0012701459,"about_ca_system_score_gemma":0.0011052309,"threshold_uncertainty_score":0.99986845},"labels":[],"label_agreement":null},{"id":"W2298992290","doi":"10.1182/blood-2016-03-703868","title":"RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature","year":2016,"lang":"en","type":"letter","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Core binding factor; RUNX1; Biology; NPM1; Genetics; Fusion gene; Transcription factor; Computational biology; Gene; Molecular biology; Karyotype; Chromosome","score_opus":0.04385148627232477,"score_gpt":0.30956506967483993,"score_spread":0.26571358340251516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2298992290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9349732,0.0026382764,0.00009589067,0.05917653,0.00033269325,0.0008505855,0.001290999,0.00010208845,0.00053974026],"genre_scores_gemma":[0.89192986,0.006171981,0.003164584,0.053737048,0.008869735,0.0003476615,0.0138831325,0.00055130175,0.02134468],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969452,0.00011185346,0.0006610709,0.0007220088,0.0009813879,0.00057845854],"domain_scores_gemma":[0.9975761,0.0006453305,0.00047464302,0.00066332583,0.00049014034,0.00015044399],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026921174,0.0004467648,0.00115418,0.0020466694,0.00017406029,0.00006399163,0.00028181038,0.0009580019,0.00041480723],"category_scores_gemma":[0.00060028915,0.00032457153,0.00042553435,0.0012124635,0.00024766324,0.00012755241,0.00021919303,0.0017194053,0.000025807474],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018440218,0.00023222908,0.023287749,0.003917928,0.015335286,0.0025091649,0.002516966,0.0000046503,0.5850018,0.00005141009,0.3569109,0.010047447],"study_design_scores_gemma":[0.041570727,0.0038815371,0.105173245,0.025620135,0.17664345,0.0015924595,0.003679739,0.0018911216,0.30190882,0.0016827498,0.3279607,0.008395292],"about_ca_topic_score_codex":0.00013470314,"about_ca_topic_score_gemma":0.00005959451,"teacher_disagreement_score":0.283093,"about_ca_system_score_codex":0.0003231788,"about_ca_system_score_gemma":0.00048011323,"threshold_uncertainty_score":0.9999206},"labels":[],"label_agreement":null},{"id":"W2299133976","doi":"10.3109/10428194.2016.1157878","title":"Pre- and post-treatment serum ferritin levels in patients with higher risk myelodysplastic syndromes receiving azacitidine","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Myelodysplastic syndromes; Azacitidine; Medicine; Myeloid leukemia; Internal medicine; Serum ferritin; Anemia; Oncology; Ferritin; Myeloid; Bone marrow; Gene","score_opus":0.011453141841531444,"score_gpt":0.23782365249906168,"score_spread":0.22637051065753022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299133976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96764034,0.0017044537,0.000017222355,0.02331287,0.0004915456,0.002909177,0.0019560512,0.00037566607,0.0015926702],"genre_scores_gemma":[0.90321934,0.0027823688,0.0008093462,0.058149267,0.0030959288,0.00072797626,0.0016092465,0.00091936585,0.028687168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9895198,0.00065024116,0.0016646878,0.0031698758,0.0019354791,0.0030599253],"domain_scores_gemma":[0.99402934,0.0015998161,0.00086930057,0.0019099237,0.0005926676,0.0009989592],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00057191163,0.0025089902,0.003172453,0.0015542507,0.0005686634,0.00036070845,0.0006682525,0.0028748363,0.0003831517],"category_scores_gemma":[0.00032222504,0.0018031,0.00037703826,0.0008760871,0.0010913936,0.0006673646,0.0006326317,0.0013768703,0.0001622015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0069104107,0.0005752903,0.49709213,0.0034372786,0.0034500752,0.014198651,0.0014454161,0.000012765261,0.0004685678,0.00007022278,0.088179976,0.38415924],"study_design_scores_gemma":[0.045913596,0.003082742,0.8083161,0.0033620924,0.0009809975,0.00152158,0.000064273176,0.00015406971,0.0002353773,0.00008958304,0.13439685,0.0018827461],"about_ca_topic_score_codex":0.0044743535,"about_ca_topic_score_gemma":0.00023607948,"teacher_disagreement_score":0.38227648,"about_ca_system_score_codex":0.031255536,"about_ca_system_score_gemma":0.0073617976,"threshold_uncertainty_score":0.99876463},"labels":[],"label_agreement":null},{"id":"W2299693436","doi":"10.1007/s12185-016-1973-7","title":"Roles of IDH1/2 and TET2 mutations in myeloid disorders","year":2016,"lang":"en","type":"review","venue":"International Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"IDH1; Isocitrate dehydrogenase; Epigenetics; Context (archaeology); Biology; Myeloid leukemia; Genome instability; Genetics; IDH2; Cancer research; Myeloid; Mutation; Enzyme; Bioinformatics; Gene; DNA; DNA damage; Biochemistry","score_opus":0.025937572712807406,"score_gpt":0.38813160190337986,"score_spread":0.3621940291905725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299693436","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008905951,0.995433,0.00017153575,0.0021051567,0.000336827,0.00022659278,0.000032180258,0.0000039553515,0.0008001945],"genre_scores_gemma":[0.0029924929,0.9961059,0.0005532621,0.00003055438,0.00014756277,0.000010230721,0.000016386311,0.000026793454,0.00011683196],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978928,0.00014377352,0.0011868754,0.00015982134,0.00044119608,0.00017555471],"domain_scores_gemma":[0.9977168,0.00076858705,0.00086454954,0.000130407,0.00042198467,0.0000976843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039433784,0.00018587262,0.0014649584,0.001293782,0.000011409181,0.0000087476155,0.00037418382,0.00023489092,0.00018956831],"category_scores_gemma":[0.00076917914,0.00012177878,0.00029362683,0.00014427357,0.00024905597,0.00009185161,0.00011663697,0.00054593454,0.0000181901],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011396486,0.00013766412,0.00095509994,0.00217501,0.00084185996,0.00065567525,0.0001079499,4.799788e-7,0.000025594547,0.0024259828,0.00042333588,0.9921374],"study_design_scores_gemma":[0.0026619567,0.00028860086,0.00017764975,0.02555017,0.00033769375,0.022613926,0.00012836848,0.000009912382,0.000058403257,0.003471506,0.9445207,0.00018112491],"about_ca_topic_score_codex":0.000009403226,"about_ca_topic_score_gemma":0.000028433808,"teacher_disagreement_score":0.99195623,"about_ca_system_score_codex":0.00025926094,"about_ca_system_score_gemma":0.0009524748,"threshold_uncertainty_score":0.49659947},"labels":[],"label_agreement":null},{"id":"W2300062471","doi":"10.1182/blood.v124.21.4607.4607","title":"Somatic Mutations in TET2, but Not SF3B1, Are Prevalent during Normal Aging Hematopoiesis in Human","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Population; Myelodysplastic syndromes; Biology; Cancer; Epigenetics; Myeloid; Somatic cell; Genetics; Medicine; Bioinformatics; Oncology; Gene; Cancer research; Immunology; Bone marrow","score_opus":0.016573645529887868,"score_gpt":0.2851755153641487,"score_spread":0.2686018698342608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300062471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695385,0.000068087444,0.000022550048,0.00069878274,0.000020822392,0.0004506308,0.0000043217588,0.00006337484,0.0017176091],"genre_scores_gemma":[0.99825305,0.000008092664,0.00059961784,0.00008453817,0.00011970678,0.000102153004,0.000013381731,0.000032853884,0.0007866158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983994,0.00010731567,0.00040245152,0.00027525533,0.00037063763,0.00044498706],"domain_scores_gemma":[0.999247,0.00013900241,0.00008155973,0.00036812946,0.000042668922,0.00012163278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041870584,0.00014827609,0.00033136044,0.00043511143,0.00009610654,0.000024972114,0.0001506445,0.00008060651,0.00012475967],"category_scores_gemma":[0.0003450089,0.00014535413,0.000060475948,0.0002856208,0.000054756823,0.00011350137,0.0001132245,0.00038450013,0.00008049432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004822079,0.0013100896,0.7116845,0.0027457199,0.00009208407,0.00069777697,0.0030740146,0.00014415487,0.27970296,0.00015374385,0.0000405416,0.00030617963],"study_design_scores_gemma":[0.0076115406,0.00006927452,0.7907398,0.00081115944,0.00007439555,0.00014842335,0.00077106425,0.0007780077,0.19870123,0.00009426208,0.000023112834,0.00017775013],"about_ca_topic_score_codex":0.00021610541,"about_ca_topic_score_gemma":0.000322525,"teacher_disagreement_score":0.08100172,"about_ca_system_score_codex":0.00021555768,"about_ca_system_score_gemma":0.00008728298,"threshold_uncertainty_score":0.59273696},"labels":[],"label_agreement":null},{"id":"W2300107978","doi":"10.1186/s40164-016-0037-2","title":"Rare MLL-ELL fusion transcripts in childhood acute myeloid leukemia—association with young age and myeloid sarcomas?","year":2015,"lang":"en","type":"article","venue":"Experimental Hematology and Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Fusion transcript; Sanger sequencing; Exon; Breakpoint; Fusion gene; Myeloid leukemia; Chromosomal translocation; Myeloid sarcoma; Karyotype; Myeloid; Biology; Cancer research; Cytogenetics; Leukemia; Molecular biology; Medicine; Pathology; Gene; Genetics; DNA sequencing; Chromosome","score_opus":0.018831109176002888,"score_gpt":0.3061671611899829,"score_spread":0.28733605201398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300107978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98383236,0.0063889306,0.000022382681,0.002042361,0.00020154651,0.00079984555,0.000008915166,0.000071318624,0.0066323276],"genre_scores_gemma":[0.99611104,0.0004981967,0.0012354851,0.00094539794,0.0000939726,0.0001232547,0.00008554046,0.000040338164,0.0008667555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776876,0.00027870573,0.0004130176,0.0005859304,0.00030953044,0.0006440735],"domain_scores_gemma":[0.9990232,0.00014567934,0.0001384153,0.00022444969,0.00007237599,0.0003958783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044796063,0.0003117771,0.00086551736,0.00026674222,0.00014094172,0.00002040839,0.000119346114,0.00062355364,0.0000620708],"category_scores_gemma":[0.000060260514,0.00026102012,0.000049691047,0.00024579422,0.00036736653,0.00019570276,0.00014660036,0.0007305139,0.000028693763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011777599,0.0024894108,0.7085471,0.00024106789,0.0007520937,0.027482841,0.05667141,0.0000032288235,0.16906059,0.004460074,0.010725101,0.007789487],"study_design_scores_gemma":[0.09182475,0.019050343,0.42784664,0.00048244395,0.0005269191,0.050299406,0.03275112,0.0005580724,0.35261416,0.0008524201,0.02151341,0.0016803078],"about_ca_topic_score_codex":0.0002672453,"about_ca_topic_score_gemma":0.0004369433,"teacher_disagreement_score":0.28070045,"about_ca_system_score_codex":0.0021083257,"about_ca_system_score_gemma":0.0006503202,"threshold_uncertainty_score":0.9999842},"labels":[],"label_agreement":null},{"id":"W2300582939","doi":"10.1182/blood.v122.21.2595.2595","title":"Functional and Phenotypic Characterization Of Acute Myeloid Leukemia By Analysis Of Diagnostic/Relapse Paired Samples","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"CD117; Medicine; Myeloid leukemia; Internal medicine; Transplantation; CD34; Minimal residual disease; Leukemia; Oncology; Myeloid; Stem cell; Gastroenterology; Immunology; Biology","score_opus":0.014141621093510408,"score_gpt":0.23585202671424754,"score_spread":0.22171040562073713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300582939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977336,0.00018145883,0.00092613575,0.00034343902,0.000026417438,0.0003765958,0.00025873154,0.000026873138,0.00012673852],"genre_scores_gemma":[0.99663436,0.00054561807,0.0005790084,0.00011376336,0.00005830377,0.00005385466,0.0014220574,0.00002017035,0.0005728892],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987364,0.0000562815,0.0003833525,0.00025597448,0.000360376,0.00020762875],"domain_scores_gemma":[0.9986939,0.00041912653,0.00017406224,0.00029196005,0.0002818566,0.00013908352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015447375,0.00013903949,0.00048223516,0.00032479383,0.000041014046,0.000012421314,0.00008037306,0.00011714744,0.0007379189],"category_scores_gemma":[0.00038886545,0.00011996475,0.000113810784,0.0007127246,0.00015298674,0.00013168225,0.00006780954,0.00013928574,0.000018748642],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008804348,0.0002721729,0.17306991,0.00008559626,0.0036457283,0.000004444294,0.00016355331,0.0000026058235,0.81846654,0.000082067934,0.0011821383,0.0029372117],"study_design_scores_gemma":[0.0024707692,0.00020134627,0.8963712,0.000035190005,0.004362232,0.000010436812,0.000042551466,0.0006938415,0.095493056,0.000030631316,0.00018724597,0.00010152804],"about_ca_topic_score_codex":0.00033271252,"about_ca_topic_score_gemma":0.0000056257454,"teacher_disagreement_score":0.7233013,"about_ca_system_score_codex":0.000069631344,"about_ca_system_score_gemma":0.00018347723,"threshold_uncertainty_score":0.80796945},"labels":[],"label_agreement":null},{"id":"W2300878904","doi":"10.1038/leu.2016.44","title":"Harmonemia: a universal strategy for flow cytometry immunophenotyping—A European LeukemiaNet WP10 study","year":2016,"lang":"en","type":"letter","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Immunophenotyping; Medicine; Flow cytometry; Pathology; Internal medicine; Immunology","score_opus":0.038221568517568846,"score_gpt":0.299599397122505,"score_spread":0.26137782860493614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300878904","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.053171616,0.0040637027,0.016674517,0.70352054,0.0057584113,0.033463754,0.0052626017,0.004377132,0.17370771],"genre_scores_gemma":[0.07628893,0.0005531607,0.0063087037,0.5617572,0.05619853,0.0009535192,0.007392991,0.0029255606,0.28762144],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99149936,0.00082306,0.0012950968,0.0022446606,0.0016316756,0.0025061325],"domain_scores_gemma":[0.99428064,0.001026678,0.00057291647,0.0028215041,0.0007806923,0.00051756506],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0016894463,0.0014984697,0.002038133,0.0013406762,0.00043885433,0.00024923895,0.0017473305,0.0019362149,0.000977074],"category_scores_gemma":[0.0005232854,0.0012341539,0.00078373903,0.0009070942,0.00044989097,0.00033238932,0.0007087036,0.007161238,0.0020421864],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011148325,0.000100863974,0.00016954656,0.00078636303,0.0013336455,0.009976199,0.00038352326,0.00001891625,0.0018936559,0.000013239158,0.9625097,0.021699533],"study_design_scores_gemma":[0.018568322,0.0025637904,0.0010225828,0.0007520859,0.0011951032,0.0005411821,0.00057830225,0.0007219301,0.000342186,0.00009944518,0.97200704,0.001608025],"about_ca_topic_score_codex":0.0003660616,"about_ca_topic_score_gemma":0.000014547513,"teacher_disagreement_score":0.14176337,"about_ca_system_score_codex":0.012581407,"about_ca_system_score_gemma":0.005570581,"threshold_uncertainty_score":0.99993616},"labels":[],"label_agreement":null},{"id":"W2304370660","doi":"10.1089/nat.2015.0593","title":"Considerations for the Characterization and Interpretation of Results Related to Alternative Complement Activation in Monkeys Associated with Oligonucleotide-Based Therapeutics","year":2016,"lang":"en","type":"review","venue":"Nucleic Acid Therapeutics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Oligonucleotide; Computational biology; Complement (music); Complement system; Alternative complement pathway; Mechanism (biology); Biology; Pharmacology; Medicine; Immunology; Biochemistry; Phenotype; DNA; Gene; Epistemology","score_opus":0.08239835438761318,"score_gpt":0.36816523813822527,"score_spread":0.2857668837506121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304370660","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027786452,0.6825738,0.17821264,0.036774956,0.0009235826,0.06628491,0.005997232,0.00055106386,0.00089538377],"genre_scores_gemma":[0.22531779,0.76890725,0.0014859088,0.0018397337,0.000075221564,0.0006529223,0.0013721574,0.00021667832,0.00013233899],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99746627,0.00035434283,0.0010195087,0.00043375604,0.00041029684,0.000315838],"domain_scores_gemma":[0.99553937,0.002541786,0.0008226092,0.00046513733,0.00055815344,0.000072941824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006602605,0.0003858353,0.0010219775,0.0004043924,0.00013404869,0.000049410733,0.00017366912,0.00027886333,0.000019275822],"category_scores_gemma":[0.0003359543,0.00022902482,0.00014052194,0.00050397194,0.00018691206,0.000102398226,0.000051347266,0.00042155373,0.000004878731],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010235275,0.00019630391,0.00003257495,0.0008370508,0.0018956875,0.000002894779,0.001985236,0.000027724387,0.0023299712,0.0007402053,0.000022817761,0.990906],"study_design_scores_gemma":[0.043080993,0.0091804825,0.005372962,0.11314818,0.01340718,0.000071761424,0.0010380408,0.1280533,0.013104476,0.00239968,0.66811866,0.0030242899],"about_ca_topic_score_codex":0.000011911732,"about_ca_topic_score_gemma":0.0000222159,"teacher_disagreement_score":0.9878817,"about_ca_system_score_codex":0.0006518739,"about_ca_system_score_gemma":0.0006128623,"threshold_uncertainty_score":0.9339361},"labels":[],"label_agreement":null},{"id":"W2312524572","doi":"10.1038/sj.leu.2402463","title":"Long-term outcome of allogeneic transplants in acute myeloid leukemia","year":2002,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myeloid leukemia; Medicine; Term (time); Leukemia; Transplantation; Oncology; Immunology; Hematology; Myeloid; Outcome (game theory); Internal medicine","score_opus":0.03850079750921362,"score_gpt":0.30823014051609526,"score_spread":0.26972934300688167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312524572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901299,0.0008059272,0.00013157321,0.0005261007,0.0001634663,0.00075307745,0.000055579352,0.00011422859,0.007320158],"genre_scores_gemma":[0.9879912,0.0013510373,0.0008145436,0.000710179,0.00016336759,0.00005676214,0.00008372008,0.00009301715,0.008736185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963938,0.00011136928,0.0010339075,0.0006650446,0.00081452075,0.0009813312],"domain_scores_gemma":[0.9982077,0.00016272663,0.00017610383,0.0009461786,0.00011987053,0.00038742696],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004167847,0.00042975624,0.0010077454,0.0005714845,0.00006291967,0.000020972027,0.00055156957,0.00044903855,0.0018869839],"category_scores_gemma":[0.0000996069,0.00038637442,0.0002935667,0.00075353094,0.00026478292,0.00019027959,0.00011660805,0.0010424034,0.00079750735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005689219,0.00016629128,0.9200006,0.00059615844,0.00032614355,0.00327975,0.0008194283,0.00007613788,0.058122437,0.0000905167,0.002191418,0.013762172],"study_design_scores_gemma":[0.010153369,0.00046999185,0.9532201,0.0004165073,0.00029927227,0.00094114285,0.0000495438,0.002281127,0.030709328,0.00003993553,0.0008564616,0.00056320423],"about_ca_topic_score_codex":0.0003125354,"about_ca_topic_score_gemma":0.00015255892,"teacher_disagreement_score":0.033219494,"about_ca_system_score_codex":0.00360509,"about_ca_system_score_gemma":0.0005076072,"threshold_uncertainty_score":0.9999805},"labels":[],"label_agreement":null},{"id":"W2314236616","doi":"10.1586/ehm.11.65","title":"Stem cells and beyond: report on the 40th Annual Scientific Meeting of the International Society of Experimental Hematology","year":2011,"lang":"en","type":"article","venue":"Expert Review of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Stem cell; Haematopoiesis; Hematology; Stem cell biology; Context (archaeology); Medicine; Internal medicine; Biology; Genetics; Gene","score_opus":0.03806977854366482,"score_gpt":0.3371279983015401,"score_spread":0.2990582197578753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314236616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78386,0.18586199,0.0000307159,0.010711825,0.0011463037,0.001805434,0.00003376894,0.000024373698,0.01652554],"genre_scores_gemma":[0.98653436,0.007408101,0.0028081094,0.0024216492,0.000045773035,0.00008890326,0.000009155486,0.000026881517,0.00065709447],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99805206,0.00015987581,0.0008111384,0.00031792582,0.00045398858,0.0002050333],"domain_scores_gemma":[0.9981223,0.0002588799,0.0005814691,0.00068675063,0.000298748,0.000051876803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012156388,0.000145025,0.00072408083,0.000055615466,0.000074080934,0.0000027383905,0.00042986064,0.000095292584,0.00025468803],"category_scores_gemma":[0.00015613924,0.00007691451,0.00025237942,0.00018518863,0.0011020564,0.000040430532,0.00037704437,0.0002065655,0.000004163815],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003805677,0.0015503941,0.013444266,0.009561319,0.0009758049,0.00021712194,0.021862064,1.3511635e-7,0.29932314,0.08325696,0.566754,0.0026742562],"study_design_scores_gemma":[0.0004334667,0.00015356112,0.00010586022,0.0024851537,0.000029392766,0.0021151674,0.0035389136,0.00003313687,0.9771915,0.00004993244,0.013791379,0.00007251017],"about_ca_topic_score_codex":0.000036933263,"about_ca_topic_score_gemma":0.0000011763627,"teacher_disagreement_score":0.67786837,"about_ca_system_score_codex":0.000055749137,"about_ca_system_score_gemma":0.00025624395,"threshold_uncertainty_score":0.40605727},"labels":[],"label_agreement":null},{"id":"W2315127558","doi":"10.1097/pai.0000000000000145","title":"De Novo Acute Myeloid Leukemia in Adults","year":2015,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Calgary Laboratory Services","funders":"Calgary Laboratory Services","keywords":"Myeloid leukemia; Karyotype; Epigenetics; Myeloid; Oncology; Progenitor cell; Leukemia; microRNA; Internal medicine; Medicine; Cancer research; Biology; Immunology; Stem cell; Chromosome; Genetics; Gene","score_opus":0.010496189533237596,"score_gpt":0.2817302396954806,"score_spread":0.271234050162243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315127558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96306676,0.0009463349,0.00089294347,0.00055184,0.000116267125,0.0006358797,0.000012051995,0.00013843288,0.033639494],"genre_scores_gemma":[0.989933,0.00006016106,0.00555224,0.002095052,0.00012740174,0.000365247,0.0002793903,0.00010972924,0.0014777556],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996968,0.00006159588,0.00057694054,0.0008251598,0.000477651,0.0010906955],"domain_scores_gemma":[0.997846,0.00004901931,0.00013905659,0.0012292379,0.00022506608,0.00051163766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005024372,0.0004332008,0.00069356425,0.00022000146,0.000056005814,0.00002256627,0.0005631193,0.00061411154,0.00019320434],"category_scores_gemma":[0.00028159405,0.0004750378,0.00015659671,0.0005650189,0.0004439387,0.00004503072,0.00033607244,0.0012944883,0.00034532478],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002223526,0.00010393483,0.00030850252,0.0000821112,0.00014825616,0.0054683937,0.0003867916,0.000053925633,0.9861098,0.00026014345,0.003601547,0.0012530526],"study_design_scores_gemma":[0.014732811,0.0003510777,0.001268511,0.000121224904,0.00017411807,0.007074307,0.0006000056,0.0002728362,0.97220653,0.00065307855,0.0018366955,0.000708807],"about_ca_topic_score_codex":0.00031357235,"about_ca_topic_score_gemma":3.7425923e-7,"teacher_disagreement_score":0.03216174,"about_ca_system_score_codex":0.006076452,"about_ca_system_score_gemma":0.0028087115,"threshold_uncertainty_score":0.9997701},"labels":[],"label_agreement":null},{"id":"W2315481411","doi":"10.1158/1538-7445.am2012-1696","title":"Abstract 1696: Targeting EVI1-overexpressing AML with darinaparsin","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McGill University","funders":"","keywords":"Arsenic trioxide; Medicine; Internal medicine; Cancer research; Bone marrow; Oncology; Biology; Apoptosis","score_opus":0.10227864170550705,"score_gpt":0.4302239543152163,"score_spread":0.32794531260970927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315481411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9607218,0.0045546014,0.00006262739,0.002191164,0.000119447104,0.00074637646,0.000014482289,0.00009086285,0.03149867],"genre_scores_gemma":[0.992327,0.00037880568,0.0014870274,0.00017389511,0.0015712491,0.00020412674,0.00002666015,0.00009528002,0.0037360045],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954322,0.00018061815,0.00027921793,0.00046123215,0.0017658689,0.0018808577],"domain_scores_gemma":[0.9975428,0.00035801192,0.000061827806,0.0006267001,0.0006197826,0.00079086126],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026455105,0.0002172107,0.00035461638,0.00036116253,0.00042764813,0.000112949674,0.0003307046,0.00016070747,0.0023701529],"category_scores_gemma":[0.0004902252,0.00016337374,0.00006923377,0.0008687544,0.0004915675,0.00047553427,0.00027214587,0.0019139872,0.00043013663],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025759374,0.00045565708,0.13297045,0.0011008424,0.0002741669,0.00033035595,0.0023138602,0.000032032338,0.6669228,0.00049040245,0.15053232,0.042001154],"study_design_scores_gemma":[0.00676522,0.000802641,0.21760431,0.0027593558,0.00009357141,0.00025154947,0.003835309,0.0002555632,0.36812082,0.00012148344,0.39846054,0.0009296324],"about_ca_topic_score_codex":0.0012481041,"about_ca_topic_score_gemma":0.00002364242,"teacher_disagreement_score":0.29880202,"about_ca_system_score_codex":0.0016015376,"about_ca_system_score_gemma":0.0014319234,"threshold_uncertainty_score":0.99854183},"labels":[],"label_agreement":null},{"id":"W2315989994","doi":"10.1038/sj.onc.1205328","title":"Differentiation induction as a treatment for hematologic malignancies","year":2002,"lang":"en","type":"article","venue":"Oncogene","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"National Cancer Institute","keywords":"Biology; Hematologic Neoplasms; Carcinogenesis; Cancer research; Hematologic malignancy; Immunology; Cancer; Internal medicine; Genetics","score_opus":0.08143655902129922,"score_gpt":0.33108228067720535,"score_spread":0.24964572165590615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315989994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99249315,0.0005075888,0.00063411816,0.0024995946,0.000101463134,0.00072425185,0.000008586665,0.00007227143,0.002958999],"genre_scores_gemma":[0.9824496,0.00034382043,0.001313573,0.00017576502,0.00022761204,0.00026214952,0.00006562715,0.000018807865,0.015143071],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99925977,0.000020565623,0.00014126369,0.00020177971,0.00015689268,0.00021974296],"domain_scores_gemma":[0.9995459,0.00004339755,0.000045404122,0.000194851,0.00008375429,0.000086700784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056361852,0.00010836133,0.00020335715,0.000090013564,0.00007971049,0.000012692997,0.00003990319,0.00009398062,0.00057095074],"category_scores_gemma":[0.00008826669,0.00007925648,0.00009234203,0.00012091144,0.000029080442,0.000043821536,0.000013977256,0.000050882078,0.000287142],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002966176,0.0010115823,0.004015619,0.0001504663,0.0002934621,0.00009312433,0.0009215449,0.000005099306,0.8373424,0.001187587,0.014122352,0.14056017],"study_design_scores_gemma":[0.009916327,0.0046673776,0.004987222,0.000092941504,0.00035325048,0.00092709885,0.0004191009,0.004714932,0.89290404,0.0008647092,0.079817064,0.00033591315],"about_ca_topic_score_codex":0.000034633023,"about_ca_topic_score_gemma":0.000007189428,"teacher_disagreement_score":0.14022425,"about_ca_system_score_codex":0.00052837195,"about_ca_system_score_gemma":0.000049279424,"threshold_uncertainty_score":0.62515104},"labels":[],"label_agreement":null},{"id":"W2317406171","doi":"10.1097/00043426-200206000-00005","title":"A Practical, Comprehensive Classification for Pediatric Myelodysplastic Syndromes: The CCC System","year":2002,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Chronic myelomonocytic leukemia; Cytogenetics; Schema (genetic algorithms); Juvenile myelomonocytic leukemia; Pediatrics; Pathology; Bone marrow; Stem cell","score_opus":0.1296714298412195,"score_gpt":0.3915200461978638,"score_spread":0.2618486163566443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317406171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87530667,0.012635445,0.022019327,0.078116745,0.0038978222,0.0039493633,0.00004213167,0.00018571994,0.0038467923],"genre_scores_gemma":[0.97383344,0.0044600554,0.01589767,0.0006962687,0.0045433063,0.00015029604,0.0000067505275,0.00007150565,0.00034072922],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9957597,0.0006809557,0.0017090188,0.00038863588,0.00068656803,0.00077507034],"domain_scores_gemma":[0.98653257,0.009043967,0.0018100865,0.0004811753,0.0016580342,0.0004741892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015034123,0.00032613447,0.0014018314,0.0008639083,0.00028722183,0.00003498812,0.0004524196,0.00068027125,0.00016035422],"category_scores_gemma":[0.0042509693,0.00021196397,0.00041890587,0.0010053748,0.00025413785,0.00020901031,0.00010968334,0.0016017432,0.00034007945],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021736675,0.0021834057,0.019209871,0.0033385656,0.0009519474,0.0069742235,0.001360451,0.000029384377,0.00089169544,0.009369396,0.95092684,0.002590551],"study_design_scores_gemma":[0.037701804,0.028738651,0.021400405,0.0002803058,0.017730523,0.50025374,0.022153882,0.040385958,0.00030449027,0.0005439779,0.32896942,0.0015368133],"about_ca_topic_score_codex":0.0000033671768,"about_ca_topic_score_gemma":0.00000137225,"teacher_disagreement_score":0.6219574,"about_ca_system_score_codex":0.0014290188,"about_ca_system_score_gemma":0.002002579,"threshold_uncertainty_score":0.86436397},"labels":[],"label_agreement":null},{"id":"W2320984091","doi":"10.1158/1535-7163.targ-13-c225","title":"Abstract C225: IL1RAP as functionally relevant target for stem-cell directed therapy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Myeloid leukemia; Medicine; Stem cell; Myelodysplastic syndromes; CD34; Cancer research; Progenitor cell; clone (Java method); Internal medicine; Immunology; Biology; Bone marrow; Genetics","score_opus":0.022164490800552113,"score_gpt":0.28871054114473743,"score_spread":0.2665460503441853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320984091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823254,0.010373617,0.00095309113,0.0025254628,0.00026194332,0.002542041,0.00007708301,0.0001708485,0.00077056524],"genre_scores_gemma":[0.9786838,0.009196555,0.0025167041,0.0038927537,0.00013120915,0.0012032412,0.000116165626,0.00020593114,0.0040536067],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99697953,0.00009890542,0.00058244227,0.00077037635,0.0006880165,0.00088074955],"domain_scores_gemma":[0.99821913,0.00029946014,0.00017724458,0.0005575624,0.00043825092,0.00030837132],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030218644,0.00048760636,0.00068283896,0.00031285046,0.00015170778,0.00014274473,0.00027952372,0.0003547422,0.00058986346],"category_scores_gemma":[0.000023027167,0.00044384107,0.00019262063,0.0004935002,0.00020837542,0.00018423461,0.00008017213,0.0007055786,0.000088725676],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018987816,0.00031421444,0.006340803,0.00039632857,0.0016846186,0.00037828193,0.0005703396,0.0002453563,0.89410913,0.0001026055,0.002006276,0.091953285],"study_design_scores_gemma":[0.055354625,0.008839925,0.2772216,0.0012799734,0.0016310096,0.00092800695,0.0012033919,0.031365138,0.4062245,0.0072255307,0.20463495,0.004091374],"about_ca_topic_score_codex":0.0011436545,"about_ca_topic_score_gemma":0.00007073732,"teacher_disagreement_score":0.4878846,"about_ca_system_score_codex":0.0010545081,"about_ca_system_score_gemma":0.0014006635,"threshold_uncertainty_score":0.99980134},"labels":[],"label_agreement":null},{"id":"W2322089364","doi":"10.1038/sj.leu.2401821","title":"The PEBP2β/CBFβ-SMMHC chimeric protein is localized both in the cell membrane and nuclear subfractions of leukemic cells carrying chromosomal inversion 16","year":2000,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Cytoplasm; Fusion protein; Biology; Molecular biology; Gene; Subcellular localization; DNA; Nuclear localization sequence; Cell biology; Genetics","score_opus":0.010142556058730542,"score_gpt":0.24397304628322378,"score_spread":0.23383049022449323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322089364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798968,0.00059404754,0.000008838181,0.0023536577,0.000050179977,0.0012231262,0.000017187502,0.000050843337,0.01580536],"genre_scores_gemma":[0.99228805,0.001737549,0.00019265889,0.0009748067,0.00014909866,0.00005711781,0.000010413626,0.000063016974,0.004527293],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99741495,0.00031225992,0.0005028091,0.00045658086,0.0006878347,0.0006255864],"domain_scores_gemma":[0.998466,0.00036986775,0.00015021091,0.0007764178,0.00006670439,0.0001708133],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006452523,0.00028684118,0.00042867215,0.00015782072,0.00039885024,0.00005296917,0.00044240538,0.00021997397,0.0013128442],"category_scores_gemma":[0.00006319848,0.00016879218,0.000144992,0.0006886424,0.0005132068,0.0001751681,0.00010578647,0.0008960622,0.00019467855],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016574435,0.00013793702,0.00068009476,0.00039111866,0.00009342934,0.00013667792,0.004574597,0.00006604699,0.9599624,0.00014162027,0.01474416,0.017414436],"study_design_scores_gemma":[0.026506951,0.0016484897,0.0075987177,0.0013104227,0.00042663884,0.00058672944,0.013506534,0.022314405,0.60969484,0.00038411564,0.31479818,0.0012239973],"about_ca_topic_score_codex":0.0020899472,"about_ca_topic_score_gemma":0.000044380206,"teacher_disagreement_score":0.35026762,"about_ca_system_score_codex":0.0015408694,"about_ca_system_score_gemma":0.0007756401,"threshold_uncertainty_score":0.9996001},"labels":[],"label_agreement":null},{"id":"W2323809396","doi":"10.1038/sj.leu.2401975","title":"Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML)","year":2000,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Progenitor cell; Haematopoiesis; Leukemia; Biology; Immunology; Stem cell; Cancer research; Internal medicine; Medicine; Cell biology","score_opus":0.009751766853521653,"score_gpt":0.2553992964289454,"score_spread":0.2456475295754237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323809396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874416,0.0002050484,0.000070412134,0.00009528398,0.000071666684,0.0024924884,0.00040842398,0.00015984758,0.009055219],"genre_scores_gemma":[0.99081945,0.00019812855,0.0046971086,0.0003732215,0.00024447084,0.0002325993,0.00072700233,0.00014071842,0.002567289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957519,0.00016298475,0.00071006163,0.0008541109,0.0012513588,0.001269586],"domain_scores_gemma":[0.99729645,0.00019565185,0.00025030383,0.0009088806,0.00066149834,0.0006871959],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013967195,0.00055632676,0.0009976557,0.00022335586,0.00017659951,0.000040998788,0.000343573,0.00034114963,0.0013118485],"category_scores_gemma":[0.00010757713,0.00042374193,0.00018948592,0.00057867245,0.0005381064,0.00026035987,0.00011038844,0.00087704125,0.0003422445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038854264,0.0024228247,0.7083043,0.00095497974,0.009735155,0.003141551,0.040992312,0.00044829893,0.048685413,0.00044669653,0.010098293,0.13591592],"study_design_scores_gemma":[0.037232257,0.007487253,0.61313,0.001099146,0.0021419665,0.0002900222,0.001509183,0.00082454877,0.32202137,0.00047400736,0.0118984645,0.0018917931],"about_ca_topic_score_codex":0.0014059378,"about_ca_topic_score_gemma":0.00005446154,"teacher_disagreement_score":0.27333593,"about_ca_system_score_codex":0.005200689,"about_ca_system_score_gemma":0.0056257145,"threshold_uncertainty_score":0.9998214},"labels":[],"label_agreement":null},{"id":"W2324275148","doi":"10.1097/01.cot.0000427345.49043.c6","title":"ASH Annual Meeting","year":2013,"lang":"en","type":"article","venue":"Oncology Times","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Environmental science","score_opus":0.01635732550844187,"score_gpt":0.32616471655667895,"score_spread":0.30980739104823707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324275148","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34409449,0.00021467905,0.000017593424,0.018291378,0.00010957798,0.00039109794,0.0000033039064,0.00011317404,0.6367647],"genre_scores_gemma":[0.71407133,0.00007476455,0.013082374,0.0045475103,0.0007694622,0.00014912165,0.000029737941,0.0000457563,0.26722994],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99902165,0.000081106766,0.00016498785,0.00020175836,0.00016689014,0.00036359785],"domain_scores_gemma":[0.99915284,0.00022563893,0.000042186042,0.00021790816,0.00018714915,0.00017426634],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002759565,0.00009432295,0.00025375982,0.000096520824,0.000066327666,0.000009802264,0.00011471965,0.0001822576,0.006496511],"category_scores_gemma":[0.00032516994,0.00007502558,0.00005272026,0.00013359434,0.0001508527,0.00009163803,0.00011498306,0.0003353538,0.007364225],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005194681,0.000107812215,0.007961196,0.000019857818,0.000074412696,0.00013675973,0.00042232228,0.0000014171925,0.01109216,0.0002717306,0.916635,0.063225426],"study_design_scores_gemma":[0.0026171217,0.0012870391,0.037577715,0.000040593797,0.00006331703,0.00045149046,0.0015007528,0.0007459948,0.0048533897,0.0005845232,0.9500937,0.00018439906],"about_ca_topic_score_codex":0.00019932444,"about_ca_topic_score_gemma":0.0000068700333,"teacher_disagreement_score":0.36997685,"about_ca_system_score_codex":0.0002977261,"about_ca_system_score_gemma":0.00044439896,"threshold_uncertainty_score":0.9944117},"labels":[],"label_agreement":null},{"id":"W2325667248","doi":"10.1097/mph.0000000000000543","title":"Do Not Forget the Glycophorin A: An Unusual Case of Myeloid Sarcoma","year":2016,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Myeloid sarcoma; Medicine; Glycophorin; Myeloid leukemia; Sarcoma; Biopsy; Pathology; Bone marrow; Myeloid; Leukemia; Presentation (obstetrics); Cancer research; Immunology; Radiology; Antigen","score_opus":0.03891957503888419,"score_gpt":0.3669613623087706,"score_spread":0.32804178726988636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325667248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814421,0.0014408214,0.0005268086,0.014353114,0.0007316927,0.0003853825,0.000021268053,0.000020363732,0.0010784436],"genre_scores_gemma":[0.99232036,0.0015016138,0.002947703,0.0005209851,0.0023432272,0.000013711764,0.0000015347807,0.00004460656,0.0003062384],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9960171,0.00079765497,0.0015926469,0.0003199802,0.00055837474,0.0007142465],"domain_scores_gemma":[0.99383205,0.0027799015,0.0012881231,0.00061921094,0.0009339929,0.0005466946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031620741,0.00027869354,0.0013811638,0.00074780214,0.00013027062,0.000009945105,0.0006039144,0.0005925675,0.0001863703],"category_scores_gemma":[0.0021725225,0.00014140514,0.00034597403,0.00064364757,0.0005357735,0.00023160531,0.00023025516,0.0010729338,0.000055637614],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019778915,0.004959531,0.20033164,0.0008558742,0.0018907732,0.24968913,0.005714281,0.000007533133,0.07119025,0.014574938,0.19864938,0.23235774],"study_design_scores_gemma":[0.02735058,0.023335379,0.011554949,0.0000985157,0.0018368637,0.8302031,0.0048615136,0.000089546586,0.025022136,0.0021528406,0.07291108,0.00058349076],"about_ca_topic_score_codex":0.000047992533,"about_ca_topic_score_gemma":0.00004505056,"teacher_disagreement_score":0.58051395,"about_ca_system_score_codex":0.00071774033,"about_ca_system_score_gemma":0.0032621406,"threshold_uncertainty_score":0.57868975},"labels":[],"label_agreement":null},{"id":"W2325916270","doi":"10.1158/1538-7445.am2012-1488","title":"Abstract 1488: Role of niche requirements in transient leukemia of Down syndrome","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children","funders":"","keywords":"Haematopoiesis; GATA1; Bone marrow; Stromal cell; Leukemia; Trisomy; Fetus; Extramedullary hematopoiesis; Stem cell; Cancer research; CD34; Myeloid leukemia; Myeloid; Biology; Pathology; Medicine; Immunology; Cell biology; Genetics; Pregnancy","score_opus":0.090553124337799,"score_gpt":0.42018626079575644,"score_spread":0.32963313645795744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325916270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851915,0.0036270437,0.0000024978415,0.00037100582,0.00006526034,0.0008440439,0.000033886394,0.000012552868,0.009852165],"genre_scores_gemma":[0.9979551,0.0007955858,0.00010538345,0.000026100677,0.00010048498,0.00017001342,0.0000135898,0.000039555383,0.0007942035],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9962127,0.00016259175,0.0005700437,0.0003024354,0.0016783699,0.0010738608],"domain_scores_gemma":[0.99828583,0.00021995805,0.00008398629,0.0006099299,0.00043224805,0.00036802038],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027425617,0.00014949018,0.00049640617,0.0006739324,0.00004308357,0.0000071443897,0.00037537888,0.00017855714,0.0014360112],"category_scores_gemma":[0.00026458295,0.00012956608,0.00010524952,0.0011141975,0.00041197435,0.00019378186,0.00014870644,0.0010298823,0.00006983344],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010099197,0.0005201112,0.09893095,0.0010184414,0.00012972117,0.00007213518,0.0020442365,0.000028507526,0.8820254,0.00019349802,0.0026912307,0.011335817],"study_design_scores_gemma":[0.0030694627,0.000478667,0.68189627,0.00075407047,0.000023865497,0.000036200247,0.0011068663,0.00006285794,0.30651864,0.00009385941,0.005808788,0.00015046561],"about_ca_topic_score_codex":0.0037833676,"about_ca_topic_score_gemma":0.00013544176,"teacher_disagreement_score":0.5829653,"about_ca_system_score_codex":0.0022271767,"about_ca_system_score_gemma":0.0017954966,"threshold_uncertainty_score":0.9994768},"labels":[],"label_agreement":null},{"id":"W2325939231","doi":"10.1182/blood-2016-03-705053","title":"Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Deutsche Krebshilfe; Université de Montréal; Government of Canada; Génome Québec; Compute Canada; Canadian Cancer Society Research Institute; Genome Canada","keywords":"CEBPA; Cancer research; Gene; Biology; Mutation; Genetics; Medicine","score_opus":0.016148082189855677,"score_gpt":0.28136002797993775,"score_spread":0.26521194579008206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325939231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962912,0.00006206309,0.00028647832,0.0021818837,0.000074289,0.0006685039,0.000057223082,0.000045294797,0.0003330189],"genre_scores_gemma":[0.99821836,0.00003095865,0.0010902736,0.00009037939,0.00012743978,0.000029542667,0.000039216324,0.000024444524,0.00034936325],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876803,0.0001153614,0.0003318681,0.00029909957,0.00023244739,0.0002531828],"domain_scores_gemma":[0.99897105,0.00023006246,0.00010236081,0.00026226882,0.0002190434,0.00021522994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048809568,0.00013443096,0.00028506122,0.000217998,0.000044144927,0.0000095030055,0.000049332968,0.00008683619,0.000043598404],"category_scores_gemma":[0.00046960026,0.000100785735,0.000056951,0.00026319065,0.00012066757,0.0000814156,0.00010429034,0.000136454,0.000067066736],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022216384,0.0002316192,0.0105553325,0.0000820191,0.00008889485,0.00004381259,0.0009712338,4.5756826e-7,0.9782412,0.000041787767,0.00050303567,0.009018442],"study_design_scores_gemma":[0.008766654,0.0007293932,0.16739134,0.0005457537,0.00022013561,0.0002372113,0.000526968,0.00006532443,0.82087064,0.00012101512,0.00032028486,0.00020528297],"about_ca_topic_score_codex":0.00008543065,"about_ca_topic_score_gemma":0.00006308794,"teacher_disagreement_score":0.15737057,"about_ca_system_score_codex":0.00022216637,"about_ca_system_score_gemma":0.00017842426,"threshold_uncertainty_score":0.4109923},"labels":[],"label_agreement":null},{"id":"W2326247416","doi":"10.1097/mph.0b013e31829d46f3","title":"Acute Lymphoblastic Leukemia With Pancytopenia at Presentation","year":2013,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital","funders":"","keywords":"Pancytopenia; Medicine; Lymphoblastic Leukemia; Incidence (geometry); Pediatrics; Presentation (obstetrics); Internal medicine; Multivariate analysis; Leukemia; Acute leukemia; Gastroenterology; Surgery; Bone marrow","score_opus":0.017140499231816837,"score_gpt":0.3151692444280704,"score_spread":0.2980287451962536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326247416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876402,0.0008774627,0.00092779024,0.00572955,0.00037989081,0.0007114395,0.0000037738628,0.000035824924,0.0036940519],"genre_scores_gemma":[0.98254955,0.001405386,0.011194482,0.00085652916,0.0014530665,0.00006991128,0.0000132218665,0.000063978885,0.0023938701],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9969453,0.00029014505,0.0011027947,0.00031732034,0.00064732524,0.00069711753],"domain_scores_gemma":[0.99612033,0.00090581866,0.0010123313,0.00033632046,0.0010198874,0.00060531846],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00055693486,0.00028563797,0.0012092122,0.0006770153,0.00012533217,0.000024147848,0.0003518678,0.00049552816,0.0011880015],"category_scores_gemma":[0.00045658424,0.00019460592,0.0001947552,0.0006283416,0.00024298312,0.00036025458,0.00017428424,0.0008861362,0.00088400545],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008466671,0.001015893,0.3613893,0.0005994481,0.002164366,0.021765856,0.0018400977,0.00009860543,0.019925227,0.0005092314,0.5706105,0.011614766],"study_design_scores_gemma":[0.09350865,0.04481585,0.21850532,0.0002712883,0.0110657,0.5033553,0.003197613,0.003662546,0.023914387,0.0018634852,0.09388007,0.0019597332],"about_ca_topic_score_codex":0.00004445886,"about_ca_topic_score_gemma":0.000018756242,"teacher_disagreement_score":0.4815895,"about_ca_system_score_codex":0.0035222175,"about_ca_system_score_gemma":0.00483166,"threshold_uncertainty_score":0.9998939},"labels":[],"label_agreement":null},{"id":"W2328622211","doi":"10.1016/j.exphem.2014.07.246","title":"Critical modulation of hematopoietic lineage fate by the PAR/bZIP transcription factor hepatic leukemia factor","year":2014,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council","keywords":"Haematopoiesis; Biology; Progenitor cell; Cell biology; Transcription factor; Stem cell; Multipotent Stem Cell; Immunology; Myeloid; Cancer research; Genetics; Gene","score_opus":0.024813366040090948,"score_gpt":0.33063134947577233,"score_spread":0.3058179834356814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328622211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99026024,0.0015208025,0.005325442,0.0011504457,0.00025765237,0.0006363305,0.000026449472,0.00008412859,0.0007384793],"genre_scores_gemma":[0.99851704,0.000017092603,0.00060465035,0.00035258677,0.00008666911,0.00009392116,0.00007039812,0.000047513357,0.00021013044],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978288,0.00026817663,0.0005891153,0.00039392363,0.0004475611,0.0004724556],"domain_scores_gemma":[0.9986766,0.00041598885,0.00010583781,0.0004992769,0.00010534689,0.00019696176],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017106476,0.00026427372,0.00062361424,0.00010197613,0.00013146398,0.000018701861,0.00021541686,0.00024844098,0.00093375024],"category_scores_gemma":[0.00024883993,0.00019078527,0.00017317048,0.00016224312,0.00052337674,0.00013487662,0.000063764666,0.0003759882,0.00011123724],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035032598,0.00037070503,0.0044649295,0.0003006011,0.00007584016,0.000018503626,0.0022921353,0.0000031766322,0.9752066,0.014231588,0.0020415795,0.0006439979],"study_design_scores_gemma":[0.0017695385,0.0005758057,0.0033078233,0.00007246058,0.000030552408,0.00032759926,0.00050054234,0.010997137,0.9815461,0.00017116022,0.0005250403,0.00017624978],"about_ca_topic_score_codex":0.00009855949,"about_ca_topic_score_gemma":0.000004051311,"teacher_disagreement_score":0.014060428,"about_ca_system_score_codex":0.00035482383,"about_ca_system_score_gemma":0.000107650434,"threshold_uncertainty_score":0.99997956},"labels":[],"label_agreement":null},{"id":"W2333006871","doi":"10.1038/modpathol.2016.67","title":"Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms","year":2016,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"National Cancer Institute; European Hematology Association","keywords":"clone (Java method); Hematopathology; Medicine; Myeloid; Cytotoxic T cell; Pathology; Internal medicine; Biology; Cytogenetics","score_opus":0.016285385016970987,"score_gpt":0.2491721522021818,"score_spread":0.2328867671852108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333006871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917963,0.00016242007,0.0010165767,0.0046375366,0.000082273415,0.0016756168,0.00007537291,0.00024481295,0.00030909196],"genre_scores_gemma":[0.99545556,0.00016999803,0.0005107845,0.0013429521,0.000030332003,0.00016698801,0.00019925652,0.00017832029,0.001945804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959344,0.000533084,0.00065206044,0.000965214,0.00072780834,0.0011873841],"domain_scores_gemma":[0.9978545,0.0003031632,0.00030234436,0.0008289068,0.00044863563,0.00026250168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006009379,0.00056543667,0.0009424786,0.0005028052,0.00016187639,0.000023153782,0.00035487444,0.00062249857,0.00044626626],"category_scores_gemma":[0.0002417223,0.0003201716,0.000104879095,0.0007176811,0.0004697019,0.00023009213,0.00011099583,0.0007932131,0.000074431715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017651238,0.0014470749,0.7993545,0.000024810106,0.0009640188,0.0012729836,0.005424194,0.000072150106,0.14238212,0.00004804258,0.0004851074,0.030873755],"study_design_scores_gemma":[0.050140817,0.0065721855,0.93447745,0.00030639462,0.0001009895,0.00013680362,0.00010195379,0.0016066174,0.0053330646,0.0001615982,0.0003533338,0.0007087745],"about_ca_topic_score_codex":0.000087853485,"about_ca_topic_score_gemma":0.00030060078,"teacher_disagreement_score":0.13704905,"about_ca_system_score_codex":0.0006379239,"about_ca_system_score_gemma":0.00049313094,"threshold_uncertainty_score":0.999925},"labels":[],"label_agreement":null},{"id":"W2333656541","doi":"10.1038/sj.leu.2402773","title":"Cytogenetic and molecular heterogeneity of 7q36/12p13 rearrangements in childhood AML","year":2002,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"NIH Clinical Center; University of Calgary","keywords":"Breakpoint; ETV6; Fusion transcript; Biology; Genetics; Chromosomal translocation; Gene rearrangement; Chromosomal rearrangement; Myeloid leukemia; Alu element; Gene duplication; Gene; Chromosome; Cancer research; Karyotype; Genome; Human genome","score_opus":0.021484259173320305,"score_gpt":0.27737966425519384,"score_spread":0.25589540508187353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333656541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922662,0.002326659,0.00003422254,0.0003480028,0.000026653328,0.00046526472,0.000008174549,0.000027024154,0.00449784],"genre_scores_gemma":[0.99754953,0.00059365784,0.0009956601,0.00042121683,0.00004100282,0.00002482916,0.000008951338,0.000034275166,0.0003308782],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984963,0.000072519586,0.00032232952,0.0003528712,0.00037508106,0.00038091317],"domain_scores_gemma":[0.9992008,0.000033501787,0.00006281798,0.00046635116,0.000054935033,0.000181545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018691254,0.00017074154,0.0003569637,0.00022322721,0.000027973669,0.000010596965,0.00014209509,0.00013826933,0.00018737193],"category_scores_gemma":[0.00010664798,0.00016142915,0.00007068208,0.00034447672,0.00012299212,0.000048046637,0.00012654398,0.00031068688,0.00006387907],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028447516,0.00063626026,0.40595314,0.0007508132,0.00039791886,0.0013606254,0.0020283903,0.00011046524,0.5289088,0.00016364094,0.0047559217,0.05464953],"study_design_scores_gemma":[0.008835658,0.00059409306,0.783032,0.0003031857,0.00010028288,0.00023079035,0.00010060233,0.002618458,0.20125747,0.0001330498,0.0024607203,0.00033371386],"about_ca_topic_score_codex":0.00016485242,"about_ca_topic_score_gemma":0.000019410814,"teacher_disagreement_score":0.37707883,"about_ca_system_score_codex":0.00046257506,"about_ca_system_score_gemma":0.00012106705,"threshold_uncertainty_score":0.658289},"labels":[],"label_agreement":null},{"id":"W2334189786","doi":"10.1016/j.exphem.2016.04.001","title":"GFI136N as a therapeutic and prognostic marker for myelodysplastic syndrome","year":2016,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"Canadian Institutes of Health Research; Deutsche Krebshilfe; Leukemia and Lymphoma Society","keywords":"Myeloid leukemia; Oncology; Internal medicine; Allele; Medicine; International Prognostic Scoring System; Bone marrow; Myelodysplastic syndromes; Stem cell; Leukemia; Immunology; Cancer research; Biology; Genetics; Gene","score_opus":0.02033244734453484,"score_gpt":0.3284593388528063,"score_spread":0.3081268915082715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334189786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98665005,0.0064143934,0.0007971286,0.0028935447,0.000188382,0.0014460472,0.0000107289325,0.00010004273,0.0014996908],"genre_scores_gemma":[0.99513805,0.00003589852,0.0010169005,0.0005192961,0.000041116647,0.0005703418,0.000007689736,0.000049031238,0.0026216847],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986362,0.000053125394,0.0002353078,0.00041287226,0.00017032851,0.0004921847],"domain_scores_gemma":[0.99880713,0.0006312426,0.000047267764,0.00024941788,0.000047401492,0.00021751717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012327865,0.00019791625,0.00041010842,0.00012449069,0.0000853469,0.000011391027,0.000096730575,0.00014709267,0.000832225],"category_scores_gemma":[0.00017865784,0.00012674571,0.000070458096,0.00008447996,0.00032869985,0.0000725849,0.000103159604,0.00009962056,0.00029938086],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009009935,0.0018351964,0.12931402,0.001064843,0.001305183,0.0038215267,0.0013481545,7.7748055e-8,0.5493084,0.27848116,0.008439115,0.01607237],"study_design_scores_gemma":[0.02716727,0.010849576,0.052645735,0.0009027124,0.00027903344,0.09557699,0.0014758784,0.00045217582,0.78707755,0.005808127,0.016742542,0.0010224109],"about_ca_topic_score_codex":0.00000708387,"about_ca_topic_score_gemma":8.271052e-7,"teacher_disagreement_score":0.272673,"about_ca_system_score_codex":0.00016207415,"about_ca_system_score_gemma":0.00013780974,"threshold_uncertainty_score":0.91122806},"labels":[],"label_agreement":null},{"id":"W2334501021","doi":"10.1158/1538-7445.am2013-2989","title":"Abstract 2989: Loss of methylation in a regulatory region of BCL2 in MDS/AML.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myelodysplastic syndromes; DNA methylation; Myeloid leukemia; Bone marrow; Cancer research; Methylation; Biology; International Prognostic Scoring System; Leukemia; Azacitidine; Oncology; Internal medicine; Medicine; Immunology; Genetics; Gene; Gene expression","score_opus":0.08747754957051372,"score_gpt":0.4177919529338563,"score_spread":0.33031440336334256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334501021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99248034,0.0010625905,0.000007782741,0.00200416,0.0000311296,0.0010982531,0.0000039341185,0.000009119848,0.0033027176],"genre_scores_gemma":[0.9976254,0.0007934158,0.000100902245,0.000024567287,0.00008545674,0.0002442304,0.000008032724,0.000028989873,0.0010890086],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972654,0.00024595586,0.0005326802,0.00032605638,0.0010855049,0.0005444011],"domain_scores_gemma":[0.9980718,0.000379825,0.00009682461,0.00055431935,0.000746703,0.00015053403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020951144,0.00010922979,0.0004035008,0.001164111,0.000023004843,0.000008935569,0.0002532773,0.00019344392,0.0006602432],"category_scores_gemma":[0.0006410984,0.00009776925,0.0000614782,0.0014689704,0.00043921944,0.00019494588,0.00012554218,0.0009608185,0.000045868313],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014275651,0.0004360116,0.32759255,0.0019546768,0.000066671164,0.00024083312,0.002265053,0.00017732881,0.5949247,0.0006590553,0.0106471535,0.05960841],"study_design_scores_gemma":[0.002563733,0.00020095194,0.82624346,0.00082896405,0.0000043683553,0.000008661253,0.0005441376,0.00035690493,0.16759332,0.0009568975,0.00060245773,0.000096152144],"about_ca_topic_score_codex":0.01613294,"about_ca_topic_score_gemma":0.0006155645,"teacher_disagreement_score":0.4986509,"about_ca_system_score_codex":0.0012375718,"about_ca_system_score_gemma":0.0012774448,"threshold_uncertainty_score":0.99041873},"labels":[],"label_agreement":null},{"id":"W2336690489","doi":"10.1111/bjh.14093","title":"Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the <scp>NOPHO</scp>‐<scp>AML</scp> 2004 study","year":2016,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"Stiftelsen Assar Gabrielssons Fond","keywords":"Flow cytometry; Myeloid leukaemia; Minimal residual disease; Myeloid; Residual; Disease; Medicine; Immunology; Oncology; Cancer research; Internal medicine; Leukemia; Computer science","score_opus":0.012338223372052443,"score_gpt":0.26754120234998485,"score_spread":0.2552029789779324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336690489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932238,0.0027260918,0.000086692235,0.00057555723,0.0005038503,0.001148249,0.0015573218,0.000032245942,0.00014618729],"genre_scores_gemma":[0.99756587,0.0009880139,0.0002874977,0.00012733508,0.00025345388,0.000023773067,0.000029468098,0.00009526228,0.0006293403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99214315,0.0014533661,0.002505826,0.00069860934,0.0021902332,0.0010087934],"domain_scores_gemma":[0.9934481,0.0020630222,0.0015216646,0.0009857866,0.0011459837,0.00083549356],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024909633,0.00043853564,0.0019116227,0.00085761957,0.00013091836,0.00004248963,0.0013563909,0.00047282892,0.000043302756],"category_scores_gemma":[0.0130246775,0.00032749062,0.00038129493,0.0011274982,0.00066763384,0.00039093607,0.000503688,0.0015862299,0.000011377095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029051057,0.009634334,0.72344023,0.0005421722,0.0035073282,0.06510905,0.006550867,0.00002980518,0.051390294,0.0000146019265,0.12915854,0.0077176727],"study_design_scores_gemma":[0.031478405,0.0029502525,0.89905715,0.0015470053,0.0006440002,0.030854372,0.0029291455,0.000040337887,0.029819895,0.00016638463,0.00039958465,0.00011344124],"about_ca_topic_score_codex":0.00036629612,"about_ca_topic_score_gemma":0.00038514458,"teacher_disagreement_score":0.17561695,"about_ca_system_score_codex":0.00046079865,"about_ca_system_score_gemma":0.0021939566,"threshold_uncertainty_score":0.9999177},"labels":[],"label_agreement":null},{"id":"W2337260374","doi":"10.1111/bjh.14076","title":"Economic impact of genomic diagnostics for intermediate‐risk acute myeloid leukaemia","year":2016,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Terry Fox Research Institute; Canadian Centre for Applied Research in Cancer Control; Vancouver General Hospital; Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Simon Fraser University; BC Cancer Agency","funders":"Canadian Cancer Society; European Society for Medical Oncology; Genome British Columbia; Canadian Centre for Applied Research in Cancer Control","keywords":"Transplantation; Medicine; Quality of life (healthcare); Myeloid leukaemia; Oncology; Cost effectiveness; Cost-effectiveness analysis; Intensive care medicine; Internal medicine; Risk analysis (engineering)","score_opus":0.01220701428138869,"score_gpt":0.310135410717287,"score_spread":0.2979283964358983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337260374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940627,0.0020855477,0.002066386,0.00046956752,0.00041955398,0.00038079516,0.0004135393,0.0000121457,0.00008971327],"genre_scores_gemma":[0.980392,0.01698718,0.0018929174,0.00006726502,0.00041514463,0.00001329466,0.000010384301,0.000055770055,0.00016608622],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.99786514,0.00012816746,0.0010946294,0.00022063366,0.00017055363,0.0005209041],"domain_scores_gemma":[0.9968066,0.0012773814,0.0009198217,0.0002549283,0.00041302774,0.00032820576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006986012,0.00018727031,0.0012244717,0.00032240208,0.000055468554,0.000019225376,0.00038003875,0.00023299958,0.0003843501],"category_scores_gemma":[0.0014984466,0.00014444653,0.00063083577,0.00005734337,0.00038863477,0.00016692346,0.000112520975,0.00042167006,0.000069485126],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008187911,0.0004965486,0.2311017,0.0005642405,0.008145468,0.058115985,0.00042888988,0.00006723961,0.073135406,0.0005059552,0.34327507,0.27597558],"study_design_scores_gemma":[0.023812758,0.0073224558,0.2560585,0.0016484014,0.0014276917,0.68227243,0.00013226469,0.00026410265,0.019959712,0.0031344446,0.00346061,0.0005065941],"about_ca_topic_score_codex":0.00016397265,"about_ca_topic_score_gemma":0.000072230345,"teacher_disagreement_score":0.6241565,"about_ca_system_score_codex":0.0011306138,"about_ca_system_score_gemma":0.0019797927,"threshold_uncertainty_score":0.5890358},"labels":[],"label_agreement":null},{"id":"W2337848504","doi":"10.1182/blood-2015-11-683649","title":"GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":234,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; McGill University Health Centre; Montreal Children's Hospital; BC Cancer Agency; Centre hospitalier de l'Université Laval; Hôpital Maisonneuve-Rosemont; Université Laval; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Deutsche Krebshilfe; Université de Montréal; Vetenskapsrådet; Government of Canada; Génome Québec; Genome Canada","keywords":"Myeloid leukemia; Biology; In vivo; Leukemia; Cancer research; Myeloid; Phenotype; Immunology; Genetics; Gene","score_opus":0.010378095141719564,"score_gpt":0.25521648198375857,"score_spread":0.244838386842039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337848504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99496317,0.000066582084,0.00011050778,0.0005297985,0.00011048822,0.00055608235,0.000022255417,0.00014661286,0.0034944965],"genre_scores_gemma":[0.98334783,0.00006582913,0.0022671102,0.00018837552,0.00042332144,0.000051496994,0.000024428078,0.00008313154,0.013548459],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972971,0.00009080155,0.00053884665,0.0006325298,0.00074532,0.00069537485],"domain_scores_gemma":[0.99866,0.00007676647,0.00017390796,0.00073784817,0.00013678246,0.00021465881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038482025,0.0002863937,0.0005194636,0.00031752823,0.00015101917,0.000055995315,0.00026659633,0.00019001396,0.00033847755],"category_scores_gemma":[0.000057391364,0.0001864727,0.00010231916,0.0003537513,0.0001958508,0.0002642197,0.00022873869,0.00040801853,0.00009635147],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002543199,0.00019184154,0.017109554,0.00010940104,0.00024180832,0.0027863728,0.00015063815,0.0000051894776,0.9767449,0.000072402516,0.001588918,0.00074468815],"study_design_scores_gemma":[0.017225064,0.00066546455,0.10028416,0.00074589724,0.00048950146,0.00075254904,0.00013709797,0.000016064358,0.8785313,0.00025781908,0.00042384345,0.00047128592],"about_ca_topic_score_codex":0.00084406364,"about_ca_topic_score_gemma":0.00014331621,"teacher_disagreement_score":0.09821361,"about_ca_system_score_codex":0.00066410523,"about_ca_system_score_gemma":0.00048284724,"threshold_uncertainty_score":0.7604136},"labels":[],"label_agreement":null},{"id":"W2339034661","doi":"10.1182/blood.v124.21.527.527","title":"Loss of MiR-143 and MiR-145 Inhibits Hematopoietic Stem Cell Self-Renewal through Dysregulated TGFβ Signaling","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Biology; Haematopoiesis; Bone marrow; Myeloid; Stem cell; Cancer research; Myelodysplastic syndromes; Hematopoietic stem cell; Progenitor cell; Myeloid leukemia; Immunology; Genetics","score_opus":0.012854694502043011,"score_gpt":0.24928771325112592,"score_spread":0.2364330187490829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339034661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941985,0.0010433948,0.000113918875,0.0004047152,0.00004904385,0.0005125567,0.000010460835,0.00013846945,0.0035289384],"genre_scores_gemma":[0.99571025,0.00006827769,0.0031112432,0.0001756285,0.00016316008,0.00001671505,0.000020655134,0.000066413806,0.00066766003],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997761,0.00014299575,0.0005147562,0.00047250008,0.0005820877,0.0005266453],"domain_scores_gemma":[0.9986528,0.00022768119,0.00016657743,0.00049631984,0.00021080708,0.00024579474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004545931,0.0002775127,0.0006292631,0.00012864417,0.00008889641,0.000026123967,0.00018094898,0.0002490973,0.000078008394],"category_scores_gemma":[0.000044647306,0.00024140814,0.00010644776,0.00037441682,0.00017710376,0.000099332115,0.00017103058,0.00035159476,0.000056224835],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028986164,0.0017932402,0.01499431,0.0028236923,0.00054170657,0.00023286029,0.0057910685,0.00001265708,0.9711274,0.0005738511,0.0010973616,0.0007219983],"study_design_scores_gemma":[0.009614119,0.0006459091,0.00071768055,0.00036197974,0.00044565517,0.00035384178,0.0003445375,0.00030051792,0.98571503,0.00029829965,0.0009255331,0.00027691014],"about_ca_topic_score_codex":0.00009202325,"about_ca_topic_score_gemma":0.000006239239,"teacher_disagreement_score":0.014587624,"about_ca_system_score_codex":0.000065052285,"about_ca_system_score_gemma":0.00019985672,"threshold_uncertainty_score":0.9844338},"labels":[],"label_agreement":null},{"id":"W2339393782","doi":"10.3747/co.23.2877","title":"Hematogones: A Sensitive Prognostic Factor for Chinese Adult Patients with Acute Myeloid Leukemia","year":2016,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Public Health Grand Research Foundation; National Natural Science Foundation of China","keywords":"Medicine; Internal medicine; Myeloid leukemia; Bone marrow; Gastroenterology; Chemotherapy; Myeloid; Retrospective cohort study; CD34; Leukemia; Oncology; Immunology","score_opus":0.03417922515592886,"score_gpt":0.3628153518640843,"score_spread":0.32863612670815545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339393782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98910177,0.00007592018,0.0046290453,0.001639223,0.00054897927,0.003059726,0.0004870856,0.00013811252,0.00032013434],"genre_scores_gemma":[0.99582475,0.00014159847,0.0017718485,0.000286207,0.0004813319,0.00061988865,0.00023327424,0.00008402787,0.00055707316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764645,0.00010643844,0.0003970229,0.0006349137,0.0004317328,0.00078344677],"domain_scores_gemma":[0.99669516,0.0009123634,0.00019784457,0.00041616123,0.0013735818,0.0004048594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013510678,0.00037242752,0.00073760434,0.00022114247,0.000112479676,0.000013692932,0.00018053508,0.00022319505,0.00011322682],"category_scores_gemma":[0.0012296039,0.0001939687,0.00015184944,0.00029034264,0.00030465057,0.00015154744,0.00013043964,0.000357921,0.0001974814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00907344,0.0015471916,0.68223256,0.00058896834,0.00093320804,0.0002656862,0.0015353083,3.850984e-7,0.004701983,0.00029013047,0.012333671,0.28649744],"study_design_scores_gemma":[0.07346019,0.015445123,0.818834,0.0015679842,0.000989087,0.00059733394,0.00029379327,0.0005509367,0.0047202194,0.0003543459,0.08192446,0.001262517],"about_ca_topic_score_codex":0.000005824072,"about_ca_topic_score_gemma":0.000028975679,"teacher_disagreement_score":0.28523493,"about_ca_system_score_codex":0.002074236,"about_ca_system_score_gemma":0.0016624696,"threshold_uncertainty_score":0.7909815},"labels":[],"label_agreement":null},{"id":"W2340335756","doi":"10.1200/jco.2004.22.90140.8277","title":"A longitudinal assessment of the quality of life (QOL) of older adults with newly diagnosed acute myeloid leukemia (AML): A pilot study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Medicine; Quality of life (healthcare); Life expectancy; Cancer; Anemia; Physical therapy; Cognition; Internal medicine; Population; Psychiatry","score_opus":0.12524729031981305,"score_gpt":0.48500015376294525,"score_spread":0.3597528634431322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340335756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252486,0.0001334173,0.00064252404,0.0045099338,0.00035498585,0.0012224516,0.000015557393,0.0000067784886,0.00058951235],"genre_scores_gemma":[0.99200094,0.0003182322,0.0065237135,0.000600566,0.00043144185,0.000016446336,0.0000016967391,0.000031228305,0.00007574169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9903007,0.0015777859,0.005440311,0.00035890756,0.0019168829,0.00040537782],"domain_scores_gemma":[0.9859164,0.004677887,0.005949272,0.0007651977,0.0021427579,0.0005485134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008654574,0.0002679604,0.0034531541,0.00021658083,0.000050404626,0.000005902344,0.0007468673,0.0002923837,0.000099103054],"category_scores_gemma":[0.006964078,0.00014666295,0.00065389375,0.0005934344,0.0010165499,0.00013826926,0.0002921041,0.0022678212,0.0000021989863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046087205,0.020048738,0.9187183,0.0003189883,0.0035862185,0.00071629445,0.0009969403,0.00040453466,0.0015453389,0.00018451558,0.00073025416,0.0066626887],"study_design_scores_gemma":[0.062287506,0.08466046,0.8495586,0.00054879807,0.00086859573,0.00015362383,0.0013128005,0.000035707344,0.00031633105,0.00006104927,0.00008781694,0.00010870218],"about_ca_topic_score_codex":0.0011488487,"about_ca_topic_score_gemma":0.0007959386,"teacher_disagreement_score":0.06915968,"about_ca_system_score_codex":0.0010147427,"about_ca_system_score_gemma":0.020950345,"threshold_uncertainty_score":0.9852681},"labels":[],"label_agreement":null},{"id":"W2342022702","doi":"10.1182/blood.v124.21.1237.1237","title":"Development and Validation of a Prognostic Score Involving Disease Status, Patient Age and Donor Type for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Transplantation; Internal medicine; Hematopoietic stem cell transplantation; Cumulative incidence; Myeloid leukemia; Surgery; Single Center; Gastroenterology","score_opus":0.012293326477649306,"score_gpt":0.23805801168157126,"score_spread":0.22576468520392196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342022702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984656,0.00010781232,0.000117839474,0.000013856919,0.00001129111,0.0012309201,0.0000334058,0.0000086261225,0.000010662927],"genre_scores_gemma":[0.99210596,0.000078590034,0.0073734825,0.000023216297,0.0000039766346,0.00006660642,0.00031630782,0.000019489857,0.000012396604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990039,0.000033571323,0.0003083872,0.00020978895,0.00024944622,0.00019489064],"domain_scores_gemma":[0.99937755,0.00010474648,0.00012380879,0.00012294996,0.00013951474,0.00013143501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010663302,0.00012692116,0.0002850245,0.00013748398,0.000028046261,0.000007716495,0.00003741297,0.000040451458,0.0000021037176],"category_scores_gemma":[0.00009166801,0.000097197095,0.000017572187,0.00012255092,0.000056918696,0.000061637125,0.000024647463,0.00006514757,4.7308131e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085136475,0.00032923496,0.99232775,0.0015833954,0.000087570384,0.000013549591,0.0018246341,0.000008071629,0.001973164,0.000014487877,0.0000030021322,0.0009837743],"study_design_scores_gemma":[0.0074718636,0.0007156564,0.96536237,0.00024699367,0.0003517705,0.0000019868437,0.00006674072,0.0000415162,0.025612874,0.000016153139,0.000010555055,0.000101490245],"about_ca_topic_score_codex":0.000018548164,"about_ca_topic_score_gemma":0.000021572432,"teacher_disagreement_score":0.026965352,"about_ca_system_score_codex":0.000067910776,"about_ca_system_score_gemma":0.00030778634,"threshold_uncertainty_score":0.39635825},"labels":[],"label_agreement":null},{"id":"W2343457318","doi":"10.1038/leu.2015.171","title":"Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children’s Oncology Group","year":2015,"lang":"en","type":"letter","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute","keywords":"Ethnic group; SNP; Internal medicine; Oncology; Medicine; Clinical Oncology; Association (psychology); Single-nucleotide polymorphism; Genetics; Biology; Genotype; Cancer; Psychology; Gene","score_opus":0.056168856421066636,"score_gpt":0.36833967446116556,"score_spread":0.31217081804009894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343457318","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6685096,0.00089236925,0.00009302239,0.32517582,0.0005598325,0.0023692267,0.00019199181,0.0000976103,0.0021105248],"genre_scores_gemma":[0.3777742,0.0015696358,0.0065171053,0.57049125,0.023253573,0.00055958267,0.011193557,0.0005684922,0.008072571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99417883,0.0010806309,0.0017493798,0.0009445272,0.0014238857,0.0006227631],"domain_scores_gemma":[0.99398255,0.0027363345,0.001619877,0.0011323465,0.0003696825,0.00015922514],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0046154954,0.00044418278,0.0016148763,0.00024598977,0.000057580815,0.000031085412,0.0004049958,0.002845543,0.00005908064],"category_scores_gemma":[0.0041970476,0.0002962968,0.00020482247,0.00048551083,0.0002495268,0.00011509407,0.00025325024,0.0075421273,0.000035354606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025628062,0.00010606144,0.6002093,0.0000535263,0.0006141599,0.001148676,0.0007352721,0.0000024899273,0.00001983161,0.0000041380204,0.39345622,0.0033940745],"study_design_scores_gemma":[0.0064277723,0.00065828423,0.92026997,0.00024415302,0.0005911977,0.00045959614,0.00004936951,0.000068790534,0.0000055772553,0.00019265617,0.070760146,0.00027251925],"about_ca_topic_score_codex":0.0064166053,"about_ca_topic_score_gemma":0.0006172199,"teacher_disagreement_score":0.3226961,"about_ca_system_score_codex":0.0072463164,"about_ca_system_score_gemma":0.0043915734,"threshold_uncertainty_score":0.9999489},"labels":[],"label_agreement":null},{"id":"W2344778610","doi":"10.1182/blood.v124.21.5336.5336","title":"A Standard, 3-Tube, 10-Color Flow Cytometry Panel for Acute Myeloid Leukemia Diagnosis Can be Used for MRD Detection at Day 30 after Induction, and Is Predictive of Early Relapse","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Minimal residual disease; Myeloid leukemia; Internal medicine; CD33; Induction chemotherapy; Acute leukemia; Leukemia; Immunophenotyping; Oncology; CD34; Gastroenterology; Surgery; Immunology; Flow cytometry; Chemotherapy; Stem cell; Biology","score_opus":0.01804065520445389,"score_gpt":0.2757583530413219,"score_spread":0.257717697836868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344778610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898472,0.00015072161,0.0043903966,0.000830045,0.00015971395,0.0026066513,0.0018721536,0.000086457774,0.00005667253],"genre_scores_gemma":[0.99159575,0.00016915584,0.0032094095,0.00029913412,0.00045711535,0.0027209357,0.000103141836,0.0001030865,0.0013422774],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975958,0.000100296405,0.0004804828,0.0006748261,0.0005900759,0.00055853336],"domain_scores_gemma":[0.99760544,0.0006742836,0.0001945824,0.0005147762,0.0006897501,0.00032115998],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007978055,0.00031543017,0.00066716457,0.00040760948,0.0002132297,0.00003606779,0.00014354709,0.00041124978,0.00013434222],"category_scores_gemma":[0.0010423335,0.00028086203,0.00020122867,0.00043856993,0.00022879073,0.00018051668,0.00013522804,0.00031808577,0.0000067958867],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05740077,0.0018999617,0.2798781,0.0035797236,0.011900446,0.00012032647,0.024228688,0.00003744279,0.5121248,0.000054455264,0.04672975,0.062045563],"study_design_scores_gemma":[0.03144778,0.0128531065,0.08772495,0.00024070911,0.0032991085,0.000116240415,0.00032791877,0.0021779651,0.84512305,0.00018279518,0.01598402,0.0005223835],"about_ca_topic_score_codex":0.00014113134,"about_ca_topic_score_gemma":0.0001325658,"teacher_disagreement_score":0.33299828,"about_ca_system_score_codex":0.0008846387,"about_ca_system_score_gemma":0.00042339726,"threshold_uncertainty_score":0.99996436},"labels":[],"label_agreement":null},{"id":"W2345360418","doi":"10.1182/blood.v120.21.2516.2516","title":"Pediatric Acute Myeloid Leukemia with t(8;16)(p11;p13): A Distinct Clinical and Biological Entity. Results of a Collaborative Study by the International Berlin-Frankfurt-Munster AML Study Group.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Medicine; Myeloid leukemia; Oncology; Leukemia; Internal medicine","score_opus":0.027967082771690292,"score_gpt":0.32911404966322405,"score_spread":0.30114696689153375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345360418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947141,0.0005410375,0.000030702748,0.00046854693,0.00017769069,0.0027041116,0.0003213735,0.00005013042,0.0009923492],"genre_scores_gemma":[0.99763364,0.0002651048,0.00031140918,0.00014739395,0.0008088574,0.00017279884,0.00011404904,0.000035030786,0.0005116985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99626327,0.00066628883,0.00093731115,0.00064437627,0.0009701183,0.0005186208],"domain_scores_gemma":[0.9973201,0.0009400269,0.0003524554,0.00063588354,0.00043165227,0.000319848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026438741,0.00033686994,0.0007224293,0.00015060004,0.00016434382,0.00006427956,0.0004996632,0.00017634408,0.000054962282],"category_scores_gemma":[0.000810178,0.00018527909,0.00010311527,0.0007005874,0.0005003688,0.00019489044,0.0005353168,0.0008162704,0.000024739054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004031698,0.00891306,0.9772316,0.000016444907,0.0016103432,0.000105439954,0.0027695934,9.408981e-8,0.00024130965,0.00001472233,0.004281489,0.0007842016],"study_design_scores_gemma":[0.036908288,0.009281292,0.94355285,0.000020099607,0.0016080381,0.00012984917,0.0059779827,0.000014330233,0.00015795017,0.000007623833,0.0020946339,0.0002470542],"about_ca_topic_score_codex":0.00023637671,"about_ca_topic_score_gemma":0.00025086038,"teacher_disagreement_score":0.033678744,"about_ca_system_score_codex":0.00016413638,"about_ca_system_score_gemma":0.00037413932,"threshold_uncertainty_score":0.7555462},"labels":[],"label_agreement":null},{"id":"W2345584475","doi":"10.1093/annonc/mdu339.4","title":"Comparison of Efficacy and Safety of 5-Day and 10-Day Schedules of Sgi-110, a Novel Subcutaneous (Sc) Hypomethylating Agent (Hma), in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R Aml)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hypomethylating agent; Refractory (planetary science); Myeloid leukemia; Oncology; Internal medicine","score_opus":0.08143848979823845,"score_gpt":0.3963737014011789,"score_spread":0.31493521160294047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345584475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993982,0.0025602754,0.00013920412,0.00091162446,0.000052918065,0.0007637361,0.00006440344,0.000007478668,0.0015183623],"genre_scores_gemma":[0.9933933,0.0040948433,0.002201843,0.000079737874,0.000047804144,0.00001621043,0.000027259375,0.000026482749,0.00011253834],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967421,0.0006461827,0.0013886188,0.00035787284,0.00047322887,0.00039197548],"domain_scores_gemma":[0.99362427,0.004228801,0.0010504818,0.0005516007,0.00041207246,0.00013275158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002123136,0.0002668967,0.001756179,0.00041855057,0.000042783613,0.0000030499984,0.0002478373,0.0003225341,0.000038863647],"category_scores_gemma":[0.0011121314,0.0001880291,0.00015914896,0.00039474436,0.0009839548,0.000056177738,0.0001228094,0.00032548152,0.0000012933057],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009680469,0.005919204,0.0348261,0.00089152163,0.0013499262,0.00008038106,0.017940013,0.00025952375,0.56718373,0.0010085097,0.0005916325,0.36026898],"study_design_scores_gemma":[0.03401303,0.10638815,0.3604443,0.0010347782,0.0010886734,0.00028720184,0.0046713,0.0049376814,0.4551128,0.00029635694,0.031179953,0.00054578943],"about_ca_topic_score_codex":0.00047786155,"about_ca_topic_score_gemma":0.000110008645,"teacher_disagreement_score":0.35972318,"about_ca_system_score_codex":0.000233446,"about_ca_system_score_gemma":0.0005805575,"threshold_uncertainty_score":0.7667604},"labels":[],"label_agreement":null},{"id":"W2346269859","doi":"10.1182/blood-2016-04-709899","title":"CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML","year":2016,"lang":"en","type":"letter","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"CEBPA; Myeloid; Mutation; Medicine; Childhood cancer; Cancer research; Oncology; Genetics; Biology; Internal medicine; Cancer; Gene","score_opus":0.024179097875192252,"score_gpt":0.27582212293250924,"score_spread":0.251643025057317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346269859","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42034784,0.00070569565,0.00035427103,0.5550184,0.00023244404,0.0033154916,0.0012080831,0.00018106012,0.018636681],"genre_scores_gemma":[0.7277338,0.0009729056,0.017726548,0.16969003,0.021514267,0.0018306955,0.0063582747,0.0009078012,0.05326571],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9971931,0.00013114284,0.0005635877,0.00055846,0.0009018002,0.00065193436],"domain_scores_gemma":[0.99777985,0.00064218044,0.00029542012,0.0007549593,0.00039774788,0.00012984195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019619078,0.00036368932,0.00072582316,0.0011756163,0.000057561334,0.000018758554,0.00029990936,0.00067445653,0.00029708399],"category_scores_gemma":[0.00029319487,0.0002642142,0.00014384821,0.00066405407,0.00023709271,0.000097736694,0.00008670602,0.0017863112,0.00016597704],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034053824,0.001212998,0.1844706,0.0028710943,0.0012548298,0.01392613,0.0012600229,0.000012259722,0.0008124402,0.00017267215,0.791511,0.0021554364],"study_design_scores_gemma":[0.12018908,0.0066242334,0.55615896,0.004100482,0.0159206,0.004092866,0.00094756833,0.000111136564,0.0073372056,0.002681352,0.2777251,0.0041113924],"about_ca_topic_score_codex":0.0004613829,"about_ca_topic_score_gemma":0.0001762231,"teacher_disagreement_score":0.5137859,"about_ca_system_score_codex":0.00026383245,"about_ca_system_score_gemma":0.0017032976,"threshold_uncertainty_score":0.999981},"labels":[],"label_agreement":null},{"id":"W2362147867","doi":"10.1111/ejh.12757","title":"The fludarabine, cytarabine, and granulocyte colony‐stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline‐based therapy for the treatment of acute myeloid leukemia for patients with pre‐existing cardiac disease","year":2016,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"University of Alberta","keywords":"Flag (linear algebra); Medicine; Cytarabine; Anthracycline; Fludarabine; Myeloid leukemia; Internal medicine; Granulocyte colony-stimulating factor; Regimen; Chemotherapy; Surgery; Gastroenterology; Oncology; Cyclophosphamide; Cancer","score_opus":0.03171977461410722,"score_gpt":0.3272721738273038,"score_spread":0.29555239921319654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2362147867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797183,0.00065809744,0.010333132,0.0061647994,0.00014620533,0.0026951206,0.00025054952,0.000014610423,0.000019186375],"genre_scores_gemma":[0.9924628,0.0013263659,0.0050564404,0.00042742374,0.00029805762,0.00007389645,0.000014433881,0.00010382855,0.00023673491],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99776024,0.00039918162,0.00070138613,0.0003377725,0.00036495682,0.0004364873],"domain_scores_gemma":[0.99556005,0.0020600848,0.00070572324,0.00047594408,0.00086997706,0.00032823905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069247116,0.00030901423,0.00077326765,0.0001332098,0.0003233894,0.000035727648,0.00033500476,0.000037005037,0.000009158261],"category_scores_gemma":[0.00031333492,0.00012785394,0.00024243767,0.000121731005,0.0003637027,0.00012038532,0.000028148095,0.00013167647,0.0000012836031],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20241664,0.0014649834,0.2552656,0.00027004405,0.007867518,0.0007328671,0.010586642,0.0002715506,0.024210418,0.00021965244,0.0036755889,0.4930185],"study_design_scores_gemma":[0.1274596,0.09431534,0.659579,0.0012669204,0.0020065648,0.0003597801,0.0005567867,0.009186738,0.048132006,0.00023270235,0.0558621,0.0010424528],"about_ca_topic_score_codex":0.00001131109,"about_ca_topic_score_gemma":0.0000022993843,"teacher_disagreement_score":0.49197605,"about_ca_system_score_codex":0.00027845043,"about_ca_system_score_gemma":0.0003804375,"threshold_uncertainty_score":0.5213733},"labels":[],"label_agreement":null},{"id":"W2376118904","doi":"10.4081/hr.2016.6480","title":"Autoimmune Syndromes Presenting as a Paraneoplastic Manifestation of Myelodysplastic Syndromes: Clinical Features, Course, Treatment and Outcome","year":2016,"lang":"en","type":"article","venue":"Hematology Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Outcome (game theory); Dermatology; Immunology; Intensive care medicine; Pediatrics","score_opus":0.04708501843780152,"score_gpt":0.38125970659728176,"score_spread":0.33417468815948026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2376118904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951025,0.001193258,0.000109448476,0.0014586899,0.000352526,0.0007600907,0.0000063461985,0.000102836275,0.0009142931],"genre_scores_gemma":[0.99112934,0.0003006843,0.0005518344,0.000043038624,0.000039323986,0.00007530533,0.000023842314,0.00004314542,0.0077934875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969048,0.0001821431,0.0014127332,0.0006445162,0.0003497167,0.00050610333],"domain_scores_gemma":[0.9964702,0.0017976986,0.00063058495,0.00066973304,0.00017660664,0.00025516984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061645824,0.00029271134,0.001227825,0.00019912425,0.0000846479,0.000012134247,0.00007465678,0.00033396477,0.00016871923],"category_scores_gemma":[0.002257324,0.00018264011,0.00017065667,0.0001587356,0.00051576586,0.00009715214,0.0001039897,0.00024102168,0.00006803628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030380156,0.0004494444,0.95074093,0.0004805493,0.0006769415,0.042176798,0.00017716386,8.9392137e-7,0.000851566,0.0007574816,0.000863316,0.002521105],"study_design_scores_gemma":[0.0026812383,0.0010283496,0.6713814,0.00047153176,0.0005418949,0.3217084,0.00010017463,0.00004609043,0.00082226464,0.000408664,0.0006158543,0.00019411613],"about_ca_topic_score_codex":0.0000736961,"about_ca_topic_score_gemma":0.000017363122,"teacher_disagreement_score":0.27953163,"about_ca_system_score_codex":0.00014112251,"about_ca_system_score_gemma":0.00058747065,"threshold_uncertainty_score":0.7447848},"labels":[],"label_agreement":null},{"id":"W2395420640","doi":"10.1182/blood-2016-02-701144","title":"Acute myeloid leukemia with myelodysplasia-related changes demonstrating prominent basophilic differentiation","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pancytopenia; Bone marrow; Basophilic; Dysplasia; Myeloid leukemia; Medicine; Pathology; Leukemia; Myeloid; Preleukemia; Cytopenia; Immunology","score_opus":0.011426750208982789,"score_gpt":0.2429502136947868,"score_spread":0.23152346348580402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2395420640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98986506,0.00013514789,0.00028820246,0.005794304,0.0000647921,0.0009724085,0.000023748795,0.0002557488,0.0026006012],"genre_scores_gemma":[0.9937044,0.00021902627,0.0014779154,0.00014356633,0.00026735433,0.00016464897,0.000060565257,0.000078625744,0.0038839371],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99773437,0.00007909776,0.0003415727,0.00056300015,0.00063305954,0.0006489101],"domain_scores_gemma":[0.998651,0.00014036015,0.00017932798,0.0005292658,0.00019153777,0.00030847007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002346318,0.00032583412,0.00042498868,0.00024539788,0.00015038931,0.00003727086,0.00019296035,0.0002204009,0.000259701],"category_scores_gemma":[0.00014420194,0.0001870798,0.00008195208,0.0004043784,0.000170125,0.00015790146,0.000099336314,0.0003513099,0.00016597641],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043322105,0.0002638813,0.03841917,0.0001247374,0.0011333687,0.0004294978,0.0003175841,5.5301234e-7,0.9330993,0.0003193285,0.00037060466,0.025088737],"study_design_scores_gemma":[0.031028304,0.002913346,0.17236663,0.0013678649,0.0018820212,0.002400377,0.00015819159,0.00044285125,0.78562367,0.00019541496,0.00085020746,0.0007711133],"about_ca_topic_score_codex":0.000019001473,"about_ca_topic_score_gemma":0.000045905443,"teacher_disagreement_score":0.14747564,"about_ca_system_score_codex":0.00042678465,"about_ca_system_score_gemma":0.0005547703,"threshold_uncertainty_score":0.76288927},"labels":[],"label_agreement":null},{"id":"W2396679265","doi":"10.1158/1557-3125.metca15-a04","title":"Abstract A04: Differential dependence on sphingolipid metabolism in the normal and leukemic human hematopoietic hierarchy","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Sphingolipid; Biology; Haematopoiesis; Progenitor cell; Stem cell; Cell biology; Myeloid leukemia; Myeloid; Sphingosine; Hematopoietic stem cell; Cancer research; Biochemistry","score_opus":0.04308510546758225,"score_gpt":0.372404211101031,"score_spread":0.32931910563344874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396679265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98676765,0.0009936225,0.00009959742,0.008105896,0.000056632012,0.0009285727,0.0000148728,0.000029014926,0.0030041311],"genre_scores_gemma":[0.9974796,0.0005911312,0.000034450608,0.00048174866,0.00028742827,0.00035355944,0.000006456973,0.00005622977,0.00070939865],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9952948,0.0004802823,0.00034466502,0.00066389306,0.002102709,0.0011136213],"domain_scores_gemma":[0.99821645,0.00039980924,0.000048350485,0.0008470389,0.00019979563,0.00028858526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017896884,0.00025135805,0.00037600187,0.00059110386,0.0002648118,0.00010834059,0.00065871835,0.00017229807,0.00057713565],"category_scores_gemma":[0.0003355658,0.00014254454,0.0001078523,0.00060546846,0.00060587714,0.00012814271,0.00033108538,0.0015493094,0.00010205199],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005742617,0.0001708376,0.00224678,0.00017642802,0.00006819525,0.0010651541,0.0006850098,0.000002697167,0.97838676,0.003532599,0.0012753935,0.011815906],"study_design_scores_gemma":[0.013087577,0.00090764643,0.49280217,0.0014594616,0.000083770974,0.00037817453,0.00064308185,0.00012287206,0.4792012,0.0038472733,0.006742564,0.00072419364],"about_ca_topic_score_codex":0.0017676728,"about_ca_topic_score_gemma":0.00019848111,"teacher_disagreement_score":0.49918553,"about_ca_system_score_codex":0.0006653914,"about_ca_system_score_gemma":0.00059756526,"threshold_uncertainty_score":0.67310643},"labels":[],"label_agreement":null},{"id":"W2400101856","doi":"10.1038/leu.2016.145","title":"KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells","year":2016,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"William Lawrence and Blanche Hughes Foundation; Fondation Tuck; Leukemia and Lymphoma Society","keywords":"Tolerability; Myeloid leukemia; Medicine; Haematopoiesis; Leukemia; Progenitor cell; Cancer research; Internal medicine; Pharmacology; Oncology; Immunology; Stem cell; Biology; Adverse effect","score_opus":0.016177063618313624,"score_gpt":0.2453413937067642,"score_spread":0.22916433008845058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2400101856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929028,0.00013439707,0.00002543609,0.00061989826,0.00016639993,0.00069256144,0.00017808613,0.00011849937,0.0051618805],"genre_scores_gemma":[0.9940821,0.00044736554,0.00070159923,0.0015407691,0.0005320039,0.000030186331,0.00008283137,0.00010949733,0.002473646],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99710643,0.00014625267,0.0007298799,0.0007679472,0.0006225972,0.00062690134],"domain_scores_gemma":[0.99799156,0.00036548448,0.00035794266,0.00047437177,0.0003474636,0.00046318147],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037421467,0.0004168375,0.00069393247,0.00024592265,0.00017244807,0.00005911594,0.00014687769,0.0004327021,0.000577414],"category_scores_gemma":[0.0002911846,0.0003223158,0.0000941732,0.00035705598,0.00037830998,0.00036735393,0.0002189502,0.000532824,0.00013658444],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000493177,0.00004082786,0.0009177369,0.00016587191,0.00014465932,0.00012683164,0.0015401356,0.000002365681,0.9628377,0.00002778519,0.021968948,0.011733979],"study_design_scores_gemma":[0.009500542,0.0007523182,0.008294568,0.0005472623,0.000104271334,0.000087552355,0.0006952386,0.005871175,0.96131456,0.000019796034,0.012296121,0.0005166121],"about_ca_topic_score_codex":0.000106161235,"about_ca_topic_score_gemma":0.00005804513,"teacher_disagreement_score":0.011217367,"about_ca_system_score_codex":0.0018099826,"about_ca_system_score_gemma":0.0010379704,"threshold_uncertainty_score":0.9999229},"labels":[],"label_agreement":null},{"id":"W2401773417","doi":"10.1016/j.exphem.2016.05.004","title":"Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML","year":2016,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"Canadian Institutes of Health Research; Deutsche Krebshilfe; Leukemia and Lymphoma Society","keywords":"Epigenetics; Myeloid leukemia; Biology; Cancer research; Transcription factor; Leukemia; Gene; Genetics","score_opus":0.049468299914275475,"score_gpt":0.3663370592293199,"score_spread":0.31686875931504443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2401773417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786154,0.0036309871,0.0035631624,0.001457237,0.00017029053,0.0021812038,0.00002916835,0.00021028605,0.010142243],"genre_scores_gemma":[0.98916954,0.000039544506,0.003957072,0.0006343231,0.00012450734,0.0008140471,0.000083362276,0.00008224597,0.0050953594],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980617,0.00006300622,0.0003679863,0.0005504652,0.00026974667,0.0006871005],"domain_scores_gemma":[0.9989592,0.00016113458,0.00010482752,0.00044234798,0.00009569559,0.00023682817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019772736,0.0002695416,0.0005825674,0.00015601734,0.00015489882,0.000011639116,0.00024116808,0.00025837572,0.00080390135],"category_scores_gemma":[0.00010407856,0.00018237745,0.00018660493,0.00014440314,0.0002979576,0.000057846853,0.00011450935,0.0001534879,0.00013573453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009381141,0.002401175,0.0027968336,0.000046462745,0.0002935095,0.000051568775,0.0005377395,1.6444007e-7,0.955342,0.03055181,0.0061327345,0.00090787327],"study_design_scores_gemma":[0.015423247,0.0018737545,0.0009656578,0.00004778057,0.000016410371,0.0005985574,0.00042888714,0.00010681904,0.9770213,0.00029461237,0.0029688831,0.00025412845],"about_ca_topic_score_codex":0.00007022902,"about_ca_topic_score_gemma":0.0000023183304,"teacher_disagreement_score":0.030257197,"about_ca_system_score_codex":0.00047531573,"about_ca_system_score_gemma":0.00016913546,"threshold_uncertainty_score":0.8802156},"labels":[],"label_agreement":null},{"id":"W2406104696","doi":"10.7150/ijms.15057","title":"OCT4 Remodels the Phenotype and Promotes Angiogenesis of HUVECs by Changing the Gene Expression Profile","year":2016,"lang":"en","type":"article","venue":"International Journal of Medical Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China; People's Government of Jilin Province; University of Manitoba; National Science Foundation","keywords":"Angiogenesis; Progenitor cell; Biology; Matrigel; Endothelial stem cell; Vasculogenesis; Cell biology; KLF4; Stem cell; CD34; Ectopic expression; Gene expression; SOX2; Endothelial progenitor cell; Molecular biology; Cellular differentiation; Gene; Embryonic stem cell; Cancer research; Genetics; In vitro","score_opus":0.036870543095451146,"score_gpt":0.34770214303744246,"score_spread":0.31083159994199133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406104696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8844079,0.0010926366,0.002192875,0.11174353,0.00022057652,0.000104249244,0.0000068137765,0.0000035237679,0.00022788435],"genre_scores_gemma":[0.99733037,0.0006498053,0.0009445755,0.00040734746,0.0004356387,0.0000026932769,5.0176754e-7,0.0000040596897,0.00022501353],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968079,0.00009282646,0.00028968428,0.00010732628,0.0025386354,0.00016362815],"domain_scores_gemma":[0.998773,0.00053375313,0.00021215266,0.000081667,0.0002731613,0.00012627545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003072026,0.00006130042,0.00012837557,0.0001124815,0.00010541315,0.00002689833,0.00079777127,0.00005075299,0.00028011677],"category_scores_gemma":[0.0013674808,0.000020317108,0.00005603426,0.00018736493,0.000790317,0.00013849237,0.00019624332,0.0001402008,0.000002499838],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025835686,0.00014539006,0.007773287,0.000017824272,0.00017156677,0.000087712964,0.0013918674,0.0000024080894,0.6297056,0.0008834223,0.010405897,0.34915665],"study_design_scores_gemma":[0.0036839508,0.0012283475,0.009059854,0.002315344,0.000091050235,0.0023991263,0.001901641,0.004594036,0.96146035,0.0035343023,0.009535117,0.0001968904],"about_ca_topic_score_codex":0.000019023855,"about_ca_topic_score_gemma":0.0000013063266,"teacher_disagreement_score":0.34895974,"about_ca_system_score_codex":0.00005403693,"about_ca_system_score_gemma":0.00039029695,"threshold_uncertainty_score":0.30670822},"labels":[],"label_agreement":null},{"id":"W2407055687","doi":"10.1111/trf.13652","title":"Detection of erythroblast antibodies in mitogen‐stimulated bone marrow cultures from patients with myelodysplastic syndromes","year":2016,"lang":"en","type":"article","venue":"Transfusion","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia","keywords":"Erythroblast; Bone marrow; Erythropoietin; Myelodysplastic syndromes; Autoantibody; Medicine; Immunology; Antibody; Erythropoiesis; Anemia; Internal medicine","score_opus":0.009766566555145339,"score_gpt":0.2479126103452275,"score_spread":0.23814604379008214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2407055687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976901,0.00011079261,0.0011349301,0.00022208596,0.00008544368,0.00056128844,0.00006310086,0.000053240165,0.00007902586],"genre_scores_gemma":[0.9990275,0.00031728475,0.00029704085,0.00001551527,0.000031837073,0.0000117743275,0.000049103342,0.000031619544,0.00021830549],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998546,0.00006220856,0.00031869818,0.00033057504,0.00046290742,0.0002795832],"domain_scores_gemma":[0.9992687,0.00016042218,0.00006309494,0.00022686487,0.000181297,0.00009959159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008487969,0.00018979885,0.00038939097,0.000253088,0.00005097812,0.0000061232327,0.00007368102,0.00014932992,0.0002031219],"category_scores_gemma":[0.00006672549,0.00010741017,0.00006148633,0.00033813666,0.00015301915,0.00013212045,0.000021063423,0.00018217698,0.000030924977],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036097597,0.00019856589,0.17021216,0.00009613588,0.00007229716,0.00004221168,0.00049546594,0.000014997592,0.8120324,0.0000017144242,0.00004673763,0.013177575],"study_design_scores_gemma":[0.010632259,0.0009931058,0.7493553,0.0010857811,0.000088345056,0.000015980133,0.00008227789,0.00015349049,0.23731339,0.000028131326,0.00008932189,0.00016260917],"about_ca_topic_score_codex":0.00070161093,"about_ca_topic_score_gemma":0.0006842285,"teacher_disagreement_score":0.57914317,"about_ca_system_score_codex":0.00016547655,"about_ca_system_score_gemma":0.000071084825,"threshold_uncertainty_score":0.43800595},"labels":[],"label_agreement":null},{"id":"W2408400316","doi":"10.1182/blood-2016-02-698506","title":"Abnormal chromatin clumping in myeloblasts","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Ottawa","funders":"","keywords":"Pancytopenia; Mean corpuscular volume; Complete blood count; Medicine; Platelet; Hemoglobin; White blood cell; Blood count; Gastroenterology; Internal medicine; Pathology; Immunology; Bone marrow","score_opus":0.01461450845003958,"score_gpt":0.27558912918219275,"score_spread":0.26097462073215316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2408400316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874426,0.00011938328,0.00008269768,0.001993676,0.000034299766,0.00023065465,0.000003363169,0.00006665315,0.010026633],"genre_scores_gemma":[0.9965747,0.00004892533,0.0010846234,0.00022040786,0.00022278364,0.000024633071,0.0000025532668,0.000022197155,0.0017991647],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99889857,0.00003918106,0.00020612252,0.00020816318,0.00025921938,0.00038874595],"domain_scores_gemma":[0.9994214,0.00009980803,0.000030939933,0.00027427822,0.00004131205,0.00013224252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027294317,0.000098688215,0.0001900097,0.00015876332,0.000026294436,0.000008354111,0.000110365014,0.0000836002,0.0003536631],"category_scores_gemma":[0.00026236317,0.000064359745,0.000044072283,0.0002157245,0.00006005532,0.00009473446,0.00008691097,0.00016215202,0.0005844322],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021405431,0.0007450848,0.43845809,0.00017158051,0.000114047456,0.001384495,0.00045700994,5.591451e-7,0.5056907,0.00040340927,0.0024404305,0.049920574],"study_design_scores_gemma":[0.01760056,0.00040654512,0.7976747,0.00074068666,0.00004451311,0.000534718,0.00007630223,0.000081071514,0.17823903,0.0001242981,0.004244422,0.00023311254],"about_ca_topic_score_codex":0.00004704806,"about_ca_topic_score_gemma":0.000031157804,"teacher_disagreement_score":0.35921666,"about_ca_system_score_codex":0.00013248641,"about_ca_system_score_gemma":0.00020887863,"threshold_uncertainty_score":0.7511889},"labels":[],"label_agreement":null},{"id":"W2413316483","doi":"10.1093/ajhp/59.10.941","title":"Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia","year":2002,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; Chemotherapy; Internal medicine; Cytarabine; Mitoxantrone; Calicheamicin; Surgery; Myeloid leukemia; CD33","score_opus":0.027575807378033015,"score_gpt":0.328183563977453,"score_spread":0.30060775659942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413316483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98830605,0.00040655784,0.00024512835,0.0088255275,0.00015540152,0.0017023139,0.000054328026,0.000053330627,0.00025138273],"genre_scores_gemma":[0.9953965,0.0003409137,0.0020366092,0.001518447,0.00013760828,0.000049529135,0.000018275974,0.000100916695,0.0004012207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99570113,0.0004605184,0.0016574719,0.0003628813,0.0008551387,0.0009628323],"domain_scores_gemma":[0.9964701,0.0003228043,0.0015685471,0.0003847216,0.0006438903,0.00060994294],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010008292,0.00037791638,0.0018577037,0.00078405417,0.000167884,0.00002504892,0.00034971212,0.000049330043,0.000045663244],"category_scores_gemma":[0.00009731941,0.0002651016,0.00024763474,0.00087401364,0.00019469463,0.00021441485,0.000036951693,0.0007794271,0.000031226748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009263649,0.00078789063,0.7790176,0.000585287,0.0012772003,0.0008357637,0.0016935286,0.000065029446,0.00043280158,0.000012449845,0.00645423,0.19957456],"study_design_scores_gemma":[0.265502,0.078555256,0.57596934,0.003974353,0.001842961,0.008263216,0.0061366525,0.011567122,0.0026456092,0.000006611712,0.04358409,0.0019527994],"about_ca_topic_score_codex":0.0011903017,"about_ca_topic_score_gemma":0.000014890726,"teacher_disagreement_score":0.25623834,"about_ca_system_score_codex":0.0059939786,"about_ca_system_score_gemma":0.0012592803,"threshold_uncertainty_score":0.9999801},"labels":[],"label_agreement":null},{"id":"W2414703178","doi":"10.1182/blood-2015-07-655860","title":"Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":454,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Cancer Research UK; National Cancer Institute; National Institutes of Health; Institut National Du Cancer; Fondation de France","keywords":"Bone marrow; Stromal cell; Mesenchymal stem cell; Cancer research; Myeloid leukemia; Leukemia; Mitochondrion; In vivo; In vitro; Myeloid; Biology; Chemistry; Cell biology; Immunology; Biochemistry","score_opus":0.008614955398169194,"score_gpt":0.23800244351882635,"score_spread":0.22938748812065715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2414703178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916777,0.00007504858,0.0022772753,0.002218987,0.00030795898,0.002510898,0.00032753465,0.00020408056,0.00040049196],"genre_scores_gemma":[0.98517555,0.00012993731,0.0055220854,0.00049741345,0.0020716954,0.0003698088,0.00001918947,0.00018385782,0.0060304753],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968454,0.000107185886,0.0004553177,0.00091252755,0.0007451906,0.0009343298],"domain_scores_gemma":[0.998281,0.0001292609,0.000051958636,0.00080053357,0.00015724321,0.0005800267],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014221827,0.0004339689,0.0006641755,0.0002541721,0.00012656063,0.00004355934,0.000354857,0.00031335108,0.0010013226],"category_scores_gemma":[0.000043345608,0.00031457242,0.0002599312,0.00033340135,0.00012674488,0.00016855172,0.00009920141,0.0005155967,0.0008984084],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032140515,0.00037173752,0.00020025476,0.00004090442,0.0006023939,0.00042769825,0.00063638267,8.855208e-7,0.9914072,0.0000048578595,0.0011548293,0.0019388184],"study_design_scores_gemma":[0.025713472,0.00084137626,0.0045718593,0.00022539569,0.00027358573,0.000087938046,0.00006019306,0.0000051940146,0.96640635,0.000055764845,0.0013719628,0.00038694232],"about_ca_topic_score_codex":0.00025922531,"about_ca_topic_score_gemma":0.00002934936,"teacher_disagreement_score":0.025000868,"about_ca_system_score_codex":0.00058020424,"about_ca_system_score_gemma":0.00048073364,"threshold_uncertainty_score":0.9999306},"labels":[],"label_agreement":null},{"id":"W2417041000","doi":"10.1182/blood.v122.21.744.744","title":"NGS-Based Detection Of Multiple RAS-Mutated Clones In MLL-Rearranged Leukemias Suggests Strong Oncogenic Collaboration","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"CEBPA; Biology; KRAS; Exome sequencing; NPM1; Exome; Transcriptome; Mutation; Genetics; Leukemia; Cancer research; Deep sequencing; Gene; Karyotype; Genome; Gene expression","score_opus":0.015177345971364617,"score_gpt":0.27767023350638953,"score_spread":0.2624928875350249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417041000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997365,0.00021925328,0.00028912514,0.00038163058,0.00006603085,0.0013771581,0.000015754864,0.000086753535,0.00019928304],"genre_scores_gemma":[0.9985679,0.000027361486,0.00078460656,0.00005669535,0.00009371832,0.00018646126,0.00009967551,0.000042362743,0.00014122878],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982453,0.00016239818,0.00045375148,0.00031823508,0.0004454131,0.0003749082],"domain_scores_gemma":[0.998637,0.0002211025,0.00014584475,0.00036592185,0.0004802107,0.000149922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033106402,0.00018335356,0.0003806061,0.00039189353,0.000054240823,0.000024897072,0.000113598515,0.00021768708,0.00012298783],"category_scores_gemma":[0.00064155785,0.00017168338,0.00007729762,0.0009914609,0.00009115103,0.00017662224,0.000031448137,0.00035200574,0.00010510966],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038162793,0.0004924779,0.05781299,0.00013010926,0.00007799351,0.000052780073,0.00025012527,0.0001823197,0.9368068,0.0000025858117,0.00010787527,0.0037023483],"study_design_scores_gemma":[0.016061893,0.0005422724,0.17613423,0.00010486465,0.00010078574,0.000023030676,0.00035829248,0.014778472,0.7916303,0.0000116937235,0.000096709104,0.00015740948],"about_ca_topic_score_codex":0.0029607844,"about_ca_topic_score_gemma":0.0017792913,"teacher_disagreement_score":0.14517641,"about_ca_system_score_codex":0.00044613122,"about_ca_system_score_gemma":0.0007778453,"threshold_uncertainty_score":0.70010453},"labels":[],"label_agreement":null},{"id":"W2417090873","doi":"10.1136/jmedgenet-2015-103578.22","title":"MG-122 Atypical fish pattern consistent with insertion of 5’ CBFB into 16p13 in a case of therapy-related acute myeloid leukaemia","year":2015,"lang":"en","type":"article","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Fusion transcript; Bone marrow; Myeloid leukaemia; Fusion gene; Biology; Chromosome 16; Leukemia; Pathology; Chromosome; Medicine; Cancer research; Immunology; Genetics; Gene","score_opus":0.033105960233940114,"score_gpt":0.3080882441254735,"score_spread":0.27498228389153334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417090873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99450374,0.000112535905,0.0002125102,0.0025645879,0.000038714297,0.0007994281,0.00001027906,0.000045731173,0.0017124593],"genre_scores_gemma":[0.99756914,0.0000954533,0.0008493318,0.0006304175,0.000025563955,0.000038244205,0.00004749135,0.000036611687,0.0007077278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979638,0.00015988643,0.0006661007,0.0003403409,0.0005343134,0.0003355637],"domain_scores_gemma":[0.99840367,0.00011777661,0.00016682991,0.00050850026,0.0005042569,0.00029896502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005445199,0.00021598538,0.0006069222,0.00031505333,0.000023049142,0.0000086570235,0.00014157106,0.00023498239,0.00019726546],"category_scores_gemma":[0.00014110476,0.00014899384,0.00009158281,0.00059491745,0.00031310506,0.00011587094,0.00010212639,0.0004988589,0.000023293003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04305341,0.0050193327,0.68094987,0.00076266413,0.002580002,0.023670359,0.017309343,0.00008597109,0.099410444,0.00044102027,0.014840346,0.111877225],"study_design_scores_gemma":[0.21496327,0.031575017,0.42605823,0.0023244012,0.0009539506,0.029660095,0.019056117,0.027990637,0.24029261,0.00072532514,0.0044504893,0.001949847],"about_ca_topic_score_codex":0.0045957733,"about_ca_topic_score_gemma":0.0020730668,"teacher_disagreement_score":0.25489163,"about_ca_system_score_codex":0.00054173515,"about_ca_system_score_gemma":0.00085634494,"threshold_uncertainty_score":0.6947465},"labels":[],"label_agreement":null},{"id":"W2417320515","doi":"10.1182/blood.v122.21.612.612","title":"Abnormalities Of 12p Are Associated With High-Risk Acute Myeloid Leukemia: A Children’s Oncology Group Report","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Hospital for Sick Children","funders":"","keywords":"ETV6; Internal medicine; Cytogenetics; Oncology; Myeloid leukemia; Medicine; Leukemia; NPM1; Karyotype; Biology; Chromosome; Chromosomal translocation; Genetics; Gene","score_opus":0.009385587597040094,"score_gpt":0.24708948958014904,"score_spread":0.23770390198310895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417320515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993747,0.00023212151,0.000028936509,0.0009721191,0.00006874944,0.0010925562,0.00011603078,0.00017556938,0.0035669256],"genre_scores_gemma":[0.99239504,0.00034271218,0.0022102129,0.00036478072,0.00025607363,0.00022972483,0.0003488926,0.000077749835,0.0037748062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970451,0.00020340204,0.00072935474,0.00052145676,0.0007897936,0.00071091723],"domain_scores_gemma":[0.9970961,0.00026619647,0.00077697076,0.0007914883,0.0007585405,0.000310679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069458486,0.00032369225,0.0009622868,0.00024575065,0.00012793977,0.000027431961,0.00027833538,0.00042732403,0.0003690674],"category_scores_gemma":[0.0008798628,0.00024260813,0.0001545217,0.00044645587,0.00036744523,0.00020880929,0.00018056275,0.00095568725,0.00009351588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004069139,0.0014981192,0.96187264,0.000109011125,0.0058875987,0.004032558,0.0006629701,0.0000066420407,0.0059401235,0.00019767247,0.017360618,0.0020251367],"study_design_scores_gemma":[0.011973237,0.0025577864,0.9674059,0.00024688925,0.0015852051,0.0039151525,0.00043361096,0.000023851842,0.010975387,0.00012611118,0.00044960223,0.0003072636],"about_ca_topic_score_codex":0.005981556,"about_ca_topic_score_gemma":0.0003467169,"teacher_disagreement_score":0.016911017,"about_ca_system_score_codex":0.0007943945,"about_ca_system_score_gemma":0.001114971,"threshold_uncertainty_score":0.98932725},"labels":[],"label_agreement":null},{"id":"W2433943400","doi":"10.1002/cncr.30140","title":"Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis","year":2016,"lang":"en","type":"article","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Hematopoietic cell; Myeloid leukemia; Hematopoietic stem cell transplantation; Haematopoiesis; Transplantation; Oncology; Stem cell; Leukemia; Bone transplantation; Myeloid; Acute leukemia; Cancer research; Internal medicine; Surgery; Genetics; Biology","score_opus":0.02433315677537625,"score_gpt":0.35514869642995167,"score_spread":0.33081553965457544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2433943400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781797,0.00027233482,0.013037181,0.002021205,0.00036874053,0.0015183343,0.0044682464,0.00003905893,0.00009523146],"genre_scores_gemma":[0.99148375,0.002338109,0.0004902118,0.00008634755,0.000513173,0.0015225316,0.00046516032,0.000056170164,0.003044522],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977113,0.000101384954,0.0003849963,0.00059206225,0.0006147006,0.0005955307],"domain_scores_gemma":[0.9979127,0.00053642085,0.00008438208,0.00026708143,0.0009489975,0.00025043022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007080766,0.00023549271,0.00043749128,0.0005499778,0.00011606299,0.00006387162,0.00017310768,0.0001670594,0.00032778387],"category_scores_gemma":[0.000035834775,0.0001279308,0.00031595438,0.00036529766,0.00014897245,0.0002366936,0.000021433123,0.00019375332,0.0000071991035],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04824571,0.0005845684,0.48005328,0.0037666822,0.017889518,0.0005031244,0.012062748,0.00007684487,0.38260728,0.00015908104,0.002990978,0.05106018],"study_design_scores_gemma":[0.07056601,0.0029391386,0.39448917,0.0019833914,0.019325383,0.00024159768,0.0012254518,0.0051415777,0.49485037,0.0007247181,0.006824741,0.0016884449],"about_ca_topic_score_codex":0.00012605732,"about_ca_topic_score_gemma":0.00031514675,"teacher_disagreement_score":0.112243086,"about_ca_system_score_codex":0.0008906346,"about_ca_system_score_gemma":0.00047998686,"threshold_uncertainty_score":0.52168673},"labels":[],"label_agreement":null},{"id":"W2461331156","doi":"10.1016/j.ccell.2016.05.018","title":"Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2","year":2016,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; Canadian Institutes of Health Research; Agios Pharmaceuticals; Leukemia and Lymphoma Society","keywords":"IDH1; Mutant; Myeloid leukemia; Isocitrate dehydrogenase; DNA damage; Biology; DNA methylation; DNA repair; Histone; Molecular biology; Cancer research; Haematopoiesis; Epigenetics; Leukemia; Mutation; DNA; Gene; Stem cell; Cell biology; Genetics; Gene expression; Enzyme; Biochemistry","score_opus":0.01321738292736709,"score_gpt":0.27598657408308197,"score_spread":0.2627691911557149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461331156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960643,0.000535208,0.00007020689,0.001594401,0.000063424224,0.000424809,0.000054605633,0.000044116452,0.0011489197],"genre_scores_gemma":[0.99724543,0.0005848327,0.0002937398,0.00031315262,0.00010691834,0.000017057195,0.000002499418,0.000025270145,0.0014111224],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99877197,0.000067372326,0.00019113175,0.00038527444,0.00027370403,0.00031053254],"domain_scores_gemma":[0.9989937,0.00015995542,0.00005791649,0.00036059204,0.00010999155,0.00031784386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037570373,0.00015111192,0.00031495548,0.00007185533,0.000040569736,0.000010874926,0.000042593125,0.00008710784,0.00014769625],"category_scores_gemma":[0.00007511376,0.00010085769,0.000047924525,0.00010711023,0.00020257197,0.00010757831,0.00017793156,0.00011247657,0.000010975831],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038873282,0.000032463617,0.011312268,0.00019581972,0.000054858352,0.00018758298,0.00048723974,0.0000013203016,0.9753245,0.0000165469,0.0013792408,0.010619439],"study_design_scores_gemma":[0.0027438009,0.00032995522,0.12050425,0.0003052129,0.000080002486,0.00007741089,0.0003909213,0.00021794795,0.87100077,0.000026881462,0.0041300906,0.00019276876],"about_ca_topic_score_codex":0.00071314984,"about_ca_topic_score_gemma":0.00033038462,"teacher_disagreement_score":0.109191984,"about_ca_system_score_codex":0.00037204984,"about_ca_system_score_gemma":0.00020317055,"threshold_uncertainty_score":0.4112857},"labels":[],"label_agreement":null},{"id":"W2461691768","doi":"10.1371/journal.pcbi.1004890","title":"A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis","year":2016,"lang":"en","type":"article","venue":"PLoS Computational Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Human Genome Research Institute; Cancer Prevention and Research Institute of Texas; University of Texas MD Anderson Cancer Center; U.S. National Library of Medicine; University of Washington; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"Myeloid leukemia; Medicine; Crowdsourcing; Oncology; Machine learning; Bioinformatics; Internal medicine; Computer science; Biology","score_opus":0.0813095796812142,"score_gpt":0.34736211422493796,"score_spread":0.26605253454372374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461691768","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34721822,0.000034806395,0.647495,0.004233524,0.00003727238,0.0006677064,0.000032051055,0.00006792823,0.0002135081],"genre_scores_gemma":[0.6291798,0.0000044522826,0.36979023,0.00043659998,0.00020342153,0.00021733988,0.00010265161,0.000015559795,0.00004999959],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989815,0.00005237755,0.00021312157,0.0003601445,0.00012779084,0.00026507798],"domain_scores_gemma":[0.9989213,0.00056399667,0.000048031863,0.000067026696,0.00028347122,0.00011617643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024406092,0.00010777744,0.00020588879,0.00019592357,0.00012994201,0.000024652065,0.00005824089,0.000098479846,0.0000044101657],"category_scores_gemma":[0.00041204641,0.00007379219,0.00003165531,0.00015825876,0.00008548047,0.0000837691,0.00007420952,0.00007838288,0.0000085031115],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007930491,0.0006381394,0.29225746,0.00089544023,0.0010783721,0.000011484163,0.0012832724,0.00076095253,0.18591125,0.025601104,0.003480217,0.48728925],"study_design_scores_gemma":[0.011377536,0.0020122381,0.47165817,0.0010421606,0.0002436755,0.00056557957,0.00040404344,0.46679226,0.016142074,0.02116386,0.0077513536,0.0008470413],"about_ca_topic_score_codex":0.0000039495867,"about_ca_topic_score_gemma":2.221934e-7,"teacher_disagreement_score":0.4864422,"about_ca_system_score_codex":0.00022829737,"about_ca_system_score_gemma":0.00025841585,"threshold_uncertainty_score":0.3009158},"labels":[],"label_agreement":null},{"id":"W2462014330","doi":"10.1007/978-1-59259-307-1","title":"Treatment of Acute Leukemias","year":2003,"lang":"en","type":"article","venue":"Humana Press eBooks","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sidney Kimmel Comprehensive Cancer Center; Pritzker School of Medicine; Hospital for Sick Children; Università Campus Bio-Medico di Roma; Universität Wien; Università degli Studi di Milano-Bicocca; University of Rochester; University College London; Strong; Johns Hopkins University; University of Washington; City of Hope; University of Pennsylvania; Children's Hospital of Philadelphia; St. Jude Children's Research Hospital; University of Southern California","keywords":"Medicine; Intensive care medicine","score_opus":0.08029402770061878,"score_gpt":0.34048265481018297,"score_spread":0.2601886271095642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2462014330","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29516473,0.002384632,0.000099188386,0.000041507035,0.00009580548,0.0009253767,0.000019453439,0.000098851546,0.70117044],"genre_scores_gemma":[0.9046497,0.00062524294,0.0012545106,0.000086827305,0.00010551315,0.00011025766,0.000015894802,0.00004995737,0.0931021],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99880004,0.000066489774,0.00025287413,0.0002584328,0.00029417858,0.00032795788],"domain_scores_gemma":[0.99903685,0.00004753227,0.000067780275,0.0005898152,0.00009754696,0.00016049434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000080647245,0.0001707008,0.00036862007,0.00010243067,0.00005906767,0.000011353459,0.00010096091,0.00009615232,0.00013367576],"category_scores_gemma":[0.000021863041,0.00013276839,0.00014372851,0.000023196533,0.00014880528,0.00002486039,0.000027469587,0.000116215364,0.000026921743],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031945815,0.002350297,0.0017170617,0.0010787962,0.009582171,0.0051703155,0.014671527,0.000025397074,0.1027522,0.41077164,0.036968827,0.4117172],"study_design_scores_gemma":[0.007532396,0.0017600721,0.0006989451,0.000051701543,0.00063097547,0.00028308967,0.00007806447,0.0001265986,0.39890712,0.0003463985,0.589351,0.00023362234],"about_ca_topic_score_codex":0.0002618698,"about_ca_topic_score_gemma":0.000006412913,"teacher_disagreement_score":0.609485,"about_ca_system_score_codex":0.00038938381,"about_ca_system_score_gemma":0.00026096948,"threshold_uncertainty_score":0.5414138},"labels":[],"label_agreement":null},{"id":"W2462569956","doi":"10.1111/petr.12764","title":"Successful umbilical cord blood hematopoietic stem cell transplantation in pediatric patients with <scp>MDS</scp>/<scp>AML</scp> associated with underlying <scp>GATA</scp>2 mutations: two case reports and review of literature","year":2016,"lang":"en","type":"review","venue":"Pediatric Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Umbilical cord; GATA2; Stem cell; Mutation; Transplantation; Germline mutation; Haematopoiesis; Cord blood; Hematopoietic stem cell; Immunology; Gene; Internal medicine; Genetics; Biology","score_opus":0.0197867855980073,"score_gpt":0.29641787677395287,"score_spread":0.2766310911759456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2462569956","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37121153,0.62204134,0.0003116946,0.000010868805,0.0001212523,0.004725001,0.001209715,0.00013553743,0.00023308108],"genre_scores_gemma":[0.038094115,0.95111805,0.000422367,0.00005910116,0.00029587437,0.00070351065,0.008758014,0.00028248815,0.0002664737],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.990512,0.0011633657,0.0031387554,0.0018552194,0.0020993676,0.0012312568],"domain_scores_gemma":[0.98685396,0.0076432778,0.002867575,0.0008604252,0.0011205745,0.00065421284],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0016366376,0.001418443,0.0033683295,0.001960179,0.0002586354,0.00015774558,0.00032257833,0.0010141126,0.00000818431],"category_scores_gemma":[0.0008089084,0.0010461605,0.00045883193,0.0044862404,0.00020001126,0.0007834826,0.00003980231,0.001904132,0.000017135679],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001140116,0.0017999854,0.1530476,0.7779957,0.00074046024,0.042693067,0.005619168,0.000013114298,0.000004269822,0.000020822192,0.0005593272,0.017392432],"study_design_scores_gemma":[0.0646613,0.009201326,0.10161629,0.50998676,0.1799869,0.12268508,0.0015861717,0.000071043934,0.00018787921,0.00018390256,0.007724765,0.002108578],"about_ca_topic_score_codex":0.00008816469,"about_ca_topic_score_gemma":0.0001347954,"teacher_disagreement_score":0.3331174,"about_ca_system_score_codex":0.0005442569,"about_ca_system_score_gemma":0.0020809802,"threshold_uncertainty_score":0.9998566},"labels":[],"label_agreement":null},{"id":"W2462678394","doi":"10.1182/blood.v120.21.2534.2534","title":"NPM1, IDH1/2 and DNAH11 Gene Mutations Can Improve a Prognostic Stratification of Acute Myeloid Leukemia Patients with Normal Karyotype but Not Harboring FLT3/ITD Mutation.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"NPM1; Myeloid leukemia; Internal medicine; Oncology; IDH1; Neuroblastoma RAS viral oncogene homolog; Biology; Sanger sequencing; Myeloid; Cancer research; Immunology; Medicine; Mutation; Karyotype; Gene; Genetics; KRAS","score_opus":0.010688706390760312,"score_gpt":0.2449127783885928,"score_spread":0.2342240719978325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2462678394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749875,0.00011028824,0.00023965233,0.00016402324,0.000071902585,0.0012178506,0.0002283015,0.00006077153,0.00040847022],"genre_scores_gemma":[0.99195987,0.00002357222,0.0067567225,0.00006252686,0.0001830117,0.00016026844,0.00061913574,0.000051480947,0.00018338917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981234,0.000056383084,0.0004146579,0.00033211775,0.0005744488,0.00049896503],"domain_scores_gemma":[0.99846035,0.000116707786,0.00022054692,0.0003711344,0.00050608325,0.00032515833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023046495,0.00023031697,0.00031006537,0.00021024242,0.00014273608,0.000035229616,0.000117622614,0.00012275027,0.000025761921],"category_scores_gemma":[0.00018850177,0.00019600645,0.000045436136,0.0003758161,0.00017577603,0.000353138,0.000061717765,0.00030985518,0.000015200133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006110246,0.0011100493,0.6280882,0.00039082754,0.0010182896,0.00005215169,0.0028879542,0.000020105352,0.3606211,0.00021827997,0.000048096004,0.004933978],"study_design_scores_gemma":[0.0054937364,0.0007171678,0.6758525,0.00006753479,0.000997671,0.0000708709,0.0001700348,0.0002775328,0.31612715,0.00001038278,0.000014350551,0.00020106518],"about_ca_topic_score_codex":0.00029518703,"about_ca_topic_score_gemma":0.000030684547,"teacher_disagreement_score":0.04776435,"about_ca_system_score_codex":0.00021115635,"about_ca_system_score_gemma":0.0007305766,"threshold_uncertainty_score":0.79929113},"labels":[],"label_agreement":null},{"id":"W2463341279","doi":"","title":"Insights into acute myeloid leukemia via single cell network profiling.","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Flow cytometry; Profiling (computer programming); Leukemia; Myeloid; Cell; Computational biology; Mass cytometry; Biology; Cancer research; Computer science; Immunology; Phenotype; Gene; Genetics","score_opus":0.01578078160438932,"score_gpt":0.24361811247571408,"score_spread":0.22783733087132477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2463341279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9543461,0.0004126433,0.0005472128,0.0011997002,0.00114011,0.0023740516,0.0000028003126,0.0003348127,0.039642554],"genre_scores_gemma":[0.97504073,0.00006496455,0.011488751,0.0011748292,0.0019063747,0.001542654,0.00008733402,0.00010910796,0.008585221],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970178,0.00007162763,0.00044063278,0.00064028014,0.00065591396,0.0011737206],"domain_scores_gemma":[0.9977693,0.00014430292,0.0001310578,0.0009268812,0.00024711055,0.00078133325],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004644553,0.00033302527,0.00048590158,0.00021501613,0.00021552286,0.00007464643,0.000423836,0.00039890068,0.000089168076],"category_scores_gemma":[0.00021863644,0.00027816783,0.00016384812,0.000717997,0.00025242305,0.00021028488,0.00028717399,0.001532719,0.00035003104],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015914268,0.0007276127,0.016886894,0.00047122902,0.00065203814,0.0012484393,0.0009797664,0.00006394245,0.58647645,0.0013142829,0.07046362,0.31912434],"study_design_scores_gemma":[0.00757354,0.0004510905,0.13396183,0.00004141613,0.0005044538,0.00032420404,0.000094019015,0.0027774426,0.5635582,0.0048635406,0.28468013,0.0011701197],"about_ca_topic_score_codex":0.000112019676,"about_ca_topic_score_gemma":0.00008965831,"teacher_disagreement_score":0.3179542,"about_ca_system_score_codex":0.00084231776,"about_ca_system_score_gemma":0.0004950484,"threshold_uncertainty_score":0.99996704},"labels":[],"label_agreement":null},{"id":"W2464912596","doi":"10.1007/s10637-016-0375-2","title":"A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; University of Alberta; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chronic myelomonocytic leukemia; Internal medicine; Myeloid leukemia; Gastroenterology; Refractory (planetary science); Leukemia; Myelodysplastic syndromes; Bone marrow","score_opus":0.02233236206226961,"score_gpt":0.29068264046947645,"score_spread":0.2683502784072068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464912596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919219,0.000050094382,0.0000386347,0.0045756563,0.00033063797,0.0025125367,0.000115811155,0.00007688827,0.00037784135],"genre_scores_gemma":[0.9818884,0.000065800814,0.0013913341,0.0010234345,0.00089002564,0.00017999981,0.00012436122,0.00011663836,0.0143200075],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953869,0.00030030345,0.0009992145,0.0007694562,0.0018101372,0.0007340012],"domain_scores_gemma":[0.99652463,0.0008450974,0.00054079265,0.0010334924,0.00041390164,0.0006421003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005782469,0.00049517525,0.0007394551,0.00043336354,0.00014807706,0.00003142122,0.00059400324,0.00033775312,0.0004313013],"category_scores_gemma":[0.0017034297,0.00024281483,0.00018263518,0.0013236171,0.0009997915,0.00050474005,0.00025704023,0.0008227744,0.00010572114],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6716919,0.0031603468,0.01358306,0.00070715137,0.0014176434,0.0007123455,0.003712224,0.00013790735,0.122290164,0.001620302,0.084477894,0.09648906],"study_design_scores_gemma":[0.8489461,0.017782,0.03336828,0.003737497,0.0005250278,0.000082480256,0.00014940772,0.0005568749,0.05719195,0.001171112,0.035409283,0.0010799841],"about_ca_topic_score_codex":0.00032412785,"about_ca_topic_score_gemma":0.00013860466,"teacher_disagreement_score":0.1772542,"about_ca_system_score_codex":0.009363422,"about_ca_system_score_gemma":0.034222607,"threshold_uncertainty_score":0.9944395},"labels":[],"label_agreement":null},{"id":"W2465217728","doi":"10.1007/s40291-016-0222-3","title":"Inter-Laboratory Evaluation of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia","year":2016,"lang":"en","type":"article","venue":"Molecular Diagnosis & Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast; National Instruments Corporation","keywords":"Concordance; Myeloid leukemia; DNA sequencing; Oncology; Medicine; Gene; Internal medicine; Biology; Computational biology; Bioinformatics; Genetics","score_opus":0.1306996437713829,"score_gpt":0.3572269608685013,"score_spread":0.2265273170971184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2465217728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781109,0.0019932613,0.01479273,0.0027139743,0.00014268643,0.0020524696,0.00005956368,0.000058689035,0.000075730866],"genre_scores_gemma":[0.99100876,0.0026970052,0.0024956148,0.0014122266,0.00024344899,0.0019001801,0.00008483969,0.00008310119,0.00007484684],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99751335,0.00031420676,0.00044920732,0.00048535664,0.0008464797,0.00039141858],"domain_scores_gemma":[0.997475,0.00021889152,0.0001864073,0.00064168783,0.0013260922,0.00015189449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014874792,0.00024955664,0.0004147103,0.0002574866,0.00007580731,0.00003383543,0.00021195135,0.00019242456,0.00021729046],"category_scores_gemma":[0.0005135304,0.00018000869,0.00021505747,0.0003487931,0.00011553994,0.00022619244,0.00004082027,0.00013938319,0.000024102093],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002243926,0.00006690787,0.001000676,0.000020066062,0.0004254381,0.000013455099,0.00027223106,0.000020710193,0.82160544,0.000085757005,0.0024613289,0.17380358],"study_design_scores_gemma":[0.0066886395,0.0007882895,0.0013985953,0.00019305885,0.00034986794,0.000010848972,0.00007628195,0.00411616,0.9820971,0.00025716765,0.0038074323,0.00021654072],"about_ca_topic_score_codex":0.00005957596,"about_ca_topic_score_gemma":0.000011679778,"teacher_disagreement_score":0.17358704,"about_ca_system_score_codex":0.0021879496,"about_ca_system_score_gemma":0.0017067906,"threshold_uncertainty_score":0.73405415},"labels":[],"label_agreement":null},{"id":"W2466341936","doi":"10.1182/blood.v126.23.2903.2903","title":"Systematic Review of the Efficacy and Safety of Alternative Azacitidine Regimens in Myelodysplastic Syndrome","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Tolerability; Medicine; Azacitidine; Regimen; Dosing; Internal medicine; Randomized controlled trial; Observational study; Clinical trial; Myelodysplastic syndromes; Chronic myelomonocytic leukemia; Oncology; Adverse effect; Bone marrow","score_opus":0.02108732249662249,"score_gpt":0.28551377442810627,"score_spread":0.2644264519314838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2466341936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976295,0.019505313,0.000012390575,0.00075170735,0.000037402588,0.0020718516,0.000016144717,0.0000092739665,0.0013009073],"genre_scores_gemma":[0.996797,0.0026175433,0.0001399059,0.000104915955,0.0000150740725,0.000030120958,0.000003631804,0.000014179301,0.00027760048],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9984799,0.00021634801,0.0005456356,0.00015257172,0.00044935592,0.00015618802],"domain_scores_gemma":[0.99866545,0.00039407003,0.00021915707,0.0004314104,0.00018784803,0.0001020762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090985093,0.00010645407,0.0007454462,0.00009068648,0.000011689516,0.0000021333594,0.0001641314,0.000042326905,0.000011331032],"category_scores_gemma":[0.0031588627,0.00006309032,0.0000538746,0.0003686312,0.00013916538,0.000031254633,0.00012572552,0.0001852167,0.0000070095557],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039702054,0.0010881643,0.008640539,0.98262006,0.0009287049,0.00043552794,0.0015559486,0.000007527874,0.0026930391,0.0011409973,0.00045689766,0.0000355509],"study_design_scores_gemma":[0.022671834,0.0014087394,0.045957614,0.9160629,0.0023429613,0.003059058,0.00045731742,0.00018299604,0.0074485103,0.00013758414,0.00003393174,0.00023654914],"about_ca_topic_score_codex":0.00004035857,"about_ca_topic_score_gemma":0.0000027992496,"teacher_disagreement_score":0.06655718,"about_ca_system_score_codex":0.00007989762,"about_ca_system_score_gemma":0.00022949855,"threshold_uncertainty_score":0.37816817},"labels":[],"label_agreement":null},{"id":"W2466370808","doi":"10.1182/blood.v126.23.5244.5244","title":"Descriptive Analysis of Azacitidine Use in Four Adult University Teaching Hospitals in Quebec, Canada","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université Laval; Hôpital Notre-Dame; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; International Prognostic Scoring System; Azacitidine; Internal medicine; Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Population; Pharmacy; Pediatrics; Family medicine; Bone marrow","score_opus":0.02461848111633017,"score_gpt":0.24610899256940058,"score_spread":0.22149051145307042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2466370808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981555,0.000036343114,0.000025170266,0.00047003778,0.000017220473,0.00019313201,0.000035791294,0.000009860088,0.0010569784],"genre_scores_gemma":[0.9973808,0.000014067539,0.00064291304,0.00006271479,0.00001584927,0.0000013683201,0.000028511156,0.000009388608,0.0018444227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987899,0.00016145069,0.00020533771,0.00021619385,0.00036715687,0.00025992704],"domain_scores_gemma":[0.99915975,0.000117298274,0.00006317411,0.0002557002,0.00021744138,0.00018662665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003314935,0.00010155477,0.00041630832,0.0006557907,0.000016351654,0.0000072330554,0.00013065974,0.00006813226,0.000014398092],"category_scores_gemma":[0.00097289146,0.00010111473,0.000059874717,0.0011017091,0.000043422115,0.00016596401,0.00007746253,0.00035131682,0.000001232381],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016423342,0.00020113193,0.993601,0.000019323907,0.00051188946,0.0014823461,0.0013595424,0.000107971486,0.00076314626,0.00011633999,0.0014845707,0.00018847556],"study_design_scores_gemma":[0.0068540736,0.00011179507,0.98188704,0.00010023879,0.00073802983,0.0000066444713,0.0067148865,0.0014736418,0.0015385951,0.0000065962677,0.00041923646,0.00014924606],"about_ca_topic_score_codex":0.9879203,"about_ca_topic_score_gemma":0.99558496,"teacher_disagreement_score":0.011714013,"about_ca_system_score_codex":0.0014044222,"about_ca_system_score_gemma":0.0017300148,"threshold_uncertainty_score":0.4123339},"labels":[],"label_agreement":null},{"id":"W2466990390","doi":"10.1182/blood.v122.21.2567.2567","title":"High Levels Of IL-27 Occur In Newly Diagnosed Acute Myeloid Leukemia (AML) and May Influence Outcome By Suppressing T Cell Function","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytokine; Medicine; Immunology; Leukemia; Myeloid leukemia; Haematopoiesis; Myeloid; Immune system; Internal medicine; Stem cell; Biology","score_opus":0.01526804908344721,"score_gpt":0.2679916751975374,"score_spread":0.2527236261140902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2466990390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973151,0.00040749236,0.00008445938,0.00057263474,0.00009294888,0.00076854037,0.00010082912,0.000057936944,0.0006000423],"genre_scores_gemma":[0.9957923,0.00015214707,0.0015704221,0.0005158535,0.00007896121,0.000062697756,0.000042224186,0.00004664618,0.001738705],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99776465,0.00010337683,0.0006119706,0.00047467297,0.00049067225,0.00055465574],"domain_scores_gemma":[0.99859476,0.0002929741,0.00017757881,0.00049238844,0.0001823254,0.00025998568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031416427,0.00027558062,0.0005756169,0.00025913952,0.00006099898,0.000055692002,0.000210385,0.0002536936,0.00025316168],"category_scores_gemma":[0.00023990839,0.00024132444,0.00007027217,0.00038763956,0.00018848992,0.00042807104,0.00018281743,0.00058315444,0.00011009428],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013399041,0.0002801563,0.29009953,0.00027559564,0.00010764244,0.00011698862,0.00031187115,0.00002217696,0.7012312,0.00001829645,0.0043860334,0.0030165387],"study_design_scores_gemma":[0.014606154,0.00051168137,0.7215078,0.00017287319,0.0002797412,0.00005877469,0.00019262459,0.00015443127,0.26108256,0.00009436757,0.001027816,0.000311163],"about_ca_topic_score_codex":0.0019999947,"about_ca_topic_score_gemma":0.000025361855,"teacher_disagreement_score":0.4401486,"about_ca_system_score_codex":0.00023651593,"about_ca_system_score_gemma":0.00032198225,"threshold_uncertainty_score":0.98409253},"labels":[],"label_agreement":null},{"id":"W2467412215","doi":"10.1182/blood.v126.23.2596.2596","title":"Whole Exome Sequencing Reveals the Landscape of Clonal Evolution from MDS to AML Progression","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Exome sequencing; Somatic evolution in cancer; Exome; Biology; DNA sequencing; Computational biology; Indel; Genetics; Myeloid leukemia; Whole genome sequencing; Deep sequencing; Genome; Gene; Mutation; Cancer research; Genotype; Single-nucleotide polymorphism","score_opus":0.03904503971649254,"score_gpt":0.3181829077107077,"score_spread":0.27913786799421514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2467412215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933924,0.00068334455,0.0001390386,0.0031179034,0.0000651563,0.0004741634,0.000031360723,0.00004110931,0.0020555363],"genre_scores_gemma":[0.9954236,0.0000061421306,0.003097611,0.00022325173,0.00043624057,0.000037236103,0.000048976068,0.00001869893,0.000708227],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985914,0.00009565745,0.00022740978,0.00021169177,0.00062111014,0.00025267986],"domain_scores_gemma":[0.9990081,0.00008531796,0.0000721126,0.0004037914,0.00023613281,0.00019450589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006405087,0.00009945596,0.00021734703,0.00008933203,0.00004829564,0.000013069964,0.00017633851,0.00008982651,0.00004760489],"category_scores_gemma":[0.0004752173,0.00006148195,0.00005136747,0.0003085426,0.000053589974,0.00006070235,0.00013460052,0.00023189737,0.00013689842],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062509504,0.00041813983,0.22841431,0.000092471775,0.00019316596,0.00014133728,0.0028584003,0.000029356088,0.71387714,0.00023494093,0.050006744,0.0031088814],"study_design_scores_gemma":[0.027554525,0.005462107,0.6495591,0.0023340008,0.0009450494,0.00052416505,0.006532998,0.0026232852,0.27284154,0.0034964166,0.02735223,0.0007745592],"about_ca_topic_score_codex":0.00017662064,"about_ca_topic_score_gemma":0.000012787952,"teacher_disagreement_score":0.4410356,"about_ca_system_score_codex":0.00020081292,"about_ca_system_score_gemma":0.00054354017,"threshold_uncertainty_score":0.25071612},"labels":[],"label_agreement":null},{"id":"W2468369718","doi":"10.1182/blood.v108.11.15.15","title":"Outcome of Down Syndrome (DS) Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Treated with a Uniform Prospective Clinical Trial - Initial Report of the COG Trial A2971.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre","funders":"","keywords":"Medicine; Internal medicine; Regimen; Etoposide; Surgery; Gastroenterology; Chemotherapy","score_opus":0.0276040823361425,"score_gpt":0.3310719598564472,"score_spread":0.30346787752030474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2468369718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876816,0.000020249076,0.000024904073,0.0002150679,0.00016720389,0.0077157067,0.00020283074,0.00012386955,0.0038485182],"genre_scores_gemma":[0.9943475,0.000019436446,0.0010857813,0.000056905938,0.00082285947,0.00027860576,0.00018055066,0.000119912234,0.0030884081],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938468,0.0003099477,0.0023977016,0.00094634487,0.0017289651,0.0007702684],"domain_scores_gemma":[0.995809,0.00041279668,0.0013125935,0.0015505054,0.0006273352,0.00028774314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013660863,0.00060053397,0.0020482247,0.00030144321,0.00016875601,0.00003737916,0.00061073137,0.00051818544,0.00013098857],"category_scores_gemma":[0.00068576436,0.0003082428,0.000485755,0.0013998036,0.0012430971,0.00019387928,0.00023589518,0.0012965181,0.000011588028],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59317845,0.0033283485,0.3926665,0.000083674066,0.004213499,0.0051958715,0.00008790274,0.000006259262,0.00062385516,0.000093848605,0.00036488005,0.00015695326],"study_design_scores_gemma":[0.5632618,0.024117857,0.37957054,0.00026148272,0.0043900036,0.018576996,0.00005732495,0.000013472125,0.009252669,0.00002643191,0.00009091872,0.00038051268],"about_ca_topic_score_codex":0.0018799779,"about_ca_topic_score_gemma":0.00046711825,"teacher_disagreement_score":0.029916625,"about_ca_system_score_codex":0.00043215608,"about_ca_system_score_gemma":0.004426474,"threshold_uncertainty_score":0.99993694},"labels":[],"label_agreement":null},{"id":"W2470434425","doi":"10.1080/10245332.2000.11746507","title":"Current Clinical Practice: Acute Myeloblastic Leukemia: Management with High-Dose Cytosine Arabinoside, Daunorubicin and Marrow Transplantation","year":2000,"lang":"en","type":"article","venue":"Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Daunorubicin; Acute myeloblastic leukemia; Internal medicine; Cytarabine; Gastroenterology; Leukemia; Complete remission; Transplantation; Surgery; Bone marrow; Chemotherapy","score_opus":0.01724182538619234,"score_gpt":0.3403911795552089,"score_spread":0.3231493541690166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470434425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819911,0.001268605,0.0018185346,0.0069199395,0.0002119469,0.0013081488,0.00002108316,0.00015361587,0.006307013],"genre_scores_gemma":[0.9629365,0.018413255,0.015211981,0.0013541847,0.000182443,0.00014825507,0.00018783129,0.00006905136,0.0014964936],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973896,0.0002397556,0.0006580184,0.0006931996,0.00044630805,0.0005731213],"domain_scores_gemma":[0.9984925,0.00045242318,0.00013771433,0.00047147195,0.00012645133,0.0003194658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045408474,0.0003012158,0.0007105903,0.00020024981,0.00011652828,0.000026127293,0.00014138213,0.0002209137,0.0005468105],"category_scores_gemma":[0.00007471238,0.00023360165,0.00006762425,0.00032694897,0.0003685494,0.00020098964,0.00004648658,0.0008039789,0.00032888894],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09871049,0.0044264626,0.07261139,0.008952739,0.006761673,0.082563765,0.0016223083,0.0001972319,0.0033453747,0.061031643,0.07102654,0.58875036],"study_design_scores_gemma":[0.1075125,0.011751721,0.51427734,0.0036687672,0.014345706,0.14623407,0.0009775846,0.0049771876,0.008871011,0.0019582463,0.18269898,0.0027268808],"about_ca_topic_score_codex":0.000038292284,"about_ca_topic_score_gemma":0.000018332958,"teacher_disagreement_score":0.5860235,"about_ca_system_score_codex":0.00022737897,"about_ca_system_score_gemma":0.00027954596,"threshold_uncertainty_score":0.9525999},"labels":[],"label_agreement":null},{"id":"W2471021613","doi":"10.1182/blood.v126.23.3681.3681","title":"Identification of Existing Bioactive Compounds That Target Acute Myeloid Leukemia Stem Cells","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre","funders":"","keywords":"Stem cell; Daunorubicin; Haematopoiesis; Myeloid leukemia; Leukemia; Myeloid; Cancer research; Biology; Medicine; Oncology; Internal medicine; Immunology; Pharmacology; Genetics","score_opus":0.06591101255448366,"score_gpt":0.31787829763707476,"score_spread":0.2519672850825911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471021613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98807853,0.00027502314,0.00076228456,0.0002228756,0.00016738244,0.00077492266,0.00007372055,0.00010678931,0.009538479],"genre_scores_gemma":[0.9929498,0.000044638058,0.0025487288,0.000068770285,0.00018742781,0.00004701259,0.000058160495,0.00004538922,0.004050093],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99798316,0.00010122001,0.00044350862,0.00037101412,0.0007343046,0.0003667769],"domain_scores_gemma":[0.9982688,0.00011572288,0.00029025675,0.00058499945,0.00045205202,0.00028819768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007349783,0.00019024716,0.00042356047,0.00020604399,0.00006750732,0.000036123947,0.00026711985,0.0001512336,0.000019887817],"category_scores_gemma":[0.000072293245,0.0001718807,0.0001040358,0.00037804627,0.0001745905,0.00017025025,0.00013697098,0.00034563808,0.0001436738],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044848342,0.0004566375,0.013962605,0.00018418302,0.000632622,0.00015657644,0.001791721,0.000016503502,0.97611314,0.00022484439,0.0048240623,0.001188648],"study_design_scores_gemma":[0.0046773087,0.0003489693,0.002776917,0.000084667474,0.0003078284,0.00013245383,0.0013779554,0.0007681787,0.98698604,0.00011232861,0.0022560642,0.00017128108],"about_ca_topic_score_codex":0.000095207404,"about_ca_topic_score_gemma":0.000002433379,"teacher_disagreement_score":0.011185688,"about_ca_system_score_codex":0.0005429013,"about_ca_system_score_gemma":0.0008588871,"threshold_uncertainty_score":0.70090914},"labels":[],"label_agreement":null},{"id":"W2471444531","doi":"10.1182/blood.v116.21.1071.1071","title":"Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children's Oncology Group.","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Hospital for Sick Children","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Neutropenia; Gemtuzumab ozogamicin; Mitoxantrone; Etoposide; Common Terminology Criteria for Adverse Events; Chemotherapy; Regimen; Chemotherapy regimen; Febrile neutropenia; Adverse effect; Oncology; Gastroenterology; Surgery","score_opus":0.007731818240814547,"score_gpt":0.25890430097996237,"score_spread":0.25117248273914783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471444531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99096084,0.00033641828,0.000010550293,0.0031403922,0.00029898618,0.00076721987,0.00006291742,0.00022390908,0.0041987756],"genre_scores_gemma":[0.9877841,0.00075017713,0.0022754795,0.001286543,0.004697036,0.00009804573,0.00019223613,0.00010054372,0.0028158748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755406,0.00008330634,0.00047969216,0.000619582,0.00059622584,0.0006671206],"domain_scores_gemma":[0.9979257,0.00031002422,0.00021267627,0.0011594697,0.0001253185,0.00026679342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004584422,0.0003214776,0.0005167797,0.00013237944,0.00028548605,0.000057461315,0.00050284114,0.00041852886,0.0006685048],"category_scores_gemma":[0.0002930712,0.00022513553,0.00021143035,0.0003874757,0.00021751226,0.0001283318,0.0002499335,0.0017267955,0.000145665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000838963,0.0008963441,0.7459629,0.00007088951,0.0020146514,0.0057312152,0.0019985586,0.0000018378763,0.22065572,0.00010322938,0.01709845,0.0046271915],"study_design_scores_gemma":[0.01202623,0.0003523284,0.93852806,0.000023032375,0.0009924694,0.013336365,0.00021503527,0.000019113382,0.026560785,0.00018294023,0.007342585,0.00042107736],"about_ca_topic_score_codex":0.00073566445,"about_ca_topic_score_gemma":0.00016172274,"teacher_disagreement_score":0.19409494,"about_ca_system_score_codex":0.00031112146,"about_ca_system_score_gemma":0.0011190976,"threshold_uncertainty_score":0.91807604},"labels":[],"label_agreement":null},{"id":"W2471543430","doi":"10.11138/gchir/2015.36.5.222","title":"A rare case of myeloid sarcoma presenting as anal fissure","year":2015,"lang":"it","type":"article","venue":"Il Giornale di Chirurgia - Journal of the Italian Association of Hospital Surgeons","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Myeloid sarcoma; Medicine; Myeloid leukemia; Sarcoma; Pathology; Myeloid; Biopsy; Rare disease; Disease; Cancer research","score_opus":0.015617427355841403,"score_gpt":0.2764497438937665,"score_spread":0.26083231653792505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471543430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778584,0.0022526924,0.000013134371,0.01202802,0.00281115,0.00075402076,0.0006956741,0.000018747567,0.003568115],"genre_scores_gemma":[0.9847115,0.00031695503,0.0001344579,0.00009107154,0.00086206157,0.0000057181965,0.000023367049,0.00010526946,0.013749555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9904443,0.0013114972,0.003045439,0.00043337554,0.0036270462,0.0011383544],"domain_scores_gemma":[0.984543,0.0013465043,0.007554907,0.0008979108,0.0046221847,0.0010354723],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005822867,0.0006126605,0.0019325801,0.00069547794,0.00030433288,0.00013622078,0.0012163174,0.00060590403,0.0004149466],"category_scores_gemma":[0.01397871,0.0004834268,0.0019440419,0.0016439292,0.0004012509,0.00073379633,0.00055542716,0.0020851078,0.0000571079],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007705687,0.0016278755,0.8942304,0.0003367746,0.0036124268,0.005912946,0.006152901,0.00034402646,0.0011315206,0.00016870715,0.08470318,0.001008623],"study_design_scores_gemma":[0.029740706,0.008828429,0.8233043,0.0070309252,0.0075344075,0.019689074,0.029367171,0.0021058042,0.026979513,0.0024678297,0.040500373,0.002451478],"about_ca_topic_score_codex":0.0013756836,"about_ca_topic_score_gemma":0.00013802199,"teacher_disagreement_score":0.07092617,"about_ca_system_score_codex":0.0022813845,"about_ca_system_score_gemma":0.0033516458,"threshold_uncertainty_score":0.99976176},"labels":[],"label_agreement":null},{"id":"W2471837641","doi":"10.18632/oncotarget.10446","title":"A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia","year":2016,"lang":"en","type":"article","venue":"Oncotarget","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"Fonds de Recherche du Québec - Santé; Stem Cell Network; MEI Pharma","keywords":"Myeloid leukemia; Microtubule polymerization; Tubulin; Leukemia; Cancer research; Cytotoxic T cell; Mechanism of action; Vinblastine; Apoptosis; Cell culture; Programmed cell death; Medicine; Microtubule; Haematopoiesis; Colchicine; Immunology; Biology; In vitro; Cell biology; Stem cell; Chemotherapy; Internal medicine; Biochemistry","score_opus":0.016458933914873405,"score_gpt":0.289835202970944,"score_spread":0.2733762690560706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471837641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9249795,0.0008351445,0.00430932,0.049185343,0.00044709272,0.0015198182,0.000111364316,0.00023757781,0.018374853],"genre_scores_gemma":[0.94901305,0.0013304937,0.0063688364,0.00458853,0.00087897107,0.00025089452,0.000064149724,0.00016210538,0.037342984],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99659026,0.00012673334,0.00057998183,0.0006996884,0.00086882303,0.0011345152],"domain_scores_gemma":[0.9977676,0.0004340719,0.00013892425,0.0010995243,0.00019011315,0.00036976815],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000996701,0.00040284122,0.0006308701,0.0003102972,0.00015776661,0.000038355643,0.00062490423,0.00029602842,0.000858873],"category_scores_gemma":[0.0005276593,0.000213158,0.0002251572,0.00074013165,0.0003317316,0.00026448793,0.00032504124,0.00079988356,0.001352973],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009506209,0.00024780107,0.030132692,0.000057909903,0.00027517797,0.00044217368,0.00066138996,0.000006122011,0.85268015,0.0010394461,0.105531886,0.007974644],"study_design_scores_gemma":[0.02052375,0.0012117182,0.25839096,0.00060384744,0.00024741807,0.0008149145,0.0003959186,0.0012311919,0.08904232,0.0012718665,0.6251508,0.0011152877],"about_ca_topic_score_codex":0.0005669338,"about_ca_topic_score_gemma":0.0001979437,"teacher_disagreement_score":0.76363784,"about_ca_system_score_codex":0.0024255363,"about_ca_system_score_gemma":0.0014712088,"threshold_uncertainty_score":0.9994246},"labels":[],"label_agreement":null},{"id":"W2476655743","doi":"10.1182/blood.v122.21.2163.2163","title":"The Outcome Of Allogeneic Hematopoietic Cell Transplantation In Children With FLT3/ITD-Positive Acute Myelogenous Leukemia","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Cumulative incidence; Medicine; Hazard ratio; Hematopoietic stem cell transplantation; Internal medicine; Transplantation; Oncology; Proportional hazards model; Minimal residual disease; Leukemia; Confidence interval","score_opus":0.007420899564877665,"score_gpt":0.24201570897308392,"score_spread":0.23459480940820626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2476655743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634355,0.0003455645,0.000084506435,0.0003946949,0.0000149398775,0.0013912321,0.000028028073,0.000029951203,0.0013675276],"genre_scores_gemma":[0.9979295,0.00037871412,0.00080123794,0.00014000668,0.000041939853,0.0001229475,0.000074227246,0.000039608083,0.00047177976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837977,0.00009222573,0.0003957364,0.00028039012,0.000412312,0.00043957253],"domain_scores_gemma":[0.9990869,0.00013588976,0.000111776906,0.0004032512,0.00013786208,0.00012430288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022883584,0.00019811287,0.00036809992,0.00012155715,0.0000911554,0.000022745136,0.00024118813,0.00012238746,0.000053428437],"category_scores_gemma":[0.000016691703,0.00012186724,0.000079129495,0.0002890276,0.00017927136,0.000080228594,0.000034764184,0.00035393966,0.000115353345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025424853,0.00035868256,0.9416286,0.00012214248,0.00055560103,0.00015823165,0.0014161419,0.000022304375,0.054535702,0.00007604098,0.000076918404,0.0007953941],"study_design_scores_gemma":[0.0063473205,0.00056722877,0.84984463,0.000065753324,0.00052855426,0.0010010363,0.00019566542,0.00002554488,0.14121,0.000049112386,0.0000070008027,0.00015814649],"about_ca_topic_score_codex":0.00080752047,"about_ca_topic_score_gemma":0.0000754681,"teacher_disagreement_score":0.091783956,"about_ca_system_score_codex":0.00016310097,"about_ca_system_score_gemma":0.0003131834,"threshold_uncertainty_score":0.4969602},"labels":[],"label_agreement":null},{"id":"W2480078637","doi":"10.1017/cbo9781316017852.016","title":"Atypical chronic myeloid leukemia and chronic neutrophilic leukemia","year":2016,"lang":"en","type":"book-chapter","venue":"Cambridge University Press eBooks","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Myeloid leukemia; Chronic leukemia; Medicine; Leukemia; Computer science; Immunology; Acute leukemia","score_opus":0.01917661434618969,"score_gpt":0.22926091091221476,"score_spread":0.21008429656602506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2480078637","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006068183,0.0025988666,0.00015508382,0.00022331547,0.00024019659,0.0015442575,0.00031651146,0.00035416413,0.9884994],"genre_scores_gemma":[0.011241936,0.003745819,0.00007010207,0.00016120588,0.0017371485,0.0000052757946,0.00010921984,0.00022206163,0.9827072],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961183,0.000086757274,0.00045825835,0.0014707961,0.0007676873,0.001098222],"domain_scores_gemma":[0.99667585,0.00021456336,0.00029837652,0.0015092412,0.00033043523,0.0009715453],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00020866313,0.000948052,0.0012770827,0.00055409415,0.0003564809,0.000063076965,0.0007285736,0.0013749148,0.00008686007],"category_scores_gemma":[0.000036789974,0.0009013881,0.00046721246,0.000028210734,0.0014847585,0.0001643207,0.001310883,0.0021778706,0.00023415605],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0025946347,0.000017800572,0.000018001505,0.0016110565,0.0012062463,0.005632606,0.00005220979,0.0000034303207,0.009832321,0.8491643,0.096667714,0.033199646],"study_design_scores_gemma":[0.005989892,0.0007866042,0.00029832814,0.0012905549,0.00074971595,0.00062045356,0.000009803435,0.00023750261,0.0016020883,0.000020014259,0.98747015,0.0009249038],"about_ca_topic_score_codex":0.000111305424,"about_ca_topic_score_gemma":0.000010388413,"teacher_disagreement_score":0.89080244,"about_ca_system_score_codex":0.023550903,"about_ca_system_score_gemma":0.0064158835,"threshold_uncertainty_score":0.9999215},"labels":[],"label_agreement":null},{"id":"W2485954867","doi":"10.1182/blood.v126.23.3832.3832","title":"5-Hydroxymethylcytosine Is Correlated with TET2 or IDH1/2 Mutations However, May Not be a Prognostic Value to Predict the Survivals in Normal Karyotype AML","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"IDH1; IDH2; Mutation; Internal medicine; Biology; NPM1; Isocitrate dehydrogenase; Induction chemotherapy; Oncology; Medicine; Chemotherapy; Cancer research; Gastroenterology; Karyotype; Genetics; Gene; Chromosome","score_opus":0.04116434620026583,"score_gpt":0.30618611590368305,"score_spread":0.26502176970341723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2485954867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97664464,0.0001291221,0.00014903267,0.018042566,0.00011794174,0.0023185394,0.00010520085,0.0001356802,0.002357277],"genre_scores_gemma":[0.99143076,0.000018436782,0.0018357979,0.0020479958,0.00017480555,0.00025911038,0.00011250929,0.00007713967,0.004043472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712193,0.00026450396,0.00042401516,0.00047418007,0.0010473859,0.0006679998],"domain_scores_gemma":[0.9976548,0.00066741515,0.00009382988,0.00067365664,0.00040719795,0.0005030988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010749461,0.00029114672,0.00045346128,0.00032157765,0.00011012702,0.000053119424,0.0003578653,0.00017527335,0.00017895782],"category_scores_gemma":[0.0022429863,0.00017076249,0.00005959011,0.0017692354,0.00019716563,0.0001514433,0.000181047,0.00071990234,0.00022279168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01558943,0.0068333023,0.865132,0.0004863371,0.002396255,0.0064291274,0.022939488,0.0024245607,0.018091476,0.00065203203,0.05606055,0.0029654447],"study_design_scores_gemma":[0.103777744,0.023570782,0.6828928,0.0019686297,0.0041393638,0.004976745,0.0050456487,0.021985885,0.10721469,0.00015037526,0.042051636,0.0022257126],"about_ca_topic_score_codex":0.0012237141,"about_ca_topic_score_gemma":0.00035097188,"teacher_disagreement_score":0.18223922,"about_ca_system_score_codex":0.00020757622,"about_ca_system_score_gemma":0.0017426142,"threshold_uncertainty_score":0.6963492},"labels":[],"label_agreement":null},{"id":"W2488647697","doi":"10.1016/j.leukres.2016.07.004","title":"A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)","year":2016,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Merck","keywords":"Medicine; Regimen; Tolerability; Internal medicine; Refractory (planetary science); Gastroenterology; Phases of clinical research; Adverse effect; Surgery; Clinical trial; Biology","score_opus":0.05038255470315886,"score_gpt":0.36697083761968635,"score_spread":0.3165882829165275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488647697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904112,0.000097904835,0.000012582315,0.0010896815,0.00030077627,0.005224436,0.00012595723,0.00006606423,0.00267135],"genre_scores_gemma":[0.99158746,0.00010587554,0.00015900127,0.00007976078,0.0005936485,0.00051061943,0.000075318865,0.00013976598,0.0067485776],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9909375,0.0008097442,0.0011587758,0.0011452839,0.0040039276,0.0019447729],"domain_scores_gemma":[0.99479586,0.00063581706,0.0003271788,0.0022401058,0.0013894624,0.00061160664],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0027660462,0.0005311484,0.0010250525,0.0010800288,0.00042677083,0.00007120229,0.0013463052,0.00050316134,0.0003038565],"category_scores_gemma":[0.0005891103,0.0002834749,0.00029682138,0.0022209615,0.0014020718,0.00035276506,0.0009120905,0.0024065955,0.0001712015],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.60112685,0.009443798,0.039823767,0.00067874294,0.0010953172,0.00076189847,0.002548934,0.00000615702,0.22248814,0.0008219584,0.035786826,0.085417636],"study_design_scores_gemma":[0.8265563,0.027739124,0.02620374,0.0018419854,0.00020243063,0.00004238317,0.00024328651,0.00006114173,0.093693316,0.0002563181,0.022357767,0.00080216967],"about_ca_topic_score_codex":0.001059742,"about_ca_topic_score_gemma":0.00033075578,"teacher_disagreement_score":0.2254295,"about_ca_system_score_codex":0.013741477,"about_ca_system_score_gemma":0.007502311,"threshold_uncertainty_score":0.99996173},"labels":[],"label_agreement":null},{"id":"W2492745064","doi":"10.1038/bmt.2016.188","title":"A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation","year":2016,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; Otsuka Pharmaceutical","keywords":"Medicine; Busulfan; Clofarabine; Hematopoietic stem cell transplantation; Transplantation; Stem cell; Internal medicine; Oncology; Surgery; Hematopoietic cell; Haematopoiesis; Chemotherapy; Cytarabine","score_opus":0.017704624740230726,"score_gpt":0.26454912634805927,"score_spread":0.24684450160782856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2492745064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992609,0.000055196913,0.0028104454,0.0016806894,0.000051052702,0.0024045757,0.00026859134,0.00002082416,0.000099574965],"genre_scores_gemma":[0.996266,0.0006493511,0.0009844359,0.000058912632,0.000044801483,0.00015780026,0.00051644305,0.00003185207,0.0012903872],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998151,0.00021166289,0.0006915656,0.00032903775,0.00039032556,0.0002264118],"domain_scores_gemma":[0.9985497,0.00071865524,0.00031263486,0.00018876346,0.00015832529,0.00007193797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066209584,0.00018599154,0.00042507108,0.00022269065,0.00008410769,0.0000069985767,0.00006676344,0.00019015852,0.00009154684],"category_scores_gemma":[0.000038645518,0.00011161956,0.00009102372,0.00020550002,0.00016533342,0.00019661016,0.000009986592,0.0001453265,0.0000050602566],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13349414,0.00012870408,0.00078390195,0.0016539108,0.000042094955,0.000022637842,0.0035179928,0.000016028933,0.8566007,0.000017451237,0.0000915726,0.0036308577],"study_design_scores_gemma":[0.11465241,0.0016771711,0.028662987,0.0014622523,0.00046113014,0.00020665643,0.00046518003,0.000259751,0.85182893,0.000045862984,0.00006843235,0.00020924593],"about_ca_topic_score_codex":0.00002991659,"about_ca_topic_score_gemma":0.000069958645,"teacher_disagreement_score":0.027879084,"about_ca_system_score_codex":0.00022735004,"about_ca_system_score_gemma":0.00017239666,"threshold_uncertainty_score":0.45517138},"labels":[],"label_agreement":null},{"id":"W2493623723","doi":"10.1182/blood.v112.11.2168.2168","title":"Similar 5-Year Survival after Peripheral Blood Autotransplants (AutoPB) Versus HLA Matched Sibling Myeloablative Transplants (AlloBMT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Univariate analysis; Internal medicine; Gastroenterology; Myeloid leukemia; Bone marrow; Leukemia; Median follow-up; Surgery; Multivariate analysis; Oncology; Chemotherapy","score_opus":0.03901868597526447,"score_gpt":0.2943298293326669,"score_spread":0.2553111433574024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2493623723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927561,0.0004377687,0.00044939423,0.00080232037,0.00037582897,0.0020063622,0.00090376585,0.00028676557,0.0019816868],"genre_scores_gemma":[0.98637927,0.002406784,0.007851035,0.00025538728,0.0005503785,0.0003406976,0.00061332603,0.00021761414,0.0013855245],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947497,0.00020114958,0.0010094389,0.0012369113,0.001165157,0.0016376403],"domain_scores_gemma":[0.9974262,0.00064643746,0.00018406221,0.000813924,0.00027309393,0.0006562846],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062653125,0.00079362694,0.0013854085,0.0005339397,0.00043475142,0.000057812154,0.00055940956,0.00063781283,0.0004318513],"category_scores_gemma":[0.00016388275,0.00074902363,0.0004487442,0.0008070378,0.0003269048,0.00036983733,0.00010928796,0.0011997886,0.000073114585],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14824972,0.0066738026,0.33276868,0.004668859,0.012017486,0.03840935,0.035096515,0.0011435726,0.41708827,0.0003079536,0.002211146,0.0013646212],"study_design_scores_gemma":[0.41234034,0.0073932866,0.3903878,0.0044386643,0.008027745,0.004028873,0.0018402787,0.011642006,0.13940662,0.00021156107,0.0153660355,0.004916771],"about_ca_topic_score_codex":0.00028000516,"about_ca_topic_score_gemma":0.00034201503,"teacher_disagreement_score":0.27768168,"about_ca_system_score_codex":0.0006972733,"about_ca_system_score_gemma":0.0011679231,"threshold_uncertainty_score":0.9994961},"labels":[],"label_agreement":null},{"id":"W2503681422","doi":"10.1182/blood.v122.21.740.740","title":"Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"CEBPA; Medicine; Oncology; Mutation; Hematopoietic stem cell transplantation; Internal medicine; Exome sequencing; Germline mutation; Penetrance; Transplantation; Genetics; Biology; Phenotype; Gene","score_opus":0.04624187712409622,"score_gpt":0.3553145546802938,"score_spread":0.3090726775561976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2503681422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99767435,0.00012365851,0.0008569017,0.00037238796,0.000024569446,0.00049239397,0.00007600766,0.000040911706,0.00033883756],"genre_scores_gemma":[0.9761447,0.000021888934,0.022924839,0.00022224576,0.000065244145,0.00003314483,0.00019201562,0.000026339603,0.0003696393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982595,0.0001164235,0.00063842494,0.00035111976,0.0003579962,0.0002765229],"domain_scores_gemma":[0.99837965,0.00046441876,0.0001843116,0.00037872425,0.00038325146,0.0002096228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003873454,0.00016227302,0.0006815905,0.0005494363,0.000102713915,0.000029860137,0.00009143876,0.00011611985,0.00023742519],"category_scores_gemma":[0.00041278574,0.00012403762,0.0001738998,0.000887222,0.00035476682,0.0002071479,0.000064576045,0.00036271688,0.000015819312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009349461,0.00068377977,0.9490082,0.00014203587,0.006530032,0.0001867501,0.0010593017,0.00025820214,0.036822796,0.000063334475,0.00005997506,0.005092078],"study_design_scores_gemma":[0.005722612,0.00031765513,0.9702881,0.000047798298,0.0049914187,0.000100234414,0.0014432287,0.015599984,0.0011954191,0.00011225779,0.000020583819,0.00016073584],"about_ca_topic_score_codex":0.00067604124,"about_ca_topic_score_gemma":0.00009996231,"teacher_disagreement_score":0.035627376,"about_ca_system_score_codex":0.000084195104,"about_ca_system_score_gemma":0.00068013946,"threshold_uncertainty_score":0.50581074},"labels":[],"label_agreement":null},{"id":"W2505765078","doi":"10.1111/ijlh.12555","title":"Development of a NanoString assay to detect leukemogenic fusion transcripts in acute myeloid leukemia","year":2016,"lang":"en","type":"article","venue":"International Journal of Laboratory Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Natural Science Foundation of China","keywords":"TaqMan; Fusion gene; Myeloid leukemia; Fusion transcript; breakpoint cluster region; Biology; Gold standard (test); Minimal residual disease; Real-time polymerase chain reaction; Polymerase chain reaction; Molecular biology; Leukemia; Cancer research; Medicine; Gene; Immunology; Genetics; Internal medicine","score_opus":0.018235587251288758,"score_gpt":0.308738570709537,"score_spread":0.2905029834582482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2505765078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906356,0.00031610322,0.005541778,0.0025497102,0.0006181339,0.00019358461,0.000019848669,0.000012256037,0.00011300955],"genre_scores_gemma":[0.98090184,0.00018440658,0.018300354,0.00037849694,0.00010740046,0.000010474412,0.000002293615,0.00002751027,0.00008724124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972522,0.00014468441,0.0012063304,0.00022628042,0.00084435043,0.0003261072],"domain_scores_gemma":[0.9975511,0.00023824997,0.0004057827,0.00018681739,0.001373181,0.00024489086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010876219,0.00018274909,0.00060424913,0.0011006393,0.000026528249,0.000009746936,0.00052048167,0.00017896516,0.00017612276],"category_scores_gemma":[0.00064297253,0.00012921276,0.00012589735,0.00042621375,0.00008461982,0.00019219425,0.00011441043,0.0003443408,0.000042354564],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018153845,0.00006872264,0.010715012,0.000035148376,0.00045626744,0.0017419673,0.00065375975,0.0000051096144,0.95982575,0.00023474835,0.000621191,0.023826916],"study_design_scores_gemma":[0.005808752,0.0003173469,0.017571159,0.0009918046,0.000048225535,0.0023645894,0.00015508666,0.000014604322,0.9587369,0.00010335268,0.013717251,0.00017092959],"about_ca_topic_score_codex":0.000007043468,"about_ca_topic_score_gemma":0.000053473363,"teacher_disagreement_score":0.023655986,"about_ca_system_score_codex":0.002052556,"about_ca_system_score_gemma":0.0037612068,"threshold_uncertainty_score":0.6672219},"labels":[],"label_agreement":null},{"id":"W2507166450","doi":"10.1056/nejmc1608739","title":"Genomic Classification in Acute Myeloid Leukemia","year":2016,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Myeloid; Computational biology; Leukemia; Genetics; Cancer research; Immunology; Biology","score_opus":0.03364660698301582,"score_gpt":0.30685085746800383,"score_spread":0.27320425048498803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507166450","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024818668,0.0021563172,0.00041005222,0.9662326,0.0012758008,0.00045704015,0.00001362708,0.00002301043,0.0046128854],"genre_scores_gemma":[0.024939004,0.017022345,0.0015720036,0.68833274,0.2181637,0.000015708383,0.0002963237,0.00031339776,0.049344808],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954512,0.0003081076,0.0015647692,0.00041490846,0.0015310231,0.0007299702],"domain_scores_gemma":[0.99667776,0.00070079067,0.0010234526,0.00064002984,0.0004887079,0.0004692733],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002062305,0.00047904454,0.0016572118,0.0016003745,0.000042041287,0.000017744422,0.0006022162,0.0009361346,0.0009395159],"category_scores_gemma":[0.0007243695,0.00027902436,0.00022469707,0.00039969786,0.00030501105,0.00014113622,0.00007300725,0.005694958,0.00012547574],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011191167,0.0000104039045,0.0014692433,0.0001326672,0.0003471737,0.009516775,0.0002881638,7.36057e-7,0.016920106,0.00001194484,0.8493878,0.12079585],"study_design_scores_gemma":[0.061440922,0.0014000449,0.007715069,0.002323438,0.0005551731,0.00913138,0.000039182887,0.00003157642,0.0001537136,0.00043645388,0.9165376,0.00023543571],"about_ca_topic_score_codex":0.00015550872,"about_ca_topic_score_gemma":0.00001632548,"teacher_disagreement_score":0.2778999,"about_ca_system_score_codex":0.003233315,"about_ca_system_score_gemma":0.003957028,"threshold_uncertainty_score":0.9999738},"labels":[],"label_agreement":null},{"id":"W2508095929","doi":"10.1080/10428194.2016.1218005","title":"The mitochondria target drug avocatin B synergizes with induction chemotherapeutics to induce leukemia cell death","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre for Drug Research and Development; University of Waterloo","funders":"","keywords":"Drug; Leukemia; Programmed cell death; Cancer research; Mitochondrion; Apoptosis; Biology; Medicine; Pharmacology; Immunology; Cell biology; Biochemistry","score_opus":0.013085849444078186,"score_gpt":0.24691204312996085,"score_spread":0.23382619368588267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508095929","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57872623,0.007456903,0.0010983365,0.36196306,0.0039888853,0.009921342,0.00064061634,0.0019065923,0.03429802],"genre_scores_gemma":[0.053041477,0.0073627965,0.012505116,0.5633934,0.028513424,0.0029095402,0.0016049414,0.0027042655,0.32796502],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98553956,0.0008069229,0.002175223,0.0037554372,0.0034168754,0.00430596],"domain_scores_gemma":[0.98976976,0.0019901723,0.0012418999,0.004274218,0.0011413991,0.001582573],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0013258344,0.0031011477,0.0029313888,0.0013510368,0.0021900716,0.0011024233,0.0023593819,0.003804548,0.00020336136],"category_scores_gemma":[0.0003549002,0.0020110074,0.00075541687,0.0021682738,0.0014781598,0.0006171155,0.0009847716,0.0029989504,0.0007872984],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0024624672,0.000087769,0.00046500188,0.00091879873,0.0010907331,0.002127289,0.0010714737,0.000021437614,0.008399394,0.00011514298,0.9075421,0.07569839],"study_design_scores_gemma":[0.017074127,0.00096143293,0.0018262892,0.0015735888,0.00093274313,0.0031698288,0.000632118,0.00071141485,0.025606018,0.0004117423,0.94441134,0.0026893797],"about_ca_topic_score_codex":0.0027920303,"about_ca_topic_score_gemma":0.00012285869,"teacher_disagreement_score":0.5256848,"about_ca_system_score_codex":0.045659225,"about_ca_system_score_gemma":0.02696631,"threshold_uncertainty_score":0.9999907},"labels":[],"label_agreement":null},{"id":"W2509053325","doi":"10.1182/blood.v122.21.2680.2680","title":"Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"Plerixafor; Medicine; Cytarabine; Etoposide; CXCR4 antagonist; Leukemia; Bone marrow; CXCR4; Acute leukemia; Chemotherapy; Internal medicine; Pharmacology; Oncology; Inflammation; Chemokine","score_opus":0.007548646088943208,"score_gpt":0.2571508213574301,"score_spread":0.2496021752684869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2509053325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99686587,0.00011954381,0.000073545954,0.00007418087,0.000008366121,0.0027585332,0.00003240045,0.000023367944,0.000044171782],"genre_scores_gemma":[0.99820495,0.00028714153,0.0011005772,0.00004730639,0.000033189055,0.0001086364,0.00012789351,0.000046640555,0.000043684155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982899,0.00006386137,0.00046161274,0.0004410159,0.0004483803,0.00029522614],"domain_scores_gemma":[0.99881446,0.00008011881,0.00024099833,0.00028905302,0.00039491625,0.00018047233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018262836,0.00025679526,0.000574811,0.00034181782,0.00005338618,0.00002894812,0.000063854066,0.000110682406,0.000011620961],"category_scores_gemma":[0.00007161333,0.000190226,0.000016361737,0.0005874195,0.00017762848,0.00026534242,0.00009590165,0.00019404708,5.654717e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022124825,0.0030070194,0.97261786,0.0005829199,0.00029944192,0.00006684815,0.0032214047,0.000016478563,0.01673575,0.000008300797,0.000042450032,0.001189056],"study_design_scores_gemma":[0.07235232,0.012734426,0.89522266,0.00014534948,0.0010975227,0.00011717036,0.0012525002,0.0023811855,0.014386927,0.000011787817,0.0000067408682,0.0002914101],"about_ca_topic_score_codex":0.0005657075,"about_ca_topic_score_gemma":0.00013957644,"teacher_disagreement_score":0.07739519,"about_ca_system_score_codex":0.00008979162,"about_ca_system_score_gemma":0.0002603025,"threshold_uncertainty_score":0.7757191},"labels":[],"label_agreement":null},{"id":"W2510134076","doi":"10.1016/j.bbmt.2016.08.030","title":"Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis","year":2016,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Busulfan; Fludarabine; Cumulative incidence; Internal medicine; Total body irradiation; Regimen; Gastroenterology; Hematopoietic stem cell transplantation; Propensity score matching; Myeloid leukemia; Incidence (geometry); Population; Surgery; Transplantation; Chemotherapy; Cyclophosphamide","score_opus":0.02176171274257743,"score_gpt":0.2542751797582004,"score_spread":0.23251346701562298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2510134076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985033,0.000034054916,0.0005453578,0.00025152232,0.000028756129,0.00041901635,0.00008963253,0.00002980617,0.000098552395],"genre_scores_gemma":[0.998997,0.00013474678,0.00050182245,0.000035739926,0.000014056586,0.000016302238,0.00026488292,0.000010486926,0.000024995965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901533,0.00008481678,0.0002474918,0.0003046063,0.00013275811,0.00021501607],"domain_scores_gemma":[0.99927634,0.00013993657,0.00011647296,0.00013029287,0.0002625806,0.000074371055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020068698,0.0001314131,0.0004455024,0.00029317927,0.00004126713,0.000003949503,0.000047258975,0.000118818236,0.000021073156],"category_scores_gemma":[0.00005599742,0.0000817409,0.000049871815,0.00036068357,0.0003093332,0.00010968234,0.000011543791,0.00010153159,0.000001849065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008299214,0.000110339024,0.81075287,0.00009490939,0.00062693004,0.000020943262,0.00048728756,0.0000018749882,0.17894377,0.0000901423,0.0000047545236,0.00056698377],"study_design_scores_gemma":[0.011531634,0.0010646159,0.9240136,0.00017007171,0.001256313,0.000010513986,0.000070059396,0.000010271921,0.061722558,0.000034469544,0.0000028950874,0.00011301197],"about_ca_topic_score_codex":0.0001918008,"about_ca_topic_score_gemma":0.00019136502,"teacher_disagreement_score":0.11722121,"about_ca_system_score_codex":0.000045843353,"about_ca_system_score_gemma":0.00011073531,"threshold_uncertainty_score":0.3333297},"labels":[],"label_agreement":null},{"id":"W2512584198","doi":"10.1182/blood.v112.11.2673.2673","title":"Transplantation-Specific Cytogenetics Grouping Scheme for Patients with Myelodysplastic Syndromes: A Multicenter Validation Study","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cytogenetics; Myelodysplastic syndromes; Transplantation; Medicine; Internal medicine; Oncology; Single Center; International Prognostic Scoring System; Bone marrow; Biology","score_opus":0.03311754689248778,"score_gpt":0.275256076363018,"score_spread":0.24213852947053024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2512584198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99357957,0.000043539203,0.0036321885,0.000034868925,0.00005078005,0.0024828103,0.00004012089,0.00006157624,0.00007454084],"genre_scores_gemma":[0.9874618,0.00009680089,0.011669751,0.000034643195,0.00009086136,0.00021838125,0.00027945184,0.00005319071,0.000095104086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984763,0.000041045467,0.00028525628,0.00035830852,0.0005098325,0.00032921438],"domain_scores_gemma":[0.99904346,0.00016817563,0.000071470975,0.000274951,0.00030650164,0.00013541468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010687,0.00018321558,0.00025415618,0.00016530215,0.0001816254,0.000019475576,0.000104902654,0.00006439147,0.000032857322],"category_scores_gemma":[0.00005472279,0.00014888175,0.00005359697,0.00023536543,0.00006127548,0.000100054735,0.00001754746,0.00015608138,0.000036297053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013290285,0.004300978,0.98908675,0.00023529393,0.00036539324,0.0002259217,0.002052138,0.000016044536,0.0020716994,0.0000079247,0.00009426985,0.0002145399],"study_design_scores_gemma":[0.05295965,0.004290449,0.93416077,0.0001880108,0.0005388672,0.00022587639,0.000379441,0.0002603431,0.0064430158,0.0000027983888,0.00025106856,0.00029971285],"about_ca_topic_score_codex":0.0000071079303,"about_ca_topic_score_gemma":0.000003561032,"teacher_disagreement_score":0.054926,"about_ca_system_score_codex":0.00008425274,"about_ca_system_score_gemma":0.00011064846,"threshold_uncertainty_score":0.6071222},"labels":[],"label_agreement":null},{"id":"W2513269552","doi":"10.1200/jco.2016.67.3616","title":"Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":255,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"National Cancer Institute; Regione Lombardia","keywords":"Myelodysplastic syndromes; Medicine; International Prognostic Scoring System; Oncology; Hematopoietic stem cell transplantation; Somatic cell; RUNX1; Myeloid; Internal medicine; Myeloid leukemia; Transplantation; Gene mutation; Germline mutation; Mutation; Stem cell; Haematopoiesis; Gene; Genetics; Biology; Bone marrow","score_opus":0.044660866679790384,"score_gpt":0.3809837326136119,"score_spread":0.33632286593382155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513269552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99641967,0.000029895426,0.000673799,0.0018620552,0.00015941191,0.00066552934,0.000011857959,0.000007410486,0.00017038673],"genre_scores_gemma":[0.99826264,0.0002451726,0.00091558765,0.000269622,0.000057857997,0.000011575172,0.0000038823882,0.000027756943,0.0002058862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995114,0.0011230899,0.002510205,0.0002120101,0.0007957092,0.0002449483],"domain_scores_gemma":[0.968609,0.027917404,0.0022318258,0.00030533943,0.0006722406,0.00026422107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017281949,0.00019902854,0.001838999,0.00019575685,0.00003859188,0.0000035905755,0.00024944206,0.00029123537,0.00007097675],"category_scores_gemma":[0.0014915916,0.00007568337,0.00037845818,0.00019900422,0.0007995169,0.00008975357,0.000021555357,0.00061758864,0.000020715685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008011579,0.003365077,0.97562605,0.00035015578,0.0014268474,0.000468366,0.00018534712,0.0000181077,0.00035976662,0.00006840113,0.00013228858,0.009988028],"study_design_scores_gemma":[0.02240964,0.03540648,0.9380176,0.0007482267,0.0016503882,0.00011149173,0.00007331388,0.000015504267,0.0013797297,0.000056888653,0.00004199696,0.000088743465],"about_ca_topic_score_codex":0.0000044298995,"about_ca_topic_score_gemma":0.000008793286,"teacher_disagreement_score":0.03760844,"about_ca_system_score_codex":0.000126191,"about_ca_system_score_gemma":0.0012848373,"threshold_uncertainty_score":0.3086278},"labels":[],"label_agreement":null},{"id":"W2513310700","doi":"10.1016/j.exphem.2016.06.020","title":"Targeted therapy in aml: looking beyond mutations with leucegene project","year":2016,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Exploit; Computational biology; Session (web analytics); RNA; Drug discovery; Key (lock); Human genome; Biology; Genome; Computer science; Bioinformatics; Gene; Genetics; World Wide Web","score_opus":0.023707054088896444,"score_gpt":0.3400748200189138,"score_spread":0.31636776593001736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513310700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908319,0.0029719179,0.00014596267,0.0013341948,0.00006484511,0.000807098,0.000005198818,0.000081125865,0.0037577418],"genre_scores_gemma":[0.99625957,0.000049269664,0.0023106844,0.00033077187,0.000044204065,0.0002937738,0.00002355551,0.000041728963,0.0006464666],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99869794,0.00008152551,0.00023804707,0.0003454463,0.00021369309,0.00042332438],"domain_scores_gemma":[0.99944,0.00010304092,0.000052855503,0.00026846037,0.000047889756,0.00008772362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010155277,0.00016861776,0.00033703496,0.0002734619,0.000057808138,0.0000071357167,0.00010807264,0.00010762373,0.00058316847],"category_scores_gemma":[0.000022187365,0.00010076737,0.00004274665,0.0002899251,0.00025297696,0.00010384634,0.000050582254,0.00015261353,0.000094976655],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023601183,0.00089659763,0.0878584,0.00003430755,0.00016986577,0.0014541985,0.0036182743,7.4353386e-7,0.88345563,0.013666558,0.0024043818,0.0040809135],"study_design_scores_gemma":[0.0068079233,0.0010030679,0.003063076,0.00007565666,0.0000046229084,0.0011932642,0.001407552,0.000028826047,0.9853317,0.000086348904,0.00084952806,0.00014839307],"about_ca_topic_score_codex":0.00012585167,"about_ca_topic_score_gemma":0.000027740201,"teacher_disagreement_score":0.101876095,"about_ca_system_score_codex":0.0003510742,"about_ca_system_score_gemma":0.00031551693,"threshold_uncertainty_score":0.6385285},"labels":[],"label_agreement":null},{"id":"W2513548018","doi":"10.1002/hon.2341","title":"Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF‐AML) – a single center analysis","year":2016,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Medicine; Internal medicine; Oncology; Chemotherapy; Reverse transcriptase; Single Center; Polymerase chain reaction; Leukemia; Gastroenterology; Gene; Biology","score_opus":0.02294623130666507,"score_gpt":0.3139093602436631,"score_spread":0.29096312893699805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513548018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393797,0.000017046252,0.0025724943,0.0014538461,0.000031456828,0.00081318856,0.00009475004,0.000055174194,0.0010240866],"genre_scores_gemma":[0.99655527,0.000047702346,0.0026635064,0.00037444313,0.000015158561,0.000049080903,0.00012966148,0.000027312912,0.00013788475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763614,0.00021318856,0.00059579423,0.0005572849,0.00046469257,0.0005328929],"domain_scores_gemma":[0.9982534,0.00046213856,0.00030713718,0.0004052023,0.00030962162,0.00026249647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019415081,0.00025817577,0.0010851733,0.0005525285,0.000048231763,0.0000061626974,0.00020479049,0.0004624074,0.0005044675],"category_scores_gemma":[0.0004339831,0.00014242681,0.00019142992,0.0010114346,0.0003540832,0.00009982861,0.00011855704,0.00034433152,0.000020316556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043059634,0.0011333661,0.88524985,0.000032295186,0.0013215757,0.00030765397,0.0002004191,0.000008969476,0.10445331,0.0002534197,0.00015429797,0.0025789023],"study_design_scores_gemma":[0.02364808,0.008775144,0.87302196,0.00040748363,0.0010221384,0.00017938188,0.00019866115,0.00060033327,0.09084437,0.0001914109,0.0006707788,0.00044023225],"about_ca_topic_score_codex":0.000024121045,"about_ca_topic_score_gemma":0.000008926714,"teacher_disagreement_score":0.019342115,"about_ca_system_score_codex":0.0018258417,"about_ca_system_score_gemma":0.000516037,"threshold_uncertainty_score":0.58079964},"labels":[],"label_agreement":null},{"id":"W2514130855","doi":"10.1016/j.exphem.2016.06.195","title":"Structural basis for dimerization-mediated MLL leukemogenesis","year":2016,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Biology; Leukemia; Myeloid; Chromosomal translocation; Haematopoiesis; Cancer research; Molecular biology; Genetics; Stem cell; Gene","score_opus":0.02663527034940438,"score_gpt":0.3301090761484682,"score_spread":0.3034738057990638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514130855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904446,0.0022291986,0.001398023,0.0033038857,0.0003884792,0.0009625828,0.000067015666,0.00016829312,0.0010379507],"genre_scores_gemma":[0.9949166,0.000028661798,0.0025991153,0.000531447,0.00013220518,0.00025684768,0.00007804865,0.00005231204,0.0014047154],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986171,0.00004780229,0.0002916752,0.0003845934,0.00019380289,0.00046498954],"domain_scores_gemma":[0.99894655,0.0003729829,0.00006849292,0.0003125514,0.00009165182,0.0002077787],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007261022,0.00019083467,0.00039961823,0.0001439572,0.000110596506,0.000007554293,0.00013988416,0.00016532125,0.0019055398],"category_scores_gemma":[0.000266353,0.00012642973,0.00012112952,0.00015807069,0.00021935184,0.00009558226,0.00008500316,0.00006528812,0.00024949436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012207694,0.00013351113,0.014160504,0.00007874644,0.00020242004,0.00012382744,0.0003285212,2.8447164e-7,0.95284384,0.017942717,0.009503142,0.003461713],"study_design_scores_gemma":[0.0039281994,0.00042938773,0.0024313738,0.000045795787,0.000024280962,0.00052687334,0.0002843316,0.00027679198,0.98777634,0.00008687572,0.0040009436,0.00018881996],"about_ca_topic_score_codex":0.000026918853,"about_ca_topic_score_gemma":0.0000027576602,"teacher_disagreement_score":0.034932483,"about_ca_system_score_codex":0.00042063318,"about_ca_system_score_gemma":0.00019966364,"threshold_uncertainty_score":0.99900687},"labels":[],"label_agreement":null},{"id":"W2514277111","doi":"10.3324/haematol.2016.145821","title":"Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation","year":2016,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Children's Hospital of Eastern Ontario; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Azacitidine; Medicine; Myelodysplastic syndromes; Hematopoietic stem cell transplantation; Internal medicine; Transplantation; Leukemia; Myeloid leukemia; Oncology; Gastroenterology; Bone marrow; Surgery; Biology","score_opus":0.012551107800142756,"score_gpt":0.2570567888220094,"score_spread":0.24450568102186662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514277111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906531,0.000050504317,0.002220517,0.0040772017,0.000011950393,0.0026337134,0.000038420883,0.00012577804,0.00018880276],"genre_scores_gemma":[0.99288946,0.00006551951,0.004867772,0.00025973632,0.000007833163,0.0006258305,0.000012287098,0.00004841348,0.0012231431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978301,0.00016403936,0.00032927183,0.00064178417,0.00042674664,0.0006080746],"domain_scores_gemma":[0.9985643,0.00037816502,0.00006754697,0.00047822262,0.00008305247,0.0004287171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021978655,0.00033403796,0.00067705946,0.00039319764,0.000070873466,0.000016350186,0.00015963848,0.0001058685,0.00010236511],"category_scores_gemma":[0.00003331298,0.00016384466,0.000044566536,0.0006200377,0.00008281365,0.000090071575,0.00003010858,0.00012155428,0.00041626085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26314452,0.0026926557,0.41405618,0.0008998896,0.00063832727,0.04394442,0.0090881735,0.00035491976,0.21653232,0.0003452649,0.00031521835,0.047988135],"study_design_scores_gemma":[0.024827693,0.03715254,0.78380185,0.0023796542,0.00024936095,0.03550705,0.0005519948,0.000014776758,0.114114165,0.000017318436,0.00059156975,0.0007920424],"about_ca_topic_score_codex":0.00002160875,"about_ca_topic_score_gemma":0.00005244378,"teacher_disagreement_score":0.36974567,"about_ca_system_score_codex":0.0005788841,"about_ca_system_score_gemma":0.00028858698,"threshold_uncertainty_score":0.6681391},"labels":[],"label_agreement":null},{"id":"W2514448720","doi":"10.1038/ng.3646","title":"Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution","year":2016,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1292,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"U.S. National Library of Medicine; National Cancer Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Human Genome Research Institute; Howard Hughes Medical Institute","keywords":"Biology; Chromatin; Haematopoiesis; Stem cell; Lineage (genetic); Genetics; Hematopoietic stem cell; Leukemia; Computational biology; Enhancer; Myeloid; Epigenomics; Cancer research; Gene; Transcription factor; DNA methylation; Gene expression","score_opus":0.020556927895503726,"score_gpt":0.2904839785553225,"score_spread":0.26992705065981876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514448720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98668057,0.010377046,0.000339863,0.0007236947,0.0000988667,0.00044291336,0.000019944342,0.00007570442,0.0012414048],"genre_scores_gemma":[0.9941405,0.0006249301,0.0033683486,0.00016604621,0.00043557424,0.0000116973515,0.000013588423,0.000039578168,0.0011997356],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99830425,0.00006760286,0.00030494944,0.0005482925,0.0004080718,0.00036684333],"domain_scores_gemma":[0.9987582,0.00013456067,0.000098943994,0.00055464404,0.00020184604,0.00025180075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034473353,0.0002226791,0.000318433,0.00014092845,0.0001559973,0.000049229697,0.00013812506,0.00054651126,0.00010491402],"category_scores_gemma":[0.00014864304,0.00015315207,0.00004788364,0.0001937008,0.00029437576,0.00008589552,0.00020744525,0.0005492148,0.000019970474],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000102264865,0.00009942699,0.03190215,0.0003198148,0.000028564857,0.00003761943,0.00020261896,2.1754848e-7,0.950123,0.00010783187,0.0075160814,0.009560409],"study_design_scores_gemma":[0.004573629,0.0005412092,0.42053056,0.00029032247,0.000083066036,0.00017085164,0.0001160325,0.00019826787,0.55934906,0.000647842,0.013103942,0.00039519856],"about_ca_topic_score_codex":0.0000054912807,"about_ca_topic_score_gemma":0.000008768708,"teacher_disagreement_score":0.39077392,"about_ca_system_score_codex":0.0006875804,"about_ca_system_score_gemma":0.00016493749,"threshold_uncertainty_score":0.62453604},"labels":[],"label_agreement":null},{"id":"W2517756852","doi":"10.1016/j.exphem.2016.06.097","title":"Identification of existing bioactive molecules that target acute myeloid leukemia stem cells","year":2016,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; McGill University; McGill University Health Centre","funders":"","keywords":"Haematopoiesis; Myeloid leukemia; Stem cell; Progenitor cell; Leukemia; Cancer research; Myeloid; Flow cytometry; Bone marrow; Cancer stem cell; Biology; Medicine; Immunology; Cell biology","score_opus":0.03876285657727026,"score_gpt":0.3381853385087081,"score_spread":0.29942248193143783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2517756852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875142,0.00238827,0.0044679125,0.00056687876,0.00031307628,0.001050095,0.00006429964,0.0001232877,0.0035119802],"genre_scores_gemma":[0.9948819,0.00006319417,0.0021077455,0.000089125846,0.00005039387,0.00015073761,0.0000147724195,0.000046823614,0.002595297],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99809575,0.000114384486,0.00050930784,0.00047836226,0.0003644395,0.000437748],"domain_scores_gemma":[0.99876475,0.00017178485,0.00028830883,0.0004992577,0.00011242775,0.00016347031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020083536,0.00022703485,0.000543424,0.00020188991,0.00007919218,0.000010145877,0.00023658662,0.00019152989,0.00032414927],"category_scores_gemma":[0.000024842418,0.00016442452,0.00013241357,0.00017127302,0.0004265595,0.00015355757,0.00018229397,0.0001583711,0.00026299313],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003935231,0.00013365535,0.0011418074,0.000056529883,0.00017081166,0.00013982516,0.00051790365,3.6191042e-7,0.98650616,0.008697605,0.0012587237,0.000983105],"study_design_scores_gemma":[0.0018021624,0.0002522547,0.000225075,0.00011207326,0.000030878942,0.00046244013,0.0016234657,0.00014309309,0.99457294,0.00010223419,0.00051415846,0.00015921153],"about_ca_topic_score_codex":0.000027291584,"about_ca_topic_score_gemma":6.173808e-7,"teacher_disagreement_score":0.008595371,"about_ca_system_score_codex":0.0008174243,"about_ca_system_score_gemma":0.000239129,"threshold_uncertainty_score":0.67050374},"labels":[],"label_agreement":null},{"id":"W2519718677","doi":"10.1186/s13000-016-0541-z","title":"Multiplexed automated digital quantification of fusion transcripts: comparative study with fluorescent in-situ hybridization (FISH) technique in acute leukemia patients","year":2016,"lang":"en","type":"article","venue":"Diagnostic Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"Alberta Cancer Foundation; Calgary Laboratory Services","keywords":"Fluorescence in situ hybridization; Fusion transcript; Fusion gene; Karyotype; Biology; Chromosomal translocation; Leukemia; Molecular biology; Cancer research; Gene; Genetics; Chromosome","score_opus":0.021916786940130096,"score_gpt":0.3024936824505175,"score_spread":0.2805768955103874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519718677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935428,0.0000136073195,0.002286047,0.00020194749,0.000052612417,0.003578399,0.00010017895,0.00012573434,0.00009868204],"genre_scores_gemma":[0.99855065,0.000053170606,0.0004805969,0.000038242906,0.000010671433,0.0004870805,0.00033611088,0.000028964467,0.000014513814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785537,0.00028231886,0.00063892885,0.00050529034,0.00035631063,0.0003618133],"domain_scores_gemma":[0.99827296,0.00072343857,0.00018818284,0.00039229,0.00033156096,0.00009160112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032055928,0.00022690748,0.00058483164,0.00055599003,0.000030203579,0.000010193663,0.00016105318,0.00015058534,0.00000781938],"category_scores_gemma":[0.001121786,0.00015449358,0.000038283524,0.00063734705,0.00022757778,0.00021333895,0.000057414785,0.0002354045,0.000017984663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012414439,0.001710929,0.6503015,0.00003523196,0.00003361437,0.00053731276,0.0015237893,0.00002638779,0.3424078,0.000016879561,0.00012760084,0.0020375033],"study_design_scores_gemma":[0.00986729,0.0021498003,0.89654905,0.00040422328,0.00004739196,0.000044647564,0.00038511556,0.00037514424,0.08999734,0.000010433269,0.0000120654,0.00015752295],"about_ca_topic_score_codex":0.00006856453,"about_ca_topic_score_gemma":0.00026459392,"teacher_disagreement_score":0.25241047,"about_ca_system_score_codex":0.00076471886,"about_ca_system_score_gemma":0.0002837684,"threshold_uncertainty_score":0.63000655},"labels":[],"label_agreement":null},{"id":"W2520322016","doi":"10.1182/blood.v114.22.1761.1761","title":"Validation of a Scoring System to Establish the Pretest Probability of Myelodysplastic Syndrome in Patients with Unexplained Cytopenias or Macrocytosis.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Macrocytosis; Bone marrow; Bone marrow examination; Internal medicine; Gold standard (test); Myelodysplastic syndromes; Mean corpuscular volume; International Prognostic Scoring System; Medical diagnosis; Pediatrics; Pathology; Anemia; Hematocrit","score_opus":0.013129096304509147,"score_gpt":0.24401081157072574,"score_spread":0.2308817152662166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520322016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972161,0.000009855547,0.00005392581,0.00017556017,0.000017718885,0.002188923,0.000020677548,0.000028964363,0.00028828662],"genre_scores_gemma":[0.99839747,0.0000010181482,0.0014221576,0.000025418674,0.0000144164715,0.00006632618,0.00001757342,0.00001626992,0.000039366263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982535,0.000106342755,0.00047452157,0.00029001915,0.0005916179,0.00028395312],"domain_scores_gemma":[0.9986909,0.00021541883,0.00015454295,0.0005112224,0.0003202131,0.000107685606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052331126,0.00014739773,0.0004400054,0.000185973,0.000036419937,0.000015790558,0.0002218254,0.000064580316,0.000011040706],"category_scores_gemma":[0.0007239329,0.000086214844,0.000035842975,0.0009362305,0.000058194713,0.000119702,0.000065317276,0.00018467855,0.0000046379405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007142089,0.002814471,0.97058713,0.002525621,0.00019878853,0.00014632655,0.0018724367,0.00062308507,0.012709939,0.00027258586,0.000041356176,0.001066167],"study_design_scores_gemma":[0.009023961,0.0045233388,0.94627374,0.0017108681,0.0001854198,0.00007223504,0.00020864805,0.00011057851,0.037746027,0.0000102840695,0.000005424481,0.00012948793],"about_ca_topic_score_codex":0.00008005824,"about_ca_topic_score_gemma":0.00002399677,"teacher_disagreement_score":0.025036087,"about_ca_system_score_codex":0.00022363315,"about_ca_system_score_gemma":0.00031864975,"threshold_uncertainty_score":0.35157394},"labels":[],"label_agreement":null},{"id":"W2522134251","doi":"10.1182/blood.v120.21.411.411","title":"Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Cytarabine; Oncology; Clinical endpoint; Clinical trial","score_opus":0.015948448106605517,"score_gpt":0.28531192229843805,"score_spread":0.26936347419183254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522134251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742468,0.000121999255,0.000040212482,0.00020837138,0.00013270752,0.024256337,0.0009224733,0.00006243944,0.000008658626],"genre_scores_gemma":[0.9909013,0.00007299588,0.0005102321,0.00016193553,0.00010559297,0.0029112713,0.0051005445,0.00016409328,0.00007202022],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947787,0.00057976367,0.0015310901,0.0010391122,0.0008853038,0.0011860558],"domain_scores_gemma":[0.9954871,0.0009634596,0.000777043,0.0010853147,0.0013195347,0.00036758292],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009678211,0.00085633993,0.0019808954,0.00068094546,0.0002397467,0.00004113885,0.00034455644,0.00025444388,0.00001029601],"category_scores_gemma":[0.00061627233,0.00051140203,0.00014059528,0.0010246516,0.00028798342,0.0005762509,0.000098964054,0.00048631328,0.0000017126029],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80970365,0.10309355,0.06064978,0.00005458894,0.0017255892,0.00006793611,0.019668022,0.00009013137,0.00055269455,0.0000037599527,0.000109406676,0.004280864],"study_design_scores_gemma":[0.7947438,0.17356023,0.01861368,0.0005559372,0.0014177664,0.0000023331784,0.0015832495,0.0008898115,0.00811333,0.000009183511,0.00004047101,0.00047020637],"about_ca_topic_score_codex":0.0066130124,"about_ca_topic_score_gemma":0.0057110065,"teacher_disagreement_score":0.07046668,"about_ca_system_score_codex":0.0016456544,"about_ca_system_score_gemma":0.0009891877,"threshold_uncertainty_score":0.99973375},"labels":[],"label_agreement":null},{"id":"W2522316890","doi":"10.1182/blood.v126.23.2009.2009","title":"Outcomes of Allogeneic Transplantation in Patients Aged ≤ 60 Years with Acute Myeloid Leukemia in Second Complete Remission: A CIBMTR ® Cohort Analysis","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cumulative incidence; Transplantation; Internal medicine; Myeloid leukemia; Hematopoietic stem cell transplantation; Incidence (geometry); Leukemia; Cohort; Surgery","score_opus":0.01937515415945602,"score_gpt":0.273288429438075,"score_spread":0.253913275278619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522316890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983397,0.000040142946,0.000031843287,0.000061398874,0.000017140988,0.0006172115,0.00007838528,0.000020365247,0.00079381355],"genre_scores_gemma":[0.99766123,0.000045465473,0.0012958163,0.00011110857,0.0000139148615,0.000034323042,0.00045056647,0.000025940451,0.00036160732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979978,0.00013430882,0.00049263117,0.00036679162,0.0006819366,0.00032651823],"domain_scores_gemma":[0.99904835,0.00007406025,0.00013009348,0.00039413394,0.00013884237,0.00021449536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049712625,0.00018260234,0.0007260122,0.00069091615,0.000016347332,0.00000904279,0.00016907814,0.00013324148,0.00011359243],"category_scores_gemma":[0.000061465915,0.00014800426,0.000100486504,0.0011784848,0.000076788,0.00009223898,0.00003457742,0.00033078028,0.000013057765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092488277,0.0002706614,0.9926154,0.000059932867,0.0012600721,0.0009353764,0.0010462007,0.00016437547,0.002485506,0.0000018438318,0.00008189399,0.0001538271],"study_design_scores_gemma":[0.017494384,0.0004088741,0.978501,0.000064630774,0.0011828848,0.000023216338,0.00009016315,0.00020369343,0.0018318137,0.000007991373,0.00004312157,0.00014821647],"about_ca_topic_score_codex":0.000511469,"about_ca_topic_score_gemma":0.0010318705,"teacher_disagreement_score":0.0165695,"about_ca_system_score_codex":0.00048024624,"about_ca_system_score_gemma":0.0006284615,"threshold_uncertainty_score":0.6035438},"labels":[],"label_agreement":null},{"id":"W2522328851","doi":"10.3892/or.2016.5119","title":"RUNX1 truncation resulting from a cryptic and novel t(6;21)(q25;q22) chromosome translocation in acute myeloid leukemia: A case report","year":2016,"lang":"en","type":"article","venue":"Oncology Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Biology; Fusion transcript; RUNX1; Chromosomal translocation; Fluorescence in situ hybridization; Myeloid leukemia; Molecular biology; NPM1; Genetics; Sanger sequencing; Breakpoint; Trisomy; Karyotype; DNA sequencing; Cancer research; Chromosome; Gene; Transcription factor","score_opus":0.024408890932315026,"score_gpt":0.32203617629674774,"score_spread":0.2976272853644327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522328851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878931,0.0002826316,0.0017623645,0.006478691,0.0003024559,0.0011075952,0.000018115177,0.00012669024,0.0020283624],"genre_scores_gemma":[0.9898569,0.0002698433,0.006418266,0.00031378513,0.0003656478,0.00026592176,0.00014986332,0.000061868406,0.00229792],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9962689,0.00014059435,0.0014494903,0.001085368,0.00044306857,0.00061256654],"domain_scores_gemma":[0.99720937,0.0005413224,0.00068009505,0.0009292613,0.00029987624,0.00034007503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018399097,0.0003134988,0.00079435704,0.00039480702,0.00014279503,0.000024967992,0.000087423796,0.000607324,0.000108898814],"category_scores_gemma":[0.001705567,0.00024083215,0.000099092445,0.00046127394,0.0003123235,0.00032017843,0.00009885058,0.000594141,0.000029638042],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043399553,0.00021480818,0.021550395,0.000043797165,0.00018162058,0.47342354,0.0011211317,0.000003095276,0.46337098,0.00003575564,0.0007146547,0.038906246],"study_design_scores_gemma":[0.009949866,0.00081345526,0.09145564,0.0005723137,0.00041979871,0.86337006,0.00045850803,0.0007321209,0.021968337,0.0007037944,0.009102336,0.00045379173],"about_ca_topic_score_codex":0.0020715161,"about_ca_topic_score_gemma":0.0007942807,"teacher_disagreement_score":0.44140264,"about_ca_system_score_codex":0.0033162667,"about_ca_system_score_gemma":0.0028313184,"threshold_uncertainty_score":0.982085},"labels":[],"label_agreement":null},{"id":"W2522596820","doi":"10.1182/blood-2016-06-723098","title":"Acute myeloid leukemia with myelodysplasia-related changes demonstrating mixed-lineage phenotype","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pancytopenia; Medicine; Dysplasia; Hypoplasia; Bone marrow; Bone marrow examination; Myeloid leukemia; Pathology; Myeloid; Karyotype; Internal medicine; Biology; Genetics; Chromosome","score_opus":0.012089764852225203,"score_gpt":0.25105475674349015,"score_spread":0.23896499189126494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522596820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831086,0.0002932968,0.0003873999,0.0038778926,0.00011566446,0.00069676054,0.000041947,0.00038611976,0.01109231],"genre_scores_gemma":[0.98539966,0.00031013586,0.0055261436,0.00033442164,0.00044656105,0.000081441074,0.00004522366,0.00012530306,0.0077310787],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99727774,0.00009351744,0.0003937109,0.0006651704,0.00067679846,0.00089304516],"domain_scores_gemma":[0.9981957,0.00022652918,0.00017125961,0.0007238666,0.00024770416,0.00043495029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038430592,0.00040062214,0.0005525516,0.00024421918,0.00018592822,0.00004057806,0.00030081702,0.00030378983,0.00030405892],"category_scores_gemma":[0.00022105177,0.0002362995,0.00010036675,0.00058658916,0.00026871858,0.00017256408,0.0001441439,0.00054501084,0.00052497006],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010330463,0.0004554113,0.020151392,0.00017874515,0.00226631,0.0027280247,0.00045681934,0.0000025166,0.915039,0.00073252094,0.0030576594,0.053898565],"study_design_scores_gemma":[0.034277312,0.0033676648,0.028046373,0.0013327809,0.0020528962,0.0035818531,0.00046694255,0.00024110494,0.91943264,0.00010655615,0.006045542,0.0010483367],"about_ca_topic_score_codex":0.00003987245,"about_ca_topic_score_gemma":0.0001007812,"teacher_disagreement_score":0.052850228,"about_ca_system_score_codex":0.00035236753,"about_ca_system_score_gemma":0.0009383729,"threshold_uncertainty_score":0.9636014},"labels":[],"label_agreement":null},{"id":"W2523222835","doi":"10.1182/blood.v122.21.520.520","title":"Backtracking Subclonal Mutations Of TP53 In Myelodysplasia (MDS) With Del(5q) With Next-Generation Sequencing (NGS)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Sanger sequencing; Somatic evolution in cancer; Biology; Amplicon; DNA sequencing; Genetics; Myelodysplastic syndromes; Primer (cosmetics); Exon; Molecular biology; Computational biology; Polymerase chain reaction; DNA; Gene; Chemistry; Immunology","score_opus":0.04601201259537919,"score_gpt":0.26651704851319596,"score_spread":0.22050503591781678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523222835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995829,0.000095544136,0.00076585583,0.0005059277,0.000015186912,0.0006958079,0.0000051627467,0.000038237282,0.0020492834],"genre_scores_gemma":[0.98374575,0.000017689363,0.015475736,0.000120440774,0.00014051898,0.000106220636,0.00009426228,0.000041456802,0.00025794207],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844414,0.000059305246,0.00032191243,0.00030510384,0.0005081719,0.00036135403],"domain_scores_gemma":[0.9990097,0.00009459708,0.000110493325,0.0002855343,0.00035729833,0.0001423659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021814782,0.00017173644,0.00028943704,0.00026692107,0.00006982032,0.00004381887,0.00010919331,0.00009776001,0.00022172912],"category_scores_gemma":[0.0000871221,0.00012849,0.000033336444,0.0005798529,0.0001305391,0.0003761561,0.000028470944,0.0003535775,0.00005207956],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019314727,0.00050955307,0.17866193,0.00023450922,0.00026428793,0.0003816412,0.0019508406,0.0012143775,0.81279,0.00051779,0.0002575521,0.0030243727],"study_design_scores_gemma":[0.026160313,0.0032172734,0.36838314,0.0013356967,0.0007399013,0.0025215426,0.0044801473,0.042700864,0.5492079,0.00018879725,0.00017996151,0.0008844525],"about_ca_topic_score_codex":0.0011472551,"about_ca_topic_score_gemma":0.00068909803,"teacher_disagreement_score":0.26358208,"about_ca_system_score_codex":0.00022677281,"about_ca_system_score_gemma":0.00088887924,"threshold_uncertainty_score":0.523967},"labels":[],"label_agreement":null},{"id":"W2523237690","doi":"10.1182/blood.v124.21.116.116","title":"Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Refractory (planetary science); Pharmacodynamics; Pharmacokinetics; Adverse effect; Cytarabine; Pharmacology; Leukemia","score_opus":0.015206516914233234,"score_gpt":0.2954112388877334,"score_spread":0.28020472197350016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523237690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99567986,0.00007315203,0.000051416093,0.000104922015,0.00008408023,0.0015866007,0.000037148344,0.00006015813,0.002322697],"genre_scores_gemma":[0.99869025,0.000051098803,0.00032662277,0.00020702927,0.00013523687,0.00008571481,0.00007979126,0.00006118788,0.0003630465],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99704385,0.00025337416,0.0006768649,0.00054956594,0.00083301775,0.00064333185],"domain_scores_gemma":[0.9983195,0.00011729567,0.0001793132,0.0008575924,0.0002413798,0.00028490057],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006464173,0.00029283285,0.0007239597,0.0003890056,0.00008819163,0.000019796686,0.00035932427,0.00016296616,0.000044645585],"category_scores_gemma":[0.00027146068,0.00025242835,0.000115800016,0.00055032776,0.00010858819,0.00008489182,0.0002292871,0.00052225334,0.000086362896],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056673544,0.20183805,0.58113426,0.00056661793,0.0024976505,0.002574926,0.011412463,0.000044655604,0.098905824,0.000102532926,0.0029859887,0.09226967],"study_design_scores_gemma":[0.47919005,0.052555125,0.38944143,0.00036220046,0.0022901313,0.00032088222,0.0024019727,0.0022771885,0.06618773,0.00010447848,0.0037406026,0.0011281912],"about_ca_topic_score_codex":0.0007596869,"about_ca_topic_score_gemma":0.00010263406,"teacher_disagreement_score":0.4735227,"about_ca_system_score_codex":0.0004732746,"about_ca_system_score_gemma":0.00045485757,"threshold_uncertainty_score":0.9999928},"labels":[],"label_agreement":null},{"id":"W2523708385","doi":"10.1016/j.clml.2016.08.006","title":"An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices","year":2016,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"National Comprehensive Cancer Network; Takeda Oncology; Takeda Pharmaceutical Company","keywords":"Medicine; Internal medicine; Retrospective cohort study; Myeloid leukemia; Medical record; Cancer; Cohort; Pediatrics","score_opus":0.04286069260701756,"score_gpt":0.3989409932947389,"score_spread":0.35608030068772134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523708385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972338,0.00007832865,0.00010038414,0.0005526722,0.000097520555,0.0013318118,0.0003180973,0.000049149152,0.00023823525],"genre_scores_gemma":[0.9967564,0.0016775763,0.00047230572,0.00026248884,0.00010131098,0.0002152346,0.0004089994,0.00006131307,0.000044373603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9901793,0.004094892,0.0020735464,0.0010052248,0.0018663784,0.0007806454],"domain_scores_gemma":[0.98701847,0.00756415,0.0019764283,0.0015768101,0.0012083714,0.00065576704],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0050434307,0.0005284937,0.0027521495,0.00071327767,0.00012062182,0.000023266206,0.0005924135,0.00092469476,0.00033651132],"category_scores_gemma":[0.0071526254,0.0003325926,0.00041401864,0.0011225538,0.00090840046,0.0004327463,0.00021575799,0.00086770917,0.0000080835025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0031053626,0.0014479172,0.63091195,0.000015298869,0.0040912325,0.00009675226,0.00051923207,0.000006001022,0.0002013807,0.000013718812,0.000016801607,0.35957435],"study_design_scores_gemma":[0.034934577,0.021481378,0.9314091,0.00022888677,0.006441696,0.000020518839,0.00045836618,0.0040614866,0.00040134252,0.00018168252,0.000073444004,0.00030747076],"about_ca_topic_score_codex":0.04315553,"about_ca_topic_score_gemma":0.061753035,"teacher_disagreement_score":0.35926688,"about_ca_system_score_codex":0.018979678,"about_ca_system_score_gemma":0.014137339,"threshold_uncertainty_score":0.9999126},"labels":[],"label_agreement":null},{"id":"W2524493588","doi":"10.1182/blood.v124.21.961.961","title":"The FLAG Chemotherapy Regimen Is an Alternative to Anthracycline Based Therapy for the Treatment of Acute Myeloid Leukemia for Patients with Multiple Co-Morbidities or Preexisting Cardiac Disease","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Flag (linear algebra); Anthracycline; Cytarabine; Internal medicine; Regimen; Myeloid leukemia; Surgery; Filgrastim; Chemotherapy regimen; Cardiotoxicity; Fludarabine; Chemotherapy; Neutropenia; Cancer; Cyclophosphamide; Breast cancer","score_opus":0.02900352675951404,"score_gpt":0.3261072911198131,"score_spread":0.29710376436029906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524493588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987627,0.00023630405,0.0020993226,0.0018678646,0.00007992903,0.00681363,0.0011852428,0.000046217385,0.000044484703],"genre_scores_gemma":[0.98754394,0.0008804605,0.0055226884,0.00081990054,0.00071511127,0.0027086833,0.00037541948,0.00012346999,0.0013103499],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982364,0.00010021342,0.00030743756,0.00042924646,0.00046498948,0.00046168047],"domain_scores_gemma":[0.99611664,0.0021378666,0.00019382102,0.0008522671,0.000448632,0.00025074818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003639285,0.0002995351,0.00046052356,0.00006562724,0.0004106851,0.00004746478,0.00030866428,0.000056408604,0.000014381327],"category_scores_gemma":[0.00022798649,0.0001346583,0.00020833196,0.00013811047,0.00021373399,0.00007481559,0.000016595435,0.000082987804,0.0000018513505],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2435777,0.012957965,0.29077062,0.00054868247,0.015784945,0.000024305373,0.02017948,0.00027386224,0.013898217,0.00024959247,0.012366152,0.38936847],"study_design_scores_gemma":[0.16356361,0.06612342,0.18598989,0.00035010133,0.002685963,0.0000033135543,0.0014364275,0.041026272,0.36133525,0.00016130348,0.17635325,0.0009712261],"about_ca_topic_score_codex":0.00017270421,"about_ca_topic_score_gemma":0.000022525408,"teacher_disagreement_score":0.38839725,"about_ca_system_score_codex":0.00025247288,"about_ca_system_score_gemma":0.0005023724,"threshold_uncertainty_score":0.5491206},"labels":[],"label_agreement":null},{"id":"W2524612988","doi":"10.1182/blood.v126.23.1247.1247","title":"Integrative Analysis of the Mutational Landscape of Mouse and Human AML Identifies Functionally Relevant Leukemia Disease Alleles","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Biology; Myeloid leukemia; Leukemia; Genetics; Allele; Immunophenotyping; Cancer research; Myeloid; Exome sequencing; Exome; Mutation; Gene; Flow cytometry","score_opus":0.020706417938867315,"score_gpt":0.2877555855156352,"score_spread":0.2670491675767679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524612988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99825126,0.00032547186,0.000042182797,0.00036578096,0.000016688608,0.00017704532,0.000112377944,0.000011430802,0.0006977403],"genre_scores_gemma":[0.9961672,0.000021790036,0.00015955229,0.000045964865,0.00003957454,0.000014686247,0.00016089316,0.0000097763805,0.0033805578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881244,0.00008126374,0.00026411464,0.0001785895,0.0005531864,0.00011042099],"domain_scores_gemma":[0.9988499,0.00013147575,0.0001289019,0.000266245,0.0004781056,0.00014531735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026536017,0.00009794426,0.00028841832,0.00024544293,0.000050240204,0.0000108573595,0.00011172257,0.000042782565,0.00007686257],"category_scores_gemma":[0.0005359587,0.00005961409,0.00013719764,0.0004743048,0.0002422625,0.000060599905,0.00009397048,0.0001459715,0.0000025268102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000985585,0.00089287094,0.9137489,0.00023551402,0.007642304,0.0000612926,0.0035834596,0.0006522618,0.057532217,0.0054144426,0.009087925,0.00016322877],"study_design_scores_gemma":[0.003839192,0.00019517129,0.97529656,0.000065079104,0.003823165,0.0000119856995,0.0025292584,0.00132902,0.012052645,0.00061584375,0.0001384151,0.00010365385],"about_ca_topic_score_codex":0.00017119442,"about_ca_topic_score_gemma":0.00022342046,"teacher_disagreement_score":0.06154767,"about_ca_system_score_codex":0.00006863933,"about_ca_system_score_gemma":0.0006351491,"threshold_uncertainty_score":0.2430992},"labels":[],"label_agreement":null},{"id":"W2525872647","doi":"10.1182/blood.v118.21.5057.5057","title":"Azacitidine Has Limited Activity in Patients with MDS and AML","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Azacitidine; Cytarabine; Internal medicine; Chemotherapy regimen; Chemotherapy; Oncology","score_opus":0.03317195565536706,"score_gpt":0.2428581854032528,"score_spread":0.20968622974788573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525872647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956146,0.00002738357,0.000013455444,0.00014455401,0.000010119594,0.00033543044,0.0000065773793,0.00003128979,0.0038165746],"genre_scores_gemma":[0.9988731,0.000012286313,0.00080113247,0.000086258806,0.000026443022,0.0000152932,0.0000114271015,0.000019085499,0.00015497775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99923104,0.000031843512,0.000087178196,0.00020442063,0.0002083237,0.0002372226],"domain_scores_gemma":[0.9995235,0.000029196613,0.00002759331,0.00022115967,0.000068543566,0.00012997267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010150416,0.00009998677,0.00018273792,0.00013045073,0.00003243921,0.0000093826475,0.000051877676,0.00006739911,0.000075137454],"category_scores_gemma":[0.00007017434,0.00007401168,0.000014802946,0.00021517226,0.000109621134,0.00008575572,0.00005638617,0.00023655956,0.00001656958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008401064,0.0012740635,0.99247795,0.00004080121,0.00006143558,0.00009223948,0.00039261603,2.7920253e-8,0.0013906974,0.00001699796,0.000116116935,0.0032969527],"study_design_scores_gemma":[0.011344079,0.001022268,0.972593,0.000052280986,0.000054760978,0.000013077127,0.00001923295,0.000019365334,0.014610009,0.00001523607,0.00017071592,0.000085963125],"about_ca_topic_score_codex":0.00023515226,"about_ca_topic_score_gemma":0.00005205689,"teacher_disagreement_score":0.019884933,"about_ca_system_score_codex":0.00004245889,"about_ca_system_score_gemma":0.00009657951,"threshold_uncertainty_score":0.30181086},"labels":[],"label_agreement":null},{"id":"W2528244543","doi":"10.1038/cddis.2016.298","title":"Attenuated DNA damage repair delays therapy-related myeloid neoplasms in a mouse model","year":2016,"lang":"en","type":"article","venue":"Cell Death and Disease","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Ministry of Education, Culture, Sports, Science and Technology","keywords":"DNA damage; Cancer research; DNA repair; Myeloid; DNA; Biology; Medicine; Genetics","score_opus":0.01834096728404802,"score_gpt":0.2578202535658038,"score_spread":0.23947928628175577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528244543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993768,0.00089620496,0.00016441024,0.0012967899,0.000023122326,0.00062000385,0.000088213135,0.00020839198,0.0029348698],"genre_scores_gemma":[0.9773058,0.0012279776,0.00030667218,0.0009321496,0.000035506368,0.000060347593,0.000054843993,0.000053275773,0.020023393],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99828345,0.00007858249,0.00030076646,0.0005161356,0.0002876062,0.00053347833],"domain_scores_gemma":[0.997964,0.00010031292,0.000048703445,0.00056188303,0.00008923406,0.0012358649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022275708,0.00024240755,0.0002888874,0.00021905013,0.00007575479,0.000019950066,0.000121794095,0.00013727823,0.00016159716],"category_scores_gemma":[0.00022060855,0.00015830762,0.00012371315,0.0002159497,0.0001235034,0.00015019796,0.000094124276,0.00022662223,0.00013967804],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014939033,0.002220675,0.37586975,0.0005116041,0.00022621086,0.004097822,0.0012804539,0.00032612972,0.56390435,0.0009000098,0.020137476,0.015586488],"study_design_scores_gemma":[0.09589176,0.0016453036,0.246948,0.0008750083,0.0005028487,0.00008289955,0.0004167744,0.5839508,0.054383803,0.0066188285,0.0062177936,0.0024661305],"about_ca_topic_score_codex":0.00005809959,"about_ca_topic_score_gemma":0.0000063112675,"teacher_disagreement_score":0.5836247,"about_ca_system_score_codex":0.00018257467,"about_ca_system_score_gemma":0.0006661967,"threshold_uncertainty_score":0.6455598},"labels":[],"label_agreement":null},{"id":"W2528750776","doi":"10.3324/haematol.2016.147835","title":"Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group","year":2016,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Radboud Universitair Medisch Centrum; Erasmus Medisch Centrum; Vrije Universiteit Amsterdam; Radboud Universiteit","keywords":"Myelodysplastic syndromes; Flow cytometry; Cohort; Medicine; International Prognostic Scoring System; Dysplasia; Internal medicine; Confidence interval; Pathology; Oncology; Immunology; Bone marrow","score_opus":0.03187328569843767,"score_gpt":0.28627629038101154,"score_spread":0.2544030046825739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528750776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99289435,0.0010072881,0.0011632418,0.0020710377,0.00011078841,0.00046874926,0.000019801519,0.00007302697,0.0021916903],"genre_scores_gemma":[0.99765575,0.0002050219,0.0013985455,0.00020465642,0.00004344178,0.00007898433,0.00005729749,0.000026170714,0.00033014442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971701,0.0002246934,0.00088674744,0.0005973329,0.0005763584,0.0005447673],"domain_scores_gemma":[0.9961527,0.0020914588,0.00033407184,0.0011988276,0.0001049639,0.00011795015],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007943761,0.00025819393,0.00119942,0.0004523466,0.00008800983,0.000019211284,0.0004463514,0.0002317526,0.0010011089],"category_scores_gemma":[0.0016132204,0.00012658988,0.00030240935,0.0020069934,0.00040679105,0.00007358423,0.0002515181,0.00038864388,0.00010826012],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013566582,0.00037062302,0.9435418,0.000074645366,0.0036613783,0.013484095,0.0006208831,0.000020719077,0.024376014,0.0019583178,0.0018282156,0.008706614],"study_design_scores_gemma":[0.002092551,0.0001913364,0.98976177,0.0006329232,0.0013168671,0.0016100676,0.00031331286,0.0005358229,0.00073686184,0.00088569376,0.0016797058,0.00024306029],"about_ca_topic_score_codex":0.0005365302,"about_ca_topic_score_gemma":0.00028276155,"teacher_disagreement_score":0.04621996,"about_ca_system_score_codex":0.00028735714,"about_ca_system_score_gemma":0.00018264585,"threshold_uncertainty_score":0.9999121},"labels":[],"label_agreement":null},{"id":"W2529749106","doi":"10.1182/blood.v118.21.2955.2955","title":"Identification and Characterization of Human Leukemia Stem Cell Functional Regulators","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University Health Network","funders":"","keywords":"Stem cell; Biology; Haematopoiesis; Cancer stem cell; Leukemia; Hematopoietic stem cell; Cord blood; Cancer research; Gene signature; Myeloid leukemia; Immunology; Cell biology; Gene; Gene expression; Genetics","score_opus":0.028941415344314922,"score_gpt":0.24656077677349647,"score_spread":0.21761936142918153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529749106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978493,0.000030092086,0.0001314727,0.000023756762,0.00003701766,0.00020719931,0.0000068314603,0.000028922623,0.0016854133],"genre_scores_gemma":[0.9962239,0.000018562252,0.00006914819,0.000019867039,0.00007338118,0.000012403008,0.00007595301,0.00001516709,0.0034915693],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992796,0.000025428479,0.00021761104,0.00017019284,0.00020076802,0.000106375795],"domain_scores_gemma":[0.9994814,0.000009390743,0.00010516423,0.00021456284,0.000118587675,0.00007091142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001649938,0.00006929534,0.00012624728,0.000115049974,0.000050433304,0.0000066657058,0.000044873457,0.00007350996,0.00011900028],"category_scores_gemma":[0.0000059284944,0.00006473568,0.000028024117,0.00012606283,0.000068189656,0.00009008097,0.000031243962,0.00009349547,0.000019996776],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004176499,0.00013873167,0.03481412,0.00010520961,0.00002949119,0.0000039719653,0.00035353276,2.657327e-8,0.9634091,0.0004232569,0.00005977067,0.00062097405],"study_design_scores_gemma":[0.0009872161,0.000084429645,0.4836326,0.000015051345,0.00006058372,0.00001518512,0.000046261073,0.000020472473,0.51503533,0.000028226546,0.00003892479,0.000035712106],"about_ca_topic_score_codex":0.000018790275,"about_ca_topic_score_gemma":8.792587e-7,"teacher_disagreement_score":0.44881848,"about_ca_system_score_codex":0.00005896409,"about_ca_system_score_gemma":0.00010652155,"threshold_uncertainty_score":0.2639844},"labels":[],"label_agreement":null},{"id":"W2530076245","doi":"10.1182/blood.v110.11.1023.1023","title":"Growth Factor Independent 1b (Gfi1b) Is Highly Expressed in Human CML and Accelerates p210BCR-ABL Induced Leukemia in Mice.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"","keywords":"Myeloid leukemia; Tyrosine kinase; Cancer research; Haematopoiesis; Leukemia; Biology; Stem cell; Myeloid; Imatinib mesylate; Tyrosine-kinase inhibitor; ABL; Immunology; Imatinib; Cancer; Signal transduction; Cell biology; Genetics","score_opus":0.031074058810876805,"score_gpt":0.3042216675846502,"score_spread":0.27314760877377336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530076245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99587524,0.00028337122,0.0000062792537,0.00043751957,0.000051659412,0.00075753743,0.0000232982,0.00006912121,0.0024959848],"genre_scores_gemma":[0.99830097,0.00011758859,0.00028521838,0.0005516645,0.00019547495,0.00004181465,0.00003563465,0.000063623935,0.00040802616],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971291,0.00008972304,0.00062643876,0.0006631672,0.0006297227,0.0008618599],"domain_scores_gemma":[0.9988225,0.00020464674,0.0001076567,0.00039722802,0.00012810381,0.00033982546],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000692293,0.00033364477,0.0005612971,0.0007880365,0.0000808876,0.000067848814,0.0002988428,0.00042364444,0.0001770727],"category_scores_gemma":[0.00021452428,0.00030967005,0.00006336929,0.000652991,0.00009072768,0.00023862289,0.0002433963,0.0011389396,0.000037283316],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020843408,0.00050669996,0.20953393,0.00014002238,0.000069658665,0.0008042045,0.0018282019,3.1649284e-7,0.78563195,0.00009910152,0.00036251222,0.0008149789],"study_design_scores_gemma":[0.012164423,0.00027179558,0.4095628,0.00013879962,0.000031322295,0.000043105756,0.00035825552,0.000021226546,0.5768267,0.00014007835,0.0001937769,0.00024769508],"about_ca_topic_score_codex":0.003177921,"about_ca_topic_score_gemma":0.00084209326,"teacher_disagreement_score":0.20880523,"about_ca_system_score_codex":0.0008332336,"about_ca_system_score_gemma":0.00052937004,"threshold_uncertainty_score":0.99993557},"labels":[],"label_agreement":null},{"id":"W2530614832","doi":"10.1038/leu.2016.275","title":"Isocitrate dehydrogenase mutations in myeloid malignancies","year":2016,"lang":"en","type":"review","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":343,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; Celgene","keywords":"IDH2; Isocitrate dehydrogenase; Biology; Myeloid leukemia; IDH1; Myeloid; Cancer research; Myelodysplastic syndromes; Epigenetics; Histone; Mutation; Genetics; Gene; Biochemistry; Enzyme; Immunology","score_opus":0.04582845719732767,"score_gpt":0.35164557350211884,"score_spread":0.30581711630479114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530614832","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047496994,0.98958987,0.00003840054,0.0001946132,0.00016120767,0.001741336,0.00016537706,0.00015470236,0.007479501],"genre_scores_gemma":[0.000071037684,0.9827378,0.0004905657,0.00024250954,0.0004860297,0.000619101,0.00037866028,0.00019091771,0.014783386],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962277,0.00027235117,0.0010882698,0.0008354521,0.00057752477,0.0009987231],"domain_scores_gemma":[0.9976674,0.00051374384,0.0003083895,0.0009770433,0.00014413556,0.00038930099],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00056110637,0.00068717013,0.0023904738,0.0008633948,0.0001011227,0.000050833485,0.00048183464,0.00083358184,0.00062493613],"category_scores_gemma":[0.00045482806,0.0004787372,0.0007410391,0.0011354386,0.00028199516,0.000142237,0.0001939504,0.0013368288,0.003916742],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000030411087,0.00005277294,0.000032585176,0.015816154,0.00030160448,0.0019824249,0.00013971631,0.0000015442548,0.000065239336,0.0005729954,0.0065978616,0.9744067],"study_design_scores_gemma":[0.0012576137,0.000078457444,0.000024998948,0.02563838,0.00043058762,0.0006020453,0.00003196555,0.000019944038,0.000054229095,0.0001422718,0.97122234,0.00049715204],"about_ca_topic_score_codex":0.000123688,"about_ca_topic_score_gemma":0.00004210253,"teacher_disagreement_score":0.97390956,"about_ca_system_score_codex":0.0073331,"about_ca_system_score_gemma":0.0087438105,"threshold_uncertainty_score":0.9997664},"labels":[],"label_agreement":null},{"id":"W2530740161","doi":"10.1182/blood.v114.22.1588.1588","title":"FLT3 ITD Signaling Profiles in AML Samples Harboring Mutations.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Signal transduction; Context (archaeology); Cancer research; Mutation; Biology; Medicine; Oncology; Gene; Internal medicine; Genetics","score_opus":0.03043076232155739,"score_gpt":0.3056566482622949,"score_spread":0.2752258859407375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530740161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99450475,0.00039211081,0.000116402174,0.0014688992,0.00002246701,0.00037772875,0.000005468494,0.000089121626,0.003023076],"genre_scores_gemma":[0.99015415,0.000034084667,0.008975272,0.00023911509,0.00023075183,0.000028886448,0.00003433941,0.000017326867,0.00028609578],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988845,0.00003863976,0.00023073143,0.0002335794,0.00027777202,0.0003347731],"domain_scores_gemma":[0.9994645,0.000106493506,0.000035545276,0.00021473228,0.00007066275,0.00010808154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025596493,0.00011050759,0.00020428257,0.00023137443,0.000056267756,0.000026102198,0.00010233387,0.00007277147,0.000104740415],"category_scores_gemma":[0.0003386376,0.00010113779,0.000047734644,0.0003627527,0.000035150886,0.00008878381,0.00002440168,0.0003002612,0.00006529345],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017552942,0.0014205709,0.15265489,0.00019491058,0.00012444818,0.00106563,0.0018770347,0.00011959779,0.8164758,0.002134597,0.0006431777,0.023113834],"study_design_scores_gemma":[0.009444157,0.00056401436,0.3524667,0.0004952865,0.00016041585,0.00016393905,0.0007741278,0.0007103438,0.63168913,0.0013214553,0.0018501906,0.00036024873],"about_ca_topic_score_codex":0.000075195516,"about_ca_topic_score_gemma":0.000008344096,"teacher_disagreement_score":0.19981182,"about_ca_system_score_codex":0.00009655849,"about_ca_system_score_gemma":0.00022456792,"threshold_uncertainty_score":0.41242793},"labels":[],"label_agreement":null},{"id":"W2530865543","doi":"10.1182/blood.v108.11.2007.2007","title":"Management of Hyperleukocytosis in Acute Myelogenous Leukemia Using Hydroxyurea Rather Than Leukopheresis.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Western University; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Health Sciences Centre","funders":"","keywords":"Leukostasis; Leukapheresis; Medicine; Cohort; Internal medicine; Surgery; Retrospective cohort study; Leukemia; Gastroenterology; Pediatrics","score_opus":0.017115321737536777,"score_gpt":0.2687622228218589,"score_spread":0.25164690108432214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530865543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777032,0.0007987427,0.00008037007,0.00010068529,0.000038965354,0.0006526278,0.000012281712,0.00005909233,0.02055401],"genre_scores_gemma":[0.98832345,0.00020252517,0.008441167,0.00006960135,0.00012797632,0.00003441278,0.000027894344,0.0000719126,0.0027010357],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978449,0.000071555296,0.00051657966,0.00042693963,0.00053740566,0.0006026612],"domain_scores_gemma":[0.9990236,0.00004298151,0.00012267254,0.00062028493,0.00007804511,0.00011239782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030464752,0.00026178185,0.0005441857,0.0003104325,0.00005958875,0.000017030834,0.00026267167,0.0001813642,0.000114294606],"category_scores_gemma":[0.0000101271935,0.00023781564,0.00016277365,0.00067580066,0.00012333969,0.00008238726,0.00016617418,0.0003048609,0.000050808474],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001181919,0.003312089,0.2885587,0.0011944843,0.0026944112,0.01109729,0.00057034096,0.0008213939,0.6807565,0.0015666763,0.0012389923,0.0070071644],"study_design_scores_gemma":[0.03548714,0.0008986509,0.466802,0.0011279704,0.0031864075,0.0010651371,0.0008417401,0.0027450859,0.48342654,0.00080347754,0.0025269175,0.001088936],"about_ca_topic_score_codex":0.002157925,"about_ca_topic_score_gemma":0.00010391722,"teacher_disagreement_score":0.19733,"about_ca_system_score_codex":0.0007081817,"about_ca_system_score_gemma":0.00036216318,"threshold_uncertainty_score":0.969784},"labels":[],"label_agreement":null},{"id":"W2531315909","doi":"10.1182/blood.v126.23.800.800","title":"Prevalence and Prognostic Significance of KIT Mutations in Pediatric Core Binding Factor AML Patients Treated with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Population Health Research Institute; Hospital for Sick Children","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; Core binding factor; Internal medicine; Exon; Oncology; Missense mutation; CD33; Mutation; Gastroenterology; Biology; Genetics","score_opus":0.031900483545970845,"score_gpt":0.30485540291485325,"score_spread":0.2729549193688824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531315909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923361,0.00022666465,0.000019847817,0.00012461335,0.00005036275,0.0064809117,0.0006079354,0.000036461177,0.00011713701],"genre_scores_gemma":[0.99825674,0.00020022324,0.0003790376,0.000022059374,0.00019265902,0.0002646095,0.00059812877,0.000027812757,0.000058751524],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99749583,0.00048272975,0.0007046175,0.0004660465,0.00051797816,0.0003327926],"domain_scores_gemma":[0.99607724,0.0027137927,0.0004265458,0.00033909405,0.00024745666,0.0001958517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000715885,0.00022468109,0.0007860744,0.00022101494,0.000067582136,0.000017968978,0.00019292157,0.00014561591,0.000012485792],"category_scores_gemma":[0.0036819351,0.00013652723,0.00006548541,0.00058478856,0.00033050362,0.00010093667,0.000066795204,0.00039939236,0.000004811988],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56442034,0.0026939048,0.42903692,0.00004763815,0.00024960493,0.00005908099,0.002371147,0.0000041127696,0.0003597021,0.0000049035384,0.000088362525,0.0006642883],"study_design_scores_gemma":[0.8350117,0.004155903,0.15875182,0.000100485464,0.0011122208,0.000010808675,0.00011714495,0.00015537192,0.00044216533,0.000010938055,0.0000037209554,0.00012773737],"about_ca_topic_score_codex":0.0009200865,"about_ca_topic_score_gemma":0.000068235015,"teacher_disagreement_score":0.27059135,"about_ca_system_score_codex":0.00019682535,"about_ca_system_score_gemma":0.0006950763,"threshold_uncertainty_score":0.5567419},"labels":[],"label_agreement":null},{"id":"W2531339322","doi":"10.1002/cam4.845","title":"A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia","year":2016,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University Health Network","funders":"Ontario Ministry of Research and Innovation; Stem Cell Network; Cancer Center, University of Kansas; National Cancer Institute; National Institutes of Health; Leukemia and Lymphoma Society","keywords":"Tigecycline; Myeloid leukemia; Medicine; Pharmacodynamics; Pharmacology; Refractory (planetary science); Pharmacokinetics; Myeloid; Internal medicine; Antibiotics; Biology","score_opus":0.01923384069786624,"score_gpt":0.3347315085748791,"score_spread":0.31549766787701283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531339322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963729,0.00019115627,0.00007611867,0.0013013326,0.000097801036,0.0014360227,0.000056505054,0.000021174057,0.00044703684],"genre_scores_gemma":[0.9985211,0.00039277397,0.00008925014,0.0001785393,0.00016037219,0.00009962452,0.000024489354,0.00003863474,0.0004952387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976636,0.00007035923,0.00071929133,0.00035221985,0.00082195306,0.000372561],"domain_scores_gemma":[0.99821705,0.00017290268,0.00026670148,0.00060028996,0.0005016129,0.0002414643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003202802,0.00022086318,0.00089580443,0.0004783284,0.000026823858,0.0000010519052,0.0002144244,0.000090585825,0.00065097836],"category_scores_gemma":[0.00026390006,0.00011418414,0.00003507542,0.00081631984,0.00043950375,0.00007472495,0.00008903797,0.00028688507,0.0000046831806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018808821,0.0078181485,0.6603211,0.00033964287,0.0010314015,0.00036766345,0.009754194,0.000009665764,0.09832302,0.000034248085,0.003567301,0.1996248],"study_design_scores_gemma":[0.18106082,0.03937193,0.7660531,0.0029517612,0.00064434094,0.000015360818,0.0014807932,0.000047990823,0.0071473927,0.000024414587,0.0009485959,0.00025348816],"about_ca_topic_score_codex":0.001444991,"about_ca_topic_score_gemma":0.0002946708,"teacher_disagreement_score":0.19937132,"about_ca_system_score_codex":0.00078465673,"about_ca_system_score_gemma":0.0009747745,"threshold_uncertainty_score":0.71277565},"labels":[],"label_agreement":null},{"id":"W2531543939","doi":"10.1080/10428194.2016.1243680","title":"Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Azacitidine; Incidence (geometry); Myeloid leukemia; Adverse effect; Internal medicine; Randomization; Clinical trial; Emergency medicine","score_opus":0.007809037247689415,"score_gpt":0.2445108173246626,"score_spread":0.23670178007697318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531543939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960121,0.0005839349,0.00009092858,0.00018336848,0.00008833262,0.002308441,0.00022080986,0.00013091663,0.00038114798],"genre_scores_gemma":[0.99529576,0.0010907655,0.00089284097,0.00010783043,0.000056672598,0.00030965253,0.00070616696,0.0001755537,0.0013647291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99501187,0.00022060025,0.0010704689,0.001492698,0.0011424455,0.0010618937],"domain_scores_gemma":[0.99646133,0.00021094209,0.0008328165,0.0008930894,0.00093482493,0.0006670234],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021039262,0.0010169196,0.0014396199,0.0006683394,0.00028580628,0.000031097723,0.00029268963,0.00044692488,0.000085133695],"category_scores_gemma":[0.00006907477,0.00063134456,0.00014479867,0.001160537,0.0009247801,0.0007126555,0.00017624919,0.00016709194,0.000015931173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011332958,0.00041525543,0.9707021,0.00049043563,0.0013569163,0.00092441734,0.0023667314,0.00014928772,0.0040174443,0.00016012411,0.00022781902,0.007856502],"study_design_scores_gemma":[0.08584023,0.0035992477,0.8919214,0.003243273,0.00071080023,0.00081064866,0.0021622174,0.00071264,0.009891286,0.000031008527,0.00020680824,0.00087046635],"about_ca_topic_score_codex":0.0014371176,"about_ca_topic_score_gemma":0.0003911839,"teacher_disagreement_score":0.07878073,"about_ca_system_score_codex":0.018832577,"about_ca_system_score_gemma":0.006356872,"threshold_uncertainty_score":0.99961376},"labels":[],"label_agreement":null},{"id":"W2531677764","doi":"10.1182/blood.v104.11.1134.1134","title":"Redundant Leukemogenicity of NUP98-HOX Fusion Genes in Primary Murine Bone Marrow Cells Correlates with Gene Expression Changes Consistent with Common Key Target Genes.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Hox gene; Fusion gene; Biology; Gene; Myeloid leukemia; Homeobox; Myeloid; Molecular biology; Cancer research; Gene expression; Genetics","score_opus":0.011479420623789495,"score_gpt":0.22540458215255899,"score_spread":0.2139251615287695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531677764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99051154,0.0065140715,0.00012719102,0.0007805705,0.000059094025,0.0013308584,0.000052490355,0.000084268715,0.00053993386],"genre_scores_gemma":[0.9708565,0.0021059825,0.025870143,0.00023274339,0.00013109714,0.00009304474,0.00019870572,0.000100047386,0.00041172508],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99712485,0.00012337415,0.00054754986,0.00064812024,0.000903861,0.00065226026],"domain_scores_gemma":[0.9982793,0.00008903636,0.00030065305,0.00078615727,0.00024007485,0.0003048242],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004104007,0.00042280168,0.00094462396,0.00035994445,0.00011331154,0.000018855735,0.00023893274,0.00023726754,0.000081143444],"category_scores_gemma":[0.00002205306,0.00029547713,0.00009392351,0.00051574624,0.00037167658,0.00010072392,0.0002763271,0.00051956635,0.000015024259],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025912991,0.001704596,0.05620457,0.000521611,0.00015540856,0.001563847,0.00048450488,0.0005961424,0.93526226,0.000008379423,0.000123179,0.00078418147],"study_design_scores_gemma":[0.017906416,0.0020775476,0.022276701,0.0010659504,0.00024272868,0.00096156244,0.00020288806,0.000082369595,0.95443124,0.000021493812,0.00038140835,0.00034970324],"about_ca_topic_score_codex":0.0005613664,"about_ca_topic_score_gemma":0.00033919094,"teacher_disagreement_score":0.03392787,"about_ca_system_score_codex":0.00048340653,"about_ca_system_score_gemma":0.00096210797,"threshold_uncertainty_score":0.99994975},"labels":[],"label_agreement":null},{"id":"W2531697186","doi":"10.1182/blood.v124.21.377.377","title":"Gemtuzumab Ozogamicin (GO) in Infants with Acute Myeloid Leukemia (AML) – Combined Results from the Children’s Oncology Group (COG) Trials, AAML03P1 and AAML0531","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; Internal medicine; Leukemia; Induction chemotherapy; Myeloid leukemia; Juvenile myelomonocytic leukemia; Acute promyelocytic leukemia; Pediatrics; Clinical trial; Chemotherapy; Oncology; Surgery; Stem cell; CD33; CD34","score_opus":0.019084675674363297,"score_gpt":0.28482379123994617,"score_spread":0.2657391155655829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531697186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989014,0.00045368157,0.00006873677,0.0041521974,0.00013970544,0.0022102208,0.0002516889,0.00014767844,0.003562042],"genre_scores_gemma":[0.99333817,0.0007774165,0.0020037345,0.0017532511,0.0007636076,0.00013522126,0.00059711025,0.00009710895,0.00053435616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99505675,0.0011555589,0.0011349337,0.0010280468,0.00074126385,0.0008834415],"domain_scores_gemma":[0.99464184,0.0031844052,0.0004256179,0.0012510959,0.0001372065,0.00035983545],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033951064,0.0005066006,0.0015170483,0.00027884648,0.0001967733,0.00007995659,0.0005643652,0.0004785838,0.000057083933],"category_scores_gemma":[0.0024135953,0.00031516855,0.00013717935,0.000572668,0.00045948869,0.00016810052,0.0003682128,0.0013926121,0.00008624974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20346552,0.006568815,0.37040377,0.00024074095,0.013737906,0.00414272,0.01179849,0.00006356759,0.114547685,0.0028619838,0.055291116,0.21687768],"study_design_scores_gemma":[0.17420653,0.0083368765,0.7933859,0.00043726835,0.00227161,0.0008860309,0.00032606383,0.0007890696,0.007731711,0.00049134466,0.01039536,0.00074220006],"about_ca_topic_score_codex":0.004745739,"about_ca_topic_score_gemma":0.001897114,"teacher_disagreement_score":0.4229822,"about_ca_system_score_codex":0.0005878623,"about_ca_system_score_gemma":0.0010365478,"threshold_uncertainty_score":0.99993},"labels":[],"label_agreement":null},{"id":"W2532235959","doi":"10.1182/blood.v124.21.1328.1328","title":"Preliminary International Validation of the Quality of Life in Myelodysplasia Scale (QUALMS)","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Children's Hospital of Eastern Ontario; Princess Margaret Cancer Centre","funders":"","keywords":"Quality of life (healthcare); International Prognostic Scoring System; Medicine; Psychosocial; Scale (ratio); Transplantation; Gerontology; Myelodysplastic syndromes; Internal medicine; Psychiatry; Bone marrow","score_opus":0.02493340395833677,"score_gpt":0.317302365270445,"score_spread":0.2923689613121082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2532235959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917174,0.00002735834,0.0000816033,0.0013461779,0.00006980353,0.00022287971,0.000008717884,0.000008417746,0.006517657],"genre_scores_gemma":[0.99897647,0.000010798318,0.0005081345,0.0000909335,0.00008533113,0.000010665203,0.000015199273,0.000008691841,0.00029380253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987118,0.00018515968,0.00039924748,0.00012978184,0.0004663356,0.00010765671],"domain_scores_gemma":[0.999129,0.0002032026,0.00015709117,0.00032032377,0.00014313559,0.000047247177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008819234,0.00006139504,0.00020700977,0.00009411577,0.0000136715325,0.0000030499348,0.00021407026,0.00006817215,0.00007531037],"category_scores_gemma":[0.0013104638,0.00004440283,0.00006538943,0.00018738788,0.00009612757,0.000046217123,0.00011713675,0.00016392607,0.000008731025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004643557,0.0008846537,0.90940845,0.00024017441,0.00007693219,0.0000011083206,0.0006817607,0.0000315719,0.08567705,0.0007278954,0.00042606393,0.0013799617],"study_design_scores_gemma":[0.003507106,0.00016194342,0.82718176,0.000100344754,0.000029365923,0.000006307629,0.000113520655,0.0003453059,0.16817586,0.00014405682,0.0001916069,0.00004280378],"about_ca_topic_score_codex":0.00018986838,"about_ca_topic_score_gemma":0.00001872112,"teacher_disagreement_score":0.082498804,"about_ca_system_score_codex":0.00004007007,"about_ca_system_score_gemma":0.00017597318,"threshold_uncertainty_score":0.18106948},"labels":[],"label_agreement":null},{"id":"W2533984748","doi":"10.1182/blood.v120.21.1385.1385","title":"WT1 snp rs16754 Genotype Predicts Treatment Related Mortality (TRM) in African-American and Asian Pediatric AML Patients: A Report From the Children's Oncology Group","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Idarubicin; Internal medicine; Minor allele frequency; Regimen; Cytarabine; Medicine; Chemotherapy regimen; Oncology; SNP; Genotype; Context (archaeology); Gastroenterology; Allele frequency; Chemotherapy; Biology; Single-nucleotide polymorphism; Genetics","score_opus":0.017855258345023453,"score_gpt":0.29178696226287604,"score_spread":0.2739317039178526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2533984748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99313444,0.0009250914,0.0000029546773,0.0011442375,0.00011574612,0.001220191,0.000082650135,0.00007258679,0.003302082],"genre_scores_gemma":[0.99741745,0.00051793066,0.00044993256,0.00017533592,0.0007051046,0.00012990591,0.00046800612,0.000043223365,0.000093107476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975439,0.00029999338,0.0005466515,0.0004932143,0.00045321084,0.0006630288],"domain_scores_gemma":[0.998306,0.00023349994,0.00028168564,0.0007192493,0.00007060712,0.00038899953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050071906,0.0002662882,0.00054478267,0.00014744308,0.000107538435,0.000015598434,0.00015836452,0.0001828364,0.00007731602],"category_scores_gemma":[0.0003824395,0.00017712201,0.000087390676,0.0006427231,0.0002538933,0.000107976935,0.00014776732,0.0004782168,0.000034252353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011749411,0.0029918745,0.986688,0.000007373587,0.0003746118,0.00029551412,0.0019568438,1.7992555e-7,0.000057906498,0.000010685721,0.00048581744,0.007013674],"study_design_scores_gemma":[0.0071078567,0.0014410029,0.9883065,0.000011058793,0.0008487577,0.0001939374,0.0002963093,0.000007449707,0.0000421596,0.000030369421,0.0015572342,0.00015733867],"about_ca_topic_score_codex":0.0067271627,"about_ca_topic_score_gemma":0.00033519458,"teacher_disagreement_score":0.0069903624,"about_ca_system_score_codex":0.00057158264,"about_ca_system_score_gemma":0.00037590865,"threshold_uncertainty_score":0.9998871},"labels":[],"label_agreement":null},{"id":"W2534077863","doi":"10.1182/blood.v126.23.4446.4446","title":"A Qualitative Research Study to Understand Post-Transfusion Well-Being in Patients with Myelodysplastic Syndromes","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; St. Joseph's Hospital; McMaster University","funders":"","keywords":"Medicine; Qualitative research; Coding (social sciences); Content analysis; Anemia; Family medicine; Summative assessment; Population; Pediatrics; Internal medicine; Psychology; Formative assessment","score_opus":0.06780434265700358,"score_gpt":0.39831451743745355,"score_spread":0.33051017478045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534077863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925313,0.000020720754,0.0000604317,0.0007805188,0.000032148128,0.002618283,0.000006721589,0.000039704708,0.003910148],"genre_scores_gemma":[0.9987501,0.0000036681156,0.0005057657,0.000083055966,0.000036102363,0.00004904368,0.000020028114,0.00004743006,0.00050481386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996013,0.00075086975,0.00029399403,0.0005043757,0.0017938293,0.00064392015],"domain_scores_gemma":[0.9975765,0.00056502066,0.000027903603,0.00040283,0.0009226872,0.0005050714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023724132,0.00018532987,0.00037092765,0.0008023332,0.00010481743,0.000040726423,0.00019158419,0.000068630005,0.00004301786],"category_scores_gemma":[0.001056833,0.00013967151,0.000026514355,0.0013711371,0.00011812186,0.00012508527,0.00015197076,0.0006644734,0.00020003786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073713223,0.009684218,0.62204784,0.00014747564,0.0003195612,0.001066533,0.35808328,0.000018932196,0.0003311326,0.00018449507,0.0005327074,0.00021251527],"study_design_scores_gemma":[0.051423125,0.035906147,0.52563274,0.0005949437,0.00016556351,0.000040063518,0.38490364,0.000026600366,0.0004909116,0.00036683597,0.00006567367,0.00038375353],"about_ca_topic_score_codex":0.0007418986,"about_ca_topic_score_gemma":0.00080429617,"teacher_disagreement_score":0.09641508,"about_ca_system_score_codex":0.0005843433,"about_ca_system_score_gemma":0.00070212595,"threshold_uncertainty_score":0.56956387},"labels":[],"label_agreement":null},{"id":"W2536084185","doi":"10.1182/blood.v126.23.4865.4865","title":"Outcomes of Mixed Phenotype Leukemia, Not Otherwise Specified (NOS), in Adults: A Single Centre Retrospective Review from 2000 to 2014","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Leukemia; Monosomy; Myeloid leukemia; Myeloid; Cytogenetics; Internal medicine; Not Otherwise Specified; Cancer; Oncology; Pathology; Karyotype; Pediatrics; Biology; Chromosome; Genetics","score_opus":0.028185245746012607,"score_gpt":0.28116089106202535,"score_spread":0.25297564531601274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536084185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783087,0.0078038685,0.000016326932,0.0041187266,0.0001406911,0.0014793299,0.0001753688,0.00006706162,0.007889977],"genre_scores_gemma":[0.9885343,0.0012128499,0.004561895,0.0023322687,0.00034989882,0.000048331865,0.000101221536,0.00009826758,0.0027609908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744046,0.00015601482,0.0006165154,0.00054602383,0.00075629423,0.00048467566],"domain_scores_gemma":[0.9979989,0.00015819314,0.00016241774,0.00084852515,0.00039952004,0.00043246514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048272844,0.00027420808,0.0010346984,0.00019987741,0.000018873237,0.0000112263415,0.0003059477,0.00015231395,0.00060996966],"category_scores_gemma":[0.0016022051,0.0002291303,0.00014243906,0.0006106969,0.000076488985,0.00008245757,0.00014851536,0.0003961611,0.0007324814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058783656,0.0046388158,0.7255525,0.0018455975,0.0009774178,0.00081962533,0.008237712,0.000008172101,0.019002892,0.00026693274,0.22357804,0.009193947],"study_design_scores_gemma":[0.044468243,0.0019130534,0.86890346,0.009071333,0.0007363966,0.000023767709,0.0015188187,0.00004933431,0.049847044,0.00033598603,0.022202278,0.0009302681],"about_ca_topic_score_codex":0.0027770628,"about_ca_topic_score_gemma":0.0012270123,"teacher_disagreement_score":0.20137577,"about_ca_system_score_codex":0.0015009964,"about_ca_system_score_gemma":0.0010274258,"threshold_uncertainty_score":0.9414811},"labels":[],"label_agreement":null},{"id":"W2536114505","doi":"10.1182/blood.v124.21.278.278","title":"Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Down Syndrome Acute Myeloid Leukemia (DS-AML): Results of the Children’s Oncology Group (COG) Phase III AAML0431 Trial","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Medicine; Daunorubicin; Cytarabine; Internal medicine; Minimal residual disease; Oncology; Myeloid leukemia; Absolute neutrophil count; Gastroenterology; Leukemia; Toxicity; Neutropenia","score_opus":0.02415389287430947,"score_gpt":0.3225078377355551,"score_spread":0.2983539448612456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536114505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942883,0.00011590794,0.000027750699,0.0007372359,0.000105857594,0.004548341,0.0000637795,0.000016511682,0.000096262746],"genre_scores_gemma":[0.9985305,0.00011762711,0.0004203933,0.00007507253,0.00008099287,0.00031805472,0.00008074586,0.000025418447,0.00035120855],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969867,0.00024405846,0.0014266162,0.000525933,0.00041832504,0.00039839212],"domain_scores_gemma":[0.99798733,0.00042835754,0.00050331216,0.0008675397,0.0000614755,0.00015200429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010677255,0.00024951238,0.00085028296,0.00032823216,0.00003402705,0.000015167986,0.000292668,0.00021747872,0.00000977694],"category_scores_gemma":[0.00079090684,0.00016822985,0.00014135624,0.00042056592,0.00021168213,0.00008104952,0.00018406144,0.0003302748,0.0000044746575],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12934776,0.024413021,0.24561864,0.00052945974,0.0028203519,0.0003917322,0.005492032,0.000019085046,0.34981915,0.00030892924,0.00035873955,0.2408811],"study_design_scores_gemma":[0.5816257,0.018778289,0.36391014,0.00019554881,0.0012592764,0.00024318925,0.000085006905,0.00071343797,0.032626186,0.00014224112,0.00018199859,0.00023900808],"about_ca_topic_score_codex":0.0021046782,"about_ca_topic_score_gemma":0.00047528505,"teacher_disagreement_score":0.45227793,"about_ca_system_score_codex":0.0006996353,"about_ca_system_score_gemma":0.0006243038,"threshold_uncertainty_score":0.6860214},"labels":[],"label_agreement":null},{"id":"W2536240519","doi":"10.1182/blood.v124.21.5105.5105","title":"Mixed Fields on RHD Typing As an Indicator of Malignancy-Associated Loss of Heterozygosity on Chromosome 1p in Myeloid Neoplasm","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Bone marrow; Leukemia; Myeloid leukemia; Malignancy; Myeloid; Pathology; Myeloproliferative neoplasm; Induction chemotherapy; Immunology; Gastroenterology; Internal medicine; Chemotherapy; Myelofibrosis","score_opus":0.01848761709350681,"score_gpt":0.2731125052129551,"score_spread":0.2546248881194483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536240519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959219,0.000030643256,0.0000069222087,0.00033682794,0.00007343941,0.0003622073,0.000020906115,0.00003823317,0.0032089283],"genre_scores_gemma":[0.9991299,0.00003267078,0.00012963015,0.00035935658,0.000086057495,0.000016693437,0.000040349376,0.00003266028,0.00017266223],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981218,0.00022235213,0.00043758753,0.00036148287,0.00046883343,0.00038792615],"domain_scores_gemma":[0.9987017,0.00025408572,0.0002168348,0.0005604063,0.00009002319,0.0001769396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005976848,0.00018691662,0.00056769146,0.00032703017,0.00003850285,0.0000070512824,0.00025786317,0.00032061533,0.000090591406],"category_scores_gemma":[0.0006683442,0.00017029533,0.00009833865,0.0003498022,0.00010527433,0.000057619254,0.00008206297,0.00051534496,0.00006951858],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002982522,0.015770521,0.7104686,0.0013822434,0.0009624809,0.0005753386,0.0036336503,0.0000655435,0.24866904,0.0036191333,0.0010937274,0.010777192],"study_design_scores_gemma":[0.011992702,0.0050449716,0.48356727,0.0010356577,0.00010706411,0.000038274364,0.00008996352,0.00023234836,0.49722204,0.0002505814,0.000162192,0.00025694052],"about_ca_topic_score_codex":0.0003144247,"about_ca_topic_score_gemma":0.00012546749,"teacher_disagreement_score":0.248553,"about_ca_system_score_codex":0.0001389931,"about_ca_system_score_gemma":0.0002174789,"threshold_uncertainty_score":0.6944442},"labels":[],"label_agreement":null},{"id":"W2536726826","doi":"10.1182/blood.v126.23.3583.3583","title":"PLAG1 and USF2 Regulate Primitive Hematopoietic Expression of Musashi-2","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Biology; Ectopic expression; Stem cell; Transcription factor; Haematopoiesis; Regulation of gene expression; Context (archaeology); Gene expression; Cell biology; Genetics; Gene","score_opus":0.030816457340551183,"score_gpt":0.2904943886512641,"score_spread":0.25967793131071293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536726826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98919886,0.0005587388,0.000033492048,0.0003963268,0.000023473158,0.00028474635,0.000005598478,0.00003255156,0.009466222],"genre_scores_gemma":[0.9962802,0.00004460061,0.0024204347,0.00008342161,0.00007179124,0.000011457937,0.000009139377,0.000019851133,0.0010590958],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990342,0.000046750356,0.00017704835,0.00019912006,0.0003461636,0.00019670605],"domain_scores_gemma":[0.99918634,0.00006763231,0.00005924386,0.0002895168,0.00015095972,0.00024629862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002555338,0.00009833795,0.00025318193,0.000086501896,0.00002255594,0.0000069028188,0.00007088867,0.00009746357,0.0000317082],"category_scores_gemma":[0.0002564394,0.000075630116,0.000033519,0.00011992505,0.00012260096,0.000058905563,0.00012571408,0.00016591129,0.000020553936],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009600633,0.001258662,0.035346918,0.0007475759,0.00019165326,0.00053377287,0.0072088013,0.0000022330048,0.9373809,0.0008893354,0.013504237,0.0019758104],"study_design_scores_gemma":[0.010986938,0.00066644145,0.02277253,0.00045146604,0.00016568876,0.00048461524,0.0010415413,0.0000609425,0.9611119,0.0005285205,0.0015841373,0.0001452476],"about_ca_topic_score_codex":0.00001940908,"about_ca_topic_score_gemma":0.0000012265829,"teacher_disagreement_score":0.023730991,"about_ca_system_score_codex":0.000035045952,"about_ca_system_score_gemma":0.00020246698,"threshold_uncertainty_score":0.30841067},"labels":[],"label_agreement":null},{"id":"W2536902940","doi":"10.1182/blood.v126.23.5252.5252","title":"Assessing Disease Stability of Patients with Myelodysplastic Syndrome for an Age of Blood Randomized Controlled Trial: A Chart Review","year":2015,"lang":"en","type":"review","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; St. Joseph's Hospital; McMaster University","funders":"","keywords":"Medicine; Blood transfusion; Randomized controlled trial; Hematology; Pediatrics; Emergency medicine; Internal medicine; Intensive care medicine","score_opus":0.07038150723377104,"score_gpt":0.3750382234111799,"score_spread":0.30465671617740886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536902940","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009283175,0.9302646,0.000045738983,0.000016391554,0.00010391416,0.05964725,0.00048890576,0.000044644774,0.0001054168],"genre_scores_gemma":[0.0016414087,0.98767453,0.00078148587,0.000026622758,0.00012277029,0.0072173486,0.0023094271,0.00016567655,0.00006070153],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99185365,0.0022811287,0.0030916096,0.0008078283,0.0014267787,0.0005389985],"domain_scores_gemma":[0.9905495,0.0032667932,0.0024463388,0.0014725397,0.0015270091,0.0007378409],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0064656297,0.0007371461,0.018152267,0.00035138795,0.000049487953,0.00003323391,0.0004399315,0.00028982662,0.000070957],"category_scores_gemma":[0.01249329,0.00043513862,0.002086528,0.00053879834,0.0004344637,0.00019074362,0.00011312261,0.0005282031,0.0000036565393],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6270572,0.0070189727,0.000027295177,0.3462198,0.0057560843,0.00011757909,0.000022875938,3.1450995e-8,0.0000011816002,0.0000121229195,0.000040564115,0.0137263],"study_design_scores_gemma":[0.8033372,0.0023855893,0.000014054125,0.08789075,0.099453755,0.000025454012,0.000004553483,0.000004245205,9.141472e-7,0.000010415106,0.0065649967,0.00030803782],"about_ca_topic_score_codex":0.000009790744,"about_ca_topic_score_gemma":0.0000013109609,"teacher_disagreement_score":0.25832906,"about_ca_system_score_codex":0.00013586367,"about_ca_system_score_gemma":0.005377151,"threshold_uncertainty_score":0.99981004},"labels":[],"label_agreement":null},{"id":"W2537032954","doi":"10.1017/9781139939508.154","title":"Mutated IDH-1 (mIDH1-R132H, R132S, R132G)","year":2016,"lang":"en","type":"book-chapter","venue":"Cambridge University Press eBooks","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chemistry","score_opus":0.0261204158875672,"score_gpt":0.23597360405565623,"score_spread":0.20985318816808904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537032954","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007045139,0.00031018,0.00029605336,0.00027811434,0.00031825545,0.0014350679,0.0008322186,0.0005037096,0.99532187],"genre_scores_gemma":[0.0021373802,0.00055342587,0.0001767155,0.00033270815,0.0006169327,0.0000030425758,0.0002570374,0.00022651016,0.99569625],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99635106,0.00008701105,0.0004390013,0.001215432,0.0009594349,0.0009480328],"domain_scores_gemma":[0.9962896,0.00021601091,0.00034065632,0.0015879774,0.0006904664,0.00087530736],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025342594,0.0008540036,0.0011754661,0.0007073642,0.00024209177,0.000053531727,0.00089329266,0.0011591759,0.00015590324],"category_scores_gemma":[0.000071130984,0.00080906076,0.0005856474,0.000030086141,0.0008724706,0.00014503808,0.00096039934,0.0016376299,0.0006263207],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018425453,0.00004594711,0.000014969121,0.00051737606,0.0013649126,0.009852308,0.00009585924,4.3725848e-7,0.002636357,0.66368884,0.31149772,0.008442728],"study_design_scores_gemma":[0.004392187,0.00027045739,0.00004241023,0.0009103087,0.00076970743,0.00031703123,0.00003482611,0.00003820132,0.0026851725,0.000020007064,0.9896925,0.0008271592],"about_ca_topic_score_codex":0.00020414543,"about_ca_topic_score_gemma":0.000003228584,"teacher_disagreement_score":0.6781948,"about_ca_system_score_codex":0.0020092076,"about_ca_system_score_gemma":0.0011649708,"threshold_uncertainty_score":0.999436},"labels":[],"label_agreement":null},{"id":"W2537595153","doi":"10.1182/blood.v106.11.546.546","title":"Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nature Conservancy of Canada","funders":"","keywords":"Medicine; Internal medicine; Complete remission; Retrospective cohort study; Transplantation; Pediatrics; Surgery; Chemotherapy","score_opus":0.019225923631018913,"score_gpt":0.27532749540933704,"score_spread":0.2561015717783181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537595153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467176,0.00021012365,0.000067192705,0.0020530121,0.000056445042,0.0006436246,0.000021999442,0.000025325677,0.002250537],"genre_scores_gemma":[0.9972825,0.00004296066,0.00081760174,0.00058715034,0.00024090004,0.000102649734,0.000028218714,0.00003288374,0.0008651329],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822783,0.00017952519,0.0003338727,0.00033231167,0.0005574398,0.0003689972],"domain_scores_gemma":[0.9987295,0.00027018852,0.00011971243,0.0004529271,0.0002499884,0.00017764475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025195465,0.00019582233,0.00043294232,0.00007131846,0.00015046367,0.000018118284,0.00024008335,0.00011171316,0.00027631066],"category_scores_gemma":[0.0001862234,0.000112046444,0.00006734735,0.00025679468,0.00034750177,0.00013757408,0.00020482544,0.0004299692,0.000042370593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070710937,0.0027222345,0.96389645,0.0001273813,0.00041915438,0.00025408994,0.016512118,0.000013668901,0.002056669,0.00006205934,0.0017412294,0.005123826],"study_design_scores_gemma":[0.03845772,0.00945705,0.7742515,0.0011736781,0.00049160863,0.000153521,0.0050363457,0.0011042067,0.0030276068,0.0000046391483,0.16620368,0.00063841103],"about_ca_topic_score_codex":0.000053597032,"about_ca_topic_score_gemma":0.00017541788,"teacher_disagreement_score":0.18964495,"about_ca_system_score_codex":0.00016301205,"about_ca_system_score_gemma":0.0002408697,"threshold_uncertainty_score":0.45691216},"labels":[],"label_agreement":null},{"id":"W2537710036","doi":"10.1002/cam4.880","title":"Clofarabine versus fludarabine‐based reduced‐intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS","year":2016,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Institut National Du Cancer","keywords":"Fludarabine; Clofarabine; Medicine; Busulfan; Internal medicine; Regimen; Myeloid leukemia; Gastroenterology; Transplantation; Surgery; Hematopoietic stem cell transplantation; Cytarabine; Chemotherapy; Cyclophosphamide","score_opus":0.02805507194491621,"score_gpt":0.32706087848064236,"score_spread":0.29900580653572617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537710036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9418756,0.00037214748,0.0011003404,0.053872198,0.00035237064,0.0011836345,0.00004245566,0.000099385084,0.0011018931],"genre_scores_gemma":[0.9942705,0.00041047248,0.0007579424,0.0024714542,0.0006314159,0.00030806536,0.00014007308,0.000056746343,0.0009533203],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976348,0.0000677604,0.00042543618,0.0006322832,0.0006641064,0.0005755861],"domain_scores_gemma":[0.99827904,0.00022678066,0.00010891481,0.00047282872,0.00045844616,0.00045396684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040789382,0.00028734774,0.000601542,0.0004401133,0.00007837409,0.0000058873184,0.00017153179,0.00013195614,0.0006909998],"category_scores_gemma":[0.00033734264,0.0001730814,0.000046072884,0.0007350232,0.0003220303,0.00011381071,0.000020913261,0.00031522624,0.00004774592],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19966766,0.00034290802,0.053056188,0.0015919938,0.00052465935,0.0030644578,0.0064056865,0.00035493515,0.61761236,0.00021411046,0.03455008,0.08261494],"study_design_scores_gemma":[0.20174427,0.013890418,0.53075254,0.028860925,0.0008743305,0.00034330462,0.0016237812,0.0009199851,0.2072704,0.000042623113,0.01241933,0.0012580964],"about_ca_topic_score_codex":0.00089979626,"about_ca_topic_score_gemma":0.00062252145,"teacher_disagreement_score":0.47769636,"about_ca_system_score_codex":0.0013567487,"about_ca_system_score_gemma":0.0008036054,"threshold_uncertainty_score":0.7565963},"labels":[],"label_agreement":null},{"id":"W2544600340","doi":"10.1182/blood.v120.21.1517.1517","title":"Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML)","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"Decitabine; Medicine; Cytarabine; Internal medicine; Oncology; Etoposide; Azacitidine; Induction chemotherapy; Leukemia; Idarubicin; Daunorubicin; Chemotherapy regimen; Chemotherapy; Surgery; DNA methylation; Biology","score_opus":0.027338459029147905,"score_gpt":0.32228407957705196,"score_spread":0.2949456205479041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544600340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988947,0.00014204628,0.00013974676,0.0002134951,0.000053965523,0.010415703,0.000004577169,0.000016563477,0.00006694875],"genre_scores_gemma":[0.99591756,0.0001757438,0.0032111157,0.00013342632,0.000075918724,0.00031707803,0.000036357065,0.00006710217,0.00006568542],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966818,0.00061050395,0.00097246707,0.00048403148,0.0007908769,0.00046028703],"domain_scores_gemma":[0.997714,0.0003547721,0.00042714048,0.0007798285,0.00044502204,0.00027924794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025742606,0.00031572705,0.0011419427,0.00029182943,0.000081797385,0.000030585827,0.00035020235,0.00007710129,0.0000254898],"category_scores_gemma":[0.0006287562,0.00018284665,0.000044923778,0.00049539335,0.00015989656,0.00020248382,0.00027216747,0.0003103182,0.0000027914978],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33457974,0.020757986,0.59770966,0.00012377002,0.0015555513,0.00020668116,0.03578326,0.000032165826,0.0031031314,0.000002971745,0.000019841867,0.0061252685],"study_design_scores_gemma":[0.50452566,0.009912349,0.47903705,0.00011871941,0.0016811034,0.00008307675,0.0009830426,0.000065300395,0.0034002138,0.00000286566,0.000008230587,0.00018237854],"about_ca_topic_score_codex":0.0009802459,"about_ca_topic_score_gemma":0.0001658823,"teacher_disagreement_score":0.16994591,"about_ca_system_score_codex":0.00029131395,"about_ca_system_score_gemma":0.00048603717,"threshold_uncertainty_score":0.74562705},"labels":[],"label_agreement":null},{"id":"W2544886025","doi":"10.1038/leu.2016.302","title":"Modeling human MLL-AF9 translocated acute myeloid leukemia from single donors reveals RET as a potential therapeutic target","year":2016,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Institute for Research in Immunology and Cancer; Université de Montréal; Université Laval; Hôpital de l'Enfant-Jésus; Centre hospitalier universitaire de Québec","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Myeloid leukemia; Cancer research; Biology; Haematopoiesis; Myeloid; Progenitor cell; Receptor tyrosine kinase; Stem cell; Leukemia; Hematopoietic stem cell; Immunology; Receptor; Genetics","score_opus":0.02650162313280356,"score_gpt":0.28890859544666486,"score_spread":0.2624069723138613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544886025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96675587,0.0009248401,0.022719089,0.003138597,0.00034649135,0.0011834112,0.00017992238,0.0006462699,0.004105505],"genre_scores_gemma":[0.9828711,0.00042047646,0.0032303687,0.0022048543,0.0011064156,0.00011891341,0.000416427,0.00028275582,0.009348668],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99407953,0.0003238199,0.001169949,0.0014703188,0.0013203985,0.0016360087],"domain_scores_gemma":[0.9967356,0.000196502,0.00021940439,0.0016215596,0.0004168093,0.00081016583],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00066866324,0.0008153347,0.001208877,0.00046619485,0.0004384939,0.00013643337,0.00088974205,0.00082158623,0.0022401921],"category_scores_gemma":[0.00015508734,0.0006012067,0.0005157458,0.00067666447,0.00038846067,0.0004995602,0.00021996499,0.0011904078,0.0012191425],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014994091,0.00010846311,0.00059879705,0.00006629696,0.0009605288,0.0010610593,0.0006026117,0.0006747613,0.97841537,0.00021845364,0.003296886,0.0124973785],"study_design_scores_gemma":[0.06639974,0.00558285,0.008308877,0.0035543686,0.0045976066,0.00196056,0.0012564991,0.18942933,0.6398157,0.052977603,0.02013392,0.0059829806],"about_ca_topic_score_codex":0.003835091,"about_ca_topic_score_gemma":0.00010067857,"teacher_disagreement_score":0.33859968,"about_ca_system_score_codex":0.006923323,"about_ca_system_score_gemma":0.0023101522,"threshold_uncertainty_score":0.9996439},"labels":[],"label_agreement":null},{"id":"W2546446541","doi":"10.1182/blood.v106.11.4605.4605","title":"Acute Leukemia in Patients Sixty Years of Age and Older: A Retrospective Review.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Leukemia; Myeloid leukemia; Acute leukemia; Retrospective cohort study; Univariate analysis; Internal medicine; Surgery; Population; Chemotherapy regimen; Chemotherapy; Pediatrics; Multivariate analysis","score_opus":0.00802559563790155,"score_gpt":0.2761007397175632,"score_spread":0.26807514407966165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2546446541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951498,0.0019267467,0.0000012280907,0.00026033822,0.00001193201,0.0005958098,0.000016829254,0.000017073296,0.00202026],"genre_scores_gemma":[0.9939278,0.004157126,0.0009119304,0.0004861478,0.000058506193,0.000017362969,0.000021743002,0.000019670195,0.00039971145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892676,0.000037366175,0.00025783843,0.0002335545,0.0003188363,0.00022567499],"domain_scores_gemma":[0.99944055,0.000030887953,0.00006696173,0.00027844042,0.000083663035,0.000099516845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021077659,0.00009415251,0.00037591712,0.00011377143,0.00001258517,0.0000042169704,0.00008376446,0.0000766051,0.000049479797],"category_scores_gemma":[0.00021850217,0.00009193442,0.000049881703,0.00027801652,0.0000779857,0.00006482086,0.0000875227,0.0002854976,0.00002488045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003299576,0.0012204758,0.92607474,0.0011894704,0.0004362456,0.000756436,0.001221923,6.126529e-7,0.005991821,0.00012475571,0.011842068,0.05081148],"study_design_scores_gemma":[0.008093707,0.00034049537,0.98732156,0.00078494905,0.00016713602,0.000020456257,0.00001056115,0.000013206197,0.0019698595,0.000018906389,0.0011706066,0.00008855392],"about_ca_topic_score_codex":0.000057931255,"about_ca_topic_score_gemma":0.000019815561,"teacher_disagreement_score":0.06124681,"about_ca_system_score_codex":0.00039915205,"about_ca_system_score_gemma":0.00017998314,"threshold_uncertainty_score":0.3748977},"labels":[],"label_agreement":null},{"id":"W2546853358","doi":"10.1182/blood.v114.22.790.790","title":"Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; Interim analysis; Cytarabine; Internal medicine; Randomization; Induction chemotherapy; Randomized controlled trial; Surgery; Oncology; Chemotherapy","score_opus":0.03119918099127266,"score_gpt":0.3468058883991452,"score_spread":0.31560670740787256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2546853358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9709262,0.00009750399,0.0015969252,0.00081108965,0.001293113,0.01890598,0.0059809354,0.00013432573,0.00025392472],"genre_scores_gemma":[0.97758514,0.0004887721,0.0013936292,0.00023214036,0.00092837296,0.0017804236,0.017404992,0.00009056992,0.00009594939],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936453,0.0014271842,0.00201348,0.0010310295,0.0012962722,0.0005867266],"domain_scores_gemma":[0.9936835,0.0018808943,0.0012321115,0.000788091,0.002137857,0.0002775165],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030038839,0.00063610676,0.0019017665,0.0008982347,0.0003098068,0.00010745927,0.0005624821,0.000408547,0.00054149906],"category_scores_gemma":[0.001653916,0.0004951697,0.00047418702,0.00077947596,0.00023351805,0.00070406386,0.000073704105,0.0006022519,0.000007824808],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8701676,0.0045178747,0.000008985937,0.000014398306,0.002687865,0.0000097302445,0.00482267,0.00012512614,0.07590333,0.000029437166,0.0047661215,0.03694685],"study_design_scores_gemma":[0.80740577,0.1500873,0.00029507617,0.0001237464,0.0006078547,0.000022534576,0.0016690053,0.00043183158,0.036539685,0.000025640931,0.0024400323,0.00035153137],"about_ca_topic_score_codex":0.00029023734,"about_ca_topic_score_gemma":0.00021517277,"teacher_disagreement_score":0.14556943,"about_ca_system_score_codex":0.0020124195,"about_ca_system_score_gemma":0.0012530818,"threshold_uncertainty_score":0.99975},"labels":[],"label_agreement":null},{"id":"W2547366458","doi":"10.1182/blood.v124.21.5857.5857","title":"Reduced Intensity Versus Myeloablative Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Internal medicine; Transplantation; Hematopoietic stem cell transplantation; Incidence (geometry); Leukemia; Cumulative incidence; Graft-versus-host disease; Regimen; Surgery; Myeloid leukemia; Gastroenterology; Oncology","score_opus":0.024385111947191507,"score_gpt":0.2858085364435489,"score_spread":0.2614234244963574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547366458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932568,0.000057197547,0.0019038828,0.00032841464,0.00017390662,0.00092958583,0.00005422995,0.0000819151,0.003214045],"genre_scores_gemma":[0.9953696,0.00010803322,0.002857509,0.00021692952,0.00019029573,0.00014002313,0.00038535523,0.000044220524,0.00068801804],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998377,0.00009509828,0.0003434432,0.00043805203,0.00028207124,0.00046431745],"domain_scores_gemma":[0.99883026,0.0003891906,0.000104092665,0.00028345935,0.00022775402,0.0001652414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045955373,0.0002091202,0.0004294279,0.0002344942,0.00011384707,0.00002369808,0.0001395778,0.00019105934,0.000027850961],"category_scores_gemma":[0.00007651675,0.00020387331,0.00011573601,0.00027945745,0.00008739758,0.00013038801,0.000029844476,0.00037332566,0.00004766674],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0108988,0.00046757,0.007929019,0.0006666995,0.00072339387,0.0003032113,0.0041569173,0.00016556735,0.9654286,0.00066180166,0.0011367287,0.007461683],"study_design_scores_gemma":[0.043408077,0.0017486335,0.054095022,0.00020433812,0.0009770752,0.00016638714,0.0007239481,0.0022895422,0.8951126,0.00017857483,0.0006844113,0.00041144027],"about_ca_topic_score_codex":0.00006973015,"about_ca_topic_score_gemma":0.000042571723,"teacher_disagreement_score":0.07031606,"about_ca_system_score_codex":0.00046777187,"about_ca_system_score_gemma":0.0003998922,"threshold_uncertainty_score":0.8313712},"labels":[],"label_agreement":null},{"id":"W2547395346","doi":"10.1182/blood.v126.23.4891.4891","title":"Favorable Risk Group Acute Myeloid Leukemia in Children and Young Adult Treated in Uniform Protocol in Casablanca, Morocco. a Preliminary Analysis","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Cytarabine; Medicine; Etoposide; Daunorubicin; Pediatrics; Myeloid leukemia; Internal medicine; Leukemia; Surgery; Chemotherapy","score_opus":0.010370943646529516,"score_gpt":0.2736849881499889,"score_spread":0.26331404450345935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547395346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96676123,0.000094897325,0.000009731662,0.00007466873,0.0000075315756,0.03148927,0.000058288606,0.000060672053,0.0014437078],"genre_scores_gemma":[0.97608274,0.0001247729,0.000902028,0.000064582295,0.000060700495,0.021907475,0.0002393325,0.000053375916,0.0005649632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706453,0.00024658607,0.0006779257,0.0007123119,0.0005222777,0.0007763693],"domain_scores_gemma":[0.99867904,0.000063565116,0.00015402731,0.00059852016,0.00014646706,0.00035836754],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009589768,0.00035526606,0.0008709715,0.0015394023,0.000045383855,0.000044071225,0.00024344354,0.0003152254,0.000027355774],"category_scores_gemma":[0.00030699998,0.00030920317,0.00009891573,0.003202904,0.000113992246,0.00028444375,0.0002084984,0.0009742729,0.000024566738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020251586,0.00064939883,0.99294347,0.000059454436,0.0006459109,0.0009473394,0.0009980338,0.00011097206,0.00033035607,0.000008069371,0.00023425235,0.0010475749],"study_design_scores_gemma":[0.034248915,0.0011236646,0.9511471,0.00015595176,0.00079648854,0.00035498856,0.0004009446,0.01020262,0.0011841443,0.00005369134,0.000023398656,0.0003080937],"about_ca_topic_score_codex":0.06278252,"about_ca_topic_score_gemma":0.016093183,"teacher_disagreement_score":0.046689335,"about_ca_system_score_codex":0.0015334362,"about_ca_system_score_gemma":0.0006813651,"threshold_uncertainty_score":0.999936},"labels":[],"label_agreement":null},{"id":"W2547836063","doi":"10.1182/blood.v114.22.389.389","title":"Leukemic and Normal Stem Cell Transcriptional Signatures Determined by Functional Assays Are Predictive of the Overall Survival of AML Patients.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; Institute for Clinical Evaluative Sciences; University Health Network; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Stem cell; Haematopoiesis; CD34; Progenitor cell; Biology; Leukemia; Cancer research; Hematopoietic stem cell; Cancer stem cell; Immunology; Stem cell marker; Cell biology","score_opus":0.009999280107587417,"score_gpt":0.2127123861217811,"score_spread":0.20271310601419368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547836063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997161,0.0005048333,0.00006599114,0.00016910088,0.000077658944,0.00036922772,0.0003687393,0.000014677304,0.0012688191],"genre_scores_gemma":[0.9990227,0.000035175337,0.000054529883,0.0001460129,0.000076477176,0.0000072924017,0.00007283617,0.0000124152075,0.000572565],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985331,0.0000868383,0.00027851405,0.0002130159,0.0006829185,0.0002055589],"domain_scores_gemma":[0.9992305,0.00010225129,0.00014763899,0.00019127835,0.00023692456,0.000091396796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015139923,0.00014173186,0.00027090774,0.00006734899,0.000053690386,0.0000055139067,0.00012164519,0.00013511839,0.000046365625],"category_scores_gemma":[0.000031104366,0.00010063631,0.000110529065,0.00011924884,0.00013605705,0.00008251402,0.000033442455,0.00032820538,9.2988523e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002394183,0.0024289472,0.2985303,0.00027241206,0.00028940744,0.000010870666,0.0005186672,0.00006421396,0.6870408,0.00018478262,0.006758357,0.0015070246],"study_design_scores_gemma":[0.008932555,0.0008841556,0.91797686,0.00006641085,0.00017641296,0.000009291218,0.00007503986,0.00021600701,0.0713758,0.000042767333,0.00015598442,0.000088737455],"about_ca_topic_score_codex":0.000017848435,"about_ca_topic_score_gemma":0.0000032424093,"teacher_disagreement_score":0.6194465,"about_ca_system_score_codex":0.000075061114,"about_ca_system_score_gemma":0.00021678119,"threshold_uncertainty_score":0.41038296},"labels":[],"label_agreement":null},{"id":"W2548302270","doi":"10.1182/blood.v118.21.3587.3587","title":"A High-Throughput Screen to Identify Compounds Preserving Primary Human AML Stem Cells Ex-Vivo,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"Ex vivo; Stem cell; Leukemia; Biology; CD34; Myeloid leukemia; Myeloid; Population; Cancer research; Cancer stem cell; Flow cytometry; Immunology; In vivo; Cell biology; Medicine; Genetics","score_opus":0.05385136489301224,"score_gpt":0.3112405400632569,"score_spread":0.2573891751702447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2548302270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9562928,0.00017458736,0.00021635157,0.00043217302,0.00021133698,0.0011796041,0.00004073828,0.00024816516,0.041204236],"genre_scores_gemma":[0.9757354,0.00002972417,0.010344836,0.00096038636,0.0006709956,0.00007379033,0.000046659083,0.00011827524,0.012019901],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971619,0.00012911885,0.0004827123,0.00065907685,0.00080047105,0.0007666732],"domain_scores_gemma":[0.99784267,0.00008525832,0.00010992783,0.0012261714,0.00022686573,0.0005091293],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00053297076,0.00030107758,0.0005666408,0.00026486194,0.00018943136,0.00007041996,0.0007043212,0.00019123737,0.0008244328],"category_scores_gemma":[0.000030118857,0.0002803713,0.00014340716,0.00043453556,0.00011302604,0.00022728239,0.0008588893,0.0005294259,0.00084114744],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029583403,0.0023327342,0.020386463,0.0006044963,0.0006861831,0.0010877155,0.003309046,0.0000015174296,0.84949666,0.0006424066,0.12027358,0.0008833642],"study_design_scores_gemma":[0.01347358,0.002346809,0.17738968,0.000634539,0.0007460283,0.00015609924,0.00069131673,0.000021760547,0.77998745,0.0003813659,0.023260469,0.0009108813],"about_ca_topic_score_codex":0.002031173,"about_ca_topic_score_gemma":0.00008002115,"teacher_disagreement_score":0.15700322,"about_ca_system_score_codex":0.00025231251,"about_ca_system_score_gemma":0.00023589203,"threshold_uncertainty_score":0.99996483},"labels":[],"label_agreement":null},{"id":"W2548935397","doi":"10.1182/blood.v116.21.1861.1861","title":"Prognostic Impact of Monosomy 7 as a Single Anomaly In Primary MDS – Reclassification From Poor to Intermediate Prognosis","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"International Prognostic Scoring System; Myelodysplastic syndromes; Univariate analysis; Monosomy; Internal medicine; Medicine; Multivariate analysis; Chromosome abnormality; Oncology; Chemotherapy regimen; Bone marrow; Pediatrics; Chemotherapy; Karyotype; Biology; Genetics","score_opus":0.01917499101201396,"score_gpt":0.2964932101345466,"score_spread":0.2773182191225326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2548935397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953175,0.00005623028,0.000015338166,0.000891216,0.0000642923,0.001351829,0.000040773786,0.000055578203,0.0022072222],"genre_scores_gemma":[0.9953421,0.00001043771,0.0037977244,0.00013070775,0.00017896567,0.00022259285,0.00012643907,0.000041013893,0.00015005813],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984338,0.000060665145,0.0004054956,0.00038834047,0.00034555155,0.00036610436],"domain_scores_gemma":[0.9987711,0.00021631537,0.00011710899,0.0004401101,0.00017763056,0.00027774053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024965385,0.00017714305,0.00037945228,0.00036022742,0.000021747574,0.000025071351,0.00023122714,0.00017332286,0.0001869356],"category_scores_gemma":[0.0011973795,0.00014747343,0.00011755748,0.0005470569,0.00008983814,0.00011372775,0.00011341482,0.00048045,0.00012741733],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025595026,0.0012565427,0.46821916,0.000039479695,0.00007792394,0.000044209894,0.00028911338,3.033103e-7,0.52260125,0.0000038717585,0.00018763806,0.0070245494],"study_design_scores_gemma":[0.0028766647,0.0014033173,0.8773473,0.00016696277,0.000113594964,0.000029719462,0.00004147654,0.00009977659,0.11762169,0.000041956115,0.00013253841,0.0001250341],"about_ca_topic_score_codex":0.0011519068,"about_ca_topic_score_gemma":0.0001324237,"teacher_disagreement_score":0.40912813,"about_ca_system_score_codex":0.00023176796,"about_ca_system_score_gemma":0.0007336199,"threshold_uncertainty_score":0.60137916},"labels":[],"label_agreement":null},{"id":"W2549173225","doi":"10.1182/blood.v114.22.1582.1582","title":"Single Cell Network Profiles in Non-M3 AML Associated with Patient Response to Standard Induction Therapy.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Induction chemotherapy; Flow cytometry; Cell cycle; Context (archaeology); Biology; Medicine; Bioinformatics; Oncology; Immunology; Chemotherapy; Internal medicine; Cancer","score_opus":0.014066238969745836,"score_gpt":0.2573540539009737,"score_spread":0.24328781493122786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549173225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556005,0.0001374673,0.000027152058,0.0017991931,0.000037732665,0.0010911585,0.000009922895,0.00006318968,0.0012741389],"genre_scores_gemma":[0.99728477,0.000019016226,0.0013140568,0.0006737841,0.00013711232,0.00004363767,0.000025071024,0.000028430817,0.00047412456],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983685,0.00019139407,0.00022117089,0.00028444038,0.0004868512,0.0004476282],"domain_scores_gemma":[0.9992221,0.00010221328,0.00007119013,0.00027464403,0.00017063247,0.0001592245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058307627,0.00015260899,0.0002680253,0.00017278644,0.00006325383,0.000024401208,0.00008134545,0.00012529273,0.000034928842],"category_scores_gemma":[0.00022284058,0.00011723862,0.000033915,0.0007905342,0.000029581352,0.000059663293,0.000023749404,0.00034549454,0.000017741975],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06290047,0.0080713555,0.07068122,0.00003748931,0.0002717295,0.0013071935,0.007763533,0.0005920051,0.74354655,0.000009050888,0.023367107,0.08145232],"study_design_scores_gemma":[0.023065126,0.034335814,0.55797225,0.00066805095,0.000080218066,0.000049857015,0.0006560845,0.00006147852,0.37576854,0.00006718022,0.0068056425,0.0004697637],"about_ca_topic_score_codex":0.000029034907,"about_ca_topic_score_gemma":0.000024659248,"teacher_disagreement_score":0.487291,"about_ca_system_score_codex":0.00042607007,"about_ca_system_score_gemma":0.00033312268,"threshold_uncertainty_score":0.47808522},"labels":[],"label_agreement":null},{"id":"W2549224192","doi":"10.1182/blood.v120.21.1875.1875","title":"Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Biology; Haematopoiesis; Stem cell; Progenitor cell; CD34; CD38; Myeloid leukemia; Cancer research; Myeloid; CD90; Immunology; Cell biology","score_opus":0.04465295989519462,"score_gpt":0.28784342391448725,"score_spread":0.24319046401929262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549224192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965915,0.0019160069,0.00055719534,0.0003457916,0.000042972817,0.0003742046,0.000110557405,0.000021179496,0.000040562943],"genre_scores_gemma":[0.9955118,0.00004452796,0.0037877304,0.000027525079,0.00005563094,0.000034682616,0.00023319472,0.000014150423,0.0002908052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884784,0.000046033947,0.0003490956,0.00019331546,0.00032497654,0.00023874214],"domain_scores_gemma":[0.99939173,0.00009963639,0.00007065511,0.00016150466,0.00012897581,0.00014749618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029745937,0.00011676405,0.00033947086,0.00045451362,0.00006386593,0.000013120971,0.000045596098,0.00009475137,0.000035613033],"category_scores_gemma":[0.000067574736,0.00010386133,0.000076270866,0.0005354443,0.00011160274,0.00016002706,0.000033957105,0.00015828096,0.000001916252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000203324,0.0008145534,0.883425,0.0000760929,0.00097384414,0.00000469599,0.0004984999,0.000055350276,0.11322461,0.0004988866,0.000039726834,0.00018540106],"study_design_scores_gemma":[0.004156255,0.00006183965,0.988646,0.000028720153,0.0011576581,0.0000413668,0.00019893551,0.004160736,0.0012922118,0.000023234024,0.0001408572,0.0000921931],"about_ca_topic_score_codex":0.00022369908,"about_ca_topic_score_gemma":0.0005019595,"teacher_disagreement_score":0.1119324,"about_ca_system_score_codex":0.00004437046,"about_ca_system_score_gemma":0.000068958165,"threshold_uncertainty_score":0.42353424},"labels":[],"label_agreement":null},{"id":"W2549339569","doi":"10.1182/blood.v110.11.3377.3377","title":"Leukemia-Initiating Cells in Acute Megakaryoblastic Leukemia and Transient Leukemia of Down Syndrome.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Hospital for Sick Children","funders":"","keywords":"Acute megakaryoblastic leukemia; Leukemia; GATA1; Haematopoiesis; Down syndrome; Transplantation; Immunology; Acute leukemia; Medicine; Population; Cord blood; Biology; Stem cell; Cancer research; Internal medicine; Genetics","score_opus":0.011996066961740902,"score_gpt":0.26332576664020985,"score_spread":0.25132969967846897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549339569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907258,0.00049736793,0.00039684586,0.00009982241,0.00010965425,0.0007950678,0.000041834195,0.00008667432,0.0072468934],"genre_scores_gemma":[0.99524766,0.0003239616,0.0034479722,0.00022727321,0.00010499732,0.000025333848,0.000033741064,0.000080664184,0.00050836545],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99638563,0.000089207504,0.0010143549,0.00066919683,0.00080376584,0.001037852],"domain_scores_gemma":[0.9979917,0.0006102261,0.00020138429,0.00056915707,0.00016188642,0.00046567843],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012321805,0.0004047374,0.0008990441,0.0006966035,0.00009281485,0.00002753465,0.00027358046,0.00036468206,0.00010375655],"category_scores_gemma":[0.00021212769,0.00037756254,0.00016244441,0.0008994731,0.00030822633,0.00018693964,0.00015414123,0.0010120476,0.000041774736],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018701667,0.00078802963,0.029016387,0.0019423391,0.0011952673,0.015921876,0.0042352155,0.00028100517,0.9346911,0.00034876517,0.0014613012,0.008248554],"study_design_scores_gemma":[0.03534363,0.0027411964,0.38421857,0.0017312991,0.0014827742,0.006336863,0.0014502492,0.0030079954,0.5613435,0.00013441681,0.0011288231,0.001080681],"about_ca_topic_score_codex":0.0005180696,"about_ca_topic_score_gemma":0.00012363744,"teacher_disagreement_score":0.3733476,"about_ca_system_score_codex":0.0018253885,"about_ca_system_score_gemma":0.0018517178,"threshold_uncertainty_score":0.9998676},"labels":[],"label_agreement":null},{"id":"W2549431830","doi":"10.1182/blood.v116.21.2474.2474","title":"Re-Expression of the AML1/ETO Target Gene LAT2/NTAL/LAB Results In Direct Interference with Myeloid Differentiation In AML1/ETO-Positive Cells","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Biology; Myeloid; Molecular biology; Myeloid leukemia; Cell culture; Cell sorting; Transfection; Cell growth; Flow cytometry; Cancer research; Genetics","score_opus":0.00849449465902358,"score_gpt":0.24462484205948654,"score_spread":0.23613034740046296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549431830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99227244,0.00006827846,0.00006151341,0.00062786107,0.00012968233,0.00085921475,0.000096128235,0.000033750883,0.005851147],"genre_scores_gemma":[0.9971135,0.000059765065,0.00180862,0.000117207914,0.00011071322,0.000051437608,0.00008034302,0.000041439987,0.0006169664],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99768,0.00023832051,0.0005426195,0.00053541106,0.00056387624,0.00043978717],"domain_scores_gemma":[0.99842983,0.00023532231,0.00023459048,0.0007946063,0.00017709876,0.0001285766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000535257,0.000257789,0.00046659567,0.00028367923,0.000058626498,0.000021967047,0.00039081924,0.00022950226,0.00006501123],"category_scores_gemma":[0.00035934712,0.00016432922,0.000076935365,0.0006450635,0.00018645199,0.00013678418,0.0002788741,0.0010638407,0.000013047375],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015250779,0.0007949343,0.07146014,0.000072533396,0.00003401469,0.00006232804,0.0018197111,0.000018987981,0.9235422,0.000008062203,0.00026218433,0.00039983515],"study_design_scores_gemma":[0.0060778474,0.00031457847,0.27721372,0.0004610255,0.000041336276,0.000010910999,0.00014158162,0.00028373557,0.71524054,0.000020079486,0.000060279715,0.00013437172],"about_ca_topic_score_codex":0.0004709303,"about_ca_topic_score_gemma":0.0013911976,"teacher_disagreement_score":0.20830165,"about_ca_system_score_codex":0.00013660942,"about_ca_system_score_gemma":0.00028016654,"threshold_uncertainty_score":0.6701151},"labels":[],"label_agreement":null},{"id":"W2549668171","doi":"10.1182/blood.v106.11.1378.1378","title":"Dominant and Pharmacologically Sensitized ENU Mutagenesis Screens Uncover Novel Regulators of Hematopoiesis and Model Hematopoietic Disease.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Ontario Institute for Cancer Research; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Biology; Haematopoiesis; Genetic screen; Genetics; Mutation; Mutagenesis; Frameshift mutation; Mutant; Gene; Stem cell","score_opus":0.017569629850471,"score_gpt":0.2775685893243949,"score_spread":0.2599989594739239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549668171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949816,0.0011351787,0.00078547007,0.0019826205,0.000010530812,0.00055785157,0.00006315623,0.000046900837,0.0004366939],"genre_scores_gemma":[0.98530614,0.00049740734,0.012963969,0.00050464546,0.00009136319,0.000025066478,0.000009643254,0.000037860063,0.0005639239],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983329,0.00004443924,0.00037435256,0.00043393075,0.00043544985,0.00037893385],"domain_scores_gemma":[0.9987707,0.00015399815,0.00010304179,0.00034413714,0.00014671293,0.00048138943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033038433,0.00023880694,0.00056999794,0.0002221308,0.00008527232,0.000017210763,0.0000889969,0.00012269171,0.00006312574],"category_scores_gemma":[0.0001796467,0.0001887867,0.00010518276,0.00026824712,0.00031981035,0.00008987353,0.00020078207,0.00017198976,0.0000066401176],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016076852,0.0015923533,0.008765368,0.0008814493,0.0005295133,0.00032983394,0.00048184593,0.00020947601,0.98185825,0.0010156232,0.0017469246,0.000981675],"study_design_scores_gemma":[0.05748162,0.0006225332,0.065830484,0.00065830257,0.0045415475,0.0019004329,0.00057564443,0.100566894,0.76490164,0.00076082343,0.0010249234,0.0011351649],"about_ca_topic_score_codex":0.0000135966675,"about_ca_topic_score_gemma":0.0000027399453,"teacher_disagreement_score":0.21695662,"about_ca_system_score_codex":0.000044436794,"about_ca_system_score_gemma":0.00020436852,"threshold_uncertainty_score":0.7698498},"labels":[],"label_agreement":null},{"id":"W2549878120","doi":"10.1182/blood.v124.21.1059.1059","title":"Identification of Cytogenetically Normal Human CD34+CD38+ Hematopoietic Stem/Progenitor Cells from Inv(16)+ Leukemic Bone Marrow","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation","funders":"","keywords":"CD34; Bone marrow; CD38; CD33; Haematopoiesis; Biology; Population; Leukemia; Progenitor cell; Stem cell; Immunology; Molecular biology; Cancer research; Medicine; Cell biology","score_opus":0.015047907244236054,"score_gpt":0.2623423048366062,"score_spread":0.24729439759237015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549878120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966403,0.0003918577,0.00063386065,0.0002464925,0.00012461742,0.00064419274,0.000051248742,0.000091833295,0.0011755537],"genre_scores_gemma":[0.9965275,0.000035937974,0.000807974,0.00013795483,0.00050795166,0.00006291558,0.00010744144,0.00007446385,0.0017378777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99708927,0.00017107945,0.00089292065,0.00054037484,0.00080708525,0.0004992866],"domain_scores_gemma":[0.9978908,0.00015841598,0.00027278005,0.0010664986,0.0002914245,0.00032012543],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060755934,0.00026470402,0.0005756685,0.00021308937,0.0001112334,0.000041261388,0.000384893,0.00025720004,0.00030226432],"category_scores_gemma":[0.00010747753,0.00025349463,0.00018985504,0.00029873234,0.00022509474,0.000086967404,0.0001856053,0.0003921902,0.00044214542],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009255573,0.0005071433,0.009172812,0.00025513922,0.00016521914,0.00003837973,0.00022865624,0.0000022219403,0.98730797,0.0002268611,0.0010939754,0.00090908504],"study_design_scores_gemma":[0.0049059256,0.00035981523,0.0104135275,0.00011380065,0.0004521352,0.00007360432,0.00011546174,0.00019258469,0.9822385,0.00033938303,0.00055970286,0.00023558208],"about_ca_topic_score_codex":0.00018761377,"about_ca_topic_score_gemma":0.000026204634,"teacher_disagreement_score":0.0050694738,"about_ca_system_score_codex":0.00019250876,"about_ca_system_score_gemma":0.00030550032,"threshold_uncertainty_score":0.9999917},"labels":[],"label_agreement":null},{"id":"W2550328916","doi":"10.1182/blood.v108.11.560.560","title":"Twenty Years of Follow-Up among Survivors of Childhood and Young Adult Acute Myeloid Leukemia (AML): A Report from the Childhood Cancer Survivor Study (CCSS).","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cumulative incidence; Internal medicine; Incidence (geometry); Cancer; Pediatrics; Chemotherapy; Myeloid leukemia; Breast cancer; Surgery; Cohort","score_opus":0.007519316263921244,"score_gpt":0.2506116853578316,"score_spread":0.24309236909391038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550328916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951401,0.0009625149,0.000010479751,0.00017493128,0.00032447334,0.0019386073,0.00035690796,0.000075316144,0.0010167095],"genre_scores_gemma":[0.9974267,0.00039486264,0.00019371806,0.0000633612,0.00043460052,0.00013376352,0.00015829886,0.00009771749,0.001096992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99605304,0.00024611494,0.0010742756,0.00078567705,0.0012404359,0.0006004408],"domain_scores_gemma":[0.9971908,0.00029655715,0.00058850506,0.0012754934,0.00044570595,0.0002029856],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083668804,0.00039582865,0.0010113147,0.00018354628,0.00013104091,0.000037107984,0.0004690643,0.00022635059,0.00008319248],"category_scores_gemma":[0.0004018649,0.0003066535,0.00026344974,0.00069888245,0.00038079446,0.00015478741,0.00034782366,0.00066928734,0.0000062854992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020116582,0.0015608689,0.98643875,0.000039230817,0.0018302293,0.00050334044,0.0034287781,0.0000049387504,0.0036058049,0.000011011455,0.0010849275,0.0012909656],"study_design_scores_gemma":[0.012324695,0.00041822434,0.97478086,0.00019682726,0.0014594101,0.00017499557,0.0016094309,0.000019331312,0.00862144,0.000049472463,0.000072910625,0.00027238112],"about_ca_topic_score_codex":0.19554678,"about_ca_topic_score_gemma":0.040846784,"teacher_disagreement_score":0.1547,"about_ca_system_score_codex":0.00017478333,"about_ca_system_score_gemma":0.0009000946,"threshold_uncertainty_score":0.99993855},"labels":[],"label_agreement":null},{"id":"W2550339374","doi":"10.1182/blood.v112.11.2685.2685","title":"Iron Overload and Haematopoiesis in MDS: Does Blood Transfusion Promote Progression to AML?","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Sunnybrook Hospital","funders":"","keywords":"Haematopoiesis; Myelodysplastic syndromes; Stem cell; Progenitor cell; Immunology; Biology; Medicine; Cancer research; Bone marrow; Cell biology","score_opus":0.013346613029223358,"score_gpt":0.2825761477354372,"score_spread":0.26922953470621386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550339374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99471736,0.0005782843,0.00001355301,0.0022832553,0.000035575307,0.001362894,0.00000834002,0.00009255429,0.00090818177],"genre_scores_gemma":[0.9935941,0.001033875,0.0041672788,0.00020053957,0.00012515095,0.00011847322,0.000011245429,0.000041467734,0.00070784555],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99819773,0.00006728689,0.00029601247,0.00047774383,0.0005075084,0.000453689],"domain_scores_gemma":[0.99918157,0.00005014964,0.000037625243,0.00036436564,0.000063093496,0.00030321552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026008955,0.00020609597,0.00038668077,0.0002735468,0.00012290169,0.000017149507,0.000117727875,0.00016856991,0.00008118987],"category_scores_gemma":[0.00014854371,0.00013909572,0.00005724359,0.00041225724,0.00010877899,0.00010819942,0.00010470761,0.0003422751,0.000034211505],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010169294,0.00420991,0.34185395,0.0010373652,0.00013640395,0.005478451,0.008993919,0.0000011645635,0.61510354,0.000053737393,0.00084195955,0.021272656],"study_design_scores_gemma":[0.02293725,0.0025515317,0.27865663,0.0015495012,0.00033820793,0.003105351,0.00043475447,0.00008475362,0.68667656,0.00009047225,0.0030109193,0.0005640682],"about_ca_topic_score_codex":0.000216005,"about_ca_topic_score_gemma":0.00010964646,"teacher_disagreement_score":0.071573004,"about_ca_system_score_codex":0.0000583306,"about_ca_system_score_gemma":0.00016996419,"threshold_uncertainty_score":0.5672159},"labels":[],"label_agreement":null},{"id":"W2550344624","doi":"10.1182/blood.v110.11.899.899","title":"A Phase I Study of Tipifarnib Combined with Conventional Induction and Consolidation Therapy for Previously Untreated Patients with Acute Myeloid Leukemia Age 60 and Over.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Hamilton Health Sciences; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cytarabine; Regimen; Daunorubicin; Myeloid leukemia; Internal medicine; Gastroenterology; Toxicity; Leukemia; Surgery","score_opus":0.01623682542114622,"score_gpt":0.29938824926713586,"score_spread":0.2831514238459896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550344624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99610543,0.00006557545,0.00018596866,0.000026839381,0.000014221433,0.0034731063,0.000033159642,0.000031832427,0.00006388388],"genre_scores_gemma":[0.99869657,0.00006295187,0.00058425416,0.000042597898,0.000034824956,0.00008839188,0.0003497147,0.000029764456,0.000110961104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988024,0.000043969943,0.0002624147,0.0003027534,0.00035715016,0.00023131233],"domain_scores_gemma":[0.9991342,0.000096974734,0.00016799952,0.00017943817,0.00029105693,0.00013035507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028125834,0.00017074357,0.00032382362,0.00016685322,0.00009273848,0.00002019411,0.000043406115,0.000079771475,0.000015932608],"category_scores_gemma":[0.000029600924,0.000119335324,0.000020457575,0.00022469103,0.00015789366,0.00011848221,0.0000215137,0.0001502762,3.770335e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0992937,0.024992684,0.80957466,0.00036409724,0.005041257,0.0004677374,0.004400232,0.0000025379245,0.034083437,0.000121606805,0.00027387743,0.021384146],"study_design_scores_gemma":[0.27576232,0.051164962,0.66060865,0.00011738084,0.0008231636,0.000077809585,0.0005404293,0.00006723395,0.010513731,0.000020283156,0.000111413,0.00019262529],"about_ca_topic_score_codex":0.00008142544,"about_ca_topic_score_gemma":0.00004897642,"teacher_disagreement_score":0.17646861,"about_ca_system_score_codex":0.00009273028,"about_ca_system_score_gemma":0.00020875351,"threshold_uncertainty_score":0.48663533},"labels":[],"label_agreement":null},{"id":"W2550415955","doi":"10.1182/blood.v120.21.2593.2593","title":"Whole Exome Sequencing Analysis in AML with Normal Karyotype Not Harboring FLT3/ITD Mutation Reveals Novel Genetic Alterations.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Sanger sequencing; Biology; Genetics; Mutation; Exome sequencing; Missense mutation; dbSNP; Germline mutation; Gene; Cancer research; Genotype","score_opus":0.027635033462801783,"score_gpt":0.2834611603062218,"score_spread":0.25582612684342004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550415955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953115,0.00021353218,0.0030180872,0.00031485522,0.00003301551,0.00036736237,0.000014484982,0.00004597492,0.000681179],"genre_scores_gemma":[0.9800417,0.000013227839,0.01874696,0.00022625842,0.00030771364,0.00006381111,0.000093211485,0.000032463613,0.0004746453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983217,0.00006187465,0.00035489502,0.00027980295,0.00046122275,0.00052051473],"domain_scores_gemma":[0.99909085,0.00007965399,0.00009304234,0.0003810752,0.00014445849,0.00021089996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000483819,0.00016474767,0.00033706625,0.0005955943,0.00008527452,0.000040117786,0.00010490289,0.000089005254,0.00009565723],"category_scores_gemma":[0.00013268336,0.00014395101,0.00007044089,0.0013519289,0.00004420339,0.00032032997,0.000047888385,0.0003059162,0.00007459121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013833503,0.00045216383,0.63899785,0.00012040632,0.00072685577,0.00021647604,0.0021741246,0.0022318885,0.3542275,0.00007007452,0.00003105417,0.00061323773],"study_design_scores_gemma":[0.0040765703,0.00020543816,0.94776744,0.00009297085,0.0012208468,0.00020931527,0.00025529985,0.005119022,0.04073359,0.000003979794,0.000084862186,0.00023063808],"about_ca_topic_score_codex":0.00045196514,"about_ca_topic_score_gemma":0.0001725213,"teacher_disagreement_score":0.3134939,"about_ca_system_score_codex":0.00032534066,"about_ca_system_score_gemma":0.00025440223,"threshold_uncertainty_score":0.5870152},"labels":[],"label_agreement":null},{"id":"W2550485756","doi":"10.1182/blood.v104.11.4148.4148","title":"Induction of Transient Cytopenia to Detect Hematopoietic Defects in the Mouse.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Biology; Phenotype; Genetics; Penetrance; Cytopenia; Haematopoiesis; Genetic screen; Mutant; Immunology; Gene; Bone marrow; Stem cell","score_opus":0.019890808841104113,"score_gpt":0.27924340426676314,"score_spread":0.259352595425659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550485756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99636716,0.000120777404,0.00019463271,0.0016173649,0.00001646921,0.000694826,0.000001913792,0.0000181524,0.00096868776],"genre_scores_gemma":[0.99851406,0.00001788419,0.00097462576,0.0003264114,0.000047497095,0.00004948151,0.0000028666784,0.000014250651,0.000052931053],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990675,0.000049550927,0.00017971033,0.0001595713,0.00033136414,0.00021229079],"domain_scores_gemma":[0.9995213,0.00003574282,0.00002327372,0.00030386372,0.000043906846,0.00007190933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003265868,0.00008256269,0.00017978571,0.0001455375,0.000025060592,0.000006596541,0.00013808612,0.00006411195,0.000019476785],"category_scores_gemma":[0.00010835036,0.000055992732,0.00005509624,0.0004719678,0.00003622174,0.00003064796,0.000021705227,0.00024024368,0.00004891936],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024689754,0.00085722964,0.002206083,0.00023820293,0.000060821825,0.00023923893,0.007557192,0.00016208587,0.9857898,0.00039742346,0.00034959722,0.0018954652],"study_design_scores_gemma":[0.0070061404,0.0009333827,0.038366165,0.00011718009,0.000091376496,0.00041450068,0.0005961297,0.0000022146533,0.95153254,0.00027297827,0.0005677406,0.00009965276],"about_ca_topic_score_codex":0.00014720089,"about_ca_topic_score_gemma":0.000098618744,"teacher_disagreement_score":0.03616008,"about_ca_system_score_codex":0.0000914289,"about_ca_system_score_gemma":0.0001680229,"threshold_uncertainty_score":0.22833173},"labels":[],"label_agreement":null},{"id":"W2550682521","doi":"10.1182/blood.v126.23.4122.4122","title":"Diffron C, a Novel Oligonucleotide Based Gene-Silencing Agent, Induces Terminal Differentiation in Primary Murine Cells","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Haematopoiesis; Stem cell; Bone marrow; Biology; Cancer research; Progenitor cell; Leukemia; Myeloid; Myelodysplastic syndromes; Cancer stem cell; Immunology; Cellular differentiation; Cell biology; Genetics; Gene","score_opus":0.03549281945001561,"score_gpt":0.27132520160638424,"score_spread":0.23583238215636862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550682521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997049,0.000120483324,0.00035781434,0.0002615352,0.00012375003,0.00047237016,0.000016407745,0.00006886823,0.0015297836],"genre_scores_gemma":[0.9945671,0.000018269087,0.0040931352,0.0003995332,0.00029887957,0.00004223474,0.00010464652,0.00004420286,0.00043198696],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981849,0.000064314,0.00035621086,0.00038198958,0.00056430016,0.0004482846],"domain_scores_gemma":[0.99904597,0.0000691462,0.00010202607,0.00038286284,0.00009954201,0.00030044914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003616038,0.00020802599,0.0003472609,0.0003476783,0.000039683488,0.000031759882,0.00017980188,0.00013010546,0.000048802394],"category_scores_gemma":[0.00012335427,0.0001860167,0.00007374665,0.000299956,0.000050916387,0.000121982725,0.00012566232,0.00039493677,0.00006611335],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019655864,0.0014895089,0.03002188,0.00016547808,0.000044447916,0.00032798073,0.00046886306,0.00002751473,0.9656772,0.0000036214321,0.00035588845,0.0012210669],"study_design_scores_gemma":[0.014567786,0.00034396,0.39114627,0.00018278392,0.00014219449,0.000092800256,0.00012881379,0.0024187595,0.5905783,0.0000098832015,0.00016181378,0.00022662156],"about_ca_topic_score_codex":0.00026615316,"about_ca_topic_score_gemma":0.000029426585,"teacher_disagreement_score":0.37509888,"about_ca_system_score_codex":0.00047242016,"about_ca_system_score_gemma":0.00058814144,"threshold_uncertainty_score":0.7585541},"labels":[],"label_agreement":null},{"id":"W2551167602","doi":"10.1182/blood.v116.21.lba-3.lba-3","title":"GATA2 is a New Predisposition Gene for Familial Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"CEBPA; Genetics; Biology; Missense mutation; GATA2; Mutation; Myeloid leukemia; Cancer research; Gene; Transcription factor","score_opus":0.01069589578026284,"score_gpt":0.26379597518658676,"score_spread":0.2531000794063239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551167602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448115,0.00021256247,0.0015320382,0.0012171975,0.00031445845,0.0013515273,0.0002755191,0.00014693635,0.00046863334],"genre_scores_gemma":[0.9729656,0.00027439196,0.018191908,0.0008268582,0.0012675665,0.00018206672,0.00033207823,0.00011379142,0.0058457535],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978431,0.000024416588,0.00035945946,0.0006451084,0.00046768753,0.0006602586],"domain_scores_gemma":[0.9983654,0.00019039969,0.000089627865,0.0005682692,0.0001617819,0.0006245319],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002395493,0.0003165263,0.00047672846,0.0002195823,0.00018252974,0.00006924519,0.00022221892,0.0003553879,0.00017706689],"category_scores_gemma":[0.00022808943,0.0002870815,0.0001387446,0.00025542994,0.00016654778,0.00019724843,0.00015221188,0.00067341764,0.00011228373],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009781554,0.00025548728,0.0021160454,0.00027928437,0.00070398126,0.0005602329,0.0004731459,0.0000010317268,0.9779716,0.00021778699,0.01016058,0.0062826285],"study_design_scores_gemma":[0.076350704,0.0072545838,0.1710353,0.0005006623,0.006798918,0.0285585,0.00019230648,0.0054988894,0.6713348,0.0020705317,0.028581906,0.001822876],"about_ca_topic_score_codex":0.00017387707,"about_ca_topic_score_gemma":0.000033386,"teacher_disagreement_score":0.3066368,"about_ca_system_score_codex":0.00015513528,"about_ca_system_score_gemma":0.001089438,"threshold_uncertainty_score":0.99995816},"labels":[],"label_agreement":null},{"id":"W2551712301","doi":"10.1182/blood.v124.21.3693.3693","title":"Predictive Value of Molecular Remissions Post Consolidation Chemotherapy in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemias – a Single Centre Analysis","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Cytarabine; Daunorubicin; Medicine; Chemotherapy; Chemotherapy regimen; Gastroenterology; Internal medicine; Myeloid leukemia; Leukemia; Induction chemotherapy; Surgery","score_opus":0.009692334264617368,"score_gpt":0.25239856009881784,"score_spread":0.24270622583420046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551712301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976444,0.000016867021,0.0006381653,0.00021806835,0.0000156185,0.00068360654,0.00015619276,0.00004308478,0.00058396516],"genre_scores_gemma":[0.9975555,0.0000112928465,0.0015353714,0.00014723353,0.000026065756,0.000010652261,0.0005334195,0.000043364093,0.00013712129],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810123,0.0001052514,0.00036735288,0.00041658228,0.000633191,0.00037641035],"domain_scores_gemma":[0.99855596,0.00011920766,0.00021584943,0.0004747698,0.00041771124,0.00021650954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015981332,0.00022230136,0.0005487372,0.0006019427,0.00005418372,0.000015736698,0.00015810861,0.00016476482,0.00010654896],"category_scores_gemma":[0.00028832167,0.00017651134,0.00013497361,0.0012569656,0.00011019039,0.00009717738,0.00005686099,0.0003004662,0.000006498862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011918956,0.0014550915,0.7742475,0.000071990864,0.0024881805,0.000035919635,0.0013405445,0.00009981547,0.21812849,0.000041991214,0.000041595493,0.0008569686],"study_design_scores_gemma":[0.021527007,0.0019971912,0.68720007,0.00033638914,0.0027898748,0.00000809612,0.000363065,0.0026503506,0.2827305,0.000013768574,0.00007402236,0.00030968268],"about_ca_topic_score_codex":0.00008489838,"about_ca_topic_score_gemma":0.000014541486,"teacher_disagreement_score":0.08704745,"about_ca_system_score_codex":0.0003520482,"about_ca_system_score_gemma":0.00030395025,"threshold_uncertainty_score":0.71979237},"labels":[],"label_agreement":null},{"id":"W2552170145","doi":"10.1182/blood.v116.21.64.64","title":"Differential Gene and MicroRNA Expression In a HOXA9-MEIS1 Model of Leukemia","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Leukemia; Biology; Cancer research; Myeloid leukemia; Fusion gene; Phenotype; Hox gene; Immunology; Gene; Gene expression; Genetics","score_opus":0.014859684098693267,"score_gpt":0.2644805373627279,"score_spread":0.24962085326403466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552170145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99876183,0.000096746364,0.0002440013,0.00012154906,0.0000342932,0.0002405557,0.000014055854,0.000018367262,0.00046861338],"genre_scores_gemma":[0.9918725,0.00007703833,0.0075044394,0.000040540366,0.000099561235,0.000015155395,0.000013188303,0.000021830205,0.00035573068],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99907786,0.000019962681,0.00021159189,0.00023287574,0.0002199377,0.00023775628],"domain_scores_gemma":[0.99942046,0.000035800775,0.00004766546,0.00030876874,0.000051438776,0.00013588362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010179509,0.00011354306,0.0002717272,0.0001492034,0.000024053279,0.000008103015,0.00010656872,0.0001624336,0.00006541588],"category_scores_gemma":[0.00008257097,0.00009201468,0.000042149237,0.00009730245,0.000101969345,0.00004585518,0.00014214778,0.00048891513,0.0000051300017],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013817684,0.00022452089,0.013928131,0.000071828654,0.000017480039,0.00002229711,0.00023286216,0.0000040685404,0.9845211,0.000025349207,0.00015318673,0.0006610314],"study_design_scores_gemma":[0.0071595074,0.00009246047,0.03050537,0.00006696124,0.0000521205,0.000061422565,0.000023658102,0.007691407,0.9540962,0.000104876635,0.000050899394,0.000095112264],"about_ca_topic_score_codex":0.00006718399,"about_ca_topic_score_gemma":0.000027676804,"teacher_disagreement_score":0.030424863,"about_ca_system_score_codex":0.000037862625,"about_ca_system_score_gemma":0.00027006713,"threshold_uncertainty_score":0.37522495},"labels":[],"label_agreement":null},{"id":"W2552533929","doi":"10.1182/blood.v126.23.3792.3792","title":"Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Leukemia; Cancer research; Medicine; Acute leukemia; Histone H3; Pharmacology; Internal medicine; Biology; Methylation; Gene; Genetics","score_opus":0.017467892813978342,"score_gpt":0.28176794928908505,"score_spread":0.2643000564751067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552533929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958545,0.0003586769,0.000005134778,0.00047807634,0.000064190455,0.0027443618,0.00006497055,0.000022221971,0.0004078993],"genre_scores_gemma":[0.99874157,0.000054061748,0.00029263017,0.0000714517,0.00010661708,0.0000754434,0.000045599736,0.00004847632,0.00056413224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707466,0.00034008588,0.00079926563,0.00046689322,0.0009945201,0.00032455384],"domain_scores_gemma":[0.99782467,0.000108677035,0.0005022057,0.0011060638,0.00028805668,0.0001703251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009914142,0.0002625412,0.0005716887,0.00019928387,0.000091405396,0.000011395239,0.000244344,0.00018398589,0.000015713746],"category_scores_gemma":[0.00053103967,0.00013381388,0.00007534924,0.0008732034,0.00033912872,0.00014413243,0.00040689152,0.0008121098,0.0000011500309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011853031,0.009242436,0.9394914,0.00016277174,0.001076355,0.0017974798,0.007722566,0.000032247102,0.025550526,0.000009697954,0.0022959365,0.0007655706],"study_design_scores_gemma":[0.08140299,0.020061081,0.8327632,0.00060630083,0.0012075406,0.0054022,0.004165285,0.000031916923,0.05375291,0.00004200771,0.00026223843,0.00030234168],"about_ca_topic_score_codex":0.00039339482,"about_ca_topic_score_gemma":0.00008879106,"teacher_disagreement_score":0.106728196,"about_ca_system_score_codex":0.00030049175,"about_ca_system_score_gemma":0.001645189,"threshold_uncertainty_score":0.5456772},"labels":[],"label_agreement":null},{"id":"W2552596132","doi":"10.1182/blood.v120.21.2490.2490","title":"Different Characteristics Identified by Single Nucleotide Polymorphism Array Analsysis in Leukemia Suggest the Need for Different Application Strategics Depending On Disease Category.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"SNP array; SNP; Single-nucleotide polymorphism; Karyotype; Leukemia; Biology; Oncology; Cytogenetics; Genetics; Medicine; Internal medicine; Genotype; Chromosome; Gene","score_opus":0.023656376102816037,"score_gpt":0.27310434108822934,"score_spread":0.2494479649854133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552596132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949674,0.00033502388,0.0012185404,0.0011796334,0.00017573277,0.0016340511,0.00013049372,0.000071060465,0.00028804204],"genre_scores_gemma":[0.9971245,0.000112611204,0.000032368644,0.0003095593,0.0006132811,0.00046646319,0.0008312355,0.00008208836,0.00042790803],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976828,0.00011888799,0.0004968659,0.00042000666,0.0005167749,0.0007646659],"domain_scores_gemma":[0.99818796,0.00034394997,0.00020558247,0.00069966365,0.00007481423,0.00048800078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033803852,0.00034304228,0.00046979444,0.00019615683,0.00015794934,0.0000954062,0.00029911168,0.00013323018,0.00007536213],"category_scores_gemma":[0.00017468873,0.00023518111,0.00016453098,0.00024863554,0.00009108263,0.00011994089,0.000066722896,0.0004477552,0.00003865933],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001163035,0.004691559,0.28169483,0.0004352483,0.00029876796,0.000023265484,0.0005570471,0.0000032748512,0.7044931,0.0019005928,0.0016206806,0.003118584],"study_design_scores_gemma":[0.007007232,0.00033312375,0.8772769,0.00019032847,0.00087708136,0.000016821868,0.0004838895,0.0009908255,0.11056788,0.00027153504,0.0014487703,0.00053563423],"about_ca_topic_score_codex":0.00013182532,"about_ca_topic_score_gemma":0.0000309961,"teacher_disagreement_score":0.59558207,"about_ca_system_score_codex":0.00075636635,"about_ca_system_score_gemma":0.00013122607,"threshold_uncertainty_score":0.9590407},"labels":[],"label_agreement":null},{"id":"W2552867110","doi":"10.1182/blood.v126.23.223.223","title":"On the Origins of AML Relapse","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Population; clone (Java method); Biology; Oncology; Leukemia; CD33; Stem cell; Myeloid; Immunology; Medicine; Internal medicine; CD34; Genetics; Gene","score_opus":0.04237384355777724,"score_gpt":0.3058867926023476,"score_spread":0.26351294904457034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552867110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9527291,0.00008874022,0.000009186254,0.0035579463,0.000043960543,0.00019110968,0.00000396333,0.000022887187,0.043353096],"genre_scores_gemma":[0.99664044,0.000014572068,0.00024588805,0.0004799051,0.00011640556,0.000009626138,0.0000034180036,0.000012499878,0.002477244],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99928814,0.000039116156,0.000100700396,0.0000971433,0.00033378816,0.00014111905],"domain_scores_gemma":[0.9992329,0.00013868087,0.000027927634,0.0003847774,0.00010291818,0.000112798094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000334169,0.00005599888,0.00011766685,0.00004559137,0.000018286944,0.000003835067,0.000115829374,0.000044400767,0.000103109145],"category_scores_gemma":[0.0006629294,0.00003101516,0.000038338883,0.00015983256,0.00007035433,0.000015939744,0.00003992162,0.0002146847,0.00031877146],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015209505,0.004266444,0.03732145,0.00019218554,0.0008480251,0.0008226875,0.0036682931,0.000013362199,0.05261274,0.4015576,0.49339157,0.00378471],"study_design_scores_gemma":[0.038243458,0.006484375,0.019781942,0.00043010167,0.00072148925,0.00056863885,0.001855263,0.00043118084,0.5144051,0.009267868,0.40734994,0.00046067103],"about_ca_topic_score_codex":0.00009420796,"about_ca_topic_score_gemma":0.000003322372,"teacher_disagreement_score":0.46179235,"about_ca_system_score_codex":0.00010279131,"about_ca_system_score_gemma":0.00030408823,"threshold_uncertainty_score":0.40972686},"labels":[],"label_agreement":null},{"id":"W2552984492","doi":"10.1182/blood.v126.23.2861.2861","title":"Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"","keywords":"Panobinostat; Medicine; Azacitidine; Chronic myelomonocytic leukemia; Internal medicine; Phases of clinical research; International Prognostic Scoring System; Neutropenia; Myelodysplastic syndromes; Bone marrow; Clinical endpoint; Gastroenterology; Oncology; Toxicity; Clinical trial","score_opus":0.03451281276309057,"score_gpt":0.32088668575843354,"score_spread":0.286373872995343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552984492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996453,0.00003381467,0.0000052300497,0.00020090722,0.000036642014,0.0016742432,0.0001495018,0.000043064443,0.0014036156],"genre_scores_gemma":[0.99829537,0.000013514485,0.0005605508,0.000100632686,0.00007198359,0.00006902962,0.00015232567,0.00004083513,0.00069577736],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99766725,0.00012198048,0.0005068894,0.00039287005,0.00089816115,0.00041287436],"domain_scores_gemma":[0.99814624,0.00011444169,0.0001383675,0.0005758751,0.00070050533,0.00032459068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004015362,0.00020174097,0.00049842725,0.0002687976,0.000024001703,0.000011612281,0.00018164997,0.000080104604,0.000025613004],"category_scores_gemma":[0.0011987797,0.00013276152,0.00003410161,0.00067368255,0.00010002154,0.00010815786,0.00011403325,0.00031575587,0.000030960557],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12476373,0.078393474,0.74584,0.00042062462,0.0009916876,0.0046681557,0.02078202,0.00002211392,0.0019750667,0.000026054826,0.015135042,0.006982011],"study_design_scores_gemma":[0.8097191,0.050296072,0.11342708,0.00062596885,0.0005848665,0.000083525956,0.00907624,0.00030259686,0.013982069,0.000010728256,0.001379664,0.0005121327],"about_ca_topic_score_codex":0.0009972659,"about_ca_topic_score_gemma":0.00057749165,"teacher_disagreement_score":0.68495536,"about_ca_system_score_codex":0.00020767082,"about_ca_system_score_gemma":0.00094333553,"threshold_uncertainty_score":0.54138577},"labels":[],"label_agreement":null},{"id":"W2553030279","doi":"10.1182/blood.v120.21.3823.3823","title":"SF3B1 Mutations Are Associated with Favorable Cytogenetics in Patients with Myelodysplastic Syndromes with Ring Sideroblasts","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Myelodysplastic syndromes; International Prognostic Scoring System; Gene mutation; Medicine; Cytogenetics; Dysplasia; Internal medicine; Exon; Mutation; Oncology; Genetics; Pathology; Biology; Bone marrow; Chromosome; Gene","score_opus":0.01584725277878122,"score_gpt":0.2403556184477952,"score_spread":0.224508365669014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553030279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99817157,0.00007188412,0.00012323803,0.00007568636,0.000016963337,0.00067924184,0.000025817664,0.000079158635,0.0007564565],"genre_scores_gemma":[0.9974028,0.00000446725,0.0019370024,0.000054393993,0.000035679557,0.00006841466,0.00010240868,0.00008076795,0.00031409768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997987,0.00007025076,0.00022884294,0.0002852617,0.00068972935,0.00073894334],"domain_scores_gemma":[0.9987782,0.00020139835,0.00014806264,0.0003106685,0.00027150376,0.00029011947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016467359,0.00024970406,0.00039059267,0.00025269928,0.00010901137,0.000032001502,0.000105493695,0.00010500576,0.000040081864],"category_scores_gemma":[0.00023216911,0.0001705466,0.000022830898,0.00074987824,0.00012574662,0.0001946518,0.00004900361,0.00039480918,0.000041292016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026570048,0.001462658,0.9967286,0.00007900467,0.0003546897,0.00014038986,0.00042045373,0.00035326375,0.00010023121,0.000011190095,0.000026968457,0.000056841527],"study_design_scores_gemma":[0.013853421,0.001385551,0.98121643,0.0008833274,0.00037456022,0.0000947218,0.00034010832,0.00009082749,0.0014962585,0.0000036785189,0.000015755277,0.0002453851],"about_ca_topic_score_codex":0.00004339314,"about_ca_topic_score_gemma":0.00028424393,"teacher_disagreement_score":0.015512204,"about_ca_system_score_codex":0.00025805924,"about_ca_system_score_gemma":0.00028055493,"threshold_uncertainty_score":0.69546884},"labels":[],"label_agreement":null},{"id":"W2553114211","doi":"10.1182/blood.v126.23.2580.2580","title":"Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Cytarabine; Myeloid leukemia; Mdm2; Leukemia; Minimal residual disease; Internal medicine; Stem cell; Cancer research; Oncology; Immunology; Biology; Apoptosis","score_opus":0.026269537097037745,"score_gpt":0.30767903773946204,"score_spread":0.2814095006424243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553114211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951484,0.00012279139,0.000008561933,0.00027880643,0.00006876334,0.00396352,0.00010995679,0.00011080555,0.00018837857],"genre_scores_gemma":[0.9925851,0.00009735901,0.0013197849,0.00036855644,0.000092465525,0.00047769892,0.00005061043,0.00011700178,0.0048914272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99457127,0.001050365,0.0011213339,0.001220939,0.00102955,0.0010065449],"domain_scores_gemma":[0.9971233,0.0004602669,0.000277741,0.00083662366,0.00034786822,0.0009541897],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019730784,0.000566367,0.0010886823,0.00065090595,0.00006862086,0.000049284856,0.00032195757,0.00054911367,0.00002095465],"category_scores_gemma":[0.00054068776,0.00044164844,0.00010481498,0.0009885731,0.00020437993,0.0002137472,0.00035948976,0.0008241864,0.000120004064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056537233,0.0051411726,0.61970204,0.000109032066,0.00059397443,0.0021353012,0.0066619385,0.000053410306,0.2956494,0.0000010227104,0.003905216,0.009510241],"study_design_scores_gemma":[0.099565014,0.018658316,0.5154144,0.0028012705,0.00031268504,0.000073359646,0.00060663145,0.0006740489,0.3594296,0.000019277535,0.0015683625,0.00087702554],"about_ca_topic_score_codex":0.0002968374,"about_ca_topic_score_gemma":0.00023976406,"teacher_disagreement_score":0.10428763,"about_ca_system_score_codex":0.0055802236,"about_ca_system_score_gemma":0.002903268,"threshold_uncertainty_score":0.99980354},"labels":[],"label_agreement":null},{"id":"W2553187720","doi":"10.1182/blood.v116.21.3985.3985","title":"Identification of AML and MDS Patients Who Could Potentially Benefit From Temozolomide Therapy: Proportion of Patients with Low Methyl Guanine Methyltransferase (MGMT) Expression Level","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada); McMaster University Medical Centre; London Health Sciences Centre; Collège de Maisonneuve; Princess Margaret Cancer Centre","funders":"","keywords":"Temozolomide; Methyltransferase; O-6-methylguanine-DNA methyltransferase; Myeloid leukemia; Methylation; Medicine; Cancer research; Oncology; Leukemia; Decitabine; DNA methylation; Cytarabine; DNA methyltransferase; Bone marrow; Chemotherapy; Internal medicine; Biology; Gene expression; DNA; Genetics","score_opus":0.010951990293684561,"score_gpt":0.25385913638132007,"score_spread":0.2429071460876355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553187720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99686134,0.00008881131,0.0011385051,0.00007948504,0.000071705545,0.0012872423,0.00042107774,0.000025134015,0.000026696927],"genre_scores_gemma":[0.995278,0.000105729836,0.0037545783,0.00003492781,0.00005316589,0.000042470405,0.00061171444,0.000047707428,0.00007170301],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99765104,0.000069928305,0.0006747444,0.00043234768,0.0009338502,0.00023810832],"domain_scores_gemma":[0.9978256,0.00008358033,0.0003786256,0.0005555905,0.001000745,0.00015585063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037118752,0.00022240392,0.00047855658,0.0001982568,0.00006843784,0.000017702821,0.00017085332,0.00021360151,0.00008711284],"category_scores_gemma":[0.00020216052,0.00016172211,0.00007229086,0.00023586814,0.00018876181,0.00021294411,0.00005265801,0.0003790177,0.0000026632567],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012344056,0.0015366988,0.2985368,0.000097866716,0.00015790669,0.0000031229856,0.00021714946,0.0000012883097,0.6892204,0.000012366614,0.000031487136,0.008950493],"study_design_scores_gemma":[0.008163786,0.00051416026,0.47717914,0.000086024804,0.00013550941,7.079993e-7,0.00001894277,0.000030004154,0.51371187,0.000054832133,0.000016847353,0.00008819339],"about_ca_topic_score_codex":0.00027445288,"about_ca_topic_score_gemma":0.00004650153,"teacher_disagreement_score":0.17864233,"about_ca_system_score_codex":0.000028606348,"about_ca_system_score_gemma":0.00015091886,"threshold_uncertainty_score":0.6594836},"labels":[],"label_agreement":null},{"id":"W2553279539","doi":"10.1182/blood.v118.21.2561.2561","title":"Elderly AML Patients Treated with Intensive Chemotherapy- Developing A Prognostic Scoring System. A Study On 381 Patients From British Columbia","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Vancouver Hospital and Health Sciences Centre; University of British Columbia; Vancouver General Hospital","funders":"","keywords":"Medicine; Internal medicine; Proportional hazards model; Cytarabine; Chemotherapy; Performance status; Univariate analysis; Chemotherapy regimen; Population; Induction chemotherapy; Surgery; Oncology; Multivariate analysis","score_opus":0.022520384456630137,"score_gpt":0.2366253162829681,"score_spread":0.21410493182633797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553279539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954089,0.000021739172,0.000014758408,0.000013461122,0.00006429234,0.0034791306,0.000044207343,0.00019373903,0.00075979484],"genre_scores_gemma":[0.9981998,0.000005256284,0.00082621496,0.0002283891,0.000068300214,0.00028734677,0.0001081535,0.000097902965,0.00017863113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767387,0.00010612621,0.0003908234,0.0006449505,0.0006739527,0.00051029806],"domain_scores_gemma":[0.9979586,0.00008190377,0.00015983732,0.0004282352,0.0011563393,0.00021506166],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010292444,0.00023710313,0.0005272553,0.000104277395,0.00015846376,0.00012618054,0.00019740987,0.0001102624,0.00005148595],"category_scores_gemma":[0.0002886419,0.00026044511,0.000055345077,0.0003997256,0.000066551205,0.00010199428,0.000080207225,0.00033729244,0.000058776805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046695277,0.0030810947,0.9892282,0.000090805624,0.0006854799,0.0005722484,0.002160165,2.6158615e-8,0.000053584215,5.0274116e-7,0.00030291162,0.0033580633],"study_design_scores_gemma":[0.02506491,0.008264806,0.96179324,0.0019007407,0.00036174833,0.000026752512,0.0018263662,0.000005948317,0.0004552021,0.0000022691904,0.000022139073,0.00027587067],"about_ca_topic_score_codex":0.025366979,"about_ca_topic_score_gemma":0.0030479014,"teacher_disagreement_score":0.027434919,"about_ca_system_score_codex":0.00038625137,"about_ca_system_score_gemma":0.0002440099,"threshold_uncertainty_score":0.9999848},"labels":[],"label_agreement":null},{"id":"W2553294201","doi":"10.1182/blood.v118.21.3515.3515","title":"Genome-Wide Single-Nucleotide Polymorphism-Array Can Improve Prognostic Stratification of Core Binding Factor Acute Myeloid Leukemia, Especially in the Subgroup with Inv(16)/t(16;16) or without D816 C-KIT Mutation,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"SNP array; Core binding factor; SNP; Single-nucleotide polymorphism; Cytogenetics; Biology; Cytarabine; Karyotype; Myeloid leukemia; Leukemia; Pathology; Cancer research; Internal medicine; Molecular biology; Oncology; Medicine; Genetics; Chromosome; Gene; Genotype","score_opus":0.04162617733784461,"score_gpt":0.26409597598572626,"score_spread":0.22246979864788166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553294201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99310017,0.00011331035,0.0003878589,0.00048618455,0.00009829744,0.0028407976,0.00015361715,0.00010141086,0.00271838],"genre_scores_gemma":[0.995711,0.00005710743,0.0015924054,0.00029839753,0.00030703426,0.00022624423,0.0004328928,0.00012496093,0.0012499013],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99631727,0.0001992419,0.0009104951,0.00075151864,0.0010142991,0.0008071771],"domain_scores_gemma":[0.9973585,0.0004035025,0.0005715154,0.0009340289,0.0004518046,0.00028066392],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000590579,0.00048586118,0.0007020869,0.0005197576,0.00018883887,0.00008637962,0.00064626517,0.00025069306,0.0002473865],"category_scores_gemma":[0.0005361492,0.00032023116,0.00011629739,0.0011518743,0.00043681287,0.0002857718,0.00007358525,0.00079597125,0.000035172514],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021565116,0.0013776325,0.27036786,0.00033547566,0.0007146429,0.00060790934,0.016130377,0.0000016372255,0.7060287,0.00019286746,0.00015443197,0.0019319778],"study_design_scores_gemma":[0.016296377,0.0068528387,0.49715894,0.0006255003,0.0016746266,0.0009014327,0.009113232,0.000041662224,0.4655238,0.00034281565,0.00038863978,0.0010801242],"about_ca_topic_score_codex":0.0021058077,"about_ca_topic_score_gemma":0.006331461,"teacher_disagreement_score":0.24050488,"about_ca_system_score_codex":0.0013764822,"about_ca_system_score_gemma":0.0020847113,"threshold_uncertainty_score":0.99992496},"labels":[],"label_agreement":null},{"id":"W2553316197","doi":"10.1182/blood.v124.21.3236.3236","title":"HSC-Independent Yolk Sac Progenitors Bear Hallmarks of JMML in a PTPN11D61Y Mouse Model","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University Health Network","funders":"","keywords":"Juvenile myelomonocytic leukemia; Biology; Yolk sac; Myeloid; Progenitor cell; Transplantation; Haematopoiesis; PTPN11; Cancer research; Bone marrow; Embryonic stem cell; Stem cell; Immunology; Internal medicine; KRAS; Cell biology; Genetics; Medicine; Mutation; Embryo","score_opus":0.015600654543327739,"score_gpt":0.271610204845462,"score_spread":0.25600955030213424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553316197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919349,0.00014947448,0.000330584,0.00040557812,0.00003262114,0.0006475845,0.000013468394,0.000055737873,0.006430085],"genre_scores_gemma":[0.99346197,0.000045179688,0.0034700097,0.00013846936,0.00015212066,0.0000663446,0.000017925639,0.00005363294,0.0025943387],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997951,0.00009373845,0.00042134535,0.0003687718,0.00068253186,0.00048265318],"domain_scores_gemma":[0.9988471,0.00006976893,0.000091117494,0.00060921983,0.00014320412,0.00023956758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006377364,0.0001881063,0.000446938,0.00030022307,0.0000324794,0.000012691992,0.00026152597,0.00021544012,0.000060368417],"category_scores_gemma":[0.0003132616,0.00016723147,0.00015455701,0.0002583597,0.00009241399,0.00007496385,0.00015142334,0.000507539,0.000063269756],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016338206,0.008804991,0.24298564,0.0016325756,0.0011411585,0.0004924735,0.0038647081,0.0013380562,0.71891445,0.0026481766,0.0039253095,0.01261864],"study_design_scores_gemma":[0.037099753,0.0018752684,0.022216214,0.0004710564,0.000635317,0.00029046953,0.0005991822,0.083868854,0.84957796,0.000780426,0.0017325818,0.00085289165],"about_ca_topic_score_codex":0.00024198828,"about_ca_topic_score_gemma":0.00006624669,"teacher_disagreement_score":0.22076942,"about_ca_system_score_codex":0.0001357097,"about_ca_system_score_gemma":0.00042075437,"threshold_uncertainty_score":0.68195015},"labels":[],"label_agreement":null},{"id":"W2553350762","doi":"10.1182/blood.v116.21.182.182","title":"Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Hospital for Sick Children","funders":"","keywords":"Medicine; Gemtuzumab ozogamicin; Cytarabine; Regimen; Internal medicine; Etoposide; Induction chemotherapy; Transplantation; Myeloid leukemia; Surgery; Gastroenterology; Pediatrics; Chemotherapy; CD33; Stem cell","score_opus":0.028875405537464385,"score_gpt":0.3402817247852424,"score_spread":0.311406319247778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553350762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893553,0.00010506407,0.000022670058,0.0034975566,0.0004616763,0.004320939,0.00014997013,0.00021367015,0.0018731207],"genre_scores_gemma":[0.9921153,0.00030612288,0.002194314,0.0011770299,0.0023925123,0.00021469746,0.000980593,0.0001439078,0.0004755017],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949778,0.0005368388,0.0011786197,0.0013552201,0.0009270533,0.001024512],"domain_scores_gemma":[0.9960331,0.0009345148,0.0006356244,0.0014495646,0.000503312,0.00044391572],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014217388,0.0006620206,0.0012989262,0.00042582647,0.00040889313,0.00010891902,0.00064474996,0.0008150567,0.00013179047],"category_scores_gemma":[0.0020863777,0.00039755547,0.00017495923,0.001028477,0.0005573087,0.00038883873,0.00033315248,0.0037281162,0.000051495528],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61496794,0.004650577,0.0030616005,0.000031468717,0.0022207128,0.0026750944,0.0124273235,0.0000040256073,0.31878358,0.00006874975,0.0068167597,0.03429218],"study_design_scores_gemma":[0.8459977,0.0148054585,0.019971369,0.0009084687,0.001993546,0.004214757,0.006326814,0.0003855107,0.10067493,0.00011377908,0.003652659,0.00095503975],"about_ca_topic_score_codex":0.0036416026,"about_ca_topic_score_gemma":0.0014153961,"teacher_disagreement_score":0.23102973,"about_ca_system_score_codex":0.0008310373,"about_ca_system_score_gemma":0.0035688435,"threshold_uncertainty_score":0.99984765},"labels":[],"label_agreement":null},{"id":"W2553701282","doi":"10.1182/blood.v108.11.3009.3009","title":"Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from Matched Related Donors (MRD) with a Myeloablative Once Daily IV Busulfan (Bu)/Fludarabine (Flu) Based Regimen (FLUBUP) with Thymoglobulin: Outcomes in 200 Patients with over One Year Follow-Up.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Thymoglobulin; Medicine; Busulfan; Fludarabine; Transplantation; Surgery; Internal medicine; Gastroenterology; Regimen; Cumulative incidence; Folinic acid; Hematopoietic stem cell transplantation; Chemotherapy; Antimetabolite; Cyclophosphamide; Tacrolimus; Fluorouracil","score_opus":0.008813277192227563,"score_gpt":0.2187481092584244,"score_spread":0.2099348320661968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553701282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282247,0.00017912213,0.001564217,0.000506536,0.00003254457,0.0035455413,0.00030017341,0.0001738105,0.00087558123],"genre_scores_gemma":[0.9826486,0.000023112589,0.013946096,0.0001652432,0.00003269869,0.00040170562,0.0011245784,0.00015725743,0.0015006978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961617,0.00016072564,0.00080660585,0.0010128357,0.0010048284,0.0008533068],"domain_scores_gemma":[0.99785554,0.0004113652,0.00042405693,0.0007369094,0.00034696583,0.00022518117],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002634946,0.00063346623,0.0012431996,0.00032726765,0.00013622906,0.000054978296,0.00028391398,0.00032404673,0.00010261572],"category_scores_gemma":[0.000021156931,0.0004358469,0.00012907443,0.00086986955,0.00019719468,0.000284051,0.000031374468,0.00052481197,0.000030677347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013325529,0.0031332478,0.976127,0.0007952477,0.0006246955,0.00058417296,0.002003669,0.0003117537,0.002731584,0.00010917935,0.00019796086,0.000055941204],"study_design_scores_gemma":[0.16893195,0.005043684,0.7695288,0.0026465629,0.001951992,0.000058747817,0.0011733223,0.000565356,0.048581675,0.00027058518,0.000033948592,0.0012133798],"about_ca_topic_score_codex":0.0010126098,"about_ca_topic_score_gemma":0.00061572576,"teacher_disagreement_score":0.20659822,"about_ca_system_score_codex":0.00032824354,"about_ca_system_score_gemma":0.0005427331,"threshold_uncertainty_score":0.9998093},"labels":[],"label_agreement":null},{"id":"W2553727767","doi":"10.1182/blood.v106.11.4619.4619","title":"A Multicenter Randomized Trial Comparing Response-Adapted (RA), Non-Cross-Resistant Induction and Consolidation with Idarubicin/Cytarabine (IDAC) Followed by Mitoxantrone/Etoposide (NOVE) Compared with Consolidation with High Dose Cytarabine (HDAC) in Adult Patients with AML. A Study by the Canadian Leukemia Studies Group (CLSG).","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Idarubicin; Cytarabine; Etoposide; Mitoxantrone; Medicine; Internal medicine; Nuclear medicine; Gastroenterology; Chemotherapy","score_opus":0.013516994683953678,"score_gpt":0.2718383185078674,"score_spread":0.2583213238239137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553727767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847425,0.00021789693,0.00007585868,0.0013503354,0.000055302902,0.013312972,0.000118265234,0.00008357533,0.0000432629],"genre_scores_gemma":[0.99631697,0.000037730148,0.0011351098,0.00029523412,0.0001142953,0.0011742585,0.0006525724,0.00011934535,0.00015449678],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945342,0.0009124789,0.0011376052,0.0010780026,0.001349841,0.0009878876],"domain_scores_gemma":[0.9962243,0.0008248173,0.00064513995,0.00073143916,0.0011228845,0.000451438],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016374638,0.00078482245,0.0018981735,0.0005613805,0.000649463,0.00025883075,0.00027077863,0.00019217152,0.00001506257],"category_scores_gemma":[0.00047343,0.00044932056,0.000068542744,0.0008973191,0.0010955587,0.0005356534,0.00008182173,0.0009465417,0.000005291052],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8656414,0.0022234411,0.11996822,0.00006783642,0.0020266555,0.00011434631,0.003288516,0.00021343426,0.005918359,0.0000074643576,0.000450583,0.000079713674],"study_design_scores_gemma":[0.87236536,0.007396467,0.10896641,0.0006020421,0.0015609727,0.000064287546,0.00300586,0.0015862293,0.003774624,0.0000011530179,0.00008306742,0.0005935397],"about_ca_topic_score_codex":0.06447321,"about_ca_topic_score_gemma":0.3793032,"teacher_disagreement_score":0.31482998,"about_ca_system_score_codex":0.002218064,"about_ca_system_score_gemma":0.0014725251,"threshold_uncertainty_score":0.99979585},"labels":[],"label_agreement":null},{"id":"W2554220734","doi":"10.1182/blood.v120.21.3626.3626","title":"CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Internal medicine; Medicine; Gastroenterology; Cytarabine; Adverse effect; Leukemia; Surgery","score_opus":0.006283914608022035,"score_gpt":0.2377982916331505,"score_spread":0.23151437702512848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554220734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979691,0.00015944023,0.000028433486,0.000045545366,0.000021709466,0.001411437,0.000039896826,0.00003452869,0.00028990477],"genre_scores_gemma":[0.9989099,0.00003100877,0.00062025886,0.00010678664,0.000066186636,0.000097155564,0.000032382446,0.00004402629,0.00009229419],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986652,0.000089762245,0.00012726693,0.00027864872,0.00036253288,0.00047655625],"domain_scores_gemma":[0.998892,0.0004047818,0.00006521365,0.0002683957,0.0000868824,0.00028270806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001448151,0.00020151224,0.00029883656,0.00014471776,0.00005928935,0.000014662283,0.000062309206,0.000097298405,0.00004749254],"category_scores_gemma":[0.0002456537,0.00012376448,0.00002540477,0.00026820067,0.00010256685,0.00017201455,0.00005511339,0.00038803634,0.000020906382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000377939,0.0011479738,0.99258155,0.000047896498,0.00016958275,0.000028836197,0.003525399,8.014713e-7,0.00008494314,0.0000011056488,0.00021213535,0.0018218233],"study_design_scores_gemma":[0.028098218,0.0009691303,0.96514755,0.00011384178,0.00017637854,0.000007098063,0.0003134497,0.000024456374,0.004773858,0.0000012942187,0.00021403033,0.00016069012],"about_ca_topic_score_codex":0.0013664324,"about_ca_topic_score_gemma":0.00017577759,"teacher_disagreement_score":0.02772028,"about_ca_system_score_codex":0.00009902911,"about_ca_system_score_gemma":0.00006603397,"threshold_uncertainty_score":0.50469685},"labels":[],"label_agreement":null},{"id":"W2554333293","doi":"10.1182/blood.v118.21.1556.1556","title":"Selective Small Molecule Inhibition of P110α and δ Isoforms of PI3 Kinase Is Cytotoxic to Human AML Progenitors","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"IC50; Kinase; Myeloid leukemia; Progenitor cell; Molecular biology; Protein kinase B; Gene isoform; Chemistry; Biology; Stem cell; Cancer research; Biochemistry; In vitro; Signal transduction; Gene; Cell biology","score_opus":0.02857760411720545,"score_gpt":0.27477208911779405,"score_spread":0.2461944850005886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554333293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967295,0.00005334762,0.000040270563,0.000055243057,0.000008760466,0.0007755883,0.000018940882,0.00002354068,0.0022948273],"genre_scores_gemma":[0.99811435,0.0000088307925,0.0014819192,0.0000859927,0.000044617867,0.000051285162,0.000008402033,0.000025493955,0.00017908592],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990295,0.000028288237,0.0002515651,0.00022913927,0.00022382138,0.00023766591],"domain_scores_gemma":[0.99925613,0.000015788633,0.000085491876,0.00023791306,0.00023872603,0.00016593309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001594469,0.00012043708,0.00026321833,0.00021732625,0.000039404305,0.0000034363236,0.000066616354,0.000096011296,0.00006315081],"category_scores_gemma":[0.00008482042,0.000102068545,0.000058173122,0.00030774254,0.00010410884,0.00004364406,0.00008882418,0.00016060236,0.000011033853],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001976381,0.00075627264,0.026450366,0.00024021091,0.00013009355,0.000031318777,0.003038519,4.677638e-8,0.96862584,0.00008716539,0.000223018,0.00021951084],"study_design_scores_gemma":[0.0025719574,0.0019849823,0.04809645,0.00010623574,0.00010863018,0.000026751259,0.00023164901,0.000006028354,0.94665223,0.00011421694,0.000011250847,0.00008961222],"about_ca_topic_score_codex":0.00027850037,"about_ca_topic_score_gemma":0.00002377457,"teacher_disagreement_score":0.021973604,"about_ca_system_score_codex":0.000052044765,"about_ca_system_score_gemma":0.00012854072,"threshold_uncertainty_score":0.41622344},"labels":[],"label_agreement":null},{"id":"W2554485111","doi":"10.1182/blood.v108.11.3201.3201","title":"Oral Administration of PBI-1402 Significantly Reduces Erythropenia and Accelerates Peripheral Blood Recovery in Myeloablated Mice Post Transplantation.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Cytopenia; Transplantation; Medicine; Bone marrow; Progenitor cell; White blood cell; Red blood cell; Andrology; Pharmacology; Internal medicine; Stem cell; Biology","score_opus":0.012588727399299934,"score_gpt":0.2629151406986487,"score_spread":0.25032641329934874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554485111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99627346,0.00055217557,0.00000779508,0.0007976387,0.00003310807,0.0005282895,0.00008636432,0.000039774244,0.0016814007],"genre_scores_gemma":[0.99643385,0.0004694941,0.0018909455,0.00008088725,0.00010130583,0.000025111005,0.0003457033,0.000030739804,0.000621971],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99843264,0.00009930803,0.0005037774,0.0003580892,0.00029228014,0.00031392518],"domain_scores_gemma":[0.99932957,0.00010228149,0.00011579681,0.00016527284,0.00019352058,0.00009357628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025131347,0.00019381935,0.00037246596,0.000206706,0.000060458835,0.000052423635,0.000106011634,0.00016099983,0.00015594668],"category_scores_gemma":[0.000060884173,0.00017856093,0.00005463979,0.00039983008,0.0001478107,0.00026264184,0.000018105844,0.00025968967,0.000006670171],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018021893,0.0011518467,0.020552723,0.0002357483,0.00015543116,0.0005640799,0.0004231483,0.00001559515,0.9739334,0.000051763218,0.0002170437,0.0008970313],"study_design_scores_gemma":[0.009986862,0.0016675988,0.24384537,0.00019694952,0.00045642507,0.0007458121,0.00047124445,0.000104369086,0.74214846,0.00006361363,0.000063718704,0.00024960027],"about_ca_topic_score_codex":0.0012791592,"about_ca_topic_score_gemma":0.00048412936,"teacher_disagreement_score":0.23178497,"about_ca_system_score_codex":0.000044053868,"about_ca_system_score_gemma":0.00047731525,"threshold_uncertainty_score":0.72815037},"labels":[],"label_agreement":null},{"id":"W2554537892","doi":"10.1182/blood.v114.22.sci-34.sci-34","title":"Point: AML Stem Cells are Immature, Rare, and Targets for Curative Therapy in AML.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Stem cell; Haematopoiesis; Leukemia; clone (Java method); Biology; Cancer stem cell; Progenitor cell; Cancer research; Homogeneous; Mitosis; Immunology; Cell biology; Genetics; DNA","score_opus":0.019253157655615517,"score_gpt":0.2861368933592812,"score_spread":0.2668837357036657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554537892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871732,0.005086233,0.000085680906,0.004104577,0.000054401593,0.0017062061,0.00004873601,0.000057096542,0.0016838912],"genre_scores_gemma":[0.99363375,0.001046149,0.0014933954,0.001684482,0.0001860428,0.00007026467,0.000023799108,0.000030501304,0.0018315986],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99883586,0.00005140903,0.00021181062,0.00031831287,0.00020912832,0.00037350415],"domain_scores_gemma":[0.9992972,0.00012514506,0.000070575006,0.0002467767,0.00011810267,0.000142219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002180651,0.0001742226,0.00035376544,0.00014592984,0.000053556687,0.000025341038,0.000102684855,0.0001422455,0.000029403967],"category_scores_gemma":[0.000040106926,0.00013466386,0.000064157015,0.0002045843,0.00004865084,0.00010496319,0.000024067389,0.00032248057,0.000014529863],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014331519,0.0076828836,0.032819856,0.0009241566,0.0011564009,0.0029249028,0.013750972,0.000011216093,0.6312534,0.002999701,0.13142808,0.1607169],"study_design_scores_gemma":[0.045957416,0.0040673222,0.122873865,0.00042412907,0.000099690405,0.00017309547,0.0018206296,0.00033173407,0.793877,0.002027529,0.027769132,0.00057842984],"about_ca_topic_score_codex":0.0000140153925,"about_ca_topic_score_gemma":0.000008363787,"teacher_disagreement_score":0.16262361,"about_ca_system_score_codex":0.000065539105,"about_ca_system_score_gemma":0.00011222103,"threshold_uncertainty_score":0.5491433},"labels":[],"label_agreement":null},{"id":"W2555341938","doi":"10.1182/blood.v114.22.3226.3226","title":"Peripheral Blood Stem Cell Harvests Performed Beyond the Initial Two Days of Apheresis May Not Contribute to Accelerate Granulocyte and Platelet Engraftment After Autologous Stem Cell Transplantation.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Leukapheresis; Medicine; Apheresis; CD34; Stem cell; Etoposide; Transplantation; Haematopoiesis; Cyclophosphamide; Granulocyte colony-stimulating factor; Internal medicine; Chemotherapy; Immunology; Urology; Platelet; Biology","score_opus":0.016693710225210715,"score_gpt":0.27257413159382093,"score_spread":0.2558804213686102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555341938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931924,0.00087941426,0.000065209424,0.0021412706,0.00007888958,0.001717217,0.00039334144,0.000072920106,0.0014593584],"genre_scores_gemma":[0.9953614,0.00041479972,0.0006272301,0.0018915586,0.00017905934,0.00015690345,0.000074226664,0.000048479687,0.001246343],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99709916,0.00023369062,0.0006447367,0.00056809705,0.00068780954,0.00076652394],"domain_scores_gemma":[0.99847335,0.00023198969,0.00015430537,0.00051906257,0.00021786735,0.00040340255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048343677,0.00042076397,0.00069281727,0.00017107229,0.00020462941,0.000102483486,0.00030114924,0.00019685978,0.00014001517],"category_scores_gemma":[0.000007942645,0.00030159208,0.00015874783,0.0003118276,0.00015594265,0.00017453672,0.000065459775,0.0005321552,0.000028446571],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036636773,0.008749571,0.021160182,0.0037583015,0.0026183827,0.013667316,0.04358264,0.00030262212,0.78553534,0.00040442773,0.0034883674,0.08009608],"study_design_scores_gemma":[0.026886638,0.0025492876,0.057555076,0.00011930428,0.0010809609,0.00056189223,0.0005590874,0.00013541433,0.90924984,0.000012809301,0.00088164315,0.00040802266],"about_ca_topic_score_codex":0.00007236037,"about_ca_topic_score_gemma":0.000067251196,"teacher_disagreement_score":0.12371453,"about_ca_system_score_codex":0.000094827046,"about_ca_system_score_gemma":0.00032840215,"threshold_uncertainty_score":0.9999436},"labels":[],"label_agreement":null},{"id":"W2555379581","doi":"10.1182/blood.v126.23.4106.4106","title":"Age-Associated Acquired Mutations in Hematopoietic Cells Predominantly Affect Epigenetic Regulators TET2 and DNMT3A and Are Associated with Distinct Biological and Hematological Profiles","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"CEBPA; NPM1; Biology; Myeloid; Myelodysplastic syndromes; Population; Neuroblastoma RAS viral oncogene homolog; Myeloid leukemia; Genetics; Cancer research; KRAS; Oncology; Immunology; Mutation; Internal medicine; Medicine; Gene; Bone marrow; Chromosome; Karyotype","score_opus":0.030212744178972618,"score_gpt":0.2745883247164481,"score_spread":0.2443755805374755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555379581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99718547,0.0010406133,0.000010419823,0.00040199625,0.000015015695,0.0010944763,0.000037391732,0.00007264341,0.00014199161],"genre_scores_gemma":[0.99900496,0.00006781301,0.0005264824,0.000029067964,0.000017576442,0.00009531755,0.00007637103,0.000028586512,0.00015383527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979665,0.00035260207,0.00033504062,0.0005440651,0.0003168787,0.00048488047],"domain_scores_gemma":[0.99852365,0.0006012228,0.00016207364,0.0002026173,0.00012382877,0.00038662675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006396973,0.00027690074,0.0007271691,0.00014690126,0.00010525364,0.000052000963,0.000082405684,0.00032698372,0.000011758656],"category_scores_gemma":[0.0020612539,0.00018627803,0.00003436938,0.00040762892,0.0007170564,0.000057759262,0.00015049642,0.00024627833,0.0000037392476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002883773,0.00095284666,0.9895975,0.000115881776,0.00018858268,0.0015395028,0.000892243,0.0000010689809,0.0060974425,0.00003874312,0.00012246726,0.00016534304],"study_design_scores_gemma":[0.011041821,0.001411215,0.9758591,0.00047190711,0.00024927,0.000458961,0.0009771824,0.0002564921,0.008530978,0.00045467197,0.000009404687,0.00027896813],"about_ca_topic_score_codex":0.000027260317,"about_ca_topic_score_gemma":0.000108980064,"teacher_disagreement_score":0.013738373,"about_ca_system_score_codex":0.0001125168,"about_ca_system_score_gemma":0.00015134522,"threshold_uncertainty_score":0.7596198},"labels":[],"label_agreement":null},{"id":"W2555473291","doi":"10.1182/blood.v124.21.2238.2238","title":"Aldehyde Dehydrogenases Play a Role in Acute Myeloid Leukemia and Have Prognostic and Therapeutic Significance","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Aldehyde dehydrogenase; CD34; Haematopoiesis; Stem cell; Cancer research; Myeloid leukemia; Biology; Leukemia; Flow cytometry; Acute leukemia; Molecular biology; Chemistry; Immunology; Cell biology; Biochemistry; Enzyme","score_opus":0.011979279263112815,"score_gpt":0.2615263201239825,"score_spread":0.2495470408608697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555473291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943663,0.0025923941,0.000034928526,0.0004500217,0.000014414113,0.00076966,0.000010115338,0.00006437229,0.0016978219],"genre_scores_gemma":[0.99757445,0.00046261304,0.0007024636,0.0005458977,0.000108217275,0.00013181569,0.000013425682,0.00004530668,0.00041579697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983549,0.00011212506,0.00025559362,0.0004875773,0.00029145947,0.00049831264],"domain_scores_gemma":[0.99895215,0.00035540274,0.000058028058,0.00032554977,0.000050429615,0.000258448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003531493,0.00023114044,0.0003937142,0.00017836038,0.0000783177,0.000043132193,0.00011865443,0.00014452646,0.000020635729],"category_scores_gemma":[0.00020938457,0.00019376782,0.000038849288,0.00019282298,0.00022293873,0.000064579064,0.00010156223,0.0003895465,0.000020489259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005055622,0.0005282619,0.6138126,0.0003008293,0.0005423421,0.0005423957,0.002002705,0.000009197645,0.35427698,0.00053267146,0.00014739374,0.026799046],"study_design_scores_gemma":[0.028816491,0.002902591,0.6488693,0.00063414057,0.0014733606,0.002286484,0.00089507835,0.015448695,0.28843474,0.002928968,0.006226378,0.001083792],"about_ca_topic_score_codex":0.00019363905,"about_ca_topic_score_gemma":0.000122043464,"teacher_disagreement_score":0.06584224,"about_ca_system_score_codex":0.00011170097,"about_ca_system_score_gemma":0.00027524834,"threshold_uncertainty_score":0.7901622},"labels":[],"label_agreement":null},{"id":"W2555770765","doi":"10.1182/blood.v124.21.2186.2186","title":"Characterizing Transcriptional and Epigenetic Signatures Induced By FLT3-ITD Activation","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Biology; Gene expression; Epigenetics; Gene; Mutant; Cancer research; Genetics; Molecular biology","score_opus":0.016361155378703054,"score_gpt":0.2604758264768682,"score_spread":0.24411467109816512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555770765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99603474,0.0001772345,0.00030245804,0.0021203402,0.00003303526,0.00022557641,0.000006552284,0.000043593758,0.0010564799],"genre_scores_gemma":[0.99821055,0.00003753653,0.00039686816,0.0007331182,0.00024168122,0.000021830285,0.000081907325,0.000021345762,0.00025514132],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991448,0.000053098473,0.0001301133,0.00021706308,0.0002510649,0.00020387028],"domain_scores_gemma":[0.99957615,0.000073281386,0.00003322739,0.00014058217,0.000053106334,0.00012367024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017926714,0.00010434229,0.0001546743,0.00008307185,0.00007037536,0.000023416198,0.00005699014,0.00012559086,0.00007451277],"category_scores_gemma":[0.00011827495,0.00009260364,0.000030735362,0.000098102275,0.000036718833,0.00007872725,0.000017481578,0.00028739634,0.000015645137],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005168686,0.00011744491,0.0015361861,0.000042580992,0.000042970994,0.0000019229694,0.0001555539,1.00487036e-7,0.9908223,0.00013529585,0.00018088568,0.006913031],"study_design_scores_gemma":[0.003818603,0.00034067038,0.24859606,0.000068111025,0.00007394755,0.000024064482,0.000034597135,0.00015534833,0.7377453,0.0000979494,0.008908447,0.00013694483],"about_ca_topic_score_codex":0.000024290282,"about_ca_topic_score_gemma":0.0000011741346,"teacher_disagreement_score":0.2530771,"about_ca_system_score_codex":0.00003160839,"about_ca_system_score_gemma":0.00006253164,"threshold_uncertainty_score":0.37762666},"labels":[],"label_agreement":null},{"id":"W2555926193","doi":"10.1182/blood.v120.21.3083.3083","title":"Are Outcomes After Myeloablative Conditioning Regimen in Double Cord Blood Transplantation (UCBT) Better Than Single UCBT for Adults with Acute Leukemia in Remission?.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; ThioTEPA; Internal medicine; Transplantation; Regimen; Hematopoietic stem cell transplantation; Gastroenterology; Surgery; Chemotherapy; Cyclophosphamide","score_opus":0.020518483581718407,"score_gpt":0.28995703417033986,"score_spread":0.26943855058862143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555926193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99602944,0.0001428417,0.00013900938,0.0009170017,0.00005141484,0.0016000138,0.00008900417,0.00006352463,0.00096773886],"genre_scores_gemma":[0.99240106,0.000029998439,0.00475734,0.000549782,0.00016949174,0.0006365884,0.00030055773,0.000071655355,0.0010835234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978383,0.00007455202,0.00043696715,0.00045083728,0.00043220923,0.00076710456],"domain_scores_gemma":[0.9988452,0.0002294763,0.00020768045,0.00033704986,0.00013849225,0.00024209736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034056604,0.00031019785,0.00054360315,0.00037129642,0.000078530116,0.000031821288,0.00013329467,0.00022957502,0.00009464807],"category_scores_gemma":[0.00005434387,0.00024471447,0.00009365586,0.0003635418,0.00009238851,0.00046199915,0.000033299882,0.0004801959,0.000023122244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010948176,0.0008389694,0.9733112,0.00041194077,0.00041773036,0.00079451693,0.0056438977,0.000008946361,0.007077051,0.000033290344,0.0002092126,0.0003050692],"study_design_scores_gemma":[0.059307545,0.0009050329,0.8634315,0.0018023658,0.0008704105,0.0003640633,0.0013236449,0.000071616116,0.071104795,0.000058563055,0.00027334492,0.00048709445],"about_ca_topic_score_codex":0.0001944468,"about_ca_topic_score_gemma":0.00039938136,"teacher_disagreement_score":0.10987968,"about_ca_system_score_codex":0.0004909678,"about_ca_system_score_gemma":0.0002668433,"threshold_uncertainty_score":0.9979166},"labels":[],"label_agreement":null},{"id":"W2555998803","doi":"10.1182/blood.v126.23.2020.2020","title":"Extramedullary Disease at Diagnosis of Acute Myeloid Leukemia Does Not Influence Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant in First Complete Remission","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Hematopoietic stem cell transplantation; Myeloid leukemia; Transplantation; Bone marrow; Surgery; Gastroenterology; Leukemia; Myeloid; Chemotherapy","score_opus":0.02473724611772345,"score_gpt":0.27051655221250254,"score_spread":0.24577930609477908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555998803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978216,0.0004803685,0.000010239216,0.0004065428,0.000054995013,0.00072373444,0.00034721787,0.000031716052,0.00012357363],"genre_scores_gemma":[0.99753475,0.0012898244,0.0006068614,0.00017130708,0.00002499793,0.000066755856,0.00015276311,0.000047969697,0.000104770625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971415,0.00010984584,0.00089183537,0.00045386088,0.00092060765,0.00048238708],"domain_scores_gemma":[0.997854,0.00041232503,0.00026390818,0.00063309446,0.00021717508,0.0006195019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033195384,0.00028711229,0.00069293485,0.00025525034,0.000055570323,0.000007952622,0.0003400705,0.00016146236,0.000046146088],"category_scores_gemma":[0.00030994214,0.00021634575,0.0001694291,0.00033442365,0.00019566207,0.00013186851,0.00020843727,0.0003110059,0.0000182511],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010746195,0.0008843283,0.97851557,0.0016976728,0.000102683305,0.00034682188,0.0008642072,0.00012045715,0.016256655,0.000009764158,0.00007899397,0.00004822204],"study_design_scores_gemma":[0.015490043,0.0005591425,0.81417334,0.0012480732,0.00070650724,0.000024349309,0.00009167608,0.00013490922,0.16694894,0.00005204351,0.00024144806,0.00032954154],"about_ca_topic_score_codex":0.0002475175,"about_ca_topic_score_gemma":0.00012945016,"teacher_disagreement_score":0.16434225,"about_ca_system_score_codex":0.00060380285,"about_ca_system_score_gemma":0.00062823435,"threshold_uncertainty_score":0.88223237},"labels":[],"label_agreement":null},{"id":"W2556091347","doi":"10.1182/blood.v126.23.1675.1675","title":"Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Methylenetetrahydrofolate reductase; XRCC1; Myelodysplastic syndromes; Single-nucleotide polymorphism; Genotype; Internal medicine; International Prognostic Scoring System; XRCC3; Biology; Oncology; Hazard ratio; Genetics; Proportional hazards model; Gastroenterology; Medicine; Gene; Bone marrow; Confidence interval","score_opus":0.016695920142588926,"score_gpt":0.27090638050264637,"score_spread":0.25421046036005746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556091347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99847245,0.00038450136,0.000017210004,0.0000346658,0.000019882998,0.0006903242,0.00002101108,0.000019349221,0.00034059954],"genre_scores_gemma":[0.9985659,0.000030918625,0.0012166353,0.000013733484,0.000027006039,0.000024734849,0.000021565185,0.000031668787,0.00006779904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986453,0.00006012715,0.00024371731,0.00026076267,0.00043646255,0.00035360747],"domain_scores_gemma":[0.99903345,0.00012580046,0.000071791925,0.00026277496,0.00019446011,0.00031172065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012566132,0.00016598332,0.00036172778,0.00023685742,0.000016286525,0.000013083623,0.00009469354,0.00008296524,0.00002989749],"category_scores_gemma":[0.00054703717,0.00011428163,0.000030426938,0.00037144677,0.00011377405,0.0000712703,0.00007418045,0.00020069157,0.00001928495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031469556,0.0008010703,0.99700767,0.000120737706,0.00016518586,0.00026206565,0.00033371456,0.000017889954,0.00020131457,0.000004554881,0.00010764902,0.0006634437],"study_design_scores_gemma":[0.012799053,0.003250333,0.9826852,0.00025354023,0.00019235243,0.00023801261,0.000044644177,0.00027616034,0.000104871884,0.000032964166,0.000006002173,0.000116859315],"about_ca_topic_score_codex":0.00021087221,"about_ca_topic_score_gemma":0.000019561798,"teacher_disagreement_score":0.014322472,"about_ca_system_score_codex":0.000113623566,"about_ca_system_score_gemma":0.0006637966,"threshold_uncertainty_score":0.46602696},"labels":[],"label_agreement":null},{"id":"W2556440321","doi":"10.1182/blood.v126.23.799.799","title":"Treatment of 11q23/MLL + AML with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Population Health Research Institute; Hospital for Sick Children","funders":"","keywords":"Gemtuzumab ozogamicin; CD33; Internal medicine; Medicine; Myeloid leukemia; Leukemia; Oncology; Gastroenterology; Biology; CD34; Stem cell; Genetics","score_opus":0.034103467105335544,"score_gpt":0.3246124944877472,"score_spread":0.2905090273824117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556440321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98581153,0.00068134256,0.00008365799,0.0030812079,0.00015878948,0.0047604013,0.0002575785,0.00007528612,0.0050902036],"genre_scores_gemma":[0.99474406,0.00033147386,0.0014776847,0.00020957203,0.0013424124,0.00024642126,0.0007708007,0.000051436586,0.0008261099],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968652,0.00065557426,0.00079024944,0.00053439185,0.0006893825,0.0004651689],"domain_scores_gemma":[0.9964061,0.0016790705,0.00037960176,0.0009770831,0.00022948059,0.00032871208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010112281,0.00033172485,0.0015768324,0.00011887343,0.00008264552,0.000019349605,0.000285787,0.00022074445,0.000059857477],"category_scores_gemma":[0.0008655739,0.00016821166,0.00027997445,0.00029000084,0.00051435805,0.00006392173,0.00007995898,0.0003191147,0.000043809985],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9790001,0.0064962455,0.00015310575,0.0000046844098,0.002170833,0.00038865383,0.0025682477,0.0000026108678,0.00084533804,0.000071990224,0.0026137223,0.0056844503],"study_design_scores_gemma":[0.9675504,0.018718898,0.00019036143,0.000042999523,0.0024058586,0.00019661016,0.00037481383,0.00012821316,0.005902866,0.000059381266,0.0042656413,0.00016393578],"about_ca_topic_score_codex":0.005159606,"about_ca_topic_score_gemma":0.00018456034,"teacher_disagreement_score":0.012222653,"about_ca_system_score_codex":0.00049745245,"about_ca_system_score_gemma":0.0013250716,"threshold_uncertainty_score":0.77998155},"labels":[],"label_agreement":null},{"id":"W2556574152","doi":"10.1182/blood.v114.22.245.245","title":"The Population Based Incidence of Myelodysplastic Syndrome (MDS): Utility of Multiple Data Sources and Follow-up.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Shared Health; CancerCare Manitoba","funders":"","keywords":"Incidence (geometry); Chronic myelomonocytic leukemia; Medicine; Cancer registry; Myelodysplastic syndromes; Population; Internal medicine; Bone marrow; Epidemiology; Diagnosis code; Pediatrics","score_opus":0.030219923904350174,"score_gpt":0.2926817103978841,"score_spread":0.2624617864935339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556574152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99854934,0.00047445841,0.00014782949,0.00034787421,0.000025582216,0.00031991795,0.000051081268,0.000018372271,0.00006553036],"genre_scores_gemma":[0.998937,0.000036203623,0.00081590033,0.000037521215,0.00002016971,0.0000029346763,0.00008241987,0.00000782322,0.000059996622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987882,0.000076093995,0.00030445357,0.00024040973,0.00040468207,0.00018620725],"domain_scores_gemma":[0.99825495,0.0006369408,0.00012404646,0.0007999961,0.000102111146,0.00008197205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006228262,0.00009463096,0.00025363057,0.00006646036,0.0000801729,0.0000102333415,0.0002839085,0.00006586301,0.000017098344],"category_scores_gemma":[0.0019422458,0.00006521319,0.000032548636,0.00020483554,0.00012140594,0.00009519864,0.00012151541,0.00015224773,0.0000020004375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048228158,0.00029825798,0.9826901,0.0001868874,0.00007647791,0.000034238197,0.000091194706,0.000005202431,0.010632387,0.000030174395,0.00013453409,0.00533827],"study_design_scores_gemma":[0.0032874895,0.00032590586,0.9781823,0.00011976704,0.00014215904,0.0000615043,0.000048146572,0.012590565,0.005044856,0.00008793599,0.00005279071,0.00005657937],"about_ca_topic_score_codex":0.00038287003,"about_ca_topic_score_gemma":0.000096907665,"teacher_disagreement_score":0.012585362,"about_ca_system_score_codex":0.000015722684,"about_ca_system_score_gemma":0.00015749829,"threshold_uncertainty_score":0.26593167},"labels":[],"label_agreement":null},{"id":"W2556627884","doi":"10.1182/blood.v124.21.486.486","title":"Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3-ITD+ Acute Myeloid Leukemia: A Report from the Children's Oncology Group","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; Calicheamicin; CD33; Internal medicine; Oncology; Induction chemotherapy; Chemotherapy; Myeloid leukemia; Stem cell; CD34; Biology","score_opus":0.009803910134536695,"score_gpt":0.2724915109283486,"score_spread":0.2626876007938119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556627884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861754,0.0007834827,0.00009616368,0.0035728614,0.00027705295,0.0011049114,0.00006462827,0.00017789815,0.0077475784],"genre_scores_gemma":[0.9917294,0.0011227251,0.002879325,0.00091356976,0.0014275737,0.00013688694,0.0004093161,0.00010128455,0.0012799385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99575514,0.00069074554,0.0008982191,0.0010246206,0.00074256177,0.00088869693],"domain_scores_gemma":[0.9964828,0.0010266707,0.00042612283,0.001624639,0.00013173319,0.00030802574],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020258364,0.0004197425,0.0008902569,0.0002475643,0.00023735498,0.00005103577,0.00069363875,0.00056835316,0.00016011731],"category_scores_gemma":[0.0019371447,0.00029544518,0.00023833443,0.0006537858,0.00037986485,0.00015321556,0.00041555488,0.0022947807,0.00029831968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004375214,0.0036049422,0.677606,0.00007057776,0.005238052,0.013988762,0.0044393656,0.00004113157,0.09547767,0.0007852829,0.07200936,0.12236362],"study_design_scores_gemma":[0.028742459,0.0027393745,0.9016591,0.00024431729,0.002575629,0.0066948337,0.0005155073,0.00046797318,0.020374175,0.0015069774,0.03371391,0.0007657636],"about_ca_topic_score_codex":0.006943203,"about_ca_topic_score_gemma":0.0007405554,"teacher_disagreement_score":0.22405306,"about_ca_system_score_codex":0.0011546467,"about_ca_system_score_gemma":0.0011591646,"threshold_uncertainty_score":0.99994975},"labels":[],"label_agreement":null},{"id":"W2557057878","doi":"10.1182/blood.v124.21.1247.1247","title":"Nonmyeloablative Versus Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Deficiency","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Fludarabine; Medicine; Busulfan; Total body irradiation; Internal medicine; Hematopoietic stem cell transplantation; Cyclophosphamide; Gastroenterology; Transplantation; Oncology; Immunology; Chemotherapy","score_opus":0.02572765525116614,"score_gpt":0.27615175575716994,"score_spread":0.2504241005060038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557057878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95350415,0.00089712,0.011861931,0.0006713268,0.00023988487,0.0019378678,0.00012740391,0.0001814373,0.030578865],"genre_scores_gemma":[0.99444747,0.0000968921,0.0029533552,0.00016772826,0.0002303588,0.00019117542,0.00008263035,0.00007229013,0.0017581265],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99763775,0.00011159628,0.00039086927,0.00060731935,0.0004912052,0.00076127273],"domain_scores_gemma":[0.9979921,0.00080667046,0.000117251046,0.00054979057,0.00021276834,0.00032143475],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005352233,0.00031878363,0.0005268523,0.0001781952,0.00019407443,0.000027571476,0.00028753615,0.00019773425,0.00009500458],"category_scores_gemma":[0.00007818508,0.00026939003,0.0002221335,0.0003334354,0.00016571378,0.00009366836,0.000058121153,0.0003382244,0.0002092004],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027507583,0.014242395,0.027669892,0.00987542,0.0039074523,0.0011162112,0.06616224,0.0004040684,0.7406012,0.040038873,0.011306383,0.057168286],"study_design_scores_gemma":[0.085896604,0.009784085,0.006625174,0.0005577594,0.0028249011,0.00040116513,0.003292111,0.003378998,0.8704328,0.00096642657,0.01426187,0.001578119],"about_ca_topic_score_codex":0.000020681508,"about_ca_topic_score_gemma":0.000011076797,"teacher_disagreement_score":0.1298316,"about_ca_system_score_codex":0.00014212835,"about_ca_system_score_gemma":0.00033385277,"threshold_uncertainty_score":0.9999758},"labels":[],"label_agreement":null},{"id":"W2557322602","doi":"10.1182/blood.v126.23.169.169","title":"Rearrangements in Nucleoporin Family of Genes in Childhood Acute Myeloid Leukemia: A Report from Children Oncology Group and NCI/COG Target AML Initiative","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Cog; Myeloid leukemia; ETV6; Oncology; NPM1; Cancer research; Internal medicine; Gene; Biology; Medicine; Genetics; Chromosomal translocation; Karyotype; Chromosome","score_opus":0.027037623847647577,"score_gpt":0.2955566117537695,"score_spread":0.26851898790612194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557322602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911564,0.0019697887,0.000019787885,0.00030396818,0.00008250781,0.0010461815,0.00011188043,0.000041839172,0.00526762],"genre_scores_gemma":[0.99049836,0.00078496145,0.0074130613,0.00039886605,0.00022361007,0.00009729682,0.00045041836,0.000056448906,0.000077002085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719894,0.00022473703,0.00081573037,0.0006563854,0.0005792835,0.00052494294],"domain_scores_gemma":[0.9986257,0.00012199177,0.00027983735,0.00051593763,0.00014592976,0.00031058647],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089387875,0.00028533462,0.00088209985,0.00047370774,0.000029648021,0.000013098435,0.00022952605,0.00034130257,0.000033217708],"category_scores_gemma":[0.00039507603,0.00026730724,0.00007163756,0.0005648984,0.00020048287,0.0001849777,0.00033416675,0.00070715515,0.000018116523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071964326,0.0018566995,0.9600874,0.000033205633,0.0008664129,0.0054700733,0.0049228673,0.0000034020345,0.018590314,0.000025166315,0.0014183769,0.006006439],"study_design_scores_gemma":[0.022741104,0.0010794115,0.96722513,0.00012797822,0.0002564478,0.0005907361,0.0010191823,0.000048664784,0.0054807863,0.0005246201,0.00066235417,0.0002435778],"about_ca_topic_score_codex":0.0045054476,"about_ca_topic_score_gemma":0.00046890628,"teacher_disagreement_score":0.022021461,"about_ca_system_score_codex":0.0005981798,"about_ca_system_score_gemma":0.0013527082,"threshold_uncertainty_score":0.9999779},"labels":[],"label_agreement":null},{"id":"W2557857454","doi":"10.1182/blood.v112.11.4880.4880","title":"Somatic CNVs and LOH in Acute Myelomonocitic Leukemia","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Copy-number variation; SNP array; Loss of heterozygosity; Biology; Genetics; Comparative genomic hybridization; Copy number analysis; Single-nucleotide polymorphism; Cytogenetics; Gene dosage; SNP genotyping; SNP; Allele; Genome; Gene; Chromosome; Genotype; Gene expression","score_opus":0.01932669342744189,"score_gpt":0.27212961806239755,"score_spread":0.2528029246349557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557857454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931491,0.00056988257,0.00002256046,0.00061388727,0.000024861118,0.00036884568,0.0000039716892,0.00006462918,0.005182255],"genre_scores_gemma":[0.99429506,0.00067252555,0.0022500693,0.0003669518,0.00009936221,0.00003865191,0.000012322078,0.00003215547,0.0022329034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987279,0.000048338214,0.0002478169,0.00027960638,0.00028464987,0.00041164825],"domain_scores_gemma":[0.99928355,0.00010902498,0.000034160534,0.00032235376,0.000043216885,0.00020766548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017473628,0.00015080045,0.0003492568,0.00020837077,0.000071878385,0.000011467752,0.00010360523,0.00011997801,0.000081637125],"category_scores_gemma":[0.00015132077,0.00013258931,0.000047289544,0.00029759487,0.00016531722,0.00009006923,0.00008947948,0.0003755671,0.00015992917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050542917,0.0014392094,0.75353336,0.0009786478,0.0011124967,0.027210262,0.0068573393,0.000006780676,0.18922153,0.0005344505,0.0069978163,0.011602658],"study_design_scores_gemma":[0.023681406,0.0007216766,0.9282585,0.00032823702,0.0004368398,0.010416383,0.00032971468,0.0015275045,0.03187792,0.00067656103,0.001266641,0.0004786429],"about_ca_topic_score_codex":0.000105861545,"about_ca_topic_score_gemma":0.000013927271,"teacher_disagreement_score":0.1747251,"about_ca_system_score_codex":0.00022907366,"about_ca_system_score_gemma":0.00052008696,"threshold_uncertainty_score":0.54068357},"labels":[],"label_agreement":null},{"id":"W2557914993","doi":"10.1182/blood.v126.23.458.458","title":"Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Regimen; Internal medicine; Chemotherapy regimen; Clinical endpoint; Chemotherapy; Neutropenia; Gastroenterology; Surgery; Adverse effect; Clinical trial","score_opus":0.06681648524867487,"score_gpt":0.3531600435505407,"score_spread":0.28634355830186586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557914993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634945,0.00051571795,0.00017621837,0.00038386337,0.000053744847,0.0019048895,0.00042037066,0.000022619139,0.0001731435],"genre_scores_gemma":[0.9887626,0.0002064889,0.010266345,0.00008491565,0.00008399393,0.000033288907,0.0002486072,0.00006643024,0.00024733672],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971566,0.00012655361,0.0010722267,0.0006115324,0.000496805,0.00053628127],"domain_scores_gemma":[0.9967834,0.0009684973,0.00057092565,0.00046249037,0.00089570624,0.00031902635],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009270554,0.0003828201,0.0012413145,0.00040634803,0.00007656684,0.000019964595,0.00013796461,0.00021661058,0.000006519652],"category_scores_gemma":[0.0022807915,0.00031612185,0.000097864795,0.00045360925,0.00026872926,0.00012328496,0.00014926396,0.00023944702,0.0000011675062],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03382653,0.005126713,0.1440913,0.0005946188,0.003185708,0.000068096015,0.04776664,0.00020900772,0.7189641,0.000034096865,0.0012055922,0.0449276],"study_design_scores_gemma":[0.23577368,0.0100152865,0.16167077,0.0010876112,0.0012191804,0.00006269192,0.0038446398,0.016929114,0.5675392,0.000024927002,0.0011846382,0.0006482383],"about_ca_topic_score_codex":0.0006185,"about_ca_topic_score_gemma":0.00007608866,"teacher_disagreement_score":0.20194715,"about_ca_system_score_codex":0.00077561906,"about_ca_system_score_gemma":0.0005829881,"threshold_uncertainty_score":0.9999291},"labels":[],"label_agreement":null},{"id":"W2558443141","doi":"10.1182/blood.v112.11.2459.2459","title":"A Functional Screen to Identify Novel Effectors of Hematopoietic Stem Cell Activity","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal","funders":"","keywords":"Stem cell; Biology; Haematopoiesis; Cell biology; Hematopoietic stem cell; Gene expression profiling; Cellular differentiation; Context (archaeology); Genetics; Gene expression; Gene","score_opus":0.03810562865189869,"score_gpt":0.29635357189884814,"score_spread":0.25824794324694944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558443141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518335,0.00007038279,0.0018882246,0.00024045137,0.000058224596,0.0005095652,0.000022475548,0.0000483353,0.0019789715],"genre_scores_gemma":[0.99646086,0.000007640488,0.00087813276,0.00009297926,0.00013429385,0.00002908867,0.000008656211,0.000027633829,0.0023607085],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99863136,0.000039172646,0.00018224257,0.0002704058,0.00059962436,0.00027720915],"domain_scores_gemma":[0.9990638,0.00015835823,0.000056991976,0.00034929972,0.00013364034,0.0002379476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021894438,0.0001331424,0.00031776226,0.0001783977,0.00006659344,0.000005418861,0.00011532835,0.00009420496,0.00012060231],"category_scores_gemma":[0.000052538027,0.000117155345,0.000121138786,0.0003775541,0.00007810118,0.000058648486,0.00011536604,0.00024806804,0.0002003163],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003181157,0.0014453618,0.021506492,0.00026487553,0.00013051042,0.00011229577,0.00027985423,0.0000069951743,0.97217727,0.00001974613,0.003355886,0.00038257983],"study_design_scores_gemma":[0.0046812836,0.00040477814,0.32650343,0.000062384715,0.00010416478,0.00034656777,0.00004074528,0.000030337704,0.6675315,0.0000020286,0.00018830271,0.000104484156],"about_ca_topic_score_codex":0.00013538875,"about_ca_topic_score_gemma":0.000004230327,"teacher_disagreement_score":0.30499694,"about_ca_system_score_codex":0.00008466276,"about_ca_system_score_gemma":0.00028564243,"threshold_uncertainty_score":0.47774562},"labels":[],"label_agreement":null},{"id":"W2558604928","doi":"10.1182/blood.v120.21.2526.2526","title":"Genome-Wide Genotype-Based Risk Model for Survival in Acute Myeloid Leukemia Patients with Normal Karyotype.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Single-nucleotide polymorphism; Proportional hazards model; Minor allele frequency; SNP; Oncology; Myeloid leukemia; Biology; Genome-wide association study; Genotype; Linkage disequilibrium; Internal medicine; Tag SNP; Genetics; Medicine; Gene","score_opus":0.014540412130725051,"score_gpt":0.2499428317118142,"score_spread":0.23540241958108915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558604928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904303,0.00017198827,0.0064197206,0.00010776193,0.00007953406,0.0014495808,0.00020264521,0.000077143384,0.001061348],"genre_scores_gemma":[0.98462653,0.000038328337,0.013313881,0.00032143158,0.00022756563,0.00018630321,0.00044527542,0.00010849441,0.0007321716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748015,0.0000789518,0.00036530718,0.00039931844,0.00060190586,0.0010743884],"domain_scores_gemma":[0.99840266,0.00022540169,0.00012605969,0.00056781305,0.00025595867,0.0004221297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005800976,0.00031086322,0.00047946422,0.00027257405,0.00011944778,0.00002045453,0.00024445305,0.00020521472,0.00005973979],"category_scores_gemma":[0.00023015954,0.0002503718,0.000118638505,0.0003608852,0.00010119686,0.00022800558,0.0000918106,0.00054728484,0.00010122052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023269,0.00092816766,0.99347055,0.00009815197,0.00029318617,0.000015473188,0.00035509764,0.0009980054,0.00084308325,0.000021802927,0.0001793251,0.00047026697],"study_design_scores_gemma":[0.026234265,0.0007223586,0.9542054,0.000039050654,0.00061312213,0.0000058274986,0.000028553974,0.014707274,0.0023684923,0.000024023022,0.00067810254,0.00037352255],"about_ca_topic_score_codex":0.00014159051,"about_ca_topic_score_gemma":0.000098492725,"teacher_disagreement_score":0.039265133,"about_ca_system_score_codex":0.00057020533,"about_ca_system_score_gemma":0.0010121966,"threshold_uncertainty_score":0.9999949},"labels":[],"label_agreement":null},{"id":"W2558739263","doi":"10.1182/blood.v104.11.2552.2552","title":"FLT3 Expression Is Increased by MEIS1 and Collaborates with NUP98-HOX Fusion Genes in the Induction of Acute Myeloid Leukemia.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Hox gene; Biology; Cell culture; Fusion gene; Cancer research; Myeloid; Myeloid leukemia; Cell biology; Transcription factor; Genetics; Gene","score_opus":0.009865528840342657,"score_gpt":0.25539101980702505,"score_spread":0.24552549096668239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558739263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621254,0.0011709628,0.000025601023,0.0014908557,0.000017460045,0.00066346594,0.000048174898,0.000028521132,0.00034241317],"genre_scores_gemma":[0.99630016,0.0014303869,0.0015687275,0.000334135,0.00008658607,0.000060061615,0.00007326756,0.000028944933,0.00011770567],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985271,0.00010383749,0.00025782394,0.00031997648,0.00052172283,0.00026953302],"domain_scores_gemma":[0.99916726,0.00007251861,0.00010914791,0.0003737642,0.00016797693,0.00010930224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000348633,0.00018422917,0.00031508712,0.00016437467,0.0000977698,0.00002569864,0.00015394473,0.00016715426,0.000032488293],"category_scores_gemma":[0.000049627834,0.00011031,0.000028647199,0.0007273458,0.00017159562,0.0001479197,0.00007547041,0.00032098262,0.0000060268953],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000653559,0.00038249363,0.016211648,0.00008912531,0.000098954195,0.00008912586,0.0016170834,0.0000041245485,0.9779756,0.000018048315,0.0016284207,0.0012318345],"study_design_scores_gemma":[0.011848489,0.000814024,0.025543792,0.00030292058,0.00023455328,0.00024814793,0.0011973948,0.000021682536,0.958585,0.00006645824,0.0009899642,0.00014752499],"about_ca_topic_score_codex":0.00078116154,"about_ca_topic_score_gemma":0.00003491516,"teacher_disagreement_score":0.019390535,"about_ca_system_score_codex":0.00016798967,"about_ca_system_score_gemma":0.0006843784,"threshold_uncertainty_score":0.44983113},"labels":[],"label_agreement":null},{"id":"W2558920446","doi":"10.1182/blood.v116.21.123.123","title":"Induction of Micro RNA-143 and 145 In Pre-Treatment CD34+ Cells From Patients with Myelodysplastic Syndrome (MDS) After In Vitro exposure to Lenalidomide Correlates with Clinical Response In Patients Harboring the Del5q Abnormality","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lenalidomide; CD34; Oncology; Medicine; Internal medicine; Cohort; microRNA; Myelodysplastic syndromes; Immunology; Cancer research; Bone marrow; Stem cell; Biology; Multiple myeloma; Gene; Genetics","score_opus":0.007451592987781739,"score_gpt":0.24800559568296301,"score_spread":0.24055400269518126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558920446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981808,0.000037084206,0.0000034163834,0.00010821464,0.00009614564,0.0014910082,0.000067331566,0.000010905686,0.000005078192],"genre_scores_gemma":[0.998818,0.000013791673,0.00085538643,0.00005215013,0.000028959004,0.00015217485,0.00002789871,0.000032781645,0.000018893526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977163,0.00037446516,0.0006461414,0.00047789523,0.00040969523,0.00037548612],"domain_scores_gemma":[0.9984474,0.0006539637,0.00015091362,0.00046071346,0.0001190811,0.00016789825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007215894,0.00024576875,0.00051860913,0.0002772603,0.00003040035,0.000019971978,0.00012968315,0.00019755783,0.000013203158],"category_scores_gemma":[0.00026780876,0.00015037663,0.000036811594,0.00036804224,0.00016396384,0.00013735023,0.00010761548,0.000751678,0.0000058983],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047616195,0.0022292812,0.93189275,0.00002927665,0.000096952775,0.00020479137,0.0013257797,0.00002162712,0.015997794,1.7477215e-7,0.0000020220277,0.0005833503],"study_design_scores_gemma":[0.024056166,0.003972402,0.946504,0.00033095857,0.0001156514,0.000013574067,0.000083482286,0.000018530929,0.0247448,0.0000027981985,0.0000075326993,0.00015012786],"about_ca_topic_score_codex":0.001325886,"about_ca_topic_score_gemma":0.0010480726,"teacher_disagreement_score":0.02356003,"about_ca_system_score_codex":0.00019246979,"about_ca_system_score_gemma":0.00024628243,"threshold_uncertainty_score":0.61321807},"labels":[],"label_agreement":null},{"id":"W2559062045","doi":"10.1182/blood.v108.11.4489.4489","title":"Presence of Comorbidities Do Not Predict Early Mortality or Survival in Older Patients (≥60 Years) with Acute Myeloid Leukemia (AML) Undergoing Intensive Induction Therapy.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Comorbidity; Internal medicine; Cytarabine; Myeloid leukemia; Pediatrics; Surgery","score_opus":0.02570946057538467,"score_gpt":0.27852819928661005,"score_spread":0.2528187387112254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559062045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99787533,0.000076851,0.000032076077,0.00009715189,0.0001309469,0.00097120577,0.00006978257,0.00006156609,0.0006850717],"genre_scores_gemma":[0.99837345,0.00021875101,0.00027495154,0.000079886195,0.00018919657,0.000057512334,0.00009186048,0.00005302749,0.0006613468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748284,0.00015432903,0.00048332597,0.00045492148,0.00096414256,0.00046045115],"domain_scores_gemma":[0.99833935,0.00023340236,0.00020766494,0.0005132621,0.0005993709,0.00010695233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003160658,0.00025364736,0.0005136074,0.00026226844,0.000053766726,0.00003489758,0.00021946381,0.00018617792,0.00006616435],"category_scores_gemma":[0.00021317707,0.00019108485,0.00007489453,0.00054370775,0.00027794528,0.00028698816,0.00011398994,0.0005478444,0.000009196994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024976383,0.0008563595,0.9828759,0.00014993438,0.0005549759,0.0007781615,0.0016489365,0.00005008931,0.009052575,0.00006925357,0.0006353939,0.00083081634],"study_design_scores_gemma":[0.011964585,0.0012608367,0.964022,0.00032483292,0.00014329788,0.000049064245,0.0007798049,0.000040491825,0.021134807,0.00004552815,0.000038935974,0.00019585593],"about_ca_topic_score_codex":0.004671258,"about_ca_topic_score_gemma":0.0008615606,"teacher_disagreement_score":0.018853905,"about_ca_system_score_codex":0.0003110945,"about_ca_system_score_gemma":0.00096282735,"threshold_uncertainty_score":0.7792214},"labels":[],"label_agreement":null},{"id":"W2559063049","doi":"10.1080/10428194.2016.1207765","title":"A common ancestral DNMT3A-mutated preleukemic clone giving rise to AML and MDS in an adolescent girl","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Gene; clone (Java method); Myeloid leukemia; Mutation; Myeloid; Genetics; Biology; Methyltransferase; Cancer research; Medicine; Methylation","score_opus":0.01909827924751811,"score_gpt":0.2877261521024222,"score_spread":0.2686278728549041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559063049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93754965,0.003602893,0.000071099326,0.051573336,0.0006876181,0.0037618217,0.00048421623,0.00069587346,0.0015735129],"genre_scores_gemma":[0.727114,0.0044966387,0.0014382197,0.24585178,0.007688442,0.0010278566,0.0012748045,0.0011490188,0.009959219],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9854185,0.0010160129,0.0026202765,0.004244935,0.0022663802,0.004433895],"domain_scores_gemma":[0.99250984,0.0008500115,0.0008274769,0.0029763796,0.00050403987,0.002332259],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0013661117,0.0028063038,0.0040045986,0.002487265,0.00059125037,0.0006066303,0.0015648393,0.004201211,0.00017790304],"category_scores_gemma":[0.00036415187,0.0024811935,0.0005338242,0.0017831584,0.0013639942,0.0010143692,0.0013320555,0.002740816,0.00030716226],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005563875,0.00042616506,0.040721796,0.00463408,0.00069879997,0.024950977,0.0023803134,0.000035228273,0.0139447255,0.00006463506,0.56761867,0.3389607],"study_design_scores_gemma":[0.055206705,0.003309896,0.21704935,0.010343264,0.00092465646,0.010547425,0.0005392325,0.0063898456,0.004536382,0.00043048945,0.6851483,0.0055744294],"about_ca_topic_score_codex":0.005696386,"about_ca_topic_score_gemma":0.0006272127,"teacher_disagreement_score":0.33338627,"about_ca_system_score_codex":0.038789593,"about_ca_system_score_gemma":0.0114990305,"threshold_uncertainty_score":0.9995599},"labels":[],"label_agreement":null},{"id":"W2559223604","doi":"10.1182/blood.v112.11.1355.1355","title":"Heterogeneity of Acute Myeloid Leukemia at the Stem Cell Level.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; BC Cancer Agency","funders":"","keywords":"Stem cell; Biology; Myeloid leukemia; Myeloid; Leukemia; Bone marrow; Transplantation; Cancer research; Immunology; Molecular biology; Cell biology; Medicine; Internal medicine","score_opus":0.04330468186836346,"score_gpt":0.2801666809180438,"score_spread":0.23686199904968036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559223604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99089515,0.00074008544,0.000031676704,0.00041813077,0.00005923829,0.00045748346,0.00008515444,0.000051737094,0.0072613657],"genre_scores_gemma":[0.9746317,0.0006121998,0.00044210174,0.00033459032,0.00014812856,0.000028662183,0.000027848455,0.00004200365,0.023732722],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99820065,0.00009249874,0.0003329952,0.00032294204,0.00061648735,0.00043443943],"domain_scores_gemma":[0.9985704,0.00012125801,0.000114397946,0.000852034,0.00015328299,0.00018864393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027273945,0.00019291107,0.00037391591,0.000079871344,0.00020071551,0.000006047338,0.0003232723,0.00014247658,0.00017032947],"category_scores_gemma":[0.000017884771,0.00012632509,0.00020339155,0.0002867978,0.00032310182,0.000051089526,0.00030595987,0.0003703241,0.0003211295],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006252653,0.0007519081,0.09702273,0.00026545735,0.0012295886,0.0013291371,0.001210106,0.000012048489,0.86315393,0.000038094844,0.032036945,0.002324792],"study_design_scores_gemma":[0.004624653,0.00032086423,0.049759135,0.000024168778,0.00035570667,0.001328182,0.000058776644,0.000039876202,0.93740547,0.00000384249,0.005941847,0.00013746055],"about_ca_topic_score_codex":0.00011585873,"about_ca_topic_score_gemma":0.000022691756,"teacher_disagreement_score":0.074251555,"about_ca_system_score_codex":0.0003463264,"about_ca_system_score_gemma":0.00066837226,"threshold_uncertainty_score":0.51513875},"labels":[],"label_agreement":null},{"id":"W2559499926","doi":"10.1182/blood.v106.11.4183.4183","title":"A Multicenter, Randomized, Controlled Clinical Pilot Trial of the Feasibility of an Intensive RBC Transfusion Policy for Patients with Acute Leukemia Treated with Induction Chemotherapy or Stem Cell Transplant.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Dalhousie University; Queen Elizabeth II Health Sciences Centre; University of Waterloo; McMaster University; Canadian Blood Services","funders":"","keywords":"Medicine; Randomized controlled trial; Chemotherapy; Internal medicine; Induction chemotherapy; Acute leukemia; Surgery; Blood transfusion; Clinical trial; Leukemia","score_opus":0.03304321397160581,"score_gpt":0.33178530807059814,"score_spread":0.29874209409899233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559499926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981801,0.000014984654,0.00022607036,0.00050611317,0.000047370828,0.017180208,0.00012893623,0.000030242463,0.00006512355],"genre_scores_gemma":[0.99753124,0.00018613129,0.001055157,0.000203508,0.00023488812,0.00034080664,0.00005543886,0.000049812526,0.00034301475],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99693805,0.000641836,0.001116185,0.00043278973,0.00055981794,0.00031133852],"domain_scores_gemma":[0.99707085,0.0006843844,0.00052868266,0.0005529509,0.0009970487,0.00016609317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010802145,0.00028966277,0.0019525893,0.00014819435,0.00006770106,0.000008758339,0.00020201271,0.00018455976,0.00001738195],"category_scores_gemma":[0.00022121954,0.00012745585,0.0004406602,0.0003158936,0.00044270023,0.00011196616,0.000011521153,0.0003581181,4.993712e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9769938,0.00742864,0.0052177235,0.00010397557,0.0014356825,0.0000053109297,0.00091375527,0.0000048665484,0.0054204413,0.0000022153288,0.000013502152,0.0024601028],"study_design_scores_gemma":[0.9320087,0.024962755,0.0030132553,0.0001885035,0.0027201665,0.000020994246,0.00019588578,0.00075726275,0.035993677,0.0000018367598,0.000007811232,0.0001291821],"about_ca_topic_score_codex":0.0003329291,"about_ca_topic_score_gemma":0.00016884106,"teacher_disagreement_score":0.044985116,"about_ca_system_score_codex":0.00021027341,"about_ca_system_score_gemma":0.0011989683,"threshold_uncertainty_score":0.5197498},"labels":[],"label_agreement":null},{"id":"W2559698750","doi":"10.1182/blood.v108.11.1404.1404","title":"Identification of Meis1 Target Genes Involved in the Induction of AML in Collaboration with NUP98-HOXD13.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Hox gene; Biology; Homeobox; Cancer research; Downregulation and upregulation; Transcription factor; Leukemia; Molecular biology; Cell biology; Genetics; Gene","score_opus":0.013573322949529697,"score_gpt":0.27047657623779203,"score_spread":0.25690325328826236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559698750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980146,0.00026701717,0.00008889345,0.0007156174,0.000018640529,0.0005712443,0.000007927269,0.000007985313,0.0003080269],"genre_scores_gemma":[0.99900466,0.000040823594,0.0006408015,0.000019800576,0.00006712489,0.00005205547,0.000073236806,0.000010053019,0.00009142475],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99891,0.00011396576,0.00037029892,0.00014165654,0.00034886715,0.00011522939],"domain_scores_gemma":[0.99932307,0.0000432482,0.0001558546,0.00024880504,0.00021475228,0.000014264925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055782835,0.0000687489,0.0001709761,0.0002460269,0.00001610397,0.000008455563,0.00009224774,0.00007419329,0.000008801178],"category_scores_gemma":[0.000076560296,0.000047900696,0.000016937614,0.0010718284,0.00007667968,0.00011209274,0.000011817798,0.00013362853,0.0000025413467],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002215056,0.0009537036,0.28561136,0.00013838142,0.000024428582,0.000013071678,0.0010834835,0.00019863214,0.7105408,0.00057985896,0.0003273334,0.00030745598],"study_design_scores_gemma":[0.0035054921,0.00019711576,0.42374852,0.00006106186,0.00004267649,0.00000926173,0.0019265218,0.00032534832,0.5697222,0.00027776073,0.00013023421,0.000053797474],"about_ca_topic_score_codex":0.000701245,"about_ca_topic_score_gemma":0.0009836409,"teacher_disagreement_score":0.14081857,"about_ca_system_score_codex":0.0000718182,"about_ca_system_score_gemma":0.00024379422,"threshold_uncertainty_score":0.19533336},"labels":[],"label_agreement":null},{"id":"W2559764713","doi":"10.1182/blood.v108.11.4222.4222","title":"PBI-1402: A Low Molecular Weight Synthetic Hematopoietic Growth Stimulant.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Haematopoiesis; Bone marrow; Cancer research; Progenitor cell; Myeloid; Hematopoietic growth factor; Biology; Neutropenia; Stem cell; Pharmacology; Chemistry; Immunology; Internal medicine; Medicine; Cell biology; Chemotherapy","score_opus":0.0057404006294827295,"score_gpt":0.23691024993433443,"score_spread":0.2311698493048517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559764713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9725806,0.0011648707,0.000805559,0.0015103074,0.00005901302,0.0005607123,0.0000116025385,0.0002016877,0.023105625],"genre_scores_gemma":[0.99534875,0.000050665676,0.0019573544,0.0003714344,0.00026335593,0.000051864667,0.000038954015,0.000076942146,0.0018406505],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979087,0.00006780973,0.00032018076,0.0004499159,0.0006386609,0.0006147282],"domain_scores_gemma":[0.9988311,0.00010207474,0.000058164984,0.0006259073,0.00015490958,0.00022785093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020267085,0.00024931866,0.00040656148,0.00020264907,0.00007690884,0.000034162647,0.00023157016,0.00016216417,0.00038620408],"category_scores_gemma":[0.00015671464,0.0002112754,0.00016983361,0.000385635,0.00014062601,0.000054566593,0.00010668944,0.00037678616,0.0007286364],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007554704,0.008922814,0.032563217,0.002274493,0.0012577033,0.024678051,0.00039444145,0.0000425759,0.8621748,0.035981733,0.029400246,0.0015544717],"study_design_scores_gemma":[0.016775731,0.00088227977,0.010501955,0.0006876357,0.0012520576,0.003786052,0.00006096382,0.0010602114,0.9546572,0.0060930345,0.0034362029,0.0008066518],"about_ca_topic_score_codex":0.0001586966,"about_ca_topic_score_gemma":0.0000036348504,"teacher_disagreement_score":0.09248244,"about_ca_system_score_codex":0.00010496938,"about_ca_system_score_gemma":0.00024295751,"threshold_uncertainty_score":0.936539},"labels":[],"label_agreement":null},{"id":"W2559793479","doi":"10.1182/blood.v112.11.2549.2549","title":"Distinct Proteomic Signaling Networks Stratify Responses to Ara-C Based Induction Therapy in Patients with Acute Myeloid Leukemia (AML)","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Daunorubicin; Cytarabine; Myeloid leukemia; Cytokine; Cancer research; Medicine; Leukemia; Signal transduction; Immunology; Biology; Internal medicine; Cell biology","score_opus":0.020508332030833937,"score_gpt":0.26496548882235665,"score_spread":0.24445715679152272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559793479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99623394,0.000039615694,0.0008574999,0.00030185175,0.00004550754,0.002261272,0.000014978646,0.00009835235,0.00014696218],"genre_scores_gemma":[0.9945355,0.000024118362,0.004167125,0.00037006437,0.00022625095,0.0002560856,0.00010372751,0.00006864439,0.00024845978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771047,0.0001913088,0.00037914864,0.000521225,0.00062511204,0.0005727234],"domain_scores_gemma":[0.9988289,0.00011342422,0.000105099636,0.00048278307,0.00020805924,0.00026177158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003472301,0.00029112754,0.00040325115,0.00035450133,0.00016825492,0.000029506971,0.00018628784,0.00019475854,0.000063914056],"category_scores_gemma":[0.0001300809,0.00022494618,0.00006519067,0.00080023595,0.00009738533,0.00013894695,0.000038135622,0.0007183434,0.000024961317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018802593,0.0012149254,0.93135554,0.000037088837,0.00029950266,0.00074282894,0.0005098673,0.00078858656,0.04042556,0.000004209935,0.000356219,0.005463099],"study_design_scores_gemma":[0.016879752,0.0033871261,0.93955344,0.00018942956,0.000067253335,0.0000726851,0.000029943902,0.0007079455,0.03869985,0.000004624963,0.000104488114,0.0003034386],"about_ca_topic_score_codex":0.00017088903,"about_ca_topic_score_gemma":0.000022980545,"teacher_disagreement_score":0.008197945,"about_ca_system_score_codex":0.0005334965,"about_ca_system_score_gemma":0.0012966769,"threshold_uncertainty_score":0.9173039},"labels":[],"label_agreement":null},{"id":"W2559898148","doi":"10.1182/blood.v106.11.2765.2765","title":"Studies on GM-CSF Induced Signaling and Cell Growth in JMML: An Experimental Model To Identify Mechanism Directed Targeted Therapeutics.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Juvenile myelomonocytic leukemia; Signal transduction; Granulocyte macrophage colony-stimulating factor; Cytokine; Cancer research; Antibody; Biology; Leukemia inhibitory factor receptor; Context (archaeology); Immunology; Cell biology; Stem cell; Haematopoiesis; Leukemia inhibitory factor","score_opus":0.07053464675567143,"score_gpt":0.36817974374404644,"score_spread":0.297645096988375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559898148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976136,0.0007226309,0.00003320447,0.00051541685,0.00003772939,0.00057644176,0.00000553367,0.00012284385,0.0003725944],"genre_scores_gemma":[0.99391675,0.00006303269,0.0043871207,0.0012106065,0.0001292438,0.00008245988,0.000011164039,0.000052670748,0.0001469224],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99841243,0.000094292365,0.00028113343,0.000437965,0.00039278186,0.0003814258],"domain_scores_gemma":[0.9993333,0.000063994106,0.00004596324,0.00023428448,0.00011756018,0.0002048463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031679322,0.00021466994,0.0003291032,0.00030248938,0.000084616084,0.00003279334,0.00012830521,0.000121033234,0.000019025709],"category_scores_gemma":[0.000059947,0.00019152148,0.00003794763,0.00027656517,0.000032187178,0.00013331258,0.000115440394,0.00034010885,0.000024386769],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019338429,0.00096635445,0.00022736366,0.000027672235,0.000098060234,0.000051503688,0.0062343236,0.000048342506,0.99179876,0.00014641593,0.00003414652,0.00017365726],"study_design_scores_gemma":[0.004751858,0.0007387485,0.0005568272,0.00006787523,0.00007013698,0.000010805765,0.0018855022,0.009405976,0.9821424,0.00017105413,0.0000053673953,0.00019346047],"about_ca_topic_score_codex":0.000043406402,"about_ca_topic_score_gemma":0.000023301553,"teacher_disagreement_score":0.009656387,"about_ca_system_score_codex":0.00019972595,"about_ca_system_score_gemma":0.0001033776,"threshold_uncertainty_score":0.7810019},"labels":[],"label_agreement":null},{"id":"W2559948760","doi":"10.1182/blood.v118.21.4269.4269","title":"Targeting EVI1-Overexpressing AML with Darinaparsin","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Jewish General Hospital; McGill University","funders":"","keywords":"Arsenic trioxide; Medicine; Cancer research; Cytarabine; Mitoxantrone; Myeloid; Internal medicine; Oncology; Chemotherapy; Myeloid leukemia; Biology; Apoptosis","score_opus":0.03344768634119733,"score_gpt":0.2682430929113709,"score_spread":0.23479540657017356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559948760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92610985,0.0003088979,0.00037701154,0.00012336868,0.00002811901,0.00027524406,0.0000028257978,0.00011378462,0.0726609],"genre_scores_gemma":[0.9710123,0.000020514848,0.02738917,0.00018078859,0.00018552472,0.00001627923,0.000011647654,0.000041747542,0.0011420586],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988182,0.000037157948,0.00015870959,0.0002727046,0.00031532225,0.00039790288],"domain_scores_gemma":[0.9992911,0.00003466269,0.000052923497,0.0003448518,0.000097866316,0.00017855041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020774048,0.00013440751,0.00021324767,0.00008356697,0.00009570002,0.00002016571,0.0001277049,0.00007421794,0.00043991505],"category_scores_gemma":[0.00011045674,0.00009961184,0.00003826499,0.00018647453,0.000102281956,0.000112148875,0.00008601185,0.00032829292,0.00012402922],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024537854,0.0037645423,0.48950666,0.0007963045,0.0011312278,0.0047465255,0.008102842,0.000005312877,0.45816603,0.0015468987,0.016503977,0.0132759055],"study_design_scores_gemma":[0.032538783,0.0037128264,0.15596385,0.0017832591,0.0012456643,0.0026120683,0.0024911903,0.00073843094,0.7725619,0.0004245904,0.02465021,0.0012772148],"about_ca_topic_score_codex":0.00014832587,"about_ca_topic_score_gemma":0.000002969516,"teacher_disagreement_score":0.3335428,"about_ca_system_score_codex":0.000056956455,"about_ca_system_score_gemma":0.00022790009,"threshold_uncertainty_score":0.48167613},"labels":[],"label_agreement":null},{"id":"W2559984635","doi":"10.1038/bcj.2016.110","title":"MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia","year":2016,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Deutsche Krebshilfe; Medizinische Fakultät, Universität Ulm; Canadian Institutes of Health Research; Universität Ulm; European Hematology Association; Barncancerfonden; Cancerfonden; Deutsche Forschungsgemeinschaft; Västra Götalandsregionen","keywords":"Myeloid leukemia; Medicine; Leukemia; Cancer research; Hematology; Myeloid; Suppressor; Oncology; Immunology; Internal medicine; Cancer","score_opus":0.016155506416765553,"score_gpt":0.29283192201753755,"score_spread":0.276676415600772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559984635","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041328896,0.004134185,0.000036779486,0.947373,0.0017397414,0.0013356698,0.0010218171,0.00010059499,0.0029293594],"genre_scores_gemma":[0.0017377426,0.009691426,0.001167846,0.90471214,0.039829995,0.00049589167,0.00013955687,0.0005149921,0.04171041],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918755,0.00034614757,0.0014661328,0.0011748674,0.0026675218,0.0024698263],"domain_scores_gemma":[0.9959783,0.0002058448,0.0008084032,0.0012180579,0.0010386797,0.00075071654],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0006979853,0.0010530652,0.0018300504,0.0012216566,0.00024772043,0.00023258796,0.0012740887,0.001349274,0.0044243527],"category_scores_gemma":[0.00021631981,0.00075298426,0.00080594316,0.00056709483,0.0003036628,0.00032535885,0.00036274988,0.011669384,0.00045201267],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00068199344,0.00009542701,0.0007161382,0.00044675285,0.0018634207,0.043986518,0.0003226505,0.000001217596,0.0069799833,0.0000020525538,0.94033015,0.0045736902],"study_design_scores_gemma":[0.016709162,0.00074982503,0.0008970439,0.004699199,0.0018286862,0.02238477,0.0000489171,0.000049622828,0.015605695,0.000120628334,0.9358877,0.0010187336],"about_ca_topic_score_codex":0.0008421041,"about_ca_topic_score_gemma":0.000076681536,"teacher_disagreement_score":0.042660818,"about_ca_system_score_codex":0.005593727,"about_ca_system_score_gemma":0.008230497,"threshold_uncertainty_score":0.9999472},"labels":[],"label_agreement":null},{"id":"W2560012305","doi":"10.1038/nature20598","title":"A 17-gene stemness score for rapid determination of risk in acute leukaemia","year":2016,"lang":"en","type":"article","venue":"Nature","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":920,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"European Hematology Association","keywords":"Oncology; Medicine; Internal medicine; Induction chemotherapy; Stem cell; Chemotherapy; Cohort; Framingham Risk Score; Adverse effect; Gene signature; Transplantation; Gene; Biology; Gene expression; Disease","score_opus":0.017011272837884398,"score_gpt":0.31976153089296866,"score_spread":0.30275025805508426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560012305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941354,0.00077246205,0.0018166708,0.0015843452,0.00013653695,0.00087477744,0.0002193543,0.000029726078,0.00043073192],"genre_scores_gemma":[0.9928362,0.00028323475,0.004506979,0.00022350965,0.00016887404,0.00007140297,0.000045991383,0.000028721877,0.0018351091],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886566,0.000049743,0.00023302903,0.00025645545,0.0003303777,0.00026471706],"domain_scores_gemma":[0.99883676,0.0003449776,0.00011237884,0.00032963103,0.00029651914,0.000079748585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044190022,0.000121253295,0.00029369924,0.00025897715,0.000028126835,0.0000049697032,0.00016162584,0.0009287493,0.000071270624],"category_scores_gemma":[0.0007447427,0.00007591181,0.000094158895,0.00029820084,0.00006484778,0.00009961905,0.000048394937,0.0009201323,0.000007762387],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036808567,0.00017670538,0.043725565,0.00041399905,0.00014039059,0.00015458063,0.00059129164,8.0710595e-7,0.3941713,0.00031520618,0.018798292,0.537831],"study_design_scores_gemma":[0.021909242,0.00092400366,0.22713621,0.0011058864,0.00029396013,0.00015661356,0.00012567772,0.00084879366,0.7316682,0.0013746808,0.014067666,0.00038907802],"about_ca_topic_score_codex":0.0000118589305,"about_ca_topic_score_gemma":0.000036970952,"teacher_disagreement_score":0.5374419,"about_ca_system_score_codex":0.0003457883,"about_ca_system_score_gemma":0.00026837247,"threshold_uncertainty_score":0.7163365},"labels":[],"label_agreement":null},{"id":"W2560215254","doi":"10.1182/blood.v108.11.860.860","title":"SCL and Its Partner E2A Are Required for Long-Term Stem Cell Activity.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Haematopoiesis; Biology; Stem cell; Transplantation; Progenitor cell; Myeloid; Bone marrow; Molecular biology; Immunology; Cell biology; Cancer research; Internal medicine; Medicine","score_opus":0.03585712411166919,"score_gpt":0.3007376615160513,"score_spread":0.2648805374043821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560215254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941327,0.0011163001,0.000063282285,0.00081946066,0.00004010993,0.00084139785,0.000029483985,0.000070691654,0.0028865528],"genre_scores_gemma":[0.98219824,0.00005459536,0.00013490538,0.000093333474,0.00043280996,0.00008831693,0.000024580206,0.000042876818,0.016930345],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99882495,0.00003400169,0.00015472082,0.00033168128,0.00025168853,0.00040293345],"domain_scores_gemma":[0.99925894,0.000112173184,0.000073754454,0.00028040292,0.0001252345,0.00014948202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017261984,0.00015187878,0.0002814167,0.00008742537,0.00008761488,0.0000315973,0.00008806341,0.00013126551,0.000025532243],"category_scores_gemma":[0.000028448687,0.00012948588,0.000068844936,0.00012186276,0.00004607033,0.00010394042,0.00007205133,0.00017119062,0.00004554726],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001298538,0.0033752082,0.31623194,0.0030802088,0.0003323633,0.0011810807,0.0002786114,0.0000021735523,0.6402094,0.00029432733,0.020432703,0.013283447],"study_design_scores_gemma":[0.015198996,0.0005366693,0.35749412,0.00018363904,0.00035874228,0.00016651716,0.00005246631,0.00020350095,0.6226049,0.000040048835,0.0028656563,0.0002947678],"about_ca_topic_score_codex":0.000016730119,"about_ca_topic_score_gemma":0.000023930432,"teacher_disagreement_score":0.04126216,"about_ca_system_score_codex":0.00006423407,"about_ca_system_score_gemma":0.00012249468,"threshold_uncertainty_score":0.52802813},"labels":[],"label_agreement":null},{"id":"W2560622290","doi":"10.1182/blood.v104.11.5156.5156","title":"Fludarabine and Busulfan (FluBuP Regimen) as Myeloablative Conditioning Regimen for Allogeneic PBSCT in 71 Leukemic Patients (A Unicenteric Study).","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Busulfan; Fludarabine; Mucositis; Gastroenterology; Regimen; Internal medicine; Surgery; Hemorrhagic cystitis; Transplantation; Cyclophosphamide; Toxicity; Chemotherapy; Hematopoietic stem cell transplantation","score_opus":0.014573127512305243,"score_gpt":0.29173611566313595,"score_spread":0.27716298815083074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560622290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947154,0.00035984913,0.000034606477,0.00060811656,0.000060785373,0.0028711471,0.000034109406,0.000069322494,0.0012466908],"genre_scores_gemma":[0.9968652,0.000095301286,0.001000774,0.00037335296,0.00011089748,0.00030604732,0.00021997966,0.00006655982,0.0009618741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977486,0.00010687856,0.00046481684,0.00064591435,0.00043327577,0.00060048053],"domain_scores_gemma":[0.9987968,0.00012278672,0.00015202304,0.00044721543,0.0002387765,0.00024237833],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004231567,0.00029714647,0.0005168834,0.0003581039,0.0001637687,0.000038854418,0.00018873891,0.00014264841,0.000041699233],"category_scores_gemma":[0.0003881685,0.00027796463,0.00007404237,0.0004840994,0.00015122499,0.00020941783,0.00016208063,0.00038082132,0.000040652736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008441255,0.021646732,0.826411,0.0010822362,0.003743543,0.002617715,0.025347259,0.0003417326,0.092324086,0.0015661612,0.0027439317,0.013734337],"study_design_scores_gemma":[0.16065696,0.0118351765,0.79629874,0.0008342865,0.000811345,0.00030059143,0.004787118,0.00015470959,0.020566983,0.0014141165,0.0014440835,0.0008958731],"about_ca_topic_score_codex":0.00045846403,"about_ca_topic_score_gemma":0.00007547785,"teacher_disagreement_score":0.1522157,"about_ca_system_score_codex":0.00069718796,"about_ca_system_score_gemma":0.00054042565,"threshold_uncertainty_score":0.9999673},"labels":[],"label_agreement":null},{"id":"W2560868850","doi":"10.1182/blood.v126.23.3201.3201","title":"Analysis of Impact of Comorbidities Constituting the HCT-CI Score on the Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Hematopoietic stem cell transplantation; Bone marrow; Single Center; Transplantation; Hematopoietic cell; Gastroenterology; Surgery; Acute leukemia; Leukemia; Haematopoiesis; Stem cell","score_opus":0.05229257650455247,"score_gpt":0.32170096523119884,"score_spread":0.26940838872664635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560868850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99701554,0.00017676638,0.00015255818,0.00013564382,0.00003675582,0.0007963984,0.0005572201,0.000012642235,0.001116468],"genre_scores_gemma":[0.9994318,0.00006678184,0.00015192172,0.000074500706,0.000028515351,0.000026429603,0.000117837335,0.000023139297,0.000079066755],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980418,0.00011607664,0.0006731394,0.00021413792,0.0006236481,0.00033117313],"domain_scores_gemma":[0.99740094,0.0011124044,0.00040271776,0.00059905765,0.00037011472,0.00011476963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072982523,0.00020826844,0.0008130138,0.00026581378,0.00008154814,0.000009173627,0.00035617952,0.00009775878,0.00003174273],"category_scores_gemma":[0.00029062768,0.000108694556,0.0005797121,0.00058581564,0.0004193399,0.000036688336,0.0000625566,0.00022902664,0.0000026227094],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070759177,0.0005483159,0.9767421,0.00045500125,0.007118503,0.000014015476,0.003124242,0.0012820058,0.009072256,0.0005118522,0.00035054368,0.000073563584],"study_design_scores_gemma":[0.033738565,0.0072929766,0.35082304,0.0010849348,0.04594078,0.000068805384,0.0074225017,0.0047358037,0.5476611,0.00041771756,0.00006670963,0.00074705255],"about_ca_topic_score_codex":0.00027050343,"about_ca_topic_score_gemma":0.000056924287,"teacher_disagreement_score":0.62591904,"about_ca_system_score_codex":0.00021680704,"about_ca_system_score_gemma":0.0010528774,"threshold_uncertainty_score":0.44324353},"labels":[],"label_agreement":null},{"id":"W2560917069","doi":"10.1038/nm.4255","title":"SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia","year":2016,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada; Ludwig-Maximilians-Universität München; Frankfurter Stiftung für krebskranke Kinder; José Carreras Leukämie-Stiftung; LOEWE-Zentrum für Translationale Medizin und Pharmakologie; Hilfe für krebskranke Kinder Frankfurt; Deutsche Forschungsgemeinschaft","keywords":"Cytarabine; Myeloid leukemia; Medicine; Biomarker; Leukemia; Myeloid; Oncology; Immunology; Cancer research; Biology","score_opus":0.019348863865990707,"score_gpt":0.335436191806298,"score_spread":0.3160873279403073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560917069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8340569,0.008883712,0.0008978215,0.15361767,0.00024721576,0.0016375056,0.00008110889,0.00009258597,0.0004854722],"genre_scores_gemma":[0.9721929,0.001097347,0.0022789866,0.014314268,0.00045833256,0.00018235322,0.000035996898,0.00009074016,0.009349117],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972096,0.00018339683,0.00049538567,0.00071497465,0.0006598927,0.0007367698],"domain_scores_gemma":[0.9971357,0.0014772217,0.000106427375,0.00062951323,0.00027787226,0.00037327642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020824163,0.00037771647,0.0007923377,0.0007395231,0.000079263424,0.000009594834,0.00023553318,0.0006857274,0.0005014412],"category_scores_gemma":[0.0018413191,0.00020413085,0.00010138044,0.0007300648,0.00051031314,0.00009077961,0.00009501562,0.0008904158,0.000027758255],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031808168,0.00007230376,0.008925333,0.00017450911,0.00039531683,0.00040862078,0.000911086,7.241917e-8,0.8545659,0.00025787824,0.051186085,0.051294684],"study_design_scores_gemma":[0.060767002,0.0046383077,0.36963117,0.0020924956,0.00053647417,0.0011745167,0.00033274223,0.0012087262,0.0645975,0.0035579407,0.49070904,0.00075408706],"about_ca_topic_score_codex":0.000047730933,"about_ca_topic_score_gemma":0.000014905528,"teacher_disagreement_score":0.78996843,"about_ca_system_score_codex":0.0010126054,"about_ca_system_score_gemma":0.0006988342,"threshold_uncertainty_score":0.8324214},"labels":[],"label_agreement":null},{"id":"W2561477522","doi":"10.1182/blood.v126.23.1668.1668","title":"Suspicious, Non-MDS-Diagnostic Bone Marrows Have a High Incidence of Clonal Hematopoiesis (CHIP), with MDS-like Clone Size but Restricted Mutation Burden","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Cytopenia; Myelodysplastic syndromes; Medicine; Sanger sequencing; Internal medicine; Dysplasia; International Prognostic Scoring System; Oncology; Biology; Bone marrow; DNA sequencing; Genetics; Gene","score_opus":0.012901542360262419,"score_gpt":0.2587920971529594,"score_spread":0.245890554792697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561477522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994982,0.0005923733,0.00022539965,0.0018435057,0.000076588956,0.0012146737,0.00005879309,0.00011776321,0.0008888908],"genre_scores_gemma":[0.9877024,0.00009992973,0.009603869,0.00021886121,0.00037954035,0.00015481269,0.00012996713,0.00008282017,0.0016277545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99645436,0.00015131415,0.0006733776,0.0005754044,0.0015075101,0.0006380242],"domain_scores_gemma":[0.9958377,0.0015019435,0.00032934517,0.0007871486,0.000983273,0.0005605875],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050797337,0.00035468914,0.00078674173,0.00030816684,0.00008995826,0.00003560155,0.00030896123,0.00025951883,0.00010671638],"category_scores_gemma":[0.0048261033,0.00029687394,0.000098148805,0.0007729905,0.00031442815,0.0001868228,0.0001939343,0.0005741774,0.000097503864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018252198,0.008912544,0.44539037,0.0042487886,0.004070493,0.04989391,0.014691417,0.00083267805,0.3964509,0.001000298,0.052323487,0.0039329063],"study_design_scores_gemma":[0.10428215,0.014983983,0.56181014,0.0034901672,0.0043273955,0.013064784,0.007420061,0.002830668,0.28258023,0.0017542664,0.001182281,0.0022739011],"about_ca_topic_score_codex":0.00594777,"about_ca_topic_score_gemma":0.00027611034,"teacher_disagreement_score":0.11641975,"about_ca_system_score_codex":0.00029691434,"about_ca_system_score_gemma":0.0016751321,"threshold_uncertainty_score":0.9999483},"labels":[],"label_agreement":null},{"id":"W2561481733","doi":"10.1182/blood.v106.11.4987.4987","title":"Long-Term Results of a Low-Dose Cytarabine-Based Regimen for the Treatment of Acute Megakaryoblastic Leukemia and Myelodysplastic Syndrome in Children with Down Syndrome.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Cytarabine; Medicine; Acute megakaryoblastic leukemia; Regimen; Chemotherapy; Internal medicine; Down syndrome; Leukemia; Chemotherapy regimen; Population; Gastroenterology; Pediatrics","score_opus":0.009387277260244554,"score_gpt":0.25414687957566945,"score_spread":0.2447596023154249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561481733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99561894,0.0006669357,0.00012039771,0.0006030262,0.00001476038,0.0026397246,0.00025046142,0.00002934838,0.000056422086],"genre_scores_gemma":[0.9975468,0.0003431977,0.0012652086,0.000036740523,0.00004908702,0.00026391185,0.00012893222,0.00004601977,0.00032012904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997941,0.000056021334,0.00058525946,0.0004881829,0.00044251085,0.00048701986],"domain_scores_gemma":[0.99810535,0.00067245524,0.00022720055,0.00069661305,0.00012136672,0.00017700253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025613263,0.00032904503,0.00074211275,0.00032283246,0.00006193763,0.000014723866,0.00021677715,0.0001359423,0.000013185212],"category_scores_gemma":[0.00008893605,0.00019894833,0.00011894987,0.00043055834,0.00033801433,0.00008158784,0.00003230604,0.00019172186,0.0000047141993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081770696,0.021652695,0.79776883,0.0032574907,0.02350726,0.0056794034,0.0035244094,0.0045302254,0.034565534,0.00013677868,0.000524642,0.02308206],"study_design_scores_gemma":[0.06272264,0.011007789,0.9032057,0.0007010601,0.00208621,0.003161845,0.000017550234,0.0017256901,0.015137643,0.00000450856,0.000012905973,0.00021644172],"about_ca_topic_score_codex":0.0001652667,"about_ca_topic_score_gemma":0.00010455025,"teacher_disagreement_score":0.10543692,"about_ca_system_score_codex":0.00039231073,"about_ca_system_score_gemma":0.0007555831,"threshold_uncertainty_score":0.8112877},"labels":[],"label_agreement":null},{"id":"W2561655537","doi":"10.1182/blood.v126.23.4973.4973","title":"Practical Acute Myeloid Leukemia (AML) Biomarker Testing Using Next-Generation Sequencing (NGS) Technology: A Comprehensive, Rapid, Inexpensive and Flexible Approach","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"","keywords":"CEBPA; Computational biology; Minimal residual disease; Personalized medicine; NPM1; Biomarker; DNA sequencing; Myeloid leukemia; Biomarker discovery; Medicine; Bioinformatics; Oncology; Biology; Leukemia; Gene; Internal medicine; Genetics; Mutation; Proteomics; Chromosome","score_opus":0.2668825862060752,"score_gpt":0.3620575923762642,"score_spread":0.09517500617018904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561655537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893451,0.00107294,0.0048057204,0.0010737394,0.00008666921,0.000986029,0.000008344777,0.00034991995,0.0022715556],"genre_scores_gemma":[0.71150535,0.00007795952,0.28713563,0.0005399806,0.00037419863,0.000057224883,0.00007481912,0.00008298431,0.0001518452],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9973017,0.00015568879,0.00047616096,0.0007634198,0.00059970253,0.00070331985],"domain_scores_gemma":[0.9974889,0.00021017382,0.00020070482,0.0005658456,0.0010799535,0.0004543836],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051899714,0.00036865417,0.00059803185,0.00060468784,0.00025674104,0.00013768607,0.00015085381,0.00043803724,0.000010052224],"category_scores_gemma":[0.0018014214,0.00033433616,0.00006212502,0.0013112513,0.0004091535,0.00050590833,0.00038953745,0.0008439307,0.000027735698],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018588168,0.00015644488,0.003748008,0.00010176974,0.00043453995,0.0006862731,0.00032559742,0.000050362953,0.9889598,0.00015896281,0.0018090333,0.003383327],"study_design_scores_gemma":[0.0237513,0.0016721706,0.001521685,0.00043446492,0.0022148984,0.039097182,0.008790612,0.517803,0.40049288,0.00032637615,0.0025787402,0.0013166787],"about_ca_topic_score_codex":0.00022613247,"about_ca_topic_score_gemma":0.000002805064,"teacher_disagreement_score":0.58846694,"about_ca_system_score_codex":0.0009849132,"about_ca_system_score_gemma":0.0027298864,"threshold_uncertainty_score":0.9999109},"labels":[],"label_agreement":null},{"id":"W2561740607","doi":"10.1182/blood.v110.11.1450.1450","title":"Preliminary Results of a Phase II Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults with Myelodysplastic Syndrome (MDS).","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Decitabine; Medicine; International Prognostic Scoring System; Regimen; Internal medicine; Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Phases of clinical research; Clinical endpoint; Bone marrow; Surgery; Gastroenterology; Clinical trial","score_opus":0.021236378653873487,"score_gpt":0.3115170207281743,"score_spread":0.29028064207430077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561740607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943612,0.00008864198,0.0005093018,0.00017449538,0.000057796817,0.003989777,0.0002821578,0.000048758277,0.00048785328],"genre_scores_gemma":[0.99376804,0.0000045452475,0.0048536644,0.000054484324,0.000089541085,0.000163436,0.00010029233,0.000069196896,0.00089682057],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99691683,0.000052076764,0.0009774388,0.0006115179,0.0008344574,0.00060769665],"domain_scores_gemma":[0.99700123,0.00077933347,0.0002885038,0.000920278,0.0005769336,0.00043372344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009084379,0.00029701996,0.0008091704,0.00051383977,0.0000926851,0.000007025594,0.00032551817,0.00013451299,0.00001959501],"category_scores_gemma":[0.0011903044,0.00023753694,0.000096068965,0.00072113035,0.000109136694,0.00008927057,0.00022886069,0.00025330536,0.0000074380296],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7747926,0.10101896,0.0060778027,0.002869532,0.003025285,0.0063766786,0.027530773,0.00004397879,0.06000029,0.000028425417,0.004576639,0.013659018],"study_design_scores_gemma":[0.28072137,0.5725937,0.09056824,0.0020407818,0.0018730436,0.0015554121,0.0082230335,0.00022392538,0.041204233,0.000007989999,0.00047502376,0.0005132537],"about_ca_topic_score_codex":0.00011061919,"about_ca_topic_score_gemma":0.00010305282,"teacher_disagreement_score":0.49407127,"about_ca_system_score_codex":0.000089781235,"about_ca_system_score_gemma":0.00046834754,"threshold_uncertainty_score":0.96864754},"labels":[],"label_agreement":null},{"id":"W2561937338","doi":"10.1182/blood.v126.23.5246.5246","title":"Validation of Predictive Models for Response to Erythropoiesis-Stimulating Agents in Myelodysplastic Syndromes","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; International Prognostic Scoring System; Cohort; Internal medicine; Myelodysplastic syndromes; Anemia; Darbepoetin alfa; Epoetin alfa; Erythropoietin; Retrospective cohort study; Bone marrow; Oncology","score_opus":0.08688143157122795,"score_gpt":0.35472902064484113,"score_spread":0.26784758907361317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561937338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98786557,0.000037062182,0.00997545,0.0004622123,0.00004892293,0.0011544705,0.000049404523,0.00003333894,0.0003736001],"genre_scores_gemma":[0.99114424,0.0000026174507,0.00825165,0.000044017455,0.00005087386,0.00012024538,0.000029250728,0.000029778768,0.00032730377],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99860317,0.00011811205,0.00032860987,0.00025137048,0.00042065288,0.00027811297],"domain_scores_gemma":[0.99860454,0.0005454149,0.00006735992,0.00024801228,0.00032545722,0.00020924112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009442468,0.00011597014,0.0003051864,0.0003514537,0.000026799618,0.000008997372,0.00010330398,0.00008883137,0.000010484568],"category_scores_gemma":[0.0031722556,0.000108613836,0.000048728907,0.0003786735,0.000043359352,0.00012546047,0.0000817846,0.0001192628,0.00001339346],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08732511,0.005937428,0.20171143,0.0019942645,0.001521342,0.00070773,0.034033984,0.43247363,0.2235635,0.00047906302,0.007564809,0.0026877006],"study_design_scores_gemma":[0.07342168,0.016694356,0.12580107,0.0020713473,0.0009795101,0.00030628228,0.0050258962,0.57320803,0.19747883,0.0039004951,0.00031287572,0.0007996172],"about_ca_topic_score_codex":0.000039725022,"about_ca_topic_score_gemma":0.0000023664784,"teacher_disagreement_score":0.14073442,"about_ca_system_score_codex":0.00024722907,"about_ca_system_score_gemma":0.0004908258,"threshold_uncertainty_score":0.44291437},"labels":[],"label_agreement":null},{"id":"W2561981345","doi":"10.1182/blood.v120.21.4261.4261","title":"Utilization and Costs of Red Blood Cell Transfusions Pre- and Post-Azacitidine in Higher-Risk Myelodysplastic Syndromes","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Azacitidine; Myelodysplastic syndromes; Blood transfusion; Anemia; Internal medicine; Retrospective cohort study; Pediatrics; Surgery; Bone marrow","score_opus":0.025144437800082985,"score_gpt":0.2738148508525346,"score_spread":0.2486704130524516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561981345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946626,0.0031957624,0.000021780133,0.00029379234,0.00004554673,0.00056216604,0.00006276526,0.000030968364,0.0011246289],"genre_scores_gemma":[0.99626124,0.0026726753,0.00045889636,0.00003384009,0.00006017167,0.000023915885,0.000037832957,0.000029228077,0.00042217292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998781,0.00010128379,0.0002866123,0.00023411207,0.00025315717,0.00034379956],"domain_scores_gemma":[0.9991497,0.00025202104,0.00006810184,0.00019334201,0.00009204758,0.0002448116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002858888,0.00015461716,0.0003249661,0.00024519447,0.00005343235,0.000008929605,0.000054447533,0.0001443535,0.00010461675],"category_scores_gemma":[0.00020303421,0.00013624033,0.000031758995,0.00031613692,0.00011861679,0.0001321159,0.00005627488,0.00026558363,0.0000033706112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041722972,0.0022445603,0.6348555,0.00058313453,0.00017344549,0.000076182994,0.0013290917,0.0000013145338,0.3557626,0.00018815648,0.00007313474,0.0042956728],"study_design_scores_gemma":[0.009681648,0.0007819472,0.9365926,0.00023463124,0.0006512357,0.000281645,0.00017713482,0.000101124126,0.051215794,0.000012286613,0.00012544615,0.00014454973],"about_ca_topic_score_codex":0.00018041162,"about_ca_topic_score_gemma":0.0000332174,"teacher_disagreement_score":0.3045468,"about_ca_system_score_codex":0.000032464635,"about_ca_system_score_gemma":0.000087006454,"threshold_uncertainty_score":0.5555719},"labels":[],"label_agreement":null},{"id":"W2562208778","doi":"10.1182/blood.v126.23.3754.3754","title":"The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Myelodysplastic syndromes; Azacitidine; Adverse effect; Population; Neutropenia; Lenalidomide; Oncology; Multiple myeloma; Chemotherapy; Bone marrow","score_opus":0.0195225028924699,"score_gpt":0.2586856472973217,"score_spread":0.23916314440485179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562208778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971785,0.00035479208,0.000028650025,0.00041825688,0.00007703591,0.0009770008,0.00013006803,0.000049012673,0.00078670244],"genre_scores_gemma":[0.99801755,0.00030429635,0.00063635997,0.00005327966,0.000052251857,0.00004112782,0.000046813057,0.000042560205,0.0008057878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972639,0.00021869899,0.000620095,0.0004895646,0.00082260027,0.00058513775],"domain_scores_gemma":[0.9975677,0.00061339507,0.00028213242,0.00072062446,0.00043414184,0.00038197436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007832662,0.00030647728,0.0008399584,0.00013936004,0.00015523816,0.000035254794,0.00027312027,0.00014898373,0.000044284865],"category_scores_gemma":[0.000520095,0.00017437233,0.0000540627,0.0005969077,0.00048499226,0.00015810816,0.00020235188,0.0006161437,0.000018376033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0101122,0.0007179856,0.98591083,0.0001887804,0.0005003627,0.00019414334,0.00031797038,0.000076822704,0.00011122134,0.000059750677,0.00076686894,0.0010430363],"study_design_scores_gemma":[0.024059646,0.0021498653,0.9696555,0.0002824303,0.0004172843,0.00010253987,0.00026221067,0.00031594263,0.0010109803,0.000074126285,0.001431199,0.0002382599],"about_ca_topic_score_codex":0.000370583,"about_ca_topic_score_gemma":0.00025922316,"teacher_disagreement_score":0.016255341,"about_ca_system_score_codex":0.0005018949,"about_ca_system_score_gemma":0.00090622867,"threshold_uncertainty_score":0.7110697},"labels":[],"label_agreement":null},{"id":"W2562222354","doi":"10.1182/blood.v110.11.594.594","title":"Mutations That Cooperate with Nf1 Inactivation in Leukemogenesis Influence Therapeutic Response to MEK Inhibition.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Haematopoiesis; Myeloid leukemia; Cancer research; Progenitor cell; Leukemia; MEK inhibitor; Biology; Myeloid; Immunology; MAPK/ERK pathway; Stem cell; Kinase; Genetics","score_opus":0.02148522940554561,"score_gpt":0.2969390722871466,"score_spread":0.275453842881601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562222354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99504006,0.00006627501,0.0012943539,0.002200166,0.000011647921,0.0007729197,0.0000058595215,0.00006515171,0.00054354995],"genre_scores_gemma":[0.99592465,0.00001335741,0.0019008233,0.0015345579,0.000037362974,0.00008419681,0.00002082891,0.00003420899,0.00045003238],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998563,0.00012253638,0.00023175686,0.0002956601,0.0004150382,0.00037200772],"domain_scores_gemma":[0.99885124,0.00035422266,0.00004798432,0.00029743573,0.00026788426,0.00018123531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094332435,0.00014747151,0.00019438208,0.00054172706,0.00009433695,0.000029445824,0.000076613826,0.0000887962,0.00003895232],"category_scores_gemma":[0.00032939468,0.00012120393,0.000025085346,0.0013046995,0.00007935502,0.00019651887,0.000033765653,0.0002453618,0.000088063236],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007006736,0.00054752245,0.08666149,0.000042290252,0.000093853414,0.00073187216,0.0019507939,0.00045623406,0.8995752,0.00013944891,0.0000576534,0.0027369477],"study_design_scores_gemma":[0.0047319103,0.0005564545,0.5818203,0.00012455894,0.000050873507,0.00016584505,0.0006458962,0.000031813914,0.41129652,0.000025820655,0.0004120977,0.00013793142],"about_ca_topic_score_codex":0.00018248257,"about_ca_topic_score_gemma":0.00021012328,"teacher_disagreement_score":0.4951588,"about_ca_system_score_codex":0.0004486384,"about_ca_system_score_gemma":0.0006297159,"threshold_uncertainty_score":0.49425527},"labels":[],"label_agreement":null},{"id":"W2562528138","doi":"10.1182/blood.v126.23.174.174","title":"CSF3R Mutations Represent a Novel Therapeutic Target in Pediatric AML with a High Degree of Overlap with CEBPA Mutations: a Report from COG AAML0531 and COG/NCI Target AML Initiative","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"CEBPA; Medicine; Missense mutation; Cohort; Mutation; Oncology; Cog; Myeloid leukemia; Myeloid; Cancer research; Internal medicine; Genetics; Biology; Gene","score_opus":0.053502024397418704,"score_gpt":0.2992414327905266,"score_spread":0.24573940839310793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562528138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908671,0.0014763902,0.0029669388,0.0010023967,0.00003651424,0.0014966354,0.00027664885,0.00006708003,0.0018103028],"genre_scores_gemma":[0.96250796,0.000061515915,0.035952672,0.00020356121,0.00016309203,0.00028157962,0.0005744807,0.00006673052,0.0001884161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971479,0.0001487634,0.00064044166,0.00067513733,0.0009393637,0.0004483582],"domain_scores_gemma":[0.99727076,0.0005453342,0.0004086588,0.000642621,0.0007927209,0.00033990588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005159112,0.0003111593,0.00065970566,0.00047466793,0.00007101101,0.00003316489,0.0001590483,0.00015514635,0.00005062835],"category_scores_gemma":[0.00076899776,0.00023585245,0.000052366308,0.0011049818,0.00034318023,0.000249587,0.00009895795,0.000529014,0.0000106139],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021371017,0.0029416254,0.9775024,0.00018017509,0.0012383988,0.0040085167,0.008189216,0.00024564148,0.0026330594,0.0002037747,0.0005457506,0.00017433356],"study_design_scores_gemma":[0.05038843,0.0033863431,0.9204263,0.00031741738,0.002508776,0.0023004324,0.006506984,0.0018648406,0.008525774,0.0027390276,0.0003258437,0.0007098069],"about_ca_topic_score_codex":0.0021425146,"about_ca_topic_score_gemma":0.0003995603,"teacher_disagreement_score":0.05707608,"about_ca_system_score_codex":0.00015854005,"about_ca_system_score_gemma":0.0023552312,"threshold_uncertainty_score":0.96177834},"labels":[],"label_agreement":null},{"id":"W2562950597","doi":"10.1158/1538-7445.am2015-4260","title":"Abstract 4260: Clinical testing and implementation of the TruSight Myeloid Next Generation Sequencing (NGS) panel for identification of clinically relevant variants in hematological malignancies","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"CEBPA; Myeloid leukemia; Myeloid; Concordance; DNA sequencing; Computational biology; Medicine; Myeloproliferative neoplasm; CHEK2; Sanger sequencing; Cancer; Biology; Gene; Cancer research; Oncology; Genetics; Internal medicine; Germline mutation; Mutation; Myelofibrosis; Bone marrow","score_opus":0.5251459821520618,"score_gpt":0.5129109473678247,"score_spread":0.012235034784237042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562950597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961682,0.00031881058,0.00021291817,0.0015316078,0.00012334053,0.0015384643,0.000030912415,0.000009475734,0.00006625181],"genre_scores_gemma":[0.9968438,0.00037603267,0.002172225,0.00005867178,0.00020945183,0.00023349094,0.00001638174,0.000018926135,0.0000710227],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9964929,0.0004095782,0.001505584,0.0004048239,0.0008068732,0.0003802185],"domain_scores_gemma":[0.99585575,0.0017265059,0.00038741514,0.00037525498,0.0015032424,0.00015185561],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010382999,0.000105318686,0.00039977374,0.00017883164,0.00009614909,0.000035241577,0.00023446145,0.00017192464,0.000025463505],"category_scores_gemma":[0.010344733,0.00007354821,0.00007103567,0.0006013101,0.00042698256,0.00016505826,0.00016418294,0.0005296962,0.000002601654],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046642238,0.00008455278,0.17017739,0.000392346,0.000033780183,0.000011306763,0.0007700375,0.000038678263,0.8074035,0.00033486882,0.0006639487,0.019623172],"study_design_scores_gemma":[0.0059484057,0.0010035674,0.78343195,0.00057315733,0.000055923425,0.00006042439,0.0046774843,0.013481814,0.18875869,0.0016947747,0.00013652901,0.00017726896],"about_ca_topic_score_codex":0.0011218328,"about_ca_topic_score_gemma":0.00025760042,"teacher_disagreement_score":0.61864483,"about_ca_system_score_codex":0.00051109964,"about_ca_system_score_gemma":0.0027063088,"threshold_uncertainty_score":0.99799156},"labels":[],"label_agreement":null},{"id":"W2562964272","doi":"10.1182/blood.v108.11.3140.3140","title":"Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from 10/10 Matched Unrelated Donors (MUD) with a Myeloablative Once Daily IV Fludarabine (Flu)/Busulfan Based Regimen (FLUBUP) with Thymoglobulin: Outcomes According to Stem Cell Source.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Medicine; Thymoglobulin; Busulfan; Internal medicine; Fludarabine; Transplantation; Gastroenterology; Surgery; Folinic acid; Regimen; Mucositis; Total body irradiation; Chemotherapy; Hematopoietic stem cell transplantation; Cyclophosphamide; Tacrolimus; Fluorouracil","score_opus":0.013045653217476236,"score_gpt":0.2365764519191797,"score_spread":0.22353079870170345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562964272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96455264,0.00039693463,0.027131084,0.0012585003,0.000042143416,0.0038232806,0.00021891823,0.0004351356,0.002141335],"genre_scores_gemma":[0.9677495,0.00002031739,0.020502752,0.00034846226,0.00010201398,0.0005913655,0.0005943461,0.0002316934,0.009859559],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99518377,0.00022606342,0.0010153797,0.0013622973,0.0010155432,0.0011969754],"domain_scores_gemma":[0.9966272,0.00092197704,0.00051201857,0.0010056136,0.00047606713,0.00045713378],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045529814,0.00088644976,0.0015453137,0.00042161596,0.0003272634,0.00013062646,0.00050636206,0.00041188567,0.00018144741],"category_scores_gemma":[0.000017624256,0.0006457217,0.0002459006,0.0010927989,0.0001647342,0.00026849896,0.00007141719,0.0005634458,0.00017000278],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05827511,0.010659997,0.49415272,0.012057028,0.0040499535,0.007951169,0.023574483,0.014352469,0.36542538,0.00039341935,0.0062169638,0.0028912853],"study_design_scores_gemma":[0.0722929,0.0058727046,0.023485905,0.0029491975,0.003896666,0.00045542736,0.011787272,0.0032719187,0.8731509,0.00012598907,0.00050068815,0.0022104213],"about_ca_topic_score_codex":0.0005651786,"about_ca_topic_score_gemma":0.00011342903,"teacher_disagreement_score":0.50772554,"about_ca_system_score_codex":0.0003981373,"about_ca_system_score_gemma":0.000654835,"threshold_uncertainty_score":0.9995994},"labels":[],"label_agreement":null},{"id":"W2563337857","doi":"10.1182/blood.v126.23.170.170","title":"Comprehensive Genomic and Transcript Profiling of CBL Gene in Childhood AML: A Report from Children's Oncology Group Studies AAML03P1, AAML0531 and COG/NCI Target AML Initiative","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Biology; Exon; Genetics; Gene; Alternative splicing; Cancer research; Molecular biology","score_opus":0.0552990024581399,"score_gpt":0.3227903526443341,"score_spread":0.2674913501861942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563337857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738069,0.023477668,0.000050667073,0.0006798196,0.000081481674,0.0013515195,0.00015836461,0.000048257338,0.00034530694],"genre_scores_gemma":[0.9830997,0.0014514837,0.014495442,0.0003314424,0.00021649087,0.000082647915,0.00024986718,0.000051270952,0.000021660177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975677,0.00024769508,0.0007117025,0.00065875985,0.00036497504,0.00044913308],"domain_scores_gemma":[0.99844116,0.000296374,0.0002533134,0.00035605658,0.00035818256,0.0002948913],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050203875,0.00031214522,0.0011217896,0.00027707775,0.00006381353,0.0000132551695,0.00012617011,0.00022084385,0.000007639725],"category_scores_gemma":[0.00043927605,0.00027866082,0.00007006367,0.00025514208,0.00050528016,0.00012128285,0.00021810416,0.00058505294,0.0000033892106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001535894,0.0027996278,0.7058512,0.00037256101,0.0044950703,0.0044977926,0.040740788,0.000009285144,0.23623571,0.00008713745,0.0008123819,0.0025625518],"study_design_scores_gemma":[0.031062903,0.0025307217,0.8952688,0.00022705928,0.0008518351,0.0024536918,0.009149897,0.00010678855,0.05661414,0.0007567327,0.0005474857,0.0004299783],"about_ca_topic_score_codex":0.00045518563,"about_ca_topic_score_gemma":0.00007006928,"teacher_disagreement_score":0.18941757,"about_ca_system_score_codex":0.00019869355,"about_ca_system_score_gemma":0.00075789104,"threshold_uncertainty_score":0.99996656},"labels":[],"label_agreement":null},{"id":"W2563488799","doi":"10.1182/blood.v118.21.254.254","title":"CPX-351: A Randomized Phase 2b Study of CPX-351 v. Intensive Salvage Therapy in '65 Yo First Relapse AML Patients: Initial Efficacy and Safety Report","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Regimen; Cytarabine; Salvage therapy; Gastroenterology; Randomized controlled trial; Phases of clinical research; Surgery; Leukemia; Clinical trial; Chemotherapy","score_opus":0.035677114588055434,"score_gpt":0.3225631896485131,"score_spread":0.28688607506045766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563488799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919907,0.0003010433,0.00002116356,0.0001875336,0.00013492908,0.0051786755,0.000025998297,0.00006221291,0.0020977415],"genre_scores_gemma":[0.9983712,0.00043722577,0.00029131942,0.00027536563,0.00011722696,0.00022014669,0.00008417852,0.00006748182,0.00013590093],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963639,0.0004973769,0.0013277539,0.0006546257,0.00067076646,0.00048557698],"domain_scores_gemma":[0.9968825,0.00075338,0.00043696575,0.0008691589,0.0007944611,0.0002635157],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015020537,0.0003577756,0.0014849666,0.0004277386,0.00009593908,0.000015527601,0.00022096827,0.00019925322,0.00021225364],"category_scores_gemma":[0.0047138734,0.00027314678,0.0001692579,0.00047679484,0.00037675118,0.00014739893,0.00021137702,0.0006851938,0.000014686052],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7149354,0.05245232,0.13351479,0.00022153147,0.0029299823,0.0109973885,0.07267784,9.848533e-7,0.0020557872,0.000045781886,0.001293693,0.008874454],"study_design_scores_gemma":[0.9015172,0.0069037713,0.08354698,0.00025064603,0.00051101705,0.00025380144,0.002759719,0.00003145221,0.0036209116,0.00003732261,0.00027148463,0.00029568968],"about_ca_topic_score_codex":0.0011803262,"about_ca_topic_score_gemma":0.00012245866,"teacher_disagreement_score":0.18658178,"about_ca_system_score_codex":0.000112062604,"about_ca_system_score_gemma":0.00027820576,"threshold_uncertainty_score":0.99997205},"labels":[],"label_agreement":null},{"id":"W2563604752","doi":"10.1182/blood.v122.21.3393.3393","title":"Lymphocyte Recovery At Day 28 Post-Transplant Is Predictive Of Relapse In Patients With Acute Myeloid Leukemia Transplanted With Peripheral Blood Stem Cell Grafts","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Transplantation; Univariate analysis; Myeloid leukemia; Population; Lymphocyte; Hematopoietic stem cell transplantation; Gastroenterology; Surgery; Leukemia; Donor lymphocyte infusion; Multivariate analysis","score_opus":0.004266038600922059,"score_gpt":0.19102897523805715,"score_spread":0.18676293663713509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563604752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99456084,0.00023586211,0.000048985523,0.000118825774,0.00005205686,0.0023242065,0.0009816716,0.00009539912,0.0015821331],"genre_scores_gemma":[0.9954862,0.0006325595,0.00074461155,0.0002829616,0.000049581777,0.00019698005,0.00055954774,0.00013543424,0.0019121075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962712,0.00017343464,0.0006736774,0.0008341932,0.0011385577,0.000908934],"domain_scores_gemma":[0.9979025,0.00013781805,0.00024830966,0.00076962315,0.0005192311,0.00042251288],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021241004,0.0005660036,0.0008979591,0.00036339037,0.00010436768,0.000029455294,0.0003537763,0.00033935969,0.00026705986],"category_scores_gemma":[0.000007921455,0.0004023569,0.00015165063,0.000626599,0.00026647848,0.00040201592,0.00006847129,0.00062785245,0.000057037316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030659767,0.0039000527,0.8839045,0.0012173175,0.003574138,0.0021704594,0.010818706,0.000086245665,0.062156197,0.0000035906123,0.00043309364,0.001075915],"study_design_scores_gemma":[0.09288655,0.014285677,0.66152155,0.0019712872,0.0029047611,0.0006666389,0.00044559885,0.00025885296,0.2241283,0.0000039450438,0.000092976836,0.0008338231],"about_ca_topic_score_codex":0.0010566585,"about_ca_topic_score_gemma":0.00019494104,"teacher_disagreement_score":0.22238293,"about_ca_system_score_codex":0.00088399375,"about_ca_system_score_gemma":0.001309453,"threshold_uncertainty_score":0.9998428},"labels":[],"label_agreement":null},{"id":"W2563880171","doi":"10.1182/blood.v114.22.3829.3829","title":"Two-Year Analysis of Efficacy and Safety of Deferasirox (Exjade®) Treatment in Myelodysplastic Syndrome Patients Enrolled in the US03 Study.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Deferasirox; Medicine; Tolerability; Myelodysplastic syndromes; International Prognostic Scoring System; Internal medicine; Creatinine; Adverse effect; Anemia; Ferritin; Gastroenterology; Pediatrics; Surgery; Thalassemia; Bone marrow","score_opus":0.013413101692993075,"score_gpt":0.28984071861084504,"score_spread":0.27642761691785195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563880171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99784386,0.00009233959,0.0000010574537,0.00010041652,0.000006451127,0.0013310134,0.000016152171,0.0000062075715,0.0006025145],"genre_scores_gemma":[0.9997236,0.000059569502,0.0000865547,0.000022434357,0.0000075242638,0.000024432136,0.000026336957,0.000008920364,0.00004062092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829125,0.00023875722,0.00051297754,0.0002655684,0.00044921093,0.00024223517],"domain_scores_gemma":[0.9989296,0.00043732268,0.00010188353,0.00040098702,0.00006286421,0.00006733421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040944226,0.00015700585,0.00074537535,0.0007133958,0.000023426912,0.00000607874,0.0001345581,0.00005755578,0.000038482685],"category_scores_gemma":[0.00022677933,0.00010045191,0.00009417912,0.001521537,0.000056489032,0.00003074662,0.00003358738,0.00016600722,0.0000025131399],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011743221,0.01023668,0.98305863,0.000021242575,0.0010423582,0.00013995856,0.0030104956,0.000118440264,0.00036244094,0.000027402399,0.0000028194672,0.00080521114],"study_design_scores_gemma":[0.038882993,0.0040143747,0.95404273,0.000045739067,0.001731499,0.000010222885,0.00092944794,0.00012551658,0.00013807214,0.0000060569582,0.0000036346323,0.000069703405],"about_ca_topic_score_codex":0.0002563806,"about_ca_topic_score_gemma":0.00017086472,"teacher_disagreement_score":0.03770867,"about_ca_system_score_codex":0.00011879223,"about_ca_system_score_gemma":0.000100589554,"threshold_uncertainty_score":0.40963098},"labels":[],"label_agreement":null},{"id":"W2563965053","doi":"10.1182/blood.v126.23.2416.2416","title":"Copy Number Variants Underlying Inherited Bone Marrow Failure Syndromes","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Janeway Children's Health and Rehabilitation Centre; London Health Sciences Centre; McMaster University; University of Alberta; Centre hospitalier universitaire de Québec; Centre Hospitalier Universitaire de Sherbrooke; Centre Hospitalier Universitaire Sainte-Justine; CancerCare Manitoba; Population Health Research Institute; Children's Hospital of Eastern Ontario; BC Children's Hospital; Royal University Hospital; Montreal Children's Hospital; University of Toronto; SickKids Foundation; Princess Margaret Cancer Centre; Kingston General Hospital; University of Manitoba; Alberta Children's Hospital; Izaak Walton Killam Health Centre; Hospital for Sick Children","funders":"","keywords":"Copy-number variation; Exact test; SNP array; Genetics; Biology; Genotype; Genotype-phenotype distinction; Genetic testing; Bone marrow failure; SNP; Copy number analysis; Single-nucleotide polymorphism; Bioinformatics; Medicine; Gene; Genome; Internal medicine; Haematopoiesis","score_opus":0.06830775344702059,"score_gpt":0.3305787179845353,"score_spread":0.26227096453751475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563965053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97890997,0.00029867544,0.0001299472,0.0031852701,0.00010554048,0.00041603055,0.000011743411,0.00019934266,0.016743502],"genre_scores_gemma":[0.9859674,0.000023754566,0.007296415,0.00045968272,0.00016820717,0.00002968091,0.000049841914,0.00006112735,0.005943868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822813,0.00008697934,0.0002520878,0.00033860136,0.00059808104,0.0004961278],"domain_scores_gemma":[0.99867404,0.00006877287,0.000057826484,0.00048867223,0.00022195569,0.0004887163],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004050352,0.00019008594,0.00037379077,0.000112817055,0.00006800782,0.000049602862,0.00015603236,0.00019869645,0.00063319696],"category_scores_gemma":[0.0003856221,0.00016768233,0.00007296083,0.00046872988,0.000087513596,0.00014090376,0.00012455447,0.00045366504,0.0013823122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008064599,0.0028768298,0.6344813,0.0006225115,0.0016966664,0.013549797,0.0027479087,0.0000056789595,0.062415317,0.001682992,0.27588245,0.0032320737],"study_design_scores_gemma":[0.19919327,0.00490091,0.35084,0.002556715,0.0037537531,0.07739618,0.012636357,0.0018902088,0.05607519,0.0065584304,0.2798565,0.0043424987],"about_ca_topic_score_codex":0.00012990486,"about_ca_topic_score_gemma":0.000020802767,"teacher_disagreement_score":0.2836413,"about_ca_system_score_codex":0.00017148783,"about_ca_system_score_gemma":0.00057300704,"threshold_uncertainty_score":0.99939525},"labels":[],"label_agreement":null},{"id":"W2564033819","doi":"10.1182/blood.v124.21.1052.1052","title":"An Adverse Prognostic Effect of Homozygous TET2 Mutational Status on the Relapse Risk of Acute Myeloid Leukemia Patients of Normal Karyotype","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"CEBPA; NPM1; Internal medicine; Myeloid leukemia; Frameshift mutation; Medicine; Missense mutation; Oncology; Gastroenterology; Mutation; Leukemia; Nonsense mutation; Karyotype; Cancer research; Immunology; Biology; Genetics; Gene; Chromosome","score_opus":0.005191108252441897,"score_gpt":0.24640715071108205,"score_spread":0.24121604245864015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564033819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970801,0.000030080315,0.000023551092,0.000027261516,0.000062035324,0.0010092389,0.00025034437,0.000024342184,0.001493086],"genre_scores_gemma":[0.99902993,0.0000429329,0.00047859162,0.0000336882,0.00006803149,0.000042494412,0.0001956252,0.00003691398,0.000071789815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99753904,0.00048909936,0.00048218243,0.00026889078,0.0008604573,0.00036034387],"domain_scores_gemma":[0.9970581,0.0013573798,0.00038510145,0.00062347244,0.00040249096,0.00017346985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007963534,0.00020498887,0.00047450888,0.00018824109,0.00006646007,0.0000037656,0.00024981983,0.00012919179,0.000081518],"category_scores_gemma":[0.0018188134,0.0001310626,0.0001542717,0.00033889784,0.00031026208,0.000086364926,0.000074539224,0.00043638368,0.000031231622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036330232,0.0015510157,0.97208893,0.00045644675,0.0011017768,0.000054097618,0.00080142514,0.00019190171,0.014311032,0.00021928453,0.00029133074,0.0052997214],"study_design_scores_gemma":[0.013221501,0.014332385,0.8325624,0.00020702582,0.0015511953,0.000030632033,0.000058232054,0.0010146457,0.13675061,0.000058227695,0.000063100284,0.00015007664],"about_ca_topic_score_codex":0.0002195974,"about_ca_topic_score_gemma":0.0000075808084,"teacher_disagreement_score":0.13952658,"about_ca_system_score_codex":0.000111694506,"about_ca_system_score_gemma":0.00045270156,"threshold_uncertainty_score":0.53445774},"labels":[],"label_agreement":null},{"id":"W2564173457","doi":"10.1182/blood.v116.21.4194.4194","title":"Functional Role of BAALC In Leukemogenesis","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Bone marrow; Biology; Myeloid; Cancer research; Transplantation; Haematopoiesis; Retinoic acid; Leukemia; Myeloid leukemia; Immunology; Molecular biology; Stem cell; Cell culture; Cell biology; Medicine; Genetics; Internal medicine","score_opus":0.012358175209991905,"score_gpt":0.2550206340140814,"score_spread":0.24266245880408951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564173457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98823905,0.00012134062,0.000006437509,0.0002876747,0.000052917407,0.00013230996,0.0000047141493,0.000018031795,0.011137496],"genre_scores_gemma":[0.99765676,0.000012870287,0.0010890748,0.000073177725,0.00017781703,0.000015052516,0.000012108107,0.000013783923,0.00094934966],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992686,0.0000148647905,0.00015451854,0.00014158592,0.0002469296,0.0001734889],"domain_scores_gemma":[0.99951965,0.000055847177,0.000026193806,0.00023981044,0.00007701323,0.00008148499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001904124,0.00006417455,0.00015356747,0.00015527432,0.000015279238,0.0000029932285,0.000071606904,0.00009324472,0.0007408382],"category_scores_gemma":[0.0001547446,0.0000562136,0.000051327577,0.00022037154,0.000058890215,0.000031589512,0.000042922624,0.00028056538,0.000099790486],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008437441,0.0003704528,0.20304182,0.000024068291,0.000036321304,0.000027136051,0.000051675044,0.0000012807589,0.79216194,0.00046086634,0.00046272037,0.003277328],"study_design_scores_gemma":[0.0041480702,0.000102129314,0.5813101,0.000015162942,0.00004456169,0.00011585006,0.00007694695,0.00010563972,0.40987533,0.0001779473,0.00396451,0.000063772495],"about_ca_topic_score_codex":0.00014246804,"about_ca_topic_score_gemma":0.00008052361,"teacher_disagreement_score":0.3822866,"about_ca_system_score_codex":0.000028336706,"about_ca_system_score_gemma":0.00033271,"threshold_uncertainty_score":0.8111658},"labels":[],"label_agreement":null},{"id":"W2564732019","doi":"10.1182/blood.v110.11.400.400","title":"NR2F6, the Mammalian Homologue of Drosophila Seven Up, Can Initiate Myelodysplasia and Acute Leukemia.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Biology; Haematopoiesis; Bone marrow; Stem cell; clone (Java method); Cancer research; Myelodysplastic syndromes; Leukemia; Cell culture; Immunology; Gene; Genetics","score_opus":0.01689573403599705,"score_gpt":0.28065460324198593,"score_spread":0.2637588692059889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564732019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875374,0.00030504348,0.000041873594,0.0022610442,0.000093739414,0.00050875376,0.000063975946,0.000051337767,0.009136863],"genre_scores_gemma":[0.99587274,0.00018427632,0.0005275334,0.00078640523,0.0002708513,0.000017103035,0.000040892613,0.000045348894,0.0022548737],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99819034,0.000073768904,0.00039052148,0.00032851822,0.00044195246,0.00057490246],"domain_scores_gemma":[0.99866414,0.0002224665,0.00012182319,0.00057143014,0.00015365978,0.00026646472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008410942,0.00021681133,0.00040573307,0.00017773297,0.00012896875,0.000019355239,0.0002690986,0.00020498045,0.000056816232],"category_scores_gemma":[0.00015254617,0.00015171006,0.00009180406,0.00038196173,0.00043561973,0.000058882008,0.00019258517,0.0005115183,0.000022505294],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056296405,0.0023068236,0.24212274,0.0020848368,0.008611324,0.03048891,0.026394345,0.000012475926,0.573007,0.020537756,0.03212796,0.05667619],"study_design_scores_gemma":[0.02461681,0.002207394,0.5634891,0.00034650764,0.0024007868,0.010510826,0.0022352869,0.0001044477,0.37982368,0.0027744279,0.010670889,0.0008198598],"about_ca_topic_score_codex":0.00045305584,"about_ca_topic_score_gemma":0.00022707274,"teacher_disagreement_score":0.32136634,"about_ca_system_score_codex":0.00015347746,"about_ca_system_score_gemma":0.00054905616,"threshold_uncertainty_score":0.6186557},"labels":[],"label_agreement":null},{"id":"W2564864293","doi":"10.1182/blood.v124.21.268.268","title":"Inhibition of Fatty Acid Oxidation with Avocatin B Selectively Targets AML Cells and Leukemia Stem Cells","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Leukemia & Lymphoma Society of Canada; University Health Network; Princess Margaret Cancer Centre; University of Waterloo","funders":"","keywords":"Leukemia; Stem cell; Myeloid leukemia; Cancer research; Clonogenic assay; Haematopoiesis; Biology; Bone marrow; Progenitor cell; Apoptosis; Immunology; Cell biology; Biochemistry","score_opus":0.010313414577760669,"score_gpt":0.23136432079772623,"score_spread":0.22105090621996556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564864293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934201,0.000082004975,0.003918029,0.00010823537,0.000019949975,0.00050725095,0.000012815356,0.00004768242,0.0018839188],"genre_scores_gemma":[0.99351627,0.000045048306,0.0056613195,0.000101784935,0.00009329088,0.000024943558,0.000025217116,0.000031782543,0.00050033705],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987234,0.000106530126,0.00023384264,0.0003151347,0.00035880663,0.00026231247],"domain_scores_gemma":[0.9991385,0.00008922904,0.00013757849,0.0002454298,0.00024743332,0.00014183226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035764583,0.0001579272,0.0002940205,0.0001364762,0.00006082261,0.000015927304,0.00005812149,0.000117582545,0.00002848321],"category_scores_gemma":[0.000032368098,0.0001273998,0.00003154337,0.00025904956,0.00011694887,0.00010781352,0.00004565623,0.00025656648,0.000032921467],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001793414,0.00015826736,0.0030852864,0.000254838,0.000067116314,0.000010195244,0.00039089326,0.0000060804578,0.99301535,0.00006031433,0.00040177556,0.002370541],"study_design_scores_gemma":[0.0047083246,0.0008875283,0.00964954,0.000116928306,0.000117842326,0.00003900835,0.00013754086,0.0003485226,0.98355055,0.000027540813,0.00029041225,0.00012624207],"about_ca_topic_score_codex":0.00006452653,"about_ca_topic_score_gemma":0.0000146510065,"teacher_disagreement_score":0.009464783,"about_ca_system_score_codex":0.00015296222,"about_ca_system_score_gemma":0.00027775025,"threshold_uncertainty_score":0.5195213},"labels":[],"label_agreement":null},{"id":"W2565019685","doi":"10.1182/blood.v120.21.1414.1414","title":"Outcome of Pediatric Patients with Acute Myeloid Leukemia and -5/5q-Abnormalities Enrolled On Five Children's Oncology Group Acute Myeloid Leukemia Treatment Protocols","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Acute promyelocytic leukemia; Cog; Leukemia; Myeloid; Hematology; Chromosome abnormality; Cancer; Bone marrow; Oncology; Gastroenterology; Chromosome; Karyotype; Biology","score_opus":0.01751639390199533,"score_gpt":0.29904683518655556,"score_spread":0.28153044128456023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565019685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97766536,0.00017019456,0.000013106211,0.00013955605,0.0000848149,0.019192485,0.00031626676,0.00013234296,0.0022858456],"genre_scores_gemma":[0.9851666,0.00034005393,0.0022183144,0.00032559093,0.0008569556,0.008226801,0.0004033733,0.00014727158,0.0023150223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99560624,0.00033391302,0.00096345134,0.0007459952,0.0010307175,0.0013197066],"domain_scores_gemma":[0.9972048,0.00033605986,0.0005194243,0.0009130534,0.00028670614,0.0007399807],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000566999,0.0007639021,0.0015523387,0.00058415864,0.00022836222,0.000039139428,0.00034068237,0.00047164925,0.00011282177],"category_scores_gemma":[0.000111317015,0.0005298878,0.00025115052,0.0005507847,0.00033662046,0.00038177153,0.00026108627,0.00072378723,0.00007876619],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041222326,0.0028075327,0.98328733,0.00020138345,0.0028183912,0.00015963412,0.0016490057,0.0000041192575,0.0004167562,0.00016104316,0.0004021609,0.003970422],"study_design_scores_gemma":[0.061629813,0.019162146,0.9084591,0.000102886646,0.0036990342,0.00032667257,0.00022642034,0.000014017975,0.0046080654,0.00001469867,0.0010829598,0.00067417684],"about_ca_topic_score_codex":0.0003245475,"about_ca_topic_score_gemma":0.000023541545,"teacher_disagreement_score":0.07482821,"about_ca_system_score_codex":0.0024455036,"about_ca_system_score_gemma":0.0012787138,"threshold_uncertainty_score":0.99971527},"labels":[],"label_agreement":null},{"id":"W2565471235","doi":"10.1182/blood.v124.21.2364.2364","title":"Differences of Somatic Mutations and Gene Expression in Blasts of Transient Leukemia and Acute Myeloid Leukemia of Down Syndrome","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; Ontario Institute for Cancer Research; Hospital for Sick Children","funders":"","keywords":"GATA1; Myeloid leukemia; Leukemia; clone (Java method); Exome sequencing; Cancer research; Myeloid; Bone marrow; Biology; Down syndrome; Mutation; Medicine; Haematopoiesis; Immunology; Gene; Genetics; Stem cell","score_opus":0.011146298884666804,"score_gpt":0.2516582278345652,"score_spread":0.2405119289498984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565471235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987127,0.00034362523,0.00020395817,0.000067196146,0.000014711606,0.00038035022,0.000030452664,0.000010905229,0.00023609294],"genre_scores_gemma":[0.99606955,0.00029221777,0.0035075538,0.000010705946,0.000011856879,0.000021267237,0.000015057455,0.000015770196,0.0000560108],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99856603,0.00009392628,0.0005190487,0.00024369157,0.00036417556,0.00021313802],"domain_scores_gemma":[0.999098,0.00025175087,0.00017140842,0.0002735115,0.00008026338,0.0001250702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026353248,0.00014970571,0.0006076448,0.00028877618,0.000026563699,0.00000502867,0.00010695594,0.000119974095,0.00002498106],"category_scores_gemma":[0.000115492054,0.000118058364,0.00004989095,0.00021637736,0.00031166573,0.000072855364,0.000069305584,0.00017920409,0.0000010162053],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013306213,0.00021375311,0.04662354,0.000983156,0.00013418718,0.00003344444,0.002060857,0.000011570575,0.94848347,0.00003705253,0.000013980544,0.0012719026],"study_design_scores_gemma":[0.0055819363,0.0007087354,0.55718625,0.00062805373,0.00023543126,0.0002211223,0.00024797703,0.0010721338,0.43387374,0.00014692992,0.0000036572346,0.00009404934],"about_ca_topic_score_codex":0.00012831046,"about_ca_topic_score_gemma":0.00002140762,"teacher_disagreement_score":0.51460975,"about_ca_system_score_codex":0.00007145331,"about_ca_system_score_gemma":0.0002917734,"threshold_uncertainty_score":0.48142803},"labels":[],"label_agreement":null},{"id":"W2565751798","doi":"10.1182/blood.v116.21.742.742","title":"Tyrosine Phosphorylation of Runx1 In Megakaryocytes by Src Family Kinases","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Tyrosine phosphorylation; Phosphorylation; Protein tyrosine phosphatase; Biology; Tyrosine; Receptor tyrosine kinase; Haematopoiesis; Proto-oncogene tyrosine-protein kinase Src; Cancer research; Cell biology; Molecular biology; Stem cell; Biochemistry","score_opus":0.011373860712128883,"score_gpt":0.26745458241470643,"score_spread":0.25608072170257756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565751798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993807,0.0010519021,0.000009809572,0.0004182899,0.00006229797,0.00029331946,0.00002091371,0.0000338571,0.0043025822],"genre_scores_gemma":[0.9977101,0.00013477493,0.001185843,0.00014416693,0.00008711674,0.000019143645,0.000060374285,0.000022384054,0.00063610746],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989925,0.000022116094,0.00024870195,0.00019590209,0.00030789894,0.00023285317],"domain_scores_gemma":[0.9993172,0.000112966685,0.00005905935,0.00030977532,0.000106328414,0.000094625684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024327011,0.00010741697,0.0002434624,0.00014171921,0.00002240353,0.000007900914,0.00011360173,0.00012493049,0.000129729],"category_scores_gemma":[0.0003353196,0.00009413426,0.000048656595,0.00031904917,0.00009869337,0.00007236002,0.000048391834,0.00037528796,0.00003122367],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011082875,0.00056212407,0.08078401,0.000053131702,0.00002707146,0.00003061902,0.00008705674,5.6326826e-7,0.91226214,0.00016445115,0.004097576,0.001820414],"study_design_scores_gemma":[0.004531478,0.00022668309,0.20348184,0.00005544147,0.0000518952,0.000022643373,0.00006530922,0.00012614724,0.7880175,0.00006635381,0.003261108,0.00009357229],"about_ca_topic_score_codex":0.00053101976,"about_ca_topic_score_gemma":0.000058029524,"teacher_disagreement_score":0.12424462,"about_ca_system_score_codex":0.00003509936,"about_ca_system_score_gemma":0.00017287316,"threshold_uncertainty_score":0.38386837},"labels":[],"label_agreement":null},{"id":"W2565816025","doi":"10.1182/blood.v122.21.sci-27.sci-27","title":"Novel Targeting Strategies for Leukemia-Initiating Cells in Myeloid Neoplasms","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Leukemia & Lymphoma Society of Canada; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Myeloid leukemia; Leukemia; Personalized medicine; Myeloid; Computational biology; Medicine; Bioinformatics; Biology; Cancer research; Immunology","score_opus":0.02240041980591328,"score_gpt":0.2745181585874696,"score_spread":0.2521177387815563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565816025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869199,0.00014305244,0.0019788325,0.00045759242,0.00009632377,0.0013170398,0.000020553032,0.00010494658,0.008961753],"genre_scores_gemma":[0.9531314,0.000029032228,0.044939224,0.00042779508,0.00041179842,0.00033130418,0.000052545063,0.00006360989,0.00061329757],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981672,0.00002914487,0.000430405,0.00037455113,0.00029430745,0.00070438103],"domain_scores_gemma":[0.9988476,0.00041711505,0.00009606439,0.00026545825,0.00019963383,0.00017415282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041837944,0.00020861567,0.00035612864,0.00019381374,0.00009630062,0.000104172024,0.00018010952,0.00016881805,0.00017327865],"category_scores_gemma":[0.00035523265,0.00018840184,0.00009882825,0.00028601976,0.00006437124,0.00031416168,0.00008981201,0.0004490731,0.00016558841],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053302596,0.00031448176,0.0029460322,0.00035117342,0.000077746176,0.00003876139,0.0008692155,0.0001261397,0.9894595,0.00049818144,0.0034562005,0.0018092371],"study_design_scores_gemma":[0.047493033,0.0016143274,0.020155195,0.00080111047,0.00031004456,0.00030989022,0.021038687,0.03466357,0.8638734,0.0022009583,0.0061789397,0.001360809],"about_ca_topic_score_codex":0.00081133994,"about_ca_topic_score_gemma":0.000042721724,"teacher_disagreement_score":0.12558609,"about_ca_system_score_codex":0.00024996366,"about_ca_system_score_gemma":0.0009838669,"threshold_uncertainty_score":0.76828045},"labels":[],"label_agreement":null},{"id":"W2565899626","doi":"10.1182/blood.v126.23.2562.2562","title":"Phase I Study of Non-Engrafting Allogeneic, Mismatched, Unmanipulated Peripheral Blood Mononuclear Cell Infusions to Treat Poor-Prognosis Acute Myeloid Leukemia","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Oncology; Myeloid; Gastroenterology; Leukemia; Immunology","score_opus":0.03356059748126945,"score_gpt":0.3130414238184905,"score_spread":0.27948082633722104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565899626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993466,0.00016580912,0.00003398455,0.00038606566,0.00007875386,0.0025839354,0.000048969516,0.00021721036,0.0030192775],"genre_scores_gemma":[0.9927085,0.000053768705,0.0044549517,0.00031418173,0.00026216102,0.00017268588,0.00007938186,0.00017159498,0.0017827909],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959489,0.00019890658,0.000914894,0.0008886611,0.0010725242,0.00097609113],"domain_scores_gemma":[0.99683505,0.00009908185,0.00022973602,0.0009626414,0.0006411961,0.0012322675],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061130465,0.0005623215,0.0010847567,0.00049209,0.00021075098,0.00006608482,0.0005967589,0.00032219986,0.00015440544],"category_scores_gemma":[0.00021318799,0.0005043191,0.00023971086,0.0012134742,0.00010035026,0.00016515976,0.0005585748,0.0007228084,0.00013096789],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015841658,0.019058222,0.022222027,0.00015760063,0.0013850577,0.0017207442,0.014485075,0.0002942315,0.93383557,0.000002041538,0.003080913,0.0021743337],"study_design_scores_gemma":[0.14210767,0.026879225,0.004974627,0.0002202298,0.0066400324,0.0004721236,0.017182907,0.0028801684,0.79688424,0.0000103833345,0.0006714061,0.0010769705],"about_ca_topic_score_codex":0.001719495,"about_ca_topic_score_gemma":0.000073751784,"teacher_disagreement_score":0.1405235,"about_ca_system_score_codex":0.00043454772,"about_ca_system_score_gemma":0.00096459367,"threshold_uncertainty_score":0.99974084},"labels":[],"label_agreement":null},{"id":"W2566445060","doi":"10.1158/1538-7445.transcagen-a2-14","title":"Abstract A2-14: Integrated genetic and epigenetic analysis of model and patient acute myeloid leukemias","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Centre Hospitalier Universitaire Sainte-Justine; Université Laval","funders":"","keywords":"Myeloid leukemia; Epigenetics; Leukemia; Context (archaeology); Fusion gene; Cancer research; DNA methylation; Chromosomal translocation; Biology; Myeloid; CD34; Gene; Immunology; Genetics; Gene expression; Stem cell","score_opus":0.09162343728472427,"score_gpt":0.3942510717701566,"score_spread":0.30262763448543234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566445060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98963636,0.0076792003,0.00014185756,0.0008129044,0.000028222854,0.0006446317,0.000115219664,0.000024505965,0.0009171042],"genre_scores_gemma":[0.99118704,0.006293243,0.0012847366,0.000109815366,0.000041967254,0.00013614552,0.000038233316,0.00004349479,0.0008653177],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9967898,0.00015706588,0.00045132462,0.00060023397,0.0013035283,0.0006980383],"domain_scores_gemma":[0.996922,0.00018937708,0.00008310901,0.0005932076,0.0014087481,0.000803537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009071325,0.00021469583,0.00063998403,0.0012046711,0.00009832591,0.00005075994,0.00021815441,0.00019006353,0.0001435422],"category_scores_gemma":[0.00035935504,0.0001734926,0.000090521185,0.001955041,0.000708227,0.0000829524,0.00032684868,0.0008415075,0.000012686512],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006393553,0.0005870876,0.080463,0.001008248,0.010851847,0.000919578,0.014099481,0.02204698,0.4840353,0.00016547863,0.035990704,0.34343874],"study_design_scores_gemma":[0.012103415,0.003542866,0.43757778,0.0006688017,0.0039721937,0.00013821182,0.0050020423,0.4313918,0.095684834,0.0011934146,0.007553259,0.0011713854],"about_ca_topic_score_codex":0.0027007004,"about_ca_topic_score_gemma":0.000334353,"teacher_disagreement_score":0.40934482,"about_ca_system_score_codex":0.0010211215,"about_ca_system_score_gemma":0.002450879,"threshold_uncertainty_score":0.70748234},"labels":[],"label_agreement":null},{"id":"W2566555267","doi":"10.1073/pnas.1617929114","title":"The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development","year":2016,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; Government of Canada; Leukemia and Lymphoma Society","keywords":"IDH2; Angioimmunoblastic T-cell lymphoma; Isocitrate dehydrogenase; Cancer research; Mutation; IDH1; Biology; Lymphoma; Biomarker; Pathology; T cell; Gene; Medicine; Immunology; Genetics; Immune system; Enzyme","score_opus":0.0222528194832915,"score_gpt":0.2798492841099209,"score_spread":0.2575964646266294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566555267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943036,0.00016635786,6.333722e-7,0.0041259914,0.000008515853,0.00034866956,0.0000039258034,0.000008659677,0.0010336362],"genre_scores_gemma":[0.9989437,0.00008890933,0.00041479967,0.00009181705,0.00001921077,0.000019666928,1.4833373e-7,0.0000060904713,0.0004156923],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978787,0.00001238167,0.00031360926,0.00023996046,0.0013066576,0.00024872742],"domain_scores_gemma":[0.9986871,0.0004931381,0.0003496398,0.000011069001,0.00040883466,0.000050216036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002203944,0.00010475551,0.00015647874,0.00018573285,0.00023373388,0.000030317333,0.00037592388,0.000067453606,0.0000027766707],"category_scores_gemma":[0.0014646953,0.00004363338,0.00002508312,0.00083809276,0.0009868187,0.00031693027,0.00010953909,0.00008293736,0.0000016249361],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019568401,0.00013412499,0.032841057,0.00007268028,0.000042290016,1.0403718e-7,0.00077539013,0.0000068681748,0.9603327,0.00082515564,0.0003255146,0.0044484218],"study_design_scores_gemma":[0.0013818555,0.00011357156,0.3533041,0.00041365583,0.00001104896,0.000021572161,0.00025372178,0.00019953388,0.643238,0.0009277899,0.00007196064,0.00006319168],"about_ca_topic_score_codex":0.00001016746,"about_ca_topic_score_gemma":8.287585e-7,"teacher_disagreement_score":0.32046303,"about_ca_system_score_codex":0.00037349993,"about_ca_system_score_gemma":0.00047688562,"threshold_uncertainty_score":0.36359745},"labels":[],"label_agreement":null},{"id":"W2566694224","doi":"10.1182/blood.v118.21.939.939","title":"Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status – Comparison of Morphology and Multidimensional Flow Cytometry; A Report From the Children's Oncology Group AML Protocol AAML0531","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Hospital for Sick Children","funders":"","keywords":"Induction chemotherapy; Medicine; Internal medicine; Chemotherapy; Oncology; Bone marrow; Transplantation; Flow cytometry; Gastroenterology; Immunology","score_opus":0.03407734058277411,"score_gpt":0.3428306592702668,"score_spread":0.3087533186874927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566694224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750258,0.00014781386,0.0005390829,0.00056223717,0.00017486754,0.02310725,0.00020030752,0.000059501912,0.0001831943],"genre_scores_gemma":[0.9079414,0.000027165665,0.08700811,0.00016748784,0.0001862431,0.0041034194,0.0004635706,0.00005519244,0.00004743079],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99504006,0.0008525057,0.0013248142,0.0009435987,0.0011445845,0.0006944131],"domain_scores_gemma":[0.99569213,0.0011452934,0.0010469429,0.0011114773,0.0006919708,0.00031216352],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019191778,0.00045199686,0.0010926892,0.00037512986,0.00027035855,0.000011344648,0.0003374775,0.00053428754,0.00042449243],"category_scores_gemma":[0.0011829534,0.00025709032,0.00022130096,0.0006739142,0.0007913253,0.0001254404,0.00053977355,0.0013163349,0.000008087419],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021258914,0.0032485386,0.20798114,0.000068932364,0.00052092155,0.0003344215,0.0005535044,0.00001398401,0.778334,0.000022194235,0.0006887896,0.0061076405],"study_design_scores_gemma":[0.009293722,0.004131362,0.81832284,0.000119853226,0.00047472108,0.001591885,0.0009936908,0.0048782993,0.15957165,0.000037560723,0.0003264261,0.00025796006],"about_ca_topic_score_codex":0.0019381708,"about_ca_topic_score_gemma":0.000039578812,"teacher_disagreement_score":0.6187624,"about_ca_system_score_codex":0.00026681097,"about_ca_system_score_gemma":0.0009960855,"threshold_uncertainty_score":0.99998814},"labels":[],"label_agreement":null},{"id":"W2566718115","doi":"10.1182/blood.v106.11.238.238","title":"The First Fully Experimental In Vivo Model of Human Leukemogenesis: Human Hematopoietic Stem Cells Infected with MLL-ENL Induce Pro-B Acute Lymphoblastic Leukemia in NOD/SCID Mice.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Biology; Haematopoiesis; Leukemia; Myeloid; Bone marrow; Severe combined immunodeficiency; Progenitor cell; Immunology; Stem cell; Acute lymphocytic leukemia; Cancer research; Transplantation; CD19; Molecular biology; Antigen; In vivo; Medicine; Cell biology; Internal medicine","score_opus":0.018603602659400677,"score_gpt":0.2674211626186581,"score_spread":0.24881755995925744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566718115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966894,0.00036002762,0.000016359321,0.00018213932,0.000023521798,0.00154513,0.000014239975,0.0000842612,0.0010849488],"genre_scores_gemma":[0.9980683,0.00003730345,0.00030948946,0.00014171815,0.00010463312,0.00034322994,0.000012241367,0.00011422248,0.00086887466],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996522,0.00011869675,0.00092155434,0.0006763101,0.00084793783,0.0009134806],"domain_scores_gemma":[0.9983715,0.00013724931,0.0002589211,0.0008438008,0.00015783805,0.00023068557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045770407,0.0004791278,0.00075625465,0.0004683783,0.00027081365,0.00005660136,0.00058177573,0.00027655053,0.000063179396],"category_scores_gemma":[0.000017756269,0.00035618004,0.0001223737,0.00081326516,0.00035840165,0.00019626749,0.00027196738,0.00058574206,0.00005049904],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044723556,0.0012384476,0.00674365,0.00022310557,0.0002313206,0.00025572386,0.003257876,0.0013454494,0.9857749,0.00013375786,0.0002785212,0.00007005329],"study_design_scores_gemma":[0.016569085,0.0010865176,0.0021446196,0.0005754819,0.00021177653,0.00018673726,0.00106863,0.0069714566,0.9707053,0.000016336966,0.000058223355,0.00040583534],"about_ca_topic_score_codex":0.0004114871,"about_ca_topic_score_gemma":0.0017481816,"teacher_disagreement_score":0.01612185,"about_ca_system_score_codex":0.0024183083,"about_ca_system_score_gemma":0.0015614752,"threshold_uncertainty_score":0.999889},"labels":[],"label_agreement":null},{"id":"W2566911125","doi":"10.1182/blood.v124.21.16.16","title":"Engraftment Patterns in NOD.SCID Mice Predict Outcome in Human AML","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"CD33; Xenotransplantation; Myeloid; Haematopoiesis; Stem cell; Nod; CD19; Biology; Transplantation; Leukemia; Cancer research; CD34; Myeloid leukemia; Immunology; Flow cytometry; Severe combined immunodeficiency; Immunophenotyping; Medicine; In vivo; Internal medicine; Cell biology","score_opus":0.02216890756424876,"score_gpt":0.3090627421746761,"score_spread":0.28689383461042733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566911125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943841,0.00004746182,0.00003988903,0.000997666,0.00004728593,0.00052589516,0.000010305316,0.000052936975,0.003894442],"genre_scores_gemma":[0.9979229,0.000013913998,0.00025341692,0.0005864145,0.00020367169,0.000077709556,0.000052491967,0.00003273047,0.00085678033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826854,0.00011661733,0.00040463614,0.00034187283,0.00039302855,0.00047530571],"domain_scores_gemma":[0.99923736,0.00009241869,0.000047600697,0.00042862384,0.00003470777,0.00015928784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006429003,0.00016040198,0.00035041422,0.00031639743,0.000031787844,0.000016040662,0.00020564534,0.00011904703,0.00020431423],"category_scores_gemma":[0.00018691608,0.00014044756,0.000062506726,0.00022843866,0.000041816053,0.00004873445,0.00012605084,0.00051815814,0.00016528186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033900404,0.0007375734,0.9833664,0.00012066817,0.00002970789,0.00022320906,0.00034370023,0.0000023660812,0.014216354,0.000087221146,0.00026459858,0.0005743599],"study_design_scores_gemma":[0.013432792,0.00048904243,0.9686415,0.00018064554,0.000052777417,0.000044544846,0.00011459926,0.00026631312,0.014375859,0.000059857248,0.002165429,0.00017663439],"about_ca_topic_score_codex":0.0007648739,"about_ca_topic_score_gemma":0.0006006632,"teacher_disagreement_score":0.014724836,"about_ca_system_score_codex":0.00023943683,"about_ca_system_score_gemma":0.00007338032,"threshold_uncertainty_score":0.5727285},"labels":[],"label_agreement":null},{"id":"W2567464243","doi":"10.1182/blood.v116.21.4962.4962","title":"Cost-Effectiveness of Deferasirox (Exjade®) Versus No Chelation In Patients with Lower Risk Myelodysplastic Syndromes (MDS): A Canadian Perspective","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Deferasirox; Medicine; Myelodysplastic syndromes; Internal medicine; Cost effectiveness; Clinical trial; International Prognostic Scoring System; Transplantation; Quality of life (healthcare); Pediatrics; Intensive care medicine; Thalassemia","score_opus":0.014585219598852539,"score_gpt":0.27512223370208294,"score_spread":0.2605370141032304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567464243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933968,0.000021901811,0.000011433956,0.000042375,0.00020988828,0.0014691327,0.00007255217,0.000021614298,0.0047542723],"genre_scores_gemma":[0.9994079,0.000005752354,0.00026852477,0.000007257463,0.000052670865,0.000087209446,0.00005762561,0.00003937845,0.00007369648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985051,0.0001286806,0.00017134033,0.00035700528,0.00041173407,0.00042614824],"domain_scores_gemma":[0.99819195,0.00040048637,0.0000863136,0.00035172925,0.0006605226,0.00030900748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034271582,0.00019131074,0.00034958404,0.0004274559,0.00006540757,0.000014257943,0.00012467426,0.0001889995,0.00021453452],"category_scores_gemma":[0.0013320002,0.00016038088,0.00005339322,0.00048161153,0.00016192628,0.0001268285,0.00003190763,0.0007775306,0.0000800631],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050496827,0.0008321478,0.99183667,0.000094022005,0.00032723043,0.000085023734,0.000392641,0.000019832254,0.00088000094,0.00027610044,0.000024934981,0.00018171871],"study_design_scores_gemma":[0.025319511,0.0018409182,0.97087234,0.0001557069,0.00024095192,0.000014851282,0.00012042582,0.00011147839,0.0010345413,0.00002889239,0.000090685324,0.000169709],"about_ca_topic_score_codex":0.040612247,"about_ca_topic_score_gemma":0.04626484,"teacher_disagreement_score":0.020964338,"about_ca_system_score_codex":0.0006505892,"about_ca_system_score_gemma":0.0010866193,"threshold_uncertainty_score":0.97113836},"labels":[],"label_agreement":null},{"id":"W2567610518","doi":"10.1182/blood.v106.11.4300.4300","title":"The Involvement of Reactive Oxygen Species in Polyploidization of the M-07e Human Megakaryocytic Cell Line.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Héma-Québec","funders":"","keywords":"Biology; Cell biology; Endoreduplication; Reactive oxygen species; Cytokinesis; Cell division; Cell; Cell cycle; Biochemistry","score_opus":0.023302022842813724,"score_gpt":0.27380452119453214,"score_spread":0.2505024983517184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567610518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881497,0.00051867537,0.0000070859724,0.0017091125,0.000022743416,0.00052134815,0.0000063149896,0.000008797181,0.009056244],"genre_scores_gemma":[0.99658483,0.00017183078,0.00015447571,0.00010053077,0.00014044956,0.000016247894,0.00000942799,0.000015508316,0.002806675],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988393,0.00008180541,0.0003388576,0.0001347328,0.00041451355,0.00019075834],"domain_scores_gemma":[0.9991243,0.00011821893,0.00014977071,0.00043393823,0.00013563712,0.000038152983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003745934,0.00009059037,0.00018531253,0.00008572602,0.000075418335,0.0000060964635,0.0002321736,0.00005726584,0.000028387583],"category_scores_gemma":[0.0001336871,0.000051512015,0.00006959023,0.00033563658,0.00014886363,0.000044914104,0.00012273178,0.00022613998,0.0000055380888],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012845741,0.0011071292,0.02773294,0.00012880491,0.000115071096,0.0000053470603,0.002438062,0.000054199732,0.9655191,0.0013757027,0.00090470136,0.00049053965],"study_design_scores_gemma":[0.0032209205,0.0002172897,0.09221396,0.0000875265,0.00008435285,0.0000033376464,0.0009199334,0.0001339921,0.90037245,0.00010720806,0.0025832155,0.000055846813],"about_ca_topic_score_codex":0.00020439138,"about_ca_topic_score_gemma":0.00031486712,"teacher_disagreement_score":0.065146625,"about_ca_system_score_codex":0.00020918211,"about_ca_system_score_gemma":0.00025118145,"threshold_uncertainty_score":0.21005991},"labels":[],"label_agreement":null},{"id":"W2567682454","doi":"10.1182/blood.v126.23.4978.4978","title":"Discordance Between Morphologic and Cytogenetic Findings Following Induction Chemotherapy for Acute Myeloid Leukemia Is Prevalent in Patients with Bone Marrow Blasts &gt;2% and Is Associated with Poor Clinical Outcomes","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Induction chemotherapy; Internal medicine; Acute promyelocytic leukemia; Bone marrow; Cytogenetics; Chemotherapy; Leukemia; Myeloid leukemia; Biopsy; Cytarabine; Chemotherapy regimen; Fludarabine; Myeloid; Gastroenterology; Oncology; Surgery; Cyclophosphamide","score_opus":0.03420774971938598,"score_gpt":0.32133016040681844,"score_spread":0.2871224106874325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567682454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966793,0.00013919841,0.000045067816,0.0013500925,0.000038057202,0.0016150562,0.00007586667,0.00003933239,0.0000180379],"genre_scores_gemma":[0.9958345,0.000080811296,0.0024734372,0.0006728942,0.00006521577,0.00009622379,0.00007715937,0.00006315464,0.0006365821],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978056,0.00008326069,0.00045092305,0.00063348626,0.00054341584,0.00048331186],"domain_scores_gemma":[0.9989413,0.00016959342,0.00017445508,0.00026967796,0.00014893814,0.00029603357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006789199,0.00029864023,0.00078997517,0.00015671311,0.000074884025,0.000039978077,0.00010722077,0.0002330523,0.000006159362],"category_scores_gemma":[0.00023090388,0.00020676342,0.000081100734,0.00029220612,0.00017566822,0.00015566546,0.00008192131,0.00038167296,0.000002330505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010123481,0.0003152078,0.9941529,0.000037251455,0.00094683375,0.000042065014,0.0004510908,2.7567896e-7,0.00035112517,5.078199e-7,0.00045879954,0.0022315702],"study_design_scores_gemma":[0.040852096,0.0036509552,0.952205,0.00021291329,0.00077670254,0.000020395642,0.00006112871,0.00004341706,0.0018433644,0.000034684886,0.00004844115,0.00025091827],"about_ca_topic_score_codex":0.000028546947,"about_ca_topic_score_gemma":0.000015506632,"teacher_disagreement_score":0.041947942,"about_ca_system_score_codex":0.00032491694,"about_ca_system_score_gemma":0.00030246383,"threshold_uncertainty_score":0.84315675},"labels":[],"label_agreement":null},{"id":"W2568905911","doi":"10.71781/28069","title":"Caractérisation de l'oncogène MLF1 (Myeloid Leukemia Factor 1)","year":2005,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Cancer Research Society","keywords":"Myeloid leukemia; Cancer research; Biology","score_opus":0.009297068425321216,"score_gpt":0.2200513795970206,"score_spread":0.21075431117169938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568905911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87492114,0.03511209,0.00043805386,0.0010980607,0.0024483495,0.0012902087,0.00028082833,0.00028481742,0.084126435],"genre_scores_gemma":[0.77933073,0.0047672656,0.00177422,0.00034697115,0.0026212092,0.00007924991,0.0020188442,0.00014711042,0.20891441],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99333197,0.00047335902,0.001033226,0.0013933678,0.0019730076,0.0017950964],"domain_scores_gemma":[0.9952271,0.0004695525,0.0008044245,0.0009994222,0.0009369858,0.001562538],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0005780565,0.0011142718,0.0011340383,0.0009659773,0.0076406407,0.00013956029,0.00088607793,0.0018888172,0.00082969473],"category_scores_gemma":[0.0004973182,0.0013166332,0.0007911365,0.0008549105,0.0006399679,0.0008711674,0.00031396459,0.0024106302,0.0012143448],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010615566,0.0012382756,0.16170695,0.00254243,0.00397725,0.025028592,0.16526188,0.01099382,0.47613543,0.023326863,0.011282008,0.10789092],"study_design_scores_gemma":[0.008160546,0.00071317353,0.543575,0.0021161013,0.0021872162,0.0062471456,0.08817654,0.020222157,0.09399658,0.0001510975,0.23214343,0.002311028],"about_ca_topic_score_codex":0.09690609,"about_ca_topic_score_gemma":0.016466754,"teacher_disagreement_score":0.38213885,"about_ca_system_score_codex":0.13162497,"about_ca_system_score_gemma":0.026842784,"threshold_uncertainty_score":0.99989086},"labels":[],"label_agreement":null},{"id":"W2569186978","doi":"10.1182/blood.v116.21.874.874","title":"Liver Fibrosis In Myeloid Leukemia of Down Syndrome","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Hospital for Sick Children","funders":"","keywords":"Acute megakaryoblastic leukemia; Medicine; Leukemia; Myeloid leukemia; Immunology; Myeloid; Population; GATA1; Cancer research; Pathology; Internal medicine; Anemia","score_opus":0.011227144689095123,"score_gpt":0.2565122409598603,"score_spread":0.24528509627076517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569186978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924912,0.00013399225,0.0000042430815,0.00023224059,0.00006522765,0.00031659944,0.00001292603,0.000038935872,0.006704642],"genre_scores_gemma":[0.9958337,0.0000773276,0.002499521,0.00009387708,0.00008568615,0.000023977516,0.000014530385,0.000028095074,0.0013433172],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987141,0.000030311761,0.00028680288,0.00026005376,0.00035882177,0.00034989574],"domain_scores_gemma":[0.99906784,0.00011121946,0.00005762305,0.0005110046,0.0000899011,0.00016241724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030061437,0.00013375493,0.00034652566,0.00025912875,0.000024356123,0.000008769812,0.00020093769,0.00020261794,0.0007687456],"category_scores_gemma":[0.0002494519,0.000116265284,0.00008986693,0.0004060767,0.00014426482,0.00007777575,0.00011539227,0.00070807885,0.0002049226],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020666509,0.0006751262,0.11022764,0.0003715574,0.00012123183,0.0013007639,0.00045024938,0.0000017590362,0.8818757,0.00036197467,0.0012480608,0.0031592522],"study_design_scores_gemma":[0.0072639612,0.0005226074,0.7274041,0.00016501758,0.00012001211,0.0013724398,0.000069498055,0.00015547202,0.25961313,0.00007847635,0.0030337786,0.0002015014],"about_ca_topic_score_codex":0.000571413,"about_ca_topic_score_gemma":0.00011948139,"teacher_disagreement_score":0.6222626,"about_ca_system_score_codex":0.00010406127,"about_ca_system_score_gemma":0.00050247443,"threshold_uncertainty_score":0.8417225},"labels":[],"label_agreement":null},{"id":"W2570279763","doi":"10.1182/blood.v114.22.4133.4133","title":"Transfusional Iron Overload: An Underappreciated Danger in AML Patients?","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Dexrazoxane; Anthracycline; Medicine; Doxorubicin; Cardiotoxicity; Cancer; Cardiomyopathy; Population; Internal medicine; Adverse effect; Toxicity; Oncology; Chemotherapy; Breast cancer; Heart failure","score_opus":0.013917132430472394,"score_gpt":0.2769227942229623,"score_spread":0.2630056617924899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570279763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282366,0.00008026131,0.000011758365,0.00065137364,0.00003385408,0.00038877295,0.000011380502,0.00005685828,0.005942105],"genre_scores_gemma":[0.9978597,0.000053247375,0.00042125766,0.00093320664,0.000117446085,0.000009794989,0.00016145654,0.000017729853,0.00042612923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986942,0.0000634959,0.0002046819,0.00028525846,0.00041522153,0.00033718866],"domain_scores_gemma":[0.9994359,0.000032409367,0.000023771228,0.0002643439,0.00006442497,0.00017915023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014482549,0.00012853666,0.0002043934,0.0001760449,0.00003981443,0.0000132909945,0.00010740013,0.00013214865,0.00033817426],"category_scores_gemma":[0.00004943584,0.00011254358,0.000052242656,0.0003028937,0.000031924887,0.00011762257,0.000013860867,0.00033520654,0.00004580386],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028015105,0.030836718,0.6120495,0.00014269994,0.00017823609,0.0008549324,0.0038684516,0.000034741624,0.2013693,0.0008035796,0.0066872463,0.14037305],"study_design_scores_gemma":[0.013498711,0.0013282162,0.9783723,0.000053215666,0.000046461137,0.000018525187,0.000052338262,0.00015178796,0.0049400134,0.00016002434,0.001225769,0.00015264754],"about_ca_topic_score_codex":0.000088053006,"about_ca_topic_score_gemma":0.000058043533,"teacher_disagreement_score":0.36632276,"about_ca_system_score_codex":0.00013086616,"about_ca_system_score_gemma":0.00015651352,"threshold_uncertainty_score":0.4589394},"labels":[],"label_agreement":null},{"id":"W2570876655","doi":"10.1182/blood.v112.11.853.853","title":"Identification of Mir-145 and Mir-146a as Micrornas Involved in the Pathogenesis of 5q- Syndrome","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Health Sciences Centre; Sunnybrook Health Science Centre; BC Cancer Agency","funders":"","keywords":"Haematopoiesis; Bone marrow; Cancer research; Biology; microRNA; Myeloid leukemia; Immunology; Leukemia; Thrombocytosis; Megakaryocytopoiesis; Myeloid; Medicine; Stem cell; Megakaryocyte; Gene; Genetics; Platelet","score_opus":0.02366835082884752,"score_gpt":0.2738834227437285,"score_spread":0.250215071914881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570876655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99738914,0.0013864331,0.000005624059,0.0005060727,0.000016542679,0.00044774174,0.000016812859,0.000009633058,0.00022201342],"genre_scores_gemma":[0.9989186,0.00045406836,0.00021727782,0.00008875512,0.000019765706,0.000028934934,0.000015763178,0.00001577267,0.00024107732],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987308,0.0001158273,0.0004087045,0.00020356431,0.0003628227,0.0001783211],"domain_scores_gemma":[0.9991545,0.00010923172,0.00013161951,0.0004285683,0.00011967854,0.000056381145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005286801,0.00009956703,0.00028723103,0.00018398638,0.000039673916,0.0000049571063,0.0001793669,0.0000945361,0.000020877766],"category_scores_gemma":[0.00023817827,0.00007408263,0.000058673264,0.0003974603,0.00021179813,0.000050075098,0.000052533054,0.00015238357,0.000017815375],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000890181,0.00054411095,0.070987284,0.00020973297,0.000058475573,0.0002852076,0.0015092975,2.36799e-7,0.9258734,0.00004299755,0.00022684097,0.00017339148],"study_design_scores_gemma":[0.0026766479,0.00022571595,0.7357694,0.000084180174,0.00010380447,0.0010134015,0.0005627325,0.00001744037,0.25927186,0.00006212484,0.00014354255,0.00006918972],"about_ca_topic_score_codex":0.000272279,"about_ca_topic_score_gemma":0.000026406926,"teacher_disagreement_score":0.66660154,"about_ca_system_score_codex":0.00002910581,"about_ca_system_score_gemma":0.00018237569,"threshold_uncertainty_score":0.30210018},"labels":[],"label_agreement":null},{"id":"W2571019625","doi":"10.1182/blood.v116.21.4008.4008","title":"Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality?","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"clone (Java method); Karyotype; Chromosome abnormality; Internal medicine; Myelodysplastic syndromes; Univariate analysis; Multivariate analysis; Abnormality; Cytopenia; Biology; Bone marrow; Gastroenterology; Oncology; Medicine; Pathology; Chromosome; Genetics","score_opus":0.014968318209936193,"score_gpt":0.2803139900972123,"score_spread":0.2653456718872761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571019625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873302,0.00006206588,7.110996e-7,0.0011568082,0.00013418123,0.00040641704,0.000015444868,0.000025909863,0.010868236],"genre_scores_gemma":[0.9960264,0.000023017425,0.00024070081,0.00016325232,0.00014902119,0.000018866374,0.000013540544,0.00002340739,0.003341814],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99863946,0.000066387875,0.0003406009,0.00020516948,0.0004160614,0.00033232203],"domain_scores_gemma":[0.9990923,0.00009778836,0.000078361256,0.0005504906,0.00007146889,0.0001096252],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047129794,0.00012179205,0.0002768067,0.00010485569,0.000041919193,0.000008802415,0.0003011466,0.00017404204,0.00092658383],"category_scores_gemma":[0.00023492398,0.00007301608,0.00008079512,0.0005445479,0.0003178456,0.00006103083,0.00016193156,0.00091637403,0.000056176694],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097163994,0.004194306,0.37366173,0.00057655445,0.0005433921,0.003338636,0.0030104448,0.000007377778,0.6043838,0.0056672925,0.0012300512,0.002414771],"study_design_scores_gemma":[0.025152365,0.0007862354,0.8502615,0.0002659505,0.00026775626,0.0018023206,0.00017833895,0.00017500222,0.11249944,0.0012096035,0.007040604,0.0003608505],"about_ca_topic_score_codex":0.0002362203,"about_ca_topic_score_gemma":0.00022089064,"teacher_disagreement_score":0.49188438,"about_ca_system_score_codex":0.00005826782,"about_ca_system_score_gemma":0.00053464784,"threshold_uncertainty_score":0.9999867},"labels":[],"label_agreement":null},{"id":"W2571162532","doi":"10.1182/blood.v118.21.2562.2562","title":"GATA1 mutations Outside the Blast Cell Population in Transient Leukemia of Down Syndrome","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"GATA1; Haematopoiesis; Biology; Population; Molecular biology; Myeloid; clone (Java method); Leukemia; Myelopoiesis; CD34; Precursor cell; Myeloid leukemia; Immunology; Stem cell; Cell; Cell biology; Genetics; Medicine","score_opus":0.023754427226991087,"score_gpt":0.256570534527671,"score_spread":0.2328161073006799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571162532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900824,0.00007638518,0.000057595356,0.00021430354,0.000032494918,0.00048790613,0.000015299041,0.000023591907,0.009010045],"genre_scores_gemma":[0.9984615,0.000014792109,0.0008785086,0.00006640413,0.000023316741,0.00003424107,0.00004513466,0.000018899653,0.00045721256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989185,0.000063244945,0.00032114217,0.00017850156,0.0002887299,0.00022991194],"domain_scores_gemma":[0.99936813,0.00007398494,0.00006760214,0.0003500035,0.00006319747,0.000077071585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025129705,0.000099924044,0.0002094046,0.00016499117,0.000039737282,0.0000049734904,0.00013811236,0.00007803872,0.00017279222],"category_scores_gemma":[0.00006155064,0.00007101717,0.000069506495,0.00034178083,0.000082992534,0.00006342308,0.000027109978,0.00026815603,0.000053859592],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013972969,0.00777466,0.74563456,0.0017555197,0.0007522672,0.0030805322,0.055921428,0.00065264147,0.16966216,0.0022008724,0.0023867283,0.008781349],"study_design_scores_gemma":[0.0039046563,0.00030877872,0.9667938,0.00008342343,0.00016413472,0.00023495361,0.00070240116,0.00032245347,0.027135698,0.00017180934,0.00008232637,0.00009556538],"about_ca_topic_score_codex":0.0017946166,"about_ca_topic_score_gemma":0.00023356167,"teacher_disagreement_score":0.22115926,"about_ca_system_score_codex":0.00016074858,"about_ca_system_score_gemma":0.00024734458,"threshold_uncertainty_score":0.28959963},"labels":[],"label_agreement":null},{"id":"W2571229748","doi":"10.1002/cncr.30515","title":"Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia","year":2017,"lang":"en","type":"article","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"NPM1; Nucleophosmin; Myeloid leukemia; Cancer research; Leukemia; Molecular biology; Propidium iodide; Flow cytometry; Apoptosis; Biology; Chemistry; Cell biology; Programmed cell death; Biochemistry; Immunology","score_opus":0.023947202727975264,"score_gpt":0.335646800345947,"score_spread":0.3116995976179717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571229748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98863715,0.0010329722,0.000046905767,0.0061235824,0.00034675494,0.000930862,0.000042782944,0.000087273846,0.0027516924],"genre_scores_gemma":[0.9922833,0.0008461164,0.0020917263,0.0009440613,0.00064306695,0.00021004501,0.000030065868,0.00009805812,0.002853586],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99736106,0.00007097791,0.00050381495,0.00067612226,0.0005116317,0.00087639916],"domain_scores_gemma":[0.998132,0.00009046871,0.00030803867,0.0009085519,0.00025475846,0.00030621106],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063157483,0.00033688603,0.00063894346,0.00021791956,0.00044587077,0.00014637824,0.00055206235,0.00017090845,0.00052563957],"category_scores_gemma":[0.0006561529,0.0002948807,0.00012926529,0.00025622555,0.00035078934,0.0003859171,0.00039018778,0.0009401651,0.00009499314],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024990372,0.00017868746,0.09471057,0.0005068075,0.0006051053,0.0032502,0.008884732,0.00013024644,0.8014886,0.00021157078,0.043732986,0.043801464],"study_design_scores_gemma":[0.018346516,0.0003065483,0.40865058,0.0028892541,0.00035259005,0.00019779593,0.0021623778,0.017382346,0.5120196,0.00049246306,0.03573878,0.001461204],"about_ca_topic_score_codex":0.002645313,"about_ca_topic_score_gemma":0.00032174922,"teacher_disagreement_score":0.31394,"about_ca_system_score_codex":0.0031394642,"about_ca_system_score_gemma":0.0016914667,"threshold_uncertainty_score":0.99995035},"labels":[],"label_agreement":null},{"id":"W2571311836","doi":"10.1182/blood.v126.23.2587.2587","title":"ASXL1 and ASXL2 Mutations in Childhood AML Are Strongly Associated with t(8;21) but Do Not Independently Impact on Prognosis: A Report from the Children's Oncology Group and NCI/COG Target Initiative","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Biology; Gene; Epigenetics; Mutation; Genetics; Nonsense mutation; Cancer research; Missense mutation","score_opus":0.02415841168431884,"score_gpt":0.296528748715443,"score_spread":0.2723703370311242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571311836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944611,0.0006370812,0.000008570527,0.0018757753,0.000026947113,0.0015957541,0.00045657862,0.000064651045,0.000873502],"genre_scores_gemma":[0.99810207,0.000042117816,0.00043382467,0.000373132,0.00017187299,0.00020663222,0.0005819981,0.0000519082,0.000036458012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973796,0.00039304994,0.00041256423,0.0006041042,0.0007036303,0.00050706096],"domain_scores_gemma":[0.99805874,0.0006036131,0.00036541006,0.00035872596,0.00024422928,0.00036928625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008949708,0.00031905415,0.0005976145,0.0001992524,0.00013344658,0.00008208882,0.00015813367,0.00027870157,0.00002133729],"category_scores_gemma":[0.001782719,0.00020023406,0.000058835543,0.00041034422,0.00025715303,0.00018319568,0.00014060613,0.001100292,0.000006934706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060100364,0.0019379995,0.9898094,0.0000069554894,0.001205581,0.0016753767,0.0037140523,0.000012831034,0.000054051376,0.0000114778395,0.0005224494,0.00044880217],"study_design_scores_gemma":[0.016463267,0.0029575913,0.97512174,0.00025821305,0.00046367053,0.0007787535,0.0031214973,0.00005227041,0.000398116,0.00013964728,0.00003197004,0.00021328586],"about_ca_topic_score_codex":0.0010235244,"about_ca_topic_score_gemma":0.0005779081,"teacher_disagreement_score":0.015862262,"about_ca_system_score_codex":0.000416947,"about_ca_system_score_gemma":0.0013639976,"threshold_uncertainty_score":0.8165308},"labels":[],"label_agreement":null},{"id":"W2571617651","doi":"10.1182/blood.v106.11.101.101","title":"A Lymphoid Progenitor Propagates AML in a Mouse Model of CALM/AF10 Positive Leukemia.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Myeloid; Bone marrow; Myeloid leukemia; Leukemia; Progenitor cell; Population; Transplantation; Spleen; Biology; Cancer research; Stem cell; Immunology; Molecular biology; Pathology; Medicine; Internal medicine; Cell biology","score_opus":0.016598570107957508,"score_gpt":0.2720131212767919,"score_spread":0.2554145511688344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571617651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99561894,0.00032368285,0.00006274595,0.0006186735,0.000009657915,0.0010074847,0.00006934904,0.00006291392,0.0022265625],"genre_scores_gemma":[0.98921746,0.00006786394,0.006944883,0.00021966718,0.00018345552,0.00013356927,0.000025617519,0.000049134902,0.0031583242],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998278,0.000056639197,0.0003953262,0.0003388885,0.00045405456,0.00047706216],"domain_scores_gemma":[0.99908906,0.000058588143,0.00008241563,0.00037731204,0.00019515964,0.00019747409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024328707,0.00019573596,0.00042531913,0.00025928408,0.000033248874,0.000011289562,0.00018617403,0.00016421558,0.000028189099],"category_scores_gemma":[0.0001806159,0.00016660262,0.000101324724,0.0003107256,0.00013683934,0.00012471624,0.00011123554,0.00032874595,0.00006379208],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007460621,0.0020099864,0.017226025,0.00023414874,0.00021164189,0.00014536509,0.0017344471,0.0005248383,0.9726286,0.0001583786,0.00046096605,0.0039195227],"study_design_scores_gemma":[0.009405663,0.00034980435,0.0007827134,0.00011874424,0.000103930055,0.00020684316,0.00013247866,0.04245494,0.9461403,0.000033744924,0.00009212358,0.00017871638],"about_ca_topic_score_codex":0.00025933702,"about_ca_topic_score_gemma":0.00005880857,"teacher_disagreement_score":0.0419301,"about_ca_system_score_codex":0.0007219613,"about_ca_system_score_gemma":0.0016038872,"threshold_uncertainty_score":0.6793858},"labels":[],"label_agreement":null},{"id":"W2572113748","doi":"10.1182/blood.v118.21.2619.2619","title":"Significance of Prior HSCT on the Outcome of Salvage Therapy with CPX-351 or Conventional Chemotherapy Among First Relapse AML Patients","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Salvage therapy; Internal medicine; Regimen; Chemotherapy regimen; Clinical endpoint; Cytarabine; Surgery; Chemotherapy; Randomized controlled trial; Gastroenterology","score_opus":0.042431709011144035,"score_gpt":0.2743322192836887,"score_spread":0.23190051027254469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2572113748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957317,0.000046929003,0.000020324887,0.00034405896,0.000032972603,0.0012245473,0.000030331214,0.000024026438,0.002545071],"genre_scores_gemma":[0.9975372,0.000097021795,0.0006323369,0.00033625556,0.000043928343,0.00007895049,0.000012504773,0.00004389934,0.0012179223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984136,0.00006745227,0.0003932361,0.00025432082,0.00062375894,0.00024762703],"domain_scores_gemma":[0.9986197,0.00023260053,0.0002673872,0.00055687706,0.00023437217,0.00008910022],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032176712,0.00017828222,0.00037066638,0.00008874912,0.00006282338,0.0000048996085,0.00027129042,0.00008986585,0.0009355834],"category_scores_gemma":[0.00012899641,0.00009160517,0.00011501428,0.00025762228,0.0003833355,0.000054263586,0.000027760147,0.00027455387,0.000017247005],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004383303,0.0029756788,0.9871594,0.00012095464,0.00044364418,0.000025674733,0.0011141659,4.3786048e-7,0.0019626406,0.00036050193,0.00062021223,0.00083339785],"study_design_scores_gemma":[0.0132087385,0.0029843138,0.9017329,0.00016528404,0.000060981376,0.0000049615314,0.00010578904,0.000009705994,0.08110791,0.000024722733,0.00048321066,0.000111471905],"about_ca_topic_score_codex":0.00017227809,"about_ca_topic_score_gemma":0.000031224372,"teacher_disagreement_score":0.08542647,"about_ca_system_score_codex":0.00005021975,"about_ca_system_score_gemma":0.00017254884,"threshold_uncertainty_score":0.9999777},"labels":[],"label_agreement":null},{"id":"W2572471102","doi":"10.1182/blood.v110.11.5027.5027","title":"Should Patients with Myelodysplasia and/or Acute Myeloid Leukemia (MDS/AML) Be Screened for Inherited RUNX1 Mutations Prior to Sibling Donor Allografting?.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"RUNX1; Medicine; Proband; Sibling; Platelet disorder; CEBPA; Myeloid leukemia; Leukemia; Bone marrow; Myeloid; Internal medicine; Oncology; Genetics; Immunology; Mutation; Haematopoiesis; Biology; Stem cell; Gene; Platelet","score_opus":0.02949248383752329,"score_gpt":0.3122175405950061,"score_spread":0.28272505675748283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2572471102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898855,0.00006337762,0.0038894624,0.0016605372,0.00006112647,0.003402209,0.0001669014,0.00024043297,0.0006304574],"genre_scores_gemma":[0.88948524,0.000042435986,0.1042764,0.0029580714,0.00034631917,0.00034991407,0.00057024596,0.0001832632,0.0017881402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966878,0.00004264912,0.00062412734,0.000779751,0.00076912984,0.0010964997],"domain_scores_gemma":[0.99730676,0.00052530895,0.00016402904,0.00053977803,0.0006738177,0.00079028314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007013213,0.0004344212,0.0006001304,0.0007330805,0.0003951502,0.00010224439,0.00027756434,0.00030407493,0.000047173573],"category_scores_gemma":[0.0007114354,0.00033496728,0.00011453085,0.0013080833,0.00017226778,0.00022517199,0.00018342918,0.00053269387,0.000016102971],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043562934,0.004560849,0.6876499,0.0014570552,0.0065578423,0.001536369,0.008051031,0.000105537845,0.1421819,0.00048449897,0.0075389566,0.0963131],"study_design_scores_gemma":[0.07536642,0.010405388,0.8179661,0.0007832101,0.003161868,0.0004027689,0.001717634,0.00079193054,0.052972008,0.000045722965,0.03476347,0.0016234543],"about_ca_topic_score_codex":0.00015199148,"about_ca_topic_score_gemma":0.00038725816,"teacher_disagreement_score":0.1303162,"about_ca_system_score_codex":0.00037695357,"about_ca_system_score_gemma":0.0007472888,"threshold_uncertainty_score":0.99991024},"labels":[],"label_agreement":null},{"id":"W2572761220","doi":"10.1002/pbc.26450","title":"FISH identifies a KAT6A/CREBBP fusion caused by a cryptic insertional t(8;16) in a case of spontaneously remitting congenital acute myeloid leukemia with a normal karyotype","year":2017,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Cancer Centre; Nova Scotia Health Authority; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Myeloid leukemia; Fluorescence in situ hybridization; Medicine; Karyotype; Chromosomal translocation; Leukemia; NPM1; Cancer research; Genetics; Internal medicine; Biology; Chromosome; Gene","score_opus":0.012283766931369464,"score_gpt":0.2797464746572697,"score_spread":0.26746270772590025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2572761220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995914,0.0013604687,0.000019623063,0.0006767964,0.00017794008,0.0008375898,0.00025330568,0.00006039947,0.0006998766],"genre_scores_gemma":[0.9948806,0.0012614563,0.00030126874,0.0002482775,0.00078665727,0.00018391843,0.00008130427,0.00007991509,0.002176607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996906,0.00009033333,0.0007039888,0.0006775876,0.0008353575,0.00078674254],"domain_scores_gemma":[0.9975775,0.00028084402,0.0005288527,0.0008081277,0.00046398994,0.0003406797],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005078406,0.0003920392,0.0007226133,0.00041669005,0.00038270096,0.0001090816,0.0004128962,0.00027147055,0.0004251549],"category_scores_gemma":[0.0005297218,0.0003433108,0.0001455366,0.00050688896,0.00028084897,0.0004301643,0.00029995403,0.00088476227,0.000021589536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008568635,0.0008782847,0.8280636,0.0017665894,0.0016945851,0.0986309,0.0035999466,0.00005256695,0.038535383,0.000023112023,0.013495547,0.004690833],"study_design_scores_gemma":[0.111200914,0.007696928,0.72168595,0.00227077,0.018048711,0.077732965,0.002976846,0.0077882754,0.04355407,0.00012014603,0.0022730741,0.004651358],"about_ca_topic_score_codex":0.020016117,"about_ca_topic_score_gemma":0.011353481,"teacher_disagreement_score":0.106377676,"about_ca_system_score_codex":0.0008714138,"about_ca_system_score_gemma":0.0024721625,"threshold_uncertainty_score":0.9999019},"labels":[],"label_agreement":null},{"id":"W2572789227","doi":"10.1182/blood.v126.23.1859.1859","title":"The Novel Leukemia Stem Cell Marker GPR56 Discriminates Leukemic Subclones with Divergent Stem Cell Properties in Human Acute Myeloid Leukemia","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Leukemia & Lymphoma Society of Canada; Hôpital Maisonneuve-Rosemont; Centre hospitalier universitaire de Québec; Université Laval; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Myeloid leukemia; CD34; CD38; Biology; Haematopoiesis; Stem cell; Leukemia; Molecular biology; Myeloid; Population; Cancer research; Immunology; Cell biology; Medicine","score_opus":0.034916840566066185,"score_gpt":0.2517710068041954,"score_spread":0.2168541662381292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2572789227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987348,0.0027533544,0.000035330137,0.000488479,0.0001875004,0.0017649488,0.00003813582,0.00020061198,0.0071836277],"genre_scores_gemma":[0.9603887,0.0005262056,0.0002949513,0.00017769924,0.00025279305,0.00033761602,0.000053154006,0.00018874393,0.0377801],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99484813,0.00024380628,0.00088172354,0.0010154792,0.0015108703,0.00149998],"domain_scores_gemma":[0.9969824,0.00017468595,0.00030063553,0.0013784122,0.00046775246,0.0006961045],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011241975,0.00076419645,0.00090875896,0.00032888027,0.0004930625,0.00020916024,0.0009925675,0.00033561478,0.000023701155],"category_scores_gemma":[0.000024665429,0.00045620048,0.00020134571,0.0006980456,0.00058595015,0.00036248798,0.0006813998,0.0012917195,0.00015266307],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006100688,0.0027375869,0.09514956,0.0016906017,0.0013356729,0.002425072,0.0144066615,0.00040861891,0.857812,0.0003343474,0.013600908,0.0039982926],"study_design_scores_gemma":[0.043606304,0.0033594181,0.037624836,0.0009322824,0.0018372852,0.0008800144,0.023213416,0.0018576807,0.8744913,0.000054960852,0.010283923,0.0018586358],"about_ca_topic_score_codex":0.0013235653,"about_ca_topic_score_gemma":0.0003463143,"teacher_disagreement_score":0.057524726,"about_ca_system_score_codex":0.0036326197,"about_ca_system_score_gemma":0.0034734926,"threshold_uncertainty_score":0.999789},"labels":[],"label_agreement":null},{"id":"W2572821833","doi":"10.1182/blood.v126.23.2850.2850","title":"Tet2-Deficient Bone Marrow Progenitors Have a Proliferative Advantage in the Presence of TNF-Alpha and IFN-Gamma: Implications for Clonal Dominance in Inflammaging and MDS","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Biology; Bone marrow; Haematopoiesis; Progenitor cell; Myeloid; Stem cell; Cancer research; Immunology; Molecular biology; Genetics","score_opus":0.028382483631900053,"score_gpt":0.323324025954704,"score_spread":0.29494154232280395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2572821833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99363315,0.0010475507,0.00006629563,0.002507949,0.000012253358,0.0022927504,0.000026062937,0.000007781675,0.00040621177],"genre_scores_gemma":[0.99672073,0.00003995444,0.0021907892,0.00005187225,0.000052962198,0.0007394596,0.000009511423,0.0000130198305,0.00018168047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988281,0.00008049628,0.0002962239,0.00028183984,0.00023057492,0.00028277186],"domain_scores_gemma":[0.9991414,0.00026900865,0.000084039275,0.00024389211,0.00016689017,0.00009475033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008553945,0.000120969664,0.00024935917,0.000152548,0.000045893816,0.000020040812,0.00010411093,0.000060358278,0.0000010196176],"category_scores_gemma":[0.0005815579,0.00008701718,0.000024796229,0.00022594228,0.00021792194,0.00010720648,0.00009512747,0.0002593756,4.3933585e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000610371,0.0006371115,0.9584547,0.00022974648,0.000032475946,0.000058619178,0.015030026,0.000005401204,0.02013419,0.000894132,0.00020366073,0.0037095633],"study_design_scores_gemma":[0.02441821,0.0013640086,0.9228743,0.00039988232,0.00014915499,0.0007848554,0.007889315,0.001460545,0.03684497,0.001576521,0.0019236124,0.0003146471],"about_ca_topic_score_codex":0.0002617383,"about_ca_topic_score_gemma":0.00095068227,"teacher_disagreement_score":0.035580423,"about_ca_system_score_codex":0.00009490464,"about_ca_system_score_gemma":0.0005059498,"threshold_uncertainty_score":0.35484576},"labels":[],"label_agreement":null},{"id":"W2574119868","doi":"10.1200/jco.2016.71.6712","title":"Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":470,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Internal medicine; Autologous stem-cell transplantation; Oncology; Lymphoma; Transplantation; Hematopoietic stem cell transplantation; Cumulative incidence; Myeloid; Cohort","score_opus":0.08473478358565387,"score_gpt":0.44151671627837075,"score_spread":0.35678193269271685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2574119868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868283,0.000061889354,0.0006073297,0.009753506,0.0005500423,0.00037614233,0.000026825865,0.000013180875,0.0017827334],"genre_scores_gemma":[0.9913665,0.00016782962,0.004252513,0.0015993584,0.00037702915,0.000022245084,0.0000070861015,0.000027974027,0.0021794538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970432,0.00028546678,0.0016178146,0.00020952139,0.0004996458,0.00034435643],"domain_scores_gemma":[0.99232185,0.004020585,0.0022174218,0.00031121372,0.0007506254,0.00037829246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032418924,0.00016665127,0.0016039655,0.00012127637,0.00014501633,0.000018618424,0.00031935872,0.00054569467,0.00008025422],"category_scores_gemma":[0.0025711278,0.00010391519,0.00060455047,0.000044921737,0.00039792238,0.00020886454,0.000036517766,0.0005764851,0.000018612292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045582157,0.0027320797,0.84688026,0.00020436398,0.0016356269,0.0076910774,0.00031106925,0.000008672637,0.000103387065,0.00007788358,0.004880278,0.089893155],"study_design_scores_gemma":[0.02826858,0.007597965,0.9562903,0.0001342143,0.00089238014,0.000667292,0.00010850091,0.00011894804,0.00017051079,0.00010363868,0.0055331346,0.000114522496],"about_ca_topic_score_codex":0.000014550459,"about_ca_topic_score_gemma":0.00009285449,"teacher_disagreement_score":0.10941006,"about_ca_system_score_codex":0.00040816233,"about_ca_system_score_gemma":0.0029967236,"threshold_uncertainty_score":0.5316059},"labels":[],"label_agreement":null},{"id":"W2574134106","doi":"10.1182/blood.v112.11.950.950","title":"QLT0267, a Small Molecule Inhibitor of ILK and FLT3 Is Cytotoxic to Acute Myeloid Leukemia (AML) ‘Stem Cells’ Detected in Immunodeficient Mice.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Integrin-linked kinase; Cancer research; Protein kinase B; Fms-Like Tyrosine Kinase 3; CD34; Myeloid leukemia; Leukemia; Biology; Myeloid; Kinase; CD38; Cytotoxic T cell; Stem cell; Molecular biology; Chemistry; Signal transduction; Immunology; In vitro; Cell biology; Protein kinase A; Biochemistry; Mutation; Cyclin-dependent kinase 2","score_opus":0.01616144116951526,"score_gpt":0.24045743195559433,"score_spread":0.22429599078607906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2574134106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99684536,0.0009464461,0.00007761683,0.00026878976,0.00006914598,0.001128809,0.00006430792,0.000074890755,0.0005246126],"genre_scores_gemma":[0.99584496,0.00041486163,0.0018622399,0.00040748905,0.000073706644,0.00008570873,0.00001242663,0.00007518339,0.0012233977],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973666,0.00009462329,0.0006344234,0.0006369152,0.0005599732,0.0007074327],"domain_scores_gemma":[0.9985491,0.00009788472,0.00012357609,0.0006634352,0.00022674786,0.00033923824],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027977466,0.00033531483,0.00065605756,0.00056375755,0.00009526072,0.000017768418,0.00028487656,0.0002574878,0.000043842298],"category_scores_gemma":[0.00006458793,0.00031494684,0.00012002135,0.0010475513,0.00017609165,0.00006253964,0.0003425859,0.000559897,0.00009291547],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004972286,0.00040276747,0.0027349996,0.00015699973,0.00015844067,0.000777334,0.002245232,0.0000061875526,0.9920039,0.0000055176592,0.0005764204,0.00043493797],"study_design_scores_gemma":[0.007772822,0.00090643036,0.010528279,0.0002223527,0.00015194509,0.00066991424,0.00028248562,0.00028010117,0.9785056,0.0000035735543,0.00038864336,0.00028784922],"about_ca_topic_score_codex":0.0004447854,"about_ca_topic_score_gemma":0.00004543608,"teacher_disagreement_score":0.01349833,"about_ca_system_score_codex":0.00046657491,"about_ca_system_score_gemma":0.00082927506,"threshold_uncertainty_score":0.99993026},"labels":[],"label_agreement":null},{"id":"W2575033743","doi":"10.1182/blood.v116.21.1508.1508","title":"Population Based Study on the Utilization and Cost of Azacitidine In a Canadian Province.","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Population; Azacitidine; Pharmacy; Regimen; Pediatrics; Emergency medicine; Internal medicine; Family medicine; Environmental health","score_opus":0.03449646704828803,"score_gpt":0.3072835384810917,"score_spread":0.2727870714328037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2575033743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99671876,0.0000074034874,0.000002367346,0.001162661,0.000014725582,0.0011593495,0.000009061707,0.000006431934,0.00091923424],"genre_scores_gemma":[0.9996752,0.0000011782126,0.00003931671,0.00013704321,0.000026248454,0.00003127537,0.000026010464,0.00000825698,0.00005543336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994472,0.00004381711,0.000109281136,0.0001082369,0.00015691516,0.00013449382],"domain_scores_gemma":[0.9995815,0.00007080767,0.000025089998,0.00018587921,0.000045977325,0.0000907455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036246917,0.00005063642,0.00009476058,0.00015992137,0.00003353395,0.0000068800246,0.00004356087,0.00004238235,0.000048518268],"category_scores_gemma":[0.00037390942,0.000034603894,0.000008995761,0.00017672121,0.000020127109,0.000021547683,0.0000090461945,0.00019177704,0.0000024076667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038997063,0.00031290334,0.9942908,0.000015477655,0.0000083811765,0.000019628022,0.00011923546,0.0000013391901,0.0035717443,0.000326183,0.000037302456,0.0012579832],"study_design_scores_gemma":[0.0024412416,0.00026301542,0.9923225,0.000023344386,0.000022239303,0.0000036602762,0.00013635396,0.0012611961,0.0032442238,0.000013141353,0.00023687555,0.000032229134],"about_ca_topic_score_codex":0.12949131,"about_ca_topic_score_gemma":0.5718389,"teacher_disagreement_score":0.44234762,"about_ca_system_score_codex":0.00005994911,"about_ca_system_score_gemma":0.00044935994,"threshold_uncertainty_score":0.87630546},"labels":[],"label_agreement":null},{"id":"W2575321765","doi":"10.1038/leu.2017.17","title":"The clonal origins of leukemic progression of myelodysplasia","year":2017,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Biology; Exome sequencing; Genetics; Mutation; Exome; Myeloid leukemia; Somatic evolution in cancer; Myelodysplastic syndromes; Somatic cell; Germline mutation; DNA methylation; Gene; Myeloid; Leukemia; Cancer research; Immunology; Bone marrow; Gene expression","score_opus":0.023828967406149936,"score_gpt":0.3466196165419312,"score_spread":0.32279064913578126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2575321765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820157,0.00035124327,0.000045789555,0.0012343882,0.0002173027,0.0004988052,0.000015368856,0.000032370324,0.015589008],"genre_scores_gemma":[0.99513274,0.0003474866,0.0012444488,0.000049821047,0.00024693873,0.00002948147,0.000013044077,0.0000342091,0.0029018412],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979794,0.000057003585,0.00048292187,0.0002777693,0.0007661189,0.0004367626],"domain_scores_gemma":[0.9972644,0.00023736192,0.0004921017,0.001521351,0.00031679883,0.00016798856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065153994,0.00018299754,0.00042494936,0.000091750895,0.00044702363,0.00003931899,0.00080840423,0.00018264835,0.000064949374],"category_scores_gemma":[0.0007525092,0.00011257149,0.00017407075,0.00012277516,0.0009877918,0.00012972772,0.00031029672,0.00053382514,0.000051401257],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040822537,0.00022895353,0.16969134,0.0010085292,0.0005951176,0.00027846548,0.0007544914,0.000024151046,0.5035532,0.042487074,0.027242677,0.25005373],"study_design_scores_gemma":[0.007389062,0.0011633688,0.47929418,0.0009935042,0.00020081566,0.00028058907,0.00024750925,0.0032651157,0.388513,0.0011222186,0.1171923,0.0003383566],"about_ca_topic_score_codex":0.00045857724,"about_ca_topic_score_gemma":0.000029018727,"teacher_disagreement_score":0.30960283,"about_ca_system_score_codex":0.0016295305,"about_ca_system_score_gemma":0.0023473368,"threshold_uncertainty_score":0.45905322},"labels":[],"label_agreement":null},{"id":"W2575327981","doi":"10.1182/blood.v116.21.1587.1587","title":"Gpx3 Determines Competitiveness of Normal and Leukemic Stem Cells.","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Stem cell; Biology; Haematopoiesis; Leukemia; Molecular biology; Cancer research; GPX3; Immunology; Cell biology; Glutathione peroxidase; Oxidative stress; Superoxide dismutase; Biochemistry","score_opus":0.011796505088733766,"score_gpt":0.2548636973507261,"score_spread":0.24306719226199236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2575327981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965365,0.00011958401,0.000013079193,0.00007184185,0.0000863952,0.00019850284,0.000014781389,0.000027474054,0.0029318603],"genre_scores_gemma":[0.99751776,0.000053260042,0.000919702,0.000054034088,0.00014573224,0.000009242363,0.000004660842,0.000019175848,0.0012764466],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992133,0.000023338898,0.00017398906,0.00017850418,0.00019976345,0.00021114515],"domain_scores_gemma":[0.9993348,0.000104432555,0.00005012582,0.00025954586,0.00011767064,0.00013343478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016530581,0.000103694656,0.0002467712,0.000091270835,0.000035289264,0.000009036602,0.00010146449,0.00009614231,0.000118603166],"category_scores_gemma":[0.000022849037,0.00008700945,0.0000422984,0.00010524023,0.00019263758,0.00005207373,0.00009832305,0.00030032333,0.000019902853],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000709651,0.00014139031,0.11308368,0.00020074255,0.000041046165,0.00008417715,0.00012327927,1.5677071e-7,0.8829526,0.00008979673,0.000026582922,0.0031856329],"study_design_scores_gemma":[0.004416714,0.00022404784,0.102356575,0.00006394448,0.000103063096,0.00040283572,0.000109675406,0.00013192417,0.89028364,0.0000078642515,0.0017982825,0.00010144614],"about_ca_topic_score_codex":0.00006216792,"about_ca_topic_score_gemma":0.000030393461,"teacher_disagreement_score":0.01072711,"about_ca_system_score_codex":0.000014939997,"about_ca_system_score_gemma":0.00019332007,"threshold_uncertainty_score":0.35481426},"labels":[],"label_agreement":null},{"id":"W2575626416","doi":"10.1182/blood.v120.21.2391.2391","title":"Epigenetic Therapy Inhibits NUP98-HOXA9-Mediated Myeloid Disease – Decitabine and Valproic Acid Work Synergistically to Rescue Normal Hematopoiesis in Transgenic Zebrafish.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Atlantic Cancer Research Institute; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Biology; Cancer research; Myeloid leukemia; Decitabine; Zebrafish; Myeloid; Haematopoiesis; GATA1; Leukemia; Immunology; Stem cell; DNA methylation; Cell biology; Genetics; Gene expression; Gene","score_opus":0.016643509791405907,"score_gpt":0.26286608214303026,"score_spread":0.24622257235162434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2575626416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888856,0.006165294,0.0001741078,0.002813821,0.00008199614,0.0013936494,0.00003544359,0.00011974848,0.0003303328],"genre_scores_gemma":[0.99499947,0.00078028295,0.0020136514,0.0010960147,0.00037502896,0.00027857066,0.000065624365,0.00010872703,0.0002826226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966139,0.00019560254,0.000614721,0.00059252046,0.00072013604,0.0012631238],"domain_scores_gemma":[0.99709207,0.00029918362,0.000049816736,0.0006716516,0.00013410662,0.0017531487],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007220007,0.00041256644,0.0006395003,0.00044798665,0.000105588275,0.000046557892,0.000263349,0.00021693025,0.00030923737],"category_scores_gemma":[0.00092922273,0.00035490678,0.00013411003,0.0012612162,0.00018136043,0.000184024,0.00014115169,0.00054071564,0.00023396462],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007917062,0.0063906084,0.6643341,0.00074951147,0.0006724229,0.0006523296,0.0044434965,0.000022829792,0.30218115,0.00030642987,0.0015836175,0.010746406],"study_design_scores_gemma":[0.013029966,0.0005475442,0.91350764,0.0003736806,0.0002505473,0.00007362703,0.00012164838,0.00003959609,0.069812275,0.000058449827,0.0015890364,0.0005960088],"about_ca_topic_score_codex":0.000042825133,"about_ca_topic_score_gemma":0.000036106005,"teacher_disagreement_score":0.24917349,"about_ca_system_score_codex":0.0001460217,"about_ca_system_score_gemma":0.00041989403,"threshold_uncertainty_score":0.99989027},"labels":[],"label_agreement":null},{"id":"W2575850575","doi":"10.1182/blood.v120.21.2624.2624","title":"Glutaminase Inhibition Selectively Slows the Growth of Primary Acute Myeloid Leukemia (AML) Cells with Isocitrate Dehydrogenase (IDH) Mutations.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Glutaminase; Isocitrate dehydrogenase; Glutamine; IDH1; IDH2; Glutaminolysis; Biology; Myeloid leukemia; Enzyme; Glutamate dehydrogenase; Biochemistry; Cancer research; Mutant; Glutamate receptor; Gene; Amino acid","score_opus":0.010948669861248782,"score_gpt":0.23675952498464028,"score_spread":0.2258108551233915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2575850575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99339616,0.00044150205,0.00040473868,0.00040598685,0.00004208948,0.0011203614,0.00008560364,0.00009142698,0.0040121344],"genre_scores_gemma":[0.99500424,0.00014190451,0.002943459,0.00059388974,0.00027226243,0.00014821802,0.00015512836,0.0000761675,0.0006647445],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976806,0.00018851593,0.00039998308,0.0003407862,0.00069649954,0.00069361227],"domain_scores_gemma":[0.9983837,0.00022067373,0.00022311466,0.00044577362,0.00041795813,0.0003088018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006087061,0.00029861342,0.00043748118,0.00019945535,0.00021229316,0.000026066695,0.00015169269,0.00017022649,0.00006220854],"category_scores_gemma":[0.000080837795,0.00019886499,0.00014411511,0.0008849459,0.00037334312,0.00035184243,0.00009100567,0.000598627,0.000101298014],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007520178,0.0011113627,0.0084492415,0.0003061848,0.0009802952,0.00027605513,0.002314195,0.000013343723,0.98318887,0.0003601009,0.0015959255,0.00065241917],"study_design_scores_gemma":[0.006794084,0.0006926366,0.02223953,0.000107638065,0.0011786245,0.0008937738,0.0003421919,0.00009697745,0.9671366,0.000090638445,0.00016968929,0.00025760106],"about_ca_topic_score_codex":0.00016138927,"about_ca_topic_score_gemma":0.00001295712,"teacher_disagreement_score":0.016052244,"about_ca_system_score_codex":0.00059146463,"about_ca_system_score_gemma":0.0012372752,"threshold_uncertainty_score":0.8109479},"labels":[],"label_agreement":null},{"id":"W2575984860","doi":"10.1182/blood.v114.22.3115.3115","title":"Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Internal medicine; Oncology; ETV6; Myeloid leukemia; NPM1; Medicine; Incidence (geometry); Cohort; Hepatosplenomegaly; Leukemia; Biology; Karyotype; Genetics; Disease; Chromosome; Gene; Chromosomal translocation","score_opus":0.02207788450904444,"score_gpt":0.3587832996083014,"score_spread":0.33670541509925694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2575984860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98414284,0.000750828,0.000041928608,0.012951835,0.000016669923,0.00070138567,0.000042512922,0.0000239389,0.0013280588],"genre_scores_gemma":[0.99633783,0.00063012965,0.0021724033,0.0005246687,0.00016280354,0.00002978244,0.000078564284,0.000008749975,0.000055065604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986865,0.00013442979,0.00052889675,0.0003096991,0.00015888836,0.00018162126],"domain_scores_gemma":[0.9984915,0.00063799124,0.00015079044,0.00054097833,0.00007512085,0.00010358829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005420588,0.00008745614,0.00026438272,0.00006106972,0.000055230543,0.00000721279,0.00016266137,0.000126084,0.000025225174],"category_scores_gemma":[0.0011077295,0.000063148866,0.00006780821,0.00025028846,0.00021036579,0.000044771747,0.00005924676,0.0004272387,0.0000069730936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027190357,0.0016816178,0.9852088,0.000005796787,0.000092178205,0.00006475959,0.00025808034,2.9845054e-7,0.0005154942,0.00026535837,0.00048334277,0.011397086],"study_design_scores_gemma":[0.0032084791,0.00050262385,0.9936651,0.000052111827,0.00024523414,0.00065082544,0.000035957924,0.000007675327,0.00012251765,0.0012650229,0.0001893778,0.00005505681],"about_ca_topic_score_codex":0.0001994465,"about_ca_topic_score_gemma":0.00006310471,"teacher_disagreement_score":0.012427167,"about_ca_system_score_codex":0.000041408442,"about_ca_system_score_gemma":0.0004296271,"threshold_uncertainty_score":0.25751358},"labels":[],"label_agreement":null},{"id":"W2575989280","doi":"10.1182/blood.v120.21.529.529","title":"Cryptic NUP98/NSD1 Translocations Are Highly Prevalent in FLT3/ITD-Positive Acute Myeloid Leukemia and Lead to High Rate of Induction Failure. Report From Children's Oncology Group","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Hospital for Sick Children","funders":"","keywords":"Chromosomal translocation; NPM1; Myeloid leukemia; Sanger sequencing; Internal medicine; CEBPA; Fusion transcript; Oncology; Biology; Cancer research; Medicine; Genetics; Mutation; Gene; Karyotype","score_opus":0.013823085785360678,"score_gpt":0.28017487062929103,"score_spread":0.26635178484393035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2575989280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927434,0.0005763642,0.00032797488,0.004301654,0.0001658545,0.0014698778,0.00013338264,0.000059481426,0.00022201896],"genre_scores_gemma":[0.99259627,0.00022562128,0.005475221,0.00025908698,0.0004933995,0.00019853628,0.0004260443,0.000051735995,0.00027406393],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99754053,0.00027441068,0.0006835774,0.00056355435,0.00036048327,0.00057744206],"domain_scores_gemma":[0.99840826,0.00020179851,0.00025839618,0.00055700785,0.0002035216,0.00037101316],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006511088,0.00028721252,0.00069092814,0.0004055845,0.00008533386,0.000016934808,0.00016280617,0.00034396967,0.00006508806],"category_scores_gemma":[0.00022107652,0.00026864262,0.000089514906,0.0005694313,0.00017584019,0.00028191032,0.00010100738,0.00063889875,0.000047155536],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014963901,0.0035157232,0.32955912,0.0002561467,0.0025385618,0.00086760806,0.0077793254,0.000029794362,0.6431119,0.0005870521,0.0028881335,0.0073702643],"study_design_scores_gemma":[0.006227285,0.00073381973,0.90110487,0.0002561038,0.0010577303,0.0007116561,0.00041256731,0.000014734264,0.0886671,0.00010097884,0.00045324018,0.00025992567],"about_ca_topic_score_codex":0.0022054566,"about_ca_topic_score_gemma":0.00035397342,"teacher_disagreement_score":0.5715457,"about_ca_system_score_codex":0.00087586965,"about_ca_system_score_gemma":0.00047353838,"threshold_uncertainty_score":0.9999766},"labels":[],"label_agreement":null},{"id":"W2576009444","doi":"10.1158/1078-0432.ccr-16-2353","title":"Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medicine; Myeloid leukemia; Oncology; Myeloid; Flow cytometry; Internal medicine; Leukemia; Cancer; Cancer research; Receptor expression; Cell; Receptor; Immunology; Biology","score_opus":0.09331618270559418,"score_gpt":0.4623432076157812,"score_spread":0.369027024910187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2576009444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98163855,0.0014451075,0.00003714365,0.013744752,0.00021350302,0.002082805,0.0003921437,0.000025495146,0.00042047526],"genre_scores_gemma":[0.97483975,0.021573845,0.000917956,0.00016329401,0.0013274716,0.0003079443,0.00025258306,0.00005334843,0.000563822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953202,0.0008539697,0.0011834769,0.0009752549,0.00091687375,0.0007502291],"domain_scores_gemma":[0.99172705,0.0041753445,0.00057242776,0.0021031052,0.0006671703,0.0007549221],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0041488074,0.0002274504,0.00075174274,0.00012853091,0.0005535086,0.000096428485,0.0010193407,0.00039288282,0.000174478],"category_scores_gemma":[0.010125364,0.00015937391,0.00015720338,0.00035611255,0.0014271067,0.00016082561,0.0012956327,0.0026490607,0.000040150604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017774457,0.00042251727,0.96948373,0.00009549618,0.00006124391,0.0002583172,0.00012992258,6.545968e-7,0.007674079,0.00001821076,0.012261782,0.007816583],"study_design_scores_gemma":[0.0028068624,0.00045234285,0.9934215,0.0001615626,0.0001695037,0.00001618995,0.000053168347,0.00008495326,0.0004357778,0.00022443544,0.0020256147,0.00014808694],"about_ca_topic_score_codex":0.0015346913,"about_ca_topic_score_gemma":0.00016026956,"teacher_disagreement_score":0.023937754,"about_ca_system_score_codex":0.00081524055,"about_ca_system_score_gemma":0.004234533,"threshold_uncertainty_score":0.99965185},"labels":[],"label_agreement":null},{"id":"W2579125732","doi":"10.1182/blood.v120.21.4941.4941","title":"Interlaboratory Validation of a 3-Tube 10-Color Antibody Flow Cytometry Panel for Diagnosis of Myelodysplastic Syndromes","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytometry; CD34; Medicine; Flow cytometry; CD33; Antigen; Antibody; Immunology; Pathology; Biology; Stem cell","score_opus":0.039722465870081054,"score_gpt":0.329344464250231,"score_spread":0.28962199838014996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2579125732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99728644,0.00061127124,0.00068303506,0.0001038602,0.00013496204,0.0007368151,0.00018364876,0.000035586418,0.00022437698],"genre_scores_gemma":[0.9947994,0.00008965012,0.004321444,0.000034744775,0.00018757307,0.00017232381,0.00014674717,0.000041157793,0.00020695977],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985173,0.00006554791,0.0004334147,0.00020342127,0.00038975768,0.0003905658],"domain_scores_gemma":[0.99814,0.00070551265,0.00017568772,0.00035373928,0.00044522478,0.00017983723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053702586,0.00016135743,0.0005032167,0.00040638217,0.00003351083,0.00000697768,0.00015694943,0.00015267324,0.000311071],"category_scores_gemma":[0.0016489365,0.00013979615,0.00013168108,0.00061031495,0.00012168544,0.00017233918,0.000080270904,0.0001443479,0.000041245876],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074116094,0.003951632,0.683519,0.003073277,0.0010690191,0.000025138528,0.0010329504,0.000009371552,0.30093294,0.00013570365,0.0031997303,0.0023100688],"study_design_scores_gemma":[0.006546124,0.0016220638,0.11803107,0.00039472472,0.0009128882,0.00007609881,0.00032716896,0.00034790128,0.870428,0.000015647627,0.001105486,0.00019277389],"about_ca_topic_score_codex":0.000011082518,"about_ca_topic_score_gemma":6.098394e-7,"teacher_disagreement_score":0.56949514,"about_ca_system_score_codex":0.00008182545,"about_ca_system_score_gemma":0.00024650505,"threshold_uncertainty_score":0.5700721},"labels":[],"label_agreement":null},{"id":"W2579376283","doi":"10.1182/blood.v106.11.1860.1860","title":"A Phase II Study of Temozolomide Therapy for Poor Risk Patients Age ≥ 60 Years with Acute Myeloid Leukemia (AML) - Low Levels of MGMT May Predict for Response.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Leukemia; Cytarabine; Nausea; Decitabine; Temozolomide; Induction chemotherapy; Surgery; Phases of clinical research; Gastroenterology; Oncology; Chemotherapy","score_opus":0.021989801246705583,"score_gpt":0.315142500201624,"score_spread":0.2931526989549184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2579376283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908804,0.00010498719,0.0002283913,0.00016802871,0.00004010362,0.006679529,0.0017781084,0.000058520345,0.000061923696],"genre_scores_gemma":[0.99057245,0.0000708363,0.0066574845,0.0001245332,0.000176052,0.0005974963,0.000093599614,0.000111566915,0.0015959524],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972263,0.00019381708,0.00071523944,0.0005453061,0.0007384806,0.0005808442],"domain_scores_gemma":[0.9975849,0.0005484316,0.00042922504,0.0007422855,0.0004734605,0.00022172755],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010402972,0.00032096813,0.0008272266,0.00034314,0.00013462972,0.000012982287,0.0003708305,0.00017736797,0.000037399364],"category_scores_gemma":[0.00047571605,0.00024873728,0.00020515503,0.00037108056,0.00018264141,0.00013349498,0.00010237692,0.00030773765,0.000003819319],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37398046,0.07606967,0.04371079,0.0006294726,0.010600898,0.0006974869,0.015005865,0.00010788618,0.3412617,0.000017634495,0.009967317,0.12795079],"study_design_scores_gemma":[0.3994377,0.1584873,0.19333935,0.00029575982,0.0020495737,0.000043326778,0.00101479,0.0005907388,0.23756568,0.000026109336,0.0066207163,0.0005289455],"about_ca_topic_score_codex":0.00009568354,"about_ca_topic_score_gemma":0.00004749195,"teacher_disagreement_score":0.14962856,"about_ca_system_score_codex":0.00027770668,"about_ca_system_score_gemma":0.0009920571,"threshold_uncertainty_score":0.9999965},"labels":[],"label_agreement":null},{"id":"W2579581480","doi":"10.1182/blood.v120.21.2318.2318","title":"GATA1s Induces Hyperproliferation of Eosinophil Precursors.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"GATA1; Progenitor cell; Haematopoiesis; Myeloid; Cancer research; Eosinophilia; Biology; Gene knockdown; Myeloid leukemia; Cellular differentiation; Immunology; Molecular biology; Stem cell; Cell culture; Cell biology; Genetics","score_opus":0.02743425637401255,"score_gpt":0.2949856177065621,"score_spread":0.2675513613325496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2579581480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98943394,0.0008609664,0.000016431783,0.00046239776,0.00006931584,0.0002710637,0.0000067150154,0.000034218127,0.008844926],"genre_scores_gemma":[0.9973741,0.0000554969,0.0013610218,0.00012823891,0.00051133614,0.000020170073,0.00002498214,0.000017566334,0.0005070796],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991168,0.000039367947,0.00017513796,0.00011241691,0.0002949183,0.00026140484],"domain_scores_gemma":[0.9994011,0.000045410856,0.00005112889,0.00025191635,0.000098394186,0.00015204969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026210293,0.00008349859,0.00018284333,0.00009652119,0.000031150976,0.0000060077923,0.000075132266,0.000093752,0.00012281095],"category_scores_gemma":[0.00020064316,0.00006812753,0.000044854874,0.0001706195,0.000057743066,0.00014463872,0.00004136673,0.00017579156,0.00009422718],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021473752,0.0023790968,0.26889437,0.00028749686,0.00025888468,0.000014961384,0.0015965472,7.5439505e-7,0.7156969,0.0013315354,0.0032953185,0.00602941],"study_design_scores_gemma":[0.0032517002,0.00035540774,0.14154367,0.000070329006,0.00021397194,0.00016701248,0.00011075017,0.000021673995,0.8514746,0.00005794585,0.0026158765,0.000117056814],"about_ca_topic_score_codex":0.000030805382,"about_ca_topic_score_gemma":9.4954714e-7,"teacher_disagreement_score":0.13577771,"about_ca_system_score_codex":0.000033394972,"about_ca_system_score_gemma":0.0001489946,"threshold_uncertainty_score":0.277816},"labels":[],"label_agreement":null},{"id":"W2579757892","doi":"10.1182/blood.v120.21.414.414","title":"Results From the Dose Escalation Phase of a Randomized Phase 1–2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Decitabine; Tolerability; Medicine; Hypomethylating agent; Regimen; Neutropenia; Phases of clinical research; Pharmacodynamics; Pharmacokinetics; Internal medicine; Nausea; Adverse effect; Febrile neutropenia; Pharmacology; Oncology; Clinical trial; Toxicity; Chemistry","score_opus":0.024895926030192483,"score_gpt":0.28826588558876093,"score_spread":0.26336995955856846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2579757892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959869,0.00029645854,0.000056209854,0.000038756367,0.000047208385,0.0032329354,0.00022428037,0.000014286133,0.000102981554],"genre_scores_gemma":[0.998633,0.000017546503,0.00057451625,0.0000200642,0.00011587615,0.000087569104,0.00040148245,0.000038506074,0.00011142793],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99706644,0.00041503794,0.0010794192,0.00038127275,0.00068043574,0.00037739397],"domain_scores_gemma":[0.99775684,0.0008012167,0.00056547014,0.00050654175,0.00022707519,0.00014286718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018918478,0.00023656547,0.00085970346,0.0002796564,0.00009708026,0.000022347886,0.00012031122,0.00012443698,0.000069335845],"category_scores_gemma":[0.0010476111,0.00016568752,0.00006463273,0.0004202877,0.00013255792,0.00026107175,0.00008073201,0.00041221845,0.0000014255289],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29994828,0.095792614,0.3322416,0.00032139805,0.0013069857,0.00012167707,0.05326417,0.00035535818,0.21052928,0.000011410348,0.0002588296,0.005848419],"study_design_scores_gemma":[0.8841583,0.0049631754,0.09629239,0.00022857975,0.00047039703,0.000007445924,0.0010348865,0.0062748687,0.00631641,0.0000047123335,0.000034684013,0.00021414529],"about_ca_topic_score_codex":0.001882171,"about_ca_topic_score_gemma":0.0012612226,"teacher_disagreement_score":0.58421004,"about_ca_system_score_codex":0.00017609035,"about_ca_system_score_gemma":0.00012405534,"threshold_uncertainty_score":0.6756542},"labels":[],"label_agreement":null},{"id":"W2580337570","doi":"10.1182/blood.v124.21.3579.3579","title":"Modeling the Multi-Step Pathogenesis of Acute Myeloid Leukemia of Down Syndrome","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; University Health Network","funders":"","keywords":"Acute megakaryoblastic leukemia; GATA1; Down syndrome; Population; Myeloid leukemia; Leukemia; Medicine; Immunology; Trisomy; Acute leukemia; Cancer research; Myeloid; Biology; Internal medicine; Genetics; Erythropoiesis; Anemia","score_opus":0.02229596918701218,"score_gpt":0.2758438360047926,"score_spread":0.25354786681778047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2580337570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99199086,0.00029343704,0.006127145,0.00026708876,0.000046431407,0.00043790293,0.00003978961,0.00004111612,0.0007561964],"genre_scores_gemma":[0.9883699,0.00017549764,0.01065785,0.00011914706,0.00007590992,0.000030656043,0.000018834206,0.000044466295,0.00050772884],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99817413,0.00012369743,0.00048932125,0.0002953141,0.00054963795,0.00036787777],"domain_scores_gemma":[0.9984657,0.00014724107,0.00012592587,0.00086591695,0.00025712943,0.00013806789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007294182,0.00018683191,0.0005343693,0.0001487397,0.000069622874,0.000007915223,0.00038102272,0.00015404697,0.000054698707],"category_scores_gemma":[0.00022041888,0.00012335081,0.00020483097,0.00033559557,0.00015808968,0.00005404335,0.0001831079,0.00029953968,0.000035534566],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048043733,0.0010528285,0.014669814,0.00087830005,0.0022098704,0.00024457538,0.0011176342,0.0016472695,0.9643426,0.0005498325,0.00031034907,0.012496517],"study_design_scores_gemma":[0.026603164,0.0020624418,0.06405116,0.00075416843,0.0044862563,0.0024572294,0.0007725791,0.6565143,0.24047694,0.00013888288,0.00095328473,0.0007295856],"about_ca_topic_score_codex":0.00037277088,"about_ca_topic_score_gemma":0.000014003544,"teacher_disagreement_score":0.7238656,"about_ca_system_score_codex":0.000092455186,"about_ca_system_score_gemma":0.0003676252,"threshold_uncertainty_score":0.50301},"labels":[],"label_agreement":null},{"id":"W2580495053","doi":"10.1182/blood.v114.22.1046.1046","title":"Modulation of Histone H3K4 and H3K27 Methylation Levels Via Pharmacological Inhibition of LSD1 and Degradation of the EZH2-Containing Polycomb Repressive Complex 2 Stimulates ATRA-Mediated Differentiation of AML Cells.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"EZH2; Cellular differentiation; Retinoic acid; Cancer research; Tretinoin; Biology; Acute promyelocytic leukemia; Haematopoiesis; Retinoid; Retinoic acid receptor; Gene silencing; Stem cell; Cell biology; Epigenetics; Cell culture; Biochemistry; Genetics","score_opus":0.03744741966734066,"score_gpt":0.3270388937491313,"score_spread":0.28959147408179065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2580495053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972502,0.0002416286,0.0015864572,0.00019917486,0.000020952813,0.00059345405,0.000050544786,0.000012139595,0.00004546456],"genre_scores_gemma":[0.9990346,0.000052523137,0.0007172146,0.000020551486,0.000021514914,0.0000041337494,0.00012917694,0.0000081748285,0.0000121311405],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998625,0.00017076901,0.0005476431,0.00019860613,0.00034136185,0.00011663909],"domain_scores_gemma":[0.99866766,0.00025101422,0.0005757591,0.0001589101,0.0002991264,0.000047541223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029994542,0.00011488984,0.00037276454,0.00015870424,0.000042285155,0.0000032597384,0.00004765981,0.00011888396,0.00002675609],"category_scores_gemma":[0.00023225568,0.00008796752,0.000056556964,0.00024180375,0.0001744527,0.00011094636,0.000040210234,0.00013932934,1.2236949e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037422674,0.0003216818,0.010341297,0.00012478228,0.00008202066,0.0000010334281,0.0005370977,0.00016713983,0.9831736,0.000056869354,0.0000078526,0.004812399],"study_design_scores_gemma":[0.002911936,0.00039813135,0.4090191,0.00006902339,0.00020866864,0.0000043000937,0.000034624136,0.018320376,0.568707,0.0002862351,3.903352e-7,0.000040218227],"about_ca_topic_score_codex":0.000093049886,"about_ca_topic_score_gemma":0.0000034688612,"teacher_disagreement_score":0.41446662,"about_ca_system_score_codex":0.000054356035,"about_ca_system_score_gemma":0.000053545802,"threshold_uncertainty_score":0.35872114},"labels":[],"label_agreement":null},{"id":"W2581002727","doi":"10.1182/blood.v124.21.1009.1009","title":"The Prognostic Impact of High MEL1 Gene Expression in Pediatric Acute Myeloid Leukemia","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Myeloid leukemia; Fusion gene; NPM1; Cancer research; Gene expression; Biology; Gene; Acute promyelocytic leukemia; Gene expression profiling; Leukemia; Haematopoiesis; Immunology; Stem cell; Genetics; Retinoic acid; Karyotype","score_opus":0.010257205961350196,"score_gpt":0.2780282461467004,"score_spread":0.2677710401853502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581002727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997564,0.0006365501,0.00008535717,0.0002067693,0.00005867469,0.00060465466,0.000011292478,0.000043095886,0.00078957906],"genre_scores_gemma":[0.99681425,0.0009376672,0.0013288002,0.00003196093,0.0004294419,0.0000626823,0.00002627771,0.00004077102,0.00032817526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980663,0.00016536775,0.0004018127,0.00030641124,0.0005313149,0.0005287806],"domain_scores_gemma":[0.9983334,0.0005462654,0.00013935009,0.0006426986,0.00014324223,0.00019504575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006873668,0.0001967307,0.0003990188,0.00021472086,0.00008716756,0.000020962769,0.00032092413,0.00015344199,0.00003941732],"category_scores_gemma":[0.000830383,0.000115055744,0.00015107033,0.0005437975,0.000092988696,0.0000716352,0.00017064443,0.00046056003,0.000054239536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006882678,0.0006095762,0.71981394,0.0001784236,0.00026797602,0.00016844418,0.00031416575,0.000067985646,0.26985776,0.000091970534,0.0033006924,0.0046407706],"study_design_scores_gemma":[0.007093979,0.0010717325,0.8683057,0.00007350149,0.00036123383,0.00012143247,0.000019727779,0.00034350983,0.12209727,0.00021612192,0.00013244724,0.00016337412],"about_ca_topic_score_codex":0.00022301197,"about_ca_topic_score_gemma":0.000014033503,"teacher_disagreement_score":0.1484917,"about_ca_system_score_codex":0.00029101514,"about_ca_system_score_gemma":0.00079220714,"threshold_uncertainty_score":0.4691837},"labels":[],"label_agreement":null},{"id":"W2581372286","doi":"10.1182/blood.v116.21.655.655","title":"Phase 2B Randomized Study of CPX-351 Vs. Cytarabine (CYT) + Daunorubicin (DNR) (7+3 Regimen) In Newly Diagnosed AML Patients Aged 60–75","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cytarabine; Regimen; Internal medicine; Clinical endpoint; Daunorubicin; Gastroenterology; Chemotherapy regimen; Randomization; Febrile neutropenia; Phases of clinical research; Leukemia; Neutropenia; Chemotherapy; Surgery; Randomized controlled trial","score_opus":0.012903436643663032,"score_gpt":0.29914894753650567,"score_spread":0.2862455108928426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581372286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926557,0.00009750581,0.00001166827,0.00033484207,0.00023191562,0.0054149562,0.000028912555,0.00008875894,0.0011357741],"genre_scores_gemma":[0.9971559,0.00006751023,0.0007577196,0.00020091824,0.0002149065,0.00040191508,0.00011950188,0.0000880244,0.000993612],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99568737,0.0006351604,0.0011840655,0.00070922915,0.0010650611,0.0007191383],"domain_scores_gemma":[0.9966785,0.0010233945,0.00035609695,0.0012439024,0.00031881995,0.0003793154],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018786367,0.00042195249,0.0017535178,0.00061732973,0.00008926318,0.000028068222,0.00047060053,0.0002595312,0.00038189735],"category_scores_gemma":[0.0032996947,0.0003394431,0.00023757266,0.000815812,0.00027585687,0.0001737827,0.00021663858,0.0013271756,0.00007377869],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26735497,0.13296995,0.32847375,0.00040968516,0.0018307314,0.0030842926,0.011528849,0.000012741784,0.24005394,0.00005173534,0.0072571384,0.006972234],"study_design_scores_gemma":[0.8820079,0.004415135,0.09134009,0.00012887192,0.0006321348,0.000017131482,0.00047150653,0.00021003356,0.020187663,0.000029823073,0.00025566283,0.0003040684],"about_ca_topic_score_codex":0.0019234366,"about_ca_topic_score_gemma":0.0006716964,"teacher_disagreement_score":0.61465293,"about_ca_system_score_codex":0.00012165747,"about_ca_system_score_gemma":0.00034969352,"threshold_uncertainty_score":0.99990577},"labels":[],"label_agreement":null},{"id":"W2581441713","doi":"10.1182/blood.v114.22.4125.4125","title":"Modest Prolongation of Survival for Patients 60-80 Year at Time of Acute Myelogenous Leukemia (AML) Diagnosis Who Are Treated with Conventional AML Therapy: A Provincial Cohort Analysis.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Cohort; Incidence (geometry); Transplantation; Pediatrics; Cancer registry; Surgery; Chemotherapy regimen; Induction chemotherapy; Chemotherapy; Cancer; Internal medicine","score_opus":0.011104037831921678,"score_gpt":0.2530085981590873,"score_spread":0.2419045603271656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581441713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996441,0.000049573908,0.00008965404,0.000105176296,0.0000097951315,0.0022877376,0.00066944544,0.00003654523,0.00031105353],"genre_scores_gemma":[0.996947,0.000078206765,0.00046280475,0.000045952307,0.00007495042,0.0002379033,0.0015927438,0.000032698583,0.0005277207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980279,0.000091659116,0.00044634816,0.00039193334,0.00071931916,0.00032284507],"domain_scores_gemma":[0.998223,0.00010500884,0.00037948208,0.000354969,0.0008134555,0.00012410372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027741367,0.0002193531,0.0008212706,0.00029407558,0.00008154831,0.000009608799,0.00015508414,0.00016650031,0.00008196994],"category_scores_gemma":[0.00008128646,0.00017121287,0.00025863264,0.000632775,0.0001302464,0.00007805026,0.000032417127,0.00013609776,0.000007636878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038399375,0.002203885,0.98390573,0.000070538845,0.004435879,0.000023171347,0.00018745889,0.000049722254,0.0043667806,0.000017461794,0.0003460299,0.00055340136],"study_design_scores_gemma":[0.014011158,0.004024354,0.9390306,0.000079111,0.003659172,0.0000055533997,0.000015848786,0.001016968,0.03793159,0.000017321228,0.00004012934,0.00016819098],"about_ca_topic_score_codex":0.00015279086,"about_ca_topic_score_gemma":0.00005581598,"teacher_disagreement_score":0.04487513,"about_ca_system_score_codex":0.00036795312,"about_ca_system_score_gemma":0.00047124072,"threshold_uncertainty_score":0.6981858},"labels":[],"label_agreement":null},{"id":"W2581553487","doi":"10.1182/blood.v114.22.396.396","title":"ETO2 Controls Hematopoietic Stem Cell Expansion.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Biology; Stem cell; CD34; Haematopoiesis; Cancer research; Progenitor cell; Hematopoietic stem cell; Transcription factor; Cell biology; Genetics; Gene","score_opus":0.015132631446027433,"score_gpt":0.26831886580877246,"score_spread":0.253186234362745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581553487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96479964,0.0014120602,0.00012571437,0.003013128,0.000043322332,0.00054892024,0.000004295077,0.00015268166,0.029900238],"genre_scores_gemma":[0.9904776,0.00007534354,0.00063789473,0.0018924235,0.00020179387,0.000017499407,0.000007981025,0.000022988974,0.0066664494],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986227,0.00004578972,0.00023392972,0.00027310374,0.0004128093,0.00041165025],"domain_scores_gemma":[0.9990171,0.00008162126,0.00004544578,0.00049942575,0.00009308038,0.00026331152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020241107,0.00014899025,0.00033223612,0.000095566334,0.00006185601,0.000022595674,0.00014520554,0.00012044154,0.00017872696],"category_scores_gemma":[0.00002752312,0.000119481076,0.00010601657,0.00019285339,0.000039699156,0.000052981024,0.00003277747,0.00032048882,0.000595312],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051347696,0.004016305,0.004078467,0.0003149013,0.00019271747,0.002688189,0.0015446419,0.000005008513,0.9307118,0.0017295544,0.032313652,0.021891277],"study_design_scores_gemma":[0.047918465,0.0035153497,0.020622311,0.0003537891,0.0007589368,0.0016117839,0.0012008082,0.0003460671,0.8933916,0.00091321586,0.02863542,0.00073221675],"about_ca_topic_score_codex":0.000006731673,"about_ca_topic_score_gemma":4.883225e-7,"teacher_disagreement_score":0.04740499,"about_ca_system_score_codex":0.0000619389,"about_ca_system_score_gemma":0.0002248749,"threshold_uncertainty_score":0.76517296},"labels":[],"label_agreement":null},{"id":"W2582263258","doi":"10.1182/blood.v114.22.1202.1202","title":"Impact of the Intensity of Conditioning Therapy On the Outcomes of Patients Aged 40 to 60 Years with Acute Myeloid Leukemia/Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Transplantation; Myeloid leukemia; Hematopoietic stem cell transplantation; Alemtuzumab; Population; Leukemia; Myelodysplastic syndromes; Oncology; Graft-versus-host disease; Acute leukemia; Surgery; Bone marrow","score_opus":0.012251677819701906,"score_gpt":0.2599270747477609,"score_spread":0.24767539692805898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582263258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99855876,0.000025097446,0.0000677812,0.00023159957,0.000025977568,0.00084346323,0.00008101554,0.000016091364,0.00015018576],"genre_scores_gemma":[0.99927354,0.00007087522,0.00023011897,0.00028355693,0.00000830536,0.000011761837,0.000027573757,0.000025241468,0.000069003305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983646,0.000106689855,0.00039566358,0.00022379107,0.0006334148,0.00027583347],"domain_scores_gemma":[0.99850094,0.00044580814,0.00024970275,0.0004905827,0.0002184478,0.00009452129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020781042,0.0002047072,0.00051263184,0.000156483,0.0000770396,0.000008651189,0.00028554676,0.00007954804,0.000045054],"category_scores_gemma":[0.00010031185,0.00010671934,0.0002102412,0.00044068415,0.00015449124,0.00004861508,0.000027758046,0.000288541,0.000005555662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00465845,0.0021608563,0.7988383,0.0002926525,0.002899688,0.00041120502,0.007021697,0.001618393,0.18147434,0.00010825807,0.00026829334,0.0002478318],"study_design_scores_gemma":[0.005026032,0.0028483062,0.9254939,0.0002615629,0.00033989982,0.00010204571,0.00010628472,0.000007715517,0.06566933,0.000045762277,5.0783336e-7,0.00009863932],"about_ca_topic_score_codex":0.0000776544,"about_ca_topic_score_gemma":0.0000125373535,"teacher_disagreement_score":0.12665558,"about_ca_system_score_codex":0.00015842462,"about_ca_system_score_gemma":0.0005147985,"threshold_uncertainty_score":0.43518883},"labels":[],"label_agreement":null},{"id":"W2582666002","doi":"10.1002/cncr.30567","title":"Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for <scp>I</scp>nternational <scp>B</scp>lood and <scp>M</scp>arrow <scp>T</scp>ransplant <scp>R</scp>esearch cohort analysis","year":2017,"lang":"en","type":"article","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Health Resources and Services Administration","keywords":"Medicine; Myeloid leukemia; Transplantation; Leukemia; Internal medicine; Oncology; Myeloid; Single Center; Immunology","score_opus":0.01787820695318891,"score_gpt":0.2930733863054508,"score_spread":0.2751951793522619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582666002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827527,0.0020720763,0.00076145446,0.00014773592,0.00045435282,0.004693467,0.0076336805,0.00013247912,0.0013520548],"genre_scores_gemma":[0.97448283,0.00544522,0.0012214985,0.0009193165,0.000553848,0.0027787352,0.0030829727,0.0003729188,0.011142658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9892355,0.00060777104,0.0019696027,0.0027712213,0.0025234353,0.0028924488],"domain_scores_gemma":[0.9879602,0.006317989,0.0011969063,0.0019941812,0.0012309545,0.0012997411],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0016388422,0.0016892917,0.0026444793,0.0021961797,0.0008090934,0.0005745752,0.0016476123,0.0009645638,0.00007752561],"category_scores_gemma":[0.002716423,0.0013692403,0.000781462,0.0013162211,0.0008636353,0.0009852602,0.00045976433,0.0018923826,0.000051626917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020912223,0.0004230237,0.97492665,0.0009520393,0.0038113627,0.00075528177,0.0074993256,0.0004458511,0.0044490774,0.000006381316,0.0054899435,0.0010319195],"study_design_scores_gemma":[0.020113712,0.00057048816,0.94683987,0.00096544524,0.0023314562,0.00017524353,0.0016095992,0.0052933944,0.008711365,0.00008222657,0.0131112505,0.0001959212],"about_ca_topic_score_codex":0.0010292672,"about_ca_topic_score_gemma":0.006944144,"teacher_disagreement_score":0.028086774,"about_ca_system_score_codex":0.002278727,"about_ca_system_score_gemma":0.0016754483,"threshold_uncertainty_score":0.9995854},"labels":[],"label_agreement":null},{"id":"W2582847085","doi":"10.1182/blood.v108.11.4449.4449","title":"Percent of Peripheral Blood Leukemic Blasts (PPBLB) at Diagnosis as a Predictor of Short- and Long-Term Survival in Acute Myeloid Leukemia (AML).","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Univariate analysis; Acute promyelocytic leukemia; Internal medicine; Myeloid leukemia; Leukemia; Bone marrow; Surgery; Population; Multivariate analysis; Gastroenterology","score_opus":0.012634142514567898,"score_gpt":0.26848169079500367,"score_spread":0.25584754828043577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582847085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953787,0.0021581452,0.000006438068,0.00016343905,0.00009675083,0.0010351331,0.00013948607,0.000062852036,0.00095909735],"genre_scores_gemma":[0.99579227,0.0020025037,0.00027745118,0.000065504144,0.00027635795,0.0001359827,0.00013882028,0.00009089075,0.0012202295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996374,0.00015296928,0.0009603265,0.0007200119,0.0010023159,0.00079036487],"domain_scores_gemma":[0.99835044,0.00023621132,0.00018506622,0.0006947472,0.00021849094,0.0003150371],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041449603,0.00044398694,0.0010753811,0.0003911512,0.000069268244,0.000021512224,0.00032742418,0.00035266965,0.00042099526],"category_scores_gemma":[0.00014508043,0.0004090268,0.00022724114,0.00049436756,0.00048077275,0.0001498,0.00041956545,0.0005529153,0.000013296412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081540353,0.0011904587,0.8214263,0.0004689709,0.0004888138,0.0007185817,0.00040116452,0.00001138164,0.17371875,0.000035742825,0.0002205406,0.00050391775],"study_design_scores_gemma":[0.012992428,0.0014275735,0.8558916,0.0004512569,0.0009317906,0.00057321065,0.00007312158,0.00008326838,0.12716883,0.000018233277,0.00008249468,0.00030618533],"about_ca_topic_score_codex":0.000997746,"about_ca_topic_score_gemma":0.0008185804,"teacher_disagreement_score":0.046549916,"about_ca_system_score_codex":0.00083995936,"about_ca_system_score_gemma":0.0008979932,"threshold_uncertainty_score":0.99983615},"labels":[],"label_agreement":null},{"id":"W2582892663","doi":"10.1038/leu.2017.30","title":"Biological and clinical consequences of NPM1 mutations in AML","year":2017,"lang":"en","type":"review","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":229,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"NPM1; Myeloid leukemia; Haematopoiesis; Mutation; Leukemia; Myeloid; Cancer research; Bone marrow; Gene mutation; Biology; Gene; Medicine; Stem cell; Immunology; Genetics; Karyotype","score_opus":0.2722373400079822,"score_gpt":0.4954348384625376,"score_spread":0.2231974984545554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582892663","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003441639,0.9914052,0.0000041225862,0.00013907603,0.00011169642,0.0009529594,0.000058157962,0.000017753471,0.0038694104],"genre_scores_gemma":[0.0011514304,0.996933,0.0007073065,0.000042769607,0.00019177972,0.000055748944,0.00014347026,0.000025252146,0.00074923254],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973897,0.00038886748,0.0011488328,0.0005174517,0.00022992128,0.0003252558],"domain_scores_gemma":[0.9972091,0.00135432,0.0004960977,0.0006461107,0.00009069253,0.00020368675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011471224,0.00028361953,0.0024961245,0.0002897927,0.00006063911,0.0000234403,0.00035694166,0.0008453494,0.00012852393],"category_scores_gemma":[0.0029264393,0.00018904192,0.00037751114,0.00019567103,0.0019286879,0.000047086072,0.00020938853,0.0013192804,0.000099077246],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003012274,0.000041832383,0.0024774428,0.0040661213,0.00015829476,0.00042194006,0.000024979836,4.7250843e-8,0.0000029601383,0.00018517092,0.00054697145,0.9920441],"study_design_scores_gemma":[0.0011680924,0.00035495157,0.0029677139,0.010723337,0.00045989096,0.00047757238,0.000029617531,0.000013410498,0.000003275243,0.0002450622,0.98332775,0.00022934284],"about_ca_topic_score_codex":0.00018569423,"about_ca_topic_score_gemma":0.00003053343,"teacher_disagreement_score":0.9918148,"about_ca_system_score_codex":0.00064258784,"about_ca_system_score_gemma":0.0044846814,"threshold_uncertainty_score":0.7955632},"labels":[],"label_agreement":null},{"id":"W2583180477","doi":"10.1182/blood.v114.22.2737.2737","title":"ARNT Mediates Chemotherapy Resistance by Modulating the Response to Oxidative Stress in AML Cells.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Aryl hydrocarbon receptor nuclear translocator; Apoptosis; Cancer research; Haematopoiesis; Etoposide; Biology; Chemistry; Transcription factor; Cell biology; Internal medicine; Stem cell; Medicine; Chemotherapy; Biochemistry","score_opus":0.009977501110921898,"score_gpt":0.2786471813479287,"score_spread":0.2686696802370068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583180477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976549,0.00050204893,0.000041877753,0.02101159,0.00001962159,0.00063255243,0.00002671906,0.00004363932,0.0011729123],"genre_scores_gemma":[0.99317926,0.00009824293,0.0018329314,0.0021869875,0.000114199574,0.00003528533,0.000011765306,0.000021336666,0.0025199857],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983745,0.00020974605,0.0002507247,0.00032380348,0.0004291018,0.0004120927],"domain_scores_gemma":[0.9987968,0.00044696307,0.000058875008,0.00046586787,0.00008041606,0.00015103437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077594223,0.00015852871,0.00024712936,0.00011820379,0.00007376815,0.00002777079,0.00025129548,0.00008350348,0.00004597353],"category_scores_gemma":[0.00052186433,0.00011114791,0.0000443967,0.0005177147,0.000059700218,0.00005089067,0.000036929334,0.00037918857,0.000033364442],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002682078,0.00052896806,0.0025375343,0.000019896444,0.00004399911,0.00011139924,0.0038965356,0.000022940856,0.97786015,0.000027640543,0.009233309,0.0030355414],"study_design_scores_gemma":[0.005602149,0.0004739494,0.04931873,0.00020210176,0.000024424715,0.000006381668,0.0007544289,0.00017867667,0.9369704,0.00015443974,0.0061251093,0.00018919042],"about_ca_topic_score_codex":0.000055425637,"about_ca_topic_score_gemma":0.00006094118,"teacher_disagreement_score":0.046781197,"about_ca_system_score_codex":0.0001601645,"about_ca_system_score_gemma":0.00015392381,"threshold_uncertainty_score":0.45324802},"labels":[],"label_agreement":null},{"id":"W2583386249","doi":"10.1182/blood.v110.11.1469.1469","title":"Improved Leukemia-Free and Overall Survival in Patients with Myelodysplastic Syndrome Receiving Iron Chelation Therapy: A Subgroup Analysis.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Univariate analysis; International Prognostic Scoring System; Myelodysplastic syndromes; Anemia; Gastroenterology; Multivariate analysis; Neutropenia; Subgroup analysis; Bone marrow; Chemotherapy; Confidence interval","score_opus":0.008335129943534018,"score_gpt":0.23434987927183684,"score_spread":0.22601474932830282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583386249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983306,0.00013347153,0.00031883217,0.00006534424,0.0000318106,0.00062598404,0.0000082082,0.00005059953,0.00043513087],"genre_scores_gemma":[0.99851304,0.000049152313,0.0009825715,0.000069653295,0.00004991319,0.000014000599,0.00009418835,0.00004049442,0.00018699591],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807715,0.000068776724,0.00035424475,0.0004520303,0.0005335364,0.0005142596],"domain_scores_gemma":[0.99882936,0.00025150122,0.0001132428,0.0004883191,0.000119090306,0.00019849035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078990596,0.00022588647,0.00047563267,0.00057507714,0.00006376518,0.00003340768,0.0001420014,0.0001646433,0.000043778942],"category_scores_gemma":[0.00023789477,0.00017957702,0.000062944615,0.0009318282,0.00007795486,0.00017198652,0.0000888563,0.0004363449,0.000004544592],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012352978,0.0003790956,0.9936474,0.000054056523,0.00047357258,0.000114161165,0.00024016913,0.00001717785,0.0025771188,0.000015859423,0.0000071883337,0.0012388936],"study_design_scores_gemma":[0.021368966,0.0009979635,0.97583735,0.00005801934,0.00039873194,0.000021875845,0.000036002515,0.0007679367,0.00028927327,0.000017952885,0.000013803876,0.00019212783],"about_ca_topic_score_codex":0.0004834235,"about_ca_topic_score_gemma":0.0005322222,"teacher_disagreement_score":0.020133667,"about_ca_system_score_codex":0.0004203389,"about_ca_system_score_gemma":0.00017674475,"threshold_uncertainty_score":0.73229384},"labels":[],"label_agreement":null},{"id":"W2583481547","doi":"10.1182/blood.v116.21.2740.2740","title":"Flow Cytometric Assessment of Post Induction Response In Patients with Sub-Optimal Morphologic Response to Induction Chemotherapy- A Report From the Children's Oncology Group AML Protocol AAML0531","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Hospital for Sick Children","funders":"","keywords":"Induction chemotherapy; Medicine; Internal medicine; Chemotherapy; Cohort; Refractory (planetary science); Induction therapy; Chemotherapy regimen; Oncology; Bone marrow; Complete response; Gastroenterology; Cytarabine; Surgery; Biology","score_opus":0.011811866891324864,"score_gpt":0.3150428928005589,"score_spread":0.30323102590923406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583481547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9560191,0.0000019082909,0.000074221316,0.0025722089,0.000094528754,0.041105296,0.000042709205,0.00005196806,0.000038030063],"genre_scores_gemma":[0.97109455,9.886583e-7,0.012525666,0.00033161853,0.0001945659,0.015623141,0.0001297509,0.000052818872,0.0000468994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965446,0.0008655902,0.00063679606,0.0006483199,0.0008689949,0.0004356748],"domain_scores_gemma":[0.9975143,0.0004879063,0.00036647334,0.00096689234,0.0004762661,0.00018812556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003372027,0.00026924428,0.00049612526,0.0009356335,0.000096919066,0.000025732457,0.0002882633,0.00038903428,0.00012386817],"category_scores_gemma":[0.00222262,0.00017665845,0.00007965963,0.0020612238,0.00020364062,0.00014446852,0.00013682505,0.0013676324,0.000012692765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0783399,0.0037218693,0.53736895,0.000011425841,0.00016829795,0.00026004884,0.00036711674,0.000018344988,0.3742791,0.0000011530228,0.00026683393,0.005196963],"study_design_scores_gemma":[0.017637769,0.010828254,0.95122,0.00004831104,0.00007407647,0.0004425078,0.00009704441,0.000031659674,0.018823557,0.0000034224688,0.000618139,0.00017525771],"about_ca_topic_score_codex":0.00043971054,"about_ca_topic_score_gemma":0.00005824271,"teacher_disagreement_score":0.41385105,"about_ca_system_score_codex":0.000535528,"about_ca_system_score_gemma":0.0012568042,"threshold_uncertainty_score":0.7203922},"labels":[],"label_agreement":null},{"id":"W2583600258","doi":"10.1182/blood.v118.21.3545.3545","title":"Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse – a Report From the Children's Oncology Group,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Hospital for Sick Children","funders":"","keywords":"Gemtuzumab ozogamicin; Internal medicine; Medicine; Minimal residual disease; Induction chemotherapy; Chemotherapy; Oncology; Cohort; Gastroenterology; Bone marrow; Biology; Stem cell","score_opus":0.008735062536538957,"score_gpt":0.2341179727407999,"score_spread":0.22538291020426093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583600258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975353,0.0003174849,0.000037445803,0.000072500225,0.00006627947,0.0008139484,0.0010719647,0.000034913024,0.000050145933],"genre_scores_gemma":[0.99393815,0.000062713894,0.00484852,0.00002879609,0.00006389601,0.000041862688,0.0007688052,0.000035233177,0.00021200585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974627,0.00029766274,0.0005193548,0.00046661147,0.0009528729,0.00030081003],"domain_scores_gemma":[0.9972849,0.00064684945,0.0004855181,0.000931676,0.00041498814,0.00023605839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000375748,0.00019378083,0.00041110543,0.00011470644,0.00010762629,0.0000038182006,0.0002589719,0.00013790124,0.00020147617],"category_scores_gemma":[0.0020135897,0.000119709635,0.000089031615,0.0003265847,0.0005329289,0.00008673762,0.00035644745,0.0003925817,0.000012101401],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004447536,0.0019851392,0.9802768,0.00002806936,0.0007886438,0.0003318917,0.00042363076,0.000001379401,0.007567154,0.0000030190363,0.003873115,0.00027359935],"study_design_scores_gemma":[0.008587549,0.00085643766,0.9496146,0.00010216241,0.00089240586,0.000040703988,0.00004615576,0.000024091894,0.039654102,0.0000337349,0.000031642845,0.000116424344],"about_ca_topic_score_codex":0.0037943549,"about_ca_topic_score_gemma":0.00017020213,"teacher_disagreement_score":0.032086946,"about_ca_system_score_codex":0.00009244337,"about_ca_system_score_gemma":0.000305655,"threshold_uncertainty_score":0.57359546},"labels":[],"label_agreement":null},{"id":"W2584502320","doi":"10.1182/blood.v116.21.680.680","title":"Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; Foothills Medical Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Cytogenetics; Internal medicine; Oncology; Transplantation; Medicine; Proportional hazards model; Hematopoietic stem cell transplantation; Leukemia; Biology; Chromosome","score_opus":0.02660478337144088,"score_gpt":0.3131698445044549,"score_spread":0.286565061133014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584502320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976769,0.000073540636,0.000013917882,0.00027368107,0.000064406726,0.0008185023,0.000026647569,0.000022848015,0.0010295695],"genre_scores_gemma":[0.99915016,0.00007372239,0.00025776125,0.000080395446,0.000098904886,0.00006126852,0.000015321792,0.000018902243,0.00024353963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876535,0.000089988825,0.0003649825,0.0001624794,0.00039114547,0.0002260551],"domain_scores_gemma":[0.9992666,0.00014274441,0.000056633766,0.00039429156,0.000077298115,0.00006238799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006226972,0.00010682126,0.00022545009,0.00012353226,0.000035988873,0.000008985096,0.00019939423,0.0000823386,0.000080248166],"category_scores_gemma":[0.00010841241,0.00007122451,0.00005599771,0.00019363842,0.000114783164,0.00003295897,0.00003459834,0.00041482144,0.000012477225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001216212,0.00073455885,0.9673251,0.000099061865,0.0000897366,0.000114077586,0.0028366982,0.000006362318,0.02834903,0.000060506532,0.000019286792,0.00024397999],"study_design_scores_gemma":[0.0060424237,0.0005643521,0.9553042,0.000018882713,0.0002684848,0.00015263031,0.0013780894,0.000044546774,0.036011703,0.000026894204,0.00011252867,0.000075243785],"about_ca_topic_score_codex":0.00030774073,"about_ca_topic_score_gemma":0.00091234624,"teacher_disagreement_score":0.012020857,"about_ca_system_score_codex":0.000017004195,"about_ca_system_score_gemma":0.00013936288,"threshold_uncertainty_score":0.29044512},"labels":[],"label_agreement":null},{"id":"W2584566446","doi":"10.1182/blood.v118.21.4101.4101","title":"Outcome of Children Who Experience Disease Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Transplantation; Internal medicine; Juvenile myelomonocytic leukemia; Leukemia; Myeloid leukemia; Oncology; Pediatrics; Stem cell; Haematopoiesis","score_opus":0.035588721607233,"score_gpt":0.2818038307582915,"score_spread":0.24621510915105851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584566446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964598,0.000901578,0.0008994257,0.000037220343,0.0000681696,0.0011112365,0.000048950835,0.00006535103,0.00040826743],"genre_scores_gemma":[0.9965438,0.000083284554,0.002454667,0.00010081725,0.000032521846,0.00021213,0.000046095764,0.000036949197,0.00048973213],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99842256,0.000044951532,0.000464883,0.00036124792,0.000327266,0.00037906293],"domain_scores_gemma":[0.9990252,0.00007907326,0.0001151743,0.0004366628,0.0000997194,0.0002441489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020766901,0.00019020677,0.00044302334,0.00011159761,0.00007561708,0.000007412695,0.00022619612,0.00010411808,0.00003855151],"category_scores_gemma":[0.00006676131,0.00015855092,0.0002634611,0.00017910433,0.00008364609,0.00009564717,0.000036213176,0.00012218622,0.000013964144],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043694963,0.00072532496,0.9733315,0.0011577131,0.0001294362,0.00031709313,0.0057760724,9.986438e-7,0.017623516,0.00035478608,0.000069360285,0.00007726613],"study_design_scores_gemma":[0.011226203,0.00063222717,0.38902792,0.00043447406,0.0014473146,0.000247283,0.0010590758,0.000027357648,0.5952444,0.00017724073,0.0000348832,0.0004416384],"about_ca_topic_score_codex":0.00003506902,"about_ca_topic_score_gemma":0.000002447152,"teacher_disagreement_score":0.58430356,"about_ca_system_score_codex":0.000040046903,"about_ca_system_score_gemma":0.00014361969,"threshold_uncertainty_score":0.6465519},"labels":[],"label_agreement":null},{"id":"W2584753464","doi":"10.1182/blood.v110.11.1827.1827","title":"The Presence of Central Nervous System Disease at Diagnosis in Pediatric Acute Myeloid Leukemia Does Not Affect Outcome.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Disease; Myeloid; Univariate analysis; Central nervous system; Gastroenterology; Immunology; Multivariate analysis","score_opus":0.013911644536992233,"score_gpt":0.28257905180232945,"score_spread":0.2686674072653372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584753464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574876,0.0011060204,0.000018270419,0.00084339466,0.00028065225,0.0012237615,0.00007032307,0.00008990631,0.0006189127],"genre_scores_gemma":[0.9965494,0.0015074377,0.00013971055,0.00008490506,0.00051763095,0.00013552773,0.000016413765,0.000048164493,0.0010008101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966899,0.00016683109,0.0007036913,0.00046036125,0.0009263104,0.001052895],"domain_scores_gemma":[0.99669385,0.0015813101,0.00019603652,0.00083859474,0.00011866346,0.00057156204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011732148,0.0002721221,0.0004987818,0.00024698433,0.00016561076,0.000028259003,0.00048655184,0.00014431878,0.000019551915],"category_scores_gemma":[0.00094735896,0.00015874604,0.00022795322,0.0006563269,0.00017316207,0.00011017173,0.0003396486,0.0004813485,0.000046287973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009868774,0.00025120605,0.99248296,0.0007642843,0.00012412187,0.0016839398,0.00019092359,0.000013254851,0.0016314953,0.00017330618,0.0005942087,0.0011034295],"study_design_scores_gemma":[0.0040527713,0.0001664816,0.97028,0.000116081996,0.0006456402,0.00006196826,0.00013820465,0.00016822392,0.023813073,0.000005004569,0.00036523043,0.00018735297],"about_ca_topic_score_codex":0.00040670217,"about_ca_topic_score_gemma":0.00033489364,"teacher_disagreement_score":0.022202985,"about_ca_system_score_codex":0.0011089254,"about_ca_system_score_gemma":0.0005292578,"threshold_uncertainty_score":0.64734757},"labels":[],"label_agreement":null},{"id":"W2584835682","doi":"10.1182/blood.v120.21.555.555","title":"Enforced Expression of the Toll/Interleukin-1 Receptor Associated Protein in Murine Marrow Results in MDS-Like Bone Marrow Failure Mediated by Interferon Gamma","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Bone marrow; Immunology; Haematopoiesis; Medicine; Bone marrow failure; Cancer research; Myeloid; Innate immune system; Stem cell; Biology; Immune system; Cell biology","score_opus":0.011175606717066192,"score_gpt":0.24778937374714702,"score_spread":0.23661376703008083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584835682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99396694,0.00035632076,0.0000021419448,0.0023408358,0.00013487008,0.0018150555,0.00014698658,0.00006575136,0.0011710714],"genre_scores_gemma":[0.9931208,0.00002968674,0.00031568494,0.00012504075,0.00010809348,0.00019899626,0.0003259478,0.00006893422,0.0057068546],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99631476,0.0005352231,0.0010030404,0.0004411036,0.00081578305,0.0008901095],"domain_scores_gemma":[0.9982381,0.00022599891,0.00037874636,0.00075007265,0.00014801905,0.000259049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015504924,0.00033777245,0.00068177545,0.00034890868,0.000044174634,0.000016540565,0.00043819728,0.00044279845,0.00029846877],"category_scores_gemma":[0.0022388455,0.00024066326,0.00013957656,0.00086863403,0.00014069024,0.00021974833,0.00037229908,0.0011213571,0.00005480051],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002121361,0.0012789645,0.024429388,0.00014031606,0.000057226167,0.000029348668,0.0015298616,6.664377e-7,0.94916284,0.0000054438196,0.0210139,0.00023068118],"study_design_scores_gemma":[0.023928432,0.00063400663,0.016417988,0.0021402254,0.000050661944,0.0000254297,0.00063292385,0.00007576613,0.9494789,0.0000068437075,0.006306207,0.0003025896],"about_ca_topic_score_codex":0.0005991642,"about_ca_topic_score_gemma":0.00054107344,"teacher_disagreement_score":0.02180707,"about_ca_system_score_codex":0.0005986464,"about_ca_system_score_gemma":0.00024240537,"threshold_uncertainty_score":0.98139626},"labels":[],"label_agreement":null},{"id":"W2584868908","doi":"10.1182/blood.v106.11.3447.3447","title":"TNF-α Stimulates Matrix Metalloproteinase Expression in Myelodysplastic Syndromes (MDS): Therapeutic Potential for Inhibitors of TNF-α and MMPs.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of Alberta","funders":"","keywords":"Tumor necrosis factor alpha; Matrigel; Matrix metalloproteinase; Cancer research; Biology; Zymography; Secretion; Internal medicine; Immunology; Endocrinology; Angiogenesis; Medicine","score_opus":0.01445540135918462,"score_gpt":0.29314660856734076,"score_spread":0.27869120720815616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584868908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939307,0.0035718952,0.00045732365,0.00058802887,0.000048466416,0.0012755936,0.00002135688,0.000044310687,0.000062313346],"genre_scores_gemma":[0.990971,0.00016828356,0.008016193,0.000046649206,0.00018404289,0.00010745072,0.000023376899,0.000049576884,0.00043338168],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99825406,0.00006767434,0.0004900466,0.00037671314,0.00038515104,0.00042635904],"domain_scores_gemma":[0.99908614,0.00022972567,0.00011760649,0.00029360305,0.000106540916,0.00016639366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038915774,0.00022752826,0.0005033329,0.00035360947,0.000061266896,0.000020985124,0.00012815358,0.00018162117,0.0000801002],"category_scores_gemma":[0.00020975224,0.00018265881,0.00011329215,0.00024423783,0.0001359725,0.0001477095,0.000108051696,0.00026651725,0.000011482212],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013334544,0.00138595,0.0051425155,0.00095710944,0.00031449035,0.00020232046,0.000417225,0.0003310297,0.97513074,0.000112000715,0.00023407981,0.014439098],"study_design_scores_gemma":[0.03222091,0.0021264472,0.025745247,0.00094788213,0.0009122109,0.00057502766,0.0003781844,0.0082017975,0.92645955,0.00051987445,0.0013828666,0.0005300091],"about_ca_topic_score_codex":0.000035801215,"about_ca_topic_score_gemma":0.00000757164,"teacher_disagreement_score":0.048671182,"about_ca_system_score_codex":0.000073405965,"about_ca_system_score_gemma":0.00018045808,"threshold_uncertainty_score":0.744861},"labels":[],"label_agreement":null},{"id":"W2585432338","doi":"10.1182/blood.v112.11.2420.2420","title":"Microenvironment Determines Myeloid-Erythroid Lineage Switch in MN1 Leukemia","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Haematopoiesis; Biology; Myeloid; Leukemia; Bone marrow; Cancer research; Phenotype; Stem cell factor; Myeloid leukemia; Cell biology; Lineage (genetic); Stem cell; Immunology; Genetics; Gene","score_opus":0.0200376804355847,"score_gpt":0.2580991761476483,"score_spread":0.23806149571206361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2585432338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948576,0.0009045503,0.000031018055,0.00063554494,0.000062868465,0.0005588717,0.000008535106,0.00008097377,0.0028600278],"genre_scores_gemma":[0.9887726,0.0015031853,0.0028795488,0.0007058935,0.00042900967,0.00007227514,0.000037507543,0.00006777219,0.0055322535],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978506,0.000057183708,0.0004519698,0.0005078549,0.00047734362,0.00065506704],"domain_scores_gemma":[0.998887,0.00009377571,0.000071152666,0.0006460113,0.00003881759,0.0002632597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002282623,0.0002711469,0.0004838982,0.00025715661,0.00010086111,0.0000120927625,0.00023639301,0.00018907692,0.00024796295],"category_scores_gemma":[0.00013435975,0.00024330107,0.0001277564,0.00033568763,0.00021232314,0.00009825667,0.00018383763,0.0005664598,0.0005192748],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003632148,0.0017293497,0.42722067,0.00024009559,0.00018459577,0.010187903,0.0013288014,0.000024002378,0.54774857,0.0000137562665,0.006991936,0.0039670905],"study_design_scores_gemma":[0.01841971,0.0007260046,0.48628235,0.00021140024,0.00015498791,0.004984779,0.00020358032,0.0004443823,0.4578104,0.000018259474,0.03017591,0.00056823436],"about_ca_topic_score_codex":0.00021383475,"about_ca_topic_score_gemma":0.00005185784,"teacher_disagreement_score":0.08993818,"about_ca_system_score_codex":0.00063652877,"about_ca_system_score_gemma":0.00052072294,"threshold_uncertainty_score":0.992153},"labels":[],"label_agreement":null},{"id":"W2585970811","doi":"10.1182/blood.v114.22.2772.2772","title":"Cytogenetic Risk Features in MDS-Update and Present State.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"International Prognostic Scoring System; Multivariate analysis; Univariate analysis; Myelodysplastic syndromes; Univariate; Medicine; Internal medicine; Oncology; Bone marrow; Cytogenetics; Multivariate statistics; Computer science; Biology","score_opus":0.009596251328094545,"score_gpt":0.27898288625285367,"score_spread":0.2693866349247591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2585970811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99127847,0.0041322974,0.000011595127,0.0024259735,0.000013667537,0.000367432,0.000013085579,0.00003453164,0.0017229484],"genre_scores_gemma":[0.9945393,0.0030422134,0.0011096307,0.00043447252,0.00011126094,0.0000098908695,0.00001169776,0.000014041962,0.00072748784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897176,0.000064305874,0.00014852858,0.00025117822,0.00024328052,0.00032092247],"domain_scores_gemma":[0.9994615,0.000040782368,0.0000307454,0.00027054886,0.000034905162,0.00016153228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019313763,0.000112853464,0.00019482117,0.00013923121,0.000035145364,0.000021944266,0.00008299074,0.000067964735,0.00003765991],"category_scores_gemma":[0.00009285738,0.000091622445,0.000028748083,0.00018656785,0.00004924531,0.000035534144,0.000051747185,0.00035221354,0.000035839537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013661248,0.0029743938,0.6010697,0.00023471563,0.00039608762,0.0037253813,0.0019645824,0.00008289988,0.0526891,0.00038710452,0.026811417,0.3082985],"study_design_scores_gemma":[0.006782194,0.0005242948,0.9576762,0.000048704645,0.00008874701,0.00021265452,0.00004866212,0.000086100954,0.028016549,0.0011262601,0.00525477,0.0001349029],"about_ca_topic_score_codex":0.00015202105,"about_ca_topic_score_gemma":0.000045905257,"teacher_disagreement_score":0.35660645,"about_ca_system_score_codex":0.000040257626,"about_ca_system_score_gemma":0.00009852516,"threshold_uncertainty_score":0.3736255},"labels":[],"label_agreement":null},{"id":"W2586430923","doi":"10.1182/blood.v112.11.346.346","title":"Non-Myeloablative Hematopoietic Stem Cell Transplantation in Older Patients with AML and MDS: Results from the Center for International Blood and Marrow Transplant Research (CIBMTR)","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Fludarabine; Internal medicine; Transplantation; Univariate analysis; Hematopoietic stem cell transplantation; Incidence (geometry); Graft-versus-host disease; Surgery; Oncology; Multivariate analysis; Chemotherapy; Cyclophosphamide","score_opus":0.02177960655277359,"score_gpt":0.26957434509862266,"score_spread":0.24779473854584907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586430923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99573743,0.00013414558,0.00006390244,0.0007793994,0.000043835378,0.0015465984,0.0010141256,0.000014303438,0.00066623447],"genre_scores_gemma":[0.9975476,0.00066777033,0.00053696416,0.00010020834,0.00011666755,0.000116693394,0.0006337075,0.000031936408,0.00024842808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981019,0.00010711781,0.0003275528,0.00047079756,0.0006268284,0.00036583724],"domain_scores_gemma":[0.99849904,0.0006933331,0.00006254372,0.00022746621,0.0003897677,0.0001278622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004408128,0.00017307521,0.00024144008,0.00016526098,0.00015844479,0.000030854364,0.00015180431,0.00010780233,0.000012637501],"category_scores_gemma":[0.00004697841,0.000113860835,0.00003322959,0.00019135818,0.00023418415,0.00013015428,0.0000314253,0.00042249772,0.000003768022],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007756792,0.0019974315,0.940807,0.0003089095,0.00032490835,0.0003707127,0.04464912,0.000002901937,0.0022901357,0.000016414022,0.0008579079,0.0006177768],"study_design_scores_gemma":[0.070882924,0.0009252174,0.9083645,0.00071099855,0.00021265526,0.00012627058,0.0011266642,0.00019627431,0.016940983,0.000034707584,0.0002641401,0.0002146821],"about_ca_topic_score_codex":0.0002328428,"about_ca_topic_score_gemma":0.00014431916,"teacher_disagreement_score":0.06312613,"about_ca_system_score_codex":0.000046462796,"about_ca_system_score_gemma":0.00012906556,"threshold_uncertainty_score":0.46431103},"labels":[],"label_agreement":null},{"id":"W2586682261","doi":"10.1182/blood.v108.11.2672.2672","title":"Erythroid Response (ER) Rates in Myelodysplastic Syndromes (MDS) Patients Treated with Epoetin Alfa (EPO) or Darbepoetin Alfa (DARB) Using International Working Group Response Criteria (IWGc): Comparative Meta-Analysis.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Darbepoetin alfa; Medicine; Internal medicine; Epoetin alfa; Anemia; Meta-analysis; Myelodysplastic syndromes; Subgroup analysis; International Prognostic Scoring System","score_opus":0.08887509152284004,"score_gpt":0.3531866603420115,"score_spread":0.2643115688191715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586682261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99650437,0.00050993694,0.00022491388,0.00078333827,0.000069280184,0.0011738082,0.0001506265,0.00011389348,0.00046983015],"genre_scores_gemma":[0.99053,0.000015138761,0.0067408793,0.00018941195,0.00010832199,0.00016953688,0.00052010117,0.000098915945,0.0016276776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928232,0.0023934527,0.0013222733,0.0011619929,0.0013692569,0.00092981197],"domain_scores_gemma":[0.9952246,0.0026772122,0.0005229849,0.0007797989,0.0005218787,0.00027352478],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023894438,0.0007121781,0.0021354465,0.0020303056,0.00022648198,0.00022073952,0.00047137245,0.000250731,0.00091133645],"category_scores_gemma":[0.0011320786,0.00050979713,0.0005212497,0.0030119678,0.0003785226,0.00029583828,0.0002378384,0.0007038732,0.000053990712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24979779,0.008487874,0.52589035,0.00014494879,0.10890397,0.009492968,0.0023800493,0.0017720206,0.09105105,0.00006753264,0.0018902159,0.000121246194],"study_design_scores_gemma":[0.03176987,0.0035311729,0.84967667,0.00039963634,0.085934475,0.0010472834,0.0010586175,0.00822846,0.014928446,0.000049383012,0.0019228127,0.0014531713],"about_ca_topic_score_codex":0.0010421106,"about_ca_topic_score_gemma":0.00075194344,"teacher_disagreement_score":0.32378635,"about_ca_system_score_codex":0.0007293408,"about_ca_system_score_gemma":0.0006507058,"threshold_uncertainty_score":0.99973536},"labels":[],"label_agreement":null},{"id":"W2586706001","doi":"10.71781/30593","title":"Nouveau rôle d'E2A et HEB dans la régulation du facteur de transcription hématopoiétique SCL","year":2006,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Biology; Molecular biology","score_opus":0.005410578801687043,"score_gpt":0.20279785026932995,"score_spread":0.1973872714676429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586706001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9106577,0.0062879845,0.0053169103,0.0013352532,0.0013639323,0.0011127576,0.00020292387,0.0002723818,0.07345014],"genre_scores_gemma":[0.92252797,0.0015364363,0.001293441,0.00019033252,0.00070759427,0.00007724153,0.004157913,0.00012737757,0.06938171],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.994758,0.0008655787,0.0008379162,0.0010578305,0.0013879689,0.0010926663],"domain_scores_gemma":[0.9971059,0.00034923715,0.0005236439,0.0006357074,0.00066890963,0.00071660726],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0008813176,0.00084832654,0.00082648365,0.0007626196,0.0050359024,0.00014636059,0.0005663056,0.0015109096,0.00012987114],"category_scores_gemma":[0.00018708584,0.0010080624,0.00065864925,0.0006842745,0.0005868817,0.0008741562,0.00012591218,0.0016429834,0.0001847702],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0038408001,0.001151149,0.09539429,0.0013399975,0.0009882239,0.011903859,0.10891646,0.01598797,0.6607724,0.09333046,0.0032804,0.0030940287],"study_design_scores_gemma":[0.007807136,0.0004907347,0.6803365,0.0019829192,0.0018096002,0.007784301,0.08368253,0.028171236,0.09619437,0.00068580743,0.08934778,0.0017071031],"about_ca_topic_score_codex":0.12943548,"about_ca_topic_score_gemma":0.027178235,"teacher_disagreement_score":0.5849422,"about_ca_system_score_codex":0.028433483,"about_ca_system_score_gemma":0.009434089,"threshold_uncertainty_score":0.99978536},"labels":[],"label_agreement":null},{"id":"W2586868361","doi":"10.1182/blood.v106.11.100.100","title":"The AML1-ETO Fusion Gene and the FLT3 Length Mutation Collaborate in Inducing Acute Leukemia in a Murine Bone Marrow Transplantation Model.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Leukemia; Bone marrow; Fusion gene; Cancer research; RUNX1; Biology; Acute leukemia; Neuroblastoma RAS viral oncogene homolog; Transplantation; Mutation; Immunology; Phenotype; Point mutation; Haematopoiesis; Gene; Stem cell; Medicine; Genetics; Internal medicine","score_opus":0.010308944083696679,"score_gpt":0.261547095882428,"score_spread":0.2512381517987313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586868361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922906,0.00093456835,0.0001401255,0.0049965633,0.000023614866,0.0010044543,0.000015937838,0.000029427078,0.0005646894],"genre_scores_gemma":[0.99288094,0.00443771,0.001651391,0.00030108303,0.000118911004,0.000136148,0.000057481688,0.00002898205,0.00038734623],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99836123,0.00018848795,0.0004108786,0.00029971736,0.00037863938,0.00036102335],"domain_scores_gemma":[0.99922156,0.00023602342,0.00008729228,0.00027521397,0.000099299235,0.000080627375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011976188,0.00016706345,0.00027234093,0.00020233227,0.00016168869,0.000050911618,0.00011864445,0.000126936,0.000006706994],"category_scores_gemma":[0.00011294921,0.00010409442,0.000033872988,0.00064185535,0.00013256748,0.00017587295,0.00004672443,0.00050617295,0.0000090362955],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018858407,0.00086732674,0.0133112455,0.00054615556,0.0005773113,0.002924416,0.041618593,0.034913883,0.80067605,0.002219026,0.0007519646,0.0827356],"study_design_scores_gemma":[0.09887665,0.00042154713,0.048924178,0.00046602596,0.0006874562,0.0014397777,0.0015869841,0.68347037,0.16230404,0.00093859195,0.0003501258,0.0005342861],"about_ca_topic_score_codex":0.0003988455,"about_ca_topic_score_gemma":0.0019072761,"teacher_disagreement_score":0.6485565,"about_ca_system_score_codex":0.000470791,"about_ca_system_score_gemma":0.0005699958,"threshold_uncertainty_score":0.42448473},"labels":[],"label_agreement":null},{"id":"W2586876045","doi":"10.1182/blood.v108.11.376.376","title":"Uniform Approach Better Defines Natural History of Transient Myeloproliferative Disorder (TMD) in Down Syndrome (DS) Neonates: Outcomes from Children’ Oncology Group (COG) Study A2971.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Organomegaly; Internal medicine; Gastroenterology; Pediatrics; Surgery; Polyneuropathy","score_opus":0.01315323781331471,"score_gpt":0.2502322310022915,"score_spread":0.23707899318897682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586876045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914569,0.002624567,0.000037671063,0.0008821298,0.00015245186,0.0022709589,0.000059650032,0.00007262924,0.002443036],"genre_scores_gemma":[0.9955824,0.000026178774,0.002351986,0.00042410474,0.00010791176,0.00027660778,0.0004358573,0.000060781957,0.0007341619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996992,0.00023457872,0.0008039349,0.00068831776,0.0006740018,0.0006071955],"domain_scores_gemma":[0.9987902,0.00024506156,0.00017170509,0.00053703244,0.00013132844,0.00012467508],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036161582,0.00042089762,0.0011308345,0.0004772914,0.000053170992,0.000011062574,0.0003384557,0.00025937945,0.00013580015],"category_scores_gemma":[0.000074240634,0.0003234902,0.00019775562,0.00038198134,0.00028664828,0.00015374857,0.00012082295,0.00091939484,0.000017778506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005035544,0.011392031,0.97838295,0.000079272344,0.0009729262,0.00044895895,0.0040749377,0.000021017502,0.0013375062,0.000067226545,0.00082530663,0.0018943156],"study_design_scores_gemma":[0.020539617,0.0014086356,0.9751415,0.000043737404,0.0005067214,0.00018796555,0.0008151874,0.00016229914,0.000091394926,0.00006377631,0.0007238302,0.00031529288],"about_ca_topic_score_codex":0.0071207895,"about_ca_topic_score_gemma":0.0019120537,"teacher_disagreement_score":0.020036064,"about_ca_system_score_codex":0.0007890188,"about_ca_system_score_gemma":0.00045319553,"threshold_uncertainty_score":0.99992174},"labels":[],"label_agreement":null},{"id":"W2587171772","doi":"10.1002/pmic.201600361","title":"Integrated analysis of proteome, phosphotyrosine‐proteome, tyrosine‐kinome, and tyrosine‐phosphatome in acute myeloid leukemia","year":2017,"lang":"en","type":"article","venue":"PROTEOMICS","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Princess Margaret Cancer Centre; Hospital for Sick Children","funders":"National Human Genome Research Institute; Canadian Cancer Society Research Institute; National Institute of General Medical Sciences; Brain Tumour Foundation of Canada; Genome Canada","keywords":"Proteome; Myeloid leukemia; Biology; Protein tyrosine phosphatase; Phosphorylation; Cancer research; Signal transduction; Tyrosine kinase; Kinome; Tyrosine; Computational biology; Cell biology; Biochemistry","score_opus":0.019910898638280685,"score_gpt":0.29654771414096415,"score_spread":0.2766368155026835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587171772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99078697,0.0010565715,0.0009020583,0.0011165737,0.00013283119,0.004413529,0.00025233216,0.00012269901,0.0012164138],"genre_scores_gemma":[0.96889067,0.0013906112,0.026230047,0.00023081293,0.00010567548,0.00072759355,0.00021864678,0.00013819829,0.0020677685],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99526983,0.000114044706,0.0013792141,0.0012230111,0.00087592733,0.0011379912],"domain_scores_gemma":[0.99544996,0.00010262838,0.00093717553,0.0022921443,0.0006854873,0.00053259224],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013561499,0.0007250537,0.0020731795,0.0017821777,0.00039317735,0.00029800233,0.000988743,0.0005952708,0.00017482943],"category_scores_gemma":[0.0010913832,0.00064365583,0.00040171633,0.0024323948,0.0010458865,0.0006300421,0.00074656704,0.001376937,0.000033061115],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004795111,0.0005066535,0.44441086,0.00070680206,0.0035650847,0.00059915776,0.0007512396,0.0001710679,0.53477556,0.0008260271,0.000433452,0.008458981],"study_design_scores_gemma":[0.007171077,0.00065596745,0.54888594,0.00045673898,0.0017051665,0.0001251021,0.0001270311,0.02657014,0.41240972,0.00026666734,0.0008477251,0.00077872653],"about_ca_topic_score_codex":0.0037200025,"about_ca_topic_score_gemma":0.00027083102,"teacher_disagreement_score":0.12236585,"about_ca_system_score_codex":0.0014419281,"about_ca_system_score_gemma":0.0014579883,"threshold_uncertainty_score":0.9996015},"labels":[],"label_agreement":null},{"id":"W2587188409","doi":"10.1097/pai.0000000000000477","title":"Detection of Novel t(12;17)(p12;p13) in Relapsed Refractory Acute Myeloid Leukemia by Anchored Multiplex PCR(AMP)-based Next-Generation Sequencing","year":2017,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brandon Regional Health Authority","funders":"","keywords":"Medicine; Myeloid leukemia; Fusion transcript; Fusion gene; Myelodysplastic syndromes; Multiplex; NPM1; Leukemia; Oncology; Internal medicine; Cancer research; Karyotype; Bioinformatics; Biology; Gene; Bone marrow; Genetics; Chromosome","score_opus":0.038790850350141085,"score_gpt":0.2951051405358488,"score_spread":0.2563142901857077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587188409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98375607,0.0005854314,0.011935245,0.00022176321,0.00019675639,0.0010487578,0.00005890841,0.00009593958,0.0021011122],"genre_scores_gemma":[0.9904819,0.00006249833,0.0064746295,0.00052615063,0.00014748637,0.00039342858,0.001018265,0.00013495391,0.000760655],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963311,0.0000780662,0.0010098463,0.0011259969,0.00061082706,0.0008441864],"domain_scores_gemma":[0.9960608,0.000091408016,0.00083651126,0.002476484,0.0003030267,0.00023180261],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060159754,0.0005759171,0.00094991253,0.00027285097,0.00035533324,0.00006198675,0.00078387733,0.0009418388,0.000109447275],"category_scores_gemma":[0.0006169931,0.000656869,0.00025349605,0.00024731492,0.000802645,0.00013007749,0.0002432773,0.0014427372,0.000025613825],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015247193,0.00022638698,0.000095337185,0.00012310981,0.00019772594,0.00021033948,0.000112860536,0.00027085576,0.99405646,0.00000966986,0.0010994581,0.0020730963],"study_design_scores_gemma":[0.010224045,0.00022374638,0.0008756107,0.00008163365,0.00016898144,0.00018328973,0.000077935045,0.004506179,0.9826836,0.000011997442,0.00047726007,0.00048570466],"about_ca_topic_score_codex":0.0012647092,"about_ca_topic_score_gemma":0.00001144659,"teacher_disagreement_score":0.011372824,"about_ca_system_score_codex":0.0043478375,"about_ca_system_score_gemma":0.0012985154,"threshold_uncertainty_score":0.99958825},"labels":[],"label_agreement":null},{"id":"W2587615733","doi":"10.1182/blood.v126.23.443.443","title":"Targeting MTHFD2 in Acute Myeloid Leukemia","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"Gene knockdown; Myeloid; Cancer research; Myeloid leukemia; Biology; Retinoic acid; Leukemia; Tretinoin; Acute promyelocytic leukemia; Cell growth; Cellular differentiation; Cell culture; Downregulation and upregulation; Molecular biology; Immunology; Biochemistry; Gene; Genetics","score_opus":0.026030473170628274,"score_gpt":0.2961985301848284,"score_spread":0.2701680570142001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587615733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777326,0.0006601033,0.000058528465,0.0010669028,0.00010069519,0.00038470665,0.0000058402716,0.00011786652,0.019872744],"genre_scores_gemma":[0.9893505,0.00013211652,0.0055330354,0.0006060984,0.00043192864,0.000044507917,0.000056455618,0.000053835374,0.0037914955],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99824256,0.00006737815,0.00030440246,0.000334794,0.00049452105,0.00055636273],"domain_scores_gemma":[0.998993,0.0000594903,0.000050027415,0.00036892065,0.00014415203,0.00038445773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006690324,0.00016739362,0.0003455301,0.00022341336,0.000035189263,0.000023498562,0.00019596344,0.00015363704,0.000087022745],"category_scores_gemma":[0.0005149831,0.00014714133,0.000061189545,0.00048262233,0.00006922123,0.000117468946,0.00015790321,0.00057047734,0.0005416383],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016513168,0.0019884023,0.5120607,0.00035328983,0.0010865703,0.013554339,0.005935436,0.00017547654,0.296371,0.0009662189,0.15352666,0.012330566],"study_design_scores_gemma":[0.18757938,0.005303226,0.18398575,0.0011969014,0.00206862,0.0056684455,0.0071029207,0.014288945,0.326203,0.0028277647,0.2603405,0.0034345442],"about_ca_topic_score_codex":0.00023515549,"about_ca_topic_score_gemma":0.000014814221,"teacher_disagreement_score":0.32807496,"about_ca_system_score_codex":0.0006115752,"about_ca_system_score_gemma":0.0012087156,"threshold_uncertainty_score":0.6961845},"labels":[],"label_agreement":null},{"id":"W2587781085","doi":"10.1182/blood.v128.22.987.987","title":"Donor Chip Causes Donor-Derived Clonal Hematopoiesis As an Early Complication of Allogeneic Stem Cell Transplantation","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Stem cell; Transplantation; Haematopoiesis; Hematopoietic stem cell transplantation; Immunology; Leukemia; Myeloid leukemia; Myeloid; Medicine; Biology; Cancer research; Internal medicine; Genetics","score_opus":0.02612325067268327,"score_gpt":0.2787777229280316,"score_spread":0.2526544722553483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587781085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972839,0.0001278908,0.00046946487,0.00061555445,0.000023479335,0.00048385054,0.00007026535,0.000068098794,0.00085751194],"genre_scores_gemma":[0.9978417,0.0002557404,0.0009828719,0.00009576647,0.00009667195,0.0000566244,0.00006486267,0.000033574983,0.0005721784],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99863505,0.000096672804,0.0003238928,0.00031971614,0.00035856242,0.00026607525],"domain_scores_gemma":[0.9989556,0.00014279337,0.00012316016,0.00041625678,0.00017654344,0.0001856432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017432205,0.00015368874,0.00028506757,0.00013131271,0.00005955606,0.000012622008,0.00017391058,0.000119734905,0.00016046323],"category_scores_gemma":[0.000013935095,0.00011024472,0.000081486636,0.00013860848,0.00011016826,0.0001444808,0.000021832298,0.00010227588,0.00016837462],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003871854,0.00047606986,0.050368365,0.00024107666,0.00010050695,0.00003310875,0.0005538467,4.5681773e-7,0.9460856,0.0002975008,0.000044196826,0.0014121223],"study_design_scores_gemma":[0.0043921047,0.000497805,0.2511226,0.0000937057,0.00020583764,0.00011347489,0.000073032126,0.0000039436336,0.743224,0.000070743496,0.00008857903,0.00011417929],"about_ca_topic_score_codex":0.00020498478,"about_ca_topic_score_gemma":0.000033786506,"teacher_disagreement_score":0.20286156,"about_ca_system_score_codex":0.00006469414,"about_ca_system_score_gemma":0.00022128598,"threshold_uncertainty_score":0.44956493},"labels":[],"label_agreement":null},{"id":"W2587827034","doi":"10.1182/blood.v108.11.4839.4839","title":"Comparison of Erythroid Response (ER) Rates in Myelodysplastic Syndromes (MDS) Patients Treated with Different Therapeutic Strategies Using Epoetin Alfa (EPO).","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Internal medicine; Myelodysplastic syndromes; Epoetin alfa; Erythropoietin; Oncology; Anemia; Bone marrow","score_opus":0.031682199334184376,"score_gpt":0.321288315025565,"score_spread":0.2896061156913806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587827034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99825734,0.0005949974,0.00005666253,0.0000756827,0.000021775184,0.00068760646,0.000018864857,0.000052426618,0.00023465161],"genre_scores_gemma":[0.9993731,0.000018930288,0.00026534812,0.000014371801,0.000030569874,0.000028108647,0.00007442329,0.00005575701,0.00013939403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975992,0.00032548487,0.0006065405,0.00038099685,0.0005770902,0.00051067467],"domain_scores_gemma":[0.998657,0.00047403446,0.00020810052,0.00037155682,0.00018881862,0.00010052619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021617138,0.00032074619,0.0007706862,0.00041908838,0.00006998408,0.00004253893,0.00014987258,0.00014143797,0.000055564626],"category_scores_gemma":[0.00008125172,0.00022786576,0.00006939696,0.0005458016,0.00023880282,0.000109951485,0.0000550946,0.00034976815,0.000007983763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040683122,0.002972888,0.9190078,0.00016927812,0.00018398842,0.00015914976,0.0003001025,0.00023412111,0.07267187,0.000033502805,0.000026093468,0.00017291243],"study_design_scores_gemma":[0.011175567,0.0022392317,0.9207073,0.00045260027,0.00031695593,0.00007963457,0.0007841338,0.0014814495,0.062467393,0.000043183667,0.000017154529,0.00023543125],"about_ca_topic_score_codex":0.00065298827,"about_ca_topic_score_gemma":0.00014040756,"teacher_disagreement_score":0.010204472,"about_ca_system_score_codex":0.00021788094,"about_ca_system_score_gemma":0.00037038545,"threshold_uncertainty_score":0.92920965},"labels":[],"label_agreement":null},{"id":"W2587842268","doi":"10.3390/ijms18020415","title":"Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group","year":2017,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene","keywords":"Azacitidine; Medicine; Front line; Clinical trial; Internal medicine; Oncology; Biology","score_opus":0.11765571314472241,"score_gpt":0.4236414251960598,"score_spread":0.3059857120513374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587842268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903295,0.00036674496,0.0019287207,0.003360067,0.00056741096,0.0010715671,0.0021356917,0.0000039688557,0.00023632054],"genre_scores_gemma":[0.9965113,0.00008293451,0.0023594883,0.000051729807,0.0003590764,0.000007152817,0.000561952,0.000017072378,0.000049328093],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953318,0.0001816763,0.0009688334,0.000581758,0.0027508014,0.00018510308],"domain_scores_gemma":[0.99233776,0.0004892472,0.002888765,0.0026781291,0.0015217331,0.0000843658],"candidate_categories":["open_science"],"consensus_categories":[],"category_scores_codex":[0.0028254616,0.00018781921,0.0005647416,0.00013685085,0.00017076425,0.00017432822,0.0080470005,0.000054392254,0.00004243145],"category_scores_gemma":[0.00422638,0.00009413556,0.00010486138,0.00018251549,0.0011523888,0.0007029255,0.0008359515,0.00033930287,1.8616055e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25061727,0.01968826,0.6060604,0.000047159323,0.0068611996,0.00011952521,0.0012556794,0.00042757203,0.056987394,0.000092856535,0.02785978,0.029982941],"study_design_scores_gemma":[0.49808803,0.03248128,0.25975046,0.0025301466,0.0012800065,0.000104600294,0.004610334,0.011706707,0.1674715,0.00015008617,0.02106601,0.0007608557],"about_ca_topic_score_codex":0.00080405845,"about_ca_topic_score_gemma":0.00010519863,"teacher_disagreement_score":0.3463099,"about_ca_system_score_codex":0.0000660613,"about_ca_system_score_gemma":0.00082883687,"threshold_uncertainty_score":0.99731994},"labels":[],"label_agreement":null},{"id":"W2588294477","doi":"10.1182/blood-2016-10-745471","title":"Myelodysplastic syndrome with excess blasts-2 associated with erythroid predominance","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pancytopenia; Bone marrow; Medicine; Hemoglobin; Myelodysplastic syndromes; Bone marrow aspirate; Platelet; White blood cell; Pathology; Internal medicine; Gastroenterology","score_opus":0.014267805545394549,"score_gpt":0.2610625344501995,"score_spread":0.24679472890480494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588294477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904559,0.000102025,0.0001314025,0.0007602604,0.00004723349,0.0006378212,0.000024955902,0.000120829245,0.0077195396],"genre_scores_gemma":[0.99210757,0.00003800838,0.0008282341,0.00007192986,0.000103756625,0.00009023312,0.000024690822,0.00007906178,0.0066565275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978777,0.000044797707,0.00020928889,0.0005063984,0.00071667106,0.0006451053],"domain_scores_gemma":[0.99789435,0.00015320249,0.00025741773,0.0011423841,0.00027946805,0.00027320872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026495117,0.00027896717,0.00053259695,0.000102468,0.00043410144,0.00013246803,0.00045844566,0.00014945543,0.000088049295],"category_scores_gemma":[0.00058855413,0.00019094007,0.00005180007,0.00018017855,0.0005322649,0.00026434803,0.00014481579,0.0005064062,0.000119157536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006037389,0.0062970594,0.9044796,0.0009784542,0.005570461,0.054458037,0.0011200878,0.00006133388,0.013879979,0.00039230983,0.0043073567,0.0024179325],"study_design_scores_gemma":[0.025107775,0.0037627781,0.95423806,0.0015939827,0.0008602569,0.0051687392,0.0000744751,0.00023044531,0.007959796,0.000030455685,0.00052564236,0.00044758298],"about_ca_topic_score_codex":0.00007872836,"about_ca_topic_score_gemma":0.0001563436,"teacher_disagreement_score":0.04975847,"about_ca_system_score_codex":0.00015481446,"about_ca_system_score_gemma":0.0006328254,"threshold_uncertainty_score":0.77863103},"labels":[],"label_agreement":null},{"id":"W2588373691","doi":"10.1182/blood.v108.11.3039.3039","title":"Myeloablative Allogeneic Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade Lymphoma Is Not Superior to Autologous Stem Cell Transplantation - Reduced Relapse Risk Is Offset by Higher Treatment Related Mortality.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver General Hospital","funders":"","keywords":"Medicine; Transplantation; Cumulative incidence; Internal medicine; Gastroenterology; Surgery; Autologous stem-cell transplantation; Lymphoma; Incidence (geometry)","score_opus":0.013901441978245433,"score_gpt":0.25807124525495906,"score_spread":0.24416980327671362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588373691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913383,0.0006021404,0.00025667885,0.00074599683,0.00015692138,0.0027889782,0.0036900963,0.00017082992,0.00025004288],"genre_scores_gemma":[0.98993737,0.0016418298,0.00086246483,0.00034537617,0.00008203613,0.00037193022,0.002004417,0.000114090646,0.004640465],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99672836,0.00028225197,0.0008689602,0.0009616854,0.0004964998,0.0006622582],"domain_scores_gemma":[0.99848616,0.00029364103,0.0002720953,0.00045071746,0.00014719229,0.00035017467],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002698005,0.00054262084,0.00075327227,0.0002895166,0.00025147112,0.00005946624,0.00016615355,0.00043933326,0.000038582704],"category_scores_gemma":[0.0000027189099,0.00048346084,0.00023030488,0.00036564659,0.00013515068,0.00017671289,0.000019073415,0.00024532163,0.00004946232],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057538506,0.0027081426,0.027964301,0.0014776364,0.0010561222,0.0007872234,0.019605255,0.000060136328,0.9286374,0.00001874207,0.0027288985,0.009202294],"study_design_scores_gemma":[0.028151253,0.0021810026,0.16840266,0.00018759488,0.0026336887,0.00017004757,0.00022919393,0.00047321166,0.79658717,0.000022383258,0.00048784024,0.00047396106],"about_ca_topic_score_codex":0.00086582097,"about_ca_topic_score_gemma":0.000052647123,"teacher_disagreement_score":0.14043835,"about_ca_system_score_codex":0.00046813575,"about_ca_system_score_gemma":0.000225534,"threshold_uncertainty_score":0.9997617},"labels":[],"label_agreement":null},{"id":"W2588526377","doi":"10.1182/blood.v124.21.2204.2204","title":"Novel Evidence That Pituitary Gonadotropins Directly Stimulate Human Leukemic cells—studies on Myeloid Cell Lines and Primary Patient AML and CML Cells","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Biology; Haematopoiesis; Internal medicine; Endocrinology; Myeloid; Progenitor cell; Luteinizing hormone; Myeloid leukemia; Stem cell; Population; Cancer research; Hormone; Cell biology; Medicine","score_opus":0.03963293132510984,"score_gpt":0.28795475274938254,"score_spread":0.2483218214242727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588526377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905696,0.0064628455,0.000040891457,0.0006156126,0.00019441423,0.00076578534,0.000027017053,0.00011654219,0.0012072767],"genre_scores_gemma":[0.98888713,0.005136418,0.0021232571,0.0018544481,0.00033812973,0.000043344626,0.000019873874,0.00007820584,0.0015192006],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99745816,0.000116977884,0.00043628216,0.00079918833,0.0005977993,0.0005916157],"domain_scores_gemma":[0.99797463,0.00069591316,0.0002088657,0.0005996119,0.00017693208,0.00034405015],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003719894,0.00043597282,0.00069954025,0.00023041878,0.00028382716,0.00005011812,0.00018856312,0.00016794054,0.000016328997],"category_scores_gemma":[0.00019544111,0.00035116944,0.00009178622,0.00017364352,0.00038027344,0.00019878059,0.00042283183,0.00055862236,0.000040587634],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021534282,0.0005348245,0.0024701518,0.0010786578,0.00017651089,0.00008240996,0.0010775913,0.000043359425,0.98871297,0.00002347672,0.002081386,0.003503322],"study_design_scores_gemma":[0.008522953,0.003513815,0.031915627,0.0015300384,0.00058668025,0.00011752607,0.0003266189,0.0005738841,0.9481886,0.000062963896,0.0039651524,0.0006961272],"about_ca_topic_score_codex":0.00016982145,"about_ca_topic_score_gemma":0.00001855232,"teacher_disagreement_score":0.040524356,"about_ca_system_score_codex":0.00023752793,"about_ca_system_score_gemma":0.00017260644,"threshold_uncertainty_score":0.999894},"labels":[],"label_agreement":null},{"id":"W2588572219","doi":"10.1182/blood.v114.22.1591.1591","title":"Low-Level FLT3-ITD Mutations Do Not Predict for Higher Relapse Rate in AML with Standard Risk Karyotpye.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Cytarabine; Medicine; Internal medicine; Gastroenterology; Chemotherapy regimen; Chemotherapy; Daunorubicin; Oncology; Surgery","score_opus":0.020341190133452137,"score_gpt":0.28770179659600603,"score_spread":0.2673606064625539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588572219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990296,0.00015569,0.0012489238,0.0033426639,0.00007031211,0.0015186616,0.00054355577,0.000118914286,0.0027052704],"genre_scores_gemma":[0.98686767,0.00010062641,0.008242959,0.00050384604,0.00027671378,0.00015527723,0.00014046657,0.000054161585,0.0036582872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810565,0.00009423028,0.0003501924,0.00043751145,0.00047773757,0.00053470855],"domain_scores_gemma":[0.9986653,0.00025917304,0.00010278884,0.0004841232,0.00025300647,0.00023561441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006079801,0.00022229049,0.00039740794,0.00025101035,0.00011831173,0.000040775933,0.00016273334,0.00015622596,0.0001252819],"category_scores_gemma":[0.0003691207,0.00017260543,0.00008740356,0.00046372847,0.00009891286,0.00013852883,0.00003027026,0.000537927,0.00004761164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06794098,0.018325254,0.48960054,0.0021797095,0.0048998552,0.009156992,0.015126619,0.0022741286,0.10839064,0.010826212,0.13535124,0.13592784],"study_design_scores_gemma":[0.08175771,0.008111153,0.82662624,0.0007494215,0.001128057,0.00013688239,0.0003570797,0.0006989608,0.06317734,0.002490755,0.014036816,0.0007296031],"about_ca_topic_score_codex":0.000058176403,"about_ca_topic_score_gemma":0.000048508184,"teacher_disagreement_score":0.3370257,"about_ca_system_score_codex":0.00027978962,"about_ca_system_score_gemma":0.0006272714,"threshold_uncertainty_score":0.7038645},"labels":[],"label_agreement":null},{"id":"W2588972323","doi":"10.1182/blood.v108.11.249.249","title":"Improved Survival in Patients with Myelodysplastic Syndrome (MDS) Receiving Iron Chelation Therapy.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Internal medicine; International Prognostic Scoring System; Anemia; Ferritin; Gastroenterology; Chelation therapy; Hemoglobin; Bone marrow; Surgery; Pediatrics; Thalassemia","score_opus":0.0073793239404041835,"score_gpt":0.2234912166053888,"score_spread":0.2161118926649846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588972323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99741596,0.00007394701,0.00005915901,0.00011940194,0.000053930657,0.00064862095,0.0000055670357,0.00005995501,0.0015634624],"genre_scores_gemma":[0.99856466,0.000012283083,0.0005129514,0.000030217543,0.000085496606,0.00003108008,0.00010631169,0.000044147713,0.00061282614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861515,0.00006128875,0.00024221005,0.0003003931,0.00040893164,0.0003720487],"domain_scores_gemma":[0.99938416,0.000103262646,0.0000700108,0.00026736895,0.000098290366,0.00007689649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022081591,0.00016370474,0.00025777746,0.00018515709,0.000048527803,0.000020474115,0.00008919084,0.00011153295,0.0000779521],"category_scores_gemma":[0.00007756625,0.00012723384,0.00003233189,0.0003728939,0.00004682128,0.000117946896,0.0000315718,0.00031462635,0.000032848275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005379168,0.0009778494,0.9906133,0.00004867786,0.00004453047,0.00007556697,0.00006274789,0.000021521839,0.006019107,0.000017648299,0.000028294542,0.0015528438],"study_design_scores_gemma":[0.015940255,0.0008902696,0.98156154,0.00008941695,0.000038740458,0.000022410726,0.000014261303,0.00027546228,0.0009556206,0.000015270352,0.000052837444,0.00014394162],"about_ca_topic_score_codex":0.00043388343,"about_ca_topic_score_gemma":0.000096531345,"teacher_disagreement_score":0.015402338,"about_ca_system_score_codex":0.00017198788,"about_ca_system_score_gemma":0.0001438129,"threshold_uncertainty_score":0.51884454},"labels":[],"label_agreement":null},{"id":"W2589000699","doi":"10.1182/blood.v114.22.528.528","title":"Allogeneic Hematopoietic Cell Transplantation Can Cure Some Patients with Acute Leukemia in Relapse or Primary Induction Failure: A CIBMTR Study.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Internal medicine; Transplantation; Acute leukemia; Leukemia; Myeloid leukemia; Acute lymphocytic leukemia; Hematopoietic stem cell transplantation; Gastroenterology; Surgery; Lymphoblastic Leukemia","score_opus":0.008912289069390116,"score_gpt":0.24219286935502976,"score_spread":0.23328058028563964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589000699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695545,0.000072246636,0.000019020992,0.00074504904,0.000039281767,0.0018376171,0.000022800195,0.00008330004,0.00022524815],"genre_scores_gemma":[0.99746513,0.00015410532,0.00092310354,0.00046777853,0.00010311832,0.000086029046,0.00028939766,0.00004525879,0.00046610076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978123,0.00011384485,0.0003870524,0.00051556155,0.00070352206,0.00046777134],"domain_scores_gemma":[0.99911493,0.000037349062,0.00010906393,0.00042401897,0.000119733646,0.0001949329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020563848,0.00027955128,0.0004241758,0.00033953437,0.00008231297,0.000026578664,0.00016695634,0.00019444241,0.00003335527],"category_scores_gemma":[0.000018072518,0.00020454773,0.000053150357,0.0006601434,0.000048362108,0.00022928455,0.000022016344,0.00064196094,0.00002161586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013201221,0.016602622,0.8579208,0.0012381863,0.0010373358,0.011720504,0.019950865,0.00015574717,0.070033,0.00006489796,0.0027759566,0.0052988585],"study_design_scores_gemma":[0.044063903,0.0066033187,0.9325932,0.00025537386,0.0010358581,0.0005343061,0.00072291965,0.000010186042,0.013547963,0.00006626156,0.0001072959,0.00045937407],"about_ca_topic_score_codex":0.00012310097,"about_ca_topic_score_gemma":0.00025168172,"teacher_disagreement_score":0.07467244,"about_ca_system_score_codex":0.0007867321,"about_ca_system_score_gemma":0.0011324411,"threshold_uncertainty_score":0.83412147},"labels":[],"label_agreement":null},{"id":"W2589020689","doi":"10.1182/blood.v110.11.2468.2468","title":"Coalescence of the German-Austrian and IMRAW Cytogenetic MDS Databases: Modification of Patient Risk Groups.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"International Prognostic Scoring System; Internal medicine; Cohort; Myelodysplastic syndromes; Karyotype; Oncology; Medicine; Bone marrow; Pediatrics; Biology; Chromosome; Genetics","score_opus":0.027504762760764842,"score_gpt":0.31324018193770464,"score_spread":0.2857354191769398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589020689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998299,0.00046878424,0.00034333582,0.00007794397,0.000025733241,0.00045889092,0.000063324944,0.000008449054,0.00025452583],"genre_scores_gemma":[0.9987841,0.00027902977,0.0007935492,0.00003246973,0.000039646467,0.0000056094555,0.000018675033,0.000010983871,0.00003593038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894387,0.00005733479,0.0002990071,0.00017488252,0.00034907213,0.00017581812],"domain_scores_gemma":[0.9989652,0.00011191888,0.00017894147,0.0005446877,0.00011383965,0.00008540643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003939941,0.0000817008,0.00016750152,0.00007401618,0.000043349173,0.0000028631066,0.0001233899,0.000047388276,0.000014410107],"category_scores_gemma":[0.0002346992,0.000056806202,0.00004092296,0.00023595273,0.00021348578,0.000032051976,0.00011138339,0.00017423276,0.0000030947062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026881634,0.0008629288,0.6624208,0.00029274912,0.00012685846,0.000020168518,0.0011786898,0.000005866711,0.323254,0.00040369085,0.00023607133,0.01092934],"study_design_scores_gemma":[0.0026144756,0.00026461703,0.5014466,0.00011633842,0.00020729675,0.00005363524,0.0002778012,0.00018127279,0.49444655,0.000034608707,0.0002837556,0.00007302746],"about_ca_topic_score_codex":0.00026312855,"about_ca_topic_score_gemma":0.0000272962,"teacher_disagreement_score":0.17119256,"about_ca_system_score_codex":0.000032732933,"about_ca_system_score_gemma":0.00011357435,"threshold_uncertainty_score":0.23164897},"labels":[],"label_agreement":null},{"id":"W2589025718","doi":"10.1182/blood.v116.21.2745.2745","title":"Validation of Monosomal Karyotype Based Model In the Risk Stratification of Acute Myeloid Leukemia","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Monosomy; Internal medicine; Cytarabine; Medicine; Myeloid leukemia; Gastroenterology; Chemotherapy regimen; Transplantation; Induction chemotherapy; Chromosome 7 (human); Chemotherapy; Oncology; Karyotype; Biology; Genetics; Chromosome","score_opus":0.017628828577959065,"score_gpt":0.2831599524219569,"score_spread":0.26553112384399785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589025718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99641585,0.000016270227,0.00072403526,0.00034152553,0.00002398045,0.00048350668,0.0000472095,0.000014809627,0.001932803],"genre_scores_gemma":[0.9940707,0.000028791554,0.005601002,0.00004319935,0.00004945433,0.000032172004,0.00009750804,0.000014900554,0.00006226832],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987965,0.000093445255,0.0003503371,0.00018413075,0.00041174536,0.00016380439],"domain_scores_gemma":[0.99886924,0.00014441386,0.00018172446,0.00058100466,0.0001768498,0.000046747246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006401148,0.000100558645,0.00021381216,0.00015595758,0.000031398748,0.000007998957,0.00023088565,0.00013695404,0.000035523088],"category_scores_gemma":[0.000179958,0.0000720653,0.00007081036,0.00033680903,0.00010266337,0.00008236973,0.000021645656,0.00050607853,0.00000805876],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023825782,0.00049581454,0.04687754,0.00007326903,0.00008733674,0.000007786631,0.00051871664,0.000817026,0.9490463,0.0008194885,0.00014387972,0.00087457674],"study_design_scores_gemma":[0.0036639345,0.00025645876,0.1266807,0.000027592412,0.00036226606,0.000013797243,0.00008679406,0.08814595,0.7800782,0.0005880479,0.000013317052,0.000082987244],"about_ca_topic_score_codex":0.00021860519,"about_ca_topic_score_gemma":0.00004733134,"teacher_disagreement_score":0.16896816,"about_ca_system_score_codex":0.000042699972,"about_ca_system_score_gemma":0.00074786844,"threshold_uncertainty_score":0.29387373},"labels":[],"label_agreement":null},{"id":"W2589026218","doi":"10.1182/blood.v126.23.4893.4893","title":"Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&amp;7","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; CancerCare Manitoba; University of Toronto","funders":"","keywords":"Medicine; Flag (linear algebra); Cytarabine; Internal medicine; Etoposide; Idarubicin; Mitoxantrone; Salvage therapy; Fludarabine; Refractory (planetary science); Oncology; Surgery; Gemcitabine; Gastroenterology; Chemotherapy; Cyclophosphamide","score_opus":0.04440066489194252,"score_gpt":0.3057987817389067,"score_spread":0.2613981168469642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589026218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953142,0.0005005516,0.00013414102,0.0012682764,0.000076762524,0.002159203,0.00015112241,0.00008137766,0.00031441182],"genre_scores_gemma":[0.9825903,0.00021297146,0.011419053,0.0013323504,0.00021699017,0.000094286406,0.0005526347,0.00013640859,0.0034449976],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981262,0.000058873393,0.00036365647,0.000550701,0.00042471476,0.00047585327],"domain_scores_gemma":[0.9982762,0.00021040498,0.000119788936,0.000392896,0.00041247703,0.0005882717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035674893,0.00033236173,0.0006421222,0.00013123848,0.00012044512,0.00006620104,0.00014048629,0.00015472573,0.00013649186],"category_scores_gemma":[0.00017539588,0.00021650243,0.00004570678,0.0001547536,0.00012715973,0.00013285731,0.00009303466,0.00028973835,0.000013768483],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1001458,0.0055974564,0.24437912,0.00091854506,0.0030094942,0.00008478091,0.009659007,0.000012030719,0.5466736,0.000055171357,0.038110904,0.051354058],"study_design_scores_gemma":[0.36973995,0.019346483,0.4483081,0.0008111714,0.00046878014,0.00015073367,0.00080410356,0.003221954,0.034616392,0.00040290042,0.12034519,0.0017842181],"about_ca_topic_score_codex":0.00016501955,"about_ca_topic_score_gemma":0.000080706144,"teacher_disagreement_score":0.51205724,"about_ca_system_score_codex":0.00008847486,"about_ca_system_score_gemma":0.0003448155,"threshold_uncertainty_score":0.88287127},"labels":[],"label_agreement":null},{"id":"W2589070781","doi":"10.1093/annonc/mdw375.43","title":"Phase 3 study of quizartinib (AC220) monotherapy vs salvage chemotherapy (SC) in patients (pts) with FLT3-ITD+ acute myeloid leukemia (AML) refractory to or relapsed (R/R) after 1st-line treatment with or without hematopoietic stem cell transplant (HSCT) consolidation: the QuANTUM-R study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Mitoxantrone; Idarubicin; Oncology; Salvage therapy; Phases of clinical research; Febrile neutropenia; Etoposide; Chemotherapy regimen; Myeloid leukemia; Chemotherapy; Surgery; Neutropenia","score_opus":0.05300243935670836,"score_gpt":0.3718103538949401,"score_spread":0.31880791453823176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589070781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895196,0.00007934492,0.00014291877,0.002570504,0.000056856286,0.0073734536,0.00010378471,0.00004826016,0.00010530834],"genre_scores_gemma":[0.9954014,0.0005946707,0.00018597735,0.0010653264,0.000068143905,0.0010747447,0.000019145855,0.00012543132,0.0014651612],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9954692,0.00074914435,0.0013082797,0.0008496198,0.000878875,0.00074485544],"domain_scores_gemma":[0.996516,0.0007324523,0.00063072715,0.0012138502,0.00058881275,0.0003181636],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000801317,0.000609679,0.0018216536,0.00044452632,0.000089538386,0.00001532393,0.00043749507,0.00022557242,0.0002811416],"category_scores_gemma":[0.00002351773,0.0002621354,0.00011510055,0.000743713,0.00035769382,0.00017645229,0.00005242839,0.00036097135,0.000023510998],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59887815,0.062229823,0.18089947,0.00016316818,0.0025872893,0.0016743932,0.074959114,0.00001839012,0.010455203,0.0000044923004,0.0006357523,0.06749477],"study_design_scores_gemma":[0.22986336,0.6801387,0.027048312,0.00055440504,0.00068558066,0.00010320024,0.011619713,0.00008361802,0.045564976,0.0000036720626,0.0037372978,0.0005971565],"about_ca_topic_score_codex":0.00036843945,"about_ca_topic_score_gemma":0.0014425155,"teacher_disagreement_score":0.6179089,"about_ca_system_score_codex":0.00081592175,"about_ca_system_score_gemma":0.0018734819,"threshold_uncertainty_score":0.9999831},"labels":[],"label_agreement":null},{"id":"W2589081489","doi":"10.1182/blood.v110.11.3380.3380","title":"Independent and Converging Pathways in Leukemia Stem Cells.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Leukemia; Stem cell; NPM1; Transplantation; Bone marrow; Myeloid leukemia; Biology; Cancer research; Immunology; Minimal residual disease; Myeloid; Molecular biology; Medicine; Gene; Internal medicine; Genetics","score_opus":0.01971435543269155,"score_gpt":0.25893892270037083,"score_spread":0.2392245672676793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589081489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920645,0.00049879664,0.000079128426,0.00008986521,0.00005625075,0.00029275654,0.0000027538795,0.000047551268,0.006868409],"genre_scores_gemma":[0.9983366,0.00011796788,0.00038623795,0.00022779188,0.00010644458,0.000006481531,0.0000032481048,0.00002364824,0.00079153856],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987182,0.000026050107,0.00023749011,0.00026839442,0.0003272252,0.00042261902],"domain_scores_gemma":[0.99937475,0.000107976965,0.00003648176,0.00022755237,0.000042744803,0.00021051677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074417674,0.00011904518,0.00021930417,0.00021916699,0.000036420337,0.000016468448,0.000082828235,0.00013073412,0.000042185835],"category_scores_gemma":[0.000022263946,0.00010807042,0.000031252486,0.0002155038,0.00005864504,0.00005457204,0.00010639283,0.00044380134,0.00005548831],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044592726,0.0005676001,0.46396524,0.0004329941,0.00014861822,0.007819567,0.0031013065,0.0000055129744,0.48695862,0.0009798071,0.00074502634,0.0348298],"study_design_scores_gemma":[0.020438498,0.00039695718,0.25350493,0.0002339012,0.000100102436,0.0007054837,0.002205905,0.00044672762,0.7177742,0.0000916926,0.0037547208,0.0003468405],"about_ca_topic_score_codex":0.00013966468,"about_ca_topic_score_gemma":0.00006366137,"teacher_disagreement_score":0.23081562,"about_ca_system_score_codex":0.00033430225,"about_ca_system_score_gemma":0.00029604632,"threshold_uncertainty_score":0.4406984},"labels":[],"label_agreement":null},{"id":"W2589193943","doi":"10.1182/blood.v118.21.2370.2370","title":"Tif1gamma Is Essential for Macrophage Differentiation","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Biology; Haematopoiesis; Progenitor cell; Stem cell; GATA2; Embryonic stem cell; Bone marrow; Molecular biology; Cell biology; CD34; Cancer research; Immunology; Gene; Genetics","score_opus":0.031413714253844975,"score_gpt":0.28726663881848746,"score_spread":0.2558529245646425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589193943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99020416,0.00012620477,0.0027255204,0.00026635133,0.000106537926,0.0005802807,0.000027291204,0.000066600915,0.0058970647],"genre_scores_gemma":[0.9901415,0.000022220605,0.0038610916,0.00023216385,0.0003427922,0.00006933032,0.000051022205,0.000030221516,0.0052496456],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991817,0.000015683396,0.00014650797,0.00020860753,0.00018833215,0.0002591755],"domain_scores_gemma":[0.9994552,0.000026103506,0.000039010396,0.00026019287,0.00010408575,0.00011539983],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000096880205,0.000094467716,0.00015307288,0.00007801246,0.00005717646,0.000011527002,0.00009324619,0.00009185272,0.0010863945],"category_scores_gemma":[0.00006337102,0.000080342725,0.00009620504,0.00009181568,0.00003693569,0.000048079914,0.000040998162,0.00012024007,0.00017715982],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002345806,0.005395095,0.07240764,0.0011708895,0.0016116423,0.00041505886,0.0065273065,1.0448756e-7,0.8152206,0.0037944948,0.056946903,0.034164462],"study_design_scores_gemma":[0.0094432,0.00047317555,0.070031874,0.000032332413,0.0004206107,0.00006642279,0.00006266648,0.00030619616,0.91482025,0.00051837123,0.0036699635,0.00015495365],"about_ca_topic_score_codex":0.00003901339,"about_ca_topic_score_gemma":0.0000033898245,"teacher_disagreement_score":0.09959964,"about_ca_system_score_codex":0.000032528802,"about_ca_system_score_gemma":0.000083622894,"threshold_uncertainty_score":0.9998267},"labels":[],"label_agreement":null},{"id":"W2589217902","doi":"10.1182/blood.v120.21.1424.1424","title":"Presence of Minimal Residual Disease by Flow Cytometry After Induction Chemotherapy Is Less Predictive of Overall and Progression-Free Survival Compared to Conventional Prognostic Factors Including Cytogenetic Risk and Age","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Calgary Laboratory Services; Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Medicine; Minimal residual disease; Induction chemotherapy; Immunophenotyping; Acute promyelocytic leukemia; Internal medicine; Oncology; Chemotherapy; Leukemia; Chemotherapy regimen; Myeloid leukemia; Bone marrow; Transplantation; Surgery; Immunology; Flow cytometry; Biology","score_opus":0.033555692717299676,"score_gpt":0.31320657855195855,"score_spread":0.27965088583465886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589217902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99642277,0.0014193961,0.00013238851,0.00017806899,0.000050616785,0.0009968379,0.00076000433,0.000018526169,0.000021402568],"genre_scores_gemma":[0.99769974,0.000110915375,0.0018124549,0.000025729309,0.00013203421,0.00007666029,0.00006451132,0.000027591144,0.000050363073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981799,0.00013974844,0.00031550968,0.00031699476,0.0007272105,0.00032065055],"domain_scores_gemma":[0.9987518,0.00023560393,0.00014650215,0.00027680493,0.00015826906,0.0004309918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034724432,0.00018703839,0.00037629536,0.00019705042,0.000061738494,0.000014448428,0.00011722708,0.000099068144,0.000042483054],"category_scores_gemma":[0.0005797034,0.00015640762,0.000050006453,0.0002308019,0.0003007544,0.00014133092,0.00025935087,0.00020743695,5.9202455e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022783247,0.0008391933,0.97216064,0.0003325639,0.00023149447,0.00000996801,0.0017597263,0.0000010237126,0.021177886,0.0000026383238,0.0005433632,0.0006631839],"study_design_scores_gemma":[0.0050096717,0.00051118544,0.9551699,0.00029685994,0.00026854,0.000009880466,0.00034310814,0.00012932162,0.038060993,0.00002949156,0.00004051606,0.0001305408],"about_ca_topic_score_codex":0.00005354941,"about_ca_topic_score_gemma":0.0000028438415,"teacher_disagreement_score":0.016990744,"about_ca_system_score_codex":0.000046710466,"about_ca_system_score_gemma":0.00012615656,"threshold_uncertainty_score":0.6378118},"labels":[],"label_agreement":null},{"id":"W2589488562","doi":"10.1182/blood.v124.21.2650.2650","title":"The Cost-Effectiveness of Clinical Genomic Tests to Aid CR1 Treatment Decisions in Intermediate-Risk AML","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"NPM1; Medicine; Guideline; Oncology; Myeloid leukemia; Internal medicine; Intensive care medicine; Biology","score_opus":0.05482478339056106,"score_gpt":0.4015646334241789,"score_spread":0.34673985003361785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589488562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99690753,0.00013071709,0.00017371577,0.00021297562,0.00014013368,0.0014724738,0.000019044357,0.000019531635,0.00092384865],"genre_scores_gemma":[0.998191,0.0006137906,0.00053097,0.000070865884,0.00019244131,0.00023696735,0.000009928257,0.000026208068,0.00012781168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978081,0.0007226488,0.00054607244,0.00032616663,0.00025455432,0.0003424855],"domain_scores_gemma":[0.99140286,0.007452702,0.00009792516,0.00067766494,0.000107632244,0.00026122635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025322135,0.0001447374,0.0005141472,0.00013377247,0.000064767315,0.000013193381,0.0002520858,0.00011386922,0.000016565262],"category_scores_gemma":[0.0062415786,0.00008596568,0.00015129066,0.00024419063,0.00014788662,0.000022400855,0.00016094325,0.0003215865,0.00018716292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015150507,0.0014629959,0.7509395,0.00001859942,0.00018583723,0.000050781033,0.00017928405,0.000022923381,0.0046535144,0.000074066455,0.00018488403,0.24071257],"study_design_scores_gemma":[0.0119951535,0.0026835804,0.9712738,0.00015280966,0.00012796353,0.00001725257,0.00005065329,0.00021498762,0.006744706,0.00012370871,0.0065335636,0.000081826925],"about_ca_topic_score_codex":0.0002717924,"about_ca_topic_score_gemma":0.00041539417,"teacher_disagreement_score":0.24063075,"about_ca_system_score_codex":0.00022052242,"about_ca_system_score_gemma":0.00037860373,"threshold_uncertainty_score":0.74722034},"labels":[],"label_agreement":null},{"id":"W2589693443","doi":"10.1182/blood.v120.21.3097.3097","title":"The Benefit of Allogeneic Hematopoietic Cell Transplantation in Older Patients with Acute Myeloid Leukemia Is Restricted to Those in First Complete Remission At the Time of Transplantation.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cumulative incidence; Transplantation; Internal medicine; Myeloid leukemia; Hematopoietic stem cell transplantation; Gastroenterology; Leukemia; Incidence (geometry); Acute leukemia; Bone marrow; Surgery; Myeloid","score_opus":0.010940924925292876,"score_gpt":0.2454269506333944,"score_spread":0.2344860257081015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589693443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972903,0.0003033758,0.000028019273,0.00063903263,0.00001717612,0.0012130607,0.0001432009,0.000010700103,0.00035513786],"genre_scores_gemma":[0.9979028,0.00085601147,0.00037451988,0.00012750234,0.000018335493,0.00006138119,0.00019469378,0.000030963874,0.0004337664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981803,0.00009393593,0.0005038603,0.0002260196,0.00059460034,0.000401253],"domain_scores_gemma":[0.9988191,0.00036419352,0.00015021268,0.00040715397,0.00012824575,0.00013106382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000269801,0.0001808587,0.00031677852,0.00017212723,0.00009580209,0.0000067158335,0.00022952026,0.00010977895,0.000084593026],"category_scores_gemma":[0.000023026048,0.0001032836,0.00005875895,0.0006280418,0.000093721974,0.00008101805,0.000034454388,0.00023111388,0.000028105533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057420717,0.0013746055,0.7928131,0.0010445764,0.00020779589,0.00007827917,0.027420633,0.0002132181,0.16963506,0.000025174277,0.00075386575,0.00069161644],"study_design_scores_gemma":[0.008645497,0.00031325786,0.86175436,0.00047861403,0.00027930213,0.000046296267,0.00012446035,0.000046364974,0.12802584,0.000007146865,0.00015363058,0.00012523089],"about_ca_topic_score_codex":0.00022922047,"about_ca_topic_score_gemma":0.00018953964,"teacher_disagreement_score":0.06894126,"about_ca_system_score_codex":0.00020924312,"about_ca_system_score_gemma":0.00015999445,"threshold_uncertainty_score":0.4211783},"labels":[],"label_agreement":null},{"id":"W2589908125","doi":"10.1182/blood.v128.22.2876.2876","title":"Replication of New Genomic Classification System in Acute Myeloid Leukemia with Normal Karyotype","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"CEBPA; Myeloid leukemia; NPM1; Biology; Oncology; Mutation; Genetics; Cancer research; Gene; Internal medicine; Karyotype; Medicine; Chromosome","score_opus":0.021296347538988573,"score_gpt":0.26918356971489055,"score_spread":0.24788722217590198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589908125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99325,0.00010465937,0.00060795556,0.0007918976,0.00002218329,0.00057071296,0.000010095775,0.00006840039,0.0045741065],"genre_scores_gemma":[0.9951282,0.00010282508,0.002145954,0.000038293365,0.00013359524,0.00004281006,0.000027467062,0.000032579424,0.0023482414],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986296,0.00004185576,0.00035698013,0.0004066393,0.000301192,0.00026369106],"domain_scores_gemma":[0.99851257,0.000056172586,0.00016121032,0.0009913074,0.00013271264,0.00014602183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033537226,0.00012738083,0.0002744843,0.00020526139,0.00002465089,0.000006842268,0.0001842739,0.00012091761,0.000030310774],"category_scores_gemma":[0.000073203846,0.00008170402,0.00004090083,0.0003425482,0.00006835817,0.00011658641,0.000046614252,0.00015085455,0.00011806256],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092041114,0.00012576941,0.14404012,0.00016579335,0.00017133888,0.000044908433,0.00019827142,0.0000016568131,0.8382721,0.0013631401,0.00077376614,0.013922703],"study_design_scores_gemma":[0.010980433,0.00061930803,0.78993595,0.0004822764,0.00025454263,0.0003956875,0.0001817892,0.00018482069,0.19552383,0.000018455052,0.0012538775,0.00016905824],"about_ca_topic_score_codex":0.00024049466,"about_ca_topic_score_gemma":0.00003356739,"teacher_disagreement_score":0.6458958,"about_ca_system_score_codex":0.000776138,"about_ca_system_score_gemma":0.0012100181,"threshold_uncertainty_score":0.33317932},"labels":[],"label_agreement":null},{"id":"W2590096408","doi":"10.1182/blood.v108.11.239.239","title":"Expression of MLL Fusion Genes in Human Hematopoietic Cells Is Sufficient To Induce Both Acute Lymphoid and Acute Myeloid Leukemia In Vivo.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Biology; Haematopoiesis; Lymphopoiesis; Leukemia; Myeloid; Cancer research; Immunology; Bone marrow; clone (Java method); Acute leukemia; Stem cell; Gene; Genetics","score_opus":0.01085910169809486,"score_gpt":0.26926460586991124,"score_spread":0.2584055041718164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590096408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99676067,0.00051445316,0.000020945667,0.00027440846,0.00004493446,0.00086212,0.00003910854,0.000036304922,0.001447083],"genre_scores_gemma":[0.9967556,0.00028117944,0.001095546,0.00026826083,0.00009227238,0.00005592038,0.000019841831,0.000051780476,0.0013796011],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99744344,0.000069295966,0.00064604724,0.00060967286,0.00063921907,0.0005923259],"domain_scores_gemma":[0.9989532,0.000068465946,0.00012663206,0.00055565214,0.00008128025,0.0002147453],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039170255,0.00029222367,0.00060736475,0.0006660293,0.00007330397,0.000024780447,0.00024456062,0.00025097647,0.00011271052],"category_scores_gemma":[0.000019266947,0.00025814597,0.00007637876,0.0006839265,0.00010526573,0.00009203389,0.00037234844,0.0003145194,0.000017564736],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017125724,0.0005855292,0.01971538,0.00014915087,0.000026797396,0.00046981254,0.0012265571,0.000026275766,0.9753609,0.000025613774,0.0019886785,0.0002540554],"study_design_scores_gemma":[0.0067043323,0.00041596685,0.022164404,0.00046714186,0.000102007405,0.00015760263,0.0002609,0.000107659245,0.968751,0.000042054144,0.0005907039,0.00023620023],"about_ca_topic_score_codex":0.0016417113,"about_ca_topic_score_gemma":0.00015329283,"teacher_disagreement_score":0.006609866,"about_ca_system_score_codex":0.00055883126,"about_ca_system_score_gemma":0.00045009595,"threshold_uncertainty_score":0.99998707},"labels":[],"label_agreement":null},{"id":"W2590229274","doi":"10.1182/blood.v116.21.2922.2922","title":"Will a Peripheral Blood (PB) Sample Yield the Same Diagnostic and Prognostic Cytogenetic Data as the Concomitant Bone Marrow (BM) In Myelodysplasia? An International Study Comparing Cytogenetics and Interphase FISH Using Parallel PB and BM Samples","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"North York General Hospital","funders":"","keywords":"Myelodysplastic syndromes; International Prognostic Scoring System; Fluorescence in situ hybridization; Cytogenetics; Bone marrow; Biology; Pathology; Concordance; Leukemia; Oncology; Concomitant; Chromosome; Internal medicine; Medicine; Immunology; Genetics","score_opus":0.06715068969143526,"score_gpt":0.3309408066033175,"score_spread":0.26379011691188226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590229274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539685,0.00071323843,0.00019258792,0.001382383,0.000109200635,0.0019315608,0.00020354483,0.000033069402,0.000037541577],"genre_scores_gemma":[0.99377006,0.00048322292,0.00472149,0.00045812834,0.00029572996,0.00009065122,0.000110229674,0.000055311233,0.000015149207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974561,0.0002297402,0.00053078553,0.0007691235,0.0005063775,0.00050791353],"domain_scores_gemma":[0.9955633,0.0028543423,0.00014064931,0.0010410431,0.00011556556,0.0002850834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009245668,0.00035004472,0.0004986678,0.00014671577,0.00027918338,0.00033217084,0.0006544962,0.00012885447,0.000053641277],"category_scores_gemma":[0.0045758463,0.00023877741,0.00003226935,0.00019862367,0.00062757416,0.00028825185,0.0011933662,0.0008727877,0.0000010502457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029264923,0.0012052492,0.969076,0.000057467307,0.00035469874,0.00036612057,0.0028663059,0.000017564518,0.02447718,0.000065892935,0.000025584794,0.0011953362],"study_design_scores_gemma":[0.019407228,0.0023004017,0.9418602,0.00041422917,0.0017377972,0.0050662598,0.0061180824,0.019727683,0.0018499525,0.000311869,0.00057233905,0.00063396286],"about_ca_topic_score_codex":0.0019217958,"about_ca_topic_score_gemma":0.009459062,"teacher_disagreement_score":0.027215756,"about_ca_system_score_codex":0.000039551596,"about_ca_system_score_gemma":0.0002499043,"threshold_uncertainty_score":0.973706},"labels":[],"label_agreement":null},{"id":"W2590329281","doi":"10.1182/blood.v128.22.52.52","title":"Longitudinal Tracking of MDS Patients Using Next Generation Sequencing Provides a Predictive Measure for Azacitidine Response and AML Progression","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Azacitidine; Myelodysplastic syndromes; Oncology; Internal medicine; Medicine; Myeloid leukemia; International Prognostic Scoring System; Hypomethylating agent; Bone marrow; Biology; Gene; Genetics","score_opus":0.11538503938323698,"score_gpt":0.3352456667797034,"score_spread":0.21986062739646645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590329281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933634,0.00025869004,0.0047357646,0.00021958153,0.00003290497,0.0013015749,0.00004284065,0.0000314862,0.000013754057],"genre_scores_gemma":[0.99247116,0.00001568047,0.0071477336,0.0000160038,0.0001998603,0.00007225344,0.000014542795,0.00002958713,0.00003318467],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99862224,0.0001271879,0.000278497,0.00031001106,0.00040022845,0.0002618085],"domain_scores_gemma":[0.9987606,0.00020716494,0.00014451946,0.00017778213,0.0006125575,0.00009737858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007190609,0.00013537321,0.00024324912,0.00015738932,0.00011441584,0.000022580081,0.000053351192,0.00010638864,0.000005435995],"category_scores_gemma":[0.0016138653,0.00008829646,0.000052946598,0.00013549028,0.000114006005,0.00030414824,0.000048330534,0.00009553503,4.810226e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030205862,0.00017649675,0.11569163,0.00016089667,0.000086634594,0.000012365852,0.000360033,0.0000017433848,0.86474025,0.000006203284,0.000035599114,0.015707549],"study_design_scores_gemma":[0.013829029,0.0033360098,0.089021236,0.0018697347,0.00038824748,0.000103724116,0.0001291226,0.005986923,0.88508165,0.000031302283,0.00004338994,0.00017962826],"about_ca_topic_score_codex":0.000014904907,"about_ca_topic_score_gemma":0.0000053548324,"teacher_disagreement_score":0.0266704,"about_ca_system_score_codex":0.00027303683,"about_ca_system_score_gemma":0.00047301437,"threshold_uncertainty_score":0.3600625},"labels":[],"label_agreement":null},{"id":"W2590520833","doi":"10.1182/blood.v112.11.920.920","title":"Pediatric Patients with Extramedullary Leukemia Involving the Central Nervous System Have a Superior Outcome.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Medicine; Leukemia; Central nervous system; Bone marrow; Chemotherapy; Pathology; Internal medicine; Oncology","score_opus":0.017220474479343058,"score_gpt":0.23424135509247732,"score_spread":0.21702088061313426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590520833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966789,0.00077721913,0.000025952422,0.00017926774,0.00011759214,0.0010371014,0.000018912275,0.00016514544,0.0009999464],"genre_scores_gemma":[0.99764866,0.000085298874,0.0005872584,0.00028208343,0.00063329155,0.00006629038,0.000040196217,0.00007452686,0.0005823986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736136,0.00010742515,0.0004155593,0.0003997503,0.0008982812,0.00081760314],"domain_scores_gemma":[0.99850726,0.00014575898,0.00010322767,0.0006677549,0.00021991594,0.00035608222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019818514,0.00027894758,0.0004233406,0.0001501903,0.00034848097,0.00003671695,0.00031503648,0.00015255492,0.000040893043],"category_scores_gemma":[0.0001789918,0.00016439971,0.00012840932,0.00038867124,0.00016642702,0.00011768519,0.00013182641,0.00065194094,0.000078294084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001697917,0.00025020997,0.99624765,0.00026459064,0.00010782247,0.00095847313,0.00078377326,0.0000071045897,0.00009073614,0.000024884195,0.00090207404,0.00019287491],"study_design_scores_gemma":[0.007653866,0.00050607306,0.9887272,0.00007026933,0.00042544235,0.00077370467,0.00072401273,0.00023093885,0.00029707173,8.041345e-7,0.00035734425,0.00023325122],"about_ca_topic_score_codex":0.0002712329,"about_ca_topic_score_gemma":0.00002262273,"teacher_disagreement_score":0.0075204433,"about_ca_system_score_codex":0.0006766746,"about_ca_system_score_gemma":0.0010060334,"threshold_uncertainty_score":0.6704026},"labels":[],"label_agreement":null},{"id":"W2590631360","doi":"10.1182/blood.v110.11.2431.2431","title":"High-Resolution CGH Analysis of CD34+ Cells from Lower-Risk Myelodysplastic Patients Reveals Cryptic Copy Number Alterations and Predicts Overall and Leukemia-Free Survival.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Myelodysplastic syndromes; Biology; International Prognostic Scoring System; Cytogenetics; Myeloid leukemia; Leukemia; Comparative genomic hybridization; Myeloid; Chromosome abnormality; Internal medicine; Oncology; Karyotype; Bone marrow; CD34; Cancer research; Immunology; Genetics; Chromosome; Medicine; Gene; Stem cell","score_opus":0.008800520466095418,"score_gpt":0.24865166966648686,"score_spread":0.23985114920039144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590631360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639577,0.00019030589,0.0014319347,0.00006783088,0.00016062865,0.000521382,0.0006763617,0.00004508525,0.00051068014],"genre_scores_gemma":[0.9936479,0.00042308882,0.00486686,0.000086456545,0.00018306663,0.000012760435,0.00040367307,0.00003455682,0.00034168232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975315,0.00014493916,0.00059065805,0.000529935,0.0007456499,0.00045734335],"domain_scores_gemma":[0.9974117,0.0009601975,0.00026145784,0.00067130197,0.00033737934,0.00035795142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060866156,0.00025675958,0.0006969515,0.00036899062,0.00013831448,0.00003973722,0.00015736224,0.00021962072,0.00020320978],"category_scores_gemma":[0.0008007493,0.00023583649,0.00011420319,0.0006559748,0.00019821388,0.00015511106,0.00019569306,0.00036512362,0.000022570088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007187663,0.0008064125,0.97145665,0.00013725343,0.0030821397,0.00007256329,0.0004212977,0.00020680095,0.019090526,0.0001914113,0.0033001867,0.00051602075],"study_design_scores_gemma":[0.01193285,0.00052901154,0.9708276,0.00012643768,0.0062763453,0.0000044118638,0.000039790306,0.0027632024,0.0067818533,0.000349797,0.00012612245,0.00024259459],"about_ca_topic_score_codex":0.0017448551,"about_ca_topic_score_gemma":0.0003072685,"teacher_disagreement_score":0.012308673,"about_ca_system_score_codex":0.00022281367,"about_ca_system_score_gemma":0.0001645527,"threshold_uncertainty_score":0.9617133},"labels":[],"label_agreement":null},{"id":"W2590633005","doi":"10.1182/blood.v128.22.769.769","title":"Chemo-Transcriptomic Analysis of Complex Karyotype AML Reveals Increased Expression of Cell Cycle Components and Exquisite Dependency on Polo-like Kinase 1","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Leukemia & Lymphoma Society of Canada; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Neuroblastoma RAS viral oncogene homolog; Biology; RUNX1; Cancer research; Transcriptome; Myeloid; Internal medicine; Oncology; Haematopoiesis; Gene; Medicine; Genetics; KRAS; Stem cell; Mutation; Gene expression","score_opus":0.020880022443714775,"score_gpt":0.2725980691153113,"score_spread":0.25171804667159653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590633005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978163,0.00021305449,0.00006508246,0.00014209493,0.00001972693,0.00035309474,0.00018030216,0.000027903761,0.0011824117],"genre_scores_gemma":[0.998167,0.00014518817,0.0011528141,0.00013319377,0.000031833668,0.0000089619325,0.00008981288,0.000027889932,0.00024333685],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981441,0.00014713427,0.00047110964,0.00038535654,0.0005428582,0.00030945597],"domain_scores_gemma":[0.9985224,0.0002398256,0.0002048719,0.000631664,0.00015774625,0.00024347502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032309306,0.00019570618,0.00072829064,0.00053988385,0.00004568464,0.000005343953,0.0001990074,0.00013410657,0.00042186267],"category_scores_gemma":[0.00008932184,0.00013569217,0.0001766532,0.0004969287,0.00016504947,0.00006560285,0.00009757189,0.00015187684,0.000018017678],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008367856,0.00087696064,0.10497062,0.00017295039,0.00035831376,0.000039571823,0.00012385189,7.117563e-7,0.89219844,0.00001097709,0.00018568206,0.0002251531],"study_design_scores_gemma":[0.0065290225,0.00031130997,0.38142842,0.00021096219,0.0010179929,0.000006737562,0.000028310966,0.000083946,0.6102237,0.00002866888,0.000027897753,0.000103016035],"about_ca_topic_score_codex":0.00042776932,"about_ca_topic_score_gemma":0.000012824027,"teacher_disagreement_score":0.2819747,"about_ca_system_score_codex":0.00006417604,"about_ca_system_score_gemma":0.00007650903,"threshold_uncertainty_score":0.5533366},"labels":[],"label_agreement":null},{"id":"W2591433699","doi":"10.71781/28203","title":"Étude de l'influence du facteur de transcription EKLF sur la régulation épigénétique du locus de la [Bêta]-globine humaine lors de l'hématopoïèse","year":2004,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Molecular biology","score_opus":0.013062127441759644,"score_gpt":0.31689871292558164,"score_spread":0.303836585483822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591433699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98267394,0.0010254898,0.0056598717,0.0013036925,0.00024200448,0.0025049944,0.00015650455,0.00003120527,0.006402286],"genre_scores_gemma":[0.9789393,0.0023028848,0.0092490865,0.00030688473,0.0007335991,0.0002979615,0.002230413,0.00024696827,0.00569292],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9929956,0.0017479123,0.0012285545,0.00120332,0.00095378456,0.0018708347],"domain_scores_gemma":[0.99598795,0.0009884689,0.0005533562,0.0008011189,0.00066602003,0.0010030604],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00519328,0.0009777257,0.0011651221,0.00053862727,0.0004914457,0.0006817654,0.0013902843,0.0019174541,0.0025840923],"category_scores_gemma":[0.0022310826,0.0010763648,0.00036177563,0.00082735554,0.0005021436,0.001051141,0.00015645001,0.002336235,0.00062609813],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0037857466,0.0015168018,0.08570783,0.0015515992,0.00070304173,0.0045590317,0.04485434,0.027745198,0.78620136,0.0010410107,0.0009327652,0.04140128],"study_design_scores_gemma":[0.01455006,0.0008542924,0.65200955,0.005222044,0.0014932322,0.0033608384,0.0048832865,0.015045934,0.27815047,0.0010603649,0.021494107,0.0018757982],"about_ca_topic_score_codex":0.020373225,"about_ca_topic_score_gemma":0.0061459015,"teacher_disagreement_score":0.56630176,"about_ca_system_score_codex":0.007612739,"about_ca_system_score_gemma":0.010274136,"threshold_uncertainty_score":0.9999654},"labels":[],"label_agreement":null},{"id":"W2591845364","doi":"10.1182/blood.v110.11.1102.1102","title":"Early Recovery of Absolute Lymphocyte Count (ALC) Is a Predictor of Long-Term Outcome Following Related Allogeneic Peripheral Blood Stem Cell Transplantation in Adults with AML/MDS.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Busulfan; Transplantation; Internal medicine; Incidence (geometry); Stem cell; Cohort; Cumulative incidence; Hematopoietic stem cell transplantation; Lymphocyte; Donor lymphocyte infusion; Total body irradiation; Surgery; Gastroenterology; Cyclophosphamide; Chemotherapy","score_opus":0.01082810601048695,"score_gpt":0.24991298511161678,"score_spread":0.23908487910112983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591845364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99682164,0.0010044691,0.000116908705,0.000032035874,0.000087332766,0.0009857543,0.00008996057,0.000050868643,0.00081101165],"genre_scores_gemma":[0.99773735,0.000482473,0.00068673945,0.00006264382,0.000048307258,0.000023830235,0.00008149819,0.00007083611,0.0008063176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703515,0.00007278282,0.0010216058,0.0004607349,0.0008343856,0.0005753711],"domain_scores_gemma":[0.99874943,0.00013200918,0.000303253,0.00045095236,0.00017167315,0.00019270199],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006669681,0.00028945802,0.00069666386,0.00037767095,0.000037188132,0.000011635154,0.0002170284,0.00029198642,0.0000606981],"category_scores_gemma":[0.000016715721,0.00024968153,0.00022773299,0.00057933957,0.00009879624,0.00019186447,0.000031554795,0.00034292985,0.000007080003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051274975,0.0010921682,0.9323186,0.0016480983,0.0007575024,0.002625148,0.0057277367,0.000020020214,0.049773965,0.0000028907896,0.0000071365903,0.0008992143],"study_design_scores_gemma":[0.037993878,0.0020235688,0.8585908,0.0013369845,0.00094730355,0.000275347,0.00020269293,0.00005179341,0.09833705,0.0000015480266,0.0000032580733,0.00023579976],"about_ca_topic_score_codex":0.0006248443,"about_ca_topic_score_gemma":0.00024633628,"teacher_disagreement_score":0.073727846,"about_ca_system_score_codex":0.0002893428,"about_ca_system_score_gemma":0.00049908063,"threshold_uncertainty_score":0.9999955},"labels":[],"label_agreement":null},{"id":"W2591902475","doi":"10.1016/j.stem.2017.02.010","title":"Bringing a Leukemic Stem Cell Gene Signature into Clinics: Are We There Yet?","year":2017,"lang":"en","type":"letter","venue":"Cell stem cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Biology; Stem cell; Gene; Gene signature; Signature (topology); Genetics; Cell; Cell biology; Computational biology; Cancer research; Evolutionary biology; Bioinformatics; Gene expression","score_opus":0.031709717673830094,"score_gpt":0.2859833727700769,"score_spread":0.25427365509624683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591902475","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19120695,0.21544477,0.00054637867,0.2959235,0.00959257,0.011732659,0.0008629162,0.0019584482,0.2727318],"genre_scores_gemma":[0.07199438,0.01106918,0.0009637968,0.118463635,0.014261309,0.00024026063,0.0010194484,0.0013470927,0.7806409],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99141705,0.0004965663,0.0014040588,0.0024812897,0.0019288198,0.0022721868],"domain_scores_gemma":[0.99167836,0.00082923163,0.0017625578,0.0045108586,0.0005418501,0.000677136],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0010216162,0.0016653005,0.002491716,0.000690866,0.00063085044,0.0004160945,0.0027174298,0.0047500907,0.0006194384],"category_scores_gemma":[0.000019936562,0.0014912694,0.001096155,0.00035491106,0.00036863767,0.00022246559,0.0011664494,0.012997118,0.0034191387],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017732706,0.00013232588,0.00033289188,0.010055387,0.00018620635,0.013318373,0.00092193775,0.000020435791,0.016793266,3.8835216e-7,0.95253116,0.0055302787],"study_design_scores_gemma":[0.004122768,0.00035788436,0.00003944289,0.002056831,0.0006114259,0.00016646028,0.00085913704,0.0005402086,0.059837613,0.000027086218,0.9299433,0.0014377948],"about_ca_topic_score_codex":0.00018120765,"about_ca_topic_score_gemma":0.000011413064,"teacher_disagreement_score":0.50790906,"about_ca_system_score_codex":0.0028705082,"about_ca_system_score_gemma":0.0022838821,"threshold_uncertainty_score":0.9996094},"labels":[],"label_agreement":null},{"id":"W2592005338","doi":"10.1182/blood.v128.22.1680.1680","title":"Genetic Determinants of Response to Guadecitabine (SGI-110) in AML","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Decitabine; Biology; International Prognostic Scoring System; CEBPA; Internal medicine; Genetics; Medicine; Mutation; Myelodysplastic syndromes; Bone marrow; Gene; DNA methylation","score_opus":0.018382417904745516,"score_gpt":0.30619381110834115,"score_spread":0.2878113932035956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592005338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99746853,0.000118512486,0.00003607857,0.0015282532,0.0000311849,0.00041441547,0.0000145307695,0.000020048543,0.0003684553],"genre_scores_gemma":[0.99453163,0.000039655864,0.0027296422,0.00017171784,0.000076714714,0.000035252768,4.821282e-7,0.0000278756,0.0023870408],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99858093,0.00011652115,0.00034043664,0.00026299513,0.00032955437,0.00036953174],"domain_scores_gemma":[0.99884015,0.00029165193,0.000045287834,0.0005247711,0.000095509444,0.00020261612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000511149,0.000114595816,0.00031082807,0.0003427984,0.000013951475,0.000003799458,0.00018686145,0.00008852593,0.00019100768],"category_scores_gemma":[0.0014307665,0.00007632427,0.000051459287,0.000364237,0.000071109476,0.00003645431,0.00012545288,0.00010033756,0.00025146265],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002261758,0.00034965313,0.2984958,0.000044066175,0.000021038497,0.0006101505,0.000201392,2.6742651e-7,0.6716727,0.0000033660426,0.00053721154,0.025802622],"study_design_scores_gemma":[0.0073781344,0.00081876834,0.76659256,0.0002606652,0.000029147239,0.0001322783,0.000027901553,0.0000093147755,0.22292098,0.000026338495,0.0017109499,0.00009292132],"about_ca_topic_score_codex":0.00007237005,"about_ca_topic_score_gemma":0.0000694931,"teacher_disagreement_score":0.4680968,"about_ca_system_score_codex":0.00010882208,"about_ca_system_score_gemma":0.0003106906,"threshold_uncertainty_score":0.32321274},"labels":[],"label_agreement":null},{"id":"W2592196376","doi":"10.1182/blood.v118.21.422.422","title":"Pre-Screening for Low Methyl Guanine Methyltransferase (MGMT) Expression Results in High Response Rates to Temozolomide (TMZ) Therapy in AML and MDS Patients.","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; McMaster University Medical Centre; Merck Canada Inc. (Canada); Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Temozolomide; Methyltransferase; Medicine; O-6-methylguanine-DNA methyltransferase; Oncology; Internal medicine; Induction chemotherapy; Myeloid leukemia; Chemotherapy; Decitabine; DNA methylation; Methylation; Biology; Gene expression","score_opus":0.03785284742677013,"score_gpt":0.31350372330765197,"score_spread":0.27565087588088183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592196376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99551857,0.00029341754,0.00069811346,0.0007657901,0.00003865285,0.002440213,0.00009999126,0.000051099407,0.0000941828],"genre_scores_gemma":[0.96922195,0.00017919527,0.029393092,0.0003985075,0.000060738676,0.0003832833,0.00008026304,0.00006587702,0.00021708442],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972913,0.0004810669,0.00063893886,0.0006517584,0.00034433088,0.0005926009],"domain_scores_gemma":[0.9979769,0.0009931318,0.00007478911,0.0005015489,0.00016718126,0.00028646685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021281338,0.00028448965,0.0005516187,0.0006246784,0.00006589026,0.000020776231,0.00021200159,0.00020949995,0.00003347111],"category_scores_gemma":[0.002017314,0.00022963963,0.00006986278,0.00054046826,0.00007079478,0.00016518754,0.00009380282,0.00041164763,0.0000041128924],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17189616,0.0023687417,0.11093846,0.00014352104,0.00012334972,0.00023513532,0.009251165,0.000014741309,0.67980444,0.000021173368,0.00075801456,0.024445085],"study_design_scores_gemma":[0.036199044,0.0032284227,0.3555506,0.00032350374,0.000027974449,0.0000061186593,0.00019042895,0.00008571254,0.6037254,0.000079545134,0.00037098667,0.00021227701],"about_ca_topic_score_codex":0.0008161817,"about_ca_topic_score_gemma":0.00013879348,"teacher_disagreement_score":0.24461211,"about_ca_system_score_codex":0.000100999074,"about_ca_system_score_gemma":0.00016397706,"threshold_uncertainty_score":0.9364432},"labels":[],"label_agreement":null},{"id":"W2592332357","doi":"10.1182/blood.v128.22.2248.2248","title":"Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Midostaurin; Medicine; Internal medicine; Oncology; Adverse effect; Maintenance therapy; Clinical endpoint; Phases of clinical research; Randomized controlled trial; Clinical trial; Chemotherapy; Leukemia","score_opus":0.008505898755819464,"score_gpt":0.2653194782138638,"score_spread":0.25681357945804434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592332357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894258,0.000300912,0.0004761506,0.00011647661,0.000089914574,0.008999483,0.00034830734,0.000069483795,0.00017348611],"genre_scores_gemma":[0.99625516,0.00022237282,0.0020608928,0.000039258943,0.000052329488,0.0005408548,0.00008882576,0.0001442324,0.00059609604],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947092,0.0005713267,0.0014375189,0.0008271972,0.0016250104,0.00082973344],"domain_scores_gemma":[0.99712807,0.00046131547,0.00048877776,0.00088515115,0.000546054,0.000490636],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010231211,0.00061016355,0.0028253326,0.0005471354,0.000062524334,0.000017469341,0.0004095259,0.00025316578,0.000050784125],"category_scores_gemma":[0.00013753952,0.0003274934,0.0003968648,0.0007847642,0.00025167613,0.00015962006,0.00008554992,0.00037784106,0.000006606901],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.949281,0.002816277,0.0049730707,0.00090927206,0.0018487602,0.00075080217,0.009490928,0.000014215227,0.028718168,0.0000040662367,0.00004226807,0.0011512185],"study_design_scores_gemma":[0.6942453,0.017927451,0.000050255738,0.002689356,0.0021936523,0.000039129645,0.00069427706,0.000006717209,0.28176695,0.0000021163498,0.00004703959,0.0003377695],"about_ca_topic_score_codex":0.00012842682,"about_ca_topic_score_gemma":0.00018891667,"teacher_disagreement_score":0.25503567,"about_ca_system_score_codex":0.00089367566,"about_ca_system_score_gemma":0.0025527682,"threshold_uncertainty_score":0.9999177},"labels":[],"label_agreement":null},{"id":"W2592403451","doi":"10.1182/blood.v124.21.1337.1337","title":"NR2F6 (EAR-2) Is a Novel Leukemia Oncogene Whose Cellular Function Is to Regulate Terminal Differentiation of Erythrocytes at the Proerythroblast Stage","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Biology; Leukemia; Stem cell; Bone marrow; Progenitor cell; Haematopoiesis; Myeloid; Cancer research; Immunology; Cellular differentiation; Myeloid leukemia; Cell biology; Genetics; Gene","score_opus":0.016123039467541293,"score_gpt":0.2550693821930926,"score_spread":0.23894634272555132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592403451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99313104,0.00013577213,0.0031751338,0.001711911,0.00008521635,0.0009531356,0.000055511675,0.000057335827,0.0006949593],"genre_scores_gemma":[0.97954583,0.00003329112,0.00067134155,0.00096841407,0.0004062102,0.00006856659,0.0000730444,0.000062552775,0.018170733],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976672,0.000080789505,0.00045794673,0.00051900436,0.0008092888,0.00046575602],"domain_scores_gemma":[0.9983803,0.000107746775,0.00021346279,0.00079853,0.0002785313,0.00022143484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044118703,0.0002730878,0.0004254627,0.0001800912,0.00019248463,0.000037393827,0.00021284021,0.00017970538,0.00068056997],"category_scores_gemma":[0.00014294984,0.00019489563,0.00013351404,0.00039774712,0.00014917654,0.00010321137,0.0002830185,0.0002991478,0.00021438158],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006485624,0.0004094678,0.004955738,0.00027574805,0.0002462495,0.000008650644,0.0010629109,0.000019621732,0.9842613,0.000040738007,0.004515102,0.003555911],"study_design_scores_gemma":[0.005872451,0.0018507718,0.045959607,0.00020861694,0.00050533,0.000055699704,0.00015697743,0.0028021692,0.92598367,0.000029824761,0.016332204,0.00024267824],"about_ca_topic_score_codex":0.00019446493,"about_ca_topic_score_gemma":0.000060864983,"teacher_disagreement_score":0.05827763,"about_ca_system_score_codex":0.00045058626,"about_ca_system_score_gemma":0.0003019402,"threshold_uncertainty_score":0.79476136},"labels":[],"label_agreement":null},{"id":"W2592656165","doi":"10.1182/blood.v114.22.4688.4688","title":"Diagnostic Cytogenetic Analysis in Pediatric Acute Myeloid Leukemia (AML): Evaluation of Methodological Issues with a Special Focus On Missing Data.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Oncology; Cytogenetics; Internal medicine; Myeloid leukemia; Clinical trial; Risk stratification; Pediatrics; Biology","score_opus":0.1146270348921136,"score_gpt":0.40265905793702234,"score_spread":0.2880320230449087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592656165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99391985,0.0012385097,0.00049707224,0.0015159731,0.000025526591,0.0008126551,0.000031286014,0.00003276076,0.001926383],"genre_scores_gemma":[0.9808746,0.00085455173,0.016744616,0.00009487066,0.0011573886,0.000022239094,0.00017669746,0.000020723945,0.00005434531],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960667,0.0007955243,0.00052045565,0.0006999275,0.0014804008,0.00043699986],"domain_scores_gemma":[0.99711245,0.0012304614,0.0001861558,0.0010175101,0.00027356675,0.00017986896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025870332,0.0002477224,0.0007965719,0.0009026455,0.000052774532,0.000027069915,0.00038877083,0.00018320656,0.00021123135],"category_scores_gemma":[0.0039104647,0.00018507295,0.00011204461,0.0023617987,0.00008332357,0.00009859076,0.00010028887,0.0004331654,0.00002247033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048755305,0.0053218924,0.7058286,0.00024033623,0.00470917,0.0032555894,0.0016445273,0.004252487,0.03053658,0.00020520609,0.002462903,0.2366672],"study_design_scores_gemma":[0.009825421,0.0022767703,0.9471018,0.00008950402,0.017830903,0.00011427055,0.00006681836,0.0045356653,0.017150912,0.0006716498,0.000051181454,0.00028515168],"about_ca_topic_score_codex":0.000114364026,"about_ca_topic_score_gemma":0.00010593455,"teacher_disagreement_score":0.24127316,"about_ca_system_score_codex":0.00037494733,"about_ca_system_score_gemma":0.00094907795,"threshold_uncertainty_score":0.75470555},"labels":[],"label_agreement":null},{"id":"W2592730573","doi":"10.1002/cyto.b.21519","title":"Visualization of Cell Composition and Maturation in the Bone Marrow Using 10‐Color Flow Cytometry and Radar Plots","year":2017,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Flow cytometry; Bone marrow; Visualization; Haematopoiesis; Cell; Cytometry; Computational biology; Biology; Computer science; Stem cell; Immunology; Data mining; Cell biology; Genetics","score_opus":0.08758636724954841,"score_gpt":0.4193764445140727,"score_spread":0.33179007726452425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592730573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940098,0.0008149193,0.002216089,0.0007164931,0.0002665822,0.001012771,0.000051804887,0.0000496245,0.00086191605],"genre_scores_gemma":[0.9919422,0.0007615153,0.0058687227,0.00048751928,0.0005311349,0.000020856982,0.00012500801,0.00006132956,0.00020169985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956583,0.0006181455,0.0014008915,0.00076538074,0.001010519,0.0005467621],"domain_scores_gemma":[0.9957995,0.001648929,0.0007655293,0.0011170463,0.0003377673,0.00033122735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045060054,0.00036075833,0.001062681,0.0013411295,0.0004777168,0.0002429066,0.00041516186,0.0005805342,0.00012314368],"category_scores_gemma":[0.0031510745,0.00028464771,0.00018076863,0.0016439646,0.0009471509,0.00056493905,0.0004087974,0.00089256954,0.000031850122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064151986,0.0021236357,0.7272474,0.0018292612,0.00025898562,0.00044877795,0.0004574811,0.000012604816,0.24615009,0.00015710953,0.002978567,0.011920859],"study_design_scores_gemma":[0.008585124,0.0012578564,0.9496955,0.0005019641,0.00034308239,0.00033143235,0.0004452062,0.019517241,0.017686583,0.0000841917,0.0010722612,0.00047951788],"about_ca_topic_score_codex":0.000038786508,"about_ca_topic_score_gemma":0.000005677146,"teacher_disagreement_score":0.22846352,"about_ca_system_score_codex":0.00021199779,"about_ca_system_score_gemma":0.00021356174,"threshold_uncertainty_score":0.99996054},"labels":[],"label_agreement":null},{"id":"W2592897778","doi":"10.1182/blood.v128.22.5176.5176","title":"Outcome of Acute Myeloid Leukemia in Children and Young Adults Treated with an Uniform Protocol in Casablanca, Morocco","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; McMaster Children's Hospital","funders":"","keywords":"Medicine; Pediatrics; Acute promyelocytic leukemia; Myeloid leukemia; Young adult; Internal medicine","score_opus":0.010350883642442278,"score_gpt":0.2812372507731492,"score_spread":0.2708863671307069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592897778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97150123,0.0000073583947,0.000003976896,0.00008065983,0.0000033679498,0.02767868,0.000053295444,0.00003878897,0.0006326538],"genre_scores_gemma":[0.9904188,0.000018282102,0.0005575324,0.000035944096,0.000042551455,0.00834729,0.000029478297,0.000043286014,0.00050685543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983007,0.000060251525,0.00044925124,0.00041183102,0.00032979727,0.0004481915],"domain_scores_gemma":[0.9991216,0.000035387922,0.000102776656,0.0004549792,0.000094953306,0.00019026751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027792234,0.00022861062,0.00050552445,0.00035435465,0.000022336078,0.00000997307,0.00016225946,0.00015691399,0.000039571438],"category_scores_gemma":[0.000052588293,0.00013376007,0.000031819756,0.00043607506,0.00015179446,0.00021540043,0.00007693538,0.00027554008,0.00000902705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002465465,0.000298675,0.98879224,0.000082754676,0.00013191008,0.00027704527,0.00021243923,3.8366957e-7,0.005546051,0.000013609675,0.000017558816,0.0021618505],"study_design_scores_gemma":[0.04354608,0.0016009097,0.93506366,0.00041873433,0.00008476317,0.00062336354,0.00005661506,0.00006436125,0.018339608,0.000010088412,0.000013237575,0.00017855444],"about_ca_topic_score_codex":0.00454123,"about_ca_topic_score_gemma":0.0023104195,"teacher_disagreement_score":0.053728573,"about_ca_system_score_codex":0.0004267994,"about_ca_system_score_gemma":0.00038997797,"threshold_uncertainty_score":0.68650115},"labels":[],"label_agreement":null},{"id":"W2592957633","doi":"10.3324/haematol.2016.159053","title":"Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1","year":2017,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Arsenic trioxide; Aldehyde dehydrogenase; Cancer research; Haematopoiesis; Myelodysplastic syndromes; Stem cell; Myeloid leukemia; Cyclophosphamide; Leukemia; Myeloid; Biology; Immunology; Chemistry; Medicine; Chemotherapy; Internal medicine; Apoptosis; Bone marrow; Biochemistry; Cell biology; Enzyme","score_opus":0.08955761268395121,"score_gpt":0.3647987528107573,"score_spread":0.2752411401268061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592957633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942789,0.00077522034,0.00038995477,0.0012135326,0.000083745945,0.0015875081,0.000196587,0.000073647585,0.0014009239],"genre_scores_gemma":[0.99003446,0.0011487006,0.0075607924,0.00024695424,0.000057377554,0.00018939121,0.00012793219,0.000048443093,0.0005859494],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99777216,0.00010030578,0.0005478909,0.0004913956,0.00052488456,0.00056338945],"domain_scores_gemma":[0.9969255,0.00028487266,0.0006930711,0.001537549,0.00032962114,0.00022943763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005287846,0.00030538754,0.0011446327,0.00016309074,0.0002705167,0.000025932595,0.0007604415,0.00036144673,0.0002863219],"category_scores_gemma":[0.0005429491,0.0002072295,0.00037954905,0.00011103389,0.0005728935,0.00016324512,0.00025336776,0.0002951886,0.000025502586],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006864341,0.00049251365,0.027942035,0.0006215917,0.0005314316,0.00048361195,0.00062525104,0.0000029643168,0.9360998,0.0006413501,0.023435403,0.0022596698],"study_design_scores_gemma":[0.005999026,0.00090526004,0.012752088,0.00024833423,0.00011397568,0.00024375827,0.00013562247,0.00033102016,0.97513855,0.000649759,0.0032784669,0.00020414278],"about_ca_topic_score_codex":0.00008548786,"about_ca_topic_score_gemma":0.0000068330824,"teacher_disagreement_score":0.03903871,"about_ca_system_score_codex":0.00010399384,"about_ca_system_score_gemma":0.0003672041,"threshold_uncertainty_score":0.8450574},"labels":[],"label_agreement":null},{"id":"W2592973432","doi":"10.1038/leu.2017.81","title":"High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells","year":2017,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Agence Nationale de la Recherche","keywords":"mTORC1; Pentose phosphate pathway; Myeloid leukemia; Glycolysis; Cancer research; Biology; Leukemia; Myeloid; Pharmacology; Biochemistry; Signal transduction; Metabolism; PI3K/AKT/mTOR pathway; Immunology","score_opus":0.012914908594169449,"score_gpt":0.27787442286273506,"score_spread":0.2649595142685656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592973432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99420846,0.0000329154,0.00080333574,0.0020018057,0.00026952097,0.0010391612,0.00009172948,0.00014923299,0.001403842],"genre_scores_gemma":[0.99464095,0.000314437,0.0016087643,0.0005905221,0.0004924282,0.00010094067,0.000059467693,0.00007319573,0.0021193041],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99687594,0.00022904889,0.00040403384,0.000987621,0.00068531296,0.00081806554],"domain_scores_gemma":[0.99746996,0.0002235616,0.000253415,0.0012936348,0.00018895588,0.0005704688],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008584518,0.00044284711,0.0008070565,0.00052246294,0.00057607313,0.00023656603,0.00014049036,0.00045618525,0.000087953835],"category_scores_gemma":[0.00042218348,0.000437388,0.00015018722,0.0003732308,0.00033882697,0.0007774657,0.000532637,0.0010770856,0.00023520233],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016983852,0.00008725324,0.005805541,0.00008205255,0.00021197497,0.0021559265,0.000580419,0.0002361491,0.9368193,0.00011727005,0.0060532927,0.04615245],"study_design_scores_gemma":[0.0049934573,0.00042577344,0.50310874,0.0003201259,0.00022681203,0.00029898103,0.000087815664,0.0045680306,0.48329645,0.00010360705,0.002049593,0.0005205771],"about_ca_topic_score_codex":0.0064808745,"about_ca_topic_score_gemma":0.0014547654,"teacher_disagreement_score":0.49730322,"about_ca_system_score_codex":0.0062737972,"about_ca_system_score_gemma":0.0010570972,"threshold_uncertainty_score":0.9998078},"labels":[],"label_agreement":null},{"id":"W2593028431","doi":"10.1182/blood.v126.23.1368.1368","title":"TET2 Mutations Are Highly Associated with RUNX1-RUNX1T1 Translocations and NPMc+ in Childhood AML: a Report from Children's Oncology Group AAML03P1, AAML0531 and NCI/COG Target AML Initiative","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Missense mutation; Gemtuzumab ozogamicin; Medicine; Frameshift mutation; Nonsense mutation; Oncology; Hepatoblastoma; Mutation; Pediatric cancer; Genetics; Internal medicine; Cancer research; Biology; Cancer; Gene","score_opus":0.021305409382570122,"score_gpt":0.2764131315293978,"score_spread":0.25510772214682764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593028431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98899925,0.0011941597,0.00019911537,0.00525855,0.000045951332,0.001348047,0.00038532747,0.00015797134,0.0024116468],"genre_scores_gemma":[0.992659,0.00009494862,0.0045754495,0.0004127052,0.00015813246,0.00024298346,0.001649769,0.00007231208,0.00013472063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973041,0.0002958363,0.0005834403,0.0007390342,0.0005257699,0.00055185775],"domain_scores_gemma":[0.9978868,0.00047203407,0.00030721928,0.0004202143,0.00038087557,0.00053286925],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006325565,0.00034193974,0.00074236153,0.00039559524,0.00016454319,0.000051339193,0.00014376527,0.0003401525,0.000026654821],"category_scores_gemma":[0.0013495041,0.0003002968,0.00005621743,0.00078565517,0.0004066178,0.00026698882,0.00008426635,0.00083911617,0.0000094768675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003984003,0.004760319,0.9722263,0.00003941016,0.001882637,0.00347971,0.013297203,0.00001635283,0.0010327481,0.00019222351,0.0013223353,0.0013523585],"study_design_scores_gemma":[0.020149838,0.001175594,0.972031,0.00022342631,0.0007464718,0.0010717697,0.002092445,0.00013370613,0.00083114405,0.000722063,0.00046622514,0.00035634873],"about_ca_topic_score_codex":0.0008700483,"about_ca_topic_score_gemma":0.0015725376,"teacher_disagreement_score":0.019751437,"about_ca_system_score_codex":0.0003351265,"about_ca_system_score_gemma":0.001522171,"threshold_uncertainty_score":0.9999449},"labels":[],"label_agreement":null},{"id":"W2593232986","doi":"10.1182/blood.v112.11.51.51","title":"Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in Adults","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Underweight; Internal medicine; Overweight; Transplantation; Body mass index; Population; Surgery; Leukemia","score_opus":0.008823736359961256,"score_gpt":0.2603788038322051,"score_spread":0.2515550674722438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593232986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99412215,0.0001830596,0.00063058967,0.0002668404,0.000056312387,0.0031399366,0.00018401077,0.000070743845,0.0013463871],"genre_scores_gemma":[0.99310875,0.0014990116,0.003504172,0.00017616423,0.00014044734,0.00046295754,0.00014335192,0.000052061772,0.000913057],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99790776,0.00013415134,0.00038988845,0.00062956754,0.00039171558,0.0005469479],"domain_scores_gemma":[0.99855375,0.00063698855,0.00010868464,0.00029623372,0.00017204256,0.00023230024],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033921478,0.0003142574,0.00059086597,0.0002512062,0.0001863535,0.00001558667,0.0001363736,0.00025125258,0.000028798991],"category_scores_gemma":[0.00012440729,0.00024703477,0.00011923939,0.00029520466,0.00020998764,0.00020509172,0.000050823215,0.00048453338,0.000026131896],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029090805,0.003874034,0.41773146,0.0097566005,0.0017188204,0.004352092,0.071608424,0.000050290186,0.45177945,0.00038465206,0.00084037083,0.008812986],"study_design_scores_gemma":[0.024457589,0.0010572101,0.34143564,0.00043369655,0.00051765266,0.0006576819,0.0003222777,0.0002882775,0.6302306,0.00017947225,0.000080983096,0.00033889184],"about_ca_topic_score_codex":0.0002564997,"about_ca_topic_score_gemma":0.00016842966,"teacher_disagreement_score":0.17845117,"about_ca_system_score_codex":0.00038814146,"about_ca_system_score_gemma":0.00040643028,"threshold_uncertainty_score":0.9999982},"labels":[],"label_agreement":null},{"id":"W2593255690","doi":"10.1182/blood.v120.21.3807.3807","title":"MCL-1 and Mir-181c in GATA2 Mutation Associated Monomac and Familial Myelodysplastic Syndrome","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"GATA2; Haploinsufficiency; Biology; Cancer research; Myeloid; RUNX1; Mutation; CEBPA; Immunology; Genetics; Stem cell; Haematopoiesis; Phenotype; Gene","score_opus":0.014673774856724088,"score_gpt":0.2664312987781708,"score_spread":0.2517575239214467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593255690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980609,0.0006423444,0.000010580293,0.0002044942,0.000053364278,0.0003304878,0.000015765992,0.000037801117,0.0006442567],"genre_scores_gemma":[0.9990845,0.0000763367,0.000297716,0.000083440675,0.00005787457,0.000026162903,0.000046718505,0.00002237784,0.0003048746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989345,0.00006646477,0.0001937401,0.00019807855,0.00021351012,0.00039367372],"domain_scores_gemma":[0.9993915,0.0001839753,0.000042553525,0.00012376891,0.000039127357,0.00021909067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034062244,0.00012388134,0.00025216318,0.00017014831,0.000046092504,0.0000169914,0.00004121639,0.00013463528,0.00002888536],"category_scores_gemma":[0.00045195044,0.0001151356,0.000019082598,0.000202226,0.000078698744,0.00015440621,0.00006361476,0.00026264024,0.000036679365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023020254,0.0010397544,0.9723571,0.00021803744,0.00024233112,0.0007323359,0.0016785398,0.0000013768203,0.020712888,0.00013567711,0.00039874302,0.0022530179],"study_design_scores_gemma":[0.006576184,0.00027855753,0.989924,0.00008160449,0.00014042851,0.0008244405,0.00018778954,0.000432956,0.0012752654,0.00004619564,0.00010709012,0.00012548867],"about_ca_topic_score_codex":0.00020310635,"about_ca_topic_score_gemma":0.00004024562,"teacher_disagreement_score":0.019437622,"about_ca_system_score_codex":0.000107122636,"about_ca_system_score_gemma":0.00008157114,"threshold_uncertainty_score":0.46950933},"labels":[],"label_agreement":null},{"id":"W2593273640","doi":"10.1182/blood.v126.23.sci-10.sci-10","title":"Clonal Events in Normal Aging Hematopoiesis","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Myeloid; Biology; Population; Haematopoiesis; Somatic evolution in cancer; Bone marrow failure; Bone marrow; Immunology; Genetics; Internal medicine; Stem cell; Cancer; Medicine","score_opus":0.03199805272937629,"score_gpt":0.30788577468454303,"score_spread":0.27588772195516675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593273640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98702234,0.00021998509,0.000026665159,0.0012695974,0.00004698396,0.00016771619,0.0000020341768,0.000037823047,0.011206865],"genre_scores_gemma":[0.9967582,0.000009497697,0.0012364861,0.00027513425,0.00018674454,0.000017826687,0.000012506853,0.000017554805,0.0014860323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893343,0.000038274313,0.00016249916,0.00016143636,0.00039616742,0.00030816096],"domain_scores_gemma":[0.9994468,0.000035768917,0.00002282466,0.00020824699,0.00006834642,0.00021800894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003977099,0.00008396875,0.0001767245,0.00014509473,0.000018900795,0.0000047804983,0.00010268961,0.00006129232,0.000080216945],"category_scores_gemma":[0.00020496424,0.00007481611,0.000039843955,0.0002398929,0.000026689384,0.00007467005,0.00009838974,0.00024474738,0.00025850607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017515243,0.0009105024,0.987137,0.000113424285,0.00010014311,0.00091356965,0.001006856,0.0000057776665,0.003522327,0.00025251965,0.004760854,0.0011018383],"study_design_scores_gemma":[0.061717547,0.0008831375,0.79407144,0.0006218749,0.00028232278,0.0029492124,0.0019694697,0.00071845204,0.117741674,0.0013319841,0.016976645,0.0007362585],"about_ca_topic_score_codex":0.00013856344,"about_ca_topic_score_gemma":0.000023875322,"teacher_disagreement_score":0.19306561,"about_ca_system_score_codex":0.00012795007,"about_ca_system_score_gemma":0.00036103968,"threshold_uncertainty_score":0.33226588},"labels":[],"label_agreement":null},{"id":"W2593342731","doi":"10.1182/blood.v128.22.4307.4307","title":"The Clonal Origins of Leukemic Progression of Myelodysplasia","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Exome sequencing; Deep sequencing; Oncology; Biology; Exome; Internal medicine; Medicine; Mutation; Genetics; Gene; Genome","score_opus":0.014063405181400469,"score_gpt":0.30235367060497886,"score_spread":0.2882902654235784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593342731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521744,0.00040414286,0.000037885336,0.0013059628,0.000050057733,0.000289594,0.000013125295,0.000021233667,0.0026605306],"genre_scores_gemma":[0.99750566,0.0003230881,0.0007201249,0.000018656152,0.00012432244,0.00001830115,0.000002751521,0.000016622127,0.0012704883],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988309,0.000045463563,0.00026999807,0.00014652636,0.0004633098,0.00024379928],"domain_scores_gemma":[0.99894506,0.0002794228,0.00011782098,0.00039118566,0.00017790851,0.000088627574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033426,0.00008764095,0.00020258705,0.00006272725,0.00004741816,0.000003143078,0.0001919593,0.00007600362,0.00006476491],"category_scores_gemma":[0.00027722507,0.00003834468,0.00007906748,0.00016726764,0.00030173958,0.000036653433,0.0000823498,0.00012864063,0.000034856293],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004858081,0.00034885237,0.05163413,0.0001156113,0.00017676476,0.00003354127,0.00008529702,7.2428705e-8,0.8928282,0.005484386,0.0017646626,0.047042638],"study_design_scores_gemma":[0.007337179,0.00086009735,0.056015782,0.00051074964,0.00013098885,0.00015291672,0.000050689083,0.00001541776,0.90830487,0.0002536985,0.026282692,0.00008489385],"about_ca_topic_score_codex":0.000022962806,"about_ca_topic_score_gemma":0.0000034911195,"teacher_disagreement_score":0.046957746,"about_ca_system_score_codex":0.00013995521,"about_ca_system_score_gemma":0.00059287803,"threshold_uncertainty_score":0.15636507},"labels":[],"label_agreement":null},{"id":"W2593474440","doi":"10.5858/arpa.2016-0547-ra","title":"Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies","year":2017,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"DNA sequencing; Computational biology; CEBPA; Context (archaeology); Identification (biology); Myeloid; Informatics; Gene; Biology; Genetics; Mutation; Cancer research","score_opus":0.1510344880193546,"score_gpt":0.341747440851437,"score_spread":0.1907129528320824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593474440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97928965,0.00028619025,0.0165544,0.0021843335,0.000048080343,0.0010529567,0.000055773893,0.000008983375,0.00051960413],"genre_scores_gemma":[0.96698666,0.00024150265,0.032312766,0.00010172327,0.000072696064,0.00010611132,0.00015933694,0.0000106793195,0.0000085144375],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984287,0.00023769839,0.00070003775,0.00019592232,0.00026341708,0.00017421022],"domain_scores_gemma":[0.99806803,0.0005138315,0.00062482187,0.00055483094,0.00019408329,0.000044411747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019534791,0.0001386667,0.0005181087,0.00030492188,0.000108102075,0.000008676518,0.0002421802,0.000101633916,0.000005198234],"category_scores_gemma":[0.001881419,0.000087181965,0.00004124322,0.00015067346,0.0013089755,0.00020193441,0.000068779686,0.00022790585,1.229476e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013942496,0.00006735243,0.0030241373,0.00041631926,0.00002819801,0.000015898533,0.005922739,0.000014654526,0.98287886,0.0041432665,0.00005887331,0.0032902823],"study_design_scores_gemma":[0.006839439,0.0037611646,0.38090947,0.0012903978,0.00037252155,0.00020433446,0.017778885,0.03595035,0.55076575,0.0018162841,0.000080886166,0.00023050427],"about_ca_topic_score_codex":0.00006704156,"about_ca_topic_score_gemma":0.000037750902,"teacher_disagreement_score":0.43211308,"about_ca_system_score_codex":0.00005563092,"about_ca_system_score_gemma":0.00048376512,"threshold_uncertainty_score":0.48229748},"labels":[],"label_agreement":null},{"id":"W2593877575","doi":"10.1182/blood.v128.22.1720.1720","title":"A Novel Role for INPP4B in Haematopoiesis and Leukemia","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Haematopoiesis; Myeloid leukemia; Progenitor cell; Cancer research; Biology; Myeloid; Leukemia; Population; Stem cell; Internal medicine; Oncology; Immunology; Medicine; Cell biology","score_opus":0.0186421034162389,"score_gpt":0.2790129586342145,"score_spread":0.2603708552179756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593877575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99433976,0.0003084538,0.00091331004,0.0023117452,0.000016439533,0.0005074073,0.000022515143,0.000035594043,0.0015447927],"genre_scores_gemma":[0.99025977,0.000080779304,0.006939849,0.00028408298,0.000121800425,0.00013901584,0.000003728648,0.000028509505,0.0021424934],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99917394,0.000010591609,0.00015752672,0.00022690788,0.00014154223,0.00028948838],"domain_scores_gemma":[0.99938184,0.00020486952,0.000025586938,0.00021728045,0.000053389544,0.000117026684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022335509,0.00009434989,0.00023258345,0.00013303486,0.000027928209,0.000009492811,0.000072304836,0.000093373295,0.000034666275],"category_scores_gemma":[0.00038538783,0.00006126322,0.000038269904,0.00011974328,0.00006966247,0.000064414744,0.00006824002,0.00008734811,0.000023689296],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045616023,0.0004714293,0.07324173,0.00027910754,0.00014191966,0.000089179084,0.00053219224,1.726991e-7,0.8905992,0.0018219338,0.0024906974,0.0298763],"study_design_scores_gemma":[0.11894326,0.001579336,0.28010494,0.0013703246,0.00043545818,0.0017148518,0.0008136745,0.0005789772,0.5244198,0.0035547635,0.06565955,0.00082508795],"about_ca_topic_score_codex":0.00009470403,"about_ca_topic_score_gemma":0.0000528392,"teacher_disagreement_score":0.36617938,"about_ca_system_score_codex":0.0001550687,"about_ca_system_score_gemma":0.00027845145,"threshold_uncertainty_score":0.24982418},"labels":[],"label_agreement":null},{"id":"W2594234261","doi":"10.1182/blood.v128.22.2814.2814","title":"Long-Term Outcomes of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Etoposide and Cyclophosphamide","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Leukemia & Lymphoma Society of Canada; University of British Columbia","funders":"","keywords":"Cytarabine; Medicine; Etoposide; Internal medicine; Cyclophosphamide; Myeloid leukemia; Busulfan; Induction chemotherapy; Regimen; Oncology; Leukemia; Chemotherapy regimen; Salvage therapy; Chemotherapy; Surgery; Gastroenterology","score_opus":0.008111254755101997,"score_gpt":0.24534440161414514,"score_spread":0.23723314685904315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594234261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99801296,0.00010793983,0.000052014813,0.0003680648,0.000019303288,0.00086382625,0.00010606177,0.00009465188,0.00037515312],"genre_scores_gemma":[0.99598753,0.00020265438,0.0012396309,0.00015732701,0.000036843674,0.000047066485,0.000070228845,0.00008181703,0.0021768988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797577,0.000049518243,0.00034130947,0.0004927499,0.0006296819,0.00051095383],"domain_scores_gemma":[0.9984324,0.00017591169,0.00017322414,0.00064150925,0.00026141392,0.00031553992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011083123,0.00034590115,0.00067952496,0.00018330738,0.00006716964,0.000017927912,0.00017520125,0.00014118265,0.0000817278],"category_scores_gemma":[0.00006554551,0.00017166957,0.00005932223,0.0002858866,0.00036010766,0.00018067323,0.00011651528,0.00021399788,0.000024485254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021969546,0.00043978656,0.98334074,0.00008917783,0.0012376565,0.0006613337,0.00007731397,1.7133922e-7,0.008729928,0.000030513094,0.000081887665,0.0031145094],"study_design_scores_gemma":[0.030436687,0.0017454287,0.9078011,0.00027352848,0.0008397502,0.00008408822,0.0000091079655,6.1132494e-7,0.058544554,0.000008427295,0.000025931577,0.00023077692],"about_ca_topic_score_codex":0.00021720512,"about_ca_topic_score_gemma":0.000059859864,"teacher_disagreement_score":0.075539656,"about_ca_system_score_codex":0.00023097097,"about_ca_system_score_gemma":0.0003864908,"threshold_uncertainty_score":0.7000482},"labels":[],"label_agreement":null},{"id":"W2594242280","doi":"10.1182/blood.v116.21.2571.2571","title":"The Effects of Azacitidine on Quality of Life Measured Longitudinally In MDS Patients Treated at a Tertiary Care Center","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre; Western University; University of Toronto","funders":"","keywords":"International Prognostic Scoring System; Medicine; Azacitidine; Myelodysplastic syndromes; Quality of life (healthcare); Internal medicine; Oncology; Randomized controlled trial; Bone marrow","score_opus":0.013834058494775767,"score_gpt":0.28214921894385825,"score_spread":0.2683151604490825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594242280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99804157,0.00018119763,2.9434935e-7,0.00015744075,0.00008157471,0.00074419304,0.00003357019,0.000016149554,0.000743993],"genre_scores_gemma":[0.9996127,0.000029525323,0.0000255481,0.000071592905,0.00004268607,0.000036736743,0.000052749994,0.00002142889,0.00010703792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830467,0.00019356993,0.0004150278,0.00022170114,0.000591435,0.00027358366],"domain_scores_gemma":[0.9984297,0.00043982943,0.00013743562,0.00052251725,0.0003363483,0.00013415421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003417115,0.00014408816,0.00036874067,0.00011057101,0.00004509899,0.000004516545,0.00017186462,0.00012575743,0.000015979776],"category_scores_gemma":[0.0019753724,0.000091269205,0.00011058043,0.00019649627,0.00013807726,0.00002689383,0.00009958884,0.0003540571,0.000008856472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008797728,0.0011125744,0.88917345,0.00050342927,0.00013323402,0.000018625864,0.0004026702,8.5710326e-8,0.106838055,0.000010157126,0.00017673026,0.000751222],"study_design_scores_gemma":[0.011743416,0.00056371075,0.8178286,0.00017017177,0.000054261658,0.0000020003997,0.00002859432,0.000002687746,0.16949101,0.0000024118901,0.000050834595,0.00006232603],"about_ca_topic_score_codex":0.00031717742,"about_ca_topic_score_gemma":0.00072055287,"teacher_disagreement_score":0.07134487,"about_ca_system_score_codex":0.000097445125,"about_ca_system_score_gemma":0.00013920381,"threshold_uncertainty_score":0.37218502},"labels":[],"label_agreement":null},{"id":"W2594319486","doi":"10.1182/blood.v128.22.347.347","title":"Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Decitabine; Azacitidine; Internal medicine; Medicine; Gastroenterology; Hypomethylating agent; International Prognostic Scoring System; Myelodysplastic syndromes; Phases of clinical research; Refractory (planetary science); Neutropenia; Bone marrow; Oncology; Clinical trial; DNA methylation; Toxicity; Biology","score_opus":0.030230985891311204,"score_gpt":0.31391851202022725,"score_spread":0.28368752612891607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594319486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963067,0.0000916794,0.000005300317,0.00033251013,0.00012515028,0.0021219715,0.0007232384,0.000034962264,0.00025849158],"genre_scores_gemma":[0.99397576,0.00018706034,0.0004521136,0.000066301276,0.00016677886,0.00022557916,0.00003635065,0.00007109037,0.0048189703],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965224,0.00021772155,0.001112995,0.0006595622,0.00092613354,0.00056115707],"domain_scores_gemma":[0.9975397,0.0003969069,0.00035564433,0.0009906562,0.00040445232,0.0003126431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048635044,0.00036268606,0.000871354,0.000512665,0.000057508,0.000008472111,0.00020785935,0.00016140647,0.00058744627],"category_scores_gemma":[0.0009798465,0.00019727756,0.0001017497,0.00068009313,0.000105012754,0.00015243287,0.000211929,0.00023302124,0.00003896078],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28898054,0.23863374,0.20051032,0.0005090301,0.0024748638,0.003377972,0.02205836,0.0000072167477,0.14478922,0.0000036791303,0.006841479,0.09181356],"study_design_scores_gemma":[0.43309942,0.16621533,0.31509975,0.0029672526,0.0011834044,0.000028403347,0.0014293484,0.000024091518,0.070692465,0.0000065310624,0.008583101,0.0006709287],"about_ca_topic_score_codex":0.0006021534,"about_ca_topic_score_gemma":0.0009810795,"teacher_disagreement_score":0.14411888,"about_ca_system_score_codex":0.0007300381,"about_ca_system_score_gemma":0.000427819,"threshold_uncertainty_score":0.80447453},"labels":[],"label_agreement":null},{"id":"W2594379076","doi":"10.1182/blood.v128.22.2800.2800","title":"Remissions after Third Induction Chemotherapy for Primary Non-Responders with Acute Myeloid Leukemia (AML) Are Uncommon and Short-Lived","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Induction chemotherapy; Medicine; Chemotherapy; Internal medicine; Regimen; Chemotherapy regimen; Flag (linear algebra); Cytarabine; Oncology; Bone marrow; Myeloid leukemia; Gastroenterology; Surgery","score_opus":0.017561323064774887,"score_gpt":0.27712744694779723,"score_spread":0.25956612388302236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594379076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899668,0.00018132372,0.0013008752,0.0061219325,0.000050576604,0.0011938895,0.00003618587,0.00010458368,0.0010437941],"genre_scores_gemma":[0.9833762,0.00064057345,0.006411727,0.0012675747,0.00040262655,0.00038064682,0.000037817263,0.00011182493,0.0073710005],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982834,0.00004340108,0.00025451978,0.0005364678,0.00039674927,0.00048545448],"domain_scores_gemma":[0.9987124,0.00014611657,0.00008368472,0.00053788035,0.00018945795,0.0003304307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002764631,0.00028321287,0.00042869122,0.00020005033,0.00013422524,0.000029485147,0.00013898232,0.0002571782,0.00005641293],"category_scores_gemma":[0.000070421935,0.00016704299,0.00009166333,0.00022864254,0.00020587262,0.00019512043,0.00007543279,0.00031448054,0.000011772579],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013791196,0.00038143274,0.048201643,0.00025349535,0.0011029189,0.00034554326,0.0007755227,5.120984e-7,0.8913687,0.000010274753,0.010707267,0.033061486],"study_design_scores_gemma":[0.044957645,0.0033017055,0.56266433,0.0017073222,0.0013336213,0.0013130461,0.0008272777,0.000040157713,0.36088088,0.0002591975,0.021727066,0.0009877116],"about_ca_topic_score_codex":0.000021943602,"about_ca_topic_score_gemma":0.000018404966,"teacher_disagreement_score":0.53048784,"about_ca_system_score_codex":0.00047897644,"about_ca_system_score_gemma":0.0007025322,"threshold_uncertainty_score":0.68118155},"labels":[],"label_agreement":null},{"id":"W2594526180","doi":"10.1182/blood.v114.22.3961.3961","title":"NUP98-HOXA9 Reprograms Embryonic Hematopoiesis, Suppresses Cellular Apoptosis, and Causes Malignant Tissue Infiltrates in Transgenic Zebrafish.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Biology; Zebrafish; Myeloid; Cancer research; Myeloid leukemia; Haematopoiesis; GATA1; Downregulation and upregulation; Embryonic stem cell; Cell biology; Stem cell; Genetics; Gene","score_opus":0.014582821848042302,"score_gpt":0.27514301474813085,"score_spread":0.2605601929000885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594526180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98692137,0.0082278345,0.000022782346,0.0029484848,0.00004177085,0.00097582396,0.000015115024,0.00017423372,0.0006725986],"genre_scores_gemma":[0.9960326,0.00160198,0.001074862,0.00034779526,0.00016353403,0.00007458603,0.000067995046,0.0000530734,0.0005835955],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974203,0.00011453429,0.0004932115,0.00070809014,0.0004644228,0.0007994093],"domain_scores_gemma":[0.9986602,0.00013184987,0.00007948492,0.0007187311,0.000093134244,0.00031659726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003980529,0.00035385744,0.00067225593,0.0002802455,0.00009536105,0.00009914004,0.00024462093,0.0002594503,0.00015608144],"category_scores_gemma":[0.00015620374,0.00030685472,0.00010223816,0.0005956493,0.00017551897,0.00019980001,0.0000574204,0.00048704538,0.00004577402],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019567709,0.0015831859,0.018108876,0.00051363406,0.00018982953,0.00043190323,0.00089780224,0.0000022121556,0.9737204,0.00039030577,0.001509772,0.0024564248],"study_design_scores_gemma":[0.00509057,0.0009012008,0.012883359,0.0003215223,0.00025727917,0.0003336457,0.00037481118,0.000016548885,0.975442,0.00031055562,0.0037194057,0.00034908098],"about_ca_topic_score_codex":0.00020168867,"about_ca_topic_score_gemma":0.00005402527,"teacher_disagreement_score":0.009111223,"about_ca_system_score_codex":0.00007180312,"about_ca_system_score_gemma":0.00026769927,"threshold_uncertainty_score":0.99993837},"labels":[],"label_agreement":null},{"id":"W2594637709","doi":"10.1182/blood.v114.22.4689.4689","title":"Familial Platelet Disorder and Predisposition to Myeloid Leukemia (FPD/AML) in the Absence of RUNX1 Mutations- A Report of Three Families.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"RUNX1; Platelet disorder; Haploinsufficiency; Myeloid leukemia; Genetics; Biology; Leukemia; Locus (genetics); Cancer research; Immunology; Gene; Phenotype; Transcription factor; Platelet","score_opus":0.01197889769395351,"score_gpt":0.27211632141780295,"score_spread":0.26013742372384946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594637709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954877,0.00020391312,0.00030076772,0.0009384503,0.000021454229,0.0008814539,0.00002357723,0.000018194529,0.0021244963],"genre_scores_gemma":[0.9980277,0.000103921535,0.0014295096,0.0002047865,0.00006217594,0.000037867063,0.000049373288,0.000011296567,0.000073378294],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984899,0.000044924564,0.00047013542,0.00026811758,0.00049162225,0.00023526484],"domain_scores_gemma":[0.99911463,0.00013058941,0.00011365648,0.00042456083,0.000139958,0.000076584634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004832382,0.00013115388,0.00030497444,0.00021075124,0.000042893244,0.000009107728,0.00015842765,0.00010067437,0.000010010585],"category_scores_gemma":[0.00034742535,0.0000974243,0.000052561216,0.00054027315,0.00013499387,0.00008261267,0.00004432576,0.0002466506,0.0000034574018],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025626123,0.0033608484,0.36657357,0.0008367378,0.00035669963,0.003661519,0.017344575,0.0004565605,0.4958236,0.0019634776,0.0019252169,0.10513459],"study_design_scores_gemma":[0.0041257953,0.0008905372,0.9756972,0.00016962958,0.000071019815,0.0007321367,0.0010179926,0.0003372997,0.016073385,0.00056258484,0.00020199773,0.00012037328],"about_ca_topic_score_codex":0.00062678463,"about_ca_topic_score_gemma":0.0002093465,"teacher_disagreement_score":0.6091237,"about_ca_system_score_codex":0.000079217774,"about_ca_system_score_gemma":0.00033078343,"threshold_uncertainty_score":0.39728478},"labels":[],"label_agreement":null},{"id":"W2594701169","doi":"10.1111/bjh.14460","title":"Incidence and outcomes of paediatric myelodysplastic syndrome in the United States","year":2017,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Incidence (geometry); Medicine; Myelodysplastic syndromes; Pediatrics; Intensive care medicine; Internal medicine; Bone marrow","score_opus":0.018600780384170408,"score_gpt":0.29613254222005475,"score_spread":0.27753176183588435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594701169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7716071,0.0044032694,0.000022065886,0.22340909,0.00019654876,0.00027034315,0.000036280522,0.0000044841254,0.000050809464],"genre_scores_gemma":[0.84820545,0.014348107,0.0006289801,0.13529128,0.0007040109,0.000020832524,0.00016183115,0.00009883483,0.00054068246],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9969826,0.0005297113,0.0010496938,0.00022745559,0.0007433078,0.00046726115],"domain_scores_gemma":[0.9956289,0.0022924505,0.0011553466,0.00038183096,0.00044939847,0.00009205612],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012426266,0.00023786232,0.0017542168,0.0010825015,0.000087293505,0.000067957415,0.0008040322,0.0006305938,0.000047258454],"category_scores_gemma":[0.0030179792,0.000181545,0.00017835632,0.00028473072,0.0006705866,0.00011973595,0.00016602826,0.0039742794,0.0000072969224],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000566476,0.000042900985,0.027498804,0.00078057585,0.00021262099,0.6139461,0.00014158984,0.000002526995,0.0000022088816,0.00000778527,0.35672414,0.000584138],"study_design_scores_gemma":[0.0019271241,0.000445561,0.11496983,0.00128118,0.00031029215,0.85924965,0.00012972254,0.00003749106,0.0000034202048,0.00045438524,0.02104371,0.00014761559],"about_ca_topic_score_codex":0.0007858553,"about_ca_topic_score_gemma":0.00007379148,"teacher_disagreement_score":0.33568043,"about_ca_system_score_codex":0.00009991198,"about_ca_system_score_gemma":0.00054850493,"threshold_uncertainty_score":0.9983236},"labels":[],"label_agreement":null},{"id":"W2594808128","doi":"10.1182/blood.v106.11.496.496","title":"Disease Stage Strongly Modulates Responsiveness to Targeted Agents in Nf1 Mutant Mice with Myeloprolfierative Disease (MPD) and Acute Myeloid Leukemia (AML).","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Cancer research; Myeloid leukemia; Myeloid; Biology; Leukemia; Haematopoiesis; Cre recombinase; Bone marrow; Neuroblastoma RAS viral oncogene homolog; Clonogenic assay; Molecular biology; Immunology; Stem cell; Mutation; Transgene; Genetically modified mouse; Cell culture; Genetics; KRAS; Gene","score_opus":0.014949632427981438,"score_gpt":0.283687685398438,"score_spread":0.2687380529704566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594808128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99333626,0.00068665814,0.00017804814,0.0029961143,0.000033225366,0.002054308,0.00042470053,0.00010805434,0.00018264817],"genre_scores_gemma":[0.9925282,0.00014612699,0.0025824113,0.0009146236,0.00020516383,0.00028367311,0.00017714014,0.00010230357,0.003060369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966142,0.00022193039,0.00045976668,0.0009872257,0.0008038445,0.00091302977],"domain_scores_gemma":[0.99702007,0.00015668821,0.00010463472,0.00072007894,0.0002798322,0.0017187133],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035434068,0.00048769324,0.0005964513,0.00049743865,0.00016784534,0.000089767665,0.00028131867,0.00011947605,0.00014685278],"category_scores_gemma":[0.0003526653,0.00040004836,0.000081764876,0.0007624133,0.00020355811,0.00035134488,0.00026794733,0.00055765134,0.00007218322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11347887,0.00499083,0.48776433,0.0013095862,0.0030897511,0.039662592,0.009129331,0.009606058,0.317712,0.00058048195,0.0019712609,0.0107049085],"study_design_scores_gemma":[0.022650678,0.0011319601,0.9158067,0.00060768216,0.0008725967,0.0000887197,0.0007432422,0.0070924703,0.04576068,0.000045918103,0.0042664525,0.0009328869],"about_ca_topic_score_codex":0.00014023451,"about_ca_topic_score_gemma":0.00013534352,"teacher_disagreement_score":0.42804238,"about_ca_system_score_codex":0.0008217726,"about_ca_system_score_gemma":0.0021559251,"threshold_uncertainty_score":0.99984515},"labels":[],"label_agreement":null},{"id":"W2595026465","doi":"10.1182/blood.v124.21.1013.1013","title":"Bone Marrow Adipocyte-Derived Free Fatty Acids Induce Gene Signature Linking Transcription with Metabolic Changes That Contribute to Survival of Acute Monocytic Leukemia Cells","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Biology; Downregulation and upregulation; Transcription factor; Stromal cell; Cancer research; Bone marrow; Cell biology; Biochemistry; Immunology; Gene","score_opus":0.020341772598522274,"score_gpt":0.24985592665146558,"score_spread":0.22951415405294331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595026465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894184,0.0015381901,0.0053440486,0.0014500273,0.00020370023,0.0013702883,0.0002521511,0.00014134274,0.00028183623],"genre_scores_gemma":[0.99022496,0.00048849045,0.0072838,0.00067576376,0.0005222969,0.0001129143,0.00019499272,0.00011499943,0.0003818145],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99677986,0.00025595105,0.00039156753,0.0006796267,0.0010420075,0.00085096795],"domain_scores_gemma":[0.99767184,0.00016152419,0.00020713458,0.001067176,0.00040015246,0.0004921816],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008307258,0.00046501128,0.0011571074,0.00039528555,0.00012034963,0.000047110192,0.00050817814,0.00045371527,0.000057840167],"category_scores_gemma":[0.0001118239,0.0003747773,0.00017365857,0.0006542296,0.00014678459,0.00014797524,0.00015768113,0.00089864194,0.000028104088],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011201681,0.00017654459,0.0019101966,0.00018464978,0.0011517444,0.00014128885,0.0007874862,0.000030432979,0.9926398,0.00007344661,0.00016790512,0.0016163397],"study_design_scores_gemma":[0.014652431,0.0011147385,0.014353533,0.00026309022,0.0020955452,0.00011898754,0.00009879938,0.00026735527,0.9646015,0.00003793235,0.0020145162,0.0003815388],"about_ca_topic_score_codex":0.00019055557,"about_ca_topic_score_gemma":0.00020099283,"teacher_disagreement_score":0.028038265,"about_ca_system_score_codex":0.00027900963,"about_ca_system_score_gemma":0.00047721187,"threshold_uncertainty_score":0.9998704},"labels":[],"label_agreement":null},{"id":"W2595261433","doi":"10.1182/blood.v120.21.3574.3574","title":"High-Dose Cytarabine-Based Consolidation Shows Superior Results for Elderly AML Patients with Intermediate Risk Cytogenetics in First Complete Remission","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Cytarabine; Medicine; Internal medicine; Regimen; Etoposide; Gastroenterology; Mitoxantrone; Idarubicin; Surgery; Leukemia; Chemotherapy","score_opus":0.0222480989188224,"score_gpt":0.26815559109811926,"score_spread":0.24590749217929686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595261433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964961,0.0000649266,0.00037349714,0.00040161546,0.000106055326,0.001767774,0.0006376368,0.00005245607,0.00009998421],"genre_scores_gemma":[0.9901595,0.000037677823,0.007930775,0.00015507366,0.00022008638,0.00014985989,0.0012313946,0.00004813373,0.00006749237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797976,0.00010585735,0.00048845046,0.0003673641,0.00044057128,0.00061799673],"domain_scores_gemma":[0.9983841,0.00035931705,0.00017431758,0.00048793358,0.00026685782,0.00032748282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004672629,0.00024338825,0.00038766014,0.00022928692,0.00011575278,0.000025629824,0.00015832236,0.00015911115,0.000030435996],"category_scores_gemma":[0.0007817371,0.00018983726,0.00006652465,0.00025114388,0.00011860313,0.00012106671,0.000045300894,0.0003378869,0.000023801567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010661375,0.0022560821,0.97057325,0.0002762565,0.0001280057,0.000032209824,0.00073125045,0.000071066046,0.008927715,0.000008721566,0.0015910056,0.0047430536],"study_design_scores_gemma":[0.07593872,0.0036841754,0.87449735,0.0004251431,0.00032271032,0.000013162904,0.00007392964,0.0010965327,0.039326575,0.0000098790415,0.0042538405,0.00035795092],"about_ca_topic_score_codex":0.0001547199,"about_ca_topic_score_gemma":0.00017585834,"teacher_disagreement_score":0.09607588,"about_ca_system_score_codex":0.00021103406,"about_ca_system_score_gemma":0.00028133055,"threshold_uncertainty_score":0.77413386},"labels":[],"label_agreement":null},{"id":"W2595323673","doi":"10.1182/blood.v128.22.904.904","title":"Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Regimen; Clinical endpoint; Gastroenterology; Neutropenia; Phases of clinical research; Decitabine; Adverse effect; Chemotherapy regimen; Febrile neutropenia; Surgery; Clinical trial; Chemotherapy; Biology","score_opus":0.04218165801584925,"score_gpt":0.34323655601432224,"score_spread":0.30105489799847296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595323673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972736,0.0006950349,0.000012393006,0.00023802806,0.00006477282,0.0014192805,0.00013335656,0.00005744993,0.00010607711],"genre_scores_gemma":[0.9973199,0.0016695138,0.00031625194,0.000050625476,0.000080338716,0.00008071234,0.00006956223,0.000071947914,0.00034117463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99600905,0.00064493634,0.0012119405,0.0007660646,0.00067787705,0.000690143],"domain_scores_gemma":[0.9958109,0.0025884009,0.00031865816,0.00061555946,0.00038465043,0.00028182002],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001157902,0.0004080144,0.0013144676,0.0005841913,0.00005996722,0.000015696125,0.00023672775,0.00025028494,0.00002426364],"category_scores_gemma":[0.0024680214,0.00025706607,0.0000967076,0.0006407059,0.0008377864,0.00021641789,0.0002422681,0.00062110735,0.000013457157],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011314031,0.003552842,0.96503294,0.00016314017,0.0008052907,0.0018077334,0.00034442707,1.2191714e-7,0.010045766,0.0000087273975,0.000044698823,0.006880289],"study_design_scores_gemma":[0.078465536,0.0073820306,0.910511,0.001060522,0.00051371136,0.00008429255,0.00010224398,0.000010189714,0.0015378742,0.000011077,0.0000428842,0.000278641],"about_ca_topic_score_codex":0.00019250734,"about_ca_topic_score_gemma":0.00067475147,"teacher_disagreement_score":0.06715151,"about_ca_system_score_codex":0.0005483371,"about_ca_system_score_gemma":0.00065098435,"threshold_uncertainty_score":0.99998814},"labels":[],"label_agreement":null},{"id":"W2595496294","doi":"10.1182/blood.v118.21.3641.3641","title":"Investigating the Potential Use of L-Asparaginase in Myeloid Leukemia,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Propidium iodide; Asparagine synthetase; Myeloid leukemia; Cancer research; Leukemia; Asparaginase; Glutamine; Asparagine; K562 cells; Myeloid; Cell culture; Biology; Programmed cell death; Apoptosis; Chemistry; Biochemistry; Immunology; Enzyme; Amino acid","score_opus":0.05270448775701249,"score_gpt":0.2729060486275812,"score_spread":0.22020156087056875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595496294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99645996,0.0001486618,0.000038879884,0.00029138615,0.000038572558,0.0003612282,0.0000051729157,0.000029867533,0.0026262943],"genre_scores_gemma":[0.9942958,0.000042633816,0.0047160867,0.00035222754,0.000090981666,0.000024933437,0.000007324778,0.000025201944,0.0004448393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871314,0.00010152028,0.000315001,0.00021442736,0.00032805034,0.00032789382],"domain_scores_gemma":[0.99909794,0.00010255642,0.0000884861,0.0004825695,0.000097456854,0.00013098081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039086203,0.00012363304,0.00024910155,0.00014450142,0.000045576828,0.0000119449505,0.00019968089,0.00009465727,0.00010884972],"category_scores_gemma":[0.0005389029,0.00008606323,0.00007093728,0.00037653564,0.0002704776,0.00012024733,0.00013652931,0.00046189927,0.000037746977],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038248324,0.0015088554,0.5857986,0.0004209267,0.00042658538,0.001618568,0.008473461,0.0000739449,0.38784847,0.0022484988,0.0033765335,0.00782303],"study_design_scores_gemma":[0.008916684,0.0005096594,0.67351055,0.00030595675,0.00029709688,0.00050939294,0.00079256867,0.0018446238,0.31147146,0.00077221805,0.0007978153,0.0002719772],"about_ca_topic_score_codex":0.002165566,"about_ca_topic_score_gemma":0.00005744479,"teacher_disagreement_score":0.087711915,"about_ca_system_score_codex":0.000096420015,"about_ca_system_score_gemma":0.000525558,"threshold_uncertainty_score":0.35095564},"labels":[],"label_agreement":null},{"id":"W2595557001","doi":"10.1182/blood.v128.22.1075.1075","title":"Transcriptional Landscape of APL Identifies Aberrant Podoplanin Expression As a Defining Feature and Missing Link for the Bleeding Disorder of This Disease","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Institute for Research in Immunology and Cancer; Leukemia & Lymphoma Society of Canada; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Cancer research; Podoplanin; GATA1; Medicine; Biology; Immunology; Gene; Gene expression; Genetics; Lymphatic system","score_opus":0.016365107776869163,"score_gpt":0.27466791414130814,"score_spread":0.258302806364439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595557001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9685237,0.014858185,0.0015401931,0.013944182,0.00006659263,0.0004958638,0.00014095964,0.000029624889,0.0004007083],"genre_scores_gemma":[0.9969768,0.00048546848,0.0011399775,0.000048938167,0.00009613531,0.00002838092,0.00001972829,0.000020209465,0.0011843621],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999134,0.000027307957,0.00018230065,0.00018244676,0.00029493563,0.00017899906],"domain_scores_gemma":[0.9990248,0.000518884,0.00007975889,0.00018012787,0.00010815316,0.000088265544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026929905,0.000102734935,0.00020602334,0.0000800487,0.00010586536,0.00001431379,0.000094663854,0.00007363927,0.000077888966],"category_scores_gemma":[0.00039565665,0.00005236101,0.000088973546,0.00008234194,0.000118435826,0.000079507394,0.000038651982,0.000117230775,0.0000017168151],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013338239,0.00018779591,0.04297317,0.0007416625,0.00020667535,0.000015382355,0.0013663867,8.174439e-7,0.93806607,0.000823738,0.0023972518,0.011887263],"study_design_scores_gemma":[0.060191214,0.0013595961,0.3171499,0.013360218,0.003959536,0.00039016997,0.004443029,0.0024898262,0.57414454,0.006929456,0.01471841,0.0008641023],"about_ca_topic_score_codex":0.000012857457,"about_ca_topic_score_gemma":0.0000022187007,"teacher_disagreement_score":0.36392152,"about_ca_system_score_codex":0.000009808584,"about_ca_system_score_gemma":0.0001420159,"threshold_uncertainty_score":0.213522},"labels":[],"label_agreement":null},{"id":"W2596175104","doi":"10.1182/blood.v126.23.87.87","title":"Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Missense mutation; Mutation; Cog; Biology; Myeloid leukemia; Exome sequencing; Exome; Point mutation; Genetics; Cancer research; Fms-Like Tyrosine Kinase 3; Leukemia; Gene; Oncology; Medicine","score_opus":0.06235173547707459,"score_gpt":0.28867605802401364,"score_spread":0.22632432254693904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596175104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947808,0.0002876147,0.0014635532,0.00095426023,0.00009619888,0.00046084978,0.00065233855,0.00002329859,0.0012811088],"genre_scores_gemma":[0.9938629,0.00014299095,0.0040489365,0.00009309156,0.00058817514,0.000035052628,0.0010656796,0.00002410187,0.0001390661],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982841,0.00010930607,0.00046192703,0.00034219655,0.00056896394,0.00023351691],"domain_scores_gemma":[0.997943,0.001177488,0.0002232249,0.00027459816,0.00027747313,0.00010422327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006151976,0.00015623285,0.0002669006,0.0001864644,0.00008472021,0.0000421472,0.0001017459,0.00011903113,0.000013124198],"category_scores_gemma":[0.001361608,0.00011763987,0.000047619593,0.00062195695,0.00012534326,0.00041368586,0.00011745592,0.0004930567,0.000009940749],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010877468,0.0047375355,0.62631536,0.00022186113,0.0022548868,0.00039255084,0.043219402,0.003256324,0.280982,0.0015711482,0.024028849,0.0021426314],"study_design_scores_gemma":[0.046171155,0.00053283176,0.8377934,0.00014462165,0.0005717711,0.00010177256,0.006798919,0.0016468429,0.10442686,0.0009667209,0.00046813622,0.0003769802],"about_ca_topic_score_codex":0.0002777799,"about_ca_topic_score_gemma":0.000015843114,"teacher_disagreement_score":0.21147804,"about_ca_system_score_codex":0.00027224654,"about_ca_system_score_gemma":0.0011094097,"threshold_uncertainty_score":0.4797215},"labels":[],"label_agreement":null},{"id":"W2596458707","doi":"10.1200/jco.2009.27.15_suppl.3580","title":"Clinical, pharmacokinetic (PK), and pharmacodynamic findings from a phase I trial of an Eg5 inhibitor (AZD4877) in patients with refractory acute myeloid leukemia (AML)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Mucositis; Pharmacodynamics; Pharmacokinetics; Internal medicine; Myeloid leukemia; Refractory (planetary science); Bone marrow; Gastroenterology; Myeloid; Toxicity; Pharmacology","score_opus":0.056220188537247785,"score_gpt":0.4726576236598117,"score_spread":0.41643743512256387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596458707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956399,0.00016283544,0.000028927761,0.0016756646,0.0010910532,0.00096240785,0.000050795563,0.000016348056,0.0003720743],"genre_scores_gemma":[0.9891836,0.0019843308,0.0040210555,0.002489874,0.0021301783,0.0000059404933,0.000046064513,0.000043206666,0.00009576123],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9912124,0.0014100008,0.005252369,0.0005693689,0.0010218275,0.00053400366],"domain_scores_gemma":[0.99190235,0.0032333347,0.0026396946,0.0003995034,0.00071843975,0.0011066714],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0056644664,0.0003491741,0.003076033,0.00049526425,0.000047980888,0.000017863316,0.0004474179,0.00076883944,0.00021251391],"category_scores_gemma":[0.0028516697,0.00024888286,0.00046352,0.0004061679,0.00066660653,0.00047879983,0.000105530584,0.0038173771,0.000009309069],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49343246,0.0132014435,0.042566195,0.000022977627,0.0007285608,0.0013308525,0.00013610306,0.000005367212,0.0044518723,0.0000026070625,0.0017900333,0.44233152],"study_design_scores_gemma":[0.51480085,0.14602692,0.32671908,0.00023007735,0.0011754892,0.000070442766,0.000051036102,0.00071513903,0.000413354,0.0000791452,0.009477251,0.0002412218],"about_ca_topic_score_codex":0.000045908255,"about_ca_topic_score_gemma":0.000015762982,"teacher_disagreement_score":0.4420903,"about_ca_system_score_codex":0.000799722,"about_ca_system_score_gemma":0.0042215115,"threshold_uncertainty_score":0.99999636},"labels":[],"label_agreement":null},{"id":"W2597247499","doi":"10.1182/blood.v108.11.4273.4273","title":"The Ubiquitin Specific Peptidase 42 Gene (USP42) Is Recurrently Involved as a Fusion Gene with RUNX1 in Acute Myeloid Leukemia with the t(7;21)(p22;q22) Cryptic Translocation.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"RUNX1; Fusion gene; Biology; Chromosomal translocation; Myeloid leukemia; Fusion transcript; Karyotype; Molecular biology; Fusion protein; Leukemia; Genetics; Cancer research; Gene; Chromosome; Transcription factor","score_opus":0.011776877344481946,"score_gpt":0.24329501486352648,"score_spread":0.23151813751904454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597247499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792513,0.005123484,0.000327626,0.011119827,0.00005694841,0.0020735983,0.000035835597,0.00012494363,0.0018864207],"genre_scores_gemma":[0.98725486,0.0037119228,0.0030393738,0.0011547928,0.00065882056,0.00047211323,0.00021944841,0.00015885556,0.0033298421],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99582934,0.00023393368,0.0006866003,0.00084847666,0.001334192,0.0010674627],"domain_scores_gemma":[0.99743944,0.0002980521,0.00024221616,0.0013627379,0.0003855274,0.00027199546],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009155382,0.00054701744,0.00056103733,0.00027259704,0.00058725604,0.00018224733,0.0006798939,0.000218495,0.00017140908],"category_scores_gemma":[0.00003878798,0.00029213508,0.0001484568,0.0014112116,0.0005741982,0.00017933473,0.00009432696,0.0011338583,0.00024637076],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014039696,0.0034593744,0.020030444,0.00041591967,0.001919544,0.004499831,0.012211531,0.00030087394,0.8669966,0.0014012435,0.039951388,0.034773596],"study_design_scores_gemma":[0.044888508,0.003667579,0.05945267,0.0010211386,0.0013177393,0.002087794,0.0029040165,0.0009975843,0.82456285,0.00044557618,0.057201937,0.0014525908],"about_ca_topic_score_codex":0.0008890092,"about_ca_topic_score_gemma":0.0008936053,"teacher_disagreement_score":0.042433694,"about_ca_system_score_codex":0.0006871564,"about_ca_system_score_gemma":0.0016024313,"threshold_uncertainty_score":0.9999531},"labels":[],"label_agreement":null},{"id":"W2598038468","doi":"10.1200/jco.2012.30.15_suppl.6627","title":"Post hoc analysis of association between treatment response and various indicators of efficacy and safety in a randomized phase III trial of decitabine in older patients with acute myeloid leukemia.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Decitabine; Internal medicine; Cytarabine; Myeloid leukemia; Post-hoc analysis; Gastroenterology; Azacitidine; Neutropenia; Surgery; Chemotherapy","score_opus":0.030669062270419694,"score_gpt":0.4196863267027829,"score_spread":0.3890172644323632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598038468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997734,0.00020238655,0.000040155453,0.000717391,0.000068823596,0.0011492132,0.000049236114,0.0000016010044,0.000037169248],"genre_scores_gemma":[0.9976067,0.0012484856,0.000911693,0.000056502726,0.000104330706,0.000008380745,0.000024476034,0.0000122064275,0.000027220369],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9920162,0.0028687224,0.0040245806,0.00018075717,0.00062944187,0.00028029882],"domain_scores_gemma":[0.9727597,0.022050263,0.004226935,0.00018024692,0.00045059167,0.0003322669],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015860066,0.00016607619,0.00496846,0.001556914,0.00001551697,0.0000026442572,0.00009998502,0.0004697048,0.000024394176],"category_scores_gemma":[0.012754152,0.00010391286,0.0004025159,0.0009482152,0.00035175346,0.000122053265,0.000058594145,0.0006355662,1.8318836e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59835815,0.003535053,0.3716165,0.000010772919,0.005014642,0.000029018016,0.0008422013,0.000004403708,0.00008854901,0.0000021134078,0.000006204465,0.020492353],"study_design_scores_gemma":[0.48485094,0.01976904,0.49079093,0.000047750516,0.004322756,0.0000032522942,0.000048136684,0.000026223197,0.00006170731,0.0000027752224,0.000036939146,0.000039548402],"about_ca_topic_score_codex":0.00014938739,"about_ca_topic_score_gemma":0.00007065828,"teacher_disagreement_score":0.1191744,"about_ca_system_score_codex":0.001382508,"about_ca_system_score_gemma":0.0023963717,"threshold_uncertainty_score":0.99556184},"labels":[],"label_agreement":null},{"id":"W2598163766","doi":"10.1182/blood.v124.21.2529.2529","title":"Evaluation of the Disease Risk Index on Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Internal medicine; Univariate analysis; Transplantation; Myeloid leukemia; Hematopoietic stem cell transplantation; Surgery; Myeloid; Oncology; International Prognostic Scoring System; Bone marrow; Gastroenterology; Multivariate analysis","score_opus":0.017819161390609142,"score_gpt":0.29588063515144114,"score_spread":0.278061473760832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598163766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965903,0.00020971593,0.0010434295,0.0002768917,0.00011746328,0.0014385472,0.000063008665,0.000030339474,0.00023030321],"genre_scores_gemma":[0.9990257,0.00009956898,0.00030991528,0.00011268407,0.000041276024,0.00017814469,0.00003820818,0.000039366798,0.00015513675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770004,0.0002749622,0.00031955822,0.0003547135,0.001065068,0.00028569033],"domain_scores_gemma":[0.99844843,0.0006032149,0.00015640781,0.00044067178,0.00017894077,0.00017234121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013510957,0.00020795666,0.00037082908,0.00013936171,0.00015971408,0.000019237254,0.00015694444,0.00010382678,0.000012573839],"category_scores_gemma":[0.0007501991,0.00014008442,0.00022497671,0.00016989293,0.00007987568,0.00006605354,0.000034843033,0.0002084975,0.0000066658954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061364286,0.00048634637,0.9742184,0.0010029336,0.0014905606,0.000029517496,0.0008222712,0.0008719634,0.014545403,0.00018204711,0.000079655554,0.0056572426],"study_design_scores_gemma":[0.0134612415,0.00037855076,0.952027,0.00022568917,0.011179664,0.000033210054,0.000059139184,0.0063604102,0.015168102,0.00090759684,0.00001852679,0.00018083594],"about_ca_topic_score_codex":0.000020306843,"about_ca_topic_score_gemma":0.000011020699,"teacher_disagreement_score":0.022191383,"about_ca_system_score_codex":0.00015765194,"about_ca_system_score_gemma":0.0005223734,"threshold_uncertainty_score":0.5712477},"labels":[],"label_agreement":null},{"id":"W2598417540","doi":"10.1111/ijlh.12649","title":"Expression of <scp>CD</scp>4 is correlated with an unfavorable prognosis in wild‐type <scp>NPM</scp>1, <scp>FLT</scp>3‐<scp>ITD</scp>‐negative cytogenetically normal adult acute myeloid leukemia","year":2017,"lang":"en","type":"article","venue":"International Journal of Laboratory Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"NPM1; Internal medicine; Medicine; CD34; Oncology; Population; Hematopoietic stem cell transplantation; Clinical significance; Myeloid leukemia; Gastroenterology; Karyotype; Stem cell; Immunology; Biology; Transplantation; Gene; Genetics","score_opus":0.015054792498725156,"score_gpt":0.30378271944066926,"score_spread":0.2887279269419441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598417540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99207,0.00087160245,0.00038594657,0.0007232586,0.0011968332,0.00097648724,0.0003158728,0.00009016493,0.0033697973],"genre_scores_gemma":[0.98623675,0.0013938796,0.008378794,0.0009940887,0.0006259626,0.00008528842,0.00011999031,0.0002202322,0.0019450295],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99112153,0.000751731,0.002554153,0.0011439478,0.0028985918,0.0015300454],"domain_scores_gemma":[0.98056453,0.00354697,0.0035126458,0.001197466,0.0099910395,0.0011873485],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001580337,0.0009876582,0.0021832322,0.0016692441,0.00040428512,0.00028584976,0.002769343,0.0011907712,0.00007145101],"category_scores_gemma":[0.0134592615,0.0008338958,0.0003722509,0.0011162942,0.0013730336,0.0017008986,0.00074245007,0.003001647,0.0001406322],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001348114,0.0027878021,0.6294365,0.00056279125,0.0052500265,0.018241605,0.011716612,0.00059927243,0.22721294,0.0019299915,0.10029437,0.0006200048],"study_design_scores_gemma":[0.020363478,0.0060210954,0.08966619,0.003426885,0.00091606006,0.00909956,0.00880898,0.0023286033,0.84447825,0.0010001258,0.013662784,0.00022801654],"about_ca_topic_score_codex":0.00018142366,"about_ca_topic_score_gemma":0.00015357784,"teacher_disagreement_score":0.6172653,"about_ca_system_score_codex":0.0014128315,"about_ca_system_score_gemma":0.0058511845,"threshold_uncertainty_score":0.9997847},"labels":[],"label_agreement":null},{"id":"W2598701304","doi":"10.1200/jco.2012.30.15_suppl.6103","title":"Development of a disease-specific measure of quality of life in myelodysplastic syndromes (MDS): The “QUALMS-1”.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Laurentian University","funders":"","keywords":"Medicine; Quality of life (healthcare); Cohort; Debriefing; Disease; Focus group; Gerontology; Family medicine; Clinical psychology; Nursing; Pathology; Medical education","score_opus":0.33621499780270037,"score_gpt":0.49580175825931116,"score_spread":0.1595867604566108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598701304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99265856,0.0022103854,0.00026648364,0.0034898394,0.00048142008,0.00027249003,0.000006098395,0.0000027654255,0.0006119364],"genre_scores_gemma":[0.9932487,0.00051165913,0.0054985285,0.00026831205,0.00039002983,0.0000048259703,0.0000015671916,0.00001609929,0.000060294733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99119776,0.0015464586,0.005560264,0.00014831423,0.0011816737,0.00036555415],"domain_scores_gemma":[0.9857982,0.008868099,0.0033643886,0.00037582597,0.00090046925,0.0006930471],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018262306,0.000149663,0.002297432,0.0002506082,0.000025316527,0.0000019930412,0.0004090591,0.00031195124,0.00019269844],"category_scores_gemma":[0.020247439,0.00008778158,0.00047980214,0.00037152055,0.00064949994,0.00010342233,0.00014596949,0.0012667399,0.000010704081],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030393213,0.009177886,0.87815094,0.0008599656,0.0012249287,0.00011846713,0.0023999254,0.00003303157,0.003926632,0.001353819,0.003451573,0.06890962],"study_design_scores_gemma":[0.0064910008,0.0021392654,0.97861034,0.00033161938,0.00013610243,0.000046385416,0.000865898,0.000018846882,0.0002518259,0.000098684315,0.010929949,0.00008009237],"about_ca_topic_score_codex":0.000017412356,"about_ca_topic_score_gemma":0.000025039788,"teacher_disagreement_score":0.1004594,"about_ca_system_score_codex":0.0003139453,"about_ca_system_score_gemma":0.0074108336,"threshold_uncertainty_score":0.9982162},"labels":[],"label_agreement":null},{"id":"W2599152948","doi":"10.1097/pai.0000000000000452","title":"Acute Myeloid Leukemia (AML): Upregulation of BAALC/MN1/MLLT11/EVI1 Gene Cluster Relate With Poor Overall Survival and a Possible Linkage With Coexpression of MYC/BCL2 Proteins","year":2017,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Calgary Laboratory Services; Foothills Medical Centre","funders":"","keywords":"NPM1; Myeloid leukemia; Oncology; Gene; Internal medicine; Leukemia; Medicine; Biology; Bioinformatics; Karyotype; Genetics; Chromosome","score_opus":0.007960962176226884,"score_gpt":0.2628389754634652,"score_spread":0.2548780132872383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599152948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872256,0.0005144447,0.0052491454,0.00038069472,0.000045535384,0.0015815796,0.000047675072,0.000052474446,0.004902877],"genre_scores_gemma":[0.98034054,0.00010296883,0.017252166,0.0001305234,0.00006006131,0.0002209897,0.00027625117,0.00012537387,0.0014910973],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969857,0.00007645084,0.0006996482,0.0008987818,0.00070244697,0.00063696865],"domain_scores_gemma":[0.9962542,0.000065095985,0.000941836,0.002075223,0.00043148617,0.00023214736],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039111212,0.0005322577,0.001085309,0.00014737656,0.00027738756,0.00004015703,0.00058870413,0.0005853919,0.0000766854],"category_scores_gemma":[0.00010219375,0.00043820174,0.00013500039,0.00016096531,0.0014277307,0.00013420227,0.000516188,0.0008419063,0.0000072982657],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075013735,0.00014009206,0.0006596319,0.00045740305,0.0006474214,0.0004126324,0.00018994632,0.00008098079,0.98899,0.00015393022,0.00015993371,0.00060664373],"study_design_scores_gemma":[0.0112171555,0.0008227562,0.0071501196,0.00039643294,0.00049082,0.0008806839,0.00006891384,0.00020885972,0.9781877,0.00008743728,0.00006990925,0.00041925313],"about_ca_topic_score_codex":0.0002647054,"about_ca_topic_score_gemma":7.6675605e-7,"teacher_disagreement_score":0.01200302,"about_ca_system_score_codex":0.00048041894,"about_ca_system_score_gemma":0.00077987753,"threshold_uncertainty_score":0.999807},"labels":[],"label_agreement":null},{"id":"W2599455091","doi":"10.1200/jco.2013.31.15_suppl.7078","title":"The role of salvage induction chemotherapy after azacitidine (AZA) treatment failure.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Azacitidine; Chemotherapy; Salvage therapy; Induction chemotherapy; Surgery; Oncology","score_opus":0.056182440377792194,"score_gpt":0.42690926001585827,"score_spread":0.3707268196380661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599455091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9504169,0.000619592,0.000030610827,0.046236932,0.0003530707,0.0003447137,0.0000012595079,0.000006010419,0.0019908852],"genre_scores_gemma":[0.99126285,0.0024405827,0.0024200755,0.0010461211,0.0017475656,0.000023939141,0.0000010824895,0.000019918105,0.0010378708],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971426,0.00038334672,0.001689888,0.00013512814,0.00039036205,0.00025867345],"domain_scores_gemma":[0.9962598,0.0015201116,0.0010098933,0.00027127733,0.00063694245,0.00030195297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019727026,0.00012462444,0.0009808743,0.00009941155,0.00004156176,0.000011577377,0.00017371988,0.00035616304,0.0006159153],"category_scores_gemma":[0.0012570875,0.00006242883,0.00047345902,0.00013592321,0.00037099782,0.00012483656,0.000035004065,0.00084412895,0.00007724148],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053120577,0.001446441,0.043299753,0.000010629116,0.00080862,0.00012120623,0.00019063374,0.0000017222828,0.012443161,0.00010290695,0.013570008,0.92269284],"study_design_scores_gemma":[0.01091465,0.023152433,0.3492891,0.000050886454,0.0002092406,0.0005095176,0.0006844038,0.00013657747,0.007980524,0.0017186459,0.6052628,0.000091218986],"about_ca_topic_score_codex":0.00006787358,"about_ca_topic_score_gemma":0.000039997984,"teacher_disagreement_score":0.92260164,"about_ca_system_score_codex":0.00042089738,"about_ca_system_score_gemma":0.0013790868,"threshold_uncertainty_score":0.674384},"labels":[],"label_agreement":null},{"id":"W2600110340","doi":"10.1200/jco.2013.31.15_suppl.7067","title":"Do quality of life and physical function at diagnosis predict short-term outcomes during intensive chemotherapy in acute myeloid leukemia patients?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Univariate analysis; Quality of life (healthcare); Internal medicine; Intensive care unit; Logistic regression; Comorbidity; Performance status; Prospective cohort study; Myeloid leukemia; Multivariate analysis; Chemotherapy","score_opus":0.09308544646276525,"score_gpt":0.4433040097069141,"score_spread":0.35021856324414885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600110340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99384123,0.000100323494,0.000011531189,0.004984008,0.00038324826,0.000502446,0.000006710918,0.000008923437,0.00016158924],"genre_scores_gemma":[0.99542254,0.001627369,0.00023811126,0.0020135357,0.00052656856,0.000026017735,0.0000047699414,0.000025533926,0.000115554576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99542135,0.0005780906,0.0027249665,0.0002984421,0.0006402653,0.0003368622],"domain_scores_gemma":[0.9928718,0.0036851938,0.0012993377,0.0002749573,0.0013074141,0.00056129636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001810275,0.00020514936,0.0023280676,0.00022463333,0.00003738507,0.000010900974,0.0001849907,0.00043846146,0.00017712703],"category_scores_gemma":[0.007857629,0.000139343,0.0004867362,0.00017359156,0.00044109713,0.0002529837,0.00020132663,0.0014267414,0.000015409332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007483068,0.0009972345,0.94953585,0.00007451467,0.0007136414,0.0000528081,0.00033192703,0.000002790679,0.0014621963,0.000006490456,0.002015253,0.03732424],"study_design_scores_gemma":[0.01553716,0.0067762113,0.976237,0.00008867719,0.00015924318,0.000028773724,0.00024111246,0.00008482708,0.00034079378,0.00010409312,0.00029436316,0.0001077324],"about_ca_topic_score_codex":0.00007729211,"about_ca_topic_score_gemma":0.000025239322,"teacher_disagreement_score":0.037216507,"about_ca_system_score_codex":0.001014238,"about_ca_system_score_gemma":0.0009738106,"threshold_uncertainty_score":0.9406884},"labels":[],"label_agreement":null},{"id":"W2600545212","doi":"10.1200/jco.2014.32.15_suppl.7030","title":"First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Regimen; Clinical endpoint; Internal medicine; Neutropenia; Refractory (planetary science); Phases of clinical research; Gastroenterology; Surgery; Decitabine; Clinical trial; Chemotherapy","score_opus":0.1540066286250848,"score_gpt":0.46430109972436145,"score_spread":0.31029447109927666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600545212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925753,0.00038730603,0.001004091,0.0029416617,0.0008264928,0.0017322965,0.00006363902,0.0000069975827,0.00046224982],"genre_scores_gemma":[0.9912372,0.0007954011,0.0057611284,0.00018916761,0.0010660011,0.000019132844,0.0000033779763,0.000050791605,0.00087774923],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.991938,0.0012070665,0.004948988,0.00038443552,0.001046818,0.00047469878],"domain_scores_gemma":[0.96496326,0.025386212,0.006857457,0.0010204382,0.0014369161,0.00033573376],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0104153715,0.00031166052,0.002690404,0.0002508659,0.00014908674,0.0000086987375,0.00071231904,0.00047553008,0.000039322113],"category_scores_gemma":[0.016081812,0.00015908707,0.0012553518,0.00044917187,0.00078298006,0.00008712747,0.00017912453,0.0010617345,0.0000019661352],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24498859,0.06448259,0.0078126555,0.00046352175,0.018145423,0.0011061042,0.01475071,0.0034108309,0.13385685,0.000100978075,0.008822514,0.5020592],"study_design_scores_gemma":[0.2392869,0.47717363,0.02925964,0.00097363914,0.011021198,0.0016613848,0.003999274,0.031324394,0.01475321,0.00019277199,0.1898339,0.0005200823],"about_ca_topic_score_codex":0.00023401152,"about_ca_topic_score_gemma":0.0001115432,"teacher_disagreement_score":0.5015392,"about_ca_system_score_codex":0.001610866,"about_ca_system_score_gemma":0.004173626,"threshold_uncertainty_score":0.99220616},"labels":[],"label_agreement":null},{"id":"W2601049681","doi":"10.1182/blood.v110.11.1417.1417","title":"Histone Deacetylase Inhibitor Valproic Acid Has Differential Effects on Trafficking of Normal Hematopoietic Stem/Progenitor Cells and Leukemic Blasts.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of Alberta","funders":"","keywords":"Cancer research; Haematopoiesis; Progenitor cell; Bone marrow; Stem cell; CD34; Leukemia; Biology; Myeloid; CXCR4; Myeloid leukemia; Stromal cell; Homing (biology); Myelopoiesis; Stem cell factor; Immunology; Cell biology; Chemokine; Inflammation","score_opus":0.013617114109270531,"score_gpt":0.2601441598105263,"score_spread":0.24652704570125578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601049681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99763757,0.0005875344,0.00012429278,0.00008628034,0.00024164648,0.0009286899,0.000029888233,0.000101729674,0.00026234105],"genre_scores_gemma":[0.99809444,0.000024972325,0.00051393214,0.00006890634,0.0006556293,0.00003405191,0.000027717711,0.00007759488,0.0005027404],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975098,0.000079455225,0.0005178426,0.0004938054,0.0007115427,0.0006875531],"domain_scores_gemma":[0.9984619,0.00038524106,0.00016551997,0.00045148304,0.000111527435,0.00042429977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033107089,0.00033968367,0.0006242911,0.0003412633,0.00013633145,0.000030326051,0.00016820435,0.00025106632,0.00013380499],"category_scores_gemma":[0.000093403876,0.00029950473,0.00016877514,0.00028154653,0.00024641794,0.00007296303,0.00013201477,0.0005936046,0.00007944373],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008414358,0.0009263257,0.00060354406,0.001264789,0.00019950038,0.00048292705,0.0008042078,9.989891e-7,0.9860195,0.000013905947,0.0012210938,0.007621755],"study_design_scores_gemma":[0.010546412,0.0015299662,0.0019311397,0.00049687247,0.00037822718,0.00035405907,0.0001330124,0.0000801994,0.9840664,0.0000025046195,0.00023543362,0.0002457553],"about_ca_topic_score_codex":0.000021045427,"about_ca_topic_score_gemma":0.000007915852,"teacher_disagreement_score":0.009704976,"about_ca_system_score_codex":0.00028005507,"about_ca_system_score_gemma":0.00032985175,"threshold_uncertainty_score":0.9999457},"labels":[],"label_agreement":null},{"id":"W2602084921","doi":"","title":"Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin","year":2015,"lang":"en","type":"book-chapter","venue":"Author eBooks","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's & Women's Health Centre of British Columbia","funders":"","keywords":"Medicine; Alemtuzumab; Melphalan; Transplantation; Fludarabine; Internal medicine; Hematopoietic stem cell transplantation; Hematology; Immunosuppression; Aplastic anemia; Anemia; Regimen; Surgery; Immunology; Gastroenterology; Bone marrow; Cyclophosphamide; Chemotherapy","score_opus":0.05441645796709919,"score_gpt":0.3129030795973973,"score_spread":0.2584866216302981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602084921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9062118,0.00033706764,0.0003959894,0.00009013223,0.000049156417,0.0016267706,0.00013444411,0.000066851775,0.091087766],"genre_scores_gemma":[0.9482023,0.00003356113,0.0027762433,0.00011542767,0.00008199783,0.00002164952,0.00024869965,0.00012922022,0.048390895],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973875,0.00005217499,0.0007309616,0.0006497409,0.00074837066,0.0004312374],"domain_scores_gemma":[0.99824846,0.000057482655,0.00043954194,0.00057091686,0.00044791694,0.00023565679],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032844837,0.00047794284,0.001160718,0.00052352657,0.00007303524,0.000025573614,0.00023914372,0.0005441263,0.00020413949],"category_scores_gemma":[0.000017574894,0.00041328082,0.0001425602,0.0000659639,0.00035226837,0.00005229276,0.00006461081,0.00093788106,0.000041579813],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025042892,0.0012394894,0.53940314,0.030252667,0.009025735,0.03487953,0.054349504,0.0008913683,0.2031825,0.06786959,0.021016303,0.012847294],"study_design_scores_gemma":[0.056339733,0.008154624,0.07992873,0.033924524,0.01472942,0.09455902,0.0020509085,0.0027126023,0.6388687,0.053754054,0.005176675,0.009801011],"about_ca_topic_score_codex":0.00049187633,"about_ca_topic_score_gemma":0.000044010045,"teacher_disagreement_score":0.45947438,"about_ca_system_score_codex":0.00048020182,"about_ca_system_score_gemma":0.0011117903,"threshold_uncertainty_score":0.9998319},"labels":[],"label_agreement":null},{"id":"W2602169105","doi":"10.1182/blood-2016-11-750158","title":"A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of Calgary","funders":"National Cancer Institute; Karyopharm Therapeutics","keywords":"Medicine; Internal medicine; Adverse effect; Myeloid leukemia; Population; Hazard ratio; Toxicity; Phases of clinical research; Refractory (planetary science); Oncology; Cancer; Gastroenterology; Confidence interval; Biology","score_opus":0.1026217167358261,"score_gpt":0.4179450152060915,"score_spread":0.3153232984702654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602169105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931136,0.00010874533,0.000037631045,0.001223437,0.00033780298,0.0010723589,0.000031449217,0.00003792227,0.0040370985],"genre_scores_gemma":[0.9946389,0.00030679096,0.0021910456,0.00019715706,0.0009859144,0.000049694514,0.000028700537,0.000040413994,0.001561342],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99746484,0.00014283348,0.0009638456,0.00045133295,0.00052493677,0.00045219515],"domain_scores_gemma":[0.9975515,0.00021957167,0.0003648613,0.0014001742,0.00016696593,0.000296914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014252969,0.00019550612,0.00079921214,0.00017845965,0.00009500271,0.00004120062,0.00052560755,0.0002732894,0.00009907626],"category_scores_gemma":[0.002381551,0.00016411106,0.00027332114,0.0001281015,0.00032544514,0.00011872454,0.00026992426,0.0006390015,0.00009474371],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2794412,0.06876911,0.04456968,0.0005033454,0.0029128906,0.0073840534,0.0009344252,0.0000025335203,0.3798719,0.00023144014,0.016006941,0.19937246],"study_design_scores_gemma":[0.8983233,0.013137867,0.011225838,0.00027815774,0.0008828503,0.0001845627,0.00007000392,0.00045080433,0.06340632,0.00008080187,0.011641416,0.00031806694],"about_ca_topic_score_codex":0.00015168828,"about_ca_topic_score_gemma":0.000038527243,"teacher_disagreement_score":0.6188821,"about_ca_system_score_codex":0.00022247671,"about_ca_system_score_gemma":0.0012157111,"threshold_uncertainty_score":0.66922545},"labels":[],"label_agreement":null},{"id":"W2602321039","doi":"10.1186/s12920-017-0253-6","title":"Large-scale gene network analysis reveals the significance of extracellular matrix pathway and homeobox genes in acute myeloid leukemia: an introduction to the Pigengene package and its applications","year":2017,"lang":"en","type":"article","venue":"BMC Medical Genomics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Department of Mechanical Engineering, University of Texas at Austin; Terry Fox Research Institute; Genome British Columbia; Texas State University; BC Cancer Foundation; University of Texas at Austin","keywords":"Myeloid leukemia; Bioconductor; Computational biology; Biology; Gene expression profiling; DNA microarray; Microarray; Bioinformatics; MMP9; Gene; Gene expression; Genetics; Cancer research","score_opus":0.018758641705854395,"score_gpt":0.29688997995581096,"score_spread":0.27813133824995656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602321039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9472127,0.010013266,0.034460224,0.006398876,0.00008135031,0.0017005,0.00009226399,0.0000193787,0.000021416281],"genre_scores_gemma":[0.9781172,0.009008874,0.008298866,0.00027236482,0.0026309136,0.0004197768,0.00012754192,0.000049303304,0.0010751197],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99732226,0.00029542754,0.00060013874,0.0006537057,0.00060021126,0.0005282508],"domain_scores_gemma":[0.99717885,0.0003447021,0.0002678538,0.0015670159,0.00015596503,0.0004856162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035335093,0.00022437757,0.00059921056,0.00014921773,0.0005351778,0.0000753783,0.00070266647,0.0002502995,0.00006018322],"category_scores_gemma":[0.0005306771,0.00014528327,0.00010164363,0.0005594603,0.0003459231,0.000092163595,0.00042898234,0.0005354633,0.000011941073],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025706813,0.00088526204,0.2005937,0.0012837437,0.0036076342,0.00025037723,0.010363493,0.010469627,0.6472999,0.007344469,0.0057511507,0.10957997],"study_design_scores_gemma":[0.00856952,0.0010885891,0.5678863,0.00016046903,0.0047931415,0.000489091,0.0050423923,0.17706122,0.04926967,0.0012493117,0.18280517,0.0015851634],"about_ca_topic_score_codex":0.00006713077,"about_ca_topic_score_gemma":0.0011261188,"teacher_disagreement_score":0.5980302,"about_ca_system_score_codex":0.000255788,"about_ca_system_score_gemma":0.00072453014,"threshold_uncertainty_score":0.592448},"labels":[],"label_agreement":null},{"id":"W2602461976","doi":"10.1182/blood.v128.22.731.731","title":"TNF-Alpha Promotes Clonal Expansion of Tet2 Deficient Bone Marrow Progenitors in MDS","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Progenitor cell; Bone marrow; Haematopoiesis; Biology; Tumor necrosis factor alpha; Immunology; Molecular biology; Stem cell; Cancer research; Apoptosis; Cell biology; Genetics","score_opus":0.017285373236599753,"score_gpt":0.27559676202512234,"score_spread":0.2583113887885226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602461976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99666053,0.00049990584,0.000028447108,0.001143047,0.000056672474,0.0006617283,0.000014776872,0.000041337044,0.0008935258],"genre_scores_gemma":[0.99736804,0.00005276445,0.0015251209,0.000033614033,0.00013340371,0.000061601735,0.000008558896,0.000030222707,0.0007866679],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99827695,0.000067908855,0.00036030772,0.00030904348,0.0005795346,0.00040623083],"domain_scores_gemma":[0.9991457,0.00011210441,0.00007685235,0.00036682523,0.00014531662,0.0001531867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045378943,0.00014514892,0.00031221457,0.00025547337,0.000027525555,0.000005571267,0.00012884951,0.00012586772,0.00014916954],"category_scores_gemma":[0.00039442707,0.00009123775,0.000086095635,0.00034387098,0.00013876492,0.00006317643,0.00010882325,0.00017981652,0.00007175822],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023785139,0.0010578514,0.10744992,0.00015267824,0.000045378052,0.0002262882,0.00021352363,1.5429968e-7,0.8750779,0.0001041582,0.00038023922,0.015054051],"study_design_scores_gemma":[0.007834835,0.0007940778,0.052274168,0.00044674482,0.00006829408,0.00021500251,0.000094693394,0.000020910935,0.93717855,0.00010544052,0.00082402333,0.0001432662],"about_ca_topic_score_codex":0.000054263306,"about_ca_topic_score_gemma":0.000010598513,"teacher_disagreement_score":0.062100638,"about_ca_system_score_codex":0.00013625564,"about_ca_system_score_gemma":0.00046531565,"threshold_uncertainty_score":0.37205675},"labels":[],"label_agreement":null},{"id":"W2602588549","doi":"10.1182/blood.v128.22.2794.2794","title":"Relapse Following Initial Remission and Subsequent Outcome for Children with Relapsed Acute Myeloid Leukemia on the AAML0531 Phase III Study of Gemtuzumab Ozogamicin: A Report from the Children's Oncology Group","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; Cumulative incidence; Internal medicine; Oncology; Chemotherapy regimen; Induction chemotherapy; Univariate analysis; Chemotherapy; CD33; Surgery; Transplantation; Multivariate analysis; Stem cell","score_opus":0.027817250505030897,"score_gpt":0.33008278561666476,"score_spread":0.30226553511163384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602588549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99113446,0.00012444584,0.00016891035,0.0027653351,0.00015344426,0.0051437146,0.00012042546,0.00008591781,0.0003033396],"genre_scores_gemma":[0.9975675,0.00006895021,0.0004428707,0.0004972011,0.0005039918,0.00029742828,0.00015641362,0.000096837706,0.0003688476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963183,0.00036077428,0.00095425645,0.0008901313,0.00087684573,0.0005997142],"domain_scores_gemma":[0.9960931,0.0014765009,0.0005263733,0.0014600013,0.00019860458,0.00024539733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015265432,0.00043873757,0.0009377992,0.00014520348,0.00040454292,0.000031162297,0.00048370435,0.00027117663,0.00003508843],"category_scores_gemma":[0.0012510279,0.00018962327,0.00023604828,0.00030078573,0.00029243386,0.0001315564,0.00027136967,0.000728829,0.0000059653357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035922367,0.010627019,0.8002249,0.000046220823,0.015567587,0.0041724844,0.007547276,0.0000030032022,0.09439075,0.0003309909,0.006644321,0.024523085],"study_design_scores_gemma":[0.35630727,0.037257437,0.5562064,0.0009813877,0.009625432,0.0033405176,0.0023263542,0.00004244785,0.03144147,0.0002346765,0.0012546398,0.0009819538],"about_ca_topic_score_codex":0.000881849,"about_ca_topic_score_gemma":0.00011104499,"teacher_disagreement_score":0.32038492,"about_ca_system_score_codex":0.00061743194,"about_ca_system_score_gemma":0.0007448984,"threshold_uncertainty_score":0.77326125},"labels":[],"label_agreement":null},{"id":"W2605064360","doi":"10.1182/blood-2017-01-764324","title":"Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children; Izaak Walton Killam Health Centre; Dalhousie University","funders":"National Cancer Institute","keywords":"Medicine; Myeloid leukemia; Oncology; Internal medicine; Leukemia; Pediatrics","score_opus":0.02602040476858037,"score_gpt":0.3267331675037752,"score_spread":0.3007127627351948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605064360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99013275,0.00015894583,0.00011075515,0.0040315907,0.0005079127,0.003425063,0.00019395212,0.00005998581,0.0013790419],"genre_scores_gemma":[0.99321616,0.000053619,0.0030736448,0.0003699808,0.00083225855,0.0004701838,0.00023403327,0.000059174563,0.0016909273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975888,0.0000943221,0.0007640035,0.0005674591,0.00045583397,0.0005295642],"domain_scores_gemma":[0.99579734,0.00087583886,0.0007242258,0.0022127852,0.00019681707,0.00019302635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011744763,0.00027066117,0.0009857785,0.000079405625,0.00038250073,0.000060093236,0.0008660156,0.00035237946,0.00010210488],"category_scores_gemma":[0.0039542406,0.0001703716,0.00043625096,0.00006881883,0.00041216615,0.00011771479,0.0003639081,0.00054894673,0.000018274235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0716311,0.0059270565,0.7265341,0.00031386683,0.011527513,0.004137386,0.001485185,9.985956e-7,0.09671379,0.0006424839,0.03614176,0.04494471],"study_design_scores_gemma":[0.2059743,0.0037238488,0.77286816,0.000076832446,0.0014296728,0.0017610759,0.00010034073,0.00006161374,0.007012195,0.00033529176,0.006367309,0.00028934696],"about_ca_topic_score_codex":0.0033643085,"about_ca_topic_score_gemma":0.00024454354,"teacher_disagreement_score":0.13434319,"about_ca_system_score_codex":0.00035542733,"about_ca_system_score_gemma":0.0014537642,"threshold_uncertainty_score":0.69475526},"labels":[],"label_agreement":null},{"id":"W2605707138","doi":"10.1182/blood.v128.22.1705.1705","title":"CD200 Is a Marker of LSC Activity in Acute Myeloid Leukemia","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Toronto; Princess Margaret Cancer Centre; McGill University; University Health Network","funders":"","keywords":"CD34; CD38; Stem cell; Population; Myeloid leukemia; Biology; Leukemia; Myeloid; Haematopoiesis; Immunology; Bone marrow; Stem cell marker; Molecular biology; Side population; Cancer research; Medicine; Cancer stem cell; Cell biology","score_opus":0.015627541688724073,"score_gpt":0.2832251319817756,"score_spread":0.2675975902930515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605707138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879529,0.00013776796,0.00004749011,0.0022377863,0.00003585698,0.0003684279,0.000045285866,0.000039159517,0.00913533],"genre_scores_gemma":[0.99033624,0.00034281888,0.000649407,0.00030818893,0.00009468602,0.000032661246,0.0000028132533,0.000034992456,0.008198217],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99841577,0.000075320626,0.0002630923,0.00034864293,0.00044181553,0.00045533362],"domain_scores_gemma":[0.99883837,0.0001716893,0.00008064707,0.00059019367,0.00010361588,0.00021551336],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037664405,0.00016938247,0.0004324824,0.00023979289,0.000022881093,0.000005754061,0.00019072699,0.00017810168,0.0014522296],"category_scores_gemma":[0.00026173948,0.00011245717,0.00011695028,0.0003817351,0.00014282376,0.00011972104,0.00014506796,0.0002821659,0.0002477597],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096197147,0.0005569668,0.15042359,0.00012973396,0.00034264082,0.00039220776,0.00024189908,7.1347316e-8,0.8096876,0.000047808684,0.007587895,0.029627578],"study_design_scores_gemma":[0.014095293,0.0003961766,0.38276342,0.00032029455,0.0001981185,0.0001729966,0.000028445444,0.000052519295,0.5958332,0.00010692115,0.005819849,0.0002128241],"about_ca_topic_score_codex":0.00023166179,"about_ca_topic_score_gemma":0.000028628127,"teacher_disagreement_score":0.23233981,"about_ca_system_score_codex":0.00045412924,"about_ca_system_score_gemma":0.0010051184,"threshold_uncertainty_score":0.9994606},"labels":[],"label_agreement":null},{"id":"W2606566776","doi":"10.1182/blood-2017-03-772384","title":"Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children’s Oncology Group report","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medicine; Pediatric oncology; Oncology; Myeloid leukemia; Internal medicine; Leukemia; Pediatrics; Cancer","score_opus":0.02062085654835358,"score_gpt":0.31165989809748856,"score_spread":0.29103904154913496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606566776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99170375,0.00059246446,0.000011843868,0.0021089038,0.00009461399,0.0009996569,0.000022858305,0.00005946481,0.004406447],"genre_scores_gemma":[0.9932462,0.0018174779,0.0021461952,0.00019330304,0.00079623214,0.0001338657,0.00006922972,0.000052968528,0.0015445589],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792546,0.00006939688,0.00049761607,0.0006584411,0.0002606554,0.0005884435],"domain_scores_gemma":[0.99816895,0.00009018706,0.00026199134,0.0011316704,0.000037271275,0.00030990594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039332814,0.0003018596,0.000704973,0.00033177747,0.00023068077,0.000058784084,0.00028357352,0.0003138801,0.00002857129],"category_scores_gemma":[0.00023540943,0.00023472328,0.00013003971,0.000097892414,0.00017250144,0.000075288364,0.0002998711,0.00065613125,0.000044627443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021550125,0.00045641285,0.97196,0.000031200183,0.0002776399,0.009493679,0.00027559008,0.0000012660034,0.0019510704,0.00001934272,0.00010330358,0.015214982],"study_design_scores_gemma":[0.013787515,0.001246261,0.97088367,0.000012249936,0.000728069,0.0108442055,0.000016784812,0.000011134277,0.000336273,0.00005562658,0.0018738719,0.00020433714],"about_ca_topic_score_codex":0.0010563806,"about_ca_topic_score_gemma":0.00052373996,"teacher_disagreement_score":0.015010646,"about_ca_system_score_codex":0.0012313111,"about_ca_system_score_gemma":0.00080920674,"threshold_uncertainty_score":0.95717376},"labels":[],"label_agreement":null},{"id":"W2607182299","doi":"10.1182/blood.v112.11.681.681","title":"MN1 Overexpression Promotes Proliferation and Self-Renewal of Primitive Normal Human Hematopoietic Cells","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Haematopoiesis; Cord blood; Biology; CD34; Cell culture; Molecular biology; Leukemia; Myeloid; Stem cell; Transfection; Immunology; Cancer research; Cell biology; Genetics","score_opus":0.015088923504081751,"score_gpt":0.26427938607163864,"score_spread":0.2491904625675569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607182299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99625313,0.00009962402,0.00001556117,0.00008874214,0.00001082977,0.00063604943,0.0000061907863,0.000055211003,0.002834641],"genre_scores_gemma":[0.99709,0.00005839552,0.0021642789,0.00003167395,0.00011495482,0.000027487415,0.000021034637,0.000020200603,0.00047198837],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989402,0.000051238494,0.00022728209,0.00022109045,0.00034678454,0.00021336401],"domain_scores_gemma":[0.999412,0.0000432145,0.000079796926,0.00020541078,0.00013599935,0.00012357032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012313001,0.00012188817,0.00023977508,0.00009029308,0.00012090182,0.0000076217393,0.000060076094,0.00010418877,0.000045930814],"category_scores_gemma":[0.000047000347,0.00009971304,0.000041211944,0.00010343088,0.000109879315,0.00008908706,0.00008108421,0.0001792869,0.000008906735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007118926,0.0012025376,0.028893247,0.00034448964,0.000079778736,0.000077930374,0.0024962418,4.412021e-7,0.9663735,0.00012373734,0.00029265124,0.00004425659],"study_design_scores_gemma":[0.0039695916,0.0007052391,0.023959836,0.00017549265,0.000087667184,0.00039048976,0.00006201505,0.00006145193,0.9703948,0.00004832922,0.000047625785,0.00009744862],"about_ca_topic_score_codex":0.000025969344,"about_ca_topic_score_gemma":0.0000016573418,"teacher_disagreement_score":0.004933411,"about_ca_system_score_codex":0.00003504449,"about_ca_system_score_gemma":0.00019849249,"threshold_uncertainty_score":0.40661797},"labels":[],"label_agreement":null},{"id":"W2607531045","doi":"10.1111/bjh.14720","title":"Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia","year":2017,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"Barncancerfonden; International Business Machines Corporation","keywords":"Medicine; Myeloid leukaemia; Hematology; Stem cell; Myeloid; Oncology; Internal medicine; Intensive care medicine","score_opus":0.029290773422042834,"score_gpt":0.29209955568642304,"score_spread":0.2628087822643802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607531045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863784,0.0097569,0.000073295996,0.0028978935,0.000420217,0.00032158077,0.000013224639,0.000010779842,0.00012772315],"genre_scores_gemma":[0.9818004,0.016465949,0.00053506333,0.00058502884,0.00019057491,0.000014019918,0.0000040059913,0.000037021142,0.00036796115],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9978941,0.00020775874,0.00085448986,0.0002887538,0.00031760207,0.00043729783],"domain_scores_gemma":[0.9983839,0.00010851301,0.0005104618,0.00031868022,0.00044028813,0.00023817476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073329825,0.00019390078,0.00097481784,0.00038510057,0.00014359165,0.00007938279,0.00029453242,0.00032789793,0.000051554867],"category_scores_gemma":[0.00012664458,0.00018164598,0.00017579274,0.00010051425,0.00028984362,0.00028873576,0.000072967094,0.0012314735,0.000013165338],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005421761,0.00021547319,0.41747206,0.0003292316,0.00040997952,0.4881253,0.0013755244,0.0000034339587,0.017352596,0.000028579816,0.0025721595,0.06669392],"study_design_scores_gemma":[0.013116939,0.0009500263,0.29955518,0.00041536934,0.00026083452,0.67557144,0.000571008,0.000038151207,0.00816632,0.00015119542,0.0009087492,0.0002947731],"about_ca_topic_score_codex":0.00014386358,"about_ca_topic_score_gemma":0.000104371786,"teacher_disagreement_score":0.18744618,"about_ca_system_score_codex":0.00018235113,"about_ca_system_score_gemma":0.0002853805,"threshold_uncertainty_score":0.7407308},"labels":[],"label_agreement":null},{"id":"W2607649265","doi":"10.1182/blood.v128.22.906.906","title":"Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytarabine; Medicine; Daunorubicin; Internal medicine; Induction chemotherapy; Gastroenterology; Leukemia; Transplantation; Surgery; Myeloid leukemia; Chemotherapy regimen; Randomized controlled trial; Chemotherapy; Oncology","score_opus":0.009812300967628565,"score_gpt":0.2733147008563751,"score_spread":0.2635023998887465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607649265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968203,0.00007388502,0.00080375007,0.00003458829,0.00012150277,0.0014019723,0.00057355297,0.00005812294,0.00011235057],"genre_scores_gemma":[0.9983164,0.0005303995,0.00023703295,0.000016384618,0.00008087316,0.00008049471,0.0006235982,0.00005634292,0.000058481342],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969202,0.00030364844,0.00074651197,0.0006287594,0.0008519782,0.00054889906],"domain_scores_gemma":[0.9985751,0.00033337926,0.00030108314,0.0003562174,0.00021792443,0.00021629389],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064235093,0.0003589759,0.0011066351,0.0009585844,0.00010455597,0.00002405192,0.0001303858,0.00023682509,0.000064399166],"category_scores_gemma":[0.00008078661,0.0002518087,0.00022259358,0.0015125606,0.00009432082,0.00025446707,0.000040640618,0.00028679002,0.0000030232643],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51924366,0.004148649,0.3889122,0.00028484693,0.010071088,0.0011321328,0.002495102,0.000051058527,0.07122086,0.000022491486,0.0000150346195,0.0024029075],"study_design_scores_gemma":[0.789249,0.015047831,0.11786172,0.00024963898,0.017760647,0.00001727084,0.00020078846,0.000101652586,0.05909775,0.000005993164,0.000006202124,0.00040147835],"about_ca_topic_score_codex":0.00091510115,"about_ca_topic_score_gemma":0.0009646952,"teacher_disagreement_score":0.27105048,"about_ca_system_score_codex":0.00046146743,"about_ca_system_score_gemma":0.0003848896,"threshold_uncertainty_score":0.99999344},"labels":[],"label_agreement":null},{"id":"W2607762492","doi":"10.1182/blood-2017-01-764951","title":"Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias","year":2017,"lang":"en","type":"letter","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Stem cell; Medicine; Transplantation; Immunology; Internal medicine; Biology; Genetics","score_opus":0.022244495493890164,"score_gpt":0.25529660750469013,"score_spread":0.23305211201079998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607762492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84064114,0.00031576247,0.000014147645,0.13487123,0.00025793514,0.002488738,0.0006396542,0.0002391845,0.020532181],"genre_scores_gemma":[0.6913511,0.00044819195,0.0005625658,0.18338333,0.0052452604,0.00052123156,0.0043804967,0.00071063224,0.113397144],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952387,0.00024332103,0.0006212653,0.0011763166,0.0014721138,0.0012482586],"domain_scores_gemma":[0.99614966,0.00020672186,0.00046956335,0.0025463435,0.00022950221,0.00039822495],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00039418496,0.0008746173,0.0015332727,0.00043953367,0.00038392984,0.00019714113,0.0012168466,0.0015063842,0.00027017723],"category_scores_gemma":[0.000014514044,0.0006579206,0.00031847882,0.00024501857,0.00036900764,0.00017280146,0.00016304992,0.005072888,0.00039021074],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010582592,0.00054662395,0.07214465,0.001246382,0.0013085399,0.030621143,0.00143552,3.7440324e-7,0.0008448793,0.0000010564611,0.89023423,0.00055833126],"study_design_scores_gemma":[0.049785525,0.0033760536,0.050140034,0.0061559617,0.006045921,0.0024695233,0.00012453813,0.00007396845,0.049107965,0.000014651921,0.83004725,0.0026585942],"about_ca_topic_score_codex":0.00078421773,"about_ca_topic_score_gemma":0.00012112295,"teacher_disagreement_score":0.14929003,"about_ca_system_score_codex":0.0002969975,"about_ca_system_score_gemma":0.0006374245,"threshold_uncertainty_score":0.9997899},"labels":[],"label_agreement":null},{"id":"W2609406841","doi":"10.1002/pbc.26612","title":"Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group","year":2017,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"National Institutes of Health; Children’s Oncology Group; National Cancer Institute; St. Baldrick's Foundation","keywords":"Medicine; Internal medicine; Myeloid leukemia; Disease; Central nervous system; Overall survival; Myeloid; Oncology; Gastroenterology","score_opus":0.013418672308656935,"score_gpt":0.2935980482402192,"score_spread":0.2801793759315622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609406841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795253,0.01121786,0.000031969143,0.0045127408,0.0013333631,0.0016901038,0.0003413437,0.0001790262,0.001168262],"genre_scores_gemma":[0.9665141,0.015525489,0.00021387792,0.0005071981,0.015704257,0.000573603,0.00022265073,0.000109252825,0.0006295747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952191,0.0002298871,0.00092386303,0.0011674507,0.0010455261,0.0014141877],"domain_scores_gemma":[0.99548304,0.0003507816,0.00078662793,0.0022765356,0.00019223793,0.0009107967],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007250836,0.0005102407,0.00092166703,0.00027262943,0.0006106391,0.00016619264,0.0012391271,0.0004069573,0.00014783308],"category_scores_gemma":[0.00064426794,0.00037360907,0.0003383138,0.0005658861,0.00021093797,0.00029224213,0.00063753617,0.0016403918,0.00008082053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006545111,0.0002443309,0.9719381,0.0002068966,0.0003136575,0.009892867,0.00022367464,0.00003535899,0.00002899336,0.000039361446,0.013566589,0.0028556834],"study_design_scores_gemma":[0.006039907,0.00016703352,0.98618275,0.000051997435,0.004677034,0.000456693,0.000052626816,0.00026391735,0.000018033636,0.000030256877,0.0016723701,0.00038738683],"about_ca_topic_score_codex":0.0227198,"about_ca_topic_score_gemma":0.0012094539,"teacher_disagreement_score":0.021510346,"about_ca_system_score_codex":0.0024191213,"about_ca_system_score_gemma":0.0054863133,"threshold_uncertainty_score":0.9998716},"labels":[],"label_agreement":null},{"id":"W2609558812","doi":"10.1182/blood.v128.22.899.899","title":"The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Etoposide; Oncology; Mitoxantrone; Chemotherapy; Bortezomib; Induction chemotherapy; Gemtuzumab ozogamicin; Idarubicin; Leukemia; Minimal residual disease; Myeloid leukemia; Surgery; Multiple myeloma; Stem cell; CD33","score_opus":0.016141066221819492,"score_gpt":0.29011373622437386,"score_spread":0.2739726700025544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609558812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98150706,0.00048093635,0.002601928,0.011015387,0.00014039822,0.002778188,0.0011594219,0.00008813326,0.0002285202],"genre_scores_gemma":[0.99231833,0.0010528276,0.0022912296,0.0018722839,0.001406904,0.00037414164,0.0002281286,0.00008948261,0.0003666898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973072,0.0001525386,0.00066687557,0.00057221943,0.00069973303,0.00060146605],"domain_scores_gemma":[0.9962411,0.0015853802,0.0003972666,0.0011239456,0.00040319786,0.00024911025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012722099,0.00030525526,0.0006282614,0.00010496566,0.00038139944,0.000046322442,0.00051405333,0.00025243845,0.00012527966],"category_scores_gemma":[0.0005856004,0.00014622923,0.000264541,0.0003695335,0.0002914032,0.000089882706,0.00011481676,0.0003115431,0.000016019669],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030557858,0.0018194199,0.36129344,0.00008309392,0.007408821,0.0002575944,0.0015415952,0.0000024193823,0.3380642,0.0009283478,0.060779884,0.19726335],"study_design_scores_gemma":[0.050807633,0.006932064,0.7389285,0.00018314559,0.00349829,0.0008379046,0.00018914629,0.00004448539,0.12870899,0.0031767047,0.065997936,0.0006952132],"about_ca_topic_score_codex":0.000440015,"about_ca_topic_score_gemma":0.00023206096,"teacher_disagreement_score":0.37763506,"about_ca_system_score_codex":0.00069409487,"about_ca_system_score_gemma":0.0016007195,"threshold_uncertainty_score":0.5963055},"labels":[],"label_agreement":null},{"id":"W2609603988","doi":"10.1002/ajmg.a.38119","title":"A case of familial transmission of the newly described <i>DNMT3A</i>‐Overgrowth Syndrome","year":2017,"lang":"en","type":"article","venue":"American Journal of Medical Genetics Part A","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Macrocephaly; Proband; Genetics; Short stature; Missense mutation; Sanger sequencing; Exome sequencing; Exon; Mutation; Medicine; Biology; Pediatrics; Gene","score_opus":0.026576707472196787,"score_gpt":0.32275777747433365,"score_spread":0.2961810700021369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609603988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99188274,0.0004425447,0.0012890304,0.0056381347,0.00023962435,0.00018544252,0.0000112358,0.0000034549432,0.00030778465],"genre_scores_gemma":[0.9951495,0.0013504124,0.002831381,0.00033633807,0.00020642833,0.000001830011,6.66858e-7,0.000026272712,0.00009716822],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9964034,0.00022117226,0.0009160072,0.00016481202,0.0019619872,0.000332649],"domain_scores_gemma":[0.9968603,0.00021881546,0.0010813099,0.0007167818,0.00038989092,0.0007328567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013424415,0.00016606925,0.0008137218,0.00011288734,0.00013068975,0.000014313805,0.0009847782,0.00012475518,0.00015974295],"category_scores_gemma":[0.0012851323,0.00010055293,0.0003652073,0.00022243071,0.002050449,0.000047673595,0.00019845377,0.00083636283,0.0000023948462],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046869214,0.0016275666,0.07059399,0.00062634423,0.001566254,0.03823518,0.0037567264,0.00006391512,0.061613403,0.00012917508,0.011411329,0.8056892],"study_design_scores_gemma":[0.045084957,0.042598438,0.27428356,0.0093089,0.0035162964,0.4297023,0.0063772257,0.0113821905,0.13075708,0.00075159344,0.044943057,0.0012944154],"about_ca_topic_score_codex":0.0002896929,"about_ca_topic_score_gemma":0.000014840031,"teacher_disagreement_score":0.8043948,"about_ca_system_score_codex":0.0000761786,"about_ca_system_score_gemma":0.001749984,"threshold_uncertainty_score":0.75549644},"labels":[],"label_agreement":null},{"id":"W2610901832","doi":"10.3747/co.24.3485","title":"Characteristics Predicting Outcomes of Allogeneic Stem-Cell Transplantation in Relapsed Acute Myelogenous Leukemia","year":2017,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Cohort; Transplantation; Hematopoietic stem cell transplantation; Population; Oncology; Myeloid leukemia; Proportional hazards model; Retrospective cohort study; Confidence interval","score_opus":0.07705150479981326,"score_gpt":0.3916373337355074,"score_spread":0.31458582893569415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610901832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956016,0.00028861195,0.00014201293,0.00048328866,0.00087588996,0.0006783089,0.00009476649,0.00003598967,0.0017995513],"genre_scores_gemma":[0.9962233,0.0026402785,0.00031670657,0.0000566273,0.00014741566,0.000059446207,0.00013123298,0.000032400894,0.0003926354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980392,0.00014574961,0.00067251275,0.00036295605,0.00030807217,0.0004714976],"domain_scores_gemma":[0.99830514,0.0002387742,0.0005017346,0.00062717195,0.00016886655,0.00015830292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000570153,0.00021135533,0.00078815746,0.00023600101,0.0001509943,0.000016136257,0.00040230685,0.00027892328,0.00005007003],"category_scores_gemma":[0.00014467564,0.0001870109,0.00012376688,0.00008188963,0.00024697237,0.00008043933,0.000109613095,0.0006911622,0.00004978425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070139265,0.0003850308,0.90353477,0.00048252285,0.00011034976,0.00046945974,0.0013159073,0.0000041712997,0.017796269,0.00003435131,0.00017185594,0.0749939],"study_design_scores_gemma":[0.0068222624,0.00081266253,0.98334664,0.00014518194,0.0003415028,0.00014097845,0.00012894046,0.0008020094,0.0051737837,0.000018299957,0.002101121,0.00016662345],"about_ca_topic_score_codex":0.000075991644,"about_ca_topic_score_gemma":0.0000524976,"teacher_disagreement_score":0.07981185,"about_ca_system_score_codex":0.0011195267,"about_ca_system_score_gemma":0.0011411938,"threshold_uncertainty_score":0.76260835},"labels":[],"label_agreement":null},{"id":"W2610988607","doi":"10.1016/j.leukres.2017.11.005","title":"Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?","year":2017,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Myelodysplastic syndromes; Chelation therapy; Medicine; Internal medicine; Chelation; International Prognostic Scoring System; Oncology; Chemistry","score_opus":0.06300820510607573,"score_gpt":0.3745029270335802,"score_spread":0.31149472192750444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610988607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744105,0.000525663,0.00003293176,0.0027698944,0.00024687036,0.0013956256,0.000022045793,0.00009005013,0.020506442],"genre_scores_gemma":[0.9848802,0.0028069383,0.00038718074,0.0000691418,0.00049794954,0.000199412,0.000055158802,0.00011817383,0.010985835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99407953,0.00044119265,0.000569091,0.0010304989,0.0022139302,0.0016657391],"domain_scores_gemma":[0.9948354,0.0009972191,0.00019755318,0.002437914,0.0010138554,0.0005181086],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003967852,0.00037477043,0.0006366109,0.0010299959,0.0011123095,0.00038571356,0.0011845184,0.0005862019,0.0008076551],"category_scores_gemma":[0.004644149,0.00032155024,0.0001394158,0.0009966107,0.00060524564,0.00055738847,0.0005732626,0.0036618763,0.0015993667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010072498,0.0008749369,0.80128396,0.0005598941,0.00033696188,0.0024938097,0.0021328328,0.00074631145,0.03472257,0.0023621356,0.0069325226,0.13748156],"study_design_scores_gemma":[0.0087461155,0.0013841597,0.9655079,0.00036922065,0.000024112182,0.00012472863,0.000179438,0.011983172,0.0039134184,0.0014761267,0.005891585,0.0004000277],"about_ca_topic_score_codex":0.0048836973,"about_ca_topic_score_gemma":0.0014356351,"teacher_disagreement_score":0.16422392,"about_ca_system_score_codex":0.0054679676,"about_ca_system_score_gemma":0.002786416,"threshold_uncertainty_score":0.99992365},"labels":[],"label_agreement":null},{"id":"W2611139037","doi":"10.11144/javeriana.10554.19646","title":"Characterization and targeting of metabolic alterations in the leukemic microenvironment","year":2020,"lang":"en","type":"dissertation","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency; Departamento Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS)","keywords":"Bone marrow; Paracrine signalling; Leukemia; Oxidative phosphorylation; Cell biology; Mesenchymal stem cell; Tumor microenvironment; Haematopoiesis; Stromal cell; Context (archaeology); Stem cell; Cancer research; Chemistry; Biology; Biochemistry; Immunology; Receptor","score_opus":0.013831418465296851,"score_gpt":0.2773133003984834,"score_spread":0.26348188193318656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611139037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942922,0.00078385125,0.00015328903,0.0014149912,0.00004258801,0.0007833657,0.000015654916,0.000008957556,0.0025050733],"genre_scores_gemma":[0.980838,0.0030487918,0.0007139801,0.00069381855,0.0001444612,0.00009580512,0.0080695925,0.000032812786,0.0063627074],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989414,0.00008051302,0.0003522758,0.00022239401,0.0002648112,0.0001385792],"domain_scores_gemma":[0.99958724,0.000052586736,0.00012389726,0.00015708388,0.00003408352,0.00004513949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020137415,0.00014019117,0.00031172595,0.00014261596,0.00003963712,0.000018140474,0.00009446722,0.00011359238,0.00014323673],"category_scores_gemma":[0.000095333766,0.00009754023,0.000046297624,0.00019655994,0.00002911712,0.00005428151,0.000019285253,0.00038205774,0.00001620682],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014184444,0.00004774063,0.0013800142,0.00030541906,0.00004911466,0.000011514478,0.0055024647,9.983492e-7,0.98790103,0.00064929505,0.0003084698,0.0037020973],"study_design_scores_gemma":[0.0027216705,0.00026076834,0.63174826,0.00042058845,0.00045900914,0.000041412775,0.011800547,0.0030268715,0.30746725,0.000042024967,0.041610286,0.00040129037],"about_ca_topic_score_codex":0.00008509151,"about_ca_topic_score_gemma":0.000032200544,"teacher_disagreement_score":0.68043375,"about_ca_system_score_codex":0.000057589496,"about_ca_system_score_gemma":0.00017777174,"threshold_uncertainty_score":0.3977575},"labels":[],"label_agreement":null},{"id":"W2611202021","doi":"10.1182/blood.v128.22.4616.4616","title":"Anti-Thymocyte Globulin Kills Leukemic Stem Cells in Vitro","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Foothills Medical Centre; Alberta Health Services; University of Alberta; University of Calgary","funders":"","keywords":"Anti-thymocyte globulin; Leukemia; Stem cell; Immunology; Myeloid leukemia; Haematopoiesis; Peripheral blood mononuclear cell; Flow cytometry; Transplantation; Hematopoietic stem cell transplantation; Graft-versus-host disease; CD34; Medicine; Biology; Cancer research; In vitro; Internal medicine; Globulin","score_opus":0.01511192327513591,"score_gpt":0.259114402957377,"score_spread":0.24400247968224106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611202021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99435186,0.00059023773,0.000063204556,0.001220535,0.00011527657,0.00049272925,0.000037652153,0.00010240509,0.0030260698],"genre_scores_gemma":[0.9912501,0.00052741077,0.0006790093,0.00036865816,0.0002625316,0.000029143397,0.000005993298,0.000050159244,0.006826987],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99802065,0.00008864071,0.00035764562,0.00044370777,0.0004404217,0.00064894994],"domain_scores_gemma":[0.99880856,0.00019505515,0.00006278092,0.0005967659,0.00008193995,0.00025490366],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003831982,0.00020506638,0.00044818976,0.00023298782,0.000035434463,0.000016568212,0.00025239366,0.00018099094,0.00015748998],"category_scores_gemma":[0.00006841937,0.00013675111,0.000105693114,0.0003602383,0.00010735853,0.00010439818,0.00014033326,0.00030333965,0.0014157548],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021723629,0.00030790246,0.006689156,0.000053244952,0.00006039769,0.000656689,0.0000682973,5.2237044e-7,0.975585,0.000021149071,0.0015840151,0.014756416],"study_design_scores_gemma":[0.012072809,0.0001566449,0.010730101,0.00020354571,0.00006216382,0.00012285436,0.000044792563,0.00002753279,0.96797603,0.000021154594,0.00839319,0.00018919434],"about_ca_topic_score_codex":0.00008858207,"about_ca_topic_score_gemma":0.000005784125,"teacher_disagreement_score":0.014567222,"about_ca_system_score_codex":0.00044943945,"about_ca_system_score_gemma":0.00051322376,"threshold_uncertainty_score":0.99936175},"labels":[],"label_agreement":null},{"id":"W2611533293","doi":"10.1182/blood.v128.22.2790.2790","title":"Excess Treatment-Related Mortality in Obese Children and Adolescents with Acute Myeloid Leukemia on AAML0531: A Report from the Children's Oncology Group","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Induction chemotherapy; Hematopoietic stem cell transplantation; Chemotherapy; Transplantation; Underweight; Body mass index; Oncology; Leukemia; Pediatrics; Overweight","score_opus":0.011588120132491867,"score_gpt":0.27981629410621955,"score_spread":0.26822817397372767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611533293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959699,0.00030181638,0.000008806906,0.0012758715,0.00004882436,0.001543769,0.00013449666,0.00009567186,0.0006208301],"genre_scores_gemma":[0.9977351,0.00082944287,0.00011069381,0.00030469507,0.00022449561,0.00010840174,0.00023001939,0.00006208829,0.0003950749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972334,0.00025039207,0.00050332263,0.0008828866,0.00052148703,0.00060850935],"domain_scores_gemma":[0.99821043,0.000175092,0.00021316583,0.0010500719,0.000063405496,0.00028784448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039267883,0.00039263128,0.00065538357,0.0001382286,0.000117575946,0.00002891592,0.0002731357,0.00030696264,0.000056185527],"category_scores_gemma":[0.00012557485,0.00018845417,0.00009674798,0.0003396771,0.00038208207,0.000126351,0.00014676328,0.0005121652,0.000053617987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009925395,0.0012037265,0.9809917,0.0000063157245,0.0013935362,0.0033072003,0.00025520075,4.0302368e-7,0.0026652098,0.000016398457,0.00018252371,0.008985206],"study_design_scores_gemma":[0.02861208,0.0016201608,0.962864,0.00051274674,0.0008197113,0.0024765697,0.000026823513,0.000004908414,0.0026774625,0.000066670094,0.000087476496,0.00023139581],"about_ca_topic_score_codex":0.0052871383,"about_ca_topic_score_gemma":0.0011583719,"teacher_disagreement_score":0.027619539,"about_ca_system_score_codex":0.0009956739,"about_ca_system_score_gemma":0.000777061,"threshold_uncertainty_score":0.7992607},"labels":[],"label_agreement":null},{"id":"W2611734568","doi":"10.1182/blood.v128.22.5550.5550","title":"Comparison of the IPSS and IPSS-R in Predicting Survival and Response of Myelodysplastic Syndrome Patients to 5-Azacitidine","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Azacitidine; International Prognostic Scoring System; Medicine; Myelodysplastic syndromes; Internal medicine; Oncology; Cohort; Decitabine; Bone marrow","score_opus":0.02047426465743408,"score_gpt":0.29904641992612563,"score_spread":0.27857215526869156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611734568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988748,0.000070470924,0.000012462494,0.00044253733,0.000045057568,0.00042375017,0.000045631252,0.000008913319,0.00007642118],"genre_scores_gemma":[0.99968785,0.000010928804,0.00013811496,0.000013077719,0.000014086813,0.0000096375925,0.0000012903704,0.000014504297,0.00011048009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872327,0.00017757202,0.00033814728,0.0001964717,0.0003538695,0.00021064973],"domain_scores_gemma":[0.99860597,0.0008431638,0.000090673304,0.0002434038,0.000100995254,0.00011576893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005511795,0.00009851191,0.0003565355,0.0001549681,0.000028267901,0.0000037921254,0.0001002019,0.00006469795,0.000011126987],"category_scores_gemma":[0.002056066,0.000057559137,0.000023541095,0.00025189813,0.00015181948,0.00004196478,0.00021121088,0.00013036176,0.0000018469833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001232561,0.00027717388,0.9459409,0.00010522765,0.000037309685,0.000011303214,0.0006446822,8.3127924e-7,0.0510086,0.000010395478,0.000026252852,0.00070472795],"study_design_scores_gemma":[0.0062605306,0.001003212,0.9693863,0.00056768325,0.000054024455,0.00003222002,0.00019488015,0.000047615442,0.02236746,0.0000071140284,0.00002181077,0.000057155925],"about_ca_topic_score_codex":0.000048781592,"about_ca_topic_score_gemma":0.000031942152,"teacher_disagreement_score":0.02864114,"about_ca_system_score_codex":0.00004806883,"about_ca_system_score_gemma":0.0001075719,"threshold_uncertainty_score":0.24614514},"labels":[],"label_agreement":null},{"id":"W2613385908","doi":"10.1182/blood.v128.22.4652.4652","title":"Fludarabine/Busulfan Plus Low Dose TBI As Reduced Intensity Conditioning in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Myeloid Malignancies","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Fludarabine; Busulfan; Internal medicine; Regimen; Total body irradiation; Myeloid leukemia; Myeloid; Transplantation; Clofarabine; Hematopoietic stem cell transplantation; Population; Gastroenterology; Oncology; Cytarabine; Surgery; Chemotherapy; Cyclophosphamide","score_opus":0.012972409280034156,"score_gpt":0.2527781063836014,"score_spread":0.23980569710356722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613385908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616826,0.0001528554,0.00039744365,0.0010260915,0.00013782803,0.0014416246,0.00007474657,0.000091998336,0.00050916977],"genre_scores_gemma":[0.99704754,0.00012343876,0.000741892,0.0004664156,0.00011911162,0.00018113836,0.00014839262,0.000071496484,0.0011005942],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99763453,0.00007019528,0.000521068,0.00057691033,0.00044198785,0.0007553141],"domain_scores_gemma":[0.99852175,0.0003683242,0.00012948908,0.00042037887,0.00030805724,0.00025203422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003432013,0.0003013172,0.0005513682,0.0002646464,0.00014109719,0.00002925662,0.00020578525,0.00020672743,0.000116643954],"category_scores_gemma":[0.00035890378,0.00022454625,0.00016376346,0.00025064332,0.00014337397,0.00014940025,0.000070692266,0.00024282277,0.00010287703],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017521974,0.001911824,0.08897836,0.001652334,0.00025473165,0.0005334139,0.0035157932,0.00001692637,0.89878124,0.00025337233,0.0013784622,0.00097131974],"study_design_scores_gemma":[0.048820425,0.0011291906,0.13998036,0.0027245667,0.000300602,0.00026519407,0.0006158783,0.000060422986,0.8050506,0.00038112176,0.00011369012,0.00055790925],"about_ca_topic_score_codex":0.000052384243,"about_ca_topic_score_gemma":0.000047206137,"teacher_disagreement_score":0.09373063,"about_ca_system_score_codex":0.00041030126,"about_ca_system_score_gemma":0.0007310765,"threshold_uncertainty_score":0.9156731},"labels":[],"label_agreement":null},{"id":"W2613537197","doi":"10.1182/blood.v128.22.5253.5253","title":"RUNX1 Mutation in Cytogenetically Normal Acute Myeloid Leukemia : Clinical Implications, Co-Mutation Analysis","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"CEBPA; NPM1; Neuroblastoma RAS viral oncogene homolog; RUNX1; Myeloid leukemia; Mutation; Leukemia; Biology; Myeloid; Oncology; Medicine; Cancer research; Internal medicine; Genetics; Karyotype; Gene; Haematopoiesis; Chromosome; Stem cell; KRAS","score_opus":0.02836690807924474,"score_gpt":0.36383829173010257,"score_spread":0.3354713836508578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613537197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98649114,0.000077086544,0.006479202,0.0043650297,0.000033028853,0.00056911877,0.00006346781,0.000090163034,0.0018317801],"genre_scores_gemma":[0.99333787,0.00031659508,0.004593872,0.00044496093,0.00022709974,0.00012355772,0.00026539687,0.000034654815,0.00065599504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973319,0.0002195351,0.00089595607,0.0005787,0.00047737974,0.00049648574],"domain_scores_gemma":[0.99810046,0.00047746536,0.00016663231,0.000653137,0.00028445615,0.0003178498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095126824,0.00019928976,0.0005091918,0.0006129619,0.000078559584,0.000030509016,0.00022987968,0.00027299186,0.00022373727],"category_scores_gemma":[0.00057837635,0.00014899383,0.00026972333,0.0012445013,0.00018671408,0.00016861607,0.00007326528,0.00032773826,0.00042545956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048384635,0.00067518407,0.89247286,0.000029565212,0.0021429304,0.0004503595,0.00015030353,0.000029445097,0.047987234,0.0006216945,0.00080927345,0.054147303],"study_design_scores_gemma":[0.008442367,0.00043794198,0.9725473,0.00003350132,0.0020289007,0.00020716869,0.000036129073,0.00045440343,0.014768932,0.00027216066,0.00056145893,0.00020975553],"about_ca_topic_score_codex":0.00007679455,"about_ca_topic_score_gemma":0.000100289755,"teacher_disagreement_score":0.08007442,"about_ca_system_score_codex":0.00047629,"about_ca_system_score_gemma":0.00095010275,"threshold_uncertainty_score":0.6075792},"labels":[],"label_agreement":null},{"id":"W2614343481","doi":"10.1182/blood.v128.22.1166.1166","title":"Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Cytarabine; Transplantation; Internal medicine; Idarubicin; Oncology; Hazard ratio; Hematopoietic stem cell transplantation; Leukemia; Surgery; Confidence interval","score_opus":0.03813434342249572,"score_gpt":0.30598481845754855,"score_spread":0.2678504750350528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614343481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918254,0.00013555388,0.00019315057,0.00012846547,0.00013505184,0.006328232,0.0012257677,0.000018917577,0.000009446789],"genre_scores_gemma":[0.9979635,0.0015167047,0.0002491571,0.000008921163,0.00004906044,0.00007364869,0.00008772335,0.000042803596,0.0000084938065],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952454,0.00147302,0.0012199495,0.0005802072,0.0011560584,0.0003253585],"domain_scores_gemma":[0.99577326,0.0018524991,0.0009386748,0.0008730372,0.0004629716,0.00009957276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013702097,0.00036215392,0.0013154662,0.00014693971,0.00015506415,0.000009108327,0.0003420421,0.00015083555,0.00003838631],"category_scores_gemma":[0.00018931707,0.00015434828,0.00017564248,0.00057177496,0.0005496735,0.00013108565,0.00003078619,0.00038307207,3.163404e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78043514,0.0036503735,0.14614497,0.000086204454,0.0006979948,0.000027864644,0.018698195,0.0001366661,0.049435224,0.0000013848072,0.000004379515,0.0006815607],"study_design_scores_gemma":[0.5434577,0.0043080044,0.30031583,0.0005252944,0.0005491388,0.0000037166024,0.00091714936,0.000036326786,0.14974745,0.000016148935,7.605118e-7,0.00012249911],"about_ca_topic_score_codex":0.015529117,"about_ca_topic_score_gemma":0.0028670176,"teacher_disagreement_score":0.2369775,"about_ca_system_score_codex":0.00026609303,"about_ca_system_score_gemma":0.00051443756,"threshold_uncertainty_score":0.9910266},"labels":[],"label_agreement":null},{"id":"W2614562262","doi":"10.1182/blood.v128.22.1211.1211","title":"Prognostic Significance of 11q23/MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Internal medicine; Medicine; Monosomy; Oncology; Gemtuzumab ozogamicin; Myeloid leukemia; Leukemia; Pediatrics; Biology; Chromosome; Genetics; CD33","score_opus":0.017554334581264014,"score_gpt":0.28630986131914776,"score_spread":0.2687555267378837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614562262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99106836,0.00020156727,0.00005574624,0.0025022316,0.00008180278,0.0044744047,0.00041365257,0.00008872959,0.0011135088],"genre_scores_gemma":[0.99633867,0.0004036529,0.0010920772,0.00027343884,0.000804317,0.0003318914,0.00032962876,0.00007225059,0.00035410264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963002,0.00035287626,0.00084462034,0.0008966152,0.0008276844,0.0007779663],"domain_scores_gemma":[0.9966589,0.0014502706,0.00041428456,0.0010606373,0.0001571299,0.00025875977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094076176,0.00039032038,0.0008024917,0.00018381249,0.0001095801,0.000021516616,0.0006280313,0.00035477756,0.00007029349],"category_scores_gemma":[0.0011002376,0.00020270706,0.00014749457,0.0006390863,0.00061184686,0.00014559424,0.00023974015,0.0007237498,0.00006137484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19639882,0.0039762068,0.61277497,0.000035937755,0.0038947598,0.00076763367,0.0015735059,0.000009509156,0.12544408,0.00018945544,0.007223323,0.047711782],"study_design_scores_gemma":[0.25540257,0.0061380905,0.7144946,0.00043249657,0.0012028991,0.00025109647,0.0000810014,0.000013783182,0.020668091,0.0000997634,0.000832094,0.0003835568],"about_ca_topic_score_codex":0.0024659773,"about_ca_topic_score_gemma":0.00048396923,"teacher_disagreement_score":0.104775995,"about_ca_system_score_codex":0.0004808724,"about_ca_system_score_gemma":0.0017868557,"threshold_uncertainty_score":0.8266154},"labels":[],"label_agreement":null},{"id":"W2615182797","doi":"10.1002/pbc.26632","title":"Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada","year":2017,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"American Lebanese Syrian Associated Charities","keywords":"Medicine; Myeloid leukemia; Refractory (planetary science); Clinical trial; Myeloid; Intensive care medicine; Internal medicine","score_opus":0.09841217624907318,"score_gpt":0.38936142634420545,"score_spread":0.2909492500951323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615182797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98933953,0.0026644126,0.000021093982,0.0042018653,0.0006176906,0.0027040206,0.00035600393,0.000021755406,0.00007364378],"genre_scores_gemma":[0.8769792,0.111948386,0.00040574936,0.0017546517,0.0058349404,0.001672048,0.0002064661,0.00007162835,0.0011269746],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974924,0.00014293198,0.00071695267,0.00053175143,0.00048152692,0.00063449173],"domain_scores_gemma":[0.996402,0.0020898692,0.00042973756,0.00055204914,0.00021255715,0.0003137711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018914782,0.00028354104,0.0006126103,0.00029811866,0.00055441604,0.00013507047,0.00035600833,0.00020923681,0.000014090713],"category_scores_gemma":[0.0010771165,0.00020692195,0.000105822175,0.000155441,0.00015708701,0.00016654542,0.00014739188,0.00057822245,2.4502896e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0702611,0.0005332292,0.68230784,0.0025704037,0.0011257583,0.00060732104,0.0023189979,0.000023337607,0.00006639165,0.00017058654,0.22362384,0.016391195],"study_design_scores_gemma":[0.55672514,0.010806605,0.24704714,0.00018691909,0.013641952,0.00014239583,0.007479283,0.00332894,0.00016856735,0.00052030693,0.15799385,0.001958886],"about_ca_topic_score_codex":0.17760907,"about_ca_topic_score_gemma":0.062470887,"teacher_disagreement_score":0.48646402,"about_ca_system_score_codex":0.0005612426,"about_ca_system_score_gemma":0.005407945,"threshold_uncertainty_score":0.9593462},"labels":[],"label_agreement":null},{"id":"W2618292946","doi":"10.1038/leu.2017.159","title":"A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts","year":2017,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Azacitidine; Panobinostat; Chronic myelomonocytic leukemia; Neutropenia; Myelodysplastic syndromes; International Prognostic Scoring System; Regimen; Adverse effect; Gastroenterology; Phases of clinical research; Oncology; Bone marrow; Clinical trial; Toxicity","score_opus":0.028693664420219048,"score_gpt":0.334618221240216,"score_spread":0.305924556819997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2618292946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559146,0.00002971798,0.000056207788,0.00028456404,0.00005848892,0.0025846772,0.000044071585,0.00006502127,0.0012857751],"genre_scores_gemma":[0.9964307,0.000038443293,0.0009879087,0.00017675145,0.00011381745,0.00017366296,0.000045362598,0.000099084566,0.0019342822],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99681175,0.00011702891,0.0005584277,0.0007421959,0.0009538296,0.0008167792],"domain_scores_gemma":[0.9972194,0.0001290196,0.0003545578,0.001563729,0.00035659943,0.00037672778],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034089413,0.0004428209,0.00093140197,0.00031655474,0.00018796437,0.00007442786,0.00057040463,0.00015853757,0.0002771971],"category_scores_gemma":[0.0003095257,0.0002750223,0.00006155071,0.00031232915,0.00043553763,0.0003453325,0.00027067369,0.00081012887,0.00007413157],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28098485,0.020836823,0.56987137,0.002425789,0.0017938816,0.031829044,0.03807893,0.00031052958,0.007802447,0.000038718124,0.007040793,0.038986836],"study_design_scores_gemma":[0.62727696,0.049928408,0.26442823,0.004500127,0.000589834,0.00039300404,0.016878776,0.018550651,0.014408525,0.000005674607,0.0018535248,0.001186304],"about_ca_topic_score_codex":0.005776031,"about_ca_topic_score_gemma":0.0072333976,"teacher_disagreement_score":0.34629208,"about_ca_system_score_codex":0.0016324355,"about_ca_system_score_gemma":0.0015977877,"threshold_uncertainty_score":0.9999702},"labels":[],"label_agreement":null},{"id":"W2618381598","doi":"10.1038/leu.2017.171","title":"Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia","year":2017,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Deutsche Krebshilfe; Terry Fox Research Institute; Deutsche Forschungsgemeinschaft","keywords":"RUNX1; Biology; Myeloid; Myelopoiesis; Epigenomics; Cancer research; Transcription factor; Epigenetics; Myeloid leukemia; Cellular differentiation; Haematopoiesis; DNA methylation; Cell biology; Molecular biology; Stem cell; Genetics; Gene; Gene expression","score_opus":0.03526885580970547,"score_gpt":0.31712891689365286,"score_spread":0.2818600610839474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2618381598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98007053,0.00012058467,0.00040440855,0.001779654,0.00034983558,0.0008737011,0.000017755527,0.00014465065,0.016238863],"genre_scores_gemma":[0.9923412,0.0004409912,0.002658489,0.00057893555,0.0005645982,0.000066798726,0.000043778335,0.00013412298,0.0031710886],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962881,0.0000967919,0.0007314706,0.0009488817,0.0006807737,0.0012539396],"domain_scores_gemma":[0.9965343,0.00013713543,0.00030468276,0.0023852976,0.00015366045,0.00048492695],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00095858163,0.0004724967,0.00087759277,0.00044381258,0.0005243765,0.00020322982,0.0010765585,0.0005041042,0.00016518941],"category_scores_gemma":[0.00043905491,0.0004441915,0.00023679959,0.00025412373,0.00024180615,0.00043888553,0.0004829533,0.0016414801,0.0009039031],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072745135,0.00007035208,0.011418389,0.00012008084,0.00020282011,0.0034627435,0.00090747734,0.00015521256,0.95533425,0.0004992919,0.001176893,0.025925033],"study_design_scores_gemma":[0.025680155,0.0010016548,0.16869408,0.001455395,0.00052815466,0.0017172404,0.00064986723,0.087237805,0.6950837,0.002411061,0.013268752,0.0022721859],"about_ca_topic_score_codex":0.00214942,"about_ca_topic_score_gemma":0.00027879822,"teacher_disagreement_score":0.2602506,"about_ca_system_score_codex":0.006183795,"about_ca_system_score_gemma":0.0023993892,"threshold_uncertainty_score":0.999874},"labels":[],"label_agreement":null},{"id":"W2618501159","doi":"10.1182/blood.v128.22.2818.2818","title":"Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Azacitidine; Chemotherapy regimen; Pediatrics; Chemotherapy","score_opus":0.01705127111205544,"score_gpt":0.2930885542918426,"score_spread":0.27603728317978715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2618501159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99714375,0.00010791965,0.0000036921138,0.00020256388,0.00004766916,0.0018599293,0.00013294759,0.000021100444,0.00048044405],"genre_scores_gemma":[0.99927235,0.00008462419,0.00012156946,0.00005084704,0.00006329598,0.00007363681,0.00014335474,0.000034589142,0.00015574846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976704,0.00025006008,0.00043711415,0.00043663778,0.00079543993,0.00041033415],"domain_scores_gemma":[0.99865854,0.00038077094,0.00013573407,0.0005215273,0.00017362343,0.0001298095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049829733,0.0002232628,0.00044228393,0.00026261777,0.000058878613,0.00001418188,0.0002453533,0.00010394341,0.00006895322],"category_scores_gemma":[0.00019646807,0.00013606851,0.000051403542,0.00045929855,0.00023396553,0.00011231693,0.00012112382,0.0003751767,0.000015947722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074308164,0.016830374,0.85909456,0.00024307492,0.0020722514,0.00275028,0.012600405,0.0000056072663,0.012879523,0.0001618947,0.0014718428,0.017582038],"study_design_scores_gemma":[0.27016065,0.0056232475,0.71967226,0.00023942675,0.00035193167,0.000026521067,0.0018135096,0.0000036457086,0.0016243206,0.0000045473844,0.00030163123,0.00017832826],"about_ca_topic_score_codex":0.00016530906,"about_ca_topic_score_gemma":0.00023622578,"teacher_disagreement_score":0.19585249,"about_ca_system_score_codex":0.00039358527,"about_ca_system_score_gemma":0.00041187744,"threshold_uncertainty_score":0.55487126},"labels":[],"label_agreement":null},{"id":"W2619649452","doi":"10.1111/ejh.12909","title":"Extramedullary disease at diagnosis of <scp>AML</scp> does not influence outcome of patients undergoing allogeneic hematopoietic cell transplant in <scp>CR</scp>1","year":2017,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Univariate analysis; Multivariate analysis; Gastroenterology; Hematopoietic stem cell transplantation; Transplantation; Chemotherapy; Leukemia; Disease; Single Center; Surgery","score_opus":0.022036240563716364,"score_gpt":0.2794230375608566,"score_spread":0.2573867969971403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619649452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964818,0.0012971878,0.00006353813,0.0005406191,0.00026394226,0.00039292438,0.00006739793,0.000012906621,0.0008796801],"genre_scores_gemma":[0.99649626,0.0022700517,0.0005910093,0.00027607422,0.00006195546,0.000006348804,0.000011410799,0.000084952866,0.00020191673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952941,0.0008438836,0.0019645172,0.00039265593,0.0008169999,0.00068785966],"domain_scores_gemma":[0.99400043,0.0021053827,0.0019293389,0.000910664,0.00044788822,0.000606316],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013529395,0.00036787923,0.0014433261,0.0005647017,0.00015265503,0.000028337055,0.0011062862,0.00011905351,0.000028950608],"category_scores_gemma":[0.0051833116,0.00027110163,0.000380288,0.0001559948,0.00067726645,0.00028938477,0.0003679054,0.0007853205,0.000050269304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002011978,0.00059465406,0.9746235,0.0017655763,0.0001459231,0.01617498,0.0015311136,0.00010669605,0.0041452735,0.00006571103,0.00051081163,0.0001345355],"study_design_scores_gemma":[0.0067012077,0.0008429483,0.9451747,0.0013903459,0.00033707116,0.0013394878,0.0003997045,0.00002777245,0.042863294,0.00006999908,0.00076793,0.00008553717],"about_ca_topic_score_codex":0.00001943936,"about_ca_topic_score_gemma":0.000034192315,"teacher_disagreement_score":0.03871802,"about_ca_system_score_codex":0.00019040551,"about_ca_system_score_gemma":0.00036685902,"threshold_uncertainty_score":0.99997413},"labels":[],"label_agreement":null},{"id":"W2620822975","doi":"10.3892/ijo.2017.4027","title":"Fli-1 overexpression in erythroleukemic cells promotes erythroid de-differentiation while Spi-1/PU.1 exerts the opposite effect","year":2017,"lang":"en","type":"article","venue":"International Journal of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"National Natural Science Foundation of China","keywords":"Haematopoiesis; Biology; Progenitor cell; Erythropoiesis; Transcription factor; Cell biology; Cell growth; Myeloid; Molecular biology; Cellular differentiation; Cancer research; Stem cell; Gene; Internal medicine; Genetics","score_opus":0.021947100240355306,"score_gpt":0.3584369236127072,"score_spread":0.3364898233723519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620822975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847207,0.00013974927,0.00029609003,0.010032663,0.00087099354,0.00034132617,0.0000065721897,0.000009278673,0.0035826],"genre_scores_gemma":[0.9971362,0.0003065365,0.00060159585,0.00043964793,0.0010202171,0.000015126421,0.000009270899,0.00002283906,0.00044856855],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979618,0.0002934452,0.00055745116,0.00018869965,0.0006949163,0.00030364454],"domain_scores_gemma":[0.99779624,0.00047349767,0.0007807902,0.00034107507,0.00046604083,0.00014234988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013330517,0.00016324043,0.000412211,0.00031037888,0.00014387818,0.000115781026,0.00089061557,0.00021346996,0.0002564544],"category_scores_gemma":[0.0007515639,0.00010447765,0.00018256216,0.00005112378,0.00018853041,0.00035164913,0.00026932254,0.0008795044,0.00003618245],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037696462,0.00053819985,0.073218234,0.000057052937,0.00038778354,0.0016273954,0.0009452563,0.00011423884,0.84745824,0.00010522474,0.012367835,0.059410878],"study_design_scores_gemma":[0.019935317,0.0053494023,0.46386516,0.0022575378,0.0001843813,0.0064501474,0.00015660936,0.006772137,0.4677163,0.0012183967,0.025775833,0.00031879282],"about_ca_topic_score_codex":0.00012927283,"about_ca_topic_score_gemma":0.000036913654,"teacher_disagreement_score":0.3906469,"about_ca_system_score_codex":0.0019230467,"about_ca_system_score_gemma":0.0008636648,"threshold_uncertainty_score":0.50287},"labels":[],"label_agreement":null},{"id":"W2620862566","doi":"10.1016/j.leukres.2017.05.023","title":"Sharing post-AML consolidation supportive therapy with local centers reduces patient travel burden without compromising outcomes","year":2017,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Consolidation (business); Myeloid leukemia; Chemotherapy; Internal medicine; Business","score_opus":0.07686276982342112,"score_gpt":0.38999897339934586,"score_spread":0.31313620357592475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620862566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817255,0.0000899548,0.0003080197,0.0062665893,0.00010357013,0.002139249,0.000032363452,0.00008937779,0.009245358],"genre_scores_gemma":[0.9949157,0.00014290013,0.000943125,0.00028942397,0.00023033797,0.00016471045,0.00012533486,0.00011783325,0.0030705957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942765,0.0002777691,0.0005643095,0.001053906,0.0023465704,0.0014809187],"domain_scores_gemma":[0.9955432,0.0003251451,0.00027491784,0.0017039839,0.0015165603,0.0006362293],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0016413789,0.00041383487,0.0007550739,0.00056479394,0.0014094933,0.0005819218,0.0010351561,0.0002583073,0.00027152328],"category_scores_gemma":[0.00069383555,0.00029872122,0.00015685582,0.00027637382,0.0018009685,0.00055098307,0.0005998237,0.0018935521,0.00017401953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023773674,0.0008416635,0.41009766,0.00054935354,0.0020203867,0.00317963,0.01947423,0.00020466217,0.27000856,0.0007804097,0.0045707603,0.264499],"study_design_scores_gemma":[0.022819102,0.005516667,0.68886316,0.0012247087,0.00008705847,0.00049684325,0.017387854,0.013840727,0.2462262,0.00020558262,0.0023362008,0.0009959185],"about_ca_topic_score_codex":0.0070511745,"about_ca_topic_score_gemma":0.00014712187,"teacher_disagreement_score":0.27876547,"about_ca_system_score_codex":0.0034202635,"about_ca_system_score_gemma":0.002793829,"threshold_uncertainty_score":0.9999465},"labels":[],"label_agreement":null},{"id":"W2621173929","doi":"10.1016/j.critrevonc.2017.05.010","title":"Azacitidine in adult patients with acute myeloid leukemia","year":2017,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene","keywords":"Azacitidine; Myeloid leukemia; Medicine; Clinical trial; Oncology; Internal medicine; Biology","score_opus":0.08975523865005734,"score_gpt":0.4533416505009695,"score_spread":0.3635864118509121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621173929","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009195124,0.9793858,0.000047744725,0.0012855654,0.00055633666,0.006326234,0.00008186584,0.00006804762,0.012156457],"genre_scores_gemma":[0.000061887535,0.9910589,0.0032989127,0.001123027,0.0002441648,0.002929879,0.0005472562,0.00020798315,0.00052798534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.989607,0.0020308748,0.0036171796,0.001942873,0.00064578635,0.002156319],"domain_scores_gemma":[0.99186426,0.0033611576,0.0008851578,0.0024801039,0.000617795,0.0007914953],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0021080675,0.0013906378,0.013939348,0.0013210586,0.00016276438,0.000049039085,0.0015037949,0.0028550758,0.00056546484],"category_scores_gemma":[0.018503387,0.0009610805,0.0008717722,0.0009479614,0.0020358346,0.00023281704,0.00075286283,0.005458633,0.0017224883],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003091698,0.0007567563,0.0010065982,0.037285317,0.00022814986,0.009559429,0.000041638934,1.673577e-8,1.8044703e-7,0.010383654,0.0070327497,0.93339634],"study_design_scores_gemma":[0.004135524,0.0012468854,0.00011032419,0.077727556,0.0014084327,0.0037096615,0.000010213592,0.000007932824,0.0000010985177,0.00028624505,0.91060406,0.00075208617],"about_ca_topic_score_codex":0.00005428691,"about_ca_topic_score_gemma":0.00023330322,"teacher_disagreement_score":0.93264425,"about_ca_system_score_codex":0.0061954283,"about_ca_system_score_gemma":0.00651403,"threshold_uncertainty_score":0.9998844},"labels":[],"label_agreement":null},{"id":"W2624452439","doi":"10.1182/blood.v128.22.3947.3947","title":"Novel Fatty Acid Oxidation Inhibitor Avocatinb Induces AMPK-Dependent Apoptosis of AML Cells Co-Cultured with BM-Adipocytes","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Apoptosis; Stromal cell; Bone marrow; Adipocyte; Beta oxidation; Cell culture; Cancer research; Mesenchymal stem cell; AMPK; Biology; Chemistry; Stem cell; Internal medicine; Cell biology; Endocrinology; Fatty acid; Biochemistry; Adipose tissue; Immunology; Medicine; Phosphorylation; Protein kinase A","score_opus":0.018922615781695004,"score_gpt":0.2684599733449065,"score_spread":0.2495373575632115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624452439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957065,0.00010057714,0.001031824,0.0007592288,0.00006203657,0.00066432817,0.00007695719,0.00006491226,0.0015336644],"genre_scores_gemma":[0.9915206,0.000056466128,0.00676908,0.00009271578,0.0002867102,0.00005719663,0.000047868285,0.00004471953,0.0011246625],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979903,0.000055307046,0.00037448417,0.00041752003,0.00077269285,0.0003896896],"domain_scores_gemma":[0.99856263,0.00012396202,0.0002207474,0.0005020799,0.00037331076,0.00021727153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028558768,0.00023935082,0.0004032465,0.00016924736,0.00006143387,0.000024586321,0.00022017863,0.00019471804,0.00018659484],"category_scores_gemma":[0.00016714259,0.00013820079,0.00007913321,0.00027912576,0.00020508825,0.000192671,0.0000754781,0.00023765855,0.000181555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002847975,0.00077439134,0.0028658533,0.00012728476,0.00025083937,0.00000836767,0.00037057558,4.287735e-7,0.9930098,0.00003042572,0.00087771623,0.0013995344],"study_design_scores_gemma":[0.008860538,0.00065531424,0.0032928009,0.00032928414,0.00023365083,0.000054626747,0.00026008234,0.0000020804275,0.98583037,0.000007319467,0.00028408528,0.00018984133],"about_ca_topic_score_codex":0.000084252664,"about_ca_topic_score_gemma":0.0000132046935,"teacher_disagreement_score":0.00857574,"about_ca_system_score_codex":0.00015999621,"about_ca_system_score_gemma":0.00032901077,"threshold_uncertainty_score":0.56356645},"labels":[],"label_agreement":null},{"id":"W2624497242","doi":"10.1182/blood.v128.22.5173.5173","title":"Outcome of acute Myeloid Leukemia in Adults Patients Treated According to Morocco National AML-MA-2011 Protocol in Casablanca, Morocco","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; McMaster Children's Hospital","funders":"","keywords":"Medicine; Bone marrow; Internal medicine; Myeloid leukemia; Biopsy; Giemsa stain; Surgery; Pediatrics; Pathology","score_opus":0.021023420167819395,"score_gpt":0.3171388374506465,"score_spread":0.29611541728282714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624497242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9653199,0.000003578726,0.000009611239,0.00029481392,0.00003332286,0.03191547,0.0001309654,0.000052131036,0.0022402408],"genre_scores_gemma":[0.9740737,0.00000531504,0.00063202955,0.00022450298,0.000102238824,0.023892257,0.000045113753,0.000060405688,0.0009644085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996724,0.00010360213,0.0009489148,0.00059306575,0.0009508826,0.0006795342],"domain_scores_gemma":[0.9984227,0.00018184281,0.00018483451,0.00044215875,0.0005005863,0.00026788464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004874065,0.00031634117,0.00067874766,0.0008781016,0.000035432022,0.000012067062,0.0003441125,0.00022917641,0.00020617135],"category_scores_gemma":[0.0006405002,0.00022791784,0.00011223856,0.00073172303,0.000074094954,0.00024388159,0.00022984964,0.0003493455,0.0002703881],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002189994,0.000678978,0.97956944,0.00018448317,0.00011463026,0.00016343856,0.00024651253,0.0000035853895,0.013598753,0.000023056684,0.00057836075,0.002648776],"study_design_scores_gemma":[0.044411395,0.00086604996,0.91437584,0.00090246124,0.000056126595,0.00003145885,0.00007655035,0.000096129515,0.038487833,0.00003774337,0.0003351207,0.00032327662],"about_ca_topic_score_codex":0.0014571511,"about_ca_topic_score_gemma":0.00029192233,"teacher_disagreement_score":0.06519357,"about_ca_system_score_codex":0.0019596855,"about_ca_system_score_gemma":0.00076605665,"threshold_uncertainty_score":0.929422},"labels":[],"label_agreement":null},{"id":"W2624620803","doi":"10.1189/jlb.5ri0317-083r","title":"Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromes","year":2017,"lang":"en","type":"review","venue":"Journal of Leukocyte Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canada Foundation for Innovation; Ontario Institute for Cancer Research; Southeastern Ontario Academic Medical Organization; European Hematology Association","keywords":"Biology; Myelodysplastic syndromes; Bone marrow; Immune system; Bone marrow failure; Immunology; Cancer research; Haematopoiesis; Cell biology; Stem cell","score_opus":0.0963081048577527,"score_gpt":0.37012298246174585,"score_spread":0.27381487760399315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624620803","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006045113,0.995897,0.00019876198,0.001787147,0.00038796835,0.0008175265,0.000034317596,0.0000064355645,0.00026636416],"genre_scores_gemma":[0.016851485,0.9819697,0.00026309566,0.00007257862,0.0002702751,0.000052882777,0.000026713184,0.00006311507,0.00043014274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99651796,0.0006204184,0.001625724,0.0003237058,0.0004443689,0.0004678465],"domain_scores_gemma":[0.9945955,0.0020731133,0.0021730957,0.00091658795,0.000097494,0.00014420426],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018870066,0.00046358415,0.0031041019,0.0010240932,0.0001229118,0.000023093997,0.0008495947,0.0005727711,0.0002614317],"category_scores_gemma":[0.00066051394,0.00024966305,0.0009042545,0.00024475556,0.00058318215,0.00005726,0.00013307345,0.0020792,0.00004064128],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012743506,0.0016741593,0.0007354945,0.008820656,0.0034005868,0.0010918063,0.00009742336,0.000061215134,0.0034216952,0.0005441886,0.0006121498,0.9782663],"study_design_scores_gemma":[0.002201968,0.0014586142,0.0011552839,0.009763844,0.0010817294,0.0023484633,0.000021912363,0.000106599,0.00012353399,0.000023188559,0.9814728,0.00024208029],"about_ca_topic_score_codex":0.000055941404,"about_ca_topic_score_gemma":0.000011991973,"teacher_disagreement_score":0.98086065,"about_ca_system_score_codex":0.0012615927,"about_ca_system_score_gemma":0.0018518079,"threshold_uncertainty_score":0.9999956},"labels":[],"label_agreement":null},{"id":"W2624748903","doi":"10.1182/blood.v128.22.1974.1974","title":"Combined DNA and Transcriptome Sequencing Reveals Discrete Subtypes of Myelodysplasia","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Biology; CD34; Transcriptome; Myelodysplastic syndromes; Proportional hazards model; Myeloid; Survival analysis; Bone marrow; Gene; NPM1; Cancer research; Genetics; Immunology; Gene expression; Molecular biology; Stem cell; Internal medicine; Medicine; Karyotype","score_opus":0.017248883058844342,"score_gpt":0.26582666400589666,"score_spread":0.24857778094705232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624748903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99464065,0.0002574817,0.0000865346,0.0018247749,0.000034711393,0.00030790857,0.000027918524,0.00004762278,0.0027724125],"genre_scores_gemma":[0.99676466,0.00020427273,0.00065959885,0.00009428768,0.00007722639,0.000012552507,0.00000521035,0.000027097973,0.0021550946],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886,0.000054494183,0.00026357148,0.0002453998,0.00028171323,0.00029482617],"domain_scores_gemma":[0.9992123,0.00014479882,0.00006017864,0.00031192656,0.000093727394,0.00017705784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003034703,0.00012990502,0.00034666626,0.00012013584,0.000037436097,0.0000073636456,0.000101047706,0.000092372225,0.00010511107],"category_scores_gemma":[0.00019772224,0.00008079158,0.00006206003,0.00015750807,0.000191988,0.00009260372,0.00003948324,0.0001202103,0.000021771619],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019497244,0.000053944896,0.032801285,0.00018000844,0.000124015,0.00006797058,0.0002934942,1.7110368e-8,0.9644772,0.0005617574,0.0002530478,0.0009922867],"study_design_scores_gemma":[0.015149505,0.001165435,0.12376513,0.00076289935,0.00037521168,0.0002574607,0.0001902041,0.000013392124,0.8564753,0.0009338408,0.00067517767,0.00023646088],"about_ca_topic_score_codex":0.0000325373,"about_ca_topic_score_gemma":0.0000039961024,"teacher_disagreement_score":0.108001925,"about_ca_system_score_codex":0.00006648128,"about_ca_system_score_gemma":0.00017576924,"threshold_uncertainty_score":0.3294585},"labels":[],"label_agreement":null},{"id":"W2624807098","doi":"10.1101/124263","title":"A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML","year":2017,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"National Institutes of Health; Arkansas Biosciences Institute; Johns Hopkins University; Children's Hospital Colorado; Eisai; St. Baldrick's Foundation","keywords":"Decitabine; Medicine; Internal medicine; Oncology; Neutropenia; Cytarabine; Induction chemotherapy; Azacitidine; Tolerability; Gastroenterology; Chemotherapy; Adverse effect; DNA methylation; Biology","score_opus":0.015218656816375806,"score_gpt":0.2686463488222023,"score_spread":0.2534276920058265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624807098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98986745,0.00046082516,0.00032106086,0.00023500258,0.00011968738,0.008846457,0.000017178654,0.00012283755,0.0000095094565],"genre_scores_gemma":[0.99305385,0.00041209962,0.0050816084,0.00006416361,0.00023722324,0.00091399945,8.3718254e-7,0.00022335803,0.000012872166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99591357,0.0003783132,0.000847367,0.0012394089,0.00097642816,0.00064490974],"domain_scores_gemma":[0.99551904,0.000101401914,0.0009835765,0.0022826341,0.0008093013,0.0003040435],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015067889,0.000714865,0.0020441639,0.0007844523,0.00013236544,0.00011705322,0.0005883344,0.00044524105,0.000033084765],"category_scores_gemma":[0.0005747127,0.0005470033,0.00014124642,0.0004722803,0.0004413828,0.0001455058,0.00033840802,0.0014964639,0.000010599243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10691344,0.004312095,0.73723435,0.00078337756,0.004115767,0.00029896584,0.00050902163,0.00018319406,0.14556508,0.000018691642,0.000022379578,0.000043609878],"study_design_scores_gemma":[0.22377564,0.0010372456,0.70347124,0.0015536435,0.0006465314,4.1031805e-7,0.00004266941,0.0002957868,0.06860591,4.4587568e-7,0.000018365312,0.0005521104],"about_ca_topic_score_codex":0.001666546,"about_ca_topic_score_gemma":0.00004315554,"teacher_disagreement_score":0.11686219,"about_ca_system_score_codex":0.0006885077,"about_ca_system_score_gemma":0.0017864323,"threshold_uncertainty_score":0.99969816},"labels":[],"label_agreement":null},{"id":"W2626574197","doi":"","title":"Transcriptional repression of the rara pathyway is crucial for leukemogenesis","year":2000,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Psychological repression; Biology; Cancer research; Medicine; Genetics; Gene; Gene expression","score_opus":0.022116223042506496,"score_gpt":0.28068675703731577,"score_spread":0.2585705339948093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626574197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927224,0.00042770364,0.000056134253,0.0018377446,0.000057912937,0.00060367526,0.000087777924,0.000021130896,0.004185504],"genre_scores_gemma":[0.98726994,0.00011197074,0.0011691543,0.00059449935,0.000364587,0.00006943091,0.000015093835,0.00002501394,0.010380297],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998949,0.000040335697,0.00022435831,0.00021881355,0.000364889,0.00020262359],"domain_scores_gemma":[0.9993497,0.000060791157,0.000038503716,0.00038363598,0.00009518338,0.00007215065],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018885086,0.00009287028,0.00019374701,0.000040554496,0.00009598396,0.0000059133013,0.00016971903,0.00010176222,0.0014318685],"category_scores_gemma":[0.00006648194,0.000059620794,0.0002245266,0.00012482052,0.00008639182,0.000038421298,0.000019182384,0.00012223075,0.000022772127],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020894466,0.0012945186,0.016189873,0.0003234453,0.00034416316,0.000021154307,0.0019463059,0.000017686745,0.88235503,0.0003158192,0.021025319,0.07407724],"study_design_scores_gemma":[0.01490854,0.00042037744,0.17054677,0.00022016698,0.00045769732,0.00012645613,0.0000726477,0.0003191047,0.7433186,0.00045885373,0.06897145,0.00017930077],"about_ca_topic_score_codex":0.000034842302,"about_ca_topic_score_gemma":0.0000034585662,"teacher_disagreement_score":0.1543569,"about_ca_system_score_codex":0.00004224246,"about_ca_system_score_gemma":0.0003196155,"threshold_uncertainty_score":0.99948096},"labels":[],"label_agreement":null},{"id":"W2626683404","doi":"10.1101/125609","title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","year":2017,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"BC Cancer Agency; Children’s Oncology Group; Arkansas Biosciences Institute; Alex's Lemonade Stand Foundation for Childhood Cancer; University of Southern California; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services; National Science Foundation","keywords":"Myeloid leukemia; Gene; microRNA; CpG site; DNA methylation; Mutation; Myeloid; Leukemia; DNA sequencing","score_opus":0.021615312159627146,"score_gpt":0.2876801683705351,"score_spread":0.266064856210908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626683404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99076265,0.005075585,0.00047787285,0.0008307763,0.0010547584,0.0011759094,0.00047757642,0.00010262904,0.00004224101],"genre_scores_gemma":[0.98965037,0.004063962,0.004799258,0.00006184076,0.0010321937,0.00023744623,0.000008533827,0.00009868496,0.000047731184],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997013,0.00018750415,0.0008208439,0.00074357697,0.00070719083,0.0005279229],"domain_scores_gemma":[0.99590534,0.00026416223,0.0007767757,0.0016560325,0.0010470701,0.00035063212],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064005604,0.0004914206,0.0006800956,0.00041825496,0.0006480584,0.0004148048,0.00060860976,0.00033043104,0.000049325383],"category_scores_gemma":[0.00046436116,0.00040496385,0.00022028865,0.00032412307,0.00034403973,0.00018228295,0.0006548755,0.0015810182,0.000023521956],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009047059,0.0001888989,0.030592607,0.0015822874,0.0027203697,0.0013092168,0.0002219165,0.00024269568,0.9394579,0.0077981185,0.014832813,0.00014849292],"study_design_scores_gemma":[0.004211462,0.00037753355,0.90019643,0.00094583485,0.0019161262,0.0000041996896,0.0000393968,0.0043295994,0.07414706,0.00010410089,0.012114402,0.0016138521],"about_ca_topic_score_codex":0.000030699142,"about_ca_topic_score_gemma":0.0000047484787,"teacher_disagreement_score":0.8696038,"about_ca_system_score_codex":0.00067880814,"about_ca_system_score_gemma":0.0017944445,"threshold_uncertainty_score":0.9998402},"labels":[],"label_agreement":null},{"id":"W2646599743","doi":"10.1182/blood.v128.22.1212.1212","title":"Expanded Phenotypic and Genetic Heterogeneity in the Clinical Spectrum of FPD-AML: Lymphoid Malignancies and Skin Disorders Are Common Features in Carriers of Germline RUNX1 Mutations","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Platelet disorder; RUNX1; Germline; Germline mutation; Genetics; Leukemia; Biology; Cancer research; Mutation; CEBPA; Medicine; Immunology; Gene; Haematopoiesis; Stem cell; Platelet","score_opus":0.017713579701339015,"score_gpt":0.3114942413868977,"score_spread":0.29378066168555866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2646599743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99534565,0.0022782895,0.000012670622,0.0017989996,0.000017525614,0.0004325243,0.000038192018,0.0000069257812,0.0000692383],"genre_scores_gemma":[0.998174,0.0013621611,0.0002686321,0.00010039771,0.000034161592,0.000024223193,0.000005656062,0.000013805026,0.00001695327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868363,0.00021965239,0.0004208185,0.00022940125,0.0002209549,0.00022556563],"domain_scores_gemma":[0.99904126,0.00042998174,0.00012234275,0.00030047435,0.000030887975,0.000075076634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039561198,0.00012047944,0.00038702282,0.0001471442,0.000029216033,0.0000061934234,0.00012278873,0.000108156215,0.0000070915507],"category_scores_gemma":[0.00027760022,0.000072752526,0.00005651582,0.0002104957,0.00049123005,0.00003496025,0.000072520044,0.00015273472,4.3577225e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018433972,0.00034002162,0.9881225,0.000097689306,0.000060537324,0.00003325371,0.0007810513,0.000001818604,0.0049034636,0.000033765442,0.00003959733,0.0054019187],"study_design_scores_gemma":[0.0071397764,0.00028361124,0.9783916,0.00014786152,0.00008019133,0.0000791707,0.00066619687,0.000014953855,0.012641214,0.00045443577,0.000025229336,0.00007579695],"about_ca_topic_score_codex":0.00036363088,"about_ca_topic_score_gemma":0.0043796576,"teacher_disagreement_score":0.009730981,"about_ca_system_score_codex":0.00002685848,"about_ca_system_score_gemma":0.00013108006,"threshold_uncertainty_score":0.2966762},"labels":[],"label_agreement":null},{"id":"W2663047463","doi":"","title":"Phosphoproteomic Analysis of Acute Myeloid Leukemia","year":2012,"lang":"fr","type":"dissertation","venue":"Library and Archives Canada (Government of Canada)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Cancer research; LYN; Haematopoiesis; Cytarabine; Daunorubicin; Myeloid; Leukemia; Acute leukemia; Biology; Progenitor cell; Stem cell; Tyrosine kinase; Immunology; Medicine; Cell biology; Signal transduction","score_opus":0.004234607480673448,"score_gpt":0.19087942077859735,"score_spread":0.1866448132979239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2663047463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8312031,0.0055555864,0.000056543293,0.0015993387,0.00093020726,0.0008414382,0.0028482156,0.000012998279,0.15695255],"genre_scores_gemma":[0.910259,0.003290113,0.0010083866,0.0004281408,0.00024513394,0.000038062088,0.00095961767,0.00009489338,0.083676666],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99249333,0.00018861132,0.0011722645,0.0006527146,0.004388243,0.0011048435],"domain_scores_gemma":[0.99663234,0.00065994466,0.00090364314,0.00072030834,0.0000052044893,0.0010785584],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000044974036,0.0006818328,0.0017687298,0.00028700347,0.00023828575,0.00002225226,0.0006161763,0.0002426871,0.0009868466],"category_scores_gemma":[0.000016137581,0.0006812866,0.00029854255,0.00090449635,0.00031202706,0.00046246214,0.0002634255,0.0008599689,3.2585234e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009682946,0.00021198537,0.23258062,0.005013174,0.03518393,0.00091935974,0.0017169376,0.0004987301,0.63291,0.044377763,0.0022145824,0.034689937],"study_design_scores_gemma":[0.001138895,0.00020650114,0.47776335,0.0007257888,0.00830364,0.000019072322,0.006587114,0.009824014,0.48905393,0.00007767187,0.0056942706,0.0006057438],"about_ca_topic_score_codex":0.07318831,"about_ca_topic_score_gemma":0.11144905,"teacher_disagreement_score":0.24518275,"about_ca_system_score_codex":0.00022865119,"about_ca_system_score_gemma":0.020077216,"threshold_uncertainty_score":0.9999264},"labels":[],"label_agreement":null},{"id":"W2724638186","doi":"10.1182/blood-2017-01-762336","title":"Gemtuzumab ozogamicin in infants with AML: results from the Children’s Oncology Group trials AAML03P1 and AAML0531","year":2017,"lang":"en","type":"review","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Gemtuzumab ozogamicin; Medicine; Oncology; Internal medicine; Myeloid leukemia; Leukemia; Pediatrics; Clinical trial; CD33","score_opus":0.1302847990664755,"score_gpt":0.416543857673311,"score_spread":0.2862590586068355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2724638186","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008120375,0.98202085,0.0000017048017,0.00064273924,0.0001584829,0.004887978,0.0010974573,0.00006877543,0.003001636],"genre_scores_gemma":[0.0007308016,0.9946768,0.0005024899,0.00020711287,0.0014906435,0.00028526044,0.0013605177,0.0001396213,0.0006067411],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938305,0.0017568435,0.001748624,0.0012285047,0.0006595556,0.00077595824],"domain_scores_gemma":[0.9912262,0.0047842786,0.0013876443,0.0022174888,0.00009553718,0.00028885718],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0046049003,0.00075674994,0.005421626,0.00038262364,0.00021079485,0.00012446861,0.0009820617,0.0010296829,0.000050395196],"category_scores_gemma":[0.0055688065,0.00039876797,0.00039200648,0.00031594225,0.00050768064,0.000108867316,0.0005304846,0.0023670916,0.00010079123],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015734377,0.00044813595,0.000635373,0.0010588368,0.0017793397,0.000863856,0.00025361427,4.1571447e-8,0.0000029247688,0.00002612591,0.0033834325,0.98997486],"study_design_scores_gemma":[0.029538881,0.0015229054,0.0077698724,0.01590331,0.005534026,0.0012136261,0.000039670413,0.0000017107766,0.0000057341663,0.000025268866,0.9379516,0.0004933977],"about_ca_topic_score_codex":0.0039852792,"about_ca_topic_score_gemma":0.0014775161,"teacher_disagreement_score":0.9894815,"about_ca_system_score_codex":0.0005256123,"about_ca_system_score_gemma":0.0025625692,"threshold_uncertainty_score":0.9999345},"labels":[],"label_agreement":null},{"id":"W2726845895","doi":"10.1182/blood.v128.22.901.901","title":"SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Idarubicin; Medicine; Internal medicine; Cytarabine; Vorinostat; Oncology; Clinical endpoint; Gastroenterology; Transplantation; Randomized controlled trial; Chemotherapy; Histone deacetylase; Biology","score_opus":0.015487240033292589,"score_gpt":0.2988562247141778,"score_spread":0.28336898468088517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2726845895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834616,0.00026139617,0.0002694447,0.0002760594,0.00009242392,0.014941135,0.00023341179,0.00023882784,0.00022570112],"genre_scores_gemma":[0.99443144,0.00069897756,0.0017100858,0.00012189175,0.00014197917,0.0011232212,0.00023119905,0.00031901966,0.001222178],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9915549,0.0008453161,0.0016291991,0.0016660361,0.0026993982,0.0016051255],"domain_scores_gemma":[0.994231,0.0008865639,0.000903382,0.0019067606,0.0013905029,0.0006818193],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013299966,0.0013289958,0.004206803,0.0009323589,0.00018932899,0.000072627976,0.00066485815,0.00030617084,0.000320446],"category_scores_gemma":[0.00026455935,0.00062021863,0.0001855275,0.0019781352,0.0009365072,0.0006407801,0.00018951237,0.00087661593,0.000020390302],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9012208,0.007066591,0.07043672,0.00013434318,0.0064550694,0.0018385681,0.0036039343,0.000044787776,0.0055895788,0.000014606167,0.00008000442,0.00351497],"study_design_scores_gemma":[0.891652,0.071487926,0.011664491,0.0013405248,0.0033412145,0.000120064215,0.00095392106,0.000069905764,0.018397627,0.000004483673,0.00007268148,0.0008951545],"about_ca_topic_score_codex":0.0043847766,"about_ca_topic_score_gemma":0.0027306667,"teacher_disagreement_score":0.06442133,"about_ca_system_score_codex":0.0016393468,"about_ca_system_score_gemma":0.0035501027,"threshold_uncertainty_score":0.9999461},"labels":[],"label_agreement":null},{"id":"W2727267635","doi":"10.3899/jrheum.170106","title":"Calcium Pyrophosphate Crystal Inflammatory Arthritis (Pseudogout) with Myelodysplastic Syndrome: A New Paraneoplastic Syndrome?","year":2017,"lang":"en","type":"letter","venue":"The Journal of Rheumatology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Medicine; Chondrocalcinosis; Internal medicine; Bone marrow; Pseudogout; Arthritis; Gastroenterology; Dermatology; Pathology; Osteoarthritis","score_opus":0.015196605261671542,"score_gpt":0.25555394868491493,"score_spread":0.24035734342324339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2727267635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71000344,0.0053774687,0.0016916558,0.2797786,0.0017720315,0.0010152279,0.00005092517,0.00007402954,0.00023663975],"genre_scores_gemma":[0.9371603,0.007097609,0.00096094044,0.039675,0.0008987304,0.000042038424,0.00011515405,0.0006242998,0.013425909],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.99380493,0.0007130591,0.0017462238,0.00051339186,0.0017212075,0.0015012012],"domain_scores_gemma":[0.9920097,0.002424203,0.0026884899,0.0015884959,0.000656351,0.0006327684],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0013320041,0.0009405743,0.0031444102,0.00082648214,0.00043984386,0.00012823938,0.0017695415,0.001444882,0.0007877957],"category_scores_gemma":[0.0012997068,0.00057713484,0.00045691506,0.00025879501,0.0015305097,0.00027139919,0.00032191447,0.008788896,0.0005052337],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002537934,0.000052359126,0.006273914,0.0011188455,0.0023208596,0.15435173,0.00036751034,0.000060115934,0.00007053586,0.000016160242,0.8323277,0.00050231535],"study_design_scores_gemma":[0.006738163,0.0029160164,0.0027701731,0.0058426037,0.0011436186,0.8778331,0.00007128554,0.00008426208,0.000026562286,0.0001618637,0.10186435,0.0005479567],"about_ca_topic_score_codex":0.00055507483,"about_ca_topic_score_gemma":0.00008679455,"teacher_disagreement_score":0.7304634,"about_ca_system_score_codex":0.00059551094,"about_ca_system_score_gemma":0.0064422744,"threshold_uncertainty_score":0.99985147},"labels":[],"label_agreement":null},{"id":"W2727740953","doi":"10.1111/bjh.14825","title":"Overall survival in lower <scp>IPSS</scp> risk <scp>MDS</scp> by receipt of iron chelation therapy, adjusting for patient‐related factors and measuring from time of first red blood cell transfusion dependence: an <scp>MDS</scp>‐<scp>CAN</scp> analysis","year":2017,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre; Foothills Medical Centre; Université Laval; Centre hospitalier universitaire de Québec; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University of Saskatchewan; Leukemia & Lymphoma Society of Canada; CancerCare Manitoba; Ottawa Hospital; Health Sciences Centre; University Health Network; University of Alberta Hospital; University of Alberta; Jewish General Hospital; Sunnybrook Health Science Centre; Université de Moncton; University of Toronto; McMaster University; St. Paul's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; Celgene","keywords":"Medicine; Comorbidity; Hazard ratio; Internal medicine; Multivariate analysis; Proportional hazards model; International Prognostic Scoring System; Prospective cohort study; Myelodysplastic syndromes; Physical therapy; Confidence interval","score_opus":0.016676949285730536,"score_gpt":0.2494884291091361,"score_spread":0.23281147982340555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2727740953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900584,0.0067244894,0.00039825164,0.00007710198,0.00036223064,0.0012138641,0.0005957627,0.000047793008,0.00052209524],"genre_scores_gemma":[0.9889618,0.008791879,0.0012804467,0.000031429856,0.00013402954,0.00002512826,0.00030676357,0.00015166825,0.00031686554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923013,0.001074148,0.0027642157,0.0010479579,0.001562243,0.0012501541],"domain_scores_gemma":[0.9879989,0.0055044824,0.0036914162,0.0008772714,0.0012477344,0.0006802086],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026718224,0.0007143789,0.003063349,0.0011390806,0.0005991948,0.00017402112,0.00093526277,0.0011863983,0.00004483638],"category_scores_gemma":[0.01124492,0.00073697005,0.00078520796,0.00069082173,0.0005545864,0.00091091666,0.00022431747,0.0019826938,0.0000035925182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020457398,0.0020929521,0.8735395,0.00065300154,0.0031493213,0.0030198835,0.010979472,0.0006296265,0.09884621,0.0000057348,0.003111838,0.0037678757],"study_design_scores_gemma":[0.033799652,0.0044800728,0.7440381,0.0024510594,0.005112659,0.0048690964,0.00957668,0.0077090356,0.18620367,0.0005992209,0.0009215123,0.00023923388],"about_ca_topic_score_codex":0.004713892,"about_ca_topic_score_gemma":0.0019269539,"teacher_disagreement_score":0.1295014,"about_ca_system_score_codex":0.00028557467,"about_ca_system_score_gemma":0.00044100313,"threshold_uncertainty_score":0.99950814},"labels":[],"label_agreement":null},{"id":"W2728241634","doi":"10.1182/blood-2017-04-777029","title":"DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":379,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research; Concordia University","keywords":"Biology; Haematopoiesis; Epigenetics; Genetics; Gene; Mutation; Myeloid; Population; Phenotype; Immunology; Medicine; Stem cell","score_opus":0.012306119368155576,"score_gpt":0.2669459064091549,"score_spread":0.2546397870409993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2728241634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950541,0.0017475992,0.00004235821,0.0013953175,0.000021775642,0.00032943295,0.00003684755,0.000024983221,0.0013475728],"genre_scores_gemma":[0.9965952,0.0007436389,0.0020954695,0.000049280163,0.00010928573,0.000030043646,0.000008011671,0.000019534002,0.00034952437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990817,0.000032040716,0.00015032449,0.00030536728,0.00017473746,0.00025584898],"domain_scores_gemma":[0.999208,0.000088421446,0.000059425493,0.00033857086,0.000049106955,0.00025647852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009632439,0.00015542621,0.0002661325,0.000066735294,0.00042764045,0.00013437636,0.000087537475,0.00008934627,0.000027725817],"category_scores_gemma":[0.00009043491,0.00012227948,0.000027665505,0.00002364971,0.00043690766,0.00008156257,0.00019409241,0.0001808505,0.000004097964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005892593,0.0009940456,0.7627547,0.0010945952,0.0009839586,0.00083207444,0.001266384,3.3807217e-7,0.18874949,0.0021915345,0.00055931415,0.039984312],"study_design_scores_gemma":[0.005011826,0.00027544622,0.9704861,0.00013307483,0.00047060274,0.0008373801,0.000099603225,0.00025857138,0.020937031,0.0012362882,0.000095101976,0.00015896875],"about_ca_topic_score_codex":0.000046423476,"about_ca_topic_score_gemma":0.00003196024,"teacher_disagreement_score":0.20773141,"about_ca_system_score_codex":0.000016633629,"about_ca_system_score_gemma":0.000056933914,"threshold_uncertainty_score":0.49864122},"labels":[],"label_agreement":null},{"id":"W2730325962","doi":"10.1182/blood.v128.22.595.595","title":"Marked Differences in the Genomic Landscape of Pediatric Compared to Adult Acute Myeloid Leukemia: A Report from the Children's Oncology Group and NCI/COG Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Cog; Oncology; Myeloid leukemia; Medicine; Transcriptome; Internal medicine; Clinical trial; Bioinformatics; Gene; Biology; Genetics","score_opus":0.03269638115181099,"score_gpt":0.3212255211498859,"score_spread":0.2885291399980749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2730325962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902199,0.00050469773,0.00013786438,0.0036395516,0.000029645164,0.0041680983,0.00015930884,0.000024322835,0.0011166236],"genre_scores_gemma":[0.9952339,0.0006803159,0.0011525044,0.0009023219,0.00041869277,0.0013872492,0.000058802445,0.000037100333,0.00012910426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960634,0.0012209605,0.0005220454,0.0007536878,0.00073240785,0.000707465],"domain_scores_gemma":[0.9952192,0.003333339,0.00013832042,0.00072767184,0.00032385648,0.00025762536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016517218,0.0002940482,0.0007133457,0.00029021635,0.00019290583,0.000040358158,0.0005507407,0.00019985042,0.00005518699],"category_scores_gemma":[0.0004820009,0.00013595981,0.00008552315,0.0008834731,0.00024280162,0.00006188381,0.0003727911,0.0005811363,0.000051029514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036361276,0.0011064876,0.9296688,0.000021372109,0.0016920862,0.0005810843,0.004786082,9.2600476e-7,0.049366817,0.00008728965,0.0022038284,0.006849144],"study_design_scores_gemma":[0.009499776,0.0021496434,0.98255396,0.000047967296,0.0005235672,0.00016171914,0.0005886127,0.000032011932,0.0037720585,0.00032726626,0.00017084643,0.00017259897],"about_ca_topic_score_codex":0.0008884954,"about_ca_topic_score_gemma":0.00022421227,"teacher_disagreement_score":0.052885175,"about_ca_system_score_codex":0.00044449282,"about_ca_system_score_gemma":0.00065502845,"threshold_uncertainty_score":0.55442804},"labels":[],"label_agreement":null},{"id":"W2730666287","doi":"10.1038/nature22993","title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","year":2017,"lang":"en","type":"article","venue":"Nature","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":582,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Occupational Cancer Research Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Stem cell; Haematopoiesis; Myeloid; Progenitor cell; Medicine; Cancer research; Chemotherapy; Immunology; Biology; Oncology; Internal medicine; Genetics","score_opus":0.017772199741437133,"score_gpt":0.32414473596473325,"score_spread":0.30637253622329613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2730666287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818046,0.00037684388,0.000016452113,0.01129921,0.00030511172,0.0006120634,0.000024297606,0.000023731276,0.005537694],"genre_scores_gemma":[0.99192643,0.00009407461,0.0005811684,0.0012381629,0.00020221688,0.000017299028,0.0000035642975,0.000028979084,0.005908129],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99855304,0.00004902701,0.00023694761,0.00028774692,0.0005112272,0.000362021],"domain_scores_gemma":[0.99829125,0.00012388284,0.000114809445,0.0011783064,0.00014361022,0.0001481092],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.000578074,0.00015055729,0.0003310105,0.00015382284,0.0001611218,0.00004102259,0.00066828274,0.0008332398,0.00004031785],"category_scores_gemma":[0.00018287197,0.00009515181,0.00009427896,0.00023380657,0.000105294435,0.00011821806,0.00019671081,0.0038811797,0.0000855108],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029071423,0.00029993345,0.03914764,0.00057650637,0.00052617304,0.0021645739,0.007255583,0.000115049195,0.7201686,0.0067261313,0.13702059,0.0830921],"study_design_scores_gemma":[0.0050494703,0.0004530668,0.12138473,0.0007464812,0.00017805662,0.00016853664,0.00083225244,0.00048226482,0.7080057,0.00014791903,0.1621792,0.0003722795],"about_ca_topic_score_codex":0.00022440556,"about_ca_topic_score_gemma":0.00013301741,"teacher_disagreement_score":0.082719825,"about_ca_system_score_codex":0.0006986705,"about_ca_system_score_gemma":0.0003709696,"threshold_uncertainty_score":0.9984169},"labels":[],"label_agreement":null},{"id":"W2731034946","doi":"10.1182/blood.v128.22.5117.5117","title":"Using the Zebrafish to Model the Tumour-Suppressor Effects of NUP98 in NUP98-NSD1 mediated AML","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Zebrafish; Cancer research; Myeloid leukemia; Biology; Oncogene; Epigenetics; Leukemia; Cancer; Gene; Genetics; Cell cycle","score_opus":0.025856489904854073,"score_gpt":0.29717197556737307,"score_spread":0.271315485662519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2731034946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98945016,0.00021078034,0.0007803145,0.0071216607,0.000062904735,0.0012602734,0.000020313577,0.000038406815,0.0010552068],"genre_scores_gemma":[0.99747264,0.000034512377,0.0007532958,0.0009333768,0.00015891418,0.00008142541,0.0000028381241,0.000046048404,0.0005169459],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980967,0.00020129266,0.00032290598,0.00029190467,0.0005815581,0.00050566386],"domain_scores_gemma":[0.99784607,0.0010751096,0.000082784994,0.00069987914,0.00013250235,0.00016363118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062547013,0.0001818047,0.0003546467,0.00014619237,0.00007224064,0.0000152017465,0.0004718518,0.00011430196,0.000054109005],"category_scores_gemma":[0.0016825002,0.00007968726,0.00009357677,0.0004812761,0.00017764594,0.00007732269,0.00024903842,0.00032635304,0.000055755958],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020588402,0.0003452079,0.0030405382,0.000119744545,0.000113971684,0.00009404647,0.00111959,0.00009221665,0.99138725,0.00016245451,0.0026887285,0.0006303602],"study_design_scores_gemma":[0.013435146,0.00039830923,0.017561762,0.00093508867,0.00033038965,0.00010135118,0.00021091056,0.014377355,0.95133233,0.00041229613,0.0006381601,0.0002668922],"about_ca_topic_score_codex":0.00015923005,"about_ca_topic_score_gemma":0.00004066652,"teacher_disagreement_score":0.040054917,"about_ca_system_score_codex":0.00012738316,"about_ca_system_score_gemma":0.00034448004,"threshold_uncertainty_score":0.32495522},"labels":[],"label_agreement":null},{"id":"W2731162750","doi":"10.1111/bjh.14741","title":"Acute myeloid leukemia with mutated <i><scp>NPM</scp>1</i> demonstrating multilineage dysplasia and marked thrombocytosis","year":2017,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Thrombocytosis; NPM1; Dysplasia; Myeloid; Pathology; Trisomy 8; Polycythemia vera; Medicine; Bone marrow; Internal medicine; Karyotype; Immunology; Biology; Platelet; Genetics; Chromosome","score_opus":0.01509676414474175,"score_gpt":0.2863323800750135,"score_spread":0.27123561593027173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2731162750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99362963,0.0013972528,0.00050117046,0.00074337283,0.00015949478,0.0004040883,0.000027416641,0.000042109736,0.0030954485],"genre_scores_gemma":[0.9819173,0.0021937124,0.014663927,0.00033226103,0.00018680177,0.000010798333,0.000010941489,0.00007535372,0.00060887967],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99714464,0.00020534266,0.00091793225,0.00042173092,0.0005634692,0.0007468964],"domain_scores_gemma":[0.9966797,0.00054032844,0.0010873525,0.00048456862,0.00066123356,0.00054676394],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00076820276,0.0003197954,0.0014347323,0.00023953809,0.0006628135,0.00030734966,0.0005351901,0.0003345736,0.000040868916],"category_scores_gemma":[0.0019091761,0.00029406988,0.00016529545,0.00014488923,0.0010792741,0.0005381755,0.00022847272,0.0014755664,0.000015124294],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018073214,0.00039914544,0.13024345,0.0008597412,0.004081182,0.7069366,0.00077407726,0.000016010808,0.07063985,0.00016104431,0.029844938,0.054236665],"study_design_scores_gemma":[0.011088737,0.0009797027,0.08498549,0.0013567487,0.0006815289,0.87380385,0.0006857638,0.0011523688,0.024017012,0.00007989474,0.0009995855,0.00016929989],"about_ca_topic_score_codex":0.00021333407,"about_ca_topic_score_gemma":0.00025483104,"teacher_disagreement_score":0.1668673,"about_ca_system_score_codex":0.00023520672,"about_ca_system_score_gemma":0.0010555064,"threshold_uncertainty_score":0.9999511},"labels":[],"label_agreement":null},{"id":"W2732441612","doi":"10.1182/blood.v128.22.454.454","title":"Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Myeloid; Leukemia; Myeloid leukemia; Biology; Acute lymphocytic leukemia; Immunology; Cancer research; Medicine; Lymphoblastic Leukemia","score_opus":0.014138770153635048,"score_gpt":0.25932859678282927,"score_spread":0.24518982662919422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2732441612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99265546,0.0006426787,0.000088692344,0.0004416074,0.0000913561,0.0002540673,0.000034918114,0.00006491359,0.0057263393],"genre_scores_gemma":[0.9943114,0.0007113276,0.0011786934,0.000076183336,0.0006898299,0.000014541261,0.000012300139,0.000040527986,0.0029652056],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987434,0.000037830247,0.00027243927,0.00026831258,0.0003143287,0.00036366572],"domain_scores_gemma":[0.9989819,0.00013059143,0.00009085883,0.00048315295,0.00013166467,0.00018182753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020328804,0.00014228372,0.00033634686,0.0002005763,0.000032068827,0.0000057376697,0.0002032109,0.00012540407,0.00047509486],"category_scores_gemma":[0.00013528728,0.000089896224,0.0001070399,0.00028290795,0.000061935985,0.000053373282,0.000120570796,0.000154376,0.0005350656],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054109463,0.00039707762,0.33228543,0.00017388797,0.0007058634,0.00027287495,0.00015062864,5.6915076e-7,0.63654315,0.00034301702,0.021626947,0.0069594905],"study_design_scores_gemma":[0.036732603,0.0015141334,0.7411381,0.00010315905,0.0028828895,0.00033219205,0.00007317155,0.000053916465,0.20976196,0.00037781126,0.006475216,0.00055484654],"about_ca_topic_score_codex":0.000022249948,"about_ca_topic_score_gemma":0.0000035491241,"teacher_disagreement_score":0.42678115,"about_ca_system_score_codex":0.00013683445,"about_ca_system_score_gemma":0.0007991851,"threshold_uncertainty_score":0.68773645},"labels":[],"label_agreement":null},{"id":"W2732727228","doi":"10.3324/haematol.2016.162230","title":"High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia","year":2017,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Leukemia and Lymphoma Society","keywords":"Myeloid leukemia; Temsirolimus; Leukemia; Cancer research; Tumor microenvironment; PI3K/AKT/mTOR pathway; Biology; Bone marrow; Signal transduction; Immunology; Cell biology","score_opus":0.025313561182599316,"score_gpt":0.29439122386803,"score_spread":0.2690776626854307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2732727228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900718,0.00028410842,0.005890938,0.0019919472,0.00014207384,0.0013043825,0.000014513742,0.000058165773,0.00024210176],"genre_scores_gemma":[0.9749948,0.0003251959,0.023627559,0.00040619395,0.00003534722,0.00014757275,0.000060898445,0.00003972317,0.00036272916],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976914,0.00013859171,0.00058395683,0.0005684087,0.0004764979,0.0005411589],"domain_scores_gemma":[0.9983477,0.0001529372,0.00039287214,0.0008693563,0.00010549432,0.00013163545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007137422,0.00027604055,0.0007405552,0.00021361858,0.0003295859,0.00007588962,0.0005418312,0.00023802657,0.0000773355],"category_scores_gemma":[0.00019953829,0.00023649407,0.00012149064,0.0001786876,0.0002751891,0.00017848838,0.00021719422,0.00042655217,0.000031293355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005120105,0.00047977784,0.012734353,0.0003671141,0.00023392565,0.0017600984,0.00057783304,0.00085515046,0.9642856,0.010863406,0.00071773573,0.0020048972],"study_design_scores_gemma":[0.0044854837,0.00046945427,0.027909592,0.00046245978,0.00004954336,0.000037943606,0.0001949005,0.0030896042,0.9607393,0.002218105,0.00007063608,0.0002729678],"about_ca_topic_score_codex":0.00013236345,"about_ca_topic_score_gemma":0.000048872887,"teacher_disagreement_score":0.017736621,"about_ca_system_score_codex":0.0005985243,"about_ca_system_score_gemma":0.00016164493,"threshold_uncertainty_score":0.96439487},"labels":[],"label_agreement":null},{"id":"W2733156470","doi":"10.1158/2159-8290.cd-17-0476","title":"Novel Mitochondrial Mechanisms of Cytarabine Resistance in Primary AML Cells","year":2017,"lang":"en","type":"letter","venue":"Cancer Discovery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Cytarabine; Myeloid leukemia; Cancer research; Leukemia; Chemotherapy; Oxidative phosphorylation; Bone marrow; Myeloid; Cancer; Medicine; Phosphorylation; Biology; Immunology; Internal medicine; Cell biology; Biochemistry","score_opus":0.022764658243610684,"score_gpt":0.2877569485687249,"score_spread":0.26499229032511423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2733156470","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0136880055,0.009458255,0.010555493,0.89773786,0.011216567,0.006692891,0.007088737,0.00015367809,0.043408535],"genre_scores_gemma":[0.0047143674,0.004085795,0.015226081,0.5089644,0.028901877,0.0013698697,0.002916624,0.0007603809,0.4330606],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99623644,0.000072180424,0.00072271895,0.00097077305,0.0011679488,0.0008299114],"domain_scores_gemma":[0.9970907,0.00018594312,0.00059838034,0.0018185212,0.00019460896,0.000111838315],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0002258082,0.0005403471,0.0014906557,0.00042610033,0.000071539056,0.00008432883,0.0008842234,0.0010803803,0.0001895036],"category_scores_gemma":[0.00012356584,0.00048644686,0.0003560741,0.00022438246,0.00039241908,0.00036954295,0.00030703202,0.0029804518,0.000031983458],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010397194,0.00007546074,0.000042963733,0.002289331,0.00016772938,0.0010643097,0.00005821442,0.0000050577482,0.22211154,0.000056151286,0.77295685,0.00013271208],"study_design_scores_gemma":[0.011476999,0.00029767887,0.0023105054,0.006834994,0.00047854517,0.00004333624,0.00002414214,0.000018751709,0.09515498,0.0011796639,0.88104117,0.001139227],"about_ca_topic_score_codex":0.0010464572,"about_ca_topic_score_gemma":0.00033373627,"teacher_disagreement_score":0.38965207,"about_ca_system_score_codex":0.0025497824,"about_ca_system_score_gemma":0.0038380087,"threshold_uncertainty_score":0.9997587},"labels":[],"label_agreement":null},{"id":"W2733623866","doi":"10.1097/mph.0000000000000893","title":"Prenatally Diagnosed Infant AML","year":2017,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Children's Hospital of Eastern Ontario","funders":"","keywords":"Medicine; Fetus; Myeloid leukemia; In utero; Gestation; Leukemia; Chemotherapy; Malignancy; Trisomy; Induction chemotherapy; Pediatrics; Myeloid; Down syndrome; Obstetrics; Pregnancy; Internal medicine","score_opus":0.032059776620499185,"score_gpt":0.3715712999279483,"score_spread":0.3395115233074491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2733623866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9656686,0.002398726,0.00029710503,0.016279293,0.0013322053,0.0004425536,0.000007907547,0.000032692857,0.013540898],"genre_scores_gemma":[0.98583513,0.0036252085,0.0058395825,0.00076775334,0.0032586656,0.000018565393,0.0000044474164,0.00004419383,0.0006064712],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969484,0.0002534599,0.0012266489,0.00029862658,0.0005797678,0.000693055],"domain_scores_gemma":[0.99479574,0.0010212099,0.0019129873,0.0008265698,0.0008093443,0.0006341639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018495268,0.00025705254,0.0014160858,0.0006627108,0.00029626282,0.000049657516,0.0009668685,0.0006657323,0.00036919478],"category_scores_gemma":[0.0062011443,0.00019464466,0.00035526688,0.0001818531,0.00040290155,0.0003400444,0.00038305984,0.0016644847,0.00023408707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028072523,0.0015549863,0.5960806,0.00047935176,0.00076806283,0.068711415,0.0010765281,0.000005607981,0.0016690216,0.0016453089,0.29991773,0.025284106],"study_design_scores_gemma":[0.044314757,0.015301608,0.4107254,0.00019076376,0.0027016096,0.110721305,0.0009859244,0.000309344,0.0044851406,0.002240646,0.40706187,0.0009615955],"about_ca_topic_score_codex":0.000048405003,"about_ca_topic_score_gemma":0.000030838106,"teacher_disagreement_score":0.18535519,"about_ca_system_score_codex":0.0007023583,"about_ca_system_score_gemma":0.004320103,"threshold_uncertainty_score":0.7937379},"labels":[],"label_agreement":null},{"id":"W2734059981","doi":"10.1002/ajh.24842","title":"ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems","year":2017,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Predictive power; Medicine; Internal medicine","score_opus":0.041434262351583755,"score_gpt":0.34633243900680855,"score_spread":0.3048981766552248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734059981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98492926,0.0008514829,0.0017874101,0.011196814,0.0005976388,0.00030040607,0.000007789917,0.000013051411,0.000316154],"genre_scores_gemma":[0.99837965,0.00013484151,0.000792305,0.00013583581,0.00019119102,0.00000526903,0.0000014970358,0.00003523913,0.00032418582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977879,0.00039178203,0.0006848907,0.0002012772,0.0006164473,0.00031770617],"domain_scores_gemma":[0.996129,0.00071739196,0.0017821077,0.000612787,0.0005701998,0.00018851856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010343109,0.00018501349,0.000820698,0.0002496584,0.00014860791,0.00005488307,0.0006203617,0.00006853874,0.0001147311],"category_scores_gemma":[0.002240255,0.000115874325,0.00018604846,0.00013345982,0.0009331356,0.00018334959,0.0002195232,0.0005475293,0.000010317442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03311492,0.0005558295,0.8775286,0.00032993246,0.0062206746,0.005640015,0.021101424,0.0014745173,0.026419409,0.0006544657,0.013287274,0.013672919],"study_design_scores_gemma":[0.025380502,0.02373352,0.7036335,0.010446132,0.0017978427,0.1333941,0.062809296,0.010829257,0.01964944,0.0006783425,0.0064295246,0.0012185607],"about_ca_topic_score_codex":0.00031321455,"about_ca_topic_score_gemma":0.0000035278345,"teacher_disagreement_score":0.17389514,"about_ca_system_score_codex":0.00019635669,"about_ca_system_score_gemma":0.00065724575,"threshold_uncertainty_score":0.47252178},"labels":[],"label_agreement":null},{"id":"W2736663104","doi":"10.14740/jh329w","title":"<i>De Novo</i> Precursor B-Lymphoblastic Leukemia/Lymphoma With Double-Hit Gene Rearrangements (<i>MYC/BCL-2</i>) Presented With Spinal Cord Compression and Acquired Factor XIII Deficiency","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunophenotyping; Pathology; Bone marrow; CD20; Fluorescence in situ hybridization; Medicine; Lymphoma; Molecular biology; Cancer research; Biology; Flow cytometry","score_opus":0.032050621231733925,"score_gpt":0.3206012209874957,"score_spread":0.2885505997557618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736663104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99304134,0.0013180753,0.0021740948,0.0015779606,0.00017772669,0.0006284021,0.000012654232,0.000030872587,0.0010388672],"genre_scores_gemma":[0.9942879,0.00035589482,0.004283311,0.00018832594,0.00015810417,0.000019883166,0.0000056391577,0.0000641445,0.00063680403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708325,0.00011998059,0.0006954422,0.00043342396,0.0008909662,0.00077694276],"domain_scores_gemma":[0.99683976,0.0001373851,0.0011193657,0.0007380601,0.0006024821,0.0005629178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003735313,0.00037813358,0.0010602445,0.00032109892,0.0004439947,0.0001448213,0.000613994,0.00023842712,0.00008160072],"category_scores_gemma":[0.00019824634,0.000240392,0.000105185914,0.00015276553,0.0007159911,0.00039304158,0.0002489857,0.00037957015,0.00001527084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29127958,0.0022652675,0.45462388,0.002235245,0.0020556115,0.024353752,0.0011620453,0.00007479672,0.18579811,0.00050954695,0.009910441,0.02573174],"study_design_scores_gemma":[0.14575696,0.040273737,0.42183802,0.006036951,0.0016779483,0.24631363,0.00084205647,0.002588542,0.12583368,0.00021311165,0.007238889,0.0013864769],"about_ca_topic_score_codex":0.000092591545,"about_ca_topic_score_gemma":0.0000248142,"teacher_disagreement_score":0.22195987,"about_ca_system_score_codex":0.00061503943,"about_ca_system_score_gemma":0.0015156221,"threshold_uncertainty_score":0.9802901},"labels":[],"label_agreement":null},{"id":"W2738119439","doi":"10.1182/blood.v128.22.4662.4662","title":"Improving Revised International Prognostic Scoring System (IPSS-R) Pre-Allogeneic Stem Cell Transplant Does Not Translate into Better Post-Transplant Outcomes for Patients with Myelodysplastic Syndromes","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dr. Georges-L.-Dumont University Hospital Centre; Vancouver General Hospital; BC Cancer Agency; McMaster University; Leukemia & Lymphoma Society of Canada; University of British Columbia","funders":"","keywords":"Medicine; International Prognostic Scoring System; Cytopenia; Internal medicine; Myelodysplastic syndromes; Univariate analysis; Multivariate analysis; Oncology; Transplantation; Cumulative incidence; Bone marrow","score_opus":0.008626040680261805,"score_gpt":0.23410929524631746,"score_spread":0.22548325456605567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738119439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98842645,0.00007159929,0.006062798,0.001147053,0.00033808526,0.0029311252,0.00077527465,0.00021361878,0.00003401307],"genre_scores_gemma":[0.99599296,0.000034234912,0.0024427965,0.00015341942,0.0001557848,0.00048990845,0.00015387422,0.00012667729,0.0004503292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967527,0.00008098241,0.0007200918,0.0008024232,0.0008791587,0.000764658],"domain_scores_gemma":[0.9980636,0.0005792402,0.0002069597,0.00045763212,0.00038108113,0.0003114906],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032084624,0.00049154524,0.00071733916,0.00032338267,0.00015930254,0.00006852256,0.00043495325,0.00018512596,0.000026888412],"category_scores_gemma":[0.000048107057,0.0002566402,0.00023359383,0.00013152801,0.00010717563,0.00032590656,0.000039028193,0.00026499876,0.00002715566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031676034,0.0007821998,0.81327784,0.005691795,0.0011417462,0.00039888694,0.0012082114,0.000003478087,0.16655107,0.000035200992,0.0000052383893,0.0077367295],"study_design_scores_gemma":[0.07272447,0.005101254,0.70971525,0.011778099,0.0049905432,0.00052063825,0.00028238076,0.00043965178,0.19259465,0.000010560942,0.00017780042,0.0016647154],"about_ca_topic_score_codex":0.000054484066,"about_ca_topic_score_gemma":0.000028371716,"teacher_disagreement_score":0.1035626,"about_ca_system_score_codex":0.00026550202,"about_ca_system_score_gemma":0.00028196644,"threshold_uncertainty_score":0.99998856},"labels":[],"label_agreement":null},{"id":"W2740776800","doi":"10.1158/1538-7445.am2017-1509","title":"Abstract 1509: RUNX1 dosage dictates gene signature and <i>in vitro</i> response to glucocorticoids in acute myeloid leukemia","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"RUNX1; Myeloid leukemia; Myeloid; Leukemia; Gene knockdown; Gene signature; Biology; Cancer research; Ex vivo; Cytarabine; Small hairpin RNA; Glucocorticoid receptor; Haematopoiesis; Internal medicine; Stem cell; Cell culture; In vivo; Medicine; Gene; Gene expression; Glucocorticoid; Immunology; Genetics","score_opus":0.03676145882723393,"score_gpt":0.388285097323117,"score_spread":0.3515236384958831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740776800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97956,0.0022070045,0.000004186395,0.015013912,0.00011136663,0.0017972643,0.000112806505,0.000043787786,0.0011496725],"genre_scores_gemma":[0.9910557,0.0029363967,0.00046346558,0.00055982557,0.00030960477,0.00069191726,0.00002523338,0.00009847698,0.0038593244],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9948888,0.00036469867,0.00053077127,0.0010397012,0.0014466485,0.0017293713],"domain_scores_gemma":[0.9963957,0.0007101579,0.00009399213,0.0015474561,0.0003779113,0.000874775],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0042912248,0.00034569757,0.0006834828,0.0011805248,0.00046560052,0.00032056845,0.00089649466,0.00040464438,0.00021051285],"category_scores_gemma":[0.0020906196,0.0003071469,0.00008800963,0.00083287724,0.0007068842,0.00036566667,0.0009145224,0.0029808255,0.00013504668],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026335916,0.00007833296,0.010967192,0.00014230834,0.00006876044,0.0038752186,0.0008091891,0.000021553386,0.9379214,0.0000072404537,0.003514441,0.016258458],"study_design_scores_gemma":[0.005507172,0.00030844656,0.5336051,0.0004188075,0.000017798006,0.00005840437,0.00023422814,0.00019100404,0.4528961,0.000102806116,0.0063597374,0.0003004039],"about_ca_topic_score_codex":0.004420741,"about_ca_topic_score_gemma":0.0008915253,"teacher_disagreement_score":0.5226379,"about_ca_system_score_codex":0.0036583757,"about_ca_system_score_gemma":0.002998422,"threshold_uncertainty_score":0.9999381},"labels":[],"label_agreement":null},{"id":"W2740846152","doi":"10.1002/stem.2655","title":"Brief Report: Human Acute Myeloid Leukemia Reprogramming to Pluripotency Is a Rare Event and Selects for Patient Hematopoietic Cells Devoid of Leukemic Mutations","year":2017,"lang":"en","type":"article","venue":"Stem Cells","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Reprogramming; Biology; Myeloid leukemia; Induced pluripotent stem cell; Haematopoiesis; Cancer research; Leukemia; Myeloid; Stem cell; Population; Immunology; Genetics; Cell; Embryonic stem cell; Gene; Medicine","score_opus":0.01942503573374269,"score_gpt":0.3097946691394899,"score_spread":0.2903696334057472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740846152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99316555,0.00028652124,0.0011979089,0.0007584271,0.0002053555,0.0033759512,0.00011215571,0.00007729078,0.00082086603],"genre_scores_gemma":[0.9852346,0.00006682555,0.0061974996,0.00027006108,0.00012311999,0.00034267563,0.000059656984,0.00009777995,0.0076077688],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99656755,0.00005912353,0.0009995408,0.00095227006,0.0006616644,0.00075984426],"domain_scores_gemma":[0.9963065,0.00014232959,0.00070817384,0.0017129616,0.000616644,0.00051342737],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005858664,0.00036914306,0.0007730384,0.00025892485,0.00067676743,0.00012484245,0.00038242756,0.00021557277,0.00004848197],"category_scores_gemma":[0.00012569335,0.00034865827,0.00025220233,0.00021891367,0.00023333088,0.00017052419,0.00036153663,0.0003543055,0.000031789994],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038778345,0.00020021276,0.0014837927,0.0017781996,0.00052323507,0.0012196366,0.009964112,0.000041854357,0.93321484,0.00011430831,0.015810993,0.035261013],"study_design_scores_gemma":[0.003058365,0.0014650088,0.0015121944,0.000675712,0.0004154841,0.0007401228,0.0010720751,0.00035337853,0.9775178,0.0002091804,0.012532846,0.00044786735],"about_ca_topic_score_codex":0.00042144017,"about_ca_topic_score_gemma":0.000039078335,"teacher_disagreement_score":0.044302907,"about_ca_system_score_codex":0.0009084841,"about_ca_system_score_gemma":0.0010229643,"threshold_uncertainty_score":0.9998965},"labels":[],"label_agreement":null},{"id":"W2741997980","doi":"10.1158/1538-7445.am2017-1087","title":"Abstract 1087: CPX-351 works synergistically in combination with FLT3 inhibitors against AML with FLT3-ITD","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celator Pharmaceuticals (Canada)","funders":"","keywords":"Daunorubicin; Midostaurin; Cytarabine; Viability assay; Pharmacology; Flow cytometry; Ex vivo; Cancer research; In vivo; Leukemia; Myeloid leukemia; Medicine; Chemistry; Cell; Biology; Internal medicine; Immunology; Biochemistry; Genetics","score_opus":0.05326379269320802,"score_gpt":0.3919127049360759,"score_spread":0.33864891224286786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741997980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635185,0.0003677635,0.000078027995,0.008628126,0.000108187276,0.0014545877,0.000016077563,0.00006668182,0.02576205],"genre_scores_gemma":[0.99440277,0.0007607537,0.00038241586,0.00013218587,0.00046111338,0.00048964797,0.00005130538,0.00011049942,0.0032093218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994895,0.00017268812,0.0004049712,0.00082029396,0.0023435026,0.0013635852],"domain_scores_gemma":[0.99617267,0.00040803928,0.00014257403,0.0014645075,0.0012027706,0.0006094555],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002101569,0.00031098738,0.00053127157,0.000670864,0.0006546281,0.00043243894,0.0008035312,0.0002956415,0.00036358627],"category_scores_gemma":[0.001110564,0.00022621258,0.00006034276,0.00074534176,0.0014719823,0.00048333264,0.00032721093,0.0027917402,0.0001657232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028220544,0.0027649393,0.41006276,0.0026651477,0.0009067759,0.014419736,0.002735017,0.0009942577,0.10460027,0.0034793394,0.047064915,0.3820863],"study_design_scores_gemma":[0.025541307,0.0030292857,0.91121215,0.009091681,0.00007503292,0.00008579258,0.001622978,0.0023239017,0.031405874,0.00037559506,0.014152063,0.001084344],"about_ca_topic_score_codex":0.0029385749,"about_ca_topic_score_gemma":0.002538076,"teacher_disagreement_score":0.50114936,"about_ca_system_score_codex":0.0022470132,"about_ca_system_score_gemma":0.0029647634,"threshold_uncertainty_score":0.99950886},"labels":[],"label_agreement":null},{"id":"W2741998413","doi":"10.1186/s12889-017-4644-6","title":"The incidence of acute myeloid leukemia in Calgary, Alberta, Canada: a retrospective cohort study","year":2017,"lang":"en","type":"article","venue":"BMC Public Health","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Calgary Laboratory Services; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Incidence (geometry); Myeloid leukemia; Epidemiology; Demography; Population; Retrospective cohort study; Biostatistics; Pediatrics; Internal medicine; Environmental health","score_opus":0.028503130615975786,"score_gpt":0.3352093937633103,"score_spread":0.3067062631473345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741998413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97513556,0.000109040855,0.000051425814,0.015175101,0.00020998367,0.002765366,0.000018154547,0.000018758356,0.00651662],"genre_scores_gemma":[0.99475443,0.00023565236,0.00018344048,0.000632413,0.00011363562,0.00019520811,0.000015106139,0.00003395676,0.0038361796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99577206,0.0004243299,0.00078920217,0.00056626793,0.0013716414,0.0010765106],"domain_scores_gemma":[0.99592143,0.0004889251,0.0005107071,0.0019963642,0.00044694872,0.000635617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048238477,0.00022539945,0.0007879812,0.00016216385,0.0007853552,0.000107873784,0.0010199136,0.000101133526,0.00004312229],"category_scores_gemma":[0.0042751725,0.00015855253,0.00006922497,0.00037932355,0.00033653362,0.00023752954,0.0004507327,0.0008941808,0.000011450984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00012822282,0.00008938407,0.98803824,0.00005133154,0.00013853451,0.000077743905,0.00064821803,5.401791e-7,0.0000102724225,0.00056595117,0.008277803,0.001973753],"study_design_scores_gemma":[0.0020385073,0.00048562494,0.9917067,0.000049268816,0.000021108548,0.00004809631,0.00063065876,0.00093282183,0.00001668583,0.000031658325,0.0039179362,0.000120916135],"about_ca_topic_score_codex":0.9856344,"about_ca_topic_score_gemma":0.99088496,"teacher_disagreement_score":0.052153677,"about_ca_system_score_codex":0.017407676,"about_ca_system_score_gemma":0.069561355,"threshold_uncertainty_score":0.9863643},"labels":[],"label_agreement":null},{"id":"W2745668487","doi":"10.1016/s1470-2045(17)30576-4","title":"Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Astex Pharmaceuticals","keywords":"Medicine; Myeloid leukaemia; Internal medicine","score_opus":0.05811141162999822,"score_gpt":0.3966105076241037,"score_spread":0.3384990959941055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745668487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97501624,0.00009999566,0.000029422363,0.011532716,0.00043815168,0.0051284037,0.0009883792,0.00007213162,0.006694553],"genre_scores_gemma":[0.99104434,0.00074538647,0.0014419544,0.00091274135,0.0022536775,0.00057337584,0.0011245367,0.00006977726,0.0018342262],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963411,0.0005990194,0.0007810821,0.0007623364,0.000510317,0.0010061575],"domain_scores_gemma":[0.9951888,0.001597174,0.0006637366,0.0020190394,0.00021940646,0.0003118527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000999634,0.00044470988,0.0017598927,0.00016683537,0.0003878445,0.00007844487,0.0008291398,0.00035172675,0.000197712],"category_scores_gemma":[0.0018758866,0.00025120293,0.00017326359,0.00017303658,0.00061315566,0.00022927088,0.00022310729,0.0008769841,0.00016776289],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93315905,0.004629975,0.002053884,0.000010280453,0.000880783,0.0017657003,0.0018831915,0.0000040751056,0.0011532563,0.000014855789,0.0062740534,0.048170876],"study_design_scores_gemma":[0.9462946,0.012809262,0.005321898,0.00007860585,0.0007107223,0.000030920717,0.00018750489,0.0007928487,0.0011249654,0.000058711375,0.032335564,0.00025440138],"about_ca_topic_score_codex":0.0020883474,"about_ca_topic_score_gemma":0.0010904478,"teacher_disagreement_score":0.047916472,"about_ca_system_score_codex":0.0018311486,"about_ca_system_score_gemma":0.0011400668,"threshold_uncertainty_score":0.99999404},"labels":[],"label_agreement":null},{"id":"W2746136596","doi":"10.1016/j.exphem.2017.06.041","title":"New strategies for targeting leukemia stem cells","year":2017,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Leukemia; Stem cell; Redundancy (engineering); Exploit; Computational biology; Ex vivo; Biology; Cancer research; Immunology; Computer science; In vivo; Genetics","score_opus":0.0402136962044235,"score_gpt":0.3633992290645622,"score_spread":0.3231855328601387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2746136596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92239976,0.011717448,0.01170514,0.0030047596,0.0020764852,0.002911615,0.000023876464,0.000356923,0.045803975],"genre_scores_gemma":[0.9802163,0.000013324242,0.013352235,0.00020467499,0.00032078507,0.00009826522,0.000014205674,0.00004705114,0.0057331407],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986068,0.000025748313,0.00027813297,0.0003832585,0.00017985926,0.000526227],"domain_scores_gemma":[0.99887073,0.00008778223,0.00014364683,0.000591884,0.0000543887,0.00025154618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014294033,0.00019704415,0.00045493737,0.00006750943,0.00040810186,0.00010118802,0.00035165055,0.00018046575,0.0004602186],"category_scores_gemma":[0.000025720137,0.00017593842,0.00012894014,0.000027943199,0.00018359743,0.00022381102,0.00020842314,0.00021151443,0.00019877467],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010178426,0.0001289194,0.0011695345,0.00024922597,0.00016335631,0.00036266632,0.0014666964,0.0000034472184,0.5856329,0.19089192,0.2157847,0.0031287905],"study_design_scores_gemma":[0.003153051,0.0003896525,0.00006914886,0.000042406427,0.000016404543,0.00025530224,0.004488094,0.0004272822,0.9793234,0.00060868857,0.011057832,0.00016872596],"about_ca_topic_score_codex":0.000208429,"about_ca_topic_score_gemma":0.000005300166,"teacher_disagreement_score":0.3936905,"about_ca_system_score_codex":0.00042668116,"about_ca_system_score_gemma":0.00085816375,"threshold_uncertainty_score":0.71745604},"labels":[],"label_agreement":null},{"id":"W2747211312","doi":"10.1200/jco.2017.35.15_suppl.tps7068","title":"A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Clinical endpoint; Internal medicine; Surgery; Gastroenterology; Clinical trial; Adverse effect","score_opus":0.17253060229991982,"score_gpt":0.5040483404656478,"score_spread":0.33151773816572805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747211312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891655,0.00007495065,0.00013163916,0.004367063,0.00073148997,0.0051609976,0.00016242315,0.000007335687,0.00019861499],"genre_scores_gemma":[0.99193805,0.0018451979,0.0035021133,0.0012994111,0.0007535608,0.000288784,0.000088679815,0.00005291664,0.0002312879],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934296,0.0007388559,0.0040822146,0.00050958025,0.0007325228,0.0005072048],"domain_scores_gemma":[0.9873529,0.0033659898,0.004718155,0.00073324115,0.0034970627,0.00033267116],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025150066,0.00040169875,0.0032173283,0.00039847972,0.00027149354,0.000060320086,0.001015561,0.00043036893,0.000069250906],"category_scores_gemma":[0.006351569,0.00025054574,0.0003797777,0.00028638678,0.0006182955,0.0005552488,0.00023231648,0.0008699797,0.0000017960003],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3630945,0.17273119,0.012722055,0.00015585359,0.004768846,0.0044774064,0.0190646,0.000026335272,0.010751668,0.000021047023,0.004772307,0.40741417],"study_design_scores_gemma":[0.5306304,0.39984137,0.045622405,0.0005169547,0.0012537587,0.00037168158,0.010747021,0.00084827683,0.0070720892,0.0000651884,0.0027609048,0.00026994405],"about_ca_topic_score_codex":0.0009701101,"about_ca_topic_score_gemma":0.0005555043,"teacher_disagreement_score":0.40714425,"about_ca_system_score_codex":0.0012968008,"about_ca_system_score_gemma":0.002768332,"threshold_uncertainty_score":0.9999947},"labels":[],"label_agreement":null},{"id":"W2747596230","doi":"10.1016/j.leukres.2017.08.011","title":"Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification","year":2017,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Medical Research Council; World Health Organization","keywords":"Myeloid leukemia; Medicine; Myeloid; Myelodysplastic syndromes; Leukemia; Internal medicine; Oncology; Immunology; Bone marrow; Cancer research","score_opus":0.19457947418994617,"score_gpt":0.4626872585099872,"score_spread":0.268107784320041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747596230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89143074,0.0002719814,0.00039103974,0.031094482,0.00032336876,0.0035914946,0.00004547519,0.00007251842,0.07277892],"genre_scores_gemma":[0.98466384,0.0005542747,0.0006872055,0.00030094213,0.00089139666,0.0005325102,0.000055627537,0.00008899275,0.012225223],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9911188,0.0009966606,0.00070504233,0.000913984,0.005015888,0.0012496567],"domain_scores_gemma":[0.99050844,0.0006544408,0.0003220163,0.004209548,0.003805018,0.00050056237],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.016406981,0.00030187736,0.0005978957,0.00072948524,0.0017171949,0.00036625325,0.002127833,0.0003635693,0.00032877037],"category_scores_gemma":[0.006537031,0.0002140427,0.00021715593,0.000910744,0.00089023315,0.0005058273,0.0011941195,0.0019096634,0.0011316069],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.002948192,0.00015679546,0.021366665,0.00036729936,0.0009666786,0.00012040555,0.0031219085,0.00022672996,0.21733703,0.0034461005,0.48606208,0.26388013],"study_design_scores_gemma":[0.01606139,0.0020827195,0.5483915,0.0020899065,0.0011056849,0.00016800496,0.012402637,0.18165298,0.14063051,0.0031253602,0.091177836,0.001111467],"about_ca_topic_score_codex":0.0019831918,"about_ca_topic_score_gemma":0.00022795262,"teacher_disagreement_score":0.5270248,"about_ca_system_score_codex":0.010570867,"about_ca_system_score_gemma":0.0102022905,"threshold_uncertainty_score":0.9996461},"labels":[],"label_agreement":null},{"id":"W2747688448","doi":"10.1007/s00277-017-3097-4","title":"Return to work and work-related disability among AML survivors","year":2017,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Sick leave; Medicine; Hematology; Myeloid leukemia; Productivity; Transplantation; Work productivity; Internal medicine; Gerontology; Physical therapy","score_opus":0.05535312647928641,"score_gpt":0.3657163758760145,"score_spread":0.3103632493967281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747688448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95580006,0.00030210317,0.000009862837,0.040535722,0.00011477264,0.0004073598,0.0000035043447,0.000034134056,0.0027924597],"genre_scores_gemma":[0.9988455,0.000077542,0.0002044839,0.0003460589,0.000029286455,0.000018889954,0.000007073047,0.000021394537,0.00044976687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843985,0.00011453759,0.00039493392,0.00037726448,0.00021391745,0.00045950364],"domain_scores_gemma":[0.99794704,0.000293671,0.00017488984,0.0011110622,0.0001490385,0.0003242972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006323452,0.00015691052,0.0006581275,0.00008181859,0.00014985108,0.000026850455,0.00030146478,0.00025630926,0.00017257997],"category_scores_gemma":[0.0018908867,0.00012945241,0.0000932646,0.00017971804,0.0011416383,0.00011581297,0.0003346291,0.00036522397,0.000035933255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046210346,0.00008874974,0.98795676,0.00009757935,0.00010448113,0.00009534606,0.0002698416,4.0727036e-7,0.00011848321,0.00068845606,0.006256861,0.0038609195],"study_design_scores_gemma":[0.0006619133,0.00019131815,0.9898461,0.00018838313,0.000025800195,0.000059561095,0.000086156775,0.000010230354,0.007312195,0.00075565424,0.00073124527,0.00013146116],"about_ca_topic_score_codex":0.00046546094,"about_ca_topic_score_gemma":0.00016375956,"teacher_disagreement_score":0.043045424,"about_ca_system_score_codex":0.00001824364,"about_ca_system_score_gemma":0.000058613594,"threshold_uncertainty_score":0.52789164},"labels":[],"label_agreement":null},{"id":"W2747815891","doi":"10.1016/j.exphem.2017.06.329","title":"A cluster of enhancer modules directs differential MYC expression along the normal and leukemic haematopoietic stem cell hierarchies","year":2017,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Haematopoiesis; Enhancer; Biology; Stem cell; Progenitor cell; Transcription factor; RUNX1; Myeloid; Cell biology; Cancer research; Genetics; Gene","score_opus":0.016811895441017202,"score_gpt":0.30228371146671734,"score_spread":0.28547181602570015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747815891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910047,0.0051703462,0.00013770601,0.0005228143,0.00023055835,0.0005570273,0.0000058944297,0.000031382748,0.0023395668],"genre_scores_gemma":[0.99794024,0.00012842953,0.0004351809,0.000074565214,0.000091800815,0.000114402486,0.000007641949,0.00003499913,0.0011727525],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984253,0.0001355463,0.00035257274,0.0003696388,0.0003035691,0.00041336683],"domain_scores_gemma":[0.99867135,0.00015716266,0.00021298922,0.00077467243,0.000041829673,0.00014199696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012351226,0.00023421225,0.0005634524,0.00009472234,0.00041905834,0.00004295006,0.0003570441,0.00015760181,0.00024511243],"category_scores_gemma":[0.00002397215,0.00015192726,0.00010283763,0.000033807424,0.0009561496,0.00014978615,0.0007434566,0.00031412434,0.000023317925],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012889213,0.00034665733,0.009276204,0.00054840173,0.00008550795,0.00014532416,0.005490992,0.0000010049943,0.97727346,0.0020983329,0.002105032,0.001340181],"study_design_scores_gemma":[0.0026629204,0.00023832184,0.0067027174,0.000209456,0.000028055825,0.0006248565,0.0013656681,0.00058215787,0.9873086,0.000047676655,0.00009083584,0.00013870375],"about_ca_topic_score_codex":0.00013781912,"about_ca_topic_score_gemma":0.000010360499,"teacher_disagreement_score":0.01003519,"about_ca_system_score_codex":0.00009670801,"about_ca_system_score_gemma":0.000081319,"threshold_uncertainty_score":0.6195414},"labels":[],"label_agreement":null},{"id":"W2747878830","doi":"10.1182/blood.v128.22.1046.1046","title":"Divergent Epigenomes in Pediatric and Adult Acute Myeloid Leukemia Implicate Cell of Origin and Transcriptional Silencing of Immune Responses As Sources of Clinically Relevant Heterogeneity: A Report from the Children's Oncology Group and NCI/COG Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"DNA methylation; Myeloid leukemia; Biology; Methylation; RUNX1; Decitabine; Leukemia; Cancer research; Oncology; Cancer; Myeloid; Internal medicine; Bioinformatics; Medicine; Stem cell; Genetics; Haematopoiesis; DNA; Gene; Gene expression","score_opus":0.03230629537192327,"score_gpt":0.3430110246948542,"score_spread":0.310704729322931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747878830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922525,0.00452847,0.00009933084,0.00067583896,0.00001603026,0.0020304269,0.00031535272,0.000011057944,0.000070948714],"genre_scores_gemma":[0.98468316,0.012643596,0.002175401,0.00009585307,0.00009035659,0.00020437794,0.0000291457,0.00003277002,0.000045339184],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9962824,0.00087758846,0.0010903481,0.00070958456,0.00057480676,0.00046527642],"domain_scores_gemma":[0.99575675,0.0027807965,0.00036461992,0.00044376517,0.00042173755,0.00023234484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022026387,0.00025814265,0.0008588657,0.00030585565,0.00011558819,0.000011479937,0.00020989156,0.00021239898,0.000013953972],"category_scores_gemma":[0.0004887079,0.00015539918,0.000108619926,0.000417762,0.0006948322,0.00007659978,0.00029874354,0.00037612472,0.000002413631],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004702685,0.0005332599,0.48932397,0.00005935281,0.0007108794,0.00010518974,0.0017708506,8.3962306e-7,0.49879968,0.000051131236,0.0000065204777,0.0039356435],"study_design_scores_gemma":[0.0082164025,0.0042500934,0.78048617,0.00009734057,0.00055034476,0.00017662164,0.0002395552,0.000008715606,0.20535067,0.00045837805,0.00003204429,0.00013367902],"about_ca_topic_score_codex":0.0013944925,"about_ca_topic_score_gemma":0.00005865661,"teacher_disagreement_score":0.293449,"about_ca_system_score_codex":0.0002228711,"about_ca_system_score_gemma":0.0007639496,"threshold_uncertainty_score":0.6336995},"labels":[],"label_agreement":null},{"id":"W2748215501","doi":"10.1172/jci94031","title":"Mice expressing KrasG12D in hematopoietic multipotent progenitor cells develop neonatal myeloid leukemia","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institutes of Health; University of Toronto; School of Medicine, Indiana University; Riley Children's Foundation","keywords":"Juvenile myelomonocytic leukemia; Progenitor cell; Biology; Myeloid; Haematopoiesis; Cancer research; Immunology; Stem cell; Cell biology","score_opus":0.09245152628540647,"score_gpt":0.39662340188534867,"score_spread":0.3041718755999422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748215501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941401,0.00018972425,0.0005831392,0.0036771232,0.00077403587,0.00040986028,0.0000023508296,0.00001562164,0.00020802696],"genre_scores_gemma":[0.95302576,0.00014033719,0.044572443,0.00047702124,0.0013866712,0.000008850066,0.000005824638,0.00003694812,0.00034614909],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99582946,0.00031277913,0.0022892347,0.00030847167,0.0008828011,0.00037724007],"domain_scores_gemma":[0.995448,0.00067965564,0.0018677197,0.00051153084,0.0008459642,0.00064713997],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0038351084,0.0002108721,0.00081453065,0.00023590923,0.00020210595,0.00015408797,0.0005295012,0.0003678038,0.000033002707],"category_scores_gemma":[0.010257259,0.00016981702,0.00026195706,0.00017378949,0.0005934197,0.0006680662,0.00018235517,0.0016585775,0.00006063216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025300416,0.000435057,0.5472105,0.0006647562,0.00034830795,0.0033188201,0.0023166733,0.0002301971,0.34423837,0.00011820257,0.0077731917,0.09081587],"study_design_scores_gemma":[0.011969969,0.000666494,0.66150624,0.002456695,0.00018409162,0.0013708759,0.0004699308,0.0067475648,0.30978817,0.0013114084,0.003128689,0.00039987755],"about_ca_topic_score_codex":0.000059608305,"about_ca_topic_score_gemma":0.000011864791,"teacher_disagreement_score":0.11429572,"about_ca_system_score_codex":0.00058939157,"about_ca_system_score_gemma":0.0032736417,"threshold_uncertainty_score":0.9980798},"labels":[],"label_agreement":null},{"id":"W2748380902","doi":"10.1016/j.exphem.2017.06.054","title":"Dissecting the cellular of down syndrome TMD and AMKL","year":2017,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"GATA1; Acute megakaryoblastic leukemia; Biology; Progenitor cell; Population; Myeloid leukemia; Cancer research; Haematopoiesis; Myeloid; Stem cell; Cell biology; Immunology; Medicine","score_opus":0.024334608182095315,"score_gpt":0.3437074688321111,"score_spread":0.3193728606500158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748380902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870988,0.0044683055,0.000012145932,0.0010809742,0.00015897633,0.0002724543,0.0000017026389,0.000017358776,0.0068892967],"genre_scores_gemma":[0.9987525,0.000017346443,0.0002278405,0.000062093204,0.00003982592,0.000026720043,0.0000034330408,0.000016303517,0.0008539467],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99919343,0.000031251093,0.00018441107,0.00020203507,0.00015138015,0.00023750134],"domain_scores_gemma":[0.99910355,0.000087617416,0.00011038065,0.00057580916,0.000035416946,0.00008721324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015400295,0.00010576157,0.00031865883,0.00004212922,0.00030292195,0.000018716242,0.00021776879,0.00008307792,0.0002405184],"category_scores_gemma":[0.00012712985,0.00006986333,0.00005149949,0.00002930965,0.0006073568,0.00006153529,0.0003046706,0.00019245427,0.000028564045],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048696483,0.0004326502,0.09824725,0.00031695375,0.00028638323,0.0021618553,0.0035337128,2.050353e-7,0.80662113,0.08547836,0.001718764,0.00071576406],"study_design_scores_gemma":[0.0011530987,0.00028627645,0.010187088,0.00005558133,0.000016636488,0.0031572108,0.0022371095,0.00010724184,0.98223454,0.00014086536,0.00034785032,0.00007653141],"about_ca_topic_score_codex":0.0001530184,"about_ca_topic_score_gemma":0.0000033488964,"teacher_disagreement_score":0.17561337,"about_ca_system_score_codex":0.000048673635,"about_ca_system_score_gemma":0.00003621077,"threshold_uncertainty_score":0.2848944},"labels":[],"label_agreement":null},{"id":"W2748755285","doi":"10.1016/j.exphem.2017.06.211","title":"Competitive in vivo screening of 64 candidate leukemia stem cell self-renewal regulators selects for genes protracting stem cell latency","year":2017,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Stem cell; Biology; Haematopoiesis; CD34; Transplantation; Hematopoietic stem cell; CD38; Cancer research; Bone marrow; Progenitor cell; Cell biology; Immunology; Medicine; Internal medicine","score_opus":0.025015238082885378,"score_gpt":0.32027471410856784,"score_spread":0.2952594760256825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748755285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871803,0.0022897224,0.000057610392,0.00010547551,0.00017599037,0.001999674,0.000024462803,0.000071957715,0.008094839],"genre_scores_gemma":[0.99335194,0.000034489945,0.0049340124,0.000037652568,0.00008883725,0.000305935,0.000016989123,0.000074893556,0.0011552607],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997565,0.00012292233,0.0006316669,0.0006015436,0.0003232218,0.0007557028],"domain_scores_gemma":[0.9983016,0.00020807891,0.0005196934,0.00061800965,0.00014150701,0.00021110143],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034532015,0.00033079935,0.00088245777,0.00023577745,0.0003195663,0.000032634154,0.0003944513,0.00028672258,0.00007458646],"category_scores_gemma":[0.000014579552,0.00031732276,0.00014466172,0.00011985372,0.00021945342,0.00019728545,0.0002748114,0.0003546769,0.000011517588],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002293667,0.00083383644,0.074160874,0.001699492,0.00021488528,0.00059090904,0.0065328935,0.000021788708,0.90464616,0.007229854,0.0006285387,0.0011470877],"study_design_scores_gemma":[0.0055827037,0.00064878794,0.0005981134,0.0002473478,0.000034733683,0.0002600889,0.005554609,0.0012865289,0.9850252,0.000014336617,0.00048734582,0.00026018173],"about_ca_topic_score_codex":0.0006333572,"about_ca_topic_score_gemma":0.000087362256,"teacher_disagreement_score":0.08037905,"about_ca_system_score_codex":0.0007646757,"about_ca_system_score_gemma":0.0005916751,"threshold_uncertainty_score":0.9999279},"labels":[],"label_agreement":null},{"id":"W2749521159","doi":"10.1182/blood.v128.22.5206.5206","title":"Ex Vivo High-Throughput Flow Cytometry Screening Identifies Subsets of Responders to Differentiation Agents in Individual AML Patient Samples","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Ex vivo; Acute promyelocytic leukemia; Flow cytometry; Myeloid; Population; Haematopoiesis; Progenitor cell; Immunophenotyping; Biology; Leukemia; Myeloid leukemia; In vivo; CD34; Cancer research; Immunology; Stem cell; Retinoic acid; Medicine; Cell culture; Cell biology","score_opus":0.0566600850589305,"score_gpt":0.3161915275369681,"score_spread":0.2595314424780376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749521159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995395,0.00008250245,0.002836973,0.0006729848,0.00010949993,0.0005691883,0.0002128913,0.000042429958,0.000078504214],"genre_scores_gemma":[0.994607,0.000047129237,0.0046737604,0.00015412149,0.00008643936,0.000033448774,0.00008624375,0.000035094978,0.00027678427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752176,0.00015851515,0.0004990041,0.00041057143,0.00095674524,0.0004534286],"domain_scores_gemma":[0.9987984,0.0002935072,0.00013174805,0.0004443217,0.00014642507,0.00018565716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041509987,0.00018916215,0.00038468937,0.0008537544,0.000049865008,0.0000279486,0.0002250833,0.00013586145,0.00029594733],"category_scores_gemma":[0.0008710484,0.00014134041,0.00008386533,0.00069138163,0.000081279206,0.00017675174,0.0002734877,0.00017142524,0.00005678421],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00162884,0.0015099683,0.5028089,0.00028757594,0.00073438475,0.0002221844,0.0056764125,0.000025415498,0.44027737,0.000084313404,0.009369403,0.037375234],"study_design_scores_gemma":[0.0058863405,0.00038195367,0.7081335,0.00042547873,0.0001068245,0.000011357681,0.00048144965,0.000026936634,0.2840784,0.00007439447,0.000232024,0.00016135338],"about_ca_topic_score_codex":0.00029014616,"about_ca_topic_score_gemma":0.00012162678,"teacher_disagreement_score":0.20532458,"about_ca_system_score_codex":0.00015869123,"about_ca_system_score_gemma":0.00012289401,"threshold_uncertainty_score":0.57636946},"labels":[],"label_agreement":null},{"id":"W2749902186","doi":"10.1016/j.exphem.2017.08.001","title":"Tet2 restrains inflammatory gene expression in macrophages","year":2017,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":290,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University","funders":"Southeastern Ontario Academic Medical Organization; Queen's University; Ontario Institute for Cancer Research; Canada Foundation for Innovation; Canadian Institutes of Health Research; European Hematology Association","keywords":"Biology; Epigenetics; Haematopoiesis; Myeloid; Molecular biology; Inflammation; Gene expression; Cancer research; Gene; Stem cell; Immunology; Cell biology; Genetics","score_opus":0.02830469098849471,"score_gpt":0.36253254496753745,"score_spread":0.33422785397904275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749902186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835104,0.0030533408,0.000015142277,0.0008233397,0.00021665737,0.00042359557,0.0000036274275,0.000056781133,0.011897151],"genre_scores_gemma":[0.9956834,0.000053975382,0.0027331118,0.00014617888,0.000115286115,0.00010463419,0.0000138655205,0.00003541882,0.0011141698],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985621,0.0000694409,0.00029847908,0.00038233172,0.00022871795,0.00045894244],"domain_scores_gemma":[0.99876946,0.0000444322,0.000109002656,0.0008657836,0.000026794802,0.00018453403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000163843,0.00017972772,0.00039330978,0.00016006413,0.00022773928,0.00003107514,0.00034234297,0.00020456496,0.0006346502],"category_scores_gemma":[0.00013454926,0.00015931236,0.00006904908,0.00004076368,0.00041447618,0.00015266692,0.0003764637,0.0003001608,0.00020401849],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003939051,0.00025534912,0.055959627,0.00005438638,0.000017731209,0.0038524338,0.00059853576,3.8070323e-7,0.9336675,0.0024864594,0.0023412977,0.0003724262],"study_design_scores_gemma":[0.0028255216,0.00015164111,0.027953085,0.00009652865,0.0000033905455,0.0009815714,0.0005217362,0.000046543715,0.9661645,0.00008131987,0.0010422207,0.00013188353],"about_ca_topic_score_codex":0.000047447254,"about_ca_topic_score_gemma":0.000013109927,"teacher_disagreement_score":0.03249709,"about_ca_system_score_codex":0.0002639931,"about_ca_system_score_gemma":0.00015053051,"threshold_uncertainty_score":0.6948975},"labels":[],"label_agreement":null},{"id":"W2752690034","doi":"10.1016/j.exphem.2017.08.006","title":"Identification of novel biomarkers for MLL-translocated acute myeloid leukemia","year":2017,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Centre hospitalier de l'Université Laval; Hôpital de l'Enfant-Jésus; Centre hospitalier universitaire de Québec; Université Laval; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Myeloid leukemia; Fusion gene; Leukemia; Biology; Chromosomal translocation; Gene; Myeloid; Cancer research; Biomarker; Acute leukemia; Immunology; Genetics","score_opus":0.03720484173229242,"score_gpt":0.37281480250347004,"score_spread":0.3356099607711776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752690034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98657846,0.0013941675,0.006094723,0.0017324318,0.0005198134,0.0016320947,0.00008941197,0.000083948784,0.0018749292],"genre_scores_gemma":[0.9952128,0.000032243937,0.0034149613,0.00009396916,0.00005640786,0.00024174376,0.00010512505,0.000044584795,0.0007981655],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840105,0.00002258697,0.0005323994,0.00041666688,0.00023284958,0.00039446697],"domain_scores_gemma":[0.99841416,0.00007564732,0.0003190864,0.0008851742,0.00015767131,0.00014824854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025302335,0.00019412168,0.0005177051,0.00016541716,0.00027292926,0.000027730952,0.00042052235,0.00022202796,0.00011008888],"category_scores_gemma":[0.00012546424,0.00018295475,0.00017316037,0.0000805788,0.0005884694,0.00016049013,0.000114212424,0.00014174261,0.00003867438],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012825007,0.00030340042,0.00080427487,0.0001420953,0.00041966033,0.00003910577,0.0002908717,5.5747853e-7,0.98327386,0.010298692,0.0026095787,0.00053541595],"study_design_scores_gemma":[0.006085912,0.00032922925,0.0022357628,0.000050745493,0.00008429191,0.0004776538,0.00040238438,0.0028555319,0.9867396,0.000053051273,0.00053706917,0.0001487767],"about_ca_topic_score_codex":0.0001270996,"about_ca_topic_score_gemma":0.0000054957814,"teacher_disagreement_score":0.010245641,"about_ca_system_score_codex":0.0003610264,"about_ca_system_score_gemma":0.00030371148,"threshold_uncertainty_score":0.7460679},"labels":[],"label_agreement":null},{"id":"W2753016068","doi":"10.1158/1078-0432.ccr-17-1259","title":"Chemogenomic Landscape of <i>RUNX1</i> -mutated AML Reveals Importance of <i>RUNX1</i> Allele Dosage in Genetics and Glucocorticoid Sensitivity","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Institute for Research in Immunology and Cancer","funders":"","keywords":"RUNX1; Biology; Myeloid leukemia; Leukemia; Myeloid; Allele; Pharmacogenomics; Glucocorticoid receptor; Cancer research; Gene; Genetics; Transcription factor","score_opus":0.1365045459684899,"score_gpt":0.48259546705936207,"score_spread":0.34609092109087214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753016068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911474,0.0028707597,0.000006784742,0.0023305416,0.000083433064,0.0013613896,0.00010292735,0.000014591484,0.0020821444],"genre_scores_gemma":[0.98873305,0.009591804,0.000375613,0.0002205581,0.0002447717,0.00005807085,0.000024794663,0.000056946457,0.00069438486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99516034,0.00065003004,0.0013869781,0.000821045,0.0010849222,0.0008967132],"domain_scores_gemma":[0.9949542,0.0016188385,0.00049973675,0.0017371374,0.0007431516,0.00044691234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008281244,0.00023194878,0.0012656682,0.00024717467,0.00014262596,0.000042593838,0.0005146236,0.0003680904,0.00019845915],"category_scores_gemma":[0.0035444256,0.00020705721,0.00018407946,0.00035532663,0.0017732488,0.00011534732,0.0008733381,0.001647636,0.000025547964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021990044,0.00029931497,0.8776708,0.0006213715,0.00011513481,0.00031048447,0.00011699126,0.000011817761,0.10737306,0.000026069652,0.0028485784,0.008407347],"study_design_scores_gemma":[0.0070282803,0.00077610544,0.9533734,0.000336602,0.000049718266,0.000031778338,0.00013658515,0.0017834513,0.034951646,0.00017401396,0.0011501813,0.0002082434],"about_ca_topic_score_codex":0.0013383403,"about_ca_topic_score_gemma":0.0012410192,"teacher_disagreement_score":0.07570256,"about_ca_system_score_codex":0.00024942245,"about_ca_system_score_gemma":0.0015943842,"threshold_uncertainty_score":0.8443548},"labels":[],"label_agreement":null},{"id":"W2753485911","doi":"10.1182/blood-2017-03-774653","title":"H3 K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"RUNX1; Myeloid leukemia; Context (archaeology); Mutation; Cancer research; Leukemia; Biology; Chromosomal translocation; Myeloid; Genetics; Gene; Transcription factor","score_opus":0.01922175462295055,"score_gpt":0.2968200042722698,"score_spread":0.27759824964931923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753485911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98278004,0.00009289514,0.0013634373,0.0037904538,0.000053339816,0.0015133687,0.00006131868,0.00008663373,0.010258524],"genre_scores_gemma":[0.99599373,0.000093826755,0.0014894416,0.00018291402,0.00011510413,0.0002512121,0.0001776755,0.000039155737,0.0016569585],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99830043,0.000048669823,0.00037295825,0.00033124312,0.0005188685,0.00042782078],"domain_scores_gemma":[0.9986024,0.000040911345,0.00012777107,0.0007839819,0.0002442803,0.00020065198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033109734,0.00020563006,0.00033729975,0.00023055282,0.0004779227,0.00018308985,0.00028172924,0.00013144851,0.00008643541],"category_scores_gemma":[0.00012974162,0.00016831837,0.00007440889,0.00017895648,0.00016245946,0.0006281872,0.000045948982,0.00050934934,0.0001346369],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006290035,0.009858351,0.16513148,0.0023559972,0.01066537,0.01022915,0.08135379,0.0015107541,0.38611427,0.022308903,0.003951518,0.30023038],"study_design_scores_gemma":[0.11623354,0.004572635,0.4438429,0.0015867173,0.003619805,0.0039706873,0.0033807224,0.014784874,0.3899156,0.0011297625,0.015072673,0.0018901341],"about_ca_topic_score_codex":0.00054324296,"about_ca_topic_score_gemma":0.001127453,"teacher_disagreement_score":0.29834023,"about_ca_system_score_codex":0.00038638586,"about_ca_system_score_gemma":0.0010321421,"threshold_uncertainty_score":0.68638235},"labels":[],"label_agreement":null},{"id":"W2753511274","doi":"10.1182/blood.v128.22.4338.4338","title":"Azacitidine Use in the Real World Does Not Replicate AZA-001 Results in Higher Risk MDS/Low Blast Count AML: An Audit of 1101 Patients in the Cancer Care Ontario Registry","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Population; Proportional hazards model; Cancer registry; Cancer; Confidence interval","score_opus":0.030862540737387246,"score_gpt":0.2858397053328404,"score_spread":0.25497716459545317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753511274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935358,0.000038066595,2.0956932e-7,0.0027072388,0.00008345308,0.0010102635,0.00069600285,0.000019884767,0.0019090684],"genre_scores_gemma":[0.995747,0.00041735487,0.000055575918,0.0004323864,0.00020567993,0.00023192976,0.00013210987,0.000036063833,0.0027418563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968322,0.00041904123,0.00070126384,0.00064707705,0.00084456924,0.0005558728],"domain_scores_gemma":[0.9971417,0.00054913945,0.0002983457,0.0016793186,0.00023094167,0.000100538135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011469239,0.00024956366,0.0004189838,0.00025597645,0.00005756148,0.00003492365,0.0006665095,0.0001547346,0.00010692061],"category_scores_gemma":[0.0004456396,0.0001135566,0.00006686744,0.00060884695,0.00022343264,0.00019086002,0.00012883278,0.0008353373,0.000012423223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020742505,0.0012386348,0.9844193,0.00007301258,0.000047880803,0.00022554456,0.0061127213,0.000004757613,0.0014191291,0.00003742499,0.0026309225,0.0017164471],"study_design_scores_gemma":[0.015887322,0.00034506404,0.971939,0.0006050595,0.000074520365,0.000003943135,0.0004886831,0.000004724754,0.0038010762,0.000024076335,0.0066615846,0.00016491805],"about_ca_topic_score_codex":0.42789173,"about_ca_topic_score_gemma":0.8588636,"teacher_disagreement_score":0.4309719,"about_ca_system_score_codex":0.0010503542,"about_ca_system_score_gemma":0.0006028092,"threshold_uncertainty_score":0.57591796},"labels":[],"label_agreement":null},{"id":"W2754051730","doi":"10.1172/jci.insight.95679","title":"Emerging therapies for acute myeloid leukemia: translating biology into the clinic","year":2017,"lang":"en","type":"review","venue":"JCI Insight","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; University of Toronto; Leukemia and Lymphoma Society","keywords":"Myeloid leukemia; Disease; Leukemia; Myeloid; Medicine; Malignancy; Biology; Bioinformatics; Immunology; Internal medicine","score_opus":0.13751939894376417,"score_gpt":0.45932405445295105,"score_spread":0.3218046555091869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754051730","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022526081,0.98408693,0.00037398972,0.0024116845,0.000779586,0.0035911796,0.000061061924,0.00012800418,0.008545051],"genre_scores_gemma":[0.00003542254,0.98472947,0.00200131,0.00042637804,0.0021640747,0.0011050227,0.00044667098,0.0002260279,0.0088655995],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961274,0.00038989776,0.0012817519,0.00094504014,0.00035543798,0.000900452],"domain_scores_gemma":[0.99538386,0.0014600378,0.00082488934,0.0018898357,0.00023826321,0.00020314031],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014263244,0.0007881195,0.0032798643,0.000402783,0.00095523655,0.00012693665,0.0013266366,0.0011450795,0.00023367627],"category_scores_gemma":[0.00061348575,0.00043145719,0.0015728489,0.00031874795,0.00057000533,0.00014020728,0.00025997133,0.0022261445,0.00030775717],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066148146,0.000024239089,0.0000054923053,0.005533071,0.0022926754,0.000045139153,0.0020409743,4.125548e-8,0.000027723,0.00026456453,0.0043619885,0.985338],"study_design_scores_gemma":[0.0011858246,0.00037756062,0.0000031401437,0.0046943696,0.0030465636,0.00012072329,0.00011369611,0.000038365295,0.000010895392,0.00038877106,0.98958856,0.0004315318],"about_ca_topic_score_codex":0.000109288536,"about_ca_topic_score_gemma":0.000051223662,"teacher_disagreement_score":0.9852266,"about_ca_system_score_codex":0.00091709994,"about_ca_system_score_gemma":0.0032110745,"threshold_uncertainty_score":0.99981374},"labels":[],"label_agreement":null},{"id":"W2754234593","doi":"10.1182/blood.v128.22.2843.2843","title":"Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Minimal residual disease; Oncology; Cytarabine; Internal medicine; Flow cytometry; Refractory (planetary science); Myeloid leukemia; Leukemia; Clinical trial; Immunology; Biology","score_opus":0.015705951130273153,"score_gpt":0.3182589468307045,"score_spread":0.3025529957004313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754234593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885852,0.0004831279,0.00034880062,0.00087666867,0.0001261673,0.005162237,0.004045113,0.00021676972,0.00015593231],"genre_scores_gemma":[0.98557675,0.0002582453,0.0092617,0.00019512023,0.00028441276,0.0014853614,0.0017145085,0.00022477275,0.0009991234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937217,0.0003159165,0.0010308509,0.0014791089,0.0019758402,0.0014765394],"domain_scores_gemma":[0.99503314,0.0013998437,0.0004096069,0.0014000474,0.0006026395,0.0011547275],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007933361,0.0007716812,0.0010772293,0.001106643,0.00026048158,0.0001111415,0.0006914798,0.0003887286,0.00011190402],"category_scores_gemma":[0.0023173043,0.00050088455,0.00022500422,0.0017906164,0.00042772832,0.00041999717,0.0003264842,0.0007419622,0.000039974155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018095937,0.020338833,0.90215176,0.00041272194,0.0009192208,0.0011805202,0.00012816205,6.8035047e-7,0.016965251,0.000005119664,0.014503214,0.02529857],"study_design_scores_gemma":[0.32547948,0.01848977,0.60795486,0.0017160105,0.0024079587,0.0000550434,0.00013450996,0.0012533545,0.037869662,0.000027011496,0.0031106118,0.0015017544],"about_ca_topic_score_codex":0.00007540122,"about_ca_topic_score_gemma":0.000017241711,"teacher_disagreement_score":0.30738354,"about_ca_system_score_codex":0.0016796641,"about_ca_system_score_gemma":0.0024394884,"threshold_uncertainty_score":0.9997443},"labels":[],"label_agreement":null},{"id":"W2756152695","doi":"10.14740/jh330w","title":"A Case of Therapy-Related Acute Myeloid Leukemia in a Patient With Heterozygous Mutations in the Ataxia Telangiectasia Mutated Gene","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Bone marrow; Oncology; Myeloid leukemia; Biopsy; Chemotherapy; Induction chemotherapy; Internal medicine; Pathology; Cancer","score_opus":0.021839502206437707,"score_gpt":0.3131178192826842,"score_spread":0.29127831707624646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756152695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968477,0.00064931577,0.000034712113,0.0016259064,0.000061279796,0.0005110999,0.000009088776,0.0000057679017,0.00025516885],"genre_scores_gemma":[0.99862945,0.00019575062,0.0009266832,0.0001588565,0.000018470946,0.000019079807,0.000007252475,0.000023482064,0.000020945261],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99807936,0.0002500417,0.0008464279,0.00016505609,0.00032010532,0.0003390209],"domain_scores_gemma":[0.9980273,0.00023960942,0.0008421105,0.0005235005,0.00027054234,0.00009689943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055641745,0.00017018564,0.00069210853,0.00050674344,0.00010549419,0.00002264256,0.00035490814,0.00016549404,0.000046571127],"category_scores_gemma":[0.0002595726,0.00009694464,0.00011325095,0.0002919959,0.00031409462,0.00014576175,0.000054312302,0.0008708581,0.000005956816],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057719275,0.0007411206,0.048712213,0.00011718578,0.0012520151,0.89104944,0.019353328,0.0004110646,0.022292193,0.00022828642,0.00088534615,0.009185864],"study_design_scores_gemma":[0.013040069,0.003129083,0.02020817,0.00028822455,0.0001558759,0.94024193,0.0025633925,0.0011138998,0.018672172,0.00031215136,0.00011616609,0.00015885176],"about_ca_topic_score_codex":0.00045992274,"about_ca_topic_score_gemma":0.000320166,"teacher_disagreement_score":0.04919249,"about_ca_system_score_codex":0.00038499114,"about_ca_system_score_gemma":0.00087074947,"threshold_uncertainty_score":0.39532876},"labels":[],"label_agreement":null},{"id":"W2762616050","doi":"10.1182/blood.v128.22.1638.1638","title":"Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Cytarabine; Azacitidine; Gastroenterology; Oncology; Chemotherapy regimen; Leukemia; Chemotherapy; Biology","score_opus":0.008975817158364137,"score_gpt":0.23595505171657424,"score_spread":0.22697923455821012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762616050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99470884,0.000115101015,0.00014636443,0.0008584161,0.000043485685,0.0026163412,0.00017490829,0.00014167382,0.0011948864],"genre_scores_gemma":[0.9953744,0.000022541164,0.002090469,0.00017675277,0.00013451096,0.0003339808,0.0005260561,0.00012304056,0.0012182944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964397,0.00012358635,0.00040208126,0.0008363758,0.0013073959,0.0008908911],"domain_scores_gemma":[0.99787426,0.00017995108,0.00020154731,0.0005630976,0.0008126471,0.00036847414],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017538968,0.0004916193,0.0007188022,0.00028551838,0.00011746719,0.00004340091,0.00027224558,0.00016850288,0.00016843755],"category_scores_gemma":[0.00007105122,0.00026983587,0.000072889954,0.00047305785,0.00041303912,0.0002950742,0.000112399444,0.00046579316,0.00006238489],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00805382,0.0010674039,0.98558784,0.00025683866,0.0009532144,0.001153861,0.0004537481,0.0000070689134,0.0014788053,0.00015357604,0.00054035056,0.00029349545],"study_design_scores_gemma":[0.073487945,0.004695978,0.91289306,0.0016548557,0.0007342827,0.00030322996,0.00021185733,0.000023523637,0.004929696,0.000018631852,0.00047371702,0.0005732554],"about_ca_topic_score_codex":0.00017943309,"about_ca_topic_score_gemma":0.00042101715,"teacher_disagreement_score":0.07269479,"about_ca_system_score_codex":0.00065725617,"about_ca_system_score_gemma":0.001597282,"threshold_uncertainty_score":0.9999754},"labels":[],"label_agreement":null},{"id":"W2762936931","doi":"10.1007/s00277-017-3137-0","title":"A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry","year":2017,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Queen Elizabeth II Health Sciences Centre; McGill University Health Centre; University of Ottawa; Hamilton Health Sciences; Dr. Georges-L.-Dumont University Hospital Centre; St. Paul's Hospital; Alberta Hospital Edmonton; University of British Columbia; Saskatchewan Cancer Agency; CancerCare Manitoba; Ottawa Hospital; University Health Network; Health Sciences Centre; University of Alberta Hospital; Princess Margaret Cancer Centre; Vancouver General Hospital; University of Toronto; Jewish General Hospital; Sunnybrook Health Science Centre; Juravinski Cancer Centre; University of Manitoba","funders":"Celgene","keywords":"Medicine; Internal medicine; International Prognostic Scoring System; Erythropoietin; Multivariate analysis; Cohort; Univariate analysis; Univariate; Multivariate statistics; Myelodysplastic syndromes","score_opus":0.09251550070832838,"score_gpt":0.37531389489247513,"score_spread":0.28279839418414676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762936931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779964,0.000101800986,0.00009558842,0.020303335,0.000058926118,0.00054262555,0.00021194358,0.00000744317,0.0006819009],"genre_scores_gemma":[0.99837923,0.000016362326,0.00071471225,0.0007371484,0.000011503674,0.000033944994,0.000015440135,0.000021489102,0.00007018347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816537,0.0002073108,0.00050462264,0.0003037493,0.00035370683,0.00046526195],"domain_scores_gemma":[0.99743277,0.00073162,0.0002870315,0.0010252574,0.00024555996,0.00027774286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055692194,0.00014878596,0.00056478934,0.00022570175,0.00018108253,0.000012795956,0.00045528993,0.00019482816,0.000059968857],"category_scores_gemma":[0.0058326055,0.0001164925,0.00007602115,0.00012360181,0.00041436523,0.000057299556,0.00023660611,0.0003607342,0.000014385618],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026260015,0.0007444815,0.85583186,0.0005762943,0.0010445598,0.0055261715,0.018764216,0.020605529,0.018618114,0.0013673275,0.04749449,0.003166944],"study_design_scores_gemma":[0.003635201,0.0026142125,0.86181146,0.0019197057,0.00009229057,0.00048072395,0.0017421327,0.10809787,0.017311156,0.0016659547,0.00029306725,0.00033620663],"about_ca_topic_score_codex":0.09139397,"about_ca_topic_score_gemma":0.029118152,"teacher_disagreement_score":0.08749234,"about_ca_system_score_codex":0.00011407919,"about_ca_system_score_gemma":0.0013587051,"threshold_uncertainty_score":0.9885979},"labels":[],"label_agreement":null},{"id":"W2765705238","doi":"10.1038/ncb3625","title":"Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche","year":2017,"lang":"en","type":"article","venue":"Nature Cell Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Western University; University of Manitoba; McMaster University","funders":"","keywords":"Haematopoiesis; Erythropoiesis; Bone marrow; Adipogenesis; Stem cell; Myeloid; Cancer research; Biology; Endogeny; Progenitor cell; Cell biology; In vivo; Immunology; Medicine; Endocrinology; Mesenchymal stem cell; Internal medicine; Anemia; Genetics","score_opus":0.02004647405497359,"score_gpt":0.3071248666327045,"score_spread":0.28707839257773093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765705238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90529287,0.02182255,0.00008854276,0.02488668,0.0013489298,0.0015559657,0.00027648933,0.00021030259,0.044517696],"genre_scores_gemma":[0.9838488,0.0022774031,0.00083159946,0.003087123,0.0007935785,0.000059699476,0.00036671144,0.000096120406,0.008638952],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99669945,0.00027794545,0.00047818382,0.0009241478,0.00040865922,0.0012116109],"domain_scores_gemma":[0.9962297,0.00044456273,0.0004063097,0.0022936107,0.00027138906,0.00035443326],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00073635706,0.00051687565,0.0008745407,0.00014526884,0.0014020337,0.00014181221,0.0013406223,0.001505364,0.00037656826],"category_scores_gemma":[0.000573607,0.00033122726,0.00030606793,0.0001929917,0.00143619,0.00013178593,0.00071074517,0.003481787,0.0003317424],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007517739,0.00011648904,0.0036209286,0.00008227989,0.0003972615,0.0004875398,0.00022408809,5.446733e-7,0.9190012,0.00016894126,0.06454018,0.010608773],"study_design_scores_gemma":[0.005544344,0.00072776893,0.004801266,0.00007021579,0.00057135354,0.0013010362,0.00016552024,0.00023670086,0.54233927,0.0002821222,0.44332436,0.000636035],"about_ca_topic_score_codex":0.00028057385,"about_ca_topic_score_gemma":0.000051336403,"teacher_disagreement_score":0.37878418,"about_ca_system_score_codex":0.0005528625,"about_ca_system_score_gemma":0.00048591587,"threshold_uncertainty_score":0.999914},"labels":[],"label_agreement":null},{"id":"W2766129023","doi":"10.3324/haematol.2017.176719","title":"Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple <i>TP53</i> alterations","year":2017,"lang":"en","type":"letter","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital du Saint-Sacrement","funders":"Centre Hospitalier Universitaire de Nantes; Science for Life Laboratory; Radiumhemmets Forskningsfonder; Cancerfonden","keywords":"Myeloid leukemia; Myelodysplastic syndromes; Clinical significance; Somatic cell; Myeloid; Cancer research; Mutation; Leukemia; Karyotype; Medicine; Biology; Immunology; Internal medicine; Genetics; Gene; Bone marrow; Chromosome","score_opus":0.03837447523164675,"score_gpt":0.2796043368568231,"score_spread":0.24122986162517637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766129023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7626293,0.0010943655,0.0015509188,0.21673445,0.00037125373,0.0036548614,0.00066241506,0.0005059024,0.012796528],"genre_scores_gemma":[0.8828035,0.00054540206,0.01456887,0.09027861,0.0010614789,0.00043032484,0.0017173463,0.00034763676,0.008246852],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962027,0.00017684138,0.0007275268,0.00106439,0.0008832244,0.0009453011],"domain_scores_gemma":[0.9963936,0.00074781844,0.0007088789,0.0014887273,0.00041273233,0.0002482423],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00023796466,0.00074309926,0.001992342,0.0004354166,0.00043792918,0.00015766856,0.0005873619,0.001159009,0.00011534678],"category_scores_gemma":[0.00061854935,0.00053393334,0.00021258194,0.00022829542,0.0011367636,0.00020315843,0.0003634211,0.002392803,0.000067171284],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008845699,0.00014651201,0.002923862,0.0050787865,0.0031884308,0.096844524,0.00069784746,0.000013327462,0.07619485,0.00012721663,0.8131759,0.0007241801],"study_design_scores_gemma":[0.02288008,0.01439732,0.0048881457,0.016416825,0.012221556,0.27890846,0.00060731324,0.005862186,0.21386157,0.00069156283,0.42297417,0.0062908363],"about_ca_topic_score_codex":0.00015267354,"about_ca_topic_score_gemma":0.000029782039,"teacher_disagreement_score":0.39020175,"about_ca_system_score_codex":0.0007810191,"about_ca_system_score_gemma":0.0015134668,"threshold_uncertainty_score":0.99990875},"labels":[],"label_agreement":null},{"id":"W2766970124","doi":"10.3324/haematol.2017.172353","title":"Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia","year":2017,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Queen Elizabeth II Health Sciences Centre; CancerCare Manitoba","funders":"Celgene","keywords":"Lenalidomide; Medicine; Azacitidine; Myelodysplastic syndromes; Internal medicine; Myeloid leukemia; Oncology; Adverse effect; Multiple myeloma; Bone marrow","score_opus":0.03213945077736108,"score_gpt":0.3138549973378398,"score_spread":0.2817155465604787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766970124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941774,0.0003759487,0.00004141312,0.0007861122,0.00007843668,0.0038163692,0.000063090105,0.000083002975,0.0005782366],"genre_scores_gemma":[0.9954938,0.0010166215,0.0016532326,0.00020105184,0.00009370229,0.00035033087,0.000029668461,0.00007040303,0.0010911615],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99608546,0.00054129714,0.00095145823,0.00094062474,0.0007142671,0.00076685805],"domain_scores_gemma":[0.9966709,0.0010665766,0.0006534101,0.001033381,0.00019209473,0.00038362792],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014215839,0.0005546743,0.0031027626,0.00045241992,0.00030414728,0.00017160451,0.00042086726,0.00031643774,0.00029397375],"category_scores_gemma":[0.0014517454,0.00035976173,0.00015408032,0.00026870536,0.0016154095,0.0003439369,0.00049858895,0.0007241829,0.000009060265],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8083564,0.0016783909,0.10389778,0.00079650985,0.003394753,0.055476528,0.0060080118,0.000023762115,0.011474292,0.0013396102,0.0035279482,0.0040260307],"study_design_scores_gemma":[0.8578602,0.003521511,0.12466612,0.0007359929,0.0013947403,0.003677224,0.0032457486,0.0006974635,0.0030301455,0.0002024465,0.00023783078,0.0007305459],"about_ca_topic_score_codex":0.004583437,"about_ca_topic_score_gemma":0.0015074491,"teacher_disagreement_score":0.051799305,"about_ca_system_score_codex":0.0002274925,"about_ca_system_score_gemma":0.0004912551,"threshold_uncertainty_score":0.99988544},"labels":[],"label_agreement":null},{"id":"W2767843030","doi":"","title":"Long-term results of a low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukemia and myelodysplastic syndrome in children with Down syndrome","year":2006,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Cytarabine; Medicine; Regimen; Chemotherapy; Internal medicine; Leukemia; Acute megakaryoblastic leukemia; Population; Myelodysplastic syndromes; Gastroenterology; Refractory (planetary science); Chemotherapy regimen; Surgery; Pediatrics; Bone marrow","score_opus":0.02188701874693273,"score_gpt":0.3266099236945285,"score_spread":0.3047229049475958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767843030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925373,0.0016398816,0.00010468873,0.001005894,0.000025443493,0.004136766,0.00044565415,0.000021691023,0.000082668375],"genre_scores_gemma":[0.9961633,0.0009239382,0.00020270042,0.000015074961,0.00007267143,0.0012137598,0.00015396642,0.000060560826,0.0011940367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965483,0.000170024,0.00061833556,0.0006745602,0.00108521,0.0009035739],"domain_scores_gemma":[0.9968559,0.0014513519,0.00016308326,0.0008464744,0.00047316164,0.00021002839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084773224,0.0003152414,0.00077392807,0.000717424,0.00013863806,0.00003156286,0.00035990344,0.00016025086,0.000032701042],"category_scores_gemma":[0.00012340388,0.00019286235,0.00011326742,0.0011710224,0.0010719897,0.00009043869,0.00006475243,0.00045522416,0.000004354745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12787114,0.0045120935,0.7294297,0.0049951635,0.006921902,0.0052641183,0.0015161295,0.007943787,0.09257066,0.00030970914,0.0030797357,0.015585835],"study_design_scores_gemma":[0.02735976,0.009054633,0.9435651,0.0011673595,0.00035472563,0.0006733206,0.000031025473,0.0016992532,0.015821217,0.000032526033,0.00003317104,0.00020794681],"about_ca_topic_score_codex":0.0046295826,"about_ca_topic_score_gemma":0.0006853996,"teacher_disagreement_score":0.21413533,"about_ca_system_score_codex":0.002043866,"about_ca_system_score_gemma":0.0025639536,"threshold_uncertainty_score":0.7864698},"labels":[],"label_agreement":null},{"id":"W2768941569","doi":"10.1111/ejh.13000","title":"Impact of comorbidities constituting the hematopoietic cell transplant (HCT)‐comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia","year":2017,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Myeloid leukemia; Hematopoietic cell; Medicine; Comorbidity; Internal medicine; Oncology; Hematopoietic stem cell transplantation; Myeloid; Haematopoiesis; Transplantation; Stem cell; Biology","score_opus":0.05127480759335997,"score_gpt":0.33675227348287484,"score_spread":0.2854774658895149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768941569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99366903,0.00015157243,0.0007957715,0.0012336083,0.0003183141,0.0005492787,0.0000802043,0.000008639868,0.003193595],"genre_scores_gemma":[0.9991207,0.0002252102,0.00021910772,0.00017646026,0.00011672709,0.0000031204318,0.000008308591,0.00004937144,0.000080973434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99683225,0.00070649356,0.0012792394,0.0002052616,0.00051255553,0.0004642038],"domain_scores_gemma":[0.99499893,0.0015305142,0.0019800658,0.0008465409,0.000489128,0.00015481851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021899545,0.00028827004,0.0010943059,0.00019449534,0.00045040646,0.00003844171,0.0011439321,0.000079735684,0.000062977895],"category_scores_gemma":[0.0009957156,0.00014827574,0.000628218,0.000078512145,0.0011681459,0.000110057896,0.00017469072,0.00082097325,0.000012635351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044387626,0.000535092,0.9667634,0.0010297959,0.0027754544,0.003749089,0.0033517496,0.00040284955,0.0069657303,0.0027026688,0.0064175976,0.000867839],"study_design_scores_gemma":[0.0245897,0.009764144,0.89142036,0.0021691187,0.0022975514,0.013700715,0.0019092603,0.0006838475,0.051131707,0.00071107363,0.00092871155,0.00069380645],"about_ca_topic_score_codex":0.000034459004,"about_ca_topic_score_gemma":0.00001279324,"teacher_disagreement_score":0.075343005,"about_ca_system_score_codex":0.00023401428,"about_ca_system_score_gemma":0.00084000546,"threshold_uncertainty_score":0.6046509},"labels":[],"label_agreement":null},{"id":"W2769549375","doi":"10.1080/14728222.2018.1406924","title":"Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas","year":2017,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Targets","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Hungarian Scientific Research Fund; Canadian Institutes of Health Research; Austrian Science Fund; Österreichische Forschungsförderungsgesellschaft; Canada Research Chairs","keywords":"Biology; Cancer research; Epigenetics; Leukemia; Haematopoiesis; Chromatin remodeling; Myeloproliferative Disorders; JAK-STAT signaling pathway; Cancer; Lymphoma; Carcinogenesis; Signal transduction; Genetics; Immunology; Gene; Stem cell; Receptor tyrosine kinase","score_opus":0.07735420331731752,"score_gpt":0.39340608895262985,"score_spread":0.31605188563531234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769549375","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000031511237,0.99288464,0.00007284459,0.0006569015,0.00088470284,0.0027666646,0.000033547843,0.00012477669,0.0025444373],"genre_scores_gemma":[0.0008666004,0.99368143,0.000513381,0.0013358284,0.0008111337,0.00065611774,0.00026808298,0.00031288777,0.0015545102],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943866,0.00066545577,0.0011389537,0.0016977562,0.0008260136,0.0012852321],"domain_scores_gemma":[0.9969537,0.00046949863,0.00058814505,0.0012944986,0.00013667348,0.0005574322],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00078660814,0.001442369,0.0033635027,0.0007599933,0.00055822014,0.00025341276,0.00058690994,0.0010217311,0.00041047],"category_scores_gemma":[0.00010398152,0.0011143698,0.0004412601,0.00028652226,0.0005334344,0.0002788443,0.00032610487,0.001684764,0.000072291215],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003700886,0.00018745686,0.00007490973,0.0024102926,0.0004939758,0.0001621545,0.0035193625,0.0000011872122,0.000040840234,0.00035955574,0.0008266557,0.99155354],"study_design_scores_gemma":[0.0040337653,0.0007568499,0.0001788275,0.00521693,0.000075985576,0.00042316297,0.00039406863,0.00067955814,0.00006295305,0.00015848961,0.98698324,0.0010361894],"about_ca_topic_score_codex":0.00012276357,"about_ca_topic_score_gemma":0.000014254,"teacher_disagreement_score":0.9905173,"about_ca_system_score_codex":0.0020508126,"about_ca_system_score_gemma":0.0020503001,"threshold_uncertainty_score":0.99983263},"labels":[],"label_agreement":null},{"id":"W2769980455","doi":"10.1002/ajh.24980","title":"Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia","year":2017,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; Jewish General Hospital; Queen's University; University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Randomized controlled trial; Cytarabine; Clinical trial; Oncology; Myeloid leukemia; Internal medicine; Intensive care medicine","score_opus":0.03236221611949127,"score_gpt":0.3474311390534881,"score_spread":0.31506892293399685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769980455","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5829207,0.00032279684,0.0035426232,0.4050642,0.0015846066,0.006101413,0.00007822062,0.000046420184,0.00033906844],"genre_scores_gemma":[0.46971008,0.0019807492,0.015233363,0.48909572,0.019494297,0.0012385123,0.0003597493,0.00085875555,0.0020287784],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99178976,0.00054551207,0.0032354784,0.0009228792,0.001981406,0.0015249578],"domain_scores_gemma":[0.98825675,0.004704793,0.0041510738,0.0013093199,0.0008975812,0.0006804555],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0026326624,0.0010610991,0.007988744,0.0017541976,0.00014467369,0.0001167049,0.0018813376,0.0011754663,0.00019920414],"category_scores_gemma":[0.002501495,0.0006955539,0.0010280246,0.0005672742,0.0023462703,0.00023668943,0.00029508982,0.008467093,0.000036167407],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8698031,0.0010863412,0.000016043125,0.0001565179,0.00293089,0.025195898,0.0011482659,0.0000010185355,0.00008071711,0.000010018824,0.08462753,0.014943689],"study_design_scores_gemma":[0.90889657,0.02979536,0.0000052396604,0.0026201827,0.0017330123,0.026853254,0.0006034803,0.00017990885,0.0001373,0.000021125612,0.028521474,0.0006330788],"about_ca_topic_score_codex":0.00038622064,"about_ca_topic_score_gemma":0.00009642227,"teacher_disagreement_score":0.11321057,"about_ca_system_score_codex":0.0015172443,"about_ca_system_score_gemma":0.0066546523,"threshold_uncertainty_score":0.99954957},"labels":[],"label_agreement":null},{"id":"W2770273110","doi":"10.1182/blood-2017-07-746453","title":"Age-related clonal hematopoiesis","year":2017,"lang":"en","type":"review","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Haematopoiesis; Biology; Progenitor cell; Stem cell; Somatic cell; Immunology; Stem cell theory of aging; Cancer; Somatic evolution in cancer; Genetics; Stem cell factor; Gene","score_opus":0.10768796225740501,"score_gpt":0.4030714379170683,"score_spread":0.2953834756596633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770273110","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013818537,0.95284194,9.417414e-7,0.00012122013,0.00016934288,0.0010827548,0.000046602265,0.00012520596,0.045598157],"genre_scores_gemma":[0.0000042675592,0.9668075,0.0003978594,0.000037495483,0.00056980376,0.00013886983,0.00039735466,0.00013544921,0.03151139],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974947,0.00012604822,0.00066738005,0.00057625386,0.00058085285,0.00055474404],"domain_scores_gemma":[0.99740803,0.00018745539,0.0003730197,0.0016010462,0.000098603174,0.0003318617],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045586465,0.0004802772,0.0027202712,0.0003177313,0.00017712574,0.00007717072,0.0006477625,0.0008098106,0.000711669],"category_scores_gemma":[0.000580529,0.00035345295,0.0009568549,0.00021674378,0.00025094714,0.000052105068,0.00031648806,0.0013998095,0.0027639659],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009724675,0.00044197464,0.000010457933,0.037286457,0.0025396547,0.007101566,0.000033555367,4.4432733e-9,0.0000019981715,0.00038730208,0.016049447,0.93613786],"study_design_scores_gemma":[0.0016274531,0.00008630608,0.000011209064,0.01622563,0.00457148,0.0031492729,0.0000027216565,4.2884608e-7,0.0000055993214,0.000048156315,0.97397834,0.00029340512],"about_ca_topic_score_codex":0.000029160517,"about_ca_topic_score_gemma":0.0000023646035,"teacher_disagreement_score":0.9579289,"about_ca_system_score_codex":0.0002054275,"about_ca_system_score_gemma":0.0017680846,"threshold_uncertainty_score":0.99989176},"labels":[],"label_agreement":null},{"id":"W2770587365","doi":"10.1016/j.exphem.2017.11.002","title":"An inflammatory environment containing TNFα favors Tet2-mutant clonal hematopoiesis","year":2017,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University","funders":"Southeastern Ontario Academic Medical Organization; Queen's University; Canada Foundation for Innovation; Ontario Institute for Cancer Research; Academic Medical Organization of Southwestern Ontario; Canadian Institutes of Health Research; European Hematology Association","keywords":"Mutant; Haematopoiesis; Tumor necrosis factor alpha; Cancer research; Biology; Cell biology; Genetics; Immunology; Gene; Stem cell","score_opus":0.025088362622599853,"score_gpt":0.3396907714574392,"score_spread":0.31460240883483936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770587365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99045634,0.0016255981,0.000111598405,0.0013165851,0.00026067192,0.0006307775,0.000010003464,0.00012733914,0.00546106],"genre_scores_gemma":[0.99685913,0.00003846715,0.001954533,0.0003739685,0.00019229497,0.00017392704,0.00004071975,0.00007251473,0.0002944674],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99748296,0.00011275963,0.0004975108,0.0006560999,0.000505198,0.0007454795],"domain_scores_gemma":[0.99768347,0.00008054126,0.00024401859,0.0014516053,0.000035016266,0.00050536374],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031865572,0.0003494567,0.0007162034,0.0001505696,0.0006270668,0.00007720706,0.0005685542,0.0002720008,0.002013882],"category_scores_gemma":[0.00008303876,0.00032168766,0.00015650416,0.000031844236,0.000826159,0.0003177522,0.0004295423,0.00044007652,0.00065662345],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026787992,0.0018212672,0.15117164,0.00022784303,0.0005326519,0.007192839,0.0060272603,0.0000064792903,0.74825335,0.07851869,0.0018137385,0.0017554397],"study_design_scores_gemma":[0.003764553,0.0010647019,0.009420499,0.00008074601,0.00003482097,0.003193482,0.005301718,0.00056439184,0.9724151,0.00017776458,0.0035996728,0.00038253024],"about_ca_topic_score_codex":0.000088374894,"about_ca_topic_score_gemma":0.000005844851,"teacher_disagreement_score":0.22416177,"about_ca_system_score_codex":0.00060782494,"about_ca_system_score_gemma":0.00022531066,"threshold_uncertainty_score":0.9999235},"labels":[],"label_agreement":null},{"id":"W2770772275","doi":"10.1182/blood.v128.22.1623.1623","title":"Genome-Wide Genotype-Based Risk Model for Survival in Core Binding Factor Acute Myeloid Leukemia Patients","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Single-nucleotide polymorphism; SNP; Core binding factor; Internal medicine; Myeloid leukemia; Oncology; Genotype; Medicine; Biology; Genetics; Gene; Transcription factor","score_opus":0.03360631329366281,"score_gpt":0.28385398652205684,"score_spread":0.25024767322839403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770772275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892357,0.00004561658,0.007613453,0.0002116909,0.00010812939,0.0014270013,0.0009985475,0.00009647661,0.00026339607],"genre_scores_gemma":[0.99318063,0.00011362166,0.004216582,0.0001653262,0.00014658367,0.00016153682,0.00021014536,0.00010908205,0.0016964995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974669,0.00006311428,0.00046078707,0.0005919144,0.0005648674,0.0008523838],"domain_scores_gemma":[0.99813825,0.0005419631,0.00015821749,0.0005784097,0.00026173962,0.00032143612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003738454,0.00031156067,0.00051767763,0.00038363063,0.00011884427,0.000022011587,0.00031269708,0.00024981343,0.00009233648],"category_scores_gemma":[0.00088418304,0.00022052422,0.00018465344,0.00030428972,0.00010164967,0.00012663398,0.00011462692,0.00035229907,0.00016509807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012233312,0.0004976104,0.90926385,0.0001102395,0.0003133803,0.00004448706,0.00029564087,0.00009646254,0.08457963,0.000020241172,0.00028909062,0.0032660256],"study_design_scores_gemma":[0.073174894,0.0013470702,0.8605243,0.0002815222,0.0006559372,0.0000069192183,0.00004998678,0.022467641,0.038878184,0.0002830574,0.0014444645,0.0008860053],"about_ca_topic_score_codex":0.0000697407,"about_ca_topic_score_gemma":0.000074645024,"teacher_disagreement_score":0.07195157,"about_ca_system_score_codex":0.0011634587,"about_ca_system_score_gemma":0.0011397663,"threshold_uncertainty_score":0.89927167},"labels":[],"label_agreement":null},{"id":"W2770841484","doi":"10.1002/ijc.31178","title":"Prognostic utility of six mutated genes for older patients with acute myeloid leukemia","year":2017,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Power Generation","funders":"College of Medicine, University of Cincinnati; National Natural Science Foundation of China; Strong; University of Cincinnati","keywords":"CEBPA; NPM1; Medicine; Myeloid leukemia; Oncology; Internal medicine; Cohort; Nomogram; Sanger sequencing; Myeloid; Gene; Mutation; Genetics; Biology; Karyotype","score_opus":0.020813929323050182,"score_gpt":0.3558995867278623,"score_spread":0.3350856574048121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770841484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956189,0.0002751592,0.001048274,0.0015969835,0.00055141706,0.00042397666,0.00013921695,0.0000054672173,0.00034061464],"genre_scores_gemma":[0.99736303,0.00020577174,0.0014218542,0.00013735528,0.00043415825,0.000024263814,0.000022294198,0.000022862276,0.00036840502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983153,0.000018184719,0.00043413817,0.00014255858,0.0009069385,0.00018290745],"domain_scores_gemma":[0.9950279,0.00010284239,0.00077411014,0.00021929035,0.003749286,0.00012658919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022878933,0.00012243242,0.00031225625,0.0001542171,0.000068427966,0.000047422087,0.0005221793,0.00006442564,0.00023322178],"category_scores_gemma":[0.00035745485,0.00008375846,0.00013675568,0.000040984858,0.00018147482,0.00026994414,0.00007396045,0.0002234179,0.000002206459],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072535793,0.00021317526,0.89930516,0.00007917262,0.0028703446,0.00014677484,0.0001790311,0.000035850793,0.0025222157,0.000031885236,0.0031300173,0.08423277],"study_design_scores_gemma":[0.009611552,0.00047322112,0.97005296,0.000451751,0.0003441376,0.00007467074,0.000023470038,0.0007518129,0.01407265,0.00009713339,0.0039536427,0.00009300289],"about_ca_topic_score_codex":0.00014446158,"about_ca_topic_score_gemma":0.000042377465,"teacher_disagreement_score":0.084139764,"about_ca_system_score_codex":0.00047191465,"about_ca_system_score_gemma":0.0014033096,"threshold_uncertainty_score":0.3415571},"labels":[],"label_agreement":null},{"id":"W2771414232","doi":"10.1002/cncr.31138","title":"Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia","year":2017,"lang":"en","type":"article","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Stand Up To Cancer; Astex Pharmaceuticals","keywords":"Medicine; Regimen; Internal medicine; Adverse effect; Gastroenterology; Refractory (planetary science); Surgery","score_opus":0.03316210548809689,"score_gpt":0.35506958955974977,"score_spread":0.32190748407165287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771414232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98941183,0.0016812325,0.000014063517,0.0025512509,0.00019339591,0.0005773938,0.000042318374,0.000030027357,0.0054984577],"genre_scores_gemma":[0.98080516,0.0059590433,0.000901074,0.00031486223,0.0003049546,0.000046703222,0.000015976802,0.00005470672,0.011597524],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982775,0.00004626623,0.00043537305,0.0004275443,0.00038147188,0.00043188236],"domain_scores_gemma":[0.9981682,0.00018491474,0.00023114294,0.0010217106,0.00015924891,0.00023479271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040527873,0.00021059583,0.0006022307,0.00020860789,0.00014418279,0.000029330911,0.00036048048,0.00022587963,0.00060604117],"category_scores_gemma":[0.0009138071,0.00015991624,0.00006894944,0.0001927153,0.00044123724,0.00017020237,0.0002796188,0.00065599603,0.000029153096],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053392723,0.00058258895,0.14858925,0.0012958361,0.0012620073,0.0021169921,0.0025466743,0.00007050311,0.293575,0.00080364995,0.020202361,0.47556242],"study_design_scores_gemma":[0.025456045,0.00062705897,0.92329854,0.0008187696,0.0001666666,0.0000700205,0.00012306623,0.0005795954,0.012598089,0.000045600813,0.03591151,0.00030503087],"about_ca_topic_score_codex":0.0006372441,"about_ca_topic_score_gemma":0.00033340428,"teacher_disagreement_score":0.7747093,"about_ca_system_score_codex":0.0011805735,"about_ca_system_score_gemma":0.0016267474,"threshold_uncertainty_score":0.66357255},"labels":[],"label_agreement":null},{"id":"W2771627443","doi":"10.1186/s12885-017-3803-6","title":"Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens","year":2017,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre; CancerCare Manitoba","funders":"Kite Pharma; Agios Pharmaceuticals; Genentech; Celgene; Sunesis; Jazz Pharmaceuticals; Servier; Amgen; Pfizer; Astellas Pharma; Ariad Pharmaceuticals","keywords":"Azacitidine; Medicine; Cytarabine; Hazard ratio; Internal medicine; Randomization; Myeloid leukemia; Oncology; Randomized controlled trial; Confidence interval","score_opus":0.028164137579252825,"score_gpt":0.3440797206553275,"score_spread":0.31591558307607465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771627443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944572,0.00017787085,0.000049933253,0.0014999729,0.00018872555,0.0018922001,0.00018529886,0.00008459321,0.0014642208],"genre_scores_gemma":[0.9915558,0.00012414095,0.0017471628,0.00033712664,0.00017014003,0.00044142758,0.0003562054,0.00010774885,0.0051602116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968672,0.00009353466,0.00050028483,0.0008413784,0.00096573774,0.00073189085],"domain_scores_gemma":[0.9972645,0.00014687343,0.0004859003,0.0010574308,0.0006844587,0.0003608599],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002333897,0.00046550483,0.0010198,0.00021783118,0.00029808126,0.000093485876,0.0004136628,0.00024698087,0.00024835454],"category_scores_gemma":[0.000083130304,0.00028720833,0.00011299604,0.00021781951,0.000839726,0.00026833094,0.00016569752,0.000815108,0.000028712599],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062332507,0.00026719892,0.989036,0.00018411776,0.0008781516,0.00021697175,0.00043800092,0.000016399177,0.00008823169,0.000040873896,0.0010925179,0.0015082741],"study_design_scores_gemma":[0.032588527,0.0015517368,0.9621594,0.0008561793,0.00040525428,0.000040364666,0.000387378,0.00013570208,0.00033223856,0.0000043675086,0.0011206781,0.00041820452],"about_ca_topic_score_codex":0.0010470516,"about_ca_topic_score_gemma":0.012348976,"teacher_disagreement_score":0.026876641,"about_ca_system_score_codex":0.0008082092,"about_ca_system_score_gemma":0.001698039,"threshold_uncertainty_score":0.999958},"labels":[],"label_agreement":null},{"id":"W2773514102","doi":"10.1038/nm.4439","title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","year":2017,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":875,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Biology; KRAS; Neuroblastoma RAS viral oncogene homolog; Myeloid leukemia; Cancer research; Genetics; DNA methylation; STK11; Gene; microRNA; Mutation; Gene expression","score_opus":0.01839391499378195,"score_gpt":0.3467394608742709,"score_spread":0.3283455458804889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773514102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679551,0.010614248,0.00017355401,0.016136251,0.0009626236,0.0005964576,0.000047079084,0.00003116729,0.0034835208],"genre_scores_gemma":[0.9927815,0.0026472327,0.0010396893,0.0003112175,0.0015881325,0.000031117484,0.00019260758,0.00002545375,0.001383052],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.998167,0.00007735356,0.00046831332,0.0002942882,0.000698748,0.00029431062],"domain_scores_gemma":[0.99786,0.00039348355,0.00033154307,0.0007470629,0.00046146518,0.00020642436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047527518,0.00020657036,0.00039126587,0.00022735217,0.00069287966,0.00006634308,0.00034048109,0.00018374347,0.00013810558],"category_scores_gemma":[0.0009989085,0.00012351191,0.00008053577,0.00021229051,0.00048195655,0.00014602634,0.00013589897,0.0014103777,0.000007756752],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004419425,0.00019650858,0.06559403,0.0008663069,0.002682342,0.0029533184,0.0071449718,0.00005308187,0.27470046,0.06584461,0.4496046,0.12594032],"study_design_scores_gemma":[0.012723974,0.0014394774,0.901311,0.00056534976,0.0014449272,0.002074787,0.0011322343,0.0029237256,0.0063861157,0.0054054013,0.063973315,0.00061971624],"about_ca_topic_score_codex":0.000021599557,"about_ca_topic_score_gemma":0.000024528978,"teacher_disagreement_score":0.83571696,"about_ca_system_score_codex":0.00019886237,"about_ca_system_score_gemma":0.00025905273,"threshold_uncertainty_score":0.6127468},"labels":[],"label_agreement":null},{"id":"W2774464689","doi":"10.1200/jco.2017.35.15_suppl.10515","title":"Four versus five chemotherapy courses in patients with low risk acute myeloid leukemia: A Children’s Oncology Group report.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Cytarabine; Etoposide; Mitoxantrone; Internal medicine; Chemotherapy; Oncology; Induction chemotherapy; Hazard ratio; Idarubicin; Leukemia; Surgery; Confidence interval","score_opus":0.05032753287687038,"score_gpt":0.42965592205768055,"score_spread":0.3793283891808102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774464689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865492,0.00007297279,0.000070510716,0.0080804145,0.0017240304,0.0007099746,0.000018189845,0.000016874958,0.002757833],"genre_scores_gemma":[0.9873472,0.0022194409,0.0064570094,0.0012829322,0.0020380286,0.000015527985,0.000020994983,0.00006664157,0.00055224856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939291,0.00078236824,0.0030316396,0.000550932,0.0009975977,0.0007084024],"domain_scores_gemma":[0.98743933,0.0030714762,0.0065947147,0.0010213624,0.0010900447,0.0007830534],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005798725,0.00034510923,0.0028504555,0.00031904262,0.00022154508,0.00004237412,0.0008545665,0.001162452,0.00015118194],"category_scores_gemma":[0.012479868,0.00023427652,0.0005787716,0.00015527259,0.0010727164,0.00038288368,0.0002292281,0.004533201,0.00003962327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06784217,0.002211749,0.7702408,0.000011985012,0.0018395184,0.01008869,0.00010842087,0.000013411451,0.000012124089,0.000013161325,0.006771304,0.14084668],"study_design_scores_gemma":[0.085116416,0.04305532,0.85757077,0.0001290907,0.00062160456,0.0013586261,0.000064993845,0.00007265256,0.000021786498,0.00007683237,0.011714015,0.00019788061],"about_ca_topic_score_codex":0.000398191,"about_ca_topic_score_gemma":0.00054358266,"teacher_disagreement_score":0.14064881,"about_ca_system_score_codex":0.0029201743,"about_ca_system_score_gemma":0.008549805,"threshold_uncertainty_score":0.9977634},"labels":[],"label_agreement":null},{"id":"W2775090033","doi":"10.1016/j.leukres.2017.12.003","title":"Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia","year":2017,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University","funders":"European Hematology Association","keywords":"Chronic myelomonocytic leukemia; Arginase; Cancer research; Myelodysplastic syndromes; Bone marrow; Myeloid; Biology; Immune dysregulation; Immune system; Epigenetics; Immunology; Innate immune system; Inflammation; Genetics; Arginine; Gene","score_opus":0.06930819219866653,"score_gpt":0.39275013868571823,"score_spread":0.3234419464870517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2775090033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921639,0.0007102195,0.000034761375,0.0031112912,0.0000726721,0.00164881,0.000050130024,0.000043395958,0.0021648365],"genre_scores_gemma":[0.9945017,0.0009917992,0.0009898558,0.000094427895,0.00018617055,0.00020159257,0.000023454026,0.00008590578,0.0029250672],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.995258,0.00028444867,0.00065684086,0.0010482512,0.0014422934,0.0013102164],"domain_scores_gemma":[0.9956624,0.0012340066,0.00013000457,0.0016519672,0.0004402618,0.00088136137],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016694856,0.0003847773,0.0008219462,0.0013669695,0.00069608126,0.00024266765,0.00070087553,0.00041514012,0.00021310744],"category_scores_gemma":[0.0031792535,0.00034783038,0.00009428878,0.0007091636,0.0013895002,0.00042246908,0.0012651469,0.001884528,0.00012474137],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034638701,0.00040045733,0.04927358,0.0043288693,0.0003254957,0.0027815786,0.0048026294,0.0002481264,0.88800895,0.0011447939,0.0070099565,0.038211685],"study_design_scores_gemma":[0.020895377,0.00429358,0.81737876,0.0067924545,0.00013627233,0.0008113928,0.0014108493,0.048010405,0.090610206,0.0025731896,0.0060381447,0.0010493646],"about_ca_topic_score_codex":0.0021678805,"about_ca_topic_score_gemma":0.0002468175,"teacher_disagreement_score":0.79739875,"about_ca_system_score_codex":0.0059386296,"about_ca_system_score_gemma":0.0046894467,"threshold_uncertainty_score":0.99989736},"labels":[],"label_agreement":null},{"id":"W2775826629","doi":"10.3324/haematol.2017.177485","title":"Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia","year":2017,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Myeloid leukemia; Leukemia; Myeloid; Cancer research; Medicine; Internal medicine; Chemistry","score_opus":0.029660900517050837,"score_gpt":0.3095504216536833,"score_spread":0.27988952113663246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2775826629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97790307,0.00036636068,0.000043106582,0.004539414,0.000119031836,0.00083529984,0.00011326427,0.000107414366,0.015973045],"genre_scores_gemma":[0.9864347,0.0005033829,0.007467215,0.0013484545,0.00006765174,0.00008867617,0.000028993863,0.00005519455,0.0040057576],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99691516,0.00013299166,0.00068994256,0.0007693757,0.0006165091,0.00087600714],"domain_scores_gemma":[0.99713635,0.00016816914,0.00042294554,0.0017466245,0.00022927171,0.0002966594],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00058565714,0.0004036288,0.0014537205,0.00033658918,0.00027940192,0.000067539295,0.0009938051,0.00046863704,0.00092522474],"category_scores_gemma":[0.0008908643,0.00031252526,0.0003087241,0.00025054297,0.00075733144,0.00023081571,0.00069940696,0.0007604844,0.00045209765],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031975203,0.00048121516,0.17639206,0.0007340948,0.00077847636,0.012623299,0.002166383,0.0000031323614,0.75679725,0.00058739854,0.04295781,0.003281342],"study_design_scores_gemma":[0.0053270003,0.0004874411,0.1603195,0.00037984404,0.00017802777,0.0013984542,0.00020431442,0.0006895322,0.81946397,0.0003570474,0.010715304,0.00047957522],"about_ca_topic_score_codex":0.00056267175,"about_ca_topic_score_gemma":0.000050865994,"teacher_disagreement_score":0.062666684,"about_ca_system_score_codex":0.00056452677,"about_ca_system_score_gemma":0.00065956195,"threshold_uncertainty_score":0.9999881},"labels":[],"label_agreement":null},{"id":"W2776794568","doi":"10.1016/j.clml.2017.12.004","title":"The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Lenalidomide; Medicine; Placebo; Myelodysplastic syndromes; Discontinuation; Quality of life (healthcare); Internal medicine; International Prognostic Scoring System; Anemia; Randomized controlled trial; Physical therapy; Multiple myeloma; Bone marrow","score_opus":0.0369554667939113,"score_gpt":0.35811880182063327,"score_spread":0.32116333502672195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2776794568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925628,0.0001868457,0.0000062518775,0.0018046391,0.000609976,0.0039314963,0.0003281513,0.000049594742,0.0005202555],"genre_scores_gemma":[0.99880475,0.00019277005,0.000055494824,0.00024368845,0.0002180398,0.000101322876,0.00009968445,0.00010323433,0.0001810397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98687357,0.0042551435,0.004488927,0.0013068455,0.0020543113,0.0010212306],"domain_scores_gemma":[0.96106535,0.029075785,0.004038172,0.004749554,0.0004166135,0.00065450015],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013486379,0.0006824341,0.0029241457,0.00015757275,0.000841033,0.00009523518,0.0019893749,0.0005143677,0.00002372706],"category_scores_gemma":[0.046097144,0.00034906596,0.0005439296,0.0004983283,0.002065858,0.00017752332,0.00066116673,0.0015896771,0.00011052249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08599262,0.0010303056,0.8323872,0.000105493644,0.0009698396,0.0000921808,0.00043829868,0.000058128662,0.00000851657,0.000014342513,0.0021519572,0.07675112],"study_design_scores_gemma":[0.0713485,0.0173127,0.9087258,0.0010499511,0.00023501972,0.0000039927513,0.00024331834,0.00057167344,0.00005200125,0.00005153929,0.00010849703,0.0002970228],"about_ca_topic_score_codex":0.016783878,"about_ca_topic_score_gemma":0.0014175237,"teacher_disagreement_score":0.076454096,"about_ca_system_score_codex":0.0016460166,"about_ca_system_score_gemma":0.0034650248,"threshold_uncertainty_score":0.9998961},"labels":[],"label_agreement":null},{"id":"W2777262489","doi":"10.3324/haematol.2017.181404","title":"Emergence and evolution of <i>TP53</i> mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide","year":2017,"lang":"en","type":"letter","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"Institut National Du Cancer","keywords":"Lenalidomide; Myelodysplastic syndromes; Disease; Library science; Medicine; Political science; Internal medicine; Multiple myeloma; Computer science; Bone marrow","score_opus":0.011336250537362402,"score_gpt":0.2666876846676132,"score_spread":0.2553514341302508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2777262489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844264,0.00072548393,0.000088371,0.012137198,0.000040672152,0.0018684134,0.0003683758,0.000044288085,0.00030081967],"genre_scores_gemma":[0.996991,0.0001619734,0.00087097316,0.0008197955,0.000066809436,0.00019654691,0.00057814183,0.0000532581,0.0002615258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735093,0.00023352845,0.00046790065,0.00064029515,0.0008591122,0.0004482441],"domain_scores_gemma":[0.997101,0.00024082907,0.0011314705,0.00072889973,0.00062399736,0.0001737901],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014706867,0.00042845737,0.0011135228,0.0004132993,0.00015161723,0.000018425442,0.0002727857,0.0004765338,0.000054601074],"category_scores_gemma":[0.0008079729,0.00025139848,0.000085585445,0.00032804193,0.00082886184,0.00012156686,0.00011630221,0.0011970317,0.0000049370115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006620836,0.0003429821,0.9226521,0.0020531446,0.00018420986,0.0028729436,0.000092147115,0.000019796518,0.000026207434,0.000010041738,0.06474959,0.00037596654],"study_design_scores_gemma":[0.0059566055,0.0021353143,0.9819399,0.0070169284,0.0009443203,0.00014520243,0.00010092248,0.00015863245,0.00020908024,0.00007538978,0.0008937034,0.00042398713],"about_ca_topic_score_codex":0.00025722344,"about_ca_topic_score_gemma":0.000087100736,"teacher_disagreement_score":0.06385589,"about_ca_system_score_codex":0.00014089636,"about_ca_system_score_gemma":0.0004399514,"threshold_uncertainty_score":0.9999938},"labels":[],"label_agreement":null},{"id":"W2777359937","doi":"10.18632/oncotarget.23575","title":"Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype","year":2017,"lang":"en","type":"article","venue":"Oncotarget","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"CEBPA; NPM1; Myeloid leukemia; Cancer research; Biology; Karyotype; Mutation; Genetics; Gene; Medicine; Chromosome","score_opus":0.028497108350266986,"score_gpt":0.3288650894895783,"score_spread":0.30036798113931135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2777359937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9592452,0.00006525942,0.0005567054,0.00087009626,0.00009157023,0.000662194,0.000015134397,0.0000429789,0.03845083],"genre_scores_gemma":[0.9831151,0.00007109434,0.012790224,0.00006933832,0.00018977352,0.000041699077,0.00005753435,0.000041425643,0.0036238446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829173,0.000050580235,0.00039494547,0.0003683449,0.00049880485,0.00039560618],"domain_scores_gemma":[0.9981558,0.000036670375,0.00033113468,0.0010944316,0.00014190639,0.00024006574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046240792,0.00019235436,0.0005090526,0.00020714529,0.00012605678,0.000048240203,0.0004139492,0.00014629569,0.000074676835],"category_scores_gemma":[0.000045974943,0.00015307555,0.0000714419,0.00015022591,0.00013207989,0.00021668008,0.00013779041,0.00045611785,0.000067844856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009010745,0.000097173724,0.9079307,0.0003151609,0.00022950869,0.00028512612,0.00029686533,0.000043428434,0.08262322,0.0021760839,0.0034079328,0.0016937386],"study_design_scores_gemma":[0.004323449,0.00052893907,0.9816031,0.00027898874,0.00010063239,0.00011969089,0.00027214203,0.008317213,0.0014188831,0.000011964103,0.0028725748,0.00015241205],"about_ca_topic_score_codex":0.0017134127,"about_ca_topic_score_gemma":0.00020900035,"teacher_disagreement_score":0.08120433,"about_ca_system_score_codex":0.0026203366,"about_ca_system_score_gemma":0.0038079915,"threshold_uncertainty_score":0.6852089},"labels":[],"label_agreement":null},{"id":"W2781382720","doi":"10.3747/co.24.3738","title":"Adult Chronic Myelomonocytic Leukemia with Trisomy 11: A Case Report","year":2017,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chronic myelomonocytic leukemia; Medicine; Trisomy; Bone marrow; Anemia; Pathology; Trisomy 8; Abnormality; Leukemia; Internal medicine; Karyotype; Myelodysplastic syndromes; Chromosome; Biology; Genetics","score_opus":0.10117006084304545,"score_gpt":0.43633228335430013,"score_spread":0.3351622225112547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781382720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97839606,0.0009418043,0.00049908826,0.00381914,0.00094407954,0.0011424124,0.000010657452,0.000130259,0.014116483],"genre_scores_gemma":[0.993533,0.00034993817,0.0008682177,0.00012636834,0.0014386289,0.000253902,0.000061661594,0.00006211662,0.0033061558],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.99752474,0.00010544192,0.0005001841,0.0006934432,0.0003945798,0.00078159926],"domain_scores_gemma":[0.99659413,0.00015056398,0.00046357958,0.001789969,0.00051625026,0.00048552972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005152913,0.00030031867,0.00072216406,0.000196354,0.0005106028,0.00006476151,0.0003964591,0.0002593357,0.00024071088],"category_scores_gemma":[0.0010473689,0.00022684055,0.00013618055,0.00013310567,0.0006891776,0.0001791503,0.0003001504,0.0010196157,0.0002664049],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011739163,0.0004863126,0.052946854,0.0005602637,0.00025791992,0.61925304,0.00042495405,0.000007146243,0.00046108567,0.0005031816,0.04326077,0.28066456],"study_design_scores_gemma":[0.017020067,0.0031523611,0.012693359,0.00035904892,0.00045720098,0.459914,0.00031199973,0.0035344488,0.0011083233,0.0000784451,0.5009129,0.0004578092],"about_ca_topic_score_codex":0.0006463175,"about_ca_topic_score_gemma":0.0013185915,"teacher_disagreement_score":0.45765215,"about_ca_system_score_codex":0.0071192947,"about_ca_system_score_gemma":0.0076910974,"threshold_uncertainty_score":0.9979344},"labels":[],"label_agreement":null},{"id":"W2783138054","doi":"10.14740/jh365w","title":"Role of Nucleophosmin Gene Mutation in Leukemogenesis of Acute Myeloid Leukemia","year":2018,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Shaqra University","keywords":"Nucleophosmin; Myeloid leukemia; Mitosis; Cancer research; Cell cycle; Biology; Cell culture; Mutation; Leukemia; Haematopoiesis; Cell growth; Myeloid; Gene mutation; Stem cell; Cell; Gene; Cell biology; Immunology; Genetics","score_opus":0.01264542992510854,"score_gpt":0.2966362080296415,"score_spread":0.283990778104533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783138054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971864,0.00093479676,0.00019211436,0.0005413699,0.00012465598,0.00016791241,0.000006771118,0.000005517956,0.00084044354],"genre_scores_gemma":[0.9916778,0.00034121063,0.0076096533,0.00010438967,0.00014416977,0.0000025680977,0.0000037284062,0.000026389465,0.00009006674],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978224,0.00012307694,0.0011598037,0.00015653283,0.00043534162,0.00030282387],"domain_scores_gemma":[0.99782974,0.00017002145,0.00079900434,0.00027531813,0.0007910048,0.00013491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065025623,0.00014339329,0.0009392157,0.0007653816,0.000023226585,0.000003164151,0.00025003022,0.00021880704,0.00023137825],"category_scores_gemma":[0.00027528073,0.00011930361,0.0001844097,0.0004879123,0.0003355712,0.00011365486,0.000073904754,0.0003409108,0.000023864046],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024115616,0.00020635573,0.033841956,0.00020502157,0.0004951465,0.0008907109,0.0011116373,0.000015491576,0.95244217,0.00048962486,0.0014634815,0.0064268145],"study_design_scores_gemma":[0.0041395263,0.0018553179,0.04972197,0.00018350774,0.00023216792,0.011148365,0.0005561506,0.00073308445,0.93001634,0.00095072825,0.00036160904,0.000101254984],"about_ca_topic_score_codex":0.00010565981,"about_ca_topic_score_gemma":0.000023706752,"teacher_disagreement_score":0.02242588,"about_ca_system_score_codex":0.00047841284,"about_ca_system_score_gemma":0.0012866318,"threshold_uncertainty_score":0.48650602},"labels":[],"label_agreement":null},{"id":"W2783313741","doi":"10.1182/blood-2017-09-803809","title":"A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium","year":2018,"lang":"en","type":"letter","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"National Cancer Institute","keywords":"Childhood leukemia; Azacitidine; Leukemia; Medicine; Chemotherapy; Chemotherapy regimen; Oncology; Pediatrics; Internal medicine; Lymphoblastic Leukemia; Biology","score_opus":0.01774558876828727,"score_gpt":0.28934808157544445,"score_spread":0.2716024928071572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783313741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8788814,0.0001787803,0.000005546535,0.11574057,0.00007978181,0.0037111267,0.00012321176,0.00007448483,0.001205112],"genre_scores_gemma":[0.84603673,0.00008648268,0.0002872347,0.14514013,0.0044916975,0.0005054736,0.0015732978,0.0002882894,0.0015906434],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956624,0.00027913763,0.0010491421,0.0009879542,0.0013449432,0.00067640457],"domain_scores_gemma":[0.99616903,0.00047653675,0.0006465435,0.002210031,0.00037759202,0.00012024492],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006235218,0.0006048881,0.0015376061,0.0002917712,0.00008024517,0.000035721067,0.0006329054,0.000711118,0.00031810973],"category_scores_gemma":[0.0003060048,0.0003717237,0.00016771613,0.0006864764,0.00045379868,0.00006859824,0.00015427376,0.0033616372,0.000023140217],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003703007,0.017859535,0.03025304,0.00019546052,0.004342687,0.04563453,0.0041940217,3.2775094e-7,0.0012998161,0.0000018806975,0.8922138,0.00030188652],"study_design_scores_gemma":[0.6329358,0.06583076,0.07411927,0.0028151518,0.0066520846,0.008050848,0.0034389393,0.00007878179,0.01643218,0.00015667218,0.18721433,0.002275194],"about_ca_topic_score_codex":0.0016800716,"about_ca_topic_score_gemma":0.00019728203,"teacher_disagreement_score":0.7049995,"about_ca_system_score_codex":0.00032611066,"about_ca_system_score_gemma":0.0020548222,"threshold_uncertainty_score":0.99987346},"labels":[],"label_agreement":null},{"id":"W2783692764","doi":"10.1038/nature25193","title":"A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies","year":2018,"lang":"en","type":"article","venue":"Nature","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":358,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Deutsches Krebsforschungszentrum","keywords":"Haematopoiesis; Enhancer; Biology; Stem cell; Progenitor cell; Myeloid; Transcription factor; RUNX1; Cell biology; Cancer research; Enhancer RNAs; Molecular biology; Genetics; Gene","score_opus":0.007558521614313518,"score_gpt":0.27313948145983524,"score_spread":0.2655809598455217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783692764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97921276,0.00410481,0.000031390908,0.0039486666,0.00018756263,0.0004035496,0.000008378597,0.00008542812,0.012017456],"genre_scores_gemma":[0.9717116,0.00018554002,0.0011796574,0.0023774134,0.0006959603,0.000017627151,0.000013498993,0.000040756247,0.02377797],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99853283,0.00005751362,0.00018925009,0.00037278925,0.0004047616,0.00044282744],"domain_scores_gemma":[0.99902606,0.0001103333,0.00005062797,0.00041776523,0.00019695627,0.00019828048],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0002319063,0.00019659245,0.00029803134,0.00017565138,0.00013431492,0.00004175971,0.00015939081,0.00097114325,0.00026273998],"category_scores_gemma":[0.00004075508,0.00014788135,0.00006367494,0.00026360757,0.00037462503,0.0001263533,0.00019404701,0.0023582794,0.00019327445],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004144882,0.00029436234,0.016292706,0.00272141,0.00037381635,0.00056921324,0.012465329,0.0000027224237,0.36959893,0.0012102086,0.5500949,0.0422315],"study_design_scores_gemma":[0.007976281,0.0014376726,0.027657917,0.0006548585,0.00022451898,0.0016068275,0.0009910279,0.0020621358,0.81434417,0.0008581222,0.14144449,0.00074196194],"about_ca_topic_score_codex":0.000013159512,"about_ca_topic_score_gemma":0.000016722117,"teacher_disagreement_score":0.44474524,"about_ca_system_score_codex":0.00014259176,"about_ca_system_score_gemma":0.00019490904,"threshold_uncertainty_score":0.9999433},"labels":[],"label_agreement":null},{"id":"W2784467022","doi":"10.1182/blood.v130.suppl_1.464.464","title":"Two Cycles of Consolidation Chemotherapy Are Associated with Similar Clinical Outcomes to Three Cycles in AML Patients with Favorable Risk Cytogenetics","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Leukemia & Lymphoma Society of Canada; University of Alberta","funders":"","keywords":"Cytarabine; Medicine; Induction chemotherapy; Myeloid leukemia; Internal medicine; Chemotherapy; Oncology; Chemotherapy regimen; Leukemia; Anthracycline; Surgery; Cancer","score_opus":0.037201712826959395,"score_gpt":0.34722138044299133,"score_spread":0.31001966761603195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784467022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99781936,0.00002068238,0.000063911335,0.0006334274,0.000023052567,0.0009044681,0.000103745886,0.00003009916,0.00040122756],"genre_scores_gemma":[0.9963958,0.00006955911,0.0030929472,0.00023291551,0.000039801616,0.00002304281,0.000042681608,0.00004890631,0.000054327702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981897,0.00010569022,0.00044009788,0.00035399233,0.0005616506,0.00034889256],"domain_scores_gemma":[0.9978638,0.0002650801,0.0005266685,0.00080203114,0.00036561675,0.00017676427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053360144,0.00020230803,0.0006482638,0.0001274947,0.0001293051,0.00003927207,0.0002958741,0.00013814964,0.000021141279],"category_scores_gemma":[0.0013149895,0.00014114067,0.00006953493,0.00014481373,0.00024035039,0.00008586498,0.000088575405,0.00034465638,0.000009860798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063399354,0.001417982,0.9956707,0.00002016872,0.0004342793,0.000025808813,0.00012235648,0.000033350003,0.00009074326,0.0000059517492,0.00006664423,0.0014780542],"study_design_scores_gemma":[0.023937607,0.0009845736,0.9706688,0.00025822257,0.00020000442,0.0000012770957,0.00008032965,0.00007074467,0.0035534312,0.000059349924,0.000023521425,0.00016211782],"about_ca_topic_score_codex":0.00036354834,"about_ca_topic_score_gemma":0.0022142793,"teacher_disagreement_score":0.025001846,"about_ca_system_score_codex":0.0000876716,"about_ca_system_score_gemma":0.00024814307,"threshold_uncertainty_score":0.57555497},"labels":[],"label_agreement":null},{"id":"W2785287594","doi":"10.1182/blood.v130.suppl_1.299.299","title":"Mitochondrial Carrier Homolog 2 (MTCH2) Regulates the Differentiation of AML Cells By Controlling Pyruvate Entry into the Mitochondria, Nuclear Localization of Pyruvate Dehydrogenase Complex and H3 and H4 Histone Acetylation","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Biology; Haematopoiesis; Cell biology; Stem cell; Mitochondrion; Gene knockdown; Molecular biology; Cancer research; Cell culture; Genetics","score_opus":0.010357158832103147,"score_gpt":0.2577830226473378,"score_spread":0.24742586381523468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785287594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577236,0.0010641352,0.00062933966,0.001311697,0.00014424634,0.00091951643,0.000042527117,0.000020147892,0.000096017946],"genre_scores_gemma":[0.99851507,0.00049410795,0.00039510767,0.00009278204,0.00016586439,0.000018328232,0.000080711514,0.00003484597,0.0002031586],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984894,0.00016229255,0.0004398937,0.00030169365,0.00037350436,0.00023324952],"domain_scores_gemma":[0.9983346,0.00019224752,0.00050223625,0.00065751164,0.00021381315,0.00009957927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027214014,0.00018898453,0.00041400135,0.00007313624,0.0005256475,0.00006933933,0.00023387461,0.0001610311,0.00003969284],"category_scores_gemma":[0.00029386446,0.000122007266,0.000076297394,0.000087265274,0.0007963497,0.0001378932,0.00016387182,0.00022082492,0.000001732673],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050195603,0.00013575985,0.003377135,0.00013093813,0.00024215863,0.000003590547,0.0022449936,0.00003665313,0.99068445,0.00011098703,0.001449018,0.0010823748],"study_design_scores_gemma":[0.015495141,0.00041908794,0.0134327235,0.00017999538,0.0010222931,0.000021051348,0.00057222194,0.04646253,0.9192023,0.0005239357,0.0024238112,0.00024485972],"about_ca_topic_score_codex":0.00055506965,"about_ca_topic_score_gemma":0.000052872816,"teacher_disagreement_score":0.071482085,"about_ca_system_score_codex":0.000055530312,"about_ca_system_score_gemma":0.00006239884,"threshold_uncertainty_score":0.4975312},"labels":[],"label_agreement":null},{"id":"W2786854070","doi":"10.1016/j.stem.2018.01.011","title":"Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies","year":2018,"lang":"en","type":"review","venue":"Cell stem cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":450,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Cancer Institute; Damon Runyon Cancer Research Foundation","keywords":"Biology; Haematopoiesis; Somatic evolution in cancer; Immunology; Cancer research; Evolutionary biology; Genetics; Stem cell; Cancer","score_opus":0.03664998042485567,"score_gpt":0.3074273032066217,"score_spread":0.27077732278176603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786854070","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008112238,0.97963965,0.00012695916,0.00007942441,0.00024550338,0.0016438143,0.000051568266,0.000111580644,0.01729026],"genre_scores_gemma":[0.00021875171,0.9443041,0.00090724486,0.00011818842,0.0005216412,0.00024520367,0.00007534459,0.00016870696,0.053440783],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964694,0.00019007226,0.00083131774,0.0009955526,0.00069432077,0.00081938645],"domain_scores_gemma":[0.9975441,0.0002760823,0.00027931153,0.0009872904,0.00023345064,0.00067974295],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005800578,0.00069759786,0.0022772837,0.0004904158,0.00017210867,0.00007825139,0.0003869006,0.00062925473,0.00028027678],"category_scores_gemma":[0.00002811847,0.00055399834,0.00047518482,0.0006835545,0.00022109335,0.00006508551,0.00050878583,0.0006185266,0.0036729362],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016035442,0.0005888224,0.00009063014,0.56147677,0.00041746272,0.00093346945,0.0012833679,2.7642514e-7,0.000700621,0.0005271524,0.2730264,0.16079465],"study_design_scores_gemma":[0.00043355624,0.00030925326,0.000008991158,0.010615512,0.00087549305,0.0005565261,0.0001819147,0.000005061538,0.0006778677,0.000018022736,0.985803,0.0005147794],"about_ca_topic_score_codex":0.000025290024,"about_ca_topic_score_gemma":0.0000025948825,"teacher_disagreement_score":0.7127766,"about_ca_system_score_codex":0.0010487308,"about_ca_system_score_gemma":0.0011163,"threshold_uncertainty_score":0.9996911},"labels":[],"label_agreement":null},{"id":"W2789218687","doi":"10.1016/j.bbmt.2018.02.007","title":"Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience","year":2018,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; International Prognostic Scoring System; Myelodysplastic syndromes; Proportional hazards model; Internal medicine; Transplantation; Hematopoietic stem cell transplantation; Hazard ratio; Oncology; Single Center; Bone marrow; Confidence interval","score_opus":0.01122078964666029,"score_gpt":0.25513844272666003,"score_spread":0.24391765307999974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789218687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744025,0.00004639939,0.022422515,0.00017625082,0.00029693905,0.0019189169,0.0006258626,0.00007951534,0.00003114178],"genre_scores_gemma":[0.99208134,0.00020003504,0.005813503,0.00010079287,0.000087309636,0.00026163645,0.0013828735,0.00004400873,0.00002848216],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99794406,0.000111580586,0.0006466999,0.0006046475,0.00030946388,0.0003835453],"domain_scores_gemma":[0.99871564,0.00027768908,0.00026743446,0.0001683671,0.00044248227,0.00012836404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022173341,0.0003308482,0.00047373804,0.00032154267,0.00016670518,0.000033659406,0.00016320463,0.00021006374,0.000010281671],"category_scores_gemma":[0.000016096694,0.00023604179,0.000100107536,0.00012948307,0.00028028537,0.0003108105,0.0000080305035,0.00014860049,0.0000019633976],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069949436,0.0003055875,0.36721674,0.007055599,0.0002745323,0.000038577677,0.0061595603,0.00000252854,0.60565686,0.000029151612,4.6675575e-7,0.006265447],"study_design_scores_gemma":[0.034995582,0.008803223,0.47658578,0.003215565,0.003649043,0.0006420069,0.00088756846,0.0006816194,0.46965405,0.0000171413,0.000018865201,0.0008495506],"about_ca_topic_score_codex":0.00009434682,"about_ca_topic_score_gemma":0.00009393751,"teacher_disagreement_score":0.1360028,"about_ca_system_score_codex":0.00006619318,"about_ca_system_score_gemma":0.00009673671,"threshold_uncertainty_score":0.9625505},"labels":[],"label_agreement":null},{"id":"W2789326640","doi":"10.1038/s41375-017-0005-9","title":"Pharmacologic inhibition of STAT5 in acute myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Mitacs; Hungarian Scientific Research Fund; Austrian Science Fund","keywords":"Cancer research; STAT5; Myeloid leukemia; Mediator; Leukemia; Haematopoiesis; Tyrosine kinase; Transcription factor; Myeloid; Biology; Medicine; Immunology; Signal transduction; Internal medicine; Stem cell; Cell biology; Gene","score_opus":0.024414295980904506,"score_gpt":0.3269247589845998,"score_spread":0.3025104630036953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789326640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98017657,0.00012308908,0.00020919292,0.00062034576,0.00020028642,0.00071126455,0.000030806405,0.00011563021,0.017812805],"genre_scores_gemma":[0.9927314,0.00029343952,0.0021950551,0.0013922569,0.00045939127,0.000063473075,0.00007889735,0.000053122647,0.002732943],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99739736,0.0001265534,0.0006469203,0.00052039133,0.0005893159,0.00071948284],"domain_scores_gemma":[0.9986057,0.00013457594,0.0001759608,0.0005081161,0.0003214934,0.0002540963],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00061806664,0.00027946173,0.0005831225,0.0005245042,0.00007586361,0.000016779344,0.00022753,0.00029375454,0.0010905574],"category_scores_gemma":[0.00017526613,0.00024887093,0.00013468559,0.0010550687,0.0005500817,0.00021684868,0.00020176134,0.0007754722,0.0005278633],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021507186,0.00014229126,0.013285215,0.00023240793,0.00020127036,0.000856107,0.0010544006,0.00003153395,0.9312499,0.00051667343,0.03592753,0.014351921],"study_design_scores_gemma":[0.013860557,0.0020672749,0.079990886,0.00037261055,0.00023348043,0.000308779,0.00038929304,0.0054695643,0.88116115,0.0009969166,0.01462465,0.00052480836],"about_ca_topic_score_codex":0.0005346322,"about_ca_topic_score_gemma":0.0000806608,"teacher_disagreement_score":0.066705674,"about_ca_system_score_codex":0.0050122724,"about_ca_system_score_gemma":0.0023434388,"threshold_uncertainty_score":0.99999636},"labels":[],"label_agreement":null},{"id":"W2789431138","doi":"10.1016/j.leukres.2018.02.005","title":"Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy","year":2018,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Incidence (geometry); Internal medicine; Hazard ratio; International Prognostic Scoring System; Deferasirox; Blood transfusion; Anemia; Surgery; Thalassemia; Confidence interval; Bone marrow","score_opus":0.014959519650715038,"score_gpt":0.28039519484022407,"score_spread":0.26543567518950906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789431138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949996,0.00007582526,0.00022758529,0.00016537536,0.00014478959,0.0021776436,0.000024578301,0.000055118857,0.0021294795],"genre_scores_gemma":[0.99791425,0.00023442271,0.0009931964,0.000009232954,0.00011610374,0.00018253918,0.000046181416,0.0000578196,0.00044622386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99660605,0.00025935363,0.0005380167,0.00062989106,0.001378073,0.00058859214],"domain_scores_gemma":[0.9975373,0.0006901809,0.00013638691,0.00043626584,0.00094475626,0.00025511984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001364884,0.00022384482,0.00034089517,0.001362594,0.00030630885,0.00006706192,0.00020273656,0.00023037958,0.000095664764],"category_scores_gemma":[0.0007805858,0.00019280605,0.00004701541,0.0015852089,0.00021268934,0.00035577183,0.00013378082,0.0010159911,0.000043507618],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019461911,0.00047324464,0.9787111,0.0003363206,0.000067436195,0.000045705478,0.0011921177,0.0007419165,0.013345259,0.00007217348,0.000029305242,0.0030392231],"study_design_scores_gemma":[0.0074566863,0.003779884,0.97946537,0.0016634222,0.000048558217,0.00005104607,0.00022871114,0.0054344167,0.0016270145,0.000033080916,0.000032544944,0.00017927786],"about_ca_topic_score_codex":0.0013878187,"about_ca_topic_score_gemma":0.00032721637,"teacher_disagreement_score":0.011718245,"about_ca_system_score_codex":0.0021961057,"about_ca_system_score_gemma":0.0005853918,"threshold_uncertainty_score":0.7862403},"labels":[],"label_agreement":null},{"id":"W2790109530","doi":"10.1002/pbc.27034","title":"Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study","year":2018,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Leukemia and Lymphoma Society; European Hematology Association; St. Baldrick's Foundation","keywords":"Medicine; Juvenile myelomonocytic leukemia; Juvenile; Oncology; Pediatric oncology; Internal medicine; Disease; Randomized controlled trial; Leukemia; Pediatrics; Cancer","score_opus":0.01272837117521919,"score_gpt":0.3203608596922169,"score_spread":0.3076324885169977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790109530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988075,0.0027218414,0.00002575111,0.00072241295,0.00011420706,0.008065242,0.00005173,0.000073545474,0.0001502538],"genre_scores_gemma":[0.9915685,0.0010789557,0.00022175047,0.0002156203,0.004152837,0.002389654,0.00009990819,0.00007144926,0.0002013076],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963094,0.0005779118,0.00080718665,0.0009274895,0.0005948738,0.00078313594],"domain_scores_gemma":[0.99821216,0.00037306876,0.0003090772,0.00048194677,0.00013680696,0.00048696055],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001382247,0.0004082409,0.0014595502,0.0008321273,0.00021481678,0.00003908389,0.00021901302,0.00020168298,0.00023458598],"category_scores_gemma":[0.0004594926,0.00032965912,0.000118008094,0.0011624157,0.00044680547,0.00019563724,0.00023001341,0.0009281985,0.000012286964],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.599776,0.0047180816,0.3855727,0.0000714985,0.00094844156,0.0005260981,0.0033639492,0.00002960316,0.000033818895,0.000018166622,0.000626561,0.0043150214],"study_design_scores_gemma":[0.8973354,0.011005147,0.08749965,0.00007006906,0.002874121,0.000118291384,0.00017742072,0.00045623854,0.000014908798,0.0000471725,0.000043583193,0.00035799763],"about_ca_topic_score_codex":0.006270423,"about_ca_topic_score_gemma":0.0009841921,"teacher_disagreement_score":0.29807305,"about_ca_system_score_codex":0.001138089,"about_ca_system_score_gemma":0.0028384165,"threshold_uncertainty_score":0.99991554},"labels":[],"label_agreement":null},{"id":"W2790326841","doi":"10.1016/j.leukres.2018.02.009","title":"The importance of meaningful activity in people living with acute myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Deconditioning; Quality of life (healthcare); Psychology; Psychological intervention; Qualitative research; Gerontology; Population; Observational study; Medicine; Disease; Incentive; Physical therapy; Psychiatry; Environmental health; Psychotherapist; Pathology","score_opus":0.03365902177792159,"score_gpt":0.3485649236618035,"score_spread":0.31490590188388196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790326841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97107595,0.00020161475,0.000085018495,0.0017549626,0.00007000672,0.0011817042,0.000009108313,0.00007482083,0.025546815],"genre_scores_gemma":[0.9923827,0.00057835196,0.0007032278,0.00012230095,0.00042307985,0.00019772924,0.000006398399,0.000105486644,0.0054807095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934457,0.00053475855,0.00060370576,0.0008832813,0.0026378059,0.0018947498],"domain_scores_gemma":[0.9934514,0.0027671414,0.00014378442,0.0017708943,0.0014409226,0.00042582027],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0062334393,0.00035306628,0.00070457096,0.0006609926,0.00066138373,0.00011398118,0.0010496557,0.00030636048,0.00027215207],"category_scores_gemma":[0.002130524,0.00023217352,0.0001345375,0.0034544151,0.0019835748,0.00033272224,0.000824518,0.002775234,0.00019014638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009221893,0.00032746224,0.7403465,0.00064937887,0.0007672756,0.0010691758,0.006835178,0.000029335559,0.19611222,0.0029504283,0.01790087,0.02379029],"study_design_scores_gemma":[0.0052690785,0.0028275491,0.8969863,0.0010804035,0.00007012286,0.00043419184,0.0027379312,0.007106706,0.07736403,0.00040585504,0.00517835,0.0005394725],"about_ca_topic_score_codex":0.0030836123,"about_ca_topic_score_gemma":0.009392556,"teacher_disagreement_score":0.15663981,"about_ca_system_score_codex":0.008143968,"about_ca_system_score_gemma":0.009646833,"threshold_uncertainty_score":0.9995254},"labels":[],"label_agreement":null},{"id":"W2790713100","doi":"10.1186/s12878-017-0094-8","title":"Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"BMC Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Azacitidine; Internal medicine; Dosing; Regimen; Randomized controlled trial; Myelodysplastic syndromes; Clinical trial; Oncology; Myeloid leukemia; Observational study; Meta-analysis","score_opus":0.016104305833988888,"score_gpt":0.2995533355622908,"score_spread":0.28344902972830194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790713100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95781654,0.03383804,0.0006193401,0.0014654585,0.00017957482,0.0033816444,0.000018849638,0.00009903582,0.002581517],"genre_scores_gemma":[0.98241395,0.011108497,0.003637756,0.0010821365,0.00005606222,0.00025880538,0.000031461237,0.00006715173,0.0013441636],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99730456,0.00029173764,0.0010673637,0.00045480326,0.00034784075,0.0005337195],"domain_scores_gemma":[0.99788487,0.00063812017,0.000283927,0.0007297944,0.00025033246,0.00021295011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008970917,0.0002614703,0.001988653,0.0003989754,0.000043077365,0.0000059724966,0.0002167344,0.00022053822,0.00024643337],"category_scores_gemma":[0.0016330095,0.00020763608,0.00010368558,0.00060766086,0.0005417901,0.00007509283,0.00018512446,0.0003324906,0.00022879276],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024082979,0.00008835951,0.009478133,0.9776874,0.00037993453,0.0016334667,0.00020780381,1.512941e-7,0.0022570542,0.0049730786,0.0030373456,0.000016406579],"study_design_scores_gemma":[0.009227235,0.003198935,0.01779513,0.818954,0.0028315391,0.13538817,0.0004707062,0.0016913627,0.008532364,0.00073323597,0.00025473727,0.00092258066],"about_ca_topic_score_codex":0.00003510947,"about_ca_topic_score_gemma":0.000030591073,"teacher_disagreement_score":0.15873343,"about_ca_system_score_codex":0.0003370875,"about_ca_system_score_gemma":0.00066416076,"threshold_uncertainty_score":0.84671533},"labels":[],"label_agreement":null},{"id":"W2791304015","doi":"10.1002/gcc.22532","title":"<i>NUP98‐BPTF</i> gene fusion identified in primary refractory acute megakaryoblastic leukemia of infancy","year":2018,"lang":"en","type":"article","venue":"Genes Chromosomes and Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Hôpital Maisonneuve-Rosemont; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Terry Fox Research Institute","keywords":"Acute megakaryoblastic leukemia; Fusion gene; Fusion protein; Clofarabine; Biology; Cancer research; Chromatin; Chromatin remodeling; Chimeric gene; Gene; Genetics; Myeloid leukemia; Gene expression","score_opus":0.013518666177851444,"score_gpt":0.29166098666393725,"score_spread":0.2781423204860858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791304015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98289144,0.014328075,0.00003872984,0.00026304435,0.00033161632,0.00041563617,0.00005554355,0.000035227382,0.0016406854],"genre_scores_gemma":[0.9652022,0.029978592,0.00055222574,0.00068753876,0.00064011005,0.000090222595,0.00006217639,0.00005359219,0.0027333181],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981138,0.00005006897,0.00045485896,0.00047338335,0.00045321588,0.00045463225],"domain_scores_gemma":[0.998956,0.00006239477,0.00014264522,0.0004418865,0.00020779818,0.00018927858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021561126,0.00023668527,0.00055143796,0.00024931922,0.000085232976,0.000019335428,0.00017257316,0.00018952954,0.00052031735],"category_scores_gemma":[0.000027040012,0.00019916524,0.000083448365,0.0004785647,0.0003623886,0.0001703881,0.00024790742,0.0002745388,0.000027344373],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007993145,0.00007984162,0.03225982,0.00046705457,0.0001859189,0.00012906794,0.0005872766,0.000005489071,0.88969624,0.00001846163,0.003778197,0.071993314],"study_design_scores_gemma":[0.0075020893,0.0010335281,0.5561241,0.00087474624,0.00032877317,0.00020749056,0.00016717007,0.00055842526,0.3976444,0.00012285882,0.034894787,0.0005416264],"about_ca_topic_score_codex":0.0005753557,"about_ca_topic_score_gemma":0.00017579577,"teacher_disagreement_score":0.52386427,"about_ca_system_score_codex":0.0004800503,"about_ca_system_score_gemma":0.0010474719,"threshold_uncertainty_score":0.81217223},"labels":[],"label_agreement":null},{"id":"W2791883352","doi":"10.1016/j.leukres.2018.02.012","title":"AML refractory to primary induction with Ida-FLAG has a poor clinical outcome","year":2018,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care; Princess Margaret Cancer Foundation","keywords":"Flag (linear algebra); Refractory (planetary science); Medicine; Complete remission; Internal medicine; Induction chemotherapy; Oncology; Chemotherapy; Salvage therapy; Transplantation; Surgery; Biology","score_opus":0.2133251517237102,"score_gpt":0.46321697722524635,"score_spread":0.24989182550153616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791883352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9498978,0.000092007824,0.0003127399,0.015505525,0.00033396974,0.0019970287,0.000012535666,0.00023958634,0.031608783],"genre_scores_gemma":[0.9545179,0.00008779158,0.0068147024,0.0037903287,0.0041913176,0.0002426457,0.00006006391,0.00017314359,0.03012208],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9917058,0.0009241771,0.0009915087,0.0013483453,0.003199762,0.001830457],"domain_scores_gemma":[0.9934766,0.00094931887,0.00011828229,0.0017777997,0.0021826073,0.0014953364],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0073606414,0.0003826235,0.00086238474,0.0011827584,0.0006624739,0.00020733738,0.00081093877,0.0006228591,0.0008540507],"category_scores_gemma":[0.0031313866,0.00028829914,0.00019005233,0.0024409504,0.00220995,0.00033756727,0.0008064801,0.0043469043,0.0064272378],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.023808016,0.0011932919,0.15594831,0.0007035428,0.00064807135,0.0022251208,0.0018144037,0.0000071689083,0.06361833,0.00063086406,0.58474606,0.1646568],"study_design_scores_gemma":[0.010046024,0.014310667,0.34387186,0.00044059928,0.000090722846,0.0005855665,0.0008502709,0.0004916556,0.006971584,0.00018610894,0.62144893,0.0007059809],"about_ca_topic_score_codex":0.001072455,"about_ca_topic_score_gemma":0.00023829135,"teacher_disagreement_score":0.18792355,"about_ca_system_score_codex":0.007095864,"about_ca_system_score_gemma":0.007826228,"threshold_uncertainty_score":0.9999569},"labels":[],"label_agreement":null},{"id":"W2792374337","doi":"10.1007/s00277-018-3260-6","title":"Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients","year":2018,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Single-nucleotide polymorphism; SNP; Internal medicine; Myeloid leukemia; Core binding factor; Hematology; Oncology; Genotype; Medicine; Biology; Gastroenterology; Genetics; Gene; Transcription factor","score_opus":0.08397813695239313,"score_gpt":0.359400887521034,"score_spread":0.27542275056864085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792374337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926319,0.00010472536,0.0046009514,0.0007025269,0.00014603861,0.0009946426,0.00039195686,0.000043471748,0.0003837576],"genre_scores_gemma":[0.9951446,0.00013550148,0.003373179,0.00069690874,0.00007182698,0.00007017501,0.0002594433,0.000063945095,0.0001843876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755836,0.0000896899,0.00066353654,0.0004937596,0.0003613801,0.00083327084],"domain_scores_gemma":[0.99777514,0.0005556968,0.00029537058,0.00053380535,0.0006202726,0.00021971675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041091337,0.00026943441,0.0008943051,0.0005300735,0.000101908474,0.0000080109885,0.00031829748,0.0003333143,0.000113388305],"category_scores_gemma":[0.0010749414,0.00024120377,0.000195739,0.00034632251,0.00035579898,0.00008459729,0.00012009739,0.00037397002,0.000081365964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046252874,0.0003945475,0.9706162,0.00045670453,0.00047911736,0.00005611293,0.0009887562,0.00018701094,0.016542975,0.0004699675,0.0036730464,0.0015102668],"study_design_scores_gemma":[0.025630133,0.0058280407,0.45193344,0.00037778998,0.00035759277,0.000053290627,0.00026390687,0.24408719,0.2634295,0.0041212896,0.0026406874,0.0012771304],"about_ca_topic_score_codex":0.00011401425,"about_ca_topic_score_gemma":0.00011260148,"teacher_disagreement_score":0.5186828,"about_ca_system_score_codex":0.00017988811,"about_ca_system_score_gemma":0.0008739174,"threshold_uncertainty_score":0.98360044},"labels":[],"label_agreement":null},{"id":"W2792733346","doi":"10.14740/cmmr.v1i1.26","title":"Recent Advances in Characterization of Pre-Leukemic/Leukemic Stem Cells in Acute Myeloid Leukemia","year":2018,"lang":"en","type":"article","venue":"Cellular and Molecular Medicine Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Stem cell; Leukemia; Haematopoiesis; Cancer research; Biology; Epigenetics; Somatic evolution in cancer; Myeloid; Immunology; Cancer; Genetics; Gene","score_opus":0.02385328301259286,"score_gpt":0.3305998329755517,"score_spread":0.3067465499629588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792733346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817361,0.01177074,0.0008497757,0.0012453088,0.00014899562,0.0015624291,0.000012468062,0.000030547075,0.0026436264],"genre_scores_gemma":[0.9323102,0.06524207,0.00017231988,0.0002480173,0.0002651049,0.000100413345,0.00012810143,0.00007983818,0.0014538957],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99498296,0.00062229956,0.00092048274,0.0008647924,0.0015313927,0.0010780888],"domain_scores_gemma":[0.99763244,0.00021215114,0.00014747267,0.0007932775,0.0007780988,0.000436566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031959827,0.00033527095,0.0008692991,0.0016533419,0.000092918424,0.000018782604,0.00040314393,0.0003295404,0.00017529364],"category_scores_gemma":[0.00026996827,0.00028623812,0.00006886438,0.002288049,0.0013702998,0.00021957864,0.00033298056,0.001327937,0.000033008586],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011126045,0.00009088127,0.001729312,0.00042161258,0.000045026703,0.000622754,0.0012807464,0.0000031216894,0.93356043,0.00015814284,0.00016665089,0.060808737],"study_design_scores_gemma":[0.006109697,0.0018000586,0.008938085,0.0012781516,0.000053817297,0.00008875954,0.0006772433,0.0027046574,0.94830287,0.00016757067,0.029610373,0.0002687307],"about_ca_topic_score_codex":0.00022523977,"about_ca_topic_score_gemma":0.000038034046,"teacher_disagreement_score":0.06054001,"about_ca_system_score_codex":0.0015302968,"about_ca_system_score_gemma":0.0013964523,"threshold_uncertainty_score":0.999959},"labels":[],"label_agreement":null},{"id":"W2793687898","doi":"10.1002/cncr.31311","title":"Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center","year":2018,"lang":"en","type":"article","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Transplantation; Internal medicine; Myeloid leukemia; Hazard ratio; Acute leukemia; Leukemia; Monosomy; Oncology; Hematopoietic stem cell transplantation; Gastroenterology; Immunology; Karyotype; Biology; Confidence interval; Chromosome; Genetics","score_opus":0.02468838235731237,"score_gpt":0.27250021937418145,"score_spread":0.2478118370168691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793687898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99270666,0.001143319,0.0017440547,0.0020172237,0.00013296492,0.001177177,0.00084522844,0.000012073033,0.00022131256],"genre_scores_gemma":[0.98602843,0.012287301,0.0006043488,0.00037559427,0.00023897254,0.000026129452,0.000108288914,0.000027897355,0.00030301133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887985,0.00014263911,0.0002318955,0.00032019892,0.00021103543,0.00021438663],"domain_scores_gemma":[0.99900097,0.00033741552,0.00019509028,0.00023173081,0.00017415782,0.000060633378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000582997,0.00015822923,0.00029819904,0.000018844623,0.0002596526,0.000018182003,0.00013206904,0.00009052262,0.000026581261],"category_scores_gemma":[0.000015229586,0.000090983085,0.00013915899,0.00011789793,0.00092590915,0.00008671375,0.000042948264,0.00020453164,1.4136945e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050752938,0.000084363084,0.69630104,0.002040386,0.007306807,0.0001573498,0.063095585,0.00002175226,0.13304721,0.00016462711,0.024047915,0.022980047],"study_design_scores_gemma":[0.029374482,0.00025064172,0.9437539,0.00078058755,0.0068883826,0.0001947569,0.0017544036,0.0020336623,0.008884935,0.00016352149,0.005637224,0.00028350824],"about_ca_topic_score_codex":0.0011599791,"about_ca_topic_score_gemma":0.0018470563,"teacher_disagreement_score":0.24745288,"about_ca_system_score_codex":0.00017672982,"about_ca_system_score_gemma":0.00031959152,"threshold_uncertainty_score":0.37101826},"labels":[],"label_agreement":null},{"id":"W2795076534","doi":"10.1016/j.blre.2018.03.006","title":"Time to repeal and replace response criteria for acute myeloid leukemia?","year":2018,"lang":"en","type":"review","venue":"Blood Reviews","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb; Agios Pharmaceuticals; Celgene; Daiichi-Sankyo; Pfizer; Amgen","keywords":"Medicine; Clinical trial; Intensive care medicine; Minimal residual disease; Myeloid leukemia; Oncology; Disease; Immunology; Internal medicine; Leukemia","score_opus":0.07172630987163685,"score_gpt":0.4155518578424391,"score_spread":0.3438255479708022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795076534","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000048326998,0.98320025,0.00003167171,0.0006074523,0.00018811565,0.013921061,0.00033038933,0.0001368056,0.0015359266],"genre_scores_gemma":[2.4301409e-8,0.8940704,0.014043886,0.0010612417,0.0015308751,0.0024726398,0.00035309608,0.00026379648,0.086204045],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99302125,0.0015159214,0.0021115637,0.0018203781,0.0004894186,0.0010414813],"domain_scores_gemma":[0.9943541,0.0010211098,0.000705791,0.0026317595,0.00033804998,0.0009491319],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.007556249,0.0010704807,0.006313758,0.0005987848,0.00021245226,0.000116145755,0.0006839803,0.00080143847,0.0011222815],"category_scores_gemma":[0.0057873554,0.00075747975,0.001265892,0.0008569985,0.0002662663,0.000108717984,0.00061766634,0.0008744226,0.0057534655],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009359078,0.0000489829,1.1316166e-7,0.029237896,0.0006602999,0.0001510574,0.0000801859,1.6015619e-9,0.00012249804,0.0000027888598,0.45044976,0.5183105],"study_design_scores_gemma":[0.0014494573,0.0017256195,9.28235e-7,0.03833685,0.0092664445,0.0029278137,0.000004760241,0.000005163195,0.000026478534,0.0000031289721,0.94559807,0.00065530644],"about_ca_topic_score_codex":0.000006834846,"about_ca_topic_score_gemma":0.0000012151976,"teacher_disagreement_score":0.5176552,"about_ca_system_score_codex":0.0007413786,"about_ca_system_score_gemma":0.00256184,"threshold_uncertainty_score":0.99979085},"labels":[],"label_agreement":null},{"id":"W2795918664","doi":"10.1097/mph.0000000000001136","title":"GATA2 Deficiency Due to de Novo Complete Monoallelic Deletion in an Adolescent With Myelodysplasia","year":2018,"lang":"en","type":"review","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; GATA2; Immunodeficiency; Myeloid leukemia; Leukemia; Myeloid; Myelodysplastic syndromes; Bone marrow; Pediatrics; Genetics; Immunology; Biology; Stem cell; Haematopoiesis","score_opus":0.07908106682554285,"score_gpt":0.40336372779517377,"score_spread":0.32428266096963093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795918664","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032112185,0.9610418,0.002342295,0.0013523366,0.0005042178,0.0020623377,0.000025262285,0.000040924915,0.00051860843],"genre_scores_gemma":[0.0015607,0.9781828,0.016542863,0.00063720805,0.0027546661,0.000096338044,0.00004491561,0.00013601204,0.000044525837],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931792,0.0013968938,0.0026405328,0.0007265848,0.00074372545,0.0013130542],"domain_scores_gemma":[0.9945632,0.0007764926,0.0019101786,0.00068502425,0.0009353911,0.0011296931],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.002973806,0.0006947886,0.0051319795,0.0030266966,0.00010612772,0.000029956567,0.0009918733,0.0014686435,0.00011259271],"category_scores_gemma":[0.0008701256,0.0004992732,0.000473475,0.0018591464,0.00026847894,0.00016171778,0.0002503752,0.0032196748,0.00030022775],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0054089804,0.0070146355,0.018187355,0.055579316,0.0009339563,0.13020267,0.0021852152,0.00003782743,0.000038446804,0.00048993045,0.06070398,0.7192177],"study_design_scores_gemma":[0.0044566216,0.011881541,0.0010681603,0.0036298446,0.0025965616,0.1870578,0.00024133905,0.000045486297,0.0000026870612,0.00004432762,0.7883613,0.00061431935],"about_ca_topic_score_codex":0.00002510559,"about_ca_topic_score_gemma":0.00016748952,"teacher_disagreement_score":0.7276573,"about_ca_system_score_codex":0.0046992535,"about_ca_system_score_gemma":0.013503725,"threshold_uncertainty_score":0.9998277},"labels":[],"label_agreement":null},{"id":"W2796064294","doi":"10.1101/295808","title":"Target variant detection in leukemia using unaligned RNA-Seq reads","year":2018,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Université de Montréal; Compute Canada; Genome Canada","keywords":"Myeloid leukemia; Computational biology; DNA sequencing; Computer science; Mutation; Identification (biology); Genetics; Biology; Gene; Cancer research","score_opus":0.02301943526566669,"score_gpt":0.2682163451100134,"score_spread":0.24519690984434672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796064294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98694366,0.000548694,0.0083999215,0.00023601261,0.001427809,0.0017567744,0.00011258249,0.0004970887,0.000077463956],"genre_scores_gemma":[0.9739576,0.0001995332,0.02314258,0.0003341698,0.0018096691,0.00020326203,0.0000013222112,0.000325611,0.000026279658],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99435467,0.00039972793,0.0011125613,0.0017826487,0.0010357453,0.0013146648],"domain_scores_gemma":[0.99529433,0.00011272353,0.0005457359,0.0023080478,0.0010887501,0.00065040146],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0021151127,0.0008951498,0.0012985447,0.001296787,0.00021577076,0.00020598139,0.000684338,0.0015595013,0.0002213055],"category_scores_gemma":[0.0009921577,0.0009478223,0.0002783322,0.0015840525,0.00033456553,0.0002344506,0.00095434906,0.0024691008,0.00021067556],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00045026647,0.00015548289,0.0045837048,0.00080302655,0.00028167618,0.0013425796,0.00002656211,0.00019205142,0.99169123,0.00008130972,0.000385882,0.00000624867],"study_design_scores_gemma":[0.003184109,0.00029505487,0.054250415,0.0018357821,0.00033409204,0.0000011270406,0.000007029702,0.030696215,0.9050731,0.000019887048,0.0029744485,0.0013287251],"about_ca_topic_score_codex":0.0014432726,"about_ca_topic_score_gemma":0.000020407002,"teacher_disagreement_score":0.086618096,"about_ca_system_score_codex":0.008234546,"about_ca_system_score_gemma":0.006081699,"threshold_uncertainty_score":0.9998323},"labels":[],"label_agreement":null},{"id":"W2798037083","doi":"10.1016/j.stemcr.2018.03.006","title":"PLAG1 and USF2 Co-regulate Expression of Musashi-2 in Human Hematopoietic Stem and Progenitor Cells","year":2018,"lang":"en","type":"article","venue":"Stem Cell Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research; Canada Research Chairs; Canadian Blood Services; Ontario Institute for Cancer Research","keywords":"Biology; Transactivation; Chromatin immunoprecipitation; Progenitor cell; Haematopoiesis; Transcription factor; Stem cell; Cell biology; CD34; Molecular biology; Promoter; Gene expression; Genetics; Gene","score_opus":0.017910507524466247,"score_gpt":0.2915030978195229,"score_spread":0.2735925902950566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2798037083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932388,0.00045926525,0.000008249607,0.000039112034,0.00009125232,0.0008729538,0.00000354506,0.000033116416,0.0052537043],"genre_scores_gemma":[0.99431497,0.000032626504,0.00022466987,0.00001710572,0.000108053246,0.000025439156,0.0000072716807,0.000039030576,0.0052308105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99797094,0.00007819333,0.0006486836,0.00049756974,0.00045747738,0.00034713084],"domain_scores_gemma":[0.9987336,0.000059748214,0.0002885675,0.00055363664,0.00012700241,0.00023748439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005882348,0.00019539552,0.00047222275,0.00020058281,0.00008018595,0.000021744068,0.00006143838,0.00017796514,0.00005906747],"category_scores_gemma":[0.00000856142,0.00015853798,0.000044245382,0.00016225148,0.00031397038,0.00008196108,0.00014513222,0.00021809792,0.000008311102],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011727231,0.00012011718,0.03442138,0.0009257813,0.000013944837,0.0014295146,0.0017711448,3.2287411e-7,0.9584988,0.000005879488,0.0018374074,0.0008584815],"study_design_scores_gemma":[0.0011244153,0.0004569141,0.0059051868,0.00046333723,0.000031244286,0.0007804186,0.00065951585,0.00003552011,0.98843926,0.000040496983,0.0019151341,0.00014853006],"about_ca_topic_score_codex":0.000046605426,"about_ca_topic_score_gemma":0.000010121668,"teacher_disagreement_score":0.029940533,"about_ca_system_score_codex":0.00009626994,"about_ca_system_score_gemma":0.00015675889,"threshold_uncertainty_score":0.64649916},"labels":[],"label_agreement":null},{"id":"W2799410313","doi":"10.1002/ptr.6091","title":"Therapeutic effect of <scp>Northern Labrador</scp> tea extracts for acute myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Phytotherapy Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; McGill University","keywords":"Myeloid leukemia; Ursolic acid; Medicine; Traditional medicine; Hematological malignancy; Population; Pharmacology; Biology; Immunology; Internal medicine; Botany; Environmental health","score_opus":0.04475516002405896,"score_gpt":0.3951620720484103,"score_spread":0.35040691202435137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799410313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838931,0.0020806764,0.00063344295,0.0008464256,0.00018547106,0.004006205,0.000075699,0.00015511212,0.008123898],"genre_scores_gemma":[0.97535026,0.0010543051,0.0010043917,0.00040606005,0.001747374,0.0007764021,0.000058071597,0.0002895139,0.01931362],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99382174,0.0007769379,0.00061706215,0.0009241753,0.001971139,0.0018889393],"domain_scores_gemma":[0.99189633,0.0041369274,0.00017075885,0.00144674,0.0018173931,0.0005318195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0049859816,0.0004748624,0.0010376635,0.00084855134,0.00043916106,0.000089990266,0.00088814826,0.00040334003,0.00028589962],"category_scores_gemma":[0.0011038646,0.0003603593,0.00040181447,0.001595833,0.0013683994,0.00022188494,0.00016513614,0.0013013565,0.00045809822],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004735507,0.00032936066,0.015144954,0.00066058955,0.0018098075,0.00007004744,0.0028801484,0.0000027803644,0.7901898,0.00035618388,0.020676298,0.16314451],"study_design_scores_gemma":[0.011997532,0.016573358,0.014341785,0.00027193737,0.00018669279,0.00012221042,0.0003894008,0.0015414826,0.83184713,0.0011364326,0.12137102,0.00022099199],"about_ca_topic_score_codex":0.00037778556,"about_ca_topic_score_gemma":0.00014511368,"teacher_disagreement_score":0.16292351,"about_ca_system_score_codex":0.0011263953,"about_ca_system_score_gemma":0.0017240912,"threshold_uncertainty_score":0.99988484},"labels":[],"label_agreement":null},{"id":"W2800708348","doi":"10.3324/haematol.2017.180844","title":"GFI1 is required for <i>RUNX1/ETO</i> positive acute myeloid leukemia","year":2018,"lang":"en","type":"letter","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Myeloid leukemia; Art; Theology; Art history; Philosophy; Medicine; Internal medicine","score_opus":0.03831771610229713,"score_gpt":0.3187925590230001,"score_spread":0.28047484292070296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800708348","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006163511,0.0008205173,0.0009422203,0.95109725,0.0009983685,0.0059637544,0.002032101,0.0007496237,0.031232646],"genre_scores_gemma":[0.0012217899,0.00058988837,0.010736416,0.9075162,0.0077091483,0.0012063446,0.004173323,0.00036853075,0.06647838],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99311554,0.0002546515,0.0011182803,0.0020212727,0.00129767,0.0021925713],"domain_scores_gemma":[0.99484414,0.0009577242,0.0006190354,0.0020410232,0.0011297775,0.00040830765],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.000591847,0.0012001522,0.00277231,0.0005390928,0.00046632922,0.00014251008,0.0011837693,0.003822218,0.0015155196],"category_scores_gemma":[0.0006084994,0.0009317207,0.0010565895,0.00057511823,0.0010729687,0.00017986682,0.0005880915,0.0036034759,0.002903768],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010786034,0.00004894608,0.000043606673,0.00087851135,0.0013057746,0.009592928,0.00026925994,4.751421e-8,0.0009701958,0.00011399705,0.98492056,0.0007775765],"study_design_scores_gemma":[0.0032928186,0.0019045306,0.000101172016,0.0006982301,0.0012667715,0.0056292983,0.000048948154,0.000115569215,0.0131651275,0.0011572362,0.9716194,0.0010008863],"about_ca_topic_score_codex":0.00009005838,"about_ca_topic_score_gemma":0.0000044636013,"teacher_disagreement_score":0.043581076,"about_ca_system_score_codex":0.001968654,"about_ca_system_score_gemma":0.0019109508,"threshold_uncertainty_score":0.9993972},"labels":[],"label_agreement":null},{"id":"W2800860839","doi":"10.1016/j.ebiom.2018.04.018","title":"Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents","year":2018,"lang":"en","type":"article","venue":"EBioMedicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Janssen Biotech; AbbVie; National Cancer Institute; Ministère des Affaires Sociales et de la Santé; Childhood Cancer Canada; Ligue Contre le Cancer; Association Laurette Fugain; Pharmacyclics; Celgene; Janssen Pharmaceuticals; Gilead Sciences; National Center for Research Resources; Novartis; Amgen","keywords":"Chronic myelomonocytic leukemia; Medicine; Internal medicine; Azacitidine; Hazard ratio; Decitabine; Oncology; Multivariate analysis; Proportional hazards model; Odds ratio; Hypomethylating agent; Cohort; Gastroenterology; Confidence interval; Gene; DNA methylation; Myelodysplastic syndromes; Biology; Genetics; Bone marrow","score_opus":0.018554798298088118,"score_gpt":0.29727706364119977,"score_spread":0.2787222653431117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800860839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953048,0.00027061038,0.000100287914,0.00015135785,0.00004100439,0.0011220792,0.000017002052,0.00005922727,0.0029335804],"genre_scores_gemma":[0.9970412,0.000021414324,0.0016519702,0.00008936358,0.00030708796,0.00006834244,0.00032166985,0.00005432346,0.00044460272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977662,0.00007147986,0.00055827165,0.00040241514,0.00065268215,0.0005489291],"domain_scores_gemma":[0.9985245,0.00017225317,0.00018561249,0.00041905293,0.00045505722,0.00024352537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030110634,0.00023916966,0.0005201176,0.0008025245,0.00007423166,0.0000074116233,0.00016523706,0.000119810546,0.00024546083],"category_scores_gemma":[0.00046922956,0.00017615591,0.000044952038,0.0018464788,0.00059526163,0.00009627189,0.000057970272,0.00031075027,0.00008289552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072085694,0.00033101707,0.8423449,0.000265939,0.00023671589,0.00016050201,0.0019315362,0.000029707004,0.1211492,0.000013143585,0.0003574809,0.032459017],"study_design_scores_gemma":[0.012513421,0.006337051,0.92693365,0.00080387853,0.00020712079,0.000048376776,0.00039446415,0.010720451,0.04129262,0.00003650346,0.000499426,0.00021301502],"about_ca_topic_score_codex":0.0006865193,"about_ca_topic_score_gemma":0.000082953324,"teacher_disagreement_score":0.08458878,"about_ca_system_score_codex":0.0024009452,"about_ca_system_score_gemma":0.0011572054,"threshold_uncertainty_score":0.71834296},"labels":[],"label_agreement":null},{"id":"W2801482851","doi":"10.1002/pbc.27089","title":"Acute myelogenous leukemia in adolescents and young adults","year":2018,"lang":"en","type":"review","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Young adult; Incidence (geometry); Lymphoblastic Leukemia; Leukemia; Pediatrics; Clinical trial; Oncology; Intensive care medicine; Internal medicine","score_opus":0.024242671407302255,"score_gpt":0.33127666536052075,"score_spread":0.3070339939532185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801482851","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009229112,0.9870849,0.0000013742622,0.00002886491,0.00064582704,0.0023136863,0.00020712511,0.0000895028,0.00039955546],"genre_scores_gemma":[0.0007409748,0.99154574,0.00013703368,0.00014128108,0.0053667133,0.00063431385,0.0001097022,0.00020505868,0.0011191824],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99569774,0.00016834727,0.0010054245,0.0012485303,0.00073867076,0.0011412844],"domain_scores_gemma":[0.99795747,0.000069712594,0.0004179661,0.0008080307,0.00022348158,0.0005233485],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040699515,0.0008026709,0.002562495,0.0009413464,0.00010278886,0.000050074916,0.0004801514,0.0009026335,0.00012726152],"category_scores_gemma":[0.00013597838,0.000658145,0.00038283993,0.0015088214,0.00016382344,0.00010103505,0.00042408332,0.0018028417,0.00022567273],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036729066,0.0002576453,0.026679978,0.1336717,0.0010994647,0.002045985,0.00044057076,1.4211368e-7,0.000001078575,0.0000029897692,0.010798564,0.8246346],"study_design_scores_gemma":[0.012431145,0.00094219344,0.0042602587,0.056620076,0.029480176,0.0027799981,0.000040580537,0.000036250374,0.000004968404,0.000010915267,0.8913896,0.0020038262],"about_ca_topic_score_codex":0.001820454,"about_ca_topic_score_gemma":0.00045036184,"teacher_disagreement_score":0.88059103,"about_ca_system_score_codex":0.002207491,"about_ca_system_score_gemma":0.006518547,"threshold_uncertainty_score":0.999587},"labels":[],"label_agreement":null},{"id":"W2801938323","doi":"10.14740/jh394w","title":"A Rare t(5;11)(q35;q13) Translocation in an Elderly Patient With Acute Myeloid Leukemia With Maturation: A Case Report","year":2018,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chromosomal translocation; Myeloid leukemia; Chromosomal Abnormality; Abnormality; Medicine; Myeloid; Leukemia; Cancer research; Pathology; Immunology; Biology; Karyotype; Genetics; Chromosome; Gene","score_opus":0.015354552505677934,"score_gpt":0.30078292959003544,"score_spread":0.28542837708435753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801938323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924725,0.00021677846,0.0030619313,0.0033542004,0.00010464171,0.00046878486,0.0000026393168,0.00002110932,0.00029739575],"genre_scores_gemma":[0.9875385,0.00003617905,0.011736226,0.00031487804,0.00022481519,0.000021547225,0.000017170109,0.000038015896,0.000072639916],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9977363,0.00015356533,0.00090675225,0.00029385317,0.00052768516,0.00038185786],"domain_scores_gemma":[0.99748254,0.00007270339,0.0006069858,0.00044473368,0.0011090284,0.00028399655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044844885,0.00021883298,0.00070252817,0.00046655812,0.00009472906,0.000030370864,0.00013970854,0.00019729944,0.00012337188],"category_scores_gemma":[0.00008268336,0.00014006479,0.00006648232,0.0004994984,0.0002610712,0.00041307366,0.000018878069,0.0006460937,0.000009756543],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009338802,0.00029211852,0.01302704,0.00013461983,0.00029451525,0.96054864,0.004122536,0.000028103608,0.003490761,0.00018749626,0.0020104751,0.006524886],"study_design_scores_gemma":[0.00465463,0.008966035,0.0020830864,0.0003638039,0.00016176044,0.9695168,0.0015390026,0.00044694848,0.011209751,0.000054516997,0.00084315916,0.00016052143],"about_ca_topic_score_codex":0.00010475533,"about_ca_topic_score_gemma":0.0015726892,"teacher_disagreement_score":0.010943954,"about_ca_system_score_codex":0.0005531404,"about_ca_system_score_gemma":0.0021351988,"threshold_uncertainty_score":0.57116765},"labels":[],"label_agreement":null},{"id":"W2803047175","doi":"10.14740/wjon1094w","title":"Concomitant <i>ATM</i> Mutations Identified by Next Generation Sequencing in a Patient With New-Onset Acute Myeloid Leukemia Following Imatinib Treatment for Chronic Myeloid Leukemia","year":2018,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Concomitant; Imatinib; Myeloid; Oncology; Cancer research; Internal medicine","score_opus":0.05184627910091566,"score_gpt":0.33975373111238616,"score_spread":0.2879074520114705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803047175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98965406,0.0009189242,0.004128205,0.0021781723,0.00068042305,0.0015478047,0.000044394757,0.000032180367,0.00081585173],"genre_scores_gemma":[0.9798251,0.00023385824,0.015292127,0.001134884,0.0012319568,0.00015229618,0.00015103661,0.00008636401,0.0018923787],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964389,0.00024214672,0.0014482128,0.00046928003,0.0005833426,0.00081807957],"domain_scores_gemma":[0.99715763,0.0005581981,0.00090555573,0.00037807666,0.0005254574,0.00047507478],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008472301,0.00041039908,0.0011289646,0.0007705922,0.00028667253,0.00009371249,0.00026348233,0.00022013599,0.00012692489],"category_scores_gemma":[0.00021792405,0.00031829174,0.00033481838,0.0007787742,0.00024772796,0.00048415066,0.00006154674,0.0006725314,0.000029392873],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005021392,0.00028918148,0.0028836762,0.00007431432,0.002021667,0.0026279204,0.0067069153,0.0010979563,0.8228063,0.00007982077,0.07294434,0.08344649],"study_design_scores_gemma":[0.13366023,0.099232934,0.0033648359,0.0019653738,0.0045770514,0.017734699,0.005883568,0.048691306,0.45663482,0.0006222995,0.22563066,0.0020022441],"about_ca_topic_score_codex":0.00061333226,"about_ca_topic_score_gemma":0.0064180107,"teacher_disagreement_score":0.3661715,"about_ca_system_score_codex":0.042826988,"about_ca_system_score_gemma":0.020559166,"threshold_uncertainty_score":0.9999269},"labels":[],"label_agreement":null},{"id":"W2803360616","doi":"10.1038/s41586-018-0125-z","title":"Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host","year":2018,"lang":"en","type":"article","venue":"Nature","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":405,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute; Hôpital Maisonneuve-Rosemont; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Institute of Biomedical Imaging and Bioengineering; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; National Institutes of Health; National Cancer Institute; Crohn's and Colitis Foundation; University of Chicago","keywords":"Haematopoiesis; Biology; Myeloid; Stem cell; Immunology; Epigenetics; Somatic cell; Cancer research; Lymphopoiesis; Myelopoiesis; Cell biology; Genetics; Gene","score_opus":0.00955968055772751,"score_gpt":0.3053104804324196,"score_spread":0.2957507998746921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803360616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892487,0.00047055757,0.00008373339,0.0045629996,0.00026632703,0.00087280903,0.000019816905,0.000072092116,0.004402981],"genre_scores_gemma":[0.9918706,0.00003504108,0.0009902809,0.003696078,0.00095634226,0.000032510958,0.00006791945,0.000032809487,0.002318458],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99829656,0.000076106604,0.00026661807,0.0004266425,0.000482521,0.00045154817],"domain_scores_gemma":[0.99898565,0.00007006045,0.000061643994,0.00036617828,0.0003805745,0.00013589718],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00041386596,0.0001805064,0.00027371707,0.00031871177,0.000088907196,0.00003715805,0.00018898178,0.0013190894,0.00031907234],"category_scores_gemma":[0.00047264117,0.00015009704,0.00007081345,0.0006288086,0.0001538769,0.00010021313,0.000098578545,0.0030694269,0.00032414292],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009888445,0.00018268664,0.010308488,0.00007717697,0.00003952539,0.00013054308,0.0020489837,0.000006687673,0.9359656,0.0002337066,0.048187517,0.0018302664],"study_design_scores_gemma":[0.008941389,0.0016372666,0.1527954,0.0006688682,0.00009014083,0.0004957307,0.0004223127,0.0034096274,0.7595286,0.0002673831,0.07110299,0.0006403013],"about_ca_topic_score_codex":0.00005368509,"about_ca_topic_score_gemma":0.00012885935,"teacher_disagreement_score":0.17643699,"about_ca_system_score_codex":0.0006628154,"about_ca_system_score_gemma":0.00058630254,"threshold_uncertainty_score":0.9999774},"labels":[],"label_agreement":null},{"id":"W2803478601","doi":"10.1182/blood-2018-01-829937","title":"Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research","keywords":"Myeloid; Biology; Haematopoiesis; Lineage (genetic); clone (Java method); Stem cell; Mutation; Genetics; Multipotent Stem Cell; Immunology; Progenitor cell; Molecular biology; Gene","score_opus":0.1255946732299508,"score_gpt":0.37441067995669913,"score_spread":0.24881600672674833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803478601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526906,0.00045946284,0.0013731001,0.0004042156,0.00007888144,0.0019276348,0.000058216545,0.000057659294,0.0003717686],"genre_scores_gemma":[0.990082,0.0002533511,0.0073210937,0.00013179066,0.0006699112,0.00029790783,0.000068828485,0.000044562243,0.0011305406],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985177,0.000053461823,0.00035257192,0.0004191396,0.00023056242,0.00042658456],"domain_scores_gemma":[0.99889773,0.00033923704,0.000117235344,0.0002996297,0.00016590246,0.00018027668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000510787,0.00017398405,0.00033816887,0.00043632448,0.00011388286,0.000031096428,0.00011446231,0.0001633516,0.0000101741325],"category_scores_gemma":[0.00024141891,0.00014186128,0.00009103366,0.0004185479,0.000106004925,0.0000745458,0.000058206053,0.0002114806,0.00001794332],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004180737,0.0031141506,0.15681607,0.0019199897,0.0006812457,0.00013027845,0.002328043,0.000018362089,0.7940182,0.0002099341,0.006223967,0.030359007],"study_design_scores_gemma":[0.029767081,0.0032624495,0.07770401,0.00018709485,0.00061478605,0.000048213806,0.00066561456,0.0071799294,0.860013,0.00010092086,0.02007991,0.00037696393],"about_ca_topic_score_codex":0.0001511088,"about_ca_topic_score_gemma":0.00005476754,"teacher_disagreement_score":0.07911205,"about_ca_system_score_codex":0.00011744884,"about_ca_system_score_gemma":0.00022299551,"threshold_uncertainty_score":0.57849354},"labels":[],"label_agreement":null},{"id":"W2804724049","doi":"10.1111/bjh.15273","title":"Azacitidine in the ‘real‐world’: an evaluation of 1101 higher‐risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada","year":2018,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"Sunnybrook Foundation; Cancer Care Ontario; Celgene","keywords":"Medicine; Azacitidine; Myelodysplastic syndromes; Internal medicine; Dosing; Myeloid leukaemia; Confidence interval; International Prognostic Scoring System; Cohort; Surgery; Pediatrics; Bone marrow","score_opus":0.017853528374629706,"score_gpt":0.2824927445244323,"score_spread":0.26463921614980257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804724049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973795,0.00018163853,0.000013167475,0.00030818212,0.00050721905,0.00063428073,0.000049342372,0.000005462031,0.0009212169],"genre_scores_gemma":[0.99896497,0.00022701226,0.0002227193,0.00025858614,0.000106445215,0.000022926184,0.000060505135,0.000033243432,0.00010362234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994908,0.0009874842,0.0013985806,0.00031795067,0.0017728416,0.00061514304],"domain_scores_gemma":[0.9966674,0.0003949195,0.0007721035,0.00034933575,0.0015904706,0.00022577058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027533118,0.0002357705,0.0010724107,0.0005722067,0.00010325108,0.00003386908,0.0005261143,0.00017850607,0.00079046626],"category_scores_gemma":[0.00061911513,0.00021044309,0.000096826014,0.0006807138,0.00035796204,0.00027357126,0.000077711826,0.0013723988,0.000008028284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016797979,0.0011313461,0.9200469,0.0001846632,0.0004794157,0.053319223,0.0012896289,0.00018194954,0.00027593874,0.00013852637,0.012779642,0.008492968],"study_design_scores_gemma":[0.007904619,0.001363269,0.94350797,0.0008997383,0.0003442637,0.043948665,0.00023286075,0.0006642809,0.00023732675,0.0002486537,0.00047193575,0.00017641262],"about_ca_topic_score_codex":0.87887126,"about_ca_topic_score_gemma":0.9949127,"teacher_disagreement_score":0.11604139,"about_ca_system_score_codex":0.0031504645,"about_ca_system_score_gemma":0.0067732823,"threshold_uncertainty_score":0.9988574},"labels":[],"label_agreement":null},{"id":"W2805661432","doi":"10.1002/stem.2845","title":"Concise Review: Age-Related Clonal Hematopoiesis: Stem Cells Tempting the Devil","year":2018,"lang":"en","type":"review","venue":"Stem Cells","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Cancer Institute; National Institutes of Health; Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Biology; Haematopoiesis; clone (Java method); Context (archaeology); Stem cell; Somatic evolution in cancer; Immunology; Aplastic anemia; Epigenetics; Cancer; Population; Cancer research; Genetics; Gene; Bone marrow","score_opus":0.06879236380997629,"score_gpt":0.34734712603787954,"score_spread":0.27855476222790326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805661432","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000016023756,0.9814364,0.000008764585,0.00037012034,0.0010716307,0.006686162,0.00012971263,0.00022819423,0.010052992],"genre_scores_gemma":[0.000004806434,0.9406622,0.00015298623,0.001068941,0.0009638435,0.00043934063,0.00011419456,0.00032171988,0.05627195],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.991321,0.0014782493,0.0027466347,0.0014040531,0.0016589233,0.0013911397],"domain_scores_gemma":[0.99326533,0.001531567,0.0014389257,0.0026281744,0.0005382293,0.00059779064],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.004051,0.0012855763,0.0051594083,0.00031124937,0.00038416608,0.00013265715,0.0015650564,0.0010189364,0.0010515604],"category_scores_gemma":[0.0000705872,0.00076003803,0.0018182645,0.0013952142,0.0006607685,0.00010902567,0.0007569619,0.0026769976,0.011368958],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000215885,0.00007262501,8.969235e-7,0.21039926,0.0011073897,0.0010025887,0.00017146875,1.417805e-7,0.00004304507,0.000053990352,0.4245437,0.3625833],"study_design_scores_gemma":[0.0005828861,0.00013396185,1.3063433e-7,0.15678635,0.0031200054,0.000610849,0.000115548835,0.000008406618,0.00031404253,0.00000423648,0.8377408,0.0005827874],"about_ca_topic_score_codex":0.000025777901,"about_ca_topic_score_gemma":0.0000040974137,"teacher_disagreement_score":0.4131971,"about_ca_system_score_codex":0.0013200567,"about_ca_system_score_gemma":0.002612063,"threshold_uncertainty_score":0.9999896},"labels":[],"label_agreement":null},{"id":"W2805988570","doi":"10.1038/s41598-018-24440-w","title":"Attenuated DNA damage responses and increased apoptosis characterize human hematopoietic stem cells exposed to irradiation","year":2018,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Sackler Faculty of Medicine, Tel-Aviv University; Israel Cancer Research Fund; Israel Science Foundation; Council for Higher Education; Tel Aviv University; National Cancer Institute; University of California, Los Angeles; German-Israeli Foundation for Scientific Research and Development; International Graduate School in Molecular Medicine Ulm; Deutsche Forschungsgemeinschaft","keywords":"Haematopoiesis; DNA damage; Progenitor cell; DNA repair; Cell biology; Biology; Bone marrow; Apoptosis; Stem cell; Non-homologous end joining; Cancer research; DNA; Genetics; Immunology","score_opus":0.033931349291167964,"score_gpt":0.2963862253312184,"score_spread":0.2624548760400504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805988570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962495,0.000014886361,0.0000204208,0.0008082207,0.0011169838,0.0010357207,0.000011319112,0.00014274906,0.00060018396],"genre_scores_gemma":[0.9859123,0.0000017305136,0.00031607546,0.00028401264,0.00018477275,0.000053186744,0.000105769344,0.000040414052,0.01310173],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968172,0.0001814514,0.000634299,0.0010158011,0.0008333127,0.0005179606],"domain_scores_gemma":[0.9972878,0.000088067136,0.00025171862,0.0013043659,0.0004971072,0.0005709184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025320495,0.00021679308,0.00037576753,0.0005955439,0.0005485046,0.000323796,0.00013849205,0.00012081765,0.0003035179],"category_scores_gemma":[0.0002833782,0.00019313121,0.00006979927,0.00095047447,0.00050192175,0.00020029926,0.00017479892,0.0001796519,0.00024593042],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017938718,0.00007359113,0.0031892993,0.00006679277,0.000026192783,0.00031516372,0.0012410438,6.6479885e-8,0.9747896,0.0000065509707,0.019268395,0.0008438865],"study_design_scores_gemma":[0.0006297179,0.0003079243,0.05385124,0.00013684224,0.00005266589,0.00027967468,0.00025078518,0.00006309374,0.9325177,0.000069789494,0.011625767,0.0002148043],"about_ca_topic_score_codex":0.000078383455,"about_ca_topic_score_gemma":0.000016183936,"teacher_disagreement_score":0.05066194,"about_ca_system_score_codex":0.0002573845,"about_ca_system_score_gemma":0.00039158083,"threshold_uncertainty_score":0.78756624},"labels":[],"label_agreement":null},{"id":"W2806336174","doi":"10.5430/jhm.v4n1p1","title":"AML Subtype M5 Linked to Pulmonary Leukemic Infiltrates and Respiratory Failure and the Importance of Early Induction Chemotherapy","year":2018,"lang":"en","type":"article","venue":"Journal of Hematological Malignancies","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chemotherapy; Lung; Induction chemotherapy; Biopsy; Lung biopsy; Myeloid leukemia; Pathology; Leukemia; Internal medicine","score_opus":0.0286616736207096,"score_gpt":0.29576183750776586,"score_spread":0.26710016388705626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806336174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98886853,0.002230952,0.000042114654,0.008266986,0.00005065,0.00029956436,0.0000016447333,0.000012045627,0.00022751477],"genre_scores_gemma":[0.9965339,0.00033134746,0.0010874955,0.0016974891,0.0002418305,0.0000065066774,3.4426776e-7,0.000013292158,0.00008779939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985127,0.00011521183,0.0006011291,0.00017536002,0.00035978243,0.00023580545],"domain_scores_gemma":[0.9984909,0.00024098577,0.00038492313,0.00019699302,0.00051730534,0.00016887738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009509144,0.00015318586,0.00061039906,0.00014902158,0.00009085681,0.00002763895,0.000158305,0.00017802935,0.000050350336],"category_scores_gemma":[0.0007520823,0.00008027793,0.00008397998,0.00029561558,0.0010371398,0.00014970372,0.000076867946,0.00043981435,0.0000041478565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007870356,0.0001427863,0.55079687,0.00027843026,0.00021857145,0.00045947704,0.0016092985,0.0000010920443,0.424471,0.0050798315,0.0069090435,0.002163246],"study_design_scores_gemma":[0.004959649,0.004546474,0.9208938,0.00058334385,0.00010901282,0.009186056,0.0015767236,0.000050451337,0.048182532,0.005158636,0.0045126085,0.00024070263],"about_ca_topic_score_codex":0.0000112563785,"about_ca_topic_score_gemma":0.000004811221,"teacher_disagreement_score":0.37628847,"about_ca_system_score_codex":0.000062389634,"about_ca_system_score_gemma":0.0002158459,"threshold_uncertainty_score":0.38213846},"labels":[],"label_agreement":null},{"id":"W2806893210","doi":"10.1038/s41375-018-0158-1","title":"Response kinetics and factors predicting survival in core-binding factor leukemia","year":2018,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Leukemia; Kinetics; Oncology; Cancer research; Immunology; Internal medicine; Biology; Medicine","score_opus":0.047954288853922694,"score_gpt":0.3224987165656892,"score_spread":0.27454442771176646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806893210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590766,0.00007483483,0.000080840065,0.00030317451,0.00037020602,0.00055345846,0.000047647864,0.00017515279,0.0024870383],"genre_scores_gemma":[0.9958353,0.000045015844,0.0008107935,0.00021568792,0.00045074758,0.000015889025,0.000037338126,0.00009043606,0.0024987909],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99693364,0.0002157502,0.00055969215,0.0006763579,0.00069142156,0.0009231368],"domain_scores_gemma":[0.99765134,0.0009775348,0.00013338952,0.0005908729,0.00018440266,0.0004624862],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00088563655,0.00038041567,0.00058684294,0.0005335893,0.00016903729,0.000069974456,0.0002631583,0.0003889239,0.00025906402],"category_scores_gemma":[0.0022170409,0.00033637416,0.00008634322,0.0007174802,0.00048780837,0.00018134076,0.00030501015,0.00097327336,0.00011212687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003235963,0.000041241965,0.7204798,0.000105138024,0.00007448214,0.00029852195,0.004302015,0.00000834721,0.26760328,0.00007077256,0.0013173524,0.0024631019],"study_design_scores_gemma":[0.0050028274,0.001250134,0.93764776,0.0003003867,0.000045662033,0.00012325331,0.0014172085,0.0059802444,0.042406704,0.00005245362,0.0053331023,0.0004402831],"about_ca_topic_score_codex":0.000713351,"about_ca_topic_score_gemma":0.00024175021,"teacher_disagreement_score":0.22519659,"about_ca_system_score_codex":0.0054639773,"about_ca_system_score_gemma":0.0013601121,"threshold_uncertainty_score":0.9999088},"labels":[],"label_agreement":null},{"id":"W2807075145","doi":"10.1038/s41375-018-0167-0","title":"Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Cancer research; Stem cell; Haematopoiesis; Myeloid leukemia; Biology; Leukemia; Progenitor cell; Population; Myeloid; Immunology; Medicine; Cell biology","score_opus":0.04710331547225144,"score_gpt":0.3552115564327113,"score_spread":0.30810824096045986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807075145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755432,0.00018909301,0.00008425734,0.0009817451,0.00040750497,0.0018985128,0.00001937457,0.00007054662,0.020805743],"genre_scores_gemma":[0.995215,0.00005796049,0.0008167865,0.00086788536,0.0007437866,0.00016564626,0.00004016276,0.000076269986,0.0020165038],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9951583,0.0007763358,0.00091820565,0.00077186245,0.0016185322,0.0007567534],"domain_scores_gemma":[0.9965654,0.00036288064,0.0003146789,0.0011574107,0.001366957,0.0002326847],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030112318,0.00035437974,0.00064031885,0.0003032709,0.00015558425,0.00002979037,0.0006061752,0.0005141429,0.00028765408],"category_scores_gemma":[0.0025244225,0.00026414986,0.0002646952,0.0015580719,0.0007467107,0.00014892436,0.0004138227,0.001369006,0.00020518254],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006693475,0.0008361843,0.145571,0.00045152107,0.0016585218,0.00018484872,0.008138909,0.00057668425,0.6925527,0.0011561363,0.069984205,0.07219586],"study_design_scores_gemma":[0.017542712,0.0017217541,0.30706367,0.00070321193,0.00097564154,0.00020834537,0.00037294283,0.056414805,0.6100038,0.0012294735,0.0031400751,0.0006235235],"about_ca_topic_score_codex":0.000704505,"about_ca_topic_score_gemma":0.0006651131,"teacher_disagreement_score":0.16149268,"about_ca_system_score_codex":0.008343049,"about_ca_system_score_gemma":0.009217962,"threshold_uncertainty_score":0.99998105},"labels":[],"label_agreement":null},{"id":"W2807346792","doi":"10.1038/s41408-018-0087-2","title":"Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network; McGill University; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Myeloid leukemia; Stem cell; Leukemia; Myeloid; Haematopoiesis; Cancer research; Medicine; Pharmacology; Oncology; Biology; Immunology; Genetics","score_opus":0.027511754514813476,"score_gpt":0.325757277402375,"score_spread":0.2982455228875615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807346792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98056304,0.011649534,0.001564997,0.0014333625,0.0013358697,0.0004479018,0.000048641217,0.00012801682,0.0028286271],"genre_scores_gemma":[0.97142285,0.0058531933,0.00439021,0.0034782686,0.0070381486,0.00003425716,0.000014488052,0.00016716763,0.007601401],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962194,0.00011804225,0.00075012486,0.0005403933,0.0012151622,0.0011569007],"domain_scores_gemma":[0.99746436,0.0001129542,0.00043246688,0.00049407437,0.00092154805,0.00057458447],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0009141611,0.00044061508,0.0005954828,0.00035404554,0.00063613907,0.00025146714,0.00067083724,0.00037870524,0.0007705557],"category_scores_gemma":[0.000027659555,0.00035694952,0.0003099818,0.00058992003,0.0003193839,0.0003267814,0.00020771482,0.002526582,0.00015098085],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006063955,0.00021545625,0.0031523025,0.000106219806,0.0013662229,0.00043777598,0.0011717879,0.00004591461,0.95185673,0.000023461906,0.027935691,0.013082063],"study_design_scores_gemma":[0.0185224,0.0020383482,0.009822113,0.0007266247,0.003189176,0.0044796085,0.0011357084,0.0026602885,0.8669276,0.0001440803,0.08928877,0.0010652711],"about_ca_topic_score_codex":0.00012642649,"about_ca_topic_score_gemma":0.000019246885,"teacher_disagreement_score":0.0849291,"about_ca_system_score_codex":0.0019369833,"about_ca_system_score_gemma":0.003941911,"threshold_uncertainty_score":0.99988824},"labels":[],"label_agreement":null},{"id":"W2808074814","doi":"10.1038/s41467-018-04831-3","title":"miR-143/145 differentially regulate hematopoietic stem and progenitor activity through suppression of canonical TGFβ signaling","year":2018,"lang":"en","type":"article","venue":"Nature Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; BC Cancer Foundation; University of British Columbia; Terry Fox Research Institute; Centre for Blood Research, University of British Columbia; Michael Smith Health Research BC; Leukemia and Lymphoma Society of Canada; Canadian Institutes of Health Research; Cancer Research Society; Leukemia and Lymphoma Society; U.S. Department of Defense","keywords":"Haematopoiesis; Progenitor cell; Biology; Stem cell; Cell biology; Cancer research; microRNA; Transforming growth factor; Context (archaeology); Progenitor; Myeloid; Immunology; Genetics; Gene","score_opus":0.039450962810801904,"score_gpt":0.3575928819539763,"score_spread":0.3181419191431744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808074814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886424,0.0027206324,0.00018701947,0.006282797,0.00009877086,0.0006854452,0.000029495048,0.00007089313,0.0012825776],"genre_scores_gemma":[0.98978966,0.0002702654,0.0092201615,0.00011970964,0.00012955329,0.000042450836,0.000042301795,0.00003286318,0.00035300135],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844825,0.0002886609,0.00030429012,0.00028076893,0.00040438882,0.00027361224],"domain_scores_gemma":[0.9967691,0.0004388415,0.00015466977,0.00202652,0.00046464018,0.00014628263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028895208,0.00017063694,0.0003749458,0.00008890447,0.00030872208,0.000026182202,0.00064402696,0.0004467373,0.00005952665],"category_scores_gemma":[0.0001867924,0.00013753533,0.000093012335,0.00032318677,0.00074337685,0.00012666803,0.0007809166,0.0013401066,0.000008592454],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006107325,0.0007003257,0.008053331,0.0003074156,0.0002796355,0.000007557469,0.0021318952,4.5942886e-7,0.9743032,0.0045015747,0.0050064875,0.0040974193],"study_design_scores_gemma":[0.0039130915,0.00071960245,0.05913023,0.0010063049,0.0004629279,0.00024375063,0.00044993317,0.0022197724,0.90563655,0.0007332482,0.025013644,0.0004709189],"about_ca_topic_score_codex":0.0000734612,"about_ca_topic_score_gemma":0.00014046745,"teacher_disagreement_score":0.06866659,"about_ca_system_score_codex":0.0001457093,"about_ca_system_score_gemma":0.00038050022,"threshold_uncertainty_score":0.5822171},"labels":[],"label_agreement":null},{"id":"W2808759948","doi":"10.1016/j.bbmt.2018.06.010","title":"Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression","year":2018,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal Children's Hospital; BC Children's Hospital; University of Calgary; Université de Montréal; Alberta Children's Hospital; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Minimal residual disease; Hematopoietic stem cell transplantation; Flow cytometry; Wilms' tumor; Myeloid leukemia; Internal medicine; Transplantation; Oncology; Prospective cohort study; Disease; Myeloid; Leukemia; Pathology; Gastroenterology; Immunology","score_opus":0.010852024569239171,"score_gpt":0.24910187804307446,"score_spread":0.2382498534738353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808759948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632573,0.0026324505,0.00021199902,0.00004459492,0.000023978493,0.0003383211,0.00040915952,0.000009402523,0.0000043556947],"genre_scores_gemma":[0.99327505,0.004877607,0.0016025257,0.000013553152,0.000033073018,0.00002675089,0.00014620184,0.00001287727,0.000012373237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883986,0.00010285584,0.00038631496,0.00030399588,0.00018617933,0.00018079036],"domain_scores_gemma":[0.9993703,0.00014109115,0.0001599949,0.00013018302,0.00009932558,0.000099130084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017337028,0.00018358066,0.0005309696,0.00024936144,0.00004086856,0.0000034278323,0.00005391083,0.00010249471,0.00000421794],"category_scores_gemma":[0.000007126056,0.00012796767,0.000027629163,0.00014438912,0.00039578724,0.00009748269,0.00001780681,0.00011977442,1.4368229e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026341416,0.00005307671,0.6777175,0.0013035439,0.000112494,0.000035292305,0.0031322509,9.562074e-7,0.31479847,0.0000014528221,6.6759117e-7,0.0002101385],"study_design_scores_gemma":[0.003143202,0.00066765596,0.5946741,0.00024910475,0.00082310435,0.000023395232,0.0001738184,0.000020854515,0.40011287,0.000032372573,6.4991944e-8,0.00007943704],"about_ca_topic_score_codex":0.00008871863,"about_ca_topic_score_gemma":0.00007542205,"teacher_disagreement_score":0.08531438,"about_ca_system_score_codex":0.000013214798,"about_ca_system_score_gemma":0.00010321332,"threshold_uncertainty_score":0.521837},"labels":[],"label_agreement":null},{"id":"W2808926344","doi":"10.1038/s41375-018-0166-1","title":"Reduced expression but not deficiency of GFI1 causes a fatal myeloproliferative disease in mice","year":2018,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Montreal Clinical Research Institute","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Deutsche Krebshilfe","keywords":"Myeloid leukemia; Myeloid; Biology; Myeloproliferative Disorders; Cancer research; Leukemia; Gene knockdown; Immunology; Apoptosis; Genetics","score_opus":0.02630895190364619,"score_gpt":0.3133176343384345,"score_spread":0.28700868243478833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808926344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574256,0.00016461422,0.00009595286,0.0004830484,0.00010948726,0.00061414693,0.000047358364,0.000056933237,0.0026858833],"genre_scores_gemma":[0.9962082,0.000042854583,0.0013056165,0.00039190837,0.00032065713,0.0000628585,0.000039728555,0.000038156348,0.001590044],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997797,0.00009661434,0.00045894415,0.0005099783,0.0006146154,0.00052283355],"domain_scores_gemma":[0.9985642,0.00012861044,0.00012179654,0.00053382857,0.00030507043,0.0003465256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029137003,0.00022882568,0.00040842794,0.00030861254,0.00009223093,0.000017100543,0.00026616722,0.00014743698,0.00019308555],"category_scores_gemma":[0.0008319214,0.00018800421,0.00009076468,0.0005499304,0.00044249813,0.00017659723,0.0002107946,0.00044533485,0.00015010752],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025976012,0.00014542267,0.0142192915,0.00020038597,0.000017782833,0.00026490766,0.0020086698,0.000011896501,0.97695947,0.00016692984,0.0022971332,0.0011104884],"study_design_scores_gemma":[0.0028920337,0.0003903217,0.10164274,0.00044599193,0.000038568985,0.000029868244,0.00044370565,0.0013951097,0.8920045,0.000097468044,0.00040550323,0.0002141908],"about_ca_topic_score_codex":0.0006284069,"about_ca_topic_score_gemma":0.000049819955,"teacher_disagreement_score":0.08742345,"about_ca_system_score_codex":0.0011767385,"about_ca_system_score_gemma":0.002275704,"threshold_uncertainty_score":0.7666589},"labels":[],"label_agreement":null},{"id":"W2809163343","doi":"10.1002/mgg3.388","title":"<i>ERCC6L2</i>‐associated inherited bone marrow failure syndrome","year":2018,"lang":"en","type":"review","venue":"Molecular Genetics & Genomic Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; SickKids Foundation; Hospital for Sick Children","funders":"C17 Council","keywords":"Medicine; Exome sequencing; Microcephaly; Pathology; Bone marrow; Bone marrow failure; Craniofacial; Dysmetria; Sensorineural hearing loss; Hearing loss; Ataxia; Phenotype; Pediatrics; Genetics; Biology","score_opus":0.03620704011889411,"score_gpt":0.32742831006940604,"score_spread":0.2912212699505119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809163343","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004075511,0.98857987,0.00031424794,0.0012697164,0.0005681802,0.003801843,0.00013485907,0.00023964922,0.0010161056],"genre_scores_gemma":[0.00049152755,0.9870527,0.0019949507,0.0014739296,0.0009997516,0.00026155598,0.0029466844,0.00069690595,0.0040820255],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9916784,0.00079890154,0.0023096057,0.0018369268,0.0016654469,0.0017107226],"domain_scores_gemma":[0.99417424,0.00023596291,0.00095296017,0.002747779,0.0006455745,0.0012435034],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0016059439,0.0016105061,0.0058971304,0.0012640224,0.000160175,0.000054876204,0.001137186,0.0017614736,0.0013668052],"category_scores_gemma":[0.0010083858,0.0013180387,0.0010065753,0.0018750649,0.0010179713,0.000031405496,0.0007437196,0.0022342887,0.0015822881],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002827205,0.0009279694,0.00006150771,0.06011589,0.012877612,0.049897727,0.0010373063,0.000005631811,0.02212943,0.0001897485,0.20382778,0.64864665],"study_design_scores_gemma":[0.0030231983,0.0015162595,0.000051535924,0.018136892,0.005740414,0.005972342,0.00004027519,0.00005613233,0.000044572087,0.000057398745,0.9643698,0.0009912086],"about_ca_topic_score_codex":0.00010629593,"about_ca_topic_score_gemma":0.000023442975,"teacher_disagreement_score":0.760542,"about_ca_system_score_codex":0.0028900534,"about_ca_system_score_gemma":0.002551138,"threshold_uncertainty_score":0.99966425},"labels":[],"label_agreement":null},{"id":"W2810120321","doi":"10.1016/j.jval.2018.04.213","title":"Cost Effectiveness Analysis of Azacitidine in Patients with Acute Myeloid Leukemia With &gt;30% Blasts and who are Not Candidate for Curative-Intend Chemotherapy","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Azacitidine; Medicine; Myeloid leukemia; Hypomethylating agent; Oncology; Internal medicine; Chemotherapy; Leukemia; Cost effectiveness; DNA methylation","score_opus":0.02851383953554438,"score_gpt":0.33395888648280764,"score_spread":0.30544504694726327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810120321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465084,0.00006208896,0.0014397416,0.00064558163,0.000022846934,0.0028821754,0.00024283241,0.000017439506,0.000036426092],"genre_scores_gemma":[0.9976252,0.00021193438,0.0012412709,0.00049168285,0.000041903262,0.00017079306,0.000119147364,0.000051410094,0.00004666674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975801,0.00028220887,0.0004957222,0.00057066634,0.00046910177,0.00060218625],"domain_scores_gemma":[0.99816936,0.00037114945,0.0003205307,0.00038781957,0.0005009444,0.00025018802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097589166,0.00027773684,0.0012213367,0.00086034555,0.00008332194,0.000015272342,0.00012211576,0.000106405525,0.000025726917],"category_scores_gemma":[0.000115804585,0.00019798549,0.00005611009,0.001687231,0.00036298478,0.0001261501,0.00004051612,0.00031233326,0.0000017327128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021593444,0.00028082775,0.9681831,0.00091522315,0.0012464002,0.000029508707,0.002235192,0.00064239453,0.00032625566,0.00007892056,0.000096973825,0.0043717674],"study_design_scores_gemma":[0.01751844,0.0051276726,0.9453316,0.0015671551,0.00019161335,0.000004740703,0.00021340627,0.025639173,0.004039139,0.000012004926,0.00015110591,0.00020399346],"about_ca_topic_score_codex":0.0051080626,"about_ca_topic_score_gemma":0.0019287175,"teacher_disagreement_score":0.024996778,"about_ca_system_score_codex":0.0017533085,"about_ca_system_score_gemma":0.0011206246,"threshold_uncertainty_score":0.80736136},"labels":[],"label_agreement":null},{"id":"W2810481689","doi":"10.1016/j.jval.2018.04.180","title":"Cost-Effectiveness Analysis of Midostaurin (MIDO) With Standard of Care (SOC) for Acute Myeloid Leukemia (AML) in Canada","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Incremental cost-effectiveness ratio; Cost effectiveness; Quality-adjusted life year; Economic evaluation; Demography","score_opus":0.039087229412345915,"score_gpt":0.35913062030158643,"score_spread":0.3200433908892405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810481689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945468,0.00055332953,0.0008054167,0.00044843444,0.0000689368,0.0027217264,0.00071510207,0.000010568183,0.00012971039],"genre_scores_gemma":[0.9967563,0.00022512939,0.0024561635,0.00015847529,0.000046431884,0.00016050354,0.00013024265,0.000038455946,0.000028254228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99705684,0.0003590039,0.00075395394,0.00044313827,0.0007272535,0.0006597918],"domain_scores_gemma":[0.9975756,0.00066648936,0.00028999697,0.0005508615,0.00066935713,0.00024774205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012863047,0.00021081546,0.0014195815,0.00087708636,0.000051828607,0.0000044595454,0.00020811068,0.00010031825,0.000029118328],"category_scores_gemma":[0.00021551715,0.0001784332,0.00010772244,0.0024411764,0.00018212928,0.000055195764,0.000059795686,0.000331878,5.133728e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.032798413,0.00017686703,0.8837406,0.008665964,0.002983032,0.00025344125,0.012478833,0.030609073,0.001904914,0.00037926517,0.0008090983,0.0252005],"study_design_scores_gemma":[0.028152492,0.015529732,0.82252485,0.004056831,0.0016229956,0.00004514345,0.014324597,0.051478785,0.057176527,0.000086138694,0.0042634094,0.00073848676],"about_ca_topic_score_codex":0.94334966,"about_ca_topic_score_gemma":0.90554315,"teacher_disagreement_score":0.06121574,"about_ca_system_score_codex":0.018660808,"about_ca_system_score_gemma":0.026705733,"threshold_uncertainty_score":0.98510635},"labels":[],"label_agreement":null},{"id":"W2811401701","doi":"10.1158/1538-7445.am2018-819","title":"Abstract 819: High response rates with entospletinib in patients with t(v;11q23.3);<i>KMT2A</i> rearranged acute myeloid leukemia and acute lymphoblastic leukemia","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cytarabine; Myeloid leukemia; Leukemia; Acute leukemia; Chemotherapy; Internal medicine; Gastroenterology; Induction chemotherapy; Myeloid; Acute lymphocytic leukemia; Vincristine; Oncology; Immunology; Cyclophosphamide","score_opus":0.02137495479313491,"score_gpt":0.3333395373591177,"score_spread":0.3119645825659828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811401701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937611,0.0002469752,0.000016336819,0.002148842,0.00009804608,0.0022735803,0.00020302588,0.00011735282,0.001134711],"genre_scores_gemma":[0.9931114,0.00073037995,0.00065899995,0.0004897826,0.0004322142,0.0005981949,0.00012292252,0.00021670833,0.0036394529],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9924517,0.00061715516,0.0006352695,0.0014855759,0.0026544328,0.0021558404],"domain_scores_gemma":[0.99473965,0.0010201492,0.0001705504,0.0012648938,0.00183434,0.0009704363],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026630207,0.0006204398,0.0009362362,0.0011595605,0.00049929396,0.00022270168,0.0006474349,0.00038672084,0.00070425996],"category_scores_gemma":[0.0005407858,0.00044971876,0.0000714087,0.0023484733,0.0023095664,0.0004343518,0.00041887598,0.0020134281,0.00026344715],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.36720395,0.0005794413,0.34055647,0.00073557737,0.0021435767,0.0033013965,0.0038201213,0.0000477368,0.23882465,0.00009898884,0.030681001,0.012007067],"study_design_scores_gemma":[0.026931265,0.0068258173,0.90998447,0.0014182759,0.00019673117,0.00010579604,0.00035248837,0.00012920905,0.04728318,0.000042986878,0.0060205963,0.0007091819],"about_ca_topic_score_codex":0.0037167047,"about_ca_topic_score_gemma":0.0008937503,"teacher_disagreement_score":0.56942797,"about_ca_system_score_codex":0.007520325,"about_ca_system_score_gemma":0.0079254005,"threshold_uncertainty_score":0.99979544},"labels":[],"label_agreement":null},{"id":"W2830196912","doi":"10.1038/s41586-018-0317-6","title":"Prediction of acute myeloid leukaemia risk in healthy individuals","year":2018,"lang":"en","type":"article","venue":"Nature","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":861,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Instituto de Salud Carlos III; Hellenic Health Foundation; Medical Research Council; Leukemia and Lymphoma Society; Clalit Health Services; Agència de Gestió d'Ajuts Universitaris i de Recerca; Associazione Italiana per la Ricerca sul Cancro; Abisch-Frenkel-Stiftung; National Institute for Health and Care Research; Generalitat de Catalunya; Cancer Research UK; Wellcome Trust; European Regional Development Fund; World Health Organization","keywords":"Haematopoiesis; Myeloid; Bone marrow; Somatic cell; Incidence (geometry); Medicine; Allele; Internal medicine; Cohort; Progenitor cell; Oncology; Gene; Immunology; Stem cell; Biology; Genetics","score_opus":0.01739391057448661,"score_gpt":0.3234536506395245,"score_spread":0.3060597400650379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2830196912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99083215,0.00069224654,0.000028377353,0.0024846368,0.00027390345,0.0005170367,0.0002771909,0.000060146715,0.0048343316],"genre_scores_gemma":[0.99492806,0.00058799825,0.0017106195,0.0014192768,0.0006241247,0.0000175191,0.00010711168,0.00002697905,0.00057833694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829805,0.00010293392,0.00033012146,0.0003118264,0.00059092103,0.00036616353],"domain_scores_gemma":[0.9989372,0.00008679061,0.0001323083,0.00042442986,0.00026502035,0.00015428099],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0006991381,0.00013776026,0.00032686623,0.0003764822,0.000059531616,0.000007516251,0.00018065516,0.0014641711,0.00018939623],"category_scores_gemma":[0.00037135076,0.00011386724,0.00007038092,0.00075944583,0.00017358911,0.00010246342,0.000088902954,0.0039976807,0.00007500134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002994912,0.00027663095,0.82429266,0.00022816028,0.0004273147,0.0000837703,0.0018200286,0.0000018063506,0.016331766,0.00042267438,0.13496144,0.01815885],"study_design_scores_gemma":[0.0055967793,0.002073909,0.9350415,0.00017339524,0.00014884456,0.00009739301,0.00012958237,0.0004093805,0.021022083,0.0003981472,0.034784358,0.00012466652],"about_ca_topic_score_codex":0.0001309196,"about_ca_topic_score_gemma":0.0000394705,"teacher_disagreement_score":0.11074882,"about_ca_system_score_codex":0.00040844284,"about_ca_system_score_gemma":0.00053364504,"threshold_uncertainty_score":0.99983215},"labels":[],"label_agreement":null},{"id":"W2883022536","doi":"10.1373/jalm.2018.026500","title":"Incidence of Myelodysplastic Syndromes in a Major Canadian Metropolitan Area","year":2018,"lang":"en","type":"article","venue":"The Journal of Applied Laboratory Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Myelodysplastic syndromes; Incidence (geometry); Epidemiology; Medicine; Demography; Metropolitan area; Census; Myeloid leukemia; Pediatrics; Bone marrow; Environmental health; Population; Pathology; Internal medicine","score_opus":0.01817514642854098,"score_gpt":0.2909078284430866,"score_spread":0.27273268201454565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883022536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853469,0.0008889096,0.00006818587,0.0041605555,0.0001895267,0.00033467475,0.000011958721,0.00000772755,0.008991558],"genre_scores_gemma":[0.9976078,0.00017814554,0.00036571998,0.0011600297,0.00057990203,0.0000038065555,0.000001887182,0.00002924538,0.00007345396],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99755394,0.00012005053,0.0008534343,0.00013747746,0.0008714973,0.00046356872],"domain_scores_gemma":[0.9970931,0.0005114862,0.00041905927,0.0004433119,0.00097104633,0.00056202686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030535492,0.00019358352,0.000749622,0.0010419503,0.00007991872,0.0000043242144,0.00047920932,0.0001143807,0.0006450245],"category_scores_gemma":[0.0010841042,0.000111196845,0.0000400599,0.0016946722,0.0012106961,0.00007660635,0.00004985997,0.00078708073,0.000030827392],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016977338,0.0005197311,0.04169099,0.0011409713,0.0018140386,0.0042572315,0.023603609,0.000057584668,0.76722765,0.018196939,0.12031124,0.0042026904],"study_design_scores_gemma":[0.06624304,0.029795142,0.47357917,0.011712009,0.004947522,0.009165868,0.12812674,0.0017939511,0.20401077,0.009364125,0.05931118,0.001950501],"about_ca_topic_score_codex":0.008881213,"about_ca_topic_score_gemma":0.015596756,"teacher_disagreement_score":0.56321687,"about_ca_system_score_codex":0.0013377861,"about_ca_system_score_gemma":0.003038037,"threshold_uncertainty_score":0.99771875},"labels":[],"label_agreement":null},{"id":"W2883674070","doi":"10.1172/jci.insight.121086","title":"Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes","year":2018,"lang":"en","type":"article","venue":"JCI Insight","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Children's Hospital Research Institute of Manitoba; BC Children's Hospital; Manitoba Health; University of British Columbia","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; V Foundation for Cancer Research; Burroughs Wellcome Fund; American Cancer Society","keywords":"Monosomy; Chromosome 7 (human); Germline; Myeloid leukemia; Germline mutation; Myeloid; Mutation; Somatic evolution in cancer; Bone marrow; Leukemia; Cancer research; Medicine; Biology; Genetics; Cancer; Immunology; Chromosome; Gene; Karyotype","score_opus":0.028566028262012096,"score_gpt":0.29374932988651886,"score_spread":0.26518330162450676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883674070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959884,0.00054564903,0.00038073992,0.0019362045,0.000049484483,0.00043889426,0.00001558679,0.00008019533,0.0005648201],"genre_scores_gemma":[0.99625206,0.000067950845,0.0020823474,0.0006241118,0.000081258055,0.000021665703,0.00003521891,0.000022108023,0.00081327243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885386,0.0000685438,0.00018847144,0.00033570052,0.00028475287,0.0002686832],"domain_scores_gemma":[0.9987717,0.00020021173,0.0001143147,0.00022917935,0.00050518074,0.00017938085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009324467,0.0001709204,0.00035733794,0.0001782159,0.0002496611,0.000026452246,0.00005218397,0.00013611958,0.00006579575],"category_scores_gemma":[0.00073451834,0.00011732408,0.00003036704,0.0002904749,0.0005500543,0.000097838674,0.00009406605,0.00020735596,0.00004157261],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020939363,0.00017096411,0.9903013,0.000076699034,0.0003010117,0.0005825173,0.0019491819,0.0000023382702,0.002617043,0.00031421683,0.002592233,0.00088309625],"study_design_scores_gemma":[0.0026192334,0.00054809725,0.993167,0.00010270663,0.00017265466,0.0002158375,0.0008006758,0.00093377155,0.00037903612,0.00043175192,0.0004738218,0.00015540373],"about_ca_topic_score_codex":0.00011270063,"about_ca_topic_score_gemma":0.00027056516,"teacher_disagreement_score":0.0028657047,"about_ca_system_score_codex":0.0002459916,"about_ca_system_score_gemma":0.00013435722,"threshold_uncertainty_score":0.47843373},"labels":[],"label_agreement":null},{"id":"W2883998043","doi":"10.1016/j.clml.2018.07.290","title":"Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Stem cell; Myeloid leukemia; Transplantation; Oncology; Hematopoietic stem cell transplantation; Internal medicine; Propensity score matching; Autologous stem-cell transplantation; Chemotherapy; Surgery; Biology; Genetics","score_opus":0.03240517190489464,"score_gpt":0.2981481263687543,"score_spread":0.26574295446385965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883998043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951969,0.00015571862,0.001829036,0.00019133711,0.00015185702,0.0015450321,0.00014614912,0.00016551575,0.00061849947],"genre_scores_gemma":[0.9922436,0.0048276777,0.0014636889,0.00028732835,0.0001300674,0.000058137455,0.00041248425,0.00010440522,0.00047261943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941976,0.00070097786,0.002042443,0.0014231763,0.0008687344,0.000767036],"domain_scores_gemma":[0.9955357,0.0013037372,0.001145124,0.00090489973,0.00061790535,0.0004926594],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012760508,0.0006896111,0.002228599,0.0007900366,0.00029138415,0.00006852375,0.00042920138,0.00070486387,0.0000649583],"category_scores_gemma":[0.00006272789,0.000553917,0.00038887523,0.0018131909,0.0010447713,0.0003435074,0.00008631115,0.00073527347,0.000026592737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012889124,0.00021008648,0.9450003,0.00071902986,0.0013178289,0.00061200926,0.0022776197,0.00017476625,0.0026300887,0.000010020739,0.00009736994,0.034061793],"study_design_scores_gemma":[0.017827127,0.0021490906,0.95067126,0.0005002308,0.0029391143,0.00020528593,0.00045397013,0.007373435,0.01728515,0.000019485813,0.00003269412,0.0005431414],"about_ca_topic_score_codex":0.0005162451,"about_ca_topic_score_gemma":0.001855882,"teacher_disagreement_score":0.033518653,"about_ca_system_score_codex":0.002892205,"about_ca_system_score_gemma":0.0027206508,"threshold_uncertainty_score":0.99969125},"labels":[],"label_agreement":null},{"id":"W2884841488","doi":"10.1038/s41408-018-0103-6","title":"High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Medical Research Council; Université de Montréal; King's College London; Cancer Research UK; Compute Canada; National Institute for Health and Care Research; Leukemia and Lymphoma Society; Genome Canada; Blood Cancer UK; McGill University; Génome Québec","keywords":"Internal medicine; Oncology; Medicine; Myeloid leukemia; Cytogenetics; Cohort; Clinical trial; HMGA2; Biology; Gene; Genetics","score_opus":0.030074068534258973,"score_gpt":0.3631047606822544,"score_spread":0.3330306921479954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884841488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956731,0.0005546344,0.00011844195,0.001564141,0.0010227314,0.00039348283,0.000044836903,0.000033358036,0.0005952831],"genre_scores_gemma":[0.98976946,0.002335227,0.0030069875,0.00089067366,0.0021752284,0.000028987079,0.0000072106495,0.000056680597,0.0017295536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99613345,0.0002548399,0.0012950043,0.00041836657,0.0012195398,0.00067878026],"domain_scores_gemma":[0.9977711,0.00019122755,0.00049306225,0.000463746,0.0005232795,0.0005575961],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014517086,0.00027375013,0.00093794864,0.0004226607,0.00012388361,0.000039320614,0.0004985539,0.0003715025,0.0010656394],"category_scores_gemma":[0.0004567402,0.00020101883,0.0002887042,0.00039554932,0.0003613089,0.00025793348,0.00025092525,0.0018592962,0.000044436365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022372203,0.0007224733,0.9295992,0.00006415074,0.0008200608,0.00095360127,0.00038088538,0.00000797776,0.034784786,0.000020336325,0.015726533,0.014682752],"study_design_scores_gemma":[0.02518163,0.0028248236,0.7988568,0.0010397161,0.00063589925,0.0011863923,0.00016174917,0.00011849328,0.16762999,0.00020961168,0.0018494253,0.00030549217],"about_ca_topic_score_codex":0.00047131203,"about_ca_topic_score_gemma":0.00015500358,"teacher_disagreement_score":0.13284521,"about_ca_system_score_codex":0.000664908,"about_ca_system_score_gemma":0.0029625185,"threshold_uncertainty_score":0.99984753},"labels":[],"label_agreement":null},{"id":"W2886599486","doi":"10.1002/cam4.1733","title":"Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐<scp>CBF</scp>it)","year":2018,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Myeloid leukemia; Core binding factor; Medicine; Risk factor; Internal medicine; Leukemia; Myeloid; Core (optical fiber); Oncology; Cancer research; Computer science; Chemistry; Transcription factor; Gene; Biochemistry; Telecommunications","score_opus":0.057862305826370544,"score_gpt":0.3297399504435127,"score_spread":0.27187764461714214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886599486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98991394,0.0009847268,0.0022496104,0.00064627116,0.0008610968,0.0011984005,0.00016498125,0.0003143088,0.003666668],"genre_scores_gemma":[0.9911041,0.0011334072,0.0006956816,0.00053011725,0.002896181,0.00012529215,0.000061895546,0.00016867869,0.0032846408],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957369,0.00006326979,0.00067372416,0.0010612623,0.0012520128,0.001212828],"domain_scores_gemma":[0.99643916,0.00064803276,0.00042252633,0.0008481972,0.00056992983,0.0010721729],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059031247,0.00069322216,0.0012876949,0.00055393565,0.00046498998,0.00004782362,0.00037488318,0.00031363172,0.00020175925],"category_scores_gemma":[0.0007391281,0.00044066823,0.00009432692,0.0009898879,0.0012956671,0.00025843902,0.00021457499,0.001219662,0.000061039806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001067041,0.00009223931,0.6405942,0.00196918,0.0030975381,0.0007332754,0.017139342,0.000013300868,0.30200592,0.00040344303,0.025402354,0.007482188],"study_design_scores_gemma":[0.056073327,0.013584793,0.6005273,0.022372587,0.0062841647,0.0030605241,0.04864262,0.0115434,0.14822744,0.0000289168,0.08806539,0.001589564],"about_ca_topic_score_codex":0.0029507924,"about_ca_topic_score_gemma":0.0002606733,"teacher_disagreement_score":0.15377846,"about_ca_system_score_codex":0.00337755,"about_ca_system_score_gemma":0.0014026358,"threshold_uncertainty_score":0.9998045},"labels":[],"label_agreement":null},{"id":"W2887246354","doi":"10.1158/1538-7445.am2018-2991","title":"Abstract 2991: Cytoplasmic mislocalization of CTCF by NPM1c in acute myeloid leukemia resulting in inhibited CTCF regulatory functions generating aberrant genetic and epigenetic profiles","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"CTCF; Epigenetics; Biology; Cytoplasm; Cell biology; Molecular biology; Cancer research; Gene expression; Genetics; Gene; Enhancer","score_opus":0.03573272656724166,"score_gpt":0.34782331184081655,"score_spread":0.3120905852735749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887246354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943263,0.002774906,0.00013260084,0.00074954855,0.000084630505,0.0013784902,0.00007632136,0.00003678986,0.0004404183],"genre_scores_gemma":[0.99530935,0.0017171497,0.0009624016,0.00008349593,0.00031209845,0.00033336965,0.000102535654,0.00008261094,0.001096999],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99571174,0.00037687365,0.0009330676,0.0008369615,0.0011047233,0.0010366233],"domain_scores_gemma":[0.99789125,0.00031989848,0.00015922125,0.0005876304,0.000752512,0.00028947936],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020249232,0.00027300918,0.000523422,0.0011378229,0.00024963112,0.00006115541,0.00024805966,0.0003214637,0.00020618114],"category_scores_gemma":[0.0006628609,0.00026306068,0.000055084463,0.001978685,0.0009806892,0.00016972165,0.0002328348,0.0011809677,0.000027019321],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067080586,0.00008247749,0.05818309,0.00040191357,0.000062549676,0.00007603274,0.0012555475,0.0004563269,0.921727,0.0000104438495,0.005021221,0.012052617],"study_design_scores_gemma":[0.0064757275,0.00069744186,0.37915927,0.0017930417,0.000047389563,0.00006254008,0.0012285174,0.034111816,0.57485,0.000085365486,0.0010435391,0.0004453176],"about_ca_topic_score_codex":0.0045091156,"about_ca_topic_score_gemma":0.002114295,"teacher_disagreement_score":0.34687695,"about_ca_system_score_codex":0.0022916822,"about_ca_system_score_gemma":0.0021592416,"threshold_uncertainty_score":0.9999822},"labels":[],"label_agreement":null},{"id":"W2887418186","doi":"10.1038/s41375-018-0227-5","title":"The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'Adolescent","keywords":"Medicine; Myeloid leukemia; Internal medicine; Oncology; Proportional hazards model; Multivariate analysis; Myeloid; Quartile; Risk stratification; Gene signature; Clinical significance; Leukemia; Gene; Gene expression; Biology; Confidence interval","score_opus":0.012333704885818317,"score_gpt":0.2658568440210441,"score_spread":0.2535231391352258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887418186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99134374,0.0010586955,0.00025474565,0.000479144,0.00038415045,0.0012235194,0.000047989786,0.00021642122,0.0049915942],"genre_scores_gemma":[0.9832367,0.0031907007,0.00093490304,0.00029710744,0.001104703,0.00015197994,0.00017603481,0.000104852494,0.010803074],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99571973,0.00048600088,0.0008078505,0.00085868983,0.0010654341,0.0010622882],"domain_scores_gemma":[0.99696773,0.00053855823,0.00047062756,0.0012200953,0.00045096796,0.00035199051],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014497407,0.0004508195,0.0005082369,0.00031811863,0.0006499995,0.00013716676,0.0007250531,0.00075030065,0.00009473382],"category_scores_gemma":[0.0002608517,0.00032032584,0.00018683335,0.0013766938,0.0002562485,0.00025110116,0.00022890119,0.0020536394,0.00046678216],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022311625,0.0002809793,0.072798334,0.00016366695,0.00028137118,0.0004212828,0.0031849646,0.00025548314,0.7796351,0.00013060482,0.11806803,0.02254907],"study_design_scores_gemma":[0.014235619,0.0016207823,0.31952173,0.00024078842,0.0008327237,0.00009404658,0.0012900807,0.020192008,0.6282214,0.0006121882,0.0117429495,0.0013956855],"about_ca_topic_score_codex":0.00030212692,"about_ca_topic_score_gemma":0.0002768814,"teacher_disagreement_score":0.24672338,"about_ca_system_score_codex":0.0059825876,"about_ca_system_score_gemma":0.002802807,"threshold_uncertainty_score":0.9999249},"labels":[],"label_agreement":null},{"id":"W2887798331","doi":"10.1158/2159-8290.cd-17-0841","title":"Targeting the MTF2–MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy","year":2018,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Stem Cell Network; Esri (Canada); University of Ottawa","funders":"National Institutes of Health; Ottawa Hospital Research Institute; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Society; National Institute of General Medical Sciences; University of Ottawa","keywords":"Myeloid leukemia; Refractory (planetary science); Mdm2; Cancer research; Chemotherapy; Leukemia; Medicine; Myeloid; Biology; Immunology; Internal medicine; Apoptosis; Genetics","score_opus":0.017131457338046982,"score_gpt":0.3131510983975472,"score_spread":0.2960196410595002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887798331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97333616,0.0010702389,0.00092031754,0.016900077,0.00078092626,0.00089345995,0.00008417376,0.00014507594,0.0058695553],"genre_scores_gemma":[0.9503335,0.0019788076,0.00070268713,0.019733626,0.0049974937,0.00015733443,0.000041987056,0.00012847522,0.021926096],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99749076,0.000092470276,0.00035103463,0.0006302282,0.0006358716,0.0007996268],"domain_scores_gemma":[0.99825275,0.00016776919,0.000109548855,0.00087518117,0.00030083323,0.00029391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045899957,0.0003288948,0.000449325,0.00013860449,0.00032941636,0.00013531688,0.0003851669,0.00016073248,0.00067248],"category_scores_gemma":[0.00015956783,0.00021870661,0.00016958632,0.00057500636,0.00045187798,0.00035997274,0.00021828814,0.00060447206,0.00044468069],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023224074,0.000057421024,0.0032603212,0.00009171267,0.0007123472,0.00014739664,0.0034047342,0.000035156172,0.50509226,0.00011326443,0.44979537,0.03496758],"study_design_scores_gemma":[0.004692492,0.0012094986,0.036003534,0.00051911554,0.0003307019,0.00014467584,0.0019536042,0.0010210263,0.27434567,0.00017527092,0.67865366,0.0009507678],"about_ca_topic_score_codex":0.0007132927,"about_ca_topic_score_gemma":0.00007495709,"teacher_disagreement_score":0.23074663,"about_ca_system_score_codex":0.0022125829,"about_ca_system_score_gemma":0.0016213721,"threshold_uncertainty_score":0.8918597},"labels":[],"label_agreement":null},{"id":"W2888306988","doi":"10.1016/j.exphem.2018.06.195","title":"Mutations in Human Histone H3 are Pre-Leukemic Events and Promote Hematopoietic Stem Cell Expansion and Leukemic Aggressiveness","year":2018,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; McGill University and Génome Québec Innovation Centre; Jewish General Hospital; Terry Fox Research Institute; McGill University; McGill University Health Centre","funders":"","keywords":"Biology; Histone H3; Epigenetics; Haematopoiesis; Myeloid; Histone; Cancer research; Leukemia; Mutation; Myeloid leukemia; Stem cell; RUNX1; Somatic evolution in cancer; Genetics; Gene","score_opus":0.018616112230634158,"score_gpt":0.34257486095572165,"score_spread":0.3239587487250875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888306988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98892343,0.009267834,0.000032461874,0.00020783815,0.000118082375,0.0009511595,0.000006012637,0.00006733679,0.00042586398],"genre_scores_gemma":[0.9981176,0.00006356587,0.0003403535,0.00011708645,0.00005722247,0.00019593624,0.00003275715,0.000054653858,0.0010208141],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99799436,0.00014455919,0.00046202505,0.00063656864,0.0002638532,0.0004986582],"domain_scores_gemma":[0.99905133,0.00006850725,0.00018703751,0.0003796198,0.0000716105,0.00024191542],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016373166,0.00028701458,0.00061183935,0.00030352594,0.00022542423,0.000014344247,0.00013836051,0.00023931597,0.00014664968],"category_scores_gemma":[0.000016377278,0.00027338133,0.000045320954,0.00021103307,0.00062294136,0.00013821473,0.0002756808,0.0003347248,0.00004036943],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071835256,0.0008844276,0.037685037,0.00087556685,0.000058317117,0.00095950614,0.015627356,9.4729876e-7,0.9401896,0.0014088989,0.0007008788,0.00089111156],"study_design_scores_gemma":[0.005838439,0.00081669015,0.013884439,0.0007047876,0.000031299052,0.003173286,0.005287519,0.00042525228,0.96919036,0.00026268978,0.00008614839,0.00029907617],"about_ca_topic_score_codex":0.00013322907,"about_ca_topic_score_gemma":0.000023658433,"teacher_disagreement_score":0.02900077,"about_ca_system_score_codex":0.00077090575,"about_ca_system_score_gemma":0.00018573955,"threshold_uncertainty_score":0.99997187},"labels":[],"label_agreement":null},{"id":"W2888359735","doi":"10.1016/j.exphem.2018.06.129","title":"Loss-of-Function Mutation in TET2 in Zebrafish Leads to Early MDS Like Phenotype","year":2018,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"GATA1; Zebrafish; RUNX1; Biology; Haematopoiesis; Myeloid leukemia; Phenotype; Myeloid; Bone marrow; Mutant; Cancer research; Progenitor cell; Leukemia; Molecular biology; Mutation; Genetics; Stem cell; Immunology; Gene","score_opus":0.021469888957624438,"score_gpt":0.3384464523761968,"score_spread":0.3169765634185724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888359735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99454796,0.0004665531,0.00012772175,0.0004535106,0.00031396915,0.00051427877,0.0000014599437,0.00003249791,0.003542049],"genre_scores_gemma":[0.99804324,0.0000021510434,0.0010055114,0.00048273825,0.00009474733,0.00007848078,0.00001744274,0.000026569587,0.0002491448],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986538,0.00008075445,0.00037401708,0.00032143042,0.00021901287,0.00035094906],"domain_scores_gemma":[0.9994542,0.000060519582,0.00005369876,0.00024881272,0.00007395183,0.000108832544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018272102,0.00013478812,0.00036901122,0.0004452558,0.00002637339,0.0000058040077,0.0001077973,0.00016595313,0.0005767471],"category_scores_gemma":[0.00007578454,0.00013425387,0.000038519443,0.0005407855,0.00021116367,0.00010605862,0.00009449076,0.00021367629,0.00046059897],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007429104,0.0015880832,0.37592563,0.00016790083,0.00006117947,0.00087730645,0.013627207,0.0000060083353,0.57361215,0.020403842,0.0040909285,0.0022106268],"study_design_scores_gemma":[0.0037896272,0.0029790038,0.07630481,0.00011442531,0.0000075492308,0.00025298298,0.0013154492,0.0001960568,0.91412455,0.00023914318,0.00051276403,0.00016366893],"about_ca_topic_score_codex":0.00050949136,"about_ca_topic_score_gemma":0.00016473632,"teacher_disagreement_score":0.34051234,"about_ca_system_score_codex":0.00038275722,"about_ca_system_score_gemma":0.00012114605,"threshold_uncertainty_score":0.6314976},"labels":[],"label_agreement":null},{"id":"W2888369836","doi":"10.1097/moh.0000000000000465","title":"Age-related clonal hematopoiesis: implications for hematopoietic stem cell transplantation","year":2018,"lang":"en","type":"review","venue":"Current Opinion in Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Context (archaeology); Hematopoietic stem cell transplantation; Haematopoiesis; Transplantation; Immunology; Progenitor cell; Stem cell; Myeloid; Medicine; Population; Disease; Biology; Internal medicine; Genetics","score_opus":0.14220096492230566,"score_gpt":0.43209873603556137,"score_spread":0.2898977711132557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888369836","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002786972,0.98926216,0.0013856194,0.0004459113,0.003258207,0.004900088,0.0003025249,0.00014411891,0.0002734752],"genre_scores_gemma":[0.00006514166,0.9910572,0.0004252225,0.00001455444,0.00040903845,0.003532618,0.0041582445,0.00014631913,0.00019166422],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953825,0.0003347248,0.0020398884,0.0011000944,0.00028580855,0.0008569916],"domain_scores_gemma":[0.9968901,0.0010374737,0.0006496499,0.0008954895,0.00024143088,0.0002858178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057075114,0.0006906936,0.0029832954,0.0009837397,0.00014196923,0.000031867155,0.0005168174,0.0009917405,0.0001234613],"category_scores_gemma":[0.000062278355,0.0006073549,0.0008170899,0.000906056,0.0003495018,0.00008372833,0.00010299702,0.0010568234,0.00037677577],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018094703,0.0011035632,0.00017491895,0.67366403,0.00039482143,0.000041930638,0.0009922864,6.5874684e-7,0.0000030452356,0.042585246,0.047719803,0.23313875],"study_design_scores_gemma":[0.0023197192,0.00021087968,0.000028505132,0.036158368,0.00073413784,0.0037558826,0.000054898763,0.000028934315,0.000015874291,0.0015659838,0.9545437,0.0005831155],"about_ca_topic_score_codex":0.000003534767,"about_ca_topic_score_gemma":0.0000017814466,"teacher_disagreement_score":0.9068239,"about_ca_system_score_codex":0.00057815644,"about_ca_system_score_gemma":0.001347582,"threshold_uncertainty_score":0.9996378},"labels":[],"label_agreement":null},{"id":"W2888450494","doi":"10.1097/moh.0000000000000464","title":"Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome","year":2018,"lang":"en","type":"review","venue":"Current Opinion in Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Minimal residual disease; Medicine; Myelodysplastic syndromes; Myeloid leukemia; Oncology; Hematopoietic stem cell transplantation; Transplantation; Clinical trial; Internal medicine; Leukemia; Myeloid; Stem cell; Disease; Immunology; Bone marrow; Biology","score_opus":0.15089150420606467,"score_gpt":0.386555132357494,"score_spread":0.23566362815142933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888450494","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0758585,0.90692246,0.0009815702,0.00008032031,0.00772617,0.007878518,0.00041079125,0.00013528278,0.000006371609],"genre_scores_gemma":[0.018123077,0.9714469,0.0008613422,0.000011891934,0.0008822954,0.003046081,0.0053310506,0.00024138686,0.000056021858],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9938024,0.00068464724,0.002109252,0.0015202641,0.000708987,0.0011744441],"domain_scores_gemma":[0.9965973,0.0011650209,0.0007658344,0.00073080155,0.00028495584,0.00045607288],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007097725,0.00095562416,0.002821878,0.0016279127,0.00015448967,0.00007240909,0.00050436653,0.00081035355,0.000036626494],"category_scores_gemma":[0.0002672686,0.00083689485,0.00042135743,0.0009663826,0.0001850095,0.00024436435,0.00010863189,0.0011090353,0.00007043846],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0066764755,0.0016099706,0.027015539,0.7330368,0.0006939455,0.0012283471,0.0014223626,0.00024228703,0.00007988978,0.000113916765,0.003328135,0.22455229],"study_design_scores_gemma":[0.067069545,0.011298912,0.019394403,0.7071233,0.013040439,0.0055778427,0.0005948216,0.018825458,0.0012522057,0.00011001279,0.14543569,0.010277364],"about_ca_topic_score_codex":0.000010314387,"about_ca_topic_score_gemma":0.000011385816,"teacher_disagreement_score":0.21427493,"about_ca_system_score_codex":0.0041724243,"about_ca_system_score_gemma":0.006114482,"threshold_uncertainty_score":0.99965036},"labels":[],"label_agreement":null},{"id":"W2888483044","doi":"10.1016/j.exphem.2018.06.106","title":"Identification of Novel Therapeutic Targets in Acute Megakaryoblastic Leukemia","year":2018,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Acute megakaryoblastic leukemia; Megakaryocyte; Transcriptome; Interactome; Biology; Bone marrow; Leukemia; Cancer research; Spleen; Gene; Immunology; Gene expression; Cell biology; Genetics; Stem cell; Haematopoiesis","score_opus":0.025220422379167988,"score_gpt":0.35255304863971665,"score_spread":0.32733262626054865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888483044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915278,0.00281671,0.002489877,0.00034634295,0.00031055268,0.0005777056,0.000007882024,0.000049215232,0.001873891],"genre_scores_gemma":[0.99820656,0.000017058463,0.00094535813,0.00021995499,0.00006235661,0.00006805759,0.00002164738,0.00002844188,0.0004305859],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99855214,0.000045779634,0.0004963216,0.00032453897,0.0002373733,0.00034385014],"domain_scores_gemma":[0.9992667,0.00007289941,0.00011947391,0.0003602703,0.000091483154,0.0000891961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017830165,0.00015088094,0.00041025697,0.00025859813,0.00004320559,0.000005664348,0.00017318473,0.00014900004,0.00047399595],"category_scores_gemma":[0.000043129643,0.00013704263,0.00006516516,0.00030500966,0.00046040834,0.000085619904,0.000100054036,0.00019040654,0.00016848855],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060499465,0.00046877985,0.0020891072,0.000044057957,0.000102829785,0.000060791823,0.0011841727,9.5359013e-7,0.97591925,0.018735124,0.00059149874,0.00019844838],"study_design_scores_gemma":[0.0028259116,0.0005252517,0.0037835005,0.000039833958,0.000023818266,0.00059612683,0.00054864073,0.0040300796,0.9872555,0.000111052235,0.00015501353,0.000105232],"about_ca_topic_score_codex":0.000046498502,"about_ca_topic_score_gemma":0.000008468555,"teacher_disagreement_score":0.018624071,"about_ca_system_score_codex":0.0005083035,"about_ca_system_score_gemma":0.0002348259,"threshold_uncertainty_score":0.5588436},"labels":[],"label_agreement":null},{"id":"W2888583703","doi":"10.1016/j.exphem.2018.06.098","title":"Development of ERG-Enhancer Fluorescent Reporter System to Decipher Functional Heterogeneity in Leukemia","year":2018,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Biology; Leukemia; Haematopoiesis; Cancer research; Myeloid leukemia; Stem cell; Enhancer; Transcriptome; Cell biology; Immunology; Genetics; Gene; Gene expression","score_opus":0.036876625281978596,"score_gpt":0.34571482619879507,"score_spread":0.30883820091681646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888583703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99460286,0.00049729453,0.0006986197,0.00008766906,0.000437671,0.00060138525,0.0000018139282,0.000048563972,0.0030241255],"genre_scores_gemma":[0.98353976,0.0000010082821,0.015605963,0.00020177565,0.00013328352,0.0002160911,0.000018028282,0.000030681917,0.00025341014],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978299,0.000058684313,0.00075588713,0.00048498795,0.0004180801,0.0004524703],"domain_scores_gemma":[0.9990879,0.00002840936,0.00011342294,0.00040619355,0.00013910857,0.00022493595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028013674,0.00019970287,0.00052487245,0.00023033083,0.00006900675,0.0000056501444,0.00012712886,0.00016079153,0.0007777889],"category_scores_gemma":[0.000033295153,0.00017683745,0.000073907155,0.00026032265,0.00017252195,0.000049015758,0.00023231244,0.00014461133,0.00036784858],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038199502,0.0008060326,0.043275278,0.00038324215,0.00026570694,0.000690019,0.004487102,0.0000050520557,0.9277081,0.004694491,0.012158903,0.0017061277],"study_design_scores_gemma":[0.0015788286,0.000264476,0.013087193,0.0001825375,0.00000657437,0.00094799197,0.0011912351,0.00014500125,0.97975874,0.0000019351169,0.0026906116,0.00014485465],"about_ca_topic_score_codex":0.00005143372,"about_ca_topic_score_gemma":0.00010607508,"teacher_disagreement_score":0.052050665,"about_ca_system_score_codex":0.0024408544,"about_ca_system_score_gemma":0.0006615152,"threshold_uncertainty_score":0.85162437},"labels":[],"label_agreement":null},{"id":"W2888596288","doi":"10.1016/j.exphem.2018.06.271","title":"Generation of a Novel Mouse Model Recapitulating Features of Human Acute Megakaryoblastic Leukemia","year":2018,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Acute megakaryoblastic leukemia; Biology; Progenitor cell; Megakaryocyte; Haematopoiesis; Bone marrow; Myeloid; Cancer research; Leukemia; Myeloid leukemia; Spleen; Transcriptome; Stem cell; Immunology; Cell biology; Genetics; Gene; Gene expression","score_opus":0.0699901214307369,"score_gpt":0.37840367609989217,"score_spread":0.30841355466915527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888596288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940744,0.00046828348,0.0021039806,0.00007376082,0.00007861665,0.00035873364,0.000016898524,0.000039430277,0.002785884],"genre_scores_gemma":[0.9802445,0.0000053176946,0.018354999,0.000104210485,0.00013590817,0.00003381489,0.000059775786,0.000037287486,0.0010241444],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985699,0.000037456542,0.00048220786,0.000313565,0.0002975244,0.00029931433],"domain_scores_gemma":[0.9991029,0.0000423374,0.00019343077,0.00038016425,0.00017627362,0.000104902945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001244488,0.0001789241,0.0005421064,0.0001953649,0.000096025185,0.000004857798,0.00015208808,0.00018865021,0.00015338032],"category_scores_gemma":[0.000054220556,0.00016160267,0.00009849309,0.000149393,0.00046776372,0.000083777064,0.00015466429,0.00019750207,0.000009416458],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026218145,0.00025714136,0.00015470122,0.00006235605,0.00012426576,0.000010055221,0.001653459,0.000041046,0.96941745,0.026177814,0.0017915515,0.000047989903],"study_design_scores_gemma":[0.0023745757,0.00093090185,0.00006554273,0.000051991734,0.00004104655,0.0002877969,0.00037291658,0.056793693,0.93893117,0.000038520648,0.000004464824,0.00010736071],"about_ca_topic_score_codex":0.00011138654,"about_ca_topic_score_gemma":0.0000141176615,"teacher_disagreement_score":0.05675265,"about_ca_system_score_codex":0.0003088102,"about_ca_system_score_gemma":0.0002416068,"threshold_uncertainty_score":0.6589966},"labels":[],"label_agreement":null},{"id":"W2889269891","doi":"10.12688/f1000research.15442.1","title":"Blood Relatives: Splicing Mechanisms underlying Erythropoiesis in Health and Disease","year":2018,"lang":"en","type":"preprint","venue":"F1000Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Natural Sciences and Engineering Research Council of Canada; National Institutes of Health","keywords":"RNA splicing; Erythropoiesis; Biology; Alternative splicing; Transcriptome; Erythroblast; Ineffective erythropoiesis; Biogenesis; Gene; Haematopoiesis; Genetics; Cell biology; Stem cell; Gene expression; Messenger RNA; Medicine; RNA; Anemia; Internal medicine","score_opus":0.0923737782078555,"score_gpt":0.4065543812552689,"score_spread":0.31418060304741335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889269891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9212451,0.011100401,0.0050668623,0.048507977,0.00032849732,0.0077126306,0.0001810554,0.0004113461,0.005446155],"genre_scores_gemma":[0.9634877,0.008802856,0.016230758,0.0012088887,0.0004012291,0.0005323325,0.00036244668,0.0003302717,0.008643533],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9933792,0.0008957699,0.000847558,0.0015251094,0.0018107874,0.0015415697],"domain_scores_gemma":[0.99484366,0.0006695379,0.0001972379,0.0014550807,0.0003903161,0.0024441858],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0035091068,0.00051621156,0.0010489069,0.0015670311,0.0003600905,0.00018316424,0.00056766474,0.00047346365,0.00050067017],"category_scores_gemma":[0.003218875,0.00048737772,0.00016764522,0.0008089303,0.00079844426,0.00013867993,0.003318002,0.0038451545,0.0001482701],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025454028,0.0092821205,0.3374296,0.16016148,0.0074456977,0.02540932,0.060704414,0.00061507366,0.041139312,0.11080694,0.13342085,0.08813114],"study_design_scores_gemma":[0.027588865,0.008542332,0.3536774,0.045411196,0.00069893716,0.0006087316,0.018406209,0.061765134,0.0021632914,0.46949428,0.007301942,0.00434171],"about_ca_topic_score_codex":0.0024882257,"about_ca_topic_score_gemma":0.000104431725,"teacher_disagreement_score":0.35868734,"about_ca_system_score_codex":0.0015995068,"about_ca_system_score_gemma":0.008197786,"threshold_uncertainty_score":0.99975777},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"theoretical_or_conceptual","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2889905232","doi":"10.1182/bloodadvances.2018015677","title":"A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Juravinski Hospital; London Health Sciences Centre; Population Health Research Institute; McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Cytarabine; Medicine; Tolerability; Myeloid leukemia; Internal medicine; Acute leukemia; Refractory (planetary science); Pharmacology; Oncology; Leukemia; Adverse effect; Gastroenterology; Biology","score_opus":0.018134387283612014,"score_gpt":0.33993825940579453,"score_spread":0.32180387212218253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889905232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99585366,0.00013626376,0.000080593716,0.00026669045,0.00008674276,0.0022414655,0.000011542357,0.000055217137,0.0012678034],"genre_scores_gemma":[0.99267185,0.00005367108,0.0062559294,0.00013886638,0.0002478254,0.00019996628,0.00012075391,0.000045046458,0.00026608483],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974915,0.00012235924,0.00044783286,0.0005133119,0.00091128214,0.00051373965],"domain_scores_gemma":[0.99880344,0.00012570097,0.00018530607,0.0003562185,0.0003978234,0.00013152561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005953459,0.0002602538,0.00049847626,0.00039856235,0.00008062414,0.000026204158,0.00017054725,0.00009006916,0.000059708473],"category_scores_gemma":[0.00027362411,0.00018096704,0.000030838837,0.001061787,0.00022379885,0.0004944483,0.00005601627,0.0004524845,0.000024903096],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6651329,0.011067523,0.21517025,0.00023684176,0.00049841095,0.00063058466,0.0017705086,0.000079235455,0.010780153,0.00015224067,0.00012780548,0.09435355],"study_design_scores_gemma":[0.8329955,0.079887696,0.07351988,0.0006703792,0.0003282962,0.000037756126,0.00017010572,0.0016477744,0.009534881,0.00014034669,0.0006436755,0.0004237293],"about_ca_topic_score_codex":0.000067781475,"about_ca_topic_score_gemma":0.00033127074,"teacher_disagreement_score":0.16786258,"about_ca_system_score_codex":0.0004638173,"about_ca_system_score_gemma":0.00082462316,"threshold_uncertainty_score":0.7379622},"labels":[],"label_agreement":null},{"id":"W2890094313","doi":"10.1200/jco.2017.35.15_suppl.e18507","title":"Overall survival (OS) and stem cell transplant (SCT) in patients with FLT3 mutations treated with CPX-351 versus 7+3: Subgroup analysis of a phase III study of older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Cytarabine; Gastroenterology; Neutropenia; Oncology; Surgery; Leukemia; Toxicity","score_opus":0.03385748828145582,"score_gpt":0.37456946737509494,"score_spread":0.34071197909363915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890094313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981157,0.000038350037,0.00014910637,0.00016572856,0.00011548141,0.0011544585,0.00012869792,0.000007844092,0.0001246126],"genre_scores_gemma":[0.9985027,0.00045611121,0.00074197515,0.000033213786,0.00009341491,0.000020068086,0.000054396398,0.000041257645,0.0000569039],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945948,0.0008076262,0.0025119702,0.0005051276,0.0011441386,0.000436329],"domain_scores_gemma":[0.9905861,0.0030432066,0.0039846725,0.0006799281,0.0011616923,0.00054442405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018462063,0.00035546446,0.00337208,0.0007100315,0.00012627618,0.000024391109,0.00042874098,0.00035727964,0.00004187871],"category_scores_gemma":[0.0002896688,0.00021093516,0.00026882032,0.00057379453,0.0006465294,0.00032113466,0.00006829556,0.0014381838,9.13723e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23803718,0.008956066,0.7309466,0.00005405728,0.007836443,0.0020760137,0.0023126404,0.00046129787,0.00002604773,0.0000028512238,0.000027054319,0.009263713],"study_design_scores_gemma":[0.25823855,0.077875935,0.65170664,0.00020656773,0.009903634,0.00001597357,0.0013045128,0.00053067226,0.000060239046,8.0864805e-7,0.000009730447,0.00014672906],"about_ca_topic_score_codex":0.004132365,"about_ca_topic_score_gemma":0.009657255,"teacher_disagreement_score":0.07923997,"about_ca_system_score_codex":0.0004785482,"about_ca_system_score_gemma":0.0020262075,"threshold_uncertainty_score":0.86016864},"labels":[],"label_agreement":null},{"id":"W2890099753","doi":"10.1200/jco.2016.34.15_suppl.7045","title":"Up-regulation of <i>BAALC/MN1/MLLT11/EVI1</i> gene cluster in relation to <i>MYC</i> / BCL2 protein co-expression and poor overall survival in acute myeloid leukemia (AML).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Oncology; NPM1; Internal medicine; Gene signature; Cancer research; Neuroblastoma RAS viral oncogene homolog; Gene expression; Gene; Bioinformatics; Cancer; Karyotype; Biology; Genetics; KRAS","score_opus":0.05827811660056799,"score_gpt":0.4142460874379162,"score_spread":0.3559679708373482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890099753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98034567,0.00011902576,0.0010717008,0.016137816,0.0004789366,0.0009267376,0.000011445645,0.000009590462,0.0008990611],"genre_scores_gemma":[0.98919654,0.0005832109,0.0065191463,0.0015284986,0.00067842455,0.000019113453,0.000008045119,0.000038641567,0.0014283919],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9936049,0.0012585259,0.0034400742,0.0004074688,0.00083489,0.00045416615],"domain_scores_gemma":[0.9947289,0.0023875337,0.0015219245,0.00032288724,0.00054297864,0.00049574644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072239563,0.00023373298,0.001739322,0.0005629293,0.000031975786,0.0000107068945,0.00025316956,0.000810515,0.000105224135],"category_scores_gemma":[0.004874339,0.0001518663,0.00025419012,0.000326637,0.0002474322,0.00041062656,0.00019351378,0.001269243,0.00002759571],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03030656,0.0006391172,0.15923244,0.00008455917,0.0001546543,0.00029946456,0.00026586684,0.00008955037,0.73878,0.0001335201,0.0068187444,0.06319551],"study_design_scores_gemma":[0.046106927,0.0097550545,0.8807849,0.0013786298,0.00014255905,0.00033300745,0.00006243743,0.0005079889,0.037286874,0.0010196159,0.022325084,0.00029692272],"about_ca_topic_score_codex":0.00007643568,"about_ca_topic_score_gemma":0.00009877294,"teacher_disagreement_score":0.7215525,"about_ca_system_score_codex":0.0015152988,"about_ca_system_score_gemma":0.0026102427,"threshold_uncertainty_score":0.6251434},"labels":[],"label_agreement":null},{"id":"W2890325820","doi":"10.1038/s41586-018-0436-0","title":"The genetic basis and cell of origin of mixed phenotype acute leukaemia","year":2018,"lang":"en","type":"article","venue":"Nature","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":374,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"National Institute of General Medical Sciences; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; Canada's Michael Smith Genome Sciences Centre; American Lebanese Syrian Associated Charities; St. Jude Children's Research Hospital","keywords":"Myeloid; Haematopoiesis; Biology; Phenotype; Cancer research; Genetic heterogeneity; Somatic cell; Immunology; B cell; Stem cell; Genetics; Gene","score_opus":0.01005525437862627,"score_gpt":0.2942993459725573,"score_spread":0.28424409159393105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890325820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99043643,0.0031602639,0.000019492474,0.0011326617,0.00013633019,0.00021247841,0.000016479416,0.000010956924,0.004874873],"genre_scores_gemma":[0.99396634,0.00052201684,0.0026176702,0.0002196143,0.00020415123,0.0000033191934,0.000004895659,0.000016821301,0.0024451779],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99913293,0.00003941297,0.00016008252,0.00015652554,0.00031973128,0.00019134326],"domain_scores_gemma":[0.9990315,0.00014441065,0.00007207623,0.00037020553,0.0003054297,0.000076402706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001965467,0.000090343376,0.00019862893,0.000059532547,0.000056904857,0.000005828571,0.00016606228,0.00049183104,0.000074479256],"category_scores_gemma":[0.00013308763,0.0000543678,0.000044924665,0.0002544122,0.00032205845,0.000019711428,0.000080717604,0.0009691695,0.000015002211],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002168647,0.0001376289,0.044002622,0.0005259277,0.00053162087,0.000066029264,0.00094636076,8.2301256e-7,0.6867059,0.0013292681,0.20578767,0.057797506],"study_design_scores_gemma":[0.0034833362,0.0010826268,0.22116672,0.00010480276,0.0003524806,0.0000582832,0.0001904789,0.00047538403,0.6699545,0.0005018274,0.10245691,0.00017266705],"about_ca_topic_score_codex":0.00003274101,"about_ca_topic_score_gemma":0.000020994705,"teacher_disagreement_score":0.1771641,"about_ca_system_score_codex":0.00005616107,"about_ca_system_score_gemma":0.00026335337,"threshold_uncertainty_score":0.4210613},"labels":[],"label_agreement":null},{"id":"W2890405016","doi":"10.1200/jco.2017.35.15_suppl.e18529","title":"Burden of illness in patients with acute myeloid leukemia aged ò65 years ineligible for intensive chemotherapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Cytarabine; Myeloid leukemia; Internal medicine; Chemotherapy; Decitabine; Chemotherapy regimen; Pediatrics","score_opus":0.06297915824340701,"score_gpt":0.43908598297760104,"score_spread":0.37610682473419405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890405016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99294364,0.00003812311,0.00012642787,0.005159458,0.00047467518,0.0005884196,0.000010507253,0.00000441365,0.0006543058],"genre_scores_gemma":[0.9920452,0.00040359903,0.0049260557,0.0013631579,0.00070398394,0.000009192423,0.000006405032,0.000036348407,0.0005060281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969352,0.0001693772,0.0018313844,0.00022715768,0.0004946091,0.00034227656],"domain_scores_gemma":[0.99348235,0.0013109802,0.002471224,0.0004795851,0.0019602494,0.00029559687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026890787,0.00015677283,0.0018454461,0.00024466077,0.000059206122,0.000015087088,0.00054690434,0.0004496177,0.000047614536],"category_scores_gemma":[0.0074091894,0.000106862826,0.00034417,0.000110034205,0.0005549347,0.00018860096,0.00012390414,0.001266512,0.000006253796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1059902,0.0013505233,0.5160014,0.00014914395,0.0023125713,0.0014750536,0.0017441593,0.000060235358,0.0011978908,0.00005812548,0.022560691,0.3471],"study_design_scores_gemma":[0.053881682,0.015383772,0.9133042,0.00027485468,0.0002694365,0.00007987552,0.0003692081,0.00013570403,0.00047406,0.00023602438,0.01544872,0.00014245452],"about_ca_topic_score_codex":0.00014316913,"about_ca_topic_score_gemma":0.000044419237,"teacher_disagreement_score":0.3973028,"about_ca_system_score_codex":0.0005817536,"about_ca_system_score_gemma":0.003793573,"threshold_uncertainty_score":0.8870027},"labels":[],"label_agreement":null},{"id":"W2892247627","doi":"10.1016/j.ccell.2018.08.007","title":"Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence","year":2018,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; McMaster University","funders":"Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"Myeloid leukemia; Chemotherapy; In vivo; Cancer research; Stem cell; Disease; Leukemia; Medicine; Immunology; Biology; Oncology; Internal medicine; Cell biology; Genetics","score_opus":0.03922489339316691,"score_gpt":0.35159496491442493,"score_spread":0.312370071521258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892247627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964104,0.0006074337,0.0003218626,0.00017270955,0.00018932098,0.00065928075,0.000039598763,0.000022282824,0.0015771042],"genre_scores_gemma":[0.99796206,0.00019189177,0.00033851856,0.00010839698,0.00029963828,0.000055134355,0.000012685102,0.000028174516,0.0010035273],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981018,0.00011586358,0.0007015137,0.00040880605,0.0003925136,0.00027951095],"domain_scores_gemma":[0.99817365,0.000057491532,0.00034459174,0.00066852703,0.0006381046,0.000117648866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078281295,0.00015562569,0.0004075493,0.00007398892,0.000082420884,0.000008551257,0.00022652338,0.00011953449,0.000473999],"category_scores_gemma":[0.000051992258,0.0001434374,0.00011079895,0.00031947266,0.00026547324,0.000081629885,0.000029018112,0.00022500433,0.000010598287],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000119772536,0.00012864813,0.0009695878,0.0004905014,0.000026126114,6.50749e-7,0.0019483013,0.0000072410903,0.98595846,0.000028408125,0.001598649,0.008723636],"study_design_scores_gemma":[0.0013582234,0.0003873921,0.0045781597,0.00018481338,0.000044473803,0.0000013555899,0.00018321724,0.0006846656,0.9922459,0.000028425393,0.0001894739,0.00011387216],"about_ca_topic_score_codex":0.0007226866,"about_ca_topic_score_gemma":0.000079715486,"teacher_disagreement_score":0.008609763,"about_ca_system_score_codex":0.00062931766,"about_ca_system_score_gemma":0.0004710955,"threshold_uncertainty_score":0.5849207},"labels":[],"label_agreement":null},{"id":"W2892949113","doi":"10.1038/s41375-018-0257-z","title":"Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care","year":2018,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Medical Research Council; National Institute for Health and Care Research; Celgene","keywords":"Azacitidine; Medicine; Internal medicine; Myeloid leukemia; Cytogenetics; Cytarabine; Oncology; Myelodysplastic syndromes; Leukemia; Neuroblastoma RAS viral oncogene homolog; Karyotype; Decitabine; Gastroenterology; Cancer; Biology; Bone marrow; Chromosome; Genetics; DNA methylation; Gene","score_opus":0.012867545244878556,"score_gpt":0.27467918526775975,"score_spread":0.2618116400228812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892949113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997288,0.00006611674,0.00018354351,0.00010042175,0.000035621844,0.0010861793,0.00017263654,0.00008321832,0.0009842593],"genre_scores_gemma":[0.9928921,0.000066165245,0.004535171,0.00024928083,0.00014151081,0.00011354599,0.0007836035,0.00008324736,0.0011353868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974627,0.00008456513,0.00040455224,0.0006600598,0.0007599301,0.0006281958],"domain_scores_gemma":[0.99794096,0.00011862858,0.00012757622,0.00047068708,0.0009998279,0.0003422941],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012254388,0.0003817322,0.0004878331,0.00032890675,0.000195796,0.000055805922,0.00018466469,0.00020844852,0.00018978883],"category_scores_gemma":[0.00007778255,0.00026513965,0.00004209106,0.0009033626,0.00075869623,0.00020094764,0.00011105936,0.00045472427,0.000050995808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004491194,0.000099735495,0.98711944,0.00014855652,0.00034204844,0.0006755729,0.0011167299,0.0001377482,0.0036869345,0.00006358232,0.00018469343,0.0019337495],"study_design_scores_gemma":[0.018748678,0.0029147707,0.9611791,0.00031042166,0.00027005878,0.00024262637,0.00045589017,0.00048912794,0.014500373,0.000015583413,0.0004479757,0.00042540848],"about_ca_topic_score_codex":0.0005927705,"about_ca_topic_score_gemma":0.0009252141,"teacher_disagreement_score":0.025940368,"about_ca_system_score_codex":0.0024971988,"about_ca_system_score_gemma":0.0026826104,"threshold_uncertainty_score":0.9999801},"labels":[],"label_agreement":null},{"id":"W2894024905","doi":"10.21037/sci.2018.09.02","title":"Reversing pathological remodelling of the bone marrow microenvironment in acute myeloid leukemia","year":2018,"lang":"en","type":"letter","venue":"Stem Cell Investigation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Myeloid leukemia; Medicine; Bone marrow; Pathological; Disease; Leukemia; Immunology; Pathology","score_opus":0.02910620776298026,"score_gpt":0.24122079055244486,"score_spread":0.2121145827894646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894024905","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80212486,0.00055070117,0.00017792404,0.19260319,0.00037121234,0.0017273994,0.000045433375,0.00004846352,0.0023507925],"genre_scores_gemma":[0.33079463,0.0019235308,0.024055177,0.58148426,0.0059421933,0.00020978168,0.0018363773,0.00052053673,0.053233504],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99644244,0.00048367787,0.0008323929,0.00072517205,0.0009303362,0.00058599707],"domain_scores_gemma":[0.9981212,0.00013857748,0.00053943,0.0009845401,0.00010171842,0.00011455444],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00083008746,0.00040201665,0.0007008637,0.0002850236,0.00013225568,0.000024996272,0.000395967,0.0011753547,0.00007975659],"category_scores_gemma":[0.000036432866,0.00030002833,0.0002294801,0.0004345433,0.0008331537,0.000094359595,0.00028352306,0.0028014225,0.000088672496],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014272225,0.000031454536,0.0027962453,0.0014296375,0.00007504102,0.00084866886,0.0011634887,0.00013973589,0.34643823,0.0000052761266,0.6460685,0.00086096226],"study_design_scores_gemma":[0.0060163424,0.0009962328,0.008134202,0.007059597,0.0012875004,0.0009193512,0.0005055261,0.010744995,0.67742217,0.0012755062,0.2840066,0.0016319717],"about_ca_topic_score_codex":0.000088268105,"about_ca_topic_score_gemma":0.000004671965,"teacher_disagreement_score":0.47133026,"about_ca_system_score_codex":0.002762354,"about_ca_system_score_gemma":0.0006131401,"threshold_uncertainty_score":0.99994516},"labels":[],"label_agreement":null},{"id":"W2896731673","doi":"10.1002/jcp.27629","title":"Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Journal of Cellular Physiology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"China Postdoctoral Science Foundation; Six Talent Peaks Project in Jiangsu Province; National Natural Science Foundation of China","keywords":"Myeloid leukemia; Methylation; DNA methylation; Medicine; Internal medicine; Bisulfite sequencing; Leukemia; Acute promyelocytic leukemia; Bone marrow; Polymerase chain reaction; Oncology; Gastroenterology; Cohort; Biology; Gene expression; Cell culture; Gene","score_opus":0.01727249031608907,"score_gpt":0.2805497517703246,"score_spread":0.2632772614542355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896731673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980755,0.0001519114,0.00015999624,0.0008026153,0.000091540336,0.0002455773,0.0000062455583,0.000008199022,0.00045841077],"genre_scores_gemma":[0.9978122,0.00010832945,0.0010593456,0.00030575896,0.00032107462,0.000004445466,0.000016734606,0.00003047055,0.00034164634],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981212,0.00022036898,0.00065978937,0.00019636175,0.00045034205,0.00035194238],"domain_scores_gemma":[0.99791455,0.0001665193,0.0006850296,0.00017924629,0.0009246413,0.00013000006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066570693,0.00016765573,0.00076449837,0.0004272077,0.000037773647,0.0000058808146,0.00020452923,0.00022894306,0.0002060166],"category_scores_gemma":[0.00027839415,0.0001186183,0.0001530807,0.0005827031,0.00033509097,0.00013641793,0.000055995653,0.00059928343,0.000020229592],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017447139,0.00019208409,0.008549919,0.000039724997,0.0005118996,0.00019547892,0.00044853572,0.00000969876,0.98605084,0.000018715233,0.001144055,0.0010943104],"study_design_scores_gemma":[0.005213252,0.0053706244,0.16188732,0.00028346677,0.00027899756,0.0002481342,0.00013725852,0.0012546702,0.8244258,0.00030028497,0.00045385308,0.00014629975],"about_ca_topic_score_codex":0.000033446293,"about_ca_topic_score_gemma":0.000008154533,"teacher_disagreement_score":0.16162503,"about_ca_system_score_codex":0.0005532369,"about_ca_system_score_gemma":0.00087251456,"threshold_uncertainty_score":0.4837114},"labels":[],"label_agreement":null},{"id":"W2896822607","doi":"10.1182/blood-2018-04-848028","title":"Next-generation sequencing–based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Chonnam National University Hwasun Hospital; National Research Foundation of Korea; Chonnam National University; National Natural Science Foundation of China; Ministry of Science, ICT and Future Planning; National Research Foundation; Natural Sciences and Engineering Research Council of Canada; Princess Margaret Cancer Foundation","keywords":"Myeloid leukemia; Medicine; Oncology; Internal medicine; Leukemia; Intensive care medicine","score_opus":0.035319199620235504,"score_gpt":0.2730305429663111,"score_spread":0.23771134334607558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896822607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985015,0.000100158024,0.00008854017,0.00004079052,0.00033240314,0.0004440144,0.000262448,0.000047176993,0.00018300123],"genre_scores_gemma":[0.99552464,0.00026169038,0.003035252,0.000026550002,0.0004515456,0.000019099822,0.00028719322,0.00004278677,0.00035121205],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978871,0.00011472758,0.00056087517,0.0003511907,0.00073300616,0.0003531497],"domain_scores_gemma":[0.9982024,0.000095541385,0.00030676977,0.0005675696,0.0006744908,0.00015323142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003679767,0.00020403259,0.0004131288,0.00023757227,0.00014048324,0.000015475822,0.00019409838,0.00018214801,0.00007531367],"category_scores_gemma":[0.00018072418,0.00017907351,0.00013367446,0.000312203,0.00023274812,0.0001671175,0.00007564071,0.0002657411,0.000044707696],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042637702,0.00016469571,0.21859401,0.00016121045,0.00041374253,0.000033548324,0.0004663978,0.000012250095,0.7791099,0.000008794991,0.00029608968,0.0003129877],"study_design_scores_gemma":[0.0055910307,0.00096225744,0.09893128,0.00022432346,0.0009706335,0.000016087057,0.000044641027,0.00047554914,0.8926067,0.000012915658,0.00003223627,0.00013234498],"about_ca_topic_score_codex":0.0011334135,"about_ca_topic_score_gemma":0.00003531278,"teacher_disagreement_score":0.119662724,"about_ca_system_score_codex":0.00057941326,"about_ca_system_score_gemma":0.0005944736,"threshold_uncertainty_score":0.7302406},"labels":[],"label_agreement":null},{"id":"W2897323513","doi":"10.1002/gcc.22689","title":"From cellular morphology to molecular and epigenetic anomalies of myelodysplastic syndromes","year":2018,"lang":"en","type":"review","venue":"Genes Chromosomes and Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Leukemia and Lymphoma Society of Canada","keywords":"Telomere; Genome instability; Epigenetics; Biology; Myelodysplastic syndromes; Context (archaeology); Chromosome instability; DNA methylation; Genetics; Gene; Chromosome; Immunology; DNA; DNA damage; Bone marrow; Gene expression","score_opus":0.03498653845575484,"score_gpt":0.3368051377166385,"score_spread":0.30181859926088367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897323513","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10535816,0.8930128,0.000051141873,0.00011522418,0.00021540684,0.0008109615,0.00036675547,0.000019361378,0.000050184204],"genre_scores_gemma":[0.001359526,0.99621314,0.00065702124,0.00011610984,0.00050555536,0.0002536888,0.00012854509,0.00009792924,0.00066850596],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779874,0.000111315996,0.00054200256,0.0007930296,0.0002956726,0.0004592528],"domain_scores_gemma":[0.9986422,0.00014971737,0.00019367949,0.0005529431,0.00012076549,0.00034067934],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011462822,0.00048881135,0.002175972,0.0002922577,0.000058403803,0.000025540792,0.00021347545,0.00039388714,0.0005898362],"category_scores_gemma":[0.000043355056,0.00037921526,0.00019960066,0.00032131045,0.00041437865,0.000026653037,0.00036669974,0.00023692747,0.000041485535],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051705363,0.000040702347,0.00018637214,0.021641508,0.0012279842,0.0005806464,0.00023646647,0.0000013314599,0.005033759,0.00001892292,0.001231541,0.96974903],"study_design_scores_gemma":[0.0006821446,0.0006623224,0.00016455952,0.009449112,0.0023804596,0.00038384256,0.00006166733,0.000010925405,0.0031248697,0.000049279886,0.98253334,0.0004974654],"about_ca_topic_score_codex":0.00041947828,"about_ca_topic_score_gemma":0.000014594099,"teacher_disagreement_score":0.9813018,"about_ca_system_score_codex":0.00015953304,"about_ca_system_score_gemma":0.00064774445,"threshold_uncertainty_score":0.99986595},"labels":[],"label_agreement":null},{"id":"W2897936701","doi":"10.1016/j.cancergen.2018.07.003","title":"Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms","year":2018,"lang":"en","type":"review","venue":"Cancer Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly and Company","keywords":"Loss of heterozygosity; Myelodysplastic syndromes; Copy-number variation; Oncology; Personalized medicine; Medicine; Genetic testing; Bioinformatics; Internal medicine; Biology; Genetics; Genome; Allele; Gene","score_opus":0.18066630620243557,"score_gpt":0.4979247004656751,"score_spread":0.31725839426323954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897936701","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.111163415,0.87657803,0.0021251275,0.0009542372,0.0007089855,0.006432282,0.0019912436,0.00002453433,0.000022113758],"genre_scores_gemma":[0.0283079,0.96000034,0.007322292,0.0013774362,0.0010867466,0.0014089631,0.00030966496,0.00015727314,0.00002939515],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99125594,0.0021423467,0.0030905022,0.0017145613,0.0008747765,0.0009218718],"domain_scores_gemma":[0.9791034,0.013785518,0.0029203289,0.0015896572,0.0020523039,0.0005488244],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.004156271,0.0010226123,0.0039375955,0.00007648046,0.00081813784,0.0003127944,0.0009455764,0.00072465517,0.00011949669],"category_scores_gemma":[0.004563386,0.000669023,0.0005248484,0.0007263333,0.003650894,0.00046054178,0.00056228327,0.0018478564,0.000007485693],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008641725,0.0023810822,0.1446761,0.29502186,0.015755428,0.00035751614,0.00787271,0.00025611743,0.00039558348,0.00036192633,0.0036803794,0.52059954],"study_design_scores_gemma":[0.007842459,0.004862873,0.059882812,0.39199743,0.036792208,0.0016977178,0.002029176,0.006348405,0.0004782475,0.000119884164,0.48476514,0.0031836587],"about_ca_topic_score_codex":0.0006491521,"about_ca_topic_score_gemma":0.0008713566,"teacher_disagreement_score":0.5174159,"about_ca_system_score_codex":0.0007109371,"about_ca_system_score_gemma":0.0073150788,"threshold_uncertainty_score":0.9995761},"labels":[],"label_agreement":null},{"id":"W2899466366","doi":"10.1007/s40273-018-0732-4","title":"Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Midostaurin; Medicine; Cytarabine; Daunorubicin; Quality-adjusted life year; Internal medicine; Myeloid leukemia; Placebo; Oncology; Cost effectiveness; Leukemia; Surgery; Pathology","score_opus":0.04306016700287379,"score_gpt":0.37204935814548384,"score_spread":0.32898919114261005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899466366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959766,0.00016515334,0.000028501936,0.0008482043,0.00009630046,0.002318615,0.00014147736,0.000015219435,0.00040991543],"genre_scores_gemma":[0.99464923,0.0037807173,0.00008583129,0.00069293496,0.000108745706,0.0002827323,0.0003362961,0.000034652505,0.000028882607],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977458,0.0007500434,0.0005726032,0.00031076634,0.00018967249,0.0004311215],"domain_scores_gemma":[0.9968871,0.0022163205,0.00018208838,0.00049689255,0.00013663863,0.00008096809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014428643,0.00025308342,0.00056220905,0.00042954928,0.00005024437,0.000021028725,0.0004631783,0.00008666143,0.00008215502],"category_scores_gemma":[0.00006639265,0.000156975,0.00011805578,0.00074469874,0.0003946699,0.00009731946,0.000046522746,0.00029950647,0.000033648455],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060693517,0.009932617,0.3075264,0.0020790782,0.005036152,0.002701375,0.16420235,0.022832068,0.31481642,0.0010667242,0.010559691,0.098553605],"study_design_scores_gemma":[0.05859732,0.004903118,0.16879259,0.0003022996,0.00066117145,0.00013670375,0.0080148075,0.06762555,0.6618998,0.00041758153,0.028097088,0.0005519345],"about_ca_topic_score_codex":0.005071077,"about_ca_topic_score_gemma":0.00031682584,"teacher_disagreement_score":0.34708342,"about_ca_system_score_codex":0.0018697778,"about_ca_system_score_gemma":0.00058285706,"threshold_uncertainty_score":0.7665985},"labels":[],"label_agreement":null},{"id":"W2899626818","doi":"10.1038/s41598-018-35198-6","title":"Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine","year":2018,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health; Ministry of Education, Culture, Sports, Science and Technology","keywords":"Cytarabine; Beta oxidation; Bone marrow; Cancer research; Apoptosis; Myeloid leukemia; Chemistry; Stromal cell; Leukemia; Fatty acid synthesis; Pharmacology; Biology; Fatty acid; Biochemistry; Immunology","score_opus":0.015149297720241489,"score_gpt":0.28466446946531904,"score_spread":0.26951517174507755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899626818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465126,0.000013431563,0.0018748844,0.00020344742,0.00027210952,0.00060577475,0.0000043933646,0.000015574196,0.0023591167],"genre_scores_gemma":[0.9958122,0.0000014302243,0.0026541315,0.000029274703,0.00004201392,0.0000070920278,0.00011094172,0.000013377301,0.0013295688],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982409,0.000031918513,0.00042236786,0.00044813554,0.0006520358,0.00020464436],"domain_scores_gemma":[0.998487,0.000018737152,0.0002055958,0.00042309327,0.000756962,0.00010859781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013240575,0.00010154809,0.00029885862,0.0002738244,0.000053023,0.000025555804,0.000032637592,0.00007046056,0.0000591106],"category_scores_gemma":[0.00027206904,0.00007807544,0.000024387322,0.00093686115,0.00041135526,0.000108876055,0.000044918874,0.00008617016,0.000010386362],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023551706,0.00007578198,0.0037709307,0.00012162943,0.000014149255,0.00025169936,0.0009309241,0.000008042579,0.9924368,0.00016476079,0.0016962795,0.00029342977],"study_design_scores_gemma":[0.0007261249,0.00035223624,0.004585535,0.00027128417,0.000021391128,0.00031716583,0.00035367426,0.00019268571,0.99170244,0.0009114631,0.00048351847,0.0000824607],"about_ca_topic_score_codex":0.00008693175,"about_ca_topic_score_gemma":0.00012437107,"teacher_disagreement_score":0.001212761,"about_ca_system_score_codex":0.00011128178,"about_ca_system_score_gemma":0.00026117347,"threshold_uncertainty_score":0.3183824},"labels":[],"label_agreement":null},{"id":"W2899806166","doi":"10.1007/s00277-018-3539-7","title":"Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes","year":2018,"lang":"en","type":"review","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Pharmaceuticals Corporation; University of British Columbia; University of Arizona; Celgene","keywords":"Medicine; Internal medicine; Myelodysplastic syndromes; Hematology; Meta-analysis; Chelation therapy; Oncology; Disease; Bone marrow; Thalassemia","score_opus":0.057904941213714825,"score_gpt":0.3848248380881768,"score_spread":0.326919896874462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899806166","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.040921316,0.9541142,0.0000011639688,0.00014430797,0.00001486144,0.0046950043,0.000093623035,0.000003934045,0.00001160111],"genre_scores_gemma":[0.044373356,0.95525515,0.000009514695,0.00003324141,0.0000028923325,0.00020853501,0.00007171144,0.000028174547,0.000017409106],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.995744,0.0020130884,0.0010872508,0.00039466342,0.0005553773,0.0002056185],"domain_scores_gemma":[0.9956762,0.0015048482,0.0017547776,0.0007584189,0.00019220597,0.000113520626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012377986,0.00037900088,0.008627341,0.00047195266,0.00002527825,0.0000037012478,0.00017957772,0.00018674567,0.000035506484],"category_scores_gemma":[0.001597795,0.00015799944,0.00082264503,0.0006464605,0.0003175133,0.000037828355,0.00009045484,0.00027539965,0.0000010694107],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005677555,0.00017816602,0.008951503,0.941842,0.04747216,0.000010325558,0.000018108954,5.902909e-7,7.506126e-8,0.000038861926,0.00004921071,0.00087122124],"study_design_scores_gemma":[0.0017459306,0.0046974695,0.009110341,0.21896604,0.76503,0.000024201965,0.0000018681696,0.000029147594,0.00001290524,0.000013835003,0.000109448665,0.00025877258],"about_ca_topic_score_codex":0.00001372891,"about_ca_topic_score_gemma":0.0000031935883,"teacher_disagreement_score":0.72287595,"about_ca_system_score_codex":0.000019745967,"about_ca_system_score_gemma":0.00013854694,"threshold_uncertainty_score":0.644303},"labels":[],"label_agreement":null},{"id":"W2899834545","doi":"10.1155/2018/7918091","title":"Endothelial Function in Children with Acute Lymphoblastic Leukemia (ALL) May Reflect the Clinical Outcome","year":2018,"lang":"en","type":"article","venue":"BioMed Research International","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Jiangsu National Synergistic Innovation Center for Advanced Materials; Ministerstwo Edukacji i Nauki","keywords":"Medicine; Lymphoblastic Leukemia; Endothelial dysfunction; Internal medicine; Gastroenterology; E-selectin; P-selectin; Oncology; Immunology; Leukemia; Platelet; Biology; Platelet activation; Cell","score_opus":0.10574559381400997,"score_gpt":0.4566198963193239,"score_spread":0.35087430250531393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899834545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773239,0.00003089903,0.00048471877,0.010593326,0.0009596195,0.0011706292,0.00006225373,0.000075103504,0.009299534],"genre_scores_gemma":[0.98550355,0.000112060465,0.00074039627,0.00082974456,0.0037298882,0.00015352949,0.00015429074,0.00005319636,0.008723341],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949749,0.00056086463,0.00064931065,0.00065133866,0.0023136004,0.00084999134],"domain_scores_gemma":[0.99739754,0.0006755797,0.00009820569,0.00062179955,0.00089371845,0.00031314156],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0043042493,0.00021182281,0.00031109038,0.0009720163,0.00020623229,0.00012056,0.00084758806,0.00021925097,0.0008572486],"category_scores_gemma":[0.0013214098,0.00012432801,0.0001294642,0.0010525833,0.0016348925,0.00016791951,0.00041464812,0.0013618638,0.0012273144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012901951,0.00050016976,0.8983363,0.000018443938,0.002300714,0.00034396994,0.00020651378,0.0000030699568,0.013990437,0.0021288618,0.04703669,0.022232916],"study_design_scores_gemma":[0.009351426,0.0029777957,0.9068286,0.000085900785,0.00007594342,0.00082926126,0.00009590659,0.0020169367,0.0017061196,0.00034560877,0.07546806,0.00021845379],"about_ca_topic_score_codex":0.0006830439,"about_ca_topic_score_gemma":0.00019864601,"teacher_disagreement_score":0.028431378,"about_ca_system_score_codex":0.002371163,"about_ca_system_score_gemma":0.001849151,"threshold_uncertainty_score":0.99955034},"labels":[],"label_agreement":null},{"id":"W2900883426","doi":"10.1182/blood-2018-99-113918","title":"High Expression of SPAG1 Is Associated with a Worse Clinical Outcome in Intermediate Risk Acute Myeloid Leukemia That Can be Partially Overcome By Hematopoietic Stem Cell Transplantation","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"NPM1; CEBPA; Oncology; Internal medicine; Hematopoietic stem cell transplantation; Hazard ratio; Medicine; Transplantation; Myeloid leukemia; Univariate analysis; Proportional hazards model; Immunology; Multivariate analysis; Biology; Karyotype; Gene; Confidence interval","score_opus":0.02693370500462444,"score_gpt":0.3033483830629298,"score_spread":0.2764146780583054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900883426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978612,0.00006539204,0.00013538872,0.00042955665,0.00011942862,0.0007295838,0.00044171122,0.00007414145,0.00014360994],"genre_scores_gemma":[0.99740267,0.00053403684,0.00040735418,0.00044307797,0.00011562524,0.00004974684,0.00020097331,0.00007026972,0.0007762212],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99655414,0.00040392773,0.0010030499,0.00059359166,0.00083446794,0.0006108464],"domain_scores_gemma":[0.9979611,0.00042864718,0.000532266,0.0005734079,0.00018205163,0.00032251418],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010059938,0.0003357844,0.00095162936,0.00021521983,0.00007275176,0.000024413936,0.00030520375,0.0003905534,0.0001250551],"category_scores_gemma":[0.00008625778,0.00025532235,0.00016470512,0.0004269575,0.00036092405,0.00014180038,0.00008738534,0.0008702068,0.000027386575],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026463296,0.0013012326,0.9499419,0.000291499,0.00041408584,0.000663302,0.0049467096,0.0000030231004,0.037118398,0.0000044236385,0.0020336586,0.0006354911],"study_design_scores_gemma":[0.029814404,0.002600361,0.35735703,0.0009823045,0.0013096643,0.00007418756,0.00047087524,0.00015955152,0.6066721,0.000026127633,0.000106816165,0.00042658218],"about_ca_topic_score_codex":0.0005550901,"about_ca_topic_score_gemma":0.00056167436,"teacher_disagreement_score":0.59258485,"about_ca_system_score_codex":0.00032224433,"about_ca_system_score_gemma":0.000556687,"threshold_uncertainty_score":0.9999899},"labels":[],"label_agreement":null},{"id":"W2901041030","doi":"10.1182/blood-2018-99-110260","title":"Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor (ClinTrialGov 00342316)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Hôpital de l'Enfant-Jésus; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Fludarabine; Transplantation; Medicine; Busulfan; Sibling; Internal medicine; Pediatrics; Surgery; Hematopoietic stem cell transplantation; Cyclophosphamide; Chemotherapy; Psychology","score_opus":0.024479457781221677,"score_gpt":0.27489440295125855,"score_spread":0.2504149451700369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901041030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961981,0.000011276816,0.00009416142,0.00007812444,0.00024424738,0.002995858,0.0003048929,0.000050833794,0.000022497574],"genre_scores_gemma":[0.99753463,0.00039273952,0.001159824,0.000038360642,0.00019167697,0.00011034991,0.00047492998,0.000058738686,0.000038760063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99694854,0.00024756815,0.00077045104,0.0008539628,0.0005773684,0.0006021232],"domain_scores_gemma":[0.99876523,0.00018028158,0.000237738,0.00029559038,0.00030273164,0.00021840072],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005786467,0.00035713648,0.0007718872,0.0008847735,0.00016157479,0.00004708721,0.00016617768,0.00022441229,0.000044809392],"category_scores_gemma":[0.0002089552,0.00030130692,0.00005775218,0.0007586734,0.00024108886,0.00026219775,0.000099422345,0.000918385,0.000026927826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17185833,0.0044122916,0.80215096,0.00018138949,0.00045260033,0.001456882,0.009211225,0.000031492815,0.009952161,5.2603036e-7,0.000016575135,0.0002755473],"study_design_scores_gemma":[0.19060859,0.005042446,0.7973253,0.0011284457,0.0004420032,0.00005885912,0.00054976455,0.00158077,0.0029642473,0.0000026666523,0.000003416525,0.00029348404],"about_ca_topic_score_codex":0.0023444588,"about_ca_topic_score_gemma":0.0119458,"teacher_disagreement_score":0.018750278,"about_ca_system_score_codex":0.0010949686,"about_ca_system_score_gemma":0.00026715454,"threshold_uncertainty_score":0.9999439},"labels":[],"label_agreement":null},{"id":"W2901211944","doi":"10.1016/j.ccell.2018.10.012","title":"Metabolic Flexibility in Leukemia—Adapt or Die","year":2018,"lang":"en","type":"letter","venue":"Cancer Cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Flexibility (engineering); Leukemia; Biology; Computational biology; Cancer research; Cell biology; Immunology; Mathematics","score_opus":0.06326788812452953,"score_gpt":0.3480338698095618,"score_spread":0.28476598168503225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901211944","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041922063,0.052259404,0.000055460263,0.77295345,0.003341881,0.0047353185,0.0006307138,0.00042679269,0.12367493],"genre_scores_gemma":[0.0025094734,0.010597897,0.0006741274,0.72081566,0.021583341,0.0006656241,0.00048324603,0.00030384946,0.24236679],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99590343,0.00019939679,0.00063212577,0.001190996,0.00087881536,0.0011952616],"domain_scores_gemma":[0.9974405,0.000232311,0.00018980198,0.0016096408,0.00028843823,0.00023930611],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0005029266,0.00058797916,0.0013008807,0.0002686995,0.00006473017,0.000039784787,0.00062162115,0.0014178957,0.008533902],"category_scores_gemma":[0.00016336776,0.0004418772,0.00026427893,0.0004445344,0.00040123935,0.00011819787,0.00028416121,0.003924017,0.0007720504],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00046473785,0.00003865618,0.00035334448,0.0010536113,0.0000965326,0.0020947487,0.00021174688,0.0000021860174,0.00042305022,0.0000011893551,0.99121004,0.00405016],"study_design_scores_gemma":[0.0024735183,0.00017778379,0.0007238526,0.00029337523,0.00019969532,0.000028083796,0.000038403465,0.00015520032,0.0065195346,0.000039041144,0.98890716,0.00044432777],"about_ca_topic_score_codex":0.008428712,"about_ca_topic_score_gemma":0.0020444249,"teacher_disagreement_score":0.118691854,"about_ca_system_score_codex":0.006453518,"about_ca_system_score_gemma":0.006489721,"threshold_uncertainty_score":0.99987847},"labels":[],"label_agreement":null},{"id":"W2901234956","doi":"10.14740/jh461w","title":"Vasculitis in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia: A Report of Two Cases","year":2018,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chronic myelomonocytic leukemia; Medicine; Myelodysplastic syndromes; Vasculitis; Polyarteritis nodosa; Immunology; Leukemia; Myeloid leukemia; Dermatology; Pathology; Disease; Bone marrow","score_opus":0.021998229948710854,"score_gpt":0.3269820506132049,"score_spread":0.30498382066449403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901234956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995477,0.002561727,0.00028081215,0.00076613104,0.00021189649,0.00018762381,0.0000015770936,0.0000077317145,0.0005054517],"genre_scores_gemma":[0.9977594,0.0003737568,0.001428405,0.00006371782,0.00018408359,0.000004341205,0.0000015709982,0.000022630082,0.00016206813],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99784994,0.00011382684,0.0010809625,0.00021385722,0.0003518182,0.00038961784],"domain_scores_gemma":[0.9980466,0.00052224746,0.0005333969,0.00029897742,0.00038914647,0.00020966708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007784247,0.00015943896,0.0010386822,0.0006250174,0.000035254838,0.0000071626882,0.00014326116,0.00016111252,0.00021113173],"category_scores_gemma":[0.0013420017,0.00012690916,0.00011969559,0.00034254455,0.00055762206,0.000121156794,0.00010315703,0.00058799237,0.00001794898],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022632147,0.0004620208,0.20529674,0.0026816016,0.0013357094,0.7500543,0.0011770014,0.00003850864,0.019973144,0.0038782367,0.005871003,0.006968519],"study_design_scores_gemma":[0.0060611404,0.0032675285,0.030052027,0.0006597757,0.00017947632,0.95192,0.00018144028,0.00045529663,0.0056897816,0.000745423,0.00067059015,0.00011757144],"about_ca_topic_score_codex":0.0001368373,"about_ca_topic_score_gemma":0.00012213421,"teacher_disagreement_score":0.20186564,"about_ca_system_score_codex":0.00092397886,"about_ca_system_score_gemma":0.0022336585,"threshold_uncertainty_score":0.51752055},"labels":[],"label_agreement":null},{"id":"W2901356976","doi":"10.1016/j.stemcr.2018.10.016","title":"A Prospective Analysis of Human Leukemogenesis","year":2018,"lang":"en","type":"review","venue":"Stem Cell Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; University of British Columbia; University of Manchester; Terry Fox Foundation; Leukemia and Lymphoma Society of Canada; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Society; Terry Fox Research Institute; Cancer Research Institute","keywords":"Biology; Myeloid leukemia; Leukemia; Haematopoiesis; Computational biology; Exploit; Mechanism (biology); Cancer; Bioinformatics; Immunology; Genetics; Stem cell; Computer science","score_opus":0.053108238872862014,"score_gpt":0.3681817859501515,"score_spread":0.31507354707728946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901356976","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012492457,0.95362186,0.000011687035,0.0000028431623,0.0001292396,0.0021252069,0.000023877325,0.000071018476,0.042765044],"genre_scores_gemma":[0.0012808267,0.95856094,0.000142681,0.000008869232,0.00026697398,0.00021789441,0.00036489975,0.00013053157,0.039026365],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995267,0.00018761602,0.0019191004,0.0011441415,0.0009794866,0.0005026665],"domain_scores_gemma":[0.99497557,0.00013061603,0.0018407917,0.002147425,0.0006147523,0.00029084884],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010615533,0.00055883883,0.00493442,0.0017472999,0.00009690868,0.000022491744,0.0002305033,0.0005503188,0.00059279136],"category_scores_gemma":[0.000057056383,0.00041977462,0.002310721,0.0032965671,0.00024409631,0.000039260554,0.00024817715,0.0004969805,0.00011831338],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006711005,0.0007576053,0.0065806997,0.13285382,0.03871345,0.016560659,0.0006134775,0.000001113023,0.00018011748,0.00003892327,0.012628585,0.7910044],"study_design_scores_gemma":[0.00027641965,0.00044530362,0.00034743868,0.006065355,0.05726048,0.00088866334,0.000050803832,0.0000060219327,0.00055208436,0.000012961787,0.9335965,0.00049796863],"about_ca_topic_score_codex":0.00013958605,"about_ca_topic_score_gemma":0.000024093752,"teacher_disagreement_score":0.92096794,"about_ca_system_score_codex":0.0015286705,"about_ca_system_score_gemma":0.0023731727,"threshold_uncertainty_score":0.9998254},"labels":[],"label_agreement":null},{"id":"W2901397494","doi":"10.1016/j.jcjo.2018.10.008","title":"Serous retinal detachment as an initial presentation of childhood acute myeloid leukemia","year":2018,"lang":"en","type":"letter","venue":"Canadian Journal of Ophthalmology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Medicine; Presentation (obstetrics); Serous fluid; Retinal; Retinal detachment; Pathology; Ophthalmology; Internal medicine; Surgery","score_opus":0.028582835030568327,"score_gpt":0.3352541783455454,"score_spread":0.30667134331497703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901397494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.889742,0.00037048632,0.00001608071,0.08872345,0.0014657436,0.000710416,0.00021678218,0.000008364259,0.018746672],"genre_scores_gemma":[0.9215765,0.000046870024,0.0022638305,0.051304672,0.01675149,0.000024658693,0.0010162764,0.00024911723,0.006766586],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9956732,0.00057942036,0.0012853132,0.000499014,0.0008720675,0.0010909967],"domain_scores_gemma":[0.9952396,0.00017245683,0.0011263399,0.0007333383,0.0014456181,0.0012826482],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0007468492,0.00049438106,0.0013382774,0.0015912252,0.00015333043,0.000052331216,0.000910903,0.0015316873,0.0046326197],"category_scores_gemma":[0.00046028302,0.00046193323,0.00038882945,0.0003684788,0.00084131974,0.00023612849,0.0000658683,0.0040286765,0.00011480791],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061884953,0.000054242002,0.004753517,0.00021631745,0.001381362,0.43515337,0.0009914015,0.000004917789,0.0002984332,0.0000146126595,0.55589676,0.00061620877],"study_design_scores_gemma":[0.0032234513,0.010300988,0.0181148,0.0004275691,0.00097632466,0.9103478,0.00019177113,0.000016674845,0.0019082989,0.0005767679,0.05345983,0.0004557],"about_ca_topic_score_codex":0.00892964,"about_ca_topic_score_gemma":0.00015894088,"teacher_disagreement_score":0.50243694,"about_ca_system_score_codex":0.0025366896,"about_ca_system_score_gemma":0.023579909,"threshold_uncertainty_score":0.9997832},"labels":[],"label_agreement":null},{"id":"W2901763385","doi":"10.1182/blood-2018-99-110871","title":"Treatment Patterns and Healthcare Resource Utilization (HRU) in Patients with Relapsed/Refractory (R/R) FLT3-Mutated (FLT3mut) and FLT3-Wild Type (FLT3wt) Acute Myeloid Leukemia (AML): A Multi-Country Medical Chart Study","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; CEBPA; Internal medicine; Clofarabine; Chemotherapy regimen; Hematopoietic stem cell transplantation; Transplantation; Oncology; NPM1; Myeloid leukemia; Pediatrics; Cytarabine; Chemotherapy; Mutation; Biology","score_opus":0.022135249482547033,"score_gpt":0.30290709179672626,"score_spread":0.28077184231417923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901763385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620473,0.00046556114,0.000014523361,0.00053499604,0.000084100444,0.0023905486,0.00007977554,0.00012846029,0.00009732196],"genre_scores_gemma":[0.9973768,0.00070797413,0.00016697231,0.00047140082,0.00021966921,0.00010791192,0.0004886483,0.00010840314,0.00035224744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962138,0.0003194591,0.0005996665,0.00097633945,0.0011397334,0.000751029],"domain_scores_gemma":[0.9979485,0.00013144608,0.00017457551,0.0006638379,0.00038209418,0.0006995403],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043003954,0.0004909726,0.00072572107,0.00039146683,0.00023340364,0.00005569163,0.00018750611,0.0003899109,0.000087399065],"category_scores_gemma":[0.00024862296,0.0003705131,0.000036895173,0.00064000505,0.00031247258,0.00019240177,0.00020545653,0.0006810776,0.000029982673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028506932,0.003109184,0.97973704,0.00013459135,0.00049671147,0.00063040794,0.004005747,3.8947564e-7,0.000095713636,0.0000033743963,0.00018085726,0.008755299],"study_design_scores_gemma":[0.052666858,0.013890124,0.92824554,0.0004755624,0.00044218957,0.00015634045,0.0012262741,0.00063213054,0.00041300736,0.0000016123396,0.0014680921,0.0003822818],"about_ca_topic_score_codex":0.0019105286,"about_ca_topic_score_gemma":0.0026717572,"teacher_disagreement_score":0.051491503,"about_ca_system_score_codex":0.00090278784,"about_ca_system_score_gemma":0.001088717,"threshold_uncertainty_score":0.9998747},"labels":[],"label_agreement":null},{"id":"W2902667315","doi":"10.1182/blood-2018-99-113911","title":"Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Transplantation; Medicine; Myeloid leukemia; Hematopoietic stem cell transplantation; Human leukocyte antigen; Immunology; Myeloid; Internal medicine; Leukemia; Oncology; Antigen","score_opus":0.010402470694813539,"score_gpt":0.2548453137556772,"score_spread":0.24444284306086367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902667315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994488,0.0017654097,0.00012244117,0.0005783285,0.00021740762,0.0010510583,0.000043362874,0.00015017712,0.0015837899],"genre_scores_gemma":[0.99390846,0.001190537,0.0021574073,0.00045281497,0.00026350116,0.00019329201,0.000083030856,0.00012153992,0.0016293955],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964578,0.00018441916,0.00077013235,0.0008339378,0.00068083504,0.0010728699],"domain_scores_gemma":[0.99824506,0.000096527634,0.00011637015,0.0009161739,0.00017007487,0.00045577934],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038958335,0.00046665414,0.00071352866,0.00040095806,0.00008308653,0.0000336284,0.00038991,0.0004812917,0.00070269336],"category_scores_gemma":[0.00003571038,0.0004099848,0.00020678471,0.00079652393,0.00033447993,0.00008040586,0.00012353907,0.0009428966,0.0012273175],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009907567,0.004801754,0.36578378,0.0019123731,0.0018756755,0.03214298,0.017800372,0.000021558475,0.55831337,0.00006091184,0.003725836,0.003653824],"study_design_scores_gemma":[0.055239048,0.0041991696,0.40683275,0.0017756243,0.0029078017,0.0055956882,0.0003530461,0.00081337517,0.516378,0.00045235603,0.0036141244,0.0018390148],"about_ca_topic_score_codex":0.000100474106,"about_ca_topic_score_gemma":0.000092135095,"teacher_disagreement_score":0.045331478,"about_ca_system_score_codex":0.0005575964,"about_ca_system_score_gemma":0.0008299305,"threshold_uncertainty_score":0.9998352},"labels":[],"label_agreement":null},{"id":"W2903097628","doi":"10.1200/jco.2018.36.34_suppl.210","title":"Preliminary validation of the Edmonton Symptom Assessment Scale – Acute Leukemia (ESAS-AL) in patients with acute leukemia (AL).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Constipation; Itching; Anxiety; Physical therapy; Internal medicine; Psychiatry; Surgery","score_opus":0.0379535662499178,"score_gpt":0.4291157522819904,"score_spread":0.3911621860320726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903097628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98648995,0.000028153823,0.00018035396,0.008486559,0.00093052874,0.00074143976,0.000013406021,0.000011042395,0.003118558],"genre_scores_gemma":[0.9888004,0.0002518424,0.006223494,0.0035307356,0.0006204068,0.000012293953,0.00001586582,0.00004312058,0.00050183653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938429,0.00096049136,0.0028996821,0.00038371162,0.0014143039,0.00049893826],"domain_scores_gemma":[0.99329746,0.0014586569,0.0025871457,0.0006483979,0.0016014756,0.00040689387],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0042442707,0.00026506613,0.0016939894,0.00028509359,0.00009182069,0.000015943422,0.00065862795,0.0005534147,0.00013095747],"category_scores_gemma":[0.0011120971,0.00015277193,0.0004406714,0.0005440611,0.000879691,0.00032295618,0.00032437127,0.0023633086,0.000020353653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.021874638,0.0018014505,0.91154236,0.0000398592,0.0013144553,0.00034412916,0.00032178962,0.000054459586,0.0015045016,0.00003544589,0.03398754,0.02717938],"study_design_scores_gemma":[0.018414447,0.03325322,0.9345888,0.0003391965,0.00078911614,0.00020465963,0.00008277551,0.00060798903,0.0015182903,0.00008673742,0.009968152,0.00014663843],"about_ca_topic_score_codex":0.000073116564,"about_ca_topic_score_gemma":0.00005614034,"teacher_disagreement_score":0.03145177,"about_ca_system_score_codex":0.0038847353,"about_ca_system_score_gemma":0.011788542,"threshold_uncertainty_score":0.9999392},"labels":[],"label_agreement":null},{"id":"W2903296906","doi":"10.1097/hs9.0000000000000159","title":"Maintenance Therapy With Interleukin‐2 for Childhood AML","year":2018,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Assistance publique-Hôpitaux de Paris; Institut National Du Cancer; Fondation ARC pour la Recherche sur le Cancer; CNIB; Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'Adolescent; Association Laurette Fugain","keywords":"Medicine; Cytarabine; Internal medicine; Mitoxantrone; Maintenance therapy; Acute myeloblastic leukemia; Population; Randomized controlled trial; Leukemia; Chemotherapy; Surgery; Oncology","score_opus":0.019421724370781965,"score_gpt":0.2944160902014198,"score_spread":0.2749943658306378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903296906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9227957,0.0009874717,0.008773375,0.006055968,0.0001790909,0.002358342,0.000021165872,0.00026716935,0.05856173],"genre_scores_gemma":[0.9596288,0.00011853716,0.016254283,0.0021767926,0.00095734757,0.00018149734,0.000017339265,0.000085523454,0.020579845],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987662,0.000017636718,0.00016182727,0.0003462934,0.00023456253,0.00047346734],"domain_scores_gemma":[0.9989161,0.00006429962,0.000052029285,0.0004799944,0.00032221913,0.00016536156],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015288679,0.00017624786,0.00027078608,0.000036242494,0.00009943518,0.000022974571,0.00016590659,0.00009096072,0.0009859445],"category_scores_gemma":[0.00008027049,0.00011278143,0.00008423054,0.00020900872,0.00023841533,0.000072434246,0.000038192524,0.00021550493,0.00024555039],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011861512,0.0012342553,0.015662262,0.0004737468,0.0010195326,0.00028253198,0.004884251,0.000001709473,0.019550316,0.004850725,0.6592826,0.2808965],"study_design_scores_gemma":[0.02119614,0.010225945,0.02894916,0.0008172078,0.00006681666,0.000786183,0.0015257599,0.0005430922,0.076645024,0.00077701616,0.8579211,0.0005465139],"about_ca_topic_score_codex":0.000025398118,"about_ca_topic_score_gemma":0.000034432345,"teacher_disagreement_score":0.28035,"about_ca_system_score_codex":0.0001580953,"about_ca_system_score_gemma":0.0003842227,"threshold_uncertainty_score":0.9999273},"labels":[],"label_agreement":null},{"id":"W2903979174","doi":"10.1016/j.leukres.2018.12.002","title":"The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study","year":2018,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"Celgene","keywords":"Medicine; Observational study; Myelodysplastic syndromes; Pediatrics; Intensive care medicine; Internal medicine","score_opus":0.06938188478336435,"score_gpt":0.33238649535146897,"score_spread":0.26300461056810465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903979174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947288,0.000036577458,0.000011015998,0.0008367034,0.000031461394,0.002298401,0.000022604729,0.000031852982,0.0020025964],"genre_scores_gemma":[0.9914973,0.000012716685,0.0011891426,0.000057923855,0.000047935962,0.00007614985,0.000052881307,0.000053344873,0.007012636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99528974,0.00030356008,0.00034998584,0.0006506229,0.0026171631,0.0007889442],"domain_scores_gemma":[0.99665505,0.00047591337,0.00010695809,0.001063088,0.0013738613,0.0003251161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010564146,0.00025719547,0.00045976456,0.00021997026,0.0006782555,0.00012732706,0.0005062742,0.0000926672,0.000090189664],"category_scores_gemma":[0.0001553418,0.00014134817,0.000048352053,0.00076709344,0.0013018693,0.00022203947,0.00046143762,0.0006661636,0.000029531184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035211244,0.0009906328,0.9899962,0.00021978721,0.0011405394,0.00035799146,0.0012042867,0.000014106233,0.000044320608,0.00027777074,0.00096314837,0.0012701051],"study_design_scores_gemma":[0.0072697224,0.008353578,0.97505814,0.000160385,0.00015930552,0.00007742952,0.00773226,0.00026544498,0.00004741933,0.000029347982,0.00067154196,0.00017544751],"about_ca_topic_score_codex":0.00019000498,"about_ca_topic_score_gemma":0.000400412,"teacher_disagreement_score":0.014938069,"about_ca_system_score_codex":0.0015023937,"about_ca_system_score_gemma":0.0007419762,"threshold_uncertainty_score":0.5764011},"labels":[],"label_agreement":null},{"id":"W2904118627","doi":"10.1002/ijc.32063","title":"Abnormal morphological and functional nature of bone marrow stromal cells provides preferential support for survival of acute myeloid leukemia cells","year":2018,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Centre for Interdisciplinary Research in Rehabilitation; Israel Cancer Association; Israel Cancer Association USA","keywords":"Mesenchymal stem cell; Myeloid leukemia; Stromal cell; Bone marrow; Haematopoiesis; Progenitor cell; Leukemia; Cancer research; Myeloid; Cytokine; CD34; Biology; In vivo; Immunology; Ex vivo; Stem cell; Medicine; Pathology; Cell biology","score_opus":0.020097956170564136,"score_gpt":0.3229260078153471,"score_spread":0.30282805164478294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904118627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427545,0.00028368397,0.0014122064,0.0008106304,0.0020247346,0.00027921319,0.00049769535,0.0000065878544,0.00040978982],"genre_scores_gemma":[0.99310726,0.0003347148,0.0028568918,0.00019249353,0.0022341511,0.000011942002,0.00003827945,0.000022966333,0.0012012952],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99754435,0.000046714544,0.0007667457,0.00021100299,0.0011798842,0.00025128725],"domain_scores_gemma":[0.996304,0.00016275377,0.0006610576,0.000121704456,0.0025817652,0.00016875657],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052443217,0.00017379565,0.00050725276,0.00029180368,0.00003489688,0.000022424443,0.00025438415,0.00023839364,0.0012810568],"category_scores_gemma":[0.00008746929,0.00013209433,0.000247064,0.00009560441,0.00040527456,0.00022336253,0.00012731599,0.00056916167,0.0000028656273],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015170468,0.00018059871,0.009543707,0.00011659421,0.0019571295,0.00015186484,0.00011741978,0.000046897472,0.95302695,0.00028638457,0.016000172,0.003401823],"study_design_scores_gemma":[0.010266513,0.0035358944,0.083814226,0.00026919667,0.00062540924,0.0010661226,0.00010780888,0.00068876945,0.88682705,0.00028247593,0.012303584,0.00021296035],"about_ca_topic_score_codex":0.000045221954,"about_ca_topic_score_gemma":0.000020124398,"teacher_disagreement_score":0.07427052,"about_ca_system_score_codex":0.00041823732,"about_ca_system_score_gemma":0.0014576666,"threshold_uncertainty_score":0.9996319},"labels":[],"label_agreement":null},{"id":"W2904696422","doi":"10.1182/blood-2018-99-111390","title":"Comprehensive Single-Cell RNA-Sequencing Mapping of Primary Acute Myeloid Leukemias and Profiling of NPM1-Mutated Cells","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"NPM1; Biology; Myeloid leukemia; Computational biology; RNA; Transcriptome; Massive parallel sequencing; Single-cell analysis; Leukemia; Stem cell; Haematopoiesis; Deep sequencing; Myeloid; DNA sequencing; Genetics; Cancer research; Gene; Cell; Karyotype; Genome; Gene expression; Chromosome","score_opus":0.037113768101205404,"score_gpt":0.26270053718529013,"score_spread":0.22558676908408473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904696422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98824394,0.00067086326,0.00030225396,0.00006839859,0.00007710168,0.0007405732,0.000032366082,0.000065809676,0.009798671],"genre_scores_gemma":[0.9683185,0.00018300329,0.030590342,0.00020303507,0.00018734613,0.00001076959,0.000041194195,0.000059078793,0.00040669343],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978297,0.00009080652,0.00063890766,0.00044094888,0.00050993136,0.0004897021],"domain_scores_gemma":[0.99804753,0.00022576435,0.00031900604,0.00047399531,0.0007333335,0.00020036312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029123758,0.00025736025,0.0007432015,0.00032785526,0.00008417013,0.000014970025,0.00019533804,0.00019030215,0.0000357544],"category_scores_gemma":[0.000077875,0.00023665621,0.00010542384,0.0005205358,0.0005727264,0.00011507614,0.00026109905,0.0003964683,0.000019033498],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021559028,0.00023360517,0.0014890025,0.0012039123,0.0003182017,0.00014672289,0.0012918641,0.0000031676198,0.9938942,0.000011525782,0.00013911694,0.0010530654],"study_design_scores_gemma":[0.0059563764,0.0009748522,0.0014071501,0.00042257895,0.000339509,0.00020802571,0.0008656859,0.00039765128,0.98899615,0.000028507528,0.00020935599,0.00019416782],"about_ca_topic_score_codex":0.00011809132,"about_ca_topic_score_gemma":0.0000016641168,"teacher_disagreement_score":0.030288087,"about_ca_system_score_codex":0.00032047968,"about_ca_system_score_gemma":0.000866064,"threshold_uncertainty_score":0.96505606},"labels":[],"label_agreement":null},{"id":"W2905066790","doi":"10.1182/blood-2018-99-116013","title":"Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Venetoclax; Medicine; Refractory (planetary science); Internal medicine; Pharmacokinetics; Ven; Oncology; Pharmacology; Leukemia; Chronic lymphocytic leukemia; Biology","score_opus":0.056373079134783344,"score_gpt":0.39210336875744756,"score_spread":0.3357302896226642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905066790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99059623,0.00036017364,0.000033312623,0.000108016,0.00020802737,0.008006632,0.000069496695,0.000059516722,0.00055858877],"genre_scores_gemma":[0.99726033,0.00013633199,0.0010167784,0.00016528842,0.0003832512,0.00034880853,0.00008631321,0.00013738046,0.00046548923],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947296,0.0007574074,0.0014768653,0.0010703545,0.0011863023,0.00077949825],"domain_scores_gemma":[0.996388,0.00081365637,0.0005658115,0.00094625406,0.00078047236,0.00050576497],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017485558,0.00061700644,0.002017378,0.000840547,0.00025049556,0.00007099002,0.0005669343,0.00024553307,0.00019587665],"category_scores_gemma":[0.0013060633,0.00042842314,0.000112062255,0.0015139845,0.0010754134,0.00033930785,0.00090080965,0.0006900035,0.00003628446],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83815163,0.050150305,0.016797801,0.0004706478,0.0029969632,0.00084372435,0.0045820116,0.0000051712555,0.07250698,0.000001841299,0.0025077634,0.010985148],"study_design_scores_gemma":[0.92799467,0.018174153,0.020133272,0.000897291,0.0019166977,0.000034646913,0.00050665985,0.001476763,0.02803838,0.0000033085664,0.0002963587,0.0005277874],"about_ca_topic_score_codex":0.00092030055,"about_ca_topic_score_gemma":0.00016947075,"teacher_disagreement_score":0.08984304,"about_ca_system_score_codex":0.0005402222,"about_ca_system_score_gemma":0.0012617159,"threshold_uncertainty_score":0.9998168},"labels":[],"label_agreement":null},{"id":"W2905400988","doi":"10.3324/haematol.2018.195172","title":"The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Biology; Mitochondrial DNA; Oxidative phosphorylation; Respiratory chain; Mitochondrial respiratory chain; Myeloid leukemia; Mitochondrion; Molecular biology; Polymerase; DNA polymerase; Cellular differentiation; Cell biology; Cancer research; Biochemistry; DNA; Gene","score_opus":0.016604256531932135,"score_gpt":0.2778918988496143,"score_spread":0.26128764231768214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905400988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98995554,0.0007196229,0.0002082904,0.006632602,0.00016659356,0.001640937,0.000017170676,0.00010093372,0.00055828836],"genre_scores_gemma":[0.99765205,0.0005529752,0.000490231,0.00041957299,0.00024328296,0.0001793527,0.00006929658,0.000035414705,0.0003578482],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99736124,0.00033283935,0.0005982818,0.0005738926,0.0004889922,0.0006447769],"domain_scores_gemma":[0.9980186,0.0007249289,0.00026279315,0.000596916,0.00022441793,0.00017230296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052541716,0.00034483604,0.0005351642,0.00017764731,0.0006498057,0.00013207246,0.0003048235,0.00023430587,0.00009696316],"category_scores_gemma":[0.0010243781,0.000178338,0.00010844981,0.00068328186,0.00082605414,0.00020968803,0.0002861241,0.0005864895,0.00009353158],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013356369,0.00053601805,0.06663831,0.0002416129,0.0014164739,0.0006998018,0.008580456,0.0000090795575,0.84981924,0.0067375326,0.017693464,0.03427163],"study_design_scores_gemma":[0.007718467,0.0025800732,0.39329323,0.0003366368,0.0004584727,0.0008537477,0.0016343746,0.016603174,0.56939995,0.005132923,0.0013285337,0.00066038925],"about_ca_topic_score_codex":0.00035404437,"about_ca_topic_score_gemma":0.00048537116,"teacher_disagreement_score":0.3266549,"about_ca_system_score_codex":0.0004871324,"about_ca_system_score_gemma":0.000299613,"threshold_uncertainty_score":0.7272413},"labels":[],"label_agreement":null},{"id":"W2905527935","doi":"10.1186/s40364-018-0149-4","title":"The orphan nuclear receptor EAR-2 (NR2F6) inhibits hematopoietic cell differentiation and induces myeloid dysplasia in vivo","year":2018,"lang":"en","type":"article","venue":"Biomarker Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Hospital for Sick Children; Government of Ontario; Health Sciences Centre Foundation","keywords":"Bone marrow; Haematopoiesis; Myeloid; HES1; Biology; Stem cell; Immunology; Cancer research; Ex vivo; Pathology; Molecular biology; In vivo; Cell biology; Medicine; Notch signaling pathway; Signal transduction","score_opus":0.04320740230132695,"score_gpt":0.33614867433190704,"score_spread":0.29294127203058007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905527935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824471,0.0005362252,0.000004637552,0.004537251,0.00012622985,0.0011155112,0.000009305494,0.00005613419,0.011167596],"genre_scores_gemma":[0.99213266,0.0007141361,0.00019624238,0.00008894527,0.0002841392,0.00007862804,0.000011237295,0.00007462704,0.006419392],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99571306,0.000720318,0.00043410415,0.0006398554,0.0014037172,0.0010889228],"domain_scores_gemma":[0.9976754,0.00066477776,0.000070886024,0.0006765653,0.00052339747,0.00038897266],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032617815,0.00023458542,0.00030673013,0.00062405906,0.00069187954,0.00025911818,0.000410467,0.00027986907,0.0011119817],"category_scores_gemma":[0.000799508,0.00016264094,0.00006106259,0.001382482,0.0012082079,0.0001776536,0.0006213989,0.0009163721,0.0007533529],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001809296,0.00027354687,0.01643649,0.000251873,0.00006952164,0.00005250914,0.0018037355,1.7239685e-8,0.9107268,0.00042189076,0.056399275,0.011755055],"study_design_scores_gemma":[0.009165132,0.0024507288,0.27352923,0.0008401767,0.000047280588,0.00021794398,0.0053995284,0.0021546446,0.56654793,0.0006514534,0.13822038,0.00077557104],"about_ca_topic_score_codex":0.00033815834,"about_ca_topic_score_gemma":0.00022163412,"teacher_disagreement_score":0.34417886,"about_ca_system_score_codex":0.00047207292,"about_ca_system_score_gemma":0.00038586112,"threshold_uncertainty_score":0.99980116},"labels":[],"label_agreement":null},{"id":"W2906457520","doi":"10.1073/pnas.1813666116","title":"Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome","year":2018,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Cancer Institute; Canadian Institutes of Health Research","keywords":"Transcriptome; Proteome; Azacitidine; Biology; Epigenetics; DNA methylation; Myeloid leukemia; Methyltransferase; Gene; Cell; Cancer research; Cell culture; Cell cycle; Methylation; Genetics; Gene expression","score_opus":0.045568570600116064,"score_gpt":0.31012799033686383,"score_spread":0.2645594197367478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906457520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99049276,0.00018194594,0.00000876292,0.0034925845,0.000018502004,0.00079093507,0.000035778732,0.000010114493,0.004968586],"genre_scores_gemma":[0.9876683,0.00016690328,0.010610305,0.00027111656,0.00006909931,0.000009905098,3.7063734e-7,0.000007869863,0.001196157],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977429,0.000015328233,0.0003697096,0.00028672512,0.0013473476,0.00023800359],"domain_scores_gemma":[0.99835217,0.00018326654,0.0004823424,0.00002359281,0.0008874445,0.00007121268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023888974,0.00012400335,0.0002621284,0.00011844989,0.00022736214,0.000016856879,0.00061615836,0.00011752197,0.000033375898],"category_scores_gemma":[0.0004502658,0.00006770058,0.00005719454,0.00079493615,0.0021338342,0.00026180712,0.00025135645,0.00024709522,0.0000022255413],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008604383,0.00004880203,0.005700972,0.00019874335,0.000025654026,1.13437e-8,0.00032248048,0.000043685388,0.98815393,0.002327982,0.0030674262,0.000024262317],"study_design_scores_gemma":[0.00053535536,0.00013715499,0.008165591,0.00014405417,0.00003139442,0.000011344486,0.00024852832,0.013273611,0.9713063,0.005839157,0.00023944213,0.00006806375],"about_ca_topic_score_codex":0.00003800774,"about_ca_topic_score_gemma":4.124493e-8,"teacher_disagreement_score":0.016847635,"about_ca_system_score_codex":0.0000845369,"about_ca_system_score_gemma":0.00013385035,"threshold_uncertainty_score":0.7862201},"labels":[],"label_agreement":null},{"id":"W2906757730","doi":"10.1182/blood-2018-99-110470","title":"Unsuccessful Cytogenetics and Outcomes in Acute Leukemia","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Cytogenetics; Medicine; Leukemia; Internal medicine; Acute leukemia; Oncology; Bone marrow; Myeloid leukemia; Karyotype; Chromosome abnormality; Biology; Chromosome","score_opus":0.016634628328675446,"score_gpt":0.308878373676749,"score_spread":0.2922437453480735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906757730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934431,0.00018390664,0.000022380787,0.00086734805,0.000045005552,0.00025942535,0.000008325646,0.000041209827,0.005129354],"genre_scores_gemma":[0.9947493,0.0002111653,0.0023832913,0.00055462966,0.00015960053,0.000014385779,0.000006891097,0.000025696223,0.0018950327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989455,0.000028263847,0.00019160032,0.00026002902,0.00023931923,0.00033528995],"domain_scores_gemma":[0.9993485,0.000060184248,0.000029220093,0.00032311984,0.00008006282,0.00015888114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016192491,0.00012909195,0.00028762862,0.00016198508,0.00004507069,0.000020798036,0.00011840936,0.0001140331,0.000089085814],"category_scores_gemma":[0.00010972771,0.00010406106,0.00003380289,0.00023767557,0.0002038131,0.000046320336,0.00013759827,0.00022908385,0.00011060035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075250784,0.00014243944,0.98255926,0.00003188115,0.00016219036,0.00030168658,0.00026267307,1.2696292e-7,0.01351591,0.00010358419,0.0005288332,0.002316188],"study_design_scores_gemma":[0.0095510995,0.00067975634,0.9087293,0.000054394117,0.00023433861,0.000313817,0.000091582195,0.00014724441,0.07617362,0.00018811817,0.003641781,0.00019491035],"about_ca_topic_score_codex":0.00010753049,"about_ca_topic_score_gemma":0.00008988158,"teacher_disagreement_score":0.0738299,"about_ca_system_score_codex":0.000119148644,"about_ca_system_score_gemma":0.00028055577,"threshold_uncertainty_score":0.42434865},"labels":[],"label_agreement":null},{"id":"W2907087254","doi":"10.1182/blood-2018-99-116618","title":"Quantification of Fusion Transcripts Reveals Slower Treatment Kinetics As Compared with Multiparameter Flow Cytometry during Induction Treatment of Acute Myeloid Leukemia in Children","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University Health Network","funders":"","keywords":"Minimal residual disease; Myeloid leukemia; Medicine; Bone marrow; Leukemia; Oncology; Flow cytometry; Internal medicine; Fusion transcript; Immunology; Fusion gene; Cancer research; Biology; Genetics","score_opus":0.02540567221413169,"score_gpt":0.293604899073447,"score_spread":0.2681992268593153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907087254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978559,0.00015438473,0.000111192436,0.000074800024,0.000048207457,0.001492029,0.00006707561,0.000036355155,0.00016007313],"genre_scores_gemma":[0.9934218,0.00041170703,0.005360859,0.000009652244,0.00012920027,0.00008129397,0.00020140415,0.000044264212,0.00033985157],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99809563,0.00009445893,0.00057351997,0.0004521424,0.00044563503,0.00033859783],"domain_scores_gemma":[0.9987483,0.0000430089,0.00021035639,0.00062316126,0.00024178771,0.00013341052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011504892,0.00028112868,0.00065498427,0.0005481715,0.000051871757,0.000010110038,0.00010860736,0.00017594817,0.000055823617],"category_scores_gemma":[0.00002654274,0.00020482943,0.000120973906,0.00068693224,0.0002198524,0.000088748275,0.000018441036,0.000118113516,0.000018396377],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023501734,0.0026063174,0.1260189,0.000059271893,0.00085518573,0.00002762349,0.0015483332,0.000043534506,0.86365485,0.0000025112495,0.000007991073,0.0028252853],"study_design_scores_gemma":[0.013677919,0.0046504065,0.42017072,0.00012978808,0.0005279312,0.00015769944,0.000074212476,0.00022179859,0.56026393,0.0000025786028,0.0000161201,0.000106877706],"about_ca_topic_score_codex":0.0008270665,"about_ca_topic_score_gemma":0.000066816065,"teacher_disagreement_score":0.30339095,"about_ca_system_score_codex":0.0010726943,"about_ca_system_score_gemma":0.0002624446,"threshold_uncertainty_score":0.83527017},"labels":[],"label_agreement":null},{"id":"W2907180647","doi":"10.14740/jocmr3712","title":"Massive Hemoptysis Due to the Rupture of Thoracic Aortic Aneurysm Caused by Leukemic Cell Infiltration in a Patient With Chronic Myelomonocytic Leukemia","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chronic myelomonocytic leukemia; Malignancy; Chest pain; Bronchial artery; Pathology; Radiology; Lung; Surgery; Internal medicine; Myelodysplastic syndromes; Bone marrow","score_opus":0.05307085546662188,"score_gpt":0.4337590877048464,"score_spread":0.3806882322382245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907180647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97622937,0.0010907948,0.00016672765,0.018931352,0.00022158645,0.0018196544,0.000005529134,0.000008877259,0.0015260894],"genre_scores_gemma":[0.99611664,0.0010121441,0.00033452804,0.00068979734,0.0008773427,0.00003351298,0.000012043087,0.00005912465,0.00086484425],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99054855,0.0016298217,0.0027507255,0.0005095265,0.0036676468,0.0008937161],"domain_scores_gemma":[0.99052835,0.0048470753,0.0009250102,0.0009584183,0.0019437488,0.0007973847],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009772614,0.0003032341,0.0016979178,0.0010096331,0.00007968489,0.000025643656,0.00074712315,0.00035473926,0.00041757268],"category_scores_gemma":[0.0055686105,0.00016029389,0.00023723493,0.0023388779,0.00069068087,0.00019152358,0.00024167499,0.0049821576,0.00009443244],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04393297,0.002691032,0.22708672,0.0055961437,0.001354718,0.01599658,0.009907516,0.0053597963,0.2484766,0.0000783306,0.15222114,0.28729847],"study_design_scores_gemma":[0.069823936,0.22621697,0.44517016,0.020571448,0.0015006034,0.008220058,0.019907359,0.038398694,0.14197882,0.0008045245,0.025684291,0.0017231524],"about_ca_topic_score_codex":0.00040363055,"about_ca_topic_score_gemma":0.000114497576,"teacher_disagreement_score":0.2855753,"about_ca_system_score_codex":0.002679618,"about_ca_system_score_gemma":0.007380427,"threshold_uncertainty_score":0.9982468},"labels":[],"label_agreement":null},{"id":"W2907470518","doi":"10.1016/j.stem.2018.12.007","title":"The Making of a Leukemic Stem Cell: A Novel Role for IKZF2 in AML Stemness and Differentiation","year":2019,"lang":"en","type":"letter","venue":"Cell stem cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Stem cell; Myeloid leukemia; Biology; Leukemia; Myeloid; Cancer research; Chromatin; Cellular differentiation; Haematopoiesis; Immunology; Cell biology; Genetics","score_opus":0.0234308865697399,"score_gpt":0.2594904279318855,"score_spread":0.23605954136214558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907470518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8938164,0.01495022,0.003072108,0.050573837,0.0018719023,0.016075242,0.00061190367,0.00017223967,0.018856108],"genre_scores_gemma":[0.8527214,0.0005080983,0.00028924708,0.02468769,0.0012643588,0.00054265384,0.00046881317,0.000415708,0.119102046],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963653,0.00018528951,0.00090817845,0.0008456469,0.00077920826,0.0009163447],"domain_scores_gemma":[0.99687696,0.0010844663,0.00070120796,0.001026296,0.0002488433,0.0000622429],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067433325,0.00056119106,0.0010898557,0.00039428863,0.00013237611,0.00009945306,0.0005718671,0.0010412299,0.00001927972],"category_scores_gemma":[0.000009121403,0.00041906055,0.00026496733,0.00028723266,0.0001317419,0.000083788276,0.0003092536,0.0019852119,0.00003992],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017560094,0.00052795676,0.0048333937,0.045597535,0.00029155385,0.00018044144,0.005135924,0.00007293877,0.28283378,0.000022253582,0.6462045,0.012543724],"study_design_scores_gemma":[0.021383004,0.001133585,0.0016937188,0.0026521054,0.0008413046,0.00006588154,0.0045582764,0.01797058,0.09987484,0.00003883772,0.84826845,0.001519434],"about_ca_topic_score_codex":0.00008544536,"about_ca_topic_score_gemma":0.000022843114,"teacher_disagreement_score":0.20206395,"about_ca_system_score_codex":0.0009617224,"about_ca_system_score_gemma":0.0006480586,"threshold_uncertainty_score":0.99982613},"labels":[],"label_agreement":null},{"id":"W2907714971","doi":"10.1182/blood-2018-99-116241","title":"Identification of High Risk Group for Leukemic Transformation in Higher Risk MDS Patients Using Targeted RNA-Sequencing: Hematopoietic Stem Cell Signature As a High Risk Profile for Leukemic Transformation","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Occupational Cancer Research Centre; University of Toronto","funders":"","keywords":"Decitabine; Oncology; Azacitidine; Internal medicine; Myelodysplastic syndromes; Leukemia; Myeloid; Myeloid leukemia; Bone marrow; International Prognostic Scoring System; Medicine; Biology; Bioinformatics; Computational biology; Gene; Genetics; DNA methylation; Gene expression","score_opus":0.018564046637274016,"score_gpt":0.26255205115011615,"score_spread":0.24398800451284214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907714971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670208,0.00015678794,0.02473207,0.000050981507,0.00031583253,0.0062485654,0.0012520704,0.000115885894,0.00010700859],"genre_scores_gemma":[0.99372745,0.000180408,0.0036755959,0.00003829925,0.00024746536,0.0006246527,0.0012169704,0.00011373818,0.00017543879],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99603796,0.00028839477,0.0015495357,0.0006181464,0.00078025943,0.0007256752],"domain_scores_gemma":[0.9969214,0.00033489597,0.0011245969,0.00056113617,0.00087169226,0.00018627799],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001405831,0.0004333453,0.00071851315,0.00064185925,0.00033290815,0.0000532326,0.00031511008,0.00059669284,0.00004762494],"category_scores_gemma":[0.00021194218,0.00037680162,0.00027842773,0.000813694,0.0001576793,0.0007501471,0.000026109015,0.00071863295,0.000029174966],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00490466,0.0026004112,0.009796126,0.0068801045,0.00082168076,0.000006811657,0.026345093,0.0011225134,0.9265928,0.0014243135,0.0007465447,0.018758902],"study_design_scores_gemma":[0.0346764,0.0035595282,0.013895864,0.00041579164,0.0016962532,0.00001396247,0.0012616221,0.03865603,0.9027392,0.0024528636,0.00015992658,0.0004725438],"about_ca_topic_score_codex":0.0017552365,"about_ca_topic_score_gemma":0.00006416777,"teacher_disagreement_score":0.037533518,"about_ca_system_score_codex":0.0014312108,"about_ca_system_score_gemma":0.00063628994,"threshold_uncertainty_score":0.9998684},"labels":[],"label_agreement":null},{"id":"W2907895732","doi":"10.3324/haematol.2018.205948","title":"Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come","year":2018,"lang":"en","type":"editorial","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Gemtuzumab ozogamicin; Myeloid leukemia; Calicheamicin; Medicine; Leukemia; Oncology; Internal medicine; CD33; Biology; Genetics; Stem cell","score_opus":0.015626789455013577,"score_gpt":0.31325345522887643,"score_spread":0.2976266657738629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907895732","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3686375,0.0007953639,0.00016126959,0.009204883,0.5739288,0.009480243,0.00094211724,0.0012015514,0.035648335],"genre_scores_gemma":[0.0222101,0.0013239476,0.007974071,0.0021408012,0.9354142,0.0010859993,0.002724887,0.00060031965,0.026525678],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99256694,0.00025171685,0.0010436804,0.0019283708,0.0024157353,0.001793564],"domain_scores_gemma":[0.99492747,0.0010203135,0.00038002638,0.0020192382,0.0008696097,0.0007833617],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.00086490513,0.0011806128,0.003133982,0.0011308718,0.00020706942,0.000117983975,0.0013499045,0.0029147537,0.001020236],"category_scores_gemma":[0.0019731773,0.00082026294,0.0002970335,0.0013474794,0.0007133721,0.00015431695,0.0008476549,0.004480217,0.0020860462],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005829018,0.00015039496,0.00070203125,0.0007473897,0.00042326824,0.012848453,0.00053826754,0.0000027907242,0.00017808624,0.000035686808,0.9779478,0.000596856],"study_design_scores_gemma":[0.0062947427,0.005017527,0.0015102419,0.001923045,0.0004780984,0.00161719,0.00036761427,0.000068651236,0.0005707173,0.00005128366,0.98097664,0.0011242261],"about_ca_topic_score_codex":0.00052651175,"about_ca_topic_score_gemma":0.00035834708,"teacher_disagreement_score":0.36148545,"about_ca_system_score_codex":0.004813927,"about_ca_system_score_gemma":0.0048205964,"threshold_uncertainty_score":0.99989295},"labels":[],"label_agreement":null},{"id":"W2907901533","doi":"10.1182/blood-2018-99-112037","title":"RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Minimal residual disease; Fusion gene; Biology; Myeloid leukemia; Gene; Leukemia; Cancer research; Computational biology; Genetics","score_opus":0.07279583285388672,"score_gpt":0.31779115377525297,"score_spread":0.24499532092136625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907901533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656594,0.00033990605,0.0002689449,0.0004107211,0.00031234184,0.0015234089,0.00023464584,0.00008894818,0.00025513128],"genre_scores_gemma":[0.9940413,0.000039318867,0.0043865624,0.00008250745,0.0008986693,0.00016950298,0.000052906762,0.0000894407,0.00023974164],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99623436,0.000083007384,0.00073026255,0.00065254146,0.0014117418,0.0008880621],"domain_scores_gemma":[0.9977397,0.00017767402,0.00019076449,0.00064782996,0.0007035212,0.00054056535],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00086656836,0.00037065052,0.00062419474,0.0004961387,0.00017118131,0.00003165017,0.00036806968,0.0002036163,0.000094475996],"category_scores_gemma":[0.00074075203,0.00034065213,0.00022828918,0.0004905825,0.00024719254,0.00014164332,0.00008841605,0.00044139035,0.000024647305],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002958577,0.00034384406,0.042597957,0.00053509837,0.00027920952,0.00023196673,0.00066179817,0.000011863505,0.9510999,0.00001627385,0.0004684167,0.0007951296],"study_design_scores_gemma":[0.016242867,0.0013267467,0.0501835,0.0011577706,0.00063721644,0.000014284818,0.00035502278,0.0009323681,0.92832077,0.000029280669,0.00041276912,0.00038741808],"about_ca_topic_score_codex":0.00019758879,"about_ca_topic_score_gemma":0.0000681675,"teacher_disagreement_score":0.022779113,"about_ca_system_score_codex":0.0020243488,"about_ca_system_score_gemma":0.004046073,"threshold_uncertainty_score":0.9999046},"labels":[],"label_agreement":null},{"id":"W2907933864","doi":"10.1182/blood-2018-99-112906","title":"Residual Allelic Burden Measured By Next-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Neuroblastoma RAS viral oncogene homolog; Minimal residual disease; KRAS; Oncology; Internal medicine; Medicine; Myeloid leukemia; Core binding factor; Leukemia; Cancer; Gene; Biology; Genetics","score_opus":0.08726598268565837,"score_gpt":0.31505686867048516,"score_spread":0.22779088598482677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907933864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951583,0.00047005963,0.000058380963,0.0010941692,0.00013937346,0.00267031,0.00007064557,0.0002240457,0.00011468902],"genre_scores_gemma":[0.99330634,0.00018329303,0.0017059197,0.00029915274,0.0008964884,0.00016216532,0.00043997497,0.0001244013,0.0028822564],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99581486,0.00022810095,0.00085984706,0.0010680058,0.0011116304,0.0009175656],"domain_scores_gemma":[0.9978317,0.00023110001,0.00021696613,0.0006803914,0.0003431612,0.0006966533],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008666167,0.0004912478,0.00067341677,0.0005569024,0.0003490019,0.00014995204,0.00031682296,0.00046754206,0.00006841219],"category_scores_gemma":[0.0024913922,0.00042321516,0.00008548591,0.00070494594,0.00018878058,0.00037595077,0.00041090287,0.00072404003,0.00007492099],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041524722,0.000066752,0.3118995,0.00016220254,0.00015087881,0.00029298212,0.0014462755,0.0000053241697,0.68279195,0.0000021187207,0.0016534616,0.0011132803],"study_design_scores_gemma":[0.021250973,0.0050045117,0.39722642,0.0027018618,0.0013020374,0.0013404997,0.0004678112,0.008977125,0.55939174,0.000017820996,0.00080234144,0.001516838],"about_ca_topic_score_codex":0.00031009445,"about_ca_topic_score_gemma":0.0002162036,"teacher_disagreement_score":0.12340022,"about_ca_system_score_codex":0.0025416813,"about_ca_system_score_gemma":0.0009744144,"threshold_uncertainty_score":0.99982196},"labels":[],"label_agreement":null},{"id":"W2907997089","doi":"10.1182/blood-2018-99-110439","title":"Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Refractory (planetary science); Medicine; Pharmacology; Cancer research; Biology","score_opus":0.01136844868066464,"score_gpt":0.28137589329560836,"score_spread":0.2700074446149437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907997089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865729,0.00041257223,0.00019992716,0.0004675707,0.00013011124,0.011660755,0.00004943603,0.000056984594,0.0004497205],"genre_scores_gemma":[0.9983215,0.0002694901,0.00021974699,0.00016969461,0.00026203916,0.000553552,0.00009854072,0.000055552715,0.00004990292],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99403036,0.0014881125,0.0018100255,0.00086808443,0.001092373,0.00071106805],"domain_scores_gemma":[0.9962461,0.0013925498,0.00087329815,0.00056540687,0.000625,0.00029765296],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029135647,0.000565961,0.0024289468,0.00041451876,0.00016993693,0.00007795497,0.00029597172,0.0003285856,0.000030225217],"category_scores_gemma":[0.0023221658,0.00035295353,0.0002398091,0.0009020561,0.0007618822,0.00021040678,0.00014661194,0.000747864,0.000010960407],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97080314,0.006041834,0.007963897,0.000050123537,0.00139595,0.00010809268,0.002194195,0.0000046837245,0.0094894795,0.000059600225,0.00013079403,0.0017582327],"study_design_scores_gemma":[0.9662567,0.010467345,0.014709306,0.00042383256,0.0013571217,0.00009605301,0.00027983746,0.0015735363,0.0043692742,0.000064528926,0.00006796745,0.00033449157],"about_ca_topic_score_codex":0.0003460826,"about_ca_topic_score_gemma":0.00013088969,"teacher_disagreement_score":0.011748558,"about_ca_system_score_codex":0.0010710527,"about_ca_system_score_gemma":0.00091902533,"threshold_uncertainty_score":0.99989223},"labels":[],"label_agreement":null},{"id":"W2908312420","doi":"10.1182/blood-2018-99-117198","title":"Postnatally Acquired Mutations Underlie the Progression of Transient Leukemia to Myeloid Leukemia of Down Syndrome","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; SickKids Foundation; Hospital for Sick Children; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"GATA1; Biology; Haploinsufficiency; Leukemia; Myeloid leukemia; Genetics; Mutation; Cancer research; Haematopoiesis; Gene; Phenotype; Stem cell","score_opus":0.018335980615901273,"score_gpt":0.30228421754157364,"score_spread":0.2839482369256724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908312420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99131376,0.00019796685,0.0002958069,0.001713372,0.00008428547,0.0013320831,0.00005840597,0.00006140503,0.004942894],"genre_scores_gemma":[0.99546844,0.000025981846,0.0033460115,0.00026692546,0.00011656562,0.00007416283,0.00005281166,0.000045423876,0.0006037053],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99760705,0.00009943802,0.000584507,0.00037622196,0.00087247236,0.00046030988],"domain_scores_gemma":[0.99802554,0.00018358862,0.00016994707,0.00081476674,0.00054975075,0.00025643146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048370313,0.00021913656,0.00045706754,0.0002620009,0.00014599545,0.00001592681,0.0004451208,0.00016421462,0.00024451644],"category_scores_gemma":[0.00027066772,0.00014681394,0.00016172198,0.00084004435,0.00061776966,0.00009286915,0.00014688102,0.00022164313,0.00010237517],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014820716,0.0010396615,0.0025260116,0.00067604834,0.00084219046,0.00038465654,0.007347276,0.00006057517,0.96695316,0.0010997788,0.004075838,0.013512735],"study_design_scores_gemma":[0.0118626235,0.007965949,0.23277992,0.0012126329,0.0009101389,0.0018982937,0.0017008528,0.00051788444,0.7364432,0.00020381421,0.0040505505,0.00045412895],"about_ca_topic_score_codex":0.0001518998,"about_ca_topic_score_gemma":0.00004037185,"teacher_disagreement_score":0.23050995,"about_ca_system_score_codex":0.0003326152,"about_ca_system_score_gemma":0.0019228637,"threshold_uncertainty_score":0.59868985},"labels":[],"label_agreement":null},{"id":"W2908534685","doi":"10.1182/blood-2018-99-111532","title":"Older Adults with Acute Myeloid Leukemia in Rural Areas Are Less Likely to Receive Azacitidine with Worsened Overall Survival","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Leukemia & Lymphoma Society of Canada; University of British Columbia","funders":"","keywords":"Medicine; Azacitidine; Population; Cancer registry; Myelodysplastic syndromes; Cohort; Pediatrics; Internal medicine; Cancer; Bone marrow","score_opus":0.012052438910200776,"score_gpt":0.25732891481309916,"score_spread":0.2452764759028984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908534685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99237406,0.000069821705,0.00012373562,0.001803517,0.00009391309,0.001510341,0.000055290766,0.00015881305,0.0038104898],"genre_scores_gemma":[0.99222237,0.000056895817,0.0031753706,0.0009553261,0.00072426436,0.0001778346,0.00010614215,0.00013444078,0.0024473497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965941,0.00012214886,0.0004078143,0.0007919198,0.0009995427,0.0010845198],"domain_scores_gemma":[0.9976174,0.00011173624,0.00014948822,0.00084782153,0.0006389815,0.00063456735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031528025,0.0005026234,0.00080633006,0.00042147943,0.0001273346,0.00006457537,0.00036557592,0.00022953232,0.00018009459],"category_scores_gemma":[0.000111032925,0.0003610197,0.00007926416,0.0010749532,0.00030876414,0.00022161625,0.00017829766,0.0007145849,0.00020595385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08662967,0.0030606615,0.8194066,0.0008458726,0.0037742846,0.019041976,0.01702268,0.000055462864,0.022388102,0.00043614575,0.011856758,0.015481764],"study_design_scores_gemma":[0.06313683,0.0064462963,0.8709489,0.0050331233,0.0006245146,0.0018211582,0.0056908713,0.00022348344,0.043805014,0.000029675559,0.0009804849,0.0012596585],"about_ca_topic_score_codex":0.0014858944,"about_ca_topic_score_gemma":0.004667955,"teacher_disagreement_score":0.05154226,"about_ca_system_score_codex":0.00084827887,"about_ca_system_score_gemma":0.0012134408,"threshold_uncertainty_score":0.9998842},"labels":[],"label_agreement":null},{"id":"W2908541188","doi":"10.1182/blood-2018-99-116149","title":"Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Gene duplication; Tandem exon duplication; Internal medicine; Medicine; Biology; Gene; Genetics","score_opus":0.02006874160011539,"score_gpt":0.3099494255746088,"score_spread":0.2898806839744934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908541188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658245,0.00012662233,0.00010820777,0.0006849754,0.000035794055,0.0017401475,0.00007960163,0.000048366976,0.0005938455],"genre_scores_gemma":[0.9982837,0.00006853401,0.000566881,0.00010248792,0.00038788517,0.00011105906,0.000110275316,0.000036126414,0.00033306898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777216,0.00017486469,0.00056383206,0.0005124587,0.00060899556,0.00036771427],"domain_scores_gemma":[0.9979707,0.00034612298,0.00025796966,0.00088007544,0.00040833856,0.00013680098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060871936,0.00023832568,0.0003989842,0.00009425747,0.00009132659,0.00004142066,0.000377689,0.00011364438,0.000059534592],"category_scores_gemma":[0.0005370449,0.00014064678,0.000081137914,0.0007325189,0.00024801557,0.00016394941,0.0001310022,0.0005395783,0.00009060222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003978487,0.000873675,0.9511299,0.000012018198,0.00064846664,0.00013978605,0.0037910934,0.000011747017,0.03742455,0.0000044764747,0.0008065026,0.0011792737],"study_design_scores_gemma":[0.014395593,0.003922076,0.96877384,0.000325345,0.00033003895,0.00006830414,0.0003418445,0.0007730063,0.010831197,0.000020641062,0.00007324054,0.00014488024],"about_ca_topic_score_codex":0.0033114518,"about_ca_topic_score_gemma":0.0017358627,"teacher_disagreement_score":0.026593352,"about_ca_system_score_codex":0.0005039915,"about_ca_system_score_gemma":0.00095837103,"threshold_uncertainty_score":0.5735409},"labels":[],"label_agreement":null},{"id":"W2908606174","doi":"10.1182/blood-2018-99-110223","title":"High Healthcare Utilization and Costs in Patients with Higher-Risk MDS/Low Blast Count AML Treated with Azacitidine in Ontario, Canada","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Azacitidine; Population; Emergency medicine; Health care; Emergency department; Internal medicine; Demography; Pediatrics; Environmental health","score_opus":0.010308871555503763,"score_gpt":0.2266011312865167,"score_spread":0.21629225973101296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908606174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99838144,0.000051320963,0.0000020395664,0.0003803941,0.00002854848,0.0008181951,0.00006651038,0.00002188876,0.000249639],"genre_scores_gemma":[0.9987881,0.000025681851,0.00017528019,0.00027373453,0.000045316756,0.000035495024,0.0003209746,0.0000347973,0.0003005876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838716,0.00007522582,0.00023836429,0.0003716797,0.00051262096,0.00041496102],"domain_scores_gemma":[0.9990681,0.00004205584,0.00008491339,0.0002667539,0.00032309425,0.00021509612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114481314,0.00019620695,0.0003293108,0.00016494413,0.00006574809,0.000016253649,0.00006765783,0.000094004,0.000104893916],"category_scores_gemma":[0.000030487266,0.00014391453,0.000007549966,0.00047418373,0.00011355543,0.00008226741,0.00003161516,0.0003767102,0.0000027415858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013942552,0.00033808115,0.9965725,0.00004605712,0.000050505063,0.00014966857,0.00020150821,0.000002025836,0.000020435751,0.000015150229,0.0003511839,0.0008586302],"study_design_scores_gemma":[0.018338483,0.002284831,0.9771362,0.0004202991,0.000053778484,0.0000115179555,0.00006431221,0.0000428683,0.00095117814,0.0000018381705,0.00054296036,0.00015174646],"about_ca_topic_score_codex":0.98629177,"about_ca_topic_score_gemma":0.99859715,"teacher_disagreement_score":0.019436311,"about_ca_system_score_codex":0.0019558577,"about_ca_system_score_gemma":0.002004343,"threshold_uncertainty_score":0.58686644},"labels":[],"label_agreement":null},{"id":"W2908744276","doi":"10.1038/s41375-018-0351-2","title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","year":2019,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council; National Institute of Diabetes and Digestive and Kidney Diseases; Blood Cancer UK; Deutsche Forschungsgemeinschaft; National Cancer Institute; Washington University in St. Louis; Vanderbilt University; National Institute for Health and Care Research; Associazione Italiana per la Ricerca sul Cancro; Celgene","keywords":"Myelodysplastic syndromes; International Prognostic Scoring System; Internal medicine; Monosomy; Karyotype; Biology; Oncology; Chromosome 7 (human); Genetics; Medicine; Chromosome; Bone marrow; Gene","score_opus":0.017877490743142606,"score_gpt":0.2753827537101337,"score_spread":0.2575052629669911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908744276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98937315,0.00016400951,0.00080641295,0.00043632044,0.00013337279,0.0013910943,0.000022507209,0.0002763481,0.0073968084],"genre_scores_gemma":[0.9925908,0.00002567593,0.0037939684,0.00024406046,0.0001545722,0.00010490449,0.00054278714,0.000102871534,0.0024403944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99705684,0.000106372056,0.00040709888,0.00067482184,0.0008797717,0.00087511935],"domain_scores_gemma":[0.99780655,0.0007490672,0.0001476693,0.0006304902,0.00024462232,0.0004216203],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024369279,0.0003894188,0.0006026832,0.00028761872,0.00016048494,0.00009502913,0.00024417092,0.00016274517,0.00080927025],"category_scores_gemma":[0.0005191443,0.0002928454,0.000092272676,0.00064228417,0.0002835987,0.00023472763,0.000150525,0.0005305617,0.0013675035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016031737,0.0001547783,0.97198796,0.0014394469,0.0004109018,0.0012666893,0.0012182285,0.00035474275,0.007338852,0.0012259228,0.003219278,0.0097800465],"study_design_scores_gemma":[0.00476724,0.0020149553,0.9744233,0.0004898484,0.0002720272,0.0007785914,0.00037474532,0.009795966,0.0007331371,0.0004282929,0.0054346886,0.00048721305],"about_ca_topic_score_codex":0.00070538133,"about_ca_topic_score_gemma":0.0002531776,"teacher_disagreement_score":0.009441223,"about_ca_system_score_codex":0.0019881902,"about_ca_system_score_gemma":0.0013622575,"threshold_uncertainty_score":0.9999524},"labels":[],"label_agreement":null},{"id":"W2908908514","doi":"10.1182/blood-2018-99-113090","title":"Molecular Residual Disease Monitoring Provides Insufficient Lead-Time to Prevent Morphologic Relapse in the Majority of Patients with Core-Binding Factor AML","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Minimal residual disease; Medicine; Internal medicine; Bone marrow; Oncology; Myeloid leukemia; Pathology","score_opus":0.021612390333653423,"score_gpt":0.28232590341301245,"score_spread":0.260713513079359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908908514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977339,0.00006701964,0.000013249652,0.00030847648,0.000035300956,0.0015774382,0.00006184064,0.000029964714,0.00017284162],"genre_scores_gemma":[0.99877626,0.0000032412615,0.0007352162,0.00007806439,0.000115866766,0.00008289192,0.000025431355,0.000026332185,0.00015667883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979451,0.00014568713,0.0002917812,0.00037522474,0.0008304434,0.00041179243],"domain_scores_gemma":[0.99880964,0.000100798025,0.00009800219,0.0005766067,0.00021480834,0.00020014709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038038843,0.00018164191,0.0002665421,0.00019381866,0.00007605794,0.000020031286,0.0003096671,0.00007123563,0.00004601066],"category_scores_gemma":[0.000646685,0.00011309087,0.000051289357,0.00051063206,0.00016288219,0.00006165343,0.00017354164,0.0003174783,0.00008670123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016392698,0.0053225677,0.9310537,0.00018274825,0.00012380528,0.0004968536,0.0021723488,0.00002028086,0.058067914,0.000020572925,0.00028802795,0.0006119069],"study_design_scores_gemma":[0.004110787,0.0029827363,0.90424496,0.00034708765,0.00017517316,0.000007806028,0.0002407071,0.000038826216,0.08755133,0.000015929088,0.000090138594,0.00019454214],"about_ca_topic_score_codex":0.00005520932,"about_ca_topic_score_gemma":0.0000029690425,"teacher_disagreement_score":0.029483417,"about_ca_system_score_codex":0.0001785084,"about_ca_system_score_gemma":0.00024694813,"threshold_uncertainty_score":0.46117118},"labels":[],"label_agreement":null},{"id":"W2908999604","doi":"10.1182/blood-2018-99-113403","title":"Developing Applicable and Cost-Efficient Screens for Early Detection of AML","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Leukemia; Myeloid; Computational biology; Biology; Medicine; Bioinformatics; Oncology; Internal medicine","score_opus":0.03616010690561902,"score_gpt":0.31531506695959677,"score_spread":0.2791549600539778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908999604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95060885,0.000075066535,0.04714664,0.00017942734,0.000021803577,0.0009908836,0.0000075884536,0.000028600947,0.0009411572],"genre_scores_gemma":[0.98863333,0.000011465842,0.010735874,0.00007356667,0.00017333818,0.00009648837,0.0000035805929,0.00001582,0.000256546],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99933165,0.000010114684,0.00013303367,0.00017150116,0.00014484624,0.00020886364],"domain_scores_gemma":[0.99944913,0.00006025259,0.000038911774,0.00015457501,0.00022128005,0.00007582615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021481415,0.00006577857,0.00014779743,0.000083240775,0.00007609287,0.000008274875,0.000046812173,0.00006245895,0.0000082719625],"category_scores_gemma":[0.000111744164,0.000057448146,0.00002650381,0.00016428661,0.000110806344,0.000018108874,0.0000468984,0.0000751526,0.000012858538],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008594073,0.00043246493,0.013786303,0.00049106876,0.00026394252,0.000009809451,0.0006622921,0.0000023522405,0.90853953,0.0014670996,0.00037233034,0.073113374],"study_design_scores_gemma":[0.0056833136,0.0010205553,0.033949446,0.00007807929,0.000112713285,0.000058491805,0.0001119612,0.0016127334,0.9476232,0.0000812755,0.009563844,0.000104368555],"about_ca_topic_score_codex":0.00009329637,"about_ca_topic_score_gemma":0.000018761253,"teacher_disagreement_score":0.07300901,"about_ca_system_score_codex":0.000051081315,"about_ca_system_score_gemma":0.000112998954,"threshold_uncertainty_score":0.23426674},"labels":[],"label_agreement":null},{"id":"W2909129451","doi":"10.1182/blood-2018-99-113062","title":"Genetic Characterization of ABT-199 Sensitivity in Human AML","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"NPM1; Myeloid leukemia; Gene mutation; Leukemia; Oncology; Mutation; Internal medicine; Concomitant; Cancer research; Cytarabine; Biology; Medicine; Gene; Genetics; Karyotype","score_opus":0.016490683470503722,"score_gpt":0.2881090579277114,"score_spread":0.2716183744572077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909129451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99810934,0.000008584115,0.000092961556,0.00015517263,0.00002457144,0.00023365261,0.000006692284,0.000020691932,0.0013483554],"genre_scores_gemma":[0.9988955,0.000011341236,0.0003692959,0.00010937345,0.00028056325,0.000005525676,0.000028388691,0.000015060224,0.0002848987],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992565,0.00005342239,0.00017427038,0.00015620684,0.00018352421,0.00017606733],"domain_scores_gemma":[0.9995245,0.000018532277,0.000048315716,0.00024279483,0.0001071961,0.000058685815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002073655,0.000067972964,0.00017550787,0.00013466967,0.000026304766,0.00000461012,0.000041068866,0.000069135676,0.00009432517],"category_scores_gemma":[0.00006124453,0.000064214095,0.00002730223,0.00021900324,0.00010921338,0.000034684712,0.000044982397,0.00011929743,0.000044446795],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027994856,0.00023669476,0.13603489,0.000042265343,0.000017672355,0.00007408602,0.00020084022,6.885089e-8,0.8623802,0.00003365743,0.000023770453,0.0009278575],"study_design_scores_gemma":[0.0015789886,0.00020170533,0.676837,0.000041417366,0.000023866703,0.00004150641,0.000009264611,0.000109098604,0.32095683,0.000013127202,0.0001456803,0.00004150291],"about_ca_topic_score_codex":0.0001319118,"about_ca_topic_score_gemma":0.0000777815,"teacher_disagreement_score":0.5414234,"about_ca_system_score_codex":0.000042026804,"about_ca_system_score_gemma":0.00009093761,"threshold_uncertainty_score":0.26185748},"labels":[],"label_agreement":null},{"id":"W2909182124","doi":"10.1182/blood-2018-99-111514","title":"Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Internal medicine; Cytarabine; Chemotherapy regimen; Oncology; Myelodysplastic syndromes; Decitabine; Regimen; Gastroenterology; Leukemia; Chemotherapy; Bone marrow","score_opus":0.010559426140119,"score_gpt":0.27632452406411334,"score_spread":0.26576509792399433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909182124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952799,0.00011352941,0.000005500729,0.000117200434,0.00004283335,0.00394323,0.00004163631,0.000047956917,0.00040818058],"genre_scores_gemma":[0.9989298,0.0001054851,0.0005111584,0.000032159725,0.000047920275,0.00014711147,0.00006724802,0.00007430598,0.000084824846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969665,0.00021578239,0.00070877577,0.0006633574,0.0008261342,0.0006194838],"domain_scores_gemma":[0.9979856,0.00046023092,0.0003192147,0.0006427278,0.0003526731,0.00023953656],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050562527,0.00040724542,0.0011267888,0.00072931417,0.000057481062,0.000013102017,0.00024571098,0.00020790259,0.00007381665],"category_scores_gemma":[0.000261054,0.00029669487,0.000044756875,0.0015170559,0.00047382055,0.00013652218,0.00015824143,0.0005335229,0.0000061446212],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13394083,0.017785959,0.812708,0.00026602735,0.0023482826,0.001132109,0.019534865,0.000010717064,0.005541163,0.000012160835,0.00006159982,0.0066582714],"study_design_scores_gemma":[0.36060256,0.021667052,0.6112856,0.00052946,0.0005795114,0.000017722601,0.001021016,0.000114802235,0.0039284676,0.0000011219229,0.000017519567,0.00023510249],"about_ca_topic_score_codex":0.00075347506,"about_ca_topic_score_gemma":0.00220031,"teacher_disagreement_score":0.22666173,"about_ca_system_score_codex":0.00028991717,"about_ca_system_score_gemma":0.0005986254,"threshold_uncertainty_score":0.9999485},"labels":[],"label_agreement":null},{"id":"W2909627742","doi":"10.1101/513887","title":"Genetic Landscape of Electron Transport Chain Complex I Dependency in Acute Myeloid Leukemia","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cegep Edouard Montpetit; Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Université de Montréal; Terry Fox Foundation; Government of Canada; Compute Canada; Fondation du cancer du sein du Québec; McGill University; Génome Québec; Genome Canada","keywords":"Myeloid leukemia; Oxidative phosphorylation; NPM1; Cancer research; Leukemia; Gene; Apoptosis; In vitro; Biology; Chemistry; Genetics; Biochemistry","score_opus":0.015094888326215902,"score_gpt":0.25095989442347955,"score_spread":0.23586500609726363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909627742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99411327,0.0016562323,0.0006473968,0.0002684357,0.0003393853,0.0023650732,0.00028470837,0.00022118445,0.00010430374],"genre_scores_gemma":[0.99214774,0.0017908056,0.004950012,0.00020932787,0.00034434968,0.00023006622,0.000005512976,0.00027102174,0.000051165018],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99461937,0.00020414707,0.0012722068,0.0015069941,0.001113209,0.0012841031],"domain_scores_gemma":[0.9960476,0.00010014295,0.0005326991,0.002253916,0.0006098661,0.00045578816],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00092488446,0.00085854786,0.0017950032,0.0011121397,0.000062644904,0.000041056923,0.0009588181,0.0011367259,0.00021785553],"category_scores_gemma":[0.00012323789,0.0008952667,0.0003697282,0.0010892192,0.00018923568,0.00010731556,0.00040181653,0.0025390037,0.00013365252],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055688876,0.00023418682,0.21541494,0.0018700061,0.00055968564,0.0007561781,0.000033651453,0.00044503086,0.7796174,0.000102268845,0.0004043023,0.0000054447682],"study_design_scores_gemma":[0.003404915,0.00032720593,0.8211251,0.00077712536,0.00038596932,4.5779774e-7,0.000005159512,0.0029244372,0.1694201,0.0000024360606,0.00083799893,0.00078908174],"about_ca_topic_score_codex":0.00040333287,"about_ca_topic_score_gemma":0.00003066966,"teacher_disagreement_score":0.6101973,"about_ca_system_score_codex":0.0019568389,"about_ca_system_score_gemma":0.0060172193,"threshold_uncertainty_score":0.9997622},"labels":[],"label_agreement":null},{"id":"W2910326971","doi":"10.1182/blood-2018-99-118577","title":"PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Medicine; Tolerability; Azacitidine; Internal medicine; Oncology; Cohort; Adverse effect; Cancer; Pembrolizumab; Immunotherapy","score_opus":0.017595141718359266,"score_gpt":0.29007160154806483,"score_spread":0.2724764598297056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910326971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99643743,0.00012764292,0.00012798124,0.000363364,0.00004095112,0.0004296341,0.000039268332,0.000092248105,0.0023414844],"genre_scores_gemma":[0.9976344,0.00010193736,0.0011912625,0.00009129912,0.0003068137,0.000017624661,0.000074223266,0.000049645376,0.00053278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766546,0.00018148027,0.00038845968,0.0006373087,0.0005257398,0.00060155574],"domain_scores_gemma":[0.99845535,0.00023478066,0.0001043466,0.0006381498,0.0001512889,0.0004160908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036242072,0.00027778104,0.00067091966,0.0006818292,0.00015573,0.000046326906,0.00019262529,0.0001902983,0.0005443762],"category_scores_gemma":[0.00017992151,0.0002168526,0.000075059026,0.0017518646,0.00042683948,0.00011162893,0.00012235269,0.0005651705,0.00008585432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025684573,0.006417482,0.9071001,0.00041294273,0.0123350965,0.014958952,0.004004069,0.00020519133,0.005001255,0.00045452063,0.00028794646,0.023137903],"study_design_scores_gemma":[0.020134045,0.003415565,0.9685127,0.00011439199,0.0034298466,0.00086126366,0.00009195704,0.0011841094,0.001411905,0.000026192516,0.00050443655,0.00031359028],"about_ca_topic_score_codex":0.00040472418,"about_ca_topic_score_gemma":0.0003859009,"teacher_disagreement_score":0.061412625,"about_ca_system_score_codex":0.0001387619,"about_ca_system_score_gemma":0.00029144657,"threshold_uncertainty_score":0.8842992},"labels":[],"label_agreement":null},{"id":"W2910614206","doi":"10.1182/blood-2018-99-110465","title":"Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Decitabine; Internal medicine; Myelodysplastic syndromes; Adverse effect; Neutropenia; International Prognostic Scoring System; Phases of clinical research; Gastroenterology; Febrile neutropenia; Hypomethylating agent; Clinical trial; Bone marrow; Chemotherapy; Biology","score_opus":0.021611702975837824,"score_gpt":0.3030744257456999,"score_spread":0.2814627227698621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910614206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934078,0.00012610317,0.00014730879,0.000024047704,0.00015721601,0.0057478347,0.00027478317,0.00007800182,0.000036922633],"genre_scores_gemma":[0.9977318,0.00010041451,0.0010219206,0.000016664415,0.00016823107,0.00030944817,0.00007723115,0.00014068473,0.00043362676],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99285275,0.0011185982,0.0024948474,0.0010435177,0.0014680922,0.001022176],"domain_scores_gemma":[0.99083626,0.005377999,0.001428379,0.0012303236,0.00073335203,0.00039371083],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027698737,0.0006913592,0.002682885,0.0013821428,0.00012745881,0.00004040024,0.0006057514,0.00025554284,0.00018406831],"category_scores_gemma":[0.012337253,0.00043625632,0.00022716752,0.0018238055,0.0008381727,0.00019431023,0.00040072892,0.0008348016,0.000028355065],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94559216,0.010936023,0.013946058,0.00055461295,0.0022277634,0.0032550732,0.007005267,0.00008274212,0.009087753,8.0464804e-7,0.000019955374,0.0072918036],"study_design_scores_gemma":[0.77043885,0.047136378,0.16858803,0.0016537394,0.002022084,0.00040154933,0.0006099518,0.0021563487,0.0065133106,0.0000030227422,0.0000033761596,0.00047335683],"about_ca_topic_score_codex":0.0012164621,"about_ca_topic_score_gemma":0.0016364453,"teacher_disagreement_score":0.17515329,"about_ca_system_score_codex":0.0014491272,"about_ca_system_score_gemma":0.0027689787,"threshold_uncertainty_score":0.9998089},"labels":[],"label_agreement":null},{"id":"W2911094905","doi":"10.1182/blood-2018-99-113582","title":"Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Midostaurin; Internal medicine; Clinical endpoint; Maintenance therapy; Surgery; Transplantation; Oncology; Chemotherapy regimen; Randomized controlled trial; Myeloid leukemia; Chemotherapy","score_opus":0.01583776255456517,"score_gpt":0.29424815104342794,"score_spread":0.2784103884888628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911094905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99379474,0.0017806455,0.00006448391,0.00017030296,0.00010987495,0.0030742246,0.00022339981,0.000058622856,0.00072371354],"genre_scores_gemma":[0.9975207,0.00010642266,0.0013826666,0.00011567274,0.00030569194,0.0002615865,0.00009763283,0.00005773279,0.00015190513],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969055,0.0005499102,0.0009121998,0.0004490456,0.00063753733,0.00054579147],"domain_scores_gemma":[0.9984783,0.00033543564,0.00018457364,0.000435687,0.00027611534,0.00028987366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010799406,0.00028677707,0.0012969995,0.00034552434,0.000048798098,0.000020077834,0.00019422668,0.00020756437,0.00017990594],"category_scores_gemma":[0.00017089673,0.00022932263,0.00025602806,0.00046284418,0.0004988797,0.000069537295,0.000049275564,0.00041801817,0.00001848545],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8970485,0.0007224667,0.0010085413,0.0006213054,0.00029474363,0.00063812913,0.012845871,0.0000017380885,0.08560318,0.0000059021327,0.000071061506,0.0011385806],"study_design_scores_gemma":[0.64475715,0.0024572518,0.000031956726,0.000348553,0.00046753514,0.00003081444,0.0005727208,0.000109463355,0.35094807,0.000011174653,0.0001188333,0.00014645993],"about_ca_topic_score_codex":0.00015424412,"about_ca_topic_score_gemma":0.00013103477,"teacher_disagreement_score":0.2653449,"about_ca_system_score_codex":0.00018418419,"about_ca_system_score_gemma":0.0009562741,"threshold_uncertainty_score":0.93515056},"labels":[],"label_agreement":null},{"id":"W2911244264","doi":"10.1182/blood-2018-99-118938","title":"Impact of Genetic Profile on Clinical Outcomes in Adults ≥60 with AML: The Princess Margaret Cancer Centre Experience","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Internal medicine; Oncology; Acute promyelocytic leukemia; Leukemia; Cancer; Bone marrow; Myeloid; Gene; Genetics; Biology","score_opus":0.029802715637877737,"score_gpt":0.38533895859087514,"score_spread":0.3555362429529974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911244264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976434,0.00006035963,0.0000026246823,0.0005596334,0.000043404365,0.0007166713,0.000020666235,0.000017301636,0.0009359199],"genre_scores_gemma":[0.9987247,0.00008066115,0.00036610643,0.00015923787,0.00017467093,0.00006824379,0.0000033976644,0.000021452599,0.0004015323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985517,0.00009684866,0.0003167576,0.0002951099,0.00040168245,0.0003378577],"domain_scores_gemma":[0.9989415,0.00016043278,0.000102230886,0.0005128446,0.00015783265,0.00012517156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018492203,0.00013639245,0.00031399305,0.000058706348,0.00003462921,0.000008079149,0.00025166015,0.00007859502,0.0004145217],"category_scores_gemma":[0.00023184522,0.00006587126,0.000082400205,0.00025323997,0.00039938246,0.00003188709,0.00007715875,0.0002923683,0.000028048766],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009593018,0.0006229185,0.9941992,0.000030793228,0.000113419825,0.00006723795,0.0015463326,0.0000020155617,0.000099392855,0.000004646131,0.00032369,0.0020310415],"study_design_scores_gemma":[0.005328174,0.0019753748,0.9897413,0.00026646644,0.000036328744,0.00001307426,0.00028565296,0.000110925845,0.002068156,0.0000022151899,0.000092419,0.00007991334],"about_ca_topic_score_codex":0.0013953934,"about_ca_topic_score_gemma":0.0006817146,"teacher_disagreement_score":0.0044579105,"about_ca_system_score_codex":0.00009756632,"about_ca_system_score_gemma":0.0005478566,"threshold_uncertainty_score":0.4538722},"labels":[],"label_agreement":null},{"id":"W2911268218","doi":"10.1182/blood-2018-99-110021","title":"The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Stem cell; Biology; Haematopoiesis; CD34; Progenitor cell; Cell biology; Population; Myeloid leukemia; Mitochondrion; Cancer research","score_opus":0.012341740049882253,"score_gpt":0.267667596272133,"score_spread":0.25532585622225074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911268218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98995745,0.0016153088,0.000119862394,0.006025857,0.00016747479,0.0015821644,0.00002479552,0.000045866433,0.00046121064],"genre_scores_gemma":[0.99548405,0.0001276762,0.00045012616,0.0016389636,0.0006766492,0.0002209365,0.0000019699364,0.000052704043,0.0013469404],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99776345,0.00022782902,0.00035346646,0.00040041536,0.00052262755,0.00073222944],"domain_scores_gemma":[0.998317,0.0002515072,0.000047543297,0.0008035986,0.00016517888,0.00041514297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010841364,0.00022940744,0.00035757603,0.00014704057,0.00029513735,0.00011699791,0.00046935066,0.00009679158,0.00006724883],"category_scores_gemma":[0.0001344524,0.00012965214,0.00006417433,0.000633098,0.00020545104,0.00005893158,0.00044067507,0.00032420087,0.0005994016],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013611501,0.007499745,0.06407182,0.0020440475,0.0036935913,0.006194666,0.066366866,0.000116071154,0.4180654,0.047596604,0.11898783,0.25175187],"study_design_scores_gemma":[0.0072249565,0.0013764842,0.00911989,0.00020152464,0.00032907826,0.0006066096,0.0047991606,0.00037226497,0.6097689,0.000111497175,0.365605,0.00048463352],"about_ca_topic_score_codex":0.00031368318,"about_ca_topic_score_gemma":0.00036316607,"teacher_disagreement_score":0.25126722,"about_ca_system_score_codex":0.000082953506,"about_ca_system_score_gemma":0.00021899256,"threshold_uncertainty_score":0.7704295},"labels":[],"label_agreement":null},{"id":"W2911359328","doi":"10.1158/2326-6074.cricimteatiaacr18-b170","title":"Abstract B170: Therapeutic implications of altered epigenetics and DNA damage responses in IDH2-mutated hematologic diseases","year":2019,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"IDH2; Epigenetics; Cancer research; Biology; Myeloid; DNA methylation; Histone; Myeloid leukemia; IDH1; Haematopoiesis; Mutation; Stem cell; Genetics; Gene; Gene expression","score_opus":0.08231214431460641,"score_gpt":0.42227017969243935,"score_spread":0.3399580353778329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911359328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742993,0.01895452,0.000002936412,0.0047390237,0.00005835814,0.0011269837,0.00007937167,0.00003137635,0.0007081147],"genre_scores_gemma":[0.99340945,0.005276939,0.00005156924,0.00010548254,0.000028333849,0.00025725903,0.000037764115,0.000034528057,0.0007986413],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975678,0.0004633392,0.00042528252,0.0004787807,0.00033560558,0.0007292439],"domain_scores_gemma":[0.9971524,0.0013098205,0.000085400105,0.00084525044,0.00047425006,0.00013290721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072759675,0.0001661683,0.0005168489,0.00073052215,0.00009429687,0.000019482079,0.00038266202,0.00022981415,0.0006565686],"category_scores_gemma":[0.00049613963,0.0001413358,0.000057781097,0.0008837028,0.0011285695,0.000075300704,0.00028098785,0.0008965969,0.00008514071],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020118067,0.00018760005,0.35626057,0.00023298863,0.00017224443,0.00003943204,0.00031038927,0.0000042680354,0.63536584,0.00040605204,0.00023813682,0.0047706594],"study_design_scores_gemma":[0.0023176703,0.00045461534,0.9546445,0.00014702382,0.000021870463,0.000045566445,0.0006335243,0.00006558906,0.039886437,0.0011164983,0.0005518698,0.00011482052],"about_ca_topic_score_codex":0.00038850773,"about_ca_topic_score_gemma":0.000060288537,"teacher_disagreement_score":0.59838396,"about_ca_system_score_codex":0.00040975751,"about_ca_system_score_gemma":0.0012971925,"threshold_uncertainty_score":0.71889657},"labels":[],"label_agreement":null},{"id":"W2911441731","doi":"10.1182/blood-2018-99-115842","title":"Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Medicine; Oncology; Leukemia; Internal medicine; Cancer research; Immunology","score_opus":0.021026784088619226,"score_gpt":0.2961449774553005,"score_spread":0.27511819336668125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911441731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994861,0.0002032708,0.00007026534,0.00028898718,0.00022365242,0.0028520187,0.00006120265,0.00011253055,0.001327083],"genre_scores_gemma":[0.995869,0.000052287225,0.002472502,0.00039701798,0.00031912042,0.00012744978,0.00022262597,0.00008005405,0.0004599364],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970112,0.00028017382,0.00073757046,0.00055245205,0.0008673084,0.000551308],"domain_scores_gemma":[0.9971519,0.000161345,0.0003582416,0.0008781834,0.0012389875,0.00021135622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003114414,0.00035345674,0.00066012295,0.00012444129,0.00018547551,0.00003590582,0.00044115802,0.0002415082,0.00006523118],"category_scores_gemma":[0.00038492773,0.00024005318,0.00018773506,0.0008264636,0.000779779,0.000107600725,0.00018226505,0.0006126885,0.00011986655],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038356163,0.0013144662,0.014537617,0.00024059763,0.0026463594,0.00042330733,0.0015543614,0.000028338556,0.9383611,0.0003147048,0.0012187564,0.0010042449],"study_design_scores_gemma":[0.09519526,0.003375746,0.0049635815,0.00016374316,0.00077637524,0.00004666779,0.00016795768,0.0009977812,0.893699,0.000051703388,0.00029967132,0.00026250022],"about_ca_topic_score_codex":0.00019647696,"about_ca_topic_score_gemma":0.000009556564,"teacher_disagreement_score":0.0568391,"about_ca_system_score_codex":0.0002706227,"about_ca_system_score_gemma":0.00090745656,"threshold_uncertainty_score":0.9789085},"labels":[],"label_agreement":null},{"id":"W2911576962","doi":"10.1182/blood-2018-99-114314","title":"Identification of Gene Regulatory Networks Governing Stemness Properties of Human HSC and LSC","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; University Health Network; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Stem cell; Biology; Hematopoietic stem cell; Haematopoiesis; Chromatin; Gene; Progenitor cell; Transcription factor; Computational biology; Cell biology; Genetics","score_opus":0.024989102033489103,"score_gpt":0.27207084111767754,"score_spread":0.24708173908418843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911576962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99777454,0.0013112167,0.00016100905,0.000036538484,0.0000367881,0.0002295568,0.0000028874463,0.000016841941,0.00043064484],"genre_scores_gemma":[0.9986917,0.000031743188,0.00012180355,0.000013292587,0.00022714793,0.000008963712,0.000005577551,0.000016431613,0.00088334334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99913263,0.000040920066,0.0002842699,0.0001545369,0.0002568286,0.00013081185],"domain_scores_gemma":[0.9992409,0.000013506905,0.00014787985,0.00031091226,0.00023656822,0.00005026945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036837248,0.00006840047,0.00019738077,0.000058971367,0.000057445166,0.000007175754,0.000081709666,0.000071312184,0.000018212324],"category_scores_gemma":[0.00006537556,0.000056260273,0.000026543074,0.000116079835,0.00030222905,0.000054892214,0.00005608235,0.00009575054,0.000003965037],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006190047,0.000113095644,0.010746709,0.00022069659,0.000075810305,0.0000025933277,0.00048717242,0.0000016504251,0.98692137,0.000070162714,0.00013096433,0.0011678768],"study_design_scores_gemma":[0.0014901118,0.00024406418,0.088819146,0.00020239479,0.00011518855,0.000018437717,0.0002100186,0.0009099021,0.90788364,0.000006927046,0.000043401553,0.000056780482],"about_ca_topic_score_codex":0.000043676984,"about_ca_topic_score_gemma":0.0000061356977,"teacher_disagreement_score":0.07903774,"about_ca_system_score_codex":0.000028045004,"about_ca_system_score_gemma":0.000066167384,"threshold_uncertainty_score":0.22942273},"labels":[],"label_agreement":null},{"id":"W2911644503","doi":"10.1182/blood-2018-99-112557","title":"The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Internal medicine; Cytarabine; Clinical endpoint; Transplantation; Regimen; Chemotherapy regimen; Phases of clinical research; Gastroenterology; Daunorubicin; Hematopoietic stem cell transplantation; Chemotherapy; Surgery; Oncology; Randomized controlled trial","score_opus":0.017697652083110034,"score_gpt":0.3120321033799052,"score_spread":0.2943344512967952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911644503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987179,0.00004026527,0.000018183742,0.0000058745013,0.000033080447,0.00089202414,0.00017445277,0.000010492121,0.000107705855],"genre_scores_gemma":[0.9996708,0.00006768568,0.000045375247,0.0000039409324,0.000024377754,0.000037347578,0.000117594645,0.000027984484,0.0000048985107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979973,0.00034849934,0.0004921912,0.00027928187,0.0006395056,0.00024322137],"domain_scores_gemma":[0.99807936,0.0004967427,0.0003223143,0.00063449447,0.0003515198,0.000115560535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048966234,0.00017789793,0.0005882623,0.00049456104,0.000049965027,0.0000069268335,0.0001939059,0.00006770266,0.000074245305],"category_scores_gemma":[0.00007601601,0.0001111164,0.000117066826,0.001160782,0.0001736186,0.00010869068,0.000020473391,0.00023048003,0.0000023375294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016811654,0.02894374,0.9235568,0.00016400548,0.0031615621,0.00006337643,0.02315495,0.00019266634,0.002125661,0.0000041702206,0.000033704506,0.0017876977],"study_design_scores_gemma":[0.08627923,0.026340215,0.86290693,0.00006629352,0.0027930497,4.1022275e-7,0.005278862,0.00013018507,0.016093938,0.0000024741364,5.099029e-7,0.00010787279],"about_ca_topic_score_codex":0.0025944023,"about_ca_topic_score_gemma":0.0024719918,"teacher_disagreement_score":0.069467574,"about_ca_system_score_codex":0.000075197706,"about_ca_system_score_gemma":0.00028480386,"threshold_uncertainty_score":0.45311952},"labels":[],"label_agreement":null},{"id":"W2911701104","doi":"10.1016/j.bbmt.2018.12.408","title":"The Impact of Hematopoietic Cell Transplantation (HCT) on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML (sAML)","year":2019,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Cytarabine; Hazard ratio; Transplantation; Hematopoietic cell; Confidence interval; Overall survival; Haematopoiesis; Chemotherapy; Stem cell","score_opus":0.011976321138585275,"score_gpt":0.28846697376775265,"score_spread":0.2764906526291674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911701104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982163,0.00012441582,0.000050584757,0.000007638144,0.000043599113,0.0009931938,0.00052225543,0.000006940337,0.000035083987],"genre_scores_gemma":[0.9980092,0.001071536,0.000055343065,0.000003343797,0.0000069802973,0.000025909336,0.0008090993,0.000015752337,0.0000028094605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983125,0.00039756598,0.0005584863,0.00028820755,0.00025392234,0.00018935237],"domain_scores_gemma":[0.9984327,0.0006532907,0.00038214677,0.00028443674,0.00017788593,0.00006952438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043347702,0.0001800573,0.0006691491,0.00049185543,0.00003209135,0.0000029600665,0.00011187016,0.00012271157,0.000028929855],"category_scores_gemma":[0.000014211919,0.00011776129,0.00010190153,0.00050381373,0.00016761795,0.000104605046,0.000005555366,0.00018591345,4.1535736e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027203793,0.004578585,0.89715827,0.0006534512,0.001856673,0.00001518936,0.012559069,0.0003758308,0.053359307,0.000019665862,0.000001819705,0.0022183764],"study_design_scores_gemma":[0.06257073,0.021726811,0.8805564,0.00011218575,0.003466342,0.0000015001164,0.0033121933,0.00011243049,0.028010257,0.000007915094,2.1809757e-7,0.000123019],"about_ca_topic_score_codex":0.0020878036,"about_ca_topic_score_gemma":0.0015390376,"teacher_disagreement_score":0.035366938,"about_ca_system_score_codex":0.000023677614,"about_ca_system_score_gemma":0.00015134014,"threshold_uncertainty_score":0.4802166},"labels":[],"label_agreement":null},{"id":"W2912279633","doi":"10.1182/blood.v128.22.1683.1683","title":"Differential Gene Expression Using RNA Sequencing Between Elderly Acute Myeloid Leukemia (AML) Patients with Long Versus Short-Term Survival","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"","keywords":"Oncology; Myeloid leukemia; Medicine; Internal medicine; Population; Survival analysis; Transcriptome; Bioinformatics; Biology; Gene; Genetics; Gene expression","score_opus":0.036512948176246104,"score_gpt":0.28961118042338724,"score_spread":0.2530982322471411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912279633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928132,0.00003428644,0.005568286,0.000047634836,0.00028013892,0.0006563084,0.00010265194,0.00014192784,0.0003555267],"genre_scores_gemma":[0.9959911,0.00003993161,0.0025416075,0.000012745463,0.00091383286,0.000019526584,0.00014508475,0.00012144628,0.00021473598],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99658984,0.00012852426,0.00045517882,0.0007307871,0.00118957,0.0009060906],"domain_scores_gemma":[0.9980983,0.00020979247,0.00014083003,0.0007515271,0.00030960428,0.0004899248],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016474849,0.00042973857,0.0006288278,0.00022857879,0.00023590737,0.000060820592,0.00034189102,0.00027415532,0.00019858833],"category_scores_gemma":[0.00008905577,0.0002701492,0.00014418885,0.00024523752,0.00017767762,0.00033404774,0.00029499072,0.0004577771,0.000043727967],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011661516,0.00011370714,0.4007492,0.000039885963,0.00059192756,0.00026212254,0.0000896436,0.0000010541016,0.5899732,0.0000021267804,0.000014517131,0.0069964402],"study_design_scores_gemma":[0.024080358,0.0013494221,0.38158396,0.00056808593,0.0012203226,0.000031567437,0.00003105965,0.000017052836,0.59064245,0.0000053888443,0.0000139719,0.00045635668],"about_ca_topic_score_codex":0.00010009674,"about_ca_topic_score_gemma":0.0000143642765,"teacher_disagreement_score":0.022914207,"about_ca_system_score_codex":0.0013444088,"about_ca_system_score_gemma":0.00096581207,"threshold_uncertainty_score":0.9999751},"labels":[],"label_agreement":null},{"id":"W2912419506","doi":"10.1111/ejh.13216","title":"Influence of <i>FLT3‐ITD</i> and <i>NPM1 </i>status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML","year":2019,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"NPM1; Medicine; Internal medicine; Proportional hazards model; Cumulative incidence; Transplantation; Hematopoietic stem cell transplantation; Oncology; Biology; Gene; Karyotype; Genetics","score_opus":0.005951508004904088,"score_gpt":0.22412590677303704,"score_spread":0.21817439876813294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912419506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754536,0.00016295203,0.00003095342,0.00032905172,0.000043314878,0.00031551448,0.000009947193,0.000006389684,0.0015565017],"genre_scores_gemma":[0.9984712,0.00012138709,0.0008098905,0.0004820237,0.000011747193,8.4512436e-7,0.0000038023172,0.00004280986,0.000056295514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976411,0.00039384834,0.0008114543,0.0002286533,0.00047554495,0.0004494324],"domain_scores_gemma":[0.9986514,0.00019886756,0.00035669698,0.0002943742,0.00022992685,0.00026874433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004994075,0.00021737089,0.0008857688,0.00033262055,0.000020939822,0.000007995997,0.0002353688,0.00005554707,0.000039311795],"category_scores_gemma":[0.00006681237,0.00014585182,0.00008263609,0.00016106322,0.00022325946,0.0000768097,0.000063637024,0.0005550503,0.000054992128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023224896,0.0003614195,0.9879352,0.0002747976,0.000085014326,0.0036179556,0.00055748085,0.00037794176,0.0042076833,0.0000571232,0.000045333407,0.00015756597],"study_design_scores_gemma":[0.010485387,0.0049953363,0.97463125,0.0003862266,0.00008489542,0.0022877932,0.00006340918,0.0000075322937,0.0066917157,0.0000072655657,0.00020426938,0.00015494667],"about_ca_topic_score_codex":0.000004975469,"about_ca_topic_score_gemma":0.000002931109,"teacher_disagreement_score":0.013303973,"about_ca_system_score_codex":0.00005078747,"about_ca_system_score_gemma":0.00020490002,"threshold_uncertainty_score":0.59476644},"labels":[],"label_agreement":null},{"id":"W2912825657","doi":"10.1038/s41409-019-0439-y","title":"Outcome of allografting for AML-CR2 is equivalent across BSBMT and EBMT and is associated with encouraging OS and DFS across all age groups","year":2019,"lang":"en","type":"letter","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Distributed File System; Oncology; Internal medicine; Operating system","score_opus":0.04350163831757877,"score_gpt":0.3353134391491834,"score_spread":0.29181180083160463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912825657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9475726,0.0004866602,0.00086876407,0.04661111,0.00008711492,0.0020587286,0.0021765863,0.00006289812,0.00007555724],"genre_scores_gemma":[0.9215007,0.001306797,0.0010919354,0.06981085,0.00034054148,0.00013970575,0.0036177547,0.00018128553,0.0020104297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967068,0.00010835183,0.0007209991,0.00082548364,0.0007596767,0.0008787088],"domain_scores_gemma":[0.9981834,0.00072535663,0.00042417657,0.00032203656,0.00021857975,0.00012643357],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010317313,0.00051604403,0.0011067322,0.00017855932,0.00017716063,0.00013109039,0.00012337937,0.0007552123,0.000013948615],"category_scores_gemma":[0.00008231643,0.00044625538,0.00013051672,0.0001625072,0.0003209759,0.00021698288,0.000058623664,0.0011189212,0.0000016031402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008919144,0.0003063372,0.5756698,0.06608447,0.0057663796,0.007921261,0.13954854,0.000008430144,0.085194744,0.000023782435,0.09703692,0.013520166],"study_design_scores_gemma":[0.15669984,0.009783807,0.67166746,0.024111643,0.015499558,0.008981921,0.011812564,0.0075035607,0.028068786,0.00059307145,0.05665632,0.008621459],"about_ca_topic_score_codex":0.00034013475,"about_ca_topic_score_gemma":0.00019790609,"teacher_disagreement_score":0.14778069,"about_ca_system_score_codex":0.00019475113,"about_ca_system_score_gemma":0.00008431792,"threshold_uncertainty_score":0.9997989},"labels":[],"label_agreement":null},{"id":"W2912923795","doi":"10.1182/blood-2018-99-119318","title":"Isolation of CD34− and CD34+ Leukemia Stem Cells from Acute Myeloid Leukemia Blasts Using CD200","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"CD34; Myeloid leukemia; CD38; Population; Biology; Stem cell; Haematopoiesis; Molecular biology; clone (Java method); Leukemia; Myeloid; Flow cytometry; Immunology; Cancer research; Medicine; Cell biology; Genetics; Gene","score_opus":0.02190746870018337,"score_gpt":0.2781117039048168,"score_spread":0.2562042352046334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912923795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951237,0.00034435606,0.0021329105,0.00008530601,0.00018524185,0.0005175521,0.000090189875,0.00008517326,0.0014356014],"genre_scores_gemma":[0.9833581,0.00018784548,0.014209613,0.00018846367,0.0008603416,0.0000087807,0.000037689344,0.00007722449,0.0010719718],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99763644,0.00010107982,0.000544384,0.00058623153,0.00059058325,0.0005412643],"domain_scores_gemma":[0.99829847,0.00017222368,0.0002293291,0.00066163554,0.0003353643,0.00030299393],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031209807,0.00030826597,0.00059191056,0.00025487944,0.0001470105,0.00004223703,0.00021710433,0.00032024915,0.0001947686],"category_scores_gemma":[0.000043363703,0.00028411436,0.000111555586,0.00042350646,0.0004656554,0.00022581647,0.00023418553,0.00043056937,0.0001242347],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038725202,0.0000968378,0.009816298,0.00009323278,0.00048497086,0.00009024076,0.00080307387,0.00000871087,0.9835334,0.000029218383,0.001048201,0.0036085593],"study_design_scores_gemma":[0.008574027,0.0008166543,0.014357346,0.0003333483,0.0010334564,0.00017961032,0.0003093004,0.013774353,0.95909655,0.000098517005,0.0010651837,0.00036165144],"about_ca_topic_score_codex":0.00073753146,"about_ca_topic_score_gemma":0.000043486227,"teacher_disagreement_score":0.024436852,"about_ca_system_score_codex":0.0007112226,"about_ca_system_score_gemma":0.001185355,"threshold_uncertainty_score":0.9999611},"labels":[],"label_agreement":null},{"id":"W2912934447","doi":"10.1182/blood-2018-99-118594","title":"Loss-of-Function Mutation in tet2 in Zebrafish Leads to Early MDS like Phenotype","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Zebrafish; Biology; GATA1; Myeloid leukemia; Phenotype; Mutant; Myeloid; Cancer research; Haematopoiesis; Leukemia; Genetics; Mutation; Molecular biology; Loss function; Gene; Stem cell","score_opus":0.01829648522703515,"score_gpt":0.2912914208634463,"score_spread":0.27299493563641114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912934447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947733,0.000049383623,0.00014182401,0.00051092025,0.00011751139,0.00042558843,0.0000026533237,0.000030848125,0.0039479407],"genre_scores_gemma":[0.99789363,0.000004665982,0.0008662654,0.00034774703,0.00026469337,0.000026993917,0.000013990332,0.000023829287,0.00055820425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988478,0.000053566964,0.00027023384,0.00024419415,0.00030758395,0.00027664282],"domain_scores_gemma":[0.9993735,0.00005734844,0.000041212457,0.00026393673,0.00016535491,0.00009864918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003520884,0.000098516524,0.00021247468,0.00041700847,0.000019682773,0.000010481159,0.0000971906,0.00011728173,0.00014253047],"category_scores_gemma":[0.00028429276,0.000094910174,0.00003086193,0.00084192026,0.00007795221,0.00010438668,0.000051554867,0.00024035612,0.00033674436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018561856,0.0012631617,0.78501505,0.00016862573,0.000068251895,0.00028893235,0.0040047276,0.000013328322,0.19421943,0.0003368444,0.0015260063,0.011239449],"study_design_scores_gemma":[0.0068717245,0.0024081368,0.938606,0.0001725256,0.00005209823,0.00002618564,0.0001478666,0.00012486216,0.050142482,0.00026943506,0.0010392034,0.00013945908],"about_ca_topic_score_codex":0.0006777358,"about_ca_topic_score_gemma":0.0005308004,"teacher_disagreement_score":0.15359096,"about_ca_system_score_codex":0.00013573279,"about_ca_system_score_gemma":0.00020065448,"threshold_uncertainty_score":0.43282795},"labels":[],"label_agreement":null},{"id":"W2913194197","doi":"10.1158/1538-7445.pedca17-a19","title":"Abstract A19: Human models of multilineage leukemia induced by NUP98-KDM5A chimeric fusion oncogene","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; BC Cancer Agency; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Acute megakaryoblastic leukemia; Cancer research; Fusion gene; Myeloid; Leukemia; Bone marrow; Myeloid leukemia; Myelofibrosis; Oncogene; Biology; Medicine; Immunology; Cancer; Genetics; Cell cycle; Gene","score_opus":0.14019311718461736,"score_gpt":0.4541145200893945,"score_spread":0.31392140290477716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913194197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98248124,0.0009566402,0.000057072244,0.00061163487,0.00011949875,0.0011778636,0.000081009384,0.00007468825,0.014440361],"genre_scores_gemma":[0.9923889,0.00061987934,0.00027475698,0.00015356943,0.0009716675,0.00019610961,0.0000851497,0.00011135446,0.005198629],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9951026,0.00022000454,0.0006296954,0.00079238566,0.0020410672,0.0012142455],"domain_scores_gemma":[0.99632454,0.0002327942,0.00014032607,0.0011189084,0.0015687455,0.0006147088],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001955339,0.00029157577,0.0006114627,0.0006165902,0.00040790407,0.00003972747,0.0006940344,0.00035399268,0.0025326347],"category_scores_gemma":[0.00030883797,0.00025213312,0.00014941157,0.0013349932,0.00096469885,0.0002241295,0.00047378705,0.0016787045,0.0002669068],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007396459,0.00019238685,0.00035256695,0.00023994285,0.00010286472,0.00003966924,0.0005985775,0.00001393409,0.9571504,0.00006813,0.024906961,0.0155949015],"study_design_scores_gemma":[0.004212546,0.0013776884,0.00568947,0.00041901943,0.00003238232,0.0000133819585,0.00035677192,0.0037951816,0.97692007,0.00023712877,0.006643398,0.0003029637],"about_ca_topic_score_codex":0.008740338,"about_ca_topic_score_gemma":0.00022879748,"teacher_disagreement_score":0.019769648,"about_ca_system_score_codex":0.002435478,"about_ca_system_score_gemma":0.0028318218,"threshold_uncertainty_score":0.9999931},"labels":[],"label_agreement":null},{"id":"W2913197449","doi":"10.1182/blood-2018-99-116795","title":"Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Fludarabine; Internal medicine; Busulfan; Melphalan; Transplantation; Alemtuzumab; Oncology; Gastroenterology; Proportional hazards model; Surgery; Hematopoietic stem cell transplantation; Cyclophosphamide; Chemotherapy","score_opus":0.02312116928575433,"score_gpt":0.30142788708525686,"score_spread":0.27830671779950256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913197449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904327,0.0003935634,0.0032126273,0.0026111468,0.00016432036,0.0017605716,0.00038994756,0.00013453387,0.00090059557],"genre_scores_gemma":[0.99024063,0.00009375913,0.0070284093,0.00066040835,0.00045585618,0.00010450271,0.0010022436,0.000087500004,0.00032670694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99692607,0.00017883889,0.00081231777,0.00078321976,0.00063672394,0.0006628402],"domain_scores_gemma":[0.996848,0.0007948422,0.00042186273,0.00089656055,0.00073766033,0.0003010998],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006316849,0.0004372679,0.0009888604,0.00020849233,0.00044358103,0.000063785184,0.00034212958,0.00029788786,0.00010418115],"category_scores_gemma":[0.00022753734,0.00034713635,0.00022214801,0.00045714455,0.0007076684,0.00015031123,0.00007920373,0.00057930296,0.000031245392],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037599797,0.00070455496,0.013915769,0.0005597748,0.0009371378,0.000105423154,0.0075213765,0.000014113545,0.9564254,0.00018135733,0.015345848,0.0005292124],"study_design_scores_gemma":[0.017146247,0.0018851853,0.029041657,0.00052861025,0.0028660542,0.00021831726,0.0016317826,0.004274063,0.9411046,0.00029362552,0.00057447806,0.00043540276],"about_ca_topic_score_codex":0.0003969502,"about_ca_topic_score_gemma":0.00006304137,"teacher_disagreement_score":0.015320876,"about_ca_system_score_codex":0.00024961247,"about_ca_system_score_gemma":0.00065656455,"threshold_uncertainty_score":0.9998981},"labels":[],"label_agreement":null},{"id":"W2913408183","doi":"10.1107/s010876731809863x","title":"Cfp1/Cps40 stabilizes MLL complex formation through multi-valent interactions","year":2018,"lang":"en","type":"article","venue":"Acta Crystallographica Section A Foundations and Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Crystallography; Materials science; Chemistry; Biophysics; Biology","score_opus":0.05577310702672465,"score_gpt":0.36527280798761375,"score_spread":0.3094997009608891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913408183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88814497,0.00044919096,0.088394396,0.008739571,0.00086786295,0.0015270972,0.00006853361,0.0004934628,0.0113149425],"genre_scores_gemma":[0.98133785,0.0020094672,0.014999579,0.00042208153,0.00037256783,0.000112517046,0.00022013207,0.000025613968,0.00050020486],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850166,0.00008327227,0.00040602448,0.00040718066,0.00027898003,0.00032289937],"domain_scores_gemma":[0.9987153,0.00014021597,0.00016806959,0.00032827625,0.000500797,0.00014737983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018501654,0.0002075485,0.0002498926,0.0004065053,0.0008863259,0.00013263391,0.000093559924,0.00008499581,0.00062028057],"category_scores_gemma":[0.0001729862,0.00018148038,0.000115985495,0.00086427265,0.0006533552,0.0017322666,0.00007505154,0.0003187272,0.000007634797],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014275023,0.0022260356,0.023554446,0.0007902928,0.00072594493,0.000025987654,0.006526857,0.000038473812,0.89457977,0.0041314596,0.014650973,0.051322237],"study_design_scores_gemma":[0.0017764609,0.00060302025,0.031869207,0.00007775994,0.00008678769,0.00025751197,0.0022984678,0.004008467,0.0003456955,0.0009298756,0.9575141,0.00023261753],"about_ca_topic_score_codex":0.00014275062,"about_ca_topic_score_gemma":0.0016999043,"teacher_disagreement_score":0.94286317,"about_ca_system_score_codex":0.00015973824,"about_ca_system_score_gemma":0.00008525877,"threshold_uncertainty_score":0.74005556},"labels":[],"label_agreement":null},{"id":"W2913683730","doi":"10.1038/s41375-019-0386-z","title":"A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity","year":2019,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Ministry of Science and Technology, Israel; Israel Science Foundation; Council for Higher Education; Israel Cancer Research Fund","keywords":"Biology; Haematopoiesis; Leukemia; Stem cell; Cancer research; Population; Transcriptome; Immunology; Genetics; Gene expression; Gene; Medicine","score_opus":0.01872517658327876,"score_gpt":0.2959579050251315,"score_spread":0.2772327284418527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913683730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877773,0.00015962169,0.008989348,0.00051616196,0.00009902228,0.0021978926,0.00011372111,0.00006173473,0.00008518314],"genre_scores_gemma":[0.9937716,0.000013215514,0.0031163103,0.0004465849,0.000103327904,0.00010324319,0.000024258567,0.00007590438,0.0023455317],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9974361,0.00025809408,0.0005072685,0.0006614939,0.00041866847,0.00071834336],"domain_scores_gemma":[0.99768025,0.0010742121,0.00015129588,0.00060862186,0.00010254895,0.0003830631],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022772239,0.00033539548,0.0006203326,0.00019724619,0.00021837054,0.00007897477,0.0001509895,0.00011332404,0.00001301974],"category_scores_gemma":[0.00020694666,0.00025283766,0.00010540616,0.00025699998,0.00017267745,0.00013332703,0.00029362753,0.0007781301,0.0000065001236],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010748167,0.000078442565,0.16719924,0.002861983,0.00012230803,0.00030715318,0.0042335144,0.00063506793,0.8193813,0.000120244105,0.00017481335,0.0038111305],"study_design_scores_gemma":[0.035774235,0.0006738079,0.31372595,0.0012733722,0.000768864,0.00081731175,0.0056230687,0.42098093,0.21686675,0.0009116088,0.00079393294,0.0017901814],"about_ca_topic_score_codex":0.0031193162,"about_ca_topic_score_gemma":0.000816375,"teacher_disagreement_score":0.60251456,"about_ca_system_score_codex":0.0011624134,"about_ca_system_score_gemma":0.0006477614,"threshold_uncertainty_score":0.9999924},"labels":[],"label_agreement":null},{"id":"W2913903457","doi":"10.1182/blood-2018-99-119688","title":"Combination of Enasidenib and Venetoclax Shows Superior Anti-Leukemic Activity Against IDH2 Mutated AML in Patient-Derived Xenograft Models","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Venetoclax; IDH2; Medicine; Cancer research; Pharmacology; Isocitrate dehydrogenase; Refractory (planetary science); Internal medicine; Oncology; Mutant; Leukemia; Chemistry; Biology; IDH1; Enzyme; Gene; Biochemistry; Chronic lymphocytic leukemia","score_opus":0.019848479157771968,"score_gpt":0.27125006066385116,"score_spread":0.25140158150607916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913903457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980247,0.00015139727,0.000069927395,0.00012400938,0.0000423127,0.0008356928,0.000025914695,0.000053227614,0.00067281845],"genre_scores_gemma":[0.99914837,0.00014582323,0.00041975113,0.00008960379,0.000046879024,0.000037295915,0.000040074912,0.00003791062,0.000034269066],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984067,0.0001273148,0.00033318833,0.0003642364,0.0003795268,0.00038904443],"domain_scores_gemma":[0.9990499,0.00008484189,0.00010794723,0.00035020313,0.00025209412,0.00015501078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023654518,0.00019150988,0.0004435678,0.00031931317,0.00006487533,0.000019857926,0.00011651029,0.00017421531,0.000027626227],"category_scores_gemma":[0.00015380328,0.00018172986,0.000057167083,0.00041051113,0.0003202452,0.00024298081,0.00013251495,0.0003126685,0.000009106853],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003432501,0.00048228077,0.009355188,0.00011355033,0.00009133896,0.0001447703,0.0017552858,0.000025490226,0.9796745,0.000022234955,0.000045808425,0.007946311],"study_design_scores_gemma":[0.012098913,0.001264709,0.05667636,0.00020924822,0.00009030722,0.000107710264,0.00033059093,0.025167638,0.9036268,0.0001685338,0.000036178757,0.00022303821],"about_ca_topic_score_codex":0.0004323204,"about_ca_topic_score_gemma":0.00010643697,"teacher_disagreement_score":0.07604772,"about_ca_system_score_codex":0.00030497814,"about_ca_system_score_gemma":0.0005564907,"threshold_uncertainty_score":0.7410729},"labels":[],"label_agreement":null},{"id":"W2913936095","doi":"10.1182/blood-2018-99-114327","title":"Health Related Quality of Life Remains Stable over Time in Myelodysplastic Syndrome: An MDS-CAN Prospective Study","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Princess Margaret Cancer Centre; Centre hospitalier de l'Université Laval; University of British Columbia; Dr. Georges-L.-Dumont University Hospital Centre; St. Paul's Hospital; McMaster University; Queen Elizabeth II Health Sciences Centre; University of Alberta; CancerCare Manitoba; Saskatchewan Cancer Agency; Health Sciences Centre; Ottawa Hospital; University Health Network; Dalhousie University; University of Toronto; Jewish General Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); International Prognostic Scoring System; Myelodysplastic syndromes; Internal medicine; Azacitidine; Prospective cohort study; Decitabine; Physical therapy; Pediatrics","score_opus":0.02840776455512473,"score_gpt":0.33600840608707794,"score_spread":0.3076006415319532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913936095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959224,0.000089969646,0.0000053708854,0.00043808788,0.00004317576,0.0019555732,0.000042652013,0.00008348833,0.0014193146],"genre_scores_gemma":[0.99813455,0.000008076785,0.00029444476,0.00012704871,0.00007637011,0.000042329935,0.000027748454,0.00004775522,0.001241699],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99671495,0.00057703437,0.00085914496,0.00054729235,0.00071821787,0.00058333453],"domain_scores_gemma":[0.99812424,0.0001899829,0.00025505698,0.0007507542,0.00026978404,0.00041018726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021455677,0.00020422968,0.0008987663,0.00030692483,0.00009378479,0.000014175566,0.000201572,0.00012814254,0.0003905045],"category_scores_gemma":[0.0012318391,0.00018111579,0.00005365955,0.0009907727,0.0002256475,0.00012620608,0.00013053106,0.00052613317,0.000112515576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010173648,0.007470415,0.980596,0.00022999078,0.0004046463,0.00020388686,0.005485904,0.0000023761736,0.0038732083,0.00018077425,0.0004551824,0.00008022692],"study_design_scores_gemma":[0.013767535,0.0071931886,0.97698987,0.00014326771,0.00006674629,0.00007604561,0.00084586383,0.00017997746,0.00043396433,0.00012947601,0.00001180225,0.0001622899],"about_ca_topic_score_codex":0.0032409043,"about_ca_topic_score_gemma":0.001711269,"teacher_disagreement_score":0.01275017,"about_ca_system_score_codex":0.00048920786,"about_ca_system_score_gemma":0.0016685558,"threshold_uncertainty_score":0.7385687},"labels":[],"label_agreement":null},{"id":"W2914073197","doi":"10.1016/s2352-3026(19)30010-9","title":"Eltrombopag use in higher risk myeloid cancers: fitting a square “pag” into a round hole?","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Eltrombopag; Thrombopoietin; Medicine; Thrombopoietin receptor; Myeloid; Lenalidomide; Myelodysplastic syndromes; Internal medicine; Cancer research; Pharmacology; Haematopoiesis; Bone marrow; Immunology; Platelet; Stem cell; Biology; Cell biology; Multiple myeloma","score_opus":0.0568963901246791,"score_gpt":0.32652688668588453,"score_spread":0.2696304965612054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914073197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98154914,0.000725251,0.000033504,0.012844999,0.00035779495,0.0009312503,0.000015733269,0.00012363405,0.0034186912],"genre_scores_gemma":[0.9924672,0.00031927731,0.001069217,0.0025892453,0.00046797236,0.000112135785,0.000025730955,0.000061153405,0.0028880364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723047,0.00047437343,0.00045109805,0.0005372935,0.00035673875,0.00095],"domain_scores_gemma":[0.9974852,0.0008619103,0.00019826711,0.0012087215,0.000111614354,0.00013426482],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00092455646,0.00027413,0.0013475806,0.00021471722,0.0001067776,0.000051972773,0.00050155073,0.00026561858,0.00078969967],"category_scores_gemma":[0.0005123482,0.0001883501,0.0001110794,0.00054035545,0.0002502939,0.00019550315,0.00027728322,0.001347122,0.0010102581],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014464542,0.00009174811,0.9677847,0.0006549932,0.00020407367,0.0010956354,0.0031229588,0.00017651138,0.002998567,0.0045438595,0.015812915,0.0020675769],"study_design_scores_gemma":[0.023576645,0.0011419138,0.8637417,0.0013313302,0.00033576987,0.0023578594,0.0032509472,0.0068198857,0.0023473606,0.0051690936,0.08880388,0.001123616],"about_ca_topic_score_codex":0.0057079718,"about_ca_topic_score_gemma":0.0017903295,"teacher_disagreement_score":0.10404301,"about_ca_system_score_codex":0.0007745048,"about_ca_system_score_gemma":0.0004120179,"threshold_uncertainty_score":0.99976754},"labels":[],"label_agreement":null},{"id":"W2914576346","doi":"10.1182/blood-2018-99-115518","title":"Delayed Hematologic Recovery in AML Patients after Induction Chemotherapy Is Associated with Inferior Relapse-Free Survival and Persistence of Preleukemic Mutations","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Induction chemotherapy; Chemotherapy regimen; Bone marrow; Gastroenterology; Myeloid; Oncology; Surgery","score_opus":0.01633460785572742,"score_gpt":0.2513236050758728,"score_spread":0.23498899722014538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914576346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986035,0.00006209005,0.000012689711,0.00030887238,0.000034868117,0.00045225307,0.000032881526,0.000026964059,0.0004658877],"genre_scores_gemma":[0.9987811,0.000054943663,0.00069577585,0.00014498398,0.00002748746,0.000044743058,0.00003313413,0.000022628697,0.00019523066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886906,0.000072312076,0.00025547933,0.0002631866,0.00031023705,0.00022974903],"domain_scores_gemma":[0.9991221,0.00008402687,0.0001246403,0.00029010605,0.00030622902,0.00007289742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020089942,0.00012841722,0.0002922883,0.00017429508,0.00004074461,0.000010122264,0.000092072354,0.00016192289,0.00007122902],"category_scores_gemma":[0.00048437904,0.000104566425,0.000036009944,0.00042911072,0.00024489482,0.00013064487,0.000050375063,0.00022535757,0.0000058603655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015441102,0.00077971286,0.99060714,0.00006216371,0.00029031985,0.000028823788,0.0021481304,5.104952e-7,0.0036402096,0.000005360298,0.0002500159,0.00064348563],"study_design_scores_gemma":[0.012223964,0.002255818,0.97422516,0.00022551806,0.00012688617,0.000033684144,0.0003358576,0.00007035963,0.010257639,0.00009636541,0.000016730954,0.00013199143],"about_ca_topic_score_codex":0.0001345517,"about_ca_topic_score_gemma":0.00019675745,"teacher_disagreement_score":0.016381972,"about_ca_system_score_codex":0.00020190881,"about_ca_system_score_gemma":0.00023952797,"threshold_uncertainty_score":0.4264095},"labels":[],"label_agreement":null},{"id":"W2914775586","doi":"10.1182/blood-2018-99-114318","title":"Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Midostaurin; NPM1; Internal medicine; Medicine; Oncology; Myeloid leukemia; Chemotherapy regimen; Chemotherapy; Biology; Genetics; Gene","score_opus":0.008338723426162282,"score_gpt":0.2722119528022429,"score_spread":0.26387322937608065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914775586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99573535,0.00016450489,0.00020119014,0.0001024858,0.000015293688,0.003246183,0.00033980008,0.000078364974,0.00011683951],"genre_scores_gemma":[0.9912417,0.00020732629,0.0076036826,0.00007833415,0.0000811177,0.00015651814,0.00036821683,0.000116487754,0.00014663563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703324,0.00014915367,0.00051376,0.0006569399,0.00082284096,0.00082408293],"domain_scores_gemma":[0.99785054,0.0003092891,0.00028649665,0.0005289106,0.00061336806,0.00041137345],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027523524,0.00048977963,0.00085406436,0.00029438312,0.00010102241,0.000059153168,0.00015641825,0.00019008761,0.00013902564],"category_scores_gemma":[0.000262269,0.00031042477,0.000060936116,0.0010707064,0.00053401425,0.0002692464,0.000050499042,0.0003803781,0.000007785941],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11170605,0.0010721587,0.8691188,0.00024936165,0.0009078595,0.0011644305,0.0028805584,0.000049288352,0.007432499,0.0000066279854,0.00032505253,0.0050872816],"study_design_scores_gemma":[0.14368148,0.018805945,0.8049746,0.0007950201,0.00035316433,0.00007758314,0.0002686966,0.00024586645,0.030326817,0.000010734758,0.00005445593,0.00040563216],"about_ca_topic_score_codex":0.0009477085,"about_ca_topic_score_gemma":0.00081759144,"teacher_disagreement_score":0.064144224,"about_ca_system_score_codex":0.0012961909,"about_ca_system_score_gemma":0.0024652302,"threshold_uncertainty_score":0.9999348},"labels":[],"label_agreement":null},{"id":"W2915022322","doi":"10.1182/blood-2018-99-111728","title":"Genotypic Representation of Myelodysplastic/Myeloproliferative Neoplasms in Nrg, Nrg-3GS and Srg-W41 Mice with Transgenic Expression of Human Cytokines","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Chronic myelomonocytic leukemia; Juvenile myelomonocytic leukemia; Cancer research; Leukemia; Biology; Myelodysplastic syndromes; Bone marrow; Myeloid; CD34; Immunology; Stem cell; Haematopoiesis; Genetics","score_opus":0.01863917191312366,"score_gpt":0.2970871510892594,"score_spread":0.2784479791761358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915022322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978162,0.00018406348,0.00023676429,0.0001305691,0.000022744165,0.0006522542,0.000016055337,0.00002242491,0.00091889274],"genre_scores_gemma":[0.9965273,0.000078806275,0.0028930996,0.000029074721,0.00013621892,0.00003774085,0.000027753978,0.000032547152,0.0002374678],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983262,0.00011092638,0.0004458259,0.00039134023,0.00044402218,0.00028171125],"domain_scores_gemma":[0.99888587,0.00016899634,0.00016272938,0.00032672417,0.00034005768,0.00011562484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021080526,0.00018837403,0.00048320822,0.00029825402,0.00006831478,0.0000093948665,0.00012342793,0.00013128486,0.00007483348],"category_scores_gemma":[0.00012260138,0.00014484495,0.000043990454,0.00050342584,0.00042133746,0.00013299409,0.000057757723,0.0002370839,0.0000051005227],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015420506,0.00036485482,0.075682975,0.0002704045,0.00009105571,0.000028833443,0.004063701,0.0000037059363,0.91742814,0.00009427567,0.000059115606,0.00037087893],"study_design_scores_gemma":[0.00847963,0.0018245254,0.12719996,0.0004120275,0.00015795181,0.00006841031,0.000597751,0.000120591125,0.86090446,0.000095013536,0.000015954169,0.00012370503],"about_ca_topic_score_codex":0.00023416802,"about_ca_topic_score_gemma":0.00028654505,"teacher_disagreement_score":0.05652367,"about_ca_system_score_codex":0.000041307907,"about_ca_system_score_gemma":0.00021050352,"threshold_uncertainty_score":0.5906606},"labels":[],"label_agreement":null},{"id":"W2915117294","doi":"10.1182/blood-2018-99-110363","title":"Modeling the Initiation and Evolution of Down Syndrome Associated Leukemia Using CRISPR/Cas9","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"GATA1; Haematopoiesis; Myeloid leukemia; Biology; Leukemia; Progenitor cell; Cancer research; Myeloid; Acute leukemia; Stem cell; CRISPR; Immunology; Genetics; Gene","score_opus":0.03366271168343069,"score_gpt":0.3024676171566177,"score_spread":0.268804905473187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915117294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957501,0.00028662686,0.0027982756,0.00016670767,0.000037679263,0.00026203028,0.000007740734,0.000033181615,0.0006576019],"genre_scores_gemma":[0.99909514,0.000024985937,0.0006174273,0.00006453697,0.00011918087,0.000004974834,0.000010379827,0.000017397217,0.00004595557],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99900657,0.0000804057,0.00022093822,0.00016641601,0.00030908984,0.0002165591],"domain_scores_gemma":[0.99926263,0.000064447304,0.00007486471,0.0002173374,0.00032023052,0.000060489554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051320647,0.00008936981,0.00018563266,0.00011243867,0.00014465794,0.000014776468,0.00007445122,0.0001174257,0.00002402507],"category_scores_gemma":[0.00046659794,0.000065847635,0.00003751596,0.0002969163,0.00013102792,0.00010298484,0.000071958435,0.00021020109,0.0000093278795],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007393881,0.0012693929,0.19348153,0.0006390699,0.001954702,0.00030623135,0.0063623753,0.002143387,0.7881776,0.0022121544,0.0008615438,0.0018525877],"study_design_scores_gemma":[0.006966542,0.00079803367,0.088241875,0.0004207936,0.00079218706,0.0008872859,0.00071642216,0.8814073,0.018765505,0.00076603785,0.000021323645,0.00021665453],"about_ca_topic_score_codex":0.000622439,"about_ca_topic_score_gemma":0.000030471556,"teacher_disagreement_score":0.87926394,"about_ca_system_score_codex":0.00045930324,"about_ca_system_score_gemma":0.0004374778,"threshold_uncertainty_score":0.26851887},"labels":[],"label_agreement":null},{"id":"W2915517176","doi":"10.1182/blood-2018-99-111015","title":"Targeting the Mitochondrial Metallochaperone Cox17 Reduces DNA Methylation and Promotes AML Differentiation through a Copper Dependent Mechanism","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Stem cell; Haematopoiesis; Gene knockdown; Clonogenic assay; Biology; Leukemia; Cancer research; Myeloid leukemia; Small hairpin RNA; Intermembrane space; Molecular biology; Cell biology; Chemistry; Apoptosis; Biochemistry; Immunology; Gene","score_opus":0.021842327363755173,"score_gpt":0.2837363163207829,"score_spread":0.2618939889570277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915517176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99249077,0.00051317597,0.002860984,0.002272738,0.00024261094,0.0010316581,0.0000075742582,0.000076446544,0.00050402654],"genre_scores_gemma":[0.99075043,0.0001220917,0.007197439,0.00016418712,0.001163647,0.000079286896,0.000051259725,0.000034331897,0.00043730927],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99833375,0.0001702604,0.00027564712,0.00037569777,0.00052421406,0.00032041728],"domain_scores_gemma":[0.9991906,0.00013221076,0.00011845813,0.00026971695,0.0002033412,0.00008563485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037530615,0.00018097373,0.0002605251,0.00006369173,0.00031119183,0.00007721673,0.00013119342,0.00013246901,0.0001505677],"category_scores_gemma":[0.00044422896,0.00011616228,0.000056688103,0.00015621047,0.00016361909,0.0001825722,0.00013900198,0.00026719947,0.00004291098],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012291071,0.00018290263,0.00011997101,0.000030984527,0.00026534923,0.0000073130514,0.0018617806,1.8587376e-7,0.9953619,0.0008654285,0.0002578151,0.00092343334],"study_design_scores_gemma":[0.0040682945,0.0006005974,0.001267214,0.000051711548,0.00054387574,0.00007180563,0.0005240543,0.0007746623,0.9890343,0.002588829,0.00031498593,0.0001597009],"about_ca_topic_score_codex":0.000071163144,"about_ca_topic_score_gemma":0.000017798546,"teacher_disagreement_score":0.0063276566,"about_ca_system_score_codex":0.000058894933,"about_ca_system_score_gemma":0.00010451226,"threshold_uncertainty_score":0.47369605},"labels":[],"label_agreement":null},{"id":"W2915866752","doi":"10.1182/blood-2018-99-116128","title":"RNA-Seq Analysis of Clonal Hematopoiesis (CHIP) Blood Leukocytes Shows Dysregulation of Neutrophil / Innate Immunity-Related Genes","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University","funders":"","keywords":"Biology; Myeloid; Haematopoiesis; Transcriptome; Gene; Immunology; Innate immune system; Gene expression; Cancer research; Genetics; Stem cell; Immune system","score_opus":0.017965576849921915,"score_gpt":0.279425923879767,"score_spread":0.2614603470298451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915866752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996062,0.0011446861,0.000042234566,0.0002838523,0.000049330927,0.00033110185,0.000062373954,0.000065732835,0.0019587222],"genre_scores_gemma":[0.997145,0.0001785251,0.0016850696,0.000053672968,0.00013403788,0.00001568462,0.00017443042,0.00004386288,0.0005697457],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99741995,0.00020500128,0.0008763997,0.0003683259,0.00073056563,0.00039977964],"domain_scores_gemma":[0.9975494,0.00022086351,0.00040495986,0.0008968124,0.00076655264,0.00016140997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062516285,0.00025673636,0.00095327804,0.0011211325,0.000121637626,0.000014554502,0.0003335266,0.00025701217,0.0007235073],"category_scores_gemma":[0.00026007486,0.00022702874,0.00039634,0.0025430412,0.0005589032,0.000121472425,0.00020323339,0.0003354847,0.00002218587],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045279,0.0015765603,0.07590772,0.0002707758,0.012153476,0.000048213285,0.00091597013,0.00008624449,0.9059241,0.0010352602,0.000103937266,0.0015249848],"study_design_scores_gemma":[0.0054420508,0.0007815628,0.16289952,0.00010636193,0.00980494,0.00006824003,0.00018323348,0.0026877436,0.81750786,0.0002197919,0.00008145099,0.00021724508],"about_ca_topic_score_codex":0.00056256476,"about_ca_topic_score_gemma":0.00009958039,"teacher_disagreement_score":0.08841621,"about_ca_system_score_codex":0.00006710217,"about_ca_system_score_gemma":0.00033690306,"threshold_uncertainty_score":0.92579633},"labels":[],"label_agreement":null},{"id":"W2916599355","doi":"10.1016/j.bbmt.2007.11.002","title":"The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review","year":2008,"lang":"en","type":"review","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Oncology; Hematopoietic stem cell transplantation; Internal medicine; Transplantation; Leukemia; Busulfan; Disease; Chronic myelogenous leukemia; Stem cell; Intensive care medicine","score_opus":0.030033180114442826,"score_gpt":0.30274906699820026,"score_spread":0.2727158868837574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916599355","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15524898,0.8416563,0.000015301373,0.000062369174,0.000012417574,0.0028249884,0.000139507,0.000007760314,0.000032338194],"genre_scores_gemma":[0.13229994,0.8667598,0.00010282973,0.00007246025,0.000017499393,0.00028325003,0.00043320184,0.000028433224,0.0000026022174],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99671793,0.0011703041,0.0011052196,0.0003988898,0.0003146984,0.0002929807],"domain_scores_gemma":[0.9977334,0.0010270346,0.00062703557,0.0004335317,0.00012711713,0.000051885097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009245435,0.0003752289,0.0015679603,0.00028464248,0.000059935526,0.000004504775,0.00038198725,0.00035247183,0.000004919357],"category_scores_gemma":[0.000005964918,0.00018927954,0.00021714368,0.0005558514,0.00046157427,0.000086965694,0.0000040806553,0.00045829304,4.6010686e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072988267,0.0005870924,0.0018061054,0.11091337,0.0006627063,0.00022865154,0.006501778,0.0000033254123,0.017365875,0.00009351247,0.0000053208464,0.85453343],"study_design_scores_gemma":[0.05421733,0.03908493,0.006295417,0.7274861,0.0126460595,0.010709214,0.0027402337,0.00009133415,0.12485397,0.00020591976,0.019225337,0.0024441702],"about_ca_topic_score_codex":0.0002710464,"about_ca_topic_score_gemma":0.00011671463,"teacher_disagreement_score":0.8520893,"about_ca_system_score_codex":0.000062486986,"about_ca_system_score_gemma":0.0012864205,"threshold_uncertainty_score":0.7718596},"labels":[],"label_agreement":null},{"id":"W2916620152","doi":"10.1182/blood-2018-10-881441","title":"A stemness screen reveals C3orf54/INKA1 as a promoter of human leukemia stem cell latency","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Natural Sciences and Engineering Research Council of Canada; Ontario Genomics; Terry Fox Foundation; Canada First Research Excellence Fund; Hospital for Sick Children; Ontario Genomics Institute; Krembil Foundation; University of Toronto; Princess Margaret Hospital Foundation; Deutsche Forschungsgemeinschaft; Canadian Institutes of Health Research; Genome Canada","keywords":"Stem cell; Haematopoiesis; Biology; Progenitor cell; Cancer research; Gene silencing; CD34; Cell biology; Hematopoietic stem cell; Leukemia; Immunology; Genetics; Gene","score_opus":0.01910847136617008,"score_gpt":0.2824806832355092,"score_spread":0.2633722118693391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916620152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9475147,0.00029722962,0.000004865157,0.00017553852,0.000048341284,0.0015373419,0.000022814938,0.000086843094,0.05031233],"genre_scores_gemma":[0.94733465,0.000022039461,0.0003675389,0.0001593716,0.00014906724,0.00003964264,0.00003549127,0.00007344084,0.05181877],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974987,0.00012884711,0.0005556615,0.0005128913,0.0007414836,0.0005624389],"domain_scores_gemma":[0.9981514,0.00007730872,0.00020269514,0.0010294967,0.00027903347,0.00026003504],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00058326876,0.00026102294,0.00068807864,0.00023345742,0.000061100756,0.000022962138,0.00038586883,0.0002568482,0.0007634131],"category_scores_gemma":[0.000026681319,0.00021543357,0.00017809017,0.0003812668,0.000091092115,0.000121301026,0.00022385691,0.00051684876,0.0010776955],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026847716,0.00095367554,0.11097876,0.0020438947,0.00031722462,0.00032067482,0.001187636,0.0000013400324,0.8802189,0.0005059511,0.0018410406,0.0013623931],"study_design_scores_gemma":[0.033519126,0.005963716,0.11767007,0.0018584412,0.00086188613,0.0005305229,0.0010244778,0.00012088303,0.8344337,0.0005324123,0.0025798117,0.0009049701],"about_ca_topic_score_codex":0.00039588782,"about_ca_topic_score_gemma":0.000007484397,"teacher_disagreement_score":0.04578525,"about_ca_system_score_codex":0.00022697434,"about_ca_system_score_gemma":0.00066399394,"threshold_uncertainty_score":0.99970007},"labels":[],"label_agreement":null},{"id":"W2916634237","doi":"10.1182/blood-2018-99-116599","title":"Long Term AML Survivors Have Increased Mortality and High Prevalence of Clonal Hematopoiesis","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Cohort; Disease; Leukemia; Pediatrics","score_opus":0.026404491206395035,"score_gpt":0.3091116873562066,"score_spread":0.28270719614981155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916634237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99812776,0.00024671233,0.000044927034,0.00012332377,0.00003288183,0.00032493033,0.000053978263,0.00003637344,0.0010091125],"genre_scores_gemma":[0.99858516,0.000093986026,0.00058219914,0.00008069566,0.00022209193,0.000014913409,0.000015784255,0.000019921868,0.00038521647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986065,0.00008354215,0.00026871613,0.0003070879,0.00045555318,0.00027858428],"domain_scores_gemma":[0.9988725,0.00014437927,0.00008781249,0.00047992653,0.00021363454,0.0002017549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045683346,0.00013771089,0.00031693757,0.00009240134,0.000059823487,0.000011442728,0.00014235845,0.00010298828,0.00039276193],"category_scores_gemma":[0.00030999372,0.00011625909,0.00005497053,0.00013702735,0.00052556826,0.00007147175,0.00014813301,0.00016517707,0.000018953535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010747143,0.00032622062,0.9828248,0.00093351124,0.00018241811,0.00008546951,0.00017518747,1.3989793e-8,0.014838827,0.00009740984,0.0001339259,0.00029474296],"study_design_scores_gemma":[0.0023039219,0.00028260052,0.87856406,0.00014415734,0.00027605635,0.00011404908,0.000028989818,0.000024161165,0.11808757,0.00006814903,0.0000131994975,0.00009308023],"about_ca_topic_score_codex":0.0022240723,"about_ca_topic_score_gemma":0.0003252698,"teacher_disagreement_score":0.10426073,"about_ca_system_score_codex":0.00003878759,"about_ca_system_score_gemma":0.00020391773,"threshold_uncertainty_score":0.4740908},"labels":[],"label_agreement":null},{"id":"W2917438066","doi":"10.1182/bloodadvances.2018028480","title":"Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition","year":2019,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Canadian Institutes of Health Research","keywords":"PLK1; Myeloid leukemia; Myelodysplastic syndromes; Cancer research; KRAS; NPM1; Leukemia; Biology; Medicine; Oncology; Internal medicine; Karyotype; Cancer; Cell cycle; Gene; Bone marrow; Genetics; Chromosome","score_opus":0.013014442551224687,"score_gpt":0.28194717570945704,"score_spread":0.26893273315823235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917438066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864433,0.0009178049,0.0000578477,0.0022997966,0.00008830778,0.00064995076,0.000037695936,0.00007010822,0.009435224],"genre_scores_gemma":[0.99398106,0.00017874672,0.0028351194,0.0014072219,0.00020637002,0.000012055155,0.00006631506,0.000024388317,0.0012887235],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99880606,0.000045824327,0.00013956385,0.00038121841,0.00031425062,0.00031308475],"domain_scores_gemma":[0.999257,0.00013055626,0.000039634862,0.00025645283,0.0001012946,0.00021503156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014809283,0.00015894402,0.00030164013,0.000110292305,0.00007129858,0.000022047176,0.00004997681,0.00009220053,0.00010540287],"category_scores_gemma":[0.00011276903,0.0001309358,0.00004279884,0.00024717505,0.00007801592,0.00020434834,0.000100512036,0.000308633,0.00023839306],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007238919,0.0002726333,0.056938164,0.00042130845,0.00009660725,0.00032851697,0.0004381315,0.00004163679,0.91989315,0.00082952465,0.002863214,0.017153215],"study_design_scores_gemma":[0.013087446,0.0036250998,0.6219302,0.00088644295,0.00036509466,0.0016731268,0.001617245,0.0012035632,0.1612541,0.00079677784,0.19243386,0.001127057],"about_ca_topic_score_codex":0.000020284278,"about_ca_topic_score_gemma":0.00003445046,"teacher_disagreement_score":0.75863904,"about_ca_system_score_codex":0.000051434756,"about_ca_system_score_gemma":0.000065431625,"threshold_uncertainty_score":0.53394073},"labels":[],"label_agreement":null},{"id":"W2917467665","doi":"10.1182/blood-2018-99-116145","title":"Donor Cell Leukemia: The Role of Recipient Microenvironment","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Leukemia; Population; Myeloid; Medicine; Oncology; Internal medicine; RUNX1; Myelodysplastic syndromes; Haematopoiesis; Bone marrow; Biology; Stem cell; Genetics","score_opus":0.008544603280817577,"score_gpt":0.23483125606652341,"score_spread":0.22628665278570584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917467665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95857984,0.000900538,0.000018698927,0.00047209798,0.000045760575,0.00036517731,0.000007750957,0.00001760744,0.039592527],"genre_scores_gemma":[0.995437,0.00017974319,0.0011351513,0.00030098035,0.0003609686,0.000023160796,0.0000061268397,0.000022130422,0.0025347376],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998964,0.00004285497,0.00020035035,0.00020481879,0.0003073076,0.00028067434],"domain_scores_gemma":[0.99917865,0.000055242857,0.00006518585,0.0005450567,0.00005318425,0.00010268242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024404001,0.00010384532,0.0001717063,0.000048521317,0.00007193322,0.000006679409,0.00020565333,0.00007457441,0.00038550398],"category_scores_gemma":[0.000036439666,0.0000654356,0.00007655184,0.00012504078,0.0002881697,0.000021249727,0.00015696792,0.00023173435,0.00036077586],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022395312,0.00080669654,0.023016062,0.000056132758,0.00014951492,0.000028700528,0.0010588584,0.0000011931215,0.9606902,0.00020332467,0.0063059404,0.007459446],"study_design_scores_gemma":[0.0025031664,0.00059777615,0.01367212,0.000028510007,0.00014388368,0.00005362211,0.00034340832,0.000066774155,0.8749271,0.00006061547,0.10753332,0.0000697044],"about_ca_topic_score_codex":0.00011288785,"about_ca_topic_score_gemma":0.000009116536,"teacher_disagreement_score":0.10122738,"about_ca_system_score_codex":0.00018810955,"about_ca_system_score_gemma":0.000198592,"threshold_uncertainty_score":0.46371642},"labels":[],"label_agreement":null},{"id":"W2917823598","doi":"10.1002/cncr.32034","title":"Analysis of acute myeloid leukemia incidence and geographic distribution in Canada from 1992 to 2010 reveals disease clusters in Sarnia and other industrial US border cities in Ontario","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; McGill University; University of Ottawa","funders":"Fonds de Recherche du Québec - Santé","keywords":"Incidence (geometry); Medicine; Demography; Population; Myeloid leukemia; Environmental health; Distribution (mathematics); Internal medicine","score_opus":0.01504906954202816,"score_gpt":0.2741894569970657,"score_spread":0.25914038745503754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917823598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973771,0.0005140711,0.0000039646966,0.0006097458,0.000085169355,0.0005942655,0.00078152725,0.0000035697653,0.00003056654],"genre_scores_gemma":[0.99858767,0.00018611028,0.00001626657,0.00064629194,0.000024652787,0.000063368294,0.00017881882,0.000012782855,0.00028403374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984614,0.00008123286,0.0003852319,0.00039826828,0.00034147195,0.0003323614],"domain_scores_gemma":[0.99923486,0.00011486261,0.00008736576,0.0002769243,0.000046762212,0.00023924041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002484374,0.00016239067,0.00058023544,0.0004975364,0.00001624529,0.000014617959,0.0001072157,0.00011673395,0.00032354725],"category_scores_gemma":[0.000083036386,0.00015301934,0.00003793757,0.0009235148,0.000085954984,0.00009700052,0.000108440385,0.00050640927,8.269697e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010013541,0.000009819642,0.9958663,0.000023200328,0.00020806349,0.000059883598,0.0004989918,0.0007178875,0.0004517216,0.0000018091766,0.00037327717,0.00078769034],"study_design_scores_gemma":[0.0025668573,0.000037218353,0.9940465,0.00027757822,0.0002601735,6.770833e-7,0.0002063947,0.0015730885,0.000036774887,0.00001028053,0.0008382351,0.00014621287],"about_ca_topic_score_codex":0.9982554,"about_ca_topic_score_gemma":0.9994034,"teacher_disagreement_score":0.0018197922,"about_ca_system_score_codex":0.00572061,"about_ca_system_score_gemma":0.004698249,"threshold_uncertainty_score":0.9980962},"labels":[],"label_agreement":null},{"id":"W2920738037","doi":"10.1038/s41408-019-0190-z","title":"Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia","year":2019,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Cancer Research UK","keywords":"Myeloid leukemia; Medicine; Myeloid; Internal medicine; Expression (computer science); MEDLINE; Bioinformatics; Computer science; Biology; Political science; Law","score_opus":0.024372206675235007,"score_gpt":0.3449138785461871,"score_spread":0.3205416718709521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920738037","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56553394,0.021784015,0.00021453816,0.005788119,0.3696617,0.004803791,0.0010336818,0.00026610275,0.030914128],"genre_scores_gemma":[0.095943294,0.072614856,0.0009993382,0.0017996059,0.02130296,0.00018644409,0.00046221758,0.00046249223,0.8062288],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99225324,0.00053349434,0.0025306644,0.00094073534,0.002674559,0.0010672933],"domain_scores_gemma":[0.99523383,0.00043107767,0.0017543281,0.0009742389,0.0008533588,0.00075317756],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0018104382,0.0007601663,0.0028198424,0.0010921265,0.00014475234,0.0000934344,0.000996499,0.0022342806,0.001672707],"category_scores_gemma":[0.00083483726,0.0005942003,0.0008950425,0.00060393254,0.0002624703,0.00031355952,0.0004820804,0.012465343,0.00008046488],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014908091,0.000576502,0.15218455,0.0003147968,0.0016312799,0.0013972054,0.00012693994,0.000025013333,0.0005498062,0.000001515439,0.83546793,0.0062336717],"study_design_scores_gemma":[0.058412787,0.0066713193,0.65024734,0.020614522,0.0061444067,0.0077553685,0.00042718163,0.00065347727,0.010425079,0.000097870856,0.23664966,0.0019009861],"about_ca_topic_score_codex":0.0009672157,"about_ca_topic_score_gemma":0.0002507138,"teacher_disagreement_score":0.7753147,"about_ca_system_score_codex":0.0025223778,"about_ca_system_score_gemma":0.016552197,"threshold_uncertainty_score":0.99965096},"labels":[],"label_agreement":null},{"id":"W2921272064","doi":"10.1007/s00277-015-2563-0","title":"Erratum to: Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant","year":2015,"lang":"en","type":"erratum","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"CEBPA; Hematology; Myeloid leukemia; Karyotype; Internal medicine; Oncology; Medicine; Stem cell; Mutation; Leukemia; Cancer research; Biology; Genetics; Chromosome; Gene","score_opus":0.03626374896610787,"score_gpt":0.29222279866856005,"score_spread":0.2559590497024522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921272064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9346879,0.002904499,0.00009303098,0.0019708024,0.0062128613,0.0042323563,0.0036585652,0.0002033635,0.046036623],"genre_scores_gemma":[0.77912956,0.0026724332,0.0024663156,0.0022209005,0.0016351528,0.0010560445,0.04149927,0.0008149293,0.1685054],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9936196,0.00022467275,0.0013708362,0.0014433529,0.0017350101,0.0016065228],"domain_scores_gemma":[0.99426675,0.00020909445,0.00083470676,0.0011885148,0.00258295,0.0009180033],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00049561344,0.0010485585,0.0028706463,0.00075788324,0.00015451426,0.000053678537,0.0008680475,0.0017515713,0.00021656664],"category_scores_gemma":[0.00004024105,0.0008799521,0.00036064917,0.0005493966,0.0002945551,0.00025327326,0.0002662666,0.0019968927,0.0003609597],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017331416,0.0009052064,0.029179368,0.0017879776,0.0028480291,0.0018407443,0.0014288647,0.000061653,0.0008889914,0.00005148246,0.9428618,0.00081445783],"study_design_scores_gemma":[0.10389957,0.057993893,0.07158176,0.013544931,0.013954308,0.0026975118,0.0045955693,0.0026141712,0.4480773,0.00094985054,0.2676394,0.01245176],"about_ca_topic_score_codex":0.0031297046,"about_ca_topic_score_gemma":0.00082641956,"teacher_disagreement_score":0.6752224,"about_ca_system_score_codex":0.0003659116,"about_ca_system_score_gemma":0.0038482929,"threshold_uncertainty_score":0.9995444},"labels":[],"label_agreement":null},{"id":"W2921394315","doi":"10.1182/blood-2018-99-115611","title":"Quantitative Modeling of Ineffective Hematopoiesis in Myelodysplastic Syndrome Patients Yields Distinct Clinical Phenotypes and Can Identify a State of Disease Predictive of Loss of Response to Azacitidine","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; University of Toronto","funders":"","keywords":"Haematopoiesis; Myelodysplastic syndromes; Bone marrow; International Prognostic Scoring System; Myeloid; Disease; Progenitor cell; Immunology; Oncology; Population; Medicine; Internal medicine; Biology; Bioinformatics; Stem cell; Genetics","score_opus":0.024539937133281245,"score_gpt":0.33776402166404657,"score_spread":0.31322408453076533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921394315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972302,0.00007253406,0.0009871483,0.00006098051,0.000033641616,0.0008892223,0.0006961585,0.000008229432,0.000021927877],"genre_scores_gemma":[0.99903834,0.000019336725,0.00083905156,0.000009084325,0.000012595216,0.000029174604,0.000015786176,0.000024657616,0.000011989771],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754965,0.00040787217,0.0009483383,0.00034595057,0.0005063495,0.00024184294],"domain_scores_gemma":[0.996435,0.001731508,0.00031562688,0.0003172016,0.00095806905,0.00024259044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010386674,0.00017112703,0.00085604604,0.0004327248,0.000021515652,0.000002762482,0.0001339198,0.00007637213,0.00000966266],"category_scores_gemma":[0.007527556,0.00014903146,0.000091972644,0.0005599275,0.00063070393,0.00007221621,0.00021020984,0.00020129031,0.0000013088876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07318939,0.0032204087,0.9057785,0.0019609013,0.0007812154,0.0001151989,0.006273079,0.00032896615,0.00801601,0.000054131964,0.000010800656,0.0002713597],"study_design_scores_gemma":[0.0076037073,0.010558012,0.96170396,0.0017565084,0.00039259176,0.000006865339,0.00042500906,0.008474417,0.008650679,0.0003043021,2.2265786e-7,0.0001237531],"about_ca_topic_score_codex":0.0003490548,"about_ca_topic_score_gemma":0.00011121449,"teacher_disagreement_score":0.06558569,"about_ca_system_score_codex":0.000063572385,"about_ca_system_score_gemma":0.00043006561,"threshold_uncertainty_score":0.9011731},"labels":[],"label_agreement":null},{"id":"W2922145728","doi":"10.1182/blood-2018-99-109468","title":"Metabolic Dysregulation in Normal and Malignant Hematopoiesis","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Biology; Carcinogenesis; Haematopoiesis; Malignant transformation; Myeloid; Cancer research; Genome instability; Isocitrate dehydrogenase; Phenotype; Leukemia; Cell biology; Stem cell; Cancer; Immunology; Genetics; DNA damage; Gene; Biochemistry; Enzyme","score_opus":0.014672360246995432,"score_gpt":0.27611255142411567,"score_spread":0.26144019117712025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922145728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933528,0.00059135904,0.000022485685,0.0006363977,0.00002253796,0.00019225742,0.0000019121262,0.000026338868,0.005153921],"genre_scores_gemma":[0.9973279,0.000057426285,0.0015964806,0.00016204471,0.00021510792,0.000013411143,0.0000054139005,0.000013005959,0.0006092038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992783,0.000023455013,0.00014040056,0.0001665153,0.00017598669,0.00021535537],"domain_scores_gemma":[0.9996156,0.000026846594,0.000022541277,0.00018867907,0.000059777605,0.00008651735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000225798,0.000073610114,0.00017210106,0.00015512256,0.00003653182,0.000011909315,0.000043927223,0.00006142571,0.00017612321],"category_scores_gemma":[0.00008034366,0.000060454993,0.000026497035,0.00023361518,0.000100585414,0.00007264598,0.00005755028,0.00009261787,0.00007126343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053805986,0.0011703311,0.60177696,0.0003416002,0.00041277113,0.000508547,0.0032419127,7.491956e-7,0.35915565,0.01342259,0.0020945556,0.017336281],"study_design_scores_gemma":[0.006783495,0.0002770759,0.6793593,0.00008916227,0.00016951757,0.00047228936,0.0001638295,0.0004116921,0.30697072,0.00035304597,0.004797394,0.00015244092],"about_ca_topic_score_codex":0.00009701001,"about_ca_topic_score_gemma":0.000049509945,"teacher_disagreement_score":0.07758238,"about_ca_system_score_codex":0.00001941404,"about_ca_system_score_gemma":0.00007872204,"threshold_uncertainty_score":0.2465283},"labels":[],"label_agreement":null},{"id":"W2922326480","doi":"10.1182/blood-2018-99-120168","title":"The Clonal Hematopoietic Spectrum of Down Syndrome and ML-DS","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Izaak Walton Killam Health Centre","funders":"","keywords":"GATA1; Myeloid; Haematopoiesis; Biology; Epigenetics; Medicine; Oncology; Cancer research; Immunology; Genetics; Bioinformatics; Gene; Stem cell","score_opus":0.010559153827508867,"score_gpt":0.2672958792687105,"score_spread":0.25673672544120163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922326480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893679,0.0005928301,0.000012079974,0.0031542277,0.000044995948,0.00020456612,0.0000048854863,0.000022067916,0.0065964162],"genre_scores_gemma":[0.997761,0.00010817613,0.00031214126,0.00010202433,0.0001638658,0.000007632344,0.000002315706,0.000014301498,0.001528531],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991086,0.00002777514,0.00016188876,0.00015595538,0.0002909677,0.0002547822],"domain_scores_gemma":[0.9993359,0.00012282388,0.000039007366,0.0003296114,0.00006497038,0.000107679516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028463494,0.00008168436,0.00017812662,0.000046655045,0.00010262576,0.000013684003,0.00011917818,0.00005737279,0.00015431613],"category_scores_gemma":[0.00011885614,0.00005006427,0.000039367183,0.00015246961,0.000459486,0.00002419317,0.00010174084,0.00017064372,0.000089635374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031533698,0.0054916707,0.43859532,0.0028939426,0.004954302,0.0050264522,0.008412754,5.176394e-7,0.36830696,0.078780085,0.067188844,0.017195787],"study_design_scores_gemma":[0.019640734,0.006788628,0.62121016,0.00049995526,0.0007873251,0.018607259,0.0008737287,0.00025536842,0.29000744,0.007625403,0.03317278,0.0005311963],"about_ca_topic_score_codex":0.00003513483,"about_ca_topic_score_gemma":0.000012610898,"teacher_disagreement_score":0.18261485,"about_ca_system_score_codex":0.000022060862,"about_ca_system_score_gemma":0.0001406035,"threshold_uncertainty_score":0.20415618},"labels":[],"label_agreement":null},{"id":"W2922999432","doi":"10.1016/j.celrep.2019.02.071","title":"Enhanced Renewal of Erythroid Progenitors in Myelodysplastic Anemia by Peripheral Serotonin","year":2019,"lang":"en","type":"article","venue":"Cell Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut National de la Recherche Scientifique","funders":"Centre National de la Recherche Scientifique; Fédération pour la Recherche sur le Cerveau; Ministère de l'Enseignement Supérieur et de la Recherche; Fondation pour la Recherche Médicale; Institut National de la Santé et de la Recherche Médicale; Institut de Recherche Clinique De Montréal; Labex; T.C. İstanbul Kültür Üniversitesi; Agence Nationale de la Recherche; Fondation de France; Institut des maladies génétiques Imagine","keywords":"Peripheral; Progenitor cell; Serotonin; Progenitor; Myelodysplastic syndromes; Biology; Anemia; Cell biology; Peripheral blood; Stem cell; Bone marrow; Medicine; Immunology; Internal medicine; Genetics","score_opus":0.0065851356245282995,"score_gpt":0.2531683005059426,"score_spread":0.24658316488141427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922999432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810745,0.0002662292,0.000028734918,0.000083887455,0.00026153645,0.0011906665,0.0000028234845,0.000040889485,0.017050713],"genre_scores_gemma":[0.97976136,0.00003552933,0.00044073496,0.000037414666,0.00007700638,0.00006293094,0.00005660941,0.000046153244,0.019482246],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978121,0.000048672704,0.00064499554,0.0004965071,0.00053729437,0.00046044542],"domain_scores_gemma":[0.99875236,0.00006318818,0.00024378106,0.0006156825,0.00013732415,0.00018767634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034277383,0.00019975875,0.00048099653,0.0001479145,0.000020547437,0.000010585499,0.00009635707,0.00019230065,0.0006508382],"category_scores_gemma":[0.00014405532,0.00018028961,0.00009430786,0.00031381907,0.00009746927,0.000074976735,0.00007941802,0.00038179738,0.000059533155],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002470493,0.00016889529,0.08603346,0.00039480755,0.000016578932,0.00091260736,0.00036284205,0.00003552412,0.90852803,0.0000021345968,0.002898793,0.00039929512],"study_design_scores_gemma":[0.0016607807,0.00049609033,0.0074626184,0.00015436103,0.00002584286,0.00048516385,0.00019792486,0.00013183067,0.9868008,0.000031709304,0.0023502621,0.00020264766],"about_ca_topic_score_codex":0.00013826163,"about_ca_topic_score_gemma":0.000009984711,"teacher_disagreement_score":0.07857084,"about_ca_system_score_codex":0.00043271418,"about_ca_system_score_gemma":0.0007257255,"threshold_uncertainty_score":0.73519975},"labels":[],"label_agreement":null},{"id":"W2926453305","doi":"10.1002/ajh.25484","title":"Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia","year":2019,"lang":"en","type":"review","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene","keywords":"Medicine; Myeloid leukemia; Oncology; Internal medicine; Leukemia; Overall survival","score_opus":0.04014980143188264,"score_gpt":0.36836509498511977,"score_spread":0.32821529355323714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2926453305","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010918876,0.9860685,0.00012606909,0.0011436818,0.00033116146,0.00088716805,0.00001091929,0.00002464867,0.000488982],"genre_scores_gemma":[0.00063257874,0.9924143,0.0058818893,0.00038013537,0.00011759644,0.000018045623,0.000028670669,0.000166162,0.0003606317],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954589,0.0007054607,0.0017119764,0.00050676375,0.000793347,0.00082356296],"domain_scores_gemma":[0.9950522,0.0011272626,0.00223639,0.00071474037,0.0004622749,0.0004071125],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00091265625,0.0007213552,0.008233725,0.0013906329,0.000047526664,0.000026088595,0.000731508,0.00036511707,0.00015191497],"category_scores_gemma":[0.00022617758,0.00041097176,0.00086407317,0.0009968878,0.0005116168,0.00013737193,0.00014393886,0.0027695938,0.000066144945],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013634707,0.0001459063,0.003632189,0.0028667657,0.0025664528,0.0064249234,0.0002511383,0.000005317921,0.000023522241,0.00005726118,0.0004029951,0.98226005],"study_design_scores_gemma":[0.01015414,0.0149559975,0.0008309416,0.034381136,0.003136359,0.11230494,0.0015064663,0.000021143062,0.000057943926,0.000015241721,0.8212778,0.0013578907],"about_ca_topic_score_codex":0.00009427588,"about_ca_topic_score_gemma":0.000006356827,"teacher_disagreement_score":0.9809022,"about_ca_system_score_codex":0.0014161934,"about_ca_system_score_gemma":0.0064580366,"threshold_uncertainty_score":0.99983424},"labels":[],"label_agreement":null},{"id":"W2929055980","doi":"10.1007/7651_2019_216","title":"Targeted, Amplicon-Based, Next-Generation Sequencing to Detect Age-Related Clonal Hematopoiesis","year":2019,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"European Hematology Association","keywords":"Amplicon sequencing; Amplicon; Biology; Computational biology; Haematopoiesis; Genetics; Stem cell; Gene; Polymerase chain reaction","score_opus":0.06553382273419003,"score_gpt":0.3994833799490471,"score_spread":0.3339495572148571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2929055980","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43449482,0.00038315495,0.56249243,0.0009108358,0.00021591988,0.00077156024,0.0000045476463,0.00005799665,0.00066875893],"genre_scores_gemma":[0.16682734,0.000009429181,0.8296142,0.002957301,0.00006805863,0.00010952018,0.000109269895,0.000051902985,0.00025298516],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965514,0.001462749,0.00050202885,0.0006857252,0.00019028621,0.00060778775],"domain_scores_gemma":[0.9985761,0.00037885338,0.0000822564,0.0006424237,0.00012289365,0.00019749084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021709604,0.00025403072,0.0005921376,0.0005724499,0.000045934292,0.000023399123,0.00024152966,0.0004395312,0.00041159964],"category_scores_gemma":[0.0013313056,0.00023169263,0.00015741627,0.0007969447,0.000116155126,0.0000345384,0.0001362138,0.000608195,0.00019195356],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010651346,0.000016715934,0.0014474975,0.00004405223,0.00006018905,0.00022605469,0.000080447295,0.0008329697,0.98245853,0.0008607293,0.00008122509,0.013785044],"study_design_scores_gemma":[0.0017150706,0.00056071323,0.00041102432,0.000053567648,0.000033665186,0.00011244259,0.000054748743,0.018071491,0.97445637,0.0018364512,0.0024015398,0.00029292383],"about_ca_topic_score_codex":0.00025958146,"about_ca_topic_score_gemma":0.000022313972,"teacher_disagreement_score":0.26766747,"about_ca_system_score_codex":0.0007376515,"about_ca_system_score_gemma":0.00047800053,"threshold_uncertainty_score":0.9448151},"labels":[],"label_agreement":null},{"id":"W2929065785","doi":"10.3390/cells8040304","title":"3D Telomere Structure Analysis to Detect Genomic Instability and Cytogenetic Evolution in Myelodysplastic Syndromes","year":2019,"lang":"en","type":"article","venue":"Cells","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Genome instability; Telomere; Myelodysplastic syndromes; Biology; Evolutionary biology; Computational biology; Genetics; DNA; Bone marrow; DNA damage; Immunology","score_opus":0.008802282306175238,"score_gpt":0.2539109191726162,"score_spread":0.24510863686644097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2929065785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981485,0.00037095635,0.00025121585,0.000087756125,0.00006812344,0.00076571945,0.000029889981,0.000023768467,0.00025405595],"genre_scores_gemma":[0.9975884,0.000030344761,0.0018635056,0.00007481727,0.000031009706,0.000010682219,0.000013317311,0.000021200052,0.00036670247],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985189,0.00008273297,0.00026156844,0.0004993101,0.00026038173,0.00037709973],"domain_scores_gemma":[0.999046,0.00012969856,0.00004001853,0.0004986296,0.00006411512,0.00022152154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021473065,0.00017174383,0.000456372,0.0006481081,0.000032724547,0.000020867401,0.00012299683,0.00014032,0.0005837992],"category_scores_gemma":[0.00009247933,0.00015053764,0.00006881501,0.0011930123,0.00006434255,0.000046176283,0.00013599248,0.0002981685,0.0002316262],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021644433,0.000022741051,0.40148273,0.00021445159,0.00024424042,0.000041009574,0.0002908491,0.0021129248,0.5913209,0.000007161929,0.000036676927,0.0040099323],"study_design_scores_gemma":[0.000997242,0.0002442915,0.984967,0.00002778366,0.00026655768,0.000031527616,0.00012003892,0.0027708698,0.01015039,0.000070135146,0.00018772263,0.00016643043],"about_ca_topic_score_codex":0.00017374844,"about_ca_topic_score_gemma":0.00023120026,"teacher_disagreement_score":0.5834843,"about_ca_system_score_codex":0.00081879506,"about_ca_system_score_gemma":0.00022736263,"threshold_uncertainty_score":0.63921916},"labels":[],"label_agreement":null},{"id":"W2934434513","doi":"10.1111/pde.13824","title":"Disseminated De Novo Myeloid Sarcoma in a 17‐year‐old Boy","year":2019,"lang":"en","type":"article","venue":"Pediatric Dermatology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Myeloid sarcoma; Myeloid; Myeloid leukemia; Myeloid cells; Differential diagnosis; Sarcoma; Pathology; Myeloid leukaemia; Dermatology; Immunology","score_opus":0.008790344693448351,"score_gpt":0.2800889655322312,"score_spread":0.27129862083878287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2934434513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838544,0.0006078212,0.000040870404,0.005226754,0.00016185673,0.0006163839,0.000007494363,0.00012073207,0.009363651],"genre_scores_gemma":[0.9917308,0.00039998494,0.00075154734,0.0010632357,0.00021117894,0.000052690717,0.00004961281,0.000050285576,0.0056906682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976683,0.00014818044,0.00045478303,0.00045756798,0.00030615108,0.00096499466],"domain_scores_gemma":[0.9986855,0.00030898512,0.00008906521,0.0005397618,0.000094934076,0.00028176507],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029726533,0.0002280425,0.0005964394,0.00070627534,0.000036771427,0.000017170421,0.0002981115,0.0003615177,0.0006446196],"category_scores_gemma":[0.00038334943,0.00021349428,0.00009857189,0.001001988,0.00005813218,0.00009629056,0.00018461324,0.0008127168,0.00195033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026638957,0.00016904643,0.9683647,0.00023849036,0.000023291002,0.0022658056,0.00028982526,0.0000030971928,0.0015648806,0.0002751168,0.02611231,0.00042701847],"study_design_scores_gemma":[0.013409467,0.00032470826,0.9490343,0.00005300905,0.00017464477,0.014002478,0.0007216712,0.0022837655,0.0025057904,0.0004595824,0.01638033,0.00065027026],"about_ca_topic_score_codex":0.00011586809,"about_ca_topic_score_gemma":0.00002333602,"teacher_disagreement_score":0.019330446,"about_ca_system_score_codex":0.00037619498,"about_ca_system_score_gemma":0.00056391145,"threshold_uncertainty_score":0.99882674},"labels":[],"label_agreement":null},{"id":"W2935992323","doi":"10.1200/jco.2015.33.15_suppl.7066","title":"Digital <i>Fusion-Gene</i> expression profiling in acute leukemia (AL): Clinical validation of throughput molecular technology in laboratory medicine.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Fusion gene; Chromosomal translocation; Medicine; Concordance; Gene expression profiling; breakpoint cluster region; ABL; Fusion transcript; Oncology; Cancer research; Gene expression; Computational biology; Gene; Bioinformatics; Internal medicine; Biology; Genetics; Tyrosine kinase","score_opus":0.10116976483108321,"score_gpt":0.4765078047867848,"score_spread":0.3753380399557016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935992323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98006696,0.0006677813,0.0005970545,0.015636928,0.0009087581,0.0004464229,0.000006494683,0.000018375651,0.0016512288],"genre_scores_gemma":[0.98155814,0.0012281449,0.014727914,0.0017712638,0.0005956869,0.000009819922,0.000016477381,0.00003758576,0.000054941193],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9913445,0.0010566752,0.0057318583,0.00043799193,0.0009903342,0.0004386348],"domain_scores_gemma":[0.9927854,0.0023996388,0.0024014967,0.00049005944,0.0013665227,0.0005568756],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.012071541,0.00023052271,0.0025840746,0.00083926966,0.000018060051,0.000008984077,0.0005005136,0.0012775153,0.00002808705],"category_scores_gemma":[0.02854583,0.00016592354,0.00030539383,0.0011226628,0.0009364967,0.00042541025,0.00031900153,0.003346436,0.000019066802],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012732178,0.0025940312,0.8036315,0.000079163896,0.00033275838,0.008975797,0.00025728683,0.0004023437,0.10196432,0.00017711308,0.013140363,0.055713173],"study_design_scores_gemma":[0.2214386,0.11189192,0.11446077,0.0054207835,0.001290804,0.0037913558,0.0074729747,0.0046357084,0.41846967,0.013512001,0.096136525,0.0014788823],"about_ca_topic_score_codex":0.000014191154,"about_ca_topic_score_gemma":0.000004765289,"teacher_disagreement_score":0.6891707,"about_ca_system_score_codex":0.0010398985,"about_ca_system_score_gemma":0.008810888,"threshold_uncertainty_score":0.99895287},"labels":[],"label_agreement":null},{"id":"W2939038933","doi":"10.1097/01.cot.0000557846.91598.e8","title":"Metabolism","year":2019,"lang":"en","type":"article","venue":"Oncology Times","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemistry","score_opus":0.017198547924663108,"score_gpt":0.33350994179333465,"score_spread":0.3163113938686715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939038933","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38224468,0.00040275638,0.000010562581,0.006917185,0.00020958425,0.00027640356,0.0000016538058,0.00006457959,0.60987264],"genre_scores_gemma":[0.57116735,0.00009352275,0.003994732,0.0032888693,0.0003274526,0.000025189613,0.000019030005,0.000027057042,0.4210568],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999234,0.000052995703,0.000116055366,0.00018825218,0.00014830033,0.0002603777],"domain_scores_gemma":[0.9993835,0.00012040846,0.000028895074,0.00028574019,0.000067691035,0.000113748516],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00022284508,0.00007868326,0.000298524,0.00009780121,0.000023526209,0.0000045885904,0.00009852679,0.00015285803,0.0099439295],"category_scores_gemma":[0.00007835528,0.000060682818,0.000063442596,0.00013015013,0.00007540914,0.000043707678,0.000074000774,0.00028885552,0.012874103],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009618431,0.00045714932,0.030697888,0.00009884872,0.0004681088,0.0005710625,0.0006132109,0.000005223079,0.11882719,0.019135509,0.7308725,0.097291484],"study_design_scores_gemma":[0.0020728963,0.0003524851,0.020760192,0.000007542998,0.00004874755,0.00018614561,0.00008805106,0.0001968422,0.0037519909,0.00024670712,0.97221947,0.000068938],"about_ca_topic_score_codex":0.000022572636,"about_ca_topic_score_gemma":0.0000015608746,"teacher_disagreement_score":0.24134697,"about_ca_system_score_codex":0.00019091765,"about_ca_system_score_gemma":0.0005151009,"threshold_uncertainty_score":0.99096113},"labels":[],"label_agreement":null},{"id":"W2939154568","doi":"10.1101/604397","title":"Profiling Myelodysplastic Syndromes by Mass Cytometry Demonstrates Abnormal Progenitor Cell Phenotype and Differentiation","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Stanford Cancer Institute; National Institutes of Health; Novartis Pharmaceuticals Corporation; Pfizer; Hamilton Health Sciences Foundation; Bill and Melinda Gates Foundation; U.S. Department of Defense","keywords":"Mass cytometry; Cytometry; Myelodysplastic syndromes; Progenitor cell; Flow cytometry; Cluster of differentiation; Bone marrow; Myeloid; Biology; CD44; Stem cell; Cell; Pathology; Phenotype; Immunology; Medicine; Cell biology; Genetics","score_opus":0.011919103411297954,"score_gpt":0.23402844413568424,"score_spread":0.2221093407243863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939154568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98690087,0.003266136,0.0057168347,0.00014610554,0.00080137746,0.0023620238,0.00037418274,0.00040501417,0.000027481608],"genre_scores_gemma":[0.98949623,0.00054497004,0.008826646,0.00007094406,0.00048134362,0.0002647794,0.000008786246,0.0002437176,0.000062561194],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958484,0.00017480865,0.00072240026,0.0014004195,0.0008673574,0.0009865777],"domain_scores_gemma":[0.9969673,0.00021367957,0.0004588554,0.0011266257,0.000647494,0.00058600015],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005695299,0.0008222357,0.0010438248,0.0006238649,0.00018708497,0.0003184403,0.00043451323,0.0009870061,0.0000670929],"category_scores_gemma":[0.0003249482,0.0008055516,0.00016434859,0.00064736186,0.00021442755,0.00022906219,0.00056544016,0.0018596932,0.00022801569],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016829744,0.0001684764,0.174673,0.0031355224,0.00030800398,0.000094757124,0.000005848007,0.000010132243,0.8211986,0.000033562636,0.00019957463,0.0000042613833],"study_design_scores_gemma":[0.0025276155,0.0003416766,0.169134,0.0008512997,0.00069800863,4.229406e-7,0.000014879782,0.0064390167,0.81855196,0.0000015313974,0.00028736782,0.0011522281],"about_ca_topic_score_codex":0.000021572812,"about_ca_topic_score_gemma":2.477623e-7,"teacher_disagreement_score":0.0064288843,"about_ca_system_score_codex":0.0007388781,"about_ca_system_score_gemma":0.0015937013,"threshold_uncertainty_score":0.99943954},"labels":[],"label_agreement":null},{"id":"W2942550491","doi":"10.1200/jco.19.00321","title":"FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Astellas Pharma","keywords":"Medicine; Transplantation; Randomized controlled trial; Placebo; Internal medicine; Oncology; Alternative medicine; Pathology","score_opus":0.05451053573607225,"score_gpt":0.4402787948149593,"score_spread":0.38576825907888707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942550491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.917205,0.0004648297,0.0005929636,0.06932624,0.0031135876,0.0028730545,0.0000069093744,0.000014786111,0.006402663],"genre_scores_gemma":[0.9576126,0.002863907,0.00405612,0.024937583,0.0046094838,0.00011410364,0.000003548012,0.000038447328,0.0057642595],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9907795,0.0028957648,0.0045559253,0.00034251946,0.0009626056,0.0004636513],"domain_scores_gemma":[0.97941554,0.016896429,0.0018412614,0.0003256318,0.00090710353,0.00061406195],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.020376317,0.00024028632,0.0050375247,0.00023422598,0.000032831515,0.000019612884,0.00029236384,0.0015315822,0.0025495489],"category_scores_gemma":[0.013033801,0.00014161893,0.002254177,0.00017946764,0.0005026797,0.000111548514,0.00004772127,0.0044401903,0.0005351832],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9758183,0.0006160912,0.0009186159,0.00006627953,0.0011492597,0.0017972884,0.00022314463,0.000004593341,0.0002155817,0.00010137858,0.0131949205,0.0058945427],"study_design_scores_gemma":[0.9524499,0.007865611,0.0007731713,0.00017531253,0.0010594472,0.0008396607,0.00005207275,0.00032285377,0.00009247471,0.0003789584,0.03585442,0.00013609976],"about_ca_topic_score_codex":0.000009803795,"about_ca_topic_score_gemma":0.000008263925,"teacher_disagreement_score":0.044388656,"about_ca_system_score_codex":0.0003193649,"about_ca_system_score_gemma":0.0045936606,"threshold_uncertainty_score":0.9997646},"labels":[],"label_agreement":null},{"id":"W2943259648","doi":"10.1016/s2352-3026(19)30029-8","title":"Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Agios Pharmaceuticals; European Hematology Association; Stand Up To Cancer; Entertainment Industry Foundation; Celgene; Astex Pharmaceuticals; Van Andel Research Institute; Pfizer; Amgen","keywords":"Decitabine; Medicine; Myelodysplastic syndromes; Hypomethylating agent; International Prognostic Scoring System; Azacitidine; Internal medicine; Clinical endpoint; Phases of clinical research; Clinical trial; Chronic myelomonocytic leukemia; Oncology; Bone marrow","score_opus":0.044043358952204334,"score_gpt":0.35056373520004225,"score_spread":0.3065203762478379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943259648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98751706,0.00008304627,0.00007571009,0.002260197,0.0007118981,0.008066001,0.00088689954,0.000090836525,0.00030836367],"genre_scores_gemma":[0.9954189,0.00017598696,0.0010619088,0.0008160183,0.00035252146,0.0003610163,0.0010006095,0.000089575784,0.0007234294],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99513185,0.0009548812,0.0012020384,0.0009515511,0.000629436,0.0011302674],"domain_scores_gemma":[0.99334604,0.0039000774,0.00061618735,0.0016310596,0.00020796289,0.00029865064],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012612259,0.00050312624,0.0029067916,0.0002978139,0.00011168881,0.00008182982,0.0012491305,0.00028842696,0.0007980852],"category_scores_gemma":[0.0038184114,0.00027295045,0.00006880235,0.0006155972,0.00038271482,0.00026624175,0.0005598853,0.0012428835,0.00083496555],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9790433,0.003864809,0.0048880684,0.00011833557,0.00048022007,0.0016868544,0.0009808642,0.000010452879,0.000120175886,0.000041149848,0.0060160235,0.0027497564],"study_design_scores_gemma":[0.9819606,0.008750103,0.0034601528,0.00048687393,0.00041394553,0.0001450223,0.00020451682,0.002895704,0.00018540192,0.00008791934,0.0010576982,0.0003520873],"about_ca_topic_score_codex":0.0009332674,"about_ca_topic_score_gemma":0.00040915536,"teacher_disagreement_score":0.0079018865,"about_ca_system_score_codex":0.00030232902,"about_ca_system_score_gemma":0.0005592273,"threshold_uncertainty_score":0.9999723},"labels":[],"label_agreement":null},{"id":"W2943902055","doi":"10.1111/ijlh.13022","title":"Genomic testing in myeloid malignancy","year":2019,"lang":"en","type":"review","venue":"International Journal of Laboratory Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"","keywords":"Genetic testing; Computational biology; Disease; DNA sequencing; Biology; Genomics; Genetics; Genome; Cytogenetics; Bioinformatics; Gene; Medicine; Chromosome; Pathology","score_opus":0.07841812897691511,"score_gpt":0.3982507409140998,"score_spread":0.3198326119371847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943902055","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011306517,0.99543095,0.000021250627,0.00030266587,0.0017126331,0.00040990586,0.000051022063,0.000013425391,0.00092749775],"genre_scores_gemma":[0.00027338087,0.9964513,0.001979537,0.0002585399,0.0007250084,0.000015412197,0.00002697278,0.00008403367,0.00018581211],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964982,0.00030100878,0.0018573917,0.0003149303,0.00066174933,0.00036668882],"domain_scores_gemma":[0.995492,0.0008163125,0.001510583,0.00031486736,0.001692103,0.00017415539],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00088662753,0.0003552145,0.002595859,0.001667637,0.000016214182,0.00003239528,0.00090755016,0.0004978776,0.0002687398],"category_scores_gemma":[0.001518831,0.00028503127,0.00038865412,0.0006087829,0.000099362434,0.00014241935,0.00021017288,0.0016561873,0.0003839379],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040614663,0.00060494564,0.015012516,0.023724798,0.003328397,0.04756425,0.00016400797,0.000009727113,0.00030193504,0.0028868506,0.008231216,0.8977652],"study_design_scores_gemma":[0.0015527536,0.00020207622,0.00018295753,0.02294497,0.00035879077,0.02261886,0.000028753415,0.000011602376,0.00002298086,0.00007051296,0.9517668,0.00023895015],"about_ca_topic_score_codex":0.0000069838406,"about_ca_topic_score_gemma":0.0000027392384,"teacher_disagreement_score":0.94353557,"about_ca_system_score_codex":0.0015026913,"about_ca_system_score_gemma":0.006609322,"threshold_uncertainty_score":0.9999602},"labels":[],"label_agreement":null},{"id":"W2943967571","doi":"10.1182/blood.2018862383","title":"Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Centre hospitalier universitaire de Québec; BC Cancer Agency; Institute for Research in Immunology and Cancer; Université Laval; Université de Montréal","funders":"","keywords":"NPM1; Stem cell; Leukemia; Regulator; Cancer research; Biology; Medicine; Immunology; Karyotype; Genetics; Gene","score_opus":0.015219965049069702,"score_gpt":0.25354746397311984,"score_spread":0.23832749892405014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943967571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995271,0.0007861431,0.00002201708,0.0003263226,0.00013277862,0.0015964784,0.00008714237,0.0001250206,0.0016530682],"genre_scores_gemma":[0.98395455,0.00014667277,0.00059214886,0.0004824151,0.00011565815,0.000051836163,0.000042541506,0.00010564069,0.014508529],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969059,0.00008737839,0.0006374093,0.00082485826,0.00069520605,0.00084920635],"domain_scores_gemma":[0.99818,0.00021575828,0.0001626065,0.0008707636,0.00014756214,0.00042336062],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035843943,0.0004162071,0.00082491164,0.00048011757,0.000063977575,0.000060459282,0.00029072986,0.0003668452,0.0004041219],"category_scores_gemma":[0.000063360945,0.00037093103,0.00013754198,0.0007284682,0.00012337667,0.00019838584,0.00021236793,0.0008216462,0.000519082],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070234924,0.0007424767,0.23059922,0.0011618262,0.00025908556,0.00025157887,0.0022989577,0.000008136886,0.7598827,0.000047506503,0.0021734193,0.0018727592],"study_design_scores_gemma":[0.08599184,0.0017987653,0.4225658,0.000999895,0.00048836763,0.00065368967,0.0015358194,0.014628957,0.465753,0.00005512903,0.0042046444,0.0013241211],"about_ca_topic_score_codex":0.00058461644,"about_ca_topic_score_gemma":0.00004031329,"teacher_disagreement_score":0.2941297,"about_ca_system_score_codex":0.0011386309,"about_ca_system_score_gemma":0.001488884,"threshold_uncertainty_score":0.99987423},"labels":[],"label_agreement":null},{"id":"W2944184498","doi":"10.1016/j.jgo.2019.04.009","title":"Age-related cytokine effects on cancer-related fatigue and quality of life in acute myeloid leukemia","year":2019,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Toronto Rehabilitation Institute; University of Toronto; University Health Network","funders":"Leukemia and Lymphoma Society","keywords":"Medicine; Cytokine; Myeloid leukemia; Minimal clinically important difference; Quality of life (healthcare); Internal medicine; Myeloid; Tumor necrosis factor alpha; Oncology; Cancer; Cancer-related fatigue; Proinflammatory cytokine; Immunology; Inflammation; Randomized controlled trial","score_opus":0.025640539446309743,"score_gpt":0.3540582091713006,"score_spread":0.32841766972499087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944184498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99202377,0.0014403155,0.000007983237,0.0027759674,0.0007303957,0.00069064024,0.000007688895,0.000018254292,0.0023050094],"genre_scores_gemma":[0.9948653,0.003071514,0.00064138684,0.00038506187,0.00021683903,0.000008956022,0.0000062318877,0.000035072313,0.0007696417],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99633676,0.000705929,0.001659688,0.0002898283,0.0005697214,0.00043804772],"domain_scores_gemma":[0.9963544,0.0014012107,0.0012721445,0.0002975843,0.00031663448,0.00035802144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021232476,0.00024406156,0.0017278359,0.00092839997,0.000030355117,0.000009113344,0.00023830117,0.0005695591,0.00023216534],"category_scores_gemma":[0.0008709184,0.00019021455,0.00020176178,0.0009590416,0.00012504404,0.00012397408,0.00010511712,0.0015540447,0.00002845061],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022235515,0.0014420799,0.43457624,0.002248189,0.004016783,0.004499126,0.0034045249,0.00078315096,0.45862338,0.0007588168,0.0077611436,0.059651032],"study_design_scores_gemma":[0.0443263,0.012095925,0.93015015,0.00050094945,0.00059280306,0.00068828184,0.00018783066,0.0005354497,0.0069780727,0.00027493812,0.0033281832,0.00034108758],"about_ca_topic_score_codex":0.0005086419,"about_ca_topic_score_gemma":0.00004795072,"teacher_disagreement_score":0.49557394,"about_ca_system_score_codex":0.002659699,"about_ca_system_score_gemma":0.003266472,"threshold_uncertainty_score":0.7756724},"labels":[],"label_agreement":null},{"id":"W2944232399","doi":"10.1016/j.jaad.2018.05.543","title":"Epidemiology and geographic trends for chronic myelomonocytic leukemia in Canada","year":2018,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Chronic myelomonocytic leukemia; Epidemiology; Environmental health; Immunology; Pathology; Myelodysplastic syndromes","score_opus":0.02965277291069233,"score_gpt":0.34949860411378364,"score_spread":0.3198458312030913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944232399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9491963,0.0017975286,0.00007125158,0.048598956,0.0000917586,0.0001454385,0.0000063454395,0.0000027476278,0.000089691464],"genre_scores_gemma":[0.9939667,0.00074476394,0.0011527301,0.003853981,0.00020569381,0.0000061921423,5.7966986e-7,0.00001734217,0.000052032174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978303,0.000359939,0.0009274573,0.00017376675,0.00018604305,0.000522504],"domain_scores_gemma":[0.9973294,0.0010670683,0.001161856,0.00015731355,0.00009676888,0.00018758667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057492265,0.00014946597,0.0011746648,0.0005002664,0.00005457956,0.0000012376365,0.00040538842,0.00010450259,0.000016803013],"category_scores_gemma":[0.0007337312,0.00009849423,0.00016440988,0.0005920072,0.0015979641,0.000051112875,0.00011591309,0.00081894954,7.157471e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001579119,0.000024769599,0.93020624,0.00018325484,0.00043115858,0.00008463244,0.00012235901,0.00004564938,0.0043795086,0.0005050086,0.019682182,0.04275609],"study_design_scores_gemma":[0.0034891702,0.00079576665,0.9580032,0.00014058509,0.00017342455,0.014207188,0.00022080315,0.0040677385,0.0038964192,0.0010332974,0.013832164,0.00014019322],"about_ca_topic_score_codex":0.079538636,"about_ca_topic_score_gemma":0.042958677,"teacher_disagreement_score":0.044770405,"about_ca_system_score_codex":0.0019317108,"about_ca_system_score_gemma":0.0039027077,"threshold_uncertainty_score":0.9745048},"labels":[],"label_agreement":null},{"id":"W2944256950","doi":"10.1016/j.mpdhp.2019.04.004","title":"Molecular genetic testing in the diagnosis of myeloid neoplasms","year":2019,"lang":"en","type":"article","venue":"Diagnostic histopathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Myeloid; Genetic testing; Computational biology; Biology; Medicine; Genetics; Cancer research","score_opus":0.018015900982134965,"score_gpt":0.27386094722731796,"score_spread":0.255845046245183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944256950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894416,0.001233551,0.00009314177,0.0012790845,0.0001603531,0.0009157369,0.000007565354,0.000026307196,0.006842661],"genre_scores_gemma":[0.99577063,0.0001300993,0.0022395002,0.0013977442,0.00005013348,0.0002636796,0.000013740403,0.000032905016,0.00010157571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809515,0.00029591945,0.00043122438,0.00038236706,0.00034199722,0.0004533583],"domain_scores_gemma":[0.99386156,0.005107327,0.00011360546,0.0007056638,0.00013081002,0.000081031554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005739621,0.00017567648,0.0004571134,0.00027454924,0.00003204414,0.000006261699,0.00034727852,0.00015659799,0.00020603341],"category_scores_gemma":[0.008329423,0.00013494054,0.000086970766,0.0006279291,0.00023359295,0.00002970494,0.0001024125,0.0004713772,0.00032097485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004145518,0.00022334159,0.9716662,0.00013595297,0.000007370524,0.0034247562,0.0010370405,0.00019383128,0.01504659,0.00037909305,0.00078868325,0.007055687],"study_design_scores_gemma":[0.0017830158,0.00095753063,0.9887337,0.00017119087,0.000077733,0.0012972414,0.0003130631,0.00043721637,0.0033183,0.00027489115,0.002465061,0.00017107511],"about_ca_topic_score_codex":0.00021235681,"about_ca_topic_score_gemma":0.000019593133,"teacher_disagreement_score":0.017067483,"about_ca_system_score_codex":0.00015870875,"about_ca_system_score_gemma":0.00026676356,"threshold_uncertainty_score":0.99717},"labels":[],"label_agreement":null},{"id":"W2946250058","doi":"10.1136/archdischild-2019-esdppp.135","title":"P97 Busulfan/sulfolane metabolic ratio on the third day of conditioning may predict the event-free survival in children receiving busulfan based conditioning prior to hematopoietic stem-cell transplantation","year":2019,"lang":"en","type":"article","venue":"Archives of Disease in Childhood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"European Commission","keywords":"Busulfan; Medicine; Cohort; Transplantation; Internal medicine; Hematopoietic stem cell transplantation; Receiver operating characteristic; Gastroenterology; Surgery","score_opus":0.007433368230316081,"score_gpt":0.2437206145535481,"score_spread":0.236287246323232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946250058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99096847,0.00024877125,0.000398453,0.0033218327,0.000071633964,0.00295796,0.00057470816,0.00003396831,0.0014242011],"genre_scores_gemma":[0.9983983,0.000112180365,0.00019662605,0.00040597562,0.000076374075,0.00016629825,0.0004800316,0.00005179714,0.00011241346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965653,0.0008118353,0.0007991388,0.0005067239,0.00085079443,0.00046623868],"domain_scores_gemma":[0.9960596,0.0023295197,0.00028242083,0.0010467218,0.000059528316,0.0002222399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009915893,0.0003054138,0.0005802856,0.0005157348,0.00013872665,0.00003496645,0.00069805724,0.00006605094,0.00012721786],"category_scores_gemma":[0.0004109771,0.00021282634,0.0002117602,0.00061272667,0.00021363598,0.00014438549,0.000112496746,0.000632875,0.000022835731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021039913,0.0014179013,0.94900125,0.0006585538,0.00029781734,0.0000328082,0.013293144,0.01348395,0.013192623,0.0044872146,0.0001642192,0.0018665544],"study_design_scores_gemma":[0.0052810586,0.00028803124,0.97812504,0.001552382,0.00016995448,0.000006311447,0.0007435262,0.0014357504,0.011694148,0.0004971152,0.00000870646,0.00019797312],"about_ca_topic_score_codex":0.0001410735,"about_ca_topic_score_gemma":0.00004814011,"teacher_disagreement_score":0.029123819,"about_ca_system_score_codex":0.000058855534,"about_ca_system_score_gemma":0.000645767,"threshold_uncertainty_score":0.86788064},"labels":[],"label_agreement":null},{"id":"W2946281117","doi":"10.1111/bjh.15990","title":"Longitudinal sequencing of <i><scp>RUNX</scp>1</i> familial platelet disorder: new insights into genetic mechanisms of transformation to myeloid malignancies","year":2019,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; Ontario Institute for Cancer Research; Fundação de Amparo à Pesquisa do Estado de São Paulo; Southeastern Ontario Academic Medical Organization; European Hematology Association","keywords":"Transformation (genetics); Myeloid; Cancer research; Genetics; Immunology; Medicine; Gene; Biology","score_opus":0.03612463633027961,"score_gpt":0.3049050492315919,"score_spread":0.26878041290131227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946281117","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0724735,0.9087917,0.016397072,0.00008960719,0.0004964374,0.0015144079,0.000045570036,0.000017088569,0.00017456726],"genre_scores_gemma":[0.0073744874,0.9844884,0.0074826768,0.000085152875,0.00021187669,0.000020832582,0.00005843703,0.000108533044,0.0001695656],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99419194,0.00040255254,0.0032499365,0.0004395181,0.001063956,0.000652066],"domain_scores_gemma":[0.9957371,0.0005486767,0.0019592198,0.0004273987,0.0008635783,0.00046404396],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067926326,0.0005397547,0.0056213867,0.0011913143,0.000080483216,0.000035100296,0.0007645127,0.0007962009,0.000042376567],"category_scores_gemma":[0.0007941456,0.00051240285,0.001022862,0.000786983,0.00021985118,0.00025295312,0.00016351069,0.0013028979,0.00004448444],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013099799,0.00018809641,0.000021507967,0.067301,0.0013731914,0.017735444,0.0022036952,0.000082279505,0.0012290562,0.00081669685,0.0038380905,0.90507996],"study_design_scores_gemma":[0.005018125,0.003326736,0.00010035049,0.08066278,0.0031717648,0.51459897,0.0012595606,0.00005474947,0.0045569306,0.0017262973,0.38503516,0.00048858876],"about_ca_topic_score_codex":0.0006337415,"about_ca_topic_score_gemma":0.00022458835,"teacher_disagreement_score":0.9045914,"about_ca_system_score_codex":0.0005336185,"about_ca_system_score_gemma":0.0046096523,"threshold_uncertainty_score":0.99973273},"labels":[],"label_agreement":null},{"id":"W2946643325","doi":"10.1016/j.celrep.2019.04.064","title":"Functional Dominance of CHIP-Mutated Hematopoietic Stem Cells in Patients Undergoing Autologous Transplantation","year":2019,"lang":"en","type":"article","venue":"Cell Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Infection and Immunity; Hessisches Ministerium für Wissenschaft und Kunst; Deutsche Forschungsgemeinschaft; University of Capetown","keywords":"Stem cell; Haematopoiesis; Biology; Progenitor cell; Hematopoietic stem cell transplantation; Cancer research; Transplantation; Germline mutation; clone (Java method); Somatic cell; Immunology; Mutation; Medicine; Internal medicine; Gene; Genetics","score_opus":0.010352830705838511,"score_gpt":0.23425721585323758,"score_spread":0.22390438514739908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946643325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943652,0.000071317234,0.00012449181,0.00003185622,0.00029321856,0.000648833,0.0000030736308,0.000027271786,0.0044347346],"genre_scores_gemma":[0.99615234,0.000047247595,0.00016051152,0.000034395103,0.000014079111,0.000012047962,0.00006677484,0.000022515194,0.003490116],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99842215,0.000042799988,0.0005467707,0.00032216683,0.0004205309,0.00024561328],"domain_scores_gemma":[0.9991363,0.000113094524,0.00025049056,0.00030713307,0.00012023164,0.00007272583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025462234,0.00012382331,0.0003186754,0.00016752978,0.000019909301,0.0000054683646,0.000041697687,0.00011217988,0.00014920773],"category_scores_gemma":[0.000015962747,0.00011385362,0.00006600123,0.00025229977,0.000041471238,0.00007341237,0.000018946419,0.0002126312,0.00008264194],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011509234,0.00063463574,0.8530192,0.002779319,0.000048100803,0.0023161178,0.0012816489,0.001129188,0.13492525,0.000026648357,0.0010768614,0.0016121281],"study_design_scores_gemma":[0.005091806,0.000477805,0.49426457,0.00041993044,0.000056234312,0.00043496204,0.00015504107,0.0004139298,0.49828917,0.00007708453,0.00013288908,0.00018657633],"about_ca_topic_score_codex":0.000026502348,"about_ca_topic_score_gemma":0.000006041255,"teacher_disagreement_score":0.36336392,"about_ca_system_score_codex":0.0002246977,"about_ca_system_score_gemma":0.00039201402,"threshold_uncertainty_score":0.4642816},"labels":[],"label_agreement":null},{"id":"W2947694610","doi":"10.2196/13554","title":"Core Data Elements in Acute Myeloid Leukemia: A Unified Medical Language System–Based Semantic Analysis and Experts’ Review","year":2019,"lang":"en","type":"article","venue":"JMIR Medical Informatics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science; Documentation; Metadata; Data dictionary; Information retrieval; Unified Medical Language System; Data science; World Wide Web","score_opus":0.03851090297430942,"score_gpt":0.37155328697744205,"score_spread":0.33304238400313263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947694610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833248,0.0030480123,0.0012481763,0.00424525,0.00014838293,0.0031571973,0.000113666516,0.00021352811,0.0045009535],"genre_scores_gemma":[0.9496695,0.009579775,0.0045954054,0.029418577,0.00023054704,0.00029561273,0.005220883,0.00008569717,0.0009040242],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9936906,0.00014087552,0.0017184536,0.00037975333,0.00337605,0.0006942739],"domain_scores_gemma":[0.9963057,0.00037815658,0.00030390272,0.001811708,0.00012536855,0.001075134],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030775361,0.00033590145,0.0013743916,0.00063264754,0.000052059597,0.00003875651,0.0010681256,0.0005051546,0.0023139399],"category_scores_gemma":[0.0011276125,0.0002445723,0.0001362646,0.001780072,0.0002286744,0.00031693504,0.0008983619,0.001178451,0.0002612028],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020542336,0.0018105025,0.27396142,0.21223141,0.013596266,0.01689466,0.020943599,0.00001384613,0.0007661563,0.0011691933,0.2201381,0.23642059],"study_design_scores_gemma":[0.011716047,0.00037971284,0.007914113,0.018630954,0.0018715928,0.00067660166,0.007924796,0.93903124,0.000057025405,0.000002869377,0.011160094,0.0006349587],"about_ca_topic_score_codex":0.00017598072,"about_ca_topic_score_gemma":0.00011591415,"teacher_disagreement_score":0.9390174,"about_ca_system_score_codex":0.0006621843,"about_ca_system_score_gemma":0.0021505465,"threshold_uncertainty_score":0.9985981},"labels":[],"label_agreement":null},{"id":"W2947731597","doi":"10.1200/jco.2019.37.15_suppl.10002","title":"Effect of intensification of induction II chemotherapy and liberalization of stem cell donor source on outcome for children with high risk acute myeloid leukemia: A report from the Children’s Oncology Group.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Induction chemotherapy; Internal medicine; Minimal residual disease; Oncology; Myeloid leukemia; Chemotherapy; Regimen; Chemotherapy regimen; Leukemia; Surgery","score_opus":0.03208573921117659,"score_gpt":0.3784880680724489,"score_spread":0.3464023288612723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947731597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941002,0.00011972332,0.001165071,0.002668072,0.0003305578,0.001524572,0.000028492439,0.000007965663,0.000055311324],"genre_scores_gemma":[0.9956733,0.00087954465,0.0021390386,0.00047668812,0.0005298166,0.000014189494,0.000057867637,0.000038537135,0.00019101572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952616,0.0009795564,0.002749618,0.00033344718,0.00046983888,0.0002059213],"domain_scores_gemma":[0.987609,0.0048601185,0.0061397557,0.00046796107,0.0007758683,0.00014729207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005825273,0.00020908433,0.0021290688,0.00018102952,0.000051980507,0.0000044510875,0.0002505895,0.000658587,0.000020590303],"category_scores_gemma":[0.0010800485,0.00011604815,0.00036443112,0.00020932624,0.00040587512,0.0001067798,0.00007422321,0.0012583315,0.0000013646118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03356933,0.0007862368,0.80088127,0.00007062373,0.001716378,0.00001172247,0.0004286411,0.00011149179,0.006561832,0.000027616881,0.0010920824,0.15474279],"study_design_scores_gemma":[0.023324432,0.07686384,0.8822238,0.00011241462,0.0013790507,0.0005178653,0.00009812672,0.00017972793,0.01423344,0.000054729055,0.0009130168,0.00009957722],"about_ca_topic_score_codex":0.00046841017,"about_ca_topic_score_gemma":0.000024102912,"teacher_disagreement_score":0.15464321,"about_ca_system_score_codex":0.00045439985,"about_ca_system_score_gemma":0.001027521,"threshold_uncertainty_score":0.5466894},"labels":[],"label_agreement":null},{"id":"W2947940526","doi":"10.1016/j.exphem.2019.05.003","title":"Pediatric leukemia: Moving toward more accurate models","year":2019,"lang":"en","type":"review","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital de l'Enfant-Jésus; Université de Montréal; Centre hospitalier universitaire de Québec; Institute for Research in Immunology and Cancer","funders":"Canadian Cancer Society Research Institute","keywords":"Leukemia; Computer science; Medicine; Computational biology; Internal medicine; Biology","score_opus":0.12844701459762323,"score_gpt":0.4224455466601128,"score_spread":0.2939985320624896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947940526","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011833704,0.9902744,0.0000934135,0.00008111763,0.00073567824,0.0025235706,0.00004066712,0.00021650163,0.0059162923],"genre_scores_gemma":[0.0010364064,0.9936047,0.00085555774,0.00024026174,0.00061826216,0.0006035605,0.00040446437,0.00027521394,0.0023615663],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955471,0.0002357764,0.001199816,0.00125019,0.00061978446,0.0011473404],"domain_scores_gemma":[0.9974723,0.00033078546,0.00047377252,0.001191565,0.000095608484,0.00043600553],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024080166,0.0009664334,0.0045114146,0.00072966097,0.00010538272,0.00004186669,0.00070565264,0.0013661433,0.0008020191],"category_scores_gemma":[0.000074787706,0.00078398,0.0009828657,0.0006283188,0.00019717195,0.00022133025,0.00087919814,0.0017884616,0.0025132203],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007452299,0.0019779715,0.00012224908,0.38294557,0.003834726,0.01532553,0.004154768,0.000046714365,0.000054366705,0.067660436,0.14279523,0.3803372],"study_design_scores_gemma":[0.0041672266,0.00081058807,0.0000017298999,0.008084218,0.0027244284,0.021183778,0.0011663451,0.0019139039,0.0011658014,0.00010337228,0.95656335,0.002115275],"about_ca_topic_score_codex":0.0000492158,"about_ca_topic_score_gemma":3.255563e-7,"teacher_disagreement_score":0.8137681,"about_ca_system_score_codex":0.0029822385,"about_ca_system_score_gemma":0.0031052392,"threshold_uncertainty_score":0.9999303},"labels":[],"label_agreement":null},{"id":"W2948813254","doi":"10.1111/ejh.13272","title":"Implementation of an NGS‐based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignancies","year":2019,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; London Health Sciences Centre; Queen's University; Canadian Electricity Association; University of Ottawa; Kingston Health Sciences Centre; Western University","funders":"European Hematology Association","keywords":"Fusion gene; DNA sequencing; Hematologic Neoplasms; Medicine; Gene; Oncology; Internal medicine; Computational biology; Genetics; Biology; Cancer","score_opus":0.07699446865798654,"score_gpt":0.3604213250905318,"score_spread":0.2834268564325453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948813254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99487174,0.00009126141,0.0042995736,0.00017237493,0.00005162836,0.00045624768,0.000012739109,0.000007456935,0.000036979196],"genre_scores_gemma":[0.9631507,0.000022740775,0.036644187,0.00009432704,0.0000252082,9.134523e-7,0.000027780214,0.000026683718,0.0000074958834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781793,0.00051206717,0.001009592,0.00017506708,0.00027556333,0.00020975625],"domain_scores_gemma":[0.99758905,0.0002931117,0.001018692,0.00019153435,0.00078622974,0.000121390345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001457723,0.000120182056,0.000745664,0.00022840379,0.000032882966,0.0000053887097,0.00013569451,0.00004429116,0.00006130577],"category_scores_gemma":[0.00023324208,0.00008282056,0.00008899697,0.0001221298,0.00016524165,0.00010378664,0.000054068674,0.00021105354,0.000001421813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003981188,0.00017483985,0.94641024,0.00052907865,0.00019189143,0.0008472896,0.00043306095,0.00002517434,0.043477543,0.00011131956,0.00010269368,0.0037156597],"study_design_scores_gemma":[0.018659582,0.011186299,0.91880566,0.00041054544,0.00021885837,0.0023857735,0.002086473,0.00075326115,0.045263145,0.000018752988,0.000071614675,0.00014006003],"about_ca_topic_score_codex":0.000008169949,"about_ca_topic_score_gemma":0.0000032906587,"teacher_disagreement_score":0.032344613,"about_ca_system_score_codex":0.00003831365,"about_ca_system_score_gemma":0.00024649085,"threshold_uncertainty_score":0.33773246},"labels":[],"label_agreement":null},{"id":"W2948900598","doi":"10.1016/s1470-2045(19)30150-0","title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":479,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"Daiichi-Sankyo; Incyte; National Cancer Institute; National Cancer Research Institute; Celgene","keywords":"Medicine; Cytarabine; Internal medicine; Chemotherapy; Salvage therapy; Chemotherapy regimen; Febrile neutropenia; Etoposide; Surgery; Mitoxantrone; Fludarabine; Phases of clinical research; Transplantation; Refractory (planetary science); Oncology; Gastroenterology; Neutropenia; Cyclophosphamide","score_opus":0.09386240084003972,"score_gpt":0.4315224040450322,"score_spread":0.3376600032049925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948900598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95338273,0.0004359538,0.000020446028,0.014408673,0.0016789129,0.014454041,0.000038868813,0.00013928284,0.015441098],"genre_scores_gemma":[0.9594557,0.0038808289,0.002068767,0.011433624,0.0032696282,0.0023739014,0.00016666266,0.00023987307,0.017110975],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940971,0.0018220068,0.0012242467,0.0008429292,0.00061851996,0.0013952062],"domain_scores_gemma":[0.99159557,0.005741438,0.0005953174,0.001549245,0.00019635048,0.00032206895],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0048349807,0.00051604887,0.00322813,0.0002583583,0.00015604934,0.00008163437,0.0014324634,0.000593186,0.0024863544],"category_scores_gemma":[0.002403027,0.00030977165,0.00021460374,0.0006310203,0.00035937873,0.00020426566,0.00039456686,0.0019401954,0.0010269302],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9343994,0.0025961269,0.000091356946,0.00005597408,0.0009621986,0.0008062828,0.0010768995,0.000006421541,0.027127923,0.0002044086,0.021573666,0.011099324],"study_design_scores_gemma":[0.8707371,0.014714375,0.00009417959,0.0000802201,0.00035469752,0.00008397985,0.00042867186,0.005053406,0.0007152452,0.000042381558,0.10737738,0.00031836616],"about_ca_topic_score_codex":0.00023712897,"about_ca_topic_score_gemma":0.00025184784,"teacher_disagreement_score":0.08580371,"about_ca_system_score_codex":0.0018656424,"about_ca_system_score_gemma":0.0026940643,"threshold_uncertainty_score":0.99993545},"labels":[],"label_agreement":null},{"id":"W2948903259","doi":"10.1136/jclinpath-2019-205851","title":"Emerging patterns in clonal haematopoiesis","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University Health Network; Toronto General Hospital","funders":"","keywords":"Haematopoiesis; Biology; Somatic evolution in cancer; Myeloid; Myelodysplastic syndromes; Disease; Hematology; Immunology; Stem cell; Leukemia; Mutation; Gene; Cancer research; Genetics; Internal medicine; Medicine; Bone marrow","score_opus":0.23836048319979602,"score_gpt":0.5419496756751434,"score_spread":0.3035891924753474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948903259","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037414143,0.99228215,0.0000901595,0.00088104594,0.0017467458,0.00052364904,0.000019438203,0.00000871658,0.0007066947],"genre_scores_gemma":[0.00015439936,0.9956332,0.0008956424,0.000514744,0.001982201,0.000008404581,0.000019165713,0.000077427765,0.00071480224],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99131423,0.0016616744,0.0054105823,0.0004376446,0.00063454796,0.00054130174],"domain_scores_gemma":[0.9926899,0.0034408567,0.0025929962,0.00059575547,0.00031634682,0.00036410955],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0069221854,0.000384097,0.007653774,0.0009417478,0.000020104162,0.000013845993,0.0005853124,0.0013227055,0.00045978386],"category_scores_gemma":[0.0052517066,0.00025831445,0.0024072197,0.00036885514,0.0001873824,0.00008180149,0.00026603075,0.0056457124,0.0003610948],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018302938,0.00029839907,0.008325376,0.011566235,0.000324988,0.019958569,0.000029393459,4.4488942e-7,4.1753077e-7,0.000033880995,0.0029731106,0.95630616],"study_design_scores_gemma":[0.0024374737,0.0010395288,0.0041761124,0.018124547,0.0012015286,0.017759886,0.000030355728,0.000006907376,1.5812162e-7,0.000062925355,0.95494574,0.00021485775],"about_ca_topic_score_codex":0.000004454898,"about_ca_topic_score_gemma":0.0000050244516,"teacher_disagreement_score":0.9560913,"about_ca_system_score_codex":0.00031881477,"about_ca_system_score_gemma":0.0030365835,"threshold_uncertainty_score":0.9999869},"labels":[],"label_agreement":null},{"id":"W2949134677","doi":"10.1097/01.hs9.0000562560.17744.f0","title":"PS1066 AXICABTAGENE CILOLEUCEL (AXI‐CEL) IN REFRACTORY LARGE B CELL LYMPHOMA: OUTCOMES IN PATIENTS ≥ OR &lt; 65 YEARS OF AGE IN THE PIVOTAL PHASE 1/2 ZUMA‐1 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Leukapheresis; Lymphoma; Adverse effect; Gastroenterology; Phases of clinical research; Clinical endpoint; Oncology; Surgery; Chemotherapy; Clinical trial; Stem cell; CD34","score_opus":0.01893548555659678,"score_gpt":0.31333592288334955,"score_spread":0.29440043732675275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949134677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99350935,0.00018922555,0.0000014015403,0.000081614366,0.00010795088,0.0022454641,0.00003642799,0.000021305466,0.0038072357],"genre_scores_gemma":[0.99493724,0.000032985758,0.00008854831,0.0002686058,0.000034064145,0.00008702492,0.000045891265,0.000056783138,0.004448834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99680144,0.0003434559,0.0007417792,0.0005092434,0.00094421755,0.00065985933],"domain_scores_gemma":[0.9983939,0.00034784578,0.00015959307,0.0009094499,0.00007105456,0.00011813883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009184244,0.00028096169,0.0007971461,0.0002587881,0.000024959458,0.000017214601,0.0004510107,0.00019387374,0.00075105525],"category_scores_gemma":[0.0002662126,0.00019929075,0.000113770235,0.0008072819,0.00006570518,0.0001420625,0.0002199846,0.00055182393,0.00021219159],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020577966,0.028938137,0.9503882,0.00026033146,0.000049354658,0.0019236262,0.007067134,0.0000041384146,0.002326692,0.000012595592,0.0014135876,0.0055584405],"study_design_scores_gemma":[0.07196912,0.0028845107,0.9137741,0.00014529817,0.00002862822,0.0000052890728,0.007958993,0.00007652056,0.0007113544,0.000008929234,0.002185342,0.00025196376],"about_ca_topic_score_codex":0.0005447033,"about_ca_topic_score_gemma":0.0016924716,"teacher_disagreement_score":0.06991133,"about_ca_system_score_codex":0.0006126746,"about_ca_system_score_gemma":0.0004105758,"threshold_uncertainty_score":0.8223528},"labels":[],"label_agreement":null},{"id":"W2949176693","doi":"10.1016/j.critrevonc.2019.06.002","title":"Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions","year":2019,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"Novartis Pharmaceuticals Canada; Celgene","keywords":"Myelodysplastic syndromes; Medicine; Chelation therapy; Myeloid leukemia; Anemia; Clinical trial; Randomized controlled trial; Intensive care medicine; Internal medicine; Haematopoiesis; Blood transfusion; Oncology; Stem cell; Thalassemia; Bone marrow; Biology","score_opus":0.22302558547096987,"score_gpt":0.5055964256629083,"score_spread":0.28257084019193845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949176693","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014831625,0.98715603,0.003923837,0.0013692795,0.000657348,0.0063045127,0.000052118066,0.00005777284,0.00033077374],"genre_scores_gemma":[0.00070404366,0.9875753,0.009517903,0.00045534625,0.00011900443,0.00095821853,0.00048334652,0.000106186904,0.000080678445],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9901457,0.002637816,0.0035925426,0.002008374,0.00043015223,0.0011854122],"domain_scores_gemma":[0.99136263,0.0057237055,0.0006480675,0.0016868662,0.00014918229,0.00042953808],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.005294392,0.00089797407,0.008724106,0.00083670404,0.00009491572,0.000040390525,0.0007746687,0.0021439712,0.00027619605],"category_scores_gemma":[0.008069465,0.0006055138,0.00034264353,0.0007393654,0.0009896472,0.00020751655,0.0007620765,0.0035493034,0.00032977716],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032878402,0.0011855285,0.0004322939,0.045447893,0.0002073414,0.0042172605,0.00003770695,3.6454088e-7,0.000004499006,0.03026607,0.00071210566,0.91716015],"study_design_scores_gemma":[0.008700058,0.0092974445,0.00016045842,0.10342533,0.003177557,0.02854593,0.00020869759,0.000987127,0.0000014086919,0.003195877,0.84078,0.0015200865],"about_ca_topic_score_codex":0.000020552017,"about_ca_topic_score_gemma":0.00005073714,"teacher_disagreement_score":0.91564006,"about_ca_system_score_codex":0.0013787426,"about_ca_system_score_gemma":0.0023198281,"threshold_uncertainty_score":0.99963963},"labels":[],"label_agreement":null},{"id":"W2949420727","doi":"10.1097/01.hs9.0000564700.06449.e7","title":"S1613 ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION CAN ABROGATE INCREASING RISK OF RELAPSE FROM PERSISTENT MUTATIONS MEASURED BY TARGETED SEQUENCING AT REMISSION IN NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Oncology; Cumulative incidence; Medicine; Internal medicine; Hazard ratio; Minimal residual disease; Myeloid leukemia; Proportional hazards model; Hematopoietic stem cell transplantation; Transplantation; Myeloid; Leukemia; Immunology; Confidence interval","score_opus":0.011044685027055674,"score_gpt":0.2357432481250833,"score_spread":0.22469856309802763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949420727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99477637,0.0016121096,0.00008476891,0.0001787603,0.000092948496,0.00090170157,0.00027816894,0.00007527033,0.0019998932],"genre_scores_gemma":[0.9916031,0.000848123,0.0037391149,0.000084390456,0.00003314738,0.000029542285,0.0013787311,0.00008181693,0.0022020726],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969289,0.0003671334,0.0007205624,0.00061827665,0.00079670426,0.00056846556],"domain_scores_gemma":[0.99831474,0.00025124685,0.0003273019,0.0005653007,0.0002170495,0.00032435465],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005827409,0.00034290718,0.0006334048,0.00015412287,0.0001444727,0.000018112518,0.00021025863,0.00034300267,0.00087491487],"category_scores_gemma":[0.00013315165,0.000323554,0.00024356709,0.00052639656,0.00009799665,0.00016886408,0.000072451454,0.0006860589,0.00010939568],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015369635,0.00006490703,0.1307629,0.0004496969,0.00022129208,0.00019223399,0.0043130624,0.0013890222,0.8603316,0.0000028075108,0.00036397853,0.0003715593],"study_design_scores_gemma":[0.011241551,0.00059753325,0.071602345,0.0013778387,0.0013230364,0.00042962458,0.006442792,0.008536645,0.89738494,0.00005969678,0.0002834679,0.0007205581],"about_ca_topic_score_codex":0.008813262,"about_ca_topic_score_gemma":0.0007171648,"teacher_disagreement_score":0.059160557,"about_ca_system_score_codex":0.0031204,"about_ca_system_score_gemma":0.0010467017,"threshold_uncertainty_score":0.9999217},"labels":[],"label_agreement":null},{"id":"W2949512078","doi":"10.1097/01.hs9.0000563628.38037.c3","title":"PS1337 IVOSIDENIB (AG‐120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1‐MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME IN A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Isocitrate dehydrogenase; Medicine; IDH1; Internal medicine; Myelodysplastic syndromes; Refractory (planetary science); Myeloid leukemia; Bone marrow; Gastroenterology; Oncology; Pharmacodynamics; Pharmacokinetics; International Prognostic Scoring System; Mutant; Chemistry; Biology; Gene","score_opus":0.011476636537717237,"score_gpt":0.26962185674816475,"score_spread":0.2581452202104475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949512078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967327,0.00019712851,0.000016113128,0.00013009243,0.00005345433,0.0026165268,0.000007055497,0.00003821689,0.00020872826],"genre_scores_gemma":[0.9992294,0.0001462151,0.00017742494,0.000032483873,0.00001286473,0.000066296634,0.000024616218,0.000047620273,0.0002631042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973524,0.00017337644,0.00049710594,0.00071528857,0.0008287158,0.00043309198],"domain_scores_gemma":[0.9988619,0.00023690729,0.00011063708,0.00039690608,0.00011832143,0.00027532782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047089,0.00029383943,0.0005442764,0.00028772323,0.00009644003,0.000037473288,0.00010156811,0.00027013215,0.00041421867],"category_scores_gemma":[0.00018015278,0.00022493552,0.000023661358,0.00064439717,0.0000796114,0.0004884906,0.00009299112,0.00096506695,0.000021541133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040648854,0.0022624661,0.92361915,0.00029628866,0.000033043187,0.00064023794,0.0030446134,0.000029988718,0.060457636,0.0000062933477,0.000020599924,0.0055247694],"study_design_scores_gemma":[0.031478286,0.004720445,0.9567696,0.0014980384,0.000054979035,0.00013656908,0.00309686,0.0009280376,0.0009846793,0.000026730864,0.00001824354,0.00028754372],"about_ca_topic_score_codex":0.0004515342,"about_ca_topic_score_gemma":0.00045094785,"teacher_disagreement_score":0.059472956,"about_ca_system_score_codex":0.00032059863,"about_ca_system_score_gemma":0.00032692906,"threshold_uncertainty_score":0.91726047},"labels":[],"label_agreement":null},{"id":"W2949995351","doi":"10.1097/01.hs9.0000562472.96992.e6","title":"PS1044 THE PROGNOSTIC SIGNIFICANCE OF BCR‐1 AND BCR‐3 ISOFORM OF PML‐RARA AND FLT3‐ITD IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group; University of Calgary","funders":"","keywords":"Medicine; Acute promyelocytic leukemia; breakpoint cluster region; Internal medicine; Regimen; Oncology; Gastroenterology; Biology; Gene","score_opus":0.005892820207575328,"score_gpt":0.2284704105657468,"score_spread":0.22257759035817146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949995351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99487454,0.00041317416,0.000013979046,0.00022081855,0.00002206789,0.0024136368,0.000017688797,0.000016428588,0.0020076553],"genre_scores_gemma":[0.9977157,0.000078977995,0.00089518825,0.00006622396,0.000019705643,0.0000636413,0.000014892001,0.000036779715,0.0011089056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983489,0.00005303572,0.0003707422,0.00035712295,0.0005047182,0.00036549018],"domain_scores_gemma":[0.9987957,0.0002343762,0.0001745241,0.00047014025,0.00020812945,0.00011714387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025146757,0.00021111053,0.000522064,0.00006797533,0.000034646207,0.000012383849,0.00014769277,0.00012038773,0.00013977182],"category_scores_gemma":[0.00011609439,0.0001275018,0.000035476874,0.00032716242,0.00035749108,0.00012060916,0.00012368387,0.00037229707,0.0000130072785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015323905,0.00013017727,0.9859519,0.0013148432,0.00017451594,0.00003152368,0.0011354169,0.00001203743,0.0029491044,0.00014011086,0.0003102988,0.006317689],"study_design_scores_gemma":[0.007448867,0.001922637,0.9824455,0.000638604,0.00014448189,0.00003943531,0.0006630196,0.0008079567,0.0053591873,0.00008832183,0.0002501684,0.00019183473],"about_ca_topic_score_codex":0.0001709832,"about_ca_topic_score_gemma":0.000056055826,"teacher_disagreement_score":0.0061258543,"about_ca_system_score_codex":0.00022764443,"about_ca_system_score_gemma":0.0006399576,"threshold_uncertainty_score":0.5199372},"labels":[],"label_agreement":null},{"id":"W2950158180","doi":"10.1097/01.hs9.0000563624.30413.c3","title":"PS1336 DISCREPANCE OF ALLELIC BURDEN CHANGES AND CLINICAL RESPONSE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME TREATED WITH HYPOMETHYLATING AGENTS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Decitabine; Azacitidine; Medicine; Internal medicine; Myelodysplastic syndromes; International Prognostic Scoring System; Hypomethylating agent; Allele; Gastroenterology; Myeloid; Oncology; Bone marrow; Gene; Genetics; DNA methylation; Biology","score_opus":0.015556206433921428,"score_gpt":0.2852610328947903,"score_spread":0.2697048264608689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950158180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980566,0.0001512186,0.0000075307917,0.00025784914,0.000026239264,0.000992539,0.00002232702,0.000035391844,0.0004503],"genre_scores_gemma":[0.99503934,0.00006961652,0.0014466038,0.000043264554,0.000030486877,0.000025173837,0.000023638466,0.000060151924,0.0032617177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978129,0.000317625,0.0003946203,0.0005178599,0.0005492059,0.0004077775],"domain_scores_gemma":[0.9982202,0.0006883219,0.00023918289,0.00049600494,0.00015129967,0.00020497508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005643492,0.00024332953,0.0006781132,0.00012471352,0.000036144404,0.00001251762,0.00011681369,0.00016314608,0.00039465254],"category_scores_gemma":[0.0003059758,0.00015983249,0.000039286555,0.000496756,0.00018824151,0.000087843044,0.00010061942,0.00048403844,0.000042820204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015666539,0.00019144724,0.9807756,0.00018911307,0.0002138797,0.00018011355,0.00019844247,0.000027475171,0.00018809664,0.0000038158537,0.0000515237,0.002313971],"study_design_scores_gemma":[0.011297602,0.006441697,0.98014873,0.0007735773,0.000112472575,0.0000270089,0.00018619801,0.0005060429,0.00008302382,0.0000036216834,0.0002322381,0.00018777471],"about_ca_topic_score_codex":0.00035066996,"about_ca_topic_score_gemma":0.000093110306,"teacher_disagreement_score":0.0062502497,"about_ca_system_score_codex":0.00014447833,"about_ca_system_score_gemma":0.00014634864,"threshold_uncertainty_score":0.651778},"labels":[],"label_agreement":null},{"id":"W2950383245","doi":"10.1097/01.hs9.0000562228.80333.3e","title":"PS982 THE ROLE OF STAT3 ISOFORMS IN ACUTE MYELOID LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"STAT3; Myeloid leukemia; Cancer research; STAT protein; Transactivation; Biology; Myeloid; Leukemia; Medicine; Immunology; Transcription factor; Signal transduction; Cell biology; Gene; Genetics","score_opus":0.00818188320902069,"score_gpt":0.2644259495847453,"score_spread":0.2562440663757246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950383245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93499124,0.00089915725,0.0000152228495,0.00073576526,0.000063416664,0.00077258586,0.000015674826,0.000037140773,0.06246979],"genre_scores_gemma":[0.9827173,0.0002333919,0.0006549496,0.0003745202,0.00007188335,0.000033246422,0.00001762871,0.000043645126,0.015853472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983293,0.000045071065,0.00035569025,0.00028430973,0.0005027516,0.00048291875],"domain_scores_gemma":[0.99880975,0.00013141132,0.00009225443,0.0007450352,0.000106072934,0.0001154443],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003672256,0.00017552439,0.00040616153,0.00007034085,0.000034269848,0.000012616739,0.00029946037,0.00015053042,0.002676054],"category_scores_gemma":[0.00006325049,0.000107332206,0.000116370065,0.00047533345,0.000116060415,0.0001167286,0.00016230896,0.0005892374,0.00087981054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025428438,0.0003587808,0.49006748,0.0008000046,0.00069440395,0.00032232565,0.0054356996,0.00019692109,0.32862908,0.009294236,0.019655272,0.14200296],"study_design_scores_gemma":[0.017855741,0.0023146595,0.3651065,0.0010449025,0.0003007508,0.00063918694,0.022448633,0.014454256,0.3155301,0.0065000723,0.25271988,0.0010853466],"about_ca_topic_score_codex":0.00043144613,"about_ca_topic_score_gemma":0.000093699826,"teacher_disagreement_score":0.2330646,"about_ca_system_score_codex":0.0005318915,"about_ca_system_score_gemma":0.00073661923,"threshold_uncertainty_score":0.99989814},"labels":[],"label_agreement":null},{"id":"W2950620394","doi":"10.1097/01.hs9.0000561796.30124.a4","title":"S879 RESULTS OF ASTRAL‐1 STUDY, A PHASE 3 RANDOMIZED TRIAL OF GUADECITABINE (G) VS TREATMENT CHOICE (TC) IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN‐AML) NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY (IC)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta Hospital; Alberta Hospital Edmonton","funders":"","keywords":"Medicine; Decitabine; Internal medicine; Clinical endpoint; Cytarabine; Randomized controlled trial; Regimen; Induction chemotherapy; Oncology; Gastroenterology; Chemotherapy; Surgery","score_opus":0.03473661491423022,"score_gpt":0.3619602162914029,"score_spread":0.32722360137717266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950620394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754093,0.00042704615,0.000059186525,0.0013897073,0.0002562076,0.020902686,0.00033628114,0.000058546826,0.0011609909],"genre_scores_gemma":[0.9821744,0.0010312246,0.0018468635,0.00017611652,0.00029543487,0.0018320341,0.00032924575,0.00012861789,0.0121860625],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951363,0.00033115997,0.0019689803,0.000996525,0.00074390444,0.00082311063],"domain_scores_gemma":[0.9947783,0.002110452,0.0007423189,0.0012852309,0.0008366204,0.00024712677],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011094275,0.00071129977,0.0036530418,0.00033282992,0.000050943425,0.00002181059,0.00031087679,0.00032284055,0.00032130565],"category_scores_gemma":[0.0010108354,0.0004994931,0.0009154184,0.0006398528,0.00022663604,0.00014539267,0.00007619598,0.00030294774,0.00004966025],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9210572,0.0053835865,0.0002517357,0.00017927542,0.00286109,0.000084547246,0.004840673,0.00003663373,0.04688104,0.000021235941,0.0014389926,0.016963974],"study_design_scores_gemma":[0.76774853,0.032661494,0.00015708679,0.00024240618,0.00076266605,0.00001908683,0.0027053668,0.00066443265,0.19170085,0.000021215394,0.003037528,0.0002793244],"about_ca_topic_score_codex":0.0031797274,"about_ca_topic_score_gemma":0.00035234145,"teacher_disagreement_score":0.15330867,"about_ca_system_score_codex":0.0026926112,"about_ca_system_score_gemma":0.0016762469,"threshold_uncertainty_score":0.99974567},"labels":[],"label_agreement":null},{"id":"W2950623518","doi":"10.1097/01.hs9.0000559048.84930.7b","title":"PF208 MN1 IS INDISPENSABLE FOR MLL‐REARRANGED ACUTE MYELOID LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Biology; Cancer research; Leukemia; Myeloid leukemia; clone (Java method); Cell culture; Myeloid; Cytotoxic T cell; Oncogene; U937 cell; Apoptosis; Cell cycle; Molecular biology; In vitro; Immunology; Genetics; Gene","score_opus":0.020453164644980325,"score_gpt":0.29962421660561406,"score_spread":0.27917105196063374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950623518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9007607,0.00061091926,0.0003611816,0.0035401043,0.00034557763,0.0028839414,0.00011279077,0.00024396753,0.09114082],"genre_scores_gemma":[0.66063523,0.00027920984,0.01055659,0.004700347,0.0007194541,0.0003006866,0.0002654055,0.00024572609,0.32229736],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972264,0.00004063949,0.00040846347,0.0007183671,0.00064311636,0.0009630203],"domain_scores_gemma":[0.9979723,0.00018549651,0.000117812466,0.0010409083,0.0002833376,0.000400164],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00035825718,0.00035834458,0.00070896064,0.00010507213,0.00014318926,0.000059174094,0.0003458213,0.00037691928,0.010939906],"category_scores_gemma":[0.00011217959,0.00031000742,0.00031509952,0.00043500576,0.00010441441,0.00020583629,0.00015903157,0.00062412815,0.005478177],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026340878,0.00020192841,0.019603789,0.0013847145,0.0011875809,0.00035067165,0.0015482822,0.000014450732,0.13775593,0.0011500486,0.8165252,0.017643321],"study_design_scores_gemma":[0.019624382,0.0017147661,0.010256797,0.0005077768,0.0005434689,0.0005324363,0.0014910667,0.004312265,0.116664596,0.00092944026,0.8423727,0.0010503035],"about_ca_topic_score_codex":0.0001643975,"about_ca_topic_score_gemma":0.00003383156,"teacher_disagreement_score":0.24012549,"about_ca_system_score_codex":0.0010098981,"about_ca_system_score_gemma":0.0010554149,"threshold_uncertainty_score":0.9999352},"labels":[],"label_agreement":null},{"id":"W2950780445","doi":"10.1097/01.hs9.0000562468.89369.69","title":"PS1043 OUTCOMES OF PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A POPULATION‐BASED REAL‐WORLD STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary; Western University","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Refractory (planetary science); Myeloid leukemia; Regimen; Population; Chemotherapy regimen; Intensive care; Chemotherapy; Pediatrics; Surgery; Intensive care medicine","score_opus":0.01713439800318669,"score_gpt":0.2992449930988417,"score_spread":0.28211059509565506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950780445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99122745,0.000020257765,0.000016176351,0.00020600951,0.00011713447,0.0027121408,0.000043759657,0.00013639031,0.00552071],"genre_scores_gemma":[0.9631043,0.0000086329865,0.0022603802,0.00030574636,0.000048701124,0.0000799079,0.0002233463,0.00010985072,0.033859152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968224,0.00013834494,0.0006549569,0.00060350256,0.0012708948,0.0005098612],"domain_scores_gemma":[0.9974117,0.00030384678,0.00033686068,0.0012728883,0.0004240244,0.00025066052],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002850291,0.000375221,0.0009881319,0.00024692967,0.00008095634,0.000019023842,0.00027649425,0.00017026113,0.0028579792],"category_scores_gemma":[0.00014147935,0.00024016548,0.00014408494,0.0008958184,0.00006804414,0.00020793546,0.00011536387,0.00063970464,0.00022564766],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042914823,0.0009829529,0.9903156,0.00021727191,0.0005204062,0.00009924381,0.0002612961,0.000035709065,0.00019994799,0.000026646661,0.001991274,0.0010581604],"study_design_scores_gemma":[0.016379882,0.0031507853,0.9777107,0.00016323896,0.00032594465,0.0000028327172,0.00045729073,0.00017234668,0.00027152142,0.0000070678966,0.0010775727,0.00028081785],"about_ca_topic_score_codex":0.001281499,"about_ca_topic_score_gemma":0.0010196343,"teacher_disagreement_score":0.028338442,"about_ca_system_score_codex":0.0012187414,"about_ca_system_score_gemma":0.0010522096,"threshold_uncertainty_score":0.99805355},"labels":[],"label_agreement":null},{"id":"W2950921432","doi":"10.1182/blood-2018-99-114275","title":"A Novel Predictor of Response to Gemtuzumab Ozogamicin Therapy in AML Provides Strategies for Sensitization of Leukemia Stem Cells in Individual Patients","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Gemtuzumab ozogamicin; Stem cell; Leukemia; Medicine; Calicheamicin; Oncology; Immunology; Sensitization; Internal medicine; Myeloid leukemia; Cancer research; CD33; Biology; CD34; Genetics","score_opus":0.03047327767904125,"score_gpt":0.2925056112534201,"score_spread":0.2620323335743789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950921432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970763,0.000022788527,0.00024809802,0.00011542111,0.000039957496,0.0021723881,0.00024049488,0.000015211364,0.00006934387],"genre_scores_gemma":[0.99734217,0.000010529727,0.0022623213,0.00008404998,0.00006657466,0.000068061876,0.000034154396,0.00003245356,0.000099681005],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983442,0.00012224812,0.00052313175,0.00028503334,0.00041862257,0.000306786],"domain_scores_gemma":[0.99872124,0.0003445319,0.00014976034,0.0002902761,0.0004153498,0.00007885961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007066178,0.0001508497,0.0003862171,0.0005526595,0.000019134352,0.000012703091,0.00015271653,0.00014315252,0.000008344616],"category_scores_gemma":[0.00022322607,0.00013368696,0.000047901634,0.0005466872,0.00011980672,0.000120406236,0.000066545916,0.0001384361,0.0000029327432],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013225466,0.0012934993,0.070704505,0.00030821902,0.000098778175,0.0000072442135,0.007996679,0.00006798928,0.9037275,0.00006519425,0.00024129271,0.0022636708],"study_design_scores_gemma":[0.029440874,0.0072676074,0.3245521,0.00045139864,0.00004510784,0.0000045115253,0.0014888038,0.0006759877,0.63577366,0.00005494923,0.0000913639,0.00015365443],"about_ca_topic_score_codex":0.00030236552,"about_ca_topic_score_gemma":0.00019464742,"teacher_disagreement_score":0.2679538,"about_ca_system_score_codex":0.00029230182,"about_ca_system_score_gemma":0.0014441741,"threshold_uncertainty_score":0.54515964},"labels":[],"label_agreement":null},{"id":"W2951076122","doi":"10.1097/01.hs9.0000562392.68284.f5","title":"PS1024 IMPACT OF MINIMAL RESIDUAL DISEASE AND COMPLETE REMISSION (CR)/CR WITH PARTIAL HEMATOLOGIC RECOVERY ON SURVIVAL AFTER GILTERITINIB THERAPY IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY AML","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Adverse effect; Nausea; Refractory (planetary science); Myeloid leukemia; Neutropenia; Chemotherapy","score_opus":0.01674566369118301,"score_gpt":0.27405793809520557,"score_spread":0.25731227440402255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951076122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99745446,0.00024161077,0.0000033293745,0.00021309634,0.000044070766,0.0012516637,0.00013339471,0.00004433921,0.0006140244],"genre_scores_gemma":[0.9988327,0.00007211121,0.0003313994,0.00011678247,0.000053688622,0.000045288223,0.00016640329,0.00007759318,0.0003040179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99741876,0.000235448,0.00043228202,0.00062402675,0.0007439963,0.0005454954],"domain_scores_gemma":[0.99846023,0.00022586355,0.00018587621,0.0005998071,0.00013422284,0.00039400609],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000227388,0.0003808626,0.0007343503,0.000120636665,0.00004156867,0.000025473402,0.0001229192,0.00017091008,0.00096540933],"category_scores_gemma":[0.000095317744,0.00023300934,0.000095659445,0.00029587498,0.00020559448,0.00018317346,0.000074475596,0.00053128524,0.00003215703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11351246,0.0007510847,0.8805076,0.00027360223,0.00017864347,0.00043210358,0.00019346502,0.000031809654,0.0025184283,0.0000054605025,0.0005498761,0.0010454673],"study_design_scores_gemma":[0.016502503,0.012187598,0.96847975,0.0011090754,0.000048848826,0.000021950402,0.00014252814,0.00012035804,0.00083765475,0.000014295695,0.00021572612,0.0003196898],"about_ca_topic_score_codex":0.000105286235,"about_ca_topic_score_gemma":0.000021838307,"teacher_disagreement_score":0.09700996,"about_ca_system_score_codex":0.00028677547,"about_ca_system_score_gemma":0.000488674,"threshold_uncertainty_score":0.99994785},"labels":[],"label_agreement":null},{"id":"W2951135883","doi":"10.1097/01.hs9.0000559340.02182.80","title":"PF282 THE EFFECT OF MODERN THERAPEUTICS IN ADULT ACUTE MYELOID LEUKEMIA (AML): POPULATION‐BASED ANALYSIS OF LONG‐TERM OUTCOMES FROM THE MANITOBA CANCER REGISTRY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Cancer registry; Relative survival; Population; Cancer; Cohort; Myeloid leukemia; Demography; Internal medicine; Pediatrics; Environmental health","score_opus":0.022140299836415783,"score_gpt":0.31686439306914493,"score_spread":0.29472409323272913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951135883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958967,0.0008864636,0.00015816979,0.0013712933,0.000087550754,0.0010075829,0.00015746779,0.000026450607,0.00040831976],"genre_scores_gemma":[0.9977125,0.00016457855,0.00013290092,0.0007335171,0.00006493231,0.00007451652,0.000212591,0.000047023117,0.000857471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757993,0.00028220328,0.0005821304,0.00038851786,0.0008087661,0.00035847584],"domain_scores_gemma":[0.9967474,0.0011258838,0.00036265847,0.0015087235,0.00018634014,0.00006904591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039913275,0.00029417442,0.0009782468,0.000119681696,0.00005773164,0.000020099216,0.0005636551,0.00021923972,0.0006550132],"category_scores_gemma":[0.00009038704,0.0001526715,0.00044597103,0.0010411429,0.0001423874,0.00007212126,0.0001118349,0.00056919374,0.000016621912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008667027,0.000035238456,0.9794919,0.00016506707,0.0029050973,0.00001986554,0.0003599791,0.0022630012,0.0042649675,0.000012239965,0.00016358067,0.009452348],"study_design_scores_gemma":[0.0031276487,0.00016665009,0.9620057,0.00022312404,0.0027400623,0.0000023268353,0.00018332562,0.023240382,0.00812234,0.000020743651,0.000022782644,0.0001449318],"about_ca_topic_score_codex":0.014698348,"about_ca_topic_score_gemma":0.011844923,"teacher_disagreement_score":0.02097738,"about_ca_system_score_codex":0.0007535434,"about_ca_system_score_gemma":0.00037908548,"threshold_uncertainty_score":0.99186283},"labels":[],"label_agreement":null},{"id":"W2951229452","doi":"10.1097/01.hs9.0000562388.60660.bc","title":"PS1023 MUTANT IDH1 INHIBITOR IVOSIDENIB (AG‐120) IN COMBINATION WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Medicine; Internal medicine; Gastroenterology; Isocitrate dehydrogenase; IDH1; Adverse effect; Azacitidine; Bone marrow; Nausea; Leukemia; Cytarabine; Chemistry; Mutant","score_opus":0.013060103779296627,"score_gpt":0.2728298898142398,"score_spread":0.25976978603494316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951229452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889367,0.00023550799,0.00067745347,0.0023295898,0.00021529806,0.003743912,0.00005226379,0.00017723184,0.003632046],"genre_scores_gemma":[0.98524284,0.0001549545,0.004613773,0.00069729425,0.000319772,0.00037782593,0.00027489333,0.00015985116,0.008158817],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99690634,0.0000750719,0.0005787888,0.0007689355,0.0007842107,0.00088667806],"domain_scores_gemma":[0.99798274,0.00043496865,0.00017744827,0.0007309775,0.00035083105,0.00032300508],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044966364,0.00042699004,0.00079300645,0.00022608244,0.00009449516,0.0000636773,0.0002655979,0.00033169935,0.00083141215],"category_scores_gemma":[0.00020692476,0.00035006998,0.00015976494,0.0007279498,0.00012431934,0.0003565751,0.000115211194,0.00067854417,0.0004611942],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016007336,0.0017425522,0.11639402,0.003452912,0.0011904525,0.004213228,0.0035019233,0.0005686982,0.7460119,0.0058415015,0.07150827,0.0295672],"study_design_scores_gemma":[0.1892884,0.015402959,0.075903505,0.0050054137,0.0009176434,0.0016947836,0.007349467,0.0324975,0.60209244,0.0020968297,0.064503,0.0032480557],"about_ca_topic_score_codex":0.00033771852,"about_ca_topic_score_gemma":0.00039218756,"teacher_disagreement_score":0.17328106,"about_ca_system_score_codex":0.0017793896,"about_ca_system_score_gemma":0.0011753832,"threshold_uncertainty_score":0.99989516},"labels":[],"label_agreement":null},{"id":"W2951238591","doi":"10.1016/j.exphem.2019.06.001","title":"Remission clone in acute myeloid leukemia shows growth advantage after chemotherapy but is distinct from leukemic clone","year":2019,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada; National Research Foundation of Korea; Ministry of Health and Welfare","keywords":"clone (Java method); Myeloid leukemia; Cancer research; Chemotherapy; Somatic evolution in cancer; Leukemia; Biology; Myeloid; Medicine; Oncology; Immunology; Gene; Genetics","score_opus":0.009584824039175115,"score_gpt":0.29764075351478325,"score_spread":0.28805592947560815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951238591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867932,0.005745759,0.000044771416,0.0012540186,0.00040493475,0.0012950493,0.00008994272,0.00015669547,0.0042156074],"genre_scores_gemma":[0.9874141,0.00036022384,0.0020494387,0.0028700707,0.00019104066,0.00024308039,0.0002719764,0.00015044345,0.0064496333],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99618447,0.00014927618,0.0008053987,0.0012067059,0.00061486755,0.0010392545],"domain_scores_gemma":[0.9981595,0.00018532839,0.00016825495,0.0009923148,0.00007326779,0.0004213029],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00021009948,0.00059622247,0.0012843449,0.00033326773,0.00007435584,0.000028712568,0.00042994684,0.0005735131,0.010578646],"category_scores_gemma":[0.00003849155,0.0005318845,0.00024635743,0.00037073035,0.00028310335,0.00025630344,0.00038695883,0.00096481055,0.0018244764],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077640875,0.00047136305,0.14332303,0.00012845329,0.00022381358,0.0021147646,0.001882542,2.4104776e-7,0.836242,0.00047929285,0.006745233,0.0006251729],"study_design_scores_gemma":[0.011543922,0.00064570655,0.019028705,0.0002774113,0.000041076702,0.0011332706,0.0011238662,0.0006254693,0.96287876,0.00019294191,0.0019485749,0.0005602984],"about_ca_topic_score_codex":0.0008709802,"about_ca_topic_score_gemma":0.000014353029,"teacher_disagreement_score":0.12663676,"about_ca_system_score_codex":0.002688306,"about_ca_system_score_gemma":0.0004937286,"threshold_uncertainty_score":0.99971324},"labels":[],"label_agreement":null},{"id":"W2951365685","doi":"10.1097/01.hs9.0000566860.46379.37","title":"PB2094 A SINGLE CENTRE EXPERIENCE WITH AZACITIDINE FOR MDS, AML AND CMML IN RELATION TO CYTOGENETIC RISK AND PERFORMANCE STATUS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Azacitidine; Medicine; Myelodysplastic syndromes; Chronic myelomonocytic leukemia; Internal medicine; International Prognostic Scoring System; Cytogenetics; Oncology; Bone marrow","score_opus":0.014594104408073412,"score_gpt":0.25887850042652266,"score_spread":0.24428439601844926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951365685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968268,0.00053748605,0.00026481628,0.0002269257,0.000015985777,0.0011103448,0.000011355237,0.000021432606,0.0009848041],"genre_scores_gemma":[0.9915062,0.0002059403,0.006187735,0.00010005281,0.000032186414,0.000052922023,0.00001338396,0.000026322408,0.0018752343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895525,0.000021353422,0.00015144616,0.0003260164,0.0001865472,0.00035937675],"domain_scores_gemma":[0.9994081,0.00007940945,0.000041929557,0.00021139889,0.00006969169,0.00018943737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010579428,0.00012512112,0.0002027454,0.000055117085,0.000049454946,0.000019962295,0.000037046386,0.00006643271,0.00013463723],"category_scores_gemma":[0.00007838812,0.00010070218,0.000012947733,0.00020957887,0.000054777258,0.00011067428,0.000047112117,0.00014865107,0.000024450495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012608719,0.000052841224,0.96391135,0.0003101951,0.0000136174085,0.000012864987,0.003955784,0.00008909282,0.012083929,0.000033397646,0.0002458017,0.01803027],"study_design_scores_gemma":[0.009822497,0.0037804574,0.92935073,0.0008493731,0.00005162886,0.00011053123,0.0069245636,0.015013047,0.020925997,0.000028681829,0.012722436,0.00042003227],"about_ca_topic_score_codex":0.000086472086,"about_ca_topic_score_gemma":0.00013889174,"teacher_disagreement_score":0.03456058,"about_ca_system_score_codex":0.00015745658,"about_ca_system_score_gemma":0.00009177857,"threshold_uncertainty_score":0.41065156},"labels":[],"label_agreement":null},{"id":"W2951414864","doi":"10.1158/1078-0432.ccr-18-1897","title":"Functional Properties of <i>KIT</i> Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Hyundai Hope On Wheels; Hyundai Motor Group; National Cancer Institute; St. Baldrick's Foundation","keywords":"Gemtuzumab ozogamicin; Medicine; Exon; Myeloid leukemia; Mutation; Internal medicine; Core binding factor; Cancer research; Oncology; Targeted therapy; Tyrosine kinase; Transfection; Cytokine; CD33; Cancer; Biology; Receptor; Gene; Genetics; Stem cell; CD34","score_opus":0.1810267263433989,"score_gpt":0.45773596769156527,"score_spread":0.2767092413481664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951414864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891753,0.00026801266,0.000020157579,0.008299139,0.00022786784,0.0017811839,0.00008876378,0.000042612144,0.00009694721],"genre_scores_gemma":[0.99287796,0.00048514502,0.00012169216,0.00097055204,0.00015974202,0.00022677975,0.000035724446,0.00006542088,0.0050569833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932618,0.0021887305,0.0012816007,0.0008133748,0.0016652078,0.0007892701],"domain_scores_gemma":[0.99266,0.004625615,0.00020707893,0.000645999,0.0013674081,0.0004939294],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0062906174,0.0002552858,0.0011261388,0.00049742026,0.00012411166,0.000049474456,0.00032402066,0.00043203324,0.00032276314],"category_scores_gemma":[0.0045520305,0.00017344038,0.00020687496,0.0011447709,0.0011622967,0.000117498355,0.00037095862,0.002470398,0.000085129315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037187476,0.0005611512,0.94269544,0.00007947664,0.00085420883,0.00006176391,0.00028882053,0.000028644212,0.014280661,0.000015620068,0.001308817,0.002637892],"study_design_scores_gemma":[0.01006827,0.0025695926,0.9829148,0.0004868133,0.000118344695,0.000005777197,0.0004825273,0.0005670054,0.001809796,0.000031903648,0.0007463036,0.00019888915],"about_ca_topic_score_codex":0.00032542186,"about_ca_topic_score_gemma":0.0005221958,"teacher_disagreement_score":0.040219307,"about_ca_system_score_codex":0.0010041316,"about_ca_system_score_gemma":0.004316982,"threshold_uncertainty_score":0.99983096},"labels":[],"label_agreement":null},{"id":"W2951452128","doi":"10.1097/01.hs9.0000559332.56440.58","title":"PF280 INTENSIVE TREATMENT OF ELDERLY AML PATIENTS IS SAFE AND FEASIBLE, PRINCESS MARGARET CANCER CENTRE EXPERIENCE","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Internal medicine; Acute promyelocytic leukemia; Induction chemotherapy; Hazard ratio; Cumulative incidence; Cancer; Proportional hazards model; Incidence (geometry); Population; Cohort; Oncology; Chemotherapy; Pediatrics; Confidence interval","score_opus":0.02058978345610138,"score_gpt":0.3075071428970854,"score_spread":0.28691735944098407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951452128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99235964,0.0011527451,0.0000046366285,0.0010281559,0.00011359106,0.0009478269,0.00004461383,0.000021486027,0.004327304],"genre_scores_gemma":[0.9849092,0.0009799994,0.00041238565,0.00042569768,0.00004804863,0.000047975944,0.00002362754,0.00003056812,0.013122532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859256,0.000029287226,0.00024206801,0.00040122773,0.0003851941,0.00034964582],"domain_scores_gemma":[0.9987288,0.000053164094,0.00010413597,0.00040846426,0.000504115,0.00020129753],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000028455564,0.00020201967,0.0004285263,0.000042211464,0.000037293637,0.0000124829185,0.00009669591,0.00010600744,0.003366659],"category_scores_gemma":[0.00004467022,0.00015064304,0.00006888856,0.0001861648,0.00011964145,0.000096816315,0.00007792491,0.00011172708,0.00007820994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050191965,0.00021436193,0.9561353,0.00027207803,0.0001196245,0.000034526358,0.007223441,0.0000011958784,0.0015505045,0.00004240553,0.004352952,0.02955171],"study_design_scores_gemma":[0.02051959,0.004968476,0.75763077,0.0014154334,0.0002130085,0.00005111829,0.021330336,0.0007099934,0.10990684,0.00005737845,0.08249305,0.00070402527],"about_ca_topic_score_codex":0.00095108734,"about_ca_topic_score_gemma":0.000086502325,"teacher_disagreement_score":0.19850454,"about_ca_system_score_codex":0.00043361407,"about_ca_system_score_gemma":0.00024255522,"threshold_uncertainty_score":0.9975444},"labels":[],"label_agreement":null},{"id":"W2951457160","doi":"10.1097/01.hs9.0000559376.17429.23","title":"PF291 A PHASE 1B/2 CLINICAL STUDY OF TARGETED IDH1 INHIBITION WITH IVOSIDENIB, IN COMBINATION WITH THE BCL‐2 INHIBITOR VENETOCLAX, FOR PATIENTS WITH IDH1‐MUTATED (MIDH1) MYELOID MALIGNANCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Venetoclax; Ven; IDH1; Medicine; Tolerability; Internal medicine; Oncology; Refractory (planetary science); Myeloid; Myeloid leukemia; Gastroenterology; Leukemia; Adverse effect; Chronic lymphocytic leukemia; Chemistry; Biology; Mutation","score_opus":0.016503030005904973,"score_gpt":0.3079110771014915,"score_spread":0.29140804709558654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951457160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909205,0.00007462284,0.00021231317,0.00037612603,0.00005993248,0.008103163,0.00004272061,0.00006764227,0.00014296823],"genre_scores_gemma":[0.9975165,0.000008966067,0.00085789454,0.00015889475,0.00007737512,0.00056561606,0.00029923962,0.00010146571,0.00041404265],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99670345,0.00025553122,0.00076058495,0.0006641327,0.0010740956,0.0005422104],"domain_scores_gemma":[0.9972762,0.00040288916,0.00044388266,0.0006577076,0.0010512565,0.00016807135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007025887,0.00037262152,0.000806548,0.0001570879,0.000110650515,0.000037138223,0.0001812269,0.00019173369,0.00009902704],"category_scores_gemma":[0.00016107138,0.00021399863,0.00007310937,0.0010513763,0.00026447626,0.0002762097,0.000077683384,0.0005899632,0.000021273321],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0627798,0.021829702,0.88465464,0.0011698691,0.0008450484,0.00023618285,0.005416804,0.0004508967,0.014161765,0.0001623786,0.0043594525,0.00393348],"study_design_scores_gemma":[0.44474828,0.15513407,0.3274167,0.0034559383,0.00086741993,0.00008333033,0.026433803,0.0048419284,0.03410788,0.00008016949,0.0014926477,0.0013378378],"about_ca_topic_score_codex":0.00020426906,"about_ca_topic_score_gemma":0.000586343,"teacher_disagreement_score":0.5572379,"about_ca_system_score_codex":0.00047720602,"about_ca_system_score_gemma":0.0009127735,"threshold_uncertainty_score":0.8726611},"labels":[],"label_agreement":null},{"id":"W2952127660","doi":"10.1186/s13148-017-0411-x","title":"A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML","year":2017,"lang":"en","type":"article","venue":"Clinical Epigenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Eisai; National Cancer Institute; National Institutes of Health; Translational Genomics Research Institute; Morgan Adams Foundation; Johns Hopkins University; Children's Hospital Colorado; St. Baldrick's Foundation; Arkansas Biosciences Institute; University of Arizona; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"Decitabine; Medicine; Induction chemotherapy; Internal medicine; Oncology; Neutropenia; Azacitidine; Cytarabine; Tolerability; Gastroenterology; Chemotherapy; Adverse effect; DNA methylation; Biology","score_opus":0.047210476310517564,"score_gpt":0.3975289006784662,"score_spread":0.35031842436794863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952127660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99420387,0.0001504681,0.00058181776,0.00060314214,0.00007362865,0.0041323765,0.0000020755695,0.000024004512,0.00022864342],"genre_scores_gemma":[0.9926252,0.0008712255,0.0057397475,0.00015920502,0.00019729149,0.0001068403,0.000007657329,0.00006997079,0.00022288277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968055,0.0004020417,0.0011501622,0.00060500787,0.0006227649,0.000414526],"domain_scores_gemma":[0.9968951,0.00048398314,0.0006450259,0.001397063,0.00031261815,0.0002662356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018611319,0.0002808685,0.001416118,0.00017374118,0.00013205649,0.000043251515,0.0004409163,0.00021101812,0.00004762361],"category_scores_gemma":[0.002198976,0.00018624081,0.00013867138,0.00017499649,0.00096176093,0.000066570574,0.00014246597,0.0007158095,0.000013053383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07477162,0.0029700284,0.8976468,0.000028424896,0.0006396588,0.000038410042,0.0006339223,0.00007208522,0.00018498511,0.0000060773305,0.000009678954,0.022998337],"study_design_scores_gemma":[0.29001373,0.0044005318,0.70299554,0.00016044233,0.0002750575,0.000023932871,0.00026855292,0.00051836536,0.0011351564,0.000031986176,0.000019515717,0.00015717965],"about_ca_topic_score_codex":0.0007576001,"about_ca_topic_score_gemma":0.00026861668,"teacher_disagreement_score":0.21524212,"about_ca_system_score_codex":0.00009788293,"about_ca_system_score_gemma":0.00043779,"threshold_uncertainty_score":0.75946796},"labels":[],"label_agreement":null},{"id":"W2952177114","doi":"10.1097/01.hs9.0000562400.45413.a7","title":"PS1026 ENASIDENIB ASSOCIATED WITH IMPROVED SURVIVAL COMPARED WITH STANDARD OF CARE FOR R/R AML PATIENTS WITH AN IDH2 MUTATION BASED ON DATA FROM STUDY AG221‐C‐001 AND A REVIEW OF PATIENT CHARTS IN FRANCE","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Alberta","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Propensity score matching; IDH2; Hematopoietic stem cell transplantation; Transplantation; Confidence interval; Mutation; IDH1; Biology","score_opus":0.050355798225258826,"score_gpt":0.351584830850553,"score_spread":0.30122903262529416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952177114","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11781187,0.8522387,0.000044178512,0.000018073517,0.00004986813,0.021640552,0.008098611,0.000033435233,0.000064689775],"genre_scores_gemma":[0.12882479,0.7844436,0.0034934168,0.00019811334,0.00009264632,0.0017862056,0.08048149,0.0005852947,0.00009440844],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9956249,0.0005157005,0.0010785788,0.001063445,0.00132559,0.00039178904],"domain_scores_gemma":[0.9948433,0.0006266857,0.0014108032,0.0016740204,0.0012716596,0.0001735047],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005334418,0.0006206797,0.0041563367,0.00013580002,0.000046372355,0.00001892642,0.0003769543,0.00020600903,0.00007193658],"category_scores_gemma":[0.0003839992,0.0003847266,0.000089721594,0.0005932547,0.000116183415,0.00015943575,0.000109083725,0.00052178156,0.000001282391],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016453251,0.006503774,0.09026384,0.52125263,0.003304891,0.00022229475,0.0030134951,0.00002455722,0.0000023999905,0.0000022487827,0.00055327645,0.35840333],"study_design_scores_gemma":[0.06272616,0.06960344,0.01790899,0.8119684,0.007242257,0.0000063643865,0.0033699882,0.0009798784,0.00001961446,0.0000012037412,0.024716286,0.0014574204],"about_ca_topic_score_codex":0.00057178846,"about_ca_topic_score_gemma":0.0021373972,"teacher_disagreement_score":0.3569459,"about_ca_system_score_codex":0.00064244267,"about_ca_system_score_gemma":0.0018606992,"threshold_uncertainty_score":0.99986047},"labels":[],"label_agreement":null},{"id":"W2952482267","doi":"10.1097/01.hs9.0000558668.31452.51","title":"S112 MLL FUSIONS AFFECT SPLICING TO INDUCE EXPLOITABLE METABOLIC DEPENDENCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Genetics","funders":"","keywords":"PKM2; Biology; Cell biology; Warburg effect; Small hairpin RNA; Alternative splicing; Glycolysis; Cell growth; RNA splicing; Cancer research; Exon; Chemistry; Pyruvate kinase; Gene; Biochemistry; RNA; Metabolism","score_opus":0.027358971629896298,"score_gpt":0.30676860134906336,"score_spread":0.27940962971916705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952482267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93607265,0.0010126437,0.00020214815,0.0013872607,0.00020633616,0.00119968,0.0000067775204,0.00017708894,0.059735395],"genre_scores_gemma":[0.9462743,0.00008775344,0.0035509337,0.0013492972,0.0002805923,0.000102224345,0.00001462841,0.00007427268,0.048266005],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977094,0.000066032546,0.00026583887,0.00052421866,0.00066272763,0.0007717896],"domain_scores_gemma":[0.9982193,0.00018700228,0.000051495444,0.0008909793,0.00016728468,0.00048395398],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004021848,0.00026058668,0.0005597712,0.00014791168,0.00012713211,0.000045513254,0.0002702301,0.00017557593,0.0063411533],"category_scores_gemma":[0.00032175804,0.00021598769,0.00014417915,0.00077017315,0.00003360528,0.00019491711,0.0003458356,0.0005705233,0.00652185],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000309281,0.00027277358,0.08937641,0.00042366493,0.0002724923,0.0004035573,0.0020246566,0.00012232551,0.8283958,0.0033606235,0.06152896,0.013509446],"study_design_scores_gemma":[0.0070393016,0.0013998955,0.13958412,0.0011569934,0.00037998654,0.00078436924,0.01166056,0.0008650949,0.46692112,0.00024106535,0.3685885,0.0013789788],"about_ca_topic_score_codex":0.0007868311,"about_ca_topic_score_gemma":0.00019284754,"teacher_disagreement_score":0.3614747,"about_ca_system_score_codex":0.00023963534,"about_ca_system_score_gemma":0.00054516405,"threshold_uncertainty_score":0.99456716},"labels":[],"label_agreement":null},{"id":"W2952821043","doi":"10.1097/01.hs9.0000562176.15402.a3","title":"PS968 GENETIC LANDSCAPE OF FLT3‐MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS TREATED WITHIN THE RATIFY TRIAL: CALGB 10603 (ALLIANCE)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Midostaurin; CEBPA; NPM1; Oncology; Neuroblastoma RAS viral oncogene homolog; Medicine; Internal medicine; Alectinib; Sanger sequencing; Myeloid leukemia; Cancer research; KRAS; Mutation; Biology; Genetics; Gene; Cancer; Crizotinib; Karyotype","score_opus":0.013724678406278864,"score_gpt":0.27149035263312354,"score_spread":0.25776567422684465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952821043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989244,0.0005566755,0.000024196952,0.0004180695,0.00036597578,0.0032159633,0.00005476133,0.00013425753,0.0059860987],"genre_scores_gemma":[0.9814614,0.00022722885,0.0010963499,0.00038755112,0.00020725178,0.00013390413,0.00025635445,0.00012624441,0.016103692],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965272,0.00024624262,0.0009081036,0.0006509137,0.0009998995,0.0006676597],"domain_scores_gemma":[0.9973377,0.00023435308,0.00040200583,0.0012498058,0.00048691704,0.00028923727],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00038583766,0.0004451603,0.00092522113,0.00007964115,0.000118361284,0.00004318073,0.0004974029,0.0003580555,0.0023901232],"category_scores_gemma":[0.00021597554,0.00028529373,0.00026513633,0.00086590956,0.00020287714,0.00012365491,0.00016498604,0.0007652854,0.00092021126],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.118458,0.001832969,0.5956222,0.0018672737,0.004617241,0.0008079633,0.0052022166,0.0012859452,0.12409274,0.0004234181,0.12642626,0.01936376],"study_design_scores_gemma":[0.4085298,0.013368293,0.32878822,0.0016776484,0.0024538736,0.00031492312,0.002652292,0.022580989,0.20212081,0.00028767684,0.014862687,0.0023628033],"about_ca_topic_score_codex":0.00034720494,"about_ca_topic_score_gemma":0.000062413856,"teacher_disagreement_score":0.2900718,"about_ca_system_score_codex":0.00053536583,"about_ca_system_score_gemma":0.0010324878,"threshold_uncertainty_score":0.99995995},"labels":[],"label_agreement":null},{"id":"W2952930577","doi":"10.1097/01.hs9.0000559236.73191.39","title":"PF256 RATIFY: PROGNOSTIC IMPACT OF FLT3 TYROSINE KINASE DOMAIN (TKD) AND NPM1 MUTATION STATUS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) TREATED WITH MIDOSTAURIN + STANDARD CHEMOTHERAPY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Midostaurin; Medicine; NPM1; Internal medicine; Oncology; Myeloid leukemia; Tyrosine kinase; Survival analysis; Cancer research; Biology; Genetics; Receptor; Gene","score_opus":0.005263333271571992,"score_gpt":0.25244300062050856,"score_spread":0.24717966734893657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952930577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956376,0.00027720418,0.00011784836,0.00010793794,0.000016505797,0.0032005422,0.00021163015,0.00007322575,0.00035750424],"genre_scores_gemma":[0.99412286,0.00013392983,0.0046281195,0.00007389998,0.000030468058,0.000090160254,0.00055122026,0.00013001569,0.00023929679],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971023,0.0001269323,0.00049936096,0.0006438491,0.0008510055,0.0007765391],"domain_scores_gemma":[0.99806803,0.00026274484,0.00026387002,0.00058063964,0.00044298472,0.00038174808],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000213798,0.00049360417,0.00091273006,0.00022150937,0.000056518464,0.00005056989,0.00012329247,0.0002016661,0.0005002428],"category_scores_gemma":[0.00010083187,0.00033076692,0.00008662787,0.0009162305,0.00022744376,0.000296447,0.00004822998,0.0004478804,0.000017997841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029433781,0.0003803933,0.95430154,0.00032512206,0.00043789647,0.00043838593,0.0015963484,0.00019453,0.005076658,0.000014293683,0.00028880913,0.0075122397],"study_design_scores_gemma":[0.05753274,0.010697576,0.92120355,0.000837864,0.00015266996,0.000041807314,0.00077521044,0.0003360624,0.007909298,0.00002359106,0.00007839254,0.00041122577],"about_ca_topic_score_codex":0.0012587128,"about_ca_topic_score_gemma":0.00039219807,"teacher_disagreement_score":0.03309798,"about_ca_system_score_codex":0.001745392,"about_ca_system_score_gemma":0.0015194917,"threshold_uncertainty_score":0.9999144},"labels":[],"label_agreement":null},{"id":"W2953077540","doi":"10.1097/01.hs9.0000562152.07779.48","title":"PS962 PHASE 1 RESULTS OF ZUMA‐4: KTE‐X19, AN ANTI‐CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Refractory (planetary science); Gastroenterology; Bone marrow; Acute lymphocytic leukemia; Internal medicine; Hematopoietic stem cell transplantation; Transplantation; Immunology; Leukemia; Lymphoblastic Leukemia; Biology","score_opus":0.00894242772849638,"score_gpt":0.2504569139496639,"score_spread":0.24151448622116753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953077540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947306,0.0011620583,0.000013767204,0.000050777224,0.00016357277,0.0017965344,0.0001296725,0.000071313705,0.0018817352],"genre_scores_gemma":[0.9924441,0.003920072,0.00096149615,0.00016729612,0.00016317057,0.000024192375,0.0003045037,0.00013850543,0.0018766775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996381,0.00019681305,0.00078762183,0.00096149754,0.00088846183,0.0007846155],"domain_scores_gemma":[0.99764633,0.00015801698,0.00044946928,0.0009938759,0.00029314478,0.0004591814],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034312796,0.00051361887,0.000885083,0.000302274,0.000072913565,0.000029674582,0.00032242524,0.00032472258,0.00037196997],"category_scores_gemma":[0.00005074847,0.00040058262,0.00010401062,0.00088706217,0.0001540606,0.00032988063,0.00013527878,0.0007195733,0.00017999532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020263799,0.0061303684,0.8514506,0.0016067288,0.00014833499,0.0001839025,0.001765201,0.00007069776,0.09751571,0.000002561124,0.012098225,0.00876385],"study_design_scores_gemma":[0.16140088,0.0200653,0.74687475,0.0007589007,0.00030518943,0.000035132107,0.0009091032,0.0011662447,0.061429735,0.0000070655074,0.0056925216,0.0013551669],"about_ca_topic_score_codex":0.00016056426,"about_ca_topic_score_gemma":0.000012261177,"teacher_disagreement_score":0.1411371,"about_ca_system_score_codex":0.000691837,"about_ca_system_score_gemma":0.0012309379,"threshold_uncertainty_score":0.9998446},"labels":[],"label_agreement":null},{"id":"W2953189973","doi":"10.1158/2159-8290.cd-17-1271","title":"MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia","year":2018,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Cancer Institute; National Institutes of Health; Rita Allen Foundation; American Society of Hematology; Damon Runyon Cancer Research Foundation; Alex's Lemonade Stand Foundation for Childhood Cancer; Burroughs Wellcome Fund","keywords":"MEF2C; Myeloid leukemia; Cancer research; Phosphorylation; Kinase; Leukemia; Cancer; Medicine; Transcription factor; Biology; Immunology; Internal medicine; Cell biology; Genetics; Gene","score_opus":0.02393687192951087,"score_gpt":0.32884486045938366,"score_spread":0.3049079885298728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953189973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97750676,0.002679481,0.0027880794,0.009153029,0.00044461756,0.0015540506,0.00018968729,0.00007701543,0.0056072576],"genre_scores_gemma":[0.9356207,0.0028459674,0.0031745734,0.007324697,0.0014062634,0.0006545189,0.000093711096,0.00009820442,0.04878134],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998129,0.000025900074,0.00035590338,0.0005653136,0.00036896026,0.00055491476],"domain_scores_gemma":[0.9989073,0.00008160638,0.00011553956,0.0005514135,0.00021903845,0.00012508305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002902825,0.00022582634,0.00040275848,0.00016031714,0.00010409136,0.000059196216,0.00021011755,0.00017642128,0.0002707893],"category_scores_gemma":[0.00007030147,0.00020524937,0.00013310829,0.00051822024,0.00025530747,0.00049056235,0.000046307294,0.0002292553,0.000043280157],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02814814,0.00021056329,0.030652441,0.0008013774,0.00091935083,0.00008966764,0.0069505167,0.000012382055,0.2690581,0.0026671728,0.6139195,0.046570774],"study_design_scores_gemma":[0.017086042,0.00071351044,0.07247216,0.0009856293,0.00020671592,0.000012509461,0.00034386394,0.0017710762,0.5187714,0.0040162075,0.38283545,0.0007854244],"about_ca_topic_score_codex":0.00028377667,"about_ca_topic_score_gemma":0.0005038197,"teacher_disagreement_score":0.24971329,"about_ca_system_score_codex":0.0029630659,"about_ca_system_score_gemma":0.0015531584,"threshold_uncertainty_score":0.8369826},"labels":[],"label_agreement":null},{"id":"W2954132446","doi":"10.1200/jco.2019.37.15_suppl.e18505","title":"A retrospective, real-world population-based analysis of treatment patterns and outcomes in adult patients with relapsed/refractory acute myeloid leukemia in Alberta, Canada.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Cancer registry; Cohort; Relative survival; Population; Relative risk; Refractory (planetary science); Medical record; Cancer; Retrospective cohort study; Pediatrics; Confidence interval","score_opus":0.022238132854649432,"score_gpt":0.37009089599570305,"score_spread":0.3478527631410536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954132446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972845,0.0000061839355,0.000003345879,0.0016565399,0.00014886205,0.00040274113,0.000033685512,0.000002153179,0.00046203507],"genre_scores_gemma":[0.9980485,0.00017399121,0.00039636562,0.0006876379,0.000044083397,0.0000063705957,0.000046492652,0.00001951824,0.0005770841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99617094,0.00040570748,0.0022332054,0.0003047388,0.0005896049,0.0002958154],"domain_scores_gemma":[0.994629,0.0027226922,0.0015343011,0.00030968137,0.00050991256,0.0002943829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086514844,0.00019935664,0.0026728124,0.0009590778,0.000015176208,0.000004676045,0.0001349169,0.0002523846,0.00010852164],"category_scores_gemma":[0.0012056519,0.00012800242,0.00026877312,0.00078052253,0.000073835225,0.00010274756,0.00003188767,0.00090598245,0.0000011999956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005273833,0.0007602298,0.988184,0.000021311142,0.0018889823,0.00022854154,0.00008116112,0.0004326051,0.000004194975,0.000016600505,0.00005721998,0.003051368],"study_design_scores_gemma":[0.021715453,0.008530507,0.96675205,0.00010627807,0.0010900357,0.0000032525995,0.000045941368,0.0014523339,0.000005443685,0.000007046774,0.00018528532,0.00010636137],"about_ca_topic_score_codex":0.7597864,"about_ca_topic_score_gemma":0.97118586,"teacher_disagreement_score":0.21139944,"about_ca_system_score_codex":0.010001446,"about_ca_system_score_gemma":0.009017727,"threshold_uncertainty_score":0.9966002},"labels":[],"label_agreement":null},{"id":"W2954391632","doi":"10.1200/jco.2019.37.15_suppl.tps7063","title":"MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Interim analysis; Clinical endpoint; Oncology; Refractory (planetary science); Population; Phases of clinical research; Hematopoietic stem cell transplantation; Transplantation; Gastroenterology; Clinical trial","score_opus":0.07389082348103082,"score_gpt":0.4581241315676492,"score_spread":0.3842333080866184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954391632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99466836,0.00005369414,0.000053509273,0.0009008787,0.001098748,0.0021273894,0.000009511541,0.000012355189,0.0010755438],"genre_scores_gemma":[0.99033046,0.00054395694,0.006468746,0.0009953602,0.0007968417,0.000017814407,0.000025998328,0.000054864937,0.0007659692],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99006414,0.002611849,0.005259947,0.0003992409,0.0011748394,0.0004899754],"domain_scores_gemma":[0.98496085,0.008669976,0.0040637823,0.00057335093,0.0010910719,0.00064094237],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01330753,0.0002811102,0.0050667888,0.0005570942,0.000028756145,0.000012422099,0.00044443514,0.00081378914,0.00047821464],"category_scores_gemma":[0.011744953,0.000160768,0.0006463268,0.00040624998,0.0005361874,0.00040551744,0.000089730616,0.0030022415,0.000040388844],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9466321,0.0075810924,0.01170525,0.00005375253,0.0008655928,0.00071162067,0.00020144234,0.000012293882,0.00046952715,0.000013671824,0.0007025842,0.031051109],"study_design_scores_gemma":[0.861858,0.11793214,0.014197381,0.00027922404,0.00060041127,0.00006690298,0.00011566827,0.00037427296,0.0001124257,0.00004083527,0.0042682174,0.0001545014],"about_ca_topic_score_codex":0.00005959082,"about_ca_topic_score_gemma":0.000047866102,"teacher_disagreement_score":0.11035105,"about_ca_system_score_codex":0.0011004676,"about_ca_system_score_gemma":0.010187019,"threshold_uncertainty_score":0.99929786},"labels":[],"label_agreement":null},{"id":"W2954407538","doi":"10.1007/s11095-019-2654-z","title":"Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia","year":2019,"lang":"en","type":"review","venue":"Pharmaceutical Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada); Spinal Cord Injury BC; University of British Columbia; Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency","funders":"","keywords":"Myeloid leukemia; Immunotherapy; Medicine; Leukemia; Nanotechnology; Cancer research; Immunology; Immune system; Materials science","score_opus":0.10853797583573603,"score_gpt":0.45660486645175563,"score_spread":0.3480668906160196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954407538","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025151335,0.98832184,0.0000018789382,0.0035744035,0.000044705317,0.0050010523,0.000023139995,0.000015204081,0.00050264935],"genre_scores_gemma":[0.0111232195,0.98783416,0.000031204523,0.000041244162,0.0000551501,0.00051140925,0.000029346254,0.000052803654,0.00032149607],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958936,0.00133904,0.000646678,0.00053850637,0.0008566647,0.00072549685],"domain_scores_gemma":[0.99602836,0.0026191794,0.00019160686,0.00071474427,0.00035993202,0.00008614433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045050755,0.0003322781,0.0015507842,0.0010167726,0.00013731733,0.0000293435,0.00047131724,0.00029775783,0.00004101304],"category_scores_gemma":[0.0003674003,0.00015617261,0.00014370208,0.0020908494,0.0018468341,0.0000717047,0.000394087,0.0017312644,0.000008789088],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010711446,0.00013759911,0.00008844264,0.004946097,0.00057543436,0.000007802946,0.0004654317,1.7323612e-7,0.00043155655,0.002845932,0.000009099233,0.9894213],"study_design_scores_gemma":[0.005615981,0.000629394,0.00002401853,0.001864801,0.00062726566,0.000110861874,0.0005858394,0.0010256984,0.0024797942,0.00059566676,0.986295,0.00014568622],"about_ca_topic_score_codex":0.000036021924,"about_ca_topic_score_gemma":0.0000027623635,"teacher_disagreement_score":0.9892756,"about_ca_system_score_codex":0.0006892954,"about_ca_system_score_gemma":0.0012568381,"threshold_uncertainty_score":0.75215787},"labels":[],"label_agreement":null},{"id":"W2954634447","doi":"10.1038/s41467-019-10705-z","title":"Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness","year":2019,"lang":"en","type":"article","venue":"Nature Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University and Génome Québec Innovation Centre; Jewish General Hospital; University of Toronto; University Health Network; McGill University; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; National Cancer Institute; National Institutes of Health; Children's Hospital Foundation; Fondation de l'Hôpital de Montréal pour enfants; Canadian Institutes of Health Research; McGill University Health Centre; National Heart, Lung, and Blood Institute; McGill University; American University of Beirut","keywords":"Epigenetics; Histone; RUNX1; Haematopoiesis; Biology; Myeloid leukemia; Histone H3; Stem cell; Cancer research; Mutation; Acetylation; Myeloid; Leukemia; Hematopoietic stem cell; Genetics; Gene","score_opus":0.016212175291906796,"score_gpt":0.3133988979938906,"score_spread":0.2971867227019838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954634447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752739,0.017119557,0.000019618665,0.0023556994,0.00011915255,0.0015921673,0.000023304368,0.00016674378,0.0033298736],"genre_scores_gemma":[0.991104,0.0020402232,0.0011815886,0.0003242354,0.00005263895,0.00013237886,0.00020285638,0.00007519141,0.004886897],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997896,0.0002498513,0.00043911612,0.000512142,0.00048165742,0.0004212145],"domain_scores_gemma":[0.99538755,0.00031425292,0.00025437708,0.0034395151,0.00036569,0.00023859476],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00036921725,0.00030366538,0.0005101324,0.00027716852,0.0004421123,0.000047758807,0.0010844041,0.0005827011,0.000067969304],"category_scores_gemma":[0.000056248613,0.00026565546,0.000116043106,0.00043805578,0.00036923314,0.00018005085,0.00094481924,0.0024436389,0.00012722024],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016992952,0.0004119709,0.011087666,0.0006839041,0.00011146126,0.00004297229,0.004870667,0.000008301147,0.973196,0.0029717132,0.0027068628,0.003738528],"study_design_scores_gemma":[0.030989034,0.0029469256,0.22876003,0.009188668,0.0016957475,0.003907748,0.010469292,0.017779537,0.5132087,0.0026231904,0.17434317,0.0040879734],"about_ca_topic_score_codex":0.00007606945,"about_ca_topic_score_gemma":0.000049865434,"teacher_disagreement_score":0.45998734,"about_ca_system_score_codex":0.0010390922,"about_ca_system_score_gemma":0.0006195942,"threshold_uncertainty_score":0.99997956},"labels":[],"label_agreement":null},{"id":"W2955264692","doi":"10.1200/jco.2019.37.15_suppl.7059","title":"Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed/refractory chronic myelomonocytic leukemia (CMML).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Chronic myelomonocytic leukemia; Refractory (planetary science); Internal medicine; Gastroenterology; Vomiting; Interleukin-3 receptor; Malignancy; Stage (stratigraphy); Leukemia; Oncology; Bone marrow; Myelodysplastic syndromes","score_opus":0.1029157698071348,"score_gpt":0.465666030387402,"score_spread":0.3627502605802672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955264692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99181384,0.00018857032,0.000036095837,0.0012164557,0.0026378066,0.0012743794,0.000040438805,0.000014747302,0.0027776521],"genre_scores_gemma":[0.99254125,0.00081053283,0.0024159236,0.00059442257,0.0030617137,0.000006091166,0.000052672134,0.00006186865,0.00045549657],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98646635,0.002038236,0.008761157,0.0006844062,0.0013909782,0.0006588723],"domain_scores_gemma":[0.9758456,0.015643662,0.0057647154,0.00094156613,0.0009798333,0.0008246321],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.012262535,0.00034656958,0.004049348,0.00046289014,0.000034239572,0.000014792125,0.00064704346,0.001335511,0.00030589988],"category_scores_gemma":[0.020773016,0.00023958174,0.0008989115,0.00046542924,0.0006281986,0.000327495,0.00021459261,0.005453803,0.00014245228],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64275146,0.008443925,0.12916863,0.000051462688,0.0007239355,0.0006812632,0.00011282883,0.000057833506,0.00011350173,0.000013329013,0.003481964,0.21439989],"study_design_scores_gemma":[0.5737791,0.14781618,0.2500665,0.0005276967,0.00036970226,0.000020716394,0.000076838216,0.00053548237,0.000051272105,0.00005969562,0.026495403,0.00020142297],"about_ca_topic_score_codex":0.00018857859,"about_ca_topic_score_gemma":0.00013063491,"teacher_disagreement_score":0.21419847,"about_ca_system_score_codex":0.0030745456,"about_ca_system_score_gemma":0.019393349,"threshold_uncertainty_score":0.99996096},"labels":[],"label_agreement":null},{"id":"W2955662388","doi":"10.1200/jco.2019.37.15_suppl.7011","title":"Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Gastroenterology; Leukocytosis; Adverse effect; Febrile neutropenia; Anemia; Hypokalemia; Nausea; Chemotherapy","score_opus":0.05347255513071011,"score_gpt":0.4111684294296463,"score_spread":0.35769587429893623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955662388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791984,0.00017946617,0.00062658434,0.01576983,0.0013422068,0.0015852985,0.000015758953,0.000024772828,0.0012576876],"genre_scores_gemma":[0.9846466,0.00086675707,0.008210222,0.0031796906,0.0018535441,0.000049020302,0.000028212964,0.00007947024,0.0010864902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939106,0.00057438685,0.003312566,0.0004973497,0.0009862655,0.00071882847],"domain_scores_gemma":[0.9889504,0.0066773845,0.0020044497,0.00044105703,0.0012183085,0.0007084426],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0057181036,0.00033299444,0.0025900658,0.0005668112,0.000060195278,0.000034067354,0.0004414652,0.0008806116,0.00022463457],"category_scores_gemma":[0.0050934036,0.00023591169,0.000569339,0.0004930444,0.00035101213,0.0004115109,0.00012511786,0.0026611397,0.00010272022],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1517612,0.010054664,0.38967884,0.0008076264,0.0039191903,0.021230798,0.0012011088,0.0005862454,0.088760294,0.0018432948,0.08729842,0.24285834],"study_design_scores_gemma":[0.27203092,0.1465478,0.39617774,0.0016496503,0.0015949071,0.004326916,0.0011543209,0.0070174662,0.013561267,0.0020358686,0.15293065,0.0009725011],"about_ca_topic_score_codex":0.00007552298,"about_ca_topic_score_gemma":0.00021020198,"teacher_disagreement_score":0.24188583,"about_ca_system_score_codex":0.002282478,"about_ca_system_score_gemma":0.007838614,"threshold_uncertainty_score":0.99963975},"labels":[],"label_agreement":null},{"id":"W2955919420","doi":"10.1200/jco.2019.37.15_suppl.e18531","title":"Intensive minimal residual disease monitoring to drive early intervention after allogeneic hematopoietic stem cell transplant for pediatric acute leukemia.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Minimal residual disease; Hematopoietic stem cell transplantation; Internal medicine; Leukemia; Bone marrow; Transplantation; Oncology; Myeloid leukemia","score_opus":0.059789456338762106,"score_gpt":0.41691488435006385,"score_spread":0.35712542801130176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955919420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920584,0.0006038545,0.0006058947,0.0036560455,0.0019406452,0.0010035498,0.000037302354,0.000014790053,0.00007953328],"genre_scores_gemma":[0.99102694,0.0005029574,0.0027068849,0.0009967226,0.0029911185,0.00005244675,0.000005944554,0.000051558873,0.0016654476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995493,0.00040367697,0.002510819,0.00042068306,0.00063055195,0.0005412613],"domain_scores_gemma":[0.9939606,0.002125823,0.0010109079,0.0003260792,0.0014060914,0.0011704812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024444282,0.00024758425,0.0015489232,0.00037529116,0.00003710785,0.000023424493,0.0003537695,0.0004437346,0.00008108108],"category_scores_gemma":[0.0007152058,0.00018901582,0.0010618342,0.00020723123,0.00009042779,0.00017380215,0.00012638448,0.0013359501,0.00017139871],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09748396,0.0012301465,0.8674152,0.00077197544,0.001026402,0.0062125954,0.0018462148,0.000052190047,0.0026820693,0.000016850165,0.0064094276,0.0148529755],"study_design_scores_gemma":[0.02482416,0.042206567,0.9197676,0.0006260433,0.003485617,0.00052875694,0.0013067571,0.00011425325,0.0023809816,0.00010418565,0.004259832,0.00039521442],"about_ca_topic_score_codex":0.000009522497,"about_ca_topic_score_gemma":0.000003697548,"teacher_disagreement_score":0.0726598,"about_ca_system_score_codex":0.0008298761,"about_ca_system_score_gemma":0.002401661,"threshold_uncertainty_score":0.7707841},"labels":[],"label_agreement":null},{"id":"W2956339027","doi":"10.1016/j.ccell.2019.06.003","title":"Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia","year":2019,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":262,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Fonds de Recherche du Québec - Santé; Institut de Valorisation des Données; Université de Montréal; Canada First Research Excellence Fund; Canada Research Chairs; McGill University; Génome Québec; Human Frontier Science Program; Government of Canada; Ministère de l'Économie, de la Science et de l'Innovation - Québec; Genome Canada","keywords":"Myeloid leukemia; Dependency (UML); Cancer research; Leukemia; Oxidative phosphorylation; Cell biology; Biology; Computational biology; Computer science; Immunology; Biochemistry","score_opus":0.013984882174361318,"score_gpt":0.27849246268396965,"score_spread":0.2645075805096083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956339027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97790575,0.006431463,0.000010301045,0.0017717102,0.0000644817,0.0011908951,0.000046272835,0.000018270948,0.0125608565],"genre_scores_gemma":[0.98940516,0.005223138,0.000063861866,0.0008484187,0.00011205571,0.00009216001,0.000039414517,0.000035263285,0.004180542],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983642,0.00009272636,0.00034395937,0.00033210817,0.00038247765,0.0004844899],"domain_scores_gemma":[0.99907225,0.00015458281,0.00010656618,0.0004830074,0.00008750753,0.00009606717],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005896573,0.00018385678,0.00041496943,0.000061955194,0.000060009672,0.000009310635,0.0003071239,0.00011339176,0.0009945799],"category_scores_gemma":[0.000014388932,0.0001091466,0.00008269477,0.00027234686,0.00013225076,0.000067359724,0.000052810454,0.0005554377,0.000021589121],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001682156,0.00012595227,0.39976984,0.000904399,0.0002757612,0.00014240672,0.005596197,0.00008360931,0.57084954,0.00030329762,0.012983007,0.007283848],"study_design_scores_gemma":[0.010401598,0.0009198264,0.85472584,0.00033772446,0.00029327354,0.00013878568,0.002047766,0.0026477652,0.10548212,0.00024837023,0.022267772,0.0004891606],"about_ca_topic_score_codex":0.0012951526,"about_ca_topic_score_gemma":0.00060427474,"teacher_disagreement_score":0.4653674,"about_ca_system_score_codex":0.000408498,"about_ca_system_score_gemma":0.000623378,"threshold_uncertainty_score":0.99991864},"labels":[],"label_agreement":null},{"id":"W2958858057","doi":"10.1038/s41375-019-0485-x","title":"Genetic characterization of ABT-199 sensitivity in human AML","year":2019,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Université du Québec; Institute for Research in Immunology and Cancer","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Biology; Cancer research; Computational biology; Genetics; Oncology","score_opus":0.012969382715629836,"score_gpt":0.2766586464065515,"score_spread":0.26368926369092166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958858057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962378,0.000011963714,0.00009526584,0.00016278651,0.000064637185,0.0005159449,0.000008334587,0.00003330147,0.0028699464],"genre_scores_gemma":[0.9970368,0.000020696061,0.0002597304,0.0002504645,0.00011092004,0.00000906867,0.000081292725,0.000028801876,0.0022022207],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998773,0.00007626004,0.00029604614,0.00026726894,0.000304954,0.00028249365],"domain_scores_gemma":[0.9992628,0.000046243415,0.0000889589,0.00042923048,0.00008641927,0.00008635889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028899263,0.00012287819,0.0003390936,0.00021927796,0.000020265965,0.000008142073,0.00007516822,0.00014211364,0.00025806014],"category_scores_gemma":[0.000046656063,0.00011810429,0.00005956801,0.00032879785,0.00006139948,0.00007839455,0.000072249706,0.00032390293,0.0002022046],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007073875,0.000031893975,0.2014738,0.00013482763,0.000013384994,0.000080624115,0.00017696574,0.00002082987,0.7960047,0.00010715048,0.00006594605,0.0018190987],"study_design_scores_gemma":[0.0018003539,0.0001388802,0.90017813,0.000111595764,0.000013418811,0.00004414454,0.000027197731,0.0026546712,0.09431138,0.00002884425,0.00058865105,0.00010272266],"about_ca_topic_score_codex":0.00045374018,"about_ca_topic_score_gemma":0.000052624706,"teacher_disagreement_score":0.70169336,"about_ca_system_score_codex":0.00088662544,"about_ca_system_score_gemma":0.00038718496,"threshold_uncertainty_score":0.48161533},"labels":[],"label_agreement":null},{"id":"W2961134298","doi":"10.1182/blood-2018-99-109470","title":"Mitochondrial Dysfunction in Normal and Malignant Hematopoiesis","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Biology; Stem cell; Oxidative stress; Myeloid leukemia; Mitochondrion; Haematopoiesis; Cancer research; Respiratory chain; Oxidative phosphorylation; Preleukemia; Mitochondrial DNA; Leukemia; Cell biology; Immunology; Genetics; Biochemistry; Gene","score_opus":0.013304267480336177,"score_gpt":0.26345548648232125,"score_spread":0.25015121900198506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961134298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920192,0.00011071028,0.000054821667,0.00064280437,0.00013437787,0.00024119805,0.0000023275104,0.000032346357,0.0067622336],"genre_scores_gemma":[0.9960361,0.000029900286,0.0017218938,0.00019863139,0.00081449613,0.00002136714,0.0000062288727,0.00001546798,0.001155932],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99919105,0.000027172182,0.00014693312,0.00020396261,0.00018990124,0.00024095709],"domain_scores_gemma":[0.9995895,0.000034044588,0.000021904372,0.00019160674,0.0000615052,0.000101413374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012813734,0.000081845465,0.00015862673,0.00013471952,0.00004535204,0.000014350502,0.00004475961,0.00008588572,0.00026358775],"category_scores_gemma":[0.00012337958,0.00006769565,0.000024749577,0.00018583974,0.00011026976,0.00006770201,0.00006164289,0.00014285558,0.00012737475],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022203126,0.001398111,0.18509287,0.0003775363,0.000249701,0.0009620545,0.0020249744,2.8375675e-7,0.7841406,0.0013687584,0.015309289,0.0068555074],"study_design_scores_gemma":[0.045360673,0.0031757075,0.20338939,0.0004168332,0.00035339873,0.0023885556,0.0007612692,0.0005079522,0.72256005,0.00052789785,0.020033417,0.00052482414],"about_ca_topic_score_codex":0.00013018397,"about_ca_topic_score_gemma":0.000077512035,"teacher_disagreement_score":0.061580528,"about_ca_system_score_codex":0.000044220633,"about_ca_system_score_gemma":0.00010462941,"threshold_uncertainty_score":0.2886101},"labels":[],"label_agreement":null},{"id":"W2961373787","doi":"10.1097/pai.0000000000000787","title":"Bone Marrow Immunohistochemistry and Flow Cytometry in the Diagnosis of Malignant Hematologic Diseases With Emphasis on Lymphomas: A Comparative Retrospective Study","year":2019,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Immunohistochemistry; Bone marrow; Pathology; Lymphoma; Malignancy; Leukemia; Hematologic malignancy; Chronic lymphocytic leukemia; Hematology; Minimal residual disease; Flow cytometry; Internal medicine; Immunology","score_opus":0.011242507490494508,"score_gpt":0.29337702021001877,"score_spread":0.2821345127195243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961373787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99110436,0.0026250586,0.000028892518,0.00023199302,0.000035273864,0.0024150002,0.00005319877,0.000047049423,0.003459142],"genre_scores_gemma":[0.99734205,0.000075005424,0.00046459414,0.0003758825,0.000021793625,0.0013908808,0.00013095063,0.000060156697,0.00013868535],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99668634,0.00016257468,0.0006730791,0.0010886837,0.00075656094,0.00063274556],"domain_scores_gemma":[0.99737996,0.0002845734,0.00035269503,0.0016350336,0.0002099196,0.00013781225],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040126132,0.00058088213,0.0014175314,0.00024219016,0.00011074397,0.000025293491,0.0005340213,0.00028716392,0.00023249017],"category_scores_gemma":[0.00015190983,0.0004312378,0.00016377379,0.00088081777,0.0008379419,0.000039541603,0.000243954,0.0007825576,0.000032983262],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034417147,0.0019876715,0.057984907,0.00025463395,0.00043291756,0.0015978287,0.0012908631,0.000017091783,0.93238515,0.00009256181,0.00034742817,0.00016721347],"study_design_scores_gemma":[0.019586142,0.004086987,0.1665717,0.00040948798,0.0007408106,0.0026769328,0.01622295,0.000075197975,0.7883743,0.0001618378,0.000041252166,0.0010523662],"about_ca_topic_score_codex":0.00009408084,"about_ca_topic_score_gemma":2.3687656e-7,"teacher_disagreement_score":0.14401084,"about_ca_system_score_codex":0.0009329018,"about_ca_system_score_gemma":0.00031297526,"threshold_uncertainty_score":0.9998139},"labels":[],"label_agreement":null},{"id":"W2961670806","doi":"10.1182/blood-2018-99-118017","title":"Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; University of Calgary","funders":"","keywords":"Germline mutation; Platelet disorder; Germline; Malignancy; Genetics; Penetrance; Genetic testing; Medicine; Biology; Bioinformatics; Mutation; Internal medicine; Gene","score_opus":0.03561656374646475,"score_gpt":0.3111472051199699,"score_spread":0.27553064137350514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961670806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398863,0.00011211841,0.0039097276,0.00017627013,0.000009356983,0.0008456667,0.00089328474,0.0000055275664,0.00005944055],"genre_scores_gemma":[0.9524046,0.000042230153,0.04371508,0.00004054897,0.000054830318,0.000032138152,0.003673085,0.00001386155,0.000023613115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988906,0.000020308897,0.00033337696,0.0003392459,0.0002525914,0.00016388475],"domain_scores_gemma":[0.9987345,0.000059388298,0.00011400717,0.000918054,0.00012193835,0.000052159612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005354336,0.0000920688,0.00026726746,0.00021812513,0.00004828943,0.00000842786,0.00036133113,0.000049382168,0.000010406138],"category_scores_gemma":[0.00009708765,0.000062588435,0.000014947467,0.0005623479,0.000096943375,0.00013607372,0.00037427235,0.00006435835,7.1226225e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009161937,0.00333424,0.5076443,0.0011879331,0.01122064,0.00007065059,0.022385482,0.000065506385,0.14463346,0.00045143403,0.0010010477,0.29884338],"study_design_scores_gemma":[0.012155462,0.0012764749,0.9102794,0.00035263156,0.003435293,0.000045261357,0.0018230582,0.018545063,0.048242457,0.000021253541,0.0035212918,0.00030233292],"about_ca_topic_score_codex":0.00013939007,"about_ca_topic_score_gemma":0.0024529821,"teacher_disagreement_score":0.40263513,"about_ca_system_score_codex":0.000030099776,"about_ca_system_score_gemma":0.0003731643,"threshold_uncertainty_score":0.25522822},"labels":[],"label_agreement":null},{"id":"W2961690031","doi":"10.1182/blood.v128.22.1687.1687","title":"Down Syndrome AML Is Unique in Phenotype Both at Diagnosis and in Post Chemotherapy Regeneration","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Hospital for Sick Children","funders":"","keywords":"Medicine; Internal medicine; Down syndrome; Chemotherapy; Oncology; Myeloid leukemia; Immunophenotyping; Minimal residual disease; Bone marrow; Leukemia; Immunology; Gastroenterology; Pathology; Flow cytometry","score_opus":0.013075281456186041,"score_gpt":0.26551842900611544,"score_spread":0.2524431475499294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961690031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985139,0.000498802,0.000008716015,0.0134902075,0.00001604951,0.00042500504,0.000013337407,0.000022928025,0.00038591886],"genre_scores_gemma":[0.99464995,0.0021892625,0.0003851769,0.0011608221,0.00005151729,0.00008251848,0.000011684633,0.00002674631,0.0014423233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990641,0.000056651854,0.00018150831,0.00027279562,0.00017560742,0.00024936022],"domain_scores_gemma":[0.9994773,0.00010261967,0.000031523436,0.00025276036,0.000040774677,0.00009497084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022669473,0.00011292729,0.000212173,0.00018730995,0.000025469553,0.000010276069,0.000066853856,0.00012385356,0.0004236174],"category_scores_gemma":[0.00010316195,0.00007912779,0.000023457847,0.00022088383,0.000057351885,0.00008454492,0.00005049417,0.00012651487,0.000050454775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036606484,0.00053190417,0.7266959,0.00006579365,0.000061636245,0.00034070486,0.0007119697,2.2328723e-7,0.25730154,0.00008222322,0.0024326383,0.011409419],"study_design_scores_gemma":[0.010930223,0.00044524728,0.78829306,0.00024597943,0.000023387518,0.00019632665,0.000023381208,0.00002607927,0.19747882,0.00011198828,0.0020636793,0.00016183053],"about_ca_topic_score_codex":0.00033333283,"about_ca_topic_score_gemma":0.00059356773,"teacher_disagreement_score":0.06159718,"about_ca_system_score_codex":0.0002578275,"about_ca_system_score_gemma":0.00013183168,"threshold_uncertainty_score":0.46383134},"labels":[],"label_agreement":null},{"id":"W2964166353","doi":"10.1182/bloodadvances.2018028423","title":"Distinct clinical and biological implications of CUX1 in myeloid neoplasms","year":2019,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Edward P. Evans Foundation","keywords":"Frameshift mutation; Myeloid; Cancer research; Biology; Myeloid leukemia; Somatic cell; Gene knockdown; Progenitor cell; Locus (genetics); Germline; Bone marrow; Myelodysplastic syndromes; Genetics; Germline mutation; Gene; Molecular biology; Mutation; Immunology; Stem cell","score_opus":0.034966826256635074,"score_gpt":0.3643098961475505,"score_spread":0.32934306989091544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964166353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247473,0.0014237378,0.000020854917,0.0009996904,0.000045652163,0.00037248197,0.0000149747975,0.000021869684,0.004626016],"genre_scores_gemma":[0.99557954,0.001503684,0.0023906485,0.00012167816,0.00006687165,0.00002062332,0.000015446794,0.000008104939,0.00029338672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897903,0.000058946367,0.00036178698,0.00028812853,0.00011225238,0.00019986533],"domain_scores_gemma":[0.9990209,0.00048805392,0.00007142894,0.00026191204,0.00005414426,0.000103588376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031167537,0.000088910776,0.0003473269,0.000072150244,0.0000181592,0.0000044127837,0.00010553759,0.00009207649,0.000088205474],"category_scores_gemma":[0.00043714582,0.000063026055,0.00005111425,0.00020855888,0.00027039569,0.000069809175,0.00009095013,0.00024696707,0.00003565879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011158192,0.00020161604,0.97742736,0.000049492297,0.000018582541,0.0000070011843,0.000023388679,6.5143337e-7,0.0039223605,0.00078531995,0.000044369495,0.017408267],"study_design_scores_gemma":[0.0022673674,0.0005500134,0.98719627,0.000050686696,0.000019171917,0.00004850325,0.0000810649,0.000029969493,0.001020633,0.00078451127,0.00787998,0.000071824936],"about_ca_topic_score_codex":0.000016844955,"about_ca_topic_score_gemma":0.000026829399,"teacher_disagreement_score":0.017336441,"about_ca_system_score_codex":0.000013737495,"about_ca_system_score_gemma":0.00010069054,"threshold_uncertainty_score":0.25701278},"labels":[],"label_agreement":null},{"id":"W2964681165","doi":"10.1182/bloodadvances.2019000306","title":"Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML","year":2019,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Persistence (discontinuity); Mutation; Chemotherapy; Allele; Induction chemotherapy; Medicine; Leukemia; Immunology; Oncology; Biology; Genetics; Internal medicine; Gene","score_opus":0.01736502105976898,"score_gpt":0.30250963145663357,"score_spread":0.28514461039686456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964681165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99704576,0.0014157367,0.000100057005,0.00027550067,0.000044205513,0.00073707884,0.000030581683,0.000022184482,0.00032888903],"genre_scores_gemma":[0.99707127,0.00061103,0.0015868052,0.00009114018,0.000047101945,0.000084933024,0.000013962121,0.000015572301,0.00047818842],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9993372,0.000018210909,0.0001441045,0.0002271813,0.00010039213,0.0001729345],"domain_scores_gemma":[0.9994205,0.00016563316,0.00008095621,0.00019004285,0.00009027147,0.000052597257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088795845,0.00011587961,0.00024950402,0.00010047385,0.000028127482,0.000007444509,0.00005446041,0.00006684952,0.000059692582],"category_scores_gemma":[0.00008750563,0.00007541498,0.00011407739,0.00012418699,0.000082247345,0.00016210692,0.000012227791,0.00011492969,0.000007019146],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0172571,0.001665008,0.3971263,0.0024704887,0.0016176831,0.000020791682,0.00391968,0.0008520914,0.45870435,0.00027282274,0.0006298116,0.1154639],"study_design_scores_gemma":[0.02304707,0.029536575,0.60391796,0.0013598676,0.00033806925,0.00084354496,0.004051282,0.0023430765,0.32458588,0.006274418,0.002871483,0.0008307484],"about_ca_topic_score_codex":0.000009225243,"about_ca_topic_score_gemma":0.0000020887703,"teacher_disagreement_score":0.2067917,"about_ca_system_score_codex":0.00010114165,"about_ca_system_score_gemma":0.00014480218,"threshold_uncertainty_score":0.30753335},"labels":[],"label_agreement":null},{"id":"W2964771088","doi":"10.1101/702001","title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Qatar National Research Fund; John and Lucille Van Geest Foundation; Fonds National de la Recherche Luxembourg","keywords":"Immunotherapy; Myeloid leukemia; Immune system; Immunology; Myeloid; Chemotherapy; Disease; Leukemia; Bone marrow; Medicine; Biology; Cancer research; Internal medicine","score_opus":0.008973786963714054,"score_gpt":0.243629072927788,"score_spread":0.23465528596407392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964771088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825662,0.011417253,0.0002153431,0.0021913196,0.0004599058,0.0024625296,0.00025011078,0.0003945047,0.000042851498],"genre_scores_gemma":[0.98020256,0.013310865,0.0043493127,0.00068484823,0.00034245275,0.00037908496,0.000002165155,0.000380622,0.00034808886],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.994708,0.0004915485,0.0010648293,0.0017038909,0.00088032545,0.0011514112],"domain_scores_gemma":[0.99553275,0.0003625544,0.00048902165,0.0027352115,0.00048303563,0.00039744301],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002497949,0.0009799483,0.0016643356,0.0009551104,0.00014146329,0.00022766688,0.0008034712,0.0012323207,0.00011205918],"category_scores_gemma":[0.00036948727,0.00097348687,0.00026700116,0.0009052717,0.00028128776,0.00021769298,0.00058563944,0.0026352315,0.000091575836],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016607901,0.00016209343,0.023071425,0.000889253,0.00083059265,0.0005847987,0.000090245885,0.000029754232,0.9565462,0.00005725619,0.0011193625,0.000011107618],"study_design_scores_gemma":[0.0101411985,0.0004171571,0.7938244,0.0021926416,0.00015920222,4.9061475e-7,0.000012642339,0.00093939155,0.1725969,0.0000035131463,0.018541113,0.0011713415],"about_ca_topic_score_codex":0.00011437107,"about_ca_topic_score_gemma":0.0000067396145,"teacher_disagreement_score":0.7839493,"about_ca_system_score_codex":0.0026296836,"about_ca_system_score_gemma":0.004155175,"threshold_uncertainty_score":0.99966574},"labels":[],"label_agreement":null},{"id":"W2965356525","doi":"10.1016/j.humimm.2019.07.034","title":"OR32 Modified chimerism approach for predicting acute myeloid leukemia relapse after allogeneic hematopoietic cell transplantation","year":2019,"lang":"en","type":"article","venue":"Human Immunology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Myeloid leukemia; Hematopoietic cell; Medicine; Hematopoietic stem cell transplantation; Immunology; Haematopoiesis; Transplantation; Myeloid; Leukemia; Acute leukemia; Cancer research; Biology; Stem cell; Internal medicine; Genetics","score_opus":0.01583977510930981,"score_gpt":0.2673176886427529,"score_spread":0.25147791353344306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965356525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98446244,0.00083247275,0.0052877706,0.00013027007,0.00021252625,0.0021276176,0.000039966722,0.00019105792,0.006715871],"genre_scores_gemma":[0.9840598,0.00027418428,0.0043030484,0.0002730098,0.00016831215,0.00069354457,0.0007635971,0.00011695862,0.009347548],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974911,0.00012704165,0.0005650696,0.000723151,0.00028368275,0.0008099545],"domain_scores_gemma":[0.99867433,0.00012132407,0.0001684904,0.0007732299,0.00013912171,0.00012352705],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036204356,0.00035290731,0.00064629945,0.00032546412,0.00021215875,0.00002994021,0.00032645324,0.0005027153,0.0003070865],"category_scores_gemma":[0.000021973705,0.0003283467,0.00023708804,0.00020195868,0.00022425299,0.00014152931,0.000093302006,0.0007781123,0.00021345455],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005280945,0.000323762,0.014564395,0.001534803,0.001079022,0.00018985978,0.005041058,0.00018152385,0.9690515,0.00090712245,0.00076540513,0.0010806447],"study_design_scores_gemma":[0.09491521,0.012245352,0.39224926,0.0008188269,0.004966691,0.007129282,0.004755076,0.015006324,0.45565745,0.0021215712,0.006167666,0.0039672796],"about_ca_topic_score_codex":0.000063705396,"about_ca_topic_score_gemma":0.0000036329236,"teacher_disagreement_score":0.513394,"about_ca_system_score_codex":0.0005212177,"about_ca_system_score_gemma":0.0003222356,"threshold_uncertainty_score":0.99991685},"labels":[],"label_agreement":null},{"id":"W2965591646","doi":"10.1200/jco.2012.30.15_suppl.6572","title":"Treatment outcomes in patients older than age 60 with acute myeloid leukemia (AML) in the nonclinical trial setting.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lions Gate Hospital","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Induction chemotherapy; Chemotherapy; Cohort; Cytarabine; Population; Multivariate analysis; Leukemia; Oncology; Surgery","score_opus":0.09302125964452963,"score_gpt":0.4642829151428726,"score_spread":0.371261655498343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965591646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98305327,0.00006359554,0.000010201505,0.012761806,0.0010377996,0.0012262302,0.0000055366645,0.000008217082,0.0018333567],"genre_scores_gemma":[0.9918531,0.0003231102,0.0017940189,0.003431757,0.001987481,0.000039714156,0.0000114158165,0.000035185338,0.000524216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9922443,0.002044536,0.0035968192,0.00030162875,0.0010170148,0.0007956875],"domain_scores_gemma":[0.98679656,0.010381618,0.0015068119,0.0004882182,0.00024198467,0.00058483554],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0085700285,0.0003046752,0.0025447581,0.0003048565,0.00004933473,0.00001916539,0.00047808903,0.0007087061,0.00007921307],"category_scores_gemma":[0.00605755,0.00014354356,0.0006703516,0.00035203138,0.00038540887,0.00024177654,0.00011064353,0.002843377,0.000048929025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09095435,0.007701508,0.8579038,0.000008666448,0.00053747016,0.0043786773,0.00085344334,0.000003024411,0.0000042215,0.000015508114,0.0015241187,0.036115214],"study_design_scores_gemma":[0.18240617,0.03561414,0.76966804,0.00005565519,0.00035325444,0.0002265146,0.0002517459,0.000014197166,0.000005913306,0.00002147031,0.011267526,0.00011534753],"about_ca_topic_score_codex":0.00010901256,"about_ca_topic_score_gemma":0.00021070322,"teacher_disagreement_score":0.09145182,"about_ca_system_score_codex":0.0020049717,"about_ca_system_score_gemma":0.004058146,"threshold_uncertainty_score":0.9994571},"labels":[],"label_agreement":null},{"id":"W2965988596","doi":"10.1007/s40258-019-00503-5","title":"Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting","year":2019,"lang":"en","type":"article","venue":"Applied Health Economics and Health Policy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Université de Montréal; Canada Research Chairs; Government of Canada; Génome Québec; Genome Canada","keywords":"Medicine; Myeloid leukemia; Quality-adjusted life year; Cost effectiveness; Oncology; Internal medicine; Risk analysis (engineering)","score_opus":0.04636349966392015,"score_gpt":0.4010658594285578,"score_spread":0.35470235976463765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965988596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95498466,0.0003042269,0.00006817742,0.032976866,0.00004506266,0.009784634,0.0006711086,0.000023436278,0.00114184],"genre_scores_gemma":[0.98229074,0.0026077265,0.0010597805,0.012694995,0.00013223066,0.0007607031,0.00034280733,0.00005253195,0.00005849921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969867,0.00005717269,0.0008862398,0.00056494103,0.000084753294,0.0014202237],"domain_scores_gemma":[0.9971237,0.0007715356,0.0003834436,0.0003932216,0.00007562659,0.001252443],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025412804,0.00023259081,0.0013900269,0.0018975887,0.00017565861,0.000021690867,0.00013053417,0.00016989483,0.000013596208],"category_scores_gemma":[0.00011297302,0.00024598642,0.000106430125,0.00096615683,0.00006925252,0.000050006343,0.000058707934,0.0003681849,0.00001304934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009179698,0.000178548,0.7842814,0.0073748813,0.0016703426,0.0000060400375,0.0048885755,0.0020007924,0.00014554376,0.07373055,0.0010092787,0.12379613],"study_design_scores_gemma":[0.0065869214,0.0011348081,0.917463,0.00022312517,0.0002048561,0.00001647478,0.00042007366,0.055577308,0.000054662047,0.0004940131,0.017512033,0.00031272514],"about_ca_topic_score_codex":0.6277263,"about_ca_topic_score_gemma":0.3743389,"teacher_disagreement_score":0.25338742,"about_ca_system_score_codex":0.010883004,"about_ca_system_score_gemma":0.03387867,"threshold_uncertainty_score":0.9999992},"labels":[],"label_agreement":null},{"id":"W2966178814","doi":"10.1111/bjh.16116","title":"Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with <i>NPM1</i> mutation: from definition of molecular relapse to MRD‐driven salvage approach","year":2019,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Minimal residual disease; NPM1; Medicine; Myeloid leukaemia; Oncology; Mutation; Salvage therapy; Residual; Internal medicine; Disease; Leukemia; Genetics; Chemotherapy; Biology; Karyotype; Gene","score_opus":0.0277667867759721,"score_gpt":0.2855302546066979,"score_spread":0.2577634678307258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966178814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9177329,0.0031141473,0.0014982603,0.07459714,0.00025715976,0.0017194785,0.00042736533,0.000020318263,0.0006332585],"genre_scores_gemma":[0.83337814,0.00076512335,0.068215504,0.08721285,0.0024225004,0.00030195256,0.0070064683,0.00042573415,0.00027170108],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99315697,0.0011163887,0.0017558208,0.0008390209,0.0023870561,0.00074473553],"domain_scores_gemma":[0.99566126,0.0005005259,0.0013150673,0.00062584615,0.0015662969,0.00033102685],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011601993,0.0005110371,0.0021886323,0.0011026736,0.00006745792,0.00007087873,0.0005843523,0.0009805424,0.00018201978],"category_scores_gemma":[0.0009743574,0.0005355554,0.00035338034,0.000607763,0.00041270495,0.00030623103,0.00017470735,0.0037331423,0.000047772955],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057809106,0.00037719004,0.0059701083,0.0011566163,0.0015008919,0.53291625,0.0003796165,0.0004321487,0.0011719334,0.000037989455,0.44880334,0.0014730229],"study_design_scores_gemma":[0.04282041,0.0061533167,0.08572163,0.016227208,0.0112638585,0.8213377,0.0008464948,0.0013837843,0.0026993933,0.0025176983,0.00670752,0.0023209786],"about_ca_topic_score_codex":0.00033192337,"about_ca_topic_score_gemma":0.00006737056,"teacher_disagreement_score":0.44209582,"about_ca_system_score_codex":0.00087013334,"about_ca_system_score_gemma":0.0032971594,"threshold_uncertainty_score":0.9997096},"labels":[],"label_agreement":null},{"id":"W2966276947","doi":"10.1016/j.humimm.2019.07.164","title":"P111 Somatic gene mutational landscape in acute myeloid leukemia patients of alberta","year":2019,"lang":"en","type":"article","venue":"Human Immunology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Myeloid leukemia; Somatic cell; Gene; Myeloid; Genetics; Biology; Cancer research","score_opus":0.010275731651565414,"score_gpt":0.26946204184886374,"score_spread":0.2591863101972983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966276947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921364,0.00016010414,0.0000048386014,0.00016666108,0.0001182161,0.00054157,0.000008432666,0.000019378911,0.006844405],"genre_scores_gemma":[0.9937944,0.000035597674,0.00032036842,0.00014190174,0.000031438885,0.000036130183,0.00041482068,0.000032639364,0.0051927133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845904,0.00009218727,0.0004856458,0.00029469628,0.00027074022,0.000397662],"domain_scores_gemma":[0.9990047,0.00017280779,0.00014667881,0.00046947817,0.00015319618,0.000053127103],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014930277,0.00016538563,0.0004878494,0.000418461,0.000039496,0.0000063968255,0.00023789179,0.0001988528,0.0019323993],"category_scores_gemma":[0.000096493,0.00015186376,0.000083253595,0.0002487873,0.00014031398,0.00008714186,0.00015122275,0.0003948501,0.00077859726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082232716,0.0004394584,0.7327174,0.00021106796,0.0007013494,0.00009001252,0.0022832064,0.000033114953,0.25793973,0.001819406,0.0011880643,0.0017548882],"study_design_scores_gemma":[0.008805075,0.00086420996,0.97792184,0.000081978236,0.000052688007,0.00008325908,0.00015112633,0.0003669664,0.010663666,0.0003875006,0.0004584184,0.0001632968],"about_ca_topic_score_codex":0.0005444724,"about_ca_topic_score_gemma":0.000102609316,"teacher_disagreement_score":0.24727605,"about_ca_system_score_codex":0.00043317088,"about_ca_system_score_gemma":0.00038234214,"threshold_uncertainty_score":0.9999994},"labels":[],"label_agreement":null},{"id":"W2966760111","doi":"10.1182/blood.v130.suppl_1.2524.2524","title":"The Thymidine Dideoxynucleoside Analogue, Alovudine, Inhibits the Mitochondrial DNA Polyermase, POLG, Impairs Oxidative Phosphorylation and Promotes Monocytic Differentiation in AML","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Biology; Mitochondrial DNA; Molecular biology; Mitochondrion; Respiratory chain; Oxidative phosphorylation; Phosphorylation; Nuclear DNA; DNA polymerase; DNA replication; DNA; Cell biology; Biochemistry; Gene","score_opus":0.016856302334789113,"score_gpt":0.27751911610081714,"score_spread":0.260662813766028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966760111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99003786,0.0006471922,0.000031086103,0.0071899467,0.00012799242,0.0012943982,0.000025674062,0.00003954041,0.00060634076],"genre_scores_gemma":[0.99842644,0.00035044653,0.0001670484,0.000106321866,0.00036022742,0.0000925088,0.00006502689,0.000034947647,0.000397064],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981905,0.00015619115,0.00037657292,0.0003829793,0.0004393298,0.00045440724],"domain_scores_gemma":[0.99825954,0.00038228516,0.00027233886,0.0008124163,0.00013468254,0.00013876206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045518085,0.00023717283,0.000303106,0.00012151452,0.0008421876,0.00026855234,0.00034036735,0.0001344699,0.000018537385],"category_scores_gemma":[0.0014610065,0.00013512187,0.000082535444,0.00018523974,0.00035842563,0.00028846733,0.0002683908,0.00048929435,0.00002362201],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022710492,0.0010093446,0.28709835,0.00014882772,0.0007972793,0.00013316025,0.003440669,0.0000057804477,0.68508744,0.0013790085,0.0023322075,0.01629687],"study_design_scores_gemma":[0.0073386137,0.00038745892,0.82048315,0.00013319663,0.00022245396,0.00004750673,0.00030970614,0.0018276898,0.1679264,0.00089415093,0.00024557958,0.00018412917],"about_ca_topic_score_codex":0.0008802504,"about_ca_topic_score_gemma":0.0010065073,"teacher_disagreement_score":0.5333848,"about_ca_system_score_codex":0.00014955892,"about_ca_system_score_gemma":0.00019153766,"threshold_uncertainty_score":0.64775115},"labels":[],"label_agreement":null},{"id":"W2966833955","doi":"10.1002/ajh.25601","title":"Isolated isochromosomes i(X)(p10) and idic(X)(q13) are associated with myeloid malignancies and dysplastic features","year":2019,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Isochromosome; Myeloid; Medicine; Internal medicine; Biology; Genetics; Gene","score_opus":0.008288603416969935,"score_gpt":0.24722726755154503,"score_spread":0.2389386641345751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966833955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6081951,0.005585109,0.000096654294,0.3851434,0.00024715828,0.00045683852,0.00005886215,0.000044704324,0.00017210896],"genre_scores_gemma":[0.7496586,0.0020283696,0.0009872793,0.24400418,0.00094807456,0.00001511397,0.00009838933,0.00024346905,0.0020165376],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9967574,0.00039952647,0.00075979903,0.0005172763,0.00073217653,0.0008338604],"domain_scores_gemma":[0.9950652,0.0016341251,0.0019643595,0.0003882263,0.00070511864,0.00024293347],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00033629383,0.000593625,0.002861637,0.0007523986,0.00010848811,0.00006077175,0.00030097176,0.0006977926,0.00008270201],"category_scores_gemma":[0.0008790562,0.0004109219,0.0001578632,0.0004738489,0.0017948294,0.00012450997,0.00015146763,0.004042524,0.000014252275],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012882606,0.00008775361,0.04044259,0.00086038176,0.0027993747,0.030114269,0.0005243482,0.000001646452,0.0007708174,0.000021486516,0.9220391,0.0010499683],"study_design_scores_gemma":[0.017806198,0.03445541,0.12271601,0.012006095,0.0054483465,0.6758082,0.004344443,0.00022056582,0.00093157147,0.000218981,0.123349175,0.0026949807],"about_ca_topic_score_codex":0.00003907176,"about_ca_topic_score_gemma":0.000012398639,"teacher_disagreement_score":0.7986899,"about_ca_system_score_codex":0.00027844866,"about_ca_system_score_gemma":0.0009100725,"threshold_uncertainty_score":0.99983424},"labels":[],"label_agreement":null},{"id":"W2967055487","doi":"10.1182/blood.v130.suppl_1.813.813","title":"Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Venetoclax; Refractory (planetary science); Medicine; MEK inhibitor; Lenalidomide; Internal medicine; Oncology; Leukemia; Chemistry; Multiple myeloma; Biology; Kinase; Chronic lymphocytic leukemia; MAPK/ERK pathway","score_opus":0.04089107456193912,"score_gpt":0.3463352910666302,"score_spread":0.30544421650469106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967055487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99156666,0.00007942025,0.0000047194358,0.00030607378,0.00021859414,0.007224575,0.00024903278,0.00012152573,0.00022942715],"genre_scores_gemma":[0.995,0.000016725315,0.0023549176,0.000075381446,0.00048557812,0.0006465797,0.00063115254,0.00017876364,0.0006109187],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99319,0.00077545486,0.0014997995,0.0014820617,0.0021259002,0.0009268077],"domain_scores_gemma":[0.99502915,0.000940339,0.0010464888,0.0018919455,0.00068072486,0.00041135828],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021922737,0.0006756877,0.0011664452,0.00071834953,0.00040063178,0.00019415242,0.0005965806,0.00038706503,0.00008012126],"category_scores_gemma":[0.004844394,0.0004610744,0.00007654058,0.0007405195,0.00030718674,0.00073798635,0.0004095255,0.001541061,0.000046616704],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48698086,0.05478023,0.41254455,0.00034460897,0.00066387805,0.0046884543,0.0130337225,0.00003715013,0.008389395,0.0000021898545,0.0016242412,0.016910715],"study_design_scores_gemma":[0.40847132,0.11766249,0.45654494,0.0033137249,0.00053334085,0.000023177521,0.002507272,0.0008895654,0.009085984,0.000009388124,0.00018532701,0.0007735069],"about_ca_topic_score_codex":0.0015764912,"about_ca_topic_score_gemma":0.0017764736,"teacher_disagreement_score":0.07850957,"about_ca_system_score_codex":0.0012712847,"about_ca_system_score_gemma":0.0025594837,"threshold_uncertainty_score":0.9997841},"labels":[],"label_agreement":null},{"id":"W2967499714","doi":"10.3324/haematol.2018.211201","title":"Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia","year":2019,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Deutsche Krebshilfe; Medizinischen Hochschule Hannover; Deutsche Forschungsgemeinschaft; European Commission","keywords":"Cancer research; Myeloid leukemia; Leukemia; Biology; Myeloid; MCL1; Haematopoiesis; Acute leukemia; Progenitor cell; Immunology; Stem cell; Cell biology; Gene; Genetics","score_opus":0.029336498116598806,"score_gpt":0.305588594474818,"score_spread":0.2762520963582192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967499714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9702727,0.00033856646,0.0004950888,0.0027600317,0.0003590861,0.003140875,0.000108291824,0.00041552258,0.022109818],"genre_scores_gemma":[0.9509726,0.00015671834,0.014099593,0.0024766435,0.00023669719,0.0004401211,0.00030249922,0.000114136084,0.031201003],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960894,0.00011291121,0.0007292909,0.0010521242,0.0007182624,0.0012980254],"domain_scores_gemma":[0.99723494,0.000460094,0.00026392797,0.001228568,0.00035277827,0.000459662],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000719345,0.00053519715,0.0014169142,0.0003407002,0.00025309453,0.000086438,0.00059951044,0.0006567211,0.0020331412],"category_scores_gemma":[0.00039022774,0.0004166349,0.0004981538,0.00063037605,0.00018458968,0.00020851284,0.00030305746,0.0007774876,0.003392227],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007391439,0.0003565307,0.021807969,0.001987496,0.0024124053,0.0028262436,0.0020451895,0.000034509583,0.23972821,0.005214127,0.7101458,0.0060500856],"study_design_scores_gemma":[0.025648788,0.00412762,0.012484459,0.00067119213,0.0010944902,0.005660423,0.0016001423,0.013538082,0.62893575,0.0012034538,0.30309713,0.001938441],"about_ca_topic_score_codex":0.00009365108,"about_ca_topic_score_gemma":0.000011463368,"teacher_disagreement_score":0.40704867,"about_ca_system_score_codex":0.0013700873,"about_ca_system_score_gemma":0.0011417494,"threshold_uncertainty_score":0.9998286},"labels":[],"label_agreement":null},{"id":"W2967523897","doi":"10.3389/fonc.2019.00824","title":"Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications","year":2019,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Montreal Clinical Research Institute","funders":"Canadian Institutes of Health Research; Deutsche Krebshilfe; Deutsche Forschungsgemeinschaft","keywords":"Epigenetics; Biology; Cancer research; Myeloid leukemia; DNA methylation; Enhancer; Genetics; Gene; Transcription factor; Gene expression","score_opus":0.03984894373226914,"score_gpt":0.35784628530841917,"score_spread":0.31799734157615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967523897","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009920738,0.9958486,0.0009468984,0.000115087365,0.00010116747,0.0016168611,0.000028815708,0.0000056555646,0.00034486013],"genre_scores_gemma":[0.002831561,0.98698395,0.009732596,0.000028708344,0.000024185341,0.0001768553,0.000056927736,0.00003618736,0.00012903602],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982718,0.00030881504,0.0006921289,0.00036233716,0.00012848007,0.00023640684],"domain_scores_gemma":[0.99893945,0.00019200306,0.00034084744,0.00039565456,0.000068249334,0.0000637781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055098644,0.00019543992,0.0018480577,0.0007566296,0.0000132396535,0.0000023567802,0.00014257389,0.0005889648,0.000012994688],"category_scores_gemma":[0.00006652852,0.00017038298,0.0000886868,0.00041930663,0.00018501135,0.000018517774,0.00009932978,0.0003208518,0.0000015253414],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049412425,0.00008030228,0.0022853685,0.004545133,0.00009933316,0.0000028245972,0.00017188102,0.0000015894515,0.000886927,0.0004962095,0.00008127413,0.99129975],"study_design_scores_gemma":[0.0060772877,0.003232043,0.1175623,0.009362293,0.0029728967,0.0003660423,0.00122454,0.0013458679,0.00026948217,0.02306494,0.83376545,0.00075687637],"about_ca_topic_score_codex":0.000044029952,"about_ca_topic_score_gemma":0.000027312033,"teacher_disagreement_score":0.9905429,"about_ca_system_score_codex":0.0005444508,"about_ca_system_score_gemma":0.00096085627,"threshold_uncertainty_score":0.69480157},"labels":[],"label_agreement":null},{"id":"W2968120913","doi":"10.1126/science.aax3649","title":"A dominant-negative effect drives selection of <i>TP53</i> missense mutations in myeloid malignancies","year":2019,"lang":"en","type":"article","venue":"Science","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":434,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Foundation Medicine; National Institute of General Medical Sciences; Instrumentariumin Tiedesäätiö; National Institutes of Health; Orionin Tutkimussäätiö; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Human Genome Research Institute; Henry and Marilyn Taub Foundation; Edward P. Evans Foundation; Howard Hughes Medical Institute; Celgene; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Leukemia and Lymphoma Society; AstraZeneca; Jane ja Aatos Erkon Säätiö; National Science Foundation","keywords":"Missense mutation; Biology; Genetics; Gene; Mutagenesis; Mutation; Tumor suppressor gene; Suppressor; Cancer research; Carcinogenesis","score_opus":0.00899976534460787,"score_gpt":0.2973290718442946,"score_spread":0.2883293064996867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968120913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99623334,0.000040352304,0.000054246768,0.00030647698,0.00008216766,0.000669417,0.0000029284784,0.000018085479,0.0025929643],"genre_scores_gemma":[0.9969511,0.000014916932,0.0016058505,0.000059755752,0.000018497109,0.000022724596,0.0000014208119,0.000007976766,0.0013177695],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99851644,0.00007147829,0.00019771978,0.00032811824,0.00053918763,0.00034707887],"domain_scores_gemma":[0.9990011,0.00035791023,0.00007295915,0.00021595582,0.00025466902,0.00009740968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009969217,0.000098764816,0.00024086425,0.00044109815,0.00007827243,0.00001734239,0.0001708393,0.000044199656,0.00007500622],"category_scores_gemma":[0.0011224744,0.00007730307,0.000043710595,0.002086072,0.0006938384,0.00025285172,0.0000644166,0.000194818,0.000109076806],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013293668,0.00003668967,0.05253333,0.00007425826,0.000004518382,0.000017039603,0.0012993539,0.000052202337,0.9444996,0.00011299501,0.00004194967,0.0011951426],"study_design_scores_gemma":[0.001295921,0.0005989682,0.18087317,0.00017232691,0.00001091932,0.00008586477,0.00054709957,0.0030076986,0.81313145,0.00010653557,0.00009003191,0.00008000237],"about_ca_topic_score_codex":0.00015007534,"about_ca_topic_score_gemma":0.000040230163,"teacher_disagreement_score":0.13136812,"about_ca_system_score_codex":0.00029598986,"about_ca_system_score_gemma":0.0008529489,"threshold_uncertainty_score":0.31523275},"labels":[],"label_agreement":null},{"id":"W2968198730","doi":"10.1111/ejh.13314","title":"Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment","year":2019,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cerebrospinal fluid; Internal medicine; Central nervous system; Myeloid leukemia; Cumulative incidence; Incidence (geometry); Pathological; Oncology; Leukemia; Gastroenterology; Transplantation","score_opus":0.01665544431114275,"score_gpt":0.29888103237909525,"score_spread":0.2822255880679525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968198730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977615,0.00022371135,0.00019685327,0.0001725919,0.0001492289,0.00041186388,0.0000433748,0.000006311918,0.0010345911],"genre_scores_gemma":[0.9992326,0.0001220165,0.0005241249,0.00004531991,0.00002291991,0.0000013355566,0.000005724884,0.000026184076,0.000019811476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997084,0.0006974888,0.0011452154,0.00021068146,0.0004706393,0.0003919415],"domain_scores_gemma":[0.99877584,0.00012830795,0.0004161288,0.00030483239,0.00015744232,0.00021745263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012207513,0.0002114271,0.0011386182,0.0003338545,0.00001273403,0.0000063517577,0.00020325801,0.000057783072,0.00012896852],"category_scores_gemma":[0.000027269482,0.00013893784,0.00025449178,0.000108908505,0.00013690839,0.00006708497,0.000045898734,0.00052882684,0.000006998161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041231383,0.00035407834,0.9767393,0.0016966669,0.0003997205,0.009628031,0.00074197614,0.00004474188,0.005774163,0.00014445603,0.0000787952,0.00027491536],"study_design_scores_gemma":[0.005064236,0.0037013604,0.9833625,0.0013647218,0.000110578265,0.004702036,0.00021365182,0.00046297337,0.0009017475,0.0000027491174,0.000018999972,0.00009444098],"about_ca_topic_score_codex":0.00006871425,"about_ca_topic_score_gemma":0.00000964007,"teacher_disagreement_score":0.006623189,"about_ca_system_score_codex":0.0002184606,"about_ca_system_score_gemma":0.0003348543,"threshold_uncertainty_score":0.56657207},"labels":[],"label_agreement":null},{"id":"W2968763813","doi":"10.1182/blood.v130.suppl_1.4276.4276","title":"Spliceosome Mutations Are Associated with Frailty in Older Patients with Myeloid Malignancies","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Medicine; Myeloid leukemia; Grip strength; Weight loss; Internal medicine; Gerontology; Oncology; Obesity; Physical therapy; Biology","score_opus":0.01945734949908235,"score_gpt":0.271853245221163,"score_spread":0.25239589572208065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968763813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559104,0.000030943866,0.000010376428,0.00076480437,0.000019353547,0.0006774755,0.00005753035,0.000054587243,0.002793872],"genre_scores_gemma":[0.99730337,0.0000049807,0.0003943738,0.00016889884,0.000045904115,0.000085601336,0.00012012288,0.00004223987,0.001834526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853706,0.00003479915,0.00017644209,0.0003120716,0.0005277191,0.00041192252],"domain_scores_gemma":[0.9986132,0.00006848762,0.00020478074,0.0006359256,0.0003284135,0.0001492115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001358495,0.00017420892,0.00030921167,0.00013852214,0.00025392027,0.00007203095,0.00022507246,0.00011106426,0.00007406567],"category_scores_gemma":[0.00050554227,0.00012225113,0.000032642387,0.00019206875,0.00020319753,0.00020817484,0.00007799978,0.00033681752,0.000045421093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011762209,0.0010048768,0.99752295,0.000036253612,0.00012812148,0.0002407467,0.00032554692,0.000003201546,0.00024294318,0.000024521567,0.00018640973,0.00016679874],"study_design_scores_gemma":[0.015492328,0.00035999538,0.981932,0.0004284908,0.00013337954,0.000010721881,0.0001660134,0.0000199441,0.0011630094,0.000016462767,0.00011295146,0.00016469331],"about_ca_topic_score_codex":0.0001706576,"about_ca_topic_score_gemma":0.00072952465,"teacher_disagreement_score":0.015590948,"about_ca_system_score_codex":0.00014773446,"about_ca_system_score_gemma":0.00028703033,"threshold_uncertainty_score":0.49852565},"labels":[],"label_agreement":null},{"id":"W2969571340","doi":"10.3390/jcm8081261","title":"Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Antibody; CD33; Antibody-dependent cell-mediated cytotoxicity; Myeloid leukemia; Immunology; Cancer research; Immunotherapy; Cytarabine; Stem cell; Monoclonal antibody; Immune system; CD34; Biology","score_opus":0.11635145066575327,"score_gpt":0.47760422407899367,"score_spread":0.3612527734132404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969571340","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013577323,0.9858685,0.00053782127,0.0035449497,0.003202195,0.004559901,0.00014186247,0.000071450995,0.0007155636],"genre_scores_gemma":[0.00021874039,0.987474,0.0018817659,0.0013815154,0.0059592896,0.00005850124,0.00047466645,0.00028115482,0.0022703472],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98677105,0.0009193134,0.008416973,0.0010142961,0.0016817359,0.0011966367],"domain_scores_gemma":[0.9824294,0.0078450255,0.005307342,0.0011793184,0.0016655271,0.0015733867],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.008463316,0.0013516438,0.013541311,0.001179013,0.00017965064,0.00007003892,0.00100389,0.002006161,0.00025455412],"category_scores_gemma":[0.0066577783,0.000780757,0.0025268802,0.00076908676,0.0012860066,0.00042022706,0.00029580103,0.0054615093,0.00008948732],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041931644,0.00031678705,0.00024092988,0.025600858,0.011849624,0.0012212782,0.00028638804,6.8992125e-7,0.00020936047,0.00006646893,0.018667843,0.93734664],"study_design_scores_gemma":[0.024317557,0.010277307,0.00020588329,0.045810997,0.016923625,0.007178877,0.00022859,0.0001778845,0.000017227092,0.0001249138,0.89407325,0.0006638613],"about_ca_topic_score_codex":0.000029056362,"about_ca_topic_score_gemma":0.0000027028586,"teacher_disagreement_score":0.93668276,"about_ca_system_score_codex":0.0009898471,"about_ca_system_score_gemma":0.005282061,"threshold_uncertainty_score":0.99992347},"labels":[],"label_agreement":null},{"id":"W2969766498","doi":"10.1038/s41375-019-0546-1","title":"Cryptic genomic lesions in adverse-risk acute myeloid leukemia identified by integrated whole genome and transcriptome sequencing","year":2019,"lang":"en","type":"letter","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Ontario Institute for Cancer Research","keywords":"Myeloid leukemia; Transcriptome; Genome; Biology; Myeloid; Genetics; Computational biology; Gene; Immunology; Gene expression","score_opus":0.01857236055710469,"score_gpt":0.26149952350665656,"score_spread":0.24292716294955188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969766498","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92843086,0.0030863537,0.0002982108,0.057909336,0.0008732256,0.004002992,0.0024617123,0.00045259733,0.0024847009],"genre_scores_gemma":[0.18614104,0.012058307,0.0038092574,0.52576536,0.005653659,0.0009873138,0.030308245,0.0021659583,0.23311089],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9917328,0.00058373006,0.0016863346,0.0023487185,0.0013576543,0.0022907984],"domain_scores_gemma":[0.99612194,0.0005356598,0.00058396044,0.0019761762,0.00029672333,0.00048556484],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0010321237,0.0015066598,0.002465176,0.0017334939,0.0002955318,0.00021229839,0.0011224188,0.003157821,0.00058233837],"category_scores_gemma":[0.0002685924,0.0014277492,0.0005635975,0.0012613246,0.00059511926,0.00046509693,0.00039519876,0.012580844,0.0019221321],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00035705746,0.000020707901,0.00077012356,0.0009292064,0.0008249988,0.004333862,0.0011010346,0.00010007675,0.35172078,0.0000035710184,0.63878936,0.0010492336],"study_design_scores_gemma":[0.012688762,0.00060899026,0.007861889,0.0015602409,0.0019823124,0.0011432145,0.0009516022,0.0043978365,0.0016695218,0.0001441935,0.9645398,0.0024516296],"about_ca_topic_score_codex":0.0048035863,"about_ca_topic_score_gemma":0.00012755074,"teacher_disagreement_score":0.74228984,"about_ca_system_score_codex":0.03096319,"about_ca_system_score_gemma":0.008452547,"threshold_uncertainty_score":0.99976826},"labels":[],"label_agreement":null},{"id":"W2969918675","doi":"10.1182/bloodadvances.2018024729","title":"Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis","year":2019,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Baycrest Hospital; University of Toronto; Health Sciences Centre; Queen's University","funders":"Ontario Institute for Cancer Research; Southeastern Ontario Academic Medical Organization; Canadian Cancer Society Research Institute; European Hematology Association","keywords":"Haematopoiesis; Inflammation; Immunology; Interleukin 6; Medicine; Biology; Bioinformatics; Stem cell; Genetics","score_opus":0.007020401147990897,"score_gpt":0.254749389596823,"score_spread":0.24772898844883207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969918675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953555,0.003241602,0.000010036535,0.00007089034,0.00004551389,0.00022638698,0.000020867881,0.000011897019,0.0010173105],"genre_scores_gemma":[0.9957915,0.0011901013,0.0025874048,0.00003402472,0.000051933705,0.0000052308487,0.0000072456696,0.000013595271,0.0003189535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991525,0.000021267291,0.0002872267,0.00014702327,0.0002476709,0.0001443111],"domain_scores_gemma":[0.99932516,0.00012087602,0.00014375226,0.00022038283,0.0001226389,0.00006718658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010242171,0.00009077562,0.0003585017,0.000081982726,0.000013509558,0.0000030629162,0.00008019058,0.000049430128,0.000111454545],"category_scores_gemma":[0.0000833091,0.00007589943,0.00003986304,0.000091197995,0.00017117946,0.000061320105,0.00006228135,0.00010021814,0.000013131118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015896354,0.000092587645,0.9126272,0.0013765985,0.00008411456,0.000024033525,0.00012269849,0.000001091208,0.081643395,0.00041965712,0.000026452048,0.0034231732],"study_design_scores_gemma":[0.0015178736,0.0003619702,0.8915738,0.00021413523,0.00009636635,0.00009441493,0.00013337198,0.000046873134,0.102980375,0.00012679193,0.0027598906,0.000094137344],"about_ca_topic_score_codex":0.000008360044,"about_ca_topic_score_gemma":0.0000021951682,"teacher_disagreement_score":0.02133698,"about_ca_system_score_codex":0.000010807203,"about_ca_system_score_gemma":0.00011779966,"threshold_uncertainty_score":0.30950886},"labels":[],"label_agreement":null},{"id":"W2969981815","doi":"10.25082/agpm.2019.01.005","title":"Current trends in targeted therapy of leukaemia and lymphoma","year":2019,"lang":"en","type":"article","venue":"Advances in General Practice of Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Regional Development Fund; Hrvatska Zaklada za Znanost; Terry Fox Foundation; European Commission","keywords":"Visualization; Computer science; Mass cytometry; Field (mathematics); Cell sorting; Computational biology; Flow cytometry; Nanotechnology; Chemistry; Data mining; Biology; Mathematics; Molecular biology; Materials science; Gene; Biochemistry","score_opus":0.018995162978677715,"score_gpt":0.37663505314341356,"score_spread":0.35763989016473585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969981815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8958752,0.09011079,0.000019262803,0.0045466847,0.0002555109,0.00033838174,0.0000029276578,0.00000941471,0.008841838],"genre_scores_gemma":[0.92162645,0.075241566,0.0022259613,0.00039753504,0.00016416663,0.000013502267,0.000027787175,0.00002036104,0.00028267803],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980776,0.00017295194,0.0006014734,0.00031709188,0.00055187504,0.00027904395],"domain_scores_gemma":[0.9985439,0.00054551876,0.00029642813,0.00035162613,0.00016411475,0.000098366174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010104612,0.00016910565,0.0006474178,0.0006143422,0.000009769263,0.0000017738582,0.00013891704,0.00008363843,0.00024700863],"category_scores_gemma":[0.0008949676,0.00012456928,0.000034707522,0.000847142,0.0003138541,0.00047952935,0.000057416215,0.00032994107,0.0000037074003],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00337869,0.00041197395,0.088290714,0.00025829163,0.000041296553,0.00006474425,0.0008345072,0.00010621442,0.04467292,0.00082542934,0.00068177853,0.86043346],"study_design_scores_gemma":[0.07672322,0.0072131134,0.38988128,0.0023173909,0.000107480926,0.0003751041,0.0029738625,0.0054230858,0.02847102,0.00089903164,0.48506072,0.0005546918],"about_ca_topic_score_codex":0.00038270256,"about_ca_topic_score_gemma":0.000031928175,"teacher_disagreement_score":0.8598787,"about_ca_system_score_codex":0.0001710298,"about_ca_system_score_gemma":0.0001517818,"threshold_uncertainty_score":0.5079788},"labels":[],"label_agreement":null},{"id":"W2969991859","doi":"10.1016/j.exphem.2019.06.405","title":"INTEGRATIVE EPIGENOMIC ANALYSIS TO IDENTIFY POTENTIAL BIOMARKERS IN KMT2A TRANSLOCATED ACUTE MYELOID LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Epigenomics; Myeloid leukemia; Biology; Computational biology; Myeloid; Leukemia; Cancer research; DNA methylation; Genetics; Gene","score_opus":0.012132535892798727,"score_gpt":0.3434443823308263,"score_spread":0.3313118464380276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969991859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282205,0.0016301268,0.0008106826,0.0008549977,0.00030559103,0.0014063612,0.000024061828,0.00008881006,0.0020573256],"genre_scores_gemma":[0.9964831,0.00004550712,0.0014768746,0.0005014004,0.000034690085,0.00016022433,0.00021510062,0.000055706216,0.0010274212],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970479,0.00020368605,0.0006748887,0.00088331563,0.00038602005,0.00080419995],"domain_scores_gemma":[0.9987623,0.000076795404,0.0000963112,0.0006177094,0.00008445889,0.00036242759],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028762044,0.00039048743,0.0011750757,0.0014925413,0.00006501838,0.00002978722,0.0003754578,0.00030850098,0.0026407104],"category_scores_gemma":[0.000025546555,0.00034844154,0.00037871947,0.0019455269,0.00018974517,0.00014540312,0.00018265005,0.0004854001,0.001719185],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032593862,0.0003480026,0.017207593,0.000043482018,0.005474505,0.0013817094,0.0038269009,0.00009748584,0.9651066,0.0011547535,0.0016554795,0.00044409293],"study_design_scores_gemma":[0.005111011,0.00072728575,0.018006736,0.00006070712,0.00047585522,0.0006070045,0.0051381807,0.0034890105,0.9655899,0.000029542207,0.00032659742,0.00043821728],"about_ca_topic_score_codex":0.0009420145,"about_ca_topic_score_gemma":0.00012008199,"teacher_disagreement_score":0.00499865,"about_ca_system_score_codex":0.0020658986,"about_ca_system_score_gemma":0.00042208057,"threshold_uncertainty_score":0.99989676},"labels":[],"label_agreement":null},{"id":"W2971699541","doi":"10.1242/dev.148296","title":"RUNX transcription factors: orchestrators of development","year":2019,"lang":"en","type":"review","venue":"Development","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council; Horizon 2020 Framework Programme; Medical Research Council Canada; Cancer Research UK","keywords":"Biology; RUNX1; Transcription factor; Embryonic stem cell; Carcinogenesis; Developmental biology; Cell biology; RUNX2; Stem cell; Genetics; Gene; Computational biology","score_opus":0.15029203188878318,"score_gpt":0.37460415535394836,"score_spread":0.2243121234651652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971699541","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001941111,0.99305356,0.0001590248,0.000016229216,0.00032975787,0.0025220932,0.000018110528,0.00008657507,0.0018735141],"genre_scores_gemma":[0.00016988468,0.98313445,0.01027219,0.000025937172,0.00008063227,0.00021674814,0.0012352387,0.00013615222,0.004728761],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99589604,0.00011513523,0.0016307222,0.00068851974,0.0010305037,0.00063905213],"domain_scores_gemma":[0.99832046,0.0001359486,0.000430377,0.0005897705,0.0002110006,0.00031245354],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006323023,0.0007153185,0.0027392425,0.0007208142,0.000077271725,0.00002278507,0.00040614145,0.00062482915,0.000353498],"category_scores_gemma":[0.00007678047,0.00052970485,0.00043378823,0.0006291936,0.00008042389,0.00007230363,0.00012758787,0.0008215199,0.00070194557],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022166285,0.00015697349,0.00012789022,0.052248824,0.00085477374,0.000031382835,0.0013363857,9.727659e-8,0.000025487041,0.00003312038,0.0008430169,0.9443199],"study_design_scores_gemma":[0.0005440313,0.000071057584,0.00074115343,0.015049825,0.0004197985,0.0000418328,0.00009390846,4.6959835e-7,0.0010035051,0.0000010422546,0.98156315,0.00047020504],"about_ca_topic_score_codex":0.000009636545,"about_ca_topic_score_gemma":0.000003756499,"teacher_disagreement_score":0.98072016,"about_ca_system_score_codex":0.0023658013,"about_ca_system_score_gemma":0.014853951,"threshold_uncertainty_score":0.99971545},"labels":[],"label_agreement":null},{"id":"W2972659374","doi":"10.1158/0008-5472.can-19-0274","title":"Diminished AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University","funders":"Canadian Institutes of Health Research; Government of Canada; Ontario Institute for Cancer Research; Canadian Blood Services","keywords":"Aryl hydrocarbon receptor; Haematopoiesis; Stem cell; Myeloid leukemia; Cancer research; Signal transduction; Progenitor cell; Cell biology; Leukemia; Downregulation and upregulation; Myeloid; Biology; Immunology; Gene; Transcription factor; Biochemistry","score_opus":0.0498136568298746,"score_gpt":0.37421210590182136,"score_spread":0.32439844907194676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972659374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9658015,0.0009422332,0.000043916683,0.0018073496,0.00024238192,0.00186549,0.000042866275,0.00015487234,0.029099392],"genre_scores_gemma":[0.8710502,0.00081350416,0.00027320042,0.00037424432,0.0005740371,0.00036056832,0.000042143867,0.0001454467,0.12636667],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.993687,0.00038685845,0.0005543798,0.0011631213,0.0021758997,0.002032781],"domain_scores_gemma":[0.99629635,0.00042868988,0.00011511266,0.0013896504,0.0010488424,0.0007213625],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0019532978,0.00037955458,0.00074004236,0.00065135874,0.00044574283,0.00016813337,0.00097484747,0.00031931367,0.0028712112],"category_scores_gemma":[0.00006324339,0.00032299198,0.00022862859,0.0012865297,0.0005753079,0.00027807237,0.0006561193,0.002605448,0.0021390684],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074194936,0.00008483622,0.008056661,0.00057302497,0.00021546867,0.00044560654,0.0013061131,0.000052589305,0.94825757,0.0004777066,0.035617072,0.0041714106],"study_design_scores_gemma":[0.009586651,0.0018324014,0.011757542,0.0012320579,0.00012737133,0.000101672435,0.004557625,0.0009162248,0.91090876,0.00035511158,0.05774718,0.0008774275],"about_ca_topic_score_codex":0.00081144733,"about_ca_topic_score_gemma":0.00003396945,"teacher_disagreement_score":0.097267285,"about_ca_system_score_codex":0.0042250124,"about_ca_system_score_gemma":0.003077532,"threshold_uncertainty_score":0.9999222},"labels":[],"label_agreement":null},{"id":"W2972816620","doi":"10.1182/blood.v130.suppl_1.3859.3859","title":"Outcomes Based on CNS Disease Status in Pediatric Acute Myeloid Leukemia and the Role of Peripheral Blood Contamination in Diagnostic Lumbar Punctures; A Report from the Children's Oncology Group Studies AAML0531 and AAML1031","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Oncology; Myeloid leukemia; Leukemia; Cog","score_opus":0.00980078755354569,"score_gpt":0.2887167770377611,"score_spread":0.2789159894842154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972816620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881457,0.0065973685,0.0000029184964,0.003272084,0.000068921785,0.0015861361,0.000094252915,0.000018214885,0.00021437925],"genre_scores_gemma":[0.99302596,0.0057662837,0.00011518139,0.0004801367,0.0001903101,0.0002548557,0.000084057974,0.000030441914,0.00005276042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976081,0.00037645455,0.00056595495,0.00051879743,0.00049491716,0.00043574924],"domain_scores_gemma":[0.99555176,0.0029014626,0.00038537922,0.00087641214,0.00010733476,0.00017762888],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0010220223,0.00029408882,0.0007767287,0.00016586654,0.00024566933,0.000058214842,0.00028246507,0.00014456392,0.00000937639],"category_scores_gemma":[0.008906112,0.00016239275,0.00009782974,0.00014319325,0.0006931733,0.00011684347,0.00028216347,0.00061018387,0.0000011001528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007276194,0.00051287614,0.9932778,0.000041298157,0.00036732518,0.0009985513,0.0012891092,0.000007657903,0.00012277969,0.00008284642,0.00006166166,0.0025105067],"study_design_scores_gemma":[0.027415693,0.00039525304,0.96912086,0.00008241995,0.001469035,0.000051417315,0.0004282688,0.00035374513,0.00010101231,0.000365282,0.0000657342,0.00015128149],"about_ca_topic_score_codex":0.0023933083,"about_ca_topic_score_gemma":0.0018682621,"teacher_disagreement_score":0.026688073,"about_ca_system_score_codex":0.00026260744,"about_ca_system_score_gemma":0.00065231684,"threshold_uncertainty_score":0.9994423},"labels":[],"label_agreement":null},{"id":"W2973474652","doi":"10.1182/blood-2018-99-116576","title":"Validation and Clinical Impact of the Oncomine Myeloid Targeted DNA and RNA Ion Semiconductor Sequencing Assay","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Ion semiconductor sequencing; DNA sequencing; Computational biology; Biology; Medicine; Bioinformatics; Gene; Genetics","score_opus":0.04038048989938673,"score_gpt":0.352317190312023,"score_spread":0.31193670041263627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973474652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983635,0.00014686395,0.00001145866,0.00036710795,0.00009381982,0.00033665908,0.000015361407,0.000021683973,0.00064355246],"genre_scores_gemma":[0.99852985,0.000096957476,0.0004860112,0.00008542098,0.00053703145,0.0000029472546,0.000012737859,0.000018738643,0.0002303019],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998786,0.00020232316,0.00032646226,0.00023770555,0.00024301626,0.00020452424],"domain_scores_gemma":[0.99895686,0.00024692185,0.00013214811,0.00032628464,0.00018853451,0.00014924457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010375485,0.000116904106,0.00027873667,0.00006857474,0.00007362322,0.000015616157,0.00009045151,0.00013984491,0.000069621645],"category_scores_gemma":[0.0011626518,0.000071035276,0.00008834236,0.00018972415,0.00033746898,0.00008659199,0.00012252959,0.00029602688,0.0000065007366],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009746018,0.00011640107,0.11316153,0.000032484193,0.00016376104,0.000004413297,0.00023799257,9.424403e-8,0.88394237,0.000008658901,0.0005918285,0.0016430048],"study_design_scores_gemma":[0.0054780566,0.0013660627,0.24621344,0.00011539649,0.00024861225,0.00015728499,0.00008282332,0.00042400186,0.745661,0.00007157153,0.000083422296,0.000098287936],"about_ca_topic_score_codex":0.00018821527,"about_ca_topic_score_gemma":0.000010116871,"teacher_disagreement_score":0.13828133,"about_ca_system_score_codex":0.00012861087,"about_ca_system_score_gemma":0.00045286855,"threshold_uncertainty_score":0.28967345},"labels":[],"label_agreement":null},{"id":"W2974725190","doi":"10.1200/po.19.00119","title":"Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; European Hematology Association","keywords":"Decitabine; Medicine; Cohort; Confidence interval; Myelodysplastic syndromes; Internal medicine; Oncology; Azacitidine; Hypomethylating agent; Bioinformatics; Gene; Genetics; Biology; DNA methylation","score_opus":0.052698284647689414,"score_gpt":0.3537519948482408,"score_spread":0.3010537102005514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974725190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99041164,0.000027502834,0.00475346,0.00065415906,0.00040726076,0.0024709608,0.00001798761,0.000042232154,0.0012148123],"genre_scores_gemma":[0.96173674,0.0000056214376,0.037170384,0.00048205716,0.00006935855,0.0000521096,0.000016879148,0.000056041376,0.00041082798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968007,0.00024015842,0.0007288136,0.0007993999,0.0007165812,0.00071432826],"domain_scores_gemma":[0.9976943,0.0008887697,0.00015504459,0.0005745063,0.0002565724,0.0004308122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009403641,0.00026102035,0.00065074867,0.0010210654,0.00007968569,0.000031456024,0.0003503603,0.00023197508,0.00035675266],"category_scores_gemma":[0.0014050738,0.00021962941,0.000056834593,0.0013586378,0.0000741963,0.000117715164,0.000379515,0.00043122418,0.0007409066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030755483,0.0011157651,0.7086263,0.00022875913,0.00028626097,0.0004718734,0.0018831176,0.009985133,0.032252636,0.00013627173,0.0020861372,0.21217227],"study_design_scores_gemma":[0.0029328675,0.0068767816,0.97177804,0.0010249509,0.00007200577,0.000038279602,0.0004584761,0.00788241,0.002223133,0.00031345797,0.005871825,0.00052779296],"about_ca_topic_score_codex":0.00006897689,"about_ca_topic_score_gemma":0.00014966633,"teacher_disagreement_score":0.26315174,"about_ca_system_score_codex":0.0027602601,"about_ca_system_score_gemma":0.0007038814,"threshold_uncertainty_score":0.9523102},"labels":[],"label_agreement":null},{"id":"W2975748077","doi":"10.1007/s41669-019-00180-z","title":"Economic Evaluation of Azacitidine in Elderly Patients with Acute Myeloid Leukemia with High Blast Counts","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Azacitidine; Medicine; Myeloid leukemia; Cost effectiveness; Internal medicine; Oncology; Cytarabine; Population; Hypomethylating agent; Environmental health; DNA methylation","score_opus":0.02051727135984825,"score_gpt":0.3295631370827624,"score_spread":0.30904586572291415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975748077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971776,0.000018240245,0.0000068140926,0.00022535006,0.00012500383,0.0023032597,0.000118891585,0.000011483922,0.025414972],"genre_scores_gemma":[0.99759,0.000067179746,0.00047880202,0.00028516797,0.00005832765,0.00009900809,0.0002529582,0.000053630414,0.0011149159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986708,0.000059191778,0.00035276177,0.00039326333,0.00023801079,0.00028596626],"domain_scores_gemma":[0.999078,0.000052980045,0.00019832837,0.00036708772,0.00018220914,0.000121445475],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006567334,0.00018898697,0.00045257583,0.00018589936,0.000023859042,0.000046715748,0.0003695638,0.00006410479,0.0037359716],"category_scores_gemma":[0.0000071756344,0.00015862522,0.000030722407,0.00009890501,0.000064568085,0.00044115834,0.00014580559,0.00025418794,0.0010115852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023697393,0.00075585116,0.8302199,0.00043249928,0.003561429,0.00006419597,0.0008753948,0.025689118,0.007804716,0.0012578989,0.027239561,0.078402035],"study_design_scores_gemma":[0.198482,0.006128869,0.57910633,0.0007502914,0.0020880722,0.000116638024,0.00035790552,0.12123547,0.05453187,0.0005135732,0.034601886,0.0020870944],"about_ca_topic_score_codex":0.0006240565,"about_ca_topic_score_gemma":0.00014332391,"teacher_disagreement_score":0.25111356,"about_ca_system_score_codex":0.0021640551,"about_ca_system_score_gemma":0.0019375357,"threshold_uncertainty_score":0.99976623},"labels":[],"label_agreement":null},{"id":"W2976049443","doi":"","title":"Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines.","year":2017,"lang":"en","type":"review","venue":"PubMed","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Ottawa; McMaster University; Princess Margaret Cancer Centre; University of Manitoba; University of Saskatchewan; Université de Montréal; University of Alberta","funders":"","keywords":"Medicine; Gemtuzumab ozogamicin; Internal medicine; Cytarabine; Induction chemotherapy; Acute promyelocytic leukemia; Oncology; Idarubicin; Myeloid leukemia; Azacitidine; Hematopoietic stem cell transplantation; Leukemia; Decitabine; Chemotherapy; Transplantation; Stem cell","score_opus":0.10534717456217974,"score_gpt":0.3570185955992668,"score_spread":0.25167142103708706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976049443","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002943585,0.97723496,0.0000014787903,0.0005445371,0.00027529465,0.012735078,0.0010690369,0.000059003258,0.0077862535],"genre_scores_gemma":[0.00013054902,0.97724724,0.00037177576,0.0001250533,0.00042814348,0.0047130142,0.0015414776,0.0002155348,0.015227191],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99524677,0.00017167484,0.0013752057,0.00093083846,0.0008650928,0.0014104269],"domain_scores_gemma":[0.9938445,0.0001757585,0.0010140194,0.00229076,0.0011415416,0.0015333868],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000402546,0.0009292273,0.004107065,0.00083391665,0.00019337333,0.0000657436,0.0006024154,0.00065960776,0.00009064843],"category_scores_gemma":[0.0006577529,0.00058884174,0.00071584375,0.00039369508,0.00038664005,0.00005730106,0.00009102063,0.000514068,0.00009468995],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00013631495,0.00008596825,0.0004920074,0.0045404807,0.002247114,0.0008012097,0.000020290438,1.2664309e-7,2.2220144e-8,0.0000052175196,0.015436936,0.9762343],"study_design_scores_gemma":[0.0052327737,0.00027505652,0.0063931365,0.0039530913,0.0049246335,0.00025895625,0.000004054607,0.0000023364141,0.0000022004979,9.741899e-7,0.97846,0.0004927652],"about_ca_topic_score_codex":0.032993346,"about_ca_topic_score_gemma":0.0049439296,"teacher_disagreement_score":0.97574157,"about_ca_system_score_codex":0.009189671,"about_ca_system_score_gemma":0.012901035,"threshold_uncertainty_score":0.9996563},"labels":[],"label_agreement":null},{"id":"W2978042162","doi":"10.14740/jh531","title":"Changes in <i>IDH2</i>, <i>TET2</i> and <i>KDM2B</i> Gene Expression After Treatment With Classic Chemotherapeutic Agents and Decitabine in Myelogenous Leukemia Cell Lines","year":2019,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Decitabine; Cancer research; Leukemia; Medicine; Epigenetics; Gene expression; Myeloid leukemia; Azacitidine; Pharmacology; Gene; DNA methylation; Biology; Immunology; Genetics","score_opus":0.01375506307669139,"score_gpt":0.26502445862601265,"score_spread":0.25126939554932126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978042162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99041283,0.006738693,0.000017279011,0.0021112494,0.00007082078,0.00047845527,0.0000026716502,0.000006600395,0.00016139659],"genre_scores_gemma":[0.9916045,0.0053693047,0.0016706885,0.00091409846,0.000073694464,0.000024204595,0.000002907833,0.000039949315,0.0003006743],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844587,0.00010513679,0.00047208814,0.0002950699,0.00025762184,0.00042422302],"domain_scores_gemma":[0.99908984,0.00016739397,0.00023335128,0.00022888873,0.00009189707,0.00018860269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025300897,0.00025609744,0.0008883076,0.00045382485,0.000021769754,0.000014980827,0.00008754573,0.00020489912,0.00006844686],"category_scores_gemma":[0.0000130344915,0.00016543437,0.000046241774,0.0002138368,0.000121307305,0.000097592085,0.00006335975,0.00039955578,0.000007986451],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051081902,0.0005322339,0.7071502,0.00041103983,0.00009428128,0.0036115327,0.0016015099,0.00000953378,0.27641407,0.0000031688382,0.00020004145,0.0048642214],"study_design_scores_gemma":[0.054612868,0.012827907,0.12805414,0.0017514552,0.0002781885,0.03236335,0.001611742,0.000728848,0.7611242,0.00015023556,0.005837019,0.000660046],"about_ca_topic_score_codex":0.000034196648,"about_ca_topic_score_gemma":0.00019614284,"teacher_disagreement_score":0.579096,"about_ca_system_score_codex":0.00044566288,"about_ca_system_score_gemma":0.0003403161,"threshold_uncertainty_score":0.67462176},"labels":[],"label_agreement":null},{"id":"W2978185859","doi":"10.14740/jh390","title":"Quantitative Assay of Mutated Nucleophosmin in Acute Myeloid Leukemia","year":2019,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Nucleophosmin; Myeloid leukemia; Minimal residual disease; Flow cytometry; Biomarker; Leukemia; Myeloid; Cancer research; Medicine; Computational biology; Biology; Immunology; Genetics","score_opus":0.018260768847751168,"score_gpt":0.3246313844342997,"score_spread":0.3063706155865485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978185859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942036,0.00065560563,0.00014547119,0.0020436347,0.00024317067,0.00026154667,0.000004393012,0.000007665156,0.0024349026],"genre_scores_gemma":[0.99337745,0.00026696606,0.0055475743,0.00021106357,0.000026124653,0.000002076393,0.000003831158,0.000027998749,0.0005369327],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99782103,0.00022519991,0.0009935207,0.00017201934,0.0004296311,0.00035858073],"domain_scores_gemma":[0.99788684,0.0005913485,0.0006235882,0.00025616543,0.00049406546,0.00014800618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010555116,0.00015647308,0.001130027,0.00073512585,0.0000139436315,0.0000053249414,0.00024946732,0.00021774358,0.00053332426],"category_scores_gemma":[0.0005676439,0.0001211132,0.00018525025,0.00050216273,0.00015777242,0.00014373222,0.00007363165,0.000878155,0.00016505581],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013276299,0.0007536014,0.31226048,0.001069848,0.0019572387,0.012912652,0.0033237298,0.00015727706,0.6207615,0.013046702,0.017732214,0.0027484575],"study_design_scores_gemma":[0.057525855,0.020476826,0.2626252,0.0032059625,0.0010047195,0.08375438,0.010148142,0.012696828,0.53469396,0.0069740084,0.005791697,0.0011024337],"about_ca_topic_score_codex":0.00005307297,"about_ca_topic_score_gemma":0.0000108961995,"teacher_disagreement_score":0.086067535,"about_ca_system_score_codex":0.00050276367,"about_ca_system_score_gemma":0.0011721489,"threshold_uncertainty_score":0.58395267},"labels":[],"label_agreement":null},{"id":"W2978658748","doi":"10.1101/790287","title":"Epigenetic regulation of protein translation in <i>KMT2A</i> -rearranged AML","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Smiths Detection (Canada)","funders":"University of Colorado Denver; Children's Hospital Colorado; National Heart, Lung, and Blood Institute; University of Pennsylvania; Children's Hospital of Philadelphia","keywords":"EZH2; PRC2; Histone methyltransferase; Methyltransferase; Histone H3; Biology; Cancer research; Epigenetics; Histone; Methylation; Genetics; Gene","score_opus":0.02225839745949342,"score_gpt":0.2529679201108704,"score_spread":0.23070952265137695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978658748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910083,0.0016967246,0.0019060501,0.00064830284,0.00025450747,0.0041581276,0.000094316434,0.00015348548,0.000080182675],"genre_scores_gemma":[0.99137485,0.00018264574,0.0076475283,0.00006286376,0.0002375648,0.00030540588,0.0000023515508,0.00015624493,0.000030515432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965436,0.00026846203,0.0009003476,0.00092426356,0.00080022635,0.0005631001],"domain_scores_gemma":[0.99712354,0.00009527488,0.000439357,0.0015432704,0.000584747,0.0002138053],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001095799,0.00046912805,0.00094413717,0.0007552838,0.000040769966,0.000042885553,0.00032476892,0.0008498588,0.00009499364],"category_scores_gemma":[0.00030859906,0.0005022825,0.00019976698,0.0008665843,0.00014437448,0.00011740296,0.00017283317,0.00123616,0.00008421159],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032855527,0.00018062994,0.01176146,0.001993322,0.00009751785,0.000027671658,0.00003347919,0.00028188594,0.9851248,0.00008084176,0.000064999855,0.000024814179],"study_design_scores_gemma":[0.002457136,0.00015535693,0.33464628,0.0018082394,0.000109003726,2.3454062e-8,0.000003525974,0.0032304928,0.6561725,0.000004635235,0.0009784475,0.000434361],"about_ca_topic_score_codex":0.00020120126,"about_ca_topic_score_gemma":0.000009944229,"teacher_disagreement_score":0.3289523,"about_ca_system_score_codex":0.0007470515,"about_ca_system_score_gemma":0.0017559114,"threshold_uncertainty_score":0.99974287},"labels":[],"label_agreement":null},{"id":"W2979363781","doi":"10.1182/blood.v124.21.3870.3870","title":"Propensity Score Matching Analysis Comparing Reduced Intensity Versus Myeloablative Conditioning in AML/MDS Patients Transplanted with Fludarabine-Busulfan-Low Dose Total Body Irradiation Based Regimen","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Busulfan; Fludarabine; Medicine; Total body irradiation; Internal medicine; Propensity score matching; Regimen; Transplantation; Hematopoietic stem cell transplantation; Oncology; Surgery; Chemotherapy; Cyclophosphamide","score_opus":0.024134020601869876,"score_gpt":0.2589182373673408,"score_spread":0.23478421676547095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979363781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99689925,0.0000069939183,0.00093869824,0.00017191702,0.00005849985,0.00090820476,0.000024566636,0.00010422874,0.0008876291],"genre_scores_gemma":[0.9974611,0.0000028393079,0.000898966,0.00008390901,0.000074287214,0.00004198952,0.0013691961,0.000037632544,0.000030121424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975691,0.00025133917,0.0004442851,0.00060234225,0.0006374446,0.000495497],"domain_scores_gemma":[0.99843585,0.00023439764,0.00021658912,0.00045085678,0.0004373822,0.0002249464],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055575726,0.00029616736,0.00080840656,0.000630904,0.00022443103,0.00005846709,0.00014342132,0.00013892881,0.000030733896],"category_scores_gemma":[0.0003067311,0.0002570074,0.00012450237,0.0012939827,0.00012437023,0.00026795152,0.00004816808,0.00065125444,0.000013773817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014227643,0.0012186444,0.9525563,0.00022192347,0.0016989113,0.00016848008,0.0020488235,0.004336791,0.023068959,0.000029769082,0.000031840482,0.00039188482],"study_design_scores_gemma":[0.024166266,0.0007581367,0.9246591,0.0005487833,0.0012873958,0.00001416173,0.00013903537,0.036811236,0.011333134,0.000006135153,0.0000015201757,0.00027511144],"about_ca_topic_score_codex":0.0007570231,"about_ca_topic_score_gemma":0.00030446032,"teacher_disagreement_score":0.032474443,"about_ca_system_score_codex":0.00041280972,"about_ca_system_score_gemma":0.00025240978,"threshold_uncertainty_score":0.9999882},"labels":[],"label_agreement":null},{"id":"W2979416306","doi":"10.1182/blood.v128.22.2372.2372","title":"Burden of Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation on Health Care Resource Utilization in the Management of Acute Leukemia and Myelodysplastic Syndrome","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Transplantation; Medical record; Internal medicine; Disease; Myelodysplastic syndromes; Health care; Oncology; Intensive care medicine; Bone marrow","score_opus":0.016759242856853266,"score_gpt":0.27389275208317326,"score_spread":0.25713350922632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979416306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970225,0.0007947808,0.00019794775,0.00044350387,0.000021953174,0.00075557805,0.000024210727,0.000014495872,0.00072503317],"genre_scores_gemma":[0.9983768,0.001066152,0.00024183826,0.00005747494,0.000012481782,0.00002948141,0.000029774963,0.00002157631,0.00016445383],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9985634,0.00014174225,0.00036740364,0.00024609437,0.00045359772,0.00022776103],"domain_scores_gemma":[0.9993072,0.00016155746,0.00011813321,0.00030977026,0.00003976716,0.00006353443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036276592,0.00012816556,0.00029421935,0.00017844977,0.00004183713,0.000004943817,0.00013590282,0.00007161621,0.0000043627633],"category_scores_gemma":[0.000006243292,0.00007971262,0.000060924383,0.00026812422,0.00004972975,0.000039543575,0.000028346016,0.00011451099,0.000003725957],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01327895,0.004441934,0.08467905,0.110058054,0.00924321,0.020597817,0.38331234,0.0010918226,0.21732944,0.008091556,0.0017557921,0.14612003],"study_design_scores_gemma":[0.13349406,0.017569596,0.46707997,0.03830958,0.010600624,0.0030872654,0.07892001,0.0003289751,0.24687575,0.0003034588,0.0017556428,0.0016750762],"about_ca_topic_score_codex":0.000037774953,"about_ca_topic_score_gemma":0.0000057618777,"teacher_disagreement_score":0.3824009,"about_ca_system_score_codex":0.00017906401,"about_ca_system_score_gemma":0.00013531814,"threshold_uncertainty_score":0.3250586},"labels":[],"label_agreement":null},{"id":"W2979429674","doi":"10.1182/blood.v120.21.4143.4143","title":"Association Between Busulfan First-Dose Pharmacokinetics and Outcome in Children Receiving Myeloablative Busulfan-Based Conditioning Before Unrelated Umbilical Cord Blood Transplantation for Malignancies","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Busulfan; Medicine; Transplantation; Internal medicine; Gastroenterology; Acute leukemia; Pharmacokinetics; Cyclophosphamide; Surgery; Hepatic veno-occlusive disease; Leukemia; Mucositis; Graft-versus-host disease; Dosing; Toxicity; Oncology; Hematopoietic stem cell transplantation; Chemotherapy","score_opus":0.021829648741822527,"score_gpt":0.30771313624655705,"score_spread":0.2858834875047345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979429674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960771,0.0001936604,0.00048735444,0.0010395739,0.00005542545,0.0015909415,0.0003552188,0.00010044274,0.000100279016],"genre_scores_gemma":[0.99567896,0.00008360631,0.002087312,0.00016758611,0.00034117626,0.0001552822,0.0012606819,0.000057263205,0.00016811342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977995,0.00013296257,0.0005865851,0.0003564546,0.00043803846,0.0006864366],"domain_scores_gemma":[0.998288,0.0008533255,0.00023668849,0.00016820156,0.00020692513,0.00024689405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009536202,0.00026136645,0.0004871026,0.00028733438,0.00019860739,0.00003952746,0.00010200054,0.0003102706,0.000047767207],"category_scores_gemma":[0.0007420677,0.00025960457,0.00009769756,0.00044524108,0.0000820881,0.0002450386,0.000026508147,0.00052072137,0.000008129611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021460852,0.00035546086,0.99346936,0.00021136811,0.0005001935,0.000009060981,0.00095659227,0.000020390133,0.0029390017,0.00003152048,0.000052941872,0.0012394986],"study_design_scores_gemma":[0.015737072,0.00048826763,0.96380717,0.00021832349,0.0018948208,0.000053537435,0.00006487982,0.0003995727,0.017001126,0.000047998623,0.000050114853,0.00023712433],"about_ca_topic_score_codex":0.00011512877,"about_ca_topic_score_gemma":0.000043130483,"teacher_disagreement_score":0.0296622,"about_ca_system_score_codex":0.00028054893,"about_ca_system_score_gemma":0.00012169294,"threshold_uncertainty_score":0.99998564},"labels":[],"label_agreement":null},{"id":"W2979436156","doi":"10.1182/blood.v116.21.2730.2730","title":"A Prognostic Score of Overall Survival In Adults with Acute Myeloid Leukemia","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Internal medicine; Proportional hazards model; Hazard ratio; Concordance; Oncology; Myeloid leukemia; Performance status; Cytogenetics; Malignancy; Chemotherapy; Gastroenterology; Confidence interval; Biology","score_opus":0.01123630471411018,"score_gpt":0.25703478816529385,"score_spread":0.24579848345118366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979436156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938737,0.000052174335,0.000011703509,0.00027204293,0.00006762636,0.0008560333,0.000020316276,0.000052674313,0.004793685],"genre_scores_gemma":[0.9966164,0.00004901563,0.002450181,0.00007330933,0.00015981932,0.000063828724,0.000042605483,0.000046625923,0.00049819687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982864,0.000038421425,0.00030311354,0.00035953315,0.0005524242,0.00046008933],"domain_scores_gemma":[0.99885756,0.00013483205,0.00008938847,0.0005179952,0.00019662596,0.00020359294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027313206,0.00019629179,0.000446517,0.00021857559,0.000026952343,0.000011818124,0.0002182317,0.00017130238,0.00011207299],"category_scores_gemma":[0.00028335472,0.00014711912,0.000063894906,0.00040437173,0.00018550725,0.00009170474,0.00009598368,0.0008767848,0.000035603614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002440982,0.00091855245,0.8824635,0.00048636703,0.00033807772,0.0018966577,0.0007636697,0.000002717022,0.1083658,0.00057579996,0.0002355188,0.0015123737],"study_design_scores_gemma":[0.028323237,0.0018067227,0.9247769,0.00087604974,0.00035988176,0.00085844775,0.00013126734,0.00029037855,0.041834414,0.000095038464,0.0003308049,0.00031683792],"about_ca_topic_score_codex":0.00050762546,"about_ca_topic_score_gemma":0.00078241416,"teacher_disagreement_score":0.06653138,"about_ca_system_score_codex":0.0000915949,"about_ca_system_score_gemma":0.0012426552,"threshold_uncertainty_score":0.59993434},"labels":[],"label_agreement":null},{"id":"W2979495882","doi":"10.1182/blood.v114.22.1576.1576","title":"CD34, CD56 and CD2 Are Predictive of NPM1 Mutation, FLT3-ITD and Their Favorable Prognosis Combination in Cytogenetically Normal Acute Myeloid Leukemia.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"","keywords":"NPM1; CD33; Myeloid leukemia; Biology; Fms-Like Tyrosine Kinase 3; CD117; Cancer research; Myeloid; Mutation; Internal medicine; CD34; Immunology; Molecular biology; Medicine; Genetics; Stem cell; Gene; Karyotype","score_opus":0.009980209771996745,"score_gpt":0.25058723007311895,"score_spread":0.24060702030112222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979495882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953543,0.00075266,0.00029877786,0.0012496078,0.00001618492,0.0009827975,0.00004923097,0.00004519936,0.0012512596],"genre_scores_gemma":[0.9976524,0.0003936844,0.001444707,0.0001877006,0.000049401853,0.000056639597,0.000058028698,0.000022408956,0.00013499033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842995,0.000091629816,0.00039262546,0.00038267602,0.00034495426,0.00035814164],"domain_scores_gemma":[0.9990161,0.00012422091,0.00013235607,0.00022146135,0.00032141333,0.00018445808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036554073,0.0002092629,0.00044128692,0.00027964334,0.0000743837,0.000029934085,0.00010810767,0.00018226882,0.000014245184],"category_scores_gemma":[0.0002089361,0.00017722546,0.00004507031,0.00042900257,0.0001887744,0.00018133075,0.00007580287,0.0003307741,0.0000027054396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016789217,0.002869911,0.8404185,0.0006157674,0.0008686081,0.0004989755,0.0068293735,0.00007938981,0.11601389,0.0010252276,0.0006600153,0.028441405],"study_design_scores_gemma":[0.011632258,0.0024733152,0.87241876,0.00028652445,0.00029062887,0.00030776116,0.00085165456,0.0049526966,0.10552992,0.0009850875,0.000054709144,0.00021665578],"about_ca_topic_score_codex":0.000054407854,"about_ca_topic_score_gemma":0.000025063262,"teacher_disagreement_score":0.032000277,"about_ca_system_score_codex":0.00015152428,"about_ca_system_score_gemma":0.00036465886,"threshold_uncertainty_score":0.72270447},"labels":[],"label_agreement":null},{"id":"W2979519729","doi":"10.1182/blood.v128.22.1562.1562","title":"The Mitochondrial Carrier Homolog 2 (MTCH2) Regulates the Differentiation of AML Cells By Influencing the Localization of Pyruvate Dehydrogenase Complex and H3 and H4 Histone Acetylation","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Gene knockdown; Biology; Haematopoiesis; Cell biology; Molecular biology; Stem cell; Cancer research; Apoptosis; Genetics","score_opus":0.009723854391474926,"score_gpt":0.24919708682128813,"score_spread":0.23947323242981322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979519729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961962,0.0009801527,0.0007014802,0.0014703406,0.000049495768,0.0005271167,0.00003011193,0.000011539275,0.00003353671],"genre_scores_gemma":[0.99915594,0.00039389377,0.000063362124,0.00006191925,0.00006994239,0.000016462187,0.000019995477,0.000014962819,0.0002035016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989377,0.00016033735,0.0002932322,0.00016307624,0.00028149385,0.0001641355],"domain_scores_gemma":[0.9988532,0.00041237488,0.00020363764,0.0003239959,0.00015751632,0.00004925449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002915944,0.000106259184,0.00017932555,0.000039142156,0.00021246506,0.000016232108,0.000109216904,0.00007829776,0.000016404863],"category_scores_gemma":[0.00020057897,0.00004459986,0.000035476656,0.00013509755,0.0005493369,0.00006381493,0.000082101615,0.00009457138,8.238498e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014374696,0.000041366136,0.0046569607,0.00004166718,0.00009816297,6.9528613e-7,0.000854434,0.000007028017,0.99062616,0.000090320136,0.0011112813,0.0023281826],"study_design_scores_gemma":[0.003951682,0.00018115721,0.020740762,0.00007876234,0.00027205513,0.000016264485,0.00025579784,0.001801892,0.9709513,0.0003757633,0.0012940193,0.00008049985],"about_ca_topic_score_codex":0.00013472435,"about_ca_topic_score_gemma":0.000038100992,"teacher_disagreement_score":0.01967481,"about_ca_system_score_codex":0.000049646802,"about_ca_system_score_gemma":0.0000646467,"threshold_uncertainty_score":0.20240547},"labels":[],"label_agreement":null},{"id":"W2979532487","doi":"10.1182/blood.v126.23.2899.2899","title":"Targeting Cell-Bound MUC1 on Myelomonocytic and Monocytic Leukemias and Leukemic Stem Cells: Therapeutic Implications","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biomod (Canada)","funders":"","keywords":"Chronic myelomonocytic leukemia; Monocytic leukemia; Juvenile myelomonocytic leukemia; Biology; Leukemia; Stem cell; Cancer research; Haematopoiesis; Molecular biology; Immunology; Cell biology; Myelodysplastic syndromes","score_opus":0.04963958323945775,"score_gpt":0.294967298003222,"score_spread":0.24532771476376428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979532487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98821527,0.0052579683,0.00014094065,0.0007682169,0.00006460297,0.00079222996,0.000012013298,0.00013961055,0.004609165],"genre_scores_gemma":[0.99547714,0.001023152,0.0006325794,0.0006854814,0.00019575603,0.000080577156,0.000015911508,0.000077556026,0.001811818],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979804,0.00011261279,0.00036523127,0.0006142366,0.00035333075,0.000574154],"domain_scores_gemma":[0.9982789,0.0003035012,0.00010997407,0.0005721473,0.00015463436,0.0005808518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005080191,0.00030789603,0.00041254045,0.00022041041,0.00019591366,0.00010353091,0.00017981174,0.0001899634,0.00001421252],"category_scores_gemma":[0.00005803848,0.0002681278,0.000055741944,0.0002920291,0.00021406727,0.000124608,0.0001648487,0.00055069965,0.000118705946],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015305018,0.00251434,0.06478359,0.0023303244,0.0014400419,0.0007006886,0.010942104,0.00033653804,0.83978623,0.0027090823,0.012530901,0.060395673],"study_design_scores_gemma":[0.11146426,0.009601549,0.04467431,0.0009834842,0.0047412342,0.0039034635,0.018709257,0.034211732,0.724953,0.006508004,0.0361673,0.004082389],"about_ca_topic_score_codex":0.0001090495,"about_ca_topic_score_gemma":0.0000028090603,"teacher_disagreement_score":0.1148332,"about_ca_system_score_codex":0.00074197876,"about_ca_system_score_gemma":0.0009704487,"threshold_uncertainty_score":0.9999771},"labels":[],"label_agreement":null},{"id":"W2979538470","doi":"10.1182/blood.v128.22.902.902","title":"Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytarabine; Daunorubicin; Medicine; Internal medicine; Gastroenterology; Surgery; Leukemia","score_opus":0.012806519909864866,"score_gpt":0.2791860526841156,"score_spread":0.26637953277425075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979538470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634606,0.00006171849,0.00015067436,0.00008721956,0.0000350115,0.0023910822,0.00074563257,0.00005919364,0.00012338832],"genre_scores_gemma":[0.99581444,0.000068129564,0.00028107275,0.000030258083,0.000068063295,0.00021174073,0.0024715716,0.00005399589,0.0010007367],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99754786,0.0001431802,0.00063416787,0.00065753434,0.00054373726,0.00047354196],"domain_scores_gemma":[0.9983167,0.00046102263,0.00030889647,0.00039882064,0.00027441132,0.0002401331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030959555,0.0003517239,0.0010331628,0.00091073004,0.00009187353,0.000024962977,0.00012862036,0.00020463187,0.00014382426],"category_scores_gemma":[0.00015564756,0.00022204654,0.00016182943,0.0014947674,0.000274714,0.0002160977,0.00004589058,0.00027699705,0.000002455103],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8059962,0.006522489,0.054165576,0.00012385921,0.01605111,0.00034712895,0.00041600614,0.000014973945,0.10788241,0.000010739679,0.00059860613,0.007870935],"study_design_scores_gemma":[0.87235373,0.02720472,0.06324855,0.00021863321,0.008844833,0.000023554909,0.00006640313,0.00025538087,0.027333552,0.0000027822346,0.00011434241,0.00033351238],"about_ca_topic_score_codex":0.0005777013,"about_ca_topic_score_gemma":0.0002612446,"teacher_disagreement_score":0.08054886,"about_ca_system_score_codex":0.0005140138,"about_ca_system_score_gemma":0.0004929714,"threshold_uncertainty_score":0.90547955},"labels":[],"label_agreement":null},{"id":"W2979561552","doi":"10.1182/blood.v120.21.2190.2190","title":"Thrombocytopenia and Platelet Ultra-Structural Abnormalities Associated with RUNX1 Haploinsufficiency in Monosomy 21 Mosaicism.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"RUNX1; Haploinsufficiency; Platelet disorder; Monosomy; Chromosome 7 (human); Biology; Internal medicine; Medicine; Genetics; Platelet; Endocrinology; Cancer research; Karyotype; Phenotype; Gene; Transcription factor; Chromosome","score_opus":0.01706266976980778,"score_gpt":0.26184296200053875,"score_spread":0.24478029223073097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979561552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99288446,0.0008202813,0.0000039762717,0.00029180877,0.000048859794,0.00048857176,0.000026746882,0.00007879742,0.005356477],"genre_scores_gemma":[0.9985717,0.0000743978,0.00033210826,0.00020678737,0.00012815933,0.000030473357,0.00005585154,0.00003847985,0.0005620544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981488,0.00008302149,0.00028174472,0.00026635287,0.0004286851,0.0007913909],"domain_scores_gemma":[0.9991541,0.00015836842,0.000078233425,0.00026311414,0.00007814719,0.0002680213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036632412,0.00023231629,0.00046981897,0.00016547402,0.00010651526,0.000039696035,0.00013277624,0.0001594609,0.000100255376],"category_scores_gemma":[0.00021498972,0.00017205297,0.000037554422,0.00037207096,0.00021479408,0.0003365532,0.0000576765,0.0004962142,0.000021256466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028918195,0.00073669065,0.97580695,0.000110511166,0.0002745857,0.00033690574,0.0059784343,0.000006193369,0.014681374,0.00070702896,0.00037217318,0.0006999967],"study_design_scores_gemma":[0.011714215,0.0006509747,0.9447357,0.00018160531,0.0001509418,0.00089123554,0.0012550943,0.00015357272,0.039397426,0.00007158528,0.00042500446,0.00037265205],"about_ca_topic_score_codex":0.00031015844,"about_ca_topic_score_gemma":0.00006474295,"teacher_disagreement_score":0.031071234,"about_ca_system_score_codex":0.00015758976,"about_ca_system_score_gemma":0.00019429663,"threshold_uncertainty_score":0.70161164},"labels":[],"label_agreement":null},{"id":"W2979594948","doi":"10.1093/annonc/mdz374.003","title":"Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Myeloid leukemia; Refractory (planetary science); Oncology; Internal medicine; Cancer research","score_opus":0.07441932910703952,"score_gpt":0.4003566984012877,"score_spread":0.32593736929424816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979594948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.953054,0.00035068186,0.0000050500767,0.010355322,0.00074061943,0.0017096668,0.00006837366,0.00008516733,0.033631094],"genre_scores_gemma":[0.98996645,0.001316133,0.00029421423,0.0021084652,0.00037728713,0.000072627154,0.00020787804,0.0000702987,0.0055866414],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99546206,0.0005822329,0.0015209059,0.00075574865,0.0006596898,0.0010193537],"domain_scores_gemma":[0.9964025,0.0011992899,0.0005615524,0.0009556031,0.00053453393,0.00034650683],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026154062,0.00034134267,0.0014331443,0.0007159333,0.000047608286,0.000012102664,0.00044979053,0.00086276897,0.00043495506],"category_scores_gemma":[0.0017809685,0.0003024905,0.0002841863,0.0008663255,0.00032314248,0.00022675928,0.0002361058,0.0015183304,0.0010084078],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63498104,0.0028686025,0.0047803004,0.0002985096,0.0012045915,0.0032088808,0.0028336612,0.00011664537,0.11660678,0.0011280027,0.18397167,0.04800132],"study_design_scores_gemma":[0.4251396,0.06869788,0.021567088,0.00043540995,0.00028659255,0.00049179513,0.0010638994,0.0022729223,0.042238895,0.00091904425,0.4359926,0.0008942831],"about_ca_topic_score_codex":0.00059116114,"about_ca_topic_score_gemma":0.00010509019,"teacher_disagreement_score":0.25202093,"about_ca_system_score_codex":0.00084713026,"about_ca_system_score_gemma":0.0038529418,"threshold_uncertainty_score":0.9999427},"labels":[],"label_agreement":null},{"id":"W2979679841","doi":"10.1182/blood.v110.11.3491.3491","title":"Allogeneic Stem Cell Transplant in First Complete Remission Overcomes the Poor Prognosis Associated with the FLT-3 Internal Tandem Duplication in Acute Myeloid Leukemia.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"NPM1; Internal medicine; Cytarabine; Induction chemotherapy; Medicine; Oncology; Transplantation; Chemotherapy; Chemotherapy regimen; Myeloid leukemia; Gastroenterology; Biology; Genetics; Karyotype; Gene","score_opus":0.018670967193013942,"score_gpt":0.2551994610937699,"score_spread":0.23652849390075595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979679841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918507,0.00037567198,0.00014568651,0.0051876474,0.000025858526,0.0012977644,0.000024672583,0.000055087774,0.0010369556],"genre_scores_gemma":[0.99795806,0.00034285444,0.00009087419,0.0005611467,0.00007216724,0.00010629922,0.000071230905,0.000044272827,0.000753071],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977149,0.00016084824,0.00046101803,0.00040403826,0.0006511428,0.0006081042],"domain_scores_gemma":[0.9986395,0.0005769529,0.000168343,0.00038442115,0.00009602813,0.0001347153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015532052,0.00025037385,0.00037648302,0.0001874141,0.00016048893,0.000038252678,0.00046605256,0.00019007799,0.000026556161],"category_scores_gemma":[0.000037384554,0.00013213875,0.00008904568,0.0007542498,0.00013839912,0.000077000535,0.000078285084,0.0008707932,0.000015332063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001376383,0.0010123261,0.86649835,0.000105767744,0.00045119962,0.00084610377,0.00440863,0.000049359984,0.12081996,0.00003771402,0.0013084039,0.0030857911],"study_design_scores_gemma":[0.011277507,0.00051701174,0.91182774,0.0007090624,0.00035784722,0.00024244387,0.00080240465,0.0012676625,0.07003306,0.0000112528505,0.0026790006,0.0002749933],"about_ca_topic_score_codex":0.00042669178,"about_ca_topic_score_gemma":0.0026816989,"teacher_disagreement_score":0.050786905,"about_ca_system_score_codex":0.00088322465,"about_ca_system_score_gemma":0.00033128908,"threshold_uncertainty_score":0.5388462},"labels":[],"label_agreement":null},{"id":"W2979727212","doi":"10.1182/blood.v128.22.1535.1535","title":"Modeling of Pediatric Acute Megakaryoblastic Leukemia Using Cord Blood Stem/Progenitor Cells","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Institute for Research in Immunology and Cancer; Université de Montréal","funders":"","keywords":"Fusion gene; Cancer research; Biology; Chimeric gene; Progenitor cell; Molecular biology; Stem cell; Acute megakaryoblastic leukemia; CTL*; Myeloid; Myeloid leukemia; Gene; In vitro; Cytotoxic T cell; Gene expression; Cell biology; Genetics","score_opus":0.03346565617792274,"score_gpt":0.2857944216548569,"score_spread":0.25232876547693417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979727212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99480724,0.0006348865,0.003222079,0.0000665278,0.00019301417,0.00058257,0.000066570516,0.00010397844,0.00032310188],"genre_scores_gemma":[0.9918443,0.000452311,0.005669068,0.000041551815,0.0010325956,0.000021167085,0.0000051071315,0.00009521689,0.0008386784],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99732596,0.00007727776,0.0006336826,0.0005222501,0.00074930297,0.0006915449],"domain_scores_gemma":[0.9982175,0.0002040374,0.00016145907,0.00068638934,0.00037318302,0.00035739038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032189116,0.00030531394,0.00059767446,0.00037349996,0.000091193426,0.000017988597,0.00032801027,0.00023240484,0.000100250814],"category_scores_gemma":[0.00010146043,0.0002150373,0.00021558173,0.00053622166,0.00009145845,0.00015527176,0.00022453709,0.00031169195,0.000105442465],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052244216,0.0005740773,0.009209296,0.00035682565,0.00097131776,0.0004914419,0.00010052261,0.00021863809,0.98638666,0.000034716173,0.00019173382,0.0009423607],"study_design_scores_gemma":[0.024623115,0.001816128,0.000413908,0.0004231069,0.009390406,0.0009117795,0.000116075455,0.039382838,0.9220602,0.000080895916,0.00007460241,0.0007069378],"about_ca_topic_score_codex":0.0000836405,"about_ca_topic_score_gemma":0.0000024181472,"teacher_disagreement_score":0.06432642,"about_ca_system_score_codex":0.00026779663,"about_ca_system_score_gemma":0.0013367948,"threshold_uncertainty_score":0.8768967},"labels":[],"label_agreement":null},{"id":"W2979755727","doi":"10.1182/blood.v118.21.2520.2520","title":"Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"NPM1; Internal medicine; Medicine; Oncology; Univariate analysis; Gemtuzumab ozogamicin; Myeloid leukemia; Proportional hazards model; Minimal residual disease; Bone marrow; Biology; Multivariate analysis; Genetics; Gene; CD33; Stem cell","score_opus":0.020723960275824103,"score_gpt":0.277662064979687,"score_spread":0.25693810470386286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979755727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953636,0.00017980376,0.00002216359,0.000041233103,0.000010730498,0.0034283719,0.00005938659,0.000031934967,0.00086275657],"genre_scores_gemma":[0.99812967,0.000061118975,0.0011864178,0.000033471286,0.000022714787,0.00031037672,0.000017261329,0.000046028938,0.00019293971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979492,0.00016875585,0.00046267823,0.0005148916,0.0005071914,0.0003973297],"domain_scores_gemma":[0.9987445,0.0002659881,0.0001705492,0.00043674477,0.00017916993,0.00020304942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047177722,0.00025371398,0.00058937573,0.00028600593,0.000057318455,0.000012786016,0.00017450936,0.0000955566,0.000024299434],"category_scores_gemma":[0.00026953916,0.0002051693,0.000029699619,0.0005326828,0.00030355537,0.00009062245,0.00010098726,0.00041592712,0.0000028991128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027724192,0.0077734767,0.93238646,0.00037132512,0.00070072466,0.0019519201,0.024459654,0.0000033280492,0.028306654,0.000013637408,0.000089241374,0.0011711842],"study_design_scores_gemma":[0.02849076,0.014842826,0.9208281,0.00051038055,0.0009091711,0.0001378405,0.010411506,0.00005918761,0.02351283,0.000030417326,0.000009566159,0.00025741555],"about_ca_topic_score_codex":0.0015597708,"about_ca_topic_score_gemma":0.0008043723,"teacher_disagreement_score":0.02571834,"about_ca_system_score_codex":0.00013637936,"about_ca_system_score_gemma":0.00053196965,"threshold_uncertainty_score":0.83665615},"labels":[],"label_agreement":null},{"id":"W2979791675","doi":"10.1101/790626","title":"Genetic predisposition to myeloproliferative neoplasms implicates hematopoietic stem cell biology","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"New York Stem Cell Foundation; Howard Hughes Medical Institute","keywords":"Biology; Genetics; Genome-wide association study; CHEK2; Disease; Stem cell; Myeloid; Haematopoiesis; Mutation; Gene; Germline mutation; Cancer research; Single-nucleotide polymorphism; Genotype; Internal medicine; Medicine","score_opus":0.01400753858046705,"score_gpt":0.25337865249081987,"score_spread":0.23937111391035282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979791675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867417,0.0016409453,0.0042940127,0.0011627675,0.0007989425,0.0043578623,0.00044051296,0.00050148345,0.00006173294],"genre_scores_gemma":[0.98855394,0.0003535678,0.008007534,0.000905956,0.0007489785,0.0010711517,0.0000031082893,0.00028330507,0.00007247389],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9951094,0.00026847218,0.00088128657,0.0019649467,0.0005709136,0.0012050124],"domain_scores_gemma":[0.9951061,0.00017713294,0.00038981476,0.002436055,0.0010122505,0.00087866903],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005143588,0.00091636897,0.0013260219,0.0006803632,0.00016540273,0.00018079155,0.00078701164,0.0011745811,0.00010663918],"category_scores_gemma":[0.00009545779,0.00089424785,0.00027832945,0.0007812191,0.00018120049,0.00009335922,0.0012197644,0.0016650805,0.0015638528],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003014783,0.0002457899,0.0184293,0.0017143694,0.000300256,0.00013310573,0.00008334102,0.00024173508,0.9766108,0.0002778478,0.0016535963,0.000008377889],"study_design_scores_gemma":[0.002010322,0.0008493916,0.11453018,0.000888333,0.0004008923,5.50404e-7,0.00001963754,0.0020257437,0.8746083,0.0000069550124,0.0033471,0.0013126056],"about_ca_topic_score_codex":0.000060534752,"about_ca_topic_score_gemma":0.0000012442179,"teacher_disagreement_score":0.10200252,"about_ca_system_score_codex":0.0013500308,"about_ca_system_score_gemma":0.0022964757,"threshold_uncertainty_score":0.99935085},"labels":[],"label_agreement":null},{"id":"W2979796411","doi":"10.1182/blood.v118.21.4305.4305","title":"Outcome of Patients with Refractory Acute Leukemia Treated with a Third Induction Chemotherapy Regimen","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Induction chemotherapy; Regimen; Refractory (planetary science); Log-rank test; Internal medicine; Chemotherapy regimen; Surgery; Chemotherapy; Acute leukemia; Leukemia; Survival analysis","score_opus":0.023017816656497516,"score_gpt":0.26166293091531617,"score_spread":0.23864511425881865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979796411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99226505,0.000020349462,0.000021783459,0.000067671615,0.000014359537,0.00063296285,0.000012282364,0.00008333722,0.0068822345],"genre_scores_gemma":[0.9945572,0.000025728596,0.002851559,0.00014497053,0.0000498746,0.00003513409,0.00005074259,0.000059045044,0.0022257464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986373,0.00003795612,0.00026241218,0.0003044044,0.00046850782,0.00028939467],"domain_scores_gemma":[0.99883413,0.000016049149,0.00017410082,0.00053856004,0.00029161014,0.00014552551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011832409,0.00020125182,0.00039270904,0.00017412852,0.00004051017,0.0000055439477,0.0001327489,0.0001461978,0.00012808932],"category_scores_gemma":[0.000019809298,0.00012518218,0.000049006405,0.0003549699,0.00015428604,0.00014124994,0.000026450422,0.00034727625,0.000021016427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050228504,0.0012421716,0.9845693,0.000067995745,0.0011002434,0.00008916211,0.0009845047,1.3587939e-7,0.005088262,0.000018417148,0.0005519353,0.0012649826],"study_design_scores_gemma":[0.021629263,0.0047519375,0.89451194,0.00009911199,0.00059164834,0.000055191715,0.00011609721,0.0000038405624,0.07745319,0.000008018484,0.0005799338,0.00019985516],"about_ca_topic_score_codex":0.00032393218,"about_ca_topic_score_gemma":0.0000105625,"teacher_disagreement_score":0.090057425,"about_ca_system_score_codex":0.00024180459,"about_ca_system_score_gemma":0.00028074143,"threshold_uncertainty_score":0.5104781},"labels":[],"label_agreement":null},{"id":"W2979825973","doi":"10.1182/blood.v124.21.3672.3672","title":"Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML) Have Increased Treatment-Related Mortality with Similar Outcomes -- a Report from the Children's Oncology Group Trials AAML03P1 and AAML0531","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Internal medicine; Population; Induction chemotherapy; Chemotherapy; Adverse effect; Chemotherapy regimen; Oncology; Pediatrics","score_opus":0.01624827527453899,"score_gpt":0.29058954246376884,"score_spread":0.27434126718922985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979825973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947343,0.0003887135,0.00006058774,0.0010414171,0.00005969518,0.0027509395,0.00019828872,0.00016496562,0.0006010844],"genre_scores_gemma":[0.9963878,0.00047610278,0.0011193942,0.00055520755,0.00024942352,0.00017765969,0.0006574769,0.00009845931,0.0002784693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99561393,0.00086319563,0.0009210297,0.0011345375,0.00077054685,0.0006967807],"domain_scores_gemma":[0.99668384,0.0007644361,0.00061307626,0.0012072066,0.00018581004,0.00054561824],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016157596,0.0006533579,0.0017990539,0.00013766889,0.0003008487,0.0000912276,0.00023670333,0.00040358191,0.000033149998],"category_scores_gemma":[0.0007856755,0.00033928186,0.00016606129,0.0002456902,0.0006256033,0.0001689447,0.00016574924,0.00066580315,0.000008350887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038962937,0.0007203962,0.9825403,0.000035846246,0.0052717635,0.0021559293,0.00072081387,6.6169525e-7,0.0010456752,0.000012734347,0.00016262385,0.0034369708],"study_design_scores_gemma":[0.05781927,0.0030401943,0.9267291,0.00033077277,0.0059202937,0.0037356135,0.00026867248,0.0001403496,0.0013230006,0.000043108004,0.0002658241,0.00038383433],"about_ca_topic_score_codex":0.0131163355,"about_ca_topic_score_gemma":0.0028784533,"teacher_disagreement_score":0.055811226,"about_ca_system_score_codex":0.00045723715,"about_ca_system_score_gemma":0.0008504574,"threshold_uncertainty_score":0.99990594},"labels":[],"label_agreement":null},{"id":"W2979834153","doi":"10.1182/blood.v128.22.2859.2859","title":"Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"CEBPA; NPM1; Medicine; Internal medicine; Oncology; Azacitidine; Myeloid leukemia; Gastroenterology; Mutation; Gene; Biology; Genetics","score_opus":0.01328118774093202,"score_gpt":0.2785716039095239,"score_spread":0.2652904161685919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979834153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712604,0.000024391085,0.000053696236,0.0001324782,0.00001850829,0.0009902394,0.00063840795,0.000049492395,0.00096675125],"genre_scores_gemma":[0.99677414,0.000029458473,0.00072635827,0.000036012887,0.00006401407,0.00007861797,0.0007190168,0.00007022677,0.0015021478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978074,0.00009421318,0.0003561489,0.00046056235,0.00078905287,0.00049266365],"domain_scores_gemma":[0.99833745,0.0001763394,0.0001682924,0.00046843078,0.0006087533,0.00024075691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010113104,0.0003123927,0.0005176471,0.00034899687,0.000059995644,0.000012649884,0.00014321634,0.00013457486,0.0004067082],"category_scores_gemma":[0.00007337274,0.00015902428,0.000119387696,0.00046725362,0.00019850417,0.00014768033,0.000035277306,0.00023688545,0.000029097366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01044949,0.0016188645,0.9637206,0.000084500396,0.0016197298,0.0006901648,0.0004214898,0.000037676764,0.020386491,0.00006490203,0.00033783214,0.00056823256],"study_design_scores_gemma":[0.057657734,0.006226936,0.9053716,0.0005394163,0.00040109304,0.0000925908,0.00008849561,0.000012263417,0.029325692,0.000005949252,0.000026392216,0.0002518086],"about_ca_topic_score_codex":0.0004343095,"about_ca_topic_score_gemma":0.0001623982,"teacher_disagreement_score":0.058348995,"about_ca_system_score_codex":0.0010612916,"about_ca_system_score_gemma":0.001573762,"threshold_uncertainty_score":0.6484822},"labels":[],"label_agreement":null},{"id":"W2979861852","doi":"10.1182/blood.v120.21.1753.1753","title":"Niche Requirements of Transient Leukemia Cells in Down Syndrome","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Haematopoiesis; GATA1; Bone marrow; Biology; Leukemia; Context (archaeology); Fetus; Trisomy; Stem cell; Immunology; Pathology; Cancer research; Medicine; Cell biology; Genetics; Pregnancy","score_opus":0.028323981704892327,"score_gpt":0.2941409615994923,"score_spread":0.2658169798946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979861852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99132174,0.0004700111,0.000013859709,0.00014382905,0.00008892098,0.00042697598,0.00001060039,0.000022708204,0.0075013605],"genre_scores_gemma":[0.9981212,0.0000806355,0.0006946759,0.00011978286,0.000064759144,0.000023796096,0.000011599395,0.000024481249,0.0008590395],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845314,0.00005778728,0.00034321417,0.0001805601,0.00045005354,0.0005152272],"domain_scores_gemma":[0.9992521,0.000051084906,0.000054946067,0.0003794023,0.00004849373,0.00021397357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000503079,0.00012581485,0.0003233203,0.0001887794,0.00001727132,0.000003773333,0.00014114872,0.00011641035,0.00026887786],"category_scores_gemma":[0.0000539041,0.00010828208,0.00007933078,0.00033339515,0.000070151116,0.00010453254,0.000052757998,0.0002894823,0.00013742053],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002645132,0.002569677,0.15124266,0.0005803678,0.000258793,0.000428969,0.0019156361,0.000006778525,0.83833784,0.00013961572,0.0028161367,0.0014390014],"study_design_scores_gemma":[0.012967127,0.0006200654,0.48068383,0.00029498746,0.00025201525,0.00041629694,0.00023532638,0.000046462163,0.5001618,0.000022400658,0.0040681465,0.00023149682],"about_ca_topic_score_codex":0.000111074536,"about_ca_topic_score_gemma":0.000006857578,"teacher_disagreement_score":0.338176,"about_ca_system_score_codex":0.00029119666,"about_ca_system_score_gemma":0.00027385785,"threshold_uncertainty_score":0.4415615},"labels":[],"label_agreement":null},{"id":"W2979878225","doi":"10.1182/blood.v124.21.3624.3624","title":"Development of a Clinically Relevant in Vitro Drug Screening Platform for Chemo-Refractory AML Patients","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pharmacology; Bortezomib; Homoharringtonine; Oncology; Myeloid leukemia; Cytarabine; Proteasome inhibitor; Internal medicine; Panobinostat; Idarubicin; Cancer research; Multiple myeloma; Biology; Histone deacetylase","score_opus":0.027766607716471707,"score_gpt":0.3055776461738024,"score_spread":0.2778110384573307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979878225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972928,0.000024081468,0.0009190453,0.0001118633,0.000040366587,0.00068496284,0.0000091249285,0.000026609563,0.0008911427],"genre_scores_gemma":[0.8583854,0.000007466052,0.14100704,0.00016636262,0.00008443314,0.00006441166,0.00009072458,0.000030935058,0.00016322572],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811417,0.000022995906,0.00079240534,0.00027910378,0.00041648682,0.00037483554],"domain_scores_gemma":[0.99878585,0.00039726592,0.00018824822,0.00029105204,0.000184302,0.00015326557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011134642,0.00013818279,0.00041168559,0.00015869601,0.00004371194,0.000006232961,0.00016726264,0.00011275457,0.000015021839],"category_scores_gemma":[0.0013452466,0.0001173198,0.00008882605,0.00014137257,0.000050913826,0.000062332016,0.000114834715,0.00030556397,0.000015684474],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008299476,0.006910525,0.18702362,0.0013162113,0.0005242429,0.000024039953,0.005170026,0.0000025631664,0.27825728,0.00007236852,0.0014195926,0.51098007],"study_design_scores_gemma":[0.075414255,0.0012591644,0.26307508,0.0009084914,0.00022387627,0.000013323523,0.0004931267,0.0019515379,0.60696,0.00012656489,0.048945356,0.00062919484],"about_ca_topic_score_codex":0.00001748547,"about_ca_topic_score_gemma":0.000012987259,"teacher_disagreement_score":0.5103509,"about_ca_system_score_codex":0.00011704211,"about_ca_system_score_gemma":0.00039405018,"threshold_uncertainty_score":0.4784163},"labels":[],"label_agreement":null},{"id":"W2979914039","doi":"10.1182/blood.v128.22.774.774","title":"Alteration of Chromatin Modifiers and Misregulation of Transcription Factors Define the Genomic Profile of Infant AML","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Biology; Cancer research; Exome; Transcriptome; Haematopoiesis; Genome; Genetics; Computational biology; Stem cell; Exome sequencing; Mutation; Gene","score_opus":0.019327343196059714,"score_gpt":0.2527766367166423,"score_spread":0.23344929352058258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979914039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983778,0.00015413733,0.0005589697,0.00027674015,0.000013954166,0.0004311589,0.000038963,0.000006786457,0.00014151722],"genre_scores_gemma":[0.9992466,0.000057521123,0.00054561184,0.000005919875,0.000022031787,0.000009074781,0.000022108334,0.000008695768,0.000082434075],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993089,0.000045310175,0.000272859,0.00009772107,0.00018790428,0.00008732339],"domain_scores_gemma":[0.99949324,0.000071217284,0.0001333137,0.00017636351,0.00009559502,0.00003025252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019152183,0.00006426701,0.000180711,0.000079875186,0.000018536286,0.0000019963863,0.00004593356,0.000051157742,0.000045475997],"category_scores_gemma":[0.0000751773,0.00003418913,0.000040735045,0.000084494175,0.00012728052,0.000057746845,0.000011885671,0.000043359287,8.822461e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000098823024,0.00008080635,0.01857525,0.00016683793,0.000056031906,2.5993546e-7,0.0008635916,0.0000036473646,0.97801787,0.0001967601,0.000034373064,0.0019057444],"study_design_scores_gemma":[0.0021799114,0.00024248248,0.3202587,0.00008857801,0.0000808146,0.000004940171,0.000085573134,0.00036949545,0.6765932,0.000052810177,0.000015361727,0.000028114753],"about_ca_topic_score_codex":0.000111659654,"about_ca_topic_score_gemma":0.000008124589,"teacher_disagreement_score":0.30168346,"about_ca_system_score_codex":0.000027663507,"about_ca_system_score_gemma":0.00008416171,"threshold_uncertainty_score":0.13941921},"labels":[],"label_agreement":null},{"id":"W2980046939","doi":"10.1182/blood.v124.21.3670.3670","title":"Pediatric Acute Megakaryoblastic Leukemia without Down Syndrome: A Retrospective Study by the International Berlin-Frankfurt-Munster Study Group (I-BFMSG)","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Acute megakaryoblastic leukemia; Internal medicine; Transplantation; Retrospective cohort study; Down syndrome; Leukemia; Myeloid leukemia; Acute leukemia; Pediatrics; Surgery","score_opus":0.008341565081181385,"score_gpt":0.26505632564225534,"score_spread":0.25671476056107395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980046939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99272305,0.00013011902,0.00019931473,0.00057565846,0.0004283746,0.0031842995,0.000045345427,0.00018644628,0.002527377],"genre_scores_gemma":[0.99488264,0.000035957535,0.00018148724,0.00041744736,0.0008751828,0.0004048215,0.000054737997,0.000105130646,0.0030425715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953552,0.00038482444,0.000657137,0.0009785563,0.001922507,0.00070180686],"domain_scores_gemma":[0.9976187,0.0003197196,0.00022358472,0.0011987141,0.00034024304,0.00029906025],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001526333,0.00048087558,0.00075122115,0.00033171746,0.0003141018,0.00017578063,0.0010576547,0.00015966692,0.00028432196],"category_scores_gemma":[0.0004924919,0.00032315726,0.00018613106,0.0007510538,0.00015455998,0.00021996211,0.0005839449,0.0012530976,0.00036548555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048646893,0.005472679,0.9790702,0.000028000233,0.0025092538,0.0006253519,0.002449892,0.0000027755925,0.0008719738,0.000040688632,0.008137926,0.00030481917],"study_design_scores_gemma":[0.031504713,0.008583241,0.9505434,0.000034567503,0.0038854321,0.0012283687,0.0020573132,0.00061642117,0.0001426136,0.000093149334,0.0008031274,0.0005076317],"about_ca_topic_score_codex":0.00033052004,"about_ca_topic_score_gemma":0.0001270041,"teacher_disagreement_score":0.031018242,"about_ca_system_score_codex":0.0007758757,"about_ca_system_score_gemma":0.00032070413,"threshold_uncertainty_score":0.99992204},"labels":[],"label_agreement":null},{"id":"W2980055023","doi":"10.1182/blood.v126.23.6.6","title":"The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cytarabine; Midostaurin; Medicine; Internal medicine; Gastroenterology; Chemotherapy; Oncology; Surgery; Leukemia","score_opus":0.03245016808503368,"score_gpt":0.3022962509159641,"score_spread":0.2698460828309304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980055023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743197,0.00008367674,0.0003663801,0.0011501606,0.00025540363,0.023473376,0.00004735957,0.000102778096,0.0002011591],"genre_scores_gemma":[0.990379,0.0002449375,0.0019600845,0.00008949921,0.00019984685,0.0056739743,0.0010490716,0.000103349856,0.00030025587],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944286,0.0011661197,0.001202969,0.0010950869,0.0013575057,0.0007497726],"domain_scores_gemma":[0.9959947,0.00090764277,0.0007793553,0.00058217096,0.001342711,0.00039340896],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024997452,0.00068601617,0.0015884623,0.0005719476,0.00029593534,0.00033409017,0.00035824708,0.0002927981,0.000019881662],"category_scores_gemma":[0.0007930881,0.0004232615,0.00009891904,0.0009877648,0.0009873037,0.0009908543,0.00007833255,0.0011141879,0.000007745122],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9609457,0.004024558,0.027046913,0.000025663889,0.00096197316,0.0005572562,0.0038279442,0.00050284894,0.00092346716,0.0002726961,0.000025823634,0.0008851558],"study_design_scores_gemma":[0.9444584,0.0076557193,0.03815255,0.00033597776,0.00037484692,0.00007795972,0.0015455383,0.0038399587,0.0028525034,0.00016836301,0.00002918297,0.0005089606],"about_ca_topic_score_codex":0.0028082032,"about_ca_topic_score_gemma":0.008760114,"teacher_disagreement_score":0.017799402,"about_ca_system_score_codex":0.0014790244,"about_ca_system_score_gemma":0.0019942974,"threshold_uncertainty_score":0.9998219},"labels":[],"label_agreement":null},{"id":"W2980088373","doi":"10.1182/blood.v128.22.2666.2666","title":"CSF1R Is Associated with Poor Overall Survival in AML and Mediates Supportive Interactions Between AML and Stromal Cells in the AML Microenvironment","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Stromal cell; Haematopoiesis; Cytokine; Bone marrow; Myeloid; Myeloid leukemia; Biology; Cancer research; Cell biology; Immunophenotyping; Stem cell; Immunology; Flow cytometry","score_opus":0.014955770887005912,"score_gpt":0.2600988974472439,"score_spread":0.24514312656023798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980088373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937667,0.00007823024,0.0000051278143,0.005131134,0.000021117858,0.00050476106,0.00020378196,0.00001343518,0.00027567576],"genre_scores_gemma":[0.9986281,0.00023135678,0.00009544217,0.0002711112,0.00008465474,0.000036451176,0.000040387604,0.000025077914,0.0005874609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998417,0.00019531361,0.00027382665,0.00034506185,0.00035123312,0.0004175615],"domain_scores_gemma":[0.998821,0.00071467116,0.00009543727,0.00020604748,0.000027562577,0.00013528862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046810365,0.00018482782,0.00034637866,0.00014811412,0.000048090675,0.000027677022,0.00011466343,0.00009140391,0.00012083866],"category_scores_gemma":[0.00012724155,0.000104192426,0.0000307589,0.00013908459,0.00020914145,0.00012869656,0.00010930104,0.00038172258,0.000016720125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016407047,0.00047076662,0.94082606,0.000019386007,0.00022699214,0.000240817,0.001924984,1.2161873e-7,0.054623947,0.000007465298,0.000809515,0.0006858928],"study_design_scores_gemma":[0.008906213,0.0006040653,0.96534675,0.00017052688,0.00015383627,0.00002933374,0.0007967309,0.000007831114,0.023339082,0.000032915523,0.00047080003,0.00014188331],"about_ca_topic_score_codex":0.0003871113,"about_ca_topic_score_gemma":0.0005966626,"teacher_disagreement_score":0.031284865,"about_ca_system_score_codex":0.00020028866,"about_ca_system_score_gemma":0.00009884825,"threshold_uncertainty_score":0.4248844},"labels":[],"label_agreement":null},{"id":"W2980113071","doi":"10.1182/blood.v108.11.2134.2134","title":"RIZ1 Is Downregulated during CML Progression and Displays Tumor Suppressor Properties in CML Cell Lines.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Bone marrow; Cancer research; Myeloid; Biology; Loss of heterozygosity; CD34; Tumor suppressor gene; Myeloid leukemia; Pathology; Immunology; Medicine; Stem cell; Genetics; Cancer; Gene; Carcinogenesis","score_opus":0.00940533670119168,"score_gpt":0.24437811980038857,"score_spread":0.2349727830991969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980113071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949115,0.001720978,9.2193596e-7,0.00072748575,0.000025075227,0.00082004943,0.000013188901,0.000090123955,0.0016907114],"genre_scores_gemma":[0.9957524,0.000046920897,0.00044268405,0.00006051615,0.00020949305,0.000086907,0.00002823971,0.000047373305,0.0033254453],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983201,0.00005112511,0.00033228408,0.00041442027,0.00038324884,0.00049881736],"domain_scores_gemma":[0.99935496,0.00002607544,0.000067210654,0.00032859776,0.00008633935,0.00013680916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015845217,0.000216502,0.0003289925,0.00020147613,0.00009501862,0.000045532004,0.00011880679,0.00012344793,0.000065809174],"category_scores_gemma":[0.000054193537,0.0001548669,0.000048014605,0.00028087798,0.00013575637,0.00012242919,0.00016654292,0.00036222863,0.00003140024],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004362294,0.0012412537,0.08748628,0.00082395703,0.000027153585,0.0007370659,0.00038298863,0.0000059101544,0.90785843,0.0000059688464,0.00076983497,0.00022493917],"study_design_scores_gemma":[0.008678689,0.00016893882,0.20942585,0.00043776445,0.000067178466,0.00021648717,0.000058086327,0.0006981915,0.77968806,0.000014180625,0.00036513925,0.00018143238],"about_ca_topic_score_codex":0.00024264576,"about_ca_topic_score_gemma":0.000026625557,"teacher_disagreement_score":0.12817036,"about_ca_system_score_codex":0.00007413337,"about_ca_system_score_gemma":0.00012289993,"threshold_uncertainty_score":0.63152885},"labels":[],"label_agreement":null},{"id":"W2980116131","doi":"10.1182/blood.v114.22.526.526","title":"Comparable Disease-Free and Overall Survival After “Well-Matched” Unrelated Donor and Matched Sibling Donor Transplantation in Acute Myeloid Leukemia with Adverse Risk Karyotype in First Complete Remission: A Report From the Acute Leukemia Working Committee of the Centre for International Blood and Marrow Transplant Research.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Internal medicine; Myeloid leukemia; Medicine; Oncology; Transplantation; Hematopoietic stem cell transplantation; Gastroenterology","score_opus":0.0211312943778187,"score_gpt":0.26708225049304873,"score_spread":0.24595095611523005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980116131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99253595,0.00069888466,0.000044031312,0.0043727458,0.000070619004,0.0015758777,0.0005010651,0.000028225024,0.00017261517],"genre_scores_gemma":[0.994452,0.0032112428,0.0014960347,0.0001454565,0.000106022504,0.000059683764,0.00031142877,0.000040014274,0.00017812294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970891,0.0003007128,0.0006869927,0.00065568887,0.0007279919,0.0005395093],"domain_scores_gemma":[0.99762076,0.0010500283,0.00023416859,0.0006195663,0.00023287063,0.00024262628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011547838,0.00032452084,0.00059038267,0.0002349577,0.00023370651,0.000069408095,0.00037966314,0.0001839826,0.000022528415],"category_scores_gemma":[0.00020097598,0.00021182079,0.00008600589,0.00047691623,0.00031856092,0.0001915663,0.00012163178,0.0010008583,6.934911e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015355406,0.000249374,0.97241485,0.00019553442,0.0007236388,0.0017623841,0.0041976003,0.0001558877,0.0044798832,0.000029550702,0.00026560272,0.00017030464],"study_design_scores_gemma":[0.027086455,0.00022096962,0.9618329,0.0023287479,0.0013526545,0.00032546418,0.00049487577,0.003846232,0.0012842477,0.0005522021,0.0003959117,0.00027933388],"about_ca_topic_score_codex":0.0018258974,"about_ca_topic_score_gemma":0.0033194178,"teacher_disagreement_score":0.011731049,"about_ca_system_score_codex":0.00025808936,"about_ca_system_score_gemma":0.00045371335,"threshold_uncertainty_score":0.86378014},"labels":[],"label_agreement":null},{"id":"W2980133902","doi":"10.1182/blood.v118.21.1717.1717","title":"Immunosuppressive Treatment for Patients with Myelodysplastic Syndromes: A Review of 358 Patients","year":2011,"lang":"en","type":"review","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Alemtuzumab; Clinical trial; Myelodysplastic syndromes; Daclizumab; Eltrombopag; Internal medicine; Transplantation; Oncology; Tacrolimus","score_opus":0.042072958654804544,"score_gpt":0.32577499875524807,"score_spread":0.28370204010044353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980133902","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030045497,0.98760027,0.0000052837336,0.0000052198466,0.000093474766,0.010283534,0.0010256284,0.00003342873,0.00065271056],"genre_scores_gemma":[0.000020856567,0.9928059,0.0008083625,0.00003410678,0.00006626154,0.002249456,0.0032396468,0.00017138229,0.00060401874],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969954,0.00014725712,0.0010787223,0.00066478306,0.00054802746,0.0005658307],"domain_scores_gemma":[0.9965205,0.00041869842,0.0009181707,0.0010716241,0.0008232303,0.00024774266],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013954708,0.0007392151,0.003799441,0.0002944778,0.000060269107,0.000009018735,0.0003669723,0.00030713322,0.00020005573],"category_scores_gemma":[0.00051366276,0.00043013913,0.00078722724,0.00039644397,0.000129175,0.00006421305,0.00011982929,0.00031148616,0.000091674636],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026864442,0.0057518515,0.00048105785,0.47775188,0.004374922,0.000042292584,0.00006015371,3.974103e-9,6.1527146e-8,0.0000139197955,0.001265255,0.50999],"study_design_scores_gemma":[0.009918312,0.007895393,0.0002561919,0.323189,0.016643392,0.000054439282,0.0000023737,1.12683566e-7,0.0000037033728,0.0000019056722,0.6416895,0.0003457235],"about_ca_topic_score_codex":0.000021405946,"about_ca_topic_score_gemma":7.8822546e-7,"teacher_disagreement_score":0.6404242,"about_ca_system_score_codex":0.00044058255,"about_ca_system_score_gemma":0.0014315387,"threshold_uncertainty_score":0.99981505},"labels":[],"label_agreement":null},{"id":"W2980145352","doi":"10.1182/blood.v114.22.325.325","title":"Classification of Acute Myeloid Leukemia (AML) Based On Apoptosis and Myeloid Signaling Networks.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Cancer research; Myeloid; Biology; Signal transduction; Immunology; Leukemia; Medicine; Cell biology","score_opus":0.018189904617942815,"score_gpt":0.27384785418803925,"score_spread":0.25565794957009647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980145352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910153,0.00022086246,0.0018581166,0.0018117148,0.0000466407,0.00055896566,0.000011699281,0.0001091079,0.004367597],"genre_scores_gemma":[0.9940162,0.00024029794,0.0040653776,0.0010139374,0.0002581501,0.000022813201,0.00008812704,0.000036083315,0.00025905488],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980781,0.00008561373,0.000418083,0.00045661017,0.00052524,0.00043632102],"domain_scores_gemma":[0.9986651,0.00018866264,0.00016081844,0.00055416225,0.00017788932,0.00025339334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004416784,0.00024235762,0.00044622517,0.00027848667,0.000105346946,0.00002970928,0.00017455823,0.00023087242,0.000057771158],"category_scores_gemma":[0.00011521462,0.00021499717,0.00011979704,0.0005014256,0.00012039401,0.00008757745,0.000032928325,0.0004725552,0.000016856804],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011381629,0.00079585984,0.009768233,0.00011362732,0.00036098657,0.00005251794,0.00016647056,0.0005532784,0.9542575,0.000510226,0.0017295392,0.030553585],"study_design_scores_gemma":[0.017035313,0.0038021496,0.17452641,0.00066459214,0.0016434771,0.00009476671,0.00016565078,0.1012731,0.69896144,0.00019508487,0.0009850848,0.0006529654],"about_ca_topic_score_codex":0.000021377535,"about_ca_topic_score_gemma":8.2807566e-7,"teacher_disagreement_score":0.2552961,"about_ca_system_score_codex":0.00022787627,"about_ca_system_score_gemma":0.00036830385,"threshold_uncertainty_score":0.876733},"labels":[],"label_agreement":null},{"id":"W2980226374","doi":"10.1182/blood.v126.23.802.802","title":"Mutational and Transcriptomic Landscape of AML with Core-Binding Factor Rearrangements","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Core binding factor; Biology; RUNX1; NPM1; Neuroblastoma RAS viral oncogene homolog; Gene; Genetics; Sanger sequencing; Mutation; Transcriptome; Cancer research; Gene expression; Transcription factor; Chromosome; KRAS","score_opus":0.049539934073913806,"score_gpt":0.2983059213550274,"score_spread":0.24876598728111363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980226374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967339,0.00015815545,0.000037190384,0.00016652497,0.000017885857,0.00021519535,0.000035285942,0.000021017759,0.0026148404],"genre_scores_gemma":[0.99792814,0.000012518586,0.0013706287,0.000038892777,0.000046019988,0.000007970672,0.000041510026,0.000014119655,0.0005401769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992884,0.0000129378695,0.00010866377,0.00012947184,0.00032175146,0.00013876824],"domain_scores_gemma":[0.99959046,0.00002657873,0.000033364606,0.00010347897,0.00010108119,0.00014504256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010414392,0.00007125263,0.00015541584,0.00009203894,0.000018293402,0.0000068407376,0.00004423546,0.000038816306,0.00007625869],"category_scores_gemma":[0.000040260213,0.00005235238,0.000017115279,0.00010898094,0.000059436312,0.0000496514,0.00001310407,0.0001006318,0.00001230869],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013086399,0.0005023198,0.85115415,0.00024305952,0.0005355819,0.00022421163,0.0034231371,0.0000021341086,0.13864055,0.00014466696,0.0023589958,0.0014625444],"study_design_scores_gemma":[0.08799007,0.004102577,0.78007627,0.00044740326,0.00085033884,0.0011694768,0.0032928025,0.0006204827,0.1181515,0.00016685322,0.002650311,0.00048191648],"about_ca_topic_score_codex":0.000028811057,"about_ca_topic_score_gemma":0.00000914953,"teacher_disagreement_score":0.086681426,"about_ca_system_score_codex":0.00002625837,"about_ca_system_score_gemma":0.00019023944,"threshold_uncertainty_score":0.21348682},"labels":[],"label_agreement":null},{"id":"W2980237789","doi":"10.1182/blood.v126.23.1638.1638","title":"Fishing with a Transgenic Line: Using Zebrafish to Elucidate Mechanisms and Therapeutics in NUP98-NSD1 AML","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Zebrafish; Biology; Cancer research; Myeloproliferative neoplasm; Myeloid leukemia; Myeloid; Genetics; Gene; Immunology; Myelofibrosis; Bone marrow","score_opus":0.054046360722011764,"score_gpt":0.3128327379445687,"score_spread":0.25878637722255693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980237789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912508,0.00020825678,0.0047846246,0.00264109,0.000027692407,0.000587543,0.0000073795095,0.00005420243,0.00043838084],"genre_scores_gemma":[0.97228664,0.000032609,0.025744738,0.0015993908,0.00010380428,0.00001895351,0.000007826755,0.000053923497,0.00015211939],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985895,0.000061540355,0.0002064437,0.00032527337,0.00039984845,0.00041738115],"domain_scores_gemma":[0.9991855,0.000043705484,0.00003313076,0.0002977807,0.00010735521,0.0003325014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046462874,0.00017102208,0.0003007807,0.00019602227,0.0000403208,0.00005166127,0.00012796801,0.00011263455,0.000014093701],"category_scores_gemma":[0.000054834756,0.00013641198,0.00002873145,0.00044433158,0.000042074756,0.0001204798,0.00006135827,0.00036834495,0.000012051343],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038871688,0.002079596,0.030570477,0.00050463044,0.0011032848,0.0021693152,0.02089184,0.0004635932,0.9236242,0.0005966402,0.00060397695,0.013505278],"study_design_scores_gemma":[0.10844447,0.011206098,0.021360684,0.0021617236,0.0024999275,0.0036266884,0.007489864,0.025797207,0.80217457,0.0032689262,0.009649594,0.0023202316],"about_ca_topic_score_codex":0.00021351571,"about_ca_topic_score_gemma":0.00025446084,"teacher_disagreement_score":0.12144961,"about_ca_system_score_codex":0.000120907556,"about_ca_system_score_gemma":0.0003926821,"threshold_uncertainty_score":0.5562719},"labels":[],"label_agreement":null},{"id":"W2980263526","doi":"10.1182/blood.v108.11.2349.2349","title":"Molecular Characterization of Distinct Hot Spot Regions on Chromosome 7q in Myeloid Leukemias.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Biology; Chromosomal translocation; Breakpoint; Genetics; Myeloid leukemia; Fluorescence in situ hybridization; Chromosome; Myeloid; Chromosome regions; Chromosome 7 (human); Comparative genomic hybridization; Candidate gene; Molecular biology; Gene; Cancer research","score_opus":0.012320525303801955,"score_gpt":0.2523666776143828,"score_spread":0.24004615231058085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980263526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907716,0.00005497957,0.00011069971,0.0006835321,0.00003492425,0.00046704017,0.000032924345,0.00005172939,0.007792596],"genre_scores_gemma":[0.9981405,0.000035583198,0.00014890872,0.00016278014,0.0001822857,0.00004019643,0.00038366817,0.000041998235,0.00086404104],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849683,0.00006423062,0.00036949848,0.00031430987,0.00041992613,0.00033521003],"domain_scores_gemma":[0.9991944,0.000052143263,0.00010663182,0.0004622036,0.00009194507,0.00009266537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017537891,0.00016937623,0.00034299833,0.0002973933,0.000033120272,0.000010688965,0.00014282108,0.00013810639,0.000068811314],"category_scores_gemma":[0.00012718106,0.00015723314,0.00008768036,0.0005483451,0.00009801134,0.00006110292,0.00005263562,0.00031277814,0.000061077204],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018438809,0.00092283933,0.012404501,0.000112766866,0.00003476862,0.00056001375,0.000056705823,0.0000067590254,0.98366964,0.0013389571,0.0003018572,0.00040681916],"study_design_scores_gemma":[0.0054968107,0.00040769044,0.41358072,0.00026120254,0.00008080117,0.00010257634,0.000014470319,0.00015289504,0.5777017,0.00008783222,0.0019362938,0.00017702102],"about_ca_topic_score_codex":0.00024596773,"about_ca_topic_score_gemma":0.00002251284,"teacher_disagreement_score":0.40596792,"about_ca_system_score_codex":0.00023172746,"about_ca_system_score_gemma":0.00027999445,"threshold_uncertainty_score":0.64117813},"labels":[],"label_agreement":null},{"id":"W2980289955","doi":"10.1182/blood.v128.22.2886.2886","title":"Utility of Next Generation Sequencing in Prognostication and Therapeutic Decision Making in Cytogenetically Normal AML with DNMT3A Mutations","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"CEBPA; NPM1; DNA sequencing; Sanger sequencing; Myeloid leukemia; Biology; Oncology; Genetics; Bioinformatics; Computational biology; Internal medicine; Medicine; Gene; Karyotype; Mutation; Chromosome","score_opus":0.06727627985738448,"score_gpt":0.3194251479342947,"score_spread":0.2521488680769102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980289955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99027544,0.00016237776,0.008585545,0.00024241331,0.0000062725526,0.00048860686,0.0000030129922,0.00001045651,0.00022588961],"genre_scores_gemma":[0.9879041,0.00004290662,0.011926836,0.000040359875,0.000027938688,0.00003305775,0.0000053890017,0.000011088055,0.000008336806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905795,0.00006716565,0.0002628885,0.00020948134,0.00022958902,0.0001729416],"domain_scores_gemma":[0.9993538,0.000258544,0.000049892507,0.00017545445,0.00011733238,0.00004493666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032034022,0.000077353616,0.00014395932,0.00018002579,0.000024316876,0.000011078121,0.000047328293,0.0000641844,0.000028899303],"category_scores_gemma":[0.00031051858,0.000050901905,0.000012793597,0.00027063992,0.00009975694,0.00008892688,0.00002752079,0.00009879202,0.0000027668425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020450153,0.00014087978,0.5346378,0.00003840432,0.000017262748,0.00002681025,0.0004416306,0.000013390286,0.3822515,0.00016277602,0.0000011029564,0.08206393],"study_design_scores_gemma":[0.004286384,0.00033036128,0.9060948,0.00043997882,0.000057406953,0.00008423031,0.00013529554,0.011873554,0.076304965,0.00030346971,0.0000052226565,0.00008437394],"about_ca_topic_score_codex":0.000044530974,"about_ca_topic_score_gemma":0.0003911462,"teacher_disagreement_score":0.37145695,"about_ca_system_score_codex":0.00009545951,"about_ca_system_score_gemma":0.00039306516,"threshold_uncertainty_score":0.20757194},"labels":[],"label_agreement":null},{"id":"W2980383141","doi":"10.1182/blood.v118.21.834.834","title":"Influence of Cytogenetic, Molecular Abnormalities and Other Risk Factors on the Outcomes of Children with Acute Myelogenous Leukemia Given An Unrelated Cord Blood Transplantation. A Survey on Behalf of Eurocord, ALWP and PDWP of EBMT","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Internal medicine; Transplantation; Leukemia; Cord blood; Busulfan; Gastroenterology; Oncology; Surgery; Hematopoietic stem cell transplantation","score_opus":0.023335814333689333,"score_gpt":0.25571999136478746,"score_spread":0.23238417703109812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980383141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978905,0.00013159584,0.0000118095395,0.000008659613,0.0000037516966,0.0007142379,0.0010575273,0.000012253566,0.00016971101],"genre_scores_gemma":[0.9991126,0.00045725045,0.00027937794,0.000040531802,0.000003190004,0.000009885951,0.000042100368,0.00003878312,0.000016295287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983089,0.000325074,0.00044425062,0.00026996437,0.0004316662,0.00022013602],"domain_scores_gemma":[0.998544,0.00031606772,0.00035972957,0.0004552781,0.00022157311,0.0001033533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038022074,0.00023659904,0.0005605821,0.00017721506,0.000044266642,0.0000040778787,0.0002052966,0.000119867495,0.000016749178],"category_scores_gemma":[0.00009567169,0.0001471538,0.000058512716,0.00021629356,0.0005576684,0.00004738725,0.00003536076,0.00024362274,4.2724844e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015506658,0.00051580375,0.96393526,0.000088345856,0.0022863057,0.000033703825,0.004036332,0.00006484292,0.027325083,0.00008666081,9.984418e-7,0.00007603074],"study_design_scores_gemma":[0.0032083574,0.0037787508,0.6750856,0.000080261045,0.0011072301,0.000060538376,0.00013076687,0.0000040672535,0.3164397,0.000014813555,2.1297043e-7,0.000089675064],"about_ca_topic_score_codex":0.0107039,"about_ca_topic_score_gemma":0.00022472712,"teacher_disagreement_score":0.28911462,"about_ca_system_score_codex":0.000013593739,"about_ca_system_score_gemma":0.00018768864,"threshold_uncertainty_score":0.9958839},"labels":[],"label_agreement":null},{"id":"W2980508820","doi":"10.1182/blood-2018-99-111030","title":"Chemogenomic Approach Unveils the Increased Susceptibility of RUNX1-Mutated AML to Glucocorticoids","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"RUNX1; Biology; Transcriptome; Myeloid; Core binding factor; Glucocorticoid receptor; Leukemia; Allele; Myeloid leukemia; Cancer research; Gene; Genetics; Transcription factor; Gene expression","score_opus":0.019347517583490445,"score_gpt":0.2836708683690674,"score_spread":0.26432335078557695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980508820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989483,0.000057050507,0.00013661348,0.00083429215,0.00003550491,0.0013023341,0.000021180409,0.00007391982,0.008056083],"genre_scores_gemma":[0.9956065,0.0000074480804,0.0028246697,0.0005336751,0.00036461046,0.000062076266,0.00003591671,0.000038412112,0.0005266907],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998082,0.00013305199,0.00041534906,0.000430872,0.00045006516,0.0004886814],"domain_scores_gemma":[0.9979737,0.00012516491,0.00009021537,0.0011268483,0.00037541467,0.0003086615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089265214,0.00018840004,0.0003999051,0.0001226778,0.000104367515,0.000017407698,0.00039684697,0.000121604215,0.00028404355],"category_scores_gemma":[0.00068967894,0.00012553057,0.00012112145,0.0006800831,0.00049057644,0.00003875164,0.00022157172,0.0002311972,0.00022885797],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000755891,0.001337643,0.0488785,0.00014918047,0.00030665693,0.00002104014,0.0011044999,0.0000014734114,0.94318944,0.00008823644,0.0024581729,0.0017092375],"study_design_scores_gemma":[0.006600176,0.001150617,0.20098574,0.00003751888,0.00032651026,0.00013300324,0.0005098613,0.00042317505,0.78800184,0.00007826134,0.0015528551,0.00020042088],"about_ca_topic_score_codex":0.0006513218,"about_ca_topic_score_gemma":0.000043746426,"teacher_disagreement_score":0.15518762,"about_ca_system_score_codex":0.00016383153,"about_ca_system_score_gemma":0.0005864392,"threshold_uncertainty_score":0.51189876},"labels":[],"label_agreement":null},{"id":"W2980543393","doi":"10.1182/blood.v122.21.2609.2609","title":"Disease Characteristics and Prognostic Implications Of Cell Surface FLT3 Receptor (CD135) Expression In Pediatric Acute Myeloid Leukemia – A Report From Children’s Oncology Group","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Oncology; Myeloid leukemia; Medicine; Population; Internal medicine; Leukemia; Cancer research; Immunology","score_opus":0.00988660560107224,"score_gpt":0.2616738076224849,"score_spread":0.25178720202141264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980543393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962933,0.00060338835,0.00007415517,0.00070147373,0.000060942446,0.0017096469,0.00022642889,0.000056549983,0.0002740963],"genre_scores_gemma":[0.98973805,0.0015574174,0.0068625477,0.00007886305,0.00028035554,0.00018389364,0.0010042301,0.000048551006,0.00024611907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790525,0.00012130057,0.00067216175,0.0005803081,0.0003022215,0.00041873424],"domain_scores_gemma":[0.9979707,0.00033718397,0.00033691677,0.0006664643,0.000201469,0.00048724507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021804507,0.00023341249,0.00052345276,0.00017373126,0.0000638288,0.000023298968,0.00019913532,0.000217067,0.00017198907],"category_scores_gemma":[0.00050446676,0.00020550913,0.00007357197,0.00032669373,0.00011283461,0.00014330707,0.00023493919,0.00046389707,0.0000663794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011409014,0.00076452084,0.7660224,0.00008863004,0.00004438024,0.0001394157,0.00016186183,3.816744e-7,0.23062117,0.0000038739295,0.0015319302,0.000507364],"study_design_scores_gemma":[0.0036570013,0.00026438772,0.98636246,0.00006115184,0.00047878,0.00009746431,0.000036053498,0.000050011397,0.008613384,0.000071944705,0.00012349257,0.0001838551],"about_ca_topic_score_codex":0.00042886502,"about_ca_topic_score_gemma":0.000010933441,"teacher_disagreement_score":0.2220078,"about_ca_system_score_codex":0.000292336,"about_ca_system_score_gemma":0.00089288095,"threshold_uncertainty_score":0.8380419},"labels":[],"label_agreement":null},{"id":"W2980861407","doi":"10.1182/blood.v122.21.2893.2893","title":"ALDH Genes and Reactive Aldehydes Play Important Roles in HSCs and Leukemia and May Be Exploited to Treat AML","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Leukemia; Acute leukemia; Biology; Cancer research; Haematopoiesis; Reactive oxygen species; Cell biology; DNA damage; Signal transduction; Chemistry; Stem cell; Biochemistry; Immunology; DNA","score_opus":0.017682094776624285,"score_gpt":0.2742593570421745,"score_spread":0.2565772622655502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980861407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936267,0.002584233,0.0000022945846,0.0022077777,0.000010433944,0.00080323406,0.000020050304,0.000041681862,0.0007035754],"genre_scores_gemma":[0.9952195,0.0020919219,0.0011553838,0.0005100406,0.00009041008,0.00014437403,0.000022098528,0.00003912821,0.0007271088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985778,0.000052823983,0.0002729683,0.0004644683,0.00023414243,0.00039784054],"domain_scores_gemma":[0.99905753,0.00017362635,0.000050616625,0.0002622868,0.0000722443,0.0003836796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020372805,0.00022534674,0.00039626512,0.00026776502,0.00006243155,0.000061221705,0.000067341905,0.00014497418,0.000043976725],"category_scores_gemma":[0.00016245073,0.00017738079,0.000022862088,0.00020713684,0.00014653824,0.00019123613,0.00015875121,0.00024049116,0.000009840025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028528602,0.00022056577,0.5358993,0.00013860645,0.00014725284,0.00046680684,0.003417813,5.8958125e-7,0.44234195,0.000072304996,0.0022020137,0.014807508],"study_design_scores_gemma":[0.013532483,0.0012070802,0.72369486,0.00028035472,0.0002832799,0.0009919527,0.005776862,0.00031407326,0.25044426,0.00020289994,0.00274315,0.00052874186],"about_ca_topic_score_codex":0.002375745,"about_ca_topic_score_gemma":0.00037768844,"teacher_disagreement_score":0.19189769,"about_ca_system_score_codex":0.00012434824,"about_ca_system_score_gemma":0.00014677027,"threshold_uncertainty_score":0.7233379},"labels":[],"label_agreement":null},{"id":"W2980978150","doi":"10.1182/blood-2018-99-115323","title":"Identification of Compounds That Target Acute Myeloid Leukemia Stem Cells Using a Scalable Next-Generation Screening Platform","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Stem cell; Gene signature; Haematopoiesis; Minimal residual disease; Progenitor cell; Cancer research; Transplantation; Population; Medicine; Leukemia; Druggability; Immunology; Biology; Internal medicine; Gene expression; Gene; Genetics","score_opus":0.0802634306510698,"score_gpt":0.30208179351234576,"score_spread":0.22181836286127596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980978150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98584044,0.0001835631,0.012448643,0.00007777866,0.00018704095,0.00056782836,0.000033689194,0.00007902571,0.0005820058],"genre_scores_gemma":[0.98185784,0.000058265967,0.016104665,0.000091565824,0.00067570375,0.000016037504,0.00009632148,0.000055009474,0.0010445914],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978339,0.000054724136,0.0005468185,0.00042353023,0.00069124566,0.00044976315],"domain_scores_gemma":[0.99846315,0.000053018513,0.00029813187,0.00058375177,0.00042366737,0.00017826205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006771587,0.00021503733,0.00040060133,0.00028080924,0.0002554184,0.000103693295,0.00023400797,0.0001978287,0.000088502704],"category_scores_gemma":[0.000024199706,0.00020314683,0.00011285245,0.0004904431,0.00021856242,0.00052514876,0.00012877546,0.0002816408,0.00007553142],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012616151,0.00012518387,0.0037333404,0.000082775936,0.0002572717,0.000019684918,0.000331687,0.000045283996,0.99319243,0.000046250247,0.0008759923,0.0011639126],"study_design_scores_gemma":[0.0027574827,0.00020057327,0.0010809781,0.00009820837,0.00033262616,0.00012188083,0.00024569323,0.07898029,0.91563535,0.000021332813,0.00035819717,0.00016738885],"about_ca_topic_score_codex":0.00015344375,"about_ca_topic_score_gemma":0.000011132327,"teacher_disagreement_score":0.078935005,"about_ca_system_score_codex":0.00038347952,"about_ca_system_score_gemma":0.0005162375,"threshold_uncertainty_score":0.8284088},"labels":[],"label_agreement":null},{"id":"W2981123209","doi":"10.1182/blood.v122.21.2491.2491","title":"A Single Nucleotide Polymorphism Of Growth Factor Independence 1 (GFI136N) is a Novel Prognostic Marker For The Progression Of Myelodysplastic Syndrome To Acute Myeloid Leukemia","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Myeloid leukemia; Single-nucleotide polymorphism; Internal medicine; Myeloid; Myelodysplastic syndromes; Biology; SNP; Immunology; Oncology; Odds ratio; Hematology; Medicine; Cancer research; Genotype; Bone marrow; Genetics; Gene","score_opus":0.01940704259718913,"score_gpt":0.2715511009333244,"score_spread":0.2521440583361353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981123209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99137574,0.00025834414,0.0014867135,0.0016658587,0.00012213114,0.0045852675,0.00023630798,0.00006240608,0.00020723486],"genre_scores_gemma":[0.9893119,0.00003282498,0.008747417,0.00032574785,0.000104088154,0.000678956,0.00001913483,0.0000917141,0.0006882575],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99688405,0.000048209844,0.000692086,0.0005552438,0.0010910251,0.0007293598],"domain_scores_gemma":[0.9968417,0.0009566373,0.00031444692,0.0007231921,0.0008015985,0.00036242435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003306251,0.0003558764,0.0006989665,0.0003087317,0.00011897312,0.000041002455,0.00059521524,0.00024072785,0.00031979365],"category_scores_gemma":[0.001154557,0.00023607755,0.00022560856,0.0006838815,0.0002775792,0.00020880337,0.00033957168,0.00043558492,0.0000896444],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078343146,0.001500025,0.039396808,0.00093286036,0.0011794656,0.00007353853,0.0010197015,0.0000016466765,0.9483964,0.00009993337,0.0017686686,0.004847533],"study_design_scores_gemma":[0.011631513,0.0061157173,0.61536723,0.0019385879,0.0016780898,0.0012396079,0.00031556285,0.0015029383,0.35886613,0.00012802318,0.00061939744,0.0005972223],"about_ca_topic_score_codex":0.00029079692,"about_ca_topic_score_gemma":0.0000063183606,"teacher_disagreement_score":0.5895303,"about_ca_system_score_codex":0.00018053669,"about_ca_system_score_gemma":0.00081393565,"threshold_uncertainty_score":0.9626963},"labels":[],"label_agreement":null},{"id":"W2981158858","doi":"10.1182/blood-2018-99-111304","title":"Chemogenomic Profiling of Complex Karyotype AML Reveals a Novel Susceptibility to G2/M Checkpoint Inhibition Mediated By HMGA2 Overexpression","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"Transcriptome; Biology; Gene expression profiling; Cancer research; NPM1; Myeloid leukemia; HMGA2; Karyotype; Gene signature; CEBPA; Leukemia; Gene; Oncology; Internal medicine; Genetics; Medicine; Gene expression; microRNA; Mutation; Chromosome","score_opus":0.034635431480898156,"score_gpt":0.3069147900190483,"score_spread":0.27227935853815016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981158858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99525726,0.00005010312,0.00041399224,0.000662481,0.000038347418,0.001343565,0.0002225737,0.00008948357,0.0019221724],"genre_scores_gemma":[0.9879576,0.000010023991,0.010481697,0.00044045525,0.00031629097,0.000039304545,0.000439653,0.000047882957,0.00026711117],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977541,0.00007206705,0.00060769235,0.0005471824,0.00054720376,0.00047175935],"domain_scores_gemma":[0.99821806,0.000110314,0.00018210983,0.0006652456,0.00048943085,0.00033486963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007652198,0.0002229819,0.0004950241,0.00015841538,0.00008583849,0.000013362367,0.00016721607,0.00019443082,0.0005030791],"category_scores_gemma":[0.0009769954,0.00019509894,0.00010397574,0.00045510352,0.00021596115,0.000081170445,0.00025223196,0.00030052365,0.00020585168],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006022926,0.0008941895,0.009750461,0.00020378617,0.00006455402,0.000005691419,0.00028964336,2.832922e-7,0.9824868,0.000017949524,0.005527275,0.00015708766],"study_design_scores_gemma":[0.00567597,0.0009500812,0.02894014,0.000326281,0.00006990532,0.000033451062,0.00009576863,0.00019645724,0.96310085,0.000044026845,0.00038716898,0.0001799215],"about_ca_topic_score_codex":0.00017368344,"about_ca_topic_score_gemma":0.000013651936,"teacher_disagreement_score":0.019385956,"about_ca_system_score_codex":0.0002635878,"about_ca_system_score_gemma":0.0002890117,"threshold_uncertainty_score":0.7955904},"labels":[],"label_agreement":null},{"id":"W2981288534","doi":"10.1182/blood-2018-99-119417","title":"Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-Transplantation Cyclophosphamide and Anti-Thymocyte Globulin As Graft Versus Host Disease Prophylaxis","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Busulfan; Anti-thymocyte globulin; Fludarabine; Transplantation; Cyclophosphamide; Cumulative incidence; Internal medicine; Hematopoietic stem cell transplantation; Graft-versus-host disease; Myelofibrosis; Myeloid; Total body irradiation; Gastroenterology; Surgery; Immunology; Chemotherapy; Bone marrow","score_opus":0.0136670454168724,"score_gpt":0.27249140455245946,"score_spread":0.25882435913558705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981288534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954157,0.0014985524,0.0008249686,0.00014857017,0.00011778339,0.0014860461,0.00037723788,0.000056253735,0.000074888376],"genre_scores_gemma":[0.9942351,0.0023006673,0.0028739627,0.000057441266,0.00019434936,0.000023965129,0.00016080703,0.000055123684,0.00009859339],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99797213,0.00008459161,0.000488864,0.00053660764,0.0004655171,0.000452268],"domain_scores_gemma":[0.99860245,0.0002730251,0.00012899347,0.00025684692,0.00037430326,0.00036435766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026797192,0.00028867243,0.00044580558,0.00015036049,0.00023889857,0.000055001536,0.000109772314,0.00016060002,0.00002046825],"category_scores_gemma":[0.000092865834,0.0002669843,0.00011214178,0.00023498353,0.000465161,0.000212745,0.000034901354,0.00018277307,0.0000045227303],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04499527,0.0012841489,0.048426878,0.0049777087,0.0005062526,0.00067872,0.0036898595,0.000015302352,0.8928938,0.00024680924,0.0000045165075,0.0022807585],"study_design_scores_gemma":[0.04626578,0.004348855,0.5471506,0.00053694425,0.003450482,0.0003821768,0.0004771913,0.00046172715,0.39641014,0.000013525331,0.000059622333,0.00044290844],"about_ca_topic_score_codex":0.00020095726,"about_ca_topic_score_gemma":0.000030896394,"teacher_disagreement_score":0.49872378,"about_ca_system_score_codex":0.0000617831,"about_ca_system_score_gemma":0.00040294172,"threshold_uncertainty_score":0.99997824},"labels":[],"label_agreement":null},{"id":"W2981305723","doi":"10.1182/blood-2018-99-114525","title":"Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of Mitochondrial Vulnerability in Acute Myeloid Leukemia","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Myeloid leukemia; Leukemia; Stem cell; Biology; Cancer research; Ex vivo; Immunology; Medicine; In vivo; Genetics","score_opus":0.017556859661834325,"score_gpt":0.2884165497073718,"score_spread":0.27085969004553745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981305723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924784,0.00042422107,0.00002893359,0.0031059205,0.000060604358,0.0011323807,0.000046671426,0.000029866616,0.0026930547],"genre_scores_gemma":[0.99768,0.00018465047,0.0005584416,0.00045523082,0.00061227096,0.000068794485,0.00004608724,0.000027633456,0.00036687675],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979409,0.00025714363,0.00046614258,0.0003840881,0.00043995734,0.0005117954],"domain_scores_gemma":[0.99869037,0.00030534432,0.00010127919,0.00063338963,0.0001580471,0.00011156921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011133496,0.00019518888,0.0004742539,0.00008892079,0.0001577885,0.000013629196,0.0003156296,0.00013863055,0.00018853854],"category_scores_gemma":[0.00022249192,0.00011211655,0.00009781284,0.0003956667,0.0006195571,0.000054757686,0.00006983581,0.0006208822,0.000009940072],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003245749,0.0007903336,0.20249489,0.00029196206,0.00068931986,0.00016352757,0.0054215463,0.0000025612078,0.7732957,0.0006582818,0.009805786,0.0031403254],"study_design_scores_gemma":[0.01565616,0.0019869627,0.86908674,0.00012871873,0.0004834888,0.00041825252,0.00045834793,0.00045968886,0.104967326,0.0006348183,0.0054173972,0.00030207343],"about_ca_topic_score_codex":0.000269735,"about_ca_topic_score_gemma":0.0003366977,"teacher_disagreement_score":0.6683284,"about_ca_system_score_codex":0.00009632219,"about_ca_system_score_gemma":0.00039353693,"threshold_uncertainty_score":0.45719802},"labels":[],"label_agreement":null},{"id":"W2982464227","doi":"10.1158/2159-8290.cd-18-1463","title":"Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene–Driven Myeloid Leukemia","year":2019,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Gertrude von Meissner-Stiftung; Institut Gustave-Roussy; Cancéropôle Ile de France; Fondation de France; Fondation pour la Recherche Médicale; Blood Cancer UK; Institut National Du Cancer; Institut National de la Santé et de la Recherche Médicale; Novartis Foundation; Association Laurette Fugain; Health Research Foundation; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Direction Générale de l’offre de Soins; National Science Foundation","keywords":"Biology; Myeloid leukemia; Phenotype; Cancer research; Myeloid; Haematopoiesis; Oncogene; Fusion gene; Oncogene Proteins; Leukemia; Transcriptome; GATA1; Stem cell; Immunology; Genetics; Cell cycle; Regulation of gene expression; Gene; Gene expression","score_opus":0.019141414620229894,"score_gpt":0.2808454084909132,"score_spread":0.2617039938706833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982464227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899805,0.006805625,0.000013906511,0.0012906239,0.00023409238,0.0010804419,0.000059766804,0.000030787167,0.0005042475],"genre_scores_gemma":[0.98777395,0.008436446,0.000073973504,0.0005412915,0.0005424053,0.00014152989,0.00004552161,0.00005758051,0.0023873027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977523,0.00008847423,0.00035360403,0.0007065981,0.00046796008,0.00063105236],"domain_scores_gemma":[0.9987693,0.00013265718,0.00009437376,0.00053942145,0.000051471445,0.0004127796],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023002643,0.00029334467,0.00055389194,0.00051241275,0.000042343425,0.00004881996,0.00020613315,0.00013933954,0.00034642345],"category_scores_gemma":[0.0001100932,0.00026219277,0.00008283263,0.00068653293,0.000101403304,0.00029407727,0.00028627025,0.00051787565,0.000069346715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013654028,0.0001214499,0.97246957,0.0008725291,0.000021143655,0.00037207364,0.0005750643,0.00014067435,0.018781437,0.00007020426,0.00038255975,0.0048278915],"study_design_scores_gemma":[0.00627169,0.0002609693,0.9861811,0.00050751993,0.000106059604,0.000022126173,0.00027179884,0.0021784413,0.0022584994,0.00031687244,0.0011257817,0.0004991852],"about_ca_topic_score_codex":0.00081823237,"about_ca_topic_score_gemma":0.002055005,"teacher_disagreement_score":0.016522937,"about_ca_system_score_codex":0.0023712758,"about_ca_system_score_gemma":0.0018527835,"threshold_uncertainty_score":0.999983},"labels":[],"label_agreement":null},{"id":"W2982555809","doi":"10.1126/scitranslmed.aax2863","title":"Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response","year":2019,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Venetoclax; Azacitidine; Cancer research; Integrated stress response; Myeloid leukemia; Pharmacology; Medicine; Chemistry; Biology; Leukemia; Translation (biology); Biochemistry; Immunology; Chronic lymphocytic leukemia; Gene; DNA methylation; Gene expression","score_opus":0.028547677512174637,"score_gpt":0.32219298013786335,"score_spread":0.2936453026256887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982555809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98041147,0.00016219512,0.00091260823,0.015908837,0.0002059252,0.0010909277,0.00002411644,0.000009348482,0.0012745758],"genre_scores_gemma":[0.99779403,0.000016587075,0.0017694664,0.00013348463,0.00007028648,0.000015323541,0.000028462144,0.000008610375,0.00016373246],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973179,0.00020106106,0.00052394625,0.00027174852,0.001478279,0.00020704359],"domain_scores_gemma":[0.99827975,0.0007568295,0.00018187096,0.00035656584,0.00038383418,0.000041157356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013142886,0.000114817594,0.00026618547,0.00027495433,0.00008054791,0.0000050929816,0.0002443312,0.000064824104,0.00013513891],"category_scores_gemma":[0.00063930603,0.000065363754,0.000059496982,0.0024631335,0.0013755267,0.00036482533,0.000013524854,0.00032463882,0.0000022619372],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043225666,0.000043134438,0.011168087,0.0001081194,0.000009840246,8.965946e-7,0.00499154,0.0006736648,0.97569793,0.0023508254,0.00006664497,0.00056675164],"study_design_scores_gemma":[0.0070989113,0.00036473197,0.6348965,0.0024173888,0.000038168724,0.000005910756,0.0013638559,0.00361191,0.34570312,0.003577542,0.00079642644,0.00012549749],"about_ca_topic_score_codex":0.00024759,"about_ca_topic_score_gemma":0.0001656902,"teacher_disagreement_score":0.6299948,"about_ca_system_score_codex":0.00029686393,"about_ca_system_score_gemma":0.0016319351,"threshold_uncertainty_score":0.50681853},"labels":[],"label_agreement":null},{"id":"W2982692810","doi":"10.1002/cncr.32552","title":"Mixed‐phenotype acute leukemia: A cohort and consensus research strategy from the Children’s Oncology Group Acute Leukemia of Ambiguous Lineage Task Force","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Agricultural Research Institute of Ontario; University of Ottawa","funders":"Children’s Oncology Group; St. Jude Children's Research Hospital; National Cancer Institute; National Institutes of Health; Children's Hospital of Philadelphia; St. Baldrick's Foundation","keywords":"Medicine; Cohort; Oncology; Internal medicine; Chemotherapy; Induction chemotherapy; Cog; Prospective cohort study; Leukemia; Hematopoietic stem cell transplantation; Myeloid leukemia; Retrospective cohort study; Transplantation","score_opus":0.037036666961161764,"score_gpt":0.3509355804911021,"score_spread":0.3138989135299403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982692810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873067,0.0038154717,0.00002909084,0.0017491251,0.0003908743,0.002251439,0.0006410586,0.00006531453,0.003750905],"genre_scores_gemma":[0.9872213,0.003961615,0.00043640955,0.00093793834,0.0006980039,0.00023230982,0.0002729728,0.00010158883,0.0061378703],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9959245,0.000472941,0.00062869175,0.0009300405,0.0010113555,0.0010324811],"domain_scores_gemma":[0.99648255,0.0010837804,0.00022437917,0.0012063654,0.0006221985,0.000380746],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013389182,0.00037788504,0.0009991397,0.00019490128,0.00021769447,0.0000516814,0.00059056573,0.00057438423,0.00056775333],"category_scores_gemma":[0.0002309185,0.00026881738,0.00015672835,0.0006243529,0.001275139,0.00009155363,0.0005012878,0.0021884637,0.00017131414],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010880386,0.00028694875,0.25652453,0.0003622394,0.00967924,0.0012678793,0.002711187,0.00024095178,0.42610484,0.0020909621,0.21955423,0.07029659],"study_design_scores_gemma":[0.016093722,0.0041327844,0.9265409,0.00052490656,0.0018134617,0.00053940975,0.0014348779,0.0043704635,0.02601353,0.0005836018,0.0171626,0.00078973494],"about_ca_topic_score_codex":0.020145621,"about_ca_topic_score_gemma":0.0010705657,"teacher_disagreement_score":0.67001635,"about_ca_system_score_codex":0.0037601723,"about_ca_system_score_gemma":0.0053807558,"threshold_uncertainty_score":0.9999764},"labels":[],"label_agreement":null},{"id":"W2982755933","doi":"10.1182/blood-2019-127253","title":"Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Decitabine; Medicine; Internal medicine; Discontinuation; Clinical endpoint; Randomization; Cytarabine; Azacitidine; Surrogate endpoint; Gastroenterology; Chemotherapy regimen; Oncology; Phases of clinical research; Chemotherapy; Randomized controlled trial; Biology","score_opus":0.015904654197551417,"score_gpt":0.33272079441835567,"score_spread":0.31681614022080423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982755933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98605067,0.000094516574,0.000021237276,0.00014692714,0.000025829817,0.01128978,0.0022452192,0.000023236802,0.00010260629],"genre_scores_gemma":[0.99746704,0.000046088004,0.0006201278,0.000042018582,0.000038352027,0.000570348,0.000931643,0.000042353284,0.00024205176],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99658996,0.00030939147,0.0011146744,0.00080375496,0.00074939453,0.00043283158],"domain_scores_gemma":[0.9967468,0.000905335,0.00054178055,0.000885582,0.0007417641,0.00017875916],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034380596,0.0004661966,0.0026419212,0.00023981191,0.000031713254,0.000015556901,0.00019527558,0.000113465016,0.00008618819],"category_scores_gemma":[0.0003310439,0.00029819435,0.00038751884,0.0009706305,0.0001080792,0.000079126265,0.00004315302,0.00011052115,0.000007433742],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3020063,0.05655353,0.6146324,0.000017503102,0.018819265,0.000027805989,0.0054876343,0.000019098628,0.0003220091,6.6458136e-7,0.00005593014,0.002057849],"study_design_scores_gemma":[0.7823918,0.02301758,0.17840582,0.00006238089,0.0073291995,9.891517e-7,0.0052920277,0.00017642848,0.0030930042,0.0000067172846,0.000029326102,0.0001947482],"about_ca_topic_score_codex":0.013125822,"about_ca_topic_score_gemma":0.0021729374,"teacher_disagreement_score":0.48038548,"about_ca_system_score_codex":0.0006871169,"about_ca_system_score_gemma":0.00023104477,"threshold_uncertainty_score":0.999947},"labels":[],"label_agreement":null},{"id":"W2982913861","doi":"10.1182/blood-2019-129990","title":"A 9-Gene Expression Signature Identifies Patients with Core-Binding Factor Acute Myeloid Leukemia at High Risk of Relapse after Achieving Complete Remission","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Oncology; Internal medicine; Cytarabine; Proportional hazards model; Hazard ratio; Myeloid leukemia; Medicine; Univariate analysis; Gene signature; Hematology; Chemotherapy regimen; Chemotherapy; Biology; Gene expression; Gene; Multivariate analysis; Confidence interval; Genetics","score_opus":0.010505659448691486,"score_gpt":0.23932540916040174,"score_spread":0.22881974971171026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982913861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99765515,0.00023529108,0.000028823335,0.00004099876,0.00016695456,0.0011460204,0.00045164945,0.00008500576,0.00019007738],"genre_scores_gemma":[0.9936305,0.00014173466,0.0028011624,0.00005389622,0.00010052231,0.00003504555,0.00042355666,0.00009602515,0.0027175145],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996973,0.00012697322,0.0004946506,0.00068322435,0.0011575853,0.0005646006],"domain_scores_gemma":[0.9978357,0.000207491,0.00042354007,0.0009165163,0.00031581652,0.00030095386],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022999333,0.00038214566,0.00068107084,0.00026959582,0.00017036327,0.000031308846,0.00029671707,0.0003411773,0.0005784563],"category_scores_gemma":[0.00017339418,0.00026359592,0.00016210126,0.00035294238,0.00011633978,0.0002478212,0.00049122155,0.0008891059,0.00015579646],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021903636,0.00015156453,0.4432802,0.00017969366,0.00026162935,0.000071614246,0.0003599774,0.000005387061,0.5529483,9.830873e-7,0.00039228637,0.00015797645],"study_design_scores_gemma":[0.011430813,0.0007910125,0.5135545,0.0012012193,0.00047073563,0.00003292361,0.000058148256,0.000031135653,0.471858,0.000008207621,0.00025619566,0.00030707638],"about_ca_topic_score_codex":0.000073706644,"about_ca_topic_score_gemma":0.000007469766,"teacher_disagreement_score":0.08109032,"about_ca_system_score_codex":0.0005489764,"about_ca_system_score_gemma":0.00022240554,"threshold_uncertainty_score":0.99998164},"labels":[],"label_agreement":null},{"id":"W2982997998","doi":"10.1182/blood-2019-124660","title":"Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Pfizer (Canada)","funders":"","keywords":"Medicine; Quality of life (healthcare); Myeloid leukemia; Family medicine; Affect (linguistics); Internal medicine; Pediatrics; Psychology; Nursing","score_opus":0.023917873102624648,"score_gpt":0.31672658603077164,"score_spread":0.292808712928147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982997998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981526,0.00021404831,0.000012879472,0.000062806226,0.00005142932,0.0007139581,0.000031091065,0.000012209192,0.0007489915],"genre_scores_gemma":[0.9988059,0.00010133614,0.00081734697,0.00015114638,0.00002027594,0.000010803804,0.00001572647,0.000019935667,0.000057556146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989561,0.000026816753,0.0003172071,0.00026821424,0.00020613473,0.00022551684],"domain_scores_gemma":[0.99925786,0.00021998797,0.000070821596,0.00030183952,0.00005668565,0.000092815775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011779222,0.00013152348,0.0003474666,0.00015881906,0.000013120621,0.0000062364943,0.000079533325,0.000077812525,0.000021725302],"category_scores_gemma":[0.00013137175,0.00008745318,0.000052405132,0.00019732674,0.00002144197,0.000040618917,0.0000664342,0.000106046406,0.00001946467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021630866,0.0004788349,0.9674059,0.000023372815,0.000038132548,0.000012455814,0.0009888225,0.0000010318503,0.0024754226,0.0000048797046,0.00004385339,0.028310964],"study_design_scores_gemma":[0.005752237,0.0014880827,0.98724324,0.00018859374,0.000022585153,0.0000022395982,0.000614479,0.000028248176,0.003990676,0.000028233018,0.0005610555,0.000080336606],"about_ca_topic_score_codex":0.000116024654,"about_ca_topic_score_gemma":0.00007427876,"teacher_disagreement_score":0.028230628,"about_ca_system_score_codex":0.00012885699,"about_ca_system_score_gemma":0.00009667963,"threshold_uncertainty_score":0.3566237},"labels":[],"label_agreement":null},{"id":"W2983035886","doi":"10.1182/blood-2019-125780","title":"Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; NPM1; Transplantation; Hematopoietic stem cell transplantation; Myeloid; Fludarabine; Myeloid leukemia; Hazard ratio; Proportional hazards model; Chemotherapy; Cyclophosphamide; Biology; Karyotype; Genetics","score_opus":0.03108196507504248,"score_gpt":0.280488176020727,"score_spread":0.24940621094568452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983035886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962575,0.0012633237,0.000031809166,0.00006180812,0.000038085193,0.0021409187,0.00010618586,0.000034359393,0.000066039735],"genre_scores_gemma":[0.9960005,0.001167508,0.0018491915,0.000054227756,0.000019356336,0.00029724813,0.0003178086,0.00006223126,0.00023190657],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99798405,0.00012078215,0.0005222424,0.0005103378,0.00041663813,0.00044592159],"domain_scores_gemma":[0.99898624,0.00027600955,0.00014963126,0.0003588582,0.00005175462,0.00017750642],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013157974,0.00036728126,0.000687876,0.00024409046,0.00006697574,0.00003337478,0.00009889871,0.0001726102,0.000030096015],"category_scores_gemma":[0.000011203864,0.0002843316,0.00022594274,0.00025750816,0.000037035865,0.0000764103,0.000037539685,0.00014936943,0.00003094502],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084343796,0.00025857298,0.5430312,0.000173976,0.00026999114,0.00012050087,0.00087238173,0.0002470709,0.45448086,6.6910206e-7,0.000009035691,0.00045138522],"study_design_scores_gemma":[0.008441517,0.0026422513,0.42078498,0.00020189589,0.0009876122,0.00012464722,0.00006068107,0.0015054876,0.5650066,0.0000020850491,0.0000025025822,0.00023972664],"about_ca_topic_score_codex":0.0003411013,"about_ca_topic_score_gemma":0.000050390572,"teacher_disagreement_score":0.12224622,"about_ca_system_score_codex":0.00168987,"about_ca_system_score_gemma":0.0004405718,"threshold_uncertainty_score":0.9999609},"labels":[],"label_agreement":null},{"id":"W2983038788","doi":"10.1182/blood-2019-130129","title":"Predictors of Disease Progression and Survival in Patients with Myelodysplastic Syndrome Secondary to Inherited Bone Marrow Failure Syndromes","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Janeway Children's Health and Rehabilitation Centre; Hospital for Sick Children; University of Saskatchewan; Queen's University; London Health Sciences Centre; McMaster Children's Hospital; Stollery Children's Hospital; Izaak Walton Killam Health Centre; Alberta Children's Hospital; Centre hospitalier de l'Université Laval; Centre Hospitalier Universitaire de Sherbrooke; Kingston General Hospital; Princess Margaret Cancer Centre; University of Toronto; Royal University Hospital; Montreal Children's Hospital; University of Manitoba; Children's Hospital of Eastern Ontario; BC Children's Hospital; University Health Network; SickKids Foundation","funders":"","keywords":"Cytopenia; Medicine; Internal medicine; Myelodysplastic syndromes; International Prognostic Scoring System; Oncology; Bone marrow failure; Bone marrow; Stem cell; Haematopoiesis; Biology","score_opus":0.005455734290218736,"score_gpt":0.228996443804602,"score_spread":0.22354070951438326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983038788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99789196,0.00013369611,0.000001914035,0.00023924708,0.000054162847,0.0014367679,0.000077381446,0.000037574962,0.0001272778],"genre_scores_gemma":[0.99909616,0.0000057584452,0.0004197432,0.000032210362,0.00001587217,0.000043896816,0.00010175513,0.000042638658,0.00024197645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983158,0.00006929336,0.00027526473,0.0003831731,0.0006128785,0.00034359566],"domain_scores_gemma":[0.99896026,0.000079841004,0.0000723852,0.0003504174,0.000119291115,0.00041783828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001636927,0.00019273347,0.00045641785,0.0003245968,0.000022913784,0.000013672187,0.000098223114,0.00009164958,0.00013154105],"category_scores_gemma":[0.00013654405,0.00014382393,0.000031045704,0.00046357905,0.00008673728,0.00011949369,0.00014710751,0.00030040357,0.000024085744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015446827,0.0007289388,0.9953571,0.0007329465,0.00011108221,0.00031258908,0.00014128097,0.0000029722726,0.00071833655,0.0000047429867,0.00008289894,0.000262454],"study_design_scores_gemma":[0.011722118,0.0025226504,0.98415494,0.0009514598,0.00011314219,0.000049028127,0.000063940926,0.000021856067,0.00014819713,0.0000031231934,0.00009752184,0.00015201622],"about_ca_topic_score_codex":0.0000133638805,"about_ca_topic_score_gemma":0.000012977895,"teacher_disagreement_score":0.011202129,"about_ca_system_score_codex":0.00006197461,"about_ca_system_score_gemma":0.00029802442,"threshold_uncertainty_score":0.58649695},"labels":[],"label_agreement":null},{"id":"W2983059016","doi":"10.1182/blood-2019-129078","title":"Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Transplantation; Hematopoietic stem cell transplantation; Oncology; Cohort; Log-rank test; Chemotherapy; Chemotherapy regimen; Survival analysis","score_opus":0.010819720058870193,"score_gpt":0.2221658558371315,"score_spread":0.2113461357782613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983059016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966803,0.000106411106,0.00003083279,0.00012888468,0.00006803647,0.0011835987,0.000042256295,0.000061113446,0.0016985751],"genre_scores_gemma":[0.99687034,0.000077952995,0.00065462926,0.00021019022,0.00004157278,0.00004105842,0.0004260233,0.00006141533,0.0016168036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828464,0.000045668912,0.0002804079,0.00042735177,0.0005119853,0.00044995663],"domain_scores_gemma":[0.9991316,0.00006799827,0.00007911971,0.0004107419,0.00015501924,0.00015550623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012059543,0.0002234011,0.00035650903,0.00023895557,0.00004361473,0.000028209455,0.00016167297,0.00017523531,0.00013454267],"category_scores_gemma":[0.0000037027687,0.00017794485,0.000056569752,0.00043131967,0.000042845695,0.00012184914,0.00002954433,0.00035171252,0.0002889256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019634427,0.0011738538,0.961191,0.0004443072,0.0003182614,0.00027961246,0.0013720937,0.00011509024,0.02991793,0.000027858738,0.00022952331,0.0029670205],"study_design_scores_gemma":[0.03065006,0.00093993056,0.9240776,0.00018676919,0.00044223876,0.000024765348,0.00008702243,0.0001613863,0.042947467,0.0000063695948,0.00021627956,0.00026016383],"about_ca_topic_score_codex":0.000111767964,"about_ca_topic_score_gemma":0.000098681914,"teacher_disagreement_score":0.03711346,"about_ca_system_score_codex":0.0002777686,"about_ca_system_score_gemma":0.0004092768,"threshold_uncertainty_score":0.72563803},"labels":[],"label_agreement":null},{"id":"W2983205654","doi":"10.1182/blood-2019-123684","title":"Persistent Red Blood Cell (RBC) Transfusion Is Associated with Increased Mortality Risk in Transfusion-Dependent (TD) Patients with Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS+)","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Alberta Hospital Edmonton; University of British Columbia; University of Ottawa; Dr. Georges-L.-Dumont University Hospital Centre; St. Paul's Hospital; McMaster University; Queen Elizabeth II Health Sciences Centre; CancerCare Manitoba; University of Alberta Hospital; Health Sciences Centre; University of Toronto; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; International Prognostic Scoring System; Internal medicine; Myelodysplastic syndromes; Comorbidity; Blood transfusion; Anemia; Population; Bone marrow","score_opus":0.008899973437385215,"score_gpt":0.21488875231073912,"score_spread":0.2059887788733539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983205654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947477,0.00009329297,0.000040306753,0.00008910748,0.00003871749,0.003005589,0.00015869015,0.00015936547,0.0016672526],"genre_scores_gemma":[0.9985328,0.00017735631,0.00037133167,0.000093958355,0.000028775201,0.00011827379,0.00018099157,0.00016048804,0.00033602607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99468416,0.0003364703,0.000650966,0.0011926345,0.002096841,0.0010389559],"domain_scores_gemma":[0.9975722,0.0003281392,0.00029513685,0.00088650436,0.00039815536,0.00051988155],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005943209,0.0006626856,0.0010788313,0.00044962962,0.00020007348,0.00006115783,0.00030743654,0.00032539616,0.00042451522],"category_scores_gemma":[0.00011014723,0.00046299776,0.00018589696,0.000936733,0.00015647401,0.00025118803,0.00006791623,0.0011795092,0.000046445686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028621554,0.005598604,0.97970444,0.00040463987,0.0016033648,0.000880375,0.0016016617,0.0002632316,0.0069851675,0.0000012472773,0.000012820369,0.00008228683],"study_design_scores_gemma":[0.07659882,0.0071628685,0.8949916,0.0018793743,0.0031753532,0.0001836661,0.0006908596,0.00063688715,0.013977472,0.0000034460124,0.000006444454,0.00069320033],"about_ca_topic_score_codex":0.003100356,"about_ca_topic_score_gemma":0.002801526,"teacher_disagreement_score":0.08471284,"about_ca_system_score_codex":0.0004073331,"about_ca_system_score_gemma":0.000668664,"threshold_uncertainty_score":0.99978215},"labels":[],"label_agreement":null},{"id":"W2983230949","doi":"10.1182/blood-2019-124552","title":"Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Hypomethylating agent; Medicine; Azacitidine; Myeloid leukemia; Oncology; Internal medicine; Decitabine; Leukemia; Phases of clinical research; Clinical trial; Biology; DNA methylation","score_opus":0.010027837225480169,"score_gpt":0.2565633593527956,"score_spread":0.24653552212731544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983230949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977569,0.00027344178,0.00003141946,0.000050495255,0.0000294083,0.0015075376,0.00007140545,0.000031715816,0.000247677],"genre_scores_gemma":[0.99686694,0.0001817364,0.0024835295,0.00003053103,0.00003147355,0.000038510316,0.00018289911,0.00006248933,0.00012191065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968978,0.00027780185,0.00072358525,0.00074184,0.00081657525,0.00054240786],"domain_scores_gemma":[0.9979741,0.000360142,0.00039866124,0.0007724757,0.00019613841,0.00029849837],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007153431,0.000370792,0.0011111007,0.00091240526,0.000074518925,0.000021990261,0.0002032342,0.00021337967,0.00010546764],"category_scores_gemma":[0.00023226131,0.0002738438,0.00008617518,0.0020224575,0.00012855098,0.00026835673,0.00017118306,0.0009480981,0.000008149395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04735283,0.0017141716,0.9154251,0.00023481839,0.0023976346,0.00019581706,0.0025040149,0.00021361907,0.01205884,0.0000032922774,0.000015419673,0.017884417],"study_design_scores_gemma":[0.16810776,0.006145192,0.8133118,0.0005015171,0.0015982729,0.0000040398345,0.0005259482,0.00021871655,0.009227045,0.0000014786986,0.000046375168,0.00031184763],"about_ca_topic_score_codex":0.00022803417,"about_ca_topic_score_gemma":0.00014614286,"teacher_disagreement_score":0.120754935,"about_ca_system_score_codex":0.0005293776,"about_ca_system_score_gemma":0.0008234854,"threshold_uncertainty_score":0.9999714},"labels":[],"label_agreement":null},{"id":"W2983257358","doi":"10.1182/blood-2019-123191","title":"Epigenomic Determinants of Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Epigenomics; Biology; H3K4me3; DNA methylation; Chromatin immunoprecipitation; Histone; Epigenetics; Wild type; Mutant; Enhancer; Genetics; Transcriptome; Cancer research; Molecular biology; Promoter; Transcription factor; Gene; Gene expression","score_opus":0.018691820575642004,"score_gpt":0.28477313549072136,"score_spread":0.26608131491507936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983257358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99691087,0.0004265626,0.000016127971,0.00007792701,0.00008236687,0.00071501103,0.000021715716,0.000025258672,0.0017241611],"genre_scores_gemma":[0.998772,0.00014773112,0.00017912175,0.000032739154,0.0000998095,0.000027603213,0.000008055239,0.000034831446,0.0006980723],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983889,0.00006989254,0.00034655377,0.00036064646,0.00037029697,0.00046374172],"domain_scores_gemma":[0.9991797,0.00009558643,0.000090658374,0.00044918514,0.000056990135,0.00012786935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035059344,0.00017657642,0.00053293025,0.00025235614,0.000023228959,0.000007529095,0.00019432203,0.00016110664,0.00037850678],"category_scores_gemma":[0.000048432907,0.00016297986,0.00013102911,0.0002781758,0.00009201754,0.00011485606,0.000055412147,0.00043378657,0.00026362058],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034691198,0.0003443302,0.13242428,0.0003908294,0.00006688529,0.00015179804,0.0001766142,0.000024255965,0.85984826,0.000053529562,0.000009664543,0.0061626574],"study_design_scores_gemma":[0.011209448,0.00071344397,0.5443532,0.0002438968,0.00009267853,0.00017955729,0.000042041076,0.0028209505,0.43979177,0.00005558945,0.00031507105,0.0001823806],"about_ca_topic_score_codex":0.0003029922,"about_ca_topic_score_gemma":0.0001581684,"teacher_disagreement_score":0.42005646,"about_ca_system_score_codex":0.001462854,"about_ca_system_score_gemma":0.0023183967,"threshold_uncertainty_score":0.6646126},"labels":[],"label_agreement":null},{"id":"W2983330076","doi":"10.1182/blood-2019-121870","title":"Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Immune system; Medicine; Interleukin-3 receptor; Immunotherapy; Chemotherapy regimen; Myeloid leukemia; Oncology; Leukemia; Immunology; Myeloid; Internal medicine; Chemotherapy; Cancer research","score_opus":0.006480575443973489,"score_gpt":0.22549820950477284,"score_spread":0.21901763406079935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983330076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99731535,0.00036517,0.000011344521,0.00015171581,0.00005310309,0.0010402377,0.000097623255,0.00006511902,0.0009003418],"genre_scores_gemma":[0.9973032,0.00032120096,0.0012346472,0.00009381377,0.00006430388,0.00003018694,0.00023084693,0.00008173584,0.0006400491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739957,0.00013875835,0.00046014725,0.00067947345,0.0008423418,0.00047969227],"domain_scores_gemma":[0.9983572,0.00010853738,0.00026226952,0.0007868804,0.00023911158,0.000245995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034616538,0.0003413972,0.00071341393,0.00035858777,0.00006845344,0.000029107718,0.00025722687,0.00024265598,0.0000831812],"category_scores_gemma":[0.000069968824,0.00028783942,0.00006703605,0.00054915017,0.00026020227,0.0004318305,0.00008607176,0.00068778306,0.000014704907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003975815,0.0010676464,0.71213907,0.00029047776,0.00039486444,0.000050677714,0.0005168033,0.000017228876,0.28051028,0.000050944724,0.00026261795,0.0007235754],"study_design_scores_gemma":[0.024660064,0.001238121,0.91433084,0.00035465852,0.0001056895,0.000017636514,0.00004477602,0.00023806943,0.05842689,0.000027538952,0.00027214404,0.000283559],"about_ca_topic_score_codex":0.00010830579,"about_ca_topic_score_gemma":0.00005269973,"teacher_disagreement_score":0.22208337,"about_ca_system_score_codex":0.0004687786,"about_ca_system_score_gemma":0.0011604127,"threshold_uncertainty_score":0.9999574},"labels":[],"label_agreement":null},{"id":"W2983461972","doi":"10.1182/blood-2019-125449","title":"Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML): Princess Margaret Cancer Centre Experience","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Acute promyelocytic leukemia; Internal medicine; Young adult; Retrospective cohort study; Cancer; Leukemia; Log-rank test; Survival analysis; Oncology; Pediatrics","score_opus":0.006551456879921741,"score_gpt":0.25218412341082663,"score_spread":0.2456326665309049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983461972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981534,0.00024271899,0.0000028851825,0.0002528625,0.00010194332,0.0009927106,0.000054147782,0.00003529878,0.00016401577],"genre_scores_gemma":[0.9981665,0.00071871566,0.00022908223,0.00026772343,0.000041481122,0.000063468186,0.00002222418,0.000038919126,0.00045191305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819195,0.00003950477,0.00028568492,0.00053002185,0.0004607428,0.00049212115],"domain_scores_gemma":[0.9991613,0.000022717319,0.00011079535,0.00034479663,0.00010890669,0.00025148483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007155865,0.00025985364,0.00047076066,0.00011845083,0.000049951104,0.00004309898,0.0001169929,0.00011597654,0.0000421745],"category_scores_gemma":[0.000038468745,0.00019334724,0.000025376057,0.0001787591,0.00013087834,0.00015693519,0.0001973608,0.00037093036,0.0000109263165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007153103,0.00019360546,0.98885167,0.00031171876,0.000092170456,0.0003619871,0.0035656765,2.449373e-7,0.0017555907,0.0000062506133,0.000016864386,0.004128933],"study_design_scores_gemma":[0.008619194,0.00031411162,0.98512137,0.001151114,0.00008605834,0.00015213169,0.0010332945,0.0001575941,0.0029447307,0.00000117504,0.00017594727,0.00024329772],"about_ca_topic_score_codex":0.00071309233,"about_ca_topic_score_gemma":0.00031256943,"teacher_disagreement_score":0.007903884,"about_ca_system_score_codex":0.00026261347,"about_ca_system_score_gemma":0.00029253578,"threshold_uncertainty_score":0.78844714},"labels":[],"label_agreement":null},{"id":"W2983490569","doi":"10.1111/ejh.13353","title":"Allogeneic stem cell transplant in myelodysplastic syndrome‐factors impacting survival","year":2019,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cumulative incidence; Myelodysplastic syndromes; Incidence (geometry); Oncology; Survival analysis; Transplantation; Ferritin; Bone marrow; Surgery","score_opus":0.022544785628342813,"score_gpt":0.2615934662579578,"score_spread":0.239048680629615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983490569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936792,0.00036456456,0.0002064433,0.00033208932,0.0005986668,0.0002044934,0.000004248308,0.00001744824,0.0045928033],"genre_scores_gemma":[0.9990407,0.00009251199,0.00021032589,0.00007442203,0.00006299959,3.5553302e-7,0.000004332137,0.00006837882,0.00044594225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99692374,0.00095172366,0.00091577746,0.00023621917,0.0004084396,0.00056412286],"domain_scores_gemma":[0.99838287,0.00052120606,0.00039095478,0.00027407144,0.00011915085,0.00031176192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001624208,0.00023273876,0.00097399566,0.00057690876,0.00003415458,0.000017043261,0.00034856127,0.00007361973,0.00027980594],"category_scores_gemma":[0.000073112904,0.00017312689,0.0001944965,0.00027575306,0.0000780748,0.000118206655,0.00006145277,0.0010609657,0.0004055806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014696269,0.00029744772,0.72492325,0.0006814043,0.00030639427,0.20923828,0.003020682,0.00030086827,0.058412205,0.00008359427,0.00037925164,0.0008869759],"study_design_scores_gemma":[0.018040072,0.005935916,0.6429537,0.0016121893,0.0003591759,0.30596474,0.0054722703,0.00040438064,0.016141668,0.000017957864,0.0023678176,0.00073012937],"about_ca_topic_score_codex":0.000008107688,"about_ca_topic_score_gemma":0.0000037945376,"teacher_disagreement_score":0.09672648,"about_ca_system_score_codex":0.0001910382,"about_ca_system_score_gemma":0.00032514846,"threshold_uncertainty_score":0.70599097},"labels":[],"label_agreement":null},{"id":"W2983492726","doi":"10.1182/blood-2019-128402","title":"Impact of Mutations in Epigenetic Modifiers in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis","year":2019,"lang":"en","type":"review","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Oncology; Meta-analysis; Isocitrate dehydrogenase; IDH1; Epigenetics; Hazard ratio; Internal medicine; Confidence interval; EZH2; Medicine; Myeloid leukemia; CEBPA; DNA methylation; Bioinformatics; Biology; Genetics; Mutation; Gene","score_opus":0.08935773024498643,"score_gpt":0.39900896486348214,"score_spread":0.3096512346184957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983492726","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029438784,0.9916659,0.000009768709,0.000041169387,0.000006169978,0.007535053,0.00026409727,0.000013096648,0.00017033165],"genre_scores_gemma":[0.00048475878,0.9969033,0.00023556242,0.00004658417,0.000008281274,0.0011872079,0.00027594078,0.00007026502,0.000788116],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9950836,0.0009156612,0.0022465724,0.000700445,0.0005571801,0.00049658894],"domain_scores_gemma":[0.996745,0.00065813685,0.0008545679,0.0013704643,0.00016089952,0.00021092083],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00146875,0.0006279074,0.016215201,0.002139923,0.000018870849,0.000020546355,0.00038269695,0.00042503822,0.00017487799],"category_scores_gemma":[0.00065904774,0.00039395905,0.0039153267,0.003878097,0.00010203674,0.00006656132,0.00014293604,0.00094733667,0.000057340458],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000032642222,0.0001392372,0.00004340927,0.77091455,0.22827211,0.00014318331,0.000059172362,0.000010324122,7.586711e-7,0.000004165387,0.000018535213,0.0003913119],"study_design_scores_gemma":[0.0009205001,0.0001580402,0.00008852997,0.053215686,0.94496536,0.00022646875,0.00001258686,0.000035798963,6.3998925e-7,0.00000504781,0.000103242135,0.00026807905],"about_ca_topic_score_codex":0.00052652776,"about_ca_topic_score_gemma":0.00006764581,"teacher_disagreement_score":0.7176989,"about_ca_system_score_codex":0.0010037835,"about_ca_system_score_gemma":0.0025390782,"threshold_uncertainty_score":0.9998512},"labels":[],"label_agreement":null},{"id":"W2983568470","doi":"10.1182/blood-2019-122262","title":"Inhibiting Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Induces Selective Leukemia Cell Death","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Western University; University Health Network; Princess Margaret Cancer Centre; University of Waterloo; University of Guelph","funders":"","keywords":"Biology; Leukemia; Clonogenic assay; Haematopoiesis; Myeloid leukemia; Myeloid; Citric acid cycle; Cancer research; Population; Bone marrow; Oxidative phosphorylation; Biochemistry; Stem cell; Cell; Immunology; Metabolism; Medicine; Cell biology","score_opus":0.015478640206971666,"score_gpt":0.2636724442333163,"score_spread":0.24819380402634464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983568470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740885,0.0005223938,0.000021346736,0.00021882614,0.000088065084,0.0009449579,0.000011758273,0.00017778382,0.02392637],"genre_scores_gemma":[0.99537385,0.00006796801,0.0006849586,0.0005191935,0.0004830204,0.00005173737,0.000046161702,0.00009688061,0.0026762427],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972943,0.00012385944,0.0003778971,0.00066707865,0.00065580616,0.0008810762],"domain_scores_gemma":[0.9985254,0.0002461832,0.0001404108,0.00052111375,0.00020620636,0.00036070836],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055950176,0.00033328737,0.00050561735,0.00030319294,0.00013970064,0.00005372268,0.00025592447,0.00029884686,0.00017959834],"category_scores_gemma":[0.00024860507,0.00030417484,0.00016652771,0.0005934691,0.000067443776,0.00021501645,0.00024148202,0.0010640956,0.0010331009],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027784955,0.0006087855,0.099878654,0.00042247435,0.00033537118,0.0011296392,0.001173738,0.000029295716,0.8933284,0.00010405661,0.000926351,0.0017853418],"study_design_scores_gemma":[0.0078098346,0.0005156168,0.013820717,0.00021225937,0.00019699222,0.00034379645,0.00043655824,0.000431304,0.97552997,0.00004679975,0.00030811413,0.00034802884],"about_ca_topic_score_codex":0.000242087,"about_ca_topic_score_gemma":0.000018044835,"teacher_disagreement_score":0.08605793,"about_ca_system_score_codex":0.0007169688,"about_ca_system_score_gemma":0.0014620568,"threshold_uncertainty_score":0.99994105},"labels":[],"label_agreement":null},{"id":"W2983625716","doi":"10.1182/blood-2019-122122","title":"Acute Myeloid Leukemia (AML) Treated with Azacitidine: Survival Outcomes for Patients Who Complete More Than Six Cycles Are Similar to High-Risk Myelodysplastic Syndrome/Low Blast Count AML","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Azacitidine; Medicine; Internal medicine; Myelodysplastic syndromes; Hypomethylating agent; International Prognostic Scoring System; Myeloid leukemia; Leukemia; Oncology; Bone marrow; Surgery","score_opus":0.01061704548477833,"score_gpt":0.24843113423198265,"score_spread":0.23781408874720433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983625716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99028474,0.000028478064,0.00021568943,0.00076596794,0.00024602035,0.0041972175,0.0037769913,0.0002879197,0.00019695866],"genre_scores_gemma":[0.9934747,0.00006871021,0.0016655858,0.0005059145,0.00017493611,0.000401322,0.0012310351,0.00028922816,0.0021885529],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99462897,0.00017221851,0.000777421,0.0013143582,0.0015994641,0.001507578],"domain_scores_gemma":[0.99565494,0.00094718806,0.0004037749,0.0013118847,0.0008479758,0.00083426305],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039109777,0.0009369208,0.001906359,0.00052079535,0.00031655602,0.0001263674,0.00065186655,0.0003509296,0.00014059684],"category_scores_gemma":[0.00047979678,0.00070725445,0.00032131808,0.0007912843,0.00022781517,0.00026143825,0.00029851493,0.0007352338,0.00045538746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026255418,0.0008820126,0.98799884,0.00055333134,0.0024393664,0.0005079335,0.0002886722,0.0002719963,0.0024999264,0.000039205668,0.0016364561,0.0002566923],"study_design_scores_gemma":[0.03110095,0.004881529,0.9542836,0.00080281316,0.0017921075,0.00015491826,0.00040250906,0.0010712823,0.003568602,0.0000136423405,0.0009960313,0.0009320363],"about_ca_topic_score_codex":0.0005923152,"about_ca_topic_score_gemma":0.00029839238,"teacher_disagreement_score":0.033715285,"about_ca_system_score_codex":0.0009340557,"about_ca_system_score_gemma":0.0005669995,"threshold_uncertainty_score":0.9995379},"labels":[],"label_agreement":null},{"id":"W2983666463","doi":"10.1182/blood-2019-128445","title":"Predictors of Outcomes in Adult Patients with Therapy Related Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - Twenty Year Experience from a Tertiary Care Centre","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Hematopoietic stem cell transplantation; Myeloid leukemia; Transplantation; Proportional hazards model; Cumulative incidence; Oncology","score_opus":0.004830761862482665,"score_gpt":0.21834557420871867,"score_spread":0.213514812346236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983666463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99817604,0.00018999007,0.000006561263,0.00004247773,0.000076107615,0.0011219798,0.000109403554,0.000052555548,0.00022486325],"genre_scores_gemma":[0.99868125,0.00039548267,0.00023704475,0.00007373538,0.00001221466,0.00002729936,0.00032306046,0.000050115235,0.00019981746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981095,0.00009222411,0.00042378367,0.00043262055,0.0005923002,0.00034954693],"domain_scores_gemma":[0.99903464,0.00011948479,0.00015079013,0.00042469896,0.00014824647,0.00012216334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000049997434,0.00023959955,0.0004249302,0.00015362876,0.00002998216,0.000011072634,0.00019323286,0.00017212323,0.00008659227],"category_scores_gemma":[0.0000069285393,0.0001788001,0.00008654958,0.00024446784,0.00007464039,0.0001435195,0.00003264288,0.00028255561,0.00002898404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046856064,0.00032330977,0.96266663,0.00022321218,0.00026635718,0.000069692105,0.026425904,0.00002447584,0.009402044,0.0000024808933,0.0000066476628,0.00012071374],"study_design_scores_gemma":[0.02355082,0.00039784744,0.8893264,0.00045609372,0.00019378542,0.0000063192033,0.0069040884,0.000022826998,0.07893651,0.000002683532,0.000004700186,0.00019793927],"about_ca_topic_score_codex":0.0002404753,"about_ca_topic_score_gemma":0.00006803501,"teacher_disagreement_score":0.073340215,"about_ca_system_score_codex":0.00026488816,"about_ca_system_score_gemma":0.00036792856,"threshold_uncertainty_score":0.7291256},"labels":[],"label_agreement":null},{"id":"W2983677619","doi":"10.1182/blood-2019-122768","title":"Growth Factor-Dependent Activation of a MYC-Induced Latent AML Program in Human Hematopoietic Cells","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Terry Fox Research Institute; BC Cancer Agency","funders":"","keywords":"Biology; CD34; Haematopoiesis; Population; Bone marrow; Myeloid; Stem cell; Cancer research; Progenitor cell; Immunology; Transplantation; Molecular biology; CD38; Cell biology; Internal medicine; Medicine","score_opus":0.02562509468783011,"score_gpt":0.30067909875880444,"score_spread":0.27505400407097436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983677619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961571,0.000016121248,0.000004507732,0.00017082857,0.00003659608,0.0015666577,0.000003312563,0.00006195437,0.001982924],"genre_scores_gemma":[0.9990121,0.000009305234,0.0002482436,0.000038597205,0.00004420464,0.00006445067,0.000018315512,0.000031659445,0.00053309795],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985023,0.000054184828,0.00032507282,0.00028616327,0.0005084314,0.00032386012],"domain_scores_gemma":[0.99925387,0.000048056267,0.000103583225,0.00036517432,0.00012359727,0.000105740764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017167204,0.00014406707,0.0003426719,0.0002302348,0.000019886551,0.000013550183,0.00014194606,0.00014307548,0.00019650118],"category_scores_gemma":[0.000043134158,0.00012358514,0.000077730605,0.00028481617,0.000026693178,0.000075263284,0.00008167957,0.00035594616,0.00009226195],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059250455,0.0015121846,0.07480988,0.0003791209,0.00006788801,0.000032368087,0.00057273585,0.000001032242,0.92181945,0.00015272186,0.000028209353,0.0005651851],"study_design_scores_gemma":[0.0056402064,0.00083655,0.090204544,0.00018411495,0.000034825724,0.00001377227,0.00012895424,0.000041269726,0.9027091,0.00006957237,0.000023600405,0.00011345107],"about_ca_topic_score_codex":0.00027074802,"about_ca_topic_score_gemma":0.000009308295,"teacher_disagreement_score":0.019110283,"about_ca_system_score_codex":0.00015717243,"about_ca_system_score_gemma":0.00015633853,"threshold_uncertainty_score":0.5039656},"labels":[],"label_agreement":null},{"id":"W2983701330","doi":"10.1182/blood-2019-122187","title":"Peripheral Blood Cell Sorting Strategies for Transcriptomic Analysis in Chronic Myelomonocytic Leukemia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Chronic myelomonocytic leukemia; Biology; CD34; Transcriptome; Haematopoiesis; Myeloid; Immunology; Stem cell; Cancer research; Molecular biology; Computational biology; Bone marrow; Genetics; Gene; Myelodysplastic syndromes; Gene expression","score_opus":0.015686559201974287,"score_gpt":0.2829441115322259,"score_spread":0.2672575523302516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983701330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911005,0.0012367343,0.00048118824,0.00011866779,0.000055139746,0.0012434435,0.000016150827,0.00009171613,0.005656497],"genre_scores_gemma":[0.99544233,0.000098166645,0.0015145637,0.000115237606,0.00021670338,0.00013258921,0.000079636586,0.00006526606,0.0023355135],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99756277,0.0000637823,0.0005611032,0.000616458,0.00035407432,0.00084179617],"domain_scores_gemma":[0.9989164,0.0001223489,0.00011572184,0.00057433464,0.00009780564,0.00017342888],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044261824,0.00029028245,0.00079069927,0.00053797336,0.00006680427,0.000081880265,0.0002735928,0.00021475542,0.0003824071],"category_scores_gemma":[0.000034182143,0.0002715221,0.00042814176,0.0009943029,0.000068383626,0.00021340782,0.000043069012,0.00051676587,0.00006493086],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060163706,0.00084503385,0.110554665,0.0020258476,0.003131743,0.0002502594,0.0026213063,0.0057198796,0.87216276,0.0005994883,0.00015626654,0.0013311389],"study_design_scores_gemma":[0.16981304,0.0073994254,0.15047045,0.0007037671,0.0252208,0.00028461815,0.0122912135,0.24439189,0.38299805,0.0012443551,0.0023489473,0.002833456],"about_ca_topic_score_codex":0.0004134396,"about_ca_topic_score_gemma":0.00050886953,"teacher_disagreement_score":0.48916468,"about_ca_system_score_codex":0.0012419814,"about_ca_system_score_gemma":0.0031371263,"threshold_uncertainty_score":0.9999737},"labels":[],"label_agreement":null},{"id":"W2983726993","doi":"10.1182/blood-2019-125852","title":"Overall Survival of Glasdegib in Combination with Low-Dose Cytarabine and Azacitidine By Bone Marrow Blasts Among Adult Patients with Previously Untreated Acute Myeloid Leukemia: Comparative Effectiveness Using Indirect Treatment Comparisons","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Myeloid leukemia; Decitabine; Oncology; Azacitidine; Population; Randomized controlled trial; Induction chemotherapy; Chemotherapy","score_opus":0.01036229489564015,"score_gpt":0.25289791523269217,"score_spread":0.24253562033705203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983726993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99576324,0.0001285815,0.00004469883,0.000024210776,0.000026793998,0.0036514783,0.00012555232,0.00005042188,0.0001849964],"genre_scores_gemma":[0.9985698,0.000067347966,0.0004185441,0.000012554551,0.000013636654,0.00009843113,0.00064409827,0.00006249464,0.000113077265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736065,0.00038220405,0.00044886686,0.0006359368,0.0006363738,0.00053596264],"domain_scores_gemma":[0.9982886,0.0003026256,0.00031903395,0.00038222288,0.00048450637,0.0002230548],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024159947,0.00048393043,0.0014089433,0.00033230282,0.00007028447,0.000029398723,0.000102294915,0.00017079189,0.000016232698],"category_scores_gemma":[0.000027801712,0.00034801548,0.000060538074,0.0006249796,0.00028417664,0.0002635801,0.00006946574,0.00036413484,0.000005150426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008405255,0.0032236006,0.9640546,0.0003585064,0.0011587853,0.00009825586,0.0007744991,0.00020867249,0.021557821,0.000011407127,0.000021650085,0.00012696943],"study_design_scores_gemma":[0.08841429,0.00815166,0.8305919,0.0012823759,0.0007237055,0.000042093317,0.00013119775,0.0031364781,0.06717769,0.0000024237834,0.000004784518,0.00034141008],"about_ca_topic_score_codex":0.0018415775,"about_ca_topic_score_gemma":0.0006292909,"teacher_disagreement_score":0.13346268,"about_ca_system_score_codex":0.0011207674,"about_ca_system_score_gemma":0.00044697322,"threshold_uncertainty_score":0.9998972},"labels":[],"label_agreement":null},{"id":"W2984034670","doi":"10.1182/blood-2019-122284","title":"IPO11 Is Upregulated in Relapsed AML and Supports Survival of Leukemic Stem Cells","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Downregulation and upregulation; CD34; Cancer research; Biology; Myeloid; Gene; Leukemia; Stem cell; CRISPR; Immunology; Genetics","score_opus":0.012393534658543051,"score_gpt":0.2503106831305267,"score_spread":0.23791714847198364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984034670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99537545,0.00027744134,0.0000013222186,0.00020877096,0.00007843714,0.00056740467,0.00001639788,0.000030727566,0.0034440588],"genre_scores_gemma":[0.99129164,0.00009211208,0.00012222561,0.000088346096,0.000032255142,0.0000060380557,0.000011625671,0.00003327597,0.008322491],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998536,0.000071156675,0.00034897964,0.00033298886,0.0003700489,0.00034085626],"domain_scores_gemma":[0.999117,0.000109874454,0.0000829617,0.0004670484,0.00008298804,0.0001401222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039653294,0.00014638029,0.0004495371,0.00019235819,0.00001326554,0.000007705102,0.00011157644,0.00017634784,0.00038790627],"category_scores_gemma":[0.000017958706,0.00012959549,0.000057212856,0.00030918402,0.000077366254,0.000046643778,0.00010346435,0.0003130617,0.00010160311],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033918087,0.00037708992,0.2988123,0.0004510876,0.00014701742,0.00022285036,0.000993577,0.0000040614277,0.6959018,0.000046824458,0.0013823365,0.0013218748],"study_design_scores_gemma":[0.022366608,0.00078135036,0.19819617,0.0003452113,0.000167191,0.00015432575,0.00045288805,0.00064580113,0.7754668,0.00005192208,0.0010961979,0.00027554118],"about_ca_topic_score_codex":0.000209763,"about_ca_topic_score_gemma":0.000010989412,"teacher_disagreement_score":0.100616135,"about_ca_system_score_codex":0.00009384974,"about_ca_system_score_gemma":0.0003311692,"threshold_uncertainty_score":0.52847505},"labels":[],"label_agreement":null},{"id":"W2984054442","doi":"10.1182/blood-2019-131394","title":"Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Internal medicine; Regimen; Medicine; Gastroenterology; Population; Neutropenia; Phases of clinical research; Median follow-up; Surgery; Chemotherapy","score_opus":0.019917274655099692,"score_gpt":0.2872504440037494,"score_spread":0.2673331693486497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984054442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99535745,0.00006187418,0.000004225096,0.000057214344,0.00021921916,0.0039218487,0.0002334744,0.000043617216,0.00010106958],"genre_scores_gemma":[0.9976888,0.000026904343,0.00009482057,0.000031729447,0.00006948831,0.00016285872,0.00095746724,0.000117357704,0.0008505872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961803,0.0003372911,0.0007743853,0.00091474043,0.0011403692,0.00065289927],"domain_scores_gemma":[0.99747896,0.000530466,0.00030374652,0.0008698542,0.00042085856,0.0003960918],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055213645,0.00044759075,0.0009843743,0.00047958276,0.00006598673,0.00003117745,0.0002514598,0.0002927551,0.00014225663],"category_scores_gemma":[0.0004995527,0.0003475713,0.00010159316,0.0004456417,0.00010486312,0.00023679524,0.00014362807,0.00050142227,0.000010084197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035111304,0.009355767,0.94230556,0.00019106889,0.0003917507,0.00018091415,0.001994408,2.739403e-7,0.008400841,1.6900151e-7,0.00003247626,0.0020354583],"study_design_scores_gemma":[0.15185294,0.007895166,0.833968,0.00041932997,0.00037302088,0.0000019462434,0.00040698724,0.00001615404,0.004756726,0.00000149529,0.0000071929326,0.000301093],"about_ca_topic_score_codex":0.00057737785,"about_ca_topic_score_gemma":0.0008384554,"teacher_disagreement_score":0.11674163,"about_ca_system_score_codex":0.00027624995,"about_ca_system_score_gemma":0.00025430816,"threshold_uncertainty_score":0.9998976},"labels":[],"label_agreement":null},{"id":"W2984163765","doi":"10.1182/blood-2019-130428","title":"High Residual Allelic Burden Increases Leukemic Transformation Irrespective of Clinical Response in Patients with Lower Risk Myelodysplastic Syndrome Treated with Azacitidine","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Azacitidine; Internal medicine; International Prognostic Scoring System; Cumulative incidence; Myelodysplastic syndromes; Medicine; Proportional hazards model; Hazard ratio; Oncology; Decitabine; Lower risk; Bone marrow; Cohort; Biology; Gene; Genetics; Confidence interval; DNA methylation","score_opus":0.009027896857375478,"score_gpt":0.26179176225880574,"score_spread":0.25276386540143025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984163765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99782574,0.000029587187,0.000014935108,0.00012496802,0.000024555635,0.0015842908,0.00012881962,0.000059550905,0.0002075417],"genre_scores_gemma":[0.99888486,0.00004301118,0.00045062124,0.000024052282,0.000050697276,0.00004375364,0.00016772705,0.000057330097,0.00027795826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99692553,0.00058624335,0.00072684785,0.00049072556,0.0008396229,0.00043103454],"domain_scores_gemma":[0.99765337,0.00094818795,0.000283489,0.00053283304,0.0003688937,0.00021322115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009695045,0.0002904844,0.0008669316,0.00048289084,0.000041042316,0.00001331931,0.00017284665,0.00021524912,0.00017304662],"category_scores_gemma":[0.0006691663,0.0002009426,0.00008079435,0.00066336186,0.00021167651,0.00022443627,0.000039578037,0.00068589806,0.000084546744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12817836,0.0022632827,0.8672178,0.00011951732,0.00058548525,0.00038644098,0.00034158022,0.00019991715,0.00045554028,0.000014308434,0.00003695839,0.00020084626],"study_design_scores_gemma":[0.054127768,0.021177571,0.9220497,0.00056052976,0.00044016624,0.0001193443,0.00017317389,0.00014800005,0.00095395924,0.0000071257546,0.00002106383,0.00022160751],"about_ca_topic_score_codex":0.0013634912,"about_ca_topic_score_gemma":0.00007830949,"teacher_disagreement_score":0.07405059,"about_ca_system_score_codex":0.0002538383,"about_ca_system_score_gemma":0.00080152304,"threshold_uncertainty_score":0.8194201},"labels":[],"label_agreement":null},{"id":"W2984527456","doi":"10.1182/blood-2019-123709","title":"Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in AML","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Cancer research; Suramin; Transplantation; Medicine; Chemistry; Molecular biology; Biology; Internal medicine; Receptor","score_opus":0.010899445987555285,"score_gpt":0.25809169288670486,"score_spread":0.24719224689914956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984527456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912924,0.000167863,0.0000030481758,0.00082883297,0.00006462617,0.0005504944,0.0000068522845,0.000016240958,0.007069614],"genre_scores_gemma":[0.9982677,0.000039449318,0.00020607436,0.00021377105,0.000067926645,0.00001012943,0.000017873755,0.000015053859,0.0011620334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990699,0.00006226341,0.0001956397,0.0001578313,0.0003288332,0.00018552179],"domain_scores_gemma":[0.99942774,0.000040789808,0.0000561115,0.00035616022,0.000071670336,0.00004751132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023738346,0.00007487923,0.00017809274,0.0001020526,0.000018148867,0.0000033042281,0.000087129214,0.000093095936,0.00034672665],"category_scores_gemma":[0.00010824149,0.0000497411,0.00006341609,0.00038336188,0.000041617823,0.00003724615,0.000107337895,0.00024559489,0.00013930832],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009418498,0.00034462064,0.0808978,0.00007976604,0.000019485518,0.000019941166,0.0001960451,0.0000036039787,0.9172297,0.000087766355,0.00038602328,0.00064104743],"study_design_scores_gemma":[0.006954976,0.0002411716,0.17752299,0.00021948873,0.000038815495,0.000034371715,0.00011724269,0.000146512,0.81338286,0.00012796189,0.0011429,0.00007073284],"about_ca_topic_score_codex":0.00012328521,"about_ca_topic_score_gemma":0.000026424452,"teacher_disagreement_score":0.10384687,"about_ca_system_score_codex":0.000087711014,"about_ca_system_score_gemma":0.00020997626,"threshold_uncertainty_score":0.37964135},"labels":[],"label_agreement":null},{"id":"W2984562897","doi":"10.1371/journal.pgen.1008463","title":"NPM and NPM-MLF1 interact with chromatin remodeling complexes and influence their recruitment to specific genes","year":2019,"lang":"en","type":"article","venue":"PLoS Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Nucleophosmin; Biology; NPM1; Chromatin; Chromatin remodeling; Gene knockdown; Nuclear export signal; Regulation of gene expression; Cancer research; Gene; Nuclear protein; Cell biology; Transcription factor; Genetics; Cell nucleus; Molecular biology; Chromosome","score_opus":0.06698824264983796,"score_gpt":0.30504985352421116,"score_spread":0.2380616108743732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984562897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949702,0.002238658,0.00012270933,0.00074428576,0.000025198517,0.0014252668,0.000013159772,0.00003862135,0.00042189818],"genre_scores_gemma":[0.980758,0.001353019,0.016956422,0.0004901903,0.0000972827,0.000040073333,0.000012138471,0.000044959248,0.00024792182],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986881,0.00004319086,0.000235249,0.00040261977,0.00031376485,0.0003171025],"domain_scores_gemma":[0.99897045,0.000119723394,0.000052600673,0.00044601652,0.0001701024,0.00024110882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001355099,0.00020206254,0.00032372135,0.00012394426,0.000061594124,0.000068561894,0.00012432007,0.000060780854,0.00005703101],"category_scores_gemma":[0.000030440511,0.0001463715,0.000019419756,0.00015111461,0.00008814076,0.000056123605,0.00021007436,0.00020722767,0.00006814402],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003274113,0.00007784614,0.04451418,0.00026059253,0.000109074295,0.000023974417,0.0021497027,0.00045850818,0.92859983,0.00002198694,0.0002574554,0.023199424],"study_design_scores_gemma":[0.00504984,0.004248769,0.09225301,0.0019641651,0.00015425977,0.0005559326,0.0026225923,0.09191214,0.76172507,0.00020311865,0.038371854,0.00093925034],"about_ca_topic_score_codex":0.0000128161555,"about_ca_topic_score_gemma":0.000012787985,"teacher_disagreement_score":0.16687478,"about_ca_system_score_codex":0.00012409667,"about_ca_system_score_gemma":0.00009027813,"threshold_uncertainty_score":0.5968857},"labels":[],"label_agreement":null},{"id":"W2985030816","doi":"10.1182/blood-2019-121743","title":"The Impact of Identifying the Syndromic and Genetic Diagnoses on Hematopoietic Stem Cell Transplantation Outcome in Patients with Inherited Bone Marrow Failure Syndromes","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Janeway Children's Health and Rehabilitation Centre; London Health Sciences Centre; McMaster Children's Hospital; University of Alberta; Centre hospitalier de l'Université Laval; Centre Hospitalier Universitaire de Sherbrooke; Queen's University; Stollery Children's Hospital; Izaak Walton Killam Health Centre; Alberta Children's Hospital; Children's Hospital of Eastern Ontario; University Health Network; BC Children's Hospital; Royal University Hospital; Montreal Children's Hospital; University of Toronto; SickKids Foundation; University of Manitoba; Kingston General Hospital; Princess Margaret Cancer Centre; University of Saskatchewan; Hospital for Sick Children","funders":"","keywords":"Medicine; Fanconi anemia; Bone marrow failure; Bone marrow; Hematopoietic stem cell transplantation; Transplantation; Pediatrics; Internal medicine; Stem cell; Haematopoiesis; Genetics","score_opus":0.01327975693376609,"score_gpt":0.26361215470471355,"score_spread":0.25033239777094746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985030816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99822533,0.00046800933,0.0000024434344,0.00014171537,0.000017785716,0.0010710268,0.00001654915,0.000013182699,0.000043968543],"genre_scores_gemma":[0.99957937,0.00017269189,0.000046173067,0.000018246885,0.000006675508,0.0000307138,0.000012954428,0.000028781085,0.000104375256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987586,0.00010317603,0.00029483953,0.0002097359,0.00037592874,0.0002577094],"domain_scores_gemma":[0.99908084,0.00034489145,0.00010846702,0.00035055671,0.0000535207,0.00006172084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017587675,0.00015708462,0.0002970884,0.00011571307,0.000060408147,0.00003464593,0.00012838494,0.000066573855,0.000018316785],"category_scores_gemma":[0.000015809404,0.000077114535,0.000060205894,0.0002395187,0.00008385527,0.00005932323,0.00002711301,0.00026246466,0.000017648958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028371668,0.00026044497,0.9959511,0.00039596806,0.00008983499,0.00009929891,0.00079893105,0.00002993503,0.0018622143,0.000003950153,0.000019842832,0.0002047493],"study_design_scores_gemma":[0.0066869846,0.00095675123,0.989377,0.00030566676,0.00012043284,0.00018634641,0.00037119637,0.000043309927,0.0018535169,0.0000074934483,0.000001714303,0.00008959114],"about_ca_topic_score_codex":0.00010800794,"about_ca_topic_score_gemma":0.000027958458,"teacher_disagreement_score":0.006574118,"about_ca_system_score_codex":0.00006901175,"about_ca_system_score_gemma":0.000077918776,"threshold_uncertainty_score":0.31446394},"labels":[],"label_agreement":null},{"id":"W2985107893","doi":"10.1182/blood-2019-129962","title":"Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Internal medicine; Survival analysis; Oncology; Medicine; Biology","score_opus":0.04732996390358868,"score_gpt":0.32995276029831666,"score_spread":0.282622796394728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985107893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975667,0.0002688675,0.00000742837,0.00040592448,0.000019115789,0.0014845942,0.00014939082,0.00003554902,0.00006245958],"genre_scores_gemma":[0.99854463,0.00008293447,0.00022293816,0.000032229138,0.000028904242,0.00007915811,0.00014280739,0.00005535147,0.0008110295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99691975,0.0009881022,0.00034580703,0.00075726234,0.00058283075,0.0004062499],"domain_scores_gemma":[0.99809086,0.0009225678,0.00012366858,0.00047965872,0.000118118216,0.00026513048],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008349709,0.00039495894,0.0007473551,0.0003835546,0.00010906813,0.000098530516,0.000072696486,0.00011523512,0.000055215143],"category_scores_gemma":[0.00017274983,0.0002581695,0.00003129388,0.00043690533,0.00011575483,0.000234325,0.00008148989,0.00022615408,0.0000071489517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13424681,0.003111033,0.8416231,0.00001862434,0.00073931785,0.0006166636,0.003582226,6.9405087e-7,0.014614611,2.361859e-7,0.0000040643977,0.001442565],"study_design_scores_gemma":[0.09404388,0.020530479,0.87572753,0.0001486973,0.0008127108,0.000035211284,0.004146384,0.00017969192,0.004075392,0.0000013156009,0.000031111944,0.00026758073],"about_ca_topic_score_codex":0.0024577286,"about_ca_topic_score_gemma":0.0009143244,"teacher_disagreement_score":0.040202934,"about_ca_system_score_codex":0.00017063605,"about_ca_system_score_gemma":0.00019779586,"threshold_uncertainty_score":0.99998707},"labels":[],"label_agreement":null},{"id":"W2985191819","doi":"10.1182/blood-2019-126806","title":"Anabolic Steroids in Myelodysplastic Syndromes: A Systematic Review","year":2019,"lang":"en","type":"review","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Medicine; Danazol; Myelodysplastic syndromes; Randomized controlled trial; Internal medicine; Systematic review; Observational study; Pediatrics; MEDLINE; Bone marrow","score_opus":0.06386093926992038,"score_gpt":0.3681208677657144,"score_spread":0.30425992849579403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985191819","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014780177,0.98724705,0.0000025638801,0.000045663914,0.00012456317,0.011192208,0.000042579133,0.000081257655,0.0012493466],"genre_scores_gemma":[0.000005364693,0.9942257,0.00007564748,0.00027336166,0.00012866875,0.0014396681,0.00019910153,0.00018661733,0.003465869],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99485976,0.000723907,0.0019484041,0.0008279866,0.00084317185,0.0007967505],"domain_scores_gemma":[0.9964531,0.00068020314,0.0005569739,0.0018880689,0.00011895535,0.00030271203],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012019232,0.0007432783,0.009270986,0.00089085056,0.000028751549,0.000039395254,0.00069737923,0.0005234061,0.00016060448],"category_scores_gemma":[0.0016271076,0.0005338972,0.00086674903,0.0015911495,0.00006432654,0.00007378854,0.00026136695,0.0014768495,0.0047293487],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002370825,0.00023528362,0.0000052741293,0.9842101,0.00072666176,0.0011839647,0.00001552539,1.3039523e-8,1.6836826e-7,0.000017615992,0.00043802243,0.013165028],"study_design_scores_gemma":[0.0014881403,0.00020560554,0.000004716653,0.8735872,0.019155871,0.004836514,0.000008945674,0.0000022395466,1.0001341e-7,0.0000014944479,0.100326985,0.000382214],"about_ca_topic_score_codex":0.000017860864,"about_ca_topic_score_gemma":0.0000036053968,"teacher_disagreement_score":0.1106229,"about_ca_system_score_codex":0.0006043377,"about_ca_system_score_gemma":0.002062362,"threshold_uncertainty_score":0.9997113},"labels":[],"label_agreement":null},{"id":"W2985248532","doi":"10.1182/blood-2019-129805","title":"Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Venetoclax; Ven; Internal medicine; Population; Tumor lysis syndrome; Refractory (planetary science); Gastroenterology; Oncology; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.004360733275188402,"score_gpt":0.23479103143714344,"score_spread":0.23043029816195504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985248532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656063,0.00019552109,0.0000034818258,0.00008659497,0.000048465634,0.002963671,0.000024688014,0.000021281869,0.00009568576],"genre_scores_gemma":[0.998808,0.00071066746,0.00011083728,0.000074284384,0.00004357795,0.000053440264,0.000027378619,0.00006125353,0.0001105629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782634,0.00013854595,0.00045257647,0.00056612864,0.0006374073,0.0003790175],"domain_scores_gemma":[0.99881154,0.00019216914,0.00022948372,0.00042949518,0.00019037267,0.0001469408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003004873,0.0003212622,0.00058136164,0.0003520191,0.00006904787,0.000029079141,0.00014909462,0.00017689235,0.0000061425458],"category_scores_gemma":[0.0000719498,0.0002111323,0.000024237374,0.00070457807,0.0001891068,0.00020549522,0.00015158794,0.0005561118,0.0000020269833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006777628,0.0017990795,0.98538953,0.00017894166,0.00024856496,0.00006984962,0.0021335282,0.000009135395,0.0019469144,0.000007592196,0.000024571675,0.0014146524],"study_design_scores_gemma":[0.15748627,0.0069147367,0.8331204,0.00023522894,0.0004601672,0.00006370362,0.00029033367,0.00029116505,0.0009165514,0.0000052244905,0.0000074962963,0.00020871358],"about_ca_topic_score_codex":0.00029027613,"about_ca_topic_score_gemma":0.00017322699,"teacher_disagreement_score":0.15226912,"about_ca_system_score_codex":0.0009012814,"about_ca_system_score_gemma":0.0010051469,"threshold_uncertainty_score":0.8609725},"labels":[],"label_agreement":null},{"id":"W2985481325","doi":"10.1182/blood-2019-130532","title":"Trial in Progress: Feasibility and Validation Study of the LSC17 Score in Acute Myeloid Leukemia Patients","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Induction chemotherapy; Myeloid leukemia; Clinical endpoint; Multivariate analysis; Clinical trial; Stem cell; Chemotherapy regimen; Chemotherapy; Biology","score_opus":0.030265238646037113,"score_gpt":0.3108536707774006,"score_spread":0.28058843213136353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985481325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940175,0.00005407186,9.133178e-8,0.000086515414,0.00008245296,0.0055653136,0.000006854257,0.000010669664,0.000176539],"genre_scores_gemma":[0.99969345,0.000013843327,0.0000394896,0.000020566597,0.000031948908,0.00008315868,0.000012716864,0.000014345506,0.00009045281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983303,0.00022507079,0.00039376417,0.0003298002,0.0004990118,0.00022205806],"domain_scores_gemma":[0.99915165,0.00007028902,0.00011454282,0.0005134469,0.000096838354,0.00005324109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005990391,0.00011899812,0.0003314832,0.00014371857,0.000022123017,0.000012744673,0.00016601071,0.000095544514,0.000017888182],"category_scores_gemma":[0.00023714312,0.00008029492,0.000038644313,0.00045277184,0.000075106655,0.0000959342,0.00018966218,0.00034780026,0.0000061309506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061558397,0.0027954862,0.9882576,0.00007146472,0.000048417012,0.000008413777,0.0010960806,0.0000013568108,0.00054332643,0.0000037379252,0.000017843638,0.0010004413],"study_design_scores_gemma":[0.15044813,0.0019004735,0.84463793,0.00009076574,0.00007111569,0.0000026389669,0.00029958933,0.00003491352,0.0024224333,0.000023147602,0.0000070448004,0.00006184102],"about_ca_topic_score_codex":0.00021305785,"about_ca_topic_score_gemma":0.00013613331,"teacher_disagreement_score":0.1442923,"about_ca_system_score_codex":0.00032126406,"about_ca_system_score_gemma":0.00034940089,"threshold_uncertainty_score":0.3274332},"labels":[],"label_agreement":null},{"id":"W2985638537","doi":"10.1182/blood-2019-130332","title":"Quantitative Modeling of Azacitidine Resistance in Patients with Myelodysplastic Syndrome Identifies Distinct Phenotypes of Disease Progression: Evidence for the Presence of a Disease Versus Native Clone Effect","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Myelodysplastic syndromes; Azacitidine; Bone marrow; Haematopoiesis; International Prognostic Scoring System; clone (Java method); Immunology; Leukemia; Disease; Oncology; Stem cell; Medicine; Biology; Internal medicine; Genetics; Gene","score_opus":0.028571509215519278,"score_gpt":0.3231478633011585,"score_spread":0.29457635408563926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985638537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936485,0.0024771593,0.0005294264,0.000102392696,0.00005985852,0.0029641532,0.00018526026,0.000011053903,0.000022187778],"genre_scores_gemma":[0.9988922,0.00003672106,0.0007060419,0.000002222906,0.000012035747,0.00023703981,0.000029928258,0.000025856272,0.000057978963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978956,0.00016545985,0.00043282012,0.00037266995,0.0008674267,0.00026601806],"domain_scores_gemma":[0.99402565,0.0043644565,0.00030320187,0.00050802383,0.0006587234,0.0001399666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048406504,0.00018678974,0.00051978754,0.00014620116,0.00004728402,0.00000824399,0.000273296,0.000036408444,0.000011051357],"category_scores_gemma":[0.005184834,0.00011650367,0.000097351774,0.0004758348,0.00036272453,0.00020621307,0.00011900624,0.00016805057,0.0000017211073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3047935,0.0021061539,0.6718358,0.0137799885,0.0008633537,0.00005448738,0.0012989885,0.002697653,0.0015741684,0.00077527994,0.000019789544,0.0002008316],"study_design_scores_gemma":[0.024967948,0.007824024,0.9239444,0.015445602,0.0013324554,6.552253e-7,0.0002604947,0.02277296,0.0029937127,0.00020895633,8.300307e-7,0.000247974],"about_ca_topic_score_codex":0.000037143906,"about_ca_topic_score_gemma":0.00002904876,"teacher_disagreement_score":0.27982554,"about_ca_system_score_codex":0.00006471412,"about_ca_system_score_gemma":0.0004442983,"threshold_uncertainty_score":0.6207105},"labels":[],"label_agreement":null},{"id":"W2985702191","doi":"10.1182/blood-2019-125338","title":"Novel Therapeutics That Can Target and Eradicate Leukemic Stem Cells in Acute Myeloid Leukemia: Investigating FDA-Approved Anti-Inflammatory Compounds","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; University Health Network; McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Acute promyelocytic leukemia; Stem cell; Myeloid leukemia; Leukemia; CD34; Cancer research; Myeloid; Haematopoiesis; Internal medicine; Acute leukemia; Immunology; Bone marrow; Progenitor cell; Oncology; Retinoic acid; Biology; Cell culture","score_opus":0.02704096117162999,"score_gpt":0.25375537533831205,"score_spread":0.22671441416668206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985702191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953033,0.0006264736,0.000036421305,0.0011611321,0.00015319264,0.0012540615,0.00006012458,0.00015089008,0.0012544346],"genre_scores_gemma":[0.9924044,0.00045438687,0.0039086854,0.001564819,0.00013956462,0.000046767815,0.000057806672,0.00013044737,0.0012930946],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968687,0.00012505183,0.0005993669,0.0007945511,0.00068256736,0.00092971546],"domain_scores_gemma":[0.99823457,0.00023669952,0.0002478784,0.00079442794,0.00007717641,0.0004092242],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00070672046,0.00047544148,0.0008459881,0.0003578859,0.00012507098,0.00009346343,0.00039426162,0.00039350675,0.000020754034],"category_scores_gemma":[0.000017887196,0.00043307585,0.00011321257,0.00046089623,0.00034753865,0.00020064294,0.00029088883,0.0013649514,0.000052593143],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061992534,0.00014013021,0.19661142,0.0002950331,0.00037094962,0.00012133032,0.0010804944,0.00002625932,0.800639,0.00008312559,0.00019765836,0.00037263797],"study_design_scores_gemma":[0.027069455,0.00052230974,0.13487805,0.00060141255,0.00058145577,0.00085207366,0.0012820837,0.010160752,0.81837505,0.00010190349,0.0045603504,0.0010151156],"about_ca_topic_score_codex":0.00022295916,"about_ca_topic_score_gemma":0.00004167168,"teacher_disagreement_score":0.061733365,"about_ca_system_score_codex":0.00083317363,"about_ca_system_score_gemma":0.0016580375,"threshold_uncertainty_score":0.9998121},"labels":[],"label_agreement":null},{"id":"W2985753547","doi":"10.1182/blood-2019-129614","title":"Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Decitabine; Internal medicine; Medicine; Oncology; Discontinuation; Clinical endpoint; Population; Randomization; Progression-free survival; Surrogate endpoint; Phases of clinical research; Cytarabine; Adverse effect; Randomized controlled trial; Gastroenterology; Clinical trial; Leukemia; Chemotherapy; Biology","score_opus":0.01945934543131652,"score_gpt":0.3314044302722122,"score_spread":0.3119450848408957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985753547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97402924,0.0003526862,0.00003578411,0.00032988546,0.00017408314,0.024244472,0.0007268296,0.000052635394,0.000054383687],"genre_scores_gemma":[0.996914,0.00007240419,0.00078355067,0.000038859147,0.0001527304,0.001507365,0.00032444342,0.00008330553,0.00012330762],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953556,0.0005857382,0.0009932112,0.0010881182,0.0012969295,0.0006804095],"domain_scores_gemma":[0.9961384,0.0010412545,0.00042995557,0.0013563508,0.00070760015,0.00032642393],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00069125096,0.000705791,0.0024983766,0.00021563935,0.000080408696,0.000041425898,0.0003684313,0.00016520785,0.00006622594],"category_scores_gemma":[0.00059525087,0.00044254327,0.00024031804,0.00043790523,0.00015202611,0.00013373609,0.00019650265,0.00021170737,0.0000049106798],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25449494,0.062045913,0.6668465,0.00005199079,0.0040290495,0.00010602288,0.00475466,0.000004213647,0.00029198593,0.0000039727074,0.000035819743,0.0073349243],"study_design_scores_gemma":[0.6845971,0.056995634,0.24998355,0.0001830412,0.0013493742,0.0000034371892,0.005383237,0.0001231757,0.0010380342,0.000035621917,0.000030718016,0.00027707804],"about_ca_topic_score_codex":0.005563291,"about_ca_topic_score_gemma":0.0040142713,"teacher_disagreement_score":0.43010217,"about_ca_system_score_codex":0.0008749977,"about_ca_system_score_gemma":0.0003933633,"threshold_uncertainty_score":0.99980265},"labels":[],"label_agreement":null},{"id":"W2985777859","doi":"10.1182/blood-2019-132008","title":"Transcriptome Analysis of Pediatric AML Reveals Non Protein-Coding RNAs Associated with Poor Survival Outcome and Treatment Resistance","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Transcriptome; Biology; Gene; Pseudogene; Bortezomib; Bioinformatics; Oncology; Genetics; Medicine; Gene expression; Genome; Immunology; Multiple myeloma","score_opus":0.02426977544349258,"score_gpt":0.28296859571622957,"score_spread":0.258698820272737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985777859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99671996,0.00028581533,0.00003063699,0.00028998952,0.000018040075,0.001104381,0.00007305459,0.000036647903,0.0014414779],"genre_scores_gemma":[0.9912101,0.000091940456,0.00040035823,0.00002820908,0.000057843034,0.00004632654,0.000050231818,0.000032080457,0.0080829235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981941,0.00010072016,0.0004063485,0.0003883841,0.00054338126,0.00036707966],"domain_scores_gemma":[0.99895567,0.00014930274,0.0001924006,0.0003747062,0.00017007165,0.0001578243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049088505,0.00020794634,0.0009138646,0.00048571287,0.000046500776,0.000016898142,0.00010051924,0.000113974114,0.00006791122],"category_scores_gemma":[0.00012578689,0.00014904041,0.00016567015,0.0014146863,0.00004741986,0.000067240835,0.000020373609,0.00017460236,0.000008156527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045260144,0.0005606762,0.9004282,0.00016705655,0.0034145392,0.00008479058,0.00032985557,0.0000025242725,0.09443169,0.000053395375,0.000022559669,0.00005213802],"study_design_scores_gemma":[0.014366997,0.0013749832,0.96039444,0.00011336908,0.009645966,0.000004196276,0.00017238264,0.00009742004,0.013509052,0.000005169933,0.00006908408,0.00024695325],"about_ca_topic_score_codex":0.00010158865,"about_ca_topic_score_gemma":0.00018500516,"teacher_disagreement_score":0.08092263,"about_ca_system_score_codex":0.00022912589,"about_ca_system_score_gemma":0.00016265416,"threshold_uncertainty_score":0.60776913},"labels":[],"label_agreement":null},{"id":"W2985908233","doi":"10.1182/blood-2019-128281","title":"The 17-Gene Leukemic Stemess Score Can Predict Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Occupational Cancer Research Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Transplantation; Myeloid leukemia; Hematopoietic stem cell transplantation; Leukemia; Cohort; Cyclophosphamide; Acute leukemia; Regimen; Gastroenterology; Oncology; Chemotherapy","score_opus":0.015775002157433028,"score_gpt":0.26094240680712694,"score_spread":0.24516740464969392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985908233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99435025,0.0012227516,0.000019197303,0.0005235816,0.00024499098,0.002195242,0.00006790646,0.000119676806,0.0012564126],"genre_scores_gemma":[0.9866107,0.0012555034,0.00014649199,0.00018305666,0.00006619413,0.00027780913,0.00017070663,0.000093386654,0.011196131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968296,0.00017420703,0.00067008147,0.00066284003,0.00077438925,0.0008888513],"domain_scores_gemma":[0.99828535,0.00034146287,0.00014561863,0.0009055008,0.00006336785,0.0002587009],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046136376,0.00046129452,0.0007842907,0.00023965612,0.00018550857,0.00006841778,0.00040622495,0.00023752623,0.000029005574],"category_scores_gemma":[0.0000092871105,0.0003048648,0.00036253143,0.0004274647,0.00007266955,0.00011848446,0.0000660802,0.0004297651,0.00011059855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003638091,0.00041735612,0.85996544,0.0003444021,0.0012115039,0.0015028893,0.0029548283,0.00015254757,0.13088237,0.00003215163,0.00011603417,0.0020566615],"study_design_scores_gemma":[0.04949368,0.0021562537,0.5223938,0.0006519364,0.0031218654,0.00080308603,0.0023669624,0.00037272737,0.41695288,0.00004615496,0.0006984925,0.00094217755],"about_ca_topic_score_codex":0.00040236147,"about_ca_topic_score_gemma":0.0003772642,"teacher_disagreement_score":0.33757165,"about_ca_system_score_codex":0.0018715175,"about_ca_system_score_gemma":0.0015155391,"threshold_uncertainty_score":0.99994034},"labels":[],"label_agreement":null},{"id":"W2986023446","doi":"10.1016/j.jmoldx.2019.10.002","title":"Clinical Validation of a Myeloid Next-Generation Sequencing Panel for Single-Nucleotide Variants, Insertions/Deletions, and Fusion Genes","year":2019,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Alberta Hospital; Alberta Hospital Edmonton","funders":"AstraZeneca; University of Alberta; Pfizer","keywords":"Myeloid leukemia; Myeloproliferative neoplasm; Fusion gene; Myeloid; DNA sequencing; Biology; Gene; Myelodysplastic syndromes; Concordance; Cancer research; Genetics; Bone marrow; Immunology; Myelofibrosis","score_opus":0.11212202136998262,"score_gpt":0.3329269903231352,"score_spread":0.2208049689531526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986023446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9630485,0.0016284235,0.033289127,0.0010766679,0.00034061781,0.0005505378,0.000011019296,0.00000751796,0.000047581412],"genre_scores_gemma":[0.96557873,0.004429754,0.029052554,0.00038208783,0.0004478231,0.0000058111214,0.000047469308,0.000031803043,0.000023947912],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99808276,0.00017844266,0.0009315884,0.00018178974,0.00044137402,0.00018402892],"domain_scores_gemma":[0.99730456,0.00076846225,0.00053430727,0.00022874393,0.0009980163,0.0001659034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012179082,0.00012874827,0.0004197705,0.00024389956,0.000058630234,0.000047866695,0.00010142998,0.00016350734,0.000020171196],"category_scores_gemma":[0.003474644,0.000113747425,0.00017694465,0.00018121269,0.00006635932,0.0002181939,0.000053843934,0.0002961276,0.0000052229575],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018934981,0.00019980343,0.015162373,0.00014937264,0.00012175806,0.00007333089,0.00007963855,0.00040022552,0.96859026,0.00015068651,0.0005644071,0.014318804],"study_design_scores_gemma":[0.009222,0.0059853396,0.024964513,0.0012267694,0.0011667161,0.0013361219,0.00060601823,0.023984512,0.9266749,0.0006964166,0.0037362836,0.0004003787],"about_ca_topic_score_codex":0.000011458183,"about_ca_topic_score_gemma":0.0000015700829,"teacher_disagreement_score":0.04191532,"about_ca_system_score_codex":0.00020177814,"about_ca_system_score_gemma":0.0005789414,"threshold_uncertainty_score":0.46384853},"labels":[],"label_agreement":null},{"id":"W2986130636","doi":"10.1182/blood-2019-124516","title":"Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Internal medicine; Cytarabine; Hazard ratio; Chemotherapy regimen; Gastroenterology; Induction chemotherapy; Neutropenia; Oncology; Myeloid leukemia; Surgery; Chemotherapy; Confidence interval","score_opus":0.011055303030863606,"score_gpt":0.2642811907120414,"score_spread":0.2532258876811778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986130636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99554116,0.00007830165,0.000023847095,0.000617031,0.0000668972,0.0018208061,0.000066067245,0.00024503033,0.0015408493],"genre_scores_gemma":[0.9948242,0.00008387169,0.001205009,0.00019135071,0.000050360366,0.00014273098,0.0005930937,0.00016136726,0.0027480314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99554247,0.00018933802,0.00052770274,0.0011368878,0.0015824819,0.0010211278],"domain_scores_gemma":[0.9970873,0.00019748995,0.0003458846,0.0013822885,0.0004219434,0.000565089],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003789547,0.0007104352,0.0015019797,0.0011546434,0.0001377827,0.00006107932,0.00041452143,0.00035088864,0.0002650544],"category_scores_gemma":[0.000080175,0.00044231513,0.00014528424,0.0030042185,0.00021722987,0.00040694026,0.00015783845,0.0010769608,0.00012188825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029442439,0.0020380816,0.95255816,0.00013100274,0.009626715,0.0008745418,0.0014711621,0.000105576146,0.002355208,0.000010711782,0.00017774428,0.0012086646],"study_design_scores_gemma":[0.22794136,0.017799538,0.73090976,0.00075218285,0.00897116,0.00004853634,0.0012193363,0.0008252623,0.009668882,0.0000025340648,0.00063630333,0.0012251162],"about_ca_topic_score_codex":0.00013238747,"about_ca_topic_score_gemma":0.00045995062,"teacher_disagreement_score":0.22164837,"about_ca_system_score_codex":0.0008122535,"about_ca_system_score_gemma":0.0010470815,"threshold_uncertainty_score":0.9998029},"labels":[],"label_agreement":null},{"id":"W2986256604","doi":"10.1182/blood.v124.21.2450.2450","title":"Plerixafor Successfully Rescues Poor Mobilizers Resulting in Adequate CD34 Cell Numbers However Stem Cell Products Yield Lower Numbers of CFU/CD34 and Delayed Neutrophil Engraftment","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Plerixafor; Autologous stem-cell transplantation; CD34; Multiple myeloma; Medicine; Filgrastim; Population; Stem cell; Apheresis; Internal medicine; Granulocyte colony-stimulating factor; Immunology; CXCR4; Oncology; Chemotherapy; Biology; Platelet; Receptor","score_opus":0.013928645510601773,"score_gpt":0.2421309664262493,"score_spread":0.22820232091564752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986256604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903152,0.0005618858,0.00001455847,0.0013662175,0.00017771382,0.0015268928,0.000031479012,0.00008511678,0.005920959],"genre_scores_gemma":[0.9938805,0.00022813419,0.0016826557,0.000265493,0.0002147599,0.000105743246,0.000029061375,0.000103485334,0.0034901444],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962459,0.0002374276,0.00084598974,0.00095873704,0.0007767158,0.00093523046],"domain_scores_gemma":[0.99771005,0.00045487972,0.0003056375,0.0008676613,0.00029790035,0.0003638632],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011435533,0.00043998926,0.00076768216,0.00031603526,0.00010351848,0.00004742406,0.00033765586,0.00027396932,0.00007335446],"category_scores_gemma":[0.00028845127,0.00038955404,0.00013689845,0.00057533593,0.00025154155,0.00021130724,0.00025600076,0.0007236331,0.00004462893],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00892956,0.0070351935,0.08676389,0.004957287,0.0009040269,0.0011467778,0.012543118,0.00036136317,0.857251,0.00019517045,0.014929419,0.004983229],"study_design_scores_gemma":[0.03331517,0.003852452,0.015810756,0.0008261051,0.00075537246,0.00013170851,0.0058283135,0.0011160201,0.93165374,0.00004123261,0.005493964,0.001175136],"about_ca_topic_score_codex":0.001952809,"about_ca_topic_score_gemma":0.00016834053,"teacher_disagreement_score":0.0744028,"about_ca_system_score_codex":0.0002127106,"about_ca_system_score_gemma":0.00036985724,"threshold_uncertainty_score":0.99985564},"labels":[],"label_agreement":null},{"id":"W2986296009","doi":"10.1182/blood-2019-128949","title":"Prognostic Performance of Frailty Measures in MDS Patients Treated with Hypomethylating Agents","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Dr. Georges-L.-Dumont University Hospital Centre; St. Paul's Hospital; Alberta Hospital Edmonton; University of British Columbia; Saskatchewan Cancer Agency; CancerCare Manitoba; University Health Network; Health Sciences Centre; University of Alberta Hospital; Ottawa Hospital; McGill University Health Centre; University of Ottawa; Hamilton Health Sciences; Dalhousie University; Hôpital de l'Enfant-Jésus; Juravinski Cancer Centre; Jewish General Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Decitabine; Myelodysplastic syndromes; International Prognostic Scoring System; Internal medicine; Azacitidine; Comorbidity; Proportional hazards model; Quality of life (healthcare)","score_opus":0.025674913556442622,"score_gpt":0.267788450369429,"score_spread":0.24211353681298636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986296009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99505305,0.000051384155,0.0000010561855,0.000017231136,0.000012349721,0.0007850171,0.000004930649,0.000023869423,0.0040511107],"genre_scores_gemma":[0.99902534,0.000015398784,0.00043055217,0.00002611437,0.000016840793,0.00002466586,0.000025902813,0.000024680981,0.00041050502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872535,0.000044643482,0.0002324075,0.00020875994,0.0005074191,0.00028142318],"domain_scores_gemma":[0.999324,0.00007445389,0.0000809469,0.00025823887,0.00018313326,0.000079202844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019610868,0.00011940565,0.00027673814,0.00018893677,0.000018785782,0.0000055288974,0.00009893238,0.00007065521,0.000067196255],"category_scores_gemma":[0.00022922328,0.00008600917,0.000028446319,0.0004759705,0.000041911968,0.00007697652,0.00004334713,0.00023224771,0.000048818907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002648631,0.00060440553,0.99041456,0.00019474037,0.00007241602,0.000014347426,0.00018724141,0.000012244805,0.0051823426,0.0000011013765,0.000016597456,0.003035115],"study_design_scores_gemma":[0.008720417,0.0016700487,0.96279246,0.00035984552,0.000064545224,0.000006899082,0.000032859236,0.0005669475,0.025655156,8.074669e-7,0.000041798903,0.00008820136],"about_ca_topic_score_codex":0.00009659483,"about_ca_topic_score_gemma":0.000007896996,"teacher_disagreement_score":0.027622111,"about_ca_system_score_codex":0.000071030605,"about_ca_system_score_gemma":0.00014803703,"threshold_uncertainty_score":0.35073522},"labels":[],"label_agreement":null},{"id":"W2986303745","doi":"10.1182/blood-2019-129529","title":"BCL-2 Inhibitor Venetoclax Enhances Temozolomide Sensitivity in AML","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Temozolomide; Methyltransferase; Venetoclax; Cancer research; Myeloid leukemia; Decitabine; O-6-methylguanine-DNA methyltransferase; Viability assay; Apoptosis; Biology; Medicine; Leukemia; DNA methylation; Immunology; Methylation; Chronic lymphocytic leukemia; DNA; Gene expression; Biochemistry; Glioma","score_opus":0.011046485691227821,"score_gpt":0.2722078270885017,"score_spread":0.26116134139727387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986303745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895897,0.0002251776,0.000007741294,0.0005818338,0.00012497816,0.000603866,0.0000057602533,0.000061438885,0.008799501],"genre_scores_gemma":[0.99605924,0.0000614407,0.00046948213,0.0002908583,0.00031445877,0.000020508807,0.000014577118,0.000026859223,0.0027425538],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986023,0.000089627814,0.0002196962,0.0003445799,0.00033418584,0.00040964942],"domain_scores_gemma":[0.9992075,0.00015663271,0.000046141133,0.000397178,0.000061520725,0.00013103784],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000505068,0.00014087703,0.00034274117,0.00015681065,0.0000243997,0.000015526435,0.00007570241,0.00013647003,0.00015222607],"category_scores_gemma":[0.00016320485,0.00012284028,0.00006811911,0.00029468647,0.000059896523,0.00009044386,0.000095111325,0.00042245036,0.0011520039],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023456452,0.00033696298,0.21446927,0.00017275188,0.000069676506,0.0007240281,0.00023980989,0.00000982085,0.7804865,0.00007248608,0.0013345964,0.0018495386],"study_design_scores_gemma":[0.009831088,0.0005668102,0.19790083,0.00031580043,0.0000638073,0.00032270097,0.00022826623,0.00064741244,0.78273135,0.0000722794,0.0070260996,0.00029352173],"about_ca_topic_score_codex":0.00025069618,"about_ca_topic_score_gemma":0.00015746162,"teacher_disagreement_score":0.016568437,"about_ca_system_score_codex":0.00027044356,"about_ca_system_score_gemma":0.00047880737,"threshold_uncertainty_score":0.99962574},"labels":[],"label_agreement":null},{"id":"W2986575254","doi":"10.1182/blood-2019-122980","title":"Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; University of Ottawa; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Decitabine; Pharmacokinetics; Adverse effect; Pharmacology; Dosing; Hypomethylating agent; Azacitidine; Tolerability; Bioavailability; Phases of clinical research; Population; Clinical endpoint; Bioequivalence; Cmax; Internal medicine; Nausea; Clinical trial","score_opus":0.030169310328721388,"score_gpt":0.3654661771086529,"score_spread":0.33529686677993153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986575254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886454,0.0010062567,0.000064150394,0.00008950095,0.00010785796,0.009827082,0.00009111572,0.000078283534,0.000090353526],"genre_scores_gemma":[0.9974985,0.000051646188,0.0017114087,0.00008602781,0.0001554961,0.00019346646,0.00005721909,0.000082193255,0.00016404288],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952043,0.00093519746,0.0011554427,0.001058626,0.0010284998,0.00061787904],"domain_scores_gemma":[0.99606943,0.0017931241,0.00027449543,0.0008866069,0.00035995664,0.00061637483],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00195693,0.0005008655,0.0018726895,0.00035881257,0.00014595366,0.00008827427,0.00034998803,0.00010620588,0.00030805933],"category_scores_gemma":[0.001282143,0.00040996756,0.00010237904,0.0006695652,0.00018756275,0.00023566894,0.0006057558,0.00048368698,0.000012858786],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53490704,0.03584479,0.18767473,0.0003741468,0.00261315,0.0007525149,0.023037447,0.00045714105,0.19962008,0.0000038007765,0.0000738989,0.014641271],"study_design_scores_gemma":[0.70583147,0.015076987,0.26473805,0.00019024154,0.0012692196,0.00004102125,0.0033686631,0.0055144215,0.0035632541,0.000006047805,0.000027505088,0.00037308314],"about_ca_topic_score_codex":0.000805426,"about_ca_topic_score_gemma":0.000026055273,"teacher_disagreement_score":0.19605683,"about_ca_system_score_codex":0.00009002057,"about_ca_system_score_gemma":0.00015452912,"threshold_uncertainty_score":0.9998352},"labels":[],"label_agreement":null},{"id":"W2986692592","doi":"10.1101/845719","title":"Quantum and Quantum-inspired Methods for <i>de novo</i> Discovery of Altered Cancer Pathways","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"Quantum annealing; Quantum; Quadratic unconstrained binary optimization; Solver; Quantum computer; Computer science; Simulated annealing; Myeloid leukemia; Binary number; Computational biology; Theoretical computer science; Algorithm; Mathematics; Biology; Mathematical optimization; Physics; Quantum mechanics; Cancer research","score_opus":0.039820079967566646,"score_gpt":0.3261658622832793,"score_spread":0.28634578231571267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986692592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9384046,0.005283671,0.04946409,0.00063155545,0.0012979095,0.0030614678,0.001639701,0.0002088127,0.000008173624],"genre_scores_gemma":[0.9536411,0.0026646147,0.04136445,0.00042106915,0.0007534859,0.00083933806,0.0000023094547,0.00028907295,0.000024545856],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99590695,0.00032258817,0.00091781036,0.0013671864,0.00048787368,0.0009976049],"domain_scores_gemma":[0.9955996,0.0005636132,0.00065572327,0.001847657,0.00089430006,0.00043905532],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020365233,0.00072521064,0.001656808,0.0004454373,0.00011262006,0.00014387594,0.00056921085,0.0008527743,0.000020459802],"category_scores_gemma":[0.0010291372,0.0006954091,0.00036046715,0.00044832318,0.0003151037,0.00021030725,0.00077574287,0.0011993714,0.000008215899],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072572374,0.00019844885,0.00887474,0.005144388,0.00058508787,0.00003126749,0.000039594855,0.000042468604,0.98173696,0.0019209157,0.00066995766,0.000030434094],"study_design_scores_gemma":[0.005274534,0.00067463727,0.059625115,0.002607937,0.0008636655,2.658743e-7,0.00002011189,0.023426626,0.89938223,0.000034932033,0.0068813562,0.0012085694],"about_ca_topic_score_codex":0.0003593262,"about_ca_topic_score_gemma":0.0000033469441,"teacher_disagreement_score":0.082354724,"about_ca_system_score_codex":0.00095863343,"about_ca_system_score_gemma":0.004484756,"threshold_uncertainty_score":0.9995497},"labels":[],"label_agreement":null},{"id":"W2986878655","doi":"10.1182/blood-2019-122099","title":"Functional Impact of MacroH2A Histone Variants in Acute Myeloid Leukemia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Biology; Myeloid leukemia; Stem cell; Haematopoiesis; Histone; Leukemia; Myeloid; Cancer research; Molecular biology; Genetics; Gene","score_opus":0.01506496602228948,"score_gpt":0.3005780907606493,"score_spread":0.2855131247383598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986878655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893777,0.00022531867,0.000025697229,0.00016575813,0.00010814823,0.00045354568,0.00003892143,0.00003404666,0.0095708845],"genre_scores_gemma":[0.99143016,0.000075469856,0.00057741633,0.00009576526,0.000120221885,0.000015898502,0.00007528892,0.000036507456,0.0075732977],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99838275,0.00004753328,0.0003434866,0.00032527157,0.00047492917,0.0004260451],"domain_scores_gemma":[0.9990368,0.000084786574,0.000088869674,0.0004939004,0.00012805001,0.00016760417],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030062685,0.00017598415,0.00047261128,0.0003202822,0.00002095047,0.000007720159,0.00015199615,0.00016343551,0.0024074442],"category_scores_gemma":[0.0000852368,0.00014551304,0.00018585433,0.00046600046,0.0000735614,0.000106867876,0.000099321645,0.00045196252,0.0006501662],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014369709,0.0007867801,0.37404183,0.00014106224,0.0008791666,0.00044496,0.00024221883,0.000074958065,0.61338574,0.00017403418,0.0070248316,0.0013674768],"study_design_scores_gemma":[0.013139997,0.0007873043,0.966077,0.00009375684,0.00016228267,0.00048233464,0.000031928237,0.0004068087,0.018283904,0.000068404865,0.00030516039,0.00016108151],"about_ca_topic_score_codex":0.00069352135,"about_ca_topic_score_gemma":0.000012825953,"teacher_disagreement_score":0.59510183,"about_ca_system_score_codex":0.0010222446,"about_ca_system_score_gemma":0.0015701622,"threshold_uncertainty_score":0.9985045},"labels":[],"label_agreement":null},{"id":"W2987021886","doi":"10.1182/blood-2019-122890","title":"High Interpatient Variability in Molecular MRD Response to Consolidation Chemotherapy in Acute Myeloid Leukemia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"Minimal residual disease; Medicine; Internal medicine; Chemotherapy; Oncology; Induction chemotherapy; Myeloid leukemia; Leukemia; Bone marrow; Chemotherapy regimen","score_opus":0.007006892470617845,"score_gpt":0.27194819545318316,"score_spread":0.2649413029825653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987021886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942456,0.000016474618,0.00035908626,0.0028851712,0.00008716006,0.00165281,0.000013033392,0.000046462166,0.0006942343],"genre_scores_gemma":[0.99383044,0.000018434288,0.0038001724,0.0016724705,0.000028797373,0.000107640575,0.000034653087,0.000040300987,0.00046709107],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976597,0.00046263819,0.00046371433,0.0005465946,0.0004121032,0.00045529456],"domain_scores_gemma":[0.99859476,0.00030507162,0.000061709,0.0007417971,0.000113708156,0.0001829567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018183168,0.00020204298,0.00045776542,0.00046808555,0.000014545827,0.000020988267,0.00021694691,0.00018338466,0.00030826306],"category_scores_gemma":[0.0006713006,0.00019394173,0.00006698901,0.00072415936,0.00004623567,0.00008806005,0.00013153409,0.00048590117,0.00030905823],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010320363,0.0008399023,0.09580544,0.00008045624,0.00012159803,0.00038938972,0.0014881495,0.000099443576,0.88739413,0.00022792572,0.0002226743,0.0030105347],"study_design_scores_gemma":[0.02746372,0.00183204,0.3788178,0.00032697403,0.00006609374,0.00008317341,0.0001764719,0.0010272098,0.587611,0.0003211909,0.0018533991,0.00042095035],"about_ca_topic_score_codex":0.00035050826,"about_ca_topic_score_gemma":0.000026654532,"teacher_disagreement_score":0.29978314,"about_ca_system_score_codex":0.0014159725,"about_ca_system_score_gemma":0.00078960846,"threshold_uncertainty_score":0.7908714},"labels":[],"label_agreement":null},{"id":"W2987036376","doi":"10.1182/blood-2019-124917","title":"Distal Enhancer Elements in ASXL1-Mutant Chronic Myelomonocytic Leukemia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Epigenomics; Biology; H3K4me3; DNA methylation; Histone; Chromatin immunoprecipitation; Epigenetics; Enhancer; Transcriptome; Genetics; Cancer research; Molecular biology; Gene; Promoter; Gene expression","score_opus":0.010919165727189047,"score_gpt":0.28327098521048377,"score_spread":0.27235181948329473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987036376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98297125,0.00062436657,0.000020256897,0.0002119822,0.00012068172,0.0008847081,0.000010885499,0.000060560236,0.015095333],"genre_scores_gemma":[0.9939538,0.00017776787,0.00028918826,0.00015656555,0.0002531846,0.00006985422,0.000045461853,0.000049654285,0.0050045145],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99791074,0.000048513877,0.00039337605,0.0004588471,0.0004999711,0.0006885547],"domain_scores_gemma":[0.9990499,0.000060894632,0.000069936126,0.00058086024,0.000055314227,0.00018311481],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00030698266,0.00020750666,0.00039999132,0.00019675275,0.00003242924,0.000024368852,0.00021892476,0.00013675625,0.0015191718],"category_scores_gemma":[0.00007771912,0.00018185945,0.000092450115,0.00038435234,0.000059583024,0.00011309946,0.00016227328,0.0005403335,0.00201423],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044311816,0.0007889512,0.16542946,0.0006220389,0.000358935,0.00095693825,0.0004895342,0.000022918783,0.8174021,0.0003826018,0.0009602101,0.012143138],"study_design_scores_gemma":[0.06571068,0.0030036713,0.18425784,0.0011216484,0.00039076357,0.0004767784,0.00050192943,0.0056694746,0.70438164,0.00027784015,0.033097934,0.0011098261],"about_ca_topic_score_codex":0.00015440295,"about_ca_topic_score_gemma":0.000092138216,"teacher_disagreement_score":0.11302053,"about_ca_system_score_codex":0.0024895833,"about_ca_system_score_gemma":0.0015921881,"threshold_uncertainty_score":0.9993936},"labels":[],"label_agreement":null},{"id":"W2987079738","doi":"10.1182/blood-2019-125178","title":"An Epigenetic Screen Identifies PRMT5 As a Target for Inhibition of FLT3-ITD AML Cell Growth in Combination with Tyrosine Kinase Inhibitors","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epigenetics; Fms-Like Tyrosine Kinase 3; Biology; Cancer research; Myeloid leukemia; Epigenetic therapy; DNA methylation; Mutation; Genetics; Gene expression","score_opus":0.008507773728075372,"score_gpt":0.2550562845008642,"score_spread":0.24654851077278883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987079738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963408,0.0001987248,0.00024446414,0.0003183377,0.000041763884,0.0019197993,0.000037675065,0.000037916885,0.00086050347],"genre_scores_gemma":[0.9963681,0.000027309214,0.002389357,0.000055905766,0.00007919805,0.000098021046,0.00039399724,0.000048934762,0.000539185],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844646,0.000076206095,0.00035244427,0.00035759812,0.00045098487,0.00031631283],"domain_scores_gemma":[0.99896866,0.00007898345,0.00014098249,0.00031898374,0.00036694357,0.00012541967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041458083,0.00017002245,0.0003391414,0.0003893366,0.000037599995,0.000024601482,0.000102113045,0.0001293749,0.000059144117],"category_scores_gemma":[0.000103126586,0.000148579,0.000058572878,0.00044846645,0.000090250665,0.00021731447,0.00004105787,0.00019609026,0.000035510562],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011551925,0.0032496422,0.12406308,0.0011336555,0.0000598173,0.000072419585,0.000700774,0.000026968766,0.86836696,0.00052618654,0.00032831164,0.0003170011],"study_design_scores_gemma":[0.016175646,0.0046106023,0.037046995,0.0003165211,0.0000949418,0.000021691223,0.00031812338,0.00036591254,0.94022685,0.0006175023,0.000038609247,0.00016661095],"about_ca_topic_score_codex":0.00045153074,"about_ca_topic_score_gemma":0.00005261602,"teacher_disagreement_score":0.08701608,"about_ca_system_score_codex":0.00009993137,"about_ca_system_score_gemma":0.00027071655,"threshold_uncertainty_score":0.6058876},"labels":[],"label_agreement":null},{"id":"W2987081466","doi":"10.1182/blood-2019-123711","title":"Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta; McGill University; Jewish General Hospital","funders":"","keywords":"Ven; Medicine; Tolerability; Internal medicine; Venetoclax; Gastroenterology; Oncology; Mucositis; Surgery; Adverse effect; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.019847388844180358,"score_gpt":0.29822986088865505,"score_spread":0.2783824720444747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987081466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930764,0.000032852702,0.000024830673,0.00043157552,0.0000619305,0.006045226,0.00015156482,0.00003208594,0.00014353271],"genre_scores_gemma":[0.9974674,0.00003498589,0.00074370677,0.00020453436,0.000093503295,0.0002727544,0.0008071869,0.000063841704,0.00031210989],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977093,0.00016230231,0.00067151024,0.00048257914,0.000591735,0.0003825963],"domain_scores_gemma":[0.9980344,0.00055585214,0.00035364568,0.0006511439,0.00031569222,0.000089241235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006736925,0.0002407455,0.00057355367,0.0002660969,0.00004576964,0.000017739336,0.0002594073,0.00019718456,0.00004850377],"category_scores_gemma":[0.00044800414,0.00014253584,0.000056408586,0.0007683626,0.00008773117,0.00014962559,0.00003877334,0.00047974839,0.0000095628875],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9265573,0.021173399,0.023241477,0.00012594106,0.000365268,0.00006193094,0.0033965176,0.0000364669,0.019504923,0.000020375968,0.0013936729,0.004122698],"study_design_scores_gemma":[0.9163699,0.037551653,0.014586727,0.0005873891,0.00010434381,0.0000037111997,0.00027264265,0.00088075065,0.028204244,0.00006220451,0.0011453923,0.00023105902],"about_ca_topic_score_codex":0.0007577601,"about_ca_topic_score_gemma":0.00043855718,"teacher_disagreement_score":0.016378252,"about_ca_system_score_codex":0.00038366014,"about_ca_system_score_gemma":0.0009702155,"threshold_uncertainty_score":0.5812443},"labels":[],"label_agreement":null},{"id":"W2987093888","doi":"10.1182/blood-2019-130263","title":"CPX-351 As First Intensive Therapy for Elderly Patients with AML","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Cytarabine; Clinical endpoint; Oncology; Leukemia; Performance status; Cancer; Randomized controlled trial","score_opus":0.011078387135582261,"score_gpt":0.2631724838861474,"score_spread":0.25209409675056516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987093888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932099,0.000120368284,0.000025284555,0.0014831019,0.00007448065,0.0019629432,0.00001929607,0.00005037776,0.0030542724],"genre_scores_gemma":[0.993324,0.00005009921,0.00073836796,0.0017708425,0.00012951707,0.00010701671,0.00008961496,0.000053559073,0.003737028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988702,0.00001463041,0.00013859606,0.00029581104,0.00033531224,0.00034546189],"domain_scores_gemma":[0.998538,0.00013303386,0.000053518444,0.0004072759,0.0007342338,0.00013390879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000084528874,0.00014846775,0.0002622836,0.000084608066,0.00005591769,0.000019055213,0.00013124546,0.000090320566,0.00027584273],"category_scores_gemma":[0.00016372529,0.000099975674,0.00007126746,0.00013979689,0.000050038347,0.00006781399,0.000034139677,0.00020021253,0.00042687968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007276958,0.0024158366,0.93500036,0.0003213502,0.0013212772,0.00008973245,0.002126067,0.0000024831668,0.0035687296,0.00031823214,0.027173609,0.020385392],"study_design_scores_gemma":[0.17178446,0.048243843,0.50224143,0.0006305127,0.00043894505,0.00013770889,0.0015129942,0.00013132021,0.044466157,0.00033191053,0.2291653,0.00091544853],"about_ca_topic_score_codex":0.000066149056,"about_ca_topic_score_gemma":0.000011478933,"teacher_disagreement_score":0.43275893,"about_ca_system_score_codex":0.00006289676,"about_ca_system_score_gemma":0.00021471862,"threshold_uncertainty_score":0.54868174},"labels":[],"label_agreement":null},{"id":"W2987120568","doi":"10.1182/blood-2019-129464","title":"Intermittent Transfusion Independence Is Associated with Improved Overall Survival in Patients with Transfusion Dependent MDS","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; McGill University Health Centre; University of British Columbia; Dr. Georges-L.-Dumont University Hospital Centre; St. Paul's Hospital; McMaster University; CancerCare Manitoba; Health Sciences Centre; Ottawa Hospital; University Health Network; Dalhousie University; University of Alberta; Princess Margaret Cancer Centre; Hôpital de l'Enfant-Jésus; Juravinski Cancer Centre; Jewish General Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Blood transfusion; Intensive care medicine; Internal medicine","score_opus":0.007673527807746279,"score_gpt":0.2285183155862673,"score_spread":0.22084478777852104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987120568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631715,0.000023082252,0.00008580097,0.00025288144,0.00008113799,0.0018974057,0.000033067066,0.000065758904,0.0012437084],"genre_scores_gemma":[0.9983903,0.000058119993,0.00011708086,0.0002556088,0.000027870856,0.000040320567,0.000092088776,0.0000655836,0.0009529832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970159,0.00011711073,0.00035202608,0.000641778,0.0012902111,0.00058299315],"domain_scores_gemma":[0.9988565,0.000077756595,0.00009318936,0.00047667278,0.00028648533,0.00020940711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041103218,0.00030856088,0.00052685017,0.00023050031,0.000053088115,0.000031130603,0.00022751027,0.00026327977,0.00033719934],"category_scores_gemma":[0.000043607393,0.00021533779,0.00007907208,0.00037427648,0.00005465862,0.00019870252,0.00005879931,0.00088645244,0.000038356167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035122095,0.0022560472,0.9765877,0.00007992282,0.00023250029,0.00013338377,0.0009092104,0.000004972094,0.014386331,0.0000053355357,0.000015868909,0.0018764929],"study_design_scores_gemma":[0.051091548,0.0040896107,0.9316033,0.00054577267,0.00016936271,0.000021282676,0.00014459858,0.0002928563,0.011699775,0.000005699098,0.000021213998,0.00031497466],"about_ca_topic_score_codex":0.00088617165,"about_ca_topic_score_gemma":0.0010994081,"teacher_disagreement_score":0.047579337,"about_ca_system_score_codex":0.00037251433,"about_ca_system_score_gemma":0.00037352764,"threshold_uncertainty_score":0.878122},"labels":[],"label_agreement":null},{"id":"W2987205136","doi":"10.1038/s41375-019-0621-7","title":"Opposing effects of NPM1wt and NPM1c mutants on AKT signaling in AML","year":2019,"lang":"en","type":"letter","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Signal transduction; Protein kinase B; Cancer research; Mutant; Leukemia; Biology; Medicine; Genetics; Gene","score_opus":0.016957897085136894,"score_gpt":0.28056003888363545,"score_spread":0.26360214179849856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987205136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91838026,0.0011546531,0.000026908356,0.070337884,0.0006219665,0.0023639272,0.000038684957,0.000092047776,0.006983656],"genre_scores_gemma":[0.49748167,0.00035998118,0.0010651062,0.48332563,0.0041424986,0.00009983696,0.00039300168,0.00043375426,0.0126985265],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99651384,0.00023554172,0.0006114632,0.0008346991,0.00095318217,0.0008512894],"domain_scores_gemma":[0.99701095,0.0016515597,0.00026070018,0.0008404868,0.000110550405,0.00012575551],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00041574257,0.00054334354,0.0013317653,0.00085215975,0.000045316672,0.00003934396,0.00032138248,0.001434246,0.00005985992],"category_scores_gemma":[0.0005807792,0.00048080992,0.00017163045,0.0004214708,0.00018898878,0.00008421087,0.00019900865,0.004449761,0.00012538205],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006770134,0.000068587855,0.0029170075,0.012825892,0.00035292996,0.012208059,0.0007112198,0.000050454055,0.1353249,0.000022807046,0.8243487,0.010492442],"study_design_scores_gemma":[0.031332027,0.0049560578,0.008024254,0.042541556,0.0010715018,0.00115269,0.0001769762,0.002718314,0.48244783,0.00040205225,0.42224345,0.0029332773],"about_ca_topic_score_codex":0.0003696686,"about_ca_topic_score_gemma":0.000005401084,"teacher_disagreement_score":0.42089862,"about_ca_system_score_codex":0.002594993,"about_ca_system_score_gemma":0.0012593932,"threshold_uncertainty_score":0.9998621},"labels":[],"label_agreement":null},{"id":"W2987282083","doi":"10.1182/blood-2019-126723","title":"High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Hospital for Sick Children","funders":"","keywords":"Cytarabine; Medicine; Internal medicine; Myeloid leukemia; Leukemia; Gastroenterology; Oncology; Pediatrics","score_opus":0.012186301892589563,"score_gpt":0.25034833818686847,"score_spread":0.2381620362942789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987282083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99515504,0.00016964832,0.00001909693,0.0012854817,0.0000798477,0.0025806318,0.0005839009,0.000029439318,0.00009689549],"genre_scores_gemma":[0.9968428,0.000031609266,0.0013114013,0.00011008434,0.0001675899,0.00008348841,0.00019486429,0.00006152698,0.0011966123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978019,0.00009011197,0.0004342267,0.000461416,0.00075753086,0.00045480148],"domain_scores_gemma":[0.99773973,0.0004821843,0.00028554743,0.000763032,0.00051628664,0.00021320063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004678476,0.00026759805,0.0006070811,0.00019518529,0.000092322145,0.000016680764,0.00030973007,0.00012534317,0.00024945254],"category_scores_gemma":[0.0003503867,0.00017103674,0.00014726687,0.00044407567,0.00031704028,0.00017868722,0.00012317489,0.00035849077,0.00003265104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03668793,0.002861622,0.71337944,0.0016841859,0.0060732886,0.00017038964,0.0030231944,0.00031044165,0.2306103,0.0009621106,0.002379631,0.0018574534],"study_design_scores_gemma":[0.016194334,0.00351168,0.8921324,0.00016653781,0.0010448085,0.00015637813,0.0004168141,0.00007119887,0.08600801,0.000059368685,0.00002974424,0.0002087297],"about_ca_topic_score_codex":0.001143817,"about_ca_topic_score_gemma":0.000043187305,"teacher_disagreement_score":0.17875294,"about_ca_system_score_codex":0.00017316823,"about_ca_system_score_gemma":0.0012878628,"threshold_uncertainty_score":0.69746757},"labels":[],"label_agreement":null},{"id":"W2987570039","doi":"10.1182/blood-2019-125865","title":"Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Fludarabine; Medicine; Busulfan; Transplantation; Melphalan; Internal medicine; Cyclophosphamide; Total body irradiation; Graft-versus-host disease; Surgery; Regimen; Cumulative incidence; Proportional hazards model; Hematopoietic stem cell transplantation; Gastroenterology; Oncology; Chemotherapy","score_opus":0.019231755795442635,"score_gpt":0.2904326922343814,"score_spread":0.2712009364389388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987570039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964527,0.000039985578,0.00066639844,0.00014222172,0.00031940948,0.001971065,0.00006900794,0.00006871471,0.00027053573],"genre_scores_gemma":[0.99631256,0.000031983844,0.002481675,0.00006909495,0.00006286226,0.00007135316,0.00038202334,0.00007350163,0.00051494024],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978089,0.00008637881,0.00051278895,0.0006059005,0.0004204827,0.00056554907],"domain_scores_gemma":[0.9984526,0.00067161315,0.00015016223,0.0002906242,0.00023960668,0.00019536873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003100249,0.00027510838,0.0005976153,0.00045069974,0.00006974251,0.00003182735,0.00013464183,0.0003532707,0.00016568386],"category_scores_gemma":[0.00034739324,0.00028531248,0.00015183185,0.00052236795,0.00013300129,0.00031318775,0.000045216708,0.0006227459,0.00015471685],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07389367,0.002682912,0.14142214,0.0026521578,0.0053433743,0.0054504215,0.018417843,0.0016009093,0.7453208,0.0026737398,0.00021301922,0.00032902774],"study_design_scores_gemma":[0.07672446,0.0025975974,0.8779978,0.0024728335,0.0014967277,0.0009747088,0.0010028385,0.015250355,0.020382382,0.0004278831,0.000016648371,0.0006557467],"about_ca_topic_score_codex":0.00021834053,"about_ca_topic_score_gemma":0.000029812149,"teacher_disagreement_score":0.73657566,"about_ca_system_score_codex":0.00048057735,"about_ca_system_score_gemma":0.00034405204,"threshold_uncertainty_score":0.9999599},"labels":[],"label_agreement":null},{"id":"W2987785410","doi":"10.1182/blood-2019-124320","title":"Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; Queen's University","funders":"","keywords":"Azacitidine; Medicine; Decitabine; Nivolumab; Internal medicine; Oncology; Myeloid leukemia; Hypomethylating agent; Myelodysplastic syndromes; Clinical trial; Cancer; Immunotherapy; Bone marrow; Biology","score_opus":0.021086858927390557,"score_gpt":0.29716861099669034,"score_spread":0.2760817520692998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987785410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908249,0.000056770765,0.00018625791,0.00004442369,0.00009481952,0.008558862,0.00018133168,0.000036701666,0.000015960466],"genre_scores_gemma":[0.9985128,0.00022316382,0.00021210693,0.00006565691,0.00011440514,0.0006004045,0.00008946378,0.000059607584,0.00012237683],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99617255,0.00046703,0.0012832624,0.00073682325,0.0006651108,0.00067520683],"domain_scores_gemma":[0.9950401,0.0035544813,0.0004697971,0.00040752382,0.00018821796,0.00033986615],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022880158,0.00043705624,0.0017976634,0.00044599778,0.000160552,0.000054997392,0.00023192744,0.00042500772,0.000059764083],"category_scores_gemma":[0.0014891373,0.00026766825,0.00018206838,0.0006165097,0.00043544156,0.00034029875,0.0001166606,0.00087415136,0.0000020938903],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93200505,0.0020928828,0.053938355,0.00014322388,0.00088715984,0.00027158807,0.001216294,0.000010103654,0.0021303867,0.000007699469,0.000021725346,0.0072755255],"study_design_scores_gemma":[0.9013213,0.02999192,0.061116815,0.00026654993,0.0013390927,0.000118122894,0.0004426242,0.001698065,0.0033745158,0.000023464532,0.0000059479157,0.00030161111],"about_ca_topic_score_codex":0.0014459605,"about_ca_topic_score_gemma":0.00064353,"teacher_disagreement_score":0.030683782,"about_ca_system_score_codex":0.00026399567,"about_ca_system_score_gemma":0.0007904508,"threshold_uncertainty_score":0.9999775},"labels":[],"label_agreement":null},{"id":"W2987820069","doi":"10.1182/blood-2019-122700","title":"Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Propensity score matching; Medicine; Internal medicine; Oncology","score_opus":0.03812831733009498,"score_gpt":0.29008553625595207,"score_spread":0.2519572189258571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987820069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922662,0.0005615575,0.00020186737,0.000029708575,0.00002499582,0.0021497498,0.004724745,0.000031038322,0.0000101584155],"genre_scores_gemma":[0.9902676,0.00008838442,0.004630662,0.000039904116,0.00009077041,0.000012422656,0.004787258,0.000055490385,0.00002753612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708736,0.00023934241,0.00043477604,0.0010535533,0.00085594767,0.00032900478],"domain_scores_gemma":[0.9965008,0.0005565396,0.0004836271,0.0019271679,0.0003491782,0.00018270935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040694646,0.00035141993,0.001083363,0.00012529088,0.00023887416,0.00018085429,0.0005145876,0.00010155212,0.000025865667],"category_scores_gemma":[0.000103878585,0.00018908837,0.000025131243,0.0003824805,0.0004731753,0.00080728816,0.00077711546,0.0005329797,4.5740458e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06649414,0.00014621398,0.922431,0.0001170654,0.004409632,0.00007926089,0.003666468,0.000035399135,0.0023518982,4.086195e-7,0.0000098189585,0.00025871015],"study_design_scores_gemma":[0.14311405,0.001861244,0.83904606,0.00064774574,0.0076600797,0.000014635303,0.0020054989,0.0049301996,0.0003281773,0.0000038460594,0.000027324904,0.00036115438],"about_ca_topic_score_codex":0.015105802,"about_ca_topic_score_gemma":0.010090785,"teacher_disagreement_score":0.08338494,"about_ca_system_score_codex":0.00012322505,"about_ca_system_score_gemma":0.0007866774,"threshold_uncertainty_score":0.9914527},"labels":[],"label_agreement":null},{"id":"W2988003492","doi":"10.1182/blood-2019-122590","title":"High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; IDH1; Medicine; Isocitrate dehydrogenase; Internal medicine; Myeloid; Peripheral blood mononuclear cell; Minimal residual disease; Bone marrow; Azacitidine; Oncology; Gastroenterology; Mutation; Biology; Gene; Genetics","score_opus":0.006214044789194348,"score_gpt":0.21711064744236075,"score_spread":0.2108966026531664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988003492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99760413,0.00015905767,0.000011548543,0.00029856805,0.00001416893,0.0016622319,0.00012353226,0.000050348983,0.00007639094],"genre_scores_gemma":[0.99875414,0.00016276618,0.00057206285,0.000098345845,0.000030916075,0.00006186396,0.00013303717,0.000062509804,0.00012434275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775547,0.00020256202,0.00037605315,0.0006182241,0.00058474933,0.00046293245],"domain_scores_gemma":[0.99845546,0.00022858994,0.00020749046,0.00044369273,0.00031926308,0.00034549367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033228524,0.000327824,0.00065807044,0.0002448627,0.00007179682,0.000042232936,0.00010254813,0.00011160066,0.00002804172],"category_scores_gemma":[0.00019194765,0.00024023089,0.000029687595,0.0005756442,0.00025310516,0.0003981625,0.00006722274,0.00036753152,0.000008697614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014286488,0.0005717068,0.94137585,0.00035820456,0.00034700026,0.00070665614,0.00031914486,0.00009665016,0.04091021,0.000038420243,0.000041354244,0.0009482846],"study_design_scores_gemma":[0.04481789,0.0021360603,0.8959907,0.00060264685,0.0004473703,0.00003302788,0.00008228811,0.00028932316,0.055282265,0.000043748263,0.0000070801157,0.00026758004],"about_ca_topic_score_codex":0.0012634258,"about_ca_topic_score_gemma":0.0002123832,"teacher_disagreement_score":0.04538516,"about_ca_system_score_codex":0.00021682284,"about_ca_system_score_gemma":0.00054654526,"threshold_uncertainty_score":0.97963315},"labels":[],"label_agreement":null},{"id":"W2988081637","doi":"10.1182/blood.v104.11.4311.4311","title":"Disordered Expression of HIPK Family Members in MDS and AML.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Cancer research; Chronic myelomonocytic leukemia; Biology; Decitabine; Progenitor cell; Leukemia; Homeobox; Myelodysplastic syndromes; Bone marrow; Haematopoiesis; Wnt signaling pathway; Myeloid; Kinase; Transcription factor; Stem cell; Immunology; Gene expression; Signal transduction; Gene; DNA methylation; Genetics","score_opus":0.01518243877398224,"score_gpt":0.27821898739353446,"score_spread":0.2630365486195522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988081637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99366856,0.0008018989,0.000018720115,0.00043280987,0.000015206647,0.00023645432,0.0000036586325,0.000018558538,0.004804146],"genre_scores_gemma":[0.9977423,0.00026130432,0.0016975239,0.00007061715,0.00002741089,0.000012573237,0.000007017114,0.000014491108,0.00016678964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992424,0.00002257259,0.00016578057,0.00016704491,0.00021832071,0.0001838527],"domain_scores_gemma":[0.9996104,0.00003705252,0.000030974552,0.00020015716,0.00003228006,0.00008914095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013046767,0.00007894381,0.00019788468,0.000121762736,0.000016888525,0.000004059573,0.00006269368,0.00007927489,0.000026490678],"category_scores_gemma":[0.00011042693,0.00006438134,0.000027123247,0.00018149671,0.00007795952,0.000045267716,0.00006732693,0.00017607218,0.000005731563],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029621995,0.0010268415,0.074958235,0.00027376745,0.000040983476,0.00018503526,0.0014700602,0.000020909227,0.9180979,0.00025466512,0.0004158179,0.0029595806],"study_design_scores_gemma":[0.04316693,0.0008401613,0.3667233,0.0008392764,0.000110678884,0.000092882416,0.0018968473,0.00005935699,0.58325326,0.0013963437,0.0013549046,0.0002660692],"about_ca_topic_score_codex":0.00038103023,"about_ca_topic_score_gemma":0.00003212504,"teacher_disagreement_score":0.33484462,"about_ca_system_score_codex":0.000045090244,"about_ca_system_score_gemma":0.00014016984,"threshold_uncertainty_score":0.26253948},"labels":[],"label_agreement":null},{"id":"W2988223869","doi":"10.1182/blood-2019-126893","title":"The Clinical Application of Oncomine Myeloid Next Generation Sequencing (NGS): Comparison of Cytogenetics and NGS in Patients with Suspected Myelodysplastic Syndrome","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Cytopenia; Internal medicine; Oncology; Myeloid leukemia; Cytogenetics; Population; Bone marrow; Biology","score_opus":0.04062848644944022,"score_gpt":0.31365860310070515,"score_spread":0.2730301166512649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988223869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984723,0.0001511363,0.00017664694,0.000074026335,0.000029275576,0.000986658,0.000006412871,0.000010761069,0.00009282619],"genre_scores_gemma":[0.9982289,0.00005604135,0.0015262645,0.000016406679,0.000037526188,0.000018239862,0.000061702805,0.000021015829,0.000033887976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840575,0.00009750493,0.0006418762,0.00025515782,0.00040294568,0.00019676758],"domain_scores_gemma":[0.9986704,0.00033383258,0.00026880138,0.0003771509,0.0002713118,0.00007851043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040844714,0.00012001351,0.0004318899,0.0001023999,0.000036439906,0.000011284469,0.00011638086,0.00011212811,0.0000062299587],"category_scores_gemma":[0.00017828187,0.00008276752,0.00003076079,0.00031222586,0.00016085437,0.00005134767,0.00006583519,0.00027352248,0.000006866617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041573503,0.0005679892,0.9550653,0.000102146776,0.000080926606,0.000002755432,0.00015075464,0.00004727745,0.04106498,0.00006313286,0.000014462706,0.0024245558],"study_design_scores_gemma":[0.010393404,0.0030087545,0.95729464,0.00010485167,0.00014111286,0.000018170691,0.00016077734,0.011562506,0.017168285,0.00001012127,0.000036858055,0.00010049396],"about_ca_topic_score_codex":0.000079631456,"about_ca_topic_score_gemma":0.00009864721,"teacher_disagreement_score":0.023896694,"about_ca_system_score_codex":0.000101981386,"about_ca_system_score_gemma":0.0002586591,"threshold_uncertainty_score":0.33751613},"labels":[],"label_agreement":null},{"id":"W2988468277","doi":"10.1182/blood-2019-124553","title":"Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Hazard ratio; Daunorubicin; Induction chemotherapy; Oncology; Chemotherapy regimen; Population; Leukemia; Gastroenterology; Surgery; Chemotherapy; Confidence interval","score_opus":0.012615997853200212,"score_gpt":0.27286611700930713,"score_spread":0.2602501191561069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988468277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971534,0.000037905556,0.000031150896,0.0003793596,0.00004613855,0.0014504245,0.00012725129,0.00008154959,0.0006928184],"genre_scores_gemma":[0.99683046,0.000086933025,0.0008093508,0.00014816236,0.000021304142,0.00010915537,0.001118611,0.00007738158,0.0007986254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722785,0.00012391993,0.00046821183,0.0006277385,0.0010656591,0.00048665114],"domain_scores_gemma":[0.9979595,0.00018303792,0.00041272218,0.00065697846,0.00058677525,0.00020101933],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027974127,0.00039762416,0.0011343253,0.0010181675,0.000056158995,0.000024713145,0.00021119269,0.0002012604,0.00048240644],"category_scores_gemma":[0.00003911297,0.00027464514,0.00011403217,0.001954691,0.00026943613,0.00026833185,0.00004164265,0.00043771724,0.000032094922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030549668,0.003064591,0.94085896,0.00012120646,0.01941741,0.000115191935,0.0013299506,0.00013366726,0.0034670287,0.000046857025,0.0001009348,0.0007945322],"study_design_scores_gemma":[0.24393088,0.0126205515,0.7170691,0.00040176656,0.0058109798,0.000014245283,0.0008017212,0.0010863097,0.017514529,0.0000033570195,0.00017400307,0.00057254813],"about_ca_topic_score_codex":0.000073286246,"about_ca_topic_score_gemma":0.00024480335,"teacher_disagreement_score":0.22378986,"about_ca_system_score_codex":0.00044632057,"about_ca_system_score_gemma":0.0008602932,"threshold_uncertainty_score":0.99997056},"labels":[],"label_agreement":null},{"id":"W2988516843","doi":"10.1182/blood-2019-128507","title":"Reevaluating the Role of Cytogenetic Testing in Patients with Suspected Myelodysplastic Syndrome in the Era of Next Generation Sequencing","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Myelodysplastic syndromes; Oncology; Pathology; Bone marrow","score_opus":0.03683705881793722,"score_gpt":0.2573519207241492,"score_spread":0.22051486190621197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988516843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983137,0.00012459104,0.000004504464,0.00005752483,0.000011487752,0.00095313496,0.0000024441933,0.00000686858,0.0005257381],"genre_scores_gemma":[0.9986527,0.000002442542,0.0012262496,0.000029629444,0.000025077743,0.000024324147,0.000014406503,0.000017645985,0.000007527334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844897,0.00020601525,0.0003559693,0.00018349066,0.0005801712,0.00022539322],"domain_scores_gemma":[0.9987845,0.0004777812,0.00015065336,0.00035265565,0.00021094081,0.00002347904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007467491,0.00010225694,0.00022754855,0.0001137745,0.000031088224,0.000011423756,0.000172091,0.00004932717,0.000020114367],"category_scores_gemma":[0.00078867876,0.000057573645,0.000020698772,0.0007795158,0.00005353322,0.0000587989,0.00004681795,0.0003718761,0.0000052955543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054947654,0.00014862094,0.81825465,0.00006191872,0.000026619184,0.0000139921685,0.0010904466,0.0008646136,0.17840308,0.00002277182,6.6646925e-7,0.0010576479],"study_design_scores_gemma":[0.0045269704,0.001053992,0.95407754,0.00044353207,0.000077624136,0.000060035956,0.00090848363,0.02366742,0.015079316,0.000032851935,4.6260075e-7,0.00007177753],"about_ca_topic_score_codex":0.0004024127,"about_ca_topic_score_gemma":0.000112679,"teacher_disagreement_score":0.16332377,"about_ca_system_score_codex":0.00012075607,"about_ca_system_score_gemma":0.00039475318,"threshold_uncertainty_score":0.23477851},"labels":[],"label_agreement":null},{"id":"W2988792442","doi":"10.1182/blood-2019-124587","title":"Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medicine; Oncology; Interleukin-3 receptor; Internal medicine; Minimal residual disease; Induction chemotherapy; Myeloid leukemia; Hematology; Hematopoietic stem cell transplantation; Transplantation; Chemotherapy; Chemotherapy regimen; Hazard ratio; Population; Leukemia; Sorafenib; Immunology; Confidence interval","score_opus":0.011934038446141229,"score_gpt":0.265790608247545,"score_spread":0.2538565698014038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988792442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978585,0.00017867974,0.00014990772,0.00052101206,0.00007266994,0.00091947336,0.000120253426,0.000023400715,0.00015610764],"genre_scores_gemma":[0.99767387,0.00032312595,0.0008579632,0.0001394183,0.0001668699,0.000037832724,0.00039532906,0.000028953902,0.00037663852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984984,0.00009510343,0.00040594678,0.00036438784,0.00039771144,0.00023848235],"domain_scores_gemma":[0.9985453,0.0004227367,0.00027893746,0.0005204853,0.00008131196,0.00015126687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002923126,0.00017231522,0.00046261764,0.00012017115,0.00004152916,0.0000118079315,0.00013198076,0.00015124613,0.000035028057],"category_scores_gemma":[0.00030058366,0.00010327354,0.00005059559,0.00020886923,0.00008583535,0.00009924522,0.00014450368,0.00047853723,0.000014807061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070555165,0.00031147664,0.9949191,0.000038064354,0.00010545578,0.0005693781,0.0002079888,0.0000019598394,0.0023557232,0.000012437,0.000148954,0.0006238649],"study_design_scores_gemma":[0.0071332366,0.00033510008,0.9911245,0.00006872166,0.0005348662,0.00017814527,0.00005301773,0.00012882413,0.00025227986,0.00002525403,0.000052356776,0.000113657785],"about_ca_topic_score_codex":0.00024440573,"about_ca_topic_score_gemma":0.000022821421,"teacher_disagreement_score":0.006427685,"about_ca_system_score_codex":0.00015587805,"about_ca_system_score_gemma":0.0006137294,"threshold_uncertainty_score":0.42113727},"labels":[],"label_agreement":null},{"id":"W2988805122","doi":"10.1182/blood-2019-122558","title":"\"Identification of Mechanisms By Which Mesenchymal Stem/Stromal Cells Contribute to Acute Myeloid Leukemia\"","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Health Canada","funders":"","keywords":"Mesenchymal stem cell; Myeloid leukemia; Haematopoiesis; Cancer research; Bone marrow; Leukemia; Stromal cell; Stem cell; Biology; Medicine; Immunology; Pathology; Cell biology","score_opus":0.00796163129554561,"score_gpt":0.25217984322045406,"score_spread":0.24421821192490845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988805122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99309766,0.00012517284,0.0024351662,0.0010450925,0.0002527932,0.001567037,0.00036447227,0.0000896066,0.0010229906],"genre_scores_gemma":[0.983822,0.00006177398,0.0014556841,0.00025969377,0.00010399499,0.000066253204,0.00014638736,0.000059296657,0.014024902],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99710095,0.000097882265,0.00066040934,0.0005907978,0.0009289314,0.0006210019],"domain_scores_gemma":[0.99778795,0.00011444828,0.00021380845,0.00089517864,0.0006130831,0.00037555772],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007222046,0.00025785592,0.0006329816,0.00022773074,0.000060418104,0.000040237108,0.00039948846,0.00024609413,0.00026582304],"category_scores_gemma":[0.00009399699,0.00023887187,0.00013171809,0.00067084504,0.000041527866,0.00014120674,0.00019608888,0.0003965074,0.0013438144],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024286358,0.0002421788,0.0008477799,0.00011508828,0.00036186943,0.000027379043,0.00015438427,0.00001093312,0.9897486,0.00041254805,0.0075324546,0.00030391262],"study_design_scores_gemma":[0.0056605227,0.0008851669,0.0015083434,0.00007377807,0.0003842273,0.00007955102,0.00017382833,0.0003764399,0.9888326,0.00004885685,0.0017566703,0.00022003443],"about_ca_topic_score_codex":0.000082263585,"about_ca_topic_score_gemma":0.0000069424455,"teacher_disagreement_score":0.013001911,"about_ca_system_score_codex":0.00034745544,"about_ca_system_score_gemma":0.0006579835,"threshold_uncertainty_score":0.99943376},"labels":[],"label_agreement":null},{"id":"W2988975841","doi":"10.1182/blood-2019-122436","title":"Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Northeast Cancer Centre; Thunder Bay Regional Research Institute; Ottawa Hospital","funders":"","keywords":"Medicine; Busulfan; Transplantation; Tolerability; Internal medicine; Myelodysplastic syndromes; Acute leukemia; Hematopoietic stem cell transplantation; Fludarabine; Surgery; Oncology; Leukemia; Chemotherapy; Gastroenterology; Cyclophosphamide; Adverse effect; Bone marrow","score_opus":0.009633156813633522,"score_gpt":0.23451748974964154,"score_spread":0.224884332936008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988975841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955951,0.000026495696,0.00047444968,0.00034707575,0.000104154904,0.0029224125,0.0003733202,0.00012295031,0.000034062734],"genre_scores_gemma":[0.99386615,0.000053889704,0.0018222124,0.0002529378,0.000038326518,0.00027846475,0.002974171,0.00012901798,0.00058485783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974136,0.00017574175,0.0005437452,0.0006629598,0.00056643435,0.00063756],"domain_scores_gemma":[0.99750304,0.0013007716,0.0003028465,0.00050650095,0.00021197692,0.00017484916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028209272,0.00043168283,0.00070105976,0.0003110712,0.00014552154,0.000074469724,0.00032263552,0.00029355625,0.00019474635],"category_scores_gemma":[0.00008109542,0.00023533753,0.000076838114,0.0006936879,0.00017044261,0.00022810564,0.000035242225,0.0007327487,0.000054637465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13329907,0.0018907057,0.81913483,0.001868643,0.004009943,0.0027651964,0.005136767,0.0066070943,0.024062945,0.000033042463,0.00011741849,0.0010743183],"study_design_scores_gemma":[0.081126966,0.0047075236,0.90034837,0.002009677,0.002125069,0.00011057353,0.0005252959,0.0018755211,0.006647818,0.000015945529,0.000012821068,0.0004944339],"about_ca_topic_score_codex":0.00044806977,"about_ca_topic_score_gemma":0.00037093798,"teacher_disagreement_score":0.0812135,"about_ca_system_score_codex":0.0004512706,"about_ca_system_score_gemma":0.0012028828,"threshold_uncertainty_score":0.9596786},"labels":[],"label_agreement":null},{"id":"W2989267509","doi":"10.1182/blood-2019-123769","title":"Single Cell Transcriptomic Analysis of the Histone H3 K27M Mutation in Pre-Leukemic Hematopoietic Stem Cells","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Biology; Haematopoiesis; Stem cell; CD34; Cancer research; Myeloid leukemia; Histone H3; Leukemia; Myeloid; Epigenomics; Molecular biology; Epigenetics; DNA methylation; Genetics; Gene expression; Gene","score_opus":0.011595625515455848,"score_gpt":0.25312205758733175,"score_spread":0.2415264320718759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989267509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99644196,0.0004772423,0.00004420512,0.00016508372,0.00008120389,0.00071946386,0.000015005751,0.000024591802,0.0020312634],"genre_scores_gemma":[0.9946974,0.000022785884,0.00013043238,0.00009039048,0.000018228211,0.000017261313,0.000015007139,0.000027933922,0.004980574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983989,0.00011663021,0.0004312597,0.0003071146,0.0004591813,0.00028693606],"domain_scores_gemma":[0.99894434,0.00010838272,0.00013818509,0.0006365705,0.00009855277,0.000073986615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029241896,0.00014600519,0.00049831986,0.00042026027,0.000023387809,0.000009131802,0.00024170446,0.00012445434,0.00018617416],"category_scores_gemma":[0.00001408926,0.00011092967,0.00022690161,0.0016066376,0.0000751609,0.000057205954,0.000041186835,0.00030188536,0.000060742736],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010862372,0.0007789769,0.019225536,0.00034780035,0.0003269453,0.000021999218,0.003638997,0.0003821746,0.9748123,0.000017009386,0.0001255894,0.00021403693],"study_design_scores_gemma":[0.0058638053,0.00024722083,0.037483186,0.00011227696,0.0020479718,0.000022188437,0.0005581338,0.0032043825,0.95015323,0.000014221348,0.00015220766,0.00014114774],"about_ca_topic_score_codex":0.00027245964,"about_ca_topic_score_gemma":0.00008440434,"teacher_disagreement_score":0.024659052,"about_ca_system_score_codex":0.00042204233,"about_ca_system_score_gemma":0.00031760306,"threshold_uncertainty_score":0.45235807},"labels":[],"label_agreement":null},{"id":"W2989524178","doi":"10.1182/blood-2019-123877","title":"Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Epigenomics; H3K4me3; Biology; Epigenetics; Chronic myelomonocytic leukemia; DNA methylation; Genetics; Medicine; Bone marrow; Immunology; Gene; Myelodysplastic syndromes; Gene expression","score_opus":0.008778857484765272,"score_gpt":0.2630572344972183,"score_spread":0.25427837701245304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989524178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994875,0.0032786634,0.00038285326,0.0000865766,0.000068274254,0.0010855568,0.000010738728,0.00003450855,0.00017782104],"genre_scores_gemma":[0.99834853,0.00058653665,0.0005092643,0.000032449883,0.00012934524,0.000023537525,0.000048983155,0.000047039455,0.00027433853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850935,0.00010432213,0.0004243191,0.0004834653,0.0001908674,0.00028769387],"domain_scores_gemma":[0.99897623,0.0003429414,0.00014335284,0.0002563216,0.00010339632,0.00017778638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029039328,0.00023101436,0.00056907407,0.00013431809,0.0000690165,0.00002517704,0.000099128505,0.00020256279,0.000040490835],"category_scores_gemma":[0.00009466303,0.0001723183,0.000046990543,0.00013889668,0.00037877331,0.000098530545,0.000057592657,0.00048979005,0.00002236774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021135386,0.00031292855,0.81908655,0.0011822094,0.00076752383,0.000066113134,0.0017727384,0.00016920062,0.17060217,0.0004574633,0.00003680031,0.0034327765],"study_design_scores_gemma":[0.024757292,0.007571449,0.9120891,0.00046318196,0.0014387334,0.00031496675,0.00034763702,0.023998545,0.0279516,0.00036455027,0.00015863407,0.0005443165],"about_ca_topic_score_codex":0.00009334845,"about_ca_topic_score_gemma":0.00010279829,"teacher_disagreement_score":0.14265057,"about_ca_system_score_codex":0.0003114242,"about_ca_system_score_gemma":0.0010672936,"threshold_uncertainty_score":0.7026936},"labels":[],"label_agreement":null},{"id":"W2989688064","doi":"10.1002/iub.2197","title":"GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome","year":2019,"lang":"en","type":"review","venue":"IUBMB Life","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; National Institute for Health and Care Research; Medical Research Council Canada; Wellcome Trust","keywords":"GATA1; Haematopoiesis; Myeloid; Cancer research; Myeloid leukaemia; Myelopoiesis; Acute megakaryoblastic leukemia; NPM1; Mutation; Transcription factor; Medicine; Myeloid leukemia; Biology; Immunology; Genetics; Gene; Karyotype; Chromosome; Stem cell","score_opus":0.07223708347900151,"score_gpt":0.377003898989164,"score_spread":0.3047668155101625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989688064","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032096913,0.9923822,0.00000948283,0.0001227337,0.00010354726,0.0017945543,0.00011907372,0.000033580007,0.0022251357],"genre_scores_gemma":[0.0018574725,0.99489576,0.0005752898,0.00012300497,0.000120620985,0.00013892511,0.00037309993,0.00008833428,0.0018274734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974096,0.00019689575,0.0010193655,0.00051416276,0.00043472726,0.00042525207],"domain_scores_gemma":[0.99805456,0.000629062,0.0002895946,0.0006102892,0.00014717886,0.000269321],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006135562,0.00037133493,0.0025176937,0.0005880724,0.000049638602,0.00003057472,0.0002359117,0.00043789364,0.00019693506],"category_scores_gemma":[0.0012436472,0.0002982192,0.00020480645,0.0007906277,0.00019154882,0.000098073164,0.00020371586,0.0011081462,0.00026735335],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036758127,0.00015564359,0.0010096021,0.121859774,0.00062732695,0.0008763394,0.0004980606,0.000009826784,0.000031183,0.0004155258,0.004052817,0.87042713],"study_design_scores_gemma":[0.0023972294,0.00040227218,0.0008925207,0.042283602,0.0012016664,0.0023735717,0.00020601701,0.00016546238,0.0000067531423,0.000010988746,0.949446,0.0006138707],"about_ca_topic_score_codex":0.00015637407,"about_ca_topic_score_gemma":0.000014400308,"teacher_disagreement_score":0.9453932,"about_ca_system_score_codex":0.00044923235,"about_ca_system_score_gemma":0.0033259576,"threshold_uncertainty_score":0.999947},"labels":[],"label_agreement":null},{"id":"W2989764345","doi":"10.1182/blood-2019-132405","title":"The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton","funders":"","keywords":"Azacitidine; Medicine; Myeloid leukemia; Internal medicine; Placebo; Randomized controlled trial; Randomization; Leukemia; Oncology; Alternative medicine; Biology; Pathology","score_opus":0.019090086419738677,"score_gpt":0.30559701496171765,"score_spread":0.28650692854197896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989764345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851899,0.00003847086,0.000021157615,0.00025118463,0.00011445307,0.01330136,0.00003875919,0.000015062229,0.0010296444],"genre_scores_gemma":[0.9983276,0.00010866563,0.00015587712,0.000014541083,0.000043705204,0.00038591088,0.00017110334,0.000035939393,0.0007566569],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99565864,0.00033433063,0.0020080903,0.00043829554,0.0011826887,0.00037797698],"domain_scores_gemma":[0.9961559,0.0011634813,0.0011991657,0.000674423,0.00071220024,0.000094829564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003251122,0.00027835686,0.0016381835,0.0005603748,0.000045580888,0.000016624623,0.00040552055,0.00015958815,0.000016204225],"category_scores_gemma":[0.0010866293,0.00016547646,0.00017742465,0.00062122056,0.00012529704,0.00021882851,0.00013229257,0.00041779684,0.0000031948505],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97617704,0.014277918,0.0057137776,0.00007132049,0.0008845706,0.00001993212,0.0013706074,0.00009997115,0.00078520615,0.000057120524,0.0000967688,0.00044578148],"study_design_scores_gemma":[0.9866843,0.004168522,0.0012687282,0.0005210724,0.00039766968,0.0000034888533,0.00058106723,0.0035860762,0.0025606316,0.00002062325,0.000060154824,0.00014765678],"about_ca_topic_score_codex":0.0013883325,"about_ca_topic_score_gemma":0.0006085883,"teacher_disagreement_score":0.013137693,"about_ca_system_score_codex":0.00038324372,"about_ca_system_score_gemma":0.0004927466,"threshold_uncertainty_score":0.6747935},"labels":[],"label_agreement":null},{"id":"W2989899656","doi":"10.1182/blood-2019-129557","title":"Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Sorafenib; Medicine; Internal medicine; Oncology; Cohort; Fms-Like Tyrosine Kinase 3; Induction chemotherapy; Chemotherapy; Chemotherapy regimen; Interim analysis; Clinical trial; Biology; Hepatocellular carcinoma; Mutation","score_opus":0.007366758900743348,"score_gpt":0.2755143311586557,"score_spread":0.26814757225791236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989899656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9184593,0.00004613752,0.000249719,0.0032436643,0.000034729648,0.07766199,0.00011465849,0.000064271895,0.00012551216],"genre_scores_gemma":[0.96070856,0.000048866677,0.0060682385,0.00018140193,0.00031143718,0.0316558,0.00056517986,0.000108278815,0.0003522473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747,0.00024333592,0.00048441708,0.0007239009,0.00063822785,0.00044010035],"domain_scores_gemma":[0.9979915,0.0003098261,0.0004335774,0.0009158682,0.00022248973,0.00012675041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011702309,0.00031934216,0.0006317453,0.00011605499,0.00014688194,0.000069414986,0.0003280627,0.00021599479,0.000037493905],"category_scores_gemma":[0.00026359916,0.00019094045,0.00006339543,0.00027918094,0.00021956829,0.00018612682,0.0001068994,0.0006003819,0.000003102271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01955132,0.0023979214,0.9475489,0.00008729036,0.0018673538,0.00011083083,0.0017221281,0.000008568286,0.013520123,0.000469247,0.0021112508,0.010605034],"study_design_scores_gemma":[0.09709148,0.009384005,0.8753475,0.00015679904,0.00027849287,0.00035846073,0.00030101492,0.000059552804,0.015353659,0.0005406582,0.0008063214,0.00032207105],"about_ca_topic_score_codex":0.0020645545,"about_ca_topic_score_gemma":0.0008843348,"teacher_disagreement_score":0.07754016,"about_ca_system_score_codex":0.0002575123,"about_ca_system_score_gemma":0.00080720003,"threshold_uncertainty_score":0.7786326},"labels":[],"label_agreement":null},{"id":"W2990218895","doi":"10.11606/t.60.2019.tde-23052019-103234","title":"Esquema de amostragem esparsa para avaliar a farmacocinética da daunorrubicina e seu metabólito daunorrubicinol em pacientes adultos e pediátricos diagnosticados com leucemia mieloide aguda","year":2019,"lang":"pt","type":"dissertation","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Air (Canada)","funders":"","keywords":"Gynecology; Physics; Medicine","score_opus":0.03209059336901866,"score_gpt":0.33486254282850003,"score_spread":0.3027719494594814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990218895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9365215,0.009030056,0.012776792,0.0028638765,0.0051312284,0.016247107,0.0017204623,0.0012591421,0.014449846],"genre_scores_gemma":[0.8620092,0.006379693,0.0022847499,0.0033264875,0.0018245919,0.0013566891,0.008533096,0.0010718985,0.11321359],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9754429,0.0024196962,0.004711249,0.0052060257,0.0055186595,0.006701499],"domain_scores_gemma":[0.9773532,0.008767119,0.002182521,0.004925124,0.0029465398,0.0038255034],"candidate_categories":["metaresearch","metaepi_narrow","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0037026096,0.004493057,0.006145267,0.0029477936,0.001206771,0.0011507119,0.0038069398,0.0041349754,0.00608701],"category_scores_gemma":[0.009021897,0.004147811,0.00222271,0.0039353115,0.0007937168,0.001029946,0.0010287928,0.009655489,0.009838291],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.031684667,0.013590243,0.22382909,0.041237626,0.021351574,0.0214291,0.05968121,0.0022372566,0.2210165,0.011120343,0.21730268,0.13551971],"study_design_scores_gemma":[0.056467988,0.008979138,0.09240778,0.016870134,0.03210792,0.0026101763,0.22716783,0.21193598,0.31296906,0.00026817134,0.022879321,0.015336499],"about_ca_topic_score_codex":0.0061351415,"about_ca_topic_score_gemma":0.00037179035,"teacher_disagreement_score":0.20969872,"about_ca_system_score_codex":0.0048243734,"about_ca_system_score_gemma":0.007654685,"threshold_uncertainty_score":0.9998862},"labels":[],"label_agreement":null},{"id":"W2990232535","doi":"10.1182/blood-2019-121996","title":"Loss of Phospholipase C Gamma 1 (PLCG1) Impairs AML1-ETO Induced Leukemia Stem Cell Self-Renewal","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Biology; Stem cell; Cancer research; Leukemia; Embryonic stem cell; Myeloid leukemia; Fusion protein; Immunology; Cell biology; Genetics; Gene","score_opus":0.01256435116694218,"score_gpt":0.25294634414771117,"score_spread":0.24038199298076898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990232535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823339,0.00041487478,0.000003590863,0.00016914883,0.0001809144,0.0010148872,0.00003177878,0.00018439972,0.015666518],"genre_scores_gemma":[0.99345875,0.000090013884,0.00064210896,0.00020844502,0.00024534753,0.000038793758,0.000034021134,0.0000948136,0.005187725],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971255,0.0000996718,0.00056777056,0.0005841303,0.00085157086,0.00077136257],"domain_scores_gemma":[0.9977554,0.00016420895,0.00020930813,0.0011319967,0.00027630248,0.0004628022],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047210438,0.00034542693,0.0007162871,0.00024948418,0.000053132193,0.000023605593,0.00042185435,0.00034546736,0.0005003183],"category_scores_gemma":[0.000038941667,0.00030349524,0.0002473195,0.0005621946,0.00007987887,0.00012262978,0.00025054018,0.0006823895,0.0009608311],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011845821,0.0026351905,0.18020013,0.00180974,0.0009910202,0.0011083502,0.002656955,0.000013668622,0.80241853,0.00021773999,0.004475025,0.0022890808],"study_design_scores_gemma":[0.020605689,0.0017984705,0.0154785365,0.00019763749,0.00054123363,0.000298433,0.000674344,0.00017835663,0.95706224,0.00003161288,0.0026813352,0.00045209113],"about_ca_topic_score_codex":0.0005024517,"about_ca_topic_score_gemma":0.000012429946,"teacher_disagreement_score":0.1647216,"about_ca_system_score_codex":0.0005791922,"about_ca_system_score_gemma":0.0018168527,"threshold_uncertainty_score":0.9999417},"labels":[],"label_agreement":null},{"id":"W2990885519","doi":"10.1016/j.clml.2019.11.017","title":"Response Kinetics and Clinical Benefits of Nonintensive AML Therapies in the Absence of Morphologic Response","year":2019,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Agios Pharmaceuticals; AbbVie; Bayer; Celgene; GlaxoSmithKline; Pfizer","keywords":"Medicine; Oncology; Internal medicine; Chemotherapy; Intensive care medicine; Venetoclax; Leukemia","score_opus":0.12426377567878884,"score_gpt":0.42504620386672626,"score_spread":0.30078242818793743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990885519","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41915587,0.57758504,0.0000035340433,0.0006017397,0.00030971222,0.0020254964,0.00014329633,0.000029571012,0.00014574217],"genre_scores_gemma":[0.030007936,0.9666519,0.0009018829,0.0011284476,0.00031535444,0.00008962868,0.00006909732,0.00015331627,0.0006824117],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.980318,0.0099319555,0.0059661325,0.0016099685,0.0012335482,0.0009404047],"domain_scores_gemma":[0.937646,0.055731226,0.0023254298,0.002974376,0.00093002943,0.00039299438],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.018378159,0.0009807673,0.007055577,0.0007044299,0.00006680662,0.00003933757,0.0017080932,0.002384821,0.000064708816],"category_scores_gemma":[0.03319356,0.0006121449,0.0019490492,0.0013847917,0.00370242,0.00009105859,0.00088727963,0.002231576,0.00016221721],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021441165,0.0005614001,0.0028112624,0.0039998363,0.0006181119,0.00083401287,0.0002728872,0.0000012370184,0.000040858093,0.00011923734,0.0019965307,0.96730345],"study_design_scores_gemma":[0.005672206,0.0071326797,0.6533562,0.015124047,0.0011761847,0.0015791181,0.00038586912,0.000055014734,0.000015672773,0.000057660054,0.3148245,0.00062087696],"about_ca_topic_score_codex":0.00007653468,"about_ca_topic_score_gemma":0.000010497159,"teacher_disagreement_score":0.9666826,"about_ca_system_score_codex":0.0010899334,"about_ca_system_score_gemma":0.007182381,"threshold_uncertainty_score":0.999633},"labels":[],"label_agreement":null},{"id":"W2990892067","doi":"10.1111/bjh.16307","title":"Prognostic relevance of CD123 expression in adult AML with normal karyotype","year":2019,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome Canada; University Health Network","funders":"University Health Network","keywords":"Karyotype; Medicine; Internal medicine; Oncology; Biology; Cancer research; Genetics; Chromosome; Gene","score_opus":0.011060819117868426,"score_gpt":0.26246253753529375,"score_spread":0.2514017184174253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990892067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8576304,0.0052479752,0.00021122907,0.13396375,0.0005431202,0.0010766991,0.000045506145,0.000019479989,0.0012618932],"genre_scores_gemma":[0.5837287,0.013603054,0.03533227,0.35028267,0.0067408057,0.00012099023,0.00052582374,0.0007824031,0.0088833],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.99651027,0.0003278807,0.0012322695,0.00035214578,0.0009272781,0.00065013074],"domain_scores_gemma":[0.99644697,0.00078013056,0.0011206483,0.00036953294,0.0011751396,0.00010758632],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00041709,0.00029089718,0.0019441845,0.00060098217,0.000030085157,0.000020584679,0.00048058297,0.0009713425,0.00017050865],"category_scores_gemma":[0.0016983387,0.00025895314,0.00019601517,0.0003154032,0.0003360352,0.00017414628,0.000121983925,0.0051885336,0.00003955202],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009882088,0.000115220864,0.01588839,0.0021878479,0.00013657047,0.3463651,0.000062425686,0.000008607106,0.0003727795,0.0000034726565,0.63208306,0.001788352],"study_design_scores_gemma":[0.007883683,0.0024623324,0.010626086,0.024613593,0.00026720576,0.8894907,0.00007787609,0.000053127453,0.0021651932,0.00006940515,0.061887316,0.00040346448],"about_ca_topic_score_codex":0.0001267855,"about_ca_topic_score_gemma":0.00006983613,"teacher_disagreement_score":0.57019573,"about_ca_system_score_codex":0.00019951504,"about_ca_system_score_gemma":0.0013071186,"threshold_uncertainty_score":0.9999863},"labels":[],"label_agreement":null},{"id":"W2990938107","doi":"10.1080/10428194.2019.1688320","title":"Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Cytarabine; Daunorubicin; Internal medicine; Myeloid leukemia; Population; Leukemia; Surgery; Oncology","score_opus":0.006292642361575587,"score_gpt":0.23580892617668242,"score_spread":0.22951628381510683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990938107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98810786,0.00044541864,0.00003669634,0.00027353133,0.000802284,0.0035357117,0.00037996052,0.0005241889,0.0058943755],"genre_scores_gemma":[0.9886045,0.0009454369,0.0010875654,0.001307111,0.00025965777,0.00031630482,0.0018926233,0.00040457782,0.0051822327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99057525,0.00046707687,0.0018417552,0.0026214123,0.0019768388,0.0025176387],"domain_scores_gemma":[0.9939256,0.0010724658,0.00085859327,0.0022721016,0.0006994522,0.0011718109],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0007504465,0.0018232865,0.0027387526,0.0014819619,0.0005047147,0.00030493538,0.0008794932,0.0012955033,0.0007782045],"category_scores_gemma":[0.00030810057,0.0015116448,0.0004377246,0.0018967233,0.00076538476,0.001257246,0.0005876448,0.0010400211,0.0009980996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016433382,0.0006285358,0.89189607,0.00046950864,0.0020729823,0.0010550125,0.0010594035,0.00019889098,0.0025090447,0.00039369517,0.0031522168,0.08013127],"study_design_scores_gemma":[0.13101566,0.002335869,0.8504254,0.00050324085,0.00088263693,0.00028440688,0.0004998541,0.002301486,0.006285353,0.00007311339,0.0037607213,0.0016322559],"about_ca_topic_score_codex":0.011143366,"about_ca_topic_score_gemma":0.00059814507,"teacher_disagreement_score":0.11458227,"about_ca_system_score_codex":0.028980039,"about_ca_system_score_gemma":0.009832718,"threshold_uncertainty_score":0.99977976},"labels":[],"label_agreement":null},{"id":"W2991436030","doi":"10.1182/blood-2019-130362","title":"Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Azacitidine; IDH2; Isocitrate dehydrogenase; Medicine; Myeloid leukemia; Internal medicine; Interim; Complete remission; Interim analysis; Oncology; Leukemia; IDH1; Gastroenterology; Clinical trial; Biology; Mutation; Chemotherapy; Enzyme; Genetics","score_opus":0.015781389020248802,"score_gpt":0.2809179710155977,"score_spread":0.2651365819953489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991436030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892067,0.00009888631,0.00010172668,0.00032029822,0.00003383935,0.0090767285,0.0008830244,0.00019627843,0.00008253542],"genre_scores_gemma":[0.9918967,0.000050670144,0.0041251034,0.000278994,0.00007906243,0.00042850236,0.0026228267,0.00018123165,0.0003369148],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99336255,0.0013219446,0.0013563301,0.0016725014,0.0013363595,0.0009502997],"domain_scores_gemma":[0.99498576,0.0016293199,0.00070609053,0.0012931385,0.00059478695,0.00079089584],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015765695,0.0008994039,0.002383231,0.0006243594,0.00031575005,0.00017962315,0.00039693003,0.000210766,0.000058878155],"category_scores_gemma":[0.00059658394,0.00060955365,0.00011701143,0.00075413927,0.0005391261,0.0007026624,0.0002182206,0.000953701,0.00001459701],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82601625,0.0054267906,0.010772706,0.00007199512,0.0017555865,0.0026118138,0.00937061,0.0001871687,0.14346163,0.000002788442,0.00005995495,0.00026268652],"study_design_scores_gemma":[0.8988561,0.032566372,0.03659599,0.0010744138,0.0015144031,0.00012263343,0.0027462642,0.005290519,0.020298427,0.000017601024,0.000031634016,0.00088561646],"about_ca_topic_score_codex":0.0031398176,"about_ca_topic_score_gemma":0.0009299652,"teacher_disagreement_score":0.12316321,"about_ca_system_score_codex":0.00072610396,"about_ca_system_score_gemma":0.0015362821,"threshold_uncertainty_score":0.9996356},"labels":[],"label_agreement":null},{"id":"W2991725433","doi":"10.3324/haematol.2019.231753","title":"Are we ready to use precision medicine in chronic myeloid leukemia practice?","year":2019,"lang":"en","type":"letter","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Precision medicine; Medicine; Internal medicine; Oncology; Intensive care medicine; Pathology","score_opus":0.09269146297885146,"score_gpt":0.36623405593882224,"score_spread":0.2735425929599708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991725433","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007967963,0.002160022,0.00009353137,0.9739749,0.00065605476,0.004412154,0.00006835139,0.00028844384,0.010378611],"genre_scores_gemma":[0.0053148353,0.0049510035,0.0029779738,0.938186,0.004254159,0.00055241433,0.00097546086,0.00031453627,0.042473633],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99226,0.0008050684,0.0013900615,0.0018594795,0.00204367,0.0016417608],"domain_scores_gemma":[0.99058264,0.004840502,0.0009998888,0.002578741,0.0006595967,0.00033864178],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0012837645,0.0009865582,0.002988454,0.0014120367,0.0001080447,0.00008835884,0.0010020664,0.0029085528,0.0015094087],"category_scores_gemma":[0.012182016,0.00069366983,0.00022985665,0.0012055214,0.0003314436,0.00036723874,0.0007230471,0.0075576846,0.0052792723],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008189331,0.000049986236,0.0007083002,0.00136078,0.00013596748,0.03669171,0.0002200345,0.000017926644,0.00038246042,0.00003863173,0.9580493,0.0015259451],"study_design_scores_gemma":[0.0028915415,0.0014390078,0.0026727484,0.0054169116,0.0002309756,0.004427203,0.00019728593,0.00015435138,0.00016735915,0.00007721561,0.98165995,0.000665456],"about_ca_topic_score_codex":0.0009721997,"about_ca_topic_score_gemma":0.00011609883,"teacher_disagreement_score":0.035788886,"about_ca_system_score_codex":0.008027962,"about_ca_system_score_gemma":0.002196516,"threshold_uncertainty_score":0.9995515},"labels":[],"label_agreement":null},{"id":"W2992103971","doi":"10.1182/hematology.2019000041","title":"Integrating patient-centered factors in the risk assessment of MDS","year":2019,"lang":"en","type":"review","venue":"Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Celgene","keywords":"Medicine; Risk assessment; Intensive care medicine; Oncology; Computer science","score_opus":0.0903438699091591,"score_gpt":0.42146998974539773,"score_spread":0.33112611983623863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992103971","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036984393,0.9893028,0.000054103937,0.00007560174,0.00024798134,0.0023013875,0.000057313027,0.000018087538,0.0042442726],"genre_scores_gemma":[0.0063008377,0.99261194,0.0005464275,0.00005181173,0.000027414177,0.00012286729,0.00023090912,0.00004690778,0.00006089948],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968072,0.0010238709,0.0010013813,0.00038496655,0.00037700337,0.00040553455],"domain_scores_gemma":[0.9969414,0.0014267486,0.00067099376,0.0008090226,0.00009297537,0.000058849186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056531647,0.00034422663,0.0027132682,0.00040137963,0.000030149635,0.000009483586,0.0004141199,0.00045248668,0.00018229088],"category_scores_gemma":[0.00065430003,0.00017696577,0.00045835148,0.0004310599,0.000119833974,0.000028809918,0.00017742356,0.0017192811,0.00004374198],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038184167,0.0007252883,0.062475096,0.08358494,0.00096706755,0.00047220095,0.001817171,3.7683887e-7,0.0000031554973,0.0063195196,0.0056257695,0.8379712],"study_design_scores_gemma":[0.0013621192,0.0007667808,0.0007352741,0.021953743,0.0012362619,0.0012489634,0.0019573702,0.000131906,0.0000122157735,0.000054924767,0.9701903,0.0003501468],"about_ca_topic_score_codex":0.00016412372,"about_ca_topic_score_gemma":0.000028806837,"teacher_disagreement_score":0.9645645,"about_ca_system_score_codex":0.00036093622,"about_ca_system_score_gemma":0.0010230184,"threshold_uncertainty_score":0.74695164},"labels":[],"label_agreement":null},{"id":"W2992713422","doi":"10.1182/blood.v112.11.4690.4690","title":"Outcomes of Elderly Patients with AML in the Hamilton Area: How Are We Doing?","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Myeloid leukemia; Pediatrics; Population; Internal medicine; Leukemia; Myelodysplastic syndromes; Bone marrow","score_opus":0.02285769125545625,"score_gpt":0.25570930491907473,"score_spread":0.23285161366361848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992713422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99511564,0.00012913987,0.000013195383,0.0026980424,0.000016525937,0.00047843673,0.000012042011,0.000018698136,0.0015182742],"genre_scores_gemma":[0.99848646,0.00009795487,0.00049956964,0.00026955587,0.000028549168,0.000026254691,0.00001420826,0.00001850359,0.00055895833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987772,0.00005612065,0.00014970503,0.00017928792,0.00058096944,0.00025668895],"domain_scores_gemma":[0.99918467,0.00012798297,0.000085467385,0.00041994706,0.00012288445,0.00005903164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012563053,0.00012662665,0.00030528096,0.0001242167,0.000048582893,0.0000072305297,0.00018554933,0.00006676913,0.00001699143],"category_scores_gemma":[0.00008510477,0.00006715466,0.000053245836,0.0002957687,0.00012342165,0.000058706242,0.000029128496,0.0002911589,0.0000072423536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000089751295,0.00077681994,0.9952019,0.000050417333,0.000078413745,0.00020540798,0.001438873,7.522977e-7,0.00007973825,0.000007930625,0.0015938458,0.00047617103],"study_design_scores_gemma":[0.008217699,0.0007208748,0.98703736,0.00011143237,0.00006211581,0.000045911198,0.0005360822,0.000005747496,0.001037473,0.0000057145894,0.0021384237,0.00008113679],"about_ca_topic_score_codex":0.00006412868,"about_ca_topic_score_gemma":0.00006926399,"teacher_disagreement_score":0.008164489,"about_ca_system_score_codex":0.000041269155,"about_ca_system_score_gemma":0.000111989284,"threshold_uncertainty_score":0.27384874},"labels":[],"label_agreement":null},{"id":"W2992748477","doi":"10.1182/blood.v110.11.161.161","title":"CD123 (IL-3 Receptor α Chain) Neutralization by a Monoclonal Antibody Selectively Eliminates Human Acute Myeloid Leukemic Stem Cells.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Ex vivo; Stem cell; CD34; Severe combined immunodeficiency; Myeloid leukemia; Myeloid; Bone marrow; Cancer research; Immunology; Biology; Leukemia; Homing (biology); In vivo; Molecular biology; Cell biology","score_opus":0.013772845104321387,"score_gpt":0.2943200173901909,"score_spread":0.28054717228586956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992748477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99459267,0.00054725155,0.0010614924,0.0004919574,0.00013154614,0.00095473137,0.00012592187,0.00029786825,0.0017965361],"genre_scores_gemma":[0.985151,0.00054828636,0.001185862,0.0004530189,0.000561016,0.00004273047,0.0007167037,0.00014130873,0.011200093],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968067,0.000107644766,0.000578367,0.0007341602,0.00072913885,0.0010439807],"domain_scores_gemma":[0.9983978,0.00013929409,0.00019293261,0.00045484415,0.00037679763,0.0004383012],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000789355,0.00041344523,0.00053173007,0.00039669857,0.0002969432,0.00006468224,0.00034008,0.00035337944,0.00016489165],"category_scores_gemma":[0.000030117157,0.00039483883,0.00016633156,0.0008770099,0.00016841332,0.00021334227,0.0001243977,0.0007232779,0.00024150604],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027016798,0.0006294848,0.006553512,0.00011479898,0.00041589967,0.00015777664,0.0006028528,0.0000019975007,0.978991,0.0002745435,0.01013423,0.0018537604],"study_design_scores_gemma":[0.006085789,0.0010587063,0.010638458,0.000106049556,0.0003758073,0.00020755555,0.00029339956,0.00015202758,0.96988285,0.00002651499,0.010747298,0.00042551997],"about_ca_topic_score_codex":0.00017700673,"about_ca_topic_score_gemma":0.000017356992,"teacher_disagreement_score":0.009441714,"about_ca_system_score_codex":0.00060806784,"about_ca_system_score_gemma":0.0003820528,"threshold_uncertainty_score":0.99985033},"labels":[],"label_agreement":null},{"id":"W2993279857","doi":"10.1182/blood.v104.11.2995.2995","title":"Functional Assessment of the Mitochondrial Pathway of Caspase Activation in Patients with Acute Myeloid Leukemia (AML).","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"XIAP; Caspase; Etoposide; Apoptosis; Effector; Caspase 3; Caspase-9; Cytochrome c; Myeloid leukemia; Cytarabine; Biology; Caspase 8; Cancer research; Leukemia; Molecular biology; Chemistry; Cell biology; Immunology; Programmed cell death; Biochemistry; Chemotherapy","score_opus":0.010523563475654144,"score_gpt":0.25172101571666783,"score_spread":0.2411974522410137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993279857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99777967,0.00000472145,0.00041505077,0.00027221531,0.000096164,0.0007453737,0.00002987467,0.000010889217,0.0006460722],"genre_scores_gemma":[0.9970126,0.0000030065437,0.0025540446,0.00006932044,0.00010277209,0.00003751274,0.00007130037,0.000020241674,0.00012921561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984062,0.000050914703,0.00031279417,0.00021600175,0.0008077157,0.00020641378],"domain_scores_gemma":[0.99906445,0.000053891028,0.00017879538,0.00037481874,0.0002620246,0.000066022774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011507733,0.00013061297,0.0002607644,0.00014126624,0.000039139148,0.0000050129906,0.00012361555,0.000099568344,0.00004576244],"category_scores_gemma":[0.000082321174,0.00008295253,0.00007273673,0.00043717638,0.00011373782,0.00010080804,0.00007210025,0.00034144486,0.0000025919128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031072414,0.0041190656,0.53235227,0.00020930091,0.0007686383,0.00004112379,0.00048511897,0.00091747707,0.45536926,0.0009772931,0.000281402,0.001371823],"study_design_scores_gemma":[0.022103587,0.0007106538,0.76950127,0.00016938863,0.000108827975,0.000008602926,0.00004150779,0.000012124425,0.20716532,0.00006903251,0.000033838078,0.00007585868],"about_ca_topic_score_codex":0.00026945162,"about_ca_topic_score_gemma":0.000040012834,"teacher_disagreement_score":0.24820395,"about_ca_system_score_codex":0.0006077413,"about_ca_system_score_gemma":0.0022304638,"threshold_uncertainty_score":0.3956747},"labels":[],"label_agreement":null},{"id":"W2993646328","doi":"10.1182/blood.v112.11.2681.2681","title":"Implementation of Standardized International Karyotype Scoring Practices Is Needed to Provide Uniform and Systematic Evaluation for Patients with Myelodysplastic Syndrome Using IPSS Criteria: An International Working Group on MDS Cytogenetics Study","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"North York General Hospital","funders":"","keywords":"International Prognostic Scoring System; Karyotype; Cytogenetics; Medicine; Myelodysplastic syndromes; Oncology; Internal medicine; Pediatrics; Biology; Chromosome; Bone marrow; Genetics","score_opus":0.07986410325240176,"score_gpt":0.40107258030197224,"score_spread":0.32120847704957045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993646328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99374366,0.0000130257995,0.0010904878,0.00008658234,0.00017444877,0.004788793,0.000053492327,0.000019187508,0.000030328332],"genre_scores_gemma":[0.9898221,0.000007698334,0.009621685,0.000060244707,0.00008897712,0.00024059038,0.00011589226,0.000034434903,0.000008397304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975658,0.00012240578,0.00050093734,0.00034668043,0.0012668298,0.00019734284],"domain_scores_gemma":[0.99809915,0.00020981838,0.00049326156,0.00022558286,0.0008634705,0.00010872014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008362196,0.00016819593,0.00033673516,0.00039511122,0.00012782974,0.00006641223,0.00015207262,0.000044281034,0.000028649962],"category_scores_gemma":[0.00058940327,0.0001412038,0.000030124753,0.00021838791,0.0000312448,0.00035128003,0.00007782596,0.00010141648,8.692171e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043445867,0.0022184865,0.97619236,0.0018587457,0.0016024075,0.00004804946,0.006670074,0.00015386347,0.005697033,0.00002564142,0.000012990549,0.0011757624],"study_design_scores_gemma":[0.06498072,0.021424,0.8564216,0.0056971996,0.0035172973,0.00046381296,0.016523995,0.02253933,0.0077781035,0.000028914337,0.000029589997,0.00059547456],"about_ca_topic_score_codex":0.00015304433,"about_ca_topic_score_gemma":0.000052943862,"teacher_disagreement_score":0.119770795,"about_ca_system_score_codex":0.00038625242,"about_ca_system_score_gemma":0.00027492995,"threshold_uncertainty_score":0.57581234},"labels":[],"label_agreement":null},{"id":"W2994089043","doi":"10.1182/blood-2019-123064","title":"Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Discontinuation; Adverse effect; Anemia; Placebo; Internal medicine; Erythropoiesis; International Prognostic Scoring System; Randomized controlled trial; Clinical trial; Erythropoietin; Myelodysplastic syndromes; Bone marrow","score_opus":0.012884303396123906,"score_gpt":0.28567389401471494,"score_spread":0.27278959061859104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994089043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811134,0.000036515798,0.00013884898,0.00006620231,0.0001296287,0.01797135,0.0000737865,0.00003837302,0.00043193836],"genre_scores_gemma":[0.9981585,0.00014373602,0.0002926371,0.0000132732475,0.000087595734,0.0010475775,0.000090497946,0.00007987783,0.00008627932],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947628,0.0007923833,0.0017305661,0.00080604665,0.0013235337,0.00058470503],"domain_scores_gemma":[0.99532866,0.0027554017,0.000696691,0.0006768697,0.00029698,0.00024541334],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020039633,0.0005492426,0.002376144,0.00086847274,0.00007753108,0.000073161784,0.00046917738,0.00019540134,0.000057776328],"category_scores_gemma":[0.00057890953,0.00031642485,0.00018329974,0.0006788278,0.00023303175,0.0002737918,0.00014044253,0.0006882641,0.0000033921713],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94286376,0.005182113,0.04144203,0.0030207096,0.00063876924,0.0004386267,0.0027008934,0.00047899227,0.002938702,0.000010796839,0.0000017293411,0.00028285146],"study_design_scores_gemma":[0.9546488,0.007617254,0.020937808,0.010856818,0.0018236819,0.000099629906,0.0008074639,0.0013044298,0.0015917682,4.3515854e-7,2.9289006e-7,0.00031164917],"about_ca_topic_score_codex":0.0001308236,"about_ca_topic_score_gemma":0.00016330018,"teacher_disagreement_score":0.02050422,"about_ca_system_score_codex":0.0003269119,"about_ca_system_score_gemma":0.00064402237,"threshold_uncertainty_score":0.9999288},"labels":[],"label_agreement":null},{"id":"W2994813762","doi":"10.14740/wjon1231","title":"Bone Marrow Features in Patients With Acute Myeloid Leukemia Treated With Novel Targeted Isocitrate Dehydrogenase 1/2 Inhibitors","year":2019,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Immunophenotyping; Bone marrow; Myeloid leukemia; Pathology; CD117; Isocitrate dehydrogenase; Basophilia; IDH1; Myeloid; Population; Cancer research; Immunology; CD34; Stem cell; Antigen; Biology","score_opus":0.007757152791119578,"score_gpt":0.261205129120931,"score_spread":0.2534479763298114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994813762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945701,0.0002456076,0.000014306214,0.0015700342,0.00014703975,0.000797674,0.000022186645,0.000023390698,0.0026096574],"genre_scores_gemma":[0.9914762,0.000060146092,0.0033090296,0.0008760722,0.00019257204,0.000012086409,0.000049088187,0.00007797083,0.003946862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972416,0.0001601821,0.00076017366,0.00035448742,0.0007797072,0.0007038272],"domain_scores_gemma":[0.9977541,0.00017855226,0.00068090373,0.00032676852,0.00063763105,0.00042206515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005525008,0.00035814923,0.0011382974,0.0011293844,0.000059114653,0.00002446513,0.00024277989,0.00024246999,0.00024275295],"category_scores_gemma":[0.00006141904,0.00022985051,0.00014129326,0.0013032497,0.00022112014,0.0002614124,0.000065825545,0.0017163858,0.000032993164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046174075,0.0015723865,0.85376096,0.00010030966,0.001698744,0.006677525,0.00058673474,0.00051473576,0.07083858,0.000050225153,0.012458431,0.005567273],"study_design_scores_gemma":[0.09293941,0.024664402,0.83162,0.00082170276,0.0007805592,0.0040268204,0.00035683397,0.00018270798,0.025735078,0.00002170801,0.018137768,0.0007130153],"about_ca_topic_score_codex":0.00012192557,"about_ca_topic_score_gemma":0.000496941,"teacher_disagreement_score":0.046765327,"about_ca_system_score_codex":0.0032475183,"about_ca_system_score_gemma":0.0027818761,"threshold_uncertainty_score":0.9373032},"labels":[],"label_agreement":null},{"id":"W2994880414","doi":"10.1182/blood.2019002697","title":"Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; Servier; Astellas Pharma; National Institutes of Health; Argenx; Incyte; MacroGenics; BeiGene; Deutsche Forschungsgemeinschaft; Agios Pharmaceuticals; Celgene; Daiichi-Sankyo; Teva Pharmaceutical Industries; Jazz Pharmaceuticals; Pfizer; Amgen","keywords":"Medicine; NPM1; Internal medicine; Oncology; Midostaurin; Myeloid leukemia; Transplantation; White blood cell; Leukemia; Hazard ratio; Confidence interval; Biology","score_opus":0.007989854079912853,"score_gpt":0.2483052702837311,"score_spread":0.24031541620381824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994880414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847838,0.00024264636,0.0000054942075,0.00012175553,0.000040657036,0.0010249912,0.00012933179,0.000045126748,0.013606145],"genre_scores_gemma":[0.99710256,0.00008389982,0.00030308252,0.00013459285,0.000069367954,0.000013470689,0.00026705553,0.000087424836,0.001938543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976108,0.0001952699,0.00042313972,0.00045188915,0.00068328745,0.0006355957],"domain_scores_gemma":[0.99821895,0.00014032639,0.00020468568,0.0010360436,0.00020121998,0.00019874163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046320038,0.00032344347,0.00055359985,0.00018628317,0.0000607965,0.000030416028,0.00051628303,0.00012186206,0.00022457377],"category_scores_gemma":[0.000104438535,0.00018705391,0.00014572039,0.00046647864,0.00016945263,0.00013554894,0.00018841635,0.00064476934,0.00044892007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015362098,0.0007166455,0.9658699,0.00007575791,0.00088162266,0.0001317654,0.0004508664,0.000039969298,0.016257893,0.00001956862,0.01240597,0.0016138456],"study_design_scores_gemma":[0.017707674,0.002418945,0.97546875,0.00011533412,0.0002700898,0.00007181557,0.000039219478,0.00006582946,0.0027690197,0.000007994317,0.0008176449,0.00024767904],"about_ca_topic_score_codex":0.0009058695,"about_ca_topic_score_gemma":0.000030572068,"teacher_disagreement_score":0.016171463,"about_ca_system_score_codex":0.00063485286,"about_ca_system_score_gemma":0.0010327719,"threshold_uncertainty_score":0.7627837},"labels":[],"label_agreement":null},{"id":"W2995549703","doi":"10.14740/wjon1232","title":"Midostaurin-Related Interstitial Lung Injury in FLT3<sup>+</sup> Acute Myeloid Leukemia Post-Allogeneic Transplant","year":2019,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Midostaurin; Myeloid leukemia; Leukemia; Oncology; Internal medicine","score_opus":0.010129133085916666,"score_gpt":0.3012760517409057,"score_spread":0.29114691865498904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995549703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98221624,0.0007642536,0.00003966418,0.007600811,0.0008120524,0.00065736414,0.00003341983,0.000031055162,0.007845123],"genre_scores_gemma":[0.99072206,0.00086199533,0.000911541,0.0020070362,0.00044964298,0.000009630857,0.000039274844,0.000071495095,0.0049273246],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961762,0.00041957636,0.0014804559,0.0004038384,0.0006453243,0.0008745961],"domain_scores_gemma":[0.9978475,0.0003790329,0.00047822937,0.0003995899,0.00041589641,0.000479742],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013332259,0.0003677769,0.0013071325,0.0018713967,0.000058855905,0.000024257753,0.00057896937,0.0004177084,0.0021804678],"category_scores_gemma":[0.000119794626,0.0003065805,0.0004040569,0.0008695157,0.000239783,0.00026589137,0.00013934345,0.00277133,0.00029723402],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07043458,0.0019079114,0.23141125,0.00076084305,0.006394398,0.053262632,0.012496117,0.0039378577,0.4598239,0.0010746476,0.046601217,0.11189464],"study_design_scores_gemma":[0.119861744,0.048303526,0.2754546,0.0052231182,0.004470882,0.06850348,0.0037947264,0.018559502,0.025514154,0.0005879573,0.42682594,0.0029003508],"about_ca_topic_score_codex":0.00013823436,"about_ca_topic_score_gemma":0.00013159867,"teacher_disagreement_score":0.43430978,"about_ca_system_score_codex":0.0050318292,"about_ca_system_score_gemma":0.0039003084,"threshold_uncertainty_score":0.9999386},"labels":[],"label_agreement":null},{"id":"W2995608308","doi":"10.1111/bjh.16325","title":"Mixed phenotype acute leukaemia with predominant myeloid blasts and a small subset of B/myeloid blasts shares the same mutation profile","year":2019,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; University of Ottawa","funders":"Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Myeloid leukaemia; Myeloid; Phenotype; Mutation; Medicine; Cancer research; Immunology; Biology; Gene; Genetics","score_opus":0.018643480693947053,"score_gpt":0.25187470689634,"score_spread":0.23323122620239295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995608308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8878495,0.0052140495,0.00024264025,0.103627436,0.00046380732,0.0018202565,0.0004518146,0.000029860177,0.0003006495],"genre_scores_gemma":[0.6831047,0.016196921,0.032631587,0.23160602,0.010790421,0.0005584905,0.0038450214,0.0017261821,0.019540673],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.99525744,0.00064160477,0.0014880361,0.00062274025,0.0010832342,0.00090695464],"domain_scores_gemma":[0.99481833,0.0010221491,0.0019183524,0.0005944435,0.0014536794,0.00019304935],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00092120946,0.0005637659,0.0024917414,0.0005432848,0.0001433788,0.00011365976,0.00074511534,0.0010931,0.0003428725],"category_scores_gemma":[0.0007256545,0.0004166134,0.0003212889,0.00037453885,0.0009891408,0.00019853181,0.00026800227,0.0042956215,0.00005161579],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029588065,0.00013358047,0.0009204788,0.0027483853,0.0023723107,0.16695085,0.00058593345,0.000009067779,0.0017488567,0.000022604469,0.8128464,0.008702719],"study_design_scores_gemma":[0.00948677,0.0036543082,0.0075335964,0.0061852965,0.002085634,0.9199549,0.00040825497,0.00026401735,0.004614192,0.0001784884,0.044984926,0.0006496279],"about_ca_topic_score_codex":0.0002776384,"about_ca_topic_score_gemma":0.00031261297,"teacher_disagreement_score":0.7678615,"about_ca_system_score_codex":0.00029588246,"about_ca_system_score_gemma":0.0022311134,"threshold_uncertainty_score":0.9998286},"labels":[],"label_agreement":null},{"id":"W2995858855","doi":"10.3324/haematol.2019.226795","title":"The novel L-nucleoside analogue, 5-Fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia","year":2019,"lang":"en","type":"letter","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Myeloid leukemia; Nucleoside analogue; Medicine; Nucleoside; Leukemia; Myeloid; Cancer research; Pharmacology; Chemistry; Immunology; Stereochemistry","score_opus":0.026645746346510693,"score_gpt":0.28190972480066717,"score_spread":0.2552639784541565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995858855","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.039977368,0.0018712409,0.0005395714,0.9155141,0.0015453884,0.0060237083,0.0006518965,0.00080890715,0.033067804],"genre_scores_gemma":[0.020101061,0.004897733,0.0032686961,0.9106417,0.0052607865,0.00078335986,0.0055334843,0.00065299694,0.0488602],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914566,0.0003566212,0.0014955632,0.0019226157,0.0020968136,0.0026717752],"domain_scores_gemma":[0.99251175,0.0022753482,0.00077233353,0.0035041412,0.0005469366,0.0003894984],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0008418379,0.0014607257,0.0026562226,0.00048370732,0.0008456334,0.0003352303,0.0021882097,0.0027819246,0.00019597146],"category_scores_gemma":[0.0011249997,0.0008740009,0.0012020903,0.0008520112,0.0010378885,0.00016802856,0.001089865,0.008538342,0.004014306],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000536741,0.00011118086,0.0001904928,0.0004669383,0.0014150618,0.010373962,0.000060433467,0.000014949266,0.0028299002,0.00032583438,0.9807413,0.0029331953],"study_design_scores_gemma":[0.004056327,0.00057871814,0.0035708451,0.00057537877,0.0008538472,0.0041210484,0.000057089455,0.0008525116,0.00068791053,0.00007095908,0.98350215,0.001073229],"about_ca_topic_score_codex":0.00012265258,"about_ca_topic_score_gemma":0.000014956397,"teacher_disagreement_score":0.019876307,"about_ca_system_score_codex":0.0020697976,"about_ca_system_score_gemma":0.001798482,"threshold_uncertainty_score":0.9998142},"labels":[],"label_agreement":null},{"id":"W2997127334","doi":"10.3324/haematol.2019.235721","title":"Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia","year":2020,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; Princess Margaret Cancer Foundation","keywords":"Myeloid leukemia; Medicine; Internal medicine; Minimal residual disease; Oncology; Chemotherapy; Leukemia; Gastroenterology; Pathology","score_opus":0.04661541952459586,"score_gpt":0.28505376704147734,"score_spread":0.23843834751688148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997127334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99368495,0.00012533997,0.000028740411,0.002987623,0.000039494495,0.00260732,0.00012058008,0.0001021244,0.0003038544],"genre_scores_gemma":[0.9976002,0.000026967837,0.001397434,0.00041456253,0.000060441675,0.0002080303,0.000058270572,0.000034091954,0.00020003297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964938,0.00030955163,0.0006057071,0.0006974029,0.0012102267,0.00068330544],"domain_scores_gemma":[0.99812436,0.00031811077,0.00023170639,0.0006242226,0.0002515652,0.0004500392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052739005,0.00035369152,0.00078909576,0.00018225095,0.00016096389,0.000040389266,0.00061632827,0.00016053603,0.00014661589],"category_scores_gemma":[0.0015612489,0.00020383243,0.00011374526,0.0009672848,0.00020406007,0.00013793196,0.0003152983,0.0007615493,0.00023438846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01175993,0.0020953908,0.9451541,0.0009501654,0.0003227825,0.00389641,0.005697236,0.00038994694,0.022512505,0.00010699258,0.005809289,0.0013052848],"study_design_scores_gemma":[0.00493299,0.0048147324,0.96146566,0.00076719443,0.00035297027,0.00009279146,0.001272433,0.00060885836,0.024306629,0.000060123446,0.00065447827,0.00067117164],"about_ca_topic_score_codex":0.00005143846,"about_ca_topic_score_gemma":0.000002463844,"teacher_disagreement_score":0.016311564,"about_ca_system_score_codex":0.0006395291,"about_ca_system_score_gemma":0.0005366827,"threshold_uncertainty_score":0.83120453},"labels":[],"label_agreement":null},{"id":"W2997260931","doi":"10.5539/gjhs.v11n14p98","title":"Myeloid Sarcoma of the Orbit Preceding Acute Myeloid Leukaemia: A Diagnostic Challenge","year":2019,"lang":"en","type":"article","venue":"Global Journal of Health Science","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Myeloid sarcoma; Medicine; Myeloid leukaemia; Myeloid; Biopsy; Sarcoma; Immunophenotyping; Myeloid leukemia; Dermatology; Pathology; Radiology; Internal medicine; Immunology; Antigen","score_opus":0.024724830943841824,"score_gpt":0.34287616168548946,"score_spread":0.31815133074164764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997260931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754828,0.0027374376,0.000096858195,0.015922816,0.0010240207,0.0007197798,0.000013031652,0.000014003812,0.003989221],"genre_scores_gemma":[0.99546933,0.0018378769,0.0013627678,0.0009847825,0.00018383231,0.0000029998632,5.045859e-7,0.000012460674,0.00014545974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951898,0.000121352474,0.0010611493,0.0003463041,0.0023407047,0.00094072474],"domain_scores_gemma":[0.99665207,0.00027450564,0.0009956814,0.0006127318,0.0008797641,0.00058522593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037014468,0.00020163239,0.0007118808,0.00019800056,0.00044571425,0.00007204552,0.0013961835,0.000099057215,0.000057671477],"category_scores_gemma":[0.0013131199,0.00012484472,0.00021494272,0.0018490729,0.0007527815,0.00044120455,0.00044831022,0.0008689069,0.000053916792],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010498008,0.0007308217,0.84208447,0.0014428941,0.00028504757,0.00036756234,0.001173686,0.00021145852,0.033097226,0.0037452455,0.012644131,0.10316765],"study_design_scores_gemma":[0.0057163183,0.004743983,0.96008635,0.0031543933,0.00013919582,0.011108461,0.0011713118,0.0007194011,0.0065888674,0.0011329901,0.005099466,0.00033926917],"about_ca_topic_score_codex":0.00016713944,"about_ca_topic_score_gemma":0.00001412386,"teacher_disagreement_score":0.11800186,"about_ca_system_score_codex":0.0021932842,"about_ca_system_score_gemma":0.008324564,"threshold_uncertainty_score":0.9972973},"labels":[],"label_agreement":null},{"id":"W2997744721","doi":"10.1101/2020.01.01.888610","title":"Recurrent pre-leukemic deletions in myeloid malignancies are the result of DNA double-strand breaks followed by microhomology-mediated end joining","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Biology; Myeloid; Myeloid leukemia; Haematopoiesis; Cancer research; Progenitor cell; Stem cell; Leukemia; Genetics","score_opus":0.02245584877979076,"score_gpt":0.25608107149886017,"score_spread":0.2336252227190694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997744721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852272,0.004540756,0.00017560799,0.004768311,0.0005919803,0.0026671996,0.0017209767,0.0002744346,0.000033478158],"genre_scores_gemma":[0.9955638,0.0016826934,0.0010684906,0.00051858264,0.00032517815,0.0005954291,0.000020839974,0.00019904938,0.000025941747],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9944283,0.00042820125,0.0015584392,0.0015279818,0.0009408943,0.0011161942],"domain_scores_gemma":[0.99536043,0.00044183398,0.0010095921,0.0018101012,0.0008666264,0.0005114015],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014588936,0.0008632809,0.0015951016,0.00057245063,0.00019634342,0.00011107078,0.0010918528,0.0010907761,0.00006545832],"category_scores_gemma":[0.0012291054,0.0007505298,0.00036155584,0.0014575362,0.0006539896,0.00011903887,0.0008883171,0.0032610695,0.00004976049],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015753114,0.0002563643,0.015778068,0.0010864931,0.00040927262,0.00029464325,0.00015728264,0.000028803737,0.97197235,0.00006251813,0.008375109,0.0000038127712],"study_design_scores_gemma":[0.012533114,0.00045313317,0.27035388,0.0042826696,0.0006540865,0.0000012388494,0.0001311847,0.0007764581,0.6986744,0.0000032721466,0.010746999,0.0013895911],"about_ca_topic_score_codex":0.00046673816,"about_ca_topic_score_gemma":0.00004267384,"teacher_disagreement_score":0.27329797,"about_ca_system_score_codex":0.0013512677,"about_ca_system_score_gemma":0.0033448858,"threshold_uncertainty_score":0.99949455},"labels":[],"label_agreement":null},{"id":"W2998102956","doi":"10.1002/cncr.32671","title":"Incidence of acute myeloid leukemia: A regional analysis of Canada","year":2019,"lang":"en","type":"letter","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre; University of Ottawa","funders":"","keywords":"Medicine; Incidence (geometry); Population; Epidemiology; Disease; Family medicine; Pathology; Environmental health","score_opus":0.021959445528397632,"score_gpt":0.3009482781809629,"score_spread":0.2789888326525653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998102956","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15035793,0.0050906534,0.00008449455,0.83240145,0.00088556606,0.0014557227,0.0033366168,0.000040976298,0.0063465936],"genre_scores_gemma":[0.03401694,0.0033478136,0.00039318472,0.86124706,0.003020815,0.00018681536,0.0020554033,0.00016828447,0.09556368],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99651,0.000073483985,0.0006408552,0.0005663947,0.0016438534,0.0005653773],"domain_scores_gemma":[0.99708444,0.000327537,0.00056156766,0.0010921154,0.00082191697,0.000112419366],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020305284,0.000334058,0.0016657101,0.000723837,0.000029377565,0.0000056478693,0.00053906435,0.00071025867,0.0014044904],"category_scores_gemma":[0.00009525633,0.0002883519,0.0004526364,0.0015940678,0.00025562718,0.000050086408,0.00015612104,0.002013306,0.000007273536],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00014914616,0.00000598807,0.0039813817,0.0007743088,0.009351137,0.0006861936,0.00007300414,0.00013281585,0.0014055665,0.000004961916,0.983119,0.0003164673],"study_design_scores_gemma":[0.0012072703,0.00013114445,0.015948536,0.00080360664,0.012038871,0.000064244094,0.000035702364,0.0013796373,0.0022071647,0.000009195061,0.965742,0.00043261427],"about_ca_topic_score_codex":0.54095024,"about_ca_topic_score_gemma":0.13459335,"teacher_disagreement_score":0.4063569,"about_ca_system_score_codex":0.0056317635,"about_ca_system_score_gemma":0.028866623,"threshold_uncertainty_score":0.99995685},"labels":[],"label_agreement":null},{"id":"W2998286748","doi":"10.1101/2019.12.23.874487","title":"<i>RAS</i> mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axis","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"National Center for Advancing Translational Sciences; Conquer Cancer Foundation; Institut Gustave-Roussy; Austrian Science Fund; Georgia Clinical and Translational Science Alliance; Ligue Contre le Cancer; American Society of Clinical Oncology; National Institutes of Health; Henry J. Predolin Foundation for Research in Leukemia; University of Wisconsin Carbone Cancer Center; National Cancer Institute; Institut National Du Cancer","keywords":"Chronic myelomonocytic leukemia; Neuroblastoma RAS viral oncogene homolog; Cancer research; Biology; HRAS; Mutation; Myelodysplastic syndromes; Gene; KRAS; Genetics; Immunology; Bone marrow","score_opus":0.02055995151224089,"score_gpt":0.2678099590836061,"score_spread":0.24725000757136523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998286748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9555502,0.0004802206,0.036464386,0.00068729295,0.0006294975,0.0052050957,0.0004687389,0.00040978266,0.000104798986],"genre_scores_gemma":[0.9884655,0.00020569543,0.009072592,0.00028665806,0.00081303774,0.00078588934,0.000011200029,0.00028774186,0.00007168082],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948901,0.0001998042,0.0011751077,0.001590152,0.0011628004,0.0009820177],"domain_scores_gemma":[0.99375033,0.00032749205,0.0010174286,0.002300457,0.002118827,0.0004854352],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007626402,0.00092563714,0.0015036911,0.0009084735,0.0001934509,0.00011930732,0.00070339476,0.001118984,0.000115754294],"category_scores_gemma":[0.0007837974,0.0009522264,0.00038235483,0.0011752207,0.00044500965,0.0003551133,0.000754513,0.002443122,0.00019722608],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00029226023,0.00036805528,0.002746561,0.002242473,0.0008603079,0.000041768973,0.000099192155,0.0019804996,0.99045545,0.0003635711,0.00053873606,0.000011101781],"study_design_scores_gemma":[0.005090702,0.0005696622,0.04753175,0.0021733204,0.00054483104,3.1478214e-7,0.000021602162,0.03566199,0.9060887,0.0000043516397,0.0012801217,0.0010326678],"about_ca_topic_score_codex":0.0003046039,"about_ca_topic_score_gemma":0.00000585815,"teacher_disagreement_score":0.08436678,"about_ca_system_score_codex":0.008833806,"about_ca_system_score_gemma":0.014590559,"threshold_uncertainty_score":0.99985826},"labels":[],"label_agreement":null},{"id":"W2998506404","doi":"10.1200/jco.2012.30.15_suppl.6632","title":"Post hoc analysis of relationship between baseline white blood cell count and renal and hepatic function and response in a randomized phase III trial of decitabine in patients age 65 or older with acute myeloid leukemia.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Creatinine; Blood urea nitrogen; Internal medicine; Renal function; White blood cell; Gastroenterology; Decitabine; Post-hoc analysis; Cytarabine; Absolute neutrophil count; Urology; Myeloid leukemia; Neutropenia; Chemotherapy","score_opus":0.05565027784404605,"score_gpt":0.40686781763520424,"score_spread":0.3512175397911582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998506404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997485,0.00036444177,0.0002929156,0.00082878134,0.000068687266,0.00090744044,0.000030579744,0.0000023875502,0.000019781219],"genre_scores_gemma":[0.9964281,0.0007016253,0.0023756868,0.00015679069,0.00018506845,0.000011210339,0.000033264772,0.000015855961,0.000092402195],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9922056,0.0032361771,0.0035055466,0.0002256789,0.00055475807,0.0002722013],"domain_scores_gemma":[0.976737,0.020068051,0.0020893225,0.00019369667,0.0005191536,0.00039278288],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021296132,0.0001818258,0.0034944005,0.0012185513,0.000027396285,0.000007217618,0.00007717665,0.00039699813,0.000034736244],"category_scores_gemma":[0.014271906,0.00011245898,0.00022949073,0.0008127819,0.0004955635,0.0002189638,0.000067071946,0.0010237243,2.362171e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5814532,0.0015114946,0.41361985,0.000034264933,0.0010264198,0.00009919141,0.0003452302,0.00000558934,0.000153209,0.0000019310182,0.000019975352,0.0017296283],"study_design_scores_gemma":[0.4812208,0.023009615,0.48991522,0.00009120419,0.0052856146,0.00002021308,0.000075408345,0.00027991916,0.000016410064,0.000010460221,0.000018593446,0.00005652461],"about_ca_topic_score_codex":0.00008025591,"about_ca_topic_score_gemma":0.00015536121,"teacher_disagreement_score":0.10023241,"about_ca_system_score_codex":0.00024484168,"about_ca_system_score_gemma":0.0016376687,"threshold_uncertainty_score":0.9940313},"labels":[],"label_agreement":null},{"id":"W2998624748","doi":"10.1093/ajcp/aqz203","title":"The Value of Next-Generation Sequencing in the Screening and Evaluation of Hematologic Neoplasms in Clinical Practice","year":2019,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital","funders":"","keywords":"Medicine; Hematology; Hematologic Neoplasms; Internal medicine; Clinical Practice; Myeloid; DNA sequencing; Hematologic disorders; Oncology; Bioinformatics; Cancer; Biology; Gene; Genetics","score_opus":0.22896660924119705,"score_gpt":0.4936777399066318,"score_spread":0.2647111306654347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998624748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925653,0.00047995956,0.00032393183,0.005774164,0.00017324538,0.000361165,5.952669e-7,0.0000014106263,0.0003202671],"genre_scores_gemma":[0.9889766,0.00091412,0.008859576,0.0010670198,0.00016552283,0.000003655169,0.0000012399447,0.000008176506,0.000004114948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98878723,0.007316777,0.002717848,0.00020540465,0.0007609712,0.00021174562],"domain_scores_gemma":[0.9806591,0.015995812,0.0022265161,0.00032556918,0.0007194998,0.000073471354],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.048434973,0.00009234988,0.0009109541,0.0001419191,0.000026503032,0.000009219948,0.00023968829,0.00013406022,0.000007970374],"category_scores_gemma":[0.03568157,0.00005034113,0.0001641957,0.0003884051,0.0009279752,0.00014691011,0.00006386664,0.0013344615,0.0000021492772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002731616,0.00029172224,0.6618403,0.000027589726,0.000112510286,0.00030192028,0.0011991231,0.0012364938,0.004332571,0.00070815155,0.00010720841,0.32711074],"study_design_scores_gemma":[0.008163913,0.010363533,0.88821226,0.00024524232,0.00035117552,0.004190336,0.016564177,0.070591114,0.00023158526,0.0006926906,0.00028001185,0.00011398269],"about_ca_topic_score_codex":0.00009142973,"about_ca_topic_score_gemma":0.000035287678,"teacher_disagreement_score":0.32699677,"about_ca_system_score_codex":0.00008611386,"about_ca_system_score_gemma":0.0011628169,"threshold_uncertainty_score":0.97983646},"labels":[],"label_agreement":null},{"id":"W2999438278","doi":"10.3390/ijms21020626","title":"Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease","year":2020,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Ontario Ministry of Health and Long-Term Care; Southeastern Ontario Academic Medical Organization; Ontario Medical Association; European Hematology Association","keywords":"Myeloid; Myeloid leukemia; Haematopoiesis; Cancer; Myelodysplastic syndromes; Biology; Cancer research; Disease; Immunology; Medicine; Stem cell; Genetics; Internal medicine; Bone marrow","score_opus":0.04044810159587383,"score_gpt":0.35925519177197485,"score_spread":0.31880709017610104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999438278","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033574952,0.99448663,0.0002733677,0.00084951497,0.00046053898,0.00030616086,0.00007064957,0.000008674445,0.00018694894],"genre_scores_gemma":[0.009878943,0.9892826,0.0004437879,0.00010864215,0.00017622116,0.000012454421,0.000031788128,0.00002161122,0.00004393946],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963419,0.00022702766,0.000775951,0.0003041911,0.0021734673,0.00017746763],"domain_scores_gemma":[0.9977326,0.00016945133,0.0007262271,0.00016331967,0.0009107004,0.0002977459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008888321,0.00022330263,0.0011948321,0.0006325551,0.00007069668,0.0000795763,0.00066604593,0.00010837886,0.00004248668],"category_scores_gemma":[0.0008870878,0.00016852959,0.0009102825,0.00061879447,0.0005914817,0.00017208535,0.00016033616,0.00049997127,0.000003864953],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007330399,0.00011266851,0.000618359,0.0011552045,0.007798375,0.005164067,0.00015626117,0.0003733149,0.000075913886,0.000118971635,0.00034569364,0.9840079],"study_design_scores_gemma":[0.0026283585,0.00064059556,0.0010209433,0.02009581,0.007932006,0.0012870524,0.00030461294,0.0004235461,0.00013035352,0.0005351985,0.9645232,0.00047832256],"about_ca_topic_score_codex":0.00009347721,"about_ca_topic_score_gemma":0.0000032405637,"teacher_disagreement_score":0.98352957,"about_ca_system_score_codex":0.00046035953,"about_ca_system_score_gemma":0.0026240475,"threshold_uncertainty_score":0.6872437},"labels":[],"label_agreement":null},{"id":"W3000816624","doi":"10.1016/j.bbmt.2019.12.076","title":"Impact of Genetic Mutations on the Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia with Antecedent Myeloproliferative Neoplasm","year":2020,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloproliferative neoplasm; Antecedent (behavioral psychology); Hematopoietic cell; Myeloid leukemia; Myeloid; Oncology; Transplantation; Haematopoiesis; Leukemia; Neoplasm; Hematopoietic stem cell transplantation; Internal medicine; Cancer research; Immunology; Stem cell; Pathology; Genetics; Bone marrow; Myelofibrosis; Biology","score_opus":0.009916236892811134,"score_gpt":0.25109065337504266,"score_spread":0.24117441648223154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000816624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978747,0.00005803043,0.0005237019,0.00030081405,0.000007953941,0.0008671613,0.00028807722,0.000009407952,0.000070185466],"genre_scores_gemma":[0.9980653,0.0005873236,0.0009089496,0.00007131394,0.00000665974,0.00003366369,0.0003049074,0.000016893779,0.0000049735304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988298,0.000115220835,0.00040816027,0.00025023488,0.00021279069,0.00018380904],"domain_scores_gemma":[0.99922335,0.0002128918,0.00021261691,0.00012568242,0.00014762334,0.00007783063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008883031,0.00019485266,0.00045701387,0.00014866823,0.00003649127,0.000003230608,0.00008767861,0.0001067679,0.000015085668],"category_scores_gemma":[0.000011280634,0.000109100765,0.00006810718,0.00023799561,0.00027612597,0.000049145343,0.0000052662494,0.00017172645,9.498287e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004982154,0.00021779537,0.8673824,0.00044050807,0.00059516524,0.000031127736,0.0043999148,0.00026295325,0.121372506,0.000066971974,0.0000017126605,0.0002467987],"study_design_scores_gemma":[0.0075994204,0.0051006624,0.8892473,0.00012175651,0.0007744194,0.00004134671,0.0001608045,0.000057986992,0.09677296,0.00001987301,2.2269128e-7,0.00010322399],"about_ca_topic_score_codex":0.00011420548,"about_ca_topic_score_gemma":0.000050951425,"teacher_disagreement_score":0.024599541,"about_ca_system_score_codex":0.000032266653,"about_ca_system_score_gemma":0.00030019807,"threshold_uncertainty_score":0.44490004},"labels":[],"label_agreement":null},{"id":"W30025801","doi":"10.1182/blood.v122.21.5216.5216","title":"Dandelion Root and Chronic Myelomonocytic Leukemia","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Regional Hospital; University of Windsor; Western University","funders":"","keywords":"Chronic myelomonocytic leukemia; Medicine; Leukemia; Acute leukemia; Bone marrow; Internal medicine; Induction chemotherapy; White blood cell; Gastroenterology; Surgery; Chemotherapy; Immunology; Myelodysplastic syndromes","score_opus":0.014025918575610705,"score_gpt":0.2659187667865284,"score_spread":0.25189284821091773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W30025801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856762,0.002375132,0.00005854607,0.0009368968,0.000034387424,0.0005030206,0.0000013521399,0.000088023764,0.0103264],"genre_scores_gemma":[0.99533993,0.00023779563,0.00050699804,0.00018726785,0.0003364009,0.00006685022,0.000013160411,0.000030438008,0.003281181],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989222,0.000027901178,0.00017120094,0.00027542553,0.00023550948,0.00036771563],"domain_scores_gemma":[0.9992388,0.00005367632,0.000031269275,0.00034296585,0.000085516665,0.0002477671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012616722,0.00013463685,0.00022651107,0.00011477558,0.00006939206,0.000041926745,0.0000915915,0.000111380476,0.0004665548],"category_scores_gemma":[0.000085439075,0.00010882613,0.000042532458,0.00016881705,0.00009373441,0.00012312472,0.00010852441,0.00030034548,0.0007054265],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026149364,0.0009716342,0.17190412,0.0016240719,0.0011316316,0.0009204972,0.0011275385,0.000013704462,0.52164006,0.0016306775,0.06399307,0.23478149],"study_design_scores_gemma":[0.03965702,0.0030045453,0.7336959,0.00051665894,0.0008126151,0.0028125783,0.00033996417,0.011311228,0.17685112,0.0014327714,0.028617045,0.0009485456],"about_ca_topic_score_codex":0.00026824264,"about_ca_topic_score_gemma":0.000024453357,"teacher_disagreement_score":0.5617918,"about_ca_system_score_codex":0.00045421932,"about_ca_system_score_gemma":0.00056276907,"threshold_uncertainty_score":0.90670663},"labels":[],"label_agreement":null},{"id":"W3002741063","doi":"10.1111/bjh.16347","title":"Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial","year":2020,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Medical Research Council; National Institute for Health and Care Research; Cancer Research UK; Australian and New Zealand Society of Blood Transfusion","keywords":"Medicine; Confidence interval; Myelodysplastic syndromes; Population; Quality of life (healthcare); Randomized controlled trial; Blood transfusion; Red Cell; Pediatrics; Internal medicine","score_opus":0.039661416918017875,"score_gpt":0.2762267365054811,"score_spread":0.23656531958746319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3002741063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955463,0.0013266465,0.0004435465,0.0012916062,0.000097878365,0.0011522253,0.000005477401,0.000012405124,0.00012392804],"genre_scores_gemma":[0.99791545,0.000936996,0.00076601707,0.0002546392,0.00006890111,0.000017376185,0.0000039427414,0.0000248391,0.0000118287335],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99784577,0.00040848326,0.0007899974,0.0002695331,0.00039238762,0.0002938487],"domain_scores_gemma":[0.9987649,0.0002850336,0.0002453821,0.00010692419,0.00021131505,0.00038647643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006024528,0.00014538116,0.0010881774,0.00016764739,0.00004787328,0.000023105553,0.00012548939,0.00014737244,0.000081846316],"category_scores_gemma":[0.00089848874,0.00013008174,0.00010014949,0.00025897633,0.00019010369,0.00015651903,0.00003664376,0.0007652326,0.0000043616214],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7964966,0.0009090273,0.015353866,0.0010115228,0.00016244229,0.1766988,0.002196034,0.000016509086,0.002276782,0.0000045802003,0.0019090218,0.0029647755],"study_design_scores_gemma":[0.8481026,0.008084973,0.005408803,0.00096046505,0.00019940203,0.1346123,0.0010255078,0.00031208727,0.00085731567,0.00005658691,0.00017091236,0.00020904046],"about_ca_topic_score_codex":0.000024679455,"about_ca_topic_score_gemma":0.00005425254,"teacher_disagreement_score":0.051605977,"about_ca_system_score_codex":0.000124038,"about_ca_system_score_gemma":0.0005357197,"threshold_uncertainty_score":0.530458},"labels":[],"label_agreement":null},{"id":"W3003349242","doi":"10.1016/j.exphem.2020.01.011","title":"Clonal hematopoiesis and inflammation: Partners in leukemogenesis and comorbidity","year":2020,"lang":"en","type":"review","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"European Hematology Association","keywords":"Inflammation; Haematopoiesis; Biology; Somatic cell; Phenotype; Immunology; Disease; clone (Java method); Genetics; Medicine; Stem cell; Gene; Internal medicine","score_opus":0.0742206715436663,"score_gpt":0.41325376456452506,"score_spread":0.33903309302085877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003349242","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023172959,0.9950678,0.0000034715267,0.00051020307,0.000082332954,0.0010890729,0.000014773971,0.00005467559,0.00086038007],"genre_scores_gemma":[0.0029680082,0.99547255,0.00066347484,0.0001086368,0.0001429616,0.0003435952,0.00012454069,0.000067711844,0.00010853337],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99768454,0.00024387572,0.00072105794,0.0006831873,0.00025627055,0.00041107732],"domain_scores_gemma":[0.9988814,0.00028407783,0.00017577481,0.000298902,0.00002480604,0.00033501443],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018659783,0.00046882502,0.0025607005,0.0002991994,0.000075005155,0.000025561316,0.00013853065,0.0004815461,0.00024118673],"category_scores_gemma":[0.00009034753,0.00040868408,0.00016647723,0.00031564172,0.00041588157,0.000077445,0.00042508423,0.000550936,0.00008665034],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006955055,0.0005541098,0.0021031885,0.094473764,0.0014113667,0.013436632,0.002681845,1.15292316e-7,0.00029897701,0.056492332,0.012524771,0.8153274],"study_design_scores_gemma":[0.0018973954,0.00024470387,0.000047809175,0.0034334848,0.00023451571,0.013730113,0.0005246366,0.000047983463,0.003191268,0.000040879237,0.9761179,0.0004893174],"about_ca_topic_score_codex":0.00005228047,"about_ca_topic_score_gemma":0.000010343299,"teacher_disagreement_score":0.9635931,"about_ca_system_score_codex":0.0005029214,"about_ca_system_score_gemma":0.00052511855,"threshold_uncertainty_score":0.9998365},"labels":[],"label_agreement":null},{"id":"W3004001433","doi":"10.1080/23723556.2020.1712182","title":"Repurposing ribosome-targeting antibiotics to overcome resistance to venetoclax in acute myeloid leukemia","year":2020,"lang":"en","type":"article","venue":"Molecular & Cellular Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Venetoclax; Myeloid leukemia; Repurposing; Cancer research; Lymphoma; Drug resistance; Medicine; Leukemia; Biology; Immunology; Chronic lymphocytic leukemia; Microbiology","score_opus":0.018154812622754576,"score_gpt":0.3035520325422672,"score_spread":0.2853972199195126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004001433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96480095,0.0012491731,0.013948659,0.01386993,0.00019837986,0.0018154084,0.000016739126,0.00015173417,0.0039490196],"genre_scores_gemma":[0.9292921,0.000104176695,0.04986235,0.019186601,0.00031184737,0.00002456226,0.00009542561,0.00015720421,0.00096576824],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99580395,0.00036000914,0.0008131187,0.0011417309,0.0006761843,0.0012050034],"domain_scores_gemma":[0.997701,0.00013011115,0.00013961126,0.0007427799,0.00021271566,0.0010738072],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007182138,0.00041614918,0.0010068314,0.00042864928,0.0001231335,0.000049341386,0.0005444739,0.00043475477,0.000104714854],"category_scores_gemma":[0.0010162127,0.00045612952,0.00019678315,0.0017444137,0.00010753941,0.00007946588,0.0006122902,0.0010692995,0.0005241087],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001189143,0.000056601424,0.0015905672,0.00014767429,0.00011905032,0.014137269,0.0014950773,0.0012112804,0.9715378,0.00018359187,0.00675892,0.0015730066],"study_design_scores_gemma":[0.0025273862,0.0013859828,0.0010957494,0.00018031012,0.000120595985,0.00007251345,0.00021914199,0.0014485411,0.7483599,0.00005728087,0.2440438,0.0004887701],"about_ca_topic_score_codex":0.000121524135,"about_ca_topic_score_gemma":0.00005773744,"teacher_disagreement_score":0.23728487,"about_ca_system_score_codex":0.0055993795,"about_ca_system_score_gemma":0.0019961167,"threshold_uncertainty_score":0.99978906},"labels":[],"label_agreement":null},{"id":"W3004028926","doi":"10.1016/j.exphem.2020.01.008","title":"60 Years of clonal hematopoiesis research: From X-chromosome inactivation studies to the identification of driver mutations","year":2020,"lang":"en","type":"review","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Identification (biology); Haematopoiesis; Genetics; Biology; Chromosome; Mutation; Computational biology; Gene; Stem cell; Botany","score_opus":0.19764509393307053,"score_gpt":0.49001401704087455,"score_spread":0.29236892310780405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004028926","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006470004,0.9903011,0.000028234492,0.00077778933,0.00019663031,0.0019420994,0.00016420035,0.000024789932,0.00009515958],"genre_scores_gemma":[0.07778873,0.9188221,0.0010305339,0.00006409229,0.00022708865,0.0010568382,0.0006932,0.000092030685,0.00022539703],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99654627,0.0005971168,0.0012355959,0.00051969447,0.0008023783,0.00029892867],"domain_scores_gemma":[0.99684316,0.0014918532,0.0005097811,0.00065106363,0.00038024638,0.0001239009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005422451,0.00024945528,0.0018956948,0.00048630591,0.00010530144,0.000010489997,0.0004437546,0.00025246097,0.00017257071],"category_scores_gemma":[0.0010863924,0.00019279646,0.00030433488,0.0010913349,0.0006843754,0.00007257712,0.00048837805,0.0005792891,0.0003623067],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017394254,0.004988594,0.00012849375,0.07413613,0.019065447,0.0029435256,0.10749064,0.000008672481,0.09437605,0.14758226,0.12444682,0.42309394],"study_design_scores_gemma":[0.0014372752,0.00095015886,0.00015482675,0.010500119,0.0009264084,0.00054226024,0.022099396,0.0000365462,0.27824774,0.0006770424,0.68391323,0.00051502866],"about_ca_topic_score_codex":0.000093586445,"about_ca_topic_score_gemma":0.000005113746,"teacher_disagreement_score":0.55946636,"about_ca_system_score_codex":0.0007334415,"about_ca_system_score_gemma":0.00061078137,"threshold_uncertainty_score":0.7862012},"labels":[],"label_agreement":null},{"id":"W3004815730","doi":"10.1007/s10637-020-00907-4","title":"Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Pharmacodynamics; Pharmacokinetics; Nausea; Pharmacology; Internal medicine; Myeloid leukemia; Gastroenterology; Adverse effect; Leukemia; Prodrug; Vomiting","score_opus":0.021709417867157913,"score_gpt":0.28512605040206335,"score_spread":0.26341663253490544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004815730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871583,0.000014205953,0.000013207247,0.010768721,0.000043200158,0.0012769089,0.000043880005,0.000029878485,0.00065168686],"genre_scores_gemma":[0.9954045,0.0000024651006,0.0007512408,0.0030912773,0.00015063531,0.000027386626,0.00010662875,0.000033685454,0.00043217483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976685,0.0001039803,0.00043367053,0.0003760095,0.0011508357,0.0002670068],"domain_scores_gemma":[0.99878275,0.00009347745,0.00016260662,0.00035486888,0.00021059871,0.00039571707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014333105,0.00019859818,0.00033719707,0.00010006609,0.00008743636,0.000021561531,0.00033155346,0.00006921339,0.000081701735],"category_scores_gemma":[0.00023029027,0.0001322051,0.000056156132,0.00095448364,0.00028098322,0.00014615725,0.000159928,0.00050135824,0.000032825916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040015993,0.0024283526,0.9416279,0.00011538352,0.0005533012,0.000118324046,0.015516504,0.00044206373,0.0071954583,0.000622363,0.02390696,0.0034717708],"study_design_scores_gemma":[0.07250133,0.0051511894,0.9034323,0.00021159717,0.00027435232,0.000016430475,0.0016312514,0.0020720982,0.01088135,0.00045437846,0.002977173,0.0003965448],"about_ca_topic_score_codex":0.00048701602,"about_ca_topic_score_gemma":0.000032444193,"teacher_disagreement_score":0.06849974,"about_ca_system_score_codex":0.00046035915,"about_ca_system_score_gemma":0.0030425242,"threshold_uncertainty_score":0.5397307},"labels":[],"label_agreement":null},{"id":"W3004873674","doi":"10.3324/haematol.2019.220962","title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group","year":2020,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Bortezomib; Medicine; Internal medicine; Chemotherapy; Randomized controlled trial; Myeloid leukemia; Oncology; Induction chemotherapy; Multiple myeloma; Leukemia; Surgery","score_opus":0.020542026871820936,"score_gpt":0.29994620438021874,"score_spread":0.2794041775083978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004873674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9414054,0.00011750514,0.0029112366,0.048453018,0.000057932575,0.0054807737,0.00094558956,0.00032289914,0.00030560207],"genre_scores_gemma":[0.9555148,0.0004298998,0.027104288,0.013234195,0.00045462488,0.001513101,0.0010026686,0.00014890205,0.00059755356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99652445,0.0001178458,0.0006530553,0.0012185274,0.0006642603,0.00082184875],"domain_scores_gemma":[0.99729097,0.0005325047,0.00045497212,0.0010780183,0.00020671073,0.00043682446],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028813726,0.00065470586,0.0017285743,0.000058662936,0.00031951797,0.000075203345,0.0004815269,0.00034044828,0.00017788592],"category_scores_gemma":[0.00019333205,0.00025714902,0.00030470264,0.00025387175,0.00048472846,0.00010700535,0.00011909874,0.0005699922,0.000027304679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05492407,0.0007763179,0.8624781,0.00007251358,0.016007697,0.008219437,0.004841451,0.000008693867,0.0066185296,0.00042444712,0.014027917,0.03160085],"study_design_scores_gemma":[0.07259815,0.046583977,0.7633582,0.0001630868,0.0040426925,0.015032729,0.001614739,0.00027547716,0.06206899,0.00028174257,0.03236258,0.0016176812],"about_ca_topic_score_codex":0.0009522591,"about_ca_topic_score_gemma":0.000305354,"teacher_disagreement_score":0.09911992,"about_ca_system_score_codex":0.0016493894,"about_ca_system_score_gemma":0.0015327816,"threshold_uncertainty_score":0.9999881},"labels":[],"label_agreement":null},{"id":"W3005831402","doi":"10.1097/01.hs9.0000562224.72710.77","title":"PS981 LONG TERM AML SURVIVORS HAVE INCREASED MORTALITY AND HIGH PREVALENCE OF CLONAL HEMATOPOIESIS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Bone marrow; Haematopoiesis; Oncology; Leukemia; Internal medicine; clone (Java method); Immunology; Stem cell; Biology; Gene","score_opus":0.02328574315126008,"score_gpt":0.30219314306076733,"score_spread":0.27890739990950725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005831402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949901,0.000780324,0.00005334144,0.0001842845,0.000060792583,0.00068474544,0.000049775397,0.000050214785,0.0031464086],"genre_scores_gemma":[0.99505883,0.00017693028,0.0006207758,0.00011384965,0.00008199285,0.000022043709,0.000030369987,0.000036524303,0.0038586827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980604,0.00010009467,0.00037704015,0.00044744476,0.000639392,0.00037561086],"domain_scores_gemma":[0.9984895,0.0002385852,0.00013383549,0.00070501823,0.00017960746,0.0002534501],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044420114,0.0002149522,0.00053321174,0.000055996294,0.00004313964,0.000015505759,0.00017526504,0.0001684356,0.003579117],"category_scores_gemma":[0.0001736164,0.0001825545,0.000101646445,0.00017051933,0.00023431669,0.00012694242,0.00018286049,0.0003064516,0.0000905797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019934443,0.00012085318,0.984549,0.0038766898,0.00013523099,0.00009060035,0.00016298465,9.886935e-7,0.009298123,0.00028077746,0.0005105483,0.0007748555],"study_design_scores_gemma":[0.0017926303,0.00018792412,0.97414947,0.00039722427,0.000120812,0.00010629521,0.00017287664,0.00018683293,0.022540355,0.00010881159,0.00006371702,0.00017304232],"about_ca_topic_score_codex":0.0024854068,"about_ca_topic_score_gemma":0.0003171034,"teacher_disagreement_score":0.013242232,"about_ca_system_score_codex":0.00013370419,"about_ca_system_score_gemma":0.0002807768,"threshold_uncertainty_score":0.99733174},"labels":[],"label_agreement":null},{"id":"W3005879325","doi":"10.1182/blood.2019003357","title":"High frequency of germline <i>RUNX1</i> mutations in patients with<i> RUNX1</i>-mutated AML","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"RUNX1; Germline; CEBPA; Germline mutation; Neuroblastoma RAS viral oncogene homolog; Myeloid leukemia; Cancer research; Biology; Platelet disorder; Genetics; Medicine; Mutation; Stem cell; Immunology; Haematopoiesis; Gene; KRAS","score_opus":0.0110456980150944,"score_gpt":0.242826236569886,"score_spread":0.2317805385547916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005879325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99602294,0.00007951898,0.000049234568,0.0020700803,0.000025780766,0.0007365416,0.00010097842,0.00007293154,0.0008419878],"genre_scores_gemma":[0.9944982,0.000011998544,0.0040518357,0.00080817234,0.00008504159,0.000036981168,0.00039875275,0.000045423007,0.00006358697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982707,0.000059025027,0.00045398023,0.00033640777,0.00052579044,0.00035411277],"domain_scores_gemma":[0.9989231,0.0000796748,0.000121388824,0.00030716803,0.00031176145,0.00025685868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000106162224,0.00018132676,0.00042756434,0.00015894858,0.00003453591,0.000009269378,0.00016999716,0.00010017352,0.00017805625],"category_scores_gemma":[0.0002729715,0.00014930384,0.000059297792,0.0009656435,0.00012614981,0.00010733958,0.00006183989,0.0003991303,0.00006641668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061608566,0.0023017589,0.96722233,0.00029185554,0.00029801062,0.00036355315,0.0010140077,0.000059990572,0.026108732,0.00023041278,0.00075815956,0.00073511386],"study_design_scores_gemma":[0.039632943,0.0019795445,0.909872,0.00020309453,0.0003817906,0.000017597138,0.0001343438,0.00012929461,0.04698175,0.00012480264,0.00020745318,0.00033539673],"about_ca_topic_score_codex":0.00034147882,"about_ca_topic_score_gemma":0.00003479862,"teacher_disagreement_score":0.05735033,"about_ca_system_score_codex":0.00007233363,"about_ca_system_score_gemma":0.00036336997,"threshold_uncertainty_score":0.6088434},"labels":[],"label_agreement":null},{"id":"W3008110097","doi":"10.1038/s41467-020-14829-5","title":"The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants","year":2020,"lang":"en","type":"article","venue":"Nature Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Foothills Medical Centre; University of British Columbia","funders":"Medical Research Council; Blood Cancer UK; Cancer Research UK; European Hematology Association","keywords":"Myeloid leukemia; Germline; Myeloid; Genetics; Exome sequencing; Myelodysplastic syndromes; Biology; Disease; Etiology; Gene; Computational biology; Bioinformatics; Cancer research; Medicine; Bone marrow; Immunology; Mutation; Internal medicine","score_opus":0.04320201286713752,"score_gpt":0.33626985026533923,"score_spread":0.2930678373982017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008110097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75828224,0.059378773,0.00025362687,0.17098199,0.00010372809,0.0016615868,0.000329843,0.00013469173,0.008873529],"genre_scores_gemma":[0.9822105,0.0062101325,0.009336852,0.0018400296,0.00010890619,0.000022641074,0.00011450044,0.000019358058,0.00013703505],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989001,0.00021081603,0.000295754,0.00016503574,0.00024486822,0.00018343466],"domain_scores_gemma":[0.9974497,0.0005981707,0.00009512472,0.0014487335,0.00025161516,0.00015668059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028143064,0.0001041038,0.00023439118,0.00004459971,0.00026374197,0.000018411834,0.00076887704,0.00018435244,0.00003474072],"category_scores_gemma":[0.00082316156,0.0000730327,0.000063776235,0.00038775534,0.0002941298,0.000027394213,0.0005661272,0.0010507815,0.000014906616],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001036842,0.00054704543,0.11840203,0.0003906587,0.0008735274,0.00005045653,0.0035497507,0.000013582704,0.559704,0.019278705,0.23560926,0.06054416],"study_design_scores_gemma":[0.0018308664,0.0002152519,0.90326416,0.000041380757,0.00014476746,0.000073192066,0.00028362026,0.011576226,0.00020472103,0.00023054828,0.08200313,0.00013210585],"about_ca_topic_score_codex":0.000013548355,"about_ca_topic_score_gemma":0.00004486243,"teacher_disagreement_score":0.78486216,"about_ca_system_score_codex":0.000031636147,"about_ca_system_score_gemma":0.00017261915,"threshold_uncertainty_score":0.4565181},"labels":[],"label_agreement":null},{"id":"W3009345572","doi":"10.1016/j.bbmt.2020.02.022","title":"Clonal Hematopoiesis in Related Allogeneic Transplant Donors: Implications for Screening and Management","year":2020,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Health Resources and Services Administration","keywords":"Medicine; Haematopoiesis; Hematopoietic cell; Immunology; Intensive care medicine; Stem cell; Genetics","score_opus":0.028059908977699402,"score_gpt":0.28864653146916003,"score_spread":0.26058662249146064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009345572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862826,0.0008790797,0.0049384627,0.006902935,0.000008900438,0.0006577319,0.00016807186,0.000020563682,0.00014169663],"genre_scores_gemma":[0.9841152,0.0074404636,0.007682561,0.0002170525,0.000015412948,0.00007026761,0.00043894947,0.000008726608,0.0000113636725],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99931514,0.000031552318,0.00024306968,0.00022760729,0.00003780732,0.00014481375],"domain_scores_gemma":[0.99970454,0.0000967458,0.000041319792,0.0000555656,0.000023689827,0.00007811506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001347121,0.0000871658,0.00020695462,0.000102920094,0.000038859976,0.0000030406418,0.00003999086,0.00010121913,0.000005743339],"category_scores_gemma":[0.0000070052815,0.00007878592,0.000034576497,0.000108837026,0.00009289808,0.000033273463,0.000006493311,0.000077200464,2.9323388e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023488528,0.00010921554,0.2487736,0.002932735,0.00051395054,0.00003759113,0.0019678304,0.000007983749,0.72006935,0.010575269,0.000051700237,0.012611933],"study_design_scores_gemma":[0.028611857,0.0024516887,0.87909985,0.00064514653,0.0024163302,0.00080575154,0.0005060535,0.00075828616,0.08109556,0.0023847818,0.0007560477,0.00046867394],"about_ca_topic_score_codex":0.000026820597,"about_ca_topic_score_gemma":0.000027847953,"teacher_disagreement_score":0.6389738,"about_ca_system_score_codex":0.0000051447105,"about_ca_system_score_gemma":0.000020947116,"threshold_uncertainty_score":0.32127964},"labels":[],"label_agreement":null},{"id":"W3010500985","doi":"10.3390/epigenomes4010003","title":"Epigenetic Modulation of Self-Renewal Capacity of Leukemic Stem Cells and Implications for Chemotherapy","year":2020,"lang":"en","type":"review","venue":"Epigenomes","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Epigenetics; Biology; Stem cell; DNA methylation; Cancer research; Epigenetic therapy; Gene silencing; DNA demethylation; Histone; Myeloid leukemia; Demethylating agent; Population; Cell biology; Genetics; Gene expression; Gene; Medicine","score_opus":0.06726865892115298,"score_gpt":0.33940769507728324,"score_spread":0.2721390361561303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010500985","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004430283,0.99052304,0.00093549234,0.00019936843,0.00005713376,0.003207574,0.00050372817,0.000040657662,0.000102732934],"genre_scores_gemma":[0.0029028736,0.9915445,0.004724816,0.000023298213,0.00020208686,0.00020398483,0.000116027244,0.00007319084,0.00020924935],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981769,0.00009021995,0.0008201674,0.0004493296,0.00019280243,0.0002706028],"domain_scores_gemma":[0.9981726,0.00038067953,0.0005293053,0.00052821013,0.00021686137,0.00017238538],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026508927,0.0003180779,0.0019207932,0.00024192523,0.000050025355,0.000007844699,0.00022168164,0.00029278672,0.00001857142],"category_scores_gemma":[0.000030191222,0.00027114592,0.00039615293,0.00036871023,0.00012808481,0.000028501303,0.00006249526,0.00023315364,0.0000055662736],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029371877,0.0000742376,0.00012972618,0.031826153,0.00066224,7.1810416e-7,0.0004590775,0.0000022383479,0.0036020018,0.00019056899,0.00020481355,0.96281886],"study_design_scores_gemma":[0.0013169083,0.00048851955,0.0006826756,0.0019813094,0.0013118645,0.000027388518,0.00003312225,0.00011785508,0.002398354,0.00030678557,0.9909978,0.00033744655],"about_ca_topic_score_codex":0.00004018625,"about_ca_topic_score_gemma":0.0000025528545,"teacher_disagreement_score":0.99079293,"about_ca_system_score_codex":0.00046538943,"about_ca_system_score_gemma":0.0011678375,"threshold_uncertainty_score":0.9999741},"labels":[],"label_agreement":null},{"id":"W3011145000","doi":"10.1002/ijc.32967","title":"Major multilevel molecular divergence between THP‐1 cells from different biorepositories","year":2020,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Leukemia and Lymphoma Society of Canada","keywords":"Biology; THP1 cell line; Myeloid leukemia; Cell culture; Loss of heterozygosity; Monocytic leukemia; Phenotype; Cancer research; Leukemia; Myeloid; Computational biology; Genetics; Molecular biology; Gene; Cell biology; Allele","score_opus":0.02820173870952105,"score_gpt":0.3402679494682558,"score_spread":0.31206621075873475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011145000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763239,0.0011233587,0.007010984,0.013968221,0.0011996782,0.00009563413,0.00015991452,0.000011248495,0.00010706025],"genre_scores_gemma":[0.99435073,0.00030791824,0.001050623,0.0011010094,0.0030508074,0.000003914817,0.000011517608,0.000018081988,0.00010541164],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99822307,0.00003279371,0.00039543275,0.00015036113,0.0010553715,0.00014299284],"domain_scores_gemma":[0.99864215,0.00009379381,0.00023867015,0.00008873269,0.0006686854,0.0002679535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005678659,0.00012232995,0.00027582186,0.00008404695,0.000024121242,0.000041881216,0.00043760147,0.000061040526,0.0005500148],"category_scores_gemma":[0.00010187869,0.00009087716,0.00016210554,0.000060006656,0.000059657687,0.00011385375,0.0001369048,0.0003732838,0.00002431951],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010167478,0.00007061912,0.29119286,0.000021285427,0.002253648,0.0011804368,0.0007760156,0.00007727269,0.6752117,0.000051238625,0.007007478,0.021140704],"study_design_scores_gemma":[0.0028226438,0.00021142987,0.21220773,0.0002097588,0.00025887176,0.000020414509,0.000070851136,0.00052396144,0.77115685,0.00020511096,0.0121757975,0.00013658301],"about_ca_topic_score_codex":0.00032906112,"about_ca_topic_score_gemma":0.000006031811,"teacher_disagreement_score":0.09594514,"about_ca_system_score_codex":0.00037891866,"about_ca_system_score_gemma":0.00027257737,"threshold_uncertainty_score":0.6022276},"labels":[],"label_agreement":null},{"id":"W3012067537","doi":"10.1016/s0735-1097(20)31298-5","title":"CLONAL HEMATOPOIESIS ASSOCIATED MUTATIONS, CARDIOVASCULAR EVENTS, AND ALL-CAUSE DEATH AMONG PATIENTS WITH ACUTE MYELOID LEUKEMIA","year":2020,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Haematopoiesis; Myeloid; Leukemia; Internal medicine; Mutation; Oncology; Immunology; Gene; Genetics; Stem cell","score_opus":0.015890517845453016,"score_gpt":0.2605659560726222,"score_spread":0.24467543822716917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012067537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961236,0.0003596812,0.00027509657,0.0023890855,0.00007234229,0.00042422782,0.00016373252,0.000011145482,0.000181102],"genre_scores_gemma":[0.99770975,0.00044548843,0.0010170932,0.000541058,0.0001752648,0.000007631342,0.000011900048,0.000037314872,0.00005447166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973897,0.00056339224,0.0005865414,0.00023602507,0.00089143444,0.0003329213],"domain_scores_gemma":[0.99755424,0.0002543111,0.00082170835,0.00034247365,0.0007271005,0.00030016183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005469957,0.00021881993,0.001529558,0.00015344174,0.00009248579,0.0000058434634,0.0003318416,0.00009085052,0.000007495082],"category_scores_gemma":[0.00067918224,0.00013711405,0.00062050385,0.00060969195,0.0006218452,0.00010884403,0.00018328834,0.0006047904,0.0000015639313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026024634,0.000050709546,0.9498832,0.00005200518,0.036672097,0.0012159287,0.00015584496,0.001011241,0.0005741558,0.00004385228,0.007366993,0.00037149267],"study_design_scores_gemma":[0.0057713054,0.0021862988,0.98137873,0.00009832818,0.005326339,0.0015621877,0.0005182819,0.00014433917,0.0004264023,0.000057548106,0.0023442472,0.00018595948],"about_ca_topic_score_codex":0.000034370863,"about_ca_topic_score_gemma":0.0000023048842,"teacher_disagreement_score":0.031495545,"about_ca_system_score_codex":0.00053963653,"about_ca_system_score_gemma":0.00090577384,"threshold_uncertainty_score":0.5591349},"labels":[],"label_agreement":null},{"id":"W3012293314","doi":"10.2217/fon-2020-0044","title":"MIRROS: A Randomized, Placebo-Controlled, Phase III Trial of Cytarabine ± Idasanutlin in Relapsed or Refractory Acute Myeloid Leukemia","year":2020,"lang":"en","type":"article","venue":"Future Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Cytarabine; Myeloid leukemia; Refractory (planetary science); Internal medicine; Placebo; Oncology; Randomized controlled trial; Myeloid; Pathology","score_opus":0.025895685441203825,"score_gpt":0.34770532389991754,"score_spread":0.3218096384587137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012293314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94490933,0.0010939685,0.00022538986,0.031158065,0.0011425934,0.0125360275,0.00007783485,0.00017949917,0.008677267],"genre_scores_gemma":[0.9629622,0.0036140005,0.0066284533,0.009326775,0.007870532,0.0026771068,0.0004176801,0.00021816601,0.0062850984],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994016,0.001581616,0.002015001,0.00083088345,0.00072227267,0.0008342284],"domain_scores_gemma":[0.9953237,0.0024269836,0.0007347366,0.0006363766,0.00028609647,0.00059207604],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026642838,0.0005248872,0.004723516,0.00050648476,0.000075377764,0.0000144852675,0.00048526755,0.0010463442,0.0017762933],"category_scores_gemma":[0.0031860892,0.00035910998,0.000623839,0.00089563616,0.00051722996,0.00011338971,0.00019378276,0.0020865577,0.00014632416],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9368089,0.0011319924,0.0000060926545,0.0001404567,0.00092522654,0.0025510557,0.0019834575,0.000011072099,0.022597397,0.00014522369,0.024597138,0.009102022],"study_design_scores_gemma":[0.8974115,0.013636057,0.000007499333,0.00007082944,0.00078940846,0.0001634441,0.0007497107,0.0031826224,0.0010675928,0.000031893826,0.082610525,0.00027888865],"about_ca_topic_score_codex":0.00019690364,"about_ca_topic_score_gemma":0.00016547999,"teacher_disagreement_score":0.058013387,"about_ca_system_score_codex":0.0019838621,"about_ca_system_score_gemma":0.005715582,"threshold_uncertainty_score":0.9999211},"labels":[],"label_agreement":null},{"id":"W3013112730","doi":"10.1016/j.exphem.2020.02.002","title":"Guest Editorial","year":2020,"lang":"en","type":"editorial","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"","keywords":"Haematopoiesis; Myeloid; Disease; Biology; Somatic cell; Phenotype; Immunology; Monocyte; Myeloid leukemia; Gene; Cancer research; Stem cell; Genetics; Medicine; Pathology","score_opus":0.01576032265775496,"score_gpt":0.348450995260251,"score_spread":0.332690672602496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013112730","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000448186,0.0059888274,0.0000028428713,0.00077519694,0.9835347,0.0007128139,0.00010434181,0.00027304253,0.008563395],"genre_scores_gemma":[0.0008216352,0.00008315977,0.00032513184,0.00019625071,0.9940894,0.00021762663,0.0019163562,0.0001871586,0.0021632751],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959425,0.0001328507,0.0006125694,0.0010047688,0.0015485429,0.0007587754],"domain_scores_gemma":[0.99774,0.00054488465,0.00019054105,0.00068457203,0.00025784617,0.0005821976],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.00016964145,0.00058236846,0.0015225393,0.00019335351,0.000111542024,0.000039302922,0.00047963564,0.0025443146,0.0009405996],"category_scores_gemma":[0.0011118331,0.00054855255,0.00031939964,0.00022544916,0.00034987085,0.00007339393,0.0005517029,0.002810407,0.0032437502],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011642097,0.00025312594,0.000014796942,0.00023903961,0.00019751817,0.0012178965,0.0001802552,1.1495129e-8,0.0016803559,0.00052991667,0.9945083,0.0000145717795],"study_design_scores_gemma":[0.0033551864,0.0010663914,5.71325e-7,0.0001091023,0.00006937737,0.00020080425,0.00016116723,0.000003982892,0.0887838,0.0000143168045,0.90587634,0.00035893772],"about_ca_topic_score_codex":0.00009284677,"about_ca_topic_score_gemma":0.0000025350882,"teacher_disagreement_score":0.08863194,"about_ca_system_score_codex":0.0009346433,"about_ca_system_score_gemma":0.0017119987,"threshold_uncertainty_score":0.9999727},"labels":[],"label_agreement":null},{"id":"W3013447738","doi":"10.1182/blood.2020004856","title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":756,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de l'Est-de-l'Île-de-Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"Genentech","keywords":"Venetoclax; Medicine; Internal medicine; Neutropenia; Febrile neutropenia; Hazard ratio; Chemotherapy regimen; Cytarabine; Adverse effect; Chemotherapy; Surgery; Oncology; Leukemia; Confidence interval; Chronic lymphocytic leukemia","score_opus":0.0321181257161765,"score_gpt":0.33604205071564375,"score_spread":0.30392392499946724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013447738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8676347,0.0010436805,0.026320072,0.022877384,0.0004688317,0.080313854,0.00018769012,0.0003557953,0.0007979897],"genre_scores_gemma":[0.90641683,0.00048292163,0.015262539,0.026021186,0.0078011723,0.03992403,0.0005897361,0.00037172477,0.0031298297],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974532,0.00016373995,0.0007705097,0.0005849138,0.00037884488,0.00064880576],"domain_scores_gemma":[0.9947076,0.0034738267,0.00025186062,0.00036642657,0.0007444406,0.0004558564],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00097486755,0.00035989485,0.00233117,0.00015745705,0.00011176119,0.000054443604,0.0002536941,0.00023037787,0.00012047937],"category_scores_gemma":[0.012920507,0.00027467753,0.00097497145,0.00026762288,0.00013998071,0.00007345288,0.000055598848,0.00031833097,0.000031597094],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9580711,0.0003708548,0.000001559768,0.00018601023,0.001649222,0.00006141707,0.0011942846,0.000025942329,0.008039362,0.000088491244,0.02929752,0.0010142287],"study_design_scores_gemma":[0.9307827,0.004234286,3.4332746e-7,0.000059926508,0.0014774159,0.000014421529,0.00025629043,0.03879286,0.014620157,0.00017700942,0.009336777,0.00024783713],"about_ca_topic_score_codex":0.000047673613,"about_ca_topic_score_gemma":0.000003936445,"teacher_disagreement_score":0.040389825,"about_ca_system_score_codex":0.0003301485,"about_ca_system_score_gemma":0.002148186,"threshold_uncertainty_score":0.99997056},"labels":[],"label_agreement":null},{"id":"W3015984203","doi":"10.1182/blood.2019004143","title":"Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Health Sciences Centre; Alberta Hospital Edmonton; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Astex Pharmaceuticals","keywords":"Decitabine; Medicine; Neutropenia; Chronic myelomonocytic leukemia; Febrile neutropenia; Internal medicine; Adverse effect; Confidence interval; Gastroenterology; Pharmacodynamics; Azacitidine; Pharmacology; Myelodysplastic syndromes; Pharmacokinetics; Toxicity; Bone marrow","score_opus":0.03744326903252199,"score_gpt":0.37880241463902276,"score_spread":0.34135914560650077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015984203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98783314,0.00069862406,0.0009088281,0.0040921164,0.00009523072,0.0054882145,0.00011484301,0.00016067718,0.0006083054],"genre_scores_gemma":[0.99472386,0.0001512673,0.0014757812,0.0017267382,0.0005886706,0.00056461926,0.00006854549,0.00008569576,0.0006148436],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99775094,0.00017327305,0.0005032788,0.00058496895,0.0004553701,0.0005321651],"domain_scores_gemma":[0.9984375,0.00045148094,0.000102969425,0.0002459211,0.00021307706,0.0005489989],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007126293,0.0003135667,0.0009992449,0.00012719815,0.0001232604,0.0000656692,0.0001890375,0.00007703456,0.0005034677],"category_scores_gemma":[0.0008373312,0.0002526803,0.00022171112,0.00034681917,0.00019877488,0.0001189033,0.0001678637,0.0003813935,0.000043349723],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6133375,0.0091978535,0.0017062259,0.00081135303,0.0038466286,0.0012242108,0.00366764,0.000013446787,0.33813396,0.0001338541,0.019652056,0.008275227],"study_design_scores_gemma":[0.94437176,0.0022740453,0.00016246957,0.00002269855,0.0024346742,0.000093957184,0.00021945284,0.023550468,0.021055406,0.000027008547,0.0055090827,0.0002789759],"about_ca_topic_score_codex":0.00003279107,"about_ca_topic_score_gemma":0.0000016749171,"teacher_disagreement_score":0.3310342,"about_ca_system_score_codex":0.00004622868,"about_ca_system_score_gemma":0.00020815496,"threshold_uncertainty_score":0.99999255},"labels":[],"label_agreement":null},{"id":"W3016229308","doi":"10.3390/cancers12040907","title":"Estrogen Receptors Alpha and Beta in Acute Myeloid Leukemia","year":2020,"lang":"en","type":"review","venue":"Cancers","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Myeloid leukemia; Estrogen receptor; Estrogen receptor beta; Cancer research; Estrogen receptor alpha; Signal transduction; Medicine; Receptor; Leukemia; Fulvestrant; Biology; Bioinformatics; Immunology; Internal medicine; Cell biology; Cancer; Breast cancer","score_opus":0.04051323429896339,"score_gpt":0.34889639755361257,"score_spread":0.3083831632546492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016229308","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012298567,0.99545944,0.0000043183163,0.00035052793,0.00030111984,0.0015373742,0.00009087324,0.00007759867,0.0020557472],"genre_scores_gemma":[0.0000065185636,0.99623173,0.00048198836,0.0003402314,0.0005222352,0.0002875079,0.00029783358,0.00015153413,0.0016803923],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972353,0.00013968947,0.0006456459,0.0008824064,0.00042974565,0.00066720514],"domain_scores_gemma":[0.9984572,0.00014885583,0.00020654342,0.0005373705,0.0000552394,0.0005947725],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025578102,0.00057625084,0.0025482043,0.0003822658,0.000052789856,0.000037073423,0.0003699512,0.0005398864,0.00019818606],"category_scores_gemma":[0.00011860951,0.00048498687,0.00035365816,0.0009791021,0.00024902736,0.00008366076,0.0002581723,0.0016677477,0.00018438108],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000057997786,0.0000027749745,0.000048180373,0.008105297,0.00058746384,0.00068952993,0.00012839082,8.1347304e-7,0.0000026983284,0.000059751,0.017971164,0.97234595],"study_design_scores_gemma":[0.0009608983,0.00016695706,0.0000071104773,0.0074071023,0.0011221122,0.0002658766,0.000053995154,0.000044486238,0.000010162801,0.0000049271152,0.98958963,0.00036671592],"about_ca_topic_score_codex":0.00042256186,"about_ca_topic_score_gemma":0.000030355084,"teacher_disagreement_score":0.9719792,"about_ca_system_score_codex":0.019504035,"about_ca_system_score_gemma":0.015020066,"threshold_uncertainty_score":0.99976015},"labels":[],"label_agreement":null},{"id":"W3016616745","doi":"10.1007/s40262-020-00888-w","title":"Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacokinetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Astellas Pharma","keywords":"Pharmacokinetics; Pharmacology; Chemistry; Medicine","score_opus":0.11511771043150763,"score_gpt":0.4183749330103149,"score_spread":0.3032572225788073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016616745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96196264,0.0010442844,0.0023176917,0.022873202,0.0010087275,0.0023790512,0.00045906618,0.00037427113,0.0075810635],"genre_scores_gemma":[0.9727931,0.0007603891,0.0107659185,0.011256709,0.0033808225,0.000052992673,0.00012372986,0.00013518574,0.00073115755],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958437,0.00016948013,0.0017341494,0.00078973285,0.0007966581,0.00066626014],"domain_scores_gemma":[0.99674857,0.00053865626,0.0003367455,0.0005202808,0.00058527803,0.0012704986],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006588439,0.0003985757,0.0010576699,0.00012964619,0.000057380777,0.000023528106,0.00049512985,0.00024973846,0.002254609],"category_scores_gemma":[0.0017719856,0.00036220677,0.00045256058,0.00084694475,0.0006733862,0.00009379428,0.00047409846,0.0014018912,0.00038555212],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034356455,0.0018841542,0.0059789554,0.0010405121,0.00030591266,0.0003123257,0.00015049233,0.00003175346,0.8355325,0.000074304975,0.12157589,0.029677544],"study_design_scores_gemma":[0.037512597,0.0044923048,0.012054281,0.0003749477,0.001151968,0.0001159735,0.00009333976,0.050239697,0.58913493,0.000030636074,0.3039742,0.0008251022],"about_ca_topic_score_codex":0.0000064007504,"about_ca_topic_score_gemma":1.7113838e-7,"teacher_disagreement_score":0.24639757,"about_ca_system_score_codex":0.000075980395,"about_ca_system_score_gemma":0.00043786882,"threshold_uncertainty_score":0.999883},"labels":[],"label_agreement":null},{"id":"W3017491625","doi":"10.14740/jh605","title":"Novel Translocation in Acute Myeloid Leukemia: Case Report and Review of Risk-Stratification and Induction Chemotherapy in Patients With Acute Myeloid Leukemia","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chromosomal translocation; Myeloid leukemia; Medicine; Induction chemotherapy; Leukemia; Myeloid; Acute leukemia; Abnormality; Oncology; Risk stratification; Chemotherapy; Bioinformatics; Internal medicine; Immunology; Cancer research; Biology; Gene; Genetics","score_opus":0.018817275935135096,"score_gpt":0.2933995645437409,"score_spread":0.2745822886086058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017491625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98872936,0.0033449817,0.001017562,0.0061815414,0.000040018167,0.000640621,0.000009979198,0.0000071837676,0.000028726427],"genre_scores_gemma":[0.9706533,0.023859963,0.0048631905,0.00049666484,0.00004691734,0.000012624303,0.000031919306,0.000027469998,0.000007974964],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9977338,0.00012301258,0.00126616,0.00030007612,0.00036184542,0.00021513166],"domain_scores_gemma":[0.9980349,0.00009222236,0.0010616505,0.00021094143,0.00042215004,0.0001781178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007930619,0.00019469047,0.00092839164,0.00032302542,0.00003422992,0.000009075512,0.00008613273,0.00021399313,0.000016663527],"category_scores_gemma":[0.0003352365,0.00015191502,0.000056159937,0.0005541187,0.00016361661,0.00028044108,0.000020026082,0.0008638629,6.9310533e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022014055,0.001451998,0.6622808,0.015663907,0.0024916318,0.07721114,0.01104315,0.00006981987,0.086055554,0.00047818417,0.003130359,0.11810939],"study_design_scores_gemma":[0.033764154,0.0036611524,0.45594653,0.0063065374,0.0010662779,0.47095832,0.0009135678,0.0009998785,0.025374895,0.00016067544,0.00032191415,0.00052608753],"about_ca_topic_score_codex":0.00012557366,"about_ca_topic_score_gemma":0.00005300113,"teacher_disagreement_score":0.39374718,"about_ca_system_score_codex":0.0005122758,"about_ca_system_score_gemma":0.0009862614,"threshold_uncertainty_score":0.6194915},"labels":[],"label_agreement":null},{"id":"W3017522974","doi":"10.14740/jh606","title":"Spontaneous Remission in a Patient With Acute Myeloid Leukemia Leading to Undetectable Minimal Residual Disease","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Minimal residual disease; Myeloid leukemia; Complete remission; Spontaneous remission; Disease; Myeloid; Leukemia; Immunology; Internal medicine; Pathology; Chemotherapy","score_opus":0.017799134159208824,"score_gpt":0.2865597218172167,"score_spread":0.26876058765800787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017522974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97961503,0.00036980808,0.00025918067,0.018769838,0.000059992086,0.00033374035,0.0000043877117,0.000018507788,0.00056950544],"genre_scores_gemma":[0.99198186,0.00006039634,0.0055479654,0.0020235449,0.00015192277,0.00000668221,0.000002898572,0.000038786482,0.00018591029],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.997854,0.00012141739,0.00067345717,0.00028179487,0.0005731638,0.0004961611],"domain_scores_gemma":[0.9981219,0.00018089647,0.00024854523,0.0002043053,0.0002100396,0.001034281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023815068,0.00019694175,0.0007648115,0.0003610277,0.000050088984,0.0000175445,0.00020869289,0.000118058524,0.00016683647],"category_scores_gemma":[0.00072845945,0.00014135262,0.00009093995,0.00047743905,0.00006533072,0.00010944609,0.000121866426,0.00082691485,0.000050615763],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05920498,0.00020206849,0.0098676225,0.00036902988,0.00031616935,0.81561744,0.0027253057,0.0005091348,0.08245708,0.00012887726,0.024111155,0.0044911117],"study_design_scores_gemma":[0.018829094,0.02676702,0.007226278,0.0030181613,0.0008256552,0.7991367,0.0044599324,0.0027110013,0.110920526,0.00026876267,0.024841728,0.0009951221],"about_ca_topic_score_codex":0.000013456801,"about_ca_topic_score_gemma":0.000014384608,"teacher_disagreement_score":0.040375885,"about_ca_system_score_codex":0.0008656895,"about_ca_system_score_gemma":0.0019328552,"threshold_uncertainty_score":0.57641923},"labels":[],"label_agreement":null},{"id":"W3017704884","doi":"10.1182/blood.2020004850","title":"<i>SF3B1</i>-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS","year":2020,"lang":"en","type":"review","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":293,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Daiichi Sankyo Europe; National Cancer Institute; Blood Cancer UK; Astellas Pharma; Pfizer; Daiichi-Sankyo; Associazione Italiana per la Ricerca sul Cancro; Celgene; Astex Pharmaceuticals","keywords":"Cytopenia; Myelodysplastic syndromes; International Prognostic Scoring System; Dysplasia; Medicine; Bone marrow; Concomitant; Bone marrow failure; Internal medicine; Oncology; Biology; Genetics; Haematopoiesis; Stem cell","score_opus":0.05206029764664723,"score_gpt":0.3366729119210564,"score_spread":0.2846126142744092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017704884","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025820997,0.9866983,0.00012157272,0.005724714,0.0003100962,0.005573455,0.000850807,0.000069384456,0.0003934023],"genre_scores_gemma":[0.004917527,0.98731047,0.0006933572,0.0003419818,0.002813256,0.0024115837,0.0011459066,0.00014975986,0.00021614514],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99706995,0.00019495252,0.00071652845,0.0006285094,0.0009920382,0.00039802253],"domain_scores_gemma":[0.99623704,0.0021529007,0.00045608572,0.0007209005,0.00017604267,0.00025700332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060428,0.00044141294,0.001196143,0.00007457418,0.00015825305,0.000099044,0.0012912324,0.00018667143,0.00014446577],"category_scores_gemma":[0.0019897614,0.00021178399,0.0008856576,0.0004759753,0.00024566735,0.000038769198,0.000551203,0.00089383585,0.000049566795],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008219856,0.001056134,0.003014578,0.008405227,0.005381155,0.0004612561,0.000285586,7.398893e-8,0.000028182201,0.0012485404,0.0055506625,0.9737466],"study_design_scores_gemma":[0.0019151266,0.00022322574,0.00036481055,0.009457082,0.008104632,0.00007193944,0.000047396148,0.00008826746,0.000020341198,0.00014783545,0.97933316,0.00022620198],"about_ca_topic_score_codex":0.00015861729,"about_ca_topic_score_gemma":0.00003319121,"teacher_disagreement_score":0.9737825,"about_ca_system_score_codex":0.00020646557,"about_ca_system_score_gemma":0.0023919344,"threshold_uncertainty_score":0.86363006},"labels":[],"label_agreement":null},{"id":"W3018274819","doi":"10.1002/pbc.28263","title":"Regional differences in access to hematopoietic stem cell transplantation among pediatric patients with acute myeloid leukemia","year":2020,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Children's Hospital; C17 Council; BC Children's Hospital; CancerCare Manitoba; Hospital for Sick Children; Centre Hospitalier Universitaire Sainte-Justine; Alberta Children's Hospital","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Odds ratio; Myeloid leukemia; Internal medicine; Transplantation; Confidence interval; Pediatrics; Univariate analysis; Population; Multivariate analysis","score_opus":0.022607549098066487,"score_gpt":0.2664406670169211,"score_spread":0.24383311791885462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3018274819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955452,0.0008251701,0.00012241126,0.0015548513,0.00010033431,0.0014078005,0.000100803925,0.000099377685,0.0002440626],"genre_scores_gemma":[0.99333614,0.0033067085,0.0002129729,0.0013448643,0.0011135434,0.00038949263,0.00006795732,0.000072614195,0.0001557002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99678016,0.00008274509,0.0005316578,0.0008002209,0.0011136816,0.00069151586],"domain_scores_gemma":[0.9984794,0.00014050894,0.00019742532,0.00028118092,0.00022902685,0.00067245],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011797002,0.00038456198,0.000604797,0.00045841595,0.0000917548,0.00008088207,0.00048297786,0.00018181518,0.00016048322],"category_scores_gemma":[0.000014511103,0.00030967258,0.000095176256,0.002214196,0.000053111115,0.0003744609,0.000108255525,0.0006643843,0.00005463835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010167737,0.00017704221,0.99231184,0.0010831007,0.00006712615,0.00022529143,0.0020072386,0.00006337295,0.00004740889,0.000003397149,0.002664021,0.00033340516],"study_design_scores_gemma":[0.0067817005,0.0006327966,0.9900248,0.000058542282,0.0013764784,0.0000080212085,0.00009508973,0.000103989456,0.0004667233,0.000005259465,0.000043197397,0.00040337356],"about_ca_topic_score_codex":0.00039084058,"about_ca_topic_score_gemma":0.0001372792,"teacher_disagreement_score":0.005764927,"about_ca_system_score_codex":0.00036616967,"about_ca_system_score_gemma":0.0013658267,"threshold_uncertainty_score":0.9999355},"labels":[],"label_agreement":null},{"id":"W3019440336","doi":"10.1101/2020.04.25.058677","title":"Interacting evolutionary pressures drive mutation dynamics and health outcomes in aging blood","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Princess Margaret Cancer Centre; Wilfrid Laurier University; Vector Institute; University of Toronto; Ontario Institute for Cancer Research","funders":"Ontario Ministry of Research and Innovation; Vector Institute; Ontario Institute for Cancer Research; Government of Canada; Government of Ontario; Canadian Institutes of Health Research; Ontario Genomics; Genome Canada","keywords":"Biology; Population; Haematopoiesis; Negative selection; Somatic evolution in cancer; Mutation; Disease; Gene; Somatic cell; Myeloid; Phenotype; Genetics; Stem cell; Cancer research; Genome; Medicine; Internal medicine","score_opus":0.02180676991828807,"score_gpt":0.2952777567809795,"score_spread":0.27347098686269145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019440336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98341465,0.0025469558,0.00087679975,0.010528817,0.00043050613,0.0016705918,0.00017445459,0.00034322424,0.000013995371],"genre_scores_gemma":[0.98764694,0.00055367104,0.010545069,0.000683916,0.00027260993,0.00015106481,0.000004001209,0.0001309792,0.000011760618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99676466,0.0002248451,0.00074720976,0.0010837115,0.0005489218,0.00063065893],"domain_scores_gemma":[0.99783397,0.00022945873,0.00046470374,0.00068946485,0.00034133036,0.00044108435],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007582095,0.00049398,0.0009574862,0.000578544,0.00014313484,0.00012657768,0.0002820117,0.0003689192,0.000016016622],"category_scores_gemma":[0.0009100257,0.0005267322,0.00011549241,0.00047726836,0.000119702745,0.00020259882,0.0008425312,0.0020765653,0.000013884524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016320843,0.00046191202,0.9413238,0.00457351,0.00093573204,0.0015194981,0.00025151015,0.00025163256,0.049099647,0.0009409349,0.00043843203,0.000040189923],"study_design_scores_gemma":[0.002115389,0.0002026923,0.9518606,0.0019368343,0.00019569328,5.015554e-7,0.00005315649,0.03738464,0.005513897,0.0000057365187,0.00017610168,0.0005547305],"about_ca_topic_score_codex":0.000698863,"about_ca_topic_score_gemma":0.000039532202,"teacher_disagreement_score":0.043585747,"about_ca_system_score_codex":0.0015252215,"about_ca_system_score_gemma":0.0019015395,"threshold_uncertainty_score":0.9997184},"labels":[],"label_agreement":null},{"id":"W3019534623","doi":"10.14740/jh618","title":"Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Decitabine; Lenalidomide; Medicine; Myelodysplastic syndromes; Internal medicine; Bone marrow; Gastroenterology; Anemia; Azacitidine; International Prognostic Scoring System; Absolute neutrophil count; Oncology; Neutropenia; Toxicity; Multiple myeloma","score_opus":0.01858495262182309,"score_gpt":0.2706879366779013,"score_spread":0.2521029840560782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019534623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910014,0.00081628846,0.00085912866,0.006915299,0.000043213593,0.00028216926,0.0000017837234,0.000007640244,0.000073050694],"genre_scores_gemma":[0.99782646,0.00020827175,0.001523596,0.00034766266,0.0000443739,0.00001105241,0.0000022758452,0.000019102596,0.000017195944],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99865913,0.000095234645,0.0005146088,0.0001750674,0.0002870075,0.00026892536],"domain_scores_gemma":[0.9989841,0.00023553027,0.0002375881,0.00009546378,0.00014560013,0.00030173827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012476889,0.00015514645,0.00074589206,0.0002510232,0.000025632207,0.000010553293,0.0000667365,0.00008900654,0.00006556839],"category_scores_gemma":[0.00022396735,0.000098816374,0.000053321965,0.00023340526,0.00009744889,0.000089136694,0.00003758467,0.00031975814,0.000011673189],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0870033,0.0027868575,0.372815,0.0028600544,0.003192139,0.4527291,0.019995216,0.0029395486,0.020539332,0.0017641374,0.0048347916,0.028540509],"study_design_scores_gemma":[0.0793286,0.05945348,0.08253175,0.0021197628,0.0008382283,0.74350214,0.0042236806,0.010448054,0.012791325,0.00039497312,0.0036891717,0.000678866],"about_ca_topic_score_codex":0.000023281964,"about_ca_topic_score_gemma":0.000025792337,"teacher_disagreement_score":0.290773,"about_ca_system_score_codex":0.0004185001,"about_ca_system_score_gemma":0.0004844303,"threshold_uncertainty_score":0.40296146},"labels":[],"label_agreement":null},{"id":"W3020515492","doi":"10.1182/blood.v130.suppl_1.3815.3815","title":"Leukemic Stem Cell Expression Signatures Identify Novel Therapeutics for Acute Myeloid Leukemia","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; Université Laval; McGill University Health Centre","funders":"","keywords":"Stem cell; Myeloid leukemia; CD33; CD34; Haematopoiesis; Population; Leukemia; Medicine; Myeloid; Cancer research; Immunology; CD38; Oncology; Biology; Genetics","score_opus":0.03937321126884538,"score_gpt":0.33999775771265445,"score_spread":0.3006245464438091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020515492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894678,0.0012020968,0.00227118,0.0006927495,0.0003752882,0.0014991426,0.00013411121,0.0001711334,0.004186477],"genre_scores_gemma":[0.97750247,0.00048817883,0.0058055427,0.0006631383,0.00076007406,0.00017710599,0.000076929035,0.00013495293,0.014391595],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99747515,0.000036160407,0.00040575175,0.0006637028,0.0006473217,0.0007719417],"domain_scores_gemma":[0.9971917,0.00019625013,0.0003212671,0.0016982834,0.00030044775,0.00029202984],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041577735,0.0003726211,0.00056752394,0.00016656844,0.0007370466,0.00024577772,0.0009594833,0.00046999328,0.00004376499],"category_scores_gemma":[0.00006250317,0.0003035328,0.00029210726,0.000088098706,0.00020849003,0.0002942458,0.0003756107,0.0007721697,0.000088149005],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045743867,0.00032312164,0.0012566522,0.00019545802,0.0003938846,0.00008292243,0.00026424605,0.0000049856044,0.9893894,0.000070095586,0.0046271523,0.0029346156],"study_design_scores_gemma":[0.01611964,0.0004452714,0.011985517,0.00022001006,0.0011192654,0.00010444383,0.00016504231,0.0006263109,0.95508707,0.000116153875,0.013620107,0.00039116663],"about_ca_topic_score_codex":0.000043503278,"about_ca_topic_score_gemma":0.0000052709806,"teacher_disagreement_score":0.034302358,"about_ca_system_score_codex":0.00044399925,"about_ca_system_score_gemma":0.00094815553,"threshold_uncertainty_score":0.9999417},"labels":[],"label_agreement":null},{"id":"W3021250802","doi":"10.1016/j.stem.2019.12.006","title":"Hematopoietic Stem and Progenitor Cells Exhibit Stage-Specific Translational Programs via mTOR- and CDK1-Dependent Mechanisms","year":2020,"lang":"en","type":"article","venue":"Cell stem cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; New York State Stem Cell Science; Leukemia and Lymphoma Society; Canadian Institutes of Health Research; American Society of Hematology","keywords":"Biology; Haematopoiesis; Cell biology; Stem cell; Progenitor cell; PI3K/AKT/mTOR pathway; Ubiquitin ligase; Reprogramming; EIF4E; Translation (biology); Polysome; Ubiquitin; Signal transduction; RNA; Genetics; Ribosome; Messenger RNA; Cell; Gene","score_opus":0.029604467647095515,"score_gpt":0.23632974035044862,"score_spread":0.2067252727033531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021250802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96977204,0.0062163924,0.013989796,0.0015635303,0.000234189,0.0042031803,0.000062215404,0.00030127604,0.003657373],"genre_scores_gemma":[0.9877693,0.0003158318,0.003736864,0.00022827098,0.00025364177,0.0001089021,0.000044964258,0.00011395223,0.0074282456],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99697477,0.00012072811,0.0005185791,0.0008875869,0.0008723211,0.0006260012],"domain_scores_gemma":[0.99840593,0.000098999604,0.00013475724,0.00036603605,0.00013530912,0.0008589725],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032275467,0.000405066,0.000551332,0.0001002133,0.00016381995,0.0001343619,0.00020006164,0.0002476734,0.0003026966],"category_scores_gemma":[0.0000013140951,0.00036351598,0.00011669815,0.0002707489,0.00015050208,0.00012920015,0.00015062619,0.000549409,0.0002456932],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006655612,0.00039781674,0.0009082625,0.0035988104,0.00008756686,0.00061952794,0.005538619,0.000011694384,0.9618876,0.00025728613,0.0011361638,0.024891088],"study_design_scores_gemma":[0.0062095434,0.0011567862,0.00011381895,0.00009817452,0.0001441797,0.00012277577,0.0036483812,0.0023471517,0.96178484,0.00008801121,0.023684792,0.00060155324],"about_ca_topic_score_codex":0.000009645189,"about_ca_topic_score_gemma":0.0000018520249,"teacher_disagreement_score":0.024289535,"about_ca_system_score_codex":0.00012923407,"about_ca_system_score_gemma":0.00019532979,"threshold_uncertainty_score":0.9998817},"labels":[],"label_agreement":null},{"id":"W3021377140","doi":"10.1182/blood.v120.21.4749.4749","title":"Hematopoietic Stem Cells Have an Intrinsic Expansion Limit","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Stem cell; Haematopoiesis; Biology; Cancer research; Transplantation; Hematopoietic stem cell; Immunology; Cell biology; Medicine; Internal medicine","score_opus":0.03225873345551179,"score_gpt":0.2869926830800133,"score_spread":0.2547339496245015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021377140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945354,0.0007487777,0.000048951686,0.000319185,0.00013380974,0.00040793922,0.0000036968968,0.000119355835,0.0036829256],"genre_scores_gemma":[0.99542165,0.00007564381,0.0008745575,0.00036904393,0.00070453255,0.000027628115,0.000012218475,0.000049145572,0.0024655752],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984479,0.00008008451,0.00022042076,0.00024634882,0.0004245242,0.00058071106],"domain_scores_gemma":[0.9986416,0.00007054574,0.000046836965,0.00062718,0.00008648767,0.00052732107],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034881136,0.0001626758,0.0002776216,0.00012984188,0.00007022792,0.000020881002,0.00014639748,0.00014604845,0.00023430995],"category_scores_gemma":[0.000024407767,0.00013382852,0.00007466318,0.00015888536,0.00006234025,0.00019349613,0.00011341702,0.00035076364,0.00084389275],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005065453,0.009105318,0.12835826,0.0009479112,0.00045271317,0.0008045599,0.011456253,0.0000024192,0.7708261,0.0011946727,0.01566296,0.060682263],"study_design_scores_gemma":[0.0061163967,0.0007617171,0.014256519,0.00013484823,0.0003248388,0.00068176404,0.0018014049,0.00007224761,0.96494055,0.000034933102,0.010555594,0.00031917135],"about_ca_topic_score_codex":0.000026980484,"about_ca_topic_score_gemma":0.000003246891,"teacher_disagreement_score":0.19411443,"about_ca_system_score_codex":0.00009595634,"about_ca_system_score_gemma":0.00014247488,"threshold_uncertainty_score":0.9999341},"labels":[],"label_agreement":null},{"id":"W3021897149","doi":"10.1158/2326-6074.tumimm18-b63","title":"Abstract B63: Immune gene expression profiling of acute myeloid leukemia identifies predictors of survival and actionable targets for treatment","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Immune system; Myeloid; Immunotherapy; Immune checkpoint; Cancer immunotherapy; Biology; Gene expression profiling; Tumor microenvironment; Immunology; Cancer research; Innate immune system; Medicine; Gene; Gene expression; Genetics","score_opus":0.06833407773161575,"score_gpt":0.37581714269050154,"score_spread":0.3074830649588858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021897149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98415864,0.011738773,0.000100577396,0.001439943,0.00023612184,0.0016570748,0.00033355394,0.000038732323,0.0002965632],"genre_scores_gemma":[0.98369914,0.012572266,0.0012123629,0.000013864596,0.00027752365,0.00065167254,0.00022608075,0.000058592836,0.0012885024],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99744195,0.00016501715,0.00058680755,0.00054182834,0.0005783536,0.0006860665],"domain_scores_gemma":[0.9977562,0.00051598035,0.00018380009,0.00044371927,0.00091728236,0.00018305024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008041782,0.00022085012,0.0007956854,0.00031516424,0.00021428583,0.000016386608,0.00029141913,0.0002835164,0.00021432237],"category_scores_gemma":[0.00040290775,0.00018121989,0.00015519859,0.0004277089,0.0008567217,0.0001638597,0.00030190658,0.0004972454,0.000008109909],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056317206,0.00009760195,0.009233135,0.0005917752,0.0012725462,0.000024129204,0.0008775352,0.000019364397,0.97909385,0.000039079707,0.0008816915,0.0022375882],"study_design_scores_gemma":[0.0041707866,0.0014470615,0.028588483,0.00014027717,0.00011129715,0.000012731986,0.0011092224,0.00018234582,0.9627033,0.000051027342,0.0013703243,0.00011317285],"about_ca_topic_score_codex":0.0005518284,"about_ca_topic_score_gemma":0.000008117403,"teacher_disagreement_score":0.019355347,"about_ca_system_score_codex":0.0009172309,"about_ca_system_score_gemma":0.001971101,"threshold_uncertainty_score":0.7389933},"labels":[],"label_agreement":null},{"id":"W3022331569","doi":"10.3324/haematol.2019.240705","title":"Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature","year":2020,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Rising Tide Foundation; Applebaum Foundation","keywords":"Dasatinib; Myeloid leukemia; Medicine; PTPN11; Cancer research; Leukemia; Oncology; Gene expression profiling; Internal medicine; Gene expression; Gene; Biology; Cancer; KRAS; Imatinib; Genetics","score_opus":0.023620898027407133,"score_gpt":0.2867136705403618,"score_spread":0.26309277251295465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022331569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827668,0.0004248906,0.00091097393,0.013893214,0.000019699639,0.0010709892,0.00004860277,0.00020837424,0.0006564324],"genre_scores_gemma":[0.9826905,0.00021560724,0.012630371,0.0036874695,0.000027312917,0.00012644034,0.00011437763,0.00004759078,0.00046034466],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976223,0.0003995537,0.00041606542,0.0006744254,0.00041443095,0.00047321746],"domain_scores_gemma":[0.9984012,0.0004821322,0.00014049016,0.00039823458,0.00016069833,0.00041722695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034675898,0.00031462242,0.00066959823,0.00021448873,0.00014796338,0.000037634298,0.00020638504,0.00047088886,0.00030539415],"category_scores_gemma":[0.0006690535,0.0002180779,0.000060771126,0.000905004,0.00027567372,0.00013444765,0.00019161939,0.0011718449,0.00007399931],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059369773,0.0002448338,0.031108743,0.00041586685,0.00038262174,0.027950088,0.017563662,0.0001860575,0.8355619,0.00034792305,0.025572756,0.001295801],"study_design_scores_gemma":[0.035118684,0.010562008,0.16990012,0.002168684,0.0007398704,0.01491666,0.006411498,0.03110934,0.71404374,0.0007944508,0.012063378,0.0021715777],"about_ca_topic_score_codex":0.000040258794,"about_ca_topic_score_gemma":0.0000065153904,"teacher_disagreement_score":0.13879137,"about_ca_system_score_codex":0.00025622163,"about_ca_system_score_gemma":0.0007090466,"threshold_uncertainty_score":0.8892959},"labels":[],"label_agreement":null},{"id":"W3022639174","doi":"10.1016/j.beha.2020.101170","title":"Establishing specific response criteria for MDS/MPN - Getting closer to reality?","year":2020,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Astex Pharmaceuticals; Takeda Pharmaceuticals U.S.A.; TG Therapeutics; Karyopharm Therapeutics; Celgene; Bristol-Myers Squibb","keywords":"Medicine; Multiple myeloma; Disease; Oncology; Intensive care medicine; Internal medicine","score_opus":0.5253634270731835,"score_gpt":0.6398598484458549,"score_spread":0.11449642137267135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022639174","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000108063505,0.8793564,0.00089459156,0.10107245,0.0011514764,0.0124540515,0.0003084555,0.00024157923,0.0044129235],"genre_scores_gemma":[0.000015917225,0.95372933,0.03319931,0.0023344525,0.004632436,0.0023424632,0.000406044,0.00051025563,0.0028297687],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9511839,0.032746106,0.0055559636,0.003912953,0.0030209783,0.0035800836],"domain_scores_gemma":[0.7775737,0.2101885,0.0013089052,0.003576116,0.004128988,0.0032237957],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.077431455,0.0011199606,0.008539557,0.0017452483,0.0007689508,0.0007755912,0.0026545094,0.002902004,0.00052934943],"category_scores_gemma":[0.52423745,0.00096527685,0.001824101,0.0034221548,0.001394101,0.00095179904,0.0033937823,0.013444569,0.0060347337],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015482226,0.0011927084,0.0000075257763,0.017099384,0.0007283076,0.015013026,0.00019578652,6.380538e-8,0.000009972231,0.0016394489,0.30261463,0.6460169],"study_design_scores_gemma":[0.0021272947,0.0057241535,0.0000037953864,0.011301261,0.0011896099,0.007814805,0.00071916124,0.00004502649,0.000004328699,0.00021928165,0.97010875,0.00074254686],"about_ca_topic_score_codex":0.00022909655,"about_ca_topic_score_gemma":0.000026672342,"teacher_disagreement_score":0.6674941,"about_ca_system_score_codex":0.0018588408,"about_ca_system_score_gemma":0.012993717,"threshold_uncertainty_score":0.9992798},"labels":[],"label_agreement":null},{"id":"W3022981622","doi":"10.1177/2050313x20919638","title":"Diagnostic challenge of aleukemic leukemia cutis preceding acute myelogenous leukemia: A case report","year":2020,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Leukemia cutis; Leukemia; Pathology; Dermatology; Biopsy; Skin biopsy; Bone marrow; Immunology","score_opus":0.03817709828008915,"score_gpt":0.3384712184635063,"score_spread":0.30029412018341717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022981622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95764744,0.002548837,0.0010585709,0.0071752234,0.00053158833,0.004236472,0.00007489561,0.00026838417,0.026458569],"genre_scores_gemma":[0.9909948,0.0017981604,0.0019237943,0.0016820526,0.0009710958,0.00036535776,0.00022085509,0.00019681152,0.001847045],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9907712,0.00034144963,0.0029029401,0.0019173058,0.0027047833,0.0013623426],"domain_scores_gemma":[0.99138653,0.0014863157,0.0011685498,0.0019949656,0.00053494814,0.0034287036],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036665618,0.00073091843,0.0020827795,0.00022929804,0.0005866735,0.00019002204,0.00057943474,0.0009654777,0.0027468966],"category_scores_gemma":[0.023856618,0.0006443798,0.0004720234,0.001148894,0.0006952555,0.00043900576,0.002207226,0.0025404692,0.0001029159],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034896805,0.00016098494,0.0011725979,0.0006496165,0.0007297208,0.9506828,0.0014079355,0.000010653186,0.0008923028,0.000017367483,0.014723655,0.02920338],"study_design_scores_gemma":[0.0030605458,0.0011201455,0.00010592678,0.0008935591,0.0009237834,0.97697365,0.0008008561,0.0016350669,0.0028009654,0.00009058026,0.0110250525,0.0005698847],"about_ca_topic_score_codex":0.006393247,"about_ca_topic_score_gemma":0.00052213395,"teacher_disagreement_score":0.03334737,"about_ca_system_score_codex":0.0029397183,"about_ca_system_score_gemma":0.012807534,"threshold_uncertainty_score":0.9997607},"labels":[],"label_agreement":null},{"id":"W3026400117","doi":"10.1177/1535370220927996","title":"Ribophorin II is upregulated in myelodysplastic syndromes and prevents apoptosis and cell cycle progression","year":2020,"lang":"en","type":"article","venue":"Experimental Biology and Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cell growth; Cell cycle; Biology; Apoptosis; Cancer research; Gene knockdown; Biochemistry","score_opus":0.020457774704462896,"score_gpt":0.34145300686590385,"score_spread":0.32099523216144094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026400117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98165417,0.0120253945,0.0000031066088,0.0053171534,0.000060179118,0.0004856942,0.000005623459,0.000028656597,0.000420051],"genre_scores_gemma":[0.9972149,0.0011612079,0.00023655912,0.0010106652,0.000092076516,0.000037230966,0.000039329017,0.000014378182,0.00019361966],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889517,0.00006592418,0.0002296588,0.00042745902,0.00011174402,0.0002700384],"domain_scores_gemma":[0.99944645,0.000064946296,0.000045257915,0.000099708035,0.000014131448,0.0003294853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012749137,0.00018170055,0.00040607507,0.0000979722,0.000104243765,0.0000036739796,0.000050466722,0.00016706983,0.00018611275],"category_scores_gemma":[0.000060972296,0.00012825847,0.000014710576,0.00015569617,0.0005181754,0.000047720154,0.00023244867,0.00024607085,0.0000042043785],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007378372,0.00013145403,0.022227943,0.00013251192,0.000041045616,0.000045632678,0.0054159677,7.584501e-8,0.96659523,0.000029051915,0.000942283,0.0037009781],"study_design_scores_gemma":[0.01572314,0.010262056,0.026596537,0.00062117685,0.00008627338,0.0002940688,0.0036489472,0.0010340571,0.93941027,0.000095339645,0.0019176583,0.0003104842],"about_ca_topic_score_codex":0.000052175437,"about_ca_topic_score_gemma":3.4099813e-7,"teacher_disagreement_score":0.027184958,"about_ca_system_score_codex":0.000043649165,"about_ca_system_score_gemma":0.000031517273,"threshold_uncertainty_score":0.5230229},"labels":[],"label_agreement":null},{"id":"W3027087419","doi":"10.1093/ajcp/aqaa038","title":"Molecular/Cytogenetic Education for Hematopathology Fellows","year":2020,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Hematopathology; Curriculum; Molecular pathology; Molecular diagnostics; Medicine; Hematologic Neoplasms; Medical education; Pathology; Medical physics; Engineering ethics; Bioinformatics; Psychology; Cytogenetics; Biology; Internal medicine; Genetics","score_opus":0.06892733517944744,"score_gpt":0.4463652343078921,"score_spread":0.37743789912844466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027087419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9478326,0.00038877796,0.018758344,0.031644754,0.00038607736,0.00032225766,0.000004306873,0.000014518827,0.00064837566],"genre_scores_gemma":[0.93439794,0.00019740543,0.04031872,0.023925364,0.0010544133,0.000013321552,0.0000061439455,0.000035929916,0.000050737814],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972674,0.00052140676,0.0013647155,0.00030056853,0.00022709083,0.0003187761],"domain_scores_gemma":[0.9968258,0.000802305,0.00089360843,0.00025638714,0.0006097193,0.0006121509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013068694,0.00014540218,0.0011926813,0.0001246038,0.000029296523,0.0000069078856,0.00026647034,0.0001384769,0.000042823507],"category_scores_gemma":[0.005676212,0.00011849814,0.00050688745,0.00028244426,0.0007397209,0.000036918616,0.000066338165,0.0007481161,0.000043323456],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074813743,0.0011784612,0.10348251,0.00016281827,0.00032154282,0.0038081328,0.00063987606,0.000047398327,0.059822716,0.0012548466,0.013069908,0.8087304],"study_design_scores_gemma":[0.046003524,0.22917297,0.31924114,0.0005414735,0.003556709,0.08210948,0.007963997,0.0032190075,0.030645851,0.010618558,0.26488003,0.0020472452],"about_ca_topic_score_codex":0.0000018772408,"about_ca_topic_score_gemma":3.4992846e-7,"teacher_disagreement_score":0.8066832,"about_ca_system_score_codex":0.000046481648,"about_ca_system_score_gemma":0.0017078894,"threshold_uncertainty_score":0.6795366},"labels":[],"label_agreement":null},{"id":"W3027683485","doi":"","title":"Mixed phenotype acute leukemia, B/myeloid, NOS with near-tetraploidy: a case report.","year":2017,"lang":"en","type":"article","venue":"PubMed","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Nova Scotia Health Authority; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Myeloid leukemia; Leukemia; Phenotype; Myeloid; Acute leukemia; Biology; Lineage (genetic); Immunology; Acute lymphocytic leukemia; Cancer research; Medicine; Genetics; Gene; Lymphoblastic Leukemia","score_opus":0.04062411687243824,"score_gpt":0.2822357230867345,"score_spread":0.24161160621429625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027683485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.961101,0.0001290375,0.00019433863,0.0040133027,0.00038761107,0.0025148743,0.00003413051,0.0002717537,0.031353958],"genre_scores_gemma":[0.9716135,0.0000460033,0.0029232074,0.00046929423,0.00058365456,0.0017879555,0.000049689806,0.00013422142,0.022392467],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9963408,0.00007186442,0.00051144615,0.0008744248,0.0008827881,0.0013186899],"domain_scores_gemma":[0.9952553,0.000152636,0.00041931568,0.0028085609,0.00041202994,0.0009521751],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009800057,0.0004090843,0.00069532666,0.00017623197,0.0009565779,0.00042896802,0.00055636966,0.00027099962,0.000116550604],"category_scores_gemma":[0.001685793,0.00031444422,0.00018055721,0.00026647578,0.00071608234,0.00043814786,0.00033763365,0.0009404789,0.00018273672],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002283166,0.0001991033,0.023567395,0.00016702406,0.0013126635,0.74260604,0.00033867126,0.0000053888284,0.00039436348,0.00020252753,0.021646047,0.20727758],"study_design_scores_gemma":[0.0098019475,0.00044040298,0.6424678,0.00010673297,0.0010598195,0.29520246,0.0002690085,0.00071076857,0.004921992,0.00011686589,0.04399398,0.00090818235],"about_ca_topic_score_codex":0.0021890455,"about_ca_topic_score_gemma":0.00053407147,"teacher_disagreement_score":0.6189004,"about_ca_system_score_codex":0.0011128102,"about_ca_system_score_gemma":0.0014344724,"threshold_uncertainty_score":0.99993074},"labels":[],"label_agreement":null},{"id":"W3028535930","doi":"10.1016/j.leukres.2020.106370","title":"Anabolic steroids in myelodysplastic syndromes: A systematic review","year":2020,"lang":"en","type":"review","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Danazol; Medicine; Randomized controlled trial; Anabolism; Myelodysplastic syndromes; Systematic review; Internal medicine; MEDLINE; Chemistry","score_opus":0.153479901526021,"score_gpt":0.4567358407268689,"score_spread":0.3032559392008479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028535930","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006756172,0.97761065,0.000008560428,0.0006818112,0.000118747485,0.017948745,0.00007304346,0.00018492859,0.0033667467],"genre_scores_gemma":[0.000013984012,0.9865637,0.00014418288,0.0004904828,0.00040616147,0.00548209,0.00034450844,0.00043312975,0.0061217933],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9824098,0.005069665,0.0034213176,0.0021252234,0.0042681075,0.002705915],"domain_scores_gemma":[0.99037105,0.0038467937,0.0005160263,0.003081629,0.00072775665,0.0014567376],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0075060343,0.0013118077,0.012335593,0.0032660451,0.00020418197,0.00019978808,0.0023642823,0.001203993,0.00049509644],"category_scores_gemma":[0.012377574,0.00097130984,0.0013298008,0.009717608,0.0005466811,0.00019799614,0.0014819712,0.010053378,0.010070288],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000035863904,0.000076261706,0.0000021600515,0.9135944,0.0005159419,0.008739787,0.000078746685,1.3852409e-7,8.3864063e-7,0.00010782571,0.010171418,0.06667662],"study_design_scores_gemma":[0.00085882243,0.00033889752,0.0000019642994,0.60967356,0.0015115621,0.0023925588,0.000058403173,0.00007717511,2.6958335e-7,0.000014980338,0.38461867,0.00045316806],"about_ca_topic_score_codex":0.00022451521,"about_ca_topic_score_gemma":0.000026498154,"teacher_disagreement_score":0.37444726,"about_ca_system_score_codex":0.018888513,"about_ca_system_score_gemma":0.020222964,"threshold_uncertainty_score":0.99996334},"labels":[],"label_agreement":null},{"id":"W3028627144","doi":"10.1200/jco.2020.38.15_suppl.e19512","title":"The comparative effectiveness of glasdegib in combination with low-dose cytarabine versus azacitidine by bone marrow blasts counts among patients with newly-diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Cytarabine; Internal medicine; Myeloid leukemia; Oncology; Hazard ratio; Confidence interval","score_opus":0.04387402461863748,"score_gpt":0.3834264577794724,"score_spread":0.3395524331608349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028627144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936133,0.00012267259,0.0004169483,0.0041161897,0.00022192272,0.0012288919,0.000029326176,0.000007892946,0.00024284452],"genre_scores_gemma":[0.9976148,0.0004554118,0.00049259886,0.0011029928,0.00016787824,0.000035122477,0.00003762651,0.000033312655,0.00006025238],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9972225,0.00048801117,0.0011995999,0.0002540805,0.00054336106,0.00029244905],"domain_scores_gemma":[0.98794144,0.0075353426,0.001536445,0.00016601842,0.0025367576,0.00028400726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015275816,0.00021212808,0.0017450837,0.00011144429,0.000049439765,0.00001256045,0.00022031998,0.0002517536,0.000016558235],"category_scores_gemma":[0.0030572405,0.00012298256,0.00016911424,0.00040769827,0.00058564986,0.00015300213,0.000046956684,0.0010226766,0.000004816994],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6078534,0.0025211805,0.30075693,0.000440701,0.0030406683,0.00062943675,0.000817085,0.00041195878,0.0015001833,0.00007536553,0.06634767,0.01560537],"study_design_scores_gemma":[0.21328184,0.065534525,0.70406294,0.0012110574,0.00045600752,0.000025347315,0.00068262697,0.0031344942,0.0029915671,0.000059975315,0.008293853,0.00026577277],"about_ca_topic_score_codex":0.000025770296,"about_ca_topic_score_gemma":0.00006389149,"teacher_disagreement_score":0.40330598,"about_ca_system_score_codex":0.0006948493,"about_ca_system_score_gemma":0.0016447303,"threshold_uncertainty_score":0.5015083},"labels":[],"label_agreement":null},{"id":"W3029006566","doi":"10.1200/jco.2020.38.15_suppl.7525","title":"Effect of early blood counts on overall survival (OS) following glasdegib + LDAC in newly diagnosed AML: BRIGHT AML 1003 post hoc analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Internal medicine; Complete blood count; Gastroenterology","score_opus":0.05853508805701754,"score_gpt":0.43895443334776163,"score_spread":0.38041934529074406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029006566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98738295,0.00020425692,0.00002828384,0.0076168007,0.00067055476,0.00027174855,0.000007784901,0.000010850955,0.00380678],"genre_scores_gemma":[0.99507856,0.0003688789,0.000351048,0.0028896327,0.0010375968,0.0000028584002,0.000007812659,0.00002933889,0.00023429269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944405,0.0017515661,0.0021998056,0.00030994494,0.00091783,0.00038033054],"domain_scores_gemma":[0.98880863,0.008972018,0.0010487906,0.00026560106,0.0003050688,0.00059988414],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0059802704,0.00020490604,0.0027993422,0.00036792227,0.000024742676,0.000013593138,0.00036297415,0.00050418114,0.00036222144],"category_scores_gemma":[0.012101343,0.00014497619,0.0013337944,0.0006929037,0.00015073172,0.00010724549,0.000091264665,0.0020332036,0.00010387998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04697113,0.0024669648,0.8524117,0.00016575145,0.0077277916,0.018813772,0.0003229916,0.00014933983,0.0018652887,0.00014451267,0.0133997975,0.055560943],"study_design_scores_gemma":[0.04838279,0.087638564,0.83519715,0.00019157991,0.004052178,0.00005989989,0.000032930668,0.0005429983,0.00049057725,0.00003443198,0.02315479,0.00022212412],"about_ca_topic_score_codex":0.0001261939,"about_ca_topic_score_gemma":0.00008439195,"teacher_disagreement_score":0.0851716,"about_ca_system_score_codex":0.00024796659,"about_ca_system_score_gemma":0.0016699719,"threshold_uncertainty_score":0.9962202},"labels":[],"label_agreement":null},{"id":"W3029453604","doi":"10.1200/jco.2020.38.15_suppl.7510","title":"Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"Jazz Pharmaceuticals","keywords":"Medicine; Cytarabine; Internal medicine; Daunorubicin; Randomization; Surgery; Gastroenterology; Phases of clinical research; Regimen; Randomized controlled trial; Leukemia; Clinical trial","score_opus":0.09289132584472974,"score_gpt":0.44653000318822916,"score_spread":0.3536386773434994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029453604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925049,0.00012574575,0.00003053098,0.0053454945,0.00035849406,0.00084959937,0.00004272124,0.000007900127,0.00073461956],"genre_scores_gemma":[0.9957439,0.00045789752,0.002362179,0.00052590936,0.0007926888,0.000008581336,0.000009098633,0.000028624634,0.00007113434],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99313664,0.0011061201,0.0040907743,0.0003949075,0.00090359926,0.00036794183],"domain_scores_gemma":[0.98772854,0.0071235956,0.0032043892,0.00036636996,0.0009231466,0.0006539367],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0035531071,0.00021816124,0.0026546794,0.0002851761,0.000027853024,0.0000050190724,0.0004314913,0.00040673505,0.0002366558],"category_scores_gemma":[0.014540951,0.0001523026,0.00031906876,0.000570053,0.0003873376,0.0001432568,0.00015673795,0.0030303267,0.000011392115],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78611004,0.021022072,0.044632662,0.0001550809,0.0012851343,0.008878134,0.0066514197,0.00015861765,0.0001289642,0.000011399837,0.016692096,0.11427435],"study_design_scores_gemma":[0.5147561,0.19606307,0.27905473,0.0002996436,0.0005094654,0.000051182833,0.0070056412,0.0003497161,0.00013277378,0.000007969729,0.0016478185,0.000121880636],"about_ca_topic_score_codex":0.00087931915,"about_ca_topic_score_gemma":0.00073094945,"teacher_disagreement_score":0.27135396,"about_ca_system_score_codex":0.00022200306,"about_ca_system_score_gemma":0.0043103625,"threshold_uncertainty_score":0.9992697},"labels":[],"label_agreement":null},{"id":"W3029791793","doi":"10.1200/jco.2020.38.15_suppl.8530","title":"Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Hôpital Maisonneuve-Rosemont; CancerCare Manitoba; Vancouver General Hospital; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"Karyopharm Therapeutics","keywords":"Medicine; Carfilzomib; Pomalidomide; Refractory (planetary science); Lenalidomide; Regimen; Internal medicine; Dexamethasone; Daratumumab; Bortezomib; Multiple myeloma; Gastroenterology; Oncology","score_opus":0.08850480127217517,"score_gpt":0.4084695183400413,"score_spread":0.3199647170678661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029791793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803537,0.0003772866,0.00015996922,0.017793007,0.00025856463,0.00036265902,0.000007349313,0.000013936951,0.0006735311],"genre_scores_gemma":[0.9782022,0.00047041656,0.014266931,0.0059566377,0.00093031855,0.0000035696155,0.000006108497,0.00003822301,0.00012555426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956441,0.00072249596,0.0021900216,0.00036006692,0.00068446057,0.00039885598],"domain_scores_gemma":[0.99230355,0.004525914,0.0012510038,0.00022004462,0.0007054204,0.0009940516],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0026751335,0.00020708522,0.0017867035,0.00017118917,0.000038419195,0.000011994966,0.00024456403,0.00052313134,0.000092931536],"category_scores_gemma":[0.016843714,0.00014124502,0.00019547918,0.00035641066,0.00037647772,0.00022031725,0.00014756009,0.0030970483,0.00002736917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023396054,0.0012130904,0.8544306,0.00005363394,0.00022083221,0.0011656961,0.00028443226,0.00001934141,0.00020722068,0.0000071768764,0.0052773426,0.113724574],"study_design_scores_gemma":[0.04206613,0.029428229,0.8789388,0.00014005085,0.0001522182,0.000091794696,0.00023880156,0.00077608065,0.000046583726,0.000018504828,0.047954734,0.00014808521],"about_ca_topic_score_codex":0.00004223313,"about_ca_topic_score_gemma":0.000070208625,"teacher_disagreement_score":0.11357649,"about_ca_system_score_codex":0.00037552725,"about_ca_system_score_gemma":0.0024821856,"threshold_uncertainty_score":0.99920285},"labels":[],"label_agreement":null},{"id":"W3029853203","doi":"10.1200/jco.2020.38.15_suppl.7503","title":"Development and validation of a pediatric disease risk index for allogeneic hematopoietic cell transplantation.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"National Institutes of Health","keywords":"Medicine; Transplantation; Internal medicine; Cohort; Proportional hazards model; Disease; Hematopoietic stem cell transplantation; Leukemia; Oncology; Myeloid leukemia; Hematopoietic cell; Haematopoiesis; Stem cell","score_opus":0.11348362665975205,"score_gpt":0.42955726609701705,"score_spread":0.316073639437265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029853203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98592347,0.00045005768,0.008773217,0.0043553836,0.00010533587,0.00030209066,0.000009875905,0.000004069965,0.000076472264],"genre_scores_gemma":[0.9745231,0.0024506624,0.02159415,0.0007349305,0.00064502173,0.000006573097,0.000007183418,0.000011861458,0.000026487274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763364,0.00020322255,0.0015849385,0.0001430539,0.00029970537,0.00013544068],"domain_scores_gemma":[0.99620557,0.0017238791,0.0010781972,0.00006842365,0.0003457391,0.0005782054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018280232,0.00008181576,0.0006993487,0.000097908254,0.000029181969,0.0000037960506,0.00009555872,0.00016368747,0.000029824432],"category_scores_gemma":[0.0025453058,0.00006104664,0.00019175041,0.00012545595,0.000071484064,0.000054278993,0.000022687218,0.00045415128,0.0000038647213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020098003,0.0011878706,0.9277818,0.0015596374,0.00034154725,0.00049751194,0.0015261658,0.00014891509,0.00063104805,0.000041796662,0.0028424612,0.043343235],"study_design_scores_gemma":[0.027393412,0.008498208,0.9376845,0.000057922203,0.0022929593,0.00012007037,0.00030978528,0.0008163229,0.003904971,0.0003588039,0.018383345,0.00017974256],"about_ca_topic_score_codex":0.0000014117633,"about_ca_topic_score_gemma":9.914327e-7,"teacher_disagreement_score":0.043163493,"about_ca_system_score_codex":0.00006466344,"about_ca_system_score_gemma":0.0030956152,"threshold_uncertainty_score":0.54914886},"labels":[],"label_agreement":null},{"id":"W3030525376","doi":"10.1200/jco.2020.38.15_suppl.7509","title":"Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); McMaster University","funders":"Pfizer","keywords":"Medicine; Cytarabine; Internal medicine; Surgery; Chemotherapy","score_opus":0.20678952505096104,"score_gpt":0.4542725518709324,"score_spread":0.24748302681997136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030525376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9407449,0.00023962418,0.00022671882,0.05329114,0.0016761611,0.00052279135,0.000008484494,0.000028302751,0.003261917],"genre_scores_gemma":[0.97175825,0.0024542478,0.0054894025,0.009240007,0.00521722,0.0000109558305,0.000016555317,0.00008960228,0.005723748],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9917772,0.0011529834,0.0044124406,0.0006714678,0.0012093871,0.0007765628],"domain_scores_gemma":[0.9908825,0.0046073785,0.0019279845,0.00045476036,0.0007416783,0.0013856816],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0075150314,0.0003689644,0.0032423944,0.0002800546,0.00007046258,0.000038495946,0.00047910633,0.0008750524,0.000983001],"category_scores_gemma":[0.027015263,0.00025740513,0.0006540757,0.0004914781,0.000520654,0.00029923147,0.00036049463,0.0039519714,0.00011177796],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17606048,0.0024901424,0.3058154,0.00053348474,0.001563145,0.30835932,0.00072606467,0.000087743094,0.0014881163,0.00045367735,0.15017304,0.05224937],"study_design_scores_gemma":[0.11099141,0.026624708,0.5146291,0.00045305688,0.0005843227,0.015929613,0.00033673496,0.0029144282,0.0001324929,0.0005880616,0.32626802,0.0005480391],"about_ca_topic_score_codex":0.00013310855,"about_ca_topic_score_gemma":0.00039241527,"teacher_disagreement_score":0.29242972,"about_ca_system_score_codex":0.0008600718,"about_ca_system_score_gemma":0.009430074,"threshold_uncertainty_score":0.99998784},"labels":[],"label_agreement":null},{"id":"W3030534638","doi":"10.1126/scitranslmed.aaz0463","title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","year":2020,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; NIH Clinical Center; Qatar National Research Fund","keywords":"Immunotherapy; Immune system; Myeloid leukemia; Immunology; Medicine; Myeloid; Leukemia; Cancer; Biology; Internal medicine","score_opus":0.017591600981190045,"score_gpt":0.30124169685355195,"score_spread":0.2836500958723619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030534638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.839024,0.0030531045,0.0007417024,0.15479785,0.000062982705,0.0006228979,0.000015450256,0.00007549666,0.0016064821],"genre_scores_gemma":[0.99175954,0.0013044634,0.0027611095,0.0034580894,0.00020671409,0.000028079092,0.000021107633,0.000028644212,0.0004322767],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9970253,0.000097952,0.0005089196,0.0006161166,0.0012609864,0.00049071945],"domain_scores_gemma":[0.99871564,0.00035709896,0.000079387675,0.0002930361,0.00018015038,0.00037467177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020469178,0.00022712538,0.0004751105,0.00041574362,0.00017932079,0.000025082296,0.00034907425,0.000078542136,0.00033263655],"category_scores_gemma":[0.00041196047,0.0001746804,0.000048908074,0.0018955292,0.0013793716,0.00032791815,0.000026703985,0.00048220207,0.000014144231],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026102616,0.000044707132,0.014415411,0.00008927753,0.00007226262,0.00015687766,0.008552604,0.00004074847,0.9403439,0.0006678999,0.0006488612,0.008864842],"study_design_scores_gemma":[0.019009965,0.0013609297,0.94436437,0.00045370095,0.000043198404,0.0001228844,0.00057100254,0.00916098,0.011817177,0.00072066253,0.012045835,0.00032928458],"about_ca_topic_score_codex":0.00003989385,"about_ca_topic_score_gemma":0.000013795849,"teacher_disagreement_score":0.929949,"about_ca_system_score_codex":0.00026826377,"about_ca_system_score_gemma":0.0015311377,"threshold_uncertainty_score":0.71232605},"labels":[],"label_agreement":null},{"id":"W3031916639","doi":"10.1200/jco.2020.38.15_suppl.7501","title":"Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant<i>-IDH2</i> (<i>mIDH2</i>) newly diagnosed acute myeloid leukemia (ND-AML).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Clinical endpoint; Gastroenterology; Azacitidine; Myeloid leukemia; Surrogate endpoint; Phases of clinical research; Surgery; Oncology; Chemotherapy; Randomized controlled trial","score_opus":0.09172971033791527,"score_gpt":0.43506980538103923,"score_spread":0.34334009504312396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031916639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9706608,0.00062972185,0.00008835833,0.026436403,0.0007236889,0.00087614614,0.00003161505,0.000030513816,0.00052273186],"genre_scores_gemma":[0.98390305,0.005663395,0.0017796275,0.0070255585,0.0013882356,0.0000153943,0.000011720817,0.000090348665,0.00012266173],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9897843,0.0040866844,0.0035591975,0.0006671151,0.0011981644,0.000704546],"domain_scores_gemma":[0.96476597,0.030890355,0.0020429988,0.0005038019,0.00042162256,0.0013752774],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00932563,0.00049435516,0.0038582813,0.0004434218,0.00007652677,0.000024967714,0.0005533109,0.0009537653,0.00014544741],"category_scores_gemma":[0.021163804,0.00036184717,0.00073871465,0.000541563,0.00060173514,0.00022917948,0.00022282971,0.003667427,0.000030319105],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73278016,0.0005067146,0.0067646895,0.00019258968,0.0008981888,0.013068889,0.00060522207,0.00023536877,0.16677548,0.000033160864,0.012508169,0.065631375],"study_design_scores_gemma":[0.3865669,0.35096782,0.09867344,0.0016019135,0.0013219619,0.0015571429,0.00027159843,0.008169671,0.057181317,0.00016580199,0.09262993,0.000892489],"about_ca_topic_score_codex":0.000083540595,"about_ca_topic_score_gemma":0.000024715046,"teacher_disagreement_score":0.35046113,"about_ca_system_score_codex":0.0017043104,"about_ca_system_score_gemma":0.004932673,"threshold_uncertainty_score":0.99988335},"labels":[],"label_agreement":null},{"id":"W3032053629","doi":"10.1200/jco.2020.38.15_suppl.8545","title":"Sporadic late-onset nemaline myopathy with monoclonal paraprotein as a malignancy rather than disimmunity and treatment with chemotherapy-based approach.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Barrie Urology Group","funders":"","keywords":"Medicine; Nemaline myopathy; Plasmapheresis; Rituximab; Monoclonal gammopathy of undetermined significance; Internal medicine; Chemotherapy; Gastroenterology; Malignancy; Autologous stem-cell transplantation; Immunosuppression; Monoclonal; Lymphoma; Oncology; Immunology; Myopathy; Antibody; Monoclonal antibody","score_opus":0.10818178105452365,"score_gpt":0.4064592163675243,"score_spread":0.29827743531300066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032053629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9609987,0.00045173123,0.0011311074,0.035967283,0.000031795615,0.000697481,0.000009825924,0.00002024867,0.0006918244],"genre_scores_gemma":[0.96897805,0.00063051865,0.022819927,0.0065128296,0.0005697882,0.00002414827,0.000016263859,0.000054256103,0.00039419893],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99689245,0.00063077913,0.0012682712,0.00034044855,0.0005121848,0.0003558447],"domain_scores_gemma":[0.9966814,0.000797031,0.0010228347,0.0002906063,0.00028980122,0.000918363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015459388,0.0002939754,0.0017883127,0.00010552546,0.000068183996,0.00001941073,0.00020183926,0.00032779766,0.00013637047],"category_scores_gemma":[0.00040534837,0.00014285489,0.00026560944,0.00028699875,0.00057863316,0.00009269523,0.00003503051,0.0012798305,0.000011709481],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19064099,0.007009328,0.6728712,0.0001542845,0.0022238395,0.009069745,0.0010901416,0.00017332168,0.000565113,0.000046563833,0.0011042973,0.11505118],"study_design_scores_gemma":[0.14073469,0.40034992,0.3655046,0.00054324075,0.0016158188,0.0041336003,0.0013803031,0.008334315,0.0012017204,0.00017536055,0.075310595,0.0007158463],"about_ca_topic_score_codex":0.0001289287,"about_ca_topic_score_gemma":0.000021918204,"teacher_disagreement_score":0.3933406,"about_ca_system_score_codex":0.00023977258,"about_ca_system_score_gemma":0.0045155883,"threshold_uncertainty_score":0.801046},"labels":[],"label_agreement":null},{"id":"W3032239860","doi":"10.1200/jco.2020.38.15_suppl.e19538","title":"A population-based study of chronic neutrophilic leukemia in the United States: 2004 to 2015.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Interquartile range; Hazard ratio; Internal medicine; Confidence interval; Incidence (geometry); Proportional hazards model; Population; Epidemiology; Survival analysis; Univariate analysis; Surveillance, Epidemiology, and End Results; Surgery; Cancer registry; Multivariate analysis","score_opus":0.14441882143898901,"score_gpt":0.4873208696631166,"score_spread":0.3429020482241276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032239860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9401912,0.0001057598,0.00011050565,0.058672354,0.00015296183,0.00067972863,0.0000029343826,0.0000058578803,0.000078699515],"genre_scores_gemma":[0.9836326,0.000061813145,0.00034275366,0.015030244,0.0008766896,0.000008262613,0.000010019791,0.000017339793,0.000020246796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99483,0.0014465757,0.0025494995,0.00019814669,0.0006988745,0.0002768835],"domain_scores_gemma":[0.99407345,0.003746829,0.0009540144,0.00028503942,0.0004991831,0.00044149766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040970966,0.0001296842,0.0013201815,0.00034202886,0.000027882646,0.000007311899,0.00046324756,0.00022271399,0.00011511627],"category_scores_gemma":[0.0063463068,0.0000783246,0.00023083568,0.0010715288,0.00007678848,0.000051740626,0.00006634201,0.001840468,0.000024736126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027249565,0.008130443,0.73867697,0.00021007507,0.0006901869,0.004533348,0.0050202846,0.13446711,0.00042074098,0.000053067666,0.057810917,0.022737276],"study_design_scores_gemma":[0.025466071,0.09031647,0.8349549,0.00010505233,0.00025887735,0.00005660066,0.0024234182,0.0179929,0.000014057684,0.000057182264,0.028243816,0.00011066345],"about_ca_topic_score_codex":0.0008548016,"about_ca_topic_score_gemma":0.00041486372,"teacher_disagreement_score":0.11647422,"about_ca_system_score_codex":0.0015159643,"about_ca_system_score_gemma":0.0065605068,"threshold_uncertainty_score":0.99907136},"labels":[],"label_agreement":null},{"id":"W3032335069","doi":"10.1200/jco.2020.38.15_suppl.7513","title":"Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta Hospital; Alberta Hospital Edmonton","funders":"","keywords":"Medicine; Dosing; Internal medicine; Maintenance therapy; Neutropenia; Minimal residual disease; Febrile neutropenia; Surgery; Oncology; Chemotherapy; Bone marrow; Gastroenterology","score_opus":0.11128410234474692,"score_gpt":0.43992396344434664,"score_spread":0.32863986109959975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032335069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9601105,0.00023216657,0.0012377081,0.03494032,0.0016958242,0.0013076692,0.00015012863,0.000024950734,0.00030077368],"genre_scores_gemma":[0.97937393,0.0012490693,0.011342875,0.004526293,0.003148394,0.000027209848,0.00009877271,0.00005976384,0.0001737198],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99153686,0.00074798195,0.0056424905,0.0005392902,0.00092429185,0.00060906267],"domain_scores_gemma":[0.9786419,0.013808047,0.004503595,0.0005451775,0.0016770846,0.00082414696],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004508211,0.0003123546,0.0025412145,0.00011582576,0.00019982748,0.00002897738,0.0007898979,0.0007526527,0.000059208254],"category_scores_gemma":[0.048239596,0.00019380452,0.0008837704,0.00044499268,0.00063050305,0.0002695406,0.00024763276,0.0023610399,0.000017642884],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8145219,0.008960428,0.0012492363,0.00007066427,0.0019196008,0.00068627123,0.0034539504,0.000036954385,0.0020665987,0.00011377919,0.07702336,0.08989727],"study_design_scores_gemma":[0.8227042,0.041247733,0.0024054328,0.0005247831,0.0009906301,0.00005521054,0.0014126798,0.005434223,0.0014304926,0.00017133601,0.12336219,0.00026110696],"about_ca_topic_score_codex":0.0001491329,"about_ca_topic_score_gemma":0.000034621975,"teacher_disagreement_score":0.08963616,"about_ca_system_score_codex":0.0009408631,"about_ca_system_score_gemma":0.004056866,"threshold_uncertainty_score":0.9999406},"labels":[],"label_agreement":null},{"id":"W3032523202","doi":"10.1200/jco.2020.38.15_suppl.7511","title":"A phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C): A six-month update.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"AbbVie","keywords":"Medicine; Cytarabine; Internal medicine; Clinical endpoint; Ven; Hazard ratio; Venetoclax; Gastroenterology; Myeloid leukemia; Febrile neutropenia; Neutropenia; Leukemia; Oncology; Randomized controlled trial; Chemotherapy; Confidence interval; Chronic lymphocytic leukemia","score_opus":0.05466129522622532,"score_gpt":0.41438983872249535,"score_spread":0.35972854349627004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032523202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945315,0.00014288405,0.00005685017,0.0024503567,0.00022702229,0.0022910296,0.000016573338,0.000020770707,0.00026301038],"genre_scores_gemma":[0.99579453,0.00038857723,0.0008704594,0.0021141665,0.0005949676,0.000028233584,0.000033351276,0.00006305353,0.0001126396],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9922616,0.0010686025,0.004339069,0.0005370978,0.001164033,0.0006295965],"domain_scores_gemma":[0.9934173,0.0012783692,0.0025825473,0.00045963158,0.0011625382,0.0010995865],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002372322,0.0003761394,0.0036599059,0.00028820723,0.00004462455,0.000013867577,0.00056066446,0.00052282424,0.00023670286],"category_scores_gemma":[0.0026990273,0.00025344995,0.000375204,0.0009079607,0.00035211,0.00023540569,0.00023492245,0.002675087,0.000029060031],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53790456,0.03334156,0.28455523,0.0003368169,0.005869471,0.026929244,0.006612387,0.0015443214,0.0008658335,0.000011055336,0.012587764,0.08944178],"study_design_scores_gemma":[0.50085616,0.24087992,0.24680518,0.00048085913,0.0018612343,0.00023417523,0.00088179106,0.0039482145,0.00017814628,0.000012155506,0.0035093667,0.0003528156],"about_ca_topic_score_codex":0.00028625,"about_ca_topic_score_gemma":0.00030288717,"teacher_disagreement_score":0.20753837,"about_ca_system_score_codex":0.0030038033,"about_ca_system_score_gemma":0.014665632,"threshold_uncertainty_score":0.9999918},"labels":[],"label_agreement":null},{"id":"W3032758825","doi":"10.1182/bloodadvances.2019000770","title":"High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Heart Institute; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research","keywords":"Haematopoiesis; Indeterminate; Sensitivity (control systems); Biology; Cell biology; Immunology; Stem cell","score_opus":0.011402129020833344,"score_gpt":0.25343473749715356,"score_spread":0.24203260847632022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032758825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995447,0.00017158547,0.00024493787,0.0029508544,0.000018562047,0.00061473495,0.00010119222,0.00006846551,0.00038269113],"genre_scores_gemma":[0.9967015,0.000012695301,0.0024602704,0.0004027125,0.00011981489,0.000031605763,0.00002853887,0.000030254248,0.00021261018],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99831975,0.00010737131,0.00024524183,0.00036703778,0.00064240536,0.00031819596],"domain_scores_gemma":[0.99899095,0.000115044255,0.00021889617,0.000185006,0.00029807744,0.00019199695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017930493,0.00019333113,0.000544828,0.00006889911,0.00006239888,0.000011482943,0.00009364153,0.00010036084,0.000075740536],"category_scores_gemma":[0.00042337342,0.00014915978,0.000089106645,0.00038061963,0.00023223991,0.00022549435,0.000083435494,0.00035685947,0.000013378331],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003552756,0.0010375862,0.0148799615,0.00060970325,0.0013305396,0.0036272337,0.0013452481,0.000040018356,0.9683105,0.00021897025,0.00031055426,0.0047369767],"study_design_scores_gemma":[0.0046293507,0.0013981118,0.016966613,0.00030281916,0.00028591134,0.00013092121,0.00030149202,0.00032027977,0.9750936,0.00013051796,0.00022612922,0.0002142371],"about_ca_topic_score_codex":0.00006539743,"about_ca_topic_score_gemma":0.000016219457,"teacher_disagreement_score":0.0067831646,"about_ca_system_score_codex":0.00006179667,"about_ca_system_score_gemma":0.00027223132,"threshold_uncertainty_score":0.6082559},"labels":[],"label_agreement":null},{"id":"W3033337455","doi":"10.3324/haematol.2020.249243","title":"Epigenetic and functional changes imposed by NUP98-HOXA9 in a genetically engineered model of chronic myeloid leukemia progression","year":2020,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre; Terry Fox Research Institute; BC Cancer Agency","funders":"BC Cancer Agency; Université Paris-Est Créteil Val-de-Marne; Université Paris-Sud; Terry Fox Research Institute; Institut National de la Santé et de la Recherche Médicale; Canadian Institutes of Health Research; Canada's Michael Smith Genome Sciences Centre","keywords":"Myeloid leukemia; Epigenetics; Genetically engineered; Cancer research; Leukemia; Biology; Medicine; Computational biology; Bioinformatics; Immunology; Genetics; Gene","score_opus":0.0364780637644815,"score_gpt":0.27953285423043717,"score_spread":0.24305479046595568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033337455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98471117,0.004652275,0.0027238694,0.0065894374,0.000020294287,0.00085970125,0.000025473424,0.000083764244,0.0003340066],"genre_scores_gemma":[0.99373543,0.0012399243,0.0041941414,0.00048470043,0.0000619362,0.000117806994,0.000053193486,0.000030527706,0.0000823394],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9982536,0.00006848307,0.00037036208,0.00046775723,0.00040456513,0.00043524368],"domain_scores_gemma":[0.99918306,0.00010768749,0.00008638174,0.00022803647,0.000089698086,0.00030515142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017048254,0.00022429758,0.00059431395,0.0001177851,0.000040442817,0.000011029286,0.00013020798,0.0002483678,0.00016624754],"category_scores_gemma":[0.00024312382,0.00017347331,0.000057161582,0.00031209915,0.00021995614,0.000039257902,0.00016681492,0.0003888564,0.000019205647],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011692081,0.00018606421,0.003641129,0.0010263214,0.00007312269,0.0001652856,0.000454654,0.00087200775,0.97660613,0.00045147087,0.0042642276,0.011090381],"study_design_scores_gemma":[0.0072449613,0.0032653606,0.014466858,0.00037760174,0.00009874339,0.00027548874,0.00014760638,0.76693225,0.20505007,0.00028865543,0.0013702352,0.00048218813],"about_ca_topic_score_codex":0.000008834105,"about_ca_topic_score_gemma":0.0000074360737,"teacher_disagreement_score":0.7715561,"about_ca_system_score_codex":0.00025027033,"about_ca_system_score_gemma":0.000527028,"threshold_uncertainty_score":0.7074036},"labels":[],"label_agreement":null},{"id":"W3033921331","doi":"10.1007/s12288-020-01293-w","title":"Does Development of Plasmacytosis have a Role in Spontaneous Remission of Acute Myeloid Leukemia?","year":2020,"lang":"en","type":"article","venue":"Indian Journal of Hematology and Blood Transfusion","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hematology; Myeloid leukemia; Plasmacytosis; Internal medicine; Spontaneous remission; Complete remission; Human genetics; Immunology; Oncology; Pathology; Chemotherapy; Multiple myeloma; Alternative medicine; Genetics; Biology","score_opus":0.01011680885726356,"score_gpt":0.2511784491352716,"score_spread":0.24106164027800803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033921331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968299,0.00052135537,0.00008341064,0.0021975893,0.000033568776,0.00022578049,0.000007645425,0.0000053595863,0.000095352465],"genre_scores_gemma":[0.9934058,0.0012473926,0.005170699,0.00010151051,0.00003509431,0.0000021144754,0.000004063726,0.000015682035,0.000017597877],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814296,0.00011746736,0.00096728804,0.00019011363,0.00033945922,0.00024272791],"domain_scores_gemma":[0.99899375,0.00017145113,0.0003031253,0.00010269848,0.00014816472,0.00028077827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046727373,0.00016165314,0.0008216088,0.00035280976,0.000051466912,0.0000035707208,0.00015345325,0.00024553356,0.00007540025],"category_scores_gemma":[0.00009011768,0.0001003623,0.00011477373,0.00021569809,0.00014333204,0.00007558279,0.000038676328,0.00062638655,0.0000012211907],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011407266,0.00045720668,0.11345168,0.0012700966,0.0008022953,0.024367187,0.03496224,0.0000070542246,0.79530376,0.00002982806,0.00004340215,0.017897988],"study_design_scores_gemma":[0.007108196,0.0013446443,0.0063421405,0.0010817281,0.00031419698,0.032620933,0.002210788,0.000058006994,0.94844484,0.00007402121,0.0002740314,0.00012649689],"about_ca_topic_score_codex":0.000020057329,"about_ca_topic_score_gemma":0.000050829905,"teacher_disagreement_score":0.15314107,"about_ca_system_score_codex":0.000066636334,"about_ca_system_score_gemma":0.0009208875,"threshold_uncertainty_score":0.40926558},"labels":[],"label_agreement":null},{"id":"W3034640472","doi":"10.1002/cyto.b.21931","title":"Analysis of erythroid maturation in the nonlysed bone marrow with help of radar plots facilitates detection of flow cytometric aberrations in myelodysplastic syndromes","year":2020,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Royal University Hospital","funders":"Region Skåne","keywords":"Erythropoiesis; Cytopenia; Myelodysplastic syndromes; Bone marrow; Flow cytometry; Biology; Pathology; Immunology; Medicine; Internal medicine; Anemia","score_opus":0.06640173155991724,"score_gpt":0.351418676037284,"score_spread":0.28501694447736675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034640472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99092084,0.00063169433,0.0061832746,0.0007815953,0.00008674892,0.001006769,0.00021590522,0.000041561903,0.00013160352],"genre_scores_gemma":[0.99669886,0.00031970342,0.0023907814,0.00018722095,0.0000963107,0.00005384466,0.00018003333,0.000041824682,0.000031419],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933283,0.0008271989,0.002855136,0.0007781812,0.001674391,0.0005368331],"domain_scores_gemma":[0.99164414,0.0057320604,0.00086474215,0.0008728363,0.0005952496,0.0002909608],"candidate_categories":["metaresearch","metaepi_narrow","bibliometrics"],"consensus_categories":[],"category_scores_codex":[0.003324834,0.0003830939,0.0023019388,0.007194368,0.000060139682,0.000024136467,0.00048116338,0.00043329445,0.00014073717],"category_scores_gemma":[0.010668858,0.00027963443,0.0005609092,0.04612388,0.0006883845,0.0002844098,0.0001374542,0.0012410088,0.000020193598],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072075166,0.0018947195,0.91328174,0.0013104329,0.0022803992,0.000198098,0.001181698,0.0012489931,0.06589397,0.000015048007,0.00015236731,0.0053350404],"study_design_scores_gemma":[0.004776821,0.0033062592,0.9575886,0.00022997976,0.0013956244,0.00004018498,0.0017784362,0.02016769,0.01034757,0.0000114511495,0.00008078887,0.00027659658],"about_ca_topic_score_codex":0.00011006339,"about_ca_topic_score_gemma":0.0001164255,"teacher_disagreement_score":0.0555464,"about_ca_system_score_codex":0.00029820364,"about_ca_system_score_gemma":0.00044488773,"threshold_uncertainty_score":0.9999656},"labels":[],"label_agreement":null},{"id":"W3036033661","doi":"10.1186/s40164-020-00170-6","title":"Leukemia incidence trends at the global, regional, and national level between 1990 and 2017","year":2020,"lang":"en","type":"article","venue":"Experimental Hematology and Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":348,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Medical Association","funders":"Department of Education of Guizhou Province; Guizhou Science and Technology Department; National Natural Science Foundation of China","keywords":"Medicine; Leukemia; Incidence (geometry); Myeloid leukemia; Chronic lymphocytic leukemia; Internal medicine; Demography","score_opus":0.12036463846384143,"score_gpt":0.4121852002020398,"score_spread":0.29182056173819837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036033661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9437476,0.011331539,0.000016465136,0.039205506,0.000041390456,0.00018726477,0.00003318991,0.00002746913,0.0054095807],"genre_scores_gemma":[0.9923555,0.00035178527,0.00053970783,0.0060640275,0.00015545834,0.000037465394,0.000047289777,0.000009425511,0.00043930043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987877,0.00012011087,0.00022053592,0.00040356774,0.00020228239,0.0002658294],"domain_scores_gemma":[0.99915826,0.00034714205,0.00007524143,0.00011038372,0.000037734335,0.00027123888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018999961,0.00016065757,0.0004064975,0.000045260524,0.0002950294,0.000010964113,0.00010241923,0.00025219898,0.00015051774],"category_scores_gemma":[0.00008863221,0.000117449956,0.00003205544,0.00012443932,0.0012699161,0.00007447231,0.00043917852,0.00028089332,0.000029091272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003176021,0.00020115198,0.49266684,0.00017141728,0.0005128492,0.0015175188,0.0060003195,8.3858487e-7,0.012161741,0.058064945,0.4138475,0.011678852],"study_design_scores_gemma":[0.016750887,0.005506565,0.5875785,0.000092994545,0.00022126298,0.046229158,0.0055781845,0.00094928854,0.028806975,0.0022404385,0.3052614,0.00078433054],"about_ca_topic_score_codex":0.00008978256,"about_ca_topic_score_gemma":0.000050727074,"teacher_disagreement_score":0.10858608,"about_ca_system_score_codex":0.00065335294,"about_ca_system_score_gemma":0.00034483275,"threshold_uncertainty_score":0.478947},"labels":[],"label_agreement":null},{"id":"W3036501203","doi":"10.1038/s41375-020-0929-3","title":"Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia","year":2020,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Neuroblastoma RAS viral oncogene homolog; Chronic myelomonocytic leukemia; Cancer research; Azacitidine; Trametinib; In vivo; Medicine; Transplantation; Leukemia; Biology; Immunology; Bone marrow; Cancer; Myelodysplastic syndromes; MAPK/ERK pathway; Internal medicine; KRAS; Gene; Gene expression; Signal transduction; DNA methylation","score_opus":0.020389211421344124,"score_gpt":0.2670072797449849,"score_spread":0.24661806832364078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036501203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930662,0.0009690839,0.0019358153,0.00040313473,0.000043537355,0.0023332129,0.00012255067,0.000093965,0.0010324924],"genre_scores_gemma":[0.99713284,0.000464788,0.000946223,0.00033410083,0.00007019752,0.00037898566,0.00011971549,0.00009147676,0.00046169007],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99661225,0.00021208546,0.0008479123,0.000825284,0.0005859739,0.0009164651],"domain_scores_gemma":[0.9986246,0.00025555605,0.00017978193,0.00046957706,0.000078288846,0.0003921788],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026355317,0.00047922594,0.0010876772,0.00039521584,0.00006491025,0.000028918132,0.0002931241,0.00025191155,0.00009936961],"category_scores_gemma":[0.00008877198,0.00044703533,0.00022608406,0.00097242557,0.00016721108,0.00026103418,0.000105561405,0.00075484085,0.000031059368],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040801405,0.0002800118,0.007569122,0.00093589595,0.00030591842,0.00057503185,0.014784085,0.047558982,0.9021886,0.000024056199,0.0030038438,0.018694337],"study_design_scores_gemma":[0.016431822,0.0011472501,0.0012078739,0.0006079341,0.0001344306,0.00002223277,0.00070975913,0.49703076,0.48191488,0.00003407167,0.00037374516,0.0003852485],"about_ca_topic_score_codex":0.005319165,"about_ca_topic_score_gemma":0.00087089377,"teacher_disagreement_score":0.44947177,"about_ca_system_score_codex":0.010301197,"about_ca_system_score_gemma":0.0023453091,"threshold_uncertainty_score":0.9997981},"labels":[],"label_agreement":null},{"id":"W3036606956","doi":"10.1007/s00277-020-04074-7","title":"Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC","year":2020,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Clofarabine; Internal medicine; Transplantation; Fludarabine; Gastroenterology; Busulfan; Hematopoietic stem cell transplantation; Surgery; Cytarabine; Myeloid leukemia; Hematology; Cyclophosphamide; Oncology; Chemotherapy","score_opus":0.05012476924367989,"score_gpt":0.3210703684726141,"score_spread":0.27094559922893424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036606956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99155706,0.00020004586,0.0001268013,0.004811779,0.00006176682,0.0022537191,0.0007847665,0.000024729552,0.00017933646],"genre_scores_gemma":[0.9990886,0.00015635794,0.00009464572,0.00035379056,0.000024706824,0.000088654626,0.00011855019,0.00003319132,0.000041535175],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99747056,0.00026716138,0.00092461414,0.0005573937,0.000440582,0.00033967677],"domain_scores_gemma":[0.9975333,0.0003700387,0.0008063582,0.0003935924,0.0007622648,0.00013442963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039449715,0.00026070463,0.0011429325,0.00013669446,0.00009349551,0.0000055276196,0.00020060595,0.00021120954,0.000010006038],"category_scores_gemma":[0.0003881049,0.00020495644,0.00019668395,0.00034009307,0.00035354972,0.00008329717,0.00006893536,0.0003531387,0.0000010298974],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018405875,0.0010044193,0.0054566227,0.0011954524,0.00049376686,0.000040065595,0.0108081605,0.000012856847,0.9594849,0.00033571458,0.0026886389,0.00007355672],"study_design_scores_gemma":[0.0069543202,0.0061197956,0.02993553,0.00031732296,0.0002893115,0.00012668001,0.0031168137,0.000066779976,0.9528191,0.00009754968,0.000015364962,0.00014141397],"about_ca_topic_score_codex":0.00009663692,"about_ca_topic_score_gemma":0.00001078405,"teacher_disagreement_score":0.024478907,"about_ca_system_score_codex":0.00005372803,"about_ca_system_score_gemma":0.00023878606,"threshold_uncertainty_score":0.8357881},"labels":[],"label_agreement":null},{"id":"W3036919729","doi":"10.1038/s41375-020-0935-5","title":"Male predominance in AML is associated with specific preleukemic mutations","year":2020,"lang":"en","type":"letter","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Biology; Leukemia; Genetics; Preleukemia; Mutation; Hematology; Medicine; Cancer research; Immunology; Gene","score_opus":0.02285359932203269,"score_gpt":0.2645555930208941,"score_spread":0.24170199369886142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036919729","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15305611,0.0012142772,0.0001635268,0.8127954,0.00034306882,0.0041375654,0.00070845755,0.00049586484,0.027085746],"genre_scores_gemma":[0.05644411,0.0007420366,0.0020981159,0.81471324,0.0043444387,0.0007711881,0.0056431973,0.00062634045,0.11461732],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99497783,0.00022326518,0.00081078394,0.0013924232,0.0013282974,0.0012673975],"domain_scores_gemma":[0.99741673,0.0005173459,0.0003971205,0.0011192262,0.0002948189,0.0002547514],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.00021370547,0.0007684621,0.0013953663,0.0005649589,0.0001245519,0.00009458481,0.0006565416,0.0014290313,0.0012188915],"category_scores_gemma":[0.00038834856,0.00069575006,0.00025143375,0.0015974087,0.0004297449,0.00017859714,0.00018439599,0.0075847087,0.0011307164],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003275431,0.000039300245,0.002867382,0.00034377608,0.0002514864,0.020096187,0.00070192834,0.00002670169,0.00037818006,0.0000064338665,0.9743678,0.0005933022],"study_design_scores_gemma":[0.009090981,0.0007000273,0.006770111,0.0022649749,0.00030606665,0.0014237831,0.00010464962,0.0020285477,0.00092781836,0.0001513776,0.97514856,0.0010831269],"about_ca_topic_score_codex":0.00027866632,"about_ca_topic_score_gemma":0.00005614287,"teacher_disagreement_score":0.096612014,"about_ca_system_score_codex":0.012345933,"about_ca_system_score_gemma":0.005039679,"threshold_uncertainty_score":0.9998673},"labels":[],"label_agreement":null},{"id":"W3037540119","doi":"10.1182/blood.2019004292","title":"Hematopoietic stem cells acquire survival advantage by loss of RUNX1 methylation identified in familial leukemia","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"RUNX1; Leukemia; Stem cell; Haematopoiesis; Biology; Cancer research; Genetics; Immunology","score_opus":0.02172580617951951,"score_gpt":0.2808943614331022,"score_spread":0.2591685552535827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037540119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648917,0.00056684465,0.00029111552,0.00058368297,0.000109074,0.0005838388,0.000059739807,0.000059350583,0.0012572105],"genre_scores_gemma":[0.99856275,0.00013155298,0.00019318105,0.0001808676,0.0001387779,0.000018100378,0.000054011656,0.000044603403,0.00067617174],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99785054,0.00015169744,0.0005469113,0.00040913303,0.00066737336,0.00037432948],"domain_scores_gemma":[0.9990196,0.0001660534,0.00012924353,0.00034969102,0.00010161553,0.00023377397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004113786,0.00019523525,0.00057665445,0.00011967982,0.000031249587,0.000015857342,0.00023580401,0.00017774857,0.00010762335],"category_scores_gemma":[0.000086003165,0.00018733609,0.00011521668,0.000534265,0.00010917839,0.0001325124,0.00014135492,0.00037600155,0.00010259117],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004382938,0.00029847806,0.017286548,0.0007154177,0.00011283376,0.00033065342,0.0016295352,0.000015072259,0.97682196,0.00011964372,0.0013432372,0.0008883386],"study_design_scores_gemma":[0.010844718,0.0003682652,0.0032351324,0.00012037705,0.00016473046,0.000021727503,0.0021216462,0.00062761846,0.9816024,0.000035902616,0.0006340267,0.00022346666],"about_ca_topic_score_codex":0.00009573348,"about_ca_topic_score_gemma":0.000012733321,"teacher_disagreement_score":0.014051416,"about_ca_system_score_codex":0.00020145175,"about_ca_system_score_gemma":0.00037409263,"threshold_uncertainty_score":0.76393443},"labels":[],"label_agreement":null},{"id":"W3037948978","doi":"10.1111/bjh.16891","title":"Clinical value of next‐generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome","year":2020,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Medicine; Cytogenetics; Myelodysplastic syndromes; Internal medicine; Oncology; Predictive value; DNA sequencing; Pathology; Bone marrow; Biology; Chromosome; Gene; Genetics","score_opus":0.07179874823036245,"score_gpt":0.3178360345580713,"score_spread":0.24603728632770885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037948978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967153,0.0001955119,0.0017546955,0.000818328,0.00011270464,0.00035379443,0.000009623851,0.000008522789,0.000031502273],"genre_scores_gemma":[0.99033576,0.000052643958,0.008950619,0.00051034236,0.00010051376,0.000002370082,0.00001744755,0.00002598413,0.000004321491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751467,0.00029998904,0.0012114627,0.00021541472,0.00047280453,0.00028567857],"domain_scores_gemma":[0.99824446,0.00019866673,0.00037449904,0.0001238376,0.0006871418,0.00037141275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039583517,0.00012045432,0.001041779,0.00020599233,0.000029996663,0.000019473973,0.0001909591,0.00013331088,0.00005658302],"category_scores_gemma":[0.0014335671,0.00012000308,0.00008510771,0.00046212377,0.00013503685,0.00008902084,0.000069806294,0.000610403,0.000010116604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028579764,0.00050181017,0.9104889,0.0003152751,0.00037061662,0.07207284,0.0004587337,0.0024549407,0.0049837157,0.00008990568,0.0023190829,0.0030861986],"study_design_scores_gemma":[0.013737797,0.006362297,0.880032,0.0011248774,0.00019911148,0.08901442,0.0002544697,0.007317906,0.0016162448,0.000025361764,0.00008099149,0.00023453076],"about_ca_topic_score_codex":0.00006000407,"about_ca_topic_score_gemma":0.00007924767,"teacher_disagreement_score":0.030456908,"about_ca_system_score_codex":0.00019905338,"about_ca_system_score_gemma":0.0006686849,"threshold_uncertainty_score":0.48935837},"labels":[],"label_agreement":null},{"id":"W3037991489","doi":"10.1097/mph.0000000000001880","title":"Clinicoepidemiologic Profile and Outcome Predicted by Minimal Residual Disease in Children With Mixed-phenotype Acute Leukemia Treated on a Modified MCP-841 Protocol at a Tertiary Cancer Institute in India","year":2020,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Medicine; Cytarabine; Myeloid leukemia; Internal medicine; Leukemia; Bone marrow; Acute leukemia; Minimal residual disease; Myeloid; Gastroenterology; Surgery","score_opus":0.03969301207031389,"score_gpt":0.3715009339655657,"score_spread":0.3318079218952518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037991489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723476,0.00030625402,0.000015270718,0.0078039863,0.0000780418,0.019090341,0.00018340677,0.00004558774,0.00012949562],"genre_scores_gemma":[0.98601884,0.00040210865,0.001081617,0.0027201343,0.00072697765,0.008784621,0.00010854531,0.000065299275,0.00009188116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947225,0.0009838762,0.0021768357,0.0007402182,0.00050315796,0.00087345176],"domain_scores_gemma":[0.996496,0.00075522246,0.0012497102,0.00029129337,0.00020915043,0.0009985856],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012036358,0.0004890711,0.0020627936,0.0008130517,0.00008069929,0.000012865098,0.00039684356,0.0007860378,0.00008249471],"category_scores_gemma":[0.0019621998,0.00033794425,0.00014252616,0.0009971253,0.0004265785,0.00022637386,0.0002718295,0.0023281227,0.000014349996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026853878,0.00062314566,0.9432991,0.00024559587,0.00033123462,0.005309444,0.00027240673,0.00008672175,0.00016249629,0.000020364378,0.022187,0.00060857093],"study_design_scores_gemma":[0.027440099,0.0069714263,0.9613303,0.00009629134,0.0006376185,0.0011132506,0.000045585275,0.0011616936,0.00013824401,0.000023545033,0.0007203765,0.00032158187],"about_ca_topic_score_codex":0.00015094435,"about_ca_topic_score_gemma":0.000073115145,"teacher_disagreement_score":0.021466624,"about_ca_system_score_codex":0.0020352982,"about_ca_system_score_gemma":0.0049774824,"threshold_uncertainty_score":0.99997354},"labels":[],"label_agreement":null},{"id":"W3039517308","doi":"10.1016/j.clml.2020.07.001","title":"Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogenic Stem Cell Transplantation","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Sanofi Pasteur; Celgene; Sanofi; Takeda Canada; MaaT Pharma; Therakos; Novartis; British Microcirculation Society; Amgen; Pfizer; Astellas Pharma; Roche","keywords":"Gemtuzumab ozogamicin; Medicine; Calicheamicin; Hepatic veno-occlusive disease; Myeloid leukemia; Internal medicine; Salvage therapy; Hematopoietic stem cell transplantation; CD33; Toxicity; Chemotherapy; Cytarabine; Gastroenterology; Transplantation; Oncology; Surgery; Stem cell; CD34","score_opus":0.016301026541720144,"score_gpt":0.2704746716757513,"score_spread":0.2541736451340311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039517308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99363077,0.00015562259,0.00044506107,0.0020516263,0.0001655291,0.00238546,0.00007540098,0.00028072376,0.0008097972],"genre_scores_gemma":[0.9835221,0.00062093337,0.0027229057,0.011456493,0.0002770704,0.0001472092,0.00042316673,0.00029199367,0.00053813396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99341893,0.00043149167,0.0017896168,0.001777008,0.0012830278,0.0012999005],"domain_scores_gemma":[0.9958837,0.00062763726,0.00053326355,0.0010232722,0.000886815,0.0010452864],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005677407,0.0009357231,0.0018300922,0.00032958988,0.00014995117,0.00009697343,0.0006085513,0.00077403075,0.00015435579],"category_scores_gemma":[0.00011586595,0.0007231187,0.0003898227,0.001313015,0.0007136618,0.00045524986,0.0001541539,0.0014056975,0.00029573904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29274493,0.00068810093,0.45249295,0.0006747587,0.0013704766,0.0077478886,0.0033535345,0.00010235285,0.002091614,0.000037421367,0.0020924686,0.2366035],"study_design_scores_gemma":[0.060500346,0.011263836,0.9202604,0.0006645617,0.00061706925,0.00017781452,0.000432156,0.0016010451,0.0027305495,0.000018431881,0.00084817474,0.00088558946],"about_ca_topic_score_codex":0.000113981674,"about_ca_topic_score_gemma":0.000054055337,"teacher_disagreement_score":0.46776748,"about_ca_system_score_codex":0.004936336,"about_ca_system_score_gemma":0.004169823,"threshold_uncertainty_score":0.999522},"labels":[],"label_agreement":null},{"id":"W3040519582","doi":"10.1182/blood.2020006374","title":"MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Canada's Michael Smith Genome Sciences Centre; Institute for Research in Immunology and Cancer; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Haematopoiesis; Myeloid; Biology; Immunology; CD34; Cancer research; Population; Stem cell; Leukemia; Granulocyte macrophage colony-stimulating factor; Progenitor cell; Myeloid leukemia; Interleukin 3; Cytokine; T cell; Medicine; Cell biology; Immune system; Interleukin 21","score_opus":0.033861214649666155,"score_gpt":0.3071939903723446,"score_spread":0.27333277572267844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3040519582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98036397,0.00024835748,0.000069238056,0.0047335895,0.00010083273,0.0009664279,0.000050761435,0.0005008348,0.012965987],"genre_scores_gemma":[0.9923494,0.0000848135,0.0011361288,0.0029562186,0.0012085156,0.000075247,0.00012278341,0.00012977276,0.0019371068],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99666035,0.00012251973,0.0006112805,0.0008221214,0.00083384715,0.00094989577],"domain_scores_gemma":[0.9978156,0.00015845812,0.00016719727,0.000724591,0.00028383106,0.0008503066],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034921814,0.00041862935,0.00079119095,0.00018024887,0.00021604924,0.00011169978,0.00050140504,0.00030644238,0.00046790455],"category_scores_gemma":[0.00073765515,0.0003873654,0.00025195268,0.00064036355,0.0001596529,0.0002347538,0.0003844043,0.0011042161,0.0007201609],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039300768,0.00021300314,0.002569825,0.00017247407,0.00070147915,0.0025226446,0.0023849928,0.0000028684276,0.97161335,0.00021693141,0.013099303,0.006110136],"study_design_scores_gemma":[0.049425185,0.0053188605,0.018629782,0.0007997838,0.0028173372,0.0011955163,0.001461592,0.0017506483,0.86457235,0.00025717253,0.052116867,0.0016549067],"about_ca_topic_score_codex":0.00018466091,"about_ca_topic_score_gemma":0.000019223637,"teacher_disagreement_score":0.10704099,"about_ca_system_score_codex":0.0004219359,"about_ca_system_score_gemma":0.0005900524,"threshold_uncertainty_score":0.99985784},"labels":[],"label_agreement":null},{"id":"W3042164741","doi":"10.1002/jha2.62","title":"Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada","year":2020,"lang":"en","type":"article","venue":"eJHaem","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Innovative Targeting Solutions (Canada); Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; Simon Fraser University; Princess Margaret Cancer Centre; Terry Fox Research Institute; Vancouver General Hospital; Canadian Centre for Applied Research in Cancer Control","funders":"Terry Fox Research Institute; Canadian Centre for Applied Research in Cancer Control","keywords":"Medicine; Socioeconomic status; Quality of life (healthcare); Proportional hazards model; Myeloid leukemia; Internal medicine; Myelodysplastic syndromes; Demography; Gerontology; Oncology; Environmental health; Population; Bone marrow","score_opus":0.03267171272506571,"score_gpt":0.27893597066259895,"score_spread":0.24626425793753326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042164741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965168,0.00012112205,0.000004768814,0.0021062961,0.000019868761,0.0002178653,0.000055902932,0.000010114336,0.0009472596],"genre_scores_gemma":[0.99929285,0.000029401886,0.00005925584,0.0004918249,0.000029857318,0.00000466477,0.00002513806,0.00001853215,0.00004845317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986087,0.00014241235,0.00045729437,0.00021754614,0.00034229894,0.00023171782],"domain_scores_gemma":[0.9989201,0.00034738862,0.00023435999,0.00015861655,0.000068944355,0.00027061274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048434213,0.00011445578,0.0006383753,0.00008506697,0.000016903043,0.000002670856,0.00011480494,0.00007749611,0.0001080134],"category_scores_gemma":[0.0008052032,0.00009943708,0.000028940138,0.00029780497,0.00015962319,0.00003950963,0.00007335763,0.00033621865,0.000002426635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041377783,0.000025841688,0.99545777,0.00015407549,0.00014670755,0.000022319886,0.0009101842,0.000015346166,0.0011413763,0.00007143872,0.0010032076,0.00063793623],"study_design_scores_gemma":[0.0035734996,0.00016672105,0.99147326,0.000036577905,0.000015253401,0.0000011425584,0.0020995103,0.00024332954,0.0021458126,0.000006897133,0.00013395365,0.00010404436],"about_ca_topic_score_codex":0.49951544,"about_ca_topic_score_gemma":0.5447936,"teacher_disagreement_score":0.04527814,"about_ca_system_score_codex":0.0011325988,"about_ca_system_score_gemma":0.007821427,"threshold_uncertainty_score":0.99780333},"labels":[],"label_agreement":null},{"id":"W3043883433","doi":"10.1016/j.bbmt.2020.07.017","title":"Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation","year":2020,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"NPM1; Medicine; Hazard ratio; Oncology; Hematopoietic stem cell transplantation; Internal medicine; Transplantation; Genotype; Leukemia; Chronic myelogenous leukemia; Minimal residual disease; Karyotype; Myeloid leukemia; Stem cell; Fms-Like Tyrosine Kinase 3; Immunology; Cancer research; Gastroenterology; Mutation; Biology; Genetics; Confidence interval; Gene; Chromosome","score_opus":0.008309579168522398,"score_gpt":0.21959960637358197,"score_spread":0.21129002720505957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043883433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99400955,0.00014349988,0.004374746,0.00026284807,0.0000366304,0.00094276795,0.00013464822,0.000026943067,0.000068361325],"genre_scores_gemma":[0.9973074,0.00052675564,0.0010934327,0.00010273914,0.00001217772,0.000025614774,0.00089379295,0.000021044718,0.000017015098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858654,0.00012234336,0.0005625107,0.00032406521,0.00019755904,0.0002069708],"domain_scores_gemma":[0.9993535,0.00011344209,0.0001688678,0.000101345584,0.00015018469,0.000112657675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019046279,0.00018529633,0.0003846388,0.00023957285,0.00006336652,0.00000782768,0.00006258125,0.00016289909,0.000008780596],"category_scores_gemma":[0.000009098706,0.00016904884,0.00003278441,0.0002684172,0.00010672676,0.00017017989,0.0000100694115,0.00016488894,0.000001401796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010385867,0.00022036054,0.6928605,0.003370515,0.00033724346,0.0000512341,0.009461731,0.0005984688,0.27914366,0.0001950275,0.0000059903277,0.0033694115],"study_design_scores_gemma":[0.016607916,0.004731496,0.925169,0.00022429111,0.0008812546,0.00007863887,0.0004751495,0.0011606641,0.050399058,0.000057881087,0.0000014243136,0.00021322268],"about_ca_topic_score_codex":0.00009451555,"about_ca_topic_score_gemma":0.000048223443,"teacher_disagreement_score":0.2323085,"about_ca_system_score_codex":0.000053530286,"about_ca_system_score_gemma":0.00014614222,"threshold_uncertainty_score":0.68936116},"labels":[],"label_agreement":null},{"id":"W3045047136","doi":"10.14740/jmc3526","title":"<i>De Novo</i> Granulocytic Sarcoma of the Humerus in an 82-Year-Old Woman: A Case Report","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Sarcoma; Radiation therapy; Pathological; Biopsy; Leukemia; Humerus; Myeloid sarcoma; Surgery; Radiology; Pathology; Internal medicine","score_opus":0.04682359248987391,"score_gpt":0.34828671887543844,"score_spread":0.30146312638556455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045047136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96589196,0.00066965516,0.000050654337,0.03287676,0.000114723036,0.00017739892,0.0000060554426,0.000009026429,0.0002037722],"genre_scores_gemma":[0.99389213,0.00012801783,0.00031123357,0.0048578414,0.000702526,0.000002624122,0.0000016584352,0.000023010241,0.00008095419],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99625957,0.00026013108,0.00097036833,0.00017487098,0.0020018406,0.00033320315],"domain_scores_gemma":[0.99762636,0.00045493135,0.0003692731,0.00033871515,0.0002515944,0.00095910596],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001938901,0.00013735914,0.0005633476,0.00013276022,0.00004590305,0.000017776154,0.00040078326,0.0001785904,0.00051572704],"category_scores_gemma":[0.009248294,0.00008331842,0.0002165537,0.0005213403,0.000300869,0.00010392976,0.00014685119,0.0014701771,0.0000048585616],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009926208,0.00032464656,0.039645158,0.0001965319,0.00005878985,0.944183,0.00087517913,0.000007187393,0.0014834282,0.00004285625,0.00884623,0.0033443933],"study_design_scores_gemma":[0.005756387,0.0018740993,0.009272548,0.0005312109,0.00014699844,0.97081953,0.0018836346,0.0009244601,0.0026215108,0.000045342273,0.0060104895,0.00011381284],"about_ca_topic_score_codex":0.00029123988,"about_ca_topic_score_gemma":0.00011314254,"teacher_disagreement_score":0.030372608,"about_ca_system_score_codex":0.00028047268,"about_ca_system_score_gemma":0.002120395,"threshold_uncertainty_score":0.9990972},"labels":[],"label_agreement":null},{"id":"W3047534042","doi":"10.1158/1538-7445.pedca19-b34","title":"Abstract B34: Cord blood CD34+ HSPCs: An in vitro model system for characterizing NUP98 fusions","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Haematopoiesis; Cancer research; Progenitor cell; CD34; Biology; Myeloid; Fusion gene; Molecular biology; Stem cell; Cell biology; Gene; Genetics","score_opus":0.17175552406438538,"score_gpt":0.42925918511824873,"score_spread":0.25750366105386335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047534042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847741,0.0004556088,0.00024412439,0.010049975,0.00008467363,0.0024523395,0.00031610962,0.0001423995,0.001480676],"genre_scores_gemma":[0.99499565,0.00030374844,0.0009994331,0.00066131,0.0009469627,0.0013294822,0.00015384943,0.00011305221,0.0004965232],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99611557,0.00015475154,0.00048794408,0.0008155082,0.0011398863,0.0012863342],"domain_scores_gemma":[0.9974322,0.00031924745,0.000068118636,0.00062748865,0.00062632404,0.0009266265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015192989,0.00023555761,0.0005636075,0.00042639545,0.0002718397,0.00009820897,0.0005753344,0.00022699244,0.00015673357],"category_scores_gemma":[0.00054520543,0.00021577885,0.00012736753,0.0009113763,0.00017696146,0.0002514276,0.0002803632,0.0015983757,0.00009767191],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046723806,0.00016626451,0.0003695998,0.001406673,0.00006510274,0.00025740504,0.0009521721,0.00006244097,0.98006904,0.00011076118,0.0020324073,0.009835764],"study_design_scores_gemma":[0.013444029,0.001883476,0.0043273135,0.0013580511,0.000108628956,0.00006828168,0.004452617,0.19554152,0.768491,0.00008053629,0.009552672,0.00069184456],"about_ca_topic_score_codex":0.00090525317,"about_ca_topic_score_gemma":0.0000814444,"teacher_disagreement_score":0.211578,"about_ca_system_score_codex":0.0012163679,"about_ca_system_score_gemma":0.0023334762,"threshold_uncertainty_score":0.87992066},"labels":[],"label_agreement":null},{"id":"W3047569349","doi":"10.1182/bloodadvances.2020001920","title":"American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Grand River Hospital; McMaster University; Health Sciences Centre; Impact","funders":"","keywords":"Medicine; Guideline; Intensive care medicine; Hematology; Myeloid leukemia; Supportive psychotherapy; Internal medicine; Disease; Family medicine; Pathology","score_opus":0.02674448791496178,"score_gpt":0.3442270041501308,"score_spread":0.31748251623516904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047569349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751028,0.004240569,0.0011674215,0.017811693,0.000047352187,0.0012693376,0.000074618336,0.00009529955,0.00019093738],"genre_scores_gemma":[0.7765596,0.0075957803,0.2053659,0.008621874,0.0008524862,0.00046386378,0.00015260364,0.00010515646,0.00028274168],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978636,0.000045610464,0.00072418025,0.0005499383,0.00031088642,0.00050582166],"domain_scores_gemma":[0.9983014,0.0005133973,0.00029754805,0.00025594924,0.00041106308,0.00022068319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017267151,0.00025595358,0.00089510763,0.000063081985,0.000052384028,0.000008871842,0.00023985504,0.000098718454,0.00003122725],"category_scores_gemma":[0.0010885405,0.00021549298,0.00025022725,0.0006947147,0.00025016797,0.00015431488,0.00010289829,0.00027694725,0.0000066267103],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007287008,0.0009807284,0.2717573,0.006485329,0.0019984357,0.0009359974,0.013581129,0.00131122,0.10801996,0.00026808286,0.11850852,0.4688663],"study_design_scores_gemma":[0.14100036,0.012037528,0.05269722,0.0045400416,0.0020912383,0.0006968114,0.0479677,0.13470826,0.51167357,0.0003567358,0.089608006,0.002622508],"about_ca_topic_score_codex":0.00026998267,"about_ca_topic_score_gemma":0.000073674164,"teacher_disagreement_score":0.46624377,"about_ca_system_score_codex":0.00014173759,"about_ca_system_score_gemma":0.0005606069,"threshold_uncertainty_score":0.87875485},"labels":[],"label_agreement":null},{"id":"W3047591876","doi":"10.1158/1538-7445.pedca19-b16","title":"Abstract B16: <i>MECOM</i> dysregulation is associated with poor outcome in pediatric therapy-related myeloid neoplasms","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid; Medicine; Cancer research; Fusion gene; Biology; Oncology; Genetics; Gene","score_opus":0.08531234762386512,"score_gpt":0.3783933516594323,"score_spread":0.29308100403556714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047591876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667267,0.0012557688,0.0000060120465,0.027363593,0.000065625245,0.0014830938,0.000044812346,0.00013052943,0.002923829],"genre_scores_gemma":[0.993966,0.0013034164,0.000045303696,0.0017330054,0.00035630248,0.00022184153,0.00008912549,0.00011325929,0.002171772],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952092,0.0002818018,0.00062716566,0.00077704166,0.0019365966,0.0011681494],"domain_scores_gemma":[0.9976311,0.00052926637,0.00013353492,0.00043120075,0.00068628346,0.00058862515],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001633808,0.00029495536,0.00059394294,0.00061047444,0.00017907193,0.00008613664,0.00042598197,0.00034633887,0.002110004],"category_scores_gemma":[0.0007223253,0.00023474764,0.00011038274,0.0037219278,0.00022351957,0.00024248725,0.00014658603,0.0023837537,0.0003926829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003932243,0.00041677206,0.9079451,0.00036587132,0.00033572066,0.0008800223,0.0036779973,0.00029446164,0.030925099,0.000051479346,0.03666368,0.014511575],"study_design_scores_gemma":[0.014653089,0.0012238664,0.9645934,0.00020936824,0.00005115332,0.00001840945,0.00042569582,0.0021380035,0.011345954,0.000095557385,0.004741503,0.000503974],"about_ca_topic_score_codex":0.00086402777,"about_ca_topic_score_gemma":0.0002543656,"teacher_disagreement_score":0.056648348,"about_ca_system_score_codex":0.001558442,"about_ca_system_score_gemma":0.0017605758,"threshold_uncertainty_score":0.9999178},"labels":[],"label_agreement":null},{"id":"W3048214116","doi":"10.1016/j.bbmt.2020.08.003","title":"A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes","year":2020,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Health Resources and Services Administration","keywords":"Medicine; Myelodysplastic syndromes; International Prognostic Scoring System; Oncology; Internal medicine; Cohort; Concordance; Transplantation; Hematopoietic stem cell transplantation; Myeloid; NPM1; Bone marrow; Gene","score_opus":0.013694134173402279,"score_gpt":0.23844841430094899,"score_spread":0.2247542801275467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048214116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98876905,0.00020235764,0.009165531,0.0004379071,0.00001570432,0.00080956396,0.00056302256,0.000022082528,0.0000147960045],"genre_scores_gemma":[0.9969767,0.00027662094,0.0018390531,0.00018403954,0.000010678669,0.00012260833,0.0005461844,0.00001786939,0.000026244046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990916,0.000036624184,0.00026614728,0.0002811344,0.00011958862,0.00020489629],"domain_scores_gemma":[0.9996277,0.00009315193,0.0000552367,0.000065431515,0.000056517936,0.000101941805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007763153,0.00015310688,0.00036431744,0.000108954744,0.000025504018,0.0000032915777,0.000044521857,0.00013253576,0.000011290451],"category_scores_gemma":[0.000009039362,0.00011347517,0.000056549812,0.00008438409,0.00011839686,0.00005445066,0.0000039179863,0.00010707455,7.356836e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009101357,0.00023979839,0.9544491,0.0020663105,0.00016552428,0.000023786703,0.0035290136,0.000068982736,0.030164365,0.000054127937,0.0000057132143,0.0001319136],"study_design_scores_gemma":[0.05611611,0.004958685,0.91129386,0.00044811942,0.0024497756,0.00009035723,0.0001705622,0.013325499,0.010599596,0.0001277794,0.000013305848,0.00040631706],"about_ca_topic_score_codex":0.000008397545,"about_ca_topic_score_gemma":0.000012884255,"teacher_disagreement_score":0.047014754,"about_ca_system_score_codex":0.000012558646,"about_ca_system_score_gemma":0.00008465226,"threshold_uncertainty_score":0.46273834},"labels":[],"label_agreement":null},{"id":"W3048622934","doi":"10.1016/j.humpath.2020.08.003","title":"Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome","year":2020,"lang":"en","type":"article","venue":"Human Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada; University of Toronto; University Health Network","funders":"","keywords":"Internal medicine; Medicine; Myeloid leukemia; Preleukemia; Dysplasia; Myelodysplastic syndromes; Cytogenetics; Leukemia; Hematopoietic stem cell transplantation; Oncology; Gastroenterology; Myeloid; NPM1; Transplantation; Bone marrow; Karyotype; Biology; Chromosome","score_opus":0.05021904350207246,"score_gpt":0.343478291107407,"score_spread":0.29325924760533456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048622934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99010104,0.00018516494,0.00016980525,0.005843484,0.0000989555,0.0016387204,0.00007382128,0.0005392335,0.0013497928],"genre_scores_gemma":[0.9880171,0.00021115903,0.005442175,0.0038299775,0.00045674405,0.0002331047,0.000342654,0.00020756664,0.0012595528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950681,0.00042303343,0.0011688571,0.0014766513,0.0006348629,0.0012285473],"domain_scores_gemma":[0.99698746,0.0004690321,0.0003295088,0.00089807215,0.00031401005,0.001001906],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067551865,0.0007371181,0.0018338942,0.00028592287,0.00031330923,0.00005959522,0.00051796186,0.0007401925,0.00069777196],"category_scores_gemma":[0.00040209727,0.00052304426,0.00020647027,0.0007151225,0.0016542972,0.00016228823,0.0002600932,0.0022520346,0.0005073025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008019528,0.00062483555,0.778428,0.0004055241,0.0017588373,0.1048339,0.0043708524,0.000028655133,0.093102664,0.00036965372,0.0023708388,0.0056866985],"study_design_scores_gemma":[0.070168264,0.033894807,0.8432678,0.00047215974,0.0029598451,0.017970355,0.0028814,0.0034178195,0.016706714,0.000040008377,0.00598787,0.0022329863],"about_ca_topic_score_codex":0.000043409815,"about_ca_topic_score_gemma":0.00037001882,"teacher_disagreement_score":0.08686354,"about_ca_system_score_codex":0.00032082497,"about_ca_system_score_gemma":0.00080076203,"threshold_uncertainty_score":0.9997221},"labels":[],"label_agreement":null},{"id":"W3048666609","doi":"10.1002/pbc.28652","title":"Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium","year":2020,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Hematopoietic stem cell transplantation; Pediatrics; Aplastic anemia; Disease; Intensive care medicine; Bone marrow; Internal medicine","score_opus":0.040573727801232626,"score_gpt":0.29299859317893623,"score_spread":0.2524248653777036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048666609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98511094,0.012035689,0.000008353186,0.0006181695,0.00019873807,0.0011526803,0.00079511025,0.000053779222,0.000026528214],"genre_scores_gemma":[0.9234251,0.07447369,0.00011329557,0.00013775242,0.0014143924,0.0002794515,0.000032783755,0.000073081945,0.000050464776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964981,0.00027489781,0.0009132969,0.00074547296,0.0008854876,0.00068274356],"domain_scores_gemma":[0.99579746,0.0018576129,0.000740855,0.0005502408,0.0004542973,0.0005995214],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020614099,0.0004759168,0.0012227313,0.00037411993,0.00011000168,0.000018107485,0.0003541214,0.0001223145,0.00014437217],"category_scores_gemma":[0.0013519161,0.00033646796,0.00021958549,0.0044768527,0.00033467327,0.00007812241,0.00020691256,0.00039998483,0.000016359027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039362372,0.000518038,0.9941668,0.0012748148,0.00022024782,0.000059934082,0.0004323005,0.00007669636,0.000023727347,0.000001307078,0.0019020033,0.0009304907],"study_design_scores_gemma":[0.0037532707,0.002116755,0.98793864,0.000011170937,0.005431183,0.00004060487,0.000045113837,0.00013801288,0.00016776161,7.830517e-7,0.00006949778,0.0002872],"about_ca_topic_score_codex":0.004486635,"about_ca_topic_score_gemma":0.000896324,"teacher_disagreement_score":0.062437996,"about_ca_system_score_codex":0.00019570184,"about_ca_system_score_gemma":0.002024716,"threshold_uncertainty_score":0.99990875},"labels":[],"label_agreement":null},{"id":"W3048782545","doi":"10.1007/s12288-020-01334-4","title":"Allogeneic Hematopoietic Stem Cell Transplantation in Therapy Related Acute Leukemia","year":2020,"lang":"en","type":"review","venue":"Indian Journal of Hematology and Blood Transfusion","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Myeloid leukemia; Hematopoietic stem cell transplantation; Acute leukemia; Leukemia; Oncology; Transplantation; Disease; Minimal residual disease; Immunology; Clinical trial; Stem cell; Internal medicine; Biology","score_opus":0.020703795687054022,"score_gpt":0.29565683358660916,"score_spread":0.27495303789955516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048782545","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10855908,0.88981783,0.000025335801,0.0004586883,0.00011143093,0.00090162276,0.000019176096,0.000017038743,0.000089815025],"genre_scores_gemma":[0.011920903,0.9875382,0.0002031831,0.000088862944,0.00006378031,0.000017912576,0.00004584681,0.000073924006,0.000047354013],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9964874,0.0006362969,0.0016625582,0.0004175312,0.00037178647,0.00042442037],"domain_scores_gemma":[0.99839175,0.0003651205,0.0005850394,0.00020747709,0.00009017435,0.00036045382],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00072170666,0.0004937768,0.0030267604,0.00089748605,0.00008412131,0.000019232215,0.00027843457,0.0010846254,0.00007599552],"category_scores_gemma":[0.000008281551,0.00035606427,0.0005871624,0.00063219917,0.00015960436,0.00011469148,0.000016845797,0.0024332434,0.000020972928],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016511728,0.00044999272,0.0007053743,0.036915496,0.0022339562,0.12627518,0.006991536,9.34898e-7,0.000573061,0.00007676254,0.000091739385,0.8240348],"study_design_scores_gemma":[0.027851965,0.0052045323,0.00022665021,0.05041961,0.012267781,0.7594217,0.00060735655,0.000005451541,0.0057097054,0.00021437893,0.13690807,0.0011627969],"about_ca_topic_score_codex":0.0000067534784,"about_ca_topic_score_gemma":0.000006954404,"teacher_disagreement_score":0.822872,"about_ca_system_score_codex":0.00016347472,"about_ca_system_score_gemma":0.001813078,"threshold_uncertainty_score":0.99988914},"labels":[],"label_agreement":null},{"id":"W3080386471","doi":"10.1158/1538-7445.am2020-6417","title":"Abstract 6417: LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML)","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Isocitrate dehydrogenase; IDH1; Cancer research; Cytarabine; Myeloid; Chemistry; Pharmacology; Mutant; Medicine; Enzyme; Biochemistry","score_opus":0.06601102206621924,"score_gpt":0.40557041916179626,"score_spread":0.33955939709557703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080386471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99218494,0.0011942298,0.00023607304,0.0029955027,0.00003917072,0.0022973279,0.00089391496,0.000024940098,0.00013392816],"genre_scores_gemma":[0.99532074,0.0036932202,0.00038980038,0.00014285762,0.00015887513,0.00015438678,0.0000136385825,0.00008609122,0.000040364477],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99527127,0.00022797617,0.0008993454,0.00089368783,0.0018964342,0.00081130397],"domain_scores_gemma":[0.9965886,0.00091405254,0.00033282948,0.00062239997,0.0010900563,0.00045205565],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018451276,0.00034688582,0.0014475328,0.00052725355,0.00006532356,0.000022780507,0.00046653496,0.0003964886,0.00013060364],"category_scores_gemma":[0.0005352502,0.00029964212,0.00025464114,0.0013461564,0.0012967398,0.00032510728,0.00041198617,0.0017854661,0.0000024720669],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019497367,0.0002604788,0.012114354,0.0019010641,0.00065161916,0.00006970657,0.0035594897,0.00011907828,0.95299095,0.000022263637,0.0007107038,0.008102935],"study_design_scores_gemma":[0.009913638,0.0017163525,0.070050694,0.001174631,0.00008775013,0.000014679207,0.0004395679,0.0064546843,0.9097356,0.00015733264,0.00004343813,0.00021159205],"about_ca_topic_score_codex":0.0036861405,"about_ca_topic_score_gemma":0.000061756946,"teacher_disagreement_score":0.05793634,"about_ca_system_score_codex":0.001467278,"about_ca_system_score_gemma":0.0037630412,"threshold_uncertainty_score":0.9999456},"labels":[],"label_agreement":null},{"id":"W3081113288","doi":"10.1158/1078-0432.ccr-20-1064","title":"Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of <i>HOXA9</i> and <i>MEIS1</i> Expression","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Gilead Sciences","keywords":"Myeloid leukemia; Induction chemotherapy; Medicine; Chemotherapy; Leukemia; Oncology; Induction therapy; Cancer research; Internal medicine; Immunology","score_opus":0.07628086996969083,"score_gpt":0.41372091109930226,"score_spread":0.33744004112961146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081113288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98144305,0.0007232545,0.00005516445,0.01526537,0.000024125318,0.0023109277,0.000034707737,0.000028137847,0.00011526808],"genre_scores_gemma":[0.990707,0.0076476783,0.00030160614,0.00056625245,0.00011339194,0.00036444096,0.0000242954,0.000047101163,0.00022824104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953619,0.0015039397,0.00077905797,0.00086069515,0.0009337056,0.00056068256],"domain_scores_gemma":[0.9971631,0.0014300197,0.00016232162,0.0003306423,0.00048169662,0.00043222043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004208655,0.00021221452,0.00071234687,0.00033538122,0.00006825365,0.000030045427,0.00019379087,0.00034953555,0.000048858445],"category_scores_gemma":[0.0015701844,0.0001697841,0.00004377219,0.001485321,0.0010743078,0.00020659599,0.00019179864,0.002003694,0.000002970295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21372725,0.0006765107,0.550188,0.0006540188,0.00015310671,0.0002644396,0.0049076686,0.000049200677,0.20073888,0.000024043156,0.0036699087,0.02494697],"study_design_scores_gemma":[0.035380665,0.012347477,0.8753924,0.0015103095,0.000054818374,0.000027143236,0.0012280168,0.0031391587,0.06796302,0.00011558097,0.0025371455,0.0003042876],"about_ca_topic_score_codex":0.00056685344,"about_ca_topic_score_gemma":0.00010448123,"teacher_disagreement_score":0.32520437,"about_ca_system_score_codex":0.00072943565,"about_ca_system_score_gemma":0.0016331727,"threshold_uncertainty_score":0.8705165},"labels":[],"label_agreement":null},{"id":"W3081404079","doi":"10.1182/blood.v130.suppl_1.2186.2186","title":"Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-Mut and FLT3-Wt Acute Myeloid Leukemia: A Multi-Country Medical Chart Study","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Internal medicine; Health care; Oncology; Family medicine; Pediatrics","score_opus":0.029213906063698714,"score_gpt":0.3212941490099947,"score_spread":0.292080242946296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081404079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963729,0.00021190918,0.000010885755,0.0012980906,0.000030654894,0.0018741032,0.00007114651,0.00004360004,0.000086703185],"genre_scores_gemma":[0.9985304,0.00046981336,0.000111189904,0.00020131844,0.00010938514,0.00012867266,0.00015344543,0.000049230188,0.00024655228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761605,0.00012902867,0.00032602082,0.00063335424,0.00081946055,0.00047608447],"domain_scores_gemma":[0.9984957,0.000059113925,0.00013899381,0.000715528,0.0001174487,0.00047324738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002887025,0.00029185016,0.0005121064,0.00016692869,0.00032353165,0.00008602081,0.0001830482,0.00022319648,0.000021600363],"category_scores_gemma":[0.00018390923,0.00020905519,0.000024963287,0.000101514066,0.00016674296,0.00015237457,0.00022474123,0.00041838363,0.0000057130046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006266715,0.0017121583,0.98304343,0.00010823451,0.00024366628,0.0006582039,0.0017673491,1.2292041e-7,0.000014168498,0.0000035296025,0.000028302848,0.01179413],"study_design_scores_gemma":[0.0440348,0.0033444627,0.95046943,0.0002644154,0.00024117016,0.00009240425,0.0006894441,0.00027996226,0.00012578223,0.0000011083043,0.00027896452,0.00017803318],"about_ca_topic_score_codex":0.002483435,"about_ca_topic_score_gemma":0.0031996884,"teacher_disagreement_score":0.043408133,"about_ca_system_score_codex":0.00042084907,"about_ca_system_score_gemma":0.0004915575,"threshold_uncertainty_score":0.8525023},"labels":[],"label_agreement":null},{"id":"W3081859925","doi":"10.1182/blood.v130.suppl_1.3734.3734","title":"A Systematic Review and Meta-Analysis of the Effect of Iron Chelation Therapy on Survival in Patients with Lower Risk Myelodysplastic Syndrome","year":2017,"lang":"en","type":"review","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Hazard ratio; Internal medicine; Meta-analysis; Cochrane Library; Randomized controlled trial; Systematic review; Observational study; Odds ratio; Clinical trial; International Prognostic Scoring System; MEDLINE; Intensive care medicine; Confidence interval; Bone marrow","score_opus":0.04061473739776392,"score_gpt":0.3321727445137441,"score_spread":0.29155800711598023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081859925","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015929135,0.97661394,6.9020757e-7,0.000010584151,0.000016485927,0.007235551,0.00012875757,0.000004879517,0.000059990824],"genre_scores_gemma":[0.014983638,0.98437095,0.00000672199,0.00000763477,0.000004873897,0.00036419457,0.00006587679,0.000044106564,0.00015199087],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99583,0.0018156685,0.0009308728,0.0003863476,0.0008471377,0.0001899472],"domain_scores_gemma":[0.9953067,0.0011521054,0.0018527199,0.0015028572,0.00012356932,0.000062104096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020358588,0.0004257321,0.009968987,0.00043402932,0.00004200326,0.000010971654,0.0003403694,0.0001918365,0.00005111316],"category_scores_gemma":[0.0013124841,0.00017012346,0.001431367,0.000788327,0.00011400508,0.00003584349,0.00007201585,0.0005187171,0.000005606358],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082367274,0.0002483104,0.002501608,0.8317487,0.16457564,0.000012136377,0.000013509726,0.0000010151348,3.625652e-8,0.0000013616495,0.0000024293192,0.0008128641],"study_design_scores_gemma":[0.0020407431,0.0015927099,0.0076023624,0.100981526,0.8875466,0.000010650822,3.7631227e-7,0.000002929457,6.8976044e-7,1.9494072e-7,0.00008964576,0.00013158371],"about_ca_topic_score_codex":0.000045328223,"about_ca_topic_score_gemma":0.0000108531885,"teacher_disagreement_score":0.7307672,"about_ca_system_score_codex":0.00008795363,"about_ca_system_score_gemma":0.00014610897,"threshold_uncertainty_score":0.69374335},"labels":[],"label_agreement":null},{"id":"W3081883385","doi":"10.1101/2020.08.31.273631","title":"A JAK/STAT-Mediated Inflammatory Signaling Cascade Drives Oncogenesis In AF10-Rearranged AML","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Memorial Sloan-Kettering Cancer Center; Leukemia and Lymphoma Society; V Foundation for Cancer Research; Rally Foundation; National Cancer Institute; National Institutes of Health; Children's Cancer Research Fund","keywords":"Cancer research; Fusion protein; Carcinogenesis; JAK-STAT signaling pathway; PIM1; Fusion gene; Biology; Signal transduction; Computational biology; Gene; Genetics; Tyrosine kinase; Phosphorylation","score_opus":0.02212064675998044,"score_gpt":0.2570370829229341,"score_spread":0.23491643616295366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081883385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99105936,0.0021807149,0.0002556847,0.0022150988,0.0005452267,0.0024957927,0.00033224252,0.00087818573,0.000037686605],"genre_scores_gemma":[0.99152637,0.0009013621,0.0043392936,0.00095830666,0.0011595817,0.0006384322,0.0000059088625,0.00045603557,0.000014694659],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9930551,0.00055977976,0.0014363375,0.0020569274,0.0013773189,0.0015145167],"domain_scores_gemma":[0.9950246,0.0004165401,0.0006089886,0.0018897534,0.00078077696,0.0012793286],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0013360138,0.0011638405,0.0018498487,0.0012759697,0.0001514273,0.0002146983,0.0009126514,0.0014901763,0.00018030497],"category_scores_gemma":[0.0020647475,0.0012523055,0.00043289352,0.0017799784,0.00036624935,0.00023043745,0.0011749604,0.0037326121,0.00050379214],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005036286,0.0002116976,0.03596147,0.0017912714,0.0005286342,0.0035640057,0.0001914634,0.00007853564,0.9562753,0.000045034903,0.00084213546,0.0000068467257],"study_design_scores_gemma":[0.0065254983,0.00028380047,0.2861258,0.003078217,0.00055400573,5.066792e-7,0.00007955744,0.0030334985,0.68453264,0.000003210063,0.013536607,0.0022466315],"about_ca_topic_score_codex":0.00032953115,"about_ca_topic_score_gemma":0.000025525902,"teacher_disagreement_score":0.2717426,"about_ca_system_score_codex":0.0023447955,"about_ca_system_score_gemma":0.0052146288,"threshold_uncertainty_score":0.9998061},"labels":[],"label_agreement":null},{"id":"W3082442646","doi":"10.1007/s40265-020-01389-7","title":"Decitabine/Cedazuridine: First Approval","year":2020,"lang":"en","type":"review","venue":"Drugs","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Decitabine; Medicine; Myelodysplastic syndromes; Cytidine deaminase; International Prognostic Scoring System; Internal medicine; Chronic myelomonocytic leukemia; Oncology; Pharmacology; Bone marrow; Immunology","score_opus":0.048028227437345174,"score_gpt":0.3567413463387515,"score_spread":0.3087131189014063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082442646","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000021984379,0.9730286,0.000025949063,0.0016683688,0.00024110937,0.0017057848,0.00007469875,0.00022283169,0.02303046],"genre_scores_gemma":[0.000003099881,0.9893153,0.00086116,0.00031912417,0.0018650788,0.00027715287,0.00057143567,0.0002105552,0.006577109],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969661,0.000107435204,0.00069505884,0.000828843,0.0007579246,0.0006445868],"domain_scores_gemma":[0.9977848,0.00039383612,0.00020287572,0.0009068347,0.00011774947,0.00059393345],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033816925,0.0006216041,0.0027993917,0.00030807182,0.00010149325,0.000050909395,0.000565976,0.00050397246,0.0005829227],"category_scores_gemma":[0.00059641374,0.0004665825,0.0009438785,0.0009869295,0.00012657393,0.000057546215,0.00040680057,0.0016642517,0.0055934605],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024721376,0.000043150594,0.0000011402109,0.027588436,0.00029805244,0.00054396415,0.000110662164,3.8263543e-8,2.2488287e-7,0.00016417481,0.10318499,0.86804044],"study_design_scores_gemma":[0.0007228301,0.00010737796,9.84441e-7,0.007281247,0.0010111252,0.0004657517,0.000032435928,0.000030718893,0.000002085284,0.000009655286,0.98996234,0.00037344042],"about_ca_topic_score_codex":0.000028058781,"about_ca_topic_score_gemma":0.0000013732746,"teacher_disagreement_score":0.88677734,"about_ca_system_score_codex":0.0009185672,"about_ca_system_score_gemma":0.002285727,"threshold_uncertainty_score":0.99977857},"labels":[],"label_agreement":null},{"id":"W3083459928","doi":"10.1182/blood.v130.suppl_1.120.120","title":"Functional and Biological Implications of CUX1 Mutations and Deletions in Myeloid Neoplasms","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Biology; Myeloid; Genetics; Mutation; Cancer research; Medicine; Gene","score_opus":0.04673571938378319,"score_gpt":0.31604310472582625,"score_spread":0.26930738534204307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083459928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923974,0.00015533394,0.00014601201,0.004455142,0.00001256155,0.00020770896,0.00003324068,0.0000128816955,0.0025797032],"genre_scores_gemma":[0.99764633,0.00021659247,0.0017500015,0.00006354738,0.00004214768,0.000047981106,0.000038469243,0.0000056267654,0.00018928749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994673,0.000018748786,0.00014346784,0.00016693649,0.00007790585,0.00012560502],"domain_scores_gemma":[0.99940085,0.00012995434,0.000051575746,0.00025047731,0.00007812175,0.00008901528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012518876,0.000060072416,0.00013591468,0.000099833844,0.0001846128,0.000018170676,0.000059764854,0.000072918294,0.000054389497],"category_scores_gemma":[0.00041430033,0.00004974113,0.000020965117,0.00006664818,0.00032406364,0.000058998157,0.000082698265,0.00014541435,0.000007349048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039410363,0.00032363334,0.9504415,0.000025864445,0.000049605664,0.000010186847,0.00011069597,0.0000013483967,0.039557748,0.0057501267,0.0003093133,0.0033805948],"study_design_scores_gemma":[0.0022238833,0.00011367996,0.9942959,0.00001799949,0.000037094254,0.00017138818,0.00007152686,0.000050049883,0.0013291687,0.0012653036,0.00037831257,0.000045672234],"about_ca_topic_score_codex":0.000091136535,"about_ca_topic_score_gemma":0.00006817183,"teacher_disagreement_score":0.04385445,"about_ca_system_score_codex":0.000017582413,"about_ca_system_score_gemma":0.00011163152,"threshold_uncertainty_score":0.20283844},"labels":[],"label_agreement":null},{"id":"W3086349886","doi":"","title":"Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study.","year":2020,"lang":"en","type":"article","venue":"PubMed","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Bristol-Myers Squibb (Canada); Ministry of Health; University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Myeloid leukemia; Internal medicine; Refractory (planetary science); Confidence interval; Population; Cohort; Cancer registry; Relative risk; Cancer","score_opus":0.03123465722504168,"score_gpt":0.283335003185006,"score_spread":0.25210034595996433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086349886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923564,0.000008609299,0.000024761406,0.0021251193,0.00007107578,0.003998699,0.00006560299,0.00016163745,0.0011880817],"genre_scores_gemma":[0.9942096,0.000007859099,0.00055130286,0.0013063954,0.0000904927,0.0010284955,0.00021990447,0.0000827308,0.0025032535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698365,0.00014161869,0.0006141227,0.0005372644,0.001147778,0.00057559105],"domain_scores_gemma":[0.9979056,0.00032374583,0.000289834,0.00062902586,0.00032248686,0.0005292869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032041236,0.00030001428,0.00081433536,0.00031246882,0.00008039423,0.0000203194,0.00027340994,0.000111840964,0.00012738173],"category_scores_gemma":[0.00071021676,0.00019526877,0.000116719355,0.0010795443,0.000083968625,0.00016012834,0.000099463155,0.0005478707,0.000019219564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064457366,0.0005158899,0.98137915,0.000106984226,0.00053755665,0.00011761341,0.00027786836,0.000021286283,0.000011656881,0.000007276967,0.0015563954,0.009022566],"study_design_scores_gemma":[0.012851788,0.0009779533,0.984421,0.000017415474,0.0003673723,6.796986e-7,0.00010311223,0.00012865549,0.0001262671,0.0000025271706,0.00079743634,0.00020576325],"about_ca_topic_score_codex":0.00090413797,"about_ca_topic_score_gemma":0.0003512621,"teacher_disagreement_score":0.008816802,"about_ca_system_score_codex":0.0011110731,"about_ca_system_score_gemma":0.0006470825,"threshold_uncertainty_score":0.796283},"labels":[],"label_agreement":null},{"id":"W3087474451","doi":"10.1200/op.20.00446","title":"Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast–Count Acute Myeloid Leukemia","year":2021,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Interquartile range; Myelodysplastic syndromes; Azacitidine; Internal medicine; Cohort; Population; Myeloid leukemia; Cancer registry; Disease burden; Cost effectiveness; Emergency medicine; Pediatrics; Cancer; Disease; Environmental health","score_opus":0.016232937907891366,"score_gpt":0.32401100230008484,"score_spread":0.30777806439219346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087474451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96651876,0.000120640056,0.000036176152,0.0038008532,0.0003680742,0.0013165962,0.00012789949,0.000081223,0.027629776],"genre_scores_gemma":[0.97883767,0.0022256349,0.007980692,0.00083832914,0.00020054058,0.00024579137,0.0004084072,0.00011850888,0.009144421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995379,0.00097296835,0.0008992443,0.00090908445,0.0009482136,0.00089149736],"domain_scores_gemma":[0.9928579,0.0038371948,0.0007765852,0.0009758957,0.0011326441,0.0004197826],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007547203,0.00050164136,0.0013513231,0.0005675768,0.00013338422,0.000030574894,0.0002452172,0.00039329726,0.0005499553],"category_scores_gemma":[0.0014071508,0.00040439857,0.00014226716,0.0015821418,0.00034209713,0.0005172605,0.0002199638,0.0012661709,0.00022095804],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.059860907,0.018446492,0.78390473,0.00062031543,0.009172757,0.03877934,0.0020836627,0.0006789136,0.008182977,0.002008168,0.012929256,0.06333249],"study_design_scores_gemma":[0.039983146,0.015156152,0.83400965,0.00053891086,0.0031215507,0.0009871006,0.0006293748,0.00044283888,0.0045202863,0.000031382744,0.0999254,0.0006541954],"about_ca_topic_score_codex":0.0028437246,"about_ca_topic_score_gemma":0.0020854517,"teacher_disagreement_score":0.086996146,"about_ca_system_score_codex":0.014214789,"about_ca_system_score_gemma":0.0062374836,"threshold_uncertainty_score":0.9998408},"labels":[],"label_agreement":null},{"id":"W3088246524","doi":"10.1080/10428194.2020.1817445","title":"Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review","year":2020,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Pfizer","keywords":"Medicine; Cytarabine; Myeloid leukemia; Concomitant; Oncology; Adverse effect; Internal medicine; Intensive care medicine","score_opus":0.01785343812651554,"score_gpt":0.278385460990264,"score_spread":0.2605320228637485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088246524","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0354603,0.9522109,0.0000824535,0.00012857768,0.00013825661,0.009733041,0.00028132912,0.0004946391,0.0014704894],"genre_scores_gemma":[0.0015064256,0.98857677,0.0020624446,0.001079328,0.00034769112,0.0017109965,0.0020481555,0.0007393002,0.0019288601],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9889154,0.0005581259,0.0026852377,0.0034163613,0.0023855881,0.0020393012],"domain_scores_gemma":[0.99344164,0.0003700532,0.0017934785,0.0019368969,0.00079184375,0.0016661076],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005499121,0.0031265847,0.007993116,0.0009481076,0.00049097085,0.00020621126,0.0009770632,0.0014389325,0.000119182725],"category_scores_gemma":[0.000071647766,0.002213787,0.0008336156,0.0033769272,0.00095850555,0.0005935442,0.0008197059,0.0009186146,0.00009523748],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.003158019,0.00028355178,0.00032310584,0.1172422,0.0061920206,0.0029824947,0.00028166038,0.0000033430222,0.000014876948,0.00007331158,0.0056508873,0.8637945],"study_design_scores_gemma":[0.052570254,0.0033898852,0.006614553,0.19257669,0.018688112,0.0074035237,0.0001731271,0.00075278955,0.00013258512,0.0000064437227,0.7141857,0.0035062996],"about_ca_topic_score_codex":0.0010841736,"about_ca_topic_score_gemma":0.000034264925,"teacher_disagreement_score":0.8602882,"about_ca_system_score_codex":0.029476235,"about_ca_system_score_gemma":0.0146861365,"threshold_uncertainty_score":0.9998574},"labels":[],"label_agreement":null},{"id":"W3088881175","doi":"10.1002/ccr3.3316","title":"Pure erythroid leukemia","year":2020,"lang":"en","type":"article","venue":"Clinical Case Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Leukemia; Acute myeloblastic leukemia; Lineage (genetic); Bone marrow; Cancer research; Immunology; Genetics; Biology; Gene","score_opus":0.10473231315479498,"score_gpt":0.40756291022853847,"score_spread":0.3028305970737435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088881175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97420293,0.0002906061,0.00014092482,0.012893026,0.00033960486,0.00055963016,0.0000050475737,0.00024726865,0.011320957],"genre_scores_gemma":[0.9865359,0.00012382494,0.0010433902,0.0085181305,0.0018601129,0.00001828565,0.000034867382,0.00005253642,0.0018129172],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9969758,0.00012009355,0.0012524432,0.0007515474,0.00048026015,0.00041988204],"domain_scores_gemma":[0.99707747,0.00038751346,0.00024384189,0.0008020474,0.00022790261,0.0012612088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011113458,0.00019475071,0.0006566883,0.000043860182,0.000084671294,0.000027510077,0.000059954797,0.00033439347,0.0008366863],"category_scores_gemma":[0.0068343007,0.00015865616,0.00038393628,0.00034918758,0.00026202964,0.000079268546,0.00020990905,0.0012478764,0.0005446996],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019541556,0.0000718298,0.019590791,0.000103244565,0.00008501875,0.8450757,0.00008165437,0.0000026397163,0.00025557965,0.000022512739,0.123671405,0.010844154],"study_design_scores_gemma":[0.002078008,0.0012481182,0.0056135682,0.00007291398,0.00021370419,0.6763577,0.00020927175,0.0008998815,0.00084586925,0.00019556972,0.31194338,0.00032202073],"about_ca_topic_score_codex":0.00003156311,"about_ca_topic_score_gemma":0.0000039378933,"teacher_disagreement_score":0.18827197,"about_ca_system_score_codex":0.00026104646,"about_ca_system_score_gemma":0.0014994694,"threshold_uncertainty_score":0.9161128},"labels":[],"label_agreement":null},{"id":"W3089665196","doi":"10.1182/bloodadvances.2020002621","title":"Comparison of outcomes of HCT in blast phase of <i>BCR-ABL1</i>− MPN with de novo AML and with AML following MDS","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Pharmaceuticals; National Institute of Allergy and Infectious Diseases; Daiichi Sankyo Europe; National Cancer Institute; Office of Naval Research; Legend Biotech; Kite Pharma; Sanofi Genzyme; Takeda Oncology; Health Resources and Services Administration; bluebird bio; Kiadis Pharma; Swedish Orphan Biovitrum; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Atara Biotherapeutics; Actinium Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; Medical College of Wisconsin; Janssen Biotech; HistoGenetics; U.S. Department of Defense; Sanofi; GlaxoSmithKline; U.S. Navy; Celgene; CSL Behring; Bristol-Myers Squibb; Terumo BCT; AstraZeneca; Astellas Pharma US; Biomedical Advanced Research and Development Authority; Amgen; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Medac; Jazz Pharmaceuticals; Be The Match Foundation","keywords":"Hazard ratio; Internal medicine; Medicine; Myeloid leukemia; Oncology; Myelodysplastic syndromes; Proportional hazards model; Transplantation; Confidence interval; Myeloid; Leukemia; International Prognostic Scoring System; Gastroenterology; Bone marrow","score_opus":0.029240018982305417,"score_gpt":0.36560192174549944,"score_spread":0.336361902763194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089665196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961506,0.001962605,0.00034073234,0.0005552863,0.000010538182,0.00036470842,0.0000212078,0.000016946668,0.0005773412],"genre_scores_gemma":[0.99003935,0.00011274141,0.009634375,0.0001108658,0.000022580867,0.000011871742,0.000007404228,0.000023807394,0.000036977213],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985763,0.000043609925,0.00041886666,0.0002521021,0.00044038333,0.0002687757],"domain_scores_gemma":[0.99914974,0.00020367192,0.0002093769,0.00020019463,0.0000884669,0.00014852064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016239738,0.00016951218,0.00089766923,0.00012250648,0.000020369936,0.0000045438815,0.00013358249,0.000049515693,0.000011743515],"category_scores_gemma":[0.0001650355,0.000116081195,0.000056849345,0.00046088302,0.0002418143,0.00015156987,0.000056746336,0.00023170628,4.7471337e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015764494,0.0006800801,0.93948233,0.0006386514,0.0002728332,0.00012171023,0.0016834134,0.0001461327,0.05300819,0.000027185248,0.000022165244,0.0023408432],"study_design_scores_gemma":[0.05188804,0.013258269,0.14526427,0.0014812698,0.0008840517,0.00008673488,0.008051909,0.001320205,0.7759442,0.000029469735,0.0013761972,0.0004153916],"about_ca_topic_score_codex":0.00009656817,"about_ca_topic_score_gemma":0.00015835112,"teacher_disagreement_score":0.79421806,"about_ca_system_score_codex":0.000025311767,"about_ca_system_score_gemma":0.00024299102,"threshold_uncertainty_score":0.4733654},"labels":[],"label_agreement":null},{"id":"W3090440918","doi":"10.1080/23723556.2020.1815503","title":"Mitochondria regulate AML differentiation independent of oxidative phosphorylation and metabolism","year":2020,"lang":"en","type":"article","venue":"Molecular & Cellular Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Myeloid leukemia; Oxidative phosphorylation; Progenitor cell; Hematologic malignancy; Cancer research; Mitochondrion; Leukemia; Stem cell; Malignancy; Myeloid; Oxidative metabolism; Biology; Medicine; Metabolism; Internal medicine; Cell biology; Immunology; Biochemistry","score_opus":0.015991553107593735,"score_gpt":0.27421105426047454,"score_spread":0.2582195011528808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090440918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9601192,0.0016542053,0.032769825,0.0036816401,0.00009654018,0.0007008188,0.000010018889,0.000037423597,0.0009303522],"genre_scores_gemma":[0.9926632,0.00013277655,0.0060197385,0.0006774284,0.000091667134,0.00002743784,0.0001592545,0.000036499834,0.0001919684],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99827653,0.00025490392,0.00038066885,0.00041772256,0.00040389915,0.00026624784],"domain_scores_gemma":[0.9990195,0.000056523426,0.00020106786,0.00026232275,0.0002103084,0.00025028415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019555981,0.0001827071,0.0005325197,0.0001308976,0.000044183696,0.000011509137,0.000116837895,0.00026374098,0.00020975096],"category_scores_gemma":[0.00021239945,0.00017209158,0.0001094498,0.00027784394,0.00015050801,0.00006329568,0.000161529,0.00037991808,0.000038164217],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046952633,0.00009515747,0.0006233814,0.00007585888,0.00019837868,0.0002091572,0.0008793721,0.000025439898,0.9913299,0.0009470041,0.00031852134,0.004828317],"study_design_scores_gemma":[0.0037545369,0.0005784888,0.011980498,0.000018090774,0.0002964909,0.0000293641,0.00016264617,0.0037703607,0.97071755,0.00036372774,0.008182234,0.00014600866],"about_ca_topic_score_codex":0.000046182355,"about_ca_topic_score_gemma":0.0000036311678,"teacher_disagreement_score":0.03254405,"about_ca_system_score_codex":0.00017249899,"about_ca_system_score_gemma":0.00024679262,"threshold_uncertainty_score":0.70176905},"labels":[],"label_agreement":null},{"id":"W3091044444","doi":"10.1016/j.bbmt.2020.09.026","title":"Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study","year":2020,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; Health Resources and Services Administration","keywords":"Medicine; Myelodysplastic syndromes; Hazard ratio; Internal medicine; Transplantation; Cohort; International Prognostic Scoring System; Oncology; Lower risk; Hematopoietic stem cell transplantation; Leukemia; Confidence interval; Surgery; Bone marrow","score_opus":0.028910315712245494,"score_gpt":0.2975582630253778,"score_spread":0.2686479473131323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091044444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9588046,0.0002484165,0.018558178,0.0012915086,0.00010142156,0.005507526,0.015435402,0.000047902497,0.000005054559],"genre_scores_gemma":[0.9860032,0.006566878,0.0005386952,0.0002051112,0.00018743594,0.0012640968,0.0051047686,0.000080061494,0.000049742903],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9971428,0.00026170362,0.000566853,0.0009096968,0.0005749378,0.0005439988],"domain_scores_gemma":[0.9976265,0.0010952911,0.00012055765,0.0002039185,0.00041920017,0.0005345365],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007720965,0.00037630316,0.000527689,0.00034070198,0.00034920537,0.000112804984,0.00019219851,0.000120594996,0.000010482986],"category_scores_gemma":[0.0001410488,0.00032021047,0.00009278449,0.00019141237,0.00029250965,0.00024019138,0.000014861591,0.00034892702,6.273494e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62357295,0.0016241288,0.23708989,0.0046831677,0.00422993,0.0027849863,0.050433993,0.00054221094,0.06920889,0.00036333033,0.0000483484,0.005418183],"study_design_scores_gemma":[0.18302882,0.009274886,0.76633877,0.00084784674,0.0026411775,0.00014386595,0.0026959174,0.017453913,0.016035467,0.0005039136,0.00010453728,0.0009309105],"about_ca_topic_score_codex":0.000112991795,"about_ca_topic_score_gemma":0.00021479647,"teacher_disagreement_score":0.52924883,"about_ca_system_score_codex":0.00010214961,"about_ca_system_score_gemma":0.00034583997,"threshold_uncertainty_score":0.999925},"labels":[],"label_agreement":null},{"id":"W3092073603","doi":"10.1182/bloodadvances.2020002904","title":"Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health; Instituto de Salud Carlos III; Associazione Italiana per la Ricerca sul Cancro; Deutsche Forschungsgemeinschaft; Agios Pharmaceuticals","keywords":"Midostaurin; Medicine; Internal medicine; Myeloid leukemia; Oncology; NPM1; Context (archaeology); Biology","score_opus":0.01202841802879141,"score_gpt":0.2649148928057713,"score_spread":0.2528864747769799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092073603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926261,0.0017567702,0.00006251741,0.0041671842,0.00003099774,0.0010736448,0.000082221166,0.000038734946,0.00016183511],"genre_scores_gemma":[0.9950206,0.0005365556,0.002617832,0.0010757996,0.00027522258,0.00011849546,0.00023683284,0.000029648681,0.000088989524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833304,0.00011788226,0.0003270604,0.00044057638,0.0004992865,0.00028214368],"domain_scores_gemma":[0.99895173,0.00037429723,0.00011439249,0.00028139626,0.000103187485,0.00017500426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012975982,0.00019499545,0.00041358074,0.00007964672,0.000107683016,0.000051587496,0.00018342066,0.00006712433,0.00006837814],"category_scores_gemma":[0.00036117242,0.00011920517,0.00005995381,0.00066140556,0.0001738805,0.0002565419,0.000080297206,0.00038521906,0.000017632754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07745413,0.0005716994,0.8757247,0.000111980255,0.0020582487,0.00047857288,0.0054180017,0.00019739837,0.0014463754,0.00007713714,0.00076653785,0.035695232],"study_design_scores_gemma":[0.35872886,0.0055771326,0.6058498,0.00030602972,0.0033767598,0.000018341132,0.0035822475,0.0020282774,0.006422236,0.00047673483,0.012786961,0.0008465914],"about_ca_topic_score_codex":0.00023191326,"about_ca_topic_score_gemma":0.00026709496,"teacher_disagreement_score":0.28127474,"about_ca_system_score_codex":0.00010525378,"about_ca_system_score_gemma":0.000357807,"threshold_uncertainty_score":0.48610458},"labels":[],"label_agreement":null},{"id":"W3092192329","doi":"10.1101/2020.10.09.334151","title":"<sup>225</sup> Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Venetoclax; Myeloid leukemia; Cytarabine; Medicine; Hypomethylating agent; Cancer research; Leukemia; CD33; Pharmacology; Oncology; Immunology; Internal medicine; Chemistry; Biology; Chronic lymphocytic leukemia; Stem cell; DNA methylation","score_opus":0.020815541613168242,"score_gpt":0.2708588750344805,"score_spread":0.25004333342131224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092192329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849852,0.00286884,0.0016534259,0.00335156,0.0006785086,0.004664491,0.00067552907,0.0010115611,0.000110915],"genre_scores_gemma":[0.96227676,0.0018836571,0.0306265,0.0018160339,0.0018584327,0.0007516026,0.000014707942,0.0006246687,0.0001476487],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9900072,0.0005297375,0.0019671193,0.0033794448,0.0018657807,0.0022507242],"domain_scores_gemma":[0.99315363,0.00026977927,0.0006898694,0.0029186702,0.0012998813,0.0016681673],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0018274011,0.001614654,0.0025503587,0.0012739643,0.00031678553,0.00036925444,0.0016523817,0.0015949665,0.00009008028],"category_scores_gemma":[0.0017936504,0.0017647147,0.00055468996,0.0029532914,0.0002916448,0.00052110286,0.0024270597,0.0045782826,0.00047607606],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0015373147,0.00015764874,0.0038989773,0.0024417555,0.0008312734,0.0025037876,0.00022280078,0.004499785,0.9649088,0.00034201896,0.018651525,0.0000043067225],"study_design_scores_gemma":[0.016864255,0.0010438949,0.039867986,0.017745744,0.002034833,0.0000013879411,0.00020651659,0.07600283,0.77083856,0.00006239952,0.067161374,0.008170225],"about_ca_topic_score_codex":0.00029349895,"about_ca_topic_score_gemma":0.00001585089,"teacher_disagreement_score":0.19407025,"about_ca_system_score_codex":0.009755691,"about_ca_system_score_gemma":0.009747276,"threshold_uncertainty_score":0.9997012},"labels":[],"label_agreement":null},{"id":"W3092483516","doi":"10.1016/j.hemonc.2020.09.001","title":"Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation","year":2020,"lang":"en","type":"article","venue":"Hematology/Oncology and Stem Cell Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myeloid leukemia; Medicine; Stem cell; Hematopoietic stem cell transplantation; Transplantation; Haematopoiesis; Oncology; Leukemia; Immunology; Internal medicine; Biology; Genetics","score_opus":0.015094147521941147,"score_gpt":0.2650793779736378,"score_spread":0.24998523045169663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092483516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940323,0.0019455508,0.0014769736,0.0010538354,0.00003361359,0.0008937207,0.00003362341,0.000056227225,0.00047411866],"genre_scores_gemma":[0.9905132,0.0070367367,0.0009541845,0.0011557724,0.000014256298,0.000056886314,0.00007284675,0.00004577046,0.00015035963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975274,0.0003122962,0.00066327496,0.000689056,0.00033055796,0.00047737692],"domain_scores_gemma":[0.9982054,0.0005643332,0.00035375258,0.00032094785,0.00022559364,0.00032994762],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016870604,0.0003978258,0.001473294,0.0003008087,0.00015310067,0.000015817079,0.00018711135,0.0004339606,0.0000510328],"category_scores_gemma":[0.0000039480215,0.00029418193,0.0001547729,0.0006174103,0.00039044628,0.00008900559,0.000054106287,0.0003796748,0.00000894562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037087891,0.0002542273,0.97693974,0.0010273255,0.002427787,0.0003710521,0.0050925566,0.000048920112,0.007187066,0.00018257942,0.000045717432,0.0027142689],"study_design_scores_gemma":[0.05740026,0.012325057,0.65785044,0.00019477082,0.008489099,0.00087741006,0.006355482,0.001563465,0.25306997,0.00013010207,0.00035165367,0.0013922633],"about_ca_topic_score_codex":0.000022311906,"about_ca_topic_score_gemma":0.00006321082,"teacher_disagreement_score":0.31908923,"about_ca_system_score_codex":0.0001344494,"about_ca_system_score_gemma":0.0004736626,"threshold_uncertainty_score":0.999951},"labels":[],"label_agreement":null},{"id":"W3093370683","doi":"10.1038/s41586-020-2819-2","title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes","year":2020,"lang":"en","type":"article","venue":"Nature","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":744,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Human Genome Research Institute; National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Aging","keywords":"Biology; Germline; Somatic cell; Genetics; Haematopoiesis; Germline mutation; Genome-wide association study; Stem cell; Genome; Gene; Mutation; Single-nucleotide polymorphism; Genotype","score_opus":0.02745570677313671,"score_gpt":0.3117134168020279,"score_spread":0.2842577100288912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093370683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96362144,0.005815078,0.0000057663224,0.028115757,0.00004670109,0.0002996656,0.000044716588,0.00004759099,0.0020032825],"genre_scores_gemma":[0.9927629,0.0001332495,0.001008912,0.004968895,0.00018894892,0.000009367553,0.00005499661,0.000025091724,0.0008476385],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887884,0.000042151565,0.00021466672,0.00022461142,0.00041034626,0.00022936861],"domain_scores_gemma":[0.99939644,0.00008054145,0.000046270743,0.0001969668,0.00013237218,0.00014740524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011872223,0.000115299925,0.00035052045,0.00013621956,0.000018810375,0.000007537456,0.00015758444,0.00071771414,0.000308987],"category_scores_gemma":[0.00044674703,0.000095996096,0.0000702663,0.0006849458,0.00007858576,0.000055227287,0.000098316326,0.0021884828,0.000081131744],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024004404,0.00046539961,0.36627227,0.0024347983,0.00046400673,0.0029132708,0.007650571,0.00004128122,0.3899975,0.0015472118,0.2133379,0.012475353],"study_design_scores_gemma":[0.008818612,0.00077553565,0.3981519,0.0004617001,0.00012725453,0.00018067582,0.0020976313,0.0015742684,0.11131503,0.000289072,0.47567,0.0005383086],"about_ca_topic_score_codex":0.0000456792,"about_ca_topic_score_gemma":0.000027468837,"teacher_disagreement_score":0.27868247,"about_ca_system_score_codex":0.00011249197,"about_ca_system_score_gemma":0.00027865556,"threshold_uncertainty_score":0.95079905},"labels":[],"label_agreement":null},{"id":"W3093553460","doi":"10.1182/bloodadvances.2020001742","title":"Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child, Adolescent and Family Mental Health","funders":"Universität Wien; Medizinische Universität Wien; Austrian Science Fund; Celgene","keywords":"CD38; CD34; Stem cell; Myeloid leukemia; Bone marrow; Molecular biology; Antigen; Biology; Leukemia; CD33; Myeloid; Cancer research; Immunology; Cell biology","score_opus":0.016458255240048153,"score_gpt":0.2756455365045918,"score_spread":0.2591872812645436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093553460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875804,0.0103652105,0.0000710361,0.00096103776,0.00002560691,0.00087230036,0.000028353992,0.000023361172,0.000072681],"genre_scores_gemma":[0.9874683,0.0022802108,0.009805973,0.00012120409,0.00012931853,0.00006322184,0.000018673996,0.00002197543,0.00009110164],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866325,0.00008267343,0.00036406596,0.00039107486,0.00026152996,0.0002374177],"domain_scores_gemma":[0.99942416,0.0001190488,0.000102866456,0.00011976036,0.000072173956,0.0001620202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020095697,0.00016234655,0.00038071786,0.00013949987,0.000032333257,0.000016492075,0.0000662118,0.00009582445,0.000009830261],"category_scores_gemma":[0.00012935659,0.00013180249,0.000018887173,0.00025991595,0.00013143914,0.0002583003,0.00011494683,0.00023156265,0.000001382613],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006436544,0.00018206885,0.36541295,0.0014245037,0.00002278159,0.00009080381,0.0018128447,0.000024220231,0.60900354,0.000021330077,0.00018461207,0.021176701],"study_design_scores_gemma":[0.0065691993,0.000817328,0.027168738,0.0006438061,0.000048190577,0.000033766057,0.0022973828,0.003109349,0.9547107,0.000088258486,0.0042763506,0.00023690572],"about_ca_topic_score_codex":0.000028601646,"about_ca_topic_score_gemma":0.000018737192,"teacher_disagreement_score":0.34570718,"about_ca_system_score_codex":0.000024759816,"about_ca_system_score_gemma":0.00009135661,"threshold_uncertainty_score":0.53747493},"labels":[],"label_agreement":null},{"id":"W3094761049","doi":"10.1016/j.clml.2020.10.014","title":"Invasive Mold Infections in FLT3-Mutated Acute Myeloid Leukemia","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Mold; Medicine; Myeloid; Leukemia; Internal medicine; Biology; Genetics","score_opus":0.04650270858194126,"score_gpt":0.3454282493436217,"score_spread":0.29892554076168043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094761049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97620046,0.0003798983,0.00022997642,0.008471503,0.0005838647,0.0017665459,0.00008923922,0.00077607395,0.011502465],"genre_scores_gemma":[0.97981036,0.001393662,0.0017486507,0.013009993,0.0016228989,0.00024632763,0.0003651942,0.0002564484,0.0015464553],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9914511,0.00070938957,0.0028193132,0.002061709,0.0011793223,0.0017791922],"domain_scores_gemma":[0.9928259,0.0023419994,0.0005053708,0.001466226,0.00056893163,0.0022915588],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013188568,0.0009387399,0.002183186,0.0005785201,0.00029461234,0.00014994689,0.0009912292,0.0013274178,0.0008109334],"category_scores_gemma":[0.0068886606,0.0008988711,0.0009621695,0.0031351366,0.0010049597,0.0005512368,0.00088367495,0.002281673,0.004098477],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008568377,0.0013440576,0.33165336,0.00075018354,0.0030772046,0.020314185,0.0020489278,0.00047938048,0.034839254,0.0015456077,0.10334541,0.49203405],"study_design_scores_gemma":[0.022173371,0.0031308203,0.92138314,0.00044890222,0.0006653538,0.0014000172,0.0003574447,0.010435591,0.008090051,0.00055853685,0.030032651,0.0013241143],"about_ca_topic_score_codex":0.00066283107,"about_ca_topic_score_gemma":0.00018278968,"teacher_disagreement_score":0.5897298,"about_ca_system_score_codex":0.0074836,"about_ca_system_score_gemma":0.01300175,"threshold_uncertainty_score":0.99996907},"labels":[],"label_agreement":null},{"id":"W3094788775","doi":"10.1182/blood-2020-136999","title":"Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Venetoclax; Medicine; Internal medicine; Oncology; Ven; Chemotherapy regimen; Induction chemotherapy; Regimen; Chemotherapy; Leukemia; Gastroenterology; Chronic lymphocytic leukemia","score_opus":0.012494036776238528,"score_gpt":0.24334769243042906,"score_spread":0.23085365565419053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094788775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683225,0.00020281767,0.000020598462,0.0006897445,0.000012849205,0.0020252087,0.000028612852,0.00009229311,0.00009564918],"genre_scores_gemma":[0.99614257,0.00027195978,0.0020392234,0.0007422557,0.000111931266,0.00019990063,0.00013388273,0.00013567995,0.00022260554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974863,0.00016990889,0.00041372786,0.0006590517,0.00070667727,0.000564325],"domain_scores_gemma":[0.99881357,0.0001528045,0.0001966526,0.00040537879,0.0001677301,0.00026384377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020484014,0.00036479317,0.0005841156,0.00041588163,0.00005918066,0.00003301829,0.00023508024,0.00017539033,0.00004908611],"category_scores_gemma":[0.00009293666,0.00024077269,0.000035573856,0.0011194424,0.00012032113,0.00017256479,0.000065934495,0.00068529305,0.000030467023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050733224,0.0010884334,0.9391033,0.0002786938,0.00028436282,0.002233274,0.0015085662,0.00017058989,0.0035703215,0.000002636546,0.00015285393,0.0008737116],"study_design_scores_gemma":[0.0761067,0.015445988,0.89608544,0.00021121839,0.0003326306,0.00017425543,0.000121822566,0.000310117,0.01037013,0.000003529033,0.000326203,0.00051197],"about_ca_topic_score_codex":0.000098954144,"about_ca_topic_score_gemma":0.00017976518,"teacher_disagreement_score":0.04301789,"about_ca_system_score_codex":0.0011598979,"about_ca_system_score_gemma":0.002656066,"threshold_uncertainty_score":0.9818425},"labels":[],"label_agreement":null},{"id":"W3094810190","doi":"10.1182/blood-2020-140895","title":"Variation in Stem Cell Driven Hierarchies Underlies Clinical Outcome and Drug Response in AML","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; University Health Network","funders":"","keywords":"Stem cell; Biology; Progenitor cell; Population; Myeloid leukemia; Leukemia; Immunology; Cancer stem cell; Oncology; Cancer research; Medicine; Genetics","score_opus":0.05312269468960214,"score_gpt":0.3386781360173143,"score_spread":0.28555544132771216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094810190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98560303,0.00017553999,0.000033520893,0.013327739,0.000026938147,0.00037095157,0.000005650279,0.000036867466,0.00041977366],"genre_scores_gemma":[0.9972774,0.0001311226,0.0011106961,0.0008443307,0.00009327455,0.000014563749,0.0000047964777,0.000019408355,0.00050440955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822223,0.0005296793,0.00047550545,0.00030921152,0.00023006067,0.00023330595],"domain_scores_gemma":[0.9986547,0.0009065932,0.000054808996,0.0001852461,0.000026918298,0.00017172926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010362109,0.000108771455,0.00034639172,0.0001843036,0.00002387439,0.000020538298,0.00010046859,0.00010179394,0.000016958007],"category_scores_gemma":[0.0004925582,0.00009717243,0.00004299679,0.00031543852,0.00009042152,0.000072431976,0.00013181152,0.00057770923,0.000039287017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002928626,0.00041280602,0.9828925,0.0001569336,0.000030457826,0.000465038,0.0058290437,0.00001106292,0.0060742525,0.00010837043,0.00022758081,0.00086333876],"study_design_scores_gemma":[0.00991812,0.00049280113,0.9863359,0.000043722113,0.000037006408,0.000011416227,0.0008351936,0.0010641898,0.0005184319,0.0000575445,0.0005789867,0.00010668478],"about_ca_topic_score_codex":0.00005284691,"about_ca_topic_score_gemma":0.00005494999,"teacher_disagreement_score":0.012483409,"about_ca_system_score_codex":0.00007068912,"about_ca_system_score_gemma":0.00024679737,"threshold_uncertainty_score":0.39625767},"labels":[],"label_agreement":null},{"id":"W3094816564","doi":"10.1182/blood-2020-142982","title":"Donor Selection May Predict Improved Survival Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia - Experience from a Tertiary Care Centre","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Chronic myelomonocytic leukemia; Hematopoietic stem cell transplantation; Transplantation; Proportional hazards model; Oncology; Cyclophosphamide; Myelodysplastic syndromes; Chemotherapy; Bone marrow","score_opus":0.012133306750545218,"score_gpt":0.2523974214637173,"score_spread":0.24026411471317208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094816564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99654865,0.001212197,0.0002459133,0.000488824,0.00008906542,0.0010477749,0.00008423363,0.00014885796,0.00013450345],"genre_scores_gemma":[0.9982617,0.00021560639,0.0003195892,0.0003418965,0.00022678924,0.00020916719,0.00017546368,0.000064761974,0.00018503539],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766636,0.00015270949,0.00048238525,0.0007026466,0.00042599268,0.00056988874],"domain_scores_gemma":[0.9991145,0.00010495684,0.00008582893,0.00030526292,0.00007692033,0.00031253143],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000082098755,0.00032900798,0.00048966863,0.00012370375,0.000058480713,0.000037248905,0.00021416415,0.00022515058,0.00018062942],"category_scores_gemma":[0.00001735164,0.00029401117,0.00014461174,0.00034418155,0.00007864102,0.00017204283,0.00006335618,0.0004931531,0.00006576139],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006803587,0.0001405709,0.83317846,0.0010919208,0.00012659619,0.0006143416,0.029974619,0.0000682642,0.13305517,0.0000012990812,0.000027298003,0.0010411233],"study_design_scores_gemma":[0.018409643,0.00045488903,0.6742129,0.00029047212,0.00057440484,0.000058742247,0.007978865,0.0041758595,0.29312843,0.000003183873,0.00017005252,0.0005426153],"about_ca_topic_score_codex":0.0007734296,"about_ca_topic_score_gemma":0.0006156498,"teacher_disagreement_score":0.16007325,"about_ca_system_score_codex":0.0014142091,"about_ca_system_score_gemma":0.0010817194,"threshold_uncertainty_score":0.9999512},"labels":[],"label_agreement":null},{"id":"W3094903924","doi":"10.1182/blood-2020-141774","title":"Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cohort; Internal medicine; Pediatrics; Cog","score_opus":0.01601178085381182,"score_gpt":0.2857167245189766,"score_spread":0.2697049436651648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094903924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952271,0.0003607161,0.000023624576,0.0033095817,0.00003096896,0.0005814059,0.000045519988,0.000044204287,0.00037688555],"genre_scores_gemma":[0.9981957,0.0008682801,0.00038024297,0.000091907,0.00014574883,0.00007073523,0.0001451626,0.00002786133,0.00007436787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849784,0.00002203471,0.00027618115,0.0004709424,0.00046140203,0.00027161694],"domain_scores_gemma":[0.9993101,0.00008363561,0.000111508685,0.00018635835,0.00010160324,0.00020679354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007422098,0.00023053432,0.0003189344,0.00016417002,0.00006441017,0.00008996266,0.00008551649,0.00005928118,0.00001632819],"category_scores_gemma":[0.00008680868,0.00014509802,0.000023504555,0.00024539654,0.000060137478,0.00019099718,0.0000807208,0.00027147573,0.0000043390473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009141539,0.0005504224,0.9952381,0.00016652669,0.00017242224,0.001740786,0.0005823648,0.0000068245354,0.000007850586,0.000115138006,0.000082900784,0.00042248826],"study_design_scores_gemma":[0.022195218,0.0032430475,0.96765846,0.000111139525,0.0004176491,0.00020469638,0.00031997974,0.000052916264,0.00015445906,0.000007869458,0.005404501,0.00023006495],"about_ca_topic_score_codex":0.0001712741,"about_ca_topic_score_gemma":0.00064395077,"teacher_disagreement_score":0.027579663,"about_ca_system_score_codex":0.00020912284,"about_ca_system_score_gemma":0.00056063716,"threshold_uncertainty_score":0.59169257},"labels":[],"label_agreement":null},{"id":"W3095188934","doi":"10.1182/blood-2020-138683","title":"Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Immunophenotyping; CD33; Minimal residual disease; Myeloid leukemia; Myeloid; Medicine; Population; Oncology; Flow cytometry; Leukemia; CD117; CD34; Immunology; Internal medicine; Biology; Genetics; Stem cell","score_opus":0.015084443704376291,"score_gpt":0.24529187410600337,"score_spread":0.23020743040162708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095188934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99339104,0.00048364303,0.00050428085,0.000854583,0.000060428567,0.0037329714,0.00083505554,0.000115454925,0.00002254143],"genre_scores_gemma":[0.99478704,0.0001245502,0.0029675988,0.00020036647,0.000053833257,0.000978553,0.00038846303,0.000119069584,0.00038050086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99561244,0.00023325994,0.0008494079,0.0009112707,0.001635058,0.0007585331],"domain_scores_gemma":[0.9970399,0.00052815716,0.00029154736,0.00070501794,0.00063829793,0.0007970912],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053556263,0.00045044062,0.0008569178,0.0003355073,0.00024304379,0.00006270792,0.00044455516,0.0001724022,0.00012474055],"category_scores_gemma":[0.0030216677,0.0003846017,0.0001476591,0.001492312,0.00014902768,0.000217093,0.00030323904,0.00034888595,0.00013501913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05763474,0.0010607137,0.6993727,0.00086546515,0.0013213451,0.00039514626,0.001383927,0.00018569164,0.2315454,0.0000014118652,0.004874539,0.0013588787],"study_design_scores_gemma":[0.054245085,0.0039487085,0.55385906,0.0006026895,0.0023338192,0.000009969217,0.00007790723,0.00045633395,0.38302666,0.000006066872,0.00069567503,0.0007380166],"about_ca_topic_score_codex":0.0001253844,"about_ca_topic_score_gemma":0.00014517466,"teacher_disagreement_score":0.15148126,"about_ca_system_score_codex":0.0019982676,"about_ca_system_score_gemma":0.0010859278,"threshold_uncertainty_score":0.9998606},"labels":[],"label_agreement":null},{"id":"W3095224165","doi":"10.1182/blood-2020-141740","title":"A Stemness-Based Screen Identifies PLK1 Inhibitors for Targeting Leukemia Stem Cells in AML","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Stem cell; CD38; Leukemia; Myeloid leukemia; Cancer research; CD34; PLK1; Biology; Immunology; Cell; Cell cycle; Cell biology; Genetics","score_opus":0.029531904501372382,"score_gpt":0.28002578584393223,"score_spread":0.25049388134255984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095224165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945828,0.00040881077,0.0006006551,0.0021724044,0.00010248549,0.00149642,0.00007344598,0.00014995347,0.0004130241],"genre_scores_gemma":[0.99537784,0.000014806169,0.0021303722,0.0009817617,0.0006268805,0.0001456454,0.00007155673,0.0000779499,0.00057319313],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978373,0.000085720305,0.00051308743,0.0005132773,0.00048191962,0.00056867744],"domain_scores_gemma":[0.9988593,0.0002868422,0.00011213817,0.00027974992,0.00015528561,0.0003067025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052401336,0.0002292092,0.00048381495,0.00019218761,0.000086917375,0.000058109694,0.0002400139,0.00017422678,0.00005671272],"category_scores_gemma":[0.0002269015,0.00021276924,0.00016255281,0.0005288709,0.000077872544,0.00011885334,0.00011548886,0.00043845095,0.00009255371],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016439019,0.0005887254,0.038895316,0.0030576536,0.00029369743,0.0007972396,0.002203997,0.00040452846,0.9044781,0.00008296852,0.04419114,0.0033627562],"study_design_scores_gemma":[0.016476305,0.0006030742,0.0014035619,0.00034818306,0.00017387548,0.0000077707,0.001488535,0.0072065326,0.9648766,0.000016467371,0.007060574,0.0003385193],"about_ca_topic_score_codex":0.00016214621,"about_ca_topic_score_gemma":0.000027651837,"teacher_disagreement_score":0.060398526,"about_ca_system_score_codex":0.00028353801,"about_ca_system_score_gemma":0.0008124402,"threshold_uncertainty_score":0.8676478},"labels":[],"label_agreement":null},{"id":"W3095231685","doi":"10.1182/blood-2020-134718","title":"The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Myeloid leukemia; Internal medicine; Oncology; Clinical trial; Leukemia; Bone marrow","score_opus":0.11294187065735843,"score_gpt":0.41569162418199473,"score_spread":0.3027497535246363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095231685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905918,0.00035694678,0.000055463377,0.0025368882,0.00030936184,0.0054834136,0.000048709946,0.00028124897,0.0003361685],"genre_scores_gemma":[0.99347514,0.0011714109,0.002543329,0.00062249624,0.0004134005,0.0006676061,0.00015689734,0.00013991824,0.00080982846],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9917353,0.002584612,0.0019406701,0.0009802426,0.0017788255,0.0009803624],"domain_scores_gemma":[0.9920699,0.0051471004,0.0008467112,0.0007587003,0.00061249395,0.0005650788],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005669458,0.0005411649,0.0015189975,0.00018113967,0.00033616123,0.00020230029,0.00059590134,0.00036779232,0.00012579578],"category_scores_gemma":[0.008842823,0.00030172247,0.00028945337,0.001276752,0.00038727233,0.00023409304,0.00022100833,0.0016612546,0.00014167419],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031196756,0.004921904,0.37848845,0.00019808412,0.0031494626,0.0006211035,0.0011059759,0.000056781628,0.00054953736,0.00010407358,0.002682997,0.57692486],"study_design_scores_gemma":[0.21803729,0.06590318,0.68757814,0.0006163191,0.002785344,0.00013519019,0.00037544727,0.017023707,0.0011332481,0.0001782374,0.0051836525,0.0010502178],"about_ca_topic_score_codex":0.000095729505,"about_ca_topic_score_gemma":0.000028268087,"teacher_disagreement_score":0.5758747,"about_ca_system_score_codex":0.0006680627,"about_ca_system_score_gemma":0.0025802122,"threshold_uncertainty_score":0.9999435},"labels":[],"label_agreement":null},{"id":"W3095490154","doi":"10.1182/blood-2020-142990","title":"CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; McMaster University; Juravinski Cancer Centre; Sunnybrook Health Science Centre; University of Alberta; Jewish General Hospital; Princess Margaret Cancer Centre; McGill University; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Cytarabine; Oncology; Myeloid leukemia","score_opus":0.04199368743495188,"score_gpt":0.29882131363440734,"score_spread":0.2568276261994554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095490154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893367,0.000027992384,0.00003517322,0.005805605,0.000057162717,0.0030034038,0.0014870254,0.00008404409,0.00016285201],"genre_scores_gemma":[0.99695534,0.00007010399,0.0006784576,0.00078186113,0.00032027403,0.00006737565,0.00089723,0.00005673779,0.0001726543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970573,0.0004221865,0.00053652446,0.0009234979,0.0005016842,0.00055878377],"domain_scores_gemma":[0.99778455,0.00015644947,0.00006414123,0.00054906466,0.00012811764,0.0013176851],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004883559,0.00028074736,0.00047076202,0.0003071748,0.00016915645,0.000049402264,0.00024023396,0.00015417155,0.00006620764],"category_scores_gemma":[0.00042329816,0.00025609825,0.00006578249,0.00061564974,0.000033945693,0.00010365545,0.000047608442,0.0006160451,0.00009178085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032106629,0.0015919239,0.91645944,0.000034750992,0.0003279515,0.0029986799,0.028819663,0.000045970562,0.038139462,0.0000013974808,0.0024109266,0.0059591713],"study_design_scores_gemma":[0.015046623,0.00093717274,0.9505134,0.00013002005,0.00033084673,0.0000067835067,0.0006987335,0.001112095,0.030323729,0.0000016473207,0.0006379396,0.000260998],"about_ca_topic_score_codex":0.7760253,"about_ca_topic_score_gemma":0.8101173,"teacher_disagreement_score":0.034091998,"about_ca_system_score_codex":0.000576814,"about_ca_system_score_gemma":0.00064351736,"threshold_uncertainty_score":0.99998915},"labels":[],"label_agreement":null},{"id":"W3095552675","doi":"10.1200/jco.20.01632","title":"Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; Agence Nationale de la Recherche; National Cancer Institute; Medical Research Council; National Institute for Health and Care Research; Agios Pharmaceuticals","keywords":"Medicine; Internal medicine; Neutropenia; Myeloid leukemia; Adverse effect; Gastroenterology; Azacitidine; Isocitrate dehydrogenase; Oncology; Surgery; Chemotherapy","score_opus":0.08517720452467968,"score_gpt":0.4167741424278661,"score_spread":0.3315969379031864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095552675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9468987,0.0001559954,0.0016787404,0.049643673,0.000316317,0.000917574,0.000017597418,0.000022026554,0.0003493694],"genre_scores_gemma":[0.9772133,0.0007748895,0.010587299,0.009416717,0.001783696,0.000037804082,0.000020094943,0.000054734217,0.00011145923],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99531406,0.00046205302,0.0027263395,0.00036615337,0.0006332959,0.0004980936],"domain_scores_gemma":[0.99281794,0.0037451878,0.0014684097,0.00019276496,0.00083216856,0.0009435169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030795299,0.00024336309,0.001960782,0.00022328399,0.000055864333,0.000022275579,0.0002959056,0.000560256,0.00007545526],"category_scores_gemma":[0.0064931624,0.0001730169,0.00048418035,0.00046927523,0.0003016933,0.00026538753,0.0000755862,0.0020279035,0.00002591382],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2788719,0.009967294,0.11915019,0.0009635256,0.0062577613,0.079555765,0.0034730383,0.0015184877,0.14935884,0.0015444412,0.10220724,0.24713154],"study_design_scores_gemma":[0.39803165,0.26236615,0.098432735,0.0011384828,0.0031656108,0.00446978,0.0020351412,0.040213455,0.054657802,0.0021674496,0.13206376,0.0012580117],"about_ca_topic_score_codex":0.000030706,"about_ca_topic_score_gemma":0.00008442987,"teacher_disagreement_score":0.25239885,"about_ca_system_score_codex":0.0011705871,"about_ca_system_score_gemma":0.007469028,"threshold_uncertainty_score":0.9981577},"labels":[],"label_agreement":null},{"id":"W3095664609","doi":"10.1182/blood-2020-140473","title":"Integrative Analysis of Single-Cell RNA-Seq and ATAC-Seq Data across Treatment Time Points in Pediatric AML","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Chromatin; Biology; RNA-Seq; Cell; Computational biology; Cancer research; Genetics; Transcriptome; Gene; Gene expression","score_opus":0.05644610041783486,"score_gpt":0.32829218368302476,"score_spread":0.2718460832651899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095664609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955348,0.000844836,0.00003316944,0.0012029991,0.0000084466255,0.0003670906,0.00057902886,0.00002634297,0.0014032993],"genre_scores_gemma":[0.99628395,0.0006249273,0.0013257773,0.00017699604,0.00012684584,0.000011039743,0.00071166625,0.000025216239,0.00071359274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983532,0.00009644907,0.00036330093,0.0005469512,0.00031639403,0.0003237014],"domain_scores_gemma":[0.9986929,0.00021563444,0.000114280854,0.0006504434,0.00008699293,0.00023971277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024325815,0.00019854367,0.0006819649,0.00026106628,0.00003145574,0.00002233338,0.00027570446,0.000097542295,0.00013539707],"category_scores_gemma":[0.00036352745,0.00014868112,0.00009113473,0.0016366971,0.00009277228,0.00012070074,0.0004944274,0.00021578005,0.00005909578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015402792,0.0076965485,0.83867455,0.00053314806,0.0056554307,0.0015577371,0.023377184,0.00002440484,0.10258943,0.000014267488,0.0043789656,0.013958031],"study_design_scores_gemma":[0.10294798,0.01613696,0.45167303,0.00025659477,0.04299724,0.00012505839,0.008806108,0.057233498,0.3145641,0.00008254082,0.003221244,0.0019556151],"about_ca_topic_score_codex":0.00029977804,"about_ca_topic_score_gemma":0.00015308434,"teacher_disagreement_score":0.38700154,"about_ca_system_score_codex":0.00013783875,"about_ca_system_score_gemma":0.00022230817,"threshold_uncertainty_score":0.60630405},"labels":[],"label_agreement":null},{"id":"W3095941038","doi":"10.1182/blood-2020-134964","title":"Gene Body Methylation and Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"DNA methylation; Biology; Methylation; Transcriptome; Epigenetics; Gene; Genetics; Gene expression profiling; Fold change; Gene expression; Molecular biology; Cancer research","score_opus":0.030054851466011286,"score_gpt":0.28587478888961376,"score_spread":0.2558199374236025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095941038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398154,0.00122996,0.00054501765,0.0030244852,0.000024520437,0.00045971668,0.000017433626,0.000058013073,0.0006592895],"genre_scores_gemma":[0.9982851,0.00033345667,0.0006293189,0.00029075527,0.00030738467,0.000028452165,0.00003257245,0.000026694976,0.00006622739],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99870163,0.00008291251,0.00020328183,0.00037062174,0.0003339983,0.00030752562],"domain_scores_gemma":[0.9994486,0.000066205015,0.000039746566,0.00016429512,0.000043090582,0.00023804644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023142593,0.00015084617,0.00030287256,0.00011485945,0.000047812464,0.000020318992,0.000079917445,0.0001284195,0.00010927937],"category_scores_gemma":[0.00012207801,0.00014263288,0.00005727947,0.00033417763,0.00007337161,0.0001421517,0.00004517689,0.00047867815,0.00004115723],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027288301,0.00011357892,0.0034366634,0.00013073617,0.00008370519,0.00015144146,0.00042282615,0.000024185672,0.9895976,0.00014874998,0.00003400654,0.0055836323],"study_design_scores_gemma":[0.015192655,0.0009135651,0.2770098,0.00006880822,0.00023178438,0.00019006692,0.000061978106,0.020856675,0.6838221,0.00013233726,0.001250988,0.00026926884],"about_ca_topic_score_codex":0.00012088671,"about_ca_topic_score_gemma":0.000027988603,"teacher_disagreement_score":0.3057755,"about_ca_system_score_codex":0.00070402375,"about_ca_system_score_gemma":0.00096989097,"threshold_uncertainty_score":0.58164006},"labels":[],"label_agreement":null},{"id":"W3096017746","doi":"10.1182/blood-2020-139727","title":"Patient Experiences with Liposomal Daunorubicin and Cytarabine (CPX-351) Versus Conventional Induction Regimens: An Analysis of Patient-Reported Outcomes Data from a Prospective Trial","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Randomized controlled trial; Internal medicine; Quality of life (healthcare); Hospital Anxiety and Depression Scale; Cytarabine; Anxiety; Physical therapy; Chemotherapy; Psychiatry","score_opus":0.058997978597421785,"score_gpt":0.3198419281657854,"score_spread":0.2608439495683636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096017746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979811,0.00011838037,0.00003768719,0.0004967595,0.00009204053,0.000999949,0.00016704458,0.00004379696,0.0000632833],"genre_scores_gemma":[0.99725837,0.000010410135,0.0011990754,0.00007696712,0.00013279507,0.0000930318,0.0012010648,0.00001764175,0.000010628938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976828,0.00011020141,0.00050218083,0.0007193374,0.00077869464,0.00020676041],"domain_scores_gemma":[0.99845815,0.00012074512,0.00032845256,0.0006386571,0.00022069768,0.00023328498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012157554,0.00019098521,0.0006154942,0.00019228777,0.00007157787,0.000025699677,0.00015428549,0.00008908733,0.00019361767],"category_scores_gemma":[0.00046146632,0.00014028474,0.000076075274,0.00075403193,0.00022335806,0.0002964015,0.00018686097,0.00022030163,0.0000020376413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22349505,0.0051327227,0.69334626,0.00006238794,0.02326712,0.00048003506,0.041242585,0.000034777415,0.010595248,0.000064021,0.0002950563,0.0019847201],"study_design_scores_gemma":[0.37322652,0.047235485,0.41239735,0.00013417371,0.020809958,0.00005758221,0.09546379,0.008029738,0.04157238,0.000022508426,0.00022686168,0.0008236545],"about_ca_topic_score_codex":0.00077974214,"about_ca_topic_score_gemma":0.00010735411,"teacher_disagreement_score":0.28094894,"about_ca_system_score_codex":0.00006342952,"about_ca_system_score_gemma":0.00029641346,"threshold_uncertainty_score":0.5720646},"labels":[],"label_agreement":null},{"id":"W3096057643","doi":"10.1182/blood-2020-136122","title":"Allogeneic Transplant Can Abrogate the Relapse Risk in the Patients with Detectable Measureable Residual Disease By Multicolor Flow-Cytometry at the Time of Assessment of Acute Myeloid Leukemia Patients in First Remission","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Cumulative incidence; Internal medicine; Hazard ratio; Minimal residual disease; Proportional hazards model; Oncology; Myeloid leukemia; Multivariate analysis; Leukemia; Transplantation; Confidence interval","score_opus":0.00862299265594178,"score_gpt":0.23770799243929946,"score_spread":0.2290849997833577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096057643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995145,0.00018362483,0.000007571951,0.0015323843,0.000016410988,0.0020061405,0.00095356285,0.0000158029,0.00013945322],"genre_scores_gemma":[0.9985207,0.00031931905,0.00020644745,0.00030856018,0.000023352984,0.00013053248,0.00031844122,0.0000450206,0.00012764975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99647,0.00056642416,0.00059862714,0.0004488042,0.0014135808,0.0005025814],"domain_scores_gemma":[0.99809355,0.0004922339,0.00028031637,0.0007069653,0.00018633927,0.0002405906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009093969,0.00028448037,0.0004794175,0.00011538195,0.00019263601,0.000016633177,0.0005916123,0.00012359978,0.000060148253],"category_scores_gemma":[0.0003631879,0.0001336737,0.0001010792,0.0009142306,0.00021872907,0.00007238026,0.00015993672,0.0007402416,0.0000071756854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034566678,0.0011010112,0.9815533,0.00018786309,0.00033096178,0.000066614004,0.002542772,0.00048125949,0.008418685,5.8027007e-7,0.0015998014,0.00026047815],"study_design_scores_gemma":[0.01837621,0.0012525197,0.9557406,0.00033305085,0.00097338966,0.00000398197,0.00016816406,0.0028734615,0.019779777,0.0000028022794,0.00030324265,0.00019281755],"about_ca_topic_score_codex":0.0008877598,"about_ca_topic_score_gemma":0.0005142671,"teacher_disagreement_score":0.025812725,"about_ca_system_score_codex":0.00050601043,"about_ca_system_score_gemma":0.00067870674,"threshold_uncertainty_score":0.5451056},"labels":[],"label_agreement":null},{"id":"W3096131635","doi":"10.1182/blood-2020-134779","title":"An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Immune system; Medicine; Oncology; Cohort; Chemotherapy regimen; Internal medicine; Gene signature; Immunology; Chemotherapy; Biology; Gene; Gene expression","score_opus":0.027772645965498825,"score_gpt":0.32776021589427506,"score_spread":0.29998756992877623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096131635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99455196,0.00030147308,0.00003426635,0.003164855,0.00008621338,0.0008565084,0.00002942237,0.00018891034,0.0007864104],"genre_scores_gemma":[0.9958818,0.0005212658,0.001901088,0.0007765629,0.0001716575,0.000044724402,0.000094920026,0.000048231945,0.0005597408],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997519,0.00016822852,0.0007680204,0.00063305895,0.00043715737,0.00047454177],"domain_scores_gemma":[0.9985439,0.00017744595,0.00011697905,0.00047209044,0.00010621743,0.00058333745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057746476,0.00024474395,0.0006984738,0.00012115856,0.00007102154,0.00003450839,0.00025204162,0.00032412153,0.000139092],"category_scores_gemma":[0.000658042,0.00020602148,0.00010768052,0.00047509672,0.00022804756,0.00021556116,0.00018042132,0.0010321126,0.00013002008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005698671,0.0007265179,0.91065246,0.00014896359,0.00049019407,0.001344193,0.00090344937,0.000005636005,0.07943053,0.00007123487,0.0005215379,0.005135426],"study_design_scores_gemma":[0.01461262,0.0013828505,0.9666377,0.00012408395,0.00034594262,0.00016279178,0.00022001617,0.0047906446,0.011235686,0.000025385843,0.00020114763,0.00026114786],"about_ca_topic_score_codex":0.00011027993,"about_ca_topic_score_gemma":0.000008086315,"teacher_disagreement_score":0.068194844,"about_ca_system_score_codex":0.00012127839,"about_ca_system_score_gemma":0.00068107387,"threshold_uncertainty_score":0.84013116},"labels":[],"label_agreement":null},{"id":"W3096141131","doi":"10.1182/blood-2020-143221","title":"Single-Cell Transcriptomic Profiling of De Novo and Relapsed Acute Myeloid Leukemia Identifies a Leukemic Stemness Program Shared across Diverse Phenotypes","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill Genome Centre; McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Biology; Single-cell analysis; Transcriptome; Gene expression profiling; Myeloid leukemia; CD34; Myeloid; Leukemia; Stem cell; Cell; Cancer research; Computational biology; Gene; Molecular biology; Gene expression; Genetics","score_opus":0.03187072893759019,"score_gpt":0.28908466323465865,"score_spread":0.25721393429706846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096141131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960927,0.0008108181,0.00016069449,0.00039193587,0.000069105656,0.0015695363,0.00022240954,0.0002926001,0.00039021936],"genre_scores_gemma":[0.9908395,0.00018580392,0.007725959,0.0002497172,0.0001810082,0.00011549936,0.00013207448,0.00008972525,0.00048071213],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973718,0.000099845114,0.000559941,0.00065871753,0.00053404947,0.00077562756],"domain_scores_gemma":[0.99864393,0.000103751474,0.00017947688,0.00039904317,0.00023461813,0.000439168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003378471,0.00034428533,0.0006967205,0.00010945411,0.00016439958,0.00010484629,0.00035279914,0.00026581896,0.000048537793],"category_scores_gemma":[0.0001825049,0.0003224589,0.00018274106,0.0005227865,0.00035377181,0.00026516474,0.00022636366,0.0006300044,0.00002856175],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012693489,0.0005231569,0.011816337,0.0016336143,0.000451234,0.00042515487,0.008060313,0.000006849482,0.9724841,0.00001260895,0.00025630507,0.0030609446],"study_design_scores_gemma":[0.020462215,0.0015170893,0.004321215,0.00031644927,0.0011054309,0.0003009138,0.0042139017,0.0015623248,0.9653306,0.000027119197,0.0004205514,0.000422202],"about_ca_topic_score_codex":0.00010492934,"about_ca_topic_score_gemma":0.00002069689,"teacher_disagreement_score":0.019192865,"about_ca_system_score_codex":0.00035788945,"about_ca_system_score_gemma":0.00085079577,"threshold_uncertainty_score":0.99992275},"labels":[],"label_agreement":null},{"id":"W3096217495","doi":"10.1182/blood-2020-137589","title":"Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Cumulative incidence; Transplantation; Hazard ratio; Univariate analysis; Oncology; Hematopoietic stem cell transplantation; Clinical endpoint; Proportional hazards model; Graft-versus-host disease; Multivariate analysis; Clinical trial; Confidence interval","score_opus":0.029376311166879693,"score_gpt":0.29683783039591555,"score_spread":0.2674615192290358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096217495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95683897,0.0003051371,0.03438644,0.00031553186,0.000032106334,0.005744769,0.0022420113,0.00006727057,0.00006773797],"genre_scores_gemma":[0.9894411,0.0013202847,0.00660171,0.000049883747,0.00016665056,0.0009951689,0.001267803,0.00012679394,0.000030581527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99574167,0.00044152877,0.0011927022,0.0009705236,0.0007971292,0.0008564628],"domain_scores_gemma":[0.99458677,0.003298799,0.00049814733,0.0004893006,0.0008312133,0.00029579873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017634527,0.0004717862,0.00083284604,0.0005638486,0.00035876397,0.00014414739,0.000527681,0.00018954341,0.000006058688],"category_scores_gemma":[0.00038510934,0.0003470902,0.00045106784,0.0008496813,0.00019648606,0.00019059257,0.000054887627,0.0006700471,9.661784e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008129794,0.00051333854,0.92412215,0.003197535,0.011412826,0.0001694235,0.012352018,0.0082603395,0.030281596,0.000059501974,0.000045483157,0.001455962],"study_design_scores_gemma":[0.07514024,0.0066010016,0.6753326,0.001453845,0.025327316,0.00041004294,0.004942301,0.17923304,0.030574424,0.00006822401,0.000010618585,0.00090634334],"about_ca_topic_score_codex":0.00027490823,"about_ca_topic_score_gemma":0.00052273617,"teacher_disagreement_score":0.24878958,"about_ca_system_score_codex":0.0005058208,"about_ca_system_score_gemma":0.0012847643,"threshold_uncertainty_score":0.99989814},"labels":[],"label_agreement":null},{"id":"W3096222995","doi":"10.1182/blood-2020-134977","title":"ASXL1-Mutant Chronic Myelomonocytic Leukemia Is Associated with Increased Intratumoral Heterogeneity and Single-Cell Chromatin Co-Accessibility","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Biology; Chromatin; Epigenomics; Computational biology; Genetics; Molecular biology; DNA methylation; Gene; Gene expression","score_opus":0.02894232841328798,"score_gpt":0.27607985175106414,"score_spread":0.24713752333777617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096222995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963077,0.0005657086,0.00004370812,0.0005427927,0.000015949765,0.00089265633,0.00009970154,0.00023284035,0.0012989512],"genre_scores_gemma":[0.9977087,0.000038174636,0.00048186132,0.0012608945,0.00021119668,0.000039562226,0.00014618492,0.000073878524,0.000039550792],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99720615,0.00017429431,0.00047636035,0.0008201898,0.0006345509,0.000688433],"domain_scores_gemma":[0.99818474,0.00017111062,0.00021496466,0.0005219616,0.00017232391,0.00073487894],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038913774,0.0003893979,0.00074390485,0.00008270905,0.00015814675,0.00010346027,0.0002557951,0.000228743,0.0001974936],"category_scores_gemma":[0.00046065426,0.00031697348,0.00009765236,0.00055125117,0.00033494076,0.000174931,0.00017426944,0.00071771874,0.00005838982],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008660532,0.0011045821,0.14768764,0.0008005987,0.000594212,0.001431281,0.0007107895,0.0000032788232,0.8450222,0.000005809236,0.0009379674,0.0008355667],"study_design_scores_gemma":[0.021151302,0.003859839,0.114033386,0.0002441468,0.00059142336,0.00026169422,0.00010714032,0.005168756,0.85391575,0.000018456134,0.00015476115,0.0004933705],"about_ca_topic_score_codex":0.00016475527,"about_ca_topic_score_gemma":0.00007743475,"teacher_disagreement_score":0.033654258,"about_ca_system_score_codex":0.0014755848,"about_ca_system_score_gemma":0.0020725862,"threshold_uncertainty_score":0.99992824},"labels":[],"label_agreement":null},{"id":"W3096229548","doi":"10.1182/blood-2020-135867","title":"A Human Model of Down Syndrome Associated Leukemia Reveals Different Cell of Origins for Initiation and Progression","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Acute megakaryoblastic leukemia; GATA1; Cancer research; Leukemia; Biology; Haematopoiesis; Genetics; Stem cell","score_opus":0.04213590924019751,"score_gpt":0.31392605378251354,"score_spread":0.27179014454231604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096229548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981542,0.0000993009,0.00019884367,0.00027315354,0.0000061212154,0.000864826,0.000097379794,0.000028876704,0.000277284],"genre_scores_gemma":[0.9985681,0.000024942901,0.0010333478,0.00007257565,0.00002580007,0.000049768485,0.000094630566,0.000022335047,0.000108473665],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989671,0.00003799059,0.00032414502,0.00019766175,0.00029301975,0.00018007764],"domain_scores_gemma":[0.9992993,0.00006310276,0.00019833843,0.00013889742,0.00016757089,0.00013282691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015895521,0.000110212575,0.00040177422,0.00007202387,0.00003891809,0.0000054113243,0.00007500799,0.00011978292,0.000010507352],"category_scores_gemma":[0.00019163461,0.00008745489,0.00006666905,0.00013010486,0.000051033065,0.0000435826,0.00006217937,0.00015327639,7.3290533e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017773498,0.0006588857,0.02204977,0.0016037923,0.00014523714,0.000015384401,0.0007907158,0.000019924359,0.9734891,0.00027282166,0.0006113528,0.00016527677],"study_design_scores_gemma":[0.03633676,0.006837126,0.09972377,0.001147479,0.001233063,0.000030251287,0.0001891412,0.04701799,0.80618685,0.0008814052,0.000037987404,0.00037819575],"about_ca_topic_score_codex":0.0000122765105,"about_ca_topic_score_gemma":0.000001549677,"teacher_disagreement_score":0.16730227,"about_ca_system_score_codex":0.0001411606,"about_ca_system_score_gemma":0.00019310707,"threshold_uncertainty_score":0.3566307},"labels":[],"label_agreement":null},{"id":"W3096269916","doi":"10.1182/blood-2020-138862","title":"Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Harboring DNMT3A/TET2/ASXL1 Mutation","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Minimal residual disease; Medicine; Myeloid leukemia; clone (Java method); Internal medicine; Oncology; Leukemia; Population; Flow cytometry; Myeloid; Acute leukemia; Mutation; Immunology; Cancer research; Biology; Gene; Genetics","score_opus":0.01343586611794314,"score_gpt":0.2604569212021956,"score_spread":0.24702105508425246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096269916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967819,0.000084817126,0.00059977506,0.00047164861,0.00002377905,0.001657692,0.0001254377,0.00008787533,0.00016710107],"genre_scores_gemma":[0.9783549,0.000006165746,0.020717371,0.00021375976,0.00007603409,0.00018167886,0.00035694506,0.000073284165,0.000019915598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690354,0.00014877645,0.0005122253,0.00058944995,0.0013000317,0.00054596417],"domain_scores_gemma":[0.9982516,0.00021498807,0.00017726097,0.00043200405,0.0003894962,0.00053461746],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028912543,0.0003000779,0.00052508694,0.0003520672,0.000063484345,0.00004006965,0.00021771518,0.00011061159,0.000051199982],"category_scores_gemma":[0.0007379491,0.00025339605,0.00009098486,0.0009983814,0.00009946929,0.00021262022,0.00008649226,0.0006033853,0.000022560895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030065528,0.0013082512,0.9788944,0.0004232142,0.00037978328,0.00049199857,0.00032012133,0.0017714999,0.01167142,0.0000058219803,0.00004562373,0.0016812909],"study_design_scores_gemma":[0.022203196,0.0016577016,0.90643954,0.0003573509,0.0007397416,0.0000037057875,0.000103344,0.038351785,0.029806703,0.000010126016,0.000033943368,0.0002928401],"about_ca_topic_score_codex":0.00008296722,"about_ca_topic_score_gemma":0.000008908086,"teacher_disagreement_score":0.07245486,"about_ca_system_score_codex":0.0005129813,"about_ca_system_score_gemma":0.001965129,"threshold_uncertainty_score":0.99999183},"labels":[],"label_agreement":null},{"id":"W3096318977","doi":"10.1182/blood-2020-138943","title":"Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Flag (linear algebra); Medicine; Internal medicine; Mathematics","score_opus":0.02171803868389241,"score_gpt":0.25923544819824573,"score_spread":0.23751740951435332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096318977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96875155,0.000049277856,0.000040724906,0.029015066,0.000018633855,0.0008032243,0.000037270074,0.0001829862,0.0011012706],"genre_scores_gemma":[0.98886216,0.000011290656,0.0038185464,0.005731784,0.00021132492,0.000084727784,0.00005087341,0.000079661535,0.0011496594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983291,0.000031057687,0.00020297282,0.0004376183,0.0005102298,0.000489037],"domain_scores_gemma":[0.99871093,0.00006264556,0.000071833245,0.00047507058,0.00017064932,0.00050884526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008261613,0.00026401723,0.0005120895,0.000078577665,0.00007865336,0.00004265894,0.00020585192,0.000098730896,0.00015501019],"category_scores_gemma":[0.00016672116,0.00016151779,0.000058156944,0.00040708628,0.00014859354,0.00007355414,0.00011012357,0.0005010723,0.000037646536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021622686,0.0006126021,0.90202796,0.0005151375,0.0014736287,0.0024642418,0.002207359,0.0000042183956,0.084530234,0.00023204288,0.0023053442,0.0014649672],"study_design_scores_gemma":[0.085250586,0.01525847,0.70244455,0.0004739713,0.0022617166,0.0008981256,0.0015802964,0.0003431967,0.1780375,0.00002448478,0.012032891,0.0013941998],"about_ca_topic_score_codex":0.00092601695,"about_ca_topic_score_gemma":0.00048936746,"teacher_disagreement_score":0.19958338,"about_ca_system_score_codex":0.0000867811,"about_ca_system_score_gemma":0.0010437137,"threshold_uncertainty_score":0.6586504},"labels":[],"label_agreement":null},{"id":"W3096338919","doi":"10.1182/blood-2020-138498","title":"CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Consolidation (business); Chemotherapy; Surgery","score_opus":0.017199722836313398,"score_gpt":0.26618430315766944,"score_spread":0.24898458032135604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096338919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894239,0.000111678506,0.00012718597,0.005381482,0.00016611494,0.0031950674,0.0014173138,0.00003110871,0.00014619582],"genre_scores_gemma":[0.99593234,0.00065050024,0.001102492,0.0006927708,0.00032804254,0.00013604213,0.0008769864,0.000080005186,0.00020079351],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99667186,0.00020866284,0.0010782903,0.00077529374,0.0007902312,0.00047566852],"domain_scores_gemma":[0.99592346,0.0011765826,0.00069455453,0.0008490194,0.0011167821,0.00023957789],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000772581,0.0003816855,0.0010242364,0.000109243665,0.00008312952,0.000030786705,0.0004117447,0.0002677649,0.000018080791],"category_scores_gemma":[0.003180389,0.00025512688,0.00013566896,0.00032932614,0.00037464415,0.00022899883,0.00020245768,0.00053532363,0.0000015594707],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9388704,0.0034603018,0.00570797,0.00031838144,0.0011321167,0.00008652323,0.007338872,0.000003604938,0.032927036,0.00006053966,0.0069938274,0.0031004495],"study_design_scores_gemma":[0.9357337,0.0067710797,0.023992693,0.00091977365,0.0005577198,0.000007133011,0.0013068998,0.0007893372,0.02691699,0.00014742924,0.002423561,0.00043370106],"about_ca_topic_score_codex":0.0015235086,"about_ca_topic_score_gemma":0.00037276212,"teacher_disagreement_score":0.018284723,"about_ca_system_score_codex":0.00026273108,"about_ca_system_score_gemma":0.00055243284,"threshold_uncertainty_score":0.9999901},"labels":[],"label_agreement":null},{"id":"W3096384900","doi":"10.1182/blood-2020-133855","title":"Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre; Hôpital Maisonneuve-Rosemont; University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Decitabine; Medicine; Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Azacitidine; International Prognostic Scoring System; Adverse effect; Internal medicine; Pharmacology; Gastroenterology; Oncology; Bone marrow","score_opus":0.02441159265760262,"score_gpt":0.2943761607689005,"score_spread":0.2699645681112979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096384900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975133,0.00071998715,0.000042344043,0.00054295384,0.000029433782,0.0008719034,0.00002410639,0.00004255614,0.0002134158],"genre_scores_gemma":[0.9979572,0.0006016919,0.0010600945,0.00014036504,0.000093990406,0.000013250494,0.000041896263,0.00005155456,0.000039910738],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976512,0.00012504046,0.00071795215,0.00060258125,0.00044188224,0.0004613321],"domain_scores_gemma":[0.998343,0.00058164116,0.00014542355,0.00031870257,0.0001239047,0.00048733872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003471709,0.00028060548,0.00087416254,0.00016046774,0.00004913737,0.0000166565,0.00015489689,0.00017651897,0.00005370878],"category_scores_gemma":[0.00097570784,0.00021802107,0.00005552281,0.00049686985,0.00040579954,0.00011536971,0.00024169033,0.00061750575,0.000017330407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00443835,0.00077386195,0.97635853,0.00082038017,0.0004477128,0.0003962366,0.0003461405,0.00003569925,0.0009605653,0.00007401723,0.00015634927,0.015192128],"study_design_scores_gemma":[0.051508,0.0050775083,0.9398183,0.00044287118,0.00039140703,0.0000956378,0.000045808767,0.0013176202,0.0006256058,0.000009080858,0.0004236522,0.00024447448],"about_ca_topic_score_codex":0.000048537644,"about_ca_topic_score_gemma":0.00003191564,"teacher_disagreement_score":0.04706965,"about_ca_system_score_codex":0.00024437162,"about_ca_system_score_gemma":0.00092596404,"threshold_uncertainty_score":0.88906413},"labels":[],"label_agreement":null},{"id":"W3096432266","doi":"10.1182/blood.v130.suppl_1.2433.2433","title":"Regulation of Lipid Metabolism and Cell Cycle Progression By PU.1 in Myeloid Progenitor Cells","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Cell growth; Cell cycle; Myeloid; Biology; Cell biology; Progenitor cell; Lipogenesis; Lipid metabolism; Cellular differentiation; ATP citrate lyase; Cancer research; Chemistry; Stem cell; Cell; Biochemistry; Citrate synthase","score_opus":0.01039083079978154,"score_gpt":0.2820967414355555,"score_spread":0.271705910635774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096432266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950363,0.00096785754,0.000005464968,0.0004239055,0.000064989144,0.0006838715,0.000012941838,0.000020159801,0.002784491],"genre_scores_gemma":[0.9962629,0.00018651974,0.0021521554,0.000016997166,0.00021583082,0.000038425074,0.000015344318,0.00002445445,0.0010873731],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998884,0.000047947527,0.00023785245,0.00025908518,0.00032600708,0.00024506936],"domain_scores_gemma":[0.9990908,0.000029649289,0.00017268804,0.00049170945,0.00008661242,0.00012852687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003096077,0.00011774162,0.0002783792,0.00010120338,0.00009464206,0.00003404675,0.00015729817,0.0001312145,0.000034719724],"category_scores_gemma":[0.000100638594,0.000096858326,0.000039394938,0.00007454621,0.00013999648,0.00014356757,0.00013508368,0.00019865623,0.000013049755],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012905739,0.00051819277,0.022794588,0.00018673907,0.000021782882,0.0000130461685,0.00019977211,2.8215462e-7,0.96793824,0.000013675576,0.0008589577,0.007325642],"study_design_scores_gemma":[0.005025924,0.00012684005,0.12050482,0.00009344877,0.000066183165,0.000011611676,0.00003241055,0.0001646739,0.8711952,0.00003736339,0.002656016,0.00008553124],"about_ca_topic_score_codex":0.00006819237,"about_ca_topic_score_gemma":0.000004014778,"teacher_disagreement_score":0.09771024,"about_ca_system_score_codex":0.000026850232,"about_ca_system_score_gemma":0.00011413459,"threshold_uncertainty_score":0.3949768},"labels":[],"label_agreement":null},{"id":"W3096717709","doi":"10.1182/blood-2020-140837","title":"CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Medicine; Chemotherapy; Chemotherapy regimen; Internal medicine; Minimal residual disease; Oncology; Leukemia; Disease; Complete remission; Myeloid","score_opus":0.01991898408853723,"score_gpt":0.25754255148845406,"score_spread":0.23762356739991683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096717709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858552,0.0000958282,0.000008404049,0.0055025453,0.00011245807,0.0075595123,0.00077851914,0.000023184291,0.000064297354],"genre_scores_gemma":[0.99804497,0.000058429003,0.00011039497,0.00051329896,0.00021992013,0.00037264777,0.00013199568,0.00006098185,0.00048737085],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.995759,0.00047369034,0.0008428359,0.0007781918,0.001621533,0.0005247114],"domain_scores_gemma":[0.99642026,0.00072931295,0.00051209674,0.0010441397,0.001010262,0.00028394413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087031425,0.00033585698,0.0007066137,0.000059765673,0.000103649756,0.000021251932,0.0007035174,0.00014145074,0.000020449272],"category_scores_gemma":[0.004010784,0.00017747693,0.00014938445,0.0004931019,0.00028257663,0.00011966747,0.00041744142,0.00058280834,0.0000032028508],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68473756,0.0065532755,0.2892172,0.00012691705,0.00086595345,0.00012549479,0.009193017,0.000012383778,0.0043112272,0.0000035731798,0.004447036,0.00040635912],"study_design_scores_gemma":[0.46676692,0.004495201,0.5061611,0.0006211886,0.00069598993,0.000003091423,0.0021054747,0.00018553402,0.018180873,0.000040003615,0.00045939276,0.00028524717],"about_ca_topic_score_codex":0.0008919432,"about_ca_topic_score_gemma":0.00030438506,"teacher_disagreement_score":0.21797064,"about_ca_system_score_codex":0.0003502282,"about_ca_system_score_gemma":0.0011275791,"threshold_uncertainty_score":0.7237299},"labels":[],"label_agreement":null},{"id":"W3096728088","doi":"10.1182/blood-2020-142638","title":"Integrated Stem Cell Signature and Cytomolecular Risk Determination in Pediatric Acute Myeloid Leukemia","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Oncology; Leukemia; Bone marrow","score_opus":0.0097375895650086,"score_gpt":0.23910612667912398,"score_spread":0.22936853711411537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096728088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961177,0.0013989008,0.00035077234,0.00048679003,0.000024883875,0.00055324053,0.00003083953,0.00009099163,0.0009458584],"genre_scores_gemma":[0.9957289,0.0015064193,0.0017536028,0.00047570217,0.00019009339,0.000026403897,0.00005167569,0.000044942815,0.0002222741],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984382,0.00013571246,0.00028042682,0.00045231907,0.00035132703,0.00034204795],"domain_scores_gemma":[0.99919415,0.00008935602,0.00009496399,0.00022024053,0.00011070258,0.00029056348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021257297,0.00021333217,0.00033942057,0.0002310357,0.000049994254,0.000034199897,0.00015053312,0.00026219425,0.000026101967],"category_scores_gemma":[0.00011246495,0.00018629472,0.00006288085,0.000847411,0.00004160472,0.000100245226,0.00011280611,0.0010358015,0.00005101754],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015645466,0.000866103,0.35631603,0.0016298422,0.00036817446,0.012418798,0.0061627543,0.000039838982,0.5559335,0.000037998085,0.004042948,0.06061952],"study_design_scores_gemma":[0.054807946,0.0042158086,0.19529134,0.00021403116,0.0040228846,0.00073272013,0.0015123877,0.04082151,0.6921489,0.00010376019,0.00456736,0.0015613026],"about_ca_topic_score_codex":0.000044471974,"about_ca_topic_score_gemma":0.000008879035,"teacher_disagreement_score":0.16102469,"about_ca_system_score_codex":0.00020046496,"about_ca_system_score_gemma":0.00046982747,"threshold_uncertainty_score":0.75968784},"labels":[],"label_agreement":null},{"id":"W3096744447","doi":"10.1182/blood-2020-134787","title":"IPO11 Regulates the Nuclear Import of BZW1/2 and Is Necessary for AML Cells and Stem Cells","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"CD34; Myeloid leukemia; Haematopoiesis; Stem cell; Biology; Cancer research; Myeloid; Progenitor cell; Population; Leukemia; Molecular biology; Immunology; Cell biology; Medicine","score_opus":0.021149983101113077,"score_gpt":0.25166779866802186,"score_spread":0.23051781556690878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096744447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99035066,0.0009903423,0.000005425577,0.007295295,0.000020277581,0.00062963733,0.000059060963,0.000026542863,0.0006227502],"genre_scores_gemma":[0.9960015,0.0005010206,0.00073867483,0.0016698055,0.00015423408,0.00000998937,0.0000039884326,0.000039183276,0.000881627],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99912107,0.00002491081,0.00020373712,0.00024853458,0.00019551678,0.00020624699],"domain_scores_gemma":[0.99931556,0.00014795696,0.00007005575,0.00023567532,0.00006435233,0.00016640838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001923812,0.000114137714,0.00027884872,0.000030852592,0.00006483339,0.000019738076,0.000115230396,0.00008306444,0.000058620823],"category_scores_gemma":[0.000020384088,0.00007606038,0.000052627456,0.0001166626,0.00015898251,0.000046411475,0.00013799021,0.0001610942,0.000008956463],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056036253,0.00021781401,0.0057378383,0.0014699395,0.00043768625,0.00006611662,0.0050293603,8.7163403e-7,0.8981062,0.00016679581,0.082165666,0.0060413415],"study_design_scores_gemma":[0.0057288865,0.0010135775,0.0028787912,0.00007627345,0.00042656035,0.00006142616,0.0017027138,0.0015233768,0.94563615,0.00007422687,0.040723387,0.00015465615],"about_ca_topic_score_codex":0.000025004647,"about_ca_topic_score_gemma":7.122628e-7,"teacher_disagreement_score":0.047529913,"about_ca_system_score_codex":0.000009466087,"about_ca_system_score_gemma":0.00007511698,"threshold_uncertainty_score":0.31016523},"labels":[],"label_agreement":null},{"id":"W3096745665","doi":"10.1101/2020.11.06.20225607","title":"Increased CHIP Prevalence Amongst People Living with HIV","year":2020,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"","keywords":"Medicine; Coronary artery disease; Disease; Human immunodeficiency virus (HIV); Internal medicine; Population; Oncology; Immunology; Environmental health","score_opus":0.02298290071587854,"score_gpt":0.279130383812302,"score_spread":0.25614748309642343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096745665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98543817,0.00043889575,0.0008159748,0.0050869714,0.00013075984,0.0014381052,0.000065485554,0.00039374526,0.0061918846],"genre_scores_gemma":[0.9916225,0.0004016318,0.0027812414,0.0006114072,0.00075544795,0.0002816733,0.00016104542,0.00015465668,0.003230371],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99629164,0.0002666184,0.0004391787,0.0012007094,0.0011292152,0.0006726382],"domain_scores_gemma":[0.996901,0.00043436146,0.00023089128,0.0014451838,0.00026733335,0.00072123803],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00072179036,0.00052739226,0.000919126,0.0002300948,0.0001082164,0.000088080604,0.00077819254,0.00037601672,0.001306814],"category_scores_gemma":[0.0017443175,0.00041840688,0.00020406157,0.00047694932,0.00019933801,0.00007510945,0.0015229748,0.002616342,0.00095024024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029110743,0.00012664341,0.98473334,0.004690039,0.00025185186,0.00047833944,0.0012387856,0.00001865407,0.0027696355,0.00003007518,0.0051004384,0.00027108204],"study_design_scores_gemma":[0.001201886,0.00027897087,0.9884028,0.0031529823,0.00038112598,0.00014103814,0.00015111541,0.003147428,0.00145182,0.000046975198,0.001145681,0.0004982146],"about_ca_topic_score_codex":0.00043664625,"about_ca_topic_score_gemma":0.000075552416,"teacher_disagreement_score":0.0061843474,"about_ca_system_score_codex":0.00042643302,"about_ca_system_score_gemma":0.001648771,"threshold_uncertainty_score":0.9998276},"labels":[],"label_agreement":null},{"id":"W3097014108","doi":"10.1182/blood-2020-136625","title":"Comparative Efficacy of CC-486 Versus Injectable Azacitidine (AZA) in Patients (Pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy: Findings from an Indirect Treatment Comparison (ITC)","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Chemotherapy regimen; Induction chemotherapy; Azacitidine; Oncology; Gastroenterology; Surgery","score_opus":0.03477449543718817,"score_gpt":0.30265461389412934,"score_spread":0.26788011845694115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097014108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99720186,0.00011737953,0.000009470729,0.0008430454,0.00006149193,0.0014428839,0.000074869116,0.000058935235,0.00019006361],"genre_scores_gemma":[0.99794793,0.00008991062,0.00085765764,0.00025077816,0.00010991249,0.000107089676,0.0005412427,0.000059433503,0.000036063753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973906,0.00014449403,0.0006290388,0.0007612835,0.0005773674,0.00049719727],"domain_scores_gemma":[0.99856454,0.00018581121,0.00022182643,0.00040524645,0.00030039038,0.00032215682],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012371977,0.00043290536,0.0011974361,0.00036740018,0.000062005645,0.000026621306,0.00019404333,0.000255619,0.00008635742],"category_scores_gemma":[0.00014336917,0.00034718015,0.00009111326,0.0010290089,0.00014972943,0.00027631116,0.000089071655,0.00064422336,0.000023213017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09119873,0.012353594,0.8184762,0.00011497335,0.0014276317,0.0003380486,0.051094145,0.00010786656,0.020760821,0.0000021234466,0.00073178957,0.0033940761],"study_design_scores_gemma":[0.15119646,0.010516055,0.58567655,0.0005157322,0.00035703008,0.000007534297,0.0021861987,0.00094552705,0.24793631,0.0000032446383,0.0002903781,0.00036899882],"about_ca_topic_score_codex":0.0017919109,"about_ca_topic_score_gemma":0.00068106985,"teacher_disagreement_score":0.23279968,"about_ca_system_score_codex":0.0015956172,"about_ca_system_score_gemma":0.0004947761,"threshold_uncertainty_score":0.999898},"labels":[],"label_agreement":null},{"id":"W3097048703","doi":"10.1182/blood-2020-142637","title":"Acute Myeloid Leukaemia in Elderly: Expression Analysis of DNA Damage Response (DDR) and Anti-Apoptosis Genes Identify Novel Targets for Potential \"Synergistic Lethality\"","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"DNA damage; DNA repair; Cancer research; PARP1; Synthetic lethality; Genome instability; Biology; Cell cycle; Medicine; Cancer; Immunology; Gene; Genetics; Poly ADP ribose polymerase; DNA","score_opus":0.027361336184324275,"score_gpt":0.3149226972238821,"score_spread":0.2875613610395578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097048703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99085015,0.0005029667,0.0056220363,0.0018391171,0.0000473779,0.00069719326,0.0003567945,0.00004979217,0.000034549077],"genre_scores_gemma":[0.9935746,0.00023501534,0.0053403587,0.00022355681,0.00014639983,0.00006309934,0.00022623282,0.00005043882,0.00014030376],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973497,0.00020145735,0.0006724462,0.00070361845,0.0005733662,0.00049944443],"domain_scores_gemma":[0.99833137,0.00039305227,0.0002101275,0.0005044332,0.00022390128,0.00033713484],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00080552464,0.0002840026,0.00097429147,0.00069220585,0.000099354176,0.000044183438,0.00027132788,0.00024970123,0.0000711752],"category_scores_gemma":[0.000831156,0.00026092184,0.00029901884,0.001289094,0.00017704749,0.00015844438,0.0002830911,0.00033435947,0.0000041062326],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029926088,0.00040603764,0.009895668,0.0002915319,0.0015583995,0.00013178078,0.0005151352,0.00010069627,0.9833638,0.000015956306,0.00042239955,0.00030600018],"study_design_scores_gemma":[0.010085298,0.00054704834,0.104360186,0.00010796643,0.0047760434,0.000013657724,0.00030700365,0.0049689603,0.874256,0.000013010622,0.00028395848,0.00028086427],"about_ca_topic_score_codex":0.00012761515,"about_ca_topic_score_gemma":0.000012376352,"teacher_disagreement_score":0.10910778,"about_ca_system_score_codex":0.000079494006,"about_ca_system_score_gemma":0.00029375093,"threshold_uncertainty_score":0.9999843},"labels":[],"label_agreement":null},{"id":"W3097082273","doi":"10.1182/blood-2020-136076","title":"Leukemia Stem Cells Demonstrate Increased DNA Damage Repair and Chemoresistance in Acute Myeloid Leukemia","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Stem cell; DNA repair; Biology; RAD51; Myeloid leukemia; DNA damage; Molecular biology; Cancer research; Cell biology; DNA; Genetics","score_opus":0.015710040178852316,"score_gpt":0.24555456078531307,"score_spread":0.22984452060646077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097082273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99304163,0.0006158127,0.000021539476,0.0010947511,0.00003225054,0.0007832232,0.000048556205,0.00032684658,0.004035397],"genre_scores_gemma":[0.99378,0.0004948972,0.0026723568,0.00175471,0.0002213282,0.000054108,0.000035090707,0.000086543434,0.00090094033],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971169,0.00014856445,0.00057702325,0.0008687565,0.0005482389,0.000740503],"domain_scores_gemma":[0.9982312,0.0001725836,0.0001298871,0.0006146932,0.000105353276,0.000746299],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004527074,0.00039080076,0.0007546825,0.00017205585,0.00009994622,0.000055617,0.00029756443,0.000280596,0.00007085207],"category_scores_gemma":[0.00011297215,0.00037241203,0.00014828402,0.00077879126,0.00025718732,0.00019627337,0.00024938,0.00092876493,0.00011468169],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001446103,0.00020666589,0.049213286,0.00079787936,0.0004843808,0.0066205845,0.00082087744,0.0000069765624,0.9313353,0.000113275244,0.0072934004,0.0016613068],"study_design_scores_gemma":[0.02275882,0.00074645673,0.104021996,0.00037351498,0.0007073937,0.0003340565,0.0006927253,0.0052173464,0.86091137,0.00004354276,0.0034196416,0.0007731459],"about_ca_topic_score_codex":0.00022448666,"about_ca_topic_score_gemma":0.000062702115,"teacher_disagreement_score":0.0704239,"about_ca_system_score_codex":0.00073292863,"about_ca_system_score_gemma":0.0017122438,"threshold_uncertainty_score":0.9998728},"labels":[],"label_agreement":null},{"id":"W3097357948","doi":"10.1182/blood-2020-140165","title":"RBC-Enhance: A Randomized Pilot Feasibility Trial of Red Cell Transfusion Thresholds in Myelodysplastic Syndromes","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University Health Network; McMaster University; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Anemia; Hemoglobin; Randomized controlled trial; Blood transfusion; Randomization; Erythropoietin; Quality of life (healthcare); Red blood cell; Life expectancy; Internal medicine; Pediatrics; Surgery; Population; Bone marrow","score_opus":0.040621411507746646,"score_gpt":0.30675477093107995,"score_spread":0.26613335942333327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097357948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896557,0.00029851028,0.00021047033,0.0020096027,0.00009030263,0.0040227002,0.000014391609,0.000066621236,0.0036317182],"genre_scores_gemma":[0.99837404,0.00039508753,0.00055912463,0.00012872265,0.0001640771,0.00013695363,0.00002009414,0.00003448535,0.00018739907],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972437,0.00040142777,0.00080398365,0.00051574066,0.00065452704,0.0003806393],"domain_scores_gemma":[0.99839413,0.00068934454,0.0001252215,0.00041517516,0.000111646055,0.00026445865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011837928,0.00022340352,0.0013159856,0.00015897395,0.00003439337,0.000011043276,0.00021445262,0.00015137627,0.00031478482],"category_scores_gemma":[0.0016580124,0.00017788034,0.00025875718,0.00062026794,0.00021049741,0.000072295275,0.000072444134,0.0005533074,0.000030511703],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8394995,0.0025731828,0.002529089,0.0006485436,0.00010549286,0.00019420485,0.0006374707,0.0000061592546,0.15345928,0.000019723544,0.0002005514,0.00012684365],"study_design_scores_gemma":[0.92830783,0.0042946725,0.0015711194,0.00014795715,0.00036212456,0.000026657759,0.000091133385,0.00047510647,0.06443455,0.0001055416,0.00002847706,0.00015481932],"about_ca_topic_score_codex":0.00009454607,"about_ca_topic_score_gemma":0.00001803017,"teacher_disagreement_score":0.08902473,"about_ca_system_score_codex":0.00008938662,"about_ca_system_score_gemma":0.0005186325,"threshold_uncertainty_score":0.725375},"labels":[],"label_agreement":null},{"id":"W3097378247","doi":"10.1182/blood-2020-136922","title":"Molecular Characterization of Clinical Response and Relapse in Patients with <i>IDH1</i>-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Internal medicine; IDH1; Azacitidine; Gastroenterology; Isocitrate dehydrogenase; Myeloid; Refractory (planetary science); Oncology; Biology; Mutant","score_opus":0.012473492353877574,"score_gpt":0.26311456876836514,"score_spread":0.2506410764144876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097378247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976269,0.000046561134,0.000045772933,0.0011534914,0.0000068496315,0.0009804516,0.00006893361,0.000042107768,0.00002891837],"genre_scores_gemma":[0.9982634,0.0002322233,0.0006125854,0.0005878957,0.000034537366,0.000031252268,0.00016637894,0.000053637777,0.000018085815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794,0.00027006693,0.0005552617,0.000514106,0.00043359702,0.00028696],"domain_scores_gemma":[0.99873513,0.0002221197,0.00019766846,0.0002839674,0.00019173202,0.000369399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034710474,0.00023658921,0.00066243863,0.00014684936,0.000033409597,0.00002065647,0.000086187574,0.00016479353,0.000009685912],"category_scores_gemma":[0.0004673907,0.00017176254,0.00003652589,0.0005435379,0.00022517181,0.00014653758,0.00008667945,0.0004098058,0.0000024682647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027267542,0.0003470633,0.6620405,0.00008217726,0.00025476387,0.0013522874,0.0003088592,0.0000012083448,0.30760273,0.000005077149,0.000011448471,0.00072638027],"study_design_scores_gemma":[0.042553153,0.005850353,0.8686884,0.00024911689,0.00041710652,0.000054265685,0.00003896839,0.00019988233,0.081700884,0.0000011442465,0.00006240321,0.00018430944],"about_ca_topic_score_codex":0.000047597692,"about_ca_topic_score_gemma":0.00000683985,"teacher_disagreement_score":0.22590186,"about_ca_system_score_codex":0.00006190422,"about_ca_system_score_gemma":0.00043738363,"threshold_uncertainty_score":0.70042735},"labels":[],"label_agreement":null},{"id":"W3097417633","doi":"10.1182/bloodadvances.2020001802","title":"CD200 expression marks leukemia stem cells in human AML","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; McGill University; University Health Network; Western University","funders":"","keywords":"Myeloid leukemia; CD34; Leukemia; NPM1; Stem cell; Population; Biology; Haematopoiesis; Phenotype; Progenitor cell; Cancer research; Molecular biology; Immunology; Gene; Medicine; Genetics; Karyotype","score_opus":0.021576943423611123,"score_gpt":0.29392016912771074,"score_spread":0.27234322570409963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097417633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861916,0.002557075,0.00007427913,0.0010049,0.000072034614,0.00053452584,0.0000131103,0.00012434176,0.009428189],"genre_scores_gemma":[0.99421126,0.0005181533,0.0018193399,0.0009077639,0.0003998979,0.000043208875,0.000017640246,0.000042818872,0.002039906],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998269,0.000077955796,0.000331264,0.0004628233,0.0004264744,0.00043244252],"domain_scores_gemma":[0.99918765,0.00008629798,0.00007724337,0.00029884165,0.00005093344,0.00029901275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001538112,0.00019394822,0.00037646756,0.0001052587,0.00007540818,0.000021632326,0.00024133066,0.00011499764,0.00039872862],"category_scores_gemma":[0.000042853288,0.00016182194,0.00007288491,0.0003556444,0.000084764775,0.00020927443,0.0001465928,0.0005378331,0.00014043614],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003122042,0.00014432856,0.019694336,0.00040965562,0.000026247273,0.00073266594,0.0006937583,0.00012963449,0.9618464,0.00007096037,0.0063341726,0.009605617],"study_design_scores_gemma":[0.0050840094,0.00054183096,0.0026386823,0.00033100403,0.00004396716,0.000026039439,0.00086067355,0.00032846673,0.91622066,0.00006832577,0.07359038,0.00026592446],"about_ca_topic_score_codex":0.000026692238,"about_ca_topic_score_gemma":0.0000124468115,"teacher_disagreement_score":0.06725621,"about_ca_system_score_codex":0.00018048777,"about_ca_system_score_gemma":0.00021745356,"threshold_uncertainty_score":0.6598907},"labels":[],"label_agreement":null},{"id":"W3097520009","doi":"10.1182/blood-2020-134645","title":"Geographical Distance from Quaternary Treatment Center Does Not Impact Choice of Upfront Therapy, Clinical Trial Participation and Outcomes in Patients with Newly Diagnosed AML","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Chemotherapy regimen; Internal medicine; Clinical trial; Chemotherapy; Pediatrics","score_opus":0.048409241041222434,"score_gpt":0.36861543943966874,"score_spread":0.32020619839844633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097520009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971462,0.00006664793,0.000019086208,0.0013311327,0.00004575761,0.0011719218,0.0001906892,0.00002037421,0.000008211062],"genre_scores_gemma":[0.9989227,0.00019763884,0.0002098753,0.00029363867,0.00015492596,0.000069052134,0.00012299411,0.000020898884,0.00000824483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835455,0.0001768564,0.00050429505,0.00036084434,0.00035691148,0.0002465426],"domain_scores_gemma":[0.9988241,0.0004845265,0.00013259434,0.0002466305,0.000053800406,0.00025834344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010826827,0.00018316871,0.0005947833,0.000052596646,0.000020404339,0.000015750396,0.00008167374,0.00009651183,0.000040068495],"category_scores_gemma":[0.00025141638,0.0000941012,0.00013025466,0.00011238083,0.00011705528,0.00007665892,0.000035872807,0.00018862502,0.0000025664583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051456995,0.0048698187,0.9375008,0.000009358496,0.00045220912,0.00003413078,0.00039141515,8.920928e-7,0.000070403454,9.283419e-7,0.000014072014,0.0051990235],"study_design_scores_gemma":[0.21843557,0.0075103575,0.7732819,0.000028951305,0.00010341341,1.0097503e-7,0.000016516515,0.000103227714,0.0003691065,0.0000032320388,0.00006885644,0.00007879972],"about_ca_topic_score_codex":0.0017629702,"about_ca_topic_score_gemma":0.00034214687,"teacher_disagreement_score":0.16697858,"about_ca_system_score_codex":0.000056485893,"about_ca_system_score_gemma":0.0000991158,"threshold_uncertainty_score":0.38373354},"labels":[],"label_agreement":null},{"id":"W3097681321","doi":"10.1182/blood-2020-136957","title":"Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant <i>IDH1</i> AML: Results from Matched Comparisons to Historical Controls","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Regimen; Internal medicine; Refractory (planetary science); Isocitrate dehydrogenase; Oncology; Gastroenterology; Surgery; Biology","score_opus":0.041513464589884565,"score_gpt":0.29874770792655153,"score_spread":0.25723424333666695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097681321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9443031,0.00049924717,0.00055665686,0.050547563,0.00020868628,0.001833166,0.0005667012,0.00020267967,0.0012821958],"genre_scores_gemma":[0.98645455,0.0000755718,0.0071327314,0.00452245,0.00052284484,0.00011615699,0.00007368286,0.0000954472,0.0010065921],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99611706,0.0003540723,0.00093430426,0.000911674,0.0009946068,0.0006882666],"domain_scores_gemma":[0.99662733,0.001409242,0.0001759907,0.0006541834,0.00024127094,0.0008919817],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051771326,0.00038673755,0.0012631107,0.00018403381,0.000089435496,0.000054949345,0.00037332397,0.0002664307,0.00011831356],"category_scores_gemma":[0.0036520176,0.0003052038,0.00015307606,0.0005887803,0.000067662426,0.00012876705,0.00023366394,0.0011276571,0.00019477132],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09055701,0.0011183565,0.0049527446,0.00006211344,0.00084088865,0.0017939905,0.022072904,0.000033009874,0.81622976,0.00018503697,0.061063804,0.0010903752],"study_design_scores_gemma":[0.21099155,0.02445077,0.09263406,0.0009976325,0.0010339672,0.000051655552,0.0066334377,0.0008732104,0.08690561,0.00046955756,0.5726244,0.0023341717],"about_ca_topic_score_codex":0.0024137408,"about_ca_topic_score_gemma":0.0006086247,"teacher_disagreement_score":0.72932416,"about_ca_system_score_codex":0.0015232522,"about_ca_system_score_gemma":0.0008279318,"threshold_uncertainty_score":0.99994},"labels":[],"label_agreement":null},{"id":"W3097756286","doi":"10.1182/blood.v130.suppl_1.27.27","title":"Response Kinetics and Factors Predicting Survival Among Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Core binding factor; Myeloid leukemia; Medicine; Internal medicine; Leukemia; Oncology; Kinetics; Immunology; Cancer research; Biology; Transcription factor; Genetics","score_opus":0.028484602731934382,"score_gpt":0.28423748166622287,"score_spread":0.2557528789342885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097756286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979779,0.000023839024,0.000019145336,0.00012308291,0.0001715408,0.0007637512,0.0002372348,0.00012451349,0.0005589535],"genre_scores_gemma":[0.99792254,0.000036831792,0.00050969503,0.000028589386,0.00014450312,0.00001714241,0.00009959945,0.000099020464,0.0011421043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974243,0.000100384015,0.0003371662,0.0005851212,0.000851933,0.0007010946],"domain_scores_gemma":[0.9975752,0.00036653472,0.00031341673,0.00097997,0.0002578995,0.0005069607],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035124514,0.0003761228,0.00052371185,0.00022578968,0.0006131744,0.00020539139,0.00038950003,0.00024801987,0.000049451937],"category_scores_gemma":[0.0013110054,0.00028168145,0.00007656069,0.00013883278,0.00046445412,0.00032449787,0.00039339298,0.0006755866,0.000014413552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00160311,0.00016806588,0.9747644,0.00005414656,0.0004094872,0.00019497551,0.000790703,6.936833e-7,0.021515016,0.0000029604998,0.0000796171,0.00041681353],"study_design_scores_gemma":[0.010050701,0.0012942542,0.9710069,0.00021630045,0.00036157624,0.000025937983,0.00023308981,0.00009811073,0.016218899,0.0000025584714,0.00019764778,0.0002940564],"about_ca_topic_score_codex":0.0002579045,"about_ca_topic_score_gemma":0.00007137926,"teacher_disagreement_score":0.008447591,"about_ca_system_score_codex":0.00034680628,"about_ca_system_score_gemma":0.00035813736,"threshold_uncertainty_score":0.9999635},"labels":[],"label_agreement":null},{"id":"W3097766015","doi":"10.1182/blood-2020-134557","title":"Characterizing Frailty in Myeloproliferative Neoplasms: Baseline Results from the Orchid Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University; Population Health Research Institute; Queen's University","funders":"","keywords":"Medicine; Internal medicine; Stroke (engine); Weight loss; Depression (economics); Physical therapy; Obesity","score_opus":0.05270650216916771,"score_gpt":0.3051623174984077,"score_spread":0.25245581532924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097766015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96524876,0.000120035016,0.000023345357,0.032065064,0.000043393582,0.0012482592,0.00019820424,0.00007914858,0.00097377005],"genre_scores_gemma":[0.99213415,0.000050852195,0.0005881132,0.005766226,0.0010235728,0.00006692945,0.00019872864,0.00003488825,0.00013654851],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777263,0.0003640674,0.00048083212,0.0005383842,0.00048641127,0.0003576955],"domain_scores_gemma":[0.99832124,0.0007836937,0.00008694799,0.00049138436,0.000096058044,0.0002206553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006982251,0.00020261337,0.000392227,0.00005481037,0.000095982105,0.000043649023,0.00028994668,0.000082919076,0.000120669734],"category_scores_gemma":[0.0027939554,0.00013325574,0.000060158403,0.0005196268,0.00006094499,0.00009064066,0.00021805732,0.0008866913,0.00021153105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01610408,0.007363327,0.5586104,0.00009941648,0.0016886799,0.0062517007,0.18746883,0.00002410244,0.19309457,0.00007963551,0.01447773,0.014737558],"study_design_scores_gemma":[0.068485126,0.0029992466,0.84705883,0.00027123175,0.0004307132,0.000051724266,0.016664604,0.005272692,0.044167895,0.000044022454,0.013977412,0.00057650317],"about_ca_topic_score_codex":0.00059968675,"about_ca_topic_score_gemma":0.00022680529,"teacher_disagreement_score":0.28844845,"about_ca_system_score_codex":0.000063476975,"about_ca_system_score_gemma":0.00035723258,"threshold_uncertainty_score":0.5434011},"labels":[],"label_agreement":null},{"id":"W3097787544","doi":"10.1182/blood-2020-133912","title":"Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Venetoclax; Azacitidine; Cytarabine; Myeloid leukemia; Medicine; Leukemia; Myeloid; Oncology; Internal medicine; Clofarabine; Quality of life (healthcare); Biology; DNA methylation","score_opus":0.02896554083932576,"score_gpt":0.2730905731527798,"score_spread":0.24412503231345403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097787544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957417,0.000035795998,0.000064180495,0.0013458013,0.000007992729,0.002717873,0.000025389982,0.00002875264,0.000032516018],"genre_scores_gemma":[0.9978602,0.000020850128,0.001288955,0.000210664,0.000006548186,0.00010668839,0.00042745678,0.000050500606,0.000028144183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963224,0.00053767394,0.0014135812,0.0004885676,0.00082693266,0.0004108449],"domain_scores_gemma":[0.9984285,0.00016154799,0.00056346087,0.00031078077,0.00033543125,0.0002002475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012134527,0.00026873912,0.0010440063,0.0005996798,0.000025597199,0.000013935765,0.00019355855,0.00016910097,0.000036785506],"category_scores_gemma":[0.0004889927,0.00021388884,0.00002720754,0.0025103597,0.000079784426,0.00031184408,0.0000759344,0.0005339525,0.000006710527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023305316,0.0018460293,0.95701355,0.00067826814,0.00010038599,0.00008178529,0.0029036982,0.0017683179,0.011164581,0.000013303116,0.000015386984,0.0011093671],"study_design_scores_gemma":[0.059147988,0.008431555,0.9235348,0.0016983326,0.000027336646,0.0000042735105,0.00017950454,0.003857055,0.0028916476,0.000010155298,0.0000016532416,0.00021567619],"about_ca_topic_score_codex":0.0026167794,"about_ca_topic_score_gemma":0.0036615569,"teacher_disagreement_score":0.035842672,"about_ca_system_score_codex":0.0015821065,"about_ca_system_score_gemma":0.0020890292,"threshold_uncertainty_score":0.87221336},"labels":[],"label_agreement":null},{"id":"W3097795751","doi":"10.1182/blood-2020-138822","title":"Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; McMaster University; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Myeloid leukemia; Pharmacodynamics; Induction chemotherapy; Oncology; Chemotherapy regimen; Leukemia; Phases of clinical research; Chemotherapy; Gastroenterology; Adverse effect; Pharmacokinetics","score_opus":0.012716654860611078,"score_gpt":0.2596851803734144,"score_spread":0.24696852551280335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097795751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968164,0.00010420611,0.0000071554587,0.00033069594,0.000033363805,0.0017789224,0.0007549468,0.000058476817,0.000115844436],"genre_scores_gemma":[0.9981969,0.00006932967,0.0009691452,0.00013386454,0.00018528655,0.000055215714,0.00029320372,0.000054025226,0.000043058546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973742,0.00017331156,0.0006068936,0.00071217713,0.00075896183,0.00037449444],"domain_scores_gemma":[0.99849737,0.00021259875,0.00023640397,0.0005308876,0.00016988805,0.0003528775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021931308,0.00028512243,0.0006525363,0.00018151342,0.000059488004,0.000019479292,0.00019349519,0.0001456816,0.000021578993],"category_scores_gemma":[0.00040723124,0.00022472157,0.000042511787,0.00057557493,0.00011787938,0.00013887692,0.00028026482,0.0006938209,0.000011951527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13144182,0.018368734,0.80207276,0.000180374,0.0022380978,0.0025667013,0.027117006,0.000025946349,0.004036714,0.0000030892074,0.002768036,0.009180703],"study_design_scores_gemma":[0.25531605,0.04978697,0.6832093,0.00023952,0.0013124011,0.000010009476,0.0015244297,0.00044143273,0.0076980046,0.000012795415,0.00013227272,0.00031679956],"about_ca_topic_score_codex":0.0028974111,"about_ca_topic_score_gemma":0.000081550534,"teacher_disagreement_score":0.123874225,"about_ca_system_score_codex":0.00015186609,"about_ca_system_score_gemma":0.00047761627,"threshold_uncertainty_score":0.91638803},"labels":[],"label_agreement":null},{"id":"W3101457631","doi":"10.14740/jh760","title":"Molecular Genetic Analysis With Flow Cytometry Sorting Identifies Angioimmunoblastic T-Cell Lymphoma and Concomitant <i>De Novo</i> Myelodysplastic Syndrome Arising From the Same Hematopoietic Progenitor","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Myelodysplastic syndromes; Concomitant; Medicine; Flow cytometry; Progenitor cell; Lymphoma; Bone marrow; Progenitor; Haematopoiesis; Pathology; Cancer research; Immunology; Stem cell; Biology; Internal medicine; Genetics","score_opus":0.009862783423716113,"score_gpt":0.2465517222482946,"score_spread":0.2366889388245785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101457631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646966,0.006984843,0.024947062,0.0029799961,0.00007567027,0.000264124,0.000008952289,0.000023887013,0.000018854958],"genre_scores_gemma":[0.98941815,0.00011621958,0.009464356,0.0008226277,0.00010590632,0.000007631848,0.0000053224358,0.000051708663,0.000008098066],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9972767,0.0002496041,0.00096489873,0.0003492774,0.0006316055,0.0005278708],"domain_scores_gemma":[0.99721414,0.0011173277,0.00066055986,0.0003339334,0.0002932358,0.00038080034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004029178,0.00029433038,0.0012451451,0.00033590014,0.00015037044,0.000106002284,0.0003478962,0.00016784672,0.00005906045],"category_scores_gemma":[0.0007823666,0.00019138058,0.00029408574,0.0011208794,0.00034102364,0.00009966227,0.00015534298,0.0005687092,0.000015857036],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034841732,0.0006539387,0.5255124,0.0014120296,0.014766028,0.088372506,0.00628109,0.0033975933,0.35435963,0.00007727781,0.000591359,0.0010919687],"study_design_scores_gemma":[0.033089694,0.006859934,0.2607321,0.002232668,0.035379548,0.34839162,0.013990956,0.11947978,0.1769634,0.00096260116,0.0001952362,0.0017224352],"about_ca_topic_score_codex":0.00002421606,"about_ca_topic_score_gemma":0.000006780494,"teacher_disagreement_score":0.26478028,"about_ca_system_score_codex":0.0001826424,"about_ca_system_score_gemma":0.00060793944,"threshold_uncertainty_score":0.78042734},"labels":[],"label_agreement":null},{"id":"W3101644750","doi":"10.1038/s41598-020-76933-2","title":"RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia","year":2020,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Research Foundation of Korea; Chonnam National University; National Natural Science Foundation of China; Natural Sciences and Engineering Research Council of Canada; Ministry of Science and ICT, South Korea; Princess Margaret Cancer Foundation; National Research Foundation; Leukemia and Lymphoma Society of Canada; Chonnam National University Hwasun Hospital; Leukemia and Lymphoma Society","keywords":"Minimal residual disease; Myeloid leukemia; Fusion gene; Core binding factor; IDH1; RUNX1T1; RNA; NPM1; Oncology; DNA sequencing; Leukemia; Medicine; Biology; Internal medicine; Mutation; Gene; Gene expression; Genetics; Transcription factor","score_opus":0.07513021499425002,"score_gpt":0.33641439647677257,"score_spread":0.2612841814825225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101644750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99492204,0.000059527447,0.00045344402,0.00057765585,0.001388032,0.0018499822,0.00004156602,0.00017088458,0.0005368595],"genre_scores_gemma":[0.9940334,0.000006554802,0.0022449917,0.00024025711,0.0004139153,0.00013553102,0.0001850622,0.00007529845,0.0026649896],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99497724,0.00010302369,0.00090016273,0.001638003,0.00142673,0.00095485745],"domain_scores_gemma":[0.99705493,0.00017889879,0.0004041503,0.0009168146,0.00050345034,0.00094176526],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023342508,0.00032163062,0.00052103016,0.0004170573,0.00052000576,0.00038620032,0.00029867285,0.00012392097,0.00014687516],"category_scores_gemma":[0.0049032914,0.00029639932,0.00017413884,0.0010578042,0.00024574154,0.0007179404,0.00019787283,0.0006247292,0.000061003284],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010511449,0.00004846084,0.023678824,0.0002671612,0.0001380158,0.011954996,0.004755428,0.0005969886,0.95004684,0.000040956278,0.0024601133,0.0049611],"study_design_scores_gemma":[0.0038308306,0.0008237397,0.0059135198,0.00068914966,0.00028659435,0.0009202125,0.0020364334,0.048704125,0.92691135,0.0042090784,0.004577718,0.0010972193],"about_ca_topic_score_codex":0.00029418664,"about_ca_topic_score_gemma":0.000044433407,"teacher_disagreement_score":0.048107136,"about_ca_system_score_codex":0.0029188695,"about_ca_system_score_gemma":0.0043523377,"threshold_uncertainty_score":0.9999488},"labels":[],"label_agreement":null},{"id":"W3102826017","doi":"10.1182/blood.v130.suppl_1.3953.3953","title":"Single Cell Transcriptome Analysis Reveals Changing Levels and Distributions of Stemness across Disease States in Pediatric AML","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Transcriptome; Stem cell; Disease; Biology; Medicine; Computational biology; Genetics; Internal medicine; Gene expression; Gene","score_opus":0.03130108368714987,"score_gpt":0.31734054518670046,"score_spread":0.2860394614995506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3102826017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99694777,0.00082400074,0.0003796465,0.00040960842,0.000020848202,0.0003005478,0.0009985085,0.00001772334,0.00010135966],"genre_scores_gemma":[0.99894816,0.00018613506,0.00016908531,0.000015584847,0.00007609741,0.000024542429,0.00010595772,0.000015617497,0.00045879793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986447,0.00005205103,0.00029251352,0.00028445947,0.00027481862,0.00045147183],"domain_scores_gemma":[0.99884486,0.00008484605,0.00013895589,0.0005573569,0.00011971645,0.000254246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004575511,0.00013059405,0.00042187647,0.0003331619,0.00022133187,0.000061625906,0.00018926252,0.00006202909,0.000024415838],"category_scores_gemma":[0.00020628147,0.000118165444,0.000118268,0.00063622865,0.0001386783,0.00014447588,0.00011091434,0.00016503462,0.0000029308449],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008030545,0.0007713746,0.9754579,0.00062865065,0.00017161759,0.00015205044,0.0012435885,0.0000075499943,0.021172242,0.000016371529,0.000022746743,0.00027558688],"study_design_scores_gemma":[0.003655687,0.00008157224,0.98369664,0.000050238967,0.0014650238,0.0000036021372,0.00038557782,0.00026575133,0.010185266,0.000055732045,0.000026687392,0.00012822798],"about_ca_topic_score_codex":0.000114434944,"about_ca_topic_score_gemma":0.000049860457,"teacher_disagreement_score":0.010986975,"about_ca_system_score_codex":0.000064025604,"about_ca_system_score_gemma":0.00010345074,"threshold_uncertainty_score":0.4818647},"labels":[],"label_agreement":null},{"id":"W3105202461","doi":"10.14740/jh691","title":"Reduce Mortality and Morbidity in Acute Myeloid Leukemia With Hyperleukocytosis With Early Admission in Intensive Care Unit: A Retrospective Analysis","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Intensive care unit; Retrospective cohort study; Myeloid leukemia; Hematology; White blood cell; Internal medicine; Intensive care medicine; Pediatrics; Emergency medicine","score_opus":0.043196552831294505,"score_gpt":0.3364286323818725,"score_spread":0.29323207955057795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3105202461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99516267,0.0005661841,0.000095740565,0.0036987418,0.000018805269,0.00029927352,0.000008584761,0.000011444673,0.00013853551],"genre_scores_gemma":[0.9979673,0.0003018512,0.0010618129,0.0005676511,0.00004768464,0.0000074718623,0.000005908572,0.000025559468,0.0000147533465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979013,0.0002045529,0.0006176956,0.0003883237,0.0005140147,0.00037408312],"domain_scores_gemma":[0.99746954,0.00011999509,0.00039822137,0.00025044082,0.0013219126,0.0004398577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029339275,0.00024000538,0.001446366,0.0007447997,0.000042316446,0.000018756366,0.00017265294,0.0001965968,0.000040477673],"category_scores_gemma":[0.0005938548,0.00015944625,0.000112640344,0.0019089445,0.0002491284,0.00019801033,0.00009472158,0.0014067936,0.0000019832166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004639349,0.000036933063,0.97721565,0.00010768039,0.0012376147,0.009643815,0.004694181,0.00008226054,0.002086356,0.000028259414,0.00010431377,0.00012356066],"study_design_scores_gemma":[0.00574322,0.0027437946,0.9703942,0.00027646282,0.001234384,0.003929299,0.008791546,0.0006564817,0.006016522,0.000025095453,0.000020946898,0.00016802717],"about_ca_topic_score_codex":0.0008193485,"about_ca_topic_score_gemma":0.0009190054,"teacher_disagreement_score":0.006821456,"about_ca_system_score_codex":0.0009837209,"about_ca_system_score_gemma":0.0014496435,"threshold_uncertainty_score":0.65020293},"labels":[],"label_agreement":null},{"id":"W3106887103","doi":"10.1016/j.leukres.2020.106489","title":"Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆","year":2020,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"F. Hoffmann-La Roche","keywords":"Cytarabine; Medicine; Myeloid leukemia; Adverse effect; Internal medicine; Gastroenterology; Refractory (planetary science); Myeloid; Leukemia; Acute leukemia; Pharmacology; Biology","score_opus":0.10250909267722716,"score_gpt":0.3992120490464178,"score_spread":0.29670295636919064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106887103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779532,0.0001527698,0.00012549483,0.01341799,0.00006669975,0.0055728005,0.00044341825,0.000381008,0.0018866173],"genre_scores_gemma":[0.98665076,0.00038442545,0.0029565422,0.001414028,0.001387603,0.00071495876,0.0022981751,0.00027298223,0.0039205384],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9876144,0.0012296779,0.0017601934,0.0027497946,0.0042227725,0.0024231805],"domain_scores_gemma":[0.9933717,0.0010355068,0.00026388915,0.0021587543,0.001138106,0.0020320448],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004084319,0.00085756625,0.001669645,0.0013315158,0.00045256945,0.00030834452,0.0010552031,0.0006120129,0.00065436924],"category_scores_gemma":[0.0011782364,0.0006555492,0.00016360648,0.005329879,0.0007335471,0.0010129387,0.0009441306,0.005478249,0.00077116553],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.588893,0.010308887,0.0067526307,0.0005623139,0.001532575,0.084836416,0.022485135,0.0006919282,0.21285966,0.000071544375,0.05551552,0.01549038],"study_design_scores_gemma":[0.6302657,0.06485773,0.018642465,0.0013640019,0.00061003544,0.000770523,0.015548421,0.045219075,0.2047341,0.00018363964,0.015384707,0.0024195781],"about_ca_topic_score_codex":0.01655885,"about_ca_topic_score_gemma":0.0051917015,"teacher_disagreement_score":0.0840659,"about_ca_system_score_codex":0.008976076,"about_ca_system_score_gemma":0.0083359275,"threshold_uncertainty_score":0.99958956},"labels":[],"label_agreement":null},{"id":"W3106971540","doi":"10.1097/icb.0000000000001100","title":"ATYPICAL PROLIFERATIVE RETINOPATHY AS THE PRESENTING FEATURE OF CHRONIC MYELOID LEUKEMIA IN A PATIENT WITH DIABETES MELLITUS","year":2020,"lang":"en","type":"review","venue":"Retinal Cases & Brief Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kensington Health; Queen's University; University of British Columbia; University of Toronto","funders":"","keywords":"Medicine; Myeloid leukemia; Diabetic retinopathy; Leukocytosis; Leukostasis; Fluorescein angiography; Bone marrow; Ophthalmology; Pathology; Diabetes mellitus; Surgery; Retinal; Internal medicine","score_opus":0.020556503216125985,"score_gpt":0.30615369217229715,"score_spread":0.28559718895617114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106971540","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036475677,0.9557087,0.0000021089718,0.0005821012,0.00009921146,0.0053970073,0.00003869832,0.00007610422,0.0016203949],"genre_scores_gemma":[0.029158158,0.96727455,0.00025564924,0.00019577821,0.0008606111,0.00089996995,0.0003918867,0.00023214093,0.0007312845],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931134,0.0008582207,0.0018304507,0.0014328259,0.0017166005,0.0010485188],"domain_scores_gemma":[0.9948208,0.0010237282,0.0018469462,0.0013781758,0.0004936808,0.0004366687],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0009797388,0.0009331396,0.0034606683,0.00029031848,0.00015708912,0.00008213182,0.00033504772,0.0006186061,0.000100889134],"category_scores_gemma":[0.003159064,0.00054494664,0.00072050706,0.001445744,0.000618568,0.00010735143,0.00051735656,0.0033711575,0.000021238697],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014809186,0.00026382983,0.0020125022,0.049420476,0.00096979714,0.32067376,0.0011564549,0.000009151387,0.000038096325,0.00009906019,0.0053918413,0.6184841],"study_design_scores_gemma":[0.0005300294,0.0031422426,0.00021948377,0.032393567,0.0014575517,0.0740346,0.00011602574,0.00008163198,0.00030473035,0.000022294082,0.8871421,0.0005557451],"about_ca_topic_score_codex":0.00015384798,"about_ca_topic_score_gemma":0.00003691673,"teacher_disagreement_score":0.8817503,"about_ca_system_score_codex":0.0035618995,"about_ca_system_score_gemma":0.012251797,"threshold_uncertainty_score":0.9997002},"labels":[],"label_agreement":null},{"id":"W3109103430","doi":"10.1101/2020.11.29.402800","title":"Mapping the Cellular Origin and Early Evolution of Leukemia in Down Syndrome","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; SickKids Foundation; University Health Network; University of Toronto; Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"","keywords":"Preleukemia; Biology; GATA1; Leukemia; Stem cell; Haematopoiesis; Trisomy; Cancer research; Myeloid leukemia; Progenitor cell; Genetics","score_opus":0.02443526448122609,"score_gpt":0.23817850227087495,"score_spread":0.21374323778964885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109103430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99260473,0.003472035,0.00096419995,0.001017928,0.00025434932,0.0014684042,0.000056731773,0.00014170753,0.000019919105],"genre_scores_gemma":[0.9973306,0.00030116685,0.0017826604,0.00008467041,0.00023703816,0.0001454991,2.6819563e-7,0.00010796205,0.000010112277],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9968103,0.00022433631,0.0007480611,0.00094534835,0.0006737524,0.0005982034],"domain_scores_gemma":[0.99759114,0.00013265584,0.00035977035,0.0012444797,0.00034951154,0.00032244],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010978802,0.00047380876,0.00094797806,0.00057107676,0.00009379748,0.000081129976,0.00053132203,0.00059256674,0.00002762587],"category_scores_gemma":[0.00046277366,0.00040619122,0.00015059765,0.0012065124,0.0003298873,0.00011204222,0.0008323946,0.0020758696,0.00004087883],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012438608,0.000048543076,0.08516384,0.0017901887,0.00022869067,0.00074913166,0.000087301436,0.00003692137,0.91069883,0.0008506769,0.0002186747,0.0000028312893],"study_design_scores_gemma":[0.0017744289,0.00017472681,0.92857856,0.00163325,0.00014096263,3.5685852e-7,0.00003142856,0.0023289868,0.062466837,0.0000129578275,0.0023197993,0.00053769886],"about_ca_topic_score_codex":0.0010956993,"about_ca_topic_score_gemma":0.0000033289177,"teacher_disagreement_score":0.848232,"about_ca_system_score_codex":0.0030243807,"about_ca_system_score_gemma":0.0033962508,"threshold_uncertainty_score":0.999839},"labels":[],"label_agreement":null},{"id":"W3109754543","doi":"10.1101/2020.11.25.20233163","title":"Clonal hematopoiesis is associated with risk of severe Covid-19","year":2020,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Queen's University","funders":"Great Southern Development Commission, Government of Western Australia; National Cancer Institute; National Institutes of Health; Stand Up To Cancer; Korea Research Environment Open Network; Korea Health Industry Development Institute; Korea Institute of Science and Technology Information; Cycle for Survival; Korea Institute of Science and Technology; Memorial Sloan-Kettering Cancer Center","keywords":"Haematopoiesis; Coronavirus disease 2019 (COVID-19); Internal medicine; Medicine; Disease; Immunology; Stem cell; Biology; Infectious disease (medical specialty); Genetics","score_opus":0.0459463680058336,"score_gpt":0.3235905387172432,"score_spread":0.27764417071140957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109754543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97765744,0.00034842748,0.00062933663,0.015937239,0.00010768308,0.0010918555,0.0011331002,0.0002153034,0.0028795989],"genre_scores_gemma":[0.9913449,0.0003804306,0.0018013469,0.0033698825,0.00022189393,0.0000959497,0.00059169513,0.000121271274,0.00207262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962862,0.00034249783,0.00059480773,0.00086569815,0.0014246785,0.00048609983],"domain_scores_gemma":[0.99641836,0.00068524806,0.0006141727,0.0010237152,0.00043940262,0.00081907905],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009479446,0.000446761,0.0013225459,0.0002446013,0.0000945615,0.000025324302,0.0005481554,0.0006020971,0.002053446],"category_scores_gemma":[0.0054669445,0.00035026285,0.00034314307,0.000558734,0.00033028185,0.00003365132,0.00089204387,0.0022744415,0.00018952189],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018059056,0.00034753294,0.864867,0.0036219715,0.004586643,0.0018600225,0.0039880546,0.00018614152,0.0011061622,0.000110291265,0.1172588,0.000261524],"study_design_scores_gemma":[0.030195205,0.0030780162,0.8398825,0.0052871048,0.0081425235,0.0011560925,0.002283463,0.008668795,0.025175812,0.009034058,0.06340779,0.0036886155],"about_ca_topic_score_codex":0.00062867947,"about_ca_topic_score_gemma":0.0000584497,"teacher_disagreement_score":0.05385101,"about_ca_system_score_codex":0.0009942038,"about_ca_system_score_gemma":0.0042148996,"threshold_uncertainty_score":0.9998949},"labels":[],"label_agreement":null},{"id":"W3110450048","doi":"10.1111/jth.15074","title":"Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH","year":2020,"lang":"en","type":"article","venue":"Journal of Thrombosis and Haemostasis","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ottawa Hospital; University of Ottawa","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Coagulopathy; Hypofibrinogenemia; Disseminated intravascular coagulation; Intensive care medicine; Hemostasis; Acute leukemia; Acute promyelocytic leukemia; Antifibrinolytic; Leukemia; Surgery; Tranexamic acid; Internal medicine; Fibrinogen; Blood loss","score_opus":0.07152483364577385,"score_gpt":0.3432874021338194,"score_spread":0.2717625684880456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110450048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90703523,0.0012243296,0.00031619633,0.09034064,0.000038498692,0.00033594077,0.00008235251,0.000002766465,0.0006240202],"genre_scores_gemma":[0.98919666,0.0036066151,0.005028863,0.0020879337,0.00003495556,0.000004205183,0.0000032252544,0.00001303577,0.0000245022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985218,0.0000922011,0.00064885145,0.00012797394,0.000464451,0.00014471637],"domain_scores_gemma":[0.99870366,0.00020736785,0.00047088065,0.00032683322,0.00019643198,0.00009483282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034250555,0.00010784619,0.00046202823,0.000045132394,0.00006669121,0.000013340754,0.0003903268,0.000045784953,0.00005411804],"category_scores_gemma":[0.000080114405,0.000058497593,0.00015389016,0.00044897784,0.00022579246,0.00006923583,0.000196464,0.00036012664,0.0000020734572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026068597,0.001227054,0.4652854,0.0020090428,0.01135517,0.00025968457,0.02380127,0.0004931242,0.075778775,0.0054120175,0.29858467,0.11318695],"study_design_scores_gemma":[0.003328165,0.00030000196,0.97193277,0.0009899273,0.0008096743,0.000034917717,0.0033256982,0.00080832065,0.013430205,0.00048249497,0.0044642566,0.00009354095],"about_ca_topic_score_codex":0.00015167626,"about_ca_topic_score_gemma":0.000012123833,"teacher_disagreement_score":0.5066474,"about_ca_system_score_codex":0.00016811037,"about_ca_system_score_gemma":0.00018662955,"threshold_uncertainty_score":0.23854627},"labels":[],"label_agreement":null},{"id":"W3110635148","doi":"10.1182/blood.2020007075","title":"<i>IDH1</i> mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Erythropoiesis; Biology; Myeloid; Isocitrate dehydrogenase; Haematopoiesis; Ineffective erythropoiesis; Myeloid leukemia; Cancer research; Cell biology; Stem cell; Biochemistry; Internal medicine; Enzyme; Anemia; Medicine","score_opus":0.01146840320203328,"score_gpt":0.2503119315040346,"score_spread":0.2388435283020013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110635148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96015555,0.0012179547,0.0002663074,0.0370211,0.00002261586,0.0005900799,0.0000587993,0.0000735121,0.00059410435],"genre_scores_gemma":[0.99477273,0.00015089731,0.0013005987,0.003470673,0.000085352935,0.0000464548,0.00004444917,0.000033639313,0.000095173644],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99863166,0.000062863226,0.00027808608,0.00040777863,0.000257704,0.00036188273],"domain_scores_gemma":[0.99918026,0.00027532,0.00004462455,0.00013869784,0.000074382115,0.0002867422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001997573,0.00017103668,0.0003613862,0.00012598824,0.000069460286,0.000045241417,0.00011006688,0.0001047279,0.00003614552],"category_scores_gemma":[0.0010248595,0.00015987507,0.000040188574,0.00058165047,0.0000810659,0.00008973419,0.00010863435,0.00023264933,0.00007202717],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000435737,0.00029673058,0.03227947,0.0002703993,0.00019495103,0.0002969638,0.0013525586,0.0000018201408,0.9452879,0.00006815542,0.014788567,0.0047267694],"study_design_scores_gemma":[0.009090375,0.00055622763,0.022328004,0.00025600215,0.00030275894,0.000099389596,0.0015771121,0.0004320856,0.9529337,0.00004862626,0.012017059,0.00035862433],"about_ca_topic_score_codex":0.00018808356,"about_ca_topic_score_gemma":0.000034447174,"teacher_disagreement_score":0.034617234,"about_ca_system_score_codex":0.00011117659,"about_ca_system_score_gemma":0.000100685415,"threshold_uncertainty_score":0.6519516},"labels":[],"label_agreement":null},{"id":"W3111184799","doi":"10.1016/s2152-2650(20)30965-4","title":"MDS-107: MDS Patients' Needs from Online Discussion Forums: An Artificial Intelligence and Natural Language Processing Analysis of 20,000 Posts in US, UK, Canada, and China","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Conversation; Context (archaeology); Psychology; Medicine","score_opus":0.024099092959422794,"score_gpt":0.32406632793393175,"score_spread":0.29996723497450895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111184799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958795,0.0009308343,0.0000664608,0.002025275,0.00010805541,0.0004531249,0.0004562829,0.000042973403,0.000037534723],"genre_scores_gemma":[0.99546385,0.000116071766,0.0010513973,0.0015763086,0.00033663906,0.00000909153,0.0013423539,0.000049091952,0.000055171316],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99593776,0.00027745962,0.0015493645,0.0008818542,0.000747955,0.0006056164],"domain_scores_gemma":[0.9976742,0.00044731182,0.00036394695,0.0004968328,0.00019541038,0.00082226435],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048026975,0.00039710477,0.001321479,0.00040152945,0.000115952236,0.00006237974,0.00035979893,0.00034994018,0.00008216373],"category_scores_gemma":[0.0015421878,0.0002835524,0.00017732641,0.0018486587,0.00045248782,0.00024627804,0.00039731432,0.000693564,0.000002172483],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014241955,0.00019257647,0.41577375,0.00007570437,0.00020983524,0.00015994262,0.0018334973,0.000023542105,0.00097279035,0.0000092789405,0.00011034832,0.5792145],"study_design_scores_gemma":[0.0014133829,0.00056074595,0.88251114,0.00017586953,0.00046605148,0.000006731378,0.0019521244,0.11198142,0.00048720208,0.00003820354,0.00011201822,0.00029511534],"about_ca_topic_score_codex":0.16769396,"about_ca_topic_score_gemma":0.23004188,"teacher_disagreement_score":0.5789194,"about_ca_system_score_codex":0.0009216232,"about_ca_system_score_gemma":0.0021019978,"threshold_uncertainty_score":0.9999617},"labels":[],"label_agreement":null},{"id":"W3111494345","doi":"10.1016/s2152-2650(20)30973-3","title":"MDS-179: Clinical Benefit of Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Anemia; Placebo; Myelodysplastic syndromes; Internal medicine; Population; Clinical trial; Refractory (planetary science); Surgery; Gastroenterology; Bone marrow","score_opus":0.03284904733416601,"score_gpt":0.3388579974242956,"score_spread":0.30600895009012963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111494345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941104,0.000119186916,0.00004743054,0.0018753211,0.0002636203,0.0031986842,0.000119028926,0.0000789488,0.00018735361],"genre_scores_gemma":[0.9973539,0.000564742,0.00029788376,0.00089312636,0.00046321115,0.00011101223,0.00012728675,0.00011796151,0.00007083648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9911109,0.0015403794,0.003089149,0.0016691085,0.0016377671,0.0009526595],"domain_scores_gemma":[0.9934063,0.0035694237,0.0006088639,0.0012257291,0.00034868272,0.0008410104],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033836507,0.00070596446,0.002340884,0.0003257161,0.00015761028,0.00007371127,0.0009578133,0.00066997716,0.00019901588],"category_scores_gemma":[0.0032119763,0.0004732068,0.00035498178,0.0013740121,0.0011524799,0.00025962025,0.00040735057,0.0017040153,0.00007199109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017118502,0.0033452606,0.75454575,0.00017220792,0.00026907556,0.001309884,0.002000442,0.000039419996,0.000029231125,0.000026008209,0.0003629364,0.22078127],"study_design_scores_gemma":[0.06547463,0.019236125,0.90947026,0.00037226945,0.0004523013,0.000041816053,0.0011832806,0.0028099294,0.000014937165,0.000051458548,0.0004416067,0.00045137195],"about_ca_topic_score_codex":0.0018790138,"about_ca_topic_score_gemma":0.000543713,"teacher_disagreement_score":0.2203299,"about_ca_system_score_codex":0.0007058227,"about_ca_system_score_gemma":0.0012975899,"threshold_uncertainty_score":0.99977195},"labels":[],"label_agreement":null},{"id":"W3111594720","doi":"10.1038/s41409-020-01153-1","title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","year":2020,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Novartis Pharmaceuticals Corporation","keywords":"Midostaurin; Medicine; Internal medicine; Myeloid leukemia; Oncology; Hematopoietic stem cell transplantation; Nausea; Transplantation; Surgery","score_opus":0.007738289485422182,"score_gpt":0.22213117030857168,"score_spread":0.2143928808231495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111594720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917428,0.00011772715,0.004260573,0.0011969174,0.00003953748,0.0013912255,0.00042571579,0.00008941738,0.00073608273],"genre_scores_gemma":[0.9960035,0.0003457483,0.0007706377,0.00096618925,0.00008026887,0.00017828106,0.0012711138,0.00007402654,0.000310227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974432,0.000120023935,0.0005455277,0.0006655795,0.00071232504,0.00051333976],"domain_scores_gemma":[0.99903625,0.000076191674,0.00012255859,0.00025221103,0.00015850646,0.0003542712],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014874592,0.00036080755,0.00046643993,0.0002170811,0.00006583289,0.00003935413,0.00017250235,0.00018678776,0.00011784415],"category_scores_gemma":[0.0000026788666,0.00031203908,0.0001124694,0.00044144024,0.00008374918,0.00025079958,0.000015098359,0.0005264244,0.00010222979],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038725745,0.0004036413,0.8743655,0.00094126083,0.0003652846,0.0028062388,0.010172515,0.00022027896,0.06664942,0.000030407075,0.00023583161,0.0050838846],"study_design_scores_gemma":[0.014913326,0.0012078765,0.9244452,0.00039578523,0.000503203,0.00011401112,0.00013490574,0.0008885709,0.05682032,0.000005674377,0.00012219946,0.0004489183],"about_ca_topic_score_codex":0.0001244469,"about_ca_topic_score_gemma":0.00012351818,"teacher_disagreement_score":0.05007971,"about_ca_system_score_codex":0.00060002133,"about_ca_system_score_gemma":0.00037072937,"threshold_uncertainty_score":0.9999332},"labels":[],"label_agreement":null},{"id":"W3111703281","doi":"10.1182/bloodadvances.2020002712","title":"Acute erythroid leukemia is enriched in <i>NUP98</i> fusions: a report from the Children’s Oncology Group","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Hematopathology; Myeloid leukemia; Leukemia; Myeloid; Myelodysplastic syndromes; Oncology; Internal medicine; Cancer research; Medicine; Karyotype; Biology; Cytogenetics; Bone marrow; Genetics; Gene; Chromosome","score_opus":0.0176872080017864,"score_gpt":0.3056332826538567,"score_spread":0.2879460746520703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111703281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9357666,0.013017444,0.00020057747,0.04543171,0.00017891178,0.0012384421,0.000105869134,0.00017037874,0.0038900864],"genre_scores_gemma":[0.9499902,0.010185228,0.006239095,0.030834662,0.0015385081,0.00024199678,0.0003723584,0.00007895183,0.00051897153],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972681,0.00015656208,0.0006327579,0.0007933703,0.0005813578,0.0005678859],"domain_scores_gemma":[0.9981514,0.0005527008,0.0002244779,0.0006779719,0.00008774264,0.00030567384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032937794,0.00029379316,0.00066226453,0.0000733758,0.00014191541,0.000031687865,0.0004819446,0.00020790963,0.00034047183],"category_scores_gemma":[0.00073244283,0.00019997302,0.00016231943,0.0007180792,0.0002475035,0.0002463139,0.00034708684,0.0010203226,0.00015435634],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003315473,0.0013525023,0.5314562,0.00012690829,0.0021392887,0.021695953,0.010521396,0.000035918176,0.19885597,0.00027502823,0.11990942,0.11031596],"study_design_scores_gemma":[0.023322051,0.002607258,0.25345674,0.00026509713,0.0013338239,0.0042554303,0.0026285497,0.00058586366,0.021567987,0.0016424579,0.6873463,0.0009884891],"about_ca_topic_score_codex":0.00081081316,"about_ca_topic_score_gemma":0.00033948396,"teacher_disagreement_score":0.5674368,"about_ca_system_score_codex":0.00037396763,"about_ca_system_score_gemma":0.00087956566,"threshold_uncertainty_score":0.8154663},"labels":[],"label_agreement":null},{"id":"W3112534080","doi":"10.1111/bjh.17247","title":"Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities","year":2020,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Genetic predisposition; Malignancy; Germline; Haematopoiesis; Myeloid; Medicine; Genetic testing; Genetics; Biology; Immunology; Bioinformatics; Disease; Stem cell; Pathology; Gene","score_opus":0.13372246372914656,"score_gpt":0.34408265996454523,"score_spread":0.21036019623539867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112534080","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009190455,0.9882203,0.00021496587,0.0009849461,0.00034002285,0.0007956546,0.00006135274,0.000038881873,0.0001534417],"genre_scores_gemma":[0.00037081927,0.9969127,0.0015828395,0.0004498136,0.00034980435,0.000088972476,0.000028980874,0.00011383623,0.00010223257],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965773,0.00042209012,0.0015603971,0.0003930316,0.000513193,0.00053394795],"domain_scores_gemma":[0.9972362,0.00032313782,0.0006837519,0.00022463448,0.00036739293,0.001164881],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006516478,0.0004045902,0.0040589827,0.00065423944,0.00014937572,0.0001272321,0.00032522142,0.00038901618,0.00014456635],"category_scores_gemma":[0.0014903409,0.0004205407,0.0004773458,0.0004020593,0.00023552388,0.00029021138,0.00028122967,0.0013909726,0.000018881654],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000106986634,0.000029488427,0.000011597356,0.027983513,0.00061317824,0.28521323,0.00050289585,2.8490587e-7,0.000010483267,0.00017030399,0.009279649,0.6760784],"study_design_scores_gemma":[0.00048541112,0.00029223718,0.0000051014945,0.042034782,0.0007257942,0.4601102,0.00069470884,0.0000041004328,0.000005929929,0.000024533085,0.49542782,0.00018940898],"about_ca_topic_score_codex":0.000032689364,"about_ca_topic_score_gemma":0.0000058822015,"teacher_disagreement_score":0.67588896,"about_ca_system_score_codex":0.00039395774,"about_ca_system_score_gemma":0.0017738781,"threshold_uncertainty_score":0.99982464},"labels":[],"label_agreement":null},{"id":"W3112890012","doi":"10.1182/blood-2020-136335","title":"Patient Preferences for Maintenance Treatment of Acute Myeloid Leukemia: Results of a Discrete Choice Experiment","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Maintenance therapy; Azacitidine; Internal medicine; Myeloid leukemia; Placebo; Oncology; Chemotherapy; Alternative medicine","score_opus":0.03536047990813374,"score_gpt":0.30758159564510723,"score_spread":0.2722211157369735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112890012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932116,0.00061852287,0.00019191239,0.0016801857,0.00004040572,0.0017024905,0.0006169263,0.00003700507,0.0019009226],"genre_scores_gemma":[0.9940755,0.00045957314,0.004407391,0.00012147748,0.00013045811,0.00028403726,0.00011070947,0.000026902502,0.0003839879],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99827653,0.000039324706,0.0005593717,0.00040267286,0.00038393182,0.00033817158],"domain_scores_gemma":[0.9987578,0.00017655552,0.00024225141,0.00038394803,0.00021323681,0.00022620645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007466978,0.00020359563,0.0005702217,0.000059816717,0.00003367895,0.000006228719,0.00014355753,0.000092184404,0.00002003241],"category_scores_gemma":[0.00021997033,0.00014155752,0.0001975028,0.00019799544,0.00012253212,0.000049549235,0.000072065435,0.00009310246,0.0000053837475],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021493496,0.0041198465,0.0075033465,0.0013192529,0.0053474475,0.00018387409,0.025936289,0.000051203508,0.8954083,0.0003497571,0.010917105,0.02737009],"study_design_scores_gemma":[0.023336202,0.015434409,0.0025032957,0.00017297488,0.0006179087,0.000014901088,0.0007256956,0.00039359348,0.9466583,0.000024302299,0.009958446,0.0001599692],"about_ca_topic_score_codex":0.00023719863,"about_ca_topic_score_gemma":0.000007924856,"teacher_disagreement_score":0.05125001,"about_ca_system_score_codex":0.00023553113,"about_ca_system_score_gemma":0.00049050414,"threshold_uncertainty_score":0.57725483},"labels":[],"label_agreement":null},{"id":"W3112994046","doi":"10.1038/s41409-020-01165-x","title":"Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing","year":2020,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Research Foundation of Korea; Ministry of Health and Welfare; Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","keywords":"Medicine; Cumulative incidence; Internal medicine; Oncology; Myeloid leukemia; Minimal residual disease; Hematopoietic stem cell transplantation; Chemotherapy; Transplantation; Leukemia; Multivariate analysis; Disease; Immunology","score_opus":0.02927323415439258,"score_gpt":0.23306846779449492,"score_spread":0.20379523364010232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112994046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948041,0.00031250084,0.0005848372,0.0023229672,0.000022890492,0.001204985,0.0006080775,0.000025938029,0.000113693466],"genre_scores_gemma":[0.995689,0.0023991705,0.00032775252,0.00024885454,0.000047005822,0.00007856674,0.001122578,0.000037953327,0.000049165254],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972763,0.00043247567,0.00060301507,0.00038681953,0.0009603548,0.00034104305],"domain_scores_gemma":[0.9988018,0.00020631423,0.00027352796,0.00034832957,0.0001829164,0.00018709138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071968226,0.0002478901,0.00036543095,0.00010306109,0.00020601104,0.000025597645,0.00023948871,0.00011206992,0.000019325742],"category_scores_gemma":[0.00009817912,0.00014631724,0.000091136484,0.0005730277,0.00013397628,0.00019897443,0.000009867908,0.00046811698,0.0000018464016],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010917643,0.00011963718,0.12205719,0.0011015153,0.00021910378,0.00022813825,0.01332483,0.004669119,0.8454365,0.000015743863,0.0009249689,0.0009856109],"study_design_scores_gemma":[0.016508194,0.0021668808,0.12508667,0.0014094154,0.0031682393,0.00014133204,0.0016107528,0.026020415,0.82293093,0.000040287803,0.00029559142,0.0006212678],"about_ca_topic_score_codex":0.0019498663,"about_ca_topic_score_gemma":0.0015853397,"teacher_disagreement_score":0.02250554,"about_ca_system_score_codex":0.0003500066,"about_ca_system_score_gemma":0.0006224638,"threshold_uncertainty_score":0.59666437},"labels":[],"label_agreement":null},{"id":"W3114000578","doi":"10.1007/5584_2020_608","title":"Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis","year":2020,"lang":"en","type":"review","venue":"Advances in experimental medicine and biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Immune dysregulation; Biology; Myelodysplastic syndromes; Immune system; Immunology; Pathogenesis; Myeloid; Myeloid leukemia; Inflammation; Cancer research; Genome instability; Haematopoiesis; RUNX1; Stem cell; Bone marrow; DNA damage; Genetics; DNA","score_opus":0.06424637560056874,"score_gpt":0.4224645243474039,"score_spread":0.35821814874683516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114000578","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0060574342,0.9924049,0.000012498308,0.000254514,0.00016085462,0.0008023033,0.000009646141,0.000019740439,0.00027813952],"genre_scores_gemma":[0.020564541,0.9782593,0.00044145537,0.00006967076,0.00015500528,0.00021031722,0.00024987847,0.00002926094,0.00002056339],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982192,0.00017891894,0.00067280553,0.00054049597,0.00009781332,0.0002907717],"domain_scores_gemma":[0.9990659,0.00048877095,0.00015203272,0.00015008368,0.000018040657,0.00012520282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019433149,0.0003208179,0.0016316456,0.00050979113,0.0000425964,0.000004463885,0.000086783875,0.00023945078,0.000039141258],"category_scores_gemma":[0.00029345386,0.00022809752,0.00005285387,0.00049015746,0.00050133036,0.00010182384,0.00013874656,0.00040706812,0.0000048919537],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005694988,0.000042702544,0.00069552346,0.0028598297,0.00003757082,0.00021217605,0.0004842817,2.6586392e-7,0.0008537434,0.00023276433,0.000004388044,0.9945198],"study_design_scores_gemma":[0.0049930634,0.0037200735,0.0012311967,0.029594187,0.00042454276,0.0023910552,0.00398592,0.00019310009,0.00013056913,0.0003342904,0.9523222,0.00067980884],"about_ca_topic_score_codex":0.000052063777,"about_ca_topic_score_gemma":0.000012297526,"teacher_disagreement_score":0.99384,"about_ca_system_score_codex":0.00025868465,"about_ca_system_score_gemma":0.000115555216,"threshold_uncertainty_score":0.9301547},"labels":[],"label_agreement":null},{"id":"W3116623649","doi":"10.1016/j.xpro.2020.100248","title":"Enriching for human acute myeloid leukemia stem cells using reactive oxygen species-based cell sorting","year":2020,"lang":"en","type":"article","venue":"STAR Protocols","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institutes of Health; National Cancer Institute; Princess Margaret Cancer Foundation; Edward P. Evans Foundation; Leukemia and Lymphoma Society","keywords":"Stem cell; Myeloid leukemia; Leukemia; Reactive oxygen species; Biology; Stem cell marker; Immunology; Cancer research; Cell biology","score_opus":0.08879875325297781,"score_gpt":0.3619028557300592,"score_spread":0.2731041024770814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116623649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6628831,0.00001990555,0.023558583,0.0012614019,0.00006991013,0.30628908,0.00022883916,0.00047910248,0.005210073],"genre_scores_gemma":[0.74851364,0.0000030182534,0.078506425,0.0045119557,0.0028070107,0.16023229,0.00025686302,0.0006031909,0.004565625],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99641705,0.00016495843,0.000767859,0.00088231557,0.0007660778,0.0010017587],"domain_scores_gemma":[0.9978026,0.00023949808,0.00043911644,0.0006014038,0.0003614223,0.0005559606],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075195084,0.00045240982,0.0007870015,0.00019045886,0.0005172712,0.00013368223,0.0004451443,0.00023751985,0.00015028616],"category_scores_gemma":[0.00010196811,0.00042068367,0.00033085124,0.000520749,0.000120862125,0.0002324354,0.0002131013,0.0009353081,0.00005771527],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014249032,0.00008454676,0.0003426473,0.0011316095,0.00014699622,0.00015158391,0.0012382104,0.00020585778,0.9921699,0.00007421119,0.0019546193,0.0010748996],"study_design_scores_gemma":[0.007950128,0.001664623,0.00016767735,0.00035826213,0.0001720332,0.000009976581,0.0009525665,0.023005962,0.9382475,0.00008633313,0.026891435,0.0004935172],"about_ca_topic_score_codex":0.00008322543,"about_ca_topic_score_gemma":0.000004524115,"teacher_disagreement_score":0.14605679,"about_ca_system_score_codex":0.0020547519,"about_ca_system_score_gemma":0.0018955352,"threshold_uncertainty_score":0.9998245},"labels":[],"label_agreement":null},{"id":"W3117586286","doi":"10.1101/2020.12.21.414649","title":"Dynamic regulation of hierarchical heterogeneity in Acute Myeloid Leukemia serves as a tumor immunoevasion mechanism","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Imperial College London; Francis Crick Institute","keywords":"Myeloid leukemia; Immunology; Immune system; Cancer research; Biology; Immunotherapy; Context (archaeology); Population; Leukemia; Tumor microenvironment; Immunosuppression; Myeloid; Bone marrow; Medicine","score_opus":0.016294222469485527,"score_gpt":0.2652572087396663,"score_spread":0.24896298627018076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3117586286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940965,0.00056499254,0.0010565305,0.0011899557,0.00039521794,0.0021139919,0.00023299498,0.00033641208,0.000013387653],"genre_scores_gemma":[0.9863904,0.00057885196,0.011974869,0.00036180424,0.00016990225,0.00025908704,0.000007285281,0.00024631675,0.000011496968],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99446714,0.00043408896,0.001334657,0.0016507739,0.0012213629,0.0008919679],"domain_scores_gemma":[0.9959436,0.00013226835,0.00067075336,0.002024514,0.00063878275,0.0005900607],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011071027,0.00081810035,0.0016013162,0.00085941615,0.000114821654,0.000094332245,0.0008548472,0.0009501756,0.0000850156],"category_scores_gemma":[0.00065440894,0.0008718464,0.00042685692,0.0012007193,0.0002705988,0.00019738675,0.00154517,0.0027859071,0.00011642498],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009769548,0.00017366398,0.0027185713,0.0013722628,0.00044012725,0.00062144594,0.000032206546,0.00006311208,0.9926554,0.00089139864,0.000048401595,0.000006455588],"study_design_scores_gemma":[0.0025574232,0.00039107775,0.3006104,0.0014478567,0.0003030546,8.3739656e-7,0.0000058641185,0.0149623575,0.6788084,0.00009277827,0.00013498301,0.00068498583],"about_ca_topic_score_codex":0.0003336406,"about_ca_topic_score_gemma":0.000013689813,"teacher_disagreement_score":0.313847,"about_ca_system_score_codex":0.0033292503,"about_ca_system_score_gemma":0.004625424,"threshold_uncertainty_score":0.9995147},"labels":[],"label_agreement":null},{"id":"W3117986169","doi":"10.1002/cyto.b.21983","title":"Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: <scp>CD45RA</scp> and <scp>CD371</scp> improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy","year":2020,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"","keywords":"Myelodysplastic syndromes; Immunophenotyping; Population; CD117; Medicine; International Prognostic Scoring System; Myeloproliferative neoplasm; Minimal residual disease; Myeloid; Bone marrow; Immunology; Stem cell; Flow cytometry; Myelofibrosis; Pathology; Internal medicine; Biology; CD34; Genetics","score_opus":0.09570394698014477,"score_gpt":0.35115420815618054,"score_spread":0.25545026117603575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3117986169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867644,0.0032370628,0.0060160197,0.00022186125,0.0005342267,0.002141957,0.0005141146,0.00016344826,0.0004069381],"genre_scores_gemma":[0.9808553,0.009349346,0.00818421,0.00045141936,0.00053563307,0.0002496207,0.0001200513,0.0002060732,0.00004838308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9890969,0.001131172,0.0037133282,0.0024709643,0.0019588494,0.0016288197],"domain_scores_gemma":[0.96546525,0.029825255,0.0013084251,0.0009880642,0.00067559135,0.00173741],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0025818727,0.0012863768,0.003882229,0.0019050202,0.00031218035,0.00017773529,0.00058626157,0.000930934,0.000020250773],"category_scores_gemma":[0.0100538405,0.001235336,0.00046714096,0.0053384323,0.0019483177,0.0011324119,0.0013878373,0.0027670038,0.000033309265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000409751,0.0015691611,0.9552527,0.006144769,0.001140771,0.00056621316,0.0017240241,0.0003095748,0.028732894,0.00012443782,0.00034581928,0.003679896],"study_design_scores_gemma":[0.012329121,0.00672911,0.90863997,0.0018616607,0.00097171887,0.0003336181,0.003812244,0.020389829,0.044199146,0.00005882494,0.00024430224,0.00043043293],"about_ca_topic_score_codex":0.000034153425,"about_ca_topic_score_gemma":0.000008508802,"teacher_disagreement_score":0.0466127,"about_ca_system_score_codex":0.00042195336,"about_ca_system_score_gemma":0.0007193752,"threshold_uncertainty_score":0.9999888},"labels":[],"label_agreement":null},{"id":"W3118040066","doi":"10.3324/haematol.2020.270595","title":"Molecular and phenotypic diversity of &lt;I&gt;CBL&lt;/I&gt;-mutated juvenile myelomonocytic leukemia","year":2020,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Alberta Children's Hospital","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; York University; European Hematology Association","keywords":"Juvenile myelomonocytic leukemia; Phenotype; Cancer research; Juvenile; Biology; Genetics; Molecular biology; Gene; Haematopoiesis","score_opus":0.029000979285829294,"score_gpt":0.26218188366792006,"score_spread":0.23318090438209077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118040066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98675084,0.0021123658,0.00070016517,0.0028320132,0.000040285307,0.0006677213,0.000023692613,0.00019839595,0.0066745025],"genre_scores_gemma":[0.99646294,0.0002706486,0.0018013894,0.0011347508,0.000037003618,0.000017217717,0.000039296443,0.00003269249,0.00020407097],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99770087,0.00015786495,0.00045662044,0.00060405023,0.0005465686,0.0005340487],"domain_scores_gemma":[0.99848026,0.00018209175,0.00018107543,0.00045154375,0.00020637558,0.00049866294],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024838265,0.00029796822,0.0009693925,0.00013503345,0.00019931782,0.000018454823,0.00035619127,0.00027621878,0.000386408],"category_scores_gemma":[0.0007184518,0.00025098328,0.00016110526,0.00056605996,0.00047089547,0.00009210285,0.001009916,0.00042261195,0.00018515914],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046582846,0.00046099012,0.019190568,0.003235,0.001235189,0.015650788,0.007247072,0.0002454869,0.8721762,0.022416016,0.041237585,0.012246867],"study_design_scores_gemma":[0.041678734,0.009389429,0.11365497,0.0013585546,0.00320302,0.0053647887,0.0024268706,0.06300199,0.6717481,0.0073947166,0.076959416,0.0038193988],"about_ca_topic_score_codex":0.000030738487,"about_ca_topic_score_gemma":0.0000052495066,"teacher_disagreement_score":0.20042804,"about_ca_system_score_codex":0.00029923115,"about_ca_system_score_gemma":0.00040568502,"threshold_uncertainty_score":0.9999942},"labels":[],"label_agreement":null},{"id":"W3118088258","doi":"10.3324/haematol.2020.271619","title":"Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis","year":2020,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Hôpital Maisonneuve-Rosemont; Université de Montréal; Université Laval; Centre hospitalier de l'Université Laval; Hôpital de l'Enfant-Jésus; Institute for Research in Immunology and Cancer","funders":"Université de Montréal; CHU Sainte-Justine Foundation; Molson Foundation","keywords":"Biology; Epigenetics; Epigenome; Genetics; Cancer research; DNA methylation; Chromatin; Regulation of gene expression; Epigenomics; Transcription factor; Demethylase; Histone; Gene expression; Gene","score_opus":0.05493851507936829,"score_gpt":0.2996878199912756,"score_spread":0.2447493049119073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118088258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877459,0.00043196607,0.00014241345,0.008736578,0.000031603126,0.00079765153,0.000010089009,0.0002364887,0.0018673558],"genre_scores_gemma":[0.9958345,0.00028262296,0.0012638276,0.0011566831,0.00012782865,0.00015724517,0.000022435377,0.00006570974,0.0010891317],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972342,0.00013504585,0.00048435185,0.0007611426,0.0005590085,0.0008262416],"domain_scores_gemma":[0.998746,0.000065880624,0.0001186489,0.0005097158,0.000090194844,0.0004695972],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002031124,0.00035132762,0.0008426815,0.00026251737,0.00017486542,0.000023217977,0.00042840355,0.00031156515,0.00028566679],"category_scores_gemma":[0.00021566701,0.00029476604,0.0001419618,0.00060676254,0.00011630935,0.000081565326,0.00034585758,0.000536248,0.0002835862],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021319843,0.00065694796,0.24841595,0.0022004943,0.0004314885,0.012036457,0.006059415,0.0019890987,0.7166159,0.0026400879,0.00504036,0.0017818309],"study_design_scores_gemma":[0.012910641,0.0018091853,0.4316602,0.0005698949,0.00025783334,0.0009186616,0.00043168792,0.026760805,0.52070904,0.0012723133,0.0012045939,0.001495132],"about_ca_topic_score_codex":0.00015002875,"about_ca_topic_score_gemma":0.000080690086,"teacher_disagreement_score":0.19590683,"about_ca_system_score_codex":0.000550928,"about_ca_system_score_gemma":0.0002459546,"threshold_uncertainty_score":0.99995047},"labels":[],"label_agreement":null},{"id":"W3119550037","doi":"10.1038/s41467-020-20491-8","title":"Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Japan Society for the Promotion of Science; Harvard Stem Cell Institute; National Cancer Institute; National Institutes of Health; Ludwig Institute for Cancer Research; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"mTORC1; Myeloid leukemia; Context (archaeology); Cancer research; Bone marrow; Biology; Myeloid; In vivo; Cell growth; Leukemia; Chemotherapy; Medicine; Signal transduction; Cell biology; Immunology; PI3K/AKT/mTOR pathway; Genetics","score_opus":0.02626307455702028,"score_gpt":0.326069922680394,"score_spread":0.2998068481233737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119550037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92763644,0.01499933,0.00003219778,0.036095656,0.00016816964,0.0012692157,0.00011762368,0.00014382017,0.019537518],"genre_scores_gemma":[0.9867417,0.0069661206,0.0023286112,0.00100993,0.00005529752,0.00012872738,0.00027384053,0.00005873517,0.0024370397],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99749494,0.0007343136,0.00036815324,0.00045750834,0.00046378572,0.0004813119],"domain_scores_gemma":[0.99567074,0.0007697425,0.00011455219,0.0030470346,0.00024817197,0.00014976112],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0010617197,0.00024027012,0.0004616436,0.00043448163,0.00015157842,0.00006044206,0.00085483375,0.0003891929,0.0005739152],"category_scores_gemma":[0.00036630558,0.00023573913,0.00012842109,0.0012624316,0.00019859607,0.0002605749,0.0005869251,0.0032981117,0.000080009944],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052384794,0.0015253851,0.10603604,0.00006771361,0.00008217079,0.00047293922,0.0015034231,0.0000027242272,0.81232715,0.00068348506,0.03346854,0.043306608],"study_design_scores_gemma":[0.0076529915,0.000120480574,0.67276686,0.00066781894,0.000023895003,0.00017415278,0.00078402396,0.0035286732,0.044313315,0.0005378666,0.26870745,0.0007224472],"about_ca_topic_score_codex":0.000053780976,"about_ca_topic_score_gemma":0.0009387845,"teacher_disagreement_score":0.76801383,"about_ca_system_score_codex":0.0012438718,"about_ca_system_score_gemma":0.0008292299,"threshold_uncertainty_score":0.9990013},"labels":[],"label_agreement":null},{"id":"W3120637385","doi":"10.2147/ott.s276912","title":"Case Report: Myeloid Sarcoma Development During Treatment for B Cell Lymphoblastic Lymphoma in a Boy with KRAS/NRAS Gene Mutations","year":2021,"lang":"en","type":"article","venue":"OncoTargets and Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hospital for Sick Children","keywords":"Neuroblastoma RAS viral oncogene homolog; KRAS; Myeloid sarcoma; Medicine; Lymphoma; Lymphoblastic lymphoma; Hematopoietic stem cell transplantation; Myeloid; Chemotherapy; Oncology; Cancer; Pathology; Internal medicine; Disease; Immunology; T cell","score_opus":0.02390182928471024,"score_gpt":0.2837764498929889,"score_spread":0.25987462060827865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120637385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490416,0.0030574333,0.0003019247,0.00049073517,0.00004376173,0.00081449107,0.000015799547,0.000035945348,0.0003357628],"genre_scores_gemma":[0.9763392,0.0010746852,0.018656079,0.0001399012,0.000100875906,0.00037515096,0.00014567914,0.000056937348,0.0031114416],"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984687,0.000039935097,0.0003519303,0.0004908243,0.00021375505,0.00043484804],"domain_scores_gemma":[0.99913675,0.00009761035,0.0000859318,0.0002994033,0.00016015809,0.0002201541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014545677,0.00024710497,0.00038786416,0.00015250947,0.00022750352,0.000040567666,0.000040352716,0.00008079652,0.000051910793],"category_scores_gemma":[0.000027700238,0.00018124215,0.00006254262,0.00024494066,0.00004956984,0.0000635846,0.000027748643,0.00006336349,0.0000056517583],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004765766,0.004025475,0.05943384,0.0003727435,0.00093148707,0.6354534,0.010010044,0.00008243182,0.1501283,0.000037635305,0.00013089165,0.13462798],"study_design_scores_gemma":[0.064872965,0.002522137,0.10402258,0.00019976533,0.000119588796,0.1989418,0.0020745161,0.00088650594,0.58725333,0.00009877149,0.038256276,0.00075178465],"about_ca_topic_score_codex":0.00018768497,"about_ca_topic_score_gemma":0.00028145453,"teacher_disagreement_score":0.437125,"about_ca_system_score_codex":0.00088787416,"about_ca_system_score_gemma":0.0015623731,"threshold_uncertainty_score":0.73908406},"labels":[],"label_agreement":null},{"id":"W3120643721","doi":"10.1080/16078454.2020.1870373","title":"Intracellular ROS profile in hematopoietic progenitors of MDS patients: association with blast count and iron overload","year":2021,"lang":"en","type":"article","venue":"Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Canada; Canadian Blood Services; Leukemia and Lymphoma Society of Canada","keywords":"Haematopoiesis; Intracellular; Progenitor cell; Medicine; Myelodysplastic syndromes; Immunology; Cancer research; Bone marrow; Biology; Stem cell; Cell biology","score_opus":0.005896770819487215,"score_gpt":0.2415728679337261,"score_spread":0.23567609711423887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120643721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977225,0.0004959469,0.00003089088,0.00067666575,0.000051276682,0.0005237386,0.000009617685,0.000018638942,0.00047071395],"genre_scores_gemma":[0.9986261,0.000058158606,0.0007344323,0.00007240391,0.000022112024,0.00006358937,0.00006423466,0.000021593318,0.00033733796],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986628,0.0001017584,0.00032222708,0.00027567102,0.00033204127,0.00030549322],"domain_scores_gemma":[0.99911076,0.00013183858,0.00014888762,0.00021334991,0.00031253308,0.00008262243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002019418,0.0001223747,0.00045463227,0.00010514256,0.000024768462,0.0000073228007,0.00004530031,0.00020046173,0.0001592742],"category_scores_gemma":[0.00037609538,0.000103529674,0.000028235547,0.00029305782,0.000090110305,0.000056153072,0.000063063744,0.00028078633,0.00001929574],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022798909,0.00044632488,0.98735785,0.000798881,0.00006335022,0.00029748632,0.00060573017,0.0000016865051,0.008122597,0.00092063076,0.00088511093,0.00027232943],"study_design_scores_gemma":[0.01657027,0.0018230405,0.21808,0.0009346899,0.00024568266,0.0016675548,0.0024697324,0.0015953985,0.7539247,0.0002905534,0.0018850543,0.000513273],"about_ca_topic_score_codex":0.00004012415,"about_ca_topic_score_gemma":0.00004847093,"teacher_disagreement_score":0.7692779,"about_ca_system_score_codex":0.00035891094,"about_ca_system_score_gemma":0.00035802432,"threshold_uncertainty_score":0.42218176},"labels":[],"label_agreement":null},{"id":"W3121321861","doi":"10.1182/blood.2020009103","title":"Modeling and targeting of erythroleukemia by hematopoietic genome editing","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Heart, Lung, and Blood Institute; European Hematology Association","keywords":"Biology; GATA1; Epigenetics; Decitabine; Genetics; Somatic evolution in cancer; Leukemia; Transcription factor; Cancer research; DNA methylation; Gene; Gene expression","score_opus":0.011969102595614995,"score_gpt":0.2564444647818105,"score_spread":0.2444753621861955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121321861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899942,0.0062853103,0.0012476533,0.0004970105,0.000027183552,0.00011521102,0.000011974737,0.000036425212,0.0017849919],"genre_scores_gemma":[0.9919738,0.00028882257,0.0069767,0.00014005016,0.00024944593,0.0000074078066,0.00005492712,0.000031074705,0.00027774228],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988016,0.000035935027,0.00029646026,0.00027293168,0.00029296605,0.00030014061],"domain_scores_gemma":[0.9993461,0.000059513844,0.00004769224,0.00021752708,0.0001866716,0.00014248947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028264234,0.00011196532,0.00030544243,0.000053687403,0.00006453489,0.000015714919,0.00006173535,0.00009058811,0.00008242281],"category_scores_gemma":[0.00034679816,0.000108838874,0.00005489891,0.00018180696,0.000054864788,0.00005463959,0.00014336008,0.0002784006,0.000007934604],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022143126,0.00022449103,0.0039076773,0.00067493325,0.00017216522,0.0002876747,0.0007233962,0.0001252381,0.992498,0.00010030314,0.00069783395,0.0005661797],"study_design_scores_gemma":[0.01655483,0.0003976548,0.0008001142,0.0008666553,0.000823337,0.0024117683,0.0068960413,0.116767734,0.8509306,0.0005347756,0.0023556675,0.0006608425],"about_ca_topic_score_codex":0.000033133983,"about_ca_topic_score_gemma":0.000001207765,"teacher_disagreement_score":0.14156738,"about_ca_system_score_codex":0.000054864162,"about_ca_system_score_gemma":0.00026300002,"threshold_uncertainty_score":0.44383204},"labels":[],"label_agreement":null},{"id":"W3121343412","doi":"10.1038/s41375-021-01137-0","title":"Germline variants drive myelodysplastic syndrome in young adults","year":2021,"lang":"en","type":"letter","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Germline; Myelodysplastic syndromes; Medicine; Germline mutation; Oncology; Genetics; Internal medicine; Biology; Mutation; Gene; Bone marrow","score_opus":0.014173326233849343,"score_gpt":0.26321503250872463,"score_spread":0.2490417062748753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121343412","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38711554,0.0020861556,0.00027465678,0.57464087,0.0034236778,0.003800705,0.00049410237,0.00057860115,0.02758571],"genre_scores_gemma":[0.19455495,0.0011891067,0.003494823,0.6563803,0.012768412,0.0006899059,0.010947541,0.0010122366,0.11896276],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99361134,0.00031665765,0.0010931853,0.0016681575,0.0015799279,0.0017307465],"domain_scores_gemma":[0.9967048,0.0006064551,0.00028711726,0.0016661105,0.00039388772,0.00034159573],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.00042365465,0.0009150314,0.0018154767,0.0010491919,0.00009627941,0.00010477411,0.00069960265,0.0026547215,0.0016733049],"category_scores_gemma":[0.0009480496,0.00088510953,0.00038685458,0.0012897368,0.00023330608,0.00016609435,0.00050269807,0.009609832,0.0014490495],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029168493,0.00006511823,0.0032651455,0.0017383627,0.0003514683,0.19170673,0.00029924317,0.000019972402,0.00028067268,0.0000158181,0.8011399,0.00082591287],"study_design_scores_gemma":[0.034534656,0.0018177935,0.27138096,0.021295758,0.0014569355,0.06756297,0.0003815953,0.011601291,0.00044419253,0.0003283344,0.5845284,0.004667151],"about_ca_topic_score_codex":0.0013956532,"about_ca_topic_score_gemma":0.00031501663,"teacher_disagreement_score":0.26811582,"about_ca_system_score_codex":0.007307061,"about_ca_system_score_gemma":0.004896356,"threshold_uncertainty_score":0.99935997},"labels":[],"label_agreement":null},{"id":"W3124329526","doi":"10.1097/md.0000000000024273","title":"Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia","year":2021,"lang":"en","type":"article","venue":"Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Anhui Medical University","keywords":"Cytarabine; Medicine; Internal medicine; Myeloid leukemia; Gastroenterology; Leukemia; Myeloid; Chemotherapy; Oncology; Surgery","score_opus":0.021526098235928062,"score_gpt":0.3173399031894082,"score_spread":0.29581380495348014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124329526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9568446,0.0022881315,0.000546186,0.035377156,0.0005210499,0.002378874,0.00031052853,0.0002236016,0.001509862],"genre_scores_gemma":[0.9435194,0.006903868,0.0057026558,0.0030261332,0.0021483754,0.0005486835,0.0035059724,0.00037291908,0.034271974],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99549276,0.00024485454,0.00089584937,0.0012412485,0.0010559345,0.0010693441],"domain_scores_gemma":[0.99517554,0.0007517051,0.00027890265,0.0014786057,0.0011879529,0.0011272972],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00107285,0.00079833827,0.001887678,0.0003774896,0.00029602836,0.000057491434,0.00035594872,0.00027268566,0.0004509662],"category_scores_gemma":[0.0016945769,0.000505256,0.00017615646,0.00066000334,0.00076268293,0.00021792318,0.00032669297,0.0006778494,0.000029686715],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06757661,0.0005007759,0.0022635015,0.00078605796,0.0026818754,0.006037165,0.0038875057,0.000014742084,0.8449553,0.00023974954,0.023109572,0.047947105],"study_design_scores_gemma":[0.3672853,0.083415054,0.08197701,0.005278225,0.007708736,0.0054646307,0.011183749,0.0067072315,0.2571182,0.0013229859,0.16990444,0.0026344478],"about_ca_topic_score_codex":0.00071760017,"about_ca_topic_score_gemma":0.0002920583,"teacher_disagreement_score":0.58783716,"about_ca_system_score_codex":0.0025640207,"about_ca_system_score_gemma":0.002775265,"threshold_uncertainty_score":0.9997399},"labels":[],"label_agreement":null},{"id":"W3124381759","doi":"10.1080/13696998.2021.1875743","title":"The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Azacitidine; Cytarabine; Internal medicine; Oncology; Myeloid leukemia; Induction chemotherapy; Cost effectiveness; Clinical trial; Chemotherapy","score_opus":0.01477245771784256,"score_gpt":0.28539256468498775,"score_spread":0.27062010696714517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124381759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986514,0.00011041257,0.00007587045,0.011629778,0.00024350487,0.0013950043,0.000023016288,9.191984e-7,0.0000074942204],"genre_scores_gemma":[0.99078244,0.008103336,0.00009202251,0.00079155044,0.000057194673,0.000116896124,0.000017986364,0.000021339265,0.000017230335],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981965,0.0001772986,0.0008059847,0.00017904576,0.00039315782,0.00024802802],"domain_scores_gemma":[0.9963302,0.0017127725,0.0004892549,0.0002020509,0.001117658,0.00014803685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093482377,0.00014877054,0.0007107528,0.00019334472,0.00002898657,0.000010791694,0.00021138861,0.00012161064,0.0000075352077],"category_scores_gemma":[0.0015948922,0.00008850135,0.000081133585,0.0003494086,0.000096824755,0.00009032279,0.000026065582,0.00041596513,2.8285098e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07310354,0.0029066456,0.40965825,0.00058637606,0.0018180346,0.00072346214,0.0073304926,0.020515153,0.00174904,0.0002435931,0.0029447335,0.47842067],"study_design_scores_gemma":[0.06556931,0.0036686598,0.87124,0.0022305835,0.00008235617,0.00006950304,0.006693566,0.009849946,0.039201453,0.000076493525,0.0011575446,0.0001605763],"about_ca_topic_score_codex":0.08446999,"about_ca_topic_score_gemma":0.4079845,"teacher_disagreement_score":0.4782601,"about_ca_system_score_codex":0.009454354,"about_ca_system_score_gemma":0.008125642,"threshold_uncertainty_score":0.9974974},"labels":[],"label_agreement":null},{"id":"W3125076999","doi":"10.1158/2159-8290.cd-20-1227","title":"Mitochondrial and Metabolic Pathways Regulate Nuclear Gene Expression to Control Differentiation, Stem Cell Function, and Immune Response in Leukemia","year":2021,"lang":"en","type":"review","venue":"Cancer Discovery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Institutes of Health Research; Canadian Cancer Society; Leukemia and Lymphoma Society","keywords":"Biology; Function (biology); Stem cell; Immune system; Leukemia; Gene; Gene expression; Cellular differentiation; Cell biology; Computational biology; Genetics","score_opus":0.02351212214866213,"score_gpt":0.2855100487200324,"score_spread":0.2619979265713703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125076999","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08571649,0.91122305,0.00021085491,0.0001502234,0.00055358454,0.0018086199,0.0002774317,0.00003429644,0.000025419773],"genre_scores_gemma":[0.004716373,0.9913018,0.00010590719,0.00018062734,0.0006561488,0.0005049922,0.00016041148,0.0001518102,0.002221943],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964205,0.00075798604,0.00084899995,0.0010029946,0.00046166373,0.00050783023],"domain_scores_gemma":[0.9981136,0.00032319545,0.0002973109,0.0007722023,0.00016534269,0.0003283499],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004089252,0.0005590825,0.0024268962,0.00049239944,0.00012722907,0.00019390804,0.00017882712,0.00046105115,0.000079948906],"category_scores_gemma":[0.00012250035,0.00044490007,0.00025850683,0.0006328178,0.00009970362,0.00027730464,0.000321788,0.0007401693,0.0000147124],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021733224,0.00030685682,0.00026304252,0.024389477,0.001468319,0.00055023097,0.0014110432,0.00006153807,0.18870953,0.00027078425,0.011147282,0.7496887],"study_design_scores_gemma":[0.012072186,0.00045553406,0.014416282,0.029619366,0.0029628528,0.00012413246,0.00027497957,0.00005569972,0.0020115331,0.000026713586,0.9368184,0.0011623139],"about_ca_topic_score_codex":0.000106689535,"about_ca_topic_score_gemma":0.0000094665875,"teacher_disagreement_score":0.9256711,"about_ca_system_score_codex":0.0012777253,"about_ca_system_score_gemma":0.0025472736,"threshold_uncertainty_score":0.99980026},"labels":[],"label_agreement":null},{"id":"W3128046611","doi":"10.1038/s41375-021-01150-3","title":"Therapy-related leukaemias with balanced translocations can arise from pre-existing clonal haematopoiesis","year":2021,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"Blood Cancer UK; CHILDREN with CANCER UK; National Cancer Research Institute; Guy's and St Thomas' Charity; Cancer Research UK; National Institute for Health and Care Research","keywords":"Haematopoiesis; Chromosomal translocation; Hematology; Biology; Immunology; Cancer research; Oncology; Stem cell; Medicine; Genetics; Gene","score_opus":0.027463614899632307,"score_gpt":0.2927900817349424,"score_spread":0.26532646683531014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128046611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98112667,0.0012653922,0.0010446943,0.004538433,0.00010064901,0.00054558954,0.000097175405,0.00027431527,0.011007059],"genre_scores_gemma":[0.98154366,0.00030419484,0.0076469686,0.0013017978,0.0002380424,0.00012071693,0.0007732118,0.00010245404,0.007968946],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973363,0.00014435653,0.0004916668,0.00070755417,0.0006954795,0.000624626],"domain_scores_gemma":[0.9978889,0.00035641855,0.0001221355,0.0008678453,0.00040109956,0.0003635855],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020688173,0.00033939164,0.0005970674,0.00012798423,0.00025690012,0.0000722833,0.0002460971,0.0002889391,0.0011038668],"category_scores_gemma":[0.00020968216,0.0002823067,0.00015851174,0.0008903956,0.00022885592,0.000118944365,0.000059205475,0.0009907393,0.00009389523],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007704143,0.0014930946,0.25440037,0.0009575602,0.0073137903,0.015251626,0.037198525,0.0041317707,0.5020109,0.006585328,0.041134816,0.12181811],"study_design_scores_gemma":[0.04610105,0.0011718911,0.49064052,0.0024440826,0.0011246788,0.0032017261,0.0047794282,0.02409337,0.38083637,0.0030541194,0.040025946,0.0025267978],"about_ca_topic_score_codex":0.002238682,"about_ca_topic_score_gemma":0.00062253897,"teacher_disagreement_score":0.23624018,"about_ca_system_score_codex":0.0016190151,"about_ca_system_score_gemma":0.004539213,"threshold_uncertainty_score":0.9999629},"labels":[],"label_agreement":null},{"id":"W3130034895","doi":"10.1016/j.exphem.2020.09.097","title":"3082 – EXPLORING GLUCOCORTICOID SENSITIVITY MODULATORS IN HUMAN ACUTE MYELOID LEUKEMIA","year":2020,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal","funders":"","keywords":"Myeloid leukemia; Leukemia; Cancer research; Myeloid; Biology; Lymphoma; Medicine; Immunology","score_opus":0.05718142379831255,"score_gpt":0.3340249883056654,"score_spread":0.27684356450735287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130034895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928166,0.0006943161,0.00013310231,0.002536019,0.00016328653,0.0007366813,0.0000049970836,0.00017831245,0.0027366711],"genre_scores_gemma":[0.99560153,0.000034912802,0.00076088595,0.003106225,0.000107094966,0.00015029077,0.000045790046,0.00007365647,0.000119591925],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99760014,0.0001926789,0.00049042795,0.0006899381,0.00035963062,0.00066718954],"domain_scores_gemma":[0.9989934,0.00009625438,0.00008415141,0.00039818365,0.000049747952,0.0003782869],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020567034,0.0003127598,0.0008042437,0.00019268352,0.000078152145,0.000018858884,0.00014062657,0.00018082213,0.0003131055],"category_scores_gemma":[0.00008714227,0.00031638792,0.00014527788,0.00040593022,0.00017287419,0.00025952887,0.00035884592,0.0006868329,0.0003724369],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000617212,0.00024378755,0.020091498,0.0001283202,0.00014878313,0.0051705935,0.0042183893,0.000058188743,0.94995165,0.018083422,0.0009862605,0.00030188373],"study_design_scores_gemma":[0.0036964023,0.00055206026,0.0051570353,0.00006483195,0.00002202038,0.0011519598,0.0026767284,0.003908912,0.9819805,0.000029024992,0.00046354902,0.00029695441],"about_ca_topic_score_codex":0.00019382361,"about_ca_topic_score_gemma":0.000012409117,"teacher_disagreement_score":0.032028858,"about_ca_system_score_codex":0.0009842967,"about_ca_system_score_gemma":0.00028754436,"threshold_uncertainty_score":0.99992883},"labels":[],"label_agreement":null},{"id":"W3130296909","doi":"10.1016/j.cell.2021.01.049","title":"Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis","year":2021,"lang":"en","type":"article","venue":"Cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Human Genome Research Institute; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; National Science Foundation","keywords":"Biology; Haematopoiesis; Stem cell; Hematopoietic stem cell; Somatic cell; Immunology; Cell division; Cell biology; Cell; Genetics; Gene","score_opus":0.030347324835754228,"score_gpt":0.2723801921477868,"score_spread":0.24203286731203258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130296909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98807204,0.00043214925,0.000058880523,0.00067831704,0.000052337764,0.0003802602,0.000010249013,0.000053401516,0.010262339],"genre_scores_gemma":[0.98780394,0.00014473166,0.0010052215,0.0006395193,0.00013236934,0.00007231485,0.000094999516,0.00003994073,0.010066986],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984534,0.00013254352,0.0003054536,0.00037386984,0.00036946754,0.00036531573],"domain_scores_gemma":[0.9990709,0.00012903452,0.000054764467,0.0003661445,0.0001988076,0.00018038126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002831753,0.00016467027,0.000310763,0.00013302296,0.000064345426,0.00006239778,0.00011074749,0.00015378006,0.0007704394],"category_scores_gemma":[0.000038039743,0.00015361124,0.00008362109,0.00051733514,0.00004309425,0.0001090458,0.00009637154,0.00035117377,0.0003286636],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001948844,0.00068943005,0.087957025,0.0005196638,0.000020730104,0.00022508972,0.00095684954,0.000013074713,0.90151626,0.00003301074,0.0072057433,0.0006682468],"study_design_scores_gemma":[0.0028029152,0.00008571448,0.029071577,0.00007743909,0.000025622161,0.00002515238,0.00060218136,0.0010023123,0.9646599,0.000032463584,0.0014626418,0.0001520624],"about_ca_topic_score_codex":0.00011534375,"about_ca_topic_score_gemma":0.000041799332,"teacher_disagreement_score":0.06314366,"about_ca_system_score_codex":0.00033827592,"about_ca_system_score_gemma":0.000690056,"threshold_uncertainty_score":0.8435771},"labels":[],"label_agreement":null},{"id":"W3131535883","doi":"10.1038/s41467-021-21233-0","title":"Biological and therapeutic implications of a unique subtype of NPM1 mutated AML","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Ontario Institute for Cancer Research; University of British Columbia; Hospital for Sick Children; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Government of Ontario; Génome Québec; Government of Canada; Ontario Institute for Cancer Research; Princess Margaret Cancer Foundation; Canadian Institutes of Health Research; Genome Canada","keywords":"NPM1; Computational biology; Medicine; Cancer research; Bioinformatics; Biology; Genetics; Gene; Karyotype","score_opus":0.05832456055818388,"score_gpt":0.3803064429345168,"score_spread":0.32198188237633296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131535883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91621083,0.028697684,0.00020782372,0.04352057,0.000022645132,0.0005348308,0.000100409365,0.00004663091,0.010658583],"genre_scores_gemma":[0.9871823,0.004210256,0.007794765,0.0004176298,0.00000819747,0.000024174164,0.00021393232,0.000009692114,0.00013900845],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992201,0.00019839634,0.00023817513,0.00013456626,0.00009669577,0.00011210395],"domain_scores_gemma":[0.99708045,0.0005770224,0.000090655856,0.0014906194,0.0006941174,0.00006716097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002001345,0.00007332783,0.00022538811,0.000091574344,0.000074564225,0.0000042846123,0.00033965756,0.0002643737,0.000069579226],"category_scores_gemma":[0.00052115443,0.00005942873,0.000056126413,0.0006497694,0.00040953717,0.00001867665,0.00029214384,0.0007624404,0.0000033251604],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011722869,0.0008045749,0.13283232,0.00008439989,0.0003546222,0.0000055837218,0.00063378876,0.0000013251743,0.7386615,0.11282412,0.0014113105,0.012269202],"study_design_scores_gemma":[0.0012324383,0.00021696048,0.90538526,0.000092953414,0.00014074324,0.00020352009,0.000463676,0.00037776586,0.0622945,0.004077088,0.025378108,0.00013700876],"about_ca_topic_score_codex":0.00001895624,"about_ca_topic_score_gemma":0.000072535215,"teacher_disagreement_score":0.7725529,"about_ca_system_score_codex":0.000050713305,"about_ca_system_score_gemma":0.00039950927,"threshold_uncertainty_score":0.33124664},"labels":[],"label_agreement":null},{"id":"W3132166484","doi":"10.1038/s41588-026-02585-z","title":"Transposable Elements Shape Stemness in Normal and Leukemic Hematopoiesis","year":2021,"lang":"en","type":"preprint","venue":"Nature Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"CIHR Skin Research Training Centre; Japan Society for the Promotion of Science; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Terry Fox Research Institute; Ontario Institute for Cancer Research; Princess Margaret Cancer Foundation","keywords":"Chromatin; Haematopoiesis; Biology; Stem cell; Myeloid leukemia; Leukemia; Cancer research; Hematopoietic stem cell; Myeloid; Cancer stem cell; Genetics; Computational biology; Gene","score_opus":0.016303144616169298,"score_gpt":0.3035756961441592,"score_spread":0.2872725515279899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132166484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96845114,0.028073099,0.000033804223,0.0006806748,0.00038297847,0.0009314622,0.00007303781,0.000042891457,0.0013309118],"genre_scores_gemma":[0.9808202,0.0067621293,0.009775278,0.000721651,0.00030978286,0.0000798328,0.00048164683,0.00008955613,0.00095996796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971033,0.000100851525,0.0005769603,0.000832874,0.0007697375,0.0006163287],"domain_scores_gemma":[0.9984967,0.000072053626,0.00011675996,0.0007853202,0.00028226292,0.00024688317],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00042508743,0.00041858866,0.0008012091,0.00033307465,0.00005403901,0.0000861744,0.00035542098,0.0018413214,0.00033481346],"category_scores_gemma":[0.00009507748,0.00041537438,0.00013627458,0.000365067,0.000102917795,0.000040394538,0.00069146795,0.0044371164,0.0000085291895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013725293,0.00085883663,0.88521236,0.019679759,0.0014315078,0.0048691477,0.0052856775,0.00073632,0.020065289,0.000071436305,0.007699239,0.052717883],"study_design_scores_gemma":[0.02718809,0.00090885337,0.7030913,0.00939272,0.0018907738,0.0017135144,0.0051727965,0.08103986,0.13516681,0.00082937325,0.029564727,0.0040411744],"about_ca_topic_score_codex":0.00003813166,"about_ca_topic_score_gemma":0.00015452904,"teacher_disagreement_score":0.18212108,"about_ca_system_score_codex":0.0006498454,"about_ca_system_score_gemma":0.0014690079,"threshold_uncertainty_score":0.9998298},"labels":[],"label_agreement":null},{"id":"W3134053447","doi":"10.2217/fon-2020-1210","title":"Role of Cedazuridine/Decitabine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia","year":2021,"lang":"en","type":"review","venue":"Future Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Decitabine; Medicine; Chronic myelomonocytic leukemia; Azacitidine; Myelodysplastic syndromes; Oncology; International Prognostic Scoring System; Internal medicine; Pharmacology; Bone marrow; DNA methylation","score_opus":0.025056787831958822,"score_gpt":0.34893973370480036,"score_spread":0.32388294587284155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134053447","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015764269,0.9908758,0.0000050430494,0.000299496,0.00020170929,0.0019120021,0.000037601516,0.0000134713755,0.005078492],"genre_scores_gemma":[0.0011272336,0.9966202,0.0007376362,0.00004667026,0.00044004305,0.00028863552,0.00020198844,0.00006770244,0.00046991822],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966464,0.0005530251,0.0011322871,0.0006116252,0.0005014153,0.0005552675],"domain_scores_gemma":[0.9976426,0.00071432325,0.000501074,0.0008983252,0.0001208112,0.00012290738],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008780507,0.000483328,0.003488232,0.000552112,0.000038521437,0.0000088401475,0.0005622086,0.00074827764,0.00020092064],"category_scores_gemma":[0.00006532305,0.00031491683,0.00036877426,0.0011739058,0.00030824676,0.00003808419,0.0004308884,0.0013735157,0.000025348592],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000802444,0.00018955157,0.0000076189685,0.06405232,0.0011374288,0.003545107,0.00025148955,0.000002724602,0.000018874442,0.0033601674,0.0010356229,0.9263188],"study_design_scores_gemma":[0.002109753,0.0014083547,0.0004555416,0.015061429,0.0024447825,0.0053281677,0.0009101006,0.0000282181,0.0000046192704,0.00004461825,0.971975,0.00022939206],"about_ca_topic_score_codex":0.0000330808,"about_ca_topic_score_gemma":0.000039897757,"teacher_disagreement_score":0.9709394,"about_ca_system_score_codex":0.003281869,"about_ca_system_score_gemma":0.0040578917,"threshold_uncertainty_score":0.99993026},"labels":[],"label_agreement":null},{"id":"W3135007625","doi":"10.1182/blood.2020009023","title":"A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Cancer research; stat; JAK-STAT signaling pathway; PIM1; Fusion protein; Carcinogenesis; Transcriptome; Myeloid leukemia; Biology; Leukemia; Signal transduction; Computational biology; Gene; STAT3; Genetics; Tyrosine kinase; Gene expression; Phosphorylation","score_opus":0.016919866997526355,"score_gpt":0.2743598381551708,"score_spread":0.25743997115764444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135007625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942363,0.0018791169,0.000016678221,0.0010913474,0.00006291923,0.00037235455,0.000020775871,0.0001167313,0.0022037802],"genre_scores_gemma":[0.99638677,0.00034684432,0.0012745451,0.00048819982,0.00029387505,0.00007286039,0.00011141874,0.00006665775,0.00095885043],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99772745,0.00022052902,0.0004325099,0.00045825547,0.0005565519,0.00060471083],"domain_scores_gemma":[0.99861044,0.0003359158,0.00007332448,0.00046362472,0.00020662417,0.00031005804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041702244,0.00022098023,0.00046141096,0.00030849726,0.00006007304,0.00003323941,0.0001594647,0.00022864284,0.00035954316],"category_scores_gemma":[0.0009138499,0.00021462783,0.00013161088,0.0007858323,0.00010100809,0.00010151873,0.00013463588,0.0005754036,0.0002377909],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001545298,0.00056083297,0.08477402,0.00021665847,0.0002607857,0.008472311,0.0020987524,0.000011638604,0.9012791,0.000021542872,0.000524926,0.0016249317],"study_design_scores_gemma":[0.016686922,0.00020873245,0.10046019,0.00048724073,0.0003039062,0.0007768326,0.0022114466,0.00028712314,0.86750007,0.00004105469,0.010562401,0.00047409657],"about_ca_topic_score_codex":0.0001372455,"about_ca_topic_score_gemma":0.00024635068,"teacher_disagreement_score":0.033779014,"about_ca_system_score_codex":0.00022307815,"about_ca_system_score_gemma":0.0012476133,"threshold_uncertainty_score":0.87522686},"labels":[],"label_agreement":null},{"id":"W3135647768","doi":"10.1038/s41375-021-01179-4","title":"Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial","year":2021,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Novartis; U.S. Department of Health and Human Services","keywords":"Midostaurin; Medicine; Internal medicine; Cytarabine; Oncology; Cumulative incidence; Myeloid leukemia; Preleukemia; Maintenance therapy; Transplantation; Surgery; Leukemia; Chemotherapy","score_opus":0.02581105720882084,"score_gpt":0.3097408282084322,"score_spread":0.28392977099961136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135647768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703875,0.0026421114,0.000046007488,0.013727793,0.0009231287,0.0018083641,0.00005262105,0.00018520732,0.01022723],"genre_scores_gemma":[0.94848555,0.003962472,0.0023501038,0.0039105993,0.0021188622,0.0005670351,0.00026618032,0.00020646573,0.03813275],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9942663,0.00055547524,0.0011627143,0.0012603336,0.0013454054,0.0014098161],"domain_scores_gemma":[0.9964479,0.00065934926,0.00025137854,0.0017833872,0.0003730292,0.00048492843],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00129483,0.00060815027,0.0010584107,0.0002062875,0.00032410925,0.0001825065,0.00083753624,0.0006711348,0.0007583978],"category_scores_gemma":[0.0013789359,0.00045237434,0.00038568434,0.0018040834,0.00048129653,0.0003058376,0.00051957957,0.0030210465,0.00070007687],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.069696836,0.00078247586,0.002360873,0.0005467453,0.0018786966,0.035158124,0.00597538,0.00055787363,0.65153193,0.0032809384,0.17950718,0.048722927],"study_design_scores_gemma":[0.19086641,0.0021294595,0.012731387,0.0013693639,0.0010497813,0.0036957765,0.0038501094,0.0071510486,0.54826176,0.0016751372,0.22504,0.0021797407],"about_ca_topic_score_codex":0.0006269428,"about_ca_topic_score_gemma":0.00042883147,"teacher_disagreement_score":0.121169575,"about_ca_system_score_codex":0.007817882,"about_ca_system_score_gemma":0.010067242,"threshold_uncertainty_score":0.9997928},"labels":[],"label_agreement":null},{"id":"W3136017577","doi":"10.1182/blood.2020008551","title":"Very long chain fatty acid metabolism is required in acute myeloid leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Western University; Population Health Research Institute; Ontario Institute for Cancer Research; University of Waterloo; University of Guelph","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Citric acid cycle; Biology; Beta oxidation; Glycolysis; Oxidative phosphorylation; Myeloid leukemia; Myeloid; Leukemia; Haematopoiesis; Fatty acid metabolism; Metabolism; Biochemistry; Cancer research; Cell biology; Stem cell; Immunology","score_opus":0.019494416410620233,"score_gpt":0.2833962493196377,"score_spread":0.2639018329090175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136017577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98489726,0.004684013,0.00016876576,0.003502689,0.0002090856,0.00045391152,0.000045958095,0.00012558866,0.005912757],"genre_scores_gemma":[0.9811087,0.0020048935,0.0046980027,0.0034954166,0.0006737742,0.00010274401,0.00018005178,0.00011097948,0.0076254234],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99700755,0.00016443097,0.0005018007,0.00072574965,0.00073789526,0.000862577],"domain_scores_gemma":[0.9982499,0.00009217525,0.00008463153,0.0009902428,0.00023051759,0.00035251697],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005112311,0.000315197,0.0007540711,0.0003092303,0.00008835638,0.000056575755,0.0002961036,0.00031398062,0.00059605186],"category_scores_gemma":[0.00037988235,0.00030082767,0.00022396714,0.0011055009,0.00012588926,0.000217081,0.00035209744,0.0008554644,0.0004143709],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055824674,0.0010134503,0.03727495,0.0003187115,0.001510046,0.021073407,0.0021422727,0.0000036899821,0.9139457,0.00045839942,0.008851739,0.012849442],"study_design_scores_gemma":[0.012923732,0.000112909875,0.12717219,0.00018508095,0.0005573196,0.0011274355,0.00027361565,0.00017874273,0.84954226,0.0001583802,0.007384196,0.0003841318],"about_ca_topic_score_codex":0.00014265275,"about_ca_topic_score_gemma":0.000069734015,"teacher_disagreement_score":0.08989724,"about_ca_system_score_codex":0.0005172079,"about_ca_system_score_gemma":0.0018950084,"threshold_uncertainty_score":0.9999444},"labels":[],"label_agreement":null},{"id":"W3136342625","doi":"10.1002/jha2.187","title":"DNA methylation analysis improves the prognostication of acute myeloid leukemia","year":2021,"lang":"en","type":"article","venue":"eJHaem","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"National Institute on Aging; Terry Fox Research Institute; Genome British Columbia","keywords":"DNA methylation; Epigenomics; Myeloid leukemia; Methylation; Oncology; Gene; Computational biology; Medicine; Bioinformatics; Internal medicine; Biology; Genetics; Gene expression","score_opus":0.018759141319488224,"score_gpt":0.3098336599191932,"score_spread":0.29107451859970496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136342625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98570895,0.00047778236,0.0038231425,0.005050457,0.0000649808,0.00045705782,0.000020487516,0.000052476906,0.0043446575],"genre_scores_gemma":[0.99279886,0.0001860898,0.0028784939,0.00024181479,0.00014178241,0.000044048043,0.0002508444,0.000018431749,0.003439605],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985557,0.0001285507,0.00032726637,0.00028621466,0.00047328358,0.00022896413],"domain_scores_gemma":[0.9983566,0.00027162026,0.00013124965,0.000657476,0.0004939039,0.00008917758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047417966,0.00011744904,0.00034462498,0.00018360077,0.00008409318,0.000023466575,0.00015063264,0.00009696694,0.00021544914],"category_scores_gemma":[0.00052048475,0.00007999252,0.00022081514,0.0017799754,0.00012830352,0.000089463436,0.00010099418,0.00026437402,0.000047979906],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001824624,0.00010506776,0.010350461,0.00009930046,0.004881371,0.00008081254,0.001375454,0.000045063556,0.9179127,0.0015344131,0.0022146401,0.061218236],"study_design_scores_gemma":[0.0009571724,0.0001440709,0.3175728,0.000028007817,0.004683332,0.000045888948,0.00054858165,0.0094693955,0.6623795,0.00031737483,0.00371612,0.00013773332],"about_ca_topic_score_codex":0.000078285804,"about_ca_topic_score_gemma":0.000025551994,"teacher_disagreement_score":0.30722234,"about_ca_system_score_codex":0.0003122265,"about_ca_system_score_gemma":0.0007511891,"threshold_uncertainty_score":0.32620004},"labels":[],"label_agreement":null},{"id":"W3136957643","doi":"10.1182/blood.2020010470","title":"Multiple Auer rods in a mixed-phenotype acute leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Leukemia; Phenotype; Pathology; Immunology; Biology; Genetics","score_opus":0.016861192859688602,"score_gpt":0.2860804658041077,"score_spread":0.26921927294441905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136957643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860989,0.00078698684,0.00006819165,0.0011782916,0.00012499101,0.00027429682,0.000015923131,0.00008334507,0.0113691045],"genre_scores_gemma":[0.98566264,0.00016295994,0.005678248,0.00065376016,0.00022035048,0.000045091794,0.00009021237,0.000051094386,0.0074356506],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983096,0.00008628673,0.0002743355,0.0004287974,0.00038443727,0.0005165553],"domain_scores_gemma":[0.9988549,0.00013716538,0.00003552682,0.0005954683,0.00016242328,0.00021454596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023322857,0.0001705166,0.00037403914,0.00015327989,0.00004749543,0.000025515425,0.00014953515,0.00017673144,0.00039552455],"category_scores_gemma":[0.0005392233,0.00015808917,0.0001033672,0.00066013256,0.00006184928,0.00007754725,0.00019418677,0.00056802185,0.0004329873],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005509441,0.0022932787,0.36959484,0.00033685492,0.0011464952,0.019583102,0.0012718774,0.00003037821,0.57312286,0.0008763121,0.0141803995,0.017012674],"study_design_scores_gemma":[0.0356869,0.0004679775,0.55373275,0.0003588897,0.0006488904,0.0010407204,0.00053467514,0.00201176,0.3666373,0.00035898987,0.037885774,0.00063537294],"about_ca_topic_score_codex":0.00021887825,"about_ca_topic_score_gemma":0.00031983608,"teacher_disagreement_score":0.20648555,"about_ca_system_score_codex":0.00036975017,"about_ca_system_score_gemma":0.0015404564,"threshold_uncertainty_score":0.6446689},"labels":[],"label_agreement":null},{"id":"W3137158297","doi":"10.1182/blood.2020009744","title":"Cabot rings in acute myeloid leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Myeloid leukemia; Medicine; Leukemia; Acute leukemia; Myeloid; Internal medicine","score_opus":0.015272653279523705,"score_gpt":0.28295162710815386,"score_spread":0.26767897382863015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137158297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97362703,0.0007002091,0.000020514786,0.00230168,0.000069252936,0.00020737281,0.000008743942,0.000077192206,0.022988006],"genre_scores_gemma":[0.98063827,0.0004694451,0.003015528,0.0011017771,0.00025964342,0.00003957894,0.00005369376,0.00004771548,0.014374382],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984206,0.000054131277,0.00025687928,0.0003927384,0.00038128323,0.0004943807],"domain_scores_gemma":[0.99904984,0.000068551075,0.000033210366,0.0005035155,0.00013478467,0.00021007983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002242635,0.00015321425,0.00034780783,0.00015624381,0.00004350879,0.000027286089,0.00014326283,0.00014823963,0.00042822244],"category_scores_gemma":[0.0002334487,0.00014614809,0.00008984127,0.00063209556,0.000061229235,0.00008131833,0.00017807246,0.0005870553,0.0003736293],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003528773,0.0013443724,0.20054641,0.00035051283,0.00087680074,0.036597535,0.0013779233,0.0000115193,0.7317823,0.001496808,0.011327222,0.013935703],"study_design_scores_gemma":[0.02107168,0.00031223425,0.31300598,0.00029827657,0.00044442652,0.0036369117,0.0004334973,0.00025715545,0.61080027,0.0002774026,0.04898872,0.00047342162],"about_ca_topic_score_codex":0.00024576686,"about_ca_topic_score_gemma":0.00010570133,"teacher_disagreement_score":0.12098203,"about_ca_system_score_codex":0.0004276155,"about_ca_system_score_gemma":0.0013980934,"threshold_uncertainty_score":0.5959746},"labels":[],"label_agreement":null},{"id":"W3137414528","doi":"10.1038/s41409-021-01255-4","title":"Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia","year":2021,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","keywords":"Medicine; Myeloid leukemia; Internal medicine; Transplantation; Oncology; Hematopoietic stem cell transplantation; Monosomy; NPM1; Chromosome 7 (human); Univariate analysis; Cancer research; Gastroenterology; Karyotype; Biology; Genetics; Chromosome; Multivariate analysis; Gene","score_opus":0.014099323371605316,"score_gpt":0.2839431116888897,"score_spread":0.2698437883172844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137414528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963782,0.0002676155,0.0007774665,0.00020576315,0.000126839,0.0016225057,0.00013368788,0.000050246723,0.00043769705],"genre_scores_gemma":[0.9977655,0.000366245,0.00052925956,0.00012352876,0.0000148511745,0.00015340737,0.0004979925,0.00007103,0.00047820676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970581,0.00031403382,0.00072388945,0.0005446047,0.00083363225,0.00052575144],"domain_scores_gemma":[0.99880165,0.00020926671,0.00018516416,0.00052678544,0.00012036495,0.00015674277],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025433738,0.00037585662,0.00059832865,0.00027835168,0.00008480741,0.000022764081,0.00020340481,0.00021757609,0.00007287765],"category_scores_gemma":[0.000020923822,0.0002859762,0.00060155825,0.0007367115,0.000072736504,0.00012978596,0.000020517567,0.00044360087,0.000030344263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064179563,0.00019540347,0.62250775,0.001247924,0.00024346595,0.0043137223,0.0013380138,0.0010838425,0.367423,0.000013215196,0.000007683565,0.0009841465],"study_design_scores_gemma":[0.0041291593,0.00024517745,0.76454103,0.00063664163,0.00080011407,0.0004585047,0.00007952706,0.00014590698,0.22874154,0.00001391626,3.180295e-7,0.00020817868],"about_ca_topic_score_codex":0.000093429466,"about_ca_topic_score_gemma":0.00013484141,"teacher_disagreement_score":0.14203323,"about_ca_system_score_codex":0.000696515,"about_ca_system_score_gemma":0.0011912817,"threshold_uncertainty_score":0.99995923},"labels":[],"label_agreement":null},{"id":"W3138046343","doi":"10.1182/blood.v130.suppl_1.3914.3914","title":"N-Myristoyltransferase 2 (NMT2) Protein Levels Predict Survival in Acute Myeloid Leukemia (AML): A Novel Prognostic Biomarker","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Alberta; University of British Columbia","funders":"","keywords":"Myeloid leukemia; Biomarker; Myeloid; Leukemia; Medicine; Cancer research; Oncology; Internal medicine; Biology; Genetics","score_opus":0.03884656240479668,"score_gpt":0.3047226401332673,"score_spread":0.2658760777284706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138046343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848307,0.00016978905,0.0007094649,0.0018985383,0.00018373817,0.003204624,0.00027885893,0.00018892447,0.008535401],"genre_scores_gemma":[0.99308574,0.000041571584,0.0024940274,0.00013354892,0.00031712383,0.0005293009,0.00008186214,0.00012882543,0.0031880192],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99600965,0.00012738965,0.0006897519,0.0009397411,0.0010600667,0.0011733874],"domain_scores_gemma":[0.997094,0.0001657097,0.00018277913,0.0017685163,0.00024472,0.0005443171],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011166215,0.00050889654,0.00082206,0.00040165498,0.00040176205,0.00019438959,0.00090557686,0.00041078005,0.00019206994],"category_scores_gemma":[0.001452759,0.00045147946,0.00023045973,0.00034472154,0.0005039864,0.00038993135,0.00031357037,0.0010637182,0.00018697568],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015746744,0.0022343162,0.204035,0.000566028,0.001081143,0.00436089,0.00042216663,0.0000020974983,0.779052,0.00030540882,0.0006133972,0.0057528457],"study_design_scores_gemma":[0.033597354,0.0008950879,0.87718636,0.00092509564,0.00067046616,0.0006575242,0.00008254558,0.00078922353,0.08216839,0.0001133769,0.002194723,0.00071983394],"about_ca_topic_score_codex":0.00090469175,"about_ca_topic_score_gemma":0.00026201425,"teacher_disagreement_score":0.6968836,"about_ca_system_score_codex":0.00059584674,"about_ca_system_score_gemma":0.002147615,"threshold_uncertainty_score":0.9997937},"labels":[],"label_agreement":null},{"id":"W3138063460","doi":"10.1007/s00277-021-04465-4","title":"Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial","year":2021,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Hospital","funders":"Incyte; Daiichi Sankyo Europe; Agios Pharmaceuticals; Jazz Pharmaceuticals; Celgene; Astellas Pharma; Ariad Pharmaceuticals; Alexion Pharmaceuticals; Servier; Pfizer; Amgen","keywords":"Medicine; Cytarabine; Internal medicine; Myeloid leukemia; Hazard ratio; Leukemia; Oncology; Confidence interval","score_opus":0.032711054536759834,"score_gpt":0.3778921484179776,"score_spread":0.34518109388121776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138063460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996853,0.0009304546,0.00010049611,0.0007392207,0.00005478636,0.0010582695,0.00012622503,0.000010198883,0.00012732731],"genre_scores_gemma":[0.99724835,0.0011512077,0.0007334408,0.0003530863,0.000029951962,0.000044382898,0.00033118663,0.000026140193,0.0000822708],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962256,0.00047408108,0.0018802818,0.0005109046,0.00043961822,0.0004695154],"domain_scores_gemma":[0.9964053,0.0012953803,0.00072165695,0.0006238525,0.0007191982,0.00023459934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014164124,0.0002579184,0.004132683,0.0007713266,0.000032016942,0.00000443198,0.00019227572,0.00037320194,0.00025832083],"category_scores_gemma":[0.001208205,0.00020261714,0.0005513211,0.0010754796,0.0008433931,0.00009059849,0.00024817113,0.00054969435,8.9376124e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86146057,0.002670655,0.12142351,0.000505472,0.008111434,0.00080073776,0.00038050054,0.00001851118,0.00091454695,0.0001950736,0.00010409468,0.003414874],"study_design_scores_gemma":[0.91618145,0.0044168117,0.059551448,0.00027477762,0.002890968,0.00012364027,0.000047177058,0.0007855959,0.015472814,0.00007726963,0.0000062674217,0.00017177018],"about_ca_topic_score_codex":0.00010588618,"about_ca_topic_score_gemma":0.00015924498,"teacher_disagreement_score":0.061872065,"about_ca_system_score_codex":0.00006940418,"about_ca_system_score_gemma":0.001773887,"threshold_uncertainty_score":0.8262487},"labels":[],"label_agreement":null},{"id":"W3138492443","doi":"10.3390/epigenomes5020007","title":"Enhancement of the Antileukemic Action of the Inhibitors of DNA and Histone Methylation: 5-Aza-2′-Deoxycytidine and 3-Deazaneplanocin-A by Vitamin C","year":2021,"lang":"en","type":"article","venue":"Epigenomes","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"EZH2; Epigenetics; Biology; DNA methylation; Histone H3; Histone; Cancer epigenetics; DNA demethylation; Histone methylation; Cancer research; Molecular biology; Histone methyltransferase; Genetics; Gene; Gene expression","score_opus":0.01599385217317148,"score_gpt":0.29081024015524415,"score_spread":0.27481638798207264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138492443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913225,0.0060678846,0.000044066568,0.0015807336,0.00016453044,0.00032986666,0.000030867188,0.0000050068834,0.00045453318],"genre_scores_gemma":[0.99572766,0.0014123046,0.00016305134,0.00005435284,0.00006460778,0.0000068655895,0.000013445117,0.00001349164,0.0025442173],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987954,0.000118294236,0.0003640657,0.00020001266,0.00037586543,0.00014638541],"domain_scores_gemma":[0.9990203,0.00015642324,0.00023761958,0.0003753146,0.00016110105,0.000049269205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032053373,0.000111998794,0.00033189962,0.00006116319,0.000067428125,0.0000038155817,0.00009399584,0.000076199154,0.000086918655],"category_scores_gemma":[0.00016497706,0.00007044782,0.000071412556,0.0003267845,0.00031795283,0.000046774552,0.00015894335,0.00017460281,7.6789934e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006794333,0.000057990725,0.0104442425,0.00027502707,0.000085621235,0.0000014905968,0.00086509925,0.0000011735613,0.98128325,0.000046420573,0.0020438645,0.0048278635],"study_design_scores_gemma":[0.00091836357,0.00011229863,0.041572522,0.000118467266,0.00007954286,0.000017728742,0.0004901241,0.000029055132,0.95273805,0.00004839872,0.0038196566,0.00005577292],"about_ca_topic_score_codex":0.00013967932,"about_ca_topic_score_gemma":0.00002316537,"teacher_disagreement_score":0.031128278,"about_ca_system_score_codex":0.00018633217,"about_ca_system_score_gemma":0.0003121852,"threshold_uncertainty_score":0.28727788},"labels":[],"label_agreement":null},{"id":"W3138496492","doi":"10.1182/bloodadvances.2020003510","title":"Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"Pharmacyclics; Genentech; Astellas Pharma; Incyte; Agios Pharmaceuticals; Jazz Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Kaiser Permanente; University of Rochester; Teva Pharmaceutical Industries; Kite Pharma; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Medicine; Hazard ratio; Internal medicine; Confidence interval; Transplantation; Cytarabine; Clinical endpoint; Neutropenia; Post-hoc analysis; Gastroenterology; Myeloid leukemia; Surgery; Oncology; Chemotherapy; Randomized controlled trial","score_opus":0.011201238644042485,"score_gpt":0.31226726340611655,"score_spread":0.30106602476207406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138496492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823601,0.012994425,0.00037607635,0.00191045,0.00006861049,0.00072779955,0.00015409186,0.00016841476,0.0012400055],"genre_scores_gemma":[0.9685051,0.0047273533,0.020579536,0.0009870996,0.00047459645,0.000111946385,0.00066764257,0.00012480232,0.0038219406],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967704,0.00019324264,0.00042949148,0.0009817486,0.000913174,0.0007119574],"domain_scores_gemma":[0.997161,0.00039499786,0.0002717118,0.0009078231,0.0007070662,0.00055743684],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018915365,0.00046320714,0.0008281479,0.00021093329,0.00028319962,0.00007897012,0.00026301364,0.000151051,0.00068405876],"category_scores_gemma":[0.00045675063,0.00030130454,0.00012493435,0.0009721856,0.00027903513,0.0005549585,0.00012174264,0.0008572422,0.00003643903],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050304182,0.009653039,0.092811994,0.0025782855,0.004067625,0.03705309,0.005133644,0.00028891678,0.10478489,0.00010543618,0.00794232,0.68527657],"study_design_scores_gemma":[0.20787328,0.019807803,0.13375743,0.0077464697,0.0037958315,0.002260477,0.014029302,0.0005379919,0.5729794,0.000053987085,0.03502383,0.0021342258],"about_ca_topic_score_codex":0.0003155764,"about_ca_topic_score_gemma":0.0006120769,"teacher_disagreement_score":0.68314236,"about_ca_system_score_codex":0.00010904488,"about_ca_system_score_gemma":0.0012782671,"threshold_uncertainty_score":0.9999439},"labels":[],"label_agreement":null},{"id":"W3138553809","doi":"10.1101/2021.03.25.437029","title":"INPP4B drives lysosome biogenesis to restrict leukemic stem cell differentiation and promote leukemogenesis","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute; Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network; Toronto Metropolitan University; University of Toronto; Ontario Institute for Cancer Research; Discovery Centre","funders":"Natural Sciences and Engineering Research Council of Canada; Government of Ontario; Leukemia and Lymphoma Society of Canada; University of Toronto; Temerty Faculty of Medicine, University of Toronto; Ontario Institute for Cancer Research; Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Biology; Cancer research; Stem cell; Lysosome; Biogenesis; Myeloid leukemia; Haematopoiesis; Hematopoietic stem cell; Leukemia; Mechanism (biology); Cell biology; Gene; Immunology; Genetics; Biochemistry","score_opus":0.016708048924377862,"score_gpt":0.2366304263686395,"score_spread":0.21992237744426166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138553809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908845,0.0036867668,0.0010277665,0.000732096,0.0005936809,0.0023467685,0.00024524724,0.0004719318,0.0000112593525],"genre_scores_gemma":[0.98856896,0.0026015348,0.0069202953,0.00036083788,0.00064300565,0.00047345686,0.0000052937767,0.0003294707,0.00009715549],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9942778,0.00035827304,0.00096726755,0.0022167487,0.0010732906,0.0011066312],"domain_scores_gemma":[0.9949104,0.00013905385,0.00045529622,0.0023153387,0.0010457751,0.0011341409],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000660606,0.0010169117,0.0014152208,0.0012042596,0.0002743457,0.00045885562,0.00063820335,0.0010624226,0.0000621904],"category_scores_gemma":[0.00023174417,0.0010526276,0.00031513735,0.0015870003,0.00016391253,0.00020942133,0.0017300147,0.0011870848,0.00009788674],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015136936,0.00021791195,0.030298874,0.0017364188,0.00037976645,0.00047239498,0.000065852444,0.000027444217,0.9661855,0.000016245735,0.00039881252,0.00004939799],"study_design_scores_gemma":[0.0013884665,0.00018375256,0.33298182,0.0008245717,0.00050113554,3.9776e-7,0.000024573457,0.00058466464,0.6616826,3.8669626e-7,0.00094498927,0.00088260666],"about_ca_topic_score_codex":0.000250288,"about_ca_topic_score_gemma":0.000006603176,"teacher_disagreement_score":0.30450287,"about_ca_system_score_codex":0.0024386414,"about_ca_system_score_gemma":0.0034038709,"threshold_uncertainty_score":0.9991924},"labels":[],"label_agreement":null},{"id":"W3138897860","doi":"10.1016/j.hemonc.2021.03.003","title":"Predictors of Outcomes of Therapy-Related Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation","year":2021,"lang":"en","type":"article","venue":"Hematology/Oncology and Stem Cell Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Cumulative incidence; Myeloid leukemia; Hematopoietic stem cell transplantation; Hazard ratio; Transplantation; Oncology; Incidence (geometry); Proportional hazards model; Gastroenterology; Confidence interval","score_opus":0.01554791111714027,"score_gpt":0.27554538541022144,"score_spread":0.2599974742930812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138897860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97719914,0.018854832,0.00012448918,0.00061730406,0.00026344493,0.0008946138,0.000046875288,0.000064163134,0.0019351394],"genre_scores_gemma":[0.9676835,0.02879431,0.00037410363,0.00047090766,0.000022168171,0.00012637231,0.00006184418,0.000060866605,0.002405924],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996795,0.00058476574,0.0010928323,0.00061888533,0.00035981118,0.0005487211],"domain_scores_gemma":[0.9978567,0.00063393713,0.00042229594,0.000583524,0.00029148546,0.00021209737],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050156924,0.00041835313,0.0016386969,0.00026899058,0.000088794055,0.00000756942,0.00021544038,0.0008999336,0.00036034448],"category_scores_gemma":[0.0000038118776,0.00032826044,0.0003100468,0.00039597112,0.00056205504,0.00008852406,0.00005734102,0.0005693786,0.000020972155],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008310652,0.0014475037,0.5043281,0.0017248128,0.0030309686,0.0032100275,0.015859786,0.000014961002,0.44991857,0.000643012,0.0005358702,0.010975732],"study_design_scores_gemma":[0.015393307,0.0021674042,0.061469547,0.00012437753,0.00044321816,0.0023318683,0.0019375118,0.000053155174,0.91395116,0.00016220451,0.0015942825,0.00037196654],"about_ca_topic_score_codex":0.000013681871,"about_ca_topic_score_gemma":0.000010955135,"teacher_disagreement_score":0.4640326,"about_ca_system_score_codex":0.00018130778,"about_ca_system_score_gemma":0.0010478976,"threshold_uncertainty_score":0.999917},"labels":[],"label_agreement":null},{"id":"W3139163066","doi":"10.1200/jco.20.02619","title":"Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Medical Research Council; National Institute for Health and Care Research","keywords":"Medicine; Placebo; Internal medicine; Adverse effect; Myelodysplastic syndromes; Anemia; Gastroenterology; Clinical endpoint; International Prognostic Scoring System; Azacitidine; Interim analysis; Randomized controlled trial; Surgery; Bone marrow","score_opus":0.05024886019407585,"score_gpt":0.4222112638362222,"score_spread":0.37196240364214633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139163066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99191326,0.00017488106,0.00036745647,0.0022773833,0.0015288467,0.0022041593,0.000009568271,0.000007807979,0.00151664],"genre_scores_gemma":[0.99506074,0.0005836928,0.0023923963,0.00040394993,0.00075843005,0.00004207153,0.000011279435,0.000033377266,0.0007140363],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.989515,0.003422619,0.005111741,0.0003399089,0.0011354594,0.00047525368],"domain_scores_gemma":[0.9755242,0.018111108,0.0038028234,0.00036249516,0.0016108103,0.0005885954],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011912035,0.0002738978,0.0074216817,0.00041961652,0.000038391936,0.000012903216,0.00026401455,0.0005747553,0.00037135434],"category_scores_gemma":[0.04692469,0.00016683798,0.0012428114,0.000427647,0.000664759,0.00015795228,0.00010334719,0.0024475262,0.000014491293],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93736297,0.036487132,0.0047661816,0.000036194513,0.0019054557,0.0031832003,0.000055920646,0.000021101336,0.000009566622,0.00003055385,0.0012156228,0.014926079],"study_design_scores_gemma":[0.93946576,0.05433955,0.0019509592,0.00023338977,0.0016590221,0.0002079513,0.000066651235,0.0007383491,0.000025751064,0.00011665364,0.0010589481,0.00013699316],"about_ca_topic_score_codex":0.00002415295,"about_ca_topic_score_gemma":0.000040587125,"teacher_disagreement_score":0.03501266,"about_ca_system_score_codex":0.00038338764,"about_ca_system_score_gemma":0.0065930644,"threshold_uncertainty_score":0.99985385},"labels":[],"label_agreement":null},{"id":"W3140531389","doi":"10.1016/j.jacc.2021.02.045","title":"Impact of Clonal Hematopoiesis in Ischemic and Nonischemic Heart Failure","year":2021,"lang":"en","type":"letter","venue":"Journal of the American College of Cardiology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cardiology; Internal medicine; Heart failure","score_opus":0.012748507287313403,"score_gpt":0.2965558216129219,"score_spread":0.28380731432560846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3140531389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76164496,0.001230281,0.000008320515,0.23620133,0.000101459,0.00021509355,0.0001899152,0.0000021593164,0.00040650673],"genre_scores_gemma":[0.96477413,0.0007690774,0.0027516927,0.028485922,0.0026030885,0.00000833168,0.000018755203,0.00008689066,0.00050211523],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99712414,0.0005689465,0.0009932239,0.00025341543,0.0006362071,0.00042405416],"domain_scores_gemma":[0.99664444,0.00070017925,0.0013886273,0.0005903559,0.00056983007,0.000106588814],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006605339,0.00030556985,0.0031932916,0.0005082872,0.000024487477,0.0000040246973,0.00045626238,0.00041234036,0.000035403285],"category_scores_gemma":[0.00049993995,0.0001955814,0.0013039904,0.00074167753,0.0012620455,0.00004705153,0.000297627,0.0031100248,8.2627827e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053870195,0.000017952345,0.06003005,0.00023768724,0.0013619558,0.0017355583,0.000018893257,0.000021833419,0.059498545,9.459297e-7,0.8764965,0.000041378225],"study_design_scores_gemma":[0.008109537,0.0049721086,0.108765505,0.002643797,0.0018375907,0.16055903,0.001202749,0.000036137968,0.022509972,0.0000960959,0.6884979,0.0007695658],"about_ca_topic_score_codex":0.00007430673,"about_ca_topic_score_gemma":0.00000272844,"teacher_disagreement_score":0.2077154,"about_ca_system_score_codex":0.00050217105,"about_ca_system_score_gemma":0.0028987776,"threshold_uncertainty_score":0.99918985},"labels":[],"label_agreement":null},{"id":"W3140744447","doi":"10.1182/blood.v130.suppl_1.3869.3869","title":"Characteristics of Venous Thromboembolism in Patients with Acute Leukemia","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Venous thromboembolism; Medicine; Acute leukemia; Leukemia; Leukostasis; Pulmonary embolism; Intensive care medicine; Internal medicine; Thrombosis","score_opus":0.010894430492074742,"score_gpt":0.2658471762923168,"score_spread":0.2549527458002421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3140744447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961702,0.000014150432,0.000004416122,0.00010243105,0.000047998616,0.00036743967,0.000042097883,0.00001558296,0.0032356633],"genre_scores_gemma":[0.99898213,0.000042525335,0.000542826,0.000057855505,0.00008102509,0.000011048584,0.000044867553,0.000028543987,0.0002091768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989416,0.000016675656,0.00021292016,0.00019774176,0.00034861307,0.00028245797],"domain_scores_gemma":[0.99877286,0.000021094784,0.00017244853,0.00077286694,0.00015815286,0.00010257899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011190614,0.00012163887,0.0004815438,0.00009505012,0.00007896414,0.000021809457,0.00026224737,0.00009507995,0.000034049302],"category_scores_gemma":[0.00013407148,0.00009401288,0.00003639678,0.00006433515,0.00016433069,0.000096544565,0.00011961783,0.0002777976,0.000028561142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004328488,0.0012025337,0.99206793,0.00009874706,0.0002748062,0.0003162129,0.0002779391,1.1130683e-7,0.0014297598,0.00007054771,0.00011429863,0.0037142606],"study_design_scores_gemma":[0.008887365,0.0007880046,0.9861721,0.00013602866,0.00021296948,0.000017298287,0.0000083339055,0.000009925182,0.0035198976,0.000019290948,0.00013514873,0.000093680355],"about_ca_topic_score_codex":0.0001576044,"about_ca_topic_score_gemma":0.0000104848805,"teacher_disagreement_score":0.0084545165,"about_ca_system_score_codex":0.0001286557,"about_ca_system_score_gemma":0.00044151855,"threshold_uncertainty_score":0.3833734},"labels":[],"label_agreement":null},{"id":"W3144087614","doi":"10.1016/j.jconrel.2021.03.042","title":"Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia","year":2021,"lang":"en","type":"article","venue":"Journal of Controlled Release","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NanoMedicines Innovation Network; University of British Columbia; Occupational Cancer Research Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Pharmacology; Chemistry; Pharmacokinetics; Liposome; Myeloid leukemia; In vivo; Daunorubicin; Bioavailability; Drug; Quercetin; Leukemia; Medicine; Cancer research; Biochemistry; Immunology; Antioxidant; Biology","score_opus":0.024385346455850134,"score_gpt":0.30043054906474165,"score_spread":0.27604520260889154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3144087614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819363,0.0003248337,0.016061887,0.0007365577,0.00007596876,0.0007768868,0.000026474832,0.0000037998368,0.000057305522],"genre_scores_gemma":[0.9816215,0.000781794,0.016327811,0.00007848183,0.00018437889,0.000028622346,0.000059580696,0.000020271642,0.0008975397],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837804,0.00003583619,0.00095002184,0.000118821605,0.00035519712,0.00016209383],"domain_scores_gemma":[0.99758625,0.00018151442,0.0007838542,0.00013574956,0.0011543953,0.00015825129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030376264,0.00013591771,0.00092987303,0.00023132465,0.00004230632,0.000010453503,0.000045903147,0.00009606067,0.000017394703],"category_scores_gemma":[0.00024199797,0.00009655704,0.00024707237,0.00014708101,0.000025209483,0.00012119358,0.00001568843,0.00007677475,4.0790334e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015636662,0.00046474917,0.00041438913,0.00016798687,0.0014282179,0.000062156396,0.0006037603,0.000015658852,0.95316666,0.00021542476,0.000028198914,0.02779612],"study_design_scores_gemma":[0.1620972,0.0027476454,0.01801555,0.00043037566,0.0017163382,0.00062860275,0.00018368586,0.02008309,0.78698075,0.00002736677,0.006926387,0.00016302531],"about_ca_topic_score_codex":0.0000027623353,"about_ca_topic_score_gemma":0.000001266091,"teacher_disagreement_score":0.16618595,"about_ca_system_score_codex":0.00052411493,"about_ca_system_score_gemma":0.0022928584,"threshold_uncertainty_score":0.40674326},"labels":[],"label_agreement":null},{"id":"W3146722950","doi":"10.1007/s00277-020-04375-x","title":"Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review","year":2021,"lang":"en","type":"review","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Quality of life (healthcare); Intensive care; Disease; Intensive care medicine; Performance status; Clinical trial; Internal medicine; Comorbidity; Myeloid leukemia; Physical therapy; Chemotherapy","score_opus":0.1707211758480028,"score_gpt":0.4611661922410932,"score_spread":0.2904450163930904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3146722950","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09650978,0.90219337,7.720432e-7,0.00019608473,0.000018488707,0.00071940426,0.00024089991,0.0000037488498,0.00011748765],"genre_scores_gemma":[0.009249751,0.9900498,0.00005161079,0.00017166063,0.0000067276746,0.000030245137,0.00038284634,0.000023881934,0.000033506592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727255,0.0005150876,0.0012174025,0.00030916612,0.00040630598,0.0002794646],"domain_scores_gemma":[0.99708986,0.0011827811,0.0008113903,0.0003981205,0.00036737585,0.00015046558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004836217,0.00029220173,0.0050870646,0.00031893066,0.000012730867,0.0000027462218,0.000074780604,0.00021732248,0.00011402327],"category_scores_gemma":[0.00143522,0.00018290474,0.00030335627,0.00025806975,0.0004007402,0.000039219944,0.00009649608,0.00039817055,8.8190086e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049801735,0.0009474104,0.56167054,0.32118577,0.0024034264,0.000067816196,0.00006996246,1.4439657e-7,4.296037e-7,0.0014005386,0.008038236,0.1037177],"study_design_scores_gemma":[0.005516322,0.0067951046,0.76418066,0.17152289,0.00092850265,0.00016215254,0.000101949125,4.3764916e-7,0.000010318908,0.00009713959,0.050071664,0.0006128345],"about_ca_topic_score_codex":0.00036346048,"about_ca_topic_score_gemma":0.00003547305,"teacher_disagreement_score":0.20251013,"about_ca_system_score_codex":0.000029424224,"about_ca_system_score_gemma":0.0010811569,"threshold_uncertainty_score":0.74586385},"labels":[],"label_agreement":null},{"id":"W3147605822","doi":"10.1182/blood.v130.suppl_1.881.881","title":"Inhibiting the Mitochondrial Sulfhydryl Oxidase Alr Reduces Cox17 and Alters Mitochondrial Cristae Structure Leading to the Differentiation of AML and Stem Cells","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Gene knockdown; Haematopoiesis; Stem cell; Biology; Clonogenic assay; Mitochondrion; Molecular biology; Bone marrow; Myeloid leukemia; Cell biology; Apoptosis; Chemistry; Cancer research; Biochemistry; Immunology","score_opus":0.018105695605676788,"score_gpt":0.27776445624343377,"score_spread":0.259658760637757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147605822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946239,0.00022001228,0.000056258436,0.0035061752,0.00044771703,0.00095866,0.00006213669,0.000017298036,0.000107844506],"genre_scores_gemma":[0.9975136,0.000044213353,0.00057429494,0.00012859139,0.0012611612,0.000019611974,0.000008214929,0.000027760225,0.00042258078],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99847966,0.00011926357,0.00029993578,0.00036100452,0.00041692218,0.0003232217],"domain_scores_gemma":[0.99865276,0.00023699577,0.00024607024,0.00058703794,0.00011818062,0.00015896559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019473214,0.00019279821,0.0003243826,0.00008028258,0.0006263491,0.00024530262,0.00030058174,0.00011130959,0.000013719918],"category_scores_gemma":[0.00031773746,0.000111128764,0.00006070022,0.0000745277,0.00028996283,0.00013054871,0.00028879393,0.00037887113,0.0000029612618],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028374876,0.000041201158,0.0016477598,0.000089375506,0.00011479682,0.000014352103,0.0023603195,0.0000026068785,0.9905604,0.000034656812,0.0018148522,0.0030359377],"study_design_scores_gemma":[0.0052564824,0.00026004162,0.0072115697,0.00021687159,0.0003399721,0.00006335327,0.0012368595,0.00018756374,0.9843825,0.00005180185,0.0006317226,0.00016125961],"about_ca_topic_score_codex":0.00016421483,"about_ca_topic_score_gemma":0.00010211938,"teacher_disagreement_score":0.006177891,"about_ca_system_score_codex":0.00004037374,"about_ca_system_score_gemma":0.00009257819,"threshold_uncertainty_score":0.48174343},"labels":[],"label_agreement":null},{"id":"W3148427215","doi":"10.21203/rs.3.rs-55355/v2","title":"CD9 is a leukemic stem cell-specific marker in human acute myeloid leukemia","year":2020,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China; Fundamental Research Funds for the Central Universities; National Science Foundation","keywords":"Myeloid leukemia; Haematopoiesis; Cancer research; Stem cell; Biology; Leukemia; Flow cytometry; Immunology; Population; Medicine; Cell biology","score_opus":0.07862078186617782,"score_gpt":0.3837962896738715,"score_spread":0.3051755078076937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148427215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9302329,0.0075497315,0.0001279881,0.009453759,0.0003315393,0.0077434178,0.00063393277,0.0004796109,0.043447126],"genre_scores_gemma":[0.94976926,0.009747554,0.00079746865,0.0007411598,0.0015647537,0.001466127,0.0011645103,0.00056028366,0.034188874],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98423326,0.0017144515,0.0016666745,0.0034494256,0.0055810306,0.0033551797],"domain_scores_gemma":[0.99182636,0.00075713644,0.0003008057,0.0038477855,0.0014864013,0.0017815025],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.004208671,0.0012211081,0.0022289485,0.00296621,0.0005114983,0.0005089173,0.0024872974,0.0020202557,0.0026715011],"category_scores_gemma":[0.00018939009,0.0011932835,0.00086247205,0.0029301664,0.00085970224,0.00022831958,0.006913577,0.017627185,0.0028143786],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004315861,0.00068114506,0.012681693,0.0127192605,0.00097318087,0.016234545,0.008417311,0.00010565052,0.11727611,0.00061884,0.8131165,0.0128599275],"study_design_scores_gemma":[0.045043256,0.0074930754,0.16305348,0.024655467,0.0007766046,0.0009867251,0.019203875,0.023027748,0.11593529,0.010128538,0.58121294,0.008482998],"about_ca_topic_score_codex":0.0015003962,"about_ca_topic_score_gemma":0.000053842745,"teacher_disagreement_score":0.23190354,"about_ca_system_score_codex":0.018551836,"about_ca_system_score_gemma":0.010130542,"threshold_uncertainty_score":0.9992753},"labels":[],"label_agreement":null},{"id":"W3151461673","doi":"10.1371/journal.pone.0249087","title":"Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review","year":2021,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University Health Network; University of Toronto; Grand River Hospital; McMaster University; Impact","funders":"National Cancer Institute; American Society of Hematology","keywords":"Medicine; Cytarabine; Idarubicin; Internal medicine; Intensive care; Hazard ratio; Intensive care unit; Adverse effect; Randomized controlled trial; Myeloid leukemia; Confidence interval; Intensive care medicine","score_opus":0.07921307120547848,"score_gpt":0.33064378529080146,"score_spread":0.25143071408532297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3151461673","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001239906,0.9779027,0.0000047292183,0.00053402095,0.00012651544,0.019529548,0.00012192176,0.00016933016,0.00037129153],"genre_scores_gemma":[0.00004018276,0.9889695,0.00037043117,0.0027982371,0.00028196734,0.0040399195,0.0013094015,0.00044011115,0.0017502157],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9911588,0.0010395113,0.0024449644,0.0018845968,0.0021046882,0.0013674336],"domain_scores_gemma":[0.9884715,0.0013230421,0.0012981957,0.0027241241,0.005642555,0.0005406041],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00083843915,0.0016228169,0.01457053,0.000921557,0.00009966161,0.00008497698,0.00094280596,0.0009711779,0.00022808372],"category_scores_gemma":[0.004063133,0.0010970503,0.0011108423,0.0025855321,0.0003206615,0.00019617277,0.00040426076,0.0040391786,0.0005482853],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0008632263,0.00052300066,0.000003672395,0.9595295,0.012342728,0.008534665,0.0004092251,5.1819217e-8,0.000008593747,0.00001024468,0.0027054092,0.015069647],"study_design_scores_gemma":[0.007950745,0.0011580923,0.0000031238983,0.96088755,0.023094444,0.0017461285,0.0014182152,0.00002563166,0.00004588782,6.556125e-7,0.0026836637,0.0009858833],"about_ca_topic_score_codex":0.00016045017,"about_ca_topic_score_gemma":0.00004521325,"teacher_disagreement_score":0.015489628,"about_ca_system_score_codex":0.0062395795,"about_ca_system_score_gemma":0.007823942,"threshold_uncertainty_score":0.9996519},"labels":[],"label_agreement":null},{"id":"W3153382454","doi":"10.1182/blood.v130.suppl_1.3941.3941","title":"Utility of Leukemic Stem Cells Markers in Determining Minimal Residual Disease in Patients with AML","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Alberta Hospital; Alberta Hospital Edmonton","funders":"","keywords":"Minimal residual disease; Interleukin-3 receptor; Medicine; CD34; Myeloid leukemia; Leukemia; Population; Bone marrow; Oncology; CD33; Immunology; Internal medicine; Stem cell; Biology","score_opus":0.01884192932014905,"score_gpt":0.26721718309099074,"score_spread":0.2483752537708417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153382454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99830204,0.00003239457,8.52342e-7,0.000059693328,0.000024977131,0.0005353485,0.000038745053,0.000011023591,0.0009949397],"genre_scores_gemma":[0.99935955,0.0000069389503,0.00031444608,0.000022613294,0.000027862128,0.000015955995,0.000010668292,0.000023210176,0.00021873401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998439,0.000084502084,0.00032612318,0.00033581184,0.0004426744,0.00037188933],"domain_scores_gemma":[0.99869853,0.00008970789,0.00015443034,0.0007769806,0.00007751478,0.00020284827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033810313,0.00014531711,0.00033518835,0.00017384645,0.000051651707,0.000018764995,0.00027845986,0.00007635429,0.000033534667],"category_scores_gemma":[0.00017386205,0.000121871126,0.000039260216,0.000097779535,0.00020877503,0.00013311717,0.00017053967,0.0003006063,0.0000074965337],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031671396,0.0005857017,0.99219066,0.0001827705,0.000030121379,0.0002943593,0.00017164634,0.0000010630625,0.000606565,9.956557e-7,0.000087001696,0.002681952],"study_design_scores_gemma":[0.015073935,0.00037638165,0.9776689,0.00036272182,0.000061759216,0.000001399225,0.00009531482,0.0002310761,0.0060011996,0.0000028384782,0.000015615438,0.00010885504],"about_ca_topic_score_codex":0.00027423204,"about_ca_topic_score_gemma":0.00012629086,"teacher_disagreement_score":0.01452178,"about_ca_system_score_codex":0.00009992647,"about_ca_system_score_gemma":0.00063047494,"threshold_uncertainty_score":0.49697605},"labels":[],"label_agreement":null},{"id":"W3153550493","doi":"10.1042/cs20200306","title":"Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure","year":2021,"lang":"en","type":"review","venue":"Clinical Science","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Leukaemia UK; European Hematology Association","keywords":"Heart failure; Inflammation; Disease; Medicine; Haematopoiesis; Pathophysiology; Ejection fraction; Heart failure with preserved ejection fraction; Somatic cell; Internal medicine; Systemic inflammation; Immunology; Bioinformatics; Cardiology; Biology; Stem cell; Gene; Genetics","score_opus":0.07727129072001318,"score_gpt":0.4387415710221928,"score_spread":0.36147028030217965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153550493","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014847517,0.98163396,0.0003338551,0.0014962372,0.00029174334,0.0012137832,0.00007314287,0.000047734873,0.0000620443],"genre_scores_gemma":[0.003353866,0.99413294,0.0014846455,0.00004985664,0.00068859715,0.000048057223,0.00007272706,0.000028952083,0.00014036584],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99628794,0.0003546371,0.0012812613,0.00080111716,0.00089690596,0.00037810806],"domain_scores_gemma":[0.9968444,0.0007293484,0.00033080994,0.0007671754,0.0004991087,0.0008291242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027714106,0.00025003374,0.0018978398,0.00035407848,0.00018457894,0.00007546707,0.000451257,0.00028720874,0.000105822604],"category_scores_gemma":[0.0048294975,0.00018900094,0.0007595816,0.0013150107,0.00247926,0.0001915542,0.0007334666,0.00093606365,0.00003460416],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000117201225,0.0000839168,0.0050593247,0.012061379,0.0003651063,0.00016718662,0.000037582442,6.8353324e-7,0.000012852342,0.00012812117,0.0015353741,0.98053676],"study_design_scores_gemma":[0.0005326886,0.0001749056,0.015914688,0.0140790045,0.0022632054,0.00013849232,0.000048071848,0.00008319637,0.000010227054,0.00008624442,0.96636415,0.000305114],"about_ca_topic_score_codex":0.000019882062,"about_ca_topic_score_gemma":0.000002933003,"teacher_disagreement_score":0.98023164,"about_ca_system_score_codex":0.0001792929,"about_ca_system_score_gemma":0.0036561757,"threshold_uncertainty_score":0.9134937},"labels":[],"label_agreement":null},{"id":"W3155027998","doi":"10.1182/blood.v130.suppl_1.24.24","title":"The LSC17 Leukemic Stem Cell Signature Predicts Outcome in Pediatric Acute Myeloid Leukemia","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"NPM1; Oncology; Myeloid leukemia; Internal medicine; Medicine; Gene signature; Multivariate analysis; Myeloid; Leukemia; Cancer; Bioinformatics; Biology; Gene; Gene expression; Genetics; Karyotype","score_opus":0.019261430068779065,"score_gpt":0.2845178960960196,"score_spread":0.2652564660272405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155027998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774918,0.0024340348,0.000010007166,0.0017642751,0.00039353344,0.0010606798,0.000034558074,0.00013313943,0.01667798],"genre_scores_gemma":[0.9749927,0.0026517792,0.0001944853,0.00030822807,0.0010461439,0.00010283232,0.000021631933,0.00009114821,0.020591041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965768,0.00012181893,0.0006448458,0.0006603687,0.0009164438,0.0010797608],"domain_scores_gemma":[0.9965857,0.00033930142,0.00034715873,0.0021706934,0.0001683923,0.00038875124],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009836685,0.00039911352,0.0006037373,0.00024880568,0.00078268576,0.0002480828,0.0014785281,0.00048068474,0.000032443906],"category_scores_gemma":[0.0002855809,0.00027254503,0.00021911119,0.00029829773,0.00024378412,0.00026733422,0.00059479446,0.0019777287,0.0003455329],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062729,0.00048216226,0.95220995,0.0004759263,0.0003226194,0.0028841712,0.0006824729,0.00001671921,0.01692276,0.00018339927,0.01911915,0.00607335],"study_design_scores_gemma":[0.024521152,0.0006604125,0.94026715,0.00011670676,0.0012050899,0.0003950147,0.00029210397,0.00061741064,0.020071713,0.00015605988,0.0109969545,0.00070023426],"about_ca_topic_score_codex":0.00014630426,"about_ca_topic_score_gemma":0.00006700194,"teacher_disagreement_score":0.023893861,"about_ca_system_score_codex":0.0008608834,"about_ca_system_score_gemma":0.0015878655,"threshold_uncertainty_score":0.9999727},"labels":[],"label_agreement":null},{"id":"W3155205336","doi":"10.1002/pbc.28979","title":"Treatment of acute myeloid leukemia in children: A practical perspective","year":2021,"lang":"en","type":"review","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Children's Hospital; Hospital for Sick Children","funders":"","keywords":"Medicine; Myeloid leukemia; Risk stratification; Hematopoietic stem cell transplantation; Intensive care medicine; Disease; Transplantation; Oncology; Childhood leukemia; Leukemia; Internal medicine; Lymphoblastic Leukemia","score_opus":0.03927794031323138,"score_gpt":0.39844504453015744,"score_spread":0.35916710421692605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155205336","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017366543,0.9936843,0.0000025368734,0.00027745156,0.00017067872,0.00260038,0.00044083316,0.0000474868,0.0010396724],"genre_scores_gemma":[0.0000888543,0.993197,0.0007109203,0.000041682935,0.0029951176,0.0011845825,0.00027324405,0.0001567215,0.0013518677],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99576926,0.000327142,0.0010748059,0.0011832836,0.0008202476,0.00082525],"domain_scores_gemma":[0.99731946,0.00041872094,0.000565882,0.00091155584,0.00041383744,0.00037054444],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002116414,0.0007865365,0.0040936098,0.0008877027,0.00004985573,0.000027561711,0.0002475581,0.0007373807,0.00059582543],"category_scores_gemma":[0.0002455497,0.00060483906,0.0011328249,0.002286332,0.00012878673,0.00009555456,0.00017939694,0.0012752287,0.000067108886],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000514688,0.005074231,0.02523426,0.029000128,0.029143231,0.008585823,0.0016353003,0.0000038053258,0.000005543051,0.00074722915,0.00936333,0.8906924],"study_design_scores_gemma":[0.016593533,0.0034842945,0.0023440507,0.007987669,0.14455687,0.008731689,0.0002850292,0.000017764616,0.000049823717,0.00002358201,0.81400424,0.001921466],"about_ca_topic_score_codex":0.0030828977,"about_ca_topic_score_gemma":0.00005101956,"teacher_disagreement_score":0.88877094,"about_ca_system_score_codex":0.009175487,"about_ca_system_score_gemma":0.027990315,"threshold_uncertainty_score":0.9996403},"labels":[],"label_agreement":null},{"id":"W3155688339","doi":"10.1038/s41409-021-01261-6","title":"Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation","year":2021,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Internal medicine; Minimal residual disease; Transplantation; Myeloid leukemia; Hematopoietic stem cell transplantation; Confidence interval; Oncology; Leukemia; Hematopoietic cell; Cohort; Myeloid; Surgery; Haematopoiesis; Stem cell","score_opus":0.03518422811167775,"score_gpt":0.345183209950756,"score_spread":0.30999898183907826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155688339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975414,0.00004855,0.00045795192,0.00022415891,0.00006774075,0.0006364024,0.0005321516,0.000018869847,0.00047277482],"genre_scores_gemma":[0.994896,0.00251971,0.0011298867,0.000053328557,0.0000140462,0.000014654354,0.0011671255,0.000044273944,0.00016096799],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99600035,0.00062849355,0.0017215746,0.0004657504,0.000845897,0.00033795135],"domain_scores_gemma":[0.99719286,0.0012615633,0.000532105,0.00046215442,0.00036758653,0.00018373384],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00095657376,0.00029211023,0.0011585443,0.00043736966,0.000042372372,0.0000063170037,0.00015126808,0.0003012408,0.000070747104],"category_scores_gemma":[0.00018227608,0.00025149575,0.00047802622,0.0005706397,0.00014847679,0.00011954057,0.000016508258,0.0003967504,0.0000065045556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032254536,0.0008079152,0.79339653,0.0019379087,0.0002643101,0.0003529823,0.0014480575,0.0005151719,0.16824791,0.000023081393,0.0000852523,0.0006663494],"study_design_scores_gemma":[0.011744844,0.0015352733,0.886963,0.00088535924,0.00042611946,0.00006518468,0.000074981006,0.00023656794,0.09786736,0.000023578268,0.0000071376126,0.00017057618],"about_ca_topic_score_codex":0.0003874974,"about_ca_topic_score_gemma":0.00025770327,"teacher_disagreement_score":0.09356649,"about_ca_system_score_codex":0.0003816063,"about_ca_system_score_gemma":0.001155283,"threshold_uncertainty_score":0.99999374},"labels":[],"label_agreement":null},{"id":"W3156234252","doi":"10.1002/ajh.26186","title":"Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases","year":2021,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Myelofibrosis; Decitabine; Medicine; Azacitidine; Internal medicine; Myeloproliferative neoplasm; Venetoclax; Essential thrombocythemia; Neuroblastoma RAS viral oncogene homolog; Gastroenterology; KRAS; Myeloid; Leukemia; Polycythemia vera; Oncology; Bone marrow; Chronic lymphocytic leukemia; Biology; Cancer","score_opus":0.020234828184528552,"score_gpt":0.3300823838677404,"score_spread":0.3098475556832119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156234252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99576557,0.00039173043,0.00042574905,0.002924201,0.00005299518,0.00024564072,0.000026302354,0.0000070607343,0.00016075272],"genre_scores_gemma":[0.98758185,0.00028547522,0.011412122,0.0004651709,0.00005131471,0.000013826369,0.0000088729685,0.000030090005,0.0001512654],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9978574,0.000321209,0.0008211263,0.00023817603,0.0003503685,0.0004117326],"domain_scores_gemma":[0.9968399,0.00095219945,0.00063499034,0.00023646446,0.0010907855,0.00024567996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023760223,0.00022170733,0.0014148614,0.00038386133,0.00003464202,0.00000883242,0.00012836068,0.0000646314,0.00028654342],"category_scores_gemma":[0.0012962384,0.00014860205,0.00010591833,0.0008029082,0.0012211888,0.0001409885,0.00007052349,0.0005599542,0.000005506088],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20393409,0.0037756022,0.27165455,0.00087483815,0.0041439324,0.41124943,0.016938766,0.00022582825,0.065825865,0.0015901563,0.0030442548,0.016742693],"study_design_scores_gemma":[0.038022213,0.033096462,0.0075849565,0.001880894,0.00043282393,0.48273036,0.054527577,0.0004959909,0.37859973,0.000079456986,0.0020807027,0.00046881317],"about_ca_topic_score_codex":0.000087356864,"about_ca_topic_score_gemma":0.00033602127,"teacher_disagreement_score":0.31277388,"about_ca_system_score_codex":0.00029761498,"about_ca_system_score_gemma":0.0033273827,"threshold_uncertainty_score":0.6059815},"labels":[],"label_agreement":null},{"id":"W3157387440","doi":"10.1182/blood.2020008812","title":"Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Intensive care; Comorbidity; Prospective cohort study; Internal medicine; Cohort; Retrospective cohort study; Quality of life (healthcare); Myeloid leukemia; Adverse effect; Intensive care unit; Cohort study; Intensive care medicine; Pediatrics","score_opus":0.022897661682954998,"score_gpt":0.2992772939892336,"score_spread":0.2763796323062786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157387440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590266,0.001032874,0.00005393363,0.0016822919,0.00011195284,0.0004030581,0.000027265445,0.000050598577,0.0007353493],"genre_scores_gemma":[0.9926619,0.0009890737,0.002504429,0.0018859409,0.0001078149,0.000055331006,0.000047354297,0.000051214043,0.0016969449],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977912,0.000113343405,0.00047734473,0.0005523475,0.0005309672,0.00053482415],"domain_scores_gemma":[0.99648225,0.00020193755,0.00012473244,0.0007070776,0.0023024124,0.00018160857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017438918,0.000257359,0.00073859445,0.00024197737,0.000055295706,0.000023437993,0.00025044053,0.00019050077,0.00018235098],"category_scores_gemma":[0.0012630654,0.00022860525,0.00016704739,0.00068773446,0.00036932912,0.00014420532,0.00029465542,0.00054465723,0.00006144442],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009266419,0.00038900864,0.29594105,0.00018204436,0.0006910682,0.0064361156,0.02766651,0.0000059522304,0.6636019,0.00040709134,0.0018823084,0.0018703474],"study_design_scores_gemma":[0.011479421,0.00039723655,0.18330823,0.0005282315,0.0002063761,0.0009761246,0.06590912,0.00015150021,0.73515296,0.00007650258,0.001476965,0.00033736072],"about_ca_topic_score_codex":0.0009087339,"about_ca_topic_score_gemma":0.00029275398,"teacher_disagreement_score":0.11263281,"about_ca_system_score_codex":0.00028715073,"about_ca_system_score_gemma":0.000651561,"threshold_uncertainty_score":0.93222517},"labels":[],"label_agreement":null},{"id":"W3157742375","doi":"10.1186/s12885-021-08259-9","title":"The effects of secondary iron overload and iron chelation on a radiation-induced acute myeloid leukemia mouse model","year":2021,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Office of the Chief Medical Examiner; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Canada; Canadian Blood Services; Leukemia and Lymphoma Society of Canada","keywords":"Medicine; Deferasirox; Myeloid leukemia; Myelodysplastic syndromes; Bone marrow; Oxidative stress; Bone marrow failure; Internal medicine; Leukemia; Myeloid; Anemia; Immunology; Cancer research; Haematopoiesis; Stem cell; Thalassemia; Biology","score_opus":0.014192418581513069,"score_gpt":0.2926846000931688,"score_spread":0.2784921815116558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157742375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948063,0.0022193159,0.00012854657,0.00066588935,0.00014771425,0.000555484,0.000034663626,0.000030755786,0.001411354],"genre_scores_gemma":[0.98338765,0.0038697766,0.0003568107,0.0005848314,0.00023109459,0.00015230906,0.000047393016,0.00004474514,0.01132542],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866295,0.00008533966,0.00023395066,0.00032401603,0.0004148015,0.00027895678],"domain_scores_gemma":[0.9988009,0.00040976336,0.00010977576,0.00042284688,0.00012878646,0.00012794486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018321812,0.00016310532,0.00026232513,0.00007332438,0.00013575479,0.00002797145,0.00008531748,0.00014921346,0.000047754525],"category_scores_gemma":[0.00027817342,0.00012402279,0.000078289166,0.00019043821,0.000073740724,0.00010694708,0.00007247885,0.00040663502,0.000011381139],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010405134,0.000057404155,0.0027086192,0.0008358069,0.00016206884,0.000024389421,0.000855628,0.0010745397,0.92096967,0.00043842656,0.0056281453,0.066204794],"study_design_scores_gemma":[0.009150261,0.0005210149,0.07349346,0.0003673896,0.0003180117,0.000028264603,0.00016321869,0.07495841,0.8385933,0.00016027312,0.0019185138,0.00032787264],"about_ca_topic_score_codex":0.00022909757,"about_ca_topic_score_gemma":0.00019434978,"teacher_disagreement_score":0.082376346,"about_ca_system_score_codex":0.0011518705,"about_ca_system_score_gemma":0.0022578775,"threshold_uncertainty_score":0.50575024},"labels":[],"label_agreement":null},{"id":"W3158519315","doi":"10.15173/sciential.v1i4.2425","title":"Battling Acute Myeloid Leukemia (AML) as both a Clinician and Scientist","year":2020,"lang":"en","type":"article","venue":"Sciential - McMaster Undergraduate Science Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Epigenetics; Myeloid leukemia; Cancer research; Stem cell; Haematopoiesis; Bone marrow; DNA methylation; Leukemia; Chemotherapy; Myeloid; Chromatin; Medicine; Hematopoietic stem cell transplantation; Biology; Gene; Acute leukemia; Immunology; Internal medicine; Gene expression; Genetics","score_opus":0.029927311368537008,"score_gpt":0.3253141441930794,"score_spread":0.2953868328245424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158519315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9175576,0.00026478365,0.005764355,0.058930706,0.002248649,0.00069561676,0.000016168375,0.00014866597,0.014373482],"genre_scores_gemma":[0.9765802,0.00035854793,0.00967323,0.007043156,0.0012947293,0.000005379015,0.000005185627,0.000058390127,0.004981155],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99228853,0.0001279066,0.0009197113,0.0014419974,0.003453139,0.0017687164],"domain_scores_gemma":[0.995367,0.000084639956,0.0003996568,0.0004696936,0.00068106264,0.0029979441],"candidate_categories":["metaepi_narrow","sts","scholarly_communication"],"consensus_categories":["sts"],"category_scores_codex":[0.0040282556,0.00042808463,0.0006238358,0.0009426742,0.0026206383,0.0024076873,0.0013353423,0.00013827646,0.00055111106],"category_scores_gemma":[0.00092932844,0.00034715005,0.0002585706,0.0040698643,0.004426044,0.002025447,0.0010365733,0.0016322229,0.00047721202],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018377644,0.0003291969,0.011669769,0.00019940276,0.00038845622,0.0028438733,0.005010143,0.00023022319,0.85773563,0.0026339765,0.027745172,0.08937639],"study_design_scores_gemma":[0.06252682,0.02300946,0.052321617,0.00277838,0.0030120257,0.072427325,0.013268149,0.28568152,0.17026281,0.025946952,0.28173855,0.0070263934],"about_ca_topic_score_codex":0.000043677468,"about_ca_topic_score_gemma":0.000009645606,"teacher_disagreement_score":0.6874728,"about_ca_system_score_codex":0.0010044144,"about_ca_system_score_gemma":0.006013801,"threshold_uncertainty_score":0.9998981},"labels":[],"label_agreement":null},{"id":"W3158536935","doi":"10.1182/blood.v130.suppl_1.2482.2482","title":"Somatic Mutations Associated with Myeloid Transformation of RUNX1 -Mutated Familial Platelet Disorders with Propensity to Myeloid Malignancies Using Targeted Next-Generation Sequencing","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"RUNX1; Platelet disorder; CEBPA; Myeloid leukemia; Myelodysplastic syndromes; Myeloid; Medicine; Leukemia; Biology; Oncology; Cancer research; Genetics; Bone marrow; Internal medicine; Mutation; Haematopoiesis; Gene; Stem cell","score_opus":0.06287888414082493,"score_gpt":0.2767635651384534,"score_spread":0.21388468099762847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158536935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99370724,0.000022723227,0.0032872928,0.00046539694,0.000038683753,0.0019294685,0.000057139114,0.000100210964,0.0003918735],"genre_scores_gemma":[0.9942626,0.000011747849,0.005038768,0.00006588445,0.000061802384,0.00006459551,0.00036430222,0.000055808167,0.0000745378],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978976,0.00010601654,0.00047374377,0.00034505167,0.0007067505,0.00047078397],"domain_scores_gemma":[0.99837106,0.000052328694,0.0003747838,0.00049205375,0.0005193223,0.00019047115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042006606,0.0002789619,0.0005188495,0.00025457342,0.0006888103,0.0001363791,0.0002097864,0.00014443934,0.00002087295],"category_scores_gemma":[0.00040974584,0.00021404687,0.00006437588,0.00036534606,0.00022782582,0.0007598138,0.000041257263,0.00027756704,0.000008982986],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042705465,0.00029659373,0.0131404055,0.00021567267,0.00041535948,0.000069095935,0.0050037173,0.003483439,0.97603506,0.000025805139,0.000013200157,0.00087462185],"study_design_scores_gemma":[0.013203513,0.001762368,0.11968955,0.0008248054,0.0008597126,0.00018428148,0.0020970283,0.053085428,0.8076731,0.00004012848,0.000012782265,0.00056732417],"about_ca_topic_score_codex":0.0011150097,"about_ca_topic_score_gemma":0.0017397555,"teacher_disagreement_score":0.16836195,"about_ca_system_score_codex":0.00040139092,"about_ca_system_score_gemma":0.0010929343,"threshold_uncertainty_score":0.8728578},"labels":[],"label_agreement":null},{"id":"W3158573488","doi":"10.15173/sciential.vi6.2723","title":"Selective Targeting of Unique Metabolic Properties of Leukemic Stem Cells in Acute Myeloid Leukemia","year":2021,"lang":"en","type":"article","venue":"Sciential - McMaster Undergraduate Science Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Stem cell; Myeloid leukemia; Cancer stem cell; Cancer research; Leukemia; Medicine; Disease; Myeloid; Radiation therapy; Cancer; Minimal residual disease; Immunology; Biology; Internal medicine; Cell biology","score_opus":0.022894022758690274,"score_gpt":0.27649320913241976,"score_spread":0.25359918637372947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158573488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99460065,0.00085868407,0.0008981436,0.0011040834,0.0006406263,0.00039926847,0.000009681121,0.000020235693,0.0014686136],"genre_scores_gemma":[0.9910699,0.0006460835,0.004791271,0.00012280843,0.00012716849,0.0000064679525,0.0000017675712,0.000032271433,0.0032022267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99415135,0.0003119548,0.0012297368,0.0007578494,0.0023910054,0.0011581165],"domain_scores_gemma":[0.99622536,0.000054411597,0.0006145781,0.00043492715,0.0021763921,0.00049435045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040155128,0.00031068426,0.00084245193,0.0014025816,0.00040237996,0.00020868685,0.000886023,0.00012720138,0.00009127612],"category_scores_gemma":[0.0002551824,0.00024348828,0.0002635743,0.005670095,0.0021142652,0.0011748995,0.0005450767,0.0011955004,0.000016007043],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002518397,0.0001432557,0.0019220739,0.00010985824,0.00009514706,0.00012292126,0.0014843263,0.00057356054,0.9918842,0.0002342301,0.0002841803,0.0028944071],"study_design_scores_gemma":[0.0022015516,0.00030849376,0.0022540402,0.00050439814,0.0001023848,0.0007306325,0.0019119529,0.0047308262,0.98629737,0.00044720684,0.00028197796,0.00022914844],"about_ca_topic_score_codex":0.00012211844,"about_ca_topic_score_gemma":0.000028455988,"teacher_disagreement_score":0.012404525,"about_ca_system_score_codex":0.0015475572,"about_ca_system_score_gemma":0.013952082,"threshold_uncertainty_score":0.99291635},"labels":[],"label_agreement":null},{"id":"W3158694679","doi":"10.1038/s41467-021-22803-y","title":"Recurrent deletions in clonal hematopoiesis are driven by microhomology-mediated end joining","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"BIRAX; Rising Tide Foundation; National Natural Science Foundation of China; Israel Science Foundation; Applebaum Foundation","keywords":"Biology; Genetics; Polymerase; DNA polymerase; Haematopoiesis; Genome editing; Stem cell; Cancer research; DNA; CRISPR; Gene","score_opus":0.026884542209482935,"score_gpt":0.3376296803886652,"score_spread":0.31074513817918226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158694679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6267967,0.09158115,0.0001345765,0.2646117,0.0003329471,0.0010735216,0.00079133234,0.00028160462,0.014396462],"genre_scores_gemma":[0.97743696,0.003738035,0.012546393,0.0023663968,0.000046460456,0.00012920795,0.0030860952,0.000031757216,0.0006187209],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983848,0.00033825627,0.00036650113,0.0002987372,0.00027401213,0.00033771584],"domain_scores_gemma":[0.99676335,0.0008284356,0.00010884303,0.0016935563,0.0004472235,0.00015860367],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.000276933,0.00015365708,0.00033739398,0.00022535335,0.00023397841,0.000024878396,0.00060171285,0.0004682911,0.0002623856],"category_scores_gemma":[0.001616,0.00015739368,0.00010328597,0.0009879811,0.00024608686,0.000066852146,0.0005667225,0.0029526604,0.00009963484],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015781674,0.002658577,0.23350099,0.0001648236,0.00045302894,0.00038992253,0.0017742275,0.0000068814225,0.1383002,0.00718836,0.61137193,0.004033252],"study_design_scores_gemma":[0.0046732053,0.00012622039,0.2546923,0.0007564472,0.00017898071,0.0010350678,0.002724158,0.00244975,0.009514845,0.00031857565,0.72292614,0.00060431275],"about_ca_topic_score_codex":0.000036054204,"about_ca_topic_score_gemma":0.001342472,"teacher_disagreement_score":0.3506402,"about_ca_system_score_codex":0.0004890921,"about_ca_system_score_gemma":0.00063389266,"threshold_uncertainty_score":0.99934757},"labels":[],"label_agreement":null},{"id":"W3158922343","doi":"10.1038/s41467-021-22625-y","title":"A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"BC Cancer Agency; National Cancer Institute; BC Cancer Foundation; Terry Fox Research Institute; Genome British Columbia; National Human Genome Research Institute; Leukemia and Lymphoma Society of Canada; Knight Cancer Institute, Oregon Health and Science University; Oregon Health and Science University; Provincial Health Services Authority; Leukemia and Lymphoma Society","keywords":"Myeloid leukemia; Transcriptome; Risk stratification; Selection (genetic algorithm); Medicine; Computational biology; Leukemia; Myeloid; Stratification (seeds); Bioinformatics; Intensive care medicine; Oncology; Biology; Computer science; Cancer research; Internal medicine; Genetics; Gene; Artificial intelligence; Gene expression","score_opus":0.04978647121744192,"score_gpt":0.3745982779622205,"score_spread":0.3248118067447786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158922343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96059746,0.009689281,0.00069498754,0.016796883,0.00008646149,0.0014754209,0.00002633845,0.00011175329,0.010521397],"genre_scores_gemma":[0.9450577,0.00867918,0.04326956,0.0021302581,0.00004867121,0.00021265805,0.0002813587,0.000026085265,0.00029454424],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981653,0.00041936757,0.00047710392,0.0004142209,0.00028281016,0.00024120272],"domain_scores_gemma":[0.9979757,0.00022987874,0.00006475376,0.0011415904,0.00038679398,0.00020128854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049891486,0.000149724,0.00030290475,0.00021601682,0.00016409914,0.00004901115,0.00034075015,0.00044325416,0.000014407959],"category_scores_gemma":[0.00026661108,0.00013971643,0.000083746694,0.0011895613,0.00012558987,0.000114982584,0.0001320921,0.0021702193,0.000012636776],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013248275,0.004338554,0.102552086,0.00011473278,0.0007920756,0.000035583093,0.007906813,0.000055438013,0.35111558,0.021877209,0.02046669,0.48942038],"study_design_scores_gemma":[0.0052340743,0.0007358176,0.8004744,0.00013092409,0.00014292017,0.0004142905,0.0016491974,0.010258124,0.0079968,0.00038281572,0.17207246,0.00050815934],"about_ca_topic_score_codex":0.000042213524,"about_ca_topic_score_gemma":0.00019325654,"teacher_disagreement_score":0.69792235,"about_ca_system_score_codex":0.00042982143,"about_ca_system_score_gemma":0.0008147174,"threshold_uncertainty_score":0.9428644},"labels":[],"label_agreement":null},{"id":"W3159489238","doi":"10.1038/s41467-021-22750-8","title":"Cut-like homeobox 1 (CUX1) tumor suppressor gene haploinsufficiency induces apoptosis evasion to sustain myeloid leukemia","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Kay Kendall Leukaemia Fund; National Institute for Health and Care Research; Cancer Research UK; Wellcome Trust; Wellcome","keywords":"Haploinsufficiency; Homeobox; Evasion (ethics); Myeloid leukemia; Suppressor; Cancer research; Gene; Myeloid; Apoptosis; Cell biology; Leukemia; Biology; Immunology; Genetics; Gene expression; Immune system; Phenotype","score_opus":0.029311058115651704,"score_gpt":0.3316865969205472,"score_spread":0.3023755388048955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159489238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92902863,0.009349312,0.00019162826,0.04844955,0.00039795222,0.0013875017,0.00016101291,0.0003487017,0.010685724],"genre_scores_gemma":[0.96287656,0.0015293821,0.024724679,0.0053996355,0.00021760071,0.00027567756,0.0007865227,0.00009864192,0.004091294],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963301,0.00046871428,0.0006205097,0.0007560995,0.0009933092,0.0008312764],"domain_scores_gemma":[0.9916869,0.0007427548,0.00015540955,0.0051918267,0.0016086483,0.0006144556],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00072822726,0.0003892075,0.000602107,0.0005554369,0.00078800635,0.00014286341,0.0021090398,0.0005929694,0.00026517428],"category_scores_gemma":[0.0027294275,0.0003675581,0.00024746748,0.0025679083,0.0002932685,0.0002421273,0.0022027113,0.0034960094,0.0003348716],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028536195,0.0013660933,0.0021985292,0.0001878576,0.00029877576,0.00014450528,0.0020827272,0.00008538958,0.8404871,0.0046846434,0.1415336,0.0066454047],"study_design_scores_gemma":[0.0029958314,0.000443271,0.021102658,0.0003362949,0.0003293354,0.00045517177,0.0036465502,0.0013865269,0.42523476,0.00016424948,0.54301965,0.0008857034],"about_ca_topic_score_codex":0.00019229314,"about_ca_topic_score_gemma":0.00037867282,"teacher_disagreement_score":0.41525236,"about_ca_system_score_codex":0.0018931968,"about_ca_system_score_gemma":0.0030332026,"threshold_uncertainty_score":0.99987763},"labels":[],"label_agreement":null},{"id":"W3160085875","doi":"10.1182/blood.v130.suppl_1.4241.4241","title":"Evidence of Targetable Immune Dysfunction in the Bone Marrow of Patients with Intermediate/High-Risk Myelodysplastic Syndrome Refractory to Hypomethylating Agents","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Bone marrow; FOXP3; Immunology; Myelodysplastic syndromes; CD8; Internal medicine; Immune system; Cancer research","score_opus":0.020106891657820827,"score_gpt":0.2691771713093096,"score_spread":0.2490702796514888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160085875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984026,0.0003597834,0.00006166873,0.00012610838,0.000106555126,0.0007726894,0.000022368451,0.000010651078,0.00013755308],"genre_scores_gemma":[0.9987283,0.00011138773,0.00086358446,0.000034604658,0.000037730584,0.00004751312,0.000017017943,0.000028048591,0.00013181163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979294,0.00016200588,0.00049536495,0.0002897613,0.00078483886,0.00033861297],"domain_scores_gemma":[0.99768,0.0004361193,0.0005317783,0.0009897016,0.00026230657,0.00010011296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010431667,0.000168604,0.0004812968,0.0002672788,0.00012780388,0.000024810397,0.00044308676,0.00008884497,0.000074173106],"category_scores_gemma":[0.00365373,0.00011034492,0.000057868874,0.00028735833,0.00016539164,0.00028847562,0.00021256116,0.00045043678,0.000023742095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014662304,0.0010868999,0.97310036,0.00048190737,0.00019138296,0.0001397255,0.0009243406,0.000036398204,0.019621441,0.000004264069,0.0000967191,0.0028503563],"study_design_scores_gemma":[0.0052743405,0.0025897285,0.98421043,0.001498742,0.0002072799,0.000016561993,0.00013721442,0.000054617823,0.0058733346,0.000013918404,0.000019720215,0.000104105224],"about_ca_topic_score_codex":0.00089624437,"about_ca_topic_score_gemma":0.000051827203,"teacher_disagreement_score":0.013748106,"about_ca_system_score_codex":0.00010298393,"about_ca_system_score_gemma":0.00016716536,"threshold_uncertainty_score":0.44997352},"labels":[],"label_agreement":null},{"id":"W3160561535","doi":"10.1182/blood.2021011517","title":"Coexistence of <i>BCR-ABL1</i> and <i>RUNX1-RUNX1T1</i> in a de novo AML","year":2021,"lang":"yi","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"breakpoint cluster region; Medicine; Internal medicine; Receptor","score_opus":0.018695602804601058,"score_gpt":0.2851669732813565,"score_spread":0.2664713704767554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160561535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9622921,0.019656982,0.000028422603,0.0022338922,0.00013546937,0.00050069386,0.000094818795,0.000031343778,0.015026319],"genre_scores_gemma":[0.9850247,0.0063841445,0.002519306,0.0013696837,0.00031223125,0.00003675406,0.00003087984,0.00006940387,0.004252878],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964921,0.00031859917,0.00073972857,0.00073640293,0.00066991703,0.0010432546],"domain_scores_gemma":[0.9976326,0.0005231821,0.00016527485,0.00086434867,0.0003428005,0.000471766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000967112,0.00034491072,0.00089296326,0.00023097859,0.000073549265,0.00004747966,0.0003190975,0.00037233485,0.00027755497],"category_scores_gemma":[0.0012592856,0.00035842712,0.00013532527,0.0008970376,0.00046435482,0.00012356619,0.0004823122,0.0010027981,0.00007418557],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008429689,0.0057709496,0.3983504,0.004456099,0.0008438125,0.020666752,0.008128896,0.00001155017,0.54850805,0.0013959575,0.0039937985,0.0070308],"study_design_scores_gemma":[0.06155035,0.0020191127,0.12684807,0.0051968102,0.0017450824,0.007818512,0.007343362,0.00087919534,0.7590886,0.00065068254,0.025503824,0.0013564422],"about_ca_topic_score_codex":0.0006007215,"about_ca_topic_score_gemma":0.0004217967,"teacher_disagreement_score":0.27150232,"about_ca_system_score_codex":0.00023207869,"about_ca_system_score_gemma":0.002461893,"threshold_uncertainty_score":0.99988675},"labels":[],"label_agreement":null},{"id":"W3161543281","doi":"10.1038/s41467-021-23186-w","title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"National Center for Advancing Translational Sciences; Conquer Cancer Foundation; Institut Gustave-Roussy; Austrian Science Fund; Georgia Clinical and Translational Science Alliance; Ligue Contre le Cancer; American Society of Clinical Oncology; National Institutes of Health; Henry J. Predolin Foundation for Research in Leukemia; University of Wisconsin Carbone Cancer Center; National Cancer Institute; Institut National Du Cancer","keywords":"Chronic myelomonocytic leukemia; Cancer research; Biology; PLK1; Myeloid leukemia; Histone H3; NPM1; Epigenetics; Mutation; Methyltransferase; Leukemia; Decitabine; Histone; Methylation; DNA methylation; Molecular biology; Gene; Genetics; Cell cycle; Gene expression; Immunology; Bone marrow; Myelodysplastic syndromes","score_opus":0.024991648164600273,"score_gpt":0.3482445861579107,"score_spread":0.32325293799331045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161543281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34487042,0.14175183,0.012292806,0.2685443,0.0012668936,0.010358071,0.00063754834,0.0021617652,0.21811639],"genre_scores_gemma":[0.96973926,0.0019032046,0.01968705,0.0017910957,0.00025383785,0.00044358606,0.0014947506,0.0000680068,0.0046192263],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.997582,0.00043707335,0.0004658553,0.000498431,0.000507459,0.00050913525],"domain_scores_gemma":[0.9937833,0.00082657905,0.00013927612,0.0036393483,0.0013002595,0.00031126823],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00031476436,0.00028640995,0.00045524578,0.0002676619,0.00071068655,0.00008138469,0.0009551896,0.00057338015,0.00035619436],"category_scores_gemma":[0.0012577843,0.00027597474,0.00021533223,0.001366466,0.00052159425,0.00022350399,0.0007669162,0.003656908,0.00048431673],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00081228075,0.0041176155,0.02579997,0.0011104957,0.0063131168,0.0016037003,0.021897962,0.00074666704,0.42571,0.16536635,0.23042922,0.11609264],"study_design_scores_gemma":[0.013452647,0.0010316051,0.08386391,0.00093781383,0.0015606158,0.0030946617,0.0042368146,0.08524197,0.11246635,0.006009065,0.6861885,0.0019160439],"about_ca_topic_score_codex":0.00006899136,"about_ca_topic_score_gemma":0.0011683748,"teacher_disagreement_score":0.6248688,"about_ca_system_score_codex":0.0040372727,"about_ca_system_score_gemma":0.0062510306,"threshold_uncertainty_score":0.99996924},"labels":[],"label_agreement":null},{"id":"W3162526259","doi":"10.1101/mcs.a006090","title":"Common clonal origin of chronic myelomonocytic leukemia and B-cell acute lymphoblastic leukemia in a patient with a germline <i>CHEK2</i> variant","year":2021,"lang":"en","type":"article","venue":"Molecular Case Studies","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; Fondation de l'Hôpital général juif; Jewish General Hospital","keywords":"Biology; Chronic myelomonocytic leukemia; Germline; Myeloid; Somatic evolution in cancer; Exome sequencing; Germline mutation; Cancer research; Leukemia; Genetics; Exome; CHEK2; Myelodysplastic syndromes; Mutation; Immunology; Cancer; Gene; Bone marrow","score_opus":0.014127410027480492,"score_gpt":0.2854065966266141,"score_spread":0.27127918659913364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162526259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98506063,0.012764342,0.0005387059,0.00032249745,0.000052104257,0.00059159385,0.000042111737,0.000032874712,0.00059514766],"genre_scores_gemma":[0.9953704,0.0015777345,0.0021135404,0.0004097715,0.00004792818,0.00010842564,0.00003787549,0.00006253943,0.00027177355],"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974145,0.00021282837,0.0005871968,0.0006458503,0.00054124853,0.0005983593],"domain_scores_gemma":[0.99842066,0.00027177608,0.00015631791,0.0005670092,0.00037224172,0.00021202135],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028676493,0.0003942745,0.0009861978,0.00023833262,0.00010335553,0.000021028383,0.000090442365,0.00012843429,0.000020619205],"category_scores_gemma":[0.00016577561,0.00031917202,0.00011671986,0.00073981157,0.00041892452,0.0000649355,0.00041444835,0.0004762932,0.000007946334],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001240783,0.00031063112,0.0009786332,0.0015654035,0.0016941804,0.88188714,0.001975898,0.0010303474,0.10291823,0.00023303133,0.0007691051,0.0053966013],"study_design_scores_gemma":[0.051774453,0.008828312,0.0013621735,0.0034166465,0.0038947347,0.3957646,0.006733824,0.051877312,0.47014147,0.0003405828,0.003892173,0.0019737105],"about_ca_topic_score_codex":0.0004039357,"about_ca_topic_score_gemma":0.00042855524,"teacher_disagreement_score":0.48612255,"about_ca_system_score_codex":0.004882829,"about_ca_system_score_gemma":0.0038488016,"threshold_uncertainty_score":0.99992603},"labels":[],"label_agreement":null},{"id":"W3162944371","doi":"10.1200/edbk_320113","title":"Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes","year":2021,"lang":"en","type":"article","venue":"American Society of Clinical Oncology Educational Book","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Myelodysplastic syndromes; Decitabine; Medicine; Disease; Myeloid leukemia; Oncology; Lenalidomide; Bioinformatics; Internal medicine; DNA methylation; Bone marrow; Multiple myeloma; Gene; Biology; Genetics","score_opus":0.06676709730006641,"score_gpt":0.46753414615332745,"score_spread":0.40076704885326103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162944371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8994073,0.0009016537,0.0003010924,0.09500133,0.00032091912,0.0003393286,0.000025038662,0.00003396966,0.0036693497],"genre_scores_gemma":[0.86765367,0.0032594274,0.088909745,0.025753835,0.0013241556,0.00010713121,0.00015477695,0.00005567767,0.012781566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99681485,0.00037904724,0.0012058482,0.00065356784,0.0005275763,0.00041909554],"domain_scores_gemma":[0.98631436,0.01125547,0.0006220054,0.00033133556,0.00096380594,0.0005130226],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0009160225,0.000236469,0.0012913254,0.000023628243,0.00016634472,0.000015551632,0.00014426491,0.00025145325,0.0008542522],"category_scores_gemma":[0.0047521335,0.00021855616,0.0004193879,0.00041865386,0.003237399,0.000131958,0.00020667068,0.0014241753,0.00006540863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013054943,0.0031504564,0.5246684,0.0005493503,0.002570513,0.00014075954,0.004152211,0.000032356114,0.0030668755,0.00410741,0.081279166,0.374977],"study_design_scores_gemma":[0.0046695834,0.003452133,0.868932,0.00039261242,0.00048498402,0.0009963475,0.011140436,0.0019857106,0.0008270613,0.0009964223,0.10566553,0.0004571905],"about_ca_topic_score_codex":0.000065211716,"about_ca_topic_score_gemma":0.00000713311,"teacher_disagreement_score":0.3745198,"about_ca_system_score_codex":0.0003776444,"about_ca_system_score_gemma":0.009425227,"threshold_uncertainty_score":0.99947524},"labels":[],"label_agreement":null},{"id":"W3163066072","doi":"10.3390/curroncol28030166","title":"Leukemia Cell Lines: In Vitro Models for the Study of Chronic Neutrophilic Leukemia","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Neuroblastoma RAS viral oncogene homolog; Leukemia; Fusion gene; Gene; Biology; Cancer research; Mutation; Computational biology; Genetics","score_opus":0.11139469329713235,"score_gpt":0.40486281134185814,"score_spread":0.2934681180447258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163066072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838679,0.009984925,0.0009929835,0.0010640553,0.0008082148,0.0024469525,0.000023955621,0.00003244296,0.0007785743],"genre_scores_gemma":[0.99638194,0.0014296237,0.00020686197,0.000119705735,0.00069399714,0.00058487273,0.000066615336,0.000044316574,0.00047205001],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9976075,0.0002567746,0.00065747194,0.00053327583,0.00034689723,0.00059807167],"domain_scores_gemma":[0.997512,0.000990254,0.0001678488,0.0007593527,0.00043225245,0.00013833847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057366636,0.0002322858,0.00075643766,0.0002073721,0.00008544924,0.000010628862,0.00037304114,0.00019795139,0.000057880046],"category_scores_gemma":[0.00023509316,0.00017085162,0.00017448132,0.0005999786,0.00016592468,0.00007052171,0.00029402657,0.0009261278,0.000016661921],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008126877,0.015032433,0.004603775,0.0036093618,0.00067247107,0.0009644338,0.011081256,0.03512413,0.31758705,0.00071758556,0.027154712,0.5753259],"study_design_scores_gemma":[0.062208697,0.00999091,0.005806594,0.00027036414,0.00092494825,0.00023534795,0.012119463,0.69850385,0.07745272,0.0008738886,0.13093288,0.0006803293],"about_ca_topic_score_codex":0.00013654269,"about_ca_topic_score_gemma":0.00027548661,"teacher_disagreement_score":0.6633797,"about_ca_system_score_codex":0.006257809,"about_ca_system_score_gemma":0.0078445375,"threshold_uncertainty_score":0.9977801},"labels":[],"label_agreement":null},{"id":"W3164281877","doi":"10.1111/bjh.17537","title":"Patient‐reported fatigue refines prognosis in higher‐risk myelodysplastic syndromes (MDS): a MDS‐CAN study","year":2021,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatoon Medical Imaging; Université Laval; Royal Victoria Hospital; Royal Victoria Regional Health Centre; Vancouver General Hospital; Princess Margaret Cancer Centre; Dr. Georges-L.-Dumont University Hospital Centre; St. Paul's Hospital; Centre hospitalier de l'Université Laval; Alberta Hospital Edmonton; University of British Columbia; Sunnybrook Health Science Centre; Jewish General Hospital; McGill University Health Centre; University of Ottawa; Queen Elizabeth II Health Sciences Centre; CancerCare Manitoba; Saskatchewan Cancer Agency; University of Alberta Hospital; Health Sciences Centre; Juravinski Cancer Centre","funders":"","keywords":"International Prognostic Scoring System; Medicine; Myelodysplastic syndromes; Quality of life (healthcare); Internal medicine; Rating scale; Risk assessment; Disease; Physical therapy; Psychology; Bone marrow","score_opus":0.052329744327299005,"score_gpt":0.31594641755058034,"score_spread":0.2636166732232813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164281877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925252,0.0033642815,0.000025429921,0.0027170242,0.0005538014,0.0005188893,0.000019201707,0.000030274792,0.0002458888],"genre_scores_gemma":[0.99727446,0.00084651913,0.0011676475,0.00018379281,0.0001183759,0.000048785994,0.000016681382,0.00005404413,0.0002896769],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9957576,0.00074800785,0.0016551138,0.00044197412,0.0007769633,0.0006203829],"domain_scores_gemma":[0.9969862,0.000586377,0.0007779462,0.00030210032,0.0010123963,0.00033495022],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006807613,0.000249766,0.001492968,0.0005185748,0.000112466594,0.000073590214,0.00022184446,0.00022590812,0.000507422],"category_scores_gemma":[0.0036796713,0.0002565165,0.00021627442,0.00091554265,0.00018042754,0.00015465742,0.00018227448,0.0013478183,0.0000124851],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030381343,0.0016905996,0.31576124,0.00016902346,0.0006533225,0.66317666,0.00047549582,0.000013253723,0.00024612405,0.0000203782,0.0048012715,0.012688799],"study_design_scores_gemma":[0.0058992305,0.001812861,0.37301514,0.0010708498,0.00036011403,0.61444366,0.0016373384,0.000038328235,0.00062603696,0.00014159273,0.00074116467,0.00021368949],"about_ca_topic_score_codex":0.0006098346,"about_ca_topic_score_gemma":0.0008467647,"teacher_disagreement_score":0.057253905,"about_ca_system_score_codex":0.00027877247,"about_ca_system_score_gemma":0.0010880348,"threshold_uncertainty_score":0.99998873},"labels":[],"label_agreement":null},{"id":"W3164396471","doi":"10.3390/cancers13112655","title":"Chromosomal Instability in Acute Myeloid Leukemia","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Myeloid leukemia; Medicine; Chromosome instability; Cancer; Oncology; Disease; Myeloid; Precision medicine; Leukemia; Internal medicine; Bioinformatics; Cancer research; Pathology; Biology; Gene; Chromosome","score_opus":0.04994399540266379,"score_gpt":0.36787431474483395,"score_spread":0.31793031934217014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164396471","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006621344,0.99077356,0.000004977684,0.00007241771,0.00043154354,0.0016215941,0.00013452665,0.00007946327,0.006219804],"genre_scores_gemma":[0.00004385119,0.99530154,0.00031196157,0.00021166645,0.00051250815,0.00052535447,0.00060675136,0.0001339533,0.0023524086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962516,0.0002891874,0.00090430974,0.0010858832,0.000597706,0.000871338],"domain_scores_gemma":[0.99772614,0.00021599724,0.00021497988,0.0012717954,0.00015965452,0.0004114256],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048417898,0.0006171628,0.0034167517,0.00041255148,0.000059695558,0.000039521365,0.00045940102,0.0007686447,0.0010517634],"category_scores_gemma":[0.00033770132,0.0005286029,0.00076550565,0.0016083424,0.00029401865,0.00010135898,0.00032123426,0.0023179331,0.00022423222],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000041016057,0.0000171473,0.00006372447,0.019140573,0.0005545813,0.0023108355,0.00010416917,0.0000049044984,0.0000061256515,0.000047224767,0.006562098,0.9711476],"study_design_scores_gemma":[0.0010079541,0.000096029085,0.000034387318,0.01752793,0.0008060932,0.00043897724,0.000056905923,0.000052882053,0.000011781331,0.0000041692715,0.97954774,0.00041515395],"about_ca_topic_score_codex":0.00070550415,"about_ca_topic_score_gemma":0.00015559733,"teacher_disagreement_score":0.9729856,"about_ca_system_score_codex":0.0683886,"about_ca_system_score_gemma":0.05470241,"threshold_uncertainty_score":0.9999838},"labels":[],"label_agreement":null},{"id":"W3165184255","doi":"10.1111/ejh.13673","title":"Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR","year":2021,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pancytopenia; Cumulative incidence; Internal medicine; Bone marrow; Cohort; Transplantation; Gastroenterology; Incidence (geometry); Myeloid leukemia; Oncology; Hematopoietic stem cell transplantation","score_opus":0.024707375714897697,"score_gpt":0.24442332911963768,"score_spread":0.21971595340473998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165184255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994072,0.0024297263,0.0016391269,0.0008615377,0.00025611988,0.00035536414,0.00015403717,0.000017791828,0.00021428635],"genre_scores_gemma":[0.9960983,0.0017770816,0.0012060091,0.00018100093,0.00006944521,0.000003883659,0.00003625981,0.00008192554,0.00054613565],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9959786,0.0016960811,0.0009424221,0.0003848185,0.000460345,0.00053776783],"domain_scores_gemma":[0.9977673,0.0007970348,0.0006054995,0.000263675,0.00029141846,0.0002750458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030774246,0.00027607204,0.0012399337,0.0002454539,0.00010758254,0.00003439231,0.00018308248,0.00014000811,0.000028034987],"category_scores_gemma":[0.0003174848,0.00020121256,0.0002324838,0.00026028958,0.00010212919,0.00011006406,0.000039674003,0.0010912239,0.0000039913716],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015538433,0.0011250604,0.23098674,0.0011833321,0.0019463997,0.69892746,0.0019481346,0.00008692327,0.047014073,0.000023238097,0.0004472511,0.0007729126],"study_design_scores_gemma":[0.14664716,0.018363507,0.38188073,0.0118226865,0.010964778,0.2622172,0.0048611723,0.0011497448,0.15589906,0.00008345812,0.0038681685,0.0022423621],"about_ca_topic_score_codex":0.000010588951,"about_ca_topic_score_gemma":0.0002830313,"teacher_disagreement_score":0.4367103,"about_ca_system_score_codex":0.00013993906,"about_ca_system_score_gemma":0.0005833993,"threshold_uncertainty_score":0.820521},"labels":[],"label_agreement":null},{"id":"W3165356648","doi":"10.1080/10428194.2021.1910685","title":"Mitochondrial metabolism: powering new directions in acute myeloid leukemia","year":2021,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University of British Columbia","funders":"BC Cancer Foundation; University of British Columbia; Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Myeloid leukemia; Leukemia; Mitochondrion; Context (archaeology); Cancer research; Oxidative phosphorylation; Myeloid; Biology; Stem cell; Medicine; Immunology; Cell biology; Biochemistry","score_opus":0.024508357642982058,"score_gpt":0.3126004999898599,"score_spread":0.28809214234687786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165356648","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005533977,0.9781935,0.00012059336,0.00019215721,0.0031087946,0.0038454845,0.00030706142,0.0007982131,0.007900202],"genre_scores_gemma":[0.00012756052,0.9609458,0.004075451,0.0007617764,0.0042732675,0.000980154,0.0017192141,0.000980589,0.026136177],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98401034,0.0010522581,0.0041492768,0.0046167714,0.0023172349,0.0038540948],"domain_scores_gemma":[0.9903274,0.0013241224,0.0013031013,0.0036324537,0.00049262773,0.0029202604],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0009791336,0.003700494,0.010796222,0.0032654663,0.00077503774,0.0008118577,0.0017756418,0.004102748,0.00064373494],"category_scores_gemma":[0.00096892676,0.0034603695,0.003066363,0.0056129666,0.0008176782,0.00092914037,0.0018694219,0.0023024909,0.00069960265],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00048138367,0.0001999283,0.000035529112,0.006110091,0.0026879227,0.0065799137,0.0005540997,0.0000097362845,0.00019803167,0.00060351676,0.025200376,0.95733947],"study_design_scores_gemma":[0.018056799,0.00025911097,0.0005823201,0.017242104,0.0062426557,0.014948224,0.00026288832,0.0003475804,0.00021569499,0.000094586605,0.93887115,0.0028768629],"about_ca_topic_score_codex":0.008080269,"about_ca_topic_score_gemma":0.0004694278,"teacher_disagreement_score":0.9544626,"about_ca_system_score_codex":0.064075865,"about_ca_system_score_gemma":0.08234224,"threshold_uncertainty_score":0.9999992},"labels":[],"label_agreement":null},{"id":"W3165799328","doi":"10.1016/j.critrevonc.2021.103367","title":"Iron overload-induced oxidative stress in myelodysplastic syndromes and its cellular sequelae","year":2021,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"Centre for Blood Research, University of British Columbia; University of British Columbia","keywords":"Oxidative stress; Reactive oxygen species; Myelodysplastic syndromes; DNA damage; Haematopoiesis; Stem cell; Cell biology; Biology; Hematopoietic stem cell; Cellular respiration; Senescence; Oxidative phosphorylation; Membrane permeability; Mitochondrion; Biochemistry; Immunology; Bone marrow; DNA","score_opus":0.12375963500328774,"score_gpt":0.4527460638293274,"score_spread":0.3289864288260397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165799328","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00087654707,0.99168605,0.0000247335,0.0011282505,0.0005618202,0.0038710781,0.000053338346,0.00004504791,0.001753135],"genre_scores_gemma":[0.00080129807,0.9958096,0.0006945644,0.00037969337,0.0001609412,0.0015117058,0.00025515,0.00013630693,0.00025071634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9884797,0.0044967732,0.0030538377,0.0018888189,0.00045063463,0.0016302401],"domain_scores_gemma":[0.98784864,0.0097851595,0.00043266793,0.0009928809,0.00025840578,0.0006822348],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.002209985,0.0011342752,0.011960854,0.0010994019,0.00008511149,0.00003594273,0.00060105347,0.0027539595,0.00085856195],"category_scores_gemma":[0.02698125,0.0009280016,0.00061276834,0.0014221999,0.00069412595,0.00014824163,0.0008693285,0.0047186953,0.000588972],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007822537,0.0013183155,0.00012876639,0.17091885,0.00024078866,0.04523309,0.0002207225,8.575922e-8,0.00012209384,0.041005373,0.0015933915,0.7391403],"study_design_scores_gemma":[0.0018524922,0.001022637,0.000012401162,0.13904291,0.0013652506,0.012125662,0.00018195313,0.0000495999,0.00010604854,0.00026171713,0.84307706,0.0009022451],"about_ca_topic_score_codex":0.000019155363,"about_ca_topic_score_gemma":0.000067914996,"teacher_disagreement_score":0.8414837,"about_ca_system_score_codex":0.0025781922,"about_ca_system_score_gemma":0.003373577,"threshold_uncertainty_score":0.99931705},"labels":[],"label_agreement":null},{"id":"W3166806880","doi":"10.1200/jco.2021.39.15_suppl.7006","title":"Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) m<i>IDH1</i> acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Gastroenterology; Myeloid leukemia; Refractory (planetary science); Interim analysis; Clinical endpoint; Surrogate endpoint; Cytarabine; Clinical trial; Surgery; Adverse effect","score_opus":0.10968179849111843,"score_gpt":0.4842132280598578,"score_spread":0.37453142956873936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166806880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521804,0.00011529546,0.00005445164,0.0017825749,0.00077614,0.00076251605,0.000526337,0.000011879546,0.00075276196],"genre_scores_gemma":[0.9950476,0.0006824106,0.0020477248,0.001022467,0.0006134211,0.000009495479,0.00036718108,0.000048438847,0.00016121838],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9816817,0.0060886545,0.009365139,0.000771527,0.0015613941,0.00053156127],"domain_scores_gemma":[0.9526821,0.037322532,0.006484962,0.0011117543,0.0014413651,0.000957293],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01332669,0.00040535087,0.006963435,0.00095615676,0.000048194106,0.000012681595,0.00064696564,0.0011218328,0.00020354342],"category_scores_gemma":[0.04571485,0.00026763976,0.0019497995,0.0015468254,0.0007077423,0.00015920826,0.00028565445,0.0043235077,0.000013138408],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8713604,0.011330494,0.051929433,0.000050525785,0.010040406,0.0032604078,0.00017112074,0.00009947227,0.0019980543,0.000004177764,0.006069176,0.04368629],"study_design_scores_gemma":[0.52471256,0.26098433,0.19367844,0.0010295203,0.0089389365,0.00003971125,0.00009052093,0.0006489143,0.001445686,0.000023122007,0.008157765,0.0002504837],"about_ca_topic_score_codex":0.00013355563,"about_ca_topic_score_gemma":0.00014479093,"teacher_disagreement_score":0.3466479,"about_ca_system_score_codex":0.0010375683,"about_ca_system_score_gemma":0.006893709,"threshold_uncertainty_score":0.9999776},"labels":[],"label_agreement":null},{"id":"W3166992895","doi":"10.1007/s40778-021-00191-9","title":"Understanding Normal and Pathological Hematopoietic Stem Cell Biology Using Mathematical Modelling","year":2021,"lang":"en","type":"article","venue":"Current Stem Cell Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Natural Sciences and Engineering Research Council of Canada; Centre de recherche du CHU Sainte-Justine","keywords":"Haematopoiesis; Stem cell; Hematopoietic stem cell; Biology; Systems biology; Leukemia; Myeloid leukemia; Blood cell; Computational biology; Cell biology; Myeloid; Immunology; Cancer research","score_opus":0.1910832004733411,"score_gpt":0.33897381935067566,"score_spread":0.14789061887733457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166992895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8044665,0.0037909267,0.18616462,0.00007807367,0.00032455838,0.00037438906,0.000003657137,0.00007581695,0.004721474],"genre_scores_gemma":[0.99639803,0.0003580718,0.002381708,0.00003209503,0.00011910561,0.00001283671,0.000026936805,0.000042649423,0.0006285695],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99725866,0.00015432033,0.0007868637,0.00074457005,0.00041627238,0.0006393075],"domain_scores_gemma":[0.9984931,0.00019886703,0.00024441045,0.00054136803,0.00013642822,0.0003858347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067130843,0.00028682474,0.0006468028,0.00013502802,0.00018506078,0.000057922873,0.000069457295,0.0002381053,0.00013453048],"category_scores_gemma":[0.000017009754,0.00023841741,0.00015015897,0.00025528081,0.00018471906,0.00008386836,0.0003069222,0.00063256576,0.000024460644],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091430376,0.007789155,0.1666279,0.04309505,0.00063070585,0.1796047,0.017248634,0.013600151,0.5191235,0.022467041,0.00368662,0.02521227],"study_design_scores_gemma":[0.0069221426,0.00096012093,0.0002325545,0.0035338749,0.0014728602,0.07227756,0.014520061,0.6481213,0.22275108,0.019700868,0.0067612343,0.0027463683],"about_ca_topic_score_codex":0.0000016438752,"about_ca_topic_score_gemma":1.7974689e-7,"teacher_disagreement_score":0.6345211,"about_ca_system_score_codex":0.00048955873,"about_ca_system_score_gemma":0.00042877605,"threshold_uncertainty_score":0.972238},"labels":[],"label_agreement":null},{"id":"W3167722320","doi":"10.1200/jco.2021.39.15_suppl.7021","title":"Effect of geriatric assessment (GA) and genetic profiling on overall survival (OS) of older adults with acute myeloid leukemia (AML).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Medicine; Internal medicine; Interim analysis; Oncology; Transplantation; Chemotherapy regimen; Myeloid leukemia; Comorbidity; Chemotherapy; Clinical trial","score_opus":0.031118780944988284,"score_gpt":0.42508589455219487,"score_spread":0.3939671136072066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167722320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953021,0.00044869818,0.0002772507,0.0012557531,0.0005046906,0.00049124815,0.000007767024,0.000006136593,0.0017063875],"genre_scores_gemma":[0.9816876,0.0024231137,0.014560633,0.0003071995,0.0007416836,0.0000074279333,0.000006425373,0.000035540237,0.00023038234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944409,0.0015193671,0.0023424807,0.00035689012,0.0009853325,0.00035503795],"domain_scores_gemma":[0.99016076,0.0061629037,0.0018665543,0.00035800718,0.0010137102,0.00043804146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004122079,0.00023198932,0.0024906385,0.00021604866,0.000032447777,0.0000087612025,0.00020215896,0.00046443657,0.00010467495],"category_scores_gemma":[0.0025162231,0.00014795987,0.00040613077,0.00029630534,0.00030865532,0.00007746178,0.00014806623,0.0017484084,0.0000031055838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10828801,0.0033648096,0.5154371,0.0024042474,0.0053410493,0.018832423,0.00028808299,0.0002996678,0.036454737,0.00021456115,0.0020425005,0.30703276],"study_design_scores_gemma":[0.05058781,0.08722372,0.83301604,0.0009101665,0.0017419177,0.0024793907,0.0001223976,0.0008818669,0.021994477,0.000037927774,0.00079443195,0.0002098426],"about_ca_topic_score_codex":0.000022206506,"about_ca_topic_score_gemma":0.000009933939,"teacher_disagreement_score":0.3175789,"about_ca_system_score_codex":0.00051991607,"about_ca_system_score_gemma":0.0074295267,"threshold_uncertainty_score":0.99819744},"labels":[],"label_agreement":null},{"id":"W3168345821","doi":"10.1200/jco.2021.39.15_suppl.7014","title":"Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Internal medicine; Proportional hazards model; Multivariate analysis; Myeloid leukemia; Neutropenia; Induction chemotherapy; Univariate analysis; Chemotherapy; Gastroenterology; Oncology","score_opus":0.11093611767303269,"score_gpt":0.44106333653889807,"score_spread":0.3301272188658654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168345821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932782,0.00018189922,0.00025926213,0.004490678,0.0005342404,0.0010748738,0.00013005322,0.000005974992,0.000044798544],"genre_scores_gemma":[0.9900229,0.0008946889,0.007502375,0.00088304013,0.00041538005,0.000017093547,0.000083471234,0.00004806269,0.00013298067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99419874,0.0011554834,0.0029647222,0.00042323914,0.0008584611,0.000399353],"domain_scores_gemma":[0.98335594,0.010577192,0.002317136,0.0005191934,0.0028640856,0.00036648402],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0028404656,0.00030307792,0.0027320911,0.00019306573,0.00004093525,0.0000149377975,0.0003672638,0.0005787909,0.00012048896],"category_scores_gemma":[0.024508148,0.00016749001,0.0005003426,0.00033903203,0.0005124064,0.00018979605,0.00021157647,0.0014368038,8.3771226e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47683915,0.0031670851,0.49032182,0.00008432754,0.0029276423,0.0005814945,0.0007433635,0.000014556603,0.0060286955,0.000015929714,0.0030755443,0.01620039],"study_design_scores_gemma":[0.22912404,0.021399342,0.7422966,0.0004574945,0.0011822215,0.000029984398,0.0005004429,0.0003046519,0.002206901,0.00042005721,0.0018949666,0.0001833414],"about_ca_topic_score_codex":0.0005438964,"about_ca_topic_score_gemma":0.0003247884,"teacher_disagreement_score":0.25197473,"about_ca_system_score_codex":0.00043736858,"about_ca_system_score_gemma":0.0033952533,"threshold_uncertainty_score":0.98370886},"labels":[],"label_agreement":null},{"id":"W3168906818","doi":"10.1200/jco.2021.39.15_suppl.e24108","title":"Testing for clonal hematopoiesis of indeterminate potential in breast cancer survivors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"V Foundation for Cancer Research","keywords":"Medicine; Breast cancer; Internal medicine; Malignancy; Cancer; Population; Oncology; Surgery","score_opus":0.13045949852623762,"score_gpt":0.4894860790317181,"score_spread":0.3590265805054805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168906818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98412585,0.00028677788,0.00017435134,0.014016975,0.0006977681,0.00014559033,0.000022665095,0.0000033530062,0.0005266811],"genre_scores_gemma":[0.98506606,0.00022171541,0.012341312,0.0008953642,0.0012332306,0.0000071510685,0.0000020948764,0.000019229434,0.00021382504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99633497,0.00039210072,0.0023879984,0.00018219982,0.00040729783,0.0002954478],"domain_scores_gemma":[0.99219257,0.004375013,0.0012431002,0.00014955636,0.0017764057,0.00026334234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003937567,0.00010472254,0.0015727695,0.00017274833,0.00002272003,0.000005416745,0.00017011561,0.00038143276,0.00019918589],"category_scores_gemma":[0.008001089,0.0000814182,0.00043180346,0.0003206289,0.0002094509,0.00008413423,0.00010698804,0.0010587237,0.0000021302951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068704574,0.0017634743,0.74610376,0.0003338271,0.00038278825,0.0042663016,0.000083222236,0.00006281748,0.012824695,0.00006158106,0.0023785802,0.2248685],"study_design_scores_gemma":[0.011088161,0.0028401446,0.975381,0.0003802274,0.0002286477,0.0035014055,0.00020454216,0.0012943646,0.0013830643,0.0004971094,0.0031060842,0.00009522362],"about_ca_topic_score_codex":0.00024207028,"about_ca_topic_score_gemma":0.00029051164,"teacher_disagreement_score":0.22927728,"about_ca_system_score_codex":0.0002922506,"about_ca_system_score_gemma":0.007182613,"threshold_uncertainty_score":0.99844575},"labels":[],"label_agreement":null},{"id":"W3169097194","doi":"10.1200/jco.2021.39.15_suppl.7040","title":"Health-related quality of life (HRQoL) in patients (pts) with myelodysplastic syndromes (MDS) in the Connect Myeloid Disease Registry.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Myelodysplastic syndromes; Internal medicine; Quality of life (healthcare); Observational study; Cohort; International Prognostic Scoring System; Disease; Pediatrics; Surgery; Bone marrow","score_opus":0.12903294958259393,"score_gpt":0.45768460865129085,"score_spread":0.3286516590686969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169097194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.958306,0.000675492,0.000020008554,0.039732423,0.00029729246,0.00037253168,0.00001552598,0.0000048636957,0.00057585427],"genre_scores_gemma":[0.99520075,0.00049365225,0.0004986594,0.0034413661,0.00016353383,0.0000066568114,0.000023568713,0.000020139609,0.00015166358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98954666,0.0038695766,0.0047721914,0.00031426025,0.0010566129,0.00044072457],"domain_scores_gemma":[0.98455787,0.010047865,0.003138248,0.0005531678,0.0008937489,0.0008091008],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009886767,0.00018331154,0.0025362538,0.00023294298,0.00003763643,0.000009997538,0.0003864944,0.00033345108,0.00014510978],"category_scores_gemma":[0.047171965,0.000109619694,0.00033362798,0.0007625894,0.0004801953,0.0001087201,0.00010369794,0.0025356752,0.000012113965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021431116,0.0049070874,0.95295954,0.00031114774,0.0003013732,0.0033681311,0.00034795023,0.000100602185,0.000008738328,0.00027284678,0.0030262093,0.012965265],"study_design_scores_gemma":[0.024112387,0.0082869455,0.96375334,0.000484482,0.00008869447,0.0002097742,0.0005444911,0.000097999306,0.0000026217374,0.00023593564,0.0020819178,0.00010142404],"about_ca_topic_score_codex":0.00027435098,"about_ca_topic_score_gemma":0.0005437581,"teacher_disagreement_score":0.037285198,"about_ca_system_score_codex":0.000617966,"about_ca_system_score_gemma":0.015356685,"threshold_uncertainty_score":0.9997655},"labels":[],"label_agreement":null},{"id":"W3169327621","doi":"10.1200/jco.2021.39.15_suppl.7019","title":"Predictive phosphoproteomic signatures for midostaurin plus chemotherapy response in FLT3 mutant positive acute myeloid leukaemia.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Midostaurin; Medicine; Myeloid leukemia; Bone marrow; Chemotherapy; Cancer research; Oncology; Internal medicine; Survival analysis","score_opus":0.05231776550546937,"score_gpt":0.4423689324410603,"score_spread":0.39005116693559094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169327621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96102047,0.0013184146,0.0018973678,0.03335942,0.0007826916,0.0010440861,0.000065893284,0.00001630288,0.00049533177],"genre_scores_gemma":[0.96770084,0.0030721093,0.016955057,0.008834217,0.0016637363,0.000056076642,0.000022392313,0.00007987254,0.0016157083],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99413323,0.0014331716,0.0026873318,0.0004830632,0.0006501203,0.00061309506],"domain_scores_gemma":[0.9867673,0.009440205,0.0012969591,0.00036316246,0.001543714,0.0005886703],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007679247,0.0002765511,0.0023341472,0.0003220431,0.000065349406,0.00002051864,0.00034799566,0.0010690712,0.00019966716],"category_scores_gemma":[0.011361666,0.0002148442,0.00086614955,0.000451715,0.0004004415,0.00016820522,0.00010366627,0.0032172713,0.000013975665],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73870933,0.0028795046,0.0041863094,0.00008689838,0.003360196,0.025620755,0.0014397185,0.0003024276,0.15238634,0.00012656508,0.012733129,0.05816882],"study_design_scores_gemma":[0.16061868,0.10027228,0.42788306,0.0011052,0.001551299,0.0072886813,0.0019000614,0.006656932,0.2222705,0.0029221717,0.06677536,0.00075575005],"about_ca_topic_score_codex":0.000020961916,"about_ca_topic_score_gemma":0.000028259223,"teacher_disagreement_score":0.57809067,"about_ca_system_score_codex":0.0023399214,"about_ca_system_score_gemma":0.016788596,"threshold_uncertainty_score":0.9990823},"labels":[],"label_agreement":null},{"id":"W3170494628","doi":"10.1200/jco.2021.39.15_suppl.7018","title":"Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Venetoclax; Azacitidine; Internal medicine; Minimal residual disease; Gastroenterology; Ven; Oncology; Myeloid leukemia; Induction chemotherapy; Leukemia; Chemotherapy; Chronic lymphocytic leukemia","score_opus":0.0880853813681059,"score_gpt":0.42639400827745705,"score_spread":0.33830862690935115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170494628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981633,0.0010177682,0.00002445144,0.015941031,0.00012433495,0.00021326674,0.000009803356,0.00001202375,0.0010242999],"genre_scores_gemma":[0.9893788,0.0024609976,0.0031964525,0.001971734,0.0005188219,0.000008310304,0.000008730401,0.00003674175,0.0024193914],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99488395,0.0018721027,0.0017944713,0.0003567235,0.0006560008,0.00043673188],"domain_scores_gemma":[0.99302036,0.0039697583,0.00066723704,0.00034681585,0.00088787253,0.0011079813],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0058906875,0.00019563791,0.0015834969,0.000277433,0.000051918647,0.000022329219,0.00016410214,0.00038718397,0.00013280887],"category_scores_gemma":[0.010897517,0.00013592948,0.00021062988,0.00048242122,0.00042341065,0.0001746798,0.00010710723,0.0019505834,0.000015330777],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41133803,0.0009616632,0.37956715,0.000096031355,0.0012468826,0.15694757,0.0001614462,0.00017829094,0.009467665,0.000072969524,0.010202688,0.029759608],"study_design_scores_gemma":[0.02482588,0.014243824,0.9266178,0.0003787759,0.0006545698,0.0046289754,0.00021435216,0.00038026532,0.0013054467,0.00016973856,0.02639851,0.00018189092],"about_ca_topic_score_codex":0.000039876013,"about_ca_topic_score_gemma":0.00006599031,"teacher_disagreement_score":0.5470506,"about_ca_system_score_codex":0.0018236456,"about_ca_system_score_gemma":0.026983539,"threshold_uncertainty_score":0.99743414},"labels":[],"label_agreement":null},{"id":"W3170618908","doi":"10.1038/s42003-021-02889-2","title":"GFI1 tethers the NuRD complex to open and transcriptionally active chromatin in myeloid progenitors","year":2021,"lang":"en","type":"article","venue":"Communications Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Centre Hospitalier Universitaire Sainte-Justine; Université Laval; Université de Montréal; Montreal Clinical Research Institute","funders":"Fonds de Recherche du Québec - Santé; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Chromatin; Nucleosome; Chromatin remodeling; Cell biology; Chromodomain; Biology; Histone; Transcription factor; Enhancer; Promoter; Repressor; Myelopoiesis; DNA; Genetics; Gene; Progenitor cell; Gene expression; Helicase; Stem cell","score_opus":0.12060047091944197,"score_gpt":0.41842786186391767,"score_spread":0.2978273909444757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170618908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7783295,0.0016632735,0.00014655353,0.19372424,0.00004595464,0.0020098097,0.00008003572,0.00003831199,0.02396235],"genre_scores_gemma":[0.9820236,0.0005515995,0.013838721,0.0024605265,0.000028544731,0.00038636193,0.00029414098,0.000014715745,0.0004017817],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987069,0.0005675222,0.00022618903,0.00021950166,0.00006996927,0.00020992578],"domain_scores_gemma":[0.99801534,0.00044080542,0.000037510006,0.001239869,0.00017009128,0.00009638818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038493637,0.0000962348,0.0002257153,0.0000951086,0.00021149426,0.000031952684,0.0010057546,0.00009092139,0.00022750374],"category_scores_gemma":[0.00033891702,0.00007135,0.000033277982,0.00048194051,0.00045137122,0.000052467374,0.00090567366,0.0003997514,0.000041154282],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057695096,0.0008914165,0.05370821,0.00005798783,0.00043121373,0.00002386321,0.012418415,0.0000065203576,0.7327268,0.0411866,0.008255878,0.14971614],"study_design_scores_gemma":[0.0031812328,0.0003751647,0.5777981,0.00010464619,0.000058104197,0.0002701094,0.009905492,0.000941987,0.0058327937,0.003068571,0.39819652,0.0002672571],"about_ca_topic_score_codex":0.00032284608,"about_ca_topic_score_gemma":0.0011953791,"teacher_disagreement_score":0.726894,"about_ca_system_score_codex":0.00020330901,"about_ca_system_score_gemma":0.00047072337,"threshold_uncertainty_score":0.29095685},"labels":[],"label_agreement":null},{"id":"W3170763689","doi":"10.1016/j.jval.2021.04.327","title":"PCN237 Patterns of Healthcare Resource Utilization (HRU) in Unfit Patients with Acute Myeloid Leukemia (AML) Receiving First-line Systemic Treatment or Best Supportive Care (BSC): A Multicenter International Study (CURRENT)","year":2021,"lang":"en","type":"article","venue":"Value in Health","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Retrospective cohort study; Pediatrics; Myeloid leukemia","score_opus":0.06428564752719745,"score_gpt":0.3636105994002395,"score_spread":0.29932495187304203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170763689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99325854,0.00095339894,0.000121422716,0.0011374466,0.00024813556,0.0037409333,0.00046392527,0.000036821904,0.000039356328],"genre_scores_gemma":[0.99589795,0.0017186949,0.00024507407,0.00011823133,0.0001145122,0.000259768,0.001323656,0.00007336497,0.0002487538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953406,0.00074816775,0.001379421,0.000834808,0.0010108523,0.0006861863],"domain_scores_gemma":[0.9974947,0.00030217535,0.00050393865,0.0006164336,0.00076438085,0.000318368],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005026876,0.0003704111,0.0008841381,0.00060777547,0.00010199328,0.00002155062,0.00022904742,0.00013263965,0.00006729897],"category_scores_gemma":[0.00029927664,0.00029086528,0.00008354707,0.0008593012,0.000045948076,0.00014634314,0.00016838773,0.00057857484,0.000009278976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027643559,0.0019498031,0.95100635,0.0026260293,0.00017356683,0.0004850641,0.022676036,0.0014942191,0.000010082636,0.000007359586,0.000021001873,0.016786147],"study_design_scores_gemma":[0.035689645,0.00978804,0.8878703,0.017071677,0.00015681313,0.00012163478,0.04009087,0.007372997,0.00033748918,0.000003532751,0.0010350413,0.00046195285],"about_ca_topic_score_codex":0.020988403,"about_ca_topic_score_gemma":0.017719766,"teacher_disagreement_score":0.063136026,"about_ca_system_score_codex":0.011739385,"about_ca_system_score_gemma":0.004042922,"threshold_uncertainty_score":0.99995434},"labels":[],"label_agreement":null},{"id":"W3172426892","doi":"10.1182/blood.v130.suppl_1.3955.3955","title":"Clinical and Genetic Relevance of Somatic Mutations in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Patients Using Serial Sequencing","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Neuroblastoma RAS viral oncogene homolog; KRAS; Core binding factor; Myeloid leukemia; Internal medicine; Medicine; Oncology; Hazard ratio; Myeloid; Cancer; Gastroenterology; Biology; Genetics; Gene; Confidence interval","score_opus":0.07426302301770765,"score_gpt":0.36639767474909113,"score_spread":0.2921346517313835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172426892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99891603,0.000056516852,0.000048282727,0.000037211306,0.00016943213,0.0005905664,0.000056303634,0.000021251266,0.00010439147],"genre_scores_gemma":[0.98713857,0.00015317206,0.012398574,0.000024974912,0.00015856535,0.000010955507,0.000021146265,0.000037022684,0.0000570358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815756,0.000074024276,0.00067810935,0.00036430557,0.00036219863,0.00036377326],"domain_scores_gemma":[0.99852103,0.00022066795,0.00036459955,0.000581257,0.00013167136,0.00018075656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023152716,0.00017372199,0.00050499506,0.00017631835,0.00021264578,0.0000464152,0.00022760658,0.00018316899,0.000021244074],"category_scores_gemma":[0.0014048042,0.00016186407,0.00007833615,0.000111257534,0.0003412146,0.0001993995,0.00020236579,0.00040907177,0.000010667787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009978822,0.00011518232,0.8687537,0.0001772901,0.00012923486,0.00016917991,0.00043758514,0.000014775009,0.12779872,0.0000056498143,0.0000062852896,0.0022926615],"study_design_scores_gemma":[0.01097738,0.00034181436,0.9690341,0.0005460999,0.0002997498,0.00009746705,0.000116721785,0.0040590568,0.014243905,0.00009075463,0.000008128112,0.00018482101],"about_ca_topic_score_codex":0.00023552316,"about_ca_topic_score_gemma":0.000053769665,"teacher_disagreement_score":0.11355481,"about_ca_system_score_codex":0.00033464885,"about_ca_system_score_gemma":0.0008647055,"threshold_uncertainty_score":0.66006255},"labels":[],"label_agreement":null},{"id":"W3172501391","doi":"10.1038/s41375-021-01308-z","title":"Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML","year":2021,"lang":"en","type":"review","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of General Medical Sciences; U.S. Department of Health and Human Services; National Cancer Institute; Foundation for the National Institutes of Health","keywords":"HSF1; Biology; Cancer research; Myeloid leukemia; Leukemia; eIF4A; Initiation factor; Gene knockdown; Eukaryotic initiation factor; Cell culture; Heat shock protein; Translation (biology); Hsp70; Genetics; Messenger RNA; Gene","score_opus":0.07219252452039793,"score_gpt":0.3509922953089347,"score_spread":0.2787997707885368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172501391","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28961036,0.7065214,0.00015551246,0.000090224436,0.00016476633,0.0023741764,0.00037630054,0.00009678539,0.0006105055],"genre_scores_gemma":[0.15406454,0.84383416,0.00026440795,0.00004946546,0.00024253422,0.00014494671,0.0011425187,0.00014434617,0.00011306517],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954139,0.00061312126,0.0012630901,0.0010955727,0.0008630884,0.0007511988],"domain_scores_gemma":[0.9973622,0.00087812863,0.0004760226,0.0007270128,0.00023589178,0.00032076627],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00041219956,0.00084723945,0.0034171944,0.0011089368,0.00009617723,0.00007602968,0.00017726567,0.0013962261,0.0002336789],"category_scores_gemma":[0.00043925486,0.00076559884,0.0005135986,0.0013640022,0.00019477156,0.0007169992,0.00015852283,0.0019854028,0.000020658441],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015232444,0.00014601684,0.0007039872,0.02840291,0.00025988845,0.00024488708,0.00067042036,0.000007960056,0.009160552,0.00002617722,0.0001949692,0.9600299],"study_design_scores_gemma":[0.025426699,0.0024576224,0.059889313,0.23111874,0.004852824,0.0017958373,0.00072239945,0.0030717575,0.117391996,0.00020255736,0.5459736,0.0070966613],"about_ca_topic_score_codex":0.00084405445,"about_ca_topic_score_gemma":0.00010430641,"teacher_disagreement_score":0.95293325,"about_ca_system_score_codex":0.008833692,"about_ca_system_score_gemma":0.005578168,"threshold_uncertainty_score":0.99990016},"labels":[],"label_agreement":null},{"id":"W3172611661","doi":"10.1101/2021.05.30.446347","title":"Pseudo-mutant p53 as a targetable phenotype of <i>DNMT3A</i> -mutated pre-leukemia","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Haematopoiesis; Phenotype; Mutant; Progenitor cell; Mutation; Leukemia; Biology; Gene; Cancer research; Molecular biology; Cell biology; Stem cell; Genetics","score_opus":0.012397068092237708,"score_gpt":0.24994386537227833,"score_spread":0.23754679728004063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172611661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99053264,0.0038948406,0.0007032785,0.00048963673,0.00099952,0.0022198216,0.00031213212,0.0006103865,0.00023776734],"genre_scores_gemma":[0.98330486,0.0013817584,0.013050622,0.0006715979,0.00067632843,0.0003535778,0.000007735395,0.00043166542,0.00012186628],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9929229,0.0003533553,0.0015034766,0.002055093,0.0016528962,0.0015123041],"domain_scores_gemma":[0.9917879,0.00020100773,0.00086950394,0.0034463515,0.002692915,0.001002283],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0013219962,0.0011438166,0.0022159647,0.0006561101,0.0001866416,0.00023672625,0.001077641,0.0014250283,0.00078659155],"category_scores_gemma":[0.0015938267,0.00117668,0.0005629794,0.0018903993,0.00042220356,0.00026607467,0.0016716537,0.0030971467,0.0002461682],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006371544,0.0004456062,0.0046302443,0.0027175087,0.0011521695,0.0013829228,0.00006228447,0.00017776348,0.9869114,0.0002761247,0.00160162,0.000005177424],"study_design_scores_gemma":[0.003177539,0.00035027225,0.028322,0.00215422,0.00084383663,8.351835e-7,0.000024792813,0.0026963633,0.9561504,0.0000049783803,0.005059756,0.0012149711],"about_ca_topic_score_codex":0.0010014313,"about_ca_topic_score_gemma":0.0000067972314,"teacher_disagreement_score":0.030760989,"about_ca_system_score_codex":0.0027445313,"about_ca_system_score_gemma":0.013682799,"threshold_uncertainty_score":0.9998713},"labels":[],"label_agreement":null},{"id":"W3172690078","doi":"10.1200/jco.2021.39.15_suppl.7011","title":"Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Azacitidine; Myelodysplastic syndromes; Internal medicine; Venetoclax; Hypomethylating agent; Gastroenterology; Decitabine; Ven; Oncology; Lenalidomide; Anagrelide; Chemotherapy; Essential thrombocythemia; Leukemia; Bone marrow; Polycythemia vera; Chronic lymphocytic leukemia; Multiple myeloma","score_opus":0.05267757731609547,"score_gpt":0.38625079278427527,"score_spread":0.3335732154681798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172690078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992812,0.00067352713,0.000111713,0.004489356,0.00054368796,0.00081604556,0.00001583576,0.000030913205,0.000506924],"genre_scores_gemma":[0.9870702,0.007931894,0.0024047366,0.0013931984,0.00022171657,0.000023320257,0.000076900986,0.00007983176,0.00079820293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99384195,0.00091102364,0.0030262147,0.0006071416,0.0009605864,0.0006531064],"domain_scores_gemma":[0.99140716,0.004086104,0.0015199551,0.000331942,0.0019617768,0.0006930385],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001953886,0.00045873728,0.0025307105,0.0005854355,0.0001077159,0.000054243566,0.00024076943,0.0007913719,0.00045949678],"category_scores_gemma":[0.0042709652,0.00029942507,0.00022103763,0.0012413458,0.00050537183,0.00032784216,0.000114359624,0.0022294326,0.000025992967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0934504,0.007429698,0.77591944,0.00023542793,0.003025203,0.01284446,0.0011253278,0.00048605856,0.0015115618,0.00035430532,0.0026197538,0.10099835],"study_design_scores_gemma":[0.09727765,0.0332103,0.85343504,0.00082661206,0.00029680674,0.003583598,0.00029881,0.002614827,0.0013996644,0.000291911,0.0063379277,0.0004268352],"about_ca_topic_score_codex":0.00004431678,"about_ca_topic_score_gemma":0.00018619621,"teacher_disagreement_score":0.10057151,"about_ca_system_score_codex":0.0011929859,"about_ca_system_score_gemma":0.008144341,"threshold_uncertainty_score":0.99994576},"labels":[],"label_agreement":null},{"id":"W3173388073","doi":"10.1101/2021.06.27.449656","title":"DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"National Cancer Institute; National Institutes of Health; Alvin J. Siteman Cancer Center; Edward P. Evans Foundation; McGill University; Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Cancer research; Myeloid leukemia; Transcriptome; Biology; Progenitor cell; Myeloid; Gene expression profiling; Cell growth; Cell biology; Stem cell; Gene expression; Gene; Genetics","score_opus":0.013705925342856739,"score_gpt":0.26440024463265016,"score_spread":0.2506943192897934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173388073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886794,0.0053295833,0.00036684226,0.0028923736,0.00044088636,0.0017375733,0.0000981689,0.00041944836,0.000035741687],"genre_scores_gemma":[0.97335917,0.0016737438,0.022827797,0.0006021918,0.0007527254,0.0005275159,0.0000035762641,0.00019060097,0.000062671716],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957948,0.0002175118,0.00065336237,0.0015970514,0.00092375354,0.0008135759],"domain_scores_gemma":[0.9962576,0.00013638624,0.00029416365,0.0014533817,0.0009886053,0.0008698628],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000808033,0.0006536956,0.0009309015,0.00054889324,0.00020988529,0.00030697632,0.00029044968,0.0007992865,0.00006976559],"category_scores_gemma":[0.0011439819,0.0006476101,0.00014712058,0.000846674,0.00025858686,0.00020096073,0.0011835564,0.0015944361,0.000064554195],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025065392,0.00013688269,0.010652313,0.0016794977,0.00015726818,0.00077436026,0.00006921945,0.0000043277773,0.9834049,0.00014092053,0.0027170996,0.000012595729],"study_design_scores_gemma":[0.0017220263,0.00016160762,0.20872778,0.006088629,0.00020976158,2.5312372e-7,0.000031691412,0.00014040375,0.77648115,0.0000032102987,0.0055395626,0.00089395524],"about_ca_topic_score_codex":0.000030545343,"about_ca_topic_score_gemma":0.0000107575925,"teacher_disagreement_score":0.20692374,"about_ca_system_score_codex":0.0012634228,"about_ca_system_score_gemma":0.0022873871,"threshold_uncertainty_score":0.9995975},"labels":[],"label_agreement":null},{"id":"W3175238317","doi":"10.1038/s41409-021-01353-3","title":"Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation","year":2021,"lang":"en","type":"erratum","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Myeloid leukemia; Hematopoietic cell; Complete remission; Transplantation; Hematopoietic stem cell transplantation; Oncology; Internal medicine; Haematopoiesis; Myeloid; Leukemia; Acute leukemia; Immunology; Stem cell; Chemotherapy","score_opus":0.030117202780046544,"score_gpt":0.34178144569326896,"score_spread":0.3116642429132224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175238317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99080694,0.000112375186,0.00054160884,0.00020605231,0.0029195158,0.0017401602,0.0014865561,0.000035460493,0.002151318],"genre_scores_gemma":[0.9743767,0.0077846334,0.0006212873,0.000085854685,0.000106408486,0.00005323799,0.009441358,0.00013490643,0.007395633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99323267,0.0010019521,0.002851107,0.00088246743,0.001510345,0.00052145805],"domain_scores_gemma":[0.9952608,0.0017755276,0.0012515577,0.00074244384,0.00064694113,0.00032275228],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014344592,0.0006461431,0.0024669485,0.0012576098,0.00006697532,0.00001392982,0.00029266215,0.0009627114,0.000095740004],"category_scores_gemma":[0.00045045355,0.00058046426,0.0009302712,0.0009811629,0.00016308224,0.00012759592,0.0000316098,0.001429514,0.000010977057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1563194,0.0026986424,0.6362887,0.017063813,0.0017611947,0.0010843043,0.0057630697,0.002660611,0.07482709,0.000010544245,0.09863271,0.0028899326],"study_design_scores_gemma":[0.009421647,0.0038719107,0.9612863,0.0067793247,0.0012268553,0.00009217051,0.00010353546,0.00046886763,0.016091522,0.000006929977,0.00021229892,0.00043862956],"about_ca_topic_score_codex":0.0016254098,"about_ca_topic_score_gemma":0.001220775,"teacher_disagreement_score":0.3249976,"about_ca_system_score_codex":0.0012092042,"about_ca_system_score_gemma":0.0029430224,"threshold_uncertainty_score":0.99966466},"labels":[],"label_agreement":null},{"id":"W3175603320","doi":"10.1080/23723556.2021.1924600","title":"Novel subtypes of <i>NPM1</i>-mutated AML with distinct outcome","year":2021,"lang":"en","type":"article","venue":"Molecular & Cellular Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"NPM1; Nucleophosmin; Myeloid leukemia; Mutation; Biology; Disease; Leukemia; Cancer research; Oncology; Medicine; Genetics; Internal medicine; Gene; Karyotype","score_opus":0.02292132919339196,"score_gpt":0.3104331040045839,"score_spread":0.28751177481119194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175603320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94748884,0.0008514414,0.03657406,0.0026465403,0.0001117866,0.00043759297,0.000021328511,0.00006902366,0.011799404],"genre_scores_gemma":[0.9813871,0.000021449261,0.0150406975,0.0009400522,0.00006280844,0.000030008785,0.00027178525,0.00007562938,0.002170518],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977056,0.00018614046,0.0005112515,0.00053856266,0.00051281333,0.0005456829],"domain_scores_gemma":[0.9981435,0.0001389805,0.00017080271,0.0007353223,0.00054610043,0.00026531005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034811057,0.00025878559,0.0008150231,0.00015735393,0.00005566093,0.000012197626,0.00021203299,0.00027314658,0.0004111167],"category_scores_gemma":[0.00032337158,0.00021427829,0.00018438813,0.0006545798,0.00034392677,0.00003565836,0.00020155903,0.00056799303,0.000087751745],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005237029,0.0005903606,0.017508125,0.000170825,0.0002608547,0.012523905,0.00011484921,0.00003167082,0.96601886,0.00043593987,0.00033554266,0.0014853892],"study_design_scores_gemma":[0.0057081413,0.001334916,0.007487673,0.000054357733,0.0003590044,0.0015221642,0.00017538945,0.00037221683,0.95314395,0.000046448367,0.029539794,0.00025595477],"about_ca_topic_score_codex":0.00015710351,"about_ca_topic_score_gemma":0.00007486834,"teacher_disagreement_score":0.033898227,"about_ca_system_score_codex":0.00039936215,"about_ca_system_score_gemma":0.0014834991,"threshold_uncertainty_score":0.87380147},"labels":[],"label_agreement":null},{"id":"W3175898740","doi":"10.1016/j.jtct.2021.06.029","title":"Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome","year":2021,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Centre Hospitalier Universitaire de Nantes","keywords":"Medicine; Donor lymphocyte infusion; Transplantation; Cumulative incidence; Internal medicine; Azacitidine; Myelodysplastic syndromes; Hematopoietic stem cell transplantation; Chronic myelogenous leukemia; Leukemia; Oncology; Surgery; Bone marrow","score_opus":0.008411363278042653,"score_gpt":0.23444896193502301,"score_spread":0.22603759865698037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175898740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521905,0.00044914274,0.001605939,0.00014872383,0.00010182833,0.0022094094,0.00019770836,0.000056544424,0.000011678559],"genre_scores_gemma":[0.9881856,0.008533986,0.0010622924,0.00026730675,0.000031858875,0.0001994981,0.0010523361,0.000071919065,0.0005951888],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99754447,0.00028294863,0.00042394907,0.0007228287,0.0005656251,0.00046015176],"domain_scores_gemma":[0.998799,0.00016215541,0.0001113368,0.0002838729,0.00016394311,0.00047963724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022418244,0.0003985446,0.0005070764,0.00029730072,0.00020354614,0.00006177158,0.00009259344,0.00014750723,0.00008656638],"category_scores_gemma":[0.000035401867,0.00027955425,0.00007309304,0.0005711916,0.00007663669,0.00025807339,0.00001649817,0.00029432113,0.000014360588],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42135486,0.003185901,0.2544094,0.005837455,0.002029575,0.06285658,0.024369307,0.0013627941,0.17634341,0.000047762303,0.000015519121,0.04818742],"study_design_scores_gemma":[0.047126826,0.0055685025,0.89938855,0.0011403162,0.0014458796,0.0005620267,0.00025165555,0.00035767045,0.043351933,0.000028853732,0.000048879843,0.0007288874],"about_ca_topic_score_codex":0.00014043368,"about_ca_topic_score_gemma":0.00017746464,"teacher_disagreement_score":0.6449792,"about_ca_system_score_codex":0.00041880753,"about_ca_system_score_gemma":0.0009509473,"threshold_uncertainty_score":0.99996567},"labels":[],"label_agreement":null},{"id":"W3176370909","doi":"10.1016/s2352-3026(21)00134-4","title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":211,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"Celator Pharmaceuticals; Jazz Pharmaceuticals","keywords":"Medicine; Cytarabine; Daunorubicin; Internal medicine; Myeloid leukemia; Chemotherapy; Myeloid leukaemia; Chemotherapy regimen; Oncology; Pediatrics","score_opus":0.03108454719582305,"score_gpt":0.33817549234273164,"score_spread":0.3070909451469086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176370909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98455125,0.0007347346,0.000038118393,0.009053932,0.00023593615,0.004319117,0.00027092226,0.000052000283,0.0007439591],"genre_scores_gemma":[0.984178,0.0071468726,0.005405994,0.0013100967,0.0003956526,0.0003935263,0.0003293854,0.00009687276,0.00074357516],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961975,0.00082637015,0.00092978444,0.0008186714,0.00040523225,0.00082242774],"domain_scores_gemma":[0.9951868,0.002656147,0.0004648045,0.0012087413,0.0002634085,0.00022008269],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001192342,0.00041342675,0.0025633895,0.00017838879,0.000117605065,0.00004622597,0.00059784995,0.0003245366,0.0003095677],"category_scores_gemma":[0.0015269654,0.00024998642,0.00006826344,0.000695057,0.0005087961,0.00017072435,0.00033833573,0.0011850173,0.000021412767],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97005886,0.0014551174,0.00056859874,0.00028780356,0.0007537687,0.0056165047,0.0025900446,0.0000048718366,0.0014037138,0.00012678184,0.008086095,0.0090478705],"study_design_scores_gemma":[0.9788458,0.0039469837,0.0014154232,0.0004374757,0.00045219663,0.0008407798,0.0012926498,0.00043339178,0.011082037,0.000040835814,0.0009293876,0.0002830784],"about_ca_topic_score_codex":0.0012669608,"about_ca_topic_score_gemma":0.0021254367,"teacher_disagreement_score":0.009678324,"about_ca_system_score_codex":0.00016954698,"about_ca_system_score_gemma":0.001238521,"threshold_uncertainty_score":0.99999523},"labels":[],"label_agreement":null},{"id":"W3176497490","doi":"10.1182/blood.v130.suppl_1.28.28","title":"Simultaneous Identification and Stratification of Low Molecular Risk AML Patients Using a Single LSC17-Based Nanostring Assay at Diagnosis","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Oncology; NPM1; Myeloid leukemia; Induction chemotherapy; Clinical trial; Chemotherapy; Framingham Risk Score; Chemotherapy regimen; Disease; Gene; Karyotype","score_opus":0.019189947427503885,"score_gpt":0.28407650297006254,"score_spread":0.26488655554255863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176497490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99815416,0.0001192643,0.00081786147,0.00009039634,0.000041375464,0.0005855667,0.000053668347,0.000022534601,0.000115145354],"genre_scores_gemma":[0.9983541,0.00003775446,0.0013875387,0.000015889627,0.000029653413,0.000020571475,0.000073703086,0.000027794642,0.000053011005],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864376,0.000094530464,0.00031858904,0.00032726707,0.0004084809,0.00020735984],"domain_scores_gemma":[0.99816364,0.00022959565,0.000447176,0.0007292209,0.00031551553,0.00011485002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030910358,0.00013010307,0.00021509951,0.00011276118,0.00027336628,0.00007666498,0.00015596014,0.000112580376,0.000014730325],"category_scores_gemma":[0.0026914987,0.00012880123,0.000057102217,0.000084665044,0.00014642756,0.00011045978,0.00008289046,0.00014020555,0.000010580982],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000821472,0.0008230704,0.38347447,0.00017709457,0.00007349057,0.000035552534,0.00008820661,0.00015705462,0.60861987,0.0000055185956,0.000010655317,0.00645289],"study_design_scores_gemma":[0.0032941676,0.00020137963,0.13994768,0.00018066597,0.00027852983,0.0000061731766,0.000017881179,0.012738097,0.8431824,0.000017080036,0.000020589378,0.000115348994],"about_ca_topic_score_codex":0.00019059314,"about_ca_topic_score_gemma":0.000021792548,"teacher_disagreement_score":0.24352679,"about_ca_system_score_codex":0.0001685349,"about_ca_system_score_gemma":0.00010498269,"threshold_uncertainty_score":0.5252362},"labels":[],"label_agreement":null},{"id":"W3176849359","doi":"10.1101/2021.06.30.21259343","title":"Clonal hematopoiesis of indeterminate potential is associated with worse kidney function and anemia in a cohort of patients with advanced chronic kidney disease","year":2021,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; St. Joseph’s Healthcare Hamilton; Population Health Research Institute; Impact; McMaster University; Queen's University","funders":"Canadian Institutes of Health Research; Canadian Society of Nephrology; Sanofi Genzyme; Physicians' Services Incorporated Foundation; Kidney Foundation of Canada; Sanofi","keywords":"Hazard ratio; Medicine; Internal medicine; Kidney disease; Renal function; Cohort; Proportional hazards model; Anemia; Oncology; Creatinine; Confidence interval; Gastroenterology","score_opus":0.006347544531813259,"score_gpt":0.24040557254204922,"score_spread":0.23405802801023595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176849359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99725586,0.00022711976,0.00009514692,0.00033780682,0.000097619086,0.0014322046,0.0004760961,0.000028056362,0.000050102437],"genre_scores_gemma":[0.99682814,0.00014215251,0.00024945816,0.00024646654,0.000039352453,0.00014779855,0.0021058016,0.000071643015,0.00016916801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99679446,0.00018240743,0.00062525866,0.0007967357,0.0011678401,0.00043327623],"domain_scores_gemma":[0.9972516,0.000064723565,0.0005544545,0.000700419,0.0007270191,0.00070182094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038785586,0.0004094138,0.0010806526,0.0004124564,0.000039203613,0.000019854262,0.00018432063,0.00032185353,0.0003334798],"category_scores_gemma":[0.0007850326,0.00032797718,0.00011916527,0.00053560216,0.00035359306,0.00011478519,0.00042430754,0.00096244714,0.0000015793007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004908212,0.0005524621,0.988764,0.0027607465,0.00053104176,0.00034770192,0.0002146466,0.000061711435,0.0011252773,0.0000016861754,0.0002528143,0.0004797025],"study_design_scores_gemma":[0.008593832,0.00066320394,0.9826249,0.004675664,0.00072166836,0.0000072806997,0.000051374387,0.0007792751,0.0015356861,0.000022882814,0.00003079422,0.00029345453],"about_ca_topic_score_codex":0.00011073509,"about_ca_topic_score_gemma":0.000039570252,"teacher_disagreement_score":0.006139113,"about_ca_system_score_codex":0.00068023556,"about_ca_system_score_gemma":0.0040520737,"threshold_uncertainty_score":0.9999172},"labels":[],"label_agreement":null},{"id":"W3176974452","doi":"10.1096/fasebj.27.1_supplement.770.2","title":"NPM new interacting partners and influence of NPM mutations on gene regulation","year":2013,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Nucleophosmin; Myeloid leukemia; Gene; Haematopoiesis; Regulator; Biology; Chromosomal translocation; Leukemia; Cancer research; Mutation; Transcription (linguistics); Transcription factor; Regulation of gene expression; Genetics; Stem cell","score_opus":0.03129103308656828,"score_gpt":0.333388019049019,"score_spread":0.3020969859624507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176974452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382263,0.000053204756,0.00026496782,0.0047887573,0.000036919715,0.0001769046,8.3728645e-7,0.0000083584855,0.00084741536],"genre_scores_gemma":[0.9970336,0.000049366663,0.001238517,0.0002753163,0.0001941684,0.000002862733,0.0000030750357,0.000009883684,0.001193202],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999204,0.000072066105,0.00022507836,0.00007794704,0.000266872,0.00015405899],"domain_scores_gemma":[0.99908566,0.00026689155,0.00014744475,0.00015127708,0.0001903513,0.00015837976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032974622,0.00006814339,0.00011582927,0.000107948865,0.00012985436,0.00004513491,0.0000847634,0.00003244978,0.0002288638],"category_scores_gemma":[0.00053595816,0.00004245586,0.000034813736,0.0001302608,0.00008663605,0.00020985983,0.000031275686,0.0004120521,0.000053248485],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018726692,0.00003901112,0.008888905,0.000018502515,0.00009232839,0.000019858544,0.0023326438,0.0031884687,0.95771945,0.00014410142,0.0047256057,0.022643834],"study_design_scores_gemma":[0.003912497,0.0009921084,0.46972054,0.000637686,0.00016353893,0.0029634116,0.002686059,0.015041587,0.49986234,0.0031392933,0.0006757721,0.00020516507],"about_ca_topic_score_codex":0.0001512892,"about_ca_topic_score_gemma":0.0000027316635,"teacher_disagreement_score":0.4608316,"about_ca_system_score_codex":0.00010403892,"about_ca_system_score_gemma":0.00020510185,"threshold_uncertainty_score":0.25058982},"labels":[],"label_agreement":null},{"id":"W3177050893","doi":"10.1182/blood.v130.suppl_1.1706.1706","title":"A Simple Tool for the Prediction of Azacytidine Treatment Failure in Patients with Myelodysplastic Syndrome","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre; University of Toronto","funders":"","keywords":"Medicine; Myelodysplastic syndromes; International Prognostic Scoring System; Internal medicine; Bone marrow; Erythropoiesis; Ruxolitinib; Oncology; Cohort; Dosing; Myelofibrosis; Anemia; Surgery","score_opus":0.014997319765032548,"score_gpt":0.26048513888174607,"score_spread":0.24548781911671352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177050893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976873,0.000015361622,0.00009828117,0.0003517802,0.00002334922,0.001594211,0.00014272235,0.000013940959,0.00007309255],"genre_scores_gemma":[0.999034,0.000011537787,0.00034897664,0.000012174234,0.0000490902,0.00022230431,0.000069593145,0.000019780353,0.00023256849],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918133,0.000013512137,0.00017155155,0.00017671648,0.00024146483,0.0002154497],"domain_scores_gemma":[0.9990249,0.00015330753,0.000099747886,0.00056142453,0.000111843576,0.000048747374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000099323064,0.00011058308,0.00023031975,0.000066485205,0.00013419305,0.0000183892,0.00013888197,0.00005538779,0.000024279285],"category_scores_gemma":[0.0002402432,0.000059950784,0.00004798264,0.00006167438,0.0000860275,0.000079146346,0.00004020682,0.0000895625,0.000004689559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010239978,0.0010160151,0.99529326,0.000096845724,0.00031738356,0.00003020453,0.00012293088,0.000013431123,0.00037164928,0.000029276678,0.00024578904,0.0014391913],"study_design_scores_gemma":[0.02220278,0.0038492437,0.97111106,0.00008725631,0.00031871226,0.000024480512,0.000031861488,0.00037560653,0.001296353,0.00001550623,0.00063487986,0.000052258867],"about_ca_topic_score_codex":0.000115143295,"about_ca_topic_score_gemma":0.000104538136,"teacher_disagreement_score":0.024182225,"about_ca_system_score_codex":0.00012622942,"about_ca_system_score_gemma":0.00017089798,"threshold_uncertainty_score":0.2444722},"labels":[],"label_agreement":null},{"id":"W3179345185","doi":"10.3390/cancers13143464","title":"Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"Austrian Science Fund; Deutsche Forschungsgemeinschaft; Wilhelm Sander-Stiftung","keywords":"Ribonucleotide reductase; Cancer research; Myeloid leukemia; Cytarabine; Apoptosis; Leukemia; Tyrosine kinase; Biology; Kinase; Chemistry; Cell biology; Signal transduction; Immunology; Biochemistry; Gene","score_opus":0.02051319002422169,"score_gpt":0.2635625880951145,"score_spread":0.24304939807089282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179345185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97975,0.0020698332,0.015867617,0.00025995643,0.000099664576,0.00081741286,0.000053651373,0.00005766225,0.0010242386],"genre_scores_gemma":[0.9937425,0.0002642213,0.004846443,0.0004157854,0.00009172203,0.00033496335,0.000038405207,0.00007159576,0.00019434224],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979562,0.00023625033,0.00024199701,0.0005104149,0.0005630345,0.0004920967],"domain_scores_gemma":[0.99862534,0.00030869272,0.00012008826,0.0005214349,0.00016477327,0.00025966676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024082972,0.00024428545,0.00047872908,0.00014756128,0.000060402926,0.000018605047,0.00014437817,0.0002961703,0.000107534914],"category_scores_gemma":[0.0003328043,0.00024426158,0.00020121205,0.00037104054,0.000108481916,0.00011987222,0.00011246018,0.00055960135,0.000023349783],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002107153,0.000041376003,0.000017046403,0.0005843487,0.00014177171,0.0027900725,0.0003978324,0.0012689776,0.99232084,0.00011939071,0.00020055861,0.001907074],"study_design_scores_gemma":[0.0019298877,0.00016111523,0.00006567334,0.00074667716,0.0002555568,0.000123996,0.00038400703,0.0032493847,0.99080366,0.0020417464,0.000028273802,0.00021000806],"about_ca_topic_score_codex":0.002341108,"about_ca_topic_score_gemma":0.000029873792,"teacher_disagreement_score":0.013992557,"about_ca_system_score_codex":0.0059514833,"about_ca_system_score_gemma":0.0048191804,"threshold_uncertainty_score":0.9978645},"labels":[],"label_agreement":null},{"id":"W3179410427","doi":"10.1182/blood.v130.suppl_1.4557.4557","title":"Comparison of Outcomes of Elderly Patients with Acute Myeloid Leukemia (AML) in CR1 Receiving Reduced Intensity Allogeneic Stem Cell Transplantation (RICT) from Matched Sibling (MSD) or Unrelated Donors (URD)","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Université Laval; Hôpital de l'Enfant-Jésus; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Cumulative incidence; Internal medicine; NPM1; Transplantation; Incidence (geometry); Proportional hazards model; Hematopoietic stem cell transplantation; Gastroenterology; Oncology; Surgery; Biology","score_opus":0.029762727557884516,"score_gpt":0.3046170071623095,"score_spread":0.274854279604425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179410427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99830437,0.000065859596,0.00011659816,0.000117543255,0.000100911246,0.0009032283,0.00009164352,0.000047807895,0.0002520416],"genre_scores_gemma":[0.9966878,0.0001914509,0.0025820388,0.000027725939,0.000024772102,0.000020275924,0.0002155809,0.0000585253,0.0001917888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731225,0.00012208564,0.0009374342,0.00050809793,0.00067226804,0.00044784506],"domain_scores_gemma":[0.99743736,0.00029609253,0.00080262846,0.00085328415,0.0004390033,0.00017160589],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034428536,0.00033082222,0.0012527999,0.00038105177,0.0001380938,0.000036081296,0.00046801483,0.00030573536,0.00003310064],"category_scores_gemma":[0.000115141745,0.00024870934,0.00012152777,0.0003442322,0.00018208683,0.00024876266,0.00009869291,0.0006240051,0.000007580228],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033754588,0.0007973277,0.87936825,0.00025993265,0.00063154224,0.00012336845,0.003428024,0.00005963256,0.11051424,0.0000011437801,0.000021776592,0.0014192777],"study_design_scores_gemma":[0.01299902,0.000784184,0.7049811,0.0004809285,0.0007294964,0.000008058149,0.00066348247,0.00022555786,0.27893072,0.0000067831206,0.0000018410515,0.00018883897],"about_ca_topic_score_codex":0.0031720737,"about_ca_topic_score_gemma":0.0007667688,"teacher_disagreement_score":0.17438719,"about_ca_system_score_codex":0.00029650686,"about_ca_system_score_gemma":0.0005742394,"threshold_uncertainty_score":0.99999654},"labels":[],"label_agreement":null},{"id":"W3180995513","doi":"10.3324/haematol.2021.278762","title":"The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy","year":2021,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"NHLBI Division of Intramural Research; Medical Research Council; University of Texas MD Anderson Cancer Center; Directorate for Biological Sciences; National Institutes of Health; Deutschen Konsortium für Translationale Krebsforschung; National University Health System; Masarykova Univerzita; Canterbury District Health Board; National Health and Medical Research Council; Universidade de São Paulo; Medizinischen Hochschule Hannover; Government of South Australia; Vanderbilt University; University of Chicago; Università degli Studi di Pavia; Sociedade Beneficente Israelita Brasileira Albert Einstein; University of Tokyo; Institut Gustave-Roussy; Semmelweis Egyetem; European Hematology Association; Erasmus Medisch Centrum; University of South Australia; Institut National de la Santé et de la Recherche Médicale; Cancer Research UK; Vanderbilt University Medical Center; Queen Mary University of London; Hospital Research Foundation; Associazione Italiana per la Ricerca sul Cancro; National Cancer Institute; Universität Heidelberg; Australian Cancer Research Foundation; Cancer Council South Australia; Université de Montréal; Ligue Contre le Cancer; Deutsches Krebsforschungszentrum; Royal Adelaide Hospital; Fondazione IRCCS Policlinico San Matteo; Bundesministerium für Bildung und Forschung; Assistance publique-Hôpitaux de Paris; Massachusetts General Hospital","keywords":"Database; RUNX1; Genomics; Medicine; Biology; Computer science; Genetics; Gene; Genome; Transcription factor","score_opus":0.03186096913012081,"score_gpt":0.30008672457718183,"score_spread":0.268225755447061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180995513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850148,0.0038125548,0.0006882072,0.006884211,0.00006340081,0.001674016,0.00055530964,0.00010728007,0.0012002133],"genre_scores_gemma":[0.95857126,0.004821687,0.025516897,0.0021522688,0.00024604428,0.0009516313,0.0052893613,0.00016530907,0.0022855178],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967364,0.00025434242,0.00064886804,0.0009180039,0.0005988377,0.00084351783],"domain_scores_gemma":[0.99636954,0.0006189148,0.00029444133,0.001770707,0.00048672705,0.00045968982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007986312,0.0003860242,0.00075429503,0.00011843672,0.00049906375,0.0001709391,0.00050394447,0.00021579671,0.000090643705],"category_scores_gemma":[0.0015462724,0.0002411711,0.00009132881,0.00053114747,0.00066251395,0.00034494756,0.0005413231,0.00048552608,0.00000814432],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06300173,0.010203935,0.026081333,0.008245237,0.0036711784,0.044632174,0.009808304,0.00005322782,0.3444609,0.11408648,0.25268954,0.123065956],"study_design_scores_gemma":[0.016375896,0.0026734301,0.002227778,0.0006476072,0.00026106212,0.012086233,0.02106817,0.0030359342,0.097803764,0.00033578032,0.84238327,0.0011010692],"about_ca_topic_score_codex":0.0002739818,"about_ca_topic_score_gemma":0.00026008152,"teacher_disagreement_score":0.5896937,"about_ca_system_score_codex":0.00015685247,"about_ca_system_score_gemma":0.0012151368,"threshold_uncertainty_score":0.9834672},"labels":[],"label_agreement":null},{"id":"W3181720537","doi":"10.1126/science.abf6202","title":"Mapping the cellular origin and early evolution of leukemia in Down syndrome","year":2021,"lang":"en","type":"article","venue":"Science","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Ontario Institute for Cancer Research; SickKids Foundation; University Health Network; University of Toronto; Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"Canada Research Chairs; Canadian Cancer Society; Human Frontier Science Program; Ontario Institute for Cancer Research; Canadian Institutes of Health Research; Alex's Lemonade Stand Foundation for Childhood Cancer; Leukemia and Lymphoma Society; International Development Research Centre","keywords":"Trisomy; Preleukemia; Context (archaeology); Down syndrome; Leukemia; Aneuploidy; Biology; Genetics; Chromosome 21; Haploinsufficiency; Chromosome; Gene; Phenotype","score_opus":0.02577887880929269,"score_gpt":0.2799756846992894,"score_spread":0.2541968058899967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181720537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99660885,0.0010604297,0.00027496915,0.0006704611,0.000051368672,0.00013564178,7.832466e-7,0.000007756614,0.0011897186],"genre_scores_gemma":[0.9986515,0.000031461845,0.0005707493,0.00003329237,0.000015414578,0.000004309347,3.0798466e-7,0.000003362736,0.0006895812],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988898,0.000035677003,0.00013820016,0.00023185239,0.00045942265,0.0002450211],"domain_scores_gemma":[0.9994294,0.000058136327,0.00003003328,0.0002818226,0.0001272755,0.00007331119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010312942,0.000050480652,0.00012209314,0.00017848775,0.00008605505,0.0000228289,0.00017063339,0.000030415194,0.000025810894],"category_scores_gemma":[0.00034950985,0.000034900488,0.000017698585,0.0017258384,0.0006736835,0.00013652195,0.0001471455,0.00020629594,0.000011271374],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001140623,0.00001204737,0.11314611,0.000057260346,0.000004082146,0.00027018573,0.0009743099,0.000014171796,0.8827414,0.0011495895,0.000044108005,0.0015753463],"study_design_scores_gemma":[0.00058366003,0.000073105155,0.9504379,0.00015078436,0.0000049178307,0.0002740289,0.0011140321,0.00348342,0.04218773,0.0005175205,0.0011087052,0.00006419902],"about_ca_topic_score_codex":0.00040255947,"about_ca_topic_score_gemma":0.000014385143,"teacher_disagreement_score":0.84055364,"about_ca_system_score_codex":0.0009312125,"about_ca_system_score_gemma":0.0022868835,"threshold_uncertainty_score":0.40568334},"labels":[],"label_agreement":null},{"id":"W3182324170","doi":"10.1182/blood.v130.suppl_1.2584.2584","title":"A Strategy of Day 14 Bone Marrows and Early Intervention Is Associated with Similar Outcomes Compared to a Strategy of No Day 14 Bone Marrows and Delayed Intervention in Patients with Acute Myeloid Leukemia","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Induction chemotherapy; Internal medicine; Chemotherapy; Retrospective cohort study; Chemotherapy regimen; Leukemia; Cohort; Bone marrow; Surgery","score_opus":0.01542028637652406,"score_gpt":0.2788541444685726,"score_spread":0.26343385809204856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182324170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99742955,0.00015551518,0.00006387285,0.0001929308,0.00003551976,0.001524512,0.00026313853,0.000030822677,0.00030412097],"genre_scores_gemma":[0.99820477,0.00003244021,0.00042567667,0.000040324427,0.00001813296,0.000062155246,0.00017378503,0.00006198574,0.0009807434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969342,0.00024431784,0.00094827334,0.00059815927,0.00076783,0.0005072477],"domain_scores_gemma":[0.99736094,0.000112312846,0.0008454061,0.0007140118,0.0006866329,0.0002806843],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010014086,0.00040181744,0.0012265084,0.0004127093,0.00011340451,0.00010602935,0.00026376077,0.00023574915,0.000065521206],"category_scores_gemma":[0.0003446158,0.00031582857,0.00013858831,0.00026444724,0.000293896,0.0004218736,0.000253087,0.00047219382,0.000004501874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053476393,0.0020458875,0.977927,0.00045674594,0.0020956846,0.0002461845,0.0011347288,0.0000107195365,0.006143242,0.000015799616,0.00036617057,0.004210165],"study_design_scores_gemma":[0.03567814,0.005756811,0.9521538,0.0014050765,0.00069396495,0.000020047155,0.00024236107,0.0002593522,0.0034440903,0.00003252047,0.000013683243,0.00030016195],"about_ca_topic_score_codex":0.0019230695,"about_ca_topic_score_gemma":0.002072196,"teacher_disagreement_score":0.0303305,"about_ca_system_score_codex":0.00025570102,"about_ca_system_score_gemma":0.0002049354,"threshold_uncertainty_score":0.99992937},"labels":[],"label_agreement":null},{"id":"W3183942893","doi":"10.1158/2159-8290.cd-21-0177","title":"Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy","year":2021,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute on Aging; New York State Stem Cell Science; Université de Recherche Paris Sciences et Lettres; National Institutes of Health; Institut National Du Cancer; Institut National de la Santé et de la Recherche Médicale; Fondation ARC pour la Recherche sur le Cancer; Agence Nationale de la Recherche; Fondation du Collège de France; European Commission; Centre National de la Recherche Scientifique","keywords":"Venetoclax; Mitochondrion; Biogenesis; Mitochondrial biogenesis; Senescence; Dual role; Myeloid","score_opus":0.03330317864172556,"score_gpt":0.3377624613201965,"score_spread":0.30445928267847094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183942893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824462,0.0037828602,0.00051024184,0.009694516,0.00071960525,0.00084168586,0.00005506722,0.000056308538,0.0018935502],"genre_scores_gemma":[0.97377235,0.0029301536,0.0022158048,0.004038701,0.00091049564,0.00035831888,0.00007923851,0.00008233199,0.01561258],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976524,0.0001279922,0.00032347656,0.00072034495,0.00051581755,0.00065995957],"domain_scores_gemma":[0.9985254,0.00012369288,0.00006579902,0.00076957484,0.00019683754,0.00031870077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014224356,0.00026227115,0.00049115624,0.00019280086,0.000070114635,0.00007486611,0.0002644079,0.00015355034,0.00042948543],"category_scores_gemma":[0.00025113663,0.0002323984,0.00013034808,0.0008583031,0.0000904384,0.00033478113,0.00017534991,0.00056665007,0.000108115164],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014542518,0.00021979018,0.15741305,0.00011642802,0.00011853705,0.0013175175,0.0014806497,0.00018226862,0.7888623,0.00009688317,0.03696426,0.011774043],"study_design_scores_gemma":[0.005878887,0.00025869985,0.35277048,0.00080491113,0.000036941685,0.00008763331,0.0010219072,0.00028345568,0.5590527,0.00005133666,0.07918587,0.0005671841],"about_ca_topic_score_codex":0.0008251269,"about_ca_topic_score_gemma":0.0007390525,"teacher_disagreement_score":0.22980963,"about_ca_system_score_codex":0.001513595,"about_ca_system_score_gemma":0.0025574758,"threshold_uncertainty_score":0.94769317},"labels":[],"label_agreement":null},{"id":"W3184564251","doi":"10.1016/j.ebiom.2021.103488","title":"MAP4K1 expression is a novel resistance mechanism and independent prognostic marker in AML-but can be overcome via targeted inhibition","year":2021,"lang":"en","type":"letter","venue":"EBioMedicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto","funders":"","keywords":"Myeloid leukemia; Medicine; Leukemia; Scopus; Oncology; Myeloid; Cancer; Internal medicine; Bioinformatics; Cancer research; Immunology; MEDLINE; Biology","score_opus":0.019689747577889764,"score_gpt":0.2665144938257296,"score_spread":0.24682474624783984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184564251","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.108746,0.0031571882,0.0011204495,0.8819435,0.00065255485,0.0029317986,0.0006481336,0.00014839547,0.00065193174],"genre_scores_gemma":[0.13366221,0.0012043929,0.0045761014,0.79786575,0.0057557295,0.00069296814,0.010744314,0.00045711675,0.04504144],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940284,0.00023230157,0.0009882589,0.0014661968,0.0021717446,0.0011130845],"domain_scores_gemma":[0.9975664,0.00035318523,0.00034111226,0.0009842621,0.00036386368,0.000391158],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00081518973,0.000768152,0.0014129822,0.0013309146,0.00011912125,0.000052601135,0.00023740123,0.0015972132,0.0009503912],"category_scores_gemma":[0.0005382602,0.000656221,0.0001447635,0.0010557424,0.00034431196,0.00011830764,0.00044079157,0.0042878333,0.000019085854],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043375496,0.00017948414,0.0007562565,0.0023587695,0.00015110668,0.013256315,0.0006550681,4.954235e-8,0.25223023,0.000013778741,0.72972226,0.00024292637],"study_design_scores_gemma":[0.03376979,0.0015016879,0.030948939,0.026996093,0.00089289935,0.0032121006,0.0009906418,0.0004979991,0.060204145,0.0017355013,0.8367243,0.0025259333],"about_ca_topic_score_codex":0.00069766963,"about_ca_topic_score_gemma":0.00022553351,"teacher_disagreement_score":0.1920261,"about_ca_system_score_codex":0.0016234892,"about_ca_system_score_gemma":0.00079280796,"threshold_uncertainty_score":0.99996287},"labels":[],"label_agreement":null},{"id":"W3184751628","doi":"10.1038/s41525-021-00224-6","title":"Incidental findings from cancer next generation sequencing panels","year":2021,"lang":"en","type":"article","venue":"npj Genomic Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Mount Sinai Hospital; London Health Sciences Centre; Grand River Hospital; Princess Margaret Cancer Centre; Hospital for Sick Children; Toronto General Hospital; University Health Network; University of Toronto","funders":"","keywords":"Germline; CHEK2; Malignancy; Cancer; DNA sequencing; Genetic testing; Genetics; Medicine; Biology; Bioinformatics; Oncology; Internal medicine; Germline mutation; Computational biology; Gene; Mutation","score_opus":0.12478177457246009,"score_gpt":0.3403662857436202,"score_spread":0.21558451117116012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184751628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98431337,0.0043612397,0.0004574488,0.007897929,0.0007126442,0.00032846018,0.000030253472,0.00006792429,0.0018307505],"genre_scores_gemma":[0.9807198,0.001539876,0.0014442854,0.005430024,0.004360875,0.00004656894,0.0006330865,0.000058449215,0.005767004],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977715,0.00009547325,0.00048478958,0.0005795902,0.00061442103,0.0004542509],"domain_scores_gemma":[0.9986583,0.00014201074,0.000085662374,0.00051451783,0.000244439,0.0003550439],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040190955,0.0002341333,0.00053541415,0.00015663642,0.0001394434,0.000030344621,0.00016154001,0.00017271886,0.009289213],"category_scores_gemma":[0.00046592345,0.0001981431,0.0000786223,0.00033888454,0.00015781041,0.00012821076,0.0001432,0.0005304486,0.00031576605],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059341997,0.000017058575,0.008830771,0.000038303766,0.00012788636,0.0007346821,0.0022680662,0.000016348498,0.96485645,0.000036539004,0.015181783,0.007832765],"study_design_scores_gemma":[0.014863942,0.00057578285,0.11306385,0.001187286,0.0009069886,0.0014030195,0.009252929,0.02495228,0.7978686,0.00037534125,0.03468559,0.0008643613],"about_ca_topic_score_codex":0.0044975653,"about_ca_topic_score_gemma":0.00029273317,"teacher_disagreement_score":0.16698782,"about_ca_system_score_codex":0.0023305358,"about_ca_system_score_gemma":0.0015487435,"threshold_uncertainty_score":0.9916164},"labels":[],"label_agreement":null},{"id":"W3184895242","doi":"10.1038/s41375-021-01323-0","title":"Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results","year":2021,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"National Cancer Institute; Astellas Pharma; Daiichi-Sankyo; Deutsche Forschungsgemeinschaft; MacroGenics; National Institutes of Health; Arog Pharmaceuticals; Astex Pharmaceuticals; Sunesis; Jazz Pharmaceuticals; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Agios Pharmaceuticals","keywords":"Midostaurin; Myeloid leukemia; NPM1; Internal medicine; Oncology; Cumulative incidence; Fms-Like Tyrosine Kinase 3; Medicine; Leukemia; Transplantation; Biology; Mutation; Gene; Genetics","score_opus":0.014340783538162613,"score_gpt":0.3084374591255631,"score_spread":0.2940966755874005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184895242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961103,0.00069086434,0.00004221582,0.00031037294,0.000053731725,0.0012444339,0.000063408486,0.00006823827,0.0014163915],"genre_scores_gemma":[0.997989,0.00026161017,0.0005641639,0.00013289397,0.000080265505,0.00007373741,0.00029124427,0.0000625755,0.0005445394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99681985,0.00031305157,0.00087164465,0.0006781516,0.0006966594,0.00062060944],"domain_scores_gemma":[0.99802965,0.00025919618,0.0001994772,0.0008228512,0.0003787911,0.00031001272],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00070857216,0.0003658672,0.000803479,0.00042548537,0.00006760155,0.0000552555,0.00017405661,0.00029967722,0.000060138682],"category_scores_gemma":[0.0009763149,0.00031287703,0.00017783613,0.0012875868,0.00011760351,0.00019036599,0.00028208096,0.0009504182,0.000039726867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031899214,0.0004499951,0.6851345,0.00023101846,0.0006505151,0.0060530105,0.0035020304,0.0008223712,0.29478395,0.000020676685,0.0015408075,0.0036212357],"study_design_scores_gemma":[0.015447443,0.0020140596,0.947192,0.00028856727,0.00031643748,0.00046976362,0.0010531216,0.007596268,0.025166558,0.00004321147,0.00007949985,0.00033303397],"about_ca_topic_score_codex":0.0009822082,"about_ca_topic_score_gemma":0.00025942453,"teacher_disagreement_score":0.26961738,"about_ca_system_score_codex":0.0023428984,"about_ca_system_score_gemma":0.0035846909,"threshold_uncertainty_score":0.99993235},"labels":[],"label_agreement":null},{"id":"W3191822403","doi":"10.1097/moh.0000000000000675","title":"Clonal hematopoiesis and myeloid malignancies: clonal dynamics and clinical implications","year":2021,"lang":"en","type":"review","venue":"Current Opinion in Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Cytopenia; Context (archaeology); Somatic evolution in cancer; Myeloid; Haematopoiesis; Myeloid leukemia; Immunology; Myelodysplastic syndromes; Preleukemia; Minimal residual disease; Medicine; Oncology; Biology; Leukemia; Internal medicine; Bone marrow; Cancer; Stem cell; Genetics","score_opus":0.15630371606593074,"score_gpt":0.48040073219729296,"score_spread":0.3240970161313622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3191822403","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012781029,0.99445516,0.00027763215,0.0016496386,0.0018592576,0.0012805603,0.00021522705,0.000049371403,0.00008534222],"genre_scores_gemma":[0.000021793818,0.9962945,0.0008412231,0.000041168398,0.00043393666,0.00041029812,0.0018123375,0.00007266425,0.00007206084],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99545574,0.0005394223,0.0018690214,0.0011904298,0.00029937757,0.000646004],"domain_scores_gemma":[0.99630314,0.0018799335,0.000434919,0.000738978,0.00021607311,0.0004269794],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007887117,0.000560195,0.0036196313,0.0005408348,0.00011160306,0.00004352085,0.00027186237,0.00092158094,0.00011579218],"category_scores_gemma":[0.0009666814,0.0004912226,0.00044948398,0.00064784504,0.000722787,0.00006668891,0.00070230715,0.001817914,0.00004127007],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027647644,0.00044589493,0.012302917,0.069960475,0.00032167192,0.00005291333,0.00004032137,3.250169e-8,1.0257503e-7,0.116044134,0.009398554,0.7914053],"study_design_scores_gemma":[0.0011924306,0.00012158925,0.0013218271,0.027855434,0.00039117524,0.010084359,0.00006337376,0.00019841203,2.1459464e-7,0.0004183916,0.9578724,0.00048042662],"about_ca_topic_score_codex":0.000008969114,"about_ca_topic_score_gemma":0.0000095949645,"teacher_disagreement_score":0.9484738,"about_ca_system_score_codex":0.00045641803,"about_ca_system_score_gemma":0.0019302098,"threshold_uncertainty_score":0.99975395},"labels":[],"label_agreement":null},{"id":"W3192544520","doi":"10.1007/s11912-021-01108-9","title":"3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?","year":2021,"lang":"en","type":"review","venue":"Current Oncology Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cytarabine; Gemtuzumab ozogamicin; Daunorubicin; Oncology; Myeloid leukemia; Midostaurin; Internal medicine; Chemotherapy; Induction chemotherapy; Intensive care medicine; Stem cell; CD33","score_opus":0.09528255377631453,"score_gpt":0.4575392051180773,"score_spread":0.36225665134176277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192544520","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000035994413,0.9750926,0.00017206116,0.0062188343,0.0024475458,0.008703251,0.0001891515,0.00018988516,0.006950679],"genre_scores_gemma":[4.6477157e-7,0.92672855,0.001541755,0.0028389432,0.0015561446,0.0026447193,0.0025408582,0.0003038159,0.061844777],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927594,0.0003239669,0.0025011236,0.002153627,0.00084618875,0.0014156663],"domain_scores_gemma":[0.9937931,0.0007586778,0.001347003,0.002182778,0.0008932988,0.0010251505],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0016110901,0.0011877739,0.007100372,0.0006841118,0.00020472983,0.00006897685,0.0005311027,0.0017065165,0.0038875304],"category_scores_gemma":[0.00084404676,0.0010011402,0.0020332204,0.0011437767,0.00024013795,0.000084843974,0.00051978807,0.0022119666,0.001981009],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00006501678,0.0002865545,0.0000054995735,0.0046849237,0.0013693158,0.002093555,0.000089608635,6.907501e-8,0.000010717475,0.0000068560207,0.47080445,0.52058345],"study_design_scores_gemma":[0.0019648816,0.0014530038,0.000006017667,0.0100714965,0.0049619447,0.008187611,0.000014240783,0.000012041737,0.00004135261,0.000025465271,0.9725836,0.0006783592],"about_ca_topic_score_codex":0.000006533498,"about_ca_topic_score_gemma":0.0000017658614,"teacher_disagreement_score":0.5199051,"about_ca_system_score_codex":0.0077039297,"about_ca_system_score_gemma":0.01930278,"threshold_uncertainty_score":0.9995895},"labels":[],"label_agreement":null},{"id":"W3192825268","doi":"10.1016/j.jmoldx.2021.07.010","title":"Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay","year":2021,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Kingston Health Sciences Centre; Queen's University","funders":"Southeastern Ontario Academic Medical Organization; Ontario Institute for Cancer Research","keywords":"Amplicon; Ion semiconductor sequencing; DNA sequencing; DNA; Biology; Computational biology; Cancer research; Polymerase chain reaction; Genetics; Gene","score_opus":0.03068961680387819,"score_gpt":0.37649122443078475,"score_spread":0.3458016076269066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192825268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99508476,0.001796189,0.00085882714,0.0017937889,0.00017588743,0.00021755185,0.000028517597,0.0000038132657,0.000040639225],"genre_scores_gemma":[0.994076,0.0031695417,0.0020832138,0.0003664867,0.00023939072,0.0000014207357,0.000020827816,0.00002438427,0.00001870083],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99788475,0.0003876999,0.0008594633,0.00017011375,0.0004961231,0.00020184835],"domain_scores_gemma":[0.9968966,0.0009881849,0.0005569006,0.00026383426,0.0010516366,0.00024281722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013274738,0.00014326237,0.00043174194,0.00010734615,0.000060577462,0.0000377925,0.000112752554,0.00011761081,0.00006415058],"category_scores_gemma":[0.00595369,0.00009815261,0.00022592074,0.00025603088,0.00014332615,0.00010815781,0.00013338996,0.00052733906,7.903167e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057693167,0.00010334649,0.17670818,0.000056293808,0.00041380222,0.0002827516,0.00019802513,0.000026569567,0.81529135,0.00005708522,0.0029800995,0.003824803],"study_design_scores_gemma":[0.0038353268,0.00091130356,0.19000162,0.00025869007,0.00050068373,0.00140402,0.00049909815,0.00010910359,0.8017158,0.0003943318,0.0002523848,0.00011762599],"about_ca_topic_score_codex":0.00003895543,"about_ca_topic_score_gemma":0.0000060569587,"teacher_disagreement_score":0.013575542,"about_ca_system_score_codex":0.00034403574,"about_ca_system_score_gemma":0.0016673211,"threshold_uncertainty_score":0.7127553},"labels":[],"label_agreement":null},{"id":"W3193110750","doi":"10.1002/pbc.29278","title":"When it comes to drug access, should children be considered small adults? Countering coverage denials of FLT3 inhibitors in children with FLT3‐ITD AML","year":2021,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; University of Toronto","funders":"","keywords":"Medicine; Sick child; Hematology; Knight; Family medicine; University hospital; Associate editor; Pediatrics; Internal medicine; Library science","score_opus":0.02485478516658402,"score_gpt":0.3016552089690529,"score_spread":0.2768004238024689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193110750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98552316,0.006314861,0.000021690335,0.005414917,0.00019009355,0.0016778569,0.0004405979,0.00007726638,0.00033953547],"genre_scores_gemma":[0.9881906,0.0059264633,0.0007464762,0.0023853453,0.0017460478,0.0002456766,0.00016778817,0.00011730344,0.0004742915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962337,0.00014725048,0.00085158966,0.0009096196,0.0010132184,0.0008446451],"domain_scores_gemma":[0.9977871,0.00023948752,0.00028849943,0.0007319997,0.0005107782,0.00044213916],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004172489,0.00046745827,0.0010749245,0.00054068223,0.00009124718,0.00008627434,0.0004889638,0.00021562568,0.00071421656],"category_scores_gemma":[0.00037702365,0.00041746875,0.00015540185,0.0013348794,0.00011507375,0.0002611617,0.0005791534,0.00080016156,0.000015656778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056660257,0.0003229321,0.97432613,0.00033191234,0.0005201757,0.00012923004,0.0013117475,0.00015946655,0.0005177571,0.0000044614712,0.020390574,0.001419009],"study_design_scores_gemma":[0.01605506,0.00037007462,0.9546219,0.0007015354,0.0013637246,0.00034012934,0.00026172315,0.000039660088,0.024580998,0.000024709798,0.0008459731,0.0007944796],"about_ca_topic_score_codex":0.010467539,"about_ca_topic_score_gemma":0.0077654314,"teacher_disagreement_score":0.02406324,"about_ca_system_score_codex":0.00038837164,"about_ca_system_score_gemma":0.002423603,"threshold_uncertainty_score":0.99982774},"labels":[],"label_agreement":null},{"id":"W3193211635","doi":"10.1097/hs9.0000000000000617","title":"Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial","year":2021,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Cytarabine; Hazard ratio; Clinical endpoint; Myeloid leukemia; Randomized controlled trial; Surgery; Confidence interval","score_opus":0.021040620247418988,"score_gpt":0.31190299356853796,"score_spread":0.29086237332111897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193211635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905725,0.0003791067,0.0013016607,0.00071547367,0.0002911563,0.005735622,0.00013612914,0.000074931115,0.0007934178],"genre_scores_gemma":[0.9873887,0.00035195332,0.0041867117,0.0007193239,0.0004605745,0.0015818139,0.00096479425,0.0001391929,0.0042069927],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972998,0.00022892178,0.00055633724,0.000643779,0.0006963203,0.0005748681],"domain_scores_gemma":[0.9979571,0.00033334963,0.00017050105,0.0005000932,0.0008518362,0.00018711116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006598194,0.00033539056,0.0011573412,0.00013125916,0.00011270379,0.00005226259,0.00011514989,0.00024514523,0.0005627338],"category_scores_gemma":[0.0005817205,0.00024149765,0.0002627902,0.00064576825,0.00015330147,0.00024778722,0.000055644457,0.0005549182,0.000024604582],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96945876,0.00066111836,0.00049323787,0.000069212656,0.00071553607,0.00011464709,0.0004121431,0.000011495665,0.002886469,0.000058155467,0.0045740423,0.02054521],"study_design_scores_gemma":[0.9175329,0.0038271123,0.00033762868,0.00016175769,0.00024100316,0.000020268519,0.00030651814,0.00019164935,0.07067008,0.00011067274,0.006333383,0.00026699548],"about_ca_topic_score_codex":0.000107549444,"about_ca_topic_score_gemma":0.000056549892,"teacher_disagreement_score":0.06778361,"about_ca_system_score_codex":0.0013903461,"about_ca_system_score_gemma":0.0027989384,"threshold_uncertainty_score":0.98479885},"labels":[],"label_agreement":null},{"id":"W3193677507","doi":"10.1097/mph.0000000000002269","title":"Acute Myeloid Leukemia Presenting as a Posterior Fossa Tumor","year":2021,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Health Sciences Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Myeloid sarcoma; Cerebrospinal fluid; Leukemia; Myeloid; Posterior fossa; Central nervous system; Pathology; Sarcoma; Cancer research; Immunology; Internal medicine; Radiology","score_opus":0.02295720564106036,"score_gpt":0.34671098261811917,"score_spread":0.3237537769770588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193677507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729523,0.004110691,0.0001488958,0.012064237,0.0011491172,0.00036679595,0.000009498609,0.000052075935,0.0091464035],"genre_scores_gemma":[0.95966727,0.0035447679,0.02096194,0.004842038,0.0060338182,0.000039129,0.000024471707,0.00014277754,0.004743808],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9951447,0.0006186453,0.0018278098,0.0005061449,0.00083527283,0.0010674192],"domain_scores_gemma":[0.9944772,0.0011794566,0.0013445101,0.00054249115,0.0016413956,0.0008149363],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014482989,0.00037498953,0.001894816,0.0008240617,0.00017379782,0.000047566242,0.0005185994,0.00062951335,0.00092741934],"category_scores_gemma":[0.0031613836,0.0003182542,0.0005886172,0.0010843431,0.00023030254,0.00028762704,0.0005238849,0.0022650615,0.00041471428],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049286517,0.0017164756,0.13319844,0.0011422092,0.003093438,0.53571457,0.0028635494,0.000013623782,0.078701384,0.0010825036,0.22154939,0.015995735],"study_design_scores_gemma":[0.016949678,0.0049735475,0.008815425,0.000116497125,0.003470659,0.7996136,0.002580858,0.0002491094,0.035115037,0.0011798955,0.12627804,0.00065765367],"about_ca_topic_score_codex":0.000020384545,"about_ca_topic_score_gemma":0.000011640939,"teacher_disagreement_score":0.26389903,"about_ca_system_score_codex":0.0021028428,"about_ca_system_score_gemma":0.016440287,"threshold_uncertainty_score":0.9999859},"labels":[],"label_agreement":null},{"id":"W3194157976","doi":"10.1016/j.jtct.2021.08.007","title":"Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes","year":2021,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; National Heart, Lung, and Blood Institute; U.S. Public Health Service; Health Resources and Services Administration; CytoSen Therapeutics; Kiadis Pharma; Pfizer; Incyte; Kyowa Kirin Pharmaceutical Development; Jazz Pharmaceuticals; Medical College of Wisconsin; Takeda Pharmaceuticals U.S.A.; Meso Scale Diagnostics; AbbVie; National Cancer Institute; Gilead Sciences; Karyopharm Therapeutics; Celgene; Novartis; GlaxoSmithKline; Otsuka America; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Roche; Astellas Pharma US; Falk Foundation; CareDx; Daiichi-Sankyo","keywords":"Medicine; Fludarabine; Busulfan; Melphalan; Alemtuzumab; Internal medicine; Transplantation; Regimen; Hematopoietic stem cell transplantation; Cumulative incidence; Incidence (geometry); Surgery; Gastroenterology; Oncology; Chemotherapy; Cyclophosphamide","score_opus":0.011113389530440035,"score_gpt":0.24564307194107604,"score_spread":0.23452968241063601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194157976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974103,0.0006743775,0.00065665296,0.0003707172,0.000021524129,0.000678829,0.00009272002,0.000023958884,0.00007094211],"genre_scores_gemma":[0.9944043,0.0039373897,0.00076513534,0.00009192858,0.000009132086,0.00002854323,0.00062216294,0.000031602965,0.00010978331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864084,0.00009648408,0.000319714,0.00038034376,0.0003357922,0.00022683886],"domain_scores_gemma":[0.9993521,0.00013156737,0.00008270712,0.00014906125,0.00014967877,0.00013488387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001234766,0.00024204246,0.0005047974,0.00018644084,0.00006292712,0.000027479906,0.00003975033,0.000083384584,0.00003549747],"category_scores_gemma":[0.0000053266676,0.00016969882,0.000024995397,0.000238073,0.0001822443,0.00014497082,0.0000043216546,0.00017774056,5.1889e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010364579,0.0005947738,0.630441,0.0016963844,0.00039612027,0.0005709264,0.00701294,0.000018392248,0.34322262,0.00009196906,0.0000033716474,0.0055868845],"study_design_scores_gemma":[0.026015049,0.00095245166,0.8310705,0.00034300121,0.00018492925,0.00020305897,0.00038924284,0.0001789015,0.14043319,0.000016019956,0.000007843891,0.00020580292],"about_ca_topic_score_codex":0.000079742196,"about_ca_topic_score_gemma":0.00009254855,"teacher_disagreement_score":0.20278943,"about_ca_system_score_codex":0.00002528081,"about_ca_system_score_gemma":0.0001076905,"threshold_uncertainty_score":0.69201165},"labels":[],"label_agreement":null},{"id":"W3194592905","doi":"10.21203/rs.3.rs-55355/v1","title":"CD9 Defines Acute Myeloid Leukemia Stem Cells and is Regulated by Alpha-2-Macroglobulin","year":2020,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China; Fundamental Research Funds for the Central Universities; National Science Foundation","keywords":"Myeloid leukemia; Cancer research; Haematopoiesis; Stem cell; Biology; Flow cytometry; Leukemia; Population; Immunology; Medicine; Cell biology","score_opus":0.05013412141770659,"score_gpt":0.3611106161569655,"score_spread":0.3109764947392589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194592905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91590756,0.013478122,0.00027140984,0.047717012,0.000530057,0.010248224,0.0050982907,0.00092424237,0.0058250697],"genre_scores_gemma":[0.8856824,0.03319339,0.0034500125,0.0026285716,0.0019486473,0.0014011203,0.0031971335,0.00092720153,0.06757151],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98851544,0.0010404362,0.0011132599,0.0028018716,0.004125595,0.0024034237],"domain_scores_gemma":[0.99261093,0.00071356597,0.0002616151,0.0023850964,0.0019143389,0.002114423],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0023862252,0.0010634824,0.0018494078,0.0009427059,0.0005187119,0.00054429314,0.0013427701,0.0017491989,0.00078266824],"category_scores_gemma":[0.00035698406,0.00095422857,0.0004817662,0.0016027443,0.0010629855,0.00017656686,0.005772925,0.008172075,0.0012286308],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027166633,0.00018902964,0.0012897662,0.005736776,0.0015314831,0.002553776,0.0015108568,0.000014192505,0.16280003,0.00012125211,0.80180097,0.01973522],"study_design_scores_gemma":[0.012536697,0.0045585018,0.0037947975,0.00511268,0.000924984,0.00072632736,0.0023137033,0.023563918,0.48160514,0.0026230682,0.4592533,0.0029868688],"about_ca_topic_score_codex":0.0013171933,"about_ca_topic_score_gemma":0.000020433334,"teacher_disagreement_score":0.34254763,"about_ca_system_score_codex":0.003516344,"about_ca_system_score_gemma":0.005133023,"threshold_uncertainty_score":0.99954903},"labels":[],"label_agreement":null},{"id":"W3194823833","doi":"10.1101/2021.08.22.21262430","title":"<i>TP53-</i> mediated clonal hematopoiesis confers increased risk for incident peripheral artery disease","year":2021,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto","funders":"Genentech; National Institutes of Health; Esperion Therapeutics; European Research Area Network on Cardiovascular Diseases; Centro Nacional de Investigaciones Cardiovasculares; Banco Bilbao Vizcaya Argentaria; Fondation Leducq; Sanofi; Kowa Company; Regeneron Pharmaceuticals; Boston Scientific Corporation; Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona; American Heart Association; Fundación BBVA; Ministerio de Ciencia e Innovación; Massachusetts General Hospital; XBiotech; Brigham and Women's Hospital; National Heart, Lung, and Blood Institute; Pfizer; Instituto de Salud Carlos III; Amgen; AstraZeneca","keywords":"Haematopoiesis; Coronary artery disease; Medicine; Bone marrow; Cancer research; Internal medicine; Immunology; Biology; Stem cell; Genetics","score_opus":0.022721317219221295,"score_gpt":0.29376214243931126,"score_spread":0.27104082522009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194823833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98745954,0.0016267578,0.0019254765,0.0035615931,0.00074622873,0.002733101,0.0013102498,0.0002834516,0.00035358345],"genre_scores_gemma":[0.9838786,0.0008840267,0.002832926,0.001998392,0.0010631352,0.0015157028,0.006820865,0.00021270101,0.000793654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946073,0.0005191484,0.0009830189,0.0014612289,0.0014189515,0.0010103299],"domain_scores_gemma":[0.9944383,0.00089497137,0.00044846963,0.0017222903,0.000925756,0.0015702317],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013748939,0.000774504,0.0014866326,0.00035988507,0.00022775968,0.00020683795,0.0006315472,0.0006224954,0.0016141969],"category_scores_gemma":[0.0045092553,0.0007156801,0.0009592521,0.00032043052,0.00037366245,0.00010983451,0.0010766684,0.0020109708,0.00012546396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074519645,0.0014297843,0.91458964,0.006820771,0.0035584818,0.0067886533,0.0017435265,0.00016476508,0.016211737,0.00013531305,0.039743215,0.0013621566],"study_design_scores_gemma":[0.020530662,0.0006480451,0.8845588,0.002993969,0.0047036447,0.0003947079,0.0016835453,0.035498105,0.0087250285,0.0011570787,0.0361435,0.0029629364],"about_ca_topic_score_codex":0.00060563406,"about_ca_topic_score_gemma":0.00011690757,"teacher_disagreement_score":0.035333343,"about_ca_system_score_codex":0.0011740034,"about_ca_system_score_gemma":0.005242706,"threshold_uncertainty_score":0.9995294},"labels":[],"label_agreement":null},{"id":"W3195012238","doi":"10.1002/cam4.4182","title":"Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with <i>IDH2</i> mutations using historical data and propensity score matching analysis","year":2021,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Alberta","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Propensity score matching; Myeloid leukemia; Matching (statistics); IDH2; Oncology; Internal medicine; Refractory (planetary science); Medicine; Biology; Mutation; Genetics; Gene; Pathology; IDH1","score_opus":0.06609593440735194,"score_gpt":0.33554641270442276,"score_spread":0.2694504782970708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195012238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933979,0.0036551296,0.0007267873,0.0010470462,0.0001671824,0.0005063483,0.00026523942,0.000036481466,0.00019786703],"genre_scores_gemma":[0.99664736,0.00056406355,0.001256145,0.000111918656,0.00015930893,0.000021061162,0.000966462,0.00005417736,0.00021953163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971471,0.00019797697,0.0005112667,0.0007584971,0.00095898286,0.00042617385],"domain_scores_gemma":[0.9971167,0.0003696939,0.00030519482,0.0008850249,0.001039058,0.00028434867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059190893,0.000288249,0.0013838018,0.00037536112,0.00012563917,0.000015127424,0.00022544275,0.00015675399,0.00006754233],"category_scores_gemma":[0.0006391014,0.0002052454,0.000049518727,0.002165737,0.00037906773,0.00018603602,0.00021771502,0.0008236815,1.8638465e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067927435,0.00030733948,0.76489896,0.0015872016,0.016268907,0.0072799507,0.01853748,0.0018181925,0.10936491,0.000029751109,0.0011126144,0.010867264],"study_design_scores_gemma":[0.1842082,0.021747714,0.6419475,0.012023625,0.057726923,0.00047363198,0.037566766,0.02119703,0.017293029,0.00003495613,0.0032032102,0.0025773868],"about_ca_topic_score_codex":0.0050549875,"about_ca_topic_score_gemma":0.02454929,"teacher_disagreement_score":0.12295143,"about_ca_system_score_codex":0.0076356824,"about_ca_system_score_gemma":0.0051471144,"threshold_uncertainty_score":0.9961738},"labels":[],"label_agreement":null},{"id":"W3195493284","doi":"10.1016/j.jtct.2021.08.010","title":"Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults","year":2021,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Ottawa Hospital","funders":"Janssen Pharmaceuticals; Janssen Biotech; Janssen Research and Development; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Patient-Centered Outcomes Research Institute; Sanofi Genzyme; Celgene; U.S. Navy; Health Resources and Services Administration; CytoSen Therapeutics; Kyowa Hakko Kirin; Daiichi-Sankyo; Janssen Scientific Affairs; CSL Behring; BC Children's Hospital; National Institutes of Health; Seattle Genetics; National Heart, Lung, and Blood Institute; Shire; Bristol-Myers Squibb; University of Wisconsin-Madison; Mayo Clinic; Government of South Australia; Pfizer; GlaxoSmithKline; U.S. Department of Defense; Boston Children's Hospital; National Cancer Institute; Gilead Sciences","keywords":"Medicine; Internal medicine; Myeloid leukemia; Regimen; Transplantation; Myelodysplastic syndromes; Leukemia; Hematopoietic stem cell transplantation; Oncology; Surgery; Bone marrow","score_opus":0.011797659604740352,"score_gpt":0.2508465873082747,"score_spread":0.23904892770353434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195493284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930429,0.0038799164,0.0009580457,0.0006437663,0.00006224418,0.00086975674,0.00006433974,0.00007366884,0.00040538283],"genre_scores_gemma":[0.91542447,0.08209535,0.00042953817,0.00065847277,0.000023666016,0.000068627975,0.0006774561,0.000051433828,0.000570988],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980536,0.00017923502,0.00042324478,0.0005948412,0.00032505541,0.0004240128],"domain_scores_gemma":[0.9992275,0.000121797275,0.000048991566,0.00022453253,0.000090167465,0.0002870111],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021377059,0.00031241993,0.00044199984,0.00031313192,0.00012116055,0.000043188236,0.00008185876,0.00023204758,0.00017949365],"category_scores_gemma":[0.000005156395,0.0002791112,0.00007363419,0.00052142487,0.000087505396,0.000122018166,0.0000067548194,0.00031455903,0.00003135279],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0098336125,0.00020100242,0.008683694,0.0006276989,0.00035356398,0.013661199,0.016917218,0.00012616294,0.89249057,0.00017943038,0.000016968292,0.056908913],"study_design_scores_gemma":[0.05778856,0.0032710964,0.35104176,0.001101543,0.0004814321,0.017987853,0.0010488792,0.0014724624,0.56377715,0.0003026908,0.00055852544,0.0011680546],"about_ca_topic_score_codex":0.00016974952,"about_ca_topic_score_gemma":0.00009330587,"teacher_disagreement_score":0.34235805,"about_ca_system_score_codex":0.00018793883,"about_ca_system_score_gemma":0.00031698664,"threshold_uncertainty_score":0.9999661},"labels":[],"label_agreement":null},{"id":"W3195611250","doi":"10.1182/blood.v130.suppl_1.2496.2496","title":"The Origin and Functional Impact of Mitochondrial DNA Mutations in Acute Myeloid Leukemia","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Biology; Mitochondrial DNA; Genetics; COLD-PCR; Myeloid leukemia; Gene; Mutation; Myeloid; Genome; Point mutation; Cancer research","score_opus":0.024591861126764494,"score_gpt":0.32432944947917747,"score_spread":0.299737588352413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195611250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99630135,0.00013363782,0.000022973125,0.00076877116,0.00012083647,0.00032550056,0.00002972802,0.000012629405,0.0022845746],"genre_scores_gemma":[0.99740237,0.00015934407,0.00046986403,0.000019519091,0.00031036642,0.000033148684,0.00002351062,0.000015931488,0.0015659707],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99903816,0.00003522308,0.00020852422,0.00018480592,0.00027958135,0.00025373232],"domain_scores_gemma":[0.9989847,0.00019207694,0.00010581551,0.0004967746,0.00010602976,0.00011458792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019637591,0.000108165805,0.00021169017,0.00009456467,0.0002980495,0.00006153164,0.00015817939,0.00008484805,0.00005465356],"category_scores_gemma":[0.00045892378,0.00006890328,0.00009177523,0.00008805779,0.00031777186,0.000120004115,0.00009426216,0.00029085277,0.000019403733],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025689865,0.00054510124,0.45443898,0.00007951764,0.0018717655,0.00039351647,0.0007979164,0.000031889867,0.5167685,0.0017199907,0.011231204,0.009552636],"study_design_scores_gemma":[0.010470261,0.0003739634,0.97607076,0.000047268728,0.00020878942,0.00022582019,0.000067313726,0.0003227694,0.01062019,0.0004420132,0.0010499129,0.0001009219],"about_ca_topic_score_codex":0.0005967787,"about_ca_topic_score_gemma":0.00013745224,"teacher_disagreement_score":0.5216318,"about_ca_system_score_codex":0.00021614444,"about_ca_system_score_gemma":0.0010891815,"threshold_uncertainty_score":0.28097942},"labels":[],"label_agreement":null},{"id":"W3197318018","doi":"10.1002/pbc.29313","title":"Cytarabine dose reduction in patients with low‐risk acute myeloid leukemia: A report from the Children's Oncology Group","year":2021,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Cytarabine; Internal medicine; Hazard ratio; Chemotherapy; Myeloid leukemia; Oncology; Confidence interval; Induction chemotherapy; Leukemia; Gastroenterology","score_opus":0.005906814161995665,"score_gpt":0.2577154745106067,"score_spread":0.25180866034861105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197318018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925621,0.0033666214,0.000024113755,0.0020110547,0.0004581414,0.0010371795,0.00017909524,0.00007498555,0.00028670294],"genre_scores_gemma":[0.9824557,0.010312627,0.0010365738,0.0005524439,0.0037105144,0.00034298573,0.00093098654,0.00008543508,0.0005727422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966919,0.00025226007,0.0006293475,0.00092162576,0.00084563816,0.0006592643],"domain_scores_gemma":[0.9978334,0.00019886407,0.00038866594,0.0009215067,0.0004127393,0.00024486257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004405802,0.0003330597,0.00062907755,0.0001817025,0.00016112848,0.00003489239,0.00024974006,0.0003094422,0.00038825299],"category_scores_gemma":[0.00029310686,0.0002283816,0.00013101943,0.001515947,0.00013691036,0.00017342344,0.00020530896,0.0015636616,0.000036464466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013372602,0.0007039134,0.9786577,0.00003352955,0.0006507574,0.001353337,0.00037823705,0.000052063606,0.0002467301,0.0000032324654,0.008381143,0.0082020825],"study_design_scores_gemma":[0.013506554,0.0005997281,0.98076457,0.000049636503,0.0023488288,0.00043129342,0.00008331418,0.00002468451,0.0004689785,0.000034226705,0.0014122776,0.00027590108],"about_ca_topic_score_codex":0.008058997,"about_ca_topic_score_gemma":0.0008632786,"teacher_disagreement_score":0.012169293,"about_ca_system_score_codex":0.0015411347,"about_ca_system_score_gemma":0.0036690796,"threshold_uncertainty_score":0.9985464},"labels":[],"label_agreement":null},{"id":"W3197580570","doi":"10.1182/bloodadvances.2020004101","title":"Abnormal B-cell development in TIMP-deficient bone marrow","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Lymphopoiesis; Haematopoiesis; Stem cell; Stromal cell; Cell biology; Biology; Bone marrow; Stem cell factor; Progenitor cell; Hematopoietic stem cell; Stromal cell-derived factor 1; Immunology; Cancer research; Chemokine; Inflammation","score_opus":0.012644632326499,"score_gpt":0.2730177191693473,"score_spread":0.2603730868428483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197580570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9613695,0.0133431535,0.00005044043,0.00082653883,0.000104511084,0.00023381031,0.0000035621001,0.00004818889,0.024020307],"genre_scores_gemma":[0.9668673,0.0007415204,0.019821009,0.0005550432,0.000116556854,0.000058905396,0.00005298746,0.00002931566,0.011757317],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983181,0.000043364922,0.00032540623,0.00036582703,0.0004643573,0.00048293974],"domain_scores_gemma":[0.99931675,0.00006673433,0.000049857652,0.00027926522,0.00012603121,0.00016135385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025435636,0.00015179813,0.00029080798,0.00013912519,0.000063274296,0.000019851528,0.00010120304,0.000067726505,0.0003192461],"category_scores_gemma":[0.00012008489,0.00013582868,0.00005103315,0.00046747958,0.000054696677,0.000121436125,0.00013825313,0.00030785138,0.00020733364],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008364389,0.007977755,0.35064808,0.002219155,0.00023207757,0.02475253,0.003459345,0.0004366496,0.38735482,0.00068305794,0.0050115995,0.21638848],"study_design_scores_gemma":[0.005389575,0.00014948023,0.02204736,0.0001774154,0.000037607406,0.0004914277,0.00061728386,0.00006390514,0.6747554,0.00003901018,0.29596722,0.00026432564],"about_ca_topic_score_codex":0.000010277099,"about_ca_topic_score_gemma":0.000077637385,"teacher_disagreement_score":0.32860073,"about_ca_system_score_codex":0.00016485856,"about_ca_system_score_gemma":0.0008503783,"threshold_uncertainty_score":0.55389327},"labels":[],"label_agreement":null},{"id":"W3197918893","doi":"10.1182/blood.2021012304","title":"The journey of a thousand miles begins with 1 step","year":2021,"lang":"en","type":"letter","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Combinatorics; Mathematics","score_opus":0.022881523067450612,"score_gpt":0.27429878945023306,"score_spread":0.25141726638278244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197918893","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04264921,0.0083535435,0.00004878616,0.93052906,0.00015746009,0.00096008606,0.000113467766,0.000058052963,0.017130313],"genre_scores_gemma":[0.013736059,0.009443495,0.009123206,0.792972,0.02403745,0.0003633747,0.0011808504,0.00076845713,0.14837506],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978793,0.00014477606,0.0002807392,0.0003231192,0.0008991057,0.00047294563],"domain_scores_gemma":[0.99807775,0.00043281945,0.0001677385,0.0009000181,0.0003324249,0.00008922944],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0002680241,0.00025020164,0.00056440703,0.00011346092,0.00011345231,0.00004995538,0.00033029664,0.00043362819,0.0001290954],"category_scores_gemma":[0.0001728449,0.00013359556,0.00015999224,0.00026143182,0.0002933729,0.000022488584,0.0001251393,0.002438324,0.000020063535],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072759794,0.00010538935,0.0011236129,0.0004161754,0.0010004145,0.0042855996,0.00012216988,1.2676745e-7,0.00046098954,0.000009933988,0.99179167,0.0006111768],"study_design_scores_gemma":[0.0034700788,0.00041685675,0.00059777265,0.0006977764,0.0008241958,0.0013692528,0.00018915487,0.000005229273,0.0032374177,0.000008991099,0.98901916,0.00016409857],"about_ca_topic_score_codex":0.000083675164,"about_ca_topic_score_gemma":0.00004805043,"teacher_disagreement_score":0.13755704,"about_ca_system_score_codex":0.00007293825,"about_ca_system_score_gemma":0.0013842889,"threshold_uncertainty_score":0.9998631},"labels":[],"label_agreement":null},{"id":"W3197991753","doi":"10.1182/bloodadvances.2020003958","title":"Engraftment characterization of risk-stratified AML in NSGS mice","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Interreg; Instituto de Salud Carlos III; Generalitat de Catalunya; Ministerio de Economía y Competitividad; Health Canada; Centres de Recerca de Catalunya","keywords":"Myeloid leukemia; Bone marrow; Medicine; Leukemia; Haematopoiesis; CD34; Transplantation; Mesenchymal stem cell; Internal medicine; Oncology; Cancer research; Stem cell; Biology; Pathology","score_opus":0.011552938393422744,"score_gpt":0.2844216532935622,"score_spread":0.2728687149001395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197991753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648416,0.001189784,0.00010005432,0.00043506824,0.00006110018,0.000215932,0.00003461387,0.000019865116,0.0014594069],"genre_scores_gemma":[0.99388784,0.0026741326,0.002475471,0.000097225304,0.000093311624,0.000025551837,0.00015474268,0.000012717791,0.00057902146],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990224,0.00007431113,0.000261144,0.00022001048,0.00024150242,0.0001805897],"domain_scores_gemma":[0.99941206,0.00009234301,0.000104569015,0.00020212197,0.00012772939,0.00006120247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014344504,0.000089953006,0.00023702398,0.00008586386,0.00002389923,0.00000811744,0.00006334424,0.000050957235,0.00010233376],"category_scores_gemma":[0.00026792433,0.000080929036,0.00004299105,0.0003463237,0.000044794175,0.00012586657,0.000033373977,0.00018335233,0.000012675688],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012499001,0.00046173958,0.046071604,0.00016684756,0.00005178564,0.00016234636,0.00047799878,0.0000068174368,0.9338143,0.00023773537,0.000011948827,0.018411884],"study_design_scores_gemma":[0.0022529592,0.000116249146,0.18218324,0.00012690658,0.000060581933,0.00003121838,0.0003274183,0.00006899491,0.81073135,0.00012517291,0.0038935856,0.0000823208],"about_ca_topic_score_codex":0.000029670808,"about_ca_topic_score_gemma":0.0000813731,"teacher_disagreement_score":0.13611163,"about_ca_system_score_codex":0.0000458155,"about_ca_system_score_gemma":0.00022007349,"threshold_uncertainty_score":0.33001903},"labels":[],"label_agreement":null},{"id":"W3198245731","doi":"10.1159/000514528","title":"Myeloid Sarcoma Presenting as Obstructive Jaundice","year":2021,"lang":"en","type":"article","venue":"Case Reports in Gastroenterology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Myeloid sarcoma; Medicine; Myeloid leukemia; Myeloproliferative neoplasm; Obstructive jaundice; Myeloid; Myeloid cells; Jaundice; Sarcoma; Internal medicine; Pathology; Bone marrow; Myelofibrosis","score_opus":0.017226265481030158,"score_gpt":0.30493546715536646,"score_spread":0.2877092016743363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198245731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99060166,0.0002156048,0.00012944629,0.001652447,0.00041294048,0.00037041408,0.000004032006,0.0000626318,0.00655084],"genre_scores_gemma":[0.99453884,0.000041004336,0.0023566629,0.0010370099,0.0002459031,0.000057378606,0.00005336125,0.00004451505,0.0016253223],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.997021,0.0002711872,0.0007406913,0.00077390193,0.00033418907,0.00085900363],"domain_scores_gemma":[0.9982237,0.00013440072,0.00022501356,0.0008268007,0.00029391286,0.00029614576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005027405,0.00022783641,0.00055841124,0.0002833519,0.00008646075,0.000025550196,0.00006348151,0.00018451495,0.0004965089],"category_scores_gemma":[0.0013185384,0.00023163029,0.00014749642,0.00032511575,0.00025817778,0.000115182454,0.0003712516,0.00083950127,0.000034124972],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021552606,0.00011594259,0.37026048,0.000050298248,0.00008064353,0.6243479,0.00021040461,0.000008556915,0.0034808135,0.00003190745,0.0004691365,0.00072834484],"study_design_scores_gemma":[0.0014530498,0.0002843638,0.103165746,0.000056444627,0.000057382647,0.88805187,0.0008813605,0.0001361804,0.0032926695,0.0003623299,0.0021679765,0.000090644644],"about_ca_topic_score_codex":0.0002412691,"about_ca_topic_score_gemma":0.00026262752,"teacher_disagreement_score":0.26709473,"about_ca_system_score_codex":0.00047365125,"about_ca_system_score_gemma":0.00046125136,"threshold_uncertainty_score":0.9445609},"labels":[],"label_agreement":null},{"id":"W3199490133","doi":"10.1182/bloodadvances.2021004965","title":"CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"Myeloid leukemia; Biology; Fusion gene; Computational biology; Myeloid; Genetics; Bioinformatics; Cancer research; Gene","score_opus":0.008445822330512004,"score_gpt":0.2703552193312903,"score_spread":0.2619093970007783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199490133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98249775,0.008344562,0.00048798774,0.0021265508,0.00009509542,0.00036211842,0.0000543796,0.00014827991,0.005883289],"genre_scores_gemma":[0.9885857,0.0014350453,0.0067586508,0.0005482311,0.00014248135,0.000048924245,0.00013925754,0.00006399252,0.0022776818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783283,0.000073837444,0.00030299663,0.00065675477,0.0006036173,0.0005299794],"domain_scores_gemma":[0.99875575,0.00015940522,0.00008802908,0.0004465392,0.00023754318,0.00031273847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014589285,0.00033774652,0.00061374484,0.00009594045,0.00018758132,0.00007276152,0.0001504552,0.000104329,0.00007903011],"category_scores_gemma":[0.00030180227,0.0002389341,0.00011141692,0.00037993843,0.0001744257,0.00019269572,0.00011065314,0.0003960827,0.000011390019],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011596221,0.00078272825,0.7070402,0.00108408,0.0016230609,0.019364143,0.0010588303,0.000022892507,0.2166319,0.000813504,0.0005236363,0.049895413],"study_design_scores_gemma":[0.02727617,0.002224982,0.48879158,0.0012444108,0.0033961372,0.0061004898,0.0018190596,0.00033921524,0.3607059,0.0007285329,0.1056791,0.0016944158],"about_ca_topic_score_codex":0.000041259384,"about_ca_topic_score_gemma":0.00017238915,"teacher_disagreement_score":0.21824859,"about_ca_system_score_codex":0.00006814912,"about_ca_system_score_gemma":0.00034889032,"threshold_uncertainty_score":0.97434497},"labels":[],"label_agreement":null},{"id":"W3200826993","doi":"10.1371/journal.pbio.3001394","title":"Interplay between the EMT transcription factors ZEB1 and ZEB2 regulates hematopoietic stem and progenitor cell differentiation and hematopoietic lineage fidelity","year":2021,"lang":"en","type":"article","venue":"PLoS Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Institute of Cancer Research; National Health and Medical Research Council; Canadian Institutes of Health Research; Medical Research Council; University of Manitoba","keywords":"Biology; Haematopoiesis; Stem cell; Progenitor cell; Transcription factor; Cell biology; Hematopoietic stem cell; Cellular differentiation; Genetics; Gene","score_opus":0.028449675092556026,"score_gpt":0.29074574471370807,"score_spread":0.26229606962115204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200826993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950421,0.0023698763,0.00021522354,0.0016682348,0.000055362703,0.0005348757,0.00003966198,0.000046016256,0.000028646717],"genre_scores_gemma":[0.9989072,0.0003722572,0.00012418797,0.00009036907,0.0001225616,0.000028318944,0.00013617986,0.00002231315,0.00019661806],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998542,0.00026267447,0.0003327381,0.00043721372,0.00013208644,0.0002933019],"domain_scores_gemma":[0.9990032,0.00037317103,0.000081310485,0.00027164244,0.00011387742,0.00015682708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019549219,0.000201014,0.00044056258,0.00007359398,0.00013241259,0.000044825956,0.000074166666,0.00023197722,0.000039240298],"category_scores_gemma":[0.00009258871,0.00012848359,0.000052599065,0.0001181803,0.00029266745,0.000060368955,0.00012218361,0.00034377957,0.0000041934627],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010522516,0.00012632119,0.51163167,0.0008435646,0.00021144234,0.000015957168,0.003091287,5.574271e-8,0.48220792,0.00012129719,0.00009866102,0.0015465589],"study_design_scores_gemma":[0.0021285862,0.0004869899,0.30607867,0.00017037649,0.0004541187,0.00017077324,0.0026213853,0.0005984504,0.68613416,0.00058335764,0.00031321988,0.000259926],"about_ca_topic_score_codex":0.000026939577,"about_ca_topic_score_gemma":0.000012447906,"teacher_disagreement_score":0.20555303,"about_ca_system_score_codex":0.000055455366,"about_ca_system_score_gemma":0.00006205163,"threshold_uncertainty_score":0.52394086},"labels":[],"label_agreement":null},{"id":"W3201071899","doi":"10.1182/bloodadvances.2021004881","title":"Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i>-rearranged AML","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"Office of Naval Research; Pharmacyclics; Sanofi Genzyme; Takeda Oncology; Genentech; Health Resources and Services Administration; National Institutes of Health; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; National Institute of Allergy and Infectious Diseases; Angiocrine Bioscience; Karyopharm Therapeutics; Actinium Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Moonshot Research and Development Program; Sanofi; Cancer Moonshot; Medical College of Wisconsin; StemCyte; Memorial Sloan-Kettering Cancer Center; Weill Cornell Medical College; CSL Behring; Bristol-Myers Squibb; Legend Biotech; American Society of Clinical Oncology; GlaxoSmithKline; Be The Match Foundation; Seagen; Astellas Pharma US; Clinical and Translational Science Center, Weill Cornell Medical College; Amgen; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Medac; Jazz Pharmaceuticals","keywords":"Internal medicine; Medicine; Adverse effect; Myeloid leukemia; Oncology; Disease; Transplantation; Leukemia; Risk stratification; Hematopoietic stem cell transplantation","score_opus":0.014142526233996474,"score_gpt":0.28569069142534126,"score_spread":0.2715481651913448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201071899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889662,0.0067952885,0.000014915412,0.001721033,0.00018494052,0.0005711164,0.00022132583,0.000091890666,0.0014332803],"genre_scores_gemma":[0.9695822,0.027208658,0.0010314444,0.0005515862,0.00014422693,0.0002382421,0.00016318056,0.000041683612,0.001038795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773455,0.00027125716,0.00043262934,0.0006256854,0.00047557088,0.0004603013],"domain_scores_gemma":[0.9980594,0.00078691635,0.00019656566,0.0004871887,0.00020809344,0.00026186643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039222307,0.00025310568,0.00052195706,0.00020941507,0.00014505385,0.000024304654,0.00014601811,0.00015097819,0.00012538901],"category_scores_gemma":[0.0025264476,0.00021217226,0.000111790156,0.00039855583,0.00022029867,0.00031924873,0.00019669114,0.00058412965,0.00006941971],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023642337,0.0003581087,0.9699002,0.00012500698,0.00012817532,0.00028098596,0.00052971987,0.000005744642,0.0040919203,0.000011941418,0.00041679907,0.023914961],"study_design_scores_gemma":[0.0054566856,0.0003462545,0.96586037,0.00016744171,0.0002742845,0.000054923763,0.0012622495,0.00014643371,0.014025051,0.00007045435,0.012124628,0.00021123826],"about_ca_topic_score_codex":0.00017319222,"about_ca_topic_score_gemma":0.001507518,"teacher_disagreement_score":0.023703722,"about_ca_system_score_codex":0.00020620308,"about_ca_system_score_gemma":0.00020193408,"threshold_uncertainty_score":0.8652134},"labels":[],"label_agreement":null},{"id":"W3201657639","doi":"10.1182/blood.2021013201","title":"The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"STAT3; Biology; Oxidative phosphorylation; Haematopoiesis; Cancer research; Stem cell; Leukemia; Myeloid leukemia; Citric acid cycle; Population; STAT protein; Cell biology; Signal transduction; Biochemistry; Immunology; Metabolism; Medicine","score_opus":0.016525582536743137,"score_gpt":0.26270489846628364,"score_spread":0.2461793159295405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201657639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99546707,0.0019774772,0.00008520562,0.00044358821,0.00004877892,0.00037117174,0.000048517173,0.00002829188,0.0015299245],"genre_scores_gemma":[0.99384826,0.00032310528,0.0010401981,0.000027902517,0.00006471162,0.000016014343,0.00004712508,0.000030173678,0.0046025035],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984972,0.00016812203,0.00030659698,0.00029092724,0.00045469016,0.00028250244],"domain_scores_gemma":[0.9985207,0.00057020056,0.00013058732,0.00035521755,0.00031612438,0.000107180414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005780605,0.00013478234,0.0002715481,0.000032314252,0.00015360197,0.000038219085,0.00009033929,0.00008911673,0.000045366654],"category_scores_gemma":[0.00021107605,0.00009822488,0.000050059545,0.00026910251,0.00016099791,0.00007515856,0.00012787017,0.0002648693,0.000009033017],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014097673,0.00015832811,0.010661595,0.00017715617,0.00027196924,0.000038684448,0.0010715849,0.0000029580651,0.9723644,0.00022751864,0.001827548,0.013057242],"study_design_scores_gemma":[0.002627542,0.00021255853,0.005033949,0.000089925765,0.000103889215,0.000029327535,0.0016833942,0.0005351501,0.9875067,0.00008394671,0.0019928133,0.000100815174],"about_ca_topic_score_codex":0.00009003322,"about_ca_topic_score_gemma":0.000022111244,"teacher_disagreement_score":0.01514225,"about_ca_system_score_codex":0.00013560633,"about_ca_system_score_gemma":0.00051418965,"threshold_uncertainty_score":0.40054944},"labels":[],"label_agreement":null},{"id":"W3201852707","doi":"10.1182/bloodadvances.2021005308","title":"Bilineal evolution of a <i>U2AF1</i>-mutated clone associated with acquisition of distinct secondary mutations","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Cancer Institute","keywords":"Myeloid; RUNX1; Somatic evolution in cancer; Biology; Mutation; Cancer research; ETV6; Myeloid leukemia; Neuroblastoma RAS viral oncogene homolog; clone (Java method); Genetics; Gene; KRAS; Transcription factor","score_opus":0.008940469371699832,"score_gpt":0.2725094340022355,"score_spread":0.26356896463053564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201852707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99400526,0.0026619455,0.00068152876,0.00036114253,0.00003765982,0.00027178624,0.00022587001,0.000051145264,0.0017036885],"genre_scores_gemma":[0.9960153,0.00007553377,0.0026934228,0.000035513647,0.00005063898,0.000020986374,0.00073744083,0.000019734769,0.0003514253],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986282,0.000104464736,0.0003797181,0.00024643878,0.0004241562,0.00021700212],"domain_scores_gemma":[0.9983366,0.00024798425,0.00024343381,0.00023102626,0.00085525675,0.00008568393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018543619,0.00012446001,0.00038045505,0.00012575167,0.00005972538,0.000005518205,0.000066883804,0.00007532212,0.00014645336],"category_scores_gemma":[0.00050258695,0.000102707585,0.00007408771,0.00090159,0.00023674988,0.00018419152,0.000037132024,0.00020968766,0.0000035064706],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015539161,0.003370587,0.279705,0.0011931948,0.0013548888,0.00070145505,0.0007739029,0.00050944224,0.70226073,0.00080782117,0.0002911874,0.007477902],"study_design_scores_gemma":[0.011208167,0.0016685296,0.47308174,0.0008442543,0.0008384,0.00030617125,0.0014554939,0.00096582004,0.508245,0.0007688938,0.00036095933,0.0002565751],"about_ca_topic_score_codex":0.000064095526,"about_ca_topic_score_gemma":0.000151252,"teacher_disagreement_score":0.19401571,"about_ca_system_score_codex":0.00014194002,"about_ca_system_score_gemma":0.0010127673,"threshold_uncertainty_score":0.41882938},"labels":[],"label_agreement":null},{"id":"W3202261548","doi":"10.30683/1929-2279.2020.09.10","title":"Advances in New Targets for Differentiation Therapy of Acute Myeloid Leukemia","year":2020,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Isocitrate dehydrogenase; Disease; Cancer research; IDH1; Myeloid; Leukemia; Biology; Targeted therapy; IDH2; Homeobox; Lineage (genetic); Gene; Medicine; Bioinformatics; Immunology; Genetics; Internal medicine; Cancer; Enzyme; Transcription factor; Biochemistry; Mutation","score_opus":0.0599990116204127,"score_gpt":0.41815683479093474,"score_spread":0.358157823170522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202261548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9120408,0.045603946,0.0019059135,0.038540468,0.00017201189,0.0012848316,0.0000567761,0.000014221174,0.0003810124],"genre_scores_gemma":[0.868598,0.12726375,0.0023037742,0.00042378437,0.0010533129,0.0000322863,0.000019084819,0.000042548214,0.00026348926],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972363,0.00015458696,0.0006708936,0.00021317552,0.0012270444,0.0004979684],"domain_scores_gemma":[0.99761754,0.0003613229,0.00030114292,0.00016548658,0.0011386527,0.000415835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010662267,0.00014353138,0.00058593944,0.0004890294,0.000053350446,0.000031805666,0.00039844066,0.00009970913,0.0003287929],"category_scores_gemma":[0.0005742964,0.000104071216,0.00018449599,0.0007544129,0.00013582672,0.000471425,0.00007608931,0.0008894304,0.0000048344177],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026388789,0.000213303,0.047111534,0.0005905597,0.0008233032,0.00014049349,0.0022613283,0.00024683747,0.566614,0.00039244472,0.064154595,0.29106286],"study_design_scores_gemma":[0.021147415,0.006121773,0.037994858,0.00076858135,0.00009701875,0.00004133117,0.0006583934,0.0031657524,0.6941436,0.003323885,0.23225929,0.00027811018],"about_ca_topic_score_codex":0.00015401571,"about_ca_topic_score_gemma":0.000058540238,"teacher_disagreement_score":0.29078475,"about_ca_system_score_codex":0.0007829863,"about_ca_system_score_gemma":0.0038534875,"threshold_uncertainty_score":0.68359214},"labels":[],"label_agreement":null},{"id":"W3202676000","doi":"10.1038/s41409-021-01450-3","title":"An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis","year":2021,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Dalhousie University","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; Fred and Pamela Buffett Cancer Center; Markey Cancer Center, University of Kentucky; Juno Therapeutics; Office of Naval Research; Irving Medical Center, Columbia University; Sanofi Genzyme; Legend Biotech; U.S. Navy; University of Florida Health; Kite Pharma; Health Resources and Services Administration; National Institutes of Health; University of Nebraska Medical Center; Christian Medical College, Vellore; Biomedical Advanced Research and Development Authority; University of Miami; King Faisal Specialist Hospital and Research Centre; Astellas Pharma; Daiichi-Sankyo; Gilead Sciences; Dalhousie University; Imperial College London; Cardinal Health; Inselspital, Universitätsspital Bern; Kiadis Pharma; Pharmacyclics; Alexion Pharmaceuticals; bluebird bio; Daiichi Sankyo Europe; Takeda Oncology; Agios Pharmaceuticals; Angiocrine Bioscience; Université Grenoble Alpes; Jazz Pharmaceuticals; Omeros Corporation; Vertex Pharmaceuticals; Leonard M. Miller School of Medicine; University of Bern; U.S. Department of Defense; Medical College of Wisconsin; StemCyte; Massachusetts General Hospital; CareDx; BeiGene; Vanderbilt University Medical Center; Actinium Pharmaceuticals; University of Texas Southwestern Medical Center; CSL Behring; Children's Hospital Los Angeles; Celgene; Falk Foundation; Moffitt Cancer Center; Sanofi; Incyte; Pfizer; Bristol-Myers Squibb; Genentech; AstraZeneca; University of Southern California; Astellas Pharma US; Be The Match Foundation; Novartis Pharmaceuticals Corporation; Amgen; Vanderbilt University","keywords":"Medicine; Internal medicine; Univariate analysis; Transplantation; Oncology; Myeloid leukemia; Multivariate analysis; Hematopoietic stem cell transplantation; Surgery","score_opus":0.01285169456137229,"score_gpt":0.26226112963746995,"score_spread":0.24940943507609767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202676000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8991457,0.00027251098,0.09717811,0.00014407521,0.00008251452,0.0011676466,0.00096857996,0.00017978584,0.00086106645],"genre_scores_gemma":[0.9640342,0.0029339958,0.013568491,0.00020123257,0.00012102599,0.00011921725,0.018455489,0.00012540174,0.00044097047],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9958798,0.00061032013,0.000980066,0.001087214,0.0007550558,0.000687502],"domain_scores_gemma":[0.99764276,0.00026974335,0.00033528093,0.0008374148,0.00048547616,0.00042931284],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005420762,0.00046867563,0.00070850225,0.0005303585,0.00034904087,0.00012808965,0.0002541037,0.00024781362,0.00015266963],"category_scores_gemma":[0.000036873378,0.0004895936,0.00041890095,0.0011900668,0.00008495121,0.000276676,0.0000129173,0.00043451446,0.00005467922],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052837306,0.0012727127,0.23321287,0.0029479444,0.0049670194,0.0020573132,0.006968765,0.012470413,0.71379346,0.00017054287,0.00050905475,0.016346201],"study_design_scores_gemma":[0.017741593,0.0014330503,0.8049719,0.00026612228,0.024184894,0.00044817696,0.00053067715,0.0215965,0.1273499,0.0001536147,0.00015650483,0.0011670701],"about_ca_topic_score_codex":0.00012078268,"about_ca_topic_score_gemma":0.00080467976,"teacher_disagreement_score":0.58644354,"about_ca_system_score_codex":0.0006563433,"about_ca_system_score_gemma":0.0010607998,"threshold_uncertainty_score":0.99975556},"labels":[],"label_agreement":null},{"id":"W3203854025","doi":"10.1038/s41375-021-01427-7","title":"Stress hematopoiesis induces a proliferative advantage in TET2 deficiency","year":2021,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Children's Hospital of Eastern Ontario; Canada's Michael Smith Genome Sciences Centre; Sunnybrook Health Science Centre; University of Ottawa; Dalhousie University","funders":"","keywords":"Haematopoiesis; Biology; Zebrafish; Context (archaeology); Stem cell; Immunology; Myeloid; Cancer research; Bone marrow; Leukemia; Hematopoietic stem cell; Epigenetics; Cell biology; Genetics; Gene","score_opus":0.020542052222839887,"score_gpt":0.3113501834843941,"score_spread":0.2908081312615542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203854025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676784,0.0008809905,0.00007513775,0.0013412654,0.00007415311,0.00043509222,0.000022161332,0.0000764323,0.029416317],"genre_scores_gemma":[0.9931213,0.00013988966,0.0017853267,0.0006318595,0.00012983734,0.000097132055,0.000058916754,0.00003797009,0.0039977394],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997859,0.0001279681,0.0003725013,0.0005291206,0.0005294907,0.0005819264],"domain_scores_gemma":[0.9988256,0.00018175978,0.00006294332,0.0005151196,0.0002122208,0.00020232529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025696433,0.00022001073,0.00045083603,0.00023471628,0.00008461129,0.000047539776,0.00018423659,0.00018671103,0.00042966052],"category_scores_gemma":[0.00067195966,0.00019257002,0.00009265746,0.00096648856,0.00012536436,0.00018137203,0.00019366867,0.0007430999,0.00017808838],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012581842,0.0018310223,0.37327522,0.0027536266,0.00031575025,0.02847566,0.01788323,0.00022933811,0.5227349,0.012618192,0.009687028,0.028937869],"study_design_scores_gemma":[0.007660378,0.00038921932,0.091973394,0.0010060531,0.00008995493,0.0011804377,0.014402273,0.0013299313,0.87605435,0.001102281,0.004084615,0.00072710274],"about_ca_topic_score_codex":0.00012976218,"about_ca_topic_score_gemma":0.00017039651,"teacher_disagreement_score":0.3533195,"about_ca_system_score_codex":0.0017144913,"about_ca_system_score_gemma":0.0028215023,"threshold_uncertainty_score":0.7852778},"labels":[],"label_agreement":null},{"id":"W3204092402","doi":"10.1038/s41408-021-00555-8","title":"6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"Genentech; Aptitude Health; AbbVie","keywords":"Medicine; Chemotherapy; Internal medicine; Oncology; Intensive care medicine","score_opus":0.011538544988294298,"score_gpt":0.27638876329451056,"score_spread":0.26485021830621625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204092402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965754,0.0013534339,0.000051229894,0.0012367612,0.000078617835,0.0005841429,0.000031780535,0.000009626757,0.00007899428],"genre_scores_gemma":[0.9964891,0.0010816982,0.0013698628,0.00037935108,0.0001165439,0.00003316555,0.000023947261,0.000039755687,0.00046657768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987398,0.000040887764,0.00035783328,0.00024221186,0.00024972134,0.0003695716],"domain_scores_gemma":[0.997846,0.00010331486,0.00017620133,0.00016190192,0.0015253178,0.0001872432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016775216,0.00017057238,0.00048419234,0.00015891831,0.00010014603,0.000030354573,0.000079190606,0.000092463684,0.000075481454],"category_scores_gemma":[0.00024391981,0.00012479397,0.00007260736,0.00037856947,0.00009366134,0.00010490835,0.00003548668,0.00037310825,3.471125e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012774601,0.0012004314,0.89679086,0.00026264144,0.0012979157,0.00015254894,0.0012923421,0.000024039195,0.07090185,0.000009479849,0.0015293519,0.013763926],"study_design_scores_gemma":[0.18593921,0.00463375,0.45410895,0.0014633185,0.00067868293,0.00042388355,0.0012148913,0.0006588741,0.3497736,0.00008171214,0.0006305141,0.00039262796],"about_ca_topic_score_codex":0.0002371683,"about_ca_topic_score_gemma":0.00026288084,"teacher_disagreement_score":0.4426819,"about_ca_system_score_codex":0.00016812608,"about_ca_system_score_gemma":0.0012105531,"threshold_uncertainty_score":0.508895},"labels":[],"label_agreement":null},{"id":"W3204954172","doi":"10.1002/pbc.29281","title":"Outcomes of intensification of induction chemotherapy for children with high‐risk acute myeloid leukemia: A report from the Children's Oncology Group","year":2021,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Division of Cancer Prevention, National Cancer Institute","keywords":"Medicine; Cytarabine; Induction chemotherapy; Busulfan; Mitoxantrone; Internal medicine; Etoposide; Fludarabine; Minimal residual disease; Oncology; Cyclophosphamide; Myeloid leukemia; Surgery; Chemotherapy; Gastroenterology; Leukemia","score_opus":0.013087460305668125,"score_gpt":0.2917643961623278,"score_spread":0.27867693585665965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204954172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091744,0.0020471897,0.0005915653,0.004557504,0.00020354618,0.0012379917,0.00037183455,0.000039742914,0.000033210625],"genre_scores_gemma":[0.98157793,0.00972398,0.0051906216,0.0005268508,0.0015907356,0.00031955782,0.000741641,0.00006566959,0.00026301693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787873,0.00010187238,0.00064451277,0.0005549766,0.00050266495,0.00031727058],"domain_scores_gemma":[0.99717665,0.00029946247,0.0008149852,0.0007784535,0.00082988205,0.000100582576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004202209,0.00023681046,0.00075057836,0.00013133913,0.000089869485,0.0000100142115,0.00021886708,0.0002577387,0.00009205249],"category_scores_gemma":[0.00034661122,0.0001547773,0.00019067159,0.00071804976,0.0001687824,0.000089677684,0.00007081297,0.00055741624,0.0000018021069],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007048133,0.00030833232,0.9737806,0.00003992695,0.002799101,0.000019689176,0.00040251485,0.000011666036,0.0039244164,0.000032517244,0.004930012,0.01304644],"study_design_scores_gemma":[0.007208964,0.00057142903,0.96831805,0.000020069872,0.0040356508,0.00028057903,0.00012897227,0.000012557607,0.018872576,0.000093224844,0.0003054859,0.00015242453],"about_ca_topic_score_codex":0.0082225045,"about_ca_topic_score_gemma":0.00035000546,"teacher_disagreement_score":0.014948159,"about_ca_system_score_codex":0.0003725846,"about_ca_system_score_gemma":0.002040689,"threshold_uncertainty_score":0.99838185},"labels":[],"label_agreement":null},{"id":"W3204987244","doi":"10.1111/trf.16703","title":"Risk factors for intracranial hemorrhage in adults with acute leukemia","year":2021,"lang":"en","type":"article","venue":"Transfusion","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Leukocytosis; Acute leukemia; Internal medicine; Platelet; Gastroenterology; Leukemia; Diabetes mellitus; White blood cell; Complication; Propensity score matching; Intracerebral hemorrhage; Surgery","score_opus":0.010727968400068018,"score_gpt":0.2671130494234221,"score_spread":0.2563850810233541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204987244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893784,0.000067169974,0.007940826,0.00065752823,0.00007237715,0.0009828267,0.000090846865,0.00006879817,0.0007412049],"genre_scores_gemma":[0.98459065,0.00075286365,0.013303102,0.00013070785,0.00014353242,0.00006360779,0.00023348354,0.00005507654,0.0007270006],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845797,0.00005920063,0.00025154973,0.00044939033,0.00035146327,0.0004304174],"domain_scores_gemma":[0.99914145,0.000181066,0.000034975368,0.00030860805,0.00015468191,0.00017922981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001855595,0.00019896255,0.00036228073,0.000133191,0.000096122465,0.000016661397,0.00009590959,0.00017490734,0.00027911077],"category_scores_gemma":[0.00007985427,0.0001488286,0.00011212433,0.00044610878,0.00005880893,0.00010173845,0.00002038739,0.0005552147,0.00001744618],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.064706996,0.0015260665,0.18941708,0.0025183954,0.0007525873,0.026318109,0.018493962,0.0002880613,0.3021798,0.00020796333,0.0015054588,0.3920855],"study_design_scores_gemma":[0.11293358,0.0068719024,0.36321384,0.0018033552,0.0014652207,0.003406249,0.007367198,0.080527805,0.417111,0.00037181992,0.0032550883,0.0016729377],"about_ca_topic_score_codex":0.0008097725,"about_ca_topic_score_gemma":0.0011787303,"teacher_disagreement_score":0.39041257,"about_ca_system_score_codex":0.00049811654,"about_ca_system_score_gemma":0.00075571676,"threshold_uncertainty_score":0.60690546},"labels":[],"label_agreement":null},{"id":"W3205063602","doi":"10.1016/s1470-2045(21)00494-0","title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; National Cancer Institute; Medical Research Council; National Institute for Health and Care Research; Bristol-Myers Squibb","keywords":"Azacitidine; Medicine; IDH2; Internal medicine; Myeloid leukaemia; Population; Clinical endpoint; Myeloid leukemia; Oncology; Myeloid; Clinical trial; Surgery; IDH1; Mutant; Biology","score_opus":0.04659093949864618,"score_gpt":0.34979027695407056,"score_spread":0.3031993374554244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205063602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98254365,0.0005975175,0.00013881407,0.009611357,0.00066268584,0.003648409,0.0002592845,0.00013056948,0.002407724],"genre_scores_gemma":[0.9904414,0.0013816729,0.001712124,0.0022046028,0.0020507101,0.0005776241,0.00090144156,0.00012865226,0.00060181087],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99473166,0.0010044804,0.0009818564,0.0009916425,0.0008450841,0.001445256],"domain_scores_gemma":[0.99497616,0.002653814,0.00038347923,0.001077375,0.0003838055,0.0005253468],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014915753,0.0006086588,0.002431788,0.00033765868,0.00023683111,0.0000861112,0.00046490403,0.000439048,0.0004567417],"category_scores_gemma":[0.0017197808,0.00043009684,0.00018296116,0.0010081774,0.00074202736,0.00026545447,0.00035658482,0.0014793496,0.00005629805],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93028367,0.007258024,0.0004327708,0.000108789885,0.000951082,0.010125466,0.0011860823,0.000016842208,0.011414046,0.00010499758,0.0052536433,0.032864567],"study_design_scores_gemma":[0.942632,0.022476442,0.00031657406,0.00015225586,0.0007895258,0.00057820074,0.00040239812,0.00047044354,0.0071697985,0.000069437476,0.024481036,0.00046185468],"about_ca_topic_score_codex":0.00019745922,"about_ca_topic_score_gemma":0.00061420485,"teacher_disagreement_score":0.032402713,"about_ca_system_score_codex":0.0020134083,"about_ca_system_score_gemma":0.0022326703,"threshold_uncertainty_score":0.9998151},"labels":[],"label_agreement":null},{"id":"W3205545929","doi":"10.1111/ejh.13717","title":"Use of midostaurin in mixed phenotype acute leukemia with <i>FLT3</i> mutation: A case series","year":2021,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"Midostaurin; Medicine; Discontinuation; Myeloid leukemia; Internal medicine; Oncology; Induction chemotherapy; Leukemia; Chemotherapy; Immunology","score_opus":0.03234183208156242,"score_gpt":0.27892429858555096,"score_spread":0.24658246650398855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205545929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954433,0.0004937095,0.0005207443,0.0021831908,0.000120685305,0.00012425923,0.000008532652,0.000010767193,0.0010948373],"genre_scores_gemma":[0.98187244,0.00014080353,0.01697445,0.00028708545,0.00007819143,0.0000010450437,0.000009832457,0.0000507249,0.0005854261],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99751776,0.0008670186,0.0008142797,0.00019672823,0.00030525198,0.00029894616],"domain_scores_gemma":[0.9981131,0.0002185757,0.00042013303,0.00032624378,0.0007351835,0.00018674422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059540063,0.00016904839,0.00076448434,0.00030703357,0.00003873053,0.000020994932,0.00013428346,0.000048809867,0.00012097256],"category_scores_gemma":[0.000468062,0.00012982462,0.000103552986,0.0004965424,0.0002603756,0.00025727568,0.00010249094,0.0006343681,0.000025494342],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023198416,0.00010792179,0.0036444482,0.00015871075,0.0003439525,0.9805339,0.0010061393,0.00010920956,0.0077335117,0.0003020133,0.0021713113,0.0015690682],"study_design_scores_gemma":[0.0043307263,0.0012728354,0.004722022,0.00032499657,0.00020345513,0.96104753,0.0012344833,0.00006169938,0.023208553,0.000027288595,0.003443151,0.00012325154],"about_ca_topic_score_codex":0.00001912953,"about_ca_topic_score_gemma":0.00010289491,"teacher_disagreement_score":0.019486334,"about_ca_system_score_codex":0.00017120372,"about_ca_system_score_gemma":0.0012565341,"threshold_uncertainty_score":0.5294094},"labels":[],"label_agreement":null},{"id":"W3206778834","doi":"10.1038/s41591-021-01521-4","title":"Distinction of lymphoid and myeloid clonal hematopoiesis","year":2021,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":298,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Howard Hughes Medical Institute; Medical Research Council; Fondation Leducq; Massachusetts General Hospital; Knut och Alice Wallenbergs Stiftelse; Deutsche Forschungsgemeinschaft; Damon Runyon Cancer Research Foundation; Leukemia and Lymphoma Society; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Myeloid; Haematopoiesis; Somatic cell; Biology; Immunology; Somatic evolution in cancer; Lineage (genetic); Cancer; Gene; Genetics; Stem cell","score_opus":0.010114019878610532,"score_gpt":0.3045070579499828,"score_spread":0.29439303807137224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206778834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9467216,0.014700133,0.00025620364,0.022495877,0.00036925115,0.00023608297,0.000013842436,0.00005671162,0.015150272],"genre_scores_gemma":[0.9917262,0.00073042366,0.0014293968,0.0016158521,0.0007214246,0.000008195012,0.00012152003,0.000024539939,0.003622429],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984368,0.000053626947,0.00030323977,0.0003173816,0.0006577464,0.0002311946],"domain_scores_gemma":[0.99867606,0.00023916272,0.000081170736,0.000338796,0.00045581043,0.00020899458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000367896,0.00015251154,0.0004928897,0.00015572908,0.00005480104,0.000004072543,0.000069233894,0.00031022233,0.00076677254],"category_scores_gemma":[0.0015288035,0.00011036807,0.000056441964,0.00053089845,0.0003309627,0.000045319684,0.0000867886,0.00067972706,0.0000085459],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016143973,0.00041902685,0.10169936,0.0025630721,0.0005740226,0.0018716106,0.0012224135,9.4146196e-7,0.748623,0.010878623,0.08165353,0.04888001],"study_design_scores_gemma":[0.01784264,0.0013362501,0.34733337,0.0019103297,0.0007676625,0.012531929,0.002262665,0.0005449588,0.45977372,0.0019135639,0.15330097,0.00048195684],"about_ca_topic_score_codex":0.00004043957,"about_ca_topic_score_gemma":0.000011870324,"teacher_disagreement_score":0.2888493,"about_ca_system_score_codex":0.00014725425,"about_ca_system_score_gemma":0.0003383807,"threshold_uncertainty_score":0.8395622},"labels":[],"label_agreement":null},{"id":"W3208012644","doi":"10.1038/s41408-021-00565-6","title":"Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy","year":2021,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Oncology; Intensive care medicine; Pediatrics","score_opus":0.01351894866652132,"score_gpt":0.28720051549605913,"score_spread":0.2736815668295378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208012644","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96947503,0.010604035,0.00010494165,0.0030058483,0.012581903,0.00310056,0.0002457355,0.000046899808,0.0008350637],"genre_scores_gemma":[0.43671155,0.028588014,0.0043985755,0.002383243,0.010167708,0.0009517791,0.0026398269,0.00106994,0.51308936],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99745935,0.000092620794,0.00074369635,0.00053521525,0.00054757664,0.0006215515],"domain_scores_gemma":[0.9955081,0.00015578096,0.0006394003,0.00031314362,0.0030588275,0.00032474304],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030856737,0.00046864,0.0013110322,0.0004926337,0.00020882252,0.00007809241,0.00018084008,0.0005357617,0.00016512541],"category_scores_gemma":[0.00051707745,0.00035643176,0.00019692765,0.0006687738,0.00017575105,0.00012743469,0.00006821754,0.0019973244,4.9539136e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0201164,0.0015643697,0.09920411,0.0011236287,0.004062903,0.00024336482,0.001535967,0.000019756826,0.0022859932,0.0000017019477,0.8533177,0.016524142],"study_design_scores_gemma":[0.45301992,0.031819683,0.28279004,0.03368616,0.008648158,0.0030476379,0.0051240316,0.0044959947,0.050289515,0.00007467562,0.123647384,0.0033567974],"about_ca_topic_score_codex":0.0007298398,"about_ca_topic_score_gemma":0.0007406848,"teacher_disagreement_score":0.7296703,"about_ca_system_score_codex":0.00058775104,"about_ca_system_score_gemma":0.004460967,"threshold_uncertainty_score":0.9998888},"labels":[],"label_agreement":null},{"id":"W3208200442","doi":"10.1084/jem.20211872","title":"<i>Dnmt3a</i> -mutated clonal hematopoiesis promotes osteoporosis","year":2021,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; Lady Davis Institute for Medical Research; National Heart, Lung, and Blood Institute; Brigham Research Institute; National Institutes of Health; Fondation de l'Hôpital général juif; Jewish General Hospital; Knut och Alice Wallenbergs Stiftelse; American Society of Hematology; Cancer Research UK; McGill University; Public Health Agency of Canada; Fondation Leducq; Edward P. Evans Foundation; Canadian Institutes of Health Research; Damon Runyon Cancer Research Foundation; Compute Canada; Deutsche Forschungsgemeinschaft; Burroughs Wellcome Fund; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Medical Research Council; Howard Hughes Medical Institute","keywords":"Proinflammatory cytokine; Bone marrow; Haematopoiesis; Cancer research; Osteoporosis; Skeletal disorder; Somatic cell; Inflammation; Biology; Immunology; Cell biology; Genetics; Stem cell; Gene; Endocrinology","score_opus":0.027398801573598707,"score_gpt":0.33180986895521114,"score_spread":0.30441106738161244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208200442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.949988,0.01785537,0.00006078847,0.027046679,0.00037836662,0.00026867757,0.0000032952348,0.000023457236,0.004375347],"genre_scores_gemma":[0.9934353,0.0005068839,0.001163648,0.002528583,0.00092531793,0.0000056504664,0.00001269599,0.000041132906,0.0013807704],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973156,0.00023812136,0.0007693845,0.00016101985,0.0011560926,0.00035976726],"domain_scores_gemma":[0.9979659,0.00038723362,0.00032692094,0.00039281807,0.0005705862,0.00035655932],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011250675,0.0002222795,0.0006708968,0.0001472476,0.00014103013,0.000013513807,0.00028758403,0.00008394882,0.00223077],"category_scores_gemma":[0.0006192865,0.000121036224,0.00016213817,0.0005280545,0.0004759454,0.00013041879,0.00014447112,0.0006545426,0.000039439696],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000995735,0.00034551165,0.00044220424,0.000047442147,0.0002830851,0.0011259913,0.0042472105,0.0000012478156,0.96471626,0.00007864055,0.027167382,0.0005493117],"study_design_scores_gemma":[0.005473571,0.0021329012,0.00081301766,0.0005819452,0.00027986433,0.017050762,0.016384842,0.000050820086,0.95380807,0.00010879453,0.0031987524,0.000116638206],"about_ca_topic_score_codex":0.000044293436,"about_ca_topic_score_gemma":0.0000019815275,"teacher_disagreement_score":0.043447297,"about_ca_system_score_codex":0.0003440725,"about_ca_system_score_gemma":0.00050334336,"threshold_uncertainty_score":0.9986813},"labels":[],"label_agreement":null},{"id":"W3208315316","doi":"10.2139/ssrn.3578143","title":"Macaque Age-Related Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Therapeutic Approaches","year":2020,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université du Québec à Montréal","funders":"","keywords":"Haematopoiesis; Rhesus macaque; Macaque; Biology; Genetics; Computational biology; Virology; Immunology; Stem cell; Neuroscience","score_opus":0.0937907030504465,"score_gpt":0.30095167068922274,"score_spread":0.20716096763877623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208315316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95570743,0.004435842,0.03366777,0.0049490645,0.000019019793,0.0007289994,0.000012981982,0.00006651946,0.0004123866],"genre_scores_gemma":[0.99342793,0.0006637033,0.00545585,0.00013214616,0.00009903748,0.000019500672,0.000017517235,0.000046726942,0.00013759396],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99716794,0.00010321652,0.0005665093,0.00035122724,0.00037363096,0.0014374555],"domain_scores_gemma":[0.9988353,0.00032223845,0.000219358,0.0001610023,0.00021932334,0.00024276316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011268128,0.00024156111,0.00052165025,0.00011765881,0.0002109695,0.000029977069,0.00017997599,0.00018690272,0.000010663408],"category_scores_gemma":[0.00049405405,0.00019184327,0.00015945932,0.0003695066,0.00025105002,0.00013850347,0.00006390695,0.0016244425,0.0000013622862],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009737428,0.0011514546,0.060145542,0.0026077922,0.0047958605,0.00015027929,0.005690747,0.0018726792,0.47590557,0.08235886,0.00033447245,0.35524932],"study_design_scores_gemma":[0.006054791,0.002389737,0.0018159042,0.00018810047,0.0005256277,0.0021718836,0.005094215,0.8083281,0.016900385,0.15609886,0.000040538984,0.0003918955],"about_ca_topic_score_codex":0.000023903032,"about_ca_topic_score_gemma":0.000018365883,"teacher_disagreement_score":0.8064554,"about_ca_system_score_codex":0.00034708687,"about_ca_system_score_gemma":0.0035842925,"threshold_uncertainty_score":0.7823142},"labels":[],"label_agreement":null},{"id":"W3208720801","doi":"10.1182/blood.v130.suppl_1.271.271","title":"Next Generation Sequencing (NGS)-Based Post-Transplant Monitoring in Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HCT)","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Transplantation; Myeloid leukemia; Stem cell; Hematopoietic stem cell transplantation; Medicine; Haematopoiesis; Hematologic Neoplasms; Leukemia; Hematopoietic cell; Myeloid; Cancer research; Oncology; Immunology; Internal medicine; Biology; Genetics","score_opus":0.03809514935073274,"score_gpt":0.27424933861959705,"score_spread":0.2361541892688643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208720801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99752593,0.00019577741,0.00031500467,0.00018904121,0.0002746489,0.00088254194,0.00004361171,0.000090338486,0.0004831228],"genre_scores_gemma":[0.9965985,0.0005729583,0.0017687037,0.00011240458,0.00029570312,0.000098816105,0.00029905626,0.0000811028,0.0001727507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972934,0.00013000055,0.0005881768,0.00062333257,0.00069499045,0.00067008415],"domain_scores_gemma":[0.9983846,0.00009340763,0.00025568422,0.0007786303,0.00024178697,0.00024591014],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004654699,0.0003498415,0.0004556808,0.00031435041,0.00043813224,0.0001999144,0.00039363911,0.00027787776,0.00001837648],"category_scores_gemma":[0.000039220373,0.00034094043,0.00013499569,0.00016237173,0.00007493606,0.0005041611,0.000041505984,0.00055957533,0.000049880753],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021226317,0.00017948738,0.32936117,0.00045779688,0.00007464262,0.0006461322,0.0018179982,0.00018015181,0.6644633,0.0000031340342,0.000009761593,0.0025941392],"study_design_scores_gemma":[0.009249716,0.00034909774,0.2859504,0.00071341806,0.00043648283,0.00010985284,0.00020298785,0.0018688941,0.70074964,0.0000032246273,0.000010923313,0.0003553515],"about_ca_topic_score_codex":0.0006733403,"about_ca_topic_score_gemma":0.0001942054,"teacher_disagreement_score":0.043410793,"about_ca_system_score_codex":0.0010920728,"about_ca_system_score_gemma":0.00096305966,"threshold_uncertainty_score":0.9999043},"labels":[],"label_agreement":null},{"id":"W3208762835","doi":"10.1038/s41408-021-00568-3","title":"A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia","year":2021,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Menzies Centre for Australian Studies, King's College London, University of London; Gillings School of Public Health; Sidney Kimmel Comprehensive Cancer Center; King's College London; CHILDREN with CANCER UK; Johns Hopkins University","keywords":"Mitoxantrone; Cytarabine; Myeloid leukemia; Medicine; Biomarker; Internal medicine; Oncology; Refractory (planetary science); Hematology; Leukemia; Myeloid; Cancer research; Chemotherapy; Chemistry; Biology","score_opus":0.01458154797642146,"score_gpt":0.28983538762658784,"score_spread":0.27525383965016637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208762835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7309856,0.07091937,0.000094295545,0.19291441,0.00086996873,0.0017240319,0.0015328481,0.00006192904,0.00089754444],"genre_scores_gemma":[0.38545468,0.22830683,0.004471084,0.2928491,0.015339953,0.0015084893,0.004927352,0.001532198,0.065610304],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99342006,0.00053275627,0.0015389078,0.0011967839,0.0020837518,0.0012277563],"domain_scores_gemma":[0.9965597,0.00030458492,0.0010484534,0.0008415704,0.0007988197,0.00044691315],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0010142758,0.00082650094,0.0028975373,0.0022177128,0.00016459107,0.00013255312,0.0005096432,0.0013940298,0.0011962729],"category_scores_gemma":[0.00022462466,0.00071862683,0.0008840174,0.002333803,0.00034155318,0.00024595644,0.0002868633,0.00745647,0.0000070345554],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014870317,0.000512254,0.05333966,0.00045205027,0.049522042,0.015479155,0.00055509224,0.000013767176,0.08081774,0.000001065995,0.79578567,0.002034497],"study_design_scores_gemma":[0.11387697,0.0055047437,0.18231386,0.0072797756,0.18714596,0.013210463,0.001086883,0.0014296331,0.058448695,0.00013293244,0.42435062,0.005219458],"about_ca_topic_score_codex":0.0014081367,"about_ca_topic_score_gemma":0.00039731388,"teacher_disagreement_score":0.37143502,"about_ca_system_score_codex":0.0043115737,"about_ca_system_score_gemma":0.0049707764,"threshold_uncertainty_score":0.99990237},"labels":[],"label_agreement":null},{"id":"W3209503376","doi":"10.1016/j.leukres.2021.106735","title":"RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia","year":2021,"lang":"en","type":"letter","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto; Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Venetoclax; Myeloid leukemia; Medicine; Refractory (planetary science); Myeloid; Oncology; Leukemia; Cancer research; Internal medicine; Biology; Chronic lymphocytic leukemia","score_opus":0.04014037466090893,"score_gpt":0.3415210087808559,"score_spread":0.301380634119947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209503376","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6057605,0.0011489707,0.00007992688,0.38276762,0.00040117468,0.00490616,0.00018926941,0.00028362338,0.0044627176],"genre_scores_gemma":[0.295983,0.0031593735,0.005878705,0.35762104,0.005907565,0.007773433,0.010049772,0.002352475,0.31127468],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9829174,0.004281534,0.0013822429,0.0024888753,0.005661562,0.0032683716],"domain_scores_gemma":[0.9881785,0.0049592974,0.00023799129,0.0030270228,0.0027851677,0.00081200653],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.005903747,0.0011626732,0.0018704393,0.005211424,0.00067982916,0.00046360507,0.0015223104,0.0030079102,0.0007914444],"category_scores_gemma":[0.0025281701,0.001051922,0.0003781363,0.00611896,0.0011460553,0.0003441814,0.00088860915,0.021884497,0.0016263278],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.014673069,0.00017589735,0.00070867373,0.00072026806,0.0011044987,0.045855694,0.0042573507,0.00055314077,0.019789776,0.00007754599,0.90857667,0.0035074013],"study_design_scores_gemma":[0.01687756,0.005647009,0.021929218,0.0037413014,0.00032985388,0.0016262176,0.0017840718,0.0021601284,0.0026794905,0.00039584973,0.94105,0.0017792969],"about_ca_topic_score_codex":0.0021948968,"about_ca_topic_score_gemma":0.00034129084,"teacher_disagreement_score":0.30977756,"about_ca_system_score_codex":0.06091841,"about_ca_system_score_gemma":0.042216472,"threshold_uncertainty_score":0.99919313},"labels":[],"label_agreement":null},{"id":"W3209797585","doi":"","title":"Clinical Utility of Next Generation Sequencing in Diagnosis, Prognosis and Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome","year":2021,"lang":"en","type":"article","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quest University Canada","funders":"","keywords":"CEBPA; Medicine; NPM1; Myeloid leukemia; Oncology; Internal medicine; Myelodysplastic syndromes; Leukemia; Bone marrow; Mutation; Biology; Gene; Karyotype; Genetics","score_opus":0.10551686574467328,"score_gpt":0.35195658532655166,"score_spread":0.24643971958187838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209797585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99743575,0.001130024,0.00007766944,0.000401201,0.00004554013,0.0005782979,0.000022983682,0.00001618069,0.00029232848],"genre_scores_gemma":[0.98467976,0.010255715,0.004599151,0.00006028781,0.000047313613,0.000086860186,0.000053198077,0.000016592745,0.00020112137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980316,0.00019025916,0.0007602513,0.00047855495,0.0002829451,0.0002563474],"domain_scores_gemma":[0.9986878,0.00051783555,0.00011324002,0.00029726542,0.00019262245,0.00019124566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004476285,0.0001772438,0.00074181904,0.00014863019,0.00003330805,0.000016763564,0.00004549329,0.00018474604,0.00015297877],"category_scores_gemma":[0.00032310237,0.00014197525,0.000086254586,0.00033833706,0.00026399465,0.0001291109,0.00009412574,0.00017880522,0.0000021429007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019080029,0.00030661805,0.9108429,0.00025017225,0.00036679447,0.0006157639,0.00034913846,0.0000035254066,0.029618843,0.0000607326,0.0001383877,0.057256315],"study_design_scores_gemma":[0.0049768295,0.0020769113,0.8840381,0.00024250649,0.0004447339,0.00053746055,0.0004012661,0.027355848,0.079569355,0.00003302664,0.00015740411,0.0001665673],"about_ca_topic_score_codex":0.0006610117,"about_ca_topic_score_gemma":0.00034207845,"teacher_disagreement_score":0.05708975,"about_ca_system_score_codex":0.0005954959,"about_ca_system_score_gemma":0.0013626765,"threshold_uncertainty_score":0.5789583},"labels":[],"label_agreement":null},{"id":"W3210311214","doi":"10.1111/ijlh.13747","title":"Reducing cytogenetic testing in the era of next generation sequencing: Are we choosing wisely?","year":2021,"lang":"en","type":"article","venue":"International Journal of Laboratory Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Medicine; Turnaround time; Cytogenetics; Bone marrow; Hematopathology; DNA sequencing; Dysplasia; Myeloid; Computational biology; Pathology; Bioinformatics; Internal medicine; Computer science; Chromosome; Genetics; Biology; DNA","score_opus":0.12796321728871438,"score_gpt":0.3596678985777841,"score_spread":0.2317046812890697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210311214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814019,0.0035917065,0.00040826877,0.013874333,0.00046168934,0.00008499977,0.0000063900725,0.0000050589992,0.00016563834],"genre_scores_gemma":[0.99096274,0.00035891385,0.007252777,0.0008641296,0.00052725436,0.0000033457723,0.0000056773756,0.000015238051,0.000009904437],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99799454,0.00030458454,0.000757445,0.00015438374,0.00061448116,0.00017458324],"domain_scores_gemma":[0.99587655,0.00039523686,0.0005742868,0.00018106033,0.0029063358,0.00006650318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008134086,0.00010643688,0.0003547927,0.00025262474,0.000036730828,0.00003740819,0.00029108924,0.000098598546,0.00007264937],"category_scores_gemma":[0.0023388048,0.00008278974,0.00007102237,0.0005287988,0.000087949156,0.00017564629,0.000054834407,0.0006817006,0.0000035177586],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001318645,0.00017097376,0.06886261,0.0000982116,0.00021222806,0.0071217916,0.0015795246,0.0010089033,0.9150002,0.0007220575,0.0015933083,0.0034983524],"study_design_scores_gemma":[0.0054506757,0.00046151236,0.024608145,0.00369738,0.00017510192,0.04636086,0.009343195,0.012526745,0.8936509,0.0009241969,0.0024798224,0.00032147294],"about_ca_topic_score_codex":0.000017173237,"about_ca_topic_score_gemma":0.00002020173,"teacher_disagreement_score":0.04425446,"about_ca_system_score_codex":0.00043570367,"about_ca_system_score_gemma":0.002188449,"threshold_uncertainty_score":0.38822147},"labels":[],"label_agreement":null},{"id":"W3211352653","doi":"10.1182/blood-2021-145854","title":"Transcriptomic Features of Immune Exhaustion and Senescence Predict Outcomes and Define Checkpoint Blockade-Unresponsive Microenvironments in Acute Myeloid Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Immune checkpoint; Myeloid leukemia; Medicine; Oncology; Internal medicine; Immunology; Immune system; Immunotherapy","score_opus":0.00876558264766543,"score_gpt":0.24904633955645578,"score_spread":0.24028075690879036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211352653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99268854,0.0053892983,0.000023778945,0.0012160992,0.000039742798,0.00044490478,0.00005597731,0.000022854394,0.00011878436],"genre_scores_gemma":[0.9924421,0.0043156315,0.0018547042,0.00013141215,0.00002814901,0.000025973644,0.000057371675,0.000032625692,0.001112082],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998251,0.00010950524,0.00046613356,0.00046834187,0.00033994453,0.00036503252],"domain_scores_gemma":[0.99919057,0.00011695673,0.00009857211,0.00036912455,0.00006505614,0.00015971003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029647385,0.00024411749,0.000611984,0.00020308746,0.00005161371,0.000018158173,0.000095993586,0.00018462416,0.000036084566],"category_scores_gemma":[0.00020651297,0.0002187654,0.00009119982,0.00024228594,0.00024988642,0.00009217438,0.00014958138,0.00044342855,0.0000036701],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052871415,0.00023015318,0.1648936,0.00018942813,0.00027055366,0.00053188746,0.00049061707,0.0000014795863,0.8316075,0.000010437854,0.000031927353,0.0012136865],"study_design_scores_gemma":[0.0067333723,0.00015385413,0.58063895,0.00015756152,0.00027441565,0.0007502939,0.00021050265,0.000022182421,0.410886,0.000019084142,0.000050597988,0.00010321246],"about_ca_topic_score_codex":0.0001512018,"about_ca_topic_score_gemma":0.000036684287,"teacher_disagreement_score":0.4207215,"about_ca_system_score_codex":0.00018819478,"about_ca_system_score_gemma":0.0003364198,"threshold_uncertainty_score":0.89209944},"labels":[],"label_agreement":null},{"id":"W3211430792","doi":"10.1182/blood-2021-154143","title":"Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor \"Triplet\" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Venetoclax; Internal medicine; Regimen; Oncology; Chemotherapy regimen; Salvage therapy; Gastroenterology; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.017150608256754806,"score_gpt":0.2574034655527049,"score_spread":0.24025285729595008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211430792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99576265,0.0014972968,0.000014625955,0.0006124711,0.000059414084,0.0014322718,0.00004554059,0.000070253416,0.00050549646],"genre_scores_gemma":[0.99600345,0.0006728327,0.0016234497,0.00070147077,0.0001868461,0.00014243816,0.00014817675,0.000109160224,0.00041216897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721956,0.00019034886,0.00037333646,0.0007379779,0.00083295867,0.00064578746],"domain_scores_gemma":[0.9983001,0.00019054873,0.00016495978,0.00050530524,0.0005628763,0.00027624858],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022811169,0.00038641118,0.0005916795,0.00028256528,0.0001320939,0.00006894709,0.0001373629,0.00018553475,0.00016407187],"category_scores_gemma":[0.000111951646,0.0002766191,0.00006490693,0.001104416,0.00015598658,0.00018952752,0.000084013845,0.00066778343,0.000019438143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012276906,0.0057435026,0.6873661,0.0003078095,0.0029023034,0.003079147,0.017098136,0.000038168622,0.10375025,0.000033328004,0.0012463556,0.16615798],"study_design_scores_gemma":[0.059304483,0.0029974994,0.60697085,0.00048888684,0.00009681175,0.000076941535,0.00083027594,0.000112284186,0.32629788,0.000029512637,0.0022918368,0.0005027511],"about_ca_topic_score_codex":0.0002190091,"about_ca_topic_score_gemma":0.000058750436,"teacher_disagreement_score":0.22254762,"about_ca_system_score_codex":0.0003771802,"about_ca_system_score_gemma":0.00094140554,"threshold_uncertainty_score":0.9999686},"labels":[],"label_agreement":null},{"id":"W3211445741","doi":"10.1182/blood-2021-145491","title":"KDM6 Demethylases Integrate DNA Repair Gene Regulation: Loss of KDM6A Sensitizes AML to PARP Inhibition and Potentiates with BCL2 Blockade","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Cancer research; Myeloid leukemia; DNA repair; Synthetic lethality; Biology; Carcinogenesis; Leukemia; Small hairpin RNA; DNA damage; PARP inhibitor; Gene knockdown; Poly ADP ribose polymerase; Cancer; Genetics; Gene; DNA; Polymerase","score_opus":0.011444731214741787,"score_gpt":0.24903668557681397,"score_spread":0.23759195436207217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211445741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99578834,0.0007174283,0.00032774245,0.0022864428,0.000025558345,0.00033030793,0.000030563053,0.00009865877,0.0003949528],"genre_scores_gemma":[0.98318815,0.00017325861,0.015216011,0.00025413863,0.0001933224,0.000018671553,0.00011511022,0.000034982615,0.0008063807],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984563,0.00012082149,0.00031523017,0.0004212863,0.00039770806,0.00028867132],"domain_scores_gemma":[0.998621,0.00012499033,0.000085625856,0.00040020034,0.00055501907,0.00021319446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002535626,0.00017894286,0.0003876077,0.0001643905,0.00007375299,0.000022362796,0.000038652634,0.00010817089,0.000080742],"category_scores_gemma":[0.00030962322,0.00014474112,0.0000767206,0.000518732,0.00015069127,0.00007737764,0.00010943852,0.00019348439,0.000012258714],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047539335,0.00038053407,0.017255988,0.00026222665,0.00041867347,0.0017253339,0.00040073408,0.000023059243,0.97729254,0.00013381569,0.000694074,0.00093765504],"study_design_scores_gemma":[0.0034321928,0.00056320394,0.037983526,0.00030971848,0.00036667177,0.001683583,0.00042771845,0.00015820119,0.9544109,0.00012575336,0.00038242262,0.00015610969],"about_ca_topic_score_codex":0.000069666916,"about_ca_topic_score_gemma":0.00007716546,"teacher_disagreement_score":0.022881614,"about_ca_system_score_codex":0.000051382183,"about_ca_system_score_gemma":0.00030608886,"threshold_uncertainty_score":0.59023714},"labels":[],"label_agreement":null},{"id":"W3211507089","doi":"10.1182/blood-2021-154105","title":"Prognostic Value of Measurable Residual Disease Assessed By Multiparameter Flowcytometry in Patients with NPM1-Mutated Acute Myeloid Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"NPM1; Medicine; Cytarabine; Minimal residual disease; Internal medicine; Myeloid leukemia; Oncology; Induction chemotherapy; Leukemia; Chemotherapy; Myeloid; Chemotherapy regimen; Hematopoietic stem cell transplantation; Gastroenterology; Transplantation; Immunology; Biology","score_opus":0.009517854523805356,"score_gpt":0.25448540588338026,"score_spread":0.2449675513595749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211507089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976318,0.0003540428,0.00006733243,0.00021912467,0.00004305679,0.0010605075,0.00022266568,0.000070234426,0.000331262],"genre_scores_gemma":[0.99387556,0.000038274782,0.0043182042,0.00017787852,0.000039526196,0.00009674244,0.0008140915,0.00008485101,0.00055487145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965838,0.00027298572,0.0005434889,0.00066290906,0.0012559775,0.00068084284],"domain_scores_gemma":[0.99758947,0.00034708853,0.00014275563,0.0007304203,0.00071766484,0.00047262618],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035208548,0.0003207594,0.00068887323,0.00033737184,0.00005950811,0.00004028121,0.0002255756,0.00016973118,0.00010245509],"category_scores_gemma":[0.001638098,0.00026513624,0.00009788221,0.0015293236,0.00015478108,0.00019843194,0.00014400519,0.0006048484,0.00003169226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021490117,0.0032293715,0.9557936,0.0003752891,0.0007984721,0.0011784635,0.00011475034,0.00006203797,0.034677643,0.0000067865294,0.0012670404,0.00034754045],"study_design_scores_gemma":[0.026107274,0.0007278051,0.84689766,0.0004820824,0.0009752716,0.000028384808,0.00006641902,0.0006617295,0.12362301,0.000017271457,0.00008096705,0.00033210602],"about_ca_topic_score_codex":0.00011898255,"about_ca_topic_score_gemma":0.00001198651,"teacher_disagreement_score":0.10889591,"about_ca_system_score_codex":0.00043472715,"about_ca_system_score_gemma":0.0023517287,"threshold_uncertainty_score":0.9999801},"labels":[],"label_agreement":null},{"id":"W3211510829","doi":"10.1182/blood-2021-150573","title":"A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Myeloid leukemia; Complete remission; Medicine; Azacitidine; Internal medicine; Leukemia; Maintenance therapy; Cytarabine; Oncology; Chemotherapy; Chemistry; Chronic lymphocytic leukemia","score_opus":0.012592767777018697,"score_gpt":0.2914724844513646,"score_spread":0.2788797166743459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211510829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978939,0.0003265429,0.000002317038,0.0001811565,0.000017908578,0.0011970877,0.0000103793855,0.000017943881,0.000352752],"genre_scores_gemma":[0.9984279,0.0004625886,0.00034059514,0.00012947118,0.000029455865,0.000060088543,0.000040069863,0.00003747998,0.0004723248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981025,0.00011760266,0.00039080152,0.00048064004,0.0005278974,0.00038056308],"domain_scores_gemma":[0.9989673,0.000059521615,0.00010361524,0.0004839804,0.00022447313,0.00016113206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002781733,0.00020563496,0.0005170618,0.00022582812,0.000049868708,0.000010616036,0.00012546586,0.00010309045,0.000046581135],"category_scores_gemma":[0.00016692623,0.00015574224,0.00003140692,0.0007556794,0.000072520816,0.00009460229,0.00016530216,0.00043956135,0.0000025214342],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016113821,0.023498222,0.80557775,0.00014988898,0.0005755829,0.0047673695,0.005829443,0.000017466893,0.109292105,0.000021010706,0.0003240766,0.033833236],"study_design_scores_gemma":[0.29796562,0.038507804,0.5589878,0.0009237032,0.00017196557,0.00017475574,0.0016212949,0.0002022052,0.10041659,0.00005054461,0.00060192525,0.0003758014],"about_ca_topic_score_codex":0.0003618202,"about_ca_topic_score_gemma":0.00012517878,"teacher_disagreement_score":0.2818518,"about_ca_system_score_codex":0.000470231,"about_ca_system_score_gemma":0.0012624358,"threshold_uncertainty_score":0.6350984},"labels":[],"label_agreement":null},{"id":"W3211546201","doi":"10.1182/blood-2021-148049","title":"Matching Adjusted Indirect Comparison (MAIC) of Oral Azacitidine (Oral-AZA) Versus Injectable AZA in Patients (pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Azacitidine; Adverse effect; Placebo; Oncology; Chemotherapy regimen; Chemotherapy; Induction chemotherapy; Gastroenterology; Pathology","score_opus":0.023330634514462,"score_gpt":0.2813407140878673,"score_spread":0.2580100795734053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211546201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778134,0.00020993725,0.00002691305,0.0005538121,0.00015293121,0.00079353567,0.00002344176,0.00005757341,0.0004004898],"genre_scores_gemma":[0.99643457,0.00017628001,0.0024221386,0.00022199037,0.000064199914,0.000076514996,0.0002777803,0.00008431446,0.00024219732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99702156,0.00018279123,0.0007175811,0.0006753606,0.00075520785,0.00064747524],"domain_scores_gemma":[0.99821377,0.00010881234,0.0002495004,0.00054049405,0.00068578124,0.00020167058],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036314066,0.00037698096,0.0010293276,0.000587085,0.00006540818,0.000031065567,0.00018100567,0.00034506276,0.00016650384],"category_scores_gemma":[0.00025147884,0.00033189973,0.00009676721,0.0016579252,0.000120402656,0.00030240588,0.00017401508,0.0010977613,0.000015087008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0364716,0.0031018662,0.8757926,0.0006124906,0.0010840851,0.0015273632,0.009809698,0.00020905853,0.056279644,0.0000090235435,0.001451958,0.013650593],"study_design_scores_gemma":[0.07171632,0.002647862,0.5677042,0.002001724,0.00038840555,0.00013997196,0.003884415,0.00042276064,0.34986708,0.000028825763,0.00061627285,0.00058216345],"about_ca_topic_score_codex":0.0015883909,"about_ca_topic_score_gemma":0.0018550213,"teacher_disagreement_score":0.30808842,"about_ca_system_score_codex":0.0013045839,"about_ca_system_score_gemma":0.00086769793,"threshold_uncertainty_score":0.9999133},"labels":[],"label_agreement":null},{"id":"W3211572770","doi":"10.1182/blood-2021-145362","title":"Impact of <i>FLT3</i> Mutation Clearance after Front-Line Treatment with Gilteritinib Plus Azacitidine, or Gilteritinib or Azacitidine Alone in Patients with Newly Diagnosed AML: Results from the Phase 2/3 Lacewing Trial","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Azacitidine; Internal medicine; Surgery; Gastroenterology; Chemotherapy; Biology","score_opus":0.029041214357268787,"score_gpt":0.31476356714797715,"score_spread":0.28572235279070834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211572770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937043,0.000228756,0.00010262293,0.00053705915,0.000061025876,0.002579611,0.0025819784,0.000059321414,0.00014529104],"genre_scores_gemma":[0.9921554,0.00018320467,0.0040972563,0.00021618574,0.0004966203,0.0004179624,0.0019565676,0.00010393769,0.00037290744],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99643344,0.00032155187,0.00094354706,0.00080022804,0.000829174,0.00067207805],"domain_scores_gemma":[0.99722904,0.0008343451,0.00032913164,0.0008843538,0.0004472255,0.00027591764],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029574233,0.0004956277,0.0010796429,0.00014163295,0.00009186969,0.00007239946,0.00019247433,0.0001571027,0.00035864982],"category_scores_gemma":[0.0006885353,0.00025779262,0.00018438052,0.00069014734,0.00019907755,0.00026453423,0.000075816155,0.00038881492,0.000013953047],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94151074,0.009682084,0.024143435,0.0000849837,0.0011118173,0.009920009,0.0025082517,0.00008291444,0.0023234684,8.1442397e-7,0.00024654367,0.008384913],"study_design_scores_gemma":[0.83224255,0.036226816,0.11467747,0.0013301794,0.0007325342,0.00015975618,0.00054604776,0.0002978485,0.01310484,0.000003496193,0.00024977446,0.0004286851],"about_ca_topic_score_codex":0.0020363047,"about_ca_topic_score_gemma":0.0024133504,"teacher_disagreement_score":0.10926821,"about_ca_system_score_codex":0.00049245066,"about_ca_system_score_gemma":0.0016453504,"threshold_uncertainty_score":0.9999874},"labels":[],"label_agreement":null},{"id":"W3211684717","doi":"10.1182/blood-2021-144648","title":"Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre; Hôpital Maisonneuve-Rosemont; University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Decitabine; Medicine; Azacitidine; Myelodysplastic syndromes; Internal medicine; Oncology; Intensive care medicine; Bone marrow; Biology; DNA methylation","score_opus":0.010361926829314454,"score_gpt":0.24925738470902611,"score_spread":0.23889545787971167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211684717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99817705,0.00019276045,0.000016430951,0.0001428418,0.00013077034,0.0010842846,0.00010204222,0.000027292139,0.00012654392],"genre_scores_gemma":[0.9989908,0.000019508638,0.00028611996,0.000062711355,0.00005601083,0.00006479478,0.00012409066,0.000055720724,0.0003402727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974031,0.00031048091,0.00041086596,0.00051584136,0.00090922,0.00045049985],"domain_scores_gemma":[0.9978416,0.00052947766,0.00014229877,0.00089695246,0.00042897472,0.000160716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038101798,0.00026292037,0.0006267711,0.00013030574,0.00007085053,0.000025722416,0.00028369634,0.000099290446,0.0003788054],"category_scores_gemma":[0.0012217613,0.00016599243,0.000091655646,0.000991745,0.00010986899,0.000082448736,0.00022813445,0.00058921165,0.00004477864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015758842,0.004694371,0.989125,0.00003046839,0.0007530512,0.0018246908,0.00097131793,0.0000061647847,0.00021093585,0.0000024996114,0.0002599168,0.0005456595],"study_design_scores_gemma":[0.041506834,0.0024785162,0.95339316,0.00022987883,0.0007707148,0.000041510884,0.00075282506,0.000041637042,0.0005709738,0.000011554424,0.000029589319,0.0001727756],"about_ca_topic_score_codex":0.00043771177,"about_ca_topic_score_gemma":0.00090198504,"teacher_disagreement_score":0.03993095,"about_ca_system_score_codex":0.00012044482,"about_ca_system_score_gemma":0.00057045143,"threshold_uncertainty_score":0.67689747},"labels":[],"label_agreement":null},{"id":"W3211699349","doi":"10.1182/blood.2021012589","title":"Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial","year":2021,"lang":"en","type":"letter","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Internal medicine; Clinical endpoint; Romiplostim; Platelet; Clinical trial; Thrombopoietin; Biology","score_opus":0.01509013717606393,"score_gpt":0.2427511755753923,"score_spread":0.22766103839932839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211699349","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8436882,0.0019591993,0.0000013815046,0.15074696,0.00020101319,0.0013092663,0.0010948819,0.000052912215,0.0009461901],"genre_scores_gemma":[0.19509089,0.0058002686,0.0011748384,0.74312496,0.036139082,0.00074680016,0.012401781,0.00069084164,0.0048305257],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99629986,0.0006857514,0.0004870222,0.000971196,0.000871238,0.00068494154],"domain_scores_gemma":[0.99709606,0.0012271787,0.00023273106,0.0011509332,0.000115646784,0.00017742525],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043596723,0.000562708,0.0011196486,0.00020234157,0.00012670107,0.000150947,0.0004166928,0.0009076772,0.0012392374],"category_scores_gemma":[0.0004321873,0.00035259232,0.00016150082,0.00030180434,0.00039123857,0.000092012255,0.00036249676,0.0055815745,0.000044382967],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020014899,0.00067439326,0.0058743716,0.0003073212,0.0015542406,0.064739235,0.00057600794,4.2945499e-7,0.0002937153,0.0000013051102,0.90293926,0.0030248428],"study_design_scores_gemma":[0.290454,0.0030488425,0.020025097,0.0018108035,0.002232625,0.0023434155,0.00041729992,0.000017490856,0.0015645431,0.00009931762,0.67682964,0.0011569229],"about_ca_topic_score_codex":0.009141754,"about_ca_topic_score_gemma":0.001277895,"teacher_disagreement_score":0.6485973,"about_ca_system_score_codex":0.00017095641,"about_ca_system_score_gemma":0.0013165232,"threshold_uncertainty_score":0.9998926},"labels":[],"label_agreement":null},{"id":"W3211710841","doi":"10.1182/blood-2021-151586","title":"Real-World Management of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence (ARC) Initiative","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Ven; Venetoclax; Medicine; Cytarabine; Decitabine; Internal medicine; Azacitidine; Chemotherapy regimen; Oncology; Myeloid leukemia; Leukemia; Chemotherapy; Chronic lymphocytic leukemia; Humanities","score_opus":0.029243344570952314,"score_gpt":0.2841597342596075,"score_spread":0.2549163896886552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211710841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98484534,0.00017170083,0.000035123026,0.0015613561,0.00003587971,0.0019618887,0.0005533185,0.00012589872,0.010709523],"genre_scores_gemma":[0.9828216,0.0011334537,0.009416056,0.00071589823,0.00015755784,0.00027970047,0.0016996864,0.000118353135,0.0036577133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956737,0.00041777198,0.00071432843,0.0010034026,0.0014408538,0.0007499416],"domain_scores_gemma":[0.995053,0.001606771,0.0004858061,0.0017376665,0.0008254742,0.00029126857],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000430012,0.0004803567,0.00078106887,0.00024874115,0.00019310121,0.000059745485,0.00047843863,0.0001069516,0.000099877674],"category_scores_gemma":[0.00019502488,0.0003044377,0.00012786163,0.002221518,0.00039427914,0.00020783301,0.00023953087,0.0006487801,0.000030446783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07306432,0.0029378345,0.8596261,0.0006497695,0.012223378,0.019080713,0.0030515385,0.0007046876,0.0026732306,0.00042826956,0.020082664,0.005477509],"study_design_scores_gemma":[0.04811854,0.002021945,0.90360266,0.004719665,0.0029323364,0.000006993413,0.00051864976,0.00021094458,0.03647372,0.000024452143,0.0009163727,0.00045369752],"about_ca_topic_score_codex":0.0061904336,"about_ca_topic_score_gemma":0.004385553,"teacher_disagreement_score":0.043976597,"about_ca_system_score_codex":0.0013497561,"about_ca_system_score_gemma":0.0023972762,"threshold_uncertainty_score":0.99994075},"labels":[],"label_agreement":null},{"id":"W3211725527","doi":"10.1182/blood-2021-147379","title":"Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Collaboration","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Medicine; Common Terminology Criteria for Adverse Events; Adverse effect; Internal medicine; Oncology; Myeloid leukemia; Population; Chemotherapy regimen; Cancer; Pediatrics; Leukemia","score_opus":0.01037928400971649,"score_gpt":0.2959992125211594,"score_spread":0.2856199285114429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211725527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99525267,0.00033301112,0.00009178621,0.0014275702,0.00018865225,0.0008888369,0.000086259904,0.00004673599,0.0016844693],"genre_scores_gemma":[0.9889199,0.0010976205,0.002976315,0.0019637947,0.0012559303,0.00027108347,0.0013318893,0.000083304556,0.002100133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787736,0.00008291874,0.0004058313,0.00042269714,0.0007426207,0.00046856108],"domain_scores_gemma":[0.9986204,0.00015157959,0.00006885521,0.0003362606,0.000530626,0.00029230866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002951272,0.00016589937,0.0003423832,0.00020283452,0.000050050774,0.000033719938,0.00015225695,0.00026635546,0.00023486275],"category_scores_gemma":[0.0011765567,0.00015499492,0.00009028817,0.00089257525,0.000039655108,0.00011026771,0.00011921684,0.00037734568,0.00009200316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075936754,0.0015016851,0.9571819,0.00043913577,0.0003608006,0.0012501504,0.00042817538,0.000008763101,0.0013622452,0.00021122658,0.03337155,0.003125],"study_design_scores_gemma":[0.15401247,0.0027420458,0.731476,0.00046137077,0.0016035521,0.00042118112,0.00037801111,0.0032348302,0.03387332,0.00034316306,0.07033586,0.0011181795],"about_ca_topic_score_codex":0.000020241625,"about_ca_topic_score_gemma":0.00012406509,"teacher_disagreement_score":0.22570588,"about_ca_system_score_codex":0.0012607245,"about_ca_system_score_gemma":0.0063775326,"threshold_uncertainty_score":0.99925536},"labels":[],"label_agreement":null},{"id":"W3211790423","doi":"10.1182/blood-2021-144905","title":"Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Azacitidine; Gastroenterology; Hypomethylating agent; Refractory (planetary science); Myeloid; Venetoclax; Leukemia; Acute leukemia; Oncology; Biology","score_opus":0.016045889082207093,"score_gpt":0.2547655137594515,"score_spread":0.23871962467724442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211790423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946136,0.00012234341,0.00001733046,0.0015316943,0.00002801773,0.0007939801,0.000046073656,0.00006183683,0.0027851118],"genre_scores_gemma":[0.99548304,0.000084928426,0.0022629034,0.00031254094,0.000042341722,0.00008344135,0.00052794284,0.00006490433,0.0011379576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723154,0.00015626344,0.00045325182,0.0006056179,0.0009009793,0.0006523349],"domain_scores_gemma":[0.998475,0.00014207298,0.00012583862,0.0005586766,0.0004273907,0.0002710046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028829047,0.00029587108,0.00059725693,0.00041983722,0.00011134972,0.000051050713,0.00021220975,0.0001809625,0.00015675582],"category_scores_gemma":[0.00022101372,0.00023221092,0.000045964916,0.0015211513,0.00012853488,0.0002743684,0.00014122613,0.00085394963,0.00003516301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018278582,0.0032039122,0.9268576,0.00023845091,0.00043151845,0.003415797,0.0008627618,0.0000849922,0.0609255,0.00019890559,0.001000659,0.0009520733],"study_design_scores_gemma":[0.042340558,0.0012793423,0.9038902,0.0010245257,0.00019378198,0.0002504994,0.00036841258,0.00015712336,0.049354974,0.00009425223,0.00065364793,0.00039269586],"about_ca_topic_score_codex":0.0003268714,"about_ca_topic_score_gemma":0.00036487848,"teacher_disagreement_score":0.040512703,"about_ca_system_score_codex":0.00077101996,"about_ca_system_score_gemma":0.0014913233,"threshold_uncertainty_score":0.9469286},"labels":[],"label_agreement":null},{"id":"W3211862217","doi":"10.1182/blood-2021-153240","title":"Inhibition of the DOT1L/MPL/JAK2 Signaling Axis Selectively Targets <i>TET2</i> Mutation-Driven Clonal Hematopoiesis","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Haematopoiesis; Biology; Cancer research; Progenitor cell; Myeloid; Epigenetics; Leukemia; Stem cell; Immunology; Genetics; Gene","score_opus":0.013500876726300903,"score_gpt":0.2600462198651964,"score_spread":0.24654534313889548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211862217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941534,0.00056421256,0.0004738142,0.001510807,0.00006156716,0.00036394713,0.00004404857,0.00004399423,0.0027842238],"genre_scores_gemma":[0.9941752,0.00002470775,0.0045938515,0.00040426376,0.00017761198,0.00003682207,0.00006469619,0.000031414194,0.00049144507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982766,0.00014609894,0.0003356533,0.0003125449,0.0006290523,0.00030006992],"domain_scores_gemma":[0.9986269,0.0002226872,0.00012727834,0.00031868438,0.00060061546,0.00010386977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022732397,0.00014941263,0.00030403206,0.000086960674,0.0001485088,0.000019254516,0.000108347216,0.0001146394,0.0002973679],"category_scores_gemma":[0.00051021494,0.00011689645,0.00018304738,0.00069719297,0.000120597746,0.00009045403,0.0001234073,0.00035415945,0.00003491237],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009418934,0.00062549644,0.010336622,0.00024252944,0.00035889394,0.00033208646,0.0010248697,0.000058329337,0.9850932,0.00043395557,0.0011764634,0.00022340828],"study_design_scores_gemma":[0.0029138695,0.0001266158,0.009427929,0.00018560218,0.00024375913,0.00051594264,0.0003888603,0.00014156113,0.9849063,0.0006019968,0.00042906104,0.00011849837],"about_ca_topic_score_codex":0.000052927273,"about_ca_topic_score_gemma":0.000023940558,"teacher_disagreement_score":0.0041200374,"about_ca_system_score_codex":0.000101130696,"about_ca_system_score_gemma":0.00081479136,"threshold_uncertainty_score":0.4766899},"labels":[],"label_agreement":null},{"id":"W3211885324","doi":"10.1182/blood-2021-148866","title":"Deleterious Germline Variants Are Present in Patients with Myelodysplastic Syndrome of All Ages Treated with Related Allogeneic Stem Cell Transplantation","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Germline; Transplantation; Hematopoietic stem cell transplantation; Medicine; Medical genetics; Myelodysplastic syndromes; Genetics; Germline mutation; Biology; Internal medicine; Bone marrow; Mutation; Gene","score_opus":0.008765423723606959,"score_gpt":0.21869479566049857,"score_spread":0.20992937193689162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211885324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986738,0.00018989963,0.000028321623,0.000094265735,0.0000144278465,0.00069640955,0.00009075136,0.00003996993,0.00017213983],"genre_scores_gemma":[0.997995,0.0001220182,0.0005596478,0.000030429275,0.000009548832,0.00003585463,0.0006479664,0.000053476153,0.0005460412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981382,0.00014376585,0.00040183176,0.00042017744,0.000529284,0.0003667733],"domain_scores_gemma":[0.9989667,0.00009845786,0.0001640482,0.00035461466,0.00026693402,0.00014925915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010029215,0.00022439414,0.0004845777,0.00020471863,0.000026452657,0.000012018788,0.00010156902,0.00014187898,0.000066389715],"category_scores_gemma":[0.000012947773,0.00016528185,0.000041814597,0.0005508703,0.00006386282,0.00007713401,0.000026268817,0.0002750905,0.000010574478],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040066894,0.004273113,0.9337526,0.0013768511,0.0010077232,0.021191064,0.0008128999,0.0005138126,0.032311283,0.0000026401715,0.000025517538,0.0007257962],"study_design_scores_gemma":[0.025159188,0.002755196,0.94510025,0.00065470353,0.0007183112,0.0008350236,0.00006512824,0.00013745662,0.024376795,0.0000011286646,0.000007747523,0.00018906427],"about_ca_topic_score_codex":0.00009763701,"about_ca_topic_score_gemma":0.000058513437,"teacher_disagreement_score":0.021152498,"about_ca_system_score_codex":0.00009285402,"about_ca_system_score_gemma":0.0002256288,"threshold_uncertainty_score":0.6739998},"labels":[],"label_agreement":null},{"id":"W3211979408","doi":"10.1182/blood-2021-154457","title":"Clinical and Pathological Characteristics of Hypocellular Myelodysplastic Syndrome : A Single-Center Retrospective Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Myelodysplastic syndromes; Single Center; Retrospective cohort study; International Prognostic Scoring System; Multivariate analysis; Oncology; Pathology; Gastroenterology","score_opus":0.036707680814483265,"score_gpt":0.3031005321545125,"score_spread":0.2663928513400292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211979408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985531,0.00013036237,0.00004683058,0.00014873211,0.000092955015,0.00044520252,0.000035702706,0.000032990036,0.00051413773],"genre_scores_gemma":[0.99847674,0.00006005964,0.0008876546,0.000085586275,0.00011274426,0.000014601815,0.000023415385,0.000023510142,0.00031570994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810773,0.00023422381,0.0005329546,0.000471594,0.00038249439,0.00027099444],"domain_scores_gemma":[0.9988128,0.00019528695,0.00010293245,0.00039272034,0.00029447136,0.0002017906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048368837,0.0001526889,0.00070143153,0.00006878051,0.000042075364,0.000017791242,0.00008474332,0.00015292696,0.00012559287],"category_scores_gemma":[0.0017538558,0.00012607539,0.00009942404,0.00023068325,0.0002483727,0.0000321251,0.0002515276,0.0005100819,0.000024095954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001625546,0.008185079,0.9663856,0.0000723556,0.00025512456,0.013696716,0.00017109468,8.5215826e-9,0.010439634,0.000033962155,0.00002760662,0.00057024416],"study_design_scores_gemma":[0.00820932,0.0038849572,0.9824161,0.000087112596,0.00039108735,0.0037898787,0.00026713134,0.00001768552,0.0007072974,0.000036849044,0.00008077314,0.000111824746],"about_ca_topic_score_codex":0.000001844744,"about_ca_topic_score_gemma":0.0000013094974,"teacher_disagreement_score":0.016030464,"about_ca_system_score_codex":0.000043203698,"about_ca_system_score_gemma":0.00016794214,"threshold_uncertainty_score":0.5141205},"labels":[],"label_agreement":null},{"id":"W3212046139","doi":"10.1182/blood-2021-152750","title":"Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with High-Risk and Relapsed/Refractory Acute Myeloid Leukemia (AML)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Refractory (planetary science); Medicine; Myeloid leukemia; Internal medicine; Leukemia; Oncology; Induction therapy; Chemotherapy","score_opus":0.007087328058147671,"score_gpt":0.22210113527182812,"score_spread":0.21501380721368046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212046139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99851036,0.00030449405,0.0000281146,0.0001546667,0.000052233358,0.0007060138,0.000029039742,0.000033289463,0.00018179836],"genre_scores_gemma":[0.9963829,0.001873896,0.001267498,0.00010254342,0.00006545864,0.000009459782,0.000086985136,0.0000485295,0.00016270945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982352,0.000123204,0.0003277533,0.0005256479,0.00045055425,0.00033763977],"domain_scores_gemma":[0.9986476,0.000120606666,0.00017078375,0.0004666519,0.00041050377,0.00018390678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024220021,0.00025119534,0.00056742795,0.00017420364,0.00008214196,0.000019727795,0.00007354849,0.00019991297,0.000028828485],"category_scores_gemma":[0.00012237218,0.00018050766,0.000031147414,0.0004275519,0.0003071858,0.00016396114,0.00009749227,0.0007863056,0.0000024630835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039891765,0.0036453267,0.8883709,0.00014987473,0.0017104245,0.0008686511,0.003056615,0.000016931797,0.011246269,0.000037256563,0.00008214281,0.05092385],"study_design_scores_gemma":[0.036109082,0.0051020863,0.94490016,0.00022397838,0.0003203639,0.00021057461,0.00024690913,0.000009024436,0.012392541,0.000014616082,0.00026222557,0.00020842603],"about_ca_topic_score_codex":0.00061287475,"about_ca_topic_score_gemma":0.0001196886,"teacher_disagreement_score":0.056529276,"about_ca_system_score_codex":0.00028010574,"about_ca_system_score_gemma":0.0006327207,"threshold_uncertainty_score":0.7360889},"labels":[],"label_agreement":null},{"id":"W3212121153","doi":"10.1182/blood-2021-145949","title":"Myelodysplastic Syndromes: A More Global 5-Hydroxymethylcytosine Deficiency Disorder Than Suggested By the Presence of TET2 Mutations","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myelodysplastic syndromes; Biology; Missense mutation; Genetics; Cancer research; Mutation; Myeloid; Myeloid leukemia; Population; Deep sequencing; Gene; Medicine; Immunology; Genome; Bone marrow","score_opus":0.013312526206543458,"score_gpt":0.2900261979436438,"score_spread":0.2767136717371004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212121153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98744226,0.005743705,0.00078067713,0.002986535,0.00006035338,0.0004833214,0.0002175329,0.00006060266,0.0022250141],"genre_scores_gemma":[0.9974924,0.00015275556,0.0006903664,0.00008931627,0.000037528618,0.000060880924,0.00014181428,0.000024570112,0.001310383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979194,0.00014080046,0.0003471153,0.00039755844,0.0007574251,0.0004376997],"domain_scores_gemma":[0.99817,0.00050524104,0.00008704084,0.00073728844,0.00034240575,0.00015798147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022632886,0.00019127846,0.00035496807,0.00005990643,0.0001467664,0.000028972452,0.00031090996,0.00010804578,0.00016648445],"category_scores_gemma":[0.0017168763,0.00013352749,0.00014096634,0.0014378598,0.0004060341,0.00008043095,0.0001890753,0.00031163692,0.000040131625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061315764,0.018907085,0.5796614,0.0029150124,0.0038124954,0.003962965,0.006239213,0.001168159,0.34879148,0.004044399,0.014058519,0.015826073],"study_design_scores_gemma":[0.04004916,0.0035282706,0.6824836,0.0016629192,0.0064206235,0.016045278,0.01603777,0.011469635,0.2071268,0.0018124385,0.011556244,0.001807256],"about_ca_topic_score_codex":0.00028791776,"about_ca_topic_score_gemma":0.00005416302,"teacher_disagreement_score":0.14166468,"about_ca_system_score_codex":0.00008279851,"about_ca_system_score_gemma":0.0008243567,"threshold_uncertainty_score":0.5445093},"labels":[],"label_agreement":null},{"id":"W3212123828","doi":"10.1182/blood-2021-149967","title":"Efficacy, Toxicity and Cost of Venetoclax-Based Combinations for the Treatment of Acute Myeloid Leukemia: Real-World Evidence from a Canadian Academic Center","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Ven; Venetoclax; Medicine; Cytarabine; Internal medicine; Chemotherapy regimen; Myeloid leukemia; Azacitidine; Tumor lysis syndrome; Posaconazole; Chemotherapy; Oncology; Leukemia; Surgery; Chronic lymphocytic leukemia; Voriconazole","score_opus":0.044092088180513,"score_gpt":0.33585577871312666,"score_spread":0.29176369053261364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212123828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924167,0.0012684712,0.00007305475,0.0037314,0.00004689545,0.0014077714,0.00082163664,0.000013267575,0.00022082274],"genre_scores_gemma":[0.99474055,0.0032359948,0.00067949423,0.00023934794,0.00008003969,0.00016412092,0.00021249626,0.000022772427,0.00062518654],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987817,0.00007291547,0.0003099755,0.00028075106,0.00025212456,0.00030258036],"domain_scores_gemma":[0.99759495,0.0013329592,0.000103037804,0.00046781785,0.00025420793,0.0002470057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016357834,0.00014504809,0.00036974536,0.00013556523,0.00010530954,0.000010155954,0.00015226548,0.00012401694,0.000049800612],"category_scores_gemma":[0.00021510432,0.00010738374,0.00012204755,0.00032932984,0.00017626162,0.000041299005,0.000030546984,0.00020977847,0.0000026386135],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00345771,0.0059291855,0.51953864,0.000741895,0.00797342,0.00065152487,0.005616122,0.00027790244,0.40872717,0.0011676669,0.01076346,0.035155285],"study_design_scores_gemma":[0.031200903,0.0012877479,0.36658353,0.00070039503,0.0023650548,0.000031377327,0.00016462604,0.003780915,0.58697945,0.00006682681,0.006637736,0.00020145874],"about_ca_topic_score_codex":0.07921218,"about_ca_topic_score_gemma":0.08677241,"teacher_disagreement_score":0.17825228,"about_ca_system_score_codex":0.0011761382,"about_ca_system_score_gemma":0.004161663,"threshold_uncertainty_score":0.9298916},"labels":[],"label_agreement":null},{"id":"W3212430506","doi":"10.1182/bloodadvances.2021005418","title":"<i>TET2</i> mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institutes of Health; Edward P. Evans Foundation; National Heart, Lung, and Blood Institute; American-Italian Cancer Foundation; Vera and Joseph Dresner Foundation; Leukemia and Lymphoma Society","keywords":"Myelodysplastic syndromes; Dioxygenase; Mutation; DNA; Cancer research; Genetics; Biology; Gene; Immunology; Bone marrow","score_opus":0.01639163811844425,"score_gpt":0.29893026594684563,"score_spread":0.2825386278284014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212430506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804165,0.009118593,0.00005850236,0.000616559,0.00010013213,0.0002466749,0.000024042329,0.00003632917,0.009382716],"genre_scores_gemma":[0.99442345,0.0010370238,0.0019362405,0.00013244088,0.000055640296,0.00005744352,0.000047068494,0.00002100501,0.0022897173],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984658,0.000066096385,0.0003706153,0.0003327346,0.00041425353,0.00035053186],"domain_scores_gemma":[0.9989462,0.00034681216,0.00007903133,0.00031495042,0.00017625533,0.00013678493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014304597,0.00013858895,0.0003547576,0.00016811762,0.000052323,0.000011428411,0.00011712012,0.000058643476,0.00021800867],"category_scores_gemma":[0.0010303198,0.00012412595,0.00007980818,0.0008622052,0.00016241994,0.00016640752,0.00006802834,0.00021766225,0.00006908375],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007920525,0.008788361,0.21063998,0.0042095906,0.00057989475,0.02499852,0.0038168568,0.0017674551,0.69424856,0.010058927,0.0012051639,0.038894664],"study_design_scores_gemma":[0.013270928,0.001832496,0.058904354,0.0017009573,0.0005544181,0.0049409843,0.0055955364,0.0003222505,0.850377,0.0042604376,0.057456605,0.00078399084],"about_ca_topic_score_codex":0.0000207797,"about_ca_topic_score_gemma":0.00008416867,"teacher_disagreement_score":0.15612851,"about_ca_system_score_codex":0.00005545841,"about_ca_system_score_gemma":0.00076442567,"threshold_uncertainty_score":0.5061709},"labels":[],"label_agreement":null},{"id":"W3212486006","doi":"10.1182/blood-2021-151597","title":"Prediction of Early Mortality with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients from MRC/NCRI and SWOG","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Oncology; Internal medicine; Midostaurin; Myeloid leukemia; Logistic regression","score_opus":0.017591307162793075,"score_gpt":0.26244641263683094,"score_spread":0.24485510547403785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212486006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978242,0.00029114567,0.00021451201,0.000088391476,0.000036068537,0.00033830595,0.00081781717,0.0000243037,0.0003652582],"genre_scores_gemma":[0.9979819,0.00031745492,0.00073032733,0.00013656678,0.000056058612,0.000018830578,0.0005808443,0.00002792355,0.00015011356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980251,0.00008798095,0.00045736457,0.0004643365,0.0007078572,0.00025735394],"domain_scores_gemma":[0.9972003,0.00012256167,0.00023361694,0.000660239,0.0016198809,0.00016336852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015886463,0.0002017407,0.00080375094,0.00026142312,0.00004554993,0.000015387524,0.00011837617,0.0001483189,0.00010612966],"category_scores_gemma":[0.00015119578,0.00015864761,0.0001711372,0.001034995,0.00022393033,0.000121018806,0.00011207304,0.00027580082,0.0000024161607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000445889,0.0003441478,0.9137668,0.00007173727,0.016768046,0.00008633591,0.0023406132,0.0000072917337,0.065574065,0.0000068928834,0.00012464219,0.00046351398],"study_design_scores_gemma":[0.0064799893,0.0007860549,0.8994517,0.000120050274,0.009755248,0.0000057744196,0.00090096507,0.00044882877,0.081899725,0.000019621446,0.000025416668,0.00010664869],"about_ca_topic_score_codex":0.0021468066,"about_ca_topic_score_gemma":0.00016169538,"teacher_disagreement_score":0.016325656,"about_ca_system_score_codex":0.00012377722,"about_ca_system_score_gemma":0.000503662,"threshold_uncertainty_score":0.6469462},"labels":[],"label_agreement":null},{"id":"W3212566661","doi":"10.1182/blood-2021-153098","title":"PLAGL2 Independently Drives Aberrant Erythropoiesis and Initiation of Preleukemic State","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; McMaster University; Population Health Research Institute","funders":"","keywords":"Haematopoiesis; Erythropoiesis; Biology; Cancer research; Progenitor cell; CD34; Stem cell; Bone marrow; Leukemia; Malignancy; Myeloid; Immunology; Anemia; Medicine; Internal medicine; Cell biology; Genetics","score_opus":0.014838370857839157,"score_gpt":0.2714841318293106,"score_spread":0.2566457609714714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212566661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955523,0.0010510271,0.000079213496,0.00044004672,0.00003369463,0.00019603907,0.000027165399,0.000030066836,0.002590473],"genre_scores_gemma":[0.9965683,0.0011866912,0.0011081003,0.00011414143,0.0000530437,0.000011409348,0.00004423349,0.000021199015,0.00089285057],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888575,0.00006483762,0.00024816638,0.0002379815,0.0003511939,0.00021209208],"domain_scores_gemma":[0.99924284,0.00011071463,0.000075044845,0.00025482153,0.0002050483,0.00011155218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015635202,0.00010406625,0.00025988187,0.00010894658,0.00004218834,0.000015331414,0.00005627321,0.00008432948,0.00014946795],"category_scores_gemma":[0.00024136985,0.000095925076,0.00004628874,0.00021403021,0.00011278682,0.00009392598,0.0001038168,0.00022720326,0.000015239358],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044460798,0.0013850132,0.2245443,0.0011596554,0.0010529605,0.0014344078,0.005253817,0.000009910075,0.75190926,0.00041752393,0.0017537351,0.010634836],"study_design_scores_gemma":[0.01033917,0.00041184374,0.2573177,0.00024256113,0.0003355122,0.00071417965,0.00097525417,0.00018510525,0.7281857,0.0005256637,0.00057989714,0.00018741783],"about_ca_topic_score_codex":0.000063740335,"about_ca_topic_score_gemma":0.000035715868,"teacher_disagreement_score":0.0327734,"about_ca_system_score_codex":0.00006213822,"about_ca_system_score_gemma":0.00054713833,"threshold_uncertainty_score":0.3911711},"labels":[],"label_agreement":null},{"id":"W3212602214","doi":"10.1182/blood-2021-153086","title":"A Phase I/II Study of Venetoclax in Combination with 5-Azacytidine in Treatment-Naïve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chronic myelomonocytic leukemia; Venetoclax; Myelodysplastic syndromes; Azacitidine; Medicine; Refractory (planetary science); Internal medicine; Phases of clinical research; Leukemia; Oncology; Gastroenterology; Chemotherapy; Chronic lymphocytic leukemia; Bone marrow; Biology; Genetics","score_opus":0.017438468941269835,"score_gpt":0.2871701145387691,"score_spread":0.2697316455974993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212602214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99706906,0.000918121,0.0000093591925,0.000068639354,0.00004253698,0.0017398744,0.000027394783,0.000041650404,0.000083360545],"genre_scores_gemma":[0.9977714,0.0007851629,0.00022285535,0.000012611506,0.00004445343,0.00025092484,0.00008788298,0.00006801665,0.00075670535],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99734503,0.00029090076,0.00063922844,0.0006963457,0.000506069,0.0005224053],"domain_scores_gemma":[0.99837184,0.00043499627,0.0002185454,0.000622966,0.00014703772,0.00020463155],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003217561,0.00035882153,0.0009197754,0.00059482636,0.00009247925,0.000021529646,0.00013200473,0.00018046176,0.000093742834],"category_scores_gemma":[0.00034500723,0.00027970906,0.000047397156,0.0011957376,0.00013556151,0.00017815962,0.00014367365,0.000591921,0.000010802853],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037391637,0.18167938,0.40942845,0.0034614576,0.0063127354,0.13381957,0.02675623,0.0026647593,0.09153137,0.0003380374,0.00015482007,0.10646157],"study_design_scores_gemma":[0.47208256,0.18853551,0.30479982,0.001445552,0.0018448171,0.0025774892,0.0035572632,0.0057829777,0.018483583,0.000070777576,0.00013375987,0.0006858899],"about_ca_topic_score_codex":0.0028175062,"about_ca_topic_score_gemma":0.005568778,"teacher_disagreement_score":0.43469092,"about_ca_system_score_codex":0.0043170354,"about_ca_system_score_gemma":0.0042408733,"threshold_uncertainty_score":0.9999655},"labels":[],"label_agreement":null},{"id":"W3212627725","doi":"10.1182/blood-2021-153657","title":"A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Decitabine; Chronic myelomonocytic leukemia; Venetoclax; Myelodysplastic syndromes; Medicine; Azacitidine; Internal medicine; Leukemia; Oncology; Bone marrow; Chronic lymphocytic leukemia; Biology; Genetics; DNA methylation","score_opus":0.01998827595166818,"score_gpt":0.2953549840939761,"score_spread":0.2753667081423079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212627725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99669987,0.0005172954,0.00002987711,0.00010233674,0.00007238763,0.0022988005,0.000044277534,0.00006194363,0.00017321335],"genre_scores_gemma":[0.9975521,0.00032766376,0.00038462292,0.00001542691,0.00007592265,0.00042196433,0.00014706173,0.0000966338,0.0009786204],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964351,0.00034860134,0.00085718214,0.0008486066,0.0007598395,0.00075066753],"domain_scores_gemma":[0.99792033,0.00044974184,0.00026666853,0.00087306206,0.00025045985,0.00023975324],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037408122,0.00047099905,0.0011692764,0.0007849024,0.000106158564,0.000029823621,0.00023965146,0.00019888234,0.00021215998],"category_scores_gemma":[0.0004355561,0.00036824413,0.000090495836,0.0020714873,0.00012216622,0.00019497602,0.00017591288,0.00063833245,0.000036847992],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.041570526,0.26190352,0.25452307,0.0036345012,0.009179,0.19446695,0.02586204,0.013797969,0.088067256,0.0007108117,0.0002920209,0.10599234],"study_design_scores_gemma":[0.53414667,0.19830807,0.20267038,0.0017656418,0.0023377477,0.003424922,0.00458663,0.011572518,0.039901026,0.000097398224,0.00016920627,0.0010198232],"about_ca_topic_score_codex":0.004101783,"about_ca_topic_score_gemma":0.007637944,"teacher_disagreement_score":0.49257612,"about_ca_system_score_codex":0.0059645413,"about_ca_system_score_gemma":0.0062144874,"threshold_uncertainty_score":0.999877},"labels":[],"label_agreement":null},{"id":"W3212668755","doi":"10.1182/blood-2021-152379","title":"Proteomics and Phospho-Proteomics Reveal Predictive Signatures of Response and Mechanisms of Resistance to Midostaurin Plus Chemotherapy in FLT3 Mutant Positive Acute Myeloid Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Midostaurin; Cancer research; Myeloid leukemia; Oncology; Medicine; Internal medicine; Chemotherapy; Bone marrow; Biology","score_opus":0.006599343522056687,"score_gpt":0.24978639197708885,"score_spread":0.24318704845503217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212668755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933411,0.0010110639,0.0015087518,0.0015769578,0.000023446471,0.0020308308,0.0003500966,0.00002229294,0.00013545105],"genre_scores_gemma":[0.9522582,0.00048047604,0.046063766,0.00033469172,0.000034603523,0.00010576522,0.00002261648,0.000057136498,0.0006427088],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99774736,0.00023733711,0.0005227502,0.0006072321,0.00047929856,0.00040603138],"domain_scores_gemma":[0.9984432,0.00028602706,0.0001839656,0.00045731245,0.00039548337,0.00023401466],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007784325,0.0002747034,0.0007770052,0.00025383715,0.000052016378,0.000017462226,0.00015431436,0.00028403822,0.000011718242],"category_scores_gemma":[0.00058996945,0.00026369418,0.00007046263,0.0006033139,0.00022183183,0.00008376469,0.00021676286,0.00054148235,7.278438e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031589452,0.00021269382,0.0005970032,0.0002567775,0.00037144322,0.0006526727,0.0028394137,0.00001048862,0.96285546,0.0003874421,0.0000679513,0.00015921814],"study_design_scores_gemma":[0.011290959,0.001212116,0.041968845,0.00070485595,0.00017168591,0.00015525761,0.0008175439,0.00014266232,0.94239247,0.00092573604,0.000016744732,0.00020115488],"about_ca_topic_score_codex":0.00009398876,"about_ca_topic_score_gemma":0.00006264857,"teacher_disagreement_score":0.044555016,"about_ca_system_score_codex":0.0005074917,"about_ca_system_score_gemma":0.0016593016,"threshold_uncertainty_score":0.9999815},"labels":[],"label_agreement":null},{"id":"W3212777568","doi":"10.1038/s41375-021-01468-y","title":"Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia","year":2021,"lang":"en","type":"letter","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Venetoclax; Myeloid leukemia; Cancer research; Myeloid; Biology; Medicine; Leukemia; Immunology; Chronic lymphocytic leukemia","score_opus":0.026652094669841975,"score_gpt":0.2921734056609885,"score_spread":0.2655213109911465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212777568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82237077,0.00015199033,0.0002171366,0.17105736,0.0008148428,0.0034474165,0.00019045842,0.0004280827,0.001321975],"genre_scores_gemma":[0.5131828,0.00027765025,0.0023227148,0.44100922,0.009582273,0.0009766512,0.011768648,0.0009531289,0.019926878],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99071676,0.0010698873,0.0014202357,0.002386517,0.0021300435,0.0022765826],"domain_scores_gemma":[0.9952673,0.0007333072,0.00045295834,0.0021773342,0.00074737525,0.00062172406],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.00095119845,0.0014078661,0.0024766233,0.0015788415,0.00020378293,0.00028548233,0.0005936501,0.003251645,0.0003968335],"category_scores_gemma":[0.0011419806,0.0014046796,0.0005982229,0.0021916092,0.00014647709,0.00029370084,0.00075371994,0.009062545,0.0009033787],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00059570244,0.00006065618,0.001171746,0.0011085636,0.0010409745,0.050811037,0.0010161216,0.000103103,0.3192384,0.000008494675,0.61911047,0.005734728],"study_design_scores_gemma":[0.021918302,0.002512343,0.09394037,0.009188039,0.003042855,0.007890317,0.0004121712,0.020188175,0.55829257,0.00044315995,0.27478,0.007391672],"about_ca_topic_score_codex":0.0035592758,"about_ca_topic_score_gemma":0.00076115003,"teacher_disagreement_score":0.34433046,"about_ca_system_score_codex":0.039499026,"about_ca_system_score_gemma":0.01347532,"threshold_uncertainty_score":0.99987453},"labels":[],"label_agreement":null},{"id":"W3212789567","doi":"10.1182/blood-2021-150649","title":"Long-Term Subgroup Analyses from Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Decitabine; Azacitidine; Medicine; Internal medicine; Myeloid leukemia; Hypomethylating agent; Oncology; Subgroup analysis; Leukemia; Cytarabine; Confidence interval; DNA methylation","score_opus":0.029208762009357014,"score_gpt":0.3070496838151518,"score_spread":0.2778409218057948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212789567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908396,0.0016187739,0.000100849495,0.003548901,0.00018630362,0.00067264587,0.0016811391,0.00011801803,0.0012337464],"genre_scores_gemma":[0.98460025,0.0015993055,0.0019039499,0.0015105972,0.0009546659,0.000091221016,0.00755545,0.000107233405,0.0016773583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99526995,0.00037133557,0.0010832633,0.0012440655,0.0011630285,0.00086835294],"domain_scores_gemma":[0.9942352,0.0023491445,0.00031526576,0.0022038415,0.0004884676,0.0004080505],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004340574,0.00052403926,0.0009772946,0.00018478112,0.00017192248,0.00015949289,0.0007531126,0.00037526997,0.00053935725],"category_scores_gemma":[0.0034678816,0.00039216166,0.000320739,0.0012628745,0.00026443705,0.00025656138,0.00050878065,0.0012196362,0.00018183474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036507198,0.002366351,0.8935404,0.00006749127,0.0023333083,0.014461792,0.0018514651,0.000016845059,0.060484927,0.000024287347,0.016556468,0.004645978],"study_design_scores_gemma":[0.038248643,0.00027648572,0.9042843,0.0005858407,0.0010820528,0.000064682754,0.00034569885,0.00007999638,0.053589452,0.00017585886,0.00084249675,0.00042450457],"about_ca_topic_score_codex":0.006153786,"about_ca_topic_score_gemma":0.0033211438,"teacher_disagreement_score":0.034597922,"about_ca_system_score_codex":0.0007316896,"about_ca_system_score_gemma":0.0011966029,"threshold_uncertainty_score":0.999853},"labels":[],"label_agreement":null},{"id":"W3212892660","doi":"10.1182/blood-2021-153960","title":"Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Hypomethylating agent; Decitabine; Venetoclax; Chemotherapy regimen; Chemotherapy; Azacitidine; Cytarabine; Oncology; Retrospective cohort study; Leukemia; Surgery; Chronic lymphocytic leukemia","score_opus":0.009273470443319116,"score_gpt":0.24900919414552905,"score_spread":0.23973572370220994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212892660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997318,0.00033851844,0.00001699205,0.000009020069,0.000006168367,0.000999631,0.0005925943,0.000016200464,0.0007028336],"genre_scores_gemma":[0.99517256,0.00003101682,0.0034028457,0.000010595782,0.000015292353,0.00004686304,0.0011585344,0.000046454832,0.00011586391],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976197,0.00016534443,0.0005749986,0.0006169002,0.0006273634,0.00039569562],"domain_scores_gemma":[0.9981541,0.000094867784,0.0003473292,0.00055849634,0.0006337565,0.0002114282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017267892,0.00034248398,0.0012771932,0.0006782252,0.00004933195,0.000015563532,0.00008136814,0.0001281308,0.00019311413],"category_scores_gemma":[0.00009914759,0.00022358724,0.00019748944,0.0019501667,0.00014129627,0.00012434556,0.00007969818,0.0003261382,6.4124663e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018488007,0.0069532054,0.97345424,0.0001081713,0.00843389,0.00006190553,0.0014719588,0.000042024185,0.00054205087,8.738739e-7,0.000007194571,0.0070756925],"study_design_scores_gemma":[0.037480474,0.008903367,0.9468515,0.000091833084,0.002909984,0.0000044944363,0.00023233003,0.00019948013,0.003135547,0.0000016181267,0.0000014122262,0.00018795033],"about_ca_topic_score_codex":0.00058154284,"about_ca_topic_score_gemma":0.00017717914,"teacher_disagreement_score":0.035631675,"about_ca_system_score_codex":0.00070023927,"about_ca_system_score_gemma":0.0007573924,"threshold_uncertainty_score":0.9117623},"labels":[],"label_agreement":null},{"id":"W3212919490","doi":"10.37766/inplasy2021.11.0078","title":"Maintenance with Hypomethylating Agents after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Internal medicine; Myelodysplastic syndromes; Myeloid leukemia; Oncology; Transplantation; Meta-analysis; Hematopoietic stem cell transplantation; Leukemia; Cohort; Bone marrow","score_opus":0.04576518692079122,"score_gpt":0.3196594353691421,"score_spread":0.27389424844835086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212919490","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032794534,0.99255484,0.00050337665,0.00008863525,0.000011559748,0.0061493963,0.00017616963,0.00004202004,0.00014603452],"genre_scores_gemma":[0.00063671474,0.9872066,0.0018850875,0.0004557325,0.000008128757,0.0025916446,0.00031800068,0.00013441876,0.0067636836],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9935386,0.0012099927,0.0021202033,0.0014665406,0.0009034056,0.0007612236],"domain_scores_gemma":[0.99663645,0.0009480513,0.0007683697,0.0009971383,0.00023308775,0.00041688568],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016241237,0.0011095625,0.014608929,0.0012084825,0.00007391135,0.00011850392,0.00026928788,0.00042494587,0.00033834233],"category_scores_gemma":[0.000083507286,0.00064271555,0.0013766177,0.0031716696,0.0001392645,0.00017856575,0.00015281998,0.0010547146,0.000029591109],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023587625,0.00002689866,0.000018603881,0.8858858,0.10685494,0.005698478,0.00008865187,0.0000021995584,7.422503e-7,0.000003538362,0.000022338172,0.0013742666],"study_design_scores_gemma":[0.00065988104,0.00015341572,0.000061291474,0.13161817,0.8598136,0.0063936505,0.000060584873,0.000054313557,0.0000013067182,5.815761e-7,0.0006069219,0.00057628716],"about_ca_topic_score_codex":0.00006480881,"about_ca_topic_score_gemma":0.000101268844,"teacher_disagreement_score":0.7542676,"about_ca_system_score_codex":0.0009491093,"about_ca_system_score_gemma":0.0009395573,"threshold_uncertainty_score":0.99960244},"labels":[],"label_agreement":null},{"id":"W3212940473","doi":"10.1182/blood-2021-144912","title":"Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Interim analysis; Clinical endpoint; Population; Refractory (planetary science); Phases of clinical research; Gastroenterology; Myeloid leukemia; Surrogate endpoint; Clinical trial; Biology","score_opus":0.0075747479113264645,"score_gpt":0.24857881542706195,"score_spread":0.2410040675157355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212940473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979362,0.0001288918,0.000050015693,0.00063265854,0.000056645342,0.00064256386,0.00012094159,0.000041675954,0.0003904315],"genre_scores_gemma":[0.99564236,0.000045989433,0.002427761,0.00072112744,0.00005402771,0.00004518438,0.00015917438,0.00008570146,0.00081866496],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9970854,0.00027683302,0.0005633779,0.00055456674,0.0009467349,0.0005730752],"domain_scores_gemma":[0.997734,0.0002030733,0.00015006283,0.0009455652,0.0005943063,0.00037300293],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046762993,0.00028120223,0.0006857339,0.00038316104,0.00004192159,0.000023152055,0.00026088496,0.00021373497,0.000082614286],"category_scores_gemma":[0.0011213013,0.0002560469,0.000100564386,0.00090711616,0.00010290251,0.00010149749,0.00024400553,0.0006349295,0.00008245507],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020401796,0.0026457647,0.32402495,0.00027839883,0.0008448388,0.008918833,0.0010872454,0.00002189503,0.6384389,0.000034458546,0.00082989206,0.0024730535],"study_design_scores_gemma":[0.014001787,0.0017018189,0.777107,0.00035324745,0.00029645505,0.000086557506,0.000075528704,0.000008755389,0.20438452,0.000007985416,0.0017086904,0.00026764744],"about_ca_topic_score_codex":0.00004990702,"about_ca_topic_score_gemma":0.000012610691,"teacher_disagreement_score":0.45308205,"about_ca_system_score_codex":0.000610449,"about_ca_system_score_gemma":0.0020459613,"threshold_uncertainty_score":0.99998915},"labels":[],"label_agreement":null},{"id":"W3212989706","doi":"10.1182/blood-2021-150231","title":"Venetoclax Therapy in a Heavily Treated Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia: Update of the Pethema Registry Experience","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Medicine; Internal medicine; Cytarabine; Decitabine; Azacitidine; Retrospective cohort study; Myeloid leukemia; Cohort; Oncology; Leukemia; Surgery; Pediatrics; Chronic lymphocytic leukemia","score_opus":0.013524814090618176,"score_gpt":0.2709590697692928,"score_spread":0.2574342556786746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212989706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979848,0.00026928564,0.000004301076,0.00015829664,0.00003360466,0.00077171205,0.000049911272,0.000022362921,0.00070570497],"genre_scores_gemma":[0.99712473,0.0006604685,0.00047840018,0.00018585954,0.000028159942,0.00008979487,0.00006842622,0.000044271732,0.0013198968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786615,0.00016597952,0.00048430916,0.00041852557,0.00072165625,0.0003433706],"domain_scores_gemma":[0.99797636,0.00011088135,0.0002642533,0.0011283171,0.00041245154,0.000107720974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019596999,0.0002150442,0.0005618716,0.000095936455,0.000047589958,0.000008972778,0.0003218381,0.00018213726,0.00014821648],"category_scores_gemma":[0.00022171905,0.00012474289,0.00010134001,0.0009227862,0.00032621645,0.00009353071,0.00011787756,0.0005070359,0.0000034602901],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046702004,0.001150183,0.9271322,0.00011558811,0.00054387737,0.00050468504,0.0014144415,0.0000074347954,0.063312806,0.000014114967,0.00035532913,0.0007791681],"study_design_scores_gemma":[0.015556218,0.0010485913,0.6915065,0.000376397,0.00015988451,0.00008528584,0.00035005805,0.000021803211,0.289877,0.0000076279753,0.000854343,0.00015626133],"about_ca_topic_score_codex":0.00024991547,"about_ca_topic_score_gemma":0.000063534324,"teacher_disagreement_score":0.23562564,"about_ca_system_score_codex":0.00046187217,"about_ca_system_score_gemma":0.0025443656,"threshold_uncertainty_score":0.5086868},"labels":[],"label_agreement":null},{"id":"W3213022568","doi":"10.1182/blood-2021-149018","title":"Characteristics and Outcomes of Adolescent and Young Adult (AYA) Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML): A Single-Center Retrospective Analysis","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Internal medicine; Retrospective cohort study; International Prognostic Scoring System; Cancer; Pediatrics; Bone marrow","score_opus":0.007393911002242059,"score_gpt":0.22771382055345166,"score_spread":0.2203199095512096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213022568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987028,0.00033629755,0.00009013033,0.00010774254,0.00003856679,0.00045519666,0.00013929176,0.000027467531,0.000102487036],"genre_scores_gemma":[0.99855834,0.0004118969,0.00054794474,0.00007481229,0.000034631452,0.000019141022,0.00012038022,0.000041795596,0.00019104479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979913,0.000069521455,0.00040842543,0.00060754444,0.0005120683,0.0004111212],"domain_scores_gemma":[0.9985347,0.000093122886,0.0001874917,0.0003952123,0.0005071107,0.000282379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104585495,0.00030172977,0.0009438005,0.00029374778,0.00009017605,0.00005880061,0.00007176516,0.0001325369,0.00003140926],"category_scores_gemma":[0.00032136703,0.00024299919,0.00007990427,0.00058574864,0.0002974344,0.000111543304,0.00020889378,0.00035720272,0.000002820704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018478496,0.0006232011,0.99415845,0.00049652846,0.0020378176,0.00039232746,0.00024282117,3.8426415e-7,0.001099215,0.000019043438,0.000010117767,0.0007353302],"study_design_scores_gemma":[0.010816101,0.000988364,0.9825843,0.00035523248,0.0032822492,0.0004439352,0.00008757273,0.00041938512,0.00078034814,0.0000047562453,0.000007814575,0.00022996296],"about_ca_topic_score_codex":0.00004881121,"about_ca_topic_score_gemma":0.00013491834,"teacher_disagreement_score":0.01157415,"about_ca_system_score_codex":0.0006273826,"about_ca_system_score_gemma":0.00036359805,"threshold_uncertainty_score":0.9909219},"labels":[],"label_agreement":null},{"id":"W3213024712","doi":"10.1182/blood-2021-149312","title":"CXCR4 Drives Lympho-Myeloid Fate of Hematopoietic Progenitors <i>Via</i> mTOR and Mitochondrial Metabolic Pathways","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Biology; Myeloid; Haematopoiesis; Progenitor cell; Cell biology; Stem cell; Bone marrow; PI3K/AKT/mTOR pathway; Immunology; Signal transduction","score_opus":0.013556429593460215,"score_gpt":0.24897907201009073,"score_spread":0.23542264241663052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213024712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99098015,0.005974985,0.000096700205,0.00062350684,0.00029255802,0.0005859315,0.000053305615,0.00008134748,0.0013115236],"genre_scores_gemma":[0.9879256,0.0009481456,0.009065372,0.00036947356,0.0008038385,0.00010966678,0.00006948853,0.000069784284,0.00063864875],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99791616,0.00012882079,0.00045091205,0.0004392265,0.00059172796,0.00047315206],"domain_scores_gemma":[0.99850154,0.00011872921,0.000118410004,0.0005790948,0.00034578863,0.00033641202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015504546,0.00025059542,0.00066447794,0.0001562009,0.00008147417,0.000037101025,0.0001596847,0.00017902901,0.000123215],"category_scores_gemma":[0.0003639908,0.00021852896,0.00018501187,0.00046183448,0.00022988018,0.00013935017,0.00022852817,0.00025286974,0.00006042655],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019203265,0.0008141926,0.011117418,0.00041062414,0.00058104005,0.000520445,0.0010807036,3.5283654e-7,0.97948337,0.0006410218,0.00090175803,0.0042570494],"study_design_scores_gemma":[0.0097483555,0.00021200231,0.0039188676,0.00011219137,0.0006218915,0.0012764522,0.0004318353,0.00002275334,0.9697083,0.00023216225,0.013474737,0.00024044488],"about_ca_topic_score_codex":0.000045578283,"about_ca_topic_score_gemma":0.000005156867,"teacher_disagreement_score":0.012572979,"about_ca_system_score_codex":0.00003919705,"about_ca_system_score_gemma":0.00083672133,"threshold_uncertainty_score":0.8911352},"labels":[],"label_agreement":null},{"id":"W3213136165","doi":"10.1182/blood-2021-152612","title":"Fitness Assessment of Elderly Patients with AML and Outcomes","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Proportional hazards model; Cohort; Retrospective cohort study; Performance status; Internal medicine; Cancer; Physical therapy","score_opus":0.011549093824666568,"score_gpt":0.29926196083058804,"score_spread":0.28771286700592147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213136165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966403,0.00007084318,0.0000533499,0.00047315613,0.00001669795,0.00017468199,0.000012214873,0.000012351342,0.0025463882],"genre_scores_gemma":[0.99459076,0.000018254692,0.00442255,0.00010484261,0.000015007151,0.000009736923,0.000031830365,0.000012692521,0.00079431356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99922955,0.00002627267,0.000121325254,0.00015830535,0.00032396984,0.00014058362],"domain_scores_gemma":[0.99936837,0.00006181559,0.000036111047,0.0002310986,0.00021827819,0.000084298845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000067277586,0.000074581505,0.00022829062,0.00004187598,0.000022945314,0.000008671615,0.000039513,0.000038590966,0.000082945764],"category_scores_gemma":[0.00006304411,0.000051432686,0.000024902467,0.0001241504,0.000053165295,0.00003535288,0.000058712296,0.00012388814,0.0000020176183],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020249832,0.00062927004,0.9957675,0.000107727996,0.00017209817,0.000078202866,0.000054062068,2.836077e-7,0.0007121818,0.000102779064,0.00009551482,0.0022601534],"study_design_scores_gemma":[0.0077676354,0.0004941499,0.9862051,0.000054985692,0.00013257582,0.000017244998,0.000078213896,0.000011581124,0.0049138935,0.000012766277,0.00025526143,0.00005659921],"about_ca_topic_score_codex":0.000019706662,"about_ca_topic_score_gemma":0.000008170066,"teacher_disagreement_score":0.009562384,"about_ca_system_score_codex":0.000023978424,"about_ca_system_score_gemma":0.000283745,"threshold_uncertainty_score":0.2097364},"labels":[],"label_agreement":null},{"id":"W3213205338","doi":"10.1182/blood-2021-153426","title":"Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Decitabine; Venetoclax; Medicine; Ven; Myeloid leukemia; Bristol-Myers; Oncology; Leukemia; Internal medicine; Cancer research; Chronic lymphocytic leukemia; Biology; Gene; Genetics","score_opus":0.005387130484892558,"score_gpt":0.23303281225113728,"score_spread":0.22764568176624472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213205338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99443465,0.00048126135,0.000059987113,0.0012600723,0.00004137338,0.001450489,0.00035768363,0.000070722155,0.0018437495],"genre_scores_gemma":[0.98834884,0.00013840066,0.0060971677,0.0015666896,0.00008328794,0.00022630376,0.0006465624,0.00011085502,0.0027819092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970705,0.0001507578,0.00048591354,0.00096263335,0.0006425657,0.00068765803],"domain_scores_gemma":[0.99769044,0.00028070153,0.00017732344,0.00054572924,0.00081659755,0.00048920285],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019657346,0.0004156303,0.00075260305,0.00031549245,0.00018406268,0.000084131214,0.00015091574,0.00018553312,0.00006677764],"category_scores_gemma":[0.00025290894,0.00035501333,0.000045618064,0.0010722823,0.00031736033,0.00034756731,0.0002076838,0.0007035822,0.000018406281],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054575946,0.0043908344,0.5938744,0.0025038517,0.008966661,0.019549573,0.049326003,0.000102348815,0.20751435,0.00035425075,0.020984082,0.03785769],"study_design_scores_gemma":[0.045160763,0.0024559016,0.83068234,0.0010632867,0.00079501467,0.00027488408,0.0012278968,0.000044367822,0.112448916,0.00005908155,0.0050846613,0.0007028719],"about_ca_topic_score_codex":0.00014993823,"about_ca_topic_score_gemma":0.00092694967,"teacher_disagreement_score":0.23680794,"about_ca_system_score_codex":0.00094187824,"about_ca_system_score_gemma":0.0027337454,"threshold_uncertainty_score":0.9998902},"labels":[],"label_agreement":null},{"id":"W3213227101","doi":"10.1182/blood-2021-145379","title":"Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed <i>FLT3</i>-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Azacitidine; Myeloid leukemia; Medicine; Chemotherapy; Chemotherapy regimen; Induction chemotherapy; Internal medicine; Acute leukemia; Leukemia; Oncology; Biology; DNA methylation","score_opus":0.03491268422275007,"score_gpt":0.34731182308565184,"score_spread":0.31239913886290177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213227101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860031,0.0001927934,0.00031130484,0.0009382216,0.00013373153,0.011997735,0.00030430124,0.000048855512,0.00006992868],"genre_scores_gemma":[0.9897819,0.0006019459,0.0043917415,0.00094643375,0.00016355557,0.002458029,0.0011945188,0.00011394076,0.00034791423],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968365,0.00024651288,0.0011072605,0.00081612344,0.00040684448,0.00058675476],"domain_scores_gemma":[0.99607086,0.00071467436,0.0003466987,0.00050014205,0.0021337909,0.00023385839],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000918283,0.00040901397,0.0018932078,0.00038399687,0.00011837794,0.00008099472,0.0002607358,0.00020993293,0.00003116293],"category_scores_gemma":[0.0022700801,0.00036633405,0.0001284204,0.0007771075,0.00018047422,0.00030885905,0.00023558682,0.00034883094,0.0000015802733],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.628468,0.0345191,0.006327803,0.0009337059,0.0042984257,0.00044039023,0.005369193,0.000009383303,0.29796255,0.000081821585,0.005736644,0.015853029],"study_design_scores_gemma":[0.8208747,0.009124111,0.0009868135,0.00025872613,0.00082447723,0.000054766228,0.0014132187,0.0006849595,0.1650456,0.00013112366,0.00029997728,0.0003015357],"about_ca_topic_score_codex":0.000280593,"about_ca_topic_score_gemma":0.000061757,"teacher_disagreement_score":0.19240674,"about_ca_system_score_codex":0.00030377827,"about_ca_system_score_gemma":0.00075440976,"threshold_uncertainty_score":0.9998789},"labels":[],"label_agreement":null},{"id":"W3213274702","doi":"10.1182/blood-2021-145639","title":"Outcomes in Patients with Poor-Risk Cytogenetics with or without <i>TP53</i> Mutations Treated with Venetoclax Combined with Hypomethylating Agents","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Venetoclax; Hypomethylating agent; Medicine; Decitabine; Oncology; Cytogenetics; Internal medicine; Leukemia; Genetics; DNA methylation; Biology; Chronic lymphocytic leukemia; Gene; Chromosome","score_opus":0.017512239752694735,"score_gpt":0.27379925292779855,"score_spread":0.25628701317510383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213274702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969762,0.00003792242,0.00014750281,0.0001761571,0.000011262055,0.0016157416,0.00008170542,0.00011207231,0.0008414198],"genre_scores_gemma":[0.97834307,0.000019115952,0.019239832,0.00025536786,0.00002827613,0.0001701694,0.00036861363,0.00015839454,0.0014171324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968438,0.00018947174,0.00042314548,0.0007076026,0.0011122416,0.00072374963],"domain_scores_gemma":[0.9977576,0.0002210088,0.00025345501,0.00072325167,0.0006937912,0.00035089487],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016302035,0.00048000386,0.0008586676,0.00029415725,0.00018729572,0.00007075746,0.00017885573,0.00013559536,0.000075967284],"category_scores_gemma":[0.00017317689,0.0002687259,0.000046711153,0.0017211854,0.00022733698,0.00013809407,0.000080113066,0.0006113173,0.000016195143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055025006,0.0014763355,0.98911035,0.00008893414,0.0010058737,0.0012010748,0.00047026615,0.0004583723,0.00021362324,0.0000035850894,0.000022486614,0.0004465941],"study_design_scores_gemma":[0.06693345,0.0105113685,0.90800685,0.0005053096,0.0012377227,0.0001750333,0.000617089,0.00035852008,0.011092031,0.0000038324147,0.00006896212,0.00048980745],"about_ca_topic_score_codex":0.00034893613,"about_ca_topic_score_gemma":0.0015133872,"teacher_disagreement_score":0.08110348,"about_ca_system_score_codex":0.0003413391,"about_ca_system_score_gemma":0.0016915257,"threshold_uncertainty_score":0.9999765},"labels":[],"label_agreement":null},{"id":"W3213549898","doi":"10.1182/blood-2021-145369","title":"High-Throughput Chemical Screen on Acute Myeloid Leukemia Stem Cells Identifies Novel Anti-LSC Compounds","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal; Université Laval; Hôpital de l'Enfant-Jésus; McGill University; McGill University Health Centre","funders":"","keywords":"Haematopoiesis; CD34; Leukemia; Stem cell; Bone marrow; Myeloid leukemia; Immunology; Cytotoxic T cell; Cord blood; Cancer research; Myeloid; Medicine; Biology; In vitro; Cell biology; Biochemistry","score_opus":0.02420899417155728,"score_gpt":0.2773976597964566,"score_spread":0.2531886656248993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213549898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991901,0.0003740843,0.00021090235,0.0015613,0.00036630602,0.00044820883,0.0002271443,0.0002383729,0.0046726908],"genre_scores_gemma":[0.98001784,0.00034146273,0.0050723646,0.0015872458,0.0009885237,0.00003556391,0.00039876692,0.00012992944,0.011428273],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99639595,0.000081357575,0.0005735466,0.00095261564,0.0011362596,0.00086025597],"domain_scores_gemma":[0.9976225,0.00025049373,0.00012974461,0.0011927414,0.00038811268,0.00041639112],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003188554,0.00043004056,0.00085148413,0.00017980699,0.00017071808,0.00014922213,0.00043752958,0.00036713076,0.00028277904],"category_scores_gemma":[0.000057585017,0.00039923674,0.0002754795,0.00065592374,0.00026340003,0.00017236176,0.00048497246,0.0010218347,0.0008485825],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018124856,0.00091665384,0.00064437627,0.0001390971,0.0008836765,0.0016632449,0.00013432019,0.000007427863,0.9742045,0.00047153878,0.020034296,0.00071964605],"study_design_scores_gemma":[0.009732012,0.00023079048,0.0029057786,0.00022639634,0.00059555995,0.00075870997,0.00018581504,0.00012819971,0.978776,0.000034773242,0.0060333805,0.00039259373],"about_ca_topic_score_codex":0.00016981525,"about_ca_topic_score_gemma":0.000009720702,"teacher_disagreement_score":0.014000917,"about_ca_system_score_codex":0.0005946074,"about_ca_system_score_gemma":0.0011590442,"threshold_uncertainty_score":0.99992937},"labels":[],"label_agreement":null},{"id":"W3213564228","doi":"10.1182/blood-2021-146016","title":"Clinical Predictors of Outcome in Adult Patients with Acute Leukemias and Myelodysplastic Syndrome and COVID-19 Infection: Report from the American Society of Hematology Research Collaborative (ASH RC) Data Hub","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; BC Cancer Agency","funders":"","keywords":"Hematology; Medicine; Internal medicine; Myelodysplastic syndromes; Coronavirus disease 2019 (COVID-19); Hematologic Neoplasms; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Oncology; Intensive care medicine; Immunology; Cancer; Disease; Bone marrow","score_opus":0.06874796974461896,"score_gpt":0.40694446466256085,"score_spread":0.3381964949179419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213564228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965936,0.00017247674,0.000060460305,0.0018445035,0.000041010277,0.0006780022,0.0005289156,0.000016048652,0.00006501319],"genre_scores_gemma":[0.9965504,0.0008165397,0.00164156,0.0003466675,0.000049465827,0.000031736767,0.00046655993,0.000024576044,0.00007248714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664026,0.00066434406,0.0008694718,0.0007095983,0.0007859167,0.00033039102],"domain_scores_gemma":[0.99406666,0.003178588,0.00039699633,0.0010735028,0.001002773,0.0002814591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015250907,0.00016993063,0.00091106154,0.00009921214,0.00009935881,0.000016718719,0.00022748756,0.00015385389,0.000021871982],"category_scores_gemma":[0.0057738195,0.000115144816,0.000047842103,0.0013159679,0.0020750791,0.00011801857,0.00083195267,0.00085591886,0.000001326596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005364438,0.0005630185,0.992325,0.00018853982,0.0009978774,0.0013689322,0.0005643001,0.0000010186628,0.00007734751,0.000022067006,0.003255582,0.00009983849],"study_design_scores_gemma":[0.009014001,0.0012011044,0.98624855,0.00015141304,0.00038683324,0.0010573086,0.001071575,0.000103695085,0.00020230464,0.000029445027,0.00043257987,0.00010116868],"about_ca_topic_score_codex":0.0018731069,"about_ca_topic_score_gemma":0.0008781814,"teacher_disagreement_score":0.008477557,"about_ca_system_score_codex":0.00014795002,"about_ca_system_score_gemma":0.0029724075,"threshold_uncertainty_score":0.76457155},"labels":[],"label_agreement":null},{"id":"W3213612154","doi":"10.1182/blood-2021-147465","title":"Prognostic Impact of <i>NPM1</i> and <i>FLT3</i> Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"NPM1; Myeloid leukemia; Medicine; Chemotherapy regimen; Cytarabine; Internal medicine; Oncology; Chemotherapy; Minimal residual disease; Leukemia; Disease; Residual; Biology; Gene; Genetics","score_opus":0.01993687099546896,"score_gpt":0.28515399052427687,"score_spread":0.2652171195288079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213612154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993676,0.00073690974,0.000019705196,0.0016917475,0.00003111792,0.0024753127,0.0013404854,0.000011947481,0.000016790027],"genre_scores_gemma":[0.9968245,0.0007250909,0.001335489,0.00020341437,0.000034507997,0.00042450396,0.0002811433,0.00004542376,0.0001259169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977145,0.00017644295,0.00061640394,0.00049167813,0.0006119721,0.0003889908],"domain_scores_gemma":[0.9961605,0.0015129229,0.00031906788,0.00053082604,0.0012272742,0.0002494145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032507986,0.00028567167,0.0008321155,0.000097246695,0.00006597144,0.000019581405,0.00016155613,0.000105949104,0.00004494538],"category_scores_gemma":[0.003057869,0.00017491209,0.00014669192,0.00038958597,0.00047335582,0.00016488458,0.00015355302,0.00022955408,4.2523385e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048801944,0.001138729,0.9415843,0.00021177506,0.000775645,0.00010836998,0.0008077943,0.0000063027924,0.0042030765,0.000004009035,0.001355365,0.0010026869],"study_design_scores_gemma":[0.105173886,0.0020839756,0.86532104,0.0008923589,0.0009446358,0.000014773588,0.00030557765,0.00010235434,0.024765957,0.00013329822,0.000054461558,0.00020770883],"about_ca_topic_score_codex":0.0006736313,"about_ca_topic_score_gemma":0.00021050511,"teacher_disagreement_score":0.07626329,"about_ca_system_score_codex":0.00016814108,"about_ca_system_score_gemma":0.00095535023,"threshold_uncertainty_score":0.7132708},"labels":[],"label_agreement":null},{"id":"W3213616525","doi":"10.1182/blood-2021-148044","title":"Impact of Post-Remission Maintenance Therapy (MT) on Outcomes in Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) in Real-World Practice","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Venetoclax; Internal medicine; Oncology; Induction chemotherapy; Cohort; Myeloid leukemia; Maintenance therapy; Azacitidine; Minimal residual disease; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.015318017967176125,"score_gpt":0.3228791073365389,"score_spread":0.3075610893693628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213616525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283576,0.00009017002,0.000003881119,0.0015237802,0.000041748364,0.00093603606,0.00004628798,0.00003820261,0.0044841073],"genre_scores_gemma":[0.9945678,0.0012169991,0.00137156,0.00090872386,0.00004592472,0.000056131532,0.0001264951,0.000074453616,0.0016318926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970129,0.0002804263,0.0005848833,0.0005909638,0.0008686521,0.00066217827],"domain_scores_gemma":[0.9972477,0.00079291133,0.00026879756,0.000817911,0.0006163818,0.0002562948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044178846,0.00035442386,0.0007971282,0.00047891744,0.000040155814,0.000025420552,0.00023847538,0.00016324988,0.00011882357],"category_scores_gemma":[0.001547989,0.00023680899,0.00016758312,0.0012450244,0.0000850226,0.00026403682,0.00010164308,0.00085244334,0.000024366276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007446598,0.004506628,0.95927,0.000049741262,0.0005081407,0.002625575,0.0007005863,0.000048434966,0.016864289,0.00002831043,0.00069059146,0.0072611338],"study_design_scores_gemma":[0.04296037,0.0033276572,0.9398668,0.0005706497,0.00009629626,0.000044747758,0.00020816024,0.00003821844,0.012286672,0.000010035697,0.00035233927,0.00023804854],"about_ca_topic_score_codex":0.004883419,"about_ca_topic_score_gemma":0.00084483885,"teacher_disagreement_score":0.035513774,"about_ca_system_score_codex":0.0015794641,"about_ca_system_score_gemma":0.0023586794,"threshold_uncertainty_score":0.96567905},"labels":[],"label_agreement":null},{"id":"W3213621509","doi":"10.1182/blood-2021-153170","title":"A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Azacitidine; Medicine; Internal medicine; Regimen; Concomitant; Myelodysplastic syndromes; Oncology; Refractory (planetary science); Cohort; Gastroenterology; Leukemia; Bone marrow","score_opus":0.015823490518004458,"score_gpt":0.28517564193859457,"score_spread":0.2693521514205901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213621509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985164,0.000454496,0.0000024014337,0.00010284922,0.00006388375,0.0005303813,0.000018459103,0.000007980428,0.00030316986],"genre_scores_gemma":[0.9993203,0.000089062734,0.000045517627,0.000016798656,0.000017636858,0.000024602621,0.0000075056923,0.000017884324,0.0004606559],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986882,0.00022393261,0.0003275812,0.00021632595,0.00038618143,0.00015777572],"domain_scores_gemma":[0.99902475,0.00024355343,0.00013978856,0.0003801352,0.00014980754,0.00006198836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029166302,0.00010261039,0.00033276665,0.00012940781,0.000033095974,0.00000484986,0.00009354407,0.000076417746,0.000072439885],"category_scores_gemma":[0.00041587432,0.00007747586,0.000039856328,0.00050031894,0.00009405511,0.00003767649,0.00012467819,0.0003575052,0.000002772973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011744464,0.045298647,0.6666779,0.0010531765,0.001159184,0.0024696596,0.0050036493,0.000054806664,0.2731848,0.0005137213,0.0002687632,0.0031412435],"study_design_scores_gemma":[0.05204956,0.0043761833,0.9212238,0.00029898458,0.00047436953,0.00023539952,0.0008445646,0.00025724704,0.019882685,0.00012923028,0.00011886323,0.000109123095],"about_ca_topic_score_codex":0.00021095642,"about_ca_topic_score_gemma":0.000049273396,"teacher_disagreement_score":0.2545459,"about_ca_system_score_codex":0.00010687202,"about_ca_system_score_gemma":0.00032357775,"threshold_uncertainty_score":0.3159374},"labels":[],"label_agreement":null},{"id":"W3213659569","doi":"10.1182/blood-2021-147769","title":"Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Decitabine; Internal medicine; Medicine; Cytarabine; Clinical endpoint; Anthracycline; Chemotherapy regimen; Chemotherapy; Surrogate endpoint; Gastroenterology; Oncology; Azacitidine; Refractory (planetary science); Randomized controlled trial; Biology; Cancer; Breast cancer","score_opus":0.016189166860232987,"score_gpt":0.30773893768878774,"score_spread":0.29154977082855477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213659569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99238694,0.0002352772,0.000006700352,0.00030753683,0.00009344249,0.0061760005,0.0005711883,0.00006223852,0.00016068394],"genre_scores_gemma":[0.9966929,0.00020956925,0.00078993564,0.00031602653,0.00014762707,0.00062298065,0.0004340871,0.00007952189,0.0007073372],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949845,0.0007162508,0.0013552626,0.0011658937,0.0011436867,0.0006344232],"domain_scores_gemma":[0.9959114,0.0008420858,0.00042703186,0.001325574,0.0011738985,0.00031999464],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004391305,0.0006102647,0.002223038,0.0002257627,0.000057200417,0.00003755575,0.0002599002,0.00020459857,0.00021817394],"category_scores_gemma":[0.0014789386,0.00039303917,0.00022310077,0.0010731173,0.00017742568,0.00017552839,0.00014787665,0.0005160607,0.000018072444],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7944696,0.0562224,0.12197377,0.000027190097,0.0063145705,0.0055748452,0.010800279,0.0000037805105,0.0009976536,2.5994186e-7,0.00021012728,0.003405519],"study_design_scores_gemma":[0.76685274,0.02128447,0.20163019,0.00021985917,0.0020464463,0.000018962868,0.0050035245,0.00003152745,0.0024837188,0.000003454047,0.00012953847,0.00029553872],"about_ca_topic_score_codex":0.0032173907,"about_ca_topic_score_gemma":0.0023771496,"teacher_disagreement_score":0.07965643,"about_ca_system_score_codex":0.0015001972,"about_ca_system_score_gemma":0.0014925345,"threshold_uncertainty_score":0.9998521},"labels":[],"label_agreement":null},{"id":"W3213660215","doi":"10.1182/blood-2021-148497","title":"Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Fludarabine; Tolerability; Transplantation; Oncology; Hematopoietic stem cell transplantation; Refractory (planetary science); Clinical trial; Adverse effect; Chemotherapy; Cyclophosphamide","score_opus":0.019088134888986346,"score_gpt":0.31811780428681447,"score_spread":0.2990296693978281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213660215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955292,0.00025095884,0.0003149658,0.00041651848,0.00004654496,0.0030775405,0.00005535646,0.000033486762,0.00027545608],"genre_scores_gemma":[0.9968495,0.0005471827,0.0013470408,0.00032636579,0.000045721703,0.00045195266,0.0002872815,0.000040526564,0.0001044381],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961795,0.0011742502,0.0008080365,0.0006365972,0.0007297082,0.00047187606],"domain_scores_gemma":[0.9973025,0.0017107155,0.00022463128,0.00039848097,0.0002001247,0.00016355293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001545556,0.00029746332,0.0009556401,0.00043764865,0.000262833,0.0000889799,0.00017894797,0.0001386044,0.00012451157],"category_scores_gemma":[0.00047104328,0.0001882985,0.00008270066,0.0011350423,0.00026999443,0.00033886815,0.000048287817,0.0005745256,0.000002260402],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90882367,0.005937184,0.03905979,0.0002380212,0.00027648162,0.0008982246,0.03248047,0.00002469461,0.0113628665,0.00004970678,0.000015716787,0.0008331821],"study_design_scores_gemma":[0.892373,0.00217347,0.0573579,0.0004540138,0.000292035,0.00004662899,0.008243885,0.00004604868,0.038531035,0.000007943168,0.00019078694,0.00028320213],"about_ca_topic_score_codex":0.000068609166,"about_ca_topic_score_gemma":0.000051145045,"teacher_disagreement_score":0.02716817,"about_ca_system_score_codex":0.00015036683,"about_ca_system_score_gemma":0.00044648623,"threshold_uncertainty_score":0.767859},"labels":[],"label_agreement":null},{"id":"W3213958873","doi":"10.1182/blood-2021-153189","title":"Initial Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndrome and Myelodysplastic/Myeloproliferative Neoplasm with <i>FLT3</i> or <i>CBL</i> Mutations","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Azacitidine; Medicine; Tolerability; Hypomethylating agent; Myelodysplastic syndromes; Internal medicine; Phases of clinical research; Decitabine; Oncology; Clinical trial; Adverse effect; Bone marrow; Biology; Genetics","score_opus":0.016054618808344186,"score_gpt":0.29324784245792823,"score_spread":0.27719322364958404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213958873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956361,0.000017197255,0.000416415,0.00016084765,0.000025557996,0.0030372315,0.00047468705,0.00002908673,0.00020288474],"genre_scores_gemma":[0.99522686,0.0000071890304,0.0036138617,0.0000351235,0.000023872803,0.000355389,0.00052808656,0.00006158473,0.00014804103],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972891,0.00014004209,0.0007666177,0.00060145365,0.00079071557,0.0004120405],"domain_scores_gemma":[0.99668354,0.0009164834,0.00037558627,0.00036159236,0.0014682818,0.00019452555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002550696,0.00033057464,0.0008283996,0.00036586024,0.00014892695,0.000022408325,0.00010341406,0.00010015891,0.000012851992],"category_scores_gemma":[0.0007644443,0.00022406096,0.000029764054,0.0011795933,0.00030144735,0.00023332477,0.00008639064,0.00030952107,8.3847993e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31466976,0.2079675,0.39963245,0.0041628308,0.0057936697,0.007602647,0.04044829,0.0009142081,0.013084348,0.0004928932,0.00022724726,0.005004164],"study_design_scores_gemma":[0.56310296,0.23298328,0.15364835,0.002025024,0.00228399,0.0012437921,0.007314048,0.0009921906,0.03562632,0.000040207397,0.000048059865,0.00069177226],"about_ca_topic_score_codex":0.000057709076,"about_ca_topic_score_gemma":0.00080971734,"teacher_disagreement_score":0.24843323,"about_ca_system_score_codex":0.00007036445,"about_ca_system_score_gemma":0.0011460317,"threshold_uncertainty_score":0.9136941},"labels":[],"label_agreement":null},{"id":"W3213974098","doi":"10.1182/blood-2021-145723","title":"Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Myeloid leukemia; Internal medicine; Oncology; Leukemia; Cytarabine; Bone marrow","score_opus":0.01253221888091933,"score_gpt":0.286206911600602,"score_spread":0.2736746927196827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213974098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968442,0.000074708005,0.0003716497,0.00025938184,0.00003253505,0.00222751,0.00014850081,0.000017643582,0.000023870183],"genre_scores_gemma":[0.9980347,0.000069827176,0.0013581697,0.00003152986,0.000018906634,0.00015640589,0.0001856134,0.0000318808,0.000112923124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99689436,0.00069924636,0.00071290554,0.0005125341,0.00085310644,0.0003278191],"domain_scores_gemma":[0.9972892,0.00095826393,0.0003305224,0.0006383667,0.00066013326,0.00012353303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014995756,0.00023272568,0.00078801555,0.00061023905,0.00011784647,0.000029982408,0.00019754957,0.000116420786,0.000026220696],"category_scores_gemma":[0.0017367837,0.00015179026,0.00010412729,0.0022694624,0.000098338656,0.00011241959,0.00013665887,0.00026068065,8.461466e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017458837,0.0020032183,0.95816946,0.00020004882,0.0025813952,0.00015807888,0.00707299,0.00016666875,0.008929912,0.0000025030188,0.000030024492,0.003226891],"study_design_scores_gemma":[0.011465958,0.005378944,0.9720732,0.00031217816,0.0045859884,0.000022187962,0.0025726021,0.0006119203,0.0027948746,0.000001415664,0.000027122065,0.00015359276],"about_ca_topic_score_codex":0.00012590211,"about_ca_topic_score_gemma":0.0007343645,"teacher_disagreement_score":0.013903785,"about_ca_system_score_codex":0.00020642996,"about_ca_system_score_gemma":0.00047650872,"threshold_uncertainty_score":0.6189827},"labels":[],"label_agreement":null},{"id":"W3214043801","doi":"10.1182/blood-2021-146572","title":"Single-Cell Proteogenomic Sequencing Allows Early Detection of Relapse Clone with CN-LOH at <i>FLT3</i>-ITD Locus from Initial Diagnosis in AML","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"NPM1; Oncology; Medicine; Internal medicine; Midostaurin; CDKN2A; Myeloid leukemia; Biology; Karyotype; Gene; Genetics","score_opus":0.021957124140736906,"score_gpt":0.2407634925257403,"score_spread":0.2188063683850034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214043801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99659956,0.0008969728,0.00007763842,0.0001847613,0.00006505972,0.0008679201,0.00004294346,0.00005716808,0.0012079878],"genre_scores_gemma":[0.9964239,0.0001327271,0.0024575994,0.000104622035,0.0002315494,0.0001996592,0.00006225174,0.00007685268,0.00031081098],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977701,0.00018711886,0.00047934693,0.0005642277,0.0005313512,0.0004678755],"domain_scores_gemma":[0.99864346,0.00022722814,0.0001662955,0.00055770576,0.00021216038,0.00019314994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002442424,0.00024015861,0.0005071515,0.0002031459,0.00007143829,0.000025781672,0.00014218454,0.00022623308,0.00015388502],"category_scores_gemma":[0.00024125003,0.00022361783,0.00010187434,0.00056554016,0.00012601358,0.00012892506,0.00017711801,0.0005969045,0.00006818018],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007697615,0.0007984858,0.045988943,0.00013108218,0.0001402116,0.0024466482,0.0009045123,0.000019064295,0.9474189,0.0000010940188,0.0000291723,0.0013521033],"study_design_scores_gemma":[0.012244232,0.0012272667,0.008099063,0.00034025114,0.00026173802,0.00023132091,0.00025417248,0.000056290643,0.97680736,0.000021979504,0.00023458456,0.00022175802],"about_ca_topic_score_codex":0.0034227655,"about_ca_topic_score_gemma":0.002030335,"teacher_disagreement_score":0.03788988,"about_ca_system_score_codex":0.0010874589,"about_ca_system_score_gemma":0.00084052334,"threshold_uncertainty_score":0.91188705},"labels":[],"label_agreement":null},{"id":"W3214072263","doi":"10.1182/blood-2021-153660","title":"Enasidenib in Combination with Venetoclax in <i>IDH2</i>-Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Venetoclax; IDH2; Medicine; Internal medicine; Ven; Myeloid leukemia; Myeloid; Oncology; IDH1; Leukemia; Biology; Mutation; Chronic lymphocytic leukemia","score_opus":0.01857005648884793,"score_gpt":0.2886640578184658,"score_spread":0.2700940013296179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214072263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949389,0.00034957493,0.000005931418,0.0015794862,0.000089752706,0.0015760196,0.00004602788,0.000028207674,0.0013861189],"genre_scores_gemma":[0.997877,0.00008306108,0.00029390753,0.00014870756,0.00008660637,0.00012840732,0.00014280093,0.000035315865,0.0012041678],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99747485,0.00032981506,0.00067502947,0.00043189197,0.0006749593,0.00041348173],"domain_scores_gemma":[0.99849766,0.00027501993,0.00019817307,0.0006597698,0.00027180708,0.000097588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007260369,0.00019602593,0.00046962762,0.000225681,0.000065117536,0.000014506585,0.00023336535,0.00017188049,0.000028205575],"category_scores_gemma":[0.0011057518,0.00014217559,0.000090149806,0.0013701641,0.00015138328,0.00010315698,0.0001978725,0.0005551466,0.0000059056533],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44348714,0.0239164,0.011940779,0.00094621937,0.0005535679,0.0094225565,0.013622309,0.000532067,0.48633224,0.00043826978,0.0035621522,0.0052463],"study_design_scores_gemma":[0.4747956,0.007657597,0.0146113355,0.0010974058,0.00015615337,0.00031193954,0.0007958669,0.0005630138,0.4988208,0.00010567678,0.00087368995,0.0002108955],"about_ca_topic_score_codex":0.0003404803,"about_ca_topic_score_gemma":0.00026309022,"teacher_disagreement_score":0.031308483,"about_ca_system_score_codex":0.00032016909,"about_ca_system_score_gemma":0.0022886614,"threshold_uncertainty_score":0.5797752},"labels":[],"label_agreement":null},{"id":"W3214073113","doi":"10.1182/blood-2021-147293","title":"OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Azacitidine; Medicine; Refractory (planetary science); Myeloid leukemia; Internal medicine; Leukemia; Oncology; Myeloid; Phases of clinical research; Gastroenterology; Clinical trial; Biology","score_opus":0.01874568387630128,"score_gpt":0.29085800065010825,"score_spread":0.272112316773807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214073113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99701965,0.00015074277,0.00001766166,0.00007788952,0.000089963236,0.001915813,0.000102046695,0.00007408343,0.00055217353],"genre_scores_gemma":[0.9962966,0.000103576036,0.0009864031,0.00016768655,0.000090170404,0.000115374685,0.00026882722,0.000098718716,0.0018726604],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964521,0.00024683468,0.00066225673,0.00077864365,0.0011202601,0.00073991495],"domain_scores_gemma":[0.997645,0.00022881078,0.0002362359,0.0009757047,0.00053227274,0.00038193178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029519803,0.00040988866,0.0009995095,0.0004044493,0.0000860772,0.000027653568,0.0003164818,0.00022199313,0.00041186484],"category_scores_gemma":[0.0003873744,0.000325034,0.00011159441,0.0013378646,0.00015578537,0.00025471914,0.00024672115,0.00086094835,0.000041748095],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08030373,0.11388529,0.62271214,0.0011003758,0.007833913,0.08961708,0.019633325,0.00035568365,0.02955051,0.00005408552,0.00973098,0.025222903],"study_design_scores_gemma":[0.707072,0.033536606,0.2282886,0.00073533115,0.0024026225,0.00022133523,0.006944165,0.00036507752,0.01637011,0.00001349451,0.0030885322,0.00096209865],"about_ca_topic_score_codex":0.00083781854,"about_ca_topic_score_gemma":0.00074209255,"teacher_disagreement_score":0.6267683,"about_ca_system_score_codex":0.0017338785,"about_ca_system_score_gemma":0.0048301057,"threshold_uncertainty_score":0.9999202},"labels":[],"label_agreement":null},{"id":"W3214093530","doi":"10.1182/blood-2021-153571","title":"A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with <i>FLT3</i>-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Azacitidine; Medicine; Internal medicine; Decitabine; Chemotherapy regimen; Regimen; Gastroenterology; Myeloid leukemia; Myeloid; Chemotherapy; Leukemia; Oncology; Chemistry","score_opus":0.015928170738365263,"score_gpt":0.28881110676484634,"score_spread":0.27288293602648106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214093530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436605,0.00010152105,0.00006900985,0.00026081572,0.00004558192,0.002325746,0.0025794667,0.00005368217,0.00019811302],"genre_scores_gemma":[0.9930397,0.000052494415,0.0022934638,0.00010163497,0.0000752831,0.0001921161,0.00390904,0.000051551913,0.00028467932],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978325,0.00011122669,0.00056867365,0.00059407495,0.0005415162,0.00035200408],"domain_scores_gemma":[0.9979867,0.00028047143,0.00021669392,0.0004859767,0.0008351261,0.00019505723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026252307,0.00024133101,0.00060884876,0.00014526752,0.00013770511,0.00002991574,0.00011889924,0.00012308855,0.00002079076],"category_scores_gemma":[0.0004975561,0.00020725043,0.00007048167,0.00045794048,0.00008888073,0.00012481229,0.00014213673,0.00026153467,0.0000018962289],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17200617,0.10575008,0.15495552,0.001421807,0.016595418,0.0049193227,0.020047374,0.000021142145,0.46972284,0.00021113949,0.012356857,0.041992333],"study_design_scores_gemma":[0.67105013,0.048860937,0.08575512,0.00053373916,0.0032955538,0.00010845913,0.0014936032,0.0009919174,0.18506844,0.00013949513,0.0020884916,0.00061413343],"about_ca_topic_score_codex":0.00016483662,"about_ca_topic_score_gemma":0.000041762898,"teacher_disagreement_score":0.4990439,"about_ca_system_score_codex":0.00021827365,"about_ca_system_score_gemma":0.000882763,"threshold_uncertainty_score":0.8451427},"labels":[],"label_agreement":null},{"id":"W3214146106","doi":"10.1182/blood-2021-154278","title":"STAT5 Signaling Promotes Resistance to Ivosidenib in <i>IDH1</i>-Mutated AML","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"IDH1; Isocitrate dehydrogenase; Cancer research; Syk; Myeloid leukemia; Myeloid; Mutant; Biology; Cell biology; Signal transduction; Tyrosine kinase; Genetics; Gene; Biochemistry","score_opus":0.01875031370733994,"score_gpt":0.2922035889889574,"score_spread":0.27345327528161745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214146106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895283,0.0009356557,0.000095421354,0.004590707,0.000037605623,0.00051886286,0.000016499422,0.000088846245,0.004188076],"genre_scores_gemma":[0.9834766,0.000046760313,0.00984441,0.000992003,0.00014035217,0.000066389955,0.000048362712,0.00004870829,0.005336424],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99810016,0.00011297227,0.0003340415,0.0004629725,0.00046432717,0.0005255073],"domain_scores_gemma":[0.9988315,0.00016213633,0.000039362207,0.0004403815,0.00026130793,0.0002652894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035816876,0.00015881479,0.00033846032,0.00017654158,0.00005298178,0.00004295037,0.00014033623,0.000094811076,0.00021515772],"category_scores_gemma":[0.0008775322,0.00015371862,0.000060075603,0.0010574196,0.0000385573,0.0000722224,0.00011960226,0.0004097589,0.00016748343],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027486918,0.0006465929,0.014408399,0.00024248488,0.000105581756,0.0065731714,0.001000971,0.000013911943,0.97238946,0.00012127814,0.0037016016,0.0005216558],"study_design_scores_gemma":[0.0053989096,0.00016721824,0.007856708,0.00052924524,0.00007527648,0.0001380589,0.0003943303,0.000033153337,0.979306,0.00025380915,0.0056297723,0.00021752332],"about_ca_topic_score_codex":0.00007412588,"about_ca_topic_score_gemma":0.0003890008,"teacher_disagreement_score":0.009748989,"about_ca_system_score_codex":0.00017513616,"about_ca_system_score_gemma":0.0007593263,"threshold_uncertainty_score":0.6268463},"labels":[],"label_agreement":null},{"id":"W3214165942","doi":"10.1182/blood-2021-147805","title":"AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an <i>IDH1</i> Mutation","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; IDH1; Interquartile range; Clinical endpoint; Myeloid leukemia; Placebo; Gastroenterology; Phases of clinical research; Randomized controlled trial; Oncology; Surgery; Clinical trial; Pathology; Biology","score_opus":0.021167656536138023,"score_gpt":0.30955397527476297,"score_spread":0.28838631873862497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214165942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921904,0.00014725329,0.00012966341,0.0001594392,0.00009451946,0.0063538733,0.00016379326,0.00011016448,0.00065085513],"genre_scores_gemma":[0.99551475,0.000079835554,0.0019196734,0.00012560181,0.00013781502,0.00077249826,0.0012685057,0.00009847656,0.00008283764],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950245,0.000523726,0.0009967764,0.0010279235,0.0016478617,0.00077919423],"domain_scores_gemma":[0.99639016,0.0005233304,0.00041839966,0.0010303557,0.0011440072,0.0004937522],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007090342,0.0005925464,0.0016767059,0.00035925594,0.00012281451,0.00008520833,0.0003172557,0.0002159824,0.000113946655],"category_scores_gemma":[0.00034893496,0.0004565791,0.00014251917,0.0020148382,0.00029372936,0.00052174606,0.00014872946,0.00063462363,0.000016602722],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9399816,0.014982628,0.0335171,0.00013899825,0.0024312506,0.005349374,0.001402182,0.00022565843,0.00083340844,0.000041065985,0.00012918662,0.0009675711],"study_design_scores_gemma":[0.961736,0.0146265915,0.004013482,0.0002897509,0.002833116,0.00013814619,0.0029967814,0.00025208946,0.01261541,0.000009769869,0.00002047277,0.00046839193],"about_ca_topic_score_codex":0.001230125,"about_ca_topic_score_gemma":0.002327476,"teacher_disagreement_score":0.02950362,"about_ca_system_score_codex":0.000739945,"about_ca_system_score_gemma":0.0019275089,"threshold_uncertainty_score":0.9997886},"labels":[],"label_agreement":null},{"id":"W3214236472","doi":"10.1182/blood-2021-146172","title":"Targeted Next Generation Sequencing Reveals a Third Breakpoint Cluster Region and New Partner Genes in the <i>KMT2A</i> Recombinome","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Breakpoint; breakpoint cluster region; Biology; Genetics; Gene; Gene rearrangement; Chromosomal translocation","score_opus":0.10079042494012913,"score_gpt":0.2965271475511858,"score_spread":0.19573672261105668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214236472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760313,0.004042482,0.00016030976,0.017336994,0.0000711762,0.0005145331,0.000001766647,0.00003560822,0.0018058361],"genre_scores_gemma":[0.9831479,0.0015304559,0.0028682298,0.007389646,0.00084298605,0.000054804288,0.000091205984,0.0000355505,0.004039175],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99833685,0.00031372003,0.00032596113,0.00038195023,0.0003058585,0.00033566347],"domain_scores_gemma":[0.9990876,0.00012448392,0.00006546321,0.00046729264,0.00011552246,0.00013967036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058868714,0.00015518734,0.00027321317,0.00009570764,0.00008984123,0.000097423035,0.000104181214,0.00013773548,0.00003849709],"category_scores_gemma":[0.00025258015,0.00011106513,0.000061780906,0.00039339962,0.000044361266,0.00016189388,0.00009169371,0.0003693252,0.000023150453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013482806,0.00030638045,0.018029192,0.00018448991,0.00014237786,0.001910325,0.004067618,0.000018569812,0.9090382,0.0004327952,0.055934064,0.0098011885],"study_design_scores_gemma":[0.06542683,0.002151614,0.092657596,0.0017030868,0.0016235379,0.03598531,0.008250005,0.015884671,0.69800353,0.0062439027,0.06980962,0.0022602824],"about_ca_topic_score_codex":0.00032761815,"about_ca_topic_score_gemma":0.00023028582,"teacher_disagreement_score":0.21103463,"about_ca_system_score_codex":0.00014094514,"about_ca_system_score_gemma":0.0005674391,"threshold_uncertainty_score":0.45291042},"labels":[],"label_agreement":null},{"id":"W3214290048","doi":"10.1182/blood-2021-151605","title":"A Phase I/II Study of Sapacitabine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Ven; Medicine; Decitabine; Internal medicine; Gastroenterology; Regimen; Concomitant; Cytarabine; Oncology; Myeloid leukemia; Mucositis; Leukemia; Chemotherapy; Chemistry; Chronic lymphocytic leukemia","score_opus":0.019874684448830796,"score_gpt":0.3076351623868574,"score_spread":0.2877604779380266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214290048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964094,0.0013114375,0.0000032044004,0.00019590057,0.000045738157,0.00065238925,0.00002169031,0.000035221852,0.0013250046],"genre_scores_gemma":[0.99752694,0.0002958376,0.00043276456,0.00011197729,0.000099859244,0.00005176416,0.000030875333,0.00004003482,0.0014099159],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998129,0.00013483204,0.0004448384,0.00046154985,0.0004521394,0.00037765218],"domain_scores_gemma":[0.9988185,0.00011679217,0.000091052374,0.0005913631,0.00017184477,0.00021040135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034267173,0.00019835195,0.0005941533,0.00025400595,0.00006773133,0.000011649645,0.00012102736,0.00014313041,0.000113051625],"category_scores_gemma":[0.00028755635,0.00018554807,0.000060976232,0.00063396676,0.00010330278,0.00007495995,0.00025449722,0.00060642976,0.000010574472],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023641472,0.026455907,0.04747181,0.00041258225,0.0015501078,0.0103977155,0.010292268,0.000013239622,0.87913054,0.000082431456,0.0012341749,0.020595092],"study_design_scores_gemma":[0.4675071,0.06230994,0.14750063,0.0008971941,0.0029999425,0.0027548103,0.013331586,0.0011526949,0.29089436,0.00020682438,0.0092583895,0.0011865133],"about_ca_topic_score_codex":0.00020832174,"about_ca_topic_score_gemma":0.00013540301,"teacher_disagreement_score":0.58823615,"about_ca_system_score_codex":0.00041196344,"about_ca_system_score_gemma":0.001368961,"threshold_uncertainty_score":0.75664306},"labels":[],"label_agreement":null},{"id":"W3214305505","doi":"10.1182/blood-2021-147095","title":"Impact of Tet2 Deficiency, and of <i>TET2</i> Mutations in Clonal Hematopoiesis, on Neutrophil/Granulocyte Immune Function","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Molecular biology; Haematopoiesis; Biology; Immune system; Granulocyte; Immunology; Bone marrow; Genetics; Stem cell","score_opus":0.013321235152191897,"score_gpt":0.28816659256660543,"score_spread":0.2748453574144135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214305505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960597,0.0017944615,0.000029803106,0.00025629578,0.000026785418,0.00021764939,0.000040392155,0.000012429446,0.0015624587],"genre_scores_gemma":[0.9992361,0.00019903606,0.0003118117,0.000027821143,0.000030161427,0.000012136682,0.00005776236,0.000016397062,0.00010877228],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988107,0.0000668298,0.00035772892,0.00022154617,0.00032329466,0.00021989111],"domain_scores_gemma":[0.99918115,0.00016301539,0.00009153571,0.00029889302,0.00018541176,0.00008000975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020089698,0.00011916501,0.0003591341,0.00022451597,0.00003600996,0.0000068971567,0.000060023638,0.00008216417,0.00008710723],"category_scores_gemma":[0.00019554717,0.000101049416,0.00012480286,0.0005749106,0.0001328087,0.000053836196,0.000053600314,0.00024232715,0.000006578398],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006838816,0.0021731975,0.091220014,0.00032454217,0.00017208404,0.0001892999,0.00041087833,0.000097690594,0.9029672,0.000587328,0.000090951944,0.0010829159],"study_design_scores_gemma":[0.00728633,0.0013812219,0.72150254,0.00019564993,0.00020048763,0.00032479505,0.00028376168,0.00010273099,0.26828203,0.0002939879,0.000038221708,0.00010823133],"about_ca_topic_score_codex":0.00031065758,"about_ca_topic_score_gemma":0.000025564797,"teacher_disagreement_score":0.63468516,"about_ca_system_score_codex":0.00007980515,"about_ca_system_score_gemma":0.00054600864,"threshold_uncertainty_score":0.41206756},"labels":[],"label_agreement":null},{"id":"W3214405719","doi":"10.1182/blood-2021-153970","title":"Integrated Transcriptomics and Proteomics Identifies Therapeutic Targets in Pediatric Acute Myeloid Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Transcriptome; Proteomics; Myeloid leukemia; Bone marrow; Haematopoiesis; Myeloid; Biology; CD34; Leukemia; Proteome; Cancer research; Stem cell; Bioinformatics; Immunology; Computational biology; Medicine; Gene; Genetics; Gene expression","score_opus":0.016017235536676357,"score_gpt":0.2657290045148789,"score_spread":0.24971176897820255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214405719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916598,0.005698026,0.00026112335,0.0008487502,0.00010434663,0.00063324126,0.00002543857,0.00007773987,0.0006915336],"genre_scores_gemma":[0.9855664,0.007761612,0.0039033396,0.00050180446,0.00019939928,0.00008748034,0.00012156912,0.00006397085,0.0017944656],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998249,0.000108343374,0.00037630313,0.00047605133,0.0003109037,0.00047939332],"domain_scores_gemma":[0.9991427,0.00007115184,0.000053901902,0.0003600533,0.00019274588,0.00017946278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003039374,0.00023608972,0.00044930892,0.0002765912,0.00006907941,0.00007507743,0.00014295364,0.00021962402,0.000079946454],"category_scores_gemma":[0.0001283568,0.0002118183,0.00008899335,0.00077919936,0.00009645177,0.00014249896,0.000078455865,0.0007535093,0.000029841165],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004935049,0.0007235454,0.087196544,0.00055942935,0.00059680635,0.0029873217,0.002302276,0.0000035916833,0.90013754,0.00025620262,0.00077085523,0.0039723986],"study_design_scores_gemma":[0.027985899,0.0005734122,0.18537478,0.00020853139,0.0021412056,0.002409606,0.0017457556,0.0018901791,0.772187,0.0015497252,0.0030003968,0.00093348714],"about_ca_topic_score_codex":0.00006754987,"about_ca_topic_score_gemma":0.000107459695,"teacher_disagreement_score":0.1279505,"about_ca_system_score_codex":0.0002757962,"about_ca_system_score_gemma":0.0014161902,"threshold_uncertainty_score":0.86376995},"labels":[],"label_agreement":null},{"id":"W3214432495","doi":"10.1182/blood-2021-145773","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination with Intensive Induction and Consolidation Chemotherapy in Adults with Newly Diagnosed <i>N</i> <i>ucleophosmin 1-</i>mutated Acute Myeloid Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cytarabine; Idarubicin; Medicine; Internal medicine; Myeloid leukemia; Oncology; Induction chemotherapy; Myeloid; Daunorubicin; Mitoxantrone; Gastroenterology; Immunology; Chemotherapy","score_opus":0.017673283038204854,"score_gpt":0.3028552899997753,"score_spread":0.2851820069615704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214432495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853955,0.00014452417,0.0001586368,0.0021063047,0.00002513273,0.012037584,0.0000108368495,0.000026443284,0.00009502492],"genre_scores_gemma":[0.9975084,0.0005565499,0.00041450208,0.00046291813,0.00003000838,0.0008380798,0.000102179445,0.00004131444,0.000046040237],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972678,0.0006283569,0.0007063558,0.00056673447,0.00051556417,0.00031520965],"domain_scores_gemma":[0.9970678,0.0013395377,0.0002867525,0.00034929518,0.0008113628,0.00014525552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014101538,0.0003017111,0.0012650681,0.00036170112,0.000072793366,0.000059201087,0.00010123641,0.00010719623,0.000011465474],"category_scores_gemma":[0.0006683646,0.00019258205,0.000045121713,0.0010988003,0.00023934801,0.00015730537,0.0000696908,0.0005164272,0.0000010865031],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9646156,0.0043349387,0.005960346,0.00007246446,0.0008819803,0.00044622773,0.012128574,0.00004547037,0.0095778145,0.000025684976,0.000021100355,0.0018898064],"study_design_scores_gemma":[0.95348257,0.0035865584,0.0077627185,0.0005781328,0.00065255107,0.00023238629,0.009555849,0.0005294235,0.023406116,0.0000063739376,0.000009751044,0.00019756364],"about_ca_topic_score_codex":0.0005347306,"about_ca_topic_score_gemma":0.0007089677,"teacher_disagreement_score":0.013828303,"about_ca_system_score_codex":0.00019200715,"about_ca_system_score_gemma":0.00067538244,"threshold_uncertainty_score":0.78532684},"labels":[],"label_agreement":null},{"id":"W3214440901","doi":"10.1182/blood-2021-150102","title":"Clinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Transplantation; Minimal residual disease; Biology; Hematopoietic stem cell transplantation; Lymphoma; Stem cell; Myeloid; Autologous stem-cell transplantation; Oncology; Immunology; Leukemia; Cancer research; Internal medicine; Genetics; Medicine","score_opus":0.03010330333754787,"score_gpt":0.3269630076835547,"score_spread":0.29685970434600684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214440901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974901,0.0002894672,0.0004562292,0.00063489925,0.000026672422,0.0004043991,0.00004738494,0.000007788035,0.0006430424],"genre_scores_gemma":[0.9952767,0.00009910058,0.004290188,0.00011403169,0.000051372637,0.000041386862,0.000029659468,0.000010080427,0.00008750867],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876714,0.00017879625,0.00047693614,0.00017214069,0.00024580586,0.00015918296],"domain_scores_gemma":[0.99821866,0.0012816949,0.00011882043,0.00021041822,0.00013896983,0.00003144353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008685527,0.00006624165,0.0003076356,0.00004401135,0.00002050154,0.0000032825792,0.00011208355,0.00009186147,0.000010465575],"category_scores_gemma":[0.00010663049,0.000049607097,0.00011925122,0.00022148028,0.00006800393,0.000020978507,0.000012948658,0.000104102335,0.0000014608298],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025690345,0.007953765,0.5971222,0.012475434,0.00052724115,0.0013438464,0.012610611,0.00004301658,0.2874816,0.0020842752,0.0013900051,0.07439898],"study_design_scores_gemma":[0.010471547,0.00045054685,0.41647428,0.000215466,0.0003259078,0.00029559454,0.0023459313,0.00041199036,0.56863207,0.0001093638,0.00017738981,0.00008990559],"about_ca_topic_score_codex":0.000022810746,"about_ca_topic_score_gemma":0.000021293066,"teacher_disagreement_score":0.28115046,"about_ca_system_score_codex":0.000020608937,"about_ca_system_score_gemma":0.00050857494,"threshold_uncertainty_score":0.20229186},"labels":[],"label_agreement":null},{"id":"W3214473897","doi":"10.1182/blood-2021-150371","title":"Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Venetoclax; Azacitidine; Medicine; Myeloid leukemia; Chemotherapy regimen; Internal medicine; Oncology; Leukemia; Chemotherapy; Cytarabine; Myeloid; Chronic lymphocytic leukemia","score_opus":0.020015693072060543,"score_gpt":0.31708747151549754,"score_spread":0.297071778443437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214473897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99394065,0.00016997241,0.000027073063,0.00019024384,0.000011158296,0.0055202935,0.00009893859,0.000020784797,0.000020868805],"genre_scores_gemma":[0.99779904,0.0002636772,0.0009733632,0.00019951485,0.000011598574,0.000144344,0.00043761384,0.000065247346,0.00010561715],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980171,0.0001461808,0.0004616077,0.0006537038,0.00033147106,0.000389989],"domain_scores_gemma":[0.99809164,0.00015612757,0.00021416735,0.00042940717,0.00095121533,0.00015746897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029311737,0.00029223697,0.0008494981,0.00024583435,0.00006830904,0.00005592728,0.0001632594,0.00010657223,0.000005812496],"category_scores_gemma":[0.00020608195,0.00023041673,0.000014894774,0.0005688361,0.00012937044,0.00027305487,0.00015202383,0.0002955532,4.6485684e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18459007,0.052641086,0.700721,0.00082483474,0.002149161,0.00078152,0.010217333,0.000034785484,0.025141472,0.000026038464,0.0000854105,0.022787265],"study_design_scores_gemma":[0.55534345,0.02684559,0.37710497,0.0012199233,0.00048534828,0.0000373622,0.0017548753,0.0012194952,0.03565808,0.0000034248703,0.000037882095,0.00028959048],"about_ca_topic_score_codex":0.00039112745,"about_ca_topic_score_gemma":0.0005918752,"teacher_disagreement_score":0.3707534,"about_ca_system_score_codex":0.0005538532,"about_ca_system_score_gemma":0.00065473234,"threshold_uncertainty_score":0.93961215},"labels":[],"label_agreement":null},{"id":"W3214589663","doi":"10.1182/blood-2021-154148","title":"A Phase II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Medicine; Myeloid leukemia; Refractory (planetary science); Internal medicine; Leukemia; Chemotherapy regimen; Oncology; Azacitidine; Chemotherapy; Biology; Chronic lymphocytic leukemia","score_opus":0.01673062602691864,"score_gpt":0.29051826080820903,"score_spread":0.27378763478129037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214589663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969183,0.0002261388,0.000008900217,0.000088558314,0.00009042591,0.0019251073,0.00006281652,0.00006828848,0.0006114186],"genre_scores_gemma":[0.9965056,0.00011287093,0.0006778231,0.00021438678,0.00012471595,0.00019184065,0.00018380789,0.000098481396,0.0018904714],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99653476,0.00021997395,0.0007033052,0.0007429957,0.0011249384,0.0006739974],"domain_scores_gemma":[0.997603,0.00025122726,0.00022790674,0.0010978777,0.00047243084,0.00034754077],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002893043,0.00037743204,0.00093091576,0.00035212238,0.00011983709,0.000022785593,0.00031861383,0.00021939547,0.0002885374],"category_scores_gemma":[0.000485375,0.0002892476,0.00010026265,0.0012141897,0.00012267033,0.00018905316,0.00034666224,0.0008761985,0.000030059531],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0660976,0.1548098,0.6129226,0.0010467769,0.0070774173,0.047108565,0.030011332,0.00030124825,0.037926316,0.000033783148,0.008069867,0.034594662],"study_design_scores_gemma":[0.61472213,0.07862166,0.27501106,0.0008487462,0.0020137588,0.00016312816,0.0042021465,0.00023569862,0.020107042,0.00001094697,0.0031862475,0.0008774036],"about_ca_topic_score_codex":0.00050271174,"about_ca_topic_score_gemma":0.000541995,"teacher_disagreement_score":0.5486245,"about_ca_system_score_codex":0.0014845217,"about_ca_system_score_gemma":0.005279423,"threshold_uncertainty_score":0.99995595},"labels":[],"label_agreement":null},{"id":"W3214689435","doi":"10.1182/blood-2021-147360","title":"Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Cladribine; Medicine; Internal medicine; Concomitant; Cytarabine; Gastroenterology; Myeloid leukemia; Leukemia; Chronic lymphocytic leukemia","score_opus":0.011253979336483009,"score_gpt":0.27869610009412255,"score_spread":0.2674421207576395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214689435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969081,0.00024294875,0.000022921802,0.00021260697,0.00002889987,0.0023665696,0.00005934105,0.000042077892,0.000116507064],"genre_scores_gemma":[0.996938,0.00009330783,0.0019573176,0.00026989574,0.000101286685,0.00016486253,0.00012105852,0.00008581393,0.00026845324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704486,0.00012040792,0.00055228284,0.0008486994,0.00083160325,0.00060215837],"domain_scores_gemma":[0.99808735,0.00018689275,0.00019278224,0.00064827455,0.00042908548,0.00045560402],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024887745,0.00040091702,0.0008328746,0.00034474378,0.00012395167,0.000046598387,0.00017395875,0.00011743551,0.000044520883],"category_scores_gemma":[0.00022395838,0.0003146103,0.000035728677,0.00093003345,0.000117294774,0.00019083482,0.00038842144,0.00053513923,0.0000028337595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01263603,0.025446955,0.82531136,0.0007447295,0.0026370767,0.010933281,0.013896802,0.00042198543,0.07984913,0.000025909456,0.0005026869,0.027594073],"study_design_scores_gemma":[0.34243798,0.03706089,0.56040037,0.0017096899,0.0011976565,0.00028445228,0.0026762253,0.0011904635,0.052137446,0.000010023151,0.000110746325,0.0007840711],"about_ca_topic_score_codex":0.0006974986,"about_ca_topic_score_gemma":0.0008920191,"teacher_disagreement_score":0.32980195,"about_ca_system_score_codex":0.00039958366,"about_ca_system_score_gemma":0.00091299537,"threshold_uncertainty_score":0.9999306},"labels":[],"label_agreement":null},{"id":"W3214698439","doi":"10.1182/blood-2021-150638","title":"DNMT3A R882 Mutation in Human Haematopoietic Stem Cells Alters Differentiation Towards Neutrophils and Monocytes","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Biology; Haematopoiesis; Stem cell; Progenitor cell; Mutation; Myeloid; Flow cytometry; Cellular differentiation; Leukemia; CD34; Immunology; Phenotype; Cancer research; Genetics; Gene","score_opus":0.022481807033848868,"score_gpt":0.2826747966274937,"score_spread":0.2601929895936448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214698439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99773294,0.0005244902,0.0000951302,0.0008365027,0.000045251967,0.00031026508,0.0000047942062,0.000037916176,0.00041271248],"genre_scores_gemma":[0.9988245,0.00015422367,0.00030018127,0.00012730199,0.00007690417,0.000029550882,0.000047396934,0.000023989249,0.00041597604],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988375,0.00009323744,0.00025072508,0.00030737653,0.00026367474,0.0002474969],"domain_scores_gemma":[0.999449,0.000049969985,0.00005285143,0.00024420657,0.00009040064,0.0001135786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001306327,0.0001265741,0.00026270226,0.00015410683,0.000056479526,0.000047490084,0.000057273464,0.0000895114,0.00004578605],"category_scores_gemma":[0.00002475948,0.000120660574,0.00004569069,0.00023081404,0.000044506698,0.000090330315,0.00007405703,0.00021666996,0.000014651243],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072860006,0.00097286067,0.028367983,0.0006863666,0.00017732717,0.0019205972,0.0022490472,0.000024729687,0.95660037,0.0005549354,0.00021409274,0.008158812],"study_design_scores_gemma":[0.00655922,0.0002602967,0.13246307,0.00016355875,0.00017264269,0.0002537071,0.00066565454,0.00081290386,0.85814804,0.00027844557,0.000058164904,0.00016428044],"about_ca_topic_score_codex":0.000077927485,"about_ca_topic_score_gemma":0.000028871693,"teacher_disagreement_score":0.10409508,"about_ca_system_score_codex":0.00010699087,"about_ca_system_score_gemma":0.00013868483,"threshold_uncertainty_score":0.49203956},"labels":[],"label_agreement":null},{"id":"W3214923683","doi":"10.1182/blood-2021-153569","title":"Myelodysplastic Syndromes: Have You Seen Your Patient Beyond His Hemoglobin?","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Population; Quality of life (healthcare); Palliative care; Disease; Psychosocial; Delirium; Hematologic disease; Pediatrics; Asymptomatic; Advance care planning; Intensive care medicine; Internal medicine; Psychiatry; Bone marrow","score_opus":0.02051867763771643,"score_gpt":0.274874113350438,"score_spread":0.25435543571272157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214923683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735421,0.00127453,0.000060634546,0.002002005,0.0002003336,0.00042189346,0.000068439585,0.00012617385,0.022303872],"genre_scores_gemma":[0.9820808,0.00013398583,0.0025568684,0.001000452,0.0002866662,0.00005882084,0.00018816262,0.00007835096,0.013615903],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975646,0.00008630244,0.00037781583,0.00057155004,0.00075115176,0.0006485403],"domain_scores_gemma":[0.99829626,0.00012929703,0.00007522086,0.00074422796,0.00032431708,0.00043065817],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015086816,0.00026184245,0.00047000832,0.0001560289,0.0001142325,0.000047219975,0.0001727051,0.00018425006,0.001130307],"category_scores_gemma":[0.0005468341,0.00023576026,0.00016598347,0.0004013206,0.00009366206,0.00008687684,0.00027594928,0.0005217342,0.00073305256],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014328458,0.01783264,0.23197834,0.003463254,0.0077161714,0.169059,0.0114688035,0.00008295435,0.34470323,0.0015384716,0.13395324,0.07677104],"study_design_scores_gemma":[0.060073383,0.007969563,0.119190566,0.0016523529,0.0048279664,0.051312756,0.010488966,0.0016945624,0.5301365,0.0011924251,0.20849834,0.0029626174],"about_ca_topic_score_codex":0.000054906057,"about_ca_topic_score_gemma":0.000013224328,"teacher_disagreement_score":0.18543327,"about_ca_system_score_codex":0.000274877,"about_ca_system_score_gemma":0.0008717198,"threshold_uncertainty_score":0.9997828},"labels":[],"label_agreement":null},{"id":"W3214959760","doi":"10.1182/blood-2021-151670","title":"Clinical Outcomes of Patients with Newly Diagnosed Myelodysplastic Syndrome with <i>MLL</i> Aberrations","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Myelodysplastic syndromes; Decitabine; Oncology; Population; Cytarabine; Hypomethylating agent; Cancer; Chemotherapy; Pediatrics; Bone marrow; DNA methylation; Biology","score_opus":0.016196650347414365,"score_gpt":0.2894902193334967,"score_spread":0.27329356898608237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214959760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973517,0.000049812064,0.00024632894,0.00048292615,0.00006003252,0.0004388428,0.000040066447,0.000044739973,0.0012855743],"genre_scores_gemma":[0.99229795,0.00002805022,0.0057222247,0.00037425777,0.000041906544,0.00003952389,0.00015362739,0.000041339077,0.0013011501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998206,0.00008969654,0.00043587186,0.00036588954,0.00059489394,0.0003076023],"domain_scores_gemma":[0.9979175,0.00062113744,0.00012405908,0.00056708313,0.0005227284,0.00024750023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014949267,0.0001757629,0.0005786219,0.00008020943,0.00005992972,0.000016814452,0.00011930151,0.00010839377,0.00015984374],"category_scores_gemma":[0.0006796576,0.00011548537,0.000097185286,0.0004451215,0.00019675883,0.000088056964,0.00007205989,0.0003716762,0.00004255008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019705883,0.0025274626,0.9937628,0.00007255875,0.0006875873,0.0018304028,0.00006873767,0.000010285898,0.00004423875,0.00007593236,0.00043916272,0.00028378336],"study_design_scores_gemma":[0.019385174,0.001642645,0.97710764,0.00013392571,0.0006390103,0.00016255685,0.00006896704,0.00001778356,0.0002515927,0.000009741032,0.00044305573,0.00013792382],"about_ca_topic_score_codex":0.000028651542,"about_ca_topic_score_gemma":0.00011063921,"teacher_disagreement_score":0.019188115,"about_ca_system_score_codex":0.000036228044,"about_ca_system_score_gemma":0.00089502736,"threshold_uncertainty_score":0.47093567},"labels":[],"label_agreement":null},{"id":"W3215020056","doi":"10.1182/blood-2021-151340","title":"Single-Cell RNA Sequencing Analysis Reveals Mechanisms of Initiation and Progression in Chronic Myelomonocytic Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chronic myelomonocytic leukemia; Biology; Haematopoiesis; Transcriptome; Progenitor cell; Cancer research; Myeloid; Stem cell; CD34; Bone marrow; Myeloid leukemia; Leukemia; Immunology; Cell biology; Genetics; Gene expression; Gene; Myelodysplastic syndromes","score_opus":0.03073158341712162,"score_gpt":0.29858406225657763,"score_spread":0.267852478839456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215020056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950116,0.0015360542,0.0009847959,0.000117977565,0.000014521986,0.0002908791,0.00000512302,0.000025807096,0.0020131862],"genre_scores_gemma":[0.992926,0.00020875756,0.0064347507,0.000063037434,0.000050328537,0.000020765003,0.00006193429,0.000020925549,0.00021347168],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984709,0.0001333162,0.0003978753,0.00034462678,0.0003673639,0.00028593387],"domain_scores_gemma":[0.99912524,0.00011343649,0.00014339545,0.0003302683,0.00017481903,0.00011283386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045199148,0.00013157354,0.0004624004,0.00041809253,0.000037219732,0.00001899576,0.00006892471,0.00014264909,0.00007120509],"category_scores_gemma":[0.00023711764,0.00012283113,0.000087756154,0.0012977273,0.00004776746,0.000097119155,0.000106010644,0.00026866305,0.0000051252678],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033819117,0.00013931416,0.005627845,0.000402536,0.0001923026,0.0003974709,0.00028687008,0.00005257417,0.99013096,0.00011734644,0.000009247455,0.0026097428],"study_design_scores_gemma":[0.0042115166,0.0003691333,0.008392898,0.0003879126,0.0009581986,0.00007450761,0.0003022556,0.0041044615,0.9805526,0.0005127034,0.00000921464,0.0001246076],"about_ca_topic_score_codex":0.000066460794,"about_ca_topic_score_gemma":0.000068394176,"teacher_disagreement_score":0.009578342,"about_ca_system_score_codex":0.0016018397,"about_ca_system_score_gemma":0.0015954658,"threshold_uncertainty_score":0.50089085},"labels":[],"label_agreement":null},{"id":"W3215031611","doi":"10.1182/blood-2021-145344","title":"Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Hematologic Neoplasms; Medicine; Hematologic disease; Hematologic malignancy; Interleukin-3 receptor; Targeted therapy; Hematologic disorders; Intensive care medicine; Leukemia; Oncology; Immunology; Internal medicine; Cancer; Disease","score_opus":0.011378290762788786,"score_gpt":0.24324819223877106,"score_spread":0.23186990147598227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215031611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981447,0.00049169257,0.00003346009,0.00015903814,0.000013450472,0.00039555796,0.00011003749,0.00008277747,0.00056928955],"genre_scores_gemma":[0.9961672,0.00012851683,0.002246502,0.00012991742,0.000007220525,0.000026907064,0.0010088279,0.000022306911,0.00026258928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821806,0.00018074915,0.00042417148,0.00036775685,0.0004653738,0.00034390262],"domain_scores_gemma":[0.9984395,0.000118214484,0.000117512274,0.00047028196,0.00075193145,0.00010257998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019492891,0.00019230033,0.00082331436,0.00055821467,0.000032686366,0.000010672102,0.00012619697,0.00013216215,0.00060952693],"category_scores_gemma":[0.00035255807,0.00013060584,0.00014411098,0.0048507205,0.00010834659,0.00004977911,0.00005670387,0.0002800366,0.000005693232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010119058,0.002134735,0.97853273,0.00004822144,0.0027358446,0.00028028662,0.0003241236,0.000014273629,0.014160033,0.000035860623,0.000112408,0.0006095505],"study_design_scores_gemma":[0.010499907,0.00049518043,0.934317,0.000107771964,0.0007900972,0.000011346575,0.00025849894,0.00031240835,0.052822948,0.000008336776,0.00022732967,0.00014921276],"about_ca_topic_score_codex":0.0002485322,"about_ca_topic_score_gemma":0.0002848308,"teacher_disagreement_score":0.044215795,"about_ca_system_score_codex":0.00010861974,"about_ca_system_score_gemma":0.0004908364,"threshold_uncertainty_score":0.6673893},"labels":[],"label_agreement":null},{"id":"W3215189460","doi":"10.1182/blood-2021-151023","title":"Clinical Characteristics and Outcomes of Patients Diagnosed with Acute Myeloid Leukemia with Expression of CD71","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Transferrin receptor; Myeloid leukemia; Medicine; Bone marrow; Myeloid; Leukemia; Induction chemotherapy; Internal medicine; Immunology; Chemotherapy; Transferrin","score_opus":0.015686041771244122,"score_gpt":0.29972915512028003,"score_spread":0.2840431133490359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215189460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990736,0.000062871724,0.00004708762,0.00008699191,0.000028043556,0.00031069384,0.000083393614,0.000016981201,0.0002903091],"genre_scores_gemma":[0.9934023,0.00036041235,0.0056006806,0.00012307425,0.000044775377,0.000014999672,0.00011517788,0.000031928234,0.00030666738],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984158,0.000082766164,0.00047362113,0.00030982366,0.0004970141,0.00022094736],"domain_scores_gemma":[0.9983383,0.00032381,0.00023573363,0.00045677816,0.00046137066,0.00018400593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017165841,0.00016256899,0.0007082328,0.00006769011,0.00003010698,0.000007780205,0.00009358194,0.00012524532,0.00004239284],"category_scores_gemma":[0.00035445645,0.00010194567,0.00006236762,0.00018458688,0.00024368944,0.00006123389,0.00013577577,0.0002967052,0.000002536546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008053343,0.0009642852,0.9865166,0.00017770096,0.0004013811,0.000481604,0.00018312554,1.0212971e-7,0.008320865,0.000008815501,0.000112470334,0.0020277123],"study_design_scores_gemma":[0.013059118,0.001362672,0.9234536,0.00029629545,0.0005119082,0.00004159442,0.00010012131,0.00000731255,0.060900632,0.000002763116,0.00015722672,0.00010670264],"about_ca_topic_score_codex":0.00001925558,"about_ca_topic_score_gemma":0.000007332301,"teacher_disagreement_score":0.06306295,"about_ca_system_score_codex":0.000037389927,"about_ca_system_score_gemma":0.00065932283,"threshold_uncertainty_score":0.41572237},"labels":[],"label_agreement":null},{"id":"W3215248009","doi":"10.1182/blood-2021-145384","title":"Elucidating the Mechanisms of Leukemogenesis Driven By <i>FBXO11</i> Depletion","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Biology; CD34; Molecular biology; Progenitor cell; Cancer research; Cell biology; Stem cell","score_opus":0.013940754134227547,"score_gpt":0.25840122818205524,"score_spread":0.2444604740478277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215248009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811508,0.00086103514,0.009672921,0.003449638,0.00006811267,0.0003653528,0.00003658542,0.000064147076,0.0043313955],"genre_scores_gemma":[0.99251163,0.00013794216,0.005275721,0.00069514284,0.0000998492,0.000025945483,0.00008215161,0.000031258718,0.0011403341],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876034,0.00010539056,0.00023381494,0.00023234294,0.00042441516,0.00024368807],"domain_scores_gemma":[0.9990327,0.00013209971,0.000079436424,0.00046069588,0.00021201187,0.00008309423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028216979,0.00010401947,0.00022219382,0.00003791697,0.000090384754,0.000014637768,0.00014577211,0.000082197694,0.00019111708],"category_scores_gemma":[0.00030417967,0.00007568617,0.0000979204,0.0003418394,0.000055922046,0.000038892595,0.000126483,0.00019840412,0.000039293493],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022136559,0.00021049933,0.0020208284,0.000064596454,0.00013941353,0.00007070937,0.00010060515,0.0000029965295,0.99168724,0.00061287684,0.003369218,0.0016988852],"study_design_scores_gemma":[0.0020799222,0.00011333115,0.0013104958,0.000053269054,0.00021044267,0.00019173835,0.00037826796,0.00021605042,0.99330336,0.00022395693,0.0018420252,0.00007711287],"about_ca_topic_score_codex":0.00006115895,"about_ca_topic_score_gemma":0.000011523477,"teacher_disagreement_score":0.011360843,"about_ca_system_score_codex":0.00006240268,"about_ca_system_score_gemma":0.00035496042,"threshold_uncertainty_score":0.30863926},"labels":[],"label_agreement":null},{"id":"W3215256792","doi":"10.1158/0008-5472.can-21-1903","title":"Clonal Hematopoiesis Mutations in Patients with Lung Cancer Are Associated with Lung Cancer Risk Factors","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"National Cancer Institute; National Institutes of Health; Cancer Prevention and Research Institute of Texas; World Health Organization","keywords":"Lung cancer; Medicine; Cancer; Oncology; Haematopoiesis; Lung; Internal medicine; Cancer research; Biology; Genetics; Stem cell","score_opus":0.033512044909596514,"score_gpt":0.3795939166029421,"score_spread":0.3460818716933456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215256792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917348,0.0030431286,0.000019595791,0.0022556859,0.0000998304,0.0014105357,0.0009732451,0.000061372935,0.00040178935],"genre_scores_gemma":[0.9928971,0.0010811214,0.00007291786,0.00013756615,0.00016195235,0.0015685316,0.00032880987,0.00012500251,0.0036269808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942402,0.00054510124,0.0003911389,0.0008713854,0.0025791468,0.0013729836],"domain_scores_gemma":[0.9951517,0.0006279098,0.0001802654,0.00057962537,0.0029621422,0.0004983736],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00067525695,0.00033676127,0.00066283194,0.0005677654,0.00044979126,0.00010491797,0.00030534304,0.00022912861,0.0026648042],"category_scores_gemma":[0.0009021344,0.0002511398,0.00008686141,0.0033068126,0.00044172787,0.00025119339,0.00020607906,0.0021060256,0.000008185795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0008650921,0.00033296872,0.98586035,0.00031452844,0.0008359165,0.00026253643,0.001385908,0.0007906483,0.00023244576,0.00001402505,0.008679677,0.00042589166],"study_design_scores_gemma":[0.0064705084,0.00017148751,0.98416257,0.0020171134,0.0001979328,0.0000024573105,0.0012454569,0.0012336733,0.0037659365,0.000010446699,0.00039363885,0.00032878297],"about_ca_topic_score_codex":0.017925082,"about_ca_topic_score_gemma":0.029692475,"teacher_disagreement_score":0.011767392,"about_ca_system_score_codex":0.0074817445,"about_ca_system_score_gemma":0.0070490185,"threshold_uncertainty_score":0.9999941},"labels":[],"label_agreement":null},{"id":"W3215635656","doi":"10.3324/haematol.2021.276048","title":"The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements","year":2021,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Downregulation and upregulation; Myeloid leukemia; Cancer research; Biology; Transcription factor; Gene knockdown; Retinoic acid; Genetics; Gene","score_opus":0.02573987258448401,"score_gpt":0.30085714445774797,"score_spread":0.27511727187326396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215635656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861616,0.0022728723,0.000024221086,0.0073103867,0.00006968427,0.0011667954,0.000050940725,0.00015026912,0.0027932418],"genre_scores_gemma":[0.98822385,0.0030053214,0.0017665525,0.0017576049,0.000036500194,0.00014538124,0.00013488687,0.000070118775,0.0048597585],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99649006,0.00047280383,0.00054376625,0.00089119887,0.00074725616,0.0008549041],"domain_scores_gemma":[0.99789214,0.0002501169,0.00018933452,0.0010919272,0.0002928934,0.00028361275],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045615478,0.00039939326,0.00080845103,0.00013879167,0.00030583752,0.00011756915,0.0003642995,0.00034415652,0.0010005108],"category_scores_gemma":[0.000262615,0.0002403225,0.00010089259,0.00082029775,0.00051905966,0.00014681103,0.0002678056,0.00085087575,0.000119231765],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00964631,0.00061907835,0.27218363,0.0007113999,0.003052481,0.013687353,0.004964752,0.000003214551,0.62829876,0.0010226539,0.056115072,0.009695279],"study_design_scores_gemma":[0.01119909,0.0015769881,0.18723865,0.0008705806,0.00027448096,0.0057460675,0.0011369287,0.0009371165,0.7299907,0.0013353247,0.058704264,0.0009897995],"about_ca_topic_score_codex":0.000058208032,"about_ca_topic_score_gemma":0.000022806284,"teacher_disagreement_score":0.10169193,"about_ca_system_score_codex":0.00053090166,"about_ca_system_score_gemma":0.0006994431,"threshold_uncertainty_score":0.99991274},"labels":[],"label_agreement":null},{"id":"W3215647656","doi":"10.26685/urncst.304","title":"First-Line Treatments for Patients with Acute Myeloid Leukemia: A Literature Review","year":2021,"lang":"en","type":"review","venue":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Myeloid leukemia; Gemtuzumab ozogamicin; Oncology; Internal medicine; Clofarabine; Clinical trial; Intensive care medicine; Cytarabine; CD33; Stem cell; Biology","score_opus":0.06446957152633805,"score_gpt":0.44698377033487285,"score_spread":0.3825141988085348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215647656","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012363777,0.96919775,0.0000057469906,0.026250191,0.0001820352,0.0029734615,0.000043244298,0.00003642288,0.00007476203],"genre_scores_gemma":[0.0003450781,0.9964228,0.0012637218,0.0002517787,0.00024145955,0.00020475616,0.0001122478,0.000050067687,0.0011080639],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.992647,0.00047611902,0.0015504695,0.0015377719,0.0020448458,0.0017437771],"domain_scores_gemma":[0.9928617,0.0016743252,0.0004883267,0.0006959152,0.0033624629,0.0009172652],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0068572173,0.00064109475,0.0030154614,0.0022286999,0.0011318917,0.00038295035,0.0009902872,0.0011164539,0.000012380959],"category_scores_gemma":[0.005086689,0.00034656987,0.00039569926,0.008427312,0.004004731,0.00045148336,0.0009507365,0.0093813585,0.00001272876],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018346426,0.00047932708,0.0009830622,0.008088705,0.0007132867,0.0020019908,0.000005575432,2.0250525e-8,5.883854e-7,0.00045536243,0.0030140262,0.9840746],"study_design_scores_gemma":[0.00843373,0.007920525,0.00025727283,0.22705437,0.0020111992,0.01050177,0.000036541616,0.00009906816,0.0000022129366,0.006217839,0.7367262,0.00073924346],"about_ca_topic_score_codex":0.000008577995,"about_ca_topic_score_gemma":0.000026854756,"teacher_disagreement_score":0.9833354,"about_ca_system_score_codex":0.002077499,"about_ca_system_score_gemma":0.0067680166,"threshold_uncertainty_score":0.9998986},"labels":[],"label_agreement":null},{"id":"W3216194626","doi":"10.1016/j.jcyt.2021.10.006","title":"Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation","year":2021,"lang":"en","type":"article","venue":"Cytotherapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Alberta Health Services; University of Calgary","funders":"","keywords":"NPM1; Medicine; Transplantation; Myeloid leukemia; Internal medicine; Hematopoietic stem cell transplantation; Chemotherapy; Oncology; Induction chemotherapy; Cumulative incidence; Myeloid; Immunology; Cancer research; Biology; Gene; Genetics","score_opus":0.012573635949240382,"score_gpt":0.29861730735657005,"score_spread":0.28604367140732967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216194626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615866,0.00042044322,0.002220306,0.0002100103,0.0000069386706,0.00038005068,0.000025959836,0.000026716303,0.0005509047],"genre_scores_gemma":[0.9955713,0.0022134692,0.0012482028,0.00007107272,0.000022433,0.00004464453,0.00019120392,0.00003501924,0.0006026689],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989498,0.00006791028,0.0002748326,0.00028288292,0.00021086536,0.00021370151],"domain_scores_gemma":[0.9993339,0.000078721125,0.000084604835,0.00023412335,0.00016045866,0.000108166816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109376604,0.00015821657,0.0003097479,0.00019382426,0.000034872137,0.000018090965,0.00006610837,0.00010196539,0.0001644962],"category_scores_gemma":[0.000008394467,0.00012288697,0.00007245609,0.00046196097,0.00010085366,0.00009037158,0.000007472599,0.00019474294,0.000007104395],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090073026,0.00013585459,0.38800442,0.00008982252,0.00022251009,0.00027110704,0.0015890322,0.00012102484,0.60582244,0.000022466495,0.000050342675,0.0027702793],"study_design_scores_gemma":[0.006463802,0.0006814133,0.72756934,0.00014442447,0.00011644687,0.00077757123,0.00015233176,0.0006350864,0.26324293,0.0000590602,0.00002318191,0.0001344113],"about_ca_topic_score_codex":0.00023743298,"about_ca_topic_score_gemma":0.000093487644,"teacher_disagreement_score":0.34257948,"about_ca_system_score_codex":0.0004927137,"about_ca_system_score_gemma":0.0006588999,"threshold_uncertainty_score":0.5011185},"labels":[],"label_agreement":null},{"id":"W3216583281","doi":"10.1182/blood-2021-152316","title":"Variant Allele Frequency Status in Elderly Patients with Acute Myeloid Leukemia Can be Early Predictors of Responsiveness to Decitabine Treatment","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Occupational Cancer Research Centre; University of Toronto","funders":"","keywords":"Decitabine; Medicine; Internal medicine; Myeloid leukemia; Oncology; Bone marrow; Azacitidine; Cytarabine; Biopsy; DNA methylation; Biology; Gene","score_opus":0.011089224717956436,"score_gpt":0.2550478201262814,"score_spread":0.24395859540832499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216583281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99679583,0.00016063028,0.000035375484,0.000673876,0.000057443915,0.0011305343,0.00040709294,0.000039865026,0.00069937704],"genre_scores_gemma":[0.99291146,0.00013380898,0.0051557566,0.00017601231,0.000068281275,0.00016880031,0.00040419083,0.000069180016,0.0009125229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972088,0.00017863892,0.0004917735,0.00059928175,0.0007728814,0.0007486316],"domain_scores_gemma":[0.99782264,0.0001615251,0.00010467794,0.0007685293,0.00062276353,0.00051987846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016791685,0.00031022078,0.00065218244,0.0003572825,0.00005575521,0.000022977836,0.00017033867,0.00015362405,0.00011437378],"category_scores_gemma":[0.00030085136,0.0002437798,0.00008808748,0.001003977,0.00008315946,0.00009602396,0.00010438627,0.00027080064,0.000010338417],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037603644,0.002871579,0.9374531,0.000099048375,0.0016827151,0.006976022,0.0046231197,0.00003086304,0.039217375,0.00014038873,0.00024473848,0.0029007173],"study_design_scores_gemma":[0.024564458,0.008582381,0.91255534,0.00020393549,0.00051847805,0.000104157494,0.00031121224,0.000005551099,0.051906187,0.000033539938,0.0009378081,0.00027693654],"about_ca_topic_score_codex":0.0041711167,"about_ca_topic_score_gemma":0.0022449507,"teacher_disagreement_score":0.024897711,"about_ca_system_score_codex":0.0014867052,"about_ca_system_score_gemma":0.0047907727,"threshold_uncertainty_score":0.99410516},"labels":[],"label_agreement":null},{"id":"W3217096783","doi":"10.1182/blood-2021-151648","title":"Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Idarubicin; Cytarabine; Cladribine; Medicine; Internal medicine; Concomitant; Gastroenterology; Fludarabine; Chemotherapy; Regimen; Surgery; Cyclophosphamide","score_opus":0.01629800285645637,"score_gpt":0.29204286724317335,"score_spread":0.27574486438671697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217096783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964936,0.00011529718,0.000018756537,0.00023713462,0.0000737956,0.0018012382,0.0001374879,0.000092200826,0.001030517],"genre_scores_gemma":[0.996978,0.00004434737,0.00083393755,0.00021058299,0.000103591265,0.000103491555,0.0006191021,0.000099306846,0.0010076718],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962042,0.00020590721,0.00088453037,0.0008210914,0.0011373033,0.00074694265],"domain_scores_gemma":[0.9975266,0.000090890666,0.00022083786,0.0010177365,0.0008128533,0.0003310883],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031230898,0.0004176404,0.0010879678,0.00040413058,0.00012325772,0.000025788704,0.00030191205,0.00018972815,0.0002731589],"category_scores_gemma":[0.00023795833,0.0003566252,0.0001047777,0.0015322769,0.00015529283,0.00017999207,0.00036405196,0.00080843735,0.000026513746],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029916797,0.14107445,0.52387094,0.00092068745,0.0059113177,0.020239431,0.010321981,0.00018440794,0.2524857,0.000044912093,0.0026485552,0.0123807965],"study_design_scores_gemma":[0.48456863,0.053179286,0.28672406,0.00072983146,0.001894051,0.0002992381,0.002790493,0.00049899326,0.16783747,0.000015125842,0.000571743,0.00089107687],"about_ca_topic_score_codex":0.00033877196,"about_ca_topic_score_gemma":0.00023114748,"teacher_disagreement_score":0.45465183,"about_ca_system_score_codex":0.0005673355,"about_ca_system_score_gemma":0.00160599,"threshold_uncertainty_score":0.9998886},"labels":[],"label_agreement":null},{"id":"W3217349842","doi":"10.1182/blood-2021-153674","title":"Iron Chelation Therapy in Low- to Intermediate- Risk Myelodysplastic Syndrome Patients: A Systematic Review and Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; St. Joseph's Hospital; McMaster University; University of Ottawa","funders":"","keywords":"Medicine; Hazard ratio; Randomized controlled trial; Meta-analysis; Internal medicine; Relative risk; Cochrane Library; Number needed to treat; Observational study; Lower risk; MEDLINE; Confidence interval","score_opus":0.04098586254030382,"score_gpt":0.33558522641567046,"score_spread":0.2945993638753666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217349842","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006416624,0.9913949,0.00001659042,0.000057405876,0.000024660172,0.0076442496,0.00016245001,0.0000285727,0.000029506025],"genre_scores_gemma":[0.00032772054,0.99593085,0.00011926477,0.00027769146,0.000022536506,0.0022032822,0.00064258656,0.000084487016,0.0003915759],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9947845,0.0014061902,0.0017927173,0.000876733,0.0007128649,0.0004270193],"domain_scores_gemma":[0.99685764,0.00074291247,0.0007298006,0.0011151123,0.0002507815,0.00030375883],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013704828,0.00065065257,0.011928613,0.001133109,0.000042710315,0.000055684264,0.00029328972,0.0003281703,0.00042342846],"category_scores_gemma":[0.0023156502,0.0004127165,0.0019125293,0.0027889046,0.00004258946,0.000077785866,0.00019477955,0.00086944783,0.000182408],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004619506,0.00040874202,0.00005940348,0.8753012,0.12152456,0.00022970248,0.00006349474,6.622671e-7,2.904135e-8,0.0000014442124,0.000039190647,0.0023669836],"study_design_scores_gemma":[0.00095792767,0.00031441948,0.00016497036,0.13297091,0.863708,0.00012774447,0.000008050777,0.0000052791447,1.4447278e-7,7.175405e-7,0.001418391,0.00032345348],"about_ca_topic_score_codex":0.00003526284,"about_ca_topic_score_gemma":0.000021870364,"teacher_disagreement_score":0.74233025,"about_ca_system_score_codex":0.00034000017,"about_ca_system_score_gemma":0.00037066275,"threshold_uncertainty_score":0.99983245},"labels":[],"label_agreement":null},{"id":"W3217461843","doi":"10.1182/blood-2021-151467","title":"Elucidating the Importance and Regulation of Key Enhancers for Human MEIS1 Expression","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Enhancer; Biology; CRISPR; Cas9; Genetics; Intron; Enhancer trap; Gene; Molecular biology; Transcription factor","score_opus":0.0230980652139318,"score_gpt":0.3156076905347915,"score_spread":0.29250962532085967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217461843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962742,0.0005358718,0.000625144,0.00059258495,0.000015026732,0.00028283757,0.000004467044,0.00001250176,0.0016574106],"genre_scores_gemma":[0.99419576,0.000037001424,0.0044949916,0.00008229253,0.00011898341,0.000031342348,0.0000340438,0.00001184843,0.0009937228],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99937826,0.000027217231,0.00016212654,0.00015191193,0.0001626026,0.00011789016],"domain_scores_gemma":[0.9994079,0.00010858813,0.000076258984,0.00024062452,0.00012988206,0.00003676237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002394211,0.000053299074,0.00012470031,0.000021684587,0.000093574534,0.0000082517645,0.000044574845,0.000043226333,0.00005666352],"category_scores_gemma":[0.00026325684,0.00003686863,0.00003327446,0.000091842936,0.000049384165,0.000039471375,0.000048010585,0.00008674035,6.3836524e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028484252,0.00004535293,0.0067098383,0.00011258238,0.000027324837,0.0000038795524,0.0002862507,8.627849e-7,0.9907996,0.00045066752,0.00053049735,0.0010046596],"study_design_scores_gemma":[0.001955906,0.00008098535,0.02166211,0.00012365206,0.00006009429,0.000021020744,0.0002703882,0.00011063973,0.97445995,0.00043222704,0.00078406994,0.000038957976],"about_ca_topic_score_codex":0.000008148652,"about_ca_topic_score_gemma":0.000010498225,"teacher_disagreement_score":0.01633965,"about_ca_system_score_codex":0.000019926194,"about_ca_system_score_gemma":0.00011350954,"threshold_uncertainty_score":0.1503459},"labels":[],"label_agreement":null},{"id":"W3217612228","doi":"10.1182/blood-2021-151285","title":"Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Venetoclax; Myeloid leukemia; Medicine; Internal medicine; Oncology; Leukemia; Intensive care medicine; Chronic lymphocytic leukemia","score_opus":0.03277429001177048,"score_gpt":0.3032070922019721,"score_spread":0.27043280219020166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217612228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440515,0.00035043445,0.000061649764,0.0004776146,0.000064184205,0.0015460509,0.0005947123,0.000054535103,0.002445646],"genre_scores_gemma":[0.99765474,0.00023140476,0.000773876,0.00024409665,0.00009097001,0.00023444083,0.00042647828,0.00004821222,0.00029577216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99661523,0.0011501851,0.00045895972,0.000576011,0.0008140549,0.0003855392],"domain_scores_gemma":[0.99040884,0.007241163,0.00031546637,0.0007984468,0.0010910252,0.00014508165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054069964,0.0003121571,0.00077352335,0.00012920587,0.00020872323,0.00005167972,0.0003411875,0.000118873984,0.00006054446],"category_scores_gemma":[0.00064450817,0.000205369,0.00012419777,0.0010429887,0.00063823856,0.00028751203,0.00017460497,0.000658025,0.000020900403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011687532,0.0018514622,0.9556185,0.00013799578,0.004782055,0.00037331844,0.016821291,0.00016152326,0.0062782643,0.0005469136,0.0013539032,0.0003872598],"study_design_scores_gemma":[0.023360599,0.0010284279,0.92273206,0.001691031,0.00061807793,0.0000033238025,0.0008381311,0.00008869316,0.049164344,0.00016115591,0.00010566523,0.00020850204],"about_ca_topic_score_codex":0.0036492944,"about_ca_topic_score_gemma":0.0022064464,"teacher_disagreement_score":0.04288608,"about_ca_system_score_codex":0.0006441583,"about_ca_system_score_gemma":0.0018070644,"threshold_uncertainty_score":0.8374704},"labels":[],"label_agreement":null},{"id":"W3217659172","doi":"10.1182/blood-2021-147827","title":"Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Chronic myelomonocytic leukemia; Medicine; Internal medicine; Oncology; Bone marrow; Myelodysplastic syndromes","score_opus":0.015545395059151097,"score_gpt":0.293888911158437,"score_spread":0.2783435160992859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217659172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996617,0.00013263694,0.000011493228,0.00011950963,0.00007938995,0.0011600972,0.0000969251,0.000060352504,0.0017225636],"genre_scores_gemma":[0.99686337,0.000030682382,0.001009856,0.00006711988,0.0002579664,0.00004003975,0.0011882936,0.000060204933,0.00048245836],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99707055,0.00021604888,0.0007285652,0.00063326105,0.0007558599,0.00059568806],"domain_scores_gemma":[0.9981117,0.0001170751,0.0002050505,0.00091868336,0.00036130426,0.00028615296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048224456,0.00026162504,0.00064190273,0.0002964242,0.00005738936,0.00002953209,0.00022337255,0.00019389216,0.00013514994],"category_scores_gemma":[0.0005043474,0.0002216484,0.00008952114,0.0010349989,0.00012752824,0.00019938867,0.0001235142,0.00059231935,0.00002739085],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7041906,0.044070665,0.043255802,0.0012784348,0.0024239111,0.008558969,0.0028960751,0.00032790666,0.08446931,0.00019322422,0.003698293,0.10463681],"study_design_scores_gemma":[0.85154945,0.0113207325,0.020897087,0.00042067186,0.00036721287,0.000052646195,0.00013786572,0.0010653373,0.11253588,0.000014545023,0.0012805044,0.000358095],"about_ca_topic_score_codex":0.00032694486,"about_ca_topic_score_gemma":0.00038384338,"teacher_disagreement_score":0.14735883,"about_ca_system_score_codex":0.0010349739,"about_ca_system_score_gemma":0.003943538,"threshold_uncertainty_score":0.903856},"labels":[],"label_agreement":null},{"id":"W3217673531","doi":"10.1182/blood-2021-153594","title":"Clinical Utility of Hematopathologist-Triaged NGS Testing When Investigating Patients with Suspected MDS","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Internal medicine; Myelodysplastic syndromes; Cytopenia; Hematology; Dysplasia; Myeloid; Retrospective cohort study; Clofarabine; Bone marrow; Oncology; Leukemia; Cytarabine","score_opus":0.06582940178956316,"score_gpt":0.330629738939636,"score_spread":0.26480033715007284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217673531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995168,0.000096479154,0.00006105308,0.00023866986,0.000037500497,0.0003926882,0.000017034998,0.00009912282,0.0038894832],"genre_scores_gemma":[0.94616604,0.0000040052373,0.053276062,0.00018459352,0.00010406676,0.000011859365,0.00006906357,0.000028640656,0.00015564241],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757314,0.000352085,0.00068576157,0.00046961554,0.0005629808,0.00035643385],"domain_scores_gemma":[0.9968661,0.0009375246,0.0002430908,0.00063183974,0.0010702205,0.0002511951],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0010577809,0.00016346463,0.00057676283,0.00006369956,0.0000798068,0.000016281216,0.00014559977,0.00015726849,0.0001299192],"category_scores_gemma":[0.018242655,0.00012837953,0.000087595276,0.000570497,0.00038144883,0.00006451801,0.000210316,0.0007032505,0.000011851504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008542929,0.0010795364,0.9917809,0.00019090403,0.00009230629,0.0003303243,0.00017535654,1.6239304e-7,0.004301888,0.000021578619,0.00025953818,0.0016821281],"study_design_scores_gemma":[0.009621891,0.0005902497,0.9664084,0.00032996252,0.00021689165,0.00010723685,0.0001559001,0.00014481142,0.022068994,0.00017922315,0.000045758286,0.00013071284],"about_ca_topic_score_codex":0.00006436879,"about_ca_topic_score_gemma":0.000015709482,"teacher_disagreement_score":0.05321501,"about_ca_system_score_codex":0.00003719311,"about_ca_system_score_gemma":0.00092580763,"threshold_uncertainty_score":0.9900271},"labels":[],"label_agreement":null},{"id":"W3217750548","doi":"10.1182/blood-2021-148935","title":"Single-Cell Analysis of Human B Lymphoid and Neutrophil/Monocyte Lineage Restriction","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Biology; Haematopoiesis; Progenitor cell; CD34; Immunology; Population; Lineage (genetic); Stromal cell; Stem cell; Cord blood; Cell biology; Lineage markers; Bone marrow; Myeloid; Molecular biology; Genetics; Cancer research; Gene; Medicine","score_opus":0.027557297300122706,"score_gpt":0.28468396479078306,"score_spread":0.2571266674906604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217750548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933382,0.00092394016,0.00004390392,0.0001900954,0.000019334226,0.00010375092,0.000012882586,0.000030548155,0.0053373324],"genre_scores_gemma":[0.9970697,0.00044023024,0.0007619626,0.000088828514,0.000118545475,0.0000050389076,0.00011060383,0.000017821636,0.0013872595],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989647,0.00006388937,0.00025751675,0.0002808067,0.00024506918,0.00018797404],"domain_scores_gemma":[0.99915063,0.00007210814,0.00007996621,0.00038909545,0.00018179086,0.00012643157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013288332,0.00010134673,0.00036354084,0.0003681847,0.00006019096,0.00001725137,0.000057704587,0.00009603606,0.00007870879],"category_scores_gemma":[0.00008759403,0.000096706186,0.00012831601,0.0012271694,0.00006294296,0.000041917323,0.00008541965,0.00015050838,0.000005473174],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004852952,0.0008646269,0.062512845,0.000088530745,0.00082401297,0.00031467748,0.00010276016,0.0000090573685,0.9346265,0.00006897819,0.00016028831,0.00037915786],"study_design_scores_gemma":[0.0055411947,0.0005057302,0.08903093,0.00003243428,0.004686526,0.000094839925,0.0001546142,0.000564171,0.8983929,0.000014492446,0.0008571398,0.00012501505],"about_ca_topic_score_codex":0.000120268254,"about_ca_topic_score_gemma":0.000024821702,"teacher_disagreement_score":0.036233623,"about_ca_system_score_codex":0.000078123856,"about_ca_system_score_gemma":0.00015495402,"threshold_uncertainty_score":0.3943564},"labels":[],"label_agreement":null},{"id":"W338936873","doi":"10.1182/blood.v126.23.908.908","title":"Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lenalidomide; Azacitidine; International Prognostic Scoring System; Internal medicine; Myelodysplastic syndromes; Chronic myelomonocytic leukemia; Oncology; Decitabine; Adverse effect; Clinical endpoint; Phases of clinical research; Gastroenterology; Randomized controlled trial; Multiple myeloma; Clinical trial; Bone marrow","score_opus":0.0458846168319952,"score_gpt":0.32696466333407215,"score_spread":0.28108004650207696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W338936873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393415,0.00022298444,0.00009900223,0.0000865958,0.000026110594,0.0046617524,0.00084241503,0.0000710989,0.000055868357],"genre_scores_gemma":[0.99687064,0.00020980631,0.0008351182,0.000031968644,0.00010686406,0.0010598437,0.00046998088,0.00011186396,0.00030390423],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99477285,0.0008792152,0.0014334023,0.0009026151,0.0013488717,0.000663045],"domain_scores_gemma":[0.995167,0.0019492548,0.0010053687,0.00079632964,0.0006077447,0.0004742825],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008620099,0.00069438474,0.0034229963,0.0010775813,0.00011594548,0.000035614004,0.00035448524,0.00007500653,0.000657066],"category_scores_gemma":[0.0006584477,0.0004383075,0.00015121751,0.002006454,0.0011058545,0.0002458211,0.00020446182,0.0006558419,0.0000037929804],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84118754,0.026982926,0.10719194,0.00037346355,0.01163555,0.0027311018,0.0051100757,0.000696628,0.00091947545,0.00000830899,0.0006988121,0.002464184],"study_design_scores_gemma":[0.78813684,0.15380153,0.044820387,0.0005845467,0.0036853938,0.00030434754,0.0041628783,0.0023813453,0.0015436149,0.000008025769,0.00003324121,0.0005378356],"about_ca_topic_score_codex":0.0025199242,"about_ca_topic_score_gemma":0.0058702994,"teacher_disagreement_score":0.1268186,"about_ca_system_score_codex":0.00063679746,"about_ca_system_score_gemma":0.001967925,"threshold_uncertainty_score":0.9998069},"labels":[],"label_agreement":null},{"id":"W34295218","doi":"10.1182/blood.v122.21.355.355","title":"Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Hospital for Sick Children","funders":"","keywords":"Medicine; Gemtuzumab ozogamicin; Induction chemotherapy; Internal medicine; Oncology; Chemotherapy regimen; Chemotherapy; Randomized controlled trial; Myeloid leukemia; Leukemia; Surgery; Stem cell","score_opus":0.009068426536026344,"score_gpt":0.2710262027850045,"score_spread":0.26195777624897815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W34295218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824319,0.001192687,0.00024962713,0.00241219,0.0002468772,0.011394682,0.0010215468,0.00022831387,0.00082216173],"genre_scores_gemma":[0.9878473,0.0023628417,0.003224748,0.00060285564,0.0014163384,0.0013538189,0.0019034115,0.00022006902,0.0010686056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99115604,0.0024337322,0.0019569464,0.0016226767,0.0011940558,0.0016365334],"domain_scores_gemma":[0.99244493,0.0030713195,0.0010150671,0.0026200332,0.00024612749,0.00060251117],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0049778214,0.0008781492,0.0024527148,0.00036016598,0.00041514845,0.00016806104,0.0015429996,0.00074006803,0.0001642872],"category_scores_gemma":[0.0044648126,0.0005722193,0.0004827072,0.00082444114,0.0007960704,0.00042155042,0.00063583785,0.0028670253,0.0001147159],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8965947,0.003603967,0.004329939,0.000015771895,0.0071586855,0.00021768949,0.0022819778,0.000027473678,0.05253005,0.000039456798,0.02043328,0.012767019],"study_design_scores_gemma":[0.9674126,0.0043800627,0.013192989,0.0001978891,0.003678427,0.00049896777,0.0003346756,0.0006182945,0.008584712,0.00021449337,0.00022015785,0.00066675426],"about_ca_topic_score_codex":0.06640956,"about_ca_topic_score_gemma":0.001262222,"teacher_disagreement_score":0.07081789,"about_ca_system_score_codex":0.0017069395,"about_ca_system_score_gemma":0.002433915,"threshold_uncertainty_score":0.99967295},"labels":[],"label_agreement":null},{"id":"W39039551","doi":"","title":"Gingival hyperplasia complicating acute myelomonocytic leukemia.","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Acute myelomonocytic leukemia; Medicine; Leukemia; Acute leukemia; Hyperplasia; Chronic myelomonocytic leukemia; Oral cavity; Dermatology; Immunology; Pathology; Dentistry; Bone marrow","score_opus":0.02810839571450801,"score_gpt":0.27274420499171265,"score_spread":0.24463580927720463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W39039551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8026102,0.00014421667,0.00005102318,0.002022601,0.000070046546,0.0013314999,0.000011596014,0.00031572158,0.19344309],"genre_scores_gemma":[0.9635283,0.00014275606,0.0015248794,0.0013335672,0.0004220403,0.0013398785,0.000043714223,0.00006883506,0.031596035],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99763656,0.00005417443,0.00034550502,0.00049054,0.00047804002,0.0009951754],"domain_scores_gemma":[0.9985559,0.00012860411,0.0000529014,0.0006656612,0.0000799494,0.0005170097],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033560913,0.0002305673,0.00040341236,0.00015529273,0.00015801187,0.000056452725,0.00030559994,0.00013517379,0.0006593458],"category_scores_gemma":[0.00012620751,0.00020629936,0.00014187777,0.00046476195,0.00015545436,0.00013536713,0.00008594265,0.0005680807,0.0010432305],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043099117,0.000070153015,0.00586626,0.00006240176,0.00028386153,0.00034860178,0.00014913014,0.000027236749,0.0008398801,0.00022731743,0.011676586,0.9800176],"study_design_scores_gemma":[0.006730393,0.00014839332,0.78705573,0.00006323598,0.00042733477,0.0032813947,0.000104800594,0.006755596,0.007244542,0.0003354838,0.18717319,0.0006799371],"about_ca_topic_score_codex":0.00007842614,"about_ca_topic_score_gemma":0.0000015722754,"teacher_disagreement_score":0.97933763,"about_ca_system_score_codex":0.0014274212,"about_ca_system_score_gemma":0.00028906937,"threshold_uncertainty_score":0.9997346},"labels":[],"label_agreement":null},{"id":"W398314045","doi":"10.1182/blood.v124.21.3585.3585","title":"Timing of the Loss of Pten Is Critical in Determining the Disease Phenotype in Mice- a Mouse Model for Pediatric Mixed MDS/MPN","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"","keywords":"PTEN; Biology; Myeloid; Phenotype; Cancer research; Epigenetics; Myeloid leukemia; Somatic cell; Germline mutation; Germline; Immunology; Mutation; Genetics; PI3K/AKT/mTOR pathway; Gene","score_opus":0.032716894905506416,"score_gpt":0.30989997042903367,"score_spread":0.2771830755235273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W398314045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99740565,0.000104045495,0.0004862016,0.0012929044,0.000018693168,0.00050130073,0.00003730086,0.000006992601,0.00014694144],"genre_scores_gemma":[0.99818367,0.000015788633,0.0012347223,0.00026301874,0.00009815013,0.00005077714,0.0000031506117,0.000025008398,0.00012571516],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99880594,0.00008803182,0.00032632193,0.00019260983,0.0002939943,0.00029310718],"domain_scores_gemma":[0.99864185,0.00069769967,0.000063268555,0.00037897666,0.00012903473,0.000089156994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050546246,0.00010361952,0.0002559529,0.0001231622,0.00003456103,0.000005928371,0.00027453736,0.00006822506,0.000007500052],"category_scores_gemma":[0.0024693755,0.00006414955,0.00009669294,0.00024920853,0.00012381682,0.00004167473,0.0001371589,0.00023264113,0.0000019724218],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001261209,0.0026711707,0.9665791,0.0025096769,0.00007998985,0.000022821538,0.0052991807,0.0005986217,0.015886102,0.0011476679,0.00096759683,0.0029769123],"study_design_scores_gemma":[0.014050417,0.00023085607,0.1796937,0.00022987042,0.00065165357,0.000004922308,0.0002989997,0.78499526,0.01846358,0.0011246947,0.000025937821,0.00023008285],"about_ca_topic_score_codex":0.000044734923,"about_ca_topic_score_gemma":0.000027527654,"teacher_disagreement_score":0.7868853,"about_ca_system_score_codex":0.000042806267,"about_ca_system_score_gemma":0.00029769915,"threshold_uncertainty_score":0.29562515},"labels":[],"label_agreement":null},{"id":"W4200019298","doi":"10.1182/bloodadvances.2021005741","title":"A clinical laboratory–developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Terry Fox Foundation; Ontario Genomics Institute; Ontario Institute for Cancer Research; Government of Canada; Canadian Institutes of Health Research; China Scholarship Council; Ontario Genomics; Genome Canada; Mayo Clinic","keywords":"Myeloid leukemia; Medicine; Oncology; Internal medicine; Cohort; Risk stratification","score_opus":0.023593416256952573,"score_gpt":0.3544770853825217,"score_spread":0.33088366912556916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200019298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904396,0.0013835552,0.0039175623,0.0002614713,0.0003072397,0.0015321069,0.00083577016,0.000076851466,0.0012458244],"genre_scores_gemma":[0.8396268,0.0035690172,0.15314801,0.00070728833,0.000462989,0.00043503498,0.00077402365,0.00014142648,0.0011354304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965517,0.000376998,0.0008733038,0.0007585212,0.0009096056,0.0005298744],"domain_scores_gemma":[0.99526143,0.00084774895,0.0005319813,0.0007441755,0.0023068136,0.00030786684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011921423,0.00032635205,0.0010093289,0.00012675849,0.00015980977,0.000036119065,0.00028322657,0.0001939484,0.00009088473],"category_scores_gemma":[0.001041889,0.00024275691,0.00018692865,0.00075360277,0.00027721198,0.00034283864,0.00016192798,0.00060290005,0.0000065846484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012815219,0.0010780996,0.96322215,0.0005846683,0.0015734492,0.00019525694,0.00006976782,0.000021400721,0.0009302288,0.0001635796,0.00083458726,0.030045278],"study_design_scores_gemma":[0.027382681,0.0030208018,0.89592737,0.0005880575,0.00170845,0.000024663159,0.00036602994,0.0002746658,0.018946411,0.000102703576,0.051098797,0.0005593451],"about_ca_topic_score_codex":0.000008262623,"about_ca_topic_score_gemma":0.000037193753,"teacher_disagreement_score":0.15081283,"about_ca_system_score_codex":0.00026033152,"about_ca_system_score_gemma":0.0052821073,"threshold_uncertainty_score":0.98993397},"labels":[],"label_agreement":null},{"id":"W4200051856","doi":"10.1182/blood-2021-154179","title":"Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre; Hôpital Maisonneuve-Rosemont; University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Decitabine; Medicine; Internal medicine; Oncology; Biology; Genetics","score_opus":0.035805484142917565,"score_gpt":0.3477579079077924,"score_spread":0.3119524237648748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200051856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927042,0.00078554096,0.000017867325,0.004452496,0.000054712134,0.001014436,0.000036384856,0.000022585871,0.0009117786],"genre_scores_gemma":[0.99845994,0.00004614965,0.0002961435,0.00056628446,0.0002460673,0.00006169676,0.000096732285,0.000029548633,0.00019745748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755704,0.0005615196,0.00041797792,0.00036405845,0.0007321285,0.00036726933],"domain_scores_gemma":[0.9972106,0.0013664762,0.00007524202,0.0010614448,0.00019596894,0.00009023409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010883008,0.00018278121,0.00041544292,0.00007310143,0.00007893758,0.000033358672,0.00048002435,0.00007317748,0.0003580951],"category_scores_gemma":[0.0017787603,0.00010063689,0.00011516462,0.0010472827,0.00011201009,0.000049364022,0.0001879897,0.0005866441,0.000044233493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005708463,0.09437678,0.64411396,0.00014007688,0.0029283543,0.011754465,0.032705385,0.000028222536,0.148326,0.00079838024,0.025192076,0.033927813],"study_design_scores_gemma":[0.13436887,0.0029533547,0.7873049,0.00018869796,0.0012528563,0.0002558038,0.02086902,0.00033724803,0.043990143,0.0001671624,0.007953721,0.00035825252],"about_ca_topic_score_codex":0.0013482111,"about_ca_topic_score_gemma":0.0005755466,"teacher_disagreement_score":0.14319089,"about_ca_system_score_codex":0.000056413974,"about_ca_system_score_gemma":0.00048816096,"threshold_uncertainty_score":0.41038534},"labels":[],"label_agreement":null},{"id":"W4200101750","doi":"10.1182/bloodadvances.2021005240","title":"Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Oncology; Risk analysis (engineering); Risk assessment; Myelodysplastic syndromes; Internal medicine; Intensive care medicine; Computer science; Cancer; Computer security; Immunotherapy","score_opus":0.015406730698258484,"score_gpt":0.2841526436120235,"score_spread":0.26874591291376504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200101750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467534,0.0019766667,0.000059244754,0.0008477909,0.00010297567,0.00069060654,0.000046279732,0.00006847775,0.0015326097],"genre_scores_gemma":[0.9902943,0.0019623076,0.0038735217,0.00011665473,0.000037493766,0.00018670433,0.00009661955,0.00003972325,0.003392718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758875,0.00014612013,0.00055112626,0.0005773591,0.0005141499,0.000622497],"domain_scores_gemma":[0.9987497,0.00042111718,0.00014952724,0.0003536155,0.00016523035,0.0001608311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039321103,0.00023924439,0.00060342846,0.00034053586,0.0000831936,0.00004135297,0.00016216961,0.00013862734,0.0002971388],"category_scores_gemma":[0.0009978905,0.00020480434,0.00005899384,0.0013388754,0.00010437439,0.00039979874,0.00010695098,0.0006378967,0.0001333449],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049207094,0.0066718487,0.8145897,0.0024352304,0.00034038525,0.042818118,0.0010796774,0.0015734985,0.04812396,0.0014280695,0.0002820171,0.07573679],"study_design_scores_gemma":[0.034237206,0.002198597,0.8354131,0.0019743326,0.00024949113,0.0038291144,0.0014900818,0.006209093,0.10942697,0.0020008602,0.0021642877,0.0008068673],"about_ca_topic_score_codex":0.0002653745,"about_ca_topic_score_gemma":0.0016528679,"teacher_disagreement_score":0.07492992,"about_ca_system_score_codex":0.00029769266,"about_ca_system_score_gemma":0.0007664477,"threshold_uncertainty_score":0.8351679},"labels":[],"label_agreement":null},{"id":"W4200103238","doi":"10.1200/jco.21.01546","title":"Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Venetoclax; Medicine; Azacitidine; Internal medicine; Minimal residual disease; Myeloid leukemia; Oncology; Complete remission; Gastroenterology; Multivariate analysis; Leukemia; Chemotherapy; Chronic lymphocytic leukemia","score_opus":0.10115982711630152,"score_gpt":0.4356241830475861,"score_spread":0.3344643559312846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200103238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756107,0.001940533,0.000008857353,0.021592226,0.00009603702,0.00032399586,0.000012857292,0.000008944107,0.00040588205],"genre_scores_gemma":[0.98569334,0.006943158,0.004580177,0.00084104977,0.00046149723,0.000021158008,0.0000068478275,0.000031832293,0.0014209696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99603456,0.0013259411,0.0013956552,0.00037508042,0.000478309,0.00039046552],"domain_scores_gemma":[0.9939666,0.0036821393,0.0005462779,0.00023012733,0.00055042456,0.0010244462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035443634,0.00020516792,0.0014862086,0.00022627646,0.000059291793,0.0000275248,0.000095810574,0.00031058738,0.000062569685],"category_scores_gemma":[0.005830083,0.00013566688,0.00015523817,0.00030687428,0.00046871562,0.00017180477,0.000094382754,0.0010604288,0.0000047842627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21727754,0.0013145499,0.58923453,0.00010055808,0.0015640578,0.087852806,0.00036780155,0.000032787262,0.0046653347,0.000054512893,0.00290587,0.09462964],"study_design_scores_gemma":[0.029891478,0.02705143,0.91228104,0.0003440158,0.0009907858,0.005646705,0.0003545431,0.00025417376,0.0015532362,0.0001646824,0.02129029,0.000177628],"about_ca_topic_score_codex":0.000043152133,"about_ca_topic_score_gemma":0.00013355615,"teacher_disagreement_score":0.3230465,"about_ca_system_score_codex":0.0016988391,"about_ca_system_score_gemma":0.018416464,"threshold_uncertainty_score":0.9871482},"labels":[],"label_agreement":null},{"id":"W4200239384","doi":"10.1111/ejh.13733","title":"Poor outcome after hematopoietic stem cell transplantation of patients with unclassified inherited bone marrow failure syndromes","year":2021,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Janeway Children's Health and Rehabilitation Centre; McMaster University; London Health Sciences Centre; McMaster Children's Hospital; University of Alberta; Centre hospitalier universitaire de Québec; Health and Social Services Centre University Institute of Geriatrics of Sherbrooke; Centre Hospitalier Universitaire de Sherbrooke; Queen's University; Centre Hospitalier Universitaire Sainte-Justine; Health Sciences Centre; CancerCare Manitoba; Izaak Walton Killam Health Centre; Alberta Children's Hospital; Children's Hospital of Eastern Ontario; Princess Margaret Cancer Centre; University of Saskatchewan; Hospital for Sick Children; BC Children's Hospital; Montreal Children's Hospital; University of Toronto","funders":"","keywords":"Medicine; Cord blood; Hematopoietic stem cell transplantation; Transplantation; Stem cell; Bone marrow; Haematopoiesis; Internal medicine; Bone marrow failure; Surgery; Oncology; Biology","score_opus":0.01897387518674901,"score_gpt":0.2488259980760348,"score_spread":0.2298521228892858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200239384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960396,0.00049305253,0.00076698005,0.0017597737,0.00010131927,0.00017586874,0.000018492443,0.000013565401,0.00063132343],"genre_scores_gemma":[0.9962413,0.000038930393,0.0027802312,0.00026834346,0.000029773277,0.0000017459982,0.000024786581,0.000058974747,0.0005559289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731565,0.00069777283,0.0009758068,0.00020529292,0.0005152247,0.00029024432],"domain_scores_gemma":[0.99818736,0.000113749986,0.00052246446,0.00026981044,0.0007013736,0.00020525075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045074563,0.00019689504,0.00086596125,0.00027832566,0.00003207492,0.000014576423,0.00015448779,0.00006610617,0.00028124457],"category_scores_gemma":[0.000045298726,0.00014164366,0.00015725437,0.0003066644,0.00015192208,0.00011309014,0.000045116558,0.000528311,0.000049138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009104817,0.0013568194,0.6281719,0.0057377364,0.00074475154,0.32580528,0.004106432,0.000022623984,0.020197961,0.0001269107,0.003051061,0.0015736679],"study_design_scores_gemma":[0.032425757,0.004307599,0.77763,0.0017035118,0.0014472844,0.13227224,0.0028779653,0.000037343954,0.04345237,0.000027633982,0.0031792137,0.0006391017],"about_ca_topic_score_codex":8.8662887e-7,"about_ca_topic_score_gemma":0.0000036859922,"teacher_disagreement_score":0.19353305,"about_ca_system_score_codex":0.00006929433,"about_ca_system_score_gemma":0.00024072743,"threshold_uncertainty_score":0.5776061},"labels":[],"label_agreement":null},{"id":"W4200341457","doi":"10.3390/cancers13246181","title":"Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Österreichische Forschungsförderungsgesellschaft; Austrian Science Fund","keywords":"Ponatinib; Cabozantinib; Myeloid leukemia; Medicine; Oncology; Drug; Cancer research; Pharmacology; Clinical trial; Internal medicine; Dasatinib","score_opus":0.014551264957074221,"score_gpt":0.2745796679648039,"score_spread":0.26002840300772967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200341457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918435,0.0031717424,0.00011508949,0.0006078418,0.0001872866,0.0002454158,0.000015564641,0.000053784934,0.0037597315],"genre_scores_gemma":[0.9932438,0.0016019521,0.0021926917,0.0005066689,0.0003313431,0.00002845444,0.0000737735,0.00006103266,0.0019602661],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983881,0.00006420917,0.00033581184,0.0004396111,0.00032031958,0.0004519235],"domain_scores_gemma":[0.99888366,0.00010694465,0.000101956306,0.0003578566,0.00025297035,0.00029662452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019264112,0.00019485707,0.0004304914,0.000121004734,0.00007593206,0.000019623134,0.0001189994,0.0001462227,0.00017105679],"category_scores_gemma":[0.0002615871,0.00018628576,0.00009671456,0.0004779199,0.00021705551,0.000057771013,0.00018063308,0.0004001227,0.000012868848],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005339681,0.00002608137,0.002485976,0.00040666063,0.0006328063,0.0012048547,0.0010916599,0.0004858067,0.95155495,0.00024316851,0.018912923,0.022421168],"study_design_scores_gemma":[0.0061786026,0.00035457005,0.003631936,0.0003715903,0.00027890757,0.00018986523,0.0014977012,0.0023493555,0.9661488,0.00002361657,0.018610531,0.0003645389],"about_ca_topic_score_codex":0.00060486863,"about_ca_topic_score_gemma":0.000045746103,"teacher_disagreement_score":0.022056628,"about_ca_system_score_codex":0.002466509,"about_ca_system_score_gemma":0.0041138413,"threshold_uncertainty_score":0.7596513},"labels":[],"label_agreement":null},{"id":"W4200407778","doi":"10.1182/blood-2021-151493","title":"Updated Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cytarabine; Chronic myelomonocytic leukemia; Daunorubicin; Internal medicine; Azacitidine; Myelodysplastic syndromes; Hypomethylating agent; Gastroenterology; Leukemia; Oncology; Surgery; Bone marrow","score_opus":0.016715334186357175,"score_gpt":0.29344233401011716,"score_spread":0.27672699982376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200407778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639463,0.00013289088,0.00006335133,0.00006766702,0.00006528002,0.0026539243,0.00056751893,0.000035596368,0.000019118896],"genre_scores_gemma":[0.99538165,0.000039652903,0.0036735886,0.000034376033,0.00007043247,0.0002329869,0.00019000923,0.00008036358,0.00029693628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969593,0.00016781902,0.00082542107,0.00075660605,0.00073122245,0.00055962335],"domain_scores_gemma":[0.99723965,0.00052570074,0.00034620005,0.00075762626,0.00079543394,0.0003353631],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003638985,0.0003573855,0.0008859403,0.0003660572,0.0000890901,0.00003074757,0.0001868504,0.00015402153,0.00010323171],"category_scores_gemma":[0.0016715135,0.00026081534,0.000076381046,0.0010245123,0.000112607064,0.00014193081,0.0002968676,0.00037626168,0.0000069587945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3220735,0.08492725,0.3766701,0.00954165,0.022095706,0.011277693,0.03370293,0.0009481593,0.043289088,0.00001525881,0.0048073903,0.0906513],"study_design_scores_gemma":[0.4124487,0.096388936,0.45099103,0.002193863,0.005389935,0.00021316289,0.00309716,0.0013909513,0.025945684,0.000020065194,0.00086407136,0.0010564396],"about_ca_topic_score_codex":0.00021168585,"about_ca_topic_score_gemma":0.00037079921,"teacher_disagreement_score":0.09037524,"about_ca_system_score_codex":0.00042729697,"about_ca_system_score_gemma":0.0011796289,"threshold_uncertainty_score":0.9999844},"labels":[],"label_agreement":null},{"id":"W4200418432","doi":"10.1038/s41408-021-00584-3","title":"Differentiation therapy for myeloid malignancies: beyond cytotoxicity","year":2021,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Leukemia & Lymphoma Society of Canada; Canada's Michael Smith Genome Sciences Centre","funders":"BC Cancer Foundation; University of British Columbia; Genome British Columbia; Leukemia and Lymphoma Society of Canada; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Leukemia and Lymphoma Society; Genome Canada; Terry Fox Research Institute","keywords":"Myeloid leukemia; Myeloid; Azacitidine; Medicine; Differentiation therapy; Acute promyelocytic leukemia; Myelodysplastic syndromes; Immunology; Haematopoiesis; Cancer research; Stem cell; Biology; Retinoic acid; Bone marrow; DNA methylation","score_opus":0.06473534785784331,"score_gpt":0.3828485920994154,"score_spread":0.3181132442415721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200418432","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042724132,0.99559826,0.00045829755,0.0003574579,0.0007062531,0.0019811722,0.00024940306,0.00003880056,0.00018310048],"genre_scores_gemma":[0.000015547956,0.9902039,0.000901147,0.00041036238,0.004514318,0.00080984813,0.00025557316,0.00016872218,0.0027205793],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996564,0.00026649152,0.0010109642,0.00056624826,0.0008251897,0.0007671398],"domain_scores_gemma":[0.99730444,0.00026528153,0.0007443187,0.0005081855,0.0007373676,0.00044039206],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007128397,0.00058701634,0.0025982284,0.00038177834,0.0003263428,0.00020728477,0.0004142919,0.00054579356,0.0011305664],"category_scores_gemma":[0.00021671169,0.00042045914,0.0015268682,0.00049924396,0.00007604506,0.00012201772,0.00009155741,0.0016898104,0.000015929554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088820816,0.00041652325,0.000046509325,0.009680831,0.0029540353,0.00021393057,0.000091412614,5.6059486e-7,0.00018905353,0.000053496507,0.017053513,0.96921134],"study_design_scores_gemma":[0.0038166207,0.00051169354,0.000035800567,0.017517483,0.0030916862,0.0026255792,0.000032579243,0.0000073606693,0.00045834546,0.000040500032,0.9714541,0.00040826452],"about_ca_topic_score_codex":0.000018447045,"about_ca_topic_score_gemma":0.0000091020665,"teacher_disagreement_score":0.96880305,"about_ca_system_score_codex":0.0011056464,"about_ca_system_score_gemma":0.006742927,"threshold_uncertainty_score":0.9998247},"labels":[],"label_agreement":null},{"id":"W4200430607","doi":"10.1084/jem.20211924","title":"Modeling human yolk sac hematopoiesis with pluripotent stem cells","year":2021,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stem Cell Network; University of Toronto; University Health Network","funders":"National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health; Fondazione Telethon","keywords":"Yolk sac; Induced pluripotent stem cell; Haematopoiesis; Stem cell; Human Induced Pluripotent Stem Cells; Cell biology; Biology; Embryonic stem cell; Embryo; Genetics; Gene","score_opus":0.04103184653596352,"score_gpt":0.32455242744421975,"score_spread":0.2835205809082562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200430607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803422,0.010873686,0.0011044674,0.00561715,0.00018653556,0.00023104192,0.0000010876032,0.000016501435,0.0016273271],"genre_scores_gemma":[0.99584496,0.0003104662,0.000780042,0.0009537373,0.00071527914,0.000003994507,0.000002439558,0.00004382965,0.0013452368],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974982,0.00016641295,0.00065331795,0.00016256481,0.0011840167,0.0003354644],"domain_scores_gemma":[0.99847734,0.00011165169,0.00021280235,0.0004365123,0.00043152875,0.0003301473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086894963,0.00021836779,0.00063504564,0.00014767995,0.0001805147,0.000013220688,0.0002656661,0.000062451174,0.00058883574],"category_scores_gemma":[0.000029301247,0.000109573215,0.0001079488,0.000293792,0.00026811298,0.00010740255,0.00011324488,0.0006294007,0.00001457443],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008672922,0.00022852184,0.00006321338,0.000049989365,0.00029099482,0.0012313935,0.0039832992,0.0002962008,0.99039155,0.00009954773,0.0022574475,0.00024056518],"study_design_scores_gemma":[0.006040477,0.0026305027,0.0000407786,0.0010811719,0.00031472044,0.007836635,0.036099494,0.0017850194,0.9435511,0.000032513253,0.00045534738,0.00013222106],"about_ca_topic_score_codex":0.00006894448,"about_ca_topic_score_gemma":0.0000030249216,"teacher_disagreement_score":0.046840414,"about_ca_system_score_codex":0.00044802044,"about_ca_system_score_gemma":0.00031741365,"threshold_uncertainty_score":0.64473385},"labels":[],"label_agreement":null},{"id":"W4200440558","doi":"10.1182/blood-2021-153847","title":"Inhibition of PINK1-Dependent Mitochondrial Quality Control Pathways Induces Senescence of Acute Myeloid Leukemia Stem Cells","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"PINK1; Mitophagy; Mitochondrion; Stem cell; Biology; Cell biology; Myeloid leukemia; Haematopoiesis; Cancer research; Apoptosis; Biochemistry; Autophagy","score_opus":0.02732148597733019,"score_gpt":0.28197719616800626,"score_spread":0.25465571019067607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200440558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99640334,0.00030828718,0.0006924816,0.000243181,0.0002769214,0.0006194314,0.00036864055,0.00004901865,0.0010386923],"genre_scores_gemma":[0.9975231,0.00021428021,0.0011745264,0.00013637607,0.00032131316,0.000032348675,0.000058339756,0.000033904464,0.0005058104],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968166,0.00035467505,0.00088054367,0.0004990334,0.0010391216,0.00041007847],"domain_scores_gemma":[0.9976671,0.00028255492,0.0003855451,0.0007030247,0.0007440395,0.00021773459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052456924,0.00023569608,0.00081858336,0.00014282633,0.00005563912,0.000017452217,0.00017702818,0.00028561655,0.00010481989],"category_scores_gemma":[0.00014297158,0.0002176959,0.00024321921,0.0004052878,0.00017216506,0.00012296783,0.00015243249,0.00048617818,0.000030630123],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053840294,0.0006412378,0.0013627869,0.00042782893,0.00048300062,0.0003815185,0.00048406146,0.0000057996413,0.9942488,0.00026780833,0.00019201911,0.00096671993],"study_design_scores_gemma":[0.013574211,0.00037730474,0.0029247375,0.0002738269,0.000516563,0.00011934097,0.0005570844,0.00003160757,0.98132074,0.00006353653,0.00006451138,0.00017651862],"about_ca_topic_score_codex":0.00015760236,"about_ca_topic_score_gemma":0.000020700802,"teacher_disagreement_score":0.013035809,"about_ca_system_score_codex":0.0002588175,"about_ca_system_score_gemma":0.0019791732,"threshold_uncertainty_score":0.8877381},"labels":[],"label_agreement":null},{"id":"W4200525569","doi":"10.1158/1535-7163.targ-21-lba013","title":"Abstract LBA013: Phosphoproteomics reveals active drug targets on pathways of resistance and predicts response to midostaurin plus chemotherapy in FLT3 mutant-positive acute myeloid leukemia","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Drug resistance; Oncology; Midostaurin; Population; Medicine; Cancer; Internal medicine; Cancer research; Biology; Pharmacology; Genetics","score_opus":0.015226976321128209,"score_gpt":0.28659163156104833,"score_spread":0.27136465523992015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200525569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855879,0.0043311617,0.00029343786,0.007050743,0.00009807488,0.0016203438,0.0005012476,0.000056551617,0.00046053017],"genre_scores_gemma":[0.98658574,0.0039193523,0.0023238228,0.005993456,0.00006815469,0.00019622828,0.00004972529,0.00013890308,0.0007246439],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996713,0.00029648584,0.00059499167,0.0008547763,0.0008220636,0.0007186746],"domain_scores_gemma":[0.99787974,0.00028263582,0.0002214631,0.0008168402,0.00048117986,0.00031813557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061341946,0.00045995705,0.00083194446,0.0002819542,0.00008810781,0.00003798006,0.00026933866,0.00027705287,0.000054937536],"category_scores_gemma":[0.00013245341,0.00045918758,0.00015692593,0.00082728284,0.00020719554,0.00008948207,0.0001338978,0.00084459176,0.000007812199],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035215147,0.00017475893,0.00028820467,0.00016920682,0.000757695,0.0020410826,0.0057536433,0.00018571292,0.94763553,0.000074493575,0.00023684106,0.0074676936],"study_design_scores_gemma":[0.0067895297,0.00039478904,0.040788904,0.00092628994,0.00014082826,0.00003579519,0.0005915492,0.00021584108,0.9475115,0.0002291526,0.001990504,0.00038530643],"about_ca_topic_score_codex":0.00017186737,"about_ca_topic_score_gemma":0.00013806099,"teacher_disagreement_score":0.040500697,"about_ca_system_score_codex":0.0032181295,"about_ca_system_score_gemma":0.002658689,"threshold_uncertainty_score":0.99978596},"labels":[],"label_agreement":null},{"id":"W4200542010","doi":"10.1182/blood-2021-149840","title":"Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gemtuzumab ozogamicin; Calicheamicin; Cytarabine; Internal medicine; Daunorubicin; Gastroenterology; Refractory (planetary science); Myeloid leukemia; Population; Oncology; CD33; Leukemia; Pharmacology; Stem cell","score_opus":0.0068502452173089135,"score_gpt":0.22922753284286135,"score_spread":0.22237728762555242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200542010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994924,0.0014392822,0.00005444416,0.001757936,0.0001020346,0.0012954379,0.00011475616,0.00012446834,0.00018762406],"genre_scores_gemma":[0.9926467,0.0009892354,0.004530101,0.0003048503,0.00009329383,0.000096883894,0.00043820645,0.00015265109,0.0007481043],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9949954,0.0005451808,0.000995058,0.0013652224,0.0010234546,0.0010756422],"domain_scores_gemma":[0.9970228,0.00085617666,0.00035755982,0.000796974,0.00049838,0.00046809707],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00091940025,0.00067947846,0.0012409874,0.0011098053,0.00022246025,0.00012173809,0.00024866493,0.00053770107,0.00009418374],"category_scores_gemma":[0.001236877,0.00062147016,0.0000887244,0.001554938,0.00031265782,0.00042337482,0.00042335625,0.0021719895,0.000034885754],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004466289,0.0026048445,0.28908125,0.0013829375,0.00139477,0.028415937,0.004319678,0.00029152763,0.65540123,0.00034189175,0.00013657118,0.012163113],"study_design_scores_gemma":[0.052671473,0.006806722,0.90923285,0.0014813979,0.00096841727,0.005934553,0.0018571666,0.0018263,0.018034039,0.00013003954,0.00014285353,0.0009141699],"about_ca_topic_score_codex":0.0021056735,"about_ca_topic_score_gemma":0.0021790839,"teacher_disagreement_score":0.6373672,"about_ca_system_score_codex":0.001361359,"about_ca_system_score_gemma":0.0015043346,"threshold_uncertainty_score":0.99962366},"labels":[],"label_agreement":null},{"id":"W4200614427","doi":"10.1038/s41375-021-01459-z","title":"Correction: Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia","year":2021,"lang":"en","type":"erratum","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Chronic myelomonocytic leukemia; In vivo; Medicine; Leukemia; Cancer research; Drug; Oncology; Immunology; Pharmacology; Biology; Bone marrow; Genetics; Myelodysplastic syndromes","score_opus":0.014528428426693354,"score_gpt":0.2684379888895411,"score_spread":0.2539095604628478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200614427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8883639,0.031354774,0.0032238716,0.00038161615,0.018100066,0.013150138,0.0013774558,0.0004723666,0.043575794],"genre_scores_gemma":[0.53240836,0.01618987,0.0010450165,0.00033751057,0.0014054383,0.003124026,0.00683369,0.0007301016,0.437926],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9934499,0.0005130548,0.0016436096,0.0016906303,0.0011953651,0.0015074228],"domain_scores_gemma":[0.9970411,0.00050824304,0.0005433357,0.0012255422,0.0002810274,0.00040077095],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00050888595,0.0011607148,0.0027066204,0.0013375654,0.0001373607,0.000080395286,0.00047418854,0.0013699351,0.00028934213],"category_scores_gemma":[0.00017750576,0.0011544846,0.0006052751,0.0016601639,0.00028739873,0.00028777012,0.00020264706,0.003500566,0.000026069994],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.003235552,0.0007184116,0.0010392497,0.0033897238,0.0012379428,0.0024244005,0.007343197,0.025484491,0.075565614,0.000005642301,0.852339,0.027216757],"study_design_scores_gemma":[0.029530551,0.002341912,0.0009658937,0.016108176,0.0011653993,0.0003971908,0.0020820359,0.709748,0.20420296,0.000042105537,0.031362355,0.0020533644],"about_ca_topic_score_codex":0.01733656,"about_ca_topic_score_gemma":0.009256294,"teacher_disagreement_score":0.8209767,"about_ca_system_score_codex":0.042604886,"about_ca_system_score_gemma":0.014655708,"threshold_uncertainty_score":0.9999265},"labels":[],"label_agreement":null},{"id":"W4205105021","doi":"10.22374/jeleu.v4i3.132","title":"Myeloid Sarcoma of the Bladder in a Patient with Chronic myelomonocytic Leukaemia","year":2021,"lang":"en","type":"article","venue":"Journal of Endoluminal Endourology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chronic myeloid leukaemia; Medicine; Chronic myelomonocytic leukemia; Myeloid leukaemia; Sarcoma; Myeloid sarcoma; Cancer research; Immunology; Pathology; Bone marrow; Myelodysplastic syndromes","score_opus":0.013355271689456369,"score_gpt":0.2652336345061413,"score_spread":0.2518783628166849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205105021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912224,0.0025368114,0.00007743982,0.003975413,0.00019726719,0.00023534764,0.00000353247,0.0000050220583,0.0017467862],"genre_scores_gemma":[0.9974023,0.00028791893,0.0011215339,0.00060119026,0.00025480601,0.000007807907,0.000001830669,0.000030828134,0.00029175318],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99740815,0.00037356635,0.0008252096,0.00022829199,0.0006554647,0.00050929125],"domain_scores_gemma":[0.99789774,0.00036041567,0.00055305177,0.00045302178,0.0005597319,0.00017605588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004605241,0.00019438528,0.00071953627,0.0003014792,0.00004591978,0.000010184736,0.00030964325,0.00014807095,0.0002695911],"category_scores_gemma":[0.0005824593,0.00012173939,0.0002473714,0.00063224026,0.00038149607,0.0000948545,0.0001824216,0.0013790313,0.000008133561],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021451872,0.0028228217,0.2282098,0.00096127397,0.0025358496,0.09902631,0.0041984282,0.002962093,0.5348373,0.0015914193,0.007563193,0.09383964],"study_design_scores_gemma":[0.036719624,0.020434787,0.36120948,0.0010850498,0.0009739216,0.27350986,0.0020421727,0.0014618261,0.2644762,0.0005714642,0.03695253,0.0005630675],"about_ca_topic_score_codex":0.00007196386,"about_ca_topic_score_gemma":0.0002503099,"teacher_disagreement_score":0.2703611,"about_ca_system_score_codex":0.00075541413,"about_ca_system_score_gemma":0.0039127055,"threshold_uncertainty_score":0.69409716},"labels":[],"label_agreement":null},{"id":"W4205155690","doi":"10.1182/blood.2021013404","title":"Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Minimal residual disease; Azacitidine; Placebo; Oncology; Chemotherapy; Hematopoietic stem cell transplantation; Transplantation; Gastroenterology; Leukemia; Pathology","score_opus":0.016671621693273783,"score_gpt":0.2585591832911514,"score_spread":0.2418875615978776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205155690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99819344,0.00012501486,0.0000027327817,0.00014994474,0.000027373777,0.0007219697,0.0002224963,0.000017522516,0.00053948705],"genre_scores_gemma":[0.99900186,0.000011896658,0.0002577812,0.000021717806,0.000018062563,0.000052257543,0.00022979396,0.00003041892,0.00037623916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973232,0.00021970221,0.00034998613,0.00028173966,0.0014472728,0.00037807893],"domain_scores_gemma":[0.9989317,0.000060538947,0.00014799861,0.00036584606,0.0002430627,0.0002508294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056831026,0.00012961245,0.00036731074,0.00024292627,0.000052531133,0.0000040615114,0.00015729827,0.000041054318,0.0002705743],"category_scores_gemma":[0.0003167271,0.00010576622,0.000042756306,0.0005365195,0.00008714169,0.000076299126,0.00021509397,0.000422758,0.0000014816513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006021633,0.002476526,0.9867343,0.0002239137,0.000078777724,0.00017164725,0.00025970404,0.000041643958,0.0033329874,0.000025979356,0.00021148834,0.0004214247],"study_design_scores_gemma":[0.019180099,0.0016535341,0.9699626,0.000099849094,0.0001376506,0.0000049276455,0.00027001114,0.000041692456,0.008205169,0.000048649134,0.00027320563,0.00012262195],"about_ca_topic_score_codex":0.00039235767,"about_ca_topic_score_gemma":0.000047031914,"teacher_disagreement_score":0.016771683,"about_ca_system_score_codex":0.00018155726,"about_ca_system_score_gemma":0.0009634219,"threshold_uncertainty_score":0.43130213},"labels":[],"label_agreement":null},{"id":"W4205165198","doi":"10.1017/cjn.2021.434","title":"P.158 Feeling Green","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pathology; Differential diagnosis; Myeloid sarcoma; Medulloblastoma; Headaches; Myeloid; Biopsy; Myeloid leukemia; Sarcoma; Radiation therapy; Radiology; Surgery; Internal medicine","score_opus":0.0529378615842102,"score_gpt":0.30985736992015284,"score_spread":0.2569195083359426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205165198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96540326,0.0024473097,0.000035904784,0.021752516,0.00073502824,0.0001251522,0.000007888128,0.000020166633,0.009472763],"genre_scores_gemma":[0.9847327,0.0006411451,0.004816632,0.008817341,0.00065201125,0.0000012301994,5.641843e-7,0.000017208307,0.0003211946],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99436444,0.0009762656,0.0009840865,0.00063489465,0.0012420865,0.0017982218],"domain_scores_gemma":[0.9936913,0.0006480193,0.00053683796,0.00023055983,0.0013287164,0.0035645142],"candidate_categories":["sts"],"consensus_categories":["sts"],"category_scores_codex":[0.004764948,0.00033201542,0.00068581407,0.001104404,0.0024438978,0.0007113164,0.0016359428,0.00025560576,0.0006992928],"category_scores_gemma":[0.0052647837,0.00022594442,0.0003841558,0.0023789296,0.0066400063,0.0008573607,0.00012630064,0.0022945185,0.000018300485],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015498811,0.000054607426,0.9003959,0.000021298516,0.00004375172,0.08437862,0.0003700339,0.0010181958,0.0005374304,0.0011240778,0.0030843953,0.008816718],"study_design_scores_gemma":[0.0016843247,0.10527975,0.29593527,0.00019941367,0.00018644705,0.5245135,0.0011010468,0.0037136395,0.0017253788,0.025503566,0.03936551,0.0007921554],"about_ca_topic_score_codex":0.0018216765,"about_ca_topic_score_gemma":0.04624232,"teacher_disagreement_score":0.6044606,"about_ca_system_score_codex":0.00054429984,"about_ca_system_score_gemma":0.016475035,"threshold_uncertainty_score":0.99885476},"labels":[],"label_agreement":null},{"id":"W4205194439","doi":"10.1002/9780470750650.ch9","title":"I","year":2003,"lang":"en","type":"other","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Citation; Medicine; Library science; Internal medicine; Family medicine; Computer science","score_opus":0.020439106360668646,"score_gpt":0.3143741181394443,"score_spread":0.2939350117787757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205194439","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000010222691,0.0005469368,0.00012108295,0.000403746,0.00007690196,0.0002412112,0.000002963959,0.00019110486,0.99841505],"genre_scores_gemma":[0.000003940349,0.00022746231,0.004099627,0.00122927,0.0002573698,0.000007883678,0.000021307587,0.0004491928,0.99370396],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994684,0.000010754878,0.000052512358,0.0001468034,0.00016745315,0.00015408112],"domain_scores_gemma":[0.999559,0.000006792623,0.000016055086,0.00030741628,0.000012300906,0.00009843107],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000040994026,0.000094534684,0.00018821887,0.00016423652,0.0000047344233,0.0000034833308,0.000046595556,0.00021563758,0.15587144],"category_scores_gemma":[0.000031122538,0.00006728507,0.000045690314,0.00008209314,0.000031663352,0.000002600286,0.000016513975,0.00021509844,0.0077690245],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000034424625,0.000012670484,0.000052615756,0.00005422941,0.000049318285,0.000071407354,0.0000012902318,1.1233428e-9,0.000024620102,0.0006583126,0.9976248,0.0014472661],"study_design_scores_gemma":[0.00042326012,0.000029077582,0.000012568853,0.000053444688,0.000020197269,0.000052078023,0.0000047742624,0.0000015805086,0.00008020031,0.0000095663845,0.99924856,0.00006471417],"about_ca_topic_score_codex":0.00011516964,"about_ca_topic_score_gemma":0.0000132777295,"teacher_disagreement_score":0.1481024,"about_ca_system_score_codex":0.00007824772,"about_ca_system_score_gemma":0.00020204643,"threshold_uncertainty_score":0.99300355},"labels":[],"label_agreement":null},{"id":"W4205432751","doi":"10.1002/9780470750650.ch18","title":"R","year":2003,"lang":"en","type":"other","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Citation; Internal medicine; Library science; Family medicine; Computer science","score_opus":0.020559893450611877,"score_gpt":0.31499020968797703,"score_spread":0.29443031623736515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205432751","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000010119002,0.00054353545,0.00012107224,0.0004092326,0.00007696669,0.0002412739,0.0000029643334,0.00019125959,0.99841267],"genre_scores_gemma":[0.0000039043985,0.00022798829,0.004137566,0.001234447,0.00025744422,0.00000788503,0.000021316531,0.0004492939,0.99366015],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99946845,0.000010752096,0.000052516654,0.00014671347,0.0001673726,0.00015417083],"domain_scores_gemma":[0.99955916,0.0000068024656,0.00001605653,0.00030723354,0.00001229366,0.000098449185],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000040922387,0.00009454461,0.00018826831,0.00016431007,0.0000047321123,0.000003481457,0.00004660163,0.00021561825,0.1560696],"category_scores_gemma":[0.000031096228,0.0000672885,0.000045695673,0.000082104205,0.000031671934,0.000002601572,0.000016517142,0.00021509624,0.0077708405],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000034818574,0.000012488338,0.000053285363,0.00005424931,0.00004933314,0.00007156452,0.0000012565424,1.1234308e-9,0.00002460123,0.00065980485,0.9976389,0.0014310279],"study_design_scores_gemma":[0.00042535,0.000028542563,0.0000128443335,0.000053471216,0.00002020304,0.000052092764,0.0000045989987,0.0000015814553,0.000079953476,0.000009570046,0.9992471,0.00006471408],"about_ca_topic_score_codex":0.00011759753,"about_ca_topic_score_gemma":0.000013823228,"teacher_disagreement_score":0.14829877,"about_ca_system_score_codex":0.000078305675,"about_ca_system_score_gemma":0.00020241507,"threshold_uncertainty_score":0.9930017},"labels":[],"label_agreement":null},{"id":"W4205445180","doi":"10.1016/j.jval.2021.11.181","title":"POSC35 Venetoclax Combination Therapies Show Significant Improvements in Overall Survival and Remission in Treatment-Naïve Patients with AML Who Are Ineligible for Intensive Chemotherapy: A Network Meta-Analysis","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Venetoclax; Azacitidine; Decitabine; Cytarabine; Medicine; Myeloid leukemia; Oncology; Internal medicine; Ven; Chemotherapy; Meta-analysis; Lorazepam; Leukemia; Psychiatry; Chronic lymphocytic leukemia; Computer science","score_opus":0.07826583072483097,"score_gpt":0.33380613268509246,"score_spread":0.2555403019602615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205445180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900158,0.0012366131,0.0000642255,0.004946155,0.00003951801,0.0035757564,0.00008708597,0.000016226968,0.000018597271],"genre_scores_gemma":[0.99630105,0.00051985757,0.00055779907,0.0013250537,0.000024419245,0.00070808723,0.00028644555,0.0000437515,0.00023354622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723136,0.00056440354,0.00058687717,0.0005497313,0.0005191438,0.0005484787],"domain_scores_gemma":[0.9987255,0.00032116126,0.00030229051,0.00031614007,0.00019639193,0.00013852621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012838546,0.00024828882,0.0012851357,0.00064527034,0.000121057055,0.000021436255,0.000107438034,0.000067133464,0.000041935524],"category_scores_gemma":[0.00009309809,0.000185656,0.00015322318,0.0012168724,0.00004046032,0.00007851764,0.00006763399,0.00033063415,2.6287967e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005715673,0.00094802596,0.9496889,0.00027356163,0.0069753234,0.000035581063,0.005084485,0.027088124,0.00011893633,0.00016218623,0.0005248252,0.0033843848],"study_design_scores_gemma":[0.041885957,0.010376477,0.81320804,0.00022072639,0.0030608564,0.0000029593784,0.004521605,0.12332958,0.0001337628,0.0014951908,0.001228245,0.0005365854],"about_ca_topic_score_codex":0.015202226,"about_ca_topic_score_gemma":0.00073818996,"teacher_disagreement_score":0.13648084,"about_ca_system_score_codex":0.0036063422,"about_ca_system_score_gemma":0.0006516575,"threshold_uncertainty_score":0.9913556},"labels":[],"label_agreement":null},{"id":"W4205475652","doi":"10.1159/000151872","title":"Leukemias","year":2008,"lang":"en","type":"review","venue":"Progress in experimental tumor research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Biology","score_opus":0.19842019303473443,"score_gpt":0.5136946855937157,"score_spread":0.3152744925589812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205475652","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00049605407,0.982948,1.883161e-7,0.000066877124,0.00015887883,0.00533521,0.000018720064,0.00014456954,0.010831488],"genre_scores_gemma":[0.00055596937,0.98986864,0.00077128224,0.000034012453,0.0006435353,0.005119638,0.00021165774,0.00033791905,0.0024573344],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9904932,0.0012708189,0.0012721978,0.0015880396,0.0030434434,0.0023323412],"domain_scores_gemma":[0.99663526,0.0005714368,0.00018482324,0.0015540788,0.00029024007,0.0007641908],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015935431,0.00084203045,0.0030829513,0.0026078084,0.00031291312,0.00012638193,0.0012863504,0.00055279926,0.0006713001],"category_scores_gemma":[0.0003359765,0.00067949906,0.0007449676,0.0030187408,0.0021304397,0.0001681995,0.0016286115,0.0056162,0.0021175083],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022504535,0.0013111789,0.0002538601,0.011361401,0.00016598823,0.01761247,0.0003354248,2.8306802e-8,0.0000061117275,0.00018793385,0.011442884,0.95709765],"study_design_scores_gemma":[0.0016375514,0.0007520243,0.000013608456,0.013675931,0.000033023156,0.0048189433,0.00031865234,0.000022876799,0.00055008405,0.000010055039,0.97763354,0.00053368654],"about_ca_topic_score_codex":0.00008447601,"about_ca_topic_score_gemma":0.000002514694,"teacher_disagreement_score":0.9661907,"about_ca_system_score_codex":0.008189894,"about_ca_system_score_gemma":0.0050799404,"threshold_uncertainty_score":0.9995656},"labels":[],"label_agreement":null},{"id":"W4205503064","doi":"10.1002/ajh.26465","title":"Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta‐analysis","year":2022,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Cancer Prevention and Research Institute of Texas","keywords":"Disease; Malignancy; Hematologic malignancy; Myeloid; Allele; Hematologic disease; Hematology; Genetic association; Haematopoiesis","score_opus":0.03151317610258437,"score_gpt":0.3728961058598902,"score_spread":0.34138292975730583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205503064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77418196,0.08325445,0.0040598195,0.13461332,0.00012063176,0.003187908,0.00014701608,0.000048570426,0.00038632948],"genre_scores_gemma":[0.98924434,0.0012278229,0.0059509235,0.0031174847,0.000009458038,0.000084384505,0.000008489452,0.00002035071,0.00033674538],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99631953,0.0011847882,0.001466734,0.00015620647,0.000681592,0.000191146],"domain_scores_gemma":[0.9942856,0.0021655932,0.0026176241,0.00026033897,0.0005197924,0.00015107967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027119094,0.00013078423,0.004615956,0.0004355262,0.00007200153,0.000004761393,0.0001648464,0.000030092197,0.00044769482],"category_scores_gemma":[0.0013248431,0.000081857215,0.0008628873,0.0011594838,0.00025797955,0.00004962134,0.00007288309,0.0005089697,0.0000021500152],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032114025,0.00058194523,0.2998836,0.038184326,0.6571503,0.0005852023,0.00047261486,0.000035365272,0.000008123212,0.0006864768,0.0020681622,0.000022720013],"study_design_scores_gemma":[0.0013554166,0.0023827958,0.008188247,0.00048733794,0.9755946,0.008760431,0.0028894173,0.000053952426,0.0000140417815,0.000078182406,0.000052606716,0.0001430015],"about_ca_topic_score_codex":0.000035050398,"about_ca_topic_score_gemma":0.000010430817,"teacher_disagreement_score":0.31844425,"about_ca_system_score_codex":0.00016697294,"about_ca_system_score_gemma":0.00038415127,"threshold_uncertainty_score":0.4901944},"labels":[],"label_agreement":null},{"id":"W4206174687","doi":"10.1182/blood.v124.21.lba-5.lba-5","title":"A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lenalidomide; Azacitidine; Internal medicine; Chronic myelomonocytic leukemia; International Prognostic Scoring System; Decitabine; Oncology; Myelodysplastic syndromes; Hypomethylating agent; Phases of clinical research; Clinical endpoint; Adverse effect; Gastroenterology; Randomized controlled trial; Clinical trial; Bone marrow; Multiple myeloma; DNA methylation","score_opus":0.01897090738087662,"score_gpt":0.2835828388358142,"score_spread":0.26461193145493755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206174687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99158,0.00017453305,0.00030866766,0.00019327791,0.000049711787,0.0074313213,0.000033012475,0.00015093686,0.00007855883],"genre_scores_gemma":[0.997051,0.00041002908,0.0005122493,0.00008060778,0.0001588377,0.001054931,0.000046627873,0.00019363523,0.00049208145],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99398637,0.001227389,0.0013840589,0.0012660535,0.0011182983,0.0010178393],"domain_scores_gemma":[0.99553555,0.0016683487,0.00080041523,0.0011932187,0.00030304008,0.0004994258],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013363175,0.000924379,0.0036174639,0.00094484753,0.00023215708,0.00007106944,0.0004695561,0.00009761925,0.000093525145],"category_scores_gemma":[0.00040646008,0.0005817462,0.00013950505,0.0017804047,0.0010198564,0.00024798745,0.0002700801,0.0010063939,0.000007142909],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.742421,0.018313624,0.2166767,0.0004284438,0.005084583,0.0019770553,0.0057390817,0.00029896028,0.0008217908,0.00001865944,0.000040668227,0.008179489],"study_design_scores_gemma":[0.76404643,0.16298375,0.062376853,0.0004295537,0.0024175958,0.00030035572,0.0018936543,0.0039739744,0.0009037783,0.0000062665895,0.000034276327,0.00063351874],"about_ca_topic_score_codex":0.0027448698,"about_ca_topic_score_gemma":0.009638529,"teacher_disagreement_score":0.15429984,"about_ca_system_score_codex":0.0006603199,"about_ca_system_score_gemma":0.00092545315,"threshold_uncertainty_score":0.9996634},"labels":[],"label_agreement":null},{"id":"W4206245401","doi":"10.1016/j.jval.2021.11.194","title":"POSA49 Projecting the Long-Term Benefits of Venetoclax Combination Therapies for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy: An Assessment of Net Health Benefit","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre","funders":"","keywords":"Venetoclax; Myeloid leukemia; Medicine; Term (time); Oncology; Intensive care medicine; Internal medicine; Leukemia","score_opus":0.03830778710592713,"score_gpt":0.3585435742328819,"score_spread":0.3202357871269548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206245401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98307854,0.0007146651,0.00041781345,0.005999515,0.000113155686,0.0091880355,0.00045029787,0.000031034582,0.000006959428],"genre_scores_gemma":[0.9903325,0.0007932387,0.0039797844,0.002643663,0.0000768349,0.0013502784,0.0006824842,0.00009564302,0.000045578847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968904,0.00030590477,0.00090620504,0.0004842407,0.0007644135,0.00064882473],"domain_scores_gemma":[0.99648905,0.0006983328,0.0011282123,0.000530741,0.0009972545,0.00015640873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018149993,0.0002631852,0.0009025036,0.00038537095,0.00037485763,0.000019598634,0.00033711726,0.0000738956,0.000008995974],"category_scores_gemma":[0.0001493229,0.00019838895,0.00010710427,0.0006938946,0.00009544344,0.00013227333,0.00010490913,0.00047081674,9.05405e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00553455,0.0012442217,0.86854625,0.003930669,0.0005489208,0.0000041794797,0.020189459,0.037821166,0.00016921536,0.002199378,0.00096675014,0.05884522],"study_design_scores_gemma":[0.019405475,0.018451432,0.92247146,0.0012082676,0.00004627101,0.0000113567,0.0041088406,0.033330016,0.00032864377,0.0002937817,0.00011856307,0.00022586322],"about_ca_topic_score_codex":0.005586762,"about_ca_topic_score_gemma":0.0003590227,"teacher_disagreement_score":0.058619354,"about_ca_system_score_codex":0.0042671394,"about_ca_system_score_gemma":0.0045022853,"threshold_uncertainty_score":0.9995553},"labels":[],"label_agreement":null},{"id":"W4206305815","doi":"10.1101/2022.01.13.476218","title":"Inflammatory signals from fatty bone marrow supports the early stages of <i>DNMT3a</i> driven clonal hematopoiesis","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"BIRAX; Rising Tide Foundation; National Natural Science Foundation of China; Israel Science Foundation; Applebaum Foundation","keywords":"Haematopoiesis; Bone marrow; Paracrine signalling; Progenitor cell; Biology; Cancer research; Stem cell; Immunology; Cell biology; Receptor; Genetics","score_opus":0.014455274864040392,"score_gpt":0.24368312246392299,"score_spread":0.2292278475998826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206305815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99057335,0.0024311387,0.0001555426,0.0015013422,0.00069725123,0.0021797677,0.0020475173,0.0003656374,0.000048449405],"genre_scores_gemma":[0.99397755,0.0005952211,0.0029407034,0.00058467657,0.00076909986,0.0007377992,0.000008589012,0.0003185758,0.00006777105],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9930432,0.00062891917,0.0014974088,0.0015314025,0.0022155237,0.0010835325],"domain_scores_gemma":[0.9933337,0.00063407904,0.001157253,0.0033347374,0.00093067833,0.0006095636],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018944186,0.0009367508,0.0016962744,0.00052890624,0.00035233414,0.00016899663,0.0013840996,0.00076149154,0.002376788],"category_scores_gemma":[0.0006165903,0.0008196205,0.000619302,0.0008171256,0.0006593568,0.00019600776,0.0026317304,0.0031577803,0.00009618663],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036698912,0.0002976345,0.22530234,0.001106217,0.0011368977,0.0012437978,0.00011471747,0.0000838731,0.7628699,0.00023087834,0.0072442507,0.0000025101726],"study_design_scores_gemma":[0.0018988673,0.00022749328,0.5245646,0.00081658864,0.00071325403,3.0906028e-7,0.000057359583,0.00014653009,0.45863932,0.000012554631,0.0118599795,0.0010630939],"about_ca_topic_score_codex":0.000604602,"about_ca_topic_score_gemma":0.0000077153,"teacher_disagreement_score":0.30423054,"about_ca_system_score_codex":0.0010573731,"about_ca_system_score_gemma":0.0036649702,"threshold_uncertainty_score":0.9994255},"labels":[],"label_agreement":null},{"id":"W4206440127","doi":"10.51731/cjht.2021.173","title":"Venetoclax (Venclexta)","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Reimbursement; Medicine; Cytarabine; Azacitidine; Drug; Intensive care medicine; Family medicine; Chemotherapy; Psychiatry; Internal medicine; Leukemia; Political science","score_opus":0.041498930668248404,"score_gpt":0.3312813472294035,"score_spread":0.2897824165611551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206440127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4508348,0.22215179,0.0005309368,0.32187584,0.00067580777,0.00038241243,0.000022120814,0.00018390155,0.0033423693],"genre_scores_gemma":[0.9941258,0.0011869399,0.0027641226,0.0014233997,0.000026584705,0.0000026755474,0.0000034253378,0.000017076083,0.0004499952],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986196,0.000056366796,0.0004429146,0.00012592689,0.00021393427,0.0005412214],"domain_scores_gemma":[0.99878114,0.00004993898,0.00018504918,0.00033469344,0.00043984342,0.00020930581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058008486,0.00009303929,0.00038610038,0.0005389445,0.00016273756,0.00002514211,0.00023720562,0.00015838195,0.00012262222],"category_scores_gemma":[0.0015793476,0.00008084089,0.0000913566,0.0005640811,0.0002120886,0.00006700828,0.000030627365,0.0008202853,0.000029384579],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029035858,0.000017737688,0.01020469,0.00024472122,0.000103661834,0.007961813,0.0002466179,0.000013539944,0.0009042421,0.002246964,0.05964709,0.9183799],"study_design_scores_gemma":[0.0011421688,0.0006997447,0.018927429,0.0005367763,0.000021855678,0.00876445,0.004875731,0.000035275727,0.008520304,0.0037837115,0.95255214,0.00014039439],"about_ca_topic_score_codex":0.0017099307,"about_ca_topic_score_gemma":0.0018104445,"teacher_disagreement_score":0.9182395,"about_ca_system_score_codex":0.002250645,"about_ca_system_score_gemma":0.034013364,"threshold_uncertainty_score":0.9714629},"labels":[],"label_agreement":null},{"id":"W4206477097","doi":"10.1159/000521509","title":"MDS/MPN-Unclassifiable with t(X;17)(q28;q21) and &lt;b&gt;&lt;i&gt;KANSL1-MTCP1/CMC4&lt;/i&gt;&lt;/b&gt; Fusion Gene","year":2021,"lang":"en","type":"article","venue":"Cytogenetic and Genome Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"University Health Network","keywords":"Biology; Myeloproliferative neoplasm; Genetics; Myelodysplastic syndromes; Myeloid; Fusion gene; Gene; Cancer research; Bone marrow; Immunology; Myelofibrosis","score_opus":0.045214513983331595,"score_gpt":0.3131277319519045,"score_spread":0.2679132179685729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206477097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.882588,0.07928338,0.0007459271,0.004506684,0.00015588781,0.0024552227,0.00018150144,0.00016530628,0.029918073],"genre_scores_gemma":[0.83039075,0.050768804,0.0074574132,0.0005786677,0.0015163817,0.00049848424,0.00059565896,0.00042833478,0.107765496],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.98791736,0.0010261055,0.0010953054,0.0026610557,0.0038862335,0.0034139396],"domain_scores_gemma":[0.99196494,0.0008848228,0.00019167038,0.0024062088,0.0021541773,0.0023981628],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036562881,0.0009977903,0.0015860521,0.001238489,0.0015308342,0.00051864213,0.000900745,0.00084686244,0.0028071569],"category_scores_gemma":[0.000682241,0.00084917387,0.00025700254,0.0028578502,0.002145875,0.00025379352,0.002042103,0.0018394191,0.000663784],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014021149,0.00045266474,0.0025498595,0.0007944507,0.0004909453,0.0025328894,0.00089456193,0.00004840472,0.9607716,0.000711887,0.014530733,0.014819879],"study_design_scores_gemma":[0.012803858,0.004084202,0.059079364,0.00069812615,0.00042824287,0.0031299083,0.0006533066,0.0029594956,0.071813986,0.00073967373,0.8418769,0.0017329351],"about_ca_topic_score_codex":0.00006681148,"about_ca_topic_score_gemma":0.00030178155,"teacher_disagreement_score":0.8889576,"about_ca_system_score_codex":0.0010538008,"about_ca_system_score_gemma":0.0038877549,"threshold_uncertainty_score":0.99976903},"labels":[],"label_agreement":null},{"id":"W4206528978","doi":"10.3390/cancers14030478","title":"Early Palliative Care in Acute Myeloid Leukemia","year":2022,"lang":"en","type":"review","venue":"Cancers","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Palliative care; Coping (psychology); Intensive care medicine; Quality of life (healthcare); Randomized controlled trial; Disease; Oncology; Internal medicine; Nursing; Psychiatry","score_opus":0.060333666618685396,"score_gpt":0.3774511679934495,"score_spread":0.31711750137476413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206528978","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020802148,0.98567367,0.000002271072,0.00003306639,0.00041949263,0.0021851975,0.0003064227,0.00008005083,0.011091816],"genre_scores_gemma":[0.000024998171,0.9924414,0.00014532251,0.0002168709,0.00035239497,0.0015364707,0.0008285078,0.00017984278,0.0042741476],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966673,0.00024041795,0.00065189344,0.0008801409,0.0007567563,0.0008034463],"domain_scores_gemma":[0.9982525,0.0002449378,0.0002674303,0.00082685385,0.00009050836,0.00031773257],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023522478,0.0005875319,0.0023805809,0.00065502495,0.00011135814,0.000031038402,0.0005986294,0.00043411006,0.0016941527],"category_scores_gemma":[0.00012806775,0.00051517645,0.0006193514,0.0014801029,0.0001625634,0.00007140707,0.00034802244,0.0028457677,0.0002458534],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000110322224,0.0000043943373,0.00004891856,0.01382075,0.0005916765,0.0014688789,0.0015185107,0.000010119857,5.3034876e-7,0.000028279062,0.0054835393,0.9769141],"study_design_scores_gemma":[0.0011542697,0.00032436533,0.00007553108,0.007015466,0.00092427863,0.000036842393,0.0006084594,0.000011956695,0.0000014072153,0.0000041894737,0.98941547,0.0004277537],"about_ca_topic_score_codex":0.0015772684,"about_ca_topic_score_gemma":0.00013750327,"teacher_disagreement_score":0.98393196,"about_ca_system_score_codex":0.105574906,"about_ca_system_score_gemma":0.030983204,"threshold_uncertainty_score":0.99973},"labels":[],"label_agreement":null},{"id":"W4206610800","doi":"10.1016/j.jval.2021.11.1131","title":"POSB364 Systematic Literature Reviews (SLRS) of Economic Evaluations and Health Utility Studies of AML Treatments for Adults Receiving High Intensity Induction Therapy, with or without Maintenance Therapy","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Systematic review; Gemtuzumab ozogamicin; MEDLINE; Quality-adjusted life year; Induction chemotherapy; Economic evaluation; Cochrane Library; Cost effectiveness; Intensive care medicine; Internal medicine; Meta-analysis; Chemotherapy; Pathology","score_opus":0.17890931844490274,"score_gpt":0.43546477481830104,"score_spread":0.25655545637339827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206610800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93563485,0.050583873,0.00004709831,0.0041057672,0.00014051251,0.009373169,0.00009487371,0.000016504093,0.0000033216331],"genre_scores_gemma":[0.9287651,0.06694905,0.0026154157,0.0004932272,0.00004144611,0.0009391258,0.00004731428,0.000026857924,0.00012243292],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.9966653,0.0011625863,0.001121658,0.00042183674,0.00029991698,0.0003286956],"domain_scores_gemma":[0.997835,0.00033538885,0.00092165946,0.00047942367,0.00031835792,0.00011020546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005454132,0.00020599086,0.0015689677,0.00025855337,0.000208725,0.0000075150847,0.00010611185,0.00004641828,0.000012230194],"category_scores_gemma":[0.00034244184,0.00012723957,0.00007142047,0.0004193478,0.000114153605,0.00009265327,0.00005065157,0.0003233722,3.591039e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057915896,0.0034555492,0.25122356,0.34654704,0.0031344558,0.000019615127,0.20104383,0.0011401144,0.0005709617,0.0007984994,0.0055444124,0.12860608],"study_design_scores_gemma":[0.07067138,0.07658901,0.52151084,0.22269347,0.00035968501,0.0010459948,0.05640152,0.04597444,0.0009918959,0.0019689975,0.0007286061,0.0010641512],"about_ca_topic_score_codex":0.0033085144,"about_ca_topic_score_gemma":0.0003071429,"teacher_disagreement_score":0.27028728,"about_ca_system_score_codex":0.001988817,"about_ca_system_score_gemma":0.0014391418,"threshold_uncertainty_score":0.5200687},"labels":[],"label_agreement":null},{"id":"W4206633944","doi":"10.2196/33581","title":"Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study","year":2022,"lang":"en","type":"article","venue":"JMIR Formative Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"American Cancer Society","keywords":"Myeloproliferative neoplasm; Intervention (counseling); Medicine; Quality of life (healthcare); Rating scale; Mobile apps; Smartphone app; Physical therapy; Psychology; Internal medicine; Psychiatry; Nursing; Myelofibrosis; Computer science","score_opus":0.06986906247635025,"score_gpt":0.424671291264249,"score_spread":0.3548022287878988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206633944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854999,0.00024092526,0.000022489625,0.001179481,0.00011329278,0.00891843,0.000046026817,0.000092646216,0.0038868028],"genre_scores_gemma":[0.9919609,0.000036562495,0.000033455217,0.000071279304,0.00015670709,0.0062585897,0.00003482473,0.000037957823,0.0014097552],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.99124134,0.004029687,0.0006139669,0.00078180997,0.0024727352,0.0008604842],"domain_scores_gemma":[0.9966549,0.0011795287,0.00012901785,0.0011108936,0.00064266665,0.00028297212],"candidate_categories":["sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010247943,0.00027588225,0.0004649018,0.00048432534,0.0020501723,0.00016712365,0.0005741077,0.000061732,0.0010824222],"category_scores_gemma":[0.00064211874,0.00018836973,0.00013825772,0.0013918388,0.00071880914,0.00036627048,0.0019655619,0.0034784935,0.000103619815],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026619103,0.02240443,0.13575955,0.0016878011,0.0011949942,0.00023283692,0.5059802,0.0004605978,0.0030498023,0.0010494266,0.020852836,0.28070843],"study_design_scores_gemma":[0.011652877,0.058031045,0.6559445,0.00013583402,0.000044785505,0.00017409155,0.25745487,0.007621906,0.001604946,0.00081759365,0.0060900114,0.00042749563],"about_ca_topic_score_codex":0.0004945662,"about_ca_topic_score_gemma":0.000035098023,"teacher_disagreement_score":0.520185,"about_ca_system_score_codex":0.0029690352,"about_ca_system_score_gemma":0.00050543767,"threshold_uncertainty_score":0.9998307},"labels":[],"label_agreement":null},{"id":"W4206730918","doi":"10.1002/9780470750650.ch19","title":"S","year":2003,"lang":"en","type":"other","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Citation; Library science; Section (typography); Medicine; Psychology; Internal medicine; Computer science","score_opus":0.020465295442971227,"score_gpt":0.31442382850115974,"score_spread":0.29395853305818853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206730918","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000010111025,0.0005532115,0.0001201855,0.0004112776,0.00007691636,0.00024113609,0.0000029604419,0.00019106279,0.99840224],"genre_scores_gemma":[0.0000040041796,0.00022780846,0.004144634,0.0012313257,0.0002571935,0.000007887081,0.000021305112,0.00044908194,0.99365675],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99946886,0.000010745346,0.000052483625,0.00014661554,0.00016720744,0.0001540716],"domain_scores_gemma":[0.99955946,0.000006787353,0.000016050126,0.0003070123,0.000012282845,0.00009840578],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00004085058,0.00009450966,0.0001881236,0.00016410777,0.000004729532,0.0000034786565,0.000046575533,0.00021556023,0.15513186],"category_scores_gemma":[0.0000310586,0.00006726643,0.00004566462,0.00008198963,0.000031659885,0.0000026003045,0.00001650646,0.0002149185,0.007750701],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000035342055,0.000012477333,0.000051666073,0.00005373815,0.000049886312,0.00007151833,0.0000012371974,1.1206744e-9,0.000024243858,0.0006652847,0.9976122,0.0014542316],"study_design_scores_gemma":[0.0004239418,0.000028519818,0.000012757032,0.000053216518,0.000020628877,0.000052077186,0.0000045065003,0.0000016095279,0.00008020497,0.000009543834,0.9992483,0.00006468346],"about_ca_topic_score_codex":0.00011644895,"about_ca_topic_score_gemma":0.000013739348,"teacher_disagreement_score":0.14738117,"about_ca_system_score_codex":0.00007725705,"about_ca_system_score_gemma":0.000201981,"threshold_uncertainty_score":0.9930219},"labels":[],"label_agreement":null},{"id":"W4206754378","doi":"10.51731/cjht.2022.237","title":"Azacitidine (Onureg)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Azacitidine; Medicine; Myeloid leukemia; Hematopoietic stem cell transplantation; Intensive care medicine; Transplantation; Family medicine; Internal medicine; Political science","score_opus":0.035742845196911094,"score_gpt":0.3107890114319356,"score_spread":0.27504616623502454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206754378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44835865,0.10711022,0.00032710374,0.44001812,0.0007634344,0.0006804734,0.000075835014,0.00024516706,0.002421021],"genre_scores_gemma":[0.99688536,0.00029634644,0.00077547214,0.0015667232,0.000018948936,0.000012584753,0.0000046560917,0.000019198718,0.00042071796],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984248,0.00008101985,0.00046235294,0.000120328485,0.00032976372,0.0005816835],"domain_scores_gemma":[0.9990618,0.00004757105,0.00025282954,0.0002889462,0.00016431768,0.0001845377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011589443,0.00009780942,0.00037691908,0.00119973,0.00050292886,0.000014611298,0.00041907933,0.000069004614,0.00035767094],"category_scores_gemma":[0.0006506542,0.000086199696,0.00008701994,0.0006744441,0.00021013177,0.000058650938,0.00006792205,0.001372568,0.000011063532],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001249307,0.000053699547,0.013264552,0.0001977181,0.00013248312,0.004383172,0.0005690184,0.00006888094,0.00042099014,0.0054554227,0.3192787,0.65605044],"study_design_scores_gemma":[0.0010635828,0.0017478957,0.0036479798,0.000072982606,0.000013546507,0.008816826,0.007812934,0.00003067879,0.0005483167,0.0024892963,0.97365004,0.000105907115],"about_ca_topic_score_codex":0.002882582,"about_ca_topic_score_gemma":0.0005788605,"teacher_disagreement_score":0.6559445,"about_ca_system_score_codex":0.0025469426,"about_ca_system_score_gemma":0.010784513,"threshold_uncertainty_score":0.9948234},"labels":[],"label_agreement":null},{"id":"W4206821587","doi":"10.1002/9780470750650.ch6","title":"F","year":2003,"lang":"en","type":"other","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Citation; Section (typography); Library science; Medicine; Psychology; Internal medicine; Computer science","score_opus":0.020559893450611877,"score_gpt":0.31499020968797703,"score_spread":0.29443031623736515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206821587","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000010050969,0.0005433419,0.00011940485,0.00041515916,0.00007695131,0.00024125197,0.0000029641212,0.00019110274,0.9984088],"genre_scores_gemma":[0.000003911001,0.0002278208,0.004133305,0.0012342833,0.0002573674,0.000007884681,0.000021314896,0.00044917443,0.9936649],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99946856,0.000010749835,0.000052509076,0.00014668803,0.00016734026,0.00015414147],"domain_scores_gemma":[0.9995592,0.0000067995575,0.000016055119,0.0003071881,0.000012291052,0.00009843484],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000040910847,0.0000945356,0.00018824877,0.00016426454,0.0000047302865,0.0000034824204,0.000046627803,0.00021558406,0.15606338],"category_scores_gemma":[0.0000310681,0.00006728384,0.000045692646,0.00008207148,0.000031667358,0.0000026025891,0.000016526123,0.00021506163,0.007770525],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000034801474,0.0000124857215,0.00005299594,0.000054242606,0.000049329734,0.000071561495,0.0000012546407,1.1231003e-9,0.000024974403,0.00066258374,0.997637,0.0014301265],"study_design_scores_gemma":[0.00042521884,0.000028566654,0.0000127676285,0.00005346302,0.000020202664,0.000052085976,0.0000045917564,0.0000015776156,0.000080236496,0.000009562161,0.999247,0.00006470866],"about_ca_topic_score_codex":0.000117589436,"about_ca_topic_score_gemma":0.000013818182,"teacher_disagreement_score":0.14829285,"about_ca_system_score_codex":0.000078282224,"about_ca_system_score_gemma":0.00020246771,"threshold_uncertainty_score":0.99300206},"labels":[],"label_agreement":null},{"id":"W4207056854","doi":"","title":"Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta‐analysis","year":2022,"lang":"en","type":"review","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Cancer Prevention and Research Institute of Texas","keywords":"Meta-analysis; Internal medicine; Medicine; Publication bias; Disease; Oncology","score_opus":0.14791464291301026,"score_gpt":0.45456114965272676,"score_spread":0.3066465067397165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4207056854","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.0922084e-7,0.9935278,0.0000812613,0.00091396796,0.000010113375,0.0045459694,0.00016495583,0.000037369264,0.0007182169],"genre_scores_gemma":[7.4871286e-7,0.98110414,0.0014641226,0.00061028276,0.000010824634,0.0016590934,0.00043049993,0.000046255675,0.014674065],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9937997,0.001686638,0.002515418,0.00051852013,0.0012234384,0.00025630902],"domain_scores_gemma":[0.9905573,0.006230283,0.001879333,0.0008418709,0.00029911476,0.00019210788],"candidate_categories":["metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0046585808,0.00041680408,0.017036444,0.00059053506,0.00007616737,0.000019502442,0.00023607771,0.00023873406,0.0042717597],"category_scores_gemma":[0.0032014984,0.00021688335,0.0041946094,0.002200971,0.00007983019,0.000052404972,0.00016183431,0.0008040671,0.00003114238],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000017238448,0.000061993655,0.000081921906,0.6122954,0.38677418,0.000014646447,0.000007721923,4.8220695e-8,3.7700704e-10,0.000048233553,0.0005664388,0.00014772378],"study_design_scores_gemma":[0.0002360797,0.000096666474,0.000013617427,0.019155717,0.9401932,0.000085998414,0.000042767413,0.0000038621974,7.464465e-9,0.0000029969738,0.039996665,0.00017243696],"about_ca_topic_score_codex":0.0000592252,"about_ca_topic_score_gemma":0.000040017414,"teacher_disagreement_score":0.59313965,"about_ca_system_score_codex":0.00056700694,"about_ca_system_score_gemma":0.0010218114,"threshold_uncertainty_score":0.9975567},"labels":[],"label_agreement":null},{"id":"W4210334637","doi":"10.1371/journal.pone.0263240","title":"Less intensive antileukemic therapies (monotherapy and/or combination) for older adults with acute myeloid leukemia who are not candidates for intensive antileukemic therapy: A systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; Impact","funders":"American Society of Hematology","keywords":"Medicine; Internal medicine; Randomized controlled trial; Azacitidine; Cytarabine; Neutropenia; Febrile neutropenia; Hazard ratio; Decitabine; Meta-analysis; Combination therapy; Relative risk; Oncology; Myeloid leukemia; Confidence interval; Chemotherapy","score_opus":0.12516346727399805,"score_gpt":0.3346962423179945,"score_spread":0.20953277504399645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210334637","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016834441,0.9569398,0.00015657597,0.0015970854,0.000025236553,0.03687548,0.0025686119,0.00014461271,0.0000091112515],"genre_scores_gemma":[0.00024431563,0.95840126,0.0010500393,0.0074063404,0.00007467723,0.027252981,0.0020230187,0.0004332939,0.0031140603],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99283,0.00075910235,0.0021553093,0.0020168712,0.0012355275,0.0010032133],"domain_scores_gemma":[0.98819286,0.0034859267,0.0024509395,0.001699882,0.0037859972,0.00038439795],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013566772,0.0017186414,0.020230718,0.0013747979,0.00048069126,0.00020220093,0.0007635431,0.0005050754,0.00027776198],"category_scores_gemma":[0.0013361262,0.0010106724,0.002387182,0.0018058394,0.00045290077,0.00028133963,0.00024255158,0.0012518682,0.000006130585],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016726992,0.0002567096,0.000006412017,0.58893704,0.40189418,0.00008534857,0.000964726,1.18313615e-7,0.000007674986,0.000022574635,0.0010522899,0.0051002204],"study_design_scores_gemma":[0.006804409,0.0018510604,0.000009378561,0.15093544,0.83018523,0.00041331685,0.0028072167,0.0003943118,0.00007512309,0.000013305484,0.005287331,0.0012238761],"about_ca_topic_score_codex":0.0001316678,"about_ca_topic_score_gemma":0.00006703379,"teacher_disagreement_score":0.4380016,"about_ca_system_score_codex":0.0018388896,"about_ca_system_score_gemma":0.001989174,"threshold_uncertainty_score":0.999556},"labels":[],"label_agreement":null},{"id":"W4210373859","doi":"10.3390/curroncol29020068","title":"Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Incyte; Ionis Pharmaceuticals; European Hematology Association; Celgene; National Institutes of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Gilead Sciences; Sanofi; Swiss Bridge Foundation; Alexion Pharmaceuticals; National Heart, Lung, and Blood Institute; Pfizer; Amgen","keywords":"Somatic evolution in cancer; Germline mutation; Germline; Allele; Genetics; Mutation; Somatic cell; Cancer research; Biology; Gene","score_opus":0.06852124320775983,"score_gpt":0.42678561209702964,"score_spread":0.3582643688892698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210373859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948328,0.00089358864,0.00024158844,0.001767537,0.0005630648,0.0011610896,0.0000805639,0.00008377872,0.00037596322],"genre_scores_gemma":[0.99550265,0.00009499329,0.0028110326,0.00039080312,0.0002997075,0.00043925387,0.00021815143,0.00004332191,0.00020010817],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99777704,0.00026680753,0.00039448452,0.0005352858,0.00050476624,0.00052162196],"domain_scores_gemma":[0.9987053,0.00029668421,0.00013759572,0.00027212634,0.00013903956,0.00044921684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004729014,0.0002297926,0.00048139616,0.00036249481,0.00044033906,0.00003294491,0.00017909954,0.0001195071,0.00026667482],"category_scores_gemma":[0.00021389067,0.00021274648,0.000054862783,0.00040322362,0.00023581242,0.00011125992,0.0004993811,0.00102683,0.000050673374],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021994256,0.0014495018,0.23916753,0.0007202183,0.00051063974,0.0010380397,0.013883096,0.00005856986,0.088662915,0.0010389466,0.031002596,0.6202685],"study_design_scores_gemma":[0.021208858,0.009786248,0.61537236,0.0004957145,0.0011000248,0.0020868252,0.002504293,0.0115005905,0.0048856596,0.0010368482,0.32880285,0.0012197292],"about_ca_topic_score_codex":0.000025017807,"about_ca_topic_score_gemma":0.000010036196,"teacher_disagreement_score":0.6190488,"about_ca_system_score_codex":0.001403777,"about_ca_system_score_gemma":0.0011241687,"threshold_uncertainty_score":0.86755496},"labels":[],"label_agreement":null},{"id":"W4210485820","doi":"10.1182/blood.2021014251","title":"Megakaryocytic emperipolesis as a dyshematopoietic feature in acute myeloid leukemia with inv(16)","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Emperipolesis; Myeloid leukemia; Feature (linguistics); Myeloid; Medicine; Cancer research; Pathology; Philosophy; Disease","score_opus":0.008839263724598652,"score_gpt":0.2547337429939986,"score_spread":0.24589447926939995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210485820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859085,0.00091561314,0.00000658782,0.004093826,0.000058084832,0.00093737757,0.000028179471,0.00015330943,0.007898503],"genre_scores_gemma":[0.98650867,0.00012650042,0.0009494499,0.001993368,0.00011774098,0.0004930428,0.00012886502,0.00011071347,0.0095716715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99694395,0.00016998124,0.0003166005,0.000667725,0.0011049702,0.0007967913],"domain_scores_gemma":[0.99854344,0.00010634608,0.00009390499,0.00083584676,0.00008611877,0.00033433503],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003931337,0.00034827561,0.0006261885,0.0005025472,0.00024474825,0.000042851323,0.0004380816,0.00015412447,0.0006824426],"category_scores_gemma":[0.000108372355,0.00029330127,0.00013032684,0.0014892829,0.00015489843,0.00011583559,0.0004415317,0.0015995393,0.00013689221],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018490588,0.009446697,0.4108017,0.0028535628,0.008280686,0.1506546,0.023024095,0.00043698732,0.20328407,0.0051406324,0.15920654,0.008379824],"study_design_scores_gemma":[0.194981,0.023011625,0.2736002,0.0018778738,0.0076699215,0.11621227,0.023517644,0.001824113,0.17455193,0.0025391572,0.17450073,0.0057135546],"about_ca_topic_score_codex":0.00068952533,"about_ca_topic_score_gemma":0.00014335597,"teacher_disagreement_score":0.17649041,"about_ca_system_score_codex":0.002276717,"about_ca_system_score_gemma":0.0020701687,"threshold_uncertainty_score":0.9999519},"labels":[],"label_agreement":null},{"id":"W4210627757","doi":"10.6004/jnccn.2022.0009","title":"NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022","year":2022,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"Astellas Pharma; Seagen","keywords":"Medicine; Myelodysplastic syndromes; Multidisciplinary approach; Intensive care medicine; Malignancy; MEDLINE; Clinical Practice; Family medicine; Internal medicine","score_opus":0.0733164020931557,"score_gpt":0.35871192283820913,"score_spread":0.2853955207450534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210627757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83975744,0.065141656,0.00036846378,0.07574984,0.013596786,0.0014023175,0.00017351212,0.00006411094,0.0037458462],"genre_scores_gemma":[0.9669274,0.0014651392,0.0012891014,0.020897472,0.0055462816,0.000047862897,0.000026054415,0.0000622032,0.0037384625],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960595,0.00029021033,0.000665113,0.00019175668,0.0025000533,0.00029340104],"domain_scores_gemma":[0.99498075,0.0005089698,0.0005807305,0.00017833678,0.003591284,0.00015993245],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000430274,0.00017135491,0.00039975485,0.00023129758,0.00058685226,0.00002122707,0.0005540081,0.00005701867,0.0013568003],"category_scores_gemma":[0.00047185208,0.00011923763,0.0003084589,0.0010880815,0.00009926458,0.00011225027,0.00053238973,0.0013226353,0.000016203727],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079883885,0.000057604862,0.0013021809,0.00002876101,0.00037172897,0.00008045768,0.000074332725,0.19660287,0.001957625,0.00031683376,0.79782844,0.0005803377],"study_design_scores_gemma":[0.0033477964,0.00050048623,0.021656502,0.00027938586,0.00019621741,0.0023356285,0.00026489093,0.010005943,0.00009754567,0.0018510375,0.9592875,0.00017701607],"about_ca_topic_score_codex":0.0000141226155,"about_ca_topic_score_gemma":0.0000021128292,"teacher_disagreement_score":0.18659692,"about_ca_system_score_codex":0.0026629267,"about_ca_system_score_gemma":0.0019692832,"threshold_uncertainty_score":0.9995561},"labels":[],"label_agreement":null},{"id":"W4210715122","doi":"10.1101/2022.01.25.476266","title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in AML","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Amgen (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Government of Ontario; Canada First Research Excellence Fund; University of Toronto; International Development Research Centre; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Princess Margaret Cancer Foundation","keywords":"Hierarchy; Computational biology; Biomarker; Leukemia; Drug response; Biology; Disease; Progenitor cell; Stem cell; Oncology; Bioinformatics; Drug; Medicine; Internal medicine; Immunology; Genetics; Pharmacology","score_opus":0.03846375972722237,"score_gpt":0.28907996073823644,"score_spread":0.25061620101101406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210715122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97173566,0.0019184119,0.020622969,0.0015746697,0.00055833795,0.0028938884,0.0003697314,0.00032177145,0.000004540097],"genre_scores_gemma":[0.9739569,0.0003023963,0.02374748,0.00033520733,0.0004269794,0.0009620619,0.0000016051625,0.00025755115,0.00000983156],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9951085,0.00069577334,0.000775901,0.001572674,0.0007743075,0.0010728562],"domain_scores_gemma":[0.995769,0.0015979875,0.00035704774,0.0015066736,0.00022100346,0.0005482566],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0043436824,0.0006380038,0.0009942388,0.0009809628,0.00040151793,0.00019328063,0.00047068828,0.00067105464,0.000058250727],"category_scores_gemma":[0.003430322,0.0007248121,0.00023274533,0.00085872994,0.00025660862,0.00012625378,0.0014995752,0.0031633822,0.0000050737826],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009918817,0.0006233936,0.25822648,0.005642675,0.0009858335,0.0019580526,0.000475976,0.0002730779,0.7140755,0.0071401447,0.0006750845,0.000004941216],"study_design_scores_gemma":[0.021425817,0.0023928643,0.4388414,0.010725769,0.0015482244,0.0000013663337,0.0009778321,0.034149442,0.4635718,0.0011101279,0.018898372,0.006356973],"about_ca_topic_score_codex":0.00008017089,"about_ca_topic_score_gemma":0.0000056455137,"teacher_disagreement_score":0.25050372,"about_ca_system_score_codex":0.0042823777,"about_ca_system_score_gemma":0.0020343685,"threshold_uncertainty_score":0.99954003},"labels":[],"label_agreement":null},{"id":"W4210808382","doi":"10.1093/bioinformatics/btac081","title":"SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data","year":2022,"lang":"en","type":"article","venue":"Bioinformatics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Canada First Research Excellence Fund","keywords":"Computer science; Source code; Modular design; Raw data; DNA sequencing; Set (abstract data type); Data mining; Scripting language; Computational biology; Biology; Genetics; Programming language; DNA","score_opus":0.07001876067722557,"score_gpt":0.3211005807529847,"score_spread":0.25108182007575913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210808382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7443832,0.0003005791,0.2503107,0.000986616,0.000029842508,0.0015145328,0.0016599839,0.00006274776,0.0007517943],"genre_scores_gemma":[0.78802115,0.000011364649,0.20195854,0.0007661233,0.000013537446,0.00004950444,0.009103161,0.000021122543,0.000055475735],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9986099,0.000027886852,0.00042422712,0.0001745383,0.00056603394,0.00019741346],"domain_scores_gemma":[0.9989511,0.00014131525,0.00021267022,0.00039031662,0.00021446799,0.00009016194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048515343,0.00011041315,0.0003211953,0.0004113907,0.00015935753,0.000047110305,0.00026337986,0.000045512956,0.000031388685],"category_scores_gemma":[0.00034408536,0.00010411997,0.000071167226,0.00085753074,0.00008909291,0.00033343825,0.0006197314,0.00015267883,0.0000011279396],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006100533,0.0035716172,0.013945485,0.023973811,0.015375593,0.00023960676,0.034408547,0.08311735,0.27256817,0.0037363488,0.045676004,0.49728692],"study_design_scores_gemma":[0.0014173083,0.00035389548,0.00063052075,0.000036982812,0.0007740577,0.000021700936,0.0015749712,0.9917772,0.0017971256,0.000071621726,0.0014290552,0.0001155889],"about_ca_topic_score_codex":0.000007831004,"about_ca_topic_score_gemma":0.0000015805429,"teacher_disagreement_score":0.9086598,"about_ca_system_score_codex":0.00016230792,"about_ca_system_score_gemma":0.00043790723,"threshold_uncertainty_score":0.42458892},"labels":[],"label_agreement":null},{"id":"W4210818981","doi":"10.1111/ejh.13752","title":"Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real‐world outcomes from a population‐based cohort","year":2022,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Terry Fox Research Institute; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Incidence (geometry); Population; Residence; Demography; Socioeconomic status; Cohort; Rural area; Pediatrics; Gerontology; Internal medicine; Environmental health; Pathology","score_opus":0.014123140668207213,"score_gpt":0.2765303402350199,"score_spread":0.2624071995668127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210818981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634606,0.00013583456,0.00006854698,0.002432767,0.00012073553,0.00033866154,0.000022224482,0.000020210497,0.0005149553],"genre_scores_gemma":[0.9975472,0.000057820456,0.0013842636,0.00067656266,0.00004556033,0.0000066456164,0.000049632203,0.000054692035,0.00017761184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746174,0.0007716973,0.0007779945,0.000306968,0.0003582706,0.00032330828],"domain_scores_gemma":[0.9984919,0.0003949281,0.000533833,0.00028161725,0.00009273837,0.00020502305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088077417,0.00021307595,0.0008950606,0.0006277841,0.0001293628,0.000019214305,0.00029088603,0.000033991782,0.00062255125],"category_scores_gemma":[0.00009676879,0.00016249709,0.00010080664,0.00019987907,0.00012962594,0.00014508035,0.00019190494,0.0010982732,0.000016498516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010537166,0.000071238595,0.98081845,0.000025470821,0.00022709234,0.015733566,0.00087322475,0.00007946034,0.00007720272,0.00002878699,0.0007309733,0.0002808036],"study_design_scores_gemma":[0.0057591465,0.00044619132,0.9889731,0.00010343381,0.00013627879,0.0032721856,0.0007127379,0.0001990245,0.00009107602,0.000022446458,0.00013620805,0.00014818704],"about_ca_topic_score_codex":0.0005933198,"about_ca_topic_score_gemma":0.00029448973,"teacher_disagreement_score":0.01246138,"about_ca_system_score_codex":0.0005916169,"about_ca_system_score_gemma":0.0004022015,"threshold_uncertainty_score":0.6816499},"labels":[],"label_agreement":null},{"id":"W4210980966","doi":"10.1007/978-3-642-36229-3_3","title":"Cytogenetic Diagnosis of Myelodysplastic Syndromes","year":2013,"lang":"en","type":"book-chapter","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Myelodysplastic syndromes; Myeloid leukemia; Medicine; Bone marrow; Oncology; Cytogenetics; International Prognostic Scoring System; Internal medicine; Bioinformatics; Biology; Genetics; Gene; Chromosome","score_opus":0.03770861024392194,"score_gpt":0.2827692959757395,"score_spread":0.24506068573181758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210980966","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050418223,0.0016486605,0.000054437463,0.00059362926,0.0001277011,0.001097665,0.000046231955,0.00008444695,0.9913054],"genre_scores_gemma":[0.0352323,0.0031892762,0.0014914242,0.00021997819,0.00019456458,0.00010110515,0.00007708551,0.00015064282,0.9593436],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978758,0.000013145123,0.00054281554,0.00046268787,0.000733786,0.00037173126],"domain_scores_gemma":[0.99798995,0.00041345466,0.00017106492,0.00077852665,0.000336242,0.00031078505],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001082209,0.00040613458,0.0009784972,0.000455345,0.00002944358,0.000013447174,0.00025396515,0.0005417399,0.049475223],"category_scores_gemma":[0.00014793388,0.00031820487,0.00028700306,0.000052901254,0.00029433612,0.000034912504,0.00021300405,0.0005939246,0.005702368],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043231132,0.00036424,0.0070378627,0.0066289003,0.004979726,0.0022457517,0.00021319692,0.000011191121,0.0021326425,0.17133576,0.70257604,0.10204236],"study_design_scores_gemma":[0.0055957814,0.0041441983,0.009207719,0.00539591,0.0028819412,0.0018320516,0.000057726458,0.00034491805,0.01013305,0.010779558,0.947655,0.0019721156],"about_ca_topic_score_codex":0.00008823756,"about_ca_topic_score_gemma":0.000008018878,"teacher_disagreement_score":0.24507897,"about_ca_system_score_codex":0.0002840692,"about_ca_system_score_gemma":0.00051245146,"threshold_uncertainty_score":0.999927},"labels":[],"label_agreement":null},{"id":"W4211002504","doi":"10.1007/978-3-540-87984-8_1","title":"Leukemia","year":2010,"lang":"en","type":"book-chapter","venue":"Pediatric oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Malignancy; Leukemia; Medicine; Lymph; Bone marrow; Cancer; Pathology; Spleen; Neoplastic disease; Hematological malignancy; Cancer research; Internal medicine","score_opus":0.026342816128935923,"score_gpt":0.32173778052378793,"score_spread":0.295394964394852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211002504","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016583388,0.0012171776,0.000027071712,0.0019555371,0.001226615,0.00078434404,0.000041189403,0.0001951115,0.9928946],"genre_scores_gemma":[0.0010179296,0.006318112,0.0034092998,0.0013748122,0.012400539,0.000044709217,0.00021358214,0.00020640904,0.9750146],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99748164,0.00002947919,0.0005777695,0.0007105149,0.0005620238,0.0006385525],"domain_scores_gemma":[0.9975073,0.00046003755,0.00031118953,0.0008645426,0.00031711248,0.0005398608],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.00044504192,0.00046742827,0.00113169,0.00070466194,0.0000984442,0.000013639569,0.00036458182,0.0028410433,0.00864157],"category_scores_gemma":[0.00028198652,0.0004244859,0.00032915137,0.000089799636,0.00027685007,0.00003837349,0.0003152861,0.0045618056,0.0074439384],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012531416,0.00024171067,0.0029713723,0.0012168008,0.000659461,0.012102473,0.00028104964,0.000001146448,0.0012307706,0.05452602,0.78869104,0.13682503],"study_design_scores_gemma":[0.0018016256,0.0008771592,0.00042854468,0.000012023412,0.0007833578,0.0008935166,0.0000037682291,0.000010185518,0.000028818493,0.0036710172,0.9911401,0.00034983738],"about_ca_topic_score_codex":0.000039952967,"about_ca_topic_score_gemma":0.000041144773,"teacher_disagreement_score":0.20244911,"about_ca_system_score_codex":0.0029498916,"about_ca_system_score_gemma":0.008309736,"threshold_uncertainty_score":0.9998207},"labels":[],"label_agreement":null},{"id":"W4211260423","doi":"10.1101/2022.02.08.22270578","title":"Signatures of immune senescence predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia","year":2022,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Stand Up To Cancer; Qatar National Research Fund; National Institutes of Health; Gabrielle's Angel Foundation for Cancer Research; John and Lucille Van Geest Foundation; Nottingham Trent University; Fonds National de la Recherche Luxembourg; Trent University; U.S. Department of Defense; Rally Foundation; National Cancer Institute; Entertainment Industry Foundation; St. Baldrick's Foundation; American Association for Cancer Research","keywords":"Blockade; Immune checkpoint; Myeloid leukemia; Transcriptome; Senescence; CD8; Immune system; Effector; Immunotherapy; Medicine; Bone marrow; Oncology; Cancer research; Myeloid; Cell cycle checkpoint; Biology; Immunology; Internal medicine; Cell cycle; Gene; Cancer; Gene expression; Receptor","score_opus":0.014635865620179274,"score_gpt":0.2817026845847653,"score_spread":0.267066818964586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211260423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99029607,0.0049107727,0.000036042737,0.001879559,0.00030964837,0.001860082,0.00034936154,0.00007087865,0.00028759954],"genre_scores_gemma":[0.98869425,0.005315108,0.0019202712,0.00025911743,0.00007650521,0.00031672942,0.00042758288,0.00013424658,0.0028562173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948278,0.00047150993,0.0013627122,0.0012697636,0.0012601984,0.00080801995],"domain_scores_gemma":[0.9969849,0.00046641598,0.00058382563,0.0015471546,0.00010766273,0.0003100695],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001469114,0.000735738,0.0017885636,0.00087923027,0.00010506776,0.000028415718,0.0008119799,0.0006102563,0.00074432604],"category_scores_gemma":[0.0008297594,0.00066175935,0.00039144765,0.0004386245,0.00057329715,0.00007019993,0.0040467256,0.003491625,0.000027477914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017877645,0.00023604349,0.57261676,0.0008404733,0.00080364326,0.0014382406,0.0008820881,0.0002956386,0.41993648,0.000011474352,0.00025780068,0.0008936013],"study_design_scores_gemma":[0.0039329245,0.00036646755,0.9211865,0.0005128231,0.00038006497,0.00014241405,0.00027630478,0.0005522066,0.07090653,0.00012496147,0.0011383038,0.0004804873],"about_ca_topic_score_codex":0.0005937532,"about_ca_topic_score_gemma":0.000022569358,"teacher_disagreement_score":0.34902996,"about_ca_system_score_codex":0.0018101701,"about_ca_system_score_gemma":0.001293262,"threshold_uncertainty_score":0.99958336},"labels":[],"label_agreement":null},{"id":"W4212787271","doi":"10.1038/s41392-021-00870-3","title":"Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"Signal Transduction and Targeted Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; Université de Paris; University of Texas MD Anderson Cancer Center; AbbVie","keywords":"Venetoclax; Myeloid leukemia; Cancer research; Leukemia; MAPK/ERK pathway; Medicine; Myeloid; Apoptosis; Biology; Immunology; Signal transduction; Cell biology; Genetics; Chronic lymphocytic leukemia","score_opus":0.018757685759984183,"score_gpt":0.2636010988375339,"score_spread":0.24484341307754973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212787271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944087,0.0006160213,0.00053224573,0.0025905247,0.00019723343,0.0012479352,0.00010912484,0.00008136872,0.0002168321],"genre_scores_gemma":[0.9968868,0.00066947314,0.00036221702,0.00071736804,0.00012213769,0.00022870133,0.00027193097,0.000049848702,0.0006915195],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976924,0.000292651,0.00049643667,0.0004723167,0.0006601911,0.00038598944],"domain_scores_gemma":[0.99915683,0.00011675407,0.00011611237,0.00024025522,0.00015902752,0.00021100008],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005567478,0.00023661811,0.0004534387,0.00054229214,0.00017542898,0.000015010172,0.00013892131,0.0001277143,0.0010957754],"category_scores_gemma":[0.000033411307,0.00022991205,0.000100291916,0.0011313453,0.00012897799,0.00015966399,0.000024400695,0.0004342287,0.0000057087386],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008841748,0.000107238375,0.0004998117,0.000053331594,0.00017123378,0.00002679991,0.0025855207,0.00032372656,0.9822518,0.00013863579,0.00063857075,0.0043615685],"study_design_scores_gemma":[0.010378623,0.0014052544,0.008857058,0.00010003964,0.000027453247,0.00002672698,0.0015491262,0.0005426992,0.9432774,0.00024534058,0.03326109,0.0003291797],"about_ca_topic_score_codex":0.00015583285,"about_ca_topic_score_gemma":0.000026368738,"teacher_disagreement_score":0.038974404,"about_ca_system_score_codex":0.0011745463,"about_ca_system_score_gemma":0.0009593483,"threshold_uncertainty_score":0.9998174},"labels":[],"label_agreement":null},{"id":"W4212869919","doi":"10.3324/haematol.2022.280677","title":"NOX2: a determinant of acute myeloid leukemia survival","year":2022,"lang":"en","type":"letter","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myeloid leukemia; Medicine; Leukemia; Myeloid; Cancer research; Oncology; Internal medicine; Immunology","score_opus":0.037218316194180666,"score_gpt":0.30629860586863217,"score_spread":0.2690802896744515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212869919","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13104576,0.0016302362,0.00013819057,0.7991617,0.002192835,0.0045423717,0.0014018955,0.0007844312,0.059102613],"genre_scores_gemma":[0.0413669,0.0030677135,0.006848491,0.86061305,0.0045220563,0.0016459525,0.0060076825,0.0007731478,0.075155005],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944291,0.0004723587,0.00106105,0.0010950391,0.0017254335,0.0012170174],"domain_scores_gemma":[0.996531,0.00064949365,0.00061827415,0.0017284106,0.00026874745,0.00020406916],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0006125871,0.00072179,0.0026418853,0.0005869462,0.00020394921,0.000029247269,0.0010984659,0.001509563,0.0069974484],"category_scores_gemma":[0.00032916875,0.00055881485,0.00075725064,0.000652467,0.00055060134,0.000064997264,0.0010790435,0.005653754,0.00035627227],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058122084,0.00006226757,0.0004796408,0.0011982856,0.00077616225,0.060502615,0.000119009484,5.372171e-7,0.0007686083,0.00008274002,0.9344648,0.0009641099],"study_design_scores_gemma":[0.001756566,0.0014505164,0.0006793767,0.00024299974,0.0009506328,0.010183906,0.00008880552,0.00008909291,0.0021956423,0.00015146009,0.98158574,0.00062526384],"about_ca_topic_score_codex":0.00021508285,"about_ca_topic_score_gemma":0.0000056504364,"teacher_disagreement_score":0.089678854,"about_ca_system_score_codex":0.0013163864,"about_ca_system_score_gemma":0.0018810361,"threshold_uncertainty_score":0.9997867},"labels":[],"label_agreement":null},{"id":"W4213044498","doi":"10.1080/10428194.2022.2042689","title":"Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health","keywords":"Decitabine; Panobinostat; Cancer research; PARP1; Olaparib; Azacitidine; Myeloid leukemia; Cytotoxicity; Pharmacology; PI3K/AKT/mTOR pathway; Poly ADP ribose polymerase; Chemistry; Leukemia; Vorinostat; Apoptosis; Histone deacetylase; Medicine; DNA methylation; In vitro; Immunology; Histone; Polymerase; Biochemistry; DNA","score_opus":0.008695234625414798,"score_gpt":0.2345867560039069,"score_spread":0.2258915213784921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213044498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99270564,0.001476174,0.00020041861,0.00027113516,0.00022726462,0.0023075275,0.0003301451,0.00024562472,0.0022360638],"genre_scores_gemma":[0.9910232,0.0017008728,0.002298449,0.0011698721,0.00015184356,0.0006416411,0.00037811365,0.00026870455,0.0023672914],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99176395,0.0005476576,0.0017489907,0.0020647182,0.0018540729,0.0020205926],"domain_scores_gemma":[0.9955233,0.0007615175,0.0007341804,0.0015917083,0.00033689555,0.001052453],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0010985875,0.0013013216,0.0024855093,0.0012629383,0.0006874732,0.00013295568,0.0008743072,0.00057079404,0.00033269645],"category_scores_gemma":[0.0001441768,0.0012059561,0.0002999344,0.001963837,0.0012011365,0.0005085716,0.0013539542,0.0008204812,0.000024088953],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04274539,0.0010100465,0.024527458,0.0015843492,0.0020545593,0.0051586716,0.009617106,0.0017564712,0.83409035,0.0014379945,0.0063798856,0.06963773],"study_design_scores_gemma":[0.13514571,0.010604428,0.21131365,0.00090217363,0.0013274895,0.005403173,0.004583291,0.02643516,0.5918309,0.00092936546,0.008188351,0.00333632],"about_ca_topic_score_codex":0.0053475616,"about_ca_topic_score_gemma":0.000365627,"teacher_disagreement_score":0.24225944,"about_ca_system_score_codex":0.02803489,"about_ca_system_score_gemma":0.014087198,"threshold_uncertainty_score":0.99997383},"labels":[],"label_agreement":null},{"id":"W4213418290","doi":"10.3324/haematol.2021.280329","title":"Pseudo-mutant P53 is a unique phenotype of &lt;i&gt;DNMT3A&lt;/i&gt;-mutated pre-leukemia","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Weizmann Institute of Science","keywords":"Mutant; Phenotype; Haematopoiesis; Mutation; Leukemia; Cancer research; Biology; Progenitor cell; Gene; Cell biology; Genetics; Stem cell","score_opus":0.020704750609857478,"score_gpt":0.28283286327596885,"score_spread":0.26212811266611136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213418290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97247535,0.0015386957,0.00031750085,0.0035081026,0.00019722368,0.0017466401,0.00017470274,0.00042680034,0.019614967],"genre_scores_gemma":[0.9892397,0.00043796797,0.003108764,0.0016380269,0.00007303613,0.00040160684,0.00015661461,0.00009731372,0.0048469473],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99523354,0.0005285746,0.0009941697,0.00090087345,0.0013186005,0.0010242413],"domain_scores_gemma":[0.9970225,0.00041809166,0.0004215486,0.0013059598,0.0004136002,0.00041828788],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000983525,0.0004780956,0.0013473994,0.00044058613,0.00039870295,0.000026765456,0.0008329697,0.0003267648,0.007063916],"category_scores_gemma":[0.00065023184,0.0003987838,0.00033622058,0.0014784695,0.0004712372,0.00010775149,0.0009826943,0.0011309865,0.0002814487],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005944896,0.0013416538,0.0029931809,0.0011563987,0.0009961992,0.008363549,0.0048430334,0.00024380034,0.7392719,0.031217664,0.19817257,0.005455167],"study_design_scores_gemma":[0.018757919,0.00979278,0.02274513,0.00075659744,0.0011811892,0.017045364,0.0018025013,0.028723184,0.28097543,0.009665275,0.6058079,0.0027467646],"about_ca_topic_score_codex":0.00008987259,"about_ca_topic_score_gemma":0.000016571526,"teacher_disagreement_score":0.45829648,"about_ca_system_score_codex":0.0012837038,"about_ca_system_score_gemma":0.0017181776,"threshold_uncertainty_score":0.9998464},"labels":[],"label_agreement":null},{"id":"W4214481726","doi":"10.14740/gr1481","title":"Isolated Enteric Myeloid Sarcoma as a Rare Etiology of Small Bowel Obstruction in a Young Female Patient","year":2022,"lang":"en","type":"article","venue":"Gastroenterology Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Northwestern University","keywords":"Medicine; Myeloid sarcoma; CD117; Bowel obstruction; Pathology; Myeloid; Myeloid leukemia; Gastroenterology; Internal medicine; CD34; Surgery; Stem cell; Biology","score_opus":0.032318313247124086,"score_gpt":0.31547199527659026,"score_spread":0.28315368202946617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214481726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952444,0.00013689106,0.00009718346,0.0022511664,0.00023159993,0.0012415628,0.000044039665,0.00004356244,0.0007096306],"genre_scores_gemma":[0.99765724,0.00008169837,0.0004918843,0.00031029515,0.00006127161,0.0005868346,0.00015136886,0.00004902518,0.0006103778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99389845,0.002332101,0.00073425996,0.00072926626,0.0008703523,0.0014355738],"domain_scores_gemma":[0.9983182,0.00019547019,0.00015213685,0.0006780683,0.00040691567,0.00024918452],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017397555,0.00022659395,0.0006077405,0.0016276801,0.00025072412,0.000012294008,0.0005112265,0.00017639186,0.0012637506],"category_scores_gemma":[0.00039991963,0.00023074745,0.00015086305,0.0010396962,0.0006131457,0.00006560431,0.0013478377,0.0025300537,0.0000632181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016760325,0.0007439582,0.9349748,0.00012459636,0.00013535903,0.0010453232,0.0024122957,0.00008218799,0.040369436,0.000049504597,0.00093526224,0.0023669486],"study_design_scores_gemma":[0.010446484,0.022512337,0.943982,0.00008604868,0.000033417367,0.008306893,0.0077561117,0.0043147397,0.0011224692,0.00026102163,0.000994589,0.0001838807],"about_ca_topic_score_codex":0.0012547097,"about_ca_topic_score_gemma":0.0004835818,"teacher_disagreement_score":0.039246965,"about_ca_system_score_codex":0.0011669779,"about_ca_system_score_gemma":0.0004392866,"threshold_uncertainty_score":0.9997712},"labels":[],"label_agreement":null},{"id":"W4214570283","doi":"10.3410/f.718276095.793491690","title":"Faculty Opinions recommendation of Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.","year":2014,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hospital for Sick Children; Terry Fox Foundation; Canadian Institutes of Health Research; Genome Canada; Ontario Genomics; Ontario Genomics Institute; Aplastic Anemia and Myelodysplasia Association of Canada","keywords":"Haematopoiesis; Stem cell; NPM1; Cancer research; Biology; Progenitor cell; Myeloid; Leukemia; Immunology; Gene; Genetics; Karyotype","score_opus":0.03005782095488288,"score_gpt":0.3650511602041722,"score_spread":0.3349933392492893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214570283","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003487699,0.0007622515,0.00010132869,0.086878374,0.0006621799,0.0031918825,0.9082966,0.000036023182,0.00003648206],"genre_scores_gemma":[0.00015757875,0.0010602421,0.00050001615,0.0016477067,0.00019066263,0.00040635618,0.9938679,0.00005500484,0.002114558],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9912151,0.000904444,0.003836423,0.0009904791,0.002501896,0.00055167556],"domain_scores_gemma":[0.98582345,0.00034391365,0.0032767823,0.002809481,0.0073438482,0.00040251823],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003542821,0.00068071997,0.002068214,0.0010870128,0.00012806371,0.00007964387,0.002071748,0.0012342584,0.00029524686],"category_scores_gemma":[0.0040499293,0.00047195578,0.00085434143,0.003570528,0.00064651377,0.0003592159,0.00069123495,0.0020542135,0.000084183404],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008823319,0.00055508467,0.000021988635,0.02570371,0.00027999535,0.000001140999,0.00019780807,4.9860694e-7,0.0001535682,0.00012736244,0.97104466,0.0018259259],"study_design_scores_gemma":[0.001746168,0.00024791318,0.0023684753,0.020548273,0.0005364682,0.00010635272,0.00004896776,0.00008166143,0.0012559794,0.000021011496,0.97269636,0.00034239073],"about_ca_topic_score_codex":0.00011714996,"about_ca_topic_score_gemma":0.00000908136,"teacher_disagreement_score":0.085571274,"about_ca_system_score_codex":0.000600148,"about_ca_system_score_gemma":0.0016791244,"threshold_uncertainty_score":0.9997732},"labels":[],"label_agreement":null},{"id":"W4214776966","doi":"10.1002/jha2.390","title":"Single cell proteogenomic sequencing identifies a relapse‐fated AML subclone carrying <i>FLT3</i>‐ITD with CN‐LOH at chr13q","year":2022,"lang":"en","type":"article","venue":"eJHaem","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Genome Canada; Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Institutes of Health Research; Canadian Cancer Society; Princess Margaret Cancer Foundation","keywords":"NPM1; Biology; Cancer research; Myeloid leukemia; Myeloid; Fms-Like Tyrosine Kinase 3; Flow cytometry; Molecular biology; Tyrosine kinase; Exon; Mutation; Gene; Karyotype; Genetics; Receptor; Chromosome","score_opus":0.027405367209557385,"score_gpt":0.24868758232348206,"score_spread":0.22128221511392468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214776966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98783463,0.0010660959,0.00005535221,0.0010518003,0.00022613026,0.0017041841,0.00004577977,0.00031351676,0.0077024796],"genre_scores_gemma":[0.9682866,0.000031287684,0.0011774017,0.00041336002,0.00024619885,0.0004004736,0.00019270118,0.00016358055,0.02908842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996374,0.00024382066,0.00048562136,0.0008115268,0.0011290301,0.0009560062],"domain_scores_gemma":[0.99827003,0.000121972065,0.0002224506,0.00087656226,0.00018384121,0.00032512043],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007512855,0.00037229812,0.00057727244,0.00034634097,0.000888505,0.00007697741,0.00040336206,0.000109608554,0.0012217105],"category_scores_gemma":[0.00010562256,0.00033772527,0.00014936326,0.0009127809,0.00021370171,0.00017868314,0.00076140015,0.0011096963,0.00029888004],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010525037,0.00014206153,0.0042945985,0.00027174817,0.00013746935,0.002523337,0.003980034,0.000377002,0.97940314,0.000013292704,0.0074002794,0.00040451658],"study_design_scores_gemma":[0.0072241416,0.002020557,0.0016405114,0.00021460993,0.0002710678,0.0026076722,0.006019839,0.0012467753,0.9476942,0.00004670645,0.030195683,0.00081826624],"about_ca_topic_score_codex":0.0010411636,"about_ca_topic_score_gemma":0.00017881257,"teacher_disagreement_score":0.03170899,"about_ca_system_score_codex":0.0056336573,"about_ca_system_score_gemma":0.0010064193,"threshold_uncertainty_score":0.9999075},"labels":[],"label_agreement":null},{"id":"W4220664559","doi":"10.1200/jco.21.01612","title":"Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3</i>/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Sorafenib; Chemotherapy; Standard of care; Myeloid leukemia; Myeloid","score_opus":0.03873391942983144,"score_gpt":0.40885538987138687,"score_spread":0.3701214704415554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220664559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9052615,0.00004204006,0.0030243462,0.046677656,0.000279216,0.04428743,0.000075408636,0.000034873396,0.00031748615],"genre_scores_gemma":[0.8964101,0.00029563237,0.039367586,0.019063113,0.0035833225,0.039796796,0.0005748205,0.00024841586,0.00066019024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927241,0.0014842417,0.003116814,0.000649419,0.0014012264,0.00062415807],"domain_scores_gemma":[0.9916459,0.0030146874,0.0035080106,0.00064234296,0.00081773434,0.0003713704],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008373816,0.00037119514,0.0024044593,0.00025435627,0.00029401807,0.000036873033,0.0007443255,0.0005128643,0.00027982498],"category_scores_gemma":[0.0010433996,0.00021630808,0.00041503113,0.0005797258,0.00057871296,0.00022954424,0.00021010835,0.004129044,0.0000034680556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.25868934,0.0069488375,0.5197179,0.000036484886,0.0059087477,0.0051057814,0.0012257345,0.00046698024,0.0007075103,0.00046754323,0.062264208,0.13846093],"study_design_scores_gemma":[0.12413931,0.10219697,0.63111496,0.000074479016,0.0007035849,0.008616961,0.00035860285,0.00015544982,0.00024716943,0.0008723579,0.13119541,0.00032474354],"about_ca_topic_score_codex":0.00047894393,"about_ca_topic_score_gemma":0.00059527805,"teacher_disagreement_score":0.1381362,"about_ca_system_score_codex":0.0042492473,"about_ca_system_score_gemma":0.013869433,"threshold_uncertainty_score":0.9995733},"labels":[],"label_agreement":null},{"id":"W4220681641","doi":"10.1177/2050313x221085760","title":"A rare case of late myelodysplasia cutis associated with essential thrombocythemia: A case report","year":2022,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré de Santé et Services Sociaux de la Gaspésie; Dr. Georges-L.-Dumont University Hospital Centre; Université Laval","funders":"","keywords":"Leukemia cutis; Medicine; Essential thrombocythemia; Myeloproliferative Disorders; Cutis; Pathology; Myelodysplastic syndromes; Dermatology; Infiltration (HVAC); Myeloid leukemia; Scarring alopecia; Bone marrow; Polycythemia vera; Internal medicine; Scalp","score_opus":0.018878316231647763,"score_gpt":0.32865448739970865,"score_spread":0.3097761711680609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220681641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98785967,0.00025707556,0.000120940356,0.0013157458,0.00026879794,0.0022539613,0.00014297935,0.00010740138,0.0076734256],"genre_scores_gemma":[0.9918947,0.000022584236,0.0005038461,0.00039014235,0.00014976044,0.00037950056,0.00041012873,0.000119970915,0.006129326],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9930095,0.00057555013,0.0017130618,0.0011848719,0.002638268,0.0008787632],"domain_scores_gemma":[0.99502563,0.0004675599,0.0011269377,0.0016683491,0.00043591316,0.0012755798],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0056648394,0.00043503576,0.0013629476,0.0002721015,0.00075212505,0.00007721476,0.00025774306,0.00035337117,0.012700917],"category_scores_gemma":[0.004912165,0.0003555827,0.00024109961,0.0013197405,0.0005720083,0.00023468821,0.0019476274,0.0021797684,0.000008390967],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005360029,0.0006706632,0.0018784765,0.00013829913,0.00065260404,0.9843076,0.00083914073,0.00001072684,0.00031263015,0.0000095762,0.007223829,0.0034204586],"study_design_scores_gemma":[0.003767614,0.0008488291,0.00013337987,0.00034091758,0.0006243254,0.98790544,0.0019469846,0.00068358413,0.0010704416,0.000042401087,0.0022785347,0.0003575158],"about_ca_topic_score_codex":0.009319317,"about_ca_topic_score_gemma":0.0024142924,"teacher_disagreement_score":0.012692527,"about_ca_system_score_codex":0.0010292894,"about_ca_system_score_gemma":0.0056551397,"threshold_uncertainty_score":0.9999819},"labels":[],"label_agreement":null},{"id":"W4220684932","doi":"10.1002/ajh.26534","title":"A t(6;14;9)(p22;q22;q34) <scp>three‐way</scp> translocation: Description of a cytogenetically visible variant t(6;9) in acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Chromosomal translocation; Myeloid leukemia; Medicine; Myeloid; Biology; Cancer research; Gene; Genetics","score_opus":0.01851038053093702,"score_gpt":0.2822152237193325,"score_spread":0.2637048431883955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220684932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800602,0.001435089,0.013494438,0.0035226233,0.00020882687,0.00045011824,0.000018705241,0.000024167086,0.00078579935],"genre_scores_gemma":[0.98696184,0.00065760774,0.011153636,0.00082610024,0.00009582547,0.00005433205,0.000014518343,0.00006310729,0.00017302149],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.9958153,0.00050969276,0.0015732031,0.0003976308,0.0009883224,0.0007158964],"domain_scores_gemma":[0.99713033,0.0005371483,0.0009811685,0.00050388987,0.0005025916,0.00034489293],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013814097,0.0002946562,0.0015389883,0.0011326318,0.000121059406,0.000016413209,0.0005987683,0.000118177675,0.00025023843],"category_scores_gemma":[0.00044171428,0.00027604456,0.0003161425,0.0017388914,0.000683515,0.00015777854,0.00017705484,0.0014040639,0.0000179708],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011661583,0.0045001055,0.18044685,0.00097334763,0.0056324955,0.04429204,0.018464768,0.0048657283,0.55175775,0.014629506,0.025345413,0.13743038],"study_design_scores_gemma":[0.049931865,0.05856628,0.18713889,0.0014191624,0.0027653484,0.50763685,0.031965565,0.019824114,0.09807149,0.007614074,0.03377365,0.00129275],"about_ca_topic_score_codex":0.0002866806,"about_ca_topic_score_gemma":0.000058189355,"teacher_disagreement_score":0.46334478,"about_ca_system_score_codex":0.0011164991,"about_ca_system_score_gemma":0.002470699,"threshold_uncertainty_score":0.9999692},"labels":[],"label_agreement":null},{"id":"W4220698916","doi":"10.1101/2022.03.01.482535","title":"A primary patient-derived model for investigating functional heterogeneity within the human Leukemic Stem Cell Compartment","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"Hospital for Sick Children; Government of Ontario; Princess Margaret Cancer Foundation","keywords":"Stem cell; Compartment (ship); Biology; Myeloid leukemia; Leukemia; Computational biology; Somatic evolution in cancer; Cancer research; Immunology; Cancer; Cell biology; Genetics","score_opus":0.05398152953633348,"score_gpt":0.2668395001150572,"score_spread":0.21285797057872372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220698916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897584,0.0006980337,0.0032635913,0.00043546193,0.0005927832,0.0042178794,0.00063706224,0.00037801868,0.000018793493],"genre_scores_gemma":[0.9858111,0.000026848342,0.008471997,0.0017625308,0.00039416907,0.0032239412,0.000018017647,0.00025729334,0.00003407081],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99506426,0.000348743,0.0010587976,0.0014374565,0.0012421177,0.00084861566],"domain_scores_gemma":[0.9958505,0.0002019444,0.00086065556,0.0019245652,0.0006466359,0.00051569345],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013162891,0.00076839514,0.0009439717,0.0002819071,0.0009994403,0.00017568048,0.000732071,0.0004123347,0.000048236045],"category_scores_gemma":[0.00009393368,0.00067374995,0.00040817188,0.0003998454,0.00033984004,0.00011533105,0.0017474964,0.0022964082,0.00001828447],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017572546,0.00026913654,0.0045693624,0.0012604157,0.00037313558,0.000028243938,0.00011303748,0.013105938,0.9775246,0.0002512183,0.0023274815,0.0000016964115],"study_design_scores_gemma":[0.0050395452,0.00054841035,0.034438558,0.0005300409,0.00073864806,2.9566897e-7,0.00008497006,0.16048379,0.7952029,0.000015919422,0.001433235,0.0014836814],"about_ca_topic_score_codex":0.000052858908,"about_ca_topic_score_gemma":0.0000034370375,"teacher_disagreement_score":0.1823217,"about_ca_system_score_codex":0.0041569555,"about_ca_system_score_gemma":0.004775124,"threshold_uncertainty_score":0.9996659},"labels":[],"label_agreement":null},{"id":"W4220791634","doi":"10.21203/rs.3.rs-1474309/v1","title":"Fusion transcript analysis reveals slower response kinetics than multiparameter flow cytometry in childhood acute myeloid leukemia","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"Rigshospitalet; Gentofte Hospital; Aarhus Universitetshospital; Sahlgrenska Universitetssjukhuset; Aarhus Universitet","keywords":"Minimal residual disease; Myeloid leukemia; Fusion transcript; Flow cytometry; Real-time polymerase chain reaction; Cancer research; Myeloid; Leukemia; Biology; Oncology; Fusion gene; Medicine; Immunology; Molecular biology; Genetics; Gene","score_opus":0.03993525837739117,"score_gpt":0.3786879206727077,"score_spread":0.33875266229531653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220791634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826022,0.0022540623,0.00055760454,0.00462454,0.00035223484,0.0061144466,0.0017869535,0.0002649496,0.0014430498],"genre_scores_gemma":[0.9718704,0.0032849067,0.0066480567,0.00035422706,0.00045765622,0.0017669181,0.00325425,0.00035976092,0.012003825],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9774785,0.0069135935,0.0018794549,0.0031455052,0.007393246,0.0031897072],"domain_scores_gemma":[0.9891159,0.0030096632,0.00030887924,0.004759777,0.0014286765,0.0013770823],"candidate_categories":["metaepi_narrow","bibliometrics","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.01381883,0.0011580467,0.0028113378,0.013848139,0.00052545575,0.00035561627,0.0023223395,0.0016881115,0.0052874573],"category_scores_gemma":[0.005266043,0.0010993711,0.0018856691,0.0130574005,0.00063137343,0.00019605643,0.0049254773,0.015199195,0.0002643488],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11649458,0.010690884,0.24086416,0.009435315,0.027668234,0.038820043,0.032371573,0.029644284,0.40711173,0.000061827624,0.052970912,0.03386646],"study_design_scores_gemma":[0.009970623,0.003331197,0.93140626,0.0018752492,0.0021922968,0.00016714686,0.0029292358,0.027066456,0.0053667515,0.00034251716,0.013544084,0.001808196],"about_ca_topic_score_codex":0.001274431,"about_ca_topic_score_gemma":0.00035867136,"teacher_disagreement_score":0.6905421,"about_ca_system_score_codex":0.012600756,"about_ca_system_score_gemma":0.0048625404,"threshold_uncertainty_score":0.9996079},"labels":[],"label_agreement":null},{"id":"W4220874793","doi":"10.1158/2159-8290.cd-20-1145","title":"Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML","year":2022,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research; Canada Research Chairs; German-Israeli Foundation for Scientific Research and Development; Cancer Council Victoria; Deutsche Forschungsgemeinschaft; Cure Cancer Australia Foundation; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Victorian Cancer Agency","keywords":"Epigenetics; Immune system; DNA methylation; Cellular differentiation; Epigenesis; Histone; Immunotherapy","score_opus":0.025482620720341718,"score_gpt":0.30448970183002505,"score_spread":0.2790070811096833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220874793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963837,0.0008113417,0.00124747,0.00042381958,0.00023402082,0.00043391055,0.00010748452,0.000014398339,0.00034384633],"genre_scores_gemma":[0.99696285,0.0005303893,0.000027009604,0.000121956116,0.00008303819,0.00015294377,0.000088396235,0.000026372592,0.0020070353],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859196,0.00009749069,0.0002918502,0.0002212404,0.00060847384,0.00018900284],"domain_scores_gemma":[0.99926394,0.00009702307,0.00020889676,0.00030005688,0.00008413488,0.00004596658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012518416,0.000112997746,0.00027994497,0.00016713626,0.00007179051,0.000008820648,0.00014963854,0.000038733022,0.00056557934],"category_scores_gemma":[0.00002851749,0.00010181343,0.00009862677,0.00026365733,0.000086800326,0.00013803202,0.00013562731,0.00023076378,0.0000018329177],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092051807,0.0002516374,0.06281627,0.00027791382,0.00026174219,0.0000032996484,0.00094753795,0.00253309,0.9220205,0.00027804164,0.00028875904,0.009400723],"study_design_scores_gemma":[0.0022977968,0.0005134146,0.24736324,0.00009631892,0.00013917155,0.0000058825767,0.0008872376,0.0014001988,0.74610984,0.00034191262,0.0007062046,0.00013877825],"about_ca_topic_score_codex":0.00022392663,"about_ca_topic_score_gemma":0.000011879385,"teacher_disagreement_score":0.18454696,"about_ca_system_score_codex":0.0006267606,"about_ca_system_score_gemma":0.0005412993,"threshold_uncertainty_score":0.6192697},"labels":[],"label_agreement":null},{"id":"W4220884427","doi":"10.15252/emmm.202114990","title":"CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"EMBO Molecular Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer; Institute of Infection and Immunity","funders":"Universitätsklinikum Heidelberg; Deutsche Krebshilfe; Deutsche Forschungsgemeinschaft","keywords":"Myeloid leukemia; Wnt signaling pathway; Biology; Cancer research; Leukemia; Venetoclax; Stem cell; Cell biology; Immunology; Signal transduction","score_opus":0.010587779404809655,"score_gpt":0.25087580200648313,"score_spread":0.24028802260167348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220884427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876543,0.0034972397,0.0008212818,0.0013568094,0.00017071336,0.0012823584,0.0000127615385,0.00015524488,0.0050492384],"genre_scores_gemma":[0.99356765,0.0003161672,0.001719051,0.00216998,0.0004664464,0.00023117,0.00035632355,0.00015755557,0.0010156732],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9952585,0.0005004494,0.0007115423,0.0010104812,0.001464386,0.0010546289],"domain_scores_gemma":[0.99809307,0.00015549944,0.0002560253,0.0007717272,0.00013812224,0.00058555295],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013958452,0.00051626534,0.0009465516,0.00049657736,0.0004038726,0.000030933144,0.00025220407,0.0001840233,0.00025880383],"category_scores_gemma":[0.000057694626,0.00043843527,0.000076006305,0.0011730103,0.0003706313,0.00018492012,0.0004108228,0.0015631951,0.000009313571],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057881097,0.00021946573,0.020348959,0.00097282266,0.000708456,0.031097533,0.008178494,0.09615756,0.7960502,0.0010146596,0.016223975,0.02323975],"study_design_scores_gemma":[0.15686525,0.060132,0.1558552,0.0075693177,0.0043610474,0.018637152,0.039240554,0.30805615,0.15841383,0.0027650578,0.079853475,0.008250978],"about_ca_topic_score_codex":0.0009742082,"about_ca_topic_score_gemma":0.00016056008,"teacher_disagreement_score":0.63763636,"about_ca_system_score_codex":0.0042342884,"about_ca_system_score_gemma":0.0017065791,"threshold_uncertainty_score":0.99980676},"labels":[],"label_agreement":null},{"id":"W4220934401","doi":"10.1038/s41409-022-01625-6","title":"Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis","year":2022,"lang":"en","type":"erratum","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Dalhousie University","funders":"","keywords":"Medicine; Hematopoietic cell; Risk stratification; Myeloid leukemia; Oncology; Internal medicine; Myeloid; Hematopoietic stem cell transplantation; Leukemia; Transplantation; Haematopoiesis; Stem cell; Genetics","score_opus":0.012930118013655128,"score_gpt":0.2622263956692592,"score_spread":0.24929627765560408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220934401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7651873,0.0014497929,0.15753663,0.0005177476,0.02107779,0.016392207,0.016990412,0.0014638422,0.01938426],"genre_scores_gemma":[0.7321691,0.009347494,0.0052679637,0.0004511488,0.0010690413,0.0011325037,0.20225321,0.0006111203,0.04769845],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99247116,0.0010997907,0.001674916,0.0020238706,0.0016499413,0.0010803004],"domain_scores_gemma":[0.9961634,0.00042642886,0.00091521814,0.0012816313,0.00050367566,0.000709645],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010181837,0.0010460841,0.0014692998,0.0019946988,0.00078654627,0.00019236784,0.0006126043,0.00060613645,0.0004930127],"category_scores_gemma":[0.00008894846,0.0011554287,0.0007972935,0.002081248,0.00009032967,0.00028196388,0.000043465552,0.002026353,0.00008170229],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026653282,0.0027646176,0.039313328,0.0122130085,0.017303316,0.0024485923,0.02133609,0.050318204,0.0529341,0.000044427896,0.7356653,0.039005708],"study_design_scores_gemma":[0.035297215,0.015324525,0.67340595,0.0023640965,0.14524826,0.0012217992,0.001700438,0.07732287,0.008367972,0.00011959814,0.032448567,0.0071787457],"about_ca_topic_score_codex":0.0007939721,"about_ca_topic_score_gemma":0.0032552576,"teacher_disagreement_score":0.70321673,"about_ca_system_score_codex":0.0030704166,"about_ca_system_score_gemma":0.0023785196,"threshold_uncertainty_score":0.9990896},"labels":[],"label_agreement":null},{"id":"W4220996407","doi":"10.1007/s00432-022-03983-6","title":"A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome","year":2022,"lang":"en","type":"article","venue":"Journal of Cancer Research and Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Novartis","keywords":"Medicine; Myeloid leukemia; Adverse effect; Internal medicine; Nausea; Gastroenterology; Neutropenia; Myeloid; Pharmacology; Toxicity; Oncology","score_opus":0.08981000935266724,"score_gpt":0.49440191941645306,"score_spread":0.4045919100637858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220996407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960008,0.00024207147,0.000005210404,0.0021480296,0.00020900085,0.0012399433,0.000040868606,0.000005169441,0.00010887836],"genre_scores_gemma":[0.9977435,0.0012258905,0.00013414137,0.00019631213,0.00016351674,0.00010367722,0.0000047563112,0.000035339064,0.00039287473],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9933644,0.0015490936,0.0016675144,0.00041161472,0.002281411,0.0007259912],"domain_scores_gemma":[0.994353,0.002765932,0.0006848909,0.00033297413,0.0011733711,0.0006898556],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0060094316,0.00019106611,0.0015297881,0.00089174445,0.00017609152,0.00001720007,0.00049141975,0.00016173566,0.0006714536],"category_scores_gemma":[0.0012448335,0.00012109419,0.00011924376,0.0013331552,0.0006510838,0.00014592797,0.00054711895,0.0041434397,0.0000032428595],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32290763,0.03409685,0.54430526,0.00016224926,0.002712548,0.022157568,0.0010243407,0.000074298856,0.0006210611,0.000019512938,0.0033247615,0.068593904],"study_design_scores_gemma":[0.12098474,0.45423797,0.4138779,0.00018874762,0.00036656053,0.0009761686,0.0030781545,0.00016212364,0.00003474998,0.00006440697,0.005868383,0.00016008866],"about_ca_topic_score_codex":0.00030323956,"about_ca_topic_score_gemma":0.0005264969,"teacher_disagreement_score":0.42014113,"about_ca_system_score_codex":0.0030065486,"about_ca_system_score_gemma":0.010137645,"threshold_uncertainty_score":0.99815404},"labels":[],"label_agreement":null},{"id":"W4221007142","doi":"10.1111/ejh.13769","title":"Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first‐line systemic treatment or best supportive care: A multicenter international study","year":2022,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"AbbVie","keywords":"Medicine; Myeloid leukemia; Intensive care medicine; Chemotherapy; Health care; Internal medicine","score_opus":0.041475496076281045,"score_gpt":0.33796020609165556,"score_spread":0.2964847100153745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221007142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99495006,0.00017888946,0.0003364288,0.0027495374,0.0002466208,0.0012569388,0.00007088066,0.000018370956,0.00019227651],"genre_scores_gemma":[0.99773055,0.00010835052,0.00050866243,0.0004792826,0.00012253337,0.000061343584,0.00022217697,0.00008728758,0.0006798378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970559,0.0006996005,0.0009906748,0.00036468238,0.0005144655,0.00037471036],"domain_scores_gemma":[0.9974837,0.00015417718,0.0007297468,0.00027097875,0.001197494,0.00016393744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058927695,0.00026124847,0.0007901283,0.0009254017,0.00016214346,0.000021526641,0.000314098,0.000035797922,0.0001225593],"category_scores_gemma":[0.00018771243,0.00018163017,0.00012470748,0.0004600894,0.00006459742,0.00010605106,0.00014079874,0.00048577797,0.0000045301645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09937391,0.0030015688,0.74822813,0.0003680818,0.002709655,0.026297905,0.06424897,0.0012265171,0.000100213736,0.000013287926,0.0043278406,0.050103936],"study_design_scores_gemma":[0.25241336,0.15971988,0.3412998,0.0025543997,0.0014949598,0.033914547,0.16476355,0.0027423892,0.0007417314,0.0000058408204,0.039198987,0.0011505428],"about_ca_topic_score_codex":0.000049522536,"about_ca_topic_score_gemma":0.00011325852,"teacher_disagreement_score":0.40692833,"about_ca_system_score_codex":0.003008777,"about_ca_system_score_gemma":0.0005039616,"threshold_uncertainty_score":0.78678477},"labels":[],"label_agreement":null},{"id":"W4221042673","doi":"10.1080/10428194.2021.2002321","title":"Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy <sup>*</sup>","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"AbbVie","keywords":"Medicine; Cytarabine; Internal medicine; Myeloid leukemia; Retrospective cohort study; Oncology; Chemotherapy","score_opus":0.019842773664186884,"score_gpt":0.3008118159603816,"score_spread":0.2809690422961947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221042673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99372005,0.0001407206,0.000065042586,0.0014821102,0.0001671906,0.00338173,0.0004489402,0.00018056859,0.00041364165],"genre_scores_gemma":[0.9880522,0.0014301442,0.0007325653,0.003918371,0.00028202208,0.0010088113,0.00072749396,0.00025224435,0.0035961657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99425846,0.0002676786,0.0013889434,0.0017273759,0.00096848747,0.0013890308],"domain_scores_gemma":[0.99601436,0.0012660186,0.00040499572,0.0011115143,0.00042810218,0.000775008],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00066553854,0.0010078113,0.002006698,0.0007757281,0.00062792917,0.00011192125,0.00041356703,0.00034916852,0.00015865249],"category_scores_gemma":[0.00022353418,0.0007959811,0.00041295556,0.0007777841,0.00048816742,0.00024954823,0.0004531146,0.00037796746,0.000012942951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009016664,0.00092906755,0.8799825,0.00017163718,0.00080999685,0.00032144983,0.0014308034,0.00015333162,0.000005516283,0.0001608463,0.0013874178,0.10563078],"study_design_scores_gemma":[0.099820994,0.0062513603,0.86663795,0.0001668519,0.00036791104,0.00016502381,0.0012668457,0.010749073,0.000092992945,0.00013689637,0.013548167,0.0007959504],"about_ca_topic_score_codex":0.009949648,"about_ca_topic_score_gemma":0.0017275655,"teacher_disagreement_score":0.104834825,"about_ca_system_score_codex":0.01959571,"about_ca_system_score_gemma":0.003498449,"threshold_uncertainty_score":0.99944913},"labels":[],"label_agreement":null},{"id":"W4221065411","doi":"10.1101/2022.03.30.486272","title":"Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; Canada Research Chairs; Michael Smith Health Research BC; BC Children's Hospital; Children's Hospital Foundation","keywords":"Bone marrow; Interstitial fluid; Haematopoiesis; Extracellular fluid; Leukemia; Pathology; Biology; Cell biology; Chemistry; Medicine; Immunology; Stem cell; Extracellular","score_opus":0.016568484195127367,"score_gpt":0.23628334164764808,"score_spread":0.21971485745252073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221065411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991002,0.0014439947,0.00027624427,0.00071523985,0.0012921118,0.0023508181,0.0027280755,0.00018010181,0.0000114053355],"genre_scores_gemma":[0.9855106,0.0002765164,0.0121697355,0.0004830684,0.00065170025,0.0005006084,0.000008193864,0.00028864443,0.00011092402],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99475217,0.0003658201,0.0011343642,0.0016615415,0.0011631993,0.00092289585],"domain_scores_gemma":[0.99583703,0.00012619955,0.0006872999,0.002741777,0.0002113881,0.00039632566],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006812261,0.0008840171,0.0012464403,0.00027271107,0.00030689794,0.00010223022,0.0013214925,0.00059798366,0.001672306],"category_scores_gemma":[0.00033932785,0.0007886617,0.0005993428,0.0004000139,0.00057266525,0.00009335863,0.0033709193,0.002887775,0.00004560039],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004965312,0.00045777278,0.0447514,0.00059523626,0.00074224686,0.00023936796,0.0000793098,0.00007462684,0.9517323,0.000008901855,0.00081930426,0.0000030348476],"study_design_scores_gemma":[0.0046920367,0.00020607217,0.0935468,0.00079615734,0.0008902209,5.157758e-7,0.00004244339,0.006018515,0.89045906,4.77759e-7,0.0025459772,0.0008017273],"about_ca_topic_score_codex":0.00058886973,"about_ca_topic_score_gemma":0.00001214325,"teacher_disagreement_score":0.061273217,"about_ca_system_score_codex":0.0032558606,"about_ca_system_score_gemma":0.002287743,"threshold_uncertainty_score":0.9994564},"labels":[],"label_agreement":null},{"id":"W4221083501","doi":"10.1016/j.jaccao.2021.11.008","title":"Cardiovascular Disease Among Patients With AML and CHIP-Related Mutations","year":2022,"lang":"en","type":"article","venue":"JACC CardioOncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Women's College Hospital; NOSM University; Toronto General Hospital; University of Toronto; Health Sciences North; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Myeloid leukemia; Coronary artery disease; Retrospective cohort study; Disease; Cohort; Cardiology; Stroke (engine); Proportional hazards model; Oncology; Confidence interval","score_opus":0.009056871233251758,"score_gpt":0.24143124606598895,"score_spread":0.2323743748327372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221083501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99199253,0.0008081991,0.000055223274,0.0008039607,0.00017420428,0.0011355245,0.00008147121,0.00008838715,0.0048605055],"genre_scores_gemma":[0.99785006,0.000032980857,0.00014559328,0.00024169125,0.00008635876,0.00044432218,0.00034709435,0.00004658353,0.0008053337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979528,0.00035513358,0.00019205493,0.0004670573,0.00064740155,0.00038553955],"domain_scores_gemma":[0.9987432,0.00011477412,0.000055349454,0.00056486827,0.00015484315,0.00036701374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039155156,0.00016604798,0.000529216,0.00022162062,0.00034415515,0.000013425491,0.000111885834,0.00007361057,0.00022714975],"category_scores_gemma":[0.00015005864,0.00014487049,0.00024998744,0.0004556111,0.00030305574,0.00007608759,0.00028758912,0.0005839931,0.000018883664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090913614,0.00021991828,0.9754955,0.00005534092,0.0031597351,0.0014657769,0.00053444074,0.0035314222,0.000021628965,0.00016076602,0.0031944271,0.0112518985],"study_design_scores_gemma":[0.0069114286,0.00065551297,0.9445454,0.000007899415,0.0010589479,0.00014191374,0.00034681326,0.00051528146,0.000006106955,0.000051338866,0.045583293,0.00017608487],"about_ca_topic_score_codex":0.00012406391,"about_ca_topic_score_gemma":0.0000049641717,"teacher_disagreement_score":0.042388868,"about_ca_system_score_codex":0.00063630793,"about_ca_system_score_gemma":0.00047272624,"threshold_uncertainty_score":0.5907647},"labels":[],"label_agreement":null},{"id":"W4221124240","doi":"10.1002/ctm2.749","title":"Phosphoproteomics profiling reveals a kinase network conferring acute myeloid leukaemia intrinsic chemoresistance and indicates HMGA1 phosphorylation as a potential influencer","year":2022,"lang":"en","type":"letter","venue":"Clinical and Translational Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Genetics","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Natural Science Foundation of China","keywords":"Phosphoproteomics; Phosphoprotein; Phosphorylation; Proteome; Myeloid leukaemia; Medicine; Phosphopeptide; Cancer research; Myeloid; Molecular biology; Bioinformatics; Biology; Protein phosphorylation; Cell biology; Protein kinase A","score_opus":0.030805164133138104,"score_gpt":0.3308185179120876,"score_spread":0.3000133537789495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221124240","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38384622,0.014070931,0.00047308387,0.5963268,0.00079429685,0.0031353494,0.0001791538,0.00016408683,0.0010100368],"genre_scores_gemma":[0.4518055,0.015963882,0.010019183,0.49017158,0.021213874,0.0007121068,0.006376581,0.00032902043,0.0034082616],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99458593,0.0002733162,0.001729555,0.0012891877,0.001372642,0.0007493433],"domain_scores_gemma":[0.9969847,0.0012625726,0.00054757815,0.00044508438,0.00031143552,0.00044859623],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0018042534,0.000628505,0.0015874653,0.00026947833,0.000432936,0.000051592626,0.00027315578,0.0011063727,0.00084433734],"category_scores_gemma":[0.0006987337,0.0005299912,0.00022962151,0.00052137225,0.0014206895,0.00015832012,0.00018517407,0.005550819,0.000017210103],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027857281,0.0005001914,0.30763015,0.0068526287,0.006983162,0.015933786,0.0016628619,0.00018010217,0.0041405307,0.0042304625,0.50358754,0.120441295],"study_design_scores_gemma":[0.05438939,0.0069897613,0.35795382,0.0072202557,0.008952503,0.00400747,0.0003390471,0.0060088662,0.001132234,0.055735692,0.49346375,0.0038072192],"about_ca_topic_score_codex":0.00010632465,"about_ca_topic_score_gemma":0.0000041831395,"teacher_disagreement_score":0.11663408,"about_ca_system_score_codex":0.00013782336,"about_ca_system_score_gemma":0.0009582404,"threshold_uncertainty_score":0.99971515},"labels":[],"label_agreement":null},{"id":"W4221127390","doi":"10.1038/s41467-022-29142-6","title":"Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"Ovarian Cancer Academy; National Center for Advancing Translational Sciences; Medical Research Council; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; Mayo Clinic; Center for Individualized Medicine, Mayo Clinic; Henry J. Predolin Foundation for Research in Leukemia","keywords":"Chronic myelomonocytic leukemia; Epigenetics; Mutant; Gene; Regulation of gene expression; Biology; Cancer research; Genetics; Gene expression; Chromatin remodeling; Mutation; Epigenesis; Cell biology; DNA methylation; Myelodysplastic syndromes; Immunology","score_opus":0.026962801719146137,"score_gpt":0.3292543027662127,"score_spread":0.3022915010470666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221127390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95142716,0.045717366,0.000088647954,0.0011843869,0.000062506755,0.00079400284,0.00003752987,0.00003855691,0.00064983044],"genre_scores_gemma":[0.9845495,0.0040052137,0.010656868,0.00019870249,0.000037997048,0.0001641389,0.00017151145,0.000039926806,0.00017610734],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99789685,0.0003521767,0.00057261175,0.00032492733,0.0005296607,0.0003237814],"domain_scores_gemma":[0.9970953,0.0002508808,0.00018385187,0.0022091286,0.00013500027,0.00012582261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083520904,0.00016470625,0.00034517935,0.00039829363,0.0003332694,0.000009664117,0.0008662603,0.0002005905,0.000105232],"category_scores_gemma":[0.00017941764,0.00016788494,0.00008027704,0.0006441858,0.00018062937,0.00006671783,0.0016363403,0.0021451449,0.000005672301],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001849565,0.00019354174,0.0070690387,0.000090536196,0.00006802502,0.000014623869,0.000569189,0.0010644223,0.97972685,0.00035313875,0.00063419883,0.010031472],"study_design_scores_gemma":[0.023227874,0.0021171265,0.15061429,0.0011879159,0.00059573684,0.00077446696,0.0036837196,0.3646351,0.3814707,0.0020553302,0.068086796,0.0015508946],"about_ca_topic_score_codex":0.0000678555,"about_ca_topic_score_gemma":0.00008913601,"teacher_disagreement_score":0.5982561,"about_ca_system_score_codex":0.0033044613,"about_ca_system_score_gemma":0.0015601929,"threshold_uncertainty_score":0.93197066},"labels":[],"label_agreement":null},{"id":"W4223534367","doi":"10.1016/j.jtct.2022.03.029","title":"Systematic Scoping Review of Studies Reporting Unexpected Donor-Derived Abnormalities from Recipients of Allogeneic Hematopoietic Cell Transplantation: A Proposed Framework for Donor Disclosure","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Ottawa Hospital; Canadian Blood Services; University of Ottawa","funders":"Canadian Blood Services","keywords":"Transplantation; Medicine; Hematopoietic stem cell transplantation; Systematic review; Hematopoietic cell; Disease; Immunology; Oncology; Internal medicine; MEDLINE; Haematopoiesis; Stem cell; Biology; Genetics","score_opus":0.056264319239792866,"score_gpt":0.3426213310586016,"score_spread":0.28635701181880874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223534367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8588402,0.12810805,0.008569957,0.0002507125,0.000093584706,0.0039388463,0.00013535193,0.000036726964,0.000026513611],"genre_scores_gemma":[0.85111856,0.14339344,0.004032466,0.00018611939,0.000032462834,0.0005774991,0.00056872686,0.000037853046,0.000052852964],"study_design_codex":"systematic_review","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99677587,0.0003934968,0.0017352843,0.000335241,0.00053506263,0.00022502724],"domain_scores_gemma":[0.99754256,0.0006069459,0.0012276802,0.00029086624,0.00025890468,0.00007305793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001055849,0.00022370092,0.001091086,0.00012770896,0.00019451133,0.00001030204,0.00012737252,0.00007095051,0.00011691869],"category_scores_gemma":[0.00009050214,0.00018258471,0.00021295963,0.00026682447,0.00011123704,0.00007159529,0.000011758554,0.00020160088,6.03522e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022276416,0.00022672053,0.0029377702,0.7490152,0.00079703226,0.0001130776,0.027293952,0.000024542094,0.21698941,0.0002152268,0.0000075397497,0.00015189884],"study_design_scores_gemma":[0.007336144,0.0009441357,0.001227892,0.334231,0.0015172762,0.00018652594,0.010387321,0.00007099002,0.6430749,0.00061517477,0.00000376512,0.00040487875],"about_ca_topic_score_codex":0.000040251613,"about_ca_topic_score_gemma":0.0000049449536,"teacher_disagreement_score":0.4260855,"about_ca_system_score_codex":0.00006659106,"about_ca_system_score_gemma":0.00020840742,"threshold_uncertainty_score":0.7445589},"labels":[],"label_agreement":null},{"id":"W4223619433","doi":"10.1182/bloodadvances.2022006968","title":"Cell origin–dependent cooperativity of mutant <i>Dnmt3a</i> and <i>Npm1</i> in clonal hematopoiesis and myeloid malignancy","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Institute on Aging","keywords":"Biology; Haematopoiesis; RUNX1; Stem cell; Cancer research; Myeloid leukemia; Myeloid; Progenitor cell; Somatic cell; Cell biology; Genetics; Gene","score_opus":0.010065092892087187,"score_gpt":0.2614607939845005,"score_spread":0.2513957010924133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223619433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786146,0.0180943,0.000017167094,0.000742054,0.000058900452,0.000498739,0.00010435823,0.000025093084,0.0018447359],"genre_scores_gemma":[0.99465823,0.0029460578,0.0012298606,0.00035467095,0.000045643814,0.00010617212,0.000014335691,0.000024424258,0.0006206127],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982035,0.00012536366,0.00035658563,0.00043472057,0.0005361261,0.00034369918],"domain_scores_gemma":[0.9992549,0.00018954936,0.000108153195,0.00024106709,0.00006361015,0.00014272887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044778798,0.00019055502,0.000492152,0.00015287913,0.00014066442,0.000015090262,0.00012665406,0.0000450852,0.00014027278],"category_scores_gemma":[0.0000611059,0.00016985009,0.000039519895,0.00036649953,0.00018729137,0.00017369549,0.00032561546,0.00040284198,0.0000021001301],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013982813,0.0023837667,0.3362486,0.0022194376,0.00016371386,0.0019805848,0.0020228685,0.00016003815,0.64266175,0.0019365816,0.0009857594,0.00783863],"study_design_scores_gemma":[0.020727709,0.0028673825,0.024693368,0.0003597951,0.00031687686,0.0026474132,0.0040661027,0.0004415928,0.87955683,0.00096378423,0.062448017,0.0009111026],"about_ca_topic_score_codex":0.0001324248,"about_ca_topic_score_gemma":0.000061465966,"teacher_disagreement_score":0.31155524,"about_ca_system_score_codex":0.00007620016,"about_ca_system_score_gemma":0.00025334238,"threshold_uncertainty_score":0.69262856},"labels":[],"label_agreement":null},{"id":"W4224221548","doi":"10.1038/s41408-022-00668-8","title":"Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; AbbVie","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Cytarabine; Placebo; Myeloid leukemia; Visual analogue scale; Oncology; Physical therapy","score_opus":0.008543927453387928,"score_gpt":0.2656750802293543,"score_spread":0.2571311527759664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224221548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964409,0.00016907515,0.0000613474,0.0021211216,0.00007398422,0.0006757152,0.00005898829,0.000009836278,0.00038903632],"genre_scores_gemma":[0.9973413,0.00006004727,0.0004142402,0.00073802605,0.00009758102,0.00021077966,0.000027678723,0.000031906075,0.0010784537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982289,0.00015524591,0.00034522222,0.00016549088,0.00081298855,0.0002921473],"domain_scores_gemma":[0.99908125,0.00005257369,0.00018212665,0.00023478015,0.00030273723,0.00014651814],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004315206,0.0001208812,0.00023746748,0.0002648617,0.00028420525,0.000029754023,0.0002767347,0.000034851528,0.0010604135],"category_scores_gemma":[0.000038368857,0.00008424003,0.000055365825,0.000732022,0.000054370186,0.00010732469,0.0001327197,0.000741308,0.000017699365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018122662,0.0045925896,0.56601024,0.00023097856,0.005402052,0.0023177594,0.016677856,0.057738382,0.11832852,0.00037198333,0.09399683,0.116210155],"study_design_scores_gemma":[0.060746793,0.016309835,0.8557125,0.0006684293,0.0015707331,0.0029153598,0.0009698566,0.007243062,0.010720068,0.00044900473,0.04173838,0.0009560197],"about_ca_topic_score_codex":0.00018870732,"about_ca_topic_score_gemma":0.00006774978,"teacher_disagreement_score":0.28970224,"about_ca_system_score_codex":0.0023197755,"about_ca_system_score_gemma":0.0026798313,"threshold_uncertainty_score":0.9998528},"labels":[],"label_agreement":null},{"id":"W4224228473","doi":"10.3390/curroncol29050239","title":"Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Nucleophosmin; NPM1; CD8; Leukemia; Stem cell; Medicine; Cancer research; Transplantation; Haematopoiesis; Cytotoxic T cell; Myeloid leukemia; Immunology; Nucleolus; Hematopoietic stem cell transplantation; Biology; Gene; Immune system; Cytoplasm; Genetics; Internal medicine; Karyotype","score_opus":0.03420300619680944,"score_gpt":0.34155159305443705,"score_spread":0.3073485868576276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224228473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955522,0.00085647084,0.00006753475,0.0011765009,0.00053564133,0.0010909548,0.00063716935,0.000022443788,0.00006108288],"genre_scores_gemma":[0.99842995,0.00029488077,0.00009798519,0.00042939486,0.00006312374,0.00031422108,0.00029161162,0.000033530694,0.00004532536],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972701,0.00071337476,0.00066858914,0.00039920842,0.00061079924,0.00033792577],"domain_scores_gemma":[0.99830973,0.00053402974,0.00026747867,0.0005469748,0.00018737001,0.00015441129],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052878464,0.0001945714,0.00052589684,0.00010563409,0.00013429928,0.000012632546,0.00040766873,0.00010093663,0.0011390621],"category_scores_gemma":[0.000018975483,0.0001247513,0.00014016096,0.00032426819,0.00035941537,0.000080095335,0.00014199651,0.0005027538,0.000026571146],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042086117,0.012478221,0.014200009,0.0013296758,0.001022868,0.00050517934,0.1642658,0.000089391506,0.3537368,0.00004246319,0.03730858,0.37293488],"study_design_scores_gemma":[0.03310509,0.01707213,0.017098775,0.00038714428,0.0024332579,0.0006961218,0.041086826,0.03204615,0.8214751,0.0006602008,0.033043843,0.0008953848],"about_ca_topic_score_codex":0.00034911302,"about_ca_topic_score_gemma":0.00004107827,"teacher_disagreement_score":0.46773827,"about_ca_system_score_codex":0.0005447845,"about_ca_system_score_gemma":0.00054535875,"threshold_uncertainty_score":0.99977404},"labels":[],"label_agreement":null},{"id":"W4224264729","doi":"10.3324/haematol.2021.280203","title":"The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Chronic myelomonocytic leukemia; Transplantation; KRAS; Hematopoietic stem cell transplantation; Neuroblastoma RAS viral oncogene homolog; International Prognostic Scoring System; Oncology; Hematopoietic cell; Multivariate analysis; Gastroenterology; Bone marrow; Haematopoiesis; Myelodysplastic syndromes; Cancer; Stem cell; Biology; Genetics","score_opus":0.037409176900426035,"score_gpt":0.3581258702767788,"score_spread":0.3207166933763527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224264729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99525785,0.0013880389,0.000083517094,0.0012721185,0.00002052016,0.0014886085,0.00021920713,0.000029284472,0.00024085719],"genre_scores_gemma":[0.99633163,0.001902663,0.00011300716,0.00012099193,0.000019088886,0.0007745283,0.0005297419,0.000024641631,0.00018372029],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973324,0.00049045525,0.00041905852,0.00052324723,0.0006524702,0.0005823467],"domain_scores_gemma":[0.99767494,0.0017463871,0.0000919878,0.00023388224,0.0001045994,0.00014819398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014547444,0.00022480827,0.0005092402,0.0006460845,0.00059913716,0.0000586667,0.00018047502,0.00010933237,0.00015394046],"category_scores_gemma":[0.000083881525,0.00014547752,0.00016722432,0.0008425552,0.00011770392,0.00006964294,0.000047637397,0.00057110377,0.000006825248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021314979,0.0013166692,0.9033197,0.0061315177,0.003764553,0.0063208733,0.011667858,0.012026898,0.02514261,0.0046687345,0.0010460614,0.00327956],"study_design_scores_gemma":[0.020139173,0.004063719,0.9280553,0.00013804792,0.0018617796,0.0039745714,0.0019142675,0.032165516,0.0059867874,0.0010135153,0.00014525914,0.0005421042],"about_ca_topic_score_codex":0.000052927575,"about_ca_topic_score_gemma":0.00016251807,"teacher_disagreement_score":0.024735574,"about_ca_system_score_codex":0.0006757807,"about_ca_system_score_gemma":0.0005135308,"threshold_uncertainty_score":0.59324014},"labels":[],"label_agreement":null},{"id":"W4224287859","doi":"10.14740/jh983","title":"A Case of Isolated Myeloid Sarcoma Associated With Germline <i>EGFR</i> T790M Variant: The Importance of Recognizing Potential Germline Variants on Somatic Tumor Sequencing Panels","year":2022,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Germline; Medicine; Germline mutation; Myeloid sarcoma; Myeloid leukemia; Sarcoma; Somatic cell; Cancer; Myeloid; T790M; Mutation; Genetics; Cancer research; Biology; Internal medicine; Pathology; Adenocarcinoma; Gene","score_opus":0.026990661520751337,"score_gpt":0.28117039540763195,"score_spread":0.2541797338868806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224287859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952017,0.00043669657,0.00071234175,0.0027148568,0.00019910178,0.00051425153,0.00007425804,0.000019915824,0.00012689614],"genre_scores_gemma":[0.9979062,0.000034290773,0.0010482975,0.0007401623,0.00009812615,0.000013629037,0.00001920146,0.00006127408,0.00007879118],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99564034,0.00076612097,0.0018765216,0.0002890231,0.00087136286,0.000556629],"domain_scores_gemma":[0.9947158,0.0009838943,0.0027471397,0.0005066217,0.0008583872,0.00018815773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025851177,0.00028511733,0.0014657041,0.00049108505,0.00026357,0.000012182293,0.00042117568,0.00012614105,0.00050683797],"category_scores_gemma":[0.0014573862,0.00018815136,0.00027030357,0.0009048811,0.00024420742,0.00012524541,0.00019796751,0.0015992948,0.0000031656348],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0155556565,0.0031224533,0.015727125,0.0013353361,0.005756625,0.64457583,0.0051409383,0.0028155972,0.30145293,0.001025127,0.0021233587,0.0013689953],"study_design_scores_gemma":[0.012521036,0.006981968,0.002997429,0.0011042135,0.0011425214,0.9300906,0.0033991404,0.024615718,0.015632361,0.0011245325,0.000041073497,0.000349425],"about_ca_topic_score_codex":0.00009034705,"about_ca_topic_score_gemma":0.000024606405,"teacher_disagreement_score":0.28582057,"about_ca_system_score_codex":0.0005714984,"about_ca_system_score_gemma":0.0017735902,"threshold_uncertainty_score":0.76725894},"labels":[],"label_agreement":null},{"id":"W4224290890","doi":"10.1056/nejmoa2117344","title":"Ivosidenib and Azacitidine in <i>IDH1</i> -Mutated Acute Myeloid Leukemia","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":483,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Servier; Agios Pharmaceuticals","keywords":"Azacitidine; Medicine; Placebo; Myeloid leukemia; Internal medicine; Hazard ratio; Clinical endpoint; Population; Oncology; Randomized controlled trial; Surgery; Confidence interval","score_opus":0.017129717592506612,"score_gpt":0.28878053976043794,"score_spread":0.27165082216793135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224290890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624831,0.0035908022,0.00012339112,0.03107581,0.0004071503,0.00029948764,0.000008324728,0.000021491134,0.0019904608],"genre_scores_gemma":[0.99019957,0.002223413,0.0006553273,0.0026018831,0.0022152432,0.000007025968,0.000025116173,0.000043962722,0.002028474],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99700665,0.00025912916,0.0008766862,0.0002491019,0.0011666826,0.00044176885],"domain_scores_gemma":[0.9982356,0.00038117685,0.00031793013,0.00024223348,0.0001981022,0.00062496145],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022736855,0.00023245774,0.0008699419,0.0008175488,0.000117000185,0.00001225506,0.0002507197,0.00007291503,0.0009704539],"category_scores_gemma":[0.00053272536,0.00016904822,0.00007808851,0.0007837273,0.0001956784,0.00014363589,0.00017011692,0.0018110434,0.0000048627007],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020933283,0.00029408582,0.051724613,0.00024285923,0.001089821,0.042589057,0.008974263,0.00047557993,0.35565916,0.00042949614,0.2180544,0.2995334],"study_design_scores_gemma":[0.4215765,0.01686169,0.040734574,0.001085626,0.0011494657,0.12420353,0.0037531534,0.001774708,0.0079949945,0.002610224,0.3776016,0.0006539106],"about_ca_topic_score_codex":0.0004398336,"about_ca_topic_score_gemma":0.000042674907,"teacher_disagreement_score":0.40064323,"about_ca_system_score_codex":0.0009243836,"about_ca_system_score_gemma":0.0012854661,"threshold_uncertainty_score":0.9999428},"labels":[],"label_agreement":null},{"id":"W4225147602","doi":"10.1681/asn.2022030262","title":"Clonal Hematopoiesis and CKD Progression","year":2022,"lang":"en","type":"letter","venue":"Journal of the American Society of Nephrology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Knut och Alice Wallenbergs Stiftelse; Edward P. Evans Foundation; American Society of Hematology; American Cancer Society","keywords":"Proinflammatory cytokine; Medicine; Disease; Immunology; Inflammation; Kidney disease; Myeloid; Population; Internal medicine","score_opus":0.0201984353470507,"score_gpt":0.3184118891590267,"score_spread":0.298213453811976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225147602","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21965785,0.0009053625,0.000015870442,0.77897996,0.00011639423,0.00021677096,0.00001710873,0.0000067861383,0.00008387719],"genre_scores_gemma":[0.0047573964,0.0015593044,0.0067771953,0.9826425,0.003095331,0.00001132299,0.000011519068,0.000067195244,0.0010782882],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99726516,0.00041583434,0.00063374446,0.00022246243,0.0010630004,0.0003998218],"domain_scores_gemma":[0.996573,0.00048703077,0.0021436806,0.00042869532,0.00027159584,0.00009602887],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00070909923,0.0002379569,0.001262268,0.00012077777,0.00014600785,0.000009349239,0.0005806735,0.0002820985,0.00028918285],"category_scores_gemma":[0.00009400256,0.00014767883,0.0009504005,0.00039165965,0.0021371252,0.000041562256,0.0005894914,0.004586553,0.0000015608828],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005275473,0.000051546678,0.0008380651,0.000218649,0.00087433367,0.00021595121,0.00031764514,0.0000010239099,0.010108104,0.0000018119744,0.98482364,0.0020216648],"study_design_scores_gemma":[0.0010271057,0.0021178024,0.006518948,0.000102864884,0.00040630574,0.006726564,0.00050835725,0.000045413748,0.00016563202,0.00011403808,0.9821481,0.000118876495],"about_ca_topic_score_codex":0.000041115192,"about_ca_topic_score_gemma":3.5833696e-7,"teacher_disagreement_score":0.21490046,"about_ca_system_score_codex":0.00037039837,"about_ca_system_score_gemma":0.0008536836,"threshold_uncertainty_score":0.99770993},"labels":[],"label_agreement":null},{"id":"W4225252886","doi":"10.1080/10428194.2022.2057484","title":"A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Atezolizumab; Medicine; Internal medicine; Cohort; Myeloid leukemia; Adverse effect; Myeloid; Gastroenterology; Phases of clinical research; Oncology; Clinical trial; Cancer","score_opus":0.018746075209494596,"score_gpt":0.29706529832496653,"score_spread":0.2783192231154719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225252886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910254,0.0016107665,0.00017093147,0.00032418937,0.00018901301,0.0058604213,0.00029304714,0.000096583906,0.00042964623],"genre_scores_gemma":[0.99343187,0.0011522281,0.00048889185,0.00020140539,0.00013419158,0.0027434055,0.00029236774,0.00016896956,0.0013866544],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99436706,0.000355354,0.0015148327,0.001182913,0.0014957055,0.0010841237],"domain_scores_gemma":[0.9960103,0.0010439868,0.0007273065,0.001462261,0.00041716476,0.00033900424],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008367776,0.0008249847,0.001766989,0.00090533955,0.00063343614,0.00005327263,0.0006957029,0.00024985272,0.00008577967],"category_scores_gemma":[0.00008297451,0.00059339224,0.00035264296,0.0018737207,0.00055698765,0.00025027926,0.00031377378,0.00025023636,0.000004218473],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.09489241,0.04878114,0.024436185,0.0010452193,0.0070875217,0.0022921762,0.04091418,0.0019378038,0.02516144,0.0018764647,0.0030171848,0.7485583],"study_design_scores_gemma":[0.6533553,0.10972285,0.08919622,0.00028969548,0.0037003348,0.002575301,0.026065307,0.06674821,0.023259092,0.00033892883,0.023287319,0.0014614721],"about_ca_topic_score_codex":0.0061202752,"about_ca_topic_score_gemma":0.000341402,"teacher_disagreement_score":0.7470968,"about_ca_system_score_codex":0.025475256,"about_ca_system_score_gemma":0.007379149,"threshold_uncertainty_score":0.99965173},"labels":[],"label_agreement":null},{"id":"W4225299329","doi":"10.1016/j.clml.2022.04.023","title":"Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myelodysplastic syndromes; International Prognostic Scoring System; Duration (music); Family medicine; Demography; Internal medicine","score_opus":0.12889227360627842,"score_gpt":0.38700451483447024,"score_spread":0.2581122412281918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225299329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964734,0.00072338665,0.000047183115,0.00028401846,0.00029544014,0.001334292,0.00022869755,0.000051080126,0.0005625317],"genre_scores_gemma":[0.9948604,0.00026322124,0.003716023,0.0002409776,0.0001162861,0.0003932204,0.00020890715,0.00005179088,0.00014914628],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99586153,0.00038506993,0.0016534255,0.0007797004,0.0007449117,0.00057535816],"domain_scores_gemma":[0.99588174,0.0026042324,0.0005252234,0.00047306743,0.00018394303,0.00033179024],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015351927,0.00030070098,0.0009303559,0.00033468998,0.00022735374,0.000032578635,0.00027311002,0.0002284152,0.000121354446],"category_scores_gemma":[0.0027062604,0.00028766788,0.00022584388,0.0005974436,0.0002816905,0.00014369338,0.0004643319,0.00047106575,0.00000744285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024119692,0.0004127898,0.28939274,0.00029968095,0.00015788888,0.00013167963,0.00031562563,0.00016701233,0.00026018036,0.0005184391,0.00052176806,0.70541024],"study_design_scores_gemma":[0.00543732,0.004683322,0.97955143,0.00018491953,0.000117503114,0.0001985239,0.0006939173,0.0061088786,0.00047396103,0.00077460275,0.0015055877,0.00027002403],"about_ca_topic_score_codex":0.00022224849,"about_ca_topic_score_gemma":0.000041570773,"teacher_disagreement_score":0.70514023,"about_ca_system_score_codex":0.0013290482,"about_ca_system_score_gemma":0.0022345912,"threshold_uncertainty_score":0.99995756},"labels":[],"label_agreement":null},{"id":"W4225302747","doi":"10.21203/rs.3.rs-1260415/v1","title":"Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Azacitidine; Chronic myelomonocytic leukemia; Myeloid leukemia; Myelodysplastic syndromes; Medicine; Leukemia; Oncology; Cancer research; Internal medicine; Biology; Genetics; Bone marrow; Gene; DNA methylation","score_opus":0.053270810492487046,"score_gpt":0.38521817132322456,"score_spread":0.3319473608307375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225302747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98525184,0.0021436275,0.000090175556,0.00072561175,0.00012582113,0.010839136,0.0004448644,0.0001299228,0.00024900664],"genre_scores_gemma":[0.9832544,0.006311427,0.000605428,0.00006948001,0.00010387807,0.0042029177,0.0016415657,0.00038040185,0.0034305106],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9873761,0.0012574063,0.0015987181,0.0021956316,0.0052852877,0.0022868593],"domain_scores_gemma":[0.99216086,0.0023160288,0.0006037797,0.00218721,0.00214784,0.00058427063],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0030674902,0.0011969478,0.0028992807,0.0047625527,0.00034968695,0.00011469617,0.0013755553,0.0007366711,0.00085466634],"category_scores_gemma":[0.0014618695,0.0008227273,0.00022590448,0.0051845433,0.0012988746,0.00045257795,0.0022762043,0.007550198,0.000042043088],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.4905859,0.012913476,0.30728707,0.045503322,0.011203044,0.0579911,0.007970509,0.014869958,0.0014177525,0.000277505,0.004461429,0.045518927],"study_design_scores_gemma":[0.2511573,0.20261979,0.4442251,0.048558176,0.0011817146,0.0008984557,0.008849401,0.03328187,0.0026873103,0.0010288794,0.001638138,0.0038738528],"about_ca_topic_score_codex":0.0027340369,"about_ca_topic_score_gemma":0.006610601,"teacher_disagreement_score":0.2394286,"about_ca_system_score_codex":0.043210216,"about_ca_system_score_gemma":0.030773558,"threshold_uncertainty_score":0.9994224},"labels":[],"label_agreement":null},{"id":"W4225642264","doi":"10.1007/s40291-022-00581-7","title":"Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies","year":2022,"lang":"en","type":"article","venue":"Molecular Diagnosis & Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Myeloid leukemia; Medicine; Fusion gene; Concordance; Oncology; Myeloproliferative neoplasm; Malignancy; Myeloid; Internal medicine; NPM1; Bioinformatics; Gene; Biology; Genetics; Bone marrow; Karyotype; Myelofibrosis","score_opus":0.03251463558139368,"score_gpt":0.3193486644763763,"score_spread":0.2868340288949826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225642264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99457043,0.00072380045,0.0006246409,0.0013494146,0.000042380914,0.002329861,0.00027293252,0.000051779658,0.000034778568],"genre_scores_gemma":[0.99433315,0.0003068451,0.0026910035,0.0012147097,0.00004624694,0.00092533673,0.0003914233,0.00006571571,0.000025565527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974303,0.00024037434,0.00059453107,0.0005456307,0.00069837924,0.0004907373],"domain_scores_gemma":[0.997809,0.0008638399,0.00025500965,0.00050029886,0.0004073926,0.00016445699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010294167,0.0002397941,0.0005591489,0.00015500805,0.00025257887,0.00001955258,0.0001990612,0.00007603398,0.0003730212],"category_scores_gemma":[0.000506335,0.00019610411,0.00018534329,0.00036321091,0.0001772156,0.000041771393,0.00017954357,0.00031060868,7.7115544e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002558569,0.0023651738,0.91167814,0.00009236473,0.00020719053,0.00003939451,0.00019097218,0.0000042033294,0.03883638,0.000013414515,0.0016511496,0.042363066],"study_design_scores_gemma":[0.023204822,0.007917921,0.88154453,0.0000988574,0.00015287103,0.0000037340833,0.00024593365,0.0020489178,0.069801174,0.000056014127,0.0146172205,0.0003080014],"about_ca_topic_score_codex":0.00012621647,"about_ca_topic_score_gemma":0.000017312028,"teacher_disagreement_score":0.042055063,"about_ca_system_score_codex":0.0001223564,"about_ca_system_score_gemma":0.00030286383,"threshold_uncertainty_score":0.79968935},"labels":[],"label_agreement":null},{"id":"W4225696246","doi":"10.3389/fmed.2022.801632","title":"Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis","year":2022,"lang":"en","type":"review","venue":"Frontiers in Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Vancouver General Hospital","funders":"","keywords":"Medicine; Decitabine; Internal medicine; Myeloid leukemia; Meta-analysis; Cumulative incidence; Myelodysplastic syndromes; Transplantation; Oncology; Hematopoietic stem cell transplantation; Incidence (geometry); Bone marrow","score_opus":0.04126380536778976,"score_gpt":0.3106706544545345,"score_spread":0.2694068490867447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225696246","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023743688,0.9916666,0.0009927119,0.00024013619,0.00007840213,0.0065305145,0.00012939276,0.000030686264,0.00009412562],"genre_scores_gemma":[0.00032140777,0.99051875,0.0024338022,0.0006367232,0.000018980936,0.0034804353,0.00037908164,0.00013169507,0.0020790964],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99301565,0.001389137,0.002264044,0.0013287213,0.0012145742,0.0007878833],"domain_scores_gemma":[0.99704957,0.00071940536,0.0009010708,0.0008828208,0.000078660516,0.00036844666],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.003123835,0.0010112101,0.015014016,0.0027020944,0.00008395136,0.000025726313,0.00039030393,0.00032251098,0.0003236231],"category_scores_gemma":[0.00018834446,0.0006165186,0.0006208626,0.0040653255,0.00033402216,0.00013663882,0.00014103802,0.0017320751,0.0000041477006],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000129309,0.00003322477,0.0002447654,0.92736715,0.059550967,0.007469316,0.00052278314,0.000006535654,2.9560707e-7,9.3210053e-7,0.00041610003,0.004258625],"study_design_scores_gemma":[0.0019426813,0.0004960336,0.0002288929,0.10895562,0.8795144,0.0028452517,0.0004003722,0.00016575941,1.5411011e-7,0.0000041247654,0.0048682746,0.00057846226],"about_ca_topic_score_codex":0.00009758677,"about_ca_topic_score_gemma":0.00004583014,"teacher_disagreement_score":0.8199634,"about_ca_system_score_codex":0.0018896635,"about_ca_system_score_gemma":0.0005704977,"threshold_uncertainty_score":0.9996286},"labels":[],"label_agreement":null},{"id":"W4226051064","doi":"10.1182/blood-2021-147088","title":"Maintenance with Hypomethylating Agents after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Meta-Analysis","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Oncology; Transplantation; Hematopoietic stem cell transplantation; Decitabine; Myelodysplastic syndromes; Odds ratio; Leukemia; Acute leukemia; Randomized controlled trial; Bone marrow; DNA methylation","score_opus":0.023290163144045077,"score_gpt":0.25775297802973546,"score_spread":0.23446281488569037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226051064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993377,0.0039493227,0.001266688,0.0001443858,0.000015757856,0.0009011173,0.000059989674,0.00004132217,0.00024443486],"genre_scores_gemma":[0.99271125,0.00044778973,0.003816977,0.00019657094,0.000012217835,0.00043515724,0.00006470628,0.0000539569,0.002261368],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99692225,0.0003708438,0.0006978477,0.00072779873,0.0007133119,0.0005679583],"domain_scores_gemma":[0.9984145,0.0003911091,0.00019293018,0.00056049856,0.00019484582,0.0002460926],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061903737,0.00036109483,0.0017373846,0.0005648988,0.00006744113,0.00007346788,0.00013576979,0.00015352156,0.00013302348],"category_scores_gemma":[0.00004825341,0.00025763793,0.00038164406,0.0018561892,0.00007589557,0.00015046049,0.00006296973,0.00041455313,0.000028961094],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020441127,0.0016132608,0.1495839,0.0937682,0.5030401,0.17700762,0.008130617,0.0020183516,0.062479723,0.00005503843,0.000041264553,0.00021784772],"study_design_scores_gemma":[0.0125738075,0.0006714902,0.18884447,0.0017605552,0.75846934,0.0108804405,0.0012891394,0.0029741542,0.021697115,0.000017738148,0.000006201334,0.0008155488],"about_ca_topic_score_codex":0.000056133424,"about_ca_topic_score_gemma":0.00019670962,"teacher_disagreement_score":0.25542927,"about_ca_system_score_codex":0.00027268194,"about_ca_system_score_gemma":0.00042407605,"threshold_uncertainty_score":0.9999876},"labels":[],"label_agreement":null},{"id":"W4226165789","doi":"10.1002/cyto.b.22067","title":"Erythroid side scatter: A parameter that improves diagnostic accuracy of flow cytometry myelodysplastic syndrome scoring","year":2022,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"European Hematology Association","keywords":"Flow cytometry; Diagnostic accuracy; Medicine; Internal medicine; Immunology","score_opus":0.06708612368517296,"score_gpt":0.3668468279981154,"score_spread":0.29976070431294244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226165789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98674953,0.0023133045,0.0026428644,0.0013231095,0.0028049068,0.0022673353,0.00051040464,0.00047607315,0.0009124961],"genre_scores_gemma":[0.9874677,0.00092099136,0.0057129967,0.002426153,0.0009903874,0.00050425116,0.00032964404,0.00034481857,0.0013030547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98613477,0.0013531336,0.0036973215,0.0025189607,0.0038491383,0.0024466766],"domain_scores_gemma":[0.9487818,0.043873686,0.0015349322,0.0034037714,0.0005644285,0.001841396],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0063475594,0.001168134,0.0034668313,0.004735822,0.0007354854,0.00017609753,0.0019922445,0.0007227584,0.0033341763],"category_scores_gemma":[0.056562904,0.0011253422,0.0016973235,0.010611113,0.0014776958,0.0006956881,0.0033928107,0.0051897396,0.00090611784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002773514,0.003870716,0.9226947,0.0018863634,0.0022868977,0.005022294,0.00017586065,0.0001573924,0.012262418,0.000041313113,0.01259536,0.036233187],"study_design_scores_gemma":[0.01382545,0.009001813,0.93691784,0.0010362597,0.0016099229,0.0057680695,0.0011998712,0.003800186,0.009954014,0.00034820035,0.014329404,0.0022089763],"about_ca_topic_score_codex":0.000060617094,"about_ca_topic_score_gemma":0.000003392131,"teacher_disagreement_score":0.050215345,"about_ca_system_score_codex":0.0013951326,"about_ca_system_score_gemma":0.001749309,"threshold_uncertainty_score":0.9998718},"labels":[],"label_agreement":null},{"id":"W4226227402","doi":"10.1182/blood-2021-152740","title":"Modulating Endothelial Cells with EGFL7 to Diminish aGVHD after Allogeneic Bone Marrow Transplantation in Mice","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Immunology; Bone marrow; Transplantation; Leukemia; Inflammation; Haematopoiesis; Stem cell; Cancer research; Internal medicine; Biology","score_opus":0.010692134018533802,"score_gpt":0.2489640674452903,"score_spread":0.23827193342675648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226227402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968637,0.00018246695,0.00027657195,0.0008128001,0.000045755216,0.0004010532,0.00005369761,0.000032754284,0.0013311668],"genre_scores_gemma":[0.98381233,0.000083922976,0.013646816,0.00076413015,0.00017720058,0.00009240568,0.000051662482,0.00004242004,0.0013290807],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99857223,0.00007486025,0.00023977975,0.00037502893,0.00036196486,0.00037612743],"domain_scores_gemma":[0.99938905,0.00007872809,0.000031180887,0.00023695733,0.00009427084,0.00016978139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015568166,0.00014916014,0.0002567236,0.00013550268,0.000030036523,0.000024525714,0.000070247195,0.000089327725,0.00015002288],"category_scores_gemma":[0.00004381683,0.00013315449,0.000048490834,0.00035853984,0.000027528575,0.00006173288,0.00003233104,0.0002465116,0.000067498986],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007785706,0.0003288657,0.016318083,0.0002017588,0.000062912026,0.0059288535,0.0012646136,0.000096488126,0.9735461,0.0000054869242,0.00007649499,0.0013917945],"study_design_scores_gemma":[0.008559657,0.00033686415,0.052368887,0.000317299,0.00020012337,0.0010036399,0.00022069717,0.00013878975,0.9360473,0.000010459745,0.0005684336,0.00022781872],"about_ca_topic_score_codex":0.0001002003,"about_ca_topic_score_gemma":0.00047993823,"teacher_disagreement_score":0.037498746,"about_ca_system_score_codex":0.000080863654,"about_ca_system_score_gemma":0.00023064672,"threshold_uncertainty_score":0.54298824},"labels":[],"label_agreement":null},{"id":"W4229013347","doi":"10.1182/blood.2021014956","title":"Lenalidomide promotes the development of <i>TP53</i>-mutated therapy-related myeloid neoplasms","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Heart, Lung, and Blood Institute; National Institutes of Health; Andrew Sabin Family Foundation; Edward P. Evans Foundation; Howard Hughes Medical Institute; Cancer Prevention and Research Institute of Texas; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Welch Foundation; University of Texas System; Leukemia and Lymphoma Society","keywords":"Lenalidomide; Progenitor cell; Haematopoiesis; Thalidomide; Myeloid; Cancer research; Biology; Pomalidomide; Stem cell; Immunology; Multiple myeloma; Genetics","score_opus":0.02093353391674051,"score_gpt":0.2662075918491015,"score_spread":0.24527405793236096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229013347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99304444,0.0007949395,0.000017164755,0.0017747186,0.00007927256,0.0010409087,0.000012905881,0.00009790375,0.0031377485],"genre_scores_gemma":[0.99571395,0.00005215208,0.0015318264,0.0003039268,0.000042788703,0.00024090413,0.00007577169,0.00005072553,0.0019879588],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997721,0.00021983951,0.0005406745,0.00030568973,0.0007993096,0.00041344762],"domain_scores_gemma":[0.9989082,0.00020419034,0.00016168492,0.00047612604,0.00013950499,0.0001102543],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001016092,0.00019062925,0.00033973853,0.00014875853,0.00038294977,0.000014422465,0.00038745446,0.00006453268,0.0009446484],"category_scores_gemma":[0.0001221422,0.00012591349,0.00011509078,0.0007549677,0.0001323511,0.000040661682,0.00030196825,0.00065220444,0.00004896167],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018298982,0.003930989,0.015648084,0.00018138418,0.0028753255,0.00036119312,0.02317215,0.00009985591,0.9092743,0.0003121431,0.00410565,0.038209025],"study_design_scores_gemma":[0.018617954,0.0010244397,0.013272021,0.00006845811,0.0002152543,0.00070979027,0.0021069024,0.00028421296,0.9284759,0.00022402842,0.034661468,0.00033952866],"about_ca_topic_score_codex":0.000043925633,"about_ca_topic_score_gemma":0.000008722117,"teacher_disagreement_score":0.037869498,"about_ca_system_score_codex":0.0001479423,"about_ca_system_score_gemma":0.0012848423,"threshold_uncertainty_score":0.99996865},"labels":[],"label_agreement":null},{"id":"W4229018428","doi":"10.1182/blood.2022015832","title":"Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta Hospital; Alberta Hospital Edmonton","funders":"National Cancer Institute; National Institutes of Health; Astex Pharmaceuticals; National Center for Advancing Translational Sciences; Leukemia and Lymphoma Society","keywords":"Azacitidine; Decitabine; Medicine; Chemotherapy regimen; Chemotherapy; Oncology; Internal medicine; Intensive care medicine; Chemistry; DNA methylation","score_opus":0.012528109539386288,"score_gpt":0.2889779682851103,"score_spread":0.27644985874572403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229018428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99729604,0.00007603595,0.00006721454,0.0006205594,0.000009484296,0.0017148061,0.000046833386,0.000016529464,0.00015251672],"genre_scores_gemma":[0.9968968,0.000004514302,0.0023519658,0.00026052428,0.000012102698,0.00025326412,0.000052368065,0.000031862197,0.0001366122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896795,0.000020542511,0.00020530341,0.00024660953,0.0003418394,0.0002177742],"domain_scores_gemma":[0.9991414,0.00009954741,0.00009317982,0.00018173279,0.0004207515,0.000063371655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114361974,0.00013150233,0.00047978846,0.00018332437,0.000052377207,0.0000053301173,0.00007091217,0.000026117157,0.000025760424],"category_scores_gemma":[0.00007947296,0.00008932617,0.000025342977,0.00033641604,0.00009757818,0.00004320054,0.000065701446,0.00021931139,3.3722978e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042753797,0.0012052143,0.9918952,0.00007020098,0.00021354051,0.0000073306505,0.0013020954,0.000007675117,0.00035615443,0.000053150423,0.00020804524,0.0004060133],"study_design_scores_gemma":[0.046958856,0.0062926165,0.9357398,0.000050177645,0.00008854871,0.000011447045,0.0017085982,0.00011836963,0.008739203,0.000045335706,0.00012952012,0.00011748392],"about_ca_topic_score_codex":0.000072398965,"about_ca_topic_score_gemma":0.000033630437,"teacher_disagreement_score":0.056155358,"about_ca_system_score_codex":0.00011697918,"about_ca_system_score_gemma":0.00012957769,"threshold_uncertainty_score":0.36426154},"labels":[],"label_agreement":null},{"id":"W4230678902","doi":"10.1182/blood.v108.11.1998.1998","title":"Long Term Follow-Up of a Randomized Trial Comparing Response Adapted (RA), Non-Cross Resistant Induction and Consolidation with Idarubicin/Cytarabine (IDAC) Followed by Mitoxantone/Etoposide (NOVE) Compared with Consolidation with High Dose Cytarabine (HDAC) in Adult Patients with AML. A Study by the Canadian Leukemia Studies Group (CLSG).","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Quebec - Clinical Research Organization in Cancer; University of Saskatchewan; Saskatchewan Hospital; Dalhousie University; Ottawa Hospital","funders":"","keywords":"Idarubicin; Etoposide; Cytarabine; Internal medicine; Mitoxantrone; Medicine; Bilirubin; Gastroenterology; Chemotherapy","score_opus":0.013677306426728292,"score_gpt":0.26572269535538634,"score_spread":0.252045388928658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230678902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98718596,0.00026382276,0.00007286202,0.00038665722,0.00006329535,0.011768194,0.00014398117,0.000063876054,0.000051349973],"genre_scores_gemma":[0.9972651,0.000028442915,0.00045217975,0.00007189604,0.00006982464,0.0008930827,0.00092282443,0.00010929785,0.0001873232],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943597,0.00096716965,0.0013697151,0.0009947742,0.0014583851,0.00085030287],"domain_scores_gemma":[0.99576133,0.00086086465,0.0009203751,0.0007667903,0.001381212,0.00030940794],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019523085,0.0007337281,0.0022721335,0.0006536162,0.0005269803,0.00017240671,0.00026968264,0.00020141157,0.0000069927546],"category_scores_gemma":[0.00043750723,0.00043249677,0.00008514794,0.0012312846,0.0012367041,0.00040498146,0.000079170626,0.0007498616,0.0000012323578],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71030456,0.0014554862,0.27567548,0.000106556596,0.0015104269,0.0001579438,0.0016899179,0.00008052552,0.008733126,0.000010466625,0.00024552,0.00003001153],"study_design_scores_gemma":[0.6786518,0.0068009594,0.30352992,0.000777532,0.0014746948,0.00006215241,0.0015586109,0.00019320576,0.00650591,0.0000029227303,0.0000062433187,0.00043603114],"about_ca_topic_score_codex":0.14544359,"about_ca_topic_score_gemma":0.5006497,"teacher_disagreement_score":0.35520607,"about_ca_system_score_codex":0.0015336457,"about_ca_system_score_gemma":0.0017606053,"threshold_uncertainty_score":0.99981266},"labels":[],"label_agreement":null},{"id":"W4231637248","doi":"10.1016/j.clml.2019.07.097","title":"Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) – Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Myeloid leukemia; Refractory (planetary science); Medicine; Tandem exon duplication; Fms-Like Tyrosine Kinase 3; Oncology; Internal medicine; Pharmacology; Cancer research; Gene duplication; Mutation; Chemistry; Gene; Biology","score_opus":0.016329411479683698,"score_gpt":0.3141284784032331,"score_spread":0.2977990669235494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231637248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812443,0.0005531831,0.00012898036,0.00065598014,0.00045350342,0.016015198,0.00007097684,0.00010852527,0.00076932565],"genre_scores_gemma":[0.9969093,0.0007340228,0.00027622242,0.0005459342,0.0003317424,0.0006848529,0.00022635379,0.00011704364,0.00017449868],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9867841,0.0035285817,0.0048819087,0.0018248903,0.0017504187,0.0012301097],"domain_scores_gemma":[0.987978,0.0073214187,0.0020054865,0.0012324057,0.0007787295,0.0006839644],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0071315663,0.0010475201,0.0053928792,0.00054762786,0.00019255438,0.00014141078,0.00066840084,0.0009563432,0.000064985055],"category_scores_gemma":[0.0061519872,0.0006830603,0.000779445,0.0013357644,0.0013383995,0.00039667106,0.00036055315,0.0013729882,0.00006255504],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91921467,0.0035801847,0.031647872,0.000105868,0.0014557767,0.00026632653,0.00081798644,0.000033385677,0.0014916067,0.00016830389,0.00027201828,0.040946014],"study_design_scores_gemma":[0.7423394,0.00866122,0.23990525,0.0006470094,0.0008387561,0.00012361785,0.0002451484,0.0060465373,0.000323622,0.000116154224,0.00022270097,0.00053063064],"about_ca_topic_score_codex":0.00048043352,"about_ca_topic_score_gemma":0.00008052895,"teacher_disagreement_score":0.20825738,"about_ca_system_score_codex":0.006158844,"about_ca_system_score_gemma":0.0036908872,"threshold_uncertainty_score":0.9995621},"labels":[],"label_agreement":null},{"id":"W4233923074","doi":"10.1503/cmaj.151077","title":"Myelodysplastic syndrome","year":2016,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Celgene","keywords":"Computer science; Myelodysplastic syndromes; Medicine; World Wide Web; Data science; Pathology; Bone marrow","score_opus":0.008623457781390167,"score_gpt":0.25319044387886747,"score_spread":0.2445669860974773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233923074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6864868,0.00014750165,0.0006518714,0.29662567,0.0010716793,0.00019577086,0.00002964503,0.000051013212,0.014740047],"genre_scores_gemma":[0.975676,0.00018727948,0.00016511195,0.010517312,0.0014670447,0.0000061449123,0.000003284065,0.000026628984,0.011951173],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968897,0.00011776665,0.00033969787,0.00015232949,0.001799284,0.0007011977],"domain_scores_gemma":[0.99526924,0.0003790936,0.000101661484,0.00012717776,0.00045058908,0.003672251],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015568192,0.00010557553,0.000236752,0.00030728313,0.0001767857,0.0000410285,0.0001899574,0.0003862096,0.019664595],"category_scores_gemma":[0.0069298088,0.00006692782,0.00010115034,0.00025598737,0.000059745336,0.00011723015,0.000018541086,0.0008725735,0.0028585452],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000048356873,0.000057265905,0.16377513,0.000018282844,0.00036969947,0.017790988,0.000086456326,2.2904473e-7,0.00036954955,0.0006190636,0.68053424,0.13633072],"study_design_scores_gemma":[0.0037837755,0.0002982149,0.19480519,0.0003298978,0.0000480424,0.02207564,0.00007390687,0.000066940556,0.000049951628,0.00028316522,0.7780073,0.00017796212],"about_ca_topic_score_codex":0.00055760774,"about_ca_topic_score_gemma":0.0030870356,"teacher_disagreement_score":0.28918922,"about_ca_system_score_codex":0.0045258463,"about_ca_system_score_gemma":0.009122895,"threshold_uncertainty_score":0.9992956},"labels":[],"label_agreement":null},{"id":"W4234878604","doi":"10.1002/0471463736.tnmp44","title":"Leukemia","year":2003,"lang":"en","type":"other","venue":"TNM Online","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Bone marrow; Leukemia; Acute leukemia; Medicine; Myeloid leukemia; Immunology; Biology; Cancer research","score_opus":0.025311871848468295,"score_gpt":0.32856726526856106,"score_spread":0.3032553934200928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234878604","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008842008,0.0014671282,0.000041205552,0.00071245653,0.00022045156,0.00053614896,0.0014614632,0.00039172446,0.995081],"genre_scores_gemma":[0.000013961211,0.0008043913,0.008729386,0.0017250151,0.0016130897,0.00002080841,0.003462717,0.0009490955,0.9826815],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843425,0.00004322961,0.00022031652,0.00041815135,0.0004401967,0.00044383938],"domain_scores_gemma":[0.99874073,0.000038381273,0.00010115608,0.0007975905,0.00005584525,0.00026629635],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009710588,0.00031679412,0.00059133285,0.00038706997,0.000020735759,0.000009741206,0.00019017786,0.00055779645,0.10878103],"category_scores_gemma":[0.00020406657,0.00026363425,0.00013842322,0.00027889482,0.00011613604,0.000011627587,0.00007079452,0.0008662591,0.0040483414],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029462246,0.00008302653,0.000044037282,0.00017958172,0.00013365137,0.00031683865,0.000007954035,9.601359e-8,0.000108202286,0.000066949186,0.99375856,0.005271635],"study_design_scores_gemma":[0.001325965,0.00010740831,0.000102479426,0.0003810343,0.00009065741,0.00014956603,0.000014697187,0.00004532628,0.000052626103,0.000016613107,0.9974865,0.00022714309],"about_ca_topic_score_codex":0.00020818676,"about_ca_topic_score_gemma":0.00010508494,"teacher_disagreement_score":0.10473269,"about_ca_system_score_codex":0.0007175451,"about_ca_system_score_gemma":0.001339156,"threshold_uncertainty_score":0.9999816},"labels":[],"label_agreement":null},{"id":"W4234928752","doi":"10.1182/blood-2020-135858","title":"The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Stem cell; Biology; Mitochondrion; Haematopoiesis; Cell biology","score_opus":0.015942526401816766,"score_gpt":0.25721996609109116,"score_spread":0.2412774396892744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234928752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9678488,0.0025546388,0.0001410961,0.02735396,0.00008237183,0.0017083007,0.00003385705,0.000055073295,0.00022190635],"genre_scores_gemma":[0.9938148,0.00018624563,0.00036297325,0.004527103,0.00042352837,0.00021443571,0.0000027857748,0.000053542943,0.0004145378],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978468,0.0002239753,0.000358418,0.0004124603,0.0005257378,0.0006326296],"domain_scores_gemma":[0.9984672,0.00025423593,0.000044173503,0.0005465368,0.000090764326,0.0005970538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065859023,0.00022777915,0.00039259408,0.00008660401,0.00019545858,0.00011232756,0.00046174185,0.000084191786,0.000047594192],"category_scores_gemma":[0.00017276124,0.00013229961,0.00007364972,0.0006957401,0.00009058822,0.000054082913,0.0004627353,0.00041348295,0.00038218917],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015101546,0.005402372,0.05654425,0.003904997,0.0038691617,0.013325581,0.096009895,0.00096056465,0.47072637,0.036275145,0.11460424,0.18327586],"study_design_scores_gemma":[0.010545911,0.0014026994,0.0063698497,0.00019033784,0.00048109007,0.00046011547,0.009435266,0.001241884,0.5268884,0.00006148045,0.4422788,0.00064416527],"about_ca_topic_score_codex":0.00016682094,"about_ca_topic_score_gemma":0.00008975241,"teacher_disagreement_score":0.32767457,"about_ca_system_score_codex":0.00006052907,"about_ca_system_score_gemma":0.00021152956,"threshold_uncertainty_score":0.53950214},"labels":[],"label_agreement":null},{"id":"W4235976609","doi":"10.21203/rs.3.rs-55355/v3","title":"CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Myeloid leukemia; Cancer research; Haematopoiesis; Leukemia; Stem cell; Biology; Flow cytometry; Stem cell marker; Drug resistance; Population; Immunology; Medicine; Cell biology","score_opus":0.023289350039434074,"score_gpt":0.3153986289206631,"score_spread":0.29210927888122906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235976609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686531,0.017868916,0.00012159962,0.0018059915,0.0003572102,0.0046049734,0.00012472304,0.00027229876,0.006191175],"genre_scores_gemma":[0.86920184,0.013568429,0.009441307,0.00017852847,0.0005676855,0.0013231491,0.001354437,0.00044020943,0.103924416],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9829281,0.002163676,0.0020675892,0.0037806577,0.0054549607,0.0036049979],"domain_scores_gemma":[0.9914912,0.0009800823,0.00043212489,0.0031575141,0.0023236934,0.0016153574],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0069662114,0.0014477605,0.0024255961,0.0026222873,0.0007725197,0.00093851076,0.0016792082,0.0018683804,0.0004483419],"category_scores_gemma":[0.00046514085,0.0014441656,0.0005162955,0.002331306,0.0010650738,0.00040943478,0.0075281058,0.01093468,0.00018766412],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.035903707,0.0021603007,0.04439423,0.11902513,0.007002701,0.12150501,0.04446015,0.0038334557,0.16862442,0.00075677637,0.32244706,0.12988704],"study_design_scores_gemma":[0.04723087,0.0011918129,0.36042732,0.062115174,0.0012284209,0.001937503,0.02967811,0.031258848,0.29806864,0.0020328243,0.15426788,0.010562575],"about_ca_topic_score_codex":0.0016195824,"about_ca_topic_score_gemma":0.0016554834,"teacher_disagreement_score":0.3160331,"about_ca_system_score_codex":0.037450373,"about_ca_system_score_gemma":0.043240972,"threshold_uncertainty_score":0.9998272},"labels":[],"label_agreement":null},{"id":"W4236520012","doi":"10.1016/j.clml.2019.07.113","title":"Delayed Hematologic Recovery in AML Patients After Induction Chemotherapy is Associated with Inferior Relapse-Free Survival and Persistence of Preleukemic Mutations","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Chemotherapy; Medicine; Induction chemotherapy; Persistence (discontinuity); Myeloid leukemia; Myeloid; Oncology; Internal medicine; Immunology","score_opus":0.023949305998262213,"score_gpt":0.2915467072011887,"score_spread":0.26759740120292647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236520012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99677074,0.00015639905,0.000014170504,0.00054041325,0.00022527059,0.0012301336,0.00006753115,0.000076725424,0.0009186126],"genre_scores_gemma":[0.9970331,0.00029649783,0.00080053677,0.00071023585,0.000059011956,0.00009163056,0.00012394054,0.0000762965,0.00080875726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99610376,0.00035486982,0.0013163773,0.0008821432,0.0007456013,0.0005972343],"domain_scores_gemma":[0.9966814,0.0010485064,0.00052857836,0.00094181957,0.00050421496,0.00029548677],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009823705,0.0003885937,0.0011947366,0.0003168914,0.000063920146,0.000032042797,0.00033649104,0.0007291696,0.00019578497],"category_scores_gemma":[0.0021565983,0.000324623,0.00023907698,0.000846695,0.0005991954,0.00034086523,0.00020950314,0.0006274462,0.00006476956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006514965,0.00048176,0.95456934,0.00013674177,0.00036950133,0.00009539707,0.00046978198,0.000008935233,0.00048823535,0.000022240212,0.00066506903,0.03617804],"study_design_scores_gemma":[0.017431214,0.0026061703,0.9769944,0.0005331729,0.00012329896,0.000057943318,0.00026536372,0.00075166166,0.000532438,0.00023229618,0.00013452873,0.0003375161],"about_ca_topic_score_codex":0.0002057565,"about_ca_topic_score_gemma":0.000097791686,"teacher_disagreement_score":0.035840526,"about_ca_system_score_codex":0.0025107083,"about_ca_system_score_gemma":0.0019136394,"threshold_uncertainty_score":0.9999206},"labels":[],"label_agreement":null},{"id":"W4237795805","doi":"10.32920/ryerson.14656716","title":"Cloning, expression and purification of the cytokine FLT3-ligand for protein interaction studies","year":2021,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; Toronto Metropolitan University","funders":"","keywords":"Western blot; Cloning (programming); Kluyveromyces lactis; Molecular biology; Haematopoiesis; Biology; Tandem affinity purification; Affinity chromatography; Ligand (biochemistry); Chemistry; Cell biology; Receptor; Stem cell; Biochemistry; Gene; Saccharomyces cerevisiae","score_opus":0.06444798793511317,"score_gpt":0.37454271703918457,"score_spread":0.31009472910407143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237795805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887659,0.0015846968,0.0017977763,0.00407586,0.00022302796,0.0029861252,0.000014116176,0.000030467021,0.0005220585],"genre_scores_gemma":[0.986842,0.00074927555,0.006724921,0.0000640517,0.00019645337,0.0005610176,0.000078736004,0.000027770586,0.0047558276],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986867,0.00008276511,0.0003618034,0.00040008014,0.00032193743,0.00014676865],"domain_scores_gemma":[0.9983968,0.00011188869,0.00026005405,0.0005664327,0.0006167647,0.00004804787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044609097,0.00016949566,0.00042576014,0.00009558423,0.000082745755,0.000033965214,0.00013785524,0.0002029442,0.000020335563],"category_scores_gemma":[0.0010442684,0.000101070706,0.00011723853,0.00009348935,0.000119839926,0.00005796337,0.0007856575,0.0005488426,6.674387e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004608729,0.00007896828,0.0005552248,0.0026190844,0.000220539,0.000002361892,0.0012831921,0.000022712185,0.98965496,0.0001116576,0.0021248315,0.0028656044],"study_design_scores_gemma":[0.0010008836,0.00011141982,0.0019850484,0.0025864556,0.00010815029,0.000016246215,0.0023673144,0.0010863685,0.9882228,0.00018912532,0.0022276547,0.00009855392],"about_ca_topic_score_codex":0.00006355167,"about_ca_topic_score_gemma":0.000018847863,"teacher_disagreement_score":0.0049271444,"about_ca_system_score_codex":0.00022985748,"about_ca_system_score_gemma":0.00029430643,"threshold_uncertainty_score":0.41215438},"labels":[],"label_agreement":null},{"id":"W4237901400","doi":"10.1177/120347540300700110","title":"Leukemia Cutis Presenting with Fingertip Hypertrophy","year":2003,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Leukemia cutis; Medicine; Cutis; Leukemia; Pathology; Biopsy; Lesion; Chronic lymphocytic leukemia; Dermatology; Bone marrow; Internal medicine","score_opus":0.06783632631419605,"score_gpt":0.3329022270765263,"score_spread":0.2650659007623302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237901400","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001557397,0.99434114,0.000030970055,0.0006601078,0.00040013363,0.0004402175,0.0000035357064,0.000020902695,0.0025455712],"genre_scores_gemma":[0.00012154265,0.993953,0.000431635,0.00059051893,0.0018524228,0.0000079856445,0.000018465398,0.00013861485,0.002885843],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952698,0.0003566553,0.0019574696,0.0004080861,0.0013260123,0.0006819725],"domain_scores_gemma":[0.9934806,0.0032136645,0.0015277886,0.00047704452,0.00056683493,0.00073404907],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013727751,0.0006472562,0.005474123,0.0013433782,0.00012731898,0.000039018116,0.00020556862,0.0004378636,0.00025198734],"category_scores_gemma":[0.0017344856,0.00035288723,0.00071400404,0.0007534645,0.00042795023,0.000111893365,0.000056824156,0.0021399588,0.000013855222],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003733019,0.00007394541,0.0004299674,0.023962246,0.0017392193,0.066499785,0.0001763066,8.933979e-7,0.000008443924,0.000010267106,0.1278795,0.77884614],"study_design_scores_gemma":[0.00048298482,0.0005576523,0.0000050180943,0.028245663,0.0025467363,0.23285131,0.00006517066,0.0000065975,0.0000014771693,0.000010542096,0.73498976,0.0002370968],"about_ca_topic_score_codex":0.000029890542,"about_ca_topic_score_gemma":0.0000014561867,"teacher_disagreement_score":0.77860904,"about_ca_system_score_codex":0.00065279735,"about_ca_system_score_gemma":0.0044309134,"threshold_uncertainty_score":0.9998923},"labels":[],"label_agreement":null},{"id":"W4239038218","doi":"10.1016/s2152-2650(11)70011-8","title":"Abstracts From: The 14th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myelomas March 17-21, 2010; Whistler, British Columbia","year":2010,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Oncology; Gerontology","score_opus":0.026824651494692812,"score_gpt":0.3099915816923784,"score_spread":0.2831669301976856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239038218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662103,0.0003560344,0.000006421057,0.007541514,0.0066573764,0.0015141587,0.0010388222,0.00038293493,0.016292453],"genre_scores_gemma":[0.9476807,0.0010375906,0.0011143206,0.0076178852,0.0033212001,0.00024091735,0.0004791874,0.00021709278,0.03829108],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9912751,0.00050916034,0.0023369133,0.0022793869,0.0020256238,0.0015738494],"domain_scores_gemma":[0.988551,0.0063610976,0.00077248004,0.0021822765,0.0008364289,0.0012966935],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0025301373,0.00081341446,0.00167897,0.00018772313,0.0007775282,0.0009319539,0.0018527756,0.0016339538,0.0024065138],"category_scores_gemma":[0.0059835496,0.00073848455,0.00064290146,0.0005376828,0.002670533,0.00038508023,0.0009031196,0.002566909,0.0011007853],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019502337,0.00069115794,0.0683148,0.00005697242,0.0005038185,0.0038557302,0.00012828756,0.0000036419676,0.00094411697,0.00043612032,0.6382613,0.28485382],"study_design_scores_gemma":[0.0097710835,0.00095614465,0.8055563,0.00055500824,0.0001480676,0.001959767,0.00026818324,0.00034941727,0.0004887357,0.0013587106,0.17785916,0.0007294027],"about_ca_topic_score_codex":0.014940902,"about_ca_topic_score_gemma":0.0112543795,"teacher_disagreement_score":0.7372415,"about_ca_system_score_codex":0.0023007756,"about_ca_system_score_gemma":0.0037237487,"threshold_uncertainty_score":0.9997342},"labels":[],"label_agreement":null},{"id":"W4241239208","doi":"10.1182/blood.v112.11.5067.5067","title":"Five New Pedigrees with Inherited RUNX1 Mutations Causing Familial Platelet Disorder with Propensity to Myeloid Malignancy (FPD/AML)","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; University of Calgary; Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Platelet disorder; Transplantation; RUNX1; Medicine; Trisomy 8; Hematopoietic stem cell transplantation; Myeloid leukemia; Myeloid; Internal medicine; Immunology; Oncology; Biology; Genetics; Haematopoiesis; Cytogenetics; Stem cell; Platelet; Gene","score_opus":0.02485628954828486,"score_gpt":0.25992894214957984,"score_spread":0.23507265260129498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241239208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937326,0.00013855922,0.0007043968,0.0015729317,0.000032809196,0.0015702152,0.00002753085,0.00017239564,0.0020486186],"genre_scores_gemma":[0.97898984,0.00004733204,0.012702801,0.0005482327,0.000352849,0.000073631374,0.00010637876,0.000090839836,0.0070881117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977767,0.000054188182,0.0002788293,0.00055362756,0.00071335153,0.000623322],"domain_scores_gemma":[0.9984912,0.00006212058,0.000082495746,0.00049775874,0.00036455182,0.0005018264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010008256,0.00031771624,0.00047959312,0.00022715368,0.0003398639,0.000036711273,0.00014415386,0.00012522413,0.00008906914],"category_scores_gemma":[0.00013398174,0.0002261672,0.00005306726,0.0009286848,0.00021198054,0.00019164992,0.00011157902,0.00045628386,0.00010618266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010940713,0.0051506325,0.805304,0.00070743414,0.0025311373,0.041010913,0.03901947,0.0011033318,0.058167774,0.00025716558,0.019582266,0.01622518],"study_design_scores_gemma":[0.03415298,0.005562337,0.90780574,0.0008815867,0.0007111904,0.014294663,0.0019604194,0.0001935712,0.024786392,0.00003058595,0.008404936,0.0012155785],"about_ca_topic_score_codex":0.0028916071,"about_ca_topic_score_gemma":0.0016788901,"teacher_disagreement_score":0.10250177,"about_ca_system_score_codex":0.00013053979,"about_ca_system_score_gemma":0.001536229,"threshold_uncertainty_score":0.9222831},"labels":[],"label_agreement":null},{"id":"W4241403525","doi":"10.1093/jnci/djh200","title":"RESPONSE: Re: Consolidation Therapy With Autologous Bone Marrow Transplantation in Adults With Acute Myeloid Leukemia: A Meta-analysis","year":2004,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Myeloid leukemia; Medicine; Bone marrow transplantation; Transplantation; Consolidation (business); Leukemia; Oncology; Internal medicine","score_opus":0.05453456614128712,"score_gpt":0.34444400420433363,"score_spread":0.28990943806304653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241403525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9621687,0.00096336094,0.0013726787,0.03434006,0.00012274315,0.00060657505,0.00011122642,0.0000156808,0.00029896916],"genre_scores_gemma":[0.9927094,0.0010823383,0.0036169116,0.0019711426,0.00015989215,0.0000773945,0.000031680072,0.000022618657,0.00032863533],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99677587,0.0002134275,0.00064933085,0.0002613375,0.0018388041,0.00026121593],"domain_scores_gemma":[0.99757534,0.00015133909,0.0006263531,0.00020374867,0.0013177952,0.00012541993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012755793,0.00023409135,0.0007897303,0.00081540714,0.00014214376,0.00003796379,0.0002827156,0.00013434548,0.000109584806],"category_scores_gemma":[0.00013991124,0.00012356773,0.00042995234,0.0019327794,0.00027128635,0.00054144056,0.000016123548,0.00077272387,0.0000031289594],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2908957,0.0006915335,0.00754764,0.00021640939,0.17903847,0.0047655534,0.0065099727,0.47620574,0.0287626,0.0015323997,0.0021834208,0.0016505681],"study_design_scores_gemma":[0.11981726,0.007062606,0.53809464,0.0014712795,0.18854113,0.027749151,0.0006891399,0.0021211898,0.098862134,0.0017267617,0.012209847,0.0016548429],"about_ca_topic_score_codex":0.0004411128,"about_ca_topic_score_gemma":0.0023956012,"teacher_disagreement_score":0.530547,"about_ca_system_score_codex":0.0031323617,"about_ca_system_score_gemma":0.0068539004,"threshold_uncertainty_score":0.9987763},"labels":[],"label_agreement":null},{"id":"W4241502190","doi":"10.1016/j.transproceed.2017.10.012","title":"Foreword","year":2017,"lang":"en","type":"article","venue":"Transplantation Proceedings","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Banff Centre","funders":"","keywords":"Biology; Haematopoiesis; Myelodysplastic syndromes; Myeloid leukemia; Cancer research; clone (Java method); Bone marrow; DNA damage; Stem cell; Myeloid; Genome instability; Leukemia; Gene; Genetics; DNA; Immunology","score_opus":0.03251935568032582,"score_gpt":0.3316404860619031,"score_spread":0.2991211303815773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241502190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92314297,0.00001335388,0.00034878432,0.0035279638,0.00005214402,0.00028796453,0.000012768187,0.00009583002,0.07251823],"genre_scores_gemma":[0.992239,0.00018204955,0.0019700862,0.00029985662,0.00014031358,0.000027701435,0.000018666948,0.000019177969,0.00510312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992324,0.0000013748022,0.00012779047,0.0001849567,0.0002446533,0.00020882877],"domain_scores_gemma":[0.9995026,0.000011432029,0.000067344525,0.00013947484,0.00015775119,0.00012141316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015015488,0.0000880147,0.00012999958,0.000076334945,0.00030142203,0.00007201133,0.00016932345,0.0000706024,0.00014995631],"category_scores_gemma":[0.00006075992,0.00007613461,0.000048708276,0.000043316002,0.00009630674,0.00035042854,0.000011603798,0.0001817401,0.00017009294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046395175,0.00024606148,0.57737833,0.0035991874,0.00027734324,0.0005449712,0.007316924,6.8823636e-7,0.26205018,0.06643612,0.028148724,0.04936198],"study_design_scores_gemma":[0.005264224,0.00028817638,0.881195,0.00027271983,0.0001914318,0.0007498976,0.00020314156,0.0007631746,0.102137126,0.0011783369,0.0075148665,0.00024188696],"about_ca_topic_score_codex":0.000033762655,"about_ca_topic_score_gemma":0.0000032743958,"teacher_disagreement_score":0.3038167,"about_ca_system_score_codex":0.00005393344,"about_ca_system_score_gemma":0.00006606998,"threshold_uncertainty_score":0.31046793},"labels":[],"label_agreement":null},{"id":"W4241854304","doi":"10.12974/2312-5411.2015.02.01.2","title":"Expansion of Primary Human AML by Aryl Hydrocarbon Receptor Antagonism Minimally Affects Leukemic Transcriptional Profiles but Alters Cellular Metabolism","year":2015,"lang":"en","type":"article","venue":"Journal of Hematology Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Aryl hydrocarbon receptor; Wnt signaling pathway; Myeloid leukemia; Downregulation and upregulation; Haematopoiesis; Leukemia; Cancer research; Cell biology; Ex vivo; Oxidative phosphorylation; Biology; In vivo; Chemistry; Stem cell; Signal transduction; Biochemistry; Immunology; Transcription factor; Gene; Genetics","score_opus":0.05694288818419192,"score_gpt":0.3409443434031565,"score_spread":0.2840014552189646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241854304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848682,0.009987451,0.00013047045,0.002780917,0.00029080382,0.0007475451,0.000030761334,0.000022435228,0.0011413876],"genre_scores_gemma":[0.9955656,0.00046218274,0.0020072227,0.0001431874,0.0004420321,0.00003140844,0.000108679014,0.00007680442,0.0011628988],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9936442,0.00091331085,0.0011658588,0.0004454196,0.0028477623,0.0009834643],"domain_scores_gemma":[0.9960331,0.00052689755,0.00048168053,0.0004981582,0.0016175368,0.00084268406],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0053548473,0.0003150599,0.0014707391,0.0013103208,0.00016802011,0.000029396871,0.0006969984,0.00046082318,0.00014110212],"category_scores_gemma":[0.0006780016,0.00025209232,0.00034146136,0.00060338835,0.0010690592,0.00031793257,0.00018539552,0.0024009906,0.000045289915],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028388514,0.00042002983,0.0021010644,0.000501754,0.0002982183,0.0007621705,0.00074473274,0.000002457935,0.9236917,0.0005397341,0.06781559,0.0002837282],"study_design_scores_gemma":[0.008027957,0.0025406003,0.0016713561,0.0003999942,0.00012869292,0.003120031,0.0013490733,0.00010807018,0.9783112,0.0005885833,0.0035309952,0.00022348754],"about_ca_topic_score_codex":0.00008044632,"about_ca_topic_score_gemma":0.0000020798386,"teacher_disagreement_score":0.064284585,"about_ca_system_score_codex":0.0009255744,"about_ca_system_score_gemma":0.0039918246,"threshold_uncertainty_score":0.99999315},"labels":[],"label_agreement":null},{"id":"W4242549471","doi":"10.1182/blood.v128.22.3153.3153","title":"Architectural and Functional Heterogeneity of Hematopoietic Stem/Progenitor Cells in Non-Del(5q) Myelodysplastic Syndromes","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CD34; Progenitor cell; Haematopoiesis; Bone marrow; Myelodysplastic syndromes; CD38; Biology; Stem cell; Cancer research; Immunology; Myeloid; Stromal cell; Genetics","score_opus":0.018071614087886986,"score_gpt":0.2520539705413163,"score_spread":0.2339823564534293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242549471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985947,0.00027027127,0.00019368395,0.00028378554,0.00008875799,0.00040731864,0.000031145297,0.00002515454,0.0001051756],"genre_scores_gemma":[0.9989507,0.000033743127,0.00043983525,0.00003217142,0.00010113683,0.000039578765,0.0000039117594,0.000027438147,0.00037144922],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99852526,0.000056743887,0.0003329829,0.00033728135,0.0003867918,0.00036096093],"domain_scores_gemma":[0.9990719,0.00028912444,0.00006920813,0.00029691798,0.00007892717,0.00019392611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020005525,0.0001773282,0.00038689503,0.00022896833,0.000033227785,0.000008203366,0.00009423746,0.00010559888,0.00008180373],"category_scores_gemma":[0.000059606024,0.000116232564,0.00008047791,0.00019496222,0.00019628501,0.00005522579,0.0001196354,0.00018118843,0.000058564125],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046664523,0.00055296166,0.17112927,0.0006477132,0.00026431866,0.00029458213,0.00023017291,0.000005053212,0.8229756,0.00004519638,0.00013682747,0.003251682],"study_design_scores_gemma":[0.012153963,0.00078728737,0.3681103,0.0005445445,0.00019244137,0.0018533298,0.000090815476,0.000115273804,0.6157292,0.000098856384,0.0000633755,0.00026059567],"about_ca_topic_score_codex":0.000024543555,"about_ca_topic_score_gemma":0.000015338008,"teacher_disagreement_score":0.20724636,"about_ca_system_score_codex":0.00007241346,"about_ca_system_score_gemma":0.0001894623,"threshold_uncertainty_score":0.47398266},"labels":[],"label_agreement":null},{"id":"W4244305813","doi":"10.1182/blood-2019-123121","title":"The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Stem cell; Biology; CD34; Haematopoiesis; Progenitor cell; Cell biology","score_opus":0.009091929553654435,"score_gpt":0.2506405552877589,"score_spread":0.2415486257341045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244305813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899448,0.0021063627,0.000039068902,0.005008526,0.00016452042,0.0022189042,0.000024198594,0.000039479743,0.00045414298],"genre_scores_gemma":[0.9952732,0.00015612955,0.00025036884,0.0013228552,0.00023885477,0.00020506824,0.000002684086,0.000053661042,0.002497208],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977795,0.00021638107,0.0003483388,0.0004077319,0.0005486568,0.00069941697],"domain_scores_gemma":[0.9983213,0.0003088007,0.000048298556,0.00085502747,0.000101752,0.00036481902],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010117862,0.00023050258,0.00040292012,0.00014446564,0.00015402284,0.000109434324,0.00045769004,0.00009786586,0.0000816563],"category_scores_gemma":[0.000080613194,0.00013064577,0.0000742376,0.0005509525,0.000075401105,0.00006320152,0.0004182148,0.00038661857,0.00095658883],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011226764,0.0067086406,0.19097558,0.0034762141,0.0034666762,0.0051518776,0.04077507,0.0008392358,0.49550223,0.050525207,0.04666787,0.14468464],"study_design_scores_gemma":[0.014709708,0.0014999713,0.022160525,0.00037456737,0.0004556567,0.00082016387,0.009164875,0.0007831459,0.5343064,0.00011761761,0.41478708,0.00082030986],"about_ca_topic_score_codex":0.00026691402,"about_ca_topic_score_gemma":0.00013505752,"teacher_disagreement_score":0.3681192,"about_ca_system_score_codex":0.00008673864,"about_ca_system_score_gemma":0.00021278123,"threshold_uncertainty_score":0.9998213},"labels":[],"label_agreement":null},{"id":"W4244933137","doi":"10.1016/b978-0-12-374279-7.01004-3","title":"Myelopoiesis","year":2016,"lang":"fr","type":"book-chapter","venue":"Elsevier eBooks","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Myelopoiesis; Biology; Haematopoiesis; Transcription factor; IRF8; Myeloid; CEBPA; Cell biology; Chromatin; RUNX1; Epigenetics; Acute promyelocytic leukemia; Myeloid leukemia; GATA1; Genetics; Cancer research; Immunology; Stem cell; Gene; Retinoic acid","score_opus":0.025847997653741274,"score_gpt":0.28532626413874634,"score_spread":0.25947826648500505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244933137","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014545326,0.008006419,0.00003087213,0.0038163473,0.0023320809,0.0018125321,0.00022996278,0.00019254356,0.9834338],"genre_scores_gemma":[0.0021978028,0.0031925214,0.0011787399,0.0016723126,0.0071750944,0.00012768447,0.000041397103,0.00049722806,0.98391724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937909,0.00018170117,0.0012473084,0.0014068944,0.0014561819,0.0019169688],"domain_scores_gemma":[0.99476516,0.00082037546,0.00042218514,0.0021571869,0.0005901377,0.0012449267],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0011338901,0.0012900187,0.0018243402,0.0006232947,0.00035754277,0.00007467845,0.0009170601,0.0015509361,0.019534525],"category_scores_gemma":[0.00040763099,0.0010089589,0.00088744937,0.000047626567,0.0020504298,0.000103268896,0.0007853521,0.0020710616,0.04404317],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001970519,0.000021934013,0.00009366979,0.00066797313,0.00091025786,0.0013435872,0.00018053167,6.3977595e-8,0.0010383344,0.090290986,0.0011401528,0.90411544],"study_design_scores_gemma":[0.002223909,0.00038358924,0.00020189132,0.006003794,0.000765929,0.00040690025,0.000029243549,0.000010152479,0.00075629365,0.007337894,0.9808337,0.0010467089],"about_ca_topic_score_codex":0.0000029926052,"about_ca_topic_score_gemma":0.000019828189,"teacher_disagreement_score":0.97969353,"about_ca_system_score_codex":0.0026524693,"about_ca_system_score_gemma":0.0020480973,"threshold_uncertainty_score":0.99998516},"labels":[],"label_agreement":null},{"id":"W4245246241","doi":"10.1182/blood.v110.11.13.13","title":"A Variant Allele of the Gene Growth Factor Independence 1 (GFI1) Is Associated with Acute Myeloid Leukemia.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"","keywords":"Myeloid leukemia; Biology; Chromosomal translocation; Haematopoiesis; Bone marrow; Cancer research; Allele; Leukemia; Myeloid; Immunology; Stem cell; Progenitor cell; Genetics; Gene","score_opus":0.014895523765063114,"score_gpt":0.2587939775509301,"score_spread":0.24389845378586697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245246241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942871,0.00013125571,0.0004126873,0.0005725576,0.000044850767,0.0006512862,0.00013450372,0.000067699766,0.0036980885],"genre_scores_gemma":[0.9955687,0.00008413387,0.0011625197,0.00076648063,0.00011487682,0.000015469594,0.000031455,0.000053593365,0.0022027863],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997188,0.00007932099,0.00039490155,0.00040488894,0.0012809559,0.0006519434],"domain_scores_gemma":[0.99816716,0.00020732344,0.00021595134,0.00067777146,0.00049180794,0.000240002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069117313,0.00024940266,0.00048097374,0.00013851491,0.00012220492,0.000019028548,0.00048400933,0.00028956242,0.00024216267],"category_scores_gemma":[0.0004525298,0.00015312505,0.00014508926,0.00079856743,0.00020413466,0.000096022835,0.00021439114,0.0007889508,0.00003113827],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020407306,0.0025609112,0.2375477,0.00022280647,0.008181559,0.0065900795,0.0048470567,0.000004118823,0.72792476,0.0006745852,0.007616684,0.0017890041],"study_design_scores_gemma":[0.009591446,0.00073023397,0.3159403,0.0001592218,0.00073219585,0.0011829815,0.00014418091,0.0000677699,0.6706292,0.000088486646,0.0004477849,0.00028619758],"about_ca_topic_score_codex":0.00043981615,"about_ca_topic_score_gemma":0.0001217437,"teacher_disagreement_score":0.078392595,"about_ca_system_score_codex":0.00046253944,"about_ca_system_score_gemma":0.0015171112,"threshold_uncertainty_score":0.62442577},"labels":[],"label_agreement":null},{"id":"W4245701085","doi":"10.1200/jco.2004.22.14_suppl.8277","title":"A longitudinal assessment of the quality of life (QOL) of older adults with newly diagnosed acute myeloid leukemia (AML): A pilot study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Medicine; Quality of life (healthcare); Life expectancy; Cancer; Physical therapy; Anemia; Cognition; Gerontology; Population; Internal medicine; Psychiatry","score_opus":0.12524729031981305,"score_gpt":0.48500015376294525,"score_spread":0.3597528634431322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245701085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252486,0.0001334173,0.00064252404,0.0045099338,0.00035498585,0.0012224516,0.000015557393,0.0000067784886,0.00058951235],"genre_scores_gemma":[0.99200094,0.0003182322,0.0065237135,0.000600566,0.00043144185,0.000016446336,0.0000016967391,0.000031228305,0.00007574169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9903007,0.0015777859,0.005440311,0.00035890756,0.0019168829,0.00040537782],"domain_scores_gemma":[0.9859164,0.004677887,0.005949272,0.0007651977,0.0021427579,0.0005485134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008654574,0.0002679604,0.0034531541,0.00021658083,0.000050404626,0.000005902344,0.0007468673,0.0002923837,0.000099103054],"category_scores_gemma":[0.006964078,0.00014666295,0.00065389375,0.0005934344,0.0010165499,0.00013826926,0.0002921041,0.0022678212,0.0000021989863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046087205,0.020048738,0.9187183,0.0003189883,0.0035862185,0.00071629445,0.0009969403,0.00040453466,0.0015453389,0.00018451558,0.00073025416,0.0066626887],"study_design_scores_gemma":[0.062287506,0.08466046,0.8495586,0.00054879807,0.00086859573,0.00015362383,0.0013128005,0.000035707344,0.00031633105,0.00006104927,0.00008781694,0.00010870218],"about_ca_topic_score_codex":0.0011488487,"about_ca_topic_score_gemma":0.0007959386,"teacher_disagreement_score":0.06915968,"about_ca_system_score_codex":0.0010147427,"about_ca_system_score_gemma":0.020950345,"threshold_uncertainty_score":0.9852681},"labels":[],"label_agreement":null},{"id":"W4246697467","doi":"10.1038/ng765","title":"MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia","year":2001,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1719,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Bristol-Myers Squibb; American Society of Hematology","keywords":"Biology; Chromosomal translocation; Leukemia; Hox gene; Gene; Haematopoiesis; Genetics; Cancer research; Gene expression; Stem cell","score_opus":0.025728755683725048,"score_gpt":0.31144017925646067,"score_spread":0.2857114235727356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246697467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9644882,0.0043820725,0.0048918636,0.0019929367,0.0003250203,0.001258805,0.00009007296,0.00024659012,0.022324454],"genre_scores_gemma":[0.96156824,0.00088813156,0.029595666,0.00048761917,0.001078701,0.00009170259,0.00037018635,0.0000862197,0.0058335136],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977261,0.00008963629,0.0003167849,0.0005698432,0.0007095724,0.0005881056],"domain_scores_gemma":[0.9982199,0.00013342674,0.0000958607,0.00084504776,0.00034253884,0.00036324252],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024711297,0.00031066578,0.000361439,0.0001737482,0.0002102262,0.00005143933,0.00035551246,0.00068035914,0.0004267467],"category_scores_gemma":[0.0003829827,0.00025580687,0.00014286666,0.0005816437,0.000166643,0.000051775736,0.00011323395,0.0016291935,0.000082157305],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018660283,0.00087169156,0.34671664,0.00075070054,0.0003220261,0.0030484342,0.0026346522,0.00013568222,0.4256955,0.00033389946,0.14853561,0.069089144],"study_design_scores_gemma":[0.0034021093,0.00041534545,0.27887973,0.0003697266,0.00020539374,0.0008550546,0.00025903442,0.0025775165,0.43009788,0.0004741524,0.2817978,0.00066622865],"about_ca_topic_score_codex":0.000031940395,"about_ca_topic_score_gemma":0.00006163143,"teacher_disagreement_score":0.13326219,"about_ca_system_score_codex":0.00065048214,"about_ca_system_score_gemma":0.00077636,"threshold_uncertainty_score":0.9999894},"labels":[],"label_agreement":null},{"id":"W4247181843","doi":"10.1007/978-3-319-95309-0_1893","title":"Acute Leukemia, Ambiguous Lineage","year":2019,"lang":"en","type":"book-chapter","venue":"Encyclopedia of pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Lineage (genetic); Leukemia; Biology; Evolutionary biology; Geography; Medicine; Genetics; Gene","score_opus":0.015432047531249146,"score_gpt":0.2794478026951891,"score_spread":0.26401575516393994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247181843","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014726844,0.0017271797,0.000099230194,0.0002941808,0.0010037712,0.0011122795,0.00027613377,0.00012095788,0.9806394],"genre_scores_gemma":[0.0013021769,0.011803287,0.0023131706,0.00086800195,0.0011331628,0.000024158438,0.0005436893,0.00024851767,0.98176384],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967682,0.000057739726,0.0009237977,0.0009195193,0.0006538003,0.00067696307],"domain_scores_gemma":[0.99713665,0.0001822489,0.0004974816,0.0015371409,0.0003591163,0.00028734075],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00038437004,0.0006375632,0.0017994712,0.0006186434,0.000044425375,0.000007079237,0.0005018327,0.0016400662,0.0025925087],"category_scores_gemma":[0.0001859745,0.0005874809,0.0005081879,0.000078840676,0.00054095115,0.00006014505,0.0004427364,0.0020786868,0.0035284555],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044634575,0.00052084576,0.0019527335,0.00482898,0.005185961,0.14019291,0.0026751147,0.000023671208,0.03604105,0.08605265,0.55290115,0.1651615],"study_design_scores_gemma":[0.0033566642,0.001814077,0.0009819155,0.00037626206,0.0010960661,0.0037311788,0.000021896836,0.000036153782,0.0010813508,0.001247288,0.98552555,0.00073160435],"about_ca_topic_score_codex":0.000038193295,"about_ca_topic_score_gemma":0.000011786492,"teacher_disagreement_score":0.43262443,"about_ca_system_score_codex":0.00069166534,"about_ca_system_score_gemma":0.002662043,"threshold_uncertainty_score":0.99965763},"labels":[],"label_agreement":null},{"id":"W4248279213","doi":"10.1182/blood.v120.21.3604.3604","title":"AAML0523: A Report From the Children's Oncology Group On the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Clofarabine; Medicine; Internal medicine; Cytarabine; Gastroenterology; Neutropenia; Ribonucleotide reductase; Oncology; Surgery; Myeloid leukemia; Toxicity; Biology","score_opus":0.009263073661050652,"score_gpt":0.24944095031283453,"score_spread":0.2401778766517839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248279213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950068,0.00015267431,0.000012615446,0.0018233856,0.00005927633,0.0020868941,0.000022173603,0.0000312321,0.00080494286],"genre_scores_gemma":[0.99826366,0.00009914976,0.0004110112,0.00033969287,0.000225603,0.00013280034,0.00040364295,0.000052717623,0.00007174743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972911,0.00033064187,0.00059765525,0.00040935018,0.0008219695,0.0005493232],"domain_scores_gemma":[0.99747705,0.0010136935,0.00038525852,0.0008358558,0.00015732303,0.00013080866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010524926,0.00027759082,0.000552022,0.00026381426,0.000074009266,0.000010972265,0.00032391428,0.00019503427,0.000038928527],"category_scores_gemma":[0.00053744385,0.00013760176,0.000063207466,0.0011483543,0.00019255027,0.00013431863,0.00010787618,0.0010392836,0.000019359019],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029074845,0.004026403,0.9903017,0.000014076842,0.0002151098,0.00015609496,0.0007566786,0.000011186636,0.00021756056,0.00013604765,0.00040498035,0.00085261976],"study_design_scores_gemma":[0.03346088,0.0026502595,0.96228224,0.000097177675,0.0004347194,0.00008642419,0.0000656131,0.000019019823,0.0005880016,0.000020728174,0.00013764373,0.00015731638],"about_ca_topic_score_codex":0.000832052,"about_ca_topic_score_gemma":0.0002079519,"teacher_disagreement_score":0.030553399,"about_ca_system_score_codex":0.0006126118,"about_ca_system_score_gemma":0.00055974594,"threshold_uncertainty_score":0.5611237},"labels":[],"label_agreement":null},{"id":"W4248354966","doi":"10.32920/ryerson.14656716.v1","title":"Cloning, expression and purification of the cytokine FLT3-ligand for protein interaction studies","year":2021,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; Toronto Metropolitan University","funders":"","keywords":"Cloning (programming); Western blot; Kluyveromyces lactis; Molecular biology; Haematopoiesis; Biology; Affinity chromatography; Chemistry; Cell biology; Stem cell; Biochemistry; Gene; Saccharomyces cerevisiae","score_opus":0.06444798793511317,"score_gpt":0.37454271703918457,"score_spread":0.31009472910407143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248354966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887659,0.0015846968,0.0017977763,0.00407586,0.00022302796,0.0029861252,0.000014116176,0.000030467021,0.0005220585],"genre_scores_gemma":[0.986842,0.00074927555,0.006724921,0.0000640517,0.00019645337,0.0005610176,0.000078736004,0.000027770586,0.0047558276],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986867,0.00008276511,0.0003618034,0.00040008014,0.00032193743,0.00014676865],"domain_scores_gemma":[0.9983968,0.00011188869,0.00026005405,0.0005664327,0.0006167647,0.00004804787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044609097,0.00016949566,0.00042576014,0.00009558423,0.000082745755,0.000033965214,0.00013785524,0.0002029442,0.000020335563],"category_scores_gemma":[0.0010442684,0.000101070706,0.00011723853,0.00009348935,0.000119839926,0.00005796337,0.0007856575,0.0005488426,6.674387e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004608729,0.00007896828,0.0005552248,0.0026190844,0.000220539,0.000002361892,0.0012831921,0.000022712185,0.98965496,0.0001116576,0.0021248315,0.0028656044],"study_design_scores_gemma":[0.0010008836,0.00011141982,0.0019850484,0.0025864556,0.00010815029,0.000016246215,0.0023673144,0.0010863685,0.9882228,0.00018912532,0.0022276547,0.00009855392],"about_ca_topic_score_codex":0.00006355167,"about_ca_topic_score_gemma":0.000018847863,"teacher_disagreement_score":0.0049271444,"about_ca_system_score_codex":0.00022985748,"about_ca_system_score_gemma":0.00029430643,"threshold_uncertainty_score":0.41215438},"labels":[],"label_agreement":null},{"id":"W4249138452","doi":"10.1007/978-3-642-11274-4_2965","title":"Polyribonucleotide","year":2011,"lang":"en","type":"book-chapter","venue":"Encyclopedia of Astrobiology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Chemistry","score_opus":0.019378575490214104,"score_gpt":0.2582617524618853,"score_spread":0.23888317697167122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249138452","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014130512,0.00081476197,0.000057039724,0.00026301586,0.000386472,0.00051059946,0.00011600386,0.00006816235,0.9963709],"genre_scores_gemma":[0.002782024,0.003690625,0.0032699537,0.0002049857,0.0007633157,0.000013774215,0.000358938,0.000137165,0.98877925],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99816924,0.000029428962,0.0006163884,0.0005197516,0.00018271434,0.00048246077],"domain_scores_gemma":[0.9983581,0.00011907391,0.00032768384,0.0007542536,0.00020956117,0.0002313326],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001880308,0.00041380577,0.0010671619,0.00038473288,0.000029268216,0.0000020460352,0.0003181824,0.00079180044,0.008199333],"category_scores_gemma":[0.00009715613,0.00035946505,0.00032722155,0.000035650006,0.0005915784,0.000030444991,0.00025673228,0.0010475605,0.0013263134],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003840482,0.00046457548,0.008587032,0.0013185751,0.003925589,0.0018517982,0.0011835364,0.000001545766,0.0072875475,0.349118,0.41664037,0.20578097],"study_design_scores_gemma":[0.0010458352,0.0012869522,0.0012166682,0.000245262,0.0002563168,0.0002583014,0.000011445727,8.4604375e-7,0.00028840866,0.0034803685,0.9916002,0.0003093685],"about_ca_topic_score_codex":0.000058182293,"about_ca_topic_score_gemma":0.000012584642,"teacher_disagreement_score":0.5749599,"about_ca_system_score_codex":0.00015307729,"about_ca_system_score_gemma":0.00068995764,"threshold_uncertainty_score":0.99988574},"labels":[],"label_agreement":null},{"id":"W4250479810","doi":"10.14740/jmc1410w","title":"A Case of Multiple Cutaneous Granulocytic Sarcomas in an Elderly Patient","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Leukemia; Sarcoma; Myeloid leukemia; Head and neck; Lesion; Myelodysplastic syndromes; Myeloid; Soft tissue; Myeloid sarcoma; Pathology; Bone marrow; Internal medicine; Surgery","score_opus":0.031389973580349145,"score_gpt":0.32900470314560837,"score_spread":0.29761472956525925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250479810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974616,0.0003928765,0.00019162247,0.0015664381,0.000119676486,0.00015491243,0.0000046066766,0.000007361623,0.00010088865],"genre_scores_gemma":[0.9983047,0.00008706879,0.00087349926,0.00040933746,0.00028663967,0.0000022003412,0.0000024764606,0.000018733983,0.000015302456],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9969626,0.00028593084,0.00085692026,0.00013869526,0.0014584203,0.0002974503],"domain_scores_gemma":[0.9970461,0.0013481837,0.00026989315,0.00024987318,0.00031017288,0.0007757603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011203322,0.00012842605,0.0005695889,0.0003554328,0.000030844825,0.000010410608,0.00019767182,0.00017605704,0.00031908057],"category_scores_gemma":[0.008281024,0.000089480156,0.00013768375,0.00023300204,0.00020186255,0.00008931328,0.000058731577,0.00086868956,0.000005926789],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021991457,0.0014284939,0.022654463,0.00029753306,0.000076916556,0.6585142,0.0016042716,0.000034693174,0.0021496515,0.00006380437,0.0024925629,0.30848426],"study_design_scores_gemma":[0.009814303,0.018171802,0.0017521769,0.00091564533,0.0001283799,0.944675,0.0019401206,0.015211361,0.0031996951,0.00014484662,0.0038648704,0.00018174101],"about_ca_topic_score_codex":0.00056325144,"about_ca_topic_score_gemma":0.00049702445,"teacher_disagreement_score":0.30830252,"about_ca_system_score_codex":0.00022866645,"about_ca_system_score_gemma":0.0007398847,"threshold_uncertainty_score":0.99137574},"labels":[],"label_agreement":null},{"id":"W4250614201","doi":"10.1200/jco.2004.22.90140.6611","title":"A randomized phase I clinical and biologic study of two schedules of BAY 43–9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A National Cancer Institute of Cancer Clinical Trials Group Study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Nausea; Gastroenterology; Regimen; Vomiting; Oncology; Surgery; Adverse effect","score_opus":0.2024794012292822,"score_gpt":0.55521098114729,"score_spread":0.35273157991800774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250614201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282265,0.00038392894,0.00017322582,0.0005997927,0.00161394,0.004279133,0.00009157678,0.000009423973,0.000026318512],"genre_scores_gemma":[0.99301744,0.0024637391,0.003332868,0.00030975018,0.000656859,0.0001395281,0.0000111410045,0.00003917351,0.000029512743],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9712965,0.008970998,0.016634256,0.0007726108,0.0018045071,0.0005211593],"domain_scores_gemma":[0.96170247,0.024923917,0.009796541,0.00042253852,0.0024977336,0.00065681594],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.051218554,0.00045738564,0.0115532745,0.0007791193,0.000055717894,0.0000113268325,0.0005830922,0.0007777878,0.00013348181],"category_scores_gemma":[0.054276943,0.0002535016,0.0009918801,0.00084844965,0.002895971,0.00030010688,0.00030461457,0.0028305615,0.000001946286],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42975104,0.027593069,0.52487713,0.000076873665,0.0056622857,0.00062221417,0.00017371718,0.00028825866,0.00002959359,0.000049726958,0.000035398556,0.010840672],"study_design_scores_gemma":[0.5019066,0.07764101,0.41658285,0.00045501164,0.0026200153,0.000054486092,0.00027036646,0.00012199268,0.000007444793,0.00014648416,0.000051705858,0.000142047],"about_ca_topic_score_codex":0.000900886,"about_ca_topic_score_gemma":0.002923052,"teacher_disagreement_score":0.108294286,"about_ca_system_score_codex":0.0007966036,"about_ca_system_score_gemma":0.015852598,"threshold_uncertainty_score":0.9999917},"labels":[],"label_agreement":null},{"id":"W4251042006","doi":"10.1182/blood.v116.21.533.533","title":"Analysis of Risk Factors Influencing Outcomes After Unrelated Cord Blood Transplantation In Children with Juvenile Myelomonocytic Leukemia. An Eurocord, EBMT, EWOG-MDS, CIBMTR Study","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Busulfan; Medicine; Juvenile myelomonocytic leukemia; Transplantation; Total body irradiation; Cyclophosphamide; Hematopoietic stem cell transplantation; Internal medicine; ThioTEPA; Surgery; Gastroenterology; Leukemia; Oncology; Chemotherapy; Stem cell; Haematopoiesis; Biology","score_opus":0.010284241721715605,"score_gpt":0.2735640216326619,"score_spread":0.2632797799109463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251042006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982454,0.000034433244,0.000023807444,0.00001119145,0.00003182216,0.0013195715,0.0001586703,0.00010097954,0.00007412927],"genre_scores_gemma":[0.9989023,0.000048280075,0.00049915415,0.000036427442,0.000036334273,0.00007854696,0.0002829421,0.000073325966,0.00004265995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99691683,0.00025531603,0.00080934644,0.00071299996,0.0007641548,0.00054137356],"domain_scores_gemma":[0.99803656,0.00025281508,0.00030796466,0.0009072856,0.00020278337,0.000292603],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057217747,0.0004167867,0.0010675439,0.0014120773,0.00008860596,0.000037672282,0.0003230982,0.00024553653,0.00014406514],"category_scores_gemma":[0.00019781762,0.00031866648,0.00019904134,0.0022460935,0.00013838061,0.00027926333,0.000054617623,0.0012945572,0.000009316565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008286545,0.0017811764,0.98365843,0.00003445556,0.0045064217,0.00023799005,0.004961824,0.0002302003,0.0033793026,0.0000019570175,8.5991866e-7,0.00037870943],"study_design_scores_gemma":[0.015020716,0.0013737637,0.9617227,0.00004169309,0.015711168,0.00006511476,0.0010433902,0.00040376635,0.004299363,0.000003935119,0.000001077311,0.0003133627],"about_ca_topic_score_codex":0.008078982,"about_ca_topic_score_gemma":0.008536373,"teacher_disagreement_score":0.021935798,"about_ca_system_score_codex":0.00014169722,"about_ca_system_score_gemma":0.00052454433,"threshold_uncertainty_score":0.99992657},"labels":[],"label_agreement":null},{"id":"W4251910573","doi":"10.1016/j.leukres.2012.09.019","title":"CD11b expression correlates with monosomal karyotype and predicts an extremely poor prognosis in cytogenetically unfavorable acute myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Medical Research Council; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Myeloid leukemia; Karyotype; Myeloid; Medicine; Oncology; Leukemia; Biology; Internal medicine; Cancer research; Immunology; Genetics; Chromosome; Gene","score_opus":0.049620682203062864,"score_gpt":0.33658012484074346,"score_spread":0.2869594426376806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251910573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98869514,0.002017558,0.000078444835,0.0008660383,0.00008917045,0.0024529572,0.0000292343,0.00020352562,0.0055679525],"genre_scores_gemma":[0.9879446,0.0012526151,0.0065499875,0.00019839493,0.000514979,0.0005787016,0.00014175996,0.00020453335,0.0026144506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99154854,0.00086226914,0.00073977775,0.0012895607,0.0025523927,0.0030074469],"domain_scores_gemma":[0.9954907,0.00071220624,0.00009056625,0.001014853,0.0007124689,0.001979207],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003025255,0.00060903054,0.00087070424,0.0011785051,0.0004736021,0.00020884721,0.00068841013,0.00073600543,0.0002917609],"category_scores_gemma":[0.00054756325,0.0004722226,0.00009472016,0.0019680029,0.0010144892,0.0011060196,0.00079635094,0.0032028884,0.00023992223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077478075,0.0006506918,0.650997,0.00040498277,0.00022330818,0.0011986656,0.0017421779,0.00007306101,0.32155824,0.00041937226,0.005417717,0.009566994],"study_design_scores_gemma":[0.017668566,0.007946791,0.62486994,0.0017840413,0.00027486184,0.0020560822,0.0019310627,0.019887427,0.31748492,0.00034210042,0.0043669324,0.0013872716],"about_ca_topic_score_codex":0.00086091075,"about_ca_topic_score_gemma":0.00013871434,"teacher_disagreement_score":0.026127052,"about_ca_system_score_codex":0.004328498,"about_ca_system_score_gemma":0.0041342415,"threshold_uncertainty_score":0.99977297},"labels":[],"label_agreement":null},{"id":"W4252495102","doi":"10.1002/9781119398929.ch4","title":"ACUTE MYELOID LEUKAEMIA, MIXED PHENOTYPE ACUTE LEUKAEMIA, THE MYELODYSPLASTIC SYNDROMES AND HISTIOCYTIC NEOPLASMS","year":2019,"lang":"en","type":"other","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Histiocyte; Myelodysplastic syndromes; Immunophenotyping; Bone marrow; Pathology; Medicine; Lymphoma; Myeloid; clone (Java method); Immunology; Cancer research; Biology; Antigen","score_opus":0.015094219996367736,"score_gpt":0.27077927876114477,"score_spread":0.25568505876477704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252495102","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013764629,0.005882389,0.00091531,0.0044119298,0.0024396812,0.0050138007,0.0004446368,0.0012833531,0.9658443],"genre_scores_gemma":[0.0067568296,0.0042877127,0.0021052496,0.0014744817,0.0009001677,0.0001848888,0.00040139913,0.0015012353,0.982388],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99450403,0.00020746674,0.0007749545,0.0015938742,0.001430292,0.0014894009],"domain_scores_gemma":[0.99560356,0.00080282334,0.00043332748,0.0022970084,0.00019625586,0.0006670146],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.00046531757,0.0012968354,0.00199243,0.0008866366,0.00023835516,0.00018773269,0.0009893946,0.001379405,0.005884962],"category_scores_gemma":[0.00027696538,0.00084767374,0.00038091044,0.00073306175,0.0009087793,0.00013149333,0.0007868368,0.0023036608,0.0072708502],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050131936,0.00007715294,0.00023135486,0.00077182584,0.0037003718,0.0010691632,0.00013996635,0.0000028005063,0.0013698047,0.0015060772,0.9855971,0.005033078],"study_design_scores_gemma":[0.008007598,0.0011320324,0.0010338259,0.0012537331,0.0055870437,0.004778337,0.00025312623,0.0013368838,0.000584805,0.00016786078,0.97422117,0.0016435566],"about_ca_topic_score_codex":0.0009570703,"about_ca_topic_score_gemma":0.00033197034,"teacher_disagreement_score":0.016543765,"about_ca_system_score_codex":0.0013820213,"about_ca_system_score_gemma":0.0024716721,"threshold_uncertainty_score":0.9999981},"labels":[],"label_agreement":null},{"id":"W4252793189","doi":"10.1002/9781444318531.ch4","title":"The Genetics of Acute Myeloid Leukemias","year":2010,"lang":"en","type":"other","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"","keywords":"Cytogenetics; Molecular genetics; Myeloid leukemia; Biology; Genetics; Myeloid; Myeloid leukaemia; Medicine; Cancer research; Chromosome; Gene","score_opus":0.015276554293940326,"score_gpt":0.30240011416392115,"score_spread":0.28712355986998084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252793189","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032582134,0.0019695894,0.00010951244,0.0010414707,0.00035401384,0.0007397482,0.000052611198,0.00014116902,0.9952661],"genre_scores_gemma":[0.00020088375,0.0081900265,0.004523185,0.00029188918,0.0007759623,0.00002577171,0.000051953706,0.00057059136,0.98536974],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998294,0.000036921236,0.0003093007,0.00030850252,0.00062417425,0.00042709478],"domain_scores_gemma":[0.9980716,0.00012806132,0.00018135451,0.0013024923,0.00012892355,0.00018755073],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000256735,0.0002773018,0.0005010556,0.00020577418,0.000053450916,0.000018382194,0.00051170547,0.000736579,0.006221836],"category_scores_gemma":[0.000076467084,0.0001557203,0.00018460778,0.00020409188,0.00048332405,0.000008008336,0.00022396173,0.0011576469,0.0005431105],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054737473,0.000023680852,0.000121558325,0.00008689431,0.0006495794,0.000044955817,0.000019657167,3.4550265e-8,0.0051568253,0.0005209934,0.96843135,0.02488971],"study_design_scores_gemma":[0.0008203834,0.00012707092,0.00018740291,0.00007899726,0.00027089467,0.0000848959,0.000025937552,0.00004843024,0.0067510274,0.00004126989,0.99141264,0.00015105786],"about_ca_topic_score_codex":0.0003581673,"about_ca_topic_score_gemma":0.00031834876,"teacher_disagreement_score":0.024738653,"about_ca_system_score_codex":0.00014305412,"about_ca_system_score_gemma":0.0010598426,"threshold_uncertainty_score":0.9946866},"labels":[],"label_agreement":null},{"id":"W4253329765","doi":"10.1097/00043426-200210000-00028","title":"A Practical, Comprehensive Classification for Pediatric Myelodysplastic Syndromes: The CCC System","year":2002,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Schema (genetic algorithms); Chronic myelomonocytic leukemia; Cytogenetics; Pediatrics; Juvenile myelomonocytic leukemia; Disease; Pathology; Bone marrow; Stem cell","score_opus":0.1296714298412195,"score_gpt":0.3915200461978638,"score_spread":0.2618486163566443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253329765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87530667,0.012635445,0.022019327,0.078116745,0.0038978222,0.0039493633,0.00004213167,0.00018571994,0.0038467923],"genre_scores_gemma":[0.97383344,0.0044600554,0.01589767,0.0006962687,0.0045433063,0.00015029604,0.0000067505275,0.00007150565,0.00034072922],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9957597,0.0006809557,0.0017090188,0.00038863588,0.00068656803,0.00077507034],"domain_scores_gemma":[0.98653257,0.009043967,0.0018100865,0.0004811753,0.0016580342,0.0004741892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015034123,0.00032613447,0.0014018314,0.0008639083,0.00028722183,0.00003498812,0.0004524196,0.00068027125,0.00016035422],"category_scores_gemma":[0.0042509693,0.00021196397,0.00041890587,0.0010053748,0.00025413785,0.00020901031,0.00010968334,0.0016017432,0.00034007945],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021736675,0.0021834057,0.019209871,0.0033385656,0.0009519474,0.0069742235,0.001360451,0.000029384377,0.00089169544,0.009369396,0.95092684,0.002590551],"study_design_scores_gemma":[0.037701804,0.028738651,0.021400405,0.0002803058,0.017730523,0.50025374,0.022153882,0.040385958,0.00030449027,0.0005439779,0.32896942,0.0015368133],"about_ca_topic_score_codex":0.0000033671768,"about_ca_topic_score_gemma":0.00000137225,"teacher_disagreement_score":0.6219574,"about_ca_system_score_codex":0.0014290188,"about_ca_system_score_gemma":0.002002579,"threshold_uncertainty_score":0.86436397},"labels":[],"label_agreement":null},{"id":"W4253900297","doi":"10.3410/f.736013740.793577579","title":"Faculty Opinions recommendation of Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1 - azacitidine induces only lymphoma remission.","year":2020,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Azacitidine; Angioimmunoblastic T-cell lymphoma; Lymphoma; Internal medicine; Medicine; Cancer research; Oncology; T-cell lymphoma; Gastroenterology; Biology; Immunology; Genetics; Gene; T cell; DNA methylation","score_opus":0.02188272119417371,"score_gpt":0.3175149833436735,"score_spread":0.2956322621494998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253900297","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032076053,0.0016992816,0.000019703291,0.115914084,0.00016066084,0.0018737497,0.879943,0.000036214715,0.00003252931],"genre_scores_gemma":[0.00095005526,0.0010540774,0.0011554604,0.0019915956,0.00010664649,0.00021774918,0.99390125,0.000052213716,0.0005709341],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949835,0.00044395484,0.0016225238,0.0009459522,0.0015295142,0.00047458493],"domain_scores_gemma":[0.99384564,0.0005088655,0.0011070588,0.0010097794,0.002904143,0.000624539],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089875574,0.00067255145,0.0014487857,0.0008201238,0.00023900975,0.00013478397,0.0007729266,0.0007319673,0.00012406927],"category_scores_gemma":[0.00712515,0.00042848554,0.0002473502,0.0032077362,0.0007797625,0.0003835745,0.0005942797,0.00096747273,0.00002665521],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012553849,0.00064362277,0.000039630508,0.01325733,0.00019161368,0.000015987902,0.00020795077,1.3646341e-7,0.0000247881,0.000037784437,0.9817268,0.0037288133],"study_design_scores_gemma":[0.004440222,0.0007013752,0.020948086,0.02244754,0.00042910865,0.001422817,0.00011941337,0.00005003057,0.0000315083,0.00001229998,0.94901204,0.0003855678],"about_ca_topic_score_codex":0.00014578247,"about_ca_topic_score_gemma":0.000012395411,"teacher_disagreement_score":0.11395825,"about_ca_system_score_codex":0.00034299743,"about_ca_system_score_gemma":0.0022895946,"threshold_uncertainty_score":0.9998167},"labels":[],"label_agreement":null},{"id":"W4254072715","doi":"10.1002/0471463736.tnmp44.pub2","title":"Leukemias","year":2006,"lang":"en","type":"other","venue":"TNM Online","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Bone marrow; Medicine; Leukemia; Acute leukemia; Immunology; Myeloid; Myeloid leukemia; Stem cell; Malignant transformation; Biology; Cancer research; Genetics","score_opus":0.023076191334644582,"score_gpt":0.32397062524911846,"score_spread":0.3008944339144739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254072715","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013955293,0.0013072495,0.000045393906,0.0010602048,0.00016006967,0.00052214565,0.0025558863,0.00058720674,0.9936223],"genre_scores_gemma":[0.000038142687,0.00027779586,0.006578881,0.0008337543,0.0037938128,0.000020227422,0.010231866,0.0009605699,0.97726494],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839014,0.00002904664,0.00024212872,0.00041741433,0.0004794998,0.0004417432],"domain_scores_gemma":[0.99884605,0.000043929795,0.00011164331,0.0007511645,0.00005589122,0.00019130383],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007757206,0.00032056432,0.0005921163,0.00043777179,0.0000206035,0.000010978009,0.0002113012,0.0005605168,0.024392698],"category_scores_gemma":[0.000103086364,0.00026653032,0.00015005107,0.0002624412,0.00012487151,0.000011986595,0.00010725841,0.0008115266,0.0021488657],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003296698,0.00014923398,0.00007802664,0.00018678089,0.000095207964,0.00043664084,0.0000048403663,2.1653085e-7,0.00009661367,0.00003494477,0.9926662,0.006218335],"study_design_scores_gemma":[0.0014154434,0.000099336175,0.00039267962,0.00041953873,0.00009226083,0.0001068055,0.000007802612,0.00008842879,0.000041522493,0.00001687513,0.9970905,0.00022877552],"about_ca_topic_score_codex":0.0012016624,"about_ca_topic_score_gemma":0.000671344,"teacher_disagreement_score":0.022243833,"about_ca_system_score_codex":0.00048489202,"about_ca_system_score_gemma":0.00077633077,"threshold_uncertainty_score":0.99997866},"labels":[],"label_agreement":null},{"id":"W4254091309","doi":"10.1182/blood.v110.11.439.439","title":"A Randomized Phase 3 Study of Tipifarnib Compared to Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Patients 70 Years or Older.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Clinical endpoint; Neutropenia; Myeloid leukemia; Cytarabine; Chemotherapy; Randomized controlled trial; Surgery; Oncology; Confidence interval","score_opus":0.033266856408351496,"score_gpt":0.3524969342320459,"score_spread":0.31923007782369445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254091309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915582,0.00015179777,0.000011899849,0.000056147503,0.00004654851,0.007734622,0.00006488675,0.000017388318,0.00035850788],"genre_scores_gemma":[0.9988883,0.000107214066,0.00024671535,0.00007560404,0.000055979042,0.00038038963,0.00012056952,0.00004130624,0.00008390138],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99662554,0.0004017553,0.0010856916,0.00045235959,0.0008675431,0.0005671064],"domain_scores_gemma":[0.99771106,0.0009934488,0.00028126582,0.00059670646,0.00022574437,0.00019179568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094262697,0.0003107467,0.0014592651,0.0006363652,0.000047101777,0.000012734797,0.0003132418,0.0001202073,0.000043361153],"category_scores_gemma":[0.00040730636,0.00020298648,0.00018828458,0.0010479235,0.00012356738,0.00006396524,0.000087966975,0.00026170735,0.000010981917],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27286455,0.055855315,0.36780575,0.0001817731,0.0016415239,0.0040765475,0.279965,0.000057468707,0.0031774684,0.000003020738,0.00019313075,0.014178429],"study_design_scores_gemma":[0.81163114,0.010999831,0.13454437,0.00024381356,0.00090209325,0.000009858822,0.032214146,0.0000425345,0.009136828,0.0000017505657,0.000078230696,0.00019539852],"about_ca_topic_score_codex":0.0028842138,"about_ca_topic_score_gemma":0.002271343,"teacher_disagreement_score":0.53876656,"about_ca_system_score_codex":0.0009370041,"about_ca_system_score_gemma":0.0004962743,"threshold_uncertainty_score":0.82775486},"labels":[],"label_agreement":null},{"id":"W4254490542","doi":"10.1038/leu.2017.333","title":"Erratum: Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches","year":2017,"lang":"en","type":"erratum","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council","keywords":"License; Computational biology; Leukemia; Computer science; Medicine; Biology; Internal medicine","score_opus":0.06472148087172934,"score_gpt":0.31382822482485834,"score_spread":0.24910674395312898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254490542","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46466404,0.019746456,0.00088044355,0.015383131,0.17741735,0.019978322,0.00092300825,0.0015039402,0.2995033],"genre_scores_gemma":[0.3712638,0.0012391105,0.00023240737,0.00023175757,0.011580067,0.00028635332,0.00370812,0.00035791128,0.61110044],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99406797,0.0002879333,0.0009755353,0.001446187,0.0020691992,0.0011531799],"domain_scores_gemma":[0.99439466,0.00009358906,0.0013542861,0.0031220205,0.00047748792,0.0005579668],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0008712028,0.0010097761,0.0032052253,0.0020557595,0.00037562833,0.00030337367,0.001711964,0.0024198294,0.0003993608],"category_scores_gemma":[0.00043365153,0.00089373876,0.0012477756,0.0012139915,0.00050441886,0.00020011811,0.0006069498,0.003753647,0.0000901064],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011501092,0.00019376143,0.00021797507,0.0014404409,0.017655848,0.0003293687,0.0009052914,0.000019435874,0.027961222,0.00047335087,0.9403489,0.009304255],"study_design_scores_gemma":[0.05935335,0.008680593,0.114905596,0.008026343,0.20432672,0.0006926487,0.0025782874,0.050321218,0.11156902,0.016847607,0.41064584,0.012052768],"about_ca_topic_score_codex":0.0030674315,"about_ca_topic_score_gemma":0.00051249185,"teacher_disagreement_score":0.5297031,"about_ca_system_score_codex":0.0025741435,"about_ca_system_score_gemma":0.009725928,"threshold_uncertainty_score":0.9993513},"labels":[],"label_agreement":null},{"id":"W4254559163","doi":"10.1515/iupac.84.0932","title":"Myelodysplastic Syndrome","year":2016,"lang":"en","type":"dataset","venue":"IUPAC Standards Online","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"","keywords":"Glossary; Immunotoxicology; Disease; Medicine; Immunology; Immune system; Pathology; Philosophy; Linguistics","score_opus":0.0170858470370092,"score_gpt":0.40941242996011673,"score_spread":0.3923265829231075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254559163","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007184553,0.0007326724,0.00012211449,0.0024510426,0.0007295674,0.00083365256,0.9941098,0.00015313795,0.00014955242],"genre_scores_gemma":[0.00007992056,0.0015962002,0.000109218825,0.00066194974,0.0013531729,0.000044347147,0.9910028,0.00012499931,0.005027406],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945686,0.000118890894,0.00071702525,0.000918993,0.002636795,0.0010396993],"domain_scores_gemma":[0.99599856,0.00033903128,0.00024466694,0.001774782,0.00092463597,0.00071832456],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007708139,0.000712926,0.0014414685,0.00071399764,0.00013138013,0.00005720316,0.0006119503,0.0008451971,0.013765863],"category_scores_gemma":[0.0023128423,0.0004960011,0.00033215847,0.0004533759,0.00039852248,0.00009534924,0.00043268167,0.0016629946,0.00009075695],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008290918,0.00026264563,0.000016258758,0.0007251607,0.0004212755,0.0056189513,0.000004282784,2.4655392e-7,0.00003961927,0.0000048546276,0.98979706,0.0022805321],"study_design_scores_gemma":[0.0037607693,0.001199363,0.0002712347,0.001756517,0.0004857866,0.0026159412,0.000012215043,0.000008227109,0.000018887651,0.000050592484,0.9893037,0.0005167863],"about_ca_topic_score_codex":0.00011660364,"about_ca_topic_score_gemma":0.00013092226,"teacher_disagreement_score":0.013675107,"about_ca_system_score_codex":0.002728285,"about_ca_system_score_gemma":0.0053355675,"threshold_uncertainty_score":0.9997492},"labels":[],"label_agreement":null},{"id":"W4254785835","doi":"10.14740/jmc3559","title":"Acute Plasma Cell Leukemia Presenting as Primary Hyperammonemic Encephalopathy","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Plasma cell leukemia; Presentation (obstetrics); Encephalopathy; Multiple myeloma; Rare disease; Pediatrics; Gastroenterology; Internal medicine; Disease; Surgery","score_opus":0.02940594188479715,"score_gpt":0.30881442865580916,"score_spread":0.279408486771012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254785835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97051716,0.0012784121,0.00015688068,0.023214739,0.0002357422,0.00019520723,0.0000067093442,0.000038128368,0.0043570227],"genre_scores_gemma":[0.9847395,0.0019871963,0.0018795273,0.008236632,0.0025815675,0.0000039100228,0.000010763253,0.000047348163,0.00051356846],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99483144,0.0001468091,0.0008648289,0.0002609425,0.0033973753,0.0004985811],"domain_scores_gemma":[0.996523,0.0007969874,0.00035720775,0.00020682244,0.00031905936,0.0017969109],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009347494,0.00021956337,0.0007114275,0.00016771001,0.00008876318,0.000045912413,0.0005665699,0.00029005547,0.0014097539],"category_scores_gemma":[0.004750901,0.00016048501,0.00029797346,0.00037824086,0.00022244405,0.00021682595,0.00028709864,0.002085394,0.00019878526],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00675763,0.00064081186,0.012558086,0.0013831371,0.0006949747,0.43647745,0.003381101,0.00003318797,0.15829106,0.000056347497,0.32085696,0.058869276],"study_design_scores_gemma":[0.044756807,0.014410883,0.007085018,0.002349101,0.0026610966,0.33807003,0.0060568717,0.016416844,0.23771451,0.0001759743,0.32888296,0.0014199085],"about_ca_topic_score_codex":0.00003743472,"about_ca_topic_score_gemma":0.0000012354393,"teacher_disagreement_score":0.09840742,"about_ca_system_score_codex":0.00061784725,"about_ca_system_score_gemma":0.005048851,"threshold_uncertainty_score":0.9995031},"labels":[],"label_agreement":null},{"id":"W4256240343","doi":"10.1182/blood.v118.21.3612.3612","title":"High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After Consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of Low Dose IL-2 Maintenance,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Randomization; Etoposide; Transplantation; Daunorubicin; Leukemia; Internal medicine; Hazard ratio; Cytarabine; Surgery; Gastroenterology; Busulfan; Minimal residual disease; Chemotherapy; Hematopoietic stem cell transplantation; Randomized controlled trial; Confidence interval","score_opus":0.016753933631717365,"score_gpt":0.22298008808980913,"score_spread":0.20622615445809175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256240343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965279,0.000032669923,0.000048640628,0.00014410297,0.00012881533,0.0027426635,0.00024979215,0.000025015515,0.00010038247],"genre_scores_gemma":[0.9986015,0.00022658288,0.0006428922,0.000057845056,0.00007043506,0.00014440915,0.000107856824,0.000048366514,0.00010013485],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99655646,0.00032454875,0.0012191307,0.00056465244,0.0009185775,0.00041661164],"domain_scores_gemma":[0.99748796,0.00020109906,0.0010318306,0.0007074122,0.00046313985,0.00010856128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086633704,0.00036921934,0.00081174844,0.0002935545,0.00013164608,0.000019303889,0.0002038917,0.00028022897,0.000015009836],"category_scores_gemma":[0.00011223989,0.00023497175,0.00010242829,0.0004963136,0.0005320023,0.00028714124,0.00008196971,0.00057527266,8.348307e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48514375,0.0022574253,0.43651643,0.0022564963,0.0008549516,0.00096014375,0.008470696,0.0001823781,0.060663912,0.00041820374,0.0000461657,0.0022294323],"study_design_scores_gemma":[0.057939943,0.0031268394,0.7761238,0.0005814245,0.00053272146,0.0003149367,0.00016700344,0.000045386565,0.16089404,0.000082497165,0.0000035468315,0.00018784727],"about_ca_topic_score_codex":0.0005461615,"about_ca_topic_score_gemma":0.00011203596,"teacher_disagreement_score":0.4272038,"about_ca_system_score_codex":0.0004780245,"about_ca_system_score_gemma":0.00088997546,"threshold_uncertainty_score":0.958187},"labels":[],"label_agreement":null},{"id":"W4280567411","doi":"10.1186/s12915-022-01315-1","title":"Polycomb contraction differentially regulates terminal human hematopoietic differentiation programs","year":2022,"lang":"en","type":"article","venue":"BMC Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Terry Fox Research Institute; University of British Columbia Hospital; Canada's Michael Smith Genome Sciences Centre","funders":"Terry Fox Research Institute; Canadian Institutes of Health Research; Canada's Michael Smith Genome Sciences Centre; Genome Canada","keywords":"Biology; Haematopoiesis; Chromatin; Cell biology; Epigenetics; Progenitor cell; Myeloid; Cellular differentiation; DNA methylation; Stem cell; Transcription factor; Embryonic stem cell; Myelopoiesis; Genetics; Immunology; Gene expression; Gene","score_opus":0.03260153589274777,"score_gpt":0.3178417339323334,"score_spread":0.2852401980395856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280567411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968555,0.00012800352,0.0008312904,0.00059576344,0.00027427592,0.00069881516,0.000009780695,0.00014098034,0.00046559225],"genre_scores_gemma":[0.9958827,0.000006503255,0.00032223994,0.000121588964,0.00022503725,0.0002575081,0.00087633566,0.000027651968,0.0022804234],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99840593,0.00028335894,0.00031108002,0.000369775,0.00022238867,0.0004074899],"domain_scores_gemma":[0.9992981,0.000059495876,0.00013370335,0.0003359861,0.00006131219,0.000111415546],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022654296,0.00016283836,0.00033114222,0.00018259065,0.00033877234,0.000021742313,0.00016756458,0.00012462336,0.0011080046],"category_scores_gemma":[0.000044916,0.00013931548,0.00012804661,0.0001689752,0.00014594228,0.000037955346,0.00020365305,0.00046280635,0.000033106953],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010638732,0.0011322794,0.36376658,0.00019753845,0.00018944177,0.00006591973,0.00033492935,0.0000023986033,0.6057138,0.008676446,0.0010621912,0.01779464],"study_design_scores_gemma":[0.009027112,0.0047970326,0.9463807,0.000055943252,0.0003361888,0.0019543238,0.00074855646,0.0023107934,0.017834902,0.0059329104,0.010030198,0.00059137534],"about_ca_topic_score_codex":0.00011567957,"about_ca_topic_score_gemma":0.0000428653,"teacher_disagreement_score":0.5878789,"about_ca_system_score_codex":0.0003159314,"about_ca_system_score_gemma":0.00014016473,"threshold_uncertainty_score":0.9998051},"labels":[],"label_agreement":null},{"id":"W4280569962","doi":"10.1002/ajh.26587","title":"Optical genome mapping for structural variation analysis in hematologic malignancies","year":2022,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Fluorescence in situ hybridization; Karyotype; Chromosomal translocation; Biology; Copy-number variation; Comparative genomic hybridization; Computational biology; Microarray; Myeloid leukemia; Structural variation; Cytogenetics; DNA microarray; Genome; Breakpoint; Genetics; Chromosome; Cancer research; Gene","score_opus":0.019104876557572377,"score_gpt":0.3051088845966437,"score_spread":0.28600400803907133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280569962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824641,0.00032469153,0.013047707,0.0037869534,0.000078762045,0.0002197804,0.000007728405,0.000009295073,0.000061012677],"genre_scores_gemma":[0.9766939,0.000020534733,0.022725245,0.00043212122,0.000044609074,0.00002986546,0.000013882272,0.000013578242,0.000026248032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981902,0.00019882918,0.00070701167,0.0001917994,0.000329868,0.0003822634],"domain_scores_gemma":[0.9985625,0.00042620912,0.0005196986,0.00017829955,0.00019369731,0.00011959366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077508297,0.00011997073,0.0010601694,0.0011329465,0.00010004043,0.000008727241,0.00022474786,0.00003718082,0.0002472264],"category_scores_gemma":[0.00036339,0.00010090547,0.0002752483,0.0014878794,0.00020662045,0.000058484526,0.00010538508,0.00047369895,0.0000018911485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008151783,0.0007966392,0.80467284,0.0005000009,0.008812588,0.0091902865,0.0108719235,0.012663831,0.09057641,0.042677253,0.0011175284,0.009968893],"study_design_scores_gemma":[0.011615484,0.010718903,0.8158094,0.000071728915,0.002516924,0.08442552,0.031801756,0.029277641,0.0021052158,0.00743474,0.0033672329,0.000855433],"about_ca_topic_score_codex":0.00003471663,"about_ca_topic_score_gemma":0.0000055028772,"teacher_disagreement_score":0.0884712,"about_ca_system_score_codex":0.00046743758,"about_ca_system_score_gemma":0.00034775326,"threshold_uncertainty_score":0.41148055},"labels":[],"label_agreement":null},{"id":"W4281259838","doi":"10.1016/j.leukres.2022.106869","title":"NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1","year":2022,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto","funders":"Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"NPM1; Internal medicine; Oncology; Medicine; Myeloid leukemia; Proportional hazards model; Exact test; Survival analysis; Biology; Genetics; Karyotype; Gene","score_opus":0.10397729320274199,"score_gpt":0.3633612639273743,"score_spread":0.25938397072463226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281259838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845874,0.00024260308,0.00002248282,0.005346136,0.00015952981,0.0029934954,0.00028411203,0.000094296935,0.0062699914],"genre_scores_gemma":[0.9898507,0.000072570474,0.00042677572,0.0010206876,0.000052688512,0.0006218336,0.0002470933,0.00013297393,0.0075746817],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9927821,0.0013702039,0.0009940637,0.00085049355,0.0028381967,0.0011649398],"domain_scores_gemma":[0.9927572,0.0033206416,0.00028220034,0.001275819,0.0016966896,0.00066745473],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003040796,0.00042948997,0.0010860795,0.0015173397,0.00047569067,0.00005229253,0.0008875436,0.00017705002,0.0043318565],"category_scores_gemma":[0.0027312138,0.00030548626,0.0001449272,0.0027750111,0.0016906599,0.00014989969,0.0006342341,0.002831943,0.00006914862],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.077997334,0.0030758262,0.18719657,0.0040339082,0.004406573,0.008140177,0.051193677,0.0050942027,0.38057652,0.005407035,0.25949457,0.013383618],"study_design_scores_gemma":[0.06518623,0.034755364,0.62066007,0.0016096705,0.00095303304,0.0008596312,0.061397433,0.022006026,0.109636515,0.00039427783,0.079866506,0.0026752437],"about_ca_topic_score_codex":0.00819763,"about_ca_topic_score_gemma":0.00091668894,"teacher_disagreement_score":0.43346348,"about_ca_system_score_codex":0.009462457,"about_ca_system_score_gemma":0.012580798,"threshold_uncertainty_score":0.99993974},"labels":[],"label_agreement":null},{"id":"W4281381512","doi":"10.1002/jha2.466","title":"The 17‐gene stemness score associates with relapse risk and long‐term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia","year":2022,"lang":"en","type":"article","venue":"eJHaem","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"Ontario Institute for Cancer Research; Princess Margaret Cancer Foundation; Leukemia and Lymphoma Society of Canada","keywords":"Medicine; Internal medicine; Transplantation; Framingham Risk Score; Haematopoiesis; Incidence (geometry); Oncology; Myeloid; Hematology; Hematopoietic stem cell transplantation; Stem cell; Disease; Biology","score_opus":0.015462458136434747,"score_gpt":0.2716811655757686,"score_spread":0.25621870743933384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281381512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99576515,0.001618754,0.0001032458,0.0010140366,0.00014758983,0.0009634102,0.000058760812,0.00007063422,0.00025841114],"genre_scores_gemma":[0.99444336,0.00094569835,0.0002464973,0.00022873796,0.000031017305,0.00025594965,0.00012575599,0.00006860102,0.0036543775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734247,0.0003511975,0.0004076068,0.00048016588,0.000823534,0.0005950477],"domain_scores_gemma":[0.9986596,0.0005121493,0.00017211084,0.0004427872,0.000051626575,0.00016170763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011146395,0.0002849423,0.0005200554,0.00018979613,0.00070632325,0.000070734255,0.0002953128,0.0001019524,0.00004387481],"category_scores_gemma":[0.00005390986,0.00019319005,0.00014002534,0.00049856136,0.00012011901,0.00013171596,0.00015299504,0.0009186122,0.000010841329],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005137802,0.000080387,0.9885512,0.00010433205,0.00031026438,0.0025901708,0.0031308,0.000081702034,0.0028864238,0.000013119786,0.00019199033,0.0015458306],"study_design_scores_gemma":[0.0059900675,0.00041897176,0.98533773,0.00009309089,0.00058636727,0.0004150235,0.0012275098,0.000086489876,0.0053776316,0.00005476365,0.00012313933,0.00028920686],"about_ca_topic_score_codex":0.00020688058,"about_ca_topic_score_gemma":0.0005269664,"teacher_disagreement_score":0.0054762876,"about_ca_system_score_codex":0.00065619574,"about_ca_system_score_gemma":0.00034339915,"threshold_uncertainty_score":0.78780615},"labels":[],"label_agreement":null},{"id":"W4281569605","doi":"10.1038/s41591-022-01819-x","title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":338,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; British Columbia Institute of Technology; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Myeloid leukemia; Leukemia; Computational biology; Biomarker; Biology; Progenitor cell; Drug response; Transcriptome; Disease; Medicine; Bioinformatics; Stem cell; Cancer research; Drug; Immunology; Gene; Internal medicine; Genetics; Gene expression; Pharmacology","score_opus":0.027364280669321034,"score_gpt":0.32835889316422107,"score_spread":0.3009946124949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281569605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9593996,0.005476953,0.0082501285,0.024319278,0.0005010241,0.0016489102,0.00006725777,0.00012373716,0.00021312783],"genre_scores_gemma":[0.99009955,0.00021111392,0.0047018277,0.0033953832,0.00058733503,0.00025323653,0.00012083943,0.00008605993,0.000544654],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99638873,0.0004725374,0.0005247924,0.00075691694,0.0010874803,0.00076955056],"domain_scores_gemma":[0.99601567,0.0028079879,0.00015103703,0.0005572274,0.000095809344,0.00037226954],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004199733,0.00032870856,0.000716423,0.0008139436,0.0004915854,0.000018494624,0.0003021772,0.0003785462,0.00012738138],"category_scores_gemma":[0.0034767808,0.00028179368,0.00010585725,0.001104217,0.00032622574,0.0000920996,0.00038847319,0.0043031243,0.0000015508784],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14195082,0.0007474886,0.17354234,0.0029329464,0.0026022322,0.011590694,0.040729497,0.0003728128,0.5056708,0.0484443,0.06049812,0.010917976],"study_design_scores_gemma":[0.15657564,0.029563092,0.117848895,0.008284986,0.0039465884,0.008594952,0.086327635,0.09182885,0.093519494,0.1644512,0.23386393,0.0051947394],"about_ca_topic_score_codex":0.00006674687,"about_ca_topic_score_gemma":0.000024446033,"teacher_disagreement_score":0.41215128,"about_ca_system_score_codex":0.0043141632,"about_ca_system_score_gemma":0.0007035093,"threshold_uncertainty_score":0.9999634},"labels":[],"label_agreement":null},{"id":"W4281677430","doi":"10.1200/jco.2022.40.16_suppl.e19024","title":"Changes in health-related quality of life in patients with newly diagnosed acute myeloid leukemia receiving ivosidenib + azacitidine or placebo + azacitidine.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Azacitidine; Quality of life (healthcare); Placebo; Clinical endpoint; Internal medicine; Myeloid leukemia; Clinical trial; Oncology; Gastroenterology","score_opus":0.10873777328544383,"score_gpt":0.42922506705934815,"score_spread":0.32048729377390434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281677430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764529,0.00027354617,0.000018815548,0.02134822,0.0005320927,0.0010300775,0.00003943566,0.000016418628,0.00028851832],"genre_scores_gemma":[0.99213654,0.0012827115,0.0021641399,0.0035969564,0.00029674068,0.000051609888,0.00003286274,0.000055795757,0.0003826369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98621255,0.0043899748,0.0066714687,0.000471979,0.0014912407,0.00076279574],"domain_scores_gemma":[0.9832765,0.009768237,0.005068625,0.00043151868,0.00062655425,0.00082855823],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01734272,0.0003003925,0.003961542,0.0009069031,0.000093905335,0.000009183029,0.0005274401,0.00044180767,0.0008827082],"category_scores_gemma":[0.017449072,0.0002187424,0.00031516523,0.0013405317,0.00035513,0.00019380098,0.00034989705,0.004444076,0.0000062035215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.098939545,0.0026977283,0.8622422,0.00021490916,0.0005469627,0.0018172618,0.0007221134,0.00058944814,0.0001233744,0.000031892567,0.004145391,0.027929144],"study_design_scores_gemma":[0.07779848,0.03344965,0.88355577,0.00041494222,0.00008980222,0.000121582074,0.00095789065,0.00024423716,0.00003143104,0.00006392061,0.0030626021,0.00020970842],"about_ca_topic_score_codex":0.0014654018,"about_ca_topic_score_gemma":0.0052905967,"teacher_disagreement_score":0.03075192,"about_ca_system_score_codex":0.003916847,"about_ca_system_score_gemma":0.014179489,"threshold_uncertainty_score":0.99990696},"labels":[],"label_agreement":null},{"id":"W4281717206","doi":"10.1200/jco.2022.40.16_suppl.e19020","title":"Treatment outcomes for newly diagnosed, untreated <i>TP53</i>-mutated acute myeloid leukemia: A systematic review and meta-analysis.","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Gilead Sciences","keywords":"Medicine; Internal medicine; Ven; Meta-analysis; Myeloid leukemia; Venetoclax; Oncology; Randomized controlled trial; Leukemia; Gastroenterology; Chronic lymphocytic leukemia","score_opus":0.3036780685263099,"score_gpt":0.5344606692025908,"score_spread":0.23078260067628092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281717206","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009708099,0.9846508,0.000053299686,0.0056059607,0.00027742938,0.008785389,0.00036625055,0.000032425032,0.00021874375],"genre_scores_gemma":[0.0000037928512,0.9853699,0.0017723403,0.0047373762,0.00026886316,0.0018930195,0.00031239158,0.00013217141,0.005510096],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97938013,0.0055546174,0.012308091,0.00092212326,0.0010848116,0.0007501974],"domain_scores_gemma":[0.95005053,0.03488393,0.011804728,0.0012117203,0.0008690145,0.0011800504],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_broad","research_integrity"],"category_scores_codex":[0.010374131,0.0011355317,0.06388625,0.0010796032,0.00015849997,0.00004544882,0.0008181132,0.0013213248,0.001088152],"category_scores_gemma":[0.015799128,0.00056523696,0.022833718,0.001584332,0.0003060174,0.00013179443,0.00029446563,0.003097176,0.000037793954],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00033111998,0.0008207002,0.000015813175,0.27790967,0.66749114,0.005168012,0.000021395144,0.0000015199695,2.6402745e-8,0.000013612358,0.004750877,0.04347611],"study_design_scores_gemma":[0.0040439153,0.007054437,0.0000065168574,0.0037437286,0.56003827,0.002218224,0.000015881937,0.000008929614,3.666626e-8,0.000008270924,0.42264092,0.00022087457],"about_ca_topic_score_codex":0.00007963226,"about_ca_topic_score_gemma":0.00004369108,"teacher_disagreement_score":0.41789004,"about_ca_system_score_codex":0.0046656225,"about_ca_system_score_gemma":0.013731501,"threshold_uncertainty_score":0.99997514},"labels":[],"label_agreement":null},{"id":"W4281770660","doi":"10.1016/j.cmet.2022.05.006","title":"Biting into a union of oncology and metabolism through leukemic stem cells","year":2022,"lang":"en","type":"letter","venue":"Cell Metabolism","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research; Canada Research Chairs; Canadian Cancer Society","keywords":"Myeloid leukemia; Stem cell; Cancer research; Leukemia; Metabolism; Biology; Medicine; Immunology; Cell biology; Endocrinology","score_opus":0.02744873713776395,"score_gpt":0.29315773271307766,"score_spread":0.2657089955753137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281770660","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2803318,0.15320747,0.0006536908,0.48580673,0.008783657,0.007102546,0.000699395,0.0006365519,0.06277817],"genre_scores_gemma":[0.025985517,0.039600264,0.022338035,0.7943646,0.022810519,0.0010069251,0.0018026136,0.0014430019,0.09064856],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937097,0.0013378669,0.0012116008,0.0012691282,0.0013461125,0.001125594],"domain_scores_gemma":[0.9964734,0.0007677799,0.00087216875,0.0013017583,0.00034615776,0.00023877558],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.001396405,0.000813283,0.0027126214,0.0008256474,0.00025011954,0.000042279873,0.0007237975,0.0015324901,0.00097529375],"category_scores_gemma":[0.000079867365,0.00074618385,0.00046304835,0.0008696858,0.0005701375,0.0001949788,0.0011419551,0.0065318397,0.00008206466],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020257098,0.00013688167,0.000015253577,0.0024987028,0.00049920497,0.0015434606,0.0035479472,0.000007353953,0.123652376,0.0002294297,0.8464178,0.02124902],"study_design_scores_gemma":[0.0036649422,0.0002265717,0.000056307697,0.00009466357,0.0012587833,0.00022515639,0.00075817783,0.000059558726,0.053787004,0.0003263222,0.9390163,0.0005262409],"about_ca_topic_score_codex":0.0012479008,"about_ca_topic_score_gemma":0.0000047694825,"teacher_disagreement_score":0.3085578,"about_ca_system_score_codex":0.0008932952,"about_ca_system_score_gemma":0.0020297137,"threshold_uncertainty_score":0.99993795},"labels":[],"label_agreement":null},{"id":"W4281912306","doi":"10.1200/jco.2022.40.16_suppl.7005","title":"Overall survival by <i>IDH2</i> mutant allele (R140 or R172) in patients with late-stage mutant-<i>IDH2</i> relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"IDH2; Medicine; Internal medicine; Myeloid leukemia; Clinical endpoint; Refractory (planetary science); Gastroenterology; Oncology; Randomized controlled trial; IDH1; Mutant; Gene; Biology; Genetics","score_opus":0.07142988887852038,"score_gpt":0.4136009994397066,"score_spread":0.3421711105611862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281912306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99236315,0.00014616652,0.000015696423,0.003359906,0.0005822181,0.0024520024,0.0003500832,0.000029059323,0.0007017062],"genre_scores_gemma":[0.9862578,0.00080126146,0.00052642747,0.004075127,0.0005120778,0.0001763444,0.00047274225,0.00013023785,0.0070480085],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9878378,0.0038089477,0.004033308,0.0007937408,0.0025622873,0.00096389686],"domain_scores_gemma":[0.98953694,0.005413976,0.002880473,0.00073097006,0.00083206396,0.0006055805],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006378476,0.000554881,0.0029058962,0.00048317644,0.00025073704,0.00004946578,0.0009377822,0.00059992285,0.0021933895],"category_scores_gemma":[0.0025220476,0.00027493434,0.00046886044,0.0011240455,0.0005537006,0.00034392727,0.00026134067,0.0056115417,0.00001366313],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9055117,0.009694005,0.02654802,0.00007778083,0.0013417038,0.032131664,0.0010988392,0.00012754777,0.0006608101,0.000016338538,0.019029906,0.003761722],"study_design_scores_gemma":[0.60647255,0.16773976,0.023193054,0.00023556588,0.0008928065,0.0007830341,0.0031788868,0.00015059275,0.00019992312,0.000011396171,0.1966262,0.0005162131],"about_ca_topic_score_codex":0.0003004601,"about_ca_topic_score_gemma":0.001243352,"teacher_disagreement_score":0.2990391,"about_ca_system_score_codex":0.004192565,"about_ca_system_score_gemma":0.0144743025,"threshold_uncertainty_score":0.99997026},"labels":[],"label_agreement":null},{"id":"W4281985872","doi":"10.1111/trf.16946","title":"Multi‐national survey of transfusion experiences and preferences of patients with myelodysplastic syndrome","year":2022,"lang":"en","type":"article","venue":"Transfusion","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Blood transfusion; Quality of life (healthcare); Audit; Hemoglobin; Pediatrics; Intensive care medicine; Internal medicine","score_opus":0.03265360828471446,"score_gpt":0.28314685893347463,"score_spread":0.25049325064876016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281985872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99862,0.000077495366,0.00035378904,0.000039937273,0.000037685913,0.0005887972,0.00016152827,0.000013396708,0.00010742309],"genre_scores_gemma":[0.9989429,0.000114977636,0.00064698525,0.000010388617,0.000003397663,0.00006851876,0.00014652559,0.000012963902,0.00005332304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981217,0.00016663459,0.00028172828,0.000255491,0.0010217539,0.00015269766],"domain_scores_gemma":[0.99924284,0.00020932459,0.00006722469,0.00010987281,0.00029194198,0.00007880634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004319885,0.00011430384,0.00029172085,0.00019146042,0.00012340579,0.0000034148914,0.000109869594,0.000041746393,0.0006789612],"category_scores_gemma":[0.000050137085,0.000085186126,0.000030160829,0.0004319799,0.00019905272,0.00007718521,0.000035689245,0.00019794986,6.4164755e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050339904,0.0010836313,0.9586998,0.00032961473,0.00007970326,0.000012781519,0.011598217,0.000107367334,0.01884757,0.00001378746,0.00003482647,0.004158685],"study_design_scores_gemma":[0.003924407,0.0022848288,0.9894277,0.00006106217,0.000029854024,0.000019713038,0.0012800064,0.0007103152,0.0021482543,0.000005724258,0.000018936502,0.000089194575],"about_ca_topic_score_codex":0.0010659581,"about_ca_topic_score_gemma":0.00025238935,"teacher_disagreement_score":0.030727878,"about_ca_system_score_codex":0.000062225736,"about_ca_system_score_gemma":0.00026480146,"threshold_uncertainty_score":0.74341494},"labels":[],"label_agreement":null},{"id":"W4282542898","doi":"10.1007/s40487-022-00200-9","title":"Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-Making","year":2022,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Pfizer (Canada)","funders":"Pfizer Canada; Astellas Pharma; Flatiron Health; Springworks Therapeutics; Agios Pharmaceuticals; Jazz Pharmaceuticals; Celgene; AstraZeneca; National Institute of Nursing Research; Daiichi-Sankyo; Amgen; Pfizer; National Institutes of Health; Helsinn","keywords":"Medicine; Qualitative research; Quality of life (healthcare); Family medicine; Stakeholder; Perspective (graphical); Intensive care medicine; Nursing; Public relations","score_opus":0.023188599716836088,"score_gpt":0.3436971896524644,"score_spread":0.3205085899356283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282542898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987773,0.00799548,0.0000132719815,0.00060555723,0.000028881592,0.00030859394,0.000003122903,0.000014502219,0.0032576066],"genre_scores_gemma":[0.9956249,0.0025698706,0.0005752099,0.00087172096,0.000041986554,0.00019138995,0.0000016067119,0.000010348155,0.00011297227],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.99929607,0.00008616774,0.00007342159,0.0002636578,0.00012625057,0.00015442018],"domain_scores_gemma":[0.99954987,0.00022791426,0.000035854366,0.00009685342,0.000026533426,0.00006300267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008121428,0.00010280142,0.00021393721,0.00006468326,0.00032351952,0.000012025764,0.000026692682,0.0000351095,0.00010841862],"category_scores_gemma":[0.0000070754027,0.00006565374,0.000015688918,0.0000940818,0.0002937046,0.00004686212,0.000048859758,0.00013259944,5.8252476e-7],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032778827,0.00033836637,0.00616248,0.0000029857968,0.00016136093,0.00021292455,0.12898007,8.6471584e-7,0.001075382,0.00025011075,0.00020777993,0.85932976],"study_design_scores_gemma":[0.010598479,0.033509687,0.03947679,0.000041195413,0.000056901194,0.00071908854,0.8274046,0.00029351196,0.00056373276,0.00062308036,0.08643154,0.00028139492],"about_ca_topic_score_codex":0.00003824236,"about_ca_topic_score_gemma":0.000011177994,"teacher_disagreement_score":0.85904837,"about_ca_system_score_codex":0.00017249248,"about_ca_system_score_gemma":0.00013596963,"threshold_uncertainty_score":0.26772818},"labels":[],"label_agreement":null},{"id":"W4282939251","doi":"10.1158/1538-7445.am2022-ct537","title":"Abstract CT537: A phase 2, multicenter, randomized, double-blind trial of maintenance therapy with FLT3 inhibitor gilteritinib (ASP2215) in patients with FLT3/ITD AML (GOSSAMER study)","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Placebo; Surgery; Internal medicine; Randomization; Discontinuation; Intention-to-treat analysis; Hazard ratio; Randomized controlled trial; Confidence interval; Pathology","score_opus":0.08475048191245492,"score_gpt":0.4207714481141023,"score_spread":0.33602096620164734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282939251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97948486,0.00036541416,0.000008503132,0.0009407007,0.00020056794,0.018168394,0.00015405512,0.000035454552,0.0006420543],"genre_scores_gemma":[0.989413,0.0002783572,0.000097575496,0.00011688865,0.0003407611,0.008539455,0.000097622345,0.00013018804,0.0009861097],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9915988,0.0011658684,0.0009877987,0.0009752583,0.0039570155,0.001315288],"domain_scores_gemma":[0.996343,0.0006935105,0.00029597533,0.000987453,0.0012798879,0.00040016894],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0052296235,0.00040684923,0.001393212,0.0010161885,0.00030953615,0.00007685192,0.0006761269,0.000104915714,0.0017466884],"category_scores_gemma":[0.00030160457,0.00027652193,0.00017230524,0.0018746015,0.0009792523,0.00023756975,0.0003756491,0.0023849548,0.000017054075],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96709836,0.010728492,0.010181996,0.00015206526,0.00053988176,0.00040221112,0.0022302472,0.000048402715,0.0016781596,0.00001082382,0.0016476276,0.0052817264],"study_design_scores_gemma":[0.9771829,0.010950975,0.0032959275,0.00032420803,0.000051333085,0.000005746065,0.0025435607,0.000077434146,0.0032334365,0.0000049825976,0.0020352323,0.00029426618],"about_ca_topic_score_codex":0.0048524765,"about_ca_topic_score_gemma":0.00031187283,"teacher_disagreement_score":0.010084532,"about_ca_system_score_codex":0.0016682361,"about_ca_system_score_gemma":0.0024049708,"threshold_uncertainty_score":0.9999687},"labels":[],"label_agreement":null},{"id":"W4282946191","doi":"10.1007/s11899-022-00663-7","title":"Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies","year":2022,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"Canadian Institutes of Health Research","keywords":"CHEK2; Germline; Myeloid leukemia; Myeloid; Germline mutation; Biology; Chronic lymphocytic leukemia; Leukemia; Cancer research; Immunology; Genetics; Mutation; Gene","score_opus":0.0919673839579153,"score_gpt":0.37176420474396765,"score_spread":0.27979682078605234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282946191","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027965908,0.99148995,0.000010878314,0.000092021604,0.0005917481,0.0032387336,0.000050004946,0.00015981871,0.0015702448],"genre_scores_gemma":[0.0004833259,0.9965495,0.0002700978,0.00009234695,0.0001359312,0.0011579923,0.00018762027,0.0001624825,0.00096072134],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99324083,0.0004204214,0.0024659312,0.0019154386,0.0008494781,0.0011079046],"domain_scores_gemma":[0.9964081,0.0004380398,0.001250239,0.0013633292,0.000082916085,0.00045738913],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016396932,0.0011038146,0.004731006,0.00077446137,0.00018909965,0.00007984243,0.00027640446,0.00059966993,0.0012845877],"category_scores_gemma":[0.00090023736,0.0008512886,0.00044503753,0.0009957631,0.00039957033,0.00011167671,0.000990537,0.0016944319,0.00003625103],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007088512,0.0010405252,0.016316313,0.22656319,0.0004766575,0.05414483,0.0006864679,1.763155e-7,0.000011521538,0.0028953317,0.005116692,0.69267744],"study_design_scores_gemma":[0.0005637332,0.00012520998,0.00020741248,0.023972988,0.0006303378,0.08167792,0.000048306432,0.0000079597885,0.0000063343773,0.0007193826,0.89129317,0.0007472298],"about_ca_topic_score_codex":0.00003611916,"about_ca_topic_score_gemma":0.000006487584,"teacher_disagreement_score":0.88617647,"about_ca_system_score_codex":0.0005017669,"about_ca_system_score_gemma":0.0012019696,"threshold_uncertainty_score":0.99962837},"labels":[],"label_agreement":null},{"id":"W4283073514","doi":"10.1182/blood.2021014901","title":"Enasidenib vs conventional care in older patients with late-stage mutant-<i>IDH2</i> relapsed/refractory AML: a randomized phase 3 trial","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Medical Research Council; National Institute for Health and Care Research; Celgene; Bristol-Myers Squibb","keywords":"Medicine; Hazard ratio; Internal medicine; Gastroenterology; Randomized controlled trial; Clinical endpoint; Cytarabine; Refractory (planetary science); Surgery; Confidence interval; Myeloid leukemia; Biology","score_opus":0.01125520532681904,"score_gpt":0.2783481008911824,"score_spread":0.26709289556436333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283073514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931387,0.0003547265,0.000014311575,0.00023129872,0.00023576496,0.0042612855,0.00027040302,0.00007575509,0.0014178015],"genre_scores_gemma":[0.99500066,0.000027653154,0.00016509449,0.00039121474,0.00016819777,0.0009792594,0.00094775116,0.00007134009,0.0022488055],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964998,0.00063596165,0.00059702154,0.0005159637,0.0012529726,0.0004982891],"domain_scores_gemma":[0.9985091,0.0004169491,0.00020991644,0.0004400932,0.00020738589,0.00021653327],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00079864805,0.00026066377,0.00084623287,0.00035663598,0.00018008488,0.000026124973,0.00021617448,0.000108199485,0.002466129],"category_scores_gemma":[0.0004166172,0.00021276102,0.0002451596,0.00045579913,0.00016891795,0.00012107778,0.00018311244,0.0009976582,0.00003525637],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.982169,0.0066749486,0.006076227,0.00012680801,0.00040316753,0.001211817,0.0016331915,0.000025456027,0.0005800157,0.00005708555,0.0006901303,0.00035220454],"study_design_scores_gemma":[0.9874678,0.0034657745,0.0009465615,0.000072806026,0.00033825214,0.000018120503,0.0005678014,0.000090935144,0.000899946,0.000011058596,0.0058832983,0.00023763787],"about_ca_topic_score_codex":0.00013712722,"about_ca_topic_score_gemma":0.000032398817,"teacher_disagreement_score":0.00529886,"about_ca_system_score_codex":0.00046082237,"about_ca_system_score_gemma":0.0010197184,"threshold_uncertainty_score":0.99844575},"labels":[],"label_agreement":null},{"id":"W4283078101","doi":"10.1182/blood.2021014875","title":"A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for testing interventions","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Institutes of Health; Wellcome Trust","keywords":"Biology; Rhesus macaque; Myeloid; Haematopoiesis; Progenitor cell; Transplantation; Cancer research; Immunology; CRISPR; Gene; Genetics; Stem cell; Internal medicine; Medicine","score_opus":0.08343526588746084,"score_gpt":0.3426128571762473,"score_spread":0.2591775912887865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283078101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949631,0.00045142445,0.0027356476,0.00047411196,0.000016343249,0.00063805666,0.0002012363,0.000050505907,0.00046956126],"genre_scores_gemma":[0.9695845,0.0000103285,0.029816369,0.000036969323,0.000024021332,0.00022575272,0.0000540827,0.000019283652,0.000228663],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9988817,0.00005536024,0.00033825162,0.00025256025,0.00025114286,0.00022099292],"domain_scores_gemma":[0.9991128,0.00032687036,0.00009336316,0.00020689113,0.00016444674,0.00009563865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003757096,0.000107208405,0.0002762392,0.00012879855,0.00021388337,0.000008943841,0.00009456741,0.00004625547,0.00006923246],"category_scores_gemma":[0.00055424933,0.00010115929,0.00013550172,0.00025249177,0.00010914216,0.000049887556,0.00022057525,0.0001975738,4.899632e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022016233,0.00674198,0.2921204,0.009336204,0.0011866059,0.00019571879,0.0022703644,0.00045443143,0.65266675,0.00329018,0.0033126345,0.026223127],"study_design_scores_gemma":[0.025089147,0.003669156,0.04170597,0.0011562546,0.0019151522,0.0019795962,0.006306523,0.674028,0.23146276,0.011643243,0.00031484582,0.0007293745],"about_ca_topic_score_codex":0.000064536056,"about_ca_topic_score_gemma":0.000009035049,"teacher_disagreement_score":0.67357355,"about_ca_system_score_codex":0.00004171528,"about_ca_system_score_gemma":0.00029687592,"threshold_uncertainty_score":0.4125156},"labels":[],"label_agreement":null},{"id":"W4283171912","doi":"10.1111/trf.16985","title":"Transfusion thresholds in myelodysplastic syndrome—Helping patients live better","year":2022,"lang":"en","type":"letter","venue":"Transfusion","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Intensive care medicine; Immunology","score_opus":0.017919491472860507,"score_gpt":0.2590376852873063,"score_spread":0.2411181938144458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283171912","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7730353,0.00022644497,0.00011062849,0.22044976,0.0007352785,0.0029514174,0.00017492406,0.00018336157,0.0021328826],"genre_scores_gemma":[0.21128981,0.006462683,0.00088367047,0.75612247,0.0033392871,0.001414096,0.011203876,0.0011374669,0.008146631],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935503,0.00040095163,0.0009911025,0.0014365147,0.0022893627,0.0013317508],"domain_scores_gemma":[0.99819213,0.00040060433,0.00013217812,0.0008966013,0.00015592748,0.00022254618],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00049719395,0.00083095423,0.0013077743,0.0014054714,0.0003134029,0.000050411756,0.0005868542,0.0014886429,0.010644224],"category_scores_gemma":[0.000055359767,0.0007827161,0.00048211316,0.000958504,0.00016584567,0.00019540462,0.00017539818,0.008748798,0.0004194557],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030902154,0.001088068,0.08615943,0.0044886805,0.00039754892,0.033054993,0.0046046763,0.000047532805,0.0025189265,0.000004527727,0.8437163,0.020829082],"study_design_scores_gemma":[0.022318864,0.0059778662,0.11371084,0.003935594,0.0009418923,0.0016737626,0.00034548255,0.0006151719,0.00030762787,0.000136126,0.8475884,0.0024483295],"about_ca_topic_score_codex":0.0013392114,"about_ca_topic_score_gemma":0.00015261008,"teacher_disagreement_score":0.56174546,"about_ca_system_score_codex":0.0018379855,"about_ca_system_score_gemma":0.0005129014,"threshold_uncertainty_score":0.99980766},"labels":[],"label_agreement":null},{"id":"W4283257157","doi":"10.14740/gr1530","title":"Budd-Chiari Syndrome as an Initial Presentation of Non-Promyelocytic Acute Myelogenous Leukemia","year":2022,"lang":"en","type":"article","venue":"Gastroenterology Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Budd–Chiari syndrome; Acute leukemia; Disseminated intravascular coagulation; Acute promyelocytic leukemia; Myeloid leukemia; Gastroenterology; Leukemia; Internal medicine","score_opus":0.0398333593690237,"score_gpt":0.38716428560943444,"score_spread":0.34733092624041073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283257157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99413365,0.000039279337,0.00019674431,0.001631424,0.00021374838,0.0017389643,0.0001109147,0.00007436991,0.0018609212],"genre_scores_gemma":[0.9956116,0.000041537132,0.00094479363,0.00050302985,0.00018411758,0.0006978225,0.000454987,0.000092231734,0.0014698522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926315,0.0018205006,0.00071264687,0.0009130651,0.0021888183,0.0017334834],"domain_scores_gemma":[0.9971675,0.00025533375,0.00016274836,0.0011761854,0.0006583422,0.00057984545],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029722378,0.0002973399,0.00076432666,0.0014222024,0.00066292426,0.00003583536,0.0010301416,0.00019723954,0.0023758623],"category_scores_gemma":[0.00025599165,0.0003039246,0.00018969066,0.0009979901,0.0010080801,0.00022889048,0.0015284804,0.0028527025,0.00019601076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07336471,0.0043197195,0.45924997,0.0010122593,0.0039480757,0.034843735,0.008842189,0.0012385416,0.38032845,0.0007259455,0.020235308,0.011891099],"study_design_scores_gemma":[0.030121924,0.08809061,0.77449954,0.00012481087,0.00059198507,0.061673556,0.00797395,0.017451836,0.01563089,0.0018640574,0.0013156674,0.00066119904],"about_ca_topic_score_codex":0.0011892999,"about_ca_topic_score_gemma":0.000059830094,"teacher_disagreement_score":0.36469755,"about_ca_system_score_codex":0.0019596117,"about_ca_system_score_gemma":0.0024789597,"threshold_uncertainty_score":0.9999413},"labels":[],"label_agreement":null},{"id":"W4283268307","doi":"10.21203/rs.3.rs-1696855/v1","title":"EIF4A inhibition targets bioenergetic homeostasis in AML and synergizes with cytarabine and venetoclax","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Fonds de Recherche du Québec - Santé; Leukemia and Lymphoma Society of Canada; Jewish General Hospital; Leukemia and Lymphoma Society","keywords":"Venetoclax; Cytarabine; Cancer research; Bioenergetics; Biology; Medicine; Internal medicine; Leukemia; Myeloid leukemia; Cell biology; Mitochondrion","score_opus":0.03614025754539126,"score_gpt":0.3584004868466034,"score_spread":0.3222602293012122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283268307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97558415,0.015839536,0.000019784362,0.0046557244,0.00005007108,0.0026125808,0.00021215194,0.000082920946,0.0009430989],"genre_scores_gemma":[0.9783053,0.017400531,0.0009252985,0.0000818613,0.00019885885,0.0011738791,0.0008438222,0.00012930659,0.00094119157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99405247,0.00090977387,0.00045937533,0.0013235398,0.0020936362,0.001161206],"domain_scores_gemma":[0.9974365,0.0005120159,0.000097159515,0.0008897627,0.00048930256,0.00057524303],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0025619387,0.000440748,0.00084158644,0.0020439646,0.00031259845,0.00015885157,0.00023513315,0.0004040947,0.00056291954],"category_scores_gemma":[0.00066719716,0.00037466537,0.0000794275,0.0012194081,0.00081497675,0.00011724841,0.0026908685,0.0042755147,0.000014889588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033888772,0.0031763748,0.5577465,0.07447772,0.0025523563,0.048247095,0.016068596,0.0066685965,0.045946777,0.0042334176,0.049134012,0.15785977],"study_design_scores_gemma":[0.033824086,0.019312833,0.78437227,0.018383333,0.00045715107,0.0017509987,0.014540143,0.02152978,0.016702162,0.007424438,0.07764567,0.0040571117],"about_ca_topic_score_codex":0.0033752376,"about_ca_topic_score_gemma":0.00049804884,"teacher_disagreement_score":0.2266258,"about_ca_system_score_codex":0.002666968,"about_ca_system_score_gemma":0.0022973495,"threshold_uncertainty_score":0.99987054},"labels":[],"label_agreement":null},{"id":"W4283271244","doi":"10.1038/s41375-022-01613-1","title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms","year":2022,"lang":"en","type":"review","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3904,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Hospital for Sick Children","funders":"Sahlgrenska Akademin; National Cancer Institute; Department of Laboratory Medicine and Pathology, University of Washington; School of Medicine, Indiana University; University of Texas MD Anderson Cancer Center; Universitätsklinikum Jena; Hospital for Sick Children; University of California, San Diego; National University Cancer Institute, Singapore; Medizinischen Hochschule Hannover; Université de Montréal; Centre National de la Recherche Scientifique; School of Medicine, Stanford University; Fudan University; Institut Gustave-Roussy; Sahlgrenska Universitetssjukhuset; Vrije Universiteit Amsterdam; University of Oxford; Wellcome Trust; University of Southampton; University of Alabama; Texas Children's Hospital; Amsterdam University Medical Centers; Moffitt Cancer Center; Institut National de la Santé et de la Recherche Médicale; University of Washington; Memorial Sloan-Kettering Cancer Center; Knight Cancer Institute, Oregon Health and Science University; Universität Ulm; University of Texas Southwestern Medical Center; Imperial College London; Children's Hospital Los Angeles; National Institute for Health and Care Research; Assistance publique-Hôpitaux de Paris; Massachusetts General Hospital; Université Paris-Saclay; University of Alabama at Birmingham; Nationwide Children's Hospital; Cincinnati Children's Hospital Medical Center; Centre International de Recherche sur le Cancer; Göteborgs Universitet; Radboud Universiteit; Radboud Universitair Medisch Centrum; Università degli Studi di Milano; University of Pennsylvania","keywords":"Histiocyte; Myeloid; Disease; Hematologic Neoplasms; Medicine; Computational biology; Computer science; Biology; Pathology; Immunology; Cancer; Internal medicine","score_opus":0.04478243319244866,"score_gpt":0.3376422626290177,"score_spread":0.292859829436569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283271244","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00048764757,0.99365664,0.0000887586,0.0016033086,0.000643023,0.0024464147,0.00013171855,0.000057536672,0.000884958],"genre_scores_gemma":[0.00221637,0.9935517,0.00012849669,0.00014892612,0.00028535892,0.00015341188,0.00055842474,0.00011371358,0.0028435974],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99626786,0.00065379875,0.0012371208,0.00046731738,0.0009733722,0.00040055127],"domain_scores_gemma":[0.995967,0.001234087,0.001335884,0.0010426596,0.00026509684,0.00015529315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010457858,0.0003584656,0.0014535085,0.00033418485,0.0004787921,0.000036013753,0.0005455898,0.00019460065,0.00017004446],"category_scores_gemma":[0.0012465508,0.00022082319,0.00025078809,0.0020535304,0.00047590747,0.00007693309,0.0003159161,0.0009819603,0.000013544498],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00007921431,0.00013305385,0.0003989306,0.048882145,0.0003601416,0.00001944406,0.00055624946,0.0000054979364,0.00008669014,0.010554086,0.049556524,0.889368],"study_design_scores_gemma":[0.0008764591,0.00015192611,0.0011167616,0.0073226993,0.00073907996,0.000668202,0.00021525884,0.00021535723,0.00013326437,0.0000890302,0.98824894,0.00022302424],"about_ca_topic_score_codex":0.0002367015,"about_ca_topic_score_gemma":0.00011179809,"teacher_disagreement_score":0.9386924,"about_ca_system_score_codex":0.0067227506,"about_ca_system_score_gemma":0.009647319,"threshold_uncertainty_score":0.9970903},"labels":[],"label_agreement":null},{"id":"W4283314633","doi":"10.1097/01.hs9.0000844964.23639.25","title":"P519: TRANSFUSION INDEPENDENCE AMONG NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING VENETOCLAX-BASED COMBINATIONS VS OTHER THERAPIES: RESULTS FROM THE AML REAL WORLD EVIDENCE (ARC) INITIATIVE","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Venetoclax; Internal medicine; Ven; Cytarabine; Decitabine; Cohort; Oncology; Myeloid leukemia; Leukemia; Chronic lymphocytic leukemia","score_opus":0.03312147384718491,"score_gpt":0.2934403156632037,"score_spread":0.26031884181601883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283314633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98553157,0.0003429496,0.00027706084,0.0050701667,0.0003028142,0.0025460573,0.00060823024,0.00022593355,0.005095238],"genre_scores_gemma":[0.99223584,0.00045380538,0.00087825186,0.0026523343,0.0001984933,0.00076184416,0.00047080024,0.00012717862,0.002221445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943129,0.0011086927,0.0008016312,0.0009866769,0.0020423748,0.00074773695],"domain_scores_gemma":[0.9932807,0.0043371897,0.00040534692,0.0012312181,0.0004525172,0.00029303465],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011962616,0.00046011197,0.0005979561,0.00017434501,0.0011232988,0.00010638591,0.00091235706,0.00018695668,0.0024505942],"category_scores_gemma":[0.0010429786,0.00036710192,0.0002446585,0.0015765443,0.00039140505,0.0004494361,0.00032270746,0.0020626418,0.00007396494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024707846,0.0016834945,0.7708138,0.00021812,0.0016401419,0.0013844353,0.06504209,0.0055372315,0.0069682933,0.0004180525,0.08937382,0.03221264],"study_design_scores_gemma":[0.024726696,0.00210748,0.9403274,0.0017407815,0.0003915313,0.00001063119,0.0063065267,0.010191021,0.003795633,0.0004871638,0.009040423,0.0008746899],"about_ca_topic_score_codex":0.014727235,"about_ca_topic_score_gemma":0.0071341107,"teacher_disagreement_score":0.1695136,"about_ca_system_score_codex":0.004091649,"about_ca_system_score_gemma":0.0026202726,"threshold_uncertainty_score":0.9998781},"labels":[],"label_agreement":null},{"id":"W4283320497","doi":"10.1097/01.hs9.0000845140.40137.c7","title":"P563: A RANDOMIZED, DOUBLE-BLIND, 2-ARM, MULTICENTER, PH3 STUDY OF VENETOCLAX &amp; ORAL AZACITIDINE VS. ORAL AZACITIDINE AS MAINTENANCE THERAPY FOR PTS WITH AML IN FIRST REMISSION AFTER INTENSIVE CHEMOTHERAPHY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Azacitidine; Venetoclax; Internal medicine; Induction chemotherapy; Maintenance therapy; Chemotherapy; Ven; Gastroenterology; Oncology; Leukemia; Surgery; Chronic lymphocytic leukemia","score_opus":0.03767137095473121,"score_gpt":0.3261266026400179,"score_spread":0.2884552316852867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283320497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98482585,0.00089619984,0.0002522147,0.0020200182,0.00013314027,0.011314008,0.000052728174,0.000081109036,0.00042471493],"genre_scores_gemma":[0.98735297,0.00034779968,0.002330473,0.0014798273,0.00012245183,0.004908492,0.00014494437,0.0001741128,0.0031389487],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958363,0.00034581558,0.0009483726,0.00094417174,0.001043128,0.0008822225],"domain_scores_gemma":[0.99708533,0.00043571455,0.0003873581,0.0009005445,0.00089928106,0.0002917799],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012934168,0.00057685806,0.0017964831,0.00031180005,0.0001957316,0.000034389774,0.0004070093,0.0001566522,0.0022847957],"category_scores_gemma":[0.0002894441,0.0004226254,0.00037148836,0.0009909143,0.00030699515,0.00016259788,0.00025982063,0.00088983314,0.000016740803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96949476,0.0023806503,0.010748219,0.0003099192,0.00070960994,0.00040664824,0.0074340063,0.00025088535,0.0022520716,0.000023792747,0.00442972,0.0015597113],"study_design_scores_gemma":[0.95215696,0.0069743292,0.001031906,0.0007061515,0.0001836501,0.00022231633,0.009829578,0.0018061821,0.0063384078,0.000083335006,0.020069435,0.0005977349],"about_ca_topic_score_codex":0.0018886798,"about_ca_topic_score_gemma":0.0011883251,"teacher_disagreement_score":0.017337793,"about_ca_system_score_codex":0.0010091546,"about_ca_system_score_gemma":0.0005556067,"threshold_uncertainty_score":0.99982256},"labels":[],"label_agreement":null},{"id":"W4283329542","doi":"10.1097/01.hs9.0000845096.01949.78","title":"P552: TREATMENT OUTCOMES IN NEWLY DIAGNOSED, UNTREATED PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Ven; Venetoclax; Oncology; Randomized controlled trial; Leukemia; Gastroenterology","score_opus":0.01886784192203424,"score_gpt":0.2840499807896953,"score_spread":0.26518213886766107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283329542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.718968,0.25936073,0.00002191363,0.0059430166,0.000039902076,0.013437997,0.0010927814,0.00026383193,0.0008718355],"genre_scores_gemma":[0.9164514,0.022967085,0.0018222074,0.0065255747,0.000030092811,0.00960826,0.003282395,0.0002662034,0.0390468],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9962509,0.00061704294,0.00082760083,0.0008066432,0.000921152,0.0005766204],"domain_scores_gemma":[0.9978008,0.00032832503,0.00030725452,0.0009958977,0.00026177327,0.00030593947],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038748066,0.0005970838,0.0039384635,0.00037393495,0.0001853539,0.00006883746,0.00021745195,0.00012424968,0.0019265823],"category_scores_gemma":[0.00013620108,0.0003429261,0.0007023917,0.0033436061,0.00006876948,0.0001577069,0.00018509827,0.0006102941,0.00002903659],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013306229,0.0026069123,0.24644145,0.07849441,0.6466139,0.014251178,0.003855808,0.00047677572,0.00003883821,0.000070342016,0.0054679634,0.00035178108],"study_design_scores_gemma":[0.01605508,0.0026304629,0.028234206,0.00221,0.94782317,0.00037816731,0.0007624885,0.00042911308,0.000055946915,0.000011599489,0.00058599864,0.00082378316],"about_ca_topic_score_codex":0.0004240796,"about_ca_topic_score_gemma":0.00034425186,"teacher_disagreement_score":0.30120924,"about_ca_system_score_codex":0.0021567347,"about_ca_system_score_gemma":0.0003705908,"threshold_uncertainty_score":0.99990225},"labels":[],"label_agreement":null},{"id":"W4283333295","doi":"10.1097/01.hs9.0000845116.46694.aa","title":"P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Placebo; Myeloid leukemia; Internal medicine; Gastroenterology; Azacitidine; Population; Surgery; Pathology; Biology","score_opus":0.011609486325459929,"score_gpt":0.2448589086781847,"score_spread":0.23324942235272475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283333295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914663,0.00015498564,0.00020975975,0.0007257791,0.00006673376,0.0040088464,0.00015648126,0.00028062894,0.0029305248],"genre_scores_gemma":[0.9875982,0.000027697564,0.005898543,0.0010723561,0.00007832842,0.0014402008,0.0008821858,0.00022194891,0.0027805334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99411744,0.00022757615,0.0007525627,0.0012945388,0.002137453,0.0014704061],"domain_scores_gemma":[0.9972289,0.00023191006,0.00038758316,0.0011840228,0.00039953864,0.0005680536],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003883963,0.00082157296,0.0013759612,0.00034234728,0.0004371031,0.0000743429,0.0005853202,0.00016890292,0.00248826],"category_scores_gemma":[0.000059258215,0.00058366643,0.00010928158,0.0018126632,0.0003489723,0.00035280606,0.00046827339,0.0015904907,0.000079958416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050268266,0.0020460864,0.9150624,0.0006344706,0.0014052049,0.008717207,0.0010476698,0.002392926,0.0021673127,0.00018509361,0.014454955,0.0016184051],"study_design_scores_gemma":[0.43265557,0.045212813,0.45461008,0.002577555,0.0019233716,0.0027981896,0.013814969,0.0054088933,0.02210734,0.00016524349,0.01346133,0.0052646617],"about_ca_topic_score_codex":0.00070631766,"about_ca_topic_score_gemma":0.0009296462,"teacher_disagreement_score":0.46045232,"about_ca_system_score_codex":0.0030986657,"about_ca_system_score_gemma":0.0016498619,"threshold_uncertainty_score":0.9996615},"labels":[],"label_agreement":null},{"id":"W4283397932","doi":"10.1097/01.hs9.0000844608.72364.51","title":"P430: MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"IDH1; Isocitrate dehydrogenase; Myeloid leukemia; Medicine; Peripheral blood mononuclear cell; Internal medicine; Bone marrow; Azacitidine; Placebo; Oncology; Gastroenterology; Mutation; Biology; Pathology; Genetics","score_opus":0.02239487869927134,"score_gpt":0.3108922617448699,"score_spread":0.2884973830455986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283397932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951012,0.00002964315,0.00022259942,0.0011034245,0.00008934719,0.002595092,0.0003024978,0.000115394825,0.00044079794],"genre_scores_gemma":[0.9943705,0.00003351274,0.0012770712,0.0009434952,0.00007569912,0.0005223607,0.0012913622,0.00012642931,0.0013595254],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9949204,0.00097552553,0.0013265758,0.00084161817,0.0012354357,0.00070044614],"domain_scores_gemma":[0.9973058,0.00049625506,0.00038234296,0.0008660291,0.00043695827,0.00051261595],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011758656,0.00042158877,0.0012356463,0.0003917235,0.00013626981,0.000024815057,0.00038012292,0.00018659605,0.001284571],"category_scores_gemma":[0.0006631379,0.00039206096,0.00018730904,0.0018270455,0.00015399678,0.00015715192,0.00036656004,0.0009037023,0.00005926199],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16311876,0.001614872,0.40878558,0.00020697618,0.0005318896,0.0041725575,0.00097260624,0.00085001695,0.41338632,0.000037735044,0.0033843354,0.0029383318],"study_design_scores_gemma":[0.05735031,0.009082534,0.82509893,0.0005033987,0.00032050625,0.00014149153,0.00081317493,0.0034056066,0.09620758,0.000008163193,0.006246935,0.00082138425],"about_ca_topic_score_codex":0.0002881401,"about_ca_topic_score_gemma":0.000067737936,"teacher_disagreement_score":0.41631332,"about_ca_system_score_codex":0.0013854932,"about_ca_system_score_gemma":0.0013185946,"threshold_uncertainty_score":0.99985313},"labels":[],"label_agreement":null},{"id":"W4283514695","doi":"10.1016/j.jval.2022.04.300","title":"EE46 Venetoclax in Combination with Azacitidine Is Cost-Effective Vs. AZA for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Perspective","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Princess Margaret Cancer Centre; ABB (Canada)","funders":"","keywords":"Azacitidine; Venetoclax; Myeloid leukemia; Medicine; Perspective (graphical); Oncology; Internal medicine; Leukemia; Intensive care medicine; Computer science","score_opus":0.03141783833154448,"score_gpt":0.32722244076908236,"score_spread":0.29580460243753787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283514695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9473761,0.0016770576,0.00014898843,0.03047181,0.00013221113,0.019380081,0.00054099545,0.00002612858,0.00024666602],"genre_scores_gemma":[0.9879634,0.0017887474,0.0003833915,0.0015153446,0.00006775508,0.007966752,0.000106985986,0.000051622512,0.00015602268],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.997559,0.0004509407,0.00039315256,0.00045167384,0.00045795314,0.0006872743],"domain_scores_gemma":[0.99768764,0.00126227,0.00016469593,0.00039959903,0.00020171472,0.0002840986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009579683,0.00022031563,0.0005681028,0.0006356691,0.00026916564,0.000011348028,0.00018028151,0.000082534774,0.000057128465],"category_scores_gemma":[0.00015730847,0.00016597369,0.00009242381,0.0010818964,0.000126736,0.00005887654,0.000033281172,0.0005103146,0.000002863217],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.046089485,0.005992714,0.13835578,0.0020631184,0.0030851667,0.0041718353,0.38282034,0.16251566,0.00054054166,0.031053698,0.023144562,0.20016712],"study_design_scores_gemma":[0.11713257,0.09239077,0.3883028,0.0008316566,0.00046158247,0.0005271284,0.04651425,0.27701706,0.0029224942,0.0036931175,0.069204554,0.0010020254],"about_ca_topic_score_codex":0.7733429,"about_ca_topic_score_gemma":0.13451108,"teacher_disagreement_score":0.63883185,"about_ca_system_score_codex":0.056243476,"about_ca_system_score_gemma":0.010613801,"threshold_uncertainty_score":0.9949951},"labels":[],"label_agreement":null},{"id":"W4284665405","doi":"10.1182/bloodadvances.2021005828","title":"HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Canada First Research Excellence Fund; Government of Canada; Institut de Valorisation des Données; Compute Canada; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Genome Canada","keywords":"Vulnerability (computing); HMGA2; Biology; Signature (topology); Computational biology; Cell biology; Cancer research; Molecular biology; Genetics; microRNA; Gene; Computer security; Computer science; Mathematics","score_opus":0.012121265216236311,"score_gpt":0.2841051392563005,"score_spread":0.2719838740400642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284665405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436253,0.003041614,0.000087858,0.0013927168,0.000031024625,0.00056871946,0.00017305225,0.000053208678,0.00028925168],"genre_scores_gemma":[0.99626184,0.000048397604,0.0027528245,0.00027915463,0.000085969354,0.00016017928,0.0001844829,0.000019125035,0.00020805681],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985597,0.000101312464,0.0002054187,0.00035577687,0.0005698133,0.00020795432],"domain_scores_gemma":[0.99940544,0.00006374652,0.00006911482,0.00021384415,0.0001226622,0.00012518752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023989216,0.00014633618,0.00027617515,0.0001327391,0.0002413499,0.0000096579815,0.00007973442,0.00005913602,0.00016293302],"category_scores_gemma":[0.000049299782,0.00010926462,0.00004561979,0.00033432205,0.00012000155,0.00015689468,0.00007390833,0.0004985863,7.4243155e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001854919,0.00037892335,0.012224168,0.00028479582,0.00003302806,0.000053410815,0.0007139893,0.000099457735,0.9821791,0.00035595772,0.00089142093,0.0009307946],"study_design_scores_gemma":[0.01049805,0.005587041,0.1567652,0.00054517284,0.00023389538,0.00053913175,0.002640988,0.000038532806,0.8032252,0.0015739588,0.017849175,0.0005036315],"about_ca_topic_score_codex":0.000018986459,"about_ca_topic_score_gemma":0.000035732974,"teacher_disagreement_score":0.1789539,"about_ca_system_score_codex":0.000056022825,"about_ca_system_score_gemma":0.00009688924,"threshold_uncertainty_score":0.44556817},"labels":[],"label_agreement":null},{"id":"W4284887577","doi":"10.1182/blood.2022016171","title":"Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Blood Cancer UK","keywords":"Medicine; Myelodysplastic syndromes; Placebo; Blood transfusion; Anemia; Internal medicine; Surgery; Bone marrow","score_opus":0.011280704140333204,"score_gpt":0.24128972764348222,"score_spread":0.23000902350314903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284887577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99782985,0.00015461398,0.000089188,0.00014156148,0.00007406635,0.000637794,0.000054112093,0.000052355663,0.00096643786],"genre_scores_gemma":[0.9983358,0.00014663333,0.00039391508,0.000036159487,0.000041226922,0.00012436823,0.000020995421,0.00006110468,0.00083981187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976861,0.000099146324,0.00037185723,0.00046579007,0.0008952254,0.00048191988],"domain_scores_gemma":[0.9989819,0.0001918642,0.000112469585,0.00047860653,0.000067496185,0.00016766462],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038471568,0.00022219308,0.00049335504,0.00042068763,0.00012759364,0.00001400131,0.0002528853,0.00007102597,0.0016766099],"category_scores_gemma":[0.000059490896,0.00019240493,0.00008990144,0.00048891775,0.0000855437,0.00007721794,0.00022265749,0.00075841445,0.000037075755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004460437,0.0063642026,0.84054935,0.0013864164,0.0010509728,0.013052008,0.009967573,0.005863488,0.1062404,0.00009711073,0.0001316579,0.010836363],"study_design_scores_gemma":[0.050960284,0.009283451,0.86800367,0.0013912717,0.0013097548,0.007552203,0.0043082046,0.0019752944,0.053849228,0.00014509073,0.00013593324,0.0010856327],"about_ca_topic_score_codex":0.0003054087,"about_ca_topic_score_gemma":0.00039770248,"teacher_disagreement_score":0.05239117,"about_ca_system_score_codex":0.00024425422,"about_ca_system_score_gemma":0.00026056642,"threshold_uncertainty_score":0.999236},"labels":[],"label_agreement":null},{"id":"W4284989340","doi":"10.1093/jjco/hyac105","title":"A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20)","year":2022,"lang":"en","type":"article","venue":"Japanese Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cytodiagnostics (Canada)","funders":"Japan Agency for Medical Research and Development","keywords":"Gemtuzumab ozogamicin; Medicine; Minimal residual disease; Internal medicine; Myeloid leukemia; Induction chemotherapy; Oncology; Acute promyelocytic leukemia; Hematopoietic stem cell transplantation; Clinical endpoint; Leukemia; Transplantation; Clinical trial; Calicheamicin; Chemotherapy; Stem cell; CD33; CD34","score_opus":0.05386085830409168,"score_gpt":0.4327060525568209,"score_spread":0.3788451942527292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284989340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850086,0.000010591843,0.0010165296,0.0006715323,0.00016197107,0.013015072,0.000101647616,0.000010005568,0.000004051169],"genre_scores_gemma":[0.9897555,0.000031347223,0.009056161,0.00009915028,0.00032339775,0.00046998696,0.00020867746,0.000046796726,0.000008984399],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9883233,0.0043115364,0.00536364,0.00056845334,0.0011124759,0.00032061798],"domain_scores_gemma":[0.9773333,0.012170861,0.0078873485,0.0003628075,0.0019414461,0.00030420502],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.024057822,0.00028818,0.0028431339,0.0004720601,0.00025067714,0.000014597716,0.0002712698,0.00022188238,0.000010851957],"category_scores_gemma":[0.012173102,0.00020209176,0.000394003,0.0004910458,0.0005306117,0.00020931168,0.00006641186,0.0013671297,1.0660039e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8394089,0.021585662,0.08747549,0.00004779447,0.0012429556,0.000014678482,0.0014429135,0.0010996781,0.00073240953,0.0000042986558,0.00001562884,0.0469296],"study_design_scores_gemma":[0.5952582,0.19694692,0.18589404,0.00006934422,0.0014969984,0.000021023241,0.0014380658,0.018640867,0.000080456484,0.0000372915,0.0000012965182,0.000115482784],"about_ca_topic_score_codex":0.00015506976,"about_ca_topic_score_gemma":0.00009487608,"teacher_disagreement_score":0.24415068,"about_ca_system_score_codex":0.0006453663,"about_ca_system_score_gemma":0.0051785605,"threshold_uncertainty_score":0.9961478},"labels":[],"label_agreement":null},{"id":"W4285252885","doi":"10.2139/ssrn.4114950","title":"A Machine Learning Model of Response to Hypomethylating Agents in Myelodysplastic Syndromes","year":2022,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myelodysplastic syndromes; Hypomethylating agent; Medicine; Computer science; Internal medicine; Biology; DNA methylation; Genetics","score_opus":0.03092141520020297,"score_gpt":0.31173847176452857,"score_spread":0.2808170565643256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285252885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99339986,0.0009900917,0.003440957,0.0015762981,0.00003943557,0.00027561016,0.000006213695,0.000021332819,0.00025023107],"genre_scores_gemma":[0.9931201,0.0003607753,0.00074791495,0.000119318654,0.000035074467,0.000026366237,0.0000054752213,0.000049247537,0.0055357246],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99584305,0.0005900434,0.00048758526,0.00025222014,0.00083707774,0.0019900147],"domain_scores_gemma":[0.9990596,0.00032307114,0.00016036011,0.00018770534,0.00008509465,0.00018414987],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0066601816,0.00015886205,0.00038792408,0.0010283266,0.00025066233,0.000012998262,0.00029078114,0.00004647962,0.00014984437],"category_scores_gemma":[0.0016752923,0.0001531642,0.00011192293,0.0009708951,0.00003107413,0.00007601916,0.00028382754,0.0052114213,0.000013318332],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.029314015,0.0009238487,0.07273911,0.00012185794,0.00075157196,0.00076491624,0.0049929307,0.6466507,0.20341155,0.004103708,0.00016633084,0.03605946],"study_design_scores_gemma":[0.016265085,0.017459493,0.013350736,0.00027402653,0.00019476106,0.01260739,0.011959459,0.90079683,0.001060929,0.02368567,0.001584322,0.00076130894],"about_ca_topic_score_codex":0.000110509776,"about_ca_topic_score_gemma":0.000056264053,"teacher_disagreement_score":0.25414613,"about_ca_system_score_codex":0.005163129,"about_ca_system_score_gemma":0.005647916,"threshold_uncertainty_score":0.99998915},"labels":[],"label_agreement":null},{"id":"W4285392789","doi":"10.1101/2022.07.12.498585","title":"KDM6A loss sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Cancer research; Myeloid leukemia; Synthetic lethality; NPM1; Epigenetics; Venetoclax; Demethylase; Biology; Poly ADP ribose polymerase; Histone; Leukemia; Context (archaeology); DNA repair; Gene; Immunology; Genetics; Polymerase; Chronic lymphocytic leukemia","score_opus":0.016896717169472896,"score_gpt":0.2687273216306209,"score_spread":0.251830604461148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285392789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99210423,0.00051169365,0.00025934505,0.0028539805,0.00059506093,0.0022886822,0.0005799921,0.0007148378,0.00009215417],"genre_scores_gemma":[0.9911692,0.00060989993,0.0037510341,0.0022324394,0.0010925743,0.0006372033,0.00000955934,0.00035123367,0.00014682703],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9943338,0.00033570136,0.00087872776,0.0020197118,0.0012202155,0.0012118426],"domain_scores_gemma":[0.9955383,0.00012559413,0.00036747285,0.002120084,0.000721357,0.0011272066],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012892119,0.00094823807,0.0013194691,0.0009661013,0.0005862887,0.00029392104,0.00045224495,0.0007857311,0.00039104908],"category_scores_gemma":[0.00033271706,0.0010470013,0.00025888253,0.0010108746,0.00033571225,0.00018159345,0.002713732,0.0028870902,0.00018656494],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035755677,0.00013442346,0.0055054263,0.0009179016,0.0006458875,0.003322736,0.00008088774,0.000043483964,0.9802595,0.00065930106,0.008064539,0.000008349276],"study_design_scores_gemma":[0.006208869,0.0011144236,0.25165635,0.0017182505,0.0014052986,0.000004587603,0.000069519236,0.00047285223,0.67918783,0.000019171172,0.054995403,0.0031474095],"about_ca_topic_score_codex":0.0003079386,"about_ca_topic_score_gemma":0.000007879453,"teacher_disagreement_score":0.30107164,"about_ca_system_score_codex":0.003896768,"about_ca_system_score_gemma":0.0024064288,"threshold_uncertainty_score":0.9999271},"labels":[],"label_agreement":null},{"id":"W4285727921","doi":"10.1182/bloodadvances.2022007300","title":"Unified gene expression signature of novel <i>NPM1</i> exon 5 mutations in acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Hôpital Maisonneuve-Rosemont; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"NPM1; Exon; Myeloid leukemia; Gene; Biology; Mutation; Myeloid; Leukemia; Gene expression; Cancer research; Genetics; Signature (topology); Karyotype; Chromosome","score_opus":0.01616325110435443,"score_gpt":0.2900097324574762,"score_spread":0.27384648135312173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285727921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912688,0.004074201,0.00047353862,0.0006049764,0.00016446567,0.0007336522,0.00020127771,0.00007464571,0.0024044313],"genre_scores_gemma":[0.9767169,0.00059314154,0.019999849,0.00034941448,0.00010621627,0.00022436265,0.00028161687,0.000045120745,0.0016834026],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997962,0.00009034611,0.000422582,0.00042461333,0.00071248325,0.0003879622],"domain_scores_gemma":[0.99898314,0.00017961542,0.000175613,0.00042107093,0.000113254784,0.00012728704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029387348,0.00019547464,0.00040959913,0.00034278762,0.00016451173,0.0000087933895,0.0003103297,0.000094159404,0.00019173304],"category_scores_gemma":[0.00011737377,0.00017874205,0.00009758115,0.0009247394,0.00011732931,0.00021683403,0.0002708982,0.00080515683,0.000004409924],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000477918,0.00051579264,0.0024984686,0.000095293755,0.00007151886,0.00023139027,0.0006078642,0.0035202764,0.9892358,0.00014840075,0.00052562315,0.0020716232],"study_design_scores_gemma":[0.010746806,0.00076160365,0.004939147,0.00015223768,0.00019840937,0.00030786084,0.0019985263,0.0007446321,0.9612342,0.0002269264,0.018365819,0.0003237935],"about_ca_topic_score_codex":0.000057375448,"about_ca_topic_score_gemma":0.000016240785,"teacher_disagreement_score":0.028001592,"about_ca_system_score_codex":0.00033829937,"about_ca_system_score_gemma":0.00064975396,"threshold_uncertainty_score":0.7288889},"labels":[],"label_agreement":null},{"id":"W4285798648","doi":"10.2217/fon-2022-0450","title":"Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia","year":2022,"lang":"en","type":"review","venue":"Future Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"AbbVie","keywords":"Venetoclax; Medicine; Azacitidine; Myeloid leukemia; Internal medicine; Oncology; Maintenance therapy; Minimal residual disease; Leukemia; Chemotherapy; Chronic lymphocytic leukemia","score_opus":0.07129580869837542,"score_gpt":0.39482913439692097,"score_spread":0.32353332569854554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285798648","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019121651,0.98723936,0.000060541224,0.0005504409,0.0011655506,0.008055661,0.00015631123,0.000023275474,0.00083667645],"genre_scores_gemma":[0.0001185558,0.9960525,0.0007368097,0.0002359076,0.00091051514,0.00074843585,0.00013310436,0.000086325446,0.0009778598],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952005,0.0017875197,0.0013045741,0.0006033603,0.00053748494,0.0005665639],"domain_scores_gemma":[0.99696255,0.00096237374,0.0009734917,0.000850975,0.00011353713,0.00013706178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017997718,0.00050310686,0.003931088,0.00042613735,0.00007836581,0.0000058357145,0.00070742157,0.00085268525,0.0005263799],"category_scores_gemma":[0.00022779059,0.0003080666,0.000492184,0.0010492798,0.0005430635,0.000042454412,0.00037742354,0.0020784645,0.0000032962046],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04898601,0.00031511637,0.0000014918601,0.0021132885,0.0006540946,0.00035611156,0.00030597328,0.000004269189,0.00020151038,0.00014310687,0.006245603,0.9406734],"study_design_scores_gemma":[0.10186744,0.007630353,0.0000041462117,0.001116859,0.00064836704,0.00056580716,0.00009057939,0.00004516665,0.00003879292,0.00003362601,0.8877555,0.00020332547],"about_ca_topic_score_codex":0.00013134125,"about_ca_topic_score_gemma":0.000027936892,"teacher_disagreement_score":0.9404701,"about_ca_system_score_codex":0.0041860533,"about_ca_system_score_gemma":0.012164194,"threshold_uncertainty_score":0.9999371},"labels":[],"label_agreement":null},{"id":"W4286294352","doi":"10.1200/jco.2022.40.16_suppl.e19062","title":"Clinical outcomes associated with azacitidine (AZA) monotherapy for treatment-naïve, higher-risk myelodysplastic syndrome (HR-MDS): A systematic literature review and meta-analysis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Gilead Sciences","keywords":"Medicine; Internal medicine; Meta-analysis; Observational study; Retrospective cohort study; Randomized controlled trial; Prospective cohort study; Relative risk; Myelodysplastic syndromes; Oncology; Confidence interval; Bone marrow","score_opus":0.1736590505472295,"score_gpt":0.48266296518030205,"score_spread":0.30900391463307253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60129166,0.2931293,0.001048241,0.09078715,0.0013490195,0.010895897,0.00102568,0.00011860979,0.00035445037],"genre_scores_gemma":[0.8462577,0.101776704,0.009708501,0.025972592,0.00058505224,0.0011595769,0.00017340026,0.00018887153,0.014177646],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9867633,0.0054428168,0.0057012835,0.0005985848,0.0009802774,0.0005137165],"domain_scores_gemma":[0.96488166,0.026932636,0.0057504377,0.00062970445,0.0010449921,0.0007605999],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015920583,0.00046510182,0.014534028,0.0004934813,0.00021201652,0.000039073173,0.0004032554,0.00048121889,0.00062884705],"category_scores_gemma":[0.011244091,0.00024242989,0.0050237053,0.0011720301,0.00030040136,0.00014682193,0.000112119276,0.0020250003,0.000005621599],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074486863,0.0057797194,0.09182352,0.007150046,0.8715689,0.0067963563,0.00012207712,0.000079798236,0.0000028032052,0.00011325516,0.0077655776,0.0013492407],"study_design_scores_gemma":[0.021470994,0.06115027,0.10591013,0.0008190719,0.8001315,0.0021810178,0.000057144774,0.00029127894,4.9900245e-7,0.00012560368,0.00756236,0.00030010598],"about_ca_topic_score_codex":0.000011535242,"about_ca_topic_score_gemma":0.000034366258,"teacher_disagreement_score":0.244966,"about_ca_system_score_codex":0.0007838883,"about_ca_system_score_gemma":0.0017191676,"threshold_uncertainty_score":0.9970846},"labels":[],"label_agreement":null},{"id":"W4286294884","doi":"10.1200/jco.2022.40.16_suppl.7042","title":"Hematologic improvements with ivosidenib + azacitidine compared to placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Azacitidine; Gastroenterology; Internal medicine; Placebo; Bone marrow; Population; Platelet; Surgery; Pathology","score_opus":0.05185352637567781,"score_gpt":0.38777019628409265,"score_spread":0.33591666990841484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896398,0.000053327924,0.0002050614,0.007029562,0.0004678893,0.0016519978,0.000040438586,0.00002927959,0.0008826085],"genre_scores_gemma":[0.9823797,0.000076497454,0.009762371,0.0067094844,0.00036610384,0.00013839189,0.00005059276,0.000069669266,0.000447232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99273944,0.00095085514,0.0031085806,0.00059326657,0.0017456274,0.00086224475],"domain_scores_gemma":[0.99320936,0.0024709825,0.0018537892,0.0005174142,0.0008852615,0.001063174],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0037681672,0.0003959536,0.002929307,0.00068273034,0.00015951453,0.000024018545,0.000696389,0.00028732003,0.00056118995],"category_scores_gemma":[0.0019282991,0.00026550103,0.00030579,0.0010282301,0.0003080904,0.00023328797,0.0004916598,0.0033445754,0.00003549767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13757071,0.00488656,0.8056258,0.000066994915,0.0013661826,0.012797004,0.000311911,0.001423065,0.00042710933,0.000044410386,0.020170111,0.015310124],"study_design_scores_gemma":[0.1612525,0.106643796,0.702741,0.0002584751,0.00067884004,0.0010555694,0.000986961,0.00045235522,0.00032806757,0.00008492921,0.024987848,0.0005296655],"about_ca_topic_score_codex":0.00013294852,"about_ca_topic_score_gemma":0.00024173073,"teacher_disagreement_score":0.102884814,"about_ca_system_score_codex":0.0033170683,"about_ca_system_score_gemma":0.005740809,"threshold_uncertainty_score":0.99997973},"labels":[],"label_agreement":null},{"id":"W4286296404","doi":"10.1200/jco.2022.40.16_suppl.7056","title":"Long-term utilization and benefit of luspatercept in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Internal medicine; Anemia; Clinical endpoint; Placebo; Neutropenia; Lenalidomide; Surgery; Clinical trial; Bone marrow; Chemotherapy; Multiple myeloma","score_opus":0.10514348294514825,"score_gpt":0.42207269695300415,"score_spread":0.3169292140078559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959407,0.00024900597,0.000055434644,0.0023067396,0.00072820403,0.00054857216,0.000035500387,0.0000042681686,0.00013157605],"genre_scores_gemma":[0.99781775,0.00089875987,0.00022073815,0.00052868924,0.00031613902,0.000012200546,0.000024928513,0.000022426231,0.00015836158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99596846,0.0008707776,0.0018542062,0.00023971245,0.0008288617,0.00023799766],"domain_scores_gemma":[0.9926546,0.004623149,0.0018118403,0.00027125602,0.000369351,0.00026978593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003285694,0.0001448259,0.0012787925,0.00017292601,0.00008641139,0.000010587808,0.0003112203,0.000200281,0.0006547518],"category_scores_gemma":[0.004524442,0.000084925916,0.00017630134,0.00029167897,0.0003138687,0.000097358505,0.00023841135,0.0016422012,0.0000031517284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.104583934,0.0019029451,0.8334767,0.000022137216,0.0003122824,0.00042769767,0.00023600124,0.0000764189,0.000008144241,0.000015742302,0.0006630159,0.058274962],"study_design_scores_gemma":[0.08378794,0.034244634,0.8792793,0.00009960343,0.00035865058,0.00009295051,0.0001525011,0.000271901,0.0000046719806,0.000116236515,0.0015179798,0.0000735892],"about_ca_topic_score_codex":0.0001709068,"about_ca_topic_score_gemma":0.00030932698,"teacher_disagreement_score":0.058201373,"about_ca_system_score_codex":0.00039639318,"about_ca_system_score_gemma":0.0012897186,"threshold_uncertainty_score":0.71690726},"labels":[],"label_agreement":null},{"id":"W4286296843","doi":"10.1200/jco.2022.40.16_suppl.7019","title":"Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"IDH1; Medicine; Isocitrate dehydrogenase; Azacitidine; Myeloid leukemia; Peripheral blood mononuclear cell; Bone marrow; Internal medicine; Gastroenterology; Oncology; Mutation; Biology","score_opus":0.05165808764749978,"score_gpt":0.397512320340821,"score_spread":0.3458542326933212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926406,0.000015774773,0.0003775267,0.0050283675,0.00029573994,0.0013845449,0.00008231399,0.000021282549,0.00015386479],"genre_scores_gemma":[0.9933955,0.0000835261,0.0031694365,0.0026337705,0.0002847493,0.00006298955,0.00012703416,0.000074972864,0.00016800153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9884532,0.0039807837,0.0048811887,0.00055630726,0.0015557098,0.0005728172],"domain_scores_gemma":[0.9892508,0.0048996485,0.0030071957,0.00055302255,0.0013612453,0.0009280896],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008450767,0.00034526514,0.0033230248,0.00077388133,0.00008438923,0.000015145164,0.000535349,0.00039693076,0.00024845128],"category_scores_gemma":[0.0057259994,0.0002504554,0.0004270269,0.001215626,0.0003977353,0.00020682736,0.00027418026,0.0027847174,0.000011667644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4365799,0.0028846858,0.539045,0.000025681322,0.00082834106,0.00562566,0.00015236354,0.0007359023,0.0064279945,0.000008507176,0.0008248069,0.006861175],"study_design_scores_gemma":[0.07442457,0.07273662,0.8452028,0.00019120892,0.0004814425,0.00020295287,0.00015456478,0.00050559425,0.0009389426,0.0000051036895,0.0049252976,0.00023087084],"about_ca_topic_score_codex":0.00006418924,"about_ca_topic_score_gemma":0.000037495738,"teacher_disagreement_score":0.36215535,"about_ca_system_score_codex":0.0014923067,"about_ca_system_score_gemma":0.0074402597,"threshold_uncertainty_score":0.99999475},"labels":[],"label_agreement":null},{"id":"W4286297779","doi":"10.1200/jco.2022.40.16_suppl.7032","title":"Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-<i>IDH2</i> relapsed or refractory acute myeloid leukemia (R/R AML).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Quality of life (healthcare); Refractory (planetary science); IDH2; Randomized controlled trial; Clinical trial; Oncology; Gastroenterology; IDH1; Mutant","score_opus":0.09316453831724156,"score_gpt":0.43260420948397377,"score_spread":0.33943967116673224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99170846,0.00040473553,0.00002138203,0.0052117268,0.00088219094,0.0009131528,0.00011808391,0.000021203507,0.0007190426],"genre_scores_gemma":[0.99450403,0.00037082855,0.001552766,0.0018968881,0.00020290197,0.000027126738,0.00012299593,0.000067635294,0.0012548314],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9887157,0.0029819224,0.005108571,0.0005242828,0.002020598,0.0006488888],"domain_scores_gemma":[0.9869124,0.0047213174,0.005596343,0.00053761376,0.0013553075,0.0008769739],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006052485,0.0003241755,0.0031380353,0.00045217815,0.0001624803,0.000009133106,0.00047067806,0.00048467732,0.0010080393],"category_scores_gemma":[0.0037209638,0.00021744461,0.00044011854,0.0007781928,0.00063326804,0.0002238226,0.00025212343,0.004767833,0.000010049603],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.52028245,0.005202415,0.44579518,0.0004413118,0.0034193222,0.0049780253,0.0022114157,0.0010965717,0.00020941961,0.00014458838,0.008070501,0.00814883],"study_design_scores_gemma":[0.1750108,0.08917916,0.7116809,0.00034737034,0.00042337316,0.00018047792,0.0034549462,0.00008079693,0.00004389088,0.000016967422,0.019228496,0.0003528251],"about_ca_topic_score_codex":0.00054874003,"about_ca_topic_score_gemma":0.0007473767,"teacher_disagreement_score":0.34527162,"about_ca_system_score_codex":0.0046671364,"about_ca_system_score_gemma":0.028773423,"threshold_uncertainty_score":0.99990517},"labels":[],"label_agreement":null},{"id":"W4289012842","doi":"10.1101/2022.07.29.22278015","title":"Genomic and phenomic landscape of clonal hematopoiesis in over a million ancestrally diverse participants","year":2022,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University","funders":"Medical Research Council; National Institutes of Health; Vanderbilt University; Office of Research and Development","keywords":"Biology; Disease; Genome-wide association study; Phenome; Genetics; Haematopoiesis; Genome; Mendelian inheritance; Mendelian randomization; Germline; Gene; Stem cell; Single-nucleotide polymorphism; Medicine; Genotype; Internal medicine","score_opus":0.052611603955500734,"score_gpt":0.3284245770943397,"score_spread":0.27581297313883896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289012842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99677485,0.0014494046,0.0000048978663,0.00032773972,0.00015643745,0.0005999448,0.000118506476,0.000024482093,0.0005437532],"genre_scores_gemma":[0.99778265,0.0010634179,0.00042166637,0.00009668705,0.000104101906,0.00010182376,0.00010531165,0.000040420655,0.0002839401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785054,0.00014534252,0.00050600234,0.00056825613,0.00046597054,0.00046389512],"domain_scores_gemma":[0.9989162,0.0001266189,0.00019510377,0.00052631844,0.000045238405,0.00019052664],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00072172284,0.00025092714,0.0007335881,0.00039727552,0.00004333661,0.00001528532,0.00027351367,0.00018451562,0.001929585],"category_scores_gemma":[0.000109865694,0.00023720755,0.00012143198,0.00020633148,0.00015744778,0.000037180223,0.0012529789,0.0009343068,0.00002312416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006116992,0.00014101423,0.98092496,0.00082500605,0.00013708728,0.00036167126,0.0009982705,0.00019742028,0.014728499,0.000047628328,0.00070889585,0.00031786828],"study_design_scores_gemma":[0.002238253,0.00013107824,0.9934724,0.00021119954,0.00011301036,0.000028463028,0.0005315727,0.0015417283,0.00071412564,0.00016542606,0.00064447615,0.00020829018],"about_ca_topic_score_codex":0.00041459047,"about_ca_topic_score_gemma":0.00010198282,"teacher_disagreement_score":0.014014373,"about_ca_system_score_codex":0.00034695107,"about_ca_system_score_gemma":0.0006205071,"threshold_uncertainty_score":0.9989828},"labels":[],"label_agreement":null},{"id":"W4289110161","doi":"10.3390/biomedicines10081841","title":"Properties of Leukemic Stem Cells in Regulating Drug Resistance in Acute and Chronic Myeloid Leukemias","year":2022,"lang":"en","type":"review","venue":"Biomedicines","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University of British Columbia","funders":"Canadian Institutes of Health Research; Mitacs","keywords":"Epigenome; Biology; Transcriptome; Stem cell; Drug resistance; Population; Stromal cell; Metabolome; Myeloid; Cancer research; Computational biology; Immunology; Bioinformatics; Medicine; Cell biology; Gene; Genetics; DNA methylation; Gene expression; Metabolomics","score_opus":0.05488611059246379,"score_gpt":0.3154546372896756,"score_spread":0.2605685266972118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289110161","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018523416,0.9782202,8.331639e-7,0.0002655649,0.00023186,0.0022823499,0.000040650702,0.000051000065,0.00038412304],"genre_scores_gemma":[0.0013020774,0.9880186,0.00018526179,0.000041524025,0.00029836016,0.00039127638,0.00008134459,0.00013682719,0.009544762],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952065,0.00041843345,0.0017760891,0.0009387253,0.00090211653,0.0007581583],"domain_scores_gemma":[0.9978809,0.00038424344,0.0006200227,0.0008455906,0.00007683016,0.0001924625],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001414812,0.0006613978,0.0034043784,0.0019285651,0.00007548597,0.000016892638,0.00049723976,0.0003552145,0.00007962293],"category_scores_gemma":[0.00011591891,0.000487023,0.0002338588,0.002328502,0.0006358648,0.000108755434,0.00049280433,0.0014111603,0.000009012854],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038836445,0.00012945678,0.00012226502,0.17460158,0.00043270722,0.0009592411,0.0020966406,0.0000010988226,0.00743888,0.000039960356,0.004542163,0.8092476],"study_design_scores_gemma":[0.00292802,0.00020462244,0.000043088414,0.0745214,0.0005605889,0.00021302486,0.0005781514,0.000055850825,0.00077551446,0.000009430644,0.9196314,0.00047891677],"about_ca_topic_score_codex":0.00032550964,"about_ca_topic_score_gemma":0.0002796639,"teacher_disagreement_score":0.91508925,"about_ca_system_score_codex":0.005316876,"about_ca_system_score_gemma":0.004333498,"threshold_uncertainty_score":0.9997581},"labels":[],"label_agreement":null},{"id":"W4289518173","doi":"10.1111/ijlh.13935","title":"Fusion transcript analysis reveals slower response kinetics than multiparameter flow cytometry in childhood acute myeloid leukaemia","year":2022,"lang":"en","type":"article","venue":"International Journal of Laboratory Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"Sahlgrenska Universitetssjukhuset","keywords":"Flow cytometry; Myeloid leukaemia; Myeloid; Kinetics; Immunology; Chemistry; Computational biology; Cancer research; Biology; Cell biology; Molecular biology; Physics","score_opus":0.011503846569915297,"score_gpt":0.30854140459294066,"score_spread":0.29703755802302534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289518173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894007,0.0007914217,0.0010764267,0.0072267903,0.000928026,0.00024508205,0.00023582023,0.000021467882,0.00007430653],"genre_scores_gemma":[0.9922447,0.00017242691,0.005317621,0.0017678402,0.00016384553,0.00002566165,0.00005646289,0.000042680877,0.00020871185],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9954759,0.00095840316,0.0012754627,0.0003617984,0.0015070227,0.00042144247],"domain_scores_gemma":[0.9970081,0.00058715,0.0005692572,0.00038082624,0.001189906,0.00026475397],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020564173,0.000256438,0.0009681369,0.0035875386,0.00007834108,0.000034477423,0.00080983,0.00018833233,0.001471048],"category_scores_gemma":[0.0009795572,0.00023635056,0.00043314425,0.0023156127,0.00013241854,0.00020296892,0.00023633245,0.001485784,0.000019675861],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036583856,0.003156714,0.33866784,0.000055211727,0.01143251,0.034838326,0.0041015972,0.003023414,0.5555648,0.00023138276,0.01050972,0.0018345852],"study_design_scores_gemma":[0.031234544,0.004363907,0.82591224,0.00033698554,0.0031672257,0.02401523,0.0029556546,0.006203829,0.067715384,0.00055113406,0.032395612,0.0011482566],"about_ca_topic_score_codex":0.0000115924,"about_ca_topic_score_gemma":0.000018674189,"teacher_disagreement_score":0.48784944,"about_ca_system_score_codex":0.0013339767,"about_ca_system_score_gemma":0.00090722874,"threshold_uncertainty_score":0.99944174},"labels":[],"label_agreement":null},{"id":"W4289522149","doi":"10.1139/bcb-2021-0507","title":"Targeting FHL1 impairs cell proliferation and differentiation of acute myeloid leukemia cells","year":2022,"lang":"en","type":"article","venue":"Biochemistry and Cell Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Shanghai Science and Technology Development Foundation","keywords":"Cell growth; Cell cycle; Myeloid leukemia; Biology; Gene knockdown; Stem cell; Cancer research; Flow cytometry; Cell biology; Myeloid; Cellular differentiation; Acute promyelocytic leukemia; Cell; Retinoic acid; Molecular biology; Apoptosis; Cell culture; Biochemistry","score_opus":0.007451505293219024,"score_gpt":0.24106636787809535,"score_spread":0.23361486258487632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289522149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99724543,0.0009920268,0.00008786482,0.00014982186,0.00005928167,0.00025654052,0.000080705715,0.000023111645,0.001105195],"genre_scores_gemma":[0.99653465,0.0005499526,0.00033484976,0.00009364461,0.00010330874,0.000041993804,0.00055608974,0.000013736658,0.001771769],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998956,0.000078134995,0.00025677655,0.00034590383,0.00011974952,0.00024339338],"domain_scores_gemma":[0.9994765,0.00005335215,0.00013681935,0.00016593242,0.00005812894,0.00010927006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023291615,0.0001443948,0.00024503883,0.000058150952,0.00016376434,0.000008757283,0.00008041017,0.00015163662,0.0001635825],"category_scores_gemma":[0.000016905911,0.00013199532,0.00003764599,0.00011508476,0.0001320715,0.00002385544,0.00021886801,0.00031827428,0.0000018511439],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027157078,0.000074043535,0.005770519,0.00028381616,0.000037591457,0.0000073497586,0.00016812516,0.0000041424114,0.99169284,0.0000070851115,0.00095655053,0.0007263721],"study_design_scores_gemma":[0.0015845007,0.00042936293,0.0005492454,0.00000617907,0.00008261126,0.00003069158,0.00037633438,0.001465115,0.9940423,0.000027953176,0.001282515,0.00012319771],"about_ca_topic_score_codex":0.00002233584,"about_ca_topic_score_gemma":1.4326761e-7,"teacher_disagreement_score":0.0052212733,"about_ca_system_score_codex":0.0001608182,"about_ca_system_score_gemma":0.00021817182,"threshold_uncertainty_score":0.5382613},"labels":[],"label_agreement":null},{"id":"W4289522686","doi":"10.1182/blood.2021014586","title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed <i>FLT3</i>mut+ AML ineligible for intensive chemotherapy","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Astellas Pharma","keywords":"Medicine; Internal medicine; Hazard ratio; Gastroenterology; Azacitidine; Chemotherapy; Interim analysis; Neutropenia; Adverse effect; Surgery; Chemotherapy regimen; Randomized controlled trial; Confidence interval","score_opus":0.037985044924683235,"score_gpt":0.34285779015501583,"score_spread":0.3048727452303326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289522686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803906,0.00034788257,0.0021646747,0.0059591504,0.00042857806,0.008133632,0.0018978559,0.00013878061,0.00053883425],"genre_scores_gemma":[0.97595114,0.000310918,0.0072388654,0.0045045936,0.0019576584,0.0059360424,0.0016001002,0.00021885349,0.0022818092],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969769,0.00009624271,0.0008385019,0.0006477336,0.00065622886,0.0007844012],"domain_scores_gemma":[0.996902,0.00088645465,0.00030401934,0.00066941726,0.00095137936,0.0002867511],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008120744,0.00036423997,0.0011273214,0.00037588004,0.00024803545,0.000027241216,0.0004054024,0.00013422716,0.00039195467],"category_scores_gemma":[0.0015220263,0.00035435252,0.0005156519,0.0005596445,0.00017471888,0.00010259718,0.00019537994,0.00042544224,0.000005926116],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5037586,0.011852854,0.00016081525,0.0011997718,0.0014821376,0.00034574646,0.0018128055,0.000032063046,0.34303483,0.00083271787,0.122845605,0.012642047],"study_design_scores_gemma":[0.6669283,0.024299169,0.000019202513,0.00008226876,0.00044015306,0.00016684603,0.0009913273,0.0009159675,0.21229875,0.00031139146,0.09319701,0.00034959093],"about_ca_topic_score_codex":0.00008616703,"about_ca_topic_score_gemma":0.000006573217,"teacher_disagreement_score":0.16316971,"about_ca_system_score_codex":0.00028905284,"about_ca_system_score_gemma":0.0009263146,"threshold_uncertainty_score":0.99989086},"labels":[],"label_agreement":null},{"id":"W4289549935","doi":"10.1038/s41375-022-01650-w","title":"Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial","year":2022,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; Bundesministerium für Bildung und Forschung; Universität Ulm; Deutsche Forschungsgemeinschaft","keywords":"Midostaurin; NPM1; Myeloid leukemia; Neuroblastoma RAS viral oncogene homolog; Cancer research; Mutation; CEBPA; Biology; Oncology; Internal medicine; Dasatinib; Leukemia; Fms-Like Tyrosine Kinase 3; Medicine; Genetics; Gene; Imatinib; KRAS","score_opus":0.012386208442374405,"score_gpt":0.2550006434376942,"score_spread":0.2426144349953198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289549935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274653,0.00013428414,0.00003094961,0.00047971567,0.0002981373,0.0029734534,0.00033709584,0.00018069352,0.002819137],"genre_scores_gemma":[0.9920167,0.000025186058,0.0003729355,0.0006320896,0.00025420278,0.0004680928,0.0012802669,0.0001551963,0.0047953613],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952882,0.00049291254,0.0009706919,0.00080081885,0.0016127125,0.00083468494],"domain_scores_gemma":[0.99713343,0.00030148696,0.0005516863,0.0013030692,0.0003765999,0.0003336999],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00084008684,0.0005386022,0.000969035,0.0003835578,0.0005940316,0.000057758683,0.0008322458,0.00022425034,0.0012394577],"category_scores_gemma":[0.00016277436,0.00035067115,0.00025336776,0.0014897581,0.0003762667,0.00014305365,0.0005201537,0.0017764274,0.00009856652],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5671316,0.0015344566,0.25587982,0.00045797607,0.0066737304,0.0019534773,0.010020345,0.010029884,0.055968873,0.00073737715,0.08157259,0.0080398815],"study_design_scores_gemma":[0.5631775,0.024677195,0.31928468,0.00023753995,0.003953433,0.00064993685,0.0039015566,0.02713865,0.03220131,0.00024571037,0.021935029,0.00259746],"about_ca_topic_score_codex":0.0010288235,"about_ca_topic_score_gemma":0.00007526431,"teacher_disagreement_score":0.06340484,"about_ca_system_score_codex":0.0052031507,"about_ca_system_score_gemma":0.0046510347,"threshold_uncertainty_score":0.9998945},"labels":[],"label_agreement":null},{"id":"W4290879107","doi":"10.1182/blood.2022016293","title":"Prognostic impact of <i>NPM1</i> and <i>FLT3</i> mutations in patients with AML in first remission treated with oral azacitidine","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Celgene; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; NPM1; Hazard ratio; Placebo; Myeloid leukemia; Gastroenterology; Transplantation; Hematopoietic stem cell transplantation; Minimal residual disease; Oncology; Confidence interval; Leukemia; Surgery; Pathology; Biology","score_opus":0.009097038633836789,"score_gpt":0.2539137939120548,"score_spread":0.24481675527821803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290879107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99847245,0.00005800606,0.0000021105266,0.0001336861,0.0000030641963,0.0009128967,0.00006545354,0.000019691175,0.00033262032],"genre_scores_gemma":[0.999211,0.000008906949,0.0003212322,0.000022794013,0.0000064412925,0.000098242745,0.00023322912,0.000027608108,0.0000705198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882406,0.00007072685,0.00021634575,0.00024225825,0.00038187197,0.0002647286],"domain_scores_gemma":[0.9994407,0.000094200164,0.00007199809,0.00018755879,0.00008677828,0.000118762146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014427744,0.00013645699,0.00028835048,0.00027789842,0.000063104395,0.0000070639753,0.00006671175,0.00003461967,0.00006966544],"category_scores_gemma":[0.00009513618,0.000092923285,0.000024461071,0.0009173506,0.00008183683,0.00007083162,0.00006814549,0.00030949444,8.548486e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016216704,0.0015796929,0.99493766,0.00006462059,0.00006242971,0.00019170414,0.0003419866,0.00014728228,0.00062724564,0.000001734145,0.00009457444,0.00032942797],"study_design_scores_gemma":[0.021980498,0.0049904645,0.9712943,0.00019687362,0.000102794904,0.00006539368,0.00013190393,0.00023971745,0.0008511024,0.000004725136,0.00003367951,0.0001085519],"about_ca_topic_score_codex":0.00084179925,"about_ca_topic_score_gemma":0.00019373548,"teacher_disagreement_score":0.023643337,"about_ca_system_score_codex":0.00021380262,"about_ca_system_score_gemma":0.0003099339,"threshold_uncertainty_score":0.37893015},"labels":[],"label_agreement":null},{"id":"W4291125094","doi":"10.1016/j.isci.2022.104931","title":"A machine learning model of response to hypomethylating agents in myelodysplastic syndromes","year":2022,"lang":"en","type":"article","venue":"iScience","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Cohort; Myelodysplastic syndromes; Medicine; Receiver operating characteristic; Hypomethylating agent; Oncology; Internal medicine; Reliability (semiconductor); Biology; Bone marrow","score_opus":0.06396719461183463,"score_gpt":0.3424153965182464,"score_spread":0.27844820190641173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291125094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99646693,0.000109963206,0.0013587814,0.0010064971,0.00003495379,0.0002611901,0.000010700308,0.000023583774,0.00072741596],"genre_scores_gemma":[0.99168783,0.0000053737,0.004664755,0.00019455132,0.0000056312183,0.000042124862,0.0000019610968,0.0000132826835,0.0033844993],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99806154,0.00022290774,0.00024354018,0.0003090914,0.0008054007,0.00035752117],"domain_scores_gemma":[0.99912995,0.0003964962,0.000058533402,0.00022349338,0.000046732148,0.00014479517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022406138,0.000085690626,0.00021055057,0.00062698143,0.00016577146,0.000009631363,0.0003002645,0.00001969528,0.00016116141],"category_scores_gemma":[0.002979028,0.00008104572,0.000034193436,0.0016875209,0.00008714526,0.00007347156,0.00057166157,0.00048557736,0.000018887778],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015204155,0.00011619047,0.042823743,0.00004643753,0.000007713546,0.0002530917,0.00406,0.43365923,0.51030654,0.00005720486,0.00010579825,0.0070436453],"study_design_scores_gemma":[0.0009953394,0.0007967641,0.037733085,0.000053863718,0.000006366968,0.00010467047,0.00065229344,0.95717645,0.0018467171,0.00007462811,0.00045158016,0.0001082603],"about_ca_topic_score_codex":0.00012892901,"about_ca_topic_score_gemma":0.0000049103965,"teacher_disagreement_score":0.5235172,"about_ca_system_score_codex":0.00046733583,"about_ca_system_score_gemma":0.00050398515,"threshold_uncertainty_score":0.35663903},"labels":[],"label_agreement":null},{"id":"W4291820501","doi":"10.1182/blood.2022015790","title":"Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Kite Pharma; Sanofi Genzyme; Takeda Oncology; Health Resources and Services Administration; National Institutes of Health; MorphoSys; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Kiadis Pharma; TG Therapeutics; bluebird bio; Actinium Pharmaceuticals; CareDx; QEII Foundation; StemCyte; Medac; Jazz Pharmaceuticals; Health Sciences Centre Foundation; Damon Runyon Cancer Research Foundation; Karyopharm Therapeutics; HistoGenetics; Amgen; Accenture; U.S. Department of Defense; Sanofi; Astellas Pharma US; CSL Behring; Bristol-Myers Squibb; Seagen; Be The Match Foundation; National Heart, Lung, and Blood Institute; Edward P. Evans Foundation; Novartis Pharmaceuticals Corporation; Incyte; Pfizer; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences","keywords":"Germline; Biology; Genetics; Exome sequencing; Internal medicine; Medicine; Gene; Oncology; Immunology; Mutation","score_opus":0.013613113551851313,"score_gpt":0.2653413020340312,"score_spread":0.2517281884821799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291820501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983531,0.000088673594,0.000010632682,0.00017312414,0.00009420024,0.00052590703,0.0001499721,0.000029217495,0.0005751467],"genre_scores_gemma":[0.9987492,0.000020186804,0.00022027543,0.00013824318,0.000036593723,0.000083238265,0.00040759947,0.000024418325,0.0003202403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984629,0.00010804088,0.00032253968,0.00025115898,0.0005639831,0.00029137934],"domain_scores_gemma":[0.9993603,0.00010595695,0.00009266797,0.00026668643,0.00007356639,0.00010081445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002648912,0.00011398763,0.0002792719,0.00028383825,0.00004547361,0.0000052670425,0.00015441945,0.00005643634,0.00045410884],"category_scores_gemma":[0.00019293238,0.00011206978,0.00005189797,0.00039229824,0.000040466206,0.00006237642,0.00021771489,0.00038192663,0.000022834713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034017009,0.027351456,0.8567127,0.0017059256,0.0012569054,0.008432511,0.003594762,0.0008652129,0.08756255,0.00025491512,0.004098026,0.004763333],"study_design_scores_gemma":[0.011442238,0.0025975462,0.98235744,0.00010699759,0.0001955651,0.00035546193,0.00007807456,0.0007541116,0.0016506366,0.000044329416,0.0002763533,0.00014127162],"about_ca_topic_score_codex":0.000074942574,"about_ca_topic_score_gemma":0.0000040695368,"teacher_disagreement_score":0.12564471,"about_ca_system_score_codex":0.00017587647,"about_ca_system_score_gemma":0.00015015181,"threshold_uncertainty_score":0.49721733},"labels":[],"label_agreement":null},{"id":"W4292478418","doi":"10.3324/haematol.2022.280723","title":"High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Sunnybrook Health Science Centre; Jewish General Hospital; St. Paul's Hospital; Dr. Georges-L.-Dumont University Hospital Centre; Queen Elizabeth II Health Sciences Centre; University of Alberta; Vancouver General Hospital; Princess Margaret Cancer Centre; CancerCare Manitoba; Saskatchewan Cancer Agency; Ottawa Hospital; Health Sciences Centre; McGill University Health Centre; Juravinski Cancer Centre","funders":"Celgene","keywords":"Medicine; Ferritin; Internal medicine; Gastroenterology; Transferrin saturation; Myelodysplastic syndromes; International Prognostic Scoring System; Univariate analysis; Anemia; Serum ferritin; Multivariate analysis; Bone marrow","score_opus":0.02863820880396554,"score_gpt":0.3032478793550697,"score_spread":0.27460967055110413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292478418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99644977,0.000021275786,0.00006664169,0.0016371153,0.00018189702,0.0011797979,0.000033936874,0.00012352545,0.00030602474],"genre_scores_gemma":[0.99780804,0.000013109005,0.00089206686,0.0004891814,0.000020107767,0.00025970052,0.00016990992,0.000027969536,0.0003199349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974236,0.0003222651,0.00062005443,0.00046131873,0.00074597186,0.00042679903],"domain_scores_gemma":[0.99881464,0.00046068686,0.00009362175,0.00037407613,0.000085681255,0.00017128275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042900833,0.0002167577,0.00081507606,0.00023964273,0.00015319546,0.000017857845,0.00021242574,0.00013014898,0.00068656664],"category_scores_gemma":[0.000493415,0.00014654809,0.00010182596,0.0004359094,0.00015882283,0.00009898425,0.00014678431,0.0008964821,0.000050092243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018909194,0.0007466157,0.99417084,0.000050461207,0.00009616479,0.0007321093,0.000116146184,0.0000555191,0.0000063241664,0.00052187697,0.00059958955,0.0010134544],"study_design_scores_gemma":[0.007250883,0.003109949,0.98831546,0.000039574265,0.00005892927,0.00015425673,0.00009326831,0.00013811525,0.00001796366,0.000057265475,0.00059985847,0.00016445457],"about_ca_topic_score_codex":0.00007499763,"about_ca_topic_score_gemma":0.00004253136,"teacher_disagreement_score":0.0058553373,"about_ca_system_score_codex":0.00026636134,"about_ca_system_score_gemma":0.00027599194,"threshold_uncertainty_score":0.7517423},"labels":[],"label_agreement":null},{"id":"W4292714598","doi":"10.1042/ebc20220028","title":"Lipids and the cancer stemness regulatory system in acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"Essays in Biochemistry","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Haematopoiesis; Stem cell; Biology; Cancer research; Myeloid; Cancer stem cell; Leukemia; Cancer; Immunology; Cell biology; Genetics","score_opus":0.009680294912013769,"score_gpt":0.26810053952122465,"score_spread":0.25842024460921087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292714598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865608,0.0036496397,0.0000045574734,0.0015642294,0.00019376108,0.00052585086,0.00004246825,0.000054948367,0.0074037104],"genre_scores_gemma":[0.9942303,0.00025416265,0.000058979032,0.00030888288,0.00022531221,0.0007545567,0.000030184083,0.00003929272,0.0040983297],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978492,0.00018383932,0.00040468114,0.00052722887,0.00059101626,0.00044399127],"domain_scores_gemma":[0.99886,0.00016285783,0.000097154574,0.00070976384,0.000049169717,0.00012103912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014760607,0.00021011007,0.00045303247,0.0001292521,0.00016840444,0.000025726995,0.00041599377,0.00014914092,0.0001519915],"category_scores_gemma":[0.00007912712,0.00016461794,0.000067821755,0.0006197857,0.0003756369,0.000041214073,0.0006296048,0.0011368819,0.0000039422716],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013698736,0.00047890557,0.26574594,0.008197703,0.0009747981,0.0041852784,0.007780965,0.00095096626,0.6257249,0.0064374837,0.046922438,0.018901896],"study_design_scores_gemma":[0.10581823,0.0004048232,0.10966399,0.0039182026,0.0007066747,0.005877771,0.05304431,0.039186686,0.6559329,0.00068173796,0.021899177,0.0028654637],"about_ca_topic_score_codex":0.000609451,"about_ca_topic_score_gemma":0.000021532334,"teacher_disagreement_score":0.15608194,"about_ca_system_score_codex":0.0040992517,"about_ca_system_score_gemma":0.0010829319,"threshold_uncertainty_score":0.99972385},"labels":[],"label_agreement":null},{"id":"W4293253462","doi":"10.1158/1078-0432.ccr-22-1183","title":"Outcomes in Patients with Poor-Risk Cytogenetics with or without <i>TP53</i> Mutations Treated with Venetoclax and Azacitidine","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech","keywords":"Venetoclax; Azacitidine; Cytogenetics; Medicine; Oncology; Genetics; Internal medicine; Biology; Leukemia; DNA methylation; Gene; Chromosome; Chronic lymphocytic leukemia","score_opus":0.10386829991800524,"score_gpt":0.45484040116070207,"score_spread":0.35097210124269684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293253462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952337,0.00013570455,0.00001801093,0.0015520408,0.00002163506,0.002391724,0.00023831526,0.000047424513,0.00036142088],"genre_scores_gemma":[0.99433917,0.00031070758,0.00094825553,0.00039139687,0.00007763236,0.001086199,0.00012200023,0.0001051484,0.0026194747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99475205,0.00090275024,0.00057097594,0.0008509965,0.0020402502,0.0008829842],"domain_scores_gemma":[0.99667615,0.0012575847,0.00013866044,0.0006398338,0.0007467979,0.00054096425],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0017909498,0.00027604474,0.0007963125,0.00043735275,0.00044798764,0.00005234032,0.0003045771,0.0001125292,0.0004664743],"category_scores_gemma":[0.0004920615,0.00015983818,0.00004892613,0.001780649,0.0011510359,0.00009055087,0.00035000904,0.002465609,0.000010719497],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02592536,0.00054198777,0.9672383,0.000061917955,0.00026194853,0.000286796,0.00017990565,0.00029027276,0.000013026807,0.000007674547,0.00054384104,0.004648944],"study_design_scores_gemma":[0.025486609,0.017716229,0.951796,0.00013995379,0.00014539197,0.00003106933,0.0005918828,0.0007066701,0.00012879768,0.000015605554,0.0029683998,0.00027339853],"about_ca_topic_score_codex":0.0025040607,"about_ca_topic_score_gemma":0.0029367367,"teacher_disagreement_score":0.01717424,"about_ca_system_score_codex":0.0012398007,"about_ca_system_score_gemma":0.0033146678,"threshold_uncertainty_score":0.9998357},"labels":[],"label_agreement":null},{"id":"W4293328688","doi":"10.1016/j.ekir.2022.06.022","title":"Response to: “Clonal Hematopoiesis of Indeterminate Potential and Diabetic Kidney Disease: A Nested Case-Control Study”","year":2022,"lang":"en","type":"article","venue":"Kidney International Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Population Health Research Institute; McMaster University; Impact; Queen's University","funders":"","keywords":"Medicine; Disease; Scopus; Context (archaeology); Internal medicine; Bioinformatics; Biology; MEDLINE","score_opus":0.0093632205617797,"score_gpt":0.2904841597925029,"score_spread":0.28112093923072323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293328688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98062056,0.00003669056,0.000093655406,0.016489876,0.0005433589,0.0012568133,0.0006211206,0.000047621485,0.00029032037],"genre_scores_gemma":[0.9925565,0.0000019043094,0.00020828944,0.002942546,0.00010453232,0.00036969254,0.00008233964,0.000040452112,0.0036937222],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9965726,0.00035580163,0.00070909905,0.00055769994,0.0014958975,0.0003088602],"domain_scores_gemma":[0.99730223,0.00023581412,0.00028124615,0.0005094273,0.00038369166,0.0012875973],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001628312,0.0002052269,0.00039886893,0.0005659581,0.00017782833,0.00003920518,0.00017626719,0.000044146665,0.0018449055],"category_scores_gemma":[0.0072900043,0.00020191526,0.00013531199,0.0003189106,0.00009776721,0.00010048885,0.00049847685,0.00034699292,0.0000072188245],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02113995,0.0020520128,0.4014563,0.0001961841,0.0014171778,0.46499184,0.0019109298,0.00016131156,0.04751602,0.00006079752,0.056892853,0.0022046196],"study_design_scores_gemma":[0.012112147,0.0022970939,0.8293864,0.00026206308,0.0008513405,0.10414909,0.001507436,0.006659608,0.0017717662,0.00041152877,0.03991341,0.0006781238],"about_ca_topic_score_codex":0.00011265474,"about_ca_topic_score_gemma":0.0000019058298,"teacher_disagreement_score":0.42793012,"about_ca_system_score_codex":0.0004791468,"about_ca_system_score_gemma":0.0017162248,"threshold_uncertainty_score":0.99906754},"labels":[],"label_agreement":null},{"id":"W4293555155","doi":"10.20944/preprints202208.0491.v1","title":"Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients With AML Unfit for First-Line Intensive Chemotherapy","year":2022,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Jewish General Hospital; McMaster University; Université de Sherbrooke; Vancouver General Hospital","funders":"Astellas Pharma; BeiGene; AstraZeneca; Celgene; Gilead Sciences; Pfizer; Amgen","keywords":"Medicine; Cytarabine; Chemotherapy; Intensive care; Internal medicine; Myeloid leukemia; Intensive care medicine","score_opus":0.12327367123540214,"score_gpt":0.41803472828357413,"score_spread":0.294761057048172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293555155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985252,0.000014043576,0.00001249837,0.0073778285,0.00028283452,0.0054560048,0.00060822535,0.00006781434,0.0009287165],"genre_scores_gemma":[0.99023515,0.0011712523,0.00024279836,0.0014515881,0.00015208192,0.0013453832,0.0010796897,0.00014050974,0.004181565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99606186,0.00016002115,0.0009076594,0.0015237082,0.0004760167,0.0008707621],"domain_scores_gemma":[0.9963584,0.0005210785,0.000304288,0.0015148376,0.00050225726,0.0007991625],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007659515,0.00058522314,0.001404641,0.0006894641,0.0001356582,0.000021740176,0.00040255542,0.00033441663,0.0012221319],"category_scores_gemma":[0.0006325515,0.00047119352,0.00031015725,0.00021322633,0.0001693789,0.000047841117,0.00081766385,0.0014056399,0.000044722703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001511181,0.00055692025,0.99335855,0.0002102179,0.0009185248,0.00012769116,0.0008095213,0.00004149926,0.0000013502269,0.000023334225,0.00009200729,0.0023492274],"study_design_scores_gemma":[0.010135496,0.00075404125,0.97997105,0.00023492717,0.00019860873,0.0000038303983,0.00016911443,0.00022889474,0.000080031336,0.00010791423,0.007719027,0.0003970718],"about_ca_topic_score_codex":0.5714666,"about_ca_topic_score_gemma":0.72515994,"teacher_disagreement_score":0.15369332,"about_ca_system_score_codex":0.0049284147,"about_ca_system_score_gemma":0.002135465,"threshold_uncertainty_score":0.999774},"labels":[],"label_agreement":null},{"id":"W4293776726","doi":"10.3390/curroncol29090491","title":"Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Fraser Health; University of British Columbia; Vancouver Coastal Health","funders":"","keywords":"Medicine; Myeloid leukemia; Azacitidine; Venetoclax; Oncology; Internal medicine; Intensive care medicine; Risk stratification; Malignancy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.21105775497601012,"score_gpt":0.51152281985516,"score_spread":0.3004650648791499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293776726","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000072377707,0.97986555,0.00007177454,0.0009923159,0.0015168493,0.009102657,0.00029565938,0.00004394494,0.008103992],"genre_scores_gemma":[1.2622637e-7,0.9802504,0.0037591215,0.00035249794,0.00039492504,0.009857487,0.0036111458,0.00011284028,0.0016614565],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945767,0.0010194822,0.0019886815,0.0009936467,0.00056048826,0.00086103287],"domain_scores_gemma":[0.99647254,0.0009324629,0.0013042329,0.00085414154,0.00018159127,0.00025501804],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022113333,0.0006068503,0.00517732,0.0008629154,0.0000836266,0.0000058788905,0.0006789167,0.0006117623,0.001240192],"category_scores_gemma":[0.00022335481,0.00052984874,0.0011113731,0.001224432,0.00023660064,0.00007279403,0.0007269304,0.0023745205,0.00007393233],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00015916042,0.00056757766,0.0000017870146,0.16549021,0.0010707786,0.0007164939,0.000032405085,3.116333e-7,4.6468588e-7,0.00074289006,0.058532342,0.7726856],"study_design_scores_gemma":[0.003022108,0.001691446,0.0000035929897,0.029940618,0.0076563703,0.0008967053,0.00005376859,0.00001970334,4.4874056e-7,0.000046401736,0.9563232,0.00034560388],"about_ca_topic_score_codex":0.00001806231,"about_ca_topic_score_gemma":0.00000773381,"teacher_disagreement_score":0.8977909,"about_ca_system_score_codex":0.018002335,"about_ca_system_score_gemma":0.008594677,"threshold_uncertainty_score":0.99992704},"labels":[],"label_agreement":null},{"id":"W4295423248","doi":"10.1080/10428194.2022.2109154","title":"A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"EVERSANA (Canada); Bristol-Myers Squibb (Canada); Dalhousie University; Hamilton Health Sciences; Hôpital de l'Enfant-Jésus; Juravinski Cancer Centre; Dr. Georges-L.-Dumont University Hospital Centre; St. Paul's Hospital; University of British Columbia; McGill University Health Centre; University of Ottawa; Sunnybrook Health Science Centre; Jewish General Hospital; University of Alberta; CancerCare Manitoba; Health Sciences Centre; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Natural history; International Prognostic Scoring System; Internal medicine; Clinical trial; Myeloid leukemia; Natural history study; Pediatrics; Bone marrow","score_opus":0.009955952144202041,"score_gpt":0.22864631906547972,"score_spread":0.2186903669212777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295423248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944759,0.002395154,0.00005242086,0.00015709383,0.00044650905,0.0006960422,0.00021596337,0.00013488061,0.0014260074],"genre_scores_gemma":[0.99393135,0.0001915379,0.00052253937,0.0004514975,0.000106900196,0.00014391365,0.0001303558,0.00014094151,0.0043809875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941138,0.00057586544,0.0010939839,0.0012416615,0.0019634299,0.0010112537],"domain_scores_gemma":[0.9951224,0.00065073045,0.0011643503,0.0022006042,0.00035608019,0.00050587323],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008205137,0.0007411641,0.001775157,0.0011346593,0.00060117635,0.000052421965,0.0010997306,0.0002800759,0.00025996423],"category_scores_gemma":[0.00036088467,0.00056178164,0.0006485088,0.002648441,0.0016738353,0.00027123652,0.00086314656,0.0006511655,0.0000034080629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04332791,0.004362213,0.51848346,0.0057837437,0.04003953,0.008518247,0.03600757,0.05129401,0.13575359,0.0052775852,0.020290071,0.13086206],"study_design_scores_gemma":[0.02842996,0.004042549,0.7600879,0.00070665835,0.01117361,0.0067592175,0.0075209024,0.15989588,0.004926873,0.000117172545,0.014613925,0.0017253398],"about_ca_topic_score_codex":0.0069717434,"about_ca_topic_score_gemma":0.0007232298,"teacher_disagreement_score":0.24160443,"about_ca_system_score_codex":0.029567195,"about_ca_system_score_gemma":0.014234636,"threshold_uncertainty_score":0.9996834},"labels":[],"label_agreement":null},{"id":"W4295763013","doi":"10.1038/s42003-022-03888-7","title":"PU.1-c-Jun interaction is crucial for PU.1 function in myeloid development","year":2022,"lang":"en","type":"article","venue":"Communications Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer; Memorial University of Newfoundland","funders":"National Heart, Lung, and Blood Institute; National Cancer Institute; National Institutes of Health; Wuhan Union Hospital; National Medical Research Council; Medical Research Council; Foundation for the National Institutes of Health","keywords":"Transactivation; Haematopoiesis; Myeloid; Transcription factor; Progenitor cell; Cell biology; Mutant; Biology; Cellular differentiation; Monocyte; Stem cell; Molecular biology; Chemistry; Cancer research; Immunology; Gene; Genetics","score_opus":0.09611932127829328,"score_gpt":0.39271571102642455,"score_spread":0.2965963897481313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295763013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9153666,0.002294677,0.008214098,0.05487595,0.0010320622,0.0034769909,0.00011076066,0.0002206546,0.014408188],"genre_scores_gemma":[0.9846815,0.0002101913,0.008989724,0.001751879,0.00007554844,0.0018317524,0.0010927273,0.00002151249,0.0013451683],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987708,0.00026483418,0.00036720993,0.0002442681,0.000094250696,0.0002586862],"domain_scores_gemma":[0.99840814,0.0003213622,0.00009550955,0.0009877195,0.00012997839,0.00005731125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061655825,0.00010339659,0.00020865828,0.00038989497,0.0004844023,0.000009588178,0.000524606,0.00009115703,0.00051698444],"category_scores_gemma":[0.00019929378,0.00010675006,0.000061266765,0.00041452138,0.00011705182,0.000059284474,0.0008083185,0.0006049995,0.00006661692],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004360503,0.0024097878,0.13365272,0.00015694615,0.0005592083,0.0000073010933,0.0106062405,0.000064762346,0.07120857,0.022522427,0.062205415,0.69224614],"study_design_scores_gemma":[0.0017140668,0.00041505366,0.022413388,0.000013690982,0.000024132514,0.00004064545,0.0011333226,0.0024236657,0.00084025646,0.001298363,0.96955425,0.00012915293],"about_ca_topic_score_codex":0.000099702615,"about_ca_topic_score_gemma":0.0001752181,"teacher_disagreement_score":0.9073489,"about_ca_system_score_codex":0.0010349979,"about_ca_system_score_gemma":0.00051270763,"threshold_uncertainty_score":0.56606174},"labels":[],"label_agreement":null},{"id":"W4296039109","doi":"10.1016/j.gim.2022.08.010","title":"Clinical implementation of genetic testing in adults for hereditary hematologic malignancy syndromes","year":2022,"lang":"en","type":"review","venue":"Genetics in Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Hospital for Sick Children; University Health Network; University of Toronto; Toronto General Hospital; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Genetic testing; Hematology; Internal medicine; Malignancy; Cancer; Oncology; Disease; Hematologic malignancy; Population; Bone marrow; Bone marrow failure; Pathology; Genetics; Haematopoiesis; Biology","score_opus":0.241117993407613,"score_gpt":0.5021494367604645,"score_spread":0.26103144335285156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296039109","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009186546,0.98547995,0.000054056327,0.00014240545,0.0004568452,0.004414802,0.00007602913,0.000022129221,0.00016721012],"genre_scores_gemma":[0.00047972894,0.98150873,0.015769232,0.000100261415,0.00049259904,0.00093631924,0.00056574866,0.0000993496,0.000048022495],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941547,0.00050918636,0.0032078184,0.00080524234,0.00070405577,0.00061902934],"domain_scores_gemma":[0.9952545,0.002964524,0.0007565148,0.00071286113,0.00014331823,0.00016828132],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025609895,0.0004402101,0.0034466034,0.0009207922,0.000038177262,0.0000029322803,0.0004861087,0.00039374645,0.00057678623],"category_scores_gemma":[0.0022764504,0.00035511167,0.00027680595,0.0012835108,0.00026570752,0.000016259848,0.00029252653,0.0010950324,0.000005332296],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005348681,0.00012457013,0.021780128,0.044815037,0.000100551835,0.0007870322,0.00015396514,0.0000025922513,9.3077205e-7,0.00000988319,0.0011347309,0.93103707],"study_design_scores_gemma":[0.024799826,0.01354786,0.043278776,0.14522775,0.003028433,0.004512556,0.0039696763,0.0007089287,0.0000068191484,0.000863577,0.75875753,0.0012982641],"about_ca_topic_score_codex":0.00020737859,"about_ca_topic_score_gemma":0.00010863455,"teacher_disagreement_score":0.9297388,"about_ca_system_score_codex":0.0005699941,"about_ca_system_score_gemma":0.0015164689,"threshold_uncertainty_score":0.9998901},"labels":[],"label_agreement":null},{"id":"W4296164616","doi":"10.1182/blood.2022016963","title":"Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Collège de Maisonneuve; Centres Intégré Universitaires de Santé et de Services Sociaux","funders":"","keywords":"Chemotherapy regimen; Medicine; Term (time); Internal medicine; Oncology; Chemotherapy","score_opus":0.013653420316964135,"score_gpt":0.2692680455346338,"score_spread":0.25561462521766964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296164616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783105,0.00006178782,0.000029535635,0.00034630252,0.000048224396,0.0013983143,0.000064487955,0.000025917552,0.00019439255],"genre_scores_gemma":[0.99782306,0.000012565721,0.00026633273,0.000492954,0.00003535578,0.00018310151,0.00026044375,0.00004489294,0.0008813201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881816,0.00003611994,0.00023424502,0.0002527234,0.00036605718,0.00029270325],"domain_scores_gemma":[0.9990434,0.00007055399,0.00008906524,0.0002932308,0.00042802515,0.00007574479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013200332,0.00013231247,0.00035502954,0.00024256438,0.00007127092,0.0000041712146,0.0001393282,0.00004710109,0.00017843355],"category_scores_gemma":[0.00011354853,0.00010759129,0.00006666936,0.00047473976,0.00005773704,0.000037510945,0.000113622904,0.0002172667,0.0000031318302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060626506,0.0010915934,0.98664033,0.00011381198,0.00026567464,0.000046662113,0.00092302164,0.0000042906613,0.0028152154,0.000011758376,0.0009752735,0.0010497334],"study_design_scores_gemma":[0.1253661,0.0054326346,0.8263897,0.00013166397,0.00020966095,0.00002689743,0.00031569263,0.00006332357,0.041366376,0.000029176155,0.00044093913,0.00022784129],"about_ca_topic_score_codex":0.00010858967,"about_ca_topic_score_gemma":0.000031362466,"teacher_disagreement_score":0.16025063,"about_ca_system_score_codex":0.00017387618,"about_ca_system_score_gemma":0.0002540367,"threshold_uncertainty_score":0.43874454},"labels":[],"label_agreement":null},{"id":"W4296207957","doi":"10.1101/2022.09.10.507366","title":"Loss of FBXO11 function establishes a stem cell program in acute myeloid leukemia through dysregulation of mitochondrial LONP1","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"","keywords":"Biology; Myeloid leukemia; Ubiquitin ligase; Myeloid; Cancer research; Progenitor cell; Stem cell; Haematopoiesis; Mitochondrion; Cell biology; CD34; Ubiquitin; Genetics; Gene","score_opus":0.017256300962612874,"score_gpt":0.25863660539050876,"score_spread":0.24138030442789588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296207957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99190843,0.0007779355,0.0010626202,0.00014818647,0.0013656468,0.0040041306,0.00034012695,0.00030581947,0.00008710126],"genre_scores_gemma":[0.9841858,0.0005033196,0.013455878,0.00005671219,0.00049818173,0.0009944364,0.000011089554,0.00022805725,0.00006650095],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99431056,0.00039164213,0.0015527532,0.0013977266,0.0015050062,0.0008423232],"domain_scores_gemma":[0.9953118,0.00016784674,0.0012037957,0.0020411785,0.0010159697,0.0002594128],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00086243456,0.00073660444,0.0015645571,0.0008883213,0.00010866383,0.00008133034,0.00073409115,0.00093827915,0.00024410877],"category_scores_gemma":[0.000144428,0.00079252385,0.00039194175,0.002032578,0.0003695212,0.00038267658,0.0010723236,0.0021314225,0.000016351334],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035900655,0.0013516062,0.053254288,0.005315576,0.00081813417,0.0003595958,0.00018875545,0.0010424915,0.9323109,0.000352155,0.0013390994,0.000077351455],"study_design_scores_gemma":[0.008930169,0.0019830554,0.28311113,0.0016050141,0.0012807488,2.9754875e-7,0.00011022007,0.0023691743,0.6881152,0.0000108505365,0.011121116,0.0013630274],"about_ca_topic_score_codex":0.0005875971,"about_ca_topic_score_gemma":0.000011251966,"teacher_disagreement_score":0.24419568,"about_ca_system_score_codex":0.003052119,"about_ca_system_score_gemma":0.004575866,"threshold_uncertainty_score":0.9994526},"labels":[],"label_agreement":null},{"id":"W4296276644","doi":"10.1002/ajh.26726","title":"Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma","year":2022,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Cancer Society; Wellcome Trust; Princess Margaret Cancer Foundation; Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Stem cell; Lymphoma; Transplantation; Hematopoietic stem cell transplantation; Haematopoiesis; Medicine; Oncology; Autologous stem-cell transplantation; Immunology; Biology; Cancer research; Internal medicine; Genetics","score_opus":0.02238040149386456,"score_gpt":0.33572820172904616,"score_spread":0.3133478002351816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296276644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99457234,0.00031968008,0.0018042228,0.002730103,0.00009150468,0.00033854868,0.000026914298,0.0000035716719,0.00011311608],"genre_scores_gemma":[0.994427,0.00009781064,0.0050419676,0.00033546446,0.00003511839,0.00003065429,0.0000049369737,0.000014752296,0.000012253099],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971245,0.00077512476,0.0012826988,0.00014810722,0.00042168144,0.00024789007],"domain_scores_gemma":[0.9954213,0.002829943,0.001302,0.0001890622,0.00019708335,0.000060618528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002366134,0.000101235564,0.0009685912,0.0002474332,0.000053775915,0.0000020020866,0.000348017,0.00004372196,0.000032899155],"category_scores_gemma":[0.00011607935,0.00007442314,0.00025750775,0.00044941553,0.00042963732,0.00003354173,0.000031894586,0.00036590878,4.8719e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023765437,0.0035955796,0.68487513,0.003076005,0.00085765566,0.0030515527,0.021753054,0.0007657826,0.01857432,0.0049071726,0.0055552376,0.22922304],"study_design_scores_gemma":[0.03441675,0.043215144,0.56861,0.0006400945,0.0015255747,0.1002212,0.16067705,0.0043315794,0.080070116,0.0018817544,0.0036346533,0.00077609136],"about_ca_topic_score_codex":0.000047898797,"about_ca_topic_score_gemma":0.000005750539,"teacher_disagreement_score":0.22844696,"about_ca_system_score_codex":0.00010035316,"about_ca_system_score_gemma":0.0007477833,"threshold_uncertainty_score":0.30348873},"labels":[],"label_agreement":null},{"id":"W4296456774","doi":"10.1038/s41467-022-33244-6","title":"Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"Hyundai Hope On Wheels; Children’s Oncology Group; St. Baldrick's Foundation; Fred Hutchinson Cancer Research Center; Rally Foundation; Office of Research Infrastructure Programs, National Institutes of Health; Leukemia and Lymphoma Society; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Myeloid leukemia; Risk stratification; Oncology; Medicine; Biomarker; Predictive power; Leukemia; Cohort; Internal medicine; Population; Myeloid; Bioinformatics; Computational biology; Biology; Genetics","score_opus":0.012658098597952158,"score_gpt":0.28927292420197165,"score_spread":0.2766148256040195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296456774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96905476,0.02200988,0.0001514453,0.003279011,0.00010862883,0.001176613,0.00019836702,0.00014382899,0.0038774572],"genre_scores_gemma":[0.9849423,0.0072049326,0.005631934,0.00059122825,0.00004110304,0.00024799237,0.00052345346,0.000046297697,0.00077074615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978313,0.0006777385,0.00033841247,0.0003673639,0.00047109218,0.0003141264],"domain_scores_gemma":[0.9974302,0.00043141528,0.00016885446,0.0016087532,0.00021800445,0.000142747],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006994781,0.0002065805,0.00028811456,0.0006630947,0.00051310606,0.00003663533,0.00091384107,0.00037552766,0.000045925517],"category_scores_gemma":[0.00013717012,0.00020291455,0.00008179105,0.0017551278,0.00010777334,0.00011775459,0.0010885415,0.006376718,0.00001172623],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026330168,0.0034797117,0.51497173,0.00079389993,0.00073951774,0.0019610962,0.015125743,0.0006534725,0.14007238,0.005523198,0.077919275,0.23612694],"study_design_scores_gemma":[0.021590577,0.0022064345,0.46581486,0.00015661454,0.0025643378,0.0016037603,0.008063726,0.16146205,0.014179398,0.0009986794,0.3189271,0.00243244],"about_ca_topic_score_codex":0.00008722956,"about_ca_topic_score_gemma":0.00016147825,"teacher_disagreement_score":0.24100785,"about_ca_system_score_codex":0.0014882877,"about_ca_system_score_gemma":0.0007586782,"threshold_uncertainty_score":0.9959156},"labels":[],"label_agreement":null},{"id":"W4296468281","doi":"10.1016/s2152-2650(22)01287-3","title":"AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Interleukin-3 receptor; Medicine; Internal medicine; Adverse effect; Chronic myelomonocytic leukemia; Bone marrow; Myeloid; Myeloid leukemia; Gastroenterology; Oncology; Myelodysplastic syndromes","score_opus":0.021524954406898934,"score_gpt":0.2972253262426553,"score_spread":0.27570037183575635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296468281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620396,0.0003434891,0.00004369999,0.00032680298,0.00016151542,0.0014492592,0.00045792622,0.00030058622,0.00071277097],"genre_scores_gemma":[0.99435276,0.00016953814,0.0013757751,0.000955036,0.000046662437,0.00023213972,0.0021948447,0.00009526551,0.00057795167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924709,0.0013391605,0.002406036,0.0012519899,0.0015170762,0.0010148358],"domain_scores_gemma":[0.9952037,0.0013819447,0.00077207416,0.0013842093,0.0008088155,0.00044925348],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019723065,0.0006029489,0.0026898945,0.0014402854,0.00025625832,0.000029456509,0.0008152639,0.00041151882,0.001923554],"category_scores_gemma":[0.0015052451,0.00045571307,0.0007891254,0.0083176885,0.0007906095,0.00014595142,0.0005230433,0.0010520318,0.00002988299],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015961515,0.0017439389,0.90437406,0.000055133776,0.0029271108,0.00045695578,0.00031783042,0.00032587993,0.00043961775,0.00013300295,0.0018632042,0.07140175],"study_design_scores_gemma":[0.015750887,0.0030219085,0.96843195,0.00008707228,0.0006721458,0.000028132457,0.00041236688,0.006348733,0.00042572123,0.000045088014,0.004303008,0.0004729714],"about_ca_topic_score_codex":0.0009357673,"about_ca_topic_score_gemma":0.00016293894,"teacher_disagreement_score":0.070928775,"about_ca_system_score_codex":0.003744808,"about_ca_system_score_gemma":0.0033048824,"threshold_uncertainty_score":0.9997895},"labels":[],"label_agreement":null},{"id":"W4296468504","doi":"10.1016/s2152-2650(22)01293-9","title":"AML-432 Overall Survival (OS) by Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant- Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Medical Research Council","keywords":"Medicine; Internal medicine; NPM1; Oncology; Myeloid leukemia; Cohort; Refractory (planetary science); Gastroenterology; Biology; Genetics","score_opus":0.045896842606901425,"score_gpt":0.3575394815419613,"score_spread":0.3116426389350599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296468504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829161,0.00031463176,0.000024226347,0.0007142512,0.0005842277,0.012349457,0.0014265197,0.00020618523,0.0014644088],"genre_scores_gemma":[0.97594285,0.0006249902,0.00045144113,0.0021360358,0.00042778006,0.002940588,0.0054799714,0.00039498013,0.011601358],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98184603,0.005384357,0.004113492,0.0027860838,0.0037016626,0.0021683453],"domain_scores_gemma":[0.9886632,0.005614372,0.0016375545,0.0024022618,0.0007309917,0.00095161796],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0061938763,0.0014963545,0.0043469756,0.00068536,0.000862645,0.00038429716,0.0026805168,0.0008777351,0.0036105288],"category_scores_gemma":[0.0021968866,0.0009042054,0.0006029895,0.0023183564,0.0016134612,0.00078855234,0.0013760584,0.0033457368,0.00012505395],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9482018,0.006099422,0.00744182,0.00014464163,0.0017888144,0.010436148,0.0011934657,0.00009284402,0.00041439687,0.0001310059,0.010472439,0.013583229],"study_design_scores_gemma":[0.9211389,0.019504186,0.025348406,0.00037515382,0.0009860443,0.00026250008,0.0015950187,0.0012740907,0.0002794658,0.000034238783,0.027882325,0.0013196594],"about_ca_topic_score_codex":0.002564262,"about_ca_topic_score_gemma":0.0012195944,"teacher_disagreement_score":0.027062861,"about_ca_system_score_codex":0.012964643,"about_ca_system_score_gemma":0.014456339,"threshold_uncertainty_score":0.99977857},"labels":[],"label_agreement":null},{"id":"W4296529438","doi":"10.1016/s2152-2650(22)00691-7","title":"Oral Abstract: AML-295 AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Azacitidine; Myeloid leukemia; Medicine; Placebo; IDH1; Oncology; Internal medicine; Mutation; Biology; Pathology; Genetics","score_opus":0.04273344456218377,"score_gpt":0.36451510903937834,"score_spread":0.3217816644771946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296529438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98628247,0.00010706783,0.0000792401,0.00025324826,0.000534623,0.011241168,0.00040836647,0.00030695027,0.0007868813],"genre_scores_gemma":[0.99281794,0.00008119747,0.0014294538,0.00043194322,0.00036642604,0.0023246466,0.0021271056,0.00026337348,0.0001579354],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9865906,0.0016690723,0.0039260755,0.0024347987,0.0036391288,0.0017402816],"domain_scores_gemma":[0.9905349,0.0029496595,0.001781037,0.0021902157,0.001173541,0.0013706401],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.004198793,0.0013373176,0.004109207,0.00084993965,0.00054686656,0.00016475571,0.0013173205,0.00057519873,0.0006114834],"category_scores_gemma":[0.0011779116,0.0010949624,0.00058884406,0.0031509504,0.0013746389,0.0010198589,0.0007241013,0.0018546891,0.00006772933],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.87013733,0.00890349,0.050582204,0.00012066521,0.0021207558,0.0055431826,0.0009120207,0.0014058636,0.00007639218,0.00009307993,0.0006699589,0.059435043],"study_design_scores_gemma":[0.7280246,0.028641012,0.23512703,0.00018038771,0.0015720109,0.00016974869,0.0028694598,0.0021038402,0.00019888973,0.0000409851,0.00016304679,0.00090900843],"about_ca_topic_score_codex":0.0044756904,"about_ca_topic_score_gemma":0.0016914451,"teacher_disagreement_score":0.18454483,"about_ca_system_score_codex":0.010339156,"about_ca_system_score_gemma":0.007480352,"threshold_uncertainty_score":0.9999378},"labels":[],"label_agreement":null},{"id":"W4296531520","doi":"10.1016/s2152-2650(22)01225-3","title":"AML-131 ERG: From a Fortuitous Discovery to Potential Treatment for AML","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Erg; Biology; Myeloid; Cancer research; ETS transcription factor family; Haematopoiesis; Myeloid leukemia; Molecular biology; Transcription factor; Stem cell; Cell biology; Genetics; Gene; Biochemistry","score_opus":0.046372543334708104,"score_gpt":0.3594096536005253,"score_spread":0.3130371102658172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296531520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848182,0.00043269157,0.0024622006,0.0044252365,0.0018915102,0.0032245487,0.0013398497,0.00030600064,0.001099757],"genre_scores_gemma":[0.96518064,0.00018905949,0.005726892,0.0059511675,0.003739057,0.0022293783,0.0013749292,0.00023909156,0.015369814],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9934431,0.00041029722,0.001705835,0.0018021226,0.0012065406,0.0014321517],"domain_scores_gemma":[0.99469244,0.0017502119,0.0003257736,0.0017597103,0.0002247008,0.0012471878],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010173687,0.0006726283,0.0015906966,0.0003197548,0.0007171318,0.00015685837,0.0008637974,0.00039073205,0.00072491047],"category_scores_gemma":[0.0011156736,0.0005976407,0.0014085021,0.0006507438,0.00030459004,0.00024520236,0.0010405924,0.00055616646,0.00042783204],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016210524,0.0015254946,0.0072312444,0.000057452133,0.0012202527,0.002257851,0.00036921704,0.00031876125,0.004630184,0.00041829038,0.087637566,0.87812316],"study_design_scores_gemma":[0.03419509,0.013689064,0.47637108,0.00012537214,0.0010388794,0.0005390627,0.00086253637,0.008478884,0.002632144,0.001984701,0.45884103,0.0012421564],"about_ca_topic_score_codex":0.0014351557,"about_ca_topic_score_gemma":0.00009048861,"teacher_disagreement_score":0.876881,"about_ca_system_score_codex":0.010228192,"about_ca_system_score_gemma":0.0054560816,"threshold_uncertainty_score":0.9996475},"labels":[],"label_agreement":null},{"id":"W4296532403","doi":"10.1016/s2152-2650(22)01303-9","title":"AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; McGill University; University of Toronto; Jewish General Hospital","funders":"","keywords":"Venetoclax; Medicine; Azacitidine; Cohort; Internal medicine; Neutropenia; Myeloid leukemia; Myeloid; Myelodysplastic syndromes; Oncology; Hypomethylating agent; Tolerability; Leukemia; Gastroenterology; Chemotherapy; Adverse effect; Chronic lymphocytic leukemia; Bone marrow","score_opus":0.02956475525237945,"score_gpt":0.32890525914134455,"score_spread":0.2993405038889651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296532403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99154514,0.00019244186,0.000015465768,0.00070300093,0.00045069816,0.005101601,0.0007724203,0.0003020862,0.0009171493],"genre_scores_gemma":[0.99311066,0.00008536974,0.0019729037,0.0012414424,0.00047371798,0.00087562006,0.0011765452,0.0003204418,0.0007433086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98591405,0.0014065682,0.0047840565,0.0026463317,0.003174841,0.002074135],"domain_scores_gemma":[0.9899096,0.003242266,0.0017438853,0.0028119995,0.0008027822,0.0014894678],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0038002967,0.001241051,0.0031444426,0.0010142009,0.0011108845,0.00009099455,0.0016752728,0.00057379634,0.00027030305],"category_scores_gemma":[0.0051860632,0.0011481509,0.000640196,0.0035194047,0.0014067586,0.0004986323,0.0025006242,0.002477221,0.0000767876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07002507,0.014506269,0.57617676,0.0004660564,0.0024733248,0.0076762782,0.006382441,0.0050187823,0.0009160416,0.00007522316,0.019283049,0.2970007],"study_design_scores_gemma":[0.17951836,0.036222048,0.76579356,0.00053735654,0.00068414083,0.00013540828,0.0013437114,0.009039472,0.0005439062,0.00007048151,0.0050065196,0.0011050184],"about_ca_topic_score_codex":0.0025335895,"about_ca_topic_score_gemma":0.0004719463,"teacher_disagreement_score":0.2958957,"about_ca_system_score_codex":0.015910089,"about_ca_system_score_gemma":0.012170118,"threshold_uncertainty_score":0.9998241},"labels":[],"label_agreement":null},{"id":"W4296533948","doi":"10.1016/s2152-2650(22)01262-9","title":"AML-295 AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Azacitidine; Myeloid leukemia; Isocitrate dehydrogenase; IDH1; Internal medicine; Placebo; Adverse effect; Gastroenterology; Mutation; Biology; Enzyme; Pathology","score_opus":0.03753250305841633,"score_gpt":0.358132601442889,"score_spread":0.3206000983844727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296533948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98527443,0.0001293318,0.0001372372,0.0002763136,0.00053640996,0.012229274,0.00036751878,0.00031721115,0.00073226285],"genre_scores_gemma":[0.9922422,0.00009935143,0.0014982062,0.0004945241,0.00041006296,0.002847204,0.0019575555,0.0002687444,0.00018214008],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9857772,0.0024888013,0.0038236768,0.0025131376,0.0036710866,0.0017261225],"domain_scores_gemma":[0.9901904,0.0031927917,0.0016913202,0.0023566103,0.0012073402,0.0013615775],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0040226937,0.0013295268,0.0041570775,0.00089810777,0.00056867494,0.00014905269,0.0013523612,0.000548439,0.0004627203],"category_scores_gemma":[0.0012896719,0.0010857253,0.00059304124,0.003632457,0.001400428,0.00091282796,0.0008265645,0.0017224633,0.000060220173],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8824024,0.008442568,0.0534897,0.00011635324,0.0023135555,0.004812453,0.0010734305,0.0015637572,0.0000615092,0.00013014066,0.0006677763,0.04492632],"study_design_scores_gemma":[0.80801874,0.03897883,0.14176226,0.00020582417,0.0018916283,0.00020169622,0.0034776833,0.0040209084,0.00021161418,0.000047934067,0.00018742129,0.0009954801],"about_ca_topic_score_codex":0.003444092,"about_ca_topic_score_gemma":0.0012461146,"teacher_disagreement_score":0.088272564,"about_ca_system_score_codex":0.011139984,"about_ca_system_score_gemma":0.007708708,"threshold_uncertainty_score":0.9999456},"labels":[],"label_agreement":null},{"id":"W4296616412","doi":"10.3390/curroncol29100535","title":"Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive Chemotherapy","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Jewish General Hospital; University of Manitoba; Vancouver General Hospital; University of British Columbia; McMaster University Medical Centre; McGill University; Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Cytarabine; Chemotherapy; Intensive care; Internal medicine; Myeloid leukemia; Intensive care medicine; Chemotherapy regimen","score_opus":0.10466454704001234,"score_gpt":0.4470581247064367,"score_spread":0.34239357766642436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296616412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98598737,0.000042465224,0.000014294605,0.011181094,0.00043997169,0.0018835817,0.00027160672,0.000016860751,0.00016278982],"genre_scores_gemma":[0.9962706,0.0005600063,0.00010320808,0.0013650943,0.0001246077,0.0005557444,0.00047756618,0.00003540391,0.00050774583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842966,0.00010036513,0.00037448123,0.0004038405,0.00016987606,0.0005217692],"domain_scores_gemma":[0.9985628,0.0004934777,0.00009781622,0.00024351041,0.00020823345,0.0003941235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027808495,0.00017970028,0.00061772653,0.00034936235,0.00011790829,0.0000062068766,0.000103720144,0.000066724744,0.00021309545],"category_scores_gemma":[0.0001579755,0.00013312757,0.00008482016,0.00018327347,0.00010995122,0.000024044026,0.00007030487,0.0004049238,0.000004177008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00114151,0.0008513283,0.92228967,0.000026699548,0.00013113226,0.00005734187,0.00038803823,0.0000027976662,2.2753292e-7,0.00003665243,0.0020313002,0.0730433],"study_design_scores_gemma":[0.015896289,0.0066166627,0.8007388,0.000020306159,0.00006249561,0.0000066818407,0.00020387606,0.00031052364,0.0000024880608,0.000026199748,0.17600842,0.00010727703],"about_ca_topic_score_codex":0.10081741,"about_ca_topic_score_gemma":0.730538,"teacher_disagreement_score":0.6297206,"about_ca_system_score_codex":0.004607069,"about_ca_system_score_gemma":0.0013919938,"threshold_uncertainty_score":0.99921405},"labels":[],"label_agreement":null},{"id":"W4296686347","doi":"10.1097/hs9.0000000000000779","title":"U2AF1 S34/Q157 Variants Detected in cis Arise Sequentially in an MDS Patient With Serial Sequencing Spanning 18 Years","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; Ontario Institute for Cancer Research; Queen's University","funders":"","keywords":"DNA sequencing; Computational biology; Genetics; Computer science; Biology; Psychology; Gene","score_opus":0.029689907945200766,"score_gpt":0.28319871875837477,"score_spread":0.253508810813174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296686347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964528,0.00013371457,0.000085533895,0.00015256603,0.00013659429,0.00079532486,0.000024090008,0.00009954696,0.002119832],"genre_scores_gemma":[0.9955349,0.000012094322,0.0033075057,0.0003295726,0.00012469878,0.00017381922,0.00007905591,0.000088940345,0.00034940292],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9967654,0.00035647495,0.0004855356,0.00059039483,0.0010968456,0.0007053885],"domain_scores_gemma":[0.9988864,0.000065486,0.000118819305,0.00054449844,0.00010172912,0.00028306013],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006210506,0.00024249537,0.00044197368,0.00025952974,0.0001184494,0.00004618281,0.0002793375,0.0001497708,0.0055893],"category_scores_gemma":[0.00017736616,0.00024246272,0.000050682847,0.0012621575,0.0000639776,0.00021140219,0.00033067702,0.0012163323,0.000034164135],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025524836,0.0025786918,0.24576315,0.00095405657,0.00057112076,0.17263469,0.04269158,0.034634408,0.34390277,0.0003089758,0.0056431717,0.12479257],"study_design_scores_gemma":[0.12243323,0.030855488,0.40851265,0.0050411327,0.0005980203,0.0166193,0.10812837,0.20906189,0.06902426,0.00082028436,0.021914486,0.0069908993],"about_ca_topic_score_codex":0.002760427,"about_ca_topic_score_gemma":0.0028951399,"teacher_disagreement_score":0.2748785,"about_ca_system_score_codex":0.0021606956,"about_ca_system_score_gemma":0.0023726828,"threshold_uncertainty_score":0.9953197},"labels":[],"label_agreement":null},{"id":"W4296690243","doi":"10.1038/s41375-022-01697-9","title":"A primary hierarchically organized patient-derived model enables in depth interrogation of stemness driven by the coding and non-coding genome","year":2022,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; Princess Margaret Cancer Foundation","keywords":"Computational biology; Biology; Epigenetics; Myeloid leukemia; Stem cell; CRISPR; Population; Cancer stem cell; Genome editing; Genetics; Cancer research; Gene; Medicine","score_opus":0.014939317964728915,"score_gpt":0.2476150822208278,"score_spread":0.23267576425609887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296690243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941545,0.00014289268,0.003233605,0.0006458194,0.00003175342,0.00078247284,0.000032280313,0.00003891641,0.00093775813],"genre_scores_gemma":[0.99763495,0.00007267216,0.001206453,0.00057188055,0.000024678755,0.00012301415,0.0001260463,0.000042972886,0.00019731416],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9981841,0.00018420084,0.00043579878,0.00033486297,0.0005115487,0.0003495114],"domain_scores_gemma":[0.9991302,0.00021186721,0.00015381046,0.00031785909,0.000084021165,0.00010226495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004590261,0.00016640357,0.00039607479,0.00021126244,0.00019836526,0.000023760955,0.00026611806,0.00007315749,0.000050165425],"category_scores_gemma":[0.00008988642,0.00013355684,0.00005149976,0.00045823955,0.00014554501,0.00010986708,0.0006196577,0.00074442424,0.000001952069],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005741303,0.000057526497,0.0021812886,0.0001973671,0.00005414493,0.000046707235,0.008208309,0.0015854794,0.9840726,0.00006377538,0.00036818773,0.0025904293],"study_design_scores_gemma":[0.020473879,0.0014260865,0.045193266,0.00049192604,0.00020001354,0.00040677979,0.020526133,0.7798208,0.12960213,0.00043211272,0.0005995736,0.00082728115],"about_ca_topic_score_codex":0.00019554491,"about_ca_topic_score_gemma":0.000035426754,"teacher_disagreement_score":0.85447055,"about_ca_system_score_codex":0.0027299454,"about_ca_system_score_gemma":0.0011313012,"threshold_uncertainty_score":0.7138712},"labels":[],"label_agreement":null},{"id":"W4296832286","doi":"10.1038/s41409-022-01817-0","title":"Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Cumulative incidence; Myeloid leukemia; Transplantation; Oncology; Leukemia; Hematopoietic stem cell transplantation; Confidence interval; Myeloid","score_opus":0.010508620883493249,"score_gpt":0.25127204543861414,"score_spread":0.2407634245551209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296832286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283785,0.0002831246,0.0004999491,0.0027540321,0.000107334294,0.0016375681,0.0009195424,0.00012275,0.0008378602],"genre_scores_gemma":[0.9896336,0.0011253242,0.00047401965,0.0010142847,0.000033717974,0.00066820014,0.00614611,0.00007514619,0.0008296063],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9970154,0.0004148434,0.00062576367,0.00052096107,0.00077929464,0.0006437378],"domain_scores_gemma":[0.9990124,0.00021640385,0.00017291344,0.0003069407,0.000091346905,0.00020000554],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006983747,0.00031071634,0.0003710956,0.0004591528,0.00045211983,0.000033035063,0.00028854667,0.00015904423,0.0006360142],"category_scores_gemma":[0.00001650088,0.00028910194,0.00013326973,0.0013124287,0.00014326745,0.00017719148,0.000027329115,0.0010435901,0.000033004144],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005316557,0.00069066626,0.085108355,0.0016186534,0.00037820198,0.0040471577,0.028488986,0.0033277136,0.86552835,0.0001760133,0.002540869,0.0027785003],"study_design_scores_gemma":[0.03902557,0.0024588923,0.5717265,0.0003750482,0.0040518,0.014314912,0.008122139,0.004462516,0.34893388,0.00055318046,0.0039687804,0.002006781],"about_ca_topic_score_codex":0.0009750339,"about_ca_topic_score_gemma":0.00059400883,"teacher_disagreement_score":0.51659447,"about_ca_system_score_codex":0.0015962836,"about_ca_system_score_gemma":0.0015827158,"threshold_uncertainty_score":0.99995613},"labels":[],"label_agreement":null},{"id":"W4296962943","doi":"10.1016/s2152-2650(22)00747-9","title":"Poster: AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; McGill University; University of Toronto; Jewish General Hospital","funders":"","keywords":"Venetoclax; Azacitidine; Myeloid leukemia; Medicine; Internal medicine; Myeloid; Oncology; Leukemia; Biology; Genetics","score_opus":0.028363067495474653,"score_gpt":0.3261240952854576,"score_spread":0.2977610277899829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296962943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99109304,0.00020130113,0.000009766797,0.00082790985,0.0004623846,0.0052654315,0.0008881237,0.00029606884,0.0009559564],"genre_scores_gemma":[0.9935665,0.00007769921,0.001307539,0.0014990694,0.00044759107,0.0007790947,0.0013041199,0.0003260444,0.0006923356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98588324,0.001443184,0.0048362054,0.002649169,0.0031128945,0.0020752912],"domain_scores_gemma":[0.9900024,0.0030986792,0.0017620019,0.00282975,0.00082428165,0.0014828894],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0035763346,0.0012622322,0.003139515,0.001031307,0.0010706233,0.000099438206,0.0016913468,0.00057654356,0.00024579908],"category_scores_gemma":[0.004451892,0.0011659599,0.0006470929,0.0032609277,0.0013321895,0.0005263551,0.0026867085,0.0024078998,0.00007755631],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07210596,0.012597424,0.6285304,0.00043922526,0.0022474655,0.007469544,0.006467382,0.0020780496,0.0010474725,0.000042982043,0.013628347,0.2533458],"study_design_scores_gemma":[0.17414528,0.039987512,0.77358484,0.0005660009,0.00067601824,0.000173586,0.0011238673,0.004272332,0.00066169316,0.000051470564,0.003668647,0.0010887426],"about_ca_topic_score_codex":0.0024283938,"about_ca_topic_score_gemma":0.00046606554,"teacher_disagreement_score":0.25225705,"about_ca_system_score_codex":0.015193188,"about_ca_system_score_gemma":0.01123247,"threshold_uncertainty_score":0.9998936},"labels":[],"label_agreement":null},{"id":"W4296965222","doi":"10.1016/s2152-2650(22)00742-x","title":"Poster: AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"IDH2; Myeloid leukemia; Refractory (planetary science); Mutant; Medicine; Internal medicine; Stage (stratigraphy); Oncology; IDH1; Cancer research; Biology; Gene; Genetics","score_opus":0.04324224856268057,"score_gpt":0.35374002342380345,"score_spread":0.3104977748611229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296965222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812191,0.0003582704,0.000017312927,0.00097093167,0.00067079184,0.013170806,0.0018029418,0.00022340976,0.0015664274],"genre_scores_gemma":[0.9754426,0.00062513375,0.00035769635,0.0026132152,0.00044537202,0.0027556294,0.006430949,0.00043500355,0.010894392],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98052204,0.005818543,0.0044652224,0.0029833252,0.0038594787,0.0023513956],"domain_scores_gemma":[0.9881359,0.0056257606,0.0018015805,0.0025863647,0.0008077195,0.0010426939],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0063060885,0.0016454149,0.004613753,0.0007880299,0.0009045667,0.0004559252,0.0028868963,0.00096457626,0.002593648],"category_scores_gemma":[0.0020676884,0.0010078019,0.00065608905,0.0024242196,0.0016568963,0.0009023592,0.0015760948,0.003490383,0.00012713987],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.94643617,0.00609255,0.008981361,0.000165138,0.0019271991,0.011132706,0.0014488234,0.00005071887,0.0006358195,0.00009456903,0.008649164,0.014385787],"study_design_scores_gemma":[0.91902107,0.022617862,0.02931518,0.0004510779,0.0010844098,0.00035321832,0.0015281838,0.0007669987,0.00037732194,0.0000318362,0.022989435,0.0014634246],"about_ca_topic_score_codex":0.0025927976,"about_ca_topic_score_gemma":0.0012416416,"teacher_disagreement_score":0.027415112,"about_ca_system_score_codex":0.013107108,"about_ca_system_score_gemma":0.013800366,"threshold_uncertainty_score":0.9996293},"labels":[],"label_agreement":null},{"id":"W4297020689","doi":"10.1158/0008-5472.can-22-1293","title":"Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Princess Margaret Cancer Foundation; Cancer Research Society","keywords":"Cancer research; Myeloid leukemia; Biology; Syk; Tyrosine kinase; Signal transduction; Cell biology","score_opus":0.050080916667233966,"score_gpt":0.39064886233310875,"score_spread":0.3405679456658748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297020689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894096,0.0027943146,0.000074494856,0.003970753,0.00026513633,0.0017707477,0.0001810018,0.00005217016,0.0014817718],"genre_scores_gemma":[0.9903972,0.0007004548,0.0011559722,0.0002662816,0.0002675428,0.0011209722,0.000061899314,0.000102505874,0.0059271622],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99295974,0.00093353755,0.0007814276,0.0008574155,0.0031013463,0.0013665434],"domain_scores_gemma":[0.99749935,0.0006881248,0.00013306174,0.00072381727,0.00062645983,0.0003291788],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003706233,0.00025971245,0.00069209555,0.0008870621,0.0005004464,0.000044962377,0.00075699337,0.00012542623,0.0014420798],"category_scores_gemma":[0.0005972281,0.00024810166,0.000116599396,0.0034055766,0.00026984868,0.00026818228,0.0014617655,0.0023409808,0.00002546028],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004558294,0.00013091436,0.011715525,0.000733801,0.00011073631,0.0005459851,0.005751036,0.0037984638,0.88541204,0.00022392708,0.08567704,0.0013422102],"study_design_scores_gemma":[0.006631598,0.0010097928,0.0053813416,0.0019114165,0.000048966875,0.000025405103,0.015004332,0.0005401066,0.8411801,0.00060248695,0.1270019,0.00066255964],"about_ca_topic_score_codex":0.0024581912,"about_ca_topic_score_gemma":0.00014018134,"teacher_disagreement_score":0.044231962,"about_ca_system_score_codex":0.0072088297,"about_ca_system_score_gemma":0.0034805662,"threshold_uncertainty_score":0.99999714},"labels":[],"label_agreement":null},{"id":"W4297323569","doi":"10.21203/rs.3.rs-2064697/v1","title":"KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canada First Research Excellence Fund; University of Toronto; Indian Council of Medical Research; Israel Science Foundation; Israel Cancer Research Fund; Department of Science and Technology, Ministry of Science and Technology, India; Department of Biotechnology, Ministry of Science and Technology, India; International Development Research Centre","keywords":"Myeloid leukemia; Poly ADP ribose polymerase; Cancer research; DNA repair; Gene; Myeloid; DNA Damage Repair; DNA; Leukemia; Biology; Medicine; Genetics; Polymerase","score_opus":0.04727373753637899,"score_gpt":0.38153985989790945,"score_spread":0.33426612236153047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297323569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909986,0.0013018032,0.00015321246,0.0023660865,0.00009243088,0.003434085,0.00056475814,0.00022079935,0.0008682198],"genre_scores_gemma":[0.98831904,0.002968009,0.0029730918,0.0001287399,0.0004732993,0.00053033757,0.0018242212,0.00015705152,0.0026262014],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.992027,0.0016455172,0.0009818856,0.0016525821,0.0025851564,0.0011079004],"domain_scores_gemma":[0.99490887,0.0008213872,0.00026412026,0.0014838501,0.0017298082,0.00079193915],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004744033,0.00056947797,0.0012271974,0.002050606,0.00062000524,0.00014089371,0.00028720038,0.0006278211,0.0004098912],"category_scores_gemma":[0.0015214636,0.00054428517,0.00027499974,0.001179471,0.00090934575,0.0001665483,0.0040691383,0.0034366602,0.00002179702],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054892767,0.00041912086,0.020173697,0.011248431,0.0017326704,0.00358613,0.006543615,0.00039393123,0.90865964,0.0020433213,0.026997529,0.012712635],"study_design_scores_gemma":[0.012137282,0.011397373,0.35230324,0.00913707,0.0011542321,0.00179811,0.011796408,0.009268624,0.56015974,0.013354181,0.014648263,0.0028454664],"about_ca_topic_score_codex":0.0017699503,"about_ca_topic_score_gemma":0.0002093092,"teacher_disagreement_score":0.3484999,"about_ca_system_score_codex":0.002844762,"about_ca_system_score_gemma":0.0019521917,"threshold_uncertainty_score":0.99970084},"labels":[],"label_agreement":null},{"id":"W4297874867","doi":"10.1182/bloodadvances.2022008376","title":"Patient perspectives on testing for clonal hematopoiesis of indeterminate potential","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Vignette; Medicine; Population; Psychology; Social psychology; Environmental health","score_opus":0.016499166848581062,"score_gpt":0.2945452642462252,"score_spread":0.27804609739764413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297874867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99600124,0.0013687655,0.000069748006,0.00036638853,0.000081173224,0.0005450371,0.00008377937,0.000034186825,0.0014496758],"genre_scores_gemma":[0.9905257,0.000019762141,0.00881021,0.000090268266,0.000099728044,0.00019885504,0.000011545661,0.00002043048,0.00022345758],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988113,0.00004125417,0.00020732991,0.0002613791,0.00044733257,0.00023142343],"domain_scores_gemma":[0.99922717,0.0002584768,0.00012293599,0.00017076808,0.00016068766,0.00005999481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015702595,0.00010251092,0.00022999229,0.00013300721,0.00018495774,0.0000055623186,0.00010147837,0.000021279198,0.00008980081],"category_scores_gemma":[0.00041880654,0.00009092918,0.00009257898,0.00021589846,0.00008494465,0.000060478862,0.00012050883,0.00019914584,0.0000015509532],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011966703,0.010839609,0.054025188,0.0031949328,0.0014344882,0.0015695394,0.02166703,0.00536759,0.49127224,0.008003764,0.0028081012,0.38785082],"study_design_scores_gemma":[0.02981906,0.059166048,0.03293406,0.00077168725,0.0011293861,0.0025174874,0.1315877,0.0068116398,0.69022214,0.0060297237,0.037454,0.0015570609],"about_ca_topic_score_codex":0.000009282244,"about_ca_topic_score_gemma":6.02853e-7,"teacher_disagreement_score":0.38629377,"about_ca_system_score_codex":0.000097855715,"about_ca_system_score_gemma":0.00015657282,"threshold_uncertainty_score":0.3707984},"labels":[],"label_agreement":null},{"id":"W4297977678","doi":"10.1155/2022/5423694","title":"Identification of Survival-Related Genes in Acute Myeloid Leukemia (AML) Based on Cytogenetically Normal AML Samples Using Weighted Gene Coexpression Network Analysis","year":2022,"lang":"en","type":"article","venue":"Disease Markers","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University","keywords":"Myeloid leukemia; Gene; Bone marrow; Biology; Myeloid; Survival analysis; Cancer research; Leukemia; Oncology; Internal medicine; Computational biology; Immunology; Medicine; Genetics","score_opus":0.01826218570226447,"score_gpt":0.28684582042631057,"score_spread":0.2685836347240461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297977678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946143,0.00042864136,0.0030863043,0.0003027394,0.00015899763,0.00081178977,0.00036629304,0.00006405639,0.00016688251],"genre_scores_gemma":[0.99575555,0.00013632818,0.0014822265,0.0002062575,0.000068821726,0.00011978274,0.0019371829,0.00006615536,0.00022767257],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99537855,0.0009090637,0.0009596705,0.0007357586,0.0013735946,0.00064336945],"domain_scores_gemma":[0.9976795,0.0003466086,0.00034320174,0.0009446991,0.00020744973,0.00047854413],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013444257,0.0003163517,0.0006731078,0.0010249309,0.00030091486,0.000032178326,0.00038342515,0.000117638614,0.0011082507],"category_scores_gemma":[0.00017917145,0.00031433962,0.00042194303,0.0033658142,0.00018272075,0.00008086257,0.00027941048,0.00046268653,0.000008132297],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011707219,0.00035945812,0.5264721,0.00010287285,0.0014259578,0.00037526913,0.00007731356,0.32652456,0.13037309,0.000034750567,0.00046502304,0.0020824152],"study_design_scores_gemma":[0.0026010629,0.00012158415,0.43356994,0.00005961127,0.0018560196,0.0000031530667,0.00013007785,0.55777836,0.0034213804,0.000036712194,0.0001617219,0.0002603636],"about_ca_topic_score_codex":0.00029986602,"about_ca_topic_score_gemma":0.000016282149,"teacher_disagreement_score":0.23125383,"about_ca_system_score_codex":0.0015824639,"about_ca_system_score_gemma":0.0013440843,"threshold_uncertainty_score":0.99993086},"labels":[],"label_agreement":null},{"id":"W4302009295","doi":"10.1016/j.bcp.2022.115283","title":"Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"Biochemical Pharmacology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Barbara Ann Karmanos Cancer Institute; New Brunswick Children's Foundation; School of Medicine, Wayne State University; Jilin University; RE Children’s Foundation; National Cancer Institute; National Institutes of Health; Wayne State University","keywords":"Myeloid leukemia; Cancer research; PI3K/AKT/mTOR pathway; Biology; Reprogramming; Myeloid; Leukemia; Transcriptome; Clofarabine; Venetoclax; Oxidative phosphorylation; Apoptosis; Pharmacology; Immunology; Cytarabine; Cell; Gene; Biochemistry; Gene expression; Chronic lymphocytic leukemia","score_opus":0.017907639582214353,"score_gpt":0.312686802694945,"score_spread":0.2947791631127306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4302009295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918786,0.005996049,0.000021426076,0.0011437993,0.00015032338,0.00064307445,0.00007027127,0.000023278699,0.000073152056],"genre_scores_gemma":[0.99686223,0.0008027068,0.0012940705,0.00040906636,0.00018763794,0.00014445373,0.00022109998,0.000020850615,0.000057857014],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980004,0.000248061,0.00052988576,0.00056811044,0.00027310656,0.0003804463],"domain_scores_gemma":[0.99930084,0.00024190216,0.00010130156,0.00010499147,0.000047520785,0.00020345945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006944021,0.00017033292,0.00045188473,0.00033992823,0.00007798214,0.000008362437,0.00007985083,0.00014660777,0.00009191561],"category_scores_gemma":[0.0001954012,0.00017428443,0.000043998247,0.00037460026,0.0003149636,0.0000651571,0.000117157455,0.0007380853,6.7876357e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009843868,0.00014267673,0.0030676783,0.00007428743,0.000100768186,0.00006625174,0.00037506592,0.000004467662,0.97814435,0.00005244309,0.0063660503,0.0017621054],"study_design_scores_gemma":[0.08985242,0.002125663,0.15014473,0.00009622839,0.0009171043,0.0007899604,0.0014469015,0.005750139,0.69263524,0.00038763843,0.055051435,0.0008025129],"about_ca_topic_score_codex":0.0002713026,"about_ca_topic_score_gemma":0.000004167811,"teacher_disagreement_score":0.28550908,"about_ca_system_score_codex":0.00028461643,"about_ca_system_score_gemma":0.00028041535,"threshold_uncertainty_score":0.7107113},"labels":[],"label_agreement":null},{"id":"W4303685384","doi":"10.3390/curroncol29100592","title":"Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; ABB (Canada); Université de Montréal","funders":"AbbVie Canada","keywords":"Venetoclax; Azacitidine; Medicine; Myeloid leukemia; Myeloid; Leukemia; Eltrombopag; Oncology; Internal medicine; Bioinformatics; Cancer research; Genetics; DNA methylation; Biology; Gene; Chronic lymphocytic leukemia","score_opus":0.07053964643869572,"score_gpt":0.38206512423977196,"score_spread":0.31152547780107626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303685384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985475,0.001253613,0.0006247907,0.0036430552,0.00024694335,0.0036137938,0.00040981357,0.000018391924,0.00033483448],"genre_scores_gemma":[0.9944876,0.0011820464,0.00016179956,0.00012466592,0.00006293472,0.0029833287,0.00080194185,0.000018979372,0.00017670551],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982803,0.00022947886,0.00035197457,0.00035796876,0.00030226927,0.00047802352],"domain_scores_gemma":[0.99828243,0.00073219906,0.00014318651,0.0004308347,0.00019682547,0.00021451994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050746364,0.00017133536,0.00061745057,0.0006390435,0.00020775344,0.0000068593395,0.00020753783,0.00008048712,0.00027573065],"category_scores_gemma":[0.00008475339,0.00012067088,0.00018000457,0.0014126875,0.00018327766,0.000032871892,0.00004537627,0.00034078033,0.0000025110828],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0071571562,0.0031084127,0.38388485,0.00016069539,0.0039736982,0.00068364537,0.0052803364,0.0050918697,0.00025190652,0.0006054383,0.008393625,0.5814084],"study_design_scores_gemma":[0.026602102,0.011741985,0.30944687,0.000018719827,0.0035182112,0.00007142873,0.0014030307,0.07674863,0.00039263975,0.00008932622,0.56973875,0.0002283093],"about_ca_topic_score_codex":0.03968302,"about_ca_topic_score_gemma":0.1731077,"teacher_disagreement_score":0.58118004,"about_ca_system_score_codex":0.017533254,"about_ca_system_score_gemma":0.005944035,"threshold_uncertainty_score":0.99969137},"labels":[],"label_agreement":null},{"id":"W4304182925","doi":"10.1053/j.ajkd.2022.08.014","title":"Clonal Hematopoiesis of Indeterminate Potential and Kidney Function Decline in the General Population","year":2022,"lang":"en","type":"review","venue":"American Journal of Kidney Diseases","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute; St. Joseph’s Healthcare Hamilton; Impact; Queen's University","funders":"National Institutes of Health; Fondation Leducq; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Human Genome Research Institute; Massachusetts General Hospital; National Institute of Environmental Health Sciences; U.S. Department of Veterans Affairs","keywords":"Medicine; Renal function; Population; Kidney disease; Internal medicine; Meta-analysis; Oncology; Immunology; Environmental health","score_opus":0.022527031579416452,"score_gpt":0.34314410429295195,"score_spread":0.3206170727135355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304182925","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014533413,0.9816193,0.000067478555,0.002204959,0.0002907207,0.000727632,0.00049041765,0.000010758849,0.00005535043],"genre_scores_gemma":[0.0050216503,0.99071234,0.00034396228,0.0027368825,0.0005729479,0.000032627682,0.0004743436,0.00005151635,0.000053714146],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964758,0.0008022301,0.0011618464,0.00024649777,0.0010404779,0.000273141],"domain_scores_gemma":[0.99686587,0.0003089319,0.0015212436,0.00031216405,0.00012847949,0.0008633176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000712406,0.0003016602,0.0018020247,0.0007405227,0.00008299261,0.00003062573,0.00034349746,0.000073242016,0.00032428186],"category_scores_gemma":[0.0021871533,0.00019386651,0.0006311003,0.0008073982,0.00030911498,0.0001277494,0.00017421444,0.0008017859,0.0000011613928],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084465934,0.00036103083,0.004986324,0.0052955267,0.00052510377,0.0006112108,0.000078940335,0.0000036257072,0.0000062370077,0.000023480115,0.012486146,0.9747777],"study_design_scores_gemma":[0.0018865234,0.0021324614,0.012236127,0.005194317,0.005139254,0.0039232047,0.0003716158,0.00008005564,8.3998935e-7,0.00010988451,0.9686134,0.00031234382],"about_ca_topic_score_codex":0.00020922351,"about_ca_topic_score_gemma":0.0000010656963,"teacher_disagreement_score":0.97446537,"about_ca_system_score_codex":0.00031194082,"about_ca_system_score_gemma":0.0031308748,"threshold_uncertainty_score":0.7905647},"labels":[],"label_agreement":null},{"id":"W4304701174","doi":"10.1097/hs9.0000000000000787","title":"Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dyskeratosis congenita; CEBPA; Myeloid leukemia; Medicine; Germline; Bone marrow failure; Myeloid; Telomerase; Oncology; Internal medicine; Telomere; Germline mutation; Immunology; Mutation; Biology; Gene; Genetics; Haematopoiesis; Stem cell","score_opus":0.013380467579370657,"score_gpt":0.2523804352887737,"score_spread":0.23899996770940302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304701174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620813,0.0005102366,0.00016038348,0.0002745349,0.0001513385,0.0018315054,0.00015819562,0.000058080008,0.0006476155],"genre_scores_gemma":[0.99446756,0.000110980145,0.0028218424,0.00015728963,0.0000865506,0.00048734513,0.00022155537,0.00009200246,0.0015548855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973615,0.00013451223,0.0004407171,0.00062590843,0.0006686303,0.00076873845],"domain_scores_gemma":[0.99903446,0.00015002183,0.00014350902,0.00037063126,0.00012315332,0.00017820402],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005115402,0.000309217,0.0005822975,0.00018988359,0.00020478891,0.00004457565,0.0001972663,0.00011484209,0.00017531027],"category_scores_gemma":[0.000102329665,0.00027652262,0.000067517765,0.0005072499,0.00009671315,0.00023891452,0.00031818263,0.0004886856,0.00000295463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004482898,0.0003011433,0.9780259,0.0003577493,0.0001686481,0.00045565597,0.0018225865,0.00034082914,0.008629229,0.00021242486,0.0007662196,0.004436705],"study_design_scores_gemma":[0.01683516,0.0012258334,0.9733991,0.00022906401,0.00008903042,0.00016100034,0.0014535133,0.0043356144,0.0008682184,0.00012962426,0.00086617685,0.00040766955],"about_ca_topic_score_codex":0.00089400687,"about_ca_topic_score_gemma":0.0009829007,"teacher_disagreement_score":0.012352263,"about_ca_system_score_codex":0.0016734594,"about_ca_system_score_gemma":0.0008480475,"threshold_uncertainty_score":0.9999687},"labels":[],"label_agreement":null},{"id":"W4304891978","doi":"10.1016/j.drudis.2022.103407","title":"Evidence-based support for phenotypic drug discovery in acute myeloid leukemia","year":2022,"lang":"en","type":"review","venue":"Drug Discovery Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Drug discovery; Clinical trial; Drug development; Medicine; Drug; Myeloid leukemia; Intensive care medicine; Bioinformatics; Oncology; Pharmacology; Internal medicine; Biology","score_opus":0.06487435808575724,"score_gpt":0.3505748385341902,"score_spread":0.28570048044843294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304891978","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00050006865,0.98351973,0.00034603145,0.0013187994,0.0014008655,0.008558575,0.0021794247,0.00020818545,0.0019683077],"genre_scores_gemma":[0.00021811188,0.9015079,0.00043517828,0.0012808429,0.0009325814,0.0049418216,0.0063023195,0.0005240452,0.08385721],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98986375,0.000969283,0.0023942182,0.0025509845,0.0020603314,0.0021614188],"domain_scores_gemma":[0.9912681,0.0044223317,0.0009379642,0.0026825552,0.00013810633,0.00055096566],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.003148124,0.0017328265,0.005374805,0.00171472,0.000374647,0.000518148,0.0019749587,0.00059678266,0.0015989502],"category_scores_gemma":[0.0012760328,0.0014352705,0.0027464319,0.002159122,0.00040170384,0.0022541685,0.0010814535,0.0034398125,0.0003276167],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0025854057,0.0007931354,0.00023732429,0.06889252,0.0019364462,0.0023966958,0.0006135228,0.0001256368,0.00003011848,0.00084457855,0.2070144,0.7145302],"study_design_scores_gemma":[0.0030624303,0.00035334544,0.00004919739,0.021539908,0.0028889773,0.00014504188,0.0002039561,0.00014775113,0.000060012077,0.00010074182,0.97006214,0.0013864829],"about_ca_topic_score_codex":0.0005115683,"about_ca_topic_score_gemma":0.00014635724,"teacher_disagreement_score":0.76304775,"about_ca_system_score_codex":0.012244452,"about_ca_system_score_gemma":0.02325319,"threshold_uncertainty_score":0.99954176},"labels":[],"label_agreement":null},{"id":"W4305070936","doi":"10.1038/s41419-022-05315-5","title":"c-Mpl-del, a c-Mpl alternative splicing isoform, promotes AMKL progression and chemoresistance","year":2022,"lang":"en","type":"article","venue":"Cell Death and Disease","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of Toronto; St. Michael's Hospital","funders":"University of Toronto; Canadian Institutes of Health Research; Sun Yat-sen University; National Natural Science Foundation of China; Government of Canada","keywords":"Acute megakaryoblastic leukemia; Cancer research; Downregulation and upregulation; Biology; Gene knockdown; Myeloid leukemia; Cell growth; Thrombopoietin; Leukemia; PI3K/AKT/mTOR pathway; Apoptosis; Signal transduction; Haematopoiesis; Cell biology; Immunology; Stem cell; Gene; Genetics","score_opus":0.015958753326727877,"score_gpt":0.2905445603696919,"score_spread":0.27458580704296404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4305070936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99108917,0.004396497,0.000056825615,0.0008501013,0.000037459467,0.0007945834,0.00006042004,0.0000575213,0.002657453],"genre_scores_gemma":[0.99545825,0.0002398052,0.00062401383,0.00057527923,0.00010653076,0.00018955847,0.000081570994,0.00002993435,0.0026950329],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856925,0.000042575044,0.00016279424,0.0004379683,0.0004189848,0.0003684297],"domain_scores_gemma":[0.9987148,0.00004789929,0.00006558927,0.00025626115,0.00005969353,0.0008557267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017028172,0.00017507536,0.00021571045,0.00010065746,0.0003747794,0.000041192186,0.00009996177,0.000028231258,0.00012788097],"category_scores_gemma":[0.000111165056,0.00014384494,0.000047801437,0.00015313228,0.000103392005,0.00009380917,0.00032466173,0.00028777748,0.000007402269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014435474,0.0022990822,0.85044837,0.0044822884,0.00020590056,0.0057335612,0.0045396797,0.000021704698,0.047660794,0.0020049121,0.0144312885,0.05373692],"study_design_scores_gemma":[0.032187603,0.0039909976,0.8184622,0.0010188541,0.0010477484,0.00042779325,0.003687688,0.05774568,0.032052014,0.009198334,0.03810609,0.002074978],"about_ca_topic_score_codex":0.000047991427,"about_ca_topic_score_gemma":0.0000014832748,"teacher_disagreement_score":0.057723977,"about_ca_system_score_codex":0.00011261055,"about_ca_system_score_gemma":0.0003135756,"threshold_uncertainty_score":0.58658266},"labels":[],"label_agreement":null},{"id":"W4306822626","doi":"10.21203/rs.3.rs-2167397/v1","title":"Hereditary acute myeloid leukemia associated with C-terminal CEBPA germline variants","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"CEBPA; Germline; Myeloid leukemia; Germline mutation; Leukemia; Myeloid; Acute leukemia; Penetrance; Cancer research; Biology; Somatic cell; Medicine; Genetics; Mutation; Gene; Phenotype","score_opus":0.05066912647016752,"score_gpt":0.3806944854331402,"score_spread":0.3300253589629727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306822626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96450233,0.0016102626,0.00011148319,0.005205106,0.00067527,0.0063312952,0.0026540947,0.0006491497,0.018261023],"genre_scores_gemma":[0.9168822,0.0020570378,0.0024138547,0.00070110406,0.0030795415,0.0031173702,0.014530957,0.00078126404,0.05643663],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.98359334,0.002336537,0.001044888,0.00244508,0.0074670576,0.0031131168],"domain_scores_gemma":[0.9910348,0.001507239,0.00036802,0.0031412926,0.0025118664,0.0014367817],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0062222285,0.0010193074,0.001850482,0.002052184,0.0010446403,0.000297454,0.0019683042,0.0012767706,0.008618345],"category_scores_gemma":[0.0022684794,0.0008796251,0.00055399566,0.002472593,0.0010004666,0.00023433293,0.0066918936,0.01680106,0.0004239249],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.022478394,0.0043683923,0.055892315,0.010139135,0.01578987,0.31451064,0.004210043,0.0014188209,0.0062468178,0.0005921847,0.54495835,0.01939506],"study_design_scores_gemma":[0.038037498,0.02290358,0.7683596,0.017334083,0.0032386642,0.010213109,0.0068586376,0.025420602,0.0024848313,0.0031688698,0.095679,0.0063015246],"about_ca_topic_score_codex":0.0013288853,"about_ca_topic_score_gemma":0.0001503629,"teacher_disagreement_score":0.7124673,"about_ca_system_score_codex":0.014399303,"about_ca_system_score_gemma":0.018228225,"threshold_uncertainty_score":0.99936545},"labels":[],"label_agreement":null},{"id":"W4306843199","doi":"10.1182/bloodadvances.2022008747","title":"An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Daiichi Sankyo Europe; National Cancer Institute; National Institutes of Health; Astellas Pharma; Incyte; Astex Pharmaceuticals; Gilead Sciences; Jazz Pharmaceuticals; Leukemia and Lymphoma Society; Acceleron; Celgene; Bristol-Myers Squibb; AstraZeneca; National Institute of Diabetes and Digestive and Kidney Diseases; Cardinal Health; Amgen; National Heart, Lung, and Blood Institute; Pfizer; National Center for Advancing Translational Sciences; Agios Pharmaceuticals","keywords":"Myelodysplastic syndromes; MEDLINE; Medicine; Computer science; Political science; Internal medicine","score_opus":0.04899527071681768,"score_gpt":0.39027327191269434,"score_spread":0.34127800119587665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306843199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787601,0.0027405948,0.00005847596,0.014995984,0.00036042734,0.0009792891,0.00012195819,0.00004961844,0.0019335077],"genre_scores_gemma":[0.9942143,0.00037739577,0.0017236246,0.0008243024,0.00036019777,0.000610852,0.00009720932,0.000036897418,0.0017552103],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964941,0.00035348054,0.0004114554,0.0007204118,0.0013529344,0.00066760584],"domain_scores_gemma":[0.99717915,0.0017350471,0.00005997419,0.00070037774,0.00014708473,0.00017836745],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014688689,0.00019053943,0.00032881807,0.00047695168,0.00030920946,0.00007223542,0.0011020282,0.0000617614,0.0014736408],"category_scores_gemma":[0.0014211216,0.0001577369,0.00005174975,0.0018935374,0.00017407454,0.00035156656,0.00071387325,0.0014857992,0.00006638023],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060611614,0.0041399985,0.86090404,0.00022951687,0.00023063895,0.0072942358,0.013061084,0.01014531,0.004842444,0.0008043861,0.01198118,0.08030599],"study_design_scores_gemma":[0.005818732,0.0011826569,0.23108521,0.0005404733,0.000029239389,0.00016845172,0.012775322,0.0022744143,0.0005849439,0.0009223267,0.744192,0.0004262386],"about_ca_topic_score_codex":0.0009020711,"about_ca_topic_score_gemma":0.00463925,"teacher_disagreement_score":0.7322108,"about_ca_system_score_codex":0.0008149455,"about_ca_system_score_gemma":0.00041400525,"threshold_uncertainty_score":0.9994391},"labels":[],"label_agreement":null},{"id":"W4306940023","doi":"10.1182/blood.2022016362","title":"Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"Foundation Medicine; Genentech","keywords":"Venetoclax; Medicine; Internal medicine; Gastroenterology; Neutropenia; Febrile neutropenia; Oncology; Leukemia; Chemotherapy; Chronic lymphocytic leukemia","score_opus":0.04777988147615729,"score_gpt":0.35964469803717614,"score_spread":0.31186481656101883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306940023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915249,0.0012168536,0.000006467215,0.0005875053,0.00016522696,0.0031535786,0.000042713174,0.000043623277,0.0032591596],"genre_scores_gemma":[0.99408686,0.00017303361,0.0007549077,0.00068574055,0.00032651695,0.001115747,0.000078447854,0.000061843835,0.0027168882],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976927,0.00043531499,0.00044948846,0.0004800247,0.0005092821,0.00043319864],"domain_scores_gemma":[0.99878114,0.000373486,0.00010532327,0.0004662803,0.000042857846,0.00023088035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016558636,0.00018638065,0.00063149654,0.00027110608,0.00017257864,0.000052238265,0.0003602421,0.00009671515,0.00055226556],"category_scores_gemma":[0.0005530044,0.00017626733,0.000055463257,0.00043187133,0.00008946281,0.000092021306,0.0007197538,0.0009888381,0.000030904655],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8875256,0.037526023,0.00078724587,0.00013372538,0.00048188257,0.0039708703,0.0013965571,0.00000710799,0.040905442,0.0001883222,0.012641004,0.014436188],"study_design_scores_gemma":[0.96745664,0.0064305663,0.00008093751,0.00003716773,0.00016460425,0.0002084341,0.0002155859,0.000577618,0.0011249944,0.00008511677,0.023430225,0.00018809758],"about_ca_topic_score_codex":0.00032990935,"about_ca_topic_score_gemma":0.000029141413,"teacher_disagreement_score":0.07993102,"about_ca_system_score_codex":0.00038408302,"about_ca_system_score_gemma":0.0011739554,"threshold_uncertainty_score":0.7187973},"labels":[],"label_agreement":null},{"id":"W4306941118","doi":"10.1038/s41375-022-01724-9","title":"Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes","year":2022,"lang":"en","type":"letter","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Takeda Oncology; Genentech; National Institutes of Health; Astellas Pharma; Pfizer; Incyte; CTI Biopharma; bluebird bio; Agios Pharmaceuticals; Syndax Pharmaceuticals; National Heart, Lung, and Blood Institute; Edward P. Evans Foundation; Acceleron; Astex Pharmaceuticals; Daiichi-Sankyo; MacroGenics; Celldex Therapeutics; Jazz Pharmaceuticals; Leukemia and Lymphoma Society; Apellis Pharmaceuticals; Alexion Pharmaceuticals; Daiichi Sankyo Europe; Servier; Aplastic Anemia and MDS International Foundation; Gilead Sciences; BioCryst; Celgene; Bristol-Myers Squibb; AstraZeneca; Cardinal Health; Amgen; American Cancer Society","keywords":"Myelodysplastic syndromes; Consistency (knowledge bases); Medicine; Myeloid; Perspective (graphical); Oncology; Myeloid leukemia; Internal medicine; Immunology; Computer science; Bone marrow; Artificial intelligence","score_opus":0.0518485078356917,"score_gpt":0.32790933514638804,"score_spread":0.27606082731069637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306941118","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11721603,0.00042547262,0.00019900683,0.84681,0.0022124632,0.0048031164,0.0017656616,0.00007835641,0.026489895],"genre_scores_gemma":[0.82569957,0.00023748337,0.0021935164,0.119822785,0.0021608127,0.0025458252,0.0016606138,0.00036959958,0.045309823],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99670124,0.00015762265,0.00082686095,0.0006717333,0.0011681668,0.00047435958],"domain_scores_gemma":[0.99499714,0.0029667607,0.000590309,0.00092818274,0.0004578507,0.000059729464],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0004313339,0.00035657626,0.00081579457,0.0009255766,0.00013600237,0.000021053615,0.0009993986,0.00057723006,0.0006486423],"category_scores_gemma":[0.002732433,0.0002902959,0.0004651299,0.0008031832,0.00044034852,0.000059172657,0.0003333278,0.0032586278,0.0000117607715],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010972308,0.00022965706,0.0027372825,0.0010194428,0.0009970156,0.0003048009,0.002725561,0.00045407133,0.0021342323,0.006144552,0.9815025,0.00065368577],"study_design_scores_gemma":[0.019026026,0.0027105734,0.036865696,0.007976375,0.0019874878,0.0012658729,0.020617738,0.008976668,0.0053086365,0.0042788903,0.88904387,0.0019421758],"about_ca_topic_score_codex":0.0002983596,"about_ca_topic_score_gemma":0.00006513027,"teacher_disagreement_score":0.7269872,"about_ca_system_score_codex":0.008796448,"about_ca_system_score_gemma":0.003997591,"threshold_uncertainty_score":0.99995494},"labels":[],"label_agreement":null},{"id":"W4307486632","doi":"10.14740/jocmr4799","title":"Cost-Effectiveness Analysis of Transplantation-Ineligible Elderly Patients With Acute Leukemia Harboring a Molecular Target: Ph-Positive Acute Leukemia and FLT3-Mutated Acute Myeloid Leukemia","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Acute leukemia; Leukemia; Transplantation; Cancer research; Oncology; Internal medicine","score_opus":0.058074688680120994,"score_gpt":0.43661383224872846,"score_spread":0.37853914356860746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307486632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99033225,0.0006980225,0.0040238807,0.0016054562,0.0002512663,0.002188444,0.00030827746,0.000033755372,0.00055867416],"genre_scores_gemma":[0.9927051,0.0037345323,0.0019671496,0.00030254488,0.0003423521,0.00016115338,0.00042266844,0.00012693681,0.00023752937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9855174,0.0031575183,0.0031500768,0.0010221874,0.005861337,0.0012915179],"domain_scores_gemma":[0.9861734,0.0057488037,0.0013534502,0.0008328129,0.0044878945,0.0014036597],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01271412,0.00059461826,0.003522625,0.0035293286,0.000504982,0.000058781374,0.0009343621,0.0003695168,0.00037182402],"category_scores_gemma":[0.0018287329,0.0004322402,0.0007273153,0.006281677,0.0015011667,0.00044701222,0.00041391893,0.0057960534,0.000006197706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.1719941,0.002089447,0.49038252,0.001637441,0.12393665,0.04210922,0.0055922857,0.010696543,0.10448324,0.0003337817,0.003912345,0.042832427],"study_design_scores_gemma":[0.07954095,0.0497792,0.77487135,0.0024894155,0.03450666,0.0020167485,0.0017742327,0.016775088,0.03551034,0.0003678011,0.0013003345,0.0010678716],"about_ca_topic_score_codex":0.00061869645,"about_ca_topic_score_gemma":0.000015820491,"teacher_disagreement_score":0.28448886,"about_ca_system_score_codex":0.004365937,"about_ca_system_score_gemma":0.0075998376,"threshold_uncertainty_score":0.99981296},"labels":[],"label_agreement":null},{"id":"W4307522818","doi":"10.1101/2022.10.21.22281368","title":"A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets","year":2022,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Impact; Queen's University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Medical Research Council; Vanderbilt University; Canadian Institutes of Health Research; Leukemia and Lymphoma Society; American Society of Hematology; Vanderbilt University Medical Center; Alexander and Margaret Stewart Trust; Ludwig Center at Harvard; National Institutes of Health; Pew Charitable Trusts","keywords":"Exome; Exome sequencing; Biology; Biobank; Population; Germline; Genetics; Computational biology; Mutation; Medicine; Gene","score_opus":0.05718008216702608,"score_gpt":0.3802776397486847,"score_spread":0.32309755758165865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307522818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99366516,0.00009010281,0.0011270713,0.0012733241,0.00016725379,0.0016215926,0.0006454266,0.000041051957,0.0013690304],"genre_scores_gemma":[0.97653395,0.00004188643,0.01983384,0.0002322949,0.00019262695,0.0005416933,0.0021792105,0.00008938879,0.00035510832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956496,0.0004877233,0.0008954885,0.0010399164,0.0013078187,0.0006194708],"domain_scores_gemma":[0.99764127,0.00011404147,0.00027905713,0.0014841051,0.00011647011,0.00036503578],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011957799,0.00038828154,0.0009895269,0.0008003615,0.00008080464,0.00003693198,0.000708728,0.0003385216,0.0009229444],"category_scores_gemma":[0.0005157967,0.00037850923,0.00020006413,0.0005068941,0.00018687056,0.00005788537,0.0036666193,0.0025171994,0.00005232123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010274387,0.019037707,0.45063543,0.032807168,0.0035469767,0.05314046,0.009175294,0.010176764,0.22714253,0.003330376,0.17210267,0.008630227],"study_design_scores_gemma":[0.012425657,0.0022279185,0.88789856,0.0015397336,0.0014047361,0.0037542447,0.001748566,0.03292166,0.024301367,0.0020009384,0.026795758,0.002980834],"about_ca_topic_score_codex":0.0004895792,"about_ca_topic_score_gemma":0.000018999475,"teacher_disagreement_score":0.43726316,"about_ca_system_score_codex":0.00052134617,"about_ca_system_score_gemma":0.001059966,"threshold_uncertainty_score":0.99999034},"labels":[],"label_agreement":null},{"id":"W4307654771","doi":"10.22541/au.166716570.05226448/v1","title":"A case of MDS/MPN overlap syndrome with ring sideroblasts and thrombocytosis: Tackling the quandary of thrombosis versus hemorrhage.","year":2022,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Health; Royal Columbian Hospital; Royal Ottawa Mental Health Centre; University of British Columbia","funders":"","keywords":"Thrombocytosis; Myeloproliferative neoplasm; Medicine; Platelet; Thrombosis; Myeloid; Myelodysplastic syndromes; Internal medicine; Gastroenterology; Myelofibrosis; Bone marrow","score_opus":0.04706161361623076,"score_gpt":0.32780342144201213,"score_spread":0.2807418078257814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307654771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99177086,0.0009865622,0.00025472816,0.0006733483,0.00019051581,0.0014196113,0.000120216915,0.00008218688,0.004501984],"genre_scores_gemma":[0.99396676,0.00037075672,0.0049960664,0.000089530615,0.000056035642,0.00014327037,0.000041655563,0.000103696315,0.00023224918],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99669254,0.00022349585,0.0007599024,0.00079558126,0.0010186246,0.00050983956],"domain_scores_gemma":[0.9966948,0.00091353187,0.00048125983,0.0014421501,0.00026363833,0.00020463161],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009328661,0.00049778965,0.0014564372,0.00034517498,0.00022208282,0.00004307613,0.00040686663,0.00027325965,0.00090497785],"category_scores_gemma":[0.00024627757,0.00032659073,0.000244148,0.00045239806,0.00057726866,0.000099765784,0.0024625682,0.0019375496,0.0000027975602],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06476758,0.0081640715,0.10335791,0.17336501,0.07083084,0.3098712,0.08598394,0.04070207,0.09449392,0.010681814,0.00939686,0.028384812],"study_design_scores_gemma":[0.10667258,0.036784142,0.083263904,0.019972268,0.023925629,0.2811893,0.21378621,0.12635659,0.09766618,0.0016009628,0.0008239854,0.007958276],"about_ca_topic_score_codex":0.0031207884,"about_ca_topic_score_gemma":0.00020326076,"teacher_disagreement_score":0.15339273,"about_ca_system_score_codex":0.0005003321,"about_ca_system_score_gemma":0.0011650271,"threshold_uncertainty_score":0.99991864},"labels":[],"label_agreement":null},{"id":"W4307776418","doi":"10.1038/s41375-022-01738-3","title":"Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients","year":2022,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Moonshot; St. Jude Children's Research Hospital; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Agios Pharmaceuticals; Takeda Oncology; AstraZeneca; Genentech; Adaptive Biotechnologies; Health Resources and Services Administration; National Institutes of Health; MorphoSys; Seagen; CTI Biopharma; CareDx; BeiGene; Swedish Orphan Biovitrum; Astellas Pharma; GlaxoSmithKline; Kiadis Pharma; Pharmacyclics; bluebird bio; Sanofi; TG Therapeutics; Medac; Jazz Pharmaceuticals; Omeros Corporation; Vertex Pharmaceuticals; StemCyte; CSL Behring; Novartis Pharmaceuticals Corporation; National Center for Advancing Translational Sciences; HistoGenetics; Atara Biotherapeutics; Actinium Pharmaceuticals; National Cancer Institute; Incyte; Servier; Gilead Sciences; Moonshot Research and Development Program; Celgene; Bristol-Myers Squibb; Amgen; National Heart, Lung, and Blood Institute; Pfizer; Mallinckrodt Pharmaceuticals; Astellas Pharma US","keywords":"Medicine; Internal medicine; Hematopoietic cell; Transplantation; Oncology; Surgery; Haematopoiesis; Stem cell","score_opus":0.01866235932603248,"score_gpt":0.30959229976373803,"score_spread":0.29092994043770554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307776418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99849063,0.00005170901,0.000047559653,0.00013396973,0.000049859256,0.0006647843,0.00036941786,0.00003257132,0.00015949013],"genre_scores_gemma":[0.998457,0.00016258555,0.00007934524,0.00011676269,0.000020950925,0.0000901493,0.0009553864,0.0000267919,0.00009100266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977994,0.00022745968,0.0005129571,0.0004374876,0.0006591561,0.0003635687],"domain_scores_gemma":[0.99910164,0.00015236676,0.00015885646,0.00036791674,0.00006744666,0.000151797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037023256,0.00023256837,0.00061384996,0.001020589,0.00010173016,0.000012931381,0.00014809844,0.000118919605,0.00025332285],"category_scores_gemma":[0.000049035058,0.00019157118,0.00024310342,0.0010444364,0.000090235335,0.00009528152,0.000047364592,0.0005693394,0.0000042659212],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016674063,0.00029199777,0.9805446,0.00007571751,0.00085716404,0.000056389184,0.0015279736,0.003529226,0.008830454,0.000022945696,0.00006766479,0.0025284493],"study_design_scores_gemma":[0.004021196,0.0010186163,0.9907264,0.000047944344,0.00052875065,0.000025813652,0.000102327205,0.0018360561,0.0014832279,0.000025804786,0.000018286408,0.0001655665],"about_ca_topic_score_codex":0.002838434,"about_ca_topic_score_gemma":0.00029006388,"teacher_disagreement_score":0.010181799,"about_ca_system_score_codex":0.0023129373,"about_ca_system_score_gemma":0.0005148526,"threshold_uncertainty_score":0.7812046},"labels":[],"label_agreement":null},{"id":"W4307979500","doi":"10.21203/rs.3.rs-2190038/v1","title":"Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: results of a pilot randomised trial RBC-ENHANCE and a combined analyses with REDDS","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre; Kingston Health Sciences Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Canadian Cancer Society Research Institute; Australian and New Zealand Society of Blood Transfusion; Ministry of Statistics and Programme Implementation, Government of India; NHS Blood and Transplant","keywords":"Myelodysplastic syndromes; Medicine; Red Cell; Randomized controlled trial; Pilot trial; Blood transfusion; Intensive care medicine; Internal medicine","score_opus":0.09159241929284628,"score_gpt":0.40652525913895315,"score_spread":0.31493283984610687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307979500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98127097,0.0005331841,0.00010930758,0.0006999877,0.00008094682,0.013349235,0.0003478945,0.00007062616,0.0035378414],"genre_scores_gemma":[0.99268687,0.0015504677,0.0007475839,0.00001330164,0.00007994358,0.0022350848,0.00079129165,0.0001468834,0.0017486053],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98881716,0.0021169807,0.0014005988,0.0017920666,0.0046308404,0.0012423461],"domain_scores_gemma":[0.9937485,0.002332617,0.00043344937,0.0017566344,0.0011613788,0.0005674326],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0047348295,0.0006640844,0.0021453889,0.0024860718,0.00027425974,0.00009567112,0.00072031235,0.0003977135,0.00024097356],"category_scores_gemma":[0.0017307911,0.00047895455,0.00020160615,0.0025499482,0.00082687027,0.0001250068,0.0010549723,0.004755261,0.00000463136],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9771701,0.002404016,0.0038630576,0.0054989876,0.00043180183,0.0015017187,0.0022553634,0.0009824745,0.004960105,0.000005318663,0.0006461855,0.0002808712],"study_design_scores_gemma":[0.8839751,0.08225086,0.012599029,0.008365163,0.00041423264,0.00007741864,0.0025874025,0.0035974819,0.0051001604,0.00009359214,0.00014876983,0.0007908139],"about_ca_topic_score_codex":0.0026647456,"about_ca_topic_score_gemma":0.0006511506,"teacher_disagreement_score":0.09319503,"about_ca_system_score_codex":0.0012460108,"about_ca_system_score_gemma":0.0037761552,"threshold_uncertainty_score":0.99976623},"labels":[],"label_agreement":null},{"id":"W4308007975","doi":"10.3324/haematol.2022.281644","title":"What doesn’t kill you makes you stronger – &lt;i&gt;bcl-2&lt;/i&gt; promotes survival independent of proliferation","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Cancer research; Biology; Molecular biology; Chemistry; Internal medicine; Medicine","score_opus":0.02814590347934173,"score_gpt":0.28616002641516736,"score_spread":0.25801412293582565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308007975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98128134,0.0021135116,0.00013115529,0.00825912,0.000708957,0.0023225036,0.000069334856,0.00022466773,0.004889411],"genre_scores_gemma":[0.9913674,0.00034343672,0.0008654987,0.00033233556,0.00016393104,0.00057448563,0.0002665481,0.00006285571,0.006023484],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.995324,0.00057644217,0.0007995705,0.00078354555,0.0017390563,0.0007773948],"domain_scores_gemma":[0.99792284,0.00021710251,0.0003444583,0.0008774182,0.00037415556,0.00026402803],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013619607,0.00038358962,0.0010028718,0.00033288056,0.0003576303,0.00009913546,0.00051113195,0.00024965993,0.0024933596],"category_scores_gemma":[0.00052903173,0.00029480466,0.00023403371,0.0005388536,0.00030193516,0.00037943624,0.0006517177,0.0007704024,0.000114899005],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011106293,0.01023215,0.11755188,0.0044642612,0.002688797,0.00903143,0.01472971,0.0006937452,0.6299563,0.10322479,0.065496646,0.03082399],"study_design_scores_gemma":[0.040330093,0.021093132,0.21939929,0.001654062,0.0019328148,0.014446013,0.024248887,0.012539194,0.24174802,0.010443643,0.40683886,0.0053259926],"about_ca_topic_score_codex":0.000015479012,"about_ca_topic_score_gemma":0.000048624857,"teacher_disagreement_score":0.3882083,"about_ca_system_score_codex":0.00047806933,"about_ca_system_score_gemma":0.00055035023,"threshold_uncertainty_score":0.9999504},"labels":[],"label_agreement":null},{"id":"W4308319341","doi":"10.1016/j.clml.2022.11.002","title":"Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis","year":2022,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Azacitidine; Observational study; Meta-analysis; Myelodysplastic syndromes; Adverse effect; Randomized controlled trial; Incidence (geometry); Retrospective cohort study","score_opus":0.06970053631404995,"score_gpt":0.36682568422570905,"score_spread":0.2971251479116591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308319341","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007454776,0.9862768,0.000010766615,0.00014650413,0.00011723629,0.011120383,0.00122077,0.00016212402,0.0001999126],"genre_scores_gemma":[0.00022712727,0.9860214,0.00043166216,0.0008987766,0.00011705532,0.0050001824,0.002780676,0.00038668734,0.0041364417],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98385453,0.004796707,0.005377125,0.0029669004,0.0016960889,0.0013086346],"domain_scores_gemma":[0.9863166,0.006126973,0.0028046106,0.0033280686,0.00035603475,0.0010677134],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0028036712,0.002338841,0.027680187,0.0018232134,0.0002827571,0.0002036019,0.0009722318,0.0012995582,0.0019751731],"category_scores_gemma":[0.0013744482,0.0013698323,0.006733675,0.006794027,0.0004974413,0.00025973274,0.00043168612,0.0021345823,0.0001656477],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052950665,0.000924549,0.0008395748,0.4085045,0.3235137,0.0041787457,0.000052452575,0.000002277751,4.87742e-9,0.00002954711,0.0006194098,0.26080576],"study_design_scores_gemma":[0.006452827,0.0031543884,0.013374746,0.044428162,0.77061415,0.0007755281,0.000006520093,0.000028738692,2.1820382e-8,0.0000100754705,0.16000092,0.0011539331],"about_ca_topic_score_codex":0.000090189395,"about_ca_topic_score_gemma":0.000026132682,"teacher_disagreement_score":0.44710043,"about_ca_system_score_codex":0.007413663,"about_ca_system_score_gemma":0.0032754783,"threshold_uncertainty_score":0.99999696},"labels":[],"label_agreement":null},{"id":"W4308434283","doi":"10.22541/au.166780268.87116983/v1","title":"Aortic Valve Thrombus, Stroke, and Endovascular Thrombectomy in a Child with APML and Trisomy 21","year":2022,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Thrombus; Medicine; Thrombosis; Asymptomatic; Stroke (engine); Complication; Cardiology; Embolism; Surgery","score_opus":0.015611717332066287,"score_gpt":0.28378862969061686,"score_spread":0.26817691235855057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308434283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96065414,0.0056393957,0.00026523267,0.0019329458,0.00006770864,0.0027938935,0.00004085467,0.00012747494,0.028478373],"genre_scores_gemma":[0.9861928,0.003969269,0.004818875,0.00041953844,0.00014718207,0.00039083583,0.0001825297,0.00012663657,0.003752306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965651,0.00021067189,0.00046374637,0.0011865771,0.00093854516,0.0006353686],"domain_scores_gemma":[0.9982747,0.00017669995,0.00012472669,0.0010104098,0.000086909706,0.0003265707],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007083355,0.00051173026,0.0012211408,0.0005529563,0.00012823395,0.00008823589,0.00025256298,0.00031362884,0.0016654761],"category_scores_gemma":[0.00013577665,0.0003897178,0.00019812585,0.00036693993,0.00031361493,0.0000883623,0.0017708136,0.0030516088,0.000011352749],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033326205,0.0021724915,0.9095479,0.009161433,0.012571962,0.0066131037,0.008433588,0.00031730614,0.0017120957,0.0016130275,0.010148465,0.034376007],"study_design_scores_gemma":[0.034777258,0.0025638172,0.92160434,0.0017859591,0.0021175228,0.0045205993,0.0055738017,0.0051587066,0.0014943328,0.0006824187,0.017696885,0.0020243658],"about_ca_topic_score_codex":0.0025638298,"about_ca_topic_score_gemma":0.0002551075,"teacher_disagreement_score":0.032351643,"about_ca_system_score_codex":0.00055410864,"about_ca_system_score_gemma":0.0007995373,"threshold_uncertainty_score":0.99985546},"labels":[],"label_agreement":null},{"id":"W4308564922","doi":"10.1101/2022.11.08.515565","title":"The human leukemic oncogene MLL-AF4 promotes hyperplastic growth of hematopoietic tissues in <i>Drosophila</i> larvae","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Helse Sør-Øst RHF; National Institutes of Health; Norges Forskningsråd; European Commission; Kreftforeningen","keywords":"Haematopoiesis; Biology; Leukemia; Phenotype; Drosophila melanogaster; Cancer research; Drosophila (subgenus); Oncogene; In vivo; Stem cell; Genetics; Cancer; Gene; Cell cycle","score_opus":0.018609342079047464,"score_gpt":0.2661628920608325,"score_spread":0.24755354998178503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308564922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912196,0.0044378163,0.000024152778,0.0010932235,0.00051492266,0.0021851154,0.00018718104,0.00026487964,0.00007310842],"genre_scores_gemma":[0.9963557,0.0010674219,0.00084785995,0.00015561396,0.00045162294,0.00076774205,0.0000027810433,0.0002851968,0.00006606651],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99445146,0.00044152205,0.0013052274,0.001329768,0.0013563533,0.0011156638],"domain_scores_gemma":[0.99565023,0.00047914882,0.00064731896,0.0021474364,0.0006788293,0.0003970276],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0017948714,0.00079732365,0.0014031746,0.00062255247,0.0004197954,0.00013293463,0.0014024511,0.0005886698,0.00017111657],"category_scores_gemma":[0.0011716384,0.00069819624,0.0003089542,0.001270201,0.00058209104,0.000111500165,0.0018724579,0.0028419567,0.00006396221],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000172413,0.000453013,0.026827697,0.0022797824,0.00033841774,0.0007951285,0.00006530334,0.000036485006,0.96690726,0.0013599301,0.00076236186,0.0000021844432],"study_design_scores_gemma":[0.004743403,0.0008198619,0.1360591,0.0025740364,0.0006244878,0.0000016764985,0.000052295134,0.0006692509,0.8470075,0.00009100492,0.0056652636,0.0016921252],"about_ca_topic_score_codex":0.00042361024,"about_ca_topic_score_gemma":0.000015572212,"teacher_disagreement_score":0.119899794,"about_ca_system_score_codex":0.0019868622,"about_ca_system_score_gemma":0.0028411318,"threshold_uncertainty_score":0.99954695},"labels":[],"label_agreement":null},{"id":"W4309098190","doi":"10.1182/bloodadvances.2022008204","title":"CNL and aCML should be considered as a single entity based on molecular profiles and outcomes","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Instituto de Salud Carlos III; Astellas Pharma; Academy of Medical Sciences; Cancer Research UK; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Wellcome Trust; Celgene; Gilead Sciences; National Institute for Health and Care Research; Jazz Pharmaceuticals; European Hematology Association; Bristol-Myers Squibb","keywords":"Medicine","score_opus":0.041805317909068766,"score_gpt":0.3431559181950238,"score_spread":0.301350600285955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309098190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845986,0.001201529,0.000018823474,0.011000602,0.000047618272,0.0005321272,0.000029639377,0.00016361094,0.0024074968],"genre_scores_gemma":[0.9940061,0.0002842964,0.0020434344,0.0024877854,0.000037582144,0.000056481844,0.000033743207,0.0000304682,0.0010201174],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986928,0.000055696233,0.00016003926,0.00037314874,0.00040670796,0.00031157458],"domain_scores_gemma":[0.9990863,0.00036083517,0.000044686174,0.00027074004,0.000063654916,0.00017378449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019453355,0.00016811615,0.00031433656,0.00017967519,0.00009484646,0.000042213385,0.00006830142,0.00007738958,0.000052977324],"category_scores_gemma":[0.0010014382,0.00013203216,0.000046137597,0.0002508692,0.00021523457,0.00010502226,0.00009330536,0.00020247085,0.000024505483],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008941754,0.0011563954,0.6055536,0.0015764448,0.00056714885,0.004374525,0.0006333775,0.00007544317,0.349221,0.0023604434,0.004558726,0.029028716],"study_design_scores_gemma":[0.020511981,0.003905404,0.18246834,0.00067790336,0.00065062207,0.0002807712,0.0017704318,0.0026171273,0.7299381,0.004407091,0.05177342,0.0009988341],"about_ca_topic_score_codex":0.000036302314,"about_ca_topic_score_gemma":0.00001713039,"teacher_disagreement_score":0.4230853,"about_ca_system_score_codex":0.000027843194,"about_ca_system_score_gemma":0.00012941957,"threshold_uncertainty_score":0.5384115},"labels":[],"label_agreement":null},{"id":"W4309246311","doi":"10.1002/cam4.5421","title":"Molecular characterization of <scp>AML‐MRC</scp> reveals <scp><i>TP53</i></scp> mutation as an adverse prognostic factor irrespective of <scp>MRC</scp>‐defining criteria, <scp><i>TP53</i></scp> allelic state, or <scp><i>TP53</i></scp> variant allele frequency","year":2022,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Leukemia and Lymphoma Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Neuroblastoma RAS viral oncogene homolog; Allele; Myeloid leukemia; Internal medicine; Medicine; Oncology; Mutation; Cancer research; Biology; Genetics; Cancer; Gene; KRAS","score_opus":0.023229752462193214,"score_gpt":0.31459205252682365,"score_spread":0.29136230006463043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309246311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.967993,0.006722878,0.003143574,0.00080778,0.0024087792,0.008021024,0.0033593576,0.0008521577,0.0066914265],"genre_scores_gemma":[0.95921135,0.0048341984,0.0026285637,0.0052496735,0.0023770696,0.0037915488,0.00815197,0.0012558894,0.012499755],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.97682256,0.0027605752,0.005180602,0.0042491728,0.0065523605,0.004434733],"domain_scores_gemma":[0.9763531,0.008627954,0.004526459,0.0035215542,0.0041600554,0.0028108645],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0045440583,0.0028682454,0.0050640902,0.0031297447,0.0011438311,0.00020079958,0.0027544934,0.0012742162,0.000753062],"category_scores_gemma":[0.03449759,0.002705712,0.00093648204,0.0061639007,0.0018821695,0.0018541289,0.0013710066,0.0042340886,0.00021019757],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025694887,0.0022945215,0.013467662,0.003664687,0.0029599722,0.00589018,0.058367148,0.0007677289,0.8657221,0.0009721561,0.042574853,0.0030619951],"study_design_scores_gemma":[0.06096486,0.036487706,0.20463732,0.009202085,0.008703367,0.005135037,0.122341245,0.009039667,0.34827578,0.005839014,0.1880552,0.0013187258],"about_ca_topic_score_codex":0.0031807455,"about_ca_topic_score_gemma":0.0003109146,"teacher_disagreement_score":0.5174464,"about_ca_system_score_codex":0.0036626484,"about_ca_system_score_gemma":0.006189227,"threshold_uncertainty_score":0.9994448},"labels":[],"label_agreement":null},{"id":"W4309998944","doi":"10.14740/jmc3996","title":"Extramedullary Myeloid Leukemia in the Setting of a Myeloproliferative Neoplasm","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloproliferative neoplasm; Myeloid leukemia; Myeloid sarcoma; Essential thrombocythemia; Leukemia; Pathology; Myeloid; Bone marrow; Biopsy; Chronic myelomonocytic leukemia; Positron emission tomography; Myeloproliferative Disorders; Myelodysplastic syndromes; Cancer research; Radiology; Internal medicine; Myelofibrosis; Polycythemia vera","score_opus":0.02790138454186601,"score_gpt":0.33009595162289174,"score_spread":0.3021945670810257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309998944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741172,0.0020970905,0.000063220665,0.022629878,0.00017569943,0.00025360024,0.000010004405,0.0000060061575,0.0006472701],"genre_scores_gemma":[0.99525756,0.00048711497,0.0005061445,0.0031247619,0.0005000734,0.000019554145,0.0000053110043,0.000017911625,0.00008157683],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9941805,0.0007049234,0.0009094613,0.00014387292,0.0037268638,0.00033437926],"domain_scores_gemma":[0.9967078,0.00216367,0.00040484828,0.00022936442,0.00021264327,0.00028169656],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0056997924,0.00013774198,0.00054151803,0.00035656846,0.00012856054,0.00001488389,0.0006011774,0.00011069954,0.0011426269],"category_scores_gemma":[0.005666017,0.000085132655,0.00019594675,0.0007165405,0.00020142086,0.00008803479,0.0002308135,0.002680252,0.000003323396],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010994817,0.0026761678,0.16094778,0.0014370375,0.0011436482,0.24354307,0.054090336,0.001412924,0.007686693,0.002205804,0.26604792,0.2478138],"study_design_scores_gemma":[0.03087068,0.014441971,0.16061991,0.0023237285,0.0006305322,0.49983296,0.14125188,0.013892743,0.005565006,0.001339865,0.128422,0.0008087317],"about_ca_topic_score_codex":0.00015272044,"about_ca_topic_score_gemma":0.000039689046,"teacher_disagreement_score":0.25628987,"about_ca_system_score_codex":0.0010172754,"about_ca_system_score_gemma":0.0051774695,"threshold_uncertainty_score":0.99977046},"labels":[],"label_agreement":null},{"id":"W4310086091","doi":"10.1111/bjh.18579","title":"Treatment response in acute myeloid leukaemia—Clues in the biopsy core","year":2022,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukaemia; Medicine; Bone marrow; Transcriptome; Myeloid; Biopsy; Core biopsy; Internal medicine; Myeloid cells; Oncology; Pathology; Cancer research; Biology; Gene; Cancer; Gene expression; Breast cancer","score_opus":0.03624912448035942,"score_gpt":0.3255512199774176,"score_spread":0.28930209549705815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310086091","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.604769,0.0046098656,0.0000035354071,0.38931683,0.00031730477,0.00058954285,0.000084677566,0.000011383639,0.00029783574],"genre_scores_gemma":[0.21396698,0.027071789,0.0022571718,0.74012643,0.0048442385,0.0006811429,0.00094478944,0.0005384642,0.009568991],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9938522,0.0022219985,0.0014873453,0.000468838,0.0010476089,0.0009220299],"domain_scores_gemma":[0.9967359,0.001698571,0.00069170684,0.0005582687,0.00019669943,0.00011889547],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0020736735,0.00042004057,0.0020845952,0.0013699955,0.00012604102,0.00007066642,0.0009670637,0.0008800466,0.00073330075],"category_scores_gemma":[0.0007906543,0.00034333082,0.00047694513,0.0007405207,0.00038817685,0.00010802084,0.00019386249,0.0072657876,0.000033438857],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033512332,0.00015617041,0.000887909,0.000078598125,0.00023589666,0.5998923,0.00047066898,0.0000022442907,0.000083965504,0.000006019913,0.39322877,0.001606214],"study_design_scores_gemma":[0.0043189307,0.0019808838,0.0035253128,0.00044280977,0.0001861667,0.6751807,0.000509192,0.000011911667,0.000025668822,0.00013056435,0.3135054,0.00018246741],"about_ca_topic_score_codex":0.0007230651,"about_ca_topic_score_gemma":0.00014501433,"teacher_disagreement_score":0.39080203,"about_ca_system_score_codex":0.0023467746,"about_ca_system_score_gemma":0.0023033852,"threshold_uncertainty_score":0.9999019},"labels":[],"label_agreement":null},{"id":"W4310096357","doi":"10.1182/blood-2022-168260","title":"Multiparameter Flow Cytometry-Based Residual Disease Analysis Identifies Intermediate-Risk AML Patients Who May Benefit from Allogeneic Hematopoietic Stem Cell Transplantation","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Cumulative incidence; Medicine; NPM1; Minimal residual disease; Internal medicine; Transplantation; Oncology; Hematopoietic stem cell transplantation; Stem cell; Myeloid leukemia; Leukemia; Biology","score_opus":0.01122539570736487,"score_gpt":0.24897952837618975,"score_spread":0.2377541326688249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310096357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941821,0.00037842142,0.0006292113,0.0001300393,0.00013005389,0.00070820714,0.0037154998,0.000092360664,0.0000341167],"genre_scores_gemma":[0.99330086,0.00009713933,0.00078139425,0.00023921227,0.00009054166,0.00026881546,0.0046236073,0.00006599383,0.00053241674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965039,0.00034631827,0.00058106205,0.0007545759,0.001311142,0.0005030356],"domain_scores_gemma":[0.9980243,0.0004016931,0.00022075175,0.000775512,0.00015387508,0.00042389613],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034583532,0.00031267985,0.000590687,0.0009635816,0.0002775321,0.000074715,0.0003779788,0.00009533884,0.0008645039],"category_scores_gemma":[0.00006103907,0.00029925822,0.00041000656,0.0012590669,0.0000944171,0.00010693923,0.00015292053,0.0005468935,0.00007966692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016038178,0.0017263292,0.9861868,0.00027617882,0.0015060497,0.0005321827,0.001563476,0.003321835,0.0019138455,8.597235e-7,0.0003651701,0.0010034784],"study_design_scores_gemma":[0.011424131,0.00041787754,0.9430299,0.000050942745,0.00914836,0.0000029662049,0.0004182497,0.006932839,0.028115626,0.000024936788,0.000062518644,0.0003716547],"about_ca_topic_score_codex":0.00034275337,"about_ca_topic_score_gemma":0.00009362212,"teacher_disagreement_score":0.043156877,"about_ca_system_score_codex":0.00024404224,"about_ca_system_score_gemma":0.00021593977,"threshold_uncertainty_score":0.99994594},"labels":[],"label_agreement":null},{"id":"W4310096545","doi":"10.1182/blood-2022-166857","title":"Identification of Novel Antigens for Normal Karyotype Triple Mutated Acute Myeloid Leukemia","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"NPM1; Myeloid leukemia; Proteome; Cancer research; Leukemia; Myeloid; Mass cytometry; Antigen; Biology; Flow cytometry; Karyotype; Immunology; Gene; Bioinformatics; Genetics; Phenotype; Chromosome","score_opus":0.02191346774358169,"score_gpt":0.29460420038208146,"score_spread":0.27269073263849974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310096545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949236,0.0001534746,0.0018584218,0.00045807636,0.00020462762,0.0011917556,0.00051021576,0.000077911536,0.0006219498],"genre_scores_gemma":[0.9907375,0.00004199377,0.0019898147,0.00016300868,0.00013711158,0.00024911275,0.0005896797,0.000050521907,0.006041261],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99825567,0.00004080931,0.00048770118,0.00032995403,0.0005157525,0.00037011981],"domain_scores_gemma":[0.9988806,0.00008459118,0.00019711751,0.0004579065,0.00026312185,0.0001166648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059141085,0.00013942829,0.0003347275,0.00024976875,0.0002174184,0.00001317093,0.00026195997,0.00007184166,0.0002069624],"category_scores_gemma":[0.00017700663,0.00014234567,0.00015524415,0.00059772434,0.00007469758,0.00008510255,0.00016854005,0.0003129403,0.000017844452],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008378491,0.0008439175,0.0022683223,0.00012976122,0.00049463275,0.000042157622,0.0003837428,0.00007719388,0.9895674,0.00025379835,0.004336726,0.000764503],"study_design_scores_gemma":[0.029847132,0.0017872836,0.030611433,0.000026558595,0.0011859236,0.00060564245,0.00057046395,0.012361637,0.91130626,0.00007015006,0.011273851,0.00035368287],"about_ca_topic_score_codex":0.000076927296,"about_ca_topic_score_gemma":0.000004249579,"teacher_disagreement_score":0.07826115,"about_ca_system_score_codex":0.0002958101,"about_ca_system_score_gemma":0.0008800215,"threshold_uncertainty_score":0.5804688},"labels":[],"label_agreement":null},{"id":"W4310103232","doi":"10.1182/blood-2022-169307","title":"Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Clinical trial; Medicine; Precision medicine; Oncology; Internal medicine; Intensive care medicine; Pathology","score_opus":0.20145469015353576,"score_gpt":0.4464099948078948,"score_spread":0.24495530465435902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310103232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9396716,0.0026779661,0.00012710605,0.025570031,0.0021011978,0.006053024,0.000075961434,0.00012332489,0.023599807],"genre_scores_gemma":[0.97976327,0.000842588,0.0006734195,0.0065575065,0.008984446,0.0011346093,0.00016866371,0.000074249976,0.0018012541],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9889135,0.0053599006,0.0021861596,0.0006300687,0.0022945432,0.00061584375],"domain_scores_gemma":[0.984756,0.013613818,0.00053465884,0.0005526007,0.00032860177,0.00021435188],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03768749,0.00025399428,0.0012046321,0.00024635455,0.00039016816,0.000024003935,0.00054973766,0.00018302102,0.0018891458],"category_scores_gemma":[0.021143185,0.00016226071,0.0003214118,0.0013401103,0.000273792,0.00007380001,0.00052882766,0.0016250451,0.00007126168],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1914287,0.0079300525,0.023396106,0.00016631669,0.0020931216,0.0014059606,0.0058707213,0.001104613,0.002632691,0.0072237686,0.7273634,0.029384552],"study_design_scores_gemma":[0.6843697,0.014632098,0.051396277,0.0006475769,0.0010445922,0.0007342115,0.0046742964,0.0026095815,0.0004939208,0.012736979,0.22586209,0.00079870934],"about_ca_topic_score_codex":0.00006856688,"about_ca_topic_score_gemma":0.000020545725,"teacher_disagreement_score":0.5015013,"about_ca_system_score_codex":0.00038683938,"about_ca_system_score_gemma":0.0019200464,"threshold_uncertainty_score":0.99902326},"labels":[],"label_agreement":null},{"id":"W4310104796","doi":"10.1182/blood-2022-158370","title":"Preliminary Results from a Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202)","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Pharmacokinetics; Tolerability; Pharmacodynamics; Pharmacology; Medicine; Clinical trial; Phases of clinical research; Adverse effect; Internal medicine","score_opus":0.03387899499718823,"score_gpt":0.33668694575457664,"score_spread":0.3028079507573884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310104796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98879296,0.00014238109,0.00004964336,0.000160632,0.000091434806,0.009956785,0.00075209234,0.000032403368,0.000021661424],"genre_scores_gemma":[0.996568,0.000281903,0.0015432697,0.000069254296,0.000024342615,0.0006328626,0.0005755118,0.00009332691,0.0002115027],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942498,0.0010295832,0.0018998012,0.001142892,0.0011294753,0.000548455],"domain_scores_gemma":[0.996647,0.0012349291,0.00082845887,0.00071977143,0.0003198173,0.00025002455],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011186118,0.0005108539,0.0012806462,0.0004576602,0.0001942131,0.000050594892,0.00063187943,0.00012459136,0.0001628274],"category_scores_gemma":[0.00064216886,0.00031865202,0.000036209436,0.0017607886,0.0004248807,0.00036650104,0.0014268744,0.0009331881,8.354499e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7386786,0.09430971,0.11651236,0.0012878078,0.0022476395,0.003796803,0.0055724583,0.019916615,0.004591796,0.000002279426,0.000058661644,0.013025291],"study_design_scores_gemma":[0.502299,0.114232905,0.23454854,0.0013635859,0.0020067892,0.0004532178,0.0012581598,0.14224382,0.0010772661,0.00000474567,0.000012537861,0.000499407],"about_ca_topic_score_codex":0.0011345167,"about_ca_topic_score_gemma":0.0006800661,"teacher_disagreement_score":0.23637955,"about_ca_system_score_codex":0.0021957457,"about_ca_system_score_gemma":0.0030039554,"threshold_uncertainty_score":0.99992657},"labels":[],"label_agreement":null},{"id":"W4310105145","doi":"10.1182/blood-2022-170223","title":"Activity of Azacitidine and Venetoclax Compared to Other Therapies in Adults with Refractory or Relapsed Acute Myeloid Leukemia, a Retrospective Study","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Venetoclax; Azacitidine; Myeloid leukemia; Medicine; Refractory (planetary science); Internal medicine; Oncology; Leukemia; Myeloid; Retrospective cohort study; Immunology; Biology; Chronic lymphocytic leukemia","score_opus":0.01697384462347137,"score_gpt":0.2813422965255065,"score_spread":0.2643684519020352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310105145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996769,0.00013318879,0.000007072257,0.00023032808,0.000022810242,0.00215395,0.0000927894,0.000048996415,0.0005418578],"genre_scores_gemma":[0.99814165,0.000033025157,0.0004037396,0.00014437152,0.000047526588,0.00040691698,0.00000842625,0.00005721207,0.00075714407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979339,0.0002447885,0.00026651242,0.0005235488,0.0006800915,0.00035111257],"domain_scores_gemma":[0.9989743,0.00011363836,0.00012705625,0.0005146826,0.00011922934,0.0001510742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046153093,0.00022306132,0.000637344,0.00033193524,0.00011109321,0.00001120619,0.00018484377,0.000055217748,0.00020705581],"category_scores_gemma":[0.00008588248,0.00016904178,0.000040206618,0.000826732,0.00011406458,0.000086080865,0.00024267603,0.00067238254,0.000003275604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07653806,0.005661121,0.74411213,0.0002324263,0.0022493189,0.001927648,0.044757653,0.000071568546,0.12132755,0.000029929937,0.000562673,0.0025298987],"study_design_scores_gemma":[0.043697264,0.01891529,0.9139392,0.00022516405,0.0002901525,0.00022260175,0.010660659,0.00017544077,0.0107429195,0.000016887752,0.0007624904,0.00035195955],"about_ca_topic_score_codex":0.0016758405,"about_ca_topic_score_gemma":0.0010148595,"teacher_disagreement_score":0.16982703,"about_ca_system_score_codex":0.0012793307,"about_ca_system_score_gemma":0.0008404836,"threshold_uncertainty_score":0.68933237},"labels":[],"label_agreement":null},{"id":"W4310106224","doi":"10.1182/blood-2022-170689","title":"Loss of FBXO11 Function Establishes a Stem Cell Program in Acute Myeloid Leukemia through Dysregulation of the Mitochondrial Protease LONP1","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Progenitor cell; Myeloid leukemia; Biology; CD34; Stem cell; Cancer research; Haematopoiesis; Cord blood; Myeloid; Hematopoietic stem cell; Molecular biology; Immunology; Cell biology","score_opus":0.014644653346449304,"score_gpt":0.25969250084260603,"score_spread":0.24504784749615674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310106224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99455166,0.00015405442,0.00008786428,0.00032438507,0.00023493648,0.0034897616,0.000050418006,0.000053983906,0.0010529257],"genre_scores_gemma":[0.9961779,0.00001687725,0.001475862,0.000055181114,0.00015625788,0.00073070225,0.000058785507,0.00004058242,0.0012878284],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974844,0.0002809151,0.00055038894,0.0003664442,0.0009674011,0.00035048273],"domain_scores_gemma":[0.9987056,0.00007689219,0.00031302517,0.00066052703,0.00017502287,0.00006891796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034081616,0.00018393487,0.0003961831,0.0001647452,0.0001161767,0.000014941006,0.00031389022,0.000115462535,0.00013144567],"category_scores_gemma":[0.000055300785,0.00014307149,0.00017303457,0.0011703669,0.00017735694,0.00018278789,0.00032865698,0.00061402883,0.0000041990475],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013417621,0.011780006,0.24828985,0.0027094013,0.0010624658,0.0003720712,0.008502969,0.0018227134,0.6710922,0.00064435555,0.005549728,0.034756623],"study_design_scores_gemma":[0.044530693,0.007172849,0.17157017,0.000398824,0.0017100746,0.00029390887,0.0034512028,0.0019265343,0.75407755,0.0007544447,0.013487405,0.0006263444],"about_ca_topic_score_codex":0.00042881252,"about_ca_topic_score_gemma":0.000029628403,"teacher_disagreement_score":0.082985364,"about_ca_system_score_codex":0.00047742616,"about_ca_system_score_gemma":0.0011459028,"threshold_uncertainty_score":0.5834286},"labels":[],"label_agreement":null},{"id":"W4310107852","doi":"10.1182/blood-2022-170230","title":"<i>IL1R1</i> Expression Predicts the Benefit from Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Intermediate-Risk Cytogenetics","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Hôpital Maisonneuve-Rosemont; Université de Montréal; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Institute for Research in Immunology and Cancer","funders":"","keywords":"CEBPA; Oncology; NPM1; Hematopoietic stem cell transplantation; Internal medicine; Medicine; Transplantation; Induction chemotherapy; Myeloid leukemia; Hazard ratio; Proportional hazards model; Leukemia; Chemotherapy; Immunology; Biology; Confidence interval; Karyotype; Gene","score_opus":0.006474025734208399,"score_gpt":0.20817614256753011,"score_spread":0.2017021168333217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310107852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974813,0.0005921684,0.000060816506,0.000078508856,0.00006591609,0.0010283103,0.0005157584,0.000044448894,0.00013280234],"genre_scores_gemma":[0.9976128,0.0009222904,0.00036697203,0.00021464066,0.00005921456,0.00020370836,0.00044741016,0.00005847442,0.00011452832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781275,0.00017913339,0.00035323398,0.00048331296,0.000778472,0.0003931045],"domain_scores_gemma":[0.99897647,0.00017419348,0.00015299006,0.0004688772,0.000060116625,0.00016733985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023297107,0.00024655674,0.0003170802,0.00013763142,0.00022937967,0.000029936724,0.00028153817,0.00009775465,0.00005882463],"category_scores_gemma":[0.0000065325053,0.00017021273,0.000050188522,0.0002847312,0.00010523768,0.000072695104,0.00021806337,0.0006888692,0.000007203664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021170028,0.000602287,0.97059894,0.00012872093,0.0001971628,0.00032394542,0.005704195,0.00030999104,0.017564166,0.0000032962344,0.00017850052,0.0022717656],"study_design_scores_gemma":[0.02433586,0.0018688226,0.8625389,0.00017419689,0.0009885868,0.000093622686,0.0011257622,0.00021644912,0.10805467,0.000063043335,0.00021141143,0.0003287329],"about_ca_topic_score_codex":0.00013906496,"about_ca_topic_score_gemma":0.00005406259,"teacher_disagreement_score":0.108060114,"about_ca_system_score_codex":0.00023168208,"about_ca_system_score_gemma":0.000261059,"threshold_uncertainty_score":0.69410735},"labels":[],"label_agreement":null},{"id":"W4310119465","doi":"10.1182/blood-2022-169710","title":"CCUS and Low-Risk MDS Are Inherently Similar, Sharing Clonal and Clinical Features","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University","funders":"","keywords":"Cytopenia; Myelodysplastic syndromes; Medicine; Myeloproliferative neoplasm; Internal medicine; Myeloid; Dysplasia; Incidence (geometry); Clinical significance; Oncology; Bone marrow; Myelofibrosis","score_opus":0.025898994057126874,"score_gpt":0.3224210220553147,"score_spread":0.29652202799818783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310119465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945611,0.0025331958,0.0000025929553,0.0012466665,0.00008100133,0.00031625037,0.00006288166,0.00005230296,0.0011440398],"genre_scores_gemma":[0.99631,0.0007246578,0.00039520048,0.00071067986,0.0003504192,0.00003726977,0.0000292273,0.00003178378,0.0014107587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847525,0.000118258875,0.0002486499,0.00044906157,0.00040850925,0.00030027813],"domain_scores_gemma":[0.9991008,0.00021152328,0.00008441299,0.0003005926,0.00004495328,0.0002577379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063881546,0.00013744646,0.00030914092,0.000093149305,0.00024892815,0.00003765035,0.00013931925,0.00009699682,0.00022015766],"category_scores_gemma":[0.00037911223,0.000120980025,0.00007110561,0.00015236712,0.0001333509,0.000043442808,0.000742171,0.0011901823,0.0000068913346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031270887,0.00052817946,0.9838303,0.00008788684,0.0002531387,0.00059880235,0.00016649012,0.0000018450542,0.0003958832,0.00005926733,0.007813016,0.005952536],"study_design_scores_gemma":[0.010214849,0.0007790479,0.9788606,0.000057285946,0.00033757903,0.00065723335,0.00048700822,0.00040295513,0.00036778505,0.00021722235,0.0074308477,0.00018757688],"about_ca_topic_score_codex":0.00007410123,"about_ca_topic_score_gemma":0.00002989577,"teacher_disagreement_score":0.009902141,"about_ca_system_score_codex":0.00005364995,"about_ca_system_score_gemma":0.00013285052,"threshold_uncertainty_score":0.5170816},"labels":[],"label_agreement":null},{"id":"W4310120207","doi":"10.1182/blood-2022-156411","title":"Treatment Patterns and Outcomes in Lower-Risk, Non-Del(5q) Myelodysplastic Syndromes: Findings from a Global Real-World Medical Record Review Study","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Medical record; Anemia; International Prognostic Scoring System; Hematologist; Internal medicine; Pediatrics; Disease; Bone marrow","score_opus":0.02122256794205495,"score_gpt":0.3259199848047975,"score_spread":0.30469741686274254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310120207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929794,0.0012599806,0.0000063452526,0.0026035658,0.00019421731,0.0020880469,0.0003446086,0.00006611003,0.00045770468],"genre_scores_gemma":[0.9885645,0.0089437645,0.00016386603,0.0005778182,0.000084219646,0.0006845368,0.00010198585,0.00004417959,0.00083512184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963428,0.0004043655,0.0006338905,0.00078171026,0.0012694052,0.00056783174],"domain_scores_gemma":[0.99813324,0.0005891796,0.00012687367,0.0006565308,0.00003955084,0.00045463417],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007155036,0.0003684708,0.0011641221,0.00021480808,0.00016865638,0.000024246474,0.0003227955,0.000080213664,0.0019271384],"category_scores_gemma":[0.00056310993,0.0002888317,0.0001467597,0.0006942021,0.000065146116,0.0000592234,0.0005133011,0.00073998177,0.00006395722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019473012,0.0036535421,0.9806225,0.00020272353,0.0005638204,0.007169537,0.00030597838,2.712055e-7,0.000004284701,0.0000032232895,0.0008860549,0.0063933353],"study_design_scores_gemma":[0.015961027,0.0042102565,0.9753816,0.00084099773,0.001052023,0.0003184099,0.0005311561,0.00010018905,0.000004715232,0.000021257592,0.0013158135,0.000262552],"about_ca_topic_score_codex":0.024967099,"about_ca_topic_score_gemma":0.00973088,"teacher_disagreement_score":0.015766297,"about_ca_system_score_codex":0.001153769,"about_ca_system_score_gemma":0.00064814463,"threshold_uncertainty_score":0.99995637},"labels":[],"label_agreement":null},{"id":"W4310126134","doi":"10.1182/blood-2022-163841","title":"Prolonged Survival in Bi-Allelic <i>TP53</i>-Mutated (<i>TP53</i>mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Hôpital Maisonneuve-Rosemont; University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Decitabine; Medicine; Chronic myelomonocytic leukemia; Internal medicine; International Prognostic Scoring System; Population; Azacitidine; Oncology; Regimen; Myelodysplastic syndromes; Gastroenterology; Biology; Bone marrow; Genetics; DNA methylation","score_opus":0.02431869810751564,"score_gpt":0.28252565881789526,"score_spread":0.25820696071037963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310126134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989152,0.0002980612,0.000005106074,0.003142543,0.00012882189,0.0044468804,0.000055087807,0.00017465102,0.0025968403],"genre_scores_gemma":[0.99590635,0.000053323987,0.00017165071,0.0007121523,0.00030172186,0.0016026949,0.00043461195,0.00013316135,0.0006843431],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932111,0.0018639594,0.0008682564,0.00095875876,0.0017623972,0.0013355328],"domain_scores_gemma":[0.99758965,0.00069191854,0.00020115163,0.0010377222,0.00021282418,0.0002667544],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032686861,0.0005681574,0.0010686406,0.0008672775,0.00028141547,0.00007249105,0.0008326633,0.00020052685,0.0003542439],"category_scores_gemma":[0.0007461722,0.00039417038,0.00016758041,0.0046994416,0.00020050535,0.0001574515,0.00031903974,0.0020638816,0.00003699596],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34591317,0.025578484,0.5331851,0.0004155383,0.0015615199,0.03396275,0.009337826,0.0009763692,0.03771586,0.0004129472,0.007579507,0.00336089],"study_design_scores_gemma":[0.7901039,0.02451721,0.15031272,0.00025936693,0.0010151281,0.0025493747,0.0057531632,0.0017331467,0.012991153,0.0001333231,0.008898101,0.0017334134],"about_ca_topic_score_codex":0.0032468026,"about_ca_topic_score_gemma":0.004292298,"teacher_disagreement_score":0.44419074,"about_ca_system_score_codex":0.00062059675,"about_ca_system_score_gemma":0.0016099833,"threshold_uncertainty_score":0.99985105},"labels":[],"label_agreement":null},{"id":"W4310159176","doi":"10.1182/blood-2022-168998","title":"Immunophenotypic Switch in Leukemic Clone Is Very Common at the Time of Post-Transplant Relapse of Acute Myeloid Leukemia While Immunophenotypic Profile at Diagnosis Correlates with Adverse Outcomes after Post-Transplant Relapse","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; clone (Java method); Immunophenotyping; Leukemia; Adverse effect; Myeloid; Oncology; Internal medicine; Immunology; Cancer research; Flow cytometry; Biology; Gene","score_opus":0.006132046537454842,"score_gpt":0.21969185731275048,"score_spread":0.21355981077529565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310159176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878948,0.0037853674,0.0000014070024,0.0013783589,0.00018733472,0.002533422,0.003694437,0.000100965764,0.0004239288],"genre_scores_gemma":[0.9887468,0.0014279672,0.00017788605,0.00089879386,0.00003631891,0.0011969382,0.0015703503,0.00019845269,0.0057464563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943213,0.00050117087,0.001520011,0.00095331337,0.0015759105,0.0011282987],"domain_scores_gemma":[0.9959304,0.0009689189,0.0006006395,0.0019223053,0.0003350656,0.00024270758],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009266657,0.00078617927,0.001635473,0.00056558935,0.00045353154,0.000016098978,0.0009831918,0.00035751064,0.003902132],"category_scores_gemma":[0.000059759655,0.000568506,0.0005188194,0.0011073829,0.00062308647,0.0002500014,0.0008202803,0.0019240078,0.00030237128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029075319,0.001606034,0.7325002,0.0005690981,0.0026333625,0.0017855747,0.012360713,0.00014515709,0.21809012,0.000020122867,0.0010324607,0.00018182257],"study_design_scores_gemma":[0.026372325,0.0043700957,0.83335483,0.0011055705,0.0040727714,0.0019539127,0.0014338644,0.000167077,0.12565166,0.000024960467,0.0004562791,0.0010366729],"about_ca_topic_score_codex":0.0031784535,"about_ca_topic_score_gemma":0.0004423096,"teacher_disagreement_score":0.100854605,"about_ca_system_score_codex":0.0022410357,"about_ca_system_score_gemma":0.0013088427,"threshold_uncertainty_score":0.99967664},"labels":[],"label_agreement":null},{"id":"W4310159356","doi":"10.1182/blood-2022-159069","title":"Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Princess Margaret Cancer Centre; University Health Network; Institute for Research in Immunology and Cancer; Centre Hospitalier Universitaire Sainte-Justine","funders":"Incyte; Celgene; Pfizer; Astellas Pharma; Bristol-Myers Squibb","keywords":"Gene expression profiling; Profiling (computer programming); Computational biology; Biology; Bioinformatics; Medicine; Genetics; Computer science; Gene; Gene expression","score_opus":0.02306219860393496,"score_gpt":0.2923445585423202,"score_spread":0.2692823599383853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310159356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99653506,0.00044517443,0.0004480787,0.0006326264,0.00005844075,0.0006924088,0.000027373826,0.00006427464,0.0010965678],"genre_scores_gemma":[0.96627676,0.00012164592,0.032185774,0.000573498,0.00011810649,0.00017228468,0.00006210082,0.000049456565,0.00044036694],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983514,0.00015030857,0.00027474097,0.00034191215,0.000433433,0.00044822777],"domain_scores_gemma":[0.9992893,0.00009537702,0.000049930433,0.00034986692,0.000055765056,0.00015980429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005345667,0.000127283,0.00024036082,0.00019914722,0.00012755483,0.000013008633,0.00021685591,0.00006750646,0.00020277315],"category_scores_gemma":[0.00038010307,0.00012657639,0.00007290647,0.0004108069,0.000055790428,0.00002441612,0.00035528108,0.0008727491,0.00006528645],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058549043,0.0029484679,0.8301169,0.00011539524,0.00021633515,0.0018272932,0.0009808074,0.0007869855,0.15391608,0.0003306387,0.0002617011,0.007913877],"study_design_scores_gemma":[0.092293255,0.0035719026,0.2954002,0.00008171243,0.0008889689,0.0019976601,0.0054880646,0.17908117,0.40733448,0.00042885914,0.012041459,0.0013922529],"about_ca_topic_score_codex":0.000120978366,"about_ca_topic_score_gemma":0.00003447856,"teacher_disagreement_score":0.5347167,"about_ca_system_score_codex":0.00026063583,"about_ca_system_score_gemma":0.00038137852,"threshold_uncertainty_score":0.5161635},"labels":[],"label_agreement":null},{"id":"W4310730362","doi":"10.1016/j.tcb.2022.11.004","title":"Contribution of metabolic abnormalities to acute myeloid leukemia pathogenesis","year":2022,"lang":"en","type":"review","venue":"Trends in Cell Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children; University Health Network","funders":"","keywords":"Biology; Myeloid leukemia; Pathogenesis; Myeloid; Cancer research; Phenotype; Somatic cell; Leukemia; Oxidative phosphorylation; Stem cell; Mitochondrion; Gene; Genetics; Immunology","score_opus":0.05482495424832923,"score_gpt":0.36912382730908916,"score_spread":0.31429887306075993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310730362","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001049825,0.9896564,0.000014125226,0.000072191004,0.00033684855,0.000763763,0.0010199858,0.00004894203,0.00703793],"genre_scores_gemma":[0.00040690898,0.9884269,0.00033378365,0.00013935106,0.00021803546,0.000655242,0.004303837,0.00007602177,0.00543989],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99577355,0.0009576746,0.0012910147,0.0007901058,0.0003097289,0.0008779026],"domain_scores_gemma":[0.99774855,0.0005838387,0.00043258173,0.0008874796,0.000111688336,0.00023587879],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011235609,0.0005794577,0.003869607,0.0023399817,0.00006844742,0.0000075240673,0.00060850533,0.0007309425,0.0033134848],"category_scores_gemma":[0.00020347332,0.00046942083,0.0007434962,0.002147655,0.00020002316,0.000034481774,0.0005923518,0.0010993503,0.00013326741],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014755565,0.00007978693,0.00008549353,0.0020028485,0.00039227857,0.00016257468,0.00011826586,0.000001606231,0.0003155429,0.0006018514,0.0010919356,0.99500024],"study_design_scores_gemma":[0.0010442756,0.00051483384,0.00010648178,0.00043938655,0.0013178585,0.00014386135,0.000044321354,0.0000046996292,0.00033422626,0.000016990169,0.9956838,0.00034927938],"about_ca_topic_score_codex":0.0003661837,"about_ca_topic_score_gemma":0.00003753873,"teacher_disagreement_score":0.99465096,"about_ca_system_score_codex":0.001337226,"about_ca_system_score_gemma":0.0014057116,"threshold_uncertainty_score":0.99977577},"labels":[],"label_agreement":null},{"id":"W4310954682","doi":"10.1172/jci.insight.150368","title":"Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"JCI Insight","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Associazione Italiana per la Ricerca sul Cancro; Technische Universität Dresden; Fundación Científica Asociación Española Contra el Cáncer; Newcastle University; Cancer Research UK; Blood Cancer UK; JGW Patterson Foundation; DNA Genotek; University of California, San Francisco; Memorial Sloan-Kettering Cancer Center","keywords":"Azacitidine; Myeloid leukemia; Cancer research; Cytarabine; Hypomethylating agent; Decitabine; Medicine; Myeloid; Mutation; Allele; Anthracycline; Leukemia; Mutant; Cancer; Biology; Oncology; Internal medicine; Gene; Genetics; DNA methylation; Breast cancer","score_opus":0.027309209160750844,"score_gpt":0.3031356013879044,"score_spread":0.27582639222715355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310954682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665613,0.000067973364,0.0003241289,0.01110134,0.00023081453,0.0011555764,0.00011411168,0.00015017428,0.020294538],"genre_scores_gemma":[0.985823,0.000039461294,0.0010040877,0.0039580315,0.00022614129,0.00031815717,0.00027617585,0.000065377295,0.008289593],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972498,0.0003225268,0.00042601544,0.00057780056,0.0007920025,0.00063187064],"domain_scores_gemma":[0.9985215,0.000264398,0.00006445652,0.00059686875,0.00018184769,0.00037093513],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006515759,0.00025202168,0.0005001898,0.0007913998,0.00029577804,0.000037272795,0.0001820477,0.00010517112,0.0013912813],"category_scores_gemma":[0.0003151307,0.0002505643,0.00012567252,0.0014983654,0.000104399034,0.00013829682,0.00049359835,0.0010555092,0.00046174566],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002174927,0.0009902744,0.012790783,0.00014409491,0.0005551601,0.01652916,0.010029897,0.0030542265,0.8776294,0.00362504,0.057300832,0.015176178],"study_design_scores_gemma":[0.012376453,0.0020914136,0.13580969,0.00012466188,0.00026858554,0.0024643417,0.0023506137,0.011497614,0.07130671,0.00049588113,0.7599513,0.0012627655],"about_ca_topic_score_codex":0.0007780835,"about_ca_topic_score_gemma":0.00035146406,"teacher_disagreement_score":0.8063227,"about_ca_system_score_codex":0.002863372,"about_ca_system_score_gemma":0.001439581,"threshold_uncertainty_score":0.99999464},"labels":[],"label_agreement":null},{"id":"W4311286231","doi":"10.1371/journal.pone.0278578","title":"Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review","year":2022,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; University Health Network; Impact","funders":"Cardiff University","keywords":"Medicine; Internal medicine; Comorbidity; Meta-analysis; Quality of life (healthcare); MEDLINE; Hematopoietic stem cell transplantation; Transplantation; Oncology","score_opus":0.07374591108098928,"score_gpt":0.3063458822697013,"score_spread":0.232599971188712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311286231","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005030459,0.9767911,0.0000029258886,0.000059998125,0.000022318656,0.022147791,0.000088166635,0.00010037892,0.00028427894],"genre_scores_gemma":[0.000049594666,0.9918464,0.00049734104,0.00033831052,0.0000657306,0.005771104,0.0006974896,0.00026305788,0.00047096258],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9939213,0.0008342729,0.0016516098,0.00075002963,0.0022555934,0.0005872369],"domain_scores_gemma":[0.99498487,0.0015850228,0.0014042467,0.0014033531,0.0003820892,0.00024041784],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007725883,0.0007084849,0.0071778954,0.0004726624,0.000101614074,0.000025819741,0.0006373266,0.00022842389,0.00086227065],"category_scores_gemma":[0.0014633778,0.00045761003,0.000623452,0.0014665116,0.00010965823,0.00009487946,0.00023670439,0.0011527612,0.00008818759],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003749734,0.0026912407,0.00033659427,0.973566,0.0047801235,0.000081319544,0.000061114675,2.7917519e-8,7.3764704e-7,0.0000033523936,0.0006048757,0.017837144],"study_design_scores_gemma":[0.0026757966,0.0010387608,0.00003172151,0.96974385,0.017053323,0.000020951697,0.000020883788,0.0000036714378,0.000005347512,7.7098656e-7,0.008986845,0.00041809838],"about_ca_topic_score_codex":0.000026674652,"about_ca_topic_score_gemma":0.0000029312478,"teacher_disagreement_score":0.017419046,"about_ca_system_score_codex":0.0013294629,"about_ca_system_score_gemma":0.002504438,"threshold_uncertainty_score":0.99978757},"labels":[],"label_agreement":null},{"id":"W4311298607","doi":"10.1101/2022.12.01.518580","title":"Multiomic Profiling of Human Clonal Hematopoiesis Reveals Genotype and Cell-Specific Inflammatory Pathway Activation","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Fondation pour la Recherche Médicale; William Guy Forbeck Research Foundation; Gilead Sciences; Ludwig Center at Harvard; National Institutes of Health; Glenn Foundation for Medical Research","keywords":"Biology; CD14; Haematopoiesis; Inflammation; Myeloid; Immunology; Cancer research; Cell biology; Immune system; Stem cell","score_opus":0.021983815590936144,"score_gpt":0.2554800362843251,"score_spread":0.23349622069338893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311298607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949688,0.0016207919,0.00019447097,0.00012837791,0.0002589462,0.002342277,0.00022207039,0.00023259468,0.00003167893],"genre_scores_gemma":[0.9902517,0.0004005006,0.00806739,0.000079968355,0.0003941081,0.0005594311,0.0000064246387,0.00020863,0.00003184634],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960635,0.0002733289,0.000995178,0.0011509402,0.000914699,0.0006023561],"domain_scores_gemma":[0.9965525,0.00016599924,0.0007832363,0.0014650848,0.0006940503,0.00033909158],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013252029,0.0005787375,0.0009943589,0.000731194,0.00031174225,0.00007953452,0.00044641356,0.0005876779,0.00024903915],"category_scores_gemma":[0.00021938609,0.000637836,0.00019657677,0.00053927395,0.00025724704,0.0001485426,0.001100743,0.0017648984,0.00001762842],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018972567,0.00017730326,0.021736098,0.0027877945,0.00016902009,0.00008620071,0.000052843316,0.000020586609,0.97365373,0.00068756007,0.00043688208,0.0000022209483],"study_design_scores_gemma":[0.0014519679,0.00013810593,0.12624834,0.0004843827,0.000091829235,9.301396e-8,0.000031132673,0.00013422845,0.86961323,0.0000045070965,0.0012770265,0.00052517507],"about_ca_topic_score_codex":0.00005436182,"about_ca_topic_score_gemma":4.3944436e-7,"teacher_disagreement_score":0.104512244,"about_ca_system_score_codex":0.0012325884,"about_ca_system_score_gemma":0.0014708894,"threshold_uncertainty_score":0.99960726},"labels":[],"label_agreement":null},{"id":"W4311339045","doi":"10.1016/j.jval.2022.09.2177","title":"PCR244 Burden of Myelodysplastic Syndromes Part I: Systematic Literature Review of Epidemiologic and Humanistic Burden","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Disease burden; Incidence (geometry); Quality of life (healthcare); Myelodysplastic syndromes; Disease; Epidemiology; Anemia; MEDLINE; Cancer; Systematic review; Gerontology; Internal medicine; Family medicine; Bone marrow","score_opus":0.06700767727458984,"score_gpt":0.3471173889155005,"score_spread":0.28010971164091064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311339045","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13327475,0.8483327,0.000036329915,0.01296292,0.0002364864,0.004638959,0.00014603155,0.00004788552,0.00032395768],"genre_scores_gemma":[0.83944625,0.15687111,0.0009636795,0.0011921185,0.00015552928,0.00036929126,0.00010961656,0.000046810695,0.00084562966],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.994967,0.0020593815,0.0015665317,0.0003689874,0.00060995936,0.0004281492],"domain_scores_gemma":[0.9965986,0.0019205088,0.0006120334,0.00055084215,0.00013046741,0.00018751857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057323347,0.00019087679,0.001704578,0.00034275357,0.00009731637,0.000005191483,0.00023378874,0.000072891526,0.00017298157],"category_scores_gemma":[0.0043735458,0.00015041063,0.000102277634,0.00080909603,0.00012867572,0.000036309764,0.00022390088,0.0006967192,0.0000057225275],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007701381,0.000068496236,0.0008116577,0.9904526,0.00007627342,0.00022306672,0.0015073431,0.00087707554,0.00008921008,0.002459069,0.0031895232,0.00016868813],"study_design_scores_gemma":[0.0026871697,0.0045191282,0.0025799705,0.9573931,0.0003092789,0.0034467021,0.0017401099,0.02195244,0.000015986798,0.001401616,0.0035622925,0.0003921793],"about_ca_topic_score_codex":0.000736888,"about_ca_topic_score_gemma":0.0000014005659,"teacher_disagreement_score":0.70617145,"about_ca_system_score_codex":0.0005409538,"about_ca_system_score_gemma":0.0006885104,"threshold_uncertainty_score":0.6133567},"labels":[],"label_agreement":null},{"id":"W4311358889","doi":"10.1038/s41408-022-00765-8","title":"Management of patients with lower-risk myelodysplastic syndromes","year":2022,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"Bristol-Myers Squibb","keywords":"Myelodysplastic syndromes; Medicine; Internal medicine; Disease; Myeloid leukemia; Oncology; Dysplasia; Hematologic disease; International Prognostic Scoring System; Intensive care medicine; Bone marrow","score_opus":0.03015095816860201,"score_gpt":0.3252116550783994,"score_spread":0.29506069690979736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311358889","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001255225,0.99585927,0.000017888227,0.00002357109,0.000490142,0.0011190082,0.00023740968,0.000019241776,0.0009782418],"genre_scores_gemma":[0.00006986382,0.99689764,0.00048364006,0.000015778543,0.00026989062,0.00021543412,0.00007318055,0.00012887275,0.0018457046],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965128,0.00022493218,0.0007419677,0.0004077803,0.0015709886,0.0005415854],"domain_scores_gemma":[0.9977927,0.00012769522,0.0010510158,0.0005077736,0.00018662757,0.00033414137],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044056954,0.0004554637,0.001881309,0.00049735885,0.0002012801,0.000035379424,0.00050472637,0.00013727727,0.00514721],"category_scores_gemma":[0.00003919107,0.0003007678,0.0004946423,0.0007335711,0.000102458594,0.00006953256,0.00027370147,0.0021824422,0.000021989166],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002587398,0.0006889771,0.001421928,0.027258947,0.007772211,0.0027531746,0.000024902345,0.000006674117,1.2275096e-8,0.00000838728,0.0024245023,0.95738155],"study_design_scores_gemma":[0.0038844177,0.001679717,0.0006395148,0.02354094,0.01616796,0.0011809359,0.00003009846,0.0000015107219,2.428058e-7,0.000003918438,0.9525807,0.0002900408],"about_ca_topic_score_codex":0.000020420579,"about_ca_topic_score_gemma":0.0000021902194,"teacher_disagreement_score":0.9570915,"about_ca_system_score_codex":0.0009806369,"about_ca_system_score_gemma":0.0018268094,"threshold_uncertainty_score":0.99994445},"labels":[],"label_agreement":null},{"id":"W4311497573","doi":"10.1016/j.jval.2022.09.265","title":"EE11 Burden of Myelodysplastic Syndromes Part II: Systematic Literature Review of Economic Burden","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Cytopenia; Myelodysplastic syndromes; Medicine; Disease burden; Disease; Haematopoiesis; Dysfunctional family; Burden of disease; Bone marrow; Intensive care medicine; Oncology; Internal medicine; Stem cell; Psychiatry; Biology; Genetics","score_opus":0.035555775977325975,"score_gpt":0.32383861803766656,"score_spread":0.2882828420603406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311497573","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38587204,0.58917814,0.0000074539994,0.016509723,0.00067268737,0.0063504144,0.00030653673,0.00006295832,0.0010400811],"genre_scores_gemma":[0.84599745,0.1482192,0.0006600645,0.0009960154,0.00035017135,0.00057512964,0.00018361966,0.00009118397,0.0029271857],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9961674,0.00092150876,0.0015364919,0.00034233998,0.0006004441,0.00043181566],"domain_scores_gemma":[0.99789417,0.00053054345,0.0005812054,0.0007080327,0.00009401405,0.00019201946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031315445,0.00018505845,0.001467469,0.00043235012,0.00009829008,0.0000056551353,0.0003336464,0.00006540225,0.00048352306],"category_scores_gemma":[0.00064853387,0.00016250435,0.00015356287,0.0006655059,0.00006756005,0.00005666564,0.0002756602,0.0006365537,0.000024273177],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001085698,0.00009329558,0.00027364463,0.98233324,0.00012262473,0.00014927657,0.0029455996,0.004292526,0.00007787226,0.0015732431,0.00779119,0.00023891889],"study_design_scores_gemma":[0.0035524832,0.0040188855,0.00040675644,0.94780445,0.00023611018,0.0023471173,0.0017630707,0.027635027,0.00008303025,0.00032602073,0.011418171,0.00040889336],"about_ca_topic_score_codex":0.0013510372,"about_ca_topic_score_gemma":0.0000030698484,"teacher_disagreement_score":0.46012542,"about_ca_system_score_codex":0.0014534421,"about_ca_system_score_gemma":0.001923929,"threshold_uncertainty_score":0.66267353},"labels":[],"label_agreement":null},{"id":"W4312035679","doi":"10.1101/2022.12.08.22283237","title":"Genetic modification of inflammation and clonal hematopoiesis-associated cardiovascular risk","year":2022,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health; Stanley Center for Psychiatric Research, Broad Institute; Knut och Alice Wallenbergs Stiftelse; Broad Institute; Fondation Leducq; Medical Research Council; American Heart Association","keywords":"Inflammasome; Inflammation; Gene; AIM2; Disease; Biology; Haematopoiesis; Gene expression; Genetics; Cancer research; Bioinformatics; Immunology; Medicine; Internal medicine; Stem cell","score_opus":0.027488871209817918,"score_gpt":0.28526607722506425,"score_spread":0.25777720601524634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312035679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938685,0.0036310703,0.0005810349,0.0002767951,0.00011983975,0.00095177075,0.0000934417,0.00006458656,0.00041293065],"genre_scores_gemma":[0.99530417,0.0024747655,0.0011963254,0.000010193895,0.00014196706,0.00022516803,0.00041315454,0.000048465343,0.00018580921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722576,0.00048281936,0.0005316289,0.0005030557,0.0010218637,0.00023486726],"domain_scores_gemma":[0.99811894,0.0001344599,0.0003658104,0.0009751404,0.00028574592,0.00011990511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001553449,0.00022009388,0.00071298046,0.0002903842,0.0001023925,0.000017966873,0.00022235556,0.00028412152,0.00022720938],"category_scores_gemma":[0.00084988476,0.00021905615,0.00034247647,0.000248492,0.00012389716,0.000028816426,0.0006445695,0.0010571177,0.000015711139],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003695036,0.00025382522,0.9405106,0.0034391237,0.006316447,0.00017934071,0.0025213321,0.009660019,0.016761243,0.0002414545,0.00084082363,0.018906325],"study_design_scores_gemma":[0.0015674147,0.00010541405,0.9748984,0.0001639405,0.0011239132,0.000032792253,0.00016353738,0.014026059,0.004640032,0.0009004085,0.0021200564,0.00025802408],"about_ca_topic_score_codex":0.0004640737,"about_ca_topic_score_gemma":0.0000092503005,"teacher_disagreement_score":0.034387846,"about_ca_system_score_codex":0.0004609551,"about_ca_system_score_gemma":0.00044229024,"threshold_uncertainty_score":0.89328504},"labels":[],"label_agreement":null},{"id":"W4312074752","doi":"10.1101/2022.12.06.519415","title":"Baseline Acute Myeloid Leukemia Prognosis Models using Transcriptomic and Clinical Profiles by Studying the Impacts of Dimensionality Reductions and Gene Signatures on Cox-Proportional Hazard","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Institute for Research in Immunology and Cancer","funders":"","keywords":"Overfitting; Myeloid leukemia; Context (archaeology); Proportional hazards model; Computer science; Artificial intelligence; Machine learning; Hazard ratio; Dimensionality reduction; Feature selection; Data mining; Biology; Statistics; Mathematics; Cancer research","score_opus":0.04464699534108364,"score_gpt":0.3147631318240592,"score_spread":0.27011613648297556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312074752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894951,0.0036826283,0.00046546635,0.0014405058,0.00041810036,0.0026650322,0.0017010783,0.00013012602,0.000001945208],"genre_scores_gemma":[0.98813426,0.002554257,0.008087452,0.00038774495,0.0003906163,0.00028527973,0.000012443562,0.00013997946,0.00000794789],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948972,0.0007272286,0.0012182181,0.001381172,0.0011800374,0.0005961322],"domain_scores_gemma":[0.99672246,0.00039922714,0.0006433101,0.0010352854,0.00072273606,0.00047696193],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0032072505,0.0006235784,0.0010974446,0.0003228217,0.0005408627,0.0001005801,0.00037038044,0.00056087546,0.000056452445],"category_scores_gemma":[0.0005104848,0.0004986322,0.00026840647,0.0005082427,0.0008156323,0.00016588983,0.00071927335,0.0027206123,9.3674186e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010887453,0.000605113,0.02056294,0.0006137338,0.001863706,0.00008620453,0.000043760338,0.00063278544,0.9724573,0.00024366139,0.0017890825,0.000012949683],"study_design_scores_gemma":[0.007514402,0.0015652825,0.3232667,0.0018384627,0.005061717,0.000003996531,0.00013646558,0.0985606,0.5591284,0.0000453607,0.00087060645,0.0020079897],"about_ca_topic_score_codex":0.00023033668,"about_ca_topic_score_gemma":0.0000027912688,"teacher_disagreement_score":0.41332892,"about_ca_system_score_codex":0.0010878886,"about_ca_system_score_gemma":0.003506067,"threshold_uncertainty_score":0.9997465},"labels":[],"label_agreement":null},{"id":"W4312129123","doi":"10.1016/j.leukres.2022.107002","title":"Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Myeloid leukemia; Internal medicine; Medicine; Trisomy 8; Myeloid; Gastroenterology; Philadelphia chromosome; Oncology; Cytogenetics; Chromosome; Chromosomal translocation; Gene; Biology; Genetics","score_opus":0.027602650302154672,"score_gpt":0.3254544267275147,"score_spread":0.29785177642536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312129123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98975325,0.00035898414,0.0004159619,0.0032092007,0.0001552327,0.0020911659,0.0003231389,0.00012322492,0.0035698486],"genre_scores_gemma":[0.99376184,0.00053217995,0.0006093163,0.00057558634,0.00031506552,0.0007079887,0.0009344521,0.00017802801,0.0023855455],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99153286,0.0011431781,0.00085805857,0.0010773925,0.0038562277,0.001532299],"domain_scores_gemma":[0.99640894,0.00032033876,0.00016537684,0.0014212256,0.0011154686,0.0005686291],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001966189,0.00040743963,0.00081006606,0.0014408831,0.00072346895,0.00006706845,0.0010523121,0.00026580886,0.0019154346],"category_scores_gemma":[0.00029156526,0.00042375806,0.00030316098,0.0033825138,0.00071206695,0.00020832988,0.0016419132,0.0030911916,0.00021176123],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0013615162,0.00017644274,0.0009455298,0.0002070537,0.0004263979,0.0020288732,0.00071016117,0.00035397825,0.9871878,0.0005981682,0.0023038571,0.0037002186],"study_design_scores_gemma":[0.008567113,0.00419983,0.066936046,0.00022495101,0.00029618546,0.0019114417,0.0008802834,0.018688153,0.87975204,0.00046734157,0.017207729,0.00086890336],"about_ca_topic_score_codex":0.00045882768,"about_ca_topic_score_gemma":0.0000037201726,"teacher_disagreement_score":0.10743578,"about_ca_system_score_codex":0.011780618,"about_ca_system_score_gemma":0.0071135843,"threshold_uncertainty_score":0.9998214},"labels":[],"label_agreement":null},{"id":"W4312156831","doi":"10.1016/j.jtct.2022.12.013","title":"An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Hematopoietic stem cell transplantation; Medicine; Myeloid leukemia; Transplantation; Incidence (geometry); Disease; Disease burden; Internal medicine; Immunology","score_opus":0.023644774512006722,"score_gpt":0.29340580692847884,"score_spread":0.2697610324164721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312156831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664546,0.0004590967,0.031602263,0.00013391307,0.000042615968,0.0008296294,0.0003359953,0.000020939984,0.000120893936],"genre_scores_gemma":[0.9953084,0.0028836003,0.00026247377,0.00015408586,0.0000114912955,0.0000892592,0.00097285287,0.000024166167,0.00029368876],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985786,0.00019468501,0.0003962064,0.00024384895,0.0004257271,0.00016095089],"domain_scores_gemma":[0.9992727,0.00010147737,0.0001807401,0.00027779458,0.00010222104,0.00006506531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037100873,0.0001354086,0.00035453148,0.00031720707,0.00017657867,0.000009009731,0.00015868124,0.000054849676,0.00012783273],"category_scores_gemma":[7.024603e-7,0.00010697101,0.00020637446,0.00085568306,0.00008048631,0.00007577255,0.000005216881,0.00014097664,2.7704502e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046197097,0.00024920868,0.01049275,0.00068504835,0.0010722028,0.000014989604,0.01600303,0.0040737386,0.9526646,0.00082814175,0.000016560563,0.009279987],"study_design_scores_gemma":[0.00542126,0.0006749868,0.03528252,0.000029490835,0.0036946961,0.000033922246,0.0019298127,0.022624187,0.929862,0.0000735255,0.0002119581,0.00016163177],"about_ca_topic_score_codex":0.0000616548,"about_ca_topic_score_gemma":0.000018765504,"teacher_disagreement_score":0.031339787,"about_ca_system_score_codex":0.000090610774,"about_ca_system_score_gemma":0.00017058029,"threshold_uncertainty_score":0.43621513},"labels":[],"label_agreement":null},{"id":"W4313148439","doi":"10.1016/j.exphem.2022.07.270","title":"3214 – DNMT3A R882 MUTATION IN HUMAN HAEMATOPOIETIC STEM CELLS ALTERS DIFFERENTIATION TOWARDS NEUTROPHILS AND MONOCYTES","year":2022,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Canada","funders":"","keywords":"Haematopoiesis; Biology; Myeloid; Stem cell; Monocyte; Mutation; CD33; Phenotype; Somatic cell; Immunology; Genetics; Cancer research; CD34; Gene","score_opus":0.02506508115797824,"score_gpt":0.3181022654254217,"score_spread":0.29303718426744346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313148439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952671,0.0025789794,0.000046981873,0.0007199437,0.00017609628,0.0006917893,0.0000064929563,0.000057117202,0.0004555154],"genre_scores_gemma":[0.9988092,0.000019583935,0.00015933748,0.00032714359,0.00002899237,0.00033514958,0.00006531429,0.000034827186,0.00022043835],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99834216,0.0002085855,0.00036767876,0.00041584784,0.0003050874,0.0003606279],"domain_scores_gemma":[0.999468,0.000055200624,0.00009525509,0.00023998402,0.000021201675,0.000120352204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014999374,0.00018380754,0.0004321007,0.00030789955,0.00019665548,0.000018868966,0.000120915334,0.00007779897,0.00036159894],"category_scores_gemma":[0.0000044318103,0.00018874688,0.000058417005,0.00020036318,0.00012694544,0.000090509086,0.0002889274,0.00032838646,0.000016670692],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092097936,0.0016609952,0.011483784,0.00040304894,0.00015017054,0.0022840607,0.010997622,0.00008427258,0.9393545,0.028506944,0.0019636098,0.0021900516],"study_design_scores_gemma":[0.0037149352,0.000967679,0.0029968305,0.000027406537,0.000020637697,0.0012624536,0.0074738762,0.0022339053,0.9807503,0.00021938706,0.00013806728,0.00019447021],"about_ca_topic_score_codex":0.00013324163,"about_ca_topic_score_gemma":0.0000047994145,"teacher_disagreement_score":0.041395888,"about_ca_system_score_codex":0.0006219719,"about_ca_system_score_gemma":0.00007202802,"threshold_uncertainty_score":0.7696875},"labels":[],"label_agreement":null},{"id":"W4313313134","doi":"10.1038/s43018-022-00486-8","title":"DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression","year":2022,"lang":"en","type":"article","venue":"Nature Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"National Center for Advancing Translational Sciences; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Heart, Lung, and Blood Institute; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; Government of Canada; MPN Research Foundation; Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Cancer research; Myeloid leukemia; PTEN; Janus kinase; DUSP6; Biology; Kinase; Myeloid; Signal transduction; Phosphatase; PI3K/AKT/mTOR pathway; Cell biology; Protein phosphatase 2; Phosphorylation","score_opus":0.008970861050342492,"score_gpt":0.32904230903919623,"score_spread":0.32007144798885373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313313134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9538381,0.019352138,0.000008461553,0.023864748,0.0002961719,0.0007558352,0.000069645685,0.0000895899,0.001725305],"genre_scores_gemma":[0.98784196,0.00065954955,0.001039507,0.0039031769,0.00044113357,0.00054381526,0.00006245811,0.000034654262,0.005473763],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984664,0.00006692768,0.00014697172,0.0003893643,0.0006292618,0.00030108672],"domain_scores_gemma":[0.9993297,0.00006865841,0.000052590367,0.00022295395,0.00012311534,0.0002030005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024886936,0.00013373449,0.00020305032,0.00017929735,0.00022455715,0.00001783029,0.00009184009,0.00015551184,0.00045477075],"category_scores_gemma":[0.00018070068,0.00011243819,0.000035969035,0.000509245,0.00007229475,0.000072505085,0.00021791406,0.0013128333,0.00000920285],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030785636,0.00012057189,0.02425833,0.00044746327,0.00010484219,0.0004330162,0.0024796687,0.00003770465,0.3329795,0.0012292523,0.5990476,0.035783485],"study_design_scores_gemma":[0.0046722577,0.00058545405,0.08074208,0.00069155375,0.000094382405,0.00011393545,0.0008392813,0.00017519713,0.09045756,0.0006585476,0.8204816,0.000488175],"about_ca_topic_score_codex":0.000018728417,"about_ca_topic_score_gemma":0.000066403176,"teacher_disagreement_score":0.24252193,"about_ca_system_score_codex":0.0011479883,"about_ca_system_score_gemma":0.00044423752,"threshold_uncertainty_score":0.57036805},"labels":[],"label_agreement":null},{"id":"W4313523467","doi":"10.14740/jh1042","title":"Acute Myeloid Leukemia Following Myeloproliferative Neoplasms: A Review of What We Know, What We Do Not Know, and Emerging Treatment Strategies","year":2022,"lang":"en","type":"review","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Myeloproliferative neoplasm; Medicine; Myeloid leukemia; Leukemia; Myeloproliferative Disorders; Myeloid; Incidence (geometry); Oncology; Immunology; Myelofibrosis; Bone marrow","score_opus":0.04391084671987824,"score_gpt":0.37739219097015286,"score_spread":0.33348134425027465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313523467","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021720538,0.9913796,0.000022621618,0.005015377,0.0011957911,0.0019237803,0.000023422626,0.000027203847,0.00019495447],"genre_scores_gemma":[0.00001616257,0.99720144,0.0011712505,0.00033775443,0.00032607323,0.0002107465,0.00006185996,0.00015905936,0.0005156221],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923062,0.0012390394,0.003508279,0.00078807387,0.0012446921,0.00091371505],"domain_scores_gemma":[0.99331725,0.0017797559,0.0031400062,0.00082187465,0.0004316722,0.00050941936],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016731211,0.0011395714,0.009594815,0.0013192474,0.00024255835,0.00026772777,0.0006681978,0.0006134722,0.0008596995],"category_scores_gemma":[0.0004229802,0.0007829634,0.002290269,0.00097316323,0.000299854,0.0016560261,0.0004613466,0.0024051678,0.000026835609],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026730515,0.00014333775,0.0000035364803,0.0974425,0.006108784,0.006622147,0.0011650043,9.865261e-7,0.000016414213,0.00042875862,0.0022673423,0.88553387],"study_design_scores_gemma":[0.0018109495,0.0015423764,2.6241014e-7,0.26223266,0.006395123,0.03518791,0.0048771347,0.000008249368,0.00006926317,0.00009123839,0.68741864,0.0003662157],"about_ca_topic_score_codex":0.00001038309,"about_ca_topic_score_gemma":0.000006976452,"teacher_disagreement_score":0.88516766,"about_ca_system_score_codex":0.0029592444,"about_ca_system_score_gemma":0.009652055,"threshold_uncertainty_score":0.99989635},"labels":[],"label_agreement":null},{"id":"W4313537617","doi":"10.1159/000528184","title":"On Behalf of the SFGM-TC: Prophylactic Donor Lymphocyte Infusion in Patients Treated with Allogeneic Stem-Cell Transplantation for High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia","year":2023,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Internal medicine; Donor lymphocyte infusion; Hematopoietic stem cell transplantation; Univariate analysis; Transplantation; Myelodysplastic syndromes; Myeloid leukemia; Oncology; Cumulative incidence; Gastroenterology; Incidence (geometry); Multivariate analysis; Bone marrow","score_opus":0.01041800617735249,"score_gpt":0.23428517201375104,"score_spread":0.22386716583639854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313537617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99670625,0.000030912488,0.000016960508,0.00023373794,0.000055032513,0.0026583583,0.00014474684,0.00008629829,0.00006769165],"genre_scores_gemma":[0.99844104,0.00046635678,0.00017943175,0.000079039106,0.00000810442,0.0003088624,0.00019638884,0.000050629165,0.00027012985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775875,0.00019217774,0.0004921291,0.0005463667,0.00050299615,0.00050756685],"domain_scores_gemma":[0.99824995,0.0007057876,0.00031202813,0.0004559574,0.00014703973,0.00012924326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027095326,0.00032664463,0.0006805611,0.00036290052,0.00017635558,0.000020717282,0.00024658997,0.00026011156,0.000014665153],"category_scores_gemma":[0.00010786199,0.0001867907,0.00008236323,0.00086590514,0.00020305504,0.0001116517,0.000086982014,0.00032896234,0.000019220577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036419474,0.0012558763,0.9020106,0.0048428066,0.0008036995,0.0023925223,0.0020908264,0.00048681122,0.035789702,0.00030214744,0.00062425423,0.012981276],"study_design_scores_gemma":[0.014169838,0.006400249,0.9490291,0.00045099857,0.0006409076,0.00040821353,0.00010166148,0.0007521674,0.027640332,0.00009400398,0.000020680629,0.00029186622],"about_ca_topic_score_codex":0.00026994525,"about_ca_topic_score_gemma":0.00006664091,"teacher_disagreement_score":0.047018476,"about_ca_system_score_codex":0.00047909722,"about_ca_system_score_gemma":0.00035035625,"threshold_uncertainty_score":0.76171035},"labels":[],"label_agreement":null},{"id":"W4313575780","doi":"10.1080/10428194.2022.2156793","title":"The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Bristol-Myers Squibb (Canada); Dalhousie University; Hamilton Health Sciences; McGill University Health Centre; University of Ottawa; Dr. Georges-L.-Dumont University Hospital Centre; St. Paul's Hospital; University of British Columbia; Health Sciences Centre; CancerCare Manitoba; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"Genentech; Otsuka Pharmaceutical; Astellas Pharma; Jazz Pharmaceuticals; Astex Pharmaceuticals; Taiho Pharmaceutical; F. Hoffmann-La Roche; Alexion Pharmaceuticals; Janssen Pharmaceuticals; Gilead Sciences; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Myelodysplastic syndromes; Blood transfusion; Anemia; International Prognostic Scoring System; Internal medicine; Quality of life (healthcare); Pediatrics; Bone marrow","score_opus":0.005771964666928705,"score_gpt":0.21999720375555107,"score_spread":0.21422523908862237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313575780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974286,0.0002679224,0.000010986603,0.00022391527,0.0000790512,0.0012102012,0.00016273216,0.00009136424,0.0005252334],"genre_scores_gemma":[0.9981401,0.0007816258,0.000117012634,0.000035170357,0.00006059686,0.000105358784,0.000057692516,0.00009342548,0.00060900586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99575984,0.0003276152,0.00091322133,0.0009854449,0.0011266785,0.00088718825],"domain_scores_gemma":[0.99644953,0.00088835414,0.0005538945,0.00139521,0.0003439722,0.00036905264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067910284,0.00056422775,0.0011939501,0.0007868298,0.0006356843,0.00009925056,0.0005864437,0.0003501597,0.000015562773],"category_scores_gemma":[0.00039686498,0.00035254197,0.0002697904,0.0038859728,0.0013170874,0.00020340172,0.00033774925,0.00035244809,0.0000022899403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038696588,0.0004946814,0.96557146,0.00061582495,0.0027151885,0.00025541775,0.00717794,0.0037447466,0.005460673,0.00019407514,0.00017647402,0.009723834],"study_design_scores_gemma":[0.01853231,0.0010630247,0.94645226,0.0004874208,0.002579548,0.00008184065,0.0032375932,0.024003739,0.0029897457,0.0000962102,0.000091095746,0.00038523212],"about_ca_topic_score_codex":0.005328476,"about_ca_topic_score_gemma":0.0011309915,"teacher_disagreement_score":0.020258991,"about_ca_system_score_codex":0.0024142212,"about_ca_system_score_gemma":0.0028111623,"threshold_uncertainty_score":0.99989265},"labels":[],"label_agreement":null},{"id":"W4313897364","doi":"10.1016/j.modpat.2022.100068","title":"A Lower Frequency of Spliceosome Mutations Distinguishes Clonal Cytopenias of Undetermined Significance From Low-Risk Myelodysplastic Syndromes, Despite Inherent Similarities in Genomic, Laboratory, and Clinical Features","year":2023,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Queen's University","funders":"","keywords":"Myelodysplastic syndromes; Clinical significance; Dysplasia; Myeloproliferative neoplasm; Medicine; Myeloid; Somatic evolution in cancer; Internal medicine; Oncology; Bone marrow; Cancer; Myelofibrosis","score_opus":0.03088262239070731,"score_gpt":0.32212099484817913,"score_spread":0.2912383724574718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313897364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969116,0.0006148993,0.00042821158,0.00025411215,0.00014788267,0.0005168639,0.0010136166,0.000048041245,0.000064770706],"genre_scores_gemma":[0.9965813,0.00035682012,0.002512015,0.000081053804,0.000079669975,0.000063443964,0.00016163479,0.000042626107,0.00012143566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759376,0.00036470004,0.00081711414,0.0005652451,0.00027013948,0.00038905075],"domain_scores_gemma":[0.99748486,0.0014586151,0.00027416548,0.0004455453,0.0001915061,0.00014530415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059525244,0.00022148529,0.00082742976,0.0003192382,0.000053368974,0.000012756535,0.00020518411,0.0002925173,0.00004449865],"category_scores_gemma":[0.001675913,0.00020693376,0.00009726653,0.00037678113,0.0007901741,0.000062784464,0.00019446055,0.00061528216,0.000014097956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008932153,0.0004610742,0.888446,0.00042018632,0.00022572502,0.0039407993,0.002232982,0.0003450574,0.09858364,0.00020046213,0.00018401077,0.004066882],"study_design_scores_gemma":[0.0025876118,0.0005908824,0.9847055,0.00018969376,0.00013147086,0.00006351946,0.0001990666,0.0064266324,0.0010941564,0.0038158074,0.000014101126,0.00018152317],"about_ca_topic_score_codex":0.0004927186,"about_ca_topic_score_gemma":0.0006998328,"teacher_disagreement_score":0.097489476,"about_ca_system_score_codex":0.00013041381,"about_ca_system_score_gemma":0.0005260119,"threshold_uncertainty_score":0.8438514},"labels":[],"label_agreement":null},{"id":"W4315782895","doi":"10.1007/s00277-022-05071-8","title":"Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study","year":2023,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences; Acceleron; Bristol-Myers Squibb","keywords":"Medicine; Myelodysplastic syndromes; Blood transfusion; Internal medicine; Serum ferritin; Anemia; Placebo; Ferritin; Hemoglobin; Surgery; Bone marrow","score_opus":0.03680524295353615,"score_gpt":0.34079650312235943,"score_spread":0.3039912601688233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315782895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980774,0.00015479083,0.000008271291,0.00075149396,0.00002190569,0.0008258382,0.000057315567,0.0000135790015,0.00008942139],"genre_scores_gemma":[0.9994954,0.00022091245,0.000019500036,0.00010193138,0.0000067002766,0.000041960873,0.000066971064,0.000019050533,0.00002758097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980201,0.00025470578,0.00063072244,0.00027051027,0.0004839449,0.00034000442],"domain_scores_gemma":[0.99794734,0.0004600033,0.00043016364,0.0006499182,0.00046415158,0.0000484408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010491372,0.00015554523,0.0011453187,0.00076862704,0.000023027682,0.0000037694685,0.0003159748,0.000100159115,0.000070005466],"category_scores_gemma":[0.00027178423,0.000092398564,0.00018806229,0.0019220426,0.00022421936,0.000041419644,0.00008889241,0.00023204315,0.0000023011062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00153516,0.0009316935,0.9863797,0.000073345225,0.0020750395,0.00004323196,0.005021035,0.000027493457,0.0014167676,0.00005578668,0.00022279796,0.002217951],"study_design_scores_gemma":[0.0036905657,0.002686598,0.9746896,0.000050123224,0.0005515339,0.0000028688205,0.0032738636,0.0008712273,0.014016834,0.000045372577,0.000025125988,0.000096265634],"about_ca_topic_score_codex":0.001136517,"about_ca_topic_score_gemma":0.0007901714,"teacher_disagreement_score":0.012600067,"about_ca_system_score_codex":0.000010979473,"about_ca_system_score_gemma":0.000057413963,"threshold_uncertainty_score":0.3767904},"labels":[],"label_agreement":null},{"id":"W4316506860","doi":"10.1038/s44161-022-00206-6","title":"TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease","year":2023,"lang":"en","type":"article","venue":"Nature Cardiovascular Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vector Institute","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Instituto de Salud Carlos III; National Institutes of Health; Agencia Estatal de Investigación; European Research Area Network on Cardiovascular Diseases; Knut och Alice Wallenbergs Stiftelse; American Heart Association; Fundación BBVA; University of Pennsylvania; Medical Research Council; Celgene; National Institute of General Medical Sciences; Ministerio de Ciencia e Innovación; Massachusetts General Hospital; Novo Nordisk; European Social Fund; Fondation Leducq; European Regional Development Fund; European Commission; Alexander and Margaret Stewart Trust; Banco Bilbao Vizcaya Argentaria; U.S. Department of Veterans Affairs","keywords":"Haematopoiesis; Disease; Atherosclerotic cardiovascular disease; Medicine; Immunology; Biology; Internal medicine; Genetics; Stem cell","score_opus":0.04792986906070916,"score_gpt":0.362481284601952,"score_spread":0.31455141554124283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316506860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769667,0.0109006865,0.00039767133,0.0032609478,0.00031172708,0.0060939617,0.00059998746,0.00061294186,0.0008553734],"genre_scores_gemma":[0.992042,0.0022563296,0.00044941786,0.00030065278,0.00094678014,0.0013872049,0.0011828252,0.00020704414,0.0012277697],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9902111,0.0013485715,0.00047930496,0.001227257,0.0049223914,0.0018113166],"domain_scores_gemma":[0.9917215,0.0023894827,0.00006921155,0.0021059513,0.0022516237,0.001462243],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011805855,0.00040710013,0.001038339,0.001369781,0.00066949724,0.00014461778,0.00071137794,0.000779644,0.00017510651],"category_scores_gemma":[0.02037148,0.0003501518,0.0019449961,0.0032343362,0.0005863246,0.00014465244,0.0005620657,0.0038847013,0.0010447367],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021827523,0.0016928884,0.17449395,0.010058435,0.040337294,0.015073429,0.00177923,0.0012280424,0.025188465,0.0044605094,0.66055375,0.043306455],"study_design_scores_gemma":[0.020945013,0.000750886,0.62565494,0.00067339523,0.0019029998,0.0001757427,0.0012459367,0.013575282,0.005392662,0.001787412,0.32675827,0.0011374658],"about_ca_topic_score_codex":0.00045608878,"about_ca_topic_score_gemma":0.000018124369,"teacher_disagreement_score":0.45116097,"about_ca_system_score_codex":0.0012173044,"about_ca_system_score_gemma":0.002226464,"threshold_uncertainty_score":0.99989504},"labels":[],"label_agreement":null},{"id":"W4317356542","doi":"10.1182/blood.2022018825","title":"A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Impact; Queen's University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute for Occupational Safety and Health; Medical Research Council; Canadian Institutes of Health Research; National Cancer Institute; Ludwig Center at Harvard; National Institutes of Health; Alexander and Margaret Stewart Trust; Vanderbilt University Medical Center; Vanderbilt University","keywords":"Exome; Biology; Exome sequencing; Population; Genetics; Biobank; Germline; DNA microarray; Computational biology; Medicine; Mutation; Gene","score_opus":0.04406056898626023,"score_gpt":0.36075093180581763,"score_spread":0.3166903628195574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317356542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975104,0.000016943024,0.00016717185,0.0006878321,0.0000216926,0.000517413,0.00011697908,0.00004511695,0.0009165038],"genre_scores_gemma":[0.99129343,0.000011937335,0.0078544505,0.000106334795,0.00009611265,0.00007450197,0.00032283322,0.000029842067,0.00021056816],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998284,0.00009306685,0.0003489666,0.0003496305,0.00050881575,0.00041556355],"domain_scores_gemma":[0.9991687,0.000065126886,0.000057450405,0.00044984158,0.000056475383,0.0002024207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003914623,0.00013096108,0.00032479712,0.00040686774,0.00004021119,0.00001575192,0.00017432147,0.00010877594,0.0000507183],"category_scores_gemma":[0.00026003906,0.00011976188,0.000058353075,0.0007536556,0.00008251478,0.000065304026,0.00029848726,0.000326882,0.00012494244],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015574769,0.011480948,0.063367516,0.0032709814,0.000932597,0.01897938,0.0025577494,0.00022267221,0.80007267,0.00194187,0.09134622,0.0042699035],"study_design_scores_gemma":[0.02582074,0.001965785,0.7666299,0.00047799834,0.00077996793,0.0037130483,0.0012440747,0.009662008,0.18476136,0.00063898956,0.0033627048,0.0009434465],"about_ca_topic_score_codex":0.00012253188,"about_ca_topic_score_gemma":0.000009866763,"teacher_disagreement_score":0.7032624,"about_ca_system_score_codex":0.000047910442,"about_ca_system_score_gemma":0.00023474343,"threshold_uncertainty_score":0.48837477},"labels":[],"label_agreement":null},{"id":"W4317359908","doi":"10.1073/pnas.2208176120","title":"Distinct and opposite effects of leukemogenic <i>Idh</i> and <i>Tet2</i> mutations in hematopoietic stem and progenitor cells","year":2023,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Weill Cornell Medical College; Hospital for Sick Children; University of Hong Kong; Memorial Sloan-Kettering Cancer Center; University of Toronto; Leukemia and Lymphoma Society; AstraZeneca","keywords":"IDH2; Biology; IDH1; Isocitrate dehydrogenase; Haematopoiesis; Epigenetics; DNA methylation; Myeloid; Progenitor cell; Stem cell; Cancer research; Myeloid leukemia; Genetics; Mutation; Molecular biology; Cell biology; Gene; Gene expression; Enzyme; Biochemistry","score_opus":0.02818019627237623,"score_gpt":0.30748520272064994,"score_spread":0.2793050064482737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317359908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683493,0.0004915076,2.4231713e-7,0.0018292239,0.000008143292,0.00048339026,0.000010170401,0.000009647814,0.00033273402],"genre_scores_gemma":[0.9992052,0.00016971816,0.00037307024,0.00006095915,0.000021062504,0.000022281327,1.9447647e-7,0.0000053083227,0.00014225318],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985949,0.000009848786,0.00027589314,0.00022867325,0.00073451025,0.0001562124],"domain_scores_gemma":[0.99917907,0.00042526028,0.0001757526,0.000009126107,0.00014612511,0.00006467686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009110407,0.00008578888,0.00021725507,0.00027715595,0.000097163516,0.000015397512,0.00017873979,0.000066203946,8.394304e-7],"category_scores_gemma":[0.00030993734,0.00005862166,0.000029260085,0.001036518,0.00112924,0.00018727446,0.00019856423,0.00015960749,5.1865413e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034690667,0.000028955896,0.061554026,0.0013914915,0.000019942207,1.8411762e-7,0.0006955277,0.0000026896346,0.933875,0.0015276743,0.00017497041,0.00069481455],"study_design_scores_gemma":[0.0008284439,0.00013148361,0.24530238,0.00038933955,0.000037367354,0.000054886164,0.00036685218,0.0014559539,0.74753743,0.0038038758,0.00002536629,0.000066636196],"about_ca_topic_score_codex":0.00000769074,"about_ca_topic_score_gemma":1.2950431e-7,"teacher_disagreement_score":0.18633762,"about_ca_system_score_codex":0.000037999776,"about_ca_system_score_gemma":0.00007764219,"threshold_uncertainty_score":0.4160732},"labels":[],"label_agreement":null},{"id":"W4318033676","doi":"10.4143/crt.2022.1407","title":"Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia","year":2023,"lang":"en","type":"article","venue":"Cancer Research and Treatment","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Ministry of Science and ICT, South Korea; National Research Foundation of Korea; Chonnam National University; Ministry of Health and Welfare; National Research Foundation; Chonnam National University Hwasun Hospital; Mike and Josie Harper Cancer Research Institute","keywords":"CEBPA; Medicine; Karyotype; Myeloid leukemia; Cancer research; Internal medicine; Genetics; Mutation; Chromosome; Biology; Gene","score_opus":0.11177764165426278,"score_gpt":0.44979739322372125,"score_spread":0.33801975156945846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318033676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928422,0.0012161833,0.0000035167868,0.002200922,0.000095366515,0.0014614795,0.00009865687,0.00006757487,0.0020141136],"genre_scores_gemma":[0.96605325,0.024155354,0.00017019127,0.000066934386,0.00021984184,0.00064110395,0.00011190882,0.000045555098,0.008535859],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996736,0.0002745183,0.00055901636,0.0006422294,0.0007619736,0.0010262814],"domain_scores_gemma":[0.99777687,0.0007220527,0.00007007723,0.00052891875,0.00036018586,0.0005419018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012170533,0.0002247329,0.0006450966,0.0006112557,0.00011994829,0.00002580863,0.00019977144,0.00020607884,0.00021903918],"category_scores_gemma":[0.00021077538,0.00017182714,0.00011979248,0.00171686,0.00076616864,0.00009880438,0.0001986409,0.0007606551,0.00017499528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015792474,0.0010468593,0.65567917,0.00042145062,0.00182996,0.005595765,0.0013959894,0.00007760087,0.02741025,0.00041566798,0.01519177,0.27514303],"study_design_scores_gemma":[0.03211428,0.012159698,0.8921332,0.0005400449,0.00019535652,0.000087079934,0.0012298382,0.002353823,0.04156912,0.00073185464,0.016417228,0.00046849847],"about_ca_topic_score_codex":0.003543707,"about_ca_topic_score_gemma":0.0005012339,"teacher_disagreement_score":0.27467453,"about_ca_system_score_codex":0.001977656,"about_ca_system_score_gemma":0.0029286167,"threshold_uncertainty_score":0.70069075},"labels":[],"label_agreement":null},{"id":"W4318619600","doi":"10.1038/s41375-023-01833-z","title":"KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition","year":2023,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Science and Engineering Research Board; Canadian Cancer Society Research Institute; Israel Science Foundation; Indian Council of Medical Research; Varda and Boaz Dotan Research Center for Hemato-Oncology Research, Tel Aviv University; Council of Scientific and Industrial Research, India; Department of Biotechnology, Ministry of Science and Technology, India","keywords":"Synthetic lethality; Cancer research; Myeloid leukemia; DNA repair; Poly ADP ribose polymerase; Biology; NPM1; Leukemia; DNA damage; Histone; Epigenetics; Daunorubicin; Gene; Immunology; Genetics; DNA; Polymerase","score_opus":0.02156514824758506,"score_gpt":0.29873715392631883,"score_spread":0.2771720056787338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318619600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963472,0.00016652435,0.00021269447,0.0011697605,0.00008763906,0.0008404237,0.00007311036,0.00046057883,0.00064210594],"genre_scores_gemma":[0.9924027,0.0005734275,0.0027006804,0.0005348533,0.0003282973,0.00006221444,0.00039770725,0.000089609406,0.0029105137],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970736,0.00018704314,0.0006923158,0.0007942116,0.0006134594,0.00063939794],"domain_scores_gemma":[0.99811214,0.0002817392,0.00018577457,0.000628991,0.00035179427,0.000439576],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089326507,0.00038222823,0.00072910584,0.00072576775,0.00023702843,0.00004889948,0.00010198862,0.0003276805,0.000050383893],"category_scores_gemma":[0.00040324486,0.0003511944,0.00013881353,0.0011203255,0.00039800577,0.00023014753,0.00034423626,0.0004911805,0.000085492684],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065769936,0.000022362272,0.005683612,0.00038512598,0.00027597306,0.000624869,0.001348314,0.00008294142,0.96984875,0.0006575429,0.014815276,0.0055975053],"study_design_scores_gemma":[0.005678269,0.0013502573,0.23027942,0.00071710086,0.00048442444,0.0008974164,0.0010340656,0.007608981,0.7461253,0.0020327405,0.0030716665,0.0007203939],"about_ca_topic_score_codex":0.0005516763,"about_ca_topic_score_gemma":0.00012527689,"teacher_disagreement_score":0.2245958,"about_ca_system_score_codex":0.0014773224,"about_ca_system_score_gemma":0.00062493427,"threshold_uncertainty_score":0.999894},"labels":[],"label_agreement":null},{"id":"W4318762955","doi":"10.1182/bloodadvances.2022009411","title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory <i>IDH1</i>-mutated AML","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Refractory (planetary science); Medicine; Internal medicine; IDH1; Oncology; Gastroenterology; Cancer research; Mutation; Biology; Genetics; Gene","score_opus":0.025514762728362655,"score_gpt":0.29738237339112256,"score_spread":0.2718676106627599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318762955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951952,0.00043123116,0.000003751919,0.0011515812,0.00010460997,0.0008928885,0.000070542206,0.00032403253,0.0018261654],"genre_scores_gemma":[0.992395,0.00072994834,0.0014109737,0.0003864503,0.00010872971,0.000114244096,0.000368957,0.00008865864,0.004397045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970257,0.00013829466,0.0004994891,0.00062245625,0.000912157,0.0008018548],"domain_scores_gemma":[0.99824566,0.0004441883,0.0001764793,0.0005574718,0.00023908782,0.00033709602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034370576,0.00030762787,0.00057115447,0.0004758352,0.00020381647,0.000035567602,0.00031975363,0.00015175642,0.00019445892],"category_scores_gemma":[0.00081619516,0.00020692474,0.000058757625,0.0020404388,0.0001917868,0.00047044698,0.0001493884,0.0007578497,0.00022297107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014095416,0.003343356,0.8024785,0.0011221329,0.00074398157,0.005076439,0.0022117854,0.00071052974,0.12472897,0.00007953636,0.025661858,0.019747527],"study_design_scores_gemma":[0.037580665,0.00449693,0.8340235,0.002127628,0.00028601597,0.000106055755,0.0017358384,0.00023837303,0.02453924,0.0002923863,0.093527146,0.001046222],"about_ca_topic_score_codex":0.00012716568,"about_ca_topic_score_gemma":0.00014097584,"teacher_disagreement_score":0.10018973,"about_ca_system_score_codex":0.00019870464,"about_ca_system_score_gemma":0.00057023217,"threshold_uncertainty_score":0.8438146},"labels":[],"label_agreement":null},{"id":"W4318763628","doi":"10.1182/blood.2022018604","title":"Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Associazione Italiana per la Ricerca sul Cancro; Cancer Research UK; Yale University; Leukemia and Lymphoma Society","keywords":"Medicine; Myelodysplastic syndromes; Clinical trial; International Prognostic Scoring System; Delphi method; Intensive care medicine; Internal medicine; Statistics","score_opus":0.05115591448008695,"score_gpt":0.3500419484903222,"score_spread":0.2988860340102353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318763628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856236,0.00012835427,0.0006916591,0.009059519,0.00097327866,0.0024937976,0.0002912956,0.00035030927,0.00038820706],"genre_scores_gemma":[0.9608193,0.000058831032,0.026829302,0.00020575839,0.0010927714,0.00087123964,0.0003106968,0.00010864687,0.0097034285],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99821216,0.00014875516,0.00034849698,0.0004304908,0.00035746448,0.0005026121],"domain_scores_gemma":[0.99684894,0.0023472337,0.00010977327,0.00030396035,0.00022976496,0.0001603064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001423676,0.00018576249,0.00033240384,0.00032850032,0.00015810145,0.00006388759,0.0002072542,0.00013570928,0.00014104479],"category_scores_gemma":[0.003348941,0.00016259712,0.00016617822,0.00033487426,0.00010459267,0.000036670204,0.00010431425,0.00022350752,0.00010841581],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11208534,0.0023169708,0.053302996,0.0030457857,0.0055800346,0.0030945032,0.0013861144,0.000025963132,0.3965266,0.00921682,0.39440018,0.019018702],"study_design_scores_gemma":[0.112493865,0.007294154,0.31254527,0.002639486,0.002987723,0.001418265,0.000619939,0.020336803,0.015840916,0.0072315503,0.51497006,0.001621947],"about_ca_topic_score_codex":0.000006585553,"about_ca_topic_score_gemma":0.0000028774164,"teacher_disagreement_score":0.3806857,"about_ca_system_score_codex":0.0001406546,"about_ca_system_score_gemma":0.0004065452,"threshold_uncertainty_score":0.66305184},"labels":[],"label_agreement":null},{"id":"W4318915833","doi":"10.3324/haematol.2022.281806","title":"Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from a 13-year follow-up","year":2023,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Hematopoietic stem cell transplantation; Transplantation; Medicine; Haematopoiesis; Internal medicine; Stem cell; Oncology; Minimal residual disease; Myeloid leukemia; Myeloid; Malignancy; Immunology; Gastroenterology; Leukemia; Biology; Genetics","score_opus":0.04714548301508147,"score_gpt":0.31095091825305016,"score_spread":0.2638054352379687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318915833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914191,0.00022061371,0.00007169552,0.00493167,0.0003845376,0.0014906784,0.0001295493,0.00035751789,0.0009946491],"genre_scores_gemma":[0.99583113,0.00024096834,0.000390673,0.0009885536,0.00007160652,0.00039119914,0.0002836659,0.00006385791,0.0017383178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956392,0.0005436633,0.0008201969,0.0008803171,0.00116839,0.0009482505],"domain_scores_gemma":[0.9963218,0.002277178,0.00018096411,0.00093233766,0.00007157243,0.00021613041],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011603319,0.0005036147,0.001219084,0.00038179907,0.0002836729,0.00009842683,0.0007543578,0.0003804792,0.0002646438],"category_scores_gemma":[0.00016627785,0.00028400353,0.00066539855,0.0010043045,0.00017130729,0.00016369532,0.00015562876,0.0006893819,0.00089237955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00149008,0.00027011806,0.9577713,0.0010984773,0.00042219,0.022551874,0.007818686,0.000012241411,0.00546291,0.00036036482,0.0023381861,0.000403601],"study_design_scores_gemma":[0.010965447,0.00030304838,0.9563249,0.00057831506,0.00057933416,0.0005702194,0.005825064,0.000056999572,0.023677811,0.00031587057,0.00015090272,0.00065210694],"about_ca_topic_score_codex":0.00021824325,"about_ca_topic_score_gemma":0.0005279391,"teacher_disagreement_score":0.021981653,"about_ca_system_score_codex":0.00017558214,"about_ca_system_score_gemma":0.00022360051,"threshold_uncertainty_score":0.9999612},"labels":[],"label_agreement":null},{"id":"W4318918842","doi":"10.1182/blood.2022018787","title":"DDX41: the poster child for familial MDS/AML grows up","year":2023,"lang":"en","type":"letter","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Hematologic Neoplasms; Pediatrics; Internal medicine; Transplantation","score_opus":0.031524114970605484,"score_gpt":0.2933775588121621,"score_spread":0.2618534438415566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318918842","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040812134,0.0003776767,0.000023338855,0.97940826,0.0015621559,0.0031472284,0.0005870622,0.00028496748,0.01052807],"genre_scores_gemma":[0.0011004217,0.00020005621,0.00016417907,0.8297521,0.036960382,0.00084656576,0.0023500994,0.00042271297,0.12820351],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99679774,0.00011563338,0.00043147505,0.0007184724,0.0009261733,0.001010525],"domain_scores_gemma":[0.99764204,0.00065338047,0.00012765748,0.0012389862,0.00021323988,0.00012471295],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046709934,0.00046517595,0.000679803,0.00026271457,0.00024570513,0.00007726425,0.0007242089,0.0010929557,0.0001647693],"category_scores_gemma":[0.00048364198,0.00029811487,0.00052076543,0.00032001568,0.00019327433,0.0000475865,0.00031961428,0.003580549,0.0010939625],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000113120856,0.000057699883,0.0001174316,0.0004741739,0.00058284035,0.0007589325,0.00016413526,6.0359206e-8,0.00017810789,0.0000152053,0.9968631,0.0006751588],"study_design_scores_gemma":[0.005798497,0.00042237533,0.00085963873,0.0002519222,0.0008626342,0.00047090076,0.000045533376,0.000013154974,0.00097872,0.000114964016,0.98985475,0.00032691352],"about_ca_topic_score_codex":0.00014103088,"about_ca_topic_score_gemma":0.000019443256,"teacher_disagreement_score":0.1496562,"about_ca_system_score_codex":0.00015491793,"about_ca_system_score_gemma":0.00047405533,"threshold_uncertainty_score":0.9999471},"labels":[],"label_agreement":null},{"id":"W4319060525","doi":"10.1111/ejh.13940","title":"Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis","year":2023,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Internal medicine; Medicine; NPM1; Myeloid leukemia; Cytogenetics; Hematopoietic stem cell transplantation; Transplantation; Oncology; Leukemia; Myeloid; Chemotherapy; Gastroenterology; Karyotype; Biology; Chromosome; Gene; Genetics","score_opus":0.009969441528545939,"score_gpt":0.2745431104625056,"score_spread":0.26457366893395967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319060525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989037,0.000120016004,0.00027943985,0.00019375856,0.000019089546,0.00029350078,0.000046647092,0.000009035243,0.00013480925],"genre_scores_gemma":[0.9985601,0.00034170027,0.00087739306,0.00005526292,0.000011052143,0.0000029078242,0.00006931281,0.000032084947,0.000050212864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997923,0.00044780123,0.00075217884,0.00022164134,0.00038871425,0.00026664807],"domain_scores_gemma":[0.9985614,0.00021681703,0.00047463604,0.00014730195,0.0004143932,0.00018546113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005038839,0.00019271157,0.00083772,0.0010657066,0.00004127032,0.0000112682255,0.00012397414,0.000052659263,0.00002749529],"category_scores_gemma":[0.000037464662,0.00013159435,0.00013694579,0.0007673761,0.00018611798,0.000091570546,0.000059304926,0.00029706824,0.000011030299],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012883544,0.000072397794,0.9801114,0.0002802682,0.0015209287,0.011370064,0.0024658279,0.0005661656,0.0014249521,0.00001724531,0.000059902715,0.00082247605],"study_design_scores_gemma":[0.0068882,0.0012315572,0.9847869,0.00010531436,0.0010523241,0.004125138,0.00032117974,0.00038866408,0.0009730445,0.000011710291,0.0000014020275,0.00011454965],"about_ca_topic_score_codex":0.000018814406,"about_ca_topic_score_gemma":0.000014540924,"teacher_disagreement_score":0.0072449255,"about_ca_system_score_codex":0.00015574286,"about_ca_system_score_gemma":0.00039624775,"threshold_uncertainty_score":0.53662616},"labels":[],"label_agreement":null},{"id":"W4319069469","doi":"10.1182/bloodadvances.2022009381","title":"Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Alberta; Université de Montréal; University of Toronto; SickKids Foundation; Stollery Children's Hospital; Hospital for Sick Children; CancerCare Manitoba","funders":"","keywords":"Myeloid leukemia; Refractory (planetary science); Medicine; Leukemia; Down syndrome; Overall survival; Oncology; Internal medicine; Biology; Psychiatry","score_opus":0.01727784567882751,"score_gpt":0.2839042528495991,"score_spread":0.2666264071707716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319069469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656904,0.0002997878,0.000010950687,0.0003955008,0.000073887364,0.000720105,0.00009119634,0.00037633505,0.0014632128],"genre_scores_gemma":[0.9882666,0.00049236295,0.00097376213,0.00009980766,0.000057483612,0.00006672702,0.00023964106,0.00009563213,0.0097080255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971351,0.0001164415,0.0004225446,0.0005348616,0.0011257316,0.0006653154],"domain_scores_gemma":[0.9980373,0.00059028924,0.00028751433,0.00060375,0.00024909127,0.00023204678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047993255,0.00034633014,0.00096903305,0.00032888917,0.00012299155,0.000019002846,0.0003086715,0.00015943138,0.00013074612],"category_scores_gemma":[0.00070432096,0.00019968815,0.000096805095,0.0015146964,0.00035146045,0.00030127057,0.00009946274,0.0005543061,0.000065459244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013428356,0.0003331125,0.9912687,0.000120856195,0.0018855243,0.0010786486,0.0001942257,0.00008509882,0.0014907892,0.00003589757,0.00042079194,0.0017435339],"study_design_scores_gemma":[0.00976932,0.0031965387,0.98210293,0.00036604365,0.0004311911,0.0003194673,0.00032968874,0.000019304078,0.002468785,0.000019267369,0.00065929873,0.00031815108],"about_ca_topic_score_codex":0.000118588854,"about_ca_topic_score_gemma":0.0002562811,"teacher_disagreement_score":0.0091657415,"about_ca_system_score_codex":0.0002758895,"about_ca_system_score_gemma":0.0010597316,"threshold_uncertainty_score":0.8143046},"labels":[],"label_agreement":null},{"id":"W4319826332","doi":"10.1111/bjh.18685","title":"Characteristics and outcome of primary resistant disease in paediatric acute myeloid leukaemia","year":2023,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Myeloid leukaemia; Medicine; Disease; Myeloid; Pediatrics; Oncology; Internal medicine; Intensive care medicine; Immunology","score_opus":0.020634197476799714,"score_gpt":0.29337911821910345,"score_spread":0.2727449207423037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319826332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947796,0.0029265601,0.00002065263,0.0016974882,0.00016125102,0.00020100149,0.00007356922,0.000017474305,0.00012242513],"genre_scores_gemma":[0.9896777,0.009091733,0.00053120375,0.00023599663,0.0001241529,0.000005475753,0.00003209935,0.000030931904,0.00027069292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99772817,0.00016261515,0.0011176851,0.00018957783,0.00041361983,0.00038835063],"domain_scores_gemma":[0.99850255,0.0003046075,0.00042086293,0.0001773316,0.00025596042,0.0003386621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091637735,0.00013062706,0.0010902015,0.0006658423,0.00004068478,0.00001889921,0.00018489575,0.00013685293,0.000037230435],"category_scores_gemma":[0.00115008,0.00013472605,0.00013588739,0.0005801472,0.00022955603,0.00011257918,0.00017007267,0.00068184384,0.000013260807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017956767,0.00014739714,0.63202834,0.0012154222,0.00016024362,0.3461097,0.00010886917,0.0000017888044,0.0023840833,0.00012617749,0.006120387,0.009801945],"study_design_scores_gemma":[0.0028482883,0.00023208246,0.9406062,0.0004115867,0.00020387005,0.05445486,0.000058298698,0.000087859386,0.000096102456,0.00026368618,0.00062123575,0.000115938055],"about_ca_topic_score_codex":0.000055386576,"about_ca_topic_score_gemma":0.000017536331,"teacher_disagreement_score":0.30857787,"about_ca_system_score_codex":0.00019075922,"about_ca_system_score_gemma":0.00059758837,"threshold_uncertainty_score":0.54939693},"labels":[],"label_agreement":null},{"id":"W4319827008","doi":"10.1158/2643-3230.bcd-22-0086","title":"<i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); Lunenfeld-Tanenbaum Research Institute; Princess Margaret Cancer Centre; McMaster University; University of Toronto; University Health Network","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Stem cell; RNA-binding protein; In vivo; RNA; Cell biology; Computational biology; Biology; Genetics; Gene","score_opus":0.02521687011719345,"score_gpt":0.29304056083478136,"score_spread":0.26782369071758794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319827008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934937,0.0030482274,0.000027901608,0.0012505525,0.00014830616,0.0013757901,0.00009010523,0.00008646897,0.00047895376],"genre_scores_gemma":[0.970374,0.00212647,0.00010749442,0.00041214676,0.00017543041,0.00058669987,0.000011456297,0.00008131071,0.026124975],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971128,0.000144573,0.00046633178,0.0006949364,0.0007106622,0.0008706969],"domain_scores_gemma":[0.9990905,0.0001986161,0.0001220556,0.00037294228,0.000061343024,0.00015456835],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005880465,0.00032843163,0.00057785556,0.00064901833,0.00011766919,0.0001862252,0.00025673088,0.00017771705,0.000112195085],"category_scores_gemma":[0.00004529179,0.00030107616,0.00010946152,0.0011374224,0.00016700776,0.00087480055,0.0002719285,0.00067681295,0.00005448583],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004099729,0.00008350779,0.026285373,0.0005688941,0.00021146127,0.0012673063,0.0019916124,0.00017699922,0.9671106,0.00010894495,0.00089529733,0.0008900653],"study_design_scores_gemma":[0.005264079,0.00023158862,0.004412975,0.0016314446,0.00012086157,0.00008125696,0.007233417,0.0005057006,0.9790651,0.00044500278,0.000569815,0.0004387314],"about_ca_topic_score_codex":0.0032678822,"about_ca_topic_score_gemma":0.00097551796,"teacher_disagreement_score":0.025646022,"about_ca_system_score_codex":0.000564692,"about_ca_system_score_gemma":0.0010804913,"threshold_uncertainty_score":0.99994415},"labels":[],"label_agreement":null},{"id":"W4319879834","doi":"10.1200/op.22.00668","title":"Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes","year":2023,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Poisson regression; Interquartile range; Health care; Public health; Population; Disease burden; Disease; Emergency medicine; Gerontology; Internal medicine; Environmental health","score_opus":0.0706928543925044,"score_gpt":0.46393207064788006,"score_spread":0.39323921625537567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319879834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853948,0.0014305478,0.000009642856,0.0047094934,0.000054385608,0.00071879674,0.000050035633,0.000039931365,0.007592405],"genre_scores_gemma":[0.99791527,0.0010812673,0.00033162447,0.00035720604,0.000032171825,0.000019265051,0.00014102145,0.000024413628,0.000097767865],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99810463,0.0005932612,0.00038101297,0.00027588112,0.0003327207,0.00031249653],"domain_scores_gemma":[0.9957109,0.0032158135,0.00031507306,0.00029348244,0.00031802157,0.00014670873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006647641,0.00012898666,0.00053119514,0.0004991906,0.00005106659,0.000004384297,0.00009207396,0.00021126904,0.000026579835],"category_scores_gemma":[0.0049153413,0.00011151163,0.000052713964,0.000836293,0.00014765628,0.000113589755,0.00010284102,0.0005281296,0.00002075488],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031235626,0.0015265257,0.22213538,0.0039835754,0.00080578704,0.002142436,0.06754644,0.0014045241,0.0029056638,0.001103968,0.03882264,0.6263874],"study_design_scores_gemma":[0.009377769,0.02901046,0.8438625,0.00084573886,0.0001814376,0.00056219555,0.059752494,0.00109579,0.00037774578,0.000011806558,0.054705363,0.00021672371],"about_ca_topic_score_codex":0.0010576631,"about_ca_topic_score_gemma":0.00026812285,"teacher_disagreement_score":0.6261707,"about_ca_system_score_codex":0.002220744,"about_ca_system_score_gemma":0.0020678868,"threshold_uncertainty_score":0.58844775},"labels":[],"label_agreement":null},{"id":"W4320158299","doi":"10.31547/bct-2022-015","title":"Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia","year":2022,"lang":"en","type":"article","venue":"BLOOD CELL THERAPY / The official journal of APBMT","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Japan Society for the Promotion of Science; Japan Agency for Medical Research and Development","keywords":"Medicine; Minimal residual disease; Oncology; Donor lymphocyte infusion; Blinatumomab; Chimeric antigen receptor; Transplantation; Hematopoietic stem cell transplantation; Myeloid leukemia; Internal medicine; Stem cell; Immunology; Immunotherapy; Leukemia; Immune system; Lymphoblastic Leukemia; Biology","score_opus":0.014757773161392979,"score_gpt":0.28582050302748757,"score_spread":0.2710627298660946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320158299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847607,0.011316052,0.00084696134,0.00095302274,0.0003195492,0.00096613937,0.000029793364,0.000015505244,0.0007922892],"genre_scores_gemma":[0.9790156,0.018727785,0.0005529364,0.00059901096,0.00042775564,0.00006350312,0.000014041521,0.00006270421,0.00053669594],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976126,0.0002735358,0.00071193243,0.00021545976,0.0007608378,0.00042565833],"domain_scores_gemma":[0.9985613,0.000337371,0.0005635851,0.0002538119,0.00016073106,0.00012316596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012185293,0.00021859542,0.0005137163,0.0002820535,0.0002538189,0.000027127857,0.0005500417,0.00007929855,0.0001174901],"category_scores_gemma":[0.000006910582,0.00015377294,0.00032534025,0.00041595838,0.00007483716,0.00013050274,0.000038845053,0.00079032517,0.0000042130696],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038706668,0.0029956058,0.0018527985,0.0005741414,0.00086286134,0.00234924,0.014284658,0.013956048,0.8339301,0.00031461884,0.0018375865,0.08833568],"study_design_scores_gemma":[0.05017083,0.014923782,0.0013259453,0.00020706812,0.001684756,0.0055122175,0.008189208,0.0007785758,0.8597321,0.0013623548,0.05532474,0.00078842096],"about_ca_topic_score_codex":0.000011120955,"about_ca_topic_score_gemma":0.000008207437,"teacher_disagreement_score":0.08754726,"about_ca_system_score_codex":0.00036462795,"about_ca_system_score_gemma":0.0010433978,"threshold_uncertainty_score":0.62706786},"labels":[],"label_agreement":null},{"id":"W4320719527","doi":"10.1101/2023.02.10.23285708","title":"Clonal Hematopoiesis of Indeterminate Potential Status is Associated with Left Main Artery Stenosis","year":2023,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Internal medicine; Coronary artery disease; Cardiology; Stenosis; Odds ratio; Cardiac catheterization; Logistic regression; Bone marrow","score_opus":0.03129514280638526,"score_gpt":0.2934193041668402,"score_spread":0.2621241613604549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320719527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99476427,0.000093688956,0.00025466262,0.0019328762,0.00033294756,0.0009826659,0.0009776566,0.00021584192,0.00044541204],"genre_scores_gemma":[0.9908471,0.00024903117,0.00070374465,0.00027087616,0.00018760133,0.00008653025,0.00071342144,0.00020121652,0.006740447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951521,0.00028116768,0.000834795,0.0009539946,0.0017493939,0.0010285176],"domain_scores_gemma":[0.9970215,0.0003204231,0.00052534416,0.0011649865,0.00054203725,0.00042573173],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010779876,0.0005539501,0.0014205929,0.0007114029,0.00009061953,0.000055602788,0.00049857603,0.0007405898,0.0008298284],"category_scores_gemma":[0.0005688977,0.000460284,0.00039205368,0.00044274563,0.000387524,0.00006577931,0.0010582495,0.0018582509,0.00020794198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002194798,0.000918269,0.9177797,0.0040172986,0.0066538607,0.013135775,0.00407862,0.00013850367,0.019527994,0.00003140822,0.029739143,0.0017846462],"study_design_scores_gemma":[0.005759071,0.0009275292,0.9574426,0.0036156792,0.0014165136,0.00040255187,0.0007481272,0.0038947419,0.02337578,0.0008679064,0.0005107881,0.0010387071],"about_ca_topic_score_codex":0.00024485,"about_ca_topic_score_gemma":0.000078979385,"teacher_disagreement_score":0.03966292,"about_ca_system_score_codex":0.0007790904,"about_ca_system_score_gemma":0.0016861494,"threshold_uncertainty_score":0.9997849},"labels":[],"label_agreement":null},{"id":"W4320856722","doi":"10.1002/pbc.30251","title":"Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group","year":2023,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health; Seattle Children's Research Institute; National Cancer Institute; St. Baldrick's Foundation","keywords":"Medicine; Monosomy; Acute megakaryoblastic leukemia; Trisomy 8; Trisomy; Cytogenetics; Myeloid leukemia; Internal medicine; Leukemia; Down syndrome; Myeloid; Karyotype; Chromosome 7 (human); Oncology; Cancer research; Chromosome; Genetics; Biology; Gene","score_opus":0.01068795744156757,"score_gpt":0.277801642502483,"score_spread":0.26711368506091543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320856722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883679,0.008068384,0.000071404065,0.0019588736,0.00012017979,0.0008265134,0.00016656792,0.000110565285,0.000309577],"genre_scores_gemma":[0.9825481,0.014208071,0.0008285076,0.0005747758,0.00092125096,0.00026219068,0.00032712833,0.000055249016,0.00027470745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997705,0.00014014471,0.0004066023,0.0006223135,0.00064983463,0.00047611137],"domain_scores_gemma":[0.9984204,0.000294746,0.00028645218,0.0006403644,0.00017326557,0.00018472738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031503988,0.00028178806,0.00057577784,0.00018107203,0.00012338937,0.000025916763,0.00025931332,0.00023203496,0.00008023059],"category_scores_gemma":[0.0001161052,0.00017347488,0.000112941336,0.00092959125,0.00022114803,0.0000517899,0.00025933445,0.0005775261,0.000009523617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008679285,0.00016420438,0.9506007,0.00014487367,0.0021108487,0.0066086566,0.00090238114,0.00003244572,0.021169718,0.0000525001,0.010940485,0.0064053023],"study_design_scores_gemma":[0.0041722646,0.0006814117,0.9840061,0.00003357917,0.004160028,0.0014371531,0.00008702708,0.000040315736,0.0047588623,0.00011869269,0.00028585264,0.00021868394],"about_ca_topic_score_codex":0.0013722245,"about_ca_topic_score_gemma":0.00010430201,"teacher_disagreement_score":0.03340547,"about_ca_system_score_codex":0.00024477713,"about_ca_system_score_gemma":0.0010595359,"threshold_uncertainty_score":0.70741},"labels":[],"label_agreement":null},{"id":"W4321850918","doi":"10.14740/jh1055","title":"Survival in Elderly Patients Diagnosed With Acute Myeloid Leukemia: A Hospital-Based Study","year":2023,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Myeloid leukemia; Regimen; Chemotherapy; Chemotherapy regimen; Proportional hazards model; Leukemia; Intensive care; Comorbidity; Retrospective cohort study; Oncology; Surgery; Confidence interval; Intensive care medicine","score_opus":0.01495898658096184,"score_gpt":0.2988640289496676,"score_spread":0.2839050423687058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321850918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639845,0.000057778878,0.000053442942,0.0021527223,0.00031958168,0.0007836996,0.000004715333,0.000039179562,0.00019045889],"genre_scores_gemma":[0.9991075,0.00004938799,0.00038376203,0.00016089795,0.00007970171,0.00003563896,0.000012575612,0.00004875986,0.00012178651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727297,0.00024469732,0.0007901949,0.00027261974,0.0008385754,0.0005809525],"domain_scores_gemma":[0.99795115,0.0005563976,0.000382303,0.00033819338,0.00051975326,0.0002521895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079971453,0.00023103967,0.0010222229,0.0009664746,0.000054398977,0.000018754843,0.00029719374,0.00017482213,0.00006906491],"category_scores_gemma":[0.0005211351,0.00016217578,0.00013031196,0.0011007817,0.000102927246,0.00013312626,0.00007864982,0.0009985092,0.00008109335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019723068,0.0013321404,0.957672,0.00007125466,0.00041051776,0.03248747,0.00084127946,0.000048246864,0.000107967695,0.000025537862,0.0040331585,0.0009981464],"study_design_scores_gemma":[0.034313045,0.01961269,0.940406,0.00025621534,0.0002524248,0.0007633635,0.002818508,0.0002639759,0.0005887652,0.00006799074,0.0004011938,0.00025581243],"about_ca_topic_score_codex":0.00006685309,"about_ca_topic_score_gemma":0.00013698403,"teacher_disagreement_score":0.03234074,"about_ca_system_score_codex":0.000623345,"about_ca_system_score_gemma":0.0014425772,"threshold_uncertainty_score":0.6613337},"labels":[],"label_agreement":null},{"id":"W4322212975","doi":"10.14740/wjon1557","title":"Real-World Experience of Adults With Acute Myeloid Leukemia on Hypomethylating Agents With or Without Venetoclax at a Comprehensive Cancer Center","year":2023,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Ohio State University","keywords":"Ven; Medicine; Internal medicine; Neutropenia; Venetoclax; Myeloid leukemia; Azacitidine; Gastroenterology; Surgery; Oncology; Leukemia; Chemotherapy","score_opus":0.053097080894151945,"score_gpt":0.3875824723297469,"score_spread":0.33448539143559497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322212975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924229,0.000070906,0.00001585412,0.0012160608,0.00023783621,0.0006312359,0.000021702526,0.00003579519,0.0053477148],"genre_scores_gemma":[0.9824631,0.0011883114,0.0039159125,0.00083122175,0.00037026659,0.000067261346,0.000013953103,0.00008275952,0.011067191],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99687594,0.00021562955,0.0008214894,0.00038676252,0.0010030369,0.0006971615],"domain_scores_gemma":[0.9968106,0.00056572974,0.0010167352,0.00038820002,0.0007984289,0.00042031528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033790796,0.00032735217,0.0012265589,0.0011380907,0.00013512376,0.0000128763195,0.00035414545,0.000107328924,0.0005239626],"category_scores_gemma":[0.00007563318,0.0001976712,0.00013035361,0.0019120128,0.00045663572,0.00013758808,0.00018558798,0.00096788973,0.000031316027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24039815,0.000600807,0.5368414,0.00073994184,0.004177952,0.030011797,0.024789553,0.0038023724,0.06305496,0.000053108415,0.04862516,0.0469048],"study_design_scores_gemma":[0.086734004,0.04986553,0.58740306,0.011110777,0.0013795632,0.010113203,0.009806681,0.0071720704,0.050269615,0.000024027348,0.18477882,0.0013426308],"about_ca_topic_score_codex":0.0006080364,"about_ca_topic_score_gemma":0.004611413,"teacher_disagreement_score":0.15366416,"about_ca_system_score_codex":0.0058376635,"about_ca_system_score_gemma":0.0035928385,"threshold_uncertainty_score":0.99797875},"labels":[],"label_agreement":null},{"id":"W4322757874","doi":"10.3324/haematol.2022.281106","title":"Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023","year":2023,"lang":"en","type":"review","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto; Toronto Public Health","funders":"National Cancer Institute; National Institutes of Health; Leukemia and Lymphoma Society; U.S. Department of Defense","keywords":"Medicine; Clinical trial; Intensive care medicine; Myeloid leukaemia; Disease; Orphan drug; Family medicine; Oncology; Internal medicine; Bioinformatics","score_opus":0.07228254196953478,"score_gpt":0.36433259856424816,"score_spread":0.2920500565947134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322757874","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013256675,0.9903508,0.0000057831735,0.00041854722,0.0004915321,0.0034843867,0.00012787491,0.00021697299,0.003578457],"genre_scores_gemma":[0.00002606319,0.97559893,0.00027739897,0.00008527844,0.00014584592,0.0005657293,0.00018718271,0.0001562765,0.022957297],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994632,0.0005878291,0.0018425741,0.00095003593,0.00095738936,0.0010301596],"domain_scores_gemma":[0.9960959,0.0011225751,0.00081912393,0.0015487572,0.00016137645,0.00025227107],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010825831,0.00072737195,0.0046053696,0.0010160446,0.00010065084,0.000025354682,0.0011599974,0.0009945588,0.00024544506],"category_scores_gemma":[0.0013975789,0.00043537424,0.0011386469,0.004313332,0.00027839025,0.00006431259,0.0009705525,0.0028014507,0.00444387],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003428922,0.00058606185,0.0017917419,0.19310795,0.0018682247,0.02076691,0.00023477481,0.0000038068033,0.000010632508,0.00059230207,0.3816531,0.3990416],"study_design_scores_gemma":[0.0013976564,0.00024398921,0.00046067243,0.0118588,0.0022357618,0.002646547,0.000021426447,0.000012138477,0.00001318707,0.0003450087,0.98015547,0.00060932984],"about_ca_topic_score_codex":0.000044956556,"about_ca_topic_score_gemma":0.000037613063,"teacher_disagreement_score":0.5985024,"about_ca_system_score_codex":0.000754471,"about_ca_system_score_gemma":0.0025134247,"threshold_uncertainty_score":0.9998098},"labels":[],"label_agreement":null},{"id":"W4323311378","doi":"10.1186/s13045-023-01417-5","title":"Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Gilead Sciences","keywords":"Meta-analysis; Hematology; Myeloid leukemia; Medicine; Internal medicine; Oncology; Hematologic Neoplasms; Intensive care medicine; Cancer","score_opus":0.13974557173687224,"score_gpt":0.455098530342097,"score_spread":0.3153529586052248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323311378","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026291136,0.9825588,0.00008717863,0.006088064,0.00018659933,0.010527849,0.00037884092,0.00007054006,0.00007586051],"genre_scores_gemma":[0.0000049230225,0.9857608,0.0020629375,0.0009441342,0.00011322551,0.0044252286,0.00028312558,0.00019927295,0.0062063634],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9896147,0.0021587762,0.005553252,0.0009871265,0.0005775135,0.0011086334],"domain_scores_gemma":[0.9809895,0.010586604,0.005591576,0.0012343863,0.0008611681,0.0007367259],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.0019411315,0.0015415283,0.05042225,0.0024795828,0.000187591,0.000044005625,0.0006350285,0.0015405001,0.00021509199],"category_scores_gemma":[0.0020332446,0.0007932673,0.012995213,0.0016755739,0.00036345643,0.0001290202,0.00017464376,0.0010911194,0.00016342243],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00010493428,0.0003810651,0.000012216557,0.34358582,0.63699174,0.011907873,0.00010088321,7.0213576e-7,2.4648142e-7,0.00009372774,0.0024406703,0.0043800925],"study_design_scores_gemma":[0.0041117184,0.00545615,0.0000018489363,0.009949524,0.8205922,0.03871297,0.000088420566,0.000008697504,0.0000015996343,0.000031992862,0.12067009,0.00037475638],"about_ca_topic_score_codex":0.00009656154,"about_ca_topic_score_gemma":0.00015640144,"teacher_disagreement_score":0.3336363,"about_ca_system_score_codex":0.007799149,"about_ca_system_score_gemma":0.0069155223,"threshold_uncertainty_score":0.9997557},"labels":[],"label_agreement":null},{"id":"W4323322156","doi":"10.1007/s10689-023-00329-0","title":"Hereditary acute myeloid leukemia associated with C-terminal CEBPA germline variants","year":2023,"lang":"en","type":"review","venue":"Familial Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"CEBPA; Germline; Myeloid leukemia; Germline mutation; Myeloid; Leukemia; Acute leukemia; Medicine; Penetrance; Cancer research; Biology; Genetics; Mutation; Internal medicine; Gene; Phenotype","score_opus":0.06724940709402184,"score_gpt":0.37585399234351985,"score_spread":0.308604585249498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323322156","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00066755054,0.9892179,0.000016696875,0.00019073662,0.0016614404,0.0029227943,0.0030637216,0.00056560565,0.001693604],"genre_scores_gemma":[0.000010328437,0.9529233,0.00019390506,0.0004958944,0.0042767036,0.0011288718,0.0030741633,0.0005160712,0.037380785],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99404025,0.00033268257,0.0011767597,0.0013999833,0.0015597761,0.0014905761],"domain_scores_gemma":[0.99667114,0.0004890678,0.0005939869,0.0011234266,0.00047124468,0.00065110484],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068108377,0.0011676152,0.00411219,0.0006308208,0.0002162632,0.000063717394,0.00075779133,0.0012679569,0.00086882425],"category_scores_gemma":[0.00036247852,0.00084675057,0.0007803968,0.001980982,0.00035196144,0.00016422222,0.00039602313,0.0028749218,0.0010803497],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00079756574,0.00015308698,0.0000811723,0.0199283,0.008851574,0.026143234,0.00012762613,0.000006147405,0.0000120417635,0.0000143803145,0.18909796,0.7547869],"study_design_scores_gemma":[0.0032323212,0.0007135983,0.0009973416,0.040651303,0.008910414,0.0012081278,0.000027979913,0.00015627916,0.0000030763977,0.000012164505,0.94299954,0.0010878517],"about_ca_topic_score_codex":0.001373596,"about_ca_topic_score_gemma":0.00048662195,"teacher_disagreement_score":0.7539016,"about_ca_system_score_codex":0.008206048,"about_ca_system_score_gemma":0.014569872,"threshold_uncertainty_score":0.99969745},"labels":[],"label_agreement":null},{"id":"W4323537975","doi":"10.1101/2023.03.06.530131","title":"Gene Expression Profiling Unveils the Temporal Dynamics of CIGB-300-Regulated Transcriptome in AML Cells","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Génome Québec; McGill University","keywords":"Transcriptome; Gene expression profiling; Biology; Gene expression; Gene; Cell cycle; Myeloid leukemia; Signal transduction; Myeloid; Microarray analysis techniques; Microarray; Molecular biology; Gene isoform; Cell biology; Cancer research; Genetics","score_opus":0.02405810556995942,"score_gpt":0.2607411307664485,"score_spread":0.2366830251964891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323537975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926093,0.00059147394,0.00093610986,0.001167824,0.0009079854,0.0028324563,0.00050281495,0.00044419753,0.000007786519],"genre_scores_gemma":[0.9916976,0.00039139224,0.006743888,0.00010091245,0.0003324928,0.00033898442,0.000008263219,0.00031768472,0.00006878182],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9949118,0.0003818978,0.0012918169,0.0012827207,0.0011192708,0.001012513],"domain_scores_gemma":[0.9958615,0.0001898946,0.0005552651,0.002305271,0.0007216127,0.0003665085],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019541865,0.00073843746,0.0012626125,0.0008865381,0.00013122437,0.000092853574,0.0010361304,0.0010679133,0.00006158778],"category_scores_gemma":[0.0003102582,0.0006040945,0.00033267375,0.0016964298,0.00037906025,0.00012435706,0.00072548573,0.0020293987,0.000064786334],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028070042,0.00021171237,0.015202736,0.0014142098,0.00018386744,0.0002932847,0.00005681212,0.000363743,0.98152244,0.000071274495,0.0003966222,0.00000259725],"study_design_scores_gemma":[0.0018243293,0.00010599957,0.035411034,0.0016748726,0.0001466996,7.694774e-8,0.0000377962,0.010896551,0.94915,0.000005472402,0.00018885275,0.00055830815],"about_ca_topic_score_codex":0.00037382043,"about_ca_topic_score_gemma":0.000020426105,"teacher_disagreement_score":0.03237243,"about_ca_system_score_codex":0.0014056138,"about_ca_system_score_gemma":0.0022170981,"threshold_uncertainty_score":0.99964106},"labels":[],"label_agreement":null},{"id":"W4323652772","doi":"10.1007/s00280-023-04516-9","title":"A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia","year":2023,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Pfizer","keywords":"Gemtuzumab ozogamicin; Medicine; Dosing; Calicheamicin; Refractory (planetary science); Pharmacokinetics; CD33; Myeloid leukemia; Internal medicine; Oncology; Pharmacology; CD34; Stem cell","score_opus":0.024792431537484075,"score_gpt":0.386802173481273,"score_spread":0.36200974194378893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323652772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963706,0.00058075826,0.000033551023,0.00056896417,0.00036016907,0.0018798872,0.00006446756,0.00006561801,0.00007598141],"genre_scores_gemma":[0.9961354,0.0021026295,0.0001397609,0.0010190632,0.00016070054,0.00012364105,0.00008155621,0.00006981162,0.00016741818],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977604,0.00028273594,0.000513109,0.0005817287,0.00038661633,0.00047542213],"domain_scores_gemma":[0.99888474,0.0003437168,0.00022505442,0.00015621725,0.00021900247,0.00017127255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063699525,0.00031014744,0.0006783137,0.00042616113,0.00014337574,0.000015266318,0.00011845898,0.0001407865,0.0002694082],"category_scores_gemma":[0.00003013619,0.00027242143,0.00006515681,0.000722391,0.00020606806,0.00019912545,0.00009702694,0.0007431939,0.000002522408],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052382592,0.002061114,0.1709447,0.00029304784,0.003832646,0.00029119718,0.011139558,0.00020328995,0.60627866,0.0000014959206,0.0018148732,0.15075684],"study_design_scores_gemma":[0.39898053,0.021283878,0.387436,0.0008903982,0.0024414018,0.000041153904,0.0027407457,0.030470768,0.15284063,0.000026476087,0.0018372088,0.0010107873],"about_ca_topic_score_codex":0.0002537337,"about_ca_topic_score_gemma":0.00001614028,"teacher_disagreement_score":0.453438,"about_ca_system_score_codex":0.0010402659,"about_ca_system_score_gemma":0.0005006518,"threshold_uncertainty_score":0.9999728},"labels":[],"label_agreement":null},{"id":"W4323667916","doi":"10.1038/s41409-023-01924-6","title":"Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)","year":2023,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Auto Workers","funders":"","keywords":"Benchmarking; Medicine; Transplantation; Accreditation; Hematopoietic cell; Medical physics; Stem cell; Internal medicine; Haematopoiesis; Medical education","score_opus":0.028428944251522353,"score_gpt":0.27484711251285915,"score_spread":0.2464181682613368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323667916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521065,0.00014177412,0.0019098152,0.00032706308,0.00012309274,0.0016501901,0.00045466443,0.00003025137,0.00015251557],"genre_scores_gemma":[0.99621826,0.0013384756,0.0019038905,0.000027323087,0.000026423091,0.000032740983,0.00036642473,0.000046543177,0.000039898383],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99737686,0.00047722313,0.00089433254,0.0003585402,0.000630608,0.0002624516],"domain_scores_gemma":[0.9984771,0.00051854044,0.000501596,0.0002766126,0.00016371516,0.00006244012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019608305,0.00025086032,0.00062316866,0.00020913377,0.00018622336,0.00002146828,0.00013355783,0.00011904354,0.0000018272767],"category_scores_gemma":[0.00002405482,0.00018211405,0.00029390803,0.00047558034,0.00024416592,0.00027605402,0.000023681185,0.00020769154,1.2905922e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008136302,0.0001449507,0.16216965,0.018601762,0.0003567972,0.00002175341,0.036782373,0.00014209822,0.77668387,0.00022844129,0.000029901312,0.0040247925],"study_design_scores_gemma":[0.008023682,0.0004482459,0.74064326,0.0013959651,0.002343387,0.00010752662,0.0036917229,0.0026637553,0.24032454,0.00012449328,0.000003724527,0.0002297128],"about_ca_topic_score_codex":0.00017498269,"about_ca_topic_score_gemma":0.00015973499,"teacher_disagreement_score":0.57847357,"about_ca_system_score_codex":0.000027637749,"about_ca_system_score_gemma":0.00016003397,"threshold_uncertainty_score":0.74263954},"labels":[],"label_agreement":null},{"id":"W4323859690","doi":"10.3389/fonc.2023.1149754","title":"LSD1 inhibition modulates transcription factor networks in myeloid malignancies","year":2023,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Population Health Research Institute; McMaster University","funders":"Government of Ontario","keywords":"Transcription factor; Haematopoiesis; Myeloid leukemia; Epigenetics; Cancer research; Biology; Myeloid; Progenitor cell; Stem cell; Enhancer; IRF8; Regulator; Bone marrow; Cell biology; Immunology; Genetics; Gene","score_opus":0.06907244263743449,"score_gpt":0.366395949071357,"score_spread":0.29732350643392247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323859690","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00061031093,0.99198216,0.0015045571,0.00033458072,0.0022770131,0.0026090639,0.000065001535,0.00014473998,0.00047257476],"genre_scores_gemma":[0.00014549645,0.99400544,0.0016865131,0.00013686964,0.00055910915,0.00070110796,0.00082676654,0.00015604378,0.0017826225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99597913,0.00066034845,0.001253627,0.0007997076,0.00034219478,0.0009650156],"domain_scores_gemma":[0.99873835,0.0002755839,0.00028548867,0.00044174094,0.00007638643,0.00018242598],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0008266579,0.0005422196,0.0033137156,0.001963638,0.000049129503,0.000021709697,0.00026108537,0.0019010239,0.00007318722],"category_scores_gemma":[0.00027477156,0.0004886228,0.0004334731,0.0017009458,0.00024659096,0.00012423583,0.00010823404,0.0022581168,0.000111153575],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015533454,0.00015950543,0.0004674584,0.008988722,0.00017269759,0.0014278116,0.0003239514,0.000083049104,0.000013385843,0.000032741642,0.024934152,0.9632412],"study_design_scores_gemma":[0.0020047908,0.00049905945,0.0005145912,0.012854769,0.000277962,0.00015340457,0.0002314966,0.0020267165,0.000003611811,0.0001681358,0.9808218,0.00044367902],"about_ca_topic_score_codex":0.00013142725,"about_ca_topic_score_gemma":0.00021829529,"teacher_disagreement_score":0.9627975,"about_ca_system_score_codex":0.0061521404,"about_ca_system_score_gemma":0.0015238805,"threshold_uncertainty_score":0.9997565},"labels":[],"label_agreement":null},{"id":"W4323928256","doi":"10.1016/j.blre.2023.101072","title":"Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)","year":2023,"lang":"en","type":"review","venue":"Blood Reviews","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"Foundation Medicine; Takeda Oncology; Genentech; National Institutes of Health; Associazione Italiana per la Ricerca sul Cancro; Fondazione Italiana per la Ricerca sul Cancro; Astellas Pharma; Daiichi-Sankyo; MacroGenics; Pfizer; Incyte; CTI Biopharma; bluebird bio; Agios Pharmaceuticals; Alexion Pharmaceuticals; Apellis Pharmaceuticals; Celgene; BioCryst; Syndax Pharmaceuticals; National Heart, Lung, and Blood Institute; Edward P. Evans Foundation; Acceleron; Loxo Oncology; Astex Pharmaceuticals; Leukemia and Lymphoma Society; Daiichi Sankyo Europe; Servier; Gilead Sciences; Jazz Pharmaceuticals; Bristol-Myers Squibb; AstraZeneca; Cardinal Health; Amgen","keywords":"Myelodysplastic syndromes; Medicine; Clinical trial; Epigenetics; Disease; Translational research; Bioinformatics; Immunology; Biology; Internal medicine; Genetics; Gene; Bone marrow","score_opus":0.3252617865824189,"score_gpt":0.49588816257378177,"score_spread":0.17062637599136288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323928256","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033271401,0.985022,0.00001637492,0.0022557606,0.0013133326,0.006516127,0.00084646605,0.000021877568,0.0006808939],"genre_scores_gemma":[0.00061684404,0.9960607,0.00025396486,0.00006529327,0.0010341591,0.0008949736,0.0005097774,0.00008825631,0.00047599722],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932311,0.00061572227,0.0029581739,0.00093300536,0.0017724971,0.0004895073],"domain_scores_gemma":[0.9887481,0.008750819,0.0010545782,0.0006295196,0.0006461584,0.0001708306],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0072972532,0.0004902724,0.0025413574,0.000603837,0.000109993875,0.000066244625,0.0016159789,0.0004633492,0.00017921203],"category_scores_gemma":[0.0061356854,0.0002650873,0.0010393863,0.0012466493,0.00064637297,0.00008507494,0.00052490016,0.002489575,0.000055050452],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051117747,0.0011033594,0.0101714,0.027696721,0.0019153978,0.000019479261,0.0003152186,0.0000014388793,0.000008474536,0.0017722405,0.023017872,0.9334672],"study_design_scores_gemma":[0.002789347,0.00022930083,0.0028881452,0.08203257,0.0013572589,0.00008528783,0.00008092969,0.00033242808,0.0000036227705,0.00016989857,0.909788,0.00024322445],"about_ca_topic_score_codex":0.000030197849,"about_ca_topic_score_gemma":0.000048152866,"teacher_disagreement_score":0.933224,"about_ca_system_score_codex":0.00017919365,"about_ca_system_score_gemma":0.0013998438,"threshold_uncertainty_score":0.99998015},"labels":[],"label_agreement":null},{"id":"W4324116807","doi":"10.1016/j.gimo.2023.100108","title":"P089: Genetic, pharmacogenetics and outcomes in a cohort of pediatric acute myeloid leukemia patients in two reference centers from Colombia","year":2023,"lang":"en","type":"article","venue":"Genetics in Medicine Open","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Misericordia Community Hospital","funders":"","keywords":"Pharmacogenetics; Myeloid leukemia; Cohort; Medicine; Pediatrics; Oncology; Internal medicine; Genetics; Genotype; Biology; Gene","score_opus":0.04194552613813434,"score_gpt":0.38351753110057757,"score_spread":0.3415720049624432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324116807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948214,0.00060809136,0.0000071187515,0.00065483205,0.00021341683,0.0025081579,0.00011295905,0.000020259004,0.0010537317],"genre_scores_gemma":[0.9738127,0.022266654,0.0023917004,0.0005039243,0.00011528097,0.0001568455,0.0002994497,0.000065231405,0.0003882228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961635,0.00024392047,0.0012072534,0.00077439763,0.000881114,0.00072984886],"domain_scores_gemma":[0.99825394,0.000410273,0.00021793346,0.0006333447,0.00017933232,0.00030517878],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009914384,0.00035415424,0.0011749722,0.0010510712,0.00003410966,0.000022492533,0.0008312923,0.00016919404,0.00013800521],"category_scores_gemma":[0.00041978527,0.0003177448,0.00003856098,0.0016833993,0.00027416405,0.00006499876,0.0011335844,0.0007210056,0.000029977013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039664016,0.00014809782,0.9865248,0.00008028636,0.00009557257,0.0003078069,0.00088790065,0.00013316532,0.003055861,0.000003370686,0.002495584,0.005870909],"study_design_scores_gemma":[0.018522745,0.00049622834,0.9761209,0.00019402117,0.00018710806,0.0000047128246,0.0002607385,0.002592326,0.00087602297,0.0001513294,0.000345313,0.00024857622],"about_ca_topic_score_codex":0.009074019,"about_ca_topic_score_gemma":0.0027138386,"teacher_disagreement_score":0.021658562,"about_ca_system_score_codex":0.0006534556,"about_ca_system_score_gemma":0.00060568936,"threshold_uncertainty_score":0.99992746},"labels":[],"label_agreement":null},{"id":"W4327611094","doi":"10.1111/ijlh.14057","title":"Combination of <scp>NeuX</scp> and <scp>NeuZ</scp> can predict neutrophil dysplasia features of <scp>myelodysplastic neoplasms</scp> in peripheral blood","year":2023,"lang":"en","type":"article","venue":"International Journal of Laboratory Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Science Foundation of Henan Province; University of Toronto","keywords":"Dysplasia; Myelodysplastic syndromes; Medicine; Receiver operating characteristic; Granulocyte; Peripheral blood; Internal medicine; Gastroenterology; International Prognostic Scoring System; Hematology; Absolute neutrophil count; Pathology; Immunology; Bone marrow; Neutropenia","score_opus":0.009630202434783719,"score_gpt":0.2753545150324635,"score_spread":0.26572431259767976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327611094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948703,0.0013688678,0.00004225786,0.0010963305,0.0011207801,0.0003937356,0.00022662398,0.00005077959,0.000830344],"genre_scores_gemma":[0.99713284,0.0010455288,0.00046833834,0.00025148873,0.00032119663,0.000024837194,0.000086650514,0.00007941819,0.00058967737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99526274,0.0004067266,0.0016254582,0.00046818663,0.0015694312,0.0006674814],"domain_scores_gemma":[0.9920248,0.003237985,0.0013162269,0.0003406168,0.002669305,0.00041108715],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010496228,0.00042851904,0.0012770161,0.002020806,0.00007597915,0.00005171089,0.0007614176,0.00048597588,0.0000203617],"category_scores_gemma":[0.006898271,0.0003991008,0.00019933823,0.0012666574,0.00063997175,0.00035385325,0.0002844323,0.0013369224,0.000011105449],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039380457,0.0019929651,0.71040976,0.0015100237,0.0033358848,0.0113291815,0.0070772166,0.00093866204,0.1945922,0.013938274,0.053891577,0.0005904235],"study_design_scores_gemma":[0.027296273,0.00424763,0.7752724,0.0020287454,0.000742788,0.015895246,0.0073089255,0.0023799466,0.15451358,0.002542653,0.0076093925,0.00016241848],"about_ca_topic_score_codex":0.00007440876,"about_ca_topic_score_gemma":0.00012529135,"teacher_disagreement_score":0.06486262,"about_ca_system_score_codex":0.0003569542,"about_ca_system_score_gemma":0.0016963085,"threshold_uncertainty_score":0.9998461},"labels":[],"label_agreement":null},{"id":"W4327656743","doi":"10.2139/ssrn.4387210","title":"Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration","year":2023,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Bone marrow transplantation; Hematologic Neoplasms; Transplantation; Bone marrow; Oncology; Internal medicine","score_opus":0.02168335248576526,"score_gpt":0.309667458574982,"score_spread":0.28798410608921676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327656743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9513072,0.00027286186,0.033870477,0.0076350467,0.0006999365,0.0029452364,0.0029545762,0.00024282801,0.00007185995],"genre_scores_gemma":[0.95667756,0.020974211,0.005605025,0.0002847088,0.0034580303,0.0005514534,0.006163184,0.00030240524,0.0059834267],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9923026,0.00036084562,0.0014626898,0.001255862,0.0013267972,0.0032912032],"domain_scores_gemma":[0.99516976,0.0015063174,0.0009602581,0.00062125706,0.0012432397,0.00049918285],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019499231,0.0007314603,0.0012657625,0.00068626384,0.00043573583,0.00037347595,0.00056137476,0.0004520499,0.000023269027],"category_scores_gemma":[0.0023960632,0.0006109713,0.0004061113,0.0010288126,0.00027110122,0.00025989485,0.00017012034,0.006958698,0.00008925372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.7088733,0.0055750194,0.069086805,0.00428515,0.054299157,0.006881183,0.026195688,0.011658136,0.012093841,0.013291224,0.020824669,0.06693587],"study_design_scores_gemma":[0.24547972,0.0810004,0.22285333,0.008484029,0.046368003,0.01825904,0.0778192,0.109396614,0.019736562,0.1518695,0.0063716127,0.012361998],"about_ca_topic_score_codex":0.0012143822,"about_ca_topic_score_gemma":0.0570507,"teacher_disagreement_score":0.46339354,"about_ca_system_score_codex":0.004340333,"about_ca_system_score_gemma":0.030446002,"threshold_uncertainty_score":0.99963415},"labels":[],"label_agreement":null},{"id":"W4327700886","doi":"10.1182/bloodadvances.2022008793","title":"Interplay between hereditary and acquired factors determines the neutrophil counts in older individuals","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Heart Institute; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research","keywords":"Myeloid; Context (archaeology); Immunology; Lymphocyte; Biology; Genome-wide association study; Medicine; Genetics; Genotype; Gene; Single-nucleotide polymorphism","score_opus":0.022208651154618588,"score_gpt":0.3343515052686889,"score_spread":0.31214285411407033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327700886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960197,0.0019156937,0.0000015203598,0.0009793839,0.00011051804,0.00024890568,0.00003568807,0.00005799673,0.0006306019],"genre_scores_gemma":[0.9982578,0.00053694757,0.000049351176,0.00012289255,0.00022555591,0.000021750908,0.000041396655,0.000017953993,0.0007263297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999161,0.000037573223,0.00015458412,0.00018699729,0.00021987612,0.00023998696],"domain_scores_gemma":[0.9994183,0.00030350516,0.000033038323,0.00016762028,0.00002299891,0.000054520202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016224894,0.00010820251,0.00019684403,0.0001318042,0.00004921158,0.00001737327,0.00013196476,0.00005543594,0.000054107586],"category_scores_gemma":[0.00010935618,0.000066372166,0.000027526055,0.00030694742,0.000105057814,0.00012110633,0.00010741061,0.00013485325,0.000053254138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016710253,0.00003283659,0.9750568,0.00008984261,0.00007351885,0.00016504723,0.0007751334,0.0000024445803,0.00053998973,0.000011742982,0.0025361602,0.020699747],"study_design_scores_gemma":[0.0011514832,0.000104994775,0.97173303,0.0001138638,0.000055061424,0.00002975852,0.0005800872,0.000031272095,0.001729022,0.00019695864,0.024168126,0.000106362175],"about_ca_topic_score_codex":0.00001939683,"about_ca_topic_score_gemma":0.000014465894,"teacher_disagreement_score":0.021631967,"about_ca_system_score_codex":0.000020239282,"about_ca_system_score_gemma":0.00004975092,"threshold_uncertainty_score":0.27065784},"labels":[],"label_agreement":null},{"id":"W4328133788","doi":"10.21203/rs.3.rs-2691216/v1","title":"Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Myeloproliferative neoplasm; Cyclophosphamide; Immunosuppression; Transplantation; Myelodysplastic syndromes; Splenectomy; Oncology; Gastroenterology; Surgery; Chemotherapy; Bone marrow; Myelofibrosis; Spleen","score_opus":0.06849550638233974,"score_gpt":0.39796583869330127,"score_spread":0.3294703323109615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328133788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9514776,0.00009733678,0.0031032593,0.009758645,0.00044252744,0.010612568,0.023686904,0.00051496015,0.00030621846],"genre_scores_gemma":[0.93688536,0.003384072,0.011278526,0.00016465368,0.00265338,0.00517441,0.03247022,0.00040522352,0.0075841597],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.98959345,0.0011185046,0.0014226948,0.0023905025,0.003661202,0.0018136533],"domain_scores_gemma":[0.98465997,0.0080890125,0.00041114615,0.0015119347,0.004331346,0.0009966121],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0024591277,0.0007713783,0.0014695883,0.0015502655,0.0006247605,0.00064685376,0.0007722023,0.0006786375,0.00010111956],"category_scores_gemma":[0.011810076,0.00065841415,0.00037185103,0.0030574733,0.0008739861,0.00026924888,0.0006947344,0.003683049,0.00042691804],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5644264,0.0051777605,0.12438068,0.031927373,0.011873896,0.017472656,0.040440522,0.005221574,0.014609084,0.001150098,0.15960675,0.023713201],"study_design_scores_gemma":[0.0717027,0.023585737,0.7057138,0.012358139,0.004375236,0.00031856066,0.029461237,0.10557625,0.029664138,0.002657519,0.010039149,0.0045475517],"about_ca_topic_score_codex":0.0042561516,"about_ca_topic_score_gemma":0.022977998,"teacher_disagreement_score":0.5813331,"about_ca_system_score_codex":0.0017001355,"about_ca_system_score_gemma":0.008324299,"threshold_uncertainty_score":0.9995867},"labels":[],"label_agreement":null},{"id":"W4360599974","doi":"10.3324/haematol.2022.282030","title":"Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)","year":2023,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"University of Texas MD Anderson Cancer Center; Astellas Pharma; Servier; Gilead Sciences; Pfizer","keywords":"Medicine; Internal medicine; Cumulative incidence; KRAS; Gastroenterology; Myeloid leukemia; Hematopoietic stem cell transplantation; White blood cell; Neuroblastoma RAS viral oncogene homolog; Myeloid; Transplantation; Oncology; Cancer; Colorectal cancer","score_opus":0.04069498217841501,"score_gpt":0.3371159216637637,"score_spread":0.2964209394853487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360599974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695355,0.000014868052,0.00004773887,0.00093017815,0.000074290874,0.0010112841,0.000110349385,0.00025708321,0.00060065516],"genre_scores_gemma":[0.99363405,0.00055431237,0.0029567347,0.0006398637,0.000047939677,0.0000655299,0.00029961357,0.00007066153,0.0017312941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970008,0.00013817487,0.0008143625,0.00064351707,0.00074882654,0.0006543008],"domain_scores_gemma":[0.99734914,0.00079727464,0.0003613595,0.0007081003,0.00039310753,0.00039099052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004614775,0.00038633277,0.0015188735,0.00026719176,0.00012836704,0.00003046434,0.0002737243,0.0003135427,0.00016001383],"category_scores_gemma":[0.0007672461,0.00019780974,0.00011656097,0.0007930916,0.0008092337,0.00012566181,0.00030217643,0.00063906505,0.00013292365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004669878,0.0002163689,0.98646456,0.00022271926,0.0007230448,0.0020047175,0.00014210748,3.5371517e-7,0.000022409497,0.00016981951,0.002476766,0.0028872706],"study_design_scores_gemma":[0.0054752612,0.003147096,0.988056,0.00015808156,0.0003976724,0.0002954711,0.00013095932,0.00012900608,0.0001167562,0.000032183674,0.0017842622,0.00027726003],"about_ca_topic_score_codex":0.00004548818,"about_ca_topic_score_gemma":0.000029448023,"teacher_disagreement_score":0.0033195019,"about_ca_system_score_codex":0.00014105553,"about_ca_system_score_gemma":0.00059936696,"threshold_uncertainty_score":0.8066447},"labels":[],"label_agreement":null},{"id":"W4360600096","doi":"10.3324/haematol.2022.282296","title":"Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial","year":2023,"lang":"en","type":"letter","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Azacitidine; Myeloid leukemia; Medicine; Internal medicine; Receipt; Chemotherapy; Oncology; Subgroup analysis; Complete remission; Maintenance therapy; Confidence interval; Biology; World Wide Web","score_opus":0.05211788543983863,"score_gpt":0.3642380091814488,"score_spread":0.31212012374161013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360600096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9256486,0.00007654244,0.00005986037,0.06954837,0.00022318722,0.003176297,0.0008260027,0.00013223084,0.00030891073],"genre_scores_gemma":[0.85124946,0.0010510661,0.0019648962,0.11364998,0.0013635976,0.0010488693,0.024159206,0.0006688451,0.004844114],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9933657,0.0008418402,0.001510832,0.0012653534,0.0018339786,0.001182313],"domain_scores_gemma":[0.9957039,0.0015724987,0.00091847335,0.0012812477,0.0003528987,0.00017100819],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0009018114,0.00094576966,0.0035071322,0.00052299467,0.000109317094,0.00005431566,0.00093053206,0.0012189304,0.00036440912],"category_scores_gemma":[0.0006081602,0.00048085384,0.00026208436,0.0015507407,0.0007035368,0.0001598972,0.00022560587,0.0035586674,0.000028566317],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22766902,0.0009990011,0.05584524,0.00024194666,0.0016380993,0.008724953,0.00044241728,0.00000489792,0.0003494872,0.0000063862576,0.7022981,0.0017804281],"study_design_scores_gemma":[0.8517544,0.012909796,0.054470193,0.0040364973,0.0015066691,0.00015478104,0.0007395261,0.0003452921,0.0032584018,0.0001883299,0.068166226,0.002469848],"about_ca_topic_score_codex":0.005178438,"about_ca_topic_score_gemma":0.0006851381,"teacher_disagreement_score":0.6341319,"about_ca_system_score_codex":0.0011948,"about_ca_system_score_gemma":0.0011376131,"threshold_uncertainty_score":0.9997643},"labels":[],"label_agreement":null},{"id":"W4360856474","doi":"10.3390/metabo13040467","title":"Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax + Azacitidine by Targeting Fatty Acid Desaturases 1 and 2","year":2023,"lang":"en","type":"article","venue":"Metabolites","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Venetoclax; Myeloid leukemia; Azacitidine; Cancer research; Fatty acid; Leukemia; Stem cell; Beta oxidation; Medicine; Pharmacology; Chemistry; Internal medicine; Biology; Biochemistry; Gene; Chronic lymphocytic leukemia; Cell biology","score_opus":0.024406699524455257,"score_gpt":0.28402479696957583,"score_spread":0.2596180974451206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360856474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832566,0.01214433,0.00006827055,0.00201598,0.00017400345,0.0011718385,0.0004889737,0.0004527954,0.00022725714],"genre_scores_gemma":[0.9778938,0.008195144,0.004912642,0.0018823518,0.00059593125,0.00021310664,0.0003558047,0.00019177036,0.0057594045],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963509,0.0002906624,0.00055807247,0.0008570301,0.00081474567,0.0011286192],"domain_scores_gemma":[0.9977029,0.00048641543,0.0001514954,0.0006581303,0.00033733808,0.0006637232],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010141702,0.00047853208,0.0009884473,0.00046746607,0.00030488582,0.00015191981,0.00027630638,0.00020597066,0.00010215538],"category_scores_gemma":[0.00029971421,0.00038018278,0.00017761876,0.001458557,0.00018694608,0.00016519369,0.00031511695,0.0005536997,0.0003193795],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012075305,0.000019041068,0.0013244379,0.000099405916,0.0003057601,0.00039821136,0.00040115393,0.000010792893,0.93012124,0.0000332719,0.059337914,0.006741211],"study_design_scores_gemma":[0.0025832022,0.00021015343,0.009136028,0.00012031188,0.00012842093,0.00003339966,0.00092263665,0.0004145302,0.8991703,0.00003994305,0.086863585,0.0003774927],"about_ca_topic_score_codex":0.00015847842,"about_ca_topic_score_gemma":0.000007212509,"teacher_disagreement_score":0.030950973,"about_ca_system_score_codex":0.0005543609,"about_ca_system_score_gemma":0.00041513616,"threshold_uncertainty_score":0.999865},"labels":[],"label_agreement":null},{"id":"W4361201146","doi":"10.1016/j.jtct.2023.03.027","title":"HLA Class I Genotype Is Associated with Relapse Risk after Allogeneic Stem Cell Transplantation for NPM1-Mutated Acute Myeloid Leukemia","year":2023,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Sanofi Genzyme; Takeda Oncology; Genentech; Health Resources and Services Administration; MorphoSys; Astellas Pharma; Adaptive Biotechnologies; Kiadis Pharma; bluebird bio; TG Therapeutics; Omeros Corporation; Vertex Pharmaceuticals; Medical College of Wisconsin; StemCyte; CSL Behring; St. Jude Children's Research Hospital; HistoGenetics; Atara Biotherapeutics; CareDx; Actinium Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; AbbVie; Sanofi; GlaxoSmithKline; Bristol-Myers Squibb; Pharmacyclics; Agios Pharmaceuticals; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Moderna; Incyte; Pfizer; Medac; Jazz Pharmaceuticals; Be The Match Foundation","keywords":"NPM1; Hazard ratio; Cumulative incidence; Internal medicine; Oncology; Hematopoietic stem cell transplantation; Transplantation; Myeloid leukemia; Medicine; Proportional hazards model; Human leukocyte antigen; Immunology; Genotype; Leukemia; Myeloid; Gastroenterology; Confidence interval; Biology; Genetics; Antigen; Gene","score_opus":0.015983639303900243,"score_gpt":0.2546206635783839,"score_spread":0.2386370242744837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361201146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990104,0.0006647875,0.0057943068,0.00039472568,0.00007621559,0.0015349156,0.00090650684,0.00028219816,0.0002423125],"genre_scores_gemma":[0.9587454,0.032125287,0.00036364235,0.00070140493,0.0000632793,0.0002902332,0.003659627,0.00011967582,0.003931443],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977834,0.00018772931,0.00040740258,0.0005768465,0.00048899645,0.0005556207],"domain_scores_gemma":[0.99892807,0.00022599261,0.00015088177,0.00026460632,0.00019854443,0.00023189545],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004933822,0.00036143986,0.0004325777,0.0002978879,0.00023941671,0.000055819815,0.00012029132,0.00030667114,0.000106765976],"category_scores_gemma":[0.00000282159,0.00029308393,0.00014784522,0.00062814704,0.000111614834,0.00015286665,0.0000047637755,0.00038310653,0.00007397475],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05056844,0.0003002976,0.021824371,0.0012849243,0.0027213034,0.0031207465,0.029722666,0.00033798584,0.8577089,0.00006260019,0.0014522343,0.030895578],"study_design_scores_gemma":[0.043913994,0.0030836107,0.10484307,0.00034639856,0.0025227885,0.0002859015,0.00087000703,0.009927394,0.8293226,0.00017042193,0.0035929764,0.001120844],"about_ca_topic_score_codex":0.000060889917,"about_ca_topic_score_gemma":0.00004858722,"teacher_disagreement_score":0.0830187,"about_ca_system_score_codex":0.00020676295,"about_ca_system_score_gemma":0.0002884637,"threshold_uncertainty_score":0.99995214},"labels":[],"label_agreement":null},{"id":"W4361252724","doi":"10.1200/jco.22.02120","title":"Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood <i>KMT2A</i>-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"National Cancer Institute; Children's Cancer and Leukaemia Group","keywords":"Medicine; Myeloid leukemia; Disease; Oncology; Internal medicine; Leukemia","score_opus":0.061764803794376405,"score_gpt":0.40195570795067576,"score_spread":0.3401909041562994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361252724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862285,0.00052052503,0.000007788366,0.010116039,0.0009712088,0.0015875387,0.000050702172,0.000030600375,0.00048706195],"genre_scores_gemma":[0.9943235,0.0029429153,0.00006671796,0.0005996342,0.0010753283,0.00005240639,0.00002379072,0.00004749305,0.00086819974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99143076,0.0030106036,0.002536052,0.0006175027,0.0018835035,0.0005215921],"domain_scores_gemma":[0.9930914,0.0042199986,0.0010631594,0.00045077183,0.00039936585,0.00077527884],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.019194234,0.00030647576,0.0015028442,0.00038954808,0.00020379687,0.00007757368,0.00055031345,0.0003857403,0.00005995249],"category_scores_gemma":[0.006774529,0.0001901207,0.00023155432,0.00048411512,0.00038840517,0.00030966193,0.0006626484,0.003795754,0.000018851628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015005638,0.0046509253,0.9355787,0.000013686042,0.0017879173,0.0038614057,0.0017805921,0.00001403621,0.00014534147,0.0000051755474,0.014492924,0.02266366],"study_design_scores_gemma":[0.039145757,0.011621928,0.93879515,0.00007342537,0.0011456148,0.0002444594,0.005125391,0.00034355145,0.0000053882254,0.0001534367,0.003185142,0.0001607707],"about_ca_topic_score_codex":0.00033132255,"about_ca_topic_score_gemma":0.0011056293,"teacher_disagreement_score":0.024140118,"about_ca_system_score_codex":0.0004835439,"about_ca_system_score_gemma":0.0017867285,"threshold_uncertainty_score":0.99850255},"labels":[],"label_agreement":null},{"id":"W4361253850","doi":"10.1158/0008-5472.c.6494330","title":"Data from Transgenic Mice Expressing the p75 CCAAT-Displacement Protein/Cut Homeobox Isoform Develop a Myeloproliferative Disease–Like Myeloid Leukemia","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Neurological Institute and Hospital; McGill University","funders":"Canadian Breast Cancer Research Alliance; Genome Canada; U.S. Department of Defense","keywords":"Biology; Genetically modified mouse; Myeloid; Haematopoiesis; Transgene; Myeloproliferative neoplasm; Cancer research; Molecular biology; Leukemia; Bone marrow; Myeloproliferative Disorders; Immunology; Pathology; Stem cell; Myelofibrosis; Gene; Cell biology; Genetics; Medicine","score_opus":0.09986266300815425,"score_gpt":0.3448612860801946,"score_spread":0.24499862307204037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361253850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8340298,0.00489701,0.048786055,0.050956305,0.0028494196,0.031959053,0.016153507,0.0029565056,0.0074123354],"genre_scores_gemma":[0.6783326,0.0042408747,0.051532663,0.0069050966,0.008790067,0.012514084,0.07389612,0.0018841614,0.16190434],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98900676,0.00061799545,0.0017921808,0.0036387905,0.0029750054,0.0019692506],"domain_scores_gemma":[0.98966205,0.0008307929,0.0005797148,0.0068749366,0.0008273778,0.0012251008],"candidate_categories":["metaepi_narrow","open_science","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0021838883,0.0016045554,0.0017712851,0.00054051273,0.00083247025,0.000662962,0.0046348586,0.0009402744,0.0015448768],"category_scores_gemma":[0.0011293561,0.001103144,0.0004686536,0.0010969592,0.00071673864,0.0005177546,0.009113583,0.004818314,0.0015173099],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.020580007,0.0015732938,0.004018461,0.01006124,0.015782395,0.0022538542,0.019906223,0.001265924,0.08359017,0.0007228669,0.8132634,0.026982171],"study_design_scores_gemma":[0.038246904,0.0012454137,0.09414382,0.030412694,0.009281011,0.00020095444,0.021468822,0.22586578,0.07752192,0.010768857,0.47725615,0.013587687],"about_ca_topic_score_codex":0.0029716312,"about_ca_topic_score_gemma":0.0014988815,"teacher_disagreement_score":0.33600727,"about_ca_system_score_codex":0.0042270375,"about_ca_system_score_gemma":0.01753624,"threshold_uncertainty_score":0.9996702},"labels":[],"label_agreement":null},{"id":"W4361266575","doi":"10.1158/0008-5472.c.6494330.v1","title":"Data from Transgenic Mice Expressing the p75 CCAAT-Displacement Protein/Cut Homeobox Isoform Develop a Myeloproliferative Disease–Like Myeloid Leukemia","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Neurological Institute and Hospital; McGill University","funders":"Canadian Breast Cancer Research Alliance; Genome Canada; U.S. Department of Defense","keywords":"Biology; Genetically modified mouse; Myeloid; Haematopoiesis; Transgene; Myeloproliferative neoplasm; Cancer research; Bone marrow; Molecular biology; Leukemia; Myeloproliferative Disorders; Immunology; Pathology; Stem cell; Myelofibrosis; Gene; Cell biology; Medicine; Genetics","score_opus":0.09986266300815425,"score_gpt":0.3448612860801946,"score_spread":0.24499862307204037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361266575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8340298,0.00489701,0.048786055,0.050956305,0.0028494196,0.031959053,0.016153507,0.0029565056,0.0074123354],"genre_scores_gemma":[0.6783326,0.0042408747,0.051532663,0.0069050966,0.008790067,0.012514084,0.07389612,0.0018841614,0.16190434],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98900676,0.00061799545,0.0017921808,0.0036387905,0.0029750054,0.0019692506],"domain_scores_gemma":[0.98966205,0.0008307929,0.0005797148,0.0068749366,0.0008273778,0.0012251008],"candidate_categories":["metaepi_narrow","open_science","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0021838883,0.0016045554,0.0017712851,0.00054051273,0.00083247025,0.000662962,0.0046348586,0.0009402744,0.0015448768],"category_scores_gemma":[0.0011293561,0.001103144,0.0004686536,0.0010969592,0.00071673864,0.0005177546,0.009113583,0.004818314,0.0015173099],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.020580007,0.0015732938,0.004018461,0.01006124,0.015782395,0.0022538542,0.019906223,0.001265924,0.08359017,0.0007228669,0.8132634,0.026982171],"study_design_scores_gemma":[0.038246904,0.0012454137,0.09414382,0.030412694,0.009281011,0.00020095444,0.021468822,0.22586578,0.07752192,0.010768857,0.47725615,0.013587687],"about_ca_topic_score_codex":0.0029716312,"about_ca_topic_score_gemma":0.0014988815,"teacher_disagreement_score":0.33600727,"about_ca_system_score_codex":0.0042270375,"about_ca_system_score_gemma":0.01753624,"threshold_uncertainty_score":0.9996702},"labels":[],"label_agreement":null},{"id":"W4361817834","doi":"10.1158/1078-0432.c.6519140.v1","title":"Data from Dynamic Single-Cell Network Profiles in Acute Myelogenous Leukemia Are Associated with Patient Response to Standard Induction Therapy","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Flow cytometry; Leukemia; Medicine; Induction chemotherapy; Intracellular; Internal medicine; Oncology; Biology; Chemotherapy; Immunology; Genetics","score_opus":0.07271221215874502,"score_gpt":0.317809410743814,"score_spread":0.245097198585069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361817834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98270106,0.0003583685,0.0008462382,0.0034083666,0.0005331979,0.004583648,0.006831556,0.000541331,0.00019622524],"genre_scores_gemma":[0.9588403,0.00083694584,0.009820373,0.0010289224,0.000402542,0.00062399183,0.022796495,0.00045547998,0.0051949127],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9935339,0.0009563051,0.0008855455,0.0019823622,0.001538212,0.0011036743],"domain_scores_gemma":[0.9947273,0.0007881358,0.00051786343,0.003032746,0.0005396111,0.0003943312],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0018992272,0.0007304209,0.001338118,0.00065512134,0.00014918472,0.0001534618,0.0010748628,0.0009925994,0.00017718176],"category_scores_gemma":[0.0008248715,0.00057624985,0.00010836844,0.0012882696,0.00013636748,0.00012667853,0.0025967672,0.0027430104,0.00014025849],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34093922,0.0029724566,0.08166506,0.00057425164,0.010220356,0.015602745,0.011532893,0.040781762,0.1170382,0.0000044273766,0.31582803,0.06284058],"study_design_scores_gemma":[0.036968995,0.020752136,0.8327597,0.015159864,0.0015587603,0.00013278543,0.00934669,0.038480457,0.017013459,0.0011635209,0.020911835,0.0057518296],"about_ca_topic_score_codex":0.0016315826,"about_ca_topic_score_gemma":0.0064283633,"teacher_disagreement_score":0.75109464,"about_ca_system_score_codex":0.010673636,"about_ca_system_score_gemma":0.0047298744,"threshold_uncertainty_score":0.9996689},"labels":[],"label_agreement":null},{"id":"W4361824681","doi":"10.1158/0008-5472.c.6513157.v1","title":"Data from &lt;i&gt;TET2&lt;/i&gt; and &lt;i&gt;DNMT3A&lt;/i&gt; Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; National Institutes of Health; Austrian Science Fund; European Commission; National Institute of Diabetes and Digestive and Kidney Diseases; ECOG-ACRIN Cancer Research Group; Memorial Sloan-Kettering Cancer Center; American College of Radiology Imaging Network; Leukemia and Lymphoma Society","keywords":"Molecular biology; Biology; DNA methylation; Cancer research; Chemistry; Gene; Genetics; Gene expression","score_opus":0.03645697205000999,"score_gpt":0.2975790861642553,"score_spread":0.26112211411424535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361824681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757384,0.0016917299,0.0012424304,0.002608818,0.0020815951,0.006095106,0.0058012316,0.0010989553,0.0036417001],"genre_scores_gemma":[0.958628,0.004330707,0.0084428815,0.000883621,0.0018712102,0.00044930747,0.008097792,0.0005221178,0.016774368],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98788965,0.0013922768,0.0018944712,0.004319001,0.0028196857,0.0016849157],"domain_scores_gemma":[0.9855629,0.005512426,0.00069025654,0.0055366284,0.00078589946,0.0019118957],"candidate_categories":["metaepi_narrow","open_science","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0037751752,0.0016804689,0.0029469046,0.0014452762,0.00048361684,0.00020647794,0.0009563602,0.0015262434,0.00028151117],"category_scores_gemma":[0.0037041167,0.0015644769,0.0005524578,0.0011036482,0.0008426385,0.0003706258,0.010005548,0.0021381718,0.00065513776],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001007435,0.00042931616,0.0009983842,0.0022753226,0.0016336564,0.002094073,0.001316158,0.00044088226,0.72673655,0.00028773068,0.25762248,0.0051580304],"study_design_scores_gemma":[0.018849963,0.0036454971,0.19919123,0.012644382,0.006152845,0.00032514613,0.00058430777,0.07192747,0.4826016,0.0016309775,0.19566281,0.006783767],"about_ca_topic_score_codex":0.0010837048,"about_ca_topic_score_gemma":0.0034498682,"teacher_disagreement_score":0.24413493,"about_ca_system_score_codex":0.002266179,"about_ca_system_score_gemma":0.0024781383,"threshold_uncertainty_score":0.99977},"labels":[],"label_agreement":null},{"id":"W4361825022","doi":"10.1158/0008-5472.c.6514302.v1","title":"Data from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Princess Margaret Cancer Foundation; Cancer Research Society","keywords":"Cancer research; Myeloid leukemia; Biology; Syk; Myeloid; Molecular biology; Chemistry; Tyrosine kinase; Signal transduction; Cell biology","score_opus":0.08082606845650221,"score_gpt":0.3651227147232879,"score_spread":0.2842966462667857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361825022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780178,0.001379956,0.004185562,0.0040329625,0.001334994,0.0030297195,0.0056110993,0.00041701188,0.0019908925],"genre_scores_gemma":[0.8845133,0.0020202263,0.08498614,0.0005875912,0.0011971164,0.00025438852,0.01410743,0.00044332165,0.011890463],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9923386,0.00040230283,0.0019391333,0.0023095438,0.0019515824,0.0010588282],"domain_scores_gemma":[0.99377716,0.0013167617,0.00055768027,0.0035768426,0.00040706524,0.00036452315],"candidate_categories":["metaepi_narrow","open_science","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019501272,0.00074968603,0.0019431127,0.0006583963,0.00010770278,0.00010757504,0.0021916854,0.0008459605,0.0004914956],"category_scores_gemma":[0.0015083904,0.0006583871,0.00021044903,0.0010822793,0.00016858918,0.00043387336,0.010134608,0.0026515243,0.00016424333],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004735973,0.00026278364,0.02563543,0.0048525105,0.0014126586,0.0018493016,0.0055600824,0.0041054906,0.37354964,0.00011667971,0.576951,0.00096841436],"study_design_scores_gemma":[0.0142061105,0.00045617463,0.03951414,0.046386532,0.0013117266,0.00001615979,0.015028609,0.0150468005,0.8037814,0.0067800432,0.05328854,0.004183755],"about_ca_topic_score_codex":0.009501441,"about_ca_topic_score_gemma":0.0014818204,"teacher_disagreement_score":0.5236625,"about_ca_system_score_codex":0.002384507,"about_ca_system_score_gemma":0.0027896925,"threshold_uncertainty_score":0.9996494},"labels":[],"label_agreement":null},{"id":"W4361943478","doi":"10.1158/1078-0432.c.6519140","title":"Data from Dynamic Single-Cell Network Profiles in Acute Myelogenous Leukemia Are Associated with Patient Response to Standard Induction Therapy","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Flow cytometry; Leukemia; Intracellular; Medicine; Internal medicine; Oncology; Biology; Immunology; Genetics","score_opus":0.07271221215874502,"score_gpt":0.317809410743814,"score_spread":0.245097198585069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361943478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98270106,0.0003583685,0.0008462382,0.0034083666,0.0005331979,0.004583648,0.006831556,0.000541331,0.00019622524],"genre_scores_gemma":[0.9588403,0.00083694584,0.009820373,0.0010289224,0.000402542,0.00062399183,0.022796495,0.00045547998,0.0051949127],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9935339,0.0009563051,0.0008855455,0.0019823622,0.001538212,0.0011036743],"domain_scores_gemma":[0.9947273,0.0007881358,0.00051786343,0.003032746,0.0005396111,0.0003943312],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0018992272,0.0007304209,0.001338118,0.00065512134,0.00014918472,0.0001534618,0.0010748628,0.0009925994,0.00017718176],"category_scores_gemma":[0.0008248715,0.00057624985,0.00010836844,0.0012882696,0.00013636748,0.00012667853,0.0025967672,0.0027430104,0.00014025849],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34093922,0.0029724566,0.08166506,0.00057425164,0.010220356,0.015602745,0.011532893,0.040781762,0.1170382,0.0000044273766,0.31582803,0.06284058],"study_design_scores_gemma":[0.036968995,0.020752136,0.8327597,0.015159864,0.0015587603,0.00013278543,0.00934669,0.038480457,0.017013459,0.0011635209,0.020911835,0.0057518296],"about_ca_topic_score_codex":0.0016315826,"about_ca_topic_score_gemma":0.0064283633,"teacher_disagreement_score":0.75109464,"about_ca_system_score_codex":0.010673636,"about_ca_system_score_gemma":0.0047298744,"threshold_uncertainty_score":0.9996689},"labels":[],"label_agreement":null},{"id":"W4361947039","doi":"10.1158/1078-0432.c.6529353","title":"Data from Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of &lt;i&gt;HOXA9&lt;/i&gt; and &lt;i&gt;MEIS1&lt;/i&gt; Expression","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Gilead Sciences","keywords":"Medicine; Cytarabine; Internal medicine; Myeloid leukemia; Gastroenterology","score_opus":0.03237606889949094,"score_gpt":0.2971865765427594,"score_spread":0.2648105076432684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361947039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828715,0.0020997766,0.0013862175,0.002894474,0.00026318757,0.0072501786,0.002342392,0.00036473453,0.0005275484],"genre_scores_gemma":[0.9623048,0.016739134,0.0045314087,0.00019575891,0.00028675128,0.0011200731,0.008422121,0.00038561155,0.0060143946],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9896702,0.0016634258,0.001965686,0.0034303518,0.0020452018,0.001225107],"domain_scores_gemma":[0.9927598,0.0015950573,0.0011416088,0.0031529714,0.00075891014,0.00059161993],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0039176545,0.0013178878,0.00238921,0.001920194,0.00017950284,0.00016977901,0.0012459485,0.0018515796,0.0001924209],"category_scores_gemma":[0.0013881368,0.001148379,0.00013450121,0.001703978,0.001047199,0.0007505801,0.0023445322,0.002576948,0.0000260052],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046100896,0.00092707924,0.008825971,0.0009739902,0.0009905805,0.00043525698,0.0047527244,0.00033733208,0.9186299,0.000109789005,0.013967937,0.0039485605],"study_design_scores_gemma":[0.05300081,0.0047142147,0.7827394,0.01106924,0.0011559179,0.00017140563,0.0008580774,0.039491303,0.09056043,0.00096281053,0.012789741,0.002486621],"about_ca_topic_score_codex":0.00076314405,"about_ca_topic_score_gemma":0.0021630393,"teacher_disagreement_score":0.82806945,"about_ca_system_score_codex":0.0030023332,"about_ca_system_score_gemma":0.0030862747,"threshold_uncertainty_score":0.99995726},"labels":[],"label_agreement":null},{"id":"W4361950517","doi":"10.1158/1078-0432.c.6532751","title":"Data from Outcomes in Patients with Poor-Risk Cytogenetics with or without &lt;i&gt;TP53&lt;/i&gt; Mutations Treated with Venetoclax and Azacitidine","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Venetoclax; Azacitidine; Internal medicine; Medicine; Leukemia; Biology; DNA methylation; Genetics; Chronic lymphocytic leukemia","score_opus":0.053242193823064554,"score_gpt":0.3166994790476033,"score_spread":0.26345728522453876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361950517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985562,0.00012985637,0.0012459592,0.0006054041,0.000056578854,0.0043709446,0.007025268,0.0003616748,0.0006422743],"genre_scores_gemma":[0.94130695,0.00047551654,0.027669802,0.00018329002,0.00012024201,0.00041661784,0.021575036,0.0003915141,0.007861061],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942015,0.00025359745,0.0008465625,0.0021352214,0.0016361392,0.00092701195],"domain_scores_gemma":[0.99463,0.0006102477,0.0004632054,0.0030590382,0.00064020365,0.00059731014],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041420304,0.0010418706,0.0018614759,0.0007997773,0.00017535569,0.00017032081,0.0008870059,0.0005351951,0.00025161638],"category_scores_gemma":[0.00037022267,0.0005994149,0.00006211783,0.00095241226,0.00061874965,0.00019913405,0.0016579368,0.0014695488,0.000077777804],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006872645,0.00033016165,0.98670816,0.00021836744,0.0019330068,0.0005064929,0.00032777945,0.0008327732,0.00011283833,0.000011002528,0.0013778942,0.000768879],"study_design_scores_gemma":[0.02340787,0.002865427,0.9563781,0.0013125723,0.001820749,0.000034266504,0.00024007462,0.01155891,0.00028162668,0.000048225433,0.0010114147,0.0010407671],"about_ca_topic_score_codex":0.0033211773,"about_ca_topic_score_gemma":0.02949588,"teacher_disagreement_score":0.044255123,"about_ca_system_score_codex":0.0009863508,"about_ca_system_score_gemma":0.0028651443,"threshold_uncertainty_score":0.9996457},"labels":[],"label_agreement":null},{"id":"W4361953852","doi":"10.1158/1078-0432.c.6529353.v1","title":"Data from Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of &lt;i&gt;HOXA9&lt;/i&gt; and &lt;i&gt;MEIS1&lt;/i&gt; Expression","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Gilead Sciences","keywords":"Medicine; Cytarabine; Internal medicine; Myeloid leukemia; Gastroenterology","score_opus":0.03237606889949094,"score_gpt":0.2971865765427594,"score_spread":0.2648105076432684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361953852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828715,0.0020997766,0.0013862175,0.002894474,0.00026318757,0.0072501786,0.002342392,0.00036473453,0.0005275484],"genre_scores_gemma":[0.9623048,0.016739134,0.0045314087,0.00019575891,0.00028675128,0.0011200731,0.008422121,0.00038561155,0.0060143946],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9896702,0.0016634258,0.001965686,0.0034303518,0.0020452018,0.001225107],"domain_scores_gemma":[0.9927598,0.0015950573,0.0011416088,0.0031529714,0.00075891014,0.00059161993],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0039176545,0.0013178878,0.00238921,0.001920194,0.00017950284,0.00016977901,0.0012459485,0.0018515796,0.0001924209],"category_scores_gemma":[0.0013881368,0.001148379,0.00013450121,0.001703978,0.001047199,0.0007505801,0.0023445322,0.002576948,0.0000260052],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046100896,0.00092707924,0.008825971,0.0009739902,0.0009905805,0.00043525698,0.0047527244,0.00033733208,0.9186299,0.000109789005,0.013967937,0.0039485605],"study_design_scores_gemma":[0.05300081,0.0047142147,0.7827394,0.01106924,0.0011559179,0.00017140563,0.0008580774,0.039491303,0.09056043,0.00096281053,0.012789741,0.002486621],"about_ca_topic_score_codex":0.00076314405,"about_ca_topic_score_gemma":0.0021630393,"teacher_disagreement_score":0.82806945,"about_ca_system_score_codex":0.0030023332,"about_ca_system_score_gemma":0.0030862747,"threshold_uncertainty_score":0.99995726},"labels":[],"label_agreement":null},{"id":"W4362419009","doi":"10.1158/0008-5472.22394655.v1","title":"Supplementary Figure Legends 1-4, Tables 1-3 from The Mixed Lineage Leukemia (MLL) Fusion–Associated Gene &lt;i&gt;AF4&lt;/i&gt; Promotes CD133 Transcription","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Fusion gene; Fusion; Biology; Gene; Genetics; Cancer research; Philosophy; Linguistics","score_opus":0.037415747005736896,"score_gpt":0.28399012556747033,"score_spread":0.24657437856173342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362419009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9284427,0.0038038427,0.0010887717,0.02496455,0.002753416,0.0066550225,0.028266089,0.0014114848,0.0026141105],"genre_scores_gemma":[0.6914698,0.0064984486,0.005460662,0.0024479516,0.0042854687,0.0015835026,0.19136192,0.00079256116,0.09609972],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9902258,0.00080265105,0.0019146508,0.002385502,0.0027811446,0.0018902896],"domain_scores_gemma":[0.99414754,0.0009837804,0.0006084016,0.0027456162,0.0008232724,0.00069136143],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0027160035,0.0014636095,0.001960577,0.00059673726,0.00070241187,0.00033360472,0.0018738923,0.0019754425,0.013859801],"category_scores_gemma":[0.00083749404,0.0010712928,0.0010757656,0.0011454561,0.00037724606,0.00018495036,0.001981715,0.003870367,0.0005974353],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060478004,0.00040589643,0.0013192628,0.00043277998,0.0024259733,0.0007046788,0.0016365271,0.00018862815,0.43431225,0.00011996881,0.55368894,0.004160284],"study_design_scores_gemma":[0.022476366,0.0015522301,0.12288329,0.0037669973,0.005908518,0.00012550692,0.0027035677,0.039205603,0.281651,0.0020537733,0.51314837,0.004524786],"about_ca_topic_score_codex":0.0117324535,"about_ca_topic_score_gemma":0.020913882,"teacher_disagreement_score":0.23697293,"about_ca_system_score_codex":0.004503439,"about_ca_system_score_gemma":0.0034904832,"threshold_uncertainty_score":0.99981135},"labels":[],"label_agreement":null},{"id":"W4362431119","doi":"10.1158/0008-5472.22433115.v1","title":"Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Myeloid leukemia; STAT5; Cancer research; Biology; Medicine; Signal transduction; Genetics","score_opus":0.06904523410055514,"score_gpt":0.35336241402930835,"score_spread":0.2843171799287532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362431119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9298114,0.001394743,0.0036466902,0.0045816884,0.0017356584,0.0045369007,0.050435927,0.00065184856,0.0032051532],"genre_scores_gemma":[0.6169614,0.002808713,0.21276195,0.0011211077,0.002420414,0.0008098969,0.12815993,0.00089179684,0.03406478],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9923879,0.0003861586,0.0019046655,0.0023170898,0.0019148068,0.0010894104],"domain_scores_gemma":[0.99315953,0.001895973,0.0005840181,0.003580114,0.00040815497,0.0003722306],"candidate_categories":["metaepi_narrow","open_science","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013706012,0.0007642194,0.0019292989,0.00062566163,0.00011993963,0.00011253304,0.0021635622,0.0008572516,0.0037188448],"category_scores_gemma":[0.0020366507,0.00067556254,0.00021997733,0.0010879133,0.00016939027,0.00044624603,0.009923979,0.0026358222,0.00032807412],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016605586,0.00011424414,0.0042576487,0.0019582224,0.00056108553,0.0007494049,0.0023519567,0.0018429123,0.08884041,0.000025202511,0.8970679,0.00057044456],"study_design_scores_gemma":[0.013664862,0.0005304683,0.025702348,0.057093997,0.001228246,0.000018241324,0.017055014,0.019067531,0.6840533,0.005228665,0.17160928,0.0047480217],"about_ca_topic_score_codex":0.01121321,"about_ca_topic_score_gemma":0.0013852577,"teacher_disagreement_score":0.7254586,"about_ca_system_score_codex":0.0022779547,"about_ca_system_score_gemma":0.0028496438,"threshold_uncertainty_score":0.99966514},"labels":[],"label_agreement":null},{"id":"W4362475482","doi":"10.1016/j.heliyon.2023.e14924","title":"Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group","year":2023,"lang":"en","type":"review","venue":"Heliyon","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of Toronto","funders":"National Natural Science Foundation of China; bluebird bio; Pfizer","keywords":"Medicine; Myeloid leukemia; Internal medicine; Intensive care medicine; Oncology; Family medicine","score_opus":0.08262965383629457,"score_gpt":0.3702089806981634,"score_spread":0.2875793268618688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362475482","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009926148,0.9696414,0.000079066114,0.0014573464,0.0024926704,0.008073404,0.007749202,0.0002122156,0.0003685887],"genre_scores_gemma":[0.000065842905,0.98009974,0.00047164253,0.00078063924,0.0009301748,0.0014326209,0.014705141,0.0002575112,0.0012566608],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995322,0.00021277455,0.0016185492,0.0012334062,0.0007751125,0.00083815155],"domain_scores_gemma":[0.9962441,0.0018563899,0.00044952368,0.0010040939,0.00021024434,0.00023570501],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063687575,0.00084410864,0.0020100393,0.0005270086,0.00012268183,0.00009940578,0.0010433242,0.0007449148,0.00009863508],"category_scores_gemma":[0.0002599286,0.0005601706,0.0008597949,0.00039052463,0.00017614344,0.000047360714,0.00015485096,0.0017034385,0.0004836519],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061088935,0.00085643417,0.00058053655,0.039232638,0.008967146,0.017570248,0.0015351308,0.0000019667466,0.002426159,0.00012632093,0.0939117,0.82868284],"study_design_scores_gemma":[0.0037266728,0.00046315347,0.00020437088,0.071078986,0.00095665373,0.0006428417,0.000045235916,0.000013624673,0.00020265208,0.000013145015,0.9221198,0.0005328962],"about_ca_topic_score_codex":0.00075558265,"about_ca_topic_score_gemma":0.0008647723,"teacher_disagreement_score":0.8282081,"about_ca_system_score_codex":0.0031614888,"about_ca_system_score_gemma":0.0015242393,"threshold_uncertainty_score":0.999685},"labels":[],"label_agreement":null},{"id":"W4362526615","doi":"10.1002/cyto.b.22118","title":"The impact of Down syndrome‐specific non‐malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease","year":2023,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Agricultural Research Institute of Ontario; University of Ottawa; Hospital for Sick Children","funders":"","keywords":"CD34; Bone marrow; Immunophenotyping; Haematopoiesis; Minimal residual disease; Myeloid; Myeloid leukemia; Leukemia; Population; Immunology; Medicine; Progenitor cell; Induction chemotherapy; Chemotherapy; Cancer research; Stem cell; Biology; Pathology; Flow cytometry; Internal medicine","score_opus":0.08034394263651055,"score_gpt":0.3773868149291594,"score_spread":0.2970428722926488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362526615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930793,0.0011758109,0.00010062231,0.0031693985,0.00032825966,0.0015145163,0.00007101216,0.00007019252,0.0004909053],"genre_scores_gemma":[0.9962264,0.0020435548,0.000019313036,0.00017766556,0.0003787577,0.00017606062,0.000058029214,0.00006677562,0.00085348147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99285233,0.0015524917,0.0019877113,0.00071842934,0.0020239083,0.00086511543],"domain_scores_gemma":[0.98764104,0.008822477,0.00060152204,0.002188052,0.00039901148,0.00034788795],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013951965,0.00039694493,0.0009886528,0.0011700644,0.00035667655,0.00008529713,0.0008836689,0.00033980623,0.000116406605],"category_scores_gemma":[0.008585184,0.00019089422,0.000764254,0.008456452,0.00093092135,0.00013472933,0.00023105097,0.0016368233,0.0002957269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021118306,0.0044058845,0.49270496,0.0013933226,0.0019525222,0.002609008,0.001210717,0.0017438055,0.3238294,0.00095717784,0.118429594,0.0296453],"study_design_scores_gemma":[0.0035407257,0.002690052,0.9623501,0.00061724184,0.00017293783,0.00023175763,0.0010600131,0.0026022894,0.024807705,0.00043606458,0.0011442091,0.00034694976],"about_ca_topic_score_codex":0.00006975242,"about_ca_topic_score_gemma":0.000014252385,"teacher_disagreement_score":0.4696451,"about_ca_system_score_codex":0.0006241506,"about_ca_system_score_gemma":0.00082782446,"threshold_uncertainty_score":0.99976593},"labels":[],"label_agreement":null},{"id":"W4362542930","doi":"10.1158/1538-7445.am2023-2530","title":"Abstract 2530: DELE1 loss and dysfunctional integrated stress signaling in <i>TP53</i> mutated AML is a novel pathway for venetoclax resistance","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Venetoclax; Myeloid leukemia; Cancer research; Integrated stress response; Leukemia; MCL1; Cytarabine; Biology; Medicine; Chronic lymphocytic leukemia; Internal medicine; Gene; Downregulation and upregulation; Genetics; Translation (biology)","score_opus":0.08802920100020656,"score_gpt":0.39442406025205257,"score_spread":0.306394859251846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362542930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99209946,0.0010081158,0.00014868082,0.0035740025,0.00010539987,0.001599861,0.0009937235,0.000108594526,0.00036217307],"genre_scores_gemma":[0.99057496,0.0006644667,0.00036590052,0.00025916364,0.00032631244,0.0012692403,0.00037037383,0.00009633623,0.0060732244],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962961,0.000097146476,0.00044739025,0.0007899095,0.0011587132,0.0012107202],"domain_scores_gemma":[0.9971139,0.0009671919,0.00006320012,0.0003953622,0.0011017872,0.00035859528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020864778,0.00023877568,0.00041631394,0.00082472543,0.00026975322,0.000101505895,0.00028652704,0.00023897461,0.0003164275],"category_scores_gemma":[0.00076043594,0.00021602171,0.00008225951,0.0024707504,0.00042904972,0.00015244489,0.00016743415,0.0013598998,0.0000598245],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007836178,0.00019321102,0.012258171,0.0021411546,0.00025758377,0.00070680765,0.001705215,0.0007911311,0.92422396,0.00038575745,0.04181192,0.0076889344],"study_design_scores_gemma":[0.030617615,0.0011657592,0.10478689,0.006561556,0.00007479117,0.000072370225,0.0055435738,0.019322375,0.6824498,0.0022283182,0.1457716,0.0014053244],"about_ca_topic_score_codex":0.0017419799,"about_ca_topic_score_gemma":0.0012463806,"teacher_disagreement_score":0.2417741,"about_ca_system_score_codex":0.0022137242,"about_ca_system_score_gemma":0.003602846,"threshold_uncertainty_score":0.880911},"labels":[],"label_agreement":null},{"id":"W4362556060","doi":"10.1158/2159-8290.22541194","title":"Supplementary Figure from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Epigenetics; Medicine; Immunology; Cancer research; Biology; Genetics; Gene","score_opus":0.04658979265368014,"score_gpt":0.3228955170245729,"score_spread":0.2763057243708928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362556060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892961,0.0001324299,0.004794046,0.0018147905,0.00040625114,0.0016330288,0.001555331,0.00007506061,0.0002929777],"genre_scores_gemma":[0.98271567,0.00092406257,0.0013454903,0.00009795876,0.00021650428,0.00011523449,0.011431237,0.000085666754,0.0030681554],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968366,0.0001838769,0.0008851972,0.00063777505,0.0011220368,0.00033452574],"domain_scores_gemma":[0.9976753,0.00046111576,0.0005137917,0.00092585396,0.00030472773,0.00011919846],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024953744,0.0003629254,0.0008300343,0.00046940232,0.000041067033,0.000018470533,0.00038905308,0.0004240318,0.0057940693],"category_scores_gemma":[0.00009880815,0.00031030146,0.00026435993,0.00020452669,0.00011268726,0.000043856442,0.0007002516,0.0008107007,0.000035617417],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011140184,0.0006000402,0.099846676,0.0018591319,0.0026994185,0.00001719322,0.0021229612,0.00076914235,0.87827736,0.00013128563,0.003669994,0.008892777],"study_design_scores_gemma":[0.0024656956,0.00031917167,0.24863198,0.00061441725,0.00045723203,0.0000012164086,0.00080358813,0.004569863,0.7390013,0.002619044,0.00025210396,0.00026439875],"about_ca_topic_score_codex":0.0046893074,"about_ca_topic_score_gemma":0.00023039061,"teacher_disagreement_score":0.14878531,"about_ca_system_score_codex":0.00047980217,"about_ca_system_score_gemma":0.0005681546,"threshold_uncertainty_score":0.9999349},"labels":[],"label_agreement":null},{"id":"W4362556075","doi":"10.1158/2159-8290.22541194.v1","title":"Supplementary Figure from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Epigenetics; Cancer research; Medicine; Biology; Genetics; Gene","score_opus":0.04658979265368014,"score_gpt":0.3228955170245729,"score_spread":0.2763057243708928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362556075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892961,0.0001324299,0.004794046,0.0018147905,0.00040625114,0.0016330288,0.001555331,0.00007506061,0.0002929777],"genre_scores_gemma":[0.98271567,0.00092406257,0.0013454903,0.00009795876,0.00021650428,0.00011523449,0.011431237,0.000085666754,0.0030681554],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968366,0.0001838769,0.0008851972,0.00063777505,0.0011220368,0.00033452574],"domain_scores_gemma":[0.9976753,0.00046111576,0.0005137917,0.00092585396,0.00030472773,0.00011919846],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024953744,0.0003629254,0.0008300343,0.00046940232,0.000041067033,0.000018470533,0.00038905308,0.0004240318,0.0057940693],"category_scores_gemma":[0.00009880815,0.00031030146,0.00026435993,0.00020452669,0.00011268726,0.000043856442,0.0007002516,0.0008107007,0.000035617417],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011140184,0.0006000402,0.099846676,0.0018591319,0.0026994185,0.00001719322,0.0021229612,0.00076914235,0.87827736,0.00013128563,0.003669994,0.008892777],"study_design_scores_gemma":[0.0024656956,0.00031917167,0.24863198,0.00061441725,0.00045723203,0.0000012164086,0.00080358813,0.004569863,0.7390013,0.002619044,0.00025210396,0.00026439875],"about_ca_topic_score_codex":0.0046893074,"about_ca_topic_score_gemma":0.00023039061,"teacher_disagreement_score":0.14878531,"about_ca_system_score_codex":0.00047980217,"about_ca_system_score_gemma":0.0005681546,"threshold_uncertainty_score":0.9999349},"labels":[],"label_agreement":null},{"id":"W4362656958","doi":"10.3324/haematol.2022.282637","title":"Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax","year":2023,"lang":"en","type":"letter","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; Children's Hospital of Philadelphia; Canadian Institutes of Health Research; Leukemia and Lymphoma Society; American Society of Hematology; V Foundation for Cancer Research; National Cancer Institute; National Institutes of Health; Conquer Cancer Foundation; U.S. Department of Defense","keywords":"Venetoclax; Azacitidine; Medicine; Refractory (planetary science); Leukemia; Oncology; Internal medicine; Pediatrics; Genetics; Biology; Chronic lymphocytic leukemia","score_opus":0.040125126004362105,"score_gpt":0.31240697663451167,"score_spread":0.27228185063014954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362656958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9653591,0.00031279802,0.000002700573,0.031290717,0.00008244063,0.0017217394,0.00009382794,0.00031777108,0.0008189279],"genre_scores_gemma":[0.6755515,0.007788157,0.0034351402,0.262196,0.0050597857,0.0015257561,0.0063003264,0.0012556852,0.036887664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99504256,0.0007248405,0.0009422281,0.001319846,0.0009780104,0.0009925079],"domain_scores_gemma":[0.9957389,0.0023369251,0.00042395975,0.0009279386,0.0002982731,0.00027398867],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0006591111,0.0006937374,0.0019041292,0.0009370476,0.00010737682,0.000044833516,0.0003200672,0.0018855751,0.00009748199],"category_scores_gemma":[0.0010894908,0.00042620354,0.00012943632,0.0010902297,0.0005895877,0.00009684578,0.00021863688,0.005072873,0.00023091113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004706479,0.00007764491,0.6073534,0.00056949776,0.00012366554,0.024990208,0.000029711191,0.0000010021993,7.5337846e-7,0.0000028456273,0.36171308,0.00043170268],"study_design_scores_gemma":[0.011546281,0.0065022884,0.860078,0.0008087109,0.0005153864,0.00059541076,0.000026958882,0.00003661892,0.0000087354165,0.000022055237,0.11911493,0.00074465194],"about_ca_topic_score_codex":0.00012614198,"about_ca_topic_score_gemma":0.000045863115,"teacher_disagreement_score":0.2898076,"about_ca_system_score_codex":0.0011132729,"about_ca_system_score_gemma":0.0019415291,"threshold_uncertainty_score":0.999819},"labels":[],"label_agreement":null},{"id":"W4364381091","doi":"10.1186/s13045-023-01431-7","title":"Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study","year":2023,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; BeiGene; Astellas Pharma; Adaptive Biotechnologies; Kiadis Pharma; bluebird bio; TG Therapeutics; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; Medical College of Wisconsin; StemCyte; HistoGenetics; Atara Biotherapeutics; CareDx; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Incyte; Pfizer; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; CSL Behring; AstraZeneca; Bristol-Myers Squibb; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen; Jazz Pharmaceuticals; Be The Match Foundation","keywords":"Hematopoietic cell; Hematology; Myelodysplastic syndromes; Medicine; Internal medicine; Oncology; Hematologic Neoplasms; Haematopoiesis; Genetics; Biology; Stem cell; Transplantation; Bone marrow","score_opus":0.029290541222779326,"score_gpt":0.30702762840655023,"score_spread":0.2777370871837709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364381091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84977764,0.00026090804,0.0038740146,0.13414752,0.0027249486,0.0078858975,0.0011802765,0.000100452344,0.00004834944],"genre_scores_gemma":[0.876873,0.00014641724,0.010393994,0.091942415,0.0035887905,0.0031878469,0.0040179333,0.0014055028,0.008444089],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99373215,0.00028599447,0.002472916,0.00087170536,0.0011670479,0.0014702],"domain_scores_gemma":[0.9896888,0.005768846,0.0020972795,0.0006485961,0.001462487,0.0003339566],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0013829493,0.0008768701,0.0046118805,0.0017409568,0.00026037992,0.00004844622,0.0008708102,0.0017383103,0.000055317505],"category_scores_gemma":[0.00073325535,0.0006233756,0.00082736544,0.00042025183,0.00045440768,0.00017330873,0.00013310384,0.003493989,0.000034493103],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010265842,0.005811684,0.14996582,0.018167887,0.016737994,0.06560723,0.009472332,0.000112256195,0.0021069038,0.0000340228,0.7216648,0.00005323656],"study_design_scores_gemma":[0.19755584,0.19218002,0.0954051,0.006006471,0.039801877,0.13363498,0.011361129,0.00024339513,0.00044634883,0.0006885842,0.31838244,0.00429379],"about_ca_topic_score_codex":0.000015422374,"about_ca_topic_score_gemma":0.000042620624,"teacher_disagreement_score":0.40328234,"about_ca_system_score_codex":0.0019310584,"about_ca_system_score_gemma":0.0036792755,"threshold_uncertainty_score":0.99962175},"labels":[],"label_agreement":null},{"id":"W4365133704","doi":"10.1038/s41586-023-05806-1","title":"Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis","year":2023,"lang":"en","type":"article","venue":"Nature","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McGill University; University of Calgary; University of Saskatchewan; Université Laval; Université de Montréal; Providence Health Care","funders":"National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; National Institute on Aging; Ludwig Center at Harvard; National Institutes of Health; U.S. Department of Health and Human Services; Boston Scientific Corporation; National Institute of Diabetes and Digestive and Kidney Diseases; Amgen; Regeneron Pharmaceuticals; Leukemia and Lymphoma Society; Genentech; AstraZeneca","keywords":"Haematopoiesis; Gene knockdown; Biology; Stem cell; Mutation; Genetics; Allele; Gene; Cancer research","score_opus":0.020266360101153017,"score_gpt":0.30521772048334134,"score_spread":0.2849513603821883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365133704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944414,0.00018836174,0.0000087001945,0.0035492922,0.00006874814,0.0004223621,0.000008738371,0.00006540833,0.0012469899],"genre_scores_gemma":[0.9968997,0.00005602474,0.0002779069,0.00018900853,0.00007268265,0.000020801692,0.00006428123,0.000021691665,0.0023978723],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987809,0.000048110094,0.00020192098,0.00021302045,0.0005267602,0.00022929058],"domain_scores_gemma":[0.99936956,0.00014387933,0.000058480255,0.00023839527,0.00012960106,0.000060099228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033637733,0.00010050605,0.00024345066,0.00034153022,0.000026481166,0.0000055713404,0.000101812635,0.0007592584,0.00006281047],"category_scores_gemma":[0.00010401216,0.0000793273,0.00005669738,0.000932008,0.00003494277,0.00007824534,0.000063880194,0.0016193314,0.00005075127],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006300109,0.0002332731,0.015212024,0.0012303316,0.00003815819,0.00023023273,0.002316423,0.000026293648,0.9309294,0.0002454765,0.036578335,0.012330042],"study_design_scores_gemma":[0.0021775877,0.00018163578,0.12393785,0.00046722352,0.000017479395,0.000018594283,0.00092903484,0.0021281303,0.867453,0.00018602177,0.0023754665,0.00012797149],"about_ca_topic_score_codex":0.000035754005,"about_ca_topic_score_gemma":0.0000074314494,"teacher_disagreement_score":0.10872582,"about_ca_system_score_codex":0.0001672451,"about_ca_system_score_gemma":0.00022816066,"threshold_uncertainty_score":0.7035279},"labels":[],"label_agreement":null},{"id":"W4365145093","doi":"10.1038/s41467-023-36906-1","title":"Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"BIRAX; Rising Tide Foundation; National Natural Science Foundation of China; Israel Science Foundation; Applebaum Foundation","keywords":"Haematopoiesis; Bone marrow; Paracrine signalling; Stem cell; Cell biology; Somatic cell; Biology; Hematopoietic stem cell; Cancer research; Immunology; Receptor; Gene; Genetics","score_opus":0.032525694511094806,"score_gpt":0.3394559850210066,"score_spread":0.3069302905099118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365145093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8438949,0.0053224806,0.00008050235,0.11605362,0.00035159424,0.0017082809,0.00072349433,0.0014803649,0.030384753],"genre_scores_gemma":[0.98375386,0.001330465,0.0071816416,0.0017715923,0.00021807381,0.00019927435,0.002849949,0.0000688828,0.0026262808],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978523,0.00022638906,0.0004584933,0.0003455409,0.0006688421,0.00044842565],"domain_scores_gemma":[0.9948862,0.0010760817,0.00013067626,0.00323263,0.00038537884,0.00028902898],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005682881,0.00022023532,0.00041554563,0.0003776181,0.000376425,0.000044989272,0.0012396688,0.0005799223,0.00086430105],"category_scores_gemma":[0.0007428609,0.00020868138,0.00020067765,0.0010144323,0.00034102812,0.00014910911,0.0011094951,0.00239103,0.0019654839],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001888293,0.00033523346,0.08138632,0.000110277906,0.00059083797,0.00033073564,0.0014582503,0.00001669799,0.09307574,0.007843715,0.8125427,0.0021206832],"study_design_scores_gemma":[0.0035989883,0.00013336436,0.34487674,0.00025414498,0.00028956612,0.0001573766,0.001020836,0.0040565627,0.011908168,0.0020590439,0.63102376,0.0006214765],"about_ca_topic_score_codex":0.00005993088,"about_ca_topic_score_gemma":0.00021285792,"teacher_disagreement_score":0.2634904,"about_ca_system_score_codex":0.00031829844,"about_ca_system_score_gemma":0.0006636373,"threshold_uncertainty_score":0.9999105},"labels":[],"label_agreement":null},{"id":"W4365479293","doi":"10.1182/bloodadvances.2023009781","title":"Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; CTI Biopharma; Incyte; Sierra Oncology; Celgene; MorphoSys; Servier; Astellas Pharma; Syndax Pharmaceuticals; Gilead Sciences; Bristol-Myers Squibb; Agios Pharmaceuticals","keywords":"Myelodysplastic syndromes; Anemia; Medicine; Oncology; Internal medicine","score_opus":0.022392367700130547,"score_gpt":0.3198697072487417,"score_spread":0.29747733954861116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365479293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983576,0.0005611954,0.00005546078,0.00018104189,0.000051118786,0.00061453076,0.000055529792,0.000024217437,0.000099313205],"genre_scores_gemma":[0.9963136,0.0026311788,0.0005466607,0.0000025395393,0.00001821438,0.000073811745,0.00002227443,0.000013151479,0.0003786228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925125,0.00003476764,0.00016641848,0.00019446196,0.00016970948,0.00018337095],"domain_scores_gemma":[0.99917513,0.0004633538,0.000104410814,0.00014253394,0.00006459891,0.00004997843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013844881,0.00010246199,0.00035956257,0.00022288875,0.00002572953,0.000003155915,0.000042693384,0.00005348589,0.00000991235],"category_scores_gemma":[0.00020066273,0.00008180792,0.000044609045,0.00030188673,0.00010477649,0.00009868145,0.000023671068,0.000044321332,0.000002368877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028790825,0.0028587098,0.56317955,0.0029977476,0.000306456,0.00017538991,0.0018994192,0.0002630091,0.13823584,0.00020234226,0.00012372939,0.28687873],"study_design_scores_gemma":[0.016030319,0.008525939,0.77546865,0.0003202308,0.00030923466,0.000042334843,0.00044136256,0.0030167548,0.1941721,0.0007276526,0.0007679282,0.00017750583],"about_ca_topic_score_codex":0.00008987415,"about_ca_topic_score_gemma":0.00007165552,"teacher_disagreement_score":0.28670123,"about_ca_system_score_codex":0.00006940058,"about_ca_system_score_gemma":0.00008088706,"threshold_uncertainty_score":0.33360302},"labels":[],"label_agreement":null},{"id":"W4365479509","doi":"10.1111/bjh.18815","title":"Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia","year":2023,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Medicine; Minimal residual disease; Oncology; Internal medicine; Chemotherapy; Disease; Myeloid; Clinical trial; Myeloid leukemia; Acute promyelocytic leukemia; Leukemia; Gene; Biology; Retinoic acid; Genetics","score_opus":0.023147937565040133,"score_gpt":0.2680327022710182,"score_spread":0.2448847647059781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365479509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8335639,0.0020960832,0.000047754216,0.16320772,0.00033058514,0.00035922808,0.00034367212,0.000015360914,0.0000356494],"genre_scores_gemma":[0.61956584,0.08421913,0.0027454926,0.25883576,0.011477525,0.00018770705,0.0074049137,0.0011089876,0.014454636],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99684757,0.0003469421,0.0012627288,0.0003385171,0.00071524456,0.0004889678],"domain_scores_gemma":[0.9983215,0.00018026504,0.00063508365,0.00019951128,0.00045532646,0.00020836492],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007095667,0.00024858842,0.0014723312,0.0008824975,0.00005370907,0.00003857025,0.0002738936,0.0006632086,0.00012506549],"category_scores_gemma":[0.0003174037,0.00028138893,0.00021222956,0.0002847199,0.0003313672,0.00018257707,0.00006890591,0.0027161916,0.000015561645],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001637511,0.000119899225,0.006337879,0.00255467,0.00088125165,0.5628654,0.00018239317,0.0000049763926,0.060569398,0.00003707842,0.36234954,0.0024600374],"study_design_scores_gemma":[0.009600904,0.00067039364,0.3865159,0.006585285,0.0014159185,0.52379906,0.00005767548,0.00013559638,0.0011406373,0.00086032064,0.068532154,0.0006861539],"about_ca_topic_score_codex":0.00012308892,"about_ca_topic_score_gemma":0.0000313686,"teacher_disagreement_score":0.380178,"about_ca_system_score_codex":0.00031649065,"about_ca_system_score_gemma":0.0015656656,"threshold_uncertainty_score":0.9999638},"labels":[],"label_agreement":null},{"id":"W4365514035","doi":"10.1158/1538-7445.am2023-ct026","title":"Abstract CT026: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Gastroenterology; IDH1; Pharmacology; Myeloid; Oncology; Mutant; Chemistry","score_opus":0.09156463445167855,"score_gpt":0.4493115501688034,"score_spread":0.35774691571712486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365514035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99501306,0.0006047062,8.6740295e-7,0.0007531632,0.00008289592,0.0030518814,0.000085102096,0.000045451005,0.00036289552],"genre_scores_gemma":[0.9971431,0.0009641669,0.000018797202,0.000016216893,0.000120340024,0.0010123407,0.000022955035,0.000067545436,0.0006345651],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99484295,0.00024446368,0.001006528,0.0006881998,0.0020681515,0.0011497324],"domain_scores_gemma":[0.99753505,0.0005362511,0.00014757038,0.00083690445,0.00068427157,0.00025996717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003071157,0.00024436624,0.0008529569,0.0021162627,0.00011490151,0.000018020895,0.0005032814,0.00014957733,0.00042903752],"category_scores_gemma":[0.000813795,0.0002203437,0.000107345084,0.0039976956,0.00042906756,0.00014953598,0.00041775464,0.0011783026,0.00004381807],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037101326,0.0033624447,0.05280917,0.001956999,0.00010400888,0.0018000656,0.0074566165,0.0006296821,0.9219706,0.000050199928,0.0012930398,0.004857048],"study_design_scores_gemma":[0.050791055,0.0080940835,0.39454362,0.0042206976,0.000038889484,0.000017140865,0.030147195,0.0008054411,0.50873315,0.0001647356,0.001946972,0.00049704587],"about_ca_topic_score_codex":0.005737454,"about_ca_topic_score_gemma":0.0031927053,"teacher_disagreement_score":0.41323745,"about_ca_system_score_codex":0.0015441744,"about_ca_system_score_gemma":0.0012497072,"threshold_uncertainty_score":0.89853555},"labels":[],"label_agreement":null},{"id":"W4366607243","doi":"10.1016/j.jtct.2023.04.011","title":"Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care","year":2023,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; Sierra Oncology; Incyte; Astex Pharmaceuticals; Astellas Pharma; TG Therapeutics; Karyopharm Therapeutics; Alexion Pharmaceuticals; Sunesis; Teva Pharmaceutical Industries; Bristol-Myers Squibb; AstraZeneca; Agios Pharmaceuticals","keywords":"Medicine; Myeloid leukemia; Transplantation; Myelodysplastic syndromes; Internal medicine; Disease registry; Comorbidity; Referral; Hematopoietic stem cell transplantation; Disease; Cancer registry; Myeloid; Cancer; Family medicine; Bone marrow","score_opus":0.020178349425369124,"score_gpt":0.2748081163798595,"score_spread":0.2546297669544904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366607243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947673,0.0004010637,0.0006088804,0.00083303766,0.000052057185,0.0019586538,0.001292338,0.000073884854,0.000012771856],"genre_scores_gemma":[0.98025084,0.014253434,0.000087278284,0.00048777222,0.000045416116,0.0002602063,0.0044977847,0.000049981598,0.00006731108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803966,0.00043662995,0.00030021253,0.00041267526,0.00040304541,0.00040775738],"domain_scores_gemma":[0.99861526,0.0005312135,0.00008859351,0.0002620807,0.00007110353,0.00043172823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034125432,0.00030980137,0.0003315126,0.00023079777,0.0006630504,0.00006367498,0.00016047482,0.00016031538,0.000019748266],"category_scores_gemma":[0.000034210963,0.00022438339,0.000051662857,0.0002990209,0.00016457634,0.00015920954,0.000016702881,0.0006275337,0.000002722785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034669694,0.00011310905,0.8374869,0.0025567675,0.0004268934,0.0010742717,0.08413879,0.00025898966,0.030272743,0.00006908196,0.00016099015,0.008771729],"study_design_scores_gemma":[0.019830314,0.0014572592,0.9700449,0.00029699865,0.00053854793,0.000076928154,0.004815882,0.0004955122,0.0018634326,0.000052676114,0.00015562789,0.00037191086],"about_ca_topic_score_codex":0.0002666032,"about_ca_topic_score_gemma":0.00021613498,"teacher_disagreement_score":0.13255797,"about_ca_system_score_codex":0.000116733514,"about_ca_system_score_gemma":0.00013501852,"threshold_uncertainty_score":0.9150089},"labels":[],"label_agreement":null},{"id":"W4366775420","doi":"10.1111/bjh.18720","title":"BSH 2023 Poster Abstract Book","year":2023,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Center, University of Kansas; Robert H. Lurie Comprehensive Cancer Center; Feinberg School of Medicine; University of North Carolina at Chapel Hill; Sierra Oncology; Śląski Uniwersytet Medyczny w Katowicach; Università degli Studi dell'Insubria; Oxford University Hospitals NHS Foundation Trust; Università degli Studi di Firenze; Leonard M. Miller School of Medicine; University of Toronto; Catholic University of Korea; Northwell Health; University Hospitals Plymouth NHS Trust; Eli Lilly and Company; Seoul St. Mary's Hospital, Catholic University of Korea; Uniwersytet Śląski w Katowicach; Northwestern University; University of Miami; Heart of England NHS Foundation Trust; Memorial Sloan-Kettering Cancer Center; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Moffitt Cancer Center; University of Oxford; University of Texas MD Anderson Cancer Center; Cleveland Clinic; Université de Paris; Sylvester Comprehensive Cancer Center, University of Miami Health Systems","keywords":"Medicine","score_opus":0.025355088687982207,"score_gpt":0.3179291228743691,"score_spread":0.2925740341863869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366775420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770159,0.004413455,0.000019544193,0.009124848,0.00043566612,0.00017596416,0.000012969453,0.000049319337,0.008752316],"genre_scores_gemma":[0.9776608,0.004121514,0.00036083124,0.0026666985,0.0005728413,0.000006701318,0.000023984518,0.000062221734,0.014524408],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9982666,0.00007315568,0.0006192582,0.00015890188,0.00041643466,0.0004656632],"domain_scores_gemma":[0.9987677,0.00022064609,0.00021713994,0.00016724707,0.0003578937,0.0002694283],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00068591285,0.00010821854,0.0006276762,0.00036503107,0.00007087175,0.000037651113,0.00022123012,0.00017769195,0.0017166588],"category_scores_gemma":[0.000594667,0.00011153138,0.00020316253,0.0003401523,0.00015830086,0.00016951475,0.00009161473,0.00081905175,0.0012641291],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017104908,0.000061420666,0.0011591321,0.000112048074,0.00013919461,0.3470431,0.000049379138,0.0000020114894,0.0015243349,0.000046903035,0.6351432,0.014548238],"study_design_scores_gemma":[0.0027530738,0.0003529872,0.05152406,0.00059132394,0.00007160102,0.8542133,0.00018740025,0.000028141923,0.0018244756,0.00034835574,0.08797281,0.00013249936],"about_ca_topic_score_codex":0.000049707895,"about_ca_topic_score_gemma":0.00001878025,"teacher_disagreement_score":0.5471704,"about_ca_system_score_codex":0.000101171114,"about_ca_system_score_gemma":0.0003894636,"threshold_uncertainty_score":0.9995135},"labels":[],"label_agreement":null},{"id":"W4367553368","doi":"10.1158/2643-3249.aml23-ia03","title":"Abstract IA03: Inducing apoptosis in leukemia stem cells by targeting metabolism","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Myeloid leukemia; Leukemia; Cancer research; Stem cell; Apoptosis; Medicine; Cancer; Population; Disease; Myelodysplastic syndromes; Cancer stem cell; Immunology; Biology; Bone marrow; Internal medicine; Cell biology; Genetics","score_opus":0.02077000338986654,"score_gpt":0.2875100773813973,"score_spread":0.2667400739915307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367553368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928454,0.003452315,0.00001004858,0.00093554537,0.00045015,0.0005481865,0.0001745336,0.0001774811,0.0014063034],"genre_scores_gemma":[0.98970205,0.0031950108,0.000084947686,0.0004940844,0.00059434836,0.00024975324,0.000096115924,0.00010609523,0.005477613],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99697524,0.00006888934,0.00055607245,0.0006938918,0.00073062925,0.00097527495],"domain_scores_gemma":[0.99889827,0.00018808678,0.00014399242,0.00046595803,0.00006993689,0.00023376406],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068811653,0.00032119162,0.0006106759,0.0004049911,0.000106601045,0.00011920303,0.00029494608,0.00022505867,0.00016710057],"category_scores_gemma":[0.00005610302,0.00029353166,0.00016859503,0.0013222422,0.000080960555,0.0005627003,0.00022018552,0.00089251605,0.0001862525],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018882609,0.00013745094,0.01068869,0.00047938683,0.00030841643,0.00016220068,0.0007481221,0.0005789584,0.8867497,0.00003084962,0.09211352,0.007813913],"study_design_scores_gemma":[0.0046497807,0.00006115784,0.022109633,0.0005627316,0.00023552927,0.00000687869,0.0016475664,0.00031441185,0.9562709,0.000029642151,0.013608137,0.00050366606],"about_ca_topic_score_codex":0.004366888,"about_ca_topic_score_gemma":0.00007941524,"teacher_disagreement_score":0.07850538,"about_ca_system_score_codex":0.00093026506,"about_ca_system_score_gemma":0.0013197348,"threshold_uncertainty_score":0.99995166},"labels":[],"label_agreement":null},{"id":"W4367603663","doi":"10.1158/2643-3249.aml23-a16","title":"Abstract A16: Multi-omic analyses in genetically engineered mice reveal distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"","keywords":"Biology; IDH2; Haematopoiesis; Isocitrate dehydrogenase; Epigenetics; Progenitor cell; Myeloid; DNA methylation; Myeloid leukemia; Stem cell; Cancer research; IDH1; Genetics; Mutation; Gene; Gene expression; Enzyme; Biochemistry","score_opus":0.026295459260253014,"score_gpt":0.3194442679006793,"score_spread":0.2931488086404263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367603663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990924,0.0077357455,0.000023751589,0.0002021538,0.00004392847,0.0009462688,0.00008713189,0.000025499208,0.000011529178],"genre_scores_gemma":[0.99773747,0.0014840055,0.0002599257,0.000029208702,0.000048944647,0.00017089816,0.000020925805,0.000037921713,0.00021072252],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99849486,0.00006394552,0.00040633432,0.00043021026,0.0002416688,0.00036297925],"domain_scores_gemma":[0.99914724,0.00036702247,0.00007745404,0.00020012265,0.000041800475,0.00016633526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018071814,0.00021315245,0.00049107434,0.00036714395,0.000034183027,0.000044236265,0.00008095122,0.00011018562,0.0000028430522],"category_scores_gemma":[0.00008092564,0.00019131263,0.000051541978,0.00053020305,0.00017178606,0.00013913059,0.00011759931,0.00025551586,0.0000019970803],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019097395,0.00016420094,0.09458684,0.0029513205,0.0001827923,0.00036397815,0.0007191414,0.00015640681,0.89880747,0.00000435928,0.000038921975,0.0018335689],"study_design_scores_gemma":[0.005528568,0.00014653549,0.74788624,0.00072427635,0.00033563253,0.000050982148,0.00024660648,0.0020510363,0.24281716,0.000014397957,0.000005975857,0.00019258738],"about_ca_topic_score_codex":0.0006751817,"about_ca_topic_score_gemma":0.00036406855,"teacher_disagreement_score":0.6559903,"about_ca_system_score_codex":0.00013884471,"about_ca_system_score_gemma":0.00036077757,"threshold_uncertainty_score":0.78015023},"labels":[],"label_agreement":null},{"id":"W4367604905","doi":"10.1016/j.leukres.2023.107230","title":"Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE","year":2023,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; International Prognostic Scoring System; Myelodysplastic syndromes; Risk stratification; Prognostic model; Intensive care medicine; Internal medicine; Oncology; Overall survival","score_opus":0.17792482982712265,"score_gpt":0.44826791603131505,"score_spread":0.2703430862041924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367604905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952546,0.000028867602,0.00007921613,0.0010795317,0.00004718589,0.0019033265,0.00046648667,0.00008306709,0.0010577323],"genre_scores_gemma":[0.995955,0.0002020463,0.0013253029,0.00006813457,0.00006374985,0.00015484024,0.00042443213,0.00007490453,0.0017316215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912407,0.0019942168,0.0014751164,0.0011184476,0.0028785819,0.001292985],"domain_scores_gemma":[0.99262595,0.003614525,0.0002536306,0.0015717525,0.001215952,0.0007181798],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008322017,0.0003876464,0.0014392539,0.002518802,0.00025901053,0.00012231471,0.0012249112,0.0004188026,0.0004891435],"category_scores_gemma":[0.0057122484,0.00027735322,0.00031259385,0.010348481,0.0005502773,0.00038736488,0.0016847184,0.0024250105,0.00006115699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063791336,0.00028271222,0.98030645,0.00022706077,0.00079978275,0.00009913653,0.0010222145,0.0026727533,0.01204442,0.0003443146,0.0006711098,0.00089212006],"study_design_scores_gemma":[0.0024407113,0.00090382196,0.79948145,0.00018893449,0.00051628606,0.0000039629863,0.0019096287,0.19196065,0.0020589223,0.00019436229,0.000094863484,0.00024639975],"about_ca_topic_score_codex":0.014502046,"about_ca_topic_score_gemma":0.0045491564,"teacher_disagreement_score":0.18928789,"about_ca_system_score_codex":0.0013476282,"about_ca_system_score_gemma":0.0022174416,"threshold_uncertainty_score":0.9999679},"labels":[],"label_agreement":null},{"id":"W4367856397","doi":"10.1016/j.isci.2023.106795","title":"RUNX1 colludes with NOTCH1 to reprogram chromatin in T cell acute lymphoblastic leukemia","year":2023,"lang":"en","type":"article","venue":"iScience","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Genome British Columbia; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Canadian Institutes of Health Research; University of British Columbia; Terry Fox Research Institute; Brigham and Women's Hospital","keywords":"RUNX1; Transcription factor; Enhancer; Gene knockdown; Biology; Chromatin; Cancer research; Leukemia; Gene; Cell biology; Genetics","score_opus":0.018750213181914048,"score_gpt":0.30552669307491026,"score_spread":0.2867764798929962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367856397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915214,0.000033534754,0.00027827366,0.0016787486,0.000069490125,0.0008246315,0.000007624614,0.00022464557,0.0053616366],"genre_scores_gemma":[0.9855238,0.000027927335,0.0055696983,0.00059417443,0.000060103226,0.00016497512,0.0000077385175,0.000029095285,0.008022439],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99743694,0.00003734596,0.00024992932,0.00064728124,0.00083344226,0.0007950621],"domain_scores_gemma":[0.9987242,0.00016118087,0.000047775866,0.00060590263,0.00010245282,0.00035847287],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00069307897,0.00017314877,0.00028324508,0.00047616594,0.00011929079,0.00007386372,0.00042912987,0.000072050476,0.00005857287],"category_scores_gemma":[0.0003007684,0.000129788,0.000037433874,0.0046023238,0.00028106672,0.00014643543,0.0002542023,0.0002284133,0.0013376207],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010389661,0.00030926117,0.049915686,0.00036038828,0.000050859602,0.0066634803,0.006539461,0.00340505,0.8524055,0.00015896409,0.035533387,0.043618985],"study_design_scores_gemma":[0.010001495,0.005062347,0.6597763,0.001204753,0.00010757413,0.0008323331,0.002852246,0.071799785,0.22671331,0.00014586275,0.020334415,0.001169618],"about_ca_topic_score_codex":0.00029041868,"about_ca_topic_score_gemma":0.00012097162,"teacher_disagreement_score":0.6256922,"about_ca_system_score_codex":0.001138937,"about_ca_system_score_gemma":0.0015982472,"threshold_uncertainty_score":0.99943995},"labels":[],"label_agreement":null},{"id":"W4368617865","doi":"10.1182/bloodadvances.2023009675","title":"Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Loxo Oncology; Genentech; National Institutes of Health; Astellas Pharma; Daiichi-Sankyo; Foundation Medicine; Sierra Oncology; Galecto; Pfizer; Incyte; Syndax Pharmaceuticals; Cycle for Survival; Constellation Pharmaceuticals; Ipsen; Jazz Pharmaceuticals; National Heart, Lung, and Blood Institute; Edward P. Evans Foundation; Daiichi Sankyo Europe; National Cancer Institute; Foghorn Therapeutics; Servier; Gilead Sciences; Sanofi; Memorial Sloan-Kettering Cancer Center; Alex's Lemonade Stand Foundation for Childhood Cancer; GlaxoSmithKline; MorphoSys; Ipsen Biopharmaceuticals; Celgene; AstraZeneca; Amgen; Damon Runyon Cancer Research Foundation","keywords":"Myeloid leukemia; Ontogeny; Myelodysplastic syndromes; Gene mutation; Internal medicine; Oncology; Leukemia; Biology; Myeloid; Cancer; Gene; Medicine; Mutation; Genetics; Bone marrow","score_opus":0.018958027206244687,"score_gpt":0.31927056758112354,"score_spread":0.30031254037487887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4368617865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99503547,0.00085071084,0.00003254967,0.0011977643,0.00013132962,0.00048895116,0.00003828385,0.00023098785,0.0019939647],"genre_scores_gemma":[0.99240917,0.002874502,0.0014175038,0.00008394245,0.00016672519,0.00008849676,0.00035909968,0.00004383243,0.0025567033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983015,0.00006716701,0.00041091567,0.0004393233,0.00032451312,0.00045655065],"domain_scores_gemma":[0.9990945,0.00029178595,0.00009410253,0.0002507118,0.00007877617,0.00019014852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028344014,0.00019994042,0.00037313803,0.0005498898,0.00011779001,0.00003187766,0.00012021613,0.00014209711,0.000056117286],"category_scores_gemma":[0.00019835653,0.0001847212,0.000060605515,0.0011429036,0.0001326872,0.00042265098,0.00010688785,0.0005048253,0.0002218633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005057428,0.0002561571,0.5905269,0.00037884677,0.0014532424,0.0025012745,0.0035842126,0.0006895398,0.21578357,0.00035353057,0.0011637902,0.18280323],"study_design_scores_gemma":[0.009391559,0.0007879653,0.8778613,0.00036903287,0.00070696056,0.00070567045,0.0017561043,0.0021052887,0.08842963,0.0017330687,0.015588924,0.00056447886],"about_ca_topic_score_codex":0.000112135756,"about_ca_topic_score_gemma":0.00010825263,"teacher_disagreement_score":0.28733444,"about_ca_system_score_codex":0.00029526497,"about_ca_system_score_gemma":0.00026763152,"threshold_uncertainty_score":0.75327116},"labels":[],"label_agreement":null},{"id":"W4376132330","doi":"10.1182/bloodadvances.2023009748","title":"<i>FLT3-ITD</i> does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years","year":2023,"lang":"en","type":"letter","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Genentech; Servier; Astellas Pharma; Sierra Oncology; Incyte; Boston Pharmaceuticals; bluebird bio; Bristol-Myers Squibb; Foghorn Therapeutics; Jazz Pharmaceuticals; Gilead Sciences; Amgen; Pfizer; Agios Pharmaceuticals; GlaxoSmithKline","keywords":"Myeloid leukemia; Medicine; Internal medicine; Leukemia; Oncology; Myeloid","score_opus":0.013620885975553698,"score_gpt":0.27509041266726314,"score_spread":0.2614695266917094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376132330","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8622044,0.0010882221,0.0000043397636,0.124660134,0.0022424594,0.005389147,0.0019601595,0.0010922453,0.0013589158],"genre_scores_gemma":[0.111992754,0.030022636,0.0077756024,0.69226664,0.025857167,0.008921556,0.017478626,0.0028208161,0.102864176],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931315,0.00027394693,0.0011778503,0.0015807862,0.0021209589,0.0017149225],"domain_scores_gemma":[0.997318,0.00059035985,0.0004700107,0.0010342909,0.0002789966,0.00030828876],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0004730571,0.00093093683,0.0016392203,0.0010594706,0.0001382018,0.00012798274,0.0009461648,0.0013309885,0.00014105595],"category_scores_gemma":[0.0006957585,0.00073656294,0.00041453913,0.0012509609,0.00040594029,0.0004988679,0.00056906976,0.004985511,0.0005009444],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062757573,0.0003960099,0.25850192,0.0023062848,0.001328053,0.025421098,0.0005594122,0.000011454599,0.0014310825,0.0000017098636,0.6938188,0.015596608],"study_design_scores_gemma":[0.01059982,0.0013321362,0.26902077,0.00219538,0.0012316518,0.000087981716,0.0000786155,0.000030875533,0.0058528,0.00007983737,0.70817626,0.0013138758],"about_ca_topic_score_codex":0.0002356304,"about_ca_topic_score_gemma":0.00017375604,"teacher_disagreement_score":0.75021166,"about_ca_system_score_codex":0.0010491912,"about_ca_system_score_gemma":0.0013224175,"threshold_uncertainty_score":0.9999655},"labels":[],"label_agreement":null},{"id":"W4376133026","doi":"10.1111/ejh.13979","title":"Impact of secondary‐type mutations in <scp><i>NPM1</i></scp> mutated <scp>AML</scp>","year":2023,"lang":"en","type":"letter","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Computer science; Computational biology; Genetics; Biology","score_opus":0.033359794818361786,"score_gpt":0.3206159618144294,"score_spread":0.28725616699606765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376133026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.930307,0.0017371499,0.00013110525,0.04755904,0.0013945303,0.00076569605,0.00017663528,0.000115998955,0.01781285],"genre_scores_gemma":[0.75612855,0.0040869205,0.0050061666,0.16976592,0.012913895,0.00003628522,0.0034954739,0.0031991885,0.045367595],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9916385,0.0026462101,0.0026704725,0.0006191049,0.0010641319,0.0013615855],"domain_scores_gemma":[0.99115664,0.0039527863,0.0021449872,0.00085490354,0.0014448952,0.00044581038],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023650904,0.00073890924,0.002816652,0.003177901,0.000093550756,0.00005561368,0.0011190986,0.00066261354,0.00022900836],"category_scores_gemma":[0.008743381,0.00060880533,0.0009103638,0.0017143919,0.00065019046,0.00020102652,0.00033674508,0.00863105,0.0012533393],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047667836,0.00011410979,0.0022267562,0.0005446995,0.0011398459,0.21086763,0.0013521884,0.00008064756,0.0012916324,0.000007671505,0.78194916,0.00037797447],"study_design_scores_gemma":[0.017277919,0.009335136,0.07155904,0.0033093214,0.0015512758,0.22248022,0.0025567147,0.0003107763,0.0023958092,0.00044917333,0.6683876,0.00038700903],"about_ca_topic_score_codex":0.000060481438,"about_ca_topic_score_gemma":0.000013286869,"teacher_disagreement_score":0.17417844,"about_ca_system_score_codex":0.00057989545,"about_ca_system_score_gemma":0.0031749867,"threshold_uncertainty_score":0.99963635},"labels":[],"label_agreement":null},{"id":"W4376641408","doi":"10.1158/2159-8290.cd-22-1396","title":"Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia","year":2023,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Cancer Council Victoria; Canadian Institutes of Health Research; Peter MacCallum Cancer Centre; University of Toronto; University of Melbourne; Australian Synchrotron; State Government of Victoria; Australian Government; Leukaemia Foundation; Canada First Research Excellence Fund; Canada Research Chairs; International Development Research Centre; Cure Cancer Australia Foundation; Australian Cancer Research Foundation; National Health and Medical Research Council; Commonwealth Scientific and Industrial Research Organisation; Cancer Council South Australia; Medical Research Council; Terry Fox Research Institute; Australian Nuclear Science and Technology Organisation; Government of Ontario; Princess Margaret Cancer Foundation","keywords":"Cytokine; Receptor; Leukemia; Biology; Computational biology; Cancer research; Immunology; Cell biology; Genetics","score_opus":0.05311667366181277,"score_gpt":0.3259111900302019,"score_spread":0.27279451636838914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376641408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961974,0.0005136372,0.000043825195,0.00057095033,0.00045176255,0.00065633684,0.00007296895,0.000114313334,0.0013787785],"genre_scores_gemma":[0.9898765,0.00075043424,0.00004318029,0.00007482786,0.00023840861,0.0003108076,0.00018729299,0.00006278721,0.008455775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997818,0.00007854319,0.0004464379,0.00044837611,0.0006315595,0.0005771018],"domain_scores_gemma":[0.99900985,0.00012978671,0.00014549342,0.00048428873,0.000097264405,0.00013334843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035321392,0.00023201428,0.0005762937,0.00028941495,0.000040726925,0.000043156386,0.0002465831,0.00012415429,0.00010231369],"category_scores_gemma":[0.00015399505,0.00019118973,0.00014216144,0.0018609852,0.00023270998,0.00033809128,0.00020552771,0.00038117505,0.00006895415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009937198,0.00017077677,0.90601206,0.001307876,0.00019642261,0.00020728333,0.00075452216,0.0001971051,0.023256354,0.00009332788,0.014475993,0.052334547],"study_design_scores_gemma":[0.004670062,0.00061494217,0.94837207,0.0015661303,0.00011354494,0.000023592085,0.0019387864,0.0011790157,0.018809473,0.00008747452,0.022099962,0.0005249507],"about_ca_topic_score_codex":0.0021116948,"about_ca_topic_score_gemma":0.00055335136,"teacher_disagreement_score":0.051809594,"about_ca_system_score_codex":0.0018178105,"about_ca_system_score_gemma":0.0010709374,"threshold_uncertainty_score":0.7796491},"labels":[],"label_agreement":null},{"id":"W4376867172","doi":"10.1101/2023.05.16.23290051","title":"Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury","year":2023,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Population Health Research Institute; Impact; Queen's University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute","keywords":"Acute kidney injury; Medicine; Internal medicine; Kidney disease; Dialysis; Disease; Cohort; Oncology; Myeloid","score_opus":0.02571545637454065,"score_gpt":0.3125495582870848,"score_spread":0.28683410191254416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376867172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99099416,0.000030521212,0.0001755209,0.004638668,0.00044359302,0.0009288587,0.0018990996,0.0002649851,0.00062457105],"genre_scores_gemma":[0.98234695,0.00024253404,0.0008584939,0.00088415697,0.00028528055,0.00016294788,0.0014161457,0.0002275651,0.013575946],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9958372,0.00018590149,0.0007497298,0.0008985444,0.0016094545,0.0007191683],"domain_scores_gemma":[0.996942,0.000114141134,0.00053815614,0.0011945557,0.00066460465,0.00054658775],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00092015177,0.00052841613,0.0013604895,0.0006602662,0.00008406364,0.000041875242,0.0006581137,0.0008366185,0.00069933914],"category_scores_gemma":[0.00082883803,0.0004302131,0.00040000962,0.0006597261,0.00039599993,0.00006239278,0.0014302451,0.002021113,0.0002842372],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008399435,0.0016281529,0.37158093,0.006936649,0.025934378,0.027850647,0.004226535,0.000028283219,0.099029325,0.00012087704,0.4513321,0.0029327117],"study_design_scores_gemma":[0.015869243,0.0034948955,0.6087149,0.013580617,0.008606505,0.0013048543,0.0003089155,0.008402437,0.3267507,0.0037795599,0.0057757944,0.0034115966],"about_ca_topic_score_codex":0.00017768098,"about_ca_topic_score_gemma":0.0000056764743,"teacher_disagreement_score":0.44555628,"about_ca_system_score_codex":0.0004878998,"about_ca_system_score_gemma":0.0026070774,"threshold_uncertainty_score":0.999815},"labels":[],"label_agreement":null},{"id":"W4377221156","doi":"10.1007/s12185-023-03614-x","title":"Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy","year":2023,"lang":"en","type":"review","venue":"International Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Oncology; Maintenance therapy; Hematology; Internal medicine; Transplantation; Stem cell; Immunotherapy; Hematopoietic stem cell transplantation; Leukemia; Targeted therapy; Immunology; Chemotherapy; Cancer; Biology","score_opus":0.06373285091864463,"score_gpt":0.3305457795898688,"score_spread":0.2668129286712242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377221156","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18527944,0.81160074,0.00042531002,0.0006064663,0.0006533555,0.001214488,0.00014976796,0.000052365704,0.000018053477],"genre_scores_gemma":[0.17204629,0.82623804,0.00024568965,0.0005382863,0.00019680284,0.00018579428,0.00015130594,0.00021061591,0.00018718638],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944811,0.0007024291,0.002305641,0.00067067484,0.0010545386,0.0007856259],"domain_scores_gemma":[0.9964027,0.0010555121,0.0012331997,0.00040789874,0.00069980713,0.00020092436],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001132972,0.00089228083,0.0028763753,0.0017551158,0.000100764315,0.0001193909,0.0009821958,0.00071529066,0.00011723302],"category_scores_gemma":[0.000018380517,0.0006508442,0.0008833412,0.00043396774,0.00027935038,0.00030129295,0.00007643479,0.0016940638,0.00002610286],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019988518,0.0008302244,0.006362392,0.008328242,0.014103714,0.030930992,0.015764149,0.000026655827,0.03931685,0.00031432344,0.00011315674,0.8639208],"study_design_scores_gemma":[0.14233069,0.012992503,0.010537695,0.12825003,0.004067439,0.21686614,0.0072643887,0.0011705485,0.11824413,0.003816374,0.34490585,0.009554216],"about_ca_topic_score_codex":0.000121776735,"about_ca_topic_score_gemma":0.000020877033,"teacher_disagreement_score":0.85436654,"about_ca_system_score_codex":0.0010309517,"about_ca_system_score_gemma":0.0014604053,"threshold_uncertainty_score":0.9995943},"labels":[],"label_agreement":null},{"id":"W4377245151","doi":"10.22541/au.168476224.44447928/v1","title":"Gemtuzumab ozogamicin monotherapy is a well-tolerated palliative chemotherapy option in pediatric multiply relapsed acute myeloid leukemia: a multi-center case series and review of the literature","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Ottawa","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; Myeloid leukemia; Refractory (planetary science); CD33; Chemotherapy; Oncology; Internal medicine; Stem cell; CD34","score_opus":0.029553203702179624,"score_gpt":0.3216928664481464,"score_spread":0.29213966274596675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377245151","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93706775,0.034632668,0.00024937655,0.017759157,0.00043474045,0.00876906,0.00063330436,0.00026317433,0.00019075866],"genre_scores_gemma":[0.093467444,0.87640774,0.0073298565,0.006659851,0.0003313795,0.0006262183,0.0005518159,0.00029894797,0.014326747],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99542034,0.00050270814,0.0013474865,0.001327432,0.0007392991,0.0006627183],"domain_scores_gemma":[0.99670523,0.00020190318,0.0006744821,0.0014433183,0.00075924763,0.00021579544],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00088263245,0.00088616257,0.0016967269,0.000677447,0.00012244492,0.000094511495,0.00048345953,0.0011090669,0.00013040559],"category_scores_gemma":[0.00022314338,0.0005973009,0.00047468813,0.0017824912,0.00023825429,0.00019150841,0.0007008771,0.0032564392,0.000030393076],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050692245,0.006865645,0.20725827,0.34930652,0.013525851,0.04306712,0.111560345,0.00041812955,0.020438218,0.00024419272,0.15466581,0.041957647],"study_design_scores_gemma":[0.27828377,0.006973237,0.17069408,0.33244914,0.006651771,0.027752263,0.0065622116,0.108233236,0.034424976,0.001039668,0.016776728,0.01015893],"about_ca_topic_score_codex":0.000761529,"about_ca_topic_score_gemma":0.0002577155,"teacher_disagreement_score":0.84360033,"about_ca_system_score_codex":0.0018147595,"about_ca_system_score_gemma":0.0015031103,"threshold_uncertainty_score":0.99964786},"labels":[],"label_agreement":null},{"id":"W4378087252","doi":"10.3390/curroncol30060395","title":"Novel Tools for Diagnosis and Monitoring of AML","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Instituto de Salud Carlos III","keywords":"Medicine; Minimal residual disease; Myeloid leukemia; Immunophenotyping; Molecular diagnostics; Digital polymerase chain reaction; Computational biology; Bioinformatics; Intensive care medicine; Leukemia; Internal medicine; Flow cytometry; Immunology; Polymerase chain reaction; Gene; Biology; Genetics","score_opus":0.5541790062787184,"score_gpt":0.5588559076241926,"score_spread":0.00467690134547416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378087252","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014527139,0.9952945,0.000078592515,0.00011407257,0.0014628794,0.002523722,0.0002292412,0.000045333407,0.000106366235],"genre_scores_gemma":[0.0000026285986,0.9948928,0.0010145403,0.000004579343,0.0012299832,0.002376058,0.00018244673,0.00007519584,0.00022176703],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982807,0.00007069741,0.000639655,0.000419354,0.0001973201,0.00039228768],"domain_scores_gemma":[0.99555683,0.0034739296,0.0002984956,0.00031455245,0.00018411153,0.00017207405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050094037,0.0002703231,0.002261238,0.0003487175,0.00004014978,0.000013317805,0.00019586437,0.0004210135,0.000016456857],"category_scores_gemma":[0.0020111375,0.00021415413,0.00035223004,0.0003255531,0.00014758314,0.000043545486,0.00025214668,0.00063898,0.000033491637],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020123116,0.00016988826,0.00028976268,0.06016224,0.00021658701,0.000009906223,0.000035665333,3.2301177e-8,0.0000020668076,0.00005600919,0.004075869,0.93496186],"study_design_scores_gemma":[0.0010664903,0.0005340984,0.00009238885,0.016283514,0.0011926068,0.00006185584,0.000039100687,0.0000075577054,0.000007960046,0.000010402854,0.98056114,0.00014286075],"about_ca_topic_score_codex":0.000007119076,"about_ca_topic_score_gemma":0.000001507994,"teacher_disagreement_score":0.9764853,"about_ca_system_score_codex":0.0007430114,"about_ca_system_score_gemma":0.0012322398,"threshold_uncertainty_score":0.8732952},"labels":[],"label_agreement":null},{"id":"W4379281959","doi":"10.1200/jco.2023.41.16_suppl.7012","title":"Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Azacitidine; Internal medicine; Myeloid leukemia; Gastroenterology; Placebo; IDH1; IDH2; Pathology","score_opus":0.10253138610034464,"score_gpt":0.420495168032642,"score_spread":0.31796378193229735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896156,0.000034872344,0.000035460012,0.007307946,0.00017746392,0.0023520289,0.00023638942,0.000050014452,0.000190179],"genre_scores_gemma":[0.99538577,0.0002608242,0.0012707798,0.001649286,0.00052160345,0.000024823163,0.0006350218,0.000067509376,0.00018438141],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99361527,0.0013946628,0.0025144392,0.0007298262,0.0011072467,0.0006385815],"domain_scores_gemma":[0.98674774,0.009560603,0.0010407428,0.0011069035,0.0007142681,0.00082974986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004293624,0.00037826915,0.002375025,0.0003571224,0.00013687229,0.000050695115,0.0009949718,0.000316466,0.00015465541],"category_scores_gemma":[0.0039628716,0.00020258145,0.00010120972,0.0013971801,0.00040746466,0.00029669586,0.0006689848,0.0021628437,0.00007937918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.111635536,0.0020478447,0.8297119,0.000007468075,0.0016930068,0.004384073,0.0004226011,0.00028181888,0.000063433086,0.0000014858387,0.039100077,0.010650718],"study_design_scores_gemma":[0.10720682,0.02053365,0.86198896,0.00021317872,0.00083241775,0.000054158332,0.00088600296,0.00076152704,0.00001620783,0.00000523682,0.0072994167,0.0002024108],"about_ca_topic_score_codex":0.0007738371,"about_ca_topic_score_gemma":0.0026027665,"teacher_disagreement_score":0.032277033,"about_ca_system_score_codex":0.0007467842,"about_ca_system_score_gemma":0.0028005773,"threshold_uncertainty_score":0.93966},"labels":[],"label_agreement":null},{"id":"W4379337520","doi":"10.1200/jco.2023.41.16_suppl.e19029","title":"Use of daunorubicin and cytarabine in adults with acute myeloid leukemia and associated risk factors for inpatient mortality: National inpatient sample review.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Daunorubicin; Myeloid leukemia; Odds ratio; Leukemia","score_opus":0.15922450178369418,"score_gpt":0.460501352641641,"score_spread":0.3012768508579468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379337520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961864,0.00030201118,0.00006453357,0.0021885769,0.00014085138,0.0008473317,0.00023392681,0.000009010344,0.000027409556],"genre_scores_gemma":[0.9587041,0.037078574,0.0027974744,0.0010627719,0.00012985,0.000022016035,0.00012880463,0.000026411457,0.000049981703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99576217,0.0005277806,0.0023861013,0.0002698875,0.00075513736,0.00029893278],"domain_scores_gemma":[0.9868022,0.009542357,0.0020644476,0.00014973253,0.0011101143,0.00033110738],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00494971,0.00017329218,0.0016986007,0.00034750038,0.000041882628,0.000007105464,0.00010869999,0.00030961807,0.000015637674],"category_scores_gemma":[0.02971576,0.000114297196,0.00018513041,0.0005071018,0.00030332303,0.00017488142,0.00011100095,0.0010178199,8.6313497e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059812823,0.0005537247,0.9715699,0.0004027344,0.00085697975,0.00013819548,0.000335966,0.00007072342,0.000066764405,0.000033299326,0.005006191,0.014984243],"study_design_scores_gemma":[0.011837658,0.015398367,0.9645233,0.0012170175,0.0005273665,0.00004277429,0.00013125471,0.0023589202,0.000057350167,0.00024009582,0.0035526776,0.000113187714],"about_ca_topic_score_codex":0.0004977994,"about_ca_topic_score_gemma":0.00048414193,"teacher_disagreement_score":0.03748223,"about_ca_system_score_codex":0.00072233594,"about_ca_system_score_gemma":0.0027313773,"threshold_uncertainty_score":0.97845733},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W4379376555","doi":"10.1182/bloodadvances.2023010179","title":"Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta Hospital; Alberta Hospital Edmonton","funders":"Astellas Pharma; Daiichi Sankyo Europe; Agios Pharmaceuticals; Celgene; Gilead Sciences; Astex Pharmaceuticals; Daiichi-Sankyo; Pfizer; Amgen","keywords":"Internal medicine; Neutropenia; Medicine; Hazard ratio; Febrile neutropenia; Gastroenterology; Cytarabine; Population; Confidence interval; Leukemia; Chemotherapy","score_opus":0.02117231845214376,"score_gpt":0.36261403877819054,"score_spread":0.3414417203260468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379376555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881125,0.002807525,0.0000253517,0.0020835763,0.00023863601,0.0048821573,0.00010499424,0.0004016415,0.001343614],"genre_scores_gemma":[0.9873259,0.005428368,0.0008958894,0.000329293,0.0005423772,0.0020925438,0.00019326557,0.00006817265,0.0031242],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961251,0.00038364,0.0008193106,0.0008793265,0.00082170207,0.0009709055],"domain_scores_gemma":[0.9972552,0.0013567846,0.00016929623,0.00071257714,0.00012916571,0.00037694207],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083295396,0.00050472375,0.0017153246,0.0003935593,0.00013463112,0.000055921057,0.00033893232,0.00014532033,0.00011899295],"category_scores_gemma":[0.0013519556,0.0003706332,0.00030956304,0.0021800122,0.00022429133,0.00033853468,0.00016915683,0.00036406572,0.00030467322],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36457282,0.02418634,0.31758964,0.0003894169,0.0076174517,0.043653805,0.0050097946,0.0007560547,0.0076600765,0.00025187843,0.004844276,0.22346844],"study_design_scores_gemma":[0.950142,0.0048020175,0.02535638,0.0001389709,0.0014076714,0.00012802155,0.0012848402,0.0009988402,0.001698369,0.00016068254,0.013439846,0.00044231073],"about_ca_topic_score_codex":0.0013137058,"about_ca_topic_score_gemma":0.0013005284,"teacher_disagreement_score":0.5855692,"about_ca_system_score_codex":0.0013262834,"about_ca_system_score_gemma":0.0008184566,"threshold_uncertainty_score":0.99987453},"labels":[],"label_agreement":null},{"id":"W4379779587","doi":"10.3904/kjim.2022.396","title":"The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine","year":2023,"lang":"en","type":"article","venue":"The Korean Journal of Internal Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Ministry of Science and ICT, South Korea; National Research Foundation of Korea; Chonnam National University; Ministry of Health and Welfare; Ministry of Science, ICT and Future Planning; National Research Foundation; Chonnam National University Hwasun Hospital; Mike and Josie Harper Cancer Research Institute","keywords":"Medicine; Decitabine; Myeloid leukemia; Internal medicine; Oncology; Azacitidine; Myeloid; Leukemia; Genetics; Gene","score_opus":0.012913925910509754,"score_gpt":0.29228865164084045,"score_spread":0.2793747257303307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379779587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945266,0.00016911587,0.00008349592,0.0038187942,0.00009409925,0.00071787875,0.000012610695,0.00002079533,0.0005566003],"genre_scores_gemma":[0.998361,0.00030497092,0.00011346601,0.0000659833,0.00044066503,0.000012161394,0.000018183273,0.00006098852,0.0006226048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99652356,0.00024483714,0.0010458928,0.00021318707,0.0013898563,0.0005826831],"domain_scores_gemma":[0.99620026,0.00107801,0.0007859427,0.000511922,0.0010900301,0.00033383718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017667968,0.0003304307,0.00084847934,0.0005828846,0.00009624603,0.000023399125,0.00073437503,0.00007561769,0.00007264874],"category_scores_gemma":[0.0011542349,0.000114100665,0.00015535255,0.0013837895,0.00069441117,0.00013257019,0.00008859605,0.0011507008,0.000010389117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09797485,0.00041092077,0.7751549,0.00016674622,0.008887973,0.01533229,0.009086355,0.00075474515,0.03165074,0.00009753568,0.015502907,0.044980045],"study_design_scores_gemma":[0.020624636,0.03225558,0.93225354,0.004760573,0.0008483103,0.004993833,0.0014238184,0.0008971661,0.0015496935,0.00012188834,0.00008924082,0.00018173181],"about_ca_topic_score_codex":0.0013914903,"about_ca_topic_score_gemma":0.000051278777,"teacher_disagreement_score":0.15709864,"about_ca_system_score_codex":0.00087935734,"about_ca_system_score_gemma":0.0010780727,"threshold_uncertainty_score":0.49992865},"labels":[],"label_agreement":null},{"id":"W4379979778","doi":"10.1002/hon.3166_ot15","title":"PHASE 1 STUDY OF PRT1419 (MCL1 INHIBITOR) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MYELOID OR B‐CELL MALIGNANCIES","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Universitat Autònoma de Barcelona","keywords":"Venetoclax; Medicine; Azacitidine; Tolerability; Internal medicine; Myeloid leukemia; Oncology; Myeloid; Ven; Rituximab; Lymphoma; Cancer research; Leukemia; Chronic lymphocytic leukemia; Adverse effect; Biology","score_opus":0.03958954685764432,"score_gpt":0.3475295426058064,"score_spread":0.30793999574816205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379979778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955631,0.000034259956,0.000011936609,0.00045375637,0.000056947243,0.0033308547,0.000009421539,0.000106256055,0.00043349536],"genre_scores_gemma":[0.9971293,0.00010633673,0.0004941656,0.00028980256,0.00002597172,0.00056159066,0.00007134011,0.000051686417,0.0012697758],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9967888,0.00045639474,0.00083062623,0.0006182049,0.0006643719,0.0006415777],"domain_scores_gemma":[0.99778783,0.0010555735,0.00031331435,0.0003964318,0.00026377934,0.00018306388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058058416,0.00033045234,0.0012814491,0.000649246,0.00005756556,0.000009910818,0.00022918424,0.0004033662,0.0004476748],"category_scores_gemma":[0.00053731137,0.00016991608,0.00004118725,0.0019126581,0.00030543396,0.00013147568,0.000120152305,0.00069917267,0.00006094797],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29587543,0.05682054,0.6080506,0.0007186936,0.00021164145,0.01971126,0.0056595565,0.00010484305,0.0033424124,0.00019677581,0.0022680415,0.0070402515],"study_design_scores_gemma":[0.29056254,0.4090038,0.2765482,0.00073330116,0.00011965752,0.00039546468,0.009546862,0.0006033352,0.007441129,0.00011739695,0.0042226575,0.0007056662],"about_ca_topic_score_codex":0.00014230132,"about_ca_topic_score_gemma":0.0007363322,"teacher_disagreement_score":0.35218325,"about_ca_system_score_codex":0.0011651012,"about_ca_system_score_gemma":0.0016941875,"threshold_uncertainty_score":0.6928976},"labels":[],"label_agreement":null},{"id":"W4380563839","doi":"10.1159/000531484","title":"Impact of Geographical Distance from Quaternary Treatment Center on Clinical Trial Participation, Intensive Induction Chemotherapy, and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia","year":2023,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Single Center; Clinical trial; Myeloid leukemia; Univariate analysis; Induction chemotherapy; Retrospective cohort study; Internal medicine; Chemotherapy; Multivariate analysis; Cancer; Univariate; Oncology; Emergency medicine; Multivariate statistics","score_opus":0.05111525454440824,"score_gpt":0.3803333338662696,"score_spread":0.32921807932186137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380563839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631965,0.000009014448,0.00000714374,0.0019233515,0.00010459129,0.0014472641,0.00010027633,0.00006931345,0.000019400728],"genre_scores_gemma":[0.9986372,0.00037293186,0.000120190285,0.00026128613,0.000050831524,0.00014981798,0.00034130632,0.000028218454,0.000038197846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977752,0.00021543697,0.00068515766,0.0005380148,0.00038587564,0.00040032103],"domain_scores_gemma":[0.9982644,0.00064880005,0.00025186752,0.00044050816,0.00019544992,0.00019897231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000199515,0.00028596492,0.0010168077,0.00024175592,0.00004879795,0.00001862961,0.00012009446,0.00024804758,0.000047752335],"category_scores_gemma":[0.00053526316,0.00016114475,0.00020468485,0.00041982793,0.00029232883,0.000106818276,0.000063534884,0.00034873016,0.000015357067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07073779,0.0010960803,0.92237306,0.000008123691,0.0007111781,0.00019576523,0.00035762123,0.0000031259328,0.00003934685,0.0000070809197,0.0006150688,0.0038557686],"study_design_scores_gemma":[0.08235289,0.011919258,0.90498394,0.000081791906,0.00009271392,0.000005075925,0.00008478731,0.00015131937,0.00009463714,0.00005607016,0.00004144655,0.00013604817],"about_ca_topic_score_codex":0.00073217734,"about_ca_topic_score_gemma":0.00007958539,"teacher_disagreement_score":0.017389096,"about_ca_system_score_codex":0.0003902206,"about_ca_system_score_gemma":0.00017588626,"threshold_uncertainty_score":0.6571292},"labels":[],"label_agreement":null},{"id":"W4380988157","doi":"10.3390/cancers15123210","title":"TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Regimen; Oncology; Transplantation; Myeloid leukemia; Venetoclax; Decitabine; Azacitidine; Hematopoietic stem cell transplantation; Hematopoietic cell; Leukemia; Haematopoiesis; Stem cell; Gene","score_opus":0.04344347381675857,"score_gpt":0.3455087319915917,"score_spread":0.30206525817483315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380988157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99874014,0.000039972216,0.00005623648,0.00031200465,0.00007338012,0.000488391,0.00006694504,0.00003432862,0.00018861733],"genre_scores_gemma":[0.9990562,0.0001314181,0.000098820936,0.000053762546,0.00003173462,0.00004733944,0.0002707706,0.00002025839,0.0002896834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886185,0.00009762122,0.00034713524,0.000244262,0.00025897767,0.00019015367],"domain_scores_gemma":[0.9993216,0.00017208538,0.00016252398,0.000116506104,0.0001372556,0.00009006578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002754475,0.00009750284,0.00029750683,0.00019723232,0.000035228433,0.000004770741,0.00004543283,0.00010723789,0.000012903164],"category_scores_gemma":[0.00018678195,0.00008278715,0.000036618327,0.00052170095,0.00014795788,0.0000671026,0.000013049912,0.00026543307,0.000005398938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005576331,0.000058683036,0.9959414,0.000106560365,0.00006362201,0.000047566005,0.0016477846,0.00042769485,0.0003376395,0.0000048549005,0.00028954432,0.0005170366],"study_design_scores_gemma":[0.0050248248,0.00036158113,0.9916148,0.00014765849,0.000102327926,0.000002757937,0.0015002644,0.0005053646,0.00061529386,0.000030538482,0.0000132196255,0.0000813394],"about_ca_topic_score_codex":0.00024713925,"about_ca_topic_score_gemma":0.00050780765,"teacher_disagreement_score":0.0044671916,"about_ca_system_score_codex":0.0010336187,"about_ca_system_score_gemma":0.00035795863,"threshold_uncertainty_score":0.33759618},"labels":[],"label_agreement":null},{"id":"W4381487668","doi":"10.1200/po.23.00132","title":"Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface","year":2023,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Carcinogenesis; Haematopoiesis; Immune system; Cancer; Oncology; Population; Interface (matter); Biology; Epigenetics; Solid tumor; Immunology; Bioinformatics; Internal medicine; Cancer research; Computational biology; Medicine; Genetics; Stem cell; Gene; Environmental health","score_opus":0.10010566176435874,"score_gpt":0.46656861484103807,"score_spread":0.3664629530766793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381487668","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020993847,0.98781013,0.00005461598,0.006217579,0.000329613,0.0024168112,0.00012790179,0.00015170735,0.0026816702],"genre_scores_gemma":[0.000027464877,0.98195136,0.0003867908,0.00032422607,0.0003219018,0.0009947245,0.00028465348,0.00012810226,0.0155807985],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963449,0.00060307956,0.0012234296,0.0008211001,0.0004052221,0.0006022743],"domain_scores_gemma":[0.9931287,0.0045511317,0.00051627064,0.0013294909,0.00021733691,0.00025706633],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001575963,0.00047608928,0.002500886,0.00038593367,0.00034528747,0.0000492762,0.00072346436,0.0006263744,0.0008297698],"category_scores_gemma":[0.0013603821,0.00027695802,0.00044664572,0.00067682186,0.0005099676,0.0000556948,0.0022586563,0.0014562503,0.003525484],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010671647,0.00009407986,0.0000064937703,0.0033130033,0.00043330982,0.00012939751,0.00011838026,3.9033424e-7,0.00004888252,0.00023700726,0.13998519,0.85552716],"study_design_scores_gemma":[0.00057898724,0.00036182298,0.00009273626,0.003985934,0.00072128803,0.00431873,0.00008835633,0.000017660775,0.00003494553,0.00034262374,0.9892346,0.00022229664],"about_ca_topic_score_codex":0.000030600175,"about_ca_topic_score_gemma":0.000048708964,"teacher_disagreement_score":0.85530484,"about_ca_system_score_codex":0.0017477475,"about_ca_system_score_gemma":0.0017460013,"threshold_uncertainty_score":0.99996823},"labels":[],"label_agreement":null},{"id":"W4381597464","doi":"10.3324/haematol.2023.283510","title":"Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia","year":2023,"lang":"en","type":"letter","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"University of Texas MD Anderson Cancer Center; Ontario Institute for Cancer Research; Princess Margaret Cancer Foundation","keywords":"Isocitrate dehydrogenase; Myeloid leukemia; Minimal residual disease; Cancer research; IDH1; Disease; RNA splicing; Gene; Residual; Medicine; Mutation; Oncology; Leukemia; Biology; Internal medicine; Genetics; Enzyme; Biochemistry; Computer science","score_opus":0.031026215968207538,"score_gpt":0.30257728020387314,"score_spread":0.2715510642356656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381597464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9291633,0.0017942061,0.000012203804,0.06658731,0.00004962405,0.002095155,0.00015879775,0.000041211442,0.00009822174],"genre_scores_gemma":[0.99059963,0.00071121665,0.000445136,0.0072572264,0.00003952298,0.00035523454,0.00028783374,0.00007923088,0.00022497548],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99643713,0.00043962325,0.00089022267,0.00067258405,0.00093006797,0.00063035364],"domain_scores_gemma":[0.9979599,0.0006415214,0.00039342197,0.0006359233,0.00022849618,0.00014071655],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055996486,0.00042137422,0.0011119174,0.0005430117,0.000100593585,0.000029379757,0.00034536535,0.00050257536,0.00003665186],"category_scores_gemma":[0.00058299693,0.0002820794,0.0003169518,0.0006521307,0.0004434378,0.00007001173,0.00036951472,0.0016589133,0.0000059294402],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002832708,0.0012557714,0.21494079,0.020225067,0.00525504,0.108966105,0.009821104,0.002176663,0.5933807,0.0003476501,0.03815722,0.002641212],"study_design_scores_gemma":[0.019123727,0.0055527412,0.8038608,0.014067649,0.00717696,0.0025275566,0.012962705,0.03171493,0.09289612,0.0029859468,0.0030368331,0.0040940233],"about_ca_topic_score_codex":0.00052471086,"about_ca_topic_score_gemma":0.000048897495,"teacher_disagreement_score":0.58892,"about_ca_system_score_codex":0.0006318489,"about_ca_system_score_gemma":0.0014944589,"threshold_uncertainty_score":0.99996316},"labels":[],"label_agreement":null},{"id":"W4382135772","doi":"10.3389/fonc.2023.1153082","title":"Biallelic disruption of DDX41 activity is associated with distinct genomic and immunophenotypic hallmarks in acute leukemia","year":2023,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"University of Toronto","keywords":"Myelodysplastic syndromes; Immunophenotyping; Phenotype; Myeloid; Leukemia; Germline; Biology; Myeloid leukemia; Cancer research; Bone marrow; Mutation; Medicine; Genetics; Immunology; Gene; Flow cytometry","score_opus":0.01726979798526305,"score_gpt":0.3051506652245145,"score_spread":0.28788086723925144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382135772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99636257,0.00019946614,0.0002808905,0.0012147967,0.00021460433,0.0005821093,0.00002827236,0.000044035467,0.0010732836],"genre_scores_gemma":[0.9967946,0.00072418526,0.0010242435,0.0001151887,0.000037536356,0.000066617766,0.00008537677,0.000035449477,0.001116802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830717,0.00025041646,0.0003335685,0.0003901876,0.00022492124,0.00049371034],"domain_scores_gemma":[0.9991686,0.00023485487,0.0001600391,0.0002775811,0.00006252851,0.000096426746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007496777,0.00018049339,0.0007564387,0.000640637,0.000044926655,0.0000072807356,0.0001519083,0.00035520789,0.00003117831],"category_scores_gemma":[0.0002778318,0.00016054563,0.00004795397,0.0009199508,0.00034181846,0.000082510975,0.00016368866,0.00066652824,0.000009953203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005891193,0.0003046554,0.87002677,0.0001249914,0.00057723065,0.0013660867,0.0025782285,0.000054525,0.025154777,0.00002501981,0.01143729,0.082459256],"study_design_scores_gemma":[0.006397872,0.0009301024,0.98243773,0.00009719549,0.00008372638,0.00004247003,0.0003780386,0.007981533,0.00030693694,0.00022178087,0.00097331824,0.00014929604],"about_ca_topic_score_codex":0.0006137527,"about_ca_topic_score_gemma":0.0007128655,"teacher_disagreement_score":0.112410985,"about_ca_system_score_codex":0.003975706,"about_ca_system_score_gemma":0.0010077077,"threshold_uncertainty_score":0.9998478},"labels":[],"label_agreement":null},{"id":"W4382402376","doi":"10.3390/curroncol30070459","title":"Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Astex Pharmaceuticals; Jazz Pharmaceuticals; F. Hoffmann-La Roche; Janssen Pharmaceuticals; Genentech; Celgene; Gilead Sciences; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Decitabine; Myelodysplastic syndromes; Lenalidomide; Cytopenia; International Prognostic Scoring System; Internal medicine; Azacitidine; Oncology; Myeloid leukemia; Multiple myeloma; Bone marrow; DNA methylation","score_opus":0.1116167074817706,"score_gpt":0.43230499756220997,"score_spread":0.32068829008043936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382402376","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008791457,0.9906236,0.000113316404,0.000027503447,0.002129397,0.0038088954,0.00031472248,0.00013048336,0.0019729582],"genre_scores_gemma":[0.000020757587,0.9962505,0.00033776974,0.000005405836,0.0002453999,0.0004693382,0.0010308989,0.00015494166,0.0014849548],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99648654,0.00031818266,0.0009060367,0.00078335707,0.0007843747,0.00072148384],"domain_scores_gemma":[0.9971014,0.00062175817,0.00082301407,0.00083662476,0.00030515896,0.00031201716],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042780954,0.00058789004,0.0029564272,0.0006590657,0.00006730761,0.000010097467,0.0004803686,0.00044834407,0.00025344122],"category_scores_gemma":[0.00016563294,0.0004010118,0.00042541893,0.00110534,0.0002987447,0.00003761023,0.0005224368,0.0015060086,0.0012165256],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002748116,0.00077108556,0.0007532787,0.06366553,0.0013165514,0.00036800443,0.000023845121,9.86827e-7,4.82399e-9,0.00008037312,0.00735029,0.92539525],"study_design_scores_gemma":[0.0030065628,0.0020998744,0.0007377094,0.02353818,0.005163402,0.000024049372,0.000020803947,0.0000202794,7.013169e-8,0.000010251664,0.9650717,0.00030712152],"about_ca_topic_score_codex":0.0000068106183,"about_ca_topic_score_gemma":0.0000070980363,"teacher_disagreement_score":0.9577214,"about_ca_system_score_codex":0.0015561682,"about_ca_system_score_gemma":0.001349901,"threshold_uncertainty_score":0.9998442},"labels":[],"label_agreement":null},{"id":"W4382929555","doi":"10.1186/s12864-023-09472-5","title":"Gene expression profiling unveils the temporal dynamics of CIGB-300-regulated transcriptome in AML cell lines","year":2023,"lang":"en","type":"article","venue":"BMC Genomics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Génome Québec; McGill University","keywords":"Biology; Gene expression profiling; Transcriptome; Cell cycle; Gene; Signal transduction; Cell culture; Gene expression; Gene isoform; Cancer research; Cell biology; Molecular biology; Genetics","score_opus":0.03426093304829849,"score_gpt":0.29062753764016963,"score_spread":0.25636660459187116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382929555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99685305,0.00024978764,0.00063985056,0.0006907453,0.00014765555,0.000991501,0.000062093546,0.000094598094,0.00027072328],"genre_scores_gemma":[0.98917866,0.00019428009,0.007873148,0.000063932624,0.00015659543,0.000043004584,0.0004344291,0.00007136776,0.0019846074],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981406,0.00011757548,0.00056473806,0.0003412066,0.00035584372,0.00048004804],"domain_scores_gemma":[0.99888474,0.00015284409,0.00012667183,0.00058870885,0.00012847398,0.00011858107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007562495,0.00020386181,0.000396592,0.00033180148,0.00007238517,0.000018014694,0.00034251198,0.00020358576,0.00003358219],"category_scores_gemma":[0.000095526746,0.0001485768,0.00013543866,0.00087414874,0.0001351454,0.000056013803,0.00013705257,0.0003416104,0.000053874162],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004368952,0.00009606365,0.03224378,0.00035967244,0.00002010422,0.000039813032,0.0012464309,0.0024752584,0.9619229,0.000031155872,0.00058356643,0.00054437376],"study_design_scores_gemma":[0.0033717037,0.00016546436,0.015261174,0.00012167757,0.000047942503,0.000021623686,0.0026244952,0.1607924,0.816593,0.00024138037,0.0005192342,0.00023988576],"about_ca_topic_score_codex":0.00014949923,"about_ca_topic_score_gemma":0.00017663588,"teacher_disagreement_score":0.15831713,"about_ca_system_score_codex":0.0004246376,"about_ca_system_score_gemma":0.0006441208,"threshold_uncertainty_score":0.60587865},"labels":[],"label_agreement":null},{"id":"W4382932713","doi":"10.1016/j.jtct.2023.06.020","title":"Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia","year":2023,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; TG Therapeutics; Jazz Pharmaceuticals; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; StemCyte; Bristol-Myers Squibb; AstraZeneca; CSL Behring; BeiGene; HistoGenetics; Atara Biotherapeutics; CareDx; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Amgen; Mallinckrodt Pharmaceuticals; Astellas Pharma US","keywords":"Medicine; Hazard ratio; Cumulative incidence; Transplantation; Myeloid leukemia; Internal medicine; Cohort; Hematopoietic stem cell transplantation; Hematopoietic cell; Surgery; Incidence (geometry); Retrospective cohort study; Confidence interval; Graft-versus-host disease; Haematopoiesis; Stem cell","score_opus":0.014020429118387346,"score_gpt":0.28286693127397733,"score_spread":0.26884650215559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382932713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977409,0.00014611417,0.00045816595,0.00014094755,0.000023478091,0.00095059024,0.00007988014,0.00007620972,0.00038368357],"genre_scores_gemma":[0.98641866,0.011970546,0.00015719047,0.00011424656,0.000016070493,0.000065443084,0.000775472,0.00004806115,0.00043433],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99846846,0.000095227384,0.00034697112,0.000354022,0.00039082702,0.0003444713],"domain_scores_gemma":[0.99939007,0.000119474156,0.00008023752,0.00022439675,0.000049182894,0.0001366459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002096763,0.00026708475,0.00044123107,0.00043332615,0.000050557803,0.000016490732,0.000096363394,0.0001374926,0.00009074547],"category_scores_gemma":[0.0000014645223,0.00018549415,0.00013346536,0.00048728616,0.00008636956,0.00008683177,0.000002969688,0.00024894436,0.00002811764],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03268531,0.0008015557,0.33179772,0.0021905114,0.0008053781,0.0068434584,0.036082163,0.000731831,0.57764417,0.00010109767,0.00007954743,0.010237277],"study_design_scores_gemma":[0.020434735,0.001605187,0.8094896,0.00034191928,0.00013509288,0.00014641417,0.00036293085,0.00024147198,0.16695279,0.000024828129,0.000008711288,0.00025632596],"about_ca_topic_score_codex":0.00027099825,"about_ca_topic_score_gemma":0.00005610122,"teacher_disagreement_score":0.4776919,"about_ca_system_score_codex":0.0001260298,"about_ca_system_score_gemma":0.00019442334,"threshold_uncertainty_score":0.7564232},"labels":[],"label_agreement":null},{"id":"W4383216145","doi":"10.1182/bloodadvances.2023010045","title":"Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in <i>RUNX1</i>, <i>GATA2</i>, and <i>DDX41</i>","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; Alberta Children's Hospital","funders":"Nemzeti Kutatási, Fejlesztési és Innovaciós Alap; National Health and Medical Research Council; Cancer Council South Australia; Medical Research Council; National Institutes of Health; Damon Runyon Cancer Research Foundation; Associazione Italiana per la Ricerca sul Cancro; NHLBI Division of Intramural Research; Royal Adelaide Hospital; Bundesministerium für Bildung und Forschung; Government of South Australia; European Commission; Hospital Research Foundation; Edward P. Evans Foundation; European Hematology Association","keywords":"RUNX1; Germline; GATA2; CEBPA; Germline mutation; Cancer research; Biology; Haematopoiesis; Somatic cell; Epigenetics; Genetics; Oncology; Medicine; Mutation; Gene; Stem cell","score_opus":0.010879256937614276,"score_gpt":0.2717886854290961,"score_spread":0.26090942849148185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383216145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882934,0.008814849,0.000024914583,0.0014233635,0.00008911015,0.0004596471,0.00016447385,0.00009999493,0.00063024316],"genre_scores_gemma":[0.9952208,0.0018791207,0.001165282,0.00029283986,0.000121830555,0.0000905671,0.00030190428,0.000043274697,0.0008843848],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980802,0.00006468044,0.0005030442,0.00036990887,0.00054671464,0.00043545204],"domain_scores_gemma":[0.9989344,0.00042697092,0.00012423923,0.00026668725,0.000097003634,0.00015068639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003872629,0.00020647555,0.0005157553,0.0002505782,0.000057566696,0.000015072921,0.00014315215,0.00009147831,0.00006777447],"category_scores_gemma":[0.00027172567,0.00017919923,0.000054054886,0.00082273805,0.00018285622,0.0002575861,0.000104066596,0.00021782007,0.000033034386],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077762577,0.0021548134,0.38888583,0.009345648,0.00074692024,0.006461254,0.004314442,0.00039503482,0.53625673,0.0009047377,0.042803697,0.006953251],"study_design_scores_gemma":[0.05017668,0.00273922,0.5193468,0.005225037,0.0010990837,0.0037008887,0.010160764,0.00857232,0.3677955,0.013041288,0.015758554,0.0023839222],"about_ca_topic_score_codex":0.000035874626,"about_ca_topic_score_gemma":0.000033544187,"teacher_disagreement_score":0.16846126,"about_ca_system_score_codex":0.00002519693,"about_ca_system_score_gemma":0.00020459163,"threshold_uncertainty_score":0.73075324},"labels":[],"label_agreement":null},{"id":"W4383302075","doi":"10.3324/haematol.2023.283426","title":"Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration","year":2023,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Hazard ratio; Internal medicine; Transplantation; Myeloproliferative neoplasm; Myelodysplastic syndromes; Cyclophosphamide; Hematopoietic stem cell transplantation; Confidence interval; Gastroenterology; International Prognostic Scoring System; Graft-versus-host disease; Surgery; Oncology; Myelofibrosis; Chemotherapy; Bone marrow","score_opus":0.023679462404266074,"score_gpt":0.3013200057034748,"score_spread":0.27764054329920873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383302075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98706275,0.00002713527,0.004188527,0.0043965853,0.00016855713,0.0019163906,0.0010922368,0.0004680581,0.0006797515],"genre_scores_gemma":[0.9874233,0.000292144,0.007328405,0.0004410058,0.00017714409,0.00054515863,0.0029928999,0.00005547726,0.00074445264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970069,0.00015490114,0.00073607726,0.000813108,0.0006055755,0.0006834399],"domain_scores_gemma":[0.9966817,0.0018714023,0.0002559779,0.00044073025,0.00043290516,0.0003173003],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003158345,0.00033679698,0.00080843276,0.00029529652,0.00027428867,0.00010205346,0.00020891445,0.0001688656,0.000044107186],"category_scores_gemma":[0.0011387715,0.00027722056,0.00015317221,0.0015995152,0.000308266,0.00017200217,0.00005940408,0.000347161,0.0007017153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20183325,0.003994264,0.32098612,0.0077140466,0.0026672622,0.020253945,0.073625825,0.0028068977,0.052712213,0.009488161,0.28673932,0.017178686],"study_design_scores_gemma":[0.03853973,0.0071552354,0.7512379,0.00065873534,0.0017410492,0.0011251984,0.01692452,0.055994526,0.11295182,0.0025713483,0.008770766,0.002329156],"about_ca_topic_score_codex":0.0001553605,"about_ca_topic_score_gemma":0.00059860636,"teacher_disagreement_score":0.43025178,"about_ca_system_score_codex":0.00020826812,"about_ca_system_score_gemma":0.00046992255,"threshold_uncertainty_score":0.999968},"labels":[],"label_agreement":null},{"id":"W4383561141","doi":"10.14740/jh1124","title":"Donor Cell Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation","year":2023,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Allegheny Health Network","keywords":"Medicine; Stem cell; Transplantation; Leukemia; Hematopoietic stem cell transplantation; Haematopoiesis; Disease; Immunology; Oncology; Pathology; Internal medicine; Biology","score_opus":0.0213289666640097,"score_gpt":0.29276947221184296,"score_spread":0.2714405055478333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383561141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99368846,0.0012160402,0.0008158569,0.0013982301,0.0005051901,0.0002292439,0.0000030646884,0.000056763074,0.0020871505],"genre_scores_gemma":[0.9962348,0.0008756263,0.00093499885,0.00026503985,0.00014032068,0.000007829711,0.0000118847165,0.000048005786,0.0014815022],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978026,0.00014275716,0.0008105546,0.00021300284,0.0005162487,0.000514836],"domain_scores_gemma":[0.99864733,0.0003477748,0.00033438051,0.00023831113,0.00016033114,0.00027184995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007627053,0.00019348347,0.0007525145,0.0006001168,0.00008518227,0.000016446342,0.00025049725,0.00023630446,0.00011457262],"category_scores_gemma":[0.000030050056,0.00015690395,0.00039549483,0.00053069147,0.00005761624,0.00012696025,0.00004043319,0.00063179206,0.00037343157],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032187733,0.0006629844,0.1314106,0.0076803654,0.001147673,0.1056497,0.009600466,0.00073890045,0.6592505,0.0013912973,0.07401591,0.005232824],"study_design_scores_gemma":[0.021589514,0.002474628,0.016138382,0.0009502158,0.0015958521,0.06322605,0.006050881,0.0011293365,0.87620884,0.00096699136,0.008868168,0.00080114976],"about_ca_topic_score_codex":0.00000823036,"about_ca_topic_score_gemma":0.000003596482,"teacher_disagreement_score":0.21695831,"about_ca_system_score_codex":0.00035678834,"about_ca_system_score_gemma":0.0008209024,"threshold_uncertainty_score":0.6398357},"labels":[],"label_agreement":null},{"id":"W4383709988","doi":"10.1111/joim.13697","title":"Novel precision medicine approaches and treatment strategies in hematological malignancies","year":2023,"lang":"en","type":"review","venue":"Journal of Internal Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"Agence Nationale de la Recherche","keywords":"Medicine; Precision medicine; Minimal residual disease; Disease; Myeloid leukemia; Hematology; Leukemia; Oncology; Bioinformatics; Internal medicine; Pathology; Biology","score_opus":0.26000321800160386,"score_gpt":0.4285399438604785,"score_spread":0.16853672585887464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383709988","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009805887,0.9938251,0.00043980073,0.0019547753,0.0004626556,0.0008629917,0.000008039914,0.000025118476,0.0014409664],"genre_scores_gemma":[0.00036904676,0.9953564,0.000849514,0.00008481925,0.0018405615,0.000037154732,0.000016556449,0.00007892985,0.0013670224],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99500597,0.00022249058,0.0026839105,0.00045404505,0.0011490085,0.0004845908],"domain_scores_gemma":[0.9960591,0.0015431333,0.0013087014,0.00035563108,0.00026523884,0.00046819335],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002076877,0.0006781276,0.0054747122,0.0018110488,0.000037712187,0.000026360698,0.00043677338,0.00046991385,0.00015226648],"category_scores_gemma":[0.0021699714,0.00031443493,0.00039179996,0.0007106966,0.0007407868,0.00014898578,0.00017079856,0.001565733,0.000018328292],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009392325,0.00042448402,0.00018124611,0.017876178,0.0015724855,0.009616249,0.0013989008,0.0000021068925,0.00011198932,0.0010436876,0.0044946778,0.96233875],"study_design_scores_gemma":[0.009559283,0.01244398,0.00042837881,0.31539395,0.0025936612,0.054169483,0.0042696334,0.000105372084,0.000011091896,0.0004049111,0.6002204,0.00039989597],"about_ca_topic_score_codex":0.00023818239,"about_ca_topic_score_gemma":0.000042777872,"teacher_disagreement_score":0.96193886,"about_ca_system_score_codex":0.0010896366,"about_ca_system_score_gemma":0.000981273,"threshold_uncertainty_score":0.9999308},"labels":[],"label_agreement":null},{"id":"W4383815651","doi":"10.1016/j.xcrm.2023.101108","title":"Leukemic progenitor compartment serves as a prognostic measure of cancer stemness in patients with acute myeloid leukemia","year":2023,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; McMaster University","funders":"Canadian Institutes of Health Research; Canada Research Chairs; Canadian Cancer Society","keywords":"Myeloid leukemia; Medicine; Oncology; Progenitor cell; Transplantation; Internal medicine; NPM1; Multivariate analysis; Stem cell; Leukemia; Myeloid; Clinical significance; Progenitor; Cancer research; Biology; Gene","score_opus":0.018359552060163,"score_gpt":0.29490782249628633,"score_spread":0.27654827043612334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383815651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99262786,0.0008901396,0.0000074041063,0.0007174548,0.00037053085,0.0033910892,0.000013303609,0.00016685812,0.0018153631],"genre_scores_gemma":[0.9940555,0.00022813218,0.00009344923,0.0001509234,0.00023795126,0.0005392372,0.00036554522,0.00010101915,0.0042282245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99512815,0.000106252315,0.0011869352,0.00077624776,0.002009451,0.00079295423],"domain_scores_gemma":[0.9971248,0.00015763464,0.0005782041,0.00087649166,0.0008074321,0.00045546083],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009143321,0.00043273752,0.0011597463,0.0006403841,0.000075877964,0.0000102979875,0.00020767759,0.00018740172,0.00023165651],"category_scores_gemma":[0.00034808568,0.0002912788,0.0000928804,0.0018216914,0.00040421277,0.00011484231,0.00014081545,0.0005957825,0.00003714662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015308672,0.00031191314,0.97045857,0.0011385184,0.00039127702,0.0056392206,0.001201561,0.0000938291,0.01107234,0.000004361328,0.0056680692,0.0024894718],"study_design_scores_gemma":[0.0117865475,0.0024527067,0.95759815,0.0030523732,0.0007677663,0.00029179538,0.0007786367,0.00026159105,0.020571277,0.000031378888,0.002015202,0.00039254664],"about_ca_topic_score_codex":0.0013273385,"about_ca_topic_score_gemma":0.00011027036,"teacher_disagreement_score":0.012860392,"about_ca_system_score_codex":0.0016653482,"about_ca_system_score_gemma":0.0031146018,"threshold_uncertainty_score":0.9999539},"labels":[],"label_agreement":null},{"id":"W4383872790","doi":"10.1001/jama.2023.8650","title":"DNA Sequencing in Adults With Acute Myeloid Leukemia to Detect Residual Disease Prior to Hematopoietic Cell Transplant","year":2023,"lang":"en","type":"letter","venue":"JAMA","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; NPM1; Myeloid leukemia; Minimal residual disease; Hematopoietic cell; Myeloid; Oncology; Hematopoietic stem cell transplantation; Disease; Leukemia; Internal medicine; Haematopoiesis; Immunology; Stem cell; Genetics; Gene; Chromosome","score_opus":0.015205947975622273,"score_gpt":0.26105561386130294,"score_spread":0.24584966588568066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383872790","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56684726,0.00010601124,0.00014171939,0.42720768,0.00019001977,0.0037750343,0.00064474944,0.0003607123,0.0007267865],"genre_scores_gemma":[0.101187624,0.0004250513,0.006254492,0.8404152,0.009005316,0.00241735,0.0023778852,0.001272146,0.036644965],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936144,0.00022339451,0.00080715196,0.0016392516,0.0019236366,0.0017921884],"domain_scores_gemma":[0.99654096,0.00044735902,0.00014261322,0.0015007928,0.00024480274,0.0011234621],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055020367,0.00087771204,0.0013001357,0.0014110883,0.00012176651,0.00013202966,0.00081287493,0.0009681534,0.00012323393],"category_scores_gemma":[0.00027283156,0.0007206086,0.00022435332,0.0015711655,0.000104660874,0.00013602752,0.00026030332,0.004393818,0.001678341],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0077283964,0.000018469811,0.00029210228,0.004341217,0.00021692758,0.13672285,0.004456733,0.000086267464,0.003992547,0.0000012324195,0.83997035,0.0021729225],"study_design_scores_gemma":[0.07154286,0.011348516,0.0500915,0.087517776,0.0052461238,0.0059777913,0.0028617543,0.0012751054,0.091808535,0.00025099865,0.6611106,0.010968448],"about_ca_topic_score_codex":0.0010771404,"about_ca_topic_score_gemma":0.00047991224,"teacher_disagreement_score":0.46565968,"about_ca_system_score_codex":0.0065662125,"about_ca_system_score_gemma":0.006039085,"threshold_uncertainty_score":0.99959576},"labels":[],"label_agreement":null},{"id":"W4383875518","doi":"10.1016/j.clml.2023.07.003","title":"Real-World Experience With CPX-351 Treatment for Acute Myeloid Leukemia in England: An Analysis From the National Cancer Registration and Analysis Service","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chinese Academy of Sciences; Jazz Pharmaceuticals; CMC Microsystems","keywords":"Medicine; Cytarabine; Cancer; Population; Pediatrics; Transplantation; Myeloid leukemia; Cancer registry; Cohort; Retrospective cohort study; Chemotherapy regimen; Internal medicine; Survival analysis","score_opus":0.06922871382395486,"score_gpt":0.411631391700547,"score_spread":0.3424026778765922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383875518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941381,0.00009351343,0.0002270006,0.0031450575,0.000090334004,0.0011507084,0.00057695416,0.00019613285,0.00038217995],"genre_scores_gemma":[0.9873056,0.0018485418,0.0017886326,0.0018451962,0.0008866112,0.0011993548,0.0030487648,0.00007378012,0.0020035387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99476826,0.00042018664,0.0013555547,0.0015690792,0.0010855984,0.0008013456],"domain_scores_gemma":[0.9943084,0.0029914652,0.0004402331,0.0010622792,0.0006522281,0.000545402],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015752899,0.0005326885,0.0014793251,0.0009221207,0.00035892063,0.00017429962,0.0005202928,0.00037068094,0.000119675664],"category_scores_gemma":[0.00043785886,0.000357133,0.00050999486,0.0077074277,0.00043421952,0.00036671927,0.00014725392,0.00033936783,0.000028694327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005454593,0.00017492539,0.87605655,0.000032286214,0.011119088,0.00025825456,0.0037141629,0.0031245365,0.0007387296,0.00020372015,0.0007562693,0.0983669],"study_design_scores_gemma":[0.0069159907,0.00049435295,0.8193557,0.000048153823,0.005342004,0.000010054413,0.0005116241,0.1627755,0.00025154845,0.00013126823,0.003824245,0.0003395121],"about_ca_topic_score_codex":0.0359854,"about_ca_topic_score_gemma":0.110094205,"teacher_disagreement_score":0.15965097,"about_ca_system_score_codex":0.007961642,"about_ca_system_score_gemma":0.0047563473,"threshold_uncertainty_score":0.99988806},"labels":[],"label_agreement":null},{"id":"W4384038204","doi":"10.1016/j.leukres.2023.107354","title":"Changing frontline AML treatment patterns from 2013 to 2022","year":2023,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Myeloid leukemia; Internal medicine; Pediatrics","score_opus":0.08757382435923698,"score_gpt":0.39717534999691767,"score_spread":0.3096015256376807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384038204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784539,0.0002352915,0.00025191813,0.015604951,0.0002468881,0.0018351894,0.0003099589,0.00043527078,0.0026266437],"genre_scores_gemma":[0.85563743,0.001816821,0.00098306,0.00083499897,0.0024667997,0.0011883352,0.0011252098,0.00021452397,0.13573283],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99363804,0.0003754411,0.0004310505,0.0010679695,0.002153398,0.0023341195],"domain_scores_gemma":[0.99617606,0.00084076455,0.00003889291,0.0014335975,0.00043892927,0.0010717603],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0019413572,0.0003504209,0.00060787663,0.0023570997,0.00044393959,0.00012340587,0.00058471254,0.0002667613,0.0032679148],"category_scores_gemma":[0.00054224173,0.00029254146,0.00019788682,0.0031474319,0.00012977674,0.00012742088,0.00094371673,0.0012115354,0.018881198],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025763824,0.0004474563,0.038076993,0.00031638108,0.0008651164,0.0074410867,0.009708363,0.00036779323,0.10161701,0.00025573224,0.6422025,0.19612521],"study_design_scores_gemma":[0.01721419,0.005056798,0.13234745,0.00086311344,0.00013197892,0.000111727604,0.011293325,0.048344824,0.1059968,0.00097304594,0.67634046,0.0013262717],"about_ca_topic_score_codex":0.01461536,"about_ca_topic_score_gemma":0.0007911687,"teacher_disagreement_score":0.19479895,"about_ca_system_score_codex":0.008303955,"about_ca_system_score_gemma":0.0016382948,"threshold_uncertainty_score":0.9999527},"labels":[],"label_agreement":null},{"id":"W4384120373","doi":"10.1001/jamaoncol.2023.2163","title":"Management of Down Syndrome–Associated Leukemias","year":2023,"lang":"en","type":"review","venue":"JAMA Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Down syndrome; Myeloid leukemia; Internal medicine; Clinical trial; Leukemia; Population; Pediatrics; Oncology; Myeloid","score_opus":0.09827267579934236,"score_gpt":0.42358201095335213,"score_spread":0.3253093351540098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384120373","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011929527,0.95513177,0.0000048848924,0.0005610078,0.00042346926,0.0025200094,0.00012099583,0.00022051296,0.04089804],"genre_scores_gemma":[0.000014328379,0.96263564,0.0004277908,0.00013585326,0.00016176628,0.00046952732,0.00069182285,0.00016212501,0.035301153],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996042,0.00053650653,0.001294153,0.0006811429,0.00065731973,0.00078884134],"domain_scores_gemma":[0.9969357,0.00095287536,0.0007426553,0.00089587754,0.00020807283,0.00026481575],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015021993,0.00048714536,0.004291206,0.00078840647,0.000056100947,0.000014872477,0.00061874354,0.0016655324,0.0005055981],"category_scores_gemma":[0.00043876035,0.00038992238,0.00085250515,0.0016339099,0.00024194576,0.000043279404,0.0007305706,0.0017181752,0.002501685],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044507247,0.00021148748,0.000004273285,0.049709648,0.0034123207,0.01583149,0.00003348999,2.526023e-7,3.25312e-7,0.0003910205,0.048883982,0.8814772],"study_design_scores_gemma":[0.0021083036,0.00089904893,0.0001387743,0.02314174,0.003236678,0.0013328287,0.00007799407,0.000008573985,5.094414e-7,0.000050393508,0.9687488,0.00025634744],"about_ca_topic_score_codex":0.0001026026,"about_ca_topic_score_gemma":0.000014019085,"teacher_disagreement_score":0.91986483,"about_ca_system_score_codex":0.0066707106,"about_ca_system_score_gemma":0.0030512083,"threshold_uncertainty_score":0.9998553},"labels":[],"label_agreement":null},{"id":"W4384120739","doi":"10.3324/haematol.2023.283225","title":"Down syndrome and leukemia: from basic mechanisms to clinical advances","year":2023,"lang":"en","type":"review","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; Cancer Council Western Australia; National Institutes of Health; Ministerio de Ciencia e Innovación; Bundesministerium für Bildung und Forschung; Deutsche Forschungsgemeinschaft; European Commission; St. Jude Children's Research Hospital; Children's Hospital of Philadelphia; American Lebanese Syrian Associated Charities; U.S. Department of Defense","keywords":"Down syndrome; Trisomy; Myeloid leukemia; Leukemia; Medicine; Acute leukemia; Population; Lymphoblastic Leukemia; Immunology; Bioinformatics; Oncology; Biology; Genetics; Psychiatry","score_opus":0.14615426216856228,"score_gpt":0.4390545652284838,"score_spread":0.29290030305992154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384120739","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005153226,0.9940854,0.00019903161,0.0004650292,0.00051722635,0.0026319611,0.00020613581,0.00046971446,0.0009102348],"genre_scores_gemma":[0.000042753494,0.99025774,0.0060806735,0.0005557161,0.00023733126,0.00055607286,0.00028656612,0.00013897469,0.0018441724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950507,0.0004967686,0.0014981303,0.0015173868,0.00063423114,0.000802762],"domain_scores_gemma":[0.9951397,0.0024766268,0.00036638026,0.0011246625,0.00009894093,0.0007936893],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010690249,0.00071656203,0.0057447404,0.0004082882,0.00014047905,0.00006189062,0.0006127284,0.0013234612,0.0005109844],"category_scores_gemma":[0.0019919162,0.00046977456,0.00068171107,0.00084998657,0.00025672518,0.00007864996,0.0009356258,0.0018474553,0.006200745],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000087921086,0.0000734587,0.000032853357,0.018665582,0.0006880082,0.017100044,0.000027181675,1.0159758e-7,6.715039e-7,0.0013100981,0.012960543,0.9490535],"study_design_scores_gemma":[0.0006231185,0.00072951894,0.00010052587,0.01598542,0.0011497138,0.0049486286,0.00004947517,0.000006533891,0.0000015854175,0.0019801,0.97392446,0.0005009124],"about_ca_topic_score_codex":0.0000664456,"about_ca_topic_score_gemma":0.000020109163,"teacher_disagreement_score":0.9609639,"about_ca_system_score_codex":0.00047901666,"about_ca_system_score_gemma":0.0010958154,"threshold_uncertainty_score":0.99997306},"labels":[],"label_agreement":null},{"id":"W4384199314","doi":"10.58931/cht.2023.2125","title":"Venetoclax-based lower-intensity regimens for acute myeloid leukemia","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; AstraZeneca (Canada); University of Toronto; University Health Network","funders":"University of Texas MD Anderson Cancer Center","keywords":"Venetoclax; Medicine; Azacitidine; Cytarabine; Myeloid leukemia; Internal medicine; Oncology; Decitabine; Chemotherapy; Leukemia; Chronic lymphocytic leukemia; DNA methylation","score_opus":0.026168025105676427,"score_gpt":0.3064412241498629,"score_spread":0.28027319904418646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384199314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93475634,0.0002684275,0.00047352235,0.052206174,0.0013837474,0.0027621696,0.00049397803,0.0006798921,0.0069757397],"genre_scores_gemma":[0.9691678,0.00004775671,0.0016767994,0.011709229,0.00033183285,0.00040782584,0.00089136517,0.00015124564,0.01561609],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971828,0.00005601385,0.00036169807,0.00065306283,0.00024056293,0.0015058678],"domain_scores_gemma":[0.9969694,0.0003324501,0.000077202894,0.0008881523,0.00038486187,0.0013479351],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044900872,0.0003015203,0.00077695533,0.00082857476,0.00030127013,0.000022889417,0.00032592475,0.0005049047,0.00031200086],"category_scores_gemma":[0.0005947544,0.00030050887,0.0002468997,0.0008158459,0.00031598978,0.000055528773,0.000055110857,0.0005356349,0.0014769165],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007202704,0.00001523907,0.007467452,0.000205879,0.00047974725,0.0068720514,0.000150459,0.00006149993,0.0024503937,0.0037916969,0.976737,0.0010482861],"study_design_scores_gemma":[0.0101313125,0.0014893131,0.018156754,0.00037665074,0.0007806585,0.0037963497,0.00035363337,0.0336855,0.03813979,0.0020364872,0.88978124,0.0012723083],"about_ca_topic_score_codex":0.015744729,"about_ca_topic_score_gemma":0.032593686,"teacher_disagreement_score":0.086955786,"about_ca_system_score_codex":0.0041284277,"about_ca_system_score_gemma":0.010921796,"threshold_uncertainty_score":0.9999447},"labels":[],"label_agreement":null},{"id":"W4384199484","doi":"10.58931/cht.2023.2235","title":"Initiating venetoclax treatment: Clinical practice pearls","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Red Deer Regional Hospital; University of Calgary","funders":"","keywords":"Venetoclax; Tumor lysis syndrome; Chronic lymphocytic leukemia; Medicine; Azacitidine; Myeloid leukemia; Lymphoma; Cancer research; Oncology; Leukemia; Internal medicine; Chemotherapy; Biology; DNA methylation","score_opus":0.08237989351488345,"score_gpt":0.4158169093391787,"score_spread":0.33343701582429525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384199484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.748175,0.0011295427,0.000020811058,0.058781046,0.00095337315,0.0013385728,0.00007600825,0.00048296995,0.18904267],"genre_scores_gemma":[0.9808052,0.00041341694,0.0017022198,0.008014797,0.0005650222,0.000121357356,0.00021968829,0.00007991355,0.008078368],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99777144,0.0002671453,0.0004576149,0.0004292651,0.0001849279,0.00088958244],"domain_scores_gemma":[0.99672806,0.0013575978,0.00008755095,0.00052421325,0.00017623589,0.0011263173],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007802711,0.00017738016,0.00051203574,0.0004522424,0.00019504363,0.00002143648,0.0001513404,0.00035450252,0.00047850673],"category_scores_gemma":[0.0045210174,0.00016281845,0.00013541766,0.00065406214,0.00019212662,0.00010312984,0.000043266486,0.00049099646,0.005087881],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043726,0.00017003706,0.2722662,0.00023016366,0.0014020302,0.07328495,0.002654446,0.000020341487,0.00015844664,0.03015935,0.56886697,0.0503498],"study_design_scores_gemma":[0.0031671075,0.00078160147,0.030495895,0.000096892036,0.00020225933,0.00512145,0.0013190525,0.0013810754,0.00031476596,0.00025102834,0.95657414,0.000294716],"about_ca_topic_score_codex":0.029436333,"about_ca_topic_score_gemma":0.024443597,"teacher_disagreement_score":0.38770717,"about_ca_system_score_codex":0.001531502,"about_ca_system_score_gemma":0.0065268823,"threshold_uncertainty_score":0.9991052},"labels":[],"label_agreement":null},{"id":"W4384199598","doi":"10.58931/cht.2023.2234","title":"Acute myeloid leukemia induction in the age of novel therapeutic agents","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"Medicine; Cytarabine; Idarubicin; Myeloid leukemia; Oncology; Internal medicine; Myeloid; Anthracycline; Daunorubicin; Transplantation; Disease; Leukemia; Intensive care medicine; Cancer","score_opus":0.05621292049936643,"score_gpt":0.3244565945704068,"score_spread":0.2682436740710404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384199598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824789,0.00014627057,0.000028250679,0.011078846,0.0002212629,0.00062067114,0.00003168043,0.00004310081,0.0053510005],"genre_scores_gemma":[0.9946122,0.00009241949,0.00008594116,0.003329729,0.00006278954,0.00007604339,0.00014924587,0.000030316356,0.0015613238],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99839556,0.00010748444,0.00031645157,0.0002801313,0.00025071256,0.00064968725],"domain_scores_gemma":[0.9989784,0.00016627008,0.000057081757,0.0005207673,0.00006742367,0.00021008251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054626085,0.00015337064,0.00038246965,0.0007946235,0.00008791099,0.000010120169,0.00033613373,0.00027806044,0.00016198377],"category_scores_gemma":[0.00015048991,0.00011653265,0.00008070458,0.0013050733,0.00024236523,0.000055747,0.0000374664,0.0005681397,0.00020472868],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080156664,0.00048976985,0.27893773,0.0011370808,0.002289233,0.034495942,0.030606644,0.00019572272,0.1296208,0.07209825,0.42321005,0.026117189],"study_design_scores_gemma":[0.009668836,0.0005518389,0.8064818,0.00034782043,0.00036202688,0.0070371246,0.005485105,0.003241625,0.013226631,0.0014005228,0.15147728,0.0007194096],"about_ca_topic_score_codex":0.022723299,"about_ca_topic_score_gemma":0.04826567,"teacher_disagreement_score":0.527544,"about_ca_system_score_codex":0.0008579117,"about_ca_system_score_gemma":0.0018733995,"threshold_uncertainty_score":0.9837845},"labels":[],"label_agreement":null},{"id":"W4384274087","doi":"10.58931/cht.2022.1317","title":"The evolving treatment landscape of higher-risk MDS","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Cytopenia; Myelodysplastic syndromes; Incidence (geometry); Myeloid leukemia; Medicine; Internal medicine; Oncology; Dysplasia; Leukemia; Bone marrow","score_opus":0.014492270602639908,"score_gpt":0.27283858115351917,"score_spread":0.25834631055087925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384274087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89478487,0.02064369,0.0000062716817,0.028930547,0.00072117464,0.000962055,0.00021141446,0.00006373686,0.053676233],"genre_scores_gemma":[0.9870085,0.00018176141,0.00007924304,0.00037641564,0.000058714642,0.00014087977,0.000029283594,0.000023869427,0.012101317],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867475,0.00018358404,0.00022237311,0.00021364159,0.00018694281,0.00051870657],"domain_scores_gemma":[0.99860585,0.0003608302,0.00007629786,0.0005090643,0.000070433765,0.00037752365],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029833044,0.00011761818,0.00031105027,0.00020662727,0.0005708242,0.000007821251,0.00021534236,0.00007315092,0.002916929],"category_scores_gemma":[0.00015356638,0.000083033075,0.000094004594,0.00029486406,0.0001435676,0.000018131748,0.00006380013,0.00033567884,0.000052813142],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021933115,0.00010116762,0.5288736,0.00006326356,0.0005905934,0.0018828107,0.0012699163,0.00003364098,0.0002307944,0.014158757,0.44079015,0.01178593],"study_design_scores_gemma":[0.0021376715,0.0007802434,0.040364254,0.000016660826,0.00012932287,0.0010661574,0.0011318749,0.00071226124,0.00090520637,0.00032613406,0.9522734,0.00015679382],"about_ca_topic_score_codex":0.044211183,"about_ca_topic_score_gemma":0.052731372,"teacher_disagreement_score":0.51148325,"about_ca_system_score_codex":0.0011564164,"about_ca_system_score_gemma":0.0020668013,"threshold_uncertainty_score":0.99799454},"labels":[],"label_agreement":null},{"id":"W4384383449","doi":"10.58931/cht.2022.1319","title":"Hereditary hematologic malignancies: a Canadian perspective","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CEBPA; Germline; Genetic predisposition; Malignancy; Myeloid; Platelet disorder; Medicine; ETV6; Germline mutation; Cancer; GATA2; Genetics; Immunology; Biology; Mutation; Internal medicine; Gene; Disease; Chromosomal translocation; Platelet","score_opus":0.01887377594990247,"score_gpt":0.2717560610194565,"score_spread":0.252882285069554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384383449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65441334,0.006204218,0.000017050957,0.15117188,0.0013498812,0.002248445,0.0008089449,0.00027901054,0.1835072],"genre_scores_gemma":[0.9802131,0.000015852927,0.00031969827,0.014252086,0.00012114071,0.00038224668,0.00014543255,0.000066961,0.0044834563],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99672437,0.00022355249,0.0003399939,0.00069433165,0.00035415697,0.0016635851],"domain_scores_gemma":[0.9962243,0.00014195831,0.00006403465,0.00073427474,0.0002629058,0.0025725688],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042617822,0.00029711588,0.0006607939,0.001328702,0.00095881434,0.000019974985,0.00049676694,0.00025109886,0.011936126],"category_scores_gemma":[0.00049123407,0.0003141658,0.00017069106,0.00091832987,0.00032252213,0.00007388058,0.0001330262,0.0011695876,0.00065506203],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0001171513,0.00008048143,0.041976854,0.000092972165,0.00034073318,0.07064436,0.0031890315,0.000023455203,0.00016425486,0.16545744,0.7177397,0.0001735661],"study_design_scores_gemma":[0.0042185355,0.0011747773,0.014588366,0.00010049978,0.00023085107,0.13609135,0.053157028,0.00073627516,0.00090204965,0.011758258,0.7755975,0.0014444909],"about_ca_topic_score_codex":0.9300631,"about_ca_topic_score_gemma":0.95403147,"teacher_disagreement_score":0.32579976,"about_ca_system_score_codex":0.010511201,"about_ca_system_score_gemma":0.018204222,"threshold_uncertainty_score":0.99993104},"labels":[],"label_agreement":null},{"id":"W4385064330","doi":"10.1002/pbc.30584","title":"Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms","year":2023,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; Astellas Pharma; National Institutes of Health; Incyte; bluebird bio; Leukemia and Lymphoma Society; Jazz Pharmaceuticals; Syndax Pharmaceuticals; CureSearch for Children's Cancer; St. Baldrick's Foundation; Servier; Amgen","keywords":"Medicine; Gemtuzumab ozogamicin; Oncology; Internal medicine; Clinical trial; Sorafenib; Myeloid leukemia; Hematopoietic stem cell transplantation; CD33; Disease; Hematology; Intensive care medicine; Stem cell; CD34","score_opus":0.09014931244591472,"score_gpt":0.41501121827740195,"score_spread":0.3248619058314872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385064330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795056,0.0027456493,0.00006111873,0.010719896,0.0008063841,0.002759406,0.00024783114,0.0004222455,0.0027318655],"genre_scores_gemma":[0.9016391,0.039491013,0.0030599649,0.0013624348,0.026360296,0.006305559,0.0006036426,0.00035048038,0.020827515],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99542236,0.00021076089,0.0005222052,0.00096169574,0.0011290512,0.0017539138],"domain_scores_gemma":[0.99660563,0.0013127073,0.00012115393,0.000745127,0.0005906383,0.00062471884],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025471505,0.00030415345,0.00062825927,0.0011430539,0.00036559138,0.000049664755,0.0005183025,0.00040426568,0.00056541484],"category_scores_gemma":[0.0011002189,0.0002753127,0.00025901324,0.0032802217,0.00022071112,0.00010805961,0.00051992666,0.0013687406,0.0012845617],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017703702,0.0010060666,0.24396056,0.0011516043,0.00095161115,0.0005270185,0.00096699037,0.00010909762,0.0047041113,0.00097035215,0.6832389,0.060643315],"study_design_scores_gemma":[0.030533854,0.0064298427,0.5689656,0.00016878465,0.0023866072,0.00041743985,0.000916681,0.001677532,0.004841617,0.002435384,0.37976322,0.0014634354],"about_ca_topic_score_codex":0.0013945705,"about_ca_topic_score_gemma":0.0002965995,"teacher_disagreement_score":0.32500505,"about_ca_system_score_codex":0.000718089,"about_ca_system_score_gemma":0.0022874898,"threshold_uncertainty_score":0.9999699},"labels":[],"label_agreement":null},{"id":"W4385064500","doi":"10.1038/s42003-023-05120-6","title":"Single-cell chromatin accessibility profiling of acute myeloid leukemia reveals heterogeneous lineage composition upon therapy-resistance","year":2023,"lang":"en","type":"article","venue":"Communications Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"U.S. National Library of Medicine; Cancer Prevention and Research Institute of Texas; University of Texas MD Anderson Cancer Center; National Cancer Institute; National Institutes of Health; Conquer Cancer Foundation; U.S. Department of Health and Human Services","keywords":"Progenitor cell; Myeloid leukemia; Myeloid; Stem cell; Biology; Chromatin; Lineage (genetic); Cell therapy; Cancer research; Bone marrow; Immunology; Genetics; Gene","score_opus":0.06914358048226885,"score_gpt":0.3629517284348441,"score_spread":0.29380814795257526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385064500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992282,0.0020694488,0.00044375865,0.00153424,0.000056735134,0.001009294,0.00015466317,0.00021331827,0.0022365765],"genre_scores_gemma":[0.97830606,0.0031173828,0.015833616,0.00020878493,0.000055291253,0.00016785215,0.0018421508,0.00003773129,0.0004311355],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977011,0.00064626266,0.00070978823,0.0003869113,0.0001617882,0.00039416068],"domain_scores_gemma":[0.9957455,0.00067685137,0.00032131764,0.002787163,0.00035758212,0.00011158552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008156743,0.00020356402,0.00051512587,0.00027352112,0.00025256225,0.000017462015,0.0011062578,0.00026044628,0.000049026716],"category_scores_gemma":[0.00013922343,0.00018071843,0.00015189275,0.0008724492,0.00050570274,0.00007846697,0.000645629,0.00048562142,0.000097120625],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025897918,0.00022981988,0.0047137244,0.00012039107,0.00012905529,0.000006879637,0.00019324887,0.000012229725,0.9918564,0.00022215584,0.00034376656,0.0019133827],"study_design_scores_gemma":[0.0021283496,0.0004770834,0.0088485945,0.00014734961,0.00008953285,0.000035264344,0.00008962056,0.0058628446,0.9792626,0.0004840643,0.0023375005,0.00023721623],"about_ca_topic_score_codex":0.000031958785,"about_ca_topic_score_gemma":0.000020548105,"teacher_disagreement_score":0.015389857,"about_ca_system_score_codex":0.0005307377,"about_ca_system_score_gemma":0.00033444748,"threshold_uncertainty_score":0.7369484},"labels":[],"label_agreement":null},{"id":"W4385294836","doi":"10.1158/1078-0432.ccr-23-0538","title":"Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Uppsala Multidisciplinary Center for Advanced Computational Science; National Cancer Institute; Radiumhemmets Forskningsfonder; Vetenskapsrådet; Karolinska Institutet; Associazione Italiana per la Ricerca sul Cancro; Cancerfonden; Knut och Alice Wallenbergs Stiftelse; Science for Life Laboratory; Fondazione AIRC per la ricerca sul cancro ETS","keywords":"Transcriptome; Myelodysplastic syndromes; Biology; Myeloid; Genetics; NPM1; Computational biology; Cancer research; Bioinformatics; Gene; Oncology; Bone marrow; Medicine; Immunology; Gene expression; Karyotype; Chromosome","score_opus":0.16458143430260408,"score_gpt":0.4683414891179336,"score_spread":0.3037600548153295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385294836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635005,0.00065662706,0.00021998442,0.0018124359,0.0000196434,0.0007228602,0.00007992393,0.000051969277,0.00008652446],"genre_scores_gemma":[0.9893936,0.00956227,0.0002572522,0.000019066349,0.000078982484,0.0001520843,0.00008992801,0.000028826344,0.00041802568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726605,0.00052716624,0.00058219506,0.00063377054,0.0005999404,0.0003908801],"domain_scores_gemma":[0.9973818,0.0009877814,0.00012562994,0.00049575156,0.0005307798,0.00047825134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031090323,0.00013365116,0.0004557352,0.0006883318,0.00015188451,0.000055985445,0.00014543219,0.00012578066,0.00004950281],"category_scores_gemma":[0.0009244087,0.00009954645,0.000091954855,0.0021490217,0.0009927143,0.000101136604,0.00007662404,0.00093715155,0.000011484139],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036706452,0.00012409082,0.856968,0.0003849085,0.001012633,0.000020324274,0.00034073472,0.000047814563,0.08112072,0.00017454241,0.0003396973,0.05579588],"study_design_scores_gemma":[0.0015224512,0.00038760636,0.9378579,0.00008923031,0.00052309217,0.0000010876681,0.0006479899,0.05796006,0.00062994915,0.00016190432,0.00012981001,0.00008892361],"about_ca_topic_score_codex":0.0012268351,"about_ca_topic_score_gemma":0.0008371522,"teacher_disagreement_score":0.08088989,"about_ca_system_score_codex":0.0001969247,"about_ca_system_score_gemma":0.000985996,"threshold_uncertainty_score":0.40715092},"labels":[],"label_agreement":null},{"id":"W4385302461","doi":"10.1172/jci168597","title":"Genetic modification of inflammation- and clonal hematopoiesis–associated cardiovascular risk","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Human Genome Research Institute; National Institute of Mental Health; National Heart, Lung, and Blood Institute; Ludwig Center at Harvard; Genentech; National Institutes of Health; XBiotech; Burroughs Wellcome Fund; Ludwig Institute for Cancer Research; NIH Office of the Director; Japan Society for the Promotion of Science; Boston Scientific Corporation; Novo Nordisk; Massachusetts General Hospital; Celgene; Eli Lilly and Company; AstraZeneca; Knut och Alice Wallenbergs Stiftelse; Fondation Leducq; National Institute of Diabetes and Digestive and Kidney Diseases; Stanley Center for Psychiatric Research, Broad Institute; Amgen","keywords":"Inflammasome; Biology; Inflammation; AIM2; Gene; Gene expression; Genetics; Haematopoiesis; Immunology; Cancer research; Bioinformatics; Stem cell","score_opus":0.0974407511545383,"score_gpt":0.38314511979098087,"score_spread":0.28570436863644255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385302461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971965,0.0003275599,0.00050553714,0.0015766689,0.000117566226,0.00019363746,0.000005024726,0.000018894929,0.00005860153],"genre_scores_gemma":[0.9948071,0.0015893048,0.0030314294,0.000045707046,0.00042974265,0.0000037281359,0.00001725171,0.000014769334,0.00006094066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99695456,0.00045710383,0.00154814,0.0001395572,0.00076817576,0.00013245046],"domain_scores_gemma":[0.9967457,0.0008897346,0.0010640904,0.00021680632,0.000842776,0.00024090434],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00507421,0.00008696955,0.00059511454,0.00025256118,0.000050533854,0.000014238203,0.000091144546,0.00019258786,0.00001126245],"category_scores_gemma":[0.011700652,0.00007152222,0.00034274114,0.0005130351,0.0002665684,0.00014137328,0.000035697773,0.00050065084,0.0000165807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003548702,0.00009926351,0.94015616,0.00028780624,0.0019671675,0.000073919386,0.00061153295,0.002767188,0.012774449,0.00036293935,0.0038318934,0.036712818],"study_design_scores_gemma":[0.0022011653,0.00031239237,0.96992296,0.00016934106,0.00043167052,0.00004477334,0.00008859014,0.01834052,0.003498763,0.004565699,0.00036108107,0.0000630164],"about_ca_topic_score_codex":0.000026359357,"about_ca_topic_score_gemma":0.000002126517,"teacher_disagreement_score":0.0366498,"about_ca_system_score_codex":0.00007051974,"about_ca_system_score_gemma":0.00049989746,"threshold_uncertainty_score":0.99662423},"labels":[],"label_agreement":null},{"id":"W4385391472","doi":"10.1016/j.jmoldx.2023.05.002","title":"Genomic Data Heterogeneity across Molecular Diagnostic Laboratories","year":2023,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Taiho Pharmaceutical; TG Therapeutics; CTI Biopharma; Karyopharm Therapeutics; Sierra Oncology; Leukemia and Lymphoma Society; Bristol-Myers Squibb","keywords":"Computational biology; Biology; Genetics","score_opus":0.03910317410278107,"score_gpt":0.3643692789306439,"score_spread":0.32526610482786283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385391472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98644745,0.0052332156,0.003981434,0.0029198856,0.0005134383,0.0003715985,0.00039471668,0.00006829211,0.00006993716],"genre_scores_gemma":[0.9858521,0.007998875,0.0036112769,0.0016208761,0.0004876673,0.000010573046,0.0002595568,0.00012188591,0.000037193997],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966488,0.00020149347,0.00082507264,0.0004072019,0.0011532317,0.0007641998],"domain_scores_gemma":[0.9949806,0.0016624817,0.0003810697,0.001447446,0.00095503306,0.0005733825],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014722428,0.0003034794,0.00067005603,0.00028291254,0.00012156928,0.00011898885,0.0010757439,0.00021616773,0.00002983554],"category_scores_gemma":[0.021967217,0.00027228225,0.00021121539,0.0011806281,0.00022533289,0.00020827082,0.0010667339,0.0008663154,0.00020013313],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064712367,0.00094490446,0.26896298,0.0007245224,0.0026796092,0.16027622,0.00084481045,0.0028565647,0.40161866,0.0008056873,0.14586256,0.013776343],"study_design_scores_gemma":[0.012646126,0.0031013612,0.33035293,0.0013455156,0.0021209244,0.006147905,0.0012000788,0.0023078641,0.49100906,0.0018355517,0.14637318,0.0015594923],"about_ca_topic_score_codex":0.000017046725,"about_ca_topic_score_gemma":0.00000637225,"teacher_disagreement_score":0.15412831,"about_ca_system_score_codex":0.00029117486,"about_ca_system_score_gemma":0.0010077758,"threshold_uncertainty_score":0.99997294},"labels":[],"label_agreement":null},{"id":"W4385620067","doi":"10.1002/cam4.6322","title":"Clinical outcome of therapy‐related acute myeloid leukemia patients. Real‐life experience in a University Hospital and a Cancer Center in France","year":2023,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Univariate analysis; Myeloid leukemia; Chemotherapy; Multivariate analysis; Population; Cancer; Leukemia; Gastroenterology; Oncology; Surgery","score_opus":0.04375012942610617,"score_gpt":0.381780135545598,"score_spread":0.3380300061194918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385620067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927372,0.0012565863,0.0000025810966,0.0042684674,0.00044563276,0.00077611196,0.000050558046,0.000050446077,0.0004124656],"genre_scores_gemma":[0.9513983,0.04640423,0.000019025103,0.0007298092,0.00012015779,0.000045806122,0.00003716849,0.000029247309,0.0012162538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759156,0.00012261185,0.00076777104,0.00054453034,0.0004892271,0.00048432182],"domain_scores_gemma":[0.9987808,0.0001900487,0.00019102778,0.00035173813,0.00017442644,0.00031199603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051854795,0.00022010836,0.00085615244,0.00043755586,0.000035547324,0.0000026426183,0.00023455493,0.0002166065,0.00026995369],"category_scores_gemma":[0.00029196416,0.00017714953,0.000069383284,0.0015420371,0.00074162584,0.00012868087,0.00014265272,0.000703849,0.000007476903],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005814508,0.000102848106,0.9759824,0.00008286729,0.00009115289,0.00023705587,0.0053833565,0.0000075666985,0.0003366339,0.000016058653,0.0017280285,0.015450537],"study_design_scores_gemma":[0.018397318,0.0005620599,0.9733925,0.00062071637,0.000030502251,0.0000018641359,0.0013127207,0.00064888643,0.000056509507,0.000007432215,0.0048159384,0.00015355089],"about_ca_topic_score_codex":0.007395986,"about_ca_topic_score_gemma":0.00028397865,"teacher_disagreement_score":0.045147646,"about_ca_system_score_codex":0.0008817398,"about_ca_system_score_gemma":0.00060893473,"threshold_uncertainty_score":0.9992139},"labels":[],"label_agreement":null},{"id":"W4385655716","doi":"10.1097/01.hs9.0000974860.48116.9c","title":"PB2012: DESCRIBING TREATMENT PATTERNS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ACCORDING TO IPSS-R RISK CATEGORY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; International Prognostic Scoring System; Myelodysplastic syndromes; Demographics; Internal medicine; Pediatrics; Demography","score_opus":0.02821752694280383,"score_gpt":0.26571849908287903,"score_spread":0.2375009721400752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385655716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973921,0.00002824414,0.00029881657,0.00022727076,0.00009867236,0.0011309272,0.00004112062,0.00019774919,0.00058509386],"genre_scores_gemma":[0.9973698,0.000038447073,0.00056117936,0.00009133915,0.0000609165,0.00018697049,0.00011055367,0.00009354241,0.001487212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977565,0.00007487777,0.00030382272,0.0005419209,0.00052240334,0.0008005231],"domain_scores_gemma":[0.9987816,0.0001899429,0.00006822158,0.0004999016,0.000092955954,0.00036738077],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019613424,0.00029710087,0.00047012692,0.00029318727,0.000112534646,0.000036110094,0.0001456128,0.00011223544,0.00028754643],"category_scores_gemma":[0.00015743067,0.00022262191,0.0000685384,0.0010037594,0.000032798544,0.00013220588,0.00013607822,0.00034114422,0.0012628412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046072758,0.00018291853,0.98514485,0.00009653782,0.00010713111,0.0010686663,0.0006354594,0.00040775788,0.000079107784,0.000008623396,0.000476549,0.011331644],"study_design_scores_gemma":[0.005537555,0.0017793456,0.98872495,0.0005352939,0.00008881089,0.000051280258,0.0018302089,0.00059712975,0.00027151647,0.00001172056,0.00029237536,0.00027979832],"about_ca_topic_score_codex":0.0013330817,"about_ca_topic_score_gemma":0.0004995824,"teacher_disagreement_score":0.011051846,"about_ca_system_score_codex":0.0012692122,"about_ca_system_score_gemma":0.00024727642,"threshold_uncertainty_score":0.9995148},"labels":[],"label_agreement":null},{"id":"W4385658467","doi":"10.1097/01.hs9.0000967408.39207.65","title":"S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Midostaurin; Medicine; Myeloid leukemia; Internal medicine; Oncology; Phosphoproteomics; Fms-Like Tyrosine Kinase 3; Refractory (planetary science); Biology; Kinase","score_opus":0.030261329363964085,"score_gpt":0.3435764329594033,"score_spread":0.31331510359543924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385658467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911741,0.00021545765,0.00014334677,0.0025699546,0.00017199006,0.0031114377,0.0002132012,0.00024277133,0.0021577298],"genre_scores_gemma":[0.98841554,0.00080751156,0.001775514,0.0008268785,0.00017516309,0.00032304972,0.00013673863,0.00015685376,0.007382728],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958399,0.00018164833,0.0008506681,0.00087998126,0.0011785778,0.0010692335],"domain_scores_gemma":[0.99760544,0.00039097428,0.00020803239,0.0009184008,0.00035710444,0.0005200485],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00094013574,0.0004830136,0.0010623608,0.00044890342,0.00009514209,0.000043412223,0.00046114402,0.0003022798,0.0006443492],"category_scores_gemma":[0.00047484465,0.00045326055,0.00019512708,0.0021158597,0.0001909516,0.00019115343,0.00038474007,0.000888289,0.00041310838],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051530294,0.0006864401,0.13870472,0.00087121397,0.0015121192,0.012271528,0.0119993035,0.0010499054,0.73567164,0.000409324,0.022793708,0.022499813],"study_design_scores_gemma":[0.014354556,0.0010788667,0.20847844,0.0009904251,0.00011581847,0.00042941063,0.0021518802,0.0022379837,0.767931,0.00018791053,0.0014486002,0.0005951149],"about_ca_topic_score_codex":0.0010024305,"about_ca_topic_score_gemma":0.00050843495,"teacher_disagreement_score":0.069773726,"about_ca_system_score_codex":0.0016457059,"about_ca_system_score_gemma":0.0019223222,"threshold_uncertainty_score":0.9997919},"labels":[],"label_agreement":null},{"id":"W4385666344","doi":"10.1097/01.hs9.0000967592.61626.0d","title":"S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Myelodysplastic syndromes; Cohort; Medicine; Internal medicine; Oncology; Overall survival; Library science; Bone marrow","score_opus":0.040441073439601675,"score_gpt":0.32979848741790174,"score_spread":0.28935741397830006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385666344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99580353,0.000046170404,0.00024359737,0.0009820652,0.00025609828,0.0008529118,0.0010415597,0.000028737832,0.0007453495],"genre_scores_gemma":[0.99437284,0.00011258063,0.00031955267,0.00021830664,0.00011641977,0.00015729273,0.0010597999,0.000034346787,0.003608845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784607,0.00008791486,0.0004955773,0.00044143264,0.00082634727,0.00030265117],"domain_scores_gemma":[0.99786586,0.0005663946,0.00027978866,0.0006780942,0.0004016152,0.00020826461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003568264,0.00018676584,0.0005213304,0.00029898458,0.00011203171,0.00002437055,0.00035153335,0.0001455831,0.00041777725],"category_scores_gemma":[0.00081119966,0.0001450123,0.0001720103,0.0009320493,0.00013444161,0.0001171053,0.00018902704,0.00021319627,0.000020159723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003002168,0.0007212211,0.83934176,0.0002703988,0.0024759392,0.000008895542,0.0029597548,0.0005392688,0.03844032,0.0009552299,0.100956775,0.010328264],"study_design_scores_gemma":[0.0027509371,0.00053471606,0.9454222,0.00019520984,0.00073966105,0.0000013315683,0.0012255957,0.035929803,0.010980827,0.00006567393,0.001987467,0.00016663522],"about_ca_topic_score_codex":0.00034905798,"about_ca_topic_score_gemma":0.00043479117,"teacher_disagreement_score":0.10608038,"about_ca_system_score_codex":0.00020834828,"about_ca_system_score_gemma":0.00018003165,"threshold_uncertainty_score":0.591343},"labels":[],"label_agreement":null},{"id":"W4385667024","doi":"10.1097/01.hs9.0000969844.13426.20","title":"P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; Hôpital Maisonneuve-Rosemont; University of Alberta Hospital; Queen Elizabeth II Health Sciences Centre; University of Ottawa; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Decitabine; Medicine; Internal medicine; Chronic myelomonocytic leukemia; International Prognostic Scoring System; Monocytosis; Oncology; Leukemia; Gastroenterology; Bone marrow; Myelodysplastic syndromes","score_opus":0.0784401128588723,"score_gpt":0.41816012080025994,"score_spread":0.3397200079413876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99270415,0.0028077858,0.000035781635,0.0033322962,0.00004035163,0.00071903475,0.000072033414,0.000045717457,0.00024284594],"genre_scores_gemma":[0.9974929,0.0012158012,0.00047123377,0.00013306757,0.00009997961,0.00003365856,0.00022973293,0.0000259713,0.00029766114],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984889,0.00014704735,0.0003825332,0.00031909326,0.00037066464,0.00029173362],"domain_scores_gemma":[0.99862427,0.00075330294,0.000079940975,0.00032301445,0.000121555306,0.00009791478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000695992,0.00017812446,0.0004619515,0.00010286777,0.00008652362,0.000015551366,0.00009585269,0.00008651282,0.00015150815],"category_scores_gemma":[0.00096567057,0.000120742436,0.0000374199,0.00076933164,0.00019134075,0.00009577228,0.000117527736,0.0002657802,0.000015040456],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026081575,0.0041593374,0.14415231,0.0020937754,0.0016769497,0.0025227347,0.035438,0.0001812843,0.11781245,0.0020661154,0.095118105,0.56869733],"study_design_scores_gemma":[0.24240309,0.0059706517,0.58996516,0.0021636947,0.0009836081,0.00028396666,0.053357743,0.03521619,0.01641673,0.0033278994,0.048640117,0.0012711402],"about_ca_topic_score_codex":0.00048385694,"about_ca_topic_score_gemma":0.00034969766,"teacher_disagreement_score":0.5674262,"about_ca_system_score_codex":0.000084441715,"about_ca_system_score_gemma":0.00009287721,"threshold_uncertainty_score":0.49237338},"labels":[],"label_agreement":null},{"id":"W4385667055","doi":"10.1097/01.hs9.0000968868.83152.da","title":"P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Servier; Agios Pharmaceuticals","keywords":"Medicine; Internal medicine; IDH1; Isocitrate dehydrogenase; Myeloid leukemia; Placebo; Azacitidine; Gastroenterology; Clinical endpoint; Randomized controlled trial; Pathology; Biology","score_opus":0.017165133778774964,"score_gpt":0.25780168387298313,"score_spread":0.24063655009420817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99076974,0.00006624313,0.00001232453,0.0012453315,0.000065875414,0.0046661436,0.0015619999,0.00032182518,0.0012904893],"genre_scores_gemma":[0.9921444,0.00015622769,0.00041065709,0.00034372706,0.00013244881,0.00024083976,0.003713416,0.0001563494,0.0027019018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99521935,0.00037573194,0.00085222814,0.0012352462,0.0013491521,0.00096831046],"domain_scores_gemma":[0.9966769,0.0008837578,0.0002166754,0.0012677453,0.0004853354,0.00046955977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008546926,0.0006412327,0.001119663,0.00021367412,0.00029243255,0.00012089979,0.0003958328,0.00019318589,0.0002835217],"category_scores_gemma":[0.0002604214,0.0004011673,0.00006435071,0.0024615205,0.00020428601,0.00024502096,0.00033642128,0.00081669143,0.00017128797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10688553,0.0010772211,0.84730756,0.00006294516,0.0023802184,0.0025832958,0.0025169163,0.0006993571,0.0014189832,0.00000703305,0.033921435,0.0011394877],"study_design_scores_gemma":[0.07351253,0.0043175765,0.91101277,0.0006316628,0.0007138058,0.000034862736,0.0048394767,0.00050415617,0.0015407423,0.000008491688,0.0022215687,0.00066234893],"about_ca_topic_score_codex":0.0054797884,"about_ca_topic_score_gemma":0.01133732,"teacher_disagreement_score":0.0637052,"about_ca_system_score_codex":0.00088916573,"about_ca_system_score_gemma":0.00068322703,"threshold_uncertainty_score":0.999844},"labels":[],"label_agreement":null},{"id":"W4385689290","doi":"10.1016/s2352-3026(23)00159-x","title":"Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts","year":2023,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK","keywords":"Medicine; Myeloid leukaemia; Perspective (graphical); Intensive care medicine; Disease; Drug response; Health care; Clinical trial; Risk analysis (engineering); Drug; Computer science; Immunology; Artificial intelligence; Pathology; Psychiatry","score_opus":0.23415766790350245,"score_gpt":0.4443996815337133,"score_spread":0.21024201363021083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385689290","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004856026,0.98962057,0.00042075093,0.0024650884,0.0008811601,0.0017362107,0.000964216,0.00019324257,0.0032331548],"genre_scores_gemma":[0.00071817834,0.9958097,0.00022317207,0.00008040308,0.0011854869,0.0004250511,0.00065345893,0.00011678146,0.0007878126],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965452,0.0006282377,0.0009829135,0.00066304073,0.00067039597,0.00051021733],"domain_scores_gemma":[0.9961921,0.001194027,0.0007894438,0.0012375257,0.00048243994,0.00010444089],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077159674,0.00042251614,0.0045999256,0.00038907747,0.00009384419,0.000044783323,0.00094818335,0.0005536996,0.00007961668],"category_scores_gemma":[0.00069353735,0.00026414916,0.0004487668,0.0005039021,0.00042163915,0.00006423774,0.0003603516,0.0009319188,0.00023367451],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038747264,0.0005779669,0.0006505452,0.10248161,0.046908785,0.01086221,0.019744722,0.000013819805,0.00045024368,0.1766322,0.28624797,0.35155523],"study_design_scores_gemma":[0.0020584222,0.00012283494,0.000084254265,0.023769077,0.0035801635,0.0048173107,0.0055091153,0.0005122263,0.000013508243,0.0010193725,0.95804346,0.00047026825],"about_ca_topic_score_codex":0.0005473209,"about_ca_topic_score_gemma":0.000021512937,"teacher_disagreement_score":0.6717955,"about_ca_system_score_codex":0.0016708117,"about_ca_system_score_gemma":0.0013700568,"threshold_uncertainty_score":0.99998105},"labels":[],"label_agreement":null},{"id":"W4385739932","doi":"10.1097/01.hs9.0000968596.43178.c6","title":"P422: TARGETING THE WT1MUT-MIR-193A TRANSCRIPTIONAL AXIS WITH INT-1B3, A NOVEL LIPID NANOPARTICLE-FORMULATED MIR-193A-3P MIMIC IN ACUTE MYELOID LEUKEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"","keywords":"Cancer research; Myeloid leukemia; DNA methylation; Epigenetics; microRNA; Decitabine; Biology; Methylation; Gene silencing; Leukemia; Gene; Immunology; Gene expression; Genetics","score_opus":0.023723318740459826,"score_gpt":0.27592224410783833,"score_spread":0.25219892536737853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385739932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98771876,0.0006260556,0.00021139979,0.0073685003,0.00021497326,0.0015172657,0.00007690146,0.00049076416,0.0017753957],"genre_scores_gemma":[0.98847616,0.00036561227,0.0020888138,0.0013612893,0.0004197632,0.0003542203,0.00031706542,0.00019676096,0.0064203176],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99505585,0.00015652334,0.00089820265,0.0009432796,0.0013451756,0.0016009901],"domain_scores_gemma":[0.9978276,0.00036876625,0.00017784732,0.0008683511,0.00030934016,0.00044811654],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011516833,0.0005953888,0.000775554,0.00027763713,0.00037855734,0.00010323643,0.0005885956,0.00038480578,0.0012564624],"category_scores_gemma":[0.0002852568,0.000412788,0.0002528434,0.0027952045,0.00037549992,0.00038503244,0.00021304791,0.0015782383,0.0009003024],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026323793,0.0003563806,0.010167688,0.00045301917,0.0006978023,0.00097441796,0.0049149054,0.00096223183,0.93842274,0.000685117,0.03653414,0.0031991585],"study_design_scores_gemma":[0.065416135,0.004064623,0.2298475,0.0032469877,0.0017093264,0.0028181067,0.019605676,0.17033267,0.26786846,0.0006413897,0.23010743,0.0043416945],"about_ca_topic_score_codex":0.00066344225,"about_ca_topic_score_gemma":0.0005848129,"teacher_disagreement_score":0.6705543,"about_ca_system_score_codex":0.0014538914,"about_ca_system_score_gemma":0.0014806682,"threshold_uncertainty_score":0.99987763},"labels":[],"label_agreement":null},{"id":"W4385835251","doi":"10.1172/jci167053","title":"RUNX1 loss renders hematopoietic and leukemic cells dependent on IL-3 and sensitive to JAK inhibition","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Stanford Bio-X; Nakayama Foundation for Human Science; Alex's Lemonade Stand Foundation for Childhood Cancer; School of Medicine, Stanford University; American Society of Hematology; Ludwig Center at Harvard; National Institutes of Health; National Science Foundation","keywords":"RUNX1; Haematopoiesis; Cancer research; Biology; Leukemia; Immunology; Stem cell; Cell biology","score_opus":0.07849238685559991,"score_gpt":0.3869725904824171,"score_spread":0.3084802036268172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385835251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98385775,0.000018965178,0.00015974711,0.015238318,0.00021670385,0.00027028774,0.0000061864957,0.000023537461,0.00020852243],"genre_scores_gemma":[0.9945361,0.00047309144,0.001032591,0.0031328578,0.0004700613,0.0000028467216,0.00000936337,0.000021167407,0.00032190807],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99771136,0.00025454324,0.0009582849,0.0002466209,0.000613547,0.00021564652],"domain_scores_gemma":[0.9975159,0.001007657,0.00036077556,0.00014611665,0.0003065571,0.0006629781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027061803,0.00013088422,0.00045938962,0.0003285944,0.000066815854,0.000037322377,0.00004420778,0.0001884017,0.0000082257],"category_scores_gemma":[0.002388375,0.00010606828,0.0000920053,0.00033561367,0.00027288188,0.00014808416,0.00006947269,0.00078507053,0.000074085714],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069601713,0.0004605695,0.06287117,0.0010090349,0.00077003165,0.006023655,0.0074047353,0.00097587146,0.75390935,0.0018100672,0.092162065,0.06564326],"study_design_scores_gemma":[0.01748636,0.009586665,0.43345606,0.0036364354,0.0005760289,0.0032806098,0.0036981998,0.006821611,0.5046608,0.014528975,0.0015645932,0.0007036729],"about_ca_topic_score_codex":0.000011630113,"about_ca_topic_score_gemma":0.0000030753752,"teacher_disagreement_score":0.37058488,"about_ca_system_score_codex":0.00018056165,"about_ca_system_score_gemma":0.00037786094,"threshold_uncertainty_score":0.4325339},"labels":[],"label_agreement":null},{"id":"W4385896603","doi":"10.21203/rs.3.rs-3231589/v1","title":"The relationship between chronic anemia caused by hematologic disease and cognitive impairment","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Government of Jiangsu Province","keywords":"Anemia; Anemia of chronic disease; Medicine; Cognition; Internal medicine; Pediatrics; Iron-deficiency anemia; Psychiatry","score_opus":0.12326845258518977,"score_gpt":0.4338828360297673,"score_spread":0.31061438344457754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385896603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95268553,0.013276378,0.00008285839,0.024855627,0.000095226205,0.007044369,0.0012375508,0.0003209561,0.00040151566],"genre_scores_gemma":[0.9837034,0.002274764,0.000017189903,0.00003472744,0.0005407912,0.0013647382,0.0021852565,0.00012570694,0.009753433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930378,0.0014188137,0.00054397655,0.0011410867,0.0023730567,0.0014852453],"domain_scores_gemma":[0.98368025,0.01300899,0.00013008453,0.001173956,0.00083860615,0.0011680967],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0042451695,0.00041461826,0.0006154779,0.00051178463,0.0011391853,0.00030622873,0.0005296991,0.0005590678,0.00006770528],"category_scores_gemma":[0.010248168,0.00028915796,0.00019895492,0.00081693096,0.0012596849,0.00006551267,0.0027042674,0.0054905033,0.0005232672],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006306548,0.000115560586,0.91494834,0.0061615882,0.00038550876,0.0009024834,0.00040511263,0.000003714507,0.000047903708,0.00055248826,0.07437048,0.0014761653],"study_design_scores_gemma":[0.0021667997,0.00067135756,0.9846848,0.0031230545,0.00023355153,0.000012439833,0.0009526188,0.0003597566,0.0001281776,0.006026742,0.0013146424,0.0003260163],"about_ca_topic_score_codex":0.0003157257,"about_ca_topic_score_gemma":0.00008409882,"teacher_disagreement_score":0.07305584,"about_ca_system_score_codex":0.0024192322,"about_ca_system_score_gemma":0.0055518094,"threshold_uncertainty_score":0.9999561},"labels":[],"label_agreement":null},{"id":"W4385983130","doi":"10.1016/j.exphem.2023.06.130","title":"3023 – ATLAS-AML: AN AUTOMATED BIOINFORMATICS PIPELINE FOR TARGET CHARACTERIZATION IN ACUTE MYELOID LEUKEMIA","year":2023,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Transcriptome; Computational biology; Bioinformatics; Leukemia; Myeloid; Atlas (anatomy); Biology; Cancer research; Medicine; Gene; Immunology; Gene expression; Genetics","score_opus":0.024831810638866282,"score_gpt":0.3559312414755823,"score_spread":0.331099430836716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385983130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99291486,0.00016004681,0.0014767002,0.0010169152,0.00043521068,0.0018239918,0.00018462389,0.0014102021,0.0005774602],"genre_scores_gemma":[0.97295296,0.00008955283,0.011735188,0.0008406693,0.0001771462,0.0007169563,0.011441073,0.0001280345,0.0019184416],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977543,0.000069286325,0.0007090209,0.00040588586,0.0002891597,0.00077235437],"domain_scores_gemma":[0.9989914,0.00009882618,0.00014356048,0.0004229002,0.000095978394,0.00024733495],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032209777,0.00028838855,0.00064606254,0.00058915745,0.00011699985,0.000028803395,0.00023095497,0.00031776808,0.0002400162],"category_scores_gemma":[0.00008844545,0.00027345426,0.00010013261,0.00079325045,0.00014108402,0.0003448139,0.00016488266,0.00026240476,0.0005696293],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002560526,0.0007372883,0.0068229525,0.00060172327,0.0002275163,0.0008986355,0.005636172,0.000053822532,0.9360141,0.0072178436,0.036838405,0.0023909884],"study_design_scores_gemma":[0.0041051707,0.00048172276,0.0024682956,0.000059148097,0.000017982571,0.00048610364,0.0011374108,0.48434043,0.5038354,0.00004449854,0.0027838254,0.00024002764],"about_ca_topic_score_codex":0.000029140714,"about_ca_topic_score_gemma":0.000005481277,"teacher_disagreement_score":0.4842866,"about_ca_system_score_codex":0.0007485901,"about_ca_system_score_gemma":0.00037064654,"threshold_uncertainty_score":0.99997175},"labels":[],"label_agreement":null},{"id":"W4386002608","doi":"10.1016/j.blre.2023.101128","title":"Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)","year":2023,"lang":"en","type":"review","venue":"Blood Reviews","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Takeda Oncology; Genentech; National Institutes of Health; Foundation Medicine; Sierra Oncology; Associazione Italiana per la Ricerca sul Cancro; Astellas Pharma; Daiichi-Sankyo; MacroGenics; Alexion Pharmaceuticals; Apellis Pharmaceuticals; Argenx; Pfizer; Incyte; CTI Biopharma; bluebird bio; Agios Pharmaceuticals; Syndax Pharmaceuticals; National Heart, Lung, and Blood Institute; Edward P. Evans Foundation; Acceleron; Loxo Oncology; Astex Pharmaceuticals; Leukemia and Lymphoma Society; Daiichi Sankyo Europe; Servier; Gilead Sciences; Jazz Pharmaceuticals; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Myelodysplastic syndromes; Medicine; Risk stratification; Risk assessment; International Prognostic Scoring System; Intensive care medicine; Internal medicine; Computer science","score_opus":0.11035384056157956,"score_gpt":0.41202824878602945,"score_spread":0.3016744082244499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386002608","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0130893355,0.96311396,0.00017176672,0.001635437,0.00094539585,0.019641105,0.00085529574,0.000045990542,0.0005016966],"genre_scores_gemma":[0.00074641535,0.9917305,0.0007489991,0.00003597522,0.0000625886,0.0022069898,0.00025765938,0.00008001459,0.0041308426],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935999,0.0015708472,0.002903414,0.00075283623,0.0008704549,0.00030255507],"domain_scores_gemma":[0.99251294,0.0024089282,0.003000569,0.0016215718,0.00034798658,0.00010799928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070435614,0.0004282901,0.0020765977,0.00041474475,0.000100744226,0.000034246073,0.0006913005,0.00027279585,0.000028422983],"category_scores_gemma":[0.0078553585,0.00024325831,0.00064408506,0.0009752179,0.00029553275,0.00005593198,0.00021408279,0.001068333,0.000027141989],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008462114,0.0016995895,0.0053090868,0.10395098,0.0021985976,0.00016146865,0.0004076939,0.000007838948,0.00053689204,0.0011487727,0.016573446,0.8671594],"study_design_scores_gemma":[0.0014020225,0.00039075981,0.015981013,0.036625553,0.0028520348,0.0006806037,0.000038895854,0.00014251375,0.00005114558,0.00007530022,0.9414793,0.00028082094],"about_ca_topic_score_codex":0.000031452866,"about_ca_topic_score_gemma":0.00006512105,"teacher_disagreement_score":0.9249059,"about_ca_system_score_codex":0.0005248961,"about_ca_system_score_gemma":0.0032592127,"threshold_uncertainty_score":0.99197865},"labels":[],"label_agreement":null},{"id":"W4386023903","doi":"10.1097/01.hs9.0000968792.87320.b0","title":"P471: POLO-LIKE KINASE 4 INHIBITION INDUCED ANTI-LEUKAEMIC EFFECTS THROUGH HISTONE MODIFICATION IN TP53 MUTATED ACUTE MYELOID LEUKAEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Health and Medical Research Fund; Innovation and Technology Commission; Li Shu Fan Medical Foundation","keywords":"Biology; Transcriptome; Cancer research; Myeloid leukemia; Gene; Epigenetics; Haematopoiesis; Myeloid; Genetics; Gene expression; Stem cell","score_opus":0.03625720728268949,"score_gpt":0.34509045741194355,"score_spread":0.30883325012925406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386023903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915198,0.00032141255,0.00017435082,0.0022564726,0.00032140032,0.0017660676,0.000023725488,0.00074060867,0.0028761332],"genre_scores_gemma":[0.993595,0.00041263856,0.00077544246,0.0007813074,0.00020746373,0.00034066648,0.0009706411,0.00014409701,0.002772732],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99631506,0.00023136193,0.00068902294,0.000926991,0.0008058375,0.001031747],"domain_scores_gemma":[0.99812424,0.00025486568,0.00019580948,0.0009121718,0.00022411437,0.0002887966],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00051476195,0.00046674296,0.00076958816,0.00040568828,0.0001795246,0.000044012795,0.00023151905,0.00055781275,0.00025446812],"category_scores_gemma":[0.00034465283,0.00045683893,0.00017655145,0.002822767,0.00018340923,0.0004339783,0.0001919463,0.0011464651,0.0019977489],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005360556,0.00026979682,0.0024730894,0.00072234153,0.0001459895,0.0032566055,0.0014774164,0.000079196405,0.9614264,0.00047980068,0.023778278,0.0053550424],"study_design_scores_gemma":[0.016213227,0.0009798062,0.0998792,0.0015710298,0.0003603676,0.0006378027,0.0013961794,0.008718316,0.86453325,0.0012655007,0.0032471062,0.0011982386],"about_ca_topic_score_codex":0.001097108,"about_ca_topic_score_gemma":0.00009887251,"teacher_disagreement_score":0.09740611,"about_ca_system_score_codex":0.0021412508,"about_ca_system_score_gemma":0.00070934044,"threshold_uncertainty_score":0.99978834},"labels":[],"label_agreement":null},{"id":"W4386023953","doi":"10.1097/01.hs9.0000969228.34230.b4","title":"P581: A MARKOV DECISION ANALYSIS OF AZACITIDINE AND VENETOCLAX VERSUS INDUCTION CHEMOTHERAPY FOR THE TREATMENT OF MEDICALLY-FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Azacitidine; Internal medicine; Adverse effect; Myeloid leukemia; Induction chemotherapy; Regimen; Venetoclax; Oncology; Ven; Leukemia; Chemotherapy","score_opus":0.025608959099345466,"score_gpt":0.31400439331626406,"score_spread":0.2883954342169186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386023953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99723804,0.0002755013,0.0005750646,0.00052589393,0.00006666897,0.0010922342,0.00007876858,0.000032083157,0.00011572309],"genre_scores_gemma":[0.9906357,0.003555713,0.0040700207,0.000056825524,0.000111807865,0.00022115116,0.00029918554,0.000054669672,0.0009949162],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984461,0.000027619411,0.0003384906,0.00031509035,0.0006017767,0.00027092305],"domain_scores_gemma":[0.9983788,0.0006025135,0.00015886237,0.00045556517,0.00027580847,0.00012845898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021523079,0.00018629717,0.0005728389,0.00020513534,0.000079166275,0.000008143566,0.00010855232,0.00013375422,0.00023627962],"category_scores_gemma":[0.0000974824,0.00010642472,0.00017770469,0.0014475664,0.00019762335,0.000049180882,0.00003087897,0.00009960761,0.0000032253586],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04690881,0.0005988052,0.046192706,0.00029899727,0.021815246,0.000047030368,0.0024783937,0.0006049428,0.005664324,0.0000745577,0.008551156,0.866765],"study_design_scores_gemma":[0.079928026,0.020567918,0.7784582,0.00042222228,0.013823306,0.000018363957,0.0022785896,0.050070956,0.023664977,0.00011168038,0.030085592,0.0005701902],"about_ca_topic_score_codex":0.0001581255,"about_ca_topic_score_gemma":0.00010497124,"teacher_disagreement_score":0.86619484,"about_ca_system_score_codex":0.0007029965,"about_ca_system_score_gemma":0.0004023534,"threshold_uncertainty_score":0.4339874},"labels":[],"label_agreement":null},{"id":"W4386024071","doi":"10.1097/01.hs9.0000967904.29417.23","title":"S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Fludarabine; Clinical endpoint; Hematopoietic stem cell transplantation; Population; Oncology; Transplantation; Total body irradiation; Randomized controlled trial; Gastroenterology; Surgery; Adverse effect; Chemotherapy; Cyclophosphamide","score_opus":0.031222843112105225,"score_gpt":0.31141390221384274,"score_spread":0.2801910591017375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909659,0.00006328938,0.0002859533,0.0024226615,0.00019796766,0.0027412008,0.00008596321,0.00036676473,0.0028703217],"genre_scores_gemma":[0.9945917,0.000048820493,0.001518373,0.00018040689,0.00039608707,0.00028758447,0.0005334014,0.00010728786,0.0023362988],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9958684,0.0003610293,0.0007187319,0.0011142491,0.00096207194,0.00097555836],"domain_scores_gemma":[0.99727666,0.0005971416,0.0002901568,0.0008592434,0.00061775994,0.00035901222],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009991932,0.00051012455,0.0012412007,0.0003169658,0.00021913591,0.000075375174,0.00024817596,0.0003590154,0.00035084024],"category_scores_gemma":[0.0008492776,0.00038244957,0.00013167095,0.002493527,0.0004756264,0.00035158775,0.00012599227,0.0013439194,0.000040034265],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84974694,0.0015957484,0.06599729,0.0006592675,0.002212812,0.006374273,0.017385755,0.0010262481,0.04117372,0.00021775148,0.0065050554,0.0071051545],"study_design_scores_gemma":[0.19516017,0.007044882,0.7456954,0.0014646397,0.00018829864,0.00027256657,0.005576326,0.0018366188,0.041366573,0.00016506304,0.00020304245,0.0010263958],"about_ca_topic_score_codex":0.0017060781,"about_ca_topic_score_gemma":0.0013683512,"teacher_disagreement_score":0.67969817,"about_ca_system_score_codex":0.0014039034,"about_ca_system_score_gemma":0.001392393,"threshold_uncertainty_score":0.99986273},"labels":[],"label_agreement":null},{"id":"W4386024479","doi":"10.1097/01.hs9.0000968744.85748.62","title":"P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"NPM1; Medicine; Minimal residual disease; Internal medicine; Oncology; Myeloid leukemia; Bone marrow; Proportional hazards model; Gastroenterology; Karyotype; Biology","score_opus":0.06057304799164782,"score_gpt":0.3564517776467327,"score_spread":0.2958787296550849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955467,0.0010254341,0.00009410341,0.0005813558,0.00023535368,0.0013345664,0.00041666735,0.00046022507,0.0003055853],"genre_scores_gemma":[0.9885607,0.0012031689,0.0022479591,0.00003816485,0.0005903879,0.00025748325,0.00057392125,0.00026472294,0.006263494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928865,0.0003793328,0.0012413508,0.0014137466,0.0023049256,0.0017741857],"domain_scores_gemma":[0.99508274,0.00022583341,0.00044461625,0.0017467798,0.0005666356,0.0019334229],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007582075,0.0009139193,0.0016031982,0.000632044,0.0005669648,0.00014628514,0.00050264556,0.0002510793,0.0006733008],"category_scores_gemma":[0.0003798604,0.000818469,0.00067839597,0.0024742421,0.00026441424,0.0006111936,0.0004288482,0.00062946614,0.00021543993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009928079,0.0016671675,0.55754393,0.0025662181,0.0065778615,0.016440133,0.0005865206,0.007042867,0.389136,0.00007105692,0.0016330717,0.00680713],"study_design_scores_gemma":[0.040841516,0.001817913,0.5095147,0.00431213,0.017420407,0.00030331715,0.0053395005,0.07877241,0.33589786,0.0004009498,0.0017907901,0.0035884927],"about_ca_topic_score_codex":0.0016308357,"about_ca_topic_score_gemma":0.00009076894,"teacher_disagreement_score":0.07172955,"about_ca_system_score_codex":0.0058797933,"about_ca_system_score_gemma":0.0031473078,"threshold_uncertainty_score":0.9994266},"labels":[],"label_agreement":null},{"id":"W4386024524","doi":"10.1097/01.hs9.0000968592.70537.d0","title":"P421: TARGETED DISRUPTION OF HUMAN FLT3 ERADICATES LEUKEMIC STEM CELLS WITHOUT HARMING HEALTHY HEMATOPOIETIC STEM CELLS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Stem cell; Haematopoiesis; Leukemia; Cancer research; Bone marrow; Myeloid leukemia; Biology; Immunology; Xenotransplantation; Hematopoietic stem cell; Transplantation; Medicine; Internal medicine; Cell biology","score_opus":0.039720430632781134,"score_gpt":0.3205576568430557,"score_spread":0.28083722621027457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99482,0.0010848759,0.00015848558,0.00072937337,0.000259699,0.0012836838,0.000040690767,0.0004989657,0.0011242307],"genre_scores_gemma":[0.98208314,0.0003213886,0.0004766922,0.00020490025,0.00023605436,0.00010053929,0.00007505217,0.00015961645,0.016342591],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99619293,0.00019756057,0.0009248341,0.000735668,0.00096141413,0.0009875942],"domain_scores_gemma":[0.9977915,0.00022196451,0.0003435731,0.00092295994,0.00021966346,0.0005003007],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00072316884,0.0004158459,0.00095335883,0.00026578899,0.0002530139,0.000037343143,0.00036108392,0.00030769434,0.0006564561],"category_scores_gemma":[0.000015520733,0.00037703497,0.00025202025,0.0011444181,0.00023823566,0.00016164573,0.00021220528,0.0007422719,0.0011735328],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034151162,0.00019790455,0.007301355,0.0035096675,0.00017504228,0.00023847121,0.0023904974,0.00010571382,0.95906025,0.00021967114,0.023219936,0.0032399637],"study_design_scores_gemma":[0.0048206444,0.0009934678,0.002167697,0.0010860007,0.00019537311,0.00011869121,0.0067959377,0.005323706,0.9740825,0.000115039205,0.0037182418,0.0005826918],"about_ca_topic_score_codex":0.00017885378,"about_ca_topic_score_gemma":0.000020093168,"teacher_disagreement_score":0.019501694,"about_ca_system_score_codex":0.0007905239,"about_ca_system_score_gemma":0.00058717676,"threshold_uncertainty_score":0.99986815},"labels":[],"label_agreement":null},{"id":"W4386024586","doi":"10.1097/01.hs9.0000968552.93087.6b","title":"P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Internal medicine; Medicine; NPM1; Oncology; Myeloid leukemia; Azacitidine; Cytogenetics; Gastroenterology; Randomization; Bone marrow; Myeloid; Clinical trial; Gene; Biology; Genetics; DNA methylation; Karyotype","score_opus":0.02367151887753247,"score_gpt":0.2916650467869095,"score_spread":0.267993527909377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975046,0.00009857132,0.00007668629,0.0010288678,0.000073891846,0.00047237234,0.000017669874,0.000027009428,0.0007003153],"genre_scores_gemma":[0.99272484,0.00019099812,0.000113440554,0.00003301946,0.00007333199,0.000013516692,0.00010883716,0.000025928735,0.0067160786],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850124,0.00011857594,0.00037459913,0.0002604444,0.00054198975,0.00020312787],"domain_scores_gemma":[0.9989592,0.000079240606,0.00020533212,0.0004964401,0.00016202769,0.00009780275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042604166,0.00011869495,0.00037015197,0.00008035438,0.000070867754,0.0000065259937,0.0001249138,0.00013761109,0.000514319],"category_scores_gemma":[0.00041646496,0.00008160839,0.00011792398,0.00090542936,0.000105208426,0.000053598673,0.00020323425,0.00017032548,0.000022388838],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046116747,0.000100121826,0.016795283,0.00028600136,0.0001708727,0.000060453163,0.00017209855,0.0000059937092,0.9743371,0.00012053443,0.0013409309,0.0019989528],"study_design_scores_gemma":[0.04713557,0.0007791506,0.40315932,0.000684996,0.00087108323,0.00009776282,0.0002500043,0.00617316,0.53769094,0.0001465327,0.0026955653,0.00031593908],"about_ca_topic_score_codex":0.000069099195,"about_ca_topic_score_gemma":0.000009145641,"teacher_disagreement_score":0.43664616,"about_ca_system_score_codex":0.00010835562,"about_ca_system_score_gemma":0.00015536459,"threshold_uncertainty_score":0.56314325},"labels":[],"label_agreement":null},{"id":"W4386024691","doi":"10.1097/01.hs9.0000968580.70418.79","title":"P418: DELE1 LOSS AND DYSFUNCTIONAL INTEGRATED STRESS SIGNALING IN TP53 MUTATED AML IS A NOVEL PATHWAY FOR VENETOCLAX RESISTANCE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Venetoclax; Myeloid leukemia; Cancer research; Cytarabine; Leukemia; MCL1; Integrated stress response; Biology; Medicine; Chronic lymphocytic leukemia; Internal medicine; Gene; Genetics; Downregulation and upregulation; Translation (biology)","score_opus":0.03089501745174479,"score_gpt":0.2949990361260349,"score_spread":0.2641040186742901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943104,0.0005352083,0.0015857237,0.0014136648,0.00008735815,0.0009608354,0.00037313823,0.00017334572,0.000560341],"genre_scores_gemma":[0.9810975,0.00007966819,0.0040313723,0.00043654733,0.00018225025,0.00029771624,0.0005210466,0.00008636045,0.013267547],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981765,0.000036139845,0.00035618307,0.00050486636,0.00038105017,0.0005452233],"domain_scores_gemma":[0.99886376,0.00033329253,0.00007160447,0.0002635077,0.00028385958,0.00018400523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036481876,0.00022023279,0.00036716173,0.00015202034,0.00010611271,0.00003584799,0.00011428722,0.00019573022,0.00032599535],"category_scores_gemma":[0.0003322891,0.00019762623,0.000074322226,0.0010027607,0.00011854322,0.00009168006,0.00007097868,0.00042211366,0.00005228422],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015538097,0.00079096586,0.0761003,0.006928741,0.0011013714,0.0030095044,0.0067294934,0.0027683626,0.7375064,0.00427511,0.12615491,0.019096758],"study_design_scores_gemma":[0.060890887,0.0020166642,0.07770459,0.008702265,0.00034602705,0.00042387503,0.016919563,0.20525043,0.43116617,0.004421095,0.18942448,0.002733929],"about_ca_topic_score_codex":0.00018873702,"about_ca_topic_score_gemma":0.0004720783,"teacher_disagreement_score":0.3063402,"about_ca_system_score_codex":0.0006088196,"about_ca_system_score_gemma":0.0008361755,"threshold_uncertainty_score":0.80589634},"labels":[],"label_agreement":null},{"id":"W4386054364","doi":"10.14740/cmmr18e","title":"Recent Advances in Characterization of Pre-Leukemic/Leukemic Stem Cells in Acute Myeloid Leukemia","year":2023,"lang":"en","type":"article","venue":"Cellular and Molecular Medicine Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Stem cell; Leukemia; Haematopoiesis; Cancer research; Epigenetics; Biology; Immunology; Medicine; Genetics; Gene","score_opus":0.02792288690490333,"score_gpt":0.33445888563886145,"score_spread":0.3065359987339581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386054364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846193,0.010080084,0.0002807393,0.001853444,0.0001323572,0.0016416266,0.00001769068,0.00006270762,0.001312044],"genre_scores_gemma":[0.84771603,0.14893167,0.000065439526,0.00016250176,0.0001313895,0.00016858937,0.00032908274,0.000092127775,0.0024031762],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99477565,0.0006186923,0.00091471185,0.000848505,0.0016755424,0.0011668908],"domain_scores_gemma":[0.99794316,0.0003174645,0.00012811707,0.0007351299,0.0004566896,0.00041946187],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0038241423,0.00032523624,0.0008840749,0.002447627,0.00008019828,0.000018179711,0.000385935,0.00031831214,0.00009129789],"category_scores_gemma":[0.00030370193,0.00028311787,0.0000778617,0.004148248,0.0006787326,0.00019989522,0.00038035357,0.0014470164,0.000050318115],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070227135,0.00006285278,0.0018950244,0.0006600448,0.000045303022,0.0015937891,0.0011310681,0.000030953386,0.93674177,0.00013741062,0.00028356077,0.056715965],"study_design_scores_gemma":[0.0077736625,0.0011321258,0.02063745,0.0016846039,0.00006319777,0.00008350987,0.001390143,0.0075896885,0.92891085,0.000255322,0.030127231,0.0003522114],"about_ca_topic_score_codex":0.00018363592,"about_ca_topic_score_gemma":0.000020444764,"teacher_disagreement_score":0.13885158,"about_ca_system_score_codex":0.0013991275,"about_ca_system_score_gemma":0.0012881057,"threshold_uncertainty_score":0.9999621},"labels":[],"label_agreement":null},{"id":"W4386170775","doi":"10.1016/j.isci.2023.107726","title":"The human leukemic oncogene MLL-AF4 promotes hyperplastic growth of hematopoietic tissues in Drosophila larvae","year":2023,"lang":"en","type":"article","venue":"iScience","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Helse Sør-Øst RHF; National Institutes of Health; Norges Forskningsråd; European Commission","keywords":"Haematopoiesis; Biology; Leukemia; Phenotype; Drosophila (subgenus); Drosophila melanogaster; Oncogene; Cancer research; Oncogene Proteins; Stem cell; Genetics; Cancer; Gene; Regulation of gene expression; Cell cycle","score_opus":0.031015952874128776,"score_gpt":0.32576880920592294,"score_spread":0.29475285633179416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386170775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99493337,0.00044960764,0.000009782068,0.002528068,0.000083173494,0.0004082281,0.000004424046,0.0000767901,0.0015065521],"genre_scores_gemma":[0.99714357,0.00015546364,0.000118466305,0.000060625203,0.00007139066,0.00004096178,0.000004434486,0.00002029413,0.0023847756],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979445,0.000068062116,0.00034119422,0.00036082923,0.0007321407,0.00055331585],"domain_scores_gemma":[0.9988317,0.00041767958,0.0000765975,0.00041527805,0.0001298533,0.00012887838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010108873,0.00013781262,0.0002743871,0.0002579031,0.0002272213,0.000035731584,0.00055184844,0.000069930386,0.000028840988],"category_scores_gemma":[0.0009949002,0.00009194751,0.000055203713,0.0017305085,0.00078019465,0.00010755039,0.00025641292,0.00029576913,0.00024648153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004170467,0.000114537244,0.024592226,0.00024075329,0.000016701482,0.0004048651,0.0018047839,0.00003333569,0.9660798,0.0026144108,0.0020280343,0.0020288571],"study_design_scores_gemma":[0.0043786,0.0016444381,0.38071907,0.0013237124,0.0000814293,0.0006739418,0.002016943,0.015930487,0.5748029,0.01495036,0.0027617968,0.0007163425],"about_ca_topic_score_codex":0.00020315652,"about_ca_topic_score_gemma":0.000061973864,"teacher_disagreement_score":0.39127693,"about_ca_system_score_codex":0.00022265565,"about_ca_system_score_gemma":0.00045316247,"threshold_uncertainty_score":0.37495106},"labels":[],"label_agreement":null},{"id":"W4386208612","doi":"10.1111/ejh.14094","title":"Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis","year":2023,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Cytarabine; Medicine; Internal medicine; Regimen; Outpatient clinic; Chemotherapy; Oncology; Surgery","score_opus":0.029474219476904533,"score_gpt":0.2961845969885831,"score_spread":0.2667103775116786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386208612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891071,0.00009914664,0.0003661757,0.009416846,0.00018975676,0.00046039617,0.000021650443,0.000051443305,0.00028750068],"genre_scores_gemma":[0.9967315,0.0003874508,0.0013525095,0.0009754107,0.00010524105,0.0000068156596,0.000118235956,0.00008074838,0.0002420886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963694,0.0009598937,0.0011077701,0.00045118155,0.0005283042,0.00058344926],"domain_scores_gemma":[0.9978925,0.00032263095,0.0005136179,0.00039556643,0.0004395746,0.0004360996],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013684945,0.00035401422,0.0014102716,0.0017068372,0.00009489302,0.00008289497,0.00032261253,0.00007994436,0.00015113757],"category_scores_gemma":[0.00038610437,0.000264566,0.00016251768,0.00162298,0.00037090175,0.00018843352,0.00018743644,0.00070780324,0.00014550658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06426932,0.0019868915,0.62930596,0.0005348934,0.012585084,0.16004114,0.01843592,0.0063539194,0.06941625,0.00015499075,0.029093714,0.007821931],"study_design_scores_gemma":[0.05431851,0.012398121,0.8839359,0.0011565244,0.0020193944,0.01574136,0.0037956676,0.003514263,0.014761582,0.00008367562,0.0072302786,0.0010446905],"about_ca_topic_score_codex":0.0000682319,"about_ca_topic_score_gemma":0.000112149355,"teacher_disagreement_score":0.25463,"about_ca_system_score_codex":0.00043500765,"about_ca_system_score_gemma":0.00038557904,"threshold_uncertainty_score":0.9999806},"labels":[],"label_agreement":null},{"id":"W4386208917","doi":"10.1182/bloodadvances.2023010460","title":"GPRC5C drives branched-chain amino acid metabolism in leukemogenesis","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"H2020 Marie Skłodowska-Curie Actions; Max-Planck-Gesellschaft; Deutsche Forschungsgemeinschaft; European Commission","keywords":"Myeloid leukemia; Leukemia; Stem cell; Haematopoiesis; Cancer research; Ectopic expression; Biology; Myeloid; Bone marrow; Oxidative phosphorylation; Internal medicine; Immunology; Cell biology; Medicine; Biochemistry; Gene","score_opus":0.01762603045761066,"score_gpt":0.3000790506303253,"score_spread":0.2824530201727147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386208917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98095167,0.01280809,0.00006475519,0.0019850216,0.00022099329,0.0005198463,0.000022288421,0.00031044387,0.0031168696],"genre_scores_gemma":[0.98525465,0.0060564023,0.0024816783,0.00047859823,0.000522087,0.00016663525,0.0000585313,0.0000684706,0.004912947],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977135,0.00010146755,0.00037755884,0.00053681777,0.0005496302,0.0007210276],"domain_scores_gemma":[0.99894154,0.00020470511,0.000076029544,0.0004788174,0.000084323714,0.00021458833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045389985,0.00025210314,0.0005459054,0.00057378085,0.000091141694,0.000025383923,0.0002726915,0.00012686482,0.00013699356],"category_scores_gemma":[0.00047206628,0.00021721034,0.00013059542,0.0015451158,0.00016554495,0.00029993648,0.00015842437,0.00035157768,0.0004968187],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006193048,0.0006508225,0.14310539,0.00074320054,0.0004222262,0.002888,0.0024284488,0.00032491985,0.5667541,0.0017249633,0.0032378433,0.27710077],"study_design_scores_gemma":[0.00985697,0.0002479473,0.41529915,0.00026178645,0.0002524735,0.00018773318,0.001667757,0.0010443527,0.44022423,0.0014981899,0.12879874,0.00066069304],"about_ca_topic_score_codex":0.00005801732,"about_ca_topic_score_gemma":0.000098812045,"teacher_disagreement_score":0.27644005,"about_ca_system_score_codex":0.0000940124,"about_ca_system_score_gemma":0.00026324653,"threshold_uncertainty_score":0.88575804},"labels":[],"label_agreement":null},{"id":"W4386258431","doi":"10.1016/j.leukres.2023.107376","title":"AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts","year":2023,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"CEBPA; Medicine; Internal medicine; Oncology; Mutation; Cohort; Hazard ratio; Genetics; Gene; Biology; Confidence interval","score_opus":0.06746631063902843,"score_gpt":0.4179117202482542,"score_spread":0.35044540960922577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386258431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958567,0.000067735564,0.000017284421,0.0013442843,0.000017939085,0.0015907586,0.000051477982,0.00006755371,0.0009862541],"genre_scores_gemma":[0.9947794,0.000054935477,0.00094545394,0.00006130237,0.000056153433,0.00022266139,0.00022344083,0.00007897964,0.0035776512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956105,0.0003182493,0.00047934108,0.00062061497,0.0019736052,0.000997724],"domain_scores_gemma":[0.99718934,0.00080805545,0.00008636331,0.00064187223,0.0009219861,0.00035240606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011473391,0.00024622816,0.0006773622,0.0014044471,0.00016684998,0.00006209856,0.00029698183,0.00018019798,0.00019156338],"category_scores_gemma":[0.0006695957,0.00016349157,0.000032447897,0.003523551,0.0009720042,0.000209242,0.00032215542,0.0012532717,0.00007998402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013849264,0.0004187301,0.9504008,0.0010925877,0.00017161951,0.0006653237,0.0070894314,0.00022800147,0.0013595783,0.00007926556,0.018408516,0.006236869],"study_design_scores_gemma":[0.016348042,0.0046228752,0.9508993,0.0011650743,0.00003865494,0.000035586756,0.0057062474,0.016821735,0.0025214334,0.00006508848,0.0014857842,0.00029016365],"about_ca_topic_score_codex":0.00078261597,"about_ca_topic_score_gemma":0.00066882704,"teacher_disagreement_score":0.016922733,"about_ca_system_score_codex":0.0012253025,"about_ca_system_score_gemma":0.0021824248,"threshold_uncertainty_score":0.66669923},"labels":[],"label_agreement":null},{"id":"W4386269939","doi":"10.1016/s2152-2650(23)00451-2","title":"POSTER: AML-391 WHO and ICC 2022 Cytogenetic Abnormalities Defining Acute Myelogenous Leukemia (AML) Myelodysplasia-Related in First-Line Decitabine in Unfit AML Patients","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Calgary","funders":"","keywords":"Decitabine; Medicine; Leukemia; Internal medicine; Oncology; Biology; Genetics; DNA methylation","score_opus":0.023337901544357626,"score_gpt":0.31111381978212793,"score_spread":0.2877759182377703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386269939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905884,0.0014312043,0.000010139586,0.0014840887,0.00080631394,0.002144039,0.00028751796,0.0005292157,0.0027190475],"genre_scores_gemma":[0.9853138,0.006854867,0.00040989887,0.0016036433,0.0003850254,0.00035690822,0.0013754471,0.00036804916,0.0033324028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98723626,0.0009222482,0.0045455825,0.0025342205,0.0017260108,0.0030356983],"domain_scores_gemma":[0.9919917,0.0035255412,0.00073827244,0.001851001,0.0005141221,0.0013793409],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0034803113,0.0013629518,0.002997732,0.002038366,0.00047121893,0.0001927548,0.0011720733,0.0017867051,0.00030250725],"category_scores_gemma":[0.0034349605,0.0013390151,0.00062306714,0.0042810547,0.001315788,0.00055492524,0.0017599628,0.0022047854,0.0013002554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00495372,0.00048415601,0.74208945,0.00046635323,0.0006771738,0.007033863,0.0020198144,0.0003083729,0.0005079509,0.00031172257,0.0036417642,0.23750567],"study_design_scores_gemma":[0.02648493,0.0022666154,0.9572133,0.0011383565,0.000308445,0.0006923428,0.0004401897,0.0059150415,0.00055260217,0.0008200657,0.0029360398,0.0012321073],"about_ca_topic_score_codex":0.0014363676,"about_ca_topic_score_gemma":0.0011811784,"teacher_disagreement_score":0.23627357,"about_ca_system_score_codex":0.0075149722,"about_ca_system_score_gemma":0.0041001653,"threshold_uncertainty_score":0.99991214},"labels":[],"label_agreement":null},{"id":"W4386269941","doi":"10.1016/s2152-2650(23)00421-4","title":"POSTER: AML-197 Clinical Outcomes and Treatment Patterns in Adult Patients With FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication Positive Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the US and Canada: CIBMTR® (Center for International Blood and Marrow Transplant Research Analysis)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Medicine; Hematopoietic cell; Haematopoiesis; Transplantation; Hematopoietic stem cell transplantation; Tandem exon duplication; Tyrosine kinase; Leukemia; Oncology; Immunology; Gene duplication; Internal medicine; Stem cell; Biology; Genetics; Gene; Receptor","score_opus":0.025514020932101332,"score_gpt":0.3305546129086902,"score_spread":0.3050405919765889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386269941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99494076,0.00007690517,0.0000782985,0.0019500689,0.00018629032,0.001891253,0.0007776997,0.000033685705,0.0000650457],"genre_scores_gemma":[0.99120015,0.004603973,0.00019899005,0.0012188443,0.00016469246,0.00026455647,0.0021394545,0.00006130581,0.00014802894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99471563,0.0007388076,0.001531001,0.0012589341,0.0009431653,0.00081245304],"domain_scores_gemma":[0.9944119,0.0038292427,0.0002731055,0.0004982454,0.00057377294,0.0004137456],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018844723,0.00047714374,0.0010223805,0.000667763,0.00020445502,0.00012987664,0.00036750644,0.00036251917,0.000008524732],"category_scores_gemma":[0.00041109926,0.0003359404,0.00022776837,0.00072525296,0.00044617118,0.00020044806,0.00012770614,0.00060890726,0.0000033505257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041226437,0.00043833433,0.97340035,0.00011887938,0.0011071045,0.00079860474,0.0007018131,0.000013299364,0.00008192809,0.000017421988,0.00012692806,0.01907267],"study_design_scores_gemma":[0.027469141,0.0018055106,0.96637946,0.0003262353,0.0010825436,0.00010393821,0.00027720674,0.0019651286,0.00017419703,0.000020036698,0.00007927447,0.00031734613],"about_ca_topic_score_codex":0.04447401,"about_ca_topic_score_gemma":0.3068573,"teacher_disagreement_score":0.26238325,"about_ca_system_score_codex":0.0021977741,"about_ca_system_score_gemma":0.0018255699,"threshold_uncertainty_score":0.9999093},"labels":[],"label_agreement":null},{"id":"W4386270961","doi":"10.1016/s2152-2650(23)01076-5","title":"AML-521 The Randomized Phase III SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) Trial: Successful Allogeneic Hematopoietic Stem Cell Transplantation Using Treatment With Iomab-B-Led Regimen for Patients With Active, Relapsed or Refractory AML With Failed Targeted Therapies","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Refractory (planetary science); Hematopoietic stem cell transplantation; Medicine; Regimen; Conditioning regimen; Internal medicine; Stem cell; Transplantation; Randomized controlled trial; Oncology; Biology","score_opus":0.03855014632654694,"score_gpt":0.3425980365523169,"score_spread":0.30404789022576995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97907066,0.00017201234,0.00025103436,0.0002153943,0.00022921768,0.01953396,0.00014170243,0.00029943333,0.00008657043],"genre_scores_gemma":[0.9926618,0.00063176133,0.0012289996,0.00012242547,0.0001969292,0.0029683462,0.00065843354,0.00036118642,0.001170151],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9888932,0.002855561,0.0032529493,0.0018715163,0.0017683731,0.0013583916],"domain_scores_gemma":[0.9845503,0.010055346,0.0021366258,0.0018610716,0.0008510096,0.00054566556],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027943419,0.0012500345,0.004162444,0.00083440216,0.00048150244,0.00011032473,0.00076663063,0.0007475034,0.000093100374],"category_scores_gemma":[0.0005158813,0.00062156044,0.00058381946,0.0024487243,0.0011707824,0.0005228251,0.000092338196,0.00075309566,0.000012813788],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9248416,0.00734055,0.003617469,0.00041815327,0.0026681419,0.0011132985,0.009380874,0.00007789365,0.0016631086,0.0000037853802,0.000112674155,0.048762497],"study_design_scores_gemma":[0.870733,0.07358052,0.03750074,0.00085962005,0.0026401533,0.000058197184,0.009285657,0.001815378,0.0024125099,0.000013802287,0.00027209503,0.0008283197],"about_ca_topic_score_codex":0.0010160061,"about_ca_topic_score_gemma":0.0011497715,"teacher_disagreement_score":0.06623997,"about_ca_system_score_codex":0.0032433805,"about_ca_system_score_gemma":0.0059458786,"threshold_uncertainty_score":0.99968946},"labels":[],"label_agreement":null},{"id":"W4386271158","doi":"10.1016/s2152-2650(23)01066-2","title":"AML-469 Ivosidenib + Azacitidine vs Placebo + Azacitidine in Patients With Newly-Diagnosed Acute Myeloid Leukemia: Updated Long-term Efficacy and Safety Results From the AGILE Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Azacitidine; Myeloid leukemia; Medicine; Placebo; Term (time); Oncology; Internal medicine; Alternative medicine; Biology; Pathology","score_opus":0.025455862086935576,"score_gpt":0.316729295405215,"score_spread":0.29127343331827943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877217,0.00013892405,0.000017003365,0.0027726062,0.00052298396,0.0064566187,0.0010406692,0.00076669303,0.0005628453],"genre_scores_gemma":[0.98812616,0.0009835839,0.0003445042,0.0018221455,0.0010599319,0.00032884107,0.0055246023,0.00033364765,0.0014766131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9872213,0.0015674515,0.0037121999,0.0030539732,0.0022425912,0.0022024722],"domain_scores_gemma":[0.9843426,0.009567159,0.0008697107,0.0031392397,0.0007045645,0.0013767212],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0037664296,0.0013746142,0.002705521,0.00063921895,0.0006777719,0.00029674466,0.0015042132,0.001057529,0.00023337439],"category_scores_gemma":[0.0046585496,0.0009780008,0.0004158401,0.0033400233,0.001454633,0.00056635245,0.0015599414,0.0022936214,0.00095903024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08319464,0.0014742804,0.7681533,0.00005964429,0.0015888986,0.0066714366,0.0010810026,0.000107938475,0.00016054646,0.000017892855,0.023096614,0.11439378],"study_design_scores_gemma":[0.14311996,0.0039673154,0.84744966,0.0006148323,0.0007356017,0.000058042056,0.00045109142,0.0009568954,0.00018110492,0.000029782108,0.0015182702,0.0009174322],"about_ca_topic_score_codex":0.0017368406,"about_ca_topic_score_gemma":0.0013320782,"teacher_disagreement_score":0.11347634,"about_ca_system_score_codex":0.004491337,"about_ca_system_score_gemma":0.003653384,"threshold_uncertainty_score":0.99990046},"labels":[],"label_agreement":null},{"id":"W4386271173","doi":"10.1016/s2152-2650(23)01206-5","title":"MDS-641 Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; London Health Sciences Centre","funders":"","keywords":"Decitabine; Myelodysplastic syndromes; Interim analysis; Medicine; Interim; Oncology; Internal medicine; Randomized controlled trial; Chemistry","score_opus":0.0443610251947838,"score_gpt":0.3911708461793387,"score_spread":0.34680982098455493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99149,0.00012367078,0.0009380843,0.00044421817,0.0007177606,0.005229549,0.00040992745,0.00031568602,0.00033108718],"genre_scores_gemma":[0.9959342,0.00091078115,0.0008701561,0.0003067523,0.000265558,0.00022993927,0.00069151114,0.00019414318,0.0005969705],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9854168,0.003262356,0.0053847414,0.0023741396,0.0018828346,0.0016790802],"domain_scores_gemma":[0.97820556,0.01597274,0.001117081,0.0021554118,0.00094615517,0.0016030543],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009990019,0.0011469725,0.0065918234,0.002665946,0.00027756902,0.00012244882,0.0010752459,0.00059879775,0.00044033004],"category_scores_gemma":[0.031522498,0.000958107,0.0015319826,0.0077135293,0.0011655542,0.00037872433,0.0016214772,0.0012233834,0.00038391148],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5122122,0.0100227045,0.2105806,0.00038967232,0.0072467197,0.0023827292,0.001347724,0.00085701374,0.00026046738,0.00005893886,0.0015673983,0.2530738],"study_design_scores_gemma":[0.31859267,0.004093157,0.65873563,0.0004008438,0.00259931,0.000028373339,0.0005467247,0.013891718,0.000059280443,0.000025640436,0.00041353487,0.0006131025],"about_ca_topic_score_codex":0.0007774517,"about_ca_topic_score_gemma":0.00028900985,"teacher_disagreement_score":0.44815505,"about_ca_system_score_codex":0.0024803204,"about_ca_system_score_gemma":0.0021303075,"threshold_uncertainty_score":0.99928695},"labels":[],"label_agreement":null},{"id":"W4386277230","doi":"10.1016/s2152-2650(23)00617-1","title":"POSTER: MDS-641 Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; London Health Sciences Centre","funders":"","keywords":"Decitabine; Interim analysis; Medicine; Myelodysplastic syndromes; Interim; Safety profile; Randomized controlled trial; Oncology; Internal medicine; Adverse effect; Chemistry","score_opus":0.042164357307559144,"score_gpt":0.3869995978362735,"score_spread":0.3448352405287144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915755,0.00012723415,0.0005129821,0.0005240389,0.00073156203,0.005400014,0.00047458534,0.00030813928,0.00034595196],"genre_scores_gemma":[0.99626327,0.0008047254,0.000575512,0.00037389924,0.00025109155,0.0002072346,0.0007698056,0.00019837008,0.0005561139],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9853201,0.0033255974,0.005438871,0.0023782144,0.0018555581,0.0016816857],"domain_scores_gemma":[0.9791251,0.014997918,0.001135018,0.0021770871,0.00097169343,0.0015931902],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009329658,0.0011675406,0.006537791,0.0026889723,0.0002711398,0.00013323851,0.0010904107,0.00060056907,0.00040026274],"category_scores_gemma":[0.026489086,0.0009745982,0.0015374919,0.0070860707,0.0011035431,0.0004004983,0.0017500707,0.0011973098,0.00037997824],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5166797,0.0090247085,0.24283391,0.00037709734,0.0067087268,0.0024086824,0.0014214435,0.00043349495,0.00027825846,0.000034824785,0.0011597961,0.21863933],"study_design_scores_gemma":[0.3163647,0.0047786497,0.666358,0.0004322679,0.0026036117,0.000038030867,0.00047786484,0.007915898,0.00006997768,0.000019343488,0.0003187038,0.0006229428],"about_ca_topic_score_codex":0.00074953126,"about_ca_topic_score_gemma":0.00028578032,"teacher_disagreement_score":0.42352408,"about_ca_system_score_codex":0.0024059725,"about_ca_system_score_gemma":0.0019944906,"threshold_uncertainty_score":0.99927044},"labels":[],"label_agreement":null},{"id":"W4386277247","doi":"10.1016/s2152-2650(23)00485-8","title":"POSTER: AML-521 The Randomized Phase III SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) Trial: Successful Allogeneic Hematopoietic Stem Cell Transplantation Using Treatment With Iomab-B-Led Regimen for Patients With Active, Relapsed or Refractory AML With Failed Targeted Therapies","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Refractory (planetary science); Hematopoietic stem cell transplantation; Medicine; Regimen; Hematopoietic cell; Transplantation; Randomized controlled trial; Internal medicine; Oncology; Stem cell; Haematopoiesis; Biology","score_opus":0.03691495735154922,"score_gpt":0.33996844779076624,"score_spread":0.30305349043921703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97882146,0.00017654609,0.0001648741,0.00024854773,0.00023319483,0.019813644,0.0001606519,0.00029156785,0.000089511406],"genre_scores_gemma":[0.99342436,0.00056339224,0.0008801104,0.00014544737,0.00018575232,0.002636955,0.0007171289,0.00036299365,0.001083839],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9888853,0.0028877456,0.003275034,0.0018650598,0.0017345054,0.001352352],"domain_scores_gemma":[0.98506916,0.009512252,0.002142215,0.0018673782,0.0008657837,0.00054323376],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026410692,0.001258505,0.0041236123,0.00084417505,0.00046581778,0.00011762747,0.00077089644,0.0007413716,0.00008564304],"category_scores_gemma":[0.00045236314,0.00062748534,0.0005855237,0.0022833454,0.001107645,0.0005440083,0.000099918674,0.0007346324,0.000012868587],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9252646,0.0070313215,0.0045550577,0.0004237,0.002630231,0.0011790863,0.010151589,0.000041500723,0.001981429,0.0000025715744,0.000091598864,0.04664734],"study_design_scores_gemma":[0.8582616,0.08089828,0.044366308,0.0008978414,0.0026062464,0.00007328508,0.008056244,0.0010028817,0.0027900164,0.000010691533,0.00021308518,0.0008235433],"about_ca_topic_score_codex":0.0009746868,"about_ca_topic_score_gemma":0.0011162768,"teacher_disagreement_score":0.073866956,"about_ca_system_score_codex":0.0031297444,"about_ca_system_score_gemma":0.005530655,"threshold_uncertainty_score":0.99961764},"labels":[],"label_agreement":null},{"id":"W4386278342","doi":"10.1016/s2152-2650(23)00511-6","title":"POSTER: AML-453 Synchronous Diagnosis of Acute Myeloid Leukemia (AML) and Colorectal Adenocarcinoma (CRC)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Myeloid leukemia; Medicine; Internal medicine; Colorectal cancer; Oncology; Cancer research; Adenocarcinoma; Myeloid; Cancer","score_opus":0.02953358290996531,"score_gpt":0.328162638471348,"score_spread":0.2986290555613827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386278342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98958683,0.0015229129,0.000019572226,0.0016921089,0.0008358279,0.0018198895,0.0003078332,0.0007585725,0.0034564699],"genre_scores_gemma":[0.9886348,0.004785102,0.0007339974,0.0015342229,0.0012218214,0.00041279694,0.00038890445,0.00029912454,0.0019891884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9908243,0.00062364945,0.002892754,0.0021100359,0.0015223364,0.0020269214],"domain_scores_gemma":[0.9914312,0.003642778,0.0007448704,0.0018513182,0.00064624596,0.0016835816],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022483815,0.00103535,0.0027022187,0.0008863929,0.0003993935,0.0001302766,0.001084338,0.0014402615,0.00039957388],"category_scores_gemma":[0.0022116727,0.00095564214,0.001038613,0.0022342687,0.002265749,0.0004222751,0.0015951366,0.001268432,0.0015477142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0035908404,0.00032128624,0.5879309,0.00056855526,0.0018921797,0.004643687,0.00058019,0.0000067304295,0.0054135513,0.00029099366,0.033067375,0.3616937],"study_design_scores_gemma":[0.01046659,0.0034508158,0.96292794,0.00046749462,0.0010143648,0.0012980647,0.00025831314,0.0015123015,0.011354287,0.0002729552,0.0060963617,0.0008805419],"about_ca_topic_score_codex":0.0005730178,"about_ca_topic_score_gemma":0.000050408446,"teacher_disagreement_score":0.37499702,"about_ca_system_score_codex":0.0043934686,"about_ca_system_score_gemma":0.005940169,"threshold_uncertainty_score":0.99985605},"labels":[],"label_agreement":null},{"id":"W4386282368","doi":"10.1016/s2152-2650(23)00484-6","title":"POSTER: AML-469 Ivosidenib + Azacitidine vs Placebo + Azacitidine in Patients With Newly-Diagnosed Acute Myeloid Leukemia: Updated Long-term Efficacy and Safety Results From the AGILE Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; College of Medicine, Catholic University of Korea; Universitätsklinikum Heidelberg; Catholic University of Korea; Fakultní nemocnice Hradec Králové; Johns Hopkins University; Duke Cancer Institute; University of Miami; Augusta University; University of Pennsylvania; Chang Gung Medical Foundation; Deutsches Krebsforschungszentrum; Seoul St. Mary's Hospital, Catholic University of Korea","keywords":"Azacitidine; Myeloid leukemia; Medicine; Placebo; Oncology; Term (time); Internal medicine; Biology; Pathology; Alternative medicine; Physics","score_opus":0.024503963590829358,"score_gpt":0.3143090550814487,"score_spread":0.28980509149061934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869208,0.00014574645,0.000010882425,0.0032030544,0.00053660583,0.0066529573,0.0011937842,0.00074520713,0.00059098116],"genre_scores_gemma":[0.987729,0.00087205664,0.00023390022,0.0021689958,0.0009904054,0.0002958251,0.0060033426,0.0003386661,0.0013677959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98714846,0.0016089149,0.0037685363,0.003057281,0.0022116993,0.0022051071],"domain_scores_gemma":[0.9847947,0.009053541,0.0008877285,0.003163842,0.0007265321,0.0013736953],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0035554452,0.0013986517,0.0027112926,0.00065503764,0.00065828394,0.0003197158,0.0015231828,0.0010572601,0.00021436169],"category_scores_gemma":[0.004003695,0.0009964781,0.00042337453,0.0031060139,0.0013788809,0.0005972824,0.0016850939,0.0022361018,0.00094352255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.088175535,0.0013676594,0.78173375,0.000059522346,0.0015074073,0.006726903,0.0011522945,0.00004924319,0.00019311055,0.000010901191,0.017046127,0.10197752],"study_design_scores_gemma":[0.14314519,0.004629173,0.8475153,0.00066222256,0.00074741564,0.00007694344,0.00039389753,0.00047993276,0.00022840916,0.000022695718,0.001166993,0.00093184074],"about_ca_topic_score_codex":0.0016716917,"about_ca_topic_score_gemma":0.0013016211,"teacher_disagreement_score":0.101045676,"about_ca_system_score_codex":0.004350088,"about_ca_system_score_gemma":0.0034170512,"threshold_uncertainty_score":0.9998764},"labels":[],"label_agreement":null},{"id":"W4386283283","doi":"10.3390/curroncol30090581","title":"Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"Taiho Pharmaceutical","keywords":"Medicine; Decitabine; Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Internal medicine; International Prognostic Scoring System; Azacitidine; Hypomethylating agent; Oncology; Bone marrow","score_opus":0.0623964353288954,"score_gpt":0.3650024742754357,"score_spread":0.3026060389465403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386283283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99491465,0.0016488201,0.000008636081,0.0014015739,0.0003346536,0.0007806527,0.000009154487,0.000016350163,0.0008855329],"genre_scores_gemma":[0.99680865,0.0027198081,0.00004208839,0.0000593936,0.000048560963,0.00016251506,0.000037774156,0.000018054943,0.000103146755],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99810547,0.00015006127,0.00046164144,0.00032992585,0.00038016873,0.0005727148],"domain_scores_gemma":[0.9989397,0.00050673424,0.00007796018,0.00032935606,0.000039570205,0.00010666828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006681914,0.00016793987,0.00047855216,0.00040739402,0.000030552943,0.0000046744603,0.00026707354,0.0000713104,0.00005179974],"category_scores_gemma":[0.00008416292,0.00012707098,0.000032725497,0.0012287113,0.00013231052,0.00003799929,0.00022914355,0.00055834744,0.000031470496],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0016887351,0.0007654023,0.3765802,0.013105753,0.00070204085,0.043703567,0.003484828,0.003658827,0.001589561,0.005281387,0.03362699,0.5158127],"study_design_scores_gemma":[0.0069625573,0.0007128849,0.952618,0.00070474745,0.00010022967,0.00061163184,0.0019573246,0.01590265,0.0000711747,0.00019554536,0.019971391,0.0001918538],"about_ca_topic_score_codex":0.061811656,"about_ca_topic_score_gemma":0.30914766,"teacher_disagreement_score":0.5760378,"about_ca_system_score_codex":0.011393357,"about_ca_system_score_gemma":0.0057422607,"threshold_uncertainty_score":0.99989426},"labels":[],"label_agreement":null},{"id":"W4386390728","doi":"10.1186/s13613-023-01172-3","title":"Characteristics and outcomes of patients with acute myeloid leukemia admitted to intensive care unit with acute respiratory failure: a post-hoc analysis of a prospective multicenter study","year":2023,"lang":"en","type":"article","venue":"Annals of Intensive Care","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University of Toronto","funders":"","keywords":"Medicine; Post-hoc analysis; Intensive care unit; Anesthesiology; Respiratory failure; Intensive care medicine; Acute respiratory failure; Emergency medicine; Myeloid leukemia; Prospective cohort study; Internal medicine; Mechanical ventilation; Anesthesia","score_opus":0.029927606567163263,"score_gpt":0.3385893508585844,"score_spread":0.3086617442914211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386390728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992516,0.000089282024,0.000008422916,0.0011895874,0.000039732175,0.0028850366,0.0032028176,0.00004943864,0.000019703046],"genre_scores_gemma":[0.9922081,0.00005449948,0.00015771155,0.006513294,0.000018869712,0.00012012788,0.00076376897,0.00008103297,0.00008256714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996762,0.00014215423,0.00079423824,0.0007285063,0.001036281,0.00053682807],"domain_scores_gemma":[0.87551343,0.00022286856,0.00051676296,0.0007217032,0.12271818,0.00030704643],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015191312,0.0004919895,0.001955826,0.001704576,0.00007627276,0.000019061528,0.00029228406,0.00015757537,0.000018354527],"category_scores_gemma":[0.0035420312,0.0003406619,0.00025975928,0.0028685138,0.0004299648,0.00014849361,0.00041975154,0.0004695994,0.000006657978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016250115,0.00009903342,0.9018712,0.00029451188,0.017991003,0.00060139794,0.06012502,0.000008067748,0.0014686214,0.0000033029844,0.00090865715,0.00037904197],"study_design_scores_gemma":[0.0040947483,0.010378667,0.71502006,0.0003167918,0.003922681,0.000003115354,0.26081932,0.00002305026,0.005156223,4.3596887e-7,0.000031771215,0.0002331733],"about_ca_topic_score_codex":0.0003861512,"about_ca_topic_score_gemma":0.00053299026,"teacher_disagreement_score":0.2006943,"about_ca_system_score_codex":0.00026528377,"about_ca_system_score_gemma":0.00071638933,"threshold_uncertainty_score":0.9999045},"labels":[],"label_agreement":null},{"id":"W4386572280","doi":"10.1038/s41375-023-02023-7","title":"Infection risk associated with clonal hematopoiesis of indeterminate potential is partly mediated by hematologic cancer transformation in the UK Biobank","year":2023,"lang":"en","type":"letter","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute; Impact; Queen's University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; U.S. Department of Veterans Affairs","keywords":"Biobank; Haematopoiesis; Cancer; Indeterminate; Hematology; Hematologic Neoplasms; Immunology; Medicine; Transformation (genetics); Biology; Internal medicine; Stem cell; Bioinformatics; Genetics","score_opus":0.018684913357260705,"score_gpt":0.28252277725024993,"score_spread":0.26383786389298924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386572280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88656235,0.00021807454,0.00010260143,0.10936021,0.00022614101,0.001609278,0.0014049349,0.00016081307,0.00035558973],"genre_scores_gemma":[0.89956146,0.0018322143,0.00002370758,0.089966066,0.0006812418,0.0006374718,0.005989634,0.000171982,0.0011362473],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99565923,0.0005506122,0.0009020417,0.0005541217,0.001548802,0.00078521523],"domain_scores_gemma":[0.9977418,0.0006322521,0.0007272458,0.0005197807,0.0003008071,0.00007811945],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0009819852,0.0005265197,0.0010625626,0.0006054931,0.00013785635,0.000048908423,0.0003740586,0.0016704716,0.0002518758],"category_scores_gemma":[0.00034613887,0.00034614612,0.00026284397,0.0015696406,0.00031437495,0.00014222894,0.000052707743,0.0039642444,0.00006061324],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031273524,0.000059565908,0.017832007,0.0008509247,0.0005956112,0.0008841823,0.0016393121,0.000054290405,0.0005809698,0.0000021936005,0.9767066,0.000481599],"study_design_scores_gemma":[0.08867828,0.008837472,0.39932692,0.0222677,0.014534914,0.003543077,0.0040614507,0.06111995,0.09264953,0.0020603195,0.29312006,0.009800334],"about_ca_topic_score_codex":0.0074440017,"about_ca_topic_score_gemma":0.0010747297,"teacher_disagreement_score":0.68358654,"about_ca_system_score_codex":0.0023474288,"about_ca_system_score_gemma":0.0015870038,"threshold_uncertainty_score":0.999899},"labels":[],"label_agreement":null},{"id":"W4386742296","doi":"10.1101/2023.09.12.557322","title":"Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Medical Research Council; Blood Cancer UK; Versus Arthritis","keywords":"Haematopoiesis; Mutant; Biology; Transcriptome; Stem cell; Inflammation; Cell biology; Progenitor cell; Somatic cell; Myeloid; Bone marrow; Mutation; Hematopoietic stem cell; Genetics; Gene; Immunology; Gene expression","score_opus":0.010903249204733225,"score_gpt":0.24716506686026105,"score_spread":0.2362618176555278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386742296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964026,0.0008154058,0.0003394176,0.000277292,0.00018597337,0.0017085354,0.00017203583,0.00009670653,0.0000019952886],"genre_scores_gemma":[0.99837065,0.00041762597,0.00076292426,0.00003475429,0.000098335986,0.00020172901,7.352749e-7,0.000108392036,0.0000048339357],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99712217,0.00029585097,0.00081222225,0.0006589472,0.00062785746,0.00048297792],"domain_scores_gemma":[0.99719685,0.0008089936,0.0006739684,0.00071588607,0.00046433732,0.00013994415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012252475,0.00039950045,0.00088844425,0.00043936918,0.00007602235,0.000040646537,0.00030892168,0.0003451011,0.0000026332548],"category_scores_gemma":[0.00042697298,0.00034625054,0.00011302558,0.0007940959,0.0002329182,0.00009489185,0.0005566971,0.0010181573,0.000005766213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094038776,0.000047445817,0.01631359,0.004859986,0.00021117614,0.00010807657,0.00018168152,0.00003380313,0.9780113,0.000032156644,0.00008716064,0.000019548163],"study_design_scores_gemma":[0.0011360901,0.00011401249,0.040413644,0.0024795672,0.00013079519,1.073449e-7,0.000057530833,0.0017201263,0.9536464,0.0000015199515,0.000036550206,0.00026364336],"about_ca_topic_score_codex":0.0002021315,"about_ca_topic_score_gemma":0.0000077888635,"teacher_disagreement_score":0.024364924,"about_ca_system_score_codex":0.00053708034,"about_ca_system_score_gemma":0.00071063096,"threshold_uncertainty_score":0.99989897},"labels":[],"label_agreement":null},{"id":"W4386799057","doi":"10.18388/abp.2020_6235","title":"A case-control study in NAT2 gene polymorphism studies in patients diagnosed with acute myeloid leukemia","year":2023,"lang":"en","type":"article","venue":"Acta Biochimica Polonica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Population and Public Health","keywords":"Myeloid leukemia; Odds ratio; Genotyping; Internal medicine; Confidence interval; Gastroenterology; Allele; Medicine; Case-control study; Leukemia; Genotype; Acute leukemia; Oncology; Immunology; Biology; Genetics; Gene","score_opus":0.03237985564675844,"score_gpt":0.3175626229696883,"score_spread":0.28518276732292985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386799057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99205554,0.00023936182,4.060854e-7,0.0041602086,0.00013990827,0.0029691628,0.00011956603,0.0001923632,0.00012350151],"genre_scores_gemma":[0.9974926,0.00047279408,0.00017321002,0.00073528633,0.00011584172,0.0004990739,0.00006304426,0.00010818135,0.0003399483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959185,0.00035176225,0.0007978573,0.000956549,0.0007553056,0.0012200222],"domain_scores_gemma":[0.99765867,0.00070142373,0.00017605476,0.0009916342,0.00018098472,0.0002912374],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008519549,0.0004884378,0.0010516804,0.0012126381,0.00015158883,0.000032568605,0.00042031182,0.00023685698,0.00003541943],"category_scores_gemma":[0.0007435297,0.00038131705,0.00011310841,0.002221072,0.0003590161,0.00016021504,0.00039253634,0.0010231612,0.00014176809],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008748092,0.002475644,0.81906456,0.00014122241,0.0029535333,0.12871698,0.011366925,0.000025200941,0.0113791,0.000014724381,0.013398294,0.0017157112],"study_design_scores_gemma":[0.037161212,0.003876531,0.9523037,0.00018619173,0.00034803522,0.001169029,0.002679535,0.0003188236,0.001248754,0.000013321214,0.00015734942,0.0005375039],"about_ca_topic_score_codex":0.0013592996,"about_ca_topic_score_gemma":0.0016092216,"teacher_disagreement_score":0.13323914,"about_ca_system_score_codex":0.001973602,"about_ca_system_score_gemma":0.0010112764,"threshold_uncertainty_score":0.99986386},"labels":[],"label_agreement":null},{"id":"W4386801739","doi":"10.1002/pbc.30675","title":"An SRF‐rearranged malignant cellular myoid neoplasm with a novel <i>SRF–MKL2</i> fusion","year":2023,"lang":"en","type":"letter","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; Izaak Walton Killam Health Centre; Dalhousie University","funders":"Terry Fox Research Institute","keywords":"Nova scotia; Library science; Health centre; Nova (rocket); Medicine; History; Family medicine; Archaeology; Engineering; Computer science","score_opus":0.021612999160722103,"score_gpt":0.2739106090825525,"score_spread":0.25229760992183037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386801739","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40829316,0.016373962,0.00040381186,0.5555397,0.0035628525,0.006848375,0.0036323825,0.002155079,0.0031906415],"genre_scores_gemma":[0.023794554,0.033642296,0.0039624977,0.67527777,0.17676385,0.0040201833,0.0078576505,0.0030608226,0.0716204],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99215984,0.0001797915,0.00085297966,0.0019968783,0.0027294743,0.0020810533],"domain_scores_gemma":[0.99594444,0.00030244794,0.000502602,0.0019300474,0.00062151987,0.0006989661],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00061162846,0.0011629798,0.00161295,0.001109389,0.00029491857,0.00014420444,0.0009209213,0.001784484,0.0007608889],"category_scores_gemma":[0.0001005704,0.0009133409,0.0003891953,0.0022289471,0.0001982976,0.00019959062,0.00029876252,0.005539053,0.0005049324],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004901733,0.00036144475,0.00716372,0.0028854911,0.0006288703,0.008414296,0.00037022014,0.000023534729,0.013017737,0.0000018049182,0.9658755,0.0007671749],"study_design_scores_gemma":[0.01605832,0.0023007141,0.002488699,0.0009451044,0.009510129,0.00080987316,0.00011974309,0.00037067433,0.004570506,0.000015196587,0.96033615,0.0024748966],"about_ca_topic_score_codex":0.0039485465,"about_ca_topic_score_gemma":0.00029669996,"teacher_disagreement_score":0.38449863,"about_ca_system_score_codex":0.00063924637,"about_ca_system_score_gemma":0.003917524,"threshold_uncertainty_score":0.9995114},"labels":[],"label_agreement":null},{"id":"W4386804619","doi":"10.1186/s13039-023-00653-1","title":"Cytogenetic profile of 1791 adult acute myeloid leukemia in India","year":2023,"lang":"en","type":"article","venue":"Molecular Cytogenetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Karyotype; Medicine; Myeloid leukemia; Internal medicine; Cytogenetics; Myeloid; Pediatrics; Pathology; Biology; Genetics; Chromosome","score_opus":0.015406973036123168,"score_gpt":0.2925581322408046,"score_spread":0.2771511592046815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386804619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99324137,0.00034253718,0.0003410052,0.00031983343,0.00009023319,0.0010747915,0.00007595181,0.00012431463,0.0043899706],"genre_scores_gemma":[0.9913263,0.0009078002,0.005461369,0.0005027363,0.00006916451,0.00013321562,0.0002354364,0.00012708677,0.0012369183],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968557,0.0001351025,0.0006713518,0.0005805839,0.00089870434,0.0008585908],"domain_scores_gemma":[0.99821806,0.00006870192,0.00013243825,0.0009421595,0.00033871786,0.00029992446],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035048745,0.0003306893,0.00060803903,0.00082798675,0.000045868193,0.000019262603,0.00041422457,0.00032933053,0.00011555248],"category_scores_gemma":[0.00028464766,0.0003333479,0.00020548997,0.0022981828,0.00022184664,0.00003179546,0.0003610939,0.00050973566,0.00048742184],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030741756,0.00009006166,0.1269602,0.00032010718,0.00029039854,0.003289955,0.00047407538,0.00060743105,0.85896856,0.00038336596,0.0025382144,0.005770207],"study_design_scores_gemma":[0.0030971954,0.00054772873,0.11938394,0.00015135924,0.00015313429,0.00013736481,0.00017409713,0.002368445,0.87248623,0.000207651,0.0009624851,0.0003303752],"about_ca_topic_score_codex":0.000078631965,"about_ca_topic_score_gemma":0.000011958205,"teacher_disagreement_score":0.013517666,"about_ca_system_score_codex":0.000715102,"about_ca_system_score_gemma":0.0013845934,"threshold_uncertainty_score":0.99991184},"labels":[],"label_agreement":null},{"id":"W4386812574","doi":"10.1016/j.retram.2023.103409","title":"Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH)","year":2023,"lang":"fr","type":"article","venue":"Current Research in Translational Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research","keywords":"Myelodysplastic syndromes; Trisomy 8; Cytogenetics; Karyotype; Molecular cytogenetics; Biology; Fluorescence in situ hybridization; Genetics; Oncology; Medicine; Internal medicine; Chromosome; Bone marrow; Gene","score_opus":0.20214543156207454,"score_gpt":0.4501980745038399,"score_spread":0.24805264294176538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386812574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6330726,0.15320776,0.008918755,0.19120614,0.004875161,0.0063376646,0.0006884701,0.000105623025,0.0015877768],"genre_scores_gemma":[0.9022478,0.09128599,0.0015793549,0.00028866407,0.0024661354,0.00077534595,0.0008635994,0.00010780144,0.00038534444],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9852973,0.0042105615,0.002376822,0.0010755324,0.0046308255,0.0024089394],"domain_scores_gemma":[0.97573185,0.021579955,0.00022085742,0.0011751201,0.0008449148,0.0004472948],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.018626846,0.0006386071,0.0011281667,0.0014954746,0.00034548272,0.000048588678,0.0019736798,0.00051801687,0.0007860938],"category_scores_gemma":[0.0030619586,0.00041600285,0.00019550417,0.008735039,0.002748577,0.00015942981,0.00034046755,0.0050143693,0.0004247469],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005237977,0.0030998955,0.28402007,0.019794043,0.0020393308,0.014153075,0.040250864,0.033234216,0.003707508,0.07476704,0.11743883,0.40225714],"study_design_scores_gemma":[0.015330728,0.0014382177,0.75879884,0.036159225,0.0003866988,0.00049815275,0.017350271,0.09231058,0.00030849624,0.042693403,0.034008604,0.00071678386],"about_ca_topic_score_codex":0.0018915294,"about_ca_topic_score_gemma":0.0009052081,"teacher_disagreement_score":0.47477877,"about_ca_system_score_codex":0.0008144778,"about_ca_system_score_gemma":0.0021003012,"threshold_uncertainty_score":0.99996537},"labels":[],"label_agreement":null},{"id":"W4386881796","doi":"10.1182/bloodadvances.2022008899","title":"CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Institute for Research in Immunology and Cancer; McGill University; Centre hospitalier universitaire de Québec; Université Laval; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Fonds de Recherche du Québec - Santé; CHU Sainte-Justine Foundation; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Leukemia and Lymphoma Society; Child Health Research Foundation; Merck Canada; Cancer Research Society; Fondation Charles-Bruneau","keywords":"Acute megakaryoblastic leukemia; Cancer research; Leukemia; Cytarabine; Haematopoiesis; Biology; Immunology; Myeloid leukemia; Stem cell; Cell biology","score_opus":0.008774708589116527,"score_gpt":0.2881528674700445,"score_spread":0.27937815888092793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386881796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99254227,0.0010507244,0.00019834396,0.0031406402,0.00020480444,0.00092887145,0.0003003306,0.00034520208,0.0012888092],"genre_scores_gemma":[0.97818905,0.0071340767,0.00170978,0.0024004267,0.0011811211,0.00018313072,0.00030706008,0.000111025955,0.008784318],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99738383,0.000070438386,0.0003602694,0.00075242925,0.0006903024,0.0007427378],"domain_scores_gemma":[0.99848753,0.00035539237,0.00009404896,0.00034568165,0.00021870769,0.0004986619],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027383142,0.00033271697,0.00048742068,0.00044154705,0.00020839136,0.00005798014,0.00011140628,0.00016501876,0.00004928201],"category_scores_gemma":[0.00031633727,0.0002971167,0.00008967759,0.0014957573,0.00012949518,0.00038094362,0.00023618729,0.0004646629,0.0005981458],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021164692,0.0004491208,0.027667677,0.0014980324,0.0010240369,0.005829252,0.0050077485,0.00012381823,0.43876004,0.00025965608,0.48067608,0.03658805],"study_design_scores_gemma":[0.029773453,0.007969683,0.070242815,0.001259819,0.0044928794,0.0027353987,0.005104532,0.0030374783,0.6737798,0.0013979087,0.19661257,0.0035937077],"about_ca_topic_score_codex":0.0000626734,"about_ca_topic_score_gemma":0.000015727846,"teacher_disagreement_score":0.28406352,"about_ca_system_score_codex":0.00031637534,"about_ca_system_score_gemma":0.00035962908,"threshold_uncertainty_score":0.9999481},"labels":[],"label_agreement":null},{"id":"W4386935853","doi":"10.1016/j.jval.2023.09.001","title":"Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis","year":2023,"lang":"en","type":"review","venue":"Value in Health","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; Impact","funders":"","keywords":"Ven; Medicine; Internal medicine; Cytarabine; Hazard ratio; Myeloid leukemia; Oncology; Confidence interval","score_opus":0.20436581651139224,"score_gpt":0.42398445399190704,"score_spread":0.2196186374805148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386935853","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015418556,0.9714085,0.00012886453,0.00055775436,0.000042478674,0.011907791,0.00046163832,0.000055667268,0.000018789166],"genre_scores_gemma":[0.0038337868,0.9896558,0.0023129315,0.0006695325,0.000068494606,0.0020519819,0.0009955815,0.00019121425,0.00022066737],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99556744,0.0010251503,0.0014105034,0.00081348245,0.00050170376,0.00068172865],"domain_scores_gemma":[0.99509,0.002551938,0.0011109773,0.00061152776,0.00047533071,0.00016024082],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010993103,0.00072345405,0.007309011,0.0015369549,0.00008778245,0.000029050885,0.000214601,0.00030221173,0.000022769156],"category_scores_gemma":[0.00008604009,0.0004543398,0.0009815434,0.0030280277,0.00024523833,0.000059514176,0.000037093272,0.0004764755,0.0000041356598],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010694942,0.0022635364,0.014407307,0.04224985,0.72249424,0.00007527225,0.03466871,0.022508603,0.0000018151663,0.0008850286,0.00142756,0.14832313],"study_design_scores_gemma":[0.11391778,0.03432604,0.021562006,0.034891933,0.4086825,0.00003040707,0.0036249824,0.041599322,0.00004349265,0.0014141058,0.33573276,0.004174657],"about_ca_topic_score_codex":0.0063051856,"about_ca_topic_score_gemma":0.0004777771,"teacher_disagreement_score":0.3343052,"about_ca_system_score_codex":0.0036844113,"about_ca_system_score_gemma":0.003899564,"threshold_uncertainty_score":0.99979085},"labels":[],"label_agreement":null},{"id":"W4386957587","doi":"10.21203/rs.3.rs-3315059/v1","title":"Functional Characterization of Cooperating MGA Mutations in RUNX1::RUNX1T1 Acute Myeloid Leukemia","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"National Institutes of Health; St. Jude Children's Research Hospital","keywords":"Myeloid leukemia; Biology; Cancer research","score_opus":0.09005798689380178,"score_gpt":0.3950158089314776,"score_spread":0.3049578220376758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386957587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98891544,0.00013455965,0.00083331234,0.0036586723,0.00039358632,0.0035495516,0.00081443036,0.00022618618,0.0014742718],"genre_scores_gemma":[0.96875685,0.0013203894,0.000807088,0.00008552206,0.0008931011,0.0014222536,0.012832688,0.00022557093,0.01365653],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99276644,0.0007846831,0.001155907,0.0011551258,0.0029265902,0.0012112685],"domain_scores_gemma":[0.99463046,0.00086282165,0.0002483416,0.0011734907,0.0026801953,0.00040471548],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00348619,0.00043352877,0.0009586565,0.0028118256,0.00029759112,0.00014683702,0.0005325487,0.0008279947,0.00066015386],"category_scores_gemma":[0.0023969645,0.00042972868,0.00027325843,0.002773175,0.00047759383,0.00021419433,0.0017199602,0.004873911,0.00056184974],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026464397,0.0008959078,0.07379112,0.0112430705,0.0014618925,0.002196121,0.004497243,0.0054489393,0.86891985,0.0022320477,0.012506453,0.01416092],"study_design_scores_gemma":[0.0048807804,0.0008194265,0.91563255,0.005853677,0.00016023764,0.00010373299,0.0016021361,0.039807897,0.027641581,0.0009631687,0.0017581141,0.0007766734],"about_ca_topic_score_codex":0.0010590877,"about_ca_topic_score_gemma":0.00017841377,"teacher_disagreement_score":0.84184146,"about_ca_system_score_codex":0.0037957076,"about_ca_system_score_gemma":0.008370243,"threshold_uncertainty_score":0.99981546},"labels":[],"label_agreement":null},{"id":"W4386987507","doi":"10.1016/j.leukres.2023.107401","title":"Deep immunophenotypic analysis of the bone marrow progenitor cells in myelodysplastic syndromes","year":2023,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"","keywords":"Myelodysplastic syndromes; Immunophenotyping; Cytopenia; Chronic myelomonocytic leukemia; Medicine; Myeloid; Bone marrow; Population; Progenitor cell; International Prognostic Scoring System; Leukocytosis; Pathology; Internal medicine; Oncology; Immunology; Stem cell; Flow cytometry; Biology; Genetics","score_opus":0.044005983657383944,"score_gpt":0.3429631793028866,"score_spread":0.29895719564550266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386987507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99450004,0.00039801275,0.000019691131,0.0010491884,0.00015414876,0.0012960352,0.000025580008,0.00008584861,0.002471479],"genre_scores_gemma":[0.9888769,0.00022482737,0.00021401592,0.0000628775,0.00010185007,0.00024655857,0.000055608947,0.00006827181,0.010149124],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99392635,0.0007698725,0.0007298917,0.0006658463,0.0024861281,0.0014219396],"domain_scores_gemma":[0.99593765,0.0015707546,0.00010600679,0.0015403891,0.00057563547,0.0002695846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035123802,0.00025542447,0.00085159886,0.0035756219,0.00023537707,0.000051447045,0.00090911146,0.00029664385,0.0004620916],"category_scores_gemma":[0.0016168958,0.00018326919,0.0003982734,0.020189501,0.00072077085,0.00010187714,0.0008903367,0.0019136283,0.0007099321],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002917071,0.00059021375,0.1754797,0.001892234,0.0046424503,0.0027918576,0.0039618425,0.0104297595,0.76847845,0.0014170357,0.016908722,0.010490679],"study_design_scores_gemma":[0.0052979784,0.0005657428,0.75097805,0.00043874432,0.0008683251,0.000087568784,0.0026471177,0.18152164,0.053591892,0.00056717766,0.002952086,0.00048368046],"about_ca_topic_score_codex":0.001110286,"about_ca_topic_score_gemma":0.0003349366,"teacher_disagreement_score":0.71488655,"about_ca_system_score_codex":0.0030481375,"about_ca_system_score_gemma":0.0024636104,"threshold_uncertainty_score":0.97003865},"labels":[],"label_agreement":null},{"id":"W4386994638","doi":"10.1111/bjh.19067","title":"Treatment outcomes of childhood <i>PICALM::MLLT10</i> acute leukaemias","year":2023,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.020307007821183592,"score_gpt":0.31756159382189847,"score_spread":0.29725458600071486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386994638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914553,0.0011922988,0.00003753546,0.0055059334,0.000262843,0.00027360613,0.00003860282,0.000038787668,0.001195088],"genre_scores_gemma":[0.99128956,0.0049732365,0.0012591599,0.00039414756,0.00014008522,0.000009116998,0.00002024875,0.00004589941,0.0018685424],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9977098,0.00014134636,0.0009454734,0.00021003294,0.00049633824,0.0004970017],"domain_scores_gemma":[0.99834615,0.00034639798,0.0003973997,0.00027160018,0.000339836,0.00029864235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003488287,0.00018465737,0.0014719573,0.0004000557,0.00006482983,0.000018183955,0.00024408424,0.00020592257,0.00024378816],"category_scores_gemma":[0.0005065413,0.00015985707,0.0004648075,0.00045601698,0.0002468719,0.00010314326,0.00010135801,0.0004930929,0.00018883758],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068617467,0.0019895728,0.14704952,0.00027989334,0.006069388,0.65237117,0.000931317,0.000019929494,0.0053413333,0.00085624255,0.11313455,0.0712709],"study_design_scores_gemma":[0.010174301,0.0022778534,0.22382088,0.0003393217,0.0006692282,0.74531657,0.0003650422,0.000048346134,0.00719354,0.0005071781,0.009086799,0.00020097237],"about_ca_topic_score_codex":0.000089454494,"about_ca_topic_score_gemma":0.000020397156,"teacher_disagreement_score":0.104047745,"about_ca_system_score_codex":0.00021540657,"about_ca_system_score_gemma":0.0006757542,"threshold_uncertainty_score":0.6518782},"labels":[],"label_agreement":null},{"id":"W4387057720","doi":"10.1038/s41375-023-02031-7","title":"Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts","year":2023,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences; Acceleron; Celgene; Bristol-Myers Squibb","keywords":"Myelodysplastic syndromes; Erythropoiesis; Medicine; Refractory (planetary science); Ineffective erythropoiesis; Anemia; Internal medicine; Intensive care medicine; Bone marrow; Biology","score_opus":0.026013440952805944,"score_gpt":0.2829500220984105,"score_spread":0.2569365811456046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387057720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783325,0.00005994739,0.0007474855,0.0000461542,0.0000724308,0.0009833667,0.000034516936,0.00013063106,0.0000922063],"genre_scores_gemma":[0.9983141,0.00043133006,0.00036219976,0.00003317284,0.0000353487,0.0000429468,0.000120967234,0.000102008285,0.00055792346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973371,0.00006639047,0.0005210193,0.0006203124,0.0008522655,0.0006029263],"domain_scores_gemma":[0.9985559,0.00035504714,0.00021830895,0.00040389452,0.00020665681,0.00026020323],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023747334,0.00036926023,0.00063729053,0.00060947664,0.00015172819,0.000039886592,0.00014724974,0.00018128319,0.00023377953],"category_scores_gemma":[0.00018543506,0.0002561445,0.00004961876,0.0009798554,0.00017508767,0.0002837958,0.00011971328,0.0005161059,0.000024361672],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033968901,0.00016689666,0.9732252,0.0009821577,0.00015985183,0.0007672225,0.0018856629,0.005437058,0.0013014878,0.000003679836,0.000020236226,0.012653667],"study_design_scores_gemma":[0.009930192,0.0019358555,0.9660788,0.0020917126,0.0001631724,0.000083098515,0.0003472538,0.018361825,0.00068706874,0.000008365177,0.0000050149642,0.00030761244],"about_ca_topic_score_codex":0.00049150723,"about_ca_topic_score_gemma":0.0016253943,"teacher_disagreement_score":0.012924767,"about_ca_system_score_codex":0.00087063765,"about_ca_system_score_gemma":0.0004268596,"threshold_uncertainty_score":0.9999891},"labels":[],"label_agreement":null},{"id":"W4387088874","doi":"10.1182/blood.2022015752","title":"Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Montreal Clinical Research Institute","funders":"National Cancer Institute","keywords":"DNA repair; Cancer research; Biology; Olaparib; DNA damage; Temozolomide; Transplantation; Molecular biology; Homologous recombination; Synthetic lethality; Myeloid leukemia; DNA; Poly ADP ribose polymerase; Genetics; Polymerase; Medicine","score_opus":0.018761235001241442,"score_gpt":0.2819424546381048,"score_spread":0.26318121963686336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387088874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926153,0.00044171506,0.0000093494245,0.0038644974,0.00010527585,0.0010198148,0.000029817797,0.0009558533,0.00095837924],"genre_scores_gemma":[0.9859045,0.0017014007,0.0027838042,0.0024915824,0.0006992987,0.00005758222,0.000049573446,0.000110867535,0.00620135],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99794835,0.00012376264,0.00024617088,0.00066853146,0.00042277842,0.0005904273],"domain_scores_gemma":[0.998255,0.00040364603,0.000051356696,0.0007053967,0.000102547536,0.0004820257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090070924,0.00027020866,0.00047604294,0.00030496586,0.00014277287,0.000052930194,0.00009234808,0.00017525489,0.000049562415],"category_scores_gemma":[0.00028207136,0.00022287983,0.000116124414,0.0006329216,0.00012746495,0.000090476584,0.00025814667,0.00034195295,0.00013057681],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005735589,0.00039266903,0.0024738074,0.00041851756,0.00056369207,0.009007052,0.0017580925,0.0000029480702,0.92881775,0.00011341324,0.052968066,0.0029104096],"study_design_scores_gemma":[0.024351317,0.00515541,0.18461019,0.0005627446,0.0005656761,0.0017509384,0.0010567928,0.0047831074,0.72602254,0.00017082272,0.04989002,0.0010804712],"about_ca_topic_score_codex":0.00009680119,"about_ca_topic_score_gemma":0.00002552757,"teacher_disagreement_score":0.20279525,"about_ca_system_score_codex":0.000051367988,"about_ca_system_score_gemma":0.0001784492,"threshold_uncertainty_score":0.90887755},"labels":[],"label_agreement":null},{"id":"W4387110236","doi":"10.1007/978-981-99-3810-0_10","title":"The Role of BCL-2/MCL-1 Targeting in Acute Myeloid Leukemia","year":2023,"lang":"en","type":"book-chapter","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Venetoclax; Myeloid leukemia; Medicine; Clinical trial; Cancer research; Leukemia; Myeloid; Population; Oncology; Immunology; Internal medicine; Chronic lymphocytic leukemia","score_opus":0.01698364202425301,"score_gpt":0.27516819267770887,"score_spread":0.25818455065345586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387110236","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011078203,0.003001275,0.000010149902,0.0013224385,0.00020631489,0.0010894118,0.00004880809,0.00018463675,0.9930291],"genre_scores_gemma":[0.005215681,0.0064253905,0.0004615105,0.0001827798,0.00037733093,0.000045154113,0.0001599504,0.00023602789,0.98689616],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99669677,0.00004150547,0.0009388219,0.00057940505,0.0010295287,0.0007139424],"domain_scores_gemma":[0.99766284,0.0006763161,0.00027675743,0.00090168277,0.00027714064,0.00020524082],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001121021,0.00045702953,0.0009144302,0.00047278387,0.000119862765,0.000030968593,0.0005651569,0.0006580425,0.00061365543],"category_scores_gemma":[0.00028854053,0.00030265658,0.00032818213,0.00019113885,0.00033207424,0.000058451613,0.00050404225,0.0018447514,0.0011570607],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021189319,0.000072727395,0.001410162,0.00087464903,0.0033859261,0.0019179396,0.0011401953,0.000033882894,0.027805168,0.48347837,0.32806143,0.14970063],"study_design_scores_gemma":[0.0024807442,0.00036036762,0.00045038346,0.000968167,0.00031643547,0.00009487706,0.00069240096,0.0015552447,0.0056526167,0.025872836,0.9608961,0.00065983395],"about_ca_topic_score_codex":0.00041209065,"about_ca_topic_score_gemma":0.0001508686,"teacher_disagreement_score":0.6328347,"about_ca_system_score_codex":0.0013723125,"about_ca_system_score_gemma":0.0016374858,"threshold_uncertainty_score":0.99994254},"labels":[],"label_agreement":null},{"id":"W4387130674","doi":"10.1007/s00277-023-05462-5","title":"TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches","year":2023,"lang":"en","type":"review","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Clinical trial; Venetoclax; Azacitidine; Myeloid leukemia; Myelodysplastic syndromes; Medicine; Myeloid; Oncology; Hematology; Immunotherapy; Internal medicine; Immunology; Immune system; Leukemia; Biology; Chronic lymphocytic leukemia; Bone marrow; DNA methylation","score_opus":0.29477799576228064,"score_gpt":0.4145194577664131,"score_spread":0.11974146200413244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387130674","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028144545,0.99339926,0.000006056196,0.0011890635,0.00011192428,0.0016313251,0.00014863911,0.0001373411,0.000561955],"genre_scores_gemma":[0.0009214208,0.9972582,0.00030968408,0.00004786107,0.00006212773,0.000368086,0.00040650414,0.0001568121,0.0004693121],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99608696,0.000419816,0.0011818642,0.0011507637,0.00021113158,0.0009494803],"domain_scores_gemma":[0.9966337,0.0015838434,0.0005524373,0.00072710484,0.00009685497,0.0004060723],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000512079,0.000857259,0.0055100825,0.0009992382,0.0001031997,0.000016045246,0.00027224363,0.0011964209,0.000026364662],"category_scores_gemma":[0.00032667594,0.00062629994,0.00039312162,0.00041024925,0.00087497575,0.0000643595,0.0004450377,0.00072955457,0.000068143345],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014848539,0.00013392678,0.00002953775,0.048803594,0.0068686763,0.0029823543,0.00033189415,1.454096e-7,0.000008043415,0.004572448,0.0006212366,0.93549967],"study_design_scores_gemma":[0.006271654,0.007990008,0.0003798684,0.04068507,0.012312826,0.12318392,0.00077964383,0.00029687525,0.000284601,0.0024106572,0.80310655,0.002298359],"about_ca_topic_score_codex":0.00007126727,"about_ca_topic_score_gemma":0.00001535735,"teacher_disagreement_score":0.9332013,"about_ca_system_score_codex":0.00018358162,"about_ca_system_score_gemma":0.0010572071,"threshold_uncertainty_score":0.9996188},"labels":[],"label_agreement":null},{"id":"W4387265992","doi":"10.54751/revistafoco.v16n10-013","title":"PROCEDIMENTOS E EVOLUÇÃO NO DIAGNÓSTICO DA LLA: UMA REVISÃO BIBLIOGRÁFICA","year":2023,"lang":"pt","type":"article","venue":"Revista Foco","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Air (Canada)","funders":"","keywords":"Gynecology; Medicine","score_opus":0.04508997207907187,"score_gpt":0.347489494881218,"score_spread":0.3023995228021461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387265992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48707134,0.19918874,0.001519325,0.07189606,0.010011326,0.0561507,0.0027879733,0.009880032,0.16149452],"genre_scores_gemma":[0.50610864,0.08736153,0.0008618379,0.0032331564,0.010780582,0.0019567576,0.001565851,0.0011984624,0.38693318],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9908304,0.0005315622,0.0016613721,0.0018516162,0.002451902,0.0026731156],"domain_scores_gemma":[0.99311453,0.0011657455,0.00048428995,0.0025847957,0.001161439,0.0014891786],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002779361,0.0010344635,0.0018862588,0.0044129253,0.00051329547,0.0007396139,0.001302519,0.00064887636,0.005425875],"category_scores_gemma":[0.0059215096,0.0009499014,0.00067806215,0.017783763,0.0004722353,0.00038635137,0.0011556951,0.0019081228,0.07724584],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004588243,0.00036161343,0.012885834,0.008344599,0.00059679965,0.0016000961,0.0005200004,0.0000045476436,0.0035286418,0.0012558026,0.9465125,0.023930706],"study_design_scores_gemma":[0.004946483,0.0014848292,0.020242091,0.005925983,0.0009272352,0.00015566131,0.0005445429,0.008265234,0.00042906837,0.000042830725,0.95578694,0.0012490889],"about_ca_topic_score_codex":0.00014483322,"about_ca_topic_score_gemma":0.000004840645,"teacher_disagreement_score":0.22543867,"about_ca_system_score_codex":0.0013701806,"about_ca_system_score_gemma":0.0018790723,"threshold_uncertainty_score":0.9992952},"labels":[],"label_agreement":null},{"id":"W4387296226","doi":"10.1111/bjh.19121","title":"Acute myeloid leukaemia relapse after allogeneic haematopoietic stem cell transplantation: Mechanistic diversity and therapeutic directions","year":2023,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Transplantation; Mechanism (biology); Stem cell; Haematopoiesis; Immunology; Oncology; Donor lymphocyte infusion; Hematopoietic stem cell transplantation; Bioinformatics; Internal medicine; Biology","score_opus":0.0449286521236952,"score_gpt":0.3134743992064491,"score_spread":0.2685457470827539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387296226","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013584538,0.9840942,0.00037256285,0.00014218855,0.000576785,0.00088514574,0.00016025777,0.00007186123,0.00011245048],"genre_scores_gemma":[0.0033682524,0.99418634,0.00030899132,0.00012665906,0.00017473647,0.00006501017,0.00004083559,0.00013369205,0.0015954725],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9961734,0.000647428,0.0014049849,0.00053799216,0.0006172873,0.000618941],"domain_scores_gemma":[0.9974209,0.0006391547,0.00080651935,0.0003378072,0.00034510554,0.00045052843],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007388427,0.00050087937,0.0035734947,0.0007249658,0.0005477751,0.00006856795,0.0004356207,0.0007746912,0.00014503008],"category_scores_gemma":[0.000047516147,0.00048321282,0.00082142797,0.00058944075,0.00031933223,0.000110362584,0.00041577625,0.001919554,0.0001200939],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039220747,0.00019027904,0.00009380159,0.05163045,0.0034831848,0.5721619,0.000600603,5.9798856e-7,0.0000084842295,0.00011673321,0.0015668335,0.36975494],"study_design_scores_gemma":[0.0017321153,0.0003875785,0.000120038196,0.017749902,0.012441778,0.8969202,0.00011621853,0.000005303926,0.000016124352,0.00027373928,0.06980668,0.00043033442],"about_ca_topic_score_codex":0.00005000823,"about_ca_topic_score_gemma":0.000061538594,"teacher_disagreement_score":0.3693246,"about_ca_system_score_codex":0.00042872963,"about_ca_system_score_gemma":0.00094758667,"threshold_uncertainty_score":0.99976194},"labels":[],"label_agreement":null},{"id":"W4387309944","doi":"10.1101/2023.10.02.560330","title":"Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Venetoclax; Myeloid leukemia; Cancer research; Oxidative phosphorylation; Calcium; Mitochondrion; Leukemia; Pharmacology; Myeloid; Biology; Stem cell; Medicine; Immunology; Cell biology; Internal medicine; Biochemistry; Chronic lymphocytic leukemia","score_opus":0.032323971142883,"score_gpt":0.27435219671362043,"score_spread":0.24202822557073744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387309944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97291714,0.0013086884,0.011931007,0.0010933183,0.0062056384,0.004009976,0.0010770314,0.0014034244,0.000053757787],"genre_scores_gemma":[0.9547795,0.0019324744,0.036185626,0.00042745416,0.0044684983,0.0006428239,0.000010778987,0.0008193137,0.00073350675],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9937497,0.00029924672,0.0014655356,0.00176968,0.00149667,0.0012192044],"domain_scores_gemma":[0.9945175,0.00031196445,0.0009469171,0.0021853708,0.0015478085,0.00049045595],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00089860347,0.00095781754,0.0016415721,0.00058904,0.0002155403,0.00015201997,0.0009264067,0.0014661237,0.00009432444],"category_scores_gemma":[0.00039973247,0.0009673091,0.0005101094,0.0012040029,0.00032914447,0.0002729134,0.001304722,0.0025141896,0.00038829187],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038410936,0.000105571264,0.0008036344,0.0016342733,0.0008633163,0.0003443946,0.00007979723,0.00027374225,0.9841785,0.00021805645,0.0111121535,0.0000024572093],"study_design_scores_gemma":[0.0024879216,0.00023277699,0.0036874963,0.0012284921,0.0007711736,1.1229127e-7,0.000030250043,0.0036565214,0.98112607,0.0000058510022,0.0058012353,0.00097210094],"about_ca_topic_score_codex":0.00032659803,"about_ca_topic_score_gemma":0.0000012577382,"teacher_disagreement_score":0.02425462,"about_ca_system_score_codex":0.0029982594,"about_ca_system_score_gemma":0.004780297,"threshold_uncertainty_score":0.9998302},"labels":[],"label_agreement":null},{"id":"W4387377204","doi":"10.1097/01.cot.0000990220.19212.44","title":"An Assortment of Journal Abstracts to Enhance Oncology Care","year":2023,"lang":"en","type":"article","venue":"Oncology Times","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Login; Pharmacy; World Wide Web; Internet privacy; Medicine; Health care; Logo (programming language); Computer science; Library science; Family medicine; Political science; Computer security","score_opus":0.025418412794520888,"score_gpt":0.41854246709575293,"score_spread":0.39312405430123204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387377204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91023195,0.00019246308,0.000028759396,0.010557672,0.00035213667,0.0004309672,0.000012017228,0.00008062379,0.07811342],"genre_scores_gemma":[0.9807073,0.00022158971,0.0050828764,0.001379886,0.0004688107,0.00004720647,0.000052696214,0.00003256378,0.012007093],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99831533,0.0001758801,0.00042285482,0.00026431427,0.00033770234,0.0004839242],"domain_scores_gemma":[0.99839693,0.0002830575,0.00016056925,0.00033076023,0.000394077,0.00043462857],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008121506,0.00012946164,0.00050487067,0.0003633117,0.0000881744,0.000008697139,0.00024609463,0.00027801067,0.0007361796],"category_scores_gemma":[0.00034297912,0.00010893087,0.00008446141,0.0003956017,0.00012668905,0.00006766699,0.00010270817,0.0005575266,0.0011666064],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012550224,0.0007244787,0.0062105185,0.00012127733,0.00031902856,0.0041178563,0.0073038316,0.0004257135,0.15027574,0.00012284388,0.35129315,0.47783056],"study_design_scores_gemma":[0.0022222155,0.015403242,0.10320757,0.000081866936,0.0001328704,0.00082408247,0.0057387897,0.00009331726,0.086582035,0.00013252301,0.78537786,0.00020365062],"about_ca_topic_score_codex":0.000036953457,"about_ca_topic_score_gemma":0.000067445726,"teacher_disagreement_score":0.4776269,"about_ca_system_score_codex":0.0016593562,"about_ca_system_score_gemma":0.0025145437,"threshold_uncertainty_score":0.9996111},"labels":[],"label_agreement":null},{"id":"W4387440169","doi":"10.1097/mph.0000000000002760","title":"Gemtuzumab Ozogamicin Monotherapy Is a Well-tolerated Palliative Chemotherapy Option in Pediatric Multiply Relapsed Acute Myeloid Leukemia: A Multicenter Case Series and Review of the Literature","year":2023,"lang":"en","type":"review","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal; Children's Hospital of Eastern Ontario; University of Ottawa","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; Myeloid leukemia; Refractory (planetary science); Chemotherapy; CD33; Oncology; Internal medicine; Stem cell; CD34","score_opus":0.03595969583777615,"score_gpt":0.37513460046169256,"score_spread":0.3391749046239164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387440169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016179949,0.9760295,0.000015512895,0.0033930482,0.00063739077,0.0035357247,0.000115886985,0.00003666187,0.000056288587],"genre_scores_gemma":[0.00018090213,0.9948386,0.0017019772,0.0012523074,0.001134151,0.00015164196,0.000047103964,0.00018636243,0.00050697045],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99136925,0.0020339165,0.004178695,0.00080869376,0.0007475544,0.00086191436],"domain_scores_gemma":[0.99080384,0.0018189184,0.005027209,0.00077818235,0.0012023688,0.00036950177],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0025442815,0.0009992102,0.0067958427,0.002079922,0.00013489467,0.000035166595,0.00071357697,0.0022730413,0.000082508035],"category_scores_gemma":[0.0010859541,0.0006323261,0.0012869443,0.0041287383,0.00032150914,0.00027939436,0.00028651563,0.004923041,0.00003656797],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008468414,0.001853408,0.00572313,0.5446484,0.006500215,0.1096856,0.009410189,0.0000045953993,0.00003562748,0.00008446552,0.06960399,0.24398196],"study_design_scores_gemma":[0.035938617,0.008317839,0.00052144116,0.11119197,0.023092132,0.26717126,0.000962119,0.0002178426,0.00005535231,0.00012796148,0.55058175,0.0018216952],"about_ca_topic_score_codex":0.00003539151,"about_ca_topic_score_gemma":0.000030382624,"teacher_disagreement_score":0.48097777,"about_ca_system_score_codex":0.0033409821,"about_ca_system_score_gemma":0.007859861,"threshold_uncertainty_score":0.9996128},"labels":[],"label_agreement":null},{"id":"W4387458316","doi":"10.3390/genes14101916","title":"The Small-Molecule E26-Transformation-Specific Inhibitor TK216 Attenuates the Oncogenic Properties of Pediatric Leukemia","year":2023,"lang":"en","type":"article","venue":"Genes","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Leukemia; Cytotoxic T cell; Cancer research; Myeloid leukemia; Haematopoiesis; Lymphoid leukemia; Apoptosis; Priming (agriculture); Venetoclax; Myeloid; Bone marrow; Biology; Immunology; Chemistry; Cell biology; Stem cell; Biochemistry; Chronic lymphocytic leukemia; In vitro","score_opus":0.047055724747334736,"score_gpt":0.27078640375680435,"score_spread":0.2237306790094696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387458316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98187387,0.009889746,0.000021467986,0.0064315847,0.00022111254,0.00077050633,0.000010492701,0.00010676655,0.00067443534],"genre_scores_gemma":[0.98167765,0.014241233,0.00004125593,0.00012315581,0.000923408,0.00012550107,0.000024850078,0.000042167147,0.0028007538],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983062,0.00010582788,0.00040804344,0.00020963192,0.00052500935,0.00044526573],"domain_scores_gemma":[0.9988198,0.0002185617,0.00008853524,0.00052564574,0.00026340818,0.000084043946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007124241,0.00016594841,0.00021587136,0.00014798292,0.00036003068,0.000052838765,0.00038096323,0.00009049429,0.000023586883],"category_scores_gemma":[0.00011533102,0.000081769984,0.0001511761,0.0009299676,0.00024169771,0.00006820065,0.00012322355,0.00027740092,0.00054274517],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008475712,0.00008262966,0.0073499265,0.00074687134,0.0003952899,0.000058223603,0.0069362894,0.00019857017,0.8444398,0.00079078536,0.080368415,0.05778561],"study_design_scores_gemma":[0.0021020044,0.0003216592,0.01170852,0.000086111264,0.00018275756,0.000065387736,0.005450105,0.0017083201,0.8841604,0.000100883524,0.09379695,0.00031692203],"about_ca_topic_score_codex":0.00007206678,"about_ca_topic_score_gemma":0.000030083489,"teacher_disagreement_score":0.05746869,"about_ca_system_score_codex":0.00020301995,"about_ca_system_score_gemma":0.00062209263,"threshold_uncertainty_score":0.6976072},"labels":[],"label_agreement":null},{"id":"W4387664554","doi":"10.1101/2023.10.12.561697","title":"Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Veterinärmedizinische Universität Wien","keywords":"Cancer research; Myeloid leukemia; Biology; Cytarabine; Tyrosine kinase; Myeloid; Leukemia; Immunology; Signal transduction; Cell biology","score_opus":0.017239299042958487,"score_gpt":0.2391417452261828,"score_spread":0.22190244618322433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387664554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889953,0.004320164,0.00032270022,0.0010802173,0.0022047134,0.0021878616,0.0001469041,0.0007232703,0.00001886628],"genre_scores_gemma":[0.99251497,0.0027389547,0.0022215927,0.0005626613,0.00078170374,0.00036454073,0.0000063169277,0.0005380353,0.00027121714],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9932785,0.00034577865,0.0011851686,0.0022953076,0.0011255394,0.0017696958],"domain_scores_gemma":[0.996306,0.00016642976,0.0004628383,0.0018297561,0.00041487394,0.0008201033],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0010455586,0.0012670648,0.0014632993,0.0013278157,0.00022523625,0.00035868312,0.0008114476,0.0013502479,0.000045170033],"category_scores_gemma":[0.00015897496,0.0012938688,0.00037204198,0.0012966793,0.00044913552,0.00020792606,0.0016317894,0.0027225586,0.00018639154],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082120625,0.0003863401,0.008390785,0.0014719279,0.0007339659,0.005595062,0.00008232123,0.00009163653,0.9810017,0.00008994022,0.0012875887,0.00004752963],"study_design_scores_gemma":[0.015375026,0.00052968843,0.3767984,0.0019450564,0.0010247069,0.0000027101848,0.00005992538,0.010192988,0.5883944,0.000015868834,0.0025560916,0.0031051538],"about_ca_topic_score_codex":0.00079626637,"about_ca_topic_score_gemma":0.00003531623,"teacher_disagreement_score":0.3926073,"about_ca_system_score_codex":0.0033504753,"about_ca_system_score_gemma":0.004353502,"threshold_uncertainty_score":0.99994624},"labels":[],"label_agreement":null},{"id":"W4387764472","doi":"10.14348/molcells.2023.0093","title":"Identification of Cell Type-Specific Effects of DNMT3A Mutations on Relapse in Acute Myeloid Leukemia","year":2023,"lang":"en","type":"article","venue":"Molecules and Cells","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Ministry of Science and ICT, South Korea; National Research Foundation of Korea; Chonnam National University; National Research Foundation; Chonnam National University Hwasun Hospital; Mike and Josie Harper Cancer Research Institute","keywords":"Myeloid leukemia; Haematopoiesis; Progenitor cell; Myeloid; Bone marrow; Cancer research; Mutation; Medicine; Stem cell; Peripheral blood mononuclear cell; Leukemia; Immunology; Biology; Oncology; Gene; Genetics","score_opus":0.010118343305629919,"score_gpt":0.2641025194496736,"score_spread":0.25398417614404367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387764472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979704,0.00026392928,0.000088550645,0.00013672879,0.0000874501,0.00039291827,0.00001292133,0.000022313585,0.001024801],"genre_scores_gemma":[0.99482536,0.0018838607,0.00018218826,0.00003803231,0.00001707577,0.000017211487,0.000053720272,0.000022374172,0.0029601934],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989797,0.000053457385,0.00030960195,0.00022431198,0.00025015994,0.00018277529],"domain_scores_gemma":[0.9993041,0.00017046327,0.00009573325,0.00027188638,0.000088762885,0.00006904751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001939472,0.000100668796,0.00022870545,0.00032379027,0.00002660515,0.0000080035215,0.000081557955,0.00008897386,0.0000154244],"category_scores_gemma":[0.000042107364,0.00009194313,0.000048975457,0.00069546007,0.00009147481,0.000030282563,0.00004517893,0.00017886318,0.000108243614],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014640602,0.000068625515,0.00017662962,0.00034357773,0.000023249235,0.00010851025,0.0005254775,0.00011128077,0.9945883,0.00023261286,0.0020469043,0.0016284174],"study_design_scores_gemma":[0.0012991717,0.0003155175,0.017626235,0.00011436805,0.0000403688,0.000003659774,0.00020195256,0.0012797907,0.9784492,0.00014020062,0.0004553406,0.000074140364],"about_ca_topic_score_codex":0.000029729374,"about_ca_topic_score_gemma":0.0000021431126,"teacher_disagreement_score":0.017449606,"about_ca_system_score_codex":0.000110957946,"about_ca_system_score_gemma":0.000115574265,"threshold_uncertainty_score":0.3749332},"labels":[],"label_agreement":null},{"id":"W4387878080","doi":"10.3389/fgene.2023.1282947","title":"Validation of next-generation sequencing-based chimerism testing for accurate detection and monitoring of engraftment in hematopoietic stem cell transplantation","year":2023,"lang":"en","type":"article","venue":"Frontiers in Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of British Columbia; Saskatchewan Cancer Agency; CancerCare Manitoba; St. Paul's Hospital; Vancouver Coastal Health; University of Saskatchewan","funders":"Strong","keywords":"Concordance; Hematopoietic stem cell transplantation; Transplantation; Reproducibility; Haematopoiesis; Immunology; Stem cell; Medicine; Biology; Internal medicine; Genetics; Chemistry; Chromatography","score_opus":0.08375418480879403,"score_gpt":0.30121503368127045,"score_spread":0.2174608488724764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387878080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95738155,0.0002737853,0.041412175,0.0000253472,0.00017846389,0.00069736916,0.000008164724,0.000015628404,0.000007524661],"genre_scores_gemma":[0.96902305,0.00023888175,0.030550059,0.0000032766882,0.000045614157,0.000071229086,0.000038084298,0.000017918575,0.000011879673],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990731,0.000055909175,0.0003620208,0.00016883734,0.00018244778,0.00015769439],"domain_scores_gemma":[0.99955857,0.00008920928,0.00011894626,0.000105109386,0.00009457997,0.000033601904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038210044,0.00008718549,0.00019637536,0.0003894137,0.000026302041,0.000008280562,0.00003835882,0.00008507503,3.3815488e-7],"category_scores_gemma":[0.000040189316,0.000094097224,0.000024133855,0.00048809656,0.000028654762,0.000048710557,0.00000772854,0.000095819254,1.9403682e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000110114284,0.000022725657,0.10025919,0.000896685,0.000009157217,0.0000045237384,0.0013964132,0.026996061,0.8543094,4.2534055e-7,0.0000093216595,0.015986025],"study_design_scores_gemma":[0.0011842028,0.00021683684,0.019358667,0.0001221607,0.000029481102,0.0000016855216,0.0008551463,0.27000076,0.70815647,0.000022841892,0.0000016178952,0.00005013614],"about_ca_topic_score_codex":0.000033238568,"about_ca_topic_score_gemma":0.0000052580413,"teacher_disagreement_score":0.24300471,"about_ca_system_score_codex":0.0002355321,"about_ca_system_score_gemma":0.00015285738,"threshold_uncertainty_score":0.38371733},"labels":[],"label_agreement":null},{"id":"W4387893581","doi":"10.1080/14656566.2023.2272659","title":"Ivosidenib in acute myeloid leukemia","year":2023,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia","keywords":"Medicine; Venetoclax; Myeloid leukemia; Midostaurin; Cytarabine; Oncology; Hedgehog; Pharmacology; Leukemia; Cancer research; Internal medicine; Signal transduction","score_opus":0.12946871703231508,"score_gpt":0.47556122090816166,"score_spread":0.34609250387584656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387893581","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011545546,0.9914255,0.000012945848,0.0010112562,0.0018961863,0.003347064,0.00008616414,0.0005145319,0.0016947633],"genre_scores_gemma":[7.1628733e-7,0.9838864,0.00025897706,0.003059446,0.0025155966,0.0016072163,0.00056848704,0.00058996235,0.0075131604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945561,0.00049906434,0.0013444606,0.0013476008,0.0011130535,0.0011397176],"domain_scores_gemma":[0.9973666,0.0005739841,0.0003446862,0.001097713,0.0000939983,0.00052300555],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00071160356,0.0010981387,0.003161775,0.0018046325,0.000114546456,0.000074851116,0.0008245701,0.0007962629,0.0013813473],"category_scores_gemma":[0.00006771406,0.0008676185,0.0010193503,0.0018948315,0.00014170096,0.00013990642,0.00015295122,0.0024312446,0.0040759128],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037029546,0.00015042022,0.0000019385395,0.0026643542,0.0008714852,0.0005919037,0.00026135254,9.195943e-7,0.00020685758,0.00008391554,0.1492562,0.84554034],"study_design_scores_gemma":[0.0041896626,0.00035531982,0.0000038974135,0.016267639,0.000055957862,0.00023327544,0.000025642837,0.00008232838,0.00027914473,0.000019297946,0.9777712,0.0007166227],"about_ca_topic_score_codex":0.00015406622,"about_ca_topic_score_gemma":0.0000028599914,"teacher_disagreement_score":0.8448237,"about_ca_system_score_codex":0.004180758,"about_ca_system_score_gemma":0.0027695943,"threshold_uncertainty_score":0.9998702},"labels":[],"label_agreement":null},{"id":"W4387957963","doi":"10.1038/s41581-023-00778-x","title":"Clonal haematopoiesis, ageing and kidney disease","year":2023,"lang":"en","type":"review","venue":"Nature Reviews Nephrology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; St. Joseph’s Healthcare Hamilton; Queen's University; McMaster University; Population Health Research Institute; Impact","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute","keywords":"Kidney disease; Medicine; Kidney; Immunology; Disease; Acute kidney injury; Bioinformatics; Biology; Internal medicine","score_opus":0.06071053585341305,"score_gpt":0.40383135217379956,"score_spread":0.3431208163203865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387957963","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000001976751,0.9919786,0.000009406777,0.0027304834,0.0003849296,0.004086413,0.00014727052,0.00019188331,0.00046902904],"genre_scores_gemma":[1.7574166e-7,0.98324746,0.00063611736,0.009253049,0.0014890014,0.0007372903,0.0011699449,0.00020976285,0.00325722],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99504405,0.0010016023,0.0013121745,0.0012311814,0.0004906571,0.0009203323],"domain_scores_gemma":[0.99602336,0.0007029077,0.00052792707,0.0012498075,0.00012185267,0.0013741502],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.001478787,0.0009001635,0.005840336,0.000704381,0.00015381568,0.000043571155,0.00049683795,0.0022091204,0.0004009887],"category_scores_gemma":[0.0042342376,0.00061295665,0.0011480913,0.0011032284,0.00035036972,0.00007253039,0.00060894206,0.005349307,0.0014263863],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043476804,0.000030159503,0.000011190239,0.13482255,0.00042267682,0.002883243,0.000009587187,4.52822e-9,6.89872e-7,0.0006339808,0.22733796,0.6338045],"study_design_scores_gemma":[0.00045980935,0.00007233103,0.000046780384,0.030771295,0.003495196,0.0014106281,0.0000010931856,0.0000054839406,4.623002e-8,0.00010438063,0.9632299,0.00040305132],"about_ca_topic_score_codex":0.000008444472,"about_ca_topic_score_gemma":0.0000048306556,"teacher_disagreement_score":0.73589194,"about_ca_system_score_codex":0.00038474423,"about_ca_system_score_gemma":0.002270465,"threshold_uncertainty_score":0.9996322},"labels":[],"label_agreement":null},{"id":"W4388036682","doi":"10.1016/j.jtct.2023.10.018","title":"Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation","year":2023,"lang":"en","type":"review","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Genentech; Health Resources and Services Administration; Swedish Orphan Biovitrum; National Institute of Environmental Health Sciences; Servier; Gateway for Cancer Research; Astellas Pharma; Sanofi; MacroGenics; Incyte; Leukemia and Lymphoma Society","keywords":"Hematopoietic stem cell transplantation; Medicine; Transplantation; Genetic testing; Germline; Oncology; CEBPA; Immunology; Internal medicine; Genetics; Biology; Mutation; Gene","score_opus":0.09424667534191573,"score_gpt":0.33992686670146655,"score_spread":0.24568019135955083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388036682","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41483054,0.5827012,0.0004553959,0.000023491757,0.000052129584,0.0016182386,0.00023839383,0.000037272406,0.00004330382],"genre_scores_gemma":[0.054425985,0.9436996,0.00023785271,0.000038618615,0.00003288438,0.00017733074,0.0012054782,0.00010769107,0.000074582465],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970295,0.00039768007,0.0010739593,0.00069453265,0.0004166529,0.00038770866],"domain_scores_gemma":[0.99888384,0.00024798998,0.0003293491,0.00026210322,0.00006808395,0.0002086255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003741112,0.0005594503,0.0014190954,0.00057762867,0.00008943513,0.000041298044,0.00011142673,0.00047967356,0.00002466788],"category_scores_gemma":[0.000001372677,0.00048694044,0.00017757862,0.00040504325,0.00017444513,0.000093090144,0.00000944697,0.00044947225,0.000008906328],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013864724,0.00026563896,0.0012379406,0.1595044,0.0004450964,0.0013294013,0.014946911,0.000015854446,0.012153485,0.000070229624,0.0000077631985,0.8086368],"study_design_scores_gemma":[0.13379663,0.014321304,0.047472924,0.19440608,0.0385301,0.016215473,0.0104431715,0.0018041859,0.45475605,0.0012203607,0.07367151,0.013362196],"about_ca_topic_score_codex":0.0002261321,"about_ca_topic_score_gemma":0.000077568046,"teacher_disagreement_score":0.7952746,"about_ca_system_score_codex":0.000067811176,"about_ca_system_score_gemma":0.00021885274,"threshold_uncertainty_score":0.99975824},"labels":[],"label_agreement":null},{"id":"W4388418754","doi":"10.2147/ppa.s421871","title":"Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell Transplantation","year":2023,"lang":"en","type":"article","venue":"Patient Preference and Adherence","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; London Health Sciences Centre","funders":"Astellas Pharma","keywords":"Medicine; Hematopoietic stem cell transplantation; Quality of life (healthcare); Transplantation; Logistic regression; Myeloid leukemia; Internal medicine; Family medicine; Nausea; Oncology","score_opus":0.03769255445004926,"score_gpt":0.2895774965175819,"score_spread":0.25188494206753265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388418754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960197,0.0003614809,0.0002849426,0.0000888559,0.000119953846,0.0016951588,0.00014197857,0.00013503707,0.0011528586],"genre_scores_gemma":[0.99502236,0.0023144833,0.00061493885,0.00018373026,0.000025636436,0.00066581316,0.00019286024,0.000033284377,0.0009468817],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978081,0.0000613263,0.00040143402,0.0006960883,0.0004225619,0.0006105037],"domain_scores_gemma":[0.9989887,0.00020248989,0.00015376846,0.00028273632,0.00011496704,0.00025734174],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011701729,0.0003354774,0.00045929305,0.0001540134,0.00024396642,0.000075081465,0.000121757876,0.000123717,0.000009845111],"category_scores_gemma":[0.000014986891,0.00026492495,0.00010550985,0.00035307015,0.00010780495,0.00029664105,0.00008836985,0.00021476195,0.00004309737],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021251177,0.00041699357,0.03681748,0.0025226169,0.00080377224,0.000320039,0.02962152,0.000034805467,0.07061159,0.00035689355,0.0021356365,0.85423356],"study_design_scores_gemma":[0.03821282,0.03837546,0.28779384,0.010240332,0.0053488673,0.00035186,0.03970675,0.017727545,0.5425675,0.010873452,0.003994014,0.004807542],"about_ca_topic_score_codex":0.00006445619,"about_ca_topic_score_gemma":0.000011280924,"teacher_disagreement_score":0.849426,"about_ca_system_score_codex":0.00016651365,"about_ca_system_score_gemma":0.0002271805,"threshold_uncertainty_score":0.9999803},"labels":[],"label_agreement":null},{"id":"W4388447055","doi":"10.1038/s41375-023-02041-5","title":"PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia","year":2023,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Juravinski Cancer Centre","funders":"Else Kröner-Fresenius-Stiftung; Deutsche Forschungsgemeinschaft; Dr. Mildred Scheel Stiftung für Krebsforschung; European Commission","keywords":"Myeloid leukemia; Downregulation and upregulation; Biology; Cancer research; Gene knockdown; Cell biology; Biochemistry; Apoptosis","score_opus":0.01220320127860157,"score_gpt":0.27920573329759335,"score_spread":0.26700253201899177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388447055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98827356,0.0027825227,0.00002892882,0.0021901922,0.00015042786,0.00091945345,0.00014787936,0.00018618933,0.005320862],"genre_scores_gemma":[0.9709765,0.0026634156,0.0020632332,0.0010055489,0.00025437327,0.00013342738,0.0001054681,0.00013116086,0.022666888],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9960798,0.00017468847,0.000785368,0.0009284555,0.00092870876,0.0011029751],"domain_scores_gemma":[0.99785525,0.0003198795,0.0001879594,0.00092849956,0.00026810306,0.0004403224],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008478843,0.00046204042,0.0011166038,0.0008443507,0.00012271723,0.000043545366,0.00038156653,0.00032645767,0.00014487516],"category_scores_gemma":[0.00027266878,0.0004301322,0.00020239773,0.002170996,0.000417172,0.00028441477,0.0003859928,0.00097557256,0.0003164012],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008521618,0.0003232611,0.08040233,0.0029600086,0.0038413652,0.0067283623,0.053105306,0.00031767087,0.5935273,0.013021058,0.2142922,0.022959488],"study_design_scores_gemma":[0.016091535,0.00026047076,0.68288255,0.0015557973,0.0007704792,0.00020188627,0.0015775026,0.010647777,0.24864922,0.0030407463,0.032985676,0.0013363477],"about_ca_topic_score_codex":0.00097260386,"about_ca_topic_score_gemma":0.00025621723,"teacher_disagreement_score":0.60248023,"about_ca_system_score_codex":0.0022799098,"about_ca_system_score_gemma":0.0019122651,"threshold_uncertainty_score":0.99981505},"labels":[],"label_agreement":null},{"id":"W4388519824","doi":"10.1101/2023.11.08.23298270","title":"Cost-effective and scalable clonal hematopoiesis assay provides insight into clonal dynamics","year":2023,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; Sierra Oncology; Taiho Pharmaceutical; National Institutes of Health; Vanderbilt-Ingram Cancer Center; Vanderbilt University; Bristol-Myers Squibb; Vanderbilt University Medical Center; Alexander and Margaret Stewart Trust","keywords":"Biology; DNA sequencing; Mutation; Mutation rate; Myeloid; Genetics; Deep sequencing; Gene; Computational biology; Genome; Cancer research","score_opus":0.04003012218633778,"score_gpt":0.33164245627504124,"score_spread":0.29161233408870346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388519824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9687837,0.0014611061,0.0036037106,0.011993335,0.00097490195,0.008491012,0.00025068264,0.00064217055,0.0037994236],"genre_scores_gemma":[0.9599132,0.0014211651,0.010791747,0.00090307195,0.0013822125,0.00627282,0.0021355716,0.0004986518,0.016681546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99552846,0.00044457318,0.0006412447,0.0013801308,0.0011986698,0.000806944],"domain_scores_gemma":[0.99629563,0.0013391663,0.00023572681,0.0010250517,0.0005267296,0.00057771936],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0020647226,0.00065668265,0.0012328785,0.000648513,0.00023107414,0.00016296515,0.00047848318,0.0008638992,0.00018355435],"category_scores_gemma":[0.0022759929,0.00056653755,0.00027441647,0.0005557862,0.00060181867,0.00012621067,0.0024529672,0.0027114698,0.00055417774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002254366,0.00082538236,0.8544278,0.015123944,0.003354373,0.0041197324,0.0056239846,0.00019715722,0.0057104034,0.0043789395,0.033743758,0.07024014],"study_design_scores_gemma":[0.010374181,0.0015743439,0.6302446,0.0065437937,0.0017978398,0.0012809742,0.0014148034,0.2091269,0.018288294,0.02599199,0.0896649,0.00369737],"about_ca_topic_score_codex":0.00081095734,"about_ca_topic_score_gemma":0.00053625484,"teacher_disagreement_score":0.2241832,"about_ca_system_score_codex":0.0019772118,"about_ca_system_score_gemma":0.0013614577,"threshold_uncertainty_score":0.9996786},"labels":[],"label_agreement":null},{"id":"W4388537425","doi":"10.3324/haematol.2023.283437","title":"Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase","year":2023,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Celgene","keywords":"Azacitidine; Myeloid leukemia; Myeloid; Cancer research; Stem cell; Myeloperoxidase; CD34; Leukemia; Pharmacology; Medicine; Immunology; Biology; DNA methylation; Cell biology; Biochemistry; Gene expression","score_opus":0.04790925169331383,"score_gpt":0.30722279638420724,"score_spread":0.2593135446908934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388537425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99779594,0.00004571743,0.00039934664,0.0004775482,0.000058457088,0.00071617897,0.00003422928,0.00008029988,0.00039230593],"genre_scores_gemma":[0.99845773,0.00014803147,0.00085650553,0.000057796715,0.000026559503,0.00005125079,0.00005503045,0.000021403332,0.00032569314],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99810106,0.00012352137,0.0006594684,0.00030109353,0.0005362682,0.00027856682],"domain_scores_gemma":[0.9984611,0.0003180357,0.0003422883,0.00043141752,0.00036368906,0.00008346273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002646343,0.000177421,0.00075198093,0.00030552197,0.000038892595,0.0000052515998,0.00020436957,0.00019203965,0.0001353793],"category_scores_gemma":[0.00025526207,0.00013220792,0.00011753902,0.0010042985,0.00013389533,0.0001257782,0.00014596975,0.00018291801,0.000034829507],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005367621,0.00020145881,0.001693412,0.0010407034,0.000088657434,0.000026060561,0.0012766141,0.000047721736,0.9907004,0.00048557494,0.0011292242,0.0027734127],"study_design_scores_gemma":[0.001166818,0.0007411885,0.04358793,0.00047743955,0.00004093226,0.000015989095,0.0013196061,0.0001122625,0.9522112,0.00019212993,0.00003323115,0.000101263315],"about_ca_topic_score_codex":0.00005679241,"about_ca_topic_score_gemma":0.0000022437912,"teacher_disagreement_score":0.04189452,"about_ca_system_score_codex":0.00010453206,"about_ca_system_score_gemma":0.00018080155,"threshold_uncertainty_score":0.53912824},"labels":[],"label_agreement":null},{"id":"W4388608383","doi":"10.1093/eurheartj/ehad670","title":"Clonal haematopoiesis of indeterminate potential predicts incident cardiac arrhythmias","year":2023,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Japan Society for the Promotion of Science; National Institutes of Health; Massachusetts General Hospital; Korea Health Industry Development Institute; Ludwig Institute for Cancer Research; John S. and James L. Knight Foundation; Fondation Leducq; European Commission; American College of Cardiology Foundation; Leukemia and Lymphoma Society; McCormick Foundation; Belgian American Educational Foundation; American Heart Association","keywords":"Medicine; Internal medicine; Cardiology; Hazard ratio; Heart failure; Atrial fibrillation; Supraventricular arrhythmia; Coronary artery disease; Ejection fraction; Proportional hazards model; Confidence interval","score_opus":0.03787285856698502,"score_gpt":0.3183264567342443,"score_spread":0.2804535981672593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388608383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918278,0.00023972387,0.000085864296,0.0024333263,0.00066991046,0.00023823394,0.00002419212,0.00010221484,0.0043787695],"genre_scores_gemma":[0.9931656,0.00039139044,0.00067171647,0.00024736358,0.0020127676,0.0000028156287,0.000017818531,0.00008224833,0.003408256],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9968912,0.00060688495,0.0005705247,0.00025280073,0.0011069805,0.0005716301],"domain_scores_gemma":[0.9985551,0.00010636759,0.00017780952,0.0003716499,0.00028989234,0.0004991455],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024695361,0.0001884761,0.0004928899,0.0005258318,0.00019951393,0.00005995367,0.00021090501,0.000065171844,0.00030959057],"category_scores_gemma":[0.00044456538,0.00015936329,0.00036953104,0.00052118575,0.0001699261,0.00014829347,0.00031017428,0.00096145994,0.0010524568],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015400928,0.0003126206,0.18607654,0.0006237029,0.0010811639,0.058607608,0.0029405477,0.00040294314,0.11838284,0.00008673209,0.6042987,0.025646511],"study_design_scores_gemma":[0.0021872872,0.0007951961,0.9318388,0.00040586042,0.00013341133,0.0137609085,0.00036298722,0.0007246137,0.006915324,0.000055055963,0.04259771,0.00022281175],"about_ca_topic_score_codex":0.000007605136,"about_ca_topic_score_gemma":3.1516407e-7,"teacher_disagreement_score":0.7457623,"about_ca_system_score_codex":0.00017533815,"about_ca_system_score_gemma":0.00043162133,"threshold_uncertainty_score":0.99972534},"labels":[],"label_agreement":null},{"id":"W4388734777","doi":"10.3390/cancers15225439","title":"Ring Chromosomes in Hematological Malignancies Are Associated with TP53 Gene Mutations and Characteristic Copy Number Variants","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; Canadian Institutes of Health Research; National Institutes of Health; National Human Genome Research Institute; Johns Hopkins University","keywords":"Karyotype; Biology; Cancer; Chromosome; Chromosome instability; Myeloid; Gene; Cancer research; Chromosomal translocation; Mutation; Genetics; Ring chromosome; Gene mutation","score_opus":0.03175380485967436,"score_gpt":0.3061054503729914,"score_spread":0.27435164551331703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388734777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99831355,0.00006713387,0.000018675291,0.0006166225,0.00004587664,0.0002610719,0.000047770565,0.00009929428,0.000530013],"genre_scores_gemma":[0.99855715,0.00015800678,0.000115899995,0.00017945493,0.0000398543,0.00010129778,0.000095862495,0.000021006503,0.00073146995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990258,0.00003930712,0.00015046785,0.00024090649,0.00020506249,0.00033845103],"domain_scores_gemma":[0.9994718,0.00015464192,0.00006198436,0.00012241611,0.000074145544,0.000115019386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015332698,0.00011049696,0.00029589975,0.000098071745,0.00007213711,0.00002050402,0.00005504914,0.000084034094,0.00014533981],"category_scores_gemma":[0.0003979658,0.000088269175,0.000018766752,0.00061599916,0.00015008917,0.00006193486,0.00004151048,0.00020635687,0.00006145028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020227554,0.00002853435,0.9824873,0.0001838814,0.00017470916,0.0037454988,0.0012672206,0.00012609779,0.009355965,0.00014005229,0.0019230657,0.000365381],"study_design_scores_gemma":[0.0018658619,0.000069722315,0.9926202,0.00042940726,0.000036651843,0.00015032936,0.0007387821,0.0022422378,0.0015566197,0.000051831194,0.000107647174,0.00013065034],"about_ca_topic_score_codex":0.00012339962,"about_ca_topic_score_gemma":0.00010388656,"teacher_disagreement_score":0.0101329405,"about_ca_system_score_codex":0.0012133196,"about_ca_system_score_gemma":0.0005185826,"threshold_uncertainty_score":0.35995126},"labels":[],"label_agreement":null},{"id":"W4388799904","doi":"10.14740/wjon1661","title":"Prevalence and Prognosis of Secondary Genetic Aberrations Among Patients With Core Binding Factor Acute Myeloid Leukemia: A Mitelman Database Analysis","year":2023,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Core binding factor; Neuroblastoma RAS viral oncogene homolog; Univariate analysis; Oncology; Internal medicine; Multivariate analysis; Trisomy; Myeloid leukemia; Chromosome 13; Proportional hazards model; Chromosome; Cancer; Gene; Genetics; Biology","score_opus":0.027712109074918875,"score_gpt":0.3186858665437394,"score_spread":0.29097375746882054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388799904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99832916,0.00020172121,0.00007728854,0.00041860246,0.00007799633,0.00044152598,0.00017634891,0.000017076145,0.0002603066],"genre_scores_gemma":[0.9936169,0.0007160125,0.004092401,0.00007946153,0.00008273683,0.000018554962,0.00007987624,0.000026553555,0.001287512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980023,0.00012942981,0.00070775533,0.00026229172,0.0005436602,0.00035458713],"domain_scores_gemma":[0.99782914,0.00036615596,0.000681093,0.0002668093,0.00054666214,0.0003101402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004110211,0.00017830303,0.00073599856,0.0019488006,0.00010805355,0.000016847223,0.00021333764,0.00010182129,0.00034506558],"category_scores_gemma":[0.00016630151,0.00013273889,0.00014770869,0.0023775226,0.00035252774,0.00022853208,0.00014451079,0.00074900925,0.0000079985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004992152,0.00014996008,0.9827562,0.00019145414,0.0022927662,0.0004958572,0.0005659203,0.000043938882,0.0029226893,0.0000042101265,0.002629856,0.0074479533],"study_design_scores_gemma":[0.0033371716,0.0018301468,0.9896859,0.0001884113,0.0026415687,0.000110994624,0.00013509256,0.00058824365,0.0005235983,0.0000051881602,0.00083768455,0.000116021845],"about_ca_topic_score_codex":0.000036957375,"about_ca_topic_score_gemma":0.0003459786,"teacher_disagreement_score":0.0073319315,"about_ca_system_score_codex":0.00060158054,"about_ca_system_score_gemma":0.0012299449,"threshold_uncertainty_score":0.5412935},"labels":[],"label_agreement":null},{"id":"W4388853118","doi":"10.1101/2023.11.20.567858","title":"Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"EZH2; PRC2; Epigenetics; Cancer research; Carcinogenesis; Myeloid leukemia; Leukemia; Biology; Downregulation and upregulation; Mutation; Cancer; Immunology; Genetics; Gene","score_opus":0.03456426635115951,"score_gpt":0.28226853922231604,"score_spread":0.24770427287115654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388853118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994059,0.00063492515,0.00146359,0.00046497234,0.0006999293,0.001551644,0.00025959415,0.00080446637,0.00006183755],"genre_scores_gemma":[0.98630637,0.00030791215,0.0115135,0.00008485109,0.0007479859,0.00057215773,0.0000028237755,0.0003682534,0.00009613202],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99512506,0.00026140545,0.001243372,0.0013212775,0.0010481542,0.001000743],"domain_scores_gemma":[0.9946539,0.00064547133,0.00066342653,0.0021720352,0.0013840025,0.00048120055],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013685538,0.00072653004,0.0013011596,0.0010286367,0.00025091416,0.00012400311,0.0006656256,0.00078387436,0.00009984706],"category_scores_gemma":[0.0030554647,0.0007881359,0.0003548467,0.0013281318,0.0004579883,0.0001674746,0.0010578285,0.002318114,0.00013970779],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011701653,0.00015875943,0.027284103,0.0042709163,0.000674487,0.00023747984,0.00012142107,0.001241174,0.9644743,0.00070915034,0.0007000139,0.000011173768],"study_design_scores_gemma":[0.0014399413,0.0002083129,0.22283058,0.0024964877,0.00038696424,9.735787e-8,0.000090259884,0.0035919535,0.7671912,0.000022344333,0.0008386993,0.0009031546],"about_ca_topic_score_codex":0.00073259877,"about_ca_topic_score_gemma":0.0000059220106,"teacher_disagreement_score":0.1972831,"about_ca_system_score_codex":0.0029374051,"about_ca_system_score_gemma":0.0052376785,"threshold_uncertainty_score":0.99998355},"labels":[],"label_agreement":null},{"id":"W4388853457","doi":"10.47749/t/unicamp.2020.1162036","title":"O estudo dos precursores hematopoiéticos e subtipos de monócitos nas síndromes mielodisplásicas para a construção de um novo score prognóstico","year":2020,"lang":"pt","type":"dissertation","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cytodiagnostics (Canada)","funders":"","keywords":"Immunophenotyping; Medicine; Bone marrow; CD34; Univariate analysis; Haematopoiesis; Myelodysplastic syndromes; Myeloid; Oncology; Cytogenetics; Myeloid leukemia; Internal medicine; Pathology; Immunology; Flow cytometry; Multivariate analysis; Stem cell; Biology; Chromosome","score_opus":0.03702756788267277,"score_gpt":0.3357795542707335,"score_spread":0.2987519863880608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388853457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96209663,0.004273602,0.0037509482,0.0050182813,0.0009847945,0.012068626,0.00033420493,0.00093346415,0.010539454],"genre_scores_gemma":[0.96194154,0.0013342649,0.008182661,0.0016218428,0.0010687583,0.0023506435,0.0029798197,0.00064206717,0.019878391],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9878563,0.00083436095,0.0023013237,0.002682429,0.0027234147,0.003602138],"domain_scores_gemma":[0.991417,0.0018530682,0.0009564717,0.0017693258,0.0011362479,0.0028678991],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0011252665,0.0022393716,0.0033303679,0.00097208616,0.0006491952,0.000540295,0.0017870421,0.0022914105,0.0029822134],"category_scores_gemma":[0.0047759153,0.0020481334,0.0010241445,0.0017589384,0.00094461907,0.0003798569,0.0004839061,0.0045423834,0.0023521744],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026241442,0.008549964,0.4613106,0.058636088,0.016879262,0.033324316,0.087164804,0.00009252297,0.1543841,0.023074191,0.08832814,0.04201456],"study_design_scores_gemma":[0.054309182,0.013799266,0.092892274,0.027880946,0.017940564,0.016726015,0.12721334,0.14238381,0.47833952,0.0019253946,0.0136988,0.012890871],"about_ca_topic_score_codex":0.0011241862,"about_ca_topic_score_gemma":0.0003167887,"teacher_disagreement_score":0.3684183,"about_ca_system_score_codex":0.0024486175,"about_ca_system_score_gemma":0.0128831025,"threshold_uncertainty_score":0.9990346},"labels":[],"label_agreement":null},{"id":"W4389121666","doi":"10.1182/bloodadvances.2023011219","title":"A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Ven; Azacitidine; Adverse effect; Internal medicine; Induction chemotherapy; Venetoclax; Oncology; Population; Regimen; Chemotherapy regimen; Transplantation; Surgery; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.013151635162512939,"score_gpt":0.2977100895233684,"score_spread":0.2845584543608555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389121666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783456,0.0002507435,0.00018869233,0.00096237945,0.000025721989,0.0005309496,0.000057160723,0.000044686072,0.00010509914],"genre_scores_gemma":[0.99263704,0.0010311018,0.0049111084,0.00022047806,0.00011290723,0.00012215496,0.000286793,0.000029314357,0.00064910995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894226,0.000018042929,0.00019698055,0.00025100063,0.00037538746,0.00021635032],"domain_scores_gemma":[0.99931157,0.00012151157,0.00009391288,0.00017854347,0.0001886974,0.00010578966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019271125,0.000106370535,0.0003713307,0.00035325086,0.000045638288,0.0000065972304,0.00006761888,0.000059185713,0.000050917755],"category_scores_gemma":[0.00015713183,0.00007665222,0.00006217136,0.0011834522,0.00013361577,0.000095258954,0.000023646418,0.00009444895,0.0000013633208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005736104,0.0004901334,0.7515914,0.0008564326,0.0057690395,0.000026577085,0.00071573653,0.00019645944,0.00636559,0.00008009785,0.0023053405,0.22586708],"study_design_scores_gemma":[0.013289206,0.0030161066,0.9489519,0.00017513889,0.0022015583,0.0000064073347,0.00023576712,0.0030522125,0.008380972,0.00013319845,0.0203316,0.00022593461],"about_ca_topic_score_codex":0.000018047114,"about_ca_topic_score_gemma":0.000025623589,"teacher_disagreement_score":0.22564115,"about_ca_system_score_codex":0.00004755332,"about_ca_system_score_gemma":0.00012178632,"threshold_uncertainty_score":0.31257868},"labels":[],"label_agreement":null},{"id":"W4389164112","doi":"10.1101/2023.11.30.23299001","title":"CHIP is associated with cardiovascular disease in the UK Biobank","year":2023,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Biobank; Disease; Confounding; Cohort; Biology; Anticipation (artificial intelligence); Genetics; Medicine; Internal medicine","score_opus":0.05242147860471145,"score_gpt":0.299508185544158,"score_spread":0.24708670693944654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389164112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98811185,0.0019543928,0.00005167123,0.006801904,0.00020821847,0.0016464456,0.00015736876,0.00017417688,0.000893947],"genre_scores_gemma":[0.9950202,0.00063600997,0.000047911624,0.00086259533,0.00033744425,0.0004272761,0.0005550178,0.000113964656,0.001999592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958354,0.00049176585,0.0003449299,0.0008595834,0.0018350016,0.00063329824],"domain_scores_gemma":[0.99675703,0.00027622806,0.00009700514,0.002414638,0.0001805194,0.00027460593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00264947,0.0003865402,0.00081320794,0.00034864317,0.00008211053,0.00006799732,0.00074505917,0.00032009167,0.00014811261],"category_scores_gemma":[0.0014398111,0.00023372506,0.0005689033,0.0008991795,0.00019835417,0.0000226975,0.00056817994,0.0021265899,0.00044517367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037715634,0.00019792179,0.9645796,0.000528485,0.003715107,0.009817955,0.0016349044,0.0006041152,0.00003775642,0.000031111565,0.01774615,0.00072976475],"study_design_scores_gemma":[0.0019989035,0.00008146998,0.9875798,0.0010110545,0.0009931654,0.000018735787,0.00011716441,0.001259867,0.00007551372,0.00035774722,0.006159104,0.00034742415],"about_ca_topic_score_codex":0.0011254904,"about_ca_topic_score_gemma":0.000105384366,"teacher_disagreement_score":0.023000278,"about_ca_system_score_codex":0.0005438047,"about_ca_system_score_gemma":0.0010908693,"threshold_uncertainty_score":0.9531032},"labels":[],"label_agreement":null},{"id":"W4389218846","doi":"10.1182/blood-2023-187455","title":"The Challenge of Treating Relapsed Myeloid Leukemia in Children with Down Syndrome - a Targeted Analysis Using Patient-Derived Xenograft Models","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Decitabine; Cytarabine; Context (archaeology); Myeloid leukemia; Venetoclax; Oncology; Down syndrome; Internal medicine; Transplantation; Leukemia; Hematopoietic stem cell transplantation; Myelopoiesis; Myeloid; GATA1; Immunology; Stem cell; Haematopoiesis; Erythropoiesis; Biology; Anemia; DNA methylation","score_opus":0.01876873671367195,"score_gpt":0.2578453370201008,"score_spread":0.23907660030642885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389218846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99786854,0.0005058983,0.000069200716,0.00018181132,0.000009995476,0.00083461596,0.000030482413,0.00011589256,0.00038359046],"genre_scores_gemma":[0.99816597,0.00029552073,0.0011763325,0.0000193681,0.000025114456,0.000069650414,0.000127365,0.000057166577,0.00006348867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974651,0.00016496138,0.00055401906,0.00046944033,0.00068936445,0.0006571279],"domain_scores_gemma":[0.9985749,0.00018475024,0.00021954041,0.00071510224,0.0001501725,0.00015555025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048769984,0.00025589025,0.00067000766,0.00082606054,0.00019251657,0.000026922875,0.000245066,0.00014985316,0.000023127272],"category_scores_gemma":[0.00013463106,0.00016911187,0.0001964125,0.0037913853,0.0001724561,0.00013135897,0.00015558857,0.0004720696,0.000008710111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022353975,0.0017856807,0.69188833,0.00043060264,0.030436883,0.00228637,0.020612484,0.097407706,0.1405362,0.00025646517,0.0001185402,0.012005339],"study_design_scores_gemma":[0.031370755,0.003588823,0.542562,0.00074509974,0.0075869393,0.0007006777,0.004521631,0.38120934,0.026180504,0.00044231053,0.000018744086,0.0010731276],"about_ca_topic_score_codex":0.0013180486,"about_ca_topic_score_gemma":0.00019145312,"teacher_disagreement_score":0.28380165,"about_ca_system_score_codex":0.00038567584,"about_ca_system_score_gemma":0.00057284517,"threshold_uncertainty_score":0.6896182},"labels":[],"label_agreement":null},{"id":"W4389219628","doi":"10.1182/blood-2023-185220","title":"Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Sierra Oncology; Daiichi Sankyo Europe; Gilead Sciences; Servier; Juno Therapeutics; Astellas Pharma; Syndax Pharmaceuticals; Incyte; CTI Biopharma; bluebird bio; CareDx; Agios Pharmaceuticals; Sarepta Therapeutics; Vertex Pharmaceuticals; Swedish Orphan Biovitrum; Omeros Corporation; Celgene; BioCryst; Astex Pharmaceuticals; Alexion Pharmaceuticals; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Amgen","keywords":"Decitabine; Medicine; International Prognostic Scoring System; Internal medicine; Hypomethylating agent; Myelodysplastic syndromes; Azacitidine; Oncology; Bone marrow","score_opus":0.018569506488095272,"score_gpt":0.26526402742254757,"score_spread":0.2466945209344523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389219628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577665,0.0005534951,0.00011546372,0.0008140563,0.00032929034,0.0016450214,0.0003726159,0.00031801302,0.00007537612],"genre_scores_gemma":[0.9984235,0.00009041706,0.00027222073,0.00010142542,0.000036918515,0.00030964706,0.00014309627,0.00009554553,0.00052723987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963632,0.00047060163,0.00062736747,0.00068353163,0.0011117257,0.0007435561],"domain_scores_gemma":[0.998015,0.0009318924,0.00015105354,0.00041283504,0.00013570461,0.00035354972],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013150696,0.00035591147,0.0005964848,0.00093788805,0.00013679385,0.000073595256,0.0003857794,0.00015283636,0.0000127334015],"category_scores_gemma":[0.00058049394,0.0003098584,0.00034909826,0.00096417725,0.00003038501,0.00008160388,0.00013222385,0.00047601,0.00008529666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008980256,0.0003802066,0.6800588,0.0002705698,0.0010247363,0.0054556895,0.0019353124,0.0006126346,0.3087941,0.0000012477038,0.000035873047,0.0005328006],"study_design_scores_gemma":[0.016530767,0.0021532956,0.9369318,0.0025023445,0.0007484543,0.00029689632,0.0067674867,0.0028989424,0.030411681,0.0000011584999,0.00011365996,0.0006435231],"about_ca_topic_score_codex":0.000087711356,"about_ca_topic_score_gemma":0.000008129213,"teacher_disagreement_score":0.27838245,"about_ca_system_score_codex":0.0005500706,"about_ca_system_score_gemma":0.0002596348,"threshold_uncertainty_score":0.9999353},"labels":[],"label_agreement":null},{"id":"W4389220199","doi":"10.1182/blood-2023-173975","title":"Interactions between Iron Overload, Oxidative Stress, and Somatic Mutations in Myelodysplastic Syndromes; Evidence from the Literature","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Oxidative stress; Myelodysplastic syndromes; Medicine; Mutation; Bone marrow; Stem cell; Cancer research; Internal medicine; Immunology; Biology; Genetics","score_opus":0.03212480228918037,"score_gpt":0.32060163983272344,"score_spread":0.2884768375435431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389220199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99456644,0.00086818635,0.000028941513,0.003602313,0.000051160685,0.0004657395,0.00023232555,0.000073870826,0.00011100571],"genre_scores_gemma":[0.9981298,0.0003945022,0.00034446848,0.0000596074,0.00016820691,0.000082478444,0.00032440812,0.00002095913,0.00047557594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987864,0.00014091967,0.00023376143,0.0002881233,0.00029001443,0.0002607786],"domain_scores_gemma":[0.9962588,0.0032022404,0.00005748895,0.00031671728,0.000059212034,0.00010556738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017961592,0.00014020765,0.00022795447,0.00019511512,0.00012326252,0.00008571745,0.00014526104,0.00007739864,0.00009061409],"category_scores_gemma":[0.0012464115,0.00009859142,0.000040601048,0.0008356054,0.000110591754,0.00026414104,0.0001325309,0.00060620473,0.00019893223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007479052,0.00025740507,0.9618533,0.00042279542,0.00033877356,0.0008036083,0.017556954,0.00004697352,0.014766699,0.000050914347,0.0014722935,0.002355495],"study_design_scores_gemma":[0.0016847546,0.00012192414,0.9898785,0.0033419477,0.00028322218,0.00006112885,0.002059516,0.00056141726,0.0014196095,0.00039101386,0.00007931384,0.00011767518],"about_ca_topic_score_codex":0.00024970956,"about_ca_topic_score_gemma":0.00019493265,"teacher_disagreement_score":0.028025178,"about_ca_system_score_codex":0.00008705675,"about_ca_system_score_gemma":0.000156978,"threshold_uncertainty_score":0.40204415},"labels":[],"label_agreement":null},{"id":"W4389220360","doi":"10.1182/blood-2023-180207","title":"Functional Deconvolution of the Leukemia Stem Cell Pool Uncovers Co-Existing Alternative Stem Cell Driven Hierarchies","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Stem cell; Biology; Leukemia; Computational biology; Myeloid leukemia; Cancer research; Genetics","score_opus":0.03628485470383753,"score_gpt":0.278726753032844,"score_spread":0.24244189832900648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389220360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820542,0.00011553547,0.00013453877,0.00022937956,0.00024709932,0.0005366326,0.000086555025,0.000106482184,0.016489623],"genre_scores_gemma":[0.9806089,0.00007190377,0.00012554458,0.00009682927,0.0002842302,0.00003669044,0.000060181188,0.000039470375,0.018676246],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99791867,0.00016452621,0.00035646016,0.00035195574,0.00078337296,0.00042501625],"domain_scores_gemma":[0.99862576,0.00042619224,0.00020565976,0.00041784975,0.00019151442,0.00013305509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003833599,0.00019106841,0.00029532175,0.00022738878,0.0001965165,0.000019526788,0.00026535537,0.000112646296,0.00006151977],"category_scores_gemma":[0.000038745715,0.00014432582,0.00017710819,0.0006277199,0.00020868087,0.0000949236,0.00020966525,0.00050171744,0.00026611146],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012602108,0.0010929467,0.35680193,0.0022681158,0.0013014806,0.00044450548,0.008089771,0.010176026,0.52818173,0.0013908586,0.08154311,0.0074492814],"study_design_scores_gemma":[0.011926276,0.0005860096,0.106114075,0.00029926293,0.0003919944,0.00008131243,0.004638713,0.007350725,0.86381793,0.00017975319,0.004252626,0.00036132493],"about_ca_topic_score_codex":0.00015366325,"about_ca_topic_score_gemma":0.000012655136,"teacher_disagreement_score":0.33563617,"about_ca_system_score_codex":0.00058517954,"about_ca_system_score_gemma":0.000980027,"threshold_uncertainty_score":0.5885436},"labels":[],"label_agreement":null},{"id":"W4389220704","doi":"10.1182/blood-2023-185951","title":"Real World Experience of FLT3-Inhibitor Post-Transplant Maintenance with Sorafenib Demonstrating Superior Overall- and Relapse Free Survival Following Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD Mutated Acute Myeloid Leukemia","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Sorafenib; Medicine; Oncology; Internal medicine; Tolerability; Transplantation; Clinical endpoint; Maintenance therapy; Hematopoietic stem cell transplantation; Fms-Like Tyrosine Kinase 3; Clinical trial; Adverse effect; Chemotherapy; Hepatocellular carcinoma; Biology","score_opus":0.011523159327589955,"score_gpt":0.2510350328995918,"score_spread":0.23951187357200182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389220704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976728,0.00016523042,0.000077910314,0.00023744792,0.00011803178,0.0009533031,0.00014559885,0.00018276523,0.00044690067],"genre_scores_gemma":[0.9966835,0.0006836515,0.0016095673,0.0000397614,0.00005982312,0.00011951304,0.00017762961,0.00009296997,0.0005335975],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965746,0.00017266421,0.0007988517,0.0007452215,0.0008434917,0.00086519244],"domain_scores_gemma":[0.99858224,0.00032069473,0.00015886499,0.0005212322,0.00013362932,0.00028331327],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005755217,0.00042229376,0.00081042247,0.00047264813,0.00014375076,0.00004620031,0.000305183,0.00019343047,0.00001511294],"category_scores_gemma":[0.000031718304,0.00036102635,0.00014674138,0.001118028,0.00022233438,0.0002901086,0.000073085306,0.0005815302,0.000011153206],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017207738,0.00017758133,0.19332825,0.00082810054,0.00026766447,0.0078685675,0.014418148,0.000066827364,0.781037,0.00006395679,0.000021436397,0.00020172964],"study_design_scores_gemma":[0.03396978,0.0012107282,0.23616526,0.0031099473,0.0012609028,0.0012475142,0.00941625,0.0010892245,0.711459,0.000040628845,0.000011400562,0.0010194073],"about_ca_topic_score_codex":0.0011126179,"about_ca_topic_score_gemma":0.0015676288,"teacher_disagreement_score":0.069578,"about_ca_system_score_codex":0.00024046199,"about_ca_system_score_gemma":0.00075253745,"threshold_uncertainty_score":0.9998842},"labels":[],"label_agreement":null},{"id":"W4389220823","doi":"10.1182/blood-2023-187244","title":"DNMT3A R882H Exhibits Greater Inflammatory Potential Than R882C in Primary Hematopoietic Stem and Progenitor Cell Knock-in Model and Population Data","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Biology; Transcriptome; Progenitor cell; Haematopoiesis; Population; Gene expression profiling; Stem cell; Genetics; Molecular biology; Gene; Gene expression","score_opus":0.029034376282497443,"score_gpt":0.26543246076238547,"score_spread":0.23639808447988803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389220823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981938,0.0003961933,0.0000088532015,0.0002817285,0.00002866551,0.000789464,0.00002739287,0.00007613089,0.00019779257],"genre_scores_gemma":[0.99843216,0.00012064038,0.00033512097,0.000048915328,0.00009944623,0.000045609137,0.00022244474,0.000045005385,0.00065064133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983091,0.00007412793,0.00033939927,0.00052735704,0.00035560853,0.00039441237],"domain_scores_gemma":[0.99916637,0.00003602758,0.000053385018,0.0005637532,0.000032189924,0.00014830408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045086938,0.00017616752,0.0003073952,0.00035798823,0.00004542612,0.0000357468,0.0001616903,0.00015487189,0.0000050255276],"category_scores_gemma":[0.000023713945,0.00016106605,0.00002250209,0.00030781268,0.000052191448,0.00024980208,0.0005440387,0.0002923946,0.000025209052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027144878,0.0002670875,0.9497325,0.0012697148,0.000048595553,0.0011990399,0.0009365435,0.00008780941,0.043782543,0.000015169129,0.0004907708,0.0018988214],"study_design_scores_gemma":[0.010241953,0.00013201084,0.9307286,0.0002908227,0.00013453666,0.0002467065,0.0002655673,0.050385095,0.007141242,0.00010173579,0.00002865258,0.0003030416],"about_ca_topic_score_codex":0.0001310506,"about_ca_topic_score_gemma":0.000072290415,"teacher_disagreement_score":0.050297286,"about_ca_system_score_codex":0.00008368706,"about_ca_system_score_gemma":0.00018344301,"threshold_uncertainty_score":0.6568083},"labels":[],"label_agreement":null},{"id":"W4389221849","doi":"10.1182/blood-2023-187251","title":"A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Cytarabine; Medicine; Fludarabine; Etoposide; Daunorubicin; Internal medicine; Randomization; Minimal residual disease; Mitoxantrone; Population; Oncology; Transplantation; Induction chemotherapy; Randomized controlled trial; Leukemia; Gastroenterology; Surgery; Chemotherapy; Cyclophosphamide","score_opus":0.037544463563562065,"score_gpt":0.33353726627993924,"score_spread":0.2959928027163772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389221849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94876176,0.00016736977,0.0000499143,0.00055004715,0.000027050595,0.050336204,0.000043713477,0.000048021702,0.000015913456],"genre_scores_gemma":[0.98565596,0.00020632384,0.0016010585,0.000018998322,0.00012570297,0.012133626,0.0001499064,0.000055852463,0.00005257626],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99592113,0.000951066,0.0013149384,0.0006127926,0.00069764786,0.000502421],"domain_scores_gemma":[0.9973221,0.000994347,0.000682887,0.0006268901,0.00022390764,0.00014986287],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015732198,0.00044784602,0.0015977358,0.0010415725,0.000110653215,0.00003447488,0.00016492687,0.00022187278,0.000025568723],"category_scores_gemma":[0.00035033785,0.0002700342,0.000096120566,0.0021499237,0.00039795128,0.00020619559,0.00005197142,0.00047593168,0.0000027970493],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42624,0.0126156565,0.3511795,0.0020557595,0.0005444267,0.00028936064,0.0048472723,0.0025046067,0.19677465,0.00008462051,0.00007561973,0.0027885067],"study_design_scores_gemma":[0.61101884,0.009399137,0.25784212,0.00041768255,0.0013717578,0.000070968046,0.0009230332,0.030920336,0.08759738,0.000068712216,0.000008266143,0.0003617977],"about_ca_topic_score_codex":0.003599449,"about_ca_topic_score_gemma":0.0011722553,"teacher_disagreement_score":0.18477881,"about_ca_system_score_codex":0.00022320868,"about_ca_system_score_gemma":0.00070909364,"threshold_uncertainty_score":0.9999752},"labels":[],"label_agreement":null},{"id":"W4389222046","doi":"10.1182/blood-2023-187284","title":"Functional Ex-Vivo Testing Combined with Machine Learning Predicts Clinical Response to Azacitidine+Venetoclax in AML","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Venetoclax; Azacitidine; Medicine; Ven; Oncology; Ex vivo; Internal medicine; Clinical trial; Leukemia; In vivo; Chronic lymphocytic leukemia; Biology; Computer science","score_opus":0.06249343809896792,"score_gpt":0.32836755752295027,"score_spread":0.26587411942398237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389222046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448764,0.000031478776,0.00006721383,0.0027474996,0.00008002069,0.000728561,0.000016931657,0.00039100696,0.0014496654],"genre_scores_gemma":[0.98875993,0.000014555184,0.0022695302,0.00042150661,0.00035219282,0.000103230035,0.000088733024,0.00007353397,0.007916786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972353,0.00042377796,0.0005059078,0.00053791935,0.0006894827,0.00060764345],"domain_scores_gemma":[0.99680966,0.0021384638,0.0000765476,0.00036150575,0.00019894534,0.0004148488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026673824,0.00020945244,0.00043510113,0.0005216196,0.00011324234,0.000027844586,0.00015291882,0.00015110726,0.00016463349],"category_scores_gemma":[0.0073887683,0.00017428675,0.000067406436,0.0018740303,0.00010252716,0.00006807495,0.0002099941,0.0010598167,0.0005047762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01749228,0.00043266517,0.94599706,0.00008882925,0.00016522082,0.0025001487,0.00021157839,0.0015812276,0.024803532,0.000022802034,0.0053683952,0.0013362854],"study_design_scores_gemma":[0.02106886,0.0071942643,0.949653,0.000415782,0.00010167999,0.00032557076,0.00015445446,0.013868479,0.0021386293,0.000023487519,0.004795455,0.00026030175],"about_ca_topic_score_codex":0.00012249766,"about_ca_topic_score_gemma":0.000062583866,"teacher_disagreement_score":0.022664903,"about_ca_system_score_codex":0.00022675582,"about_ca_system_score_gemma":0.0010756656,"threshold_uncertainty_score":0.88455796},"labels":[],"label_agreement":null},{"id":"W4389222208","doi":"10.1182/blood-2023-174891","title":"The XPO1-FOXC1-HOX Functional Axis Opens New Therapeutic Avenues to Treat DEK-NUP214 AML Patients","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer; Centre Hospitalier Universitaire Sainte-Justine","funders":"Gilead Sciences; Janssen Pharmaceuticals; AstraZeneca; Astellas Pharma; Bristol-Myers Squibb; Amgen","keywords":"Biology; Transcriptome; Karyotype; Fusion protein; Myeloid leukemia; Cancer research; Bioinformatics; Internal medicine; Computational biology; Genetics; Gene; Chromosome; Medicine; Gene expression","score_opus":0.03928453400091457,"score_gpt":0.30050463724737037,"score_spread":0.2612201032464558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389222208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868298,0.00036538855,0.00003075686,0.007060641,0.00026834675,0.0007985464,0.000029347599,0.00017044261,0.004446711],"genre_scores_gemma":[0.9429842,0.00026424383,0.00011940988,0.0016598598,0.0008889358,0.000127129,0.00014548858,0.00007861862,0.053732075],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.998175,0.00007526342,0.00022301752,0.00033692457,0.0006486384,0.0005411019],"domain_scores_gemma":[0.99869245,0.00027792776,0.000039740822,0.0005276993,0.00014582451,0.00031638393],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026407806,0.00017679267,0.00021526794,0.00014252377,0.00028446657,0.00006494142,0.00025073142,0.00009040046,0.0002830965],"category_scores_gemma":[0.0002736528,0.00011773781,0.000101311634,0.0006558538,0.00006580474,0.000060667448,0.00017691564,0.0002793642,0.0027614743],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015325844,0.0011631877,0.22911476,0.000110689485,0.0009038934,0.00026529617,0.0024058665,0.000028345868,0.020045917,0.0006674764,0.5260642,0.21769778],"study_design_scores_gemma":[0.0077041388,0.0009745522,0.8051875,0.00006813,0.00023926164,0.000035727076,0.00022996355,0.000046152327,0.0074236435,0.0004269442,0.17743106,0.00023289149],"about_ca_topic_score_codex":0.00014374986,"about_ca_topic_score_gemma":0.000047083333,"teacher_disagreement_score":0.57607275,"about_ca_system_score_codex":0.00014097481,"about_ca_system_score_gemma":0.00038388435,"threshold_uncertainty_score":0.998015},"labels":[],"label_agreement":null},{"id":"W4389228984","doi":"10.1182/blood-2023-179664","title":"Phase 3b Study Design for a Comparison of Treatment Preference between Oral Decitabine/Cedazuridine and Azacitidine in Adult Patients with IPSS-R Intermediate Myelodysplastic Syndrome, IPSS Intermediate-2 or High-Risk Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukaemia, or Chronic Myelomonocytic Leukaemia","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Decitabine; Medicine; International Prognostic Scoring System; Azacitidine; Myelodysplastic syndromes; Internal medicine; Hypomethylating agent; Discontinuation; Chronic myelomonocytic leukemia; Oncology; Population; Dysplasia; Bone marrow; Gastroenterology","score_opus":0.04386852271083277,"score_gpt":0.32260504297767184,"score_spread":0.2787365202668391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389228984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98622906,0.00009062028,0.00153014,0.0000483778,0.0002557411,0.009797692,0.001700984,0.00034033472,0.0000070247424],"genre_scores_gemma":[0.99299705,0.0004752829,0.0016705184,0.000019051258,0.00017537591,0.0025735742,0.0013698224,0.00032595717,0.00039335445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914641,0.0005490063,0.0024420475,0.0020416505,0.0013369762,0.0021662202],"domain_scores_gemma":[0.99216384,0.0037081009,0.0009980928,0.001265631,0.000842083,0.0010222698],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00085172843,0.0015280634,0.003582843,0.0019542251,0.00030903373,0.00013467575,0.0008650272,0.00049336697,0.00010143497],"category_scores_gemma":[0.0018987223,0.0010639256,0.00021866242,0.0030596415,0.0007143371,0.000552777,0.00059385155,0.0011707944,0.000099534394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06436581,0.022682576,0.8497062,0.0040329075,0.009942511,0.0072337063,0.0047714803,0.0011065392,0.0022171098,0.0000116630545,0.00052167015,0.033407837],"study_design_scores_gemma":[0.2043681,0.16623615,0.5979362,0.0032285852,0.006814955,0.0004159931,0.0012831929,0.011901524,0.0063153543,0.000025946489,0.000021393436,0.0014525868],"about_ca_topic_score_codex":0.00044163846,"about_ca_topic_score_gemma":0.0014152867,"teacher_disagreement_score":0.25176996,"about_ca_system_score_codex":0.0025998093,"about_ca_system_score_gemma":0.0032798133,"threshold_uncertainty_score":0.9997468},"labels":[],"label_agreement":null},{"id":"W4389229081","doi":"10.1182/blood-2023-181118","title":"Outcomes of Allogeneic HSCT in Elderly Patients (70 years old and above) -a Canadian Experience","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cohort; Internal medicine; Transplantation; Incidence (geometry); Retrospective cohort study; Surgery","score_opus":0.017045128320627222,"score_gpt":0.2864355119830567,"score_spread":0.2693903836624295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99856156,0.00006135202,1.6381904e-7,0.0003313034,0.00003606468,0.0002540436,0.000020604015,0.0000180786,0.0007168553],"genre_scores_gemma":[0.9985707,0.00007775921,0.00008614772,0.00019946549,0.000014231643,0.00002306015,0.000017950288,0.000015157775,0.0009955702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990871,0.00001998667,0.00016517249,0.00018210753,0.00022848982,0.00031713027],"domain_scores_gemma":[0.9994642,0.000047952282,0.000023934317,0.00021117734,0.000041285315,0.00021143595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011775369,0.00007722179,0.00019883353,0.0002950426,0.000019048477,0.000006351334,0.00009711028,0.000069177586,0.00004972016],"category_scores_gemma":[0.0001916603,0.00007004428,0.000026516302,0.00035184258,0.0000640794,0.000037583668,0.000046840647,0.000120830904,0.000047552454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000965135,0.00006514991,0.9948003,0.000021328786,0.000025814192,0.00014308201,0.0013051111,3.5440777e-7,0.00094085134,0.000024564913,0.0002728382,0.0023909477],"study_design_scores_gemma":[0.0025625767,0.00016262212,0.99483657,0.000026748074,0.000013724219,0.0000042285697,0.00028168177,0.000013146586,0.0012969823,0.000012544354,0.0007257901,0.000063390275],"about_ca_topic_score_codex":0.04224694,"about_ca_topic_score_gemma":0.019468192,"teacher_disagreement_score":0.02277875,"about_ca_system_score_codex":0.00007071636,"about_ca_system_score_gemma":0.00024095774,"threshold_uncertainty_score":0.99842393},"labels":[],"label_agreement":null},{"id":"W4389229191","doi":"10.1182/blood-2023-185149","title":"Presence of Recurrent Somatic Mutations in Mesenchymal Stromal Cell Fractions Isolated from Acute Myeloid Leukemia As an Evidence of Clonality","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Trillium Health Centre; University Health Network","funders":"","keywords":"Mesenchymal stem cell; Myeloid leukemia; Bone marrow; Cancer research; CD90; CD33; Myeloid; Biology; Leukemia; Stem cell; Immunology; Medicine; Pathology; CD34; Genetics","score_opus":0.036917236807214204,"score_gpt":0.3468444441332332,"score_spread":0.30992720732601897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99790716,0.0002728782,0.00009356857,0.00039428668,0.000081810525,0.00067256804,0.00016220413,0.00008561907,0.00032993176],"genre_scores_gemma":[0.997179,0.00029066886,0.0018717181,0.000018904528,0.00006799596,0.0000706756,0.00021003248,0.000026515332,0.0002645469],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974578,0.00021920432,0.0007216571,0.0004373391,0.0007631616,0.00040080675],"domain_scores_gemma":[0.9975689,0.0010022627,0.00025024975,0.00069196854,0.0002642764,0.00022235334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051510026,0.00018611547,0.00048742312,0.00037574608,0.00006715837,0.000013634745,0.00033303918,0.00016596979,0.00028179155],"category_scores_gemma":[0.00086517073,0.00017948319,0.00012043495,0.0012424582,0.00019558427,0.0003496905,0.00016205206,0.00057573715,0.00011786989],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009633908,0.0020428817,0.09503782,0.0006821919,0.0004562299,0.00046094577,0.0048587075,0.00031136576,0.8933875,0.0001329261,0.00048720534,0.0011788666],"study_design_scores_gemma":[0.0077224597,0.00282027,0.6541741,0.0016169912,0.0010201094,0.00009557634,0.0028225463,0.035097238,0.29164535,0.0025500646,0.000036081332,0.00039926328],"about_ca_topic_score_codex":0.0029733665,"about_ca_topic_score_gemma":0.00020209815,"teacher_disagreement_score":0.60174215,"about_ca_system_score_codex":0.00022272175,"about_ca_system_score_gemma":0.0014915685,"threshold_uncertainty_score":0.73191124},"labels":[],"label_agreement":null},{"id":"W4389229226","doi":"10.1182/blood-2023-178635","title":"The ELEMENT-MDS Trial: A Phase 3 Randomized Study Evaluating Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Non-Transfusion-Dependent, Lower-Risk Myelodysplastic Syndromes","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Anemia; Internal medicine; Erythropoiesis; Ineffective erythropoiesis; International Prognostic Scoring System; Blood transfusion; Population; Bone marrow","score_opus":0.05504110427915776,"score_gpt":0.38968085099199185,"score_spread":0.3346397467128341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870434,0.00019438192,0.00016941415,0.0005565945,0.0011318842,0.010126861,0.000038762348,0.00025783252,0.00048087243],"genre_scores_gemma":[0.9956586,0.00082661415,0.00035001998,0.000029161096,0.00038701674,0.0014218758,0.00007650128,0.00013616687,0.0011140897],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921423,0.0020317025,0.0015109535,0.000986687,0.0020254168,0.0013029019],"domain_scores_gemma":[0.99033713,0.00771243,0.0004025107,0.0009748127,0.00026525036,0.00030787685],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0100311935,0.00055343535,0.0014470216,0.00062350143,0.00081890705,0.00018170058,0.00053002633,0.00019150444,0.00045399196],"category_scores_gemma":[0.009695173,0.00039279924,0.00042348777,0.0015037302,0.00028518733,0.00014672766,0.00040752155,0.001115629,0.00038580078],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9453296,0.0059666103,0.010347771,0.00020446032,0.0029026605,0.0029675162,0.0072283484,0.00092633197,0.0077908454,0.0000064485607,0.0006646864,0.015664693],"study_design_scores_gemma":[0.9448145,0.00830922,0.0017397539,0.00025909214,0.002050724,0.000035989015,0.00707014,0.034835707,0.00042537975,0.000033331416,0.000040479317,0.0003856535],"about_ca_topic_score_codex":0.00079461274,"about_ca_topic_score_gemma":0.00040272952,"teacher_disagreement_score":0.033909377,"about_ca_system_score_codex":0.00037141985,"about_ca_system_score_gemma":0.0006082276,"threshold_uncertainty_score":0.9998524},"labels":[],"label_agreement":null},{"id":"W4389229332","doi":"10.1182/blood-2023-180499","title":"The Co-Occurrence of bZIP in-Frame <i>CEBPA</i>-Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"CEBPA; Medicine; Internal medicine; Myeloid leukemia; Acute promyelocytic leukemia; Oncology; Mutation; Genetics; Gene; Biology","score_opus":0.015570693078170014,"score_gpt":0.2744075789829805,"score_spread":0.2588368859048105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99681926,0.00020810092,0.000008841507,0.0010098156,0.000018493427,0.0010702235,0.00015168657,0.00008785412,0.00062572263],"genre_scores_gemma":[0.9977527,0.00044623617,0.00030293848,0.00018297872,0.00002390204,0.0003359874,0.00018732836,0.000038172977,0.00072970544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975131,0.0001653199,0.000455805,0.00037710532,0.0007901281,0.0006984987],"domain_scores_gemma":[0.9986278,0.00048526636,0.00019647049,0.00031470964,0.00026072314,0.000115054194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007374092,0.00023294489,0.00046729587,0.0003591197,0.00010658707,0.000046374254,0.00026916177,0.00014679105,0.000019705802],"category_scores_gemma":[0.00026344467,0.00015178218,0.000049132443,0.0021523943,0.00031630578,0.00013655634,0.000068690686,0.00054973934,0.000029700288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013925931,0.0006306503,0.97815067,0.00037330049,0.00095511385,0.002148155,0.005995944,0.0002772404,0.004641589,0.00006729905,0.003572735,0.0017947047],"study_design_scores_gemma":[0.02298429,0.003553193,0.88152236,0.0017591764,0.0006767275,0.0004944756,0.004325085,0.0035774624,0.07981268,0.00018145154,0.0005078918,0.00060518924],"about_ca_topic_score_codex":0.00062083296,"about_ca_topic_score_gemma":0.0006160642,"teacher_disagreement_score":0.0966283,"about_ca_system_score_codex":0.0003798713,"about_ca_system_score_gemma":0.0015235897,"threshold_uncertainty_score":0.6189498},"labels":[],"label_agreement":null},{"id":"W4389229675","doi":"10.1182/blood-2023-180968","title":"XPO2 Is Essential for a Subset of AML Cells and Is a Biomarker for Poor Response and Survival in Pediatric and AYA AML","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hospital for Sick Children; University of Toronto; University Health Network","funders":"","keywords":"Gene knockdown; Biology; RNA interference; Cancer research; Cell culture; Nuclear transport; Importin; Gene expression; Gene; Internal medicine; Medicine; Genetics; RNA; Cell nucleus","score_opus":0.025005493765770395,"score_gpt":0.3125618700007051,"score_spread":0.28755637623493474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995404,0.00054956484,0.000030236622,0.0022452264,0.000047596648,0.0010908941,0.0005844448,0.000021957549,0.000026080561],"genre_scores_gemma":[0.9968444,0.0009154669,0.0008263955,0.0001403759,0.0001327111,0.0001036828,0.000034442157,0.00003866729,0.00096386037],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998745,0.0000761347,0.00025741148,0.000358598,0.00020987623,0.00035294582],"domain_scores_gemma":[0.99857104,0.0009439928,0.000059464408,0.00018012735,0.00009766388,0.00014769657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010677032,0.00013823797,0.0003477279,0.00043439737,0.000048658007,0.00002121853,0.000062267485,0.00013201554,0.000016581062],"category_scores_gemma":[0.00041509696,0.00012426141,0.00005358667,0.00045952588,0.000108452616,0.000049954855,0.00011440027,0.000100181984,0.0000029875698],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03011866,0.0008584713,0.32847154,0.004823669,0.00049081666,0.0002519733,0.0049360553,1.7929503e-7,0.5591476,0.00005015172,0.06658629,0.0042645726],"study_design_scores_gemma":[0.057385713,0.0022451908,0.76101524,0.00011712478,0.00092315854,0.000096283475,0.0009557666,0.0028496936,0.16814253,0.0003059015,0.005514659,0.00044876774],"about_ca_topic_score_codex":0.00008737083,"about_ca_topic_score_gemma":0.000033792312,"teacher_disagreement_score":0.43254367,"about_ca_system_score_codex":0.000018230223,"about_ca_system_score_gemma":0.00019607012,"threshold_uncertainty_score":0.50672334},"labels":[],"label_agreement":null},{"id":"W4389230260","doi":"10.1182/blood-2023-189808","title":"Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE), a Prospective, Longitudinal Clonal Hematopoiesis Cohort and Biorepository","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Biorepository; Medicine; Population; Malignancy; Disease; Prospective cohort study; Internal medicine; Oncology; Immunology; Bioinformatics; Biology; Biobank","score_opus":0.011179087549262827,"score_gpt":0.2605504618246987,"score_spread":0.24937137427543588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389230260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948699,0.0006975994,0.000008858387,0.002047692,0.000033814857,0.0009533033,0.000014709007,0.000090289606,0.0012838274],"genre_scores_gemma":[0.99853253,0.00022307273,0.00038974642,0.00007928465,0.00028347535,0.00019179097,0.00004461063,0.000026639183,0.00022885039],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981968,0.00010855596,0.00028311656,0.0004393927,0.00061787077,0.0003542595],"domain_scores_gemma":[0.9991401,0.00026020993,0.000063704385,0.0003245304,0.000095645955,0.00011580214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007176262,0.00020284812,0.00034517873,0.00028202301,0.00018972131,0.00008282593,0.00012204432,0.00015866903,0.000019616933],"category_scores_gemma":[0.00021233689,0.00014314783,0.00007670609,0.000659123,0.00025096434,0.00014620936,0.00015380986,0.0004675678,0.000017030596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014312546,0.00015024378,0.98650146,0.0003316929,0.00029605167,0.0006276526,0.0013596034,0.0000011620891,0.007648387,0.0015684455,0.0011785087,0.00019366457],"study_design_scores_gemma":[0.0028768945,0.000121355144,0.98790246,0.00012330836,0.00022490976,0.0015084683,0.00046271103,0.00019332375,0.0055500334,0.00062104064,0.00026595223,0.00014956371],"about_ca_topic_score_codex":0.00008289395,"about_ca_topic_score_gemma":0.000053832122,"teacher_disagreement_score":0.0036626235,"about_ca_system_score_codex":0.000069716545,"about_ca_system_score_gemma":0.00014884699,"threshold_uncertainty_score":0.58373994},"labels":[],"label_agreement":null},{"id":"W4389230267","doi":"10.1182/blood-2023-188892","title":"Wilms' Tumor 1 Functions As a Tumor Suppressor to Suppress FLT3-STAT Signaling and Epigenetic Remodeling in Acute Myeloid Leukemia (CALGB 8461, 9665 and 20202; Alliance)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Terry Fox Research Institute","funders":"","keywords":"Cancer research; Biology; Myeloid leukemia; Epigenetics; NPM1; Oncogene; Transcription factor; Leukemia; Cancer; Immunology; Genetics; Gene; Cell cycle","score_opus":0.019580399701353696,"score_gpt":0.28668368007747064,"score_spread":0.26710328037611697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389230267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940723,0.0011517458,0.00017568054,0.0022992336,0.00014454263,0.0013540346,0.00012512262,0.00023931822,0.00043800124],"genre_scores_gemma":[0.98989826,0.00077893946,0.003903145,0.0011150325,0.00030668447,0.0003200668,0.00012389998,0.00014687696,0.0034070713],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996349,0.00014283761,0.00063880923,0.0010758427,0.0006688181,0.0011247337],"domain_scores_gemma":[0.997965,0.00039647732,0.00008905626,0.00062432233,0.00017714364,0.0007480186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006696409,0.0004322204,0.00072657864,0.0005113626,0.00025114568,0.00013645543,0.000270445,0.00015430676,0.00015311535],"category_scores_gemma":[0.0006036942,0.0004212113,0.000099780096,0.0012311712,0.00016656089,0.00019732422,0.0005080194,0.0007999563,0.00032592416],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014091347,0.00032059455,0.020517496,0.00076253247,0.0005493039,0.005613576,0.0027756272,0.002027261,0.9541589,0.000043215354,0.008856252,0.0029661194],"study_design_scores_gemma":[0.06558657,0.005923495,0.17018136,0.004979464,0.0040416014,0.008443044,0.01194549,0.14288317,0.5448809,0.0019264204,0.03434508,0.00486337],"about_ca_topic_score_codex":0.00044690692,"about_ca_topic_score_gemma":0.000104677885,"teacher_disagreement_score":0.40927795,"about_ca_system_score_codex":0.0002835522,"about_ca_system_score_gemma":0.00063994795,"threshold_uncertainty_score":0.999824},"labels":[],"label_agreement":null},{"id":"W4389230997","doi":"10.1182/blood-2023-190545","title":"The Presence of Somatic Mutations on Specific Pathways Such As Chromatin Modifier, Spliceosome, and Myeloid Transcription Factor at Diagnosis Was Found to Have Benefit from Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in 1,228 Patients with Acute Myeloid Leukemia in First Complete Remission (CR1)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"","keywords":"Medicine; Transplantation; Oncology; Internal medicine; Somatic evolution in cancer; Hematopoietic stem cell transplantation; Stem cell; Cancer; Biology; Genetics","score_opus":0.025860447538435364,"score_gpt":0.24637397228304694,"score_spread":0.22051352474461158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389230997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959832,0.00023519347,0.000046085304,0.0003882687,0.00005190412,0.0025382596,0.00056896004,0.00006397952,0.00012417149],"genre_scores_gemma":[0.99635863,0.0018400301,0.00034847713,0.000044101165,0.00003182056,0.00052551937,0.0006236933,0.00006940914,0.00015833086],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9967979,0.00015143589,0.00079721265,0.0007015605,0.00097421935,0.0005776258],"domain_scores_gemma":[0.99768203,0.001151829,0.00020487212,0.0005805397,0.00011395797,0.00026676545],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026298463,0.0003761277,0.0005742437,0.00046376127,0.00028542068,0.000060752114,0.0002883992,0.00018774423,0.00004241653],"category_scores_gemma":[0.000039829647,0.0002857828,0.0000847194,0.00075105333,0.00014123,0.00017378201,0.000068486304,0.0003641391,0.0000713567],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044440846,0.0015140104,0.4005936,0.0019296897,0.00035418366,0.0006815706,0.047912277,0.0032386153,0.53352547,0.00014124007,0.0001729039,0.0054923557],"study_design_scores_gemma":[0.01185215,0.0011941971,0.8609907,0.001561981,0.00020279479,0.000032004016,0.0017784103,0.0018459297,0.119763285,0.00029733242,0.00008696161,0.00039427422],"about_ca_topic_score_codex":0.00069176254,"about_ca_topic_score_gemma":0.0015867729,"teacher_disagreement_score":0.4603971,"about_ca_system_score_codex":0.00073733524,"about_ca_system_score_gemma":0.00020332022,"threshold_uncertainty_score":0.9999594},"labels":[],"label_agreement":null},{"id":"W4389231005","doi":"10.1182/blood-2023-181119","title":"Identification of Unexpected Responders to Gilteritinib in a Cohort of FLT3-WT AML Patients Using Ex-Vivo Testing","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Ex vivo; Phenotype; Medicine; In vivo; Biology; Oncology; Computational biology; Gene; Genetics","score_opus":0.04696847932394191,"score_gpt":0.33234356107957036,"score_spread":0.2853750817556284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987379,0.000011254874,0.000024868796,0.00007863263,0.00003971444,0.0007241559,0.000033108692,0.000049533162,0.00030086192],"genre_scores_gemma":[0.9984988,0.000003973113,0.0011750915,0.000022153617,0.000030668605,0.000023314456,0.000039207862,0.000027288163,0.00017952967],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983211,0.00008664098,0.0005656803,0.00026279522,0.00049265596,0.00027112736],"domain_scores_gemma":[0.9988571,0.0001903434,0.00014836162,0.00033990663,0.00037319493,0.00009111976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055083074,0.00009701567,0.00028587086,0.00064568163,0.000026518124,0.0000074259206,0.0001292848,0.00007256543,0.000018413592],"category_scores_gemma":[0.0027756875,0.00010067203,0.000039259437,0.0021680503,0.00005296501,0.000058983594,0.000107332744,0.0001335679,0.000018061346],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011063301,0.00020459297,0.39438173,0.00011163265,0.000031062253,0.000023140066,0.0004354879,0.000025480993,0.60428286,0.000003833158,0.00008035056,0.00030919333],"study_design_scores_gemma":[0.0025930149,0.00018545774,0.737827,0.00029307362,0.00005387214,0.0000058985293,0.00033409314,0.0012802467,0.2573278,0.000012976381,0.000012810415,0.00007376908],"about_ca_topic_score_codex":0.00027076268,"about_ca_topic_score_gemma":0.000015999873,"teacher_disagreement_score":0.34695503,"about_ca_system_score_codex":0.000120876466,"about_ca_system_score_gemma":0.00020698083,"threshold_uncertainty_score":0.41052863},"labels":[],"label_agreement":null},{"id":"W4389231019","doi":"10.1182/blood-2023-191011","title":"Acute Myeloid Leukemia (AML) Patients with Myelodysplasia (MDS) Related-Gene Mutations in First Complete Remission (CR1) Found to Have Benefit from Allogeneic Hematopoietic Stem Cell Transplant (HCT)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"","keywords":"Internal medicine; Medicine; Oncology; Myelodysplastic syndromes; Myeloid leukemia; International Prognostic Scoring System; Transplantation; Gene mutation; Myeloid; Leukemia; Hematopoietic stem cell transplantation; Mutation; Gene; Bone marrow; Biology; Genetics","score_opus":0.015216234474562646,"score_gpt":0.24161264134207364,"score_spread":0.226396406867511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995084,0.00014446,0.000072512594,0.00085106795,0.00010992141,0.001822412,0.0007704168,0.000282888,0.00086234347],"genre_scores_gemma":[0.993112,0.00023005389,0.0013493049,0.00021673358,0.00008353335,0.00022437086,0.002657017,0.00017203743,0.0019549467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957779,0.00009373476,0.0008679014,0.0010872205,0.0011227147,0.0010505216],"domain_scores_gemma":[0.99761415,0.00034605298,0.00017569907,0.00094815256,0.00021077234,0.00070519344],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002702517,0.00054557755,0.0008088485,0.00067600276,0.00030628016,0.000066650624,0.0004669755,0.00036375134,0.00013914163],"category_scores_gemma":[0.00002666378,0.00046882432,0.00015765415,0.0013550449,0.000117062664,0.00015534642,0.00018057233,0.00074878696,0.0007666071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004496364,0.0026211555,0.6663916,0.0010242711,0.0023325,0.009401702,0.025385728,0.0052294745,0.27748656,0.00010075032,0.0026212765,0.002908603],"study_design_scores_gemma":[0.049059547,0.0024617314,0.8281702,0.0024323813,0.0021761034,0.00041457135,0.0017524896,0.0023073151,0.10622003,0.0003235934,0.0029478243,0.0017342087],"about_ca_topic_score_codex":0.00058659667,"about_ca_topic_score_gemma":0.0006572644,"teacher_disagreement_score":0.17126654,"about_ca_system_score_codex":0.0008402749,"about_ca_system_score_gemma":0.00053250726,"threshold_uncertainty_score":0.99977636},"labels":[],"label_agreement":null},{"id":"W4389231133","doi":"10.1182/blood-2023-180644","title":"FORTITUDE: A Phase 2 Open-Label Study in Progress to Evaluate Etavopivat for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Anemia; Myelodysplastic syndromes; Medicine; Ineffective erythropoiesis; Internal medicine; Lenalidomide; Population; Erythropoiesis; Gastroenterology; Oncology; Bone marrow; Multiple myeloma","score_opus":0.0550999316811912,"score_gpt":0.3916374017796931,"score_spread":0.3365374700985019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870333,0.00009471333,0.000006923543,0.00033681167,0.00004702197,0.012361612,0.000069115515,0.000027452808,0.00002305604],"genre_scores_gemma":[0.99623793,0.000050569397,0.0004034495,0.000018294664,0.000023365079,0.0028979995,0.000045761433,0.00004356483,0.00027904342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807495,0.00009714767,0.00036385178,0.00042303713,0.0005658638,0.0004751697],"domain_scores_gemma":[0.9987132,0.00035232664,0.00010028329,0.00054223294,0.00016785764,0.00012408727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005754963,0.00021310827,0.0005139539,0.00032483644,0.00006751889,0.00003199327,0.00032451397,0.00005308849,0.00001681412],"category_scores_gemma":[0.00024797214,0.00012199458,0.000032604723,0.0011471548,0.00006708436,0.000071356815,0.00014091417,0.0001380432,0.000020188485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007244121,0.042937227,0.9303336,0.0001146874,0.0004761024,0.00029999713,0.002273848,0.00006353969,0.000040437983,0.0000035408887,0.00019543967,0.016017457],"study_design_scores_gemma":[0.22131287,0.060002595,0.7151569,0.00023930639,0.0007179249,0.0000059062454,0.0005940288,0.0012230305,0.00036273088,0.000009706775,0.00019787018,0.0001770914],"about_ca_topic_score_codex":0.00018522535,"about_ca_topic_score_gemma":0.0005555325,"teacher_disagreement_score":0.21517667,"about_ca_system_score_codex":0.00025263388,"about_ca_system_score_gemma":0.00034257743,"threshold_uncertainty_score":0.49747944},"labels":[],"label_agreement":null},{"id":"W4389231558","doi":"10.1182/blood-2023-187458","title":"Analysis of the Impact of Whole Blood and T-Cell Donor Chimerism after Allogeneic Stem Cell Transplant","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Population Health Research Institute; Juravinski Cancer Centre; Hamilton Health Sciences; Juravinski Hospital; Centre Hospitalier Universitaire Sainte-Justine; McMaster University; Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Medicine; Internal medicine; Stem cell; Transplantation; Myeloid leukemia; Oncology; Hematopoietic stem cell transplantation; Haematopoiesis; Myelodysplastic syndromes; Myeloid; Immunology; Gastroenterology; Bone marrow; Biology","score_opus":0.01153860160121315,"score_gpt":0.26015666904979173,"score_spread":0.2486180674485786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978888,0.0008270489,0.0000035867088,0.000111425186,0.0000140493,0.00031140447,0.0002862328,0.000022309767,0.00053516496],"genre_scores_gemma":[0.9981053,0.00033344014,0.00003640309,0.000023809953,0.000030327637,0.000020696023,0.00003475722,0.00002466592,0.0013906071],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99872094,0.00008278743,0.00030806006,0.0002526367,0.00033416407,0.00030138166],"domain_scores_gemma":[0.9990788,0.000090770714,0.000102683414,0.0005322282,0.0000635694,0.00013192934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025972715,0.00015629893,0.0004978887,0.00035256642,0.00003177882,0.00000727914,0.00017839414,0.00010491326,0.00008465934],"category_scores_gemma":[0.0000065193,0.00009462271,0.0004152011,0.0013408863,0.00011292305,0.00002677481,0.00007940508,0.00019787166,0.000012287764],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001433441,0.00052796805,0.46184003,0.0001944185,0.0024263607,0.00007920675,0.0013363205,0.00005883197,0.53308934,4.5533704e-7,0.00012217036,0.0001815666],"study_design_scores_gemma":[0.0039984365,0.00039117289,0.6621091,0.00004761375,0.006919117,0.000021782811,0.00017810118,0.00042077474,0.32577524,0.0000024418068,0.00003182481,0.00010441903],"about_ca_topic_score_codex":0.00030433922,"about_ca_topic_score_gemma":0.000026246624,"teacher_disagreement_score":0.20731409,"about_ca_system_score_codex":0.000019882487,"about_ca_system_score_gemma":0.0001871897,"threshold_uncertainty_score":0.3858602},"labels":[],"label_agreement":null},{"id":"W4389231824","doi":"10.1182/blood-2023-188341","title":"Final Results of the Phase Ib/II Study Evaluating Enasidenib in Combination with Venetoclax in Patients with <i>IDH2</i>-Mutated Relapsed/Refractory Myeloid Malignancies","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Venetoclax; Medicine; IDH2; Tolerability; Internal medicine; Phases of clinical research; Refractory (planetary science); Myeloid; Oncology; Myeloid leukemia; Gastroenterology; Adverse effect; Leukemia; Clinical trial; IDH1; Biology; Chronic lymphocytic leukemia","score_opus":0.033417867618704945,"score_gpt":0.31759840406593387,"score_spread":0.2841805364472289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970101,0.000028594428,8.985188e-7,0.00020223825,0.000035295245,0.002423783,0.000030899235,0.00005164272,0.0002165406],"genre_scores_gemma":[0.99912626,0.00000622491,0.0001129982,0.000037693662,0.000020281124,0.0001412822,0.00011896911,0.000041290892,0.000394979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99702036,0.0003488551,0.0005728609,0.00041125488,0.0012286333,0.00041800484],"domain_scores_gemma":[0.9985276,0.00023977815,0.0002592138,0.0005300228,0.0003712137,0.00007216884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012986959,0.00020591874,0.00038736893,0.00041019067,0.000107427695,0.000013418727,0.0002280783,0.00008663977,0.000008145516],"category_scores_gemma":[0.0008202533,0.0001313937,0.000035639056,0.0020122884,0.00012575323,0.00013558383,0.0001613556,0.00054108206,0.000008226451],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013371454,0.009570671,0.95077455,0.00015528976,0.00019810462,0.00038114903,0.009815655,0.00072179025,0.012175951,0.000008569669,0.00028287555,0.0025439262],"study_design_scores_gemma":[0.13254526,0.015733015,0.8415551,0.000654455,0.00012571097,0.000008101953,0.0014685286,0.0006649323,0.0070546786,0.000014413978,0.000021398988,0.00015437824],"about_ca_topic_score_codex":0.0004466619,"about_ca_topic_score_gemma":0.00042016897,"teacher_disagreement_score":0.1191738,"about_ca_system_score_codex":0.00038845043,"about_ca_system_score_gemma":0.0009970783,"threshold_uncertainty_score":0.5358079},"labels":[],"label_agreement":null},{"id":"W4389232433","doi":"10.1182/blood-2023-188285","title":"Targeting Mitochondrial Calcium Uptake to Eradicate Venetoclax-Resistant Acute Myeloid Leukemia Stem Cells","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Ven; Stem cell; Biology; Cancer research; Calcium; Myeloid leukemia; Leukemia; Pharmacology; Cell biology; Immunology; Medicine; Internal medicine","score_opus":0.027062683300059873,"score_gpt":0.2896289170301697,"score_spread":0.2625662337301098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389232433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992585,0.00024037935,0.00029130754,0.0016949952,0.00087422354,0.001696871,0.00015372779,0.0006958316,0.0017676606],"genre_scores_gemma":[0.91544324,0.0005228055,0.013342307,0.002594853,0.0067523196,0.0008128456,0.00048240178,0.00059148244,0.05945777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958719,0.00012113465,0.00068914046,0.00089400844,0.0010637548,0.0013600512],"domain_scores_gemma":[0.99773073,0.00018145604,0.00012381803,0.0008867931,0.00020185739,0.0008753469],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054734026,0.0004117407,0.00067506934,0.0004971917,0.00026143447,0.00009306339,0.0005383517,0.00028552653,0.00017356683],"category_scores_gemma":[0.00013163617,0.00037645793,0.00023869681,0.0015181158,0.00010119979,0.00009864658,0.00040416938,0.00075703976,0.004001201],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006774147,0.00008051355,0.00020344203,0.000120340446,0.0004587559,0.001835116,0.00053209893,0.00021178761,0.9135105,0.000045725443,0.08120619,0.0011181041],"study_design_scores_gemma":[0.012847832,0.0012557417,0.003952802,0.00029123574,0.0009061095,0.00015498868,0.0005683124,0.002418406,0.74959743,0.00003672203,0.22710082,0.0008695822],"about_ca_topic_score_codex":0.00013270772,"about_ca_topic_score_gemma":0.000008787047,"teacher_disagreement_score":0.16391306,"about_ca_system_score_codex":0.0011806405,"about_ca_system_score_gemma":0.0017656464,"threshold_uncertainty_score":0.99986875},"labels":[],"label_agreement":null},{"id":"W4389233142","doi":"10.1182/blood-2023-187408","title":"A Longitudinal Single-Cell Atlas of Treatment Response in Pediatric AML","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; BC Children's Hospital; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Biology; Epigenetics; Oncology; Internal medicine; Cancer research; Genetics; Bioinformatics; Medicine; Gene","score_opus":0.041873040313112286,"score_gpt":0.3019821434894276,"score_spread":0.2601091031763153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970156,0.00026107047,0.0000018727006,0.0004947405,0.00002855855,0.0003426007,0.000010878675,0.0000631852,0.0017814904],"genre_scores_gemma":[0.9951372,0.00028011895,0.00024015814,0.000012606012,0.00013868138,0.000036803634,0.000017698603,0.000025089079,0.0041116485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988077,0.0001038751,0.0002436867,0.0002453992,0.0002589382,0.00034040218],"domain_scores_gemma":[0.9990993,0.00035958094,0.000048785812,0.00031988323,0.000055041528,0.000117375086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003849498,0.00011937677,0.0002730972,0.00054862833,0.000020773414,0.000005949014,0.000087480534,0.000082057864,0.000059495233],"category_scores_gemma":[0.00026444026,0.00009834551,0.000084906096,0.0011266123,0.00004008287,0.000027990423,0.000064048625,0.00013818502,0.00032941072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049130307,0.0037624664,0.8393949,0.0002824125,0.00009415651,0.0032355995,0.0011107294,0.000025416037,0.14408064,0.000011721807,0.002265472,0.0008234292],"study_design_scores_gemma":[0.021724064,0.00803041,0.8555276,0.00005944475,0.0003663009,0.00013053212,0.0002559201,0.00018302843,0.11206961,0.000025144835,0.0014352378,0.00019271312],"about_ca_topic_score_codex":0.00011690545,"about_ca_topic_score_gemma":0.000022395532,"teacher_disagreement_score":0.032011036,"about_ca_system_score_codex":0.00029765494,"about_ca_system_score_gemma":0.0005189935,"threshold_uncertainty_score":0.4234018},"labels":[],"label_agreement":null},{"id":"W4389233329","doi":"10.1182/blood-2023-185956","title":"MRD Directed Treatment Intensification with Either FLAG-Ida or DA-Cladribine Improves Survival in Older AML Patients: Results from the NCRI AML18 Randomised Trial","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Minimal residual disease; Cladribine; Daunorubicin; Chemotherapy; Gemtuzumab ozogamicin; Chemotherapy regimen; Flag (linear algebra); Randomization; Randomized controlled trial; Oncology; Leukemia; Pediatrics; Surgery; Stem cell","score_opus":0.03474727807158158,"score_gpt":0.29002437810046355,"score_spread":0.255277100028882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914827,0.00003946098,0.000006585716,0.003077058,0.00022067643,0.004144708,0.00021214181,0.00023354695,0.0005831377],"genre_scores_gemma":[0.9925287,0.00015791957,0.00020602792,0.00017587956,0.00055413024,0.00056797196,0.0016827505,0.00007741084,0.0040492434],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973984,0.00036262415,0.000585968,0.00060180307,0.00058838737,0.00046282014],"domain_scores_gemma":[0.99724776,0.0013277143,0.00016992225,0.0008189331,0.00029601084,0.0001396564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005886091,0.00029069986,0.000576958,0.00016856642,0.00009328173,0.00005351149,0.0002066386,0.00014283133,0.00008096438],"category_scores_gemma":[0.002004695,0.00014347525,0.00009626977,0.0009202531,0.00012489103,0.0000781645,0.000068457186,0.00029682598,0.00010851396],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9333422,0.003919216,0.01273159,0.000030922238,0.0012865484,0.0003078228,0.0053969477,0.0000042980114,0.0200236,0.000007401414,0.008588776,0.014360676],"study_design_scores_gemma":[0.7694544,0.0024226166,0.21711038,0.00014563573,0.00039242153,0.000003586144,0.0007716489,0.00041291898,0.007728916,0.000008244869,0.0013434244,0.00020580782],"about_ca_topic_score_codex":0.0032965208,"about_ca_topic_score_gemma":0.0013528166,"teacher_disagreement_score":0.2043788,"about_ca_system_score_codex":0.0002599796,"about_ca_system_score_gemma":0.00038927727,"threshold_uncertainty_score":0.5850751},"labels":[],"label_agreement":null},{"id":"W4389233430","doi":"10.1182/blood-2023-191113","title":"Is Allogeneic Hematopoietic Stem Cell Transplant (HCT) in First Remission Beneficial to Acute Myeloid Leukemia (AML) Patients with Isocitrate Dehydrogenase(IDH) Mutations?","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"","keywords":"IDH2; Isocitrate dehydrogenase; IDH1; Oncology; Myeloid leukemia; Medicine; Hematopoietic stem cell transplantation; Internal medicine; Transplantation; Stem cell; Leukemia; Myeloid; Mutation; Biology; Genetics; Gene","score_opus":0.013833246048802664,"score_gpt":0.25261754792801494,"score_spread":0.2387843018792123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635357,0.00011082715,0.000042838183,0.0010715537,0.000059969105,0.0014263351,0.0002232365,0.00020082798,0.0005108674],"genre_scores_gemma":[0.99693364,0.00019288558,0.00043455156,0.00057356834,0.000092548915,0.0001857814,0.00045828868,0.00011619537,0.0010125632],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99672616,0.000076043776,0.00057958596,0.00076711475,0.0009418912,0.00090922933],"domain_scores_gemma":[0.998497,0.00012867076,0.00010403915,0.00057229045,0.00016996151,0.0005280481],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030348913,0.00039872958,0.0005603123,0.00054685946,0.00022333492,0.000044752254,0.00031449928,0.0002615279,0.00011221609],"category_scores_gemma":[0.000016945913,0.0003332364,0.00014402438,0.0016775841,0.00006752233,0.0001152486,0.00009738604,0.0004934361,0.0005433756],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056577143,0.004219302,0.67822224,0.0028779313,0.0016276524,0.00768851,0.042927388,0.0031034616,0.24017915,0.000064197775,0.009576982,0.0038554503],"study_design_scores_gemma":[0.043615855,0.0032909974,0.2418748,0.0019336692,0.0015980544,0.00031274106,0.001741372,0.001659973,0.69933796,0.00010234484,0.002803454,0.0017288007],"about_ca_topic_score_codex":0.00016193089,"about_ca_topic_score_gemma":0.00016236093,"teacher_disagreement_score":0.45915878,"about_ca_system_score_codex":0.0005734774,"about_ca_system_score_gemma":0.0007612415,"threshold_uncertainty_score":0.99991196},"labels":[],"label_agreement":null},{"id":"W4389233901","doi":"10.1182/blood-2023-181792","title":"Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in <i>FLT3</i>-ITD/ <i>NPM1</i>wt Patients - a Study By the NOPHO-DB-SHIP Consortium","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Gemtuzumab ozogamicin; Internal medicine; Oncology; Clinical trial; Phases of clinical research; Induction chemotherapy; Transplantation; Chemotherapy; Surgery; Stem cell; CD34; CD33","score_opus":0.11968569198844832,"score_gpt":0.42131693353384114,"score_spread":0.30163124154539284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8298069,0.000009516798,0.0000028552001,0.00026720774,0.00030759312,0.16909628,0.00015896805,0.00016974927,0.00018092588],"genre_scores_gemma":[0.8839204,0.00002738058,0.00028791337,0.000860091,0.001117169,0.11282903,0.00045361242,0.00022655628,0.00027789982],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9885779,0.002574608,0.0030706665,0.0018047947,0.0020001025,0.0019718965],"domain_scores_gemma":[0.99475837,0.0015361955,0.0008992546,0.0015599758,0.00038931542,0.00085690344],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006014876,0.00085799635,0.0017964969,0.0008145437,0.0005059129,0.00031009305,0.0018223936,0.00056711136,0.00006494403],"category_scores_gemma":[0.0033316035,0.00061679166,0.00016979703,0.0035128614,0.00030006314,0.00066330476,0.0019665963,0.0026886575,0.000075463264],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3983422,0.06627085,0.52702534,0.00007445012,0.00030225777,0.0008309134,0.0024875612,0.0000031432514,0.00024804636,0.0000011317645,0.0021916234,0.0022224712],"study_design_scores_gemma":[0.83223486,0.08493755,0.08001755,0.00013126909,0.0006708116,0.0000126801415,0.0003682349,0.00027320476,0.00015519088,0.000013635543,0.0005671081,0.0006179095],"about_ca_topic_score_codex":0.0006906099,"about_ca_topic_score_gemma":0.00070490263,"teacher_disagreement_score":0.4470078,"about_ca_system_score_codex":0.0008327278,"about_ca_system_score_gemma":0.003624489,"threshold_uncertainty_score":0.99962837},"labels":[],"label_agreement":null},{"id":"W4389233972","doi":"10.1182/blood-2023-189697","title":"Precise Single-Cell Transcriptomic Mapping of Leukemia Cell States Reveals Unconventional Lineage Priming in Acute Myeloid Leukemia","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Leukemia; Biology; Myeloid leukemia; Haematopoiesis; Transcriptome; CD34; Stem cell; Progenitor cell; Bone marrow; Cancer research; Myeloid; Computational biology; Acute leukemia; Immunology; Genetics; Gene; Gene expression","score_opus":0.029446971191672434,"score_gpt":0.2699031278656334,"score_spread":0.24045615667396097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424744,0.00057878706,0.00019490314,0.0002112352,0.00014838309,0.0010221186,0.00011059677,0.0002019943,0.0032845465],"genre_scores_gemma":[0.9852514,0.00074486923,0.0038072607,0.00012701041,0.00019640333,0.00008947174,0.00046003837,0.00011476728,0.009208764],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963533,0.0001599897,0.0010753312,0.00068032165,0.0008177237,0.0009133308],"domain_scores_gemma":[0.9982844,0.00038082723,0.00025635352,0.00059329206,0.00020424485,0.00028090444],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010882278,0.00037237132,0.00082920707,0.00093781704,0.00008484339,0.000035166868,0.0003990692,0.00029268445,0.00017353833],"category_scores_gemma":[0.00013196869,0.00037254783,0.00029570295,0.0014751693,0.0001633832,0.00019902685,0.00017052786,0.0008106349,0.00020954403],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029603174,0.0005351218,0.0131811295,0.0013959488,0.00018638853,0.0006002913,0.0018723118,0.00024385781,0.97826535,0.0000137185025,0.0027029507,0.000706923],"study_design_scores_gemma":[0.018195273,0.000577729,0.023604434,0.0010040625,0.00042991244,0.000099763674,0.0012624931,0.0032769197,0.9491087,0.00020370791,0.0017324821,0.00050451985],"about_ca_topic_score_codex":0.00018293601,"about_ca_topic_score_gemma":0.000025887806,"teacher_disagreement_score":0.029156623,"about_ca_system_score_codex":0.0012586296,"about_ca_system_score_gemma":0.001527564,"threshold_uncertainty_score":0.9998726},"labels":[],"label_agreement":null},{"id":"W4389234069","doi":"10.1182/blood-2023-185353","title":"Decoding the Epigenetic Drivers of Menin-MLL Inhibitor Resistance in KMT2A-Rearranged Acute Myeloid Leukemia","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Cancer research; Epigenetics; Chromatin; Biology; Myeloid leukemia; PRC2; EZH2; Decitabine; DNA methylation; Genetics; Gene; Gene expression","score_opus":0.018893559033513144,"score_gpt":0.2817525776908748,"score_spread":0.26285901865736166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389234069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912902,0.00063208985,0.00001306036,0.0019389322,0.000098964425,0.00065623375,0.000028398994,0.0000871593,0.005254925],"genre_scores_gemma":[0.9933493,0.0009954432,0.0010186642,0.00014429176,0.00017560227,0.00007197071,0.000030645122,0.000051235435,0.0041628582],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978082,0.00013662565,0.00043618417,0.00038625245,0.00063453225,0.00059816893],"domain_scores_gemma":[0.99864477,0.00035627888,0.00011149068,0.0006219849,0.00011871051,0.00014676843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007655517,0.00019752716,0.00043100803,0.00035459327,0.00011138603,0.00001821771,0.0003561096,0.00014804621,0.000067307614],"category_scores_gemma":[0.00036373627,0.00014991622,0.0001287318,0.0014531596,0.00022275106,0.000068397145,0.00018615506,0.0005208932,0.00015891179],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009118636,0.00029182836,0.06624246,0.0004375822,0.0008167058,0.0023083563,0.006543441,0.000052499043,0.89541197,0.00033951562,0.02306963,0.0035741564],"study_design_scores_gemma":[0.022663858,0.0006008676,0.30161157,0.0012666001,0.0008561776,0.0000955095,0.0034018306,0.00075120584,0.65504915,0.0007259432,0.012306218,0.0006710431],"about_ca_topic_score_codex":0.00015136428,"about_ca_topic_score_gemma":0.0004408125,"teacher_disagreement_score":0.24036281,"about_ca_system_score_codex":0.0003751618,"about_ca_system_score_gemma":0.00063043385,"threshold_uncertainty_score":0.6113406},"labels":[],"label_agreement":null},{"id":"W4389234172","doi":"10.1182/blood-2023-191191","title":"The Presence of Somatic Mutation in Donor Does Not Affect Long-Term Outcomes in 339 Patients Following Allogeneic Hematopoietic Stem Cell Transplantation Using Uniform Fludarabine/Busulfan Myeloablative Conditioning and Cyclosporine/Methotrexate and ATG Gvhd Prophylaxis","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Fludarabine; Medicine; Busulfan; Transplantation; Context (archaeology); Hematopoietic stem cell transplantation; Internal medicine; Oncology; Stem cell; Surgery; Immunology; Chemotherapy; Cyclophosphamide; Biology","score_opus":0.0197165680889852,"score_gpt":0.2934844320197312,"score_spread":0.273767863930746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389234172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982271,0.00009830867,0.0000714284,0.00006578705,0.000051658637,0.0013952329,0.000031738193,0.00003056309,0.000028170443],"genre_scores_gemma":[0.99915975,0.00016133272,0.00042541965,0.000008507538,0.000010291054,0.000070890135,0.00007449705,0.000027927481,0.00006138999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823445,0.00021464066,0.0004979828,0.0003187042,0.0003983601,0.0003358664],"domain_scores_gemma":[0.99858105,0.00090645324,0.00017934892,0.00018738178,0.00007025814,0.00007553375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068142015,0.00019655804,0.0004079979,0.00035674623,0.00012913038,0.000038909624,0.00009194307,0.000092214854,0.000002610202],"category_scores_gemma":[0.00014390213,0.00013194626,0.000058099187,0.0005549008,0.00011504278,0.00022954195,0.000055620174,0.00022389425,0.0000012901612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011865548,0.0001259125,0.9722568,0.001163715,0.000077507284,0.0002312164,0.005069899,0.000111862755,0.018381532,0.000009136332,1.6153331e-7,0.00245364],"study_design_scores_gemma":[0.0051334905,0.00025852383,0.9323524,0.00041919426,0.0001312528,0.000020147421,0.0009315211,0.0009079424,0.059636377,0.000077662036,6.27116e-8,0.00013138156],"about_ca_topic_score_codex":0.00017500063,"about_ca_topic_score_gemma":0.00021525355,"teacher_disagreement_score":0.041254845,"about_ca_system_score_codex":0.00010057123,"about_ca_system_score_gemma":0.000098929595,"threshold_uncertainty_score":0.5380612},"labels":[],"label_agreement":null},{"id":"W4389234266","doi":"10.1182/blood-2023-173241","title":"A Phase 2, Single-Arm, Multicohort, Open Label, Multicenter Trial of Off-the-Shelf Natural Killer Cells (SAR445419) in Patients with High-Risk Myeloid Malignancies Undergoing Allogeneic HSCT","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Transplantation; Internal medicine; Myeloid leukemia; Hematopoietic stem cell transplantation; Oncology; Leukemia; Immunology","score_opus":0.02631994969765771,"score_gpt":0.2939405461620323,"score_spread":0.2676205964643746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389234266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99470365,0.00015807709,0.000005081961,0.0003407228,0.0005034739,0.004007695,0.00006565997,0.00007771199,0.00013792246],"genre_scores_gemma":[0.996063,0.00018008995,0.0015100958,0.00021167951,0.00014727896,0.00017603375,0.0001992237,0.00009775808,0.0014148434],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966067,0.00030234375,0.00072344975,0.0006269959,0.0009216084,0.00081888365],"domain_scores_gemma":[0.99775666,0.00066264556,0.00031608684,0.0007836076,0.0002920604,0.00018891698],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007891821,0.00037153222,0.0007408415,0.00037051,0.00015162333,0.000080226084,0.0006644798,0.00016593502,0.00005315714],"category_scores_gemma":[0.00064884307,0.00024752074,0.00010162083,0.00096062734,0.00023944878,0.00023095551,0.0005834902,0.0006147507,0.000075123105],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2975514,0.124200575,0.28571278,0.0012530879,0.005297496,0.0016217957,0.006253675,0.0002561495,0.22462828,0.00009553413,0.0079414155,0.0451878],"study_design_scores_gemma":[0.87017864,0.014234607,0.04657993,0.0006450948,0.0008460922,0.0000103195,0.00051782164,0.0011310339,0.06394315,0.000014816269,0.0013071687,0.00059133075],"about_ca_topic_score_codex":0.00054921344,"about_ca_topic_score_gemma":0.00034791455,"teacher_disagreement_score":0.57262725,"about_ca_system_score_codex":0.00022485432,"about_ca_system_score_gemma":0.0004391615,"threshold_uncertainty_score":0.9999977},"labels":[],"label_agreement":null},{"id":"W4389234334","doi":"10.1182/blood-2023-189351","title":"Novel Therapeutics Targeting Acute Myeloid Leukemia (AML) Stem Cells Identified through High-Throughput Screening","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Hôpital de l'Enfant-Jésus; Institute for Research in Immunology and Cancer; McGill University; Université Laval; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Myeloid leukemia; CD34; Leukemia; Stem cell; Haematopoiesis; Cancer research; Cord blood; Medicine; Minimal residual disease; Cytotoxic T cell; Immunology; Acute leukemia; Pharmacology; In vitro; Chemistry; Biology; Cell biology; Biochemistry","score_opus":0.04831357275802787,"score_gpt":0.30684271457074636,"score_spread":0.25852914181271847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389234334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787939,0.00072109606,0.01311218,0.0016675799,0.00081277883,0.0011673486,0.0001307176,0.0011454634,0.0024489197],"genre_scores_gemma":[0.92483866,0.0014992631,0.039414912,0.0023068232,0.0019047458,0.00018285087,0.00042849066,0.00041708793,0.029007165],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99565905,0.00010654688,0.00073572993,0.00094212237,0.001187928,0.0013686231],"domain_scores_gemma":[0.9978536,0.00035105352,0.00022164593,0.0009973459,0.00029863566,0.00027776553],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00083758496,0.00048617698,0.0007190143,0.00027576069,0.00040601104,0.00015220701,0.00056739675,0.00037849345,0.0001759946],"category_scores_gemma":[0.000044345543,0.00044465187,0.0002796455,0.0015758674,0.00020152904,0.00037008588,0.0005403031,0.001043637,0.001323326],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002557888,0.00031487265,0.0011317537,0.00019207681,0.0022585243,0.0011099513,0.0022864072,0.000116196854,0.973592,0.00065245,0.012762949,0.0053270413],"study_design_scores_gemma":[0.017026562,0.0005169112,0.005898926,0.00035140358,0.0019537532,0.00037305785,0.0033114732,0.002102548,0.9400894,0.00021457401,0.027166983,0.0009944249],"about_ca_topic_score_codex":0.00044692552,"about_ca_topic_score_gemma":0.000008321984,"teacher_disagreement_score":0.053955253,"about_ca_system_score_codex":0.00038409542,"about_ca_system_score_gemma":0.00059366506,"threshold_uncertainty_score":0.9998005},"labels":[],"label_agreement":null},{"id":"W4389234373","doi":"10.1182/blood-2023-178024","title":"Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including CMML (Chronic Myelomonocytic Leukemia) By Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Azacitidine; Medicine; Decitabine; Myelodysplastic syndromes; Pharmacokinetics; Chronic myelomonocytic leukemia; Hypomethylating agent; Pharmacology; Area under the curve; Internal medicine; Lenalidomide; Adverse effect; Oncology; International Prognostic Scoring System; Myeloid leukemia; Gastroenterology; Bone marrow","score_opus":0.03044335139828663,"score_gpt":0.30152921953870404,"score_spread":0.2710858681404174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389234373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992722,0.0010670972,0.0025366093,0.0005671078,0.0001179607,0.0023093799,0.00016439173,0.00036800755,0.0001474969],"genre_scores_gemma":[0.9743051,0.0007200979,0.0225445,0.00010864703,0.00017009031,0.0005480361,0.0005417132,0.0002087581,0.00085305184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99483484,0.000115275136,0.001153374,0.0011872667,0.0010779103,0.0016313364],"domain_scores_gemma":[0.9971844,0.000875771,0.00039700704,0.0004518538,0.00047272365,0.00061825383],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00102531,0.00077248766,0.0013328865,0.0006557242,0.0005137446,0.000072972456,0.00041382693,0.00024471467,0.00011192508],"category_scores_gemma":[0.00051576254,0.0006790756,0.00013317523,0.0014978972,0.00045392406,0.000281972,0.000505134,0.00069667475,0.000057452708],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048872535,0.00055768277,0.002888429,0.0057228785,0.0021380312,0.0035214361,0.0020322022,0.0007900026,0.9669999,0.00022829023,0.003814965,0.006418962],"study_design_scores_gemma":[0.04189444,0.010251809,0.0025731274,0.0024843805,0.0021878546,0.0096331965,0.0010819793,0.052616376,0.86887753,0.00010197998,0.006215117,0.002082205],"about_ca_topic_score_codex":0.000039986,"about_ca_topic_score_gemma":0.000025077743,"teacher_disagreement_score":0.098122336,"about_ca_system_score_codex":0.0012368199,"about_ca_system_score_gemma":0.002505426,"threshold_uncertainty_score":0.999566},"labels":[],"label_agreement":null},{"id":"W4389234564","doi":"10.1182/blood-2023-184921","title":"Management of Hyperleukocytosis in Pediatric Acute Myeloid Leukemia Using Immediate Chemotherapy without Leukapheresis, in Protocol NOPHO-DBH AML-2012","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Cytarabine; Etoposide; Mitoxantrone; Leukapheresis; Internal medicine; Chemotherapy; Chemotherapy regimen; Myeloid leukemia; Leukemia; Gastroenterology; Oncology; Stem cell","score_opus":0.02525566120483506,"score_gpt":0.32172651189479484,"score_spread":0.29647085068995976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389234564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96433353,0.00010705614,0.0000150849055,0.00022121277,0.000052354066,0.033211727,0.000013705197,0.00012850082,0.0019168518],"genre_scores_gemma":[0.9477915,0.0022230498,0.0076929783,0.00023583615,0.0004941912,0.03869167,0.00005829991,0.00027477447,0.0025376615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99638903,0.00013407382,0.00089811307,0.0006868487,0.0008792378,0.0010126968],"domain_scores_gemma":[0.9986178,0.00009145147,0.0002262316,0.0007340919,0.00010241391,0.00022796028],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000916659,0.00040036257,0.00082994986,0.0012718989,0.000054551743,0.00002546673,0.00042763603,0.00027162593,0.00014215738],"category_scores_gemma":[0.000039696028,0.00037303718,0.00016587476,0.0034532205,0.00010737609,0.00021382669,0.00028541646,0.000622818,0.00013156007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029684093,0.0018081323,0.8942466,0.004251046,0.0008610624,0.0036669755,0.0011969041,0.00025892426,0.07835291,0.00004937587,0.0018218064,0.010517887],"study_design_scores_gemma":[0.06596718,0.0006844885,0.84540933,0.000929622,0.0007210712,0.00012989913,0.0006992235,0.0033320272,0.07945991,0.0001089298,0.0016659828,0.0008923078],"about_ca_topic_score_codex":0.00037772598,"about_ca_topic_score_gemma":0.00007262401,"teacher_disagreement_score":0.06299877,"about_ca_system_score_codex":0.0009464456,"about_ca_system_score_gemma":0.00081783585,"threshold_uncertainty_score":0.99987215},"labels":[],"label_agreement":null},{"id":"W4389234593","doi":"10.1182/blood-2023-187778","title":"The Impact of Clonal Hematopoiesis on Clinical Outcomes and Clonal Dynamics in Older Lymphoma Patients Receiving Chemotherapy","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Queen's University; University of Ottawa; Sunnybrook Health Science Centre","funders":"","keywords":"Chemotherapy; Oncology; Internal medicine; Population; Lymphoma; Cancer; Medicine; Biology; Immunology","score_opus":0.022939585452327493,"score_gpt":0.36223280923606777,"score_spread":0.33929322378374027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389234593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978688,0.000033658886,0.0000012164982,0.0010532311,0.000051486324,0.00034552373,0.000022851043,0.00003061519,0.00059266237],"genre_scores_gemma":[0.99892926,0.00037148813,0.00009571933,0.00014637483,0.000053507065,0.000015535545,0.000032771262,0.000030472784,0.00032485998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984528,0.00010008667,0.00044772885,0.00024274425,0.0004178094,0.00033882426],"domain_scores_gemma":[0.998166,0.0012276674,0.00009739879,0.00030775738,0.00008299266,0.0001181677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000809438,0.00014509079,0.00038624954,0.00014482744,0.000063729974,0.000016770156,0.00013949543,0.00012947673,0.000022050765],"category_scores_gemma":[0.0007500052,0.00008693093,0.00018482,0.00036186315,0.00015900443,0.00003382877,0.00009057768,0.00022134068,0.000017682754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003196353,0.0007916616,0.9818731,0.000024832598,0.00023076448,0.000023519075,0.00012599448,0.0000010860493,0.000023535025,0.000073856834,0.0009114709,0.015600557],"study_design_scores_gemma":[0.010920817,0.00055525824,0.98696035,0.00007552512,0.000022621967,0.000010801232,0.00010736405,0.0010284702,0.00010990712,0.00010686802,0.000024207662,0.000077816105],"about_ca_topic_score_codex":0.00014215066,"about_ca_topic_score_gemma":0.000054681554,"teacher_disagreement_score":0.015522741,"about_ca_system_score_codex":0.00022860373,"about_ca_system_score_gemma":0.00024731175,"threshold_uncertainty_score":0.35449404},"labels":[],"label_agreement":null},{"id":"W4389234641","doi":"10.1182/blood-2023-187651","title":"Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Azacitidine; Internal medicine; Myeloid leukemia; Medicine; Oncology; Minimal residual disease; Leukemia; Myeloid; Bone marrow; Gastroenterology; Biology; Gene; DNA methylation; Genetics","score_opus":0.018204964939673364,"score_gpt":0.27544827239026953,"score_spread":0.25724330745059615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389234641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963583,0.000031705684,0.00003063893,0.001281978,0.00011103291,0.0013661272,0.0006109668,0.00008623676,0.00012301892],"genre_scores_gemma":[0.9961639,0.00014765873,0.0009581091,0.00016874303,0.00014576255,0.00013607554,0.0015792821,0.00006546865,0.0006350148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763364,0.00012334196,0.00052434456,0.0003957063,0.0007839718,0.0005389909],"domain_scores_gemma":[0.998564,0.00035311928,0.00017613661,0.00055488065,0.00023297333,0.00011886899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033410147,0.00025785062,0.0005459122,0.00022002518,0.00012002087,0.000025233407,0.0003400329,0.00012736791,0.00008753434],"category_scores_gemma":[0.00020283877,0.00016020458,0.00012312333,0.0008770518,0.00020956762,0.00011907377,0.000097958626,0.00048535288,0.000039580635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03294369,0.001509003,0.95445406,0.000038729868,0.0017484062,0.00042690398,0.0010402123,0.00014325813,0.0043008407,0.00014624487,0.00042783865,0.0028208352],"study_design_scores_gemma":[0.16802312,0.000827286,0.8268943,0.000064472566,0.0001589437,0.000009430015,0.00022439138,0.0006467536,0.0028458603,0.00008720513,0.000041852276,0.00017637883],"about_ca_topic_score_codex":0.00095885183,"about_ca_topic_score_gemma":0.00046025802,"teacher_disagreement_score":0.13507944,"about_ca_system_score_codex":0.00042942664,"about_ca_system_score_gemma":0.0005746097,"threshold_uncertainty_score":0.65329534},"labels":[],"label_agreement":null},{"id":"W4389234838","doi":"10.1182/blood-2023-178546","title":"Long-Term Evaluation of Luspatercept in Erythropoiesis-Stimulating Agent (ESA)-Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cumulative incidence; Myelodysplastic syndromes; Internal medicine; Adverse effect; Anemia; International Prognostic Scoring System; Refractory (planetary science); Phases of clinical research; Clinical trial; Surgery; Gastroenterology; Cohort; Bone marrow","score_opus":0.04973880724398392,"score_gpt":0.3599468793225341,"score_spread":0.31020807207855017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389234838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99636436,0.000079422185,0.000016601713,0.00009979797,0.00011347076,0.0030918168,0.00003687081,0.00005444687,0.00014322839],"genre_scores_gemma":[0.99927753,0.000044729622,0.00003773209,0.000028370006,0.00006782303,0.00026609135,0.00016742617,0.00005741298,0.000052874137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99507415,0.00092415564,0.00069594703,0.0005465481,0.0022034622,0.00055575767],"domain_scores_gemma":[0.9979809,0.0005611445,0.00026542527,0.0006956977,0.0003796436,0.00011720746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028253263,0.00031028898,0.00058869837,0.0006647825,0.00011441596,0.000038459613,0.00032492308,0.00011424063,0.00020654198],"category_scores_gemma":[0.0010832691,0.00021043583,0.00007691735,0.0013804986,0.00016248501,0.00016559844,0.00013939201,0.0006083914,0.000062257546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081536267,0.009301416,0.9677054,0.00022893767,0.00025193827,0.0008140899,0.009726801,0.0009049916,0.0006419676,7.0490955e-7,0.00006326559,0.009545072],"study_design_scores_gemma":[0.043768153,0.004611858,0.9373054,0.00050466415,0.00075254386,0.000026742104,0.0026273704,0.010010207,0.00017222737,0.0000063219727,0.0000041800745,0.0002103519],"about_ca_topic_score_codex":0.00059319317,"about_ca_topic_score_gemma":0.0012337249,"teacher_disagreement_score":0.042952787,"about_ca_system_score_codex":0.00041547423,"about_ca_system_score_gemma":0.00042118004,"threshold_uncertainty_score":0.8581324},"labels":[],"label_agreement":null},{"id":"W4389234851","doi":"10.1182/blood-2023-191036","title":"Uncovering the Role of CD59 As a Novel Therapeutic Target Against High-Risk Acute Myeloid Leukemia","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Servier; Agios Pharmaceuticals","keywords":"Myeloid leukemia; CD59; Leukemia; Myeloid; Cytarabine; Cancer research; Biology; Haematopoiesis; Immunology; Medicine; Oncology; Stem cell; Complement system; Immune system; Genetics","score_opus":0.01193553498185994,"score_gpt":0.26290042385715845,"score_spread":0.2509648888752985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389234851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912616,0.000677689,0.000070350376,0.0007515591,0.00011053245,0.0006127609,0.00009673115,0.000218215,0.0062005883],"genre_scores_gemma":[0.9953688,0.001044511,0.00068949297,0.00057571323,0.00030841588,0.00007644517,0.00007860092,0.00008511415,0.0017729029],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99777716,0.00007953017,0.000376749,0.0003937398,0.00074311777,0.0006296896],"domain_scores_gemma":[0.9983879,0.0003038266,0.00015630547,0.00083477533,0.00014759647,0.00016962271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063596846,0.00025315848,0.00045237906,0.00021808165,0.00017614313,0.000031091553,0.00045379778,0.00016690377,0.00008960823],"category_scores_gemma":[0.0002299459,0.00017271805,0.00019278176,0.0010367678,0.00017462911,0.00009034161,0.0002944385,0.0006942164,0.0004765256],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047948427,0.00045305092,0.025772061,0.00013411578,0.002880878,0.00027475596,0.0019878235,0.0007537069,0.94478273,0.0010902373,0.0012193905,0.02017175],"study_design_scores_gemma":[0.019246668,0.001361177,0.08882179,0.0002858283,0.0018677228,0.0003186697,0.003173252,0.0067329807,0.82767326,0.006065142,0.043723203,0.0007303066],"about_ca_topic_score_codex":0.0007420753,"about_ca_topic_score_gemma":0.000015774885,"teacher_disagreement_score":0.117109485,"about_ca_system_score_codex":0.00023709545,"about_ca_system_score_gemma":0.0008844789,"threshold_uncertainty_score":0.70432377},"labels":[],"label_agreement":null},{"id":"W4389235051","doi":"10.1182/blood-2023-190694","title":"Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia Patients with FMS3-like Tyrosine Kinase-3 Internal Tandem Duplication (FLT3-ITD)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Takeda Canada; Merck Canada; Astellas Pharma; Celgene; Sierra Oncology; CTI Biopharma; Gilead Sciences; Jazz Pharmaceuticals; Teva Pharmaceutical Industries; Leukemia and Lymphoma Society; Agios Pharmaceuticals; Bristol-Myers Squibb; Servier; Amgen","keywords":"NPM1; Oncology; Medicine; Myeloid leukemia; Internal medicine; Minimal residual disease; Cumulative incidence; Hazard ratio; Proportional hazards model; Multivariate analysis; Log-rank test; Survival analysis; Leukemia; Biology; Transplantation; Confidence interval; Genetics; Gene","score_opus":0.012998129630276484,"score_gpt":0.27396050043053766,"score_spread":0.2609623708002612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389235051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99685824,0.00012351811,0.00040516854,0.00031270736,0.000052284988,0.0017634287,0.00017915314,0.00015562975,0.00014984231],"genre_scores_gemma":[0.9924081,0.000040243773,0.0056218053,0.000113231385,0.00007084934,0.0004412218,0.0009655565,0.00008784449,0.00025113492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99650717,0.0001576742,0.00060387293,0.00066687237,0.0013783615,0.0006860584],"domain_scores_gemma":[0.99778664,0.0003088564,0.00021631668,0.00075105275,0.0005147152,0.00042242935],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057103595,0.00033925156,0.00055146957,0.0008263739,0.000084515785,0.00004727678,0.00032277664,0.00014700808,0.000059693626],"category_scores_gemma":[0.0005299838,0.00027782918,0.000113457645,0.0017367867,0.00015707752,0.00017713764,0.0001511547,0.0006178555,0.0000629334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013944868,0.0015306448,0.97577935,0.00021163939,0.00028427015,0.0002118257,0.0000913889,0.00048923626,0.018096387,0.00001022287,0.00036821453,0.0015323567],"study_design_scores_gemma":[0.015437437,0.00091188407,0.94132453,0.00056694116,0.0005067957,0.000006079086,0.0000589956,0.024386939,0.016412593,0.000025599027,0.00009175465,0.00027042322],"about_ca_topic_score_codex":0.00020030755,"about_ca_topic_score_gemma":0.000048670514,"teacher_disagreement_score":0.034454767,"about_ca_system_score_codex":0.00077012606,"about_ca_system_score_gemma":0.0016444564,"threshold_uncertainty_score":0.9999674},"labels":[],"label_agreement":null},{"id":"W4389235194","doi":"10.1182/blood-2023-182466","title":"Improvement in Survival of Patients with FLT3 Mutated Acute Myeloid Leukemia: Results from a Retrospective Canadian Cohort","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Gemtuzumab ozogamicin; Midostaurin; Chemotherapy regimen; Myeloid leukemia; Oncology; Anthracycline; Transplantation; Decitabine; Cohort; Induction chemotherapy; Surgery; Pediatrics; Chemotherapy; Stem cell; Cancer; CD34; CD33","score_opus":0.009014258293375639,"score_gpt":0.24121950704282139,"score_spread":0.23220524874944576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389235194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934717,0.000010356845,0.0000015159021,0.000347981,0.0000866989,0.001273402,0.0019512333,0.000074644195,0.0027824754],"genre_scores_gemma":[0.9966631,0.000047162666,0.00016634892,0.000076732016,0.000069556365,0.0000691857,0.0022233475,0.00005267679,0.0006318774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974099,0.000059844442,0.00048017554,0.0005753944,0.0007984376,0.0006762815],"domain_scores_gemma":[0.99843675,0.000105353465,0.0001262366,0.0005728813,0.00037263328,0.00038617148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044974568,0.00022361723,0.00053809106,0.0005254184,0.00005724732,0.000014453782,0.00020142047,0.00017402746,0.000056499135],"category_scores_gemma":[0.00032245985,0.00018695267,0.00005849145,0.0013910012,0.000110325804,0.00007560555,0.00009876539,0.0005201089,0.000070133545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013835381,0.00023418854,0.99105185,0.00002242273,0.0008275539,0.0008007125,0.0006865814,0.000008824571,0.003629144,0.000010601382,0.00092144584,0.00042312074],"study_design_scores_gemma":[0.021324657,0.0009346046,0.9673941,0.00009817383,0.00023166662,0.0000022778636,0.00020904843,0.00015326423,0.009336287,0.00003195343,0.00010580343,0.00017812134],"about_ca_topic_score_codex":0.28376555,"about_ca_topic_score_gemma":0.15598935,"teacher_disagreement_score":0.12777619,"about_ca_system_score_codex":0.0017859067,"about_ca_system_score_gemma":0.0021302442,"threshold_uncertainty_score":0.85941166},"labels":[],"label_agreement":null},{"id":"W4389241247","doi":"10.1007/s00277-023-05552-4","title":"A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents","year":2023,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Astellas Pharma; Sierra Oncology; Taiho Pharmaceutical; Incyte; CTI Biopharma; MorphoSys; Celgene; Astex Pharmaceuticals; Servier; Pfizer; Constellation Pharmaceuticals; Agios Pharmaceuticals; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Myelodysplastic syndromes; Hypomethylating agent; Oncology; Pembrolizumab; Myeloid leukemia; Lenalidomide; Decitabine; Cancer; Bone marrow; Multiple myeloma; Immunotherapy; DNA methylation","score_opus":0.04112445603740638,"score_gpt":0.35822954392604023,"score_spread":0.31710508788863384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963257,0.00002116386,0.000017724888,0.0008417339,0.00017463816,0.0024655336,0.00004967316,0.000032601885,0.0000712606],"genre_scores_gemma":[0.9989261,0.000034098455,0.0002988079,0.0002033639,0.000016021153,0.00015135137,0.00009257092,0.0000562702,0.0002214408],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967274,0.00030818308,0.0009610368,0.0004909592,0.00082909415,0.0006833],"domain_scores_gemma":[0.99776787,0.0006913925,0.00047795576,0.0005350294,0.00034464517,0.00018313694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050435925,0.00030062385,0.001000349,0.0011013896,0.00005649573,0.000008594439,0.00028235657,0.00019605021,0.000048579826],"category_scores_gemma":[0.0012866716,0.00019211812,0.0000911368,0.0018038909,0.00024854572,0.00016527317,0.00022155399,0.00053203345,0.000021864174],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83019286,0.00836328,0.12915559,0.0017514218,0.0008852804,0.0021499682,0.0052336804,0.0002716029,0.012635581,0.00011385189,0.0029825873,0.006264297],"study_design_scores_gemma":[0.5722783,0.036268264,0.29773024,0.0031116728,0.00027978187,0.0002563097,0.00097452296,0.0021168466,0.08601564,0.00003810777,0.00025215506,0.00067815505],"about_ca_topic_score_codex":0.00015393046,"about_ca_topic_score_gemma":0.00016996323,"teacher_disagreement_score":0.25791454,"about_ca_system_score_codex":0.00033129484,"about_ca_system_score_gemma":0.0007764136,"threshold_uncertainty_score":0.783435},"labels":[],"label_agreement":null},{"id":"W4389243107","doi":"10.1182/blood-2023-181886","title":"Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Sierra Oncology; MorphoSys; Astellas Pharma; Actuate Therapeutics; Karyopharm Therapeutics; Revolution Medicines; Incyte; Syndax Pharmaceuticals; Oregon Health and Science University; BeiGene; Bristol-Myers Squibb; Constellation Pharmaceuticals; Agios Pharmaceuticals; Ascentage Pharma; Actinium Pharmaceuticals; Mateon Therapeutics; Jazz Pharmaceuticals; Astex Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Servier; Foghorn Therapeutics; Gilead Sciences; Iterion Therapeutics; Celgene; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Amgen","keywords":"Medicine; Venetoclax; Azacitidine; Internal medicine; Oncology; Myeloid leukemia; Clinical trial; Hematology; Chemotherapy; Leukemia; DNA methylation","score_opus":0.0131047628027076,"score_gpt":0.27754463292176756,"score_spread":0.26443987011905995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995947,0.00038269733,7.6972583e-7,0.0013240909,0.000036345904,0.001870097,0.00011154336,0.00005475477,0.00027269262],"genre_scores_gemma":[0.99583656,0.0014209559,0.000043452015,0.00038975605,0.0002482523,0.0002011888,0.00017925684,0.00004628644,0.0016342686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814487,0.00009708932,0.0003029744,0.0005076407,0.00059320475,0.00035425407],"domain_scores_gemma":[0.9985873,0.00048217006,0.00014498431,0.00062492985,0.000078315985,0.00008231788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018795732,0.00026638014,0.00047542428,0.00008160263,0.000057925845,0.000026461978,0.00016062304,0.00013827212,0.000011374393],"category_scores_gemma":[0.000076262084,0.00014993634,0.00007323576,0.0002910506,0.00013847275,0.000086383756,0.00006346565,0.00035904665,0.000006416203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29740798,0.0060994048,0.47191718,0.00020093654,0.006749628,0.008150717,0.021931522,0.00040292443,0.14162399,0.000044683387,0.015691658,0.029779363],"study_design_scores_gemma":[0.12694316,0.0029910961,0.8390174,0.00037377543,0.00020999322,0.000084413405,0.00020313654,0.000022813721,0.029207062,0.000016260074,0.00074424193,0.0001866754],"about_ca_topic_score_codex":0.0047011203,"about_ca_topic_score_gemma":0.00041173171,"teacher_disagreement_score":0.3671002,"about_ca_system_score_codex":0.0001466356,"about_ca_system_score_gemma":0.0002570473,"threshold_uncertainty_score":0.7106719},"labels":[],"label_agreement":null},{"id":"W4389243476","doi":"10.1182/blood-2023-178112","title":"Use of Geriatric Assessment and Genetic Profiling to Personalize Selection of Intensive Versus Low Intensity Chemotherapy in Older Adults with Acute Myeloid Leukemia (AML): Final Results of a Phase II Trial","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Oncology; Chemotherapy regimen; Performance status; Chemotherapy; Intensive care medicine","score_opus":0.034495399427425445,"score_gpt":0.3306603888898472,"score_spread":0.29616498946242176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973338,0.00003120992,0.000059121237,0.00033900383,0.000068677975,0.0020470289,0.000075739554,0.000028383682,0.000017003596],"genre_scores_gemma":[0.991464,0.00022941815,0.007862159,0.000069851965,0.00009872904,0.00006749866,0.000061179395,0.000033513035,0.00011365163],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99804056,0.00007983182,0.0005875736,0.00044002803,0.0005266999,0.0003253314],"domain_scores_gemma":[0.997883,0.00020865953,0.0002678998,0.00027005255,0.0012380555,0.00013231143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003333274,0.00020256845,0.0006659295,0.0005681901,0.00003780447,0.000007905746,0.000092845,0.0001303745,0.000011049441],"category_scores_gemma":[0.0005529496,0.00017038331,0.00008130985,0.0013791804,0.00011969068,0.00007577227,0.00010518765,0.0003162204,8.691424e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6909004,0.0019729587,0.004396033,0.00056878006,0.0008923072,0.0003089504,0.0050425576,0.0000640473,0.2890455,0.0000036586807,0.0007189114,0.006085914],"study_design_scores_gemma":[0.57094353,0.030664554,0.08505318,0.0009117692,0.0005888794,0.00016594656,0.0019911043,0.0062748217,0.3031119,0.0000026815758,0.00002137707,0.0002702529],"about_ca_topic_score_codex":0.00053365243,"about_ca_topic_score_gemma":0.000053679607,"teacher_disagreement_score":0.11995684,"about_ca_system_score_codex":0.0002821058,"about_ca_system_score_gemma":0.0011242605,"threshold_uncertainty_score":0.694803},"labels":[],"label_agreement":null},{"id":"W4389243727","doi":"10.1182/blood-2023-187498","title":"Lintuzumab-Ac225, a CD33-Directed Antibody Radiotherapy, Targets AML in a Mutation Agnostic Manner","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"CD33; Cancer research; Myeloid leukemia; Venetoclax; Leukemia; Medicine; Myeloid; Immunology; Oncology; Biology; Stem cell; CD34; Chronic lymphocytic leukemia","score_opus":0.015483427113954236,"score_gpt":0.31914375606771356,"score_spread":0.30366032895375933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423623,0.00081474904,0.00008016687,0.0018455728,0.00010892218,0.0007975617,0.000015356973,0.00057474675,0.0015266793],"genre_scores_gemma":[0.993636,0.0008066506,0.0015599739,0.00036694208,0.0002818857,0.00011439373,0.0004281125,0.00008301552,0.0027230293],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981788,0.00011470413,0.0003192348,0.00040262088,0.0004257917,0.0005588941],"domain_scores_gemma":[0.9990406,0.00026714557,0.000057092224,0.0003589295,0.00010973165,0.00016652365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037591244,0.00019069752,0.0003621685,0.0006108762,0.000059069855,0.000027960325,0.00013152556,0.00016217028,0.0002780881],"category_scores_gemma":[0.0006961384,0.00017351477,0.00008689681,0.0014443492,0.00007064818,0.00008545946,0.00005718607,0.00038527543,0.0005340817],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013761154,0.0030373377,0.107075065,0.0009212085,0.0011169162,0.024631226,0.006718015,0.00039780492,0.8049207,0.000307357,0.028227568,0.02127071],"study_design_scores_gemma":[0.03911183,0.0018369723,0.86294335,0.0007787994,0.0003271347,0.0010616361,0.00055144617,0.034196883,0.039921798,0.0005256244,0.01787246,0.0008720878],"about_ca_topic_score_codex":0.00027251657,"about_ca_topic_score_gemma":0.000047804588,"teacher_disagreement_score":0.76499885,"about_ca_system_score_codex":0.00021544134,"about_ca_system_score_gemma":0.00030277797,"threshold_uncertainty_score":0.7075727},"labels":[],"label_agreement":null},{"id":"W4389243971","doi":"10.1182/blood-2023-178856","title":"Targeting Abnormally Increased Expression of ULK1 Sensitizes Acute Myeloid Leukemia Resistant Cells to Venetoclax","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University of British Columbia","funders":"","keywords":"Myeloid leukemia; Autophagy; Biology; Venetoclax; Cancer research; Cell culture; Ven; Leukemia; Myeloid; Apoptosis; Genetics; Chronic lymphocytic leukemia","score_opus":0.012377031028460293,"score_gpt":0.2665633203097649,"score_spread":0.2541862892813046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960508,0.00008489918,0.00004220078,0.00029784226,0.000092257425,0.00075657386,0.000092933784,0.0002754752,0.002307035],"genre_scores_gemma":[0.99112743,0.00024642897,0.006070655,0.00034386525,0.0003481038,0.00005372973,0.00017376304,0.00009083075,0.0015451718],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972139,0.00014703478,0.000560919,0.00050198205,0.00083727436,0.000738884],"domain_scores_gemma":[0.99815464,0.000285475,0.00014201363,0.0006630479,0.0002910739,0.00046375822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008451368,0.0002663383,0.0005613381,0.0004904374,0.00013480542,0.000025631914,0.00027390243,0.00019540559,0.000102660735],"category_scores_gemma":[0.0004254812,0.00023476128,0.00014970485,0.0011011141,0.000084063184,0.00008662348,0.0003783942,0.00040450008,0.00041407126],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009473696,0.0000646471,0.0006922753,0.00021809722,0.00013976502,0.0012068303,0.00041657095,0.0001574038,0.9786437,0.000012481687,0.017297197,0.00020362035],"study_design_scores_gemma":[0.003847311,0.0004876871,0.006643513,0.00040040843,0.00021149496,0.000052443815,0.00032609573,0.0004926568,0.9840614,0.000015927373,0.0032239729,0.00023709479],"about_ca_topic_score_codex":0.00041430924,"about_ca_topic_score_gemma":0.000008526755,"teacher_disagreement_score":0.014073225,"about_ca_system_score_codex":0.00044333792,"about_ca_system_score_gemma":0.0012318612,"threshold_uncertainty_score":0.9573287},"labels":[],"label_agreement":null},{"id":"W4389244115","doi":"10.1182/blood-2023-189358","title":"Gimema Seifem Real-Life Study VS Randomized CPX-351 Registrative Trial for Older Patients with Secondary ACUTE Myeloid Leukemia: An Unanchored Matching-Adjusted Indirect Comparison of Infection Rates and Survival Outcomes","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Daunorubicin; Regimen; Myeloid leukemia; Chemotherapy regimen; Randomized controlled trial; Clinical trial; Leukemia; Pediatrics; Oncology; Chemotherapy","score_opus":0.03444640972525172,"score_gpt":0.3457785500579785,"score_spread":0.31133214033272677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389244115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989461,0.000029530072,0.000081881866,0.00014925061,0.0002444757,0.009417254,0.0001503925,0.00023186393,0.00023434294],"genre_scores_gemma":[0.9974403,0.00005924561,0.00028093398,0.000040343737,0.00016587345,0.0007285827,0.00075974304,0.00008997989,0.00043502913],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99612737,0.0008308484,0.0010074251,0.00070526695,0.0008104084,0.0005186757],"domain_scores_gemma":[0.99661607,0.0014440827,0.00058840023,0.00053267897,0.00052032736,0.00029847067],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018579847,0.0004455651,0.002467842,0.00046482237,0.0002312099,0.00006542251,0.00015159821,0.00025306956,0.000024435221],"category_scores_gemma":[0.0008090393,0.00031757622,0.00021164492,0.00072869775,0.00026468138,0.00027676582,0.000114110815,0.0005800509,0.0000046798295],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44820464,0.0026937786,0.5367758,0.00030816926,0.004042419,0.000031790383,0.0066284994,0.000013677875,0.0002417495,0.000026133208,0.00046543006,0.000567893],"study_design_scores_gemma":[0.5196899,0.0044320105,0.47117063,0.00006538531,0.0014139481,0.0000029873936,0.0014324825,0.00020672164,0.0013551287,0.000023502378,0.0000065296294,0.00020073194],"about_ca_topic_score_codex":0.0011873214,"about_ca_topic_score_gemma":0.00053685735,"teacher_disagreement_score":0.071485296,"about_ca_system_score_codex":0.00018440935,"about_ca_system_score_gemma":0.0009774257,"threshold_uncertainty_score":0.99992764},"labels":[],"label_agreement":null},{"id":"W4389244310","doi":"10.1182/blood-2023-188464","title":"Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC) Receiving Intensive Vs. Non-Intensive First Line Treatment","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Cytarabine; Azacitidine; Myeloid leukemia; Decitabine; Hypomethylating agent; Idarubicin; Oncology; Flag (linear algebra); Fludarabine; Leukemia; Hematology; Chemotherapy; Cyclophosphamide","score_opus":0.01398435838151412,"score_gpt":0.25894910589653825,"score_spread":0.24496474751502412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389244310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916895,0.000054798664,0.00001237836,0.0050917794,0.00012068939,0.0018883463,0.00017286645,0.0003529637,0.00061664695],"genre_scores_gemma":[0.9910126,0.0008097625,0.0008349295,0.0006479387,0.00009772976,0.00022882539,0.0007527598,0.00018354347,0.0054319394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967542,0.00006260811,0.0005464329,0.0008070796,0.0009156299,0.000913996],"domain_scores_gemma":[0.9953587,0.0003844592,0.00036846203,0.0009120354,0.002603958,0.00037237865],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018496974,0.00062060065,0.0013295261,0.00064827886,0.00018497751,0.000027626122,0.0002752324,0.0002755739,0.00007999642],"category_scores_gemma":[0.0005417679,0.0003903825,0.00016126355,0.0014346973,0.00034104098,0.00013997837,0.00021635026,0.0005416502,0.00018634279],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057760547,0.0008725237,0.9638609,0.00033851404,0.009433311,0.0034125783,0.0075587076,0.00008275419,0.0018623935,0.000012838622,0.0036769172,0.0031124984],"study_design_scores_gemma":[0.033296432,0.0119403545,0.9274592,0.0009521292,0.0024233668,0.00024145695,0.0020842385,0.00049433607,0.019753205,0.000010264417,0.0007870939,0.00055796077],"about_ca_topic_score_codex":0.00045111048,"about_ca_topic_score_gemma":0.0005496201,"teacher_disagreement_score":0.036401745,"about_ca_system_score_codex":0.0007951857,"about_ca_system_score_gemma":0.0007230975,"threshold_uncertainty_score":0.9998548},"labels":[],"label_agreement":null},{"id":"W4389246546","doi":"10.1182/blood-2023-188258","title":"Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Health Sciences Centre; University of Toronto; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Hôpital Maisonneuve-Rosemont; University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Decitabine; International Prognostic Scoring System; Medicine; Internal medicine; Discontinuation; Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Oncology; Regimen; Bone marrow; DNA methylation","score_opus":0.06943971882286408,"score_gpt":0.3432509982046634,"score_spread":0.27381127938179933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389246546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967211,0.00007517643,0.00008369211,0.0007251719,0.0006528827,0.0010322905,0.00014036945,0.00020445335,0.00036484536],"genre_scores_gemma":[0.99850285,0.00013446734,0.00029024328,0.00006978905,0.00014861183,0.00007387246,0.00013066489,0.00009978145,0.0005497344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947437,0.0011137772,0.0012081093,0.0009087027,0.0013404068,0.0006852776],"domain_scores_gemma":[0.99119735,0.006577027,0.00037709906,0.0010331877,0.00037278005,0.00044257948],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004585497,0.00041794288,0.0011743536,0.0007336008,0.00022341445,0.00008281181,0.00030372315,0.00037331803,0.000016534566],"category_scores_gemma":[0.009863244,0.00036847594,0.00014262083,0.0008279242,0.00029155423,0.0001858548,0.00043490934,0.00078832754,0.000036411177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033057223,0.00053722766,0.9903567,0.00077403826,0.00035784833,0.00030572197,0.00011959869,0.00012866047,0.0027742083,0.0003211574,0.00043176612,0.00058738765],"study_design_scores_gemma":[0.016455883,0.0017273793,0.96916574,0.00078770716,0.00026008658,0.0000417731,0.00023611316,0.010565355,0.00020371616,0.000028712571,0.00019836286,0.00032919762],"about_ca_topic_score_codex":0.00031767896,"about_ca_topic_score_gemma":0.000030134495,"teacher_disagreement_score":0.02119095,"about_ca_system_score_codex":0.00043303406,"about_ca_system_score_gemma":0.0007311224,"threshold_uncertainty_score":0.99987674},"labels":[],"label_agreement":null},{"id":"W4389246668","doi":"10.1182/blood-2023-173283","title":"Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Ven; Internal medicine; Chemotherapy regimen; Cytarabine; Surgery; Oncology; Leukemia; Chemotherapy","score_opus":0.0969243451126762,"score_gpt":0.37851784483102585,"score_spread":0.2815934997183497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389246668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937537,0.00009947106,0.000060723745,0.0027278855,0.000022472825,0.0023499348,0.0008413128,0.00008538099,0.000059129383],"genre_scores_gemma":[0.9954838,0.00052969996,0.0008216265,0.0014922754,0.0000884083,0.00016667985,0.0011058301,0.000056389672,0.00025526472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963369,0.0005991544,0.0010244773,0.0008444105,0.00071521976,0.00047987464],"domain_scores_gemma":[0.99261963,0.004856229,0.00065081735,0.00078333786,0.00089744397,0.00019255793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010275864,0.00038292346,0.0017081545,0.00047680148,0.00014663505,0.00003616288,0.0002853953,0.00018713083,0.000014746896],"category_scores_gemma":[0.0006767287,0.0002281403,0.00016829123,0.0029069239,0.00048021573,0.00015991161,0.00007729063,0.0005133615,0.000003352087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04153969,0.0002992641,0.9413881,0.000036407466,0.0056363214,0.000036860296,0.0087001445,0.00015018924,0.00003727751,0.000022094939,0.00089354714,0.0012601058],"study_design_scores_gemma":[0.03121456,0.0032981741,0.9585362,0.00057656557,0.0016700057,6.9754026e-7,0.0016498087,0.0018343454,0.00079525216,0.000034463606,0.00016428743,0.00022566172],"about_ca_topic_score_codex":0.014377138,"about_ca_topic_score_gemma":0.015575866,"teacher_disagreement_score":0.017148083,"about_ca_system_score_codex":0.00045567052,"about_ca_system_score_gemma":0.0007723605,"threshold_uncertainty_score":0.9921862},"labels":[],"label_agreement":null},{"id":"W4389246687","doi":"10.1182/blood-2023-186580","title":"Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Myelodysplastic syndromes; Harmonization; Delphi method; Cluster analysis; Hierarchical clustering; Computational biology; Medicine; Data mining; Computer science; Internal medicine; Biology; Artificial intelligence","score_opus":0.06684282480882796,"score_gpt":0.33751802717289714,"score_spread":0.27067520236406917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389246687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99333066,0.00012396734,0.0010519938,0.0021468173,0.00010088558,0.0013733455,0.0016067621,0.000042821273,0.00022272766],"genre_scores_gemma":[0.9960176,0.00021245242,0.0003484693,0.000040216677,0.000057643963,0.00017153658,0.0012095703,0.000027970744,0.0019145409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985206,0.00006735601,0.0004035068,0.00033073028,0.0004917054,0.00018609493],"domain_scores_gemma":[0.9981534,0.00069624,0.00017391054,0.00061049825,0.00029327607,0.0000726705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005566464,0.00011261248,0.00027207052,0.00019502119,0.00009782234,0.000021938591,0.00046249854,0.00006038615,0.000062284336],"category_scores_gemma":[0.00092405593,0.00008628902,0.000035993122,0.0005087933,0.00019164123,0.00009702874,0.00032283698,0.00016144449,0.00001148531],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012210673,0.007206775,0.43484604,0.0013345988,0.005855269,0.00009650395,0.005231057,0.00018186867,0.25504535,0.0030863828,0.2801656,0.005729475],"study_design_scores_gemma":[0.04423479,0.004590494,0.630645,0.00050108955,0.004356174,0.00048418215,0.013883805,0.24367543,0.033907734,0.0003294856,0.022652207,0.0007396251],"about_ca_topic_score_codex":0.000047689886,"about_ca_topic_score_gemma":0.00003261107,"teacher_disagreement_score":0.2575134,"about_ca_system_score_codex":0.000041886222,"about_ca_system_score_gemma":0.0002683581,"threshold_uncertainty_score":0.3518764},"labels":[],"label_agreement":null},{"id":"W4389246748","doi":"10.1182/blood-2023-174333","title":"Inactivation of DNA Polymerase Theta (PolΘ) Is Synthetic Lethal in DNMT3A Mutated Myeloid Malignancies - Potential Clinical Applications","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Biology; DNA repair; RAD51; Molecular biology; Homologous recombination; Cell cycle; Cancer research; DNA damage; Non-homologous end joining; DNA; Genetics; Gene","score_opus":0.02970187585995178,"score_gpt":0.334115540610714,"score_spread":0.30441366475076226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389246748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99458677,0.00012823615,0.00016908598,0.0029085209,0.00005116154,0.00079477014,0.00005898833,0.00012014752,0.0011823211],"genre_scores_gemma":[0.99776435,0.00018438943,0.00024145585,0.00016975537,0.00017492093,0.00015351431,0.00011939012,0.00003980976,0.0011524403],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99794006,0.00015104598,0.00064973155,0.00040280377,0.00046449195,0.00039188948],"domain_scores_gemma":[0.9987487,0.00026569952,0.00014672692,0.00054673664,0.00014677593,0.0001453258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006916317,0.00016024538,0.00041194053,0.00042714537,0.00006493013,0.000013314071,0.00020572208,0.00020105117,0.0001529366],"category_scores_gemma":[0.00033303953,0.00014532545,0.0001526062,0.0012245344,0.00024380053,0.00008220889,0.00012893607,0.00040570053,0.00023259701],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071427174,0.0035855626,0.035267726,0.0004324303,0.00051427283,0.0005908813,0.0011295887,0.000026989237,0.9327559,0.00090759265,0.0022371567,0.02183762],"study_design_scores_gemma":[0.0113447765,0.00064537034,0.22638424,0.00028807588,0.00042733114,0.0002670754,0.0010671421,0.0020979492,0.7547323,0.000627763,0.0017290438,0.00038894624],"about_ca_topic_score_codex":0.0002455698,"about_ca_topic_score_gemma":0.000008825007,"teacher_disagreement_score":0.19111651,"about_ca_system_score_codex":0.00007358495,"about_ca_system_score_gemma":0.00041750475,"threshold_uncertainty_score":0.59262},"labels":[],"label_agreement":null},{"id":"W4389246847","doi":"10.1182/blood-2023-182027","title":"Preliminary Results from a Phase 1b/2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine in Patients (Pts) with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Pharmacodynamics; Pharmacokinetics; Internal medicine; Oncology; Pharmacology; Azacitidine; Adverse effect; Neutropenia; Toxicity; Biology","score_opus":0.04174852668020341,"score_gpt":0.3510632918681256,"score_spread":0.3093147651879222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389246847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903573,0.000091452566,0.000034267,0.00017144131,0.00008643353,0.008725537,0.00044405131,0.000054378084,0.000035168094],"genre_scores_gemma":[0.99719584,0.00060810463,0.0008895079,0.000046077632,0.000028739896,0.000376001,0.0005473094,0.00009306549,0.00021535542],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947802,0.0007565653,0.0018042492,0.0011296197,0.0009420084,0.00058737013],"domain_scores_gemma":[0.9968211,0.0011583773,0.00071443303,0.0006982694,0.00034865993,0.00025918172],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010835769,0.00050743244,0.0012330853,0.000524832,0.00012185013,0.000058994683,0.00053957466,0.00018696638,0.000038152073],"category_scores_gemma":[0.000666483,0.0003255458,0.00003697154,0.0020680977,0.00048243112,0.00039243855,0.0009435139,0.0007513966,0.000003271111],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58099484,0.1328499,0.19909653,0.0033422054,0.003887451,0.0064544235,0.010713552,0.01763336,0.013687772,0.000004606356,0.00015014132,0.031185174],"study_design_scores_gemma":[0.45708618,0.06762051,0.26146913,0.0025361534,0.0016650589,0.00022064488,0.00086459686,0.20595,0.0021282833,0.0000064410983,0.000006467116,0.00044654222],"about_ca_topic_score_codex":0.0011850502,"about_ca_topic_score_gemma":0.00070039753,"teacher_disagreement_score":0.18831664,"about_ca_system_score_codex":0.001445913,"about_ca_system_score_gemma":0.0021722096,"threshold_uncertainty_score":0.99991965},"labels":[],"label_agreement":null},{"id":"W4389246923","doi":"10.1182/blood-2023-187145","title":"Clinical, Cytogenetic and Immunophenotypic Spectra of Post-Transplant Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Transplantation; Oncology; Hematopoietic stem cell transplantation; Population; Myelodysplastic syndromes; Bone marrow","score_opus":0.021733529518776756,"score_gpt":0.292949073751989,"score_spread":0.2712155442332122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389246923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99630827,0.0013125213,0.00046691747,0.00013942763,0.00021930932,0.0011924405,0.0001260566,0.00011767175,0.00011741506],"genre_scores_gemma":[0.9957476,0.0018313571,0.0015474558,0.00005652696,0.00006915446,0.0000894435,0.00018662318,0.00007684511,0.0003949875],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99772894,0.000106273335,0.0007638386,0.000500626,0.00038467054,0.0005156517],"domain_scores_gemma":[0.9982762,0.00085127633,0.00012592733,0.00040224753,0.00012858906,0.00021576093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007282689,0.0002469862,0.00065682805,0.00028476169,0.00011060161,0.00001789476,0.00017750435,0.00021755954,0.00001829059],"category_scores_gemma":[0.00007180176,0.00022592071,0.00029778303,0.00042222504,0.00011677678,0.000060182432,0.000032592867,0.0002848617,0.00005741719],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033764106,0.0016381583,0.15933013,0.011359367,0.0021021212,0.0045709144,0.0051008267,0.00007097421,0.8095053,0.00024335596,0.00014063429,0.0025618423],"study_design_scores_gemma":[0.034862533,0.0072134407,0.78985935,0.0017703348,0.00658195,0.0026571394,0.0011880279,0.00033388342,0.1541931,0.00030327198,0.0001622365,0.0008747176],"about_ca_topic_score_codex":0.00001856971,"about_ca_topic_score_gemma":0.000007719136,"teacher_disagreement_score":0.6553122,"about_ca_system_score_codex":0.000034555404,"about_ca_system_score_gemma":0.00028239118,"threshold_uncertainty_score":0.92127794},"labels":[],"label_agreement":null},{"id":"W4389247513","doi":"10.1182/blood-2023-181972","title":"Clonal Hematopoiesis, Inflammation, Hemostasis, and Cardiometabolic Biomarkers: The Reasons for Geographic and Racial Differences in Stroke Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Internal medicine; Population; Stroke (engine); Biomarker; Cohort; Disease; Prospective cohort study; Oncology; Genetics; Biology","score_opus":0.02663694323042657,"score_gpt":0.29918683684537783,"score_spread":0.27254989361495124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941876,0.0017503656,0.0000065024105,0.0023348636,0.0000330797,0.0014959833,0.00006406492,0.000054025575,0.00007354687],"genre_scores_gemma":[0.99850786,0.0007124684,0.0001250858,0.000030267593,0.00016368888,0.0003319861,0.000028714883,0.000016905604,0.000083035266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986934,0.00012085905,0.00023401475,0.00029105975,0.0003439655,0.00031666987],"domain_scores_gemma":[0.9990937,0.00043482505,0.000047558442,0.00024012316,0.00008144326,0.000102331454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009466381,0.000141254,0.00034814453,0.00045276896,0.00018253962,0.0000631797,0.00010561607,0.00007011562,0.000005638286],"category_scores_gemma":[0.00044874428,0.00009514404,0.000056586552,0.00079272833,0.00018034336,0.00006927154,0.000135446,0.00016353292,0.0000027904132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017423043,0.0001563938,0.98956084,0.000101322934,0.0005284448,0.000038920407,0.0015072952,9.349616e-8,0.0011612609,0.00015820528,0.0002672372,0.0063457815],"study_design_scores_gemma":[0.006047009,0.00022170342,0.98736,0.000032751832,0.00027296736,0.000048409034,0.004349724,0.00008691924,0.0005799863,0.00014671293,0.00075158925,0.00010220819],"about_ca_topic_score_codex":0.00017738948,"about_ca_topic_score_gemma":0.0002525096,"teacher_disagreement_score":0.006243573,"about_ca_system_score_codex":0.000014217182,"about_ca_system_score_gemma":0.00011576053,"threshold_uncertainty_score":0.38798612},"labels":[],"label_agreement":null},{"id":"W4389247626","doi":"10.1182/blood-2023-173092","title":"Oral Decitabine/Cedazuridine Vs Intravenous Decitabine for Acute Myeloid Leukemia: Final Results of a Randomized, Crossover, Registration-Enabling, Pharmacokinetics Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Decitabine; Medicine; Azacitidine; Discontinuation; Internal medicine; Oncology; Pharmacology; Adverse effect; Pharmacokinetics; Myeloid leukemia; Population; Dosing","score_opus":0.03697259444343578,"score_gpt":0.3463116137809439,"score_spread":0.3093390193375081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989095,0.00037153953,0.00076975545,0.0016660577,0.00030676252,0.006007008,0.0005192149,0.00029273,0.00097194547],"genre_scores_gemma":[0.9840342,0.0012626827,0.0044976473,0.00021000205,0.0008647886,0.00080367696,0.000738594,0.00014275878,0.007445679],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99483055,0.0002397069,0.0017726844,0.0008908118,0.0012447438,0.0010215235],"domain_scores_gemma":[0.99533135,0.0016330286,0.0005623975,0.0009727739,0.0011214864,0.00037898816],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035049915,0.00050699257,0.0018970142,0.00064657343,0.00023753395,0.00008976169,0.00052325125,0.00025451745,0.00005950103],"category_scores_gemma":[0.0051607504,0.00043034638,0.0005146206,0.0015410889,0.00040121892,0.00017406013,0.00025038645,0.0006719564,0.00005926576],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80578715,0.0071212337,0.0017638339,0.00087879715,0.009315953,0.002520396,0.004021097,0.0005603748,0.08223418,0.0005220378,0.07996369,0.00531127],"study_design_scores_gemma":[0.9162768,0.00506963,0.0022971383,0.00018879698,0.005271168,0.00035525486,0.00064780633,0.005089142,0.0582062,0.0003788195,0.0056514167,0.0005677877],"about_ca_topic_score_codex":0.00031943375,"about_ca_topic_score_gemma":0.000059637998,"teacher_disagreement_score":0.1104897,"about_ca_system_score_codex":0.00031123118,"about_ca_system_score_gemma":0.0015340106,"threshold_uncertainty_score":0.9998148},"labels":[],"label_agreement":null},{"id":"W4389248248","doi":"10.1182/blood-2023-180889","title":"Aberrant Splicing of <i>MBD1</i> Reshapes the Epigenome to Drive Convergent Myeloerythroid Defects in MDS","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto; McMaster University","funders":"","keywords":"RNA splicing; Alternative splicing; Biology; Gene isoform; Splicing factor; Epigenetics; Genetics; Cell biology; Gene; RNA","score_opus":0.022712816364243535,"score_gpt":0.28988020337481873,"score_spread":0.2671673870105752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389248248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99119335,0.0003376611,0.000013494538,0.004385265,0.00009289529,0.00094920094,0.000015574135,0.000078145196,0.0029344005],"genre_scores_gemma":[0.9970145,0.0004341234,0.00016127966,0.000885839,0.00015853385,0.00009192054,0.000017006925,0.000043213604,0.0011935446],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980763,0.00009730949,0.0003881687,0.00034725526,0.00051616755,0.00057477166],"domain_scores_gemma":[0.99876046,0.00030998237,0.00006637492,0.0005623026,0.00011223308,0.00018865141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008085705,0.00016846208,0.00039824168,0.00033770222,0.000074576164,0.000011230008,0.00027706113,0.00009170176,0.00010375405],"category_scores_gemma":[0.0003299693,0.000119660755,0.000112483314,0.0013864847,0.000104441664,0.000037383365,0.0002639125,0.00035975556,0.00049207767],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040798998,0.0005844349,0.11043921,0.00047101025,0.00035577855,0.0009952076,0.010204518,0.00026458505,0.86249334,0.0006116984,0.011315332,0.0018569044],"study_design_scores_gemma":[0.012222892,0.001534945,0.5440709,0.00085173093,0.00034909495,0.00015201993,0.0037801017,0.00087606953,0.4152798,0.00041172403,0.01991373,0.0005569962],"about_ca_topic_score_codex":0.00047091037,"about_ca_topic_score_gemma":0.00023057993,"teacher_disagreement_score":0.44721353,"about_ca_system_score_codex":0.00012898092,"about_ca_system_score_gemma":0.00029495527,"threshold_uncertainty_score":0.6324827},"labels":[],"label_agreement":null},{"id":"W4389248268","doi":"10.1182/blood-2023-174599","title":"Trends in Allogeneic Stem Cell Transplantation for Good Risk Acute Myelogenous Leukemia in First Complete Remission: A Longitudinal Study of &amp;gt; 15 Years from the ALWP/EBMT","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Servier; Incyte; Jazz Pharmaceuticals; Astellas Pharma; Alexion Pharmaceuticals; Mallinckrodt Pharmaceuticals; Gilead Sciences","keywords":"Medicine; Internal medicine; NPM1; Transplantation; Cumulative incidence; Proportional hazards model; Leukemia; Hematopoietic stem cell transplantation; Gastroenterology; Oncology; Karyotype","score_opus":0.05455136188636897,"score_gpt":0.30958291891863854,"score_spread":0.25503155703226954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389248268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972034,0.00032455885,0.000051950134,0.00026828665,0.00006221785,0.0012687268,0.0005657072,0.00005774108,0.00019737626],"genre_scores_gemma":[0.9973087,0.0006356646,0.00044671496,0.000035782716,0.00012180637,0.00021251176,0.0005606393,0.000054804797,0.00062340504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975869,0.00022721056,0.00061382627,0.0005484732,0.00050340715,0.00052017724],"domain_scores_gemma":[0.9983756,0.0006584781,0.00017309788,0.00059464306,0.00007216327,0.00012601411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007543438,0.00024397831,0.0005700286,0.0004287059,0.00011174809,0.0000190635,0.00037445774,0.00017159898,0.00007638314],"category_scores_gemma":[0.000034482473,0.00019140955,0.00014814176,0.0012561696,0.00006404891,0.000055416378,0.00008485724,0.0004689502,0.00003729051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031622883,0.0020689925,0.9105944,0.0002659351,0.0009211033,0.0018625191,0.029287016,0.0009630075,0.03240539,0.000009759505,0.002426427,0.016033174],"study_design_scores_gemma":[0.020534758,0.0010321491,0.97276896,0.00016609057,0.00079902564,0.0000487409,0.0015925308,0.0005934607,0.0014128467,0.000031358886,0.00081369816,0.00020639117],"about_ca_topic_score_codex":0.0033551082,"about_ca_topic_score_gemma":0.012626829,"teacher_disagreement_score":0.062174566,"about_ca_system_score_codex":0.00034124774,"about_ca_system_score_gemma":0.0002755559,"threshold_uncertainty_score":0.7805455},"labels":[],"label_agreement":null},{"id":"W4389248367","doi":"10.21203/rs.3.rs-3660527/v1","title":"Prognostic impacts of the three AKT isoforms in acute myeloid leukemia. Is AKT3 the bad AKTOR?","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genome Canada","keywords":"NPM1; AKT1; AKT3; Myeloid leukemia; Cancer research; Protein kinase B; Biology; PI3K/AKT/mTOR pathway; Myeloid; Leukemia; Carcinogenesis; RUNX1; AKT2; Haematopoiesis; Immunology; Genetics; Stem cell; Signal transduction; Gene; Karyotype","score_opus":0.0710024308867863,"score_gpt":0.39376612412165857,"score_spread":0.32276369323487225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389248367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9529193,0.0016586432,0.000033928158,0.031468853,0.0004992025,0.010227029,0.00058710395,0.00018534609,0.002420585],"genre_scores_gemma":[0.9868414,0.0028835135,0.00014385431,0.00032369737,0.0007231209,0.0013769972,0.00020190634,0.0002877215,0.007217781],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98770726,0.0010619587,0.0012644524,0.0014458785,0.005838949,0.0026814833],"domain_scores_gemma":[0.98992217,0.0027425676,0.00036330777,0.0045813397,0.0017837657,0.0006068579],"candidate_categories":["metaepi_narrow","open_science","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007776086,0.00074536284,0.0013100825,0.0014052844,0.0005229178,0.00023427572,0.003508913,0.001167881,0.0003718718],"category_scores_gemma":[0.00663669,0.00039772328,0.0008285768,0.003960101,0.0016317155,0.00016098356,0.008681283,0.00967855,0.00059986516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.002721827,0.0007086537,0.74156404,0.01266061,0.0024744235,0.002322153,0.010617782,0.0003629332,0.0068471357,0.00088436814,0.20185791,0.016978173],"study_design_scores_gemma":[0.0037902987,0.0011480654,0.9524001,0.009639877,0.00029289155,0.00018044529,0.0024984945,0.006136174,0.008159734,0.009137306,0.005879827,0.00073678873],"about_ca_topic_score_codex":0.0077338656,"about_ca_topic_score_gemma":0.0032116114,"teacher_disagreement_score":0.21083607,"about_ca_system_score_codex":0.005151566,"about_ca_system_score_gemma":0.012885209,"threshold_uncertainty_score":0.9998475},"labels":[],"label_agreement":null},{"id":"W4389258214","doi":"10.1182/blood-2023-178804","title":"KB-Lanra 1001: A Phase 1b/2 Study of Safety, PK, PD, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib in Combination with the FLT3 Inhibitor Gilteritinib in FLT3-Mutated R/R AML","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Servier; Astellas Pharma; Genentech; Actuate Therapeutics; Sierra Oncology; Incyte; Ono Pharmaceutical; Mateon Therapeutics; Jazz Pharmaceuticals; Gilead Sciences; Actinium Pharmaceuticals; Karyopharm Therapeutics; Celgene; Bristol-Myers Squibb; AstraZeneca; Syndax Pharmaceuticals; Constellation Pharmaceuticals; Agios Pharmaceuticals; GlaxoSmithKline; Amgen","keywords":"Syk; Fms-Like Tyrosine Kinase 3; Cancer research; Tyrosine-kinase inhibitor; Medicine; Sorafenib; Tyrosine kinase; Myeloid leukemia; Pharmacology; Immunology; Internal medicine; Biology; Cancer; Receptor; Mutation; Biochemistry","score_opus":0.015804677624155196,"score_gpt":0.29819815791991555,"score_spread":0.28239348029576034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389258214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949375,0.000119310185,0.0000018711684,0.0012695155,0.000038803693,0.0033253056,0.00004499394,0.000048066944,0.0002146724],"genre_scores_gemma":[0.9994378,0.000038374998,0.000028308365,0.000034133638,0.00006865036,0.00017116504,0.000049097547,0.000043769913,0.00012869807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975784,0.00046523885,0.0005414143,0.00039534914,0.00064581074,0.00037379283],"domain_scores_gemma":[0.9984061,0.0006422606,0.00019676078,0.00045183097,0.00022589683,0.00007716204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008680351,0.00022446537,0.00050995353,0.0004193367,0.00008812961,0.000015652375,0.00023873906,0.000115593306,0.000010246724],"category_scores_gemma":[0.00042017744,0.00013695785,0.000050566967,0.0021952158,0.00024563068,0.000092547154,0.0002594468,0.0006115791,0.000005509319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050422132,0.092440926,0.50895804,0.0017484453,0.0017859095,0.0017541229,0.10187066,0.00020371903,0.21817772,0.00014069371,0.0050855554,0.017412052],"study_design_scores_gemma":[0.1445013,0.011962629,0.75485003,0.00086311327,0.00036888703,0.00011544497,0.0118002985,0.0010550646,0.07409819,0.000034510136,0.000085851294,0.00026464692],"about_ca_topic_score_codex":0.00044891183,"about_ca_topic_score_gemma":0.0004672962,"teacher_disagreement_score":0.24589199,"about_ca_system_score_codex":0.00012859191,"about_ca_system_score_gemma":0.00032897876,"threshold_uncertainty_score":0.55849797},"labels":[],"label_agreement":null},{"id":"W4389259609","doi":"10.1182/blood-2023-186142","title":"mRNA Translation Inhibition Targets Bioenergetic Homeostasis in AML Cells <i>in Vitro</i> and <i>In Vivo</i> and Synergizes with Cytarabine and Venetoclax","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; Concordia University; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"mTORC1; Biology; Cancer research; Myeloid leukemia; Venetoclax; Cytarabine; Myeloid; Leukemia; Cancer cell; Cancer; PI3K/AKT/mTOR pathway; Cell biology; Chronic lymphocytic leukemia; Immunology; Signal transduction; Genetics","score_opus":0.011145903238821071,"score_gpt":0.2371572518239038,"score_spread":0.22601134858508273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389259609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952313,0.0027854368,0.0000059662084,0.0011824277,0.000014977109,0.0005588095,0.000037694168,0.00004065482,0.00014277878],"genre_scores_gemma":[0.99425995,0.0047064424,0.0006672243,0.00012167961,0.000036136138,0.000063785286,0.000051404426,0.000034033896,0.00005933757],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99861276,0.00008168958,0.00027016972,0.00041298431,0.0002391393,0.0003832493],"domain_scores_gemma":[0.99953645,0.00012721294,0.000039223058,0.00014050353,0.000025139834,0.00013148354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037098082,0.00018306104,0.00035029184,0.0005763473,0.000034846264,0.000025356452,0.000031535124,0.00012156998,0.000007445299],"category_scores_gemma":[0.000025409652,0.00016113094,0.000017001334,0.00082652306,0.00013574639,0.00013396272,0.000037656304,0.00026071238,0.000003011078],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010092282,0.00015633629,0.018150764,0.0003480536,0.000026846563,0.00079282257,0.0007519521,0.00009576682,0.9736357,0.000007800916,0.00012548795,0.0048992797],"study_design_scores_gemma":[0.022724366,0.00061621435,0.050474066,0.0005369812,0.00009864673,0.00015356773,0.00037767456,0.0040556686,0.91974616,0.00013241499,0.00072936784,0.00035486897],"about_ca_topic_score_codex":0.00038937476,"about_ca_topic_score_gemma":0.00055689755,"teacher_disagreement_score":0.0538895,"about_ca_system_score_codex":0.00009062302,"about_ca_system_score_gemma":0.000109594796,"threshold_uncertainty_score":0.6570729},"labels":[],"label_agreement":null},{"id":"W4389259644","doi":"10.1182/blood-2023-181821","title":"Interest of Cytoreductive Therapy before Allogenic Hematopoietic Stem Cell Transplantation in Childhood Myelodysplastic Syndromes: A Retrospective Study on Behalf of the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Busulfan; Hematopoietic stem cell transplantation; Transplantation; Myelodysplastic syndromes; Internal medicine; Umbilical cord; Pediatrics; Retrospective cohort study; Oncology; Surgery; Bone marrow; Immunology","score_opus":0.01884524136926775,"score_gpt":0.2895026362594403,"score_spread":0.27065739489017254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389259644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99729294,0.00021155633,0.000042045016,0.00025922176,0.000086573906,0.0017596426,0.00007744318,0.000058394173,0.0002121641],"genre_scores_gemma":[0.99918824,0.00024844677,0.00006570877,0.000053201926,0.00006206525,0.00018164261,0.000021694772,0.000076179,0.00010283318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976166,0.00040282405,0.00048646025,0.00042614623,0.0005401972,0.00052779267],"domain_scores_gemma":[0.99875706,0.00026498517,0.0002515733,0.00049872854,0.000105569525,0.00012205355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080759625,0.00028594182,0.00060971285,0.00032013256,0.00008665142,0.000009731101,0.0003670085,0.00019760056,0.000024846564],"category_scores_gemma":[0.00006871088,0.00021441837,0.00022051575,0.001082995,0.0001774649,0.0000558941,0.00007250938,0.0007423307,0.000012199607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014672697,0.011261673,0.4285703,0.00090891495,0.00132468,0.0008962794,0.2541725,0.0002894287,0.30009532,0.00020329605,0.00007627183,0.0007340699],"study_design_scores_gemma":[0.011234515,0.002876855,0.79366374,0.00046274776,0.00021689243,0.000197519,0.021788169,0.000088042245,0.16901495,0.0003172457,7.512737e-7,0.00013857083],"about_ca_topic_score_codex":0.00024228776,"about_ca_topic_score_gemma":0.00018813094,"teacher_disagreement_score":0.36509347,"about_ca_system_score_codex":0.00050214346,"about_ca_system_score_gemma":0.0010014176,"threshold_uncertainty_score":0.8743727},"labels":[],"label_agreement":null},{"id":"W4389297538","doi":"10.1038/s41416-023-02511-8","title":"Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia","year":2023,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Government of Canada","keywords":"Mutation; Medicine; Cancer research; Myeloid; Sorafenib; Transcriptome; Point mutation; Myeloid leukaemia; Oncology; Bioinformatics; Internal medicine; Biology; Genetics; Gene","score_opus":0.014348140268831489,"score_gpt":0.31258867330632395,"score_spread":0.2982405330374925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389297538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971749,0.00090692315,0.000070435344,0.0011327825,0.00021266787,0.00016552131,0.000046867204,0.000012092878,0.00027778195],"genre_scores_gemma":[0.9927935,0.0058012973,0.00017872968,0.00016746754,0.00042250502,0.000014963785,0.000022552667,0.000021600497,0.0005773543],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986584,0.000048285365,0.00054008706,0.00010457476,0.0004326829,0.0002159415],"domain_scores_gemma":[0.99917287,0.0000660479,0.0002346481,0.000093019546,0.00032112873,0.00011231111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035927742,0.000074620104,0.00032298974,0.00034849072,0.00003688466,0.000028315184,0.00011073563,0.00006798588,0.00025891536],"category_scores_gemma":[0.00022370671,0.000080931146,0.00009956995,0.0005896095,0.00005042516,0.00021195428,0.000030450712,0.0003266222,0.000016670732],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014785408,0.0006328499,0.12848341,0.00043026073,0.0012104652,0.008232655,0.0034918995,0.001292958,0.17859301,0.00008233512,0.034601025,0.6414706],"study_design_scores_gemma":[0.0033826854,0.0001884509,0.9855107,0.001283508,0.00009176296,0.00231502,0.00010711178,0.00060994376,0.005057133,0.000072461444,0.001302077,0.00007914569],"about_ca_topic_score_codex":0.00033957427,"about_ca_topic_score_gemma":0.00023913298,"teacher_disagreement_score":0.8570273,"about_ca_system_score_codex":0.00045382217,"about_ca_system_score_gemma":0.001047527,"threshold_uncertainty_score":0.33002764},"labels":[],"label_agreement":null},{"id":"W4389329605","doi":"10.1182/bloodadvances.2023011721","title":"Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; Ludwig Center at Harvard; Sierra Oncology; Astellas Pharma; U.S. Department of Defense; Gilead Sciences; Genentech; Bristol-Myers Squibb; AstraZeneca; Servier; Pfizer","keywords":"Azacitidine; Medicine; Venetoclax; Internal medicine; Hypomethylating agent; Myeloid leukemia; Adverse effect; Interleukin-3 receptor; Minimal residual disease; Leukemia; Decitabine; Myelodysplastic syndromes; Oncology; Gastroenterology; Immunology; Chronic lymphocytic leukemia; Bone marrow; Biology","score_opus":0.022409650278020325,"score_gpt":0.33712194328773853,"score_spread":0.3147122930097182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389329605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99649423,0.00019118663,0.0000698466,0.00036363886,0.000055600805,0.001903911,0.000025697955,0.0000969787,0.00079889665],"genre_scores_gemma":[0.99501175,0.0008545809,0.0022132285,0.00006033625,0.000099984674,0.0003338864,0.00013404,0.00005452256,0.0012377007],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977511,0.000093916824,0.00048337632,0.00045226724,0.00070693676,0.0005123683],"domain_scores_gemma":[0.9989652,0.00020285576,0.00018816096,0.00036702573,0.0001430402,0.00013368699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047602417,0.00025609057,0.00073013414,0.00068265863,0.00004087305,0.00001530707,0.00019353667,0.00010535649,0.000029808398],"category_scores_gemma":[0.0001533842,0.00016843538,0.000043589964,0.0022510292,0.00023404081,0.00033106146,0.00005596319,0.000420936,0.000014169234],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7585801,0.008642949,0.10316789,0.0014681468,0.0008634435,0.0070777657,0.0026162977,0.0012443176,0.05133743,0.000674615,0.00051174016,0.063815325],"study_design_scores_gemma":[0.8776702,0.035145238,0.006962709,0.0014033425,0.0003343239,0.0002682973,0.0012673135,0.003941738,0.06864189,0.00022732628,0.0036043196,0.0005332763],"about_ca_topic_score_codex":0.00018695767,"about_ca_topic_score_gemma":0.0010211368,"teacher_disagreement_score":0.11909015,"about_ca_system_score_codex":0.0004579285,"about_ca_system_score_gemma":0.0014951486,"threshold_uncertainty_score":0.6868595},"labels":[],"label_agreement":null},{"id":"W4389454730","doi":"10.1007/s40487-023-00253-4","title":"Experiences and Support Needs of Caregivers of Patients with Higher-Risk Myelodysplastic Syndrome via Online Bulletin Board in the USA, Canada and UK","year":2023,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharma; Novartis","keywords":"Myelodysplastic syndromes; Medicine; Family medicine; Disease; Gerontology; Internal medicine","score_opus":0.01175460647217719,"score_gpt":0.26545001392252043,"score_spread":0.25369540745034325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389454730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99853635,0.00015390344,9.162918e-7,0.0008661015,0.00004523117,0.00025232695,0.000027899721,0.0000031803309,0.000114079914],"genre_scores_gemma":[0.99830234,0.0011460206,0.000038082282,0.0002127684,0.000010716857,0.000021203592,0.00002040481,0.0000065922477,0.00024186677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992691,0.00009682882,0.00015183196,0.00012282425,0.00018826932,0.00017111817],"domain_scores_gemma":[0.9993375,0.0003629058,0.000077902725,0.00010628206,0.00005268363,0.00006275062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019130799,0.00009148506,0.00028758292,0.000114832175,0.000046383597,0.0000024933222,0.000069226015,0.000074309544,0.00017812371],"category_scores_gemma":[0.000021818232,0.00005417946,0.000009876463,0.00024608328,0.00042759348,0.000015000443,0.000028812141,0.00017076083,5.015857e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011612674,0.00008637414,0.981477,0.000035746758,0.00008076152,0.00017431988,0.009399338,0.0000013496361,0.000099268014,0.000017963584,0.0009539836,0.0065125776],"study_design_scores_gemma":[0.0038251416,0.0033531946,0.9798359,0.00001988197,0.000021655103,0.000040095692,0.0077526346,0.000010403617,0.00005161203,0.000010160831,0.0050211805,0.00005812531],"about_ca_topic_score_codex":0.101610616,"about_ca_topic_score_gemma":0.07783486,"teacher_disagreement_score":0.023775754,"about_ca_system_score_codex":0.000049304035,"about_ca_system_score_gemma":0.00034186817,"threshold_uncertainty_score":0.93899226},"labels":[],"label_agreement":null},{"id":"W4389509713","doi":"10.14309/crj.0000000000001213","title":"Non-Mass-Forming Myeloid Sarcoma of the Colon Presenting With Diarrhea","year":2023,"lang":"en","type":"article","venue":"ACG Case Reports Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Myeloid sarcoma; Diarrhea; Myeloid; Cancer research; Internal medicine","score_opus":0.020211947335030594,"score_gpt":0.30325712940732974,"score_spread":0.2830451820722991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389509713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99415517,0.000098012446,0.0000826236,0.0014251018,0.0002772436,0.00045836813,0.0000021225662,0.000042962154,0.0034584177],"genre_scores_gemma":[0.9968095,0.00008158256,0.0005394321,0.00007729286,0.000447659,0.000013466917,0.0000038446715,0.000048644866,0.0019785839],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99739933,0.00007292617,0.00071564736,0.0002452713,0.0009945038,0.00057234266],"domain_scores_gemma":[0.9978629,0.0001928013,0.0006325237,0.0006096498,0.00041581082,0.00028632363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018586521,0.00017301005,0.00037451,0.00025719622,0.00042379557,0.000054190677,0.0001133832,0.00010171764,0.00008603833],"category_scores_gemma":[0.0008068356,0.0000999859,0.00018934127,0.00090695283,0.00017521204,0.00019259236,0.00018035188,0.0010040299,0.000010141024],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001725839,0.00007802089,0.25261188,0.00018856087,0.0003037045,0.71108764,0.000988943,0.00011979549,0.02598415,0.000008658419,0.0059290584,0.0025270144],"study_design_scores_gemma":[0.0010857665,0.00028060228,0.031553276,0.00039145985,0.00016782472,0.9260015,0.0011666509,0.0012136969,0.03513375,0.00015998477,0.0026942317,0.00015127545],"about_ca_topic_score_codex":0.00011179299,"about_ca_topic_score_gemma":0.000021132551,"teacher_disagreement_score":0.22105859,"about_ca_system_score_codex":0.00026409279,"about_ca_system_score_gemma":0.0010449406,"threshold_uncertainty_score":0.4362066},"labels":[],"label_agreement":null},{"id":"W4389513513","doi":"10.1016/j.exphem.2023.11.009","title":"Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations","year":2023,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium; Princess Margaret Cancer Centre; University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada; Genentech; Ontario Genomics Institute; European Federation of Pharmaceutical Industries and Associations; Merck KGaA; Pfizer; Leukemia and Lymphoma Society of Canada; Ontario Genomics; Bayer; Cancer Research Society; Genome Canada; Mitacs; Leukemia and Lymphoma Society; McGill University; Bristol-Myers Squibb","keywords":"EZH2; Epigenetics; Leukemia; Cancer research; Biology; Genetics; Computational biology; Gene","score_opus":0.03660358536710746,"score_gpt":0.3578019010850984,"score_spread":0.32119831571799096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389513513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99221593,0.001022906,0.000065254106,0.00029141142,0.00012487019,0.00033683729,0.0000049926957,0.00015993157,0.0057778917],"genre_scores_gemma":[0.99725443,0.000015905554,0.0015122514,0.000056733414,0.000059057653,0.00014977423,0.0000497704,0.000034835157,0.00086723984],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998662,0.00007575567,0.00037057095,0.00026960764,0.00023819148,0.00038388572],"domain_scores_gemma":[0.9991208,0.000329229,0.00007837719,0.00029581404,0.000068004636,0.00010777782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017452081,0.00013768426,0.0003955111,0.00028268446,0.000109017186,0.0000062026625,0.00011236085,0.00010413144,0.00044751234],"category_scores_gemma":[0.00023960226,0.00013351228,0.00008291291,0.00047288678,0.0002823897,0.00006780091,0.00014861478,0.00023110089,0.00016787015],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003061917,0.00029396956,0.03256863,0.000613726,0.00021635916,0.00042613156,0.009542759,0.00013992305,0.88431114,0.06576695,0.0041528544,0.0016613734],"study_design_scores_gemma":[0.0010140111,0.00026702893,0.003216212,0.00007420558,0.0000107781925,0.00021264624,0.010235173,0.0014988648,0.9827759,0.00030436149,0.000286149,0.00010465859],"about_ca_topic_score_codex":0.00015890533,"about_ca_topic_score_gemma":0.0000024092612,"teacher_disagreement_score":0.09846479,"about_ca_system_score_codex":0.00050329464,"about_ca_system_score_gemma":0.00029017788,"threshold_uncertainty_score":0.5444473},"labels":[],"label_agreement":null},{"id":"W4389624712","doi":"10.3390/curroncol30120759","title":"The Clinical Utility of FLT3 Mutation Testing in Acute Leukemia: A Canadian Consensus","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; Canadian Electricity Association; University of Ottawa; University of Calgary; Sunnybrook Health Science Centre; University Health Network; University of Toronto; Health Sciences Centre; University of Alberta; Université de Montréal","funders":"Pfizer Canada; Amgen Canada; Bristol-Myers Squibb Canada; Servier Canada","keywords":"Medicine; Mutation; Minimal residual disease; Oncology; Hematopoietic stem cell transplantation; Clinical significance; Transplantation; Leukemia; Fms-Like Tyrosine Kinase 3; Genetic testing; Myeloid leukemia; Internal medicine; Bioinformatics; Gene; Genetics; Biology","score_opus":0.2820190550063069,"score_gpt":0.5025033313112616,"score_spread":0.22048427630495465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389624712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888825,0.00024044953,0.0000057654092,0.0050025242,0.0008058058,0.00054636016,0.000024801762,0.000043372682,0.004448436],"genre_scores_gemma":[0.998912,0.00035569337,0.00021803375,0.00008415963,0.0001548849,0.000045417713,0.000050049795,0.0000132554815,0.00016650699],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979792,0.00040129977,0.0006268021,0.00026691996,0.00020734509,0.0005184123],"domain_scores_gemma":[0.9957723,0.0032343953,0.00012632011,0.00030389105,0.00029283197,0.00027027362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025659127,0.00009872253,0.00036238116,0.00024584954,0.000103168764,0.000006063736,0.00016336786,0.0002035513,0.000027271883],"category_scores_gemma":[0.006369765,0.000074007374,0.00007150016,0.0009214696,0.0004855176,0.000015459018,0.000090550915,0.0009152546,0.00011583093],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003189508,0.000083431725,0.43189764,0.000082712446,0.000059872655,0.00110096,0.00031865883,0.0000068676873,0.00012576998,0.00012870536,0.034785457,0.531091],"study_design_scores_gemma":[0.0031542627,0.0005423854,0.89766705,0.00007688196,0.00007298252,0.00021170164,0.00052423996,0.03176449,0.0000684871,0.000418941,0.0654104,0.00008819228],"about_ca_topic_score_codex":0.011115015,"about_ca_topic_score_gemma":0.056296185,"teacher_disagreement_score":0.5310028,"about_ca_system_score_codex":0.0012483735,"about_ca_system_score_gemma":0.008228933,"threshold_uncertainty_score":0.9973935},"labels":[],"label_agreement":null},{"id":"W4389794367","doi":"10.1038/s41375-023-02107-4","title":"DELE1 haploinsufficiency causes resistance to mitochondrial stress-induced apoptosis in monosomy 5/del(5q) AML","year":2023,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec; Princess Margaret Cancer Centre; Centre Hospitalier Universitaire Sainte-Justine; Hôpital Maisonneuve-Rosemont; Université de Montréal; University of Toronto; University Health Network; Institute for Research in Immunology and Cancer","funders":"Institut de Valorisation des Données; Canada First Research Excellence Fund; Université de Montréal; Government of Canada; Génome Québec; Compute Canada; Canadian Institutes of Health Research; Genome Canada","keywords":"Haploinsufficiency; Biology; Cancer research; Myeloid leukemia; Monosomy; Genetics; Transcriptome; Chromosome 7 (human); Leukemia; Gene; Chromosome; Phenotype; Gene expression; Karyotype","score_opus":0.03124381591636909,"score_gpt":0.31058397425217127,"score_spread":0.27934015833580217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389794367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885855,0.00010141149,0.00010054224,0.003651318,0.00050185114,0.0012977454,0.0000595482,0.00045699946,0.005245134],"genre_scores_gemma":[0.9859674,0.00012731257,0.0018434131,0.00090168044,0.00072612776,0.00035184668,0.00009233405,0.00011693862,0.009872972],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958732,0.0001316939,0.0006843101,0.000977155,0.001034441,0.0012991886],"domain_scores_gemma":[0.99772006,0.00033020022,0.000099946345,0.0010635103,0.00021903831,0.0005672601],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034196133,0.00040006908,0.0006658914,0.0010063575,0.00017340691,0.00007699997,0.00057732995,0.00032817904,0.00014195537],"category_scores_gemma":[0.0012416926,0.00038319742,0.00016317004,0.0033672662,0.00009859999,0.00019490227,0.00032770817,0.00091156573,0.00169276],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027884038,0.00041929792,0.0252631,0.0006153275,0.0001866356,0.0015476592,0.004164908,0.0013712501,0.745665,0.001129865,0.21080682,0.006041707],"study_design_scores_gemma":[0.018878443,0.001713476,0.20703325,0.0022422802,0.00022444745,0.000060707505,0.0038676488,0.0056578824,0.68512255,0.0007163613,0.07212421,0.0023587581],"about_ca_topic_score_codex":0.0012481167,"about_ca_topic_score_gemma":0.001296112,"teacher_disagreement_score":0.18177015,"about_ca_system_score_codex":0.0032649778,"about_ca_system_score_gemma":0.0018076174,"threshold_uncertainty_score":0.999862},"labels":[],"label_agreement":null},{"id":"W4389949008","doi":"10.1038/s41375-023-02110-9","title":"Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms","year":2023,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Chronic myelomonocytic leukemia; Myeloid leukemia; Internal medicine; Oncology; Myelodysplastic syndromes; Leukemia; Myeloid; Refractory (planetary science); Gastroenterology; Bone marrow; Biology","score_opus":0.021973059342996197,"score_gpt":0.30872909073866134,"score_spread":0.28675603139566513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389949008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963845,0.000047320056,0.000039011913,0.0002892903,0.00083004026,0.0019190983,0.00019198918,0.00017075373,0.00012799575],"genre_scores_gemma":[0.99442023,0.0014949037,0.00044185243,0.00026940525,0.00057725684,0.00009436184,0.0008644671,0.0001239824,0.0017135133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99495775,0.0005216235,0.0016243212,0.0011226002,0.00097469636,0.00079900335],"domain_scores_gemma":[0.99616325,0.0015925481,0.0006227365,0.0007596059,0.00027176668,0.0005901033],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014530782,0.0005059589,0.0012554898,0.00062617345,0.00013573987,0.000055846653,0.00023848897,0.0008156731,0.000048006375],"category_scores_gemma":[0.001361057,0.00041614173,0.00014227057,0.0011752682,0.000729903,0.0003765305,0.00039351796,0.0018559615,0.00006216083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15068236,0.00070873724,0.78887045,0.0003364415,0.00055846636,0.00036433578,0.00044542964,0.000010561018,0.0024675317,0.00004311755,0.0022818337,0.053230707],"study_design_scores_gemma":[0.12529244,0.00783745,0.8618734,0.0003692205,0.00039956885,0.000015002319,0.000039038743,0.0009985433,0.00018170686,0.000025060963,0.0025964216,0.0003721688],"about_ca_topic_score_codex":0.00020895804,"about_ca_topic_score_gemma":0.000060800798,"teacher_disagreement_score":0.07300291,"about_ca_system_score_codex":0.0011423323,"about_ca_system_score_gemma":0.002065182,"threshold_uncertainty_score":0.99982905},"labels":[],"label_agreement":null},{"id":"W4390021910","doi":"10.1016/s2352-3026(23)00338-1","title":"Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Hôpital Maisonneuve-Rosemont; University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa","funders":"Astex Pharmaceuticals","keywords":"Decitabine; Medicine; Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Azacitidine; Internal medicine; International Prognostic Scoring System; Adverse effect; Oncology; Pharmacology; Bone marrow","score_opus":0.09378879086140673,"score_gpt":0.4066840908216205,"score_spread":0.31289529996021376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390021910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843653,0.0013255718,0.00070058985,0.00790766,0.00054172915,0.0044526733,0.00011274311,0.00030361512,0.0002901339],"genre_scores_gemma":[0.99536216,0.00093543564,0.00044736217,0.00029927393,0.00086247944,0.0010002875,0.0002644621,0.00009865654,0.00072985323],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964586,0.00028439923,0.0007522846,0.00076789403,0.00049909175,0.0012377374],"domain_scores_gemma":[0.99480563,0.0034704925,0.00022522265,0.0008621403,0.00034419724,0.00029233433],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013721391,0.00047085184,0.0018146784,0.00031728428,0.00042223439,0.00009114875,0.0005231801,0.00018939377,0.00015788994],"category_scores_gemma":[0.0025508432,0.00034380803,0.00015009395,0.0008291274,0.00068885117,0.000114588256,0.00025455636,0.0006314144,0.00013827755],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59516555,0.004354703,0.0055198674,0.006113825,0.008833014,0.017418718,0.0061809826,0.002176213,0.026961794,0.01893115,0.27642795,0.03191625],"study_design_scores_gemma":[0.8679723,0.013551996,0.005296642,0.00028074096,0.003006905,0.008903063,0.0020575884,0.07182059,0.004175074,0.0018313435,0.019886417,0.0012173166],"about_ca_topic_score_codex":0.000065147935,"about_ca_topic_score_gemma":0.00011366728,"teacher_disagreement_score":0.2728068,"about_ca_system_score_codex":0.0005146258,"about_ca_system_score_gemma":0.0010155394,"threshold_uncertainty_score":0.9999014},"labels":[],"label_agreement":null},{"id":"W4390146876","doi":"10.1016/j.sjbs.2023.103917","title":"Association of genetic predisposition studies in CYP1A1 polymorphism studies in acute myeloid leukemia","year":2023,"lang":"en","type":"article","venue":"Saudi Journal of Biological Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Population and Public Health","keywords":"Myeloid leukemia; Genetic predisposition; Genetic association; Medicine; Polymorphism (computer science); Genetics; Biology; Single-nucleotide polymorphism; Genotype; Internal medicine; Gene","score_opus":0.11680484147485139,"score_gpt":0.40183048169693,"score_spread":0.2850256402220786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390146876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98942184,0.006325583,0.00000592278,0.0036709895,0.0002667407,0.00018896989,0.000005514789,0.000012711394,0.000101710764],"genre_scores_gemma":[0.9701384,0.028662965,0.0007329479,0.00011686945,0.00015543318,0.000007870074,0.000001621351,0.0000037404573,0.00018017515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975471,0.00028721237,0.00079215766,0.0002254919,0.00072576985,0.00042228386],"domain_scores_gemma":[0.9981922,0.00082663394,0.00049021357,0.00007926361,0.00033067894,0.00008103183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037746255,0.00012825122,0.0006362122,0.0006265145,0.0000829583,0.000010415038,0.00026535234,0.00013766409,0.000016789276],"category_scores_gemma":[0.0026956878,0.0000745983,0.00011301564,0.0019351798,0.00083756173,0.0001475079,0.00016329392,0.00037925705,0.0000104577075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051441643,0.00010524895,0.89961404,0.00010090929,0.00039224172,0.0007303931,0.0021315853,0.0003190282,0.0870567,0.000050105773,0.0031657328,0.005819604],"study_design_scores_gemma":[0.0014167881,0.0020967368,0.9843692,0.0005647652,0.000053957956,0.00014234794,0.0044935117,0.00026891826,0.0037367844,0.0026888894,0.000067326306,0.00010075654],"about_ca_topic_score_codex":0.000026337804,"about_ca_topic_score_gemma":0.00002988033,"teacher_disagreement_score":0.08475518,"about_ca_system_score_codex":0.0013701086,"about_ca_system_score_gemma":0.00034557917,"threshold_uncertainty_score":0.35827863},"labels":[],"label_agreement":null},{"id":"W4390297987","doi":"10.1101/2023.12.26.573390","title":"Single-cell transcriptional mapping reveals genetic and non-genetic determinants of aberrant differentiation in AML","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Amgen (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"University of Toronto; Canada First Research Excellence Fund; Government of Ontario; International Development Research Centre; American Lebanese Syrian Associated Charities; Princess Margaret Cancer Foundation; St. Jude Children's Research Hospital","keywords":"Biology; Computational biology; Genetics; Evolutionary biology; Cellular differentiation; Gene","score_opus":0.03343084131205749,"score_gpt":0.25099957682104657,"score_spread":0.2175687355089891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390297987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955671,0.0011121815,0.0011173146,0.00014400153,0.0003964087,0.0014046712,0.00015158912,0.00010271742,0.000004036463],"genre_scores_gemma":[0.99035233,0.00086585,0.008105612,0.00006336581,0.00021927917,0.00020190801,0.0000012875146,0.0001623849,0.000027950686],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9964934,0.00015938398,0.0010504252,0.0010034819,0.00065287127,0.0006404176],"domain_scores_gemma":[0.9979296,0.0001158385,0.00041115787,0.00087920914,0.00037341614,0.00029081706],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054333144,0.0004958104,0.0009874473,0.000914465,0.0000667355,0.00006549831,0.0002940822,0.0005856393,0.000029873441],"category_scores_gemma":[0.00018816623,0.00053057575,0.00015461155,0.00062822364,0.00016816019,0.000067102505,0.0003158615,0.0008530742,0.00002737128],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006627456,0.00018430124,0.24384293,0.0025083825,0.000059577484,0.00017228551,0.00004522223,0.000025194546,0.753031,0.0000021292417,0.0000484105,0.0000142680865],"study_design_scores_gemma":[0.001727449,0.0001185876,0.87580496,0.0017580532,0.00012504825,1.4339732e-7,0.0000070218716,0.0033527026,0.11667701,0.0000037725147,0.000045027926,0.00038023546],"about_ca_topic_score_codex":0.00017664631,"about_ca_topic_score_gemma":0.000018615196,"teacher_disagreement_score":0.636354,"about_ca_system_score_codex":0.00053972774,"about_ca_system_score_gemma":0.0007027669,"threshold_uncertainty_score":0.99971455},"labels":[],"label_agreement":null},{"id":"W4390340525","doi":"10.14740/jh1162","title":"Haploidentical and Matched Sibling Transplantation for Acute Myeloid Leukemia: A Hospital-Based Study","year":2023,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Transplantation; Myeloid leukemia; Confidence interval; Acute promyelocytic leukemia; Regimen; Leukemia; Surgery","score_opus":0.024291510559375222,"score_gpt":0.34986780993817723,"score_spread":0.325576299378802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390340525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98723656,0.00013591308,0.00517947,0.0064469157,0.00021984213,0.0007068257,0.000006846365,0.000041750296,0.000025851605],"genre_scores_gemma":[0.9959954,0.00021694365,0.0032463649,0.00020633954,0.00012842852,0.000033316708,0.000012830039,0.000034288438,0.00012607255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839246,0.000078414094,0.0006133776,0.00019585525,0.00036556151,0.00035434653],"domain_scores_gemma":[0.9985289,0.000588148,0.00021192692,0.00014499945,0.0003287124,0.00019730043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083238044,0.00014384813,0.00068334135,0.00064276747,0.00008501116,0.000027633041,0.0001251264,0.00015367287,0.00002406456],"category_scores_gemma":[0.000320585,0.00011440696,0.00014579947,0.00039059573,0.000079488505,0.00011827662,0.000026480879,0.0004313726,0.000018257722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031330623,0.0038498135,0.67101294,0.0061135576,0.009129275,0.06989159,0.017683858,0.0003804258,0.13664001,0.003193202,0.0404521,0.010322603],"study_design_scores_gemma":[0.15469609,0.046293486,0.5468947,0.0018179514,0.012199282,0.050803628,0.025791848,0.046554036,0.10339094,0.008120563,0.0017396116,0.0016978504],"about_ca_topic_score_codex":0.0000060264642,"about_ca_topic_score_gemma":0.0000055143764,"teacher_disagreement_score":0.12411824,"about_ca_system_score_codex":0.00018034596,"about_ca_system_score_gemma":0.0005200031,"threshold_uncertainty_score":0.46653804},"labels":[],"label_agreement":null},{"id":"W4390344090","doi":"10.3324/haematol.2023.283776","title":"LNK/&lt;i&gt;SH2B3&lt;/i&gt; as a novel driver in juvenile myelomonocytic leukemia","year":2023,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Heart, Lung, and Blood Institute; Deutsche Krebshilfe; Frank A. Campini Foundation; National Cancer Institute; National Institutes of Health; Children's Hospital of Philadelphia; Leukemia and Lymphoma Society","keywords":"Juvenile myelomonocytic leukemia; Cancer research; KRAS; Ruxolitinib; Biology; Myeloid; Haematopoiesis; Neuroblastoma RAS viral oncogene homolog; Internal medicine; Immunology; Mutation; Medicine; Genetics; Stem cell; Bone marrow; Myelofibrosis; Gene","score_opus":0.0365812657277071,"score_gpt":0.3064503753839696,"score_spread":0.2698691096562625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390344090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9438055,0.0004795422,0.00012425517,0.0035876967,0.00022816846,0.0012789251,0.000024290011,0.00075666246,0.04971495],"genre_scores_gemma":[0.9794817,0.00048668057,0.0018216366,0.0011754817,0.00015507048,0.00034611527,0.00012409076,0.00009810194,0.01631111],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99563754,0.00015764093,0.0008323718,0.0009924866,0.00094025146,0.0014397193],"domain_scores_gemma":[0.99744374,0.0006229626,0.00017787596,0.0010816747,0.00018617464,0.00048755415],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00092803483,0.00048805107,0.001260823,0.0008536141,0.0001974496,0.000058638252,0.0006342954,0.00057520793,0.0013496075],"category_scores_gemma":[0.0016245567,0.00040202687,0.00028164368,0.0022295283,0.0004215737,0.00017817151,0.0006112202,0.0009120931,0.010813871],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00260577,0.0013036072,0.015007353,0.001815255,0.0006530309,0.049731683,0.0052022585,0.00045444333,0.4052427,0.068074204,0.43627796,0.013631717],"study_design_scores_gemma":[0.029014176,0.0026503145,0.2401379,0.0018343792,0.00044572967,0.011586001,0.0015604649,0.04003995,0.025902726,0.0088855,0.6350307,0.0029121977],"about_ca_topic_score_codex":0.00009339672,"about_ca_topic_score_gemma":0.00011826251,"teacher_disagreement_score":0.37934,"about_ca_system_score_codex":0.0015995615,"about_ca_system_score_gemma":0.0014277311,"threshold_uncertainty_score":0.9998432},"labels":[],"label_agreement":null},{"id":"W4390403333","doi":"10.3390/ijms25010496","title":"An In Vitro Model for Acute Myeloid Leukemia Relapse Using the SORE6 Reporter","year":2023,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Faculty of Medicine and Dentistry, University of Alberta; University of Alberta","keywords":"Myeloid leukemia; SOX2; In vitro; Stem cell; Cell culture; Cancer research; Bone marrow; Leukemia; Biology; Myeloid; Embryonic stem cell; Medicine; Immunology; Molecular biology; Cell biology; Gene; Genetics","score_opus":0.05012201619360847,"score_gpt":0.39180826497836146,"score_spread":0.341686248784753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390403333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95898014,0.00006965574,0.03526744,0.0050211055,0.0003100513,0.00018268796,0.000007841214,0.000011036304,0.00015004624],"genre_scores_gemma":[0.98048806,0.00006754344,0.018215682,0.00086532417,0.0001825097,0.0000069116168,0.0000065936906,0.000013548994,0.00015385251],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9977727,0.000055840817,0.0004769776,0.00020012379,0.001234666,0.00025969578],"domain_scores_gemma":[0.99882597,0.00009332329,0.00026585185,0.00016476164,0.0005465462,0.00010354633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002175445,0.000095676674,0.00018560367,0.0005733607,0.00009048087,0.000106394735,0.00078261126,0.00005503795,0.0000068989384],"category_scores_gemma":[0.00030621636,0.00006110266,0.00015437121,0.00048134045,0.00024200138,0.0003333308,0.00008860949,0.00025821512,0.0000024938397],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005383673,0.00003770091,0.00058457954,0.0000041718745,0.00015665096,0.0016640626,0.0006288042,0.04925778,0.94265795,0.00030826498,0.00048664206,0.003675051],"study_design_scores_gemma":[0.0011543981,0.00019944958,0.0005177404,0.00005738309,0.00005048155,0.0016296755,0.0004160861,0.91512823,0.077826284,0.0027812307,0.00016000807,0.000079056124],"about_ca_topic_score_codex":0.000028509523,"about_ca_topic_score_gemma":0.000004454517,"teacher_disagreement_score":0.8658704,"about_ca_system_score_codex":0.00047632962,"about_ca_system_score_gemma":0.0015406581,"threshold_uncertainty_score":0.27330613},"labels":[],"label_agreement":null},{"id":"W4390586512","doi":"10.3390/ijms25010646","title":"ULK2 Is a Key Pro-Autophagy Protein That Contributes to the High Chemoresistance and Disease Relapse in FLT3-Mutated Acute Myeloid Leukemia","year":2024,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Faculty of Medicine and Dentistry, University of Alberta; University of Alberta","keywords":"Autophagy; Myeloid leukemia; Cancer research; Disease; Myeloid; Leukemia; Medicine; Fms-Like Tyrosine Kinase 3; Biology; Oncology; Immunology; Mutation; Internal medicine; Apoptosis; Gene; Genetics","score_opus":0.013332515321866282,"score_gpt":0.3054258120653277,"score_spread":0.2920932967434614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390586512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89778775,0.005165559,0.0017776111,0.09432624,0.00029244984,0.0004477561,0.000026531845,0.000015019855,0.0001610568],"genre_scores_gemma":[0.9952892,0.00020347691,0.0014504025,0.002334956,0.00011007095,0.00002932517,0.000003316675,0.000013580238,0.0005656813],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99755764,0.000083719024,0.00037832366,0.00031049544,0.0014009482,0.00026887155],"domain_scores_gemma":[0.9989626,0.00010927546,0.0001157789,0.00014490893,0.00040756818,0.0002598733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011276542,0.00014754247,0.00022471008,0.00052946847,0.0000738225,0.00035408756,0.0006928599,0.000049007544,0.000033757064],"category_scores_gemma":[0.0006433858,0.00009112952,0.00010078197,0.000672726,0.00033795743,0.000288511,0.00017381101,0.0004280757,0.000016374592],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007671365,0.00042758192,0.012587842,0.0003658275,0.003234532,0.06757925,0.0058411136,0.0013860434,0.77777845,0.037288792,0.029231936,0.056607295],"study_design_scores_gemma":[0.009506349,0.0016988512,0.10415451,0.007442012,0.00055878784,0.0032837903,0.0011636225,0.028603686,0.7781919,0.038174547,0.026323762,0.000898152],"about_ca_topic_score_codex":0.000073267256,"about_ca_topic_score_gemma":0.0000119009155,"teacher_disagreement_score":0.09750142,"about_ca_system_score_codex":0.0006236525,"about_ca_system_score_gemma":0.00189164,"threshold_uncertainty_score":0.37161538},"labels":[],"label_agreement":null},{"id":"W4390678547","doi":"10.1002/9781119823193.ch15","title":"Familial Myeloid Neoplasms—When to Suspect and What to Do?","year":2023,"lang":"en","type":"other","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Dalhousie University; Provincial Health Services Authority","funders":"","keywords":"Germline; Medicine; Genetic testing; Myeloid; Myelodysplastic syndromes; Myeloid leukemia; Germline mutation; Myeloproliferative neoplasm; Immunology; Genetics; Internal medicine; Mutation; Biology; Myelofibrosis; Gene","score_opus":0.018522220538716182,"score_gpt":0.30278969254825794,"score_spread":0.2842674720095418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390678547","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002986435,0.0010878684,0.0002510481,0.01597088,0.0012033473,0.003363565,0.000061951105,0.0015842102,0.9734907],"genre_scores_gemma":[0.0001657301,0.0023957437,0.0043518175,0.0039377892,0.001667606,0.000120242104,0.000029739726,0.0014988574,0.98583245],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973989,0.0000442577,0.0002572917,0.00086604076,0.0007338418,0.0006996817],"domain_scores_gemma":[0.9980242,0.00016584092,0.00003972577,0.0008042651,0.00007771503,0.0008882427],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028377716,0.00042526962,0.0007375646,0.0009970937,0.000044447446,0.0002135285,0.0002800704,0.00044676807,0.009101248],"category_scores_gemma":[0.00034454826,0.0003424325,0.00009791174,0.0005003548,0.00007313214,0.00009569866,0.0005107667,0.00051948655,0.010469084],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001720355,0.000018999142,0.00021994267,0.00011469055,0.00015264605,0.0003111748,0.00040655324,2.965177e-7,0.00026147414,0.00018327161,0.9495805,0.048578452],"study_design_scores_gemma":[0.0011821823,0.000449226,0.00083150034,0.00074417295,0.00006108211,0.00005818297,0.0011204698,0.000009890122,0.00024519442,0.000041300143,0.9948711,0.0003857117],"about_ca_topic_score_codex":0.002816879,"about_ca_topic_score_gemma":0.0042368216,"teacher_disagreement_score":0.048192743,"about_ca_system_score_codex":0.00046542817,"about_ca_system_score_gemma":0.0003753633,"threshold_uncertainty_score":0.9999028},"labels":[],"label_agreement":null},{"id":"W4390942391","doi":"10.1182/bloodadvances.2023012062","title":"Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Servier; Astellas Pharma; Chugai Pharmaceutical; Agios Pharmaceuticals; Astex Pharmaceuticals; Gilead Sciences; National Comprehensive Cancer Network; Eisai; Syndax Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Celgene; Universität Ulm; AstraZeneca; Pfizer; Amgen","keywords":"Refractory (planetary science); Chemotherapy; Medicine; Oncology; Internal medicine; Biology","score_opus":0.013772402750220554,"score_gpt":0.3323051704801433,"score_spread":0.31853276772992273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390942391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96241874,0.026853321,0.00013958002,0.0056190137,0.00073181605,0.0026209156,0.00003239042,0.00019408992,0.001390135],"genre_scores_gemma":[0.98598796,0.0038022716,0.0017356756,0.0017051495,0.0013027168,0.0007896798,0.000045793404,0.00009503031,0.004535742],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973878,0.00021337385,0.0006823912,0.0006295542,0.00052600267,0.000560876],"domain_scores_gemma":[0.99823385,0.0008703722,0.000085468026,0.00040243973,0.00020137425,0.00020648692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008564253,0.00033361898,0.0011317662,0.0004662696,0.000033491087,0.000062012965,0.0001750253,0.0001734326,0.0008563363],"category_scores_gemma":[0.0014608672,0.00024172441,0.00035367397,0.00059343636,0.00034492754,0.00030272978,0.000059826,0.0008808251,0.0001537267],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9555052,0.0008796985,0.000100106154,0.00027594954,0.0004351006,0.0023661456,0.001141853,0.0000025867303,0.0062855706,0.00008155187,0.0019499385,0.030976316],"study_design_scores_gemma":[0.9212355,0.0019378302,0.000077628974,0.0006789097,0.00028927124,0.0001328125,0.0003660597,0.0004245006,0.0060517294,0.0005119919,0.06801438,0.00027939247],"about_ca_topic_score_codex":0.00003281114,"about_ca_topic_score_gemma":0.000022164915,"teacher_disagreement_score":0.06606444,"about_ca_system_score_codex":0.00018973048,"about_ca_system_score_gemma":0.0004498176,"threshold_uncertainty_score":0.9857235},"labels":[],"label_agreement":null},{"id":"W4390990818","doi":"10.1016/j.clml.2024.01.007","title":"Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"Kite Pharma; Genentech; Daiichi Sankyo Europe; Gilead Sciences; Servier; Astellas Pharma; bluebird bio; H. Lundbeck A/S; Syndax Pharmaceuticals; Argenx; Arog Pharmaceuticals; Pharmacyclics; Agios Pharmaceuticals; Loxo Oncology; Astex Pharmaceuticals; Jazz Pharmaceuticals; Pfizer; Incyte; F. Hoffmann-La Roche; Ablynx; AbbVie; Sanofi; GlaxoSmithKline; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Venetoclax; Medicine; Internal medicine; Neutropenia; Nausea; Gastroenterology; Febrile neutropenia; Salvage therapy; Mucositis; Oncology; Chemotherapy regimen; Refractory (planetary science); Leukemia; Chemotherapy; Biology; Chronic lymphocytic leukemia","score_opus":0.051772418474466675,"score_gpt":0.4032015996761817,"score_spread":0.351429181201715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390990818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98439014,0.0040515605,0.000036025012,0.0012712391,0.0014343857,0.0016740153,0.00004190455,0.00039944248,0.006701274],"genre_scores_gemma":[0.99003756,0.0012732504,0.00074165146,0.0013053598,0.002410294,0.0002058431,0.000098001176,0.00016665593,0.0037613914],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942288,0.00058469054,0.0019159093,0.0014720677,0.00077721506,0.001021329],"domain_scores_gemma":[0.9944993,0.003243285,0.00016902763,0.0010112065,0.00013699515,0.0009401773],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030982166,0.00052898,0.0013448122,0.0005666715,0.00011660775,0.00016370697,0.00039487408,0.0009530612,0.00036980995],"category_scores_gemma":[0.0032923808,0.00046352795,0.00049805787,0.0010373374,0.0008733701,0.00021576948,0.00036381796,0.001525174,0.0009427743],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.05794533,0.0010604394,0.0014722813,0.0003463265,0.00029598264,0.0064444784,0.00027078265,0.0000018510175,0.0012772897,0.0009236105,0.02488695,0.90507466],"study_design_scores_gemma":[0.39130026,0.010519356,0.13632359,0.0014205576,0.0004173073,0.0010392372,0.00020081515,0.015966244,0.00064943,0.001130153,0.4400254,0.0010076712],"about_ca_topic_score_codex":0.00020841353,"about_ca_topic_score_gemma":0.000027497716,"teacher_disagreement_score":0.904067,"about_ca_system_score_codex":0.0041717044,"about_ca_system_score_gemma":0.007814138,"threshold_uncertainty_score":0.99983513},"labels":[],"label_agreement":null},{"id":"W4391046269","doi":"10.1038/s41375-024-02151-8","title":"Inherent genome instability underlies trisomy 21-associated myeloid malignancies","year":2024,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Hannah's Heroes Foundation; Emory University; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Howard Hughes Medical Institute; St. Baldrick's Foundation; Alex's Lemonade Stand Foundation for Childhood Cancer; Leukemia and Lymphoma Society; National Cancer Institute; Ludwig Center at Harvard; U.S. Department of Health and Human Services","keywords":"Genome instability; Biology; Cancer research; Myeloid leukemia; Myeloid; Chromosome instability; GATA1; Aneuploidy; Genetics; Haematopoiesis; Stem cell; Chromosome; Gene; DNA damage","score_opus":0.030824037240009594,"score_gpt":0.2963716986218021,"score_spread":0.26554766138179253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391046269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96448797,0.003940888,0.00028846043,0.0028391303,0.00039009048,0.0009363805,0.00007387877,0.0008380886,0.026205115],"genre_scores_gemma":[0.97108257,0.00044917568,0.00038034745,0.00064465497,0.00035154363,0.00013066588,0.00018908893,0.00009441312,0.026677528],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969151,0.00015210683,0.0005725447,0.00073742843,0.0007808562,0.00084198907],"domain_scores_gemma":[0.99835485,0.00032356233,0.00006669892,0.0006945174,0.0002149727,0.00034541258],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00077099015,0.00037287403,0.0006032828,0.00033487988,0.00016663341,0.00016781347,0.00029970537,0.00035020337,0.0009767604],"category_scores_gemma":[0.00053313276,0.00030914505,0.00028325614,0.0010501065,0.00031798676,0.00023394295,0.00024581156,0.0010760274,0.0010596621],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026015532,0.0015345705,0.061512534,0.00885405,0.0050569507,0.00747182,0.014960489,0.00049588387,0.5115695,0.019787757,0.17365839,0.1924965],"study_design_scores_gemma":[0.0078246845,0.0014515172,0.3448744,0.0013558188,0.00062459294,0.0004512195,0.0026922352,0.0081985155,0.019428449,0.0032825668,0.6082209,0.0015951272],"about_ca_topic_score_codex":0.0003104998,"about_ca_topic_score_gemma":0.00010828112,"teacher_disagreement_score":0.49214107,"about_ca_system_score_codex":0.00804082,"about_ca_system_score_gemma":0.003121748,"threshold_uncertainty_score":0.99993646},"labels":[],"label_agreement":null},{"id":"W4391163993","doi":"10.1158/0008-5472.can-23-2659","title":"The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Barbara Ann Karmanos Cancer Institute; Jilin University; Children's Hospital of Michigan; Chimerix; National Institutes of Health; U CAN-CER VIVE Foundation; Children’s Hospital of Michigan Foundation; American Lebanese Syrian Associated Charities; MEI Pharma; St. Jude Children's Research Hospital; Wayne State University","keywords":"Myeloid leukemia; Haematopoiesis; Oxidative stress; Leukemia; Oxidative phosphorylation; Cancer research; Myeloid; Mitochondrion; Biology; MCL1; Stem cell; Biochemistry; Cell biology; Immunology; Downregulation and upregulation; Gene","score_opus":0.03620855809262768,"score_gpt":0.37703502994797955,"score_spread":0.34082647185535186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391163993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97741336,0.008386158,0.00005974489,0.010466043,0.00047589318,0.0023020713,0.00024016564,0.00008161166,0.0005749732],"genre_scores_gemma":[0.9843446,0.0060060928,0.00030750223,0.00019375159,0.00086408015,0.0013688272,0.00008857169,0.000109274246,0.0067173075],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99526215,0.00048041297,0.0004562882,0.0009870554,0.0014819838,0.0013321305],"domain_scores_gemma":[0.9971173,0.0010029963,0.000037777587,0.0006769154,0.0005397567,0.00062527996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001612297,0.00030755668,0.00041195587,0.00069126784,0.0004428421,0.0004059153,0.0005011009,0.00024781527,0.00023577716],"category_scores_gemma":[0.00061251427,0.00020409006,0.00008288785,0.0020138228,0.000543094,0.00032092375,0.00059573917,0.0022296663,0.00028004436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055862283,0.000086392494,0.0016336341,0.00044588107,0.0005570662,0.0016108846,0.0057898583,0.00029041112,0.9096452,0.0004958124,0.036372863,0.03748579],"study_design_scores_gemma":[0.003513762,0.0007011167,0.008644414,0.0012607946,0.00008290964,0.00007098606,0.0015379911,0.0068391617,0.90044224,0.0005268606,0.07588816,0.0004916249],"about_ca_topic_score_codex":0.0026513194,"about_ca_topic_score_gemma":0.0014068108,"teacher_disagreement_score":0.039515294,"about_ca_system_score_codex":0.0037879376,"about_ca_system_score_gemma":0.0031838953,"threshold_uncertainty_score":0.9905325},"labels":[],"label_agreement":null},{"id":"W4391329405","doi":"10.1182/bloodadvances.2023011869","title":"A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"MEDLINE; Medicine; Internal medicine; Biology","score_opus":0.04385610189046887,"score_gpt":0.43534037409903725,"score_spread":0.3914842722085684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391329405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931206,0.003593138,0.000017242039,0.0010111713,0.00006280415,0.00035232265,0.00004667419,0.000045357672,0.0017506646],"genre_scores_gemma":[0.9949974,0.002138648,0.0016604473,0.00004001144,0.00003714991,0.00002638427,0.000035095745,0.00002401363,0.0010408554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785817,0.00013406224,0.0008808523,0.00043949415,0.00041806512,0.00026933162],"domain_scores_gemma":[0.9984014,0.000828779,0.00019714105,0.0003326073,0.000109179695,0.00013086738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061126804,0.0001895559,0.0016373661,0.0010888894,0.000020322957,0.000015403306,0.00012643154,0.000100784295,0.0000976797],"category_scores_gemma":[0.00022871295,0.00012924359,0.00014914466,0.0023522119,0.00035778352,0.00012330491,0.0000784305,0.00040217844,0.000002191352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004752765,0.00039758673,0.983911,0.0005985031,0.0028711427,0.00015961782,0.0013059938,0.000028981081,0.0008794179,0.00023779474,0.000084027284,0.009050657],"study_design_scores_gemma":[0.003393716,0.0014146263,0.97672236,0.0009997508,0.0037918445,0.0000144834985,0.0010742379,0.007699185,0.0027018036,0.00006365023,0.0019303564,0.00019397208],"about_ca_topic_score_codex":0.00048964977,"about_ca_topic_score_gemma":0.0059817894,"teacher_disagreement_score":0.008856685,"about_ca_system_score_codex":0.000035616533,"about_ca_system_score_gemma":0.00017975907,"threshold_uncertainty_score":0.52704006},"labels":[],"label_agreement":null},{"id":"W4391339024","doi":"10.1007/s00277-024-05639-6","title":"Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation","year":2024,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Minimal residual disease; Transplantation; Hematology; Hematopoietic stem cell transplantation; Adverse effect; Myeloid leukemia; Flow cytometry; Leukemia; Immunology","score_opus":0.0370599322030564,"score_gpt":0.3180151213639174,"score_spread":0.280955189160861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391339024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870706,0.006192378,0.001455518,0.0034699256,0.00014940936,0.00044880534,0.0008227501,0.00010505966,0.00028554146],"genre_scores_gemma":[0.9964136,0.0006427461,0.00035270568,0.0004802693,0.00004098892,0.000059619175,0.0014628066,0.000053478616,0.0004937686],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968832,0.00020108011,0.0007767777,0.000707959,0.0008634139,0.0005675505],"domain_scores_gemma":[0.9978798,0.00055237743,0.00015120082,0.00067196606,0.00037783515,0.00036680573],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037520382,0.00031169585,0.0010068103,0.001276631,0.00008965856,0.000055185257,0.00028325594,0.00022928794,0.0005483538],"category_scores_gemma":[0.000067849636,0.00027644698,0.0004735142,0.0014714648,0.00018034971,0.00015967623,0.000049744158,0.00030640356,0.00013471491],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006785945,0.0020945596,0.8964043,0.014370844,0.009648325,0.0054235947,0.0033264272,0.004196623,0.020432616,0.001271447,0.030797677,0.0052476255],"study_design_scores_gemma":[0.0038101892,0.00058184366,0.2901549,0.0012384657,0.00612692,0.000044317097,0.0004098587,0.017540645,0.6772627,0.0014675978,0.00058131485,0.0007812376],"about_ca_topic_score_codex":0.00024143247,"about_ca_topic_score_gemma":0.00007073786,"teacher_disagreement_score":0.6568301,"about_ca_system_score_codex":0.00005526671,"about_ca_system_score_gemma":0.00035986467,"threshold_uncertainty_score":0.99996877},"labels":[],"label_agreement":null},{"id":"W4391463826","doi":"10.1016/s2352-3026(24)00001-2","title":"Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé","keywords":"Medicine; Decitabine; Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Venetoclax; Regimen; Internal medicine; Oncology; Transplantation; Leukemia; Bone marrow; Pediatrics; Chronic lymphocytic leukemia","score_opus":0.037061835381769936,"score_gpt":0.32741656185620793,"score_spread":0.290354726474438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391463826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98805374,0.005143658,0.00013563344,0.0045331074,0.00008199786,0.0019008799,0.000035661546,0.00006302268,0.00005228529],"genre_scores_gemma":[0.99765426,0.0008955718,0.0005726546,0.00025738517,0.00015680255,0.00024933284,0.00005207264,0.00005173239,0.000110218236],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99854267,0.00013073943,0.00026154984,0.00036890586,0.00021482058,0.00048133914],"domain_scores_gemma":[0.99842525,0.0007862127,0.00007602057,0.0005059326,0.00009920076,0.000107362845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000447398,0.00022639178,0.0008363731,0.00009880755,0.00010663097,0.00003698119,0.00024567012,0.00010756282,0.0000226018],"category_scores_gemma":[0.00011736155,0.000106541105,0.000041104267,0.00019074875,0.00066007173,0.000092326,0.00010236745,0.00033536815,0.000004844577],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15181425,0.0019011451,0.1714978,0.048283868,0.01778169,0.0058860993,0.03836855,0.0015076173,0.028382067,0.11494059,0.052540433,0.3670959],"study_design_scores_gemma":[0.14341101,0.0513943,0.3763539,0.004344239,0.004106364,0.029002612,0.0013863727,0.29011318,0.016283575,0.01695742,0.0641053,0.0025417306],"about_ca_topic_score_codex":0.000035735684,"about_ca_topic_score_gemma":0.000046209207,"teacher_disagreement_score":0.36455417,"about_ca_system_score_codex":0.00025576237,"about_ca_system_score_gemma":0.00067639357,"threshold_uncertainty_score":0.434462},"labels":[],"label_agreement":null},{"id":"W4391466207","doi":"10.1182/bloodadvances.2023010805","title":"Structural variants involving <i>MLLT10</i> fusion are associated with adverse outcomes in pediatric acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; Hope Foundation","keywords":"Myeloid leukemia; Medicine; Myeloid; Leukemia; Adverse effect; MEDLINE; Internal medicine; Oncology; Bioinformatics; Cancer research; Biology; Biochemistry","score_opus":0.012444261593703682,"score_gpt":0.2770061316516866,"score_spread":0.26456187005798293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391466207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899478,0.00742284,0.000008192442,0.00058724784,0.00035687984,0.0006083452,0.00006369479,0.00032020785,0.00068482454],"genre_scores_gemma":[0.99379385,0.002873307,0.00073524826,0.00030961452,0.00031229027,0.000054253873,0.00007715261,0.00007960844,0.0017646617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719775,0.00009989595,0.00045697272,0.0007043499,0.00080176396,0.0007392753],"domain_scores_gemma":[0.9987776,0.0003273173,0.00014848425,0.00037015177,0.00014408422,0.00023235659],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033394503,0.0003883703,0.0006579092,0.00051912334,0.0001357061,0.00006917498,0.00026332427,0.00019479597,0.000081694474],"category_scores_gemma":[0.00046184412,0.00027382796,0.00012593745,0.0014266071,0.000103128456,0.00076299,0.00016718668,0.0008971422,0.00005202589],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030924586,0.00012670892,0.9829556,0.00051992154,0.00048611054,0.005275676,0.00060513197,0.00018821043,0.007211991,0.00007814435,0.0004294904,0.0018137655],"study_design_scores_gemma":[0.0066935276,0.00048282367,0.9838732,0.0011520362,0.00095437525,0.00026806406,0.0006847083,0.002608422,0.0019621865,0.00018182481,0.0005377767,0.0006010652],"about_ca_topic_score_codex":0.00008630649,"about_ca_topic_score_gemma":0.00048789146,"teacher_disagreement_score":0.0063842814,"about_ca_system_score_codex":0.0007338563,"about_ca_system_score_gemma":0.0008321696,"threshold_uncertainty_score":0.9999714},"labels":[],"label_agreement":null},{"id":"W4391481439","doi":"10.1016/j.beha.2024.101537","title":"Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders","year":2024,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Dalhousie University","funders":"National Cancer Institute","keywords":"Penetrance; Germline; Myeloid; CEBPA; Medicine; Disease; ETV6; Germline mutation; Oncology; Biology; Immunology; Internal medicine; Phenotype; Genetics; Mutation; Chromosomal translocation","score_opus":0.14963439915111265,"score_gpt":0.5257713301642097,"score_spread":0.3761369310130971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391481439","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010054593,0.9800697,0.00035308255,0.005884021,0.0014263609,0.006172379,0.0003085761,0.00009740125,0.0046830457],"genre_scores_gemma":[0.00022476775,0.9828135,0.012945785,0.000112924805,0.0005234827,0.0008442119,0.00043134106,0.00018061977,0.0019233994],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9897062,0.0028269833,0.002708291,0.0017836645,0.0016506248,0.0013242455],"domain_scores_gemma":[0.9816526,0.014212454,0.00062293484,0.0015818061,0.0009966741,0.0009335237],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008458716,0.0006529504,0.0041700657,0.0009769249,0.00018465517,0.00012442889,0.0007970465,0.0012540139,0.00017801332],"category_scores_gemma":[0.011673439,0.0005387383,0.00044471453,0.0020764926,0.0011356036,0.00027560533,0.0017836284,0.005003117,0.0014187958],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00548993,0.0020805125,0.000028678622,0.12258613,0.0032736703,0.0045011262,0.00005184916,3.2969433e-7,0.0000010479406,0.017630415,0.00919059,0.83516574],"study_design_scores_gemma":[0.0022228116,0.004460607,0.000047963076,0.022392288,0.0056687193,0.0014869961,0.00015766462,0.00005462953,6.310081e-7,0.00022328059,0.9629038,0.00038062996],"about_ca_topic_score_codex":0.00027493818,"about_ca_topic_score_gemma":0.00003599536,"teacher_disagreement_score":0.9537132,"about_ca_system_score_codex":0.0005012453,"about_ca_system_score_gemma":0.0021859657,"threshold_uncertainty_score":0.9997064},"labels":[],"label_agreement":null},{"id":"W4391614682","doi":"10.1111/trf.17721","title":"Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial <scp>RBC‐ENHANCE</scp>","year":2024,"lang":"en","type":"article","venue":"Transfusion","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University Medical Centre; Kingston Health Sciences Centre; Osteoporosis Canada; McMaster University; Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Canadian Cancer Society Research Institute; Ministry of Statistics and Programme Implementation, Government of India","keywords":"Medicine; Randomized controlled trial; Hemoglobin; Myelodysplastic syndromes; Blood transfusion; Internal medicine; Surgery; Pediatrics","score_opus":0.020604475870699208,"score_gpt":0.28530148211708634,"score_spread":0.26469700624638715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391614682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98065084,0.0006043542,0.0025488143,0.00055567553,0.0004306271,0.006104744,0.00006930639,0.00019105255,0.008844612],"genre_scores_gemma":[0.9923863,0.0033392345,0.0007749301,0.00004069003,0.00014266082,0.00031175616,0.00014564945,0.00011043696,0.0027483862],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99521065,0.0004325165,0.0013371371,0.0009540172,0.0013663871,0.000699289],"domain_scores_gemma":[0.99694926,0.0018878732,0.000119532146,0.0005785864,0.00018233567,0.00028244292],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018481509,0.00047607863,0.001503728,0.0008510251,0.00008557484,0.000040438666,0.00026319135,0.0002961054,0.00010114029],"category_scores_gemma":[0.00039318044,0.00033142522,0.0003371117,0.0014917412,0.00032810334,0.00022222962,0.000037015998,0.0010025073,0.000052408996],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9058063,0.0011339402,0.0001149259,0.0014397592,0.00014988042,0.00056541926,0.0049677663,0.000108952074,0.08274459,0.000029798059,0.0007493167,0.0021893636],"study_design_scores_gemma":[0.93930507,0.010068896,0.0003371236,0.0031576713,0.00046796974,0.00009280574,0.00034527326,0.0035246764,0.04174526,0.00010207708,0.0006696591,0.00018354108],"about_ca_topic_score_codex":0.000793238,"about_ca_topic_score_gemma":0.00027714283,"teacher_disagreement_score":0.040999334,"about_ca_system_score_codex":0.00032458533,"about_ca_system_score_gemma":0.0007108163,"threshold_uncertainty_score":0.99991375},"labels":[],"label_agreement":null},{"id":"W4391722392","doi":"10.1002/ajh.27243","title":"Donor germ‐line variants associate with outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromes","year":2024,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Moonshot; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; U.S. Navy; Health Resources and Services Administration; National Institutes of Health; MorphoSys; Astellas Pharma; Adaptive Biotechnologies; Norges Idrettshøgskole; Kiadis Pharma; bluebird bio; TG Therapeutics; Jazz Pharmaceuticals; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; StemCyte; BeiGene; HistoGenetics; U.S. Department of Defense; Moonshot Research and Development Program; Sanofi; GlaxoSmithKline; Actinium Pharmaceuticals; CareDx; Incyte; Pfizer; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Amgen; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences","keywords":"Myelodysplastic syndromes; Stem cell; Medicine; Hematopoietic stem cell transplantation; Transplantation; Oncology; Germline; Hematopoietic cell; Haematopoiesis; Internal medicine; Biology; Genetics; Bone marrow; Gene","score_opus":0.009485209127532675,"score_gpt":0.25296472988582397,"score_spread":0.2434795207582913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391722392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93648237,0.00035276054,0.00030861856,0.061920118,0.00020319954,0.0005425877,0.00009209545,0.00001911653,0.0000791409],"genre_scores_gemma":[0.9766973,0.00021414037,0.0014370059,0.020806152,0.00012896323,0.000021181248,0.00011685039,0.0001763333,0.0004020577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959567,0.00036020315,0.0014179145,0.0004551856,0.0011121684,0.00069782656],"domain_scores_gemma":[0.99627775,0.00084455695,0.0018268205,0.00037938316,0.0005034737,0.00016799397],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00037366027,0.0005441374,0.0030236794,0.0012155597,0.000029225135,0.00001864761,0.000381681,0.0003821197,0.000078497724],"category_scores_gemma":[0.000035082165,0.00034457396,0.00023797565,0.0006839607,0.0005350447,0.00012308256,0.000042267184,0.002589434,0.000031362564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064318823,0.0010063744,0.8737708,0.00831789,0.0061073876,0.06979264,0.002143716,0.00011086787,0.00008555044,0.000033063818,0.0304845,0.001715348],"study_design_scores_gemma":[0.04879124,0.058910206,0.7696378,0.017084109,0.014537578,0.078919195,0.0022554647,0.00011223703,0.0021873598,0.00023358385,0.004201923,0.0031293114],"about_ca_topic_score_codex":0.0000561957,"about_ca_topic_score_gemma":0.0000133490985,"teacher_disagreement_score":0.10413299,"about_ca_system_score_codex":0.00042022532,"about_ca_system_score_gemma":0.001154977,"threshold_uncertainty_score":0.99990064},"labels":[],"label_agreement":null},{"id":"W4391738483","doi":"10.1002/ajh.27246","title":"Long‐term follow‐up of <scp>VIALE‐A</scp>: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":202,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"AbbVie Canada; Genentech; Genentech Foundation","keywords":"Venetoclax; Azacitidine; Medicine; Internal medicine; Placebo; Myeloid leukemia; Oncology; Neutropenia; Febrile neutropenia; Hazard ratio; Clinical endpoint; Leukemia; Chemotherapy; Gastroenterology; Clinical trial; Confidence interval; Chronic lymphocytic leukemia; Pathology","score_opus":0.011525101525683406,"score_gpt":0.2991369166163655,"score_spread":0.28761181509068207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391738483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920938,0.0051717306,0.00031602147,0.0013417056,0.00021433325,0.000266034,0.000012462542,0.00003317114,0.00055072835],"genre_scores_gemma":[0.99305075,0.004646791,0.0010810405,0.00035103504,0.00014861976,0.000009023845,0.0000125034185,0.000068326495,0.0006318982],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99756145,0.00015413002,0.00095936714,0.00034043728,0.00040562017,0.0005790165],"domain_scores_gemma":[0.998097,0.00061703456,0.00041188163,0.00030646764,0.00025232398,0.00031531233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005055296,0.0002962653,0.0014871673,0.0010161316,0.000031926047,0.000025454716,0.00025950803,0.00015398352,0.00007948097],"category_scores_gemma":[0.00023731423,0.00023597328,0.00022346736,0.0011301623,0.0007793097,0.000148091,0.000085702624,0.00081685575,0.000018395194],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005050099,0.0003821037,0.56112796,0.0020362413,0.0063227937,0.034606725,0.007688834,0.0000670547,0.23616268,0.0020839265,0.025533296,0.1189383],"study_design_scores_gemma":[0.04853394,0.022242574,0.24273983,0.007029,0.0025501968,0.20948355,0.0051350933,0.0042715096,0.4393232,0.0021524192,0.015536196,0.0010025017],"about_ca_topic_score_codex":0.00020106624,"about_ca_topic_score_gemma":0.000026790049,"teacher_disagreement_score":0.31838813,"about_ca_system_score_codex":0.0007183074,"about_ca_system_score_gemma":0.001698272,"threshold_uncertainty_score":0.9622711},"labels":[],"label_agreement":null},{"id":"W4391743314","doi":"10.1101/2024.02.09.579319","title":"Identification of leukemia stem cell subsets with distinct transcriptional, epigenetic and functional properties","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Government of Ontario; Princess Margaret Cancer Foundation; Celgene","keywords":"Epigenetics; Biology; Myeloid leukemia; Stem cell; Compartment (ship); Leukemia; Somatic evolution in cancer; Computational biology; Cell; Genetic heterogeneity; Cancer research; Genetics; Cancer; Gene; Phenotype","score_opus":0.023470919971466414,"score_gpt":0.2243197882332178,"score_spread":0.20084886826175138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391743314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98890406,0.0078017535,0.0009069648,0.00036168072,0.00034976227,0.0011964906,0.0002746728,0.00018950124,0.000015116078],"genre_scores_gemma":[0.99813116,0.00042435736,0.0004983187,0.000038650385,0.00027280417,0.00032040075,0.0000020113398,0.00014807707,0.00016420842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969994,0.00010256809,0.00068878365,0.0009979159,0.00081815285,0.00039320625],"domain_scores_gemma":[0.9977373,0.000048576287,0.00027598382,0.0008662972,0.00079901627,0.00027285263],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000583719,0.0004687982,0.0006080176,0.0004073562,0.00010676986,0.00013850728,0.00020474849,0.00038890672,0.00004243705],"category_scores_gemma":[0.000038685077,0.00038794134,0.00012431746,0.0004530366,0.00040541156,0.00008044238,0.00025792004,0.0010568035,0.000065653476],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003672547,0.000109536275,0.005446553,0.0058573503,0.00028120293,0.000068790934,0.000035411187,0.000070981325,0.9872446,0.00022000271,0.00029278177,0.000005528527],"study_design_scores_gemma":[0.0010281028,0.00016033537,0.28170446,0.0012677991,0.00058125553,3.4764673e-7,0.000016302136,0.0018234451,0.7123775,0.0000036737222,0.00058249425,0.00045430163],"about_ca_topic_score_codex":0.000051411458,"about_ca_topic_score_gemma":0.000003346524,"teacher_disagreement_score":0.2762579,"about_ca_system_score_codex":0.0008650556,"about_ca_system_score_gemma":0.0030510342,"threshold_uncertainty_score":0.99985725},"labels":[],"label_agreement":null},{"id":"W4392169505","doi":"10.3390/cancers16050915","title":"CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial","year":2024,"lang":"en","type":"article","venue":"Cancers","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Jazz Pharmaceuticals","keywords":"Medicine; Pharmacokinetics; Renal function; Clinical trial; Intensive care medicine; Oncology; Internal medicine; Pharmacology","score_opus":0.016737946124163135,"score_gpt":0.3122765456968036,"score_spread":0.29553859957264045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392169505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99335915,0.0039117406,0.00015913886,0.0009247947,0.00016589717,0.00083658786,0.00002340363,0.000059118054,0.000560141],"genre_scores_gemma":[0.99674135,0.0021463463,0.00014299687,0.0002675279,0.00020437765,0.000086674525,0.000024677334,0.00001866109,0.00036738467],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99904203,0.000032338856,0.00017746359,0.0003058813,0.00019357019,0.0002487293],"domain_scores_gemma":[0.9996394,0.00006364728,0.000025182992,0.00010181948,0.000035666093,0.00013430232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019883874,0.00013015112,0.00022104368,0.0001459022,0.00003958153,0.000027010681,0.000031879346,0.00006370856,0.00010115448],"category_scores_gemma":[0.00002723945,0.000092812654,0.000021717406,0.00028217956,0.00016637056,0.0000818409,0.000030811596,0.00026247086,0.0000041761828],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8316857,0.00022729917,0.004022581,0.0046402635,0.00063878915,0.0038582562,0.0056838715,0.0002279056,0.029795798,0.00070711074,0.03842997,0.08008246],"study_design_scores_gemma":[0.7723801,0.026792886,0.005977133,0.007009585,0.00093679805,0.0023717042,0.0037358683,0.062461544,0.01604894,0.00029340308,0.10089779,0.0010942245],"about_ca_topic_score_codex":0.00009895064,"about_ca_topic_score_gemma":0.000039878552,"teacher_disagreement_score":0.07898823,"about_ca_system_score_codex":0.0008817561,"about_ca_system_score_gemma":0.00063223566,"threshold_uncertainty_score":0.378479},"labels":[],"label_agreement":null},{"id":"W4392298541","doi":"10.1038/s41375-024-02191-0","title":"Nucleic acid therapeutics as differentiation agents for myeloid leukemias","year":2024,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Nucleic acid; Myeloid leukemia; Biology; Acute promyelocytic leukemia; Leukemia; Myeloid; Cancer research; Immunology; Gene; Retinoic acid; Genetics","score_opus":0.0401082372443879,"score_gpt":0.33620798485267117,"score_spread":0.2960997476082833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392298541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9721321,0.0021710766,0.005694266,0.0038984339,0.0011011175,0.001826448,0.00006446202,0.0007960263,0.012316106],"genre_scores_gemma":[0.96695745,0.0005252017,0.0014332142,0.002813955,0.0010107346,0.0002227528,0.00032510053,0.00017316874,0.02653843],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99752045,0.000057525922,0.00042843426,0.0006582238,0.00062432804,0.00071102584],"domain_scores_gemma":[0.99866176,0.00022440562,0.00006138806,0.00060496846,0.00017655488,0.00027093117],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034052864,0.00034626498,0.0004124471,0.00032988365,0.00017559878,0.00019144709,0.00028590707,0.00034571285,0.00062947423],"category_scores_gemma":[0.00013994325,0.00029168083,0.00032371568,0.00050424825,0.00011121353,0.00021674186,0.00011377975,0.0006792496,0.0014192294],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018503556,0.00024203515,0.0025391458,0.002975875,0.0022102029,0.0006710396,0.0037956156,0.000060258943,0.5132421,0.0220174,0.15740445,0.29299152],"study_design_scores_gemma":[0.006800914,0.0012355911,0.013741794,0.0007327449,0.0009873646,0.00046101346,0.00044127842,0.10185841,0.1468105,0.0060088444,0.72002125,0.00090032676],"about_ca_topic_score_codex":0.00006797386,"about_ca_topic_score_gemma":0.0000081552425,"teacher_disagreement_score":0.56261677,"about_ca_system_score_codex":0.003897094,"about_ca_system_score_gemma":0.0017695718,"threshold_uncertainty_score":0.9999535},"labels":[],"label_agreement":null},{"id":"W4392372741","doi":"10.1080/16078454.2024.2324417","title":"Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine","year":2024,"lang":"en","type":"article","venue":"Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Risk stratification; Adverse effect; Decitabine; Oncology","score_opus":0.011247228681223671,"score_gpt":0.2756642222359628,"score_spread":0.26441699355473913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392372741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9694949,0.00016488323,0.026068779,0.00054520916,0.000051089803,0.0022930077,0.00016599726,0.00029984562,0.0009162952],"genre_scores_gemma":[0.98951155,0.000041229883,0.007354429,0.00012231323,0.00008027378,0.00042136796,0.001554878,0.00012337272,0.0007906097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972286,0.00018865359,0.00050052925,0.0009508139,0.00044402358,0.0006873477],"domain_scores_gemma":[0.99791294,0.0004768177,0.00014436757,0.00067218445,0.00044506276,0.00034862955],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004041861,0.00037534581,0.0007673699,0.0009273053,0.0001846301,0.000105070474,0.00024224767,0.00014018702,0.00011147089],"category_scores_gemma":[0.0002587699,0.00026093354,0.0001421384,0.002462599,0.00012043178,0.000162517,0.00006625601,0.00048643266,0.00015970142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005833309,0.0003122976,0.9266647,0.00071512774,0.011268354,0.0019096199,0.000884197,0.00052575476,0.0026147077,0.001354763,0.0075693587,0.04034781],"study_design_scores_gemma":[0.025350852,0.025863718,0.8158618,0.0015810014,0.042754028,0.002591969,0.002305053,0.05524089,0.014255965,0.00027870233,0.011025402,0.0028906055],"about_ca_topic_score_codex":0.00012776388,"about_ca_topic_score_gemma":0.00015138306,"teacher_disagreement_score":0.11080288,"about_ca_system_score_codex":0.00078403106,"about_ca_system_score_gemma":0.0007082318,"threshold_uncertainty_score":0.99998426},"labels":[],"label_agreement":null},{"id":"W4392383403","doi":"10.1101/2024.02.29.582846","title":"Multiomic analysis of clonal development reveals new regulators of leukemic cell growth","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health","keywords":"Chromatin remodeling; Core (optical fiber); Cell biology; Chromatin; Expression (computer science); Biology; Computational biology; Computer science; Genetics; Telecommunications; Gene","score_opus":0.01679444045334561,"score_gpt":0.2542633409853304,"score_spread":0.23746890053198477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392383403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946794,0.0026098408,0.00055060076,0.00020783792,0.00038983242,0.0010367476,0.00027046408,0.00020527186,0.000049992297],"genre_scores_gemma":[0.97547626,0.00030814073,0.023392523,0.00008013228,0.00028333892,0.00007726098,0.000004362279,0.00019154578,0.00018641198],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9947637,0.00015211744,0.0017146702,0.0013759861,0.0012615653,0.0007319767],"domain_scores_gemma":[0.99530864,0.00016676306,0.0008699375,0.0017891267,0.0012240339,0.0006414755],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012623525,0.000735751,0.0020927922,0.002769373,0.0000623577,0.00005181304,0.0007577364,0.0008756741,0.00017840187],"category_scores_gemma":[0.00037745765,0.00073079974,0.0007164418,0.003362967,0.00025153803,0.000062911255,0.0013342231,0.0015362926,0.00008411269],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020788496,0.00021470706,0.026038537,0.0043851333,0.005177307,0.000107889115,0.000075253316,0.00013940256,0.96064246,0.0004545975,0.0025516192,0.0000052116966],"study_design_scores_gemma":[0.0011531608,0.00007250653,0.26316193,0.0012124885,0.0038310364,3.914565e-8,0.000006310355,0.0012732443,0.7282911,0.0000078266185,0.00041483453,0.0005755367],"about_ca_topic_score_codex":0.00042453792,"about_ca_topic_score_gemma":0.0000048761653,"teacher_disagreement_score":0.23712339,"about_ca_system_score_codex":0.0021907138,"about_ca_system_score_gemma":0.0095535945,"threshold_uncertainty_score":0.9995143},"labels":[],"label_agreement":null},{"id":"W4392384143","doi":"10.1158/2643-3249.bcdsymp24-p02","title":"Abstract P02: Uncovering Tailored Therapies for Acute Myeloid Leukemia in Children with Down Syndrome","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; McGill University","funders":"","keywords":"Myeloid leukemia; Medicine; Down syndrome; Myeloid; Intensive care medicine; Immunology; Psychiatry","score_opus":0.011496967194867575,"score_gpt":0.2869133705003545,"score_spread":0.2754164033054869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392384143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875776,0.008498587,0.00018490403,0.0009926568,0.0001873525,0.0015308014,0.00035897057,0.00017350043,0.00049562345],"genre_scores_gemma":[0.99284136,0.0024211386,0.00040057543,0.000313707,0.0004043382,0.0008408255,0.00016369953,0.00013871807,0.0024756354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758995,0.000020486877,0.00036975316,0.00074344134,0.00052919704,0.0007471827],"domain_scores_gemma":[0.9991189,0.00011882203,0.000065423104,0.00047842992,0.000059884263,0.00015849301],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024405759,0.00038433634,0.0005752861,0.00034857146,0.000083789404,0.00027380587,0.00026579853,0.00016656515,0.0001318179],"category_scores_gemma":[0.000020716667,0.00028348534,0.00018847534,0.00061803625,0.00014950367,0.0007895812,0.000093390045,0.00061641086,0.000027607824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011927556,0.0011105061,0.6025934,0.0058255293,0.04476643,0.008068013,0.005125084,0.0076068784,0.22449651,0.0018744528,0.019516379,0.067089215],"study_design_scores_gemma":[0.016010886,0.0019692588,0.9312769,0.004028447,0.0025264726,0.0025651052,0.0005288528,0.00068464957,0.033256754,0.000618326,0.005158395,0.0013759128],"about_ca_topic_score_codex":0.0021993718,"about_ca_topic_score_gemma":0.00041542374,"teacher_disagreement_score":0.3286835,"about_ca_system_score_codex":0.0015410273,"about_ca_system_score_gemma":0.0028278013,"threshold_uncertainty_score":0.99996173},"labels":[],"label_agreement":null},{"id":"W4392519553","doi":"10.1016/j.isci.2024.109443","title":"Targeting SRSF2 mutations in leukemia with RKI-1447: A strategy to impair cellular division and nuclear structure","year":2024,"lang":"en","type":"article","venue":"iScience","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Applebaum Foundation; Fundamental Research Funds for the Central Universities; National Institutes of Health; BIRAX; Chinese Academy of Medical Sciences; Israel Science Foundation; National Natural Science Foundation of China; National Heart, Lung, and Blood Institute; Rising Tide Foundation; National Cancer Institute; Weizmann Institute of Science; Edward P. Evans Foundation; Icahn School of Medicine at Mount Sinai","keywords":"Spliceosome; Myeloid leukemia; Biology; Mutation; Cancer research; Computational biology; Genetics; Bioinformatics; Gene; RNA splicing","score_opus":0.011815189636370698,"score_gpt":0.2878856519271986,"score_spread":0.27607046229082793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392519553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964388,0.000533381,0.0007363324,0.0009439392,0.000045062254,0.00036503826,0.000011164423,0.000075836186,0.00085045176],"genre_scores_gemma":[0.996372,0.0000126247605,0.0029914328,0.00018062607,0.00005345291,0.0000069490047,0.000008011246,0.000021842323,0.00035308977],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99855334,0.000031260995,0.00015705092,0.00045922888,0.00042965414,0.00036943966],"domain_scores_gemma":[0.99944526,0.00007272566,0.000016944989,0.00018601902,0.00005622114,0.00022281847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030655795,0.00012498119,0.00015042597,0.00027193862,0.00012476902,0.000155171,0.0001491155,0.000060644506,0.000113964896],"category_scores_gemma":[0.000111421024,0.00008780224,0.00001756371,0.0011250664,0.00018666388,0.00024936785,0.00011919117,0.0003943614,0.000044210014],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008838138,0.000025246229,0.004994839,0.00023803033,0.000013947665,0.0012563914,0.0075137843,0.0041151457,0.95044255,0.0013266475,0.002166228,0.02781881],"study_design_scores_gemma":[0.004003371,0.0053182035,0.15026584,0.0026687393,0.00010824245,0.0008942885,0.016350118,0.7565471,0.03851839,0.0018800913,0.02204308,0.001402529],"about_ca_topic_score_codex":0.000183013,"about_ca_topic_score_gemma":0.000049988663,"teacher_disagreement_score":0.9119242,"about_ca_system_score_codex":0.00038648717,"about_ca_system_score_gemma":0.00060010183,"threshold_uncertainty_score":0.35804713},"labels":[],"label_agreement":null},{"id":"W4392604036","doi":"10.1002/9781394180486.ch3","title":"The genetics of acute myeloid leukemia","year":2024,"lang":"en","type":"other","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Dalhousie University","funders":"","keywords":"Myeloid leukemia; Biology; Genetics; Leukemia; Myeloid; Computational biology; Medicine; Cancer research","score_opus":0.017372435833950577,"score_gpt":0.31237521847220434,"score_spread":0.29500278263825375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392604036","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000051164036,0.0139078535,0.00007079773,0.0012385974,0.0003857564,0.00062000344,0.0000712635,0.00021245303,0.9834421],"genre_scores_gemma":[0.00014486186,0.01461157,0.0016318532,0.00023715301,0.0007170509,0.000028291697,0.000036832476,0.00081170996,0.98178065],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983577,0.00003242582,0.00029842826,0.0003454256,0.00058999634,0.00037600717],"domain_scores_gemma":[0.99864435,0.00007107866,0.000094255636,0.00097171473,0.000075718526,0.00014289352],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00022077006,0.00026586335,0.0004537908,0.00024443024,0.000025114468,0.00002780452,0.00036999554,0.00041679078,0.0036154746],"category_scores_gemma":[0.000035698176,0.0001453902,0.00020587615,0.00029261204,0.00031932764,0.0000063011094,0.00026294318,0.0007068317,0.0032079048],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038136568,0.000008318962,0.00001715585,0.00031572132,0.0012196384,0.00011878162,0.000027092354,7.126652e-8,0.00080992095,0.0010030932,0.9874487,0.008993379],"study_design_scores_gemma":[0.00042713594,0.00013004757,0.000029871913,0.00029100972,0.0005275116,0.000081851984,0.00004490764,0.0001101457,0.0018230058,0.00017433702,0.9962224,0.0001377993],"about_ca_topic_score_codex":0.00025067828,"about_ca_topic_score_gemma":0.000073049996,"teacher_disagreement_score":0.008855579,"about_ca_system_score_codex":0.00039191332,"about_ca_system_score_gemma":0.0011221636,"threshold_uncertainty_score":0.9975682},"labels":[],"label_agreement":null},{"id":"W4392607009","doi":"10.1016/j.gimo.2024.100989","title":"P108: Myelodysplastic syndrome (MDS) detected by germline genetic testing for hereditary cancer","year":2024,"lang":"en","type":"article","venue":"Genetics in Medicine Open","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Germline; Genetics; Genetic testing; Germline mutation; Cancer; Biology; Medicine; Mutation; Gene","score_opus":0.05719762731838253,"score_gpt":0.3813880051941265,"score_spread":0.324190377875744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392607009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9249976,0.052587032,0.0034863518,0.009353618,0.001616148,0.0052965316,0.00023607066,0.00021965212,0.0022069446],"genre_scores_gemma":[0.95174056,0.0016323653,0.03422628,0.0014316497,0.0018656205,0.0015097621,0.0003045549,0.0002861304,0.007003057],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9966037,0.000095005125,0.0008286937,0.00091460854,0.00068144733,0.0008765444],"domain_scores_gemma":[0.9973781,0.001204651,0.000083303734,0.00062967325,0.00029257376,0.00041169635],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008310155,0.00039625374,0.000805347,0.00043875133,0.0001120873,0.00008697832,0.00081268186,0.0002408502,0.00080433965],"category_scores_gemma":[0.0014122067,0.00032508903,0.00006481875,0.0013016737,0.00028687637,0.0000857964,0.00046440016,0.000784826,0.000064981636],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011053227,0.00035465104,0.03115658,0.005156763,0.00093891524,0.009241066,0.0013800268,0.00083226664,0.14393046,0.00006366063,0.4231606,0.38267967],"study_design_scores_gemma":[0.03235065,0.014895473,0.26486462,0.020047659,0.002359959,0.008823819,0.0012027624,0.4411256,0.010679389,0.0035423837,0.19744039,0.0026672946],"about_ca_topic_score_codex":0.0012470871,"about_ca_topic_score_gemma":0.0002299999,"teacher_disagreement_score":0.44029334,"about_ca_system_score_codex":0.00064890506,"about_ca_system_score_gemma":0.0011493554,"threshold_uncertainty_score":0.9999201},"labels":[],"label_agreement":null},{"id":"W4392788581","doi":"10.1111/bjh.19314","title":"Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights","year":2024,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Venetoclax; Medicine; Myeloid leukemia; Clinical trial; Oncology; Immunology; Internal medicine; Leukemia; Chronic lymphocytic leukemia","score_opus":0.03499079100878444,"score_gpt":0.3486252767249856,"score_spread":0.3136344857162012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392788581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9428088,0.05326316,0.00012627382,0.0023697612,0.0003583352,0.00017561622,0.0000057827424,0.000025804457,0.0008664872],"genre_scores_gemma":[0.97478044,0.021216065,0.0028273908,0.00044480088,0.00028286196,0.000006172754,0.000004772572,0.000024274754,0.00041319645],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99770826,0.00032981575,0.0010140449,0.00032642452,0.00025572928,0.00036572322],"domain_scores_gemma":[0.99875486,0.0005437368,0.00012713858,0.00014381546,0.00015930027,0.0002711314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097601267,0.00014145988,0.0009566526,0.00031064462,0.000046535235,0.000063178806,0.00019643344,0.0003668218,0.000076304445],"category_scores_gemma":[0.0007605315,0.00012365352,0.00016771349,0.00033676313,0.00060354604,0.00015088983,0.000118939184,0.0016033325,0.000029678722],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013762473,0.00013835839,0.023634419,0.0003611639,0.0004990268,0.9053338,0.00028175293,0.0000011303234,0.0013140584,0.004112483,0.03485827,0.028089257],"study_design_scores_gemma":[0.0046046376,0.0009793253,0.11198614,0.0030566128,0.00015347119,0.7977906,0.00016483292,0.00020776808,0.00041293522,0.008636818,0.071741514,0.00026538508],"about_ca_topic_score_codex":0.000024769888,"about_ca_topic_score_gemma":0.00015945481,"teacher_disagreement_score":0.10754327,"about_ca_system_score_codex":0.00020963672,"about_ca_system_score_gemma":0.00089844374,"threshold_uncertainty_score":0.69657713},"labels":[],"label_agreement":null},{"id":"W4392805014","doi":"10.18632/oncotarget.28563","title":"ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells","year":2024,"lang":"en","type":"article","venue":"Oncotarget","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health","keywords":"Fludarabine; Venetoclax; Cladribine; Cancer research; Medicine; Azacitidine; Clofarabine; Pharmacology; Transplantation; Decitabine; Cytarabine; Leukemia; Chronic lymphocytic leukemia; Oncology; Immunology; Internal medicine; Chemistry; Chemotherapy; Cyclophosphamide; Biochemistry","score_opus":0.00910004801182969,"score_gpt":0.2707671269673884,"score_spread":0.26166707895555874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392805014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876064,0.002056478,0.00014260343,0.0032305236,0.00010247827,0.00063811836,0.000028606228,0.000059422167,0.006135379],"genre_scores_gemma":[0.99329245,0.00092088344,0.001385099,0.00029428487,0.0001966562,0.00004687856,0.000020410187,0.000042333282,0.003801028],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99822396,0.00010042931,0.0003431785,0.00042415896,0.00050370506,0.00040457404],"domain_scores_gemma":[0.99899155,0.00029071738,0.000058554666,0.00043215358,0.00008548046,0.00014152532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063392404,0.00022349451,0.0004418045,0.00020427967,0.000057580848,0.00004054505,0.00020043737,0.00013880269,0.00012991329],"category_scores_gemma":[0.00006883305,0.00012730154,0.000066090804,0.00067497964,0.0003671922,0.00011998131,0.00010815507,0.00069864304,0.00003438321],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008290032,0.00014076386,0.0076379175,0.00085294654,0.00023002774,0.0007439905,0.0019676525,0.00017509228,0.9705182,0.0012687622,0.012708248,0.002927453],"study_design_scores_gemma":[0.0036391742,0.0023275777,0.09899533,0.001769969,0.0001960214,0.00027815576,0.00076564593,0.015881008,0.81198233,0.00062705687,0.06296056,0.00057716004],"about_ca_topic_score_codex":0.00083428615,"about_ca_topic_score_gemma":0.0003303696,"teacher_disagreement_score":0.15853581,"about_ca_system_score_codex":0.00032912905,"about_ca_system_score_gemma":0.0007079708,"threshold_uncertainty_score":0.51912063},"labels":[],"label_agreement":null},{"id":"W4392888281","doi":"10.1016/j.leukres.2024.107485","title":"Mathematical modelling of clonal reduction therapeutic strategies in acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Centre Hospitalier Universitaire Sainte-Justine; McGill University Health Centre; Université de Montréal","funders":"Natural Sciences and Engineering Research Council of Canada; CHU Sainte-Justine Foundation; Cole Foundation; Fonds de Recherche du Québec - Santé; Fondation de l'Hôpital de Montréal pour enfants; Leukemia and Lymphoma Society of Canada","keywords":"Myeloid leukemia; Population; Medicine; Stem cell; Haematopoiesis; Cytarabine; Oncology; Pharmacology; Myeloid; Internal medicine; Cancer research; Biology","score_opus":0.10147604319015943,"score_gpt":0.3924380663267607,"score_spread":0.29096202313660124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392888281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96025985,0.0028936698,0.010095154,0.0018892211,0.00017371075,0.0013036008,0.000019074378,0.00020960638,0.023156118],"genre_scores_gemma":[0.9889497,0.0014536859,0.003915856,0.000030614192,0.00038807976,0.00017294478,0.000046146342,0.00011372491,0.00492925],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9943993,0.00041337628,0.0008565899,0.0008434936,0.0022206146,0.0012666449],"domain_scores_gemma":[0.9975941,0.00076007325,0.000037553054,0.00080108526,0.0004940971,0.00031305326],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0035612471,0.00032716338,0.00068384025,0.0016712265,0.00013546653,0.00021243378,0.00049335574,0.00045438114,0.00052108965],"category_scores_gemma":[0.00012717616,0.0002734797,0.00023390383,0.00256045,0.0008064051,0.0004957115,0.00026208346,0.0032713732,0.00047961817],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0047629187,0.0005392742,0.00041862266,0.007913609,0.0015611725,0.0041720616,0.00918544,0.02643081,0.59634644,0.2904743,0.009033025,0.04916233],"study_design_scores_gemma":[0.002933597,0.0010228624,0.000698221,0.0021713641,0.00015444796,0.0014791238,0.005096447,0.84602654,0.054576293,0.08221448,0.0031152475,0.00051135547],"about_ca_topic_score_codex":0.00062457635,"about_ca_topic_score_gemma":0.000013980019,"teacher_disagreement_score":0.81959575,"about_ca_system_score_codex":0.0068434216,"about_ca_system_score_gemma":0.009814833,"threshold_uncertainty_score":0.99997175},"labels":[],"label_agreement":null},{"id":"W4392925702","doi":"10.20944/preprints202403.0904.v1","title":"Genomic Characterization of Partial Tandem Duplication Involving the KMT2A Gene in Adult Acute Myeloid Leukemia","year":2024,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"University of Toronto","keywords":"Multiplex ligation-dependent probe amplification; Biology; Gene duplication; Genetics; Myeloid leukemia; Gene; Gene rearrangement; Exon; Cancer research","score_opus":0.06299539712023611,"score_gpt":0.3385487526799061,"score_spread":0.27555335555967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392925702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924459,0.00022315173,0.0001652806,0.002964157,0.00047682945,0.0024133658,0.000079002726,0.00016273414,0.0010695724],"genre_scores_gemma":[0.99281883,0.0029267673,0.00015733398,0.00032668075,0.00067588425,0.00070896884,0.00071366003,0.00012217842,0.0015496734],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99597216,0.0002620359,0.0012041099,0.0012802163,0.00071814045,0.00056331547],"domain_scores_gemma":[0.99670637,0.00011023553,0.00052290724,0.002030611,0.00045141776,0.00017847616],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014177529,0.0004705573,0.00080710626,0.0004676076,0.000088168636,0.00004099477,0.0008438319,0.00066051795,0.00031277703],"category_scores_gemma":[0.00044836872,0.00039229795,0.0002914133,0.0005482241,0.00022997404,0.00008861906,0.0034955735,0.002624608,0.00096443814],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022769698,0.00006814787,0.20888862,0.0005432687,0.00034533374,0.00004729837,0.0017511474,0.00014228087,0.7866985,0.00031183363,0.000032405624,0.00094343035],"study_design_scores_gemma":[0.00077207916,0.000028820561,0.60760784,0.00059638696,0.0002976448,0.000042611584,0.00007227369,0.008993287,0.38028246,0.0005629352,0.00046942863,0.0002742141],"about_ca_topic_score_codex":0.0006157796,"about_ca_topic_score_gemma":0.00003496652,"teacher_disagreement_score":0.40641606,"about_ca_system_score_codex":0.002689797,"about_ca_system_score_gemma":0.0021744778,"threshold_uncertainty_score":0.9998529},"labels":[],"label_agreement":null},{"id":"W4392978281","doi":"10.1182/bloodadvances.2023011445","title":"Multiomic profiling of human clonal hematopoiesis reveals genotype and cell-specific inflammatory pathway activation","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute for Occupational Safety and Health; National Cancer Institute; Ludwig Center at Harvard; National Institutes of Health; Edward P. Evans Foundation; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Gilead Sciences; Fondation pour la Recherche Médicale; Leukemia and Lymphoma Society; Glenn Foundation for Medical Research","keywords":"Biology; CD14; Haematopoiesis; Inflammation; Proinflammatory cytokine; Immunology; T cell; Myeloid; Cancer research; Genetics; Immune system; Stem cell","score_opus":0.01712623689656025,"score_gpt":0.29077161099723603,"score_spread":0.2736453741006758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392978281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825519,0.015646318,0.00010956531,0.00013125104,0.00006269147,0.0005308788,0.0000150360065,0.00008492408,0.00086746895],"genre_scores_gemma":[0.9929482,0.0009187972,0.0051416648,0.000024128307,0.0002235517,0.000053944557,0.000036604208,0.000032277167,0.00062085764],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988434,0.000038432427,0.00031354983,0.00030669646,0.00029226372,0.00020570784],"domain_scores_gemma":[0.99938697,0.00016014474,0.000076518554,0.00019720334,0.0000982161,0.00008093795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026070233,0.00013505829,0.00025345123,0.00019590376,0.000080089754,0.00002453205,0.000074213094,0.00007948276,0.000046916142],"category_scores_gemma":[0.000049704406,0.000114256705,0.000053423904,0.00021042781,0.00012215371,0.00023734622,0.000055057088,0.00023164591,0.000014017544],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006668366,0.00006416896,0.0060273465,0.0016400202,0.000052382846,0.00004756805,0.00037725375,0.000004238801,0.9864077,0.0015558801,0.00018963694,0.003567146],"study_design_scores_gemma":[0.0009360109,0.00017433496,0.006337645,0.00044955424,0.000043999305,0.000036466878,0.0003324761,0.000088856475,0.98651916,0.000546127,0.0044080447,0.00012732417],"about_ca_topic_score_codex":0.0000065804134,"about_ca_topic_score_gemma":0.000001464204,"teacher_disagreement_score":0.014727522,"about_ca_system_score_codex":0.000066104265,"about_ca_system_score_gemma":0.0001437918,"threshold_uncertainty_score":0.46592534},"labels":[],"label_agreement":null},{"id":"W4393157132","doi":"10.1002/pbc.30974","title":"Low‐dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia","year":2024,"lang":"en","type":"letter","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"University of Texas MD Anderson Cancer Center","keywords":"Medicine; Hematology; Hematopathology; Internal medicine; Gynecologic oncology; Cancer; Oncology; Pediatrics","score_opus":0.018582768057435327,"score_gpt":0.29169927669381074,"score_spread":0.27311650863637543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393157132","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60914403,0.039213523,0.00013778286,0.33807513,0.0017010304,0.0070130886,0.002788093,0.00068153144,0.0012458055],"genre_scores_gemma":[0.039368678,0.06421613,0.013789404,0.64307433,0.087015435,0.010176477,0.004052457,0.002782561,0.13552453],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99435085,0.000083806735,0.0008111357,0.0017510927,0.0013826267,0.0016204849],"domain_scores_gemma":[0.9973382,0.0005375767,0.00037107812,0.0009026027,0.0003980394,0.00045251247],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0004741237,0.0010472939,0.0016195588,0.0010940131,0.00021930183,0.00019626686,0.00046189394,0.0013029225,0.00037749865],"category_scores_gemma":[0.0001467091,0.00081439473,0.0003463439,0.0013984491,0.0002072417,0.0001898491,0.00037165076,0.004506985,0.00012077418],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045263008,0.000066384615,0.0018014188,0.010689906,0.0030849315,0.016641602,0.00021936266,0.000011413819,0.0002127449,0.000003985139,0.96420854,0.0026070771],"study_design_scores_gemma":[0.025729882,0.00530301,0.004951149,0.002967129,0.050090674,0.0125402035,0.000066497865,0.0009696507,0.00091194455,0.0002974865,0.8923943,0.00377805],"about_ca_topic_score_codex":0.0005499708,"about_ca_topic_score_gemma":0.000025537822,"teacher_disagreement_score":0.56977534,"about_ca_system_score_codex":0.0013276706,"about_ca_system_score_gemma":0.004047524,"threshold_uncertainty_score":0.9999936},"labels":[],"label_agreement":null},{"id":"W4393163441","doi":"10.1038/s41598-024-57578-x","title":"Differential prognostic values of the three AKT isoforms in acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fondation Toulouse Cancer Santé; Région Occitanie Pyrénées-Méditerranée; Société Française d'Hématologie; Ministère de l'Enseignement Supérieur et de la Recherche; Fondation de France; Fondation ARC pour la Recherche sur le Cancer; Fondation pour la Recherche Médicale; Institut National de la Santé et de la Recherche Médicale; Genome Canada","keywords":"NPM1; AKT1; Myeloid leukemia; AKT3; Leukemia; Cancer research; Myeloid; Protein kinase B; Biology; RUNX1; PI3K/AKT/mTOR pathway; Carcinogenesis; Haematopoiesis; Stem cell; Genetics; Gene; Signal transduction; Karyotype","score_opus":0.017530972448803042,"score_gpt":0.28946669192596786,"score_spread":0.27193571947716483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393163441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890945,0.0004113763,0.00015953158,0.0006998001,0.006032095,0.0011208111,0.000006472753,0.000101489764,0.0023739121],"genre_scores_gemma":[0.9823952,0.000014150979,0.00017134832,0.000022973487,0.00014123875,0.000056368113,0.000040592546,0.000035896144,0.017122235],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99649173,0.000048141075,0.0007572387,0.0008356473,0.0013129682,0.0005542706],"domain_scores_gemma":[0.9981095,0.00010100422,0.00014670861,0.0013086576,0.00018549424,0.00014858891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012436575,0.0002067751,0.00037262874,0.00044113724,0.00016285198,0.0002127426,0.00029866982,0.00013627704,0.0003409007],"category_scores_gemma":[0.00048359027,0.00011843251,0.00025881716,0.0016541672,0.0007519176,0.00018952522,0.00036141623,0.00050261774,0.000056967056],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002099794,0.00033669223,0.33353543,0.0014521962,0.0005446169,0.009323928,0.0028745327,0.00006308519,0.519001,0.0007527685,0.09971267,0.032193106],"study_design_scores_gemma":[0.0017820576,0.00044385353,0.46914795,0.0036661755,0.0008276941,0.0065414757,0.0003691391,0.01936311,0.417026,0.050840702,0.029191392,0.0008004595],"about_ca_topic_score_codex":0.00009527538,"about_ca_topic_score_gemma":0.00010568187,"teacher_disagreement_score":0.1356125,"about_ca_system_score_codex":0.0006273364,"about_ca_system_score_gemma":0.002152015,"threshold_uncertainty_score":0.48295376},"labels":[],"label_agreement":null},{"id":"W4393230660","doi":"10.1016/j.leukres.2024.107497","title":"Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML","year":2024,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Medical Research Council; Bristol-Myers Squibb","keywords":"IDH2; Neuroblastoma RAS viral oncogene homolog; Internal medicine; Medicine; Oncology; Mutation; Myeloid; IDH1; Biology; Gene; Genetics; KRAS","score_opus":0.03134948617511376,"score_gpt":0.35570727734812685,"score_spread":0.3243577911730131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393230660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99341387,0.0009355138,0.000083347215,0.0031214512,0.00005027372,0.0013280278,0.000019966366,0.00020018301,0.00084738224],"genre_scores_gemma":[0.9946986,0.00043339253,0.00062450516,0.0001371694,0.0001432383,0.0002796374,0.00007019257,0.00011263455,0.00350062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950857,0.00046780377,0.0005626713,0.00088952616,0.0018744459,0.0011198445],"domain_scores_gemma":[0.99688554,0.0015039681,0.000049974322,0.00070325215,0.0004245295,0.00043271255],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002037314,0.00033227837,0.0005459165,0.001555266,0.00016757907,0.00027492893,0.00032824953,0.00029318882,0.00015719574],"category_scores_gemma":[0.0010178034,0.00024859371,0.0000685911,0.0016844508,0.0004441576,0.0004091555,0.00027959063,0.0025174755,0.00037190097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032184653,0.0003597243,0.6197294,0.008051394,0.0010828308,0.059691247,0.02062031,0.0017776891,0.2164554,0.0004901025,0.0033389595,0.06518449],"study_design_scores_gemma":[0.011149256,0.002145091,0.9032673,0.0035419737,0.00011436204,0.0021046873,0.0037867443,0.045464147,0.025156772,0.0010623313,0.0014081674,0.00079914933],"about_ca_topic_score_codex":0.0055457177,"about_ca_topic_score_gemma":0.00044599676,"teacher_disagreement_score":0.28353795,"about_ca_system_score_codex":0.0039287363,"about_ca_system_score_gemma":0.0029745034,"threshold_uncertainty_score":0.9999966},"labels":[],"label_agreement":null},{"id":"W4393274863","doi":"10.1080/10428194.2024.2333451","title":"Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m <i>IDH1</i> ) acute myeloid leukemia (AML)","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Venetoclax; IDH1; Isocitrate dehydrogenase; Myeloid leukemia; Internal medicine; Medicine; Refractory (planetary science); Complete remission; Gastroenterology; Myeloid; Leukemia; Oncology; Chemotherapy; Mutant; Chemistry; Biology; Chronic lymphocytic leukemia; Enzyme","score_opus":0.006680696083015651,"score_gpt":0.2386489908476709,"score_spread":0.23196829476465525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393274863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985429,0.004752639,0.00011839304,0.000567844,0.0005106325,0.0027682248,0.0005412842,0.0009855602,0.0043264558],"genre_scores_gemma":[0.987442,0.0022950363,0.0011618559,0.003572907,0.00065362843,0.0005652625,0.0010755017,0.00061909755,0.0026146949],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9890243,0.0003883682,0.0019595874,0.0031297249,0.0023000457,0.0031979862],"domain_scores_gemma":[0.9945553,0.00067899755,0.00037647432,0.0019306361,0.00064955954,0.0018090176],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009976533,0.0019952185,0.0022215645,0.0016703554,0.0005926427,0.0006883132,0.0010182696,0.0013526555,0.00027180885],"category_scores_gemma":[0.00019613926,0.0016732858,0.0006352616,0.0031317666,0.0011117349,0.0013503109,0.0006853493,0.0011313806,0.0006993697],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03137869,0.0015674583,0.07958879,0.0058312826,0.009778474,0.07721402,0.010945499,0.0019787361,0.17376725,0.0041118576,0.027175356,0.5766626],"study_design_scores_gemma":[0.17270166,0.00986186,0.37766725,0.009049429,0.005813433,0.023417166,0.0030590543,0.11885664,0.14918496,0.0019899444,0.116927385,0.011471214],"about_ca_topic_score_codex":0.005333637,"about_ca_topic_score_gemma":0.00065177295,"teacher_disagreement_score":0.5651914,"about_ca_system_score_codex":0.05545568,"about_ca_system_score_gemma":0.030824713,"threshold_uncertainty_score":0.9999438},"labels":[],"label_agreement":null},{"id":"W4393307842","doi":"10.1158/1078-0432.ccr-23-3840","title":"Solid Organ Transplant Recipients Exhibit More <i>TET2</i> -Mutant Clonal Hematopoiesis of Indeterminate Potential Not Driven by Increased Transplantation Risk","year":2024,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute of General Medical Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Vanderbilt University Medical Center; NIH Office of the Director; National Institute for Occupational Safety and Health; Centers for Disease Control and Prevention; National Cancer Institute; National Institutes of Health; Edward P. Evans Foundation; Canadian Institutes of Health Research; Leukemia and Lymphoma Society; Burroughs Wellcome Fund","keywords":"Transplantation; Population; Biobank; Malignancy; Haematopoiesis; Internal medicine; Biology; Oncology; Medicine; Immunology; Bioinformatics; Genetics; Stem cell","score_opus":0.06296916830744788,"score_gpt":0.46586794977371754,"score_spread":0.4028987814662697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393307842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99131787,0.00083350536,0.00045679175,0.0031644404,0.00037844267,0.00111415,0.002421826,0.0001064053,0.00020656949],"genre_scores_gemma":[0.98572767,0.011905506,0.00021366052,0.00022000559,0.00055843923,0.00018311306,0.00037902477,0.00010806934,0.00070454215],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99278575,0.0010693048,0.0014242119,0.0010781221,0.0025974738,0.0010451585],"domain_scores_gemma":[0.99591064,0.0018569054,0.0001448003,0.00064335525,0.00068905036,0.0007552597],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0044586766,0.0003264107,0.0009209701,0.00051638496,0.00022938117,0.00008705651,0.0005710311,0.000517612,0.0011126386],"category_scores_gemma":[0.0006012653,0.00026863648,0.0004516889,0.001146892,0.0011728794,0.0001978369,0.00013898537,0.0030681442,0.00013864586],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030655924,0.0018199398,0.12278354,0.0045866356,0.001757689,0.0074355765,0.003494386,0.00005455454,0.7511339,0.00007433872,0.024549669,0.05165385],"study_design_scores_gemma":[0.017119378,0.0040852316,0.13995571,0.0059294035,0.0014633852,0.000687891,0.0004983868,0.02252453,0.8005834,0.00035082534,0.0057709957,0.0010308427],"about_ca_topic_score_codex":0.0017169614,"about_ca_topic_score_gemma":0.0001143601,"teacher_disagreement_score":0.05062301,"about_ca_system_score_codex":0.0005581798,"about_ca_system_score_gemma":0.0022132862,"threshold_uncertainty_score":0.9999766},"labels":[],"label_agreement":null},{"id":"W4393383233","doi":"10.1158/0008-5472.25515703","title":"Supplementary Methods from The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Oxidative phosphorylation; Oxidative stress; Mitochondrion; Leukemia; Phosphorylation; Cancer research; Myeloid; Chemistry; Medicine; Biochemistry; Immunology","score_opus":0.02589486369954439,"score_gpt":0.3510684196004825,"score_spread":0.3251735559009381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393383233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9615455,0.0020726374,0.002189581,0.015339116,0.0015421103,0.005662172,0.01103617,0.00014879464,0.0004638904],"genre_scores_gemma":[0.65184426,0.0029547885,0.30245477,0.0053630443,0.0035920108,0.002929341,0.025912423,0.00059502356,0.0043543396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99321175,0.0010633422,0.0012496784,0.0022397712,0.0011323814,0.001103061],"domain_scores_gemma":[0.9958704,0.001230437,0.0002498394,0.0016680219,0.0002974905,0.0006837865],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012803227,0.0010429423,0.0014404884,0.00061424065,0.00017876016,0.00033855424,0.00093256816,0.0008834741,0.00248226],"category_scores_gemma":[0.00042339298,0.0006951375,0.0002993785,0.00076339196,0.00034544815,0.00014594536,0.0056653856,0.004503777,0.00015282459],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011726911,0.0005754793,0.007996728,0.001391737,0.008950717,0.0032936232,0.028404297,0.0024144088,0.7686243,0.00036135936,0.12892103,0.037339408],"study_design_scores_gemma":[0.006464884,0.00046914862,0.010204697,0.0016845982,0.001759674,0.000063406886,0.0031181988,0.016800221,0.93857193,0.005478152,0.013900175,0.0014848905],"about_ca_topic_score_codex":0.028513528,"about_ca_topic_score_gemma":0.004230504,"teacher_disagreement_score":0.30970126,"about_ca_system_score_codex":0.0032358223,"about_ca_system_score_gemma":0.0023788507,"threshold_uncertainty_score":0.99955},"labels":[],"label_agreement":null},{"id":"W4393383237","doi":"10.1158/0008-5472.25515703.v1","title":"Supplementary Methods from The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Oxidative phosphorylation; Oxidative stress; Mitochondrion; Leukemia; Myeloid; Cancer research; Chemistry; Biochemistry; Biology; Immunology","score_opus":0.02589486369954439,"score_gpt":0.3510684196004825,"score_spread":0.3251735559009381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393383237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9615455,0.0020726374,0.002189581,0.015339116,0.0015421103,0.005662172,0.01103617,0.00014879464,0.0004638904],"genre_scores_gemma":[0.65184426,0.0029547885,0.30245477,0.0053630443,0.0035920108,0.002929341,0.025912423,0.00059502356,0.0043543396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99321175,0.0010633422,0.0012496784,0.0022397712,0.0011323814,0.001103061],"domain_scores_gemma":[0.9958704,0.001230437,0.0002498394,0.0016680219,0.0002974905,0.0006837865],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012803227,0.0010429423,0.0014404884,0.00061424065,0.00017876016,0.00033855424,0.00093256816,0.0008834741,0.00248226],"category_scores_gemma":[0.00042339298,0.0006951375,0.0002993785,0.00076339196,0.00034544815,0.00014594536,0.0056653856,0.004503777,0.00015282459],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011726911,0.0005754793,0.007996728,0.001391737,0.008950717,0.0032936232,0.028404297,0.0024144088,0.7686243,0.00036135936,0.12892103,0.037339408],"study_design_scores_gemma":[0.006464884,0.00046914862,0.010204697,0.0016845982,0.001759674,0.000063406886,0.0031181988,0.016800221,0.93857193,0.005478152,0.013900175,0.0014848905],"about_ca_topic_score_codex":0.028513528,"about_ca_topic_score_gemma":0.004230504,"teacher_disagreement_score":0.30970126,"about_ca_system_score_codex":0.0032358223,"about_ca_system_score_gemma":0.0023788507,"threshold_uncertainty_score":0.99955},"labels":[],"label_agreement":null},{"id":"W4393902150","doi":"10.3390/curroncol31040148","title":"Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Disease; Dysplasia; Bone marrow; Haematopoiesis; Bioinformatics; Myeloid leukemia; Oncology; Stem cell; Internal medicine; Biology; Genetics","score_opus":0.056817709652959764,"score_gpt":0.3991586053752961,"score_spread":0.3423408957223364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393902150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58481133,0.34401512,0.00027438602,0.04567954,0.014088871,0.0020699247,0.000086873406,0.00039451895,0.008579417],"genre_scores_gemma":[0.85961217,0.121003315,0.00023494406,0.0002842814,0.01525478,0.00074763584,0.0002752211,0.0001278561,0.002459788],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984445,0.00013210677,0.00025291913,0.00045645813,0.00025281997,0.0004611738],"domain_scores_gemma":[0.99879646,0.000530706,0.00003631611,0.0003170712,0.00006966561,0.00024975062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023669409,0.00025016273,0.00037534026,0.00017917845,0.00013379965,0.000058193436,0.00012800941,0.0001187661,0.00031317145],"category_scores_gemma":[0.00005511777,0.00013500747,0.00011258635,0.0003209674,0.0002067015,0.000054821467,0.00011880042,0.00081300567,0.0003856652],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018844218,0.00023853366,0.0024142978,0.00029541133,0.000120752586,0.0001668758,0.00086894183,0.0000010441415,0.000063614774,0.0013066167,0.04714695,0.9471885],"study_design_scores_gemma":[0.0016653648,0.0012628962,0.0062421616,0.00013385974,0.00028165922,0.00050829264,0.00022590831,0.0041640433,0.000040513984,0.00013044589,0.9852181,0.00012673979],"about_ca_topic_score_codex":0.0000052849123,"about_ca_topic_score_gemma":0.00002419164,"teacher_disagreement_score":0.9470618,"about_ca_system_score_codex":0.0006813842,"about_ca_system_score_gemma":0.00097909,"threshold_uncertainty_score":0.5505445},"labels":[],"label_agreement":null},{"id":"W4393951096","doi":"10.3390/curroncol31040134","title":"Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Alberta Hospital Edmonton; University of Ottawa; London Health Sciences Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; International Prognostic Scoring System; Internal medicine; Lenalidomide; Oncology; Bone marrow; Pediatrics","score_opus":0.20907890916573502,"score_gpt":0.44189185387593555,"score_spread":0.23281294471020053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393951096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58584493,0.07160621,0.010711015,0.30766842,0.0066570095,0.012677002,0.0007792434,0.00072662986,0.0033295576],"genre_scores_gemma":[0.9758946,0.020461835,0.0016267976,0.00061667635,0.00033644406,0.000118188495,0.0005440704,0.000045248864,0.0003561808],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977416,0.0004496451,0.00080310035,0.0004731461,0.00028969647,0.00024283314],"domain_scores_gemma":[0.99653584,0.0020110514,0.00033054463,0.00026113234,0.0007127686,0.00014864793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010744607,0.0001655999,0.00048464132,0.00017274261,0.00013445185,0.000031444135,0.00011340078,0.000081282924,0.0003825088],"category_scores_gemma":[0.0035771136,0.000107946355,0.000053854197,0.0009599512,0.00047339153,0.00007073117,0.000094915515,0.0007203363,0.000025289928],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038913675,0.004770255,0.20996384,0.015489923,0.0017235613,0.00018981747,0.003533306,0.000006003835,0.002065713,0.021865161,0.1301002,0.60640085],"study_design_scores_gemma":[0.018375574,0.008906614,0.5856699,0.030545872,0.0024621817,0.003655186,0.005531871,0.14634874,0.00042596835,0.0020882331,0.19483148,0.0011584318],"about_ca_topic_score_codex":0.0000078789635,"about_ca_topic_score_gemma":0.0002885981,"teacher_disagreement_score":0.60524243,"about_ca_system_score_codex":0.00082049565,"about_ca_system_score_gemma":0.0021682163,"threshold_uncertainty_score":0.44019246},"labels":[],"label_agreement":null},{"id":"W4393952544","doi":"10.1016/s2352-3026(24)00072-3","title":"Transplant without salvage: cut out the middleman","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myeloid leukaemia; Salvage therapy; Medicine; Refractory (planetary science); Chemotherapy; Transplantation; Hematology; Induction chemotherapy; Oncology; Hematopoietic stem cell transplantation; Internal medicine; Orthodoxy; Stem cell; Intensive care medicine; Haematopoiesis; Biology","score_opus":0.06128884652059418,"score_gpt":0.35350729072832854,"score_spread":0.29221844420773435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393952544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64118683,0.0063376785,0.00125708,0.31271213,0.000991261,0.0011674908,0.000045734112,0.00060078327,0.035701018],"genre_scores_gemma":[0.98654735,0.0005741603,0.00016190528,0.004862401,0.0009360313,0.00009296301,0.000023675266,0.000049485796,0.0067520174],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982189,0.00026234216,0.00026145735,0.00032267132,0.00030292873,0.0006316814],"domain_scores_gemma":[0.9983995,0.0005437038,0.00003253067,0.0008897798,0.00004303645,0.000091465336],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008630398,0.00019295205,0.0007306722,0.00008055628,0.00015823588,0.000051461782,0.00044835955,0.0001392396,0.00029396385],"category_scores_gemma":[0.000092070724,0.000085951506,0.00012858443,0.00022148881,0.00050139066,0.000044817683,0.00009236753,0.0010456002,0.0016723693],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002027188,0.0001527061,0.03255169,0.0034741235,0.0015099297,0.01923494,0.024618026,0.000012603458,0.009146999,0.16968957,0.72916377,0.00841843],"study_design_scores_gemma":[0.0045168316,0.00046354582,0.010113872,0.0011103163,0.0011518401,0.06262108,0.001088329,0.0070944806,0.010679535,0.011654942,0.88889074,0.0006144747],"about_ca_topic_score_codex":0.000047664846,"about_ca_topic_score_gemma":0.00016786714,"teacher_disagreement_score":0.34536055,"about_ca_system_score_codex":0.000078709934,"about_ca_system_score_gemma":0.00024411416,"threshold_uncertainty_score":0.9991049},"labels":[],"label_agreement":null},{"id":"W4393994707","doi":"10.3390/curroncol31040153","title":"True Donor Cell Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Diagnostic and Therapeutic Considerations—Brief Report","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Leukemia; Hematopoietic stem cell transplantation; Transplantation; Oncology; Chemotherapy; Stem cell; Internal medicine; Immunology; Biology; Genetics","score_opus":0.053543679781579076,"score_gpt":0.3587613783645575,"score_spread":0.3052176985829784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393994707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9370337,0.052737348,0.001373427,0.0027060476,0.0013230664,0.0011882056,0.000042242616,0.00018073393,0.0034152388],"genre_scores_gemma":[0.99249,0.0046367096,0.0002905424,0.0004928315,0.00036010187,0.00043482234,0.000091285714,0.00005320879,0.0011505195],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978156,0.0002057196,0.0005775713,0.00065788074,0.00029424048,0.0004490037],"domain_scores_gemma":[0.9974773,0.0016691674,0.00007735231,0.00036782687,0.00013065027,0.00027771943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040635112,0.00027855276,0.00047970164,0.0002268556,0.000104872895,0.00007375413,0.00007905209,0.00023668697,0.00057823333],"category_scores_gemma":[0.00005291984,0.00023643466,0.00012141421,0.0002224455,0.00025890663,0.0000809842,0.00005103409,0.0006795004,0.00019484438],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030672203,0.0036743076,0.18682674,0.03957053,0.0014227581,0.21703789,0.04131491,0.00016082374,0.045442984,0.008795393,0.08364456,0.3690419],"study_design_scores_gemma":[0.016479755,0.0041912114,0.078130715,0.0019033287,0.004725167,0.06900423,0.0019582764,0.0048990957,0.04421995,0.003647254,0.76874,0.0021010211],"about_ca_topic_score_codex":0.000013916416,"about_ca_topic_score_gemma":0.000028208766,"teacher_disagreement_score":0.6850954,"about_ca_system_score_codex":0.00080245535,"about_ca_system_score_gemma":0.0020330166,"threshold_uncertainty_score":0.9641526},"labels":[],"label_agreement":null},{"id":"W4393998977","doi":"10.1016/j.xcrm.2024.101485","title":"Identification of cells of leukemic stem cell origin with non-canonical regenerative properties","year":2024,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Western University; Ontario Clinical Oncology Group; McMaster University","funders":"Canadian Institutes of Health Research; Hospital for Sick Children","keywords":"CD34; Myeloid leukemia; Stem cell; Bone marrow; Regeneration (biology); Cancer research; Progenitor cell; Haematopoiesis; Biology; Transcriptome; Immunology; Medicine; Cell biology; Gene expression; Genetics; Gene","score_opus":0.025819612948679266,"score_gpt":0.28437193710225855,"score_spread":0.2585523241535793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393998977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98105574,0.0049607377,0.001331685,0.0006055074,0.0004465087,0.00102074,0.0000049591204,0.00006443477,0.010509695],"genre_scores_gemma":[0.9510962,0.00042888353,0.00024470236,0.000043726137,0.00028568224,0.00004491415,0.0000291248,0.00005994392,0.047766875],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99669355,0.00006885427,0.001291061,0.0005961759,0.0010304858,0.00031984595],"domain_scores_gemma":[0.99776614,0.00012400807,0.00046659342,0.0008592865,0.000566224,0.00021772916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011039245,0.00025844004,0.00075852073,0.00035620222,0.000039848517,0.00001159419,0.00013805203,0.00014664888,0.00015568014],"category_scores_gemma":[0.000054340933,0.00015523049,0.00009512691,0.00068335264,0.0006840964,0.00010513961,0.00006021585,0.0004712498,0.000021913309],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025164097,0.00011924427,0.00063557894,0.0029032568,0.0000890394,0.0014344866,0.001961164,0.000063495776,0.9800839,0.000025067104,0.011425344,0.0010077914],"study_design_scores_gemma":[0.0010130183,0.0010233779,0.000327827,0.0015313971,0.00033523326,0.00047136,0.0011913278,0.0019436309,0.9882427,0.000011600363,0.0037660697,0.0001424575],"about_ca_topic_score_codex":0.00019878801,"about_ca_topic_score_gemma":0.00000496424,"teacher_disagreement_score":0.03725718,"about_ca_system_score_codex":0.00041297157,"about_ca_system_score_gemma":0.002293086,"threshold_uncertainty_score":0.6330116},"labels":[],"label_agreement":null},{"id":"W4394015539","doi":"10.1016/j.jmoldx.2024.03.007","title":"Cost-Effective and Scalable Clonal Hematopoiesis Assay Provides Insight into Clonal Dynamics","year":2024,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; National Institute for Occupational Safety and Health; National Center for Research Resources; Georgia Clinical and Translational Science Alliance; National Cancer Institute; National Institutes of Health; Pew Charitable Trusts; Vanderbilt-Ingram Cancer Center; Vanderbilt University; Vanderbilt University Medical Center; Alexander and Margaret Stewart Trust; National Center for Advancing Translational Sciences; National Human Genome Research Institute; Burroughs Wellcome Fund","keywords":"Scalability; Computational biology; Haematopoiesis; Dynamics (music); Biology; Clonal selection; Computer science; Genetics; Immunology; Stem cell; Psychology","score_opus":0.011739555757193404,"score_gpt":0.30369612689207126,"score_spread":0.29195657113487783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394015539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84192437,0.04465193,0.09220079,0.015400141,0.0009024803,0.002554397,0.00006100012,0.00008838083,0.0022165345],"genre_scores_gemma":[0.9783925,0.0037016661,0.016085358,0.0009155818,0.00048019053,0.00007158107,0.000029837769,0.000095877054,0.00022742928],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771994,0.00019620771,0.0005417624,0.00027466926,0.0009051664,0.00036225776],"domain_scores_gemma":[0.996515,0.002074029,0.00014811406,0.00021491875,0.00062024937,0.0004277276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00103528,0.00025189694,0.0005361603,0.0004559609,0.00008590741,0.00016768796,0.00017371844,0.0002097258,0.0000488688],"category_scores_gemma":[0.0041723237,0.00019868692,0.00022061092,0.00045358704,0.00024504802,0.00021176305,0.00016958722,0.0011003265,0.000027772921],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002757302,0.0022896084,0.06914283,0.008312168,0.0074654846,0.12735741,0.005798365,0.0007895981,0.100537136,0.044194303,0.103628,0.5277278],"study_design_scores_gemma":[0.017521594,0.01265248,0.05156169,0.0155028645,0.006638136,0.055242192,0.0019752937,0.17571628,0.28828043,0.03420588,0.3379193,0.0027838396],"about_ca_topic_score_codex":0.000022970304,"about_ca_topic_score_gemma":0.000012726325,"teacher_disagreement_score":0.52494395,"about_ca_system_score_codex":0.0009214042,"about_ca_system_score_gemma":0.00095372373,"threshold_uncertainty_score":0.81022173},"labels":[],"label_agreement":null},{"id":"W4394201174","doi":"10.6084/m9.figshare.20329680","title":"Additional file 1 of Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Myeloid leukemia; Cancer research; Leukemia; Enhancer; Myeloid; Gene; Medicine; Biology; Computational biology; Genetics; Gene expression","score_opus":0.046483293862124866,"score_gpt":0.3278986792017767,"score_spread":0.2814153853396518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394201174","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000041008443,0.0012795185,1.13707806e-7,0.00007048589,0.00015962418,0.00069645705,0.9975843,0.00003278405,0.00013573882],"genre_scores_gemma":[0.0000034482123,0.00056328974,0.00035559273,0.00013122617,0.0010383214,0.0065621426,0.9894345,0.000075606295,0.0018359169],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963243,0.000096852316,0.00066860823,0.0008886888,0.0012648352,0.0007567351],"domain_scores_gemma":[0.9957096,0.002752492,0.00020814185,0.0005808258,0.00047824765,0.00027070512],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014413061,0.00046505764,0.00093977374,0.00062824157,0.00016212703,0.00006277995,0.00048500145,0.00047943607,0.9981923],"category_scores_gemma":[0.008026899,0.00047541122,0.00017409766,0.00079968764,0.00006971518,0.00023917209,0.0009852633,0.0018362459,0.0005372132],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012834539,0.00010956296,0.000009953104,0.0033193007,0.0001292107,0.00031163302,0.0000148083955,0.000007882417,0.00014908017,2.9508516e-7,0.9957826,0.00003730495],"study_design_scores_gemma":[0.0008878263,0.00010520814,0.0011817672,0.001759009,0.00017483444,0.00008189284,0.00004725927,0.00010258131,0.00045099735,0.0000038350695,0.99477744,0.0004273737],"about_ca_topic_score_codex":0.00035454813,"about_ca_topic_score_gemma":0.0002760639,"teacher_disagreement_score":0.9976551,"about_ca_system_score_codex":0.0012317245,"about_ca_system_score_gemma":0.005027415,"threshold_uncertainty_score":0.99976975},"labels":[],"label_agreement":null},{"id":"W4394219323","doi":"10.6084/m9.figshare.20329695","title":"Additional file 6 of Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Myeloid leukemia; Enhancer; Cancer research; Leukemia; Medicine; Myeloid; Gene; Computational biology; Oncology; Biology; Internal medicine; Genetics; Gene expression","score_opus":0.0457629271193325,"score_gpt":0.32757969965286954,"score_spread":0.28181677253353704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394219323","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004104151,0.0012934078,1.15003324e-7,0.000070467235,0.0001597418,0.0006979094,0.9975668,0.000032787488,0.00013770329],"genre_scores_gemma":[0.0000035424139,0.0005704414,0.00035162584,0.00013133482,0.0010398077,0.006447299,0.98954844,0.000075587195,0.0018319346],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963236,0.00009683234,0.0006691408,0.0008885206,0.0012650948,0.0007568223],"domain_scores_gemma":[0.99573344,0.0027301516,0.00020818935,0.0005801195,0.00047740535,0.00027071754],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001442595,0.00046507615,0.0009402444,0.00062828686,0.00016217354,0.00006294565,0.00048491306,0.0004794351,0.99809873],"category_scores_gemma":[0.0079450235,0.0004754108,0.00017411067,0.00079959154,0.000069737296,0.00023941234,0.0009850217,0.0018361699,0.00052953867],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001290799,0.00011010614,0.000009930616,0.0033509086,0.00012913087,0.0003163929,0.000014862353,0.000007761341,0.00014805408,3.06822e-7,0.9957456,0.00003786196],"study_design_scores_gemma":[0.00089677726,0.000105459934,0.0011918584,0.0017603299,0.00017468448,0.000081940605,0.000047289966,0.000101778984,0.000451702,0.0000038863577,0.9947565,0.00042774747],"about_ca_topic_score_codex":0.00036234598,"about_ca_topic_score_gemma":0.00028498916,"teacher_disagreement_score":0.99756914,"about_ca_system_score_codex":0.0012305288,"about_ca_system_score_gemma":0.005017814,"threshold_uncertainty_score":0.99976975},"labels":[],"label_agreement":null},{"id":"W4394229873","doi":"10.6084/m9.figshare.20329704","title":"Additional file 8 of Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Myeloid leukemia; Cancer research; Enhancer; Myeloid; Leukemia; Medicine; Biology; Gene; Computational biology; Immunology; Genetics; Gene expression","score_opus":0.045780246702081716,"score_gpt":0.3276117713655012,"score_spread":0.2818315246634195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394229873","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004147343,0.0012915087,1.1500024e-7,0.000070521266,0.0001597336,0.000696949,0.99757016,0.000032572738,0.00013699319],"genre_scores_gemma":[0.0000035459652,0.00056466874,0.0003518662,0.00013135393,0.0010394542,0.006439647,0.9895542,0.000075482705,0.0018397438],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963239,0.00009683033,0.0006691251,0.0008884807,0.0012648343,0.0007568414],"domain_scores_gemma":[0.99573326,0.0027303372,0.00020818984,0.0005801103,0.00047741097,0.00027071027],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014425622,0.00046509068,0.0009402587,0.000628164,0.00016219664,0.00006293908,0.00048486158,0.00047943997,0.99811554],"category_scores_gemma":[0.007945475,0.00047541276,0.00017411255,0.0007990799,0.00006973711,0.00023938129,0.0009848156,0.0018361339,0.0005326787],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012842887,0.00010956494,0.000009884508,0.0033509631,0.0001291326,0.00031654062,0.000014834109,0.000007887395,0.0001470257,3.022724e-7,0.99574697,0.000038438466],"study_design_scores_gemma":[0.00089666585,0.00010571873,0.0011792693,0.0017628458,0.00017477725,0.00008205562,0.000047222267,0.00010322617,0.0004614778,0.0000038881108,0.99475485,0.00042797404],"about_ca_topic_score_codex":0.000358174,"about_ca_topic_score_gemma":0.00027989913,"teacher_disagreement_score":0.9975829,"about_ca_system_score_codex":0.0012322657,"about_ca_system_score_gemma":0.0050191185,"threshold_uncertainty_score":0.99976975},"labels":[],"label_agreement":null},{"id":"W4394241582","doi":"10.6084/m9.figshare.20329662","title":"Additional file 12 of Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Myeloid leukemia; Leukemia; Enhancer; Myeloid; Cancer research; Gene; Biology; Medicine; Computational biology; Genetics; Gene expression","score_opus":0.04946969340132885,"score_gpt":0.3281783761346604,"score_spread":0.27870868273333155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394241582","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005699933,0.0014920987,2.1001635e-7,0.00007815392,0.00019245497,0.0007466887,0.9972443,0.00003414598,0.00015495931],"genre_scores_gemma":[0.0000071082254,0.00072256604,0.00029672158,0.00013763015,0.0011307907,0.0052016233,0.9906246,0.000078926954,0.0018000471],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961771,0.00010301923,0.0006965837,0.00091277855,0.0013194974,0.0007910664],"domain_scores_gemma":[0.99630386,0.0021658794,0.00021079417,0.0005996279,0.00043655597,0.00028330894],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017008405,0.00048239782,0.00097020174,0.00063948636,0.00016958501,0.00006564216,0.0005017479,0.0004963118,0.99487543],"category_scores_gemma":[0.0063160807,0.0004927776,0.00017985114,0.0006761584,0.000072305345,0.00025768956,0.0010064018,0.0018768563,0.00042552818],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014946784,0.00011725957,0.000019004116,0.0035440973,0.00013862725,0.0003160863,0.000018324314,0.0000118336275,0.00018514221,4.0058262e-7,0.99546474,0.000034994515],"study_design_scores_gemma":[0.0010833526,0.000117488984,0.0015149598,0.0016386419,0.00020552025,0.00008663021,0.00005188815,0.00012787757,0.00053908874,0.000004483449,0.9941704,0.00045962524],"about_ca_topic_score_codex":0.00044839212,"about_ca_topic_score_gemma":0.0004327664,"teacher_disagreement_score":0.9944499,"about_ca_system_score_codex":0.0012837,"about_ca_system_score_gemma":0.0048046303,"threshold_uncertainty_score":0.9997524},"labels":[],"label_agreement":null},{"id":"W4394280918","doi":"10.6084/m9.figshare.20329701","title":"Additional file 7 of Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Myeloid leukemia; Medicine; Cancer research; Myeloid; Leukemia; Internal medicine","score_opus":0.04581717095818846,"score_gpt":0.3276416889318447,"score_spread":0.28182451797365626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394280918","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004130629,0.0012904085,1.14887065e-7,0.000070432245,0.00015975583,0.00069685496,0.99757236,0.000032791842,0.00013596394],"genre_scores_gemma":[0.0000035269536,0.00057236734,0.0003516602,0.0001313397,0.0010399006,0.006433946,0.9895709,0.00007559668,0.0018207257],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99632347,0.000096805095,0.0006691374,0.0008885987,0.0012651068,0.000756883],"domain_scores_gemma":[0.9957359,0.002727768,0.00020816806,0.00058011245,0.00047735273,0.0002707181],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014425155,0.00046510427,0.0009402657,0.0006283429,0.00016220544,0.00006294769,0.0004849241,0.0004794471,0.9980875],"category_scores_gemma":[0.007862107,0.00047543607,0.00017411403,0.0007995529,0.00006974351,0.00023942118,0.0009850535,0.0018361892,0.0005294879],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012841735,0.00010958397,0.000009946049,0.0033799578,0.00012913131,0.0003165375,0.00001483719,0.000007884436,0.00014864598,3.0335733e-7,0.99571663,0.00003809846],"study_design_scores_gemma":[0.0008966399,0.00010567124,0.0011761511,0.0017791389,0.00017475008,0.00008201726,0.00004720085,0.00010312711,0.00045704417,0.0000038862195,0.99474645,0.00042792325],"about_ca_topic_score_codex":0.00035884953,"about_ca_topic_score_gemma":0.00028022358,"teacher_disagreement_score":0.99755806,"about_ca_system_score_codex":0.0012323273,"about_ca_system_score_gemma":0.005018587,"threshold_uncertainty_score":0.99976975},"labels":[],"label_agreement":null},{"id":"W4394313136","doi":"10.6084/m9.figshare.20462362","title":"Additional file 2 of Single-cell diploid Hi-C reveals the role of spatial aggregations in complex rearrangements and KMT2A fusions in leukemia","year":2022,"lang":"en","type":"dataset","venue":"Open MIND","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Ploidy; Biology; Leukemia; Computational biology; Genetics; Evolutionary biology; Gene","score_opus":0.04443681772189544,"score_gpt":0.3089339262851849,"score_spread":0.26449710856328945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394313136","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033989113,0.00006596283,1.0080158e-7,0.0001323605,0.000016771537,0.0013602416,0.98994267,6.09186e-7,0.0050823917],"genre_scores_gemma":[0.0005074626,0.000063232954,0.00092073967,0.000053833875,0.000053533517,0.0004992591,0.99596405,0.000019804827,0.00191811],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99782217,0.00026341603,0.0006363544,0.00039473138,0.0006187616,0.0002645517],"domain_scores_gemma":[0.9972843,0.001488135,0.0004096931,0.0006293802,0.00009929485,0.00008919487],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040013588,0.00019877385,0.0005771759,0.00038384882,0.00009689863,0.000026796253,0.00065768155,0.0001608623,0.9461775],"category_scores_gemma":[0.00095859426,0.00016794715,0.00006319941,0.00046426704,0.00024094578,0.00007396314,0.0012065299,0.0007331302,0.00008313071],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017625715,0.00034156075,0.00004919591,0.000066285276,0.000036708014,0.00004352402,0.00012933755,0.000004711443,0.002001686,3.0585832e-7,0.9925404,0.0046100263],"study_design_scores_gemma":[0.0014684807,0.00023166342,0.0030907302,0.0005418979,0.000049729228,0.000017706832,0.0005409878,0.000059016213,0.00018058377,0.000024765568,0.99366426,0.00013014615],"about_ca_topic_score_codex":0.004101221,"about_ca_topic_score_gemma":0.0042825406,"teacher_disagreement_score":0.94609433,"about_ca_system_score_codex":0.00058194145,"about_ca_system_score_gemma":0.0011627396,"threshold_uncertainty_score":0.68486863},"labels":[],"label_agreement":null},{"id":"W4394318972","doi":"10.6084/m9.figshare.20329659","title":"Additional file 11 of Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Myeloid leukemia; Medicine; Leukemia; Cancer research; Myeloid; Enhancer; Gene; Computational biology; Biology; Internal medicine; Genetics; Gene expression","score_opus":0.046933299305226224,"score_gpt":0.3289436508129166,"score_spread":0.2820103515076904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394318972","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000117430485,0.0013897896,1.69738e-7,0.000087553155,0.00018926036,0.0007404892,0.99734753,0.00003447258,0.000093322094],"genre_scores_gemma":[0.000008421686,0.00060163334,0.00032417168,0.00013530368,0.0010828102,0.005179663,0.99102783,0.000079058955,0.0015610816],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961781,0.00010290741,0.00069827616,0.00091991737,0.0013135845,0.000787251],"domain_scores_gemma":[0.9962689,0.0021410354,0.00021152743,0.00060253247,0.0004944652,0.00028152246],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016966368,0.000482957,0.00097419956,0.0006479783,0.00016924595,0.000065555665,0.0005073072,0.0004915547,0.9944921],"category_scores_gemma":[0.006387209,0.0004935746,0.00018014737,0.0008152869,0.00007276525,0.00025339643,0.0010102848,0.0016866821,0.00039358594],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011023127,0.0001173407,0.000028679502,0.0035430666,0.00011362701,0.00033279406,0.00001710642,0.000009949805,0.00017683544,5.139899e-7,0.9955213,0.000028532355],"study_design_scores_gemma":[0.0010840122,0.00010085085,0.0017876478,0.001630685,0.0002023251,0.00008725543,0.00005567771,0.000112418995,0.0006285644,0.0000041247913,0.9938492,0.00045719443],"about_ca_topic_score_codex":0.00061805436,"about_ca_topic_score_gemma":0.0006179653,"teacher_disagreement_score":0.9940985,"about_ca_system_score_codex":0.0012572901,"about_ca_system_score_gemma":0.004852533,"threshold_uncertainty_score":0.99975157},"labels":[],"label_agreement":null},{"id":"W4394335884","doi":"10.6084/m9.figshare.20329707","title":"Additional file 9 of Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Myeloid leukemia; Enhancer; Cancer research; Leukemia; Gene; Medicine; Computational biology; Biology; Internal medicine; Genetics; Gene expression","score_opus":0.04579138581119811,"score_gpt":0.32762115062664865,"score_spread":0.2818297648154505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394335884","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004129186,0.0012913287,1.15106396e-7,0.00007052285,0.00015973838,0.00069674564,0.99757123,0.000032790947,0.00013623368],"genre_scores_gemma":[0.0000035351586,0.00057150424,0.0003514426,0.00013136328,0.0010397226,0.006394996,0.9896053,0.00007554494,0.0018265852],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963239,0.00009682658,0.0006691213,0.00088837947,0.0012649987,0.0007567762],"domain_scores_gemma":[0.9957339,0.0027299165,0.00020816391,0.000579941,0.00047738262,0.00027067462],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014422691,0.00046503564,0.00094011077,0.00062831014,0.00016220556,0.00006292662,0.0004845156,0.00047936192,0.99810714],"category_scores_gemma":[0.007945077,0.0004753572,0.0001741084,0.00079951086,0.00006973553,0.00023941211,0.0009845507,0.0018354837,0.00053048116],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012844523,0.000109585846,0.000009962044,0.0033511345,0.00012912606,0.00031652075,0.0000148357785,0.000007887253,0.00014818745,2.9817923e-7,0.99574655,0.00003748821],"study_design_scores_gemma":[0.0008962694,0.00010551674,0.0011883635,0.0017627,0.00017474948,0.0000820465,0.000047231028,0.00010322279,0.00045540434,0.000003888696,0.9947527,0.0004278752],"about_ca_topic_score_codex":0.00035140483,"about_ca_topic_score_gemma":0.00027947163,"teacher_disagreement_score":0.99757665,"about_ca_system_score_codex":0.0012320145,"about_ca_system_score_gemma":0.0050163,"threshold_uncertainty_score":0.9997698},"labels":[],"label_agreement":null},{"id":"W4394470726","doi":"10.6084/m9.figshare.20329692","title":"Additional file 5 of Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Myeloid leukemia; Enhancer; Cancer research; Leukemia; Medicine; Myeloid; Gene; Computational biology; Oncology; Biology; Internal medicine; Genetics; Gene expression","score_opus":0.045770901407765345,"score_gpt":0.3276105519837599,"score_spread":0.2818396505759945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394470726","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000041319236,0.0012893877,1.1472975e-7,0.00007040652,0.00015972671,0.0006969351,0.9975734,0.000032790846,0.00013595838],"genre_scores_gemma":[0.0000035398505,0.0005712964,0.0003517453,0.00013133981,0.0010397832,0.0064398847,0.98956645,0.00007558708,0.0018204068],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963237,0.000096828095,0.000669126,0.0008885047,0.0012650897,0.00075674476],"domain_scores_gemma":[0.9957343,0.0027295465,0.00020817155,0.000580075,0.00047727063,0.00027068623],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001442543,0.00046507074,0.0009402548,0.0006282994,0.00016220161,0.00006291495,0.0004848706,0.00047945927,0.9981145],"category_scores_gemma":[0.007944669,0.00047538936,0.00017412368,0.0007995468,0.00006973307,0.00023939135,0.0009849769,0.0018360298,0.00052837393],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000128446,0.00010958768,0.0000099556155,0.0033507554,0.00012912204,0.00031652494,0.000014818008,0.000007872335,0.00014827933,3.0416837e-7,0.99574643,0.000037889837],"study_design_scores_gemma":[0.0008971097,0.000105556086,0.0012012784,0.0017628843,0.00017484225,0.000082079445,0.000047258804,0.00010249494,0.00045535745,0.0000038694607,0.9947392,0.00042808696],"about_ca_topic_score_codex":0.000358627,"about_ca_topic_score_gemma":0.0002800968,"teacher_disagreement_score":0.99758613,"about_ca_system_score_codex":0.0012321136,"about_ca_system_score_gemma":0.005016975,"threshold_uncertainty_score":0.9997698},"labels":[],"label_agreement":null},{"id":"W4394498925","doi":"10.6084/m9.figshare.20329689","title":"Additional file 4 of Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Myeloid leukemia; Enhancer; Medicine; Leukemia; Cancer research; Myeloid; Gene; Biology; Internal medicine; Genetics; Gene expression","score_opus":0.0460718661632035,"score_gpt":0.32788137572106263,"score_spread":0.2818095095578591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394498925","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000041121304,0.0012909983,1.15091986e-7,0.00007003087,0.00015972213,0.00069710665,0.99757195,0.000032789365,0.00013619961],"genre_scores_gemma":[0.000003575163,0.0005713638,0.00035178373,0.0001312646,0.0010397194,0.006440652,0.9895791,0.000075580625,0.0018069738],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99632394,0.00009674619,0.0006691475,0.00088839064,0.0012650144,0.0007567637],"domain_scores_gemma":[0.99573445,0.0027330949,0.00020818692,0.00058019604,0.0004734237,0.0002706661],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014418137,0.00046502452,0.0009400927,0.0006283248,0.0001621941,0.000062942876,0.00048505384,0.00047943593,0.99811506],"category_scores_gemma":[0.007912937,0.00047538048,0.00017410006,0.00079928787,0.000069732734,0.00023939171,0.0009849268,0.0018358133,0.0005319664],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013047359,0.00010957139,0.000009989524,0.0033495699,0.00012911187,0.00031651717,0.0000148249055,0.0000077748255,0.00014716077,3.0398328e-7,0.99574685,0.000037827882],"study_design_scores_gemma":[0.00089728856,0.000106945576,0.0011812141,0.0017608933,0.00017470904,0.00008203849,0.000047216,0.000103186314,0.00045166016,0.000003888665,0.9947631,0.0004278578],"about_ca_topic_score_codex":0.00035538417,"about_ca_topic_score_gemma":0.0002790894,"teacher_disagreement_score":0.9975831,"about_ca_system_score_codex":0.0012318431,"about_ca_system_score_gemma":0.005011343,"threshold_uncertainty_score":0.9997698},"labels":[],"label_agreement":null},{"id":"W4394536187","doi":"10.6084/m9.figshare.20329656","title":"Additional file 10 of Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Myeloid leukemia; Myeloid; Cancer research; Enhancer; Gene; Leukemia; Medicine; Biology; Computational biology; Internal medicine; Genetics; Gene expression","score_opus":0.04696615724876736,"score_gpt":0.32976811512993964,"score_spread":0.2828019578811723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394536187","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007066828,0.0015228046,1.2304174e-7,0.000077192584,0.00016271674,0.0007106347,0.9972502,0.000033867636,0.00017181845],"genre_scores_gemma":[0.0000050596227,0.00057269714,0.00029296367,0.00011547435,0.0010743955,0.0051111006,0.98919517,0.00007775828,0.0035553605],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962123,0.00010135485,0.0006908347,0.0009141368,0.0013071164,0.00077425357],"domain_scores_gemma":[0.99617964,0.0021875019,0.00021020274,0.00060205447,0.0005422385,0.0002783907],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016865855,0.00047934463,0.00096237037,0.0006404455,0.00016655435,0.000066412984,0.00050382107,0.0004993108,0.99751383],"category_scores_gemma":[0.00717121,0.00048989855,0.00017871174,0.0008063352,0.000072410665,0.00024867296,0.0010040755,0.0017434945,0.00070709083],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017338738,0.0001162313,0.000009436802,0.0034399068,0.0001339495,0.00030489825,0.00001484948,0.000007873134,0.00016695363,3.5826554e-7,0.99559337,0.000038776456],"study_design_scores_gemma":[0.0010484629,0.00012333698,0.0009923807,0.0015059226,0.00019480124,0.00007565792,0.000044795463,0.000113700095,0.0005783414,0.0000045430384,0.9948746,0.00044346118],"about_ca_topic_score_codex":0.00035372295,"about_ca_topic_score_gemma":0.00028226813,"teacher_disagreement_score":0.99680674,"about_ca_system_score_codex":0.0012518468,"about_ca_system_score_gemma":0.0049537546,"threshold_uncertainty_score":0.99975526},"labels":[],"label_agreement":null},{"id":"W4394621770","doi":"10.21203/rs.3.rs-4205555/v1","title":"Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital","funders":"Université de Toulouse","keywords":"Medicine; Myeloid leukemia; Imatinib; Imatinib mesylate; Chemotherapy; Internal medicine; Oncology","score_opus":0.059820790826072806,"score_gpt":0.4229273198069388,"score_spread":0.36310652898086604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394621770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94906586,0.0022430057,0.000084581574,0.018759802,0.00015286391,0.014340433,0.00051167695,0.00045105125,0.014390732],"genre_scores_gemma":[0.9746046,0.0011740542,0.0018450057,0.00046530107,0.0008701871,0.0030371146,0.0010518383,0.00060381996,0.016348086],"study_design_codex":"not_applicable","study_design_gemma":"qualitative","domain_scores_codex":[0.98696965,0.0011477596,0.0009916433,0.0030094266,0.0054631582,0.0024183774],"domain_scores_gemma":[0.9888762,0.00095229124,0.00023802464,0.0047180997,0.0042764232,0.0009389545],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0047164964,0.0010874585,0.0019652694,0.0025884404,0.0002416128,0.00062195567,0.0017613331,0.00082932867,0.0008685999],"category_scores_gemma":[0.0018874332,0.00075197965,0.00024008594,0.0032436897,0.0013110471,0.00017637211,0.004514302,0.014954186,0.00055180915],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07693968,0.009745194,0.19799562,0.058141325,0.009366597,0.13830355,0.049844965,0.000490779,0.0029706394,0.0011596439,0.41720632,0.037835684],"study_design_scores_gemma":[0.09815178,0.06063597,0.2273972,0.1279142,0.0015709955,0.006002846,0.34976715,0.017118111,0.0069447733,0.006542955,0.08933947,0.00861454],"about_ca_topic_score_codex":0.004019727,"about_ca_topic_score_gemma":0.0017207502,"teacher_disagreement_score":0.32786685,"about_ca_system_score_codex":0.00360778,"about_ca_system_score_gemma":0.00923767,"threshold_uncertainty_score":0.9994931},"labels":[],"label_agreement":null},{"id":"W4394711050","doi":"10.1200/jco.23.01841","title":"Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Daunorubicin; Medicine; Mitoxantrone; Flow cytometry; Minimal residual disease; Risk stratification; Internal medicine; Oncology; Stratification (seeds); Leukemia; Pharmacology; Immunology; Chemotherapy","score_opus":0.14548876113930462,"score_gpt":0.449249650039506,"score_spread":0.30376088890020136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394711050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99316216,0.0006748881,0.0006736117,0.004057575,0.0008256581,0.00031803743,0.000018175955,0.000008173321,0.00026173235],"genre_scores_gemma":[0.994027,0.0006116692,0.0035381482,0.000050600764,0.001722433,0.000005249168,0.000007034198,0.000019927813,0.000017944854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995097,0.00088107743,0.002146643,0.00025438154,0.0014052113,0.00021567888],"domain_scores_gemma":[0.9947417,0.0026812255,0.0011677878,0.0002821455,0.0007928342,0.00033434472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064429427,0.00013851254,0.0009588819,0.0008737039,0.000019638072,0.000007230239,0.00015910243,0.00028542854,0.00005999551],"category_scores_gemma":[0.008126786,0.00009466665,0.00023577728,0.0008135948,0.00019805133,0.000113497656,0.000023120114,0.0017194321,0.0000064018764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2718311,0.009904749,0.46892914,0.0011416137,0.0013180766,0.0021710747,0.00019360728,0.007107994,0.008578904,0.00013955428,0.0063571148,0.22232707],"study_design_scores_gemma":[0.018677494,0.03525625,0.93333006,0.00039254667,0.0013058616,0.00002223399,0.00014209232,0.008698818,0.0016205555,0.00005502745,0.00039134867,0.0001077171],"about_ca_topic_score_codex":0.00003868,"about_ca_topic_score_gemma":0.000058401023,"teacher_disagreement_score":0.46440092,"about_ca_system_score_codex":0.00074685516,"about_ca_system_score_gemma":0.0071694264,"threshold_uncertainty_score":0.998459},"labels":[],"label_agreement":null},{"id":"W4394750730","doi":"10.1159/000537725","title":"Evaluating the Economic Burden of Acute Myeloid Leukemia in Canada","year":2024,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University of Manitoba; Thrombosis and Atherosclerosis Research Institute; McMaster University; ABB (Canada); Université de Montréal","funders":"","keywords":"Medicine; Myeloid leukemia; Total cost; Incidence (geometry); Productivity; Economic cost; Indirect costs; Health care; Intensive care medicine; Emergency medicine; Pediatrics; Internal medicine","score_opus":0.044200847801960076,"score_gpt":0.3467356300455253,"score_spread":0.3025347822435652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394750730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856706,0.00069751905,0.0000034054083,0.007915594,0.00018196827,0.00049377064,0.000024769723,0.000041304873,0.0049710535],"genre_scores_gemma":[0.99823624,0.00026184996,0.00036914917,0.00027449784,0.00008927124,0.000059061007,0.000017304252,0.000023394105,0.0006692364],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9983034,0.00012352983,0.00046505764,0.00034922283,0.0003442185,0.00041456925],"domain_scores_gemma":[0.9985911,0.00070734974,0.00007461899,0.00049162074,0.000042745716,0.000092565366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006681633,0.00016701814,0.00048439566,0.00011965047,0.00005438608,0.000025018893,0.00037292505,0.00009688061,0.000593598],"category_scores_gemma":[0.00021173031,0.000100701465,0.00008665407,0.00027409964,0.00011793358,0.000073547955,0.0001938811,0.0005678058,0.000080717145],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004451717,0.0001019541,0.043143887,0.005274417,0.006651444,0.029842233,0.011672606,0.009490207,0.2727566,0.023010945,0.39754695,0.19605702],"study_design_scores_gemma":[0.0049388027,0.0018913354,0.038757242,0.0019569756,0.0010787648,0.008597209,0.0060916925,0.85083103,0.040744826,0.0028384367,0.0411119,0.0011617884],"about_ca_topic_score_codex":0.7041272,"about_ca_topic_score_gemma":0.21742088,"teacher_disagreement_score":0.84134084,"about_ca_system_score_codex":0.0055603227,"about_ca_system_score_gemma":0.013861807,"threshold_uncertainty_score":0.99825716},"labels":[],"label_agreement":null},{"id":"W4394760248","doi":"10.1038/s41598-024-57295-5","title":"Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Ministry of Science and ICT, South Korea; National Research Foundation of Korea; Chonnam National University; National Research Foundation; Chonnam National University Hwasun Hospital; Mike and Josie Harper Cancer Research Institute","keywords":"Medicine; Risk stratification; Internal medicine; Myeloid leukemia; Transplantation; Oncology; Hematopoietic stem cell transplantation; Adverse effect; Myeloid; Risk assessment; Leukemia; Hematopoietic cell; Haematopoiesis; Stem cell","score_opus":0.019790867759712234,"score_gpt":0.30446696314372557,"score_spread":0.28467609538401334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394760248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798843,0.0004047375,0.002203991,0.0008271443,0.006031742,0.0018335336,0.000070397225,0.00016391004,0.008580239],"genre_scores_gemma":[0.96320534,0.000044936372,0.0009696856,0.000028247228,0.00026194393,0.00006492628,0.0004853125,0.000051704992,0.0348879],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99700433,0.00017713688,0.00073682127,0.0008462104,0.0008989655,0.00033651333],"domain_scores_gemma":[0.99751997,0.00012074197,0.0003434744,0.0014879114,0.0003995149,0.0001283888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043376125,0.00016805528,0.00023332077,0.0002580444,0.00035559532,0.00027977527,0.0002474057,0.0000839932,0.00014519534],"category_scores_gemma":[0.00061562756,0.00011468873,0.0002512931,0.0011096089,0.00038102362,0.00021282812,0.00011779476,0.00038666982,0.00007436688],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006608502,0.000045734396,0.002322682,0.0003195925,0.00026382154,0.0002618945,0.0007494668,0.00021937508,0.7377933,0.00047380367,0.23653038,0.020953812],"study_design_scores_gemma":[0.00054586877,0.00015675668,0.008151963,0.0003089889,0.00073927484,0.00094254967,0.00020260771,0.0085098585,0.80032676,0.0061342274,0.17371556,0.00026558284],"about_ca_topic_score_codex":0.00004117692,"about_ca_topic_score_gemma":0.0000065622266,"teacher_disagreement_score":0.062814824,"about_ca_system_score_codex":0.000728863,"about_ca_system_score_gemma":0.0020268932,"threshold_uncertainty_score":0.46768704},"labels":[],"label_agreement":null},{"id":"W4394822828","doi":"10.1182/bloodadvances.2023011771","title":"Optimized cytogenetic risk-group stratification of <i>KMT2A</i>-rearranged pediatric acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"Daiichi Sankyo Europe; National Institutes of Health; Chugai Pharmaceutical; Sumitomo Dainippon Pharma Oncology; National Cancer Institute; Medac; Gilead Sciences; Children's Cancer and Leukaemia Group; Barncancerfonden; Swedish Orphan Biovitrum; Moderna; Syndax Pharmaceuticals; bluebird bio; St. Jude Children's Research Hospital; Jazz Pharmaceuticals; Pfizer; Amgen","keywords":"Myeloid leukemia; Risk stratification; Leukemia; Oncology; Myeloid; Cytogenetics; Medicine; Internal medicine; Biology; Cancer research; Genetics; Gene","score_opus":0.01280825383467573,"score_gpt":0.29172583952535364,"score_spread":0.2789175856906779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394822828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93293744,0.05518416,0.0035107518,0.00047486837,0.00042368882,0.00129407,0.00017806281,0.00039411316,0.005602868],"genre_scores_gemma":[0.9313866,0.034880612,0.031097675,0.00005948743,0.00076877704,0.0001477025,0.00015547409,0.0000834513,0.0014202545],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99752873,0.00013246779,0.00059271697,0.0006235992,0.00066584884,0.0004566331],"domain_scores_gemma":[0.9985221,0.00032034577,0.0001838079,0.0005856517,0.0001715303,0.0002165705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004908056,0.00028660503,0.0005253298,0.0003716364,0.00010380286,0.00005751535,0.000272644,0.00016125607,0.00017738213],"category_scores_gemma":[0.00017891321,0.00023755185,0.00021687827,0.0010065795,0.00016106122,0.00029613715,0.00006845288,0.0005423099,0.000111379675],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027623952,0.001148521,0.042488407,0.005227858,0.0029220744,0.001142657,0.0017978572,0.0020735718,0.7591614,0.0019230298,0.0063052867,0.1730469],"study_design_scores_gemma":[0.036599968,0.0073693404,0.0805276,0.001534329,0.020685317,0.0016231546,0.0019345668,0.019644,0.7468145,0.00449819,0.07563035,0.003138657],"about_ca_topic_score_codex":0.00006097408,"about_ca_topic_score_gemma":0.0000110362125,"teacher_disagreement_score":0.16990826,"about_ca_system_score_codex":0.00018226412,"about_ca_system_score_gemma":0.0006871008,"threshold_uncertainty_score":0.96870834},"labels":[],"label_agreement":null},{"id":"W4394910440","doi":"10.1371/journal.pone.0302156","title":"From code to care: Clinician and researcher perspectives on an optimal therapeutic web portal for acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"Génome Québec","keywords":"Medicine; Credibility; Qualitative research; Computer science; Internet privacy","score_opus":0.08262552089877455,"score_gpt":0.38118503241852586,"score_spread":0.2985595115197513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394910440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856705,0.0028743083,0.00007145706,0.0061162524,0.000042493335,0.0017073959,0.00045080972,0.000217652,0.0028491337],"genre_scores_gemma":[0.98437667,0.00088093255,0.007651058,0.00096481375,0.0015543455,0.0003056373,0.0002471836,0.00014866359,0.0038707207],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99732673,0.00010099033,0.00027679215,0.0009027729,0.00079631875,0.00059642346],"domain_scores_gemma":[0.99812853,0.00042493799,0.000026700036,0.0005832455,0.00031077987,0.0005258034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000456381,0.00025376753,0.00048633962,0.00031841485,0.000138847,0.00014814585,0.00023637233,0.0002054482,0.00031423484],"category_scores_gemma":[0.00025339605,0.00021580796,0.00010738721,0.00032012365,0.00018326765,0.00015984321,0.00012510183,0.00081560237,0.00016809188],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032734837,0.0038254296,0.0026125868,0.0015408008,0.01643878,0.0024637294,0.09642681,0.000027572041,0.7381643,0.002540255,0.029886136,0.07333878],"study_design_scores_gemma":[0.033949222,0.06945013,0.049020953,0.007766504,0.011968306,0.00020587476,0.21601993,0.14718789,0.37353995,0.002189046,0.08409376,0.004608437],"about_ca_topic_score_codex":0.00013333184,"about_ca_topic_score_gemma":0.00006759674,"teacher_disagreement_score":0.36462432,"about_ca_system_score_codex":0.00092283887,"about_ca_system_score_gemma":0.0011280176,"threshold_uncertainty_score":0.8800393},"labels":[],"label_agreement":null},{"id":"W4394993559","doi":"10.1080/10428194.2024.2344052","title":"Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with <i>FLT3-</i> mutant acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Pharmacyclics; Genentech; Swedish Orphan Biovitrum; Daiichi-Sankyo; Syndax Pharmaceuticals; Sierra Oncology; Incyte; National Center for Advancing Translational Sciences; Agios Pharmaceuticals; Astex Pharmaceuticals; PTC Therapeutics; AstraZeneca; Celgene; Leukemia and Lymphoma Society; Astellas Pharma; Instituto Nacional de Cancerología; TG Therapeutics; Pfizer; Amgen","keywords":"Medicine; Myeloid leukemia; Oncology; Chemotherapy; Internal medicine","score_opus":0.017783905045925752,"score_gpt":0.2946410852356914,"score_spread":0.27685718018976563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394993559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870221,0.0007113062,0.0029582677,0.00031214618,0.0006877925,0.0061702537,0.00045421373,0.00053030404,0.0011536321],"genre_scores_gemma":[0.9896959,0.00054462824,0.004382876,0.00091608264,0.0006025002,0.0016830411,0.00065727043,0.00043479333,0.0010829194],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99349403,0.0002569905,0.0012339237,0.0019939907,0.001343869,0.0016771854],"domain_scores_gemma":[0.9956049,0.0010277904,0.0003202072,0.0011685354,0.00084912515,0.0010294768],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012418217,0.0011634956,0.001754877,0.0010470053,0.00042427215,0.00026876578,0.0005499379,0.0007630928,0.00008130096],"category_scores_gemma":[0.0002861594,0.0009625874,0.00046912557,0.0020853765,0.0005331201,0.00071530405,0.00028555165,0.00038721942,0.000074454234],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.040760983,0.00079898746,0.017019117,0.006887716,0.004107745,0.00068260287,0.0037706934,0.00035130468,0.16946691,0.002720677,0.01172276,0.7417105],"study_design_scores_gemma":[0.111357026,0.0120835425,0.27980804,0.010231315,0.0028676009,0.0024694225,0.0012910941,0.01642173,0.38378373,0.00066467153,0.17489257,0.004129246],"about_ca_topic_score_codex":0.00075411575,"about_ca_topic_score_gemma":0.00003132811,"teacher_disagreement_score":0.73758125,"about_ca_system_score_codex":0.021303885,"about_ca_system_score_gemma":0.008958526,"threshold_uncertainty_score":0.9992825},"labels":[],"label_agreement":null},{"id":"W4395005490","doi":"10.1002/ajh.27321","title":"Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management","year":2024,"lang":"en","type":"review","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Leukocytosis; Neutrophilia; Monocytosis; Myeloid; Basophilia; Medicine; Chronic myelomonocytic leukemia; Immunology; Myeloproliferative neoplasm; Myeloid leukemia; Bone marrow; Leukemia; Pathology; Myelodysplastic syndromes; Myelofibrosis","score_opus":0.019823295514765547,"score_gpt":0.33458905212729784,"score_spread":0.3147657566125323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395005490","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003572504,0.99313647,0.000056669272,0.001543465,0.00040521525,0.0010555343,0.000042340536,0.00003117092,0.00015664913],"genre_scores_gemma":[0.0026773238,0.9947567,0.0007885383,0.00015790755,0.0010135958,0.0001453299,0.000039914725,0.00014777872,0.00027291593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955671,0.00054140156,0.0016972824,0.0008953479,0.00055593497,0.0007429694],"domain_scores_gemma":[0.99665415,0.0004981538,0.0013278701,0.0007720682,0.00017135369,0.000576403],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.000661445,0.00075675786,0.0035545568,0.0010381712,0.0001300004,0.00008866298,0.00047354263,0.00038451425,0.00014472369],"category_scores_gemma":[0.00010887772,0.00054607686,0.00047567923,0.0007311465,0.001363933,0.00006801472,0.0003433911,0.003118032,0.00020451569],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014557107,0.0000419354,0.00012612327,0.015636295,0.00201835,0.0020703278,0.000034264034,0.000005888329,0.0000015181226,0.0017366909,0.016854597,0.96132845],"study_design_scores_gemma":[0.0011918187,0.0038845586,0.0003702665,0.012271203,0.0068593672,0.017958246,0.00008635562,0.000093054165,0.000011921072,0.00028803694,0.9565037,0.0004814695],"about_ca_topic_score_codex":0.000020462881,"about_ca_topic_score_gemma":0.00001880914,"teacher_disagreement_score":0.96084696,"about_ca_system_score_codex":0.005040356,"about_ca_system_score_gemma":0.0038726171,"threshold_uncertainty_score":0.99969906},"labels":[],"label_agreement":null},{"id":"W4395049195","doi":"10.3390/curroncol31050175","title":"A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Germline; Somatic evolution in cancer; Disease; Bone marrow failure; Germline mutation; Myeloid; Dysplasia; Bone marrow; Cancer; Bioinformatics; Haematopoiesis; Stem cell; Mutation; Biology; Cancer research; Genetics; Immunology; Gene; Internal medicine","score_opus":0.08681469139194671,"score_gpt":0.41581674628332405,"score_spread":0.32900205489137735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395049195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94676137,0.04190513,0.00048248252,0.0021112247,0.0014827593,0.000530379,0.000033824672,0.00004110003,0.006651735],"genre_scores_gemma":[0.9979702,0.001310125,0.00015205255,0.00009593037,0.00012405604,0.000026193085,0.000013647287,0.000021962996,0.0002858222],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988047,0.00012546155,0.00034738932,0.00018357915,0.0003104609,0.00022840398],"domain_scores_gemma":[0.999052,0.00031425635,0.00007863105,0.00034461828,0.00012810076,0.00008241581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002803099,0.000111570575,0.0003877075,0.00013648512,0.000017327116,0.000004639894,0.00020382897,0.000106899926,0.00033027914],"category_scores_gemma":[0.0002772862,0.00007052686,0.00017899608,0.00053690857,0.00021404335,0.000023135339,0.0001884688,0.00043743214,0.00004292196],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001195371,0.0020910304,0.051197726,0.019774213,0.0013117206,0.0006962277,0.0036411749,0.00012789971,0.13340858,0.06881795,0.12858775,0.58915037],"study_design_scores_gemma":[0.0036052782,0.0016894325,0.0225516,0.0024322795,0.00071310846,0.0005938331,0.0002341341,0.009889094,0.021690665,0.0008154112,0.93557125,0.00021390084],"about_ca_topic_score_codex":0.000012188166,"about_ca_topic_score_gemma":0.0000063031143,"teacher_disagreement_score":0.80698353,"about_ca_system_score_codex":0.00016789667,"about_ca_system_score_gemma":0.0011238018,"threshold_uncertainty_score":0.3616325},"labels":[],"label_agreement":null},{"id":"W4395053589","doi":"10.1016/j.jtct.2024.04.016","title":"Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITDmut+ Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the United States and Canada","year":2024,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; Astellas Pharma Global Development; Astellas Pharma","keywords":"Myeloid leukemia; Medicine; Haematopoiesis; Transplantation; Hematopoietic cell; Leukemia; Oncology; Myeloid; Immunology; Internal medicine; Stem cell; Biology; Genetics","score_opus":0.016557995111714734,"score_gpt":0.2796812041758545,"score_spread":0.2631232090641398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395053589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960307,0.0012552234,0.0005022038,0.001314032,0.000032660195,0.0007181474,0.00007873258,0.00002413436,0.000044188786],"genre_scores_gemma":[0.85304147,0.14534976,0.00009084488,0.000593221,0.000017854203,0.000040804658,0.0007587327,0.000024182073,0.00008312459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985392,0.00022297926,0.00034675596,0.0003754632,0.00025554697,0.00026005483],"domain_scores_gemma":[0.999166,0.0005433897,0.000033704462,0.00012688321,0.000020748272,0.00010923752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029317994,0.00023429617,0.0002938361,0.00020157182,0.00006659178,0.000057587727,0.000057927056,0.00009275494,0.000012394682],"category_scores_gemma":[0.0000015038327,0.00014222505,0.00003337099,0.00021338763,0.00008580082,0.00007869292,0.0000027890292,0.0002744304,7.50436e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044324724,0.00015319708,0.9417007,0.0014433302,0.0003407835,0.00520394,0.026279636,0.00012607496,0.0024525202,0.000059557136,0.00001683504,0.017790955],"study_design_scores_gemma":[0.02390013,0.001714297,0.9547755,0.0008859035,0.00037550484,0.000576399,0.005580144,0.0049790745,0.006408821,0.000045128392,0.00035437566,0.00040470946],"about_ca_topic_score_codex":0.14610618,"about_ca_topic_score_gemma":0.39369774,"teacher_disagreement_score":0.24759157,"about_ca_system_score_codex":0.00018990699,"about_ca_system_score_gemma":0.00044921244,"threshold_uncertainty_score":0.85958},"labels":[],"label_agreement":null},{"id":"W4395664557","doi":"10.3390/cancers16091693","title":"Genomic Characterization of Partial Tandem Duplication Involving the KMT2A Gene in Adult Acute Myeloid Leukemia","year":2024,"lang":"en","type":"article","venue":"Cancers","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Myeloid leukemia; Gene duplication; Gene; Tandem exon duplication; Genetics; Myeloid; Biology; Cancer research; Computational biology; Medicine","score_opus":0.016982805145648167,"score_gpt":0.2848873883051303,"score_spread":0.2679045831594821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395664557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961176,0.00052599685,0.0006339459,0.0015664418,0.00023343954,0.00054134487,0.000025705485,0.00005307935,0.00030243152],"genre_scores_gemma":[0.9955821,0.0025737933,0.0001004019,0.00046786293,0.00040336806,0.00013390646,0.00014394724,0.00003347139,0.0005611592],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988687,0.00004538793,0.00030722754,0.00028003892,0.00024271564,0.00025590384],"domain_scores_gemma":[0.99938977,0.000052822703,0.00006830698,0.00030895532,0.00010812085,0.000072055045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002689367,0.000117360585,0.00020103824,0.0001519153,0.000047881313,0.000028298222,0.00015484754,0.00009819057,0.000074373405],"category_scores_gemma":[0.000059792048,0.00008891779,0.00006209503,0.0005323069,0.00011265617,0.00011803775,0.000053523152,0.00031997892,0.000039942563],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011070097,0.0000036475014,0.0035153758,0.000101934005,0.00008610415,0.000025503556,0.0011730627,0.0001623467,0.9863353,0.0004171634,0.0004757545,0.0075931014],"study_design_scores_gemma":[0.0022667428,0.00022661718,0.17675495,0.0006601112,0.00026961038,0.00008506981,0.00047042078,0.24375984,0.56287587,0.000104089275,0.012189985,0.00033671752],"about_ca_topic_score_codex":0.0004195244,"about_ca_topic_score_gemma":0.000045707144,"teacher_disagreement_score":0.42345947,"about_ca_system_score_codex":0.0058852113,"about_ca_system_score_gemma":0.0025331934,"threshold_uncertainty_score":0.997931},"labels":[],"label_agreement":null},{"id":"W4396501522","doi":"10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5541","title":"Acute Monocytic Leukemia Presenting With Acute Respiratory Distress Syndrome (ARDS) and Multisystem Organ Failure","year":2024,"lang":"en","type":"article","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"ARDS; Medicine; Acute respiratory distress; Intensive care medicine; Respiratory distress; Acute monocytic leukemia; Leukemia; Respiratory failure; Respiratory system; Immunology; Internal medicine; Lung; Surgery","score_opus":0.01507858063458157,"score_gpt":0.288225548759966,"score_spread":0.2731469681253844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396501522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921051,0.00079009973,0.0008055491,0.0013671293,0.000108276035,0.0011231769,0.00009123751,0.0006244698,0.0029849394],"genre_scores_gemma":[0.9789411,0.0000842595,0.002167134,0.00021584249,0.00017971743,0.00010090669,0.000054859967,0.00013966064,0.018116558],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971411,0.00009337789,0.00041489428,0.0008789889,0.0007394594,0.0007321443],"domain_scores_gemma":[0.9983932,0.00019251261,0.000058858113,0.0007099023,0.00015569132,0.000489865],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032834258,0.00040133263,0.0005992715,0.00034359418,0.00017479259,0.0003032366,0.0002471102,0.00023206776,0.0001828803],"category_scores_gemma":[0.00005543344,0.000272961,0.00009583399,0.00070331263,0.00024621972,0.00039044605,0.0003291852,0.00085974234,0.00022077047],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034927072,0.00036767518,0.09583248,0.01809583,0.027493138,0.39455086,0.00708316,0.000099650366,0.2618273,0.0054363445,0.16157964,0.024141224],"study_design_scores_gemma":[0.047557298,0.008313014,0.1344906,0.014706211,0.014944719,0.19204785,0.010374187,0.19902663,0.13740136,0.0002832983,0.23361954,0.0072353007],"about_ca_topic_score_codex":0.00016502538,"about_ca_topic_score_gemma":0.000071580755,"teacher_disagreement_score":0.20250303,"about_ca_system_score_codex":0.0011330438,"about_ca_system_score_gemma":0.0009677516,"threshold_uncertainty_score":0.9999723},"labels":[],"label_agreement":null},{"id":"W4396666177","doi":"10.3390/jcm13092702","title":"A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; International Prognostic Scoring System; Myelodysplastic syndromes; Internal medicine; Anemia; Oncology; Multivariate analysis; Univariate analysis; Erythropoiesis; Bone marrow; Intensive care medicine","score_opus":0.03800852065508178,"score_gpt":0.40683701109641207,"score_spread":0.3688284904413303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396666177","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46106076,0.51615304,0.000589736,0.01692772,0.002970846,0.0017239215,0.00003395921,0.00003382913,0.00050620874],"genre_scores_gemma":[0.82541746,0.17149915,0.0011696299,0.00034454538,0.0012839714,0.0000076994365,0.000007456988,0.000043773307,0.00022630063],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9909951,0.0008613176,0.00581668,0.0002915052,0.0017237221,0.0003116738],"domain_scores_gemma":[0.9880212,0.008102995,0.0019615944,0.0004856907,0.0010130552,0.00041545543],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01036277,0.00028138692,0.0036979972,0.00077701936,0.0000202002,0.0000105189665,0.0003314045,0.00029175772,0.00026898785],"category_scores_gemma":[0.055800963,0.0001571331,0.00068573275,0.001527337,0.00045746355,0.00016035682,0.000088773675,0.0023287362,0.00000856771],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008779663,0.00045418038,0.02938314,0.9327567,0.0020160985,0.0066787815,0.0009579536,0.000043601158,0.00047577475,0.000079193655,0.023481742,0.0027948183],"study_design_scores_gemma":[0.0034191415,0.0060927533,0.011434903,0.971696,0.0022434841,0.0020940038,0.00031230735,0.0017782184,0.000026492502,0.00007093232,0.0007180349,0.00011368067],"about_ca_topic_score_codex":0.0000069791577,"about_ca_topic_score_gemma":0.0000035141722,"teacher_disagreement_score":0.36435673,"about_ca_system_score_codex":0.00018612608,"about_ca_system_score_gemma":0.00084494415,"threshold_uncertainty_score":0.99997294},"labels":[],"label_agreement":null},{"id":"W4396774026","doi":"10.3324/haematol.2024.285285","title":"Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO-DBH AML 2012 Protocol","year":2024,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Leukapheresis; Etoposide; Medicine; Chemotherapy; Internal medicine; Leukocytosis; White blood cell; Leukostasis; Myeloid leukemia; Myeloid; Surgery; Leukemia; Gastroenterology; Stem cell","score_opus":0.03800216772601007,"score_gpt":0.3311627107403944,"score_spread":0.2931605430143843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396774026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95344007,0.0011572958,0.0001579797,0.0025378922,0.00016327693,0.03811887,0.00010901548,0.00024013533,0.00407544],"genre_scores_gemma":[0.95984846,0.002584712,0.012329423,0.00060978194,0.0004928005,0.022346655,0.00008366259,0.00015164421,0.001552836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99606884,0.00024890614,0.0011141228,0.00092395436,0.0008483723,0.00079582585],"domain_scores_gemma":[0.9978903,0.00050196843,0.0002592307,0.0010448061,0.00011522474,0.00018850256],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009647198,0.0004662251,0.0009590727,0.00032500864,0.00011959168,0.000081970065,0.00065471604,0.00034142434,0.00031775015],"category_scores_gemma":[0.0000977829,0.00028741854,0.0002609989,0.0014762406,0.00025456148,0.00021499782,0.0003374882,0.00085725624,0.00019768935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09945773,0.0041318918,0.26570278,0.023972338,0.014233906,0.068698145,0.020317158,0.0010044592,0.08271563,0.004567442,0.2439526,0.1712459],"study_design_scores_gemma":[0.099573664,0.0035974225,0.57917255,0.012900924,0.0065262164,0.0031719485,0.0072163944,0.056915134,0.1289098,0.004731061,0.092295155,0.004989758],"about_ca_topic_score_codex":0.0006108227,"about_ca_topic_score_gemma":0.000042934033,"teacher_disagreement_score":0.31346974,"about_ca_system_score_codex":0.0008682476,"about_ca_system_score_gemma":0.0006948384,"threshold_uncertainty_score":0.9999578},"labels":[],"label_agreement":null},{"id":"W4396872898","doi":"10.1182/bloodadvances.2024012880","title":"Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; Servier; Astellas Pharma; Galecto; CTI Biopharma; Taiho Pharmaceutical; Incyte; Astex Pharmaceuticals; Gilead Sciences; GlaxoSmithKline; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Pfizer; National Center for Advancing Translational Sciences; Agios Pharmaceuticals","keywords":"Medicine; Internal medicine; Oncology; Venetoclax; Myeloid; Myeloid leukemia; Chemotherapy; Leukemia","score_opus":0.021811294847639103,"score_gpt":0.3361240990998265,"score_spread":0.3143128042521874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396872898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98916405,0.008365962,0.000063804415,0.0005036301,0.00004786021,0.0010998236,0.00006494943,0.000027680346,0.0006622518],"genre_scores_gemma":[0.99727005,0.0013751674,0.0008703001,0.00004450828,0.000044955,0.00016997968,0.00008180763,0.000017961711,0.00012527102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880445,0.0000672934,0.00022882738,0.0003131018,0.00035541953,0.00023090417],"domain_scores_gemma":[0.9994249,0.00019346333,0.000043467815,0.00019221727,0.00007825675,0.00006772432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000976047,0.00019521071,0.0003540558,0.00014491809,0.000045966066,0.000040350347,0.00008871658,0.000030302357,0.000009395043],"category_scores_gemma":[0.000039572322,0.000090048336,0.000038830633,0.00037809397,0.00013983985,0.00019189801,0.000028698154,0.00028907153,0.0000030863703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013517026,0.004613197,0.6239804,0.0005919429,0.0005494459,0.00013821915,0.0059918864,0.000048486036,0.00007880128,0.0008347559,0.00007668892,0.36174446],"study_design_scores_gemma":[0.0529642,0.015332005,0.87796724,0.0007112449,0.0011184912,0.00013338104,0.0027982427,0.0048626475,0.006724502,0.00032488373,0.036315657,0.00074752304],"about_ca_topic_score_codex":0.000015565947,"about_ca_topic_score_gemma":0.000020154414,"teacher_disagreement_score":0.36099696,"about_ca_system_score_codex":0.00006857128,"about_ca_system_score_gemma":0.00024413814,"threshold_uncertainty_score":0.36720645},"labels":[],"label_agreement":null},{"id":"W4396921310","doi":"10.1080/17474086.2024.2356258","title":"The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Expert Review of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia","keywords":"Medicine; Myeloid leukemia; Myeloid; Leukemia; Cancer research; Oncology; Immunology","score_opus":0.010201312912358627,"score_gpt":0.3202986969299171,"score_spread":0.31009738401755843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396921310","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22871915,0.7328547,0.0034920962,0.025952637,0.0009876308,0.007094074,0.0001010903,0.00016015462,0.00063846295],"genre_scores_gemma":[0.7400565,0.2520307,0.0041561024,0.0013197695,0.00012297848,0.00084116246,0.00059895404,0.00011538832,0.0007583992],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825543,0.00013996912,0.000647001,0.00027147454,0.0003918666,0.00029424785],"domain_scores_gemma":[0.998361,0.00041811774,0.00019484595,0.00040592437,0.0005585203,0.000061619234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046008296,0.00018856947,0.0008077575,0.00011893835,0.00008041742,0.000010958685,0.00022635108,0.00010501102,0.00009473406],"category_scores_gemma":[0.0002634799,0.000100073674,0.00020533832,0.00034134593,0.00026452783,0.00007536756,0.000056597193,0.0001968356,0.000011615986],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008183729,0.0014176955,0.0029218476,0.078222595,0.0087692775,0.00033478573,0.0029916898,0.0000017056217,0.025767013,0.05681704,0.506587,0.30798557],"study_design_scores_gemma":[0.033046283,0.014265925,0.007260002,0.054611307,0.0026734092,0.002187854,0.0012220886,0.0052034976,0.09036744,0.00369358,0.7840866,0.0013820393],"about_ca_topic_score_codex":0.000017985556,"about_ca_topic_score_gemma":0.000001980123,"teacher_disagreement_score":0.5113374,"about_ca_system_score_codex":0.00016556612,"about_ca_system_score_gemma":0.00047541747,"threshold_uncertainty_score":0.4080886},"labels":[],"label_agreement":null},{"id":"W4396930286","doi":"10.21203/rs.3.rs-4339623/v1","title":"Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic syndrome","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; University of British Columbia","funders":"","keywords":"Haploinsufficiency; Cancer research; Myelodysplastic syndromes; Biology; Medicine; Genetics; Computational biology; Phenotype; Gene; Internal medicine","score_opus":0.04426442178780934,"score_gpt":0.3627712311120825,"score_spread":0.31850680932427317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396930286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9622381,0.025989475,0.000034991364,0.0022336012,0.00023767061,0.0033158874,0.0005250076,0.00013949635,0.005285788],"genre_scores_gemma":[0.98778135,0.0022389865,0.001599029,0.000026821652,0.00016377956,0.0004748358,0.00020024914,0.00018598512,0.0073289517],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.98947954,0.0009259696,0.0013964915,0.0019096312,0.0041668494,0.0021215407],"domain_scores_gemma":[0.9944382,0.0015189466,0.00018710928,0.0017050876,0.0013552487,0.00079541834],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0062496304,0.0006838975,0.001734197,0.0034674574,0.00023205741,0.0002198149,0.00097408536,0.0010132833,0.0003983683],"category_scores_gemma":[0.0040327264,0.0005984843,0.00031078127,0.0024563097,0.0011680651,0.0001317376,0.005249727,0.0074600787,0.00027452645],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01768703,0.008680048,0.10851755,0.36007446,0.0034679712,0.10640811,0.018731361,0.0018502751,0.2650092,0.015372658,0.08548364,0.008717714],"study_design_scores_gemma":[0.014501784,0.015401642,0.7463754,0.09160193,0.0010137388,0.004690072,0.014566185,0.03237866,0.017915882,0.042211592,0.014774037,0.0045690965],"about_ca_topic_score_codex":0.004647155,"about_ca_topic_score_gemma":0.0006408566,"teacher_disagreement_score":0.63785785,"about_ca_system_score_codex":0.0022354058,"about_ca_system_score_gemma":0.0065151798,"threshold_uncertainty_score":0.99964666},"labels":[],"label_agreement":null},{"id":"W4396972100","doi":"10.1002/ajh.27366","title":"Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in <i>IDH1</i>‐ or <i>IDH2</i>‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study","year":2024,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Daiichi-Sankyo; bluebird bio; Sarepta Therapeutics; Sierra Oncology; Jazz Pharmaceuticals; Dana-Farber Cancer Institute; Celgene","keywords":"Venetoclax; IDH1; Medicine; IDH2; Myeloid leukemia; Hypomethylating agent; Oncology; Internal medicine; Chemotherapy; Mutant; Leukemia; Biology; Gene; Genetics; DNA methylation","score_opus":0.023066902626930397,"score_gpt":0.3297877690618693,"score_spread":0.3067208664349389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396972100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952132,0.0004467108,0.00018326384,0.002553119,0.0003764634,0.0011391205,0.0000026482533,0.00003335103,0.000052085983],"genre_scores_gemma":[0.99533695,0.002274662,0.001153182,0.00097000063,0.000105123836,0.00005018977,0.000006634964,0.00006883389,0.000034411438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755305,0.00032515332,0.00073607196,0.0004145756,0.0005388696,0.00043230256],"domain_scores_gemma":[0.9979406,0.00064631214,0.00044137196,0.00024507672,0.0005216505,0.00020501373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007203486,0.00029780235,0.00104562,0.0007071509,0.000066070126,0.000053566957,0.00016798507,0.000096171214,0.000054970933],"category_scores_gemma":[0.00028782067,0.00019941638,0.000086547145,0.0009967517,0.00042072908,0.0002584052,0.00005257554,0.0009945594,0.0000062421022],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056392763,0.0009914121,0.7063696,0.0001424362,0.005750726,0.021508683,0.0148814935,0.000088468645,0.020920713,0.00006215053,0.0012380282,0.17165352],"study_design_scores_gemma":[0.13952552,0.09512122,0.6164533,0.0021317366,0.0014446469,0.031166252,0.073602274,0.009878971,0.02530481,0.00013797972,0.0038628776,0.0013704436],"about_ca_topic_score_codex":0.00034353853,"about_ca_topic_score_gemma":0.00005731765,"teacher_disagreement_score":0.17028308,"about_ca_system_score_codex":0.0012375771,"about_ca_system_score_gemma":0.0009798032,"threshold_uncertainty_score":0.81319636},"labels":[],"label_agreement":null},{"id":"W4398185210","doi":"10.1002/hem3.69","title":"Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)","year":2024,"lang":"en","type":"review","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Myelodysplastic syndromes; Medicine; Drug development; Clinical trial; Drug; Intensive care medicine; Oncology; Medical physics; Internal medicine; Pharmacology; Bone marrow","score_opus":0.27132309223321066,"score_gpt":0.48313530790035203,"score_spread":0.21181221566714137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398185210","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016674833,0.907046,0.002217546,0.0097697405,0.00453426,0.05233611,0.006709565,0.00032814336,0.00038375767],"genre_scores_gemma":[0.013268566,0.8522329,0.06460399,0.002610309,0.0028311017,0.039090242,0.021062177,0.0010976532,0.0032030593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927267,0.0006433475,0.0035205686,0.0012819275,0.0011391181,0.00068834744],"domain_scores_gemma":[0.97952497,0.017558552,0.0010711966,0.00059429224,0.00089968625,0.000351309],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002193071,0.0007894878,0.0033441812,0.00018525387,0.00017580057,0.00024686722,0.000347524,0.00057679066,0.00049580843],"category_scores_gemma":[0.017915858,0.0004482712,0.0007957525,0.0003631116,0.0002809219,0.00016801238,0.00025696415,0.0015080237,0.000112683985],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009900771,0.005318034,0.0042707445,0.079233736,0.01790131,0.0015843896,0.006952188,0.000011751157,5.3956046e-7,0.0011831536,0.36311534,0.510528],"study_design_scores_gemma":[0.01091401,0.00076831627,0.00016683339,0.03000001,0.004991284,0.00029919387,0.0011282408,0.0004976229,0.000006196016,0.00026439203,0.9501804,0.00078345975],"about_ca_topic_score_codex":0.00002026142,"about_ca_topic_score_gemma":0.00012840591,"teacher_disagreement_score":0.5870651,"about_ca_system_score_codex":0.0010279554,"about_ca_system_score_gemma":0.009329316,"threshold_uncertainty_score":0.9997969},"labels":[],"label_agreement":null},{"id":"W4398776441","doi":"10.1158/2159-8290.cd-23-1145","title":"Targeting Acute Myeloid Leukemia Stem Cells through Perturbation of Mitochondrial Calcium","year":2024,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Medical Science and Technology Project of Zhejiang Province; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Institutes of Health; Swim Across America; American Cancer Society; Leukemia and Lymphoma Society; U.S. Department of Veterans Affairs; Morgan Adams Foundation","keywords":"Venetoclax; Myeloid leukemia; Cancer research; Leukemia; Calcium; Oxidative phosphorylation; Mitochondrion; Biology; Stem cell; Pharmacology; Myeloid; Medicine; Immunology; Cell biology; Internal medicine; Biochemistry; Chronic lymphocytic leukemia","score_opus":0.027648104736558834,"score_gpt":0.318209665817207,"score_spread":0.2905615610806482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398776441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.940586,0.019096972,0.02239894,0.0027672604,0.006353143,0.0015366795,0.00059763517,0.0002959271,0.0063674506],"genre_scores_gemma":[0.92165655,0.0046669682,0.0019443228,0.0007747008,0.0046591274,0.00024796426,0.00018387743,0.00017162024,0.06569488],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99790686,0.000057972284,0.00044841727,0.0005354617,0.00059140456,0.00045987626],"domain_scores_gemma":[0.999111,0.00016658136,0.00008935433,0.00037673098,0.00014134923,0.00011498099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001436162,0.00024730712,0.00044706406,0.00013392862,0.00007016825,0.00010628904,0.00019246072,0.00018490515,0.0002431474],"category_scores_gemma":[0.000026685766,0.00019877143,0.00022808947,0.000492053,0.00016449104,0.0007502257,0.0001241602,0.0005246389,0.000079820624],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006083238,0.00003245313,0.00025466463,0.0010029573,0.000534111,0.00017629706,0.001566352,0.0004078636,0.8953109,0.0009774665,0.095122226,0.004006425],"study_design_scores_gemma":[0.0022896214,0.00034377514,0.0002458974,0.001325798,0.00065985357,0.000044391163,0.00090782443,0.009676495,0.9115798,0.0003507135,0.07211401,0.00046181187],"about_ca_topic_score_codex":0.00042326274,"about_ca_topic_score_gemma":0.000005941024,"teacher_disagreement_score":0.05932743,"about_ca_system_score_codex":0.0020371578,"about_ca_system_score_gemma":0.00235382,"threshold_uncertainty_score":0.81056637},"labels":[],"label_agreement":null},{"id":"W4399062026","doi":"10.1002/path.6292","title":"Multiplex imaging reveals spatially resolved <scp>DNA</scp>‐damage response neighborhoods in <scp><i>TP53</i></scp>‐mutated myelodysplastic neoplasms","year":2024,"lang":"en","type":"article","venue":"The Journal of Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"Medical Center, University of Rochester","keywords":"Biology; Myeloid; DNA damage; Myeloid leukemia; Multiplex; Molecular biology; Bone marrow; Myelodysplastic syndromes; DNA; Cancer research; Immunology; Genetics","score_opus":0.01564215269071999,"score_gpt":0.2954155237650931,"score_spread":0.2797733710743731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399062026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98640466,0.0030650396,0.003103739,0.0043158955,0.00094867614,0.00068287645,0.00003982778,0.000120906574,0.0013183961],"genre_scores_gemma":[0.9920912,0.00075265794,0.0020970823,0.0012501588,0.0007484042,0.000017926064,0.0000183037,0.00016481445,0.0028594462],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9922552,0.0032063504,0.0016778272,0.00053282,0.0009993928,0.0013284282],"domain_scores_gemma":[0.98197246,0.015556426,0.0005740146,0.00082216377,0.00056794996,0.0005070041],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009518213,0.00053649605,0.0011689282,0.001602008,0.0001843449,0.00011925505,0.00090433395,0.00036783406,0.00006672555],"category_scores_gemma":[0.020896005,0.0003738465,0.00032696003,0.0014979489,0.00062058226,0.00034933625,0.00039069296,0.003238841,0.00026961716],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020174251,0.0002235848,0.009357309,0.00023538072,0.00025783936,0.060247675,0.010024858,0.0006545753,0.89456785,0.000089322384,0.019415691,0.0029084885],"study_design_scores_gemma":[0.029795475,0.008729532,0.5938781,0.0051524546,0.002330369,0.14030011,0.016725753,0.07416671,0.08334718,0.0047739046,0.04021959,0.0005808114],"about_ca_topic_score_codex":0.000058284077,"about_ca_topic_score_gemma":0.000066293585,"teacher_disagreement_score":0.81122065,"about_ca_system_score_codex":0.0007579342,"about_ca_system_score_gemma":0.0016975837,"threshold_uncertainty_score":0.9998714},"labels":[],"label_agreement":null},{"id":"W4399213350","doi":"10.1158/2159-8290.cd-23-1092","title":"CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify <i>KDM3B</i> as a Genotype-specific Vulnerability in <i>IDH2</i> - and <i>TET2</i> -mutant Cells","year":2024,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds de Recherche du Québec - Santé; National Cancer Institute; National Institutes of Health; National Institute on Aging; Geoffrey Beene Foundation; Syndax Pharmaceuticals; Leukemia Research Foundation; “la Caixa” Foundation; Daiichi-Sankyo","keywords":"Biology; Haematopoiesis; Progenitor cell; Cell biology; Ex vivo; Mutant; Bone marrow; Stem cell; CRISPR; Cancer research; Genetics; Immunology; In vivo; Gene","score_opus":0.0212914711013381,"score_gpt":0.307616695401961,"score_spread":0.2863252243006229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399213350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94792455,0.044521935,0.00031972618,0.0012733768,0.0007913727,0.0015073249,0.00022132341,0.00011422493,0.003326133],"genre_scores_gemma":[0.9761386,0.018864894,0.000113161455,0.0011226384,0.00030836245,0.00026745122,0.000033793895,0.0001253221,0.0030257688],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99560446,0.00024278331,0.0008801942,0.0013938237,0.00089255674,0.0009861885],"domain_scores_gemma":[0.99818385,0.00039563165,0.00008672919,0.0008984395,0.00009344934,0.0003419151],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001015615,0.0005028504,0.00089277455,0.00050992507,0.00008573585,0.0003605274,0.0003508757,0.00030414402,0.00019827782],"category_scores_gemma":[0.000022196547,0.0004490299,0.00019904802,0.0013672016,0.0003294744,0.00088696386,0.00039021988,0.0015208398,0.00021721062],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016185575,0.00058360846,0.022262946,0.0063639563,0.00017086547,0.0080555305,0.0037102762,0.00019617322,0.9246932,0.00052584364,0.017923128,0.013895885],"study_design_scores_gemma":[0.0117339045,0.0008154379,0.0368485,0.010041756,0.0004060749,0.0009786163,0.003947226,0.0010434687,0.88277566,0.0033180856,0.045566745,0.002524496],"about_ca_topic_score_codex":0.0012055291,"about_ca_topic_score_gemma":0.0005529785,"teacher_disagreement_score":0.04191754,"about_ca_system_score_codex":0.0023891923,"about_ca_system_score_gemma":0.0017469695,"threshold_uncertainty_score":0.99979615},"labels":[],"label_agreement":null},{"id":"W4399318880","doi":"10.1016/j.celrep.2024.114260","title":"Immunotherapeutic targeting of surfaceome heterogeneity in AML","year":2024,"lang":"en","type":"article","venue":"Cell Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Centre Hospitalier Universitaire Sainte-Justine; Princess Margaret Cancer Centre; Centre hospitalier universitaire de Québec; Hôpital Maisonneuve-Rosemont; Université Laval; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Fonds de Recherche du Québec - Santé; Institut de Valorisation des Données; Canada First Research Excellence Fund; Université de Montréal; Government of Canada; Génome Québec; Canadian Institutes of Health Research; Alliance de recherche numérique du Canada; Genome Canada","keywords":"Immunotherapy; Myeloid leukemia; Antigen; Biology; Computational biology; Myeloid; Population; Cancer immunotherapy; Antibody; Immunology; Cancer research; Medicine; Immune system","score_opus":0.020774338237754212,"score_gpt":0.30756824042536907,"score_spread":0.28679390218761486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399318880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831517,0.009225656,0.000048816088,0.00017004879,0.00021823776,0.00027428893,0.0000010848618,0.00005958428,0.006850623],"genre_scores_gemma":[0.9964736,0.00022842178,0.00041325152,0.00005307361,0.000048838985,0.000009846824,0.000015373102,0.00003471175,0.0027228917],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986026,0.000040692594,0.00048805273,0.0003008291,0.0002949032,0.00027287862],"domain_scores_gemma":[0.999367,0.000076372155,0.00007033839,0.00037172032,0.000042665873,0.00007189755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078164984,0.000108882305,0.00026724595,0.00017925682,0.000016119297,0.000015112867,0.000052026124,0.00008811032,0.00016086601],"category_scores_gemma":[0.000077358694,0.000092681745,0.00010326074,0.000363275,0.00006241882,0.000052396495,0.00005429441,0.00030704262,0.000040866853],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005506672,0.00010757698,0.06614973,0.00072574196,0.000061831,0.011093798,0.00042333375,0.00005554688,0.91662204,0.0000054913444,0.0013599904,0.0033398503],"study_design_scores_gemma":[0.00056516676,0.00017525685,0.02695379,0.00039717514,0.000054137177,0.0013286888,0.000120077246,0.0014989087,0.9246677,0.00020918458,0.04382395,0.00020597296],"about_ca_topic_score_codex":0.0001451548,"about_ca_topic_score_gemma":0.0000063720977,"teacher_disagreement_score":0.042463962,"about_ca_system_score_codex":0.00023106724,"about_ca_system_score_gemma":0.0003692158,"threshold_uncertainty_score":0.37794518},"labels":[],"label_agreement":null},{"id":"W4399328009","doi":"10.1200/jco.2024.42.16_suppl.3521","title":"Clonal hematopoiesis of indeterminate potential (CHIP): Outcomes and adverse events in patients with solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; St. Paul's Hospital; Vancouver General Hospital; Ottawa Hospital; Providence Health Care; Princess Margaret Cancer Centre; University Health Network; Pancreas Centre (Canada); University of British Columbia","funders":"","keywords":"Medicine; Indeterminate; Adverse effect; Solid tumor; Oncology; Haematopoiesis; Internal medicine; Cancer research; Cancer; Stem cell; Genetics; Biology","score_opus":0.03944379255092406,"score_gpt":0.43019023690970976,"score_spread":0.3907464443587857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399328009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99684346,0.00008879292,0.000038997103,0.002164937,0.000405204,0.00021043714,0.000006396513,0.0000054358493,0.00023634935],"genre_scores_gemma":[0.99761266,0.00008404777,0.0015452268,0.00036208858,0.00019117155,0.0000021272954,0.000002527923,0.00001937554,0.00018076347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966013,0.00029491828,0.0020486047,0.00019384138,0.00061344064,0.00024791821],"domain_scores_gemma":[0.997444,0.0011210609,0.00069071935,0.0001369455,0.00031313274,0.0002941454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022796527,0.00013720691,0.0015456124,0.00035538492,0.000016522143,0.000002869051,0.00014543216,0.0002697691,0.00008175809],"category_scores_gemma":[0.0015339825,0.00008388095,0.00027102936,0.0001849356,0.0002763197,0.00015423383,0.0001173397,0.0012678641,0.000008194307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060631316,0.0010256536,0.96892726,0.00016587912,0.0003989121,0.001975344,0.0001000411,0.000008640771,0.000035445773,0.000028533792,0.00028056616,0.020990606],"study_design_scores_gemma":[0.011318534,0.008136406,0.97854763,0.0004151679,0.00019385769,0.00029418396,0.00007193102,0.0002542395,0.000046744073,0.00023293777,0.00041424658,0.00007412951],"about_ca_topic_score_codex":0.000016237316,"about_ca_topic_score_gemma":0.000014494909,"teacher_disagreement_score":0.020916477,"about_ca_system_score_codex":0.0001943089,"about_ca_system_score_gemma":0.0018584488,"threshold_uncertainty_score":0.5508309},"labels":[],"label_agreement":null},{"id":"W4399417477","doi":"10.2172/1035210","title":"Proline-Rich Polypeptide 1 and G&lt;sub&gt;X&lt;/sub&gt;-NH&lt;sub&gt;2&lt;/sub&gt;: Molecular and Genetic Mechanisms of Hematopoiesis Regulation","year":2011,"lang":"en","type":"report","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Proline; Haematopoiesis; Cell biology; Chemistry; Biology; Genetics; Amino acid; Stem cell","score_opus":0.021821622117924967,"score_gpt":0.27248624728330934,"score_spread":0.25066462516538435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399417477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9020243,0.020640958,0.013505165,0.0015136088,0.0010790452,0.011321664,0.00038429088,0.0009083479,0.048622597],"genre_scores_gemma":[0.9387604,0.019981882,0.020074708,0.00063814817,0.001512443,0.0011701846,0.001346285,0.0012779254,0.015238009],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9835006,0.00066641724,0.0037908228,0.0036004402,0.005800607,0.0026411165],"domain_scores_gemma":[0.9883494,0.0004816176,0.0021765195,0.0037342627,0.003490945,0.0017672566],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0031605335,0.002568651,0.0045810677,0.0026385142,0.00046671144,0.00024021155,0.0011179446,0.003066254,0.0007855244],"category_scores_gemma":[0.0017925816,0.0023332685,0.0008933498,0.0018850772,0.0010913486,0.0004736747,0.001662221,0.0020946658,0.00020870904],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009254588,0.0005567143,0.00058369373,0.005535879,0.001988658,0.0018857884,0.0005532235,0.000020670472,0.9458268,0.0026203946,0.02776594,0.011736735],"study_design_scores_gemma":[0.007948498,0.002401899,0.013293842,0.0029427654,0.003810551,0.008468672,0.0002377106,0.0022640415,0.9339851,0.0051078675,0.015971905,0.0035671117],"about_ca_topic_score_codex":0.0003105008,"about_ca_topic_score_gemma":0.0003814123,"teacher_disagreement_score":0.03673609,"about_ca_system_score_codex":0.0017836455,"about_ca_system_score_gemma":0.0048844405,"threshold_uncertainty_score":0.9987049},"labels":[],"label_agreement":null},{"id":"W4399477705","doi":"10.21203/rs.3.rs-4453206/v1","title":"Mini-consolidations or intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital","funders":"","keywords":"Cytarabine; Regimen; Medicine; Idarubicin; Multivariate analysis; Retrospective cohort study; Internal medicine; Surgery; Pediatrics; Chemotherapy","score_opus":0.07703242364805366,"score_gpt":0.42262926601888573,"score_spread":0.3455968423708321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399477705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96771294,0.0028751104,0.000022428918,0.008297624,0.00031865522,0.013256093,0.0073176427,0.000060704242,0.00013879625],"genre_scores_gemma":[0.9896774,0.0035451602,0.00008996061,0.00014270098,0.00074960897,0.0016907805,0.0024623768,0.00013034072,0.0015116361],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937696,0.0008951482,0.00076622545,0.0012796655,0.0024894322,0.0007999375],"domain_scores_gemma":[0.9891222,0.005150751,0.0002476295,0.002513561,0.0026403305,0.000325501],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0032112917,0.0004795539,0.0008343982,0.00043051725,0.0005135885,0.00031115915,0.0012449467,0.00039386575,0.00044078962],"category_scores_gemma":[0.0077548856,0.00023375782,0.00025352594,0.00083682686,0.0011505701,0.00010031921,0.004273326,0.0038382707,0.000020034839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052414622,0.005272106,0.49998325,0.002889553,0.006146048,0.00046739416,0.042326886,0.00000896478,0.004093284,0.00020516827,0.32259578,0.06359695],"study_design_scores_gemma":[0.009320326,0.0056200656,0.95721006,0.0020563917,0.0002573359,0.0000066053963,0.010995622,0.0015836625,0.00076597906,0.0011679409,0.010678338,0.00033766945],"about_ca_topic_score_codex":0.0044560567,"about_ca_topic_score_gemma":0.00066049164,"teacher_disagreement_score":0.4572268,"about_ca_system_score_codex":0.0010640746,"about_ca_system_score_gemma":0.0031601964,"threshold_uncertainty_score":0.99845994},"labels":[],"label_agreement":null},{"id":"W4399486509","doi":"10.1097/mph.0000000000002858","title":"Aortic Valve Thrombus, Stroke, and Endovascular Thrombectomy in a Child With APML and Trisomy 21","year":2024,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary; BC Children's Hospital; Hospital for Sick Children","funders":"","keywords":"Medicine; Thrombus; Asymptomatic; Stroke (engine); Surgery; Cardiology; Internal medicine","score_opus":0.013982712400867977,"score_gpt":0.313118142779217,"score_spread":0.29913543037834905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399486509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94693893,0.04393589,0.00035944293,0.0060978215,0.00022489105,0.00048792566,0.0000043974906,0.000032365195,0.0019183145],"genre_scores_gemma":[0.98317987,0.011713054,0.0039264914,0.00023670045,0.000753088,0.000016585798,0.000002777306,0.000047879515,0.00012353456],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9973396,0.00031503194,0.0009045892,0.00040996334,0.00044827617,0.0005825324],"domain_scores_gemma":[0.9979425,0.000963662,0.00028566233,0.00022472336,0.00019155603,0.00039190816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014050227,0.00028179982,0.0014112015,0.0012126403,0.00006814591,0.000036941776,0.00016054545,0.00044444427,0.000110439425],"category_scores_gemma":[0.0004401351,0.00019440836,0.00020258718,0.0007761888,0.00033165063,0.00023103518,0.00012999082,0.0019048139,0.00002159468],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003111428,0.001778918,0.8196142,0.004067565,0.0047341357,0.08596437,0.006390045,0.000015621317,0.0014542853,0.0024581454,0.031002495,0.039408803],"study_design_scores_gemma":[0.047173973,0.021028977,0.21615762,0.0009670249,0.0074773277,0.632093,0.005278192,0.0020437879,0.0011782228,0.0015591751,0.063857056,0.0011856077],"about_ca_topic_score_codex":0.000041073363,"about_ca_topic_score_gemma":0.000034696433,"teacher_disagreement_score":0.60345656,"about_ca_system_score_codex":0.00048577983,"about_ca_system_score_gemma":0.0019464663,"threshold_uncertainty_score":0.82755744},"labels":[],"label_agreement":null},{"id":"W4399487111","doi":"10.1200/jco.2024.42.16_suppl.e18504","title":"Safety outcomes in adult patients with AML who achieved their first complete remission with GO prior to HSCT.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Complete remission; Internal medicine; Oncology; Surgery; Pediatrics; Chemotherapy","score_opus":0.06613484762689062,"score_gpt":0.424071032342389,"score_spread":0.3579361847154984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399487111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9363393,0.00005540059,0.00030665763,0.06019848,0.00037515906,0.0006103208,0.000017481341,0.000020637683,0.0020765488],"genre_scores_gemma":[0.9850486,0.00025547226,0.007370632,0.005325029,0.0005203526,0.0000086472355,0.000009592269,0.00005451053,0.001407183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960142,0.00039487449,0.00207038,0.00034869177,0.0007457194,0.00042614856],"domain_scores_gemma":[0.9934777,0.0041754693,0.000542772,0.00032187867,0.00074426865,0.0007379079],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0024741401,0.00023284047,0.0018736458,0.0002962669,0.00006066684,0.000022968947,0.00031524542,0.00034729776,0.00011232509],"category_scores_gemma":[0.004191463,0.000112666974,0.00025858125,0.00044775679,0.00021016932,0.0001494356,0.0001354489,0.0023486323,0.000058176833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03676416,0.0014149788,0.8410172,0.0001285405,0.00055864936,0.0017770735,0.00055178074,0.000043167583,0.000040031864,0.00007663467,0.010316305,0.10731152],"study_design_scores_gemma":[0.014009294,0.02041069,0.7957814,0.00118937,0.00011641607,0.0001378647,0.00011153343,0.00033511556,0.000012426382,0.000025390835,0.16774169,0.0001288157],"about_ca_topic_score_codex":0.000034994577,"about_ca_topic_score_gemma":0.00039307508,"teacher_disagreement_score":0.15742539,"about_ca_system_score_codex":0.0008405473,"about_ca_system_score_gemma":0.002554424,"threshold_uncertainty_score":0.999953},"labels":[],"label_agreement":null},{"id":"W4399519774","doi":"10.1200/jco.2024.42.16_suppl.6509","title":"Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Azacitidine; Myelodysplastic syndromes; Internal medicine; Oncology; INT; Clinical trial; Bone marrow","score_opus":0.05662040660429468,"score_gpt":0.420154701999125,"score_spread":0.36353429539483034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399519774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922853,0.0005631068,0.00008712379,0.004764616,0.0010824192,0.0008337045,0.00018404088,0.000014471634,0.00018518552],"genre_scores_gemma":[0.9952431,0.0027869018,0.0008203564,0.00024281838,0.00067024725,0.0000058110872,0.000052332216,0.000037813406,0.00014061843],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99327874,0.0014023277,0.0036874705,0.00044436898,0.0007868912,0.0004001972],"domain_scores_gemma":[0.9768726,0.02037244,0.0015311973,0.00037707906,0.00039824896,0.00044841808],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0062363683,0.00026425824,0.0020365599,0.00028329305,0.00004773798,0.000025238676,0.00034352503,0.00042977984,0.00009174305],"category_scores_gemma":[0.018476872,0.00014285176,0.00033644066,0.0003981428,0.0007815935,0.00018807987,0.0001957285,0.0027993273,0.000019370365],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67323375,0.0039743804,0.014652222,0.00007432503,0.0008687358,0.002419049,0.00040632812,0.000039127062,0.000023713492,0.0000073896317,0.00551888,0.2987821],"study_design_scores_gemma":[0.35025775,0.12559947,0.51073456,0.0016584807,0.0010547881,0.00018789821,0.00016866637,0.0020682372,0.00004320149,0.000077767334,0.007992567,0.00015662958],"about_ca_topic_score_codex":0.00014929668,"about_ca_topic_score_gemma":0.0000859641,"teacher_disagreement_score":0.4960823,"about_ca_system_score_codex":0.00036143305,"about_ca_system_score_gemma":0.0022259087,"threshold_uncertainty_score":0.9995012},"labels":[],"label_agreement":null},{"id":"W4399519785","doi":"10.1200/jco.2024.42.16_suppl.6516","title":"Safety outcomes in patients with acute myeloid leukemia receiving gemtuzumab ozogamicin and proceeding to allogeneic hematopoietic stem cell transplantation.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Gemtuzumab ozogamicin; Medicine; Myeloid leukemia; Stem cell; Hematopoietic stem cell transplantation; Transplantation; Hematopoietic cell; Haematopoiesis; Leukemia; Oncology; Internal medicine; CD34; CD33","score_opus":0.040178814174143006,"score_gpt":0.38641022431902566,"score_spread":0.3462314101448827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399519785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99271065,0.0001981281,0.00049803354,0.00484986,0.00037328593,0.0005264124,0.000009588894,0.000018773811,0.00081528036],"genre_scores_gemma":[0.99323034,0.0008521413,0.0041361763,0.0009076712,0.00021923895,0.0000073316464,0.0000049197724,0.000039999333,0.00060218794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965125,0.00020618556,0.001982987,0.00034532376,0.00057329296,0.00037975522],"domain_scores_gemma":[0.9967504,0.0019177945,0.00040403084,0.00013773437,0.0003137753,0.00047626306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00250248,0.00020991526,0.001419036,0.0004576543,0.000044331537,0.000031647323,0.00018938315,0.00030117107,0.000038585986],"category_scores_gemma":[0.0002598352,0.00013651216,0.00018182881,0.0004012289,0.00011957734,0.0002167243,0.00006413233,0.0015143713,0.000021284897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0088574905,0.00047027724,0.90975744,0.00046582313,0.00065478875,0.0026344492,0.0017627969,0.00007809545,0.0004702831,0.000056934892,0.0007395925,0.074052006],"study_design_scores_gemma":[0.012522887,0.009221348,0.97282594,0.0007768574,0.0006056058,0.0005887357,0.00043389888,0.00015899491,0.00025294404,0.00005993621,0.0023577588,0.00019506851],"about_ca_topic_score_codex":0.000015750531,"about_ca_topic_score_gemma":0.000025689467,"teacher_disagreement_score":0.07385694,"about_ca_system_score_codex":0.0011475757,"about_ca_system_score_gemma":0.0030453538,"threshold_uncertainty_score":0.65792733},"labels":[],"label_agreement":null},{"id":"W4399519892","doi":"10.1200/jco.2024.42.16_suppl.6525","title":"Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Innovate UK","keywords":"Medicine; Myeloid leukemia; Drug; Algorithm; Myeloid; Oncology; Leukemia; Internal medicine; Pharmacology","score_opus":0.1403031564000324,"score_gpt":0.48609650401249865,"score_spread":0.3457933476124663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399519892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95188254,0.0021459754,0.0026508165,0.036750164,0.003925637,0.0012925004,0.000086552,0.000078232544,0.0011875803],"genre_scores_gemma":[0.75356734,0.033007096,0.16770351,0.010682864,0.011991643,0.00018055613,0.0000902576,0.00030181272,0.02247492],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931827,0.00059696264,0.003853686,0.0006401541,0.00091256946,0.00081389415],"domain_scores_gemma":[0.9911239,0.0056840894,0.00069170963,0.0004658076,0.00057866774,0.0014558097],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0044441796,0.00040756052,0.0024685266,0.0008281942,0.00007116237,0.00005988203,0.0005886471,0.0007939228,0.00034269367],"category_scores_gemma":[0.0056330618,0.0002896155,0.00079381483,0.0009640418,0.00025909208,0.0003652779,0.00027656666,0.003434585,0.0007327082],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00548919,0.0033404576,0.015341603,0.00011112126,0.0021757507,0.06002156,0.00067788025,0.00033918102,0.00057847967,0.000008447578,0.06464273,0.8472736],"study_design_scores_gemma":[0.077660315,0.04830137,0.1980344,0.0023351382,0.002729814,0.004926813,0.0006815569,0.04485072,0.0008718108,0.00020519883,0.6186552,0.0007476333],"about_ca_topic_score_codex":0.00038963836,"about_ca_topic_score_gemma":0.0005263061,"teacher_disagreement_score":0.84652597,"about_ca_system_score_codex":0.0036232444,"about_ca_system_score_gemma":0.009277957,"threshold_uncertainty_score":0.9999556},"labels":[],"label_agreement":null},{"id":"W4399700870","doi":"10.1016/j.cardfail.2024.05.011","title":"Clonal Hematopoiesis of Indeterminate Potential and Long-term Outcomes in Heart Transplantation","year":2024,"lang":"en","type":"article","venue":"Journal of Cardiac Failure","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Indeterminate; Term (time); Transplantation; Intensive care medicine; Heart transplantation; Haematopoiesis; Cardiology; Internal medicine; Stem cell; Genetics","score_opus":0.011533208524150459,"score_gpt":0.30391891158369677,"score_spread":0.2923857030595463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399700870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99325067,0.0018949475,0.00009662251,0.0043068505,0.0002187886,0.00014605881,0.000022052403,0.0000070552023,0.00005695382],"genre_scores_gemma":[0.9981831,0.0006362118,0.00081759464,0.000046597095,0.00017193524,0.0000021935227,0.000005311214,0.000017048045,0.00012003926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986804,0.00007977709,0.00045076635,0.00011495509,0.0005084602,0.00016565308],"domain_scores_gemma":[0.99945855,0.00012590644,0.000080016514,0.00009351262,0.00012962127,0.00011242013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053101114,0.00011148099,0.00055674097,0.0004458003,0.000015977164,0.000030827927,0.00005935458,0.000113863614,0.000035052126],"category_scores_gemma":[0.00004261443,0.00008274376,0.00029341975,0.00018525869,0.00007362864,0.00020865562,0.000019065534,0.00048366553,0.000003317496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000968548,0.00011005029,0.8676371,0.0030853983,0.0008532763,0.0044994694,0.001668337,0.00001935033,0.107657835,0.00008407306,0.0031330509,0.010283538],"study_design_scores_gemma":[0.001378683,0.00030280827,0.98090845,0.00088280224,0.0003342739,0.0035368267,0.00016745948,0.00006299261,0.011702001,0.00006172529,0.0005656131,0.00009633974],"about_ca_topic_score_codex":0.000008371767,"about_ca_topic_score_gemma":0.000004943193,"teacher_disagreement_score":0.1132714,"about_ca_system_score_codex":0.00009924081,"about_ca_system_score_gemma":0.0002741873,"threshold_uncertainty_score":0.33741927},"labels":[],"label_agreement":null},{"id":"W4399716508","doi":"10.22541/au.171853147.73640668/v1","title":"Comparison of Consolidation Strategies for Pediatric Patients with Acute Myeloid Leukemia -- Results of the Randomized GATLA 8-LMA-P'07 Trial","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Cytarabine; Medicine; Cumulative incidence; Idarubicin; Mitoxantrone; Regimen; Internal medicine; Chemotherapy; Randomized controlled trial; Myeloid leukemia; Surgery; Cohort","score_opus":0.03199185331950754,"score_gpt":0.3479659712533974,"score_spread":0.31597411793388985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399716508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733914,0.0002560065,0.001164086,0.0006551368,0.00092236325,0.015037918,0.00093529414,0.0000887374,0.007549046],"genre_scores_gemma":[0.9924275,0.00015397115,0.0027175946,0.00003573053,0.000522043,0.000686372,0.0012041081,0.000081629216,0.0021710277],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99497104,0.00041712576,0.002080528,0.0007548747,0.0013501284,0.00042629673],"domain_scores_gemma":[0.9940887,0.0018037085,0.0014219721,0.0011344758,0.0014172946,0.00013385186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017009239,0.0005096859,0.0025921091,0.00044819992,0.0000716515,0.00007746609,0.0005634903,0.0005931114,0.000058161357],"category_scores_gemma":[0.0011985255,0.00027433332,0.0007437102,0.00047454465,0.00052943424,0.00007184895,0.0008622621,0.0014297058,0.000012748028],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9751878,0.0003587142,0.0007239716,0.0027484996,0.0017538777,0.0000035090704,0.0011172618,0.00043916606,0.00015950695,0.0014366786,0.015678605,0.00039241381],"study_design_scores_gemma":[0.976116,0.0017475486,0.000824771,0.0006271415,0.005798818,0.000002785242,0.0006592552,0.0048433915,0.0056186183,0.003152821,0.0002243559,0.00038449408],"about_ca_topic_score_codex":0.00039691373,"about_ca_topic_score_gemma":0.000039957547,"teacher_disagreement_score":0.019036112,"about_ca_system_score_codex":0.0006232445,"about_ca_system_score_gemma":0.00789137,"threshold_uncertainty_score":0.9999709},"labels":[],"label_agreement":null},{"id":"W4399727274","doi":"10.3390/hemato5020017","title":"Effects of Autoimmune Disorders on Myelodysplastic Syndrome Outcomes: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Hemato","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Intensive care medicine; Immunology","score_opus":0.02128196549215122,"score_gpt":0.3522600757672982,"score_spread":0.33097811027514695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399727274","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000033227418,0.98579216,0.000013885281,0.0001708251,0.00032832762,0.012817628,0.000041117488,0.00019745405,0.00063526473],"genre_scores_gemma":[0.000018701696,0.99073094,0.00005082669,0.00020916045,0.000024037612,0.0026635495,0.00009515115,0.00026038996,0.00594723],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99497503,0.00046714727,0.0020898327,0.0007367562,0.0011401582,0.00059106475],"domain_scores_gemma":[0.99497104,0.0024816988,0.00063699903,0.0015780702,0.00008553174,0.0002466508],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00084206625,0.00096250064,0.011201206,0.0007526209,0.000042895423,0.000025804233,0.00056208146,0.00043322353,0.00010663661],"category_scores_gemma":[0.0032646786,0.00055447913,0.0019986103,0.0012632621,0.00011557915,0.00003907905,0.00027131595,0.0013370585,0.005365285],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000048382362,0.0001499788,2.670498e-7,0.9891454,0.0019961395,0.0012502297,0.000023965293,1.4968085e-8,3.15476e-7,0.00032255996,0.0028905317,0.0042157695],"study_design_scores_gemma":[0.00038081117,0.00032686844,0.0000031651832,0.91099995,0.027392335,0.0018804828,0.0000057944885,0.000005627617,4.3920087e-7,0.000021982658,0.05862596,0.0003566068],"about_ca_topic_score_codex":0.000010071318,"about_ca_topic_score_gemma":7.914023e-7,"teacher_disagreement_score":0.07814546,"about_ca_system_score_codex":0.00072705257,"about_ca_system_score_gemma":0.0009596724,"threshold_uncertainty_score":0.99969065},"labels":[],"label_agreement":null},{"id":"W4399850840","doi":"10.1101/2024.06.19.24309181","title":"Clonal hematopoiesis of indeterminate potential contributes to accelerated chronic kidney disease progression","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute; McMaster University; University of British Columbia; Queen's University","funders":"","keywords":"Kidney disease; Renal function; Internal medicine; Medicine; Oncology; Mendelian randomization; Kidney; Population; Bone marrow; Biology; Genotype; Genetics; Gene","score_opus":0.023148711335183477,"score_gpt":0.34248779311657,"score_spread":0.31933908178138654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399850840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97669595,0.004149492,0.000227799,0.014222022,0.0009646354,0.0025377101,0.00063993107,0.00023263901,0.0003297958],"genre_scores_gemma":[0.99517554,0.00018405622,0.00045044548,0.0004343371,0.0005904276,0.00049624266,0.00082526746,0.00012437336,0.0017193363],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962462,0.00016725337,0.00080016715,0.0010134726,0.0010716477,0.00070123485],"domain_scores_gemma":[0.9968427,0.00007827826,0.00020976667,0.0010715872,0.0006134309,0.0011842835],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067111844,0.0005143222,0.0010471389,0.0007574072,0.00007586223,0.00010575742,0.0005967122,0.00048889086,0.0007040411],"category_scores_gemma":[0.001053281,0.00041084483,0.00041278807,0.0006312591,0.00024985184,0.000040203802,0.0031082768,0.0017381753,0.00045389865],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013581902,0.0020679517,0.09611847,0.07008087,0.0049885116,0.018791737,0.0009584207,0.0003848522,0.5247399,0.0011397708,0.22140397,0.045743622],"study_design_scores_gemma":[0.014593399,0.00210447,0.19698088,0.056608897,0.0053254636,0.0003171042,0.0001302055,0.044925697,0.61263096,0.010457086,0.052984253,0.0029415633],"about_ca_topic_score_codex":0.00004109344,"about_ca_topic_score_gemma":0.0000033168858,"teacher_disagreement_score":0.16841972,"about_ca_system_score_codex":0.0009785956,"about_ca_system_score_gemma":0.0056476886,"threshold_uncertainty_score":0.9999894},"labels":[],"label_agreement":null},{"id":"W4399970144","doi":"10.1016/j.stem.2024.05.010","title":"Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging","year":2024,"lang":"en","type":"article","venue":"Cell stem cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Radcliffe Department of Medicine, University of Oxford; Canadian Institutes of Health Research; Manchester Biomedical Research Centre; Blood Cancer UK; Clarendon Fund; Medical Research Council; Versus Arthritis; National Research Council Canada; University of Toronto; Canadian Cancer Society Research Institute; Canada First Research Excellence Fund; Canada Research Chairs; International Development Research Centre; Terry Fox Foundation; University of Oxford; Canadian Cancer Society; National Institute for Health and Care Research; Government of Ontario; Princess Margaret Cancer Foundation; Pfizer; NIHR Oxford Biomedical Research Centre; Ontario Institute for Cancer Research; Ministry of Health, Ontario","keywords":"Biology; Haematopoiesis; Mutant; Stem cell; Transcriptome; Inflammation; Myeloid; Cell biology; Progenitor cell; Bone marrow; Mutation; Hematopoietic stem cell; Somatic cell; Genetics; Immunology; Gene; Gene expression","score_opus":0.011647979885392257,"score_gpt":0.2690622350208543,"score_spread":0.25741425513546207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399970144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966754,0.0002988422,0.00007239442,0.00039986754,0.000032849726,0.00091852725,0.00005576532,0.00008042882,0.0014659303],"genre_scores_gemma":[0.9930523,0.000024949388,0.00009167623,0.00005977149,0.000027841372,0.00003442542,0.000020510912,0.000060253242,0.0066282926],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99788684,0.0002654774,0.0004564484,0.00048210358,0.000501446,0.00040771416],"domain_scores_gemma":[0.9987389,0.0005074351,0.00011266401,0.00025525352,0.00020172528,0.00018405436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009962887,0.0002339389,0.00046708557,0.00055122294,0.000067907284,0.000045216937,0.000108606815,0.00014403115,0.000047014782],"category_scores_gemma":[0.000013607671,0.00019981124,0.000054383247,0.0010541555,0.000072096496,0.00011768468,0.000098093136,0.0004250312,0.00003637589],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011324438,0.00007827352,0.0024361662,0.0008438054,0.000070836526,0.00057508226,0.008055266,0.00003611142,0.98576814,0.000006866386,0.00048521042,0.0005117776],"study_design_scores_gemma":[0.002074712,0.0006303873,0.0030418246,0.00093081756,0.000075575306,0.000022162074,0.0030188968,0.0016277606,0.9878927,0.0000067471256,0.00047060277,0.00020780526],"about_ca_topic_score_codex":0.00006828929,"about_ca_topic_score_gemma":0.000036094185,"teacher_disagreement_score":0.0051623625,"about_ca_system_score_codex":0.0007959226,"about_ca_system_score_gemma":0.00034979449,"threshold_uncertainty_score":0.8148066},"labels":[],"label_agreement":null},{"id":"W4400060772","doi":"10.1182/bloodadvances.2023011833","title":"Chronic TNF in the aging microenvironment exacerbates <i>Tet2</i> loss-of-function myeloid expansion","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; Ontario Institute for Cancer Research; McMaster University; St. Joseph’s Healthcare Hamilton","funders":"Canadian Institutes of Health Research","keywords":"Myeloid; Haematopoiesis; Tumor necrosis factor alpha; Biology; Immunology; Progenitor cell; Cancer research; Mutant; Bone marrow; Stem cell; Cell biology; Genetics; Gene","score_opus":0.011443218854192026,"score_gpt":0.27801585258156086,"score_spread":0.26657263372736884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400060772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8588548,0.13521634,0.00030503116,0.0034505033,0.00025063945,0.0005857628,0.000007640755,0.00007120086,0.0012581204],"genre_scores_gemma":[0.98767364,0.010335178,0.00045120055,0.00022827304,0.00046031122,0.000071691706,0.000031568412,0.000023829296,0.0007242993],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985078,0.00007823213,0.00028929004,0.00035661022,0.00043156036,0.00033651394],"domain_scores_gemma":[0.9993033,0.00022097785,0.000045885095,0.00035932145,0.000018736122,0.000051823332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041137976,0.00016569051,0.00022837844,0.00016115133,0.00006021928,0.000030907675,0.00018013887,0.00005923061,0.000107177395],"category_scores_gemma":[0.000040995532,0.000107906715,0.00008604879,0.0004061987,0.00016317361,0.00023465762,0.00007194849,0.00039638247,0.000051158633],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002599975,0.0004665144,0.028085094,0.0025033352,0.00021754006,0.00090394483,0.0023294783,0.00061639614,0.6889651,0.00060191087,0.0015285691,0.2735221],"study_design_scores_gemma":[0.004290423,0.0019899607,0.038300723,0.0027276801,0.00048913277,0.000629973,0.0026112264,0.0010437319,0.39073855,0.001276202,0.55542314,0.0004792809],"about_ca_topic_score_codex":0.00003516621,"about_ca_topic_score_gemma":0.00002457005,"teacher_disagreement_score":0.5538946,"about_ca_system_score_codex":0.00020842261,"about_ca_system_score_gemma":0.0001721034,"threshold_uncertainty_score":0.4400308},"labels":[],"label_agreement":null},{"id":"W4400082696","doi":"10.54434/candj.171","title":"Myelodysplastic Syndrome and Hemoglobin Improved by Intravenous Nutrient Therapy: A Case Report","year":2024,"lang":"en","type":"article","venue":"CAND Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Guelph; Canadian College of Naturopathic Medicine","funders":"","keywords":"Hemoglobin; Medicine; Myelodysplastic syndromes; Internal medicine; Bone marrow","score_opus":0.011429212577133682,"score_gpt":0.27618729496483024,"score_spread":0.26475808238769655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400082696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816093,0.013341484,0.0010534958,0.002878564,0.00041995294,0.00030476984,0.000020187192,0.00004809626,0.0003241573],"genre_scores_gemma":[0.99423474,0.0015053942,0.0002156101,0.00022643237,0.00036210805,0.000012476476,0.000010917816,0.000039196875,0.0033931339],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99867666,0.000043477314,0.0003401983,0.00027227175,0.00027830814,0.0003890901],"domain_scores_gemma":[0.9990157,0.00009736637,0.000057809335,0.00018329872,0.00010932067,0.0005365307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005483851,0.00016366926,0.0002831343,0.00017570649,0.00016746481,0.00019345086,0.000059428992,0.000101818514,0.00020998853],"category_scores_gemma":[0.00013526874,0.00011575893,0.00007422676,0.00022022914,0.00015162614,0.000095136944,0.000039010007,0.0008853832,0.000015326998],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029468167,0.000094040544,0.00018247882,0.00013099726,0.0002861165,0.92182165,0.00045204366,4.0739454e-7,0.017791566,0.00003190006,0.030023197,0.02889093],"study_design_scores_gemma":[0.001919926,0.0010624025,0.00015629952,0.00018145566,0.000072837065,0.9572572,0.00029988098,0.0011370467,0.0014790425,0.00012294699,0.036188804,0.00012212088],"about_ca_topic_score_codex":0.00009480017,"about_ca_topic_score_gemma":0.0000047154076,"teacher_disagreement_score":0.0354356,"about_ca_system_score_codex":0.00044407602,"about_ca_system_score_gemma":0.00088589796,"threshold_uncertainty_score":0.4720512},"labels":[],"label_agreement":null},{"id":"W4400103943","doi":"10.14740/jh1276","title":"Frameshift Mutations in Leukemia-Associated Genes Correlate With Superior Outcomes in Patients Undergoing Allogeneic Stem Cell Transplant for <i>De Novo</i> Acute Myeloid Leukemia","year":2024,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Medicine; Frameshift mutation; Stem cell; Leukemia; Gene; Immunology; Myeloid; Cancer research; Oncology; Mutation; Biology; Genetics","score_opus":0.012441311726052263,"score_gpt":0.27428560302146127,"score_spread":0.261844291295409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400103943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953482,0.0012048001,0.0009792697,0.0013577606,0.00029688232,0.00064876955,0.000058513797,0.00003314638,0.00007266686],"genre_scores_gemma":[0.99677235,0.000611818,0.0017428161,0.00031541067,0.000033906905,0.000044426233,0.0000442601,0.00007581003,0.00035919592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731183,0.00016569116,0.0010824223,0.000317607,0.00041724497,0.0007051823],"domain_scores_gemma":[0.9980073,0.0011300772,0.00025285818,0.00018312426,0.0002210739,0.00020555689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006359511,0.00029641535,0.0010856689,0.00083437486,0.00006582255,0.0000425949,0.0002375638,0.00038092898,0.000025430249],"category_scores_gemma":[0.00008779623,0.00022109506,0.00023643223,0.00051644177,0.00011043363,0.00020698909,0.00003153691,0.0010962244,0.000011866061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021516026,0.00040031108,0.97701865,0.0008719643,0.000973316,0.007227294,0.0033552626,0.0014128907,0.0047866027,0.00022292932,0.00044768304,0.0011315137],"study_design_scores_gemma":[0.11867409,0.015503681,0.75720483,0.008518308,0.0044379043,0.023233594,0.0057645817,0.021620981,0.039390177,0.0014071118,0.0019670047,0.0022777042],"about_ca_topic_score_codex":0.000040182193,"about_ca_topic_score_gemma":0.00033337646,"teacher_disagreement_score":0.21981376,"about_ca_system_score_codex":0.003013837,"about_ca_system_score_gemma":0.0038501436,"threshold_uncertainty_score":0.90159947},"labels":[],"label_agreement":null},{"id":"W4400108462","doi":"10.1182/blood.2023022501","title":"How I treat iron overload in adult MDS","year":2024,"lang":"en","type":"review","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Chelation therapy; Intensive care medicine; Anemia; Life expectancy; Thalassemia; Internal medicine; Bone marrow; Population","score_opus":0.03732698773936028,"score_gpt":0.3471964996443165,"score_spread":0.3098695119049562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400108462","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000110392095,0.985705,4.964275e-7,0.0005038392,0.00012896661,0.0012439281,0.000080121325,0.00011031824,0.01211694],"genre_scores_gemma":[0.000012774259,0.948065,0.00011865045,0.000066304034,0.00076144875,0.00024813597,0.00024233984,0.00014317685,0.050342176],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771726,0.00011929169,0.00041078372,0.00068332214,0.0005161675,0.00055317767],"domain_scores_gemma":[0.99876,0.0001169421,0.00008373816,0.0007600474,0.00006194055,0.00021737034],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018908178,0.000509872,0.0019000829,0.00061313587,0.00002167289,0.00009041793,0.0002799689,0.0006184976,0.00009075554],"category_scores_gemma":[0.0002905566,0.000345396,0.0005653829,0.00080965454,0.00006663439,0.00005476324,0.00019342308,0.0015871617,0.0012656412],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012573295,0.00032105632,0.000019898791,0.08225691,0.00029039133,0.0037433896,0.000060307288,5.6050493e-9,0.0000051653337,0.00013164581,0.018808663,0.89435],"study_design_scores_gemma":[0.0018409396,0.0002015501,0.0000050312933,0.028710531,0.0042606927,0.00078549836,0.000022791115,0.0000026784169,0.000010115219,0.000009193002,0.96386886,0.0002820981],"about_ca_topic_score_codex":0.00011335315,"about_ca_topic_score_gemma":0.00003677043,"teacher_disagreement_score":0.9450602,"about_ca_system_score_codex":0.00060414826,"about_ca_system_score_gemma":0.0011405807,"threshold_uncertainty_score":0.9998998},"labels":[],"label_agreement":null},{"id":"W4400126925","doi":"10.1002/cyto.b.22192","title":"Updates on germline predisposition in pediatric hematologic malignancies: What is the role of flow cytometry?","year":2024,"lang":"en","type":"review","venue":"Cytometry Part B Clinical Cytometry","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; National Institutes of Health","keywords":"Germline; Flow cytometry; Hematologic Neoplasms; Medicine; Immunology; Biology; Internal medicine; Genetics; Cancer","score_opus":0.07785701110939226,"score_gpt":0.4311497638026663,"score_spread":0.35329275269327404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400126925","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0061965873,0.9857887,0.000038470553,0.0006896686,0.0018145513,0.0036742052,0.0006963483,0.00028254878,0.0008188977],"genre_scores_gemma":[0.010816813,0.9818123,0.00047433175,0.001006479,0.003122367,0.00053556054,0.0009151642,0.0003639585,0.0009530391],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9851677,0.0015574149,0.0060851583,0.0027320676,0.0026644443,0.0017932308],"domain_scores_gemma":[0.98437804,0.009188343,0.001642895,0.0033843743,0.000548799,0.0008575454],"candidate_categories":["metaepi_narrow","bibliometrics","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0076504624,0.0017380263,0.007826779,0.0077187256,0.00017825537,0.0003556965,0.0020917638,0.0030277586,0.0008883947],"category_scores_gemma":[0.005978064,0.0010808755,0.0036943387,0.021568317,0.0009230016,0.00048556062,0.0013500714,0.006992083,0.003917705],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091702334,0.003763663,0.01458754,0.08522033,0.002597959,0.0018419335,0.00017147252,0.0000034806674,0.000018108549,0.00024563892,0.03396049,0.85667235],"study_design_scores_gemma":[0.0028171272,0.0028859186,0.0016358092,0.04671432,0.009273398,0.000914955,0.00051796576,0.0005570463,0.0002152869,0.0004310873,0.9322479,0.0017891851],"about_ca_topic_score_codex":0.000010492077,"about_ca_topic_score_gemma":0.0000020339355,"teacher_disagreement_score":0.8982874,"about_ca_system_score_codex":0.0012412496,"about_ca_system_score_gemma":0.0019509959,"threshold_uncertainty_score":0.9995366},"labels":[],"label_agreement":null},{"id":"W4400128564","doi":"10.1161/circgen.123.004415","title":"Invasive Assessment of Coronary Artery Disease in Clonal Hematopoiesis of Indeterminate Potential","year":2024,"lang":"en","type":"article","venue":"Circulation Genomic and Precision Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute on Aging; National Institutes of Health","keywords":"Coronary artery disease; Phenotype; Haematopoiesis; Bone marrow; Disease; Progenitor cell; Medicine; Population; Internal medicine; Indeterminate; Cardiology; Biology; Stem cell; Genetics; Gene","score_opus":0.022424870338136928,"score_gpt":0.32472645059622307,"score_spread":0.3023015802580861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400128564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99285144,0.0026023914,0.002655516,0.00089248247,0.00015692756,0.00047339007,0.000019819898,0.00001336707,0.0003346918],"genre_scores_gemma":[0.9985776,0.00058926473,0.00041908212,0.000074200885,0.00011222895,0.000013198708,0.00008368511,0.000016584827,0.0001141334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845344,0.00008883448,0.0005913485,0.00028449806,0.00044194533,0.0001399193],"domain_scores_gemma":[0.9990193,0.00039066782,0.00009375775,0.00022427608,0.00010651994,0.00016547082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006540144,0.000121727026,0.00039691752,0.0004893198,0.000023151684,0.0000056626886,0.00006991967,0.00008065186,0.00041119833],"category_scores_gemma":[0.00016822516,0.00009588851,0.00006160658,0.0002537101,0.00022222598,0.000080983475,0.00007325653,0.00020587113,0.000003751889],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011854507,0.00018371081,0.5212029,0.0029086457,0.00022692385,0.001253642,0.0020511814,0.00090345077,0.38916817,0.0010211131,0.00080937357,0.07908542],"study_design_scores_gemma":[0.0017074555,0.00018897597,0.9572503,0.0011919078,0.00011318106,0.00014070283,0.00018252153,0.037265178,0.00027855393,0.0015260571,0.00008196048,0.00007322092],"about_ca_topic_score_codex":0.000025678251,"about_ca_topic_score_gemma":0.00000191725,"teacher_disagreement_score":0.43604738,"about_ca_system_score_codex":0.00016434693,"about_ca_system_score_gemma":0.0005246815,"threshold_uncertainty_score":0.45023334},"labels":[],"label_agreement":null},{"id":"W4400226763","doi":"10.1182/bloodadvances.2023011747","title":"Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Institut National Du Cancer; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Stem cell; Gene; Biology; Gene expression; Leukemia; Precursor cell; Cell; Cell biology; Cancer research; Genetics","score_opus":0.010980017199927299,"score_gpt":0.28488868979626547,"score_spread":0.27390867259633817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400226763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96071726,0.036862046,0.00008226731,0.00006886605,0.00014409606,0.0012793286,0.0000129530345,0.00013472534,0.00069844845],"genre_scores_gemma":[0.9810415,0.0073843715,0.010253909,0.000027861459,0.00014297823,0.00027295187,0.000020613912,0.00005692875,0.0007988675],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99760395,0.00012972312,0.0006456094,0.00060265436,0.0004933582,0.0005247278],"domain_scores_gemma":[0.9991278,0.00017521241,0.00010102387,0.00040277076,0.00006863959,0.00012452996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029311923,0.00024789647,0.00045329132,0.00054288586,0.000025358646,0.000026833275,0.00023369864,0.00018044838,0.000033109096],"category_scores_gemma":[0.000026349066,0.00021073427,0.00009593255,0.00083977496,0.0001204106,0.00022870013,0.00011158338,0.00054729177,0.000035667705],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023758176,0.00044182336,0.016910244,0.001721354,0.000018562077,0.0004726787,0.0005087682,0.00081072544,0.9024038,0.000008087806,0.00023132401,0.07623507],"study_design_scores_gemma":[0.0027338597,0.0007317826,0.011052039,0.0017218136,0.00005961566,0.00006114022,0.00030383543,0.0036028754,0.97537977,0.00011344749,0.00401201,0.00022780722],"about_ca_topic_score_codex":0.00012532141,"about_ca_topic_score_gemma":0.000052829,"teacher_disagreement_score":0.07600726,"about_ca_system_score_codex":0.0004328481,"about_ca_system_score_gemma":0.00055794837,"threshold_uncertainty_score":0.8593494},"labels":[],"label_agreement":null},{"id":"W4400241279","doi":"10.14740/jocmr5205","title":"Mapping the Grounds for Mortalities in Acute Myeloid Leukemia Through Registry Analyses: A Retrospective Cohort Study of Children, Adolescents, and Young Adults Patients","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Epidemiology; Confidence interval; Cohort; Cancer registry; Internal medicine; Retrospective cohort study; Leukemia; Pediatrics; Cancer; Population; Cohort study; Oncology; Environmental health","score_opus":0.1391200061822209,"score_gpt":0.48904362104669385,"score_spread":0.349923614864473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400241279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991731,0.0022068734,0.00011597984,0.0021893398,0.00046556004,0.0026921695,0.000021479234,0.000013031769,0.0005645557],"genre_scores_gemma":[0.99220073,0.005472962,0.0001687957,0.0001099102,0.0016003626,0.00005981259,0.000015747617,0.000049436847,0.00032223776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99133736,0.0010736015,0.0029347246,0.00061087427,0.0033770998,0.0006663277],"domain_scores_gemma":[0.993359,0.0026577231,0.0006004348,0.00065800827,0.002376085,0.0003487348],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.015754601,0.0002708936,0.0017808139,0.00089602865,0.00015780238,0.000058183654,0.0006039118,0.0002617093,0.000029960427],"category_scores_gemma":[0.010389514,0.00015182754,0.0003138324,0.001784197,0.0013531293,0.00029290284,0.0002969725,0.0039847926,0.0000020736209],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034993973,0.000683803,0.9769286,0.0005677851,0.0017576521,0.00029318122,0.0043473095,0.0000013436492,0.00005727951,0.000039498973,0.0072259987,0.004598169],"study_design_scores_gemma":[0.012110609,0.009229651,0.9581715,0.0051561464,0.00041804943,0.00019299793,0.013411242,0.00054208614,0.000028464667,0.0004295213,0.000195637,0.00011411543],"about_ca_topic_score_codex":0.0019868305,"about_ca_topic_score_gemma":0.00015112964,"teacher_disagreement_score":0.018757101,"about_ca_system_score_codex":0.0009822557,"about_ca_system_score_gemma":0.0014100692,"threshold_uncertainty_score":0.99831307},"labels":[],"label_agreement":null},{"id":"W4400345001","doi":"10.1101/2024.06.30.601363","title":"FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"International Development Research Centre; Canadian Institutes of Health Research; Hospital for Sick Children; Government of Ontario","keywords":"Haematopoiesis; Stem cell; Cancer research; Bone marrow; Leukemia; Biology; Hematopoietic stem cell; Immunology; Myeloid leukemia; Cell biology","score_opus":0.023544545199076203,"score_gpt":0.2740714462273682,"score_spread":0.25052690102829195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400345001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97398245,0.002064776,0.007579207,0.0009045372,0.002403562,0.009177342,0.0029351288,0.0009299193,0.000023085764],"genre_scores_gemma":[0.9855674,0.0003106303,0.006817214,0.00047132,0.0017961256,0.0024971487,0.000005988337,0.00092053384,0.0016136545],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9921685,0.00017023561,0.001643509,0.0028571864,0.0011480112,0.0020125476],"domain_scores_gemma":[0.99359965,0.0003853378,0.0005422693,0.002728759,0.0016946509,0.0010493279],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013158554,0.0013955967,0.0020137343,0.0007135254,0.0004081119,0.0006236263,0.0012256999,0.0015565439,0.00018953218],"category_scores_gemma":[0.000054522985,0.001415017,0.00093358883,0.0007593359,0.00042853435,0.00010561768,0.0014953314,0.0020793984,0.0005681318],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041076395,0.0002698012,0.00008007084,0.011175867,0.0010121266,0.00024267063,0.0000526159,0.000060625443,0.97114193,0.0008386087,0.014706627,0.000008290522],"study_design_scores_gemma":[0.003497006,0.00043611875,0.0001218181,0.0017176216,0.0014363414,3.6282484e-7,0.00003078295,0.006535428,0.97766185,0.00003665155,0.007184441,0.0013415703],"about_ca_topic_score_codex":0.00009280182,"about_ca_topic_score_gemma":0.0000038990293,"teacher_disagreement_score":0.011584942,"about_ca_system_score_codex":0.002373402,"about_ca_system_score_gemma":0.0041952976,"threshold_uncertainty_score":0.9998794},"labels":[],"label_agreement":null},{"id":"W4400370200","doi":"10.1002/pbc.31141","title":"Guideline for treating relapsed or refractory myeloid leukemia in children with Down syndrome","year":2024,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Guideline; Myeloid leukemia; Refractory (planetary science); Pediatrics; Intensive care medicine; Oncology; Internal medicine; Pathology","score_opus":0.014677139332590987,"score_gpt":0.30655126485628753,"score_spread":0.29187412552369657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400370200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981507,0.014064368,0.00016993936,0.0012726873,0.00019219775,0.0017623208,0.00016790818,0.00027728677,0.0005862692],"genre_scores_gemma":[0.9723196,0.0061872876,0.00789038,0.0007079357,0.0034398222,0.0012149939,0.00024339411,0.000223123,0.007773477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970649,0.000049218306,0.0007135887,0.0008102702,0.0005787636,0.0007832515],"domain_scores_gemma":[0.9986298,0.00032403372,0.00011745869,0.00047044063,0.00018824144,0.00027001655],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006117912,0.0003653328,0.00060580205,0.00064917497,0.000094146235,0.00006327663,0.00023102293,0.00024379324,0.0005844778],"category_scores_gemma":[0.00028908247,0.00024999972,0.00013701787,0.0015725608,0.000065455664,0.00020933253,0.000080111044,0.0008484528,0.00004889196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005433296,0.0006560804,0.74461544,0.0043711113,0.0026230828,0.0037043937,0.0014598652,0.0007931677,0.0028131653,0.000113127324,0.16702537,0.06639189],"study_design_scores_gemma":[0.125234,0.022741128,0.5907413,0.00518471,0.022195581,0.016817216,0.0009664418,0.028264241,0.005236442,0.00034290992,0.17614922,0.006126879],"about_ca_topic_score_codex":0.0021327003,"about_ca_topic_score_gemma":0.00033648164,"teacher_disagreement_score":0.15387419,"about_ca_system_score_codex":0.0016675828,"about_ca_system_score_gemma":0.0054419707,"threshold_uncertainty_score":0.99999523},"labels":[],"label_agreement":null},{"id":"W4400576900","doi":"10.1182/blood.2024024756","title":"Risk prediction for clonal cytopenia: multicenter real-world evidence","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Takeda Oncology; Center for Clinical and Translational Science, Mayo Clinic; Genentech; National Institutes of Health; Cancer Research UK; Alexion Pharmaceuticals; Apellis Pharmaceuticals; Sierra Oncology; Pfizer; Incyte; CTI Biopharma; TG Therapeutics; bluebird bio; Agios Pharmaceuticals; MEI Pharma; Eli Lilly and Company; Associazione Italiana per la Ricerca sul Cancro; Astex Pharmaceuticals; Acceleron; Edward P. Evans Foundation; Moffitt Cancer Center; National Cancer Institute; Gilead Sciences; Syndax Pharmaceuticals; BeiGene; MorphoSys; Celgene; AstraZeneca","keywords":"Cytopenia; Internal medicine; Cumulative incidence; Medicine; Proportional hazards model; Oncology; Cohort; Framingham Risk Score; Severe fever with thrombocytopenia syndrome; Incidence (geometry); Disease; Immunology; Bone marrow","score_opus":0.03653534945482608,"score_gpt":0.3459327650009426,"score_spread":0.30939741554611655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400576900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802782,0.0027969098,0.0023120192,0.0042703454,0.0006823305,0.0023334015,0.00031540383,0.00052306044,0.0064883446],"genre_scores_gemma":[0.9798731,0.0012723595,0.00476042,0.00016931756,0.0013582158,0.00024640185,0.000059250822,0.000049355243,0.0122115575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986925,0.000046592904,0.0002385567,0.00037389438,0.00033810042,0.0003103334],"domain_scores_gemma":[0.99891055,0.00049637177,0.000029954272,0.0002886288,0.00012431148,0.00015020689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005234514,0.00012235461,0.00018424641,0.00017850994,0.00008227129,0.000057873327,0.000110531335,0.00007782587,0.00018487455],"category_scores_gemma":[0.00048494313,0.0000979454,0.0001296712,0.0002799356,0.000054759024,0.00017702926,0.000066571316,0.0003886363,0.00023524617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003790025,0.0017144878,0.58014244,0.003932501,0.0025026943,0.0013179058,0.0016235685,0.00002410968,0.10532237,0.0023167823,0.25356695,0.04374617],"study_design_scores_gemma":[0.020996612,0.0028712936,0.52068996,0.0048799356,0.004740976,0.0004601685,0.00019218208,0.061800744,0.095490634,0.00064746675,0.2865469,0.0006831319],"about_ca_topic_score_codex":0.0002341215,"about_ca_topic_score_gemma":0.00009159565,"teacher_disagreement_score":0.061776634,"about_ca_system_score_codex":0.00019666518,"about_ca_system_score_gemma":0.0003169184,"threshold_uncertainty_score":0.39940974},"labels":[],"label_agreement":null},{"id":"W4400687031","doi":"10.20944/preprints202407.1231.v1","title":"Deciphering the Complexities of Acute Myeloid Leukemia: Emerging Roles of Epithelial to Mesenchymal Transition Transcription Factors (EMT-TFs) in Disease Progression","year":2024,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"Myeloid leukemia; Epithelial–mesenchymal transition; Cancer research; Medicine; Disease; Leukemia; Mesenchymal stem cell; Haematopoiesis; Metastasis; Immunophenotyping; Progenitor cell; Biology; Stem cell; Cancer; Immunology; Genetics; Internal medicine; Pathology; Flow cytometry","score_opus":0.08396642202281586,"score_gpt":0.3731815796700091,"score_spread":0.28921515764719324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400687031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99210495,0.0005168431,0.00044029913,0.0028381094,0.00041173605,0.0026112152,0.00038186935,0.00013893432,0.0005560443],"genre_scores_gemma":[0.99796104,0.0004204645,0.00039142126,0.00005749984,0.0002538105,0.00036817658,0.00022646606,0.000105768704,0.00021533434],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99544924,0.00035833422,0.0012608187,0.0010736185,0.0012467633,0.00061119214],"domain_scores_gemma":[0.99769926,0.00015176831,0.0002964659,0.0012141104,0.00029303864,0.00034533892],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012687312,0.0005725736,0.0010676021,0.0007011901,0.00009966238,0.00002542645,0.00069218705,0.0003978309,0.0003102873],"category_scores_gemma":[0.00021851095,0.00043668362,0.0005841801,0.000566677,0.0003757254,0.00011661396,0.0012040037,0.002091055,0.000056027686],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048852614,0.0004245141,0.10382345,0.0066170893,0.0011383326,0.00022898515,0.058936443,0.008405554,0.80840653,0.0006336287,0.00003688759,0.006463333],"study_design_scores_gemma":[0.0020745955,0.00021343518,0.58116734,0.00825147,0.0012207367,0.000023529326,0.0044257985,0.007595946,0.39022034,0.0036431262,0.00047564835,0.0006880371],"about_ca_topic_score_codex":0.000747054,"about_ca_topic_score_gemma":0.00012368665,"teacher_disagreement_score":0.4773439,"about_ca_system_score_codex":0.0011304423,"about_ca_system_score_gemma":0.0012396631,"threshold_uncertainty_score":0.9998085},"labels":[],"label_agreement":null},{"id":"W4400930923","doi":"10.1002/ccr3.9139","title":"A case of <scp>AML</scp> with complex karyotype and chromosomal rearrangement of <scp>KMT2A</scp>","year":2024,"lang":"en","type":"article","venue":"Clinical Case Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Health; University of British Columbia; Royal Columbian Hospital","funders":"","keywords":"Karyotype; Myeloid leukemia; Medicine; Cytogenetics; Chromosomal translocation; Chromosomal rearrangement; Cancer research; Chromosome; Myeloid; Fish <Actinopterygii>; Gene rearrangement; Leukemia; Gene; Genetics; Internal medicine; Biology","score_opus":0.07581368738047387,"score_gpt":0.38210349061589627,"score_spread":0.30628980323542243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400930923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879121,0.0018607884,0.00006377139,0.00021901842,0.00025067473,0.001004433,0.000059110986,0.00011022451,0.008519838],"genre_scores_gemma":[0.99469197,0.00026835132,0.0018755636,0.00016938672,0.0004255788,0.000038012135,0.0000639027,0.00008216918,0.0023850687],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9957041,0.00021493986,0.0018816567,0.0009272153,0.00072503,0.00054704817],"domain_scores_gemma":[0.9942856,0.00294604,0.00048603123,0.0011029496,0.0004905231,0.0006888871],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024470743,0.00033334474,0.0011690868,0.00025144868,0.00008870436,0.00003750734,0.00007399587,0.00032260292,0.000091611306],"category_scores_gemma":[0.004508687,0.0002491668,0.00028909784,0.00061514386,0.0009803219,0.00010967561,0.00028330227,0.000881995,0.000023021208],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007628837,0.00046488893,0.022269346,0.0015335674,0.00060115487,0.94041985,0.0005593406,0.0000031748307,0.0025422107,0.00010025476,0.026026692,0.0054032514],"study_design_scores_gemma":[0.002264813,0.0038368166,0.017236548,0.0007999372,0.0008948176,0.9299571,0.0012238108,0.0014392199,0.0028354777,0.00011748008,0.039305847,0.00008812729],"about_ca_topic_score_codex":0.0004091817,"about_ca_topic_score_gemma":0.00009079782,"teacher_disagreement_score":0.013279155,"about_ca_system_score_codex":0.00013631454,"about_ca_system_score_gemma":0.0010085088,"threshold_uncertainty_score":0.99999607},"labels":[],"label_agreement":null},{"id":"W4400972670","doi":"10.1200/cci.23.00265","title":"Identification of Novel DNA Methylation Prognostic Biomarkers for AML With Normal Cytogenetics","year":2024,"lang":"en","type":"article","venue":"JCO Clinical Cancer Informatics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Cytogenetics; DNA methylation; Identification (biology); Computational biology; Medicine; Biology; Oncology; Genetics; Chromosome; Gene","score_opus":0.09156657437258642,"score_gpt":0.4344966028089758,"score_spread":0.34293002843638937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400972670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78412205,0.0007704627,0.20828377,0.001539233,0.0007264743,0.003000158,0.0003990082,0.00015194244,0.0010069219],"genre_scores_gemma":[0.9713777,0.00042073047,0.02662939,0.00031398644,0.00035309777,0.00026171035,0.00017440593,0.000043859392,0.00042517562],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9974619,0.000023690576,0.0015488953,0.00016476195,0.0005259066,0.00027485576],"domain_scores_gemma":[0.9976742,0.00095123175,0.00032535524,0.00033718193,0.00055271067,0.00015930686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011647892,0.00015161431,0.00036435956,0.0001931184,0.000047740323,0.00005638962,0.00015514914,0.00019093837,0.000030218303],"category_scores_gemma":[0.00092950294,0.000112424736,0.00016297199,0.00052830117,0.00023494921,0.00024642996,0.000052987838,0.00030190073,0.000018270377],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009806917,0.001831124,0.12402758,0.033145785,0.0056864945,0.000027095191,0.011305821,0.0041383244,0.033749573,0.0050273295,0.03443016,0.7368238],"study_design_scores_gemma":[0.009562361,0.003353299,0.04608714,0.0015179042,0.0019565336,0.000059947106,0.0015250109,0.8538958,0.046976723,0.00014463444,0.034335926,0.0005847375],"about_ca_topic_score_codex":0.000013408822,"about_ca_topic_score_gemma":0.000014640306,"teacher_disagreement_score":0.84975743,"about_ca_system_score_codex":0.00019439196,"about_ca_system_score_gemma":0.0011208528,"threshold_uncertainty_score":0.45845476},"labels":[],"label_agreement":null},{"id":"W4401014090","doi":"10.3390/cimb46080476","title":"Advances in Microflow Cytometry-Based Molecular Detection Methods for Improved Future MDS Cancer Diagnosis","year":2024,"lang":"en","type":"review","venue":"Current Issues in Molecular Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Global Water Futures; Natural Sciences and Engineering Research Council of Canada","keywords":"Flow cytometry; Circulating tumor cell; Cytometry; Leukemia; Cancer; Computer science; Medicine; Immunology; Internal medicine; Metastasis","score_opus":0.040310810513276056,"score_gpt":0.5232807675044293,"score_spread":0.48296995699115325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401014090","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025456986,0.90279007,0.09002176,0.00049975765,0.0025018798,0.0038125867,0.00025699366,0.00007686302,0.000014641257],"genre_scores_gemma":[0.000014663055,0.9596699,0.026978634,0.00013573066,0.0006484458,0.011370193,0.00096806657,0.00019026817,0.000024088757],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951227,0.0011674024,0.0010817051,0.0014984848,0.0001633583,0.0009664053],"domain_scores_gemma":[0.99818087,0.00039682531,0.00027713756,0.000776554,0.00018485721,0.0001837876],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011255476,0.00088204833,0.0029111886,0.0022629069,0.000039428694,0.00003751898,0.00055042375,0.0012218588,0.000051482766],"category_scores_gemma":[0.0007513361,0.0007027686,0.0009458886,0.0023300445,0.00021128035,0.000050152114,0.00023932703,0.0020423653,0.000020960722],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008363676,0.00013701379,0.000023827763,0.02930752,0.00016874522,0.000083523664,0.000022365277,0.000002123795,0.0053459764,0.00007025399,0.00017137948,0.96458364],"study_design_scores_gemma":[0.0012061984,0.00039668506,9.0362806e-7,0.010685363,0.0010596383,0.00002261281,0.000011689477,0.00051162683,0.010462431,0.00034041936,0.974713,0.0005894124],"about_ca_topic_score_codex":0.000068386624,"about_ca_topic_score_gemma":0.000048158607,"teacher_disagreement_score":0.97454166,"about_ca_system_score_codex":0.0016530819,"about_ca_system_score_gemma":0.00096731284,"threshold_uncertainty_score":0.99954236},"labels":[],"label_agreement":null},{"id":"W4401229376","doi":"10.1038/s41698-024-00643-5","title":"Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials","year":2024,"lang":"en","type":"article","venue":"npj Precision Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Human Genome Research Institute; American Cancer Society; University of Florida Health; St. Baldrick's Foundation; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Internal medicine; Cohort; Etoposide; Oncology; Daunorubicin; Chemotherapy","score_opus":0.028519254467083015,"score_gpt":0.3635928269880717,"score_spread":0.3350735725209887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401229376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933514,0.0021173232,0.00023874361,0.00031140714,0.0006418469,0.0016829021,0.0005622202,0.000082372564,0.0010117966],"genre_scores_gemma":[0.9901948,0.0008625628,0.0019473635,0.0001291721,0.000118087744,0.00014859634,0.00042240304,0.000055277185,0.0061217416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953587,0.001188099,0.0013992799,0.00079897116,0.0008063101,0.00044861855],"domain_scores_gemma":[0.9942766,0.004386758,0.00027613222,0.00056795066,0.00028643862,0.00020612501],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030206204,0.0003049243,0.0016322068,0.00060528825,0.000056891815,0.000034402878,0.0002873728,0.00047902914,0.0013923907],"category_scores_gemma":[0.003923617,0.00020772255,0.00016230906,0.00049666996,0.0001837541,0.00019727822,0.0003539705,0.00073263113,0.000042101317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007227008,0.0005849665,0.85985154,0.00021434612,0.00024584346,0.00021283951,0.0009504562,0.0000040880345,0.052798767,0.00002968541,0.06170736,0.016173108],"study_design_scores_gemma":[0.013178483,0.0005853468,0.9260941,0.0018277366,0.00018680879,0.0000061524606,0.00018488365,0.0012876336,0.025343493,0.0004647144,0.030589445,0.00025120965],"about_ca_topic_score_codex":0.00030692102,"about_ca_topic_score_gemma":0.00040112357,"teacher_disagreement_score":0.06624256,"about_ca_system_score_codex":0.001235944,"about_ca_system_score_gemma":0.0010574195,"threshold_uncertainty_score":0.9995205},"labels":[],"label_agreement":null},{"id":"W4401246395","doi":"10.1182/bloodadvances.2023011540","title":"The E3 ubiquitin ligase Herc1 modulates the response to nucleoside analogs in acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Jewish General Hospital; McGill University Health Centre; McGill University; TD Bank","keywords":"Myeloid leukemia; Cytarabine; Cancer research; Ubiquitin ligase; Nucleoside analogue; Deoxycytidine kinase; Azacitidine; Leukemia; Gene knockdown; Biology; Nucleoside; Medicine; Deoxycytidine; Ubiquitin; Cell culture; Cancer; Immunology; Internal medicine; Gemcitabine; DNA methylation; Biochemistry; Gene expression; Genetics; Gene","score_opus":0.011273368243301564,"score_gpt":0.30827612789128384,"score_spread":0.2970027596479823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401246395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9429476,0.016721537,0.000028118935,0.03747939,0.00022975552,0.00087499566,0.00002999259,0.00018955064,0.0014990292],"genre_scores_gemma":[0.9840433,0.004181417,0.00082903035,0.001983601,0.00040114525,0.00023225594,0.000010039686,0.00007737604,0.008241829],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99726045,0.00032037534,0.00045383486,0.000582731,0.00060114526,0.0007814491],"domain_scores_gemma":[0.99684364,0.0019697263,0.000048097103,0.00078974594,0.00010169411,0.00024709126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018020603,0.0002894796,0.000348375,0.00026045355,0.0003088822,0.00021411698,0.00058891665,0.00011076787,0.000050708473],"category_scores_gemma":[0.001008008,0.00015640445,0.00014766774,0.0012672435,0.00028586035,0.000258253,0.0002712538,0.0008444717,0.0003415496],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014088563,0.00032800782,0.006008299,0.0005131362,0.0013774644,0.01040627,0.007587036,0.0014467353,0.6024067,0.003967236,0.030481149,0.32138944],"study_design_scores_gemma":[0.003485701,0.0015055417,0.04675678,0.0012588615,0.00045493897,0.0010273844,0.0033448408,0.0042008054,0.18983133,0.0033105682,0.74414176,0.00068148324],"about_ca_topic_score_codex":0.00016045994,"about_ca_topic_score_gemma":0.00037493202,"teacher_disagreement_score":0.7136606,"about_ca_system_score_codex":0.00047723684,"about_ca_system_score_gemma":0.0008156326,"threshold_uncertainty_score":0.63779885},"labels":[],"label_agreement":null},{"id":"W4401422101","doi":"10.1002/alz.14182","title":"Clonal hematopoiesis of indeterminate potential is associated with reduced risk of cognitive impairment in patients with chronic kidney disease","year":2024,"lang":"en","type":"article","venue":"Alzheimer s & Dementia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Center for Advancing Translational Sciences; National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; National Institute on Aging; Clinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve University; Michigan Institute for Clinical and Health Research; University of California, San Francisco; University of Illinois at Urbana-Champaign; National Institutes of Health; National Center for Research Resources; University of Pennsylvania; Georgia Clinical and Translational Science Alliance; National Institute of Diabetes and Digestive and Kidney Diseases; Johns Hopkins University; Kaiser Permanente; Deutsches Krebsforschungszentrum; Perelman School of Medicine, University of Pennsylvania; U.S. Department of Veterans Affairs","keywords":"Indeterminate; Cognitive impairment; Disease; Kidney disease; Medicine; Cognition; Internal medicine; Immunology; Oncology; Psychiatry","score_opus":0.009264431213869075,"score_gpt":0.2631599688524462,"score_spread":0.25389553763857714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401422101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926167,0.0051554185,0.000036396177,0.00023016796,0.000061716404,0.0011726444,0.0006081241,0.00003463314,0.000084173706],"genre_scores_gemma":[0.9990817,0.000055124063,0.0001352908,0.0000923718,0.00003217205,0.00007937122,0.00044733242,0.00005736772,0.000019282763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975456,0.00013814264,0.0004818037,0.0004602585,0.0009267232,0.00044744476],"domain_scores_gemma":[0.9986965,0.000101274374,0.0002293776,0.00028581065,0.00036462073,0.00032240973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003020746,0.0002650284,0.00047305605,0.00034269158,0.000046289148,0.000019345178,0.0001374635,0.00009211758,0.0004841677],"category_scores_gemma":[0.00010572781,0.00019686809,0.0001267178,0.0006132892,0.0002681742,0.00015696975,0.000120218094,0.00035546967,0.00001487113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0112600345,0.003008122,0.89367807,0.0004483058,0.07043211,0.0008354658,0.0019144189,0.000020742971,0.0010468076,0.00002478164,0.0039921547,0.013338992],"study_design_scores_gemma":[0.010917856,0.0026026096,0.9301072,0.0025737276,0.02947994,0.000006689578,0.00008839499,0.0012675067,0.022601943,0.000032320266,0.000031398708,0.00029045186],"about_ca_topic_score_codex":0.00021169857,"about_ca_topic_score_gemma":0.00002200653,"teacher_disagreement_score":0.04095217,"about_ca_system_score_codex":0.000118029595,"about_ca_system_score_gemma":0.0015049936,"threshold_uncertainty_score":0.80280477},"labels":[],"label_agreement":null},{"id":"W4401431808","doi":"10.1111/ejh.14283","title":"Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1‐mutated AML","year":2024,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"NPM1; Malignancy; Myeloid leukemia; Medicine; Internal medicine; Oncology; Myeloid; Biology; Genetics; Karyotype; Gene","score_opus":0.02174067340941448,"score_gpt":0.33769936050605315,"score_spread":0.31595868709663866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401431808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99067396,0.002422709,0.0011957512,0.003619765,0.0011439119,0.00021704387,0.000043347925,0.00007232048,0.0006111639],"genre_scores_gemma":[0.9982243,0.00032301404,0.0003825335,0.000120643286,0.0005208791,0.0000016356032,0.000027143073,0.0000896753,0.00031017952],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9960584,0.001364834,0.0011048013,0.00037264117,0.00051531993,0.0005839976],"domain_scores_gemma":[0.9985044,0.0002898159,0.00026155365,0.00039374194,0.00020848765,0.0003420278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016721869,0.00029693404,0.0010571543,0.00080387405,0.000052896146,0.000068951995,0.0004079191,0.00009179537,0.0005498813],"category_scores_gemma":[0.0003776996,0.00018163302,0.00030397435,0.00038160433,0.00018121582,0.00033182534,0.0001313564,0.0011522976,0.00034294048],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034363584,0.00083446444,0.3423816,0.000598968,0.0019576056,0.4123656,0.003143528,0.0002753988,0.21350344,0.0011234453,0.0036145286,0.016765075],"study_design_scores_gemma":[0.008513807,0.00433934,0.9371417,0.0017966774,0.00034181483,0.028391404,0.0009134445,0.0042507187,0.011235206,0.0005066038,0.0020217572,0.0005475026],"about_ca_topic_score_codex":0.00019467414,"about_ca_topic_score_gemma":0.0001323949,"teacher_disagreement_score":0.5947601,"about_ca_system_score_codex":0.0011718851,"about_ca_system_score_gemma":0.00091092143,"threshold_uncertainty_score":0.74067795},"labels":[],"label_agreement":null},{"id":"W4401434212","doi":"10.1016/j.lrr.2024.100477","title":"Successful treatment of AML using non-intensive chemotherapy in Jehovah's Witness patients","year":2024,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Acute promyelocytic leukemia; Azacitidine; Arsenic trioxide; Induction chemotherapy; Myeloid leukemia; Chemotherapy; Intensive care medicine; Venetoclax; Internal medicine; Platelet transfusion; Leukemia; Blood transfusion; Retinoic acid; Oncology; Surgery; Platelet; Apoptosis","score_opus":0.05773487502074421,"score_gpt":0.3972080560227886,"score_spread":0.3394731810020444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401434212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234456,0.0008285191,0.00009621962,0.00071289286,0.00028598605,0.0020388337,0.000011858382,0.00006267416,0.003618478],"genre_scores_gemma":[0.9953861,0.0006630881,0.00044488357,0.0000809554,0.00026568267,0.00015036289,0.00006961224,0.000121184734,0.002818111],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9940746,0.00021594125,0.0010001616,0.0010202993,0.0025108012,0.00117822],"domain_scores_gemma":[0.99526745,0.0004164359,0.0001380208,0.0011090764,0.0026717116,0.00039731283],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018456955,0.00035512183,0.000861618,0.0015310494,0.00010552105,0.00008922727,0.00020290085,0.0003027428,0.00022887062],"category_scores_gemma":[0.0009726524,0.00027937154,0.00024800305,0.0023071398,0.00059468416,0.00026124163,0.00016727974,0.0008894904,0.00004880293],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0037471647,0.0019341401,0.6969869,0.0028238702,0.0010935029,0.08067595,0.0074319188,0.00033326496,0.11975891,0.00018496226,0.013050995,0.0719784],"study_design_scores_gemma":[0.023962498,0.009874519,0.32820132,0.007349478,0.0002868507,0.005479239,0.004454574,0.07795261,0.49145713,0.0028439136,0.046435222,0.0017026527],"about_ca_topic_score_codex":0.0063797315,"about_ca_topic_score_gemma":0.0001391826,"teacher_disagreement_score":0.3716982,"about_ca_system_score_codex":0.014010742,"about_ca_system_score_gemma":0.006770687,"threshold_uncertainty_score":0.99996585},"labels":[],"label_agreement":null},{"id":"W4401504076","doi":"10.1182/blood.2024024944","title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Venetoclax; Azacitidine; Medicine; Internal medicine; Oncology; Myeloid leukemia; Placebo; Leukemia; Pathology; Biology; Genetics","score_opus":0.00841584144224182,"score_gpt":0.24473667503364538,"score_spread":0.23632083359140355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401504076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981282,0.00050087256,0.000025554044,0.000070287126,0.000007213174,0.0008212608,0.00006181085,0.00007974919,0.0003050684],"genre_scores_gemma":[0.99801505,0.00029166893,0.00085174816,0.000011840277,0.000034700686,0.00008452024,0.00009465009,0.000036682937,0.00057914044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905044,0.000037562462,0.00013544905,0.0003637925,0.00020954094,0.00020323355],"domain_scores_gemma":[0.99943584,0.0000754352,0.000039763974,0.00021988236,0.00007226801,0.00015681393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041337647,0.00018674154,0.00023286509,0.00011890311,0.000071962335,0.00006538776,0.000029734581,0.00006162718,0.000018562705],"category_scores_gemma":[0.000017704935,0.00010740554,0.000019697938,0.00018627805,0.00015769777,0.000081862614,0.000014204162,0.00012662551,0.000007309117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001561477,0.00015364596,0.9914273,0.00006253629,0.00052917574,0.00012751904,0.00027514488,0.0000025446786,0.00021789488,0.000011668804,0.000021825259,0.007014616],"study_design_scores_gemma":[0.006566718,0.002500228,0.98745537,0.000104882136,0.0009102036,0.00004095878,0.00007545609,0.00045281264,0.0016852819,0.000012431298,0.00007394388,0.000121711404],"about_ca_topic_score_codex":0.0005206454,"about_ca_topic_score_gemma":0.00012652526,"teacher_disagreement_score":0.0068929046,"about_ca_system_score_codex":0.00013735182,"about_ca_system_score_gemma":0.0001553266,"threshold_uncertainty_score":0.4379871},"labels":[],"label_agreement":null},{"id":"W4401523698","doi":"10.1080/10428194.2024.2390574","title":"Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Université Laval; Université de Montréal; Hôpital Maisonneuve-Rosemont; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Venetoclax; Ven; Azacitidine; Internal medicine; Myeloid leukemia; Salvage therapy; Neutropenia; Febrile neutropenia; Refractory (planetary science); Acute leukemia; Septic shock; Oncology; Leukemia; Gastroenterology; Sepsis; Chemotherapy","score_opus":0.012312535876723572,"score_gpt":0.27438114018462784,"score_spread":0.26206860430790424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401523698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918915,0.0012734914,0.00012054182,0.00026275977,0.00013301887,0.004321467,0.00027704524,0.0005838483,0.00113631],"genre_scores_gemma":[0.9908751,0.00057037524,0.0018957804,0.0008893003,0.0002151681,0.00063458545,0.00010262566,0.00041434914,0.004402717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931819,0.00030911434,0.0012514376,0.0022720539,0.001558565,0.001426956],"domain_scores_gemma":[0.99587363,0.00058612146,0.00035983344,0.0015332045,0.0005944124,0.0010528176],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005891985,0.0014546561,0.002461798,0.0010542668,0.00036207176,0.00027695124,0.0005252217,0.00053239684,0.00017081884],"category_scores_gemma":[0.00014151883,0.00091865694,0.000239332,0.0018955205,0.00089503726,0.00057000574,0.0003448317,0.0005302573,0.000056778306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.14101386,0.0016032435,0.67582107,0.0023944962,0.017007984,0.012742976,0.05145684,0.00012966098,0.022234246,0.0002679168,0.0042271595,0.071100585],"study_design_scores_gemma":[0.0881039,0.015563596,0.8493258,0.0035667578,0.002454183,0.002426659,0.012851043,0.009225554,0.0066130836,0.000024603572,0.007914909,0.0019299267],"about_ca_topic_score_codex":0.00654818,"about_ca_topic_score_gemma":0.0010845751,"teacher_disagreement_score":0.17350474,"about_ca_system_score_codex":0.019979887,"about_ca_system_score_gemma":0.0071453196,"threshold_uncertainty_score":0.9998203},"labels":[],"label_agreement":null},{"id":"W4401584219","doi":"10.1080/14796694.2024.2379228","title":"Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Medicine; Myelodysplastic syndromes; Family medicine; Medical record; Gerontology; Internal medicine","score_opus":0.01580949038752389,"score_gpt":0.31466583726212866,"score_spread":0.2988563468746048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401584219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9525764,0.0072476338,0.0000042632128,0.03819157,0.0007467593,0.0006812048,0.00009473952,0.000011567791,0.00044587158],"genre_scores_gemma":[0.85481477,0.1352696,0.00029034892,0.007225818,0.0006920698,0.00019617357,0.0001224626,0.000051097693,0.0013376807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804115,0.00033241877,0.00041766072,0.00044788112,0.000382616,0.00037825477],"domain_scores_gemma":[0.9976538,0.00176827,0.00005534657,0.00026688486,0.000035009332,0.00022072493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058070716,0.00024520088,0.0008392657,0.0001402886,0.000048068352,0.00002315473,0.00016728602,0.00022698528,0.00051144673],"category_scores_gemma":[0.00097291387,0.00014025193,0.00003887781,0.00038201935,0.00012541079,0.000039410148,0.00009782469,0.0010006763,0.000046247053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029553066,0.00023315806,0.7869972,0.0010989697,0.00023205046,0.041298226,0.0010898942,4.640667e-8,0.000035491325,0.000060235474,0.03663064,0.13202858],"study_design_scores_gemma":[0.0014809831,0.0010369783,0.6923942,0.0011333851,0.00016621797,0.00096544233,0.00012539056,0.00021099743,8.137492e-7,0.000007678371,0.30235744,0.00012046436],"about_ca_topic_score_codex":0.19813246,"about_ca_topic_score_gemma":0.68425626,"teacher_disagreement_score":0.4861238,"about_ca_system_score_codex":0.0010278707,"about_ca_system_score_gemma":0.0027889109,"threshold_uncertainty_score":0.8072072},"labels":[],"label_agreement":null},{"id":"W4401628988","doi":"10.2196/preprints.65460","title":"Patient and Caregiver Insights from Social Media into the Disease Burden of Myelodysplastic Syndrome With A Sub-Cohort View of High-risk Patients (Preprint)","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Social media; Psychological intervention; Cohort; Medicine; Disease; Psychology; Computer science; World Wide Web; Nursing; Pathology","score_opus":0.007002252287244209,"score_gpt":0.23017813215005364,"score_spread":0.22317587986280943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401628988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99378216,0.0020944567,0.00006717968,0.00043989922,0.00032637708,0.002486766,0.0004989938,0.000062716244,0.00024144945],"genre_scores_gemma":[0.99757266,0.0010405673,0.00027463213,0.000037593487,0.0001606634,0.00026897635,0.0004980812,0.0000920026,0.000054826556],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9957964,0.0002927449,0.0008385012,0.0010865395,0.0016478857,0.0003379345],"domain_scores_gemma":[0.9966078,0.0007528348,0.00045724932,0.0010803734,0.0007080185,0.0003937285],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019907573,0.00054534234,0.0012980839,0.00031650206,0.000097738215,0.00004057358,0.00040572492,0.0003377586,0.0001575768],"category_scores_gemma":[0.00046671135,0.00031342587,0.00022628366,0.00032804036,0.00078825414,0.00004801751,0.0029179323,0.001536671,0.000036195408],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016394231,0.0026508414,0.36283934,0.03074049,0.024609946,0.0052781557,0.38919863,0.0013945475,0.0007526575,0.0032001913,0.006077905,0.15686306],"study_design_scores_gemma":[0.0044571636,0.00089169975,0.9658982,0.004917688,0.00508567,0.000017577908,0.0028957753,0.0015958042,0.0009221595,0.012315531,0.00023578656,0.0007669317],"about_ca_topic_score_codex":0.012775833,"about_ca_topic_score_gemma":0.000525589,"teacher_disagreement_score":0.6030589,"about_ca_system_score_codex":0.00051882176,"about_ca_system_score_gemma":0.0012714829,"threshold_uncertainty_score":0.9999318},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W4401705615","doi":"10.1182/blood.2023023644","title":"Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; University of Toronto; University Health Network","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Cancer research; Epigenetics; Myeloid leukemia; Biology; Chromatin; Leukemia; Genetics; Gene","score_opus":0.012328534159373038,"score_gpt":0.28484714494871377,"score_spread":0.27251861078934075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401705615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934673,0.0036772517,0.00013300883,0.0012022442,0.00012793834,0.0006352289,0.000032627595,0.000108965454,0.0006154702],"genre_scores_gemma":[0.99328476,0.00028159784,0.003375807,0.00005299842,0.00021830041,0.000066389795,0.000057342084,0.00006921237,0.0025935648],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99743044,0.0002767337,0.00063701125,0.0005361418,0.00062446215,0.0004952111],"domain_scores_gemma":[0.9987008,0.00041964676,0.000068079324,0.0004930926,0.00011557848,0.00020277793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001147937,0.00023943077,0.0005082361,0.00056508917,0.000038753635,0.00003079248,0.00018150832,0.00027284815,0.00019556763],"category_scores_gemma":[0.0003598624,0.00021378769,0.0001448644,0.000925416,0.00016112364,0.00012420214,0.00014494614,0.0005490269,0.00011192489],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025486427,0.00020586509,0.0014150429,0.00018800754,0.00026196742,0.000650154,0.00066611357,0.00011133828,0.9902457,0.00014535635,0.0011898617,0.0023719403],"study_design_scores_gemma":[0.005613573,0.0012486456,0.078898735,0.0007997782,0.00033808805,0.00028988483,0.0000663981,0.009718333,0.9000218,0.0003796239,0.0023451908,0.00027994197],"about_ca_topic_score_codex":0.00008820627,"about_ca_topic_score_gemma":0.000016614651,"teacher_disagreement_score":0.0902239,"about_ca_system_score_codex":0.0007662307,"about_ca_system_score_gemma":0.0017357634,"threshold_uncertainty_score":0.8718009},"labels":[],"label_agreement":null},{"id":"W4401731539","doi":"10.1038/s41375-024-02358-9","title":"Identification of leukemia stem cell subsets with distinct transcriptional, epigenetic and functional properties","year":2024,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation; Canadian Cancer Society Research Institute; Government of Ontario; Leukemia and Lymphoma Society of Canada; Leukemia and Lymphoma Society","keywords":"Biology; Myeloid leukemia; Epigenetics; Stem cell; Somatic evolution in cancer; Leukemia; Compartment (ship); Computational biology; Genetic heterogeneity; Cell; Cancer research; Immunology; Genetics; Cancer; Gene; Phenotype","score_opus":0.027819333456021975,"score_gpt":0.24869087295872522,"score_spread":0.22087153950270325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401731539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98901206,0.0062317513,0.0025411393,0.00044602455,0.00013526797,0.00052068604,0.000039318602,0.00011575061,0.0009579879],"genre_scores_gemma":[0.9882018,0.00025918218,0.00016807267,0.000057119843,0.00015771567,0.000084735446,0.00006889423,0.00005243893,0.01095004],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815196,0.000055157423,0.00042514218,0.00047233832,0.0006120174,0.0002834077],"domain_scores_gemma":[0.9991894,0.000084186286,0.00006498412,0.00031520886,0.00018961758,0.00015662918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003092713,0.00021112448,0.0002863095,0.00022080274,0.000093001225,0.00007118604,0.00009318345,0.00012554188,0.00012324513],"category_scores_gemma":[0.000015618944,0.00015242967,0.000077701334,0.00037991125,0.00032749627,0.00017139515,0.00003294342,0.00037731248,0.000095360294],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010072979,0.0000646912,0.006191635,0.0033468406,0.0002186753,0.0001334548,0.0010979768,0.00028130817,0.971561,0.0010281347,0.003603893,0.011465082],"study_design_scores_gemma":[0.004578045,0.0009807843,0.3529827,0.001367022,0.00072280155,0.00087970635,0.0009749198,0.04066366,0.5808458,0.00030682652,0.014990872,0.000706905],"about_ca_topic_score_codex":0.00009055387,"about_ca_topic_score_gemma":0.000020074436,"teacher_disagreement_score":0.39071524,"about_ca_system_score_codex":0.0012287279,"about_ca_system_score_gemma":0.0018762178,"threshold_uncertainty_score":0.62159014},"labels":[],"label_agreement":null},{"id":"W4401755999","doi":"10.1182/blood.2024025049","title":"AML, myelodysplasia related, with STAG2 and SRSF2 comutations with myelocyte arrest","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Royal Jubilee Hospital","funders":"","keywords":"Cancer research; Preleukemia; Medicine; Leukemia; Internal medicine","score_opus":0.00864202056460471,"score_gpt":0.2570714231849809,"score_spread":0.24842940262037616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401755999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793369,0.0015686927,0.00015569836,0.0033792006,0.00005558224,0.0005740505,0.000027835347,0.0002972352,0.014604784],"genre_scores_gemma":[0.9905148,0.00024582574,0.0029610805,0.00014548797,0.00012545889,0.00006146032,0.00006683877,0.000078429206,0.0058005787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985608,0.000037517584,0.00018908028,0.0004284088,0.00041897356,0.00036524792],"domain_scores_gemma":[0.9991078,0.0001541895,0.000030469504,0.0003387957,0.000104733444,0.0002640587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016816781,0.0002034833,0.00025522074,0.00021430413,0.00012270958,0.00010081023,0.000084889405,0.000104406885,0.00013563578],"category_scores_gemma":[0.000039311893,0.00013469123,0.00003050499,0.0006143468,0.00028301103,0.00015202376,0.000048773738,0.0006056768,0.00016686204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010491787,0.0067973263,0.40728304,0.014394323,0.027774312,0.14774726,0.03674737,0.0007047606,0.11621361,0.08590725,0.06996728,0.07597168],"study_design_scores_gemma":[0.10822884,0.023363264,0.36749414,0.013031188,0.013677067,0.07191767,0.010827386,0.019113453,0.07071178,0.0021932798,0.29477835,0.004663585],"about_ca_topic_score_codex":0.000066401866,"about_ca_topic_score_gemma":0.00007318489,"teacher_disagreement_score":0.22481108,"about_ca_system_score_codex":0.00008225467,"about_ca_system_score_gemma":0.0006337408,"threshold_uncertainty_score":0.5492549},"labels":[],"label_agreement":null},{"id":"W4401761184","doi":"10.3390/biomedicines12081915","title":"The Role of Epithelial-to-Mesenchymal Transition Transcription Factors (EMT-TFs) in Acute Myeloid Leukemia Progression","year":2024,"lang":"en","type":"review","venue":"Biomedicines","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; Agencia Nacional de Investigación y Desarrollo; CancerCare Manitoba Foundation","keywords":"Epithelial–mesenchymal transition; Myeloid leukemia; Transcription factor; Cancer research; Mesenchymal stem cell; Leukemia; Biology; Transition (genetics); Gene; Cell biology; Immunology; Genetics","score_opus":0.029739668345193433,"score_gpt":0.35844018244007964,"score_spread":0.3287005140948862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401761184","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039724405,0.9896007,0.00003301858,0.0011329491,0.00086256093,0.003677953,0.00026962932,0.00013117991,0.00031954556],"genre_scores_gemma":[0.002519542,0.99408996,0.00014797015,0.00004717121,0.0008561656,0.00041533948,0.00075121055,0.00015762087,0.0010150251],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99532914,0.0003117742,0.0015069271,0.0008319679,0.0012316499,0.00078853784],"domain_scores_gemma":[0.99809223,0.000305406,0.00027512937,0.00075278,0.00019445106,0.00037999943],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011238499,0.0007791628,0.0023719126,0.001654124,0.0001287221,0.000046936948,0.00052766124,0.0007499987,0.000046498495],"category_scores_gemma":[0.00015824346,0.00039838627,0.00073971914,0.002629298,0.00047236038,0.00010671536,0.000092929484,0.001266857,0.00013890807],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024416906,0.000080755344,0.000015759404,0.013757924,0.0004952202,0.00016127186,0.0015118829,2.0561333e-7,0.007491614,0.00006898736,0.0015715531,0.9746007],"study_design_scores_gemma":[0.00085819256,0.00085606246,0.00010790439,0.03738062,0.0027721697,0.00020006517,0.0006880001,0.00008314427,0.0007830551,0.00008212736,0.95582354,0.00036512455],"about_ca_topic_score_codex":0.00024419356,"about_ca_topic_score_gemma":0.000038306094,"teacher_disagreement_score":0.97423553,"about_ca_system_score_codex":0.001380745,"about_ca_system_score_gemma":0.0019536125,"threshold_uncertainty_score":0.9998468},"labels":[],"label_agreement":null},{"id":"W4401794081","doi":"10.2196/54740","title":"Predictive Models for Long Term Survival of AML Patients Treated with Venetoclax and Azacitidine or 7+3 Based on Post Treatment Events and Responses: Retrospective Cohort Study","year":2024,"lang":"en","type":"article","venue":"JMIR Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Azacitidine; Venetoclax; Oncology; Medicine; Retrospective cohort study; Term (time); Internal medicine; Cohort; Overall survival; Leukemia; Biology; Genetics","score_opus":0.025581859127796498,"score_gpt":0.34380378831215375,"score_spread":0.31822192918435727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401794081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99145454,0.000118073396,0.00007736054,0.0001037564,0.00004253053,0.006847127,0.0012069352,0.000046631038,0.00010303719],"genre_scores_gemma":[0.99581796,0.00010149715,0.00003320043,0.000031983258,0.00006482353,0.0025663045,0.00011900013,0.00005685617,0.0012083721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984146,0.00009087138,0.00020979467,0.00056045555,0.00046747504,0.0002568429],"domain_scores_gemma":[0.9989919,0.00022727085,0.0000599724,0.0002499792,0.00032521243,0.00014565073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016778319,0.00024349795,0.0004902039,0.00022243442,0.00006463893,0.000018763596,0.00004637464,0.000074651136,0.000033631623],"category_scores_gemma":[0.000042514403,0.00014893975,0.00004585405,0.00025973175,0.00010445995,0.00009774659,0.00002749915,0.00013294452,5.2024694e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04323608,0.00054979534,0.9520702,0.00019689082,0.00080544193,0.000089683504,0.000889797,0.0000752204,0.00015755557,0.0000031782154,0.000047005742,0.001879184],"study_design_scores_gemma":[0.010522395,0.025621215,0.9481719,0.0005591256,0.00040344038,0.000004279842,0.00015247901,0.013868753,0.00054238655,0.0000047823028,0.000016849417,0.00013239114],"about_ca_topic_score_codex":0.0005386007,"about_ca_topic_score_gemma":0.00036271024,"teacher_disagreement_score":0.032713685,"about_ca_system_score_codex":0.0024260604,"about_ca_system_score_gemma":0.0007859125,"threshold_uncertainty_score":0.6344063},"labels":[],"label_agreement":null},{"id":"W4401815291","doi":"10.14740/jmc4286","title":"Clinical, Phenotypic and Molecular Characterization of <i>NUP214-ABL1</i> Fusion Positive Myeloid Malignancies","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Phenotype; Fusion gene; Myeloid; Cancer research; Oncology; Genetics; Gene","score_opus":0.02479438897500079,"score_gpt":0.3464772034424881,"score_spread":0.3216828144674873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401815291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813325,0.005218786,0.0017277614,0.011054443,0.0003543443,0.00014987835,0.000019585175,0.000014873652,0.00012783388],"genre_scores_gemma":[0.9880995,0.009092738,0.0004814696,0.0014650971,0.00069197075,0.0000017094746,0.000017686074,0.000023393219,0.0001264377],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99718475,0.00018495273,0.00086078944,0.00017328707,0.001401165,0.00019506789],"domain_scores_gemma":[0.99815005,0.000679768,0.00022035032,0.00013336152,0.0003720946,0.0004443624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018296206,0.00012676131,0.00051763945,0.00023232673,0.00003516446,0.000031753654,0.0001386072,0.00022160888,0.00034301876],"category_scores_gemma":[0.0024292923,0.00008676909,0.00018073746,0.0002804959,0.00032698887,0.00014858163,0.00011093848,0.00073989574,0.0000091183],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017358855,0.00054694066,0.0068054325,0.001405154,0.00059975596,0.034270104,0.00064834894,6.296853e-7,0.6864632,0.001043734,0.008306095,0.25817478],"study_design_scores_gemma":[0.019369919,0.024944417,0.29311824,0.037306175,0.0034631386,0.099111974,0.0024558564,0.008040534,0.38611147,0.0011115075,0.12369356,0.0012732178],"about_ca_topic_score_codex":0.000015496473,"about_ca_topic_score_gemma":0.000001006402,"teacher_disagreement_score":0.3003517,"about_ca_system_score_codex":0.000079085614,"about_ca_system_score_gemma":0.0009803844,"threshold_uncertainty_score":0.37558147},"labels":[],"label_agreement":null},{"id":"W4401855335","doi":"10.1101/2024.08.20.608056","title":"Impaired DNA damage response and inflammatory signalling underpins hematopoietic stem cell defects in <i>Gata2</i> haploinsufficiency","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Haploinsufficiency; GATA2; Biology; Cancer research; Haematopoiesis; Myeloid; Mutation; Cell biology; Stem cell; Genetics; Immunology; Phenotype","score_opus":0.015907875172188835,"score_gpt":0.24050730389713168,"score_spread":0.22459942872494285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401855335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98957646,0.0060040588,0.00016249543,0.0005545539,0.0005648629,0.0022113414,0.00012962768,0.00075626303,0.00004031276],"genre_scores_gemma":[0.9973301,0.00052950013,0.0008293401,0.00025938012,0.00030155882,0.00030459388,7.6149485e-7,0.00039281516,0.000051918116],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99380994,0.00063858693,0.0011717178,0.0020177308,0.001030781,0.0013312536],"domain_scores_gemma":[0.9959531,0.0005446389,0.00035841015,0.0018839949,0.00040015578,0.0008597099],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0030726949,0.0010397115,0.0013073883,0.0015045109,0.0001874375,0.0003916699,0.0006785899,0.0010991816,0.000031973632],"category_scores_gemma":[0.0003276714,0.0010749671,0.0002825751,0.0014162819,0.0004082945,0.0001665596,0.002065035,0.0034471438,0.00023038918],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008020704,0.00034694103,0.0070155235,0.007745428,0.00014526771,0.003089742,0.0002275762,0.00009214449,0.9798662,0.00030449906,0.00036293562,0.0000016880189],"study_design_scores_gemma":[0.005758304,0.00086184154,0.17341927,0.011371551,0.0007931527,0.0000020172104,0.00022166995,0.010043941,0.79278827,0.000034337525,0.0017108727,0.0029947488],"about_ca_topic_score_codex":0.000050844767,"about_ca_topic_score_gemma":0.0000067438978,"teacher_disagreement_score":0.1870779,"about_ca_system_score_codex":0.001992302,"about_ca_system_score_gemma":0.005243435,"threshold_uncertainty_score":0.99917006},"labels":[],"label_agreement":null},{"id":"W4401875886","doi":"10.1016/s2152-2650(24)01345-4","title":"MDS-157 Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Red blood cell; Blood transfusion; Clinical trial; Red Blood Cell Transfusion; Internal medicine; Oncology; Bone marrow","score_opus":0.03013156918352923,"score_gpt":0.3401590380652639,"score_spread":0.31002746888173466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401875886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98878026,0.0020009384,0.0004943117,0.001004182,0.0019041032,0.0036736275,0.0002477163,0.00023627923,0.001658606],"genre_scores_gemma":[0.97409934,0.022151789,0.0007882914,0.0002700334,0.0009609559,0.00018640305,0.00013415824,0.00022816674,0.0011808367],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9863854,0.0021670018,0.0040828376,0.0026817573,0.0030388928,0.001644115],"domain_scores_gemma":[0.9859564,0.009950152,0.0006449174,0.0019352966,0.0004522518,0.0010610372],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009870557,0.0011455241,0.0028225062,0.0006626359,0.0003665648,0.0002327339,0.0012331012,0.001599746,0.00044652293],"category_scores_gemma":[0.0021639518,0.000792261,0.0010765864,0.0015335078,0.0013434798,0.00056479,0.00037766722,0.00344136,0.00011003205],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39271355,0.014051476,0.056239124,0.0022719984,0.00267266,0.022996249,0.001747854,0.00017899851,0.017752662,0.0006119851,0.0026639914,0.48609945],"study_design_scores_gemma":[0.46210966,0.046100944,0.45015743,0.0034925658,0.0052330904,0.0032305294,0.001012638,0.013813488,0.0059077186,0.0009966088,0.0055445246,0.0024008192],"about_ca_topic_score_codex":0.0021567326,"about_ca_topic_score_gemma":0.001042848,"teacher_disagreement_score":0.48369864,"about_ca_system_score_codex":0.00086133275,"about_ca_system_score_gemma":0.0044202255,"threshold_uncertainty_score":0.9996964},"labels":[],"label_agreement":null},{"id":"W4401876095","doi":"10.1016/s2152-2650(24)01222-9","title":"AML-609 Gilteritinib-Based Combinations Improve Survival and Enhances Allogenic Transplant Eligibility in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Canadian Single Center Experience","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Refractory (planetary science); Myeloid leukemia; Single Center; Internal medicine; Transplantation; Oncology","score_opus":0.032060372399925124,"score_gpt":0.34348354237782996,"score_spread":0.31142316997790487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98852617,0.0011639721,0.0001426491,0.002191661,0.0019641228,0.0013760544,0.0005506729,0.0003515397,0.0037331844],"genre_scores_gemma":[0.99422616,0.00093833,0.0007861431,0.0016395922,0.00053655705,0.00028633958,0.00045884182,0.0001628999,0.00096514943],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99201703,0.0006807048,0.0022380964,0.00225838,0.0009854629,0.0018203371],"domain_scores_gemma":[0.9941774,0.002123818,0.00021579332,0.0013655953,0.00030957005,0.001807836],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021210625,0.0008407757,0.0015003403,0.00074844353,0.00034393606,0.00032609134,0.0007855547,0.0010682165,0.00028160587],"category_scores_gemma":[0.0009795912,0.0007929314,0.0005305148,0.0011024085,0.001618815,0.00045985164,0.00020568029,0.0015749423,0.00023503663],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0057867174,0.0025675062,0.113810875,0.0016921465,0.0013628536,0.015650788,0.0037059796,0.000027213222,0.17926729,0.002072942,0.0052951807,0.66876054],"study_design_scores_gemma":[0.024466502,0.0041142493,0.86765486,0.0021548101,0.00056746614,0.0008605406,0.0008888228,0.018904401,0.019366918,0.0007008985,0.058046028,0.0022745314],"about_ca_topic_score_codex":0.017525148,"about_ca_topic_score_gemma":0.022854393,"teacher_disagreement_score":0.75384396,"about_ca_system_score_codex":0.010083807,"about_ca_system_score_gemma":0.012329081,"threshold_uncertainty_score":0.9994522},"labels":[],"label_agreement":null},{"id":"W4401878546","doi":"10.1016/s2152-2650(24)00530-5","title":"Gilteritinib-Based Combinations Improve Survival and Enhance Allogenic Transplant Eligibility in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Canadian Single-Center Experience","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Refractory (planetary science); Myeloid leukemia; Internal medicine; Oncology; Single Center","score_opus":0.0323790115743905,"score_gpt":0.3485089521187956,"score_spread":0.31612994054440513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886862,0.0010388495,0.00023348814,0.0023795785,0.0018028874,0.0015294795,0.0004947969,0.00035225897,0.0034824703],"genre_scores_gemma":[0.9939892,0.00075280765,0.00090777304,0.0018912792,0.00047167964,0.0003338728,0.00038513506,0.00017064573,0.0010975851],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99213916,0.00064663304,0.0022055493,0.0022862013,0.0009427061,0.0017797374],"domain_scores_gemma":[0.9941286,0.0020916774,0.00019920332,0.0014412191,0.00031430364,0.0018249991],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00212777,0.0008154208,0.0014380809,0.00071917794,0.0003073622,0.00025396104,0.00074614317,0.0010849365,0.00025063902],"category_scores_gemma":[0.0010597066,0.0007892653,0.00050158275,0.0011235786,0.0014880757,0.00041180267,0.00020281792,0.0016599268,0.0002508499],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005353299,0.0022766218,0.11906452,0.0014794902,0.0010705357,0.0162641,0.002653712,0.000020680101,0.11132009,0.0016373368,0.0046471404,0.73421246],"study_design_scores_gemma":[0.022584459,0.0036862183,0.8829927,0.0021852318,0.00050362595,0.00091000245,0.0005092803,0.019515416,0.014475389,0.00054160244,0.04994237,0.0021536897],"about_ca_topic_score_codex":0.011936676,"about_ca_topic_score_gemma":0.020400861,"teacher_disagreement_score":0.7639282,"about_ca_system_score_codex":0.0118207205,"about_ca_system_score_gemma":0.013295303,"threshold_uncertainty_score":0.9994558},"labels":[],"label_agreement":null},{"id":"W4401878556","doi":"10.1016/s2152-2650(24)00388-4","title":"Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Internal medicine; Blood transfusion; Clinical trial; Red blood cell; Oncology; Bone marrow","score_opus":0.030145264743437827,"score_gpt":0.3402547526484732,"score_spread":0.3101094879050354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894118,0.0018631449,0.00048335936,0.00095996296,0.0017710226,0.0034788577,0.0002204597,0.00021713441,0.0015943076],"genre_scores_gemma":[0.9753356,0.02115369,0.0007607888,0.0002473694,0.00088536885,0.0001714966,0.000118498334,0.000207764,0.001119428],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9872543,0.002035157,0.0038355943,0.002506286,0.0028464918,0.0015221665],"domain_scores_gemma":[0.9866901,0.009514366,0.0005929699,0.0018070778,0.0004177639,0.0009777303],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009515097,0.0010566666,0.0026392657,0.00061845355,0.00033593414,0.00021363488,0.0011352831,0.0014817026,0.00040539517],"category_scores_gemma":[0.0020143308,0.0007242862,0.0009993293,0.0014394278,0.0012658188,0.0005240133,0.00034245255,0.0032223738,0.000097574455],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38559294,0.013197384,0.056189913,0.0020951133,0.0024322977,0.021521218,0.0015956816,0.00015628106,0.016325204,0.000571826,0.002302889,0.49801925],"study_design_scores_gemma":[0.4474162,0.0443872,0.47017583,0.0031830478,0.0047900123,0.0029769465,0.0009131796,0.012851496,0.0053253677,0.0009362901,0.004900493,0.0021439474],"about_ca_topic_score_codex":0.0018969751,"about_ca_topic_score_gemma":0.0009392465,"teacher_disagreement_score":0.4958753,"about_ca_system_score_codex":0.0007795071,"about_ca_system_score_gemma":0.0041453117,"threshold_uncertainty_score":0.99981457},"labels":[],"label_agreement":null},{"id":"W4401959669","doi":"10.1038/s41467-024-51646-6","title":"TOPORS E3 ligase mediates resistance to hypomethylating agent cytotoxicity in acute myeloid leukemia cells","year":2024,"lang":"en","type":"article","venue":"Nature Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Council NSW; National Health and Medical Research Council; Medical Research Council; National Imaging Facility; Translational Cancer Research Network; University of Toronto; Anthony Rothe Memorial Trust; Peter MacCallum Cancer Centre; University of New South Wales; Cancer Institute NSW; Analytical Center for the Government of the Russian Federation; Fred Hutchinson Cancer Research Center; Australian Cancer Research Foundation; Australian Government","keywords":"Myeloid leukemia; Cytotoxicity; Hypomethylating agent; Cancer research; Leukemia; Myeloid; Ubiquitin ligase; Chemistry; Medicine; Immunology; DNA methylation; Biochemistry; Gene; Ubiquitin; In vitro","score_opus":0.024892531134479468,"score_gpt":0.3428405074853562,"score_spread":0.31794797635087674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401959669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89511687,0.028781306,0.00013808523,0.053178646,0.00038289864,0.0018159563,0.00018128789,0.00048765907,0.019917281],"genre_scores_gemma":[0.96163523,0.0034806905,0.028146341,0.001816779,0.00014880077,0.00022317765,0.00016020623,0.00006441047,0.0043243375],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976713,0.00023087561,0.00052867964,0.00049745885,0.0005490736,0.0005226013],"domain_scores_gemma":[0.9956776,0.0012103855,0.00006462224,0.0024764247,0.00021505407,0.00035592253],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0010259295,0.00025669535,0.0003962168,0.0006856752,0.00022603161,0.00010189094,0.001223889,0.0004599292,0.00006809436],"category_scores_gemma":[0.0010204547,0.00023553733,0.00014411933,0.00233947,0.0001707975,0.00017200978,0.0008337003,0.0035520457,0.00029339283],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003060747,0.00030976333,0.0026757042,0.00041702684,0.0004349747,0.0006667089,0.0055312896,0.00009878672,0.8373091,0.008501325,0.13454325,0.009205965],"study_design_scores_gemma":[0.0020096926,0.00025583923,0.031702522,0.0019345878,0.00031726784,0.00009251953,0.0011416269,0.007046517,0.4654104,0.0012542267,0.48783883,0.0009959555],"about_ca_topic_score_codex":0.00010091314,"about_ca_topic_score_gemma":0.0011606183,"teacher_disagreement_score":0.3718987,"about_ca_system_score_codex":0.0022638275,"about_ca_system_score_gemma":0.0009804711,"threshold_uncertainty_score":0.9987468},"labels":[],"label_agreement":null},{"id":"W4402020309","doi":"10.3324/haematol.2024.285648","title":"Utilization of allogeneic hematopoietic stem cell transplantation among patients with newly diagnosed acute myeloid leukemia in California: a population-based linked dataset study","year":2024,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Chronic Disease Prevention and Health Promotion; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Kite Pharma; Takeda Oncology; Health Resources and Services Administration; Centers for Disease Control and Prevention; Swedish Orphan Biovitrum; Vertex Pharmaceuticals; Omeros Corporation; Pfizer; Incyte; Kiadis Pharma; TG Therapeutics; Medac; Jazz Pharmaceuticals; StemCyte; Bristol-Myers Squibb; AstraZeneca; CSL Behring; BeiGene; HistoGenetics; Atara Biotherapeutics; CareDx; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences; Astellas Pharma; Adaptive Biotechnologies; MorphoSys; California Department of Public Health; Sanofi; GlaxoSmithKline; Amgen; Mallinckrodt Pharmaceuticals; Astellas Pharma US","keywords":"Medicine; Population; Transplantation; Medicaid; Hematopoietic stem cell transplantation; Myeloid leukemia; Young adult; Relative survival; Gerontology; Demography; Internal medicine; Pediatrics; Cancer; Cancer registry; Health care; Environmental health","score_opus":0.024502288346107653,"score_gpt":0.2877900609250132,"score_spread":0.26328777257890557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402020309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994834,0.00013433173,0.0011060648,0.000081953345,0.00004588589,0.0024679138,0.0011602774,0.00012043049,0.000049139002],"genre_scores_gemma":[0.9893695,0.00005895009,0.00050085445,0.00008328737,0.000012816979,0.0002329928,0.009669048,0.00004688078,0.000025678526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974039,0.00024181383,0.00071133743,0.0005962926,0.0006716146,0.00037500457],"domain_scores_gemma":[0.9987455,0.00035119161,0.00015821784,0.00047018158,0.0001302912,0.00014459812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032799062,0.00029853184,0.00067000504,0.00044156855,0.00006929226,0.00003869451,0.00019777835,0.00020896822,0.00013980072],"category_scores_gemma":[0.00003450572,0.00021443955,0.00007338609,0.0008543591,0.0000928294,0.00015042463,0.000037508573,0.00037007945,0.000056990633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010466082,0.0006261038,0.99104923,0.0014282718,0.00012571682,0.0022011485,0.0009715606,0.0011033268,0.0001607072,0.000020132138,0.0004893762,0.0007778261],"study_design_scores_gemma":[0.007883772,0.0012172537,0.9776365,0.00060209713,0.0006092408,0.000049969098,0.0005437897,0.009312697,0.0017530452,0.000022064683,0.00006163553,0.0003079221],"about_ca_topic_score_codex":0.00065418595,"about_ca_topic_score_gemma":0.00040060558,"teacher_disagreement_score":0.013412709,"about_ca_system_score_codex":0.0005103178,"about_ca_system_score_gemma":0.00047954672,"threshold_uncertainty_score":0.87445915},"labels":[],"label_agreement":null},{"id":"W4402022264","doi":"10.1016/j.exphem.2024.104577","title":"2020 – PRECISE SINGLE-CELL TRANSCRIPTOMIC MAPPING OF NORMAL AND LEUKEMIC CELL STATES REVEALS UNCONVENTIONAL LINEAGE PRIMING IN ACUTE MYELOID LEUKEMIA","year":2024,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Priming (agriculture); Lineage (genetic); Myeloid; Cell; Transcriptome; Leukemia; Biology; Cancer research; Computational biology; Cell biology; Immunology; Genetics; Gene; Gene expression","score_opus":0.019074415488792656,"score_gpt":0.28936280711631013,"score_spread":0.2702883916275175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402022264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680281,0.028380476,0.00022048186,0.00021342885,0.00028725597,0.00071376277,0.000040257826,0.00008556735,0.002030658],"genre_scores_gemma":[0.9936899,0.0004891309,0.0034042331,0.00012708294,0.00008126923,0.0000855723,0.00015579557,0.00006808992,0.0018989457],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99747515,0.00012282285,0.0008352674,0.00063927495,0.00033276956,0.0005946949],"domain_scores_gemma":[0.99913305,0.0002384825,0.00010893429,0.0002644816,0.000048092843,0.00020696159],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003084814,0.00032567885,0.00075285183,0.00044465766,0.000057111894,0.000031057567,0.00018252555,0.00025185812,0.00048475133],"category_scores_gemma":[0.000016695103,0.00031886037,0.000162465,0.00038761145,0.00031177455,0.00022456382,0.00017009272,0.00059159886,0.000053793865],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005499461,0.00030580824,0.003076505,0.001524162,0.00010616663,0.0010598834,0.0038690036,0.000010077176,0.9865149,0.00043559895,0.0022423202,0.00030560244],"study_design_scores_gemma":[0.0036355196,0.00051802944,0.00059052836,0.0006000375,0.000059674163,0.0014287041,0.0025979348,0.0038321768,0.9857457,0.000078821184,0.0006526842,0.00026014252],"about_ca_topic_score_codex":0.0000975623,"about_ca_topic_score_gemma":0.00000732329,"teacher_disagreement_score":0.027891345,"about_ca_system_score_codex":0.0011315421,"about_ca_system_score_gemma":0.00053244916,"threshold_uncertainty_score":0.9999263},"labels":[],"label_agreement":null},{"id":"W4402024325","doi":"10.1016/j.exphem.2024.104450","title":"3129 – UTILIZING AN IPSC-DERIVED BONE MARROW-LIKE ORGANOID MODEL TO INVESTIGATE DRUG RESISTANCE MECHANISMS IN ACUTE MYELOID LEUKEMIA","year":2024,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Organoid; Myeloid leukemia; Bone marrow; Drug resistance; Leukemia; Drug; Myeloid; Medicine; Bone marrow transplantation; Cancer research; Biology; Internal medicine; Pharmacology; Neuroscience; Microbiology","score_opus":0.027322433218954823,"score_gpt":0.3240531566932399,"score_spread":0.2967307234742851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402024325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798368,0.007820617,0.0015787218,0.004822235,0.00054813275,0.0013210055,0.000028221588,0.00056770275,0.003476525],"genre_scores_gemma":[0.9536838,0.00009167618,0.03554903,0.0031472922,0.00007444979,0.00038624625,0.000104849205,0.00018573608,0.0067769354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960202,0.00019476059,0.00075680227,0.0012940889,0.00059132,0.0011428018],"domain_scores_gemma":[0.99812204,0.00009591037,0.000071304465,0.0008564472,0.00007476293,0.00077952404],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047053755,0.0005339427,0.000964418,0.00070170034,0.00015871266,0.000081984785,0.0004384895,0.00032629413,0.0003818846],"category_scores_gemma":[0.00006168332,0.00052604463,0.00013935348,0.00089549244,0.0002925046,0.00038152718,0.00048283004,0.00093958323,0.000500537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008647743,0.0001527665,0.000041040486,0.00022567235,0.00010022761,0.00402519,0.005371042,0.000035878453,0.91836387,0.059358977,0.011350573,0.000110004556],"study_design_scores_gemma":[0.0019320858,0.00023084089,0.000027214242,0.00042211564,0.000042822674,0.0011937008,0.0028180438,0.024657136,0.96429133,0.0027814836,0.0010977701,0.0005054273],"about_ca_topic_score_codex":0.00013737088,"about_ca_topic_score_gemma":0.00020207798,"teacher_disagreement_score":0.056577493,"about_ca_system_score_codex":0.002264713,"about_ca_system_score_gemma":0.0012174116,"threshold_uncertainty_score":0.9997191},"labels":[],"label_agreement":null},{"id":"W4402025472","doi":"10.1016/j.exphem.2024.104461","title":"3140 – DELINEATING HEMATOPOIETIC AND CARDIAC MESODERMAL FATES FROM HPSCS","year":2024,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stem Cell Network; University of Toronto; University Health Network","funders":"","keywords":"Haematopoiesis; Biology; Cell biology; Stem cell","score_opus":0.018126652798058935,"score_gpt":0.331363450006437,"score_spread":0.3132367972083781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402025472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8648847,0.1304581,0.00015113114,0.001363378,0.00041313632,0.00033662704,0.000020857116,0.00023466085,0.0021374212],"genre_scores_gemma":[0.99495804,0.0001419332,0.003564728,0.0002596482,0.00024482093,0.000084981715,0.00008761465,0.000055226392,0.00060301204],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99847275,0.00007084736,0.00031178407,0.0005008925,0.00023219056,0.00041151786],"domain_scores_gemma":[0.9992108,0.00026096895,0.000025380126,0.00026296836,0.000030423911,0.00020951233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000118026146,0.00022192491,0.00052036496,0.00012555844,0.000092644594,0.000050591258,0.000089898575,0.00017327274,0.00068692415],"category_scores_gemma":[0.000045671884,0.0001903127,0.00011011293,0.00014801098,0.00022201992,0.00010080343,0.0002183563,0.0003348569,0.00029472075],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006715129,0.0005185985,0.03990819,0.0012729266,0.0015079903,0.006973683,0.01568591,0.0000025684799,0.70769763,0.16538009,0.050400324,0.00998057],"study_design_scores_gemma":[0.0010278752,0.00019117472,0.00035045837,0.00026158182,0.00007796927,0.0015535216,0.0043186937,0.005214015,0.9809692,0.00031411485,0.0054516466,0.00026974504],"about_ca_topic_score_codex":0.0001649232,"about_ca_topic_score_gemma":0.0000012806364,"teacher_disagreement_score":0.27327156,"about_ca_system_score_codex":0.00015811184,"about_ca_system_score_gemma":0.00011948267,"threshold_uncertainty_score":0.7760727},"labels":[],"label_agreement":null},{"id":"W4402112430","doi":"10.14740/jh1259","title":"Breast Cancer With Release of Tumor Cells in Peripheral Blood Mimicking Acute Myeloid Leukemia","year":2024,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Peripheral blood; Breast cancer; Myeloid cells; Pathology; Leukemia; Cancer; Myeloid; Cancer research; Immunology; Internal medicine","score_opus":0.009795565567379512,"score_gpt":0.2861482074465612,"score_spread":0.2763526418791817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402112430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924526,0.0034827136,0.000066295186,0.003266509,0.0002408838,0.00017135858,0.000026901429,0.000015652233,0.00027707923],"genre_scores_gemma":[0.9965247,0.00080209505,0.0018705806,0.00023620792,0.0002121945,0.0000075432436,0.0000018433346,0.00004642457,0.00029839747],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.9981377,0.000088422945,0.00072734326,0.00021620224,0.0004192206,0.00041111076],"domain_scores_gemma":[0.99890435,0.00014372084,0.00026482626,0.00020246307,0.0002836367,0.00020098231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035778986,0.0001886794,0.0008431623,0.00053320924,0.00002399151,0.000017648963,0.00020135517,0.00012203326,0.00040678753],"category_scores_gemma":[0.000030827454,0.0001289966,0.00015716992,0.0004805175,0.0001910402,0.0001587716,0.000055866127,0.0010494896,0.00000857825],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011794082,0.00081086386,0.120805204,0.0048357686,0.0042949985,0.17227526,0.0030018566,0.00066037243,0.65098137,0.0012410465,0.020797465,0.008501738],"study_design_scores_gemma":[0.015603633,0.002698269,0.019974489,0.0073736063,0.002041801,0.6165235,0.001282357,0.004802077,0.3261065,0.0002440257,0.0027898594,0.0005598771],"about_ca_topic_score_codex":0.00017885026,"about_ca_topic_score_gemma":0.000050805094,"teacher_disagreement_score":0.44424826,"about_ca_system_score_codex":0.00063756,"about_ca_system_score_gemma":0.0027636245,"threshold_uncertainty_score":0.52603287},"labels":[],"label_agreement":null},{"id":"W4402122999","doi":"10.1038/s41409-024-02408-x","title":"Reduced Intensity transplantation vs chemotherapy in CR1. A prospective, pseudorandomized study in 50–70 year old AML patients","year":2024,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Université Laval; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Cancerfonden; NordForsk; Vetenskapsrådet; Swedish Cancer Foundation","keywords":"Medicine; Internal medicine; Transplantation; Chemotherapy; Sibling; Prospective cohort study; Gastroenterology; Surgery","score_opus":0.012106843561849778,"score_gpt":0.28303790250665706,"score_spread":0.2709310589448073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402122999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993919,0.00006684533,0.00028547976,0.0007366554,0.00019277903,0.003979746,0.000058385773,0.00015233256,0.00060873735],"genre_scores_gemma":[0.99745613,0.0007353182,0.00041515604,0.0001570594,0.00007180369,0.0003261063,0.00044956667,0.00006612585,0.00032275176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973893,0.00023440302,0.0006830815,0.0006580248,0.000624121,0.00041107068],"domain_scores_gemma":[0.99929744,0.0001589529,0.00006162319,0.00023654698,0.0001346038,0.000110840854],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008395466,0.00029225915,0.00063629716,0.0008108108,0.000048032878,0.00006222891,0.000102787366,0.00017181995,0.00009291937],"category_scores_gemma":[0.000046102396,0.00026983523,0.00012032834,0.00089813984,0.00006325309,0.00030833288,0.000007215089,0.0006222095,0.000057753492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16366024,0.002372747,0.7255072,0.0020292003,0.00023439589,0.0023567826,0.032917716,0.000047857677,0.066933595,0.00010411967,0.00030973714,0.0035264173],"study_design_scores_gemma":[0.068810046,0.0007640124,0.9186818,0.00069687894,0.00017902127,0.00008587605,0.00048445305,0.0010300722,0.008846139,0.00012988278,0.00001906041,0.00027274006],"about_ca_topic_score_codex":0.00088868476,"about_ca_topic_score_gemma":0.00075030455,"teacher_disagreement_score":0.19317463,"about_ca_system_score_codex":0.00063465856,"about_ca_system_score_gemma":0.00022116868,"threshold_uncertainty_score":0.9999754},"labels":[],"label_agreement":null},{"id":"W4402160556","doi":"10.1007/978-3-031-63366-9_9","title":"Myeloid Proliferation Associated with Down Syndrome (ML-DS, TAM)","year":2024,"lang":"en","type":"book-chapter","venue":"Pediatric oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Cancer research; Computer science; Medicine","score_opus":0.020427876355183366,"score_gpt":0.29030967573019256,"score_spread":0.2698817993750092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402160556","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015672712,0.0043547237,0.00003500173,0.0058185104,0.0010898445,0.0031375953,0.0002746882,0.00069361244,0.96892333],"genre_scores_gemma":[0.034259852,0.0032231894,0.00040515646,0.000778005,0.0036906116,0.00025207803,0.0015434846,0.00035100157,0.9554966],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962584,0.00007659934,0.000780183,0.0010669958,0.0010185069,0.00079935655],"domain_scores_gemma":[0.9974404,0.00052658457,0.00041875144,0.0006237797,0.0005440226,0.0004464358],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0007233087,0.00067819754,0.0014718414,0.0010670142,0.0001278344,0.000055651184,0.00029312912,0.0019183618,0.00175251],"category_scores_gemma":[0.0003438913,0.00053778075,0.0002531626,0.00034719548,0.00022726251,0.00009455594,0.00023350517,0.0029464662,0.0033615853],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004636704,0.0016405393,0.013170405,0.005488895,0.0080033615,0.09785255,0.0014149973,0.000043421966,0.0002159187,0.07838242,0.76302624,0.026124563],"study_design_scores_gemma":[0.007566878,0.012336537,0.003918853,0.000484322,0.007448279,0.0075302846,0.00004400126,0.00031014797,0.000018801938,0.005573087,0.95317495,0.0015938467],"about_ca_topic_score_codex":0.000029973153,"about_ca_topic_score_gemma":0.000097949065,"teacher_disagreement_score":0.19014874,"about_ca_system_score_codex":0.0039256974,"about_ca_system_score_gemma":0.004973145,"threshold_uncertainty_score":0.9998981},"labels":[],"label_agreement":null},{"id":"W4402196330","doi":"10.1016/j.actbio.2024.08.053","title":"Lipopolymer/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Acta Biomaterialia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University of British Columbia; University of Alberta","funders":"Canadian Institutes of Health Research; Alberta Innovates - Technology Futures; Natural Sciences and Engineering Research Council of Canada; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"Myeloid leukemia; Cancer research; Materials science; Chemotherapy; Leukemia; Medicine; Immunology; Internal medicine","score_opus":0.01348089768754061,"score_gpt":0.2794710668300208,"score_spread":0.2659901691424802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402196330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917401,0.0003874929,0.0011874511,0.004948064,0.00037849834,0.0008841864,0.00021056182,0.00023994347,0.000023671362],"genre_scores_gemma":[0.9945789,0.000045799145,0.0034459194,0.00027568254,0.00020312227,0.0001680277,0.0004128519,0.00011674648,0.0007529375],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99820703,0.00008342623,0.00032909046,0.0005495149,0.00031820842,0.0005127179],"domain_scores_gemma":[0.99924415,0.00013008529,0.00004028387,0.0003060965,0.0000875489,0.00019181581],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042885894,0.0003224857,0.00043203446,0.00044544233,0.00006496878,0.00018360425,0.000117012314,0.0001920808,0.00019604732],"category_scores_gemma":[0.000050220784,0.00025539397,0.00007303191,0.00047932216,0.00019032983,0.00016704283,0.00006145064,0.00015013933,0.000019515146],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028914599,0.00003802776,0.000041179308,0.000207146,0.0005265673,0.0005451902,0.00029860347,0.0000045686947,0.9645491,0.00016663685,0.0041951714,0.00051321415],"study_design_scores_gemma":[0.0070022885,0.00119385,0.006849786,0.00025680658,0.00016545279,0.00082811585,0.000083402956,0.0059534507,0.9672056,0.00004628568,0.010058369,0.0003566382],"about_ca_topic_score_codex":0.0001093712,"about_ca_topic_score_gemma":0.0000038444596,"teacher_disagreement_score":0.02191231,"about_ca_system_score_codex":0.00051896536,"about_ca_system_score_gemma":0.00064546266,"threshold_uncertainty_score":0.9999898},"labels":[],"label_agreement":null},{"id":"W4402207813","doi":"10.1101/2024.08.30.608947","title":"DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid Leukemia","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"Deutsche Forschungsgemeinschaft; Leukemia Research Foundation of Delaware; Hilfe für krebskranke Kinder Frankfurt; Frankfurter Stiftung für krebskranke Kinder; Nemours Foundation; Lisa Dean Moseley Foundation; U.S. Department of Defense","keywords":"Myeloid leukemia; Medicine; Leukemia; Cancer research; Oncology; Internal medicine; Myeloid","score_opus":0.01570755622703319,"score_gpt":0.2537136815086063,"score_spread":0.2380061252815731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402207813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857025,0.008570505,0.00005055822,0.0017408403,0.00062136946,0.0020942758,0.0005199337,0.000625041,0.000074942734],"genre_scores_gemma":[0.9945219,0.0016075693,0.0017115911,0.00094568095,0.00025037222,0.00046329698,0.0000031863299,0.00037371228,0.00012269222],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9940306,0.00030783477,0.0010343591,0.0021037746,0.001126955,0.0013964793],"domain_scores_gemma":[0.99645764,0.00018638224,0.00034441327,0.0017914518,0.0005185432,0.0007015462],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0012852473,0.0010628595,0.0016003824,0.0012414195,0.00015256263,0.00032835227,0.0007411295,0.0015823216,0.00031210383],"category_scores_gemma":[0.0004422232,0.0010569585,0.00030085773,0.0015307514,0.00031381982,0.00012303755,0.0018109137,0.0045224912,0.00042283794],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058726803,0.0009723449,0.20441635,0.00782976,0.004306962,0.01661733,0.0005188554,0.00013152378,0.75838214,0.00095961994,0.0052310615,0.000046755296],"study_design_scores_gemma":[0.0073009287,0.0006979848,0.8837586,0.007974078,0.001395503,0.0000054406814,0.000044647655,0.016016537,0.074392974,0.0002028122,0.0048307977,0.003379711],"about_ca_topic_score_codex":0.00053345313,"about_ca_topic_score_gemma":0.00002319003,"teacher_disagreement_score":0.68398917,"about_ca_system_score_codex":0.0046139997,"about_ca_system_score_gemma":0.005276822,"threshold_uncertainty_score":0.99971384},"labels":[],"label_agreement":null},{"id":"W4402266287","doi":"10.1158/1538-7445.pediatric24-a018","title":"Abstract A018 Transcriptional evolution from normal foetal haematopoiesis to myeloid leukaemia in Down syndrome","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Haematopoiesis; Myeloid leukaemia; Medicine; Down syndrome; Cancer research; Myeloid; Pathology; Biology; Genetics; Stem cell","score_opus":0.05560502137300056,"score_gpt":0.3862410180342773,"score_spread":0.33063599666127674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402266287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789679,0.005144141,0.0002005845,0.010042626,0.00038653865,0.0010947516,0.00030839397,0.00014062216,0.0037144439],"genre_scores_gemma":[0.99358445,0.00031957784,0.00031988166,0.00016938802,0.0006406973,0.00070206623,0.0001223857,0.00007940507,0.004062142],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9952061,0.00016331182,0.0004889394,0.00088522566,0.002028387,0.0012279892],"domain_scores_gemma":[0.99811035,0.00041346092,0.000018377632,0.00052168185,0.0003424706,0.00059363915],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0016535785,0.0002558096,0.00045370733,0.0014085287,0.00017284795,0.00017443908,0.00043591895,0.00027971258,0.0058884206],"category_scores_gemma":[0.00025089472,0.00023498338,0.00017557779,0.0021091376,0.0003045897,0.00040699387,0.00018315724,0.0020765709,0.0023964536],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003075794,0.00036207965,0.017423954,0.0018885882,0.00054086297,0.009880403,0.0033117938,0.0003065418,0.8587942,0.0039040826,0.07854267,0.021968998],"study_design_scores_gemma":[0.0035492505,0.00070291845,0.9073753,0.0034996509,0.00007367637,0.00057325984,0.0012846387,0.0017331376,0.021723256,0.002323311,0.056443494,0.00071815035],"about_ca_topic_score_codex":0.010144147,"about_ca_topic_score_gemma":0.0015032945,"teacher_disagreement_score":0.8899513,"about_ca_system_score_codex":0.0056196274,"about_ca_system_score_gemma":0.0033137365,"threshold_uncertainty_score":0.9983803},"labels":[],"label_agreement":null},{"id":"W4402315980","doi":"10.1016/j.bulcan.2024.06.015","title":"Prévention de la rechute des leucémies aiguës et syndromes myélodysplasiques en post-allogreffe : stratégies prophylactique et préemptive (SFGM-TC)","year":2024,"lang":"fr","type":"review","venue":"Bulletin du Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Oncology; Internal medicine; Transplantation; Myeloid leukemia; Myelodysplastic syndromes; Hematopoietic stem cell transplantation; Disease; Minimal residual disease; Leukemia; Bone marrow","score_opus":0.03103304134910481,"score_gpt":0.3874545021787158,"score_spread":0.356421460829611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402315980","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004266009,0.954383,0.00022096868,0.022535847,0.0013338508,0.00454811,0.00087172084,0.0005295643,0.011310897],"genre_scores_gemma":[0.0028300614,0.93229824,0.005278946,0.001113548,0.0018421053,0.0038391417,0.00042148333,0.0005045769,0.051871922],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.987573,0.0061754296,0.0014753279,0.001772269,0.0012129395,0.0017910178],"domain_scores_gemma":[0.9931376,0.0037433594,0.00064578134,0.00091885775,0.00094887876,0.000605553],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.005885714,0.0016940199,0.0028573023,0.0008477921,0.00028507086,0.0006646012,0.0009496532,0.002052887,0.006041729],"category_scores_gemma":[0.0038688474,0.0013732744,0.0011908094,0.00086741184,0.0014794344,0.00027633918,0.00080191117,0.0054985397,0.0020593859],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00096523983,0.0009797988,0.0008977963,0.2568789,0.007771568,0.008331246,0.010241936,0.00006321539,0.00092155265,0.025622677,0.26734486,0.4199812],"study_design_scores_gemma":[0.0009576286,0.001216034,0.001986135,0.095230795,0.0033027565,0.0025628596,0.0007197926,0.000030435545,0.0002935291,0.0006289474,0.8919548,0.0011163239],"about_ca_topic_score_codex":0.0039702943,"about_ca_topic_score_gemma":0.0004437959,"teacher_disagreement_score":0.6246099,"about_ca_system_score_codex":0.008408226,"about_ca_system_score_gemma":0.011298982,"threshold_uncertainty_score":0.9995806},"labels":[],"label_agreement":null},{"id":"W4402564542","doi":"10.1016/j.ebiom.2024.105316","title":"Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia","year":2024,"lang":"en","type":"article","venue":"EBioMedicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Innovate UK","keywords":"Midostaurin; Medicine; Phosphoproteomics; Oncology; Myeloid leukaemia; Myeloid leukemia; Chemotherapy; Internal medicine; Nilotinib; Myeloid; Cancer research; Bioinformatics; Biology; Imatinib; Genetics; Kinase","score_opus":0.010741843531698339,"score_gpt":0.3045422122924583,"score_spread":0.29380036876076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402564542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97825664,0.001526727,0.0006705698,0.015522919,0.00049132924,0.002559688,0.000106773114,0.00024214757,0.00062321173],"genre_scores_gemma":[0.9895207,0.00087646075,0.0014295069,0.0012291343,0.0003605599,0.00017833558,0.00017586161,0.00014302725,0.0060863625],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958497,0.00015748721,0.0010046641,0.0008441301,0.0013156731,0.0008283083],"domain_scores_gemma":[0.9978912,0.00032768436,0.00010118747,0.0008493168,0.00022295561,0.00060768245],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022765757,0.00043631502,0.0010806078,0.0017130204,0.000043981163,0.00003176955,0.00038340443,0.00034774808,0.00067741855],"category_scores_gemma":[0.00042853004,0.0003571564,0.00015744485,0.0027319868,0.00032533164,0.00012285866,0.00020555567,0.0010223308,0.00014662603],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042966515,0.00031941145,0.008535001,0.00085116905,0.00092661224,0.008301633,0.005429162,0.000058211368,0.877807,0.000052625262,0.034461558,0.020291053],"study_design_scores_gemma":[0.03951283,0.009070259,0.22947128,0.006357634,0.0005758889,0.0023987682,0.0016627073,0.012693261,0.6295802,0.00022954331,0.06727179,0.0011758134],"about_ca_topic_score_codex":0.0007299198,"about_ca_topic_score_gemma":0.00003872864,"teacher_disagreement_score":0.24822684,"about_ca_system_score_codex":0.0024221165,"about_ca_system_score_gemma":0.002126537,"threshold_uncertainty_score":0.99988806},"labels":[],"label_agreement":null},{"id":"W4402635352","doi":"10.1101/2024.09.15.613155","title":"DNA polymerase theta-mediated DNA repair is a functional dependency and therapeutic vulnerability in DNMT3A deficient leukemia cells","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus","funders":"National Institutes of Health; Canadian Institutes of Health Research; Edward P. Evans Foundation; Blood Cancer UK; Leukemia and Lymphoma Society","keywords":"DNA damage; DNA polymerase; Biology; Cancer research; DNA replication; Leukemia; Myeloid leukemia; Molecular biology; DNA; Genetics","score_opus":0.02156530965546669,"score_gpt":0.2549477577999516,"score_spread":0.23338244814448492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402635352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98553956,0.00869564,0.000058028196,0.0012979438,0.0010451201,0.002021236,0.00050322694,0.0007787221,0.000060521845],"genre_scores_gemma":[0.996353,0.0006208962,0.00053726946,0.0011611928,0.0004742393,0.000490117,0.0000025813874,0.00025609383,0.00010461359],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99345857,0.00044369834,0.0011555358,0.002459356,0.0013012094,0.0011816022],"domain_scores_gemma":[0.99583626,0.00038401317,0.00028842635,0.002198422,0.00056530634,0.0007275853],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0021119115,0.0010133672,0.0012423574,0.0010084738,0.00018908706,0.00021184074,0.00044370393,0.001178795,0.00047596134],"category_scores_gemma":[0.00043904057,0.0009327356,0.00044807207,0.0013404904,0.00043545626,0.00009516973,0.0013046527,0.003813456,0.00037722607],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061853457,0.00054550165,0.02146816,0.00263143,0.0007864829,0.001026329,0.000117136464,0.000043571188,0.9706366,0.00034492224,0.0017581807,0.000023136552],"study_design_scores_gemma":[0.005478096,0.00047075626,0.29958522,0.002006683,0.0012198034,0.0000018568849,0.00005521521,0.01728896,0.66591656,0.00008789519,0.005475681,0.0024132717],"about_ca_topic_score_codex":0.00043446632,"about_ca_topic_score_gemma":0.00002001344,"teacher_disagreement_score":0.30472004,"about_ca_system_score_codex":0.0036162043,"about_ca_system_score_gemma":0.0061417753,"threshold_uncertainty_score":0.99949247},"labels":[],"label_agreement":null},{"id":"W4402712904","doi":"10.1016/s2352-3026(24)00274-6","title":"Transplantation and long-term overall survival in acute myeloid leukaemia","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myeloid leukaemia; Transplantation; Term (time); Oncology; Overall survival; Internal medicine","score_opus":0.03384350003317645,"score_gpt":0.3370490494081314,"score_spread":0.303205549374955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402712904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783617,0.001754081,0.0003266802,0.016598964,0.0002237989,0.00034630232,0.000017762228,0.00011234052,0.00225834],"genre_scores_gemma":[0.99379987,0.0042518815,0.00014999641,0.0007247233,0.0002289555,0.000037025464,0.00006111003,0.00002730325,0.00071915716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987376,0.00014927467,0.00022231498,0.00029351327,0.00017804033,0.00041929792],"domain_scores_gemma":[0.99926496,0.00032694882,0.000022729353,0.00029245444,0.000023090008,0.00006980048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046273932,0.00014403371,0.0006025855,0.00014648758,0.00004338744,0.000034696142,0.00015756684,0.00014156607,0.00009558296],"category_scores_gemma":[0.000031020627,0.00009456961,0.000044743392,0.00019996664,0.00019351304,0.00008637409,0.00005268916,0.0005921726,0.0001157537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050623165,0.0001329898,0.76402503,0.0071468065,0.0008838299,0.06352679,0.008409533,0.000014786606,0.02793299,0.08788858,0.013021888,0.021954438],"study_design_scores_gemma":[0.006531953,0.00027348846,0.94891834,0.00070112356,0.0004131194,0.03137468,0.000091604314,0.0021778105,0.003634967,0.0035848732,0.0019507362,0.00034732645],"about_ca_topic_score_codex":0.00007159516,"about_ca_topic_score_gemma":0.00021705823,"teacher_disagreement_score":0.18489327,"about_ca_system_score_codex":0.000107673455,"about_ca_system_score_gemma":0.00015548078,"threshold_uncertainty_score":0.38564366},"labels":[],"label_agreement":null},{"id":"W4402731040","doi":"10.1016/j.leukres.2024.107586","title":"Outcome of adolescents and young adult acute myeloid leukemia patients compared with middle-aged patients: A single centre retrospective experience","year":2024,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Medicine; Retrospective cohort study; Pediatrics; Young adult; Internal medicine","score_opus":0.038281070651816275,"score_gpt":0.3206665925156642,"score_spread":0.2823855218638479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402731040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940158,0.00025287608,0.000051535753,0.00021518777,0.00024792674,0.0022847163,0.00019345144,0.00019356675,0.0025449437],"genre_scores_gemma":[0.99472475,0.00016580448,0.00071039126,0.00012557366,0.00015147188,0.00013297312,0.00020703558,0.00016074858,0.0036212269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99189496,0.00043420526,0.0009608311,0.001473821,0.0035858862,0.0016502725],"domain_scores_gemma":[0.9949484,0.00026990418,0.00015281982,0.0010561983,0.0027921698,0.00078050996],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00065208395,0.00057306315,0.0010091581,0.0009941206,0.00036692357,0.00024273038,0.0006303854,0.0003568923,0.00012555592],"category_scores_gemma":[0.0009956348,0.00045121732,0.00017888984,0.0022977607,0.0013453903,0.0005545863,0.00071152695,0.0024167888,0.00012402688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002953134,0.00047170155,0.9767399,0.001392152,0.00033187823,0.00039400713,0.0071591134,0.0000029957987,0.005433783,0.00013176611,0.0031845148,0.0018050958],"study_design_scores_gemma":[0.0131381275,0.0025389283,0.9627875,0.0038730088,0.00017362104,0.00006104931,0.0030413955,0.0025219664,0.010696494,0.000070036614,0.00044506765,0.00065279193],"about_ca_topic_score_codex":0.0014725934,"about_ca_topic_score_gemma":0.00033801395,"teacher_disagreement_score":0.013952346,"about_ca_system_score_codex":0.011119808,"about_ca_system_score_gemma":0.001492419,"threshold_uncertainty_score":0.99988467},"labels":[],"label_agreement":null},{"id":"W4402738236","doi":"10.1016/j.modpat.2024.100615","title":"Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])","year":2024,"lang":"en","type":"review","venue":"Modern Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Foundation Medicine; National Institutes of Health; Agence Nationale de la Recherche; Edward P. Evans Foundation; Merck","keywords":"Myelodysplastic syndromes; Medicine; Pathology; Hematopathology; Biology; Cytogenetics; Bone marrow","score_opus":0.15036843319584542,"score_gpt":0.37671255483940436,"score_spread":0.22634412164355894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402738236","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022407095,0.9419956,0.025356127,0.013151428,0.002145631,0.00728515,0.0059660412,0.00016338853,0.0016959119],"genre_scores_gemma":[0.021959137,0.95626885,0.0035960278,0.00086291146,0.00069334195,0.008281661,0.005718781,0.00028845982,0.0023308324],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952079,0.000616053,0.0015082475,0.0014401517,0.00061212695,0.0006155123],"domain_scores_gemma":[0.9914301,0.00611486,0.0006140149,0.0012530719,0.00031555534,0.00027241523],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012146338,0.0007949033,0.0022052906,0.0006164693,0.00029354094,0.00015316097,0.0011635025,0.00071200414,0.000090263144],"category_scores_gemma":[0.0017122488,0.00047098115,0.0005671861,0.0006042512,0.0006225616,0.0001259426,0.0007469274,0.0013896154,0.00021155152],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052264443,0.0008952418,0.001213888,0.016423399,0.0050733252,0.00030959165,0.0034122362,0.000053114498,0.00008234246,0.0038286666,0.31429115,0.6538944],"study_design_scores_gemma":[0.0014461379,0.0004719085,0.0010339896,0.00423609,0.004132102,0.0021928179,0.00037494628,0.01160139,0.0000055002456,0.0006382707,0.97330374,0.0005631408],"about_ca_topic_score_codex":0.00007246199,"about_ca_topic_score_gemma":0.000048999264,"teacher_disagreement_score":0.65901256,"about_ca_system_score_codex":0.00046183792,"about_ca_system_score_gemma":0.0014875727,"threshold_uncertainty_score":0.9997742},"labels":[],"label_agreement":null},{"id":"W4402785536","doi":"10.1007/s40268-024-00491-5","title":"Trametinib Sensitivity is Defined by a Myeloid Differentiation Profile in Acute Myeloid Leukemia","year":2024,"lang":"en","type":"article","venue":"Drugs in R&D","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"National Institute of General Medical Sciences; National Cancer Institute; University of Pennsylvania; U.S. Department of Veterans Affairs","keywords":"Myeloid leukemia; Myeloid; Sensitivity (control systems); Trametinib; Myeloid cells; Medicine; Cancer research; Internal medicine; Biology; Genetics; Engineering; Signal transduction; MAPK/ERK pathway","score_opus":0.012591918784938701,"score_gpt":0.29009319149394197,"score_spread":0.27750127270900327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402785536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98847026,0.0005745069,0.00029715165,0.004617043,0.0002501396,0.0009819992,0.00018194655,0.0002139539,0.004413008],"genre_scores_gemma":[0.9909743,0.0003768566,0.0012843885,0.0006892421,0.00015018231,0.00017550282,0.00043865084,0.00008325798,0.0058276043],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9970153,0.00024414563,0.0005476834,0.00079265836,0.0006647723,0.00073545414],"domain_scores_gemma":[0.9987121,0.00047894169,0.000057793775,0.00048255097,0.000077045544,0.00019152484],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010182563,0.0003335439,0.00056806207,0.0006498137,0.000051110448,0.00009430131,0.0001474331,0.00032569584,0.00042987152],"category_scores_gemma":[0.0002559666,0.00030459557,0.0001532383,0.001309896,0.000121374746,0.00022537181,0.0001393093,0.0012359986,0.00048433564],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021312956,0.00126836,0.057996627,0.002339022,0.00075180846,0.0033950822,0.023656253,0.00004617602,0.509776,0.0015335873,0.2082746,0.1888312],"study_design_scores_gemma":[0.017170971,0.00090620236,0.32830825,0.0030977682,0.00051712844,0.00062032806,0.002967478,0.2806592,0.3220878,0.0018119885,0.039621223,0.0022316687],"about_ca_topic_score_codex":0.0007632794,"about_ca_topic_score_gemma":0.00010960193,"teacher_disagreement_score":0.28061303,"about_ca_system_score_codex":0.0022049218,"about_ca_system_score_gemma":0.00078107,"threshold_uncertainty_score":0.99994063},"labels":[],"label_agreement":null},{"id":"W4402816183","doi":"10.1111/bjh.19741","title":"Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study","year":2024,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"Astex Pharmaceuticals","keywords":"Decitabine; Medicine; Pharmacokinetics; Myeloid leukaemia; Crossover study; Internal medicine; Oncology; Pharmacology; Pathology","score_opus":0.029821483431669165,"score_gpt":0.36354717657950447,"score_spread":0.3337256931478353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402816183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97347945,0.011367877,0.0068032015,0.0030838114,0.0026757226,0.002027111,0.00009829619,0.00009423122,0.000370317],"genre_scores_gemma":[0.9879185,0.0035262825,0.0058598723,0.00024892716,0.0012509198,0.00012759131,0.0000623473,0.00013049327,0.0008750876],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9960139,0.00023572915,0.0016590989,0.000518438,0.0007796911,0.00079319207],"domain_scores_gemma":[0.9960408,0.0014757921,0.00040940967,0.0003291396,0.0012822874,0.00046257346],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017283198,0.0003642714,0.0016247199,0.00047993113,0.00021602974,0.00028410822,0.00046371168,0.00027538193,0.00025722664],"category_scores_gemma":[0.0024881407,0.00036076663,0.0005074237,0.00058311276,0.00032474572,0.0003395852,0.00011474068,0.001292001,0.00003124693],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13406388,0.0025317292,0.00048100657,0.0010904879,0.0103917625,0.45468965,0.0012364687,0.00012128218,0.010904298,0.0009393077,0.314381,0.06916912],"study_design_scores_gemma":[0.24399848,0.009442153,0.00067929423,0.00088627916,0.005127747,0.6870215,0.00089564046,0.0021185107,0.0055242577,0.0007230353,0.04293831,0.00064481795],"about_ca_topic_score_codex":0.00007925167,"about_ca_topic_score_gemma":0.00009928119,"teacher_disagreement_score":0.2714427,"about_ca_system_score_codex":0.0005055495,"about_ca_system_score_gemma":0.0016587706,"threshold_uncertainty_score":0.9998844},"labels":[],"label_agreement":null},{"id":"W4402824677","doi":"10.1182/bloodadvances.2024013414","title":"Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Chronic lymphocytic leukemia; Haematopoiesis; Myeloid leukemia; Immunology; Indeterminate; Myeloid; Medicine; Leukemia; Cancer research; Biology; Stem cell; Genetics","score_opus":0.004372831565118015,"score_gpt":0.2465154665939159,"score_spread":0.2421426350287979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402824677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929097,0.005644242,0.00004628684,0.00006428206,0.00011967842,0.00044097123,0.000023297744,0.0000721338,0.0006793879],"genre_scores_gemma":[0.99799377,0.00033453,0.0008762908,0.00003799075,0.00013595213,0.000041048883,0.000031881198,0.00004239171,0.0005061762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816954,0.00003593798,0.0003572833,0.00040076533,0.000618668,0.00041782195],"domain_scores_gemma":[0.99934816,0.00008362277,0.00006844319,0.00028071765,0.00010602179,0.000113006674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014208713,0.00020683251,0.0004100065,0.0003390648,0.000034300054,0.000023236467,0.00016805984,0.00009507751,0.00011169631],"category_scores_gemma":[0.000043136897,0.00015399905,0.00008245507,0.00056947034,0.00020885219,0.00029545114,0.00008767392,0.00028940986,0.00003466199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008599711,0.001339144,0.69011444,0.022027051,0.0022038368,0.008074813,0.0019136851,0.005639052,0.028416561,0.0014728213,0.001059365,0.22913952],"study_design_scores_gemma":[0.045454957,0.007583995,0.76994693,0.007910668,0.0011154651,0.0006473311,0.00033785193,0.014047513,0.14122958,0.0008818361,0.009465494,0.0013783727],"about_ca_topic_score_codex":0.00010352611,"about_ca_topic_score_gemma":0.000050184302,"teacher_disagreement_score":0.22776115,"about_ca_system_score_codex":0.0022039576,"about_ca_system_score_gemma":0.0030586608,"threshold_uncertainty_score":0.6279899},"labels":[],"label_agreement":null},{"id":"W4402866903","doi":"10.1016/j.cancergen.2024.08.051","title":"49. Improving diagnostic paradigms with Optical Genome Mapping (OGM) for better outcomes in adult AML","year":2024,"lang":"en","type":"article","venue":"Cancer Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre","funders":"","keywords":"Computational biology; Biology; Computer science","score_opus":0.02347153992803967,"score_gpt":0.31194772898233425,"score_spread":0.28847618905429456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402866903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97966564,0.004421888,0.006553617,0.00722227,0.00025850438,0.0013059147,0.000065690365,0.00008097413,0.00042551963],"genre_scores_gemma":[0.985056,0.00092157244,0.009842867,0.0017875502,0.00065873953,0.00074879394,0.00003500179,0.00010176966,0.0008477057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983026,0.000017044771,0.00029610837,0.00046567686,0.0003043496,0.00061421405],"domain_scores_gemma":[0.9987912,0.0005315865,0.000027946537,0.00033039122,0.00011877694,0.00020007961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014476899,0.00021770579,0.00036289907,0.0002052424,0.000044344928,0.00007092784,0.00015676868,0.00012405831,0.000048138572],"category_scores_gemma":[0.00023702814,0.00016565446,0.000081170045,0.00030343904,0.000117152966,0.000047619622,0.000076294404,0.00040781917,0.0000371306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057189004,0.00024543854,0.7237134,0.005708016,0.0010470714,0.0021076184,0.0038699964,0.0016070079,0.054316226,0.0011057631,0.0033956585,0.20231189],"study_design_scores_gemma":[0.011062727,0.002061199,0.78973395,0.0022531822,0.0008118589,0.00023658453,0.00081611803,0.06846637,0.021197386,0.00042751606,0.10137254,0.001560578],"about_ca_topic_score_codex":0.000110573696,"about_ca_topic_score_gemma":0.00016674648,"teacher_disagreement_score":0.20075132,"about_ca_system_score_codex":0.000799225,"about_ca_system_score_gemma":0.00072716514,"threshold_uncertainty_score":0.6755193},"labels":[],"label_agreement":null},{"id":"W4403012542","doi":"10.1016/s1470-2045(24)00386-3","title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","year":2024,"lang":"nl","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Agence Nationale de la Recherche","keywords":"Open label; Myeloid leukaemia; Medicine; Refractory (planetary science); Cohort; Internal medicine; Oncology; Clinical trial; Biology","score_opus":0.1475039105224535,"score_gpt":0.46556586142230166,"score_spread":0.3180619508998481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403012542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9077054,0.012684577,0.00009325274,0.03178261,0.009336829,0.017065795,0.0009568042,0.0005586718,0.019816043],"genre_scores_gemma":[0.5202258,0.057716954,0.009999134,0.014882968,0.020648932,0.0053977673,0.0013820139,0.0009537667,0.36879262],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9876488,0.0037855892,0.0021902649,0.002068821,0.0011618746,0.003144687],"domain_scores_gemma":[0.98995626,0.0059001152,0.00054137455,0.0025439272,0.0002804844,0.00077782455],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.00906408,0.0010857973,0.003687281,0.0009858261,0.0003925918,0.00042477727,0.0034343486,0.0015264052,0.0065736463],"category_scores_gemma":[0.0030005984,0.00071246224,0.00023171132,0.002297349,0.0011451014,0.0004948476,0.002102406,0.0066461954,0.009587575],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.54024917,0.013265921,0.0002532202,0.0008784503,0.00395636,0.02860711,0.004769021,0.000010748868,0.019675205,0.00058835343,0.32064074,0.067105725],"study_design_scores_gemma":[0.4565805,0.011992675,0.0002604198,0.0006587405,0.0013731818,0.0004711228,0.0007869952,0.017724471,0.00028955893,0.000055816014,0.50916547,0.0006410766],"about_ca_topic_score_codex":0.0023588303,"about_ca_topic_score_gemma":0.0019072242,"teacher_disagreement_score":0.3874796,"about_ca_system_score_codex":0.008525681,"about_ca_system_score_gemma":0.009347195,"threshold_uncertainty_score":0.9997698},"labels":[],"label_agreement":null},{"id":"W4403209266","doi":"10.1186/s13287-024-03969-w","title":"Single-cell dissection reveals promotive role of ENO1 in leukemia stem cell self-renewal and chemoresistance in acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Stem Cell Research & Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Agriculture","funders":"Basic and Applied Basic Research Foundation of Guangdong Province; China Postdoctoral Science Foundation; K. C. Wong Education Foundation; Jinan University; Pearl River S and T Nova Program of Guangzhou; National Natural Science Foundation of China","keywords":"Stem cell; Myeloid leukemia; Leukemia; Cancer research; Biology; Cell; Cancer stem cell; Myeloid; Medicine; Immunology; Cell biology; Genetics","score_opus":0.02818323058036913,"score_gpt":0.3087176625545179,"score_spread":0.28053443197414873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403209266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96310616,0.018509401,0.000014771929,0.0002902601,0.00009332006,0.0033143745,0.000036436122,0.00013454663,0.014500747],"genre_scores_gemma":[0.9717028,0.011023105,0.0003293809,0.000033484586,0.00017471662,0.00040594678,0.000033632034,0.00016583382,0.0161311],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99336755,0.000993582,0.0009697173,0.0013314226,0.0018072984,0.0015304413],"domain_scores_gemma":[0.9971552,0.00092444266,0.00014663335,0.0008765895,0.00043533323,0.0004618176],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003792828,0.00051944697,0.0009484348,0.0015219753,0.00014616243,0.00017098538,0.00055154157,0.00048114223,0.000088372486],"category_scores_gemma":[0.000017227188,0.00045426743,0.00017553268,0.002723654,0.0003960996,0.0003524023,0.0002778324,0.002319614,0.00006731315],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002635471,0.0005521466,0.0055891713,0.0018941796,0.00011686172,0.00076945405,0.010301731,0.000014821618,0.94534165,0.00006838708,0.00076348655,0.031952634],"study_design_scores_gemma":[0.00620196,0.0025146657,0.004208925,0.0010873014,0.000036931684,0.00005949767,0.005382566,0.0021300549,0.97136396,0.00049338466,0.0060392576,0.000481516],"about_ca_topic_score_codex":0.00072897883,"about_ca_topic_score_gemma":0.00022548634,"teacher_disagreement_score":0.03147112,"about_ca_system_score_codex":0.006940754,"about_ca_system_score_gemma":0.0030701233,"threshold_uncertainty_score":0.99998206},"labels":[],"label_agreement":null},{"id":"W4403274656","doi":"10.1016/s2352-3026(24)00251-5","title":"Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes","year":2024,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"HORIZON EUROPE Framework Programme; Associazione Italiana per la Ricerca sul Cancro; Ministero della Salute; Agence Nationale de la Recherche","keywords":"Myelodysplastic syndromes; Medicine; Consensus conference; International Prognostic Scoring System; Intensive care medicine; Internal medicine; Bone marrow","score_opus":0.2527579179498377,"score_gpt":0.4168192831024565,"score_spread":0.16406136515261877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403274656","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002827361,0.9393344,0.0025060163,0.022679357,0.00452568,0.009734919,0.019962117,0.0004811351,0.00049365795],"genre_scores_gemma":[0.0041695978,0.9643767,0.002519659,0.00096723624,0.0031892746,0.006747455,0.015826385,0.0004069663,0.0017967161],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945876,0.0006127786,0.0016290537,0.001524421,0.0006290577,0.0010170896],"domain_scores_gemma":[0.98048645,0.01510944,0.0008384633,0.0029884155,0.00038728403,0.00018996066],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015407646,0.0008568372,0.004881515,0.00027555472,0.00037221005,0.00022560169,0.003144737,0.00074032735,0.00010675312],"category_scores_gemma":[0.0030304138,0.00045044697,0.0005620468,0.00040403235,0.00087728136,0.00008157343,0.0008117494,0.0014204279,0.00084935897],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017262138,0.00017656777,0.000040033516,0.125655,0.013095982,0.0017413804,0.00028098212,0.000006953646,0.0000803112,0.06314835,0.7557351,0.03831313],"study_design_scores_gemma":[0.002434092,0.00017306783,0.000023459015,0.014791118,0.011162994,0.014441703,0.0003819406,0.0090924315,0.0000023014125,0.00036960805,0.9466792,0.00044810423],"about_ca_topic_score_codex":0.000043166383,"about_ca_topic_score_gemma":0.0000550742,"teacher_disagreement_score":0.19094408,"about_ca_system_score_codex":0.0008429709,"about_ca_system_score_gemma":0.0023156903,"threshold_uncertainty_score":0.9999286},"labels":[],"label_agreement":null},{"id":"W4403303359","doi":"10.3390/curroncol31100451","title":"Maintenance Therapy Post-Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Myeloid leukemia; Clinical trial; Transplantation; Intensive care medicine; Oncology; Stem cell; Maintenance therapy; Haematopoiesis; Internal medicine; Immunology; Chemotherapy","score_opus":0.10345331243806435,"score_gpt":0.42753999037515733,"score_spread":0.324086677937093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403303359","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00077748636,0.9914639,0.00004990554,0.00037057177,0.0018528416,0.0030201059,0.00021100775,0.00014430578,0.0021098703],"genre_scores_gemma":[0.00008912406,0.9945113,0.00009023344,0.000134372,0.00043578402,0.00085442595,0.0009796857,0.00017868332,0.0027263614],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99564546,0.0005259155,0.0012851142,0.0010897507,0.0004941187,0.00095966575],"domain_scores_gemma":[0.99811614,0.00039911183,0.0003300448,0.0006704157,0.0001875182,0.00029678468],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006979006,0.0007978532,0.0031032697,0.0010041398,0.000052010335,0.00003971363,0.00054902595,0.00095646817,0.00016443107],"category_scores_gemma":[0.000018261484,0.0005690084,0.00076614926,0.0010235644,0.0002104853,0.00008420548,0.00012279079,0.003297625,0.0016701857],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00023289415,0.00023263932,0.000008191192,0.05100246,0.00022981469,0.002318878,0.0008533116,2.135124e-7,0.000020823258,0.00010679443,0.008485855,0.9365081],"study_design_scores_gemma":[0.0024760503,0.00079977827,0.000016594395,0.018336996,0.0019021122,0.0022899595,0.0001140479,0.000031103544,0.000017762133,0.000035644513,0.97352636,0.00045361262],"about_ca_topic_score_codex":0.000022885555,"about_ca_topic_score_gemma":0.000021745751,"teacher_disagreement_score":0.9650405,"about_ca_system_score_codex":0.006583256,"about_ca_system_score_gemma":0.0070915185,"threshold_uncertainty_score":0.9996761},"labels":[],"label_agreement":null},{"id":"W4403543935","doi":"10.1038/s41409-024-02444-7","title":"Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia","year":2024,"lang":"en","type":"letter","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; U.S. Navy; Health Resources and Services Administration; Syndax Pharmaceuticals; Office of Naval Research; Jazz Pharmaceuticals; Genentech; AstraZeneca; National Institutes of Health; U.S. Department of Health and Human Services; Foundation for the National Institutes of Health; Amgen; Gilead Sciences; U.S. Department of Defense","keywords":"Medicine; Myeloid leukemia; Tyrosine kinase; Fms-Like Tyrosine Kinase 3; Cancer research; Tyrosine-kinase inhibitor; Leukemia; Mutation; CD135; Myeloid; Transplantation; Immunology; Internal medicine; Gene; Cancer; Biology; Genetics","score_opus":0.020396742353881888,"score_gpt":0.2848752562052676,"score_spread":0.2644785138513857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403543935","genre_codex":"commentary","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.105524994,0.0037433733,0.013959927,0.825361,0.0021653862,0.010180442,0.03498778,0.0014617256,0.0026153678],"genre_scores_gemma":[0.08497675,0.00758711,0.04571087,0.31456265,0.02101318,0.007637653,0.45709646,0.002646716,0.058768604],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937909,0.00024843175,0.0013020118,0.0015675712,0.0016228679,0.0014681874],"domain_scores_gemma":[0.99758214,0.00049204763,0.00025670987,0.00086286303,0.00046646054,0.0003397682],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0008298858,0.00108724,0.0014071625,0.0011883862,0.00040599168,0.00021160183,0.00043440712,0.0018452234,0.00022063493],"category_scores_gemma":[0.000051790008,0.0010057708,0.0007459825,0.00076939375,0.0003059117,0.0002827406,0.000026201898,0.003056842,0.00031857294],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004289752,0.00010479802,0.00013763648,0.010842232,0.0024811851,0.024934562,0.0038543076,0.00007476184,0.0720889,0.00033730158,0.8780624,0.0027921556],"study_design_scores_gemma":[0.032229397,0.0036405413,0.0035265917,0.009732625,0.03840799,0.022089332,0.00046407944,0.0015160766,0.0680372,0.010963844,0.80435926,0.0050330446],"about_ca_topic_score_codex":0.0002919129,"about_ca_topic_score_gemma":0.00049834326,"teacher_disagreement_score":0.51079834,"about_ca_system_score_codex":0.0018902783,"about_ca_system_score_gemma":0.0023782875,"threshold_uncertainty_score":0.99945056},"labels":[],"label_agreement":null},{"id":"W4403568979","doi":"10.1016/j.htct.2024.09.742","title":"LUSPATERCEPT UTILIZATION PATTERNS IN LOWER-RISK MYELODYSPLASTIC SYNDROMES: FINDINGS FROM A MULTINATIONAL MEDICAL RECORD REVIEW STUDY","year":2024,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multinational corporation; Myelodysplastic syndromes; Family medicine; Internal medicine; Finance","score_opus":0.03426642712876994,"score_gpt":0.3318220713860433,"score_spread":0.2975556442572734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403568979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97447145,0.018468564,0.0027722062,0.0026624845,0.00024460006,0.0011643438,0.000021217807,0.000088932065,0.00010621512],"genre_scores_gemma":[0.7661298,0.2326609,0.000091326845,0.0007201172,0.000030439893,0.00010474719,0.000075637676,0.000030430643,0.00015661411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978783,0.00032165303,0.0004506974,0.00057070603,0.00050216966,0.0002764358],"domain_scores_gemma":[0.9990291,0.0004986341,0.0000318561,0.0002059777,0.000052069678,0.00018235293],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006305389,0.00022277207,0.0005593742,0.00026682424,0.00007480506,0.000020922294,0.0001216021,0.00023773169,0.0068122945],"category_scores_gemma":[0.00008771971,0.00016833124,0.000085086285,0.000362967,0.00008085035,0.000069409754,0.000029769044,0.0006748069,0.00008206315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015688351,0.0029298114,0.69751316,0.0038876291,0.0003191344,0.0059029977,0.0070002344,9.4804346e-7,0.0024200787,0.00008310273,0.0028806538,0.27549344],"study_design_scores_gemma":[0.060369153,0.010128684,0.7884299,0.04582657,0.0009558276,0.004414423,0.004925882,0.042784348,0.0048591774,0.000915577,0.03421848,0.002171989],"about_ca_topic_score_codex":0.00033014888,"about_ca_topic_score_gemma":0.00035839446,"teacher_disagreement_score":0.27332145,"about_ca_system_score_codex":0.00007668655,"about_ca_system_score_gemma":0.0001998252,"threshold_uncertainty_score":0.9940956},"labels":[],"label_agreement":null},{"id":"W4403572956","doi":"10.14740/jh1342","title":"Controversies in the Management of Ischemic Cerebrovascular Accidents in Patients With Non-Promyelocytic Acute Myeloid Leukemia","year":2024,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Acute promyelocytic leukemia; Myeloid leukemia; Intensive care medicine; Internal medicine; Gene; Biology","score_opus":0.006821236102267886,"score_gpt":0.26711495857752277,"score_spread":0.2602937224752549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403572956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959312,0.0008130235,0.0001011731,0.0015299016,0.00012271991,0.00052859145,0.0000020228215,0.000004573333,0.000966772],"genre_scores_gemma":[0.998333,0.00036434,0.000893377,0.00023242307,0.00003126929,0.000012055462,0.0000042806446,0.000022417848,0.000106865526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799144,0.00008883221,0.00069417077,0.00019124143,0.0006869947,0.0003473164],"domain_scores_gemma":[0.9989887,0.00027672233,0.00020161472,0.00030448547,0.00016003232,0.000068446476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006877082,0.00016963837,0.00068742427,0.00057119125,0.000018479745,0.00001890207,0.00037469115,0.00011358435,0.000052576368],"category_scores_gemma":[0.00006379637,0.00009930147,0.00015065674,0.0005727123,0.00011939479,0.00014373781,0.000096565425,0.0007557861,0.000016647364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065789414,0.00086617086,0.91549486,0.005129962,0.007166644,0.020227661,0.0035068034,0.00013214175,0.0017240181,0.0014163596,0.032135718,0.0056207143],"study_design_scores_gemma":[0.04642762,0.0033576945,0.91434884,0.006766623,0.002082081,0.007564365,0.0043616774,0.0011180596,0.0071753766,0.00040100925,0.0059349723,0.00046170756],"about_ca_topic_score_codex":0.000032129727,"about_ca_topic_score_gemma":0.00000898306,"teacher_disagreement_score":0.039848678,"about_ca_system_score_codex":0.0007378478,"about_ca_system_score_gemma":0.0004366022,"threshold_uncertainty_score":0.40493965},"labels":[],"label_agreement":null},{"id":"W4403591785","doi":"10.53876/001c.123447","title":"A retrospective chart review of outcomes of favourable risk NPM1 mutated AML patients who underwent allogeneic stem cell transplantation in CR2","year":2024,"lang":"en","type":"article","venue":"International Journal of Cancer Care and Delivery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"NPM1; Oncology; Medicine; Transplantation; Retrospective cohort study; Stem cell; Internal medicine; Chart; Biology; Genetics; Gene; Karyotype","score_opus":0.012676997042924468,"score_gpt":0.3124843303439196,"score_spread":0.2998073333009951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403591785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92806333,0.07044585,0.00006250529,0.00035799708,0.00028292768,0.00018288335,0.00024234664,0.0000032766914,0.00035887468],"genre_scores_gemma":[0.78569824,0.21394739,0.000045281173,0.00016518879,0.000045960598,0.000004238058,0.000019535759,0.000008815914,0.00006536155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984987,0.00005767472,0.00054572517,0.000122006255,0.0006811099,0.000094817435],"domain_scores_gemma":[0.9982064,0.00007525899,0.00027839153,0.00005945719,0.0013235513,0.000056987763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020344253,0.00009573556,0.00038292076,0.0003159154,0.000010359148,0.000011351716,0.00010940946,0.00004631291,0.00006333022],"category_scores_gemma":[0.000022802016,0.00007281747,0.00014834813,0.00015068972,0.000040380117,0.00015196105,0.000020342937,0.00025141265,9.937073e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011274029,0.00012960061,0.9335966,0.005900795,0.00105018,0.00039697762,0.004086442,0.00012634692,0.0019917374,0.000027307815,0.0012909577,0.050275635],"study_design_scores_gemma":[0.004469436,0.0009386976,0.9531492,0.02233836,0.0005633083,0.00007394907,0.0011967395,0.00021701734,0.016044756,0.00006611637,0.00079603563,0.00014638448],"about_ca_topic_score_codex":0.00052490697,"about_ca_topic_score_gemma":0.00009999505,"teacher_disagreement_score":0.14350154,"about_ca_system_score_codex":0.0006447743,"about_ca_system_score_gemma":0.0004405501,"threshold_uncertainty_score":0.296941},"labels":[],"label_agreement":null},{"id":"W4403602249","doi":"10.58931/cht.2023.2s1137","title":"An internet-based educational algorithm for the work-up, diagnosis and management of patients with myelodysplastic syndromes from the Canadian Consortium on MDS","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Centre Hospitalier de l’Université de Montréal; Juravinski Cancer Centre; St. Paul's Hospital","funders":"McGill University; Celgene","keywords":"Myelodysplastic syndromes; The Internet; Algorithm; Computer science; Work (physics); Medicine; Engineering; World Wide Web; Internal medicine","score_opus":0.022116641355186827,"score_gpt":0.2811855605360896,"score_spread":0.2590689191809028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403602249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9546229,0.00028724907,0.00014009528,0.041123297,0.00043047688,0.0022064403,0.00089370855,0.000025866568,0.00026996585],"genre_scores_gemma":[0.99528694,0.0000256448,0.00051715074,0.0021784066,0.00004192078,0.00073363876,0.0006517243,0.000033626784,0.0005309246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869186,0.00006698307,0.0002001161,0.00032053966,0.00021059187,0.0005099162],"domain_scores_gemma":[0.9972692,0.0014986098,0.00005871711,0.000437684,0.00015191495,0.000583854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019604115,0.00016278808,0.0002564196,0.00028910913,0.00024685255,0.00002844459,0.00027782787,0.00011364619,0.00030833558],"category_scores_gemma":[0.00012164229,0.00010005207,0.00003845538,0.00039186495,0.00039660206,0.000029200997,0.000020273475,0.00020605595,0.000041920575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015501154,0.000062795036,0.86281914,0.00010435611,0.0006442459,0.00016622951,0.00046600308,0.00003208721,2.0131874e-7,0.003596643,0.10806832,0.023884952],"study_design_scores_gemma":[0.0018114671,0.00029746548,0.98137254,0.00028751572,0.00020241852,0.000013459768,0.00034161602,0.0029738606,0.000050914132,0.00009945514,0.012398578,0.00015068948],"about_ca_topic_score_codex":0.3502776,"about_ca_topic_score_gemma":0.78257334,"teacher_disagreement_score":0.43229574,"about_ca_system_score_codex":0.0005048097,"about_ca_system_score_gemma":0.002001799,"threshold_uncertainty_score":0.654049},"labels":[],"label_agreement":null},{"id":"W4403622166","doi":"10.58931/cht.2024.3252","title":"Therapy for Myelodysplastic Syndromes Beyond the Front Line in 2024 in Canada","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Sunnybrook Research Institute; Leukemia and Lymphoma Society of Canada","keywords":"Front line; Myelodysplastic syndromes; Medicine; History; Internal medicine; Archaeology","score_opus":0.018813981114614547,"score_gpt":0.2800930793534141,"score_spread":0.2612790982387996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8657421,0.021358138,0.000049487247,0.10404621,0.0016773004,0.0021630672,0.00020612056,0.000034304623,0.004723292],"genre_scores_gemma":[0.9901916,0.000213324,0.00009238261,0.0037944596,0.00009868454,0.00033009905,0.000051110997,0.000045247845,0.0051830895],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822706,0.000072634604,0.00033664508,0.00038204412,0.00016214934,0.0008194586],"domain_scores_gemma":[0.99835515,0.0008635208,0.000018863739,0.0003348823,0.000047306014,0.00038025682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036439556,0.00018765297,0.00043873407,0.000532001,0.00005946536,0.000021841355,0.000234546,0.00016058695,0.00081389677],"category_scores_gemma":[0.00027878123,0.0001329645,0.000056871002,0.00044936143,0.00010478297,0.00004100295,0.000022679575,0.0006344703,0.000074499796],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003548546,0.000048532922,0.092081904,0.00073001767,0.00034596937,0.022845348,0.001644586,0.0001296704,0.00016897013,0.011049617,0.85145897,0.019141559],"study_design_scores_gemma":[0.0073951175,0.00057643314,0.06297938,0.0009926121,0.00009451501,0.0059479405,0.0023742705,0.03634011,0.0011861033,0.004583739,0.87668824,0.0008415193],"about_ca_topic_score_codex":0.97950983,"about_ca_topic_score_gemma":0.99966556,"teacher_disagreement_score":0.12444952,"about_ca_system_score_codex":0.0035859805,"about_ca_system_score_gemma":0.020748349,"threshold_uncertainty_score":0.9848031},"labels":[],"label_agreement":null},{"id":"W4403729575","doi":"10.3390/curroncol31110490","title":"Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Disease; Intensive care medicine; Transplantation; Stem cell; Adverse effect; Leukemia; Myeloid; Immunology; Bioinformatics; Oncology; Internal medicine","score_opus":0.1413221470811993,"score_gpt":0.44494013555929723,"score_spread":0.30361798847809796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403729575","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005215702,0.98657805,0.000035148496,0.00039800213,0.00329359,0.0035831388,0.00024409572,0.00018476977,0.00046752734],"genre_scores_gemma":[0.00006008571,0.9922978,0.0005241661,0.00040077697,0.0016659196,0.0006235507,0.0033828865,0.0001383263,0.0009064818],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99502724,0.0006515449,0.0013588952,0.0015028164,0.00050152495,0.0009579571],"domain_scores_gemma":[0.9974547,0.0005878396,0.0002593797,0.00079358066,0.00018241761,0.0007220578],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00025119534,0.0009494723,0.003953525,0.0012224029,0.00005438516,0.00004964541,0.00075552287,0.001457715,0.0007917615],"category_scores_gemma":[0.00039308626,0.0005982105,0.00067799207,0.0015022774,0.00019661931,0.00007526104,0.00080928527,0.0032594395,0.0034201688],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00014493529,0.00030357495,0.00014361691,0.0020135564,0.00065232924,0.00036730227,0.0009851893,1.00963405e-7,0.0000053523,0.0000499726,0.10293141,0.89240265],"study_design_scores_gemma":[0.002324856,0.0010576639,0.00046063296,0.009028979,0.0012437573,0.000029117225,0.000047451736,0.000008978767,0.000002556165,0.00025110005,0.98500025,0.00054462784],"about_ca_topic_score_codex":0.00018827221,"about_ca_topic_score_gemma":0.000089519235,"teacher_disagreement_score":0.89185804,"about_ca_system_score_codex":0.00985856,"about_ca_system_score_gemma":0.007767212,"threshold_uncertainty_score":0.9998386},"labels":[],"label_agreement":null},{"id":"W4403750561","doi":"10.1038/s41409-024-02449-2","title":"Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; U.S. Navy; Genentech; Health Resources and Services Administration; Syndax Pharmaceuticals; Office of Naval Research; Jazz Pharmaceuticals; AstraZeneca; National Institutes of Health; U.S. Department of Health and Human Services; Foundation for the National Institutes of Health; Takeda Pharmaceuticals U.S.A.; Amgen; Gilead Sciences; U.S. Department of Defense","keywords":"Medicine; Myeloid leukemia; IDH2; Minimal residual disease; Leukemia; Transplantation; Myeloid; Residual; Cancer research; Immunology; Mutation; Internal medicine; IDH1; Gene; Genetics; Biology","score_opus":0.019784197367617266,"score_gpt":0.2969909554947179,"score_spread":0.2772067581271006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403750561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97053516,0.0015370236,0.016605262,0.003844013,0.00049519097,0.0025509547,0.001645984,0.00080700044,0.0019794083],"genre_scores_gemma":[0.9826494,0.0017049888,0.0038800077,0.00034804599,0.0004103738,0.00043322227,0.00505964,0.0001586238,0.0053557376],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99698156,0.00009535621,0.0006290315,0.00076435204,0.0007402253,0.0007895031],"domain_scores_gemma":[0.9988773,0.00020533252,0.00005827809,0.0003517232,0.00020433428,0.00030303682],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007076035,0.00040796303,0.00054807274,0.00048087916,0.00021287132,0.00011644467,0.00018235251,0.00033371328,0.00016402341],"category_scores_gemma":[0.000026758395,0.00035739734,0.0002902978,0.00057782757,0.00012361321,0.0003239263,0.000009446193,0.00052856375,0.00015500824],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009387953,0.000121191806,0.0013011217,0.0050422885,0.0019354274,0.0060482267,0.005257258,0.00023550807,0.9308934,0.0015216309,0.01021808,0.0280379],"study_design_scores_gemma":[0.028603278,0.004834219,0.034185473,0.004625842,0.013275756,0.019099759,0.0005996912,0.0345542,0.8283288,0.0035079306,0.02589703,0.0024880616],"about_ca_topic_score_codex":0.00019463777,"about_ca_topic_score_gemma":0.0002753672,"teacher_disagreement_score":0.10256465,"about_ca_system_score_codex":0.0007790736,"about_ca_system_score_gemma":0.0012077632,"threshold_uncertainty_score":0.9998878},"labels":[],"label_agreement":null},{"id":"W4403851941","doi":"10.1038/s41375-024-02400-w","title":"Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines","year":2024,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital Maisonneuve-Rosemont; Université de Montréal; University of British Columbia; Centre hospitalier de l'Université Laval; Discovery Centre; McGill University; McGill University Health Centre; Institute for Research in Immunology and Cancer; BC Cancer Agency; Centre hospitalier universitaire de Québec; IONICS Mass Spectrometry (Canada); Centre Hospitalier Universitaire Sainte-Justine","funders":"CIHR Skin Research Training Centre; Fonds de Recherche du Québec - Santé; CHU Sainte-Justine Foundation; Cancer Research Society; Terry Fox Research Institute; Université de Montréal; Canadian Cancer Society Research Institute; Terry Fox Foundation; National Institutes of Health; Children's Hospital Foundation; Government of Canada; National Cancer Institute; Molson Foundation; Canadian Institutes of Health Research; JW and HM Goodman Family Foundation","keywords":"Leukemia; Human cell; Primary (astronomy); Cancer research; Medicine; Cell culture; Biology; Immunology; Genetics","score_opus":0.03877647701958165,"score_gpt":0.3104672159798481,"score_spread":0.27169073896026646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403851941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691286,0.0038629828,0.0018785456,0.00017421253,0.00020347456,0.0013411256,0.0001357753,0.00067700155,0.022598276],"genre_scores_gemma":[0.9764838,0.00039178642,0.007668818,0.00045818943,0.00073984836,0.0001334938,0.0007926991,0.00026258294,0.013068769],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99447757,0.00020808366,0.0014172462,0.0015087245,0.001061347,0.0013270342],"domain_scores_gemma":[0.9968507,0.00045622818,0.0002889394,0.0012191313,0.00042966678,0.0007553303],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00080784876,0.0010158647,0.0019461105,0.0010523759,0.0004056593,0.00022242009,0.0006972495,0.0007254386,0.00026121657],"category_scores_gemma":[0.000073163385,0.0009514513,0.0004914636,0.0012829748,0.0007592266,0.00040814723,0.0006681846,0.0023378846,0.00013856242],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041103803,0.000079980004,0.00081651326,0.0027478074,0.0011349191,0.0014850026,0.0026586298,0.00058608607,0.96478695,0.0014896226,0.021357697,0.00244578],"study_design_scores_gemma":[0.013801809,0.002495653,0.021493008,0.003309999,0.0023117762,0.001222398,0.0015509782,0.04363012,0.8902715,0.0005103402,0.0168902,0.002512242],"about_ca_topic_score_codex":0.0012266061,"about_ca_topic_score_gemma":0.00006820256,"teacher_disagreement_score":0.07451545,"about_ca_system_score_codex":0.007882524,"about_ca_system_score_gemma":0.004127687,"threshold_uncertainty_score":0.99996376},"labels":[],"label_agreement":null},{"id":"W4403859777","doi":"10.1182/bloodadvances.2024013890","title":"The E3 ubiquitin ligase MARCH5 promotes mitochondrial fusion and cell-cycle progression in acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculté de Médecine, Université de Genève; Fondation Medic; Ligue Genevoise Contre le Cancer; Université de Genève; Institute of Genetics; Institute of Genetics and Genomics of Geneva; Hôpitaux Universitaires de Genève","keywords":"Ubiquitin ligase; Myeloid leukemia; Ubiquitin; Cancer research; DNA ligase; mitochondrial fusion; Leukemia; Biology; Cell cycle; Cell biology; Apoptosis; Mitochondrial DNA; Immunology; Genetics; Gene","score_opus":0.007813432256689935,"score_gpt":0.2980657208130744,"score_spread":0.29025228855638446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403859777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95683473,0.035343654,0.000020063562,0.0038848,0.00035192468,0.0013450523,0.000017857898,0.00017376059,0.002028171],"genre_scores_gemma":[0.9657119,0.021234287,0.0060649207,0.00017433346,0.0011907866,0.0004237286,0.00005284338,0.00010189195,0.0050453367],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99774367,0.00011617346,0.00037151942,0.0005963473,0.00056113966,0.00061112683],"domain_scores_gemma":[0.99885976,0.00044054782,0.000061481995,0.00035925407,0.000065380525,0.00021358836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004157618,0.00025698871,0.00030657265,0.00018964356,0.00025369113,0.00017296057,0.00022175982,0.00013889988,0.000032561995],"category_scores_gemma":[0.00019627131,0.00015757562,0.00007975118,0.00049259263,0.0002890769,0.00032098702,0.00028794023,0.0007110923,0.00004450404],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013935354,0.00026074614,0.002585725,0.0010698013,0.00012350397,0.0023319507,0.0011045091,0.0000070015235,0.557079,0.0003048114,0.0021555123,0.43158388],"study_design_scores_gemma":[0.008439392,0.0022890873,0.00574167,0.0031679396,0.00041042813,0.0009129641,0.00097419036,0.0052657574,0.821991,0.00297389,0.14715995,0.0006736894],"about_ca_topic_score_codex":0.000037054226,"about_ca_topic_score_gemma":0.0000677643,"teacher_disagreement_score":0.4309102,"about_ca_system_score_codex":0.00019397691,"about_ca_system_score_gemma":0.00055318524,"threshold_uncertainty_score":0.6425747},"labels":[],"label_agreement":null},{"id":"W4403946959","doi":"10.1038/s41408-024-01166-9","title":"Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML","year":2024,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Core binding factor; Internal medicine; Genetics; Bioinformatics; Biology; Computational biology; Gene; Transcription factor","score_opus":0.054128508804982337,"score_gpt":0.3452643679558103,"score_spread":0.29113585915082796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403946959","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78605473,0.0124384165,7.0069956e-7,0.19945867,0.0010958173,0.00050119055,0.00019173279,0.000044073942,0.00021468043],"genre_scores_gemma":[0.31192726,0.13990748,0.0018504026,0.44382593,0.037780747,0.00073539466,0.00059480104,0.001855657,0.061522305],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974478,0.000103085746,0.0005476592,0.00044941987,0.0006032209,0.0008488322],"domain_scores_gemma":[0.9990248,0.00020125396,0.00020620234,0.00025371808,0.000094659976,0.00021935688],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033343938,0.00043624008,0.00079477084,0.00080618623,0.00011200571,0.00017546969,0.0002889577,0.0008198094,0.0009275916],"category_scores_gemma":[0.000082300816,0.00032140856,0.0002151404,0.00029313428,0.00012878941,0.00008021232,0.000112957656,0.0074220276,0.000050780087],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012188755,0.00015267136,0.2817398,0.00094427564,0.00618527,0.035637416,0.0022449892,0.0000041408002,0.017949153,0.0000059856934,0.6426008,0.011316663],"study_design_scores_gemma":[0.06715389,0.0027946038,0.10870132,0.0059334566,0.0025763002,0.01777148,0.0005337216,0.00019182882,0.0044619143,0.0002758612,0.7874693,0.0021362805],"about_ca_topic_score_codex":0.00018840158,"about_ca_topic_score_gemma":0.000029125244,"teacher_disagreement_score":0.47412744,"about_ca_system_score_codex":0.0017211582,"about_ca_system_score_gemma":0.0024490159,"threshold_uncertainty_score":0.9999857},"labels":[],"label_agreement":null},{"id":"W4404105468","doi":"10.1038/s41409-024-02447-4","title":"Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; U.S. Navy; Health Resources and Services Administration; Syndax Pharmaceuticals; Office of Naval Research; Jazz Pharmaceuticals; Genentech; AstraZeneca; National Institutes of Health; U.S. Department of Health and Human Services; Foundation for the National Institutes of Health; Amgen; Gilead Sciences; U.S. Department of Defense","keywords":"NPM1; IDH1; Medicine; Myeloid leukemia; Internal medicine; Oncology; Minimal residual disease; IDH2; Transplantation; Hematopoietic stem cell transplantation; Leukemia; Myeloid; Mutation; Biology; Gene; Genetics","score_opus":0.019792659004890283,"score_gpt":0.2970428500041754,"score_spread":0.2772501909992851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404105468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96984756,0.0015476055,0.017151454,0.0038986912,0.00050261494,0.0025865724,0.0016975931,0.00081867044,0.0019492392],"genre_scores_gemma":[0.98337775,0.0017107064,0.0038717194,0.00035047389,0.0004121488,0.00043472004,0.005160741,0.00015924938,0.0045225155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969824,0.00009537641,0.00062757503,0.0007644775,0.00074045855,0.00078970747],"domain_scores_gemma":[0.99887705,0.00020544324,0.00005816243,0.00035179473,0.00020433475,0.00030319],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007072168,0.00040801454,0.0005469816,0.00048004312,0.00021185918,0.0001145483,0.00018246814,0.00033366628,0.00016651851],"category_scores_gemma":[0.000026707237,0.00035743264,0.00028979994,0.00057792204,0.00012323658,0.00032385447,0.000009466302,0.00052869756,0.0001540357],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007753089,0.000099601486,0.0010886303,0.004195516,0.0016125728,0.005001881,0.0042798473,0.00019475221,0.9427323,0.0012709047,0.008687555,0.023083374],"study_design_scores_gemma":[0.024434196,0.00414125,0.025923094,0.0039640698,0.011501765,0.01672942,0.0005157151,0.029714016,0.85548973,0.0030697836,0.022360861,0.0021560912],"about_ca_topic_score_codex":0.00019386856,"about_ca_topic_score_gemma":0.00027511796,"teacher_disagreement_score":0.087242536,"about_ca_system_score_codex":0.0007731265,"about_ca_system_score_gemma":0.0012064087,"threshold_uncertainty_score":0.99988776},"labels":[],"label_agreement":null},{"id":"W4404360817","doi":"10.3324/haematol.2024.286513","title":"Germline genetics, disease, and exposure to medication influence longitudinal dynamics of clonal hematopoiesis","year":2024,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Center for Advancing Translational Sciences; National Institute for Occupational Safety and Health; National Center for Research Resources; National Institute of General Medical Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Institutes of Health; Alexander and Margaret Stewart Trust","keywords":"Germline; Genetics; Disease; Biology; Haematopoiesis; Somatic evolution in cancer; Medicine; Internal medicine; Stem cell; Cancer; Gene","score_opus":0.020920657141438388,"score_gpt":0.3146771251211383,"score_spread":0.29375646797969995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404360817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98276454,0.004277017,0.0015601129,0.010516268,0.000053230036,0.00041190482,0.00005021528,0.000094735056,0.00027200129],"genre_scores_gemma":[0.994978,0.00049335544,0.0038631056,0.00024742572,0.000053795477,0.000051906092,0.000059163438,0.000017762644,0.0002354999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985571,0.000039016388,0.00034236128,0.00038612323,0.00042934105,0.0002460752],"domain_scores_gemma":[0.9989101,0.00018511388,0.000045478017,0.00034329938,0.00016365865,0.00035232335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024690919,0.00014674127,0.00035844703,0.00018685302,0.000048013782,0.000024187573,0.00014071804,0.00010603562,0.00015522305],"category_scores_gemma":[0.00047569544,0.0001103989,0.000062578845,0.00033883005,0.00025115637,0.000054782813,0.00016948872,0.00020828542,0.00005497779],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001453969,0.00043812,0.8758575,0.008183118,0.00061600795,0.0050253654,0.000975786,0.00015499465,0.0062669083,0.06883993,0.01460352,0.01758481],"study_design_scores_gemma":[0.0006599583,0.0006468651,0.97673213,0.0009408425,0.00027986098,0.0012865798,0.0001604353,0.012418547,0.0016452755,0.003286645,0.0016697787,0.00027304806],"about_ca_topic_score_codex":0.000018006069,"about_ca_topic_score_gemma":0.000014987199,"teacher_disagreement_score":0.10087469,"about_ca_system_score_codex":0.00010546772,"about_ca_system_score_gemma":0.0002507324,"threshold_uncertainty_score":0.45019364},"labels":[],"label_agreement":null},{"id":"W4404365610","doi":"10.1002/cyto.b.22213","title":"Improved identification of clinically relevant <scp>Acute Leukemia</scp> subtypes using standardized <scp>EuroFlow</scp> panels versus non‐standardized approach","year":2024,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Hôpital Maisonneuve-Rosemont; Hôpital du Sacré-Cœur de Montréal; Centre Hospitalier Universitaire de Sherbrooke; Spinal Cord Injury BC; Université de Sherbrooke; Université de Montréal","funders":"BD Biosciences","keywords":"Immunophenotyping; Flow cytometry; Leukemia; Myeloid leukemia; Cytometry; Medicine; Acute leukemia; Myeloid; Pathology; Immunology","score_opus":0.07194693532081425,"score_gpt":0.4001930720475782,"score_spread":0.32824613672676395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404365610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9122754,0.002453236,0.07212216,0.0001626881,0.004551179,0.002728558,0.0012524939,0.00085064187,0.003603656],"genre_scores_gemma":[0.96885544,0.003984575,0.018273896,0.00036476174,0.0027650848,0.00015271113,0.00065675616,0.0004980455,0.004448753],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98198706,0.0013895042,0.0074454984,0.0032557545,0.0036178296,0.0023043265],"domain_scores_gemma":[0.9685123,0.02213259,0.0018865202,0.003391267,0.0021569831,0.0019203696],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.018592885,0.0012926343,0.004125215,0.003165399,0.00042922588,0.00055319344,0.0015758885,0.0020782175,0.00012314563],"category_scores_gemma":[0.054455422,0.0011534597,0.0025077136,0.009864481,0.0018972417,0.0007705473,0.0011071558,0.0048099877,0.00057552144],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015875243,0.0051938193,0.0812666,0.009676298,0.024397962,0.0036988454,0.0018443267,0.0003235821,0.72827184,0.00049180817,0.08367756,0.045282148],"study_design_scores_gemma":[0.113132454,0.019118298,0.0682425,0.004194755,0.019558378,0.0017866704,0.0067224028,0.2896941,0.28567073,0.0006478239,0.18896104,0.0022708683],"about_ca_topic_score_codex":0.000037264384,"about_ca_topic_score_gemma":0.0000012425231,"teacher_disagreement_score":0.4426011,"about_ca_system_score_codex":0.002368136,"about_ca_system_score_gemma":0.005470429,"threshold_uncertainty_score":0.99998254},"labels":[],"label_agreement":null},{"id":"W4404376147","doi":"10.26685/urncst.697","title":"The Implications of DNMT Mutations and the Prognostic and Therapeutic Relevance of DNMTis in AML: A Literature Review","year":2024,"lang":"en","type":"review","venue":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Relevance (law); Clinical significance; Genetics; Oncology; Psychology; Medicine; Internal medicine; Biology; Political science","score_opus":0.08199987192398275,"score_gpt":0.48587481517291314,"score_spread":0.40387494324893036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404376147","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021585233,0.88305163,0.0000010843003,0.11327877,0.00004755846,0.0013812061,0.0000075034754,0.000008057804,0.00006564264],"genre_scores_gemma":[0.041690126,0.95784277,0.00009697551,0.00008336656,0.000038987386,0.0000903698,0.0000023355474,0.000012426077,0.00014267596],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99597514,0.00079459127,0.0012745303,0.0005589483,0.0007655399,0.0006312772],"domain_scores_gemma":[0.9917909,0.006389505,0.00033835584,0.00040632664,0.0008687409,0.00020619323],"candidate_categories":["metaresearch","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.013914986,0.00022648933,0.0012068858,0.0010771799,0.00051008625,0.0001651208,0.0006382094,0.00035236703,0.0000011357768],"category_scores_gemma":[0.0105933575,0.00009582423,0.00012713778,0.006345278,0.013065016,0.00012248234,0.0006347057,0.006300864,0.0000014215759],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044710796,0.000058930862,0.0009020846,0.0063626464,0.000093357245,0.00006714682,0.000031090436,9.34015e-9,0.00000661178,0.01922563,0.00021885269,0.9729889],"study_design_scores_gemma":[0.00422129,0.002008745,0.0051366393,0.23217683,0.0013795703,0.013657041,0.00057458703,0.0006439096,0.000004233104,0.52735436,0.21235889,0.00048392065],"about_ca_topic_score_codex":0.00001584631,"about_ca_topic_score_gemma":0.0000703276,"teacher_disagreement_score":0.97250503,"about_ca_system_score_codex":0.00016445445,"about_ca_system_score_gemma":0.0017529139,"threshold_uncertainty_score":0.9977408},"labels":[],"label_agreement":null},{"id":"W4404455557","doi":"10.1111/bjh.19895","title":"Somatic co‐alteration signatures are prognostic in high‐grade <scp><i>TP53</i></scp>‐mutated myeloid neoplasms","year":2024,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Hazard ratio; Proportional hazards model; Myeloid; Somatic cell; Internal medicine; Cohort; Medicine; Oncology; Subgroup analysis; Gene signature; Survival analysis; Gastroenterology; Gene; Biology; Genetics; Confidence interval; Gene expression","score_opus":0.013073356458643819,"score_gpt":0.28831015895985046,"score_spread":0.27523680250120663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980531,0.014967016,0.00053571246,0.0024372467,0.00059106626,0.0005843246,0.00002575144,0.00008809764,0.00023979746],"genre_scores_gemma":[0.996293,0.001113223,0.0013131716,0.00042707476,0.00032684384,0.00003062672,0.000060539238,0.000071042894,0.00036445883],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9968071,0.00040053454,0.0011257025,0.00035614113,0.00065652526,0.0006540099],"domain_scores_gemma":[0.9975241,0.0013175912,0.00033764084,0.0001845667,0.00033768575,0.0002984446],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007960326,0.00025365487,0.0010687824,0.000839635,0.00009244175,0.00021585911,0.00027744268,0.00036619336,0.000097612065],"category_scores_gemma":[0.0026185617,0.00025183774,0.00019521038,0.00069905864,0.00021131424,0.00034484934,0.00005981436,0.0018624982,0.00010990123],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017945823,0.0007256878,0.022027446,0.0032677888,0.00072554994,0.84186924,0.0014073355,0.00043153632,0.020636084,0.0007078359,0.09735904,0.010663032],"study_design_scores_gemma":[0.0063387607,0.0011598013,0.059804004,0.009171137,0.0003801308,0.8884544,0.00122011,0.0070739514,0.018056244,0.003646186,0.0044489284,0.00024637836],"about_ca_topic_score_codex":0.00009398823,"about_ca_topic_score_gemma":0.00014605167,"teacher_disagreement_score":0.09291011,"about_ca_system_score_codex":0.00032896822,"about_ca_system_score_gemma":0.0008377854,"threshold_uncertainty_score":0.9999934},"labels":[],"label_agreement":null},{"id":"W4404498748","doi":"10.1002/cam4.70401","title":"A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in <scp>AML</scp>","year":2024,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Medical Research Council; Medical Research Council; Cancer Science Institute of Singapore, National University of Singapore; Networks of Centres of Excellence of Canada; National University of Singapore","keywords":"Medicine; Precision medicine; Oncology; Biomarker; Combination therapy; Clinical trial; Drug resistance; Internal medicine; Drug development; Drug; Pharmacology; Pathology","score_opus":0.05824361180376735,"score_gpt":0.3555689139625882,"score_spread":0.29732530215882086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404498748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7565281,0.10192655,0.011591806,0.08045781,0.028187532,0.008118348,0.00026320035,0.0010397705,0.011886916],"genre_scores_gemma":[0.9728678,0.0029130524,0.00009150858,0.0021560737,0.010638549,0.0013315781,0.00038636068,0.00014616585,0.009468927],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99630564,0.00014471426,0.0008185271,0.0007817057,0.0012613377,0.0006880416],"domain_scores_gemma":[0.99429643,0.004340314,0.00009899978,0.0004883608,0.00038584118,0.00039003434],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00329651,0.0003806252,0.0007842973,0.001067587,0.00013056671,0.000020354926,0.00020729375,0.0003463851,0.0013347041],"category_scores_gemma":[0.0034626154,0.000262701,0.00012832014,0.0013390674,0.00050900003,0.00022974859,0.00006237049,0.0009533831,0.00005478056],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019383008,0.0002479048,0.0024358304,0.0014952539,0.00066700234,0.00033872257,0.0067082373,0.00005760572,0.11105231,0.0059601427,0.70783335,0.14382064],"study_design_scores_gemma":[0.031229673,0.008191835,0.03870125,0.0056453003,0.0006029782,0.00029203994,0.002426717,0.018644094,0.002985126,0.008384428,0.8827142,0.00018237374],"about_ca_topic_score_codex":0.00015066362,"about_ca_topic_score_gemma":0.000021324044,"teacher_disagreement_score":0.2163397,"about_ca_system_score_codex":0.001945039,"about_ca_system_score_gemma":0.0014490577,"threshold_uncertainty_score":0.99998254},"labels":[],"label_agreement":null},{"id":"W4404525593","doi":"10.1097/md.0000000000040540","title":"Impact of cytotoxic therapy on clonal hematopoiesis and myeloid neoplasms in breast cancer patients","year":2024,"lang":"en","type":"article","venue":"Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact","funders":"Ministry of Science and ICT, South Korea; Korea Institute of Radiological and Medical Sciences; National Research Foundation of Korea; National Research Foundation","keywords":"Medicine; Haematopoiesis; Breast cancer; Cytotoxic T cell; Bone marrow; Myeloid; Cancer; Genotype; Internal medicine; Oncology; Gene; Gastroenterology; Stem cell; Genetics; Biology","score_opus":0.01734337340915128,"score_gpt":0.3407735258244989,"score_spread":0.3234301524153476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404525593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98984635,0.0019384383,0.0000030539259,0.0069769314,0.0001242246,0.0004332352,0.00006713628,0.00003498257,0.0005756215],"genre_scores_gemma":[0.9970159,0.0019430199,0.000019550067,0.00038857842,0.00026005684,0.000039342984,0.000031984804,0.000035720706,0.00026586372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984589,0.000045487417,0.00032243677,0.0003116726,0.0005528824,0.0003085728],"domain_scores_gemma":[0.9992319,0.00021856649,0.00004122876,0.00021636546,0.000100400655,0.00019153903],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002947336,0.00019748317,0.00048271858,0.00049127964,0.000022089615,0.0000071204345,0.00008410183,0.00009551485,0.0011431781],"category_scores_gemma":[0.00007891006,0.00011669834,0.000072255934,0.0006010332,0.0002316881,0.00005962424,0.000035414752,0.0003801347,0.000017246064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003202554,0.0005236148,0.8532385,0.0006245213,0.00043335304,0.00030423456,0.0032891687,0.000009931609,0.052128617,0.00012911962,0.026722403,0.059393976],"study_design_scores_gemma":[0.005177739,0.0019155206,0.98810023,0.0015195798,0.000030186025,0.000108567925,0.000061715335,0.0005857427,0.0017500278,0.000059586167,0.0005842203,0.000106891326],"about_ca_topic_score_codex":0.0016738619,"about_ca_topic_score_gemma":0.000027906031,"teacher_disagreement_score":0.13486171,"about_ca_system_score_codex":0.00047607155,"about_ca_system_score_gemma":0.0003563264,"threshold_uncertainty_score":0.9997699},"labels":[],"label_agreement":null},{"id":"W4404578574","doi":"10.1007/s00277-024-06096-x","title":"Evaluation of infectious complications in patients with myelodysplastic syndromes: a prospective cohort study from the Canadian MDS registry","year":2024,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; McGill University Health Centre; McGill University; Jewish General Hospital; Dr. Georges-L.-Dumont University Hospital Centre; St. Paul's Hospital; Alberta Hospital Edmonton; University of British Columbia; University of Manitoba; Juravinski Cancer Centre; Dalhousie University; Princess Margaret Cancer Centre; Vancouver General Hospital; University of Alberta Hospital; Ottawa Hospital; CancerCare Manitoba; Saskatchewan Cancer Agency; Université Laval","funders":"University of Manitoba","keywords":"Medicine; Internal medicine; Neutropenia; Myelodysplastic syndromes; Prospective cohort study; Cohort; Multivariate analysis; Hematology; Cohort study; Absolute neutrophil count; Chemotherapy","score_opus":0.049579619205047096,"score_gpt":0.3620163353801278,"score_spread":0.3124367161750807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404578574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99351484,0.0003217767,0.000013364533,0.0016631815,0.00004247068,0.0022287914,0.000055178218,0.000015061908,0.002145333],"genre_scores_gemma":[0.9995167,0.000008590864,0.00002076531,0.000080629725,0.000009428172,0.00026921704,0.000069408015,0.000014615071,0.000010597037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983929,0.00022519035,0.00030821434,0.00026584166,0.00060522935,0.00020263028],"domain_scores_gemma":[0.99818,0.00037558383,0.000085495754,0.00042753306,0.0008538614,0.00007755461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007879722,0.00010141401,0.0003531817,0.00025563955,0.000052688545,0.000009258191,0.0001240269,0.000080929734,0.00006954413],"category_scores_gemma":[0.00073160575,0.000067833935,0.000032069016,0.0005397304,0.00020478498,0.000045124118,0.000030527943,0.00027477686,0.0000145809245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000658136,0.00029669233,0.9966369,0.00004704613,0.0005009791,0.000025943298,0.0008127705,0.000025297233,0.00000722624,0.00057173485,0.0007172833,0.00029229966],"study_design_scores_gemma":[0.001267283,0.0006380449,0.9955436,0.0002068926,0.00023874328,0.0000430175,0.00030297655,0.000791027,0.00009956499,0.00079097616,0.000022846114,0.00005503231],"about_ca_topic_score_codex":0.08725435,"about_ca_topic_score_gemma":0.16635433,"teacher_disagreement_score":0.079099976,"about_ca_system_score_codex":0.00023423006,"about_ca_system_score_gemma":0.0018871748,"threshold_uncertainty_score":0.9188237},"labels":[],"label_agreement":null},{"id":"W4404637258","doi":"10.1002/jha2.1055","title":"Impact of secondary‐type mutations in acute myeloid leukemia with CEBPA mutation","year":2024,"lang":"en","type":"article","venue":"eJHaem","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"CEBPA; NPM1; Myeloid leukemia; Mutation; Oncology; Cancer research; Medicine; Leukemia; Gene mutation; Biology; Genetics; Internal medicine; Gene; Karyotype","score_opus":0.016944622660782407,"score_gpt":0.3350985587325181,"score_spread":0.3181539360717357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404637258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99202096,0.00043522954,0.00029995627,0.0005185206,0.00008154802,0.00043822764,0.00004176578,0.00009133457,0.0060724462],"genre_scores_gemma":[0.9959635,0.000059807444,0.0012103943,0.00005226467,0.000083779814,0.00002613619,0.00021406486,0.000046482233,0.0023435734],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99873614,0.000047349095,0.00028306036,0.00029214707,0.00032969465,0.00031163325],"domain_scores_gemma":[0.99923235,0.00014956288,0.00004340575,0.00027202073,0.00017242473,0.00013025105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021576666,0.00016211296,0.00029907987,0.0004938829,0.000033203814,0.000029850207,0.000096490236,0.0001032765,0.00071509625],"category_scores_gemma":[0.00008038062,0.000118697004,0.000097146934,0.0011889423,0.00013380317,0.00021250977,0.000034163288,0.0005517942,0.00018926922],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0096086105,0.0009276076,0.13423756,0.0034644648,0.008168544,0.03318375,0.04727897,0.007005475,0.35566688,0.005090224,0.060735516,0.3346324],"study_design_scores_gemma":[0.009110516,0.00618326,0.9041871,0.0012884949,0.00068402075,0.0037234207,0.0018087481,0.03349699,0.034578826,0.0009843699,0.0032435085,0.000710752],"about_ca_topic_score_codex":0.00067437394,"about_ca_topic_score_gemma":0.00012844671,"teacher_disagreement_score":0.76994956,"about_ca_system_score_codex":0.0012744488,"about_ca_system_score_gemma":0.0032803048,"threshold_uncertainty_score":0.78298026},"labels":[],"label_agreement":null},{"id":"W4404656377","doi":"","title":"Alteration of the tumor suppressor PDCD4 in acute myeloid leukemias","year":2024,"lang":"en","type":"dissertation","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fondation Toulouse Cancer Santé; Région Occitanie Pyrénées-Méditerranée; Société Française d'Hématologie; Ministère de l'Enseignement Supérieur et de la Recherche; Fondation pour la Recherche Médicale; Institut National de la Santé et de la Recherche Médicale; Genome Canada","keywords":"Cancer research; Suppressor; Myeloid leukemia; Medicine; Myeloid; Myeloid leukaemia; Internal medicine; Cancer","score_opus":0.011140502385757162,"score_gpt":0.26770698267999254,"score_spread":0.2565664802942354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404656377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9292693,0.0015184919,0.00026632435,0.007542728,0.0004602843,0.0013372466,0.00009584511,0.00011860386,0.05939115],"genre_scores_gemma":[0.8698677,0.00052204495,0.002688191,0.00015186108,0.000048977727,0.00017615648,0.0021728566,0.00012277596,0.12424945],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9949447,0.002259468,0.00081225665,0.0007039541,0.000857538,0.00042210158],"domain_scores_gemma":[0.9949682,0.0008175706,0.00042490612,0.0018765192,0.0017625073,0.00015032456],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031001666,0.00036726528,0.000588279,0.000462042,0.00016498807,0.0001520002,0.00093974493,0.0003394584,0.00024520236],"category_scores_gemma":[0.0016283016,0.00029817826,0.00032800846,0.0011133589,0.0001952529,0.00014010484,0.00030132983,0.001344655,0.00009353807],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010003785,0.0020309128,0.0056691086,0.006373591,0.0013087804,0.00032745386,0.08631172,0.00006834277,0.7606712,0.062616594,0.034210246,0.039411653],"study_design_scores_gemma":[0.002094227,0.0000026852017,0.024256483,0.009463793,0.00040206808,0.00009267869,0.000926649,0.01167819,0.93714994,0.001192403,0.012249657,0.00049123965],"about_ca_topic_score_codex":0.0013411109,"about_ca_topic_score_gemma":0.004057941,"teacher_disagreement_score":0.17647871,"about_ca_system_score_codex":0.0006213442,"about_ca_system_score_gemma":0.0016282168,"threshold_uncertainty_score":0.999947},"labels":[],"label_agreement":null},{"id":"W4404719809","doi":"10.1038/s41408-024-01187-4","title":"RSK1 dependency in FLT3-ITD acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Edward P. Evans Foundation; National Heart, Lung, and Blood Institute; McGill University; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services; MPN Research Foundation; Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Myeloid leukemia; Cancer research; Fms-Like Tyrosine Kinase 3; Leukemia; Biology; Cycloheximide; Immunology; Cell culture; Mutation; Genetics; Gene","score_opus":0.017955739931584908,"score_gpt":0.3294307861238656,"score_spread":0.3114750461922807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404719809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9419936,0.039081875,0.0002280301,0.007398443,0.001389929,0.00042429485,0.000035253823,0.00014919897,0.009299365],"genre_scores_gemma":[0.96077406,0.020328682,0.0017085321,0.0009970713,0.0036332295,0.00009373667,0.000012146184,0.00013244827,0.012320077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99719095,0.00009624303,0.0005619548,0.0004361594,0.00089066254,0.00082401],"domain_scores_gemma":[0.99885374,0.00009070863,0.00007319499,0.0003237333,0.00016492889,0.0004936781],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00075197616,0.0002742445,0.0004519559,0.000637037,0.00013054932,0.00021237669,0.0003462133,0.00021558134,0.0022243862],"category_scores_gemma":[0.000089086876,0.00022077895,0.00022806939,0.00085323676,0.00008656381,0.00034412494,0.000119267665,0.0025811067,0.00027470294],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017672627,0.0007417989,0.09635864,0.0013203358,0.006250406,0.10106592,0.0038768544,0.00025306962,0.14355871,0.001207007,0.14861959,0.4949804],"study_design_scores_gemma":[0.051729217,0.005285122,0.14068848,0.014613388,0.008568903,0.17240424,0.0016576198,0.017146168,0.13377975,0.009044513,0.44143865,0.003643947],"about_ca_topic_score_codex":0.00040610245,"about_ca_topic_score_gemma":0.00021681527,"teacher_disagreement_score":0.49133644,"about_ca_system_score_codex":0.002251524,"about_ca_system_score_gemma":0.0055455947,"threshold_uncertainty_score":0.99972},"labels":[],"label_agreement":null},{"id":"W4404813541","doi":"10.1002/hem3.70001","title":"Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma","year":2024,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Veterinärmedizinische Universität Wien; Universität Wien; Christian Doppler Forschungsgesellschaft; Vienna Science and Technology Fund; Austrian Science Fund; Medizinische Universität Wien; European Commission; Siemens Medical Solutions USA","keywords":"Myeloid leukemia; Dual (grammatical number); Lymphoma; Block (permutation group theory); Cancer research; Acute leukemia; Leukemia; Medicine; Immunology; Mathematics","score_opus":0.011697156603415188,"score_gpt":0.2629680298935974,"score_spread":0.2512708732901822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404813541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96131426,0.023294086,0.00007687108,0.0015832708,0.0009494402,0.0009406935,0.000028355864,0.0004637429,0.0113492925],"genre_scores_gemma":[0.9583788,0.0020378404,0.0021197759,0.0003304026,0.00064063584,0.00006198692,0.00006455243,0.00015318127,0.036212847],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970646,0.000104935636,0.00035670886,0.00091520476,0.00070038094,0.00085818145],"domain_scores_gemma":[0.99850714,0.00038769786,0.000050023627,0.00048947707,0.0000992352,0.00046642256],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002765403,0.0004752561,0.00056314305,0.0001806985,0.00017593642,0.00018022444,0.00016420151,0.0002796818,0.00041466224],"category_scores_gemma":[0.000046250003,0.00038568454,0.00020866997,0.0006614935,0.00032237888,0.00022947819,0.00021202619,0.00082334393,0.000719256],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023974,0.00042112338,0.0026558186,0.0038248228,0.002097105,0.022093361,0.004521156,0.000018061937,0.18255626,0.0023262443,0.5981347,0.17895396],"study_design_scores_gemma":[0.025509777,0.0025317527,0.051226668,0.0019654597,0.0011882012,0.012847402,0.0050097755,0.011307855,0.14198859,0.0007571976,0.7431186,0.0025487323],"about_ca_topic_score_codex":0.00010949542,"about_ca_topic_score_gemma":0.000018078053,"teacher_disagreement_score":0.17640522,"about_ca_system_score_codex":0.0015790443,"about_ca_system_score_gemma":0.0010277528,"threshold_uncertainty_score":0.9998595},"labels":[],"label_agreement":null},{"id":"W4404856681","doi":"10.1186/s12920-024-02039-7","title":"ASXL1 truncating variants in BOS and myeloid leukemia drive shared disruption of Wnt-signaling pathways but have differential isoform usage of RUNX3","year":2024,"lang":"en","type":"article","venue":"BMC Medical Genomics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"National Institute of General Medical Sciences; National Human Genome Research Institute; Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Epilepsy Research Program of the Ontario Brain Institute; NIH Office of the Director; National Heart, Lung, and Blood Institute; W. M. Keck Foundation","keywords":"Biology; Genetics; Myeloid leukemia; Epigenetics; Wnt signaling pathway; Transcriptome; DNA methylation; Cancer research; Gene; Gene expression","score_opus":0.03306656954252691,"score_gpt":0.2949023550186909,"score_spread":0.261835785476164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404856681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876705,0.0005934936,0.010361755,0.00009869452,0.00018181685,0.00058610906,0.00010471478,0.000042178777,0.00036075254],"genre_scores_gemma":[0.99502385,0.0005080807,0.0036125933,0.000057942096,0.00037941235,0.000032059463,0.00014166135,0.00005511511,0.00018928647],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9969343,0.00013246259,0.0009795662,0.000513706,0.00093178445,0.00050820666],"domain_scores_gemma":[0.9981598,0.00084713864,0.00016613935,0.00031450923,0.00009851302,0.00041388907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001208312,0.00025334413,0.00070470164,0.00035819912,0.000053243635,0.00003673869,0.00025801544,0.00038869295,0.00042674172],"category_scores_gemma":[0.0015050614,0.00021610034,0.00014672965,0.00027739443,0.0003143878,0.00011982284,0.00032072546,0.00079666043,0.000013469678],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013558844,0.00026844515,0.019964652,0.0051816846,0.00028666208,0.00051708537,0.008841186,0.00007043513,0.8977953,0.0016883187,0.0001775089,0.06385284],"study_design_scores_gemma":[0.012535934,0.0011863487,0.17750119,0.0064164824,0.0004730448,0.0005151659,0.0064387824,0.68851316,0.103942096,0.0013487902,0.00026567074,0.0008633505],"about_ca_topic_score_codex":0.00032704012,"about_ca_topic_score_gemma":0.00013670043,"teacher_disagreement_score":0.7938532,"about_ca_system_score_codex":0.0008852266,"about_ca_system_score_gemma":0.002828868,"threshold_uncertainty_score":0.8812316},"labels":[],"label_agreement":null},{"id":"W4404910207","doi":"10.1111/bjh.19924","title":"Clinical perspectives on post‐induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation","year":2024,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Maintenance therapy; Transplantation; Internal medicine; Clinical trial; Oncology; Stem cell; Midostaurin; Sorafenib; Myeloid leukemia; Intensive care medicine; Chemotherapy","score_opus":0.03584553251121494,"score_gpt":0.3575606456003801,"score_spread":0.32171511308916517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404910207","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30916294,0.6881681,0.000054566863,0.0002657827,0.00028303606,0.0019170942,0.0000874303,0.00001606833,0.00004495958],"genre_scores_gemma":[0.0097670145,0.988839,0.00052469474,0.00010088397,0.00018584049,0.00010050302,0.00011517363,0.00013461921,0.00023230498],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9952947,0.0006745865,0.0021617666,0.0007353926,0.0005529007,0.0005806781],"domain_scores_gemma":[0.99719423,0.00041075316,0.0011849656,0.00028897452,0.000702973,0.00021810204],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012785988,0.000489294,0.003889221,0.0011282499,0.000059670485,0.000056458673,0.00035395968,0.0008294808,0.000014124432],"category_scores_gemma":[0.00014073441,0.0003709991,0.0006606789,0.0006323509,0.00018723153,0.00016752638,0.00003565099,0.0025787817,0.000012876296],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008547653,0.0015770654,0.0027882173,0.034381844,0.0010921054,0.11677032,0.00096523,0.000008271516,0.000007747793,0.000075752,0.00510769,0.82867813],"study_design_scores_gemma":[0.036990356,0.0132423695,0.011189487,0.43542686,0.004018336,0.4170488,0.0025285226,0.000025739366,0.000070781156,0.00018696628,0.07771614,0.0015556085],"about_ca_topic_score_codex":0.000032671545,"about_ca_topic_score_gemma":0.00005807275,"teacher_disagreement_score":0.8271225,"about_ca_system_score_codex":0.000983115,"about_ca_system_score_gemma":0.0015820711,"threshold_uncertainty_score":0.9998742},"labels":[],"label_agreement":null},{"id":"W4405034785","doi":"10.1182/blood-2024-208884","title":"What Is the Prognostic Relevance of Responses Less Than a CR(Sub-CR) to Initial AML Treatment?","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Context (archaeology); Population; Logistic regression; Log-rank test; Proportional hazards model","score_opus":0.04269977279992594,"score_gpt":0.34940184623842596,"score_spread":0.30670207343850003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405034785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97887146,0.0063103493,0.000014373473,0.0125956405,0.00022596947,0.0010590353,0.00005228637,0.00009112516,0.0007797566],"genre_scores_gemma":[0.9930644,0.0017218265,0.00025965675,0.00064753596,0.00038834143,0.00020689574,0.000011710342,0.000047458678,0.0036521568],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984492,0.00013160399,0.00024538432,0.0003721417,0.0004473194,0.00035433954],"domain_scores_gemma":[0.9979629,0.0011743678,0.000031684296,0.0005663121,0.00011767516,0.00014705319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028909382,0.00017980502,0.00028402597,0.00017610478,0.00006898038,0.00010588535,0.00019864587,0.00011327208,0.00006944707],"category_scores_gemma":[0.0006747274,0.0001093931,0.00012955141,0.0005340862,0.00014394447,0.00014668764,0.000102479804,0.00030858352,0.00021176938],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011916787,0.0060044522,0.04670779,0.0028894285,0.0052354373,0.014151553,0.042493895,0.0000068750983,0.30840042,0.0026800528,0.028200269,0.53131306],"study_design_scores_gemma":[0.0068023507,0.006199555,0.03514254,0.003300236,0.0015029699,0.0011961339,0.0036686356,0.0003062508,0.8863264,0.0005110011,0.054620072,0.000423905],"about_ca_topic_score_codex":0.00008632491,"about_ca_topic_score_gemma":0.00004953489,"teacher_disagreement_score":0.5779259,"about_ca_system_score_codex":0.00010656012,"about_ca_system_score_gemma":0.0006692769,"threshold_uncertainty_score":0.4460921},"labels":[],"label_agreement":null},{"id":"W4405034860","doi":"10.1182/blood-2024-205584","title":"Clonal Hematopoiesis Is Associated with Changes to T Cell Contexture in Solid Tumours","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Hematologic Neoplasms; Haematopoiesis; Biology; Cancer research; Immunology; Genetics; Stem cell; Cancer","score_opus":0.015521683364364198,"score_gpt":0.28692768258107243,"score_spread":0.2714059992167082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405034860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764471,0.0011977343,0.000011892226,0.016915822,0.000050068822,0.0004942448,0.00007901308,0.0001301833,0.0046739075],"genre_scores_gemma":[0.9898563,0.00003810096,0.00021241687,0.0026674084,0.00016744452,0.00007071658,0.00004239221,0.000050434104,0.006894785],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986111,0.000038398033,0.00014253499,0.00034092623,0.00043718968,0.00042984713],"domain_scores_gemma":[0.99933815,0.00013194852,0.000021492771,0.00021195391,0.00009476193,0.00020171296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025018014,0.00016430361,0.00032961206,0.0002706076,0.00003201529,0.00004382897,0.0001188838,0.00012986096,0.00027207017],"category_scores_gemma":[0.00012050519,0.00012320299,0.000049365048,0.00067671837,0.000042232372,0.000039336333,0.00006632934,0.0004442688,0.000207167],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015253354,0.004913369,0.08770489,0.002527074,0.002337066,0.034092627,0.033643074,0.000012976428,0.22076176,0.0006595515,0.60750663,0.0043156547],"study_design_scores_gemma":[0.022251388,0.004323226,0.06757672,0.005658437,0.0011731758,0.0012898394,0.0039167795,0.0008428191,0.8456083,0.00020294127,0.045844123,0.0013122705],"about_ca_topic_score_codex":0.00009041307,"about_ca_topic_score_gemma":0.00036685792,"teacher_disagreement_score":0.6248465,"about_ca_system_score_codex":0.00019037644,"about_ca_system_score_gemma":0.0003489496,"threshold_uncertainty_score":0.50240725},"labels":[],"label_agreement":null},{"id":"W4405035165","doi":"10.1182/blood-2024-200797","title":"Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Placebo; Medicine; Anemia; Clinical trial; Double blind; Internal medicine; Alternative medicine; Pathology","score_opus":0.03583961702305943,"score_gpt":0.3624273305544276,"score_spread":0.3265877135313682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405035165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714348,0.00059997773,0.000052656378,0.0005038434,0.00016177414,0.027106948,0.00009961927,0.000030020265,0.000010375245],"genre_scores_gemma":[0.9934111,0.0010851166,0.00007952841,0.000020067326,0.0001827816,0.0050458587,0.000019364032,0.00005991686,0.00009622029],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99628687,0.00044414675,0.0011583958,0.00066051545,0.0008168373,0.00063321047],"domain_scores_gemma":[0.9947862,0.004063851,0.00014159779,0.00060401304,0.00018692079,0.00021739434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018033335,0.0004075012,0.0011705862,0.00041308315,0.00008840549,0.000056942194,0.00027557052,0.00011716967,0.00005671561],"category_scores_gemma":[0.0006296753,0.00018256328,0.00015770397,0.0007561579,0.00023404024,0.00007692401,0.00006619148,0.0003771492,0.0000047694703],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9422341,0.015237696,0.004954627,0.00037903304,0.001301453,0.00035507255,0.021749353,0.00027680153,0.0006917467,0.000003253017,0.00001381375,0.012803054],"study_design_scores_gemma":[0.932656,0.044959143,0.0039407564,0.0013038845,0.0034257642,0.000033131153,0.0041318503,0.005884114,0.0034494551,0.0000041519106,0.000011918285,0.00019985386],"about_ca_topic_score_codex":0.00052246696,"about_ca_topic_score_gemma":0.006223445,"teacher_disagreement_score":0.029721446,"about_ca_system_score_codex":0.00024522407,"about_ca_system_score_gemma":0.0010458364,"threshold_uncertainty_score":0.74447143},"labels":[],"label_agreement":null},{"id":"W4405038017","doi":"10.1182/blood-2024-206948","title":"Impact of Luspatercept on Healthcare Resource Use (HCRU) Among Patients with Lower-Risk, Myelodysplastic Syndromes (LR-MDS): A Medical Record Review in Canada, Germany, and Spain","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Health care; Family medicine; Gerontology; Internal medicine; Political science; Bone marrow","score_opus":0.011846007580593235,"score_gpt":0.27380277338951664,"score_spread":0.2619567658089234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940908,0.003417493,0.0000029518453,0.0012189987,0.000050801107,0.00096163835,0.00013168808,0.000032750624,0.000092857634],"genre_scores_gemma":[0.9953883,0.0037330803,0.00005045227,0.0004061434,0.000048466252,0.000039038434,0.00006665099,0.000060943144,0.00020690665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969852,0.00034567705,0.00048770366,0.0005072774,0.001132203,0.00054192444],"domain_scores_gemma":[0.99798715,0.0007424839,0.000111338784,0.00045662795,0.000110524685,0.0005918982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058306917,0.00028355597,0.0007169124,0.00027111836,0.000043199434,0.000022141865,0.00016296099,0.00013381819,0.0002689847],"category_scores_gemma":[0.0011687683,0.00019102183,0.00008213313,0.0005717854,0.00013505576,0.00009236895,0.00010956546,0.0010044972,0.000010138679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038913338,0.0002605012,0.9721042,0.0035895517,0.00024963397,0.002453938,0.00014610113,0.0000018543907,0.0000034081575,0.00000201904,0.006722603,0.014077082],"study_design_scores_gemma":[0.0029702478,0.002394289,0.972813,0.019791003,0.0002141779,0.00014450643,0.000026749176,0.00040476504,0.000005232003,0.0000014507822,0.0010416165,0.00019296473],"about_ca_topic_score_codex":0.6335617,"about_ca_topic_score_gemma":0.49880236,"teacher_disagreement_score":0.13475928,"about_ca_system_score_codex":0.0009042772,"about_ca_system_score_gemma":0.0035412686,"threshold_uncertainty_score":0.7789644},"labels":[],"label_agreement":null},{"id":"W4405038162","doi":"10.1182/blood-2024-209476","title":"FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Venetoclax; Flag (linear algebra); Myeloid leukemia; Refractory (planetary science); Medicine; Oncology; Cancer; Internal medicine; Center (category theory); Leukemia; Gerontology; Chronic lymphocytic leukemia; Biology","score_opus":0.015883203395651534,"score_gpt":0.29832851439194685,"score_spread":0.28244531099629533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99198115,0.0042418423,0.000026188289,0.001589989,0.00041151143,0.0010413498,0.000092821836,0.00014606223,0.00046910276],"genre_scores_gemma":[0.98224884,0.012471813,0.00032013844,0.00065437047,0.00051614473,0.00064248615,0.000035257883,0.000086133434,0.003024823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973593,0.00018502898,0.00042527492,0.0007459725,0.00060490135,0.0006795517],"domain_scores_gemma":[0.998384,0.0005216555,0.00008541506,0.0006786976,0.00007602689,0.0002542114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004134427,0.0003264331,0.00046322474,0.00020549688,0.00015017939,0.00012872893,0.0003999737,0.0002596117,0.000290283],"category_scores_gemma":[0.00026884075,0.00020052813,0.00008070517,0.00066921214,0.00031377823,0.00024749676,0.00031497178,0.0013488345,0.000051231043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011616948,0.0013812218,0.59129673,0.003174614,0.0045878394,0.056101996,0.075847164,0.00036821282,0.05093184,0.0009428477,0.060644858,0.14310575],"study_design_scores_gemma":[0.07197023,0.0027946346,0.62755007,0.0047882753,0.002020655,0.0017440056,0.0051713185,0.009007955,0.03580026,0.0002760058,0.23684719,0.0020293968],"about_ca_topic_score_codex":0.0044493857,"about_ca_topic_score_gemma":0.0015069802,"teacher_disagreement_score":0.17620234,"about_ca_system_score_codex":0.0017912721,"about_ca_system_score_gemma":0.0025548553,"threshold_uncertainty_score":0.81772995},"labels":[],"label_agreement":null},{"id":"W4405038418","doi":"10.1182/blood-2024-207342","title":"Costs of Healthcare Resource Utilization in the Management of Patients with Higher-Risk Myelodysplastic Syndrome in Canada","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Université Laval; Ottawa Hospital","funders":"AbbVie Canada","keywords":"Medicine; Myelodysplastic syndromes; Health care; Intensive care medicine; Internal medicine","score_opus":0.01378936709395237,"score_gpt":0.25594640395800916,"score_spread":0.2421570368640568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99750763,0.0005584055,0.000007726109,0.00062427233,0.000027426322,0.0006322175,0.000051588133,0.000006570632,0.00058418995],"genre_scores_gemma":[0.9996155,0.00007306322,0.000076640856,0.00005564301,0.0000064031897,0.00002707061,0.00005805644,0.00001486316,0.0000727746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873257,0.00009927973,0.00025405426,0.0001687274,0.00055785716,0.00018752509],"domain_scores_gemma":[0.9994995,0.00012011711,0.000049737653,0.00023736902,0.00005051487,0.00004276349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021456393,0.00008179664,0.00017852102,0.0001533011,0.00001251114,0.0000041310914,0.0001184858,0.000031204134,0.000017490209],"category_scores_gemma":[0.000016593587,0.00005348652,0.00001386814,0.00076389173,0.000029432977,0.000023598739,0.000037711845,0.00022543003,0.0000013717433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034786898,0.00048018817,0.9845524,0.0031333768,0.00022700398,0.0015008608,0.0005943628,0.00010890834,0.000008519457,0.0010482518,0.0004315165,0.0075667575],"study_design_scores_gemma":[0.0026377654,0.0003485006,0.9940904,0.0013678299,0.000097140735,0.000011498732,0.00052620994,0.00020576241,0.00006293345,0.0000117824575,0.00058932515,0.00005084526],"about_ca_topic_score_codex":0.32325396,"about_ca_topic_score_gemma":0.29781285,"teacher_disagreement_score":0.025441093,"about_ca_system_score_codex":0.00047266384,"about_ca_system_score_gemma":0.0005665148,"threshold_uncertainty_score":0.7150002},"labels":[],"label_agreement":null},{"id":"W4405039859","doi":"10.1182/blood-2024-204004","title":"Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; London Health Sciences Centre; University Health Network; Windsor Regional Hospital; Health Sciences Centre; Juravinski Cancer Centre; Jewish General Hospital; Sunnybrook Health Science Centre; University of Alberta; University of Calgary; Vancouver General Hospital; Princess Margaret Cancer Centre; McGill University","funders":"","keywords":"Flag (linear algebra); Propensity score matching; Myeloid leukemia; Medicine; Internal medicine; Matching (statistics); Oncology; Mathematics; Pathology","score_opus":0.03351969617593854,"score_gpt":0.3171465489825213,"score_spread":0.2836268528065828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99285173,0.00031244816,0.0015223384,0.00051720924,0.000038435835,0.0015544416,0.000047235528,0.0002206897,0.0029354556],"genre_scores_gemma":[0.9890737,0.000066979606,0.007542833,0.00017658362,0.00015481153,0.0004203417,0.0001626886,0.00008676563,0.0023152786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970989,0.0000757059,0.0004907354,0.00093253446,0.00067192235,0.0007301693],"domain_scores_gemma":[0.9985355,0.00019429436,0.00010163546,0.00070838846,0.00018218525,0.00027800174],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004925937,0.00037551406,0.0010124098,0.000902378,0.00015575122,0.00016889042,0.0002985965,0.00013415422,0.00009753949],"category_scores_gemma":[0.00003116884,0.00025683254,0.00016375504,0.002917526,0.0002157685,0.00032833772,0.00014986926,0.0010471573,0.000023173601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057943272,0.0009944194,0.90956736,0.0022471473,0.009439926,0.0077325786,0.021081356,0.00060784793,0.03387333,0.0004792282,0.0020888953,0.006093586],"study_design_scores_gemma":[0.027610024,0.004453387,0.8120125,0.003658181,0.014237353,0.0013573007,0.0048806844,0.02033402,0.104490764,0.00017843631,0.0047510015,0.002036347],"about_ca_topic_score_codex":0.0023387747,"about_ca_topic_score_gemma":0.008092424,"teacher_disagreement_score":0.09755486,"about_ca_system_score_codex":0.0007440677,"about_ca_system_score_gemma":0.0018469365,"threshold_uncertainty_score":0.9999884},"labels":[],"label_agreement":null},{"id":"W4405039867","doi":"10.1182/blood-2024-211972","title":"UM171 Cord Blood Transplantation for TP53 Mutated and EVI1 Rearranged Myelodysplasia/Acute Myeloid Leukemia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Myeloid leukemia; Medicine; Transplantation; Cord blood; Leukemia; Myeloid; Cancer research; Internal medicine; Oncology; Biology","score_opus":0.017167530271241176,"score_gpt":0.2964343957768523,"score_spread":0.27926686550561114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887964,0.0028473737,0.00087162154,0.0016019932,0.00022842486,0.0017475698,0.00032994343,0.00050258863,0.0030740546],"genre_scores_gemma":[0.98189414,0.004300814,0.006038564,0.00036402326,0.00062449824,0.0003666279,0.0008195409,0.00017071623,0.005421054],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975895,0.00007413933,0.000454937,0.0007477841,0.00048255676,0.0006510433],"domain_scores_gemma":[0.998649,0.00038389294,0.00005706255,0.0003836832,0.00017935576,0.000347031],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048091315,0.0003530414,0.00052582374,0.00037189107,0.00017344531,0.00013471088,0.0001621948,0.00029021906,0.000106835534],"category_scores_gemma":[0.0001222855,0.00031174198,0.0001763666,0.000554249,0.00016186957,0.00021747054,0.000039227616,0.0005704048,0.00009311452],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038593481,0.0004995514,0.0014093526,0.004883687,0.0040247645,0.006082133,0.002766171,0.0000039102365,0.9254337,0.0011100292,0.007250071,0.042677306],"study_design_scores_gemma":[0.07071753,0.009351645,0.032738153,0.0034980236,0.02639265,0.025902828,0.0007912299,0.008661899,0.7654989,0.001436142,0.05284834,0.0021626651],"about_ca_topic_score_codex":0.000099098135,"about_ca_topic_score_gemma":0.000033392967,"teacher_disagreement_score":0.15993479,"about_ca_system_score_codex":0.00017147764,"about_ca_system_score_gemma":0.00074815575,"threshold_uncertainty_score":0.9999335},"labels":[],"label_agreement":null},{"id":"W4405040232","doi":"10.1182/blood-2024-210688","title":"Depletion of CD59 Inhibits the Proliferation and Survival of Acute Myeloid Leukemia Cells By Altering Lipid Raft Composition and Suppression of Raf/MEK/ERK Signaling","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"MAPK/ERK pathway; Myeloid leukemia; Cancer research; Leukemia; Cell biology; Signal transduction; Myeloid; Immunology; Biology; Chemistry","score_opus":0.011030678194281983,"score_gpt":0.26358022582075824,"score_spread":0.25254954762647625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997054,0.0010861865,0.0007638754,0.00028973183,0.000077885365,0.00054393825,0.00007537697,0.00002711641,0.00008192365],"genre_scores_gemma":[0.99848205,0.00057859847,0.0005984409,0.000021482278,0.00012794968,0.000015288648,0.00009891648,0.000025620304,0.000051640727],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99863446,0.0001325401,0.0004152753,0.00024874738,0.00039825824,0.00017071734],"domain_scores_gemma":[0.9992758,0.00021099333,0.00012324257,0.00018157848,0.00013730029,0.00007108246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005550525,0.0001391012,0.00032719798,0.00013158149,0.000061073,0.000025509775,0.000067034685,0.00011356603,0.00001400421],"category_scores_gemma":[0.000029912468,0.000100722325,0.00005245247,0.00020450237,0.00015140558,0.00013208594,0.00010522692,0.00024457616,9.939059e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028346694,0.000081866485,0.0019565944,0.000979633,0.00017813279,0.000007068917,0.00074675324,0.000021950076,0.99454033,0.00003776297,0.00029219838,0.00087423256],"study_design_scores_gemma":[0.0020442426,0.00035388942,0.0014739765,0.0008274691,0.00033098832,0.00006362594,0.00009966285,0.003753258,0.9908749,0.00001796335,0.00007895164,0.000081086226],"about_ca_topic_score_codex":0.00004919279,"about_ca_topic_score_gemma":0.0000020789257,"teacher_disagreement_score":0.0037313078,"about_ca_system_score_codex":0.000054268174,"about_ca_system_score_gemma":0.00015129038,"threshold_uncertainty_score":0.41073373},"labels":[],"label_agreement":null},{"id":"W4405040408","doi":"10.1182/blood-2024-198504","title":"Time to Response and Overall Survival in Patients with m<i>IDH1</i> Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myeloid leukemia; Medicine; Internal medicine; Refractory (planetary science); Leukemia; Oncology; Gastroenterology; Biology","score_opus":0.00732204916881292,"score_gpt":0.23929702417973633,"score_spread":0.2319749750109234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634916,0.00022676119,0.0000048998795,0.00072976825,0.000023790877,0.001038191,0.00009061235,0.00019805814,0.0013387486],"genre_scores_gemma":[0.9888579,0.0000412561,0.0005822425,0.0003707203,0.00008696579,0.00007026505,0.00010547327,0.00013539878,0.009749758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997409,0.00020672035,0.0003047136,0.0007282215,0.0007364478,0.00061491097],"domain_scores_gemma":[0.99851745,0.00034304176,0.00004212197,0.00052527146,0.00014361076,0.00042850757],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049186987,0.000356732,0.00051644986,0.0005150906,0.00006371283,0.000080320475,0.00015278057,0.00017931723,0.00015100109],"category_scores_gemma":[0.0001353576,0.00025088494,0.000046139463,0.00078156334,0.00015108625,0.00023804531,0.00012443739,0.0006862665,0.00044065193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18969958,0.0029713325,0.6487679,0.0007001885,0.004201364,0.021049082,0.003740799,0.00009946989,0.10019315,0.000058790683,0.020497175,0.008021219],"study_design_scores_gemma":[0.03508079,0.009980729,0.9345348,0.0011455085,0.0007849584,0.0003192091,0.00006376296,0.00019309999,0.0058408426,0.00000877697,0.011350932,0.0006965907],"about_ca_topic_score_codex":0.00017169387,"about_ca_topic_score_gemma":0.000039655228,"teacher_disagreement_score":0.28576693,"about_ca_system_score_codex":0.00072652625,"about_ca_system_score_gemma":0.0010205008,"threshold_uncertainty_score":0.99999434},"labels":[],"label_agreement":null},{"id":"W4405040880","doi":"10.1182/blood-2024-201710","title":"Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in m<i>IDH1</i> Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Azacitidine; Myeloid leukemia; Medicine; Internal medicine; Open label; Leukemia; Phases of clinical research; Oncology; Cancer research; Clinical trial; Biology","score_opus":0.06387992848415537,"score_gpt":0.3703111879506398,"score_spread":0.3064312594664844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99221057,0.0010455186,0.000027618862,0.0018378661,0.00013063988,0.0022870726,0.00015261682,0.00008260089,0.002225518],"genre_scores_gemma":[0.9958133,0.0008196048,0.0015674274,0.00013562184,0.00013254287,0.00017850865,0.00017788298,0.00005506095,0.001120013],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976223,0.00013980077,0.0006963948,0.0005748528,0.0005210703,0.0004455498],"domain_scores_gemma":[0.9986494,0.00039899538,0.000104008366,0.00041672593,0.0001557509,0.00027511682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008864086,0.00025516227,0.0007068095,0.00047604088,0.00010738221,0.00011569902,0.00030963361,0.00022723222,0.00007974322],"category_scores_gemma":[0.00049773435,0.00022173852,0.000058597725,0.00087373884,0.00018957457,0.0003769361,0.00036093724,0.00076018885,0.00002221384],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010460667,0.0037123675,0.0004385546,0.00046982424,0.0005778433,0.0012576159,0.0006368707,0.0000016837522,0.97334355,0.0008540898,0.0030382602,0.005208701],"study_design_scores_gemma":[0.6782538,0.0059351013,0.0016483292,0.0021170387,0.0014832268,0.0010680641,0.00041506748,0.0105235865,0.2929227,0.000904718,0.0041087265,0.0006195966],"about_ca_topic_score_codex":0.000497787,"about_ca_topic_score_gemma":0.000030157898,"teacher_disagreement_score":0.6804208,"about_ca_system_score_codex":0.00031429128,"about_ca_system_score_gemma":0.0011440201,"threshold_uncertainty_score":0.90422344},"labels":[],"label_agreement":null},{"id":"W4405041412","doi":"10.1182/blood-2024-202069","title":"Intensive Chemotherapy Vs. Azacitidine + Venetoclax for AML with Secondary Mutations","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Venetoclax; Azacitidine; Chemotherapy regimen; Medicine; Internal medicine; Chemotherapy; Oncology; Leukemia; Genetics; Biology; Chronic lymphocytic leukemia; DNA methylation; Gene","score_opus":0.015333866735165793,"score_gpt":0.2955157901546872,"score_spread":0.2801819234195214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405041412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97517025,0.0014777068,0.002525467,0.01254584,0.00013616045,0.0016874052,0.0001631837,0.00032438975,0.005969574],"genre_scores_gemma":[0.9821728,0.000103396604,0.007059361,0.0029866,0.0005949202,0.00032851635,0.00029476595,0.00010313659,0.0063565155],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999087,0.000012386256,0.00014352702,0.00028986437,0.00018701455,0.0002802049],"domain_scores_gemma":[0.99912876,0.00016218518,0.000019575522,0.00023023649,0.0003333642,0.00012588435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001115471,0.00013426063,0.0002186189,0.00015191516,0.000059677302,0.0000412326,0.00007689129,0.00007372788,0.00029005442],"category_scores_gemma":[0.000094109055,0.00010081162,0.00008317157,0.00027798302,0.0001066508,0.000072974995,0.000019331008,0.00029461464,0.00008405105],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0089170085,0.0015468153,0.006338081,0.007838394,0.01195485,0.007249538,0.016808435,0.00007615244,0.33775207,0.013047919,0.4258348,0.16263592],"study_design_scores_gemma":[0.03939131,0.008120162,0.010280557,0.0015484516,0.0016449038,0.004187451,0.002597817,0.0075303605,0.42923492,0.0023663873,0.49219862,0.0008990553],"about_ca_topic_score_codex":0.000022925024,"about_ca_topic_score_gemma":0.000010028506,"teacher_disagreement_score":0.16173686,"about_ca_system_score_codex":0.00016730635,"about_ca_system_score_gemma":0.0011067826,"threshold_uncertainty_score":0.41109788},"labels":[],"label_agreement":null},{"id":"W4405041413","doi":"10.1182/blood-2024-201920","title":"Inhibition of Threonine Tyrosine Kinase Suppressed <i>TP53-</i>mutated Acute Myeloid Leukaemia Via Synergism with Venetoclax and Activation of the Cgas-Sting Pathway","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Venetoclax; Tyrosine kinase; Cancer research; Myeloid leukemia; Tyrosine; Medicine; Myeloid; Biology; Bruton's tyrosine kinase; Immunology; Signal transduction; Leukemia; Chemistry; Genetics; Biochemistry; Chronic lymphocytic leukemia","score_opus":0.009624015995524883,"score_gpt":0.24160543184544725,"score_spread":0.23198141584992238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405041413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707144,0.00048706334,0.00042299842,0.0006309658,0.00004484537,0.0006479516,0.000060851067,0.000080160105,0.0005537086],"genre_scores_gemma":[0.9986414,0.0000768522,0.0007027822,0.00007424894,0.00010773578,0.000036949637,0.000107863445,0.000052421306,0.0001997565],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844843,0.000074144154,0.00036630276,0.00033662148,0.00050123234,0.00027329102],"domain_scores_gemma":[0.99898374,0.00016396934,0.00014616345,0.00038284194,0.00023398042,0.00008928395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000266411,0.00020341469,0.00035082005,0.00016899247,0.000075470096,0.00002463915,0.00009942818,0.00013349015,0.000025162504],"category_scores_gemma":[0.000105765364,0.00013107587,0.00007201609,0.0007485682,0.00024079795,0.00016937852,0.000118147065,0.0004146626,0.0000025048812],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035936036,0.00012246521,0.0016502069,0.00065188046,0.00029296114,0.0001365278,0.00045080183,0.00006150229,0.99407774,0.00017642291,0.00012594089,0.0018942079],"study_design_scores_gemma":[0.0036016034,0.0005717441,0.0069221933,0.0015026417,0.00041718758,0.00027389525,0.00007804592,0.0026517273,0.98362374,0.00010417252,0.00012512511,0.00012792902],"about_ca_topic_score_codex":0.00015864591,"about_ca_topic_score_gemma":0.000009190479,"teacher_disagreement_score":0.010453988,"about_ca_system_score_codex":0.00014229554,"about_ca_system_score_gemma":0.00058666227,"threshold_uncertainty_score":0.53451186},"labels":[],"label_agreement":null},{"id":"W4405041605","doi":"10.1182/blood-2024-209687","title":"Survival Outcomes for Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC) in a Real-World, Retrospective Cohort Receiving Intensive Chemotherapy","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Myeloid leukemia; Retrospective cohort study; Internal medicine; Chemotherapy regimen; Chemotherapy; Cohort; Oncology; Overall survival; Leukemia; Hematologic Neoplasms; Cancer","score_opus":0.011178092107257075,"score_gpt":0.2789832337837818,"score_spread":0.26780514167652475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405041605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891847,0.00009595476,0.000039700895,0.0028748943,0.00021789434,0.0034196752,0.000114736125,0.00046811157,0.0035843789],"genre_scores_gemma":[0.9877763,0.0005626043,0.0025402703,0.00044114678,0.0001757112,0.00061220326,0.00027937672,0.00027578577,0.0073366477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965297,0.000090706075,0.00046803924,0.0010869111,0.00091450376,0.00091016944],"domain_scores_gemma":[0.9976043,0.00042286274,0.00015078299,0.0006329492,0.00093580823,0.000253301],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005725075,0.0005550728,0.0011595758,0.0007868912,0.000119399694,0.00009431623,0.00025039786,0.00025030732,0.00007813083],"category_scores_gemma":[0.00029615161,0.00038296072,0.00013366909,0.0016639716,0.00023923755,0.00022198148,0.00009188812,0.0009867704,0.000029130371],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002465825,0.00028778316,0.9885936,0.00021053181,0.003275735,0.00072571915,0.0016933207,0.000002238058,0.0006365204,0.00023112599,0.0007927891,0.0010848126],"study_design_scores_gemma":[0.016666058,0.0024558916,0.9758239,0.0010121342,0.0008223553,0.000094571864,0.00043581243,0.00031791365,0.0012068012,0.000091684335,0.0005846389,0.00048825232],"about_ca_topic_score_codex":0.0007440873,"about_ca_topic_score_gemma":0.0022120003,"teacher_disagreement_score":0.014200233,"about_ca_system_score_codex":0.0020375012,"about_ca_system_score_gemma":0.0009919226,"threshold_uncertainty_score":0.99986225},"labels":[],"label_agreement":null},{"id":"W4405041908","doi":"10.1182/blood-2024-211039","title":"<i>KMT2C</i> Mutations Co-Operate with <i>KMT2A-MLLT1</i> Fusion to Inhibit Hematopoietic Differentiation in a Zebrafish Model of Infant Leukemia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; University of Calgary; University of Ottawa; Agricultural Research Institute of Ontario","funders":"","keywords":"Zebrafish; Leukemia; Mutation; Haematopoiesis; Cancer research; Biology; Genetics; Medicine; Computational biology; Gene; Stem cell","score_opus":0.014271569384186483,"score_gpt":0.2731708813765468,"score_spread":0.2588993119923603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405041908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993096,0.0002022661,0.002127098,0.0012576806,0.000036302725,0.0010422714,0.00007554251,0.00012654299,0.002036313],"genre_scores_gemma":[0.99616694,0.000042035954,0.0020936474,0.00046043895,0.00007510665,0.00016171348,0.00016249115,0.0000674046,0.0007702285],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979056,0.000058210055,0.00050615,0.00048852415,0.0006318938,0.0004095859],"domain_scores_gemma":[0.9990407,0.00008732788,0.00005661055,0.0004187696,0.00016518694,0.00023139754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029469983,0.0002422523,0.00046615698,0.0005460132,0.000058917863,0.00006223591,0.00014231038,0.00014146765,0.00007196854],"category_scores_gemma":[0.00008655064,0.00019127126,0.00008548502,0.00095697626,0.000082213824,0.00017710227,0.00010050844,0.00046721188,0.00009046037],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063429296,0.0010636731,0.009586278,0.0017010038,0.0002778173,0.00048596744,0.008209471,0.007304022,0.96414214,0.001098609,0.0044710697,0.0010256432],"study_design_scores_gemma":[0.014875151,0.0015719285,0.00986095,0.0037470113,0.00072224956,0.00048694544,0.00086768286,0.17969844,0.78626835,0.00047751464,0.000651869,0.00077191176],"about_ca_topic_score_codex":0.00022446326,"about_ca_topic_score_gemma":0.00016126232,"teacher_disagreement_score":0.1778738,"about_ca_system_score_codex":0.00031923238,"about_ca_system_score_gemma":0.0011078656,"threshold_uncertainty_score":0.7799816},"labels":[],"label_agreement":null},{"id":"W4405042220","doi":"10.1182/blood-2024-206028","title":"ULK1 Presents As a Therapeutic Target to Sensitize Resistant Acute Myeloid Leukemia Cells to Venetoclax","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University of British Columbia","funders":"","keywords":"Venetoclax; Myeloid leukemia; Medicine; Cancer research; Leukemia; Immunology; Chronic lymphocytic leukemia","score_opus":0.01491722503326445,"score_gpt":0.2987653702526226,"score_spread":0.2838481452193582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405042220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97274816,0.0012787265,0.00028782585,0.007435032,0.0004729922,0.002276152,0.00013513917,0.0004930097,0.01487299],"genre_scores_gemma":[0.95150346,0.00014391774,0.004556158,0.0044730017,0.0008965903,0.00020044294,0.00005415247,0.00018725215,0.037985038],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965687,0.00012403475,0.0004173345,0.00089770585,0.0010060715,0.0009861748],"domain_scores_gemma":[0.99772304,0.00020421398,0.00003219687,0.00095593306,0.00018509635,0.00089954474],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039866552,0.0003827853,0.00052842963,0.0004550155,0.00012036071,0.0001711093,0.0003645442,0.00021573389,0.00038147997],"category_scores_gemma":[0.00012924246,0.00032642245,0.00020671317,0.0010885324,0.00006551666,0.00009444663,0.00033248318,0.0006598999,0.0057988963],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010572276,0.00012108711,0.00010914662,0.00025676115,0.001112624,0.006826012,0.0012526108,0.000059478694,0.94518286,0.00030573655,0.041782994,0.0019334754],"study_design_scores_gemma":[0.0036163235,0.0021102636,0.0021458506,0.0005520588,0.000891138,0.00093573664,0.00023822594,0.0010259437,0.6406417,0.0004575394,0.346747,0.00063824374],"about_ca_topic_score_codex":0.00031760224,"about_ca_topic_score_gemma":0.000014042946,"teacher_disagreement_score":0.304964,"about_ca_system_score_codex":0.0013762055,"about_ca_system_score_gemma":0.0023776467,"threshold_uncertainty_score":0.99991876},"labels":[],"label_agreement":null},{"id":"W4405042670","doi":"10.1182/blood-2024-201997","title":"Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Lymphoblastic Leukemia; Medicine; Asparaginase; Venous thromboembolism; Leukemia; Acute lymphocytic leukemia; Oncology; Intensive care medicine; Internal medicine; Pediatrics; Thrombosis","score_opus":0.009975767509150088,"score_gpt":0.24936880618761229,"score_spread":0.2393930386784622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405042670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397546,0.00033738767,0.0049203457,0.000033652672,0.00003915899,0.0005193555,0.00004046744,0.00005738501,0.000076791526],"genre_scores_gemma":[0.9973999,0.0005774475,0.0017883325,0.000018572924,0.000058050136,0.000037264024,0.000060347167,0.0000330557,0.000026982494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886316,0.000051923882,0.00024370798,0.00028003336,0.00037250656,0.00018865563],"domain_scores_gemma":[0.9995023,0.0000653835,0.00007354447,0.00018095999,0.00011046365,0.00006735353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021743814,0.0001314485,0.00023826696,0.00025408843,0.00004172426,0.00003132307,0.000052432944,0.000087499124,0.000008714707],"category_scores_gemma":[0.00005793482,0.000104760176,0.00002576228,0.00030355167,0.000056296412,0.00023142318,0.000027407015,0.00022512635,0.000003220749],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027744905,0.0020617142,0.87108403,0.0006001671,0.0011354923,0.00018447742,0.0060274852,0.006834467,0.059995137,0.00013722411,0.00011673274,0.04904859],"study_design_scores_gemma":[0.009681535,0.0012736645,0.8575152,0.0006757012,0.00033853337,0.00005411933,0.000024679453,0.10798489,0.021927377,0.00040113484,0.0000043673886,0.00011875281],"about_ca_topic_score_codex":0.00012349641,"about_ca_topic_score_gemma":0.0000032860887,"teacher_disagreement_score":0.10115042,"about_ca_system_score_codex":0.00028238163,"about_ca_system_score_gemma":0.00042844686,"threshold_uncertainty_score":0.4271996},"labels":[],"label_agreement":null},{"id":"W4405042710","doi":"10.1182/blood-2024-201848","title":"Impact of Extramedullary Disease on the Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Acute Myeloid Leukemia - a CIBMTR Analysis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Hematopoietic cell; Medicine; Transplantation; Myeloid leukemia; Hematopoietic stem cell transplantation; Disease; Leukemia; Myeloid; Immunology; Haematopoiesis; Internal medicine; Stem cell; Biology; Genetics","score_opus":0.005107032728246125,"score_gpt":0.2539863918028676,"score_spread":0.24887935907462147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405042710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971003,0.0015219167,0.000034687757,0.00029356228,0.000009116005,0.0007127994,0.00021398194,0.00003435955,0.00007929736],"genre_scores_gemma":[0.998376,0.0010109503,0.00010196698,0.00007676871,0.000025143085,0.0000962829,0.00015807363,0.000035005713,0.000119778655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985462,0.000078680154,0.00026265276,0.00039720713,0.00042068638,0.00029457224],"domain_scores_gemma":[0.9992034,0.00013238988,0.00004271337,0.00039311952,0.000038372862,0.0001899958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018023387,0.00023222345,0.00038384763,0.00044753132,0.000029990677,0.000037078597,0.00011489268,0.000067633635,0.00008629901],"category_scores_gemma":[0.000017303251,0.00012550253,0.00023800343,0.0008230461,0.000111720365,0.00007466168,0.000024608435,0.00032545064,0.000008319507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015928416,0.0002505288,0.9911509,0.00023197867,0.0031901866,0.0013402028,0.0011174729,0.000034713234,0.00085616414,0.000010021601,0.000019307456,0.00020567041],"study_design_scores_gemma":[0.0028794373,0.0003275016,0.9895203,0.00025117677,0.0052441345,0.00024355104,0.00004762211,0.0002666921,0.0010692858,0.000012905336,3.453729e-7,0.00013706357],"about_ca_topic_score_codex":0.00040557803,"about_ca_topic_score_gemma":0.00010257318,"teacher_disagreement_score":0.0020539481,"about_ca_system_score_codex":0.00014599624,"about_ca_system_score_gemma":0.00044704217,"threshold_uncertainty_score":0.51178443},"labels":[],"label_agreement":null},{"id":"W4405042792","doi":"10.1182/blood-2024-209097","title":"Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University Health Network","funders":"","keywords":"Medicine; Chemotherapy; Chemotherapy regimen; Myeloid leukemia; Internal medicine; Refractory (planetary science); Oncology; Phases of clinical research; Biology","score_opus":0.012497339251086812,"score_gpt":0.3048294359654016,"score_spread":0.29233209671431476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405042792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950188,0.0002965892,0.00004881582,0.0024643533,0.00014542701,0.0013421848,0.000114962,0.000120829354,0.00044805888],"genre_scores_gemma":[0.9956586,0.0012939345,0.0012277523,0.0004719111,0.00040139095,0.000056212437,0.00037074272,0.00009576313,0.00042369435],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978028,0.000077706405,0.0005249534,0.000635883,0.00060654915,0.00035210047],"domain_scores_gemma":[0.9988951,0.00024667534,0.00009152297,0.0004561458,0.00009212672,0.00021843104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004537012,0.00030374786,0.00065269455,0.0003877152,0.00004404908,0.000059145266,0.0002863181,0.0002612848,0.0003073379],"category_scores_gemma":[0.000062336054,0.00024136946,0.000083967956,0.00041560334,0.00021301955,0.00022335406,0.000054869983,0.0007946173,0.0000123464615],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7538657,0.007074332,0.010355346,0.00016704842,0.003467925,0.0011636836,0.004766373,0.000003835449,0.18826473,0.0002121793,0.00089247926,0.029766385],"study_design_scores_gemma":[0.8633571,0.014346841,0.050515864,0.0007062945,0.00043382286,0.00015403844,0.00014753347,0.0015619124,0.06236536,0.00010861448,0.005835718,0.00046689456],"about_ca_topic_score_codex":0.00020573958,"about_ca_topic_score_gemma":0.000028035409,"teacher_disagreement_score":0.12589936,"about_ca_system_score_codex":0.00036223608,"about_ca_system_score_gemma":0.0006821919,"threshold_uncertainty_score":0.9842761},"labels":[],"label_agreement":null},{"id":"W4405043182","doi":"10.1182/blood-2024-209217","title":"FRAIL-HRU-AML: Impact of Frailty Assessment on Health Resource Utilization in Acute Myeloid Leukemia Patients: A Population-Based Study from Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myeloid leukemia; Medicine; Leukemia; Population; Hematologic Neoplasms; Gerontology; Intensive care medicine; Immunology; Environmental health; Cancer; Internal medicine","score_opus":0.029339860549746133,"score_gpt":0.3437619648931933,"score_spread":0.31442210434344714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405043182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99685234,0.00009795004,0.00005959883,0.00047657706,0.00009744118,0.0015626221,0.00034700148,0.0000600306,0.00044646155],"genre_scores_gemma":[0.99686486,0.0000064850387,0.00035581694,0.00042075693,0.00006700469,0.000063990425,0.0019472091,0.00005738947,0.00021649229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968549,0.00024755896,0.00069707166,0.0005761493,0.0011673315,0.00045696858],"domain_scores_gemma":[0.9985498,0.00030013308,0.00015490707,0.0005967452,0.00012588485,0.00027252943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003876928,0.00028385036,0.0005790086,0.0003811615,0.000078455596,0.000038335435,0.00018404846,0.000117820935,0.0004149325],"category_scores_gemma":[0.00012280548,0.0002393426,0.00012032731,0.0006967508,0.00001955149,0.00008382054,0.00006135618,0.00074581575,0.000005450599],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003135467,0.0014468628,0.98781294,0.00008150906,0.00047499457,0.00014433563,0.0008876361,0.000650433,0.00009396591,0.000009594819,0.004581947,0.0035022527],"study_design_scores_gemma":[0.006976948,0.0024264173,0.9863018,0.00040977873,0.00015361598,0.0000016741121,0.00019943953,0.0025109644,0.00013993534,0.00001726633,0.0006918699,0.00017032739],"about_ca_topic_score_codex":0.9850278,"about_ca_topic_score_gemma":0.95692974,"teacher_disagreement_score":0.028098034,"about_ca_system_score_codex":0.0138545735,"about_ca_system_score_gemma":0.018936884,"threshold_uncertainty_score":0.98993105},"labels":[],"label_agreement":null},{"id":"W4405043362","doi":"10.1182/blood-2024-203612","title":"Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Agios Pharmaceuticals; Swedish Orphan Biovitrum; Astex Pharmaceuticals; Sierra Oncology; Jazz Pharmaceuticals; MorphoSys; FibroGen; Celgene; Gilead Sciences","keywords":"Medicine; Refractory (planetary science); Erythropoiesis; Myelodysplastic syndromes; Internal medicine; Anemia; Blood transfusion; Oncology; Intensive care medicine; Surgery; Bone marrow","score_opus":0.024571749615571025,"score_gpt":0.33798995448954816,"score_spread":0.31341820487397715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405043362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973691,0.00012415928,0.000037107275,0.000100699595,0.00016473529,0.0018703551,0.000098631164,0.000047827387,0.00018739524],"genre_scores_gemma":[0.99899966,0.000347016,0.00017090834,0.00001062931,0.000040806088,0.00006430253,0.000015661366,0.000062863845,0.00028814317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99692184,0.00069504976,0.00059682917,0.0005361896,0.0008778569,0.00037226256],"domain_scores_gemma":[0.9928905,0.0061162272,0.00019497551,0.0005689105,0.00009566481,0.00013376924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012191888,0.0003111462,0.0008156803,0.0002888017,0.00007740586,0.000017957376,0.00017425418,0.00017699451,0.00015154891],"category_scores_gemma":[0.0015206563,0.00015301866,0.0002122913,0.0006283962,0.00020440097,0.00010111358,0.000069562724,0.0007808995,0.000026879681],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03238798,0.008998578,0.88022286,0.002061589,0.0028610358,0.0012905604,0.00076327747,0.00011508039,0.00798316,0.000008106777,0.00016631317,0.06314147],"study_design_scores_gemma":[0.062397253,0.09035557,0.7500334,0.0055658715,0.0043909797,0.00007247018,0.00011451713,0.0022699928,0.08418603,0.000016110267,0.000077076,0.00052077166],"about_ca_topic_score_codex":0.00020323678,"about_ca_topic_score_gemma":0.000047296635,"teacher_disagreement_score":0.13018948,"about_ca_system_score_codex":0.00021180868,"about_ca_system_score_gemma":0.00041255218,"threshold_uncertainty_score":0.62399197},"labels":[],"label_agreement":null},{"id":"W4405043407","doi":"10.1182/blood-2024-208622","title":"Multicenter, Real-World Experience Study of FLT3-Inhibitor Post-Transplant Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with FLT3-ITD","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan; Université Laval; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Myeloid leukemia; Stem cell; Medicine; Transplantation; Maintenance therapy; Haematopoiesis; Hematopoietic stem cell transplantation; Fms-Like Tyrosine Kinase 3; Immunology; Leukemia; Acute leukemia; Oncology; Cancer research; Internal medicine; Chemotherapy; Biology","score_opus":0.014165538939920492,"score_gpt":0.2810204897333979,"score_spread":0.2668549507934774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405043407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958141,0.0010039124,0.000117837866,0.00013733811,0.00018587887,0.002135532,0.00005244375,0.0001549476,0.0003980173],"genre_scores_gemma":[0.99624926,0.0018834651,0.00047657534,0.00007767588,0.00007828361,0.00030623793,0.000057611756,0.00010577474,0.0007651001],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966678,0.00017234478,0.0007459619,0.00082240294,0.0008945011,0.00069696864],"domain_scores_gemma":[0.99878526,0.00020370784,0.000103900944,0.00057400734,0.00012275316,0.00021035205],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039852117,0.0004298902,0.0007002242,0.00052499975,0.00008240442,0.00005605359,0.00033567357,0.0001283478,0.000029897003],"category_scores_gemma":[0.0000049965242,0.0003213508,0.00018462258,0.0009651746,0.00009917001,0.0002501057,0.000034268403,0.00057306857,0.000024648245],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004510555,0.0029980536,0.22406404,0.001466232,0.0009740223,0.016225869,0.08656679,0.000064010856,0.661584,0.000027855493,0.000041718147,0.0014768573],"study_design_scores_gemma":[0.047564417,0.004692596,0.13947123,0.0044708126,0.001535656,0.0007964367,0.020968638,0.00065900426,0.7787341,0.000005888226,0.00013130208,0.0009699299],"about_ca_topic_score_codex":0.0012213505,"about_ca_topic_score_gemma":0.0012420666,"teacher_disagreement_score":0.11715008,"about_ca_system_score_codex":0.00038371806,"about_ca_system_score_gemma":0.00059463823,"threshold_uncertainty_score":0.9999239},"labels":[],"label_agreement":null},{"id":"W4405044026","doi":"10.1182/blood-2024-206253","title":"Modeling Clonal Hematopoiesis Due to Chromosome 13q Deletion in Human Hematopoietic Stem Cells","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Princess Margaret Cancer Centre; University of Toronto; Ottawa Hospital; University Health Network","funders":"","keywords":"Haematopoiesis; Stem cell; Biology; Chromosome abnormality; Immunology; Genetics; Chromosome; Karyotype; Gene","score_opus":0.023504428920999642,"score_gpt":0.29199892653441206,"score_spread":0.26849449761341243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405044026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940293,0.0009396576,0.0015108624,0.0013688692,0.000106365114,0.0006266728,0.0000121058465,0.00020578048,0.0012004063],"genre_scores_gemma":[0.9970808,0.000026845453,0.0010476685,0.0002468138,0.00030983973,0.000111259,0.000018933166,0.00007258735,0.0010852208],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978973,0.00005889505,0.0004386145,0.000528472,0.00055292825,0.00052376866],"domain_scores_gemma":[0.9991601,0.00007092963,0.000018129269,0.0004067707,0.00007932436,0.00026473743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004568746,0.00021760847,0.00042479113,0.00047814756,0.00008065564,0.000077451914,0.0001812667,0.0001621388,0.00021370273],"category_scores_gemma":[0.000020430287,0.00020235457,0.000123357,0.00068365934,0.000036499536,0.000102754406,0.00014491523,0.00049885,0.000517554],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012742064,0.0012217534,0.0006443012,0.003506258,0.0003371766,0.009145988,0.004520399,0.0016949041,0.96949816,0.004326444,0.0032345348,0.0017426406],"study_design_scores_gemma":[0.0072676786,0.000947458,0.000314147,0.004205693,0.00048693316,0.003629816,0.0014958617,0.13239405,0.8443786,0.0016862805,0.0021387935,0.0010547085],"about_ca_topic_score_codex":0.00011998224,"about_ca_topic_score_gemma":0.000032033644,"teacher_disagreement_score":0.13069913,"about_ca_system_score_codex":0.0003213788,"about_ca_system_score_gemma":0.00026986835,"threshold_uncertainty_score":0.82517797},"labels":[],"label_agreement":null},{"id":"W4405044171","doi":"10.1182/blood-2024-199697","title":"Targeted Protein Degradation Reveals a Repressive Role of Mecom at the <i>CEBPA</i> Locus to Prevent Differentiation in High-Risk Acute Myeloid Leukemia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"CEBPA; Myeloid leukemia; Biology; Leukemia; Myeloid; Genetics; Cancer research; Gene; Mutation","score_opus":0.006994282316369191,"score_gpt":0.25246213565755204,"score_spread":0.24546785334118285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405044171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927855,0.0021669792,0.00021410282,0.0015886624,0.00006952487,0.0027174645,0.00011299641,0.00008460006,0.00026013528],"genre_scores_gemma":[0.9940428,0.00018097942,0.00064938905,0.000080228245,0.00013699397,0.0005880069,0.00020340462,0.00005195734,0.0040662433],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99755996,0.0003130094,0.0005689935,0.00054935797,0.00061478344,0.00039388274],"domain_scores_gemma":[0.9986681,0.00017616244,0.00017123255,0.00069426745,0.0001463208,0.00014395367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064248237,0.00022696273,0.0004232114,0.00028267858,0.000085310516,0.000038669292,0.00024193006,0.00016474063,0.00014130995],"category_scores_gemma":[0.00039377922,0.00015672688,0.00012640056,0.0007676603,0.00005851337,0.00012221052,0.000265661,0.0005261876,0.00010699067],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041742748,0.00034592982,0.0063240835,0.00022228563,0.0005539405,0.00009826944,0.0013519565,0.000061931525,0.97935677,0.00028366895,0.0022600882,0.008723669],"study_design_scores_gemma":[0.0026200176,0.00045619704,0.04007253,0.00067063497,0.0006053918,0.000046849567,0.00012344254,0.00080283213,0.95224786,0.0012169387,0.0009355548,0.00020176375],"about_ca_topic_score_codex":0.0010337279,"about_ca_topic_score_gemma":0.00033471503,"teacher_disagreement_score":0.033748444,"about_ca_system_score_codex":0.0007772985,"about_ca_system_score_gemma":0.00040824735,"threshold_uncertainty_score":0.63911366},"labels":[],"label_agreement":null},{"id":"W4405044220","doi":"10.1182/blood-2024-211364","title":"Identification of DLK1 As a Novel Therapeutic Target in Down Syndrome Myeloid Leukemia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Myeloid leukemia; GATA1; Bone marrow; Cancer research; Leukemia; Myeloid; Haematopoiesis; CD34; Biology; Transcriptome; Decitabine; Medicine; Gene; Immunology; Gene expression; Stem cell; Genetics; DNA methylation","score_opus":0.016969054788371466,"score_gpt":0.29469396685602994,"score_spread":0.2777249120676585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405044220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927487,0.0025322763,0.0004548289,0.00094778696,0.00012498964,0.00054892845,0.000025753652,0.00010072352,0.0025160378],"genre_scores_gemma":[0.9960312,0.00013809101,0.0003927263,0.00013839954,0.000075715325,0.000066476096,0.000038015605,0.00004288641,0.003076493],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983519,0.0000397415,0.00046054757,0.00036939167,0.00046533855,0.00031313224],"domain_scores_gemma":[0.99920666,0.00011797757,0.000054775446,0.0004381412,0.000083503975,0.000098913624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005771768,0.00014915245,0.0003194763,0.00043408165,0.00002499599,0.00003703667,0.00019055157,0.00014581578,0.00024480894],"category_scores_gemma":[0.0001352404,0.0001291261,0.00010166928,0.0008137113,0.000095049516,0.00012302845,0.00006353051,0.0004341395,0.00040719614],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008485804,0.00048588545,0.002934621,0.0006830692,0.00028793776,0.0005964406,0.0007099583,0.000014056519,0.9893453,0.002613152,0.00027185454,0.001972844],"study_design_scores_gemma":[0.014303725,0.0014109286,0.22103909,0.0016866721,0.0008594958,0.0059366897,0.00078446674,0.014222689,0.723961,0.0041510253,0.010874534,0.00076966546],"about_ca_topic_score_codex":0.00017329858,"about_ca_topic_score_gemma":0.000007322573,"teacher_disagreement_score":0.26538432,"about_ca_system_score_codex":0.00035355732,"about_ca_system_score_gemma":0.0009689966,"threshold_uncertainty_score":0.52656096},"labels":[],"label_agreement":null},{"id":"W4405045016","doi":"10.1182/blood-2024-198393","title":"The Burden of Transfusion Dependence on Caregivers of Patients with Lower-Risk Myelodysplastic Syndromes in North America and Europe","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Blood transfusion; Hematologic Neoplasms; International Prognostic Scoring System; Intensive care medicine; Internal medicine; Pediatrics; Cancer; Bone marrow","score_opus":0.005946706165247346,"score_gpt":0.2221604071104836,"score_spread":0.21621370094523626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405045016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986477,0.00036756223,0.000016520704,0.00014086613,0.000030252919,0.00031430673,0.000038114,0.00001237212,0.0004323393],"genre_scores_gemma":[0.9985103,0.0012594941,0.0000515857,0.000004451296,0.000015172181,0.000005946462,0.0000076214938,0.000016552582,0.00012887083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990599,0.00005359619,0.00013939213,0.00019857835,0.00039282924,0.00015570608],"domain_scores_gemma":[0.9993365,0.00028248274,0.000039387887,0.00019178208,0.00009188111,0.00005798826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006881634,0.000093790164,0.00018232659,0.00011934712,0.000032932163,0.000008263615,0.000096704214,0.000028561091,0.0000148884055],"category_scores_gemma":[0.00012891262,0.00005415675,0.000023932138,0.00048165445,0.00018496031,0.000035220393,0.000033471788,0.00024952352,0.0000069807243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005381895,0.0011980732,0.90942293,0.0016882817,0.0008640658,0.0017360243,0.012118759,0.0007569564,0.0026081973,0.000057239147,0.0004560889,0.06371147],"study_design_scores_gemma":[0.010815194,0.010226861,0.9675096,0.0016323393,0.0007003541,0.000059150083,0.0016001933,0.0020225951,0.0020467245,0.000007887973,0.0031071582,0.00027190437],"about_ca_topic_score_codex":0.00041151745,"about_ca_topic_score_gemma":0.00012498781,"teacher_disagreement_score":0.06343956,"about_ca_system_score_codex":0.000027171442,"about_ca_system_score_gemma":0.00014985603,"threshold_uncertainty_score":0.2208448},"labels":[],"label_agreement":null},{"id":"W4405045169","doi":"10.1182/blood-2024-201058","title":"10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed <i>FLT3</i> Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Midostaurin; Medicine; Myeloid leukemia; Chemotherapy regimen; Internal medicine; Chemotherapy; Oncology; Cytarabine; Leukemia","score_opus":0.01727424317486516,"score_gpt":0.27821591567018494,"score_spread":0.2609416724953198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405045169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99383485,0.0004792286,0.0000104155,0.0004282491,0.0005783332,0.0016140623,0.00016703598,0.00015979489,0.002728011],"genre_scores_gemma":[0.99099123,0.0005776219,0.0005764241,0.000440294,0.00026556393,0.00014790556,0.0002926754,0.00018352545,0.006524774],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966223,0.0001502639,0.000703281,0.0007820112,0.0009434671,0.00079865206],"domain_scores_gemma":[0.99788594,0.0005356866,0.00013430169,0.0007432065,0.00037344074,0.00032740174],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039837917,0.00043544377,0.0008607878,0.0005267535,0.000050852956,0.00006400573,0.00039780655,0.00035609084,0.0012691093],"category_scores_gemma":[0.0007412863,0.0004097939,0.00029325482,0.0010272417,0.00022789655,0.00016983293,0.00021121006,0.0009988485,0.0006106474],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15694404,0.004097081,0.025735335,0.0030888438,0.012444554,0.053514954,0.04402805,0.00013459224,0.30110052,0.0002650273,0.33202887,0.066618174],"study_design_scores_gemma":[0.60462654,0.011190351,0.10398946,0.0034709154,0.002690342,0.00021598197,0.005421939,0.0026715838,0.21842757,0.00012850869,0.04464387,0.0025229265],"about_ca_topic_score_codex":0.0006158499,"about_ca_topic_score_gemma":0.00022545774,"teacher_disagreement_score":0.44768253,"about_ca_system_score_codex":0.001304874,"about_ca_system_score_gemma":0.0018201504,"threshold_uncertainty_score":0.9998354},"labels":[],"label_agreement":null},{"id":"W4405046417","doi":"10.1182/blood-2024-211315","title":"Targeting Metabolism to Restore Hematopoiesis in Inherited Bone Marrow Failure Syndromes: Preclinical Insights from Zebrafish Models","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Children's Hospital of Eastern Ontario; National Research Council Canada; AGADA Biosciences; University of Ottawa; SickKids Foundation; Agricultural Research Institute of Ontario","funders":"","keywords":"Zebrafish; Bone marrow; Haematopoiesis; Medicine; Bone marrow failure; Biology; Cancer research; Bioinformatics; Immunology; Stem cell; Genetics; Gene","score_opus":0.03479410346718446,"score_gpt":0.30586311105994973,"score_spread":0.27106900759276525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405046417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796443,0.012169194,0.00023444617,0.0057465797,0.00019871425,0.00088021765,0.000060398615,0.00035041038,0.0007157262],"genre_scores_gemma":[0.984295,0.00015149862,0.012962855,0.0007118743,0.0005608995,0.00017156494,0.00014561077,0.0001201695,0.0008804926],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968244,0.00020253613,0.0007599297,0.0008922794,0.00073489937,0.00058594724],"domain_scores_gemma":[0.9982338,0.0004781688,0.0000510794,0.00065215875,0.00012778555,0.00045702085],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004555396,0.0003278907,0.00085450656,0.0005695657,0.00006520995,0.00011681417,0.00029548444,0.00039440434,0.0002344582],"category_scores_gemma":[0.00090671657,0.00028019992,0.00017969061,0.0012889755,0.0000798646,0.0003169222,0.0003156497,0.0011058684,0.0002924645],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022841878,0.0061344462,0.010894272,0.0041003358,0.004862449,0.05204186,0.038200684,0.0008198805,0.620282,0.01109075,0.24495527,0.0043338435],"study_design_scores_gemma":[0.08287362,0.0035339624,0.11566095,0.027765013,0.0072867014,0.004337124,0.015211417,0.17442353,0.12254213,0.053952795,0.38354325,0.008869496],"about_ca_topic_score_codex":0.00048863696,"about_ca_topic_score_gemma":0.0001660811,"teacher_disagreement_score":0.4977399,"about_ca_system_score_codex":0.000178561,"about_ca_system_score_gemma":0.00046609767,"threshold_uncertainty_score":0.999965},"labels":[],"label_agreement":null},{"id":"W4405047635","doi":"10.1182/blood-2024-203274","title":"Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; International Prognostic Scoring System; Anemia; Myelodysplastic syndromes; Quality of life (healthcare); Internal medicine; Population; Physical therapy; Oncology; Bone marrow","score_opus":0.05733324950854096,"score_gpt":0.3573693669964672,"score_spread":0.30003611748792625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405047635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976892,0.00017069788,0.00009366107,0.00020989394,0.00007680688,0.0013867924,0.0002321813,0.00006831971,0.00007246944],"genre_scores_gemma":[0.9975127,0.00007585861,0.0019525565,0.00008289406,0.00008227202,0.000113662776,0.00010252302,0.000044088792,0.00003343976],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962626,0.00043567168,0.0009894903,0.0009069321,0.00070545723,0.0006998489],"domain_scores_gemma":[0.9974209,0.0013062872,0.0002067857,0.0005403787,0.00006487012,0.0004607989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001326901,0.00033047635,0.0009667907,0.00030951804,0.00004283845,0.00007389252,0.00017141143,0.00021316606,0.000034542867],"category_scores_gemma":[0.0017260944,0.00022600978,0.000058807287,0.00061941246,0.0002881427,0.00022613745,0.00010561714,0.0008015264,0.0000086492955],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5688467,0.012161406,0.38072667,0.0009519473,0.0012690679,0.004339094,0.0073149554,0.0001326712,0.015945958,0.00005799436,0.00009311711,0.008160433],"study_design_scores_gemma":[0.78449017,0.030699288,0.14830746,0.0028810443,0.0009960037,0.00008347129,0.002756436,0.017650766,0.0110389665,0.00012213232,0.00004376687,0.0009304861],"about_ca_topic_score_codex":0.004143489,"about_ca_topic_score_gemma":0.003289047,"teacher_disagreement_score":0.23241921,"about_ca_system_score_codex":0.00011137473,"about_ca_system_score_gemma":0.0005651288,"threshold_uncertainty_score":0.9216412},"labels":[],"label_agreement":null},{"id":"W4405047918","doi":"10.1182/blood-2024-208203","title":"Mutational and Clinical Characteristics Associated with Atherosclerotic Disease Burden in the MDS Canada Database: A Single-Center Analysis of CT Coronary Artery Calcium Scores","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Coronary artery disease; Internal medicine; Myelodysplastic syndromes; Database; Cardiology; Family history; Oncology; Bone marrow","score_opus":0.040636675609001506,"score_gpt":0.31023647736809995,"score_spread":0.2695998017590984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405047918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973493,0.00019738055,0.000023962997,0.0009935845,0.000035137582,0.00031261996,0.001043286,0.000012815415,0.000031865577],"genre_scores_gemma":[0.99815124,0.000024469779,0.00003811576,0.00031362078,0.000085441134,0.000019674217,0.0012680572,0.000016961094,0.00008241086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984693,0.00017738709,0.00034692188,0.00026649353,0.0005358446,0.00020403475],"domain_scores_gemma":[0.99864286,0.00081272924,0.00006207938,0.0002556757,0.00008100101,0.00014567863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043698677,0.00011623808,0.0003248981,0.00015715725,0.000031738346,0.000031340976,0.00010755531,0.000028475846,0.000052267438],"category_scores_gemma":[0.00044893473,0.000074927506,0.000066481625,0.00061275624,0.00016499306,0.000050427352,0.000051056417,0.00029776583,0.0000011633435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019986524,0.0006719736,0.9916166,0.00009662034,0.0021405471,0.0041829976,0.00013245079,0.0000040869063,0.00022245814,0.0000141720075,0.00035527578,0.00036292645],"study_design_scores_gemma":[0.00194685,0.00017133354,0.98755944,0.0003268486,0.0028151164,0.000076401404,0.00012756296,0.0068221823,0.000009893793,0.0000022835334,0.0000633866,0.00007868857],"about_ca_topic_score_codex":0.012509975,"about_ca_topic_score_gemma":0.04876335,"teacher_disagreement_score":0.036253378,"about_ca_system_score_codex":0.0001409222,"about_ca_system_score_gemma":0.001358461,"threshold_uncertainty_score":0.9940658},"labels":[],"label_agreement":null},{"id":"W4405050202","doi":"10.1182/blood-2024-209461","title":"Population-Based Analysis of Outcomes in Acute Myeloid Leukemia from a Provincial Cancer Registry and the Canadian Cancer Registry: A Population-Based Retrospective Cohort Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; CancerCare Manitoba","funders":"","keywords":"Cancer registry; Medicine; Myeloid leukemia; Cancer; Retrospective cohort study; Population; Internal medicine; Cohort; Oncology; Demography; Environmental health","score_opus":0.010969328582177423,"score_gpt":0.302139493982315,"score_spread":0.29117016540013757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405050202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925358,0.0005783804,0.000011870711,0.002935818,0.00010997097,0.0021134387,0.0015215292,0.00005737202,0.00013578912],"genre_scores_gemma":[0.99757266,0.00003235537,0.00013062802,0.00032312342,0.00015173119,0.00069625274,0.0006318094,0.000048394362,0.00041303196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970944,0.00020962818,0.00060954003,0.0007580755,0.0009007301,0.00042763638],"domain_scores_gemma":[0.9981505,0.00037398978,0.00022138072,0.0007888861,0.00022345931,0.00024177345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006914158,0.0003028471,0.0011324702,0.0008842893,0.00018029999,0.00010701615,0.000245492,0.00021423961,0.00017817112],"category_scores_gemma":[0.00052513386,0.00021903239,0.00023130624,0.0020935165,0.00016374516,0.00008148697,0.00004374199,0.00065218005,0.0000015647721],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00037589466,0.00013524144,0.99286115,0.00006138101,0.0048311614,0.00019761366,0.0004501465,0.00064634404,0.00005184941,0.00006001044,0.00011779521,0.00021142139],"study_design_scores_gemma":[0.0061513246,0.000076679826,0.9605164,0.00014887289,0.0074544568,0.000001434003,0.00012774099,0.025191179,0.000058807385,0.00004984299,0.000022345199,0.00020091343],"about_ca_topic_score_codex":0.9813653,"about_ca_topic_score_gemma":0.97422314,"teacher_disagreement_score":0.03234474,"about_ca_system_score_codex":0.004986937,"about_ca_system_score_gemma":0.0070252777,"threshold_uncertainty_score":0.99883276},"labels":[],"label_agreement":null},{"id":"W4405050250","doi":"10.1182/blood-2024-211936","title":"Can Optical Genome Mapping Replace Bone Marrow Biopsies in Acute Myeloid Leukemia?","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Bone marrow; Myeloid leukemia; Leukemia; Medicine; Cancer research; Pathology; Biology; Immunology","score_opus":0.017689500159258017,"score_gpt":0.272891301789172,"score_spread":0.25520180162991396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405050250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749028,0.003698562,0.000051989045,0.009839486,0.00015085001,0.0005550106,0.000038861905,0.0003147697,0.010447676],"genre_scores_gemma":[0.9809334,0.00074566563,0.0042697694,0.00053327,0.0005013548,0.000091334136,0.00009143019,0.000096269265,0.012737474],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974683,0.000059125472,0.00045684556,0.00068063464,0.00053734414,0.0007977456],"domain_scores_gemma":[0.9988,0.00017037021,0.000031595137,0.00060428143,0.0000705083,0.00032327086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006428814,0.00027336078,0.00051340705,0.0006187568,0.00006721717,0.000104730934,0.00021647174,0.00023949715,0.00021818938],"category_scores_gemma":[0.00023562157,0.00024289612,0.00014025057,0.0010378694,0.00017604665,0.00011559058,0.0002437213,0.0010097512,0.00037692176],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003375149,0.00036039038,0.006663184,0.0011510815,0.0010018931,0.03000302,0.0025382424,0.000016085212,0.94589967,0.0018393457,0.0052219704,0.0049676113],"study_design_scores_gemma":[0.046889137,0.003492086,0.21905793,0.0060416725,0.0034995652,0.042389795,0.0060578953,0.0141378315,0.3488305,0.0023260934,0.30273575,0.004541763],"about_ca_topic_score_codex":0.00022461783,"about_ca_topic_score_gemma":0.000060453003,"teacher_disagreement_score":0.5970692,"about_ca_system_score_codex":0.0010225457,"about_ca_system_score_gemma":0.0012784773,"threshold_uncertainty_score":0.9905016},"labels":[],"label_agreement":null},{"id":"W4405050440","doi":"10.1182/blood-2024-204116","title":"Expansion of <i>GATA1</i>-Mutant Clones in Blood Samples of Patients with Transient Abnormal Myelopoiesis (TAM) during Clinical Follow up Heralds Transformation to Myeloid Leukemia Associated with Down Syndrome (ML-DS)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"GATA1; Myelopoiesis; Myeloid; Myeloid leukemia; Transformation (genetics); Leukemia; Medicine; Mutant; Mutation; Biology; Cancer research; Immunology; Internal medicine; Genetics; Erythropoiesis; Haematopoiesis; Gene; Anemia","score_opus":0.016319840829150153,"score_gpt":0.2658330986708299,"score_spread":0.24951325784167971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405050440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971378,0.0001494235,0.00015512964,0.00029756388,0.00010227042,0.001647038,0.00029787055,0.0001206593,0.00009225104],"genre_scores_gemma":[0.99798775,0.00019984427,0.0011462353,0.000056353827,0.00004096119,0.000100474186,0.00031705,0.00008863716,0.000062688225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99563915,0.000211565,0.0014454904,0.000641925,0.0013689802,0.0006929036],"domain_scores_gemma":[0.99823296,0.0003423612,0.00020915622,0.00048586642,0.00040857334,0.00032107174],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008980457,0.00042284676,0.001138894,0.0006432939,0.00008122965,0.000034254943,0.00026588887,0.00031971064,0.000053059826],"category_scores_gemma":[0.00021212788,0.00030910273,0.00022819443,0.0015889211,0.00019412734,0.00039815207,0.000056828,0.00069321325,0.0000075469334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015196438,0.005834095,0.8479753,0.005312586,0.0046178605,0.0018578278,0.018946292,0.00068314,0.09226807,0.00008734563,0.00009621615,0.0071248226],"study_design_scores_gemma":[0.027646264,0.004629644,0.8812951,0.0035149744,0.0010683467,0.00013736894,0.00052032457,0.00013334853,0.08057223,0.000006530355,0.000054990272,0.00042091528],"about_ca_topic_score_codex":0.0003298644,"about_ca_topic_score_gemma":0.0003606268,"teacher_disagreement_score":0.033319756,"about_ca_system_score_codex":0.0003455535,"about_ca_system_score_gemma":0.0010020306,"threshold_uncertainty_score":0.9999361},"labels":[],"label_agreement":null},{"id":"W4405051123","doi":"10.1182/blood-2024-201875","title":"Efficacy and Safety of Revumenib in the Treatment of Acute Myeloid Leukemia with KMT2A Rearrangements or NPM1 Mutations: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"NPM1; Myeloid leukemia; Medicine; Oncology; Internal medicine; Leukemia; Myeloid; Bone marrow; Cancer research; Biology; Genetics; Karyotype","score_opus":0.04547199090986818,"score_gpt":0.3658874416028316,"score_spread":0.3204154506929634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405051123","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023817521,0.98534226,0.0000016243583,0.00011526406,0.000021355494,0.0137196295,0.0001702136,0.000021491256,0.00036997034],"genre_scores_gemma":[0.000031814565,0.99615645,0.000392934,0.000045108198,0.00005363652,0.0018396694,0.00024103667,0.000076567645,0.0011627752],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9963096,0.00057504786,0.0016122538,0.0004978038,0.0007018503,0.0003034805],"domain_scores_gemma":[0.9973879,0.000681487,0.00061430346,0.0010918371,0.00012580566,0.00009869968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009340256,0.00050272484,0.0042444826,0.00036498485,0.000036125857,0.000019276598,0.0003161728,0.00018345079,0.00003078384],"category_scores_gemma":[0.00023850636,0.000219637,0.0003560105,0.0012686966,0.00015716664,0.00004158882,0.000058919737,0.0003717805,0.000031134492],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015995564,0.00057414884,0.0000026127602,0.96796435,0.0049584615,0.0006382981,0.00054918544,2.7891092e-8,0.0000023728137,0.000024300467,0.00019246021,0.02493384],"study_design_scores_gemma":[0.0048250267,0.0021247307,0.000009847397,0.8588625,0.083425984,0.0014490387,0.00009331786,0.0000014794379,0.000005917298,0.0000025753045,0.049004503,0.00019503107],"about_ca_topic_score_codex":0.000054387718,"about_ca_topic_score_gemma":0.000014644653,"teacher_disagreement_score":0.10910179,"about_ca_system_score_codex":0.0006591149,"about_ca_system_score_gemma":0.0017763453,"threshold_uncertainty_score":0.89565367},"labels":[],"label_agreement":null},{"id":"W4405051217","doi":"10.1182/blood-2024-204446","title":"Effects of Obesity on Stem Cell Transplant Outcomes in Acute Myeloid Leukemia Patients: A Systematic Review and Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Hematopoietic stem cell transplantation; Myeloid leukemia; Transplantation; Oncology; Leukemia; Meta-analysis; Cancer; Stem cell; Biology","score_opus":0.03137697215744272,"score_gpt":0.31600252980620047,"score_spread":0.28462555764875774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405051217","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005130658,0.98918986,0.0000023869213,0.000039089788,0.000026631787,0.009596285,0.00047626882,0.00004369777,0.00011271135],"genre_scores_gemma":[0.00037362988,0.9956861,0.00004283536,0.00019861128,0.00001030075,0.0013445354,0.0001843012,0.00009643952,0.0020632192],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9945663,0.001037281,0.0020575048,0.0009172096,0.0009578546,0.0004638383],"domain_scores_gemma":[0.996733,0.0011176597,0.0006660973,0.0011209883,0.00011982723,0.00024242673],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0010598013,0.0009199187,0.018912561,0.0011997777,0.00002967959,0.000028838444,0.00042445795,0.00041857787,0.00002900957],"category_scores_gemma":[0.00010770594,0.0004989579,0.004258657,0.0018034716,0.0000641631,0.000049550792,0.00013814626,0.0011203488,0.00010898619],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005437385,0.00047885653,0.00002838875,0.7855709,0.21313938,0.0004320368,0.0000634133,3.268221e-8,3.4959493e-7,0.0000062787167,0.00005327703,0.00022161381],"study_design_scores_gemma":[0.0010143109,0.00027364455,0.000024476572,0.14955576,0.8482378,0.00003653343,0.0000033634565,0.0000011550088,0.000021175563,0.0000010428897,0.00053395896,0.000296748],"about_ca_topic_score_codex":0.000050013627,"about_ca_topic_score_gemma":0.000010592758,"teacher_disagreement_score":0.6360152,"about_ca_system_score_codex":0.00052843377,"about_ca_system_score_gemma":0.0005362833,"threshold_uncertainty_score":0.9997462},"labels":[],"label_agreement":null},{"id":"W4405051335","doi":"10.1182/blood-2024-203473","title":"Canadian Real-World Data for Acute Myeloid Leukemia Chemotherapy-Ineligible Patients on Venetoclax: An Interim Analysis from the Prospective Liven Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre; BC Cancer Agency; University of British Columbia; Baker Hughes (Canada); Vancouver General Hospital; University of Calgary; Memorial University of Newfoundland; Thunder Bay Regional Research Institute; Université de Sherbrooke; London Health Sciences Centre; CancerCare Manitoba","funders":"","keywords":"Venetoclax; Medicine; Internal medicine; Interim analysis; Cytarabine; Chemotherapy regimen; Regimen; Myeloid leukemia; Induction chemotherapy; Oncology; Pediatrics; Leukemia; Clinical trial; Chemotherapy; Chronic lymphocytic leukemia","score_opus":0.036425546038290506,"score_gpt":0.35863587391827373,"score_spread":0.3222103278799832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405051335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919656,0.00009520777,0.00002918266,0.0010700403,0.00012347243,0.0029542767,0.0023396662,0.00012442682,0.0012981134],"genre_scores_gemma":[0.99299437,0.00010012322,0.00044048185,0.0007012836,0.0006331652,0.00029521144,0.0031982667,0.00009541379,0.0015416656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744135,0.00011456542,0.0003372334,0.0010424595,0.00050254626,0.0005618149],"domain_scores_gemma":[0.9970159,0.000275553,0.00006710893,0.0020605174,0.00019626375,0.00038467924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000493933,0.00029805626,0.0005397001,0.00056352717,0.00020011903,0.0002032438,0.00095426675,0.000081061604,0.00012889178],"category_scores_gemma":[0.00010644029,0.00020526187,0.00015184702,0.001650682,0.00007845214,0.00018353302,0.00020524458,0.000499784,0.000074545394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019030009,0.0016294852,0.9140162,0.00005472547,0.0310427,0.00039262694,0.0069419923,0.00003038909,0.00072174234,0.00011613004,0.031260993,0.011890053],"study_design_scores_gemma":[0.008823962,0.004071107,0.94948125,0.00015944803,0.010661208,0.000004259264,0.0012509964,0.009635853,0.0020979133,0.0001644962,0.013165274,0.00048426434],"about_ca_topic_score_codex":0.3798532,"about_ca_topic_score_gemma":0.5458344,"teacher_disagreement_score":0.16598126,"about_ca_system_score_codex":0.0027004236,"about_ca_system_score_gemma":0.0023040255,"threshold_uncertainty_score":0.83703357},"labels":[],"label_agreement":null},{"id":"W4405052057","doi":"10.1182/blood-2024-212361","title":"Demystifying Genomic and Transcriptomic Landscape of Acute Myeloid Leukaemia-Normal Karyotype Using Deep Sequencing Technology","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Foothills Medical Centre","funders":"","keywords":"Karyotype; Myeloid leukaemia; Biology; Genetics; Deep sequencing; Computational biology; Transcriptome; Cancer research; Genome; Gene; Chromosome","score_opus":0.02101900462722959,"score_gpt":0.28051397462079897,"score_spread":0.25949496999356936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405052057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98674744,0.010518188,0.0009027479,0.00042555292,0.00010537084,0.00032053498,0.000019086341,0.00020223141,0.00075881934],"genre_scores_gemma":[0.99119294,0.00063447526,0.0077409847,0.000062078354,0.00015662466,0.000011406347,0.000015300006,0.00006326517,0.0001229092],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984931,0.00003267418,0.00036078496,0.00041417655,0.00022555828,0.0004737311],"domain_scores_gemma":[0.99938655,0.00006584638,0.00004843489,0.00029365957,0.00007031752,0.00013517424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029302982,0.0002087106,0.00042664006,0.0006749183,0.00008816924,0.000033936976,0.00016065716,0.00026947516,0.00007127443],"category_scores_gemma":[0.000038970793,0.00018932729,0.00009378805,0.00062921556,0.00018437346,0.0001337354,0.00011391967,0.0006166297,0.000021845693],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009920409,0.000034081262,0.01797642,0.00057939853,0.00066096144,0.0007175157,0.0005268472,0.000017664843,0.97573924,0.00028535165,0.000027306329,0.0033359942],"study_design_scores_gemma":[0.011302726,0.0011806982,0.015219498,0.0017172347,0.0059616277,0.020056799,0.001818693,0.0799299,0.8598299,0.000978214,0.0010460331,0.000958649],"about_ca_topic_score_codex":0.0000647367,"about_ca_topic_score_gemma":0.000011504289,"teacher_disagreement_score":0.11590933,"about_ca_system_score_codex":0.0002291334,"about_ca_system_score_gemma":0.00070297456,"threshold_uncertainty_score":0.77205426},"labels":[],"label_agreement":null},{"id":"W4405054136","doi":"10.1182/blood-2024-204066","title":"Age ≥60 Is an Added Risk Factor for Mortality in High-Risk HCT-CI Patients Undergoing Allogeneic Stem Cell Transplant","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Stem cell; Risk factor; Internal medicine; Transplantation; Oncology; Surgery; Biology","score_opus":0.03110526254752802,"score_gpt":0.28873127130911747,"score_spread":0.2576260087615894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405054136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936423,0.00049982296,0.00024242188,0.0000603851,0.00017019549,0.0012649064,0.0037883797,0.0001383201,0.00019332716],"genre_scores_gemma":[0.99758273,0.0006676204,0.0005322884,0.000107206724,0.00017877526,0.000097664975,0.00030939907,0.000081922015,0.0004423785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763954,0.00018100486,0.00044336848,0.0006586767,0.00049169525,0.00058572233],"domain_scores_gemma":[0.998754,0.00031413033,0.000077726894,0.00051197695,0.00006585935,0.00027627905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038070336,0.000272056,0.00042850059,0.00022984672,0.00009085217,0.000058840753,0.00020974678,0.00022033039,0.00014437371],"category_scores_gemma":[0.000039795712,0.00022840439,0.00017661828,0.00029798018,0.000049146478,0.00012798572,0.000043363932,0.0005669082,0.000068792295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005090108,0.002251946,0.95774126,0.0020843153,0.00094465463,0.0017044088,0.008383431,0.00002463552,0.0098734815,0.00003077427,0.0007706199,0.015681485],"study_design_scores_gemma":[0.022026094,0.0025083772,0.8933638,0.00048993994,0.001661157,0.000015137061,0.0005131368,0.0019850167,0.07524934,0.00027098972,0.0012803486,0.00063671754],"about_ca_topic_score_codex":0.00080570224,"about_ca_topic_score_gemma":0.0010210681,"teacher_disagreement_score":0.06537585,"about_ca_system_score_codex":0.00022609333,"about_ca_system_score_gemma":0.0003963868,"threshold_uncertainty_score":0.931406},"labels":[],"label_agreement":null},{"id":"W4405054563","doi":"10.1182/blood-2024-211783","title":"Clinical Relevance of NPM1 Quantitative PCR As Standard of Care with Different Cut-Off Values on Treatment Outcomes in NPM1-Mutated Acute Myeloid Leukemia Patients","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"NPM1; Myeloid leukemia; Medicine; Clinical significance; Internal medicine; Oncology; Immunology; Biology; Genetics; Gene; Karyotype","score_opus":0.027230533196165852,"score_gpt":0.3658810064137878,"score_spread":0.33865047321762193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405054563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99596226,0.0009929758,0.000012982976,0.00023861561,0.00014219634,0.0012333068,0.0004412486,0.000070392096,0.0009060229],"genre_scores_gemma":[0.9961958,0.0017592317,0.0009087151,0.000052965926,0.000035631307,0.00007412944,0.00020060723,0.00006999611,0.00070295634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968789,0.00022769863,0.00088005525,0.00062613626,0.00096873974,0.00041847277],"domain_scores_gemma":[0.99766517,0.0009945611,0.00018963453,0.00054958975,0.000410406,0.00019064458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002179578,0.00038938125,0.00133908,0.00034298724,0.00003591991,0.00001682413,0.00018252028,0.00017994047,0.000034134682],"category_scores_gemma":[0.00038336727,0.00023385572,0.00026539637,0.00044663265,0.00029591357,0.000082753075,0.000082765575,0.0005012421,0.000027215949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0156551,0.0038702644,0.93897223,0.0011943347,0.0046731886,0.0012843728,0.0084553845,0.00004221829,0.0014656448,0.00062949397,0.00028719663,0.023470579],"study_design_scores_gemma":[0.059987254,0.11279876,0.64562905,0.005763866,0.0029782264,0.0000345544,0.0036282465,0.0004264398,0.16667697,0.00031122068,0.0010247185,0.0007407028],"about_ca_topic_score_codex":0.00019469587,"about_ca_topic_score_gemma":0.00017478851,"teacher_disagreement_score":0.2933432,"about_ca_system_score_codex":0.00122912,"about_ca_system_score_gemma":0.0011363932,"threshold_uncertainty_score":0.953636},"labels":[],"label_agreement":null},{"id":"W4405072689","doi":"10.1158/2767-9764.crc-24-0522","title":"Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors","year":2024,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Regional Cancer Foundation; Vancouver General Hospital; Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; University of British Columbia; Canadian Cancer Society; University Health Network","funders":"Health Innovation Network South London; AstraZeneca","keywords":"Internal medicine; Oncology; Medicine; Adverse effect; Chemotherapy","score_opus":0.04004157953203048,"score_gpt":0.395896123513038,"score_spread":0.3558545439810075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405072689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941278,0.0010958631,0.000003422936,0.003597755,0.000009109158,0.0008827352,0.000077849756,0.00001654874,0.00018892124],"genre_scores_gemma":[0.99698615,0.0015594647,0.00025238394,0.000016684806,0.000009295268,0.00033917802,0.000049181897,0.000022590557,0.00076504983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983586,0.00023159572,0.00021514246,0.0002205353,0.0006777262,0.0002963689],"domain_scores_gemma":[0.9985175,0.00036608538,0.000054691038,0.00048935506,0.00044313472,0.00012922149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054327055,0.000112908594,0.00027668328,0.0004031083,0.00013946879,0.000013615357,0.00018452224,0.00006265293,0.000024774372],"category_scores_gemma":[0.00013062048,0.00007760057,0.0000254654,0.0005056437,0.00019777776,0.0001626795,0.00025492796,0.0004379671,0.0000038915905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041915913,0.00029783897,0.9942224,0.00021263043,0.00029793437,0.000016478885,0.0010513553,0.0000087869585,0.00025678685,0.00017459405,0.000052734966,0.002989309],"study_design_scores_gemma":[0.0032334365,0.0007011931,0.9924624,0.0006514716,0.00006549031,0.000006260168,0.00031914626,0.0016107041,0.0005934319,0.000054705917,0.00021452579,0.00008726242],"about_ca_topic_score_codex":0.00057888974,"about_ca_topic_score_gemma":0.0005397186,"teacher_disagreement_score":0.0035810703,"about_ca_system_score_codex":0.0013530294,"about_ca_system_score_gemma":0.00076512014,"threshold_uncertainty_score":0.3538125},"labels":[],"label_agreement":null},{"id":"W4405095992","doi":"10.1182/blood-2024-211434","title":"Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in the Patients with CCAAT Enhancer-Binding Protein a Gene (CEBPA) Mutated Acute Myeloid Leukemia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"CEBPA; Ccaat-enhancer-binding proteins; Flow cytometry; Myeloid leukemia; Cancer research; Molecular biology; Myeloid; Minimal residual disease; Biology; Gene; Leukemia; Mutation; Medicine; Immunology; Genetics; Nuclear protein; Transcription factor","score_opus":0.015972281502590245,"score_gpt":0.28703491048645136,"score_spread":0.27106262898386113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405095992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99360293,0.0002308739,0.00051684753,0.0010854516,0.00007646521,0.0036995148,0.00021354403,0.00019349043,0.0003808785],"genre_scores_gemma":[0.9844346,0.000016279993,0.012699863,0.00014150205,0.00014464463,0.0012131593,0.00057075225,0.0001180665,0.0006611192],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99566597,0.00036200442,0.0004966656,0.0008640679,0.0017120384,0.0008992413],"domain_scores_gemma":[0.99817693,0.0003018708,0.00008883553,0.0008340146,0.00023399026,0.00036434198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009960022,0.00043720478,0.00049698184,0.0006773798,0.00017352654,0.00023843496,0.00041318705,0.00016051247,0.00013241851],"category_scores_gemma":[0.00028178055,0.00027548932,0.0001441441,0.0018076755,0.00016825294,0.00023998324,0.000104086525,0.0012553445,0.00012616407],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011975734,0.007036989,0.09594963,0.0028201598,0.0040538386,0.01826078,0.0021430175,0.0010301796,0.8437009,0.00005678818,0.0032391371,0.0097328685],"study_design_scores_gemma":[0.08141532,0.004272383,0.12614612,0.003991408,0.0034636876,0.0001544727,0.00042775125,0.05002103,0.7270311,0.00007268406,0.0012434428,0.0017606074],"about_ca_topic_score_codex":0.00011604254,"about_ca_topic_score_gemma":0.000030364343,"teacher_disagreement_score":0.1166698,"about_ca_system_score_codex":0.0013514322,"about_ca_system_score_gemma":0.0029098126,"threshold_uncertainty_score":0.9999697},"labels":[],"label_agreement":null},{"id":"W4405424625","doi":"10.3390/cancers16244171","title":"Unveiling the Complexity of KMT2A Rearrangements in Acute Myeloid Leukemias with Optical Genome Mapping","year":2024,"lang":"en","type":"article","venue":"Cancers","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Chromosomal translocation; Biology; Fluorescence in situ hybridization; Locus (genetics); Gene rearrangement; Cytogenetics; Genetics; Breakpoint; Gene; Chromosome","score_opus":0.06162461796978779,"score_gpt":0.3209966230159786,"score_spread":0.2593720050461908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405424625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97989666,0.0013304668,0.00074112683,0.0030254102,0.00012569153,0.0006675857,0.000023242943,0.00006609974,0.014123683],"genre_scores_gemma":[0.99596953,0.0003192142,0.001930604,0.00035049592,0.00014505986,0.000051586692,0.000023885497,0.000035816527,0.0011737777],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985196,0.000041734842,0.0002700045,0.00032299853,0.0004392096,0.0004064417],"domain_scores_gemma":[0.99932015,0.00008998948,0.000035437042,0.00036015877,0.00007589996,0.00011833649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043244826,0.0001488905,0.0003065044,0.00019053201,0.00005394031,0.000027498014,0.0002097597,0.00006946879,0.00020348778],"category_scores_gemma":[0.00004007886,0.00009514543,0.00006589831,0.0007755836,0.00067113043,0.0000771341,0.00009348914,0.00058769307,0.0000464689],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075029037,0.00018522036,0.020937288,0.007349795,0.0071707,0.008623874,0.034504507,0.010718504,0.79569304,0.024644235,0.021138472,0.061531466],"study_design_scores_gemma":[0.028827693,0.0040399097,0.34973273,0.011979253,0.0018872618,0.0018529731,0.028807957,0.21518481,0.07787293,0.0026029213,0.27444053,0.00277104],"about_ca_topic_score_codex":0.00063253083,"about_ca_topic_score_gemma":0.000101136655,"teacher_disagreement_score":0.7178201,"about_ca_system_score_codex":0.00422323,"about_ca_system_score_gemma":0.0023413827,"threshold_uncertainty_score":0.9995994},"labels":[],"label_agreement":null},{"id":"W4405453428","doi":"10.1161/strokeaha.124.049631","title":"Polka Dot Intracerebral Hemorrhage in Leukemia","year":2024,"lang":"en","type":"article","venue":"Stroke","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Intracerebral hemorrhage; Leukemia; Pathology; Internal medicine; Subarachnoid hemorrhage","score_opus":0.015479843735790455,"score_gpt":0.3007858446953612,"score_spread":0.2853060009595707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405453428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9366184,0.001203461,0.00010830827,0.004110534,0.000322719,0.0003223797,0.000035311783,0.00020395812,0.057074968],"genre_scores_gemma":[0.96129584,0.000048303995,0.0015421669,0.00039877457,0.000525807,0.000026105196,0.000029817465,0.00004141127,0.036091752],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99856514,0.00003621221,0.00022457955,0.00034410754,0.00034347345,0.00048648083],"domain_scores_gemma":[0.9993719,0.00008839085,0.000012539515,0.0003206343,0.000030013642,0.00017653282],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00029199955,0.00014811862,0.00023765229,0.00034174573,0.000028254162,0.000056450514,0.00013715324,0.0001298057,0.001102885],"category_scores_gemma":[0.00011369756,0.00012476608,0.00009421175,0.00041764122,0.00008353339,0.00011702442,0.00009634803,0.0008626495,0.0011199397],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011444016,0.0002626494,0.055460528,0.0026125568,0.00037319935,0.02929855,0.0027756817,0.000055973083,0.28873,0.014064566,0.14644971,0.45877218],"study_design_scores_gemma":[0.020149931,0.0026710015,0.17493267,0.0021735197,0.00044441636,0.005833138,0.0039560706,0.14632003,0.16565906,0.002890313,0.4727002,0.0022696583],"about_ca_topic_score_codex":0.00030312611,"about_ca_topic_score_gemma":0.000071167684,"teacher_disagreement_score":0.45650253,"about_ca_system_score_codex":0.001298654,"about_ca_system_score_gemma":0.0008470812,"threshold_uncertainty_score":0.9998102},"labels":[],"label_agreement":null},{"id":"W4405555514","doi":"10.21203/rs.3.rs-5449535/v1","title":"Central Nervous System Disease and Outcome in Pediatric Acute Myeloid Leukemia: Results from NOPHO-DBH AML2012 Trial","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Myeloid leukemia; Outcome (game theory); Disease; Medicine; Central nervous system; Oncology; Pediatrics; Immunology; Internal medicine; Economics","score_opus":0.05511240332611898,"score_gpt":0.3777305015892568,"score_spread":0.3226180982631378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405555514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96649283,0.009475393,0.000012890339,0.004750964,0.0017379052,0.008803873,0.0058291587,0.00046250454,0.002434503],"genre_scores_gemma":[0.9774998,0.005918944,0.0003119699,0.000061738625,0.00727041,0.0011409594,0.0027436276,0.00030727626,0.004745279],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9856354,0.0016725222,0.002109522,0.003083267,0.0044664606,0.003032824],"domain_scores_gemma":[0.9913355,0.002024705,0.0002718603,0.0027982942,0.00076963817,0.0027999887],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0048813983,0.0010161743,0.002002328,0.0028791341,0.00028095627,0.00065611204,0.0011912225,0.0015327877,0.00009699438],"category_scores_gemma":[0.0036714,0.00087357854,0.0006346362,0.0019282994,0.00047122108,0.00016208297,0.006916712,0.01267384,0.0006928875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.56464446,0.0017752,0.12121963,0.071062,0.0030326995,0.117617905,0.0064545018,0.00080992235,0.000630676,0.0012305545,0.09701188,0.014510567],"study_design_scores_gemma":[0.23330557,0.0035771413,0.6872921,0.014409067,0.004034721,0.00024913848,0.003650359,0.04018065,0.00022394992,0.0035036812,0.005820182,0.0037534495],"about_ca_topic_score_codex":0.0077765696,"about_ca_topic_score_gemma":0.0002657009,"teacher_disagreement_score":0.56607246,"about_ca_system_score_codex":0.011270907,"about_ca_system_score_gemma":0.010689319,"threshold_uncertainty_score":0.9997634},"labels":[],"label_agreement":null},{"id":"W4405557300","doi":"10.1016/j.lrr.2024.100495","title":"Targeting menin for precision therapy in high-risk acute myeloid leukemia","year":2024,"lang":"en","type":"review","venue":"Leukemia Research Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Hamilton Health Sciences; University of Ottawa","funders":"","keywords":"Medicine; Myeloid leukemia; Cancer research; Oncology; Internal medicine","score_opus":0.08567478413901318,"score_gpt":0.43046841234776895,"score_spread":0.34479362820875575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405557300","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019840163,0.978291,0.00011166124,0.00023263294,0.0011058283,0.015720377,0.00026809477,0.00043000226,0.001856431],"genre_scores_gemma":[0.0002160556,0.9616476,0.0037112883,0.000056899862,0.0023087412,0.007217843,0.0019058761,0.0009071623,0.022028524],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9796811,0.0020931994,0.0043628444,0.0041119563,0.005874107,0.0038768305],"domain_scores_gemma":[0.98821497,0.0038628187,0.0011692334,0.0035105003,0.0020369086,0.0012055886],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.025497423,0.0017736277,0.00586399,0.0048057796,0.0005916358,0.00057278655,0.0013191211,0.0026092045,0.0002817061],"category_scores_gemma":[0.009100262,0.0012921147,0.0019619407,0.005278589,0.000636649,0.00039678506,0.001535329,0.012029744,0.00078938797],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00060080306,0.000108997825,0.00003963584,0.017938213,0.0014588264,0.019899858,0.00020545934,0.000015809712,0.00012026421,0.00008634095,0.16573769,0.7937881],"study_design_scores_gemma":[0.0023678401,0.0013917086,0.00001747875,0.026883759,0.0012267409,0.002936824,0.00007131266,0.0006979622,0.00014150063,0.0016999155,0.961506,0.0010589358],"about_ca_topic_score_codex":0.002402801,"about_ca_topic_score_gemma":0.000088776826,"teacher_disagreement_score":0.7957683,"about_ca_system_score_codex":0.046538178,"about_ca_system_score_gemma":0.042240992,"threshold_uncertainty_score":0.9999886},"labels":[],"label_agreement":null},{"id":"W4405748749","doi":"10.1016/j.jval.2024.10.199","title":"CO123 Patient Characteristics, Treatment Pattern, Treatment Outcomes, and Survival Prognosis of Elderly Patients With Myelodysplastic Syndromes in China: A Systematic Literature Review","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Canada","funders":"","keywords":"Myelodysplastic syndromes; Medicine; China; Intensive care medicine; Internal medicine; Oncology; History","score_opus":0.024337493309489422,"score_gpt":0.30066767158811003,"score_spread":0.2763301782786206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405748749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93624943,0.055224404,0.00000864806,0.0019331906,0.00015549228,0.0061312076,0.00024341533,0.000039851537,0.000014361714],"genre_scores_gemma":[0.9533649,0.045331236,0.0001406738,0.00011865402,0.000019478952,0.00067862676,0.0002191433,0.000050913364,0.000076375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99677336,0.00053147814,0.0011509837,0.0005218996,0.000538606,0.00048364644],"domain_scores_gemma":[0.99862134,0.0004318398,0.0002296306,0.0003819549,0.00009414773,0.0002410629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048134036,0.00038496568,0.0016903463,0.00045537367,0.000035176636,0.000039559498,0.00007262446,0.000092417766,0.00001182354],"category_scores_gemma":[0.00017726855,0.0002229606,0.000093340605,0.00066107913,0.000054676977,0.00008200607,0.00003452453,0.00026350893,0.000007737259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013480698,0.0011926059,0.6774128,0.29679415,0.00027125448,0.0006998246,0.003017539,0.000005118651,0.0000010839962,0.00002871559,0.0000323112,0.020409789],"study_design_scores_gemma":[0.003313272,0.011058521,0.6586765,0.32513157,0.0002042499,0.00010529103,0.00007718691,0.0011431549,0.0000048635316,0.000004832776,0.00008224709,0.00019833],"about_ca_topic_score_codex":0.0019003104,"about_ca_topic_score_gemma":0.00010401772,"teacher_disagreement_score":0.028337441,"about_ca_system_score_codex":0.0020583128,"about_ca_system_score_gemma":0.0006800208,"threshold_uncertainty_score":0.9092069},"labels":[],"label_agreement":null},{"id":"W4405757822","doi":"10.1080/10428194.2024.2438807","title":"Navigating AML treatment in vascular Ehlers–Danlos syndrome: achieving deeper remission with oral azacitidine—a first case report","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ehlers–Danlos syndrome; Medicine; Azacitidine; Dermatology; Surgery; Genetics; Biology","score_opus":0.015110241712121391,"score_gpt":0.2871527101170982,"score_spread":0.2720424684049768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405757822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890583,0.0055068457,0.00023636498,0.00076838885,0.0002947384,0.0017932211,0.000039942883,0.00068130536,0.0016208681],"genre_scores_gemma":[0.99122053,0.0012694362,0.0036933243,0.0003581617,0.00038279092,0.00047697587,0.00030293516,0.0003536389,0.0019422069],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99268466,0.0002665739,0.0014835331,0.0023740362,0.001325015,0.0018661725],"domain_scores_gemma":[0.99607855,0.0006182944,0.00026420492,0.0016177284,0.0002215078,0.0011997238],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0011686203,0.0013236102,0.0017016298,0.00057461095,0.0007200031,0.00041871454,0.0003499715,0.00081889547,0.00016622058],"category_scores_gemma":[0.00030406294,0.0010207132,0.0004902316,0.0019419353,0.00053385645,0.00076836237,0.0003519884,0.0007332279,0.00011506138],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000767385,0.00029784808,0.019578122,0.0014685498,0.00084041076,0.78961116,0.0028642467,0.00023651744,0.0019769224,0.00015371879,0.0008297457,0.18137538],"study_design_scores_gemma":[0.025561828,0.0019253688,0.03360083,0.008465171,0.0010771086,0.85185915,0.0028262453,0.036536384,0.0037972427,0.000102888225,0.032341644,0.0019061269],"about_ca_topic_score_codex":0.0126199955,"about_ca_topic_score_gemma":0.00090237363,"teacher_disagreement_score":0.17946926,"about_ca_system_score_codex":0.031502776,"about_ca_system_score_gemma":0.0073937033,"threshold_uncertainty_score":0.99995154},"labels":[],"label_agreement":null},{"id":"W4405906667","doi":"10.1182/bloodadvances.2024014865","title":"Advancing drug development in myelodysplastic syndromes","year":2024,"lang":"en","type":"review","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"Genentech; U.S. Food and Drug Administration; National Institutes of Health; Paracelsus Medizinische Privatuniversität; Cincinnati Children's Hospital Medical Center; Università degli Studi di Firenze; National Heart, Lung, and Blood Institute; Acceleron; Eli Lilly and Company; Universidad de Salamanca; Memorial Sloan-Kettering Cancer Center; University of Washington; Bristol-Myers Squibb; Cleveland Clinic; University of Miami; Pfizer; Northwestern University; Incyte; National Cancer Institute; Servier; Ohio State University; University of Pennsylvania; Alexion Pharmaceuticals; Massachusetts General Hospital; Sanofi; AstraZeneca; Celgene","keywords":"Myelodysplastic syndromes; Medicine; Decitabine; Drug development; Clinical trial; Oncology; Stem cell; Transplantation; Intensive care medicine; Hematopoietic stem cell transplantation; Food and drug administration; Drug; Internal medicine; Pharmacology; Bone marrow","score_opus":0.02886272746914764,"score_gpt":0.3608832563954044,"score_spread":0.3320205289262568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405906667","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000119562756,0.99578196,0.000011286756,0.00008112209,0.00047062678,0.0013708341,0.000017745864,0.00018164421,0.0019652257],"genre_scores_gemma":[0.0000197363,0.98574114,0.0053780354,0.000037817703,0.00030162613,0.0005274999,0.00012968003,0.00016551427,0.0076989383],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99626344,0.00011469485,0.0010890004,0.00096612854,0.00066815485,0.0008985549],"domain_scores_gemma":[0.99848825,0.00048019877,0.00019016718,0.0004900199,0.00006580501,0.00028558943],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054281316,0.0007187886,0.0025804562,0.0010625056,0.00007116474,0.000054568663,0.00039257895,0.00024376376,0.000105748375],"category_scores_gemma":[0.00040627588,0.00051344204,0.0003377421,0.0012610484,0.000100027035,0.0001913682,0.00032461653,0.0014932737,0.0012227527],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010425522,0.00012361504,0.00003952159,0.095605485,0.00037096415,0.0030717244,0.00012941327,0.0000014864407,0.0000010725167,0.00005427188,0.00079727103,0.89979476],"study_design_scores_gemma":[0.0005168822,0.000060758037,0.00000842704,0.077971265,0.0015151127,0.0012548935,0.000066218825,0.0000040824307,0.000012663698,0.000037217273,0.9181062,0.0004462808],"about_ca_topic_score_codex":0.000009032591,"about_ca_topic_score_gemma":0.00006836773,"teacher_disagreement_score":0.9173089,"about_ca_system_score_codex":0.00085881376,"about_ca_system_score_gemma":0.0032083949,"threshold_uncertainty_score":0.9997317},"labels":[],"label_agreement":null},{"id":"W4406030350","doi":"10.1002/cac2.12650","title":"A strong internal promoter drives massive expression of YEATS‐domain devoid <i>MLLT3</i> transcripts in HSC and most lethal AML","year":2025,"lang":"en","type":"article","venue":"Cancer Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Institut National Du Cancer; Association Laurette Fugain; Ministère de la Santé; Fondation ARC pour la Recherche sur le Cancer; Fondation de France; Institut National de la Santé et de la Recherche Médicale; Agence Nationale de la Recherche","keywords":"RNA polymerase II; Transcription factor; Transactivation; Molecular biology; Cell biology; Transcription (linguistics); Biology; Chemistry; Promoter; Gene expression; Genetics; Gene","score_opus":0.03057785634176597,"score_gpt":0.3543113829083722,"score_spread":0.32373352656660626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406030350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9560666,0.006142591,0.0022213697,0.017513907,0.00006703017,0.0009132651,0.0000811684,0.0000326674,0.016961414],"genre_scores_gemma":[0.9914172,0.00147171,0.005630355,0.00022228724,0.000019610836,0.0002486758,0.000034290686,0.00001470802,0.0009411442],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99899703,0.00017008524,0.00029819974,0.00019108722,0.00014708625,0.00019648089],"domain_scores_gemma":[0.99866045,0.0001481513,0.00006766067,0.00092127535,0.0001256058,0.000076862634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016854868,0.000113647344,0.0002570255,0.00021515122,0.000086518725,0.000015293126,0.00047429395,0.00008667965,0.00005867145],"category_scores_gemma":[0.000067254725,0.0001025568,0.00004449436,0.0003442646,0.0004036433,0.00010295405,0.00033522132,0.0005334118,0.0000017752487],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060321816,0.0005168442,0.09641122,0.00048700592,0.0001868069,0.000024130766,0.011162404,0.00002388868,0.8568508,0.004388277,0.0057099685,0.023635412],"study_design_scores_gemma":[0.026248246,0.00079158467,0.39270094,0.015267504,0.00045089587,0.000084369975,0.019746585,0.008255318,0.4384224,0.004993828,0.09201188,0.0010264339],"about_ca_topic_score_codex":0.00061599567,"about_ca_topic_score_gemma":0.0007407632,"teacher_disagreement_score":0.41842842,"about_ca_system_score_codex":0.0003017428,"about_ca_system_score_gemma":0.000482024,"threshold_uncertainty_score":0.4182145},"labels":[],"label_agreement":null},{"id":"W4406352467","doi":"10.1182/bloodadvances.2024014948","title":"Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Italfarmaco; EUSA Pharma; MorphoSys; Cancer Research UK; Incyte; BeiGene; Gilead Sciences; Fondazione CRT; Associazione Italiana per la Ricerca sul Cancro; AstraZeneca; Eli Lilly and Company","keywords":"Mantle cell lymphoma; Chemoimmunotherapy; Internal medicine; Lenalidomide; Medicine; Oncology; Hematopoietic stem cell transplantation; Lymphoma; Clinical trial; Transplantation; Cohort; Autologous stem-cell transplantation; Multiple myeloma; Rituximab","score_opus":0.04235724640786973,"score_gpt":0.39158264064620313,"score_spread":0.3492253942383334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406352467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98600453,0.004513071,0.000037357342,0.0028870595,0.0005578895,0.0009090631,0.00033983696,0.000040891562,0.0047103246],"genre_scores_gemma":[0.9943156,0.000894611,0.0013720882,0.000583514,0.00047747808,0.000056183344,0.00008768843,0.000019832923,0.002193004],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970269,0.00039409962,0.0011692577,0.0005008758,0.0004856663,0.00042317223],"domain_scores_gemma":[0.9944377,0.004470164,0.00023528087,0.00067525223,0.00009119466,0.00009041723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018022946,0.00020741769,0.00080674526,0.00012427788,0.00008344008,0.000016061655,0.00041513707,0.00018610278,0.000064365464],"category_scores_gemma":[0.0027898168,0.00013393656,0.00028313976,0.0004953471,0.00022918261,0.00010324624,0.00024250419,0.00036972275,0.00003721412],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15817623,0.011559211,0.7818273,0.0008665575,0.00077767845,0.0007371516,0.0010920148,0.000015068832,0.002178429,0.0017167358,0.026869666,0.01418401],"study_design_scores_gemma":[0.5264092,0.0016015976,0.33757788,0.00070673664,0.0006517763,0.00001829554,0.002048441,0.0002151374,0.03252208,0.0014935542,0.0963156,0.00043968542],"about_ca_topic_score_codex":0.00024413437,"about_ca_topic_score_gemma":0.0002737309,"teacher_disagreement_score":0.44424936,"about_ca_system_score_codex":0.00006973815,"about_ca_system_score_gemma":0.00043743738,"threshold_uncertainty_score":0.5461774},"labels":[],"label_agreement":null},{"id":"W4406364705","doi":"10.1182/blood.2024026598","title":"Precision medicine for high-risk gene fusions in pediatric AML: a focus on <i>KMT2A</i>, <i>NUP98</i>, and <i>GLIS2</i> rearrangements","year":2025,"lang":"en","type":"review","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute","keywords":"Oncology; Medicine; Bioinformatics; Fusion gene; Cancer research; Gene; Biology; Internal medicine; Genetics","score_opus":0.02961268909233812,"score_gpt":0.3402455250403277,"score_spread":0.31063283594798957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406364705","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009574238,0.98776466,0.00006998671,0.00059153244,0.0003778456,0.007014273,0.00057789683,0.00012349838,0.0025228674],"genre_scores_gemma":[0.00011224307,0.99181384,0.0015967264,0.00027244075,0.0016086051,0.001423006,0.00065358606,0.00015912857,0.0023604238],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99490285,0.00044449331,0.0013979141,0.001408733,0.0009556901,0.0008903117],"domain_scores_gemma":[0.99498993,0.0025793903,0.0005079611,0.0012649472,0.00022386386,0.00043393322],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016755617,0.00085810776,0.0032302712,0.0017808111,0.00019646599,0.000035068308,0.0005252658,0.0008100675,0.0000636642],"category_scores_gemma":[0.0025445395,0.00062439044,0.00040040133,0.0018167427,0.0001276985,0.00006817564,0.00046775964,0.0015160282,0.000049865204],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003314423,0.0010562597,0.0004776822,0.03069244,0.00044901858,0.0002452802,0.00010285068,2.5581411e-7,0.000017863247,0.00010934621,0.03468421,0.9318333],"study_design_scores_gemma":[0.027185984,0.0033340065,0.0005581188,0.038418088,0.016172286,0.00015568253,0.000027649696,0.0000066816137,0.00007719101,0.00063426216,0.91249615,0.0009339207],"about_ca_topic_score_codex":0.00035449996,"about_ca_topic_score_gemma":0.00008508188,"teacher_disagreement_score":0.93089944,"about_ca_system_score_codex":0.00032424135,"about_ca_system_score_gemma":0.0011571464,"threshold_uncertainty_score":0.99962074},"labels":[],"label_agreement":null},{"id":"W4406366803","doi":"10.21203/rs.3.rs-5760913/v1","title":"Efficacy of FLT3 Inhibitors in Patients with FLT3-Mutated Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","year":2025,"lang":"en","type":"review","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Myeloid leukemia; Meta-analysis; Medicine; Randomized controlled trial; Oncology; Chemotherapy; Internal medicine; Acute leukemia; Intensive care medicine; Leukemia","score_opus":0.08052108944263335,"score_gpt":0.43929745771275064,"score_spread":0.3587763682701173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406366803","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000110171204,0.88531715,0.000048793518,0.0003409181,0.000018330633,0.113093466,0.0009832226,0.000024821149,0.00006312687],"genre_scores_gemma":[0.00028624662,0.9786271,0.00020785318,0.00010751101,0.000026177595,0.01782552,0.001404102,0.0001296057,0.0013859202],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.96924347,0.01684807,0.0086704595,0.001249165,0.002994818,0.0009940244],"domain_scores_gemma":[0.919691,0.063341334,0.0044841534,0.0019119887,0.01018196,0.0003895369],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.046350677,0.0011351182,0.09975179,0.0069084787,0.00009239671,0.00006475307,0.00071143697,0.0006808813,0.00020761607],"category_scores_gemma":[0.11587757,0.0005513684,0.014150842,0.008229291,0.0007727047,0.00009870427,0.0003012133,0.0015446738,0.000004429229],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059601426,0.00016216599,0.0000033680617,0.5569679,0.38164976,0.000014150446,0.00009997743,0.0000011517454,6.9032865e-7,0.000024546196,0.0002968557,0.0011779827],"study_design_scores_gemma":[0.19276385,0.000561503,0.000003742366,0.20022348,0.6058519,0.0000027703334,0.000068722795,0.0000507681,0.000006691368,0.000007640071,0.00021522328,0.00024375039],"about_ca_topic_score_codex":0.00016645085,"about_ca_topic_score_gemma":0.000016738737,"teacher_disagreement_score":0.35674444,"about_ca_system_score_codex":0.0015854123,"about_ca_system_score_gemma":0.0051916456,"threshold_uncertainty_score":0.9996938},"labels":[],"label_agreement":null},{"id":"W4406447684","doi":"10.1016/j.yonc.2013.07.029","title":"10.1016/j.yonc.2013.07.029","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; NPM1; Oncology; Internal medicine; Overall survival; Residual; Mutant; Disease; Minimal residual disease; Leukemia; Genetics; Gene","score_opus":0.010429254822798184,"score_gpt":0.23162993457288916,"score_spread":0.22120067975009097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406447684","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032003717,0.00012879522,9.209257e-7,0.0038214019,0.0000012775296,0.00045563898,0.000013734196,0.00019195351,0.9921859],"genre_scores_gemma":[0.0002529684,0.0000021277867,0.00037925105,0.00027288968,0.00038590658,0.000036796406,0.00004101884,0.000055354016,0.99857366],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843246,0.000050783587,0.00021821422,0.00033289194,0.0004441076,0.0005215238],"domain_scores_gemma":[0.99875826,0.000077928904,0.000020842986,0.0005830939,0.00010342235,0.00045648223],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002493037,0.00017807136,0.00029861953,0.00014506116,0.00007576277,0.000028547172,0.00023489754,0.000119611854,0.9991506],"category_scores_gemma":[0.000107897045,0.0001558796,0.000090242625,0.00033086064,0.00007161345,0.0000773469,0.00007558212,0.00034412227,0.99924076],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028498014,0.000049664366,3.8542711e-7,0.000012514162,0.000030304209,0.00005998033,0.000017375945,0.0000069056828,0.00027154663,4.1460135e-7,0.6047111,0.39455482],"study_design_scores_gemma":[0.0010818386,0.0004290942,0.00010600205,0.000041343712,0.00003670597,0.000095748,0.0000020965315,0.00044311056,0.0004415956,0.0000036915758,0.99715346,0.00016529308],"about_ca_topic_score_codex":0.0001147856,"about_ca_topic_score_gemma":2.560369e-7,"teacher_disagreement_score":0.3943895,"about_ca_system_score_codex":0.0002496919,"about_ca_system_score_gemma":0.00019827491,"threshold_uncertainty_score":0.6356586},"labels":[],"label_agreement":null},{"id":"W4406448623","doi":"10.1016/s1155-1984(02)00038-9","title":"10.1016/s1155-1984(02)00038-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.009446208125797996,"score_gpt":0.22778072964293058,"score_spread":0.2183345215171326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406448623","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0047361637,0.00010597125,7.5936646e-7,0.0024206832,0.000001357887,0.0005058306,0.000017554057,0.00016925478,0.9920424],"genre_scores_gemma":[0.0003807936,0.0000012976295,0.00037752383,0.00030322987,0.00037866295,0.000041790823,0.000046996825,0.00006085885,0.99840885],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99831176,0.00005434694,0.0002382484,0.00036435804,0.00046770106,0.0005635599],"domain_scores_gemma":[0.99868387,0.000084097934,0.000021640191,0.000622144,0.000109040346,0.00047920214],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000269386,0.0001942816,0.00032217035,0.00017191668,0.00008530485,0.00003166879,0.00025351942,0.00012717863,0.99887997],"category_scores_gemma":[0.00014135757,0.00017238247,0.0000998024,0.00045664844,0.00007466985,0.000060639897,0.000078147925,0.00037260033,0.9986403],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038961053,0.000062238105,4.2330694e-7,0.00001602924,0.000037036105,0.000083467094,0.000022325177,0.000007294515,0.00059067266,6.073908e-7,0.57515496,0.42363533],"study_design_scores_gemma":[0.0011483814,0.0004553908,0.000141958,0.0000438985,0.000041575666,0.00010960467,0.0000022792074,0.00033998681,0.0006751827,0.0000042365737,0.9968572,0.00018030696],"about_ca_topic_score_codex":0.00008658636,"about_ca_topic_score_gemma":2.4359704e-7,"teacher_disagreement_score":0.42345503,"about_ca_system_score_codex":0.00029441246,"about_ca_system_score_gemma":0.00022790737,"threshold_uncertainty_score":0.7029553},"labels":[],"label_agreement":null},{"id":"W4406470071","doi":"10.1186/s13045-024-01657-z","title":"Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; Astellas Pharma; Syndax Pharmaceuticals; Bristol-Myers Squibb; Foghorn Therapeutics; Celgene; Jazz Pharmaceuticals; Leukemia and Lymphoma Society; GlaxoSmithKline; Servier; Daiichi-Sankyo; Pfizer","keywords":"Medicine; Refractory (planetary science); Open label; Myeloid leukemia; Azacitidine; Hematology; Internal medicine; Clinical trial","score_opus":0.046883493649556594,"score_gpt":0.38586445423521454,"score_spread":0.33898096058565796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406470071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989263,0.00016397783,0.00009829929,0.00670851,0.00026839616,0.0024761525,0.0000140294005,0.000018121325,0.0009895407],"genre_scores_gemma":[0.99120677,0.00020157083,0.0066646105,0.00090125884,0.000050460596,0.0001262694,0.00005885852,0.000044731853,0.00074548443],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957554,0.0007740812,0.0017258321,0.00048947975,0.0005614343,0.00069378555],"domain_scores_gemma":[0.9959803,0.0014066236,0.0010645232,0.00043427007,0.0008235627,0.0002906768],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001531726,0.0003579203,0.0021870446,0.0015707879,0.00014888824,0.0000307332,0.0006172684,0.00063918956,0.00009656775],"category_scores_gemma":[0.0014675356,0.00023405334,0.00006673762,0.0012963946,0.00042913965,0.0004941925,0.00023595217,0.0024698253,0.000007808353],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8699432,0.019768463,0.065633334,0.00023640438,0.0014808511,0.01606828,0.0008000924,0.00003945975,0.01080109,0.000563269,0.009615859,0.0050496897],"study_design_scores_gemma":[0.8978836,0.056402203,0.029192103,0.001782762,0.0007015934,0.003804269,0.00076031353,0.00042809392,0.0029676766,0.00021257288,0.0054855775,0.00037923214],"about_ca_topic_score_codex":0.00017715193,"about_ca_topic_score_gemma":0.0005412014,"teacher_disagreement_score":0.03663374,"about_ca_system_score_codex":0.0035900755,"about_ca_system_score_gemma":0.008303762,"threshold_uncertainty_score":0.9998315},"labels":[],"label_agreement":null},{"id":"W4406474604","doi":"10.1016/s1155-1984(20)30023-6","title":"10.1016/s1155-1984(20)30023-6","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Biology","score_opus":0.00984828694819409,"score_gpt":0.22895845003701287,"score_spread":0.21911016308881878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406474604","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024352297,0.00009804207,0.0000010573501,0.0028379238,0.000001345792,0.00049104466,0.000020083431,0.00021531421,0.99389994],"genre_scores_gemma":[0.00018997745,0.0000011350784,0.00037001426,0.00028408668,0.00039331417,0.000041729112,0.000058254325,0.000060935407,0.99860054],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983158,0.000053015465,0.00023627996,0.00036224487,0.0004688589,0.00056376413],"domain_scores_gemma":[0.9986903,0.00008437903,0.00002210699,0.00061826786,0.00010703789,0.0004778843],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002669154,0.00019215225,0.00031912184,0.00017340695,0.00008255952,0.000031140473,0.0002532957,0.00012701382,0.99898],"category_scores_gemma":[0.00012915382,0.0001707713,0.000099557365,0.00044795184,0.000074973796,0.00008069495,0.00008102161,0.00036877746,0.99874645],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035833244,0.000060039532,4.5073193e-7,0.000015561382,0.00003496438,0.000080977705,0.00001868658,0.000008357151,0.0005132069,4.619613e-7,0.60479623,0.39411274],"study_design_scores_gemma":[0.0011606275,0.0004427251,0.00009699118,0.000044198685,0.000040401002,0.000112127396,0.0000021737371,0.00040570565,0.0005922039,0.00000467955,0.9969187,0.00017948105],"about_ca_topic_score_codex":0.000050635717,"about_ca_topic_score_gemma":2.6513285e-7,"teacher_disagreement_score":0.39393327,"about_ca_system_score_codex":0.00027761768,"about_ca_system_score_gemma":0.00022832718,"threshold_uncertainty_score":0.69638515},"labels":[],"label_agreement":null},{"id":"W4406489667","doi":"10.1016/j.yonc.2013.07.036","title":"10.1016/j.yonc.2013.07.036","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukaemia; Induction therapy; Chronic myeloid leukaemia; Classifier (UML); Profiling (computer programming); Pediatrics; Oncology; Internal medicine; Artificial intelligence","score_opus":0.010484318933574604,"score_gpt":0.2317877512078496,"score_spread":0.221303432274275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406489667","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032547456,0.00012814623,0.0000013338295,0.003724783,0.0000013001368,0.00045633022,0.000013817188,0.00019370443,0.9922258],"genre_scores_gemma":[0.00026687255,0.0000021286571,0.00043359012,0.00026831235,0.00038494606,0.000036484485,0.000048778682,0.00005535163,0.9985035],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99844056,0.000051012466,0.00021701615,0.00033173183,0.0004405929,0.0005191082],"domain_scores_gemma":[0.9987631,0.00007619476,0.000020718764,0.00058212003,0.00010286924,0.0004550243],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025062746,0.00017719313,0.00029698483,0.00014368653,0.00007567617,0.000028291422,0.0002298004,0.00011912765,0.9990579],"category_scores_gemma":[0.000106551706,0.00015502199,0.00009009125,0.0003281176,0.00007118989,0.00007708547,0.00007479033,0.0003396895,0.9992324],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002861796,0.000048970072,3.3160478e-7,0.000012412267,0.000029846968,0.0000601064,0.000016826643,0.000007593804,0.00027136723,3.0086989e-7,0.57000715,0.42925894],"study_design_scores_gemma":[0.0010744664,0.00042782887,0.00009821969,0.00004118497,0.000036671678,0.00009758272,0.0000016629335,0.0004975703,0.00042806883,0.000004153771,0.99712807,0.00016451451],"about_ca_topic_score_codex":0.00012992154,"about_ca_topic_score_gemma":2.597144e-7,"teacher_disagreement_score":0.42909443,"about_ca_system_score_codex":0.0002470747,"about_ca_system_score_gemma":0.00017530927,"threshold_uncertainty_score":0.6321613},"labels":[],"label_agreement":null},{"id":"W4406548847","doi":"10.1016/s1155-1984(13)65646-0","title":"10.1016/s1155-1984(13)65646-0","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.0096974924816367,"score_gpt":0.22877591499462857,"score_spread":0.21907842251299187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406548847","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038774705,0.000094442104,9.545819e-7,0.002392882,0.0000013445141,0.00035581164,0.000016708922,0.0002098505,0.9930505],"genre_scores_gemma":[0.00028460223,0.0000012915478,0.00032713648,0.00029608008,0.00038786593,0.00004150471,0.00004833201,0.000060277027,0.9985529],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983192,0.000053143965,0.00023811604,0.00036274744,0.00046922493,0.00055757264],"domain_scores_gemma":[0.9986908,0.000084671876,0.000022265192,0.00061915873,0.00010679761,0.00047634778],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00026857134,0.00019319987,0.00032072217,0.00017150503,0.00008337482,0.000032092226,0.00025467,0.00012704257,0.9987989],"category_scores_gemma":[0.00014142916,0.00017143055,0.0001009784,0.0004398904,0.00007602628,0.00008309901,0.00008204776,0.00037145405,0.9986388],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036530348,0.000058885904,5.653532e-7,0.000015234983,0.00003416867,0.00007827186,0.000020464651,0.000008864552,0.00032555824,3.9572285e-7,0.5657033,0.43338904],"study_design_scores_gemma":[0.0011890706,0.00044132367,0.00018966456,0.00004540028,0.000041278094,0.000106681226,0.000002392213,0.00039844227,0.0004214022,0.0000036485333,0.9969807,0.00017995221],"about_ca_topic_score_codex":0.000089278416,"about_ca_topic_score_gemma":3.4842236e-7,"teacher_disagreement_score":0.4332091,"about_ca_system_score_codex":0.00027701378,"about_ca_system_score_gemma":0.00022944272,"threshold_uncertainty_score":0.69907355},"labels":[],"label_agreement":null},{"id":"W4406551903","doi":"10.1016/s1544-8800(13)70025-3","title":"10.1016/s1544-8800(13)70025-3","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Cardiology","score_opus":0.009634932431992182,"score_gpt":0.22796788861963002,"score_spread":0.21833295618763784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406551903","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041367863,0.000094171686,0.0000012156861,0.0024811563,0.0000014837993,0.0004906171,0.000014913903,0.00020679014,0.99257284],"genre_scores_gemma":[0.00036043252,0.000001321067,0.0003314276,0.000242806,0.00044602706,0.000040582778,0.00004172017,0.00005878009,0.9984769],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99832344,0.00005287746,0.00023628375,0.00036006267,0.00047389712,0.00055341976],"domain_scores_gemma":[0.9986976,0.000085156644,0.000021985448,0.0006156586,0.00010813875,0.0004714918],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025283254,0.000192611,0.00031980418,0.00016982327,0.00008174463,0.000031594493,0.00024904922,0.00012660211,0.9989617],"category_scores_gemma":[0.00013506404,0.00017051438,0.00010059031,0.00042847608,0.00007466594,0.000080714264,0.00008159375,0.00036854675,0.9987876],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035850893,0.00005912437,6.219424e-7,0.000015225504,0.000033910714,0.000076982884,0.000019243904,0.000008385016,0.00031074823,4.3185847e-7,0.575748,0.4233688],"study_design_scores_gemma":[0.0011812123,0.00043959194,0.00028940654,0.000044878037,0.0000402157,0.00010549086,0.0000023717098,0.00044022946,0.0004864891,0.0000043992723,0.9967874,0.00017826086],"about_ca_topic_score_codex":0.00011676082,"about_ca_topic_score_gemma":4.0249708e-7,"teacher_disagreement_score":0.42319053,"about_ca_system_score_codex":0.0002680992,"about_ca_system_score_gemma":0.0002268202,"threshold_uncertainty_score":0.6953375},"labels":[],"label_agreement":null},{"id":"W4406561196","doi":"10.1016/s2211-9698(17)71582-8","title":"10.1016/s2211-9698(17)71582-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Philosophy","score_opus":0.010002459901246577,"score_gpt":0.23106863574729664,"score_spread":0.22106617584605007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406561196","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022469359,0.00010344881,0.0000011329993,0.0027246606,0.0000012113949,0.0004884672,0.000016159374,0.0002050219,0.994213],"genre_scores_gemma":[0.00015928144,0.0000012635178,0.0004175988,0.00033138896,0.0004065878,0.000040341925,0.000046907393,0.000058082565,0.99853855],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99831325,0.000049642105,0.00023716681,0.00036173954,0.00047879136,0.0005594306],"domain_scores_gemma":[0.9986946,0.00007865885,0.000022169332,0.0006186298,0.00010713302,0.0004787851],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00026679123,0.00019332134,0.00031983867,0.0001688189,0.00008178717,0.00003120995,0.0002520976,0.00012771579,0.9992095],"category_scores_gemma":[0.00012422293,0.00017109266,0.000102310965,0.0004323797,0.000076462195,0.000080869264,0.00008123133,0.00036708292,0.9983357],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032267784,0.00005624333,3.9049937e-7,0.000012202145,0.000034500586,0.00007922546,0.000018156197,0.000007909828,0.0003187192,4.6365417e-7,0.61966836,0.37948117],"study_design_scores_gemma":[0.0011466461,0.0004394981,0.00012973863,0.000044076398,0.000042697375,0.00011231352,0.0000023934383,0.00042372145,0.00045393195,0.000003986045,0.99702126,0.00017975245],"about_ca_topic_score_codex":0.00005639704,"about_ca_topic_score_gemma":2.163255e-7,"teacher_disagreement_score":0.3793014,"about_ca_system_score_codex":0.00027403084,"about_ca_system_score_gemma":0.00022739734,"threshold_uncertainty_score":0.6976956},"labels":[],"label_agreement":null},{"id":"W4406584078","doi":"10.1016/j.yonc.2013.08.031","title":"10.1016/j.yonc.2013.08.031","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Sibling; Myeloid leukemia; Transplantation; Stem cell; Oncology; Internal medicine; Genetics","score_opus":0.010259504021823004,"score_gpt":0.23043509974849924,"score_spread":0.22017559572667622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406584078","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033797754,0.00012404498,9.752107e-7,0.003682,0.000001335759,0.00046737483,0.000013593168,0.00019088096,0.99214],"genre_scores_gemma":[0.00035485212,0.000002133756,0.0003786948,0.00027551135,0.00039621585,0.000036803114,0.000042060783,0.00005557837,0.99845815],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99842954,0.00005041649,0.00021972244,0.0003351609,0.0004432782,0.0005218571],"domain_scores_gemma":[0.9987667,0.00007508581,0.000020985728,0.00058285974,0.00010361947,0.00045071886],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025062638,0.00017840724,0.00029881863,0.00015346972,0.00007492888,0.00002862768,0.00023648275,0.000120128454,0.9989094],"category_scores_gemma":[0.00010463412,0.00015629288,0.00009045675,0.00036973724,0.000071890005,0.00007936259,0.000076986915,0.00034239306,0.99891883],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029427462,0.000052084244,7.296902e-7,0.000013509517,0.000032057054,0.0000649903,0.000018220471,0.000006633448,0.00025785476,4.3666807e-7,0.6393886,0.35987058],"study_design_scores_gemma":[0.0010949684,0.00041991702,0.00018451789,0.00004045578,0.000036319663,0.00009617063,0.0000021796995,0.00042728035,0.00046434873,0.000003677264,0.99706656,0.0001636192],"about_ca_topic_score_codex":0.000098679564,"about_ca_topic_score_gemma":2.577497e-7,"teacher_disagreement_score":0.35970694,"about_ca_system_score_codex":0.00024755654,"about_ca_system_score_gemma":0.00019967981,"threshold_uncertainty_score":0.6373439},"labels":[],"label_agreement":null},{"id":"W4406584098","doi":"10.1016/j.yonc.2013.08.006","title":"10.1016/j.yonc.2013.08.006","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Relevance (law); Profiling (computer programming); Oncology; Myeloid; Computational biology; Internal medicine; Law","score_opus":0.009985109756265001,"score_gpt":0.2310861462001951,"score_spread":0.2211010364439301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406584098","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032849414,0.000121765384,9.896798e-7,0.0034875916,0.0000013123042,0.0004638298,0.000014445242,0.00019026174,0.99243486],"genre_scores_gemma":[0.00032901464,0.0000018956902,0.00036260227,0.00026440376,0.0004139625,0.00003675537,0.000046026416,0.000055383483,0.99849],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998439,0.00004952924,0.00021975025,0.00033231569,0.00044210991,0.00051730615],"domain_scores_gemma":[0.99878937,0.00007534442,0.000021041256,0.0005741628,0.0001029897,0.00043707923],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00024402943,0.00017751352,0.0002959189,0.00015271422,0.000074008196,0.00002861178,0.00023218035,0.000119414864,0.9988414],"category_scores_gemma":[0.000098968405,0.00015562391,0.00008995866,0.0003656101,0.00007135463,0.00007820902,0.00007527339,0.00033553317,0.9988688],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002836458,0.000053350246,6.980335e-7,0.000013535933,0.000031439038,0.000060686463,0.000016598353,0.000007871056,0.00027436367,4.3702488e-7,0.6608419,0.3384155],"study_design_scores_gemma":[0.0011012314,0.00040127232,0.0001627525,0.000039331717,0.00003599471,0.00009136413,0.0000019662548,0.0004334318,0.0004905164,0.000003589939,0.9970767,0.00016186667],"about_ca_topic_score_codex":0.00011321918,"about_ca_topic_score_gemma":2.8657524e-7,"teacher_disagreement_score":0.33825365,"about_ca_system_score_codex":0.0002447898,"about_ca_system_score_gemma":0.00019288294,"threshold_uncertainty_score":0.6346159},"labels":[],"label_agreement":null},{"id":"W4406584408","doi":"10.1016/j.yonc.2013.07.034","title":"10.1016/j.yonc.2013.07.034","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Epigenomics; Myeloid leukemia; Myeloid; Genetics; Cancer research; Computational biology; DNA methylation; Gene; Biology","score_opus":0.010495480106582827,"score_gpt":0.23186826568746857,"score_spread":0.22137278558088574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406584408","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031356604,0.00012986179,9.375006e-7,0.0038136763,0.0000013142399,0.000456346,0.000013758497,0.00019477075,0.99225366],"genre_scores_gemma":[0.00024442986,0.0000021928843,0.0003876026,0.000274032,0.0003918026,0.00003680398,0.00004097771,0.000055513836,0.9985666],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843,0.000051120835,0.00021831272,0.00033309846,0.0004454725,0.00052197214],"domain_scores_gemma":[0.9987579,0.00007693829,0.000020854946,0.000583649,0.00010383867,0.00045679565],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002504544,0.00017806338,0.0002986262,0.00014513527,0.00007599753,0.000028615343,0.00023504104,0.00011966963,0.99908906],"category_scores_gemma":[0.000106853666,0.00015596737,0.00009024721,0.00033111047,0.00007167298,0.00007784898,0.0000755662,0.00034461316,0.99923444],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028314957,0.00004956084,3.770476e-7,0.000012616912,0.000030249557,0.000060978902,0.000017438348,0.0000068875534,0.00027383794,4.0929518e-7,0.6027333,0.39653116],"study_design_scores_gemma":[0.0010796887,0.00042911564,0.000110046894,0.000041383246,0.00003675344,0.000096909,0.0000020815817,0.0004439345,0.00043365176,0.0000037378793,0.99715734,0.00016537207],"about_ca_topic_score_codex":0.00011594132,"about_ca_topic_score_gemma":2.4726907e-7,"teacher_disagreement_score":0.3963658,"about_ca_system_score_codex":0.00024849974,"about_ca_system_score_gemma":0.00019822652,"threshold_uncertainty_score":0.6360165},"labels":[],"label_agreement":null},{"id":"W4406653410","doi":"10.1016/j.jaccao.2024.12.001","title":"Heart Failure Post-Hematopoietic Cell Transplantation in Patients With Lymphoma","year":2025,"lang":"en","type":"editorial","venue":"JACC CardioOncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; NOSM University; University Health Network; Health Sciences North; University of Toronto; University of Sudbury","funders":"","keywords":"Hematopoietic cell; Lymphoma; Medicine; Hematopoietic stem cell transplantation; Transplantation; Heart transplantation; Heart failure; Haematopoiesis; Intensive care medicine; Internal medicine; Oncology; Stem cell; Biology; Genetics","score_opus":0.0038548898398787193,"score_gpt":0.25153869761805076,"score_spread":0.24768380777817203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406653410","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22134455,0.0006237103,0.00010976996,0.005213743,0.74390376,0.0065731443,0.0016706525,0.00030193513,0.020258732],"genre_scores_gemma":[0.12998798,0.00054589263,0.0037092832,0.0018210453,0.8260419,0.001326456,0.022992758,0.0004909727,0.01308372],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964185,0.0003441151,0.00050496106,0.00084748457,0.0011568805,0.0007280805],"domain_scores_gemma":[0.9970103,0.001060418,0.00015231139,0.0006803701,0.000899853,0.0001967749],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00041238673,0.0004884717,0.001619111,0.0007651151,0.00006807776,0.000028665325,0.0002853904,0.002016786,0.000076906166],"category_scores_gemma":[0.0003464771,0.00041982156,0.00027606005,0.0005761042,0.00015129958,0.00008487783,0.00009382536,0.0013695714,0.000111623776],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038851993,0.00028772673,0.012687486,0.0015659009,0.00019646727,0.00050766754,0.0002496311,0.000011144175,0.00003511295,0.00000388783,0.97989154,0.0006782589],"study_design_scores_gemma":[0.021970985,0.0021263005,0.042626265,0.0004934486,0.00064200413,0.000044651744,0.00014514218,0.0000035674382,0.0001351342,0.000005540404,0.931392,0.00041491925],"about_ca_topic_score_codex":0.00029782383,"about_ca_topic_score_gemma":0.00028093837,"teacher_disagreement_score":0.09135656,"about_ca_system_score_codex":0.0023135284,"about_ca_system_score_gemma":0.0053502847,"threshold_uncertainty_score":0.99982536},"labels":[],"label_agreement":null},{"id":"W4406697636","doi":"10.1182/blood.2024025886","title":"FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); Ontario Institute for Cancer Research; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Stem cell; Haematopoiesis; Cancer research; Bone marrow; Biology; Leukemia; Hematopoietic stem cell; Immunology; Medicine; Cell biology","score_opus":0.020021129057359803,"score_gpt":0.300367644487132,"score_spread":0.2803465154297722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406697636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820902,0.000515859,0.009578261,0.001040475,0.0003433314,0.0043420307,0.00028158718,0.00018843258,0.0016198341],"genre_scores_gemma":[0.9130765,0.00008013451,0.0035011566,0.0007894294,0.00039481008,0.00065271417,0.00009409053,0.00014783975,0.08126332],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99684197,0.00007058179,0.00073098217,0.0008474684,0.0004790326,0.0010299573],"domain_scores_gemma":[0.9978109,0.0004201584,0.00013241865,0.0008643901,0.0004500404,0.00032207396],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043769975,0.00039846762,0.0007860569,0.0002559387,0.00030484732,0.00010778427,0.0004716702,0.00033459297,0.00017598865],"category_scores_gemma":[0.000023136909,0.00037081892,0.0003724258,0.0003903657,0.00019447325,0.00006631614,0.00020680965,0.00036178454,0.00015113648],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045178545,0.0007136441,0.0002175269,0.002055945,0.00060466904,0.00005955696,0.00027852113,0.000013819319,0.96542656,0.0011362903,0.028088108,0.0009535709],"study_design_scores_gemma":[0.014113074,0.0006153968,0.000057506382,0.00026869684,0.0009861109,0.00003236621,0.0003690967,0.001795535,0.97405946,0.0005066243,0.006863341,0.00033278167],"about_ca_topic_score_codex":0.000061292434,"about_ca_topic_score_gemma":0.0000140782395,"teacher_disagreement_score":0.07964349,"about_ca_system_score_codex":0.00032564867,"about_ca_system_score_gemma":0.000935039,"threshold_uncertainty_score":0.99987435},"labels":[],"label_agreement":null},{"id":"W4406732078","doi":"10.1016/j.bneo.2025.100070","title":"Race and age disparities in randomized trials of acute myeloid leukemia: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Blood Neoplasia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Toronto; York University; McMaster University","funders":"","keywords":"Myeloid leukemia; Meta-analysis; Race (biology); Medicine; Randomized controlled trial; Oncology; Internal medicine; Sociology; Gender studies","score_opus":0.07367181825528708,"score_gpt":0.38412831072266646,"score_spread":0.3104564924673794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406732078","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007729138,0.9813523,0.000023638622,0.000452142,0.000022448456,0.017260788,0.0005027656,0.00003513426,0.00034302013],"genre_scores_gemma":[0.000009553623,0.98625827,0.0006452016,0.00029993322,0.000025452724,0.0041880184,0.00029543802,0.000060451875,0.0082176905],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98410356,0.007835602,0.0058315117,0.000972032,0.000740584,0.0005166942],"domain_scores_gemma":[0.9794937,0.016277252,0.002438764,0.0013312738,0.00019727515,0.00026176914],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.016079124,0.0010003218,0.07901513,0.0019501336,0.000056499033,0.00007709108,0.00039797378,0.00065126905,0.00013996275],"category_scores_gemma":[0.015146706,0.00057811465,0.0077180066,0.002473033,0.00039002558,0.00009226143,0.00038006497,0.0010743703,0.0000063374596],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005061718,0.00004186488,7.121332e-7,0.6518168,0.3464386,0.00026531424,0.00003355315,4.2120128e-8,2.911744e-7,0.00009823609,0.0003127131,0.0004857436],"study_design_scores_gemma":[0.025121864,0.00004847331,5.735163e-7,0.14434059,0.8281352,0.0003576706,0.000010191594,0.0000041874523,0.0000022617846,0.000023244438,0.001666279,0.00028947747],"about_ca_topic_score_codex":0.0002460184,"about_ca_topic_score_gemma":0.000060132552,"teacher_disagreement_score":0.5074762,"about_ca_system_score_codex":0.00023731888,"about_ca_system_score_gemma":0.0016709819,"threshold_uncertainty_score":0.99966705},"labels":[],"label_agreement":null},{"id":"W4406926013","doi":"10.1111/ejh.14385","title":"Iron Overload, Oxidative Stress, and Somatic Mutations in <scp>MDS</scp>: What Is the Association?","year":2025,"lang":"en","type":"review","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Myelodysplastic syndromes; Oxidative stress; Bone marrow; International Prognostic Scoring System; Haematopoiesis; Myeloid; Medicine; Somatic cell; Bone marrow failure; Erythropoiesis; Progenitor cell; Bioinformatics; Cancer research; Internal medicine; Oncology; Stem cell; Biology; Genetics; Anemia; Gene","score_opus":0.024635990797010128,"score_gpt":0.33261495520361556,"score_spread":0.30797896440660544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406926013","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018219858,0.9916732,0.000040347175,0.0023455746,0.0003016772,0.00071504334,0.00003177823,0.000010766626,0.0030596338],"genre_scores_gemma":[0.0003139896,0.99662143,0.000283072,0.00041878308,0.00016400983,0.00001020263,0.000032243304,0.000053628803,0.0021026626],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99417627,0.0032248176,0.0014307487,0.00028258841,0.00047961815,0.00040592992],"domain_scores_gemma":[0.9921506,0.005411861,0.0016351587,0.000367654,0.00028428642,0.0001504278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021169134,0.00034338463,0.0022147105,0.00071309647,0.00011135388,0.00012689491,0.00046416346,0.00017613101,0.000052466792],"category_scores_gemma":[0.0039786464,0.00021567165,0.0003673137,0.0005091249,0.00018425327,0.00024346549,0.000233917,0.0018889959,0.00014346745],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046118577,0.0006270794,0.0032072635,0.0719006,0.0036969257,0.03697051,0.011720443,0.000007065839,0.000006264073,0.00112129,0.08197014,0.78872633],"study_design_scores_gemma":[0.002575182,0.0004113961,0.0010169328,0.06681899,0.0029546667,0.013135386,0.004914192,0.000015253289,0.000012320782,0.00020799592,0.90776813,0.0001695642],"about_ca_topic_score_codex":0.0000036192687,"about_ca_topic_score_gemma":0.00000804711,"teacher_disagreement_score":0.825798,"about_ca_system_score_codex":0.00053630926,"about_ca_system_score_gemma":0.0011687173,"threshold_uncertainty_score":0.87948346},"labels":[],"label_agreement":null},{"id":"W4407064943","doi":"10.1016/j.clml.2025.01.024","title":"A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia With Azacitidine Plus Venetoclax","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Venetoclax; Medicine; Azacitidine; Myeloid leukemia; Oncology; Myeloid; Internal medicine; Leukemia; Genetics","score_opus":0.06526847665426186,"score_gpt":0.4154694203873827,"score_spread":0.35020094373312083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407064943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741268,0.0005652668,0.0013771083,0.0013930766,0.0005123526,0.0056991014,0.00023431594,0.00026390678,0.015828036],"genre_scores_gemma":[0.96316344,0.001174144,0.012602376,0.00083138,0.0009854943,0.0017174128,0.0009475825,0.00018109406,0.018397087],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9927837,0.0005395904,0.0023840289,0.0015658499,0.0015135612,0.00121326],"domain_scores_gemma":[0.9926163,0.0020246292,0.000718337,0.0019370898,0.0020641608,0.00063951436],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033635749,0.00081472186,0.0024500256,0.00076400867,0.00026417553,0.00005966014,0.00061198074,0.0006564389,0.00020188128],"category_scores_gemma":[0.0012583401,0.000632802,0.00089240633,0.0015141409,0.00086131156,0.00021690517,0.00023602138,0.00044166678,0.00007676942],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.030314162,0.00062254537,0.014222325,0.00047984428,0.0057867435,0.00025790703,0.00024155896,0.0010538615,0.00503766,0.0030584356,0.018124735,0.9208002],"study_design_scores_gemma":[0.08901642,0.007682618,0.6846281,0.0013189918,0.00935934,0.00014712726,0.00022553613,0.1482617,0.022521859,0.0018666547,0.033988025,0.0009835919],"about_ca_topic_score_codex":0.0014829824,"about_ca_topic_score_gemma":0.00074966706,"teacher_disagreement_score":0.9198166,"about_ca_system_score_codex":0.03845377,"about_ca_system_score_gemma":0.04135444,"threshold_uncertainty_score":0.99961233},"labels":[],"label_agreement":null},{"id":"W4407187841","doi":"10.3324/haematol.2024.287056","title":"Context and timing matters in acute myeloid leukemia: females are the superior hosts","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Context (archaeology); Myeloid; Leukemia; Medicine; Biology; Immunology","score_opus":0.034466295304956554,"score_gpt":0.31275989987857,"score_spread":0.27829360457361346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407187841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93640643,0.0017365646,0.000043477758,0.05886198,0.000068078254,0.000685382,0.0000071747904,0.0000764554,0.002114457],"genre_scores_gemma":[0.9859109,0.00058946706,0.00038348758,0.011025164,0.0000208918,0.00011718223,0.000007927879,0.00001665214,0.0019283622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847513,0.00012565657,0.0003260413,0.0004012478,0.00021076604,0.00046112758],"domain_scores_gemma":[0.9989166,0.00042940574,0.00006629914,0.00042411237,0.00006698248,0.00009656304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003434711,0.00021412046,0.00059436803,0.00020857621,0.00017838558,0.00005658211,0.00024575333,0.00020000609,0.000092088085],"category_scores_gemma":[0.00029338172,0.0001298727,0.00007571128,0.0004050152,0.00042858892,0.00007348566,0.00028972427,0.0006003972,0.000082912346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017509115,0.00017922587,0.85932726,0.0012477369,0.00063457724,0.009958879,0.0030766325,0.000006799034,0.012088596,0.0074338624,0.07452885,0.029766686],"study_design_scores_gemma":[0.0070470595,0.0003378142,0.91546124,0.001991946,0.00033927785,0.004224835,0.01985241,0.0013577404,0.01411801,0.00079129945,0.033868928,0.0006094484],"about_ca_topic_score_codex":0.00015372741,"about_ca_topic_score_gemma":0.00012738128,"teacher_disagreement_score":0.05613399,"about_ca_system_score_codex":0.0003273005,"about_ca_system_score_gemma":0.0002482851,"threshold_uncertainty_score":0.5296055},"labels":[],"label_agreement":null},{"id":"W4407196446","doi":"10.1016/j.retram.2025.103500","title":"Denutrition status prevails over a standard AML risk assessment in older adults","year":2025,"lang":"en","type":"article","venue":"Current Research in Translational Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Risk assessment; Gerontology; Computer science; Computer security","score_opus":0.0585395660462999,"score_gpt":0.47290491316629907,"score_spread":0.41436534711999917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407196446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.929411,0.021247538,0.0035393143,0.031751364,0.0004908155,0.005593084,0.00022727255,0.00006725535,0.007672381],"genre_scores_gemma":[0.9890907,0.008457383,0.0008218552,0.00008293194,0.00032735826,0.00051988143,0.0004994406,0.000025738733,0.00017472982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99377215,0.00084966735,0.00085733994,0.00071037636,0.0027384036,0.0010720615],"domain_scores_gemma":[0.99687064,0.0015216015,0.00006767219,0.00043200323,0.0007499973,0.00035811157],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004587705,0.0002466566,0.0005758451,0.0026661071,0.00012827954,0.00002852791,0.00023539983,0.00017531082,0.00091383705],"category_scores_gemma":[0.0010432989,0.00020584602,0.00008260388,0.0028891887,0.0005327483,0.00022242396,0.000070517155,0.003126529,0.000018086468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046417173,0.0011890796,0.73314965,0.002434402,0.00007393254,0.0001554047,0.0014177517,0.000042010386,0.0004434819,0.003682716,0.01336959,0.23940027],"study_design_scores_gemma":[0.027177587,0.0005379248,0.93148416,0.00953,0.00003398248,0.0000059152685,0.0004714756,0.0058166613,0.00011299736,0.0063234014,0.018349707,0.000156194],"about_ca_topic_score_codex":0.0007207466,"about_ca_topic_score_gemma":0.0004822563,"teacher_disagreement_score":0.23924407,"about_ca_system_score_codex":0.0018654673,"about_ca_system_score_gemma":0.0026789003,"threshold_uncertainty_score":0.99999946},"labels":[],"label_agreement":null},{"id":"W4407548248","doi":"10.1002/cncr.35746","title":"Maintenance therapy with the <i>FMS</i>‐like tyrosine kinase 3 inhibitor gilteritinib in patients with <i>FMS</i>‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study","year":2025,"lang":"en","type":"article","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma","keywords":"Medicine; Surgery; Placebo; Gastroenterology; Internal medicine; Tyrosine-kinase inhibitor; Myeloid leukemia; Discontinuation; Hazard ratio; Clinical endpoint; Randomized controlled trial; Confidence interval; Pathology; Cancer","score_opus":0.011642492387498626,"score_gpt":0.2977045688700433,"score_spread":0.28606207648254467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407548248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871201,0.0015721578,0.0005708069,0.004919422,0.0003453734,0.0046211584,0.0001869794,0.00013815695,0.0005258714],"genre_scores_gemma":[0.9839873,0.0008506223,0.00022582451,0.007002821,0.0003698079,0.0019355116,0.0001702122,0.00013238944,0.005325513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958263,0.0002041451,0.0007025167,0.0011773235,0.001060691,0.001029004],"domain_scores_gemma":[0.9970383,0.00013149445,0.0003168723,0.001330316,0.0008815084,0.0003014944],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005251625,0.00068452203,0.00086868694,0.00037099948,0.000300411,0.00014675829,0.00064942666,0.00019165389,0.00015295793],"category_scores_gemma":[0.00005609632,0.00041497342,0.00012525977,0.0017430903,0.0005172326,0.00033716025,0.000224151,0.0012418838,0.000022485701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07508187,0.009927687,0.6494177,0.00040106277,0.002299684,0.0015178324,0.0033837436,0.00016862525,0.049070578,0.00015308647,0.13465202,0.073926106],"study_design_scores_gemma":[0.21732304,0.01495868,0.5750746,0.0036372666,0.0010134644,0.00009254876,0.0020085708,0.0010369405,0.034175314,0.000034012213,0.1488573,0.0017882701],"about_ca_topic_score_codex":0.0009237538,"about_ca_topic_score_gemma":0.00076957187,"teacher_disagreement_score":0.14224117,"about_ca_system_score_codex":0.002712276,"about_ca_system_score_gemma":0.0016321634,"threshold_uncertainty_score":0.9998302},"labels":[],"label_agreement":null},{"id":"W4407687743","doi":"10.1016/j.leukres.2025.107665","title":"Molecular genetic characterization of mixed-phenotype acute leukemia (MPAL) with BCR::ABL1 fusion","year":2025,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"breakpoint cluster region; Phenotype; Fusion gene; Cancer research; Genetics; Biology; Gene","score_opus":0.018717936051413576,"score_gpt":0.3272520593277069,"score_spread":0.3085341232762933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407687743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824452,0.00031862417,0.003842666,0.0015618026,0.00012542418,0.0017728095,0.00003508132,0.00012285355,0.00977557],"genre_scores_gemma":[0.98618907,0.0006890351,0.002710955,0.00033294474,0.00015309572,0.00020746994,0.00028525395,0.000113065566,0.009319125],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99421483,0.00054043264,0.0007265036,0.00096940383,0.0022372613,0.0013115797],"domain_scores_gemma":[0.9957729,0.00031971867,0.00015402028,0.001574541,0.0017582524,0.0004205607],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013916497,0.0004071858,0.0007885723,0.0014832515,0.00030986956,0.00009101196,0.000766583,0.00046564708,0.00027059333],"category_scores_gemma":[0.00043605856,0.00033735018,0.00016664476,0.0035998113,0.0007350021,0.00018496116,0.0006553969,0.0017854586,0.00020467471],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0028525256,0.00013431128,0.007400294,0.00074971357,0.0004859712,0.0008080886,0.0002320543,0.000112969334,0.96191573,0.0019606669,0.0022969889,0.021050675],"study_design_scores_gemma":[0.009515041,0.0022614663,0.2230101,0.0014486592,0.00039694362,0.00019056322,0.00031067815,0.012148821,0.7376854,0.0007552256,0.011652959,0.0006241414],"about_ca_topic_score_codex":0.00068530877,"about_ca_topic_score_gemma":0.000043179385,"teacher_disagreement_score":0.22423033,"about_ca_system_score_codex":0.0050269975,"about_ca_system_score_gemma":0.00933123,"threshold_uncertainty_score":0.99990785},"labels":[],"label_agreement":null},{"id":"W4407740049","doi":"10.1016/j.jbc.2025.108333","title":"Colorectal cancer hot spot mutations attenuate the ASXL-MLL4 interaction","year":2025,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital Maisonneuve-Rosemont","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; Canadian Institutes of Health Research; National Institute on Aging; National Institutes of Health","keywords":"Hot spot (computer programming); Colorectal cancer; Chemistry; Cancer; Mutation; Genetics; Cancer research; Molecular biology; Biology; Gene; Computer science","score_opus":0.036005320640841186,"score_gpt":0.3593237775734976,"score_spread":0.32331845693265643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407740049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984289,0.00044505156,0.00008055643,0.010146255,0.00016140932,0.000094047085,0.0000076281362,0.000012066005,0.004764],"genre_scores_gemma":[0.99712646,0.00034745855,0.00013782964,0.00066320715,0.0004247323,0.000011305907,0.000009012204,0.0000045779448,0.0012754108],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99914116,0.000045738525,0.00033671755,0.00011729958,0.00018283649,0.00017626774],"domain_scores_gemma":[0.9990111,0.00031073613,0.00018217356,0.00010265671,0.00030145448,0.0000918789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033705562,0.00009768605,0.00023615375,0.00003706934,0.00008481159,0.000020409301,0.00018558436,0.00014742558,0.0005098311],"category_scores_gemma":[0.0007342825,0.000049853214,0.00016101565,0.00023748665,0.00018420645,0.000041051906,0.00006353668,0.00086053787,0.000008597571],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011919368,0.00011669473,0.012720495,0.0000457398,0.00022349811,0.00012201986,0.000057794954,0.00002680099,0.9700148,0.000014282596,0.009391375,0.006074529],"study_design_scores_gemma":[0.0018266523,0.00028566644,0.10240225,0.0002735326,0.00015743215,0.0009184159,0.00084076513,0.00036544327,0.8708241,0.00034946317,0.021638531,0.00011777795],"about_ca_topic_score_codex":0.000018571658,"about_ca_topic_score_gemma":0.0000015605692,"teacher_disagreement_score":0.099190764,"about_ca_system_score_codex":0.00039028845,"about_ca_system_score_gemma":0.0003994532,"threshold_uncertainty_score":0.5582293},"labels":[],"label_agreement":null},{"id":"W4407918247","doi":"10.1038/s41375-025-02537-2","title":"Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm","year":2025,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Haploinsufficiency; Myelodysplastic syndromes; Neoplasm; Hematology; Cancer research; microRNA; Biology; Medicine; Internal medicine; Oncology; Phenotype; Pathology; Gene; Genetics; Bone marrow","score_opus":0.011827659451562616,"score_gpt":0.27093641985761885,"score_spread":0.25910876040605624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407918247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97955304,0.0026223555,0.00037685514,0.00081437203,0.00015407646,0.0006457177,0.00002589848,0.000071858434,0.015735827],"genre_scores_gemma":[0.984763,0.00026683728,0.0033500579,0.00035848448,0.000053080512,0.00005098161,0.000023594952,0.000037324135,0.011096625],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9970568,0.00012087409,0.000785348,0.00063533377,0.00062865624,0.0007730308],"domain_scores_gemma":[0.99828887,0.00051652634,0.00013754738,0.00061141304,0.00022367277,0.00022196793],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00073965196,0.00031791563,0.00077927136,0.00071682816,0.00012583108,0.00003494972,0.00032026705,0.00029719205,0.00007945741],"category_scores_gemma":[0.0011140963,0.00028590145,0.000101687205,0.0012562809,0.0003582928,0.00016204703,0.0002914861,0.0007888139,0.000039619328],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005929162,0.0010283048,0.336928,0.0058482233,0.00050615415,0.0020823327,0.003189329,0.0014064764,0.58092785,0.012791657,0.04144628,0.0079162065],"study_design_scores_gemma":[0.013174084,0.0011477194,0.9014419,0.002379489,0.00034184934,0.0002575369,0.0017873362,0.015631922,0.0414604,0.0021965753,0.019347088,0.0008341556],"about_ca_topic_score_codex":0.002255413,"about_ca_topic_score_gemma":0.0008419094,"teacher_disagreement_score":0.56451386,"about_ca_system_score_codex":0.0015583003,"about_ca_system_score_gemma":0.0029370657,"threshold_uncertainty_score":0.9999593},"labels":[],"label_agreement":null},{"id":"W4407976557","doi":"10.1016/j.jtct.2025.01.167","title":"Fnih MRD in AML Biomarkers Consortium: Evaluation of Methods for Detection of FLT3 internal Tandem Duplication Measurable Residual Disease in Acute Myeloid Leukemia","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Myeloid leukemia; Minimal residual disease; Medicine; Oncology; Leukemia; Disease; Tandem exon duplication; Internal medicine; Gene duplication; Biology; Genetics; Gene","score_opus":0.042111257552073164,"score_gpt":0.3766715540483616,"score_spread":0.33456029649628843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407976557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9071508,0.0016655232,0.089398116,0.00019971072,0.0000475162,0.0013183592,0.000019233388,0.000012079484,0.00018863245],"genre_scores_gemma":[0.9934379,0.0037976014,0.0022993342,0.00004311248,0.000010819348,0.00017662176,0.00014406425,0.000012808385,0.00007777601],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840534,0.00041595477,0.0005029242,0.0002563672,0.0002647598,0.00015464827],"domain_scores_gemma":[0.99917597,0.00020874542,0.00012803487,0.00016477094,0.0002633603,0.00005914798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023194724,0.00012148441,0.00028061724,0.00049078953,0.00003251796,0.000008321695,0.000070575,0.00010564518,0.00001797286],"category_scores_gemma":[0.00006426361,0.00011450083,0.000065196524,0.00042561858,0.00008917484,0.00009509592,0.000004326052,0.00013538313,3.4228069e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069649564,0.00007997306,0.018192751,0.00027861007,0.00014463272,0.000002980442,0.0004737161,0.00009034519,0.8336987,0.00010293584,0.000005216314,0.13996516],"study_design_scores_gemma":[0.010347378,0.00016228938,0.21980049,0.00023468494,0.0002454762,0.0000046674813,0.0001478966,0.026191788,0.742141,0.0005818614,0.000058773203,0.00008371007],"about_ca_topic_score_codex":0.0003989746,"about_ca_topic_score_gemma":0.00011142565,"teacher_disagreement_score":0.20160775,"about_ca_system_score_codex":0.00031751939,"about_ca_system_score_gemma":0.000511749,"threshold_uncertainty_score":0.46692085},"labels":[],"label_agreement":null},{"id":"W4407976599","doi":"10.1016/j.jtct.2025.01.177","title":"Frequency of Deleterious Pathogenic/Likely Pathogenic Germline Variants in Related and Unrelated Allogeneic Hematopoietic Cell Transplant Donors for Patients with Myelodysplastic Syndrome","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Germline; Hematopoietic cell; Myelodysplastic syndromes; Haematopoiesis; Medicine; Immunology; Biology; Genetics; Stem cell; Gene; Bone marrow","score_opus":0.006781966775672861,"score_gpt":0.22707340367844478,"score_spread":0.22029143690277192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407976599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992202,0.0021198497,0.0037001914,0.00009955052,0.000048235484,0.0015568304,0.00018368413,0.00003528756,0.000054370652],"genre_scores_gemma":[0.99221855,0.005988166,0.00083044305,0.000095764866,0.000003854153,0.00008216603,0.0006390263,0.000041322928,0.00010071991],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982612,0.0001201447,0.0005972347,0.00044603093,0.00022893783,0.00034644298],"domain_scores_gemma":[0.99926347,0.0001803369,0.00011650453,0.00020332674,0.00010991026,0.00012643737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026294508,0.0002839608,0.00052062026,0.0003642416,0.00007846297,0.000014614785,0.000094415205,0.0002301611,0.00003285305],"category_scores_gemma":[0.000005912784,0.00022964244,0.00007688304,0.00041291624,0.00013011676,0.00007712943,0.000005401675,0.00024737703,0.000001602853],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070937574,0.00096084166,0.25743052,0.002838414,0.0005652031,0.00092823344,0.0046727112,0.000051150775,0.7199293,0.00040716157,0.0000034247562,0.0051193046],"study_design_scores_gemma":[0.06273907,0.0031597104,0.8873407,0.0014199975,0.0009113019,0.00057276705,0.0001554161,0.0011916801,0.041082524,0.0007320124,0.000020283003,0.00067448907],"about_ca_topic_score_codex":0.00006276973,"about_ca_topic_score_gemma":0.000028645063,"teacher_disagreement_score":0.6788468,"about_ca_system_score_codex":0.00005432912,"about_ca_system_score_gemma":0.00018484674,"threshold_uncertainty_score":0.93645465},"labels":[],"label_agreement":null},{"id":"W4407976671","doi":"10.1016/j.jtct.2025.01.041","title":"Quantify Heterogeneity in Treatment Effects; A Case Study for Patients with Acute Myeloid Leukemia (AML)","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Myeloid leukemia; Medicine; Leukemia; Oncology; Internal medicine; Cancer research","score_opus":0.018076507125201025,"score_gpt":0.3114217289121087,"score_spread":0.29334522178690764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407976671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274385,0.00029646055,0.0030372231,0.000082686,0.000037948546,0.003680865,0.00003202905,0.000034391174,0.00005454004],"genre_scores_gemma":[0.9976084,0.0010466753,0.00035724178,0.00015651753,0.000013511179,0.00041116882,0.00019149619,0.000021616372,0.00019333372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989586,0.00010784834,0.00021014207,0.00033759756,0.0001545241,0.00023132749],"domain_scores_gemma":[0.9994847,0.00014456014,0.000033754794,0.00019283232,0.00006266228,0.00008145989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013682715,0.00020102663,0.0003155431,0.00019781184,0.000107658176,0.000024202931,0.00004399328,0.000075227785,0.000005577077],"category_scores_gemma":[0.0000023937496,0.00014070023,0.000056951325,0.00021407331,0.000042753272,0.00005754313,0.0000034596571,0.000107828404,0.0000017431597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029958626,0.0037357362,0.8164301,0.00076615124,0.002003117,0.011399289,0.010572689,0.000022984113,0.030976096,0.00009987114,0.000018857107,0.09401648],"study_design_scores_gemma":[0.2391293,0.026038494,0.4428662,0.00039810722,0.0016471337,0.0008372918,0.0024299847,0.0017209927,0.28320298,0.00006106244,0.0008987928,0.00076962594],"about_ca_topic_score_codex":0.0005560995,"about_ca_topic_score_gemma":0.0004431441,"teacher_disagreement_score":0.3735639,"about_ca_system_score_codex":0.00026071363,"about_ca_system_score_gemma":0.00018334297,"threshold_uncertainty_score":0.5737589},"labels":[],"label_agreement":null},{"id":"W4407976789","doi":"10.1016/j.jtct.2025.01.176","title":"Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"NPM1; Myeloid leukemia; Minimal residual disease; Medicine; Residual; Cancer research; Leukemia; Oncology; Immunology; Biology; Genetics; Computer science; Gene; Karyotype","score_opus":0.018973425728356492,"score_gpt":0.2948227699665627,"score_spread":0.27584934423820623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407976789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735506,0.0017594626,0.019458398,0.0018232015,0.00011451328,0.0014652679,0.00018849192,0.0001447115,0.0014953178],"genre_scores_gemma":[0.9785769,0.011573489,0.0013514422,0.0012676527,0.00008678766,0.00018891398,0.0015227125,0.000050075185,0.0053820047],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840343,0.00008370069,0.0003583726,0.00043308912,0.00029114407,0.00043026547],"domain_scores_gemma":[0.9993132,0.00009330432,0.000049053808,0.0002422771,0.0001447002,0.0001574927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003736647,0.00026432375,0.0003968128,0.00024737464,0.00023451904,0.000042161548,0.00013450976,0.00021191158,0.00008147154],"category_scores_gemma":[0.0000051495326,0.00021983135,0.00013257463,0.0002908551,0.000118308504,0.00009766449,0.0000042898077,0.0002629055,0.0000107762235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011361485,0.00012745998,0.004007265,0.00065504416,0.0014492255,0.00034203072,0.0032859228,0.00003063373,0.93737316,0.0014515782,0.000909601,0.039006606],"study_design_scores_gemma":[0.021463823,0.0009937764,0.01385349,0.0002866567,0.0009261032,0.00025930651,0.00025422414,0.0013166406,0.9509496,0.0009345945,0.008380079,0.0003816749],"about_ca_topic_score_codex":0.000086118285,"about_ca_topic_score_gemma":0.00004939145,"teacher_disagreement_score":0.03862493,"about_ca_system_score_codex":0.00016012532,"about_ca_system_score_gemma":0.00047519658,"threshold_uncertainty_score":0.89644617},"labels":[],"label_agreement":null},{"id":"W4407976914","doi":"10.1016/j.jtct.2025.01.098","title":"A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Gemtuzumab ozogamicin; Dosing; Calicheamicin; Toxicity; Medicine; Therapeutic index; Pharmacology; Hematopoietic cell; Hematopoietic stem cell transplantation; Therapeutic drug monitoring; Drug; CD33; Haematopoiesis; Internal medicine; Transplantation; Stem cell; Myeloid leukemia; CD34; Biology","score_opus":0.005868945256474293,"score_gpt":0.21372117983738542,"score_spread":0.20785223458091112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407976914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932076,0.0019594638,0.0031779225,0.00016084906,0.000015214045,0.0012630462,0.00014280468,0.000032831642,0.00004028646],"genre_scores_gemma":[0.99133325,0.007394335,0.000799077,0.00019407006,0.000004077987,0.000031136675,0.00012270447,0.000036727688,0.00008464758],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979347,0.0002308974,0.000562141,0.00049607584,0.00038930916,0.0003868604],"domain_scores_gemma":[0.9989813,0.00021800846,0.000230109,0.00027672292,0.0001850217,0.000108815824],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003050788,0.0003768551,0.00080459635,0.0003475522,0.000101571146,0.000023820901,0.00012088425,0.00016285288,0.000016046677],"category_scores_gemma":[0.0000037442755,0.000258489,0.000056069348,0.00042011577,0.00039543497,0.00013215165,0.000010722782,0.0003589724,2.895566e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01790841,0.0006729627,0.42347577,0.0044633597,0.0007309997,0.00023282372,0.01382762,0.00009033846,0.5329289,0.00021848413,0.0000030983979,0.0054472312],"study_design_scores_gemma":[0.033767164,0.0025304784,0.39771947,0.0020152542,0.0006818784,0.00009666127,0.001043805,0.0008418941,0.56071436,0.00017796787,0.0000049645805,0.00040608138],"about_ca_topic_score_codex":0.0004032182,"about_ca_topic_score_gemma":0.00018850318,"teacher_disagreement_score":0.027785465,"about_ca_system_score_codex":0.00010072242,"about_ca_system_score_gemma":0.00025579924,"threshold_uncertainty_score":0.9999867},"labels":[],"label_agreement":null},{"id":"W4407988405","doi":"10.1182/bloodadvances.2024013800","title":"Integrative cytogenetic and molecular studies unmask “chromosomal mimicry” in hematologic malignancies","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Biology; Clinical significance; Myeloid; Multiplex; Breakpoint; Fusion gene; Chromosome; Computational biology; Genetics; Gene; Pathology; Cancer research; Medicine","score_opus":0.015782602461741135,"score_gpt":0.3396708981396799,"score_spread":0.32388829567793875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407988405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8958699,0.10087827,0.000081295955,0.0016841595,0.000053112457,0.0004173229,0.000004521121,0.00008651695,0.0009248767],"genre_scores_gemma":[0.98552126,0.008120303,0.0050332197,0.00063182705,0.000018845258,0.0001104587,0.0000030099227,0.000019811223,0.0005412954],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879515,0.00007909216,0.00026086345,0.00037649373,0.00016875446,0.00031966018],"domain_scores_gemma":[0.9993478,0.00021427547,0.00004482099,0.0002068501,0.00012769815,0.000058559144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013649522,0.00019973058,0.0005024383,0.00022926748,0.000058726062,0.000014219075,0.0001127721,0.00007327711,0.000004534994],"category_scores_gemma":[0.00054704427,0.00014339376,0.000048133075,0.00047295858,0.00038861998,0.000088766035,0.00016107557,0.00023099848,0.0000074695517],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058735226,0.0007554949,0.3730962,0.0027440502,0.0012345418,0.0047548874,0.003496217,0.00004906925,0.5845006,0.016864572,0.0010588245,0.010858183],"study_design_scores_gemma":[0.0052842856,0.0007292369,0.01836852,0.0020140419,0.00029981532,0.00039203285,0.011169052,0.00008244886,0.9468303,0.0097523825,0.004714906,0.000363028],"about_ca_topic_score_codex":0.00001348438,"about_ca_topic_score_gemma":0.00006723537,"teacher_disagreement_score":0.36232963,"about_ca_system_score_codex":0.0000899838,"about_ca_system_score_gemma":0.00017695164,"threshold_uncertainty_score":0.5847428},"labels":[],"label_agreement":null},{"id":"W4408267715","doi":"10.5858/arpa.2024-0322-ra","title":"Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms","year":2025,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Standardization; Context (archaeology); Medical physics; Guideline; Data extraction; Bone marrow; MEDLINE; Pathology","score_opus":0.022585171750085422,"score_gpt":0.3226101202406587,"score_spread":0.3000249484905733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408267715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94550705,0.00044675817,0.043484155,0.004209467,0.001488558,0.0021758776,0.0009861868,0.000046568955,0.0016554025],"genre_scores_gemma":[0.99231577,0.00011060364,0.0055508,0.00038410103,0.00013181927,0.00021249545,0.00021760652,0.00005458695,0.0010222067],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99560934,0.00022897245,0.0023455138,0.0006266138,0.0007117367,0.00047782855],"domain_scores_gemma":[0.99120396,0.0046504806,0.0021750338,0.0008251829,0.0010036081,0.00014175022],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018836558,0.0003462697,0.0014438895,0.0008920274,0.00014306814,0.0000049732826,0.00045115987,0.00021899345,0.000062396866],"category_scores_gemma":[0.020245278,0.0002533739,0.00026620217,0.00070696784,0.0019623567,0.00006930929,0.00019957846,0.00044710372,0.0000012471947],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008202322,0.0006874473,0.052271318,0.00501615,0.0013884061,0.0004209058,0.0019564752,0.00106457,0.902494,0.017436322,0.0053508533,0.003711228],"study_design_scores_gemma":[0.05029899,0.017711336,0.29940304,0.018186998,0.004696902,0.0022864293,0.0042369673,0.0121642295,0.56709075,0.009553358,0.013246608,0.0011243623],"about_ca_topic_score_codex":0.000013830021,"about_ca_topic_score_gemma":0.000024497447,"teacher_disagreement_score":0.33540323,"about_ca_system_score_codex":0.00016995928,"about_ca_system_score_gemma":0.0017719521,"threshold_uncertainty_score":0.99999183},"labels":[],"label_agreement":null},{"id":"W4408337415","doi":"10.1002/ajh.27655","title":"<scp><i>TP53</i></scp>‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management","year":2025,"lang":"en","type":"review","venue":"American Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Astellas Pharma; Celgene; AbbVie Canada; Kura Oncology","keywords":"Myeloid leukemia; Medicine; Venetoclax; Cancer; Oncology; Myelodysplastic syndromes; Internal medicine; Myeloid; Population; Bioinformatics; Cancer research; Immunology; Leukemia; Biology; Bone marrow","score_opus":0.01547931291521099,"score_gpt":0.3319085732240816,"score_spread":0.31642926030887064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408337415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00063384115,0.9929304,0.00020777911,0.0013056,0.00044852664,0.0011719299,0.00006469433,0.00003587065,0.0032013492],"genre_scores_gemma":[0.00011519916,0.9946116,0.0026678606,0.00061266904,0.00015529667,0.00017687552,0.000075615804,0.00007911445,0.0015057633],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99546343,0.0008365962,0.0018054475,0.00065020536,0.00058799994,0.0006563193],"domain_scores_gemma":[0.9933015,0.0027383016,0.0023955714,0.00074117,0.00036444032,0.00045900812],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009073504,0.00064409024,0.004054753,0.0015534153,0.0001331993,0.000056368404,0.00057724357,0.00027832537,0.00009441902],"category_scores_gemma":[0.0011145723,0.00048107907,0.00054457394,0.0014215116,0.0007211982,0.0000775855,0.00019972108,0.0020458593,0.00017120119],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006058475,0.00021202173,0.00044419008,0.01193872,0.0023679326,0.0021732245,0.000071486094,0.0000015116104,2.479881e-7,0.0011625586,0.124601565,0.85696596],"study_design_scores_gemma":[0.00095910183,0.0011962723,0.00009580484,0.014258297,0.00371518,0.008429113,0.00044095915,0.000005554282,0.000020009367,0.0001789717,0.9705387,0.0001620771],"about_ca_topic_score_codex":0.000024464629,"about_ca_topic_score_gemma":0.0000055464516,"teacher_disagreement_score":0.8568039,"about_ca_system_score_codex":0.00040137873,"about_ca_system_score_gemma":0.0012455396,"threshold_uncertainty_score":0.9997641},"labels":[],"label_agreement":null},{"id":"W4408502310","doi":"10.1016/j.gimo.2025.102972","title":"P128: Bioinformatics analysis reveals genes involved in PI3K-Akt pathway as novel potential biomarkers and drug targets for acute myeloid leukemia (AML)","year":2025,"lang":"en","type":"article","venue":"Genetics in Medicine Open","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Myeloid leukemia; Cancer research; Drug; PI3K/AKT/mTOR pathway; Myeloid; Gene; Leukemia; Medicine; Computational biology; Bioinformatics; Biology; Genetics; Pharmacology; Immunology; Signal transduction","score_opus":0.023751064170594888,"score_gpt":0.3439000638945404,"score_spread":0.3201489997239455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408502310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9495895,0.0063717994,0.016098874,0.014244236,0.00048655586,0.006548026,0.00016659847,0.000055244436,0.0064391755],"genre_scores_gemma":[0.8035137,0.011412577,0.16305079,0.00722986,0.0004346496,0.00084297365,0.0013918228,0.00014522197,0.011978402],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9961424,0.00013444189,0.0014266364,0.0007567091,0.0006794369,0.0008603851],"domain_scores_gemma":[0.99769056,0.00039663748,0.0002688747,0.0009424848,0.0003473703,0.00035405284],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028861174,0.00046016581,0.0015089539,0.0020984374,0.00015227578,0.00009896413,0.0009605251,0.0003156066,0.000107905624],"category_scores_gemma":[0.0007975082,0.0003881687,0.00015356143,0.0028580998,0.0004545362,0.00017540676,0.0010040277,0.0005466698,0.000010068283],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009220639,0.0009673924,0.24875425,0.0037868847,0.017503176,0.0010503749,0.014035641,0.0025600542,0.40185496,0.0015702009,0.10465815,0.19403827],"study_design_scores_gemma":[0.12874019,0.0040748804,0.23844495,0.005252633,0.014263152,0.00023459633,0.025172276,0.41387862,0.085340895,0.012124023,0.0689622,0.0035115918],"about_ca_topic_score_codex":0.0019191646,"about_ca_topic_score_gemma":0.0013409279,"teacher_disagreement_score":0.41131857,"about_ca_system_score_codex":0.00093380443,"about_ca_system_score_gemma":0.0015042992,"threshold_uncertainty_score":0.999857},"labels":[],"label_agreement":null},{"id":"W4408669628","doi":"10.1182/blood.2024027590","title":"Megakaryocyte mitotic figures in de novo AML, myelodysplasia related, with STAG2, SRSF2, and ASXL1 comutations","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Megakaryocyte; Mitosis; Biology; Medicine; Haematopoiesis; Genetics; Stem cell","score_opus":0.007324978713799938,"score_gpt":0.27099811916155075,"score_spread":0.2636731404477508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408669628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97718173,0.0011082485,0.00009033442,0.0029880723,0.00002765981,0.00050778047,0.000010910779,0.0000719813,0.018013299],"genre_scores_gemma":[0.9887478,0.00023284378,0.0026609935,0.00043001358,0.00003098927,0.00005592678,0.000030788917,0.000026397578,0.0077842413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998727,0.00007884623,0.00025074533,0.0003082034,0.00024006369,0.00039510612],"domain_scores_gemma":[0.9991735,0.00024696652,0.000039737926,0.00030533195,0.00008524222,0.00014918108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023882653,0.00016021614,0.00028520072,0.00036965753,0.00009089276,0.00003437319,0.00011240959,0.00014335579,0.00007155109],"category_scores_gemma":[0.00025269084,0.00013337174,0.000031926527,0.0006845079,0.00016447749,0.0000835993,0.00006731797,0.0005484266,0.000033199743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016839228,0.002436594,0.92684656,0.0015432087,0.001735176,0.008662039,0.0038544876,0.00027328037,0.030137826,0.008568439,0.0085711,0.005687384],"study_design_scores_gemma":[0.049916282,0.0012498228,0.899646,0.001971834,0.0012150609,0.0028934206,0.0019735564,0.0023089324,0.02831178,0.0016923958,0.008218703,0.0006021995],"about_ca_topic_score_codex":0.00019072361,"about_ca_topic_score_gemma":0.00023261886,"teacher_disagreement_score":0.048232358,"about_ca_system_score_codex":0.00016985708,"about_ca_system_score_gemma":0.0007871376,"threshold_uncertainty_score":0.54387414},"labels":[],"label_agreement":null},{"id":"W4408796741","doi":"10.1016/j.labinv.2024.103508","title":"1272 A 4-Gene Co-Alteration Signature (SIG4) Predictive of Favorable Outcomes in High-Grade TP53 Mutated Myeloid Neoplasms: An International TP53 Investigators Network (iTIN) Study","year":2025,"lang":"en","type":"article","venue":"Laboratory Investigation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Myeloid; Signature (topology); Gene signature; Gene; Medicine; Cancer research; Biology; Genetics; Oncology; Gene expression","score_opus":0.014354028392792043,"score_gpt":0.3046831819884723,"score_spread":0.29032915359568023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408796741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944654,0.00009878464,0.00034517876,0.0016521246,0.0006052317,0.0021846406,0.00023414331,0.00019980215,0.00021466798],"genre_scores_gemma":[0.9929293,0.000031527226,0.0028668619,0.0017937369,0.00027121225,0.00027873184,0.0014639747,0.000057862137,0.00030683124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958127,0.00083042734,0.0010867381,0.00078939187,0.00096317613,0.00051754434],"domain_scores_gemma":[0.99724567,0.00030632128,0.00041682684,0.0006660732,0.0009947526,0.00037032852],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012469931,0.0004311288,0.0007641134,0.0008833019,0.0001745878,0.00009797836,0.00040990533,0.0004029927,0.000056121076],"category_scores_gemma":[0.0012695829,0.0004186455,0.00007174607,0.0026714941,0.00041484204,0.0009880733,0.0001048102,0.0010029727,0.000015531987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004317406,0.0006177891,0.9052935,0.00011878288,0.0003988029,0.00006387694,0.0029709768,0.0076230424,0.078999825,0.0013707861,0.0019719831,0.0001388508],"study_design_scores_gemma":[0.0077974694,0.0013623495,0.8419066,0.0004853769,0.00023423391,0.0000054155516,0.0026923723,0.016394371,0.12532085,0.0029447104,0.0004042506,0.00045198278],"about_ca_topic_score_codex":0.0005489179,"about_ca_topic_score_gemma":0.0003836394,"teacher_disagreement_score":0.06338692,"about_ca_system_score_codex":0.0010168821,"about_ca_system_score_gemma":0.0024832066,"threshold_uncertainty_score":0.99982655},"labels":[],"label_agreement":null},{"id":"W4408796964","doi":"10.1016/j.labinv.2024.103531","title":"1295 Prognostic Impact of Chromosome 7 Losses in High-Grade TP53 Mutated Myeloid Neoplasms","year":2025,"lang":"en","type":"article","venue":"Laboratory Investigation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Myeloid; Biology; Chromosome; Genetics; Cancer research; Pathology; Medicine; Gene","score_opus":0.014149019421062524,"score_gpt":0.30211557718313403,"score_spread":0.28796655776207153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408796964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969158,0.00030547057,0.00002765954,0.0013252151,0.000116059215,0.00088398444,0.000080042024,0.00010963199,0.00023612707],"genre_scores_gemma":[0.99802244,0.000051278053,0.00088630395,0.00039584722,0.0000697534,0.00008472641,0.00026506322,0.000031257332,0.0001933205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980941,0.00021076822,0.0005527446,0.00036463636,0.00039325975,0.0003845073],"domain_scores_gemma":[0.99844354,0.00026584472,0.00016522389,0.00042424738,0.0004903747,0.00021079309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038901,0.0002339617,0.00046592054,0.00065793144,0.000053064727,0.00002830178,0.00016480587,0.00022615366,0.000089045476],"category_scores_gemma":[0.0014842472,0.00020705964,0.00007127549,0.0031074542,0.00038745638,0.0002620095,0.000057415036,0.00047227409,0.00004589645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014872811,0.00015207315,0.5928441,0.000436594,0.00013358363,0.00009118428,0.00043134097,0.00031505036,0.4017786,0.000886724,0.002414392,0.00036759244],"study_design_scores_gemma":[0.0027681123,0.00042580508,0.7606112,0.00062750705,0.00008342088,0.00000947449,0.000119190634,0.0016155283,0.23201326,0.0014198406,0.0001347111,0.00017199316],"about_ca_topic_score_codex":0.0007285688,"about_ca_topic_score_gemma":0.00009357861,"teacher_disagreement_score":0.16976534,"about_ca_system_score_codex":0.0008962915,"about_ca_system_score_gemma":0.0035652546,"threshold_uncertainty_score":0.8443647},"labels":[],"label_agreement":null},{"id":"W4408861505","doi":"10.14740/jmc5087","title":"Combination of 2-Chlorodeoxyadenosine, Cytarabine, and Granulocyte Colony-Stimulating Factor and Venetoclax in a Case of Acute Myelogenous Leukemia","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"USC Norris Comprehensive Cancer Center; University of Southern California","keywords":"Medicine; Cytarabine; Granulocyte colony-stimulating factor; Venetoclax; Leukemia; Chronic myelogenous leukemia; Immunology; Cancer research; Internal medicine; Chemotherapy; Chronic lymphocytic leukemia","score_opus":0.021467518167708744,"score_gpt":0.3425524153789215,"score_spread":0.32108489721121275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408861505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99519587,0.0023976266,0.0001972521,0.0017718805,0.000076987664,0.000273607,0.00002129222,0.0000047286144,0.000060782542],"genre_scores_gemma":[0.9977965,0.0013041117,0.0006138295,0.00016125882,0.000055566965,0.0000029841656,0.000003945319,0.000011406415,0.000050396495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785733,0.00012847364,0.0008954729,0.00015310133,0.00075379806,0.00021183131],"domain_scores_gemma":[0.9977673,0.0011151776,0.00035571287,0.00013484739,0.00037002412,0.00025690295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009860954,0.00013975073,0.0007395976,0.0005445256,0.000043878088,0.000010200386,0.000114437775,0.00022720826,0.000048981703],"category_scores_gemma":[0.0027002238,0.00010972494,0.00007639487,0.00039760233,0.0003454107,0.00009553917,0.00011069905,0.00066445366,2.0997011e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012385056,0.0011498359,0.5491119,0.005778316,0.001967954,0.2001306,0.004424357,0.00022927293,0.0723279,0.0011870557,0.003579133,0.14772862],"study_design_scores_gemma":[0.045917816,0.009559018,0.690875,0.007157343,0.0015477685,0.16376391,0.0022646508,0.046295747,0.030925855,0.0007032932,0.00051753153,0.0004720585],"about_ca_topic_score_codex":0.0008357038,"about_ca_topic_score_gemma":0.000092646966,"teacher_disagreement_score":0.14725657,"about_ca_system_score_codex":0.0005175473,"about_ca_system_score_gemma":0.0018425073,"threshold_uncertainty_score":0.4474453},"labels":[],"label_agreement":null},{"id":"W4408905115","doi":"10.1182/blood.2023023717","title":"Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Clinical trial; Medicine; Population; Intensive care medicine; Family medicine; Internal medicine","score_opus":0.032838014213156644,"score_gpt":0.41168558814440365,"score_spread":0.378847573931247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408905115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99494,0.00002124876,0.0006109908,0.0007205847,0.00020928126,0.002807786,0.000050189923,0.000056909892,0.00058303087],"genre_scores_gemma":[0.9939047,0.00001271665,0.004677277,0.00042263587,0.00025832583,0.00018212978,0.00026647098,0.000018897521,0.0002568365],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982065,0.00015604934,0.00053794804,0.0004610332,0.0003307003,0.00030776628],"domain_scores_gemma":[0.9986379,0.00020359203,0.00009082054,0.0004878986,0.00031236385,0.00026739432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012477598,0.00012517563,0.0003121188,0.00009823659,0.000120802186,0.00002776771,0.00010840117,0.00011527681,0.00003877337],"category_scores_gemma":[0.0010483835,0.0000961784,0.00009497312,0.00018404207,0.00009198929,0.00010216026,0.000046206635,0.0002453946,0.000004249108],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38481352,0.015858091,0.53270066,0.0007840502,0.0019626364,0.000049103986,0.0007822268,0.0000137536645,0.0013020084,0.00052041997,0.018292187,0.042921323],"study_design_scores_gemma":[0.7784974,0.037320897,0.16471101,0.000478297,0.0017156437,0.000004846793,0.0005273505,0.00075138104,0.007893546,0.0006638429,0.006980205,0.00045555478],"about_ca_topic_score_codex":0.000058296457,"about_ca_topic_score_gemma":0.000010303609,"teacher_disagreement_score":0.3936839,"about_ca_system_score_codex":0.00023173283,"about_ca_system_score_gemma":0.0011375061,"threshold_uncertainty_score":0.39220414},"labels":[],"label_agreement":null},{"id":"W4408957812","doi":"10.1038/s41408-025-01263-3","title":"Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; AbbVie","keywords":"Azacitidine; Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Medicine; Myeloid leukemia; Venetoclax; Leukemia; Antecedent (behavioral psychology); Internal medicine; Myeloid; Oncology; Immunology; Chronic lymphocytic leukemia; Bone marrow; Psychology; Psychotherapist; Biology","score_opus":0.013960923690989883,"score_gpt":0.2738220891699498,"score_spread":0.25986116547895993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408957812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93034697,0.016228545,0.00002491975,0.048142035,0.0008956404,0.0032715313,0.0004250952,0.00018625383,0.00047902975],"genre_scores_gemma":[0.40232015,0.28265467,0.0012325868,0.21527094,0.012333934,0.0022497077,0.0037535913,0.0020220191,0.078162394],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99298763,0.0003841805,0.0015351379,0.001370692,0.0017217624,0.0020006006],"domain_scores_gemma":[0.99664676,0.00044203887,0.000819271,0.0008610064,0.00068826013,0.00054268044],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.00043548504,0.0013901626,0.0022957458,0.001888745,0.00037885673,0.00030208935,0.0007583396,0.0016316137,0.0010947791],"category_scores_gemma":[0.0001283275,0.000967567,0.00029092617,0.0017068076,0.0005055215,0.00033317963,0.00027579578,0.009116102,0.000031249063],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.019431585,0.00068096264,0.05965749,0.005397218,0.032533716,0.12247769,0.001243727,0.0014782107,0.001332025,0.0000075667654,0.6785141,0.077245675],"study_design_scores_gemma":[0.29806542,0.034635622,0.15425168,0.064954504,0.019742874,0.051578045,0.00023201382,0.0058108885,0.0044658226,0.00020290002,0.35829496,0.0077652847],"about_ca_topic_score_codex":0.0009509717,"about_ca_topic_score_gemma":0.00031381234,"teacher_disagreement_score":0.5280268,"about_ca_system_score_codex":0.024624357,"about_ca_system_score_gemma":0.02900519,"threshold_uncertainty_score":0.9998849},"labels":[],"label_agreement":null},{"id":"W4408974080","doi":"10.1007/978-3-031-65292-9_2","title":"Myeloid Leukemia Cutis","year":2025,"lang":"en","type":"book-chapter","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta Hospital; University of Alberta","funders":"","keywords":"Leukemia cutis; Myeloid leukemia; Cutis; Medicine; Dermatology; Cancer research","score_opus":0.021731963718647686,"score_gpt":0.2884826734431618,"score_spread":0.26675070972451415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408974080","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020624391,0.001006213,0.000227831,0.0025913145,0.0002623268,0.00083675544,0.00005234154,0.00031850414,0.9946841],"genre_scores_gemma":[0.00019336368,0.0019307797,0.0019946035,0.0032142631,0.0006413253,0.000023182216,0.00029328608,0.0001190954,0.9915901],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974873,0.000012763411,0.0004902227,0.00073429913,0.00075485103,0.0005205748],"domain_scores_gemma":[0.9979117,0.0001697301,0.000099394674,0.0011693948,0.00030435986,0.00034540592],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00021009787,0.00052827835,0.0009150917,0.0005961869,0.00008690801,0.0000346551,0.00034312718,0.00097543333,0.016897194],"category_scores_gemma":[0.00012158483,0.00044600468,0.0003991777,0.000082764855,0.00021527642,0.000047927977,0.0003940328,0.00173692,0.004422343],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013878707,0.000009042495,0.000021087248,0.00034205263,0.00040658997,0.0006082304,0.000017342454,2.6423e-7,0.00014199245,0.20991953,0.7448488,0.043546304],"study_design_scores_gemma":[0.0011838719,0.00016209137,0.00006860262,0.0006281762,0.00028213896,0.00016103587,0.0000087169765,0.00009744691,0.00042170123,0.0041868994,0.9924268,0.00037248683],"about_ca_topic_score_codex":0.00013925233,"about_ca_topic_score_gemma":0.00002831365,"teacher_disagreement_score":0.24757805,"about_ca_system_score_codex":0.002856709,"about_ca_system_score_gemma":0.0040261745,"threshold_uncertainty_score":0.9997992},"labels":[],"label_agreement":null},{"id":"W4409149760","doi":"10.1182/blood.2024027244","title":"Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health; Cancer Prevention and Research Institute of Texas; GlaxoSmithKline","keywords":"Medicine; Oncology; Internal medicine; Myeloid leukemia; Concordance; Biomarker; Leukemia; Proportional hazards model; Bioinformatics; Immunology; Biology","score_opus":0.023986059074822264,"score_gpt":0.32406385723277453,"score_spread":0.30007779815795227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409149760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910903,0.00028641854,0.00025556728,0.0017253556,0.00009746652,0.0015206885,0.000027468563,0.00010484501,0.004891908],"genre_scores_gemma":[0.98639596,0.00001198706,0.0065108337,0.00043518664,0.00004043516,0.00019494246,0.000033889457,0.000034534096,0.006342215],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982506,0.000049753944,0.00046174365,0.0003834887,0.0004673181,0.0003870892],"domain_scores_gemma":[0.9987157,0.00018458262,0.00011504,0.00062448747,0.0002544594,0.00010571794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004711045,0.00020794063,0.00049694505,0.00046651936,0.00007308156,0.000029726072,0.0002539618,0.00015568074,0.00008774595],"category_scores_gemma":[0.0010068122,0.00016928965,0.00019992706,0.00058838824,0.00018051325,0.000064497326,0.00014342232,0.00029513286,0.00005325409],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024251192,0.001468306,0.19103552,0.0009274746,0.000955504,0.00007784594,0.000057009915,0.0000018181977,0.80414736,0.00046201536,0.00031847315,0.0003061833],"study_design_scores_gemma":[0.01169216,0.00017013041,0.08207368,0.0003685456,0.00077581237,0.000021182163,0.000079134086,0.00024683826,0.9041217,0.00013078045,0.00017963085,0.00014042782],"about_ca_topic_score_codex":0.00024579494,"about_ca_topic_score_gemma":0.000009602852,"teacher_disagreement_score":0.10896184,"about_ca_system_score_codex":0.000063054475,"about_ca_system_score_gemma":0.0011251481,"threshold_uncertainty_score":0.69034314},"labels":[],"label_agreement":null},{"id":"W4409174715","doi":"10.1016/j.leukres.2025.107690","title":"Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 study","year":2025,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Astellas Pharma; Astellas Pharma US","keywords":"Tolerability; Pharmacokinetics; Myeloid leukemia; Medicine; Refractory (planetary science); Pharmacology; Oncology; Internal medicine; Adverse effect; Materials science","score_opus":0.05871529485145651,"score_gpt":0.4337909477996639,"score_spread":0.3750756529482074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409174715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98039085,0.0007811345,0.000046061377,0.0020882722,0.00013960025,0.004206766,0.000058774447,0.00007780096,0.012210722],"genre_scores_gemma":[0.98123604,0.002023634,0.00059515936,0.00028477743,0.00014141655,0.00032316952,0.000040861607,0.00008372752,0.015271192],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920676,0.0014349862,0.0015650572,0.0013350274,0.0021002614,0.0014970948],"domain_scores_gemma":[0.99365366,0.002985348,0.00015707473,0.0016312614,0.0010389541,0.00053373084],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006261548,0.00048537375,0.0014296665,0.0023012774,0.00027761655,0.000077445,0.00085960963,0.0005013465,0.0006052846],"category_scores_gemma":[0.003011911,0.00040143347,0.00015190459,0.0042697196,0.0011272115,0.0001949114,0.0015004083,0.0042037554,0.000054313972],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.13790226,0.014954589,0.1515673,0.00514738,0.0032574236,0.009669834,0.0106024565,0.00020007495,0.33627564,0.0012218864,0.049760647,0.27944052],"study_design_scores_gemma":[0.388778,0.04892095,0.27238068,0.0043202573,0.0017576033,0.00080434134,0.02394273,0.04985229,0.11274832,0.0023116965,0.09142465,0.0027584855],"about_ca_topic_score_codex":0.0018522555,"about_ca_topic_score_gemma":0.00043186796,"teacher_disagreement_score":0.27668205,"about_ca_system_score_codex":0.009077617,"about_ca_system_score_gemma":0.010252786,"threshold_uncertainty_score":0.9998438},"labels":[],"label_agreement":null},{"id":"W4409199387","doi":"10.1182/bloodadvances.2024014965","title":"Distinct routes of clonal progression in SF3B1-mutant myelodysplastic syndromes","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Associazione Italiana per la Ricerca sul Cancro; National Cancer Institute; National Institutes of Health; Cancer Research UK; Edward P. Evans Foundation; Università degli Studi di Pavia; Leukemia and Lymphoma Society; University of Washington; Damon Runyon Cancer Research Foundation","keywords":"Myelodysplastic syndromes; RUNX1; Progenitor cell; Biology; Mutant; Haematopoiesis; Mutation; Cancer research; Myeloid; Stem cell; Genetics; Gene; Immunology; Bone marrow","score_opus":0.011488204010377595,"score_gpt":0.32914452504345054,"score_spread":0.31765632103307295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409199387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98734814,0.006700287,0.00012267346,0.00081157853,0.00013021317,0.0004820462,0.000018024739,0.000050501185,0.004336555],"genre_scores_gemma":[0.9959869,0.00039394887,0.002597848,0.00004511341,0.000050107217,0.000059016693,0.000020361405,0.000013844876,0.0008329035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985325,0.000053237254,0.00038755932,0.00031235677,0.00038091387,0.00033344072],"domain_scores_gemma":[0.99911517,0.00036693117,0.000090893176,0.0002476717,0.000098044446,0.00008126635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021803839,0.0001593045,0.000426619,0.00029319339,0.000045176024,0.000010386592,0.000171944,0.00007677936,0.00005902947],"category_scores_gemma":[0.0006433017,0.00011853004,0.00006689436,0.00064616546,0.00020170797,0.00012861678,0.00012128071,0.0002737275,0.000010892485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009974753,0.0011774055,0.8802783,0.0018438054,0.00019767748,0.0007603265,0.0001729963,0.0000294554,0.04412451,0.0024734417,0.00022198338,0.06772265],"study_design_scores_gemma":[0.009854187,0.0013848888,0.8254644,0.005620478,0.00034082873,0.00030929674,0.00048024382,0.001080137,0.13973513,0.0025839268,0.012750402,0.00039606006],"about_ca_topic_score_codex":0.00002062685,"about_ca_topic_score_gemma":0.000038365164,"teacher_disagreement_score":0.09561062,"about_ca_system_score_codex":0.000084248044,"about_ca_system_score_gemma":0.00038658042,"threshold_uncertainty_score":0.48335147},"labels":[],"label_agreement":null},{"id":"W4409247148","doi":"10.1159/000545588","title":"Recombinant Myeloid Hematopoietic Growth Factors and Clinical Stimulation of Acute Myeloid Leukemia Cells: A Narrative Review","year":2025,"lang":"en","type":"review","venue":"Acta Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sick Kids Foundation; Case Western Reserve University; Teva Pharmaceutical Industries; Leukemia and Lymphoma Society; Bristol-Myers Squibb","keywords":"Myeloid leukemia; Neutropenia; Haematopoiesis; Medicine; Myeloid; Immunology; Hematopoietic growth factor; Internal medicine; Oncology; Cancer research; Biology; Stem cell; Chemotherapy","score_opus":0.059814397520463025,"score_gpt":0.39543655538321526,"score_spread":0.33562215786275224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409247148","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016783661,0.9903057,0.000022704957,0.0006259633,0.0004088529,0.005457887,0.00010640599,0.00015293412,0.0012411814],"genre_scores_gemma":[0.0009688352,0.9956153,0.0009671387,0.0003247165,0.000062935054,0.0002533615,0.0005748396,0.00009202105,0.0011408383],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99211246,0.0013989885,0.003380268,0.0015138731,0.00078141957,0.0008129875],"domain_scores_gemma":[0.9917791,0.0039243805,0.0018253569,0.0013955625,0.00058904925,0.00048655656],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016223949,0.0012186768,0.009882444,0.0005806145,0.00020747197,0.00004003596,0.00079062587,0.0015071495,0.00027088675],"category_scores_gemma":[0.0030301285,0.00076805224,0.0016736987,0.0014009876,0.00071545946,0.00016864123,0.0007947377,0.002279024,0.000057004876],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032692243,0.00072044256,0.0009766223,0.7073408,0.00605136,0.0012791975,0.0005550634,4.8500365e-8,0.000015163321,0.00078789826,0.0732719,0.2086746],"study_design_scores_gemma":[0.0030121356,0.0025245026,0.00047393548,0.43045402,0.025164237,0.0025479342,0.000307137,0.00003143752,0.00013455073,0.00044862277,0.53308874,0.0018127598],"about_ca_topic_score_codex":0.00005045668,"about_ca_topic_score_gemma":0.0000040253203,"teacher_disagreement_score":0.45981684,"about_ca_system_score_codex":0.00077746593,"about_ca_system_score_gemma":0.003340233,"threshold_uncertainty_score":0.9997891},"labels":[],"label_agreement":null},{"id":"W4409286918","doi":"10.1038/s41375-025-02593-8","title":"DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes","year":2025,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Institute for Research in Immunology and Cancer; Centre Hospitalier Universitaire Sainte-Justine","funders":"Directorate for Biological Sciences; Barts Health NHS Trust; University College London Hospitals NHS Foundation Trust; Université de Montréal; Semmelweis Egyetem; Institut National de la Santé et de la Recherche Médicale; Cancer Research UK; Kay Kendall Leukaemia Fund; Österreichischen Akademie der Wissenschaften; Helsingin Yliopisto; Francis Crick Institute; Genome Canada; European Hematology Association; Centre hospitalier universitaire Sainte-Justine; University College London; Helsinki Institute of Life Science, Helsingin Yliopisto; Queen Mary University of London; Barts Charity; Veterinärmedizinische Universität Wien; Cancer Research Institute","keywords":"Biology; Transcriptome; Fusion gene; Gene; Activator (genetics); Fusion protein; Leukemia; Hox gene; Myeloid leukemia; Cancer research; Chromosomal translocation; Promoter; Genetics; Transcription factor; Computational biology; Gene expression","score_opus":0.016974482969315183,"score_gpt":0.3151619623183538,"score_spread":0.2981874793490386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409286918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788748,0.00050273153,0.0012415311,0.001044274,0.0005147297,0.0007368009,0.000049112175,0.0001688275,0.01686721],"genre_scores_gemma":[0.98378897,0.00023303964,0.0012784936,0.0010140374,0.0005726961,0.000078169556,0.00017081264,0.00006869412,0.0127950795],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964845,0.00016922984,0.0006883666,0.0007591954,0.001092969,0.0008057505],"domain_scores_gemma":[0.9978891,0.00017952055,0.00015479227,0.00093819725,0.0003738081,0.00046456294],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000522422,0.0004030664,0.00071569934,0.0005245483,0.00018060712,0.000055786462,0.000553151,0.00046696066,0.0011494204],"category_scores_gemma":[0.00026448772,0.0003764837,0.00026611102,0.00067910715,0.00032172483,0.00037423545,0.00015863785,0.0008717062,0.00017630696],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0023468276,0.0002568601,0.0047376016,0.0005176947,0.0005115033,0.00025046087,0.0004621234,0.00017207261,0.9597931,0.012551707,0.005223097,0.013176958],"study_design_scores_gemma":[0.009286523,0.0006633225,0.050754927,0.00037880207,0.00042056173,0.00023533015,0.0006752204,0.0017496704,0.89909244,0.0016207293,0.0345837,0.00053881016],"about_ca_topic_score_codex":0.0010103679,"about_ca_topic_score_gemma":0.00010158744,"teacher_disagreement_score":0.060700685,"about_ca_system_score_codex":0.0042868243,"about_ca_system_score_gemma":0.008882672,"threshold_uncertainty_score":0.9998687},"labels":[],"label_agreement":null},{"id":"W4409408715","doi":"10.1186/s40364-025-00769-z","title":"IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia","year":2025,"lang":"en","type":"article","venue":"Biomarker Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec; Princess Margaret Cancer Centre; University of Toronto; Université de Montréal; Medical Council of Canada; Hôpital Maisonneuve-Rosemont; National Research Council Canada; Centre Hospitalier Universitaire Sainte-Justine; Institute for Research in Immunology and Cancer","funders":"Cole Foundation; Fonds de Recherche du Québec - Santé; Alliance de recherche numérique du Canada; CHU Sainte-Justine Foundation; Institut de Valorisation des Données; Canada First Research Excellence Fund; Fondation Charles-Bruneau; Université de Montréal; Stem Cell Network; Government of Canada; Génome Québec; Canadian Institutes of Health Research; Genome Canada","keywords":"NPM1; Myeloid leukemia; Medicine; Cancer research; Haematopoiesis; Myeloid; Leukemia; Antigen; Stem cell; Immunology; Karyotype; Biology; Gene; Genetics","score_opus":0.08034417398707672,"score_gpt":0.4165432102343647,"score_spread":0.336199036247288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409408715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91146785,0.0053902133,0.0037689854,0.023778068,0.0009191634,0.009920033,0.0005332102,0.00063698157,0.043585498],"genre_scores_gemma":[0.8008404,0.0011500501,0.008894289,0.0035166063,0.00050106674,0.0015703118,0.0012150339,0.0003019977,0.18201026],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940601,0.0006187006,0.0007189548,0.0011138787,0.0014836357,0.0020047121],"domain_scores_gemma":[0.9955409,0.0006587343,0.00007960901,0.0015800854,0.0015971232,0.00054352806],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0041960226,0.00043220288,0.000703102,0.0017874772,0.00072978437,0.00021826345,0.0010263266,0.0005255472,0.0016300934],"category_scores_gemma":[0.0005052466,0.0003785608,0.0003353985,0.0031510831,0.000700469,0.00035320758,0.00044241577,0.0012397846,0.00037992102],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031293053,0.00072502205,0.0067109466,0.00082351774,0.0034129778,0.0003776194,0.00085867173,0.0000021476544,0.51766974,0.0012490412,0.33461815,0.10225911],"study_design_scores_gemma":[0.024896538,0.0043529626,0.0670849,0.0004110955,0.00038876163,0.00019548292,0.00092965603,0.032490186,0.18393649,0.002380898,0.68195695,0.0009760719],"about_ca_topic_score_codex":0.00066219055,"about_ca_topic_score_gemma":0.000026803133,"teacher_disagreement_score":0.3473388,"about_ca_system_score_codex":0.0021613578,"about_ca_system_score_gemma":0.005003039,"threshold_uncertainty_score":0.9998666},"labels":[],"label_agreement":null},{"id":"W4409473505","doi":"10.1002/cncr.35845","title":"Real‐world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia","year":2025,"lang":"en","type":"article","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; McMaster University","funders":"Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Cytarabine; Azacitidine; Myeloid leukemia; Adverse effect; Observational study","score_opus":0.0145970464277741,"score_gpt":0.3075350676212346,"score_spread":0.2929380211934605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409473505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948917,0.00011557999,0.00003775779,0.002187825,0.000050685456,0.0010196788,0.00007481899,0.000043707758,0.0015782221],"genre_scores_gemma":[0.97935516,0.0027617386,0.00034150336,0.0012280669,0.000032675045,0.00036965637,0.000055111243,0.000039037364,0.015817033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861807,0.0000342896,0.0002003042,0.0004319552,0.0002665561,0.00044880144],"domain_scores_gemma":[0.99925834,0.00005045386,0.0000574747,0.00036656598,0.0001380783,0.00012910098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006854325,0.00027610362,0.0005105962,0.00025219153,0.000054942582,0.000024299168,0.0000954157,0.000059499533,0.0001030774],"category_scores_gemma":[0.0000067113483,0.0001530999,0.00003640011,0.00045457648,0.00013500662,0.000095729614,0.00003868111,0.00022575955,0.0000035097396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003082185,0.00010251298,0.95604515,0.000037398124,0.00045696492,0.0001250331,0.00017928128,0.00000844862,0.000049356728,0.000063623695,0.0007496401,0.039100397],"study_design_scores_gemma":[0.01847849,0.0010922612,0.97510046,0.0003560346,0.000085464344,0.0000029493106,0.000056201254,0.000056988,0.0009530636,0.000012709221,0.0036382717,0.0001670907],"about_ca_topic_score_codex":0.0069200858,"about_ca_topic_score_gemma":0.008758366,"teacher_disagreement_score":0.038933307,"about_ca_system_score_codex":0.0027451604,"about_ca_system_score_gemma":0.0008663502,"threshold_uncertainty_score":0.9996929},"labels":[],"label_agreement":null},{"id":"W4409501816","doi":"10.1038/s41586-025-08871-w","title":"Metformin reduces the competitive advantage of Dnmt3aR878H HSPCs","year":2025,"lang":"en","type":"article","venue":"Nature","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Hospital for Sick Children; Occupational Cancer Research Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Haematopoiesis; Biology; Metformin; Stem cell; Progenitor cell; Reprogramming; Cancer research; Cell biology; Genetics; Cell; Diabetes mellitus; Endocrinology","score_opus":0.007738896142385278,"score_gpt":0.33905714268343323,"score_spread":0.33131824654104797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409501816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5535816,0.0113005955,0.00007400525,0.02920148,0.00045335604,0.00097604917,0.00006294287,0.00007307323,0.4042769],"genre_scores_gemma":[0.9798725,0.00031390355,0.00095746416,0.0024599754,0.00010998328,0.000014436657,0.000025227026,0.000010975323,0.016235517],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990713,0.000051800223,0.00016323316,0.00017399885,0.00034075687,0.00019889299],"domain_scores_gemma":[0.9990152,0.00030299858,0.000049987873,0.00034919608,0.00023668938,0.000045912897],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00032727275,0.00010357615,0.00024176542,0.00013426828,0.0000633625,0.000008151858,0.00025485028,0.00053371105,0.00014220722],"category_scores_gemma":[0.0005471871,0.000059563175,0.00009318685,0.0005374201,0.00018567924,0.000047934154,0.00012117894,0.0025430294,0.000018822293],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001831598,0.0003767841,0.0045088246,0.0007046729,0.0009621293,0.00029883656,0.0016293406,0.0000025277368,0.25740245,0.3628035,0.28909752,0.080381826],"study_design_scores_gemma":[0.0020974302,0.00018999846,0.0075820037,0.00040049612,0.00016917314,0.00006711288,0.0053290734,0.00012979549,0.5841366,0.0015069166,0.39826357,0.00012785135],"about_ca_topic_score_codex":0.000010700142,"about_ca_topic_score_gemma":0.000006311989,"teacher_disagreement_score":0.42629093,"about_ca_system_score_codex":0.00012677675,"about_ca_system_score_gemma":0.0003747783,"threshold_uncertainty_score":0.9997581},"labels":[],"label_agreement":null},{"id":"W4409502374","doi":"10.1038/s41467-025-57238-2","title":"Elevated mitochondrial membrane potential is a therapeutic vulnerability in Dnmt3a-mutant clonal hematopoiesis","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; Occupational Cancer Research Centre; Princess Margaret Cancer Centre; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute on Aging; Edward P. Evans Foundation; Leukemia and Lymphoma Society; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; National Science Foundation","keywords":"Haematopoiesis; Progenitor cell; Cell biology; Oxidative phosphorylation; Biology; Mitochondrion; Mitochondrial DNA; Gene knockdown; Stem cell; Mutant; Inner mitochondrial membrane; Apoptosis; Biochemistry; Gene","score_opus":0.02149689628132493,"score_gpt":0.35486890276181937,"score_spread":0.3333720064804944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409502374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72540855,0.01432585,0.00061240414,0.23923774,0.00075452833,0.0032284625,0.00016041791,0.0003535888,0.01591845],"genre_scores_gemma":[0.9898233,0.00062117213,0.003939995,0.004038622,0.00007582039,0.00016011776,0.00018069727,0.00002312638,0.0011371401],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99789923,0.00040002135,0.00050404645,0.00038739256,0.0004271465,0.00038213975],"domain_scores_gemma":[0.99589455,0.0005836829,0.00007697673,0.0029284505,0.00040566176,0.00011070527],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0004899143,0.00021140886,0.00043170853,0.0004225735,0.0002808295,0.000043125456,0.0011253915,0.00060580444,0.0003224152],"category_scores_gemma":[0.0006574582,0.00018797418,0.0001797032,0.0015523743,0.00033893314,0.00009565368,0.00051927596,0.0031377042,0.00003819439],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032393192,0.003769687,0.019123841,0.0004271757,0.0012757641,0.000089103996,0.0018972827,0.000026997594,0.871878,0.040240668,0.05046763,0.0075645065],"study_design_scores_gemma":[0.036777712,0.00047815917,0.21375339,0.00123544,0.0012866838,0.0004101198,0.0020162493,0.039182145,0.29308665,0.015927885,0.39422154,0.0016239986],"about_ca_topic_score_codex":0.00018968839,"about_ca_topic_score_gemma":0.00037529724,"teacher_disagreement_score":0.5787914,"about_ca_system_score_codex":0.0006569325,"about_ca_system_score_gemma":0.00093995006,"threshold_uncertainty_score":0.9991621},"labels":[],"label_agreement":null},{"id":"W4409624586","doi":"10.1158/1538-7445.am2025-594","title":"Abstract 594: Lintuzumab-Ac225 has potent mutation agnostic antileukemic activity in preclinical models of AML","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Cancer research; Medicine; Mutation; Computational biology; Biology; Genetics; Gene","score_opus":0.17667081887451228,"score_gpt":0.47767883802279343,"score_spread":0.3010080191482811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409624586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863294,0.0012651144,0.0003569871,0.0044460553,0.00012412647,0.0014141155,0.000037562026,0.000038724585,0.005987939],"genre_scores_gemma":[0.9962785,0.00146147,0.0001625667,0.00009709539,0.00011570992,0.00031172638,0.00002235295,0.00003438198,0.0015161684],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9963963,0.0003318625,0.00060026505,0.0006512768,0.001204767,0.0008155153],"domain_scores_gemma":[0.99648297,0.001685212,0.000092096525,0.00070609513,0.00080502656,0.00022862655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024743094,0.00018892283,0.00057833263,0.0009835467,0.00012318682,0.00004715093,0.00040427898,0.00031056395,0.00024122819],"category_scores_gemma":[0.0021262506,0.00017395407,0.00013741612,0.0015069864,0.0006912926,0.0002193814,0.00029227644,0.0021002654,0.0000495824],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015433566,0.0025683,0.029054113,0.005554892,0.00062949775,0.0014358766,0.0019187535,0.018396357,0.5808436,0.0016126065,0.026390176,0.31616223],"study_design_scores_gemma":[0.015020518,0.0014157312,0.54283154,0.005765815,0.00012321283,0.00003774588,0.000739419,0.09146666,0.3313178,0.008194929,0.0025086582,0.00057793333],"about_ca_topic_score_codex":0.0059948945,"about_ca_topic_score_gemma":0.00049704587,"teacher_disagreement_score":0.51377743,"about_ca_system_score_codex":0.0028480666,"about_ca_system_score_gemma":0.0065418137,"threshold_uncertainty_score":0.9990902},"labels":[],"label_agreement":null},{"id":"W4409628907","doi":"10.1158/1538-7445.am2025-5407","title":"Abstract 5407: Identifying synthetic lethality targets in DDX41-mutated MDS/AML","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Synthetic lethality; Lethality; Medicine; Cancer research; Biology; Genetics; DNA repair; Gene","score_opus":0.1045919042727418,"score_gpt":0.47149523414887945,"score_spread":0.36690332987613766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409628907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9566854,0.0045984522,0.0000869163,0.010435656,0.0002789454,0.0013711703,0.000028138706,0.000101914615,0.026413398],"genre_scores_gemma":[0.98792565,0.001185816,0.00011579184,0.00029259053,0.0001659548,0.0004448063,0.000027755212,0.00004817056,0.009793493],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9955186,0.00040739306,0.0005275294,0.0007954014,0.0013803444,0.0013707008],"domain_scores_gemma":[0.9973865,0.0006997648,0.000048065293,0.00086658105,0.0006785192,0.00032053737],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0040555843,0.00022243847,0.00050090236,0.0012875543,0.00023922224,0.00011313564,0.0005623036,0.0002546595,0.0017952353],"category_scores_gemma":[0.0017326322,0.00020502278,0.00011861995,0.002446104,0.0005029844,0.0001709594,0.0004321723,0.002525131,0.0004108954],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002802075,0.00079371996,0.059031248,0.004389771,0.00046848424,0.0033543769,0.0018498608,0.0001261045,0.77067584,0.0016317609,0.082853064,0.07202371],"study_design_scores_gemma":[0.00826043,0.00023177579,0.50662464,0.004397023,0.00006793326,0.000050350765,0.0020735683,0.0011702223,0.42086154,0.0045388686,0.051066823,0.0006567926],"about_ca_topic_score_codex":0.0076355995,"about_ca_topic_score_gemma":0.0007685761,"teacher_disagreement_score":0.44759342,"about_ca_system_score_codex":0.00326898,"about_ca_system_score_gemma":0.0029670103,"threshold_uncertainty_score":0.99977607},"labels":[],"label_agreement":null},{"id":"W4409690136","doi":"10.1158/1538-7445.am2025-67","title":"Abstract 67: Deciphering the mechanisms underlying the pathophysiology and chemotherapy resistance in acute myeloid leukemia using intravital imaging and humanized NSGW41IL7 mouse","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Myeloid leukemia; Pathophysiology; Medicine; Chemotherapy; Intravital microscopy; Cancer research; Pathology; Immunology; Internal medicine","score_opus":0.05095276051385272,"score_gpt":0.3950931339809373,"score_spread":0.3441403734670846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409690136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854029,0.0048947334,0.00044523564,0.0075983037,0.000070373455,0.0010732537,0.0000082231945,0.000033676948,0.00047332904],"genre_scores_gemma":[0.99199444,0.004962406,0.0007566749,0.0011015708,0.00007069201,0.00018759903,0.000003700349,0.00005401661,0.0008688778],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973885,0.00024820722,0.00033961568,0.0006121673,0.0005351851,0.000876347],"domain_scores_gemma":[0.9983304,0.00067384343,0.00006107824,0.0005875612,0.0002246128,0.00012250853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00197268,0.00023320602,0.00037638634,0.0003032483,0.00077797857,0.00018959702,0.0004164574,0.00012823574,0.00004294529],"category_scores_gemma":[0.0001865733,0.0001513753,0.000051600677,0.00081113074,0.00087402377,0.00015881265,0.0004182763,0.0016536522,0.0000023764644],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001050773,0.000020474137,0.0014045198,0.00019913359,0.00013171653,0.00012739596,0.0015357408,0.000019370325,0.97348046,0.0018849795,0.00047738268,0.019668067],"study_design_scores_gemma":[0.02804799,0.00041497618,0.66736335,0.004255177,0.00030296427,0.00021191296,0.02710835,0.025574015,0.1630542,0.076255694,0.0057792906,0.0016320769],"about_ca_topic_score_codex":0.0013445816,"about_ca_topic_score_gemma":0.00064981566,"teacher_disagreement_score":0.81042624,"about_ca_system_score_codex":0.0017388337,"about_ca_system_score_gemma":0.0012084326,"threshold_uncertainty_score":0.71843874},"labels":[],"label_agreement":null},{"id":"W4409701890","doi":"10.3390/cancers17091405","title":"Proposed Refinement of 2022 European LeukemiaNet Adverse-Risk Group of AML Patients Using a Real-World Cohort","year":2025,"lang":"en","type":"article","venue":"Cancers","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Myeloid leukemia; Retrospective cohort study; Oncology","score_opus":0.01574284428963551,"score_gpt":0.29733806460993134,"score_spread":0.2815952203202958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409701890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94729316,0.0001065516,0.00006554368,0.000048833244,0.00019951233,0.00094379054,0.00007833718,0.000028870903,0.05123541],"genre_scores_gemma":[0.995053,0.0004215595,0.0011128621,0.000163705,0.0000586757,0.000014173044,0.00010635484,0.000034634926,0.0030350487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815845,0.00016438247,0.0005236681,0.000334698,0.000506188,0.00031260835],"domain_scores_gemma":[0.9987461,0.000049956863,0.00028553765,0.00053262385,0.00026926424,0.000116540265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005269337,0.00016206059,0.00043143568,0.0003566234,0.000059760994,0.0000033613692,0.00019776814,0.000040207276,0.00020253296],"category_scores_gemma":[0.00015032873,0.00014715486,0.000105477644,0.0008153554,0.00022119356,0.000045902776,0.00015075221,0.0003134888,0.000006163361],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014269754,0.00011773715,0.9387364,0.00094472634,0.00065819407,0.00005813322,0.00032992056,0.0008922857,0.023693053,0.0002402031,0.022693718,0.010208664],"study_design_scores_gemma":[0.010636396,0.0008555159,0.94222236,0.0012869466,0.0006973639,0.0000021069043,0.00054722175,0.0049097203,0.017732438,0.00002257538,0.020785917,0.0003014269],"about_ca_topic_score_codex":0.009511943,"about_ca_topic_score_gemma":0.00038907438,"teacher_disagreement_score":0.04820036,"about_ca_system_score_codex":0.0058288104,"about_ca_system_score_gemma":0.0019088725,"threshold_uncertainty_score":0.9979876},"labels":[],"label_agreement":null},{"id":"W4409729565","doi":"10.1007/s10198-025-01779-2","title":"Burden of myelodysplastic syndromes: a systematic literature review of economic burden","year":2025,"lang":"en","type":"article","venue":"The European Journal of Health Economics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Myelodysplastic syndromes; Systematic review; Medicine; Intensive care medicine; MEDLINE; Political science; Internal medicine","score_opus":0.024179430751319675,"score_gpt":0.31409273402664967,"score_spread":0.28991330327533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409729565","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23778318,0.6951528,0.0005296117,0.046778083,0.0012476719,0.0031360758,0.000079655285,0.00002450561,0.015268379],"genre_scores_gemma":[0.5412359,0.45352668,0.0009930523,0.0020663321,0.0006105119,0.0000059653603,0.000011419544,0.00008124648,0.0014688643],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9950989,0.0014679506,0.0028334616,0.00016534753,0.000140916,0.0002934255],"domain_scores_gemma":[0.99603254,0.0005721168,0.0022893168,0.0006583288,0.00028307465,0.00016459939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008747051,0.00019391606,0.0016341301,0.00038318534,0.00006416881,0.000021047736,0.0006738511,0.000035877256,0.00004299856],"category_scores_gemma":[0.0006255514,0.00012649734,0.00031297837,0.00021341749,0.00013812687,0.000100685356,0.00013895048,0.0006006347,0.000047435795],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047975278,0.00008134133,0.00009253898,0.9637628,0.0015642166,0.00021893479,0.0028870893,0.0013495882,0.00013352108,0.0021695197,0.01863029,0.008630408],"study_design_scores_gemma":[0.0045830063,0.0020370125,0.0010970326,0.97078043,0.00092814205,0.0053599607,0.0014574439,0.002227686,0.00010302075,0.00033649764,0.010825118,0.00026464617],"about_ca_topic_score_codex":0.000014688677,"about_ca_topic_score_gemma":9.052216e-7,"teacher_disagreement_score":0.30345276,"about_ca_system_score_codex":0.00061565184,"about_ca_system_score_gemma":0.0018972559,"threshold_uncertainty_score":0.5158412},"labels":[],"label_agreement":null},{"id":"W4409731654","doi":"10.1002/pbc.31714","title":"Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia","year":2025,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation; Centre Hospitalier Universitaire Sainte-Justine","funders":"Genentech","keywords":"Venetoclax; Medicine; Azacitidine; Cytarabine; Decitabine; Neutropenia; Internal medicine; Chemotherapy; Febrile neutropenia; Oncology; Refractory (planetary science); Chemotherapy regimen; Hypomethylating agent; Myeloid; Gastroenterology; Pediatrics; Leukemia","score_opus":0.0056515175958460565,"score_gpt":0.25570187772274633,"score_spread":0.2500503601269003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409731654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938116,0.0030342988,0.000026341017,0.0010445402,0.00011604449,0.0016231583,0.000026502934,0.00005826952,0.0002592126],"genre_scores_gemma":[0.9811285,0.015569381,0.00046729887,0.0012294621,0.00026189382,0.0003409851,0.000065247856,0.00007006149,0.0008671288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747497,0.00009635995,0.0004860418,0.0006647929,0.00065738143,0.00062044966],"domain_scores_gemma":[0.9987857,0.00013628868,0.0001907242,0.0003648182,0.0003435444,0.0001789368],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024969847,0.00035575338,0.0005978016,0.00097253826,0.00007008196,0.000033914912,0.00018013356,0.00024302796,0.000050792998],"category_scores_gemma":[0.00009465506,0.00026098444,0.00003919567,0.002580132,0.000097694756,0.00023326656,0.00007790636,0.0009459286,0.000005217007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005750238,0.00074720965,0.9846178,0.00060095027,0.0001414321,0.00014646645,0.0002998098,0.00002168951,0.00004975316,0.00001018953,0.0022285841,0.0053858627],"study_design_scores_gemma":[0.04649735,0.001149056,0.95033854,0.00036745533,0.0005509779,0.000014018431,0.00006843433,0.00020739628,0.00019998448,0.000015143343,0.00027648718,0.00031514367],"about_ca_topic_score_codex":0.0009799805,"about_ca_topic_score_gemma":0.0013678212,"teacher_disagreement_score":0.04074711,"about_ca_system_score_codex":0.0013461369,"about_ca_system_score_gemma":0.0022502167,"threshold_uncertainty_score":0.99998426},"labels":[],"label_agreement":null},{"id":"W4409831583","doi":"10.14740/jh1362","title":"Venetoclax-Azacitidine Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Single-Center Experience","year":2025,"lang":"en","type":"letter","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Venetoclax; Azacitidine; Medicine; Myeloid leukemia; Myelodysplastic syndromes; Refractory (planetary science); Salvage therapy; Oncology; Chemotherapy; Internal medicine; Leukemia; Bone marrow","score_opus":0.016759301476178164,"score_gpt":0.2871319663398511,"score_spread":0.27037266486367295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409831583","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7419166,0.003332404,0.0001622445,0.2514249,0.0012532998,0.0009087589,0.00003925677,0.000045890403,0.0009166365],"genre_scores_gemma":[0.40788966,0.007119118,0.0042357636,0.5680076,0.002839789,0.00015846806,0.0001928222,0.00043626069,0.009120498],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99536717,0.0003201821,0.0017109398,0.0006862679,0.0008763602,0.0010390811],"domain_scores_gemma":[0.99677116,0.0009547709,0.0009857815,0.0006451132,0.00036950276,0.00027367205],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00048657425,0.0006848177,0.0025754303,0.0018329149,0.000078400386,0.000054029053,0.00061499834,0.0017694995,0.00034768588],"category_scores_gemma":[0.0005143783,0.0005848419,0.00034873083,0.0005882459,0.0005656377,0.0001839736,0.00022896992,0.0064828782,0.000026002359],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023800984,0.00026502393,0.005665072,0.0018584987,0.0012306996,0.15020047,0.00088157016,0.0000039021693,0.0062588053,0.000030935935,0.82972604,0.0014988874],"study_design_scores_gemma":[0.021839052,0.004414894,0.0036521403,0.0068202717,0.00063451106,0.32821152,0.00026722712,0.00020819058,0.0028060398,0.0002732837,0.62987614,0.0009967024],"about_ca_topic_score_codex":0.000020760017,"about_ca_topic_score_gemma":0.000006218603,"teacher_disagreement_score":0.33402693,"about_ca_system_score_codex":0.0035398838,"about_ca_system_score_gemma":0.002779267,"threshold_uncertainty_score":0.9996603},"labels":[],"label_agreement":null},{"id":"W4409872473","doi":"10.1158/2643-3230.bcd-24-0342","title":"Single-cell Transcriptional Atlas of Human Hematopoiesis Reveals Genetic and Hierarchy-Based Determinants of Aberrant AML Differentiation","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; National Institutes of Health; Canada Research Chairs; Canada First Research Excellence Fund; Terry Fox Foundation; International Development Research Centre; National Cancer Institute; University of Toronto; Canadian Cancer Society; Government of Ontario; Princess Margaret Cancer Foundation; St. Jude Children's Research Hospital; American Lebanese Syrian Associated Charities; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"Atlas (anatomy); Haematopoiesis; Biology; Hierarchy; Genetics; Computational biology; Evolutionary biology; Stem cell; Political science","score_opus":0.02081339611851763,"score_gpt":0.29090548888233614,"score_spread":0.2700920927638185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409872473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99581957,0.0026769058,0.0003245041,0.00025167948,0.00006300219,0.0004319092,0.00013263948,0.000012074433,0.00028772076],"genre_scores_gemma":[0.99751407,0.00022007791,0.00039694353,0.000115779476,0.00004490485,0.0000663661,0.000031951502,0.00001999738,0.001589921],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99854916,0.00006556445,0.00048651753,0.00029271035,0.00037349653,0.00023252692],"domain_scores_gemma":[0.99926907,0.00009304825,0.00016069735,0.00028736982,0.00012098818,0.00006883287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000111829155,0.00016252512,0.0004921213,0.0002510083,0.000056954403,0.00001802741,0.00011407025,0.00009574847,0.00006597596],"category_scores_gemma":[0.000026230455,0.0001434657,0.000127732,0.00024106108,0.00020342183,0.00009777752,0.000039225273,0.00013262409,5.135764e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002850948,0.0005423703,0.18595263,0.0025267527,0.00012544995,0.00001018122,0.0001711521,0.000009397354,0.8091353,0.00008101674,0.00025002615,0.0009106052],"study_design_scores_gemma":[0.0040653255,0.0003200916,0.36514536,0.0009149819,0.000473853,0.0000046268606,0.00004772086,0.00017667949,0.6284657,0.0002431918,0.000037371316,0.00010508188],"about_ca_topic_score_codex":0.00039807954,"about_ca_topic_score_gemma":0.00015917847,"teacher_disagreement_score":0.1806696,"about_ca_system_score_codex":0.00011196553,"about_ca_system_score_gemma":0.0004535766,"threshold_uncertainty_score":0.58503616},"labels":[],"label_agreement":null},{"id":"W4409884025","doi":"10.21873/anticanres.17582","title":"<i>HOX-PBX</i>Up-regulation Predicts Favorable Prognosis in NPM1-mutated Normal Cytogenetic AML<i>via</i>WNT Signaling","year":2025,"lang":"en","type":"article","venue":"Anticancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Provincial Laboratory of Public Health; Calgary Laboratory Services; University of Alberta","funders":"","keywords":"Wnt signaling pathway; Hox gene; NPM1; Cancer research; Biology; Signal transduction; Mutation; Cytogenetics; Karyotype; Internal medicine; Genetics; Medicine; Gene; Gene expression; Chromosome","score_opus":0.05309432819143826,"score_gpt":0.38857426794989863,"score_spread":0.33547993975846035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409884025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803925,0.0014349084,0.00086528837,0.005252731,0.00018679941,0.0027325337,0.000014797316,0.00014604758,0.0089743845],"genre_scores_gemma":[0.99051654,0.0005151532,0.00063875766,0.000335687,0.00022762801,0.0005114012,0.00008375466,0.00006789351,0.0071031647],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.994007,0.0005987482,0.0007264648,0.0009201113,0.0020165592,0.0017311317],"domain_scores_gemma":[0.9971873,0.0006019297,0.00006823319,0.0006661558,0.0011018493,0.0003745315],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003052459,0.0003061844,0.00059756136,0.0015029528,0.00034559675,0.00014117763,0.00051968044,0.00029458292,0.0005348522],"category_scores_gemma":[0.0007768358,0.0002875154,0.00013011404,0.0044318778,0.00059329014,0.00026598558,0.0004489842,0.0016320568,0.0002519673],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039157467,0.0009822923,0.45090178,0.0017726221,0.0004729967,0.0005976068,0.001230942,0.0012773898,0.4790342,0.00090979424,0.017042343,0.04186231],"study_design_scores_gemma":[0.010276153,0.0012914255,0.17698978,0.0023628313,0.00015163334,0.00007544114,0.00075314444,0.051356293,0.7475037,0.0018464734,0.00678565,0.00060748495],"about_ca_topic_score_codex":0.002399242,"about_ca_topic_score_gemma":0.00026692916,"teacher_disagreement_score":0.27391198,"about_ca_system_score_codex":0.0014858205,"about_ca_system_score_gemma":0.002853258,"threshold_uncertainty_score":0.9999577},"labels":[],"label_agreement":null},{"id":"W4410029978","doi":"10.1182/bloodadvances.2025016114","title":"Finding the right fit: assessment of fitness in AML","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; University of British Columbia","funders":"","keywords":"Medicine; Biology","score_opus":0.018913909890270638,"score_gpt":0.3748222995840976,"score_spread":0.35590838969382693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410029978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93797344,0.0035561752,0.0003160861,0.0051090373,0.00017304198,0.0005758021,0.000009582684,0.000027678732,0.052259166],"genre_scores_gemma":[0.9942417,0.00045641276,0.0017594228,0.00022418574,0.000049369148,0.00004970671,0.0000048793936,0.000006934274,0.0032073455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990654,0.000056979134,0.00023443131,0.00017770007,0.00024953473,0.00021593369],"domain_scores_gemma":[0.9992227,0.00034292025,0.00005711729,0.00028686674,0.000059780657,0.000030641448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034194213,0.00008788997,0.00024025465,0.00015515367,0.000056640696,0.000009010626,0.0001982306,0.000043351323,0.00010467137],"category_scores_gemma":[0.00016035028,0.0000537082,0.000048537357,0.00053531,0.000118462536,0.000084519306,0.000089235684,0.0002743227,0.0000033172391],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020195302,0.0010816357,0.8910046,0.0012997466,0.00034444613,0.00030258487,0.0005437912,0.00055407925,0.02029297,0.030548451,0.002656263,0.051169455],"study_design_scores_gemma":[0.007569427,0.0003454105,0.79228836,0.0013854486,0.00022726966,0.000037805286,0.0011202717,0.0021897827,0.09182395,0.003409578,0.09936409,0.00023863874],"about_ca_topic_score_codex":0.000034615496,"about_ca_topic_score_gemma":0.00007231796,"teacher_disagreement_score":0.09871629,"about_ca_system_score_codex":0.000084655105,"about_ca_system_score_gemma":0.00031660197,"threshold_uncertainty_score":0.21901569},"labels":[],"label_agreement":null},{"id":"W4410140459","doi":"10.1182/bloodadvances.2025016229","title":"Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"Genentech; Swedish Orphan Biovitrum; Servier; Astellas Pharma; Incyte; bluebird bio; Agios Pharmaceuticals; Astex Pharmaceuticals; Celgene; Gilead Sciences; Syndax Pharmaceuticals; BeiGene; Daiichi Sankyo Europe; Sanofi; Pfizer; Amgen","keywords":"Azacitidine; Placebo; Medicine; Internal medicine; Oncology; Clinical endpoint; Gastroenterology; Randomized controlled trial; Biology; Pathology","score_opus":0.01056674117436585,"score_gpt":0.3171685288221179,"score_spread":0.30660178764775203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410140459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935336,0.0020178368,0.000047398273,0.0003500119,0.000060599432,0.0013795728,0.000092346585,0.000045337183,0.0024732677],"genre_scores_gemma":[0.9962615,0.00066105503,0.0014499697,0.000046047422,0.00007440606,0.00010699852,0.000031698153,0.000025464251,0.0013428712],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99760395,0.00017581136,0.00072582165,0.0004996983,0.0005921891,0.00040252478],"domain_scores_gemma":[0.998213,0.000524895,0.00028311717,0.00055459514,0.000312018,0.00011238517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044580616,0.00024753565,0.00078538875,0.00046229915,0.00005044571,0.000008028952,0.0002487806,0.000086231375,0.000024669365],"category_scores_gemma":[0.000593377,0.0001875575,0.00006136217,0.0016099724,0.0001972298,0.00016959534,0.00009367938,0.00045041478,0.0000022756021],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041252024,0.04042283,0.71149445,0.0015792112,0.0019859395,0.0024122146,0.003952515,0.0013721664,0.110582046,0.0002220216,0.00167726,0.08304731],"study_design_scores_gemma":[0.2892015,0.035857517,0.31031322,0.0017988615,0.001188935,0.00004008802,0.0049286196,0.00033668254,0.35001004,0.00020554817,0.0055231694,0.0005957938],"about_ca_topic_score_codex":0.0013033323,"about_ca_topic_score_gemma":0.00091246224,"teacher_disagreement_score":0.40118122,"about_ca_system_score_codex":0.00008656262,"about_ca_system_score_gemma":0.0004387225,"threshold_uncertainty_score":0.76483727},"labels":[],"label_agreement":null},{"id":"W4410143391","doi":"10.1111/ejh.14430","title":"Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms","year":2025,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Hematopoietic stem cell transplantation; Gastroenterology; Transplantation; Incidence (geometry); Cyclophosphamide; Myelodysplastic syndromes; Busulfan; Graft-versus-host disease; Anti-thymocyte globulin; Oncology; Chemotherapy; Bone marrow","score_opus":0.017156429193606337,"score_gpt":0.2918642025781279,"score_spread":0.27470777338452157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410143391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9496726,0.00050075434,0.04309834,0.0020190296,0.00039215607,0.00048182602,0.000020236035,0.000016590138,0.003798514],"genre_scores_gemma":[0.9929986,0.0001847639,0.005051842,0.00040742752,0.000053374883,0.000005688188,0.00000870612,0.000038075028,0.0012515225],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99762994,0.0004480207,0.001102397,0.00020896712,0.0002904673,0.0003202134],"domain_scores_gemma":[0.99772584,0.0008090991,0.00053330127,0.00023377097,0.0005568022,0.00014117107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091964955,0.00021284648,0.0010244263,0.00046826547,0.00006822048,0.000012161255,0.00027841644,0.00007374669,0.00004259016],"category_scores_gemma":[0.00016117633,0.00016107301,0.00028533462,0.00021211868,0.00017489777,0.00008158399,0.000042806452,0.00037065527,0.00003106237],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049018968,0.003509561,0.53460205,0.02576885,0.009650665,0.05769385,0.026178515,0.0016522642,0.17880037,0.038038827,0.044311337,0.03077473],"study_design_scores_gemma":[0.05640722,0.010230156,0.28053936,0.0028849368,0.004383303,0.05138278,0.006910749,0.0009794611,0.57355005,0.0014371853,0.010209501,0.0010852946],"about_ca_topic_score_codex":0.0000010425143,"about_ca_topic_score_gemma":0.0000014413306,"teacher_disagreement_score":0.39474967,"about_ca_system_score_codex":0.0000840712,"about_ca_system_score_gemma":0.0004953591,"threshold_uncertainty_score":0.6568366},"labels":[],"label_agreement":null},{"id":"W4410158978","doi":"10.1182/blood.2025028357","title":"Menin inhibition with revumenib for <i>NPM1</i>-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Swedish Orphan Biovitrum; Daiichi Sankyo Europe; National Cancer Institute; Foghorn Therapeutics; Gilead Sciences; Servier; Astellas Pharma; Genentech; Y-mAbs Therapeutics; MacroGenics; Syndax Pharmaceuticals; Pfizer; Incyte; Agios Pharmaceuticals; American Society of Pediatric Hematology/Oncology; Astex Pharmaceuticals; Jazz Pharmaceuticals; Alexion Pharmaceuticals; Kite Pharma; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Discontinuation; Myeloid leukemia; Tolerability; Population; Adverse effect; Refractory (planetary science); Phases of clinical research; Oncology; Gastroenterology; Clinical trial","score_opus":0.017444601370284602,"score_gpt":0.300949740871285,"score_spread":0.2835051395010004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410158978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98557913,0.00032890297,0.00042903368,0.003886882,0.00014453827,0.0056873565,0.000056317807,0.00025213987,0.0036357136],"genre_scores_gemma":[0.9640224,0.00019699612,0.0017992746,0.0015132078,0.00028059667,0.0015800399,0.00020031615,0.000097234464,0.030309912],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997272,0.00020941679,0.0005383121,0.0006810669,0.0006544634,0.00064472755],"domain_scores_gemma":[0.9978902,0.00045965673,0.00017279487,0.00093504053,0.0003682282,0.00017407804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000902392,0.00036441055,0.00056383363,0.00027072494,0.00039611722,0.000074828735,0.00028803482,0.00020859716,0.00009770668],"category_scores_gemma":[0.00028888715,0.00020774931,0.00015332749,0.0009990117,0.00017696647,0.00017037542,0.00016847365,0.0008145853,0.00004014464],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.068162106,0.015605262,0.015069944,0.0016916399,0.022017622,0.00573178,0.0085305115,0.000041949836,0.5129881,0.0008459885,0.32869118,0.020623941],"study_design_scores_gemma":[0.30897194,0.040621404,0.019927373,0.0027931398,0.021631127,0.001316702,0.015641026,0.00076057564,0.44746554,0.0005450999,0.13827518,0.002050909],"about_ca_topic_score_codex":0.000116086914,"about_ca_topic_score_gemma":0.00012234645,"teacher_disagreement_score":0.24080984,"about_ca_system_score_codex":0.0008754378,"about_ca_system_score_gemma":0.0019188055,"threshold_uncertainty_score":0.84717715},"labels":[],"label_agreement":null},{"id":"W4410174850","doi":"10.1038/s41375-025-02635-1","title":"Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants","year":2025,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Leukemia & Lymphoma Society of Canada; University of British Columbia","funders":"Terry Fox Foundation; National Cancer Institute; Government of Canada; V Foundation for Cancer Research; Cancer Research Foundation; Northwestern University; Canadian Institutes of Health Research; Veski; Leukemia and Lymphoma Society; Leukemia and Lymphoma Society of Canada","keywords":"CHEK2; Myeloid leukemia; Germline; Myeloid; Leukemia; Biology; Allele; Loss of heterozygosity; Cancer research; Internal medicine; Germline mutation; Immunology; Genetics; Medicine; Gene; Mutation","score_opus":0.008917620548598631,"score_gpt":0.28365386292353134,"score_spread":0.2747362423749327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410174850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740343,0.00045431996,0.006803414,0.006546908,0.0002215439,0.0009439962,0.00005402544,0.00022858237,0.010712893],"genre_scores_gemma":[0.9646539,0.00006217494,0.0024614164,0.006749655,0.00016636262,0.00016161431,0.00014007444,0.000042814314,0.025561962],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981224,0.000052175797,0.00037752112,0.00048326195,0.00039585185,0.0005687811],"domain_scores_gemma":[0.99881756,0.000080534424,0.000048944094,0.00060572335,0.00017130356,0.00027593228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025830843,0.00023778537,0.00040775043,0.00024555463,0.00012210103,0.00005505945,0.00024732668,0.00020626347,0.0002270725],"category_scores_gemma":[0.00022280515,0.0002181766,0.00010122127,0.0006887537,0.00007973585,0.0000937826,0.00018841082,0.0003627212,0.0004109918],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005976496,0.00012288081,0.0023794067,0.00049769186,0.00016131668,0.00030814245,0.0005007939,0.000018479053,0.601734,0.0009371932,0.38399708,0.008745354],"study_design_scores_gemma":[0.012799717,0.0018544475,0.11377129,0.003115141,0.00068678835,0.0010943934,0.0006094911,0.0072591202,0.6469529,0.0018259748,0.20848024,0.0015504478],"about_ca_topic_score_codex":0.00018068853,"about_ca_topic_score_gemma":0.00000910233,"teacher_disagreement_score":0.17551684,"about_ca_system_score_codex":0.0018547227,"about_ca_system_score_gemma":0.0008686437,"threshold_uncertainty_score":0.8896983},"labels":[],"label_agreement":null},{"id":"W4410267430","doi":"10.1016/j.bneo.2025.100115","title":"Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Menarini Group","keywords":"Chronic myelomonocytic leukemia; Medicine; Interleukin-3 receptor; Leukemia; Oncology; Phase (matter); Internal medicine; Cancer research; Chemistry; Myelodysplastic syndromes; Bone marrow","score_opus":0.03274721435044482,"score_gpt":0.349430216785658,"score_spread":0.3166830024352132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410267430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98887426,0.0020288117,0.00028030825,0.00096079195,0.00016946359,0.004900591,0.00015798419,0.00013990598,0.0024878918],"genre_scores_gemma":[0.991277,0.00023136768,0.0010509219,0.00023589078,0.00024651163,0.0005765607,0.00013088425,0.00005628433,0.006194596],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99700797,0.00014269516,0.00086551777,0.0007459664,0.000514521,0.0007233212],"domain_scores_gemma":[0.9976082,0.00059556746,0.00021742645,0.0009935068,0.00038281735,0.00020249562],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007733282,0.0003773975,0.0008739981,0.0005618755,0.00015670044,0.000031805946,0.00040750738,0.00023870383,0.000061445615],"category_scores_gemma":[0.000739808,0.0003210527,0.00028267506,0.0010768162,0.00016993767,0.0000893691,0.00014079246,0.0005575701,0.000022125987],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12029855,0.032153573,0.01448437,0.0031043822,0.010950947,0.0017857129,0.0068278196,0.0001370239,0.3939376,0.0009938093,0.11665937,0.29866686],"study_design_scores_gemma":[0.5324147,0.050155357,0.02564228,0.00090238266,0.0026947826,0.0002814342,0.0023085964,0.008434562,0.332676,0.000431272,0.04311297,0.00094569195],"about_ca_topic_score_codex":0.00029028815,"about_ca_topic_score_gemma":0.00012273542,"teacher_disagreement_score":0.4121161,"about_ca_system_score_codex":0.000840531,"about_ca_system_score_gemma":0.005006494,"threshold_uncertainty_score":0.9999242},"labels":[],"label_agreement":null},{"id":"W4410330493","doi":"10.1111/ejh.14434","title":"Genetic Landscape and Risk Stratification of <scp>AML</scp> With Hyperdiploid Karyotype","year":2025,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"University Health Network","keywords":"Internal medicine; Myeloid leukemia; Karyotype; Oncology; Medicine; Confounding; Cohort; Cytogenetics; Risk stratification; Chromosome; Genetics; Gene; Biology","score_opus":0.010755976729565048,"score_gpt":0.25751127013321506,"score_spread":0.24675529340365002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410330493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98139834,0.0024495975,0.0022433123,0.0004866932,0.00006370949,0.00013262329,0.0000026670807,0.000009638606,0.013213388],"genre_scores_gemma":[0.9926551,0.0009843814,0.0057316343,0.00008503064,0.00006291004,6.797329e-7,0.0000019868237,0.000021210775,0.00045707502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851483,0.0004664272,0.0005024184,0.00014661436,0.00019180025,0.00017793544],"domain_scores_gemma":[0.99864054,0.00027613202,0.00038974677,0.00023967534,0.0003390604,0.00011486461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006611643,0.00011248313,0.00046002743,0.00031397323,0.000047738646,0.000011857975,0.00015876701,0.000039047212,0.000019118479],"category_scores_gemma":[0.00051232975,0.00007796865,0.000051143674,0.00023700288,0.00019876157,0.000047357997,0.000052698466,0.00042721882,0.000017126453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078930333,0.0002678428,0.93250906,0.0005850792,0.0011217839,0.008335607,0.0011003065,0.00008753017,0.01917244,0.00119164,0.019805146,0.015034239],"study_design_scores_gemma":[0.0052754697,0.0023843483,0.9550065,0.00038508856,0.0006259727,0.02126735,0.0010417491,0.00033550835,0.007260737,0.00021129606,0.0061391327,0.000066853216],"about_ca_topic_score_codex":0.0000033498056,"about_ca_topic_score_gemma":0.0000029703021,"teacher_disagreement_score":0.022497412,"about_ca_system_score_codex":0.000021005244,"about_ca_system_score_gemma":0.0002709117,"threshold_uncertainty_score":0.31794694},"labels":[],"label_agreement":null},{"id":"W4410348902","doi":"10.1038/s41525-025-00476-6","title":"Myelodysplastic syndrome diagnosed by genetic testing for hereditary cancer: a case report","year":2025,"lang":"en","type":"article","venue":"npj Genomic Medicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Ontario Institute for Cancer Research; University Health Network; University of Toronto; Sinai Health System; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Genetic testing; Medicine; Myelodysplastic syndromes; Cancer; Genetics; Oncology; Pediatrics; Internal medicine; Biology","score_opus":0.02786309364257899,"score_gpt":0.3280978876547437,"score_spread":0.3002347940121647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410348902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751525,0.007981721,0.0035225516,0.00763359,0.0010469729,0.0022998613,0.00009821926,0.00016868861,0.0020958912],"genre_scores_gemma":[0.9764336,0.0002083528,0.005374379,0.0024579894,0.0011681834,0.0009329843,0.00021789802,0.00009977572,0.013106837],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99700284,0.00006321676,0.0009263339,0.0008144473,0.00041324442,0.00077989994],"domain_scores_gemma":[0.99643344,0.0017498495,0.00020441995,0.00079229166,0.00037515652,0.0004448523],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007599054,0.0003697927,0.00089735136,0.00038348345,0.00023825889,0.000014036796,0.0002447781,0.00020901793,0.00041792545],"category_scores_gemma":[0.0039285226,0.0003079878,0.00009925239,0.0007027242,0.00032895396,0.000043858625,0.00013437952,0.0005116057,0.0000305792],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053267524,0.00016359195,0.018971514,0.001734214,0.000680639,0.4779459,0.0003265532,0.000099118406,0.05867395,0.00002181797,0.39964688,0.041203156],"study_design_scores_gemma":[0.033381004,0.0050779562,0.099575706,0.0045103985,0.0029574179,0.74231046,0.0015170717,0.021816224,0.0016214828,0.0006026554,0.085453816,0.0011757867],"about_ca_topic_score_codex":0.002496108,"about_ca_topic_score_gemma":0.00009535527,"teacher_disagreement_score":0.31419307,"about_ca_system_score_codex":0.0010659344,"about_ca_system_score_gemma":0.0015729417,"threshold_uncertainty_score":0.99993724},"labels":[],"label_agreement":null},{"id":"W4410357872","doi":"10.1097/mph.0000000000003028","title":"Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia: Results of the Randomized GATLA 8-LMA-P’07 Trial","year":2025,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Cytarabine; Idarubicin; Cumulative incidence; Mitoxantrone; cons; Internal medicine; Chemotherapy; Randomized controlled trial; Regimen; Incidence (geometry); Induction chemotherapy; Surgery; Transplantation","score_opus":0.02517153514643089,"score_gpt":0.3682742105643238,"score_spread":0.3431026754178929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410357872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98848325,0.0009042828,0.0024126284,0.002222316,0.0011089542,0.0032068507,0.00006229173,0.00001453621,0.0015849008],"genre_scores_gemma":[0.9942591,0.0006673221,0.0039136377,0.00012087149,0.0007240017,0.0000793635,0.00003247812,0.000026387497,0.00017680276],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941675,0.0010099311,0.0032927648,0.00031536756,0.00072824035,0.00048618243],"domain_scores_gemma":[0.9865338,0.0060713245,0.0043875254,0.00043843477,0.0024071813,0.00016171369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030791073,0.00030955294,0.00323705,0.0009955397,0.000118729644,0.000014973693,0.0005523136,0.0006735945,0.00002278369],"category_scores_gemma":[0.004357891,0.00018278493,0.00060328323,0.0011004327,0.000581183,0.0001821956,0.00014972528,0.0011050208,0.0000031789057],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90983295,0.0015026229,0.045575056,0.00076379336,0.0012973114,0.00005376308,0.0009034793,0.00010662043,0.00016828692,0.0021483572,0.036986474,0.0006613077],"study_design_scores_gemma":[0.9733066,0.00840908,0.004182422,0.000081278544,0.0075261933,0.0001810052,0.0012193377,0.0002730552,0.001845204,0.001282531,0.0014869377,0.00020638743],"about_ca_topic_score_codex":0.00002413004,"about_ca_topic_score_gemma":0.000013427051,"teacher_disagreement_score":0.06347364,"about_ca_system_score_codex":0.00075603166,"about_ca_system_score_gemma":0.013236455,"threshold_uncertainty_score":0.99235755},"labels":[],"label_agreement":null},{"id":"W4410431487","doi":"10.1073/pnas.2415779122","title":"Mutant <i>IDH1</i> cooperates with <i>NPM1c</i> or <i>FLT3</i> <sup>ITD</sup> to drive distinct myeloid diseases and molecular outcomes","year":2025,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; University Health Network","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Innovation and Technology Commission; Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology; Vallee Foundation; Canadian Institutes of Health Research; Leukemia and Lymphoma Society; Cancer Research Institute; National Institutes of Health; Pershing Square Sohn Cancer Research Alliance; National Institute of Mental Health; WorldQuant Foundation; Starr Cancer Consortium","keywords":"IDH1; Isocitrate dehydrogenase; NPM1; Myeloid leukemia; Mutant; Cancer research; IDH2; Mutation; Myeloid; Biology; Gene; Genetics; Enzyme; Biochemistry","score_opus":0.0190858789934894,"score_gpt":0.3147441394947954,"score_spread":0.295658260501306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410431487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96417814,0.00024378963,0.000010748971,0.029497158,0.000009584225,0.0007528019,0.00007131824,0.000029754641,0.0052067223],"genre_scores_gemma":[0.9921339,0.0000618968,0.0022487526,0.004602569,0.000037700484,0.000053840984,7.0157455e-7,0.000010984585,0.0008496302],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972033,0.00001243551,0.00039354712,0.0004918733,0.0015728264,0.0003260545],"domain_scores_gemma":[0.9985103,0.0003475024,0.00018223471,0.000026905172,0.00076251454,0.00017055303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006846994,0.00021483838,0.00043032685,0.00032050657,0.00027756524,0.00006632673,0.0007018648,0.0000871362,0.000019869989],"category_scores_gemma":[0.0015836512,0.00011053028,0.00007764528,0.0019393297,0.0015858804,0.0003207766,0.0003987817,0.00028766488,0.0000022781499],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014876076,0.00037964043,0.4511014,0.0009426393,0.000388707,0.000002076013,0.0007504379,0.0003537855,0.47294283,0.05930881,0.010943287,0.0013987805],"study_design_scores_gemma":[0.0035042588,0.0009557054,0.3320251,0.0015852831,0.00038352524,0.0001261908,0.001877142,0.0033295793,0.6407192,0.009075553,0.00591956,0.00049891416],"about_ca_topic_score_codex":0.000016745027,"about_ca_topic_score_gemma":2.77757e-7,"teacher_disagreement_score":0.16777635,"about_ca_system_score_codex":0.000116652365,"about_ca_system_score_gemma":0.0003946874,"threshold_uncertainty_score":0.58432424},"labels":[],"label_agreement":null},{"id":"W4410479686","doi":"10.1111/cas.70097","title":"Clonal Hematopoiesis and Solid Cancers","year":2025,"lang":"en","type":"review","venue":"Cancer Science","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Japan Agency for Medical Research and Development; Japan Society for the Promotion of Science; Leukemia and Lymphoma Society of Canada; Moonshot Research and Development Program; Leukemia and Lymphoma Society","keywords":"Haematopoiesis; Somatic evolution in cancer; Biology; Somatic cell; Carcinogenesis; Germline mutation; Cancer; Germline; Cancer research; Immunology; Stem cell; Mutation; Genetics; Gene","score_opus":0.05538512062537605,"score_gpt":0.4524089969687432,"score_spread":0.39702387634336717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410479686","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015684738,0.9922783,0.00002315373,0.00034449555,0.00041084748,0.000720445,0.000054371263,0.000040784445,0.0061119213],"genre_scores_gemma":[0.000012194138,0.9924099,0.000360698,0.000368002,0.00022683071,0.00032431405,0.000006500666,0.000019899631,0.006271684],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99750733,0.000032994532,0.00033195395,0.00082088733,0.00070007285,0.000606756],"domain_scores_gemma":[0.9985534,0.0001701583,0.0001250505,0.0005580356,0.00022174405,0.0003716441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055134366,0.00029495254,0.0013054217,0.0005380963,0.0002444876,0.00008375113,0.00060076435,0.00016058292,0.00017538715],"category_scores_gemma":[0.00035625222,0.00021809287,0.00015953607,0.0021701432,0.001464277,0.00013054472,0.0004468424,0.0005566605,0.00002642902],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000062268437,0.000005720479,0.000010820939,0.023518998,0.00004987143,0.000039730876,0.00004336347,3.1183728e-7,0.000007515116,0.0002589102,0.0070934733,0.96896505],"study_design_scores_gemma":[0.00019344909,0.000034733795,0.000017316052,0.023916382,0.0003437484,0.00012321318,0.000018103668,0.000040638788,0.00003908047,0.000019294415,0.975048,0.00020602421],"about_ca_topic_score_codex":0.0002762501,"about_ca_topic_score_gemma":0.00002857373,"teacher_disagreement_score":0.96875906,"about_ca_system_score_codex":0.0032396219,"about_ca_system_score_gemma":0.031425487,"threshold_uncertainty_score":0.9740654},"labels":[],"label_agreement":null},{"id":"W4410493962","doi":"10.1186/s12885-025-14311-9","title":"Venetoclax and hypomethylating agents versus induction chemotherapy for newly diagnosed acute myeloid leukemia patients: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"BMC Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Venetoclax; Myeloid leukemia; Induction chemotherapy; Surgical oncology; Meta-analysis; Hypomethylating agent; Oncology; Internal medicine; Chemotherapy; Leukemia","score_opus":0.11553671950535584,"score_gpt":0.41472084881144655,"score_spread":0.29918412930609073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410493962","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028937526,0.9863633,0.00016116006,0.00013689138,0.0001316627,0.012589382,0.00048302728,0.000044373868,0.00006127988],"genre_scores_gemma":[0.00000280745,0.98308665,0.0013373052,0.0006715672,0.00012466255,0.010605864,0.00047206428,0.00009402844,0.0036050696],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9962238,0.0004317639,0.0013290498,0.00098383,0.00055098574,0.00048056367],"domain_scores_gemma":[0.9962995,0.0012701189,0.00096636167,0.00083441543,0.00038634214,0.00024327463],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00090064044,0.0007264749,0.008936429,0.0007024111,0.00014724398,0.00007845249,0.00024713192,0.0004167827,0.00018698852],"category_scores_gemma":[0.0013382531,0.0005035077,0.0020231926,0.0017929388,0.00008556678,0.0001194968,0.00014722893,0.00052041846,0.000005312379],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007422945,0.00001571304,0.000007204353,0.80517364,0.15774035,0.0000035321732,0.000040631945,0.0000015685855,1.7385057e-7,0.0000032599507,0.0024526857,0.03448702],"study_design_scores_gemma":[0.002635036,0.0001589515,0.000017254237,0.0535457,0.8801359,0.000005732233,0.000014261839,0.000055676115,8.937299e-7,0.0000028525396,0.063044325,0.00038342897],"about_ca_topic_score_codex":0.00027199037,"about_ca_topic_score_gemma":0.00008518795,"teacher_disagreement_score":0.7516279,"about_ca_system_score_codex":0.0035469693,"about_ca_system_score_gemma":0.002492611,"threshold_uncertainty_score":0.9997417},"labels":[],"label_agreement":null},{"id":"W4410580854","doi":"10.1158/1078-0432.ccr-24-3192","title":"Mechanism of Initial Favorable Response to Decitabine in <i>TP53</i> -Mutated MDS/AML and Potential Mechanisms of Subsequent Relapse","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome Canada","funders":"Innovation and Technology Commission; Croucher Foundation; University Grants Committee; Li Shu Fan Medical Foundation","keywords":"Decitabine; Mechanism (biology); Azacitidine; Cancer research; Leukemia; Medicine; Myelodysplastic syndromes; Biology; Internal medicine; Genetics; DNA methylation; Gene; Bone marrow","score_opus":0.09173280905897802,"score_gpt":0.4895852973011111,"score_spread":0.3978524882421331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410580854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842457,0.00043001818,0.0023194584,0.010065219,0.00026794794,0.001741002,0.00008451554,0.000027588689,0.0008185361],"genre_scores_gemma":[0.99437493,0.00084618054,0.0017067096,0.00055945915,0.00008730919,0.00020761904,0.000013886509,0.000042964057,0.0021609266],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9934315,0.0019014631,0.0015165543,0.0008089417,0.0014499732,0.00089154154],"domain_scores_gemma":[0.99463814,0.0025193188,0.00013048382,0.00080755865,0.0013718492,0.000532638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013801481,0.00021943012,0.001040275,0.0013207215,0.00009453227,0.000024893876,0.0004913395,0.00042421377,0.0003262682],"category_scores_gemma":[0.007997965,0.00019804978,0.00017003629,0.002503544,0.00070025015,0.00009376643,0.0008712097,0.0017794353,0.000022384185],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12463519,0.001540597,0.0044948286,0.0010356876,0.0003802383,0.0011774367,0.0005496515,0.000083302206,0.8245651,0.01822281,0.0067735184,0.016541641],"study_design_scores_gemma":[0.03655084,0.012127407,0.049634296,0.003474471,0.00022860285,0.00006130832,0.0019400247,0.0033050475,0.8332343,0.05586377,0.0029475226,0.00063238567],"about_ca_topic_score_codex":0.0020216473,"about_ca_topic_score_gemma":0.00026411968,"teacher_disagreement_score":0.08808435,"about_ca_system_score_codex":0.0006724828,"about_ca_system_score_gemma":0.004122072,"threshold_uncertainty_score":0.9574889},"labels":[],"label_agreement":null},{"id":"W4410595770","doi":"10.1158/1538-7445.am2025-3806","title":"Abstract 3806: Single-cell transcriptional mapping reveals genetic and non-genetic determinants of aberrant differentiation in AML","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Biology; Genetics; Computational biology; Cancer research; Evolutionary biology","score_opus":0.06854202239917861,"score_gpt":0.36745932133291653,"score_spread":0.2989172989337379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410595770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942004,0.0030811531,0.00015756136,0.00057737064,0.000076402546,0.00089714525,0.000022035654,0.000009447386,0.00097845],"genre_scores_gemma":[0.99608266,0.0014945521,0.00048791114,0.000060629744,0.000074979,0.00017016871,0.000008898788,0.000023747041,0.0015964415],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976573,0.00013341334,0.00050339365,0.00042536468,0.00070876785,0.00057174737],"domain_scores_gemma":[0.9989214,0.000233373,0.000059000955,0.0003158762,0.00032445483,0.00014590213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068152917,0.00014448415,0.0003803806,0.00086613843,0.000086247375,0.000031107673,0.00019537983,0.00014812236,0.0002031587],"category_scores_gemma":[0.00012903195,0.00013481887,0.000058453836,0.0007720121,0.00025370924,0.00006041846,0.00009183334,0.0006033936,0.000009629808],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026663646,0.000163983,0.20632665,0.0015218578,0.00002452927,0.000055099823,0.00042992612,0.000015554027,0.76705116,0.000004545674,0.00045480492,0.02368523],"study_design_scores_gemma":[0.002413169,0.00013500622,0.928716,0.0010755374,0.00001629506,0.0000066010634,0.00017532478,0.0009678701,0.06600234,0.00020020567,0.00019790523,0.00009375521],"about_ca_topic_score_codex":0.0009934638,"about_ca_topic_score_gemma":0.00034284167,"teacher_disagreement_score":0.72238934,"about_ca_system_score_codex":0.00062766124,"about_ca_system_score_gemma":0.0007554244,"threshold_uncertainty_score":0.54977536},"labels":[],"label_agreement":null},{"id":"W4410599748","doi":"10.3390/curroncol32060294","title":"Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Key Research and Development Program of China; Beijing Municipal Science and Technology Commission; Peking University; National Natural Science Foundation of China","keywords":"Medicine; RUNX1; Stem cell; Myeloid leukemia; Transplantation; Hematopoietic stem cell transplantation; Haematopoiesis; Myeloid; Leukemia; Cancer research; Hematopoietic cell; Oncology; Immunology; Bioinformatics; Internal medicine; Biology; Genetics","score_opus":0.034357173950869374,"score_gpt":0.3742318187046244,"score_spread":0.33987464475375506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410599748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99617684,0.00014231652,0.0004711738,0.0004870373,0.0001698003,0.0016513413,0.000042843698,0.000027042704,0.00083161524],"genre_scores_gemma":[0.9986729,0.00031953637,0.00017836274,0.00015371705,0.000016124377,0.00015526343,0.0001680873,0.00002104925,0.00031498104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980975,0.00036914018,0.00058087014,0.00031620663,0.00036970538,0.0002666146],"domain_scores_gemma":[0.9968568,0.0020262797,0.00028450374,0.0003999917,0.00033920506,0.000093238334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027497168,0.00021286945,0.00073720503,0.00022545244,0.000065038796,0.000004202467,0.00019698005,0.00015837236,0.000019905752],"category_scores_gemma":[0.000060692557,0.00011308698,0.00012419837,0.0004636809,0.00044715972,0.00003399036,0.000030291509,0.00046376602,0.000010278978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040235394,0.0021342153,0.9706241,0.0011254565,0.0010478566,0.00006761517,0.00067423115,0.000030344294,0.00068874744,0.00046256933,0.00059239625,0.018528955],"study_design_scores_gemma":[0.015321389,0.0059590363,0.95823705,0.0004768554,0.001976351,0.000010611844,0.00017152239,0.00008209412,0.017004225,0.000032294123,0.0005893562,0.00013920061],"about_ca_topic_score_codex":0.000016230459,"about_ca_topic_score_gemma":0.000018204066,"teacher_disagreement_score":0.018389754,"about_ca_system_score_codex":0.00039137926,"about_ca_system_score_gemma":0.0011313871,"threshold_uncertainty_score":0.46115533},"labels":[],"label_agreement":null},{"id":"W4410608796","doi":"10.1016/j.tcb.2025.04.006","title":"Translational control of leukemic metabolism and disease progression","year":2025,"lang":"en","type":"review","venue":"Trends in Cell Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Jewish General Hospital","funders":"Cole Foundation; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Biology; Disease; Metabolism; Computational biology; Cell biology; Internal medicine; Biochemistry","score_opus":0.037352313379341896,"score_gpt":0.39477214104312697,"score_spread":0.35741982766378505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410608796","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004656758,0.99458855,0.00003460025,0.0002307138,0.000090370864,0.0005547487,0.00032048972,0.000017185064,0.0041167825],"genre_scores_gemma":[0.00200466,0.99463195,0.00028277078,0.000050451392,0.00010104697,0.0001499299,0.000990153,0.000021224807,0.0017678194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981668,0.00034848112,0.0006050243,0.00045471403,0.000128141,0.0002968288],"domain_scores_gemma":[0.9987674,0.00051743275,0.00017576333,0.00030692434,0.000045537603,0.00018694898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029821065,0.00028994743,0.0018496912,0.0010191816,0.000020302003,0.0000031246345,0.0001607729,0.0004423316,0.00016248543],"category_scores_gemma":[0.000119589895,0.00019888388,0.00027857829,0.0005210258,0.0002654435,0.000017206046,0.000060768216,0.00058491575,0.0000054517786],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019645886,0.00008185975,0.00026818083,0.011669647,0.00008539347,0.00002848244,0.000013832002,2.3523117e-7,0.000033624627,0.00042923997,0.00024671276,0.98694634],"study_design_scores_gemma":[0.003859241,0.0001173701,0.00062855217,0.0059394278,0.0014147869,0.000013682623,0.000002376129,0.00007139339,0.0000074004056,0.00025888943,0.9874816,0.00020528567],"about_ca_topic_score_codex":0.000013180306,"about_ca_topic_score_gemma":0.0000020606246,"teacher_disagreement_score":0.9872349,"about_ca_system_score_codex":0.00010009996,"about_ca_system_score_gemma":0.0014351979,"threshold_uncertainty_score":0.8110249},"labels":[],"label_agreement":null},{"id":"W4410807970","doi":"10.1200/jco.2025.43.16_suppl.e18522","title":"Who benefits from gilteritinib combination therapy amongst FLT3 <sup>mut</sup> R/R AML? Genomic insights.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Cancer research; Oncology; Internal medicine","score_opus":0.0985192387814318,"score_gpt":0.43735206471058363,"score_spread":0.3388328259291518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410807970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635898,0.0024765912,0.00025991717,0.023355918,0.0009383355,0.00041383936,0.000010183269,0.00002156157,0.00893389],"genre_scores_gemma":[0.97455364,0.009695536,0.0017761225,0.009454649,0.0019934983,0.00001099236,0.000027823773,0.000038049588,0.0024497085],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948057,0.0008925189,0.002954055,0.00037062328,0.0005809209,0.00039618803],"domain_scores_gemma":[0.9927335,0.004356282,0.0012019394,0.00043347775,0.0008005658,0.00047427052],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0027638786,0.00023965212,0.0020171104,0.00042262056,0.00010319197,0.00003649288,0.0005369014,0.00084981904,0.00035616074],"category_scores_gemma":[0.0036242157,0.00017725509,0.0006246643,0.00036965753,0.00041317992,0.00020966628,0.00017389205,0.002423507,0.00009633194],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017846195,0.0043085753,0.08853292,0.000049332775,0.0022143882,0.0013931936,0.00072985457,0.00015621807,0.002895289,0.004368759,0.059898715,0.81760657],"study_design_scores_gemma":[0.025090668,0.008222417,0.58211434,0.00026062256,0.00023876157,0.000103696286,0.0002571216,0.0017330829,0.00072112615,0.0029228798,0.37816828,0.00016702278],"about_ca_topic_score_codex":0.000102315804,"about_ca_topic_score_gemma":0.000034472032,"teacher_disagreement_score":0.81743956,"about_ca_system_score_codex":0.0007278814,"about_ca_system_score_gemma":0.0036133786,"threshold_uncertainty_score":0.9998779},"labels":[],"label_agreement":null},{"id":"W4410809204","doi":"10.1200/jco.2025.43.16_suppl.6569","title":"Effect of prior treatment (tx) on the clinical activity of imetelstat (IME) in transfusion-dependent (TD) patients (pts) with erythropoiesis-stimulating agent (ESA), relapsed or refractory (R/R)/ineligible lower-risk myelodysplastic syndromes (LR-MDS).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Refractory (planetary science); Erythropoiesis; Internal medicine; Anemia; Oncology; Bone marrow","score_opus":0.07245020380775764,"score_gpt":0.4544308113750213,"score_spread":0.38198060756726365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99442846,0.0001441113,0.00018171234,0.0020018115,0.0010423595,0.0016062191,0.000023566754,0.000012544988,0.00055921986],"genre_scores_gemma":[0.9951691,0.003211902,0.0007527563,0.00020118836,0.00019685947,0.000025714397,0.0000033899398,0.000041600983,0.00039749764],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98858213,0.004981392,0.0041793464,0.0005442826,0.0011927249,0.00052009977],"domain_scores_gemma":[0.939065,0.056286752,0.0029830986,0.0006561577,0.00063145894,0.0003775312],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011083696,0.0004238435,0.003676639,0.00052659475,0.00010868546,0.000010781749,0.00042621462,0.0007214122,0.00021010073],"category_scores_gemma":[0.02308646,0.00020296469,0.0009450917,0.00060585944,0.00076866645,0.00012864433,0.0001367006,0.0028207737,0.0000124480275],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.191166,0.014066163,0.37230372,0.0003830191,0.0023096139,0.0012729551,0.00022683627,0.0006393391,0.00059967465,0.0000117909585,0.00078543887,0.41623545],"study_design_scores_gemma":[0.07249042,0.33034956,0.5861063,0.0020232843,0.002307943,0.00009435271,0.00015445067,0.001427058,0.0029772187,0.000039314302,0.0017811096,0.00024900373],"about_ca_topic_score_codex":0.00024725526,"about_ca_topic_score_gemma":0.00023636005,"teacher_disagreement_score":0.41598645,"about_ca_system_score_codex":0.0013441375,"about_ca_system_score_gemma":0.005021354,"threshold_uncertainty_score":0.9994798},"labels":[],"label_agreement":null},{"id":"W4410809231","doi":"10.1200/jco.2025.43.16_suppl.6542","title":"Novel potent and selective inhibitors targeting FLT3 for AML therapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Lapatinib; Pharmacology; Cancer research; Cancer; Trastuzumab; Internal medicine; Breast cancer","score_opus":0.10600138975053246,"score_gpt":0.4911744738460747,"score_spread":0.38517308409554224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93378097,0.0019992236,0.0074396883,0.050597154,0.0015475287,0.0007107847,0.0000042390384,0.0000138120695,0.003906626],"genre_scores_gemma":[0.95956665,0.0018991163,0.029002093,0.0061477222,0.0022379246,0.000012043734,0.0000021214585,0.000019945619,0.0011123599],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975729,0.00019600918,0.0015526795,0.00018769542,0.00022845538,0.00026226646],"domain_scores_gemma":[0.99357873,0.0044584526,0.00069889333,0.00009740837,0.00091093866,0.00025556984],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0048367735,0.00010909076,0.0010560191,0.00019157582,0.00006779577,0.000010123108,0.000119416145,0.0003795115,0.000014602138],"category_scores_gemma":[0.010579803,0.000073209645,0.00034191468,0.00019330898,0.0001757767,0.00006898849,0.00006916105,0.0012431447,0.0000020238626],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016405217,0.0018996423,0.041777346,0.00008405,0.0013253815,0.00016373117,0.00022430207,0.000013087194,0.017764537,0.00047453414,0.10857792,0.81129026],"study_design_scores_gemma":[0.05702231,0.034825746,0.2197578,0.0003233896,0.0004995299,0.0005744042,0.0008642005,0.0016622666,0.008417566,0.0026221063,0.67319334,0.00023736795],"about_ca_topic_score_codex":0.000015395195,"about_ca_topic_score_gemma":0.000005470375,"teacher_disagreement_score":0.81105286,"about_ca_system_score_codex":0.00031936137,"about_ca_system_score_gemma":0.0032586488,"threshold_uncertainty_score":0.9977545},"labels":[],"label_agreement":null},{"id":"W4410809346","doi":"10.1200/jco.2025.43.16_suppl.6527","title":"Real-world patient management practices in responders to venetoclax for newly diagnosed acute myeloid leukemia.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Venetoclax; Medicine; Myeloid leukemia; Myeloid; Oncology; Internal medicine; Leukemia; Chronic lymphocytic leukemia","score_opus":0.11610294035788578,"score_gpt":0.5120929912143497,"score_spread":0.39599005085646394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90813684,0.00016317081,0.00059083063,0.05917588,0.0016738279,0.0019957158,0.000007927397,0.000019034735,0.02823677],"genre_scores_gemma":[0.7861455,0.009366868,0.13127907,0.04615896,0.002048762,0.0003787428,0.00002181689,0.000100265985,0.024499984],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947773,0.00071097596,0.0030098518,0.00040250807,0.000563425,0.00053591584],"domain_scores_gemma":[0.9872176,0.009169589,0.0020868126,0.00042414205,0.000571669,0.00053019176],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006454858,0.00019848478,0.0015736776,0.0011293525,0.000056666868,0.000023800085,0.0004440757,0.00036598698,0.000058546513],"category_scores_gemma":[0.011804365,0.00015663824,0.0004603532,0.0009245183,0.00013764879,0.00016490281,0.00025164048,0.0015255552,0.000028701503],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07829081,0.0013882265,0.023987755,0.00024717083,0.0021531326,0.008408021,0.00040399,0.0006563486,0.00056442805,0.0019362664,0.3258351,0.55612874],"study_design_scores_gemma":[0.020887801,0.013616015,0.1661035,0.000449704,0.0006787163,0.00005848473,0.00079970347,0.0005285173,0.00023362717,0.00093090406,0.79555434,0.00015866797],"about_ca_topic_score_codex":0.00021666316,"about_ca_topic_score_gemma":0.00076501555,"teacher_disagreement_score":0.5559701,"about_ca_system_score_codex":0.005091729,"about_ca_system_score_gemma":0.009109074,"threshold_uncertainty_score":0.99872756},"labels":[],"label_agreement":null},{"id":"W4410809409","doi":"10.1200/jco.2025.43.16_suppl.6506","title":"Ziftomenib in relapsed/refractory (R/R) <i>NPM1</i> -mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; NPM1; Refractory (planetary science); Oncology; Internal medicine; Mutant; Myeloid; Cancer research; Gene; Genetics; Biology","score_opus":0.08539747359179765,"score_gpt":0.4797452026748207,"score_spread":0.394347729083023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96592295,0.00051253894,0.00008110889,0.026713956,0.0022776127,0.0011655077,0.00012851215,0.000028676683,0.003169144],"genre_scores_gemma":[0.98428524,0.006386662,0.0008979358,0.005161646,0.002127533,0.000015400245,0.000019334833,0.000043438078,0.001062836],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98511595,0.0049516344,0.0070933243,0.00093607046,0.0011201046,0.0007829157],"domain_scores_gemma":[0.9570051,0.037490524,0.0028671355,0.0010622063,0.00067336287,0.00090166955],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.02590938,0.00045273273,0.0037860011,0.0004202295,0.00019803348,0.00004814415,0.0008769921,0.0012821048,0.00008594504],"category_scores_gemma":[0.026602661,0.0002842098,0.0007777119,0.0008822104,0.0012562028,0.0002783226,0.0007155868,0.00921205,0.00003952962],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23954171,0.031725623,0.11579874,0.000030741292,0.0038104297,0.009897333,0.000571831,0.000008501959,0.0026442455,0.000046127698,0.039089013,0.5568357],"study_design_scores_gemma":[0.20330906,0.031316407,0.61678314,0.0002663254,0.0013558674,0.00030478876,0.0008159804,0.00053640414,0.00010624465,0.00029141124,0.14463504,0.00027933065],"about_ca_topic_score_codex":0.0005726656,"about_ca_topic_score_gemma":0.00071489403,"teacher_disagreement_score":0.5565564,"about_ca_system_score_codex":0.0019094222,"about_ca_system_score_gemma":0.010933488,"threshold_uncertainty_score":0.999961},"labels":[],"label_agreement":null},{"id":"W4410809590","doi":"10.1200/jco.2025.43.16_suppl.6511","title":"Reduced dose PTCy in patients with acute myeloid leukemia receiving matched unrelated donor allogeneic hematopoietic stem cell transplantation.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Hematopoietic stem cell transplantation; Stem cell; Transplantation; Haematopoiesis; Myeloid; Leukemia; Oncology; Immunology; Hematopoietic cell; Internal medicine; Genetics","score_opus":0.037513114537164584,"score_gpt":0.38099128050248665,"score_spread":0.34347816596532205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911342,0.0001999881,0.0002557128,0.0044562463,0.00059346575,0.00062375184,0.0000059088857,0.000022010498,0.0027086893],"genre_scores_gemma":[0.99126875,0.0013984665,0.00408013,0.0014660248,0.00016082377,0.000012749572,0.000017784047,0.000037765694,0.0015574812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99452597,0.00081811106,0.0031513236,0.0003863602,0.0006116863,0.00050657796],"domain_scores_gemma":[0.9948466,0.0023725585,0.0012998313,0.0003499997,0.00070005393,0.0004309844],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003075671,0.00026645474,0.0019484187,0.00055270677,0.0000614087,0.00001939433,0.0003887559,0.0007652074,0.00009788658],"category_scores_gemma":[0.00046100415,0.00018800327,0.00034303765,0.00078996393,0.00023206933,0.00018565585,0.000067932095,0.0025647879,0.00003284253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081480324,0.004593854,0.79704833,0.00071962125,0.002754465,0.007990664,0.001728154,0.0005248369,0.0061094584,0.000082873295,0.0058187526,0.09114866],"study_design_scores_gemma":[0.044938363,0.007354225,0.9417713,0.0007592761,0.0010816123,0.0003060297,0.00028308944,0.00010706547,0.0016133601,0.00011990776,0.0014484208,0.00021730793],"about_ca_topic_score_codex":0.000034529046,"about_ca_topic_score_gemma":0.00003814861,"teacher_disagreement_score":0.14472301,"about_ca_system_score_codex":0.0016225835,"about_ca_system_score_gemma":0.007991608,"threshold_uncertainty_score":0.9997363},"labels":[],"label_agreement":null},{"id":"W4410809597","doi":"10.1200/jco.2025.43.16_suppl.6517","title":"Age-related macular degeneration in individuals with clonal hematopoiesis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Conquer Cancer Foundation","keywords":"Macular degeneration; Medicine; Gerontology; Oncology; Ophthalmology","score_opus":0.07644426328947711,"score_gpt":0.46658606663048063,"score_spread":0.3901418033410035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963545,0.00047138738,0.0003276848,0.026648663,0.0003504802,0.00024970926,0.0000011871208,0.000008461439,0.008397389],"genre_scores_gemma":[0.97993606,0.0003325517,0.013497103,0.0041436767,0.00034195604,0.000006819288,0.00000820391,0.000014416583,0.0017191812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961579,0.00064291834,0.0022848302,0.0001855183,0.0004751744,0.0002536686],"domain_scores_gemma":[0.9967797,0.0016609385,0.00075077766,0.00018212177,0.00039801537,0.00022849134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055909264,0.00011941713,0.0013231023,0.00043328383,0.000032383574,0.000012466959,0.00019208866,0.0005301195,0.00016288664],"category_scores_gemma":[0.0036349685,0.000078662626,0.000241801,0.00051764876,0.00028446587,0.000100085395,0.00006891475,0.0018451312,0.000020514004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005776197,0.0029560996,0.8593744,0.00012669602,0.0016009604,0.011017062,0.0002546808,0.00031407244,0.0020417897,0.007010603,0.044869263,0.06465819],"study_design_scores_gemma":[0.034595802,0.009314169,0.8283787,0.0005519289,0.00058030227,0.0015193056,0.00022032563,0.0004815593,0.00138791,0.003801149,0.11898855,0.00018034919],"about_ca_topic_score_codex":0.000015060978,"about_ca_topic_score_gemma":0.000063668034,"teacher_disagreement_score":0.074119285,"about_ca_system_score_codex":0.0004317771,"about_ca_system_score_gemma":0.0049673226,"threshold_uncertainty_score":0.8811817},"labels":[],"label_agreement":null},{"id":"W4410812091","doi":"10.1200/jco.2025.43.16_suppl.e18578","title":"Efficacy and safety of azacitidine in the treatment of elderly patients with higher-risk myelodysplastic syndromes.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Barrie Urology Group; McMaster University","funders":"","keywords":"Medicine; Azacitidine; Myelodysplastic syndromes; Oncology; Internal medicine; Intensive care medicine; Bone marrow","score_opus":0.05468031437085299,"score_gpt":0.4206413806788454,"score_spread":0.3659610663079924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943088,0.00041820735,0.00005079124,0.0034140553,0.00019213048,0.0004272607,0.000008657428,0.0000018755106,0.0011782172],"genre_scores_gemma":[0.9960923,0.0025325406,0.00089520775,0.00018497305,0.00009624785,0.0000036268787,0.0000027742537,0.0000075879,0.00018473374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968185,0.00060919084,0.0018623846,0.00014510234,0.00038225861,0.00018257015],"domain_scores_gemma":[0.98999226,0.008191631,0.0010810421,0.00021736408,0.0003890704,0.00012864004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017492077,0.0001212484,0.0014359931,0.00022346337,0.000023457076,0.0000028629925,0.00015954953,0.0002198903,0.000042573956],"category_scores_gemma":[0.0019285867,0.00005893212,0.00016705612,0.0003226789,0.0004313956,0.000041534746,0.000027973167,0.00064487586,0.0000012404238],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033199232,0.0073283482,0.695928,0.00009166624,0.00092257326,0.000359813,0.00027179913,0.000027856198,0.000027959959,0.00017806015,0.0006714263,0.26099327],"study_design_scores_gemma":[0.03728669,0.063184045,0.8855175,0.00023783052,0.00051785226,0.000044681165,0.00007272511,0.00002324026,0.000025764624,0.00008734926,0.01296385,0.000038486098],"about_ca_topic_score_codex":0.000045520515,"about_ca_topic_score_gemma":0.000031032603,"teacher_disagreement_score":0.2609548,"about_ca_system_score_codex":0.00023881154,"about_ca_system_score_gemma":0.0013447796,"threshold_uncertainty_score":0.28017005},"labels":[],"label_agreement":null},{"id":"W4410838092","doi":"10.1007/s00277-025-06431-w","title":"Impact of secondary-type mutations on the prognosis of AML patients with NPM1 mutation: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Natural Science Foundation of Sichuan Province; Department of Science and Technology of Sichuan Province","keywords":"Meta-analysis; NPM1; Hematology; Internal medicine; Medicine; Mutation; Oncology; Genetics; Biology; Gene","score_opus":0.1272697971046132,"score_gpt":0.4394940203620863,"score_spread":0.3122242232574731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410838092","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002566815,0.9933261,0.000005863462,0.00077915186,0.000005876401,0.004956761,0.000382026,0.0000068375653,0.00028069547],"genre_scores_gemma":[0.006125783,0.99246657,0.00009227332,0.00023941125,0.0000023179111,0.0005643815,0.00036941876,0.000024542147,0.00011531674],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964331,0.0008682747,0.0016880668,0.00034195438,0.0004448383,0.00022376167],"domain_scores_gemma":[0.99358684,0.0022820116,0.0018716397,0.0008465519,0.0013336368,0.00007931242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072537665,0.00036891934,0.010538408,0.000782516,0.000035618887,0.0000051279244,0.00027194756,0.00019096836,0.0004670569],"category_scores_gemma":[0.0017984578,0.00016510049,0.0020970432,0.002158384,0.00028575535,0.000036985286,0.00007399987,0.0003460038,0.000004767001],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025875199,0.00018991581,0.00008088083,0.7963472,0.20169885,0.000010148523,0.000041532352,4.7182888e-7,3.066592e-8,0.00037934617,0.00072625966,0.0004995021],"study_design_scores_gemma":[0.00028081908,0.0013099756,0.00013012537,0.0807214,0.91703176,0.00009407681,0.000024650195,0.000002994525,0.000015882846,0.000031727,0.00020411277,0.00015245321],"about_ca_topic_score_codex":0.00004424774,"about_ca_topic_score_gemma":0.000005669155,"teacher_disagreement_score":0.71562576,"about_ca_system_score_codex":0.000026985415,"about_ca_system_score_gemma":0.0010912892,"threshold_uncertainty_score":0.7203845},"labels":[],"label_agreement":null},{"id":"W4410840101","doi":"10.1016/j.stem.2026.05.007","title":"Quantitative molecular cartography of emergency myelopoiesis reveals conserved modules of hematopoietic activation","year":2025,"lang":"en","type":"preprint","venue":"Cell stem cell","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of Toronto; University of Oxford; University of Minnesota; National Heart, Lung, and Blood Institute; Damon Runyon Cancer Research Foundation","keywords":"Myelopoiesis; Haematopoiesis; Computational biology; Cartography; Geography; Biology; Cell biology; Stem cell","score_opus":0.034610163041122396,"score_gpt":0.3111383926300103,"score_spread":0.2765282295888879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410840101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9660852,0.004412937,0.0045534256,0.00027416038,0.00030451635,0.0019482218,0.00021929778,0.000056449673,0.022145776],"genre_scores_gemma":[0.986983,0.001594057,0.0059913024,0.000042443204,0.000027645921,0.00013410236,0.00020918787,0.00006133943,0.0049569113],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963179,0.00039356452,0.0013143499,0.00076598936,0.0007870738,0.00042112803],"domain_scores_gemma":[0.9959265,0.0003464627,0.0009951192,0.0013392469,0.0012189561,0.00017372737],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057206623,0.00048845256,0.0014522233,0.00079657236,0.00005128363,0.000009750528,0.0005060346,0.00058208976,0.0002110319],"category_scores_gemma":[0.00008439732,0.00048381274,0.0007131432,0.0008545971,0.00020747478,0.000045368295,0.00064517045,0.00080692745,0.000014947255],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006549921,0.0006359264,0.0052290224,0.0394026,0.00066271424,0.000041184754,0.0025948165,0.0004857149,0.94273186,0.0008581411,0.006345457,0.00035758124],"study_design_scores_gemma":[0.0012428069,0.00032016356,0.0016660539,0.0017288958,0.0005067823,0.0000013529616,0.002008718,0.0005551281,0.99011564,0.0012843112,0.00021410009,0.00035605193],"about_ca_topic_score_codex":0.00042745093,"about_ca_topic_score_gemma":0.000005000742,"teacher_disagreement_score":0.047383785,"about_ca_system_score_codex":0.00021314457,"about_ca_system_score_gemma":0.00079460844,"threshold_uncertainty_score":0.99976134},"labels":[],"label_agreement":null},{"id":"W4410846431","doi":"10.63838/001c.136844","title":"Unraveling enigmatic peripheral blood findings in a rare case of gamma-delta T-cell acute lymphoblastic leukemia","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Medical Specialties","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba; Dalhousie University","funders":"","keywords":"Lymphoblastic Leukemia; Peripheral blood; Peripheral; Medicine; Leukemia; Delta; Pathology; Immunology; Internal medicine; Physics","score_opus":0.011227533846967702,"score_gpt":0.27702673589988835,"score_spread":0.2657992020529206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410846431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901991,0.0020629596,0.00030448998,0.0040786345,0.0005062055,0.00024581293,0.0000267642,0.0000065333106,0.002569528],"genre_scores_gemma":[0.9963845,0.00039769817,0.00063389185,0.00071259204,0.00059671735,0.0000047315116,0.000006222624,0.000028014867,0.0012356174],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99683714,0.00014449672,0.0011840588,0.00021432803,0.0009328655,0.00068711996],"domain_scores_gemma":[0.99725056,0.0004064399,0.0002121532,0.0002540689,0.00034891334,0.0015278789],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013559854,0.00023369571,0.0008733935,0.0013254416,0.00012522168,0.00005132722,0.00051107013,0.00036030405,0.001995853],"category_scores_gemma":[0.0027764568,0.00020124692,0.00021893805,0.00081253325,0.00050211244,0.00011383723,0.00006247848,0.0012188185,0.000006971428],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002043128,0.00055266405,0.08049198,0.0046905903,0.0024932474,0.73662484,0.024688989,0.00034220304,0.0045124143,0.004911706,0.08837968,0.050268546],"study_design_scores_gemma":[0.19508651,0.009855445,0.074005306,0.06254266,0.009009263,0.34777996,0.10235879,0.042445842,0.05054155,0.0069995355,0.09495465,0.004420503],"about_ca_topic_score_codex":0.01879631,"about_ca_topic_score_gemma":0.059917003,"teacher_disagreement_score":0.3888449,"about_ca_system_score_codex":0.0025002197,"about_ca_system_score_gemma":0.02884321,"threshold_uncertainty_score":0.99891645},"labels":[],"label_agreement":null},{"id":"W4410897757","doi":"10.3390/curroncol32060319","title":"Allogeneic Stem Cell Transplantation: The Relevance of Conditioning Regime Intensity for Myelodysplastic Syndromes (MDS)","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Government of Ontario; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Medicine; Myelodysplastic syndromes; Stem cell; Transplantation; Conditioning regimen; Myeloid leukemia; Conditioning; Hematopoietic stem cell transplantation; Disease; Oncology; Immunology; Myeloid; Internal medicine; Biology; Bone marrow; Genetics","score_opus":0.1378394355226542,"score_gpt":0.4331092549550701,"score_spread":0.29526981943241587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410897757","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000118213065,0.9916279,0.0021237158,0.0003039161,0.0015645581,0.0031148551,0.00037283864,0.000044296758,0.0007297338],"genre_scores_gemma":[0.00017844242,0.9954469,0.0002773113,0.000056419543,0.00027349003,0.00076419313,0.0009274579,0.000042536947,0.0020332464],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973894,0.00036819855,0.0009357746,0.00056900113,0.00028839294,0.00044925816],"domain_scores_gemma":[0.99326545,0.004963347,0.00059982075,0.00055738667,0.0004976169,0.00011638058],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006274807,0.00039690002,0.002451228,0.00032702592,0.00014700535,0.000010884361,0.00045409435,0.00045435797,0.000049898852],"category_scores_gemma":[0.0003163137,0.00026799127,0.0005944701,0.00047745445,0.00037837191,0.00003811383,0.00010206007,0.0010521553,0.000040511084],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023132864,0.00017387437,0.000017465201,0.14449361,0.00034368417,0.000086654996,0.00016074695,0.0000024586773,0.000006359432,0.00038999846,0.012294578,0.84179926],"study_design_scores_gemma":[0.0013074958,0.0005909956,0.000026698972,0.020531524,0.003808887,0.0007157529,0.00007241696,0.0000326909,0.00003118323,0.00004879291,0.972634,0.00019956929],"about_ca_topic_score_codex":0.0000035045557,"about_ca_topic_score_gemma":0.000005502859,"teacher_disagreement_score":0.9603394,"about_ca_system_score_codex":0.0008858444,"about_ca_system_score_gemma":0.0035310073,"threshold_uncertainty_score":0.99997723},"labels":[],"label_agreement":null},{"id":"W4410984224","doi":"10.1200/op-24-00776","title":"Patient-Centered Genomic Diagnostic Testing for AML: A Quality Improvement Project","year":2025,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Quality management; Quality (philosophy); Medicine; Medical physics; Computer science; Operations management; Engineering","score_opus":0.08379426349815522,"score_gpt":0.4463297829322617,"score_spread":0.3625355194341065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410984224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89294493,0.00048182945,0.0023663826,0.039196152,0.0009502025,0.008636347,0.00006316585,0.00024265038,0.055118363],"genre_scores_gemma":[0.8869755,0.00015438534,0.08044576,0.025130382,0.00046176306,0.00284032,0.00011433851,0.00007306437,0.0038044532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975451,0.0004467529,0.00064150814,0.0005393943,0.00024661768,0.0005806008],"domain_scores_gemma":[0.97809947,0.020140333,0.000412415,0.0005169353,0.0007098744,0.000120982666],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0017189172,0.0001996062,0.0004835685,0.0002253203,0.00020833845,0.000035253455,0.00017842565,0.00022507475,0.000024853312],"category_scores_gemma":[0.06762234,0.00018134962,0.00010740851,0.00043523507,0.00011859853,0.0001998306,0.00029441313,0.0006463165,0.000053636395],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009128173,0.0038817995,0.023169687,0.0011225085,0.0011277022,0.0004447374,0.0014475918,0.000008567288,0.10786709,0.0015192039,0.08438313,0.76589984],"study_design_scores_gemma":[0.011847654,0.0085658375,0.019140145,0.00016692554,0.0007734822,0.00019015295,0.0038340238,0.0009788637,0.0031836755,0.0002251712,0.9508071,0.00028698912],"about_ca_topic_score_codex":0.0008110548,"about_ca_topic_score_gemma":0.000057167712,"teacher_disagreement_score":0.86642396,"about_ca_system_score_codex":0.0023082807,"about_ca_system_score_gemma":0.0033902936,"threshold_uncertainty_score":0.9402315},"labels":[],"label_agreement":null},{"id":"W4411015159","doi":"10.1016/j.eclinm.2025.103283","title":"Incident cytopenia and risk of subsequent myeloid neoplasm in age-related clonal hematopoiesis: a multi-biobank case-control study","year":2025,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Foundation for the National Institutes of Health; American Federation for Aging Research; American Society of Hematology; Edward P. Evans Foundation; Alexander and Margaret Stewart Trust; National Cancer Institute; National Institutes of Health; Pew Charitable Trusts; Burroughs Wellcome Fund; ASH Foundation; National Center for Advancing Translational Sciences","keywords":"Medicine; Cytopenia; Biobank; Oncology; Internal medicine; Bioinformatics; Bone marrow","score_opus":0.026901281707038042,"score_gpt":0.3556942714960155,"score_spread":0.3287929897889775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411015159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909878,0.0020043284,0.00020046876,0.0031533828,0.00027047846,0.002785911,0.00004034779,0.00006915241,0.00048815817],"genre_scores_gemma":[0.9960955,0.0007138705,0.0009972084,0.0006669309,0.00010906767,0.0001262935,0.000014283013,0.000037133304,0.0012397241],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99518657,0.0006860921,0.0021002153,0.0007939717,0.0006588406,0.000574299],"domain_scores_gemma":[0.9957335,0.0023974425,0.00038101454,0.0008564342,0.00025726954,0.00037431216],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0044506346,0.00037586252,0.0017025537,0.0006611781,0.000104714825,0.000016587197,0.0002635894,0.00034124719,0.00020650949],"category_scores_gemma":[0.0058099316,0.00028919356,0.00017690336,0.0010022707,0.00071002735,0.000078716876,0.00030213993,0.001600081,0.000028596638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019484803,0.0018610175,0.96486163,0.00025590736,0.0011164853,0.02064438,0.0014088554,0.000018788402,0.0008660075,0.000106663174,0.00076209026,0.0061497134],"study_design_scores_gemma":[0.04736992,0.0016706274,0.94135416,0.00073578797,0.0011023203,0.001308524,0.0023435531,0.0033101346,0.00017454408,0.00019867471,0.00021665393,0.0002151286],"about_ca_topic_score_codex":0.0026396108,"about_ca_topic_score_gemma":0.002178617,"teacher_disagreement_score":0.04542144,"about_ca_system_score_codex":0.00036411057,"about_ca_system_score_gemma":0.00066320115,"threshold_uncertainty_score":0.999956},"labels":[],"label_agreement":null},{"id":"W4411121056","doi":"10.1038/s41409-025-02634-x","title":"Allo-SCT in relapsed CBF-AML: rethinking the remission requirement","year":2025,"lang":"en","type":"editorial","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Vanderbilt University Medical Center; Vanderbilt University","keywords":"Medicine; Complete remission; Internal medicine; Oncology; Chemotherapy","score_opus":0.018294943725693395,"score_gpt":0.3072660971132282,"score_spread":0.2889711533875348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411121056","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01936083,0.0036804993,0.0012645737,0.024250671,0.8995236,0.0074962983,0.00062167604,0.0006457677,0.043156058],"genre_scores_gemma":[0.048676524,0.03280799,0.0044791275,0.0019328056,0.80568475,0.0010944259,0.026032569,0.00051308615,0.078778714],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995061,0.00046955905,0.00097326783,0.00080499734,0.0020897356,0.0006014828],"domain_scores_gemma":[0.99709815,0.0014110566,0.00026580438,0.0007813168,0.00030320324,0.00014044337],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0025336319,0.00046683737,0.0007243891,0.0005517861,0.00021185898,0.00007282633,0.00039640185,0.0013331528,0.00011210564],"category_scores_gemma":[0.0009197395,0.00035405994,0.00022329141,0.00066281576,0.00011056368,0.000101456826,0.00005747442,0.0029888581,0.00003642885],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003686894,0.00009310792,0.0001322665,0.0026779198,0.000116835996,0.0010117259,0.0020423902,0.000027101029,0.010122228,0.000085079155,0.9764489,0.0035555807],"study_design_scores_gemma":[0.014122721,0.00054722105,0.0012796695,0.011961008,0.0012301449,0.00009534908,0.00026788784,0.0008847658,0.005092109,0.0010195408,0.96265036,0.0008492359],"about_ca_topic_score_codex":0.00080413214,"about_ca_topic_score_gemma":0.0005016657,"teacher_disagreement_score":0.09383887,"about_ca_system_score_codex":0.0014690496,"about_ca_system_score_gemma":0.0022258952,"threshold_uncertainty_score":0.99996334},"labels":[],"label_agreement":null},{"id":"W4411235400","doi":"10.1159/000546757","title":"Ring Chromosomes in Patients with Myeloid Neoplasms Are Associated with a Poor Response to Therapy","year":2025,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; MorphoSys; National Center for Advancing Translational Sciences; Swedish Orphan Biovitrum; National Cancer Institute; National Institutes of Health; Incyte; Georgia Clinical and Translational Science Alliance; Gilead Sciences","keywords":"Ring chromosome; Medicine; Myeloid; Oncology; Cancer research; Karyotype; Biology; Genetics; Chromosome; Gene","score_opus":0.014300669302121934,"score_gpt":0.2706264669331864,"score_spread":0.2563257976310645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411235400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877988,0.00006161673,0.000012503812,0.009101599,0.00002871819,0.0014240411,0.00001387675,0.00014780228,0.0014110581],"genre_scores_gemma":[0.9957262,0.00001638752,0.0006062598,0.0023746379,0.000008553115,0.00017844,0.000029594094,0.000033212946,0.001026713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780345,0.00026778347,0.00029882643,0.0005206074,0.0004965892,0.0006127606],"domain_scores_gemma":[0.99830955,0.0006505823,0.00012334567,0.00048480864,0.0002545699,0.00017713226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044739596,0.00028402178,0.0007222462,0.00047157472,0.00011752547,0.00004118615,0.00027792048,0.000196251,0.000090192414],"category_scores_gemma":[0.0014331001,0.00017295466,0.000047889545,0.0014299917,0.00011903791,0.000102749145,0.0001314557,0.00048311334,0.00003228361],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03431789,0.00069036614,0.9572938,0.000050878487,0.00020962818,0.00090321363,0.00039854617,0.0000083649975,0.0022085786,0.00003714534,0.00303184,0.0008497223],"study_design_scores_gemma":[0.009331171,0.0020991815,0.98342305,0.0007348081,0.000026664346,0.00003355517,0.00025437208,0.000025195965,0.0024927414,0.00001683039,0.0013468887,0.00021551612],"about_ca_topic_score_codex":0.000049055965,"about_ca_topic_score_gemma":0.00020011008,"teacher_disagreement_score":0.026129248,"about_ca_system_score_codex":0.0005875418,"about_ca_system_score_gemma":0.0004520669,"threshold_uncertainty_score":0.70528865},"labels":[],"label_agreement":null},{"id":"W4411283910","doi":"10.1080/10428194.2025.2514894","title":"Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control arm","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Golder Associates (Canada)","funders":"","keywords":"Venetoclax; Isocitrate dehydrogenase; Refractory (planetary science); Myeloid leukemia; Medicine; Oncology; Leukemia; Internal medicine; Biology; Chronic lymphocytic leukemia; Enzyme","score_opus":0.009896063977063402,"score_gpt":0.2783254034031928,"score_spread":0.2684293394261294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411283910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887775,0.0013804296,0.0003320598,0.00035735223,0.0007688726,0.007611928,0.00023431866,0.00024475477,0.00029278075],"genre_scores_gemma":[0.99508244,0.00055656285,0.00031644714,0.001564525,0.00023799059,0.001301173,0.00022845562,0.00026517993,0.00044722867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9891824,0.0019153993,0.0021105309,0.0021763858,0.0018176044,0.0027976385],"domain_scores_gemma":[0.99125737,0.0037934682,0.0011812173,0.0019762293,0.00074560224,0.0010461343],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0022887138,0.001514658,0.003100942,0.0012826695,0.0006646662,0.00019257083,0.0011706073,0.0009234815,0.000060140712],"category_scores_gemma":[0.001049495,0.0011376133,0.0005548153,0.0031885954,0.0007959892,0.00043058908,0.00031870967,0.0011228912,0.00003706308],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.94901824,0.00079469266,0.012085149,0.0011856226,0.0023972103,0.0008594691,0.00048463413,0.0026400664,0.0029946102,0.00015355993,0.0010439054,0.02634285],"study_design_scores_gemma":[0.729357,0.024318166,0.21314359,0.0045319544,0.0013643716,0.00009523,0.00037749816,0.008587609,0.01481562,0.000100907,0.001879504,0.0014285374],"about_ca_topic_score_codex":0.009299679,"about_ca_topic_score_gemma":0.0020630073,"teacher_disagreement_score":0.21966122,"about_ca_system_score_codex":0.08069298,"about_ca_system_score_gemma":0.057562027,"threshold_uncertainty_score":0.9997602},"labels":[],"label_agreement":null},{"id":"W4411328802","doi":"10.1016/j.htct.2025.103861","title":"CD36 as a marker of acute myeloid leukemia prognosis: A systematic review","year":2025,"lang":"en","type":"review","venue":"Hematology Transfusion and Cell Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","keywords":"Medicine; Myeloid leukemia; CD36; Oncology; Internal medicine","score_opus":0.022473494268197558,"score_gpt":0.33281673183745086,"score_spread":0.3103432375692533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411328802","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059425904,0.98490196,0.00003336544,0.00041589962,0.00009688931,0.010725813,0.00003671697,0.00008819491,0.0036417146],"genre_scores_gemma":[0.000008080066,0.9908241,0.00017733827,0.0012895145,0.000023555544,0.002207322,0.00012048607,0.00009192862,0.005257654],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9952737,0.00095479854,0.001874871,0.0008518445,0.0005017507,0.000543049],"domain_scores_gemma":[0.99736995,0.00064452545,0.0005283423,0.0009768934,0.00021553063,0.0002647769],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00096770964,0.00080422114,0.008213533,0.00054122513,0.000106473606,0.000016012835,0.0004281766,0.0009383412,0.0006497389],"category_scores_gemma":[0.00008254375,0.00051985314,0.0012383964,0.0009005286,0.00026118886,0.00004465129,0.00007832033,0.0010618132,0.00008350815],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016477844,0.0001776006,0.000005170212,0.9216945,0.0015342012,0.0002588259,0.00008824715,1.26685e-9,0.000026163205,0.00016002948,0.0019162693,0.07397421],"study_design_scores_gemma":[0.0019258359,0.0004408388,8.492001e-7,0.7967577,0.010015082,0.003290705,0.00003533434,0.0000025872496,0.00017788121,0.000025448626,0.18695185,0.0003759015],"about_ca_topic_score_codex":0.00002809469,"about_ca_topic_score_gemma":0.0000021938326,"teacher_disagreement_score":0.18503559,"about_ca_system_score_codex":0.00020320904,"about_ca_system_score_gemma":0.0024036265,"threshold_uncertainty_score":0.9997253},"labels":[],"label_agreement":null},{"id":"W4411343261","doi":"10.1016/j.omtn.2025.102611","title":"RNA activation of CEBPA improves leukemia treatment","year":2025,"lang":"en","type":"article","venue":"Molecular Therapy — Nucleic Acids","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Cole Foundation; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Canada Research Chairs","keywords":"CEBPA; Leukemia; RNA; Cancer research; Computational biology; Medicine; Biology; Internal medicine; Genetics; Mutation; Gene","score_opus":0.013975447590367623,"score_gpt":0.2951084991821662,"score_spread":0.2811330515917986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411343261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816118,0.0006724517,0.0032260886,0.0019890657,0.00007623816,0.00081582763,0.0000045188394,0.000082617895,0.011521375],"genre_scores_gemma":[0.9927085,0.0005647555,0.0016931585,0.0012983553,0.000050070445,0.0000689821,0.00003598486,0.000045983325,0.003534183],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99858797,0.0000853515,0.0003155221,0.00035567395,0.00032526767,0.00033024227],"domain_scores_gemma":[0.9989019,0.00005639618,0.00008749902,0.0006937846,0.00016050755,0.00009989846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015740962,0.00023840794,0.0004189533,0.00028635346,0.00006985964,0.000018679782,0.0001912904,0.00018364514,0.00014538884],"category_scores_gemma":[0.000062189196,0.00019011312,0.00021788872,0.000507002,0.00014452594,0.00007064686,0.000053888376,0.00021201205,0.000029400722],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073194405,0.00016163975,0.0007311755,0.0000390447,0.00042535155,0.0000313284,0.00020847282,0.000010467429,0.85238034,0.00089493877,0.00037572626,0.1440096],"study_design_scores_gemma":[0.0050328877,0.0010129538,0.0094549665,0.000079270154,0.000060519676,0.0000074404666,0.0001151164,0.0005633495,0.9616634,0.0004611465,0.021414533,0.00013441232],"about_ca_topic_score_codex":0.00020617514,"about_ca_topic_score_gemma":0.0000012034221,"teacher_disagreement_score":0.14387518,"about_ca_system_score_codex":0.0011325093,"about_ca_system_score_gemma":0.0007210937,"threshold_uncertainty_score":0.77525884},"labels":[],"label_agreement":null},{"id":"W4411391466","doi":"10.1111/bjh.20203","title":"Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies","year":2025,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Taiho Oncology","keywords":"Decitabine; Chronic myelomonocytic leukemia; Medicine; Internal medicine; Myelodysplastic syndromes; Oncology; Azacitidine; Prospective cohort study; Clinical trial; International Prognostic Scoring System; Gastroenterology; Bone marrow","score_opus":0.03687991850905249,"score_gpt":0.38576371445286745,"score_spread":0.34888379594381497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411391466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94093883,0.054209065,0.00015995053,0.0042196894,0.00007645091,0.00028940255,0.000018796141,0.0000044470635,0.00008337937],"genre_scores_gemma":[0.98764706,0.011403085,0.0006669853,0.000172288,0.000050136332,0.000005388652,0.000010687087,0.000008875657,0.000035506873],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984588,0.00024155421,0.0007306767,0.000159139,0.00018860289,0.00022123476],"domain_scores_gemma":[0.99840117,0.0009560651,0.00020791765,0.00014434312,0.00022188309,0.00006865524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007132861,0.00011234729,0.0008466549,0.00026196428,0.00008626096,0.000017371456,0.00014849217,0.000096090436,0.000026208289],"category_scores_gemma":[0.0013952415,0.00009069726,0.00006049394,0.00031005297,0.0004439889,0.000091690854,0.000100397185,0.00051497575,7.066318e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01559886,0.003044355,0.18110453,0.0030070262,0.0058240294,0.12844145,0.0068626944,0.00016654353,0.012755688,0.012881431,0.047754984,0.5825584],"study_design_scores_gemma":[0.09311392,0.0024249193,0.6624396,0.0061361836,0.0014009501,0.21010026,0.0047139656,0.0014836948,0.0023281975,0.0077383374,0.007738165,0.00038180358],"about_ca_topic_score_codex":0.00027742243,"about_ca_topic_score_gemma":0.00054946454,"teacher_disagreement_score":0.5821766,"about_ca_system_score_codex":0.00020617116,"about_ca_system_score_gemma":0.0004653252,"threshold_uncertainty_score":0.3698527},"labels":[],"label_agreement":null},{"id":"W4411399412","doi":"10.1016/j.clml.2025.06.009","title":"Incidence and Burden of Lower-Risk Myelodysplastic Syndrome: A Nationwide Population Study","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Micropalaeontological Society; Bristol-Myers Squibb; Bamfield Marine Sciences Centre","keywords":"Medicine; Myelodysplastic syndromes; Incidence (geometry); Internal medicine; Cohort; Anemia; Retrospective cohort study; International Prognostic Scoring System; Population; Pediatrics; Bone marrow","score_opus":0.017983247766018104,"score_gpt":0.34668904013915436,"score_spread":0.32870579237313624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411399412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563974,0.0003541066,0.00026594204,0.00060149,0.00047015972,0.001440418,0.000020777257,0.00013617381,0.001071192],"genre_scores_gemma":[0.9961999,0.00024778518,0.0011038933,0.00024750418,0.00019430455,0.00007626028,0.000036096477,0.000046905403,0.0018473585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954975,0.00054943084,0.0016299834,0.0009645399,0.0008396949,0.0005188245],"domain_scores_gemma":[0.99466544,0.0029650955,0.00048814062,0.0010007132,0.0005096598,0.00037093327],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021796648,0.00037489977,0.0012022336,0.000540794,0.00022170704,0.000054298333,0.0004099655,0.00043900285,0.00007417244],"category_scores_gemma":[0.008862119,0.000339658,0.00025115802,0.0011943873,0.0005040301,0.00022797116,0.0005151185,0.0006020991,0.00007929097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00175234,0.00043393686,0.72796345,0.00023635829,0.00045996328,0.0007217031,0.00018713706,0.000056558205,0.00028712203,0.00041529973,0.00089449005,0.26659164],"study_design_scores_gemma":[0.0066733826,0.0019764926,0.9823706,0.0004650888,0.0005025243,0.0002680271,0.00033540395,0.0058301073,0.00005904744,0.00076873926,0.0004981236,0.00025245233],"about_ca_topic_score_codex":0.0015436701,"about_ca_topic_score_gemma":0.00010930034,"teacher_disagreement_score":0.2663392,"about_ca_system_score_codex":0.0011614733,"about_ca_system_score_gemma":0.0019144547,"threshold_uncertainty_score":0.9999055},"labels":[],"label_agreement":null},{"id":"W4411416518","doi":"10.3390/ijms26125845","title":"Genomic Profile and Clinical Outcomes in Acute Myeloid Leukemia with Monosomal Karyotype","year":2025,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"IDH1; Myeloid leukemia; Internal medicine; Karyotype; Cytogenetics; Oncology; Leukemia; NPM1; Biology; Myeloid; Medicine; Gastroenterology; Mutation; Genetics; Chromosome; Gene","score_opus":0.018625628151688806,"score_gpt":0.36202483477431147,"score_spread":0.3433992066226227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411416518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911719,0.00036700375,0.0006021922,0.0052780057,0.0002666431,0.00013469494,0.0000025936242,0.0000051966567,0.0021717937],"genre_scores_gemma":[0.9890292,0.0003295,0.009190625,0.0009777676,0.000051544066,0.00000238763,0.0000011583875,0.000005671042,0.0004121444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984118,0.00006948436,0.00046955937,0.00020086592,0.0006756548,0.00017263231],"domain_scores_gemma":[0.999172,0.00015071158,0.00016901754,0.000093940944,0.0003166963,0.0000976551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081619073,0.000098699165,0.00028143663,0.0005327837,0.000036209363,0.00007084121,0.00046719017,0.00005995611,0.000022993892],"category_scores_gemma":[0.00020938944,0.000064890315,0.00009151137,0.00027387726,0.00040320784,0.00016907959,0.0001420087,0.00038239558,0.0000050415547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063220924,0.000090085116,0.97619367,0.000006212772,0.00051502505,0.0017379031,0.000058576876,0.00006300016,0.009502793,0.0008693835,0.00020099901,0.010130128],"study_design_scores_gemma":[0.0031625128,0.0008110065,0.98892015,0.00017244343,0.00007398227,0.0007290572,0.00014169145,0.001251175,0.0037207103,0.00051363185,0.00041618923,0.000087443615],"about_ca_topic_score_codex":0.000050878312,"about_ca_topic_score_gemma":0.000016481117,"teacher_disagreement_score":0.012726472,"about_ca_system_score_codex":0.00031011918,"about_ca_system_score_gemma":0.001746247,"threshold_uncertainty_score":0.30977672},"labels":[],"label_agreement":null},{"id":"W4411605405","doi":"10.1016/j.clml.2025.06.010","title":"Identifying Risk Factors and Outcome for CNS Involvement in AML","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Outcome (game theory); Oncology; Intensive care medicine; Internal medicine","score_opus":0.08031903326607367,"score_gpt":0.40762752288969695,"score_spread":0.32730848962362324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411605405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99346304,0.0005276987,0.0011996252,0.0010473263,0.0006493467,0.0015904707,0.000052088097,0.00013506017,0.0013353672],"genre_scores_gemma":[0.99107134,0.000624753,0.0031490878,0.001613994,0.00025967267,0.00018293266,0.00008395903,0.00006301276,0.002951268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99550724,0.0002705461,0.0018501467,0.0010574344,0.00043992896,0.00087470555],"domain_scores_gemma":[0.9953003,0.0029153377,0.0002788477,0.0008466474,0.00019832622,0.0004605757],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024119632,0.0004306733,0.0012419496,0.00053053116,0.00022690032,0.00009754246,0.00039397748,0.00056311744,0.000050696006],"category_scores_gemma":[0.004788584,0.00035973653,0.00046197802,0.0006822981,0.0004603083,0.00017739036,0.00049821544,0.0006858156,0.000050714076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061835913,0.00016102081,0.83530724,0.00031096122,0.00020762502,0.00007532799,0.00017401864,0.00000252226,0.00022786102,0.000930303,0.0032655254,0.15871921],"study_design_scores_gemma":[0.0101009775,0.00035440194,0.9710909,0.0002857057,0.00021879574,0.000010332256,0.0005648133,0.0021744203,0.00075913506,0.0021357974,0.0120046055,0.00030009932],"about_ca_topic_score_codex":0.0009187899,"about_ca_topic_score_gemma":0.00027211418,"teacher_disagreement_score":0.15841912,"about_ca_system_score_codex":0.0028479036,"about_ca_system_score_gemma":0.0017204979,"threshold_uncertainty_score":0.99988544},"labels":[],"label_agreement":null},{"id":"W4411634190","doi":"10.1007/s11912-025-01699-7","title":"Hereditary Hematopoietic Malignancies: Considerations for Optimizing Diagnosis and Management","year":2025,"lang":"en","type":"review","venue":"Current Oncology Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute; National Institutes of Health; QEII Foundation; Health Sciences Centre Foundation","keywords":"Medicine; Intensive care medicine; Oncology","score_opus":0.14151257516494944,"score_gpt":0.4452114182049845,"score_spread":0.303698843040035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411634190","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000049276896,0.9867619,0.00026297095,0.00064798724,0.0019122794,0.006978886,0.00005433167,0.00009576775,0.0032809214],"genre_scores_gemma":[0.0000026071327,0.97921574,0.008907435,0.00015105709,0.0003491636,0.009416612,0.00038202634,0.00005457068,0.0015207739],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968014,0.0001506974,0.0013051723,0.0009498759,0.00026521194,0.0005276549],"domain_scores_gemma":[0.9963141,0.0019339183,0.0005359578,0.00073175994,0.00023377096,0.00025046605],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007568305,0.00048049242,0.0025020433,0.0005312621,0.0002221295,0.000040033265,0.00009151039,0.00046603914,0.00011426391],"category_scores_gemma":[0.0010158641,0.00040571566,0.0005031266,0.00028964874,0.00022585216,0.000054815162,0.00037208814,0.0006394142,0.000012419626],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000061543174,0.00026421002,0.000035320565,0.13419016,0.0005685077,0.0054491167,0.00005526125,4.3044562e-7,5.864994e-8,0.00044511736,0.20987022,0.64911544],"study_design_scores_gemma":[0.0004302513,0.00019036431,0.000004653925,0.034187302,0.0042778994,0.008754668,0.000050752205,0.0000053808362,0.000001554642,0.0005306814,0.9513354,0.00023114971],"about_ca_topic_score_codex":0.0000028166112,"about_ca_topic_score_gemma":0.00000362049,"teacher_disagreement_score":0.74146515,"about_ca_system_score_codex":0.001018648,"about_ca_system_score_gemma":0.0028857575,"threshold_uncertainty_score":0.9998395},"labels":[],"label_agreement":null},{"id":"W4411639581","doi":"10.1182/blood.2025029250","title":"Clinical significance of preleukemic somatic <i>GATA1</i> mutations in children with Down syndrome","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Blood Cancer UK; Fondation ARC pour la Recherche sur le Cancer; University of Oxford; Imperial College Healthcare NHS Trust; Imperial College London; Kay Kendall Leukaemia Fund; University of Cambridge; Birmingham Women's and Children's NHS Foundation Trust; Hospital for Sick Children; National Institute for Health and Care Research; University Hospitals Birmingham NHS Foundation Trust; Middlesex University","keywords":"GATA1; Medicine; Mutation; Down syndrome; Internal medicine; Biology; Anemia; Genetics; Gene; Erythropoiesis","score_opus":0.012319172612852694,"score_gpt":0.3070535380022427,"score_spread":0.29473436538939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411639581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961626,0.00021819783,0.0001740683,0.00041962296,0.000019144065,0.0010490039,0.000019204965,0.00004344008,0.0018947036],"genre_scores_gemma":[0.9952061,0.00005206201,0.003542563,0.00018060004,0.000023814227,0.000097155,0.00004176619,0.000017277898,0.00083864725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985326,0.00009992841,0.0005260644,0.00030757737,0.00027136705,0.0002624872],"domain_scores_gemma":[0.9989463,0.00029492972,0.00009520047,0.00048503798,0.00008618711,0.000092308714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003745982,0.00012439454,0.00044278213,0.00022784647,0.000029662066,0.000008093936,0.00019628346,0.00011164896,0.00003341993],"category_scores_gemma":[0.00030805517,0.00009944404,0.00006941868,0.0007480194,0.00023055369,0.00005810547,0.00006120816,0.00044424008,0.000028677989],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011410751,0.0010046151,0.99501747,0.00019030532,0.000391611,0.00009154192,0.00006876966,0.000023984485,0.0014905374,0.00015404215,0.00027227178,0.001180718],"study_design_scores_gemma":[0.009338654,0.00050618383,0.9851599,0.0004988183,0.00033390583,0.00029890766,0.00006248053,0.00017119526,0.0032928342,0.00019461485,0.000041057017,0.000101484016],"about_ca_topic_score_codex":0.00017681626,"about_ca_topic_score_gemma":0.000027131275,"teacher_disagreement_score":0.00985763,"about_ca_system_score_codex":0.00010582025,"about_ca_system_score_gemma":0.0013404128,"threshold_uncertainty_score":0.40552104},"labels":[],"label_agreement":null},{"id":"W4411689221","doi":"10.1136/jcp-2024-209954","title":"Karyotypic clonal fraction predicts adverse outcome in <i>TP53</i> -mutated myeloid neoplasms: an International <i>TP53</i> investigators Network (iTiN) study","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Internal medicine; Karyotype; Myelodysplastic syndromes; Myeloid; Biology; Oncology; Myeloid leukemia; Proportional hazards model; Allele; Somatic evolution in cancer; Immunology; Medicine; Chromosome; Genetics; Cancer; Bone marrow; Gene","score_opus":0.06236960584833422,"score_gpt":0.4365306258704951,"score_spread":0.3741610200221609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411689221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885997,0.00009597727,0.0005312155,0.0042776545,0.0040436597,0.0006386022,0.00001071559,0.000047831552,0.0017545983],"genre_scores_gemma":[0.98690194,0.00023870038,0.003218219,0.0070362454,0.0020339766,0.000017878754,0.000035012014,0.00003834065,0.00047969236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924294,0.0016448675,0.0038732132,0.0005758552,0.0008665761,0.00061011873],"domain_scores_gemma":[0.9951351,0.0017911397,0.0012000463,0.0005185228,0.0007434167,0.00061172264],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007348148,0.00031962653,0.0015355304,0.0007278233,0.00009345705,0.000028833418,0.00064019155,0.00060169975,0.00015513865],"category_scores_gemma":[0.008233839,0.00026901404,0.00041256365,0.00085604284,0.00043112529,0.0005370826,0.00025683982,0.0036917913,0.00005037363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045803282,0.0019068684,0.9771383,0.000030169515,0.00030254407,0.004657488,0.00015924964,0.0007347956,0.0002824309,0.00009984153,0.004152347,0.0059556826],"study_design_scores_gemma":[0.013613253,0.0036974181,0.9713096,0.00020036998,0.00027203443,0.00094439945,0.0005875827,0.0011880349,0.00004048271,0.0012410256,0.006722525,0.00018325393],"about_ca_topic_score_codex":0.000039992938,"about_ca_topic_score_gemma":0.00010582742,"teacher_disagreement_score":0.009032925,"about_ca_system_score_codex":0.00046952334,"about_ca_system_score_gemma":0.0017749773,"threshold_uncertainty_score":0.9999762},"labels":[],"label_agreement":null},{"id":"W4411701092","doi":"10.3324/haematol.2025.288157","title":"Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Erythropoietin; Myelodysplastic syndromes; Medicine; Oncology; Internal medicine; Bone marrow","score_opus":0.042568391868135026,"score_gpt":0.3386231535157654,"score_spread":0.29605476164763034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411701092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96805835,0.0015279291,0.0038878398,0.013190757,0.00034747686,0.0012753848,0.000014198167,0.00027796664,0.011420118],"genre_scores_gemma":[0.99063516,0.0011062288,0.003804226,0.0011678997,0.0000684505,0.00013441729,0.000015752357,0.000043689197,0.0030241713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971466,0.00023589893,0.0006269011,0.00071724656,0.0004750743,0.0007982644],"domain_scores_gemma":[0.99794453,0.0008908132,0.00016012088,0.0006973077,0.00011523854,0.00019196873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053386355,0.0003794121,0.00095856545,0.00050354464,0.00018040447,0.00004901865,0.00032061365,0.00037331035,0.0006690035],"category_scores_gemma":[0.0008536537,0.00029256777,0.0001954684,0.0010221893,0.00025264543,0.00007668344,0.00023360732,0.001076998,0.00032360345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071186656,0.0028972111,0.74801856,0.0027078234,0.0013478892,0.02501325,0.0022865192,0.005388657,0.007742477,0.010403084,0.09631721,0.09075866],"study_design_scores_gemma":[0.046886068,0.006313176,0.6083579,0.0096309725,0.0009455155,0.004611123,0.0049969926,0.15471986,0.009512036,0.014823147,0.1356765,0.0035266725],"about_ca_topic_score_codex":0.00010739009,"about_ca_topic_score_gemma":0.000027423566,"teacher_disagreement_score":0.14933121,"about_ca_system_score_codex":0.00048790485,"about_ca_system_score_gemma":0.0002652173,"threshold_uncertainty_score":0.9999527},"labels":[],"label_agreement":null},{"id":"W4412031768","doi":"10.3390/curroncol32070386","title":"Correction: Niscola et al. Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies. Curr. Oncol. 2024, 31, 6632–6658","year":2025,"lang":"en","type":"erratum","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Bioinformatics; Oncology; Cancer research; Internal medicine; Biology","score_opus":0.04983342821662765,"score_gpt":0.38303825255014873,"score_spread":0.33320482433352105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412031768","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07143782,0.06854049,0.0014018134,0.044893514,0.6258042,0.020141616,0.0025448324,0.0011751916,0.16406053],"genre_scores_gemma":[0.001550948,0.07951904,0.0020342888,0.05219838,0.013683848,0.0032828948,0.045524746,0.00046840974,0.8017374],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99202377,0.00091859116,0.0017672237,0.0025385947,0.0011533523,0.00159849],"domain_scores_gemma":[0.994907,0.0011066034,0.0006008654,0.0014083714,0.0008841829,0.001092962],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.00056744483,0.0013799154,0.0030985621,0.0017781159,0.00020807047,0.00010576615,0.0012530158,0.0027793548,0.0023892648],"category_scores_gemma":[0.0013547996,0.0011447233,0.0005636243,0.0022859871,0.0003847803,0.00021652349,0.0012783805,0.00944093,0.0008157503],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0016364745,0.0012012172,0.0036017513,0.00009917816,0.00064908806,0.0003276673,0.0016199551,0.0000067686115,0.00012016573,0.000032789027,0.920864,0.06984098],"study_design_scores_gemma":[0.0093680145,0.002814163,0.025155488,0.001790305,0.0003203334,0.000021661603,0.00028036084,0.00037166296,0.00005664381,0.00025311075,0.9586178,0.00095044484],"about_ca_topic_score_codex":0.0014980858,"about_ca_topic_score_gemma":0.0014428261,"teacher_disagreement_score":0.6376769,"about_ca_system_score_codex":0.017930312,"about_ca_system_score_gemma":0.023101574,"threshold_uncertainty_score":0.9999622},"labels":[],"label_agreement":null},{"id":"W4412178544","doi":"10.3324/haematol.2025.287777","title":"Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Toronto; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"Astellas Pharma; Alexion Pharmaceuticals; Amgen","keywords":"Myeloid leukemia; Medicine; Internal medicine; Oncology","score_opus":0.019669385114657715,"score_gpt":0.2956154064342636,"score_spread":0.2759460213196059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412178544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993105,0.000011517203,0.00019506947,0.00029188488,0.000111952264,0.00482874,0.00005913927,0.00006358815,0.0013331217],"genre_scores_gemma":[0.99775624,0.000038089307,0.0005886671,0.0000793555,0.000020593401,0.00052705605,0.000080539736,0.00001867655,0.0008907672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981104,0.00021875641,0.00051196077,0.00040765852,0.0004458209,0.00030538443],"domain_scores_gemma":[0.99836487,0.0003782356,0.0002686575,0.00063268334,0.00029812122,0.00005744172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040299798,0.000190159,0.0005297616,0.00031478624,0.00015945327,0.000016597678,0.00026247857,0.00012308377,0.000026064237],"category_scores_gemma":[0.00053169037,0.00010965346,0.000079751044,0.0010702622,0.00011654188,0.000090483576,0.00013858851,0.0003805387,0.0000045690267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021872057,0.0006715561,0.99111164,0.00011807507,0.00019854857,0.00001861621,0.0004003849,0.00013933824,0.00006778049,0.0001946533,0.0033675446,0.0015246868],"study_design_scores_gemma":[0.012460475,0.0014421284,0.9824381,0.0002629241,0.0003341084,0.0000026662133,0.00038939685,0.0005443921,0.0017076841,0.00018565268,0.00014453789,0.000087942106],"about_ca_topic_score_codex":0.000843051,"about_ca_topic_score_gemma":0.000723323,"teacher_disagreement_score":0.010273268,"about_ca_system_score_codex":0.00059782784,"about_ca_system_score_gemma":0.0004188434,"threshold_uncertainty_score":0.44715384},"labels":[],"label_agreement":null},{"id":"W4412178557","doi":"10.3324/haematol.2025.288026","title":"&lt;i&gt;CSF3R&lt;/i&gt; mutations and variants in myeloid neoplasms: associated phenotypes, comutations, and survival trends","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Phenotype; Myeloid; Genetics; Biology; Cancer research; Oncology; Medicine; Gene","score_opus":0.018981944478283434,"score_gpt":0.2943129052595669,"score_spread":0.27533096078128344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412178557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9549103,0.0019367293,0.0003747734,0.0066450937,0.0001435037,0.0005109322,0.000073754556,0.00018658247,0.035218373],"genre_scores_gemma":[0.9925602,0.00045067954,0.0014678875,0.00041765376,0.000020504242,0.00009154164,0.00023290774,0.000022885259,0.004735744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781036,0.00031966204,0.0005030578,0.0005323187,0.000326318,0.0005082578],"domain_scores_gemma":[0.99821055,0.00097462995,0.0001436118,0.00030961746,0.00017380579,0.00018780833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006315761,0.00026033132,0.0007343095,0.0006401637,0.00025412635,0.00006685891,0.00014530745,0.000314851,0.00021465348],"category_scores_gemma":[0.0019778505,0.00022669822,0.000057199548,0.0012867773,0.00033732574,0.00012365406,0.00017296313,0.00042679856,0.0000346754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026492334,0.0034491147,0.39762977,0.0014532098,0.0023951072,0.008971016,0.0074174586,0.00012873675,0.034852218,0.33988202,0.076095454,0.12507668],"study_design_scores_gemma":[0.007676958,0.0003241041,0.9686683,0.00033312166,0.0002668123,0.000511954,0.0005176402,0.005807592,0.00027786833,0.0048097256,0.010386618,0.0004193427],"about_ca_topic_score_codex":0.00007691262,"about_ca_topic_score_gemma":0.0008321596,"teacher_disagreement_score":0.5710385,"about_ca_system_score_codex":0.00023595158,"about_ca_system_score_gemma":0.00034522882,"threshold_uncertainty_score":0.9244485},"labels":[],"label_agreement":null},{"id":"W4412308998","doi":"","title":"Severe Toxicity during Chemotherapy Treatment for Pediatric Acute Myeloid Leukemia","year":2018,"lang":"en","type":"article","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Chemotherapy; Toxicity; Medicine; Oncology; Myeloid; Leukemia; Internal medicine","score_opus":0.022253800171281733,"score_gpt":0.31259563982362637,"score_spread":0.2903418396523446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412308998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852151,0.000067627174,0.00075264694,0.0018490674,0.00012077637,0.0014173542,0.00003109929,0.00023487289,0.010311417],"genre_scores_gemma":[0.90562934,0.0009088249,0.010731474,0.0012774926,0.0034930706,0.0002173626,0.00004694452,0.000098351105,0.077597134],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981973,0.000022461834,0.00028269627,0.0005053379,0.00031706615,0.00067510345],"domain_scores_gemma":[0.99875265,0.00009189351,0.00006301373,0.00054276583,0.00023724139,0.0003124419],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015627051,0.00028193998,0.00041260276,0.00019612753,0.00022876104,0.000031605294,0.00016851853,0.00018254873,0.001184341],"category_scores_gemma":[0.000049664,0.00020617909,0.0002123158,0.00034559006,0.00009912419,0.000110801026,0.000058246293,0.00015138715,0.00034822797],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023444224,0.0018680764,0.10866068,0.0011012332,0.0040682917,0.0005060053,0.0045053586,0.000011865151,0.57034826,0.0009445609,0.18171345,0.10282799],"study_design_scores_gemma":[0.03617039,0.006943697,0.07508968,0.00003701315,0.0006581608,0.0007071506,0.00024653497,0.0020378793,0.8360933,0.00023098581,0.0409195,0.00086569664],"about_ca_topic_score_codex":0.00009944471,"about_ca_topic_score_gemma":0.000032059615,"teacher_disagreement_score":0.26574504,"about_ca_system_score_codex":0.002512688,"about_ca_system_score_gemma":0.0007947095,"threshold_uncertainty_score":0.99972874},"labels":[],"label_agreement":null},{"id":"W4412395052","doi":"10.1080/10428194.2025.2529451","title":"Expanding the phenotypic spectrum of DDX41-related myeloid neoplasms: a case of mature plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia with germline DDX41 mutation","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid; Myeloid leukemia; Phenotype; Germline; Mutation; Immunology; Cancer research; Plasmacytoid dendritic cell; Biology; Medicine; Dendritic cell; Gene; Genetics; Immune system","score_opus":0.006061897744530263,"score_gpt":0.24192004138317377,"score_spread":0.23585814363864352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412395052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904179,0.001353297,0.00094601343,0.0006544038,0.00027700304,0.002725347,0.00018000753,0.00030471222,0.0031412991],"genre_scores_gemma":[0.9913138,0.00052266405,0.0012501702,0.00059676316,0.00015914968,0.00030863102,0.00055697956,0.00022355859,0.005068242],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9931344,0.0005103447,0.0019342792,0.0015108719,0.0013878316,0.0015222848],"domain_scores_gemma":[0.994618,0.0012559213,0.0012726962,0.0014663411,0.0008761691,0.00051089603],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001066383,0.0012589522,0.0020002923,0.0011972309,0.0008314184,0.0001970022,0.0006510822,0.0010651615,0.000079732556],"category_scores_gemma":[0.0003889065,0.00089253014,0.00035791076,0.0034578717,0.0013313211,0.0006097998,0.00032075433,0.0008526742,0.00001784748],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.10561658,0.0053093866,0.10212845,0.01672134,0.032030776,0.092778586,0.0560729,0.016161509,0.38536444,0.0137859825,0.015718667,0.15831138],"study_design_scores_gemma":[0.130368,0.006236739,0.10519852,0.0070832763,0.008840277,0.060977176,0.011479946,0.08898447,0.575178,0.0017577145,0.000677405,0.003218449],"about_ca_topic_score_codex":0.0023574415,"about_ca_topic_score_gemma":0.0010246251,"teacher_disagreement_score":0.18981358,"about_ca_system_score_codex":0.013116587,"about_ca_system_score_gemma":0.014327372,"threshold_uncertainty_score":0.9993525},"labels":[],"label_agreement":null},{"id":"W4412588739","doi":"10.1016/bs.acr.2025.06.005","title":"In search of a targetable immune profile for acute myeloid leukemia","year":2025,"lang":"en","type":"book-chapter","venue":"Advances in cancer research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Myeloid leukemia; Immune system; Medicine; Immunology; Biology","score_opus":0.044073575535639634,"score_gpt":0.4284563707356009,"score_spread":0.38438279519996127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412588739","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027561053,0.18065943,0.00016582242,0.002862585,0.0006274241,0.012309406,0.0015308517,0.000067218796,0.7990212],"genre_scores_gemma":[0.0020805565,0.14447612,0.0031531334,0.00011836737,0.00040689294,0.0026932831,0.0002741289,0.0001838557,0.84661365],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.993434,0.00015709513,0.0012383283,0.0012855587,0.002094904,0.001790096],"domain_scores_gemma":[0.99506646,0.0017269247,0.00019008257,0.0012350756,0.0015385911,0.00024283309],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003285063,0.0005350277,0.0017907606,0.0030708492,0.00012821337,0.000031900585,0.0010634513,0.00077041297,0.0012199795],"category_scores_gemma":[0.00059682835,0.0005134453,0.00031119364,0.0011181647,0.0009503104,0.00043687728,0.00081306504,0.0041644536,0.00006599392],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.030778829,0.0011579556,0.0046937075,0.050552662,0.0035798312,0.0035083364,0.0031746102,0.001656098,0.0651007,0.19391787,0.17859398,0.46328542],"study_design_scores_gemma":[0.007571416,0.0012987667,0.00017973882,0.008267749,0.00011837443,0.000023764142,0.0002228391,0.0013172538,0.044529248,0.0154284155,0.9205467,0.00049573],"about_ca_topic_score_codex":0.0020729578,"about_ca_topic_score_gemma":0.001085552,"teacher_disagreement_score":0.7419527,"about_ca_system_score_codex":0.0075318296,"about_ca_system_score_gemma":0.011281425,"threshold_uncertainty_score":0.9997317},"labels":[],"label_agreement":null},{"id":"W4412621220","doi":"10.1182/bloodadvances.2025016399","title":"Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed <i>IDH1</i> -mutated AML","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer; Servier; Jazz Pharmaceuticals; Astellas Pharma; Aptitude Health; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Azacitidine; Placebo; IDH1; Hazard ratio; Oncology; Isocitrate dehydrogenase; Myeloid leukemia; Gastroenterology; Confidence interval; Mutation; Pathology; Biology","score_opus":0.016162170831825116,"score_gpt":0.3119642186254878,"score_spread":0.29580204779366265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412621220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99003756,0.0032894958,0.000026128115,0.0021539915,0.00017643652,0.0023118672,0.00015018717,0.00008195747,0.0017723577],"genre_scores_gemma":[0.99659973,0.00094628736,0.00024267216,0.00051304704,0.00015756195,0.0001886995,0.00014776885,0.000030745945,0.001173475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971645,0.0002870651,0.000805608,0.00063274754,0.000609048,0.0005010284],"domain_scores_gemma":[0.9961923,0.0024247083,0.00021328579,0.0008641296,0.0001899239,0.00011566048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055119407,0.00028539405,0.0007088134,0.00022671958,0.00010745841,0.00003472175,0.00053715025,0.000108144966,0.000048173082],"category_scores_gemma":[0.0015275228,0.00020054234,0.000088937464,0.0010718656,0.00017669471,0.0002031143,0.00025696022,0.0005877403,0.000020632731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026645944,0.005430897,0.8947009,0.00038788197,0.0011987104,0.0041429214,0.009294663,0.0012143113,0.029627038,0.00006684185,0.008152174,0.019137729],"study_design_scores_gemma":[0.1363536,0.0023591677,0.7718292,0.0017259372,0.0007430679,0.0000300248,0.007915751,0.00040516496,0.07524372,0.0002743748,0.0026366883,0.000483337],"about_ca_topic_score_codex":0.0024072148,"about_ca_topic_score_gemma":0.005870012,"teacher_disagreement_score":0.12287171,"about_ca_system_score_codex":0.0001748511,"about_ca_system_score_gemma":0.0004894747,"threshold_uncertainty_score":0.81778795},"labels":[],"label_agreement":null},{"id":"W4412725501","doi":"10.14740/jmc5144","title":"A Heart of Myeloid: Extramedullary Chronic Myelomonocytic Leukemia-2 Presenting as a Myeloid Sarcoma of the Pericardium Causing Recurrent Pericardial Effusions","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid sarcoma; Myeloid leukemia; Pericardiocentesis; Chronic myelomonocytic leukemia; Myeloid; Cardiac tamponade; Pericardial effusion; Biopsy; Trisomy 8; Pericardium; Bone marrow; Pathology; Radiology; Surgery; Internal medicine; Karyotype; Myelodysplastic syndromes","score_opus":0.025067555988100128,"score_gpt":0.3456004155529019,"score_spread":0.32053285956480176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412725501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9736227,0.009874541,0.00023843425,0.013343295,0.00096120744,0.00055969466,0.000012970445,0.00001845701,0.0013687013],"genre_scores_gemma":[0.9955201,0.0018623491,0.0006174595,0.00057316216,0.0010427161,0.000011985442,0.0000032911328,0.00003606878,0.0003328534],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9934663,0.00061902055,0.0016373408,0.0003203105,0.0033324012,0.0006245833],"domain_scores_gemma":[0.99547136,0.0017933443,0.000725879,0.0006709692,0.0007714965,0.00056693004],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002271336,0.00030852124,0.0013647871,0.0005271928,0.00021287141,0.000031938507,0.0006579522,0.00034196756,0.00044825018],"category_scores_gemma":[0.0112148505,0.00020104289,0.0010321736,0.0012342845,0.0010051774,0.00012363588,0.00074824697,0.0020821097,0.000005197917],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012199553,0.0046192724,0.090706214,0.013041822,0.0080039045,0.026222678,0.008393363,0.00092837657,0.26053655,0.0014619528,0.22323003,0.35065627],"study_design_scores_gemma":[0.043084417,0.01364773,0.31975588,0.04511647,0.007845838,0.13632505,0.015097936,0.026310176,0.14337496,0.0010165229,0.24648532,0.0019396854],"about_ca_topic_score_codex":0.00037669012,"about_ca_topic_score_gemma":0.000017355584,"teacher_disagreement_score":0.3487166,"about_ca_system_score_codex":0.0017064657,"about_ca_system_score_gemma":0.014033197,"threshold_uncertainty_score":0.9971141},"labels":[],"label_agreement":null},{"id":"W4412775412","doi":"10.31547/bct-2025-001","title":"Racial Disparity in Myeloablative Hematopoietic Cell Transplantation Outcomes in Patients with Hematological Malignancies Older Than 45 Years","year":2025,"lang":"en","type":"article","venue":"BLOOD CELL THERAPY / The official journal of APBMT","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Hematopoietic cell; Medicine; Hematopoietic stem cell transplantation; Hematologic Neoplasms; Oncology; Haematopoiesis; Transplantation; Internal medicine; Stem cell; Biology; Genetics","score_opus":0.009001925668180873,"score_gpt":0.2588952701815701,"score_spread":0.24989334451338924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412775412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99717957,0.00046321072,0.0002114701,0.000735149,0.00010905319,0.00075670925,0.0000071875493,0.0000103421025,0.000527322],"genre_scores_gemma":[0.9985803,0.0004489152,0.00041276438,0.00031119143,0.00004762336,0.000010762608,0.000006156515,0.000021846203,0.00016045215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977668,0.0003119643,0.0006822549,0.0002134383,0.0006406691,0.00038488564],"domain_scores_gemma":[0.9988909,0.0003302974,0.00029168866,0.00021216062,0.00018737605,0.00008757155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068927754,0.00023649509,0.00069676846,0.00036319578,0.00006982263,0.000034321725,0.00032860026,0.00016953326,0.00004665413],"category_scores_gemma":[0.00004533558,0.00013813975,0.00016636495,0.0005638009,0.00017078183,0.00011697408,0.000031905834,0.000814354,0.000004797294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008553485,0.0037300522,0.9775174,0.00014963909,0.00018236075,0.0005375057,0.0057523716,0.00014844463,0.0019980434,0.00014434748,0.00007377881,0.0012125649],"study_design_scores_gemma":[0.016601374,0.0012014593,0.96572864,0.0003289382,0.000121783865,0.000031129708,0.00064937095,0.000017368615,0.014842791,0.0002698445,0.00005003687,0.00015729143],"about_ca_topic_score_codex":0.00005047777,"about_ca_topic_score_gemma":0.00008606792,"teacher_disagreement_score":0.012844747,"about_ca_system_score_codex":0.00012756209,"about_ca_system_score_gemma":0.0004507989,"threshold_uncertainty_score":0.56331754},"labels":[],"label_agreement":null},{"id":"W4412775653","doi":"10.1002/ccr3.70602","title":"Myelodysplastic Syndrome in a Patient With Cronkhite‐Canada Syndrome","year":2025,"lang":"en","type":"article","venue":"Clinical Case Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Dysgeusia; Anemia; Pediatrics; Immune dysregulation; Etiology; Dermatology; Disease; Internal medicine; Bone marrow","score_opus":0.02001081110556824,"score_gpt":0.33165952323889414,"score_spread":0.3116487121333259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412775653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923915,0.00019921022,0.000054504024,0.0015732746,0.00044068618,0.0008602084,0.0000068327895,0.00005344243,0.0044203405],"genre_scores_gemma":[0.9951931,0.000018714512,0.00037632027,0.0012037095,0.00002790248,0.000078871155,0.000021095439,0.000032179993,0.003048096],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9964005,0.00014661673,0.0015136383,0.00076806557,0.0006013234,0.0005699028],"domain_scores_gemma":[0.9971669,0.0009703573,0.00024168452,0.000951841,0.00019696914,0.000472268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008828271,0.00024879712,0.0008434324,0.00024144838,0.000074338364,0.000022949602,0.00006375381,0.00021452439,0.00017416108],"category_scores_gemma":[0.0024591757,0.0001903087,0.00011987845,0.00082782254,0.00022259263,0.00006176196,0.00016570529,0.0010281609,0.000017985167],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028446128,0.00025639115,0.09757734,0.00016134034,0.0001195807,0.8940253,0.000011821189,0.000025332147,0.000003923122,0.000018619325,0.0046460126,0.0028698696],"study_design_scores_gemma":[0.0015395383,0.0010668878,0.17597426,0.0006268232,0.00012327587,0.81037956,0.00008917735,0.00021189362,0.000018108774,0.000056809862,0.009721355,0.00019232483],"about_ca_topic_score_codex":0.046040606,"about_ca_topic_score_gemma":0.066823356,"teacher_disagreement_score":0.08364577,"about_ca_system_score_codex":0.00090204703,"about_ca_system_score_gemma":0.0059729563,"threshold_uncertainty_score":0.9996623},"labels":[],"label_agreement":null},{"id":"W4412779753","doi":"10.3324/haematol.2025.288227","title":"Recurrence of minimal residual disease in acute myeloid leukemia: a window of opportunity for intervention","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Minimal residual disease; Myeloid leukemia; Medicine; Residual; Window of opportunity; Intervention (counseling); Therapeutic window; Disease; Internal medicine; Oncology; Leukemia; Pediatrics; Computer science; Psychiatry; Algorithm; Pharmacology","score_opus":0.04320646628438361,"score_gpt":0.35392626466955174,"score_spread":0.3107197983851681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412779753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99452496,0.00048532605,0.0006145511,0.0016672038,0.00006782735,0.001107948,0.00011612451,0.000026141106,0.0013899407],"genre_scores_gemma":[0.9964112,0.00016936855,0.0022342182,0.000113096736,0.0000136798635,0.00016438839,0.00009115112,0.0000090719805,0.0007938245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829674,0.00014647843,0.00069098425,0.0003208958,0.0002463902,0.00029850105],"domain_scores_gemma":[0.9985998,0.00035197253,0.0002206708,0.00040394044,0.00026242397,0.00016117585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006746781,0.00015023918,0.000673692,0.00036438974,0.000033489683,0.000005150262,0.00024751836,0.00015809087,0.00008693593],"category_scores_gemma":[0.0022664035,0.0001238836,0.000202103,0.00046746756,0.0002826212,0.0000703396,0.0001846272,0.00028976923,0.0000031515071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06573489,0.004833942,0.68898636,0.023350952,0.0014247478,0.0029622763,0.0015507785,0.000037146325,0.036119275,0.04130353,0.05495026,0.078745835],"study_design_scores_gemma":[0.016771998,0.0030024545,0.85638696,0.0055564772,0.00068108033,0.00013198894,0.0013240164,0.002514426,0.100112684,0.010670037,0.002375342,0.00047256524],"about_ca_topic_score_codex":0.000098635464,"about_ca_topic_score_gemma":0.000027420516,"teacher_disagreement_score":0.16740057,"about_ca_system_score_codex":0.00022813617,"about_ca_system_score_gemma":0.0011993669,"threshold_uncertainty_score":0.5051826},"labels":[],"label_agreement":null},{"id":"W4412824648","doi":"10.1167/iovs.66.11.2","title":"Clinical Manifestations and Ophthalmic Outcomes of Leukemic Retinopathy and Optic Neuropathy in Patients With Acute Leukemia","year":2025,"lang":"en","type":"article","venue":"Investigative Ophthalmology & Visual Science","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Science and Technology Council; National Taiwan University; National Taiwan University Hospital","keywords":"Medicine; Optic neuropathy; Leukemia; Retinopathy; Ophthalmology; Acute leukemia; Dermatology; Internal medicine; Optic nerve","score_opus":0.027127177232230088,"score_gpt":0.37274562884751467,"score_spread":0.3456184516152846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412824648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99769145,0.00004669183,0.0000025098745,0.00044294642,0.00010210301,0.00077152817,0.0000132924115,0.000019962505,0.0009095234],"genre_scores_gemma":[0.99646133,0.000020219659,0.0028892104,0.0002809439,0.000009265401,0.000033822424,0.000008943515,0.000017060214,0.000279224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971865,0.00029884357,0.00065147266,0.00087193673,0.00047207452,0.0005191731],"domain_scores_gemma":[0.9980314,0.00066802086,0.00021248036,0.00034986727,0.00039400047,0.00034426997],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0011425063,0.00026489093,0.0006617007,0.0006426489,0.00018098568,0.000028812188,0.00030496734,0.00014991556,0.000011763217],"category_scores_gemma":[0.0017841022,0.0002047916,0.00004037699,0.0014714224,0.008877199,0.00030310507,0.0004399213,0.0006575633,0.000004744489],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002998419,0.0001504015,0.97817606,0.000050961935,0.00005226065,0.00085994415,0.00034319144,0.0000033197523,0.019507907,0.00025215244,0.000007978568,0.0002959728],"study_design_scores_gemma":[0.0030763464,0.002272718,0.9891941,0.00017023513,0.00008646641,0.0005945501,0.00020741663,0.0006090526,0.0028047655,0.0008255126,0.0000010550415,0.00015777923],"about_ca_topic_score_codex":0.00014466362,"about_ca_topic_score_gemma":0.000002343984,"teacher_disagreement_score":0.016703142,"about_ca_system_score_codex":0.00039248212,"about_ca_system_score_gemma":0.0023250552,"threshold_uncertainty_score":0.9938201},"labels":[],"label_agreement":null},{"id":"W4413100643","doi":"10.1007/s11899-025-00754-1","title":"Allogeneic Transplant for CMML","year":2025,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Hematology; Internal medicine; Oncology; Intensive care medicine","score_opus":0.09515401914913654,"score_gpt":0.4224962066267783,"score_spread":0.32734218747764177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413100643","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000063353923,0.98661435,0.0008896386,0.00008905473,0.0019126046,0.007446067,0.00021898498,0.00027862794,0.0025443295],"genre_scores_gemma":[0.00001948432,0.98839587,0.0006437455,0.00004857144,0.00028401092,0.0035719029,0.0025620433,0.00009707207,0.00437728],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994183,0.00017276281,0.0023674427,0.0016176143,0.0005780633,0.0010811428],"domain_scores_gemma":[0.99606246,0.0006263771,0.0010127099,0.0016300887,0.000299312,0.00036907935],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008483907,0.0009990777,0.005081754,0.0006327694,0.0001579543,0.000040985702,0.00039320203,0.0008902038,0.00022290196],"category_scores_gemma":[0.00082962343,0.000703912,0.0020934853,0.0007032195,0.00014803643,0.00004863843,0.00017190637,0.0009612416,0.00007585715],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026593354,0.00025663842,0.00014167359,0.3063121,0.00038476547,0.005350171,0.000014750041,3.7879886e-8,0.0000011185623,0.0008182345,0.037458416,0.6492355],"study_design_scores_gemma":[0.00039259598,0.00010453421,0.0000021090373,0.09573487,0.0029691097,0.016990097,0.0000025979232,0.0000020217285,0.000025210395,0.00046455875,0.8827888,0.0005235142],"about_ca_topic_score_codex":0.000002849396,"about_ca_topic_score_gemma":0.0000013501466,"teacher_disagreement_score":0.84533036,"about_ca_system_score_codex":0.0004871808,"about_ca_system_score_gemma":0.0040500453,"threshold_uncertainty_score":0.9995412},"labels":[],"label_agreement":null},{"id":"W4413137758","doi":"10.1038/s41388-025-03528-4","title":"Chromosomal abnormalities of mesenchymal stromal cells in hematological malignancies","year":2025,"lang":"en","type":"review","venue":"Oncogene","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba; University of Manitoba","funders":"Mitacs","keywords":"Mesenchymal stem cell; Biology; Stromal cell; Haematopoiesis; Bone marrow; Cancer research; Carcinogenesis; Chromosome instability; Immunology; Stem cell; Cancer; Gene; Genetics; Chromosome","score_opus":0.04787923538777429,"score_gpt":0.3625253241573322,"score_spread":0.3146460887695579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413137758","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021482485,0.98486656,0.000009392448,0.0000533997,0.00018243077,0.0012713103,0.0002998238,0.00004987024,0.011118971],"genre_scores_gemma":[0.00047056828,0.9901774,0.0010631552,0.000039726692,0.00020794204,0.00019782264,0.0002279025,0.00005004119,0.007565439],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963008,0.0003429886,0.0013285874,0.00061956735,0.0006597867,0.00074826606],"domain_scores_gemma":[0.9979756,0.0006235438,0.00032610586,0.00072693423,0.00015508667,0.00019275075],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005678651,0.00057021936,0.003978285,0.0007084539,0.00004102784,0.000017334878,0.0005067257,0.0008012116,0.00055869744],"category_scores_gemma":[0.00030273676,0.00042792477,0.00077401503,0.0009414239,0.00033457455,0.00005970529,0.00045651122,0.0009125256,0.00009523293],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018649115,0.0009513317,0.00031678012,0.30065015,0.00094931904,0.0070940885,0.00023494438,0.0000023739437,0.0012518937,0.0022731395,0.007960359,0.67812914],"study_design_scores_gemma":[0.0014542365,0.00058386294,0.000031397234,0.047150694,0.00096851104,0.0012171428,0.00015880844,0.000008817868,0.0033106392,0.000027392973,0.94454557,0.0005429235],"about_ca_topic_score_codex":0.000093739895,"about_ca_topic_score_gemma":0.000018023953,"teacher_disagreement_score":0.9365852,"about_ca_system_score_codex":0.00063373504,"about_ca_system_score_gemma":0.003825723,"threshold_uncertainty_score":0.99981725},"labels":[],"label_agreement":null},{"id":"W4413344563","doi":"10.1101/2025.08.11.25333294","title":"Detection of clonal hematopoiesis of indeterminate potential via genome or exome sequencing profoundly underestimates disease associations","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Exome sequencing; Disease; Exome; Biology; Genome; Computational biology; Genetics; Indeterminate; Haematopoiesis; Medicine; Gene; Phenotype; Stem cell; Pathology","score_opus":0.03871362383053481,"score_gpt":0.32647000412667815,"score_spread":0.28775638029614337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413344563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97781616,0.00024695465,0.018988574,0.0006438066,0.00027646954,0.0012608184,0.0004427753,0.000099531804,0.00022492184],"genre_scores_gemma":[0.9959071,0.00008723192,0.0020489185,0.000057734676,0.00015238643,0.00014741685,0.00031749727,0.000045056506,0.0012366014],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99696577,0.00023894728,0.0009040628,0.00058013416,0.0008937539,0.00041731878],"domain_scores_gemma":[0.99730015,0.0003199516,0.00065500004,0.0007754072,0.0007081546,0.00024136549],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00079762633,0.00034614536,0.00093514705,0.00070428156,0.00011398327,0.000027449863,0.0003833856,0.0004081576,0.00015142943],"category_scores_gemma":[0.0014886772,0.00030457648,0.00034727246,0.0004883414,0.0002354073,0.00008450631,0.0007106587,0.00090782234,0.00001329315],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042655403,0.001212867,0.12998535,0.034874853,0.003622862,0.00090549025,0.0019129298,0.0067638424,0.81165683,0.0002799316,0.000116569645,0.0044029453],"study_design_scores_gemma":[0.0036731535,0.0005861271,0.7723657,0.0029801899,0.0028519644,0.00010408916,0.00031149882,0.070573926,0.13723972,0.008230652,0.00013909605,0.00094390666],"about_ca_topic_score_codex":0.00042870254,"about_ca_topic_score_gemma":0.000061769795,"teacher_disagreement_score":0.6744171,"about_ca_system_score_codex":0.0014482586,"about_ca_system_score_gemma":0.0030214777,"threshold_uncertainty_score":0.99994063},"labels":[],"label_agreement":null},{"id":"W4413629863","doi":"10.1038/s41408-025-01353-2","title":"Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Refractory (planetary science); Medicine; Single Center; Center (category theory); Internal medicine; Oncology; Chemistry; Biology","score_opus":0.023582005949821728,"score_gpt":0.290717206242874,"score_spread":0.26713520029305227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413629863","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17264907,0.006650538,0.000025812624,0.8048992,0.0013155445,0.0009559934,0.0059411684,0.000081311104,0.0074813687],"genre_scores_gemma":[0.19637622,0.006785009,0.00077633624,0.74890107,0.010971622,0.00037648642,0.010390707,0.00043471524,0.024987828],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99496084,0.00040895073,0.0011852031,0.00083862053,0.0011908974,0.001415483],"domain_scores_gemma":[0.99689186,0.00027459042,0.00047326,0.0007816144,0.0008191913,0.0007594668],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040721844,0.0006324935,0.0015725356,0.004343179,0.00032915294,0.00035157913,0.00074293785,0.0012446061,0.0031140086],"category_scores_gemma":[0.00027696593,0.0006237252,0.0005841301,0.0026206104,0.00013571502,0.00022606672,0.000115286806,0.0078158425,0.00003816673],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00013546711,0.0005547106,0.04341914,0.00013114866,0.007920307,0.00897799,0.00036951658,0.00006773285,0.00015441004,0.000004774428,0.93434656,0.0039182375],"study_design_scores_gemma":[0.018329982,0.000633284,0.045065984,0.0039028607,0.010333746,0.00066314754,0.00014704588,0.0003648054,0.00029226748,0.000113467606,0.9191046,0.0010488114],"about_ca_topic_score_codex":0.23831557,"about_ca_topic_score_gemma":0.31747198,"teacher_disagreement_score":0.07915641,"about_ca_system_score_codex":0.0047596856,"about_ca_system_score_gemma":0.007168121,"threshold_uncertainty_score":0.9996214},"labels":[],"label_agreement":null},{"id":"W4413637702","doi":"10.1182/blood.2025029132","title":"Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health; Cancer Center, University of Colorado; Leukemia and Lymphoma Society; Princess Margaret Cancer Foundation; Rally Foundation; V Foundation for Cancer Research; Elsa U. Pardee Foundation","keywords":"Myeloid leukemia; Oncology; Internal medicine; Metabolome; Medicine; Proportional hazards model; Metabolomics; Biomarker; Chemotherapy regimen; Leukemia; Survival analysis; Chemotherapy; Bioinformatics; Biology; Immunology; Metabolite; Genetics","score_opus":0.015998662678743437,"score_gpt":0.29272969806333893,"score_spread":0.2767310353845955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413637702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898492,0.00024947917,0.000049444112,0.0039633126,0.00013064526,0.00061057846,0.000037519272,0.00010813536,0.005001691],"genre_scores_gemma":[0.98515266,0.0004267952,0.0011415168,0.00087658485,0.00016950356,0.000060633865,0.000014712465,0.0000445947,0.0121130245],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980457,0.00021578284,0.0003549756,0.000492132,0.00037446298,0.0005169399],"domain_scores_gemma":[0.99867755,0.0004959286,0.00004663538,0.0005078802,0.00008446889,0.00018751531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001054583,0.00023901291,0.0005191021,0.00045554695,0.000073432726,0.00003831131,0.00020928726,0.00024803315,0.000096401214],"category_scores_gemma":[0.00040471926,0.0002158401,0.0000722349,0.0006598695,0.00017206285,0.00009331896,0.00015569536,0.00060289126,0.00003221175],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031479966,0.0013586904,0.37307683,0.0005708692,0.0021266907,0.0018706077,0.002498908,0.000010986919,0.5328966,0.00063481816,0.014058366,0.039416716],"study_design_scores_gemma":[0.0366262,0.000696076,0.84275395,0.00034884465,0.00023693226,0.0002378378,0.00026335928,0.00093171373,0.0994703,0.000107635155,0.0180218,0.00030537354],"about_ca_topic_score_codex":0.000097506476,"about_ca_topic_score_gemma":0.00003790032,"teacher_disagreement_score":0.4696771,"about_ca_system_score_codex":0.0004147283,"about_ca_system_score_gemma":0.0014656652,"threshold_uncertainty_score":0.8801704},"labels":[],"label_agreement":null},{"id":"W4413688430","doi":"10.1007/s00277-025-06536-2","title":"Rare germline ETV6 variant associated with thrombocytopenia and acute leukemia","year":2025,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Hospital for Sick Children; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"ETV6; Proband; Germline; Hematology; Myelodysplastic syndromes; Germline mutation; Medicine; Internal medicine; Pancytopenia; Immunology; Biology; Oncology; Mutation; Bone marrow; Genetics; Gene; Chromosomal translocation","score_opus":0.03637632098900727,"score_gpt":0.3535086353302773,"score_spread":0.31713231434127004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413688430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97106284,0.0012400238,0.00022020168,0.0182734,0.000050339575,0.00044486564,0.000032287335,0.000061645005,0.008614384],"genre_scores_gemma":[0.994168,0.00055290747,0.0006195252,0.0028568218,0.000016389407,0.000022983546,0.00006858475,0.000021404645,0.001673409],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985291,0.00010513236,0.0003749892,0.00034338966,0.00021479011,0.0004326479],"domain_scores_gemma":[0.9986787,0.0003375902,0.00013820718,0.00039958695,0.00031895327,0.0001269797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031199408,0.00018727369,0.00093582453,0.0002467842,0.0000710024,0.000010701935,0.00015946016,0.0002541478,0.00012948697],"category_scores_gemma":[0.0004342315,0.00013969399,0.000068256035,0.00044203608,0.00034254589,0.000070891365,0.00016479174,0.0003746482,0.000010633983],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012061985,0.0017338608,0.22611512,0.0030262696,0.01799539,0.022025662,0.0019081146,0.000020297739,0.09522121,0.20063394,0.40739745,0.011860689],"study_design_scores_gemma":[0.029872805,0.0054932614,0.37503177,0.004011432,0.0022090778,0.01078839,0.0007402198,0.003267628,0.54381335,0.010274787,0.013189902,0.0013073714],"about_ca_topic_score_codex":0.00007500525,"about_ca_topic_score_gemma":0.000035906265,"teacher_disagreement_score":0.44859216,"about_ca_system_score_codex":0.000057088822,"about_ca_system_score_gemma":0.00084134465,"threshold_uncertainty_score":0.5696556},"labels":[],"label_agreement":null},{"id":"W4413774258","doi":"10.1016/s2152-2650(25)00791-8","title":"POSTER: MDS-249 Outcomes With Imetelstat by Serum Erythropoietin (sEPO) Levels in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Who Were Treatment Naive or Who Had Prior Treatment With Erythropoiesis-Stimulating Agents (ESAs)","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Erythropoietin; Internal medicine; Erythropoiesis; Oncology; International Prognostic Scoring System; Anemia; Bone marrow","score_opus":0.027181587150734567,"score_gpt":0.3327986468750761,"score_spread":0.30561705972434156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413774258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99005866,0.00036836337,0.00018287476,0.0016083028,0.00038672722,0.005253451,0.000864922,0.00036618073,0.00091054133],"genre_scores_gemma":[0.97578764,0.00059544813,0.0024947962,0.000922809,0.0001454756,0.0005159985,0.0003968824,0.00039563762,0.018745318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98867387,0.0009496744,0.0027498533,0.0030904948,0.002005406,0.0025307108],"domain_scores_gemma":[0.99068743,0.003692905,0.001170824,0.0024405762,0.00075643475,0.0012518533],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00077355135,0.0022326286,0.0044925613,0.00083091675,0.0007878372,0.0003026275,0.00081801636,0.0009551403,0.0004741183],"category_scores_gemma":[0.0008101933,0.0013062544,0.00065886934,0.0018632208,0.0017100397,0.00060722674,0.00048242242,0.0010090262,0.00022103556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.021511491,0.0027493325,0.7854733,0.0002796468,0.003654602,0.002671983,0.00056140224,0.000117858064,0.000009597889,0.0000109287475,0.0017497438,0.18121013],"study_design_scores_gemma":[0.07122095,0.036915362,0.880445,0.0028438007,0.0018703743,0.0001779742,0.0005695198,0.0013173169,0.00026459745,0.000015815669,0.0029966093,0.0013626692],"about_ca_topic_score_codex":0.0017420647,"about_ca_topic_score_gemma":0.0011438061,"teacher_disagreement_score":0.17984746,"about_ca_system_score_codex":0.013514744,"about_ca_system_score_gemma":0.0075075803,"threshold_uncertainty_score":0.9990413},"labels":[],"label_agreement":null},{"id":"W4413780336","doi":"10.1016/s2152-2650(25)00858-4","title":"POSTER: MDS-1497 Primary Analysis of the Randomized, Phase 3 VERONA Study of Venetoclax With Azacitidine Versus Placebo With Azacitidine in Patients With Treatment-Naïve, Intermediate and Higher-Risk Myelodysplastic Syndromes","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus","funders":"","keywords":"Azacitidine; Medicine; Venetoclax; Myelodysplastic syndromes; Placebo; Internal medicine; Oncology; Leukemia; Alternative medicine; Pathology; Chronic lymphocytic leukemia; Bone marrow; Genetics","score_opus":0.01747856256461705,"score_gpt":0.3145682214075111,"score_spread":0.29708965884289407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413780336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438566,0.00021670692,0.000023930099,0.00010158068,0.00017634555,0.0042126887,0.00019327122,0.000050402155,0.0006394061],"genre_scores_gemma":[0.99832904,0.00021926886,0.00023705928,0.000101035344,0.00005066002,0.00030700082,0.00021270463,0.000076871795,0.00046637456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99395305,0.0011230257,0.001958041,0.0011609767,0.0011086316,0.0006962972],"domain_scores_gemma":[0.9915542,0.005156089,0.0010221761,0.0014149694,0.00050235976,0.00035020814],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010787806,0.0007429737,0.0037702236,0.0009841318,0.00014064551,0.00003807177,0.00050513697,0.00030328007,0.000050713017],"category_scores_gemma":[0.00074284844,0.000405046,0.00041583963,0.0028375976,0.0019433758,0.00018936308,0.00034798402,0.00053566654,0.0000036345953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46440297,0.002146148,0.49357265,0.00016122882,0.010315264,0.00019833016,0.00032659626,0.00014345559,0.00001946471,0.00001674912,0.000032610995,0.028664539],"study_design_scores_gemma":[0.3908394,0.012726048,0.5865844,0.00047773749,0.008179186,0.000008728424,0.000183957,0.0006450151,0.00009727237,0.0000046090577,0.000025099565,0.00022858469],"about_ca_topic_score_codex":0.00083513214,"about_ca_topic_score_gemma":0.0006262614,"teacher_disagreement_score":0.09301173,"about_ca_system_score_codex":0.002926362,"about_ca_system_score_gemma":0.0029270553,"threshold_uncertainty_score":0.99984014},"labels":[],"label_agreement":null},{"id":"W4413782934","doi":"10.1016/s2152-2650(25)02033-6","title":"MDS-736: Preliminary Efficacy and Safety Analysis of the MAXILUS Study of Luspatercept (LUSPA) Initiated at the Maximum Approved Dose in Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Internal medicine; Oncology; Bone marrow","score_opus":0.029276367505173533,"score_gpt":0.33116804191809496,"score_spread":0.3018916744129214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413782934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99279934,0.0005810998,0.000099293655,0.00093257317,0.0004525248,0.0036992389,0.00016388409,0.00007868612,0.0011933488],"genre_scores_gemma":[0.9963163,0.0017317057,0.00007265798,0.0003217118,0.00006328741,0.00015237546,0.00007526351,0.00007883653,0.0011878556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9908394,0.0022441319,0.0030707496,0.0015150917,0.0014229896,0.0009076238],"domain_scores_gemma":[0.98916596,0.0066423994,0.0008397825,0.0025638372,0.00042199917,0.00036601478],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034510903,0.00072369585,0.0025798415,0.0009367372,0.00042769933,0.000045753597,0.0012896715,0.0007247957,0.0002780784],"category_scores_gemma":[0.0033981064,0.00045576124,0.0008603477,0.0041713757,0.0016066338,0.0001318267,0.0017058298,0.0012768097,0.000023641936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048435554,0.0066979653,0.5447035,0.00072505884,0.009746689,0.0011345788,0.0042058877,0.0021294574,0.00278246,0.000079433725,0.00080511364,0.37855428],"study_design_scores_gemma":[0.023346681,0.002785269,0.9553492,0.00047579492,0.005587959,0.000093157425,0.0016389667,0.009649641,0.000396697,0.000091837166,0.00021708674,0.0003677279],"about_ca_topic_score_codex":0.0019840433,"about_ca_topic_score_gemma":0.0018138253,"teacher_disagreement_score":0.41064566,"about_ca_system_score_codex":0.0019517953,"about_ca_system_score_gemma":0.0021088314,"threshold_uncertainty_score":0.9997894},"labels":[],"label_agreement":null},{"id":"W4413783988","doi":"10.1016/s2152-2650(25)00369-6","title":"ORAL ABSTRACT: MDS-1497 Primary Analysis of the Randomized, Phase 3 VERONA Study of Venetoclax With Azacitidine Versus Placebo With Azacitidine in Patients With Treatment-Naïve, Intermediate and Higher-Risk Myelodysplastic Syndromes","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus","funders":"","keywords":"Azacitidine; Medicine; Venetoclax; Myelodysplastic syndromes; Placebo; Internal medicine; Oncology; Leukemia; Alternative medicine; Bone marrow; Pathology","score_opus":0.021537512807600735,"score_gpt":0.3250841045744558,"score_spread":0.30354659176685506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413783988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99485356,0.00016982296,0.000021838108,0.00007928319,0.00017251835,0.0038077093,0.00018698353,0.000050337356,0.00065797585],"genre_scores_gemma":[0.9983517,0.00019328507,0.00033343362,0.00007375212,0.000048765425,0.00028839815,0.00021441691,0.00007463176,0.00042164486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99430007,0.00074588065,0.0019913283,0.001128294,0.0011301049,0.0007043192],"domain_scores_gemma":[0.991858,0.004932193,0.001066164,0.001307631,0.000478796,0.00035722952],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011961933,0.00073768804,0.003734955,0.0009108184,0.00014053457,0.000039165774,0.0004895841,0.00031683684,0.00007446038],"category_scores_gemma":[0.0007721822,0.00040463437,0.00040803995,0.002642607,0.0020006741,0.00020450707,0.00028328097,0.00059482374,0.0000041246067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.469139,0.002617015,0.47388074,0.00017416847,0.010244013,0.00024255902,0.00027386102,0.000300476,0.000020703581,0.000020767533,0.000044668195,0.043042045],"study_design_scores_gemma":[0.38338158,0.009268655,0.598246,0.00042098502,0.00738494,0.000006491269,0.00019879654,0.000744535,0.00008158674,0.00000578611,0.000030403115,0.00023023147],"about_ca_topic_score_codex":0.0011406484,"about_ca_topic_score_gemma":0.0008643296,"teacher_disagreement_score":0.12436528,"about_ca_system_score_codex":0.002859857,"about_ca_system_score_gemma":0.0030774446,"threshold_uncertainty_score":0.99984056},"labels":[],"label_agreement":null},{"id":"W4413810049","doi":"10.1016/s2152-2650(25)01688-x","title":"AML-542: GO-First: Real-World Data of Frontline Gemtuzumab Ozogamicin in Intermediate- and Favorable-Risk Patients With AML in a Multicenter Retrospective Chart Review","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; Chart; Real world evidence; Intensive care medicine; Pediatrics; Internal medicine","score_opus":0.02913672146435998,"score_gpt":0.35397922078914945,"score_spread":0.3248424993247895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413810049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99134964,0.0022943392,0.00003940536,0.0012850715,0.00024251975,0.002680505,0.00042185158,0.00006923037,0.0016174504],"genre_scores_gemma":[0.96789914,0.027092373,0.0014220048,0.0015622725,0.00015640447,0.000100741425,0.00065857597,0.00009140044,0.0010170888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931443,0.00066899305,0.0026927404,0.0017812516,0.00078148337,0.0009312362],"domain_scores_gemma":[0.994204,0.0015678019,0.00082646735,0.0025195247,0.00047701434,0.00040520448],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002961833,0.00060475414,0.0026029674,0.0008090782,0.0000825587,0.000034950015,0.0010216864,0.00033852423,0.000080526486],"category_scores_gemma":[0.0052541825,0.00048693118,0.00022047598,0.0019476118,0.0011133044,0.00038499854,0.0014327917,0.0013249406,0.000059139955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045454986,0.00074675237,0.8723869,0.0013470119,0.00025896795,0.00021706262,0.000113165705,0.000002046255,0.0000067927604,0.00006657577,0.0076131904,0.112696044],"study_design_scores_gemma":[0.024653679,0.0009641076,0.9551941,0.011027526,0.00036107883,0.000006411087,0.00008516581,0.004044992,0.00003324207,0.00008194964,0.0031718079,0.00037589663],"about_ca_topic_score_codex":0.004798522,"about_ca_topic_score_gemma":0.016274784,"teacher_disagreement_score":0.11232015,"about_ca_system_score_codex":0.004583383,"about_ca_system_score_gemma":0.0021340088,"threshold_uncertainty_score":0.99975824},"labels":[],"label_agreement":null},{"id":"W4413810836","doi":"10.1016/s2152-2650(25)00817-1","title":"POSTER: MDS-736 Preliminary Efficacy and Safety Analysis of the MAXILUS Study of Luspatercept (LUSPA) Initiated at the Maximum Approved Dose in Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Oncology; Internal medicine; Bone marrow","score_opus":0.028124573699951284,"score_gpt":0.32819388254861914,"score_spread":0.30006930884866784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413810836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99250275,0.0005844059,0.00005520203,0.0010884511,0.0004594507,0.0038173546,0.00019007488,0.000077505836,0.0012248233],"genre_scores_gemma":[0.99658275,0.00151929,0.000049373844,0.00039021752,0.000059950205,0.00013713054,0.00008524723,0.000080848746,0.0010952058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9907797,0.0022861909,0.0031041272,0.0015182919,0.0014012565,0.0009104135],"domain_scores_gemma":[0.98950225,0.0062722554,0.00084957504,0.0025738433,0.00043440124,0.00036767576],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003243377,0.000735988,0.0025708163,0.0009503604,0.00041364605,0.000049926057,0.0012986733,0.00072237576,0.0002528861],"category_scores_gemma":[0.0028924565,0.00046432207,0.00086353894,0.0038378788,0.0015091518,0.00013989255,0.0018302738,0.0012435914,0.000023969003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051903754,0.005994121,0.59958446,0.0006897815,0.0088967895,0.0011459916,0.0043540318,0.0010630634,0.0028864054,0.000046322606,0.0005870787,0.32284817],"study_design_scores_gemma":[0.023829056,0.0032771677,0.9585841,0.0005122051,0.005562139,0.0001240004,0.0014262175,0.005618957,0.00045356216,0.0000687035,0.00016852077,0.00037541543],"about_ca_topic_score_codex":0.0018904683,"about_ca_topic_score_gemma":0.0017512244,"teacher_disagreement_score":0.35899958,"about_ca_system_score_codex":0.0018893532,"about_ca_system_score_gemma":0.0019670266,"threshold_uncertainty_score":0.99978083},"labels":[],"label_agreement":null},{"id":"W4413994539","doi":"10.3324/haematol.2023.283896","title":"CHIP ahoy: charting a decade of discovery in clonal hematopoiesis","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Biology; Disease; Clinical trial; Germline; Bioinformatics; Computational biology; Medicine; Genetics; Internal medicine; Gene","score_opus":0.025414745909700998,"score_gpt":0.32885372574500993,"score_spread":0.30343897983530893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413994539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768099,0.00062729855,0.00028596006,0.003929062,0.000045203433,0.00038734655,0.0000052922364,0.000052997017,0.017856933],"genre_scores_gemma":[0.99638593,0.00007001946,0.0015578463,0.0006084192,0.000020960926,0.000058387057,0.00000894489,0.000010703444,0.0012787639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847907,0.00008322425,0.0004897559,0.00030193786,0.00026314965,0.0003828595],"domain_scores_gemma":[0.99908304,0.00034321062,0.00009862992,0.00034329266,0.000065433516,0.000066376444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041516032,0.00014385863,0.00064656825,0.00033386715,0.0000467362,0.0000144228825,0.0001919365,0.00016152057,0.000120822806],"category_scores_gemma":[0.0010585915,0.000108383174,0.00012153542,0.00069584796,0.00017443052,0.00008921675,0.00020063792,0.0003632005,0.000034242654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002249466,0.0011357259,0.7667637,0.0035889063,0.00034049113,0.0026351337,0.0012273653,0.000016343723,0.058997918,0.14316459,0.013804286,0.0060760602],"study_design_scores_gemma":[0.0071606045,0.00045832386,0.6405855,0.0031301656,0.00016009001,0.0010746992,0.0019681407,0.001726364,0.32611927,0.01201732,0.0050710775,0.0005284733],"about_ca_topic_score_codex":0.00007571725,"about_ca_topic_score_gemma":0.000023344583,"teacher_disagreement_score":0.26712137,"about_ca_system_score_codex":0.00012907684,"about_ca_system_score_gemma":0.00030820974,"threshold_uncertainty_score":0.44197375},"labels":[],"label_agreement":null},{"id":"W4414003098","doi":"10.14740/jh2075","title":"Does Time Matter From Diagnosis to Induction in Acute Myeloid Leukemia?","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Leukemia; Myeloid; Immunology","score_opus":0.01025915146387699,"score_gpt":0.30198603095930543,"score_spread":0.2917268794954284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414003098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.945595,0.00027019434,0.00019069409,0.05192395,0.0005503996,0.00022199642,0.0000060262137,0.000010762853,0.0012309464],"genre_scores_gemma":[0.9829716,0.0004059899,0.0048416364,0.0067157676,0.00032368972,0.000040532577,0.000009069307,0.000030686595,0.004661024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844396,0.000117557895,0.00066897395,0.0002053012,0.00025095325,0.00031325704],"domain_scores_gemma":[0.99890125,0.00031976157,0.00017190276,0.00025510383,0.00019573138,0.00015626711],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034092832,0.00014319943,0.0007109229,0.0008740883,0.00003175893,0.000016740869,0.00022133724,0.00022875593,0.0015310271],"category_scores_gemma":[0.00028579257,0.000088034874,0.0001214981,0.00046586883,0.000063728694,0.00012927646,0.00011790296,0.00074194686,0.0005467846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019729212,0.00028391174,0.64201605,0.0001322386,0.00082805625,0.0032181577,0.000580632,0.000019739997,0.047784906,0.00021582522,0.29384995,0.0090976395],"study_design_scores_gemma":[0.0105068395,0.0010253976,0.61747456,0.0018465666,0.0007140662,0.00480857,0.0006853333,0.00020274133,0.27010003,0.00565035,0.08651391,0.00047166375],"about_ca_topic_score_codex":0.00012178135,"about_ca_topic_score_gemma":0.000026234351,"teacher_disagreement_score":0.22231513,"about_ca_system_score_codex":0.0008558057,"about_ca_system_score_gemma":0.00056842895,"threshold_uncertainty_score":0.9993817},"labels":[],"label_agreement":null},{"id":"W4414051486","doi":"10.1182/bloodadvances.2024015427","title":"The lncRNA <i>ELDR</i> suppresses tumorigenicity of AML by interfering with DNA replication and chromatin accessibility","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut de Readaptation Gingras Lindsay de Montreal; Institute for Research in Immunology and Cancer; McGill University; Université de Montréal; Hôpital Maisonneuve-Rosemont; Montreal Clinical Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Chromatin; DNA replication; Myeloid leukemia; Demethylase; Chromatin immunoprecipitation; Replication factor C; Proliferating cell nuclear antigen; Small interfering RNA; Transcription factor","score_opus":0.006719221263422101,"score_gpt":0.2986539211420436,"score_spread":0.2919346998786215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414051486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98894536,0.006513913,0.00033881326,0.0012099445,0.000029811386,0.00044412288,0.000014213976,0.000041688254,0.0024621102],"genre_scores_gemma":[0.9971241,0.001225845,0.0008117676,0.000091421294,0.00002780949,0.000059763555,0.000009470299,0.000009010042,0.00064084935],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989348,0.000052362517,0.00026898418,0.0003493376,0.00020361727,0.00019088043],"domain_scores_gemma":[0.99871796,0.00032747563,0.000118760145,0.00064847484,0.00013364639,0.00005370451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035084912,0.00011321396,0.00023332727,0.000038513273,0.00013505854,0.000032218948,0.00021405827,0.000034696146,0.0000086154905],"category_scores_gemma":[0.00043543754,0.00006676848,0.000026153397,0.00025712597,0.00030552805,0.0001905252,0.00013192499,0.00017339233,6.8220453e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011740342,0.0003459682,0.23765764,0.0013286048,0.0002875827,0.000009498311,0.0002878616,0.0000042403703,0.6951289,0.00042766056,0.0022846207,0.06106339],"study_design_scores_gemma":[0.0012437351,0.00026017832,0.053462643,0.00026083415,0.00009052836,0.000019783167,0.00028253897,0.0000911931,0.9352606,0.0003291702,0.00861996,0.00007882542],"about_ca_topic_score_codex":0.00006450622,"about_ca_topic_score_gemma":0.0000651937,"teacher_disagreement_score":0.2401317,"about_ca_system_score_codex":0.000040520797,"about_ca_system_score_gemma":0.00013973289,"threshold_uncertainty_score":0.27227396},"labels":[],"label_agreement":null},{"id":"W4414069217","doi":"10.21203/rs.3.rs-7244803/v1","title":"The Impact of Pre-Transplant Extramedullary Disease on the Outcome of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Children- on Behalf of PDWP/EBMT","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Centre Hospitalier Universitaire de Rennes; Centre hospitalier universitaire Sainte-Justine; American University of Beirut; Sahlgrenska Universitetssjukhuset; Univerzita Komenského v Bratislave","keywords":"Myeloid leukemia; Incidence (geometry); Multivariate analysis; Hematopoietic stem cell transplantation; Transplantation; Myeloid; Hematopoietic cell; Leukemia","score_opus":0.03428663285071831,"score_gpt":0.4007014095588614,"score_spread":0.3664147767081431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414069217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98207796,0.0013258023,0.00013433721,0.0011745527,0.00006222054,0.008708173,0.0059758876,0.000024346535,0.0005167059],"genre_scores_gemma":[0.9892392,0.007759184,0.00009555404,0.00003014618,0.00007740297,0.001005926,0.0010914662,0.00007425847,0.0006268197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933021,0.0010741969,0.0013842417,0.0008336565,0.0023627356,0.0010430588],"domain_scores_gemma":[0.99185705,0.004582202,0.0003981701,0.0020074246,0.0008139992,0.00034112408],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0035974388,0.0005484345,0.0011949757,0.001001486,0.00019978572,0.000037484886,0.0014211659,0.0004617178,0.00008048482],"category_scores_gemma":[0.0006503461,0.00031481017,0.0010620042,0.00076212763,0.0007545884,0.000044775516,0.00029824307,0.0027912818,0.0000066220177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.090461165,0.0039817337,0.7816387,0.050190035,0.0052417493,0.0005387021,0.0067163412,0.021807894,0.027140632,0.00336968,0.0041210493,0.004792358],"study_design_scores_gemma":[0.0045744446,0.0030944287,0.9257161,0.008149287,0.00070322875,0.000029472396,0.0003250803,0.0027745287,0.052898575,0.0013285097,0.00001777054,0.00038857333],"about_ca_topic_score_codex":0.0016433792,"about_ca_topic_score_gemma":0.00006716174,"teacher_disagreement_score":0.14407744,"about_ca_system_score_codex":0.0017286034,"about_ca_system_score_gemma":0.005562421,"threshold_uncertainty_score":0.9999304},"labels":[],"label_agreement":null},{"id":"W4414125452","doi":"10.1038/s41375-025-02752-x","title":"Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival","year":2025,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"Cancer Research UK; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Royal Marsden NHS Foundation Trust","keywords":"Androgen receptor; Androgen; Myeloid leukemia; Estrogen receptor; Leukemia; Estrogen; Myeloid; Chemotherapy","score_opus":0.030477353974341974,"score_gpt":0.30333075602871284,"score_spread":0.27285340205437086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414125452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989275,0.00026958372,0.0027630513,0.00066256255,0.00072480045,0.0018980551,0.0012754503,0.00013047791,0.0030010173],"genre_scores_gemma":[0.9760608,0.00015071465,0.008886266,0.00081848446,0.0004895455,0.00022314297,0.00018066072,0.0001275305,0.01306285],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960661,0.00016699028,0.0009003392,0.00097587705,0.00089944265,0.0009912828],"domain_scores_gemma":[0.99674845,0.0010415816,0.0002673845,0.0010825397,0.00050358113,0.00035647204],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008939119,0.0005357582,0.001185518,0.00049297075,0.0002212917,0.000070270726,0.0006737617,0.00055207586,0.0004859435],"category_scores_gemma":[0.0003124217,0.00048796134,0.00040846958,0.0006232009,0.000196378,0.00016290408,0.0002889887,0.00077444676,0.00014339834],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004147045,0.00011552346,0.00049585314,0.0006225362,0.0009516894,0.00009545344,0.00024271493,0.00032350246,0.96769845,0.0014995355,0.012689425,0.011118282],"study_design_scores_gemma":[0.008184885,0.00058667385,0.00032251663,0.0004874516,0.00038989008,0.000019447203,0.00022750146,0.0005891138,0.97217137,0.00033326301,0.01628142,0.0004064971],"about_ca_topic_score_codex":0.00023343644,"about_ca_topic_score_gemma":0.000010587846,"teacher_disagreement_score":0.013214195,"about_ca_system_score_codex":0.0020632222,"about_ca_system_score_gemma":0.0025933778,"threshold_uncertainty_score":0.99975723},"labels":[],"label_agreement":null},{"id":"W4414277141","doi":"10.7759/cureus.92549","title":"Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Myeloid Leukemia: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"Cureus","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hematopoietic stem cell transplantation; Myeloid leukemia; Transplantation; Acute promyelocytic leukemia; Sibling; Stem cell; Meta-analysis; Clinical trial; Hematopoietic cell","score_opus":0.02700431184056558,"score_gpt":0.33973749184614355,"score_spread":0.312733180005578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414277141","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002800153,0.98889816,0.0000520862,0.00010778915,0.00015162499,0.00894458,0.00019054682,0.00006529117,0.0015619458],"genre_scores_gemma":[0.000025554797,0.9919507,0.00018875064,0.000357947,0.000031114443,0.0015551306,0.00042577047,0.00009835249,0.0053666905],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9942909,0.000707449,0.0028124228,0.0007494241,0.00084920385,0.00059062685],"domain_scores_gemma":[0.99615705,0.00089918164,0.0009414503,0.001487419,0.00031369648,0.0002012094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093585404,0.00081940985,0.008563227,0.0005556235,0.000038168313,0.000016954395,0.0007860203,0.00071759045,0.00008135906],"category_scores_gemma":[0.00023892986,0.00057549967,0.0012631553,0.0011409007,0.000087841094,0.00008665606,0.00012240598,0.0010740826,0.000198853],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014810281,0.00009241863,0.000021729002,0.99048895,0.0008639309,0.00046102935,0.00014839144,1.8886485e-7,0.0000030276055,0.00007796014,0.0007182412,0.0071093044],"study_design_scores_gemma":[0.001063123,0.00011753087,0.000009684241,0.97029036,0.022840023,0.000538488,0.000065254746,0.000003488907,0.000026221758,0.0000065145596,0.004615604,0.00042372904],"about_ca_topic_score_codex":0.00006451112,"about_ca_topic_score_gemma":0.000027782316,"teacher_disagreement_score":0.021976091,"about_ca_system_score_codex":0.002087016,"about_ca_system_score_gemma":0.003248829,"threshold_uncertainty_score":0.9996697},"labels":[],"label_agreement":null},{"id":"W4414367183","doi":"10.1371/journal.pone.0332237","title":"Low survival in younger adults with Acute Myeloid Leukemia (AML) in Tanzania linked to high disease burden and socioeconomic factors","year":2025,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Georgetown Hospital","funders":"","keywords":"Myeloid leukemia; Tanzania; Socioeconomic status; Young adult; Leukemia; Disease; Survival analysis; Overall survival","score_opus":0.015121786535704963,"score_gpt":0.24973190893310263,"score_spread":0.23461012239739767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414367183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992343,0.00012354009,0.000012843301,0.005388204,0.000042608233,0.0014806465,0.00007780059,0.00006836295,0.00046296717],"genre_scores_gemma":[0.99553216,0.0002603093,0.0005039215,0.00053705776,0.00015082236,0.00015608441,0.000112539776,0.000054083193,0.0026930426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978411,0.00008969618,0.00040157005,0.0006642859,0.00040006093,0.00060328527],"domain_scores_gemma":[0.99868566,0.00020595163,0.000056739398,0.0004929548,0.000110277506,0.00044841092],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025035514,0.00030458122,0.0007382903,0.00056808867,0.000054228567,0.00004421699,0.00022608989,0.00017200217,0.00012879909],"category_scores_gemma":[0.00019740398,0.0002653599,0.000044193395,0.00044091945,0.00013056873,0.00018556532,0.00020982887,0.0006732753,0.00009419693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017936055,0.0013192967,0.9222227,0.0016693941,0.0016452598,0.0015436973,0.0035130573,0.000115851246,0.04645844,0.0004609681,0.0005078965,0.0026073803],"study_design_scores_gemma":[0.008748276,0.00034783702,0.9836979,0.0015258966,0.00025223746,0.0000019970062,0.0006391495,0.0011956634,0.0030977656,0.00010446853,0.000053527416,0.00033526096],"about_ca_topic_score_codex":0.0020433406,"about_ca_topic_score_gemma":0.00076631334,"teacher_disagreement_score":0.061475217,"about_ca_system_score_codex":0.0020820512,"about_ca_system_score_gemma":0.0012311948,"threshold_uncertainty_score":0.99997985},"labels":[],"label_agreement":null},{"id":"W4414384080","doi":"10.58931/cht.2025.4273","title":"Intensive Versus Non-intensive Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Venetoclax; Myeloid leukemia; Regimen; Clinical trial; Azacitidine; Chemotherapy; Chemotherapy regimen; Drug; Leukemia","score_opus":0.013331096633161755,"score_gpt":0.2816588606524685,"score_spread":0.26832776401930675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414384080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690318,0.00046468372,0.0005372033,0.019322464,0.0012090231,0.0040014554,0.0002477299,0.00009897214,0.005086653],"genre_scores_gemma":[0.9629185,0.00019949581,0.0014765824,0.029532652,0.00012887025,0.0007187873,0.0006488584,0.0001108745,0.004265354],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973023,0.000062421655,0.0004049952,0.00074897823,0.00023863396,0.0012426887],"domain_scores_gemma":[0.9941313,0.0008156543,0.000116469564,0.00078468595,0.003289969,0.0008618962],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013791381,0.00042957347,0.0009423729,0.0007859486,0.00028017903,0.000033162134,0.00038760566,0.00046467237,0.00015814973],"category_scores_gemma":[0.0015402491,0.00035319457,0.00018270288,0.00063151744,0.00044960593,0.00010683548,0.000065830674,0.0006279105,0.00011980395],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017880814,0.00012211903,0.12904696,0.00023556963,0.0040370026,0.0031220692,0.0018567042,0.000010727425,0.00036686283,0.0046692896,0.8239166,0.014735288],"study_design_scores_gemma":[0.24344645,0.013689038,0.2346138,0.0018704876,0.0021305822,0.0007593392,0.010910006,0.0017462635,0.020868849,0.0011163387,0.46583384,0.0030149794],"about_ca_topic_score_codex":0.018067118,"about_ca_topic_score_gemma":0.040766113,"teacher_disagreement_score":0.35808274,"about_ca_system_score_codex":0.00271309,"about_ca_system_score_gemma":0.0077046347,"threshold_uncertainty_score":0.999892},"labels":[],"label_agreement":null},{"id":"W4414384116","doi":"10.58931/cht.2025.4275","title":"Concise Review of Chronic Myelomonocytic Leukemia in Canada in 2025","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Chronic myelomonocytic leukemia; Myeloid leukemia; Incidence (geometry); Myeloproliferative neoplasm; Myelodysplastic syndromes; Leukemia","score_opus":0.012749193287566392,"score_gpt":0.28878351381781786,"score_spread":0.27603432053025145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414384116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5531509,0.29924405,0.00001539935,0.048349746,0.00071406167,0.0034224382,0.00008702392,0.000029148343,0.094987266],"genre_scores_gemma":[0.9782211,0.008061485,0.000052834264,0.01103486,0.000018871553,0.00010664676,0.00004181175,0.000019035017,0.0024433527],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99796516,0.00013064375,0.0006639825,0.0003395617,0.00016226887,0.0007383708],"domain_scores_gemma":[0.99864465,0.00025054207,0.00006915332,0.00054268003,0.0001135232,0.0003794638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003932766,0.00017652576,0.0009320955,0.0007404841,0.000024934443,0.0000023526118,0.00027699867,0.00017311344,0.00076167646],"category_scores_gemma":[0.0007902673,0.0001806797,0.000056114182,0.0011832746,0.000128417,0.000033572243,0.00005106918,0.00060353964,0.000031476877],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00010821255,0.000033195956,0.32567,0.03133077,0.00016393588,0.011151249,0.00013106105,0.000051298448,0.0001431212,0.011630507,0.6020751,0.01751153],"study_design_scores_gemma":[0.018658191,0.00037276445,0.23175143,0.12590837,0.0003600138,0.0017674115,0.00089850987,0.008358246,0.008816477,0.0010443261,0.60057217,0.0014921027],"about_ca_topic_score_codex":0.99385136,"about_ca_topic_score_gemma":0.99968904,"teacher_disagreement_score":0.42507023,"about_ca_system_score_codex":0.03999789,"about_ca_system_score_gemma":0.16725275,"threshold_uncertainty_score":0.96368736},"labels":[],"label_agreement":null},{"id":"W4414423960","doi":"10.1002/pbc.32077","title":"Acute Myeloid Leukemia With <i>KAT6A</i> Deletion in a 7‐Week‐Old","year":2025,"lang":"en","type":"letter","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Myeloid leukemia; Leukemia; Myeloid; MEDLINE; Blood cancer","score_opus":0.012551957204277575,"score_gpt":0.27105279508272523,"score_spread":0.25850083787844763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414423960","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12441972,0.016740564,0.000113661044,0.8386331,0.0014106405,0.004673124,0.00093695003,0.0005859801,0.012486238],"genre_scores_gemma":[0.003768705,0.042685807,0.0016673424,0.8263073,0.03284806,0.002634867,0.0017399455,0.00043734198,0.087910615],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940739,0.00018320655,0.0008857271,0.001578271,0.0016271677,0.0016516827],"domain_scores_gemma":[0.99727815,0.00033783432,0.0003857782,0.0012657816,0.00046116931,0.00027128172],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00039322546,0.0009622585,0.0015736732,0.0016617321,0.00012265511,0.00008945797,0.00069597916,0.0018631951,0.00054230524],"category_scores_gemma":[0.00010904323,0.00080829253,0.00031885854,0.0027414963,0.00015693848,0.00017786346,0.00028725681,0.0076425723,0.0001414938],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060168206,0.00013216335,0.016523816,0.0023833404,0.0007539774,0.0060973493,0.00011647559,0.000020322834,0.00008406139,0.0000053661324,0.97147244,0.0018090142],"study_design_scores_gemma":[0.014130253,0.0009714349,0.0038038648,0.0011731534,0.00918857,0.0005232285,0.000027068605,0.00011516158,0.0005672989,0.00004199908,0.9680276,0.0014303515],"about_ca_topic_score_codex":0.004161971,"about_ca_topic_score_gemma":0.0004248289,"teacher_disagreement_score":0.120651014,"about_ca_system_score_codex":0.002950272,"about_ca_system_score_gemma":0.009196568,"threshold_uncertainty_score":0.9994368},"labels":[],"label_agreement":null},{"id":"W4414498177","doi":"10.1200/jco-25-01694","title":"Ziftomenib in Relapsed or Refractory <i>NPM1</i> -Mutated AML","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; Hôpital Maisonneuve-Rosemont","funders":"Gilead Sciences","keywords":"Refractory (planetary science); Clinical trial; Safety profile; Overall survival; Cancer; Toxicity","score_opus":0.12806434935643887,"score_gpt":0.5223809701529823,"score_spread":0.3943166207965435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414498177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93820846,0.0004292959,0.00009726435,0.03326103,0.0015211622,0.00030179854,0.0000018672397,0.000018766608,0.026160356],"genre_scores_gemma":[0.967113,0.0017314714,0.0044924426,0.01304403,0.0008710593,0.000007280315,0.0000030201593,0.000025503938,0.012712187],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994601,0.0009316854,0.003345658,0.00024897105,0.00046701755,0.0004056719],"domain_scores_gemma":[0.9912604,0.006338189,0.0010614888,0.00031909748,0.0005999359,0.00042087163],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0069387644,0.00015410305,0.0018782456,0.0005958832,0.000031918855,0.000008997756,0.00034419968,0.0007617739,0.0004382947],"category_scores_gemma":[0.019554427,0.000099803554,0.00039105292,0.00078923913,0.00032237815,0.000094788826,0.0001262818,0.0036274593,0.00007528975],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08807817,0.0066774595,0.1171282,0.00019261734,0.0011526215,0.024911996,0.0002567918,0.000032887016,0.0048508677,0.0003892735,0.29801598,0.4583131],"study_design_scores_gemma":[0.042077716,0.018626543,0.20615691,0.00045692557,0.0002796705,0.0006900884,0.00034000634,0.00038627133,0.00040259073,0.0008020866,0.7296308,0.00015034512],"about_ca_topic_score_codex":0.000036283553,"about_ca_topic_score_gemma":0.000088527195,"teacher_disagreement_score":0.45816278,"about_ca_system_score_codex":0.0010695998,"about_ca_system_score_gemma":0.011523293,"threshold_uncertainty_score":0.99867123},"labels":[],"label_agreement":null},{"id":"W4414642437","doi":"10.1182/bloodadvances.2025017244","title":"Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in <i>FLT3</i> -mutated AML","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"RCPA Foundation; Blood Cancer UK; Astellas Pharma; National Cancer Research Institute; Servier; Amgen; Pfizer; Cancer Research UK; Royal College of Pathologists of Australasia","keywords":"Gemtuzumab ozogamicin; Midostaurin; Cytarabine; Myeloid leukemia; Cumulative incidence; Chemotherapy; Induction chemotherapy; Fms-Like Tyrosine Kinase 3; Concomitant","score_opus":0.007209435744216486,"score_gpt":0.28147252130163924,"score_spread":0.27426308555742274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414642437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99339455,0.0035020555,0.000076621116,0.0012685892,0.000024709836,0.00046710842,0.0000040162126,0.00003066936,0.0012316824],"genre_scores_gemma":[0.99496996,0.0028483304,0.0015704242,0.0001640205,0.00001905368,0.000008590994,0.0000119047345,0.000015301966,0.0003924123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990679,0.00004305184,0.0002485678,0.00027950632,0.00015788854,0.00020305418],"domain_scores_gemma":[0.999508,0.00013695653,0.00007456566,0.00016224069,0.00006259208,0.000055598204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018003512,0.00013359933,0.00035465564,0.00022323536,0.000045414687,0.000009760848,0.000054164164,0.00006387933,0.000007444564],"category_scores_gemma":[0.00007339572,0.00010603078,0.000015478345,0.0004904528,0.00022323987,0.00013037778,0.000040384333,0.00024805748,4.1185953e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01785803,0.0014077403,0.47786844,0.0015899205,0.0007255858,0.00019113428,0.0031162528,0.00019994917,0.16828996,0.0013348332,0.00013607217,0.3272821],"study_design_scores_gemma":[0.07084681,0.0022511247,0.6716025,0.002014011,0.0002772385,0.00023036648,0.0022479082,0.00049275305,0.24130307,0.00038772763,0.007964001,0.00038251912],"about_ca_topic_score_codex":0.00009916416,"about_ca_topic_score_gemma":0.000057916797,"teacher_disagreement_score":0.3268996,"about_ca_system_score_codex":0.000058644455,"about_ca_system_score_gemma":0.00014860663,"threshold_uncertainty_score":0.43238097},"labels":[],"label_agreement":null},{"id":"W4414756626","doi":"10.1182/blood.2025030114","title":"In low-risk myelodysplastic syndrome, don’t shoot the <i>STAG2</i>","year":2025,"lang":"en","type":"letter","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Shoot; Bone marrow; Chromosomal translocation; Transplantation; Chromosome abnormality","score_opus":0.008616782781362499,"score_gpt":0.25219025573659154,"score_spread":0.24357347295522905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414756626","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.052664135,0.0016342995,0.000040430696,0.9235246,0.0008961847,0.002312642,0.00032996878,0.00016854335,0.018429188],"genre_scores_gemma":[0.016442843,0.0011716436,0.00024292657,0.8871658,0.0046391063,0.00049656915,0.0005566064,0.00021545537,0.08906907],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99598044,0.00033874813,0.0006470794,0.00085771905,0.0010745133,0.0011014692],"domain_scores_gemma":[0.9966728,0.0013283374,0.00018206034,0.0015530782,0.00013643717,0.00012729976],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005979721,0.00057354406,0.0009731634,0.0006233419,0.00013701066,0.00007518405,0.00088458863,0.0012046805,0.00064132706],"category_scores_gemma":[0.00078806176,0.00039272907,0.000288329,0.0009682212,0.00025913026,0.000072640854,0.0004238199,0.008275332,0.0005837144],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005908846,0.00020711032,0.0023267514,0.0010971834,0.00044811302,0.018448738,0.000077122844,0.000003515796,0.00004348248,0.000010647427,0.977114,0.00016424368],"study_design_scores_gemma":[0.006574074,0.00031029893,0.0032529337,0.0016945305,0.0013345884,0.0018469468,0.00005053366,0.0000545718,0.0003339161,0.00015246964,0.98389196,0.00050319405],"about_ca_topic_score_codex":0.0005162708,"about_ca_topic_score_gemma":0.000067745415,"teacher_disagreement_score":0.070639886,"about_ca_system_score_codex":0.00041193055,"about_ca_system_score_gemma":0.0015356876,"threshold_uncertainty_score":0.9998525},"labels":[],"label_agreement":null},{"id":"W4414756633","doi":"10.1182/blood.2025029483","title":"AML with mutated TP53, therapy-related, with basophilic differentiation, partial CD22, and ring sideroblasts","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Mutation; Basophilic; Chromosome abnormality; Bone marrow; Chromosomal translocation","score_opus":0.008580515217785429,"score_gpt":0.24612998866464728,"score_spread":0.23754947344686184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414756633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948944,0.00056535046,0.0002280857,0.0015893447,0.000023036328,0.0005784315,0.0000033068013,0.0001292852,0.0019887828],"genre_scores_gemma":[0.9978918,0.000148151,0.00033585992,0.00023534145,0.00005003351,0.00005245836,0.00002693414,0.00003411052,0.001225341],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987431,0.0000576649,0.00020878813,0.00035860934,0.00029491298,0.0003369319],"domain_scores_gemma":[0.99927616,0.00008808212,0.000058048056,0.0003111907,0.00013081118,0.00013572296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001168508,0.00019527372,0.0002880835,0.00018076674,0.00012521658,0.000048026388,0.0000813076,0.00010047332,0.00008997603],"category_scores_gemma":[0.000041093765,0.00012818453,0.000028902736,0.0004452987,0.00014248645,0.00008410004,0.000052614763,0.0003356359,0.000014971768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006026127,0.0033600642,0.86182445,0.0007992169,0.0070005753,0.0015433447,0.0032903838,0.00017688026,0.09162523,0.0026654445,0.0011426987,0.020545596],"study_design_scores_gemma":[0.08226767,0.003042915,0.6887787,0.0014847149,0.0013109165,0.00097269757,0.00050271803,0.004230356,0.21494278,0.0004996617,0.0012611,0.0007057557],"about_ca_topic_score_codex":0.00006560586,"about_ca_topic_score_gemma":0.000039318344,"teacher_disagreement_score":0.17304572,"about_ca_system_score_codex":0.000049273836,"about_ca_system_score_gemma":0.0002529073,"threshold_uncertainty_score":0.52272135},"labels":[],"label_agreement":null},{"id":"W4414794257","doi":"10.1080/10428194.2025.2561737","title":"Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; National Center for Advancing Translational Sciences; Astellas Pharma Canada","keywords":"Discontinuation; Midostaurin; Myeloid leukemia; Sorafenib; Hematopoietic cell; Maintenance therapy; Cohort; Transplantation; Persistence (discontinuity)","score_opus":0.0442771537125276,"score_gpt":0.3291058326767186,"score_spread":0.284828678964191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414794257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942091,0.000316255,0.000006297463,0.00019894712,0.000060414375,0.0040437914,0.00013923376,0.000042919353,0.0009830595],"genre_scores_gemma":[0.99651545,0.0013888933,0.00026905845,0.00060184055,0.000033853798,0.000219333,0.00049231277,0.000055824163,0.0004234391],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995303,0.0005612567,0.0010018772,0.0013840104,0.0008991657,0.0008506862],"domain_scores_gemma":[0.99673986,0.00066460535,0.00034752293,0.0015979167,0.0004086417,0.00024143641],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00090287847,0.00071001693,0.0011529366,0.0009764907,0.00023835404,0.00011867317,0.0007315553,0.000224147,0.000014714205],"category_scores_gemma":[0.0001536705,0.00046406587,0.000094611096,0.0025957543,0.0008217028,0.00037229265,0.00035032956,0.0002752871,0.0000024333501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0071928576,0.0013641367,0.9605527,0.00013118213,0.0004900918,0.0005293285,0.008554224,0.000046911595,0.000159397,0.00009846913,0.00015053985,0.020730173],"study_design_scores_gemma":[0.036033027,0.005506384,0.92973405,0.0008808827,0.0002506659,0.00007684161,0.020889107,0.005458215,0.00031844556,0.000046703106,0.00038464848,0.00042100364],"about_ca_topic_score_codex":0.07115503,"about_ca_topic_score_gemma":0.007814961,"teacher_disagreement_score":0.06334007,"about_ca_system_score_codex":0.009617014,"about_ca_system_score_gemma":0.00743712,"threshold_uncertainty_score":0.99978113},"labels":[],"label_agreement":null},{"id":"W4414943619","doi":"10.1101/2025.10.08.679225","title":"DNMT3A-R882 mutations intrinsically drive dysfunctional neutropoiesis from human haematopoietic stem cells","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Cambridge Institute for Medical Research, University of Cambridge; Blood Cancer UK; National Institute for Health and Care Research; Cancer Research UK; Anthony Nolan; Cancer Research UK Cambridge Institute, University of Cambridge; Francis Crick Institute; Wellcome Trust","keywords":"Haematopoiesis; Stem cell; Immune system; Proinflammatory cytokine; Myeloid; Inflammation; Somatic cell; Progenitor cell; Phenotype","score_opus":0.017388917150571944,"score_gpt":0.25607545815970945,"score_spread":0.2386865410091375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414943619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882218,0.0006915388,0.0022924927,0.0022200532,0.0016369497,0.0022805515,0.0016116569,0.0008954132,0.00014951754],"genre_scores_gemma":[0.9888413,0.00021079162,0.007383394,0.0009455419,0.0013314034,0.0006719606,0.000010476995,0.00021130231,0.00039385073],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99423563,0.0003390802,0.0012174527,0.001976577,0.0012318469,0.0009994131],"domain_scores_gemma":[0.9939721,0.0004693176,0.00052487926,0.0025734648,0.0016986493,0.00076155964],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00057922414,0.00097295444,0.001473074,0.0009409737,0.00049021695,0.0003100339,0.0009391554,0.0011589639,0.00056578644],"category_scores_gemma":[0.00022435999,0.0010308753,0.0005049161,0.0010991367,0.0004933165,0.0001767365,0.0014456736,0.0028192378,0.0005735151],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000251248,0.00072645786,0.009142134,0.0014813426,0.0019345778,0.0009351849,0.00006399546,0.00018810149,0.9694421,0.0036378233,0.012185486,0.000011502178],"study_design_scores_gemma":[0.0049613924,0.00033930977,0.14215772,0.002653423,0.0021865414,2.270776e-7,0.0000590453,0.0013106024,0.82869154,0.00004607747,0.015581054,0.0020130905],"about_ca_topic_score_codex":0.00047164698,"about_ca_topic_score_gemma":0.000014807376,"teacher_disagreement_score":0.14075062,"about_ca_system_score_codex":0.0021657012,"about_ca_system_score_gemma":0.004205485,"threshold_uncertainty_score":0.9994813},"labels":[],"label_agreement":null},{"id":"W4414984131","doi":"10.1016/s2352-3026(25)00254-6","title":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Celgene; AbbVie; Bristol-Myers Squibb","keywords":"Venetoclax; Myeloid leukaemia; Refractory (planetary science); Myelodysplastic syndromes; Myeloid leukemia; Myeloid; Clinical trial","score_opus":0.03281879553664856,"score_gpt":0.3313487312351916,"score_spread":0.298529935698543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414984131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914822,0.00018455557,0.00017474871,0.002316971,0.0006454478,0.004236147,0.000080601916,0.00025045633,0.0006288561],"genre_scores_gemma":[0.9937637,0.00012701593,0.00078992994,0.0013699253,0.00018057188,0.00041523157,0.00026881884,0.00010925862,0.002975567],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99490196,0.0007711841,0.0011223656,0.00093965017,0.0007232526,0.0015415653],"domain_scores_gemma":[0.99556834,0.0020010723,0.00041903325,0.0014265254,0.00029698797,0.00028805027],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000684594,0.00062752253,0.0026503138,0.0006508374,0.00022116634,0.00005983642,0.0008402269,0.0005334605,0.00037877346],"category_scores_gemma":[0.0019232497,0.00035987305,0.00013872434,0.0015725343,0.00063484634,0.00020201683,0.00033791419,0.0017431446,0.00021118396],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9486426,0.004130279,0.0044859634,0.0009542775,0.0015509023,0.025499102,0.0015819916,0.00011054521,0.0009988021,0.00026634667,0.009291973,0.0024871824],"study_design_scores_gemma":[0.94187975,0.022176819,0.012514682,0.0022865443,0.0016900451,0.0046325056,0.00058316515,0.0045156586,0.0018061337,0.00022367493,0.006665692,0.0010253577],"about_ca_topic_score_codex":0.00019040094,"about_ca_topic_score_gemma":0.00046333147,"teacher_disagreement_score":0.020866595,"about_ca_system_score_codex":0.0025540483,"about_ca_system_score_gemma":0.0034684364,"threshold_uncertainty_score":0.9998853},"labels":[],"label_agreement":null},{"id":"W4415099256","doi":"10.1002/ccr3.71132","title":"Aseptic Meningitis as First Presentation of Acute Myeloid Leukemia With Normal Cell Blood Count","year":2025,"lang":"en","type":"article","venue":"Clinical Case Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Aseptic meningitis; Cerebrospinal fluid; Myeloid leukemia; Meningitis; Presentation (obstetrics); Myeloid; Aseptic processing; Leukemia","score_opus":0.0217446479252326,"score_gpt":0.35594495377573493,"score_spread":0.3342003058505023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415099256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97189087,0.00021886786,0.00020049064,0.0006846334,0.00023488607,0.00089012005,0.000016895825,0.00007780408,0.025785457],"genre_scores_gemma":[0.98481774,0.00033835074,0.0016766307,0.00037440332,0.00018122078,0.00006732454,0.00010109591,0.00003955193,0.012403669],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99656034,0.000113778086,0.0015336558,0.00066877494,0.0006884937,0.0004349413],"domain_scores_gemma":[0.99676347,0.0008031775,0.0005515195,0.00096387416,0.00055147696,0.00036649118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012229757,0.00024717234,0.00074488664,0.00019747287,0.00013214184,0.00003150696,0.00008510378,0.000293537,0.00032340168],"category_scores_gemma":[0.0009076756,0.00019915622,0.00025957345,0.0005362158,0.0004065615,0.00013732625,0.00017411502,0.00073370355,0.00003759739],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019218858,0.000962576,0.14267485,0.0009197539,0.0016438789,0.82312834,0.0002199214,0.00006118638,0.0022515564,0.00007439595,0.02317877,0.0029628933],"study_design_scores_gemma":[0.02587087,0.011488166,0.08873941,0.0021118955,0.013002592,0.654848,0.0008559005,0.002263626,0.14088343,0.00042994323,0.05823904,0.0012671835],"about_ca_topic_score_codex":0.0005631889,"about_ca_topic_score_gemma":0.000071366056,"teacher_disagreement_score":0.16828038,"about_ca_system_score_codex":0.00032336498,"about_ca_system_score_gemma":0.0027386912,"threshold_uncertainty_score":0.81213546},"labels":[],"label_agreement":null},{"id":"W4415226715","doi":"10.1101/2025.10.13.681683","title":"Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Leonard M. Miller School of Medicine; National Cancer Institute; National Institutes of Health; University of Miami; Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Leukemia and Lymphoma Society of Canada","keywords":"Myeloid leukemia; Demethylase; Chromatin; H3K4me3; Transcription factor; Epigenetics; Myeloid; Leukemia; Blockade","score_opus":0.01890782075679957,"score_gpt":0.27224435658526286,"score_spread":0.25333653582846327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415226715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913261,0.005551681,0.00012702798,0.00064106064,0.00022667475,0.0017724914,0.00010242056,0.00023201831,0.000020520549],"genre_scores_gemma":[0.9949125,0.0018218794,0.002417529,0.00008473978,0.0002961948,0.00033841812,0.000007233454,0.000089499365,0.00003200874],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996749,0.00027720613,0.0006301005,0.0011493551,0.00052298035,0.0006713566],"domain_scores_gemma":[0.99820065,0.00015273863,0.00026790772,0.0007587367,0.00028007574,0.00033986944],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008728333,0.00054620777,0.0008671244,0.00063982815,0.0001611964,0.00020572881,0.00024051269,0.00063898874,0.000016027032],"category_scores_gemma":[0.0005528768,0.0005359645,0.00009891365,0.00049731316,0.00026486066,0.00011919794,0.00048500302,0.0014193999,0.0000064024757],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034508892,0.00028469198,0.3436067,0.0020438666,0.00035653787,0.00026717398,0.00016129328,0.0000040840405,0.6519847,0.0002133269,0.00059872196,0.00013381918],"study_design_scores_gemma":[0.003038744,0.0001577604,0.8901246,0.0025377134,0.00029154058,1.139707e-7,0.000030383453,0.0014235638,0.09961216,0.0000057480324,0.0020615563,0.00071606727],"about_ca_topic_score_codex":0.0003779579,"about_ca_topic_score_gemma":0.00003511832,"teacher_disagreement_score":0.5523725,"about_ca_system_score_codex":0.0006623287,"about_ca_system_score_gemma":0.0008111825,"threshold_uncertainty_score":0.9997092},"labels":[],"label_agreement":null},{"id":"W4415279750","doi":"10.1002/jha2.70137","title":"Uncommon Evolution From Acute Myeloid Leukaemia to <i>JAK2</i> ‐Mutated Myeloproliferative Neoplasm: Evidence of Clonal Persistence and Divergence From <i>TET2</i> / <i>SRSF2</i> ‐Mutated Haematopoietic Progenitors","year":2025,"lang":"en","type":"article","venue":"eJHaem","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome Canada; University Health Network","funders":"","keywords":"Haematopoiesis; Persistence (discontinuity); Divergence (linguistics); Myeloid; Myeloid leukaemia; Progenitor cell; Mutation","score_opus":0.022306823247814994,"score_gpt":0.2984109368507909,"score_spread":0.27610411360297593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415279750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98697287,0.0038334355,0.0022886528,0.0033689667,0.00048130593,0.0018674652,0.00038000982,0.00022385379,0.00058343075],"genre_scores_gemma":[0.9898787,0.0005066428,0.0067857215,0.0011037028,0.00017132003,0.00019942083,0.00022057688,0.000061860956,0.0010720392],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99527425,0.00026724517,0.0010322378,0.0013648787,0.0011948019,0.0008665966],"domain_scores_gemma":[0.99632096,0.0009021609,0.00029791123,0.0009913628,0.0008793014,0.00060830434],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048175984,0.00064205646,0.0012151253,0.00042968028,0.00034937813,0.00008168504,0.0006886514,0.00038027612,0.00013219875],"category_scores_gemma":[0.00079487363,0.0005947176,0.00024267388,0.0020238946,0.0006400783,0.00047328093,0.00079082494,0.00093258475,0.00015165363],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007442358,0.00042003946,0.3013424,0.00056514586,0.0020018045,0.00096818333,0.007699813,0.00022987828,0.6591694,0.0003206761,0.0145508675,0.0052894424],"study_design_scores_gemma":[0.0065988153,0.0015949972,0.12812077,0.005474101,0.0020176203,0.00025878072,0.003862332,0.0065834555,0.84038126,0.0022780786,0.0014834498,0.0013463178],"about_ca_topic_score_codex":0.0029449565,"about_ca_topic_score_gemma":0.0003248442,"teacher_disagreement_score":0.1812119,"about_ca_system_score_codex":0.0011012851,"about_ca_system_score_gemma":0.0016298399,"threshold_uncertainty_score":0.9996504},"labels":[],"label_agreement":null},{"id":"W4415279909","doi":"10.1002/jha2.70163","title":"Standardization of Measurable Residual Disease in Acute Myeloid Leukemia by Flow Cytometry: A Multicenter Study","year":2025,"lang":"en","type":"article","venue":"eJHaem","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Air (Canada)","funders":"Pfizer Foundation; Astellas Pharma; BD; Pfizer","keywords":"Standardization; Myeloid leukemia; Multicenter study; Clinical trial; Disease; Residual; Quality (philosophy); Standard of care","score_opus":0.013543321969545908,"score_gpt":0.31522875968341585,"score_spread":0.30168543771386996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415279909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905782,0.0005456398,0.00405173,0.0011335633,0.00012272659,0.0016693465,0.00019244583,0.000068541085,0.0016378075],"genre_scores_gemma":[0.99358314,0.000094511415,0.0008181431,0.00020671583,0.00004358023,0.000082889186,0.00012065113,0.00003144576,0.0050189476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976245,0.0002102153,0.0004924091,0.0004392669,0.00082489033,0.00040871548],"domain_scores_gemma":[0.9986993,0.00012810367,0.00007907435,0.0005861426,0.00030200605,0.00020533687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007926278,0.00020273545,0.0004968481,0.0006024468,0.000067039895,0.000027912418,0.0002201772,0.00009296076,0.00012812954],"category_scores_gemma":[0.0007487192,0.00018109083,0.00007685521,0.0013949018,0.00009756923,0.00014707675,0.00016685773,0.0004028278,0.000023936554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01117108,0.0020078123,0.8471642,0.0005962545,0.0010623704,0.000824745,0.0027395973,0.0012763453,0.03394339,0.000053380616,0.08939555,0.009765252],"study_design_scores_gemma":[0.048725504,0.0015695891,0.8249353,0.0013399423,0.0012904129,0.0000072812477,0.0040656077,0.029191038,0.068930455,0.00013992077,0.01902979,0.00077516126],"about_ca_topic_score_codex":0.00033711677,"about_ca_topic_score_gemma":0.00008224125,"teacher_disagreement_score":0.07036576,"about_ca_system_score_codex":0.0015674164,"about_ca_system_score_gemma":0.0012548066,"threshold_uncertainty_score":0.738467},"labels":[],"label_agreement":null},{"id":"W4415286785","doi":"10.1182/blood.2024027904","title":"Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Cancer Institute; National Institutes of Health; Incyte; bluebird bio; Jazz Pharmaceuticals; Daiichi Sankyo Europe; U.S. Department of Defense; Sanofi; Pennsylvania Department of Health; Syndax Pharmaceuticals; BeiGene; Swedish Orphan Biovitrum; Children's Hospital of Philadelphia; AstraZeneca; Pfizer; Amgen; Seattle Children's Research Institute","keywords":"MEDLINE; Myeloid leukemia; Consensus conference; Genetic testing; Disease; Disease management","score_opus":0.03217994557747656,"score_gpt":0.33346294873077303,"score_spread":0.3012830031532965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415286785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99293226,0.0002756259,0.000010305829,0.003764399,0.00009852053,0.000313541,0.00006112687,0.000013400313,0.0025308405],"genre_scores_gemma":[0.9900423,0.0056750067,0.0034021726,0.00034784857,0.000053754095,0.000107577194,0.00019669767,0.0000073773977,0.00016725292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993222,0.00003741873,0.00021089388,0.00018397535,0.0001436533,0.00010187247],"domain_scores_gemma":[0.9995363,0.00013007151,0.000037265007,0.00017301833,0.00007536467,0.00004801566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008326041,0.00006401375,0.00012367488,0.00023103452,0.000018510911,0.000008577886,0.00008948623,0.00004033939,0.00010184706],"category_scores_gemma":[0.00007868735,0.00006158154,0.000018815505,0.00020128027,0.000028361328,0.00004030065,0.0001077834,0.000092016715,0.000003737829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057288165,0.0013712815,0.9738688,0.00005619951,0.00013437904,0.00002505389,0.00022779875,3.4284466e-7,0.000035822413,0.00018737823,0.0034743825,0.020561296],"study_design_scores_gemma":[0.0062499368,0.000076872486,0.98955023,0.00011225535,0.0001051041,6.333232e-7,0.0003451743,0.000066548055,0.00063883176,0.00009532903,0.0027049235,0.000054169832],"about_ca_topic_score_codex":0.0002810492,"about_ca_topic_score_gemma":0.000037158337,"teacher_disagreement_score":0.020507127,"about_ca_system_score_codex":0.000060853254,"about_ca_system_score_gemma":0.000041328847,"threshold_uncertainty_score":0.25112224},"labels":[],"label_agreement":null},{"id":"W4415387709","doi":"10.1038/s41598-026-53398-3","title":"LYL1 is critical for adult hematopoietic stem cell-derived B and T lymphopoiesis","year":2025,"lang":"en","type":"preprint","venue":"Scientific Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Medical Research Council; University of Manitoba; National Health and Medical Research Council; CancerCare Manitoba Foundation","keywords":"Lymphopoiesis; Haematopoiesis; Progenitor cell; Conditional gene knockout; Transcription factor; Stem cell; Progenitor; Lineage (genetic); Transplantation","score_opus":0.02443753406008424,"score_gpt":0.3226020121780865,"score_spread":0.29816447811800223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415387709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9100915,0.006427274,0.005631771,0.02415211,0.020063037,0.008834254,0.00041513826,0.00061290874,0.023771983],"genre_scores_gemma":[0.85050595,0.00030645818,0.011679104,0.0016411236,0.0004313876,0.0011663849,0.00048413855,0.00012141709,0.13366406],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9945114,0.00007680351,0.0010714621,0.0023946213,0.001135885,0.0008098217],"domain_scores_gemma":[0.99408567,0.00040969293,0.00030243123,0.0024397396,0.0022375789,0.00052486314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016954171,0.00046671857,0.00096671254,0.0005627359,0.0004571223,0.0005505203,0.00028282902,0.0006029681,0.0001805348],"category_scores_gemma":[0.0012120758,0.00042222053,0.00040159302,0.00042247205,0.0009983428,0.00008210391,0.0012840675,0.00062196073,0.00003068556],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036472594,0.0005607067,0.0025943741,0.022407316,0.00040960475,0.0036548069,0.0051311175,0.0000111846575,0.03511082,0.0006495945,0.9202095,0.008896206],"study_design_scores_gemma":[0.0055180686,0.00046308895,0.0012536559,0.008476806,0.0023797643,0.0058338903,0.006628246,0.011145386,0.7090128,0.05661347,0.18973774,0.0029370682],"about_ca_topic_score_codex":0.000064020955,"about_ca_topic_score_gemma":0.000005727111,"teacher_disagreement_score":0.7304718,"about_ca_system_score_codex":0.0005627413,"about_ca_system_score_gemma":0.003399112,"threshold_uncertainty_score":0.999823},"labels":[],"label_agreement":null},{"id":"W4415442974","doi":"10.1182/bloodadvances.2025017837","title":"Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Hospital for Sick Children; Agricultural Research Institute of Ontario; Children's Hospital of Eastern Ontario","funders":"National Institutes of Health","keywords":"Myeloid leukemia; Minimal residual disease; Down syndrome; Chemotherapy; Disease; Leukemia; Myeloid; Induction chemotherapy","score_opus":0.0054398641858060415,"score_gpt":0.2533660069236029,"score_spread":0.24792614273779684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415442974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696199,0.022854954,0.00007841227,0.0003618655,0.00008152728,0.00073513703,0.00022129524,0.00004177499,0.006005105],"genre_scores_gemma":[0.9882176,0.007180811,0.0034453766,0.00007489032,0.000019485524,0.000068039626,0.000041236883,0.00003548412,0.00091711094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970383,0.00034486983,0.000783535,0.00055209163,0.0007698863,0.0005113302],"domain_scores_gemma":[0.9978374,0.00047007692,0.00035548306,0.00084012083,0.00025152412,0.00024538452],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010495423,0.00028444364,0.00079336896,0.0006044017,0.00007196055,0.000009585971,0.00034374866,0.0001385912,0.00006546312],"category_scores_gemma":[0.0028757346,0.0002527783,0.00019224122,0.0012369911,0.00038163492,0.00020515353,0.00017513259,0.00068303,0.0000097337115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005866925,0.00090389693,0.9445602,0.0023820205,0.0011148961,0.0018021595,0.00016910033,0.004019215,0.02587419,0.0010976105,0.0011796334,0.0110301515],"study_design_scores_gemma":[0.018457625,0.0012060836,0.84694004,0.0023313889,0.002494565,0.000094370174,0.0006626692,0.0006317881,0.11505559,0.008688745,0.0028369962,0.0006001272],"about_ca_topic_score_codex":0.00079053565,"about_ca_topic_score_gemma":0.00012501498,"teacher_disagreement_score":0.09762015,"about_ca_system_score_codex":0.0002929603,"about_ca_system_score_gemma":0.0013896365,"threshold_uncertainty_score":0.99999243},"labels":[],"label_agreement":null},{"id":"W4415464815","doi":"10.1186/s40364-025-00827-6","title":"High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort","year":2025,"lang":"en","type":"article","venue":"Biomarker Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer; Centre Hospitalier Universitaire Sainte-Justine; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; University of Toronto","funders":"Alliance de recherche numérique du Canada; Government of Canada; Génome Québec; Fonds de Recherche du Québec - Santé; Genome Canada","keywords":"Myeloid leukemia; Stem cell; Cohort; Hematopoietic stem cell transplantation; Transplantation; Myeloid; Haematopoiesis","score_opus":0.028648606102229544,"score_gpt":0.3072421065102523,"score_spread":0.2785935004080228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415464815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884258,0.0032996864,0.0001328706,0.0019837278,0.00041651184,0.0020470112,0.0016786278,0.000092122136,0.0019236264],"genre_scores_gemma":[0.98738253,0.006603709,0.00026174317,0.00015785923,0.00029799124,0.00031135365,0.0007973895,0.00007857879,0.0041088695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935879,0.001064697,0.00080120616,0.0013185733,0.0019421327,0.0012854782],"domain_scores_gemma":[0.9945207,0.0032654637,0.00010760558,0.0012922517,0.0003268599,0.00048707175],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034999934,0.0004538864,0.0008086734,0.00067090284,0.0004105622,0.00018437929,0.0010188845,0.000533881,0.00035254308],"category_scores_gemma":[0.00015623063,0.00031130086,0.00014915447,0.0012409393,0.00070977386,0.00019280275,0.00094808347,0.0021003855,0.00010114393],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009706805,0.00027014784,0.60210806,0.00017497911,0.0008614183,0.0009660936,0.0015226477,0.000004984032,0.33436173,0.00007003698,0.021312095,0.028640987],"study_design_scores_gemma":[0.0071230936,0.00023251992,0.8731198,0.0008884671,0.0001997749,0.000007956148,0.0011614918,0.002162167,0.111982055,0.00044093607,0.002403289,0.00027846682],"about_ca_topic_score_codex":0.024705175,"about_ca_topic_score_gemma":0.0015550868,"teacher_disagreement_score":0.2710117,"about_ca_system_score_codex":0.0013691002,"about_ca_system_score_gemma":0.0012229241,"threshold_uncertainty_score":0.9999339},"labels":[],"label_agreement":null},{"id":"W4415496276","doi":"10.1016/j.ijrobp.2025.10.006","title":"Clonal Hematopoiesis of Indeterminate Potential After Radiation Therapy","year":2025,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Vanderbilt Institute for Clinical and Translational Research; National Cancer Institute; National Institutes of Health; Pew Charitable Trusts; Burroughs Wellcome Fund; Vanderbilt University; American Cancer Society","keywords":"Indeterminate; Radiation therapy; Haematopoiesis; Cohort; Radiation injury; Antibody therapy","score_opus":0.014746803215624719,"score_gpt":0.3488302728352282,"score_spread":0.3340834696196035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415496276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762452,0.0013692843,0.012430212,0.006337041,0.0021690845,0.0003231505,0.00005989515,0.000026855076,0.001039256],"genre_scores_gemma":[0.99296516,0.001690901,0.002001661,0.0015289917,0.0014836623,0.000020330528,0.00006806769,0.000023794018,0.00021745426],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978176,0.00026848496,0.0009822986,0.00023178298,0.0004468873,0.00025297832],"domain_scores_gemma":[0.9970197,0.0003786199,0.00093807373,0.00020065626,0.0013519406,0.00011098273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007350164,0.00020372598,0.00059584784,0.00050195353,0.000051650866,0.000023537901,0.00043711992,0.00034264216,0.00019217771],"category_scores_gemma":[0.00036484966,0.00017623311,0.00036309476,0.00031453292,0.00028235343,0.0002776432,0.00009331258,0.0006191252,0.000019854166],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054865396,0.0009902306,0.3294601,0.000047792837,0.0022202532,0.0002110396,0.00060003885,0.00027016609,0.03724853,0.008207461,0.004293188,0.61096466],"study_design_scores_gemma":[0.046101835,0.0048916307,0.623644,0.00046214575,0.0006473919,0.0011871092,0.00030973388,0.010820587,0.14498822,0.047717106,0.11851387,0.0007164066],"about_ca_topic_score_codex":0.000019092844,"about_ca_topic_score_gemma":0.0000013021174,"teacher_disagreement_score":0.61024827,"about_ca_system_score_codex":0.0010157013,"about_ca_system_score_gemma":0.0015559392,"threshold_uncertainty_score":0.7186578},"labels":[],"label_agreement":null},{"id":"W4415534197","doi":"10.1016/j.clml.2025.10.016","title":"What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Spliceosome; Disease; Relevance (law); Clinical significance; MEDLINE; Progressive disease","score_opus":0.062104025553241196,"score_gpt":0.4075722733192606,"score_spread":0.3454682477660194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415534197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97256863,0.001760997,0.00009864417,0.019067341,0.0010320373,0.0020630658,0.000055764154,0.00014212707,0.0032114063],"genre_scores_gemma":[0.97135276,0.0023021307,0.0009612734,0.009074651,0.00062512694,0.00034968354,0.000030619103,0.00007525378,0.015228496],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948322,0.00077761296,0.0016211092,0.0011020022,0.0007820365,0.0008850004],"domain_scores_gemma":[0.98709553,0.009542006,0.00028953174,0.0019971805,0.0005711669,0.0005045856],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015304347,0.00050547946,0.0012819185,0.00034840213,0.00026118086,0.00014851603,0.0008713891,0.0006696377,0.00009703454],"category_scores_gemma":[0.00830144,0.00033945436,0.0006715555,0.00137355,0.0010893634,0.00027387464,0.0005125389,0.00062036567,0.00034309627],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010458404,0.0005604771,0.05999106,0.00017722958,0.0006405074,0.0006219489,0.00070963963,0.0000034493444,0.0009578356,0.0009889405,0.012273402,0.9126171],"study_design_scores_gemma":[0.006922441,0.002684936,0.9108701,0.0013762895,0.00044796334,0.00015956379,0.0011615657,0.0004230203,0.0126314815,0.0009011607,0.06208498,0.00033652224],"about_ca_topic_score_codex":0.00027026745,"about_ca_topic_score_gemma":0.00009319064,"teacher_disagreement_score":0.91228056,"about_ca_system_score_codex":0.0018406895,"about_ca_system_score_gemma":0.006602532,"threshold_uncertainty_score":0.99990577},"labels":[],"label_agreement":null},{"id":"W4415603472","doi":"10.1007/s00277-025-06643-0","title":"Efficacy and safety of venetoclax plus azacitidine based regimens in the treatment of relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Lanzhou University","keywords":"Venetoclax; Azacitidine; Ven; Neutropenia; Myeloid leukemia; Febrile neutropenia; Chemotherapy; Refractory (planetary science); Adverse effect","score_opus":0.13319423914231435,"score_gpt":0.42072568952026357,"score_spread":0.28753145037794925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415603472","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009360061,0.99137443,0.000012123176,0.0012361349,0.000010147307,0.0068345666,0.0002935213,0.000010113346,0.00013536443],"genre_scores_gemma":[0.00035288426,0.99733806,0.00022938149,0.00044690567,0.0000063735447,0.0008137649,0.00022461773,0.000033597535,0.0005544146],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9933802,0.0020831204,0.0029914784,0.00065786496,0.00048033337,0.00040699833],"domain_scores_gemma":[0.9901543,0.005789019,0.0019355008,0.0017057544,0.00029368207,0.000121722864],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0017436248,0.0006462559,0.01988281,0.0011501045,0.00003912489,0.000005335759,0.0003995267,0.0005233377,0.00009826711],"category_scores_gemma":[0.0011897743,0.0003178514,0.0020334516,0.0018849982,0.00043573213,0.000035439865,0.000096708354,0.0004471321,0.0000017629798],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044429788,0.00018222372,0.0000016298676,0.8733783,0.12389525,0.0003004948,0.0001433881,0.0000017099995,0.0000015147994,0.00019834754,0.0004828418,0.0009700489],"study_design_scores_gemma":[0.00242928,0.0018817045,0.0000055569026,0.090034105,0.8930284,0.00058194535,0.000056617395,0.000027875469,0.00006319569,0.000008959771,0.011633321,0.00024909092],"about_ca_topic_score_codex":0.00014915723,"about_ca_topic_score_gemma":0.00003660378,"teacher_disagreement_score":0.78334415,"about_ca_system_score_codex":0.00037837075,"about_ca_system_score_gemma":0.0032749719,"threshold_uncertainty_score":0.99992734},"labels":[],"label_agreement":null},{"id":"W4415669274","doi":"10.1016/j.htct.2025.104548","title":"GERMLINE PREDISPOSITION TO MYELOID MALIGNANCIES: A COMPREHENSIVE ANALYSIS OF CEBPA, DDX41 AND RUNX1","year":2025,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"CEBPA; RUNX1; Germline; Myeloid; Myeloid leukemia; Germline mutation; ETV6; Mutation; Gene","score_opus":0.0140609083902808,"score_gpt":0.2959140025763212,"score_spread":0.28185309418604043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415669274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98797375,0.004091002,0.0032490208,0.0030313462,0.00003938765,0.0006524704,0.000019378704,0.000032936015,0.00091068324],"genre_scores_gemma":[0.98283195,0.013156797,0.00077722495,0.0023448968,0.000011159715,0.00004619284,0.00004110149,0.000012721262,0.00077796314],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99882275,0.0000924227,0.00033250643,0.00036580063,0.00015262864,0.00023386483],"domain_scores_gemma":[0.99922174,0.00016780914,0.000043752803,0.00025526725,0.00016917061,0.00014222901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014048154,0.00016792557,0.000735186,0.00067890086,0.00009306108,0.000008147764,0.000068031775,0.00017878678,0.00019020049],"category_scores_gemma":[0.000008602256,0.00013698173,0.00011925722,0.0009407364,0.0001832042,0.000029404548,0.000029598092,0.00017390646,0.0000026856012],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033135682,0.00039633835,0.0461902,0.00049698487,0.0011761363,0.00006357514,0.0027453396,0.000015035285,0.93327004,0.0017380819,0.00076874864,0.009825977],"study_design_scores_gemma":[0.015039904,0.0019295263,0.3858634,0.00041165928,0.0020029158,0.00022893655,0.002673807,0.003928016,0.57286,0.0003273147,0.014267583,0.00046692637],"about_ca_topic_score_codex":0.00008545671,"about_ca_topic_score_gemma":0.00003445929,"teacher_disagreement_score":0.36041,"about_ca_system_score_codex":0.000027322092,"about_ca_system_score_gemma":0.00008690427,"threshold_uncertainty_score":0.5585953},"labels":[],"label_agreement":null},{"id":"W4415670870","doi":"10.1016/j.htct.2025.104471","title":"DESAFIOS NA ELEGIBILIDADE PARA TRATAMENTO INTENSIVO DA LEUCEMIA MIELOIDE AGUDA NO SISTEMA ÚNICO DE SAÚDE: UM RELATO DE CASO","year":2025,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Palliative care; Intensive care unit; Anamnesis; Nursing care; Neutropenia","score_opus":0.021988625416543024,"score_gpt":0.30900214629967976,"score_spread":0.28701352088313675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415670870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97501534,0.007583007,0.002202629,0.0053051314,0.0001655338,0.0010377934,0.0000064286314,0.00014413403,0.008540027],"genre_scores_gemma":[0.96330565,0.018435473,0.0016926123,0.0083567565,0.00005800752,0.00014268818,0.00002732767,0.00006204425,0.007919457],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972199,0.0003480946,0.0005905806,0.0007165582,0.00027159438,0.0008532741],"domain_scores_gemma":[0.99826044,0.0004307128,0.000078576304,0.00064885896,0.00019639256,0.00038501833],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067478325,0.00040095032,0.00087212,0.00027914607,0.0002633455,0.000045855955,0.00025063008,0.0006300971,0.0005612682],"category_scores_gemma":[0.00009101524,0.00033614587,0.00023178884,0.00040606887,0.0003393098,0.00007734311,0.00004622591,0.0010084303,0.00007347475],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073008533,0.0011313455,0.06383554,0.0012827265,0.00047299222,0.0014575575,0.003384456,0.0000039033343,0.87945193,0.002699836,0.01991843,0.019060435],"study_design_scores_gemma":[0.023047866,0.0018633603,0.01329927,0.0009620342,0.0003325379,0.0043034456,0.0025520993,0.0022561562,0.8407209,0.0008157334,0.10898939,0.0008572301],"about_ca_topic_score_codex":0.0002763839,"about_ca_topic_score_gemma":0.00008286896,"teacher_disagreement_score":0.08907096,"about_ca_system_score_codex":0.00034022282,"about_ca_system_score_gemma":0.00083513494,"threshold_uncertainty_score":0.99990904},"labels":[],"label_agreement":null},{"id":"W4415718638","doi":"10.14740/jh2090","title":"Acute Undifferentiated Leukemia Presented With Mediastinal Sarcoma","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Bone marrow; Myeloid leukemia; Myeloid sarcoma; Leukemia; Lineage (genetic); Myeloid; Biopsy","score_opus":0.012992265420541162,"score_gpt":0.3127231261612648,"score_spread":0.29973086074072364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415718638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805119,0.0007404992,0.0055516865,0.010006745,0.0002789899,0.00024234164,0.0000029915086,0.000030326786,0.0026344897],"genre_scores_gemma":[0.9931601,0.00014700908,0.0038661796,0.00045667254,0.0001052042,0.0000056290855,0.000009276295,0.000023147271,0.0022267366],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99827546,0.00012149289,0.00059876865,0.00017377314,0.0004312359,0.00039928494],"domain_scores_gemma":[0.9983484,0.000279945,0.00030422345,0.00027171648,0.0005792999,0.0002164083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002537511,0.00017650626,0.0007831924,0.00063828187,0.00006160297,0.000016365413,0.00027093964,0.00016912622,0.00025098736],"category_scores_gemma":[0.00027307533,0.00011367223,0.00013666973,0.00051686657,0.00022865267,0.00008848588,0.000097864606,0.0009003115,0.000023214881],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035230853,0.0014039029,0.46607694,0.0013808375,0.012948152,0.049482286,0.00063988555,0.0000350179,0.07645687,0.016900448,0.33229008,0.007154731],"study_design_scores_gemma":[0.089442484,0.011734192,0.24673901,0.0049885474,0.0064222845,0.32248676,0.0019258147,0.0057187346,0.26680094,0.00663738,0.036036134,0.0010676897],"about_ca_topic_score_codex":0.00001079502,"about_ca_topic_score_gemma":0.000010394232,"teacher_disagreement_score":0.29625395,"about_ca_system_score_codex":0.00041466218,"about_ca_system_score_gemma":0.0017824412,"threshold_uncertainty_score":0.4635419},"labels":[],"label_agreement":null},{"id":"W4415721649","doi":"10.3390/curroncol32110605","title":"Unveiling the Genetic Mosaic of Pediatric AML: Insights from Southwest China","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Chongqing Medical University","keywords":"Fusion gene; Hematology; Gene; Mutation; Myeloid leukemia; Bone marrow; Pathogenicity; Lymphoblastic Leukemia; Risk stratification","score_opus":0.05149077347123861,"score_gpt":0.3805363495659782,"score_spread":0.3290455760947396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415721649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775742,0.016047077,0.0004808626,0.0013734567,0.0011278811,0.00048852747,0.000022628768,0.000039361028,0.0028459623],"genre_scores_gemma":[0.99656826,0.0016134549,0.0004108113,0.00015066528,0.00081732124,0.00004641567,0.00006831093,0.000016121488,0.0003086548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985782,0.00019683101,0.00039772686,0.00030772458,0.00023512323,0.00028442751],"domain_scores_gemma":[0.9987054,0.00045789708,0.00012284011,0.00048279925,0.00013363257,0.00009747051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014974696,0.00014977802,0.0004051085,0.00024260268,0.00009218549,0.00000763892,0.00031263242,0.00015504198,0.00016321977],"category_scores_gemma":[0.00030945064,0.00009894282,0.00010978615,0.00062668475,0.00020239795,0.000022988368,0.00021836399,0.0006570325,0.00011083244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008859464,0.00209317,0.6301349,0.00083095365,0.0005688687,0.00017343451,0.006254448,0.00013788184,0.006849481,0.002121169,0.087008424,0.26294136],"study_design_scores_gemma":[0.005031297,0.0005976803,0.7830828,0.0001063381,0.00073924183,0.000015609206,0.00059880083,0.0035182096,0.0014017536,0.0022368098,0.20247054,0.00020092064],"about_ca_topic_score_codex":0.00019291858,"about_ca_topic_score_gemma":0.000054900112,"teacher_disagreement_score":0.26274043,"about_ca_system_score_codex":0.00034251407,"about_ca_system_score_gemma":0.0012509782,"threshold_uncertainty_score":0.4034771},"labels":[],"label_agreement":null},{"id":"W4415734869","doi":"10.1182/bloodadvances.2025017745","title":"Decitabine-cedazuridine in patients with MDS and <i>TP53</i> mutations","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Oncology; University of Texas MD Anderson Cancer Center; Genentech; Sierra Oncology; Daiichi Sankyo Europe; Gilead Sciences; Servier; Celldex Therapeutics; Daiichi-Sankyo; Pfizer; Incyte; CTI Biopharma; Agios Pharmaceuticals; Alexion Pharmaceuticals; Apellis Pharmaceuticals; Celgene; BioCryst; Syndax Pharmaceuticals; Acceleron; Astex Pharmaceuticals; Ipsen; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Karyopharm Therapeutics; Ipsen Biopharmaceuticals; Bristol-Myers Squibb; AstraZeneca; Astellas Pharma; Amgen","keywords":"Propensity score matching; Parenteral nutrition; Hypomethylating agent; Myelodysplastic syndromes; Cohort; Overall survival; Retrospective cohort study","score_opus":0.0039205917959274925,"score_gpt":0.262517802524773,"score_spread":0.2585972107288455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415734869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99059904,0.0016419032,0.000082101324,0.0010593153,0.000032964832,0.00041406832,0.000010318539,0.00003333475,0.006126958],"genre_scores_gemma":[0.9953645,0.00020617511,0.003066232,0.00036173288,0.000024713643,0.000047057903,0.000035836103,0.000011542004,0.00088224583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918485,0.000020082916,0.000156421,0.00023148452,0.0001942794,0.00021289622],"domain_scores_gemma":[0.9995111,0.00011249572,0.000028687626,0.0001685816,0.00010735237,0.00007176262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000778544,0.00010532255,0.00019680183,0.00020174238,0.000052200703,0.000012069797,0.0000618436,0.000036039437,0.000015980566],"category_scores_gemma":[0.00015339661,0.00007863783,0.000015509797,0.00051061466,0.00010459352,0.00016306514,0.00004487798,0.00016481763,0.000004983838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030293365,0.00033337952,0.9863967,0.00011006869,0.000049627364,0.000030543753,0.000080040925,0.000021501755,0.0002957631,0.00046550142,0.00019621829,0.011717729],"study_design_scores_gemma":[0.014332954,0.0005975661,0.96448064,0.00033963393,0.00013475637,0.000009951262,0.00018806562,0.000067005654,0.004052226,0.00053771306,0.0150989,0.0001605901],"about_ca_topic_score_codex":0.00002011855,"about_ca_topic_score_gemma":0.000060441504,"teacher_disagreement_score":0.021916054,"about_ca_system_score_codex":0.000045218603,"about_ca_system_score_gemma":0.00015678644,"threshold_uncertainty_score":0.32067576},"labels":[],"label_agreement":null},{"id":"W4415755659","doi":"10.7554/elife.109131.1","title":"Monocyte-endothelial interactions as a targetable node in clonal hematopoiesis-mediated cardiovascular disease","year":2025,"lang":"","type":"preprint","venue":"eLife","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"In silico; Haematopoiesis; Disease; Endothelial stem cell; Monocyte; Chemokine; Druggability; Gene","score_opus":0.026379499100958475,"score_gpt":0.31665672543771034,"score_spread":0.29027722633675185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415755659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60790217,0.17389365,0.014937323,0.030617652,0.023649322,0.025977736,0.013931119,0.0016950289,0.10739598],"genre_scores_gemma":[0.84233874,0.043602575,0.0042994823,0.0054348395,0.007331764,0.0054234266,0.0053785704,0.0005623928,0.08562823],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.9873447,0.0013166191,0.002377109,0.0029788387,0.0036533398,0.002329399],"domain_scores_gemma":[0.9907963,0.0013368941,0.00042339857,0.004264793,0.0010964613,0.00208211],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00274522,0.0015517451,0.0033710902,0.002164303,0.00043958143,0.00026895615,0.0016176188,0.0009518886,0.0035834352],"category_scores_gemma":[0.007089121,0.0016450081,0.0027992562,0.0018386426,0.00053468667,0.00039667706,0.003389042,0.006906031,0.005228575],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06739335,0.0196621,0.14456795,0.039518114,0.110914074,0.058823682,0.01690366,0.26424447,0.007563339,0.005314005,0.23634394,0.028751329],"study_design_scores_gemma":[0.020423448,0.00020700056,0.015839236,0.00868919,0.004963445,0.00021154656,0.0018325399,0.086382255,0.0067584277,0.0006069041,0.85125303,0.002832976],"about_ca_topic_score_codex":0.007984892,"about_ca_topic_score_gemma":0.00011985235,"teacher_disagreement_score":0.6149091,"about_ca_system_score_codex":0.005422859,"about_ca_system_score_gemma":0.016540308,"threshold_uncertainty_score":0.9997231},"labels":[],"label_agreement":null},{"id":"W4415755707","doi":"10.7554/elife.109131","title":"Monocyte-endothelial interactions as a targetable node in clonal hematopoiesis-mediated cardiovascular disease","year":2025,"lang":"","type":"preprint","venue":"eLife","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"In silico; Haematopoiesis; Disease; Endothelial stem cell; Monocyte; Chemokine; Druggability; Gene","score_opus":0.026379499100958475,"score_gpt":0.31665672543771034,"score_spread":0.29027722633675185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415755707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60790217,0.17389365,0.014937323,0.030617652,0.023649322,0.025977736,0.013931119,0.0016950289,0.10739598],"genre_scores_gemma":[0.84233874,0.043602575,0.0042994823,0.0054348395,0.007331764,0.0054234266,0.0053785704,0.0005623928,0.08562823],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.9873447,0.0013166191,0.002377109,0.0029788387,0.0036533398,0.002329399],"domain_scores_gemma":[0.9907963,0.0013368941,0.00042339857,0.004264793,0.0010964613,0.00208211],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00274522,0.0015517451,0.0033710902,0.002164303,0.00043958143,0.00026895615,0.0016176188,0.0009518886,0.0035834352],"category_scores_gemma":[0.007089121,0.0016450081,0.0027992562,0.0018386426,0.00053468667,0.00039667706,0.003389042,0.006906031,0.005228575],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06739335,0.0196621,0.14456795,0.039518114,0.110914074,0.058823682,0.01690366,0.26424447,0.007563339,0.005314005,0.23634394,0.028751329],"study_design_scores_gemma":[0.020423448,0.00020700056,0.015839236,0.00868919,0.004963445,0.00021154656,0.0018325399,0.086382255,0.0067584277,0.0006069041,0.85125303,0.002832976],"about_ca_topic_score_codex":0.007984892,"about_ca_topic_score_gemma":0.00011985235,"teacher_disagreement_score":0.6149091,"about_ca_system_score_codex":0.005422859,"about_ca_system_score_gemma":0.016540308,"threshold_uncertainty_score":0.9997231},"labels":[],"label_agreement":null},{"id":"W4415833999","doi":"10.1016/j.clml.2025.10.027","title":"Proposed Modifications to Prognostic Classification of AML Patients Treated With Intensive Chemotherapy Based on Recent Real-World Data","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chemotherapy; Prognostic model; Overall survival; Risk assessment; MEDLINE","score_opus":0.08273501749831795,"score_gpt":0.3906585236187967,"score_spread":0.30792350612047875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415833999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767342,0.000014629138,0.00066661957,0.01016871,0.00012653504,0.003881746,0.00018233221,0.00020486431,0.008020328],"genre_scores_gemma":[0.9870289,0.00016514289,0.003940142,0.0047541074,0.00011501866,0.00019901709,0.0018753192,0.00008663315,0.0018357099],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9953757,0.00037436266,0.0014615242,0.001391331,0.0008226614,0.00057440763],"domain_scores_gemma":[0.991642,0.0015632269,0.000497613,0.0032039445,0.0026094888,0.0004837541],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008708709,0.00042505737,0.0010217597,0.00069047604,0.00014242315,0.000043797998,0.00092486985,0.0002542321,0.0000672055],"category_scores_gemma":[0.0049872007,0.00032600667,0.00014681068,0.0027433143,0.000681673,0.0001163737,0.00021519662,0.00043664846,0.000117565614],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01025013,0.0015841412,0.4270824,0.00013424916,0.00029354703,0.000027255372,0.000049629896,0.000026613001,0.0010236348,0.0005007645,0.019860242,0.5391674],"study_design_scores_gemma":[0.009166062,0.0023644061,0.9548058,0.0007218695,0.00025343645,0.0000020778814,0.00007643584,0.020395981,0.0026848384,0.00002950342,0.009223559,0.00027601008],"about_ca_topic_score_codex":0.00032784409,"about_ca_topic_score_gemma":0.00014300144,"teacher_disagreement_score":0.5388914,"about_ca_system_score_codex":0.0026711843,"about_ca_system_score_gemma":0.005029707,"threshold_uncertainty_score":0.9999192},"labels":[],"label_agreement":null},{"id":"W4415941564","doi":"10.1016/j.annonc.2025.08.1210","title":"CN136 Disease perceptions of adult patients with acute myeloid leukemia (AML) during diagnosis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Myeloid leukemia; Disease; Leukemia; Myeloid; MEDLINE","score_opus":0.020883960256373037,"score_gpt":0.3491355264644909,"score_spread":0.3282515662081179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98756135,0.00010186419,0.000037062397,0.006657011,0.00006907503,0.00061159406,0.00013632917,0.000032250726,0.0047934977],"genre_scores_gemma":[0.9948474,0.0014779083,0.0005485605,0.0013487951,0.000053520376,0.00016435998,0.00010442305,0.000023583398,0.0014314522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833614,0.00010422022,0.0004604657,0.00032951756,0.00035906813,0.00041057589],"domain_scores_gemma":[0.9976787,0.0002317569,0.00017821528,0.0004996551,0.001146143,0.0002655484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012899503,0.00018015108,0.0006000121,0.00040631156,0.00008307507,0.0000045714187,0.00022583055,0.00016163867,0.0003086355],"category_scores_gemma":[0.00044387483,0.00014615712,0.00016092989,0.00052309706,0.00040139395,0.00010368395,0.00017507187,0.00032414732,0.000026036661],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005118001,0.0012312202,0.9492062,0.0005379158,0.0008326498,0.00016509586,0.00036555773,0.000030449935,0.002388829,0.00037259003,0.019976443,0.019775093],"study_design_scores_gemma":[0.0051566777,0.0019275969,0.98145,0.0003199633,0.00028528494,0.0000058525407,0.00019892873,0.00003627408,0.006966607,0.000104858555,0.0034223676,0.0001255389],"about_ca_topic_score_codex":0.00018968737,"about_ca_topic_score_gemma":0.00005490467,"teacher_disagreement_score":0.032243893,"about_ca_system_score_codex":0.00038186062,"about_ca_system_score_gemma":0.0017107282,"threshold_uncertainty_score":0.59601146},"labels":[],"label_agreement":null},{"id":"W4415949216","doi":"10.1080/10428194.2025.2577861","title":"Real-world experience and outcomes of decitabine/cedazuridine or azacitidine for the treatment of myelodysplastic syndrome/chronic myelomonocytic leukemia","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Azacitidine; Myelodysplastic syndromes; Chronic myelomonocytic leukemia; Leukemia; Disease; Clinical trial","score_opus":0.02106423577910986,"score_gpt":0.31566702946963227,"score_spread":0.2946027936905224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415949216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98884,0.0048989193,0.0006619535,0.0005087894,0.00042602155,0.0029935562,0.00017217637,0.00016219092,0.0013364371],"genre_scores_gemma":[0.97019494,0.014321893,0.0016601273,0.00028829588,0.00018744616,0.0010432727,0.00008406103,0.00014416395,0.01207582],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9943143,0.00015480437,0.0018528698,0.0014238642,0.00085028127,0.0014038723],"domain_scores_gemma":[0.9924792,0.004196575,0.00060675055,0.001693126,0.00047472055,0.0005495954],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054706994,0.0011455448,0.0025603191,0.001042582,0.00055361533,0.00009862096,0.00069412525,0.00048743785,0.000100629346],"category_scores_gemma":[0.000604668,0.0007458936,0.0005492789,0.0017697223,0.0017565701,0.0003075201,0.00035231348,0.00018280603,0.000009415808],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02544689,0.0017883643,0.12793107,0.00857731,0.008144763,0.0016976057,0.0076370286,0.0007239107,0.042535823,0.016520098,0.0055300123,0.7534671],"study_design_scores_gemma":[0.083276466,0.008077459,0.73661375,0.002125312,0.0035243058,0.0020785185,0.002889903,0.052757267,0.07327435,0.00071294984,0.033021756,0.0016479746],"about_ca_topic_score_codex":0.0050196894,"about_ca_topic_score_gemma":0.0006369041,"teacher_disagreement_score":0.75181913,"about_ca_system_score_codex":0.02350501,"about_ca_system_score_gemma":0.014637511,"threshold_uncertainty_score":0.9994992},"labels":[],"label_agreement":null},{"id":"W4415952024","doi":"10.3324/haematol.2025.288743","title":"&lt;i&gt;IDH2&lt;/i&gt; mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Sun Pharma; MorphoSys; Astellas Pharma; Sierra Oncology; Incyte; Swedish Orphan Biovitrum; Daiichi Sankyo Europe; Oregon Health and Science University; Gilead Sciences; Amgen; Pfizer; Syndax Pharmaceuticals; Foghorn Therapeutics","keywords":"NPM1; Myeloid leukemia; Isocitrate dehydrogenase; IDH1; Hypomethylating agent; Azacitidine; Retrospective cohort study; Cohort; Mutation","score_opus":0.01789843076102343,"score_gpt":0.274959400748029,"score_spread":0.25706096998700556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415952024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871018,0.00041921073,0.0023111654,0.0017006426,0.000042788623,0.0034530556,0.000061349536,0.0007793871,0.0041306135],"genre_scores_gemma":[0.98654443,0.00013539997,0.004935741,0.0019755356,0.00003230266,0.00078481756,0.0005522972,0.00015033173,0.004889173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99458545,0.00044429553,0.0009251351,0.0013559633,0.001313766,0.0013753726],"domain_scores_gemma":[0.9956805,0.0011818997,0.0006827873,0.001063595,0.00095844397,0.0004327555],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006542176,0.0009275861,0.0018047097,0.00062436826,0.00056529173,0.00017399948,0.00048055267,0.0006028512,0.00035601057],"category_scores_gemma":[0.000570619,0.00056441745,0.00021696022,0.0029821673,0.00063265563,0.0003369299,0.00008864583,0.0009354111,0.00006194274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019943304,0.0018411297,0.9070859,0.00078877405,0.006136804,0.024039492,0.0032293305,0.0013351218,0.012354463,0.00031283527,0.010350491,0.012582377],"study_design_scores_gemma":[0.090206034,0.007830335,0.81407225,0.005418674,0.0018732224,0.00062961516,0.0012117758,0.018717181,0.056699257,0.000051235238,0.0012507632,0.0020396286],"about_ca_topic_score_codex":0.0003124087,"about_ca_topic_score_gemma":0.00048041166,"teacher_disagreement_score":0.0930136,"about_ca_system_score_codex":0.0015289899,"about_ca_system_score_gemma":0.001452784,"threshold_uncertainty_score":0.99968076},"labels":[],"label_agreement":null},{"id":"W4415965748","doi":"10.34197/ats-scholar.2025-0039ot","title":"Management of Leukostasis in Acute Myeloid Leukemia","year":2025,"lang":"en","type":"article","venue":"ATS Scholar","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System","funders":"","keywords":"Leukostasis; Myeloid leukemia; Leukemia; Myeloid; Myelopoiesis","score_opus":0.016780294991177665,"score_gpt":0.32043089568538413,"score_spread":0.30365060069420646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415965748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9458419,0.0008262535,0.00012540667,0.0016861226,0.000093101014,0.0005760288,0.000008573651,0.000047515965,0.050795067],"genre_scores_gemma":[0.97717065,0.0014374241,0.006930057,0.0006668125,0.000024735622,0.00005005665,0.000026358133,0.000023825818,0.013670075],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99839115,0.00007384097,0.0003879076,0.0003506984,0.00040589558,0.00039051875],"domain_scores_gemma":[0.99903,0.00005417254,0.000053030064,0.0006458896,0.00011401221,0.000102929465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007077574,0.00015769078,0.0003674533,0.00046214086,0.0000619201,0.000021529155,0.00028910843,0.00013352848,0.00015760773],"category_scores_gemma":[0.00008324386,0.00014607003,0.000101696874,0.001109162,0.00008594559,0.00017148131,0.00028490587,0.0007502046,0.00014006134],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031557875,0.0007771429,0.20146199,0.0033375474,0.0040454953,0.0073255254,0.00094527245,0.00010833468,0.10143425,0.026463455,0.05148855,0.59945667],"study_design_scores_gemma":[0.011125209,0.00031322023,0.7637113,0.0017389613,0.00057917705,0.000054959775,0.0012682482,0.00052230374,0.11935496,0.0013539066,0.099592924,0.00038485875],"about_ca_topic_score_codex":0.00015025485,"about_ca_topic_score_gemma":0.0000095004125,"teacher_disagreement_score":0.5990718,"about_ca_system_score_codex":0.0011786039,"about_ca_system_score_gemma":0.00043375936,"threshold_uncertainty_score":0.5956563},"labels":[],"label_agreement":null},{"id":"W4415966614","doi":"10.7759/cureus.96237","title":"Infantile Acute Myeloid Leukemia Presenting As Intussusception: A Case Report and Review of the Literature","year":2025,"lang":"en","type":"article","venue":"Cureus","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Intussusception (medical disorder); Myeloid leukemia; Laparotomy; Presentation (obstetrics); Myeloid; Bowel resection; Surgical resection; Leukemia","score_opus":0.011806826370577917,"score_gpt":0.32746005694438607,"score_spread":0.3156532305738082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415966614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86833197,0.08257908,0.000023007702,0.008664638,0.00035198306,0.0015020019,0.000023387765,0.00006616278,0.03845778],"genre_scores_gemma":[0.8720251,0.06491103,0.0010486188,0.0049038935,0.0004219704,0.00012760078,0.00009144568,0.000045341738,0.056425005],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9985897,0.00009175264,0.00044698225,0.0003202688,0.00031356522,0.0002377657],"domain_scores_gemma":[0.99838364,0.00008954698,0.00016583492,0.0008894387,0.00037632693,0.00009518873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005268487,0.0001569976,0.00037896482,0.000077921446,0.00012442167,0.000032805136,0.00017230288,0.00014285189,0.00016468434],"category_scores_gemma":[0.0013397748,0.00010136239,0.00013525005,0.0007824566,0.00016732712,0.00011552515,0.00041743176,0.00056416064,0.0000076238584],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004386525,0.00025135512,0.036651824,0.05775493,0.0020624099,0.25681442,0.0044768807,0.0000017443009,0.028193973,0.003925535,0.5774924,0.031935893],"study_design_scores_gemma":[0.0033768448,0.0002923062,0.017156633,0.061700083,0.0018953154,0.528576,0.0006740913,0.00032803047,0.018489156,0.0010260927,0.36596876,0.00051663694],"about_ca_topic_score_codex":0.00016347453,"about_ca_topic_score_gemma":0.000015019875,"teacher_disagreement_score":0.27176163,"about_ca_system_score_codex":0.00026185883,"about_ca_system_score_gemma":0.0008372495,"threshold_uncertainty_score":0.41334382},"labels":[],"label_agreement":null},{"id":"W4415973831","doi":"10.1016/j.bneo.2025.100182","title":"Single-cell proteogenomic analysis of clonal evolution in PDX models of AML treated with IDH inhibitors","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Servier","keywords":"Somatic evolution in cancer; Myeloid leukemia; Isocitrate dehydrogenase; Drug resistance; Leukemia; Myeloid","score_opus":0.01181312530648026,"score_gpt":0.24337750170542444,"score_spread":0.23156437639894417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415973831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99400914,0.00028770405,0.0004336801,0.00012659017,0.000011280113,0.0007961327,0.00003173517,0.000025387884,0.004278328],"genre_scores_gemma":[0.99776894,0.000015918038,0.0013396702,0.00001949071,0.000018227302,0.00004604647,0.00006408773,0.000019232677,0.00070838927],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983712,0.00008704119,0.0005229262,0.0003427832,0.00038321593,0.0002928564],"domain_scores_gemma":[0.99904674,0.00009080127,0.00017160879,0.0003927289,0.0002166161,0.00008151359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023354043,0.0001773592,0.00067342777,0.0015476628,0.00002425894,0.000005815244,0.00013047346,0.00015693298,0.000029449258],"category_scores_gemma":[0.000048243837,0.00014795846,0.00015337922,0.0031051512,0.00014029106,0.00007579035,0.00005979502,0.0002502961,0.000002623041],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020899542,0.0017123666,0.4003433,0.0004063173,0.0019648261,0.00007501919,0.00033545497,0.005174606,0.58693403,0.00029287208,0.00013778478,0.00053344516],"study_design_scores_gemma":[0.012065133,0.0016027939,0.14781243,0.00051345193,0.005419394,0.000026698557,0.0003726919,0.03696289,0.7948001,0.00014509776,0.000032579574,0.0002467482],"about_ca_topic_score_codex":0.0010001833,"about_ca_topic_score_gemma":0.00036798348,"teacher_disagreement_score":0.25253087,"about_ca_system_score_codex":0.00036047588,"about_ca_system_score_gemma":0.0007222385,"threshold_uncertainty_score":0.6033571},"labels":[],"label_agreement":null},{"id":"W4416166919","doi":"10.3324/haematol.2025.287443","title":"Novel and emerging therapeutic strategies for clonal haematopoiesis","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Epigenetics; Haematopoiesis; Bone marrow; Somatic evolution in cancer; Stem cell; Epigenesis; Leukemia; Hematopoietic stem cell","score_opus":0.04390705616631437,"score_gpt":0.35304966535192706,"score_spread":0.3091426091856127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416166919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8063953,0.0050470633,0.12054185,0.033058457,0.00022849027,0.0022639553,0.00003061787,0.0003981774,0.03203611],"genre_scores_gemma":[0.9845142,0.0001232987,0.011719704,0.0018088031,0.000033396373,0.00018767033,0.000012472562,0.000014751939,0.0015857404],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99893284,0.000023692608,0.00023375866,0.00031370166,0.00014959753,0.00034641128],"domain_scores_gemma":[0.9991742,0.00034697435,0.00004454457,0.00024028472,0.00011857041,0.00007544909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023664201,0.00015679639,0.00043678124,0.00015994132,0.0001805811,0.000054957953,0.00011727071,0.00013663391,0.000082448205],"category_scores_gemma":[0.00015225279,0.000114112896,0.00008774881,0.0002280206,0.00019723474,0.000075384596,0.0000939646,0.00018418302,0.000010052628],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001254904,0.0003310475,0.008915342,0.0022823869,0.00066148053,0.00019277686,0.0006903588,0.0000075413395,0.041514426,0.90522,0.017137261,0.021792501],"study_design_scores_gemma":[0.034429874,0.0030434392,0.16082203,0.002442045,0.0021037466,0.00950096,0.03515897,0.032426164,0.058246713,0.33266768,0.3266552,0.0025031425],"about_ca_topic_score_codex":0.000022827371,"about_ca_topic_score_gemma":0.000008802752,"teacher_disagreement_score":0.57255226,"about_ca_system_score_codex":0.00005517559,"about_ca_system_score_gemma":0.00031188928,"threshold_uncertainty_score":0.4653389},"labels":[],"label_agreement":null},{"id":"W4416191299","doi":"10.1016/j.cjca.2025.11.010","title":"Myelodysplastic Syndromes and Incident Cardiovascular Disease: A Nationwide, Real-world Cohort Study","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Medtronic Japan; Ministry of Health, Labour and Welfare; Boston Scientific Japan; Boston Scientific Corporation","keywords":"Myelodysplastic syndromes; Cohort study; Risk factor; Cohort; Clinical Practice; Epidemiology; Public health","score_opus":0.015785186619795152,"score_gpt":0.28469275340255673,"score_spread":0.26890756678276156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416191299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98239064,0.0047609704,0.00076557614,0.001514125,0.0005804408,0.0007524934,0.000015541664,0.000010137282,0.009210049],"genre_scores_gemma":[0.99755865,0.00046790243,0.00005563438,0.00014756294,0.00039298172,0.000022875582,0.0000063446887,0.000017341108,0.0013307158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982156,0.00033579132,0.00044583966,0.00025879018,0.00035923556,0.00038475456],"domain_scores_gemma":[0.9977319,0.00021780463,0.00008551399,0.00041757594,0.00054346386,0.0010037223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013572254,0.00015886301,0.0009156759,0.0013389492,0.00014041792,0.000033768927,0.000186205,0.00007972328,0.000020973242],"category_scores_gemma":[0.0011503482,0.00013861386,0.00029321673,0.0005079253,0.00024088661,0.00007325846,0.00004379514,0.0004851699,0.000007084087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010498352,0.000004470153,0.98077977,0.00004928277,0.0037409216,0.0048936536,0.000056617206,0.00082726125,0.000007596685,0.00023156611,0.007472184,0.0018317122],"study_design_scores_gemma":[0.001544322,0.00019718344,0.9432328,0.00008449249,0.0014495915,0.0008030822,0.00017790271,0.000044284145,0.0000026168989,0.00014601221,0.052225694,0.000092055576],"about_ca_topic_score_codex":0.0046937005,"about_ca_topic_score_gemma":0.004588392,"teacher_disagreement_score":0.04475351,"about_ca_system_score_codex":0.00086266187,"about_ca_system_score_gemma":0.0055431523,"threshold_uncertainty_score":0.9833314},"labels":[],"label_agreement":null},{"id":"W4416211821","doi":"10.1186/s13045-025-01751-w","title":"Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Hematology; Cohort; IDH1; Myeloid; Mutation; Cohort study","score_opus":0.027824730235924865,"score_gpt":0.3782625102164903,"score_spread":0.35043777998056547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416211821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9433156,0.0011800252,0.0014427688,0.049061354,0.00096393266,0.0011639951,0.00026544748,0.000041145675,0.0025656968],"genre_scores_gemma":[0.97743094,0.00090640696,0.010311921,0.0061179595,0.0010607085,0.00010461257,0.00025036378,0.00006623276,0.0037508502],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99609494,0.0004902915,0.0017216889,0.00048346524,0.00043946717,0.0007701589],"domain_scores_gemma":[0.9921944,0.004991271,0.00093476294,0.0005860874,0.0010174414,0.00027604852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019561225,0.00033549638,0.001723681,0.00042356542,0.00028020376,0.000027306509,0.0007138941,0.00074111565,0.00014247154],"category_scores_gemma":[0.0034841446,0.00022658048,0.0004983757,0.00048850226,0.00070083165,0.00014470733,0.00022116827,0.0019683018,0.00006244364],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07137945,0.0012334362,0.010164407,0.00010827955,0.0073964666,0.012261873,0.0011822697,0.00007039596,0.026370369,0.0031976504,0.85651857,0.0101168435],"study_design_scores_gemma":[0.2613925,0.023158852,0.03374397,0.0010783724,0.010543895,0.06448392,0.0046412367,0.004104834,0.068538606,0.009734811,0.5175862,0.0009927946],"about_ca_topic_score_codex":0.00017139353,"about_ca_topic_score_gemma":0.00009651098,"teacher_disagreement_score":0.33893237,"about_ca_system_score_codex":0.001776425,"about_ca_system_score_gemma":0.0064937514,"threshold_uncertainty_score":0.99913853},"labels":[],"label_agreement":null},{"id":"W4416272494","doi":"10.1007/s00428-025-04333-w","title":"Plasmacytoid dendritic cell clusters are associated with poor prognosis in chronic myelomonocytic leukemia","year":2025,"lang":"en","type":"article","venue":"Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Chronic myelomonocytic leukemia; Bone marrow; Immunohistochemistry; Myeloid leukemia; Myeloid; Interleukin-3 receptor","score_opus":0.025524393006743896,"score_gpt":0.34261500126090627,"score_spread":0.31709060825416235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416272494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716206,0.004208195,0.00066043774,0.003733997,0.00029060594,0.002754999,0.00007958099,0.0005059637,0.0161456],"genre_scores_gemma":[0.98956656,0.0016206664,0.0022136427,0.0031372395,0.00025417644,0.00048326925,0.00047032966,0.00013668554,0.0021174082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99220103,0.0011888896,0.0014218994,0.0019406737,0.0009523807,0.0022951546],"domain_scores_gemma":[0.9941226,0.0031644567,0.00056912575,0.0012618683,0.0003041359,0.0005777835],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0018412767,0.0010938351,0.002128936,0.0013429213,0.00038190497,0.00008099219,0.0012531659,0.000815652,0.00008185723],"category_scores_gemma":[0.003106276,0.00081679324,0.0004013134,0.0024013375,0.0021657846,0.0002509527,0.00082062534,0.003705979,0.00015456764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020954754,0.007459577,0.40709078,0.008125776,0.008482297,0.035827305,0.0050346768,0.011359357,0.38090932,0.0046759234,0.05094986,0.059130378],"study_design_scores_gemma":[0.07931326,0.0145247495,0.6162301,0.012686608,0.004950479,0.0003104013,0.0093223015,0.084413566,0.16001467,0.006050367,0.007537164,0.004646377],"about_ca_topic_score_codex":0.00035209826,"about_ca_topic_score_gemma":0.00049749593,"teacher_disagreement_score":0.22089465,"about_ca_system_score_codex":0.0036599918,"about_ca_system_score_gemma":0.0058334204,"threshold_uncertainty_score":0.9998026},"labels":[],"label_agreement":null},{"id":"W4416277886","doi":"10.1186/s12885-025-14761-1","title":"Prognostic significance of cytogenetic and molecular features in pediatric acute myeloid leukemia: a meta-analysis","year":2025,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CEBPA; Surgical oncology; Risk stratification; Cytogenetics; Myeloid leukemia; Prospective cohort study; Hematology; Gene expression profiling","score_opus":0.03052217396169751,"score_gpt":0.33358081494078917,"score_spread":0.3030586409790917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416277886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9407388,0.054304067,0.0013406079,0.0010898509,0.000037380352,0.0012472881,0.00006337383,0.000029644621,0.001149015],"genre_scores_gemma":[0.99126375,0.0023433622,0.0026158981,0.00044151137,0.000043240812,0.0005928172,0.000013541364,0.000021949681,0.0026639157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981588,0.00013157091,0.0004058227,0.000526224,0.0004149166,0.0003626729],"domain_scores_gemma":[0.99886286,0.00025528893,0.00011417166,0.00046891475,0.00018241226,0.00011632442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031552618,0.00022282646,0.0010873928,0.000897656,0.000030655076,0.000018399558,0.00018200658,0.00015373653,0.00014034423],"category_scores_gemma":[0.00021736701,0.00017866123,0.00045211051,0.0028667485,0.00012502464,0.00003919464,0.00012231007,0.00035551708,0.0000029278226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007576899,0.00014657307,0.89111364,0.0015682875,0.064340636,0.00026257976,0.0002884934,0.0029494648,0.03438677,0.00038044268,0.00273434,0.0010711012],"study_design_scores_gemma":[0.0020770447,0.00013172877,0.7185911,0.000027494441,0.25237384,0.000011505832,0.00006611725,0.0009407251,0.025077417,0.00019603324,0.00024659545,0.0002604327],"about_ca_topic_score_codex":0.0011225134,"about_ca_topic_score_gemma":0.0011055999,"teacher_disagreement_score":0.1880332,"about_ca_system_score_codex":0.00046194677,"about_ca_system_score_gemma":0.0017996548,"threshold_uncertainty_score":0.7285594},"labels":[],"label_agreement":null},{"id":"W4416322306","doi":"10.1172/jci171634","title":"Clonal hematopoiesis activates procalcific pathways in macrophages and promotes aortic valve stenosis","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Dr. Rolf M. Schwiete Stiftung; Deutsche Forschungsgemeinschaft; NIH Office of the Director; Deutsches Zentrum für Herz-Kreislaufforschung; Burroughs Wellcome Fund","keywords":"Oncostatin M; Proinflammatory cytokine; Bone marrow; Pathogenesis; Paracrine signalling; Haematopoiesis; Aortic valve; Mesenchymal stem cell","score_opus":0.07587172196992743,"score_gpt":0.3965108049611365,"score_spread":0.3206390829912091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416322306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98959893,0.0004750495,0.00012923029,0.0091192145,0.00013381781,0.00032704257,0.0000017195154,0.000013684346,0.00020128282],"genre_scores_gemma":[0.9934258,0.00036377908,0.005067612,0.0007687932,0.00019317775,0.000009810421,0.0000033423012,0.0000128746005,0.00015483645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973765,0.00028191548,0.0014963681,0.00021770355,0.00041736363,0.0002101274],"domain_scores_gemma":[0.9973344,0.0013634383,0.0004976422,0.00015630353,0.0003886084,0.00025960588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002382888,0.00013448713,0.00065020367,0.0003487483,0.000051887277,0.000045266188,0.00012051378,0.00021598648,0.000022244838],"category_scores_gemma":[0.0069504,0.000099278404,0.00020208574,0.00048781125,0.00037399915,0.00023908768,0.00006936805,0.000918745,0.0000049679684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007136675,0.00039865673,0.9323777,0.0006049628,0.00031062888,0.000103538216,0.0004540466,0.000006797163,0.031985004,0.00074645004,0.0017373532,0.030561173],"study_design_scores_gemma":[0.003033416,0.0007560884,0.933085,0.0012593406,0.00016017436,0.00006907833,0.00034409921,0.0011733802,0.044810265,0.015058666,0.00014832953,0.0001021472],"about_ca_topic_score_codex":0.000012319962,"about_ca_topic_score_gemma":0.0000023365858,"teacher_disagreement_score":0.030459026,"about_ca_system_score_codex":0.00014014899,"about_ca_system_score_gemma":0.0009987687,"threshold_uncertainty_score":0.832078},"labels":[],"label_agreement":null},{"id":"W4416507969","doi":"10.1182/bloodadvances.2025017083","title":"Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"Genentech; Servier; Astellas Pharma; Nippon Shinyaku; Incyte; BeiGene; Astex Pharmaceuticals; Celgene; Amgen; Ariad Pharmaceuticals; Ascentage Pharma; Jazz Pharmaceuticals; Teva Pharmaceutical Industries; Karyopharm Therapeutics; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Pfizer; Bristol-Myers Squibb","keywords":"Venetoclax; Cytarabine; Myeloid leukemia; Azacitidine; NPM1; Population; Chemotherapy; Chemotherapy regimen","score_opus":0.005691558317478645,"score_gpt":0.2824183766750267,"score_spread":0.2767268183575481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416507969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99705976,0.0009468655,0.0003354903,0.00033888908,0.000020428351,0.0010788359,0.000025690537,0.000011810507,0.0001822155],"genre_scores_gemma":[0.99499035,0.0007267018,0.0037723905,0.00017614115,0.000019025576,0.00008231794,0.000048532085,0.000011275758,0.00017326875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99929726,0.000017868204,0.00020168867,0.00021185081,0.00012660722,0.00014471314],"domain_scores_gemma":[0.9991898,0.00010593204,0.00009555815,0.00017596189,0.00039701955,0.000035742516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010291836,0.0000949568,0.00023928942,0.00014955568,0.000025678653,0.0000061117175,0.00005766737,0.000042208845,0.0000039789347],"category_scores_gemma":[0.00021642754,0.00007130392,0.000019565858,0.00027998112,0.00009845495,0.000095249474,0.00001483656,0.000110703375,4.57007e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045694932,0.00036759712,0.94046897,0.00065332174,0.00015775941,0.0000024453673,0.0003603695,0.00011987898,0.006957528,0.00028489766,0.0002179026,0.04583986],"study_design_scores_gemma":[0.022992918,0.0016259112,0.88641745,0.000569294,0.00010949747,0.0000013549555,0.0004443989,0.0006714777,0.08443622,0.0012083404,0.0013824082,0.00014072971],"about_ca_topic_score_codex":0.00004506016,"about_ca_topic_score_gemma":0.00004307936,"teacher_disagreement_score":0.07747869,"about_ca_system_score_codex":0.00006469551,"about_ca_system_score_gemma":0.00020556204,"threshold_uncertainty_score":0.29076895},"labels":[],"label_agreement":null},{"id":"W4416576228","doi":"10.1038/s41409-025-02757-1","title":"Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia","year":2025,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; U.S. Navy; Genentech; Health Resources and Services Administration; National Institutes of Health; Syndax Pharmaceuticals; Office of Naval Research; Jazz Pharmaceuticals; AstraZeneca; Takeda Pharmaceuticals U.S.A.; Amgen; Bill and Melinda Gates Foundation; Foundation for the National Institutes of Health; Gilead Sciences; U.S. Department of Defense","keywords":"NPM1; Myeloid leukemia; Minimal residual disease; Transplantation; Leukemia; Myeloid; Mutation","score_opus":0.015844700720417083,"score_gpt":0.2951343406080215,"score_spread":0.2792896398876044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416576228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9642277,0.00046893005,0.021554792,0.0043898104,0.0003183192,0.0028698302,0.0009022324,0.0003826147,0.0048858062],"genre_scores_gemma":[0.9784887,0.001140438,0.00514147,0.00088529853,0.00015962482,0.0004912484,0.0040379483,0.0000837729,0.009571533],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971998,0.00011247318,0.0006733551,0.00067389995,0.00057525875,0.0007652482],"domain_scores_gemma":[0.9987355,0.00019242693,0.000099620614,0.00042819834,0.00032093987,0.0002233194],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006356849,0.00038803852,0.00062983856,0.00052456284,0.00029405748,0.000054641598,0.0002228249,0.00035169255,0.00008728536],"category_scores_gemma":[0.000047068996,0.00035833233,0.00024812002,0.0006388268,0.00013551125,0.00021070913,0.000012512136,0.00044144946,0.00004416458],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022337994,0.0002630361,0.010014625,0.0035367885,0.0022950128,0.0016218286,0.0028188354,0.0003276186,0.91444325,0.002278663,0.013701436,0.026360927],"study_design_scores_gemma":[0.042948816,0.0022517748,0.117572315,0.002122715,0.008671332,0.002590448,0.00047294996,0.006658935,0.8021869,0.0030073842,0.010116488,0.0013999238],"about_ca_topic_score_codex":0.00025082976,"about_ca_topic_score_gemma":0.000446726,"teacher_disagreement_score":0.11225632,"about_ca_system_score_codex":0.0007774996,"about_ca_system_score_gemma":0.0013665494,"threshold_uncertainty_score":0.9998869},"labels":[],"label_agreement":null},{"id":"W4416665762","doi":"10.1172/jci181943","title":"Loss of FBXO11 establishes a stem cell program in acute myeloid leukemia by dysregulating LONP1","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"Terry Fox Research Institute; Canadian Institutes of Health Research; Killam Trusts","keywords":"Ubiquitin ligase; Myeloid leukemia; Stem cell; Haematopoiesis; Progenitor cell; Myeloid; Mitochondrion; Hematopoietic stem cell","score_opus":0.04826515329223378,"score_gpt":0.38827299562937206,"score_spread":0.34000784233713827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416665762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99384755,0.000376666,0.00036889297,0.0033592181,0.00027066268,0.000537429,0.000005604192,0.000023566632,0.0012104003],"genre_scores_gemma":[0.9847839,0.0003246413,0.012298584,0.0006561169,0.0002354911,0.000012033608,0.000017944638,0.000024724919,0.0016465776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99523205,0.0004272723,0.002988177,0.0002722939,0.0007501712,0.0003300571],"domain_scores_gemma":[0.9959485,0.0012123936,0.001417372,0.0003191978,0.00075377047,0.00034878406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037580098,0.00019041219,0.0010273658,0.0004299028,0.00004114128,0.000045129425,0.00031112187,0.00037854663,0.000020479443],"category_scores_gemma":[0.0017010712,0.00015492424,0.0003039188,0.0010467926,0.0005066483,0.0004024069,0.000103977465,0.0014929022,0.000005096287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016061569,0.0007209529,0.79226553,0.0007737851,0.00037854124,0.00024502192,0.00042995464,0.00019997086,0.028541964,0.00023285275,0.02825862,0.14634663],"study_design_scores_gemma":[0.025484527,0.006277466,0.7524125,0.0056844177,0.0010911354,0.00020351728,0.0012606295,0.022867393,0.16604212,0.004736624,0.013358136,0.0005815503],"about_ca_topic_score_codex":0.000060784394,"about_ca_topic_score_gemma":0.000010744031,"teacher_disagreement_score":0.14576508,"about_ca_system_score_codex":0.00051585893,"about_ca_system_score_gemma":0.0027999745,"threshold_uncertainty_score":0.6486},"labels":[],"label_agreement":null},{"id":"W4416690579","doi":"10.1038/s41408-025-01416-4","title":"Impact of expanding allogeneic stem cell transplantation on survival in acute myeloid leukemia: a population-based study","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Juravinski Cancer Centre; Hamilton Health Sciences; Population Health Research Institute; McMaster University","funders":"Government of Ontario; Leukemia and Lymphoma Society of Canada; Cancer Research Society; Johns Hopkins Children's Center","keywords":"Stem cell; Transplantation; Hematology; Hematopoietic stem cell transplantation; Myeloid; Haematopoiesis; MEDLINE","score_opus":0.022391468870450293,"score_gpt":0.35069953915330787,"score_spread":0.3283080702828576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416690579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998122,0.00038132435,0.00017934211,0.00015592943,0.00019179385,0.00061148254,0.000037998194,0.000016747634,0.00030339495],"genre_scores_gemma":[0.99893796,0.0004286301,0.00009041301,0.000070208844,0.00012342702,0.00004220066,0.000018571121,0.00002597499,0.00026259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979471,0.00023763432,0.0005866741,0.0002613415,0.00059285975,0.00037440247],"domain_scores_gemma":[0.9991004,0.00016890562,0.0002010941,0.00022202471,0.00015978479,0.0001477935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006418058,0.00020777485,0.0004989967,0.00077289087,0.00010495163,0.00003289131,0.00017686418,0.00011442505,0.00009544545],"category_scores_gemma":[0.000016067224,0.00016601373,0.00020224831,0.0006880157,0.000019289837,0.00009201711,0.000015298921,0.0007588934,0.0000019757722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002387573,0.0007797423,0.96322864,0.00013557877,0.0005656486,0.0004252277,0.0005754327,0.006347977,0.022228066,0.0000035675735,0.00006302515,0.0032595433],"study_design_scores_gemma":[0.015124112,0.0017111375,0.96661496,0.0005021402,0.0006458371,0.000047252564,0.00040875305,0.0003895065,0.014411203,0.000010657968,0.0000030539163,0.00013138032],"about_ca_topic_score_codex":0.0017381725,"about_ca_topic_score_gemma":0.00042960962,"teacher_disagreement_score":0.012736539,"about_ca_system_score_codex":0.0021749805,"about_ca_system_score_gemma":0.002758524,"threshold_uncertainty_score":0.67698437},"labels":[],"label_agreement":null},{"id":"W4416842599","doi":"10.1016/j.exphem.2025.105133","title":"3192 – MODELING CLONAL HEMATOPOIESIS DUE TO CHROMOSOME 13Q DELETION IN HUMAN HEMATOPOIETIC STEM CELLS","year":2025,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stem Cell Network; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Haematopoiesis; Myeloid; Stem cell; Monocyte; Macrophage; Myeloid leukemia; Transgene; In vitro","score_opus":0.023155446026430226,"score_gpt":0.3361266793464209,"score_spread":0.31297123331999066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416842599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988067,0.002882632,0.0021350747,0.0015506664,0.00029478327,0.0011556786,0.000005698375,0.00014659755,0.0037619232],"genre_scores_gemma":[0.99566597,0.000009855389,0.0015779963,0.0011096199,0.00006370756,0.00039015722,0.000026712545,0.000053279928,0.001102691],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971576,0.00013478774,0.0007757629,0.0007498513,0.00039265354,0.0007893551],"domain_scores_gemma":[0.998884,0.00009887361,0.00006735682,0.0005914922,0.00008562685,0.0002726324],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002945754,0.00035635327,0.00097445794,0.00072779786,0.00018397214,0.00002952012,0.0003101811,0.00031443508,0.0005307038],"category_scores_gemma":[0.000018580451,0.00036272593,0.00015925386,0.0006922502,0.00014496919,0.00010668967,0.00039043152,0.0004714729,0.00028504655],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008955572,0.0018610175,0.00181593,0.0010284733,0.00020784621,0.0029768064,0.0036875277,0.00035020235,0.8400773,0.13766345,0.008993611,0.00044230995],"study_design_scores_gemma":[0.002633862,0.00028172418,0.0000503276,0.00043693554,0.000021864354,0.0011633578,0.0030272128,0.0075656394,0.9836263,0.0005405561,0.00035892957,0.0002932806],"about_ca_topic_score_codex":0.00016000858,"about_ca_topic_score_gemma":0.000023994176,"teacher_disagreement_score":0.14354905,"about_ca_system_score_codex":0.001059867,"about_ca_system_score_gemma":0.0002555124,"threshold_uncertainty_score":0.99988246},"labels":[],"label_agreement":null},{"id":"W4416848478","doi":"10.1182/bloodadvances.2025017934","title":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University Hospital Foundation","funders":"","keywords":"Hematology; Myeloid leukemia; Guideline; Transplantation; Population; Hematopoietic stem cell transplantation; Venetoclax; Induction chemotherapy; Gemtuzumab ozogamicin; Azacitidine","score_opus":0.020689133210197535,"score_gpt":0.36216380644320423,"score_spread":0.3414746732330067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416848478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98060524,0.0076877754,0.0021607492,0.006680521,0.00011749312,0.0015531448,0.000055639142,0.00008694041,0.0010524691],"genre_scores_gemma":[0.691099,0.014245045,0.27979195,0.0061258813,0.00045744705,0.0012299531,0.00019321343,0.00009763964,0.006759896],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979472,0.00004717353,0.0007433456,0.00050436787,0.00024179886,0.00051611156],"domain_scores_gemma":[0.99795026,0.0008091033,0.00023993799,0.00037288436,0.00053677894,0.00009101409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027657696,0.0002457012,0.00086586433,0.0002144696,0.0000717351,0.000009376418,0.00023895029,0.000116665644,0.000018646817],"category_scores_gemma":[0.00092296215,0.00020714545,0.00024570661,0.00087561016,0.0002896875,0.00013014123,0.000108009735,0.0002529348,0.0000028438442],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032511773,0.0009831793,0.2828034,0.004694799,0.0017620352,0.00020920542,0.0023260447,0.0003987676,0.03006245,0.0011835573,0.078737184,0.5935882],"study_design_scores_gemma":[0.13323247,0.004365058,0.144797,0.012887608,0.0025852735,0.00026682406,0.032425568,0.036028404,0.5270676,0.0018913143,0.10245946,0.0019934415],"about_ca_topic_score_codex":0.00062809483,"about_ca_topic_score_gemma":0.00027956365,"teacher_disagreement_score":0.59159476,"about_ca_system_score_codex":0.00026557772,"about_ca_system_score_gemma":0.0009850786,"threshold_uncertainty_score":0.84471464},"labels":[],"label_agreement":null},{"id":"W4417001771","doi":"10.1182/blood-2025-109","title":"Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Fludarabine; Melphalan; Busulfan; Regimen; Cohort; Transplantation; Hematopoietic stem cell transplantation","score_opus":0.026670916817568342,"score_gpt":0.3027017942571621,"score_spread":0.27603087743959376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417001771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99863684,0.00018518325,0.00008869772,0.00029019726,0.000021541568,0.00052041246,0.00010459623,0.000025095256,0.00012744062],"genre_scores_gemma":[0.99769086,0.00022426118,0.00046632558,0.00012465489,0.000011031065,0.000012013328,0.0011974612,0.000019143154,0.0002542349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834174,0.0001010978,0.00039277194,0.00055875286,0.0003393518,0.00026628122],"domain_scores_gemma":[0.99859047,0.00012258375,0.000085968444,0.00090205343,0.00017427851,0.00012463178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028730466,0.00019317947,0.0006811537,0.0006144867,0.0000537675,0.000022893028,0.00027354466,0.000099596255,0.000018133242],"category_scores_gemma":[0.000027008478,0.00015132771,0.000050755825,0.0009014719,0.00010072919,0.00018163737,0.00012631623,0.00020070432,7.5224705e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005105487,0.00073969207,0.9904212,0.00042668742,0.0012299349,0.00014408905,0.00081592746,0.00000775414,0.0051129577,0.0000037589198,0.000011627487,0.00057583814],"study_design_scores_gemma":[0.009946658,0.00034690346,0.96891594,0.00018286258,0.0034205345,0.0000133423355,0.00038528544,0.0002567581,0.01639948,9.412378e-7,0.0000010869973,0.00013017913],"about_ca_topic_score_codex":0.00022650958,"about_ca_topic_score_gemma":0.0012533428,"teacher_disagreement_score":0.021505218,"about_ca_system_score_codex":0.000083755236,"about_ca_system_score_gemma":0.00029250229,"threshold_uncertainty_score":0.6170965},"labels":[],"label_agreement":null},{"id":"W4417001866","doi":"10.1182/blood-2025-763","title":"Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Tolerability; Refractory (planetary science); Regimen; Phases of clinical research; Acute leukemia; Leukemia; Adverse effect","score_opus":0.01024731356587494,"score_gpt":0.2959461322324716,"score_spread":0.2856988186665967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417001866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963525,0.00010417442,0.000027975359,0.00051436375,0.00022284652,0.002213645,0.0002256636,0.000027219588,0.00031163835],"genre_scores_gemma":[0.9975256,0.00012105664,0.00035784265,0.0004419583,0.00012625472,0.00014333992,0.00024850425,0.00004126642,0.0009941907],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975204,0.0002185378,0.0007640616,0.00046723854,0.0006413031,0.00038846926],"domain_scores_gemma":[0.99860626,0.0001707536,0.00027894595,0.0007154238,0.00013285836,0.00009575192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003930797,0.0002579832,0.00061509653,0.00041874024,0.000047408656,0.000016307687,0.0002825812,0.00022908322,0.00014130051],"category_scores_gemma":[0.00021691372,0.00016058068,0.00009658077,0.0010284282,0.0001246347,0.00016504605,0.0000875787,0.00069292134,0.000007157393],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73219347,0.02020836,0.11964235,0.00014310156,0.0015897583,0.0005259118,0.0015650073,0.000013790277,0.09739558,0.000038119768,0.0074517406,0.019232808],"study_design_scores_gemma":[0.8268505,0.004782841,0.038329158,0.00071798475,0.00043501105,0.0000024880344,0.000148367,0.00012840437,0.125274,0.00008355408,0.002975558,0.00027213764],"about_ca_topic_score_codex":0.00066080136,"about_ca_topic_score_gemma":0.00028677614,"teacher_disagreement_score":0.09465702,"about_ca_system_score_codex":0.00076966675,"about_ca_system_score_gemma":0.0016448249,"threshold_uncertainty_score":0.65482897},"labels":[],"label_agreement":null},{"id":"W4417002713","doi":"10.1182/blood-2025-7363","title":"Artificial intelligence‑driven virtual tumor board enhances precision care in myelodysplastic syndromes (MDS)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Myelodysplastic syndromes; Context (archaeology); Clinical trial; Multidisciplinary approach; Domain (mathematical analysis); Disease; Clinical decision support system; Clinical decision making","score_opus":0.017872736738031067,"score_gpt":0.3092670765136607,"score_spread":0.2913943397756296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417002713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99354815,0.0007821933,0.000750622,0.0004440203,0.0002942936,0.00066488853,0.000014292375,0.00008584841,0.0034157024],"genre_scores_gemma":[0.99758583,0.00011573118,0.0010036585,0.00013173284,0.00015747912,0.00008779225,0.000026189926,0.000023926274,0.00086764945],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979271,0.000099866105,0.0004987462,0.00051044323,0.00048437814,0.00047944344],"domain_scores_gemma":[0.9988234,0.0004214045,0.000057469893,0.00040570193,0.0001542921,0.00013774175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022128371,0.00021880449,0.00045088906,0.00055235514,0.00008794594,0.00004543106,0.00029933726,0.0001401279,0.00019888562],"category_scores_gemma":[0.000825498,0.00019075809,0.00010076457,0.0008314732,0.00015194734,0.00009627809,0.00020757572,0.00053436885,0.00029380753],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056425747,0.0050052158,0.08123598,0.0022297134,0.0010939076,0.0073497505,0.010206406,0.0008257103,0.21652827,0.010735539,0.0033294677,0.65581745],"study_design_scores_gemma":[0.0050462442,0.004374626,0.07325631,0.004243064,0.00078369345,0.00033161844,0.016297935,0.0043535284,0.88178444,0.003389235,0.0050755227,0.0010638018],"about_ca_topic_score_codex":0.00009621009,"about_ca_topic_score_gemma":0.00022247525,"teacher_disagreement_score":0.66525614,"about_ca_system_score_codex":0.0002648343,"about_ca_system_score_gemma":0.00075582805,"threshold_uncertainty_score":0.7778889},"labels":[],"label_agreement":null},{"id":"W4417004586","doi":"10.1182/blood-2025-4616","title":"Assessment of real-world treatment patterns and outcomes of olutasidenib in patients with mutated isocitrate dehydrogenase 1 Acute Myeloid Leukemia previously treated with venetoclax using electronic health record data","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Systems, Applications & Products in Data Processing (Canada)","funders":"","keywords":"Venetoclax; Regimen; IDH1; Context (archaeology); Myeloid leukemia; Cohort; Clinical trial; Retrospective cohort study; Refractory (planetary science)","score_opus":0.021230467722185117,"score_gpt":0.33693358236623355,"score_spread":0.31570311464404843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970706,0.00014901118,0.000059735954,0.00010040189,0.0000074321165,0.0021896863,0.00029723477,0.0000341032,0.00009178009],"genre_scores_gemma":[0.99603087,0.0009411277,0.0019108993,0.000069608235,0.000007970551,0.000056150657,0.0007710431,0.00004990469,0.0001624407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973663,0.00020111138,0.0006966869,0.0006406048,0.0004206883,0.0006745863],"domain_scores_gemma":[0.9981889,0.00011038354,0.00039251146,0.0009770547,0.00015902772,0.00017209105],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003206711,0.0003518477,0.0011122975,0.00048368424,0.000061984756,0.000015128436,0.00022890216,0.000082471495,0.000010377355],"category_scores_gemma":[0.000017377904,0.00024550545,0.000049887403,0.0008579635,0.00011604906,0.00013329677,0.00013542516,0.00029979282,2.8999034e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009468276,0.000812849,0.9930626,0.00032393573,0.0022431794,0.0000804825,0.0001303397,0.00009261868,0.000510564,0.000015510477,0.000009198528,0.0017718937],"study_design_scores_gemma":[0.023999006,0.0045178086,0.9612143,0.00079101877,0.0012348,0.000014738061,0.00006492286,0.0021685148,0.005789487,0.0000065397885,0.0000117754635,0.00018710374],"about_ca_topic_score_codex":0.03039682,"about_ca_topic_score_gemma":0.016049584,"teacher_disagreement_score":0.031848315,"about_ca_system_score_codex":0.0033500977,"about_ca_system_score_gemma":0.006512211,"threshold_uncertainty_score":0.9999997},"labels":[],"label_agreement":null},{"id":"W4417004589","doi":"10.1182/blood-2025-6987","title":"CPX-351 versus venetoclax plus hypomethylating agents for newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Venetoclax; Azacitidine; Hypomethylating agent; Regimen; Observational study; Systematic review; Randomized controlled trial; Clinical trial; Myeloid leukemia","score_opus":0.06132397024247202,"score_gpt":0.35514183984024283,"score_spread":0.2938178695977708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004589","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15517288,0.77215725,0.007145241,0.013083071,0.00043570148,0.04160172,0.0008300428,0.0007375031,0.008836561],"genre_scores_gemma":[0.7230334,0.061306506,0.056978635,0.03625346,0.00063346117,0.027351145,0.001476629,0.0006184301,0.0923483],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99694276,0.0002721504,0.000943263,0.0006977213,0.00055014726,0.0005939435],"domain_scores_gemma":[0.99644685,0.0016103382,0.00030796372,0.0010416621,0.00032302702,0.0002701822],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013318707,0.00040163123,0.0035804647,0.0005463159,0.00019565652,0.00007553393,0.00033963687,0.00020200657,0.00012786349],"category_scores_gemma":[0.0028515293,0.00030204142,0.0012833627,0.0018688915,0.00008127351,0.00010671011,0.00023037108,0.0004023408,0.00002868581],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037541226,0.00013218344,0.00011733096,0.25876194,0.7324202,0.00034429613,0.00028421177,0.000076403376,0.0006955514,0.00029324228,0.006393644,0.00010559706],"study_design_scores_gemma":[0.010498498,0.0002827968,0.00013117136,0.0014266352,0.9847453,0.000026348303,0.00010692662,0.0014181456,0.0007054674,0.000036243844,0.00036357678,0.0002588428],"about_ca_topic_score_codex":0.00015676036,"about_ca_topic_score_gemma":0.00003492854,"teacher_disagreement_score":0.7108508,"about_ca_system_score_codex":0.0012135695,"about_ca_system_score_gemma":0.0013177799,"threshold_uncertainty_score":0.9999432},"labels":[],"label_agreement":null},{"id":"W4417004592","doi":"10.1182/blood-2025-6990","title":"Time burden of treatment with parenteral hypomethylating agents in combination with venetoclax among patients with newly diagnosed Acute Myeloid Leukemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Venetoclax; Azacitidine; Hypomethylating agent; Regimen; Myeloid leukemia; Off-label use; Chemotherapy regimen; Chemotherapy; Retrospective cohort study","score_opus":0.010706470629511458,"score_gpt":0.2622389418092833,"score_spread":0.25153247117977184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968027,0.000044522494,0.000043065334,0.00008365527,0.000015568423,0.0016303728,0.000026162563,0.000045896748,0.0013080765],"genre_scores_gemma":[0.9965439,0.000029292436,0.0016080993,0.000042957126,0.000025268437,0.00019098577,0.000282811,0.000044897944,0.0012318073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981883,0.00009053679,0.0003538702,0.000424348,0.0005157163,0.00042721158],"domain_scores_gemma":[0.9988919,0.00013603143,0.000185162,0.0004127058,0.00024101837,0.000133196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011766984,0.00029450827,0.0005696596,0.00041755,0.00006417916,0.00002445761,0.00015293619,0.00010247682,0.000034208675],"category_scores_gemma":[0.00003860762,0.00019456034,0.000048002268,0.0008266052,0.00017431972,0.00015344482,0.00006242389,0.00024401034,0.00000849466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021799959,0.0009186411,0.98724854,0.000113424605,0.0011824929,0.00029895766,0.0012555989,0.00085457886,0.0010029386,0.000007157872,0.00008037315,0.0048572943],"study_design_scores_gemma":[0.081125826,0.010333937,0.8948901,0.0014200098,0.00085642654,0.000012186024,0.00025647148,0.0037982885,0.0069104997,0.000009637335,0.000108426786,0.00027815814],"about_ca_topic_score_codex":0.0015543753,"about_ca_topic_score_gemma":0.00015541991,"teacher_disagreement_score":0.09235842,"about_ca_system_score_codex":0.001797102,"about_ca_system_score_gemma":0.0011778562,"threshold_uncertainty_score":0.7933941},"labels":[],"label_agreement":null},{"id":"W4417004679","doi":"10.1182/blood-2025-4608","title":"CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with  myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Myeloid leukemia; Context (archaeology); Hematology; Hematopoietic stem cell transplantation; Transplantation; Leukemia; Population; Myeloid","score_opus":0.01610269223968738,"score_gpt":0.2906916307746867,"score_spread":0.2745889385349993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925825,0.0003514838,0.00020930146,0.0008722277,0.000070416834,0.0042283973,0.0004452138,0.0003082099,0.0009322426],"genre_scores_gemma":[0.9904563,0.00078633515,0.00028252392,0.00042701678,0.000035337016,0.000545715,0.00052713626,0.00014332043,0.0067963563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994559,0.0005142507,0.001049467,0.0016475251,0.0010945799,0.0011351692],"domain_scores_gemma":[0.99750096,0.00025431425,0.0003110484,0.0011102412,0.00038529804,0.0004381531],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007524855,0.0007701102,0.0017442618,0.0025096785,0.00024433443,0.00011105502,0.00047932853,0.00037486668,0.00026221733],"category_scores_gemma":[0.000035826713,0.0006015286,0.0002528096,0.010051553,0.00011376888,0.00017962523,0.00010679552,0.001101675,0.00009596181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011249565,0.0029127924,0.9106654,0.00019258374,0.014856669,0.005107828,0.025168207,0.00012158822,0.029198185,0.000026870377,0.00021450844,0.00028582936],"study_design_scores_gemma":[0.03644923,0.0025038605,0.9093099,0.0005416952,0.011358525,0.00010086095,0.002301579,0.0008317156,0.035841703,0.000038244896,0.00002479107,0.0006978948],"about_ca_topic_score_codex":0.0038634606,"about_ca_topic_score_gemma":0.027411597,"teacher_disagreement_score":0.025199667,"about_ca_system_score_codex":0.0015660245,"about_ca_system_score_gemma":0.0012360162,"threshold_uncertainty_score":0.9996436},"labels":[],"label_agreement":null},{"id":"W4417004858","doi":"10.1182/blood-2025-657","title":"A rapid gene expression profiler predicts tumor responsiveness and patient outcome for standard-of-care therapies in acute myeloid leukemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Myeloid leukemia; Decitabine; Leukemia; Ex vivo; Azacitidine; Gene signature; NPM1; Myeloid; Gene expression profiling","score_opus":0.017291609927974398,"score_gpt":0.3012204746034046,"score_spread":0.2839288646754302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903423,0.005897257,0.00015221149,0.00055912434,0.00009165194,0.0023642895,0.0002745698,0.00004795031,0.0002706039],"genre_scores_gemma":[0.9898223,0.00036096337,0.008498216,0.00032180367,0.00004192791,0.00056621083,0.000060450213,0.00003919615,0.00028891538],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981801,0.00012346862,0.0004992522,0.00042993054,0.00038603164,0.00038123815],"domain_scores_gemma":[0.99868286,0.0002818576,0.00011430018,0.00044061156,0.0003702202,0.00011018115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030745534,0.00022136242,0.0006327221,0.00040393032,0.0000839917,0.000019323246,0.00014824301,0.0001391847,0.000022889359],"category_scores_gemma":[0.00040400375,0.0001720396,0.0000990753,0.0003372929,0.00013342628,0.000083388535,0.00019161959,0.00026905598,0.0000011243189],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03191497,0.0005234981,0.21377985,0.003322048,0.00073535554,0.00041245314,0.008260368,0.000008232847,0.70211524,0.00022027662,0.0018467901,0.036860906],"study_design_scores_gemma":[0.01799003,0.002350267,0.057714134,0.0010228738,0.00024697563,0.00003735007,0.0021091653,0.000049163566,0.9120611,0.00010387434,0.006120293,0.00019475195],"about_ca_topic_score_codex":0.000014504648,"about_ca_topic_score_gemma":0.000005196042,"teacher_disagreement_score":0.20994587,"about_ca_system_score_codex":0.00032229017,"about_ca_system_score_gemma":0.0010904053,"threshold_uncertainty_score":0.7015571},"labels":[],"label_agreement":null},{"id":"W4417004860","doi":"10.1182/blood-2025-635","title":"Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Covenant Health","funders":"","keywords":"Cytopenia; Myeloid leukemia; Myelodysplastic syndromes; Clinical trial; Phases of clinical research; Adverse effect; IDH1; Myeloid; Haematopoiesis","score_opus":0.0680078998807573,"score_gpt":0.43629458244645214,"score_spread":0.36828668256569486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931367,0.00018519833,0.00007256686,0.003048225,0.00020315654,0.002405879,0.000048462167,0.000060287635,0.0008394969],"genre_scores_gemma":[0.9920864,0.00011942283,0.0016448979,0.00065941556,0.00013445831,0.0001733661,0.000034916127,0.00002867978,0.0051184036],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996448,0.00056880806,0.0013047388,0.00056656334,0.0005173004,0.000594591],"domain_scores_gemma":[0.9975187,0.0011952961,0.00014718533,0.0006002118,0.00023068122,0.00030793535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017438453,0.00022900585,0.0009826701,0.0005321798,0.00007798905,0.000023252958,0.0003433215,0.00025199656,0.00028820755],"category_scores_gemma":[0.0053024674,0.00020538445,0.00022406862,0.0012537772,0.0002091976,0.00007515866,0.00020322393,0.0005660452,0.00003447979],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5140801,0.009359349,0.01569742,0.00017534736,0.0003447124,0.0013010196,0.0003168972,0.0000049759424,0.4471795,0.00018003485,0.0064792237,0.0048814],"study_design_scores_gemma":[0.61054015,0.010771304,0.012094985,0.00050120906,0.00045652554,0.000058001344,0.00014259732,0.00019506991,0.36016,0.00012450622,0.004660708,0.0002949403],"about_ca_topic_score_codex":0.00023511284,"about_ca_topic_score_gemma":0.0001245855,"teacher_disagreement_score":0.09646003,"about_ca_system_score_codex":0.00020430898,"about_ca_system_score_gemma":0.0028247228,"threshold_uncertainty_score":0.8375335},"labels":[],"label_agreement":null},{"id":"W4417005078","doi":"10.1182/blood-2025-3240","title":"PKM2 modulation regulates leukemia cell survival.","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Guelph","funders":"","keywords":"PKM2; Pyruvate kinase; Glycolysis; Anaerobic glycolysis; Warburg effect; Anabolism; Cell growth; Phosphoenolpyruvate carboxykinase; Pentose phosphate pathway","score_opus":0.013561899101615685,"score_gpt":0.27701741164042076,"score_spread":0.26345551253880506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417005078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9105119,0.00036337017,0.00028156795,0.001017452,0.00013308386,0.00034346408,0.0000039116953,0.00013020345,0.08721506],"genre_scores_gemma":[0.96229076,0.00006766416,0.0012099977,0.00024408022,0.00015994372,0.00001945268,0.00004592496,0.000021359336,0.035940815],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988737,0.00005069805,0.00021072004,0.00028661318,0.00028489289,0.00029335753],"domain_scores_gemma":[0.99914813,0.00010533085,0.00003694657,0.00047296466,0.0001378441,0.00009878989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026057742,0.00012809112,0.0002325948,0.00019084757,0.00007746969,0.000023407498,0.00012822417,0.00014120064,0.00013725438],"category_scores_gemma":[0.00014084388,0.00011503098,0.00007938439,0.00044294843,0.000056126475,0.000060725357,0.000091061345,0.00026349587,0.00015554676],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005334723,0.0013730092,0.14948945,0.0011655929,0.0006413712,0.0003109124,0.00043059647,0.00028453497,0.7701832,0.005776675,0.050042413,0.019768752],"study_design_scores_gemma":[0.014313389,0.00024780506,0.3086785,0.00022921311,0.0004408479,0.000035666733,0.00020231407,0.0074221985,0.6437215,0.0017815125,0.022599313,0.0003277099],"about_ca_topic_score_codex":0.0001062339,"about_ca_topic_score_gemma":0.000008251689,"teacher_disagreement_score":0.15918908,"about_ca_system_score_codex":0.000263413,"about_ca_system_score_gemma":0.0005535183,"threshold_uncertainty_score":0.46908274},"labels":[],"label_agreement":null},{"id":"W4417006069","doi":"10.1182/blood-2025-7051","title":"Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"NPM1; Myeloid leukemia; Cumulative incidence; Hazard ratio; Concomitant; Proportional hazards model; Minimal residual disease; Incidence (geometry); Overall survival","score_opus":0.019316080134565886,"score_gpt":0.3159474065810198,"score_spread":0.2966313264464539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417006069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898416,0.000063061,0.00734293,0.00030675894,0.000064795626,0.0018969484,0.000056752517,0.000085030864,0.00034214882],"genre_scores_gemma":[0.9330033,0.0000044318945,0.066284806,0.0001423621,0.000013315019,0.00020433974,0.00026891177,0.000039267128,0.000039248484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975846,0.00016221764,0.0006968712,0.00047251448,0.00063625275,0.00044755515],"domain_scores_gemma":[0.99722004,0.001423011,0.00022168076,0.00039480743,0.000617331,0.00012312797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040393454,0.00025835045,0.00055765,0.0008737827,0.00010211763,0.00003448151,0.0001392705,0.00013380524,0.000027789081],"category_scores_gemma":[0.0018408461,0.00022909444,0.0000718896,0.001583171,0.00019891081,0.00015000098,0.000084663916,0.0005556905,0.0000072045395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006203237,0.0018444057,0.980684,0.00063360267,0.0003864197,0.00028469195,0.00039496797,0.0038688919,0.008285796,0.000042117485,0.00003125427,0.0029235673],"study_design_scores_gemma":[0.036779646,0.0012009196,0.8277742,0.0018144841,0.00052409247,0.00001513457,0.00046187398,0.08177049,0.049219277,0.00008781126,0.000028896857,0.0003231703],"about_ca_topic_score_codex":0.00010477163,"about_ca_topic_score_gemma":0.00006855223,"teacher_disagreement_score":0.15290976,"about_ca_system_score_codex":0.000512948,"about_ca_system_score_gemma":0.0011798189,"threshold_uncertainty_score":0.93422},"labels":[],"label_agreement":null},{"id":"W4417006141","doi":"10.1182/blood-2025-3293","title":"LSD1 inhibition enhances venetoclax efficacy in Acute Myeloid Leukemia via metabolic rewiring","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Population Health Research Institute; McMaster University; Hamilton Health Sciences","funders":"","keywords":"Venetoclax; Myeloid leukemia; Azacitidine; Clofarabine; NPM1; Leukemia; In vivo; Myeloid; Cytarabine","score_opus":0.01175402913000026,"score_gpt":0.2939082699760667,"score_spread":0.28215424084606644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417006141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877179,0.0022064473,0.00021765861,0.00070653745,0.00013288327,0.0007068731,0.0000060613047,0.00013274877,0.008172865],"genre_scores_gemma":[0.9948516,0.00087147194,0.0010476211,0.00056672713,0.0002370087,0.00011782042,0.000052519033,0.000035002206,0.002220217],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99799526,0.00009992712,0.00044373923,0.0005004882,0.00038474833,0.0005758504],"domain_scores_gemma":[0.9990307,0.00014273037,0.000074739255,0.00050907803,0.000100626086,0.00014214513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004328665,0.00023569664,0.00051139743,0.00057730306,0.00009374531,0.000037591115,0.00018362363,0.00020345309,0.000075156124],"category_scores_gemma":[0.0002285549,0.00022280261,0.0001256117,0.0011635169,0.00010564011,0.00015240614,0.00017603407,0.0006763743,0.00016778952],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003946905,0.0004588949,0.006857503,0.00021436028,0.00051775016,0.00063567667,0.00043482767,0.000044469605,0.9653486,0.00072570285,0.0011817333,0.023185804],"study_design_scores_gemma":[0.0114054615,0.00017910068,0.10123531,0.0005633895,0.00048701884,0.000117119154,0.0000672789,0.00051324494,0.8773251,0.00034031676,0.0075062267,0.00026043374],"about_ca_topic_score_codex":0.00024502006,"about_ca_topic_score_gemma":0.000057826604,"teacher_disagreement_score":0.0943778,"about_ca_system_score_codex":0.0007172441,"about_ca_system_score_gemma":0.0012074778,"threshold_uncertainty_score":0.90856266},"labels":[],"label_agreement":null},{"id":"W4417006155","doi":"10.1182/blood-2025-4295","title":"Post-transplant monitoring of multiparameter flow-cytometry (MFC)-based measurable residual disease (MRD) assessment combined with T-cell chimerism following allogeneic stem cell transplantation (HCT) in Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Minimal residual disease; Transplantation; Hematopoietic stem cell transplantation; Myeloid leukemia; Stem cell; Risk stratification; Myelodysplastic syndromes; Leukemia","score_opus":0.009019765977009887,"score_gpt":0.2543601898744024,"score_spread":0.24534042389739252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417006155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954087,0.00077861146,0.001464589,0.00015274565,0.00015835326,0.0015462784,0.00020663881,0.00009679342,0.00018726784],"genre_scores_gemma":[0.9906405,0.00030586089,0.008085644,0.00007449981,0.000026999802,0.0002002311,0.0002509814,0.000086491455,0.0003287623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99626523,0.00027565807,0.00079936016,0.00084918033,0.0010197699,0.0007907829],"domain_scores_gemma":[0.998018,0.00060804596,0.00017640511,0.00059531286,0.00017349244,0.00042874058],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006096485,0.0005446397,0.00096846384,0.0010324508,0.00016283563,0.0000628796,0.00029496828,0.00024810128,0.000010791175],"category_scores_gemma":[0.000028449882,0.0004788235,0.00018520557,0.0009704079,0.00013527606,0.00022450603,0.00005328011,0.00078306685,0.000004856522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056328215,0.0011484198,0.568015,0.0030951104,0.000820844,0.005498872,0.0004432381,0.001380247,0.41359985,0.0000036051576,0.0000058758633,0.00035613307],"study_design_scores_gemma":[0.034709033,0.0017475577,0.65888155,0.0024648635,0.0036822497,0.00013147725,0.00035072071,0.0027984323,0.29467753,0.000005829769,0.0000036579902,0.0005471293],"about_ca_topic_score_codex":0.0002282569,"about_ca_topic_score_gemma":0.000029899069,"teacher_disagreement_score":0.11892231,"about_ca_system_score_codex":0.0005144506,"about_ca_system_score_gemma":0.0019679274,"threshold_uncertainty_score":0.99976635},"labels":[],"label_agreement":null},{"id":"W4417007331","doi":"10.1182/blood-2025-3862","title":"A comparison of overall survival and quality of life in MDS patients treated with azacytidine vs decitabine: A propensity matched registry Study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St Mary's Hospital Centre; HEC Montréal; Queen Elizabeth II Health Sciences Centre; Centre de Développement du Porc du Québec; Dr. Georges-L.-Dumont University Hospital Centre; St. Paul's Hospital; McMaster University; Saskatchewan Cancer Agency; Ottawa Hospital; University of Alberta Hospital; CancerCare Manitoba; Alberta Hospital Edmonton; Vancouver General Hospital; Princess Margaret Cancer Centre; Jewish General Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Decitabine; Myelodysplastic syndromes; Azacitidine; Clinical trial; Comorbidity; Cohort; Quality of life (healthcare); Disease registry; Hypomethylating agent; Randomized controlled trial","score_opus":0.05131948358538161,"score_gpt":0.3510928731173265,"score_spread":0.2997733895319449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417007331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99771607,0.000079721445,0.000006327248,0.00012955704,0.000009763418,0.0013409711,0.000017841363,0.000017893784,0.0006818703],"genre_scores_gemma":[0.99948734,0.000008892555,0.0001871814,0.000024369318,0.000008533875,0.000023618573,0.0000261564,0.000012310619,0.0002215755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981502,0.00024686172,0.0006412713,0.00029839223,0.00046205832,0.00020121384],"domain_scores_gemma":[0.9987326,0.00017252457,0.00020714532,0.00044927603,0.0003384955,0.000099934245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005973243,0.00015158106,0.0010571389,0.00015916467,0.000022951588,0.000007158711,0.00011612775,0.000081002,0.000008723611],"category_scores_gemma":[0.00071053015,0.00011236965,0.00003418952,0.00048074283,0.00012552754,0.000043085816,0.0001480592,0.00025585896,5.755554e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060063805,0.007727476,0.9816902,0.000540877,0.00030170512,0.00001309506,0.0005717625,0.0000013954177,0.0029551687,0.000027175522,0.00009121798,0.00007350854],"study_design_scores_gemma":[0.032989204,0.0017406112,0.95804346,0.00020403328,0.00015490055,8.090184e-7,0.000757461,0.000040826493,0.005974299,0.0000035471094,0.000005966313,0.00008486744],"about_ca_topic_score_codex":0.0042375727,"about_ca_topic_score_gemma":0.00084570056,"teacher_disagreement_score":0.026982823,"about_ca_system_score_codex":0.000076955606,"about_ca_system_score_gemma":0.00040501237,"threshold_uncertainty_score":0.64059705},"labels":[],"label_agreement":null},{"id":"W4417007345","doi":"10.1182/blood-2025-3852","title":"Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Clinical trial; Myelodysplastic syndromes; Disease; MEDLINE; Myeloid leukemia; International Prognostic Scoring System; Systematic review; Clinical endpoint","score_opus":0.0915657376142063,"score_gpt":0.4157354921939886,"score_spread":0.32416975457978225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417007345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874359,0.0054015606,0.00007923381,0.0007584496,0.00016727229,0.0033513007,0.000050200975,0.000028018405,0.0027281055],"genre_scores_gemma":[0.99581593,0.0017209556,0.0020372358,0.00012641322,0.000022835626,0.00007528534,0.000035952566,0.000016990585,0.00014837229],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.978622,0.0051245713,0.014406201,0.000747669,0.000752544,0.00034700424],"domain_scores_gemma":[0.961046,0.023841966,0.010238765,0.002908771,0.0016040589,0.0003604658],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.082059234,0.00022515481,0.004618682,0.0004441343,0.00002322045,0.000013647501,0.0002888127,0.00027169415,0.000020955602],"category_scores_gemma":[0.54815674,0.00016973706,0.00031667238,0.0010426439,0.00031422035,0.00016928908,0.0002306729,0.0005534368,8.1723914e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008612027,0.0020968553,0.14259419,0.8508874,0.00077651447,0.0002033284,0.0001776289,7.582849e-7,0.0013818551,0.0003018451,0.00036688577,0.00035151778],"study_design_scores_gemma":[0.026707157,0.0021792066,0.22644319,0.7295274,0.007674841,0.00055982807,0.00054190704,0.0007622482,0.003963017,0.0012517446,0.000017348028,0.00037212716],"about_ca_topic_score_codex":0.00027715787,"about_ca_topic_score_gemma":0.000038698556,"teacher_disagreement_score":0.4660975,"about_ca_system_score_codex":0.00008849178,"about_ca_system_score_gemma":0.0015327082,"threshold_uncertainty_score":0.9452132},"labels":[],"label_agreement":null},{"id":"W4417007631","doi":"10.1182/blood-2025-5153","title":"A dynamic comprehensive geriatric assessment demonstrates improvement in patient fitness after induction and predicts survival and treatment tolerability among older adults with newly diagnosed acute myeloid leukemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Memorial University of Newfoundland","funders":"","keywords":"Tolerability; Myeloid leukemia; Observational study; Sarcopenia; Induction chemotherapy; Clinical trial; Leukemia; Randomized controlled trial","score_opus":0.0059729783990127355,"score_gpt":0.253874380423955,"score_spread":0.24790140202494226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417007631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995685,0.0005167218,0.00006789953,0.00031324945,0.000088723864,0.0030899222,0.000048401052,0.00005274308,0.00013732885],"genre_scores_gemma":[0.99683434,0.0007546941,0.0011047758,0.00006405607,0.00002694941,0.0010210129,0.00007775456,0.000025939882,0.000090509326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978543,0.00012901949,0.000447949,0.0007586425,0.00035936647,0.00045070078],"domain_scores_gemma":[0.9989403,0.00017405525,0.000109988294,0.00038118125,0.00018443179,0.00021008163],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013372434,0.00036327535,0.0005943319,0.0002943112,0.000092050956,0.000061149236,0.0000630439,0.00017600833,0.000013377207],"category_scores_gemma":[0.000022576292,0.00027223869,0.000049525544,0.00044657823,0.00023367454,0.00016220697,0.00013654989,0.0003527926,6.498057e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019843767,0.0017560286,0.9283146,0.00048144994,0.0009044524,0.0007769406,0.0014310619,0.000035046425,0.0031974942,0.0000073661176,0.000014848627,0.06109628],"study_design_scores_gemma":[0.024914915,0.0024892387,0.965339,0.00047438234,0.0005720296,0.00004903343,0.0018822568,0.002305468,0.0017267226,0.000013421856,0.000013163745,0.0002203571],"about_ca_topic_score_codex":0.0012838626,"about_ca_topic_score_gemma":0.0012512839,"teacher_disagreement_score":0.060875926,"about_ca_system_score_codex":0.0012055124,"about_ca_system_score_gemma":0.0007830487,"threshold_uncertainty_score":0.999973},"labels":[],"label_agreement":null},{"id":"W4417008372","doi":"10.1182/blood-2025-340","title":"Identifying fusions in AML/MDS: An experience from first 400 patients enrolled into myelomatch","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Fredericton","funders":"","keywords":"Concordance; Fluorescence in situ hybridization; Fusion gene; Chromosomal translocation; RNA; Karyotype; DNA sequencing; DNA","score_opus":0.017139624342320435,"score_gpt":0.3199701753135895,"score_spread":0.3028305509712691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417008372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956194,0.00024453993,0.000091270536,0.0005947942,0.00017410789,0.0006087663,0.0000105441095,0.0000893403,0.0025672263],"genre_scores_gemma":[0.9958864,0.00011062539,0.0023662166,0.00042198866,0.000089919915,0.00017431844,0.00009413309,0.000024408391,0.0008319969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815387,0.00008576218,0.0004068584,0.0005079691,0.0004389652,0.0004065744],"domain_scores_gemma":[0.9988005,0.0001693934,0.0000547654,0.00065515423,0.00012407475,0.0001961017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017472438,0.00018325013,0.0003612096,0.00034020562,0.0001926952,0.00005540931,0.00035408215,0.00015590948,0.0004242559],"category_scores_gemma":[0.0004749923,0.00016888576,0.000071104434,0.00075081957,0.0000922944,0.00021006969,0.00033090776,0.00038526856,0.000098208024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003251243,0.002331767,0.9494488,0.00012407408,0.00012071284,0.00023144059,0.018583937,0.0000024388237,0.020754261,0.00007973804,0.001074684,0.006923013],"study_design_scores_gemma":[0.018802917,0.00024255765,0.9514589,0.00071635086,0.00011499001,0.0000046413084,0.0047447323,0.0005150101,0.01953509,0.00072883244,0.0028392763,0.00029674906],"about_ca_topic_score_codex":0.0034169627,"about_ca_topic_score_gemma":0.001355917,"teacher_disagreement_score":0.018477792,"about_ca_system_score_codex":0.00023585078,"about_ca_system_score_gemma":0.0002685497,"threshold_uncertainty_score":0.6886961},"labels":[],"label_agreement":null},{"id":"W4417009029","doi":"10.1182/blood-2025-5178","title":"Performance of the ELN 2022 risk stratification in a real-world Canadian AML patient population","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Leukemia & Lymphoma Society of Canada; University of British Columbia","funders":"","keywords":"Myeloid leukemia; Cohort; CEBPA; Risk stratification; Population; Cohort study; Leukemia; Framingham Risk Score; Survival analysis","score_opus":0.010887565442296888,"score_gpt":0.27104532913407403,"score_spread":0.2601577636917771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98394203,0.000047391357,5.5609524e-7,0.00074215035,0.000048359132,0.0004731159,0.0000149890575,0.000007619731,0.014723791],"genre_scores_gemma":[0.9986063,0.00008501351,0.000082768966,0.000075308635,0.000018243769,0.000031626878,0.000035656813,0.0000053521962,0.0010596833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925154,0.000065514534,0.00021726765,0.000127265,0.00018191314,0.00015649795],"domain_scores_gemma":[0.99945587,0.000028889584,0.00006673898,0.00033210363,0.000063943444,0.000052427305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019918845,0.00005619187,0.00010605516,0.00027618546,0.00006452488,0.000005266635,0.00009079333,0.00004317662,0.000031790376],"category_scores_gemma":[0.000106781765,0.000042461623,0.000028043165,0.0007694251,0.000026196327,0.00003556576,0.000022884216,0.00022870218,0.0000045286056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030930893,0.00008846273,0.9901648,0.000048479276,0.00002157326,0.0000019505806,0.00017287597,0.0000480003,0.0011919035,0.00035106836,0.0005183817,0.007361554],"study_design_scores_gemma":[0.00076419476,0.00006143522,0.9901513,0.00009500461,0.000050218165,0.0000011835969,0.00006586142,0.0025718499,0.0058345017,0.00004731966,0.00032335633,0.00003378729],"about_ca_topic_score_codex":0.27333927,"about_ca_topic_score_gemma":0.41203916,"teacher_disagreement_score":0.1386999,"about_ca_system_score_codex":0.00031204647,"about_ca_system_score_gemma":0.0006569649,"threshold_uncertainty_score":0.7314996},"labels":[],"label_agreement":null},{"id":"W4417009100","doi":"10.1182/blood-2025-5183","title":"Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Clinical trial; Real world data; Minimal residual disease; Leukemia; Disease; Myeloid","score_opus":0.09294386827485815,"score_gpt":0.3616713012801106,"score_spread":0.2687274330052525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85102415,0.015354243,0.003120688,0.073437855,0.0017951688,0.005236941,0.0034713673,0.00046992433,0.046089694],"genre_scores_gemma":[0.977435,0.0022683155,0.003479715,0.0017103539,0.0007559113,0.00014851692,0.010570352,0.00005794677,0.0035738724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976073,0.00015164111,0.0004700238,0.00075911655,0.00063905725,0.00037286375],"domain_scores_gemma":[0.99654,0.0017587609,0.00016597439,0.0011583725,0.00019048335,0.00018640127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011955106,0.00025333342,0.00042222356,0.00023169504,0.00030169706,0.00031174574,0.00090711826,0.000094031755,0.00003734892],"category_scores_gemma":[0.0017642451,0.00018915323,0.00007611483,0.00042478117,0.00017466613,0.0005913653,0.00082986173,0.0004473702,0.0000022898864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014565029,0.00022141909,0.88578117,0.00010436796,0.0021441148,0.00010601672,0.0002860074,0.0000032673731,0.0008767014,0.0034575078,0.086428575,0.019134365],"study_design_scores_gemma":[0.009629955,0.00007399013,0.88955206,0.0008537486,0.0014294722,0.000007730898,0.00055130944,0.0034965153,0.0006027883,0.0016401277,0.091838695,0.00032364143],"about_ca_topic_score_codex":0.0019529691,"about_ca_topic_score_gemma":0.0011246975,"teacher_disagreement_score":0.1264109,"about_ca_system_score_codex":0.00031464925,"about_ca_system_score_gemma":0.0010644465,"threshold_uncertainty_score":0.7713445},"labels":[],"label_agreement":null},{"id":"W4417009140","doi":"10.1182/blood-2025-5193","title":"First-in-human trial of siltuximab in combination with standard induction chemotherapy in patients with acute myeloid leukemia: The Phase 1 siltuxilam study.","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Cytarabine; Myeloid leukemia; Induction chemotherapy; Adverse effect; Toxicity; Chemotherapy; Myeloid; Clinical trial","score_opus":0.010405047148600584,"score_gpt":0.29732188756943495,"score_spread":0.2869168404208344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940331,0.000022490793,0.000026785941,0.0008761691,0.000044971304,0.0044954554,0.000010267568,0.000023120983,0.00046764934],"genre_scores_gemma":[0.99925655,0.00002370287,0.00011047413,0.00007138549,0.000032681637,0.00024268132,0.00004157815,0.000028615466,0.00019232536],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99789375,0.00015714896,0.00052197184,0.0003847955,0.0007172374,0.00032510204],"domain_scores_gemma":[0.99901986,0.0000846991,0.00015812252,0.00047986148,0.00021162393,0.000045809313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007002508,0.00021913371,0.0005594696,0.0005928382,0.000073946176,0.000022099706,0.00021111088,0.00013094961,0.000017616112],"category_scores_gemma":[0.00008079707,0.00014043186,0.000037935944,0.0014521229,0.00013817259,0.00015128872,0.00005169848,0.00066560146,9.2781295e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27821827,0.041120272,0.6631993,0.00020381199,0.00077359064,0.00020984827,0.006891769,0.00008784177,0.0013595831,0.0001926142,0.00023127017,0.007511807],"study_design_scores_gemma":[0.6597314,0.015917808,0.317907,0.0002945284,0.0001672551,0.0000033457343,0.0009902583,0.000060339207,0.0046121553,0.00007377612,0.00010044072,0.00014172599],"about_ca_topic_score_codex":0.00055123353,"about_ca_topic_score_gemma":0.0013057307,"teacher_disagreement_score":0.3815131,"about_ca_system_score_codex":0.0011189828,"about_ca_system_score_gemma":0.0007370804,"threshold_uncertainty_score":0.5726645},"labels":[],"label_agreement":null},{"id":"W4417009147","doi":"10.1182/blood-2025-3508","title":"Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Venetoclax; Azacitidine; Myeloid leukemia; Bone marrow; Leukemia; Myeloid; Cancer; Complete remission","score_opus":0.010224258869297675,"score_gpt":0.2512293891688022,"score_spread":0.24100513029950454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939685,0.00011232429,0.000112021,0.0005757943,0.00003877685,0.002645017,0.00056492625,0.00033879877,0.001643835],"genre_scores_gemma":[0.98433346,0.00008558778,0.0013430294,0.001494031,0.00003643351,0.0003548707,0.0009213973,0.00016001897,0.011271202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951391,0.00019097363,0.0008114853,0.0011657816,0.0012491731,0.0014434794],"domain_scores_gemma":[0.9967573,0.000267866,0.00036725024,0.0015035969,0.00070695474,0.000397001],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039771342,0.00088636996,0.0017513616,0.00079834956,0.0001872354,0.00009066846,0.0006833146,0.00040558717,0.00017085063],"category_scores_gemma":[0.00036158893,0.0005697767,0.00013381768,0.001704411,0.00041916015,0.00029367785,0.0003405346,0.0012978816,0.000052245214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009116802,0.0008273783,0.97956765,0.00011783308,0.00377034,0.0028547964,0.00038800473,0.0004700787,0.0008442057,0.0000105316085,0.0014969003,0.00053549226],"study_design_scores_gemma":[0.10834945,0.0059987195,0.87071,0.00091786875,0.0016553767,0.0000732202,0.00012063401,0.0006774631,0.010459267,0.000045872417,0.00020106278,0.00079106225],"about_ca_topic_score_codex":0.0019740018,"about_ca_topic_score_gemma":0.0014232117,"teacher_disagreement_score":0.10885763,"about_ca_system_score_codex":0.006894172,"about_ca_system_score_gemma":0.005519088,"threshold_uncertainty_score":0.9996754},"labels":[],"label_agreement":null},{"id":"W4417009447","doi":"10.1182/blood-2025-3418","title":"Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Venetoclax; Myeloid leukemia; Refractory (planetary science); Azacitidine; Salvage therapy; Hematopoietic stem cell transplantation; Phases of clinical research; Complete remission; Leukemia","score_opus":0.015226456477174697,"score_gpt":0.32337671257225864,"score_spread":0.30815025609508395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879789,0.00017130497,0.000021398626,0.0013820049,0.00010646716,0.009507266,0.000262729,0.00010708363,0.00046284648],"genre_scores_gemma":[0.98143,0.00011399413,0.00079041655,0.0010262784,0.000049301932,0.0022338282,0.00049592514,0.00009223675,0.013768016],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99675614,0.0002512055,0.00071250356,0.0007910929,0.0007345884,0.0007544574],"domain_scores_gemma":[0.99768424,0.000644088,0.0001997097,0.0010738883,0.00021247278,0.00018559559],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050885754,0.00051795633,0.0008688131,0.00034784002,0.00024841435,0.000071562215,0.00045566994,0.00017920883,0.0000816672],"category_scores_gemma":[0.00029560915,0.00027846295,0.00018938568,0.0008323386,0.00011715206,0.00015333568,0.00009648484,0.00045623572,0.000025873442],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06391738,0.12839262,0.65292144,0.0005070232,0.013595163,0.0023668993,0.014286468,0.000003274278,0.00943934,0.00003528333,0.062307492,0.052227598],"study_design_scores_gemma":[0.63940567,0.06759241,0.19615702,0.00052953715,0.007860079,0.00004372867,0.0069298767,0.00012128161,0.010934443,0.000035051296,0.06923171,0.0011591685],"about_ca_topic_score_codex":0.00030027798,"about_ca_topic_score_gemma":0.00015888155,"teacher_disagreement_score":0.5754883,"about_ca_system_score_codex":0.0018082772,"about_ca_system_score_gemma":0.0014205402,"threshold_uncertainty_score":0.99996674},"labels":[],"label_agreement":null},{"id":"W4417009462","doi":"10.1182/blood-2025-3440","title":"CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Neutropenia; Febrile neutropenia; Adverse effect; Concomitant; CYP3A4; Venetoclax; Placebo; Pharmacokinetics; Myeloid leukemia","score_opus":0.008985298497670649,"score_gpt":0.28161595335693446,"score_spread":0.2726306548592638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944044,0.0002891831,0.000008475239,0.00061957614,0.00007254007,0.0035801646,0.00005198874,0.00006498646,0.0009087169],"genre_scores_gemma":[0.99815714,0.00016819389,0.00016143106,0.00064961246,0.000083114006,0.0004238611,0.000089469875,0.000055761855,0.00021139279],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963755,0.00045583854,0.0006979673,0.0008300599,0.0008593558,0.00078126974],"domain_scores_gemma":[0.9983204,0.00036135394,0.00014661491,0.00079380895,0.00014723619,0.000230574],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008342239,0.0004606544,0.00068192824,0.0006027455,0.00019306061,0.00009597341,0.00040846245,0.00021909356,0.000032213553],"category_scores_gemma":[0.00028093037,0.00029997234,0.00008311544,0.0015628504,0.00021341219,0.00024071438,0.00026183514,0.0010810449,0.000016253569],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005445018,0.01894816,0.90176725,0.0002671717,0.0008294839,0.007352338,0.01123467,0.000047671092,0.038523477,0.000041356005,0.0022779575,0.013265455],"study_design_scores_gemma":[0.35801655,0.012073855,0.49328884,0.0020472228,0.0018705078,0.00017685456,0.012535635,0.0013336275,0.115461566,0.00015736515,0.0017613502,0.0012766311],"about_ca_topic_score_codex":0.0006841901,"about_ca_topic_score_gemma":0.0005981831,"teacher_disagreement_score":0.4084784,"about_ca_system_score_codex":0.00052717834,"about_ca_system_score_gemma":0.00084271166,"threshold_uncertainty_score":0.9999452},"labels":[],"label_agreement":null},{"id":"W4417010092","doi":"10.1182/blood-2025-7849","title":"Inhibitors of RAD51 as potential novel therapies in Acute Myeloid Leukemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Lawson Health Research Institute; McMaster University; McMaster University Medical Centre","funders":"","keywords":"RAD51; Myeloid leukemia; Homologous recombination; Synthetic lethality; DNA repair; Cancer cell; Myeloid; Cancer; Cell culture","score_opus":0.009361340339531064,"score_gpt":0.2795919969100128,"score_spread":0.27023065657048173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417010092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98826486,0.0009136538,0.00012451959,0.0017761717,0.00015170782,0.00046022178,0.000013606581,0.000050518967,0.00824473],"genre_scores_gemma":[0.9935972,0.00033049134,0.0014439615,0.00041480115,0.00013205038,0.000030191006,0.000020152313,0.000025871037,0.0040052654],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998479,0.00004142562,0.00040442045,0.0003110654,0.00039565106,0.0003684353],"domain_scores_gemma":[0.9992256,0.00007675865,0.00007134436,0.00041537973,0.00012170937,0.00008918408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028719622,0.00017694983,0.00043909793,0.00047929017,0.000041571147,0.000015228952,0.00021784828,0.00018909285,0.00009930236],"category_scores_gemma":[0.00014830445,0.00015343391,0.00013300305,0.0007183523,0.00016594277,0.00007801108,0.00016004356,0.0004504598,0.0000354036],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006801559,0.00085954764,0.019599207,0.00020814127,0.00086935755,0.00032247422,0.00066631724,0.000011710785,0.96705425,0.0014752396,0.002074722,0.006178896],"study_design_scores_gemma":[0.029612362,0.0006546507,0.100368686,0.0005865913,0.0006210267,0.0002625173,0.00092034356,0.00027590053,0.8597714,0.00077510026,0.0058248444,0.00032658892],"about_ca_topic_score_codex":0.00046832126,"about_ca_topic_score_gemma":0.000022506922,"teacher_disagreement_score":0.10728284,"about_ca_system_score_codex":0.00025330042,"about_ca_system_score_gemma":0.0012654269,"threshold_uncertainty_score":0.62568533},"labels":[],"label_agreement":null},{"id":"W4417010229","doi":"10.1182/blood-2025-235","title":"Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus","funders":"","keywords":"Azacitidine; Clinical endpoint; Myelodysplastic syndromes; Subgroup analysis; International Prognostic Scoring System; Placebo; Neutropenia; Phases of clinical research; Surrogate endpoint; Eltrombopag","score_opus":0.02219161213324807,"score_gpt":0.30959028125290716,"score_spread":0.2873986691196591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417010229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99425226,0.00065840926,0.000056137582,0.00011724037,0.00008516279,0.004260314,0.00025199208,0.000060860864,0.0002576161],"genre_scores_gemma":[0.9982029,0.00026679097,0.00030978225,0.000034227145,0.000074881544,0.0005420962,0.0002826194,0.00007332765,0.00021333346],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99642044,0.0005733533,0.00068198476,0.00083827635,0.0008803803,0.0006055673],"domain_scores_gemma":[0.9956448,0.002653977,0.00037018966,0.0008481693,0.00025514074,0.0002277057],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039677985,0.00063165225,0.0017586257,0.00047644737,0.00016180544,0.000059784856,0.00030420494,0.00013058173,0.000073350326],"category_scores_gemma":[0.00028623315,0.0003326145,0.00010546157,0.0010679233,0.00069167063,0.00017649011,0.00014492088,0.00052142696,0.0000057214606],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5810567,0.005985756,0.3997457,0.00011694027,0.009079373,0.0005909611,0.0014060665,0.00012637982,0.00024831668,0.000016465261,0.00007549586,0.0015518118],"study_design_scores_gemma":[0.7191542,0.019399974,0.2507901,0.000656902,0.006630881,0.000012485265,0.001269189,0.0002859186,0.0014573741,0.000009882161,0.000026610187,0.00030648688],"about_ca_topic_score_codex":0.0033013474,"about_ca_topic_score_gemma":0.0022733733,"teacher_disagreement_score":0.1489556,"about_ca_system_score_codex":0.00044558474,"about_ca_system_score_gemma":0.0006061325,"threshold_uncertainty_score":0.99991256},"labels":[],"label_agreement":null},{"id":"W4417010464","doi":"10.1182/blood-2025-1467","title":"Enhanced FLI1 accessibility mediates STAG2-mutant leukemogenesis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Chromatin; Stem cell; Progenitor cell; Myeloid; Haematopoiesis; Hematopoietic stem cell; Population; Transcription factor","score_opus":0.01654294357995502,"score_gpt":0.316675972511159,"score_spread":0.30013302893120397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417010464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97918177,0.00081353885,0.00047495237,0.0013928224,0.00014871576,0.00057574915,0.000020689897,0.00017924981,0.017212527],"genre_scores_gemma":[0.99383044,0.00025921132,0.0009378837,0.00065250293,0.00017647025,0.00008299307,0.000030430203,0.000024892075,0.004005184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981012,0.0000854007,0.00037226672,0.00052204635,0.0004294467,0.0004896349],"domain_scores_gemma":[0.99848515,0.00024147963,0.000059635615,0.000777135,0.0002335807,0.00020300211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045879773,0.00020077464,0.00042002677,0.00021692645,0.00011096264,0.000037650687,0.000311734,0.00016770369,0.0004412173],"category_scores_gemma":[0.00082957704,0.00016307681,0.00012965522,0.00070942164,0.00013747826,0.00009734462,0.00023143632,0.0003234728,0.00014861513],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004380429,0.0011025385,0.053444,0.0005224251,0.0005531188,0.0001814565,0.00025002845,0.0000016800279,0.92382157,0.00037743826,0.0019448607,0.01736284],"study_design_scores_gemma":[0.005228283,0.00012781956,0.08215949,0.00010236937,0.0002735379,0.000013320724,0.00014018541,0.000087085115,0.90977675,0.0003518099,0.0015904363,0.00014891403],"about_ca_topic_score_codex":0.00008781883,"about_ca_topic_score_gemma":0.0000299203,"teacher_disagreement_score":0.028715484,"about_ca_system_score_codex":0.000292076,"about_ca_system_score_gemma":0.0012449995,"threshold_uncertainty_score":0.6650079},"labels":[],"label_agreement":null},{"id":"W4417011663","doi":"10.1182/blood-2025-790","title":"Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; London Health Sciences Centre","funders":"","keywords":"Decitabine; Cytopenia; Myelodysplastic syndromes; Azacitidine; Regimen; Clinical endpoint; Phases of clinical research; Dosing; Pharmacodynamics; Neutropenia","score_opus":0.005410488145994367,"score_gpt":0.23866160926690638,"score_spread":0.233251121120912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417011663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973722,0.00022432007,0.00010259933,0.00020977526,0.000077216,0.0007310782,0.000039211813,0.000094473486,0.0011491037],"genre_scores_gemma":[0.99700046,0.000105436324,0.00084713765,0.00012858571,0.000052315132,0.000047691286,0.00006910753,0.000041290114,0.0017079747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825734,0.000063742926,0.0002776421,0.00046622055,0.00044533034,0.0004897537],"domain_scores_gemma":[0.9987502,0.00022865426,0.00007825317,0.0004443608,0.00022711727,0.00027138653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019041197,0.00026236908,0.00045512925,0.00031480147,0.0001340712,0.000043374992,0.00014475903,0.00012250002,0.00009226084],"category_scores_gemma":[0.0005391,0.00019278452,0.000051221345,0.0005903736,0.00025217645,0.00013241777,0.00018040997,0.00044719776,0.00004213728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062763836,0.0010588963,0.9931798,0.0003381615,0.00046486192,0.0002740876,0.000080136575,0.0000057874545,0.0003559287,0.000051733987,0.0011073622,0.0024556024],"study_design_scores_gemma":[0.019979062,0.00085952843,0.97391343,0.00059075124,0.00061813276,0.00004030884,0.00004674747,0.00024788946,0.0032178129,0.00004283377,0.0002378064,0.00020571855],"about_ca_topic_score_codex":0.00008407011,"about_ca_topic_score_gemma":0.000048362752,"teacher_disagreement_score":0.019351423,"about_ca_system_score_codex":0.00009518493,"about_ca_system_score_gemma":0.0002928628,"threshold_uncertainty_score":0.7861524},"labels":[],"label_agreement":null},{"id":"W4417012866","doi":"10.1182/blood-2025-7369","title":"Impact of allogeneic transplant vs hypomethylating agents in high-risk myelodysplastic syndromes: A prisma-guided systematic review","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myelodysplastic syndromes; Hypomethylating agent; Transplantation; Retrospective cohort study; Cumulative incidence; Azacitidine; Prospective cohort study; Hematopoietic stem cell transplantation; Overall survival","score_opus":0.0285742479294324,"score_gpt":0.33505561178929655,"score_spread":0.30648136385986413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417012866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800406,0.016283032,0.0001621097,0.00014288431,0.000048960752,0.0028834683,0.000055416403,0.00005144447,0.00033209432],"genre_scores_gemma":[0.9898242,0.008678377,0.0007540568,0.00013924717,0.000019426956,0.00020571923,0.000043769505,0.000037359365,0.00029788713],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.9966569,0.00047766356,0.0013461874,0.00042119995,0.00055842707,0.00053962326],"domain_scores_gemma":[0.99788177,0.00070395245,0.00034207365,0.0007386076,0.00015793397,0.00017564958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001421394,0.00030420546,0.0017586679,0.0006026397,0.000048669517,0.00001321634,0.00032867407,0.00016317432,0.00010020334],"category_scores_gemma":[0.0024992505,0.00022972419,0.00034212717,0.001283694,0.00006480582,0.000061815655,0.00007820044,0.0005096474,0.00005709209],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021653494,0.0014742014,0.2617207,0.7225221,0.0037474988,0.0012913554,0.00055018254,0.000078341705,0.0074867015,0.000057608617,0.0006107253,0.00024407005],"study_design_scores_gemma":[0.015014899,0.001444753,0.5017667,0.4684073,0.00869278,0.00090340787,0.000055648175,0.00073733286,0.0024239155,0.00009764723,0.0000047039216,0.00045091618],"about_ca_topic_score_codex":0.0005688337,"about_ca_topic_score_gemma":0.000014994464,"teacher_disagreement_score":0.25411478,"about_ca_system_score_codex":0.00037481615,"about_ca_system_score_gemma":0.0007728395,"threshold_uncertainty_score":0.936788},"labels":[],"label_agreement":null},{"id":"W4417013032","doi":"10.1182/blood-2025-5240","title":"Real-world evidence evaluation of the safety and efficacy of intensive chemotherapy with or without gemtuzumab ozogamicin (GO) in patients with newly diagnosed Acute Myeloid Leukemia (AML) and favorable or intermediate risk cytogenetics","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Gemtuzumab ozogamicin; Cytarabine; Myeloid leukemia; NPM1; Chemotherapy; Chemotherapy regimen; Cytogenetics; Induction chemotherapy","score_opus":0.020144692625386727,"score_gpt":0.3102496787177446,"score_spread":0.2901049860923579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417013032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966371,0.00021750116,0.00006529416,0.0002604614,0.00003016117,0.0026152423,0.00003487831,0.000015921756,0.00012343375],"genre_scores_gemma":[0.9947483,0.003039206,0.0014186504,0.00021931197,0.000021195969,0.000043291217,0.00001306796,0.000037974525,0.00045900917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757457,0.0003017348,0.00053682347,0.00046558923,0.00080975285,0.00031154288],"domain_scores_gemma":[0.996803,0.0007272228,0.00038708674,0.0006243123,0.0013617816,0.000096597585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080912054,0.00027341468,0.0007022311,0.00030319038,0.000070431044,0.000017830807,0.0002229208,0.00010621747,0.000020620038],"category_scores_gemma":[0.0015016001,0.00014428546,0.00004406313,0.0010205831,0.00050660403,0.00011138828,0.00017191873,0.00041366168,5.8922615e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025807522,0.00029752255,0.9572335,0.00024209746,0.00067993405,0.0000143772395,0.0016803888,0.000109763256,0.0016712106,0.000006001898,0.00007176183,0.012185936],"study_design_scores_gemma":[0.054494213,0.0022920694,0.9176723,0.0028485176,0.0016347476,0.000010486245,0.00050565496,0.0016164142,0.018738104,0.000013049567,0.000016265532,0.00015821819],"about_ca_topic_score_codex":0.0010705504,"about_ca_topic_score_gemma":0.002781636,"teacher_disagreement_score":0.039561223,"about_ca_system_score_codex":0.0005055153,"about_ca_system_score_gemma":0.002488942,"threshold_uncertainty_score":0.588379},"labels":[],"label_agreement":null},{"id":"W4417013071","doi":"10.1182/blood-2025-5247","title":"Validation of the FL/IL6 score, a new dynamic cytokine-based risk-model in adults with acute myeloid leukemia, a prospective multicentre filo study.","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Myeloid leukemia; Prospective cohort study; Cohort; Overall survival; Cohort study; Survival analysis; Proportional hazards model","score_opus":0.007577081449724317,"score_gpt":0.26532991793469274,"score_spread":0.25775283648496844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417013071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99312043,0.00008009518,0.000962568,0.0005039974,0.000034801003,0.004284824,0.00007161402,0.000062790765,0.0008788519],"genre_scores_gemma":[0.9952722,0.00003916909,0.0027384092,0.000104839295,0.000029027464,0.00019149827,0.000035207224,0.000039965667,0.0015496804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773794,0.00016688637,0.00044725128,0.0005718698,0.0006575916,0.00041848383],"domain_scores_gemma":[0.99835193,0.00015529152,0.00023030568,0.0008414448,0.0003029816,0.000118025484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031102903,0.0002825206,0.0004826212,0.00034357153,0.000097951466,0.000022326849,0.00035884423,0.00013334824,0.000018341709],"category_scores_gemma":[0.0003757034,0.00018754079,0.00011185507,0.0013799302,0.00012390212,0.0001006038,0.00015651596,0.00073383236,0.000008281263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009475705,0.0042288047,0.95622605,0.0004956768,0.001561645,0.00021934262,0.005427948,0.0067319986,0.012931986,0.00006708942,0.00039172792,0.002242015],"study_design_scores_gemma":[0.09027397,0.0015739712,0.6684823,0.0021871794,0.0023441385,0.000027693815,0.0020034087,0.13620324,0.0963244,0.00020602833,0.000010678506,0.0003629734],"about_ca_topic_score_codex":0.002065162,"about_ca_topic_score_gemma":0.0018553172,"teacher_disagreement_score":0.28774375,"about_ca_system_score_codex":0.0010027285,"about_ca_system_score_gemma":0.004253237,"threshold_uncertainty_score":0.76476914},"labels":[],"label_agreement":null},{"id":"W4417013395","doi":"10.1182/blood-2025-1738","title":"Outcomes following MRD relapse in AML patients monitored by droplet digital PCR","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Leukemia & Lymphoma Society of Canada; University of British Columbia","funders":"","keywords":"Myeloid leukemia; Minimal residual disease; Leukemia; Induction chemotherapy; Bone marrow; NPM1; Chemotherapy; Chemotherapy regimen; Cancer","score_opus":0.00768189524713023,"score_gpt":0.2748417843216409,"score_spread":0.26715988907451066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417013395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99051213,0.00017858995,0.000010984844,0.0008370898,0.00019531739,0.0004500148,0.000036061854,0.000071774215,0.007708029],"genre_scores_gemma":[0.99229413,0.00001107167,0.00015238416,0.000314057,0.000027452203,0.0000401332,0.00013716113,0.000026239362,0.0069973413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855375,0.000031679014,0.00030823715,0.00030667905,0.000402092,0.00039758458],"domain_scores_gemma":[0.99929535,0.00013323643,0.00003490614,0.00036360117,0.000052086427,0.00012080706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011918266,0.00016406445,0.00035247192,0.00023073606,0.00004991043,0.00005003417,0.00017434101,0.0001275594,0.000013966767],"category_scores_gemma":[0.00066209515,0.00014065843,0.00013685382,0.0004336487,0.00003812974,0.00015964235,0.00015678647,0.00035586147,0.00008130878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045945642,0.0008262376,0.9881902,0.00003419259,0.00016473675,0.0001302784,0.00010430932,1.909559e-7,0.0006965556,0.000015625634,0.007628398,0.0021633334],"study_design_scores_gemma":[0.019055359,0.00021234028,0.97116673,0.00018412503,0.00013159547,0.0000024464787,0.00017031083,0.00002707468,0.0034505262,0.000087641885,0.00531975,0.00019210407],"about_ca_topic_score_codex":0.00009541237,"about_ca_topic_score_gemma":0.0000047238473,"teacher_disagreement_score":0.019009415,"about_ca_system_score_codex":0.00020447694,"about_ca_system_score_gemma":0.0001739936,"threshold_uncertainty_score":0.5735885},"labels":[],"label_agreement":null},{"id":"W4417014157","doi":"10.1182/blood-2025-878","title":"Optimized treatment for pediatric patients with low-risk Acute Myeloid Leukemia: A report from the Children's oncology group study AAML1831","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Astellas Pharma; Jazz Pharmaceuticals","keywords":"Cytarabine; Anthracycline; Induction chemotherapy; Myeloid leukemia; Chemotherapy; Cumulative incidence; Chemotherapy regimen; Minimal residual disease; Idarubicin; Group B","score_opus":0.008218902604893885,"score_gpt":0.28099442078964765,"score_spread":0.27277551818475376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417014157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898702,0.0003359513,0.00054925214,0.0006084368,0.00017024524,0.007505113,0.00027119648,0.00012455978,0.0005650515],"genre_scores_gemma":[0.986139,0.0004678847,0.007342743,0.00043156068,0.0007471015,0.0020140896,0.0011361842,0.000086042324,0.0016354066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971709,0.00023771607,0.0006078713,0.0008577334,0.00052558375,0.0006001663],"domain_scores_gemma":[0.9971141,0.0008925777,0.00032051274,0.0011835074,0.0002985558,0.00019074812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047273134,0.00040437022,0.0008420165,0.00019445285,0.00034238017,0.000045843397,0.00035282536,0.0002264237,0.000039622733],"category_scores_gemma":[0.0003740852,0.00022877114,0.00022612335,0.00059607334,0.000104243976,0.00007367755,0.00019288776,0.00051755767,0.000020852904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004342222,0.0076609617,0.9721093,0.000017403718,0.0050968872,0.0005682879,0.00059213926,0.000017817274,0.000025285533,0.000006882347,0.004336171,0.0052266414],"study_design_scores_gemma":[0.106965505,0.008743107,0.87030786,0.00003067129,0.0117126,0.000059897615,0.00034362412,0.000067623834,0.00025295193,0.000039661903,0.0012079219,0.0002685733],"about_ca_topic_score_codex":0.0013103612,"about_ca_topic_score_gemma":0.00012875452,"teacher_disagreement_score":0.102623284,"about_ca_system_score_codex":0.001203797,"about_ca_system_score_gemma":0.0019015494,"threshold_uncertainty_score":0.9329016},"labels":[],"label_agreement":null},{"id":"W4417015538","doi":"10.1182/blood-2025-964","title":"Grip strength predicts overall survival of patients with myelodysplastic syndrome in a multivariable model","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Leukemia & Lymphoma Society of Canada; University of Winnipeg; University of Manitoba; McMaster University; Providence Health Care; University of Alberta; Dr. Georges-L.-Dumont University Hospital Centre; Saskatchewan Cancer Agency; Ottawa Hospital; McGill University; Princess Margaret Cancer Centre; University of Calgary; Sunnybrook Hospital; Dalhousie University; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Grip strength; Logistic regression; Hand strength; Cohort; Survival analysis; Myelodysplastic syndromes; Cohort study; Prospective cohort study; Disease","score_opus":0.009447378572110457,"score_gpt":0.24505071694679414,"score_spread":0.2356033383746837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417015538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993409,0.00003766218,0.0004489372,0.00007766752,0.000044394088,0.00060981594,0.00007335653,0.000036382273,0.005262797],"genre_scores_gemma":[0.99597454,0.000011153506,0.002299876,0.000045414246,0.000012119912,0.000038336162,0.000070233196,0.000023068424,0.0015252595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846655,0.000048083915,0.00031637275,0.00031277657,0.0004831923,0.0003730336],"domain_scores_gemma":[0.99907506,0.00018259781,0.000064754255,0.00037161124,0.00019398009,0.00011200645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001768064,0.00016743015,0.00042196087,0.00030456705,0.000026289517,0.000009079741,0.00015722777,0.00011807226,0.000032966076],"category_scores_gemma":[0.00034938793,0.00013226314,0.000038740243,0.0004641374,0.00008051707,0.0000946956,0.00011460776,0.00034638026,0.000005745693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014441726,0.0039610947,0.98827946,0.0006950873,0.0004253864,0.00017625054,0.00018958985,0.001969396,0.00096335914,0.0013869823,0.00028864166,0.00022056923],"study_design_scores_gemma":[0.033998188,0.0007867588,0.9248525,0.0008033469,0.00025380697,0.000009415572,0.000031579766,0.03773434,0.0011047228,0.0002120485,0.00004547072,0.00016780799],"about_ca_topic_score_codex":0.00014840593,"about_ca_topic_score_gemma":0.000031538795,"teacher_disagreement_score":0.06342696,"about_ca_system_score_codex":0.00013004741,"about_ca_system_score_gemma":0.0006969453,"threshold_uncertainty_score":0.5393535},"labels":[],"label_agreement":null},{"id":"W4417015698","doi":"10.1182/blood-2025-1658","title":"Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"IDH1; Adverse effect; Myeloid leukemia; Refractory (planetary science); Azacitidine; First line; Absolute neutrophil count; Retrospective cohort study; Myeloid","score_opus":0.025633408944226988,"score_gpt":0.31354692187287564,"score_spread":0.28791351292864864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417015698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902413,0.00018142875,0.00015171415,0.002296506,0.00006926821,0.0067503294,0.00007769489,0.00006652205,0.00016527061],"genre_scores_gemma":[0.9973411,0.00011257917,0.00033586804,0.0003835724,0.00017243285,0.0007825945,0.00003154782,0.00007377443,0.0007665383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743056,0.00021932379,0.0007607341,0.0006069196,0.00054681057,0.00043563676],"domain_scores_gemma":[0.9972983,0.0010899446,0.00018338002,0.0010514335,0.000246755,0.00013018622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006525441,0.00034634068,0.00090341177,0.00026426106,0.00011378707,0.00003822611,0.00055391714,0.00011310915,0.00013957392],"category_scores_gemma":[0.00040344795,0.00019303923,0.00009202144,0.0009240206,0.000115044495,0.00006674573,0.0001980253,0.00048248458,0.000005125524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030485215,0.040115494,0.88956094,0.00017792768,0.0052332343,0.000480051,0.022000615,0.000036171998,0.007231842,0.000048845417,0.0029998343,0.00162986],"study_design_scores_gemma":[0.2095065,0.052955084,0.6965757,0.00088349613,0.0017544501,0.000015354182,0.026004478,0.0017260492,0.009352415,0.00015529126,0.0005819044,0.00048929633],"about_ca_topic_score_codex":0.011497473,"about_ca_topic_score_gemma":0.05410486,"teacher_disagreement_score":0.19298522,"about_ca_system_score_codex":0.00015863543,"about_ca_system_score_gemma":0.0005993417,"threshold_uncertainty_score":0.99508506},"labels":[],"label_agreement":null},{"id":"W4417015726","doi":"10.1182/blood-2025-1672","title":"FLT3 inhibition with midostaurin offsets poor prognosis in NPM1/FLT3/DNMT3a triple-mutated AML","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Midostaurin; NPM1; Survival analysis; Retrospective cohort study; Cytarabine; Induction chemotherapy; Chemotherapy; Cancer; Chemotherapy regimen","score_opus":0.011272230175628567,"score_gpt":0.27750763342586476,"score_spread":0.2662354032502362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417015726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98550284,0.00029540985,0.0000473704,0.005923389,0.00005548449,0.0016635535,0.000026111209,0.00016446898,0.006321393],"genre_scores_gemma":[0.9951552,0.00006797848,0.000945363,0.000498259,0.00008470325,0.00030760327,0.00018810353,0.00004134532,0.0027114486],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99790454,0.00012212318,0.0004185123,0.0005154987,0.00048202102,0.0005572873],"domain_scores_gemma":[0.99911433,0.00010247197,0.00007578391,0.00032655697,0.00021064766,0.00017022187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038004652,0.00024495507,0.0004367563,0.0006464591,0.000077489014,0.00004001478,0.00012930662,0.00019720495,0.00013034753],"category_scores_gemma":[0.00026513278,0.00019832543,0.00007722282,0.0015587632,0.00012624924,0.00012686191,0.00010294696,0.00058505655,0.00008897278],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050327615,0.009935851,0.7083984,0.0019738304,0.0012280842,0.0062453905,0.0015712219,0.000014962907,0.21163994,0.0008306213,0.028324258,0.02480471],"study_design_scores_gemma":[0.05174612,0.0018566438,0.23465432,0.0019481604,0.0005732948,0.00039727247,0.0007375597,0.0006899843,0.7028754,0.00021117301,0.00379236,0.00051771785],"about_ca_topic_score_codex":0.00035460488,"about_ca_topic_score_gemma":0.00024169855,"teacher_disagreement_score":0.49123546,"about_ca_system_score_codex":0.00029880926,"about_ca_system_score_gemma":0.00079610647,"threshold_uncertainty_score":0.80874765},"labels":[],"label_agreement":null},{"id":"W4417016030","doi":"10.1182/blood-2025-1644","title":"Post-transplant maintenance with sorafenib is safe and effective in pediatric patients with har FLT3/ITD AML: A report from the Children's oncology group protocol AAML1031","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Sorafenib; Cohort; Tolerability; Chemotherapy; Hematopoietic stem cell transplantation; Chemotherapy regimen; Transplantation; Induction chemotherapy","score_opus":0.0032854587040255633,"score_gpt":0.24945933932135128,"score_spread":0.24617388061732573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417016030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9339451,0.000051093728,0.00007541268,0.0015782809,0.000021011434,0.06301428,0.0001232022,0.000040756124,0.0011508458],"genre_scores_gemma":[0.9584544,0.000025790585,0.0009736887,0.0012050385,0.0001360089,0.038767703,0.00016518685,0.000042924836,0.0002292648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997915,0.00019166133,0.00035247402,0.0006483763,0.00042582868,0.00046660315],"domain_scores_gemma":[0.99859774,0.00036161512,0.00016166276,0.0005235139,0.00023109968,0.00012435559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037585167,0.00027464028,0.00048158612,0.0001744465,0.00010625996,0.000026211063,0.00019481515,0.00016635805,0.000025564212],"category_scores_gemma":[0.00015892167,0.00015005976,0.000046314282,0.00056278805,0.0002001875,0.000086484855,0.00009520929,0.0007092417,0.000008552656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048511634,0.001107591,0.989318,0.0001336711,0.00031055367,0.0011649488,0.00063436216,4.2826238e-7,0.00010957281,0.00002325132,0.0006953758,0.0016510927],"study_design_scores_gemma":[0.028085241,0.0024587149,0.96659636,0.00033752737,0.0004616951,0.00022917577,0.000064157444,0.000006370066,0.0006198876,0.000027179465,0.00093835883,0.00017531982],"about_ca_topic_score_codex":0.0012450806,"about_ca_topic_score_gemma":0.00058248115,"teacher_disagreement_score":0.024509277,"about_ca_system_score_codex":0.00020089315,"about_ca_system_score_gemma":0.00067205576,"threshold_uncertainty_score":0.61192596},"labels":[],"label_agreement":null},{"id":"W4417016281","doi":"10.1182/blood-2025-6765","title":"The mitochondrial protease YME1L regulates type 1 interferon signaling via the cgas-sting pathway in AML","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Gene knockdown; Downregulation and upregulation; Myeloid leukemia; Haematopoiesis; Signal transduction; Myeloid; Interferon; Cell growth; RNA interference","score_opus":0.01538632082903093,"score_gpt":0.2779810156672474,"score_spread":0.2625946948382165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417016281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905273,0.0009992722,0.00012539884,0.0044701365,0.00030502488,0.0013402697,0.0000022721704,0.000064010135,0.0021663662],"genre_scores_gemma":[0.9951797,0.000021446976,0.00056243327,0.0002850491,0.00047762183,0.000118445256,0.000008547734,0.00002484863,0.0033218914],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850684,0.00019077965,0.00032414598,0.00027793285,0.00028468,0.00041560302],"domain_scores_gemma":[0.9986612,0.0005457891,0.00006440469,0.0005259373,0.00013522293,0.00006739627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006350276,0.00015099703,0.0002047706,0.00010143916,0.00024692275,0.00006997865,0.00033309826,0.000104926636,0.000034304474],"category_scores_gemma":[0.0012541757,0.00008276124,0.00007220764,0.0005517502,0.00013927018,0.000044580294,0.00021035683,0.000667435,0.00004298903],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022414504,0.0004528131,0.008691418,0.00020477727,0.00032245793,0.00024315866,0.0012864036,0.000040141713,0.9528039,0.0006837089,0.0027927288,0.030237043],"study_design_scores_gemma":[0.011717112,0.0009831373,0.005620674,0.0014124482,0.000234345,0.00009437025,0.0013239254,0.0034190894,0.95117277,0.0028157919,0.020853305,0.00035303453],"about_ca_topic_score_codex":0.00016663597,"about_ca_topic_score_gemma":0.00006677624,"teacher_disagreement_score":0.029884009,"about_ca_system_score_codex":0.00013585367,"about_ca_system_score_gemma":0.00045800058,"threshold_uncertainty_score":0.33749053},"labels":[],"label_agreement":null},{"id":"W4417016420","doi":"10.1182/blood-2025-2660","title":"External validation of an online predictive model for myelodysplastic syndrome","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Cytopenia; Cohort; Myelodysplastic syndromes; Predictive value; Gold standard (test); Anemia; Predictive value of tests; Bone marrow; Retrospective cohort study","score_opus":0.029526592938433526,"score_gpt":0.317789488804225,"score_spread":0.28826289586579146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417016420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90402734,0.00006040615,0.09461571,0.00015501147,0.000040158404,0.00058733096,0.00016724122,0.000038628823,0.00030818913],"genre_scores_gemma":[0.97873574,0.000012021573,0.019070426,0.00007360191,0.000060698327,0.00006009028,0.0001560936,0.00001669342,0.0018146039],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9991047,0.000024043653,0.00023380159,0.00021968277,0.0002282019,0.0001895679],"domain_scores_gemma":[0.99924946,0.00011813463,0.00005477125,0.000262739,0.00022897613,0.000085941545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017028567,0.000095211144,0.00023436536,0.0001908181,0.000036032452,0.0000071214636,0.00012071146,0.00008693993,0.000016826632],"category_scores_gemma":[0.00027249436,0.0000853764,0.000062337735,0.00017711708,0.000054035798,0.0000874732,0.000047163707,0.00014550563,0.000003097134],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01581665,0.03006067,0.046211343,0.007241651,0.0043782145,0.00064584374,0.0031409068,0.03641015,0.82156926,0.008710484,0.0025128732,0.023301944],"study_design_scores_gemma":[0.0117530925,0.0018701869,0.043672796,0.00046739314,0.0008343744,0.00016302138,0.00009910326,0.8502035,0.08831573,0.0024664411,0.000030138299,0.00012417806],"about_ca_topic_score_codex":0.0000122363135,"about_ca_topic_score_gemma":0.0000030203778,"teacher_disagreement_score":0.8137934,"about_ca_system_score_codex":0.000071624534,"about_ca_system_score_gemma":0.00046133035,"threshold_uncertainty_score":0.34815487},"labels":[],"label_agreement":null},{"id":"W4417016685","doi":"10.1182/blood-2025-37","title":"Therapy-related core binding factor Acute Myeloid Leukemia – a Study of the french acute leukemia intergroup","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child, Adolescent and Family Mental Health","funders":"","keywords":"Acute leukemia; Myeloid leukemia; Radiation therapy; Chemotherapy; White blood cell; Complete remission; Retrospective cohort study; Chemotherapy regimen","score_opus":0.02244930580480628,"score_gpt":0.3026765162435691,"score_spread":0.28022721043876286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417016685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99256885,0.00036944478,0.000017645818,0.0003966559,0.00044046927,0.0022546474,0.00008240744,0.00016203054,0.0037078345],"genre_scores_gemma":[0.9860582,0.00027425075,0.0001240803,0.00026913677,0.00008140044,0.0001232579,0.000036467347,0.0000674356,0.012965818],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99679506,0.00018729016,0.0008171263,0.000689692,0.0008279632,0.0006828733],"domain_scores_gemma":[0.99762964,0.00021307183,0.0002758466,0.0014253559,0.0002782056,0.00017789687],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035973583,0.00045189398,0.00083190046,0.0004886761,0.00026046787,0.000049541013,0.0009964298,0.00034629335,0.00025329227],"category_scores_gemma":[0.00017096747,0.0002964091,0.00033626912,0.0018399789,0.000247473,0.00012704842,0.0006467409,0.001335741,0.000056622623],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095867034,0.0031438894,0.31838882,0.00020235326,0.017176816,0.0006575364,0.009581482,0.0000104712935,0.62684494,0.00027464618,0.011227207,0.011533142],"study_design_scores_gemma":[0.06311631,0.0042700297,0.6362048,0.0011321419,0.004135671,0.00039062946,0.003022721,0.0007215352,0.28280795,0.00025729556,0.003075286,0.0008656448],"about_ca_topic_score_codex":0.0006474528,"about_ca_topic_score_gemma":0.000081762235,"teacher_disagreement_score":0.34403703,"about_ca_system_score_codex":0.001237234,"about_ca_system_score_gemma":0.001908334,"threshold_uncertainty_score":0.9999488},"labels":[],"label_agreement":null},{"id":"W4417016749","doi":"10.1182/blood-2025-7744","title":"FluMel100 with post-transplant cyclophosphamide: A safe and effective regimen for patients aged ≥75 years with MDS and AML","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Regimen; Tolerability; Transplantation; Graft-versus-host disease; Hematopoietic stem cell transplantation; Myelodysplastic syndromes; Myeloid leukemia; Conditioning regimen; Young adult","score_opus":0.003318610541880248,"score_gpt":0.2337407390668709,"score_spread":0.23042212852499067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417016749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99604577,0.00036041348,0.00008792945,0.0003439057,0.000017897224,0.0021226148,0.000063102125,0.000038230133,0.0009201229],"genre_scores_gemma":[0.99608296,0.00013034727,0.002181534,0.0003423879,0.00002590804,0.00022185879,0.00007015176,0.000030346857,0.0009144946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989849,0.000039283696,0.00012318582,0.00036175552,0.00019278433,0.0002981056],"domain_scores_gemma":[0.99923825,0.00022222717,0.00003811248,0.00021660658,0.00014469279,0.00014010038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014782608,0.00016799346,0.00030306456,0.00012277221,0.00008759036,0.000024916466,0.000061705745,0.000086483335,0.0000055014066],"category_scores_gemma":[0.00006894721,0.00011891412,0.000023937831,0.0002040579,0.00015129286,0.000060849496,0.000037961763,0.00021350876,0.0000020703371],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009122254,0.00066602917,0.97086453,0.00080391165,0.0010478596,0.0002490168,0.0016301667,6.0606317e-7,0.0029665427,0.00011020142,0.0007252303,0.011813666],"study_design_scores_gemma":[0.025639014,0.0041878335,0.96313554,0.00056026346,0.00059090636,0.00007315418,0.000133464,0.000010267295,0.0045887306,0.000027169237,0.00088834105,0.00016531242],"about_ca_topic_score_codex":0.000121559206,"about_ca_topic_score_gemma":0.00004577665,"teacher_disagreement_score":0.01651676,"about_ca_system_score_codex":0.00005933651,"about_ca_system_score_gemma":0.0001734179,"threshold_uncertainty_score":0.4849177},"labels":[],"label_agreement":null},{"id":"W4417017164","doi":"10.1182/blood-2025-3230","title":"Ectopic BCL11B disrupts the activity of early hematopoietic transcription factors to skew lineage commitment","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Ectopic expression; Progenitor cell; Haematopoiesis; Transcription factor; Myeloid; Stem cell; Immunophenotyping; Hematopoietic stem cell","score_opus":0.024415668953041758,"score_gpt":0.3122934303938841,"score_spread":0.2878777614408423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417017164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931327,0.00014168827,0.0007068846,0.0028966425,0.00009561518,0.0009060613,0.000014516956,0.000041760508,0.0020641054],"genre_scores_gemma":[0.9973062,0.000025486761,0.0001957033,0.00021777954,0.000049273538,0.000048118847,0.0000062868176,0.000013577114,0.0021375243],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989115,0.00009045916,0.00020893305,0.00021561867,0.0003227628,0.00025071038],"domain_scores_gemma":[0.9991038,0.00015638056,0.000040225954,0.000517806,0.00007622044,0.00010556527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021635857,0.00013886743,0.00030053814,0.00012428287,0.00008069325,0.000017507282,0.00019519802,0.000084468775,0.000061025283],"category_scores_gemma":[0.000099142075,0.00008945474,0.0001307761,0.0003926313,0.00007312612,0.000042368763,0.00006799088,0.00029629152,0.000021533346],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006861699,0.0037565168,0.16123506,0.001210916,0.0010430889,0.00007534837,0.008193669,0.0000051599322,0.80765927,0.0030425817,0.002257731,0.010834468],"study_design_scores_gemma":[0.0028651797,0.00053090014,0.4527656,0.00018896941,0.00031048863,0.000008292299,0.00022492169,0.000022262024,0.54091656,0.000085004125,0.0019839352,0.000097885226],"about_ca_topic_score_codex":0.00032130847,"about_ca_topic_score_gemma":0.000043682692,"teacher_disagreement_score":0.29153055,"about_ca_system_score_codex":0.00009963248,"about_ca_system_score_gemma":0.00017298634,"threshold_uncertainty_score":0.36478585},"labels":[],"label_agreement":null},{"id":"W4417017262","doi":"10.1111/bjh.70275","title":"Real‐world experience with <scp>CPX</scp> ‐351 for secondary acute myeloid leukaemia: Comparison with <scp>FLAG</scp> ‐ <scp>IDA</scp> in a propensity score matching analysis","year":2025,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; Hôpital Maisonneuve-Rosemont; London Health Sciences Centre; Princess Margaret Cancer Centre; University of Calgary; University of British Columbia; Juravinski Cancer Centre; McGill University Health Centre; Jewish General Hospital; Sunnybrook Health Science Centre; University of Alberta; University of Toronto","funders":"","keywords":"Cytarabine; Daunorubicin; Propensity score matching; Induction chemotherapy; Hematopoietic stem cell transplantation; Transplantation; Myeloid leukemia; Clinical trial; Randomized controlled trial","score_opus":0.02457374611780042,"score_gpt":0.3081901246744311,"score_spread":0.28361637855663063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417017262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822481,0.0029523429,0.0068435515,0.000532974,0.00022599119,0.0017728587,0.000076579425,0.00010738132,0.005240218],"genre_scores_gemma":[0.97982585,0.0011416713,0.0113915745,0.0009905553,0.00021416714,0.0002255568,0.00012060464,0.00014691018,0.005943128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926661,0.0005963508,0.002321572,0.001220948,0.0012929643,0.0019020465],"domain_scores_gemma":[0.99223024,0.003016161,0.0015657257,0.00086713786,0.0015637417,0.0007569778],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019580622,0.00077562005,0.0042485064,0.002558276,0.0005263918,0.00033905034,0.0011858637,0.00057359587,0.000023917466],"category_scores_gemma":[0.0021941857,0.0006946677,0.00058911776,0.0038924157,0.0009836667,0.00082469854,0.00045110533,0.0035561663,0.000015250942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009338636,0.0015117689,0.7294613,0.0022764034,0.009879238,0.14187634,0.011227455,0.0009728956,0.005007249,0.00070668187,0.08969651,0.006450292],"study_design_scores_gemma":[0.034616034,0.004591897,0.5796876,0.009752598,0.00866184,0.2647383,0.033080533,0.0031088039,0.032355297,0.001169834,0.027765822,0.00047145196],"about_ca_topic_score_codex":0.0018541835,"about_ca_topic_score_gemma":0.010529813,"teacher_disagreement_score":0.1497737,"about_ca_system_score_codex":0.0009924188,"about_ca_system_score_gemma":0.0032706494,"threshold_uncertainty_score":0.99955046},"labels":[],"label_agreement":null},{"id":"W4417017469","doi":"10.1182/blood-2025-7006","title":"Impact of c-KIT and FLT3 mutations on survival outcomes in core-binding factor acute myeloid leukemia: A systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Hazard ratio; Myeloid leukemia; Meta-analysis; Observational study; Mutation; Incidence (geometry); Concomitant; Cumulative incidence; Survival analysis","score_opus":0.05972190516308384,"score_gpt":0.38115925115752547,"score_spread":0.3214373459944416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417017469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98607266,0.010870463,0.000022934686,0.00066063437,0.00000985942,0.0016989465,0.00023885632,0.000023126013,0.00040251322],"genre_scores_gemma":[0.9961717,0.0015430097,0.0002056696,0.00017305487,0.0000041876388,0.00013436527,0.000042188385,0.000016714348,0.001709114],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9981279,0.00019667184,0.0006981325,0.00034523787,0.0003671156,0.0002649712],"domain_scores_gemma":[0.99827725,0.00076801825,0.00019689422,0.0004987143,0.00013045825,0.00012864778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006281363,0.00024861025,0.003118844,0.00078416493,0.000051165185,0.000025047859,0.0001266416,0.00010167448,0.00010399399],"category_scores_gemma":[0.00093010115,0.00015519533,0.0006552189,0.0012800652,0.000082192084,0.000069579866,0.00009091304,0.00031014837,0.000006514231],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000091494854,0.0006007816,0.30531707,0.11686836,0.5731065,0.00020519675,0.0006051017,0.000011846189,0.0026945816,0.00036516707,0.00010685626,0.000027000793],"study_design_scores_gemma":[0.0032997439,0.00032226855,0.18312491,0.0019669926,0.8102902,0.000035203695,0.00013947327,0.00012913733,0.0004579793,0.000035626443,9.548365e-7,0.00019747858],"about_ca_topic_score_codex":0.00031951294,"about_ca_topic_score_gemma":0.00007974687,"teacher_disagreement_score":0.2371837,"about_ca_system_score_codex":0.00028588384,"about_ca_system_score_gemma":0.0003403933,"threshold_uncertainty_score":0.6328682},"labels":[],"label_agreement":null},{"id":"W4417018553","doi":"10.1182/blood-2025-6411","title":"High response rates and early treatment patterns with venetoclax and azacitidine from the prospective liven study: Real-world AML care in Canada","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Espace pour la vie; Juravinski Cancer Centre; Centre Hospitalier Universitaire de Sherbrooke; Occupational Cancer Research Centre; London Health Sciences Centre; Thunder Bay Regional Research Institute; Research Institute in Oncology and Hematology","funders":"","keywords":"Azacitidine; Venetoclax; Myeloid leukemia; Adverse effect; Concomitant; Clinical endpoint; Interim analysis; Population; Chemotherapy regimen","score_opus":0.008598570720924043,"score_gpt":0.26382870674471093,"score_spread":0.25523013602378686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417018553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99642235,0.00060545624,3.9301756e-7,0.0010732139,0.000015872465,0.0016232062,0.00011847764,0.000013858606,0.0001271854],"genre_scores_gemma":[0.99885887,0.00015145376,0.000049637594,0.00008869855,0.000044476335,0.00022691854,0.000016552733,0.000016712498,0.00054669735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890286,0.0001900495,0.00014445177,0.00034087052,0.00019960046,0.00022218018],"domain_scores_gemma":[0.99903136,0.000476021,0.000031958323,0.00030223178,0.000074078846,0.000084350424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011465291,0.00016077053,0.00030289692,0.00009097703,0.000083811865,0.00003058567,0.000071174,0.000027165406,0.000010200084],"category_scores_gemma":[0.000044973734,0.00009601816,0.000011939936,0.00025519356,0.0000565968,0.000029263652,0.00007365783,0.00018885706,5.222707e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030603977,0.00011510225,0.9904611,0.000018849212,0.0003194706,0.00075479865,0.0042486405,0.0000017214325,0.00020328707,0.000009290684,0.000046039626,0.0007613092],"study_design_scores_gemma":[0.010605137,0.0017797108,0.9757529,0.00018749198,0.00023383685,0.0000064573787,0.007446013,0.0000059900376,0.0037783454,0.0000125459355,0.00010662565,0.0000849573],"about_ca_topic_score_codex":0.9719682,"about_ca_topic_score_gemma":0.98315173,"teacher_disagreement_score":0.014708204,"about_ca_system_score_codex":0.0016743117,"about_ca_system_score_gemma":0.002666991,"threshold_uncertainty_score":0.47311273},"labels":[],"label_agreement":null},{"id":"W4417018678","doi":"10.1182/blood-2025-1389","title":"Asxl1 mutant cells suppress Dnmt3a mutant clonal expansion.","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre","funders":"","keywords":"clone (Java method); Mutant; Haematopoiesis; Mutation; Stem cell; Cell; Logistic regression; Cell culture","score_opus":0.01246813572426497,"score_gpt":0.2834808857184379,"score_spread":0.2710127499941729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417018678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734708,0.0005990405,0.00016550344,0.0026451314,0.00034601748,0.0006530658,0.00005682123,0.00016092657,0.021902679],"genre_scores_gemma":[0.987909,0.00018507289,0.001354225,0.0013565796,0.0002911439,0.000060274368,0.00004259304,0.000040269562,0.008760828],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99787694,0.00008118529,0.0003661336,0.0004906927,0.000587102,0.0005979289],"domain_scores_gemma":[0.9985877,0.00019870487,0.000050256684,0.00071894197,0.00018578426,0.00025859804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003112123,0.00023139812,0.00041622363,0.00025577855,0.0001247298,0.000039714843,0.00030097665,0.00019971734,0.0007054637],"category_scores_gemma":[0.00018677211,0.0001902499,0.0001560902,0.0004991914,0.00014022565,0.00006937445,0.0002537775,0.0005810242,0.0003504335],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029676192,0.0010699728,0.002026246,0.00023158056,0.00033758924,0.001528152,0.00021472343,0.0000045134652,0.97564906,0.00074846693,0.015169997,0.002722915],"study_design_scores_gemma":[0.0075283144,0.00025376212,0.004818549,0.00023260343,0.0003334168,0.00022557215,0.0002435288,0.00038791352,0.9420334,0.0002092654,0.04351804,0.00021559783],"about_ca_topic_score_codex":0.00008201311,"about_ca_topic_score_gemma":0.000007656551,"teacher_disagreement_score":0.03361565,"about_ca_system_score_codex":0.00014497072,"about_ca_system_score_gemma":0.0008261609,"threshold_uncertainty_score":0.7758166},"labels":[],"label_agreement":null},{"id":"W4417018929","doi":"10.1182/blood-2025-1387","title":"Prevalence and significance of cytoses in clonal hematpoiesis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Basophilia; Cytopenia; Context (archaeology); Exome; Myelodysplastic syndromes; Cohort; Thrombocytosis; Myeloid; Exome sequencing","score_opus":0.013611903210886,"score_gpt":0.29340170006537514,"score_spread":0.2797897968544891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417018929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924284,0.0017508956,0.000020412546,0.00061614934,0.000010761175,0.00025295748,0.000007292145,0.00001328004,0.0048998436],"genre_scores_gemma":[0.99653804,0.00041795024,0.0010100213,0.00009957848,0.000016451819,0.0000252926,0.0000010504255,0.0000050022422,0.0018866104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993882,0.000026297394,0.00015414343,0.00015540257,0.00014314131,0.00013279147],"domain_scores_gemma":[0.9995619,0.00016176785,0.000023644172,0.00016758086,0.00004809522,0.000036977024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017106088,0.000057601057,0.00017127456,0.00012171652,0.000013093599,0.0000037668133,0.00006982291,0.000045012028,0.000035519563],"category_scores_gemma":[0.0002721205,0.00005053037,0.00002053715,0.0002492544,0.00011090262,0.00002810087,0.00006033663,0.00012033609,0.0000032208748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016084914,0.00044178663,0.9061198,0.0021236232,0.0000696632,0.000066015,0.00015873417,6.913989e-7,0.087237865,0.0013568408,0.0006257625,0.0016383751],"study_design_scores_gemma":[0.00324357,0.00013538789,0.7859275,0.00054976746,0.00008676292,0.000023439341,0.000080029575,0.00004949699,0.20921464,0.0003014568,0.00032592684,0.00006203713],"about_ca_topic_score_codex":0.000054803113,"about_ca_topic_score_gemma":0.000008182921,"teacher_disagreement_score":0.121976785,"about_ca_system_score_codex":0.00002714458,"about_ca_system_score_gemma":0.00023369915,"threshold_uncertainty_score":0.20605686},"labels":[],"label_agreement":null},{"id":"W4417018998","doi":"10.1182/blood-2025-2013","title":"CSF3R-mutated chronic neutrophilic leukemia: A two-center study of 44 consecutive patients","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Leukocytosis; White blood cell; Retrospective cohort study; Medical record; Blood count; Institutional review board; Chronic lymphocytic leukemia; Myeloid; Stem cell","score_opus":0.011027947161160043,"score_gpt":0.2955251322044318,"score_spread":0.2844971850432717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417018998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916577,0.00020631432,0.0000060738503,0.00017021077,0.00010965615,0.0017551801,0.000031528507,0.0000687052,0.005994645],"genre_scores_gemma":[0.9985167,0.000034859466,0.00003440026,0.00023796243,0.0000692025,0.00008842661,0.000056330016,0.000029316456,0.0009328457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807334,0.00015230416,0.00045625714,0.0004324669,0.00044379072,0.0004418684],"domain_scores_gemma":[0.998686,0.00012043531,0.000110243695,0.00058672874,0.00036326237,0.00013330035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016085987,0.00021936209,0.0005137473,0.0003397044,0.000076563694,0.000013042054,0.00023117496,0.00010735651,0.00008750116],"category_scores_gemma":[0.00016454424,0.00018829636,0.00010158068,0.0006962442,0.00015324667,0.000054916563,0.00025316313,0.00050823524,0.000051602503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001758349,0.020327395,0.93684524,0.0006073014,0.0030961034,0.00063825503,0.0027246766,0.00002838826,0.024354203,0.00021499315,0.0059674005,0.003437664],"study_design_scores_gemma":[0.25241417,0.01210617,0.67453,0.0008498418,0.0020469478,0.00007787321,0.0024649897,0.00060825225,0.052337702,0.00011771289,0.0018716406,0.00057467463],"about_ca_topic_score_codex":0.00037855117,"about_ca_topic_score_gemma":0.00008081648,"teacher_disagreement_score":0.26231524,"about_ca_system_score_codex":0.0007803181,"about_ca_system_score_gemma":0.0013261895,"threshold_uncertainty_score":0.7678503},"labels":[],"label_agreement":null},{"id":"W4417019060","doi":"10.1182/blood-2025-4284","title":"Risk factor analysis of relapse risk during FLT3-inhibitor post-transplant maintenance therapy following allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia with FLT3-ITD","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; Université Laval; Princess Margaret Cancer Centre","funders":"","keywords":"Cumulative incidence; Sorafenib; Clinical endpoint; Hematopoietic stem cell transplantation; Transplantation; Incidence (geometry); Maintenance therapy; Myeloid leukemia; Multivariate analysis","score_opus":0.006184717852742649,"score_gpt":0.23821660759694768,"score_spread":0.23203188974420502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417019060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959021,0.0011054329,0.0007861039,0.0001292067,0.000078388744,0.001060375,0.00061335694,0.000098467084,0.00022657138],"genre_scores_gemma":[0.99090296,0.007301429,0.00079906743,0.00006506166,0.0000340374,0.00009118848,0.0001442664,0.0000664284,0.0005955495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965448,0.00030534543,0.00087511743,0.00080007507,0.0007341753,0.0007404789],"domain_scores_gemma":[0.9982205,0.00030959872,0.00032533106,0.00075747963,0.00018938298,0.00019771098],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050401036,0.00046694168,0.0011550054,0.0012874899,0.00016663592,0.000033370663,0.0003406836,0.00028941085,0.000040833515],"category_scores_gemma":[0.00002534396,0.00036512475,0.0005577879,0.002349191,0.00010488665,0.00017166935,0.000035065677,0.0008688843,0.000011739272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035452389,0.00047981704,0.6950773,0.000548904,0.006481028,0.0014418487,0.004600393,0.000528624,0.28649905,0.00000941305,0.000008936098,0.0007794592],"study_design_scores_gemma":[0.015669156,0.0003677508,0.5810085,0.00063280016,0.007753355,0.00006648125,0.0006616479,0.00028365012,0.39320272,0.0000066444845,0.000011771828,0.00033556143],"about_ca_topic_score_codex":0.0008987311,"about_ca_topic_score_gemma":0.0006817457,"teacher_disagreement_score":0.11406882,"about_ca_system_score_codex":0.0004831034,"about_ca_system_score_gemma":0.0007060145,"threshold_uncertainty_score":0.9998801},"labels":[],"label_agreement":null},{"id":"W4417019321","doi":"10.1182/blood-2025-343","title":"Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Surrogate endpoint; Clinical endpoint; Clinical trial; Minimal residual disease; Myeloid leukemia; Randomization; Randomized controlled trial; Disease; Cytarabine","score_opus":0.04702181082971312,"score_gpt":0.3392658178401871,"score_spread":0.292244007010474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417019321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904219,0.0008547771,0.000046036905,0.0008330848,0.00006734055,0.0039669033,0.000044161487,0.000045563418,0.003720258],"genre_scores_gemma":[0.9967476,0.0005948571,0.00034362343,0.0000988704,0.0000612959,0.00019057372,0.00004812916,0.000035588975,0.001879423],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99258834,0.004000773,0.0017193783,0.00049780315,0.0008293115,0.00036437993],"domain_scores_gemma":[0.9967261,0.0014533899,0.00050674815,0.00073126046,0.0004009677,0.00018152135],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010690735,0.0002492165,0.0019704183,0.00041952395,0.000046607107,0.0000223244,0.0003132104,0.00007575292,0.00007738009],"category_scores_gemma":[0.010850158,0.000201279,0.00029270194,0.0008104733,0.0001576899,0.000114732145,0.00018570214,0.00040318663,0.000022369619],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65044814,0.012362914,0.03181522,0.0017724645,0.008166672,0.0027601642,0.0053762533,0.00033674532,0.28057095,0.00063152914,0.0033303602,0.002428613],"study_design_scores_gemma":[0.68302935,0.0007530878,0.03373615,0.0008760461,0.004371137,0.0000106179405,0.00084883,0.00016627209,0.2754672,0.0003923032,0.000113334645,0.00023569896],"about_ca_topic_score_codex":0.00052843365,"about_ca_topic_score_gemma":0.000023655744,"teacher_disagreement_score":0.03258121,"about_ca_system_score_codex":0.0002328108,"about_ca_system_score_gemma":0.0014744711,"threshold_uncertainty_score":0.9974819},"labels":[],"label_agreement":null},{"id":"W4417019353","doi":"10.1182/blood-2025-789","title":"Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Interim analysis; Cohort; Anemia; Clinical endpoint; Myelodysplastic syndromes; Population; Discontinuation; Hemoglobin","score_opus":0.022150532401733404,"score_gpt":0.29191408717674594,"score_spread":0.2697635547750125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417019353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99202126,0.00053527625,0.0008755202,0.0014808966,0.00020938193,0.0009657925,0.00021202196,0.000110940426,0.003588924],"genre_scores_gemma":[0.9956658,0.00090942974,0.00019808431,0.00044552327,0.00005498821,0.00014830595,0.00027500343,0.00004385381,0.0022590111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969473,0.00037926572,0.0006246896,0.0008015759,0.00061861856,0.00062858616],"domain_scores_gemma":[0.99789053,0.0005809891,0.000115185256,0.0010892843,0.00012701226,0.00019696752],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005749385,0.00037447416,0.0008065796,0.00085560593,0.00018130115,0.00006726676,0.0005089287,0.00028399535,0.0022670683],"category_scores_gemma":[0.00039395082,0.00026185095,0.00034975223,0.0022153645,0.00020278807,0.00008233308,0.00039465123,0.0009696735,0.0002822725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014110932,0.010600218,0.6826328,0.00077088695,0.032564588,0.014373498,0.011228665,0.0008397164,0.18272507,0.00008300429,0.0041367146,0.045933913],"study_design_scores_gemma":[0.042037304,0.0013453732,0.8945371,0.00085157703,0.016013088,0.00023371956,0.003052738,0.008934316,0.02939881,0.00089927996,0.0017194856,0.0009771904],"about_ca_topic_score_codex":0.0051756143,"about_ca_topic_score_gemma":0.006709065,"teacher_disagreement_score":0.21190432,"about_ca_system_score_codex":0.00055824313,"about_ca_system_score_gemma":0.00037568138,"threshold_uncertainty_score":0.9999834},"labels":[],"label_agreement":null},{"id":"W4417019771","doi":"10.1182/blood-2025-5199","title":"Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cytarabine; Idarubicin; Regimen; Myeloid leukemia; Daunorubicin; Phases of clinical research; Chemotherapy; Chemotherapy regimen; Leukemia","score_opus":0.01699114744651654,"score_gpt":0.3255138417467192,"score_spread":0.3085226943002027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417019771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915246,0.00006970979,0.00045565772,0.0032051727,0.000030333118,0.003542934,0.000011795897,0.000082633436,0.0010771852],"genre_scores_gemma":[0.99347514,0.00008628507,0.00148434,0.0017253668,0.000042426786,0.00070535694,0.00008288945,0.00005115525,0.0023470486],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99791706,0.00014260295,0.00043948137,0.00057040615,0.00045720875,0.00047321912],"domain_scores_gemma":[0.9985226,0.00024892573,0.000096638905,0.0005378199,0.00046380283,0.00013024238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032845535,0.00030521106,0.00058850873,0.0007920412,0.00008885285,0.00006578554,0.000206251,0.00011641287,0.0000663559],"category_scores_gemma":[0.000210759,0.00021373967,0.000038082362,0.0019212713,0.00012633503,0.00021093861,0.00006761938,0.0006576525,0.0000144626065],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067773014,0.09994953,0.65500015,0.0006331305,0.0067148795,0.032118145,0.045810547,0.0003163974,0.049237028,0.0011125613,0.00806919,0.033265404],"study_design_scores_gemma":[0.7302478,0.025711093,0.1780146,0.0017441665,0.0013104536,0.00042145533,0.016551448,0.0052591837,0.03872428,0.00016827218,0.0009521926,0.00089508016],"about_ca_topic_score_codex":0.00082573836,"about_ca_topic_score_gemma":0.0037406215,"teacher_disagreement_score":0.66247475,"about_ca_system_score_codex":0.0008395997,"about_ca_system_score_gemma":0.002179166,"threshold_uncertainty_score":0.87160504},"labels":[],"label_agreement":null},{"id":"W4417020046","doi":"10.1182/blood-2025-5222","title":"Survival outcomes with the use of gemtuzumab-ozogamycin in patients with acute myeloid leukemia receiving intensive chemotherapy stratified by molecular risk category","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; University of Toronto; University of British Columbia","funders":"","keywords":"Cytarabine; Myeloid leukemia; Induction chemotherapy; Retrospective cohort study; Transplantation; Cohort; Gemtuzumab ozogamicin; Hematology; Chemotherapy","score_opus":0.011263189126661174,"score_gpt":0.2525757062351514,"score_spread":0.24131251710849022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417020046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635667,0.000085821135,0.00048379754,0.0013224039,0.000033823995,0.0012108246,0.000058500435,0.000040590443,0.00040755988],"genre_scores_gemma":[0.9965782,0.00011201626,0.00095822936,0.0010873633,0.000010988628,0.00005646948,0.00007819786,0.000056745794,0.0010617566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978567,0.00020927518,0.00037959786,0.00046248594,0.00063481904,0.00045714658],"domain_scores_gemma":[0.9979204,0.00037411466,0.00020958917,0.00077341846,0.00062517123,0.00009729511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002911157,0.00032418076,0.00067564443,0.00022602327,0.000079652214,0.000040403553,0.00028589752,0.00014593835,0.000022025733],"category_scores_gemma":[0.0002804773,0.00018693112,0.000084756,0.00071843405,0.0002778909,0.00013297319,0.00009352267,0.00075314584,0.0000036465237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00302899,0.00052406563,0.97882825,0.00008891928,0.0024948108,0.00013896247,0.00094093423,0.000082755796,0.008403163,0.00006889199,0.0030772227,0.002323058],"study_design_scores_gemma":[0.02662567,0.0010717101,0.92692506,0.00024298781,0.00072404236,0.000008340506,0.0008369789,0.00013761748,0.04266467,0.000025150544,0.0004365427,0.0003012398],"about_ca_topic_score_codex":0.0017048576,"about_ca_topic_score_gemma":0.00031388836,"teacher_disagreement_score":0.051903177,"about_ca_system_score_codex":0.0003538952,"about_ca_system_score_gemma":0.00090336613,"threshold_uncertainty_score":0.76228297},"labels":[],"label_agreement":null},{"id":"W4417020225","doi":"10.1182/blood-2025-3462","title":"Thioguanine and decitabine can overcome hypomethylating agent resistance in patients with advanced myeloid malignancies","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Forming Technologies (Canada)","funders":"","keywords":"Decitabine; Hypomethylating agent; Azacitidine; Regimen; Myeloid leukemia; Myeloid; Venetoclax; Bone marrow; Progressive disease","score_opus":0.006979252920071475,"score_gpt":0.24323017042918862,"score_spread":0.23625091750911714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417020225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99330705,0.0015185637,0.000037824164,0.00086349447,0.000030167788,0.0006148238,0.000018374478,0.00004378054,0.0035658951],"genre_scores_gemma":[0.98951894,0.00011546994,0.0076494142,0.00037287353,0.000022514474,0.000047736256,0.000026976075,0.000024618004,0.0022214348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985339,0.000045739038,0.00028230433,0.00037102922,0.00036682212,0.00040021725],"domain_scores_gemma":[0.9991738,0.00014479086,0.00006427585,0.0003398378,0.00016060923,0.00011667885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022311669,0.00018231034,0.0003577794,0.00029098208,0.0000767598,0.000021423515,0.00010326725,0.00007182268,0.000016876385],"category_scores_gemma":[0.00036841648,0.000145478,0.000026760994,0.00077377376,0.00009089052,0.00008481108,0.00011919146,0.0002896203,0.0000025283302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009644702,0.00052748487,0.983562,0.0003594129,0.00013080759,0.000126146,0.00051590084,0.0000073923043,0.008830208,0.000458561,0.00018569709,0.0043319426],"study_design_scores_gemma":[0.0150612425,0.00035284305,0.9766841,0.00069639774,0.00007222666,0.000003225833,0.00015874702,0.00001580202,0.0057844208,0.00012264898,0.000887181,0.00016115657],"about_ca_topic_score_codex":0.000062893785,"about_ca_topic_score_gemma":0.0003406601,"teacher_disagreement_score":0.014096772,"about_ca_system_score_codex":0.00020468766,"about_ca_system_score_gemma":0.00023896509,"threshold_uncertainty_score":0.59324205},"labels":[],"label_agreement":null},{"id":"W4417020547","doi":"10.1182/blood-2025-6959","title":"Oral n-myristoyltransferase inhibitor zelenirstat for adults with Relapsed/Refractory Acute Myeloid Leukemia (AML): A phase 1 trial in progress","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Achieve Life Sciences (Canada)","funders":"","keywords":"Venetoclax; Pharmacokinetics; Pharmacodynamics; Myeloid leukemia; Clinical trial; Leukemia; CYP3A; Adverse effect","score_opus":0.013537435268961647,"score_gpt":0.31105341883320853,"score_spread":0.29751598356424686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417020547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895572,0.00070752203,0.0004564936,0.0014999417,0.0002672486,0.0064085233,0.00018989273,0.0001939192,0.00071924616],"genre_scores_gemma":[0.9899652,0.00019124089,0.0046393047,0.00043404385,0.00048247117,0.0019992306,0.00034454846,0.00010693563,0.0018370465],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99667656,0.00013342123,0.00073094876,0.0008801457,0.0006238732,0.0009550416],"domain_scores_gemma":[0.99823225,0.0002951406,0.000110801826,0.00070791837,0.00031044657,0.0003434387],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057032437,0.0004632242,0.000886178,0.00064246677,0.00015229915,0.000061845305,0.0003187935,0.00036515517,0.00004496114],"category_scores_gemma":[0.00025734,0.0003736013,0.00022615684,0.0009537994,0.00032893117,0.00024186778,0.000073879375,0.0009787233,0.000019890656],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9005347,0.011910519,0.0030879981,0.0016133969,0.0016531663,0.0027969948,0.0021185102,0.0000031455706,0.020451251,0.0003210107,0.013607046,0.04190225],"study_design_scores_gemma":[0.897135,0.016109006,0.00041218338,0.0013445122,0.0013148384,0.00014356952,0.0005382429,0.00036186268,0.06309017,0.000077027435,0.018893147,0.0005804337],"about_ca_topic_score_codex":0.00012809184,"about_ca_topic_score_gemma":0.00020001862,"teacher_disagreement_score":0.042638917,"about_ca_system_score_codex":0.00089362595,"about_ca_system_score_gemma":0.0033597446,"threshold_uncertainty_score":0.9998716},"labels":[],"label_agreement":null},{"id":"W4417020585","doi":"10.1182/blood-2025-6963","title":"Ivosidenib with or without hypomethylating agent in IDH1-mutated AML: Real-world evidence to inform frontline therapy","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Azacitidine; Hypomethylating agent; Decitabine; Clinical endpoint; Myeloid leukemia; Performance status; Phases of clinical research; Clinical trial; Cohort; Hematology","score_opus":0.05831651651262254,"score_gpt":0.3771656489118306,"score_spread":0.31884913239920804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417020585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98562205,0.0005344203,0.00023295778,0.0067448122,0.000049221057,0.0017328007,0.000004148404,0.00015319155,0.004926372],"genre_scores_gemma":[0.9752818,0.0005565434,0.010745072,0.0026605679,0.000112917005,0.00023745006,0.000013579826,0.00005094565,0.010341124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977353,0.000083560175,0.0005306295,0.00045708218,0.0006043588,0.00058904756],"domain_scores_gemma":[0.9983582,0.00042425664,0.00009475252,0.0006247241,0.00024998633,0.00024810852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007326452,0.00026883144,0.0005967524,0.0008261752,0.00009618117,0.000055195535,0.00028869664,0.00009735975,0.00015160668],"category_scores_gemma":[0.00079560943,0.000180177,0.0000551581,0.002915636,0.00007403179,0.00019430443,0.0001531737,0.00054762745,0.00006051931],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014024317,0.0010237431,0.8280531,0.00043909255,0.00069893117,0.0012706871,0.0034030834,0.00014281225,0.09937469,0.00012039293,0.005027991,0.046421148],"study_design_scores_gemma":[0.050405867,0.006775715,0.57927215,0.008459002,0.00045474307,0.00017650245,0.0017119179,0.002904393,0.3326743,0.0001269262,0.015912933,0.0011255805],"about_ca_topic_score_codex":0.0030263974,"about_ca_topic_score_gemma":0.005920971,"teacher_disagreement_score":0.24878098,"about_ca_system_score_codex":0.00045851764,"about_ca_system_score_gemma":0.0010014764,"threshold_uncertainty_score":0.7347405},"labels":[],"label_agreement":null},{"id":"W4417020907","doi":"10.1182/blood-2025-5279","title":"Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Ottawa Hospital","funders":"","keywords":"Clinical trial; Myeloid leukemia; Cohort; Adverse effect; Disease; Myeloid; Minimal residual disease; Randomized controlled trial; Myelodysplastic syndromes","score_opus":0.032458749086411644,"score_gpt":0.3461586820832257,"score_spread":0.31369993299681403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417020907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891197,0.0032247459,0.0009956487,0.0025887373,0.000031296695,0.0036667713,0.0001080192,0.000020124315,0.00024493504],"genre_scores_gemma":[0.99353147,0.0011345762,0.0027069924,0.0013451494,0.000024913665,0.0010432464,0.00010052456,0.000018150859,0.00009499245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787253,0.00020729954,0.00069593266,0.00056610024,0.0003104867,0.00034765922],"domain_scores_gemma":[0.9976038,0.0011674819,0.0001859247,0.0007355808,0.00023647814,0.00007076611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001233821,0.00025179767,0.00085254974,0.00023317552,0.000100620804,0.000026604646,0.00023505733,0.0001955207,0.000014075798],"category_scores_gemma":[0.0008471599,0.00015417738,0.00052100484,0.00054203795,0.00021641643,0.000031533687,0.00006102005,0.00012539873,5.638326e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021731858,0.008685974,0.92396045,0.0005929477,0.0051999805,0.00009876157,0.0008849442,0.00006682691,0.016665913,0.0007291869,0.0008456465,0.04009619],"study_design_scores_gemma":[0.027680878,0.005413231,0.88034105,0.000086634536,0.00271471,0.000004878274,0.00033667203,0.0001874475,0.07305221,0.0005197746,0.0094096,0.0002528853],"about_ca_topic_score_codex":0.00009537436,"about_ca_topic_score_gemma":0.000051149065,"teacher_disagreement_score":0.0563863,"about_ca_system_score_codex":0.00009268692,"about_ca_system_score_gemma":0.00017399857,"threshold_uncertainty_score":0.6287171},"labels":[],"label_agreement":null},{"id":"W4417021874","doi":"10.1182/blood-2025-1608","title":"Clinical, cytogenetic and molecular characteriszation of Mecom- rearranged pediatric de novo Acute Myeloid Leukemia (AML): A retrospective cohort study of the international-berlin-frankfurt-Münster (I-BFM) AML-study group","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Retrospective cohort study; Myeloid leukemia; Leukemia; Acute promyelocytic leukemia; Chemotherapy regimen; Cohort; Myeloid; Myeloid sarcoma; Chemotherapy","score_opus":0.012258294986843186,"score_gpt":0.3076906259428016,"score_spread":0.29543233095595844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417021874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995301,0.00016088021,0.000106934494,0.00031731994,0.00022319217,0.0031581332,0.000038998456,0.000032388336,0.0006611231],"genre_scores_gemma":[0.9984399,0.0003556361,0.00028465726,0.00023065567,0.00016192776,0.00015899591,0.000021492351,0.000038729828,0.00030801943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968138,0.0004279221,0.0009812706,0.00062364445,0.0008534121,0.00029994725],"domain_scores_gemma":[0.9978941,0.00019252714,0.00039433516,0.00088413997,0.00052035163,0.00011454668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001464279,0.00025194293,0.00076393003,0.0003424562,0.00009278377,0.000030764582,0.00050188054,0.00017970662,0.000038323873],"category_scores_gemma":[0.0005757577,0.00019816923,0.00017643918,0.0008136951,0.00014905269,0.000074411095,0.0004611774,0.0005776792,0.0000036690426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005319024,0.0029155961,0.95721567,0.000073182215,0.0019328305,0.00009196609,0.0009933877,0.0000018071818,0.035798945,0.000014929602,0.00010697946,0.00032279704],"study_design_scores_gemma":[0.0127442395,0.0014871452,0.9768261,0.00006199052,0.002671651,0.000040430732,0.00060202484,0.00009462118,0.0052585322,0.000040975247,0.000035455032,0.00013687953],"about_ca_topic_score_codex":0.0002886231,"about_ca_topic_score_gemma":0.00017487239,"teacher_disagreement_score":0.030540412,"about_ca_system_score_codex":0.00035789932,"about_ca_system_score_gemma":0.00052625156,"threshold_uncertainty_score":0.80811065},"labels":[],"label_agreement":null},{"id":"W4417042071","doi":"10.1182/hematology.2025000691","title":"Management of iron overload in adult myelodysplastic syndrome","year":2025,"lang":"en","type":"article","venue":"Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; St. Paul's Hospital","funders":"","keywords":"Myelodysplastic syndromes; Clinical trial; Life expectancy; Stem cell; Toxicity; Adverse effect; Anemia","score_opus":0.00862403027941023,"score_gpt":0.2943667758030706,"score_spread":0.28574274552366036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417042071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9671218,0.00031228934,0.00027087453,0.0018742615,0.0001288497,0.00041349055,0.000002160915,0.00002928659,0.029847011],"genre_scores_gemma":[0.9951508,0.00017245286,0.001107928,0.00022289615,0.0000038284866,0.00004782265,0.000007653223,0.000009564445,0.0032770347],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99897426,0.00004050823,0.00031280285,0.00022945165,0.00015192626,0.00029107693],"domain_scores_gemma":[0.99941915,0.00011674455,0.000041328643,0.00031877085,0.000055678964,0.000048326056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011164817,0.0000999445,0.00041270728,0.00035905026,0.00001433338,0.0000019295737,0.000119666474,0.000118628275,0.00020751913],"category_scores_gemma":[0.00007685688,0.00009132436,0.000044504664,0.00044153954,0.00010545634,0.00002153839,0.00013421806,0.00021214191,0.000110448564],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017989054,0.0011210006,0.22556564,0.015548697,0.00066508626,0.024203997,0.00034314138,0.00003864096,0.0029637134,0.70422107,0.01331126,0.010218865],"study_design_scores_gemma":[0.024937442,0.0011622059,0.92605233,0.006897234,0.0005076935,0.0068685426,0.002212604,0.0040000733,0.015468493,0.0065720743,0.0047282674,0.00059305946],"about_ca_topic_score_codex":0.000053044867,"about_ca_topic_score_gemma":0.000016302301,"teacher_disagreement_score":0.70048666,"about_ca_system_score_codex":0.00015927487,"about_ca_system_score_gemma":0.000102808,"threshold_uncertainty_score":0.3724099},"labels":[],"label_agreement":null},{"id":"W4417055360","doi":"10.1158/2643-3230.bcd-25-0246","title":"Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"HCA International Foundation; Wellcome Trust; Nationales Centrum für Tumorerkrankungen Heidelberg; Wilhelm Sander-Stiftung; José Carreras Leukämie-Stiftung; Joachim Herz Stiftung; Deutsche Forschungsgemeinschaft; Deutsches Krebsforschungszentrum","keywords":"Juvenile myelomonocytic leukemia; Reprogramming; Fetus; Mutation; Gene; PTPN11; Leukemia","score_opus":0.016722719833164538,"score_gpt":0.30993910152471,"score_spread":0.29321638169154546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417055360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899765,0.005198139,0.000100004625,0.0013250739,0.0000960699,0.0006866052,0.000031102314,0.000042377837,0.0025441085],"genre_scores_gemma":[0.99700385,0.00043577864,0.00022713347,0.0004914486,0.000061834515,0.0002773832,0.000013969799,0.000027243446,0.0014613478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977948,0.000135321,0.0005449528,0.0006723005,0.00030345016,0.00054915814],"domain_scores_gemma":[0.9990546,0.00034565467,0.00006955052,0.0003912098,0.00004833008,0.00009063293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047066167,0.00023801047,0.0005244915,0.00039773795,0.00005332624,0.00007895102,0.00014845651,0.00015920927,0.000009615036],"category_scores_gemma":[0.0003855674,0.00021835962,0.00007809696,0.0007114952,0.00023541485,0.0001810056,0.00017349834,0.0006812283,0.0000021893088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017923785,0.0022318156,0.5974953,0.005147379,0.0016482145,0.0047904444,0.0081747575,0.010568929,0.10810075,0.010685323,0.00089511165,0.23233816],"study_design_scores_gemma":[0.075017765,0.002093371,0.6703342,0.007547948,0.0012183436,0.0002011131,0.0075532803,0.019407805,0.20005406,0.007713479,0.0070281182,0.0018305043],"about_ca_topic_score_codex":0.005196757,"about_ca_topic_score_gemma":0.002371463,"teacher_disagreement_score":0.23050766,"about_ca_system_score_codex":0.0015603384,"about_ca_system_score_gemma":0.002143937,"threshold_uncertainty_score":0.8904447},"labels":[],"label_agreement":null},{"id":"W4417135853","doi":"10.1097/mph.0000000000003151","title":"Excellent Outcomes of Hematopoietic Stem Cell Transplant for Pediatric High Risk and Relapsed Acute Myeloid Leukemia–A Decade Long Experience From Developing Nation","year":2025,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Developing country; Hematopoietic stem cell transplantation; Disease; Hematopoietic cell; Hematopoietic stem cell; Overall survival","score_opus":0.02201842363435012,"score_gpt":0.3194111564537995,"score_spread":0.2973927328194494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417135853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95671195,0.006146869,0.032995883,0.0022653043,0.00089651014,0.0008138595,0.000052519703,0.00002947694,0.00008760465],"genre_scores_gemma":[0.96287006,0.019974705,0.01610174,0.00027812258,0.00044671254,0.0000683647,0.00001670234,0.00003979454,0.000203798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99583864,0.00036264997,0.002121748,0.00050011574,0.000548735,0.0006280853],"domain_scores_gemma":[0.99333405,0.0036605904,0.0016941677,0.00032949724,0.00067879603,0.00030290915],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012070457,0.00038489592,0.0019429325,0.0012970975,0.00017732385,0.000017705957,0.000453429,0.0007776668,0.000026886402],"category_scores_gemma":[0.00036608492,0.0003123961,0.00033223777,0.0007915286,0.00018773205,0.00019145173,0.00014432694,0.0010737905,0.0000061027486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029471202,0.0005709307,0.97109073,0.001902445,0.0009252011,0.0014477198,0.007890489,0.00003680301,0.0018342022,0.00097185903,0.0049200356,0.0054624765],"study_design_scores_gemma":[0.12337151,0.012287885,0.65619063,0.0007947653,0.030734932,0.0074819443,0.017386565,0.0022551804,0.13043347,0.008821027,0.0073721753,0.0028699418],"about_ca_topic_score_codex":0.00011309258,"about_ca_topic_score_gemma":0.000026799551,"teacher_disagreement_score":0.3149001,"about_ca_system_score_codex":0.0013580474,"about_ca_system_score_gemma":0.0042021354,"threshold_uncertainty_score":0.9999328},"labels":[],"label_agreement":null},{"id":"W4417292973","doi":"10.1016/j.jpi.2025.100508","title":"Deep learning-based analysis of TP53 immunohistochemistry for enhanced prognostic accuracy in acute myeloid leukemia","year":2025,"lang":"en","type":"article","venue":"Journal of Pathology Informatics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Immunohistochemistry; Myeloid leukemia; Leukemia; Myeloid; Text mining","score_opus":0.01014745340600513,"score_gpt":0.3263463585630506,"score_spread":0.31619890515704546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417292973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89457744,0.00028370542,0.10369252,0.00029799098,0.000090821886,0.0003961625,0.000009469784,0.000011629862,0.000640249],"genre_scores_gemma":[0.97867125,0.00021432326,0.02034075,0.00036742713,0.000029006082,0.00003092512,0.00007127259,0.000013217772,0.000261808],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9973114,0.00007487347,0.0018117016,0.000096392505,0.0003415565,0.00036405787],"domain_scores_gemma":[0.9961885,0.0011494785,0.0012896375,0.00032221156,0.0009514901,0.00009869047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012348285,0.00019085023,0.0010713661,0.0016167554,0.000058320482,0.000014506245,0.00034536308,0.00029875126,0.000033895943],"category_scores_gemma":[0.004543806,0.00016172584,0.00044355012,0.0014470189,0.00020124782,0.00017365073,0.00007168418,0.0010217455,0.000002919526],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010089518,0.0009924971,0.094540015,0.005628014,0.013058402,0.0013805908,0.011809568,0.1657343,0.64415693,0.00021778213,0.0017957367,0.050596625],"study_design_scores_gemma":[0.028481593,0.0042965068,0.112023674,0.0017369244,0.017805414,0.0010790685,0.006832324,0.56933576,0.2558585,0.00032339018,0.0015095463,0.0007172983],"about_ca_topic_score_codex":0.0000031689892,"about_ca_topic_score_gemma":0.0000031903721,"teacher_disagreement_score":0.40360144,"about_ca_system_score_codex":0.0010393902,"about_ca_system_score_gemma":0.001776073,"threshold_uncertainty_score":0.6594988},"labels":[],"label_agreement":null},{"id":"W4417304678","doi":"10.1080/10428194.2025.2594059","title":"Treatment patterns and overall survival among patients with myelodysplastic syndromes treated in the US community oncology setting: a real-world retrospective observational study","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Observational study; Retrospective cohort study; Myelodysplastic syndromes; Overall survival; Survival analysis; Proportional hazards model; Hematopoietic stem cell transplantation","score_opus":0.02971087010040666,"score_gpt":0.3065243523480963,"score_spread":0.2768134822476896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417304678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913861,0.000072620605,0.000009216273,0.00036421578,0.0001204921,0.0028767285,0.000117355004,0.0001338306,0.004919433],"genre_scores_gemma":[0.99646556,0.00022405018,0.00009207859,0.00060483196,0.000081120095,0.0005665237,0.0003671626,0.00007669315,0.0015219876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947584,0.0014748959,0.0008848804,0.0010023902,0.00090435875,0.0009750475],"domain_scores_gemma":[0.996003,0.0019652147,0.0003069483,0.0010653137,0.0003409055,0.00031863412],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009129021,0.0008246112,0.0013764586,0.00072178815,0.0008115277,0.00018532111,0.00045916077,0.00035614244,0.000028086266],"category_scores_gemma":[0.0002511778,0.000559193,0.00013155222,0.0012744168,0.0006158099,0.00031285593,0.00034817253,0.0005526612,0.000006091052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026676725,0.0018415841,0.9794064,0.00014114173,0.00070454215,0.0008190216,0.0039464165,0.000023975728,0.000025507077,0.0003441286,0.00020613678,0.009873442],"study_design_scores_gemma":[0.046139754,0.004076409,0.94308066,0.00031635235,0.0005425043,0.00014957853,0.002882055,0.0017009124,0.00004037407,0.000118299366,0.0004962007,0.0004569097],"about_ca_topic_score_codex":0.08330913,"about_ca_topic_score_gemma":0.029686999,"teacher_disagreement_score":0.05362213,"about_ca_system_score_codex":0.025781559,"about_ca_system_score_gemma":0.0038679477,"threshold_uncertainty_score":0.99968594},"labels":[],"label_agreement":null},{"id":"W4417342517","doi":"10.1182/blood.2025031480","title":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Servier; Amgen; José Carreras Leukämie-Stiftung; Astellas Pharma; Jazz Pharmaceuticals; Ascentage Pharma; Syndax Pharmaceuticals; BeiGene; Deutsche Krebshilfe; Daiichi Sankyo Europe; European Commission; Pfizer; Bristol-Myers Squibb","keywords":"Minimal residual disease; Blinatumomab; Guideline; Myeloid leukemia; Disease; Hematopoietic cell; Delphi method; Hematopoietic stem cell transplantation","score_opus":0.01933422933977684,"score_gpt":0.2980073833926368,"score_spread":0.27867315405286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417342517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9525184,0.0014385615,0.000023331619,0.029897626,0.00031541745,0.0011107153,0.000044558063,0.000119683136,0.014531675],"genre_scores_gemma":[0.9823069,0.0010377737,0.001000836,0.008498166,0.00037748856,0.00017812836,0.00011663656,0.000047508853,0.0064365854],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99704397,0.0002733176,0.0005681174,0.0007008454,0.0006316081,0.0007821232],"domain_scores_gemma":[0.9976125,0.00095998985,0.00010900326,0.0010450227,0.000093366696,0.00018015168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007144909,0.00035031643,0.000578077,0.0002523229,0.00018638607,0.000093644136,0.0004974154,0.00026887763,0.00025434434],"category_scores_gemma":[0.0003603868,0.0002459015,0.00016697802,0.00091077987,0.00020213451,0.000042805605,0.00037781906,0.0014298611,0.00043045692],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009277446,0.0029891469,0.28449318,0.00033057196,0.008170712,0.011540663,0.0038733657,0.00018574517,0.07413857,0.011120362,0.50140446,0.09247577],"study_design_scores_gemma":[0.07064015,0.0011616718,0.25150213,0.0048892265,0.003478169,0.00022567129,0.0019763906,0.0009939673,0.16362083,0.007866354,0.49211502,0.0015304404],"about_ca_topic_score_codex":0.0010477847,"about_ca_topic_score_gemma":0.00032032645,"teacher_disagreement_score":0.09094533,"about_ca_system_score_codex":0.00091095513,"about_ca_system_score_gemma":0.001366969,"threshold_uncertainty_score":0.99999934},"labels":[],"label_agreement":null},{"id":"W4417457385","doi":"10.64898/2025.12.04.25340141","title":"Genomics of Acute Myeloid Leukemia at Diagnosis and Remission","year":2025,"lang":"en","type":"article","venue":"medRxiv","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Myeloid leukemia; Disease; Genomics; Myeloid; Genome; Leukemia; Genetic testing; Hematology","score_opus":0.017826750363178198,"score_gpt":0.30074949869243006,"score_spread":0.28292274832925185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417457385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98987395,0.0010135352,0.00006428269,0.002671377,0.000086791755,0.00034373914,0.000015598838,0.000040215382,0.005890489],"genre_scores_gemma":[0.97769094,0.00586751,0.0015424435,0.0005961586,0.000069759284,0.000047147085,0.000032210562,0.000027966791,0.01412586],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99883145,0.00004693635,0.00029484348,0.0003152823,0.00023928788,0.0002721814],"domain_scores_gemma":[0.9990112,0.00019188163,0.000065629465,0.00045090888,0.00010658217,0.00017379747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003359824,0.00014351765,0.00035939275,0.00020977757,0.00008552695,0.000008624446,0.00014835542,0.000145617,0.00022339508],"category_scores_gemma":[0.00024690188,0.00011799414,0.0000771792,0.00034019965,0.00017143719,0.000042613134,0.00034290407,0.00025254168,0.000049086713],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004418432,0.000042648328,0.6186323,0.00029002156,0.0002529744,0.00009889178,0.00021384952,0.0000016122004,0.34188953,0.00020248498,0.023659438,0.014274408],"study_design_scores_gemma":[0.0025997036,0.00020147306,0.3491028,0.00031919143,0.00033527703,0.00006938769,0.00006356371,0.00071676983,0.52211994,0.00021152446,0.12409757,0.00016283288],"about_ca_topic_score_codex":0.000055155706,"about_ca_topic_score_gemma":0.0000064561755,"teacher_disagreement_score":0.2695295,"about_ca_system_score_codex":0.00082267,"about_ca_system_score_gemma":0.0004459845,"threshold_uncertainty_score":0.48116615},"labels":[],"label_agreement":null},{"id":"W4417479967","doi":"10.1016/j.jval.2025.09.917","title":"EE535 Impact of Indirect Treatment Comparison (ITC) Methodology on Cost-Effectiveness of Quizartinib in Acute Myeloid Leukemia (AML) in Canada and the United Kingdom (UK)","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Reimbursement; Cohort; Cohort study; Leukemia","score_opus":0.15447653828251615,"score_gpt":0.4388684027220284,"score_spread":0.28439186443951225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417479967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99546313,0.00054419646,0.000050944567,0.00087347405,0.00008794454,0.0027882732,0.00004661446,0.0000075229214,0.00013791703],"genre_scores_gemma":[0.9986875,0.00052060006,0.00031977956,0.00022254093,0.000010550309,0.00015842976,0.000044345292,0.000018055422,0.000018198058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99239343,0.005333779,0.0009967228,0.0003766193,0.00031616943,0.00058326335],"domain_scores_gemma":[0.9905626,0.008500723,0.00028610698,0.00043350333,0.00008178343,0.00013525372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004995901,0.00024116313,0.0015696539,0.0011608491,0.000038561877,0.0000043985274,0.00017394079,0.0001349399,0.000010252865],"category_scores_gemma":[0.001054024,0.00016018307,0.00008254603,0.0019691668,0.0002125491,0.000023099628,0.00007882363,0.0006587639,4.5154042e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012500353,0.00021131743,0.94378805,0.00067634834,0.00025463387,0.00007077083,0.0016466763,0.031577364,0.00084173447,0.00081839587,0.000084652725,0.007529717],"study_design_scores_gemma":[0.017715326,0.0015412064,0.9462836,0.0014081304,0.000042307285,0.000016615933,0.00038176894,0.02612032,0.006087564,0.00022452178,0.00007555471,0.000103086306],"about_ca_topic_score_codex":0.99451363,"about_ca_topic_score_gemma":0.7500633,"teacher_disagreement_score":0.24445036,"about_ca_system_score_codex":0.01711772,"about_ca_system_score_gemma":0.015175357,"threshold_uncertainty_score":0.9904077},"labels":[],"label_agreement":null},{"id":"W4417488992","doi":"10.1016/j.bglo.2025.100049","title":"Bridging the gap: AML induction in low-resource settings","year":2025,"lang":"en","type":"article","venue":"Blood Global Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Bridging (networking); Myeloid leukemia; MEDLINE; Leukemia; Disease","score_opus":0.011453988134572027,"score_gpt":0.30215556814090855,"score_spread":0.2907015800063365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417488992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.934556,0.0010314295,0.00018101378,0.03194993,0.00016493307,0.0005258752,0.000005366417,0.00010076512,0.031484693],"genre_scores_gemma":[0.9949283,0.000020881422,0.0002192824,0.003850286,0.00010611279,0.000042094245,0.000014895991,0.00001059533,0.0008075669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984376,0.00014734514,0.0003315711,0.00035374277,0.00021170481,0.0005180794],"domain_scores_gemma":[0.9992402,0.00012471035,0.00006377565,0.0004232908,0.00007128014,0.000076704644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004155557,0.00015253977,0.00036658294,0.0001421314,0.00010000236,0.000018005281,0.0002364132,0.00021472755,0.00004845156],"category_scores_gemma":[0.0004701297,0.00011507265,0.000073849165,0.0009397696,0.00016751337,0.000041576717,0.00021258,0.0005200456,0.00007689715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013720748,0.0015471368,0.47469383,0.0015296338,0.0008700648,0.0032818064,0.0008359479,0.000071105336,0.0049226847,0.21058984,0.24374786,0.05653801],"study_design_scores_gemma":[0.058303118,0.0014107083,0.43692714,0.0073267138,0.0020227951,0.05108122,0.009041628,0.014890293,0.15970574,0.026739046,0.23031974,0.0022318696],"about_ca_topic_score_codex":0.00021504861,"about_ca_topic_score_gemma":0.0000727713,"teacher_disagreement_score":0.1838508,"about_ca_system_score_codex":0.00026878552,"about_ca_system_score_gemma":0.00034089366,"threshold_uncertainty_score":0.46925265},"labels":[],"label_agreement":null},{"id":"W4417503316","doi":"10.3390/cimb48010004","title":"Unraveling Translational Insights into Systemic Multi-Organ Toxicity of Cytosine Arabinoside (Ara-C): A Systematic Review of Preclinical Animal Evidence","year":2025,"lang":"en","type":"article","venue":"Current Issues in Molecular Biology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytarabine; Myeloid leukemia; Animal studies; Translational research; Clinical trial; Toxicity; Mechanism (biology); Dosing; Preclinical testing; Animal testing","score_opus":0.05078488548993007,"score_gpt":0.43845557667227425,"score_spread":0.3876706911823442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417503316","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3682404,0.6040317,0.024074294,0.0010880935,0.00015334798,0.0023595765,0.0000074986992,0.000022613684,0.000022481849],"genre_scores_gemma":[0.9599656,0.035908256,0.0037242481,0.00017406148,0.000029671344,0.00011036997,0.00005635062,0.000014980335,0.000016492466],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9962284,0.000987041,0.0017271015,0.00048250754,0.0003088889,0.0002660817],"domain_scores_gemma":[0.99787915,0.00063996256,0.0003479572,0.0005862313,0.00046578344,0.00008088897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012525457,0.00023508731,0.0015712611,0.00039266836,0.00002442796,0.000004012241,0.00038595469,0.0002229658,0.000017261627],"category_scores_gemma":[0.0053295754,0.00018805463,0.00022271887,0.0007360228,0.00031563392,0.000047347814,0.00014267654,0.0004773234,0.0000071991353],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023138823,0.0003351324,0.0064955316,0.5198886,0.0001623101,0.000022620055,0.00037816606,0.000010862463,0.47006118,0.0020903945,0.000027409276,0.0002964037],"study_design_scores_gemma":[0.0020622965,0.0005996731,0.001736029,0.8004295,0.0005891105,0.00004702613,0.000070226284,0.003385023,0.19033535,0.00044420466,0.000057397854,0.00024414784],"about_ca_topic_score_codex":0.000042235875,"about_ca_topic_score_gemma":0.000008391385,"teacher_disagreement_score":0.5917252,"about_ca_system_score_codex":0.00018756681,"about_ca_system_score_gemma":0.0005034181,"threshold_uncertainty_score":0.76686454},"labels":[],"label_agreement":null},{"id":"W4417507473","doi":"10.1002/cncr.70210","title":"Characterization of chromosome 5 aberrations in <i>TP53</i> mutated myeloid neoplasms with ≥5% blasts: An International <i>TP53</i> Investigators Network (iTiN) study","year":2025,"lang":"en","type":"article","venue":"Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chromosome; Clinical significance; Relevance (law); Chromosome abnormality; Myeloid; Cytogenetics; Myeloid leukemia","score_opus":0.013968897744626264,"score_gpt":0.30664069159829144,"score_spread":0.29267179385366515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417507473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99481106,0.000046802594,0.00027413582,0.0014079256,0.0003815024,0.0011806074,0.000060141294,0.000071246825,0.001766598],"genre_scores_gemma":[0.99578696,0.00012875829,0.00027858664,0.0012814194,0.00031063956,0.00038665888,0.0003359775,0.00003840233,0.0014525786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981284,0.00011591205,0.00052096334,0.00044408187,0.00043627113,0.00035433666],"domain_scores_gemma":[0.99881464,0.00006307079,0.00016612934,0.0004065811,0.00038180308,0.00016780305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027445666,0.00021643464,0.00040809842,0.00034054957,0.000077427285,0.000038426242,0.00025608082,0.00010949109,0.00021690673],"category_scores_gemma":[0.00009453017,0.00019088069,0.00003925199,0.0015443134,0.00018719856,0.0003806712,0.000083611034,0.00040535044,0.000008067134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001127735,0.0009015782,0.76164603,0.00014533379,0.00046125829,0.00009357437,0.0029974303,0.0022871506,0.22478417,0.00039044183,0.0014319898,0.0037333036],"study_design_scores_gemma":[0.011889237,0.0014550225,0.91719633,0.0014777123,0.00028996356,0.000037357084,0.00174449,0.008572971,0.047715895,0.00012238423,0.008966777,0.0005318473],"about_ca_topic_score_codex":0.0004569518,"about_ca_topic_score_gemma":0.0017153774,"teacher_disagreement_score":0.17706828,"about_ca_system_score_codex":0.00062838476,"about_ca_system_score_gemma":0.0014749148,"threshold_uncertainty_score":0.77838886},"labels":[],"label_agreement":null},{"id":"W4417535101","doi":"10.1038/s41467-025-67611-w","title":"Thrombopoietin increases susceptibility for EVI1 + KMT2A-MLLT3-driven AML expressing stem cell genes linked to poor outcome","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Heart, Lung, and Blood Institute; Genome Canada; Universität Basel; National Cancer Institute; National Science Foundation","keywords":"Haematopoiesis; Thrombopoietin; Stem cell; Clonogenic assay; Myeloid; Gene; Gene knockdown; Hematopoietic stem cell","score_opus":0.05782793113757199,"score_gpt":0.39715810435555543,"score_spread":0.3393301732179834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417535101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85832065,0.022915551,0.003988632,0.0922978,0.00058663177,0.007585713,0.0005057097,0.00071335945,0.013085946],"genre_scores_gemma":[0.93195266,0.00038227937,0.058791,0.0034200733,0.00011159719,0.00042682877,0.00030794233,0.000046073266,0.0045615383],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977319,0.00036404232,0.000598351,0.0005031913,0.0003363457,0.00046613463],"domain_scores_gemma":[0.9930689,0.0018801839,0.00013042298,0.0038560322,0.00080573995,0.00025875572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007685746,0.00027017805,0.0005631898,0.00032356952,0.0006160899,0.00008155406,0.0016632995,0.00053310883,0.000046385114],"category_scores_gemma":[0.0010055798,0.0002427177,0.00025276042,0.0007892479,0.0002437938,0.000117653544,0.0012677991,0.0015892163,0.000053001702],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010503266,0.0028241368,0.27949345,0.0015385938,0.00053430244,0.000010124499,0.0015594849,0.00006444452,0.43923244,0.0067056487,0.23172507,0.035261977],"study_design_scores_gemma":[0.0072147655,0.0005524532,0.22118503,0.0010588258,0.00087616884,0.000020135105,0.0035066507,0.0066976342,0.032862723,0.0005258884,0.72450805,0.0009916892],"about_ca_topic_score_codex":0.00017640466,"about_ca_topic_score_gemma":0.00062808633,"teacher_disagreement_score":0.49278298,"about_ca_system_score_codex":0.0006592608,"about_ca_system_score_gemma":0.00066097686,"threshold_uncertainty_score":0.98977405},"labels":[],"label_agreement":null},{"id":"W613303972","doi":"10.1182/blood.v124.21.409.409","title":"Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lenalidomide; Anemia; Internal medicine; Myelodysplastic syndromes; Placebo; Clinical endpoint; Randomization; Refractory (planetary science); Neutropenia; Gastroenterology; Randomized controlled trial; Surgery; Toxicity; Bone marrow; Multiple myeloma","score_opus":0.018595255429268674,"score_gpt":0.3049827407129871,"score_spread":0.28638748528371843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W613303972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99185544,0.0001585091,0.00047214137,0.00008649701,0.00019422523,0.0067345207,0.00035983283,0.00007451493,0.000064326545],"genre_scores_gemma":[0.9976507,0.00057694514,0.001037171,0.000057590158,0.000108441134,0.00019127926,0.00014614903,0.000116880845,0.00011488085],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930263,0.0019157635,0.0016086625,0.0013138435,0.001335745,0.0007996498],"domain_scores_gemma":[0.98799646,0.009539032,0.00061492936,0.0008238313,0.00035993176,0.0006658441],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025320724,0.00069819106,0.0021474797,0.00069879973,0.00023186099,0.00006843416,0.00030162427,0.00025431757,0.000053543798],"category_scores_gemma":[0.0120810885,0.0005020236,0.000120790806,0.0004961753,0.00037977943,0.0002516061,0.00036999755,0.00085196015,0.000015730046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9505178,0.008091315,0.02246811,0.00018712108,0.0014878621,0.00048969034,0.008691019,0.00018698827,0.0014203145,9.681869e-7,0.000033392113,0.0064254715],"study_design_scores_gemma":[0.9154546,0.0117964465,0.06145773,0.0018493168,0.0020730596,0.00003383217,0.0017686827,0.003744428,0.0012658974,0.0000045432184,0.000022554677,0.0005288925],"about_ca_topic_score_codex":0.0023590329,"about_ca_topic_score_gemma":0.0019648613,"teacher_disagreement_score":0.03898962,"about_ca_system_score_codex":0.00033325923,"about_ca_system_score_gemma":0.00040408145,"threshold_uncertainty_score":0.99974316},"labels":[],"label_agreement":null},{"id":"W62594602","doi":"10.1093/pch/12.7.573","title":"Acute lymphoblastic leukemia presenting with gross hematuria","year":2007,"lang":"en","type":"article","venue":"Paediatrics & Child Health","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Lymphoblastic Leukemia; Gross hematuria; Medicine; Pediatrics; Leukemia; Internal medicine; Surgery","score_opus":0.013087621068936146,"score_gpt":0.3002831409141669,"score_spread":0.2871955198452308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W62594602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9542745,0.0038637677,0.0098055545,0.009689748,0.0005518799,0.0024414596,0.000056947258,0.0005735161,0.018742673],"genre_scores_gemma":[0.9792388,0.0015914269,0.01036764,0.004521708,0.0027822643,0.00002671893,0.00014336954,0.00015170335,0.0011763542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99547887,0.00008324657,0.00075249176,0.0007032265,0.0012175561,0.0017646166],"domain_scores_gemma":[0.9970416,0.000470707,0.00033788866,0.00073095754,0.00027089784,0.0011479657],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019493363,0.00037748372,0.0006934577,0.00055042125,0.00053249806,0.000060620943,0.00030932712,0.00022930912,0.00006196723],"category_scores_gemma":[0.00033954935,0.00029768553,0.0001466996,0.0015682605,0.00014222207,0.00015970947,0.00019627865,0.0011980325,0.00019172461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008813159,0.001699458,0.7547614,0.007517907,0.001893261,0.00722492,0.009967327,0.00024725246,0.00079162326,0.007947052,0.15852343,0.04061324],"study_design_scores_gemma":[0.030110719,0.0038939097,0.8908303,0.00080685667,0.0009102107,0.008156783,0.0011378953,0.0035558215,0.0028038505,0.00055372686,0.05525517,0.001984762],"about_ca_topic_score_codex":0.0002966746,"about_ca_topic_score_gemma":0.00009442407,"teacher_disagreement_score":0.13606893,"about_ca_system_score_codex":0.0026667179,"about_ca_system_score_gemma":0.003059941,"threshold_uncertainty_score":0.99994755},"labels":[],"label_agreement":null},{"id":"W636666193","doi":"10.1200/jco.2005.23.16_suppl.8187","title":"Impact of intensive chemotherapy versus supportive care on quality of life (QOL) of older adults with newly diagnosed acute myeloid leukemia (AML)","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital","funders":"","keywords":"Medicine; Quality of life (healthcare); Life expectancy; Referral; Cancer; Myeloid leukemia; Intensive care; Internal medicine; Physical therapy; Pediatrics; Intensive care medicine; Population; Family medicine","score_opus":0.07599451779225107,"score_gpt":0.4753275861335163,"score_spread":0.3993330683412652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W636666193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398136,0.00027947588,0.00007322105,0.003730938,0.00029799185,0.00057697686,0.00005964627,0.000007844177,0.0009925213],"genre_scores_gemma":[0.99278057,0.0014466095,0.0030161967,0.0017676187,0.0008514557,0.0000050782046,0.000014856084,0.000043950786,0.000073676754],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99316025,0.0007474808,0.0042221034,0.00033817385,0.0010872227,0.00044477943],"domain_scores_gemma":[0.97900325,0.007064842,0.005552885,0.00053915434,0.007086532,0.0007533126],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0024703294,0.00030858163,0.0036822925,0.00031533095,0.000023885908,0.0000034896818,0.00042018775,0.00067736517,0.0003634159],"category_scores_gemma":[0.013879402,0.00019387639,0.0012624557,0.00036163823,0.0009144649,0.00015192262,0.00008268651,0.0018857074,0.000008539862],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57154745,0.0038890282,0.20426378,0.00036010033,0.00880526,0.00077051384,0.009094343,0.00037370002,0.0031463718,0.000040123537,0.017222324,0.18048704],"study_design_scores_gemma":[0.10121604,0.091601156,0.7955762,0.0006027322,0.0005678704,0.00008787266,0.0054084957,0.00007136128,0.0040371884,0.000008238785,0.00063814886,0.00018469992],"about_ca_topic_score_codex":0.0005005663,"about_ca_topic_score_gemma":0.00017515133,"teacher_disagreement_score":0.5913124,"about_ca_system_score_codex":0.0016700791,"about_ca_system_score_gemma":0.013676948,"threshold_uncertainty_score":0.9944271},"labels":[],"label_agreement":null},{"id":"W653522987","doi":"10.1182/blood.v124.21.5285.5285","title":"FLAG-IDA Has Significant Activity As Frontline Induction or Salvage Therapy for Patients with High Risk and/or Relapsed or Refractory Acute Myeloid Leukemia (AML)","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Leukemia & Lymphoma Society of Canada; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Flag (linear algebra); Medicine; Salvage therapy; Cytarabine; Internal medicine; Refractory (planetary science); Fludarabine; Surgery; Idarubicin; Transplantation; Myeloid leukemia; Oncology; Chemotherapy; Gastroenterology; Cyclophosphamide","score_opus":0.01957236013626043,"score_gpt":0.2685598724542179,"score_spread":0.2489875123179575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W653522987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99512297,0.00033039442,0.0009530378,0.00032998243,0.00014927567,0.0027273858,0.00012633107,0.00019382355,0.00006677976],"genre_scores_gemma":[0.9824831,0.0072084987,0.006116897,0.00026997193,0.00060079043,0.00042465812,0.00018196645,0.00017435767,0.002539761],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997109,0.00029285075,0.0004297865,0.0008440552,0.000660619,0.00066368206],"domain_scores_gemma":[0.9973615,0.0007714898,0.0003597814,0.0008075353,0.00030193207,0.0003977815],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006256944,0.00047422666,0.0008766327,0.00024966107,0.00037504215,0.00008341211,0.00023450996,0.00038638516,0.0001852512],"category_scores_gemma":[0.000915759,0.0002604735,0.00011299421,0.0004034509,0.00026928508,0.00033718438,0.00008755968,0.0008405889,0.000042291023],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17106147,0.0062552597,0.017823864,0.000758169,0.003727295,0.00032550955,0.0014194773,0.0000047164917,0.057076983,0.000042720883,0.0045884144,0.7369161],"study_design_scores_gemma":[0.26485306,0.11094281,0.26888537,0.0012165557,0.0055883885,0.0004293706,0.0005252614,0.000762205,0.11723799,0.00023448758,0.22658652,0.0027379969],"about_ca_topic_score_codex":0.0007031073,"about_ca_topic_score_gemma":0.00012056647,"teacher_disagreement_score":0.7341781,"about_ca_system_score_codex":0.00050647877,"about_ca_system_score_gemma":0.0014674877,"threshold_uncertainty_score":0.99998474},"labels":[],"label_agreement":null},{"id":"W6888038310","doi":"10.18130/by6z-fg34","title":"Identifying molecular features associated with overall survival outcomes in Acute myeloid leukemia patients over the age of 60; How Physician-Assisted Death Redefines the Role of Physicians","year":2024,"lang":"en","type":"article","venue":"Libra","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Overall survival; Disease; Cancer; Survival analysis; Myeloid; Survival rate","score_opus":0.013921335545880313,"score_gpt":0.26970948495060826,"score_spread":0.25578814940472794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6888038310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942901,0.0006195684,0.000024051957,0.0015401387,0.00011771464,0.0006641313,0.00011547875,0.00007474362,0.002554067],"genre_scores_gemma":[0.99727476,0.000057976624,0.00009370328,0.0006087646,0.00005871972,0.00004055274,0.00019436666,0.00008304713,0.001588093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760216,0.00023661528,0.00033280562,0.00037934244,0.0009983161,0.00045072983],"domain_scores_gemma":[0.99857074,0.00046017484,0.00019373783,0.0006142308,0.000119580094,0.00004156287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025110273,0.00030585876,0.0006759918,0.00017903239,0.00007640828,0.00011624203,0.00044940837,0.0001399139,0.000009588113],"category_scores_gemma":[0.0001503543,0.0001636987,0.00026989295,0.00086471735,0.00021793964,0.0002645724,0.0002150992,0.00068820606,0.0000029188027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010950069,0.0009038262,0.5954314,0.00055778347,0.0059793233,0.0011039615,0.0067736213,0.00013898259,0.36332616,0.0075654397,0.0047820364,0.012342479],"study_design_scores_gemma":[0.0018108903,0.00021477809,0.9716707,0.00067608344,0.0003265567,0.0000030482909,0.0004502567,0.00047539215,0.023112906,0.0006611994,0.0004160226,0.00018217272],"about_ca_topic_score_codex":0.00036283248,"about_ca_topic_score_gemma":0.000084114,"teacher_disagreement_score":0.37623933,"about_ca_system_score_codex":0.00031729956,"about_ca_system_score_gemma":0.0002921762,"threshold_uncertainty_score":0.66754395},"labels":[],"label_agreement":null},{"id":"W6901899720","doi":"10.60692/emm2y-1xb21","title":"Multiplexed automated digital quantification of fusion transcripts: comparative study with fluorescent in-situ hybridization (FISH) technique in acute leukemia patients","year":2016,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"","keywords":"Fusion gene; Fusion transcript; Chromosomal translocation; Fluorescence in situ hybridization; Karyotype; Acute leukemia; Bone marrow; Leukemia","score_opus":0.03232121819515171,"score_gpt":0.2631368236456023,"score_spread":0.2308156054504506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901899720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871519,4.762737e-7,0.007777064,0.000034426674,0.000047135163,0.004238945,0.00015629827,0.00024599375,0.00034773877],"genre_scores_gemma":[0.99912,3.412583e-7,0.00024382316,0.000014426559,0.000008532704,0.000339883,0.0002331795,0.000017556275,0.000022270724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756134,0.00013340288,0.0011260844,0.00025152636,0.00064763316,0.00028002617],"domain_scores_gemma":[0.99846536,0.000018942746,0.00041668475,0.00040402712,0.00060253544,0.0000924424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038958562,0.00023694923,0.0005034933,0.0009042504,0.000044835862,0.00005565272,0.00015053086,0.00012227675,0.0000034880375],"category_scores_gemma":[0.00003837274,0.0001491305,0.000039954008,0.00077800703,0.00006544429,0.0011972134,0.000041713596,0.00014710923,0.000056080982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028292732,0.000098447956,0.9437802,0.0003493312,0.00008212352,0.000013609483,0.043673936,0.00009098041,0.00848536,0.000010620484,0.000048867587,0.0005372774],"study_design_scores_gemma":[0.012826124,0.00086716266,0.9184481,0.001232603,0.00003817669,0.000019829617,0.010494421,0.003998578,0.051866654,1.2699113e-7,0.000008729916,0.00019949688],"about_ca_topic_score_codex":0.000034302306,"about_ca_topic_score_gemma":0.000008698033,"teacher_disagreement_score":0.043381296,"about_ca_system_score_codex":0.0015233711,"about_ca_system_score_gemma":0.00021387133,"threshold_uncertainty_score":0.60813653},"labels":[],"label_agreement":null},{"id":"W6901911718","doi":"10.6084/m9.figshare.12655469.v1","title":"Additional file 4 of Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Cytarabine; Myeloid leukemia; Absolute neutrophil count; Myeloid; Complete response; Blood count; Azacitidine","score_opus":0.03478929580295318,"score_gpt":0.30311375889959646,"score_spread":0.26832446309664326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901911718","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51299775,0.0000042167135,1.348657e-7,0.00047199198,0.0000023448313,0.0005595254,0.48588917,0.00002125772,0.00005359797],"genre_scores_gemma":[0.37291926,0.00000795262,0.0017083996,0.002716006,0.000112009424,0.0007450213,0.6210428,0.00010428425,0.00064427586],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9982383,0.00009436141,0.0003521546,0.0005108684,0.0004838255,0.00032046347],"domain_scores_gemma":[0.99673563,0.002084983,0.00009782722,0.00024934756,0.0003002513,0.0005319869],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009043399,0.0002475223,0.0006238115,0.0001790973,0.000045815,0.000027350921,0.00014103611,0.00011557815,0.3108851],"category_scores_gemma":[0.0032200655,0.00017216038,0.000046684323,0.0005839028,0.000032528467,0.00011639246,0.00017861923,0.00033600527,0.00015175722],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053015616,0.00015674804,0.16176055,0.00008925942,0.0002933309,0.00023931671,0.00024019266,0.000011149944,0.000087579734,2.9543446e-7,0.7767951,0.007310847],"study_design_scores_gemma":[0.008281422,0.0043043317,0.9618162,0.001534972,0.000018100412,0.000007436503,0.00008424083,0.00011329284,0.00008090209,4.095384e-7,0.023554493,0.00020422532],"about_ca_topic_score_codex":0.00002508627,"about_ca_topic_score_gemma":0.000035372024,"teacher_disagreement_score":0.8000556,"about_ca_system_score_codex":0.00018902791,"about_ca_system_score_gemma":0.0005067433,"threshold_uncertainty_score":0.7020496},"labels":[],"label_agreement":null},{"id":"W6901961568","doi":"10.6084/m9.figshare.12655463.v1","title":"Additional file 2 of Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Cytarabine; Myeloid leukemia; Confidence interval; Overall survival; Complete response; Ruxolitinib; Leukemia","score_opus":0.03405422949891051,"score_gpt":0.3026069387484275,"score_spread":0.26855270924951696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901961568","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.512705,0.000004244794,1.3062775e-7,0.00047266026,0.000002356747,0.000558172,0.48618156,0.00002125278,0.000054584456],"genre_scores_gemma":[0.3601009,0.000008092482,0.0017008747,0.0027326702,0.0001141555,0.0007494586,0.63382864,0.00010484286,0.0006603371],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99823886,0.00009442978,0.00035203373,0.0005106698,0.00048364606,0.00032034045],"domain_scores_gemma":[0.99674755,0.0020709045,0.0000979298,0.00024913452,0.0003025067,0.0005319493],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008993641,0.00024746457,0.0006237542,0.00017896372,0.000045800123,0.00002733952,0.00014094729,0.00011557882,0.31560636],"category_scores_gemma":[0.003227252,0.00017211771,0.000046675163,0.0005837514,0.00003252024,0.00011636615,0.00017865363,0.0003360076,0.0001516361],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051444825,0.00015515371,0.15528229,0.000088373235,0.00029067267,0.0002395314,0.00023777789,0.000011237148,0.000084918946,2.8911253e-7,0.78483254,0.0073324023],"study_design_scores_gemma":[0.008269859,0.0042480878,0.960507,0.0015189146,0.000018091197,0.0000074562076,0.00008368688,0.00011219816,0.000080493424,4.0811824e-7,0.02494976,0.00020405668],"about_ca_topic_score_codex":0.000025268733,"about_ca_topic_score_gemma":0.000035202625,"teacher_disagreement_score":0.8052247,"about_ca_system_score_codex":0.0001890618,"about_ca_system_score_gemma":0.000506158,"threshold_uncertainty_score":0.7018756},"labels":[],"label_agreement":null},{"id":"W6902195153","doi":"10.6084/m9.figshare.25750158.v1","title":"Additional file 2 of Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Google (Canada)","funders":"","keywords":"Myeloid leukemia; Leukemia; Myeloid; Lower risk; Incidence (geometry)","score_opus":0.02571594467510904,"score_gpt":0.2761728992835731,"score_spread":0.25045695460846407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902195153","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3872096,0.000115242394,0.000004175723,0.000010209471,0.00002886668,0.00032379382,0.6122071,0.000031910404,0.00006909067],"genre_scores_gemma":[0.17926341,0.000017192055,0.0048657786,0.00006572927,0.00015326108,0.00022215785,0.8096894,0.00012061735,0.0056024357],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99757105,0.000068851994,0.00039178634,0.00055208907,0.0010022239,0.00041400548],"domain_scores_gemma":[0.9977948,0.00078838033,0.00021279496,0.00036579973,0.0005663939,0.00027182777],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000060673585,0.0003232738,0.00045549864,0.00023154354,0.00012391305,0.000038156886,0.00017055483,0.00029536607,0.8293058],"category_scores_gemma":[0.00048823774,0.00023126995,0.00013946807,0.00042377898,0.00012045346,0.00027956296,0.0004496402,0.00060699676,0.00013853057],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001351451,0.00009777149,0.0034511113,0.0011014182,0.000569866,0.0005392313,0.000097300595,0.0006106266,0.0003597249,0.0000014134342,0.9914418,0.00037827663],"study_design_scores_gemma":[0.0056443433,0.0014396316,0.8396541,0.052829973,0.0011308971,0.0002898812,0.000019395644,0.08539808,0.002007486,0.000025544019,0.010418009,0.0011426496],"about_ca_topic_score_codex":0.000035417394,"about_ca_topic_score_gemma":0.000084177154,"teacher_disagreement_score":0.9810238,"about_ca_system_score_codex":0.00042528662,"about_ca_system_score_gemma":0.0010424542,"threshold_uncertainty_score":0.94309145},"labels":[],"label_agreement":null},{"id":"W6902200852","doi":"10.6084/m9.figshare.26617822","title":"Additional file 4 of Cytogenetic profile of 1791 adult acute myeloid leukemia in India","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Leukemia; Disease; Mutation; Myeloid","score_opus":0.020260312899982556,"score_gpt":0.2836828577103377,"score_spread":0.26342254481035515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902200852","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012445052,0.00017967322,9.9170116e-8,0.000044069948,0.000016269983,0.00045907276,0.97822034,0.000048514772,0.019787472],"genre_scores_gemma":[0.015131751,0.000010735389,0.0009782432,0.00010831064,0.00015540444,0.0014270276,0.97644264,0.000045192683,0.0057007186],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984717,0.000035742687,0.00037543548,0.00031212505,0.000497453,0.00030756908],"domain_scores_gemma":[0.9982368,0.0009668353,0.00008191409,0.00030368098,0.00028950986,0.000121258396],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000035797417,0.00015920121,0.0003293721,0.0003757153,0.000017322423,0.000012115124,0.00020399224,0.00018199284,0.99276537],"category_scores_gemma":[0.0025172958,0.00014377029,0.00013536909,0.0007734685,0.000033310207,0.00008598093,0.0001534742,0.00044289613,0.005061465],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061896404,0.000027357548,0.0000129356495,0.0011986254,0.0000882544,0.00028995264,0.00010092078,0.0000023166854,0.0010024183,0.000010541521,0.99421304,0.0029917175],"study_design_scores_gemma":[0.0011748702,0.00050785014,0.043126684,0.027232112,0.00004986063,0.00022040386,0.00013057313,0.0038198938,0.022723954,0.00005880047,0.90064704,0.0003079478],"about_ca_topic_score_codex":0.000016359729,"about_ca_topic_score_gemma":0.0000069132957,"teacher_disagreement_score":0.98770386,"about_ca_system_score_codex":0.00054630975,"about_ca_system_score_gemma":0.002674146,"threshold_uncertainty_score":0.99571323},"labels":[],"label_agreement":null},{"id":"W6902217597","doi":"10.6084/m9.figshare.12655463","title":"Additional file 2 of Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Cytarabine; Myeloid leukemia; Confidence interval; Overall survival; Complete response; Ruxolitinib; Leukemia","score_opus":0.03405422949891051,"score_gpt":0.3026069387484275,"score_spread":0.26855270924951696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902217597","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.512705,0.000004244794,1.3062775e-7,0.00047266026,0.000002356747,0.000558172,0.48618156,0.00002125278,0.000054584456],"genre_scores_gemma":[0.3601009,0.000008092482,0.0017008747,0.0027326702,0.0001141555,0.0007494586,0.63382864,0.00010484286,0.0006603371],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99823886,0.00009442978,0.00035203373,0.0005106698,0.00048364606,0.00032034045],"domain_scores_gemma":[0.99674755,0.0020709045,0.0000979298,0.00024913452,0.0003025067,0.0005319493],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008993641,0.00024746457,0.0006237542,0.00017896372,0.000045800123,0.00002733952,0.00014094729,0.00011557882,0.31560636],"category_scores_gemma":[0.003227252,0.00017211771,0.000046675163,0.0005837514,0.00003252024,0.00011636615,0.00017865363,0.0003360076,0.0001516361],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051444825,0.00015515371,0.15528229,0.000088373235,0.00029067267,0.0002395314,0.00023777789,0.000011237148,0.000084918946,2.8911253e-7,0.78483254,0.0073324023],"study_design_scores_gemma":[0.008269859,0.0042480878,0.960507,0.0015189146,0.000018091197,0.0000074562076,0.00008368688,0.00011219816,0.000080493424,4.0811824e-7,0.02494976,0.00020405668],"about_ca_topic_score_codex":0.000025268733,"about_ca_topic_score_gemma":0.000035202625,"teacher_disagreement_score":0.8052247,"about_ca_system_score_codex":0.0001890618,"about_ca_system_score_gemma":0.000506158,"threshold_uncertainty_score":0.7018756},"labels":[],"label_agreement":null},{"id":"W6902253599","doi":"10.6084/m9.figshare.26617828.v1","title":"Additional file 6 of Cytogenetic profile of 1791 adult acute myeloid leukemia in India","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Leukemia; Statistical analysis; Mutation; Disease","score_opus":0.020099126044516833,"score_gpt":0.2833623428747859,"score_spread":0.26326321683026904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902253599","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001241591,0.00018001752,9.9067414e-8,0.000044369564,0.000016269396,0.00045958438,0.977986,0.00004850323,0.020023597],"genre_scores_gemma":[0.014991297,0.000010724832,0.0009785587,0.00010846486,0.00015554743,0.0014298626,0.976487,0.000045234363,0.005793346],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99847156,0.0000357783,0.00037543126,0.00031217618,0.0004974884,0.00030759576],"domain_scores_gemma":[0.9982353,0.00096564926,0.00008191354,0.00030363008,0.00029222993,0.000121281795],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003581912,0.00015922099,0.00032943158,0.0003756899,0.000017319966,0.000012115721,0.00020392599,0.0001819925,0.99269557],"category_scores_gemma":[0.0025287804,0.00014378056,0.00013537832,0.0007737973,0.000033312648,0.00008598922,0.00015349075,0.00044299252,0.0050357464],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006115667,0.000027506763,0.000012850241,0.0011991531,0.00008826825,0.00028982302,0.00010120521,0.000002312173,0.0010092147,0.000010651628,0.99420315,0.0029947006],"study_design_scores_gemma":[0.0011693331,0.0004979259,0.04337717,0.027111353,0.00004964949,0.00021921207,0.00013026859,0.0037463908,0.022633545,0.00005852181,0.90070003,0.00030660353],"about_ca_topic_score_codex":0.000016718805,"about_ca_topic_score_gemma":0.0000070770425,"teacher_disagreement_score":0.9876598,"about_ca_system_score_codex":0.0005456573,"about_ca_system_score_gemma":0.0026780188,"threshold_uncertainty_score":0.9957389},"labels":[],"label_agreement":null},{"id":"W6902495751","doi":"10.6084/m9.figshare.26716003.v1","title":"Additional file 3 of Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Google (Canada)","funders":"","keywords":"Myeloid leukemia; Leukemia; Myeloid; Lower risk; Incidence (geometry)","score_opus":0.026065998573817948,"score_gpt":0.27629364174875465,"score_spread":0.2502276431749367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902495751","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38835898,0.00011391933,0.000004272526,0.000010193801,0.000028910374,0.00032368948,0.61106026,0.000031819058,0.00006793148],"genre_scores_gemma":[0.18354957,0.000017047092,0.0049216803,0.00006581904,0.00015314997,0.00022270536,0.80525166,0.00012101938,0.0056973747],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9975704,0.00006881251,0.00039178645,0.00055224367,0.0010026367,0.00041411433],"domain_scores_gemma":[0.9977854,0.00079215015,0.00021255754,0.00036593687,0.00057211035,0.0002718443],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000060949907,0.0003233253,0.0004554402,0.00023161023,0.0001238951,0.000038153517,0.00017054277,0.00029534157,0.82852006],"category_scores_gemma":[0.0004935136,0.00023128456,0.00013948437,0.00042393373,0.00012046279,0.000279586,0.00044940057,0.00060701,0.00014127974],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013719979,0.00009821669,0.0035741345,0.0011146783,0.00057210267,0.0005345018,0.000097687356,0.0006110136,0.00037398463,0.0000013898192,0.99127465,0.0003756663],"study_design_scores_gemma":[0.0056375866,0.0014267142,0.83983827,0.052916344,0.0011167958,0.00028466454,0.00001934457,0.08538441,0.002043298,0.000025236872,0.010171054,0.0011362922],"about_ca_topic_score_codex":0.00003546108,"about_ca_topic_score_gemma":0.000084248226,"teacher_disagreement_score":0.9811036,"about_ca_system_score_codex":0.00042671696,"about_ca_system_score_gemma":0.0010471978,"threshold_uncertainty_score":0.94315106},"labels":[],"label_agreement":null},{"id":"W6904865574","doi":"10.14288/1.0447438","title":"Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive Chemotherapy","year":2024,"lang":"en","type":"article","venue":"Open Collections","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytarabine; Myeloid leukemia; Intensive care; Hematology; Chemotherapy; Systemic therapy; Retrospective cohort study; Medical record","score_opus":0.04195619787665063,"score_gpt":0.38118699815154533,"score_spread":0.3392308002748947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6904865574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9268095,0.000027916747,0.0001408108,0.030769879,0.0004438865,0.009653442,0.0010495813,0.000075298056,0.03102968],"genre_scores_gemma":[0.72101337,0.0005312691,0.0007082875,0.0012852257,0.00011807041,0.000897058,0.00021360513,0.00006837801,0.27516472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989303,0.00002921645,0.00025512272,0.00035784667,0.000103748585,0.0003237712],"domain_scores_gemma":[0.9988512,0.00037842913,0.000024011753,0.00021588145,0.00021600195,0.00031447245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001551762,0.0001441509,0.00036368053,0.0002832096,0.00037621276,0.00027343162,0.00008738286,0.00006778183,0.00027245696],"category_scores_gemma":[0.00012037949,0.00010031315,0.00006683277,0.00069180585,0.000056075914,0.00008043947,0.000035535148,0.00018541889,0.000006112753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005468127,0.00024794458,0.93293685,0.000029065242,0.00046078692,0.000059589474,0.0002548497,0.0000032504113,2.2813568e-7,0.000035303932,0.060265817,0.0051594744],"study_design_scores_gemma":[0.01071199,0.0030189601,0.8533479,0.00021795265,0.00014885484,0.000011362627,0.0002317191,0.0017889366,0.000016679203,0.000110500216,0.13021359,0.00018153914],"about_ca_topic_score_codex":0.86848414,"about_ca_topic_score_gemma":0.98853856,"teacher_disagreement_score":0.24413504,"about_ca_system_score_codex":0.0018280795,"about_ca_system_score_gemma":0.0015133127,"threshold_uncertainty_score":0.4780364},"labels":[],"label_agreement":null},{"id":"W6908631097","doi":"10.26181/19469984","title":"Gendering practices in quantitative research on alcohol and violence: Comparing research from Australia, Canada and Sweden","year":2022,"lang":"en","type":"article","venue":"La Trobe University","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Qualitative research; Agency (philosophy); Sample (material); Perspective (graphical)","score_opus":0.33573075603643127,"score_gpt":0.4498557680852215,"score_spread":0.11412501204879022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6908631097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99348795,0.00012358099,0.000003350195,0.0011086065,0.00002343313,0.00034811208,0.000035295987,0.000012001784,0.0048576365],"genre_scores_gemma":[0.9977116,0.00021743153,0.00037480614,0.000026557305,0.00002379685,0.0000035230591,0.000017283892,0.000010476179,0.0016145178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964779,0.001406788,0.00010630072,0.00047509154,0.0010488415,0.0004850545],"domain_scores_gemma":[0.9972103,0.0021406256,0.00005489163,0.00024226916,0.00013883629,0.00021306674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022492027,0.000096088675,0.00022016981,0.0005090104,0.00065922906,0.00003740712,0.0002404795,0.000056995574,0.00012936104],"category_scores_gemma":[0.00043276284,0.00010708765,0.000014688321,0.0007497888,0.00029936474,0.00014646872,0.0008833006,0.0021976552,0.0000042892007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006514761,0.00033544132,0.9428579,0.0001957524,0.00024616226,0.011507337,0.008780533,0.00052198034,0.011498558,0.008861341,0.006311414,0.0023687927],"study_design_scores_gemma":[0.0046928846,0.0007403189,0.867553,0.00023076775,0.000029244236,0.00008085089,0.09551942,0.004690751,0.000643876,0.0005192456,0.025056664,0.00024295482],"about_ca_topic_score_codex":0.91095287,"about_ca_topic_score_gemma":0.58219767,"teacher_disagreement_score":0.3287552,"about_ca_system_score_codex":0.0021325457,"about_ca_system_score_gemma":0.00080348674,"threshold_uncertainty_score":0.954784},"labels":[],"label_agreement":null},{"id":"W6920751406","doi":"10.6084/m9.figshare.26617825","title":"Additional file 5 of Cytogenetic profile of 1791 adult acute myeloid leukemia in India","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Leukemia; Disease; Myeloid; Mutation","score_opus":0.020103729599170287,"score_gpt":0.28339893087098245,"score_spread":0.26329520127181216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920751406","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012512921,0.00017943533,9.882823e-8,0.00004433775,0.000016271699,0.00045898,0.97825056,0.00004852078,0.0197505],"genre_scores_gemma":[0.014973123,0.000010738369,0.0009785243,0.00010842448,0.0001554788,0.0014274211,0.97655076,0.00004521552,0.005750336],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99847156,0.000035776542,0.00037542198,0.00031216993,0.0004974861,0.00030756046],"domain_scores_gemma":[0.99823564,0.0009654438,0.00008190861,0.00030361483,0.00029214806,0.0001212704],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000035817684,0.00015921892,0.0003294357,0.00037569832,0.00001732332,0.00001210911,0.00020390599,0.00018200277,0.99276316],"category_scores_gemma":[0.0025286535,0.0001437733,0.00013538964,0.00077374885,0.00003331039,0.000085980784,0.00015348294,0.00044295468,0.0050234124],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060819173,0.000027361179,0.000012886102,0.0011990607,0.00008825921,0.00028995084,0.00010086486,0.0000023491364,0.0010109049,0.000010548347,0.99419993,0.0029970827],"study_design_scores_gemma":[0.00117999,0.000502768,0.044136036,0.027391326,0.00005013183,0.00022153746,0.00013130448,0.0038086846,0.023035618,0.000058743644,0.89917433,0.00030954427],"about_ca_topic_score_codex":0.000016526883,"about_ca_topic_score_gemma":0.0000069412276,"teacher_disagreement_score":0.98773974,"about_ca_system_score_codex":0.00054644403,"about_ca_system_score_gemma":0.0026775165,"threshold_uncertainty_score":0.9957513},"labels":[],"label_agreement":null},{"id":"W6920801185","doi":"10.6084/m9.figshare.20462365.v1","title":"Additional file 3 of Single-cell diploid Hi-C reveals the role of spatial aggregations in complex rearrangements and KMT2A fusions in leukemia","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Ploidy; Leukemia; Genome; Mutation","score_opus":0.03933951172640748,"score_gpt":0.2645081469299164,"score_spread":0.22516863520350894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920801185","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016916255,0.00009214583,5.55907e-8,0.0001581553,0.000004233451,0.0005034078,0.97394633,0.000008738685,0.008370693],"genre_scores_gemma":[0.34408528,0.0000021153958,0.00017211241,0.000099463454,0.000033740747,0.00091945444,0.6538524,0.000014246323,0.0008211846],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987894,0.0001232731,0.0002989012,0.00017862293,0.0004230297,0.00018674391],"domain_scores_gemma":[0.9983498,0.0011077308,0.00015068344,0.00023724894,0.000099156234,0.000055404867],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000078625846,0.00008835641,0.00020752173,0.00019915932,0.00009058938,0.0000054717975,0.0001708346,0.000042950156,0.96465594],"category_scores_gemma":[0.0017707883,0.00007745964,0.000045841687,0.0004155217,0.000032705706,0.00004161235,0.00037407875,0.00033398217,0.000076231765],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005641581,0.0001471398,0.00029619585,0.000086860215,0.000009424829,0.000015340953,0.00026516823,0.000030396272,0.008555245,0.0000023652092,0.98911387,0.0014215952],"study_design_scores_gemma":[0.0018486085,0.00030701124,0.13222611,0.0015978075,0.00001099008,0.000025443394,0.0011201457,0.0024390996,0.0012695102,0.00013590683,0.8588859,0.00013348345],"about_ca_topic_score_codex":0.00021382171,"about_ca_topic_score_gemma":0.0002052411,"teacher_disagreement_score":0.9645797,"about_ca_system_score_codex":0.00037681177,"about_ca_system_score_gemma":0.00037549477,"threshold_uncertainty_score":0.31587124},"labels":[],"label_agreement":null},{"id":"W6920820573","doi":"10.6084/m9.figshare.26617816","title":"Additional file 2 of Cytogenetic profile of 1791 adult acute myeloid leukemia in India","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Leukemia; Disease; Mutation; Myeloid","score_opus":0.01975040268378538,"score_gpt":0.28309921287478895,"score_spread":0.2633488101910036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920820573","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012307239,0.00018094676,9.545104e-8,0.00004411107,0.000016355178,0.00045743436,0.9778294,0.000048466147,0.020192457],"genre_scores_gemma":[0.014266062,0.000010864317,0.0009649156,0.00010816427,0.00015755607,0.0014248017,0.9772051,0.000045090597,0.0058174566],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984723,0.000035773104,0.00037528417,0.0003119825,0.0004972363,0.00030743043],"domain_scores_gemma":[0.9982422,0.00095914217,0.00008201304,0.0003033692,0.00029205848,0.00012124547],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003556622,0.00015915763,0.00032933662,0.0003753863,0.000017315819,0.000012109193,0.0002038414,0.00018199408,0.9929481],"category_scores_gemma":[0.0025238988,0.00014372845,0.0001353379,0.00077323307,0.000033300315,0.000085958105,0.00015350891,0.00044289973,0.005056744],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006035549,0.000027325013,0.00001242036,0.0011975465,0.00008826546,0.0002934139,0.00010081485,0.0000023634013,0.0009772863,0.00001038888,0.99419504,0.0030347651],"study_design_scores_gemma":[0.0011275627,0.00048069432,0.040855266,0.025860086,0.00004790326,0.00021253755,0.0001245535,0.003630553,0.021716408,0.000056295834,0.9055924,0.00029574864],"about_ca_topic_score_codex":0.000016499553,"about_ca_topic_score_gemma":0.0000068744307,"teacher_disagreement_score":0.9878914,"about_ca_system_score_codex":0.0005464247,"about_ca_system_score_gemma":0.002670527,"threshold_uncertainty_score":0.99571794},"labels":[],"label_agreement":null},{"id":"W6920894928","doi":"10.6084/m9.figshare.26617822.v1","title":"Additional file 4 of Cytogenetic profile of 1791 adult acute myeloid leukemia in India","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Leukemia; Disease; Mutation; Myeloid","score_opus":0.020260312899982556,"score_gpt":0.2836828577103377,"score_spread":0.26342254481035515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920894928","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012445052,0.00017967322,9.9170116e-8,0.000044069948,0.000016269983,0.00045907276,0.97822034,0.000048514772,0.019787472],"genre_scores_gemma":[0.015131751,0.000010735389,0.0009782432,0.00010831064,0.00015540444,0.0014270276,0.97644264,0.000045192683,0.0057007186],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984717,0.000035742687,0.00037543548,0.00031212505,0.000497453,0.00030756908],"domain_scores_gemma":[0.9982368,0.0009668353,0.00008191409,0.00030368098,0.00028950986,0.000121258396],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000035797417,0.00015920121,0.0003293721,0.0003757153,0.000017322423,0.000012115124,0.00020399224,0.00018199284,0.99276537],"category_scores_gemma":[0.0025172958,0.00014377029,0.00013536909,0.0007734685,0.000033310207,0.00008598093,0.0001534742,0.00044289613,0.005061465],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061896404,0.000027357548,0.0000129356495,0.0011986254,0.0000882544,0.00028995264,0.00010092078,0.0000023166854,0.0010024183,0.000010541521,0.99421304,0.0029917175],"study_design_scores_gemma":[0.0011748702,0.00050785014,0.043126684,0.027232112,0.00004986063,0.00022040386,0.00013057313,0.0038198938,0.022723954,0.00005880047,0.90064704,0.0003079478],"about_ca_topic_score_codex":0.000016359729,"about_ca_topic_score_gemma":0.0000069132957,"teacher_disagreement_score":0.98770386,"about_ca_system_score_codex":0.00054630975,"about_ca_system_score_gemma":0.002674146,"threshold_uncertainty_score":0.99571323},"labels":[],"label_agreement":null},{"id":"W6920982174","doi":"10.6084/m9.figshare.26654469","title":"Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical record; Anemia; Myelodysplastic syndromes; Blood transfusion; Retrospective cohort study; Medical treatment","score_opus":0.03152315046476072,"score_gpt":0.3034042153238031,"score_spread":0.27188106485904234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920982174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93510723,0.00789627,3.297523e-7,0.00532811,0.00011810103,0.0010092508,0.050254673,0.000020180436,0.0002658833],"genre_scores_gemma":[0.9559563,0.020295205,0.00005278959,0.0031552718,0.00017537533,0.0005318282,0.018237898,0.00007302965,0.0015223301],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982732,0.00012882218,0.00034345777,0.00040922657,0.00051664986,0.00032865783],"domain_scores_gemma":[0.99781454,0.0015972091,0.00004302443,0.0002844319,0.00004156676,0.00021921551],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019325572,0.00023497181,0.0005454155,0.00011067726,0.000043669144,0.000058267462,0.00017590131,0.00010154101,0.024242645],"category_scores_gemma":[0.004759395,0.00014112164,0.000037982467,0.00038091285,0.000022314645,0.00006123699,0.00012487701,0.00065522204,0.0003319964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011467438,0.00016597829,0.44864509,0.0068274476,0.000242289,0.04021765,0.0007878174,1.15338985e-7,0.000012143882,0.0000032159305,0.44250542,0.060478147],"study_design_scores_gemma":[0.00093391835,0.00029201552,0.851397,0.025895182,0.00008222436,0.00034914407,0.00003337038,0.0009051243,0.0000022925894,0.0000022576587,0.11993356,0.00017395658],"about_ca_topic_score_codex":0.1272501,"about_ca_topic_score_gemma":0.31043723,"teacher_disagreement_score":0.40275186,"about_ca_system_score_codex":0.0004507167,"about_ca_system_score_gemma":0.0014572564,"threshold_uncertainty_score":0.97664934},"labels":[],"label_agreement":null},{"id":"W6921149401","doi":"10.6084/m9.figshare.c.6147143.v1","title":"α2-fraction and haptoglobin as biomarkers for disease activity in oligo- and polyarticular juvenile idiopathic arthritis","year":2022,"lang":"en","type":"other","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Haptoglobin; Erythrocyte sedimentation rate; Serum protein electrophoresis; Confounding; Arthritis; Oligoarthritis; Acute-phase protein","score_opus":0.021109656186095713,"score_gpt":0.29258111438211976,"score_spread":0.27147145819602403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921149401","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02297386,0.1058422,0.0000099774825,0.005611258,0.00028778007,0.013131931,0.78018254,0.00075493066,0.07120553],"genre_scores_gemma":[0.41339242,0.003874789,0.00043495017,0.002153448,0.0015840915,0.01317563,0.29002422,0.00259346,0.27276698],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985752,0.00009227125,0.0001658181,0.0005232309,0.00030540297,0.00033804646],"domain_scores_gemma":[0.99910593,0.00009567782,0.00012232513,0.00032060727,0.00003155201,0.00032391297],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013777181,0.00024243632,0.00045656276,0.0003525136,0.0000755017,0.000039447124,0.00007700491,0.00023086456,0.11567634],"category_scores_gemma":[0.0012380667,0.00025312963,0.00008069463,0.00019678466,0.00002315495,0.00007257798,0.00019239206,0.00044073747,0.00014722587],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006044478,0.0000949237,0.0003279869,0.002032644,0.00009663906,0.00055450766,0.000030543037,1.6327134e-7,0.00045620705,0.000003052822,0.96409583,0.031703047],"study_design_scores_gemma":[0.003332314,0.000317603,0.006860786,0.0052572056,0.00006165015,0.00008519274,0.00006224614,0.0004190148,0.00018133404,0.000033337437,0.9830525,0.00033684552],"about_ca_topic_score_codex":0.00036006447,"about_ca_topic_score_gemma":0.00016581091,"teacher_disagreement_score":0.49015832,"about_ca_system_score_codex":0.00045080806,"about_ca_system_score_gemma":0.00050471345,"threshold_uncertainty_score":0.9999921},"labels":[],"label_agreement":null},{"id":"W6921205181","doi":"10.6084/m9.figshare.25750032.v1","title":"Additional file 1 of Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Google (Canada)","funders":"","keywords":"Myeloid leukemia; Leukemia; Myeloid; Lower risk; Incidence (geometry)","score_opus":0.02643951114486034,"score_gpt":0.2766230193519315,"score_spread":0.2501835082070712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921205181","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3876038,0.000113450405,0.000004253041,0.000010244007,0.000028677337,0.00032388978,0.6118162,0.000031875406,0.00006760684],"genre_scores_gemma":[0.18137254,0.00001677265,0.004958813,0.00006565328,0.00015106653,0.00022583692,0.80750906,0.000120636694,0.00557963],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99757046,0.000068873116,0.00039162723,0.0005524638,0.0010024504,0.0004141435],"domain_scores_gemma":[0.997783,0.0007986115,0.00021252803,0.00036644092,0.0005675428,0.00027186685],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000060975155,0.0003233669,0.0004553977,0.0002316809,0.00012390483,0.000038082035,0.00017064085,0.00029536453,0.8317309],"category_scores_gemma":[0.00049363467,0.00023133843,0.0001394925,0.00042407744,0.00012045496,0.00027938958,0.0004496975,0.00060712325,0.00013988276],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013542502,0.00009752011,0.0035428458,0.0010893309,0.00056822796,0.0005247019,0.000096947675,0.00060623954,0.00037032372,0.000001387291,0.99138033,0.00036789404],"study_design_scores_gemma":[0.0055480297,0.0014236119,0.84068525,0.052834887,0.0011221633,0.00028612415,0.000019361809,0.08496797,0.001996697,0.000025082805,0.009958537,0.0011322586],"about_ca_topic_score_codex":0.000035097215,"about_ca_topic_score_gemma":0.00008372849,"teacher_disagreement_score":0.98142177,"about_ca_system_score_codex":0.00042517635,"about_ca_system_score_gemma":0.0010466694,"threshold_uncertainty_score":0.9433707},"labels":[],"label_agreement":null},{"id":"W6921218187","doi":"10.6084/m9.figshare.26617834","title":"Additional file 8 of Cytogenetic profile of 1791 adult acute myeloid leukemia in India","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Leukemia; Statistical analysis; Mutation; Disease","score_opus":0.02010875759526436,"score_gpt":0.2834014866868606,"score_spread":0.26329272909159623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921218187","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012563162,0.00017973811,9.9073596e-8,0.00004441173,0.000016269963,0.00045891915,0.9780838,0.000048152408,0.019912276],"genre_scores_gemma":[0.015006494,0.000010602439,0.0009792165,0.00010847252,0.0001554739,0.0014278229,0.9764464,0.000045160246,0.005820346],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984717,0.00003577746,0.00037542137,0.0003121604,0.0004973736,0.00030760435],"domain_scores_gemma":[0.9982352,0.0009657227,0.00008191376,0.0003036247,0.0002922338,0.00012127814],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000035818215,0.00015922656,0.0003294372,0.0003756077,0.000017322725,0.000012114305,0.00020390176,0.00018199456,0.9927676],"category_scores_gemma":[0.0025289422,0.00014378123,0.00013537995,0.0007732434,0.000033312546,0.000085976746,0.00015345479,0.0004429828,0.005069013],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060808616,0.000027354163,0.000012782866,0.0011991147,0.00008826514,0.00028995986,0.00010098501,0.0000023541072,0.0010013317,0.00001047456,0.9941611,0.0030454535],"study_design_scores_gemma":[0.0011757305,0.00050209457,0.04311359,0.027306823,0.00004995774,0.00022078828,0.00013078973,0.0038273146,0.023307825,0.000058879872,0.8999977,0.00030850663],"about_ca_topic_score_codex":0.000016503522,"about_ca_topic_score_gemma":0.0000069357457,"teacher_disagreement_score":0.98769855,"about_ca_system_score_codex":0.0005465196,"about_ca_system_score_gemma":0.0026787994,"threshold_uncertainty_score":0.99570566},"labels":[],"label_agreement":null},{"id":"W6924664164","doi":"10.15468/dl.sr7npd","title":"Occurrence Download","year":2022,"lang":"en","type":"dataset","venue":"Global Biodiversity Information Facility","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Download; Matching (statistics); Range (aeronautics); Alien","score_opus":0.021249703757392945,"score_gpt":0.26318760596782653,"score_spread":0.2419379022104336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6924664164","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00069731066,0.00003085175,0.0000012985006,0.0005868253,0.00038096035,0.0007120987,0.99713635,0.00011148367,0.00034282656],"genre_scores_gemma":[0.000005305764,0.00015742435,0.0000018907891,0.001444838,0.0000022521192,0.000013088139,0.9983743,2.1873483e-8,8.7544396e-7],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976052,0.00009715755,0.00042926424,0.0002950369,0.0011407742,0.00043257565],"domain_scores_gemma":[0.9982536,0.000030021936,0.00023786734,0.0008204584,0.00032932067,0.0003287607],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004425493,0.00030484516,0.0004301969,0.0001935324,0.0004037888,0.000082588376,0.0005423129,0.00034494087,0.12530279],"category_scores_gemma":[0.00035685484,0.0003092308,0.00023326227,0.00059497845,0.00022483451,0.00056558184,0.0009348579,0.0009868145,0.15672581],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034607825,0.000069772046,0.0012836904,0.00038859856,0.00008117881,0.000032011812,0.000035094497,0.0000032189594,9.126591e-8,4.7832263e-8,0.9962226,0.0015376095],"study_design_scores_gemma":[0.001076045,0.00015205816,0.00017026234,0.0000024472752,0.00012017812,0.000063914275,0.00023096813,2.0212762e-7,0.0000023500425,2.5223264e-7,0.9979328,0.00024853324],"about_ca_topic_score_codex":0.00087988336,"about_ca_topic_score_gemma":0.0000057950156,"teacher_disagreement_score":0.031423014,"about_ca_system_score_codex":0.0023155261,"about_ca_system_score_gemma":0.0009543496,"threshold_uncertainty_score":0.999936},"labels":[],"label_agreement":null},{"id":"W6926671707","doi":"10.25345/c5c824s4b","title":"MassIVE MSV000096768 - The proto-oncogenic miR-106a-363 cluster enhances adverse risk acute myeloid leukemia through mitochondrial activation","year":2025,"lang":"en","type":"dataset","venue":"California Digital Library","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"","keywords":"Myeloid leukemia; Cluster (spacecraft); Adverse effect; Leukemia; Mutation; Mitochondrion","score_opus":0.008987265099593718,"score_gpt":0.2590499396028003,"score_spread":0.2500626745032066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6926671707","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022372878,0.00029167667,0.00017075984,0.0033922093,0.0008075453,0.007080073,0.9810903,0.00032760805,0.0046025333],"genre_scores_gemma":[0.00015297996,0.0015883163,0.0005588631,0.0040614093,0.0032153593,0.0017150121,0.9784854,0.00014956792,0.010073058],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939805,0.000356197,0.0013141988,0.0015919326,0.0014805394,0.0012765948],"domain_scores_gemma":[0.99506706,0.001038999,0.00088454376,0.0023542903,0.00019378256,0.0004613411],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.00017483595,0.0012525833,0.0013880914,0.00044927036,0.0005201667,0.0007231124,0.0017572067,0.0013657325,0.0015838868],"category_scores_gemma":[0.0008912402,0.0008555507,0.00093652605,0.0012442345,0.000791811,0.002526238,0.0017437357,0.0034939153,0.0028253652],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036607822,0.00017128524,0.0000720755,0.00063326315,0.0013388685,0.00029840405,0.000053421973,0.000009482174,0.00027036062,0.000008212054,0.99144566,0.00203816],"study_design_scores_gemma":[0.0036197868,0.00039946588,0.000029749503,0.00086755666,0.0008745845,0.000103315266,0.00014814603,0.00008588515,0.008534909,0.0004467276,0.98407316,0.0008166859],"about_ca_topic_score_codex":0.00008424679,"about_ca_topic_score_gemma":0.0000040107407,"teacher_disagreement_score":0.008264549,"about_ca_system_score_codex":0.0012252046,"about_ca_system_score_gemma":0.005961393,"threshold_uncertainty_score":0.9999307},"labels":[],"label_agreement":null},{"id":"W6929891478","doi":"10.5061/dryad.wwpzgmsj5","title":"Revisiting the evolution of Ostrinia moths with phylogenomics (Pyraloidea: Crambidae: Pyraustinae)","year":2021,"lang":"en","type":"dataset","venue":"Open MIND","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Agriculture and Agri-Food Canada","funders":"National Natural Science Foundation of China","keywords":"Ostrinia; Population; Phylogenetic tree; Phylogenetics; Larva","score_opus":0.03309132962601419,"score_gpt":0.3235819739183339,"score_spread":0.2904906442923197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929891478","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019080564,0.0008683779,0.000025331037,0.0012799961,0.00009967351,0.002362362,0.9732891,0.0000021158805,0.0029924938],"genre_scores_gemma":[0.0022881108,0.00041509172,0.0042337617,0.00010753666,0.00094917545,0.00007148571,0.98812294,0.00006539375,0.0037464937],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99743885,0.00017732092,0.00059375545,0.00066879415,0.0006521578,0.0004691031],"domain_scores_gemma":[0.9969587,0.0002735941,0.0004981228,0.0016382014,0.0004736718,0.00015774548],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010687131,0.00035553062,0.00087274594,0.00015681163,0.00016044323,0.00016093809,0.0011096168,0.00033790118,0.002336099],"category_scores_gemma":[0.00065021595,0.00023663744,0.00012065021,0.00063597644,0.0003037418,0.00009472941,0.0010613964,0.0012715156,0.000370978],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005854137,0.0000790661,0.00040220472,0.0004678784,0.00039017943,0.00061747676,0.00006624196,0.000015948788,0.0012544106,0.000004654908,0.9663511,0.029765425],"study_design_scores_gemma":[0.001682059,0.00026212638,0.00093817606,0.00124943,0.00063753105,0.0004142075,0.00087871595,0.000050216455,0.0011706484,0.0000048059505,0.99244153,0.00027051926],"about_ca_topic_score_codex":0.0021315052,"about_ca_topic_score_gemma":0.00014669626,"teacher_disagreement_score":0.029494906,"about_ca_system_score_codex":0.0010121497,"about_ca_system_score_gemma":0.0034259378,"threshold_uncertainty_score":0.9985759},"labels":[],"label_agreement":null},{"id":"W6930305439","doi":"10.5281/zenodo.12412361","title":"moca pdf 8.3","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cognition; Context (archaeology); Subconscious; Identification (biology); Cognitive computing","score_opus":0.028867546492988044,"score_gpt":0.27370539523912363,"score_spread":0.2448378487461356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930305439","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024843528,0.0010476855,0.00033843538,0.0018231577,0.0002086838,0.0009274678,0.00033972654,0.0025608651,0.9927291],"genre_scores_gemma":[0.00064208714,0.00060611113,0.00037034485,0.00036193134,0.0010074085,8.648881e-8,0.0035299729,0.021883762,0.97159827],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997343,0.0002122247,0.00028490782,0.0007897124,0.00076365797,0.00060650427],"domain_scores_gemma":[0.9981656,0.000014439251,0.000099789424,0.0009708588,0.00033555564,0.00041375245],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005381853,0.00031699694,0.00039564515,0.0009864867,0.00048083198,0.00059418037,0.00091403176,0.00033228815,0.40560338],"category_scores_gemma":[0.0005582115,0.00030504965,0.0001464525,0.00083747436,0.00028548876,0.00006223368,0.001623865,0.0011293889,0.5870467],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006571241,0.0000836311,2.4383644e-7,0.0006752507,0.0002352844,0.0003048923,0.00015706931,3.3978355e-7,0.0005769342,0.0011060034,0.9684048,0.028389806],"study_design_scores_gemma":[0.0006926347,0.0002995857,0.000011911719,0.00040352374,0.000098962446,0.0006458934,0.00010045768,0.00007784911,0.00008986442,0.00010796371,0.9972056,0.00026574088],"about_ca_topic_score_codex":0.00004739725,"about_ca_topic_score_gemma":4.855143e-7,"teacher_disagreement_score":0.1814433,"about_ca_system_score_codex":0.00053949177,"about_ca_system_score_gemma":0.00002262397,"threshold_uncertainty_score":0.99994016},"labels":[],"label_agreement":null},{"id":"W6930850018","doi":"10.5281/zenodo.15058300","title":"Actualización de Seguridad - Health Canada realizó una evaluación del riesgo potencial de neoplasia maligna secundaria a las terapias CAR-T.","year":2025,"lang":"es","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Public health; Cancer; Epidemiology; Disease; Radiation therapy","score_opus":0.017356458977897296,"score_gpt":0.3025952455558359,"score_spread":0.2852387865779386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930850018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57046765,0.005298182,0.019529019,0.08782765,0.0016642945,0.008711329,0.008929761,0.0033649884,0.29420713],"genre_scores_gemma":[0.9724752,0.0017211578,0.00082194566,0.006921388,0.0010620415,8.588404e-7,0.004491875,0.003122164,0.009383413],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9909464,0.002742347,0.0010263756,0.001245502,0.0016730214,0.002366338],"domain_scores_gemma":[0.9948755,0.00020913087,0.00035906592,0.0014417762,0.0017171592,0.0013973808],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0036492636,0.0006402944,0.0008487431,0.0009022644,0.004878295,0.0015313786,0.0021005003,0.00038683857,0.010141957],"category_scores_gemma":[0.003950159,0.00070792716,0.00018657335,0.0023542496,0.0006084153,0.0002977166,0.0023045645,0.0016959113,0.0017502394],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011899841,0.00031071965,0.00033940846,0.0016302378,0.00066659896,0.0005896404,0.0050914716,0.00013543265,0.00440371,0.015187727,0.9038273,0.06662778],"study_design_scores_gemma":[0.0034251781,0.0008325165,0.0076477993,0.0009597826,0.0001766643,0.0006629036,0.0023748926,0.0033483927,0.0014526106,0.0004356498,0.9781318,0.0005518514],"about_ca_topic_score_codex":0.1870268,"about_ca_topic_score_gemma":0.00406649,"teacher_disagreement_score":0.4020075,"about_ca_system_score_codex":0.011016604,"about_ca_system_score_gemma":0.0042114663,"threshold_uncertainty_score":0.99953717},"labels":[],"label_agreement":null},{"id":"W6931331296","doi":"10.5281/zenodo.7222289","title":"Neogalerucella Chujo 1962","year":2022,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Subgenus; Taxonomy (biology); Key (lock); Entomology; Taxonomic key","score_opus":0.03331866340194667,"score_gpt":0.26041261198921906,"score_spread":0.2270939485872724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931331296","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12530929,0.00029901628,0.0008287304,0.0072221877,0.00023227998,0.0014596869,0.000374042,0.0019027801,0.862372],"genre_scores_gemma":[0.9569519,0.000093254646,0.0005049645,0.0012206259,0.00038457953,2.7571713e-7,0.0023254296,0.0027366,0.035782356],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997369,0.0004385749,0.00026058982,0.0004984201,0.000879016,0.00055439794],"domain_scores_gemma":[0.9984348,0.000031465475,0.000077835604,0.0006921302,0.00042599614,0.0003378172],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010205103,0.0001541668,0.00020944282,0.0003885199,0.0035926427,0.00027307615,0.00094558985,0.00004971143,0.13770296],"category_scores_gemma":[0.0005188516,0.00016674509,0.00009297898,0.00097463455,0.00017659397,0.00011288764,0.0027347568,0.0008392689,0.009689045],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046376046,0.00032999556,0.000021677653,0.00009448948,0.000099578996,0.00028234615,0.0015907788,0.00009007423,0.018969733,0.0025818276,0.888922,0.08655375],"study_design_scores_gemma":[0.0013745535,0.00065297255,0.0007329368,0.000010920742,0.000022856339,0.0011562785,0.0006728635,0.0006883995,0.0007320035,0.000080506616,0.9937153,0.00016045065],"about_ca_topic_score_codex":0.000028599894,"about_ca_topic_score_gemma":8.200165e-8,"teacher_disagreement_score":0.8316426,"about_ca_system_score_codex":0.0011103698,"about_ca_system_score_gemma":0.000035931673,"threshold_uncertainty_score":0.99770457},"labels":[],"label_agreement":null},{"id":"W6931608343","doi":"10.5281/zenodo.5626665","title":"Philometra","year":2016,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Catostomus; Micropterus; Esox; Sparganosis; Coregonus clupeaformis; Coregonus","score_opus":0.04186929049959946,"score_gpt":0.2733552293283701,"score_spread":0.2314859388287706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931608343","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17521648,0.00020650652,0.013328447,0.028276801,0.00018413152,0.0014758813,0.00032429898,0.002984492,0.778003],"genre_scores_gemma":[0.98662555,0.00021285146,0.00056795153,0.00045907154,0.00037050186,4.5503402e-8,0.00037267822,0.0018007418,0.0095906295],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981399,0.00018745106,0.00022447815,0.0004212928,0.0005320709,0.0004947787],"domain_scores_gemma":[0.9982557,0.000048025326,0.000055580134,0.00062079285,0.00065497984,0.00036488986],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000722007,0.00013511098,0.0001817597,0.00041324238,0.0009811292,0.00020719439,0.000628721,0.00008220271,0.039118856],"category_scores_gemma":[0.001561015,0.00009873145,0.00007395878,0.00071889884,0.00025893646,0.00020853485,0.00080916326,0.00026560275,0.03660779],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002753646,0.00016650153,0.000030529707,0.0000655622,0.00008550401,0.000089346875,0.00023681103,4.864116e-7,0.10104503,0.004880276,0.4295436,0.46358097],"study_design_scores_gemma":[0.0016396712,0.00043337452,0.0022748476,0.00006297137,0.000017434295,0.00050171185,0.00007375051,0.000029991792,0.004245193,0.00022416569,0.99036187,0.00013501353],"about_ca_topic_score_codex":0.0000058755995,"about_ca_topic_score_gemma":4.7811184e-8,"teacher_disagreement_score":0.81140906,"about_ca_system_score_codex":0.00046135994,"about_ca_system_score_gemma":0.000010676316,"threshold_uncertainty_score":0.9641423},"labels":[],"label_agreement":null},{"id":"W6939345752","doi":"10.60692/54v3x-kxt63","title":"KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Synthetic lethality; Myeloid leukemia; Poly ADP ribose polymerase; PARP inhibitor; Epigenetics; NPM1; DNA repair; DNA damage; Downregulation and upregulation; Leukemia","score_opus":0.0247189590837317,"score_gpt":0.24970273313291036,"score_spread":0.22498377404917866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939345752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99601,0.000012090877,0.0016746129,0.00020587047,0.000085471205,0.0009674535,0.00023991163,0.00020673977,0.00059785735],"genre_scores_gemma":[0.99799246,0.0000019052395,0.0009425985,0.00027527363,0.00008069855,0.000105801875,0.0002471715,0.000022880295,0.00033120805],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9977928,0.00020014482,0.00084429706,0.00027313907,0.00059583964,0.00029381496],"domain_scores_gemma":[0.99868584,0.000024878274,0.00034122178,0.00039516483,0.00034689836,0.00020598723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090619794,0.00022871552,0.00046403188,0.0006842991,0.00031503531,0.000062790576,0.00006623487,0.00010831661,0.00003531768],"category_scores_gemma":[0.000052628475,0.00020342362,0.000081555416,0.00045719874,0.00009859199,0.00044861095,0.00027365555,0.00024267107,0.000037861093],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008969568,0.000051796233,0.37809816,0.009920896,0.0022877096,0.00064173405,0.4699053,0.0017617337,0.10865307,0.004002502,0.008674497,0.0070330543],"study_design_scores_gemma":[0.017692694,0.0036215829,0.53778964,0.0014109788,0.0010018076,0.007283453,0.10572522,0.028977279,0.2926861,0.000055819615,0.0022067495,0.0015486628],"about_ca_topic_score_codex":0.00006401513,"about_ca_topic_score_gemma":0.0000012165196,"teacher_disagreement_score":0.36418006,"about_ca_system_score_codex":0.0008251389,"about_ca_system_score_gemma":0.00015804466,"threshold_uncertainty_score":0.8295375},"labels":[],"label_agreement":null},{"id":"W6939483701","doi":"10.6084/m9.figshare.26617834.v1","title":"Additional file 8 of Cytogenetic profile of 1791 adult acute myeloid leukemia in India","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Leukemia; Statistical analysis; Mutation; Disease","score_opus":0.02010875759526436,"score_gpt":0.2834014866868606,"score_spread":0.26329272909159623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939483701","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012563162,0.00017973811,9.9073596e-8,0.00004441173,0.000016269963,0.00045891915,0.9780838,0.000048152408,0.019912276],"genre_scores_gemma":[0.015006494,0.000010602439,0.0009792165,0.00010847252,0.0001554739,0.0014278229,0.9764464,0.000045160246,0.005820346],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984717,0.00003577746,0.00037542137,0.0003121604,0.0004973736,0.00030760435],"domain_scores_gemma":[0.9982352,0.0009657227,0.00008191376,0.0003036247,0.0002922338,0.00012127814],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000035818215,0.00015922656,0.0003294372,0.0003756077,0.000017322725,0.000012114305,0.00020390176,0.00018199456,0.9927676],"category_scores_gemma":[0.0025289422,0.00014378123,0.00013537995,0.0007732434,0.000033312546,0.000085976746,0.00015345479,0.0004429828,0.005069013],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060808616,0.000027354163,0.000012782866,0.0011991147,0.00008826514,0.00028995986,0.00010098501,0.0000023541072,0.0010013317,0.00001047456,0.9941611,0.0030454535],"study_design_scores_gemma":[0.0011757305,0.00050209457,0.04311359,0.027306823,0.00004995774,0.00022078828,0.00013078973,0.0038273146,0.023307825,0.000058879872,0.8999977,0.00030850663],"about_ca_topic_score_codex":0.000016503522,"about_ca_topic_score_gemma":0.0000069357457,"teacher_disagreement_score":0.98769855,"about_ca_system_score_codex":0.0005465196,"about_ca_system_score_gemma":0.0026787994,"threshold_uncertainty_score":0.99570566},"labels":[],"label_agreement":null},{"id":"W6939511347","doi":"10.6084/m9.figshare.19759434.v1","title":"Additional file 1 of Polycomb contraction differentially regulates terminal human hematopoietic differentiation programs","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Progenitor cell; Enhancer; Haematopoiesis; Progenitor; Myeloid; Cellular differentiation; Myelopoiesis","score_opus":0.02884569090137048,"score_gpt":0.2775890181985116,"score_spread":0.24874332729714113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939511347","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009155071,0.000015268657,3.5765603e-7,0.000084891624,0.000020477188,0.0005484864,0.9888725,0.00007919586,0.0012237168],"genre_scores_gemma":[0.26360285,1.2118606e-7,0.00006812682,0.000034729735,0.00010915666,0.002214515,0.73013425,0.000022397695,0.0038138358],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985122,0.00007277554,0.00027816024,0.00024675753,0.0006400856,0.0002500236],"domain_scores_gemma":[0.99896973,0.00029354732,0.00021467937,0.0002571112,0.00016145276,0.000103467064],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00002666491,0.00013769694,0.0002462238,0.0001479893,0.00023881995,0.000025453533,0.00015317865,0.00006689309,0.9969436],"category_scores_gemma":[0.0005461262,0.00013369227,0.00014740392,0.00020478755,0.000019944759,0.00007955163,0.0001850152,0.0003779153,0.00037404525],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007608099,0.00031684374,0.000026633072,0.00022047177,0.000053388612,0.00003835086,0.000049015314,7.1913746e-7,0.0015342904,0.0000098268165,0.994858,0.0028163309],"study_design_scores_gemma":[0.0024346793,0.0013914976,0.13683498,0.0029669735,0.00009055428,0.00071990787,0.0003123497,0.0014896076,0.003970958,0.00023335437,0.84914076,0.00041438552],"about_ca_topic_score_codex":0.000007995335,"about_ca_topic_score_gemma":0.0000045226734,"teacher_disagreement_score":0.9965695,"about_ca_system_score_codex":0.00024052642,"about_ca_system_score_gemma":0.00020777214,"threshold_uncertainty_score":0.5451813},"labels":[],"label_agreement":null},{"id":"W6939632350","doi":"10.6084/m9.figshare.28792768.v1","title":"Additional file 1 of IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia","year":2025,"lang":"en","type":"article","venue":"Open MIND","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Hôpital Maisonneuve-Rosemont; National Research Council Canada; Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"","keywords":"Myeloid leukemia; Karyotype; Leukemia; Myeloid; Immunotherapy; Mutation","score_opus":0.03235070075774016,"score_gpt":0.34086149051883396,"score_spread":0.3085107897610938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939632350","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04177082,0.00016668827,0.00029758518,0.0017370813,0.00020433747,0.0040549124,0.8740445,0.000017625553,0.07770648],"genre_scores_gemma":[0.0115645835,0.000051308558,0.16218005,0.0028450044,0.00032429924,0.0020976062,0.41430578,0.0001327914,0.40649858],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982374,0.00006570704,0.0004685129,0.00046163535,0.00032144313,0.00044535738],"domain_scores_gemma":[0.9980592,0.0006882121,0.00014805257,0.0005567612,0.00040125014,0.0001464953],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000258294,0.00022211712,0.00050455733,0.00026109413,0.00015219738,0.000067071465,0.0006180111,0.00019862737,0.8426454],"category_scores_gemma":[0.00027576077,0.00020350296,0.0001592778,0.00057436654,0.00017197673,0.0003090997,0.00020892548,0.00031930412,0.0005594225],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002522163,0.00014637211,0.000023603432,0.00003818835,0.00060691725,0.000022166165,0.00022197365,0.0000030079038,0.00732136,0.000012576393,0.93351203,0.055569652],"study_design_scores_gemma":[0.004424967,0.0009094371,0.0018256928,0.0002302821,0.00015913787,0.00003417042,0.00021182225,0.002873049,0.030644609,0.00013756346,0.95835143,0.0001978502],"about_ca_topic_score_codex":0.0000750006,"about_ca_topic_score_gemma":0.000015937854,"teacher_disagreement_score":0.842086,"about_ca_system_score_codex":0.00043880084,"about_ca_system_score_gemma":0.003499226,"threshold_uncertainty_score":0.829861},"labels":[],"label_agreement":null},{"id":"W6939743727","doi":"10.6084/m9.figshare.26617819.v1","title":"Additional file 3 of Cytogenetic profile of 1791 adult acute myeloid leukemia in India","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Leukemia; Disease; Mutation; MEDLINE","score_opus":0.020098346102641263,"score_gpt":0.2832514472959406,"score_spread":0.2631531011932993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939743727","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012508895,0.00017891814,9.8459026e-8,0.00004415577,0.000016433127,0.00045858065,0.9781603,0.000048436093,0.019842152],"genre_scores_gemma":[0.014717092,0.0000107353335,0.0009770539,0.0001081778,0.0001571721,0.001426899,0.9766283,0.000045205008,0.00592935],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99847186,0.000035747937,0.00037528446,0.00031208986,0.000497488,0.0003075298],"domain_scores_gemma":[0.99823284,0.00096479786,0.0000819028,0.00030351648,0.00029568895,0.00012125759],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000035765133,0.00015918877,0.00032928473,0.00037551898,0.000017312737,0.000012107882,0.0002038237,0.00018197556,0.9929004],"category_scores_gemma":[0.002557345,0.0001437396,0.00013535732,0.0007735795,0.00003330348,0.00008596681,0.00015340846,0.00044291158,0.0051795687],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000611221,0.000027315857,0.000012890877,0.0012081002,0.00008816809,0.00028854705,0.000100709825,0.0000023512935,0.0010189756,0.000010116271,0.9941902,0.0029914652],"study_design_scores_gemma":[0.0011474543,0.00048450197,0.041712135,0.02640812,0.000048073645,0.00021182981,0.0001265265,0.0036997471,0.022612123,0.000056527424,0.9031936,0.0002993505],"about_ca_topic_score_codex":0.000016524535,"about_ca_topic_score_gemma":0.000006881556,"teacher_disagreement_score":0.9877208,"about_ca_system_score_codex":0.00054868095,"about_ca_system_score_gemma":0.0026854256,"threshold_uncertainty_score":0.99559504},"labels":[],"label_agreement":null},{"id":"W6940225977","doi":"10.6084/m9.figshare.26617813","title":"Additional file 1 of Cytogenetic profile of 1791 adult acute myeloid leukemia in India","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Disease; Leukemia; Mutation; Myeloid","score_opus":0.02047431015038516,"score_gpt":0.2836906265584201,"score_spread":0.26321631640803494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6940225977","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012406182,0.00017787458,9.783115e-8,0.00004438789,0.000016257889,0.00045856784,0.97830075,0.0000485032,0.019712964],"genre_scores_gemma":[0.014527374,0.000010556485,0.0009892286,0.00010818053,0.0001550349,0.0014560635,0.9769109,0.000045170345,0.0057975263],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984719,0.000035786576,0.00037509712,0.0003122425,0.00049737433,0.00030755624],"domain_scores_gemma":[0.99822557,0.0009744711,0.00008188943,0.00030403194,0.0002927955,0.00012127082],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003578332,0.0001592139,0.000329247,0.00037565958,0.000017314409,0.000012080044,0.00020396757,0.00018199292,0.9930947],"category_scores_gemma":[0.0025581135,0.0001437807,0.000135367,0.00077390135,0.000033300825,0.00008589267,0.0001535329,0.00044301306,0.005117091],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060759943,0.000027351607,0.000012881209,0.0011863321,0.000088318404,0.00028491413,0.000100781835,0.0000023522728,0.0010169105,0.000010195579,0.99426395,0.0029452357],"study_design_scores_gemma":[0.0011447635,0.0004916507,0.042544153,0.026818795,0.000049202274,0.00021688746,0.00012887763,0.0037417596,0.02236918,0.00005708427,0.9021344,0.00030325344],"about_ca_topic_score_codex":0.000016316664,"about_ca_topic_score_gemma":0.0000068294826,"teacher_disagreement_score":0.98797756,"about_ca_system_score_codex":0.00054625084,"about_ca_system_score_gemma":0.0026837655,"threshold_uncertainty_score":0.99565756},"labels":[],"label_agreement":null},{"id":"W6957921382","doi":"10.6084/m9.figshare.12655469","title":"Additional file 4 of Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Cytarabine; Myeloid leukemia; Absolute neutrophil count; Myeloid; Complete response; Blood count; Azacitidine","score_opus":0.03478929580295318,"score_gpt":0.30311375889959646,"score_spread":0.26832446309664326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957921382","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51299775,0.0000042167135,1.348657e-7,0.00047199198,0.0000023448313,0.0005595254,0.48588917,0.00002125772,0.00005359797],"genre_scores_gemma":[0.37291926,0.00000795262,0.0017083996,0.002716006,0.000112009424,0.0007450213,0.6210428,0.00010428425,0.00064427586],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9982383,0.00009436141,0.0003521546,0.0005108684,0.0004838255,0.00032046347],"domain_scores_gemma":[0.99673563,0.002084983,0.00009782722,0.00024934756,0.0003002513,0.0005319869],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009043399,0.0002475223,0.0006238115,0.0001790973,0.000045815,0.000027350921,0.00014103611,0.00011557815,0.3108851],"category_scores_gemma":[0.0032200655,0.00017216038,0.000046684323,0.0005839028,0.000032528467,0.00011639246,0.00017861923,0.00033600527,0.00015175722],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053015616,0.00015674804,0.16176055,0.00008925942,0.0002933309,0.00023931671,0.00024019266,0.000011149944,0.000087579734,2.9543446e-7,0.7767951,0.007310847],"study_design_scores_gemma":[0.008281422,0.0043043317,0.9618162,0.001534972,0.000018100412,0.000007436503,0.00008424083,0.00011329284,0.00008090209,4.095384e-7,0.023554493,0.00020422532],"about_ca_topic_score_codex":0.00002508627,"about_ca_topic_score_gemma":0.000035372024,"teacher_disagreement_score":0.8000556,"about_ca_system_score_codex":0.00018902791,"about_ca_system_score_gemma":0.0005067433,"threshold_uncertainty_score":0.7020496},"labels":[],"label_agreement":null},{"id":"W6957966199","doi":"10.6084/m9.figshare.25750032","title":"Additional file 1 of Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Google (Canada)","funders":"","keywords":"Myeloid leukemia; Leukemia; Myeloid; Lower risk; Incidence (geometry)","score_opus":0.02643951114486034,"score_gpt":0.2766230193519315,"score_spread":0.2501835082070712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957966199","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3876038,0.000113450405,0.000004253041,0.000010244007,0.000028677337,0.00032388978,0.6118162,0.000031875406,0.00006760684],"genre_scores_gemma":[0.18137254,0.00001677265,0.004958813,0.00006565328,0.00015106653,0.00022583692,0.80750906,0.000120636694,0.00557963],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99757046,0.000068873116,0.00039162723,0.0005524638,0.0010024504,0.0004141435],"domain_scores_gemma":[0.997783,0.0007986115,0.00021252803,0.00036644092,0.0005675428,0.00027186685],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000060975155,0.0003233669,0.0004553977,0.0002316809,0.00012390483,0.000038082035,0.00017064085,0.00029536453,0.8317309],"category_scores_gemma":[0.00049363467,0.00023133843,0.0001394925,0.00042407744,0.00012045496,0.00027938958,0.0004496975,0.00060712325,0.00013988276],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013542502,0.00009752011,0.0035428458,0.0010893309,0.00056822796,0.0005247019,0.000096947675,0.00060623954,0.00037032372,0.000001387291,0.99138033,0.00036789404],"study_design_scores_gemma":[0.0055480297,0.0014236119,0.84068525,0.052834887,0.0011221633,0.00028612415,0.000019361809,0.08496797,0.001996697,0.000025082805,0.009958537,0.0011322586],"about_ca_topic_score_codex":0.000035097215,"about_ca_topic_score_gemma":0.00008372849,"teacher_disagreement_score":0.98142177,"about_ca_system_score_codex":0.00042517635,"about_ca_system_score_gemma":0.0010466694,"threshold_uncertainty_score":0.9433707},"labels":[],"label_agreement":null},{"id":"W6958085482","doi":"10.6084/m9.figshare.12655466","title":"Additional file 3 of Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Cytarabine; Myeloid leukemia; Censoring (clinical trials); Confidence interval; Overall survival; Survival analysis; Ruxolitinib; Complete response","score_opus":0.03455497549504653,"score_gpt":0.30273085039625014,"score_spread":0.2681758749012036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958085482","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5127913,0.0000041986027,1.3394563e-7,0.00047243488,0.0000023631426,0.0005586139,0.48609605,0.000021213134,0.00005368822],"genre_scores_gemma":[0.36837494,0.000008012588,0.0017195074,0.0027336446,0.000113946844,0.0007505847,0.6255229,0.000105095496,0.0006713574],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9982385,0.00009437321,0.00035203397,0.0005108193,0.0004838545,0.0003204286],"domain_scores_gemma":[0.99673384,0.0020813432,0.00009782033,0.00024924427,0.00030571411,0.0005320089],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009036454,0.00024750578,0.0006236706,0.0001790176,0.000045793186,0.000027336999,0.00014093687,0.00011556879,0.31435683],"category_scores_gemma":[0.0032636086,0.00017212908,0.000046680863,0.0005839742,0.000032522876,0.000116376184,0.00017855408,0.00033601525,0.00015478267],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05230402,0.00015606079,0.1608258,0.00008958288,0.00029218078,0.0002375917,0.00023902404,0.000011256729,0.00008853679,2.8437304e-7,0.77846795,0.0072877277],"study_design_scores_gemma":[0.008308808,0.004233566,0.9609297,0.0015307642,0.000017962624,0.000007359925,0.00008395741,0.000112865375,0.00008248768,4.0540917e-7,0.02448803,0.00020408776],"about_ca_topic_score_codex":0.00002530131,"about_ca_topic_score_gemma":0.00003523369,"teacher_disagreement_score":0.8001039,"about_ca_system_score_codex":0.00018972659,"about_ca_system_score_gemma":0.0005085669,"threshold_uncertainty_score":0.701922},"labels":[],"label_agreement":null},{"id":"W6958172280","doi":"10.6084/m9.figshare.19759434","title":"Additional file 1 of Polycomb contraction differentially regulates terminal human hematopoietic differentiation programs","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Progenitor cell; Enhancer; Haematopoiesis; Progenitor; Myeloid; Cellular differentiation; Myelopoiesis","score_opus":0.02884569090137048,"score_gpt":0.2775890181985116,"score_spread":0.24874332729714113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958172280","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009155071,0.000015268657,3.5765603e-7,0.000084891624,0.000020477188,0.0005484864,0.9888725,0.00007919586,0.0012237168],"genre_scores_gemma":[0.26360285,1.2118606e-7,0.00006812682,0.000034729735,0.00010915666,0.002214515,0.73013425,0.000022397695,0.0038138358],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985122,0.00007277554,0.00027816024,0.00024675753,0.0006400856,0.0002500236],"domain_scores_gemma":[0.99896973,0.00029354732,0.00021467937,0.0002571112,0.00016145276,0.000103467064],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00002666491,0.00013769694,0.0002462238,0.0001479893,0.00023881995,0.000025453533,0.00015317865,0.00006689309,0.9969436],"category_scores_gemma":[0.0005461262,0.00013369227,0.00014740392,0.00020478755,0.000019944759,0.00007955163,0.0001850152,0.0003779153,0.00037404525],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007608099,0.00031684374,0.000026633072,0.00022047177,0.000053388612,0.00003835086,0.000049015314,7.1913746e-7,0.0015342904,0.0000098268165,0.994858,0.0028163309],"study_design_scores_gemma":[0.0024346793,0.0013914976,0.13683498,0.0029669735,0.00009055428,0.00071990787,0.0003123497,0.0014896076,0.003970958,0.00023335437,0.84914076,0.00041438552],"about_ca_topic_score_codex":0.000007995335,"about_ca_topic_score_gemma":0.0000045226734,"teacher_disagreement_score":0.9965695,"about_ca_system_score_codex":0.00024052642,"about_ca_system_score_gemma":0.00020777214,"threshold_uncertainty_score":0.5451813},"labels":[],"label_agreement":null},{"id":"W6958179985","doi":"10.6084/m9.figshare.25750158","title":"Additional file 2 of Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Google (Canada)","funders":"","keywords":"Myeloid leukemia; Leukemia; Myeloid; Lower risk; Incidence (geometry)","score_opus":0.02571594467510904,"score_gpt":0.2761728992835731,"score_spread":0.25045695460846407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958179985","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3872096,0.000115242394,0.000004175723,0.000010209471,0.00002886668,0.00032379382,0.6122071,0.000031910404,0.00006909067],"genre_scores_gemma":[0.17926341,0.000017192055,0.0048657786,0.00006572927,0.00015326108,0.00022215785,0.8096894,0.00012061735,0.0056024357],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99757105,0.000068851994,0.00039178634,0.00055208907,0.0010022239,0.00041400548],"domain_scores_gemma":[0.9977948,0.00078838033,0.00021279496,0.00036579973,0.0005663939,0.00027182777],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000060673585,0.0003232738,0.00045549864,0.00023154354,0.00012391305,0.000038156886,0.00017055483,0.00029536607,0.8293058],"category_scores_gemma":[0.00048823774,0.00023126995,0.00013946807,0.00042377898,0.00012045346,0.00027956296,0.0004496402,0.00060699676,0.00013853057],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001351451,0.00009777149,0.0034511113,0.0011014182,0.000569866,0.0005392313,0.000097300595,0.0006106266,0.0003597249,0.0000014134342,0.9914418,0.00037827663],"study_design_scores_gemma":[0.0056443433,0.0014396316,0.8396541,0.052829973,0.0011308971,0.0002898812,0.000019395644,0.08539808,0.002007486,0.000025544019,0.010418009,0.0011426496],"about_ca_topic_score_codex":0.000035417394,"about_ca_topic_score_gemma":0.000084177154,"teacher_disagreement_score":0.9810238,"about_ca_system_score_codex":0.00042528662,"about_ca_system_score_gemma":0.0010424542,"threshold_uncertainty_score":0.94309145},"labels":[],"label_agreement":null},{"id":"W6958259541","doi":"10.6084/m9.figshare.22617338.v1","title":"Additional file 1 of Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"MEDLINE; Table (database); Disease; Systematic review; Clinical trial","score_opus":0.09183994626004427,"score_gpt":0.34893824560413983,"score_spread":0.25709829934409556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958259541","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024087536,0.0035050092,4.316225e-7,0.0007433209,0.0000037862703,0.004462337,0.99090445,0.00012698614,0.00022961506],"genre_scores_gemma":[0.000117652744,0.00052799203,0.0004587942,0.0005287304,0.00002632514,0.04446297,0.91621405,0.00005148232,0.037612],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9977958,0.00012448111,0.000707145,0.0005338729,0.0003997858,0.0004388776],"domain_scores_gemma":[0.992057,0.0062389676,0.00036803365,0.0006819771,0.00039534486,0.00025863072],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000082552855,0.00042671373,0.0033583294,0.00043735423,0.00010636349,0.000030170528,0.00016413411,0.00014389129,0.93394536],"category_scores_gemma":[0.0049544442,0.0002602481,0.0018741351,0.0012978632,0.000024113588,0.00010008829,0.00008277337,0.0001045906,0.002127276],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018627328,0.000056866007,0.0000019252243,0.031707495,0.12423407,0.00013868487,0.00005047287,0.000004991688,0.0000020544599,7.229746e-7,0.8437354,0.000048675793],"study_design_scores_gemma":[0.0035027983,0.0016888764,0.00079376245,0.012198169,0.8171704,0.0001053463,0.00016339311,0.0014352192,0.00010844926,0.00001317813,0.16232309,0.00049732137],"about_ca_topic_score_codex":0.00005723954,"about_ca_topic_score_gemma":0.000050940536,"teacher_disagreement_score":0.9318181,"about_ca_system_score_codex":0.0011440795,"about_ca_system_score_gemma":0.00076497067,"threshold_uncertainty_score":0.999985},"labels":[],"label_agreement":null},{"id":"W6958336340","doi":"10.6084/m9.figshare.26617816.v1","title":"Additional file 2 of Cytogenetic profile of 1791 adult acute myeloid leukemia in India","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Leukemia; Disease; Mutation; Myeloid","score_opus":0.01975040268378538,"score_gpt":0.28309921287478895,"score_spread":0.2633488101910036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958336340","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012307239,0.00018094676,9.545104e-8,0.00004411107,0.000016355178,0.00045743436,0.9778294,0.000048466147,0.020192457],"genre_scores_gemma":[0.014266062,0.000010864317,0.0009649156,0.00010816427,0.00015755607,0.0014248017,0.9772051,0.000045090597,0.0058174566],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984723,0.000035773104,0.00037528417,0.0003119825,0.0004972363,0.00030743043],"domain_scores_gemma":[0.9982422,0.00095914217,0.00008201304,0.0003033692,0.00029205848,0.00012124547],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003556622,0.00015915763,0.00032933662,0.0003753863,0.000017315819,0.000012109193,0.0002038414,0.00018199408,0.9929481],"category_scores_gemma":[0.0025238988,0.00014372845,0.0001353379,0.00077323307,0.000033300315,0.000085958105,0.00015350891,0.00044289973,0.005056744],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006035549,0.000027325013,0.00001242036,0.0011975465,0.00008826546,0.0002934139,0.00010081485,0.0000023634013,0.0009772863,0.00001038888,0.99419504,0.0030347651],"study_design_scores_gemma":[0.0011275627,0.00048069432,0.040855266,0.025860086,0.00004790326,0.00021253755,0.0001245535,0.003630553,0.021716408,0.000056295834,0.9055924,0.00029574864],"about_ca_topic_score_codex":0.000016499553,"about_ca_topic_score_gemma":0.0000068744307,"teacher_disagreement_score":0.9878914,"about_ca_system_score_codex":0.0005464247,"about_ca_system_score_gemma":0.002670527,"threshold_uncertainty_score":0.99571794},"labels":[],"label_agreement":null},{"id":"W6958420208","doi":"10.6084/m9.figshare.22617344","title":"Additional file 3 of Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Observational study; MEDLINE; Scale (ratio); Table (database); Clinical trial","score_opus":0.09037521334139835,"score_gpt":0.3484663907098867,"score_spread":0.25809117736848836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958420208","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024265444,0.0035233747,4.341007e-7,0.00073997874,0.0000038225135,0.0044628927,0.9908874,0.00012684437,0.00023098795],"genre_scores_gemma":[0.00011899518,0.0005357356,0.00045373064,0.0005286109,0.000026638541,0.043706715,0.91624725,0.000051506526,0.038330834],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9977958,0.00012436292,0.0007074553,0.0005336434,0.00039986605,0.00043884435],"domain_scores_gemma":[0.9921085,0.006184998,0.00036810018,0.0006809862,0.00039879244,0.0002586156],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000082515966,0.00042665453,0.0033586666,0.0004372103,0.00010635447,0.00003023165,0.0001640323,0.00014387921,0.9324132],"category_scores_gemma":[0.0049531385,0.00026018271,0.0018740174,0.0012973889,0.000024115277,0.00010016424,0.000082714374,0.000104569524,0.0021501654],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018739385,0.00005684455,0.0000019279837,0.03222511,0.12417118,0.00014034707,0.00005048014,0.000004993717,0.000002059722,7.185825e-7,0.8432782,0.00004938704],"study_design_scores_gemma":[0.0035576646,0.0016899111,0.0007906139,0.012197057,0.8138458,0.000104584615,0.00016295284,0.0014403423,0.00011099119,0.0000132424775,0.16558847,0.0004983671],"about_ca_topic_score_codex":0.00005788018,"about_ca_topic_score_gemma":0.000051281873,"teacher_disagreement_score":0.93026304,"about_ca_system_score_codex":0.0011485505,"about_ca_system_score_gemma":0.0007653875,"threshold_uncertainty_score":0.99998504},"labels":[],"label_agreement":null},{"id":"W6958472942","doi":"10.6084/m9.figshare.26617831","title":"Additional file 7 of Cytogenetic profile of 1791 adult acute myeloid leukemia in India","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Leukemia; Statistical analysis; Mutation; Disease","score_opus":0.020128689119738308,"score_gpt":0.283438896936176,"score_spread":0.2633102078164377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958472942","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012508509,0.00017959399,9.897959e-8,0.000044355762,0.000016274975,0.00045891968,0.97825,0.0000485223,0.01975133],"genre_scores_gemma":[0.014904612,0.000010754879,0.0009777119,0.000108363645,0.00015541138,0.0014251423,0.97662455,0.00004519662,0.005748239],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984715,0.00003576704,0.00037542917,0.00031220692,0.0004974937,0.0003076234],"domain_scores_gemma":[0.99823624,0.0009647286,0.00008190621,0.00030363357,0.0002922012,0.00012128509],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003581692,0.00015923177,0.00032943996,0.0003757274,0.000017323777,0.00001211616,0.00020393118,0.00018199759,0.9926477],"category_scores_gemma":[0.0024991143,0.0001437891,0.00013538125,0.0007737555,0.000033315966,0.000085992775,0.0001534963,0.00044299773,0.005035209],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060807448,0.000027361697,0.000012872983,0.0012108522,0.00008827132,0.0002899802,0.00010101667,0.00000235331,0.001013757,0.000010517483,0.99416655,0.0030156663],"study_design_scores_gemma":[0.0011737793,0.0005010256,0.042917926,0.027541935,0.000049867773,0.00022031368,0.00013051066,0.003816989,0.023021957,0.000058752077,0.90025896,0.0003079637],"about_ca_topic_score_codex":0.00001653836,"about_ca_topic_score_gemma":0.000006944743,"teacher_disagreement_score":0.9876125,"about_ca_system_score_codex":0.00054655015,"about_ca_system_score_gemma":0.0026784814,"threshold_uncertainty_score":0.99573946},"labels":[],"label_agreement":null},{"id":"W6958554356","doi":"10.6084/m9.figshare.26617813.v1","title":"Additional file 1 of Cytogenetic profile of 1791 adult acute myeloid leukemia in India","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Disease; Leukemia; Mutation; Myeloid","score_opus":0.02047431015038516,"score_gpt":0.2836906265584201,"score_spread":0.26321631640803494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958554356","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012406182,0.00017787458,9.783115e-8,0.00004438789,0.000016257889,0.00045856784,0.97830075,0.0000485032,0.019712964],"genre_scores_gemma":[0.014527374,0.000010556485,0.0009892286,0.00010818053,0.0001550349,0.0014560635,0.9769109,0.000045170345,0.0057975263],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984719,0.000035786576,0.00037509712,0.0003122425,0.00049737433,0.00030755624],"domain_scores_gemma":[0.99822557,0.0009744711,0.00008188943,0.00030403194,0.0002927955,0.00012127082],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003578332,0.0001592139,0.000329247,0.00037565958,0.000017314409,0.000012080044,0.00020396757,0.00018199292,0.9930947],"category_scores_gemma":[0.0025581135,0.0001437807,0.000135367,0.00077390135,0.000033300825,0.00008589267,0.0001535329,0.00044301306,0.005117091],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060759943,0.000027351607,0.000012881209,0.0011863321,0.000088318404,0.00028491413,0.000100781835,0.0000023522728,0.0010169105,0.000010195579,0.99426395,0.0029452357],"study_design_scores_gemma":[0.0011447635,0.0004916507,0.042544153,0.026818795,0.000049202274,0.00021688746,0.00012887763,0.0037417596,0.02236918,0.00005708427,0.9021344,0.00030325344],"about_ca_topic_score_codex":0.000016316664,"about_ca_topic_score_gemma":0.0000068294826,"teacher_disagreement_score":0.98797756,"about_ca_system_score_codex":0.00054625084,"about_ca_system_score_gemma":0.0026837655,"threshold_uncertainty_score":0.99565756},"labels":[],"label_agreement":null},{"id":"W6977027452","doi":"10.6084/m9.figshare.20462365","title":"Additional file 3 of Single-cell diploid Hi-C reveals the role of spatial aggregations in complex rearrangements and KMT2A fusions in leukemia","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Ploidy; Leukemia; Genome; Mutation","score_opus":0.03933951172640748,"score_gpt":0.2645081469299164,"score_spread":0.22516863520350894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977027452","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016916255,0.00009214583,5.55907e-8,0.0001581553,0.000004233451,0.0005034078,0.97394633,0.000008738685,0.008370693],"genre_scores_gemma":[0.34408528,0.0000021153958,0.00017211241,0.000099463454,0.000033740747,0.00091945444,0.6538524,0.000014246323,0.0008211846],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987894,0.0001232731,0.0002989012,0.00017862293,0.0004230297,0.00018674391],"domain_scores_gemma":[0.9983498,0.0011077308,0.00015068344,0.00023724894,0.000099156234,0.000055404867],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000078625846,0.00008835641,0.00020752173,0.00019915932,0.00009058938,0.0000054717975,0.0001708346,0.000042950156,0.96465594],"category_scores_gemma":[0.0017707883,0.00007745964,0.000045841687,0.0004155217,0.000032705706,0.00004161235,0.00037407875,0.00033398217,0.000076231765],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005641581,0.0001471398,0.00029619585,0.000086860215,0.000009424829,0.000015340953,0.00026516823,0.000030396272,0.008555245,0.0000023652092,0.98911387,0.0014215952],"study_design_scores_gemma":[0.0018486085,0.00030701124,0.13222611,0.0015978075,0.00001099008,0.000025443394,0.0011201457,0.0024390996,0.0012695102,0.00013590683,0.8588859,0.00013348345],"about_ca_topic_score_codex":0.00021382171,"about_ca_topic_score_gemma":0.0002052411,"teacher_disagreement_score":0.9645797,"about_ca_system_score_codex":0.00037681177,"about_ca_system_score_gemma":0.00037549477,"threshold_uncertainty_score":0.31587124},"labels":[],"label_agreement":null},{"id":"W6977030307","doi":"10.6084/m9.figshare.12655466.v1","title":"Additional file 3 of Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Cytarabine; Myeloid leukemia; Censoring (clinical trials); Confidence interval; Overall survival; Survival analysis; Ruxolitinib; Complete response","score_opus":0.03455497549504653,"score_gpt":0.30273085039625014,"score_spread":0.2681758749012036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977030307","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5127913,0.0000041986027,1.3394563e-7,0.00047243488,0.0000023631426,0.0005586139,0.48609605,0.000021213134,0.00005368822],"genre_scores_gemma":[0.36837494,0.000008012588,0.0017195074,0.0027336446,0.000113946844,0.0007505847,0.6255229,0.000105095496,0.0006713574],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9982385,0.00009437321,0.00035203397,0.0005108193,0.0004838545,0.0003204286],"domain_scores_gemma":[0.99673384,0.0020813432,0.00009782033,0.00024924427,0.00030571411,0.0005320089],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009036454,0.00024750578,0.0006236706,0.0001790176,0.000045793186,0.000027336999,0.00014093687,0.00011556879,0.31435683],"category_scores_gemma":[0.0032636086,0.00017212908,0.000046680863,0.0005839742,0.000032522876,0.000116376184,0.00017855408,0.00033601525,0.00015478267],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05230402,0.00015606079,0.1608258,0.00008958288,0.00029218078,0.0002375917,0.00023902404,0.000011256729,0.00008853679,2.8437304e-7,0.77846795,0.0072877277],"study_design_scores_gemma":[0.008308808,0.004233566,0.9609297,0.0015307642,0.000017962624,0.000007359925,0.00008395741,0.000112865375,0.00008248768,4.0540917e-7,0.02448803,0.00020408776],"about_ca_topic_score_codex":0.00002530131,"about_ca_topic_score_gemma":0.00003523369,"teacher_disagreement_score":0.8001039,"about_ca_system_score_codex":0.00018972659,"about_ca_system_score_gemma":0.0005085669,"threshold_uncertainty_score":0.701922},"labels":[],"label_agreement":null},{"id":"W6977064646","doi":"10.6084/m9.figshare.22617341","title":"Additional file 2 of Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"MEDLINE; Risk assessment; Table (database); Disease; Myeloid leukemia","score_opus":0.08908673793675187,"score_gpt":0.348330588068129,"score_spread":0.25924385013137713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977064646","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002392704,0.0035592893,4.2252952e-7,0.0007395148,0.0000038075675,0.0044542886,0.9908571,0.00012694695,0.00023470695],"genre_scores_gemma":[0.000115828894,0.0005417976,0.0004491087,0.0005289528,0.000026715987,0.04368346,0.9168601,0.000051430816,0.03774261],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99779624,0.0001244399,0.0007074549,0.00053348206,0.00039968817,0.00043871973],"domain_scores_gemma":[0.99214435,0.0061533456,0.00036853997,0.00068070367,0.00039448918,0.0002585959],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00008211234,0.00042658116,0.0033591306,0.00043707446,0.00010637111,0.000030234529,0.00016404483,0.0001438921,0.9327891],"category_scores_gemma":[0.004896272,0.000260165,0.0018737814,0.0012968783,0.000024113262,0.000100155325,0.00008276199,0.000104567065,0.0021051369],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001852315,0.000056832396,0.0000018650226,0.031969935,0.12421035,0.00014235418,0.000050500737,0.000005013769,0.0000019843608,7.352069e-7,0.8434919,0.000049991486],"study_design_scores_gemma":[0.0035152,0.0016838795,0.00077883253,0.012014013,0.8122199,0.000105245206,0.00016125798,0.0014213949,0.00010745347,0.000013239216,0.1674848,0.0004947521],"about_ca_topic_score_codex":0.00005780324,"about_ca_topic_score_gemma":0.000051235187,"teacher_disagreement_score":0.9306839,"about_ca_system_score_codex":0.0011443994,"about_ca_system_score_gemma":0.0007616455,"threshold_uncertainty_score":0.99998504},"labels":[],"label_agreement":null},{"id":"W6977093023","doi":"10.6084/m9.figshare.22617338","title":"Additional file 1 of Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"MEDLINE; Table (database); Disease; Systematic review; Clinical trial","score_opus":0.09183994626004427,"score_gpt":0.34893824560413983,"score_spread":0.25709829934409556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977093023","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024087536,0.0035050092,4.316225e-7,0.0007433209,0.0000037862703,0.004462337,0.99090445,0.00012698614,0.00022961506],"genre_scores_gemma":[0.000117652744,0.00052799203,0.0004587942,0.0005287304,0.00002632514,0.04446297,0.91621405,0.00005148232,0.037612],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9977958,0.00012448111,0.000707145,0.0005338729,0.0003997858,0.0004388776],"domain_scores_gemma":[0.992057,0.0062389676,0.00036803365,0.0006819771,0.00039534486,0.00025863072],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000082552855,0.00042671373,0.0033583294,0.00043735423,0.00010636349,0.000030170528,0.00016413411,0.00014389129,0.93394536],"category_scores_gemma":[0.0049544442,0.0002602481,0.0018741351,0.0012978632,0.000024113588,0.00010008829,0.00008277337,0.0001045906,0.002127276],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018627328,0.000056866007,0.0000019252243,0.031707495,0.12423407,0.00013868487,0.00005047287,0.000004991688,0.0000020544599,7.229746e-7,0.8437354,0.000048675793],"study_design_scores_gemma":[0.0035027983,0.0016888764,0.00079376245,0.012198169,0.8171704,0.0001053463,0.00016339311,0.0014352192,0.00010844926,0.00001317813,0.16232309,0.00049732137],"about_ca_topic_score_codex":0.00005723954,"about_ca_topic_score_gemma":0.000050940536,"teacher_disagreement_score":0.9318181,"about_ca_system_score_codex":0.0011440795,"about_ca_system_score_gemma":0.00076497067,"threshold_uncertainty_score":0.999985},"labels":[],"label_agreement":null},{"id":"W6977175512","doi":"10.6084/m9.figshare.22617341.v1","title":"Additional file 2 of Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"MEDLINE; Risk assessment; Table (database); Disease; Myeloid leukemia","score_opus":0.08908673793675187,"score_gpt":0.348330588068129,"score_spread":0.25924385013137713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977175512","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002392704,0.0035592893,4.2252952e-7,0.0007395148,0.0000038075675,0.0044542886,0.9908571,0.00012694695,0.00023470695],"genre_scores_gemma":[0.000115828894,0.0005417976,0.0004491087,0.0005289528,0.000026715987,0.04368346,0.9168601,0.000051430816,0.03774261],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99779624,0.0001244399,0.0007074549,0.00053348206,0.00039968817,0.00043871973],"domain_scores_gemma":[0.99214435,0.0061533456,0.00036853997,0.00068070367,0.00039448918,0.0002585959],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00008211234,0.00042658116,0.0033591306,0.00043707446,0.00010637111,0.000030234529,0.00016404483,0.0001438921,0.9327891],"category_scores_gemma":[0.004896272,0.000260165,0.0018737814,0.0012968783,0.000024113262,0.000100155325,0.00008276199,0.000104567065,0.0021051369],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001852315,0.000056832396,0.0000018650226,0.031969935,0.12421035,0.00014235418,0.000050500737,0.000005013769,0.0000019843608,7.352069e-7,0.8434919,0.000049991486],"study_design_scores_gemma":[0.0035152,0.0016838795,0.00077883253,0.012014013,0.8122199,0.000105245206,0.00016125798,0.0014213949,0.00010745347,0.000013239216,0.1674848,0.0004947521],"about_ca_topic_score_codex":0.00005780324,"about_ca_topic_score_gemma":0.000051235187,"teacher_disagreement_score":0.9306839,"about_ca_system_score_codex":0.0011443994,"about_ca_system_score_gemma":0.0007616455,"threshold_uncertainty_score":0.99998504},"labels":[],"label_agreement":null},{"id":"W6977350458","doi":"10.6084/m9.figshare.26617828","title":"Additional file 6 of Cytogenetic profile of 1791 adult acute myeloid leukemia in India","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Leukemia; Statistical analysis; Mutation; Disease","score_opus":0.020099126044516833,"score_gpt":0.2833623428747859,"score_spread":0.26326321683026904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977350458","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001241591,0.00018001752,9.9067414e-8,0.000044369564,0.000016269396,0.00045958438,0.977986,0.00004850323,0.020023597],"genre_scores_gemma":[0.014991297,0.000010724832,0.0009785587,0.00010846486,0.00015554743,0.0014298626,0.976487,0.000045234363,0.005793346],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99847156,0.0000357783,0.00037543126,0.00031217618,0.0004974884,0.00030759576],"domain_scores_gemma":[0.9982353,0.00096564926,0.00008191354,0.00030363008,0.00029222993,0.000121281795],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003581912,0.00015922099,0.00032943158,0.0003756899,0.000017319966,0.000012115721,0.00020392599,0.0001819925,0.99269557],"category_scores_gemma":[0.0025287804,0.00014378056,0.00013537832,0.0007737973,0.000033312648,0.00008598922,0.00015349075,0.00044299252,0.0050357464],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006115667,0.000027506763,0.000012850241,0.0011991531,0.00008826825,0.00028982302,0.00010120521,0.000002312173,0.0010092147,0.000010651628,0.99420315,0.0029947006],"study_design_scores_gemma":[0.0011693331,0.0004979259,0.04337717,0.027111353,0.00004964949,0.00021921207,0.00013026859,0.0037463908,0.022633545,0.00005852181,0.90070003,0.00030660353],"about_ca_topic_score_codex":0.000016718805,"about_ca_topic_score_gemma":0.0000070770425,"teacher_disagreement_score":0.9876598,"about_ca_system_score_codex":0.0005456573,"about_ca_system_score_gemma":0.0026780188,"threshold_uncertainty_score":0.9957389},"labels":[],"label_agreement":null},{"id":"W6977399560","doi":"10.6084/m9.figshare.27932603","title":"Additional file 1 of ASXL1 truncating variants in BOS and myeloid leukemia drive shared disruption of Wnt-signaling pathways but have differential isoform usage of RUNX3","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Myeloid leukemia; Gene isoform; Leukemia; Gene; Myeloid; Mutation; Focus (optics)","score_opus":0.03418395578901297,"score_gpt":0.2756755609227484,"score_spread":0.24149160513373547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977399560","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08486722,0.0001051642,0.000006361102,0.000014522502,0.000018081408,0.00042242787,0.91367304,0.000029607601,0.00086357706],"genre_scores_gemma":[0.49954838,0.000004711547,0.00044546812,0.000010455701,0.00011364186,0.00026729665,0.49925312,0.000028280741,0.000328653],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.998109,0.00005427986,0.00060030964,0.00036560398,0.0005561723,0.0003146623],"domain_scores_gemma":[0.9976651,0.0015287794,0.00022651607,0.00022056134,0.00023880445,0.000120239514],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009262391,0.00020077793,0.00047766522,0.00035367653,0.000041778832,0.000025929627,0.00015539766,0.00019856042,0.8653713],"category_scores_gemma":[0.0030619085,0.00018353947,0.00013538224,0.0003192689,0.000048658934,0.00021716944,0.0002098569,0.00043498873,0.00009565261],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030900704,0.00013244773,0.00010038452,0.004953424,0.00018121253,0.00017137281,0.0018348029,0.000017958011,0.10432144,0.00003167487,0.8757103,0.012235942],"study_design_scores_gemma":[0.009203567,0.0022535948,0.39411888,0.17656374,0.00031300023,0.00041420775,0.00507593,0.19518882,0.18941666,0.00057646295,0.025324041,0.0015510869],"about_ca_topic_score_codex":0.000059442664,"about_ca_topic_score_gemma":0.000019892892,"teacher_disagreement_score":0.8652756,"about_ca_system_score_codex":0.00036848607,"about_ca_system_score_gemma":0.00086024916,"threshold_uncertainty_score":0.74845225},"labels":[],"label_agreement":null},{"id":"W6981087251","doi":"","title":"A Didática da História: um inventário das proximidades em pesquisas na Europa e Canadá","year":2023,"lang":"en","type":"article","venue":"Dialnet (Universidad de la Rioja)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"German; Structuring; Field (mathematics); Process (computing); Element (criminal law); Thematic map; Term (time)","score_opus":0.021373150254663645,"score_gpt":0.29840277400939424,"score_spread":0.2770296237547306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6981087251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94689125,0.00013551481,0.00009907846,0.0052764737,0.00025148722,0.00080704765,0.00008886989,0.00057793426,0.045872353],"genre_scores_gemma":[0.970732,0.00017550132,0.0007636736,0.00091558864,0.00044257505,0.000035848327,0.0003059494,0.0001325393,0.026496325],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965885,0.00039660037,0.0002803399,0.0006757893,0.0008212127,0.0012375156],"domain_scores_gemma":[0.9975602,0.00047602196,0.00011499304,0.00079985894,0.00019529743,0.00085362606],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008766574,0.00035563728,0.00054305536,0.00087998965,0.0003219189,0.00014757537,0.0005622179,0.0003316013,0.0008948548],"category_scores_gemma":[0.0007617394,0.00037285782,0.00021542214,0.0019995575,0.00035871117,0.00023752956,0.00042906715,0.0009731794,0.00094713917],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020069273,0.00060733996,0.03690862,0.0009866318,0.0011964103,0.036919937,0.020500153,0.000103225444,0.031419862,0.043025505,0.7862528,0.040072605],"study_design_scores_gemma":[0.011215856,0.0010181722,0.18569835,0.0004190804,0.0006899455,0.0008839346,0.01129198,0.012196408,0.002375916,0.0017718478,0.7710587,0.0013798114],"about_ca_topic_score_codex":0.0029234646,"about_ca_topic_score_gemma":0.0011984614,"teacher_disagreement_score":0.14878973,"about_ca_system_score_codex":0.0017915232,"about_ca_system_score_gemma":0.0020568373,"threshold_uncertainty_score":0.9998723},"labels":[],"label_agreement":null},{"id":"W6986955962","doi":"","title":"Role of DOT1L in epigenetic regulation of the HOXA9 gene expression in mixed lineage leukemia","year":2024,"lang":"en","type":"dissertation","venue":"Mspace (University of Manitoba)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Winnipeg; University of Manitoba","funders":"","keywords":"Chromatin; Epigenetics; Histone methyltransferase; Gene silencing; Myeloid leukemia; Chromosomal translocation; Chromatin remodeling; Histone; Fusion protein; H3K4me3","score_opus":0.011116829067103873,"score_gpt":0.2323966895729888,"score_spread":0.22127986050588494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6986955962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966428,0.0009509177,0.000019607756,0.00021204444,0.00013628895,0.0006596417,0.000025695006,0.0000130019425,0.0013399891],"genre_scores_gemma":[0.9955077,0.00036635384,0.0008931502,0.0000035604337,0.00003769947,0.0000011626635,0.00023526954,0.000032322794,0.0029227878],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99843204,0.00015173442,0.00027659905,0.0003357426,0.0005927272,0.00021115647],"domain_scores_gemma":[0.99881685,0.00007651249,0.00033886862,0.0005176058,0.00019530536,0.000054840253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031617415,0.00018913367,0.00055516325,0.0007309585,0.00003714099,0.0000039122797,0.0003755589,0.00042747226,0.00001896659],"category_scores_gemma":[0.000083813415,0.00018691542,0.00018872447,0.0007771711,0.00010356012,0.00007272401,0.00016276274,0.000609075,0.000010263084],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010095222,0.000115102135,0.038537465,0.0017157744,0.00006351699,0.00003486473,0.002718579,0.0004703775,0.95298135,0.000039746843,0.0009712099,0.0013424724],"study_design_scores_gemma":[0.0011043098,0.000085997,0.7137985,0.0016849401,0.00010032103,0.0000019222337,0.023058234,0.0017571839,0.25802326,0.00008303705,0.00019873638,0.00010357111],"about_ca_topic_score_codex":0.0051985574,"about_ca_topic_score_gemma":0.19910659,"teacher_disagreement_score":0.6949581,"about_ca_system_score_codex":0.0008227603,"about_ca_system_score_gemma":0.00068960566,"threshold_uncertainty_score":0.81550765},"labels":[],"label_agreement":null},{"id":"W6991054938","doi":"","title":"Estudo do quimerismo das células CD34+, no follow-up do transplante alogénico de células estaminais em leucemias agudas: revisão sistemática","year":2023,"lang":"pt","type":"dissertation","venue":"The Scientific Repository of the Polytechnic Institute of Porto (Polytechnic Institute of Porto)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Face (sociological concept); Sample (material); Statistical analysis","score_opus":0.02035961862923539,"score_gpt":0.2952022186110851,"score_spread":0.2748425999818497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6991054938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9109999,0.010371581,0.001213235,0.00085199636,0.050492797,0.0101719145,0.0010210656,0.00092200236,0.013955539],"genre_scores_gemma":[0.8962958,0.0027231332,0.00095618295,0.00009321355,0.00092667324,0.00053846464,0.0013571567,0.0005396241,0.09656976],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.97560704,0.0008893132,0.008547341,0.0038694947,0.0075953086,0.0034915272],"domain_scores_gemma":[0.9742189,0.00052655773,0.008926953,0.011695573,0.0035922355,0.0010397495],"candidate_categories":["metaepi_narrow","sts","open_science","research_integrity"],"consensus_categories":["metaepi_narrow","sts","research_integrity"],"category_scores_codex":[0.010891681,0.0029726066,0.005416207,0.0031754915,0.003171565,0.00051853945,0.010701593,0.0030822942,0.00018503562],"category_scores_gemma":[0.0031712994,0.0022844907,0.0044515887,0.0073970337,0.013043941,0.0013476108,0.0019720679,0.0052530207,0.00023274147],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062799766,0.0028525773,0.001436155,0.020405985,0.006361481,0.0031515062,0.019546121,0.0014469839,0.8875692,0.008288696,0.03198203,0.010679309],"study_design_scores_gemma":[0.011944401,0.0031750689,0.0134377275,0.06398395,0.019362727,0.0058388654,0.013460021,0.0029855852,0.8041189,0.00075926457,0.05490987,0.00602363],"about_ca_topic_score_codex":0.004319825,"about_ca_topic_score_gemma":0.0010244241,"teacher_disagreement_score":0.08345029,"about_ca_system_score_codex":0.0024616204,"about_ca_system_score_gemma":0.015214026,"threshold_uncertainty_score":0.99830043},"labels":[],"label_agreement":null},{"id":"W6994114715","doi":"","title":"Newswire","year":2008,"lang":"en","type":"article","venue":"cIRcle (University of British Columbia)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"General partnership; Work (physics); Chemical technology; Exhibition","score_opus":0.016172989589056462,"score_gpt":0.20633972152005087,"score_spread":0.1901667319309944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6994114715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985032,0.00014665753,0.0001476194,0.0003771871,0.00004442253,0.00022567502,0.00003630178,0.000083335,0.013906753],"genre_scores_gemma":[0.98290056,0.000398538,0.0010943094,0.00011940965,0.00005036023,2.2072018e-7,0.000020963118,0.000015118178,0.015400543],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990146,0.000029249517,0.000086376516,0.00027790092,0.00032957792,0.00026226576],"domain_scores_gemma":[0.9991746,0.00002946764,0.00004962201,0.00031249103,0.0002132854,0.00022052338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009650199,0.000030994393,0.00026703448,0.000051721614,0.0002231703,0.000013752289,0.00019784342,0.00010973778,0.00052572374],"category_scores_gemma":[0.000047460846,0.00012447711,0.00013173341,0.00032829941,0.00044569705,0.00015630263,0.00011922025,0.00022025414,0.00016294162],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084663596,0.0002909331,0.16338147,0.00015915748,0.00012944578,0.007876251,0.00042970473,0.000001691738,0.0022460404,0.0000016404852,0.16931504,0.65608394],"study_design_scores_gemma":[0.002118904,0.00014645612,0.9902445,0.00008612216,0.000031624037,0.0017356358,0.00061041286,0.00011091564,0.0000039213664,0.000028000364,0.004776588,0.000106917985],"about_ca_topic_score_codex":0.11009505,"about_ca_topic_score_gemma":0.054268505,"teacher_disagreement_score":0.82686305,"about_ca_system_score_codex":0.00016717045,"about_ca_system_score_gemma":0.00035767435,"threshold_uncertainty_score":0.9629886},"labels":[],"label_agreement":null},{"id":"W6996081736","doi":"","title":"Properties of Decaying First Year Sea Ice: Two Seasons of Field of Field Measurements.","year":2002,"lang":"en","type":"article","venue":"NPARC","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Borehole; Snow; Flexural strength; Field strength; Sea ice; Field (mathematics)","score_opus":0.07961763760476592,"score_gpt":0.31007132390887626,"score_spread":0.23045368630411034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6996081736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9190408,0.000482143,0.00012636592,0.004884423,0.000059247166,0.00041573093,0.000008320578,0.00002320852,0.07495977],"genre_scores_gemma":[0.99634683,0.000104969586,0.0019284654,0.0001608677,0.000058131503,0.000012206779,0.0000015124008,0.000016201233,0.001370818],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99869114,0.000044112912,0.0002743751,0.00015521444,0.0006080396,0.00022708808],"domain_scores_gemma":[0.9989877,0.00014252777,0.00010314771,0.00038964467,0.00028768257,0.000089300185],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029117105,0.000100208556,0.00033043296,0.00011003816,0.000033307108,0.0000035664611,0.00017948337,0.00008541639,0.0019542903],"category_scores_gemma":[0.0008308932,0.00008096872,0.00010056423,0.00021817016,0.000088944675,0.000053151798,0.00008641878,0.00022261683,0.000021101057],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005359733,0.00037363378,0.15393488,0.0016375643,0.00029970868,0.000015998268,0.0015587154,0.000013040656,0.7657127,0.00023868417,0.06628767,0.00939148],"study_design_scores_gemma":[0.0018079896,0.00053552113,0.0012835707,0.00059303007,0.0000785843,0.000008065073,0.00031013787,0.00096792326,0.9926588,0.000040078194,0.0016259453,0.00009038656],"about_ca_topic_score_codex":0.00017209479,"about_ca_topic_score_gemma":0.00003795228,"teacher_disagreement_score":0.22694612,"about_ca_system_score_codex":0.00006223958,"about_ca_system_score_gemma":0.0001025991,"threshold_uncertainty_score":0.99895805},"labels":[],"label_agreement":null},{"id":"W7000544720","doi":"","title":"The functional role of NCAM1 in pediatric Acute Megakaryoblastic Leukemia (AMKL) associated with the CBFA2T3::GLIS2 gene fusion","year":2023,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Acute megakaryoblastic leukemia; Gene; Fusion protein; Fusion gene; Disease","score_opus":0.012692459535557412,"score_gpt":0.2444283412365562,"score_spread":0.2317358817009988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7000544720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834969,0.00075983396,1.5424662e-7,0.00013702367,0.00073255174,0.0018623383,0.00085055834,0.0002431465,0.011917488],"genre_scores_gemma":[0.9649277,0.0022392254,0.00004302889,0.00015514802,0.00020111256,0.0005419408,0.0034706786,0.00040570777,0.028015476],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9924802,0.0007410783,0.0013125227,0.0012378297,0.002882187,0.0013461618],"domain_scores_gemma":[0.99343956,0.0025805205,0.0010360099,0.0012569868,0.0012957487,0.00039116497],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0026200854,0.0009620071,0.0012091126,0.00095197896,0.0015589836,0.000091721944,0.0010612546,0.0011647253,0.00012828718],"category_scores_gemma":[0.0030077423,0.0006079471,0.00048524037,0.0033878325,0.00022199535,0.00034131677,0.0003306188,0.0044927136,0.0002977807],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05937622,0.003383962,0.01807019,0.0036761735,0.016898777,0.005180196,0.0006792576,0.003704037,0.67290103,0.032979947,0.0033992792,0.17975093],"study_design_scores_gemma":[0.01727721,0.00281076,0.88478893,0.0019369026,0.006269156,0.0002923023,0.004417573,0.0015292368,0.056602884,0.0062940232,0.014919744,0.0028612947],"about_ca_topic_score_codex":0.0006695533,"about_ca_topic_score_gemma":0.006456884,"teacher_disagreement_score":0.8667187,"about_ca_system_score_codex":0.0042811744,"about_ca_system_score_gemma":0.0013586355,"threshold_uncertainty_score":0.99974084},"labels":[],"label_agreement":null},{"id":"W7036392187","doi":"","title":"Book Review: The Medical Effects of Nuclear War: The Report of the British Medical Association's Board of Science and Education: The Medical Effects of Nuclear War: The Report of the British Medical Association's Board of Science and Education. Published on behalf of the British Medical Association by John Wiley &amp; Sons, Chichester-New York-Toronto-Brisbane-Singapore: xx + 188 pp., 10 figs, 20.2 Ã 12.2 Ã 1.3 cm, thick paper cover [no price indicated], 1983","year":2017,"lang":"en","type":"other","venue":"reroDoc Digital Library","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nucleofection; Gestational period; TSG101; Dysgeusia; Liquation; Emperipolesis; Diafiltration; Triacetin; Demotion","score_opus":0.004119455908108543,"score_gpt":0.2363169217476888,"score_spread":0.23219746583958026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7036392187","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06012968,0.25987226,0.00000472416,0.4146015,0.0064536766,0.017728014,0.0014288253,0.00026552164,0.2395158],"genre_scores_gemma":[0.10773073,0.32803914,0.00017271066,0.07375385,0.0062560225,0.00094540755,0.0009624032,0.0013801195,0.48075962],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9669109,0.0019815126,0.0030390022,0.0013115291,0.025772423,0.0009846637],"domain_scores_gemma":[0.97711647,0.0069004702,0.009146708,0.0034990995,0.002301045,0.0010362407],"candidate_categories":["metaresearch","metaepi_narrow","sts","open_science","research_integrity","insufficient_payload"],"consensus_categories":["sts","research_integrity"],"category_scores_codex":[0.018021539,0.0006408113,0.0020815132,0.00013333783,0.0014682657,0.0008186937,0.00658497,0.002018071,0.003811085],"category_scores_gemma":[0.21539356,0.00036272587,0.00067688985,0.0017261964,0.011890165,0.0013885661,0.0030178456,0.0035484117,0.000010400007],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005335828,0.00080242794,0.009556713,0.0019810202,0.0005632126,0.000058215974,0.0003255866,5.444211e-8,0.000040484938,0.000042672527,0.9662882,0.020288054],"study_design_scores_gemma":[0.0014447828,0.00021406899,0.042670727,0.030813169,0.0005493309,0.0018462037,0.00016354064,0.000023442217,0.00017471796,0.00006228591,0.9216985,0.00033919245],"about_ca_topic_score_codex":0.005666852,"about_ca_topic_score_gemma":0.0006644623,"teacher_disagreement_score":0.34084767,"about_ca_system_score_codex":0.0009873448,"about_ca_system_score_gemma":0.036185287,"threshold_uncertainty_score":0.99988246},"labels":[],"label_agreement":null},{"id":"W7038709022","doi":"","title":"Inhibition of Mitochondrial Translation as a Therapeutic Strategy for Acute Myeloid Leukemia","year":2012,"lang":"en","type":"dissertation","venue":"TSpace","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Haematopoiesis; Stem cell; Leukemia; Myeloid; Progenitor cell; Clonogenic assay; Hematopoietic stem cell","score_opus":0.047310540487768275,"score_gpt":0.3931434147604494,"score_spread":0.3458328742726811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7038709022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94561344,0.003776317,0.0023641048,0.00067959697,0.0011469473,0.00566644,0.000115360315,0.00016949441,0.040468317],"genre_scores_gemma":[0.8911926,0.00082302175,0.005029936,0.00016227533,0.002250367,0.00074990187,0.013872149,0.00031753667,0.08560217],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978646,0.000071438386,0.00049585145,0.00042153805,0.0006368664,0.00050969707],"domain_scores_gemma":[0.99843687,0.00017262131,0.00034461243,0.00041337113,0.0004395641,0.00019299047],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021967875,0.00038511632,0.00072440144,0.00035500614,0.00008384653,0.000024566405,0.00012426142,0.00079659227,0.00050728826],"category_scores_gemma":[0.00005853279,0.00035897392,0.00035143923,0.00030317745,0.000063195,0.00014565475,0.000008760708,0.00063174893,0.0000845159],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00861132,0.00012763908,0.000017622418,0.0012751538,0.00084115955,0.000013412905,0.0075356155,0.000010474508,0.9323718,0.00061992445,0.002230419,0.046345457],"study_design_scores_gemma":[0.01747815,0.0037319935,0.0033680638,0.0014191108,0.006094002,0.00012879235,0.011024565,0.0010179343,0.93725145,0.0021879363,0.015097868,0.0012001175],"about_ca_topic_score_codex":0.00037783853,"about_ca_topic_score_gemma":0.00014949251,"teacher_disagreement_score":0.05442078,"about_ca_system_score_codex":0.00062963855,"about_ca_system_score_gemma":0.0019368887,"threshold_uncertainty_score":0.9998862},"labels":[],"label_agreement":null},{"id":"W7039991107","doi":"","title":"Nutrition and Dementia - A practical guide when caring for a person with dementia","year":2016,"lang":"en","type":"other","venue":"Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Alzheimer Society","keywords":"Dementia; Family caregivers; Disease; MEDLINE; Alzheimer's disease","score_opus":0.023305117060400563,"score_gpt":0.3103620397691588,"score_spread":0.28705692270875827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7039991107","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0061017238,0.0994476,0.0035544245,0.24343711,0.002570175,0.02795605,0.00077613845,0.0019562074,0.6142006],"genre_scores_gemma":[0.0049624285,0.003435827,0.030814229,0.0029313553,0.0046651606,0.0013867687,0.0003116677,0.0015900667,0.9499025],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99647796,0.0002712804,0.000612338,0.0009549935,0.00069695193,0.0009864839],"domain_scores_gemma":[0.9974971,0.00026912507,0.0006875871,0.0009129877,0.00008781648,0.00054537517],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034320325,0.000560488,0.0008447353,0.000285565,0.00044327037,0.00019095992,0.00031534003,0.00045443897,0.00023416831],"category_scores_gemma":[0.000066976216,0.00036599534,0.0001878836,0.00014482255,0.00033236123,0.0004289517,0.00021254817,0.0007918853,0.000030416917],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043656406,0.00022759418,0.004517262,0.0024316695,0.0011270237,0.00021620693,0.0003288176,3.3118713e-8,0.000042264288,0.00013581262,0.98881686,0.0017198881],"study_design_scores_gemma":[0.0039187064,0.002338155,0.002059132,0.003702296,0.0006570389,0.0004474536,0.00040283904,0.000037154696,0.00016824607,0.00003646397,0.98576975,0.0004627446],"about_ca_topic_score_codex":0.00061787176,"about_ca_topic_score_gemma":0.000024290272,"teacher_disagreement_score":0.33570194,"about_ca_system_score_codex":0.00031057172,"about_ca_system_score_gemma":0.0017677371,"threshold_uncertainty_score":0.9998792},"labels":[],"label_agreement":null},{"id":"W7045777507","doi":"","title":"Characterization of the Pharmacokinetic Properties and In Vivo Efficacy of a Candidate Bone Marrow Niche Altering Compound","year":2024,"lang":"en","type":"dissertation","venue":"MacSphere (McMaster University)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"TSG101; Sulfinpyrazone; Nucleofection; Proteogenomics; Articular cartilage damage; Hexamethylbenzene","score_opus":0.018315571355452243,"score_gpt":0.24153076998103035,"score_spread":0.2232151986255781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7045777507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97291654,0.00028492464,0.000003236768,0.00013717501,0.00015129714,0.00072517915,0.000036716225,0.000017275766,0.025727637],"genre_scores_gemma":[0.7489862,0.00022911493,0.000019111158,0.000018718716,0.000031663298,0.0000017864305,0.00006825292,0.00003398423,0.25061116],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988636,0.00008992499,0.00027859467,0.00029770788,0.00027441658,0.00019578866],"domain_scores_gemma":[0.999416,0.000027866057,0.00018089084,0.0002143441,0.00009931349,0.00006160102],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008802192,0.00020938742,0.0004339801,0.00031358527,0.000035708148,0.000017635648,0.00018944747,0.00014780581,0.0031220014],"category_scores_gemma":[0.00001861435,0.0001668,0.00008849868,0.00062173227,0.00011482819,0.00008476013,0.00015157746,0.00042146558,0.000003139467],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020779327,0.000072781426,0.0021357962,0.0035378162,0.00016025423,0.00013029261,0.0022923073,0.000010555841,0.9733528,0.000016748894,0.000057113564,0.016155636],"study_design_scores_gemma":[0.009028934,0.0003243473,0.06203745,0.009599989,0.0013226394,0.000080976715,0.004531128,0.003334265,0.84907085,0.000009526741,0.060048655,0.0006112148],"about_ca_topic_score_codex":0.00031600278,"about_ca_topic_score_gemma":0.00046418523,"teacher_disagreement_score":0.22488353,"about_ca_system_score_codex":0.00021312248,"about_ca_system_score_gemma":0.00026555336,"threshold_uncertainty_score":0.99778926},"labels":[],"label_agreement":null},{"id":"W7046265357","doi":"","title":"Correlation Study on HLA-DR and CD117 (c-Kit) Expressions: Its Prognosis and Treatment Response in Acute Myeloid Leukemia Patients","year":2021,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CD117; Myeloid leukemia; Pharmacy; CD34; Clinical significance; Myeloid; Cancer; Correlation","score_opus":0.2036995030575275,"score_gpt":0.5310135253913011,"score_spread":0.3273140223337736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7046265357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904976,0.005717184,0.000009199579,0.0005675937,0.00016379304,0.0024478624,0.000058749916,0.000028805913,0.0005092331],"genre_scores_gemma":[0.98366433,0.014110643,0.000117871685,0.00025616723,0.00006572623,0.00028983134,0.000044179636,0.000068046036,0.0013832258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956226,0.0011151155,0.0009353707,0.00081408577,0.0010281967,0.00048463672],"domain_scores_gemma":[0.99692005,0.0010351805,0.00046696744,0.0005590611,0.00052974885,0.00048901053],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013838812,0.000430117,0.001027406,0.0011502213,0.0002800819,0.00055663765,0.0005304222,0.00018895566,0.0008978571],"category_scores_gemma":[0.0014659369,0.00034635313,0.00010584146,0.0011235657,0.00011697958,0.0012145317,0.0009030917,0.00066186016,0.000014383007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009146426,0.0019082858,0.9077396,0.000053193588,0.00045402022,0.0007912111,0.0015270697,0.00003722893,0.056139015,0.0000036687436,0.0042165373,0.017983742],"study_design_scores_gemma":[0.0076807,0.000562448,0.96694666,0.0009605828,0.00024923283,0.000046226087,0.00071933854,0.00029212463,0.021028144,0.000061932085,0.0011518159,0.0003008114],"about_ca_topic_score_codex":0.00034047707,"about_ca_topic_score_gemma":0.000050120198,"teacher_disagreement_score":0.05920704,"about_ca_system_score_codex":0.0012966777,"about_ca_system_score_gemma":0.00086803676,"threshold_uncertainty_score":0.99989885},"labels":[],"label_agreement":null},{"id":"W7067517181","doi":"","title":"Manual of Vascular Plants of Northeastern United States and Adjacent Canada, Second Edition by Henry A. Gleason, Arthur Cronquist","year":2004,"lang":"en","type":"article","venue":"Biodiversity Heritage Library (Smithsonian Institution)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"George (robot); Context (archaeology)","score_opus":0.007302107586003875,"score_gpt":0.19544397832713764,"score_spread":0.18814187074113375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7067517181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99120396,0.00078696606,0.00010487843,0.0013335509,0.0001461014,0.00044729712,0.005370151,0.00005510647,0.00055195665],"genre_scores_gemma":[0.99677753,0.00063395005,0.0006230065,0.00082775083,0.00006880812,0.0000035248372,0.0007753383,0.000013504828,0.0002766044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984005,0.000060663944,0.0003300421,0.00034390468,0.0005266428,0.00033825662],"domain_scores_gemma":[0.99906325,0.000029758112,0.00015489683,0.00030543908,0.00009967603,0.0003469956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008421495,0.00022601779,0.00039275718,0.00022390022,0.00019453833,0.000026444983,0.00019559388,0.00014126017,0.00037135486],"category_scores_gemma":[0.000021226286,0.00022868588,0.00007791108,0.00031978934,0.0005950242,0.00067992136,0.00015787633,0.00026930228,0.000018918916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00108626,0.00047533077,0.94622874,0.0011398412,0.00045565976,0.0006504411,0.001138325,0.00012470823,0.00055278913,0.0004601174,0.04707727,0.0006105096],"study_design_scores_gemma":[0.008038193,0.000628503,0.9045748,0.0005090349,0.00013822946,0.00009955639,0.0035926192,0.00013338916,0.021229317,0.000043719298,0.060543995,0.000468624],"about_ca_topic_score_codex":0.06442631,"about_ca_topic_score_gemma":0.020168269,"teacher_disagreement_score":0.044258043,"about_ca_system_score_codex":0.0002945355,"about_ca_system_score_gemma":0.001332964,"threshold_uncertainty_score":0.9977111},"labels":[],"label_agreement":null},{"id":"W7094944311","doi":"10.6084/m9.figshare.30435128","title":"Additional file 1 of High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; Hôpital Maisonneuve-Rosemont; University Health Network; University of Toronto; Institute for Research in Immunology and Cancer","funders":"","keywords":"Interleukin 1 receptor, type I; Exact test; Contingency table; Censoring (clinical trials); Survival analysis; Interleukin-1 receptor","score_opus":0.01325532978822253,"score_gpt":0.23196786136515574,"score_spread":0.2187125315769332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7094944311","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1330737,0.002062079,0.0000026220184,0.00015557947,0.00027061198,0.0015122216,0.86174744,0.00005402299,0.0011217152],"genre_scores_gemma":[0.25523278,0.00080732617,0.00011472992,0.00019729913,0.000592007,0.0015084327,0.7389519,0.00007542754,0.0025200688],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99438685,0.00043803902,0.0013865244,0.0014315532,0.0013728659,0.0009841475],"domain_scores_gemma":[0.982655,0.014757743,0.00061894103,0.0011258047,0.00039401883,0.0004484867],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00022616403,0.0007933147,0.0013731536,0.00033867534,0.00028706758,0.0001081111,0.0011802862,0.00087229896,0.9513808],"category_scores_gemma":[0.0009866894,0.00062858354,0.00028846547,0.0007202166,0.00018244091,0.00030479595,0.00092102017,0.0021551084,0.0009612476],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015662861,0.0001669004,0.001776035,0.0004280582,0.00068973907,0.00029956654,0.0009120565,0.000037554564,0.0015497016,0.0000017746574,0.9866765,0.005895803],"study_design_scores_gemma":[0.009947247,0.00053370313,0.7160809,0.068410926,0.0009093351,0.000011508002,0.0017112745,0.006132885,0.039100032,0.00021945384,0.1560012,0.00094151386],"about_ca_topic_score_codex":0.0024486422,"about_ca_topic_score_gemma":0.00077139295,"teacher_disagreement_score":0.95041955,"about_ca_system_score_codex":0.0010950937,"about_ca_system_score_gemma":0.0024967156,"threshold_uncertainty_score":0.9998166},"labels":[],"label_agreement":null},{"id":"W7094944632","doi":"10.6084/m9.figshare.c.8107535","title":"High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort","year":2025,"lang":"","type":"other","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; Hôpital Maisonneuve-Rosemont; University Health Network; University of Toronto; Institute for Research in Immunology and Cancer","funders":"","keywords":"Myeloid leukemia; CEBPA; Hematopoietic stem cell transplantation; Stem cell; Transplantation; Cumulative incidence; NPM1; Leukemia; Cohort","score_opus":0.015107407218087676,"score_gpt":0.24099737093962662,"score_spread":0.22588996372153894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7094944632","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1416146,0.015203787,0.000012555956,0.0002473306,0.0012500378,0.0044593075,0.82543856,0.00019253386,0.011581256],"genre_scores_gemma":[0.27612257,0.018798098,0.00014983646,0.0006013082,0.0040156934,0.0016773049,0.6064429,0.00094041135,0.09125186],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9899466,0.0008509262,0.0019257868,0.0031636334,0.002176018,0.0019370075],"domain_scores_gemma":[0.9909261,0.004183111,0.0010723082,0.0025022395,0.00034239222,0.00097383687],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.00054547423,0.0020447364,0.0029526001,0.00067600206,0.00040460023,0.00032716416,0.0025526367,0.002785355,0.31676248],"category_scores_gemma":[0.0003867135,0.0015397761,0.0005025583,0.000793342,0.00019615602,0.0002775854,0.001692734,0.0053565563,0.0035092225],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004944579,0.0004036275,0.027721409,0.0023124765,0.0039423895,0.0035879563,0.004687743,0.000098748314,0.006734156,0.000006983829,0.9172747,0.02828523],"study_design_scores_gemma":[0.0349157,0.0011925308,0.5119982,0.16239764,0.0053111603,0.000035810204,0.0028034155,0.004334072,0.06423786,0.00022025756,0.2081066,0.004446743],"about_ca_topic_score_codex":0.013330142,"about_ca_topic_score_gemma":0.0030418138,"teacher_disagreement_score":0.7091681,"about_ca_system_score_codex":0.0023786833,"about_ca_system_score_gemma":0.0032700424,"threshold_uncertainty_score":0.9992295},"labels":[],"label_agreement":null},{"id":"W7094952661","doi":"10.6084/m9.figshare.30435131","title":"Additional file 2 of High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort","year":2025,"lang":"","type":"dataset","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; Hôpital Maisonneuve-Rosemont; University Health Network; University of Toronto; Institute for Research in Immunology and Cancer","funders":"","keywords":"Myeloid leukemia; Cohort; Stem cell; Transplantation; Overall survival; Myeloid; Leukemia; Hematopoietic stem cell transplantation","score_opus":0.013276261208074389,"score_gpt":0.2343240413341426,"score_spread":0.22104778012606824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7094952661","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004666803,0.0019672664,7.074233e-7,0.000071089235,0.00044226833,0.0027097112,0.989882,0.000058231755,0.000201942],"genre_scores_gemma":[0.0019549718,0.0033086631,0.00010653694,0.00025002524,0.0016724981,0.004162955,0.9867999,0.000120450066,0.001623987],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9908329,0.0007186741,0.002190066,0.0024275954,0.0024465693,0.0013841456],"domain_scores_gemma":[0.97118634,0.02385866,0.0014149082,0.0022674364,0.00054274703,0.0007298929],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.00029821345,0.0015413716,0.0026099477,0.0005694229,0.00037582376,0.00016254168,0.002524992,0.0020559456,0.9741135],"category_scores_gemma":[0.0017166225,0.001223834,0.00047363827,0.00080206484,0.00024395876,0.00034384817,0.0019513785,0.0047121127,0.0012496446],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020127632,0.00023649241,0.00014581034,0.001173828,0.0011585022,0.00086028874,0.00034109017,0.000023615548,0.00017894637,1.9356736e-7,0.9917525,0.0021159435],"study_design_scores_gemma":[0.006151755,0.00049577,0.053652007,0.0779064,0.001204394,0.000016920627,0.0005416879,0.00085463206,0.0036051697,0.000030666368,0.854472,0.0010686151],"about_ca_topic_score_codex":0.005405896,"about_ca_topic_score_gemma":0.0018255628,"teacher_disagreement_score":0.9728639,"about_ca_system_score_codex":0.0016098483,"about_ca_system_score_gemma":0.004500294,"threshold_uncertainty_score":0.9997335},"labels":[],"label_agreement":null},{"id":"W7094953113","doi":"10.6084/m9.figshare.30435128.v1","title":"Additional file 1 of High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; Hôpital Maisonneuve-Rosemont; University Health Network; University of Toronto; Institute for Research in Immunology and Cancer","funders":"","keywords":"Interleukin 1 receptor, type I; Exact test; Contingency table; Censoring (clinical trials); Survival analysis; Interleukin-1 receptor","score_opus":0.01325532978822253,"score_gpt":0.23196786136515574,"score_spread":0.2187125315769332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7094953113","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1330737,0.002062079,0.0000026220184,0.00015557947,0.00027061198,0.0015122216,0.86174744,0.00005402299,0.0011217152],"genre_scores_gemma":[0.25523278,0.00080732617,0.00011472992,0.00019729913,0.000592007,0.0015084327,0.7389519,0.00007542754,0.0025200688],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99438685,0.00043803902,0.0013865244,0.0014315532,0.0013728659,0.0009841475],"domain_scores_gemma":[0.982655,0.014757743,0.00061894103,0.0011258047,0.00039401883,0.0004484867],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00022616403,0.0007933147,0.0013731536,0.00033867534,0.00028706758,0.0001081111,0.0011802862,0.00087229896,0.9513808],"category_scores_gemma":[0.0009866894,0.00062858354,0.00028846547,0.0007202166,0.00018244091,0.00030479595,0.00092102017,0.0021551084,0.0009612476],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015662861,0.0001669004,0.001776035,0.0004280582,0.00068973907,0.00029956654,0.0009120565,0.000037554564,0.0015497016,0.0000017746574,0.9866765,0.005895803],"study_design_scores_gemma":[0.009947247,0.00053370313,0.7160809,0.068410926,0.0009093351,0.000011508002,0.0017112745,0.006132885,0.039100032,0.00021945384,0.1560012,0.00094151386],"about_ca_topic_score_codex":0.0024486422,"about_ca_topic_score_gemma":0.00077139295,"teacher_disagreement_score":0.95041955,"about_ca_system_score_codex":0.0010950937,"about_ca_system_score_gemma":0.0024967156,"threshold_uncertainty_score":0.9998166},"labels":[],"label_agreement":null},{"id":"W7094956474","doi":"10.6084/m9.figshare.30435131.v1","title":"Additional file 2 of High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort","year":2025,"lang":"","type":"dataset","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; Hôpital Maisonneuve-Rosemont; University Health Network; University of Toronto; Institute for Research in Immunology and Cancer","funders":"","keywords":"Myeloid leukemia; Cohort; Stem cell; Transplantation; Overall survival; Myeloid; Leukemia; Hematopoietic stem cell transplantation","score_opus":0.013276261208074389,"score_gpt":0.2343240413341426,"score_spread":0.22104778012606824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7094956474","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004666803,0.0019672664,7.074233e-7,0.000071089235,0.00044226833,0.0027097112,0.989882,0.000058231755,0.000201942],"genre_scores_gemma":[0.0019549718,0.0033086631,0.00010653694,0.00025002524,0.0016724981,0.004162955,0.9867999,0.000120450066,0.001623987],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9908329,0.0007186741,0.002190066,0.0024275954,0.0024465693,0.0013841456],"domain_scores_gemma":[0.97118634,0.02385866,0.0014149082,0.0022674364,0.00054274703,0.0007298929],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.00029821345,0.0015413716,0.0026099477,0.0005694229,0.00037582376,0.00016254168,0.002524992,0.0020559456,0.9741135],"category_scores_gemma":[0.0017166225,0.001223834,0.00047363827,0.00080206484,0.00024395876,0.00034384817,0.0019513785,0.0047121127,0.0012496446],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020127632,0.00023649241,0.00014581034,0.001173828,0.0011585022,0.00086028874,0.00034109017,0.000023615548,0.00017894637,1.9356736e-7,0.9917525,0.0021159435],"study_design_scores_gemma":[0.006151755,0.00049577,0.053652007,0.0779064,0.001204394,0.000016920627,0.0005416879,0.00085463206,0.0036051697,0.000030666368,0.854472,0.0010686151],"about_ca_topic_score_codex":0.005405896,"about_ca_topic_score_gemma":0.0018255628,"teacher_disagreement_score":0.9728639,"about_ca_system_score_codex":0.0016098483,"about_ca_system_score_gemma":0.004500294,"threshold_uncertainty_score":0.9997335},"labels":[],"label_agreement":null},{"id":"W7095053122","doi":"10.6084/m9.figshare.27312765","title":"Single-cell transcriptional mapping reveals genetic and non-genetic determinants of aberrant differentiation in AML - Datasets","year":2025,"lang":"","type":"dataset","venue":"Figshare","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Projection (relational algebra); Object (grammar); Sorting; Bioconductor; Typing; Cell type; Gene","score_opus":0.045121325976530686,"score_gpt":0.2937743975073079,"score_spread":0.2486530715307772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7095053122","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02507195,0.0056099254,0.000008273816,0.000045698314,0.00018676912,0.0025353432,0.966492,0.000012422483,0.000037642574],"genre_scores_gemma":[0.051338226,0.0011334948,0.00031458543,0.00018300001,0.00025891836,0.00045771842,0.94598794,0.000056094654,0.0002700292],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9936712,0.00040206072,0.0021117849,0.001510332,0.001183572,0.00112106],"domain_scores_gemma":[0.99622405,0.0006838838,0.0008205297,0.0015388053,0.00031052105,0.00042223415],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024333471,0.0009296977,0.001752805,0.0014652772,0.0001583147,0.00011266711,0.0009916185,0.0010173944,0.053917956],"category_scores_gemma":[0.0014702609,0.0009834424,0.00022953686,0.00092010543,0.00008828381,0.00018563385,0.0007203094,0.0014209128,0.00024929375],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023590201,0.00066855655,0.0014730131,0.028589152,0.00012089671,0.0006146997,0.00020373096,0.000010858357,0.009947227,3.434983e-8,0.94967484,0.008461076],"study_design_scores_gemma":[0.012358384,0.0010298037,0.5250913,0.114487275,0.0008032813,0.00021259046,0.0001974619,0.009368732,0.0040397854,0.000018707568,0.33060881,0.001783866],"about_ca_topic_score_codex":0.00021739936,"about_ca_topic_score_gemma":0.0003054703,"teacher_disagreement_score":0.61906606,"about_ca_system_score_codex":0.00064754154,"about_ca_system_score_gemma":0.0012963027,"threshold_uncertainty_score":0.9992616},"labels":[],"label_agreement":null},{"id":"W7095502542","doi":"","title":"the Canadian Nurses ’ Working Group on Azacitidine in MDS","year":2016,"lang":"en","type":"article","venue":"","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Azacitidine; Myeloid leukemia; Myelodysplastic syndromes; Adverse effect; Oncology nursing; Leukemia","score_opus":0.029590350788543236,"score_gpt":0.30188694380558295,"score_spread":0.27229659301703973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7095502542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.53406394,0.00011417424,0.000024457468,0.07110671,0.00025258947,0.00048347254,0.0000028175816,0.000056328514,0.39389548],"genre_scores_gemma":[0.9675511,0.000088168126,0.00008443154,0.0013430315,0.00018557212,0.000024521727,0.0000021625904,0.000016913213,0.030704074],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989118,0.000041663927,0.00012942289,0.00017120893,0.0002549861,0.00049091666],"domain_scores_gemma":[0.9990374,0.0003490709,0.000013505588,0.0003059624,0.000033379234,0.00026068732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037953653,0.00008572679,0.00011180051,0.0001823373,0.00014060066,0.000026199983,0.00014384465,0.00007101792,0.00040019548],"category_scores_gemma":[0.00029069473,0.000037627706,0.000031532003,0.0002392009,0.000114327246,0.000031504464,0.000022214414,0.00020910817,0.00038123966],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004583531,0.00006893546,0.14835154,0.000011673159,0.000059655726,0.0006164782,0.00026195467,6.652795e-7,0.0060107517,0.07253553,0.08477689,0.68684757],"study_design_scores_gemma":[0.0032775158,0.00037766932,0.17160507,0.00043966723,0.00001025416,0.00005753674,0.00034357724,0.0001243949,0.0037916459,0.00084420544,0.8189302,0.00019823482],"about_ca_topic_score_codex":0.09087077,"about_ca_topic_score_gemma":0.71312207,"teacher_disagreement_score":0.73415333,"about_ca_system_score_codex":0.0012879464,"about_ca_system_score_gemma":0.00044824195,"threshold_uncertainty_score":0.9151832},"labels":[],"label_agreement":null},{"id":"W7105402516","doi":"10.71781/29797","title":"Immune cell context in normal karyotype AML patients at diagnosis","year":2024,"lang":"en","type":"dissertation","venue":"Open MIND","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Karyotype; Hematopoietic cell; Bone marrow; Chromosome abnormality","score_opus":0.022937303365561806,"score_gpt":0.32728127224410836,"score_spread":0.30434396887854653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7105402516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83667624,0.0020152668,3.566973e-8,0.00015204653,0.0005544474,0.0016490429,0.00009960161,0.0000025931647,0.15885071],"genre_scores_gemma":[0.74050367,0.0003777403,0.00013871166,0.00006496253,0.00009393528,0.00028162455,0.008197602,0.00008987395,0.25025186],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99780047,0.00006582416,0.00054695754,0.00062602566,0.0005131927,0.00044753586],"domain_scores_gemma":[0.99890363,0.00012504382,0.0001407938,0.0004801979,0.00017856451,0.00017177501],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000284861,0.0003267864,0.00064593216,0.0003470275,0.00006583434,0.000119623444,0.0005278099,0.00043834987,0.013717686],"category_scores_gemma":[0.00013445722,0.0002955351,0.00013741839,0.0003886506,0.00003595164,0.00014576044,0.00038987515,0.000956518,0.011713319],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007876853,0.0018380457,0.18524073,0.0018484439,0.00047939896,0.0022298296,0.01858001,0.0000028531035,0.0039941045,0.000007041815,0.103482835,0.6744199],"study_design_scores_gemma":[0.011363303,0.0014148074,0.4450666,0.0035763548,0.0005892078,0.000014790365,0.0043213465,0.00013045398,0.11672912,0.000014287828,0.41569248,0.0010872316],"about_ca_topic_score_codex":0.0014844227,"about_ca_topic_score_gemma":0.0031863216,"teacher_disagreement_score":0.67333263,"about_ca_system_score_codex":0.0010037224,"about_ca_system_score_gemma":0.00071924075,"threshold_uncertainty_score":0.9999497},"labels":[],"label_agreement":null},{"id":"W7108068977","doi":"10.1016/j.exphem.2025.105161","title":"3220 – PERTURBED POST-TRANSCRIPTIONAL REGULATION VIA STAU1 LOSS CONTRIBUTES TO ERYTHROID DIFFERENTIATION DEFECTS IN DEL(20Q) DISORDERED HEMATOPOIESIS","year":2025,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Gene knockdown; Haematopoiesis; Haploinsufficiency; Erythropoiesis; Progenitor cell; Stem cell; Regulator; Myeloid; Progenitor","score_opus":0.00867151115985047,"score_gpt":0.29882086421968923,"score_spread":0.29014935305983874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108068977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97727644,0.005174009,0.0070074303,0.007981766,0.00037704446,0.0014518257,0.000021693102,0.00010870491,0.0006011122],"genre_scores_gemma":[0.99595547,0.000020058984,0.00068499666,0.0015433549,0.000035080284,0.00036127158,0.00044930304,0.00003387842,0.0009165594],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977627,0.00017368859,0.00058777415,0.00057216425,0.00033469129,0.0005689859],"domain_scores_gemma":[0.9989971,0.00020673477,0.00007741128,0.00037442186,0.00019026556,0.00015408962],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016982829,0.00029970356,0.00068970403,0.00066207536,0.00014680931,0.000029203104,0.00017317347,0.00028196158,0.0007030391],"category_scores_gemma":[0.00019045241,0.0002900427,0.00014756812,0.00062040455,0.0001697695,0.00014847596,0.00013423919,0.00028044634,0.00013242324],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003802595,0.0015283636,0.103403665,0.0003484213,0.00026565866,0.00012338413,0.0019080461,0.000015875225,0.79848033,0.08467963,0.005064035,0.0003799883],"study_design_scores_gemma":[0.007886321,0.00040938673,0.22817242,0.00028412422,0.000054885062,0.00020248257,0.0017903609,0.0016529921,0.7563231,0.0019044916,0.0009997067,0.00031972595],"about_ca_topic_score_codex":0.0002405916,"about_ca_topic_score_gemma":0.0001663182,"teacher_disagreement_score":0.12476875,"about_ca_system_score_codex":0.000959485,"about_ca_system_score_gemma":0.0002310558,"threshold_uncertainty_score":0.9999552},"labels":[],"label_agreement":null},{"id":"W7108439879","doi":"10.1182/blood-2025-3386","title":"Differences in outcomes with intensive chemotherapy in AML patients according to mutational status – recent real-world results","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cytarabine; Gemtuzumab ozogamicin; Midostaurin; Adverse effect; Chemotherapy; Induction chemotherapy; Retrospective cohort study; Hematopoietic stem cell transplantation","score_opus":0.02230570188941118,"score_gpt":0.32235179589054935,"score_spread":0.3000460940011382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108439879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873373,0.000018795366,0.0000089661535,0.006786808,0.000055935605,0.00077807636,0.000026280495,0.000025623242,0.0049622003],"genre_scores_gemma":[0.99545753,0.00015941383,0.0009974936,0.0020819916,0.000019714107,0.00007577444,0.00007597753,0.000015503578,0.0011165964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846643,0.000057490834,0.00035574622,0.00035362813,0.00037148094,0.00039522647],"domain_scores_gemma":[0.99895275,0.00028532778,0.000057835678,0.00022339761,0.00036767605,0.000112994414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017550787,0.00015259393,0.0003721904,0.0007085173,0.000028262524,0.000020660746,0.000114074595,0.00005116904,0.000020252735],"category_scores_gemma":[0.00085547485,0.00011172271,0.000025669155,0.0011501191,0.000043757595,0.00005732526,0.00006797341,0.0002961956,0.000010033265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018201793,0.00045782077,0.9894195,0.000025740343,0.00007985116,0.00007159078,0.0010205403,0.0000033654842,0.00012352254,0.00006815325,0.0004173688,0.006492339],"study_design_scores_gemma":[0.017313981,0.00029889267,0.97894937,0.0003311634,0.000018433726,0.0000011547254,0.0012594,0.00002998078,0.0012349705,0.000055310138,0.00040214328,0.00010519235],"about_ca_topic_score_codex":0.0015221655,"about_ca_topic_score_gemma":0.002713543,"teacher_disagreement_score":0.015493801,"about_ca_system_score_codex":0.00044101544,"about_ca_system_score_gemma":0.00046528876,"threshold_uncertainty_score":0.45559198},"labels":[],"label_agreement":null},{"id":"W7108444735","doi":"10.1182/blood-2025-3390","title":"Comparable remission rates in therapy-related and myelodysplasia-related Acute Myeloid Leukemia (AML) versus de novo AML treated with azacitidine and venetoclax: A contemporary real-world study.","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Azacitidine; Venetoclax; Myeloid leukemia; Complete remission; Hematology; Myeloid; Leukemia; Retrospective cohort study; Cancer","score_opus":0.02262684375554143,"score_gpt":0.3085555877238291,"score_spread":0.28592874396828766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108444735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788453,0.0023796733,0.000002414036,0.00056933577,0.000041526233,0.0021737327,0.000016034528,0.00020658081,0.015765388],"genre_scores_gemma":[0.99044335,0.0019615365,0.00021981412,0.00010521729,0.000026665606,0.00013330279,0.00011312,0.00007236323,0.006924604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971023,0.00032327662,0.00068185583,0.00082784845,0.0003831772,0.0006814971],"domain_scores_gemma":[0.9983351,0.00043481865,0.00016210038,0.00055123575,0.00016238088,0.00035436737],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006576413,0.0004977088,0.0009771915,0.0007714243,0.00021050307,0.000076950695,0.00019576054,0.00029344743,0.00005834348],"category_scores_gemma":[0.00008842788,0.0003895533,0.000057477446,0.0018296879,0.00031846057,0.0001890732,0.00015219675,0.00096737704,0.000007877014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023742104,0.0012662751,0.8790856,0.00019441365,0.0035359107,0.0044649746,0.0019438083,0.00004961525,0.081912845,0.00016099079,0.0012907273,0.0023527548],"study_design_scores_gemma":[0.22963507,0.007251128,0.66802365,0.0022811536,0.0014158518,0.0007027012,0.0021983227,0.004061097,0.08118467,0.00017428419,0.0020528978,0.0010191422],"about_ca_topic_score_codex":0.0026380515,"about_ca_topic_score_gemma":0.0004770134,"teacher_disagreement_score":0.21106191,"about_ca_system_score_codex":0.00089659495,"about_ca_system_score_gemma":0.0019571113,"threshold_uncertainty_score":0.99985564},"labels":[],"label_agreement":null},{"id":"W7108449712","doi":"10.1182/blood-2025-7823","title":"Factors influencing outcomes in therapy-related myeloid neoplasms following allogeneic hematopoietic stem cell transplantation","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Cumulative incidence; Myeloid leukemia; Hematopoietic stem cell transplantation; Transplantation; Myelodysplastic syndromes; Chromosome abnormality; Myeloid; Malignancy; Cytogenetics; Leukemia","score_opus":0.017828690572918377,"score_gpt":0.2770430339639212,"score_spread":0.25921434339100285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108449712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960239,0.00077792635,0.000041548956,0.00031052853,0.00013643438,0.0006900574,0.0000052410865,0.00012142834,0.0018929641],"genre_scores_gemma":[0.9976777,0.00022529931,0.0001282517,0.00025193434,0.000009894069,0.00004084832,0.000031402582,0.00003486773,0.0015997944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982342,0.00010179608,0.00049086707,0.00036942342,0.00035754748,0.00044617627],"domain_scores_gemma":[0.99918604,0.00027761742,0.000064053,0.00032569194,0.0000401182,0.000106455256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028456052,0.00025671814,0.0005081564,0.0004698305,0.00008318013,0.000029468989,0.00018243324,0.00022152494,0.000035019497],"category_scores_gemma":[0.000024996569,0.0002029254,0.00021423792,0.0006728506,0.000033194647,0.00011269635,0.00003192728,0.00044254033,0.000026048436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067291425,0.00034779237,0.89309835,0.00022228848,0.0003053495,0.0002560608,0.0042632464,0.000038304366,0.10043716,0.00004228419,0.000013902008,0.00090798805],"study_design_scores_gemma":[0.014025796,0.00018015133,0.6578617,0.00035933315,0.00030920038,0.000024681358,0.002006773,0.000051916457,0.3247415,0.00008745692,0.00007571747,0.00027578956],"about_ca_topic_score_codex":0.0001441775,"about_ca_topic_score_gemma":0.000043840846,"teacher_disagreement_score":0.23523666,"about_ca_system_score_codex":0.00018566879,"about_ca_system_score_gemma":0.0003699901,"threshold_uncertainty_score":0.8275057},"labels":[],"label_agreement":null},{"id":"W7108454742","doi":"10.1182/blood-2025-3388","title":"Extramedullary disease in AML: A high-risk feature beyond ELN 2022 classification","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Bone marrow; Retrospective cohort study; Multivariate analysis; Myeloid leukemia; Leukemia; Cohort; Propensity score matching; Myeloid; Induction chemotherapy","score_opus":0.009285117213352853,"score_gpt":0.27869146000297274,"score_spread":0.2694063427896199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108454742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800541,0.004141657,0.00007763872,0.010809299,0.00011873484,0.00067829806,0.00005643741,0.00008790901,0.0039759576],"genre_scores_gemma":[0.98839885,0.0011260018,0.0009572044,0.0007803109,0.00017600082,0.00014181122,0.00020389193,0.00002582881,0.0081900805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859565,0.00011817079,0.0002036539,0.00040029877,0.0003478893,0.0003343355],"domain_scores_gemma":[0.9989109,0.00012449529,0.000052702722,0.00060896744,0.00008397666,0.00021894168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028846925,0.00014921067,0.0002340385,0.00035199046,0.0000729147,0.00002628276,0.00018013085,0.0001652838,0.0001209791],"category_scores_gemma":[0.0005288905,0.00013487779,0.000076300494,0.00083335006,0.000081504884,0.00006882641,0.000092604874,0.0008026318,0.00006870684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009905761,0.0022171112,0.88305455,0.00041810292,0.00026803015,0.0009799558,0.00021662663,0.0000084304365,0.01510781,0.004822897,0.06570143,0.02621448],"study_design_scores_gemma":[0.0065410202,0.000101927166,0.97524124,0.0001608509,0.00034282336,0.000011171174,0.00013734707,0.0008084055,0.0019431175,0.0014268548,0.013138174,0.00014704885],"about_ca_topic_score_codex":0.00017423935,"about_ca_topic_score_gemma":0.000057967532,"teacher_disagreement_score":0.09218671,"about_ca_system_score_codex":0.00023616673,"about_ca_system_score_gemma":0.00074611185,"threshold_uncertainty_score":0.5500156},"labels":[],"label_agreement":null},{"id":"W7108456815","doi":"10.1182/blood-2025-3443","title":"ALIDHE: An ongoing open-label phase 3b study investigating ivosidenib with azacitidine in clinical practice in adult patients with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (IC)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"FPInnovations; University of Toronto; Western University","funders":"","keywords":"Azacitidine; Phases of clinical research; Adverse effect; Clinical endpoint; Myeloid leukemia; Clinical trial; Refractory (planetary science); Isocitrate dehydrogenase; Clinical Practice","score_opus":0.04281600314779762,"score_gpt":0.3916544753235229,"score_spread":0.3488384721757253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108456815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886583,0.000058413694,0.00020451042,0.0019766276,0.000086205604,0.008703439,0.000052091527,0.000097206546,0.00016319395],"genre_scores_gemma":[0.97295386,0.00015919309,0.019010484,0.0058656572,0.00016803834,0.0013265144,0.00028099454,0.00013906944,0.00009620926],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99495286,0.0005656177,0.0014957482,0.0013391962,0.0007500971,0.00089645357],"domain_scores_gemma":[0.99498963,0.0010293057,0.0006114135,0.00084163423,0.0020848494,0.00044314223],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018675153,0.0005815954,0.0012040836,0.0006386392,0.00021839519,0.00021675776,0.00054792786,0.0003189692,0.000007779951],"category_scores_gemma":[0.005194093,0.00047049273,0.000067097135,0.0021431558,0.00027499528,0.0012987809,0.00023492116,0.0014933104,0.000004873804],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05973951,0.06531058,0.73544955,0.00057365827,0.005117289,0.0047150836,0.018749155,0.0001976889,0.0755686,0.00018494095,0.001218814,0.033175144],"study_design_scores_gemma":[0.7612785,0.03876308,0.05241652,0.0034848016,0.002503422,0.0002719837,0.028660284,0.0055577387,0.10511132,0.00018454049,0.00025373622,0.0015140533],"about_ca_topic_score_codex":0.0026575502,"about_ca_topic_score_gemma":0.0023975763,"teacher_disagreement_score":0.701539,"about_ca_system_score_codex":0.000896292,"about_ca_system_score_gemma":0.0032030363,"threshold_uncertainty_score":0.9997747},"labels":[],"label_agreement":null},{"id":"W7108467868","doi":"10.1182/blood-2025-3439","title":"Analysis of hematologic improvement (HI) by time to response in Relapsed/Refractory Acute Myeloid Leukemia (AML) patients treated with olutasidenib","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Tolerability; Hemoglobin; Platelet; Cohort; Refractory (planetary science); Myeloid; Adverse effect","score_opus":0.006107269524519951,"score_gpt":0.25704375083346315,"score_spread":0.2509364813089432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108467868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700344,0.00012440087,0.000017357987,0.0004620105,0.00000992987,0.0010990242,0.00015051191,0.00006642797,0.001066888],"genre_scores_gemma":[0.991024,0.000027317301,0.00031786604,0.00051894743,0.0000071222144,0.00013912338,0.00023145329,0.000032836768,0.0077013355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973518,0.0002158421,0.00066190644,0.0006275585,0.0006021931,0.00054068794],"domain_scores_gemma":[0.9981856,0.0003207891,0.00017114071,0.0008135274,0.00028230977,0.00022664691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005362603,0.00030404015,0.0009921163,0.0015804749,0.00005280394,0.000015654741,0.00029394383,0.00021835096,0.00023644726],"category_scores_gemma":[0.00041745958,0.00023778094,0.00016353237,0.003598591,0.00010389052,0.00006403535,0.00017992046,0.0003954733,0.00009695502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02598311,0.0033052452,0.50466424,0.00015252508,0.008805988,0.00053023844,0.00041450848,0.00010416095,0.4455905,0.00000628757,0.008264997,0.0021781765],"study_design_scores_gemma":[0.027772658,0.0075754994,0.7068703,0.00037743233,0.007486381,0.000014484172,0.00013215044,0.000588896,0.24730912,0.000006256289,0.0013842663,0.0004825243],"about_ca_topic_score_codex":0.0003843171,"about_ca_topic_score_gemma":0.0000402763,"teacher_disagreement_score":0.20220608,"about_ca_system_score_codex":0.00115066,"about_ca_system_score_gemma":0.0007944779,"threshold_uncertainty_score":0.9696425},"labels":[],"label_agreement":null},{"id":"W7108469148","doi":"10.1182/blood-2025-3425","title":"Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) Acute Myeloid Leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University","funders":"","keywords":"Daunorubicin; NPM1; Myeloid leukemia; Cohort; Phases of clinical research; Chemotherapy regimen; Chemotherapy; Leukemia","score_opus":0.014366117399019501,"score_gpt":0.29485977790026263,"score_spread":0.28049366050124314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108469148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99528617,0.000082319006,0.0001284693,0.00038755173,0.000047621146,0.0038415552,0.000014315434,0.000034920275,0.00017708707],"genre_scores_gemma":[0.9969862,0.00011848545,0.0014599715,0.00037714778,0.00003069675,0.00051178253,0.000068901725,0.000057662197,0.00038915113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972806,0.00019441453,0.00078267406,0.00063313445,0.0006068301,0.0005023308],"domain_scores_gemma":[0.9982581,0.00021328621,0.00020180258,0.0006060534,0.00059909455,0.00012166068],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003024614,0.00034133054,0.0007542936,0.0011415179,0.00005917081,0.000038495982,0.00026406636,0.00013729958,0.000032324348],"category_scores_gemma":[0.00028398525,0.00026813964,0.000039612314,0.0021046414,0.000110519315,0.00022137807,0.000085242566,0.00063261884,0.0000043613163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01265032,0.024534054,0.92859274,0.0002734012,0.0006628176,0.0013747643,0.012393352,0.00028193867,0.009692364,0.000032460455,0.00030791128,0.009203845],"study_design_scores_gemma":[0.27986634,0.0139496755,0.6807338,0.001637477,0.00031220412,0.000018386856,0.0040892,0.0012231477,0.017718477,0.00002616409,0.00004174571,0.00038335906],"about_ca_topic_score_codex":0.0018802378,"about_ca_topic_score_gemma":0.0032077364,"teacher_disagreement_score":0.26721603,"about_ca_system_score_codex":0.0011275816,"about_ca_system_score_gemma":0.0013294359,"threshold_uncertainty_score":0.99997705},"labels":[],"label_agreement":null},{"id":"W7108505175","doi":"10.1182/blood-2025-490","title":"Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Cytopenia; Myelodysplastic syndromes; Neutropenia; Post-hoc analysis; Anemia; Adverse effect; Exact test; Placebo; Univariate analysis","score_opus":0.020154153455477095,"score_gpt":0.31450893329800067,"score_spread":0.29435477984252356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108505175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996777,0.00019086909,0.00033944007,0.00055928587,0.000087542976,0.0017782939,0.000154666,0.000035733283,0.000077141165],"genre_scores_gemma":[0.9980303,0.0002386581,0.00041421555,0.000043813194,0.0001016712,0.000078069905,0.00027031364,0.000030937477,0.00079200434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967436,0.00097359536,0.00065649976,0.0006824473,0.0005488212,0.00039501104],"domain_scores_gemma":[0.9959177,0.0028163816,0.0002304649,0.00068955036,0.00014067139,0.00020523285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009448912,0.00031642526,0.0009068696,0.0004298917,0.00016128233,0.00004583663,0.0001538478,0.00018758018,0.00010848814],"category_scores_gemma":[0.0007989484,0.00017661348,0.00017644593,0.0015478948,0.00021640406,0.00009993381,0.00010326387,0.0005030885,0.000023931008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13990472,0.0011510791,0.8495943,0.0000062053,0.0058772694,0.000120063516,0.00017536574,0.00003606588,0.0000062893387,0.0000019104334,0.000115179166,0.0030115757],"study_design_scores_gemma":[0.12378323,0.0083227055,0.8544476,0.00009003983,0.012034115,0.0000028221814,0.00013039299,0.00070233276,0.000045527497,0.000006571307,0.00027428326,0.00016040391],"about_ca_topic_score_codex":0.0013536427,"about_ca_topic_score_gemma":0.00083549786,"teacher_disagreement_score":0.01612149,"about_ca_system_score_codex":0.0002577375,"about_ca_system_score_gemma":0.00061682746,"threshold_uncertainty_score":0.7202089},"labels":[],"label_agreement":null},{"id":"W7108512155","doi":"10.1182/blood-2025-3431","title":"Trial in progress: A phase I study evaluating the safety of cirtuvivint (CIRT) as monotherapy and in combination with ASTX727 in patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of New Brunswick","funders":"","keywords":"Venetoclax; Decitabine; Myelodysplastic syndromes; Combination therapy; Salvage therapy; Refractory (planetary science); Clinical trial; Cancer; Phases of clinical research","score_opus":0.014787416141106954,"score_gpt":0.3297274307720428,"score_spread":0.31494001463093585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108512155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937198,0.0002150412,0.000016555672,0.00029875268,0.00002248726,0.005622362,0.0000075873822,0.000015846192,0.00008152534],"genre_scores_gemma":[0.9991283,0.00006276564,0.00027284192,0.000043111973,0.000011112133,0.0003852183,0.0000164697,0.00002677775,0.000053423286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976621,0.00036266568,0.00056172954,0.0004554819,0.0006335721,0.00032443576],"domain_scores_gemma":[0.9988725,0.00043122453,0.00016686748,0.00031565328,0.00014738295,0.00006637478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011529558,0.00023876003,0.0005907186,0.00054937595,0.00006310746,0.000035037447,0.00014070475,0.00009073887,0.000008125293],"category_scores_gemma":[0.00027213362,0.00015199886,0.000019808453,0.000990329,0.00022650427,0.00013734424,0.000098149285,0.00048135375,5.327847e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14583774,0.006444377,0.8244336,0.00014121502,0.00047200584,0.0001340069,0.003401495,0.000031819156,0.00037084005,0.00005829452,0.000003364549,0.018671216],"study_design_scores_gemma":[0.3705671,0.020803973,0.60522056,0.00066517445,0.00021603995,0.000016261643,0.00095940696,0.0011555813,0.00022422947,0.000045904362,0.0000025377249,0.00012321015],"about_ca_topic_score_codex":0.00027741268,"about_ca_topic_score_gemma":0.00037511863,"teacher_disagreement_score":0.22472937,"about_ca_system_score_codex":0.00035544924,"about_ca_system_score_gemma":0.0008818141,"threshold_uncertainty_score":0.61983335},"labels":[],"label_agreement":null},{"id":"W7108708946","doi":"10.1182/blood-2025-4776","title":"Prognostic impact of molecular genetic and cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with azacitidine and venetoclax: A real-world cohort study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"NPM1; Azacitidine; Venetoclax; IDH1; Myeloid leukemia; IDH2; Proportional hazards model; Cohort; CEBPA; Survival analysis","score_opus":0.009547124342296088,"score_gpt":0.29582519012458325,"score_spread":0.28627806578228715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108708946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99510574,0.00061225396,0.000044088232,0.00006024413,0.0000060136276,0.0035406356,0.000028277276,0.000038737264,0.0005640097],"genre_scores_gemma":[0.99782115,0.0004837876,0.00087764015,0.00003697524,0.000019071724,0.00042527032,0.000048328282,0.000039190236,0.0002486087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820805,0.00014866378,0.00042254696,0.0005267353,0.000304117,0.00038988944],"domain_scores_gemma":[0.9989024,0.00019253422,0.00008254165,0.0004658096,0.00015692027,0.00019983518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019139542,0.00028542956,0.0006230746,0.00062446186,0.00006194203,0.000039321374,0.00010519884,0.000081763435,0.000014753938],"category_scores_gemma":[0.00011516524,0.00022555559,0.000054197888,0.0011248079,0.00017437308,0.000048398746,0.00010075752,0.00026398903,0.0000013440621],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044751537,0.0004985363,0.95652735,0.00009280558,0.0011966826,0.0014261206,0.00022693646,0.00020275751,0.038626015,0.00001032531,0.000024836232,0.00072009716],"study_design_scores_gemma":[0.013617098,0.0027104367,0.9706697,0.00027044053,0.0016002117,0.00012323596,0.000072656214,0.0009944425,0.009750658,0.000018293342,0.0000026384412,0.000170201],"about_ca_topic_score_codex":0.0038674045,"about_ca_topic_score_gemma":0.001213177,"teacher_disagreement_score":0.028875357,"about_ca_system_score_codex":0.00045829502,"about_ca_system_score_gemma":0.0013603591,"threshold_uncertainty_score":0.91978896},"labels":[],"label_agreement":null},{"id":"W7114810108","doi":"10.2196/77936","title":"The Role of Iron-Overloaded Macrophages in Mesenchymal Stem Cell Senescence and Anemia in Myelodysplastic Syndromes: Protocol for an In Vitro Study","year":2025,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Mesenchymal stem cell; Senescence; In vitro; Myelodysplastic syndromes; Anemia; Cell culture","score_opus":0.09778394229423112,"score_gpt":0.4893185835052621,"score_spread":0.391534641211031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7114810108","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22151868,0.00000868456,0.0000038324347,0.00016042663,0.0000022288386,0.7777297,0.0000105542995,0.000017762333,0.0005481602],"genre_scores_gemma":[0.32338622,8.2220333e-7,0.00012060773,0.0000077593995,0.000017806413,0.67582256,0.0000022997963,0.0000279361,0.0006139735],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99442697,0.0014540027,0.000902068,0.0008229836,0.0011565393,0.0012374372],"domain_scores_gemma":[0.99669695,0.0017543792,0.000112438654,0.00087288173,0.00034628468,0.00021704321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005096066,0.0002920322,0.000650852,0.0011578451,0.00017282827,0.00012523937,0.00073088286,0.00022571399,0.0000130667695],"category_scores_gemma":[0.0004542446,0.00021184824,0.000052044667,0.002042497,0.00047486948,0.00023352368,0.0005560406,0.0015361756,0.000005796016],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0428287,0.0077042524,0.21503662,0.010765898,0.000028956634,0.0005716067,0.0038221925,0.000022469221,0.67584664,0.00016866993,0.000693678,0.042510353],"study_design_scores_gemma":[0.09532347,0.02373649,0.31446037,0.012158773,0.000012307809,0.00006153678,0.038112897,0.013583709,0.48771265,0.001370552,0.01261474,0.00085250335],"about_ca_topic_score_codex":0.00038340894,"about_ca_topic_score_gemma":0.00040685185,"teacher_disagreement_score":0.18813394,"about_ca_system_score_codex":0.00081810134,"about_ca_system_score_gemma":0.0017720226,"threshold_uncertainty_score":0.8638921},"labels":[],"label_agreement":null},{"id":"W7117151876","doi":"10.1016/j.cjca.2025.12.032","title":"Inquiry Regarding the Impact of Anemia Adjustment on Cardiovascular Disease Risk in Patients With Myelodysplastic Syndrome","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Anemia; Myelodysplastic syndromes; Disease; Hematopoietic stem cell transplantation; Stem cell; Haematopoiesis; Hematological disorders","score_opus":0.0122389677837328,"score_gpt":0.26078465657974526,"score_spread":0.24854568879601247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117151876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99618936,0.0017704002,0.0002968048,0.00020976264,0.0002863726,0.00040676113,0.00004267112,0.0000024021601,0.0007954964],"genre_scores_gemma":[0.99954504,0.000113318965,0.000022756165,0.000059370264,0.00019383588,0.00000728151,0.0000088079305,0.000017245184,0.000032334094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821067,0.0004294385,0.0003968136,0.00019376366,0.0003273512,0.00044196093],"domain_scores_gemma":[0.9981097,0.00023747247,0.00015257906,0.0005577306,0.00036019602,0.00058234355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082926976,0.00017295814,0.0008245057,0.0008225735,0.000069239606,0.0000085533975,0.0002468516,0.000106600215,0.000011418251],"category_scores_gemma":[0.0009240682,0.0000993328,0.0005281005,0.0004664149,0.00032673046,0.00004985154,0.000023707657,0.00076004915,0.000003355978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015015502,0.000009175539,0.886683,0.00005092644,0.0027085447,0.0013544285,0.00011676636,0.100379586,0.0000029577905,0.000027252621,0.003909021,0.0032568227],"study_design_scores_gemma":[0.0041413745,0.0012322832,0.9922042,0.00035528623,0.00065628096,0.00019675508,0.00010528344,0.00005216181,0.0000037077778,0.000040640673,0.0009326834,0.00007934758],"about_ca_topic_score_codex":0.0020017012,"about_ca_topic_score_gemma":0.00011829214,"teacher_disagreement_score":0.10552123,"about_ca_system_score_codex":0.0018041536,"about_ca_system_score_gemma":0.0049972725,"threshold_uncertainty_score":0.88649464},"labels":[],"label_agreement":null},{"id":"W7117163024","doi":"10.1159/000550197","title":"A Case Series of SGLT2i Improving Hemoglobin in Adults with Myelodysplastic Syndrome","year":2025,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Public Health Ontario; University of Toronto","funders":"","keywords":"Hemoglobin; Hemoglobin s; Series (stratigraphy); Red blood cell; Blood transfusion; Myelodysplastic syndromes; Hemoglobin variants","score_opus":0.011448933332664352,"score_gpt":0.2584476082515503,"score_spread":0.2469986749188859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117163024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944032,0.0001593596,0.000072685194,0.001584648,0.000038175236,0.0007535312,0.000010426911,0.00007590069,0.002902112],"genre_scores_gemma":[0.9964614,0.00003118709,0.0025763314,0.00014838163,0.0000065465188,0.000088660054,0.000010684162,0.000016857872,0.00065997965],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99842346,0.00007530595,0.00042142032,0.00040011026,0.0002362717,0.00044344328],"domain_scores_gemma":[0.9988525,0.00031427984,0.00011223305,0.00047773597,0.00013764804,0.00010561373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022279179,0.00021320928,0.0007179504,0.00036662232,0.000064572276,0.000013778275,0.00018235047,0.00017847288,0.00009578479],"category_scores_gemma":[0.00070350815,0.00014725636,0.00005746278,0.00086167903,0.00027661512,0.00013628631,0.00019177285,0.00042469855,0.00001379263],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02384315,0.0013230043,0.14842163,0.013776158,0.00060973864,0.7791582,0.0023357368,0.00002570591,0.013194101,0.0065393457,0.0030677132,0.007705524],"study_design_scores_gemma":[0.0176115,0.0059743533,0.07113884,0.0067472802,0.00036364965,0.8656411,0.0070695337,0.0027138412,0.02066464,0.00059116905,0.0006481402,0.000835961],"about_ca_topic_score_codex":0.0003392731,"about_ca_topic_score_gemma":0.00027712376,"teacher_disagreement_score":0.0864829,"about_ca_system_score_codex":0.00018158494,"about_ca_system_score_gemma":0.0004670026,"threshold_uncertainty_score":0.600494},"labels":[],"label_agreement":null},{"id":"W7117237080","doi":"10.1093/ajcp/aqaf136","title":"Review of flow cytometry findings and associated scoring approaches for identifying myelodysplastic syndrome and the future role of machine learning in improving the diagnostic algorithm","year":2025,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Flow cytometry; Identification (biology); Cytometry; Statistical classification; Diagnostic accuracy","score_opus":0.03018088576127642,"score_gpt":0.3579610130708449,"score_spread":0.32778012730956846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117237080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.937073,0.05475333,0.0043579824,0.0031589535,0.00014115767,0.000487007,0.000008613726,0.000004472804,0.000015462496],"genre_scores_gemma":[0.96507996,0.029799312,0.004476927,0.0005088202,0.00008849773,0.000013919106,0.0000031328132,0.000014549762,0.0000149025345],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969587,0.00097591005,0.0014087528,0.00020072862,0.00021965575,0.00023628754],"domain_scores_gemma":[0.9825186,0.015905827,0.0011164412,0.00016486224,0.00021598807,0.00007825855],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008825254,0.00013007502,0.0014383105,0.00025209345,0.0000727724,0.000009513558,0.00021159738,0.00009490765,0.0000029777132],"category_scores_gemma":[0.033517852,0.0000728335,0.00020837421,0.00063053146,0.0011738663,0.00005514015,0.00018084337,0.0013392161,1.3896755e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008285042,0.00013456038,0.22185563,0.0021154059,0.00039283073,0.00015211689,0.00043662696,0.000022607122,0.00033126865,0.0000749486,0.000029004479,0.7736265],"study_design_scores_gemma":[0.012512107,0.0044304854,0.9231732,0.014340969,0.0015249148,0.0023634546,0.0045465506,0.03584597,0.00009116088,0.0007698168,0.0002003932,0.00020096083],"about_ca_topic_score_codex":0.000026551244,"about_ca_topic_score_gemma":0.0000052131854,"teacher_disagreement_score":0.7734255,"about_ca_system_score_codex":0.00005006523,"about_ca_system_score_gemma":0.0002598884,"threshold_uncertainty_score":0.97462326},"labels":[],"label_agreement":null},{"id":"W7117246573","doi":"10.14740/jmc5197","title":"Acute Myeloid Leukemia With a Non-Canonical <i>FLT3</i> V491L Mutation: A Case Report With <i>Ex Vivo</i> FLT3 Inhibitors Sensitivity Testing","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Midostaurin; Chemotherapy; Bone marrow; Leukapheresis; Azacitidine; Mutation","score_opus":0.019296541421323435,"score_gpt":0.3166323958626007,"score_spread":0.2973358544412773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117246573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797165,0.000275144,0.0040079025,0.012391727,0.00027223237,0.0004984837,0.000015897775,0.00006295147,0.0027591763],"genre_scores_gemma":[0.9868548,0.00006028243,0.008145161,0.0026475757,0.0013311998,0.000015666486,0.000011251142,0.000061022663,0.0008730317],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9936801,0.00027998173,0.0013805815,0.0005272202,0.0034092462,0.0007228298],"domain_scores_gemma":[0.9929245,0.0027851083,0.00076432584,0.0005507173,0.0016649271,0.0013104212],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0033789105,0.00043269014,0.0011806135,0.00047178715,0.00026273678,0.0000968303,0.00022871199,0.0003869416,0.00013827448],"category_scores_gemma":[0.007527561,0.00027349504,0.00023000213,0.0015125187,0.000750798,0.0003194915,0.00020405665,0.0025743733,0.000010432168],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027188868,0.00024719574,0.0056171007,0.00023613483,0.0006658508,0.9584145,0.00015241843,0.00006611889,0.0018549118,0.0000099211975,0.02328281,0.006734135],"study_design_scores_gemma":[0.007789539,0.0028705506,0.0012918077,0.0029081807,0.0010478343,0.9693836,0.0008789882,0.0022444637,0.008034833,0.0000098092,0.003260101,0.00028027286],"about_ca_topic_score_codex":0.0008654939,"about_ca_topic_score_gemma":0.0005390144,"teacher_disagreement_score":0.020022709,"about_ca_system_score_codex":0.0012950681,"about_ca_system_score_gemma":0.017080376,"threshold_uncertainty_score":0.99997175},"labels":[],"label_agreement":null},{"id":"W7117430678","doi":"10.1016/j.jtct.2025.12.990","title":"Impact of Extramedullary Disease at Diagnosis on Outcomes Post Allogeneic Hematopoietic Cell Transplant in Children and Young Adults With Acute Myeloid Leukemia: A CIBMTR Report","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; Health Resources and Services Administration; Office of Naval Research; National Heart, Lung, and Blood Institute; U.S. Public Health Service; National Cancer Institute; Medical College of Wisconsin","keywords":"Young adult; Myeloid leukemia; Incidence (geometry); Cohort; Univariate analysis; Bone marrow; Hematopoietic stem cell transplantation; Hematopoietic cell","score_opus":0.006463693318586629,"score_gpt":0.26137805948538856,"score_spread":0.2549143661668019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117430678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956294,0.0021753141,0.00014238537,0.00044808062,0.000020641453,0.0011718442,0.00023383975,0.000032952925,0.00014558362],"genre_scores_gemma":[0.96721613,0.031216849,0.00009400869,0.00022445746,0.000009973863,0.00009769772,0.00086938357,0.00003244338,0.00023903619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837565,0.00008598397,0.00041216478,0.00048188993,0.0003360043,0.00030827726],"domain_scores_gemma":[0.9991988,0.000103146194,0.00009520244,0.00031121075,0.00006231619,0.00022932266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017194143,0.0003109161,0.0004909984,0.0003199731,0.00007846936,0.000017587745,0.00008921783,0.00013179946,0.00004853355],"category_scores_gemma":[0.0000044270273,0.00021711411,0.00013788331,0.0002498809,0.00014825891,0.00008188503,0.000008148617,0.000262106,0.0000018444218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012220745,0.00031535415,0.9589287,0.00035985935,0.00047748702,0.0024513006,0.0019788402,0.000021090216,0.022063639,0.000023972589,0.000015304347,0.0011437205],"study_design_scores_gemma":[0.0110872155,0.0007823733,0.9540129,0.00045553458,0.00033078747,0.00076462555,0.00005989842,0.000048955473,0.032231092,0.000012968898,0.000005426071,0.00020825003],"about_ca_topic_score_codex":0.0007605809,"about_ca_topic_score_gemma":0.00008166296,"teacher_disagreement_score":0.029041534,"about_ca_system_score_codex":0.00018640923,"about_ca_system_score_gemma":0.000361887,"threshold_uncertainty_score":0.8853656},"labels":[],"label_agreement":null},{"id":"W7117670145","doi":"10.2196/75678","title":"Random Survival Forest Versus Elastic-Net Regularized Cox Regression for Survival Prediction in Acute Myeloid Leukemia at Distinct Treatment Time Points: Model Performance Comparison Study","year":2025,"lang":"en","type":"article","venue":"JMIR Bioinformatics and Biotechnology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Censoring (clinical trials); Proportional hazards model; Random forest; Survival analysis; Hazard ratio; Clinical trial; Data set; Cross-validation; Concordance","score_opus":0.02155774782665201,"score_gpt":0.31102217705290364,"score_spread":0.28946442922625165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117670145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888824,0.000056494944,0.004269089,0.0014675516,0.00025994005,0.004046117,0.00016755797,0.00020974332,0.00064110575],"genre_scores_gemma":[0.98972565,0.0003806001,0.0057901386,0.000034353456,0.000044230517,0.00058577146,0.0006477394,0.000034553068,0.0027569828],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99758935,0.000065147244,0.00094457937,0.00042815247,0.000350847,0.00062193524],"domain_scores_gemma":[0.9985286,0.0003535377,0.0002470688,0.00061527203,0.00012858796,0.00012693774],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061713485,0.00042200665,0.0010479743,0.0006666041,0.0002991635,0.000043535212,0.00023962713,0.0006750348,0.000012379775],"category_scores_gemma":[0.00017891022,0.0003029571,0.00011734252,0.0005399918,0.00032064356,0.00015296438,0.00046992462,0.00047999428,0.000024830104],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35257053,0.006101553,0.31856725,0.0035656139,0.0053070565,0.00015976108,0.0063827857,0.003164713,0.026481172,0.002379717,0.014571587,0.26074824],"study_design_scores_gemma":[0.054552134,0.004669889,0.014618523,0.00019664472,0.00029769322,0.000019695184,0.0007068505,0.921463,0.0018179105,0.000052145868,0.0013651318,0.00024035954],"about_ca_topic_score_codex":0.00004973801,"about_ca_topic_score_gemma":0.00025432458,"teacher_disagreement_score":0.9182983,"about_ca_system_score_codex":0.0017465058,"about_ca_system_score_gemma":0.00041248262,"threshold_uncertainty_score":0.99994224},"labels":[],"label_agreement":null},{"id":"W7117713131","doi":"10.1016/j.jtct.2025.12.996","title":"Defining the Limits of Pre-Transplant Risk Prediction in AML: Evidence From Machine Learning and Regression Models","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"National Institute of Allergy and Infectious Diseases; Health Resources and Services Administration; Office of Naval Research; National Heart, Lung, and Blood Institute; U.S. Public Health Service; National Cancer Institute; Medical College of Wisconsin","keywords":"Regression; Outcome (game theory); Predictive modelling; Regression analysis; Proportional hazards model; Risk assessment","score_opus":0.022937788611117654,"score_gpt":0.3006910868030822,"score_spread":0.27775329819196454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117713131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9560421,0.02422171,0.018636342,0.00041881876,0.000027142672,0.00035315775,0.000046614256,0.000027126505,0.00022695144],"genre_scores_gemma":[0.8862451,0.11300181,0.0003942467,0.000061077524,0.000010400797,0.000015627918,0.00012787302,0.000009278737,0.00013464567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989425,0.00023701166,0.00027657102,0.00022157285,0.0001958062,0.00012651717],"domain_scores_gemma":[0.9993508,0.00039181535,0.000071924616,0.00011005074,0.000034410485,0.000041038515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004882933,0.00011525104,0.0001927436,0.0001269893,0.00010874601,0.000015071397,0.0000558983,0.000091002454,0.000022200322],"category_scores_gemma":[0.000015291524,0.00007469363,0.00003179179,0.0001764019,0.00007972595,0.00011341385,0.0000051524016,0.00038296604,6.3263235e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010150206,0.0001055209,0.60847074,0.00044014593,0.00018567726,0.00005872572,0.020550484,0.0012881351,0.27832928,0.0006636245,0.000022736558,0.0797347],"study_design_scores_gemma":[0.010326993,0.00061943854,0.34625947,0.004370925,0.00034596265,0.00004047678,0.00074265077,0.303246,0.33205235,0.0014710572,0.00030450252,0.00022017883],"about_ca_topic_score_codex":0.000985984,"about_ca_topic_score_gemma":0.00008818464,"teacher_disagreement_score":0.30195785,"about_ca_system_score_codex":0.000022239441,"about_ca_system_score_gemma":0.000058011276,"threshold_uncertainty_score":0.30459177},"labels":[],"label_agreement":null},{"id":"W7127005839","doi":"","title":"Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study","year":2010,"lang":"en","type":"article","venue":"Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Refractory (planetary science); Myeloid leukaemia; Salvage therapy; Mitoxantrone; Gemtuzumab ozogamicin; Phases of clinical research; Chemotherapy","score_opus":0.014158484237782482,"score_gpt":0.2615461679053376,"score_spread":0.2473876836675551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7127005839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989209,0.000034596957,0.000088245084,0.00017886226,0.000102959326,0.0032959648,0.0017053479,0.000109852124,0.0052751903],"genre_scores_gemma":[0.9695969,0.00006695793,0.0007202089,0.000021414497,0.000107290776,0.000003891794,0.0003648476,0.0000871718,0.029031323],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960739,0.000103843726,0.0009745729,0.0011728279,0.0009584928,0.0007163603],"domain_scores_gemma":[0.9954413,0.0003847971,0.0014274565,0.0013915844,0.0008239345,0.0005309144],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002753422,0.00073730684,0.0015564607,0.0010728497,0.00046228623,0.000029379866,0.0010032862,0.00058028614,0.000045537716],"category_scores_gemma":[0.0000614573,0.0005901175,0.00041582042,0.00093607215,0.0013036843,0.0014727234,0.0005278883,0.001165166,0.0000036044717],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4897262,0.020914316,0.14859726,0.0016245904,0.02262796,0.006211355,0.04506863,0.00010393453,0.24508025,0.00016657058,0.0070438003,0.012835135],"study_design_scores_gemma":[0.33387646,0.28246227,0.07039534,0.0026350473,0.012413413,0.0041749016,0.042220734,0.00043390872,0.19985053,0.00001333602,0.0483196,0.003204476],"about_ca_topic_score_codex":0.00034108682,"about_ca_topic_score_gemma":0.00023536666,"teacher_disagreement_score":0.26154795,"about_ca_system_score_codex":0.0011062686,"about_ca_system_score_gemma":0.0012898365,"threshold_uncertainty_score":0.999655},"labels":[],"label_agreement":null},{"id":"W7132928266","doi":"","title":"Resistance Mechanisms to Mutant IDH Inhibitors in Acute Myeloid Leukemia","year":2025,"lang":"","type":"dissertation","venue":"TSpace","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Myeloid leukemia; Isocitrate dehydrogenase; Decitabine; Azacitidine; Mutant; Transcriptome; Acquired resistance; Myeloid","score_opus":0.015873708093810304,"score_gpt":0.34059182591292697,"score_spread":0.3247181178191167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132928266","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.840442,0.005993357,0.0033385507,0.01646443,0.006905737,0.012518206,0.00026489422,0.00050213456,0.11357071],"genre_scores_gemma":[0.3542483,0.004320946,0.0066528954,0.0019996774,0.00084753294,0.0011761431,0.0014304438,0.00043928108,0.6288848],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9886898,0.00056224613,0.002168337,0.0029842535,0.0027307926,0.0028645827],"domain_scores_gemma":[0.99380314,0.0006790057,0.00066755473,0.0024770708,0.0010241327,0.0013491077],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.001993387,0.0018162682,0.0027653722,0.0033041788,0.00045377528,0.00023186246,0.0016313051,0.0021638707,0.0011970843],"category_scores_gemma":[0.0020333559,0.0019504541,0.0005777991,0.005933108,0.00015391337,0.00025913882,0.0006080718,0.0047022738,0.0016745866],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.018858124,0.00047944835,0.00017560534,0.005596783,0.0016724933,0.007270751,0.04931762,0.00025347792,0.8276656,0.009727836,0.06276949,0.016212737],"study_design_scores_gemma":[0.013762784,0.0017266847,0.0042145303,0.027275534,0.0019989463,0.00007554717,0.07381669,0.0015094691,0.7922814,0.0024266108,0.07676771,0.004144096],"about_ca_topic_score_codex":0.0030841932,"about_ca_topic_score_gemma":0.009560556,"teacher_disagreement_score":0.5153141,"about_ca_system_score_codex":0.01516436,"about_ca_system_score_gemma":0.013488473,"threshold_uncertainty_score":0.999716},"labels":[],"label_agreement":null},{"id":"W7139921962","doi":"10.1053/j.seminhematol.2026.03.009","title":"Role of MRD testing in acute myeloid leukemias. What is the status and how to get there?","year":2025,"lang":"en","type":"article","venue":"Seminars in Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institutes of Health","keywords":"Hematology; Myeloid; Myeloid leukemia; MEDLINE; Clinical trial","score_opus":0.014233997498073733,"score_gpt":0.30098124163059625,"score_spread":0.2867472441325225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7139921962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96671385,0.013909199,0.0000138556725,0.016426833,0.00007306476,0.0007033903,0.0000062473846,0.00002090697,0.0021326665],"genre_scores_gemma":[0.9884152,0.0058771255,0.002747225,0.0016670782,0.000016919725,0.00010748421,0.000005722731,0.00002490644,0.0011383571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818975,0.00014768605,0.0003393318,0.00041259808,0.00021004144,0.00070060685],"domain_scores_gemma":[0.99792105,0.0012507703,0.000081579616,0.00051739515,0.000109294444,0.000119901306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055481284,0.00019003435,0.00061130075,0.00047731336,0.00004620179,0.000029647501,0.00025639054,0.00022132792,0.000030914314],"category_scores_gemma":[0.0010823577,0.00014226937,0.0000411099,0.0010637585,0.00026916343,0.00011753763,0.00038973926,0.0005921957,0.000007753373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005330741,0.00010637703,0.8424232,0.0004262855,0.00013619514,0.0004234975,0.0066479174,0.000011956502,0.030251926,0.0019280647,0.0059542097,0.111157306],"study_design_scores_gemma":[0.013900165,0.0020477895,0.43542305,0.01401943,0.00039954684,0.0031765644,0.086748436,0.011357532,0.37287757,0.021443767,0.037350558,0.0012555931],"about_ca_topic_score_codex":0.0004188357,"about_ca_topic_score_gemma":0.00027032482,"teacher_disagreement_score":0.40700015,"about_ca_system_score_codex":0.0003852797,"about_ca_system_score_gemma":0.00052754086,"threshold_uncertainty_score":0.58015764},"labels":[],"label_agreement":null},{"id":"W763774166","doi":"10.1007/s00277-015-2443-7","title":"A rare case of acute leukemia of ambiguous lineage overexpressing C-MYC with monosomy 7 and Philadelphia chromosome","year":2015,"lang":"en","type":"letter","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Electricity Association; Children's Hospital of Eastern Ontario; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Hematology; Monosomy; Lineage (genetic); Internal medicine; Cancer research; Chromosome 7 (human); Chromosome; Medicine; Oncology; Genetics; Biology; Karyotype; Pathology; Gene","score_opus":0.06190959098888071,"score_gpt":0.3484919326592154,"score_spread":0.2865823416703347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W763774166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8094192,0.0063655716,0.000049999628,0.18062182,0.000101632315,0.0012187915,0.00090612133,0.00005838381,0.0012584318],"genre_scores_gemma":[0.93289655,0.0011518298,0.0027152246,0.06097041,0.0007554186,0.00006958116,0.00071685563,0.00023794321,0.00048619977],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966201,0.00021106255,0.0011294106,0.0006697243,0.0006482569,0.0007214241],"domain_scores_gemma":[0.996233,0.00030483247,0.0011221227,0.0011163718,0.000992334,0.00023133006],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0003060924,0.00054846104,0.0028180615,0.0006585041,0.000044764372,0.000009928057,0.00033534868,0.0013730662,0.000085387874],"category_scores_gemma":[0.00019817454,0.00043497057,0.00023421139,0.0003498906,0.0012096127,0.00012957677,0.00032000538,0.0018670943,0.0000044245658],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016741346,0.0001460067,0.0005812262,0.008413208,0.0024718074,0.099657044,0.00069072616,0.0000037996579,0.013540341,0.00005573245,0.87236035,0.0004056396],"study_design_scores_gemma":[0.013810828,0.0072212317,0.00026185854,0.008622332,0.0029261245,0.34148154,0.00057648413,0.00077624613,0.5692783,0.00048311683,0.05302728,0.0015346489],"about_ca_topic_score_codex":0.0008163318,"about_ca_topic_score_gemma":0.0000093293775,"teacher_disagreement_score":0.8193331,"about_ca_system_score_codex":0.00007653556,"about_ca_system_score_gemma":0.0016392544,"threshold_uncertainty_score":0.99992335},"labels":[],"label_agreement":null},{"id":"W764862773","doi":"10.1371/journal.pgen.1005262","title":"Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia","year":2015,"lang":"en","type":"article","venue":"PLoS Genetics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; National Institutes of Health; National Cancer Institute; American Lebanese Syrian Associated Charities; St. Jude Children's Research Hospital; Memorial Sloan-Kettering Cancer Center","keywords":"ETV6; Biology; Germline; Mutation; Germline mutation; Proband; Cancer research; Genetics; Mutant; Gene; Chromosomal translocation","score_opus":0.05912138084995459,"score_gpt":0.3317910000038291,"score_spread":0.2726696191538745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W764862773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99433166,0.00021574945,0.00062664633,0.001772217,0.00007816459,0.000905172,0.000057871566,0.0000894686,0.0019230484],"genre_scores_gemma":[0.98838574,0.00007492206,0.008655317,0.0010282024,0.0002267665,0.00004736096,0.00007590931,0.00005434571,0.0014514293],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99808264,0.00007557233,0.0003413681,0.00047613768,0.0005656293,0.00045866816],"domain_scores_gemma":[0.9977128,0.0001344486,0.000048231497,0.00062227563,0.00058662915,0.00089562085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026795393,0.00022425316,0.00043784603,0.0001458918,0.0000822507,0.000055884688,0.0001764381,0.00015024396,0.00015745527],"category_scores_gemma":[0.00053212425,0.00019981303,0.0000491568,0.00032395968,0.0002241762,0.00005561996,0.0002712823,0.00025955355,0.00047467143],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002027183,0.001016306,0.13474818,0.0005395123,0.0015337276,0.0008205109,0.008931425,0.0010123942,0.79752135,0.00061192125,0.04471926,0.006518219],"study_design_scores_gemma":[0.030498795,0.008640713,0.21583913,0.00045587987,0.003554818,0.001458298,0.002916029,0.17996645,0.5244469,0.0028997671,0.026940705,0.002382504],"about_ca_topic_score_codex":0.000031866326,"about_ca_topic_score_gemma":0.00007054934,"teacher_disagreement_score":0.27307445,"about_ca_system_score_codex":0.0009247345,"about_ca_system_score_gemma":0.0016246295,"threshold_uncertainty_score":0.8148139},"labels":[],"label_agreement":null},{"id":"W818882356","doi":"10.1007/s11899-015-0272-3","title":"Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?","year":2015,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Flow cytometry; Bone marrow; Hematology; International Prognostic Scoring System; Internal medicine; Biopsy; Pathology; Cytology; Oncology; Immunology","score_opus":0.15034249218147458,"score_gpt":0.4220731153203322,"score_spread":0.27173062313885765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W818882356","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004839427,0.9840918,0.00008063438,0.000025662848,0.0003140311,0.009893732,0.00012494011,0.000031762775,0.00059798465],"genre_scores_gemma":[0.02136781,0.97161466,0.00046195788,0.000020699203,0.0001054038,0.00434768,0.0018669477,0.00012184269,0.00009300842],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938928,0.00052498997,0.0017173591,0.00088912784,0.0023878096,0.0005879354],"domain_scores_gemma":[0.9948525,0.00046073474,0.0016679334,0.001351399,0.0015142903,0.00015318416],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0039057406,0.0006197383,0.0029001157,0.00058771984,0.000057618756,0.000026618029,0.00036894553,0.00042348844,0.00015753505],"category_scores_gemma":[0.0018005535,0.00031849399,0.00046919603,0.0012635551,0.00014310099,0.00008211525,0.000121273166,0.0006863027,0.00002300117],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012204348,0.0012962612,0.018369189,0.08632341,0.0004375117,0.00061665813,0.0003471429,0.0000028464303,8.549407e-8,0.000062960986,0.0064290226,0.8859929],"study_design_scores_gemma":[0.0048162974,0.0013102969,0.003310402,0.09504223,0.008648788,0.006424286,0.000167672,0.0005438673,0.000005398946,0.0017243504,0.87697476,0.0010316524],"about_ca_topic_score_codex":0.0000037072525,"about_ca_topic_score_gemma":0.0000018134451,"teacher_disagreement_score":0.88496125,"about_ca_system_score_codex":0.00068709994,"about_ca_system_score_gemma":0.0031436002,"threshold_uncertainty_score":0.9999267},"labels":[],"label_agreement":null},{"id":"W838111053","doi":"10.1182/blood.v124.21.10.10","title":"Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (&gt;30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; CancerCare Manitoba","funders":"","keywords":"Medicine; Internal medicine; Cytarabine; Azacitidine; Chemotherapy regimen; Randomization; Gastroenterology; Febrile neutropenia; Regimen; Chemotherapy; Neutropenia; Oncology; Randomized controlled trial","score_opus":0.011056432322382596,"score_gpt":0.24185382794184385,"score_spread":0.23079739561946125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W838111053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965802,0.00012780543,0.000082005405,0.00029212103,0.00016716369,0.0020572993,0.00023807147,0.000058172947,0.00039716673],"genre_scores_gemma":[0.9974646,0.00006028032,0.00045386798,0.00016326254,0.00021809459,0.00033195212,0.0009855501,0.00007587972,0.00024652376],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959406,0.00033543003,0.0005981872,0.0008268248,0.0015094832,0.0007894558],"domain_scores_gemma":[0.99701226,0.00064282,0.0004683934,0.0010037193,0.000591122,0.00028170322],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043902177,0.00048959756,0.0011757757,0.00077223993,0.00014066811,0.0000362435,0.00042851066,0.00027981863,0.00047638474],"category_scores_gemma":[0.00043820505,0.00031160054,0.0002534549,0.002278315,0.00046610853,0.00011144304,0.00019691318,0.00064732856,0.000029894354],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24758047,0.010679796,0.68840045,0.0010593545,0.025961738,0.0020374907,0.0039732032,0.0015518318,0.013135136,0.00052815763,0.003013018,0.002079336],"study_design_scores_gemma":[0.5405012,0.010613508,0.42885923,0.00049006817,0.013543822,0.00004520531,0.00065598846,0.0010977677,0.00308317,0.0000065071877,0.00042728867,0.0006762753],"about_ca_topic_score_codex":0.00031711295,"about_ca_topic_score_gemma":0.0014675222,"teacher_disagreement_score":0.2929207,"about_ca_system_score_codex":0.0006680472,"about_ca_system_score_gemma":0.0006510733,"threshold_uncertainty_score":0.9999336},"labels":[],"label_agreement":null},{"id":"W873112638","doi":"10.1182/blood.v122.21.5540.5540","title":"Improved Survival In Adults With Mixed-Phenotype Acute Leukemia Following Stem Cell Transplantation (SCT): A Single Centre Experience","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Immunophenotyping; Transplantation; Internal medicine; Myeloid; Oncology; Population; Autologous stem-cell transplantation; Induction chemotherapy; Myeloid leukemia; Hematopoietic stem cell transplantation; Leukemia; Chemotherapy regimen; Chemotherapy; Gastroenterology; Immunology; Pathology; Antigen","score_opus":0.009394319172079155,"score_gpt":0.23273571348752412,"score_spread":0.22334139431544497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W873112638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99619985,0.00010722447,0.00019805419,0.00018396806,0.00010931662,0.0010863433,0.000010716964,0.000093383496,0.0020111403],"genre_scores_gemma":[0.9968404,0.000039880608,0.0017877498,0.000090225345,0.00007771282,0.00010500485,0.000061998886,0.000054323613,0.0009426973],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980428,0.00008327998,0.00031864352,0.00048395907,0.00046287006,0.00060845],"domain_scores_gemma":[0.99911726,0.0000957821,0.0000752564,0.0003633331,0.000114367205,0.00023399119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013406304,0.00024688986,0.00037267743,0.00014305455,0.00006768565,0.0000494813,0.0001895786,0.00014397682,0.000070766364],"category_scores_gemma":[0.0000140543825,0.00019787703,0.00008635452,0.0004227944,0.000057379944,0.0003005112,0.000036084224,0.00035102156,0.00007834238],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00318728,0.0018402033,0.13516906,0.0010528571,0.00046039274,0.0028731308,0.03786956,0.000018059249,0.80536485,0.000029052851,0.00026489713,0.011870634],"study_design_scores_gemma":[0.06667234,0.0027784545,0.13791524,0.0016524027,0.000868604,0.00023047118,0.020409936,0.0029458983,0.76515377,0.000017442342,0.00018225204,0.0011732138],"about_ca_topic_score_codex":0.001221341,"about_ca_topic_score_gemma":0.0003886704,"teacher_disagreement_score":0.06348506,"about_ca_system_score_codex":0.00032984326,"about_ca_system_score_gemma":0.00039054346,"threshold_uncertainty_score":0.8069191},"labels":[],"label_agreement":null},{"id":"W951605309","doi":"10.1182/blood.v122.21.487.487","title":"DNMT3a Mutations Define a Pre-Leukemic Stem Cell Reservoir In Human Acute Myeloid Leukemia","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; NPM1; Sanger sequencing; Leukemia; Biology; Mutation; Cancer research; Haematopoiesis; Stem cell; Myeloid; Molecular biology; Immunology; Gene; Genetics; Karyotype; Chromosome","score_opus":0.01779519455919561,"score_gpt":0.28025473613626883,"score_spread":0.26245954157707324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W951605309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97823745,0.00040039723,0.00003257039,0.00091456145,0.000052488598,0.0016759832,0.000028379838,0.00020396741,0.018454196],"genre_scores_gemma":[0.97525483,0.000120127006,0.0016593357,0.0003591504,0.00020413223,0.00056597154,0.00017945279,0.00010450226,0.021552475],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9968813,0.00015053229,0.00069483824,0.0006686328,0.0006671324,0.0009375591],"domain_scores_gemma":[0.9979667,0.0001858446,0.00014203899,0.0010067349,0.00026755861,0.00043113396],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003853923,0.00035926356,0.00059623056,0.0005628689,0.00018478495,0.00008549207,0.00048119234,0.00030511458,0.0006369191],"category_scores_gemma":[0.00007009173,0.0003293448,0.00016102492,0.0009152959,0.0001759878,0.00032039123,0.00028087376,0.0010620867,0.0011296626],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024816822,0.0017656481,0.05632719,0.00064834516,0.0005394018,0.0012726383,0.003857259,0.00012854028,0.9048677,0.00059972185,0.027435148,0.002310208],"study_design_scores_gemma":[0.062152747,0.002997167,0.48305354,0.000896338,0.0014909955,0.0014049836,0.0030070718,0.0041015055,0.42896235,0.0028289815,0.007141586,0.0019627423],"about_ca_topic_score_codex":0.0020324406,"about_ca_topic_score_gemma":0.00018085547,"teacher_disagreement_score":0.4759054,"about_ca_system_score_codex":0.0011760148,"about_ca_system_score_gemma":0.0011804295,"threshold_uncertainty_score":0.99991584},"labels":[],"label_agreement":null},{"id":"W986955076","doi":"10.1182/blood.v122.21.1246.1246","title":"Somatic Mutations and Loss-Of-Heterozygosity Impair The DNA Repair Functions Of CUX1 in Myelodysplastic Syndromes (MDS)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Genetics; Biology; Sanger sequencing; Loss of heterozygosity; Nonsense mutation; Mutation; Exome sequencing; Compound heterozygosity; Haploinsufficiency; Molecular biology; Chromosome 7 (human); Missense mutation; Gene; Chromosome; Allele; Phenotype","score_opus":0.015017851937639765,"score_gpt":0.2625885613126934,"score_spread":0.24757070937505365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W986955076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99782765,0.00020044475,0.000055985096,0.0006568286,0.00003439387,0.00066144,0.000015072396,0.00004621092,0.0005019813],"genre_scores_gemma":[0.9988226,0.000032995504,0.0006015629,0.000033515767,0.00002706292,0.000087202054,0.000011886657,0.000015584355,0.00036756706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998888,0.00008694761,0.00036311414,0.00018065968,0.00025693828,0.0002243435],"domain_scores_gemma":[0.99878925,0.0005161492,0.00009254054,0.00038790394,0.00011878253,0.0000953504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023503618,0.00011353015,0.0002959219,0.0001941413,0.000068257315,0.000009885816,0.00010083277,0.000073641175,0.00018712842],"category_scores_gemma":[0.00041672407,0.0000773498,0.0000842725,0.0003402237,0.00030302635,0.00010646715,0.00008558036,0.0002288204,0.000059072496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061719,0.0014418409,0.96089053,0.0011453991,0.0005699797,0.00009350064,0.0020852962,0.000032808708,0.031692762,0.00021947203,0.0010462439,0.0007204315],"study_design_scores_gemma":[0.0027784563,0.00042637798,0.9903723,0.00019138707,0.00028650757,0.00040246022,0.0008563299,0.0015625983,0.0026166113,0.00038159295,0.000035779023,0.000089579786],"about_ca_topic_score_codex":0.0004052078,"about_ca_topic_score_gemma":0.000046347475,"teacher_disagreement_score":0.029481774,"about_ca_system_score_codex":0.000043623408,"about_ca_system_score_gemma":0.00017886626,"threshold_uncertainty_score":0.31542334},"labels":[],"label_agreement":null}]}